Gene,Gene ID,Category,Detail,Target,Forbidden,Reproductive RNA (nTPM),Maximum RNA (nTPM),IHC measurements,Positive IHC measurements,IHC coverage,Normal protein positive,Normal RNA above ceiling,Normal donor RNA above ceiling,Reproductive positive control,Previous CTA screen,Previous expression group,Disposable expression,Below-threshold subgroup,Donor review,Donor findings,Clinical evidence,Previous reason,Reason,RNA evidence,IHC evidence,Coverage gaps,Policy,Cell RNA review,Cell RNA findings,HPA cell RNA measured,Immune RNA review,Immune RNA findings,DICE measured,HPA immune measured,Corneal RNA review,Corneal RNA findings,Corneal measured,Antibody review,Antibody findings,Additional reproductive protein,Primary IHC measured,Cell evidence assessed,Previous category,Previous detail,Baseline policy,Publication support,Published normal protein,Publication sources,Change,Normal RNA assessed,Normal RNA measured,High normal RNA,Normal RNA maximum (TPM),Normal RNA maximum (nTPM),High normal RNA findings,Before cell review category,Previous policy,Highest normal TPM context,Highest normal nTPM context,Cancer RNA at >=5 pTPM,Cancer IHC Medium/High,Cancer RNA cohorts,Cancer IHC groups,UniProt entries,Biology sources,Biological function,Curated tissue biology,Disease biology,Biology caveats,Protein location,Function PubMed IDs,Tissue PubMed IDs,Shared UniProt entry,Biology coverage,Trial evidence,Trial sources,Reviewed literature,Reviewed literature sources,Reviewed evidence types,Nomination sources,Nomination scope,Review question,Reconsideration evidence,Limitations,Boundary review,Literature conflict priority,Literature conflict,Literature follow-up,Literature conflict source
AANAT,ENSG00000129673,Unsafe,RNA,False,True,4.5,10.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,choroid plexus: 2.4 nTPM; absolute ceiling;continuous selectivity; retina: 10.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 2.4 nTPM (limit 2); retina: 10.6 nTPM (limit 2); choroid plexus: 2.4 nTPM (baseline 2); retina: 10.6 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 4/176 (2.3%); Testicular Germ Cell Tumor (TCGA): 3/133 (2.3%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 5/283 (1.8%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q16613,https://www.uniprot.org/uniprotkb/Q16613/entry,"Controls the night/day rhythm of melatonin production in the pineal gland. Catalyzes the N-acetylation of serotonin into N-acetylserotonin, the penultimate step in the synthesis of melatonin",Highly expressed in pineal gland and at lower levels in the retina. Weak expression in several brain regions and in the pituitary gland,,,Cytoplasm,11313340,18212399|8661026,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
ABCA13,ENSG00000179869,Unsafe,RNA,False,True,1.5,44.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 44.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 1.2 nTPM; continuous selectivity; kidney: 0.9 nTPM; continuous selectivity; lung: 1.2 nTPM; continuous selectivity; pancreas: 0.7 nTPM; continuous selectivity; pituitary gland: 1.2 nTPM; continuous selectivity; salivary gland: 0.8 nTPM; continuous selectivity; skin: 0.9 nTPM; continuous selectivity; thyroid gland: 2.9 nTPM; continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 44.1 nTPM (limit 2); bone marrow: 44.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Squamous Cell Carcinoma (validation): 39/68 (57.4%); Lung Squamous Cell Carcinoma (TCGA): 273/489 (55.8%); Glioblastoma Multiforme (validation): 21/58 (36.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q86UQ4,https://www.uniprot.org/uniprotkb/Q86UQ4/entry,"May mediate the cholesterol and gangliosides transport from the plasma membrane to intracellular vesicles in an ATP hydrolysis dependent manner, thus playing a role in their internalization by endocytic retrograde transport and may also participate in the endocytosis of synaptic vesicle in cortical neurons","Significantly expressed in the bone marrow, trachea, testis, thyroid and lung as well as in skin fibroblasts",,,Cytoplasmic vesicle membrane,33478937,12697998|23266639,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ABCA4,ENSG00000198691,Unsafe,Protein,False,True,5.1,343.6,91,4,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; choroid plexus: 93.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 2.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 343.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 1.4 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 93.3 nTPM (limit 2); kidney: 2.6 nTPM (limit 2); retina: 343.6 nTPM (limit 2); choroid plexus: 93.3 nTPM (baseline 2); kidney: 2.6 nTPM (baseline 2); retina: 343.6 nTPM (baseline 2),kidney / collecting ducts: High (Enhanced); kidney / distal tubules: High (Enhanced); kidney / proximal tubules (cell body): High (Enhanced); retina / photoreceptor cells: High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Adenocarcinoma (TCGA): 147/497 (29.6%); Lung Adenocarcinoma (validation): 29/105 (27.6%); Lung Squamous Cell Carcinoma (TCGA): 89/489 (18.2%),renal cancer: 1/12 (8.3%); breast cancer: 0/12 (0.0%),31,20,P78363,https://www.uniprot.org/uniprotkb/P78363/entry,"Flippase that catalyzes in an ATP-dependent manner the transport of retinal-phosphatidylethanolamine conjugates like 11-cis and all-trans isomers of N-retinylidene-phosphatidylethanolamine (N-Ret-PE) from the lumen to the cytoplasmic leaflet of photoreceptor outer segment disk membranes, where 11-cis-retinylidene-phosphatidylethanolamine is then isomerized to its all-trans isomer and reduced by RDH8 to produce all-trans-retinol. This transport activity ensures that all-trans-retinal generated from photoexcitation and 11-cis-retinal not needed for the regeneration of rhodopsin and cone opsins are effectively cleared from the photoreceptors, therefore preventing their accumulation and the formation of toxic bisretinoid (PubMed:10075733, PubMed:20404325, PubMed:22735453, PubMed:23144455, PubMed:24097981, PubMed:29847635, PubMed:33375396). Displays ATPase activity in vitro in absence of retinal substrate (PubMed:33605212, PubMed:39128720, PubMed:29847635, PubMed:33375396). May display GTPase activity that is strongly influenced by the lipid environment and the presence of retinoid compounds (PubMed:22735453). Binds the unprotonated form of N-retinylidene-phosphatidylethanolamine with high affinity in the absence of ATP, and ATP binding and hydrolysis induce a protein conformational change that causes N-retinylidene-phosphatidylethanolamine release (By similarity)",Retinal-specific. Seems to be exclusively found in the rims of rod photoreceptor cells,"Stargardt disease 1: An autosomal recessive form of Stargardt disease, a retinal degenerative disease characterized by macular dystrophy, progressive bilateral atrophy of the foveal retinal pigment epithelium, and accumulation of fluorescent flecks around the macula and/or in the central and near-peripheral areas of the retina. STGD1 patients typically lose central vision in their first or second decade of life. Fundus flavimaculatus: Autosomal recessive retinal disorder very similar to Stargardt disease. In contrast to Stargardt disease, FFM is characterized by later onset and slowly progressive course. Macular degeneration, age-related, 2: A form of age-related macular degeneration, a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane. Cone-rod dystrophy 3: An inherited retinal dystrophy characterized by retinal pigment deposits visible on fundus examination, predominantly in the macular region, and initial loss of cone photoreceptors followed by rod degeneration. This leads to decreased visual acuity and sensitivity in the central visual field, followed by loss of peripheral vision. Severe loss of vision occurs earlier than in retinitis pigmentosa, due to cone photoreceptors degenerating at a higher rate than rod photoreceptors. Retinitis pigmentosa 19: A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. RP19 is characterized by choroidal atrophy.",,"Membrane Endoplasmic reticulum Cytoplasmic vesicle Cell projection, cilium, photoreceptor outer segment",10075733|20404325|22735453|23144455|24097981|29847635|33375396|33605212|39128720,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ABHD1,ENSG00000143994,Unsafe,Protein,False,True,21.0,21.0,75,70,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 1.1 nTPM; positive ihc; adrenal gland: 0.6 nTPM; positive ihc; bone marrow: 0 nTPM; positive ihc; cerebellum: 0.1 nTPM; positive ihc; cerebral cortex: 0.5 nTPM; positive ihc; colon: 0 nTPM; positive ihc; duodenum: 0 nTPM; positive ihc; esophagus: 0.1 nTPM; positive ihc; heart muscle: 0.5 nTPM; positive ihc; kidney: 0.3 nTPM; positive ihc; liver: 3.2 nTPM; positive ihc;absolute ceiling; lung: 0.1 nTPM; positive ihc; lymph node: 0.2 nTPM; positive ihc; pancreas: 0.1 nTPM; positive ihc; parathyroid gland: 0.4 nTPM; positive ihc; rectum: 0 nTPM; positive ihc; salivary gland: 1.4 nTPM; positive ihc; skeletal muscle: 1.8 nTPM; positive ihc; skin: 0 nTPM; positive ihc; small intestine: 0.1 nTPM; positive ihc; smooth muscle: 0.3 nTPM; positive ihc; spleen: 0.1 nTPM; positive ihc; stomach: 0.2 nTPM; positive ihc; thyroid gland: 0.4 nTPM; positive ihc; urinary bladder: 0 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",liver: 3.2 nTPM (limit 2); liver: 3.2 nTPM (baseline 2),adipose tissue / adipocytes: Medium (Uncertain); adrenal gland / glandular cells: High (Uncertain); bone marrow / hematopoietic cells: Low (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / glial cells: Low (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: Medium (Uncertain); cerebellum / cells in molecular layer: Medium (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / endothelial cells: Medium (Uncertain); cerebral cortex / glial cells: Medium (Uncertain); cerebral cortex / neuronal cells: High (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / endothelial cells: Medium (Uncertain); colon / glandular cells: High (Uncertain); colon / peripheral nerve/ganglion: Medium (Uncertain); duodenum / glandular cells: High (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: High (Uncertain); hippocampus / glial cells: Low (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in glomeruli: Medium (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / cholangiocytes: Medium (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / alveolar cells: Low (Uncertain); lung / macrophages: Low (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: High (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: High (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: Low (Uncertain); skin 1 / fibroblasts: Medium (Uncertain); skin 1 / keratinocytes: Medium (Uncertain); skin 1 / Langerhans: Medium (Uncertain); skin 2 / epidermal cells: High (Uncertain); small intestine / glandular cells: Medium (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); spleen / cells in white pulp: High (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: High (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 25/50 (50.0%); Liver Hepatocellular Carcinoma (validation): 52/231 (22.5%); Kidney Renal Papillary Cell Carcinoma (TCGA): 11/282 (3.9%),ovarian cancer: 11/11 (100.0%); endometrial cancer: 10/10 (100.0%),31,20,Q96SE0,https://www.uniprot.org/uniprotkb/Q96SE0/entry,,Ubiquitously expressed,,,Membrane,,12735795,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Jamin2021_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
ABRAXAS1,ENSG00000163322,Unsafe,Protein,False,True,10.5,10.5,78,10,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 3.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; bone marrow: 7.6 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 3.5 nTPM; absolute ceiling;continuous selectivity; colon: 3.1 nTPM; positive ihc; duodenum: 3.5 nTPM; absolute ceiling;continuous selectivity; esophagus: 5 nTPM; continuous selectivity; heart muscle: 3.6 nTPM; absolute ceiling;continuous selectivity; kidney: 3.9 nTPM; absolute ceiling;continuous selectivity; liver: 2.1 nTPM; absolute ceiling; lung: 3.6 nTPM; absolute ceiling;continuous selectivity; lymph node: 7.8 nTPM; absolute ceiling;continuous selectivity; pancreas: 3.3 nTPM; absolute ceiling;continuous selectivity; rectum: 2.7 nTPM; positive ihc; retina: 3.5 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 6.2 nTPM; absolute ceiling;continuous selectivity; skin: 5.4 nTPM; continuous selectivity; small intestine: 3 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 2.8 nTPM; absolute ceiling;continuous selectivity; stomach: 3.5 nTPM; positive ihc; thymus: 4.7 nTPM; continuous selectivity; thyroid gland: 7.2 nTPM; continuous selectivity; urinary bladder: 3.7 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 3.8 nTPM (limit 2); bone marrow: 7.6 nTPM (limit 2); choroid plexus: 3.5 nTPM (limit 2); duodenum: 3.5 nTPM (limit 2); heart muscle: 3.6 nTPM (limit 2); kidney: 3.9 nTPM (limit 2); liver: 2.1 nTPM (limit 2); lung: 3.6 nTPM (limit 2); lymph node: 7.8 nTPM (limit 6); pancreas: 3.3 nTPM (limit 2); retina: 3.5 nTPM (limit 2); skeletal muscle: 6.2 nTPM (limit 2); small intestine: 3 nTPM (limit 2); smooth muscle: 2.8 nTPM (limit 2); adrenal gland: 3.8 nTPM (baseline 2); bone marrow: 7.6 nTPM (baseline 2); choroid plexus: 3.5 nTPM (baseline 2); duodenum: 3.5 nTPM (baseline 2); heart muscle: 3.6 nTPM (baseline 2); kidney: 3.9 nTPM (baseline 2); liver: 2.1 nTPM (baseline 2); lung: 3.6 nTPM (baseline 2); lymph node: 7.8 nTPM (baseline 6); pancreas: 3.3 nTPM (baseline 2); retina: 3.5 nTPM (baseline 2); skeletal muscle: 6.2 nTPM (baseline 2); small intestine: 3 nTPM (baseline 2); smooth muscle: 2.8 nTPM (baseline 2),adrenal gland / glandular cells: Low (Uncertain); bronchus / respiratory epithelial cells: Low (Uncertain); colon / glandular cells: Medium (Uncertain); rectum / glandular cells: Medium (Uncertain); small intestine / glandular cells: Low (Uncertain); stomach 2 / glandular cells: Low (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 485/486 (99.8%); Rectum Adenocarcinoma (validation): 206/207 (99.5%); Glioblastoma Multiforme (validation): 57/58 (98.3%),lymphoma: 1/11 (9.1%); testis cancer: 1/12 (8.3%),29,20,Q6UWZ7,https://www.uniprot.org/uniprotkb/Q6UWZ7/entry,"Involved in DNA damage response and double-strand break (DSB) repair. Component of the BRCA1-A complex, acting as a central scaffold protein that assembles the various components of the complex and mediates the recruitment of BRCA1. The BRCA1-A complex specifically recognizes 'Lys-63'-linked ubiquitinated histones H2A and H2AX at DNA lesion sites, leading to target the BRCA1-BARD1 heterodimer to sites of DNA damage at DSBs. This complex also possesses deubiquitinase activity that specifically removes 'Lys-63'-linked ubiquitin on histones H2A and H2AX",,Breast cancer: A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.,,Nucleus,17525340|17643121|17643122|18077395|19261748|22357538|26778126,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | Jamin2021_CT,GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
ACAD11,ENSG00000240303,Unsafe,Protein,False,True,9.6,100.5,124,23,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 15.6 nTPM; continuous selectivity;reproductive not higher; adrenal gland: 7.4 nTPM; continuous selectivity; amygdala: 3.5 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 4.2 nTPM; absolute ceiling;continuous selectivity; bone marrow: 7.7 nTPM; continuous selectivity; cerebellum: 4.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 4.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 46.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 7.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 16.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 14.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 3.5 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 3.2 nTPM; absolute ceiling;continuous selectivity; kidney: 62.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 100.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 5.6 nTPM; continuous selectivity; midbrain: 4 nTPM; absolute ceiling;continuous selectivity; pancreas: 7.9 nTPM; continuous selectivity; parathyroid gland: 8.6 nTPM; continuous selectivity; pituitary gland: 9.5 nTPM; absolute ceiling;continuous selectivity; rectum: 3.3 nTPM; positive ihc; retina: 11.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 4.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 15.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 6.1 nTPM; continuous selectivity; spinal cord: 4.7 nTPM; absolute ceiling;continuous selectivity; stomach: 4.6 nTPM; positive ihc;continuous selectivity; thymus: 4.5 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 3.5 nTPM (limit 2); basal ganglia: 4.2 nTPM (limit 2); cerebellum: 4.2 nTPM (limit 2); cerebral cortex: 4.1 nTPM (limit 2); choroid plexus: 46.2 nTPM (limit 2); colon: 7.4 nTPM (limit 6); duodenum: 16.6 nTPM (limit 2); heart muscle: 14.9 nTPM (limit 2); hippocampal formation: 3.5 nTPM (limit 2); hypothalamus: 3.2 nTPM (limit 2); kidney: 62.1 nTPM (limit 2); liver: 100.5 nTPM (limit 2); midbrain: 4 nTPM (limit 2); pituitary gland: 9.5 nTPM (limit 2); retina: 11.3 nTPM (limit 2); skeletal muscle: 4.1 nTPM (limit 2); small intestine: 15.3 nTPM (limit 2); spinal cord: 4.7 nTPM (limit 2),caudate / neuronal cells: Low (Enhanced); cerebellum / granular cells - cytoplasm/membrane: Medium (Enhanced); cerebellum / processes in granular layer: High (Enhanced); cerebellum / processes in white matter: High (Enhanced); cerebellum / Purkinje cells - cytoplasm/membrane: Low (Enhanced); cerebellum / Purkinje cells - dendrites: Medium (Enhanced); cerebellum / white matter cells - cytoplasm/membrane: High (Enhanced); cerebral cortex / neuronal cells: Low (Enhanced); cerebral cortex / neuropil: Medium (Enhanced); colon / enterocytes - Microvilli: Medium (Enhanced); heart muscle / cardiomyocytes: Medium (Enhanced); hippocampus / glial cells: Low (Enhanced); hippocampus / neuronal cells: Low (Enhanced); kidney / proximal tubules (cell body): Medium (Enhanced); liver / hepatocytes: Medium (Enhanced); rectum / mucosal lymphoid cells: Low (Enhanced); skeletal muscle / myocytes: Medium (Enhanced); small intestine / endocrine cells: Medium (Enhanced); small intestine / enterocytes: Medium (Enhanced); small intestine / enterocytes - Gradient: Ascending (Enhanced); stomach 1 / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (validation): 231/231 (100.0%); Kidney Renal Clear Cell Carcinoma (validation): 100/100 (100.0%); Kidney Renal Clear Cell Carcinoma (TCGA): 502/521 (96.4%),renal cancer: 4/12 (33.3%); liver cancer: 3/12 (25.0%),31,20,Q709F0,https://www.uniprot.org/uniprotkb/Q709F0/entry,"Participates in fatty acid beta-oxidation (FAO) and energy production in the central nervous system (CNS), and to a lesser extent in the liver (PubMed:21237683). Catalyzes the first step in FAO, which consists in the proR-proR stereospecific alpha,beta-dehydrogenation of fatty acyl-CoA thioesters using the electron transfer flavoprotein (ETF) as their physiologic electron acceptor, with maximal activity towards saturated docosanoyl-CoA (CoA 22:0) in both the cerebellum and the liver (PubMed:21237683). Among the different mitochondrial acyl-CoA dehydrogenases, its FAO activity overlaps with that of ACADV and ACADL, but plays a primary role in tissues where it is the main long-chain ACAD expressed, such as the CNS, where together with ACAD9, they accommodate the full spectrum of long chain fatty acid substrates (PubMed:21237683)","Widely expressed with highest levels in brain (white matter of cerebellum) followed by liver, heart and kidney",,,Peroxisome Mitochondrion membrane,21237683,21237683,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ACE2,ENSG00000130234,Unsafe,Protein,False,True,48.5,237.9,134,23,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; choroid plexus: 5.4 nTPM; absolute ceiling; colon: 9.6 nTPM; positive ihc;absolute ceiling; duodenum: 179.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 41.3 nTPM; absolute ceiling;continuous selectivity; kidney: 85.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 2.4 nTPM; positive ihc;absolute ceiling; rectum: 5.8 nTPM; positive ihc; small intestine: 237.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 5.4 nTPM (limit 2); colon: 9.6 nTPM (limit 6); duodenum: 179.2 nTPM (limit 2); heart muscle: 41.3 nTPM (limit 12); kidney: 85.2 nTPM (limit 2); pancreas: 2.4 nTPM (limit 2); small intestine: 237.9 nTPM (limit 2),bronchus / ciliated cells (ciliary rootlets): Medium (Enhanced); colon / enterocytes - Microvilli: High (Enhanced); duodenum / enterocytes: Low (Enhanced); duodenum / enterocytes - Microvilli: High (Enhanced); kidney / bowman's capsule: Medium (Enhanced); kidney / proximal tubules (cell body): Medium (Enhanced); kidney / proximal tubules (microvilli): High (Enhanced); nasopharynx / ciliated cells (ciliary rootlets): Medium (Enhanced); pancreas / exocrine glandular cells: Medium (Enhanced); rectum / enterocytes - Microvilli: High (Enhanced); small intestine / enterocytes: Low (Enhanced); small intestine / enterocytes - Microvilli: High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 181/207 (87.4%); Kidney Renal Papillary Cell Carcinoma (TCGA): 244/282 (86.5%); Kidney Renal Clear Cell Carcinoma (validation): 82/100 (82.0%),renal cancer: 9/11 (81.8%); colorectal cancer: 8/12 (66.7%),31,20,Q9BYF1,https://www.uniprot.org/uniprotkb/Q9BYF1/entry,"Essential counter-regulatory carboxypeptidase of the renin-angiotensin hormone system that is a critical regulator of blood volume, systemic vascular resistance, and thus cardiovascular homeostasis (PubMed:27217402). Converts angiotensin I to angiotensin 1-9, a nine-amino acid peptide with anti-hypertrophic effects in cardiomyocytes, and angiotensin II to angiotensin 1-7, which then acts as a beneficial vasodilator and anti-proliferation agent, counterbalancing the actions of the vasoconstrictor angiotensin II (PubMed:10924499, PubMed:10969042, PubMed:11815627, PubMed:14504186, PubMed:19021774). Also removes the C-terminal residue from three other vasoactive peptides, neurotensin, kinetensin, and des-Arg bradykinin, but is not active on bradykinin (PubMed:10969042, PubMed:11815627). Also cleaves other biological peptides, such as apelins (apelin-13, [Pyr1]apelin-13, apelin-17, apelin-36), casomorphins (beta-casomorphin-7, neocasomorphin) and dynorphin A with high efficiency (PubMed:11815627, PubMed:27217402, PubMed:28293165). In addition, ACE2 C-terminus is homologous to collectrin and is responsible for the trafficking of the neutral amino acid transporter SL6A19 to the plasma membrane of gut epithelial cells via direct interaction, regulating its expression on the cell surface and its catalytic activity (PubMed:18424768, PubMed:19185582) (Microbial infection) Acts as a receptor for human coronaviruses SARS-CoV and SARS-CoV-2, as well as human coronavirus NL63/HCoV-NL63 Non-functional as a carboxypeptidase (Microbial infection) Non-functional as a receptor for human coronavirus SARS-CoV-2","Expressed in endothelial cells from small and large arteries, and in arterial smooth muscle cells (at protein level) (PubMed:15141377). Expressed in enterocytes of the small intestine, Leydig cells and Sertoli cells (at protein level) (PubMed:15141377). Expressed in the renal proximal tubule and the small intestine (at protein level) (PubMed:18424768). Expressed in heart, kidney, testis, and gastrointestinal system (at protein level) (PubMed:10924499, PubMed:10969042, PubMed:12459472, PubMed:15231706, PubMed:15671045, PubMed:32170560, PubMed:32715618). In lung, expressed at low levels in some alveolar type 2 cells, the expression seems to be individual-specific (at protein level) (PubMed:15141377, PubMed:32170560, PubMed:32425701, PubMed:32715618, PubMed:33432184). Expressed in nasal epithelial cells (at protein level) (PubMed:32333915, PubMed:33432184). Coexpressed with TMPRSS2 within some lung alveolar type 2 cells, ileal absorptive enterocytes, intestinal epithelial cells, cornea, gallbladder and nasal goblet secretory cells (PubMed:32327758, PubMed:32358202, PubMed:32413319). Coexpressed with TMPRSS4 within mature enterocytes (PubMed:32404436) Expressed in nasal and bronchial epithelial cells (at protein level)",,,"Secreted Cell membrane Cytoplasm Cell projection, cilium Apical cell membrane",10924499|10969042|11815627|14504186|14647384|15452268|15791205|15897467|18424768|19021774|19185582|19901337|24227843|27217402|32142651|32221306|32225175|33000221|33077916|33082294|33432067|33432184,10924499|10969042|12459472|15141377|15231706|15671045|18424768|32170560|32327758|32333915|32358202|32404436|32413319|32425701|32715618|33432184,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
ACOXL,ENSG00000153093,Unsafe,RNA,False,True,7.0,8.9,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,lung: 8.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 2.7 nTPM; continuous selectivity; urinary bladder: 4.5 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,lung: 8.9 nTPM (limit 2); lung: 8.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 84/133 (63.2%); Prostate Adenocarcinoma (TCGA): 181/480 (37.7%); Lung Adenocarcinoma (validation): 37/105 (35.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9NUZ1,https://www.uniprot.org/uniprotkb/Q9NUZ1/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination; inclusion depends on TGCT under this study's thresholds,,,,,,,,
ACRBP,ENSG00000111644,Unsafe,High RNA,False,True,275.6,275.6,88,6,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,True,"pbmc/platelets cluster c-9: 5316.5 nTPM, 559 reads; reproductive-cell max 1326.2",True,True,"DICE B_CELL_NAIVE (unstimulated): 77/91 values ≥5 TPM, max 13.4406; DICE MONOCYTES (unstimulated): 91/91 values ≥5 TPM, max 20.75; DICE M2 (unstimulated): 90/90 values ≥5 TPM, max 39.1126; DICE NK (unstimulated): 35/90 values ≥5 TPM, max 8.60777; DICE TREG_MEM (unstimulated): 64/89 values ≥5 TPM, max 8.61494; DICE CD4_NAIVE (unstimulated): 72/88 values ≥5 TPM, max 11.1159; DICE CD4_STIM (activated): 4/88 values ≥5 TPM, max 7.53764; DICE TREG_NAIVE (unstimulated): 83/89 values ≥5 TPM, max 12.1914; DICE TFH (unstimulated): 24/89 values ≥5 TPM, max 8.47375; DICE TH1 (unstimulated): 22/81 values ≥5 TPM, max 8.18315; DICE TH2 (unstimulated): 18/89 values ≥5 TPM, max 7.37337; DICE CD8_NAIVE (unstimulated): 86/89 values ≥5 TPM, max 14.0219; DICE CD8_STIM (activated): 20/88 values ≥5 TPM, max 9.34729; hpa_immune_cell classical monocyte: 12.5 nTPM; hpa_immune_cell intermediate monocyte: 15.8 nTPM; hpa_immune_cell myeloid DC: 17.7 nTPM; hpa_immune_cell non-classical monocyte: 31.2 nTPM; hpa_immune_cell total PBMC: 10.6 nTPM; hpa_immune_monaco basophil: 5 TPM; hpa_immune_monaco classical monocyte: 17.6 TPM; hpa_immune_monaco Exhausted memory B-cell: 5.9 TPM; hpa_immune_monaco intermediate monocyte: 30.6 TPM; hpa_immune_monaco myeloid DC: 20.3 TPM; hpa_immune_monaco naive B-cell: 5.6 TPM; hpa_immune_monaco neutrophil: 5.2 TPM; hpa_immune_monaco non-classical monocyte: 37.5 TPM; hpa_immune_monaco Non-switched memory B-cell: 5 TPM; hpa_immune_monaco plasmacytoid DC: 10.2 TPM; hpa_immune_monaco Progenitor cell: 28.5 TPM; hpa_immune_monaco Switched memory B-cell: 5.1 TPM; hpa_immune_monaco total PBMC: 10.8 TPM",True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,56.5427,5316.5,"dice_m2: blood/M2, max 39.1126 TPM, 12 observations >30; hpa_immune_cell: blood/non-classical monocyte, max 31.2 nTPM, 1 observations >30; hpa_immune_cell_samples: blood/non-classical monocyte, max 56.5427 TPM, 1 observations >30; hpa_immune_cell_samples: blood/non-classical monocyte, max 77.8462 nTPM, 1 observations >30; hpa_immune_monaco: blood/intermediate monocyte, max 30.6 TPM, 1 observations >30; hpa_immune_monaco: blood/non-classical monocyte, max 37.5 TPM, 1 observations >30; hpa_single_cell_tissue: pbmc/platelets, max 5316.5 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,56.54 TPM; blood/non-classical monocyte; hpa_immune_cell_samples; vital,5316 nTPM; pbmc/platelets; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (validation): 39/50 (78.0%); Thyroid Carcinoma (TCGA): 278/495 (56.2%); Kidney Renal Clear Cell Carcinoma (validation): 48/100 (48.0%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q8NEB7,https://www.uniprot.org/uniprotkb/Q8NEB7/entry,Acrosomal protein that maintains proacrosin (pro-ACR) as an enzymatically inactive zymogen in the acrosome. Involved also in the acrosome formation,"Expression restricted to testis in normal tissue. Expressed in a wide spectrum of cancers, including bladder, breast, liver, lung and colon cancers",,,"Secreted Cytoplasmic vesicle, secretory vesicle, acrosome",,11248070,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,Does the broad immune and platelet RNA represent endogenous ACRBP expression?,Resolve normal-cell RNA identity and reliable local protein evidence before changing the general exclusion.,The retracted PMID 35463688 is excluded; the decision uses pinned RNA. Platelet RNA does not establish peptide presentation.,,,,,
ACRV1,ENSG00000134940,Unsafe,RNA,False,True,113.4,113.4,85,2,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,basal ganglia: 2.4 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,basal ganglia: 2.4 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 6/58 (10.3%); Glioblastoma Multiforme (TCGA): 9/141 (6.4%); Skin Cuteneous Melanoma (TCGA): 5/99 (5.1%),melanoma: 1/10 (10.0%); breast cancer: 0/12 (0.0%),31,20,P26436,https://www.uniprot.org/uniprotkb/P26436/entry,,Testis,,,"Cytoplasmic vesicle, secretory vesicle, acrosome",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,Failed bulk numeric comparisons are within 20% of their cutoffs; not an automatic rescue,,,,
ACSM1,ENSG00000166743,Unsafe,RNA,False,True,209.4,209.4,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 3.5 nTPM; absolute ceiling; liver: 9.8 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 3.5 nTPM (limit 2); liver: 9.8 nTPM (limit 2); bone marrow: 3.5 nTPM (baseline 2); liver: 9.8 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Prostate Adenocarcinoma (TCGA): 422/480 (87.9%); Liver Hepatocellular Carcinoma (validation): 163/231 (70.6%); Liver Hepatocellular Carcinoma (TCGA): 229/362 (63.3%),prostate cancer: 3/10 (30.0%); glioma: 2/9 (22.2%),31,20,Q08AH1,https://www.uniprot.org/uniprotkb/Q08AH1/entry,"Catalyzes the activation of fatty acids by CoA to produce an acyl-CoA, the first step in fatty acid metabolism (PubMed:10434065). Capable of activating medium-chain fatty acids (e.g. butyric (C4) to decanoic (C10) acids), and certain carboxylate-containing xenobiotics, e.g. benzoate (PubMed:10434065). Also catalyzes the activation of lipoate to lipoyl-nucleoside monophosphate (By similarity). Activates lipoate with GTP at a 1000-fold higher rate than with ATP and activates both (R)- and (S)-lipoate to the respective lipoyl-GMP, with a preference for (R)-lipoate (By similarity)",,,,Mitochondrion matrix Mitochondrion,10434065,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ACTRT2,ENSG00000169717,Unsafe,Protein,False,True,151.0,151.0,80,9,Positive somewhere,True,False,False,True,Excluded,Normal,False,,Not assessed,,,positive normal IHC; positive ihc outside permitted; small intestine: 0 nTPM; positive ihc; stomach: 0 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,small intestine / glandular cells: Low (Enhanced); stomach 1 / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Stomach Adenocarcinoma (TCGA): 1/346 (0.3%),breast cancer: 0/10 (0.0%); cervical cancer: 0/7 (0.0%),30,20,Q8TDY3,https://www.uniprot.org/uniprotkb/Q8TDY3/entry,,,,,"Cytoplasm, cytoskeleton",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | Jamin2021_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
ACTRT3,ENSG00000184378,Unsafe,RNA,False,True,46.1,46.1,88,3,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,choroid plexus: 2.3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 2.3 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 51/283 (18.0%); Lung Squamous Cell Carcinoma (validation): 12/68 (17.6%); Uterine Corpus Endometrial Carcinoma (TCGA): 24/176 (13.6%),skin cancer: 3/10 (30.0%); liver cancer: 2/10 (20.0%),29,20,Q9BYD9,https://www.uniprot.org/uniprotkb/Q9BYD9/entry,,Ubiquitously expressed,,,"Cytoplasm, cytoskeleton Cytoplasm Nucleus",,11750065,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Jamin2021_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,Failed bulk numeric comparisons are within 20% of their cutoffs; not an automatic rescue,,,,
ACVR2B,ENSG00000114739,Unsafe,Protein,False,True,2.5,6.3,85,43,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 2 nTPM; continuous selectivity; basal ganglia: 1.7 nTPM; continuous selectivity; bone marrow: 0.2 nTPM; positive ihc; cerebellum: 4.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 2.4 nTPM; continuous selectivity; colon: 1.4 nTPM; positive ihc;continuous selectivity; duodenum: 0.8 nTPM; positive ihc;continuous selectivity; esophagus: 0.7 nTPM; positive ihc; heart muscle: 1.3 nTPM; positive ihc;continuous selectivity; hippocampal formation: 1.7 nTPM; continuous selectivity; hypothalamus: 1.9 nTPM; continuous selectivity; kidney: 1.7 nTPM; positive ihc;continuous selectivity; liver: 2.2 nTPM; continuous selectivity; lung: 1.2 nTPM; continuous selectivity; midbrain: 1.6 nTPM; continuous selectivity; pancreas: 2.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 3.2 nTPM; positive ihc;continuous selectivity;reproductive not higher; pituitary gland: 2 nTPM; continuous selectivity; rectum: 1.1 nTPM; positive ihc;continuous selectivity; retina: 6.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 1.7 nTPM; continuous selectivity; skeletal muscle: 5.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 0.7 nTPM; positive ihc; small intestine: 1.1 nTPM; positive ihc;continuous selectivity; smooth muscle: 0.9 nTPM; positive ihc;continuous selectivity; spinal cord: 1.8 nTPM; continuous selectivity; stomach: 1.5 nTPM; positive ihc;continuous selectivity; thymus: 4 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 1.5 nTPM; positive ihc;continuous selectivity; tongue: 2.7 nTPM; continuous selectivity;reproductive not higher; urinary bladder: 1.4 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 2.7 nTPM (limit 2); cerebellum: 4.8 nTPM (limit 4); pancreas: 2.4 nTPM (limit 2); retina: 6.3 nTPM (limit 2); skeletal muscle: 5.8 nTPM (limit 4),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Medium (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Low (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: Low (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Low (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Low (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Low (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Low (Approved); skin 1 / fibroblasts: Low (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Low (Approved); smooth muscle / smooth muscle cells: Low (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Low (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Low (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 44/50 (88.0%); Testicular Germ Cell Tumor (TCGA): 103/133 (77.4%),testis cancer: 5/12 (41.7%); breast cancer: 4/11 (36.4%),31,20,Q13705,https://www.uniprot.org/uniprotkb/Q13705/entry,"Transmembrane serine/threonine kinase activin type-2 receptor forming an activin receptor complex with activin type-1 serine/threonine kinase receptors (ACVR1, ACVR1B or ACVR1c). Transduces the activin signal from the cell surface to the cytoplasm and is thus regulating many physiological and pathological processes including neuronal differentiation and neuronal survival, hair follicle development and cycling, FSH production by the pituitary gland, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. Activin is also thought to have a paracrine or autocrine role in follicular development in the ovary. Within the receptor complex, the type-2 receptors act as a primary activin receptors (binds activin-A/INHBA, activin-B/INHBB as well as inhibin-A/INHA-INHBA). The type-1 receptors like ACVR1B act as downstream transducers of activin signals. Activin binds to type-2 receptor at the plasma membrane and activates its serine-threonine kinase. The activated receptor type-2 then phosphorylates and activates the type-1 receptor. Once activated, the type-1 receptor binds and phosphorylates the SMAD proteins SMAD2 and SMAD3, on serine residues of the C-terminal tail. Soon after their association with the activin receptor and subsequent phosphorylation, SMAD2 and SMAD3 are released into the cytoplasm where they interact with the common partner SMAD4. This SMAD complex translocates into the nucleus where it mediates activin-induced transcription. Inhibitory SMAD7, which is recruited to ACVR1B through FKBP1A, can prevent the association of SMAD2 and SMAD3 with the activin receptor complex, thereby blocking the activin signal. Activin signal transduction is also antagonized by the binding to the receptor of inhibin-B via the IGSF1 inhibin coreceptor",,"Heterotaxy, visceral, 4, autosomal: A form of visceral heterotaxy, a complex disorder due to disruption of the normal left-right asymmetry of the thoracoabdominal organs. Visceral heterotaxy or situs ambiguus results in randomization of the placement of visceral organs, including the heart, lungs, liver, spleen, and stomach. The organs are oriented randomly with respect to the left-right axis and with respect to one another. It can be associated with a variety of congenital defects including cardiac malformations. HTX4 clinical features include dextrocardia, right aortic arch and a right-sided spleen, anomalies of the inferior and the superior vena cava, atrial ventricular canal defect with dextro-transposed great arteries, pulmonary stenosis, polysplenia and midline liver.",,Cell membrane,8622651,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ADAD2,ENSG00000140955,Unsafe,RNA,False,True,62.9,62.9,77,2,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,basal ganglia: 2.1 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,basal ganglia: 2.1 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 4/133 (3.0%); Glioblastoma Multiforme (validation): 1/58 (1.7%); Rectum Adenocarcinoma (TCGA): 1/88 (1.1%),breast cancer: 0/12 (0.0%); cervical cancer: 0/10 (0.0%),31,20,Q8NCV1,https://www.uniprot.org/uniprotkb/Q8NCV1/entry,Required for male fertility and normal male germ cell differentiation,,,,Nucleus Cytoplasm,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,Failed bulk numeric comparisons are within 20% of their cutoffs; not an automatic rescue,,,,
ADAM12,ENSG00000148848,Unsafe,High RNA,False,True,130.4,130.4,90,3,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE TREG_MEM (unstimulated): 74/89 values ≥5 TPM, max 21.7905; DICE TREG_NAIVE (unstimulated): 3/89 values ≥5 TPM, max 6.10171; DICE THSTAR (unstimulated): 74/88 values ≥5 TPM, max 23.7591; DICE TH17 (unstimulated): 70/89 values ≥5 TPM, max 26.7627; hpa_immune_monaco MAIT T-cell: 24 TPM; hpa_immune_monaco Memory CD4 T-cell Th17: 9.5 TPM",True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,26.7626992682,179.9,"hpa_single_cell: /Cone photoreceptor cells, max 35.7 nTPM, 1 observations >30; hpa_single_cell: /Oligodendrocyte precursor cells, max 92.9 nTPM, 1 observations >30; hpa_single_cell: /Oligodendrocytes, max 48.6 nTPM, 1 observations >30; hpa_single_cell: /Rod photoreceptor cells, max 40.7 nTPM, 1 observations >30; hpa_single_cell: /granulocytes, max 41.2 nTPM, 1 observations >30; hpa_single_cell_tissue: brain/excitatory neurons, max 75.8 nTPM, 2 observations >30; hpa_single_cell_tissue: brain/inhibitory neurons, max 179.9 nTPM, 4 observations >30; hpa_single_cell_tissue: brain/oligodendrocyte precursor cells, max 92.9 nTPM, 1 observations >30; hpa_single_cell_tissue: brain/oligodendrocytes, max 63.7 nTPM, 2 observations >30; hpa_single_cell_tissue: eye/cone photoreceptor cells, max 35.7 nTPM, 1 observations >30; hpa_single_cell_tissue: eye/rod photoreceptor cells, max 48.6 nTPM, 1 observations >30; hpa_single_cell_tissue: fallopian tube/granulocytes, max 43.6 nTPM, 1 observations >30; hpa_single_cell_tissue: lung/granulocytes, max 50.9 nTPM, 1 observations >30; hpa_single_cell_tissue: pancreas/fibroblasts, max 69.3 nTPM, 1 observations >30; hpa_single_cell_tissue: salivary gland/fibroblasts, max 34.5 nTPM, 1 observations >30; hpa_single_cell_tissue: skeletal muscle/fibroblasts, max 64.5 nTPM, 1 observations >30; hpa_single_cell_tissue: skin/fibroblasts, max 50.2 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,26.76 TPM; blood/TH17; dice_th17; vital,179.9 nTPM; brain/inhibitory neurons; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (validation): 49/50 (98.0%); Lung Squamous Cell Carcinoma (validation): 65/68 (95.6%); Glioblastoma Multiforme (validation): 51/58 (87.9%),breast cancer: 0/10 (0.0%); cervical cancer: 0/12 (0.0%),31,20,O43184,https://www.uniprot.org/uniprotkb/O43184/entry,"Involved in skeletal muscle regeneration, specifically at the onset of cell fusion. Also involved in macrophage-derived giant cells (MGC) and osteoclast formation from mononuclear precursors (By similarity)","Isoform 1 is expressed in placenta and skeletal, cardiac, and smooth muscle. Isoform 2 seems to be expressed only in placenta or in embryo and fetus. Both forms were expressed in some tumor cells lines. Not detected in brain, lung, liver, kidney or pancreas",,,Cell membrane Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Bradley2020_CPA | Gong2021_reproductive_PC,No tumor-antigen validation in this source | Expression-nominated CPA; not newly validated by this study | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
ADAM20,ENSG00000134007,Unsafe,High RNA,False,True,5.1,5.1,86,6,Positive somewhere,False,False,False,True,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,CTA,Pass,oncoref.target-sets.2026-10-23.1,False,False,,CTA → Unsafe,True,True,True,1.7081693556200002,53.4,"hpa_single_cell: /Excitatory neurons, max 43.9 nTPM, 1 observations >30; hpa_single_cell: /Inhibitory neurons, max 35.8 nTPM, 1 observations >30; hpa_single_cell_tissue: brain/excitatory neurons, max 53.4 nTPM, 26 observations >30; hpa_single_cell_tissue: brain/inhibitory neurons, max 44.6 nTPM, 11 observations >30",CTA,oncoref.target-sets.2026-10-23.2,1.708 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,53.4 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 22/58 (37.9%); Pancreatic Adenocarcinoma (validation): 2/80 (2.5%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),breast cancer: 0/9 (0.0%); cervical cancer: 0/10 (0.0%),31,20,O43506,https://www.uniprot.org/uniprotkb/O43506/entry,May be involved in sperm maturation and/or fertilization,Testis specific,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Carter2023_CT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene,,,,,,,,
ADAM32,ENSG00000197140,Unsafe,High RNA,False,True,26.6,26.6,82,2,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,CTA,Pass,oncoref.target-sets.2026-10-23.1,False,False,,CTA → Unsafe,True,True,True,4.65687669324,50.1,"hpa_single_cell: /Excitatory neurons, max 36.1 nTPM, 1 observations >30; hpa_single_cell_tissue: brain/excitatory neurons, max 50.1 nTPM, 16 observations >30; hpa_single_cell_tissue: brain/inhibitory neurons, max 38.8 nTPM, 4 observations >30",CTA,oncoref.target-sets.2026-10-23.2,4.657 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,50.1 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 42/58 (72.4%); Pancreatic Adenocarcinoma (validation): 29/80 (36.2%); Breast Invasive Carcinoma (validation): 16/50 (32.0%),breast cancer: 0/10 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q8TC27,https://www.uniprot.org/uniprotkb/Q8TC27/entry,May play a role in sperm development and fertilization This is a non-catalytic metalloprotease-like protein,Testis specific,,,Membrane,,12568724,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
ADAMTS17,ENSG00000140470,Unsafe,RNA,False,True,2.7,10.4,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 1.1 nTPM; continuous selectivity; amygdala: 2 nTPM; continuous selectivity; basal ganglia: 1.8 nTPM; continuous selectivity; cerebral cortex: 1.6 nTPM; continuous selectivity; choroid plexus: 2.1 nTPM; absolute ceiling;continuous selectivity; esophagus: 2 nTPM; continuous selectivity; heart muscle: 1.2 nTPM; continuous selectivity; hippocampal formation: 1.4 nTPM; continuous selectivity; hypothalamus: 0.9 nTPM; continuous selectivity; kidney: 1 nTPM; continuous selectivity; liver: 7.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 1.4 nTPM; continuous selectivity; midbrain: 0.8 nTPM; continuous selectivity; pancreas: 4.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 1.2 nTPM; continuous selectivity; salivary gland: 2.5 nTPM; continuous selectivity; skeletal muscle: 5.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 2.1 nTPM; continuous selectivity; small intestine: 1.1 nTPM; continuous selectivity; thymus: 10.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 1.6 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 2.1 nTPM (limit 2); liver: 7.4 nTPM (limit 2); pancreas: 4.8 nTPM (limit 2); skeletal muscle: 5.4 nTPM (limit 2); thymus: 10.4 nTPM (limit 10); choroid plexus: 2.1 nTPM (baseline 2); liver: 7.4 nTPM (baseline 2); pancreas: 4.8 nTPM (baseline 2); skeletal muscle: 5.4 nTPM (baseline 2); thymus: 10.4 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 18/50 (36.0%); Liver Hepatocellular Carcinoma (validation): 43/231 (18.6%); Glioblastoma Multiforme (validation): 7/58 (12.1%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8TE56,https://www.uniprot.org/uniprotkb/Q8TE56/entry,"Extracellular metalloprotease that regulates skeletal development by modulating BMP-SMAD signaling and extracellular matrix microfibril organization, which controls chondrocyte differentiation and bone growth","Isoform 1 and isoform 2 are expressed at high levels in the lung, brain, whole eye and retina. Isoform 1 shows a weaker expression in the heart, kidney and skeletal muscle. Isoform 2 shows a weaker expression in the kidney, bone marrow and skeletal muscle. Isoform 1 and isoform 2 are expressed at high levels in the fetal heart, kidney, and whole eye, whereas a weak expression is seen in the fetal liver","Weill-Marchesani syndrome 4: An autosomal recessive syndrome characterized by lenticular myopia, ectopia lentis, glaucoma, spherophakia and short stature. Brachydactyly and decreased joint flexibility are present in some patients.",,"Secreted, extracellular space, extracellular matrix",,19836009,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ADAMTS20,ENSG00000173157,Unsafe,High RNA,False,True,0.5,0.6,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,retina: 0.6 nTPM; continuous selectivity;reproductive not higher,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,True,"brain/inhibitory neurons cluster c-5: 22.2 nTPM, 1972 reads; reproductive-cell max 9.7; brain/inhibitory neurons cluster c-6: 20.6 nTPM, 1070 reads; reproductive-cell max 9.7; brain/inhibitory neurons cluster c-8: 13.3 nTPM, 1109 reads; reproductive-cell max 9.7; brain/inhibitory neurons cluster c-21: 18.6 nTPM, 566 reads; reproductive-cell max 9.7; brain/inhibitory neurons cluster c-26: 25.3 nTPM, 566 reads; reproductive-cell max 9.7; brain/inhibitory neurons cluster c-28: 44.2 nTPM, 899 reads; reproductive-cell max 9.7; brain/inhibitory neurons cluster c-38: 100.2 nTPM, 1042 reads; reproductive-cell max 9.7; brain/oligodendrocyte precursor cells cluster c-42: 10.4 nTPM, 22 reads; reproductive-cell max 9.7",True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA027608; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA027608; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA027608; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA027608; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA027608; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Low, HPA027608; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA027608; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Medium, HPA027608; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA027608; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA027608; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA027608; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA027608; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: High, HPA027608; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA027608; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA027608; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA027608; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA027608; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA027608; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA027608; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA027608; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA027608; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA027608; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: High, HPA027608; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA027608; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA027608; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA027608; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA027608; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA027608; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA027608; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA027608; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA027608; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA027608; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA027608; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA027608; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA027608; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Low, HPA027608; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA027608; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA027608; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA027608; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: High, HPA027608; conflicting or uncurated primary profile; Adipose tissue/Adipocytes: Low, HPA027609; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA027609; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA027609; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA027609; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA027609; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA027609; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA027609; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Medium, HPA027609; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA027609; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA027609; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA027609; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA027609; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA027609; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA027609; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: High, HPA027609; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA027609; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: High, HPA027609; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: High, HPA027609; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA027609; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: High, HPA027609; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA027609; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA027609; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA027609; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA027609; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA027609; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA027609; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: High, HPA027609; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA027609; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA027609; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA027609; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA027609; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Low, HPA027609; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA027609; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA027609; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA027609; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA027609; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA027609; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA027609; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA027609; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA027609; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Low, HPA027609; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Low, HPA027609; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Medium, HPA027609; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA027609; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA027609; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA027609; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA027609; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,0.3,100.2,"hpa_single_cell_tissue: brain/inhibitory neurons, max 100.2 nTPM, 2 observations >30",Neither,oncoref.target-sets.2026-10-23.2,0.3 TPM; blood/T-reg; hpa_immune_monaco; vital,100.2 nTPM; brain/inhibitory neurons; hpa_single_cell_tissue; vital,Lung Squamous Cell Carcinoma (validation): 6/68 (8.8%); Glioblastoma Multiforme (validation): 4/58 (6.9%); Testicular Germ Cell Tumor (TCGA): 5/133 (3.8%),testis cancer: 11/12 (91.7%); pancreatic cancer: 10/12 (83.3%),31,20,,,,,,,,,,False,No exact Ensembl mapping to a reviewed UniProt entry,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
ADAMTS6,ENSG00000049192,Unsafe,High RNA,False,True,1.8,1.8,84,4,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,True,"brain/inhibitory neurons cluster c-14: 162.8 nTPM, 6452 reads; reproductive-cell max 141.8; brain/inhibitory neurons cluster c-23: 155.5 nTPM, 3613 reads; reproductive-cell max 141.8; brain/inhibitory neurons cluster c-25: 243.5 nTPM, 4551 reads; reproductive-cell max 141.8",True,True,"DICE B_CELL_NAIVE (unstimulated): 40/91 values ≥5 TPM, max 8.40812; DICE CD4_NAIVE (unstimulated): 14/88 values ≥5 TPM, max 8.10795; DICE CD8_NAIVE (unstimulated): 65/89 values ≥5 TPM, max 10.4474",True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,10.4473823972,243.5,"hpa_single_cell: /Inhibitory neurons, max 60.6 nTPM, 1 observations >30; hpa_single_cell: /Lymphatic endothelial cells, max 73.5 nTPM, 1 observations >30; hpa_single_cell: /Microglial cells, max 30.4 nTPM, 1 observations >30; hpa_single_cell: /Oligodendrocyte precursor cells, max 131.1 nTPM, 1 observations >30; hpa_single_cell_tissue: adipose tissue/fibroblasts, max 39 nTPM, 1 observations >30; hpa_single_cell_tissue: brain/excitatory neurons, max 106 nTPM, 6 observations >30; hpa_single_cell_tissue: brain/inhibitory neurons, max 243.5 nTPM, 7 observations >30; hpa_single_cell_tissue: brain/microglial cells, max 30.4 nTPM, 1 observations >30; hpa_single_cell_tissue: brain/oligodendrocyte precursor cells, max 131.1 nTPM, 1 observations >30; hpa_single_cell_tissue: eye/muller glia cells, max 44.9 nTPM, 2 observations >30; hpa_single_cell_tissue: liver/b-cells, max 33.8 nTPM, 1 observations >30; hpa_single_cell_tissue: pancreas/fibroblasts, max 50.3 nTPM, 1 observations >30; hpa_single_cell_tissue: placenta/mixed immune cells, max 44.6 nTPM, 1 observations >30; hpa_single_cell_tissue: vascular/endothelial cells, max 90.9 nTPM, 2 observations >30",CTA,oncoref.target-sets.2026-10-23.2,10.45 TPM; blood/CD8_NAIVE; dice_cd8_naive; vital,243.5 nTPM; brain/inhibitory neurons; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 55/58 (94.8%); Pancreatic Adenocarcinoma (validation): 51/80 (63.7%); Breast Invasive Carcinoma (validation): 22/50 (44.0%),pancreatic cancer: 1/8 (12.5%); breast cancer: 0/11 (0.0%),31,20,Q9UKP5,https://www.uniprot.org/uniprotkb/Q9UKP5/entry,,Expressed at low levels in placenta and barely detectable in a number of other tissues,,,"Secreted, extracellular space, extracellular matrix",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ADCY10,ENSG00000143199,Unsafe,Protein,False,True,17.1,17.1,84,41,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 0.2 nTPM; positive ihc; cerebral cortex: 0.4 nTPM; positive ihc; colon: 0.2 nTPM; positive ihc; duodenum: 0.3 nTPM; positive ihc; esophagus: 0.1 nTPM; positive ihc; kidney: 0.4 nTPM; positive ihc; liver: 5.9 nTPM; absolute ceiling;continuous selectivity; lung: 0.2 nTPM; positive ihc; pancreas: 0.4 nTPM; positive ihc; rectum: 0.1 nTPM; positive ihc; salivary gland: 0.1 nTPM; positive ihc; skeletal muscle: 0.1 nTPM; positive ihc; skin: 0.1 nTPM; positive ihc; small intestine: 0.2 nTPM; positive ihc; stomach: 0.2 nTPM; positive ihc; thyroid gland: 0.1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",liver: 5.9 nTPM (limit 4),adrenal gland / glandular cells: Low (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / neuronal cells: Low (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Low (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in tubules: Medium (Approved); lung / macrophages: Low (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / keratinocytes: Low (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Medium (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Low (Approved); thyroid gland / glandular cells: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (TCGA): 85/362 (23.5%); Liver Hepatocellular Carcinoma (validation): 31/231 (13.4%); Breast Invasive Carcinoma (validation): 2/50 (4.0%),endometrial cancer: 2/12 (16.7%); glioma: 2/12 (16.7%),31,20,Q96PN6,https://www.uniprot.org/uniprotkb/Q96PN6/entry,"Catalyzes the formation of the signaling molecule cAMP (PubMed:12609998, PubMed:15659711, PubMed:24567411, PubMed:24616449, PubMed:25040695). May function as sensor that mediates responses to changes in cellular bicarbonate and CO(2) levels (PubMed:15659711, PubMed:17591988). Has a critical role in mammalian spermatogenesis by producing the cAMP which regulates cAMP-responsive nuclear factors indispensable for sperm maturation in the epididymis. Induces capacitation, the maturational process that sperm undergo prior to fertilization (By similarity). Involved in ciliary beat regulation (PubMed:17591988)","Detected in airway epithelial cells and testis (at protein level) (PubMed:17591988). Weakly expressed in multiple tissues. Expressed in brain, heart, kidney, liver, lung, pancreas, peripheral blood leukocytes, placenta, skeletal muscle, stomach, thymus, airway epithelial cells, duodenum, jejunum and ileum. Very low level of expression in bone","Hypercalciuria absorptive 2: A common type of hypercalciuria, a condition characterized by excessive urinary calcium excretion. Absorptive hypercalciuria is due to gastrointestinal hyperabsorption of calcium and is a frequent cause of calcium oxalate nephrolithiasis.",,"Cell membrane Cytoplasm, cytoskeleton Cytoplasm, perinuclear region Nucleus Cell projection, cilium Cytoplasm Mitochondrion",15659711|17591988|24567411|24616449|25040695,11932268|15659711|17591988,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
ADGB,ENSG00000118492,Unsafe,Protein,False,True,25.4,25.4,101,17,Positive somewhere,True,True,False,True,Excluded,Normal,False,,Not assessed,,,positive ihc outside permitted; choroid plexus: 4.8 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 4.8 nTPM (limit 2),bronchus / ciliated cells (cell body): Medium (Enhanced); bronchus / ciliated cells (cilia axoneme): High (Enhanced); bronchus / ciliated cells (tip of cilia): High (Enhanced); nasopharynx / ciliated cells (cell body): Low (Enhanced); nasopharynx / ciliated cells (cilia axoneme): High (Enhanced); nasopharynx / ciliated cells (tip of cilia): High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 11/176 (6.2%); Glioblastoma Multiforme (validation): 2/58 (3.4%); Ovary Serous Cystadenocarcinoma (validation): 1/81 (1.2%),renal cancer: 3/11 (27.3%); testis cancer: 2/9 (22.2%),29,20,Q8N7X0,https://www.uniprot.org/uniprotkb/Q8N7X0/entry,"Probable chimeric globin with a bis-histidyl six-coordinate heme-iron atom through which it could bind dioxygen, carbon monoxide and nitric oxide (PubMed:22115833). Required for sperm flagellum formation and maturation of elongating spermatids, thus playing an essential role in male fertility (PubMed:36995441)",,,The calpain domain lacks the conserved active site residues. Probably catalytically inactive as a calcium-dependent cysteine-type endopeptidase,"Cell projection, cilium, flagellum",22115833|36995441,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
ADORA2A,ENSG00000128271,Unsafe,Protein,False,True,5.3,111.0,124,18,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 3.3 nTPM; continuous selectivity; adrenal gland: 5.2 nTPM; absolute ceiling;continuous selectivity; amygdala: 6.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 111 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 40.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 9.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 7.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 1.9 nTPM; continuous selectivity; colon: 4 nTPM; positive ihc;continuous selectivity; duodenum: 6.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 1.9 nTPM; continuous selectivity; heart muscle: 13.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 8.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 7.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 16.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 14.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 14.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 20 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 7.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 2.2 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 6.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 1 nTPM; positive ihc; retina: 2 nTPM; continuous selectivity; salivary gland: 3.1 nTPM; continuous selectivity; skeletal muscle: 2.4 nTPM; absolute ceiling;continuous selectivity; small intestine: 6.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 4.5 nTPM; absolute ceiling;continuous selectivity; spleen: 14.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; stomach: 3.8 nTPM; continuous selectivity; thymus: 52.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 4.2 nTPM; continuous selectivity; urinary bladder: 5.1 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 6.8 nTPM (limit 2); basal ganglia: 111 nTPM (limit 2); bone marrow: 40.1 nTPM (limit 2); cerebellum: 9.8 nTPM (limit 2); duodenum: 6.4 nTPM (limit 2); heart muscle: 13.1 nTPM (limit 12); hippocampal formation: 8.1 nTPM (limit 2); hypothalamus: 7.1 nTPM (limit 2); kidney: 16.9 nTPM (limit 2); liver: 14.2 nTPM (limit 12); lung: 14.1 nTPM (limit 12); lymph node: 20 nTPM (limit 6); midbrain: 7.5 nTPM (limit 2); pituitary gland: 6.5 nTPM (limit 2); small intestine: 6.8 nTPM (limit 2); spinal cord: 4.5 nTPM (limit 2); thymus: 52.7 nTPM (limit 10); adrenal gland: 5.2 nTPM (baseline 2); amygdala: 6.8 nTPM (baseline 2); basal ganglia: 111 nTPM (baseline 2); bone marrow: 40.1 nTPM (baseline 2); cerebellum: 9.8 nTPM (baseline 2); cerebral cortex: 7.7 nTPM (baseline 2); duodenum: 6.4 nTPM (baseline 2); heart muscle: 13.1 nTPM (baseline 2); hippocampal formation: 8.1 nTPM (baseline 2); hypothalamus: 7.1 nTPM (baseline 2); kidney: 16.9 nTPM (baseline 2); liver: 14.2 nTPM (baseline 2); lung: 14.1 nTPM (baseline 2); lymph node: 20 nTPM (baseline 6); midbrain: 7.5 nTPM (baseline 2); pancreas: 2.2 nTPM (baseline 2); pituitary gland: 6.5 nTPM (baseline 2); skeletal muscle: 2.4 nTPM (baseline 2); small intestine: 6.8 nTPM (baseline 2); spinal cord: 4.5 nTPM (baseline 2); spleen: 14.8 nTPM (baseline 10); thymus: 52.7 nTPM (baseline 10),bone marrow / hematopoietic cells: Medium (Enhanced); caudate / neuronal cells: Medium (Enhanced); caudate / neuronal projections: High (Enhanced); caudate / synapses: High (Enhanced); cerebellum / molecular layer cells - cytoplasm/membrane: Medium (Enhanced); cerebellum / processes in white matter: Medium (Enhanced); cerebellum / Purkinje cells - cytoplasm/membrane: Low (Enhanced); colon / endocrine cells: High (Enhanced); duodenum / endocrine cells: High (Enhanced); kidney / cells in glomeruli: Medium (Enhanced); kidney / proximal tubules (cell body): Medium (Enhanced); lymph node / non-germinal center cells: Medium (Enhanced); rectum / endocrine cells: High (Enhanced); small intestine / endocrine cells: High (Enhanced); thymus / cortical cells: Medium (Enhanced); thymus / medullary cells: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 121/133 (91.0%); Breast Invasive Carcinoma (validation): 45/50 (90.0%); Kidney Renal Clear Cell Carcinoma (validation): 88/100 (88.0%),ovarian cancer: 1/12 (8.3%); breast cancer: 0/12 (0.0%),31,20,P29274,https://www.uniprot.org/uniprotkb/P29274/entry,Receptor for adenosine (By similarity). The activity of this receptor is mediated by G proteins which activate adenylyl cyclase (By similarity),,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
AFF4,ENSG00000072364,Unsafe,Protein,False,True,25.8,45.9,91,66,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 20.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 27.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 10.5 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 12.1 nTPM; absolute ceiling;continuous selectivity; bone marrow: 43 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 19.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 20 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 8.3 nTPM; absolute ceiling;continuous selectivity; colon: 17.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 14 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 25.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 15.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 10.6 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 12.2 nTPM; absolute ceiling;continuous selectivity; kidney: 23.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 20.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 19.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 15.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 10.2 nTPM; absolute ceiling;continuous selectivity; pancreas: 24.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 35.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 19 nTPM; absolute ceiling;continuous selectivity; rectum: 17 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 45.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 18.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 24.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 17.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 14.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 22.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 12.6 nTPM; absolute ceiling;continuous selectivity; spleen: 16.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 24.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 18.5 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 32.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; tongue: 24.6 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 22.2 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 20.7 nTPM (limit 10); adrenal gland: 27.4 nTPM (limit 2); amygdala: 10.5 nTPM (limit 2); basal ganglia: 12.1 nTPM (limit 2); bone marrow: 43 nTPM (limit 2); cerebellum: 19.1 nTPM (limit 2); cerebral cortex: 20 nTPM (limit 2); choroid plexus: 8.3 nTPM (limit 2); colon: 17.8 nTPM (limit 6); duodenum: 14 nTPM (limit 2); esophagus: 25.9 nTPM (limit 6); heart muscle: 15.9 nTPM (limit 2); hippocampal formation: 10.6 nTPM (limit 2); hypothalamus: 12.2 nTPM (limit 2); kidney: 23.4 nTPM (limit 2); liver: 20.5 nTPM (limit 2); lung: 19.1 nTPM (limit 2); lymph node: 15.1 nTPM (limit 6); midbrain: 10.2 nTPM (limit 2); pancreas: 24.1 nTPM (limit 2); parathyroid gland: 35.1 nTPM (limit 6); pituitary gland: 19 nTPM (limit 2); rectum: 17 nTPM (limit 6); retina: 45.9 nTPM (limit 2); salivary gland: 18.5 nTPM (limit 6); skeletal muscle: 24.5 nTPM (limit 2); skin: 17.9 nTPM (limit 10); small intestine: 14.6 nTPM (limit 2); smooth muscle: 22.8 nTPM (limit 2); spinal cord: 12.6 nTPM (limit 2); spleen: 16.4 nTPM (limit 10); stomach: 24.5 nTPM (limit 6); thymus: 18.5 nTPM (limit 10); thyroid gland: 32.2 nTPM (limit 10); tongue: 24.6 nTPM (limit 6); urinary bladder: 22.2 nTPM (limit 6),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / ciliated cells (cell body): Low (Approved); caudate / glial cells: High (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: High (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: High (Approved); cerebral cortex / neuronal cells: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Low (Approved); duodenum / glandular cells: Low (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: High (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Low (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Low (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Low (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Low (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Low (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Low (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%),glioma: 10/12 (83.3%); skin cancer: 6/11 (54.5%),31,20,Q9UHB7,https://www.uniprot.org/uniprotkb/Q9UHB7/entry,"Key component of the super elongation complex (SEC), a complex required to increase the catalytic rate of RNA polymerase II transcription by suppressing transient pausing by the polymerase at multiple sites along the DNA. In the SEC complex, AFF4 acts as a central scaffold that recruits other factors through direct interactions with ELL proteins (ELL, ELL2 or ELL3) and the P-TEFb complex. In case of infection by HIV-1 virus, the SEC complex is recruited by the viral Tat protein to stimulate viral gene expression","Ubiquitously expressed. Strongly expressed in heart, placenta, skeletal muscle, pancreas and to a lower extent in brain","CHOPS syndrome: A syndrome characterized by cognitive impairment, coarse facies, heart defects, obesity, pulmonary involvement, short stature, and skeletal dysplasia.",,Nucleus Chromosome,20159561|20471948|23251033,10588740|12065898,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
AFG1L,ENSG00000135537,Unsafe,Protein,False,True,10.4,10.4,101,63,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 2 nTPM; positive ihc; bone marrow: 2.1 nTPM; positive ihc;absolute ceiling; cerebellum: 1.3 nTPM; positive ihc; cerebral cortex: 2.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 2.7 nTPM; absolute ceiling; colon: 2.4 nTPM; positive ihc; duodenum: 4.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 1.5 nTPM; positive ihc; heart muscle: 4.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; kidney: 4.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 3.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 1.7 nTPM; positive ihc; pancreas: 2 nTPM; positive ihc; parathyroid gland: 5.1 nTPM; continuous selectivity; rectum: 3 nTPM; positive ihc; retina: 2.9 nTPM; absolute ceiling;continuous selectivity; salivary gland: 1.7 nTPM; positive ihc; skeletal muscle: 3.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 1.1 nTPM; positive ihc; small intestine: 2.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 1.7 nTPM; positive ihc; spleen: 2 nTPM; positive ihc; stomach: 2.6 nTPM; positive ihc; thyroid gland: 2.9 nTPM; positive ihc; tongue: 3.9 nTPM; continuous selectivity; urinary bladder: 1.6 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 2.1 nTPM (limit 2); cerebral cortex: 2.8 nTPM (limit 2); choroid plexus: 2.7 nTPM (limit 2); duodenum: 4.1 nTPM (limit 2); heart muscle: 4.3 nTPM (limit 2); kidney: 4.8 nTPM (limit 2); liver: 3.6 nTPM (limit 2); retina: 2.9 nTPM (limit 2); skeletal muscle: 3.5 nTPM (limit 2); small intestine: 2.9 nTPM (limit 2),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / ciliated cells (cell body): High (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Medium (Approved); liver / hepatocytes: Low (Approved); lung / macrophages: Medium (Approved); nasopharynx / ciliated cells (cell body): High (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Low (Approved); pancreas / pancreatic endocrine cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Low (Approved); skin 1 / keratinocytes: Low (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Low (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 55/58 (94.8%); Colon Adenocarcinoma (validation): 333/486 (68.5%); Rectum Adenocarcinoma (validation): 110/207 (53.1%),breast cancer: 9/12 (75.0%); ovarian cancer: 7/12 (58.3%),29,20,Q8WV93,https://www.uniprot.org/uniprotkb/Q8WV93/entry,"Putative mitochondrial ATPase. Plays a role in mitochondrial morphology and mitochondrial protein metabolism. Promotes degradation of excess nuclear-encoded complex IV subunits (COX4I1, COX5A and COX6A1) and normal activity of complexes III and IV of the respiratory chain (PubMed:26759378, PubMed:27323408). Mediates mitochondrial translocation of TP53 and its transcription-independent apoptosis in response to genotoxic stress (PubMed:27323408)",,,,Mitochondrion membrane,26759378|27323408,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
AFG2A,ENSG00000145375,Unsafe,Protein,False,True,3.5,3.5,81,61,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 0.8 nTPM; positive ihc; bone marrow: 1.4 nTPM; positive ihc;continuous selectivity; cerebellum: 0.8 nTPM; positive ihc; cerebral cortex: 0.8 nTPM; positive ihc; colon: 1 nTPM; positive ihc; duodenum: 0.7 nTPM; positive ihc; esophagus: 1 nTPM; positive ihc; heart muscle: 0.8 nTPM; positive ihc; kidney: 1.1 nTPM; positive ihc;continuous selectivity; liver: 1.1 nTPM; positive ihc;continuous selectivity; lung: 0.9 nTPM; positive ihc; lymph node: 1.2 nTPM; positive ihc; pancreas: 0.8 nTPM; positive ihc; parathyroid gland: 1.5 nTPM; positive ihc;continuous selectivity; rectum: 1.2 nTPM; positive ihc; retina: 2.2 nTPM; absolute ceiling;continuous selectivity; salivary gland: 1.1 nTPM; positive ihc; skeletal muscle: 1.3 nTPM; continuous selectivity; skin: 1.2 nTPM; positive ihc; small intestine: 0.7 nTPM; positive ihc; spleen: 1.2 nTPM; positive ihc; stomach: 2.3 nTPM; positive ihc;continuous selectivity; thymus: 2 nTPM; continuous selectivity; thyroid gland: 1.5 nTPM; positive ihc; urinary bladder: 1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",retina: 2.2 nTPM (limit 2),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Low (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: High (Approved); pancreas / exocrine glandular cells: High (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: High (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Pancreatic Adenocarcinoma (validation): 77/80 (96.2%); Colon Adenocarcinoma (validation): 415/486 (85.4%),glioma: 12/12 (100.0%); testis cancer: 11/11 (100.0%),31,20,Q8NB90,https://www.uniprot.org/uniprotkb/Q8NB90/entry,"ATP-dependent chaperone part of the 55LCC heterohexameric ATPase complex which is chromatin-associated and promotes replisome proteostasis to maintain replication fork progression and genome stability. Required for replication fork progression, sister chromatid cohesion, and chromosome stability. The ATPase activity is specifically enhanced by replication fork DNA and is coupled to cysteine protease-dependent cleavage of replisome substrates in response to replication fork damage. Uses ATPase activity to process replisome substrates in S-phase, facilitating their proteolytic turnover from chromatin to ensure DNA replication and mitotic fidelity (PubMed:38554706). Plays an essential role in the cytoplasmic maturation steps of pre-60S ribosomal particles by promoting the release of shuttling protein RSL24D1/RLP24 from the pre-ribosomal particles (PubMed:35354024, PubMed:38554706). May be involved in morphological and functional mitochondrial transformations during spermatogenesis (By similarity)",,"Neurodevelopmental disorder with hearing loss, seizures, and brain abnormalities: An autosomal recessive disorder characterized by intellectual disability, intractable epilepsy, microcephaly, abnormal muscle tone, and sensorineural hearing loss.",,"Cytoplasm Mitochondrion Cytoplasm, cytoskeleton, spindle",35354024|38554706,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
AGBL2,ENSG00000165923,Unsafe,Protein,False,True,12.0,12.0,73,73,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0.3 nTPM; positive ihc; adrenal gland: 1.3 nTPM; positive ihc; bone marrow: 0.2 nTPM; positive ihc; cerebellum: 1 nTPM; positive ihc; cerebral cortex: 0.2 nTPM; positive ihc; colon: 0.8 nTPM; positive ihc; duodenum: 0.3 nTPM; positive ihc; esophagus: 0.4 nTPM; positive ihc; heart muscle: 0.2 nTPM; positive ihc; kidney: 1.5 nTPM; positive ihc; liver: 2.9 nTPM; positive ihc;absolute ceiling; lung: 1.5 nTPM; positive ihc; lymph node: 0.5 nTPM; positive ihc; pancreas: 0.8 nTPM; positive ihc; parathyroid gland: 0.3 nTPM; positive ihc; rectum: 0.2 nTPM; positive ihc; salivary gland: 0.5 nTPM; positive ihc; skeletal muscle: 0 nTPM; positive ihc; skin: 0.3 nTPM; positive ihc; small intestine: 1.2 nTPM; positive ihc; smooth muscle: 0.1 nTPM; positive ihc; spleen: 0.8 nTPM; positive ihc; stomach: 0.6 nTPM; positive ihc; thyroid gland: 1.4 nTPM; positive ihc; urinary bladder: 1.1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",liver: 2.9 nTPM (limit 2); liver: 2.9 nTPM (baseline 2),adipose tissue / adipocytes: Low (Uncertain); adrenal gland / glandular cells: High (Uncertain); bone marrow / hematopoietic cells: High (Uncertain); caudate / glial cells: High (Uncertain); caudate / neuronal cells: High (Uncertain); cerebellum / cells in granular layer: High (Uncertain); cerebellum / cells in molecular layer: High (Uncertain); cerebellum / Purkinje cells: High (Uncertain); cerebral cortex / endothelial cells: High (Uncertain); cerebral cortex / glial cells: High (Uncertain); cerebral cortex / neuronal cells: High (Uncertain); cerebral cortex / neuropil: Medium (Uncertain); colon / endothelial cells: Medium (Uncertain); colon / glandular cells: High (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: High (Uncertain); heart muscle / cardiomyocytes: High (Uncertain); hippocampus / glial cells: High (Uncertain); hippocampus / neuronal cells: High (Uncertain); kidney / cells in glomeruli: Medium (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / cholangiocytes: Medium (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / alveolar cells: Medium (Uncertain); lung / macrophages: High (Uncertain); lymph node / germinal center cells: High (Uncertain); lymph node / non-germinal center cells: High (Uncertain); nasopharynx / respiratory epithelial cells: High (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: High (Uncertain); pancreas / pancreatic endocrine cells: High (Uncertain); parathyroid gland / glandular cells: High (Uncertain); rectum / glandular cells: High (Uncertain); salivary gland / glandular cells: High (Uncertain); skeletal muscle / myocytes: High (Uncertain); skin 1 / fibroblasts: High (Uncertain); skin 1 / keratinocytes: High (Uncertain); skin 1 / Langerhans: High (Uncertain); small intestine / glandular cells: Medium (Uncertain); smooth muscle / smooth muscle cells: High (Uncertain); spleen / cells in red pulp: High (Uncertain); spleen / cells in white pulp: High (Uncertain); stomach 1 / glandular cells: High (Uncertain); stomach 2 / glandular cells: High (Uncertain); thyroid gland / glandular cells: High (Uncertain); urinary bladder / urothelial cells: High (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 28/50 (56.0%); Ovary Serous Cystadenocarcinoma (validation): 12/81 (14.8%); Liver Hepatocellular Carcinoma (validation): 31/231 (13.4%),breast cancer: 12/12 (100.0%); cervical cancer: 12/12 (100.0%),31,20,Q5U5Z8,https://www.uniprot.org/uniprotkb/Q5U5Z8/entry,"Metallocarboxypeptidase that mediates deglutamylation of tubulin and non-tubulin target proteins. Catalyzes the removal of polyglutamate side chains present on the gamma-carboxyl group of glutamate residues within the C-terminal tail of tubulin protein. Specifically cleaves tubulin long-side-chains, while it is not able to remove the branching point glutamate. Also catalyzes the removal of polyglutamate residues from the carboxy-terminus of non-tubulin proteins such as MYLK",,,"Was initially shown to catalyze the removal of carboxy-terminus tyrosine from alpha-tubulin (PubMed:21303978). However, later studies did not identified any detyrosinase or deglycylase activities from the carboxy-terminus of tubulin (By similarity) Was originally thought to have detyrosinating activity from C-terminal positions on tubulin","Cytoplasm, cytosol Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriole Cytoplasm, cytoskeleton, cilium basal body",,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
AGBL5,ENSG00000084693,Unsafe,Protein,False,True,187.3,187.3,79,69,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 8.5 nTPM; positive ihc; adrenal gland: 16.2 nTPM; positive ihc;absolute ceiling; amygdala: 7.3 nTPM; absolute ceiling; basal ganglia: 7.7 nTPM; absolute ceiling; bone marrow: 13.4 nTPM; positive ihc;absolute ceiling; cerebellum: 5.6 nTPM; positive ihc;absolute ceiling; cerebral cortex: 8 nTPM; positive ihc;absolute ceiling; choroid plexus: 14.5 nTPM; absolute ceiling; colon: 15.6 nTPM; positive ihc;absolute ceiling; duodenum: 8.6 nTPM; positive ihc;absolute ceiling; esophagus: 17.7 nTPM; positive ihc;absolute ceiling; heart muscle: 12.2 nTPM; positive ihc;absolute ceiling; hippocampal formation: 6.4 nTPM; absolute ceiling; hypothalamus: 7.2 nTPM; absolute ceiling; kidney: 21.7 nTPM; positive ihc;absolute ceiling; liver: 7 nTPM; positive ihc;absolute ceiling; lung: 10.8 nTPM; positive ihc;absolute ceiling; lymph node: 10.4 nTPM; positive ihc;absolute ceiling; midbrain: 7 nTPM; absolute ceiling; pancreas: 14.5 nTPM; positive ihc;absolute ceiling; parathyroid gland: 48.3 nTPM; positive ihc;absolute ceiling; pituitary gland: 12.2 nTPM; absolute ceiling; rectum: 11.1 nTPM; positive ihc;absolute ceiling; retina: 15.8 nTPM; absolute ceiling; salivary gland: 20.6 nTPM; positive ihc;absolute ceiling; skeletal muscle: 6.8 nTPM; positive ihc;absolute ceiling; skin: 19.9 nTPM; positive ihc;absolute ceiling; small intestine: 9.6 nTPM; positive ihc;absolute ceiling; smooth muscle: 14.1 nTPM; absolute ceiling; spinal cord: 6.9 nTPM; absolute ceiling; stomach: 11.4 nTPM; positive ihc;absolute ceiling; thymus: 15.1 nTPM; absolute ceiling; thyroid gland: 27.7 nTPM; positive ihc;absolute ceiling; tongue: 6.3 nTPM; absolute ceiling; urinary bladder: 14.4 nTPM; positive ihc;absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 16.2 nTPM (limit 2); amygdala: 7.3 nTPM (limit 2); basal ganglia: 7.7 nTPM (limit 2); bone marrow: 13.4 nTPM (limit 2); cerebellum: 5.6 nTPM (limit 2); cerebral cortex: 8 nTPM (limit 2); choroid plexus: 14.5 nTPM (limit 2); colon: 15.6 nTPM (limit 6); duodenum: 8.6 nTPM (limit 2); esophagus: 17.7 nTPM (limit 6); heart muscle: 12.2 nTPM (limit 2); hippocampal formation: 6.4 nTPM (limit 2); hypothalamus: 7.2 nTPM (limit 2); kidney: 21.7 nTPM (limit 2); liver: 7 nTPM (limit 2); lung: 10.8 nTPM (limit 2); lymph node: 10.4 nTPM (limit 6); midbrain: 7 nTPM (limit 2); pancreas: 14.5 nTPM (limit 2); parathyroid gland: 48.3 nTPM (limit 6); pituitary gland: 12.2 nTPM (limit 2); rectum: 11.1 nTPM (limit 6); retina: 15.8 nTPM (limit 2); salivary gland: 20.6 nTPM (limit 6); skeletal muscle: 6.8 nTPM (limit 2); skin: 19.9 nTPM (limit 10); small intestine: 9.6 nTPM (limit 2); smooth muscle: 14.1 nTPM (limit 2); spinal cord: 6.9 nTPM (limit 2); stomach: 11.4 nTPM (limit 6); thymus: 15.1 nTPM (limit 10); thyroid gland: 27.7 nTPM (limit 10); tongue: 6.3 nTPM (limit 6); urinary bladder: 14.4 nTPM (limit 6); adrenal gland: 16.2 nTPM (baseline 2); amygdala: 7.3 nTPM (baseline 2); basal ganglia: 7.7 nTPM (baseline 2); bone marrow: 13.4 nTPM (baseline 2); cerebellum: 5.6 nTPM (baseline 2); cerebral cortex: 8 nTPM (baseline 2); choroid plexus: 14.5 nTPM (baseline 2); colon: 15.6 nTPM (baseline 6); duodenum: 8.6 nTPM (baseline 2); esophagus: 17.7 nTPM (baseline 6); heart muscle: 12.2 nTPM (baseline 2); hippocampal formation: 6.4 nTPM (baseline 2); hypothalamus: 7.2 nTPM (baseline 2); kidney: 21.7 nTPM (baseline 2); liver: 7 nTPM (baseline 2); lung: 10.8 nTPM (baseline 2); lymph node: 10.4 nTPM (baseline 6); midbrain: 7 nTPM (baseline 2); pancreas: 14.5 nTPM (baseline 2); parathyroid gland: 48.3 nTPM (baseline 6); pituitary gland: 12.2 nTPM (baseline 2); rectum: 11.1 nTPM (baseline 6); retina: 15.8 nTPM (baseline 2); salivary gland: 20.6 nTPM (baseline 6); skeletal muscle: 6.8 nTPM (baseline 2); skin: 19.9 nTPM (baseline 10); small intestine: 9.6 nTPM (baseline 2); smooth muscle: 14.1 nTPM (baseline 2); spinal cord: 6.9 nTPM (baseline 2); stomach: 11.4 nTPM (baseline 6); thymus: 15.1 nTPM (baseline 10); thyroid gland: 27.7 nTPM (baseline 10); tongue: 6.3 nTPM (baseline 6); urinary bladder: 14.4 nTPM (baseline 6),adipose tissue / adipocytes: High (Uncertain); adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); cerebellum / cells in granular layer: Medium (Uncertain); cerebellum / cells in molecular layer: Medium (Uncertain); cerebral cortex / endothelial cells: Medium (Uncertain); cerebral cortex / neuropil: High (Uncertain); colon / endothelial cells: Medium (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: Medium (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: Low (Uncertain); kidney / cells in glomeruli: Low (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / cholangiocytes: Medium (Uncertain); liver / hepatocytes: Low (Uncertain); lung / alveolar cells: Medium (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / germinal center cells: Low (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); nasopharynx / respiratory epithelial cells: High (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: Low (Uncertain); skin 1 / fibroblasts: High (Uncertain); skin 1 / keratinocytes: Low (Uncertain); skin 1 / Langerhans: Low (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: Medium (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Squamous Cell Carcinoma (TCGA): 489/489 (100.0%); Colon Adenocarcinoma (validation): 486/486 (100.0%); Ovary Serous Cystadenocarcinoma (TCGA): 349/349 (100.0%),colorectal cancer: 12/12 (100.0%); melanoma: 11/11 (100.0%),31,20,Q8NDL9,https://www.uniprot.org/uniprotkb/Q8NDL9/entry,"Metallocarboxypeptidase that mediates deglutamylation of tubulin and non-tubulin target proteins. Catalyzes the removal of polyglutamate side chains present on the gamma-carboxyl group of glutamate residues within the C-terminal tail of alpha- and beta-tubulin. Cleaves alpha- and gamma-linked polyglutamate tubulin side-chain, as well as the branching point glutamate. Also catalyzes the removal of alpha-linked glutamate residues from the carboxy-terminus of alpha-tubulin. Mediates deglutamylation of nucleotidyltransferase CGAS, leading to CGAS antiviral defense response activation",Expressed in brain,"Retinitis pigmentosa 75: A form of retinitis pigmentosa, a retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. RP75 inheritance is autosomal recessive.",,"Cytoplasm, cytosol Nucleus Cytoplasm, cytoskeleton, spindle Midbody",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
AHCTF1,ENSG00000153207,Unsafe,Protein,False,True,31.5,31.5,78,75,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 12.2 nTPM; positive ihc;absolute ceiling; adrenal gland: 7.2 nTPM; positive ihc;absolute ceiling; amygdala: 3.2 nTPM; absolute ceiling; basal ganglia: 3.8 nTPM; absolute ceiling; bone marrow: 16.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 8.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 6.6 nTPM; positive ihc;absolute ceiling; choroid plexus: 4.9 nTPM; absolute ceiling; colon: 8.8 nTPM; positive ihc;absolute ceiling; duodenum: 6.4 nTPM; positive ihc;absolute ceiling; esophagus: 8.9 nTPM; positive ihc;absolute ceiling; heart muscle: 6.4 nTPM; positive ihc;absolute ceiling; hippocampal formation: 3.2 nTPM; absolute ceiling; hypothalamus: 3.3 nTPM; absolute ceiling; kidney: 9.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 10.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 6.9 nTPM; positive ihc;absolute ceiling; lymph node: 8.9 nTPM; positive ihc;absolute ceiling; midbrain: 3.1 nTPM; absolute ceiling; pancreas: 9.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 12.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 6.2 nTPM; absolute ceiling; rectum: 6.7 nTPM; positive ihc;absolute ceiling; retina: 7.8 nTPM; absolute ceiling; salivary gland: 6.6 nTPM; positive ihc;absolute ceiling; skeletal muscle: 10.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 7.8 nTPM; positive ihc; small intestine: 6.4 nTPM; positive ihc;absolute ceiling; smooth muscle: 7.6 nTPM; positive ihc;absolute ceiling; spinal cord: 3.2 nTPM; absolute ceiling; spleen: 9 nTPM; positive ihc; stomach: 8.3 nTPM; positive ihc;absolute ceiling; thymus: 11.9 nTPM; absolute ceiling; thyroid gland: 13.3 nTPM; positive ihc;absolute ceiling; tongue: 15.1 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 9.9 nTPM; positive ihc;absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 12.2 nTPM (limit 10); adrenal gland: 7.2 nTPM (limit 2); amygdala: 3.2 nTPM (limit 2); basal ganglia: 3.8 nTPM (limit 2); bone marrow: 16.7 nTPM (limit 2); cerebellum: 8.2 nTPM (limit 2); cerebral cortex: 6.6 nTPM (limit 2); choroid plexus: 4.9 nTPM (limit 2); colon: 8.8 nTPM (limit 6); duodenum: 6.4 nTPM (limit 2); esophagus: 8.9 nTPM (limit 6); heart muscle: 6.4 nTPM (limit 2); hippocampal formation: 3.2 nTPM (limit 2); hypothalamus: 3.3 nTPM (limit 2); kidney: 9.4 nTPM (limit 2); liver: 10.6 nTPM (limit 2); lung: 6.9 nTPM (limit 2); lymph node: 8.9 nTPM (limit 6); midbrain: 3.1 nTPM (limit 2); pancreas: 9.6 nTPM (limit 2); parathyroid gland: 12.7 nTPM (limit 6); pituitary gland: 6.2 nTPM (limit 2); rectum: 6.7 nTPM (limit 6); retina: 7.8 nTPM (limit 2); salivary gland: 6.6 nTPM (limit 6); skeletal muscle: 10.6 nTPM (limit 2); small intestine: 6.4 nTPM (limit 2); smooth muscle: 7.6 nTPM (limit 2); spinal cord: 3.2 nTPM (limit 2); stomach: 8.3 nTPM (limit 6); thymus: 11.9 nTPM (limit 10); thyroid gland: 13.3 nTPM (limit 10); tongue: 15.1 nTPM (limit 6); urinary bladder: 9.9 nTPM (limit 6); adipose tissue: 12.2 nTPM (baseline 10); adrenal gland: 7.2 nTPM (baseline 2); amygdala: 3.2 nTPM (baseline 2); basal ganglia: 3.8 nTPM (baseline 2); bone marrow: 16.7 nTPM (baseline 2); cerebellum: 8.2 nTPM (baseline 2); cerebral cortex: 6.6 nTPM (baseline 2); choroid plexus: 4.9 nTPM (baseline 2); colon: 8.8 nTPM (baseline 6); duodenum: 6.4 nTPM (baseline 2); esophagus: 8.9 nTPM (baseline 6); heart muscle: 6.4 nTPM (baseline 2); hippocampal formation: 3.2 nTPM (baseline 2); hypothalamus: 3.3 nTPM (baseline 2); kidney: 9.4 nTPM (baseline 2); liver: 10.6 nTPM (baseline 2); lung: 6.9 nTPM (baseline 2); lymph node: 8.9 nTPM (baseline 6); midbrain: 3.1 nTPM (baseline 2); pancreas: 9.6 nTPM (baseline 2); parathyroid gland: 12.7 nTPM (baseline 6); pituitary gland: 6.2 nTPM (baseline 2); rectum: 6.7 nTPM (baseline 6); retina: 7.8 nTPM (baseline 2); salivary gland: 6.6 nTPM (baseline 6); skeletal muscle: 10.6 nTPM (baseline 2); small intestine: 6.4 nTPM (baseline 2); smooth muscle: 7.6 nTPM (baseline 2); spinal cord: 3.2 nTPM (baseline 2); stomach: 8.3 nTPM (baseline 6); thymus: 11.9 nTPM (baseline 10); thyroid gland: 13.3 nTPM (baseline 10); tongue: 15.1 nTPM (baseline 6); urinary bladder: 9.9 nTPM (baseline 6),adipose tissue / adipocytes: Medium (Uncertain); adrenal gland / glandular cells: High (Uncertain); bone marrow / hematopoietic cells: High (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / glial cells: Medium (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: Medium (Uncertain); cerebellum / cells in molecular layer: Low (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / endothelial cells: Medium (Uncertain); cerebral cortex / glial cells: Medium (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: Medium (Uncertain); colon / endothelial cells: Low (Uncertain); colon / glandular cells: High (Uncertain); colon / peripheral nerve/ganglion: Medium (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: High (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / glial cells: Low (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in glomeruli: Low (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / hepatocytes: Low (Uncertain); lung / alveolar cells: Low (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / germinal center cells: High (Uncertain); lymph node / non-germinal center cells: Medium (Uncertain); nasopharynx / respiratory epithelial cells: High (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: High (Uncertain); salivary gland / glandular cells: Low (Uncertain); skeletal muscle / myocytes: Low (Uncertain); skin 1 / fibroblasts: Medium (Uncertain); skin 1 / keratinocytes: Medium (Uncertain); skin 1 / Langerhans: Medium (Uncertain); skin 2 / epidermal cells: High (Uncertain); small intestine / glandular cells: Medium (Uncertain); smooth muscle / smooth muscle cells: Low (Uncertain); spleen / cells in red pulp: Low (Uncertain); spleen / cells in white pulp: High (Uncertain); stomach 1 / glandular cells: High (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%); Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%),breast cancer: 12/12 (100.0%); colorectal cancer: 12/12 (100.0%),31,20,Q8WYP5,https://www.uniprot.org/uniprotkb/Q8WYP5/entry,Required for the assembly of a functional nuclear pore complex (NPC) on the surface of chromosomes as nuclei form at the end of mitosis. May initiate NPC assembly by binding to chromatin and recruiting the Nup107-160 subcomplex of the NPC. Also required for the localization of the Nup107-160 subcomplex of the NPC to the kinetochore during mitosis and for the completion of cytokinesis,,,,"Cytoplasm Nucleus Nucleus envelope Nucleus matrix Chromosome, centromere, kinetochore Nucleus, nucleoplasm Nucleus, nuclear pore complex",17098863|17235358,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
AHRR,ENSG00000063438,Unsafe,RNA,False,True,45.1,45.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,cerebral cortex: 2.1 nTPM; absolute ceiling; lung: 2.1 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebral cortex: 2.1 nTPM (limit 2); lung: 2.1 nTPM (limit 2); cerebral cortex: 2.1 nTPM (baseline 2); lung: 2.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Skin Cuteneous Melanoma (TCGA): 29/99 (29.3%); Breast Invasive Carcinoma (validation): 12/50 (24.0%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 23/283 (8.1%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,A9YTQ3,https://www.uniprot.org/uniprotkb/A9YTQ3/entry,"Mediates dioxin toxicity and is involved in regulation of cell growth and differentiation. Represses the transcription activity of AHR by competing with AHR for heterodimer formation with ARNT and subsequently binding to the xenobiotic response element (XRE) sequence present in the promoter regulatory region of a variety of genes. Represses CYP1A1 by binding the XRE sequence and recruiting ANKRA2, HDAC4 and/or HDAC5. Autoregulates its expression by associating with its own XRE site Represses AHR transcription activity (PubMed:19380484). Also represses transcription mediated by HIF1A and EPAS1/HIF2A but does not repress NR1I2/PXR or ESR1 transcriptional activities (PubMed:19380484) Does not repress AHR transcription activity","Highly expressed in testis, lung, ovary, spleen and pancreas. Highly expressed in mononuclear cells (MNCs) from umbilical cord blood. Down-regulated in malignant tissue from different anatomical origins, including colon, breast, lung, stomach, cervix, and ovary Predominant form which is widely expressed in multiple adult and fetal tissues Minor form which is expressed at low levels",,,Cytoplasm Nucleus,17890447|18172554|19380484,11835227|14672759|18172554|19380484,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,Failed bulk numeric comparisons are within 20% of their cutoffs; not an automatic rescue,,,,
AIPL1,ENSG00000129221,Unsafe,Protein,False,True,0.6,810.0,89,1,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; bone marrow: 0.7 nTPM; continuous selectivity;reproductive not higher; choroid plexus: 3.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; retina: 810 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 0.4 nTPM; continuous selectivity; skin: 0.5 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 3.7 nTPM (limit 2); retina: 810 nTPM (limit 2); choroid plexus: 3.7 nTPM (baseline 2); retina: 810 nTPM (baseline 2),retina / photoreceptor cells: High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 27/133 (20.3%); Pancreatic Adenocarcinoma (validation): 3/80 (3.8%); Uterine Corpus Endometrial Carcinoma (TCGA): 4/176 (2.3%),breast cancer: 0/11 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q9NZN9,https://www.uniprot.org/uniprotkb/Q9NZN9/entry,May be important in protein trafficking and/or protein folding and stabilization,Highly expressed in retina. Specifically localized to the developing photoreceptor layer and within the photoreceptors of the adult retina,"Leber congenital amaurosis 4: A severe dystrophy of the retina, typically becoming evident in the first years of life. Visual function is usually poor and often accompanied by nystagmus, sluggish or near-absent pupillary responses, photophobia, high hyperopia and keratoconus.",,Cytoplasm Nucleus,,12374762,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT,Cancer-associated RNA nomination; no antigen validation asserted,,,,,,,,
AK7,ENSG00000140057,Unsafe,Protein,False,True,23.5,23.5,111,31,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; basal ganglia: 3.9 nTPM; absolute ceiling; choroid plexus: 17.7 nTPM; absolute ceiling;continuous selectivity; duodenum: 1.8 nTPM; positive ihc; hippocampal formation: 3.6 nTPM; absolute ceiling; hypothalamus: 5.3 nTPM; absolute ceiling; kidney: 4.3 nTPM; positive ihc;absolute ceiling; lung: 3.9 nTPM; positive ihc;absolute ceiling; pancreas: 2.1 nTPM; positive ihc;absolute ceiling; pituitary gland: 5 nTPM; absolute ceiling; rectum: 1.5 nTPM; positive ihc; retina: 2.8 nTPM; absolute ceiling; small intestine: 1.2 nTPM; positive ihc; spleen: 3.2 nTPM; positive ihc; stomach: 2.6 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",basal ganglia: 3.9 nTPM (limit 2); choroid plexus: 17.7 nTPM (limit 2); hippocampal formation: 3.6 nTPM (limit 2); hypothalamus: 5.3 nTPM (limit 2); kidney: 4.3 nTPM (limit 2); lung: 3.9 nTPM (limit 2); pancreas: 2.1 nTPM (limit 2); pituitary gland: 5 nTPM (limit 2); retina: 2.8 nTPM (limit 2),bronchus / ciliated cells (ciliary rootlets): Medium (Enhanced); bronchus / ciliated cells (tip of cilia): High (Enhanced); duodenum / paneth cells: High (Enhanced); kidney / cells in glomeruli: Low (Enhanced); kidney / cells in tubules: Low (Enhanced); lung / macrophages: Low (Enhanced); nasopharynx / basal cells: Low (Enhanced); nasopharynx / ciliated cells (cell body): Low (Enhanced); nasopharynx / ciliated cells (ciliary rootlets): Medium (Enhanced); nasopharynx / ciliated cells (tip of cilia): Medium (Enhanced); pancreas / exocrine glandular cells: Low (Enhanced); pancreas / pancreatic endocrine cells: Low (Enhanced); rectum / mucosal lymphoid cells: Low (Enhanced); small intestine / paneth cells: High (Enhanced); spleen / cells in red pulp: Low (Enhanced); stomach 1 / glandular cells: Low (Enhanced); stomach 2 / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Renal Papillary Cell Carcinoma (TCGA): 201/282 (71.3%); Uterine Corpus Endometrial Carcinoma (TCGA): 82/176 (46.6%); Breast Invasive Carcinoma (validation): 22/50 (44.0%),prostate cancer: 11/11 (100.0%); breast cancer: 10/12 (83.3%),31,20,Q96M32,https://www.uniprot.org/uniprotkb/Q96M32/entry,"Nucleoside monophosphate (NMP) kinase that catalyzes the reversible transfer of the terminal phosphate group between nucleoside triphosphates and monophosphates. Has highest activity toward AMP, and weaker activity toward dAMP, CMP and dCMP. Also displays broad nucleoside diphosphate kinase activity. Involved in maintaining ciliary structure and function",Expressed in sperm and airway epithelial cells (at protein level),"Spermatogenic failure 27: An autosomal recessive infertility disorder caused by spermatogenesis defects that result in multiple morphologic abnormalities of the sperm flagella, including short, irregular, coiled, or absent flagella.",,"Cytoplasm, cytosol Cell projection, cilium, flagellum",21080915|23416111,29365104,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | Jamin2021_CT,GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
AK8,ENSG00000165695,Unsafe,Protein,False,True,25.0,25.0,108,12,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; basal ganglia: 2.2 nTPM; absolute ceiling; choroid plexus: 9.9 nTPM; absolute ceiling;continuous selectivity; kidney: 2.2 nTPM; positive ihc;absolute ceiling; retina: 2.6 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",basal ganglia: 2.2 nTPM (limit 2); choroid plexus: 9.9 nTPM (limit 2); kidney: 2.2 nTPM (limit 2); retina: 2.6 nTPM (limit 2),bronchus / ciliated cells (cilia axoneme): High (Enhanced); bronchus / ciliated cells (tip of cilia): High (Enhanced); kidney / distal tubules: Low (Enhanced); nasopharynx / ciliated cells (cilia axoneme): High (Enhanced); nasopharynx / ciliated cells (tip of cilia): High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Renal Papillary Cell Carcinoma (TCGA): 187/282 (66.3%); Thyroid Carcinoma (TCGA): 309/495 (62.4%); Glioblastoma Multiforme (validation): 29/58 (50.0%),breast cancer: 0/12 (0.0%); cervical cancer: 0/10 (0.0%),30,20,Q96MA6,https://www.uniprot.org/uniprotkb/Q96MA6/entry,"Nucleoside monophosphate (NMP) kinase that catalyzes the reversible transfer of the terminal phosphate group between nucleoside triphosphates and monophosphates. Has highest activity toward AMP, and weaker activity toward dAMP, CMP and dCMP. Also displays broad nucleoside diphosphate kinase activity",Expressed in respiratory cells (at protein level),,,"Cytoplasm, cytosol Cytoplasm, cytoskeleton, cilium axoneme",21080915|23416111,33139725,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
AK9,ENSG00000155085,Unsafe,Protein,False,True,16.1,16.1,87,78,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 3.4 nTPM; positive ihc; adrenal gland: 3 nTPM; positive ihc;absolute ceiling; amygdala: 4.8 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 5.2 nTPM; absolute ceiling;continuous selectivity; bone marrow: 3.7 nTPM; positive ihc;absolute ceiling; cerebellum: 5.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 4.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 15.5 nTPM; absolute ceiling;continuous selectivity; colon: 4.4 nTPM; positive ihc; duodenum: 3.5 nTPM; positive ihc;absolute ceiling; esophagus: 4.1 nTPM; positive ihc; heart muscle: 4.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 5.7 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 6.7 nTPM; absolute ceiling;continuous selectivity; kidney: 5.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 3 nTPM; positive ihc;absolute ceiling; lung: 4 nTPM; positive ihc;absolute ceiling; lymph node: 4 nTPM; positive ihc; midbrain: 6.2 nTPM; absolute ceiling;continuous selectivity; pancreas: 3.3 nTPM; positive ihc;absolute ceiling; parathyroid gland: 8.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 7.5 nTPM; absolute ceiling;continuous selectivity; rectum: 4.2 nTPM; positive ihc; retina: 13.6 nTPM; absolute ceiling;continuous selectivity; salivary gland: 5 nTPM; positive ihc; skeletal muscle: 4.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 3.8 nTPM; positive ihc; small intestine: 3.4 nTPM; positive ihc;absolute ceiling; smooth muscle: 3.7 nTPM; positive ihc;absolute ceiling; spinal cord: 7.4 nTPM; absolute ceiling;continuous selectivity; spleen: 3.9 nTPM; positive ihc; stomach: 4.4 nTPM; positive ihc; thymus: 7.3 nTPM; continuous selectivity; thyroid gland: 6.6 nTPM; positive ihc; urinary bladder: 3.3 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 3 nTPM (limit 2); amygdala: 4.8 nTPM (limit 2); basal ganglia: 5.2 nTPM (limit 2); bone marrow: 3.7 nTPM (limit 2); cerebellum: 5.7 nTPM (limit 2); cerebral cortex: 4.9 nTPM (limit 2); choroid plexus: 15.5 nTPM (limit 2); duodenum: 3.5 nTPM (limit 2); heart muscle: 4.7 nTPM (limit 2); hippocampal formation: 5.7 nTPM (limit 2); hypothalamus: 6.7 nTPM (limit 2); kidney: 5.1 nTPM (limit 2); liver: 3 nTPM (limit 2); lung: 4 nTPM (limit 2); midbrain: 6.2 nTPM (limit 2); pancreas: 3.3 nTPM (limit 2); parathyroid gland: 8.8 nTPM (limit 6); pituitary gland: 7.5 nTPM (limit 2); retina: 13.6 nTPM (limit 2); skeletal muscle: 4.6 nTPM (limit 2); small intestine: 3.4 nTPM (limit 2); smooth muscle: 3.7 nTPM (limit 2); spinal cord: 7.4 nTPM (limit 2),adipose tissue / adipocytes: Medium (Enhanced); adrenal gland / glandular cells: Medium (Enhanced); bone marrow / hematopoietic cells: High (Enhanced); bronchus / respiratory epithelial cells: High (Enhanced); caudate / glial cells: High (Enhanced); cerebellum / cells in granular layer: High (Enhanced); cerebellum / cells in molecular layer: Medium (Enhanced); cerebral cortex / endothelial cells: High (Enhanced); cerebral cortex / glial cells: High (Enhanced); cerebral cortex / neuronal cells: Low (Enhanced); colon / endothelial cells: Medium (Enhanced); colon / glandular cells: Medium (Enhanced); colon / peripheral nerve/ganglion: Low (Enhanced); duodenum / glandular cells: High (Enhanced); esophagus / squamous epithelial cells: High (Enhanced); heart muscle / cardiomyocytes: High (Enhanced); hippocampus / glial cells: High (Enhanced); hippocampus / neuronal cells: Low (Enhanced); kidney / cells in glomeruli: High (Enhanced); kidney / cells in tubules: High (Enhanced); liver / cholangiocytes: High (Enhanced); liver / hepatocytes: High (Enhanced); lung / alveolar cells: High (Enhanced); lung / macrophages: High (Enhanced); lymph node / germinal center cells: Low (Enhanced); lymph node / non-germinal center cells: Medium (Enhanced); nasopharynx / respiratory epithelial cells: High (Enhanced); oral mucosa / squamous epithelial cells: High (Enhanced); pancreas / exocrine glandular cells: High (Enhanced); pancreas / pancreatic endocrine cells: Medium (Enhanced); parathyroid gland / glandular cells: Medium (Enhanced); rectum / glandular cells: High (Enhanced); salivary gland / glandular cells: High (Enhanced); skeletal muscle / myocytes: High (Enhanced); skin 1 / fibroblasts: High (Enhanced); skin 1 / keratinocytes: High (Enhanced); skin 1 / Langerhans: High (Enhanced); skin 2 / epidermal cells: Medium (Enhanced); small intestine / glandular cells: High (Enhanced); smooth muscle / smooth muscle cells: Medium (Enhanced); spleen / cells in red pulp: High (Enhanced); spleen / cells in white pulp: High (Enhanced); stomach 1 / glandular cells: High (Enhanced); stomach 2 / glandular cells: High (Enhanced); thyroid gland / glandular cells: High (Enhanced); urinary bladder / urothelial cells: High (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 470/486 (96.7%); Rectum Adenocarcinoma (validation): 200/207 (96.6%); Pancreatic Adenocarcinoma (validation): 63/80 (78.8%),colorectal cancer: 12/12 (100.0%); lung cancer: 12/12 (100.0%),29,20,Q5TCS8,https://www.uniprot.org/uniprotkb/Q5TCS8/entry,"Broad-specificity nucleoside phosphate kinase involved in cellular nucleotide homeostasis by catalyzing nucleoside-phosphate interconversions. Similar to other adenylate kinases, preferentially catalyzes the phosphorylation of the nucleoside monophosphate AMP with ATP as phosphate donor to produce ADP. In vitro, can also catalyze the phosphorylation of CMP, dAMP and dCMP and use GTP as an alternate phosphate donor. Moreover, exhibits a diphosphate kinase activity, producing ATP, CTP, GTP, UTP, TTP, dATP, dCTP and dGTP from the corresponding diphosphate substrates with either ATP or GTP as phosphate donors. For this activity shows the following substrate preference CDP > UDP > ADP > TDP",,Spermatogenic failure 89: An autosomal recessive male infertility disorder due to severely reduced progressive motility of sperm.,,"Cytoplasm Nucleus Cell projection, cilium, flagellum",23416111,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | Jamin2021_CT,GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
AKAP14,ENSG00000186471,Unsafe,Protein,False,True,81.5,81.5,103,14,Positive somewhere,True,True,False,True,Excluded,Normal,False,,Not assessed,,,positive ihc outside permitted; amygdala: 4.2 nTPM; absolute ceiling; choroid plexus: 75.1 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 2.3 nTPM; absolute ceiling; hypothalamus: 4.7 nTPM; absolute ceiling; lung: 3.1 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 4.2 nTPM (limit 2); choroid plexus: 75.1 nTPM (limit 2); hippocampal formation: 2.3 nTPM (limit 2); hypothalamus: 4.7 nTPM (limit 2); lung: 3.1 nTPM (limit 2),bronchus / ciliated cells (cell body): Low (Enhanced); bronchus / ciliated cells (cilia axoneme): Medium (Enhanced); bronchus / ciliated cells (tip of cilia): Medium (Enhanced); nasopharynx / ciliated cells (cilia axoneme): Medium (Enhanced); nasopharynx / ciliated cells (tip of cilia): Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 34/176 (19.3%); Breast Invasive Carcinoma (validation): 7/50 (14.0%); Lung Adenocarcinoma (TCGA): 48/497 (9.7%),prostate cancer: 2/12 (16.7%); melanoma: 1/12 (8.3%),31,20,Q86UN6,https://www.uniprot.org/uniprotkb/Q86UN6/entry,Binds to type II regulatory subunits of protein kinase A and anchors/targets them,Present in cilia (at protein level). Expressed in tissues containing axoneme-based organelles (cilia and/or flagella): trachea and testis. Highly expressed in airway cilia,,,Cytoplasm,,12475942,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
AKAP3,ENSG00000111254,Unsafe,RNA,False,True,97.2,97.2,86,6,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,spinal cord: 2.2 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,spinal cord: 2.2 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 63/133 (47.4%); Glioblastoma Multiforme (validation): 20/58 (34.5%); Breast Invasive Carcinoma (validation): 11/50 (22.0%),colorectal cancer: 1/10 (10.0%); breast cancer: 1/11 (9.1%),31,20,O75969,https://www.uniprot.org/uniprotkb/O75969/entry,"Structural component of sperm fibrous sheath (By similarity). Required for the formation of the subcellular structure of the sperm flagellum, sperm motility and male fertility (PubMed:35228300)",Testis specific; only expressed in spermatids,Spermatogenic failure 82: An autosomal recessive male infertility disorder characterized by asthenoteratozoospermia and multiple morphologic abnormalities of the sperm flagella.,,"Cytoplasmic vesicle, secretory vesicle, acrosome Cell projection, cilium, flagellum",35228300,10334916,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,Failed bulk numeric comparisons are within 20% of their cutoffs; not an automatic rescue,,,,
AKIRIN2,ENSG00000135334,Unsafe,RNA,False,True,25.1,94.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 31.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; adrenal gland: 35.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 33.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 33.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 69.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 27.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 35.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 24.4 nTPM; absolute ceiling;continuous selectivity; colon: 19.2 nTPM; absolute ceiling;continuous selectivity; duodenum: 12.4 nTPM; absolute ceiling;continuous selectivity; esophagus: 32.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 29.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 32.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 31 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 20.2 nTPM; absolute ceiling;continuous selectivity; liver: 30.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 32.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 27.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 29.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 12.8 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 17.2 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 22.8 nTPM; absolute ceiling;continuous selectivity; rectum: 12.1 nTPM; absolute ceiling;continuous selectivity; retina: 28.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 23.8 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 94 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 22.2 nTPM; absolute ceiling;continuous selectivity; small intestine: 22.3 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 15.8 nTPM; absolute ceiling;continuous selectivity; spinal cord: 31.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 47.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; stomach: 16.3 nTPM; absolute ceiling;continuous selectivity; thymus: 30.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 16.7 nTPM; absolute ceiling;continuous selectivity; tongue: 40.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 22.5 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adipose tissue: 31.8 nTPM (limit 10); adrenal gland: 35.9 nTPM (limit 2); amygdala: 33.9 nTPM (limit 2); basal ganglia: 33.1 nTPM (limit 2); bone marrow: 69.6 nTPM (limit 2); cerebellum: 27.4 nTPM (limit 2); cerebral cortex: 35.8 nTPM (limit 2); choroid plexus: 24.4 nTPM (limit 2); colon: 19.2 nTPM (limit 6); duodenum: 12.4 nTPM (limit 2); esophagus: 32.3 nTPM (limit 6); heart muscle: 29.9 nTPM (limit 2); hippocampal formation: 32.4 nTPM (limit 2); hypothalamus: 31 nTPM (limit 2); kidney: 20.2 nTPM (limit 2); liver: 30.3 nTPM (limit 2); lung: 32.2 nTPM (limit 2); lymph node: 27.7 nTPM (limit 6); midbrain: 29.4 nTPM (limit 2); pancreas: 12.8 nTPM (limit 2); parathyroid gland: 17.2 nTPM (limit 6); pituitary gland: 22.8 nTPM (limit 2); rectum: 12.1 nTPM (limit 6); retina: 28.8 nTPM (limit 2); salivary gland: 23.8 nTPM (limit 6); skeletal muscle: 94 nTPM (limit 2); skin: 22.2 nTPM (limit 10); small intestine: 22.3 nTPM (limit 2); smooth muscle: 15.8 nTPM (limit 2); spinal cord: 31.2 nTPM (limit 2); spleen: 47.9 nTPM (limit 10); stomach: 16.3 nTPM (limit 6); thymus: 30.4 nTPM (limit 10); thyroid gland: 16.7 nTPM (limit 10); tongue: 40.9 nTPM (limit 6); urinary bladder: 22.5 nTPM (limit 6); adipose tissue: 31.8 nTPM (baseline 10); adrenal gland: 35.9 nTPM (baseline 2); amygdala: 33.9 nTPM (baseline 2); basal ganglia: 33.1 nTPM (baseline 2); bone marrow: 69.6 nTPM (baseline 2); cerebellum: 27.4 nTPM (baseline 2); cerebral cortex: 35.8 nTPM (baseline 2); choroid plexus: 24.4 nTPM (baseline 2); colon: 19.2 nTPM (baseline 6); duodenum: 12.4 nTPM (baseline 2); esophagus: 32.3 nTPM (baseline 6); heart muscle: 29.9 nTPM (baseline 2); hippocampal formation: 32.4 nTPM (baseline 2); hypothalamus: 31 nTPM (baseline 2); kidney: 20.2 nTPM (baseline 2); liver: 30.3 nTPM (baseline 2); lung: 32.2 nTPM (baseline 2); lymph node: 27.7 nTPM (baseline 6); midbrain: 29.4 nTPM (baseline 2); pancreas: 12.8 nTPM (baseline 2); parathyroid gland: 17.2 nTPM (baseline 6); pituitary gland: 22.8 nTPM (baseline 2); rectum: 12.1 nTPM (baseline 6); retina: 28.8 nTPM (baseline 2); salivary gland: 23.8 nTPM (baseline 6); skeletal muscle: 94 nTPM (baseline 2); skin: 22.2 nTPM (baseline 10); small intestine: 22.3 nTPM (baseline 2); smooth muscle: 15.8 nTPM (baseline 2); spinal cord: 31.2 nTPM (baseline 2); spleen: 47.9 nTPM (baseline 10); stomach: 16.3 nTPM (baseline 6); thymus: 30.4 nTPM (baseline 10); thyroid gland: 16.7 nTPM (baseline 10); tongue: 40.9 nTPM (baseline 6); urinary bladder: 22.5 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Kidney Renal Clear Cell Carcinoma (TCGA): 521/521 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q53H80,https://www.uniprot.org/uniprotkb/Q53H80/entry,"Molecular adapter that acts as a bridge between a variety of multiprotein complexes, and which is involved in embryonic development, immunity, myogenesis and brain development (PubMed:34711951). Plays a key role in nuclear protein degradation by promoting import of proteasomes into the nucleus: directly binds to fully assembled 20S proteasomes at one end and to nuclear import receptor IPO9 at the other end, bridging them together and mediating the import of pre-assembled proteasome complexes through the nuclear pore (PubMed:34711951). Involved in innate immunity by regulating the production of interleukin-6 (IL6) downstream of Toll-like receptor (TLR): acts by bridging the NF-kappa-B inhibitor NFKBIZ and the SWI/SNF complex, leading to promote induction of IL6 (By similarity). Also involved in adaptive immunity by promoting B-cell activation (By similarity). Involved in brain development: required for the survival and proliferation of cerebral cortical progenitor cells (By similarity). Involved in myogenesis: required for skeletal muscle formation and skeletal development, possibly by regulating expression of muscle differentiation factors (By similarity). Also plays a role in facilitating interdigital tissue regression during limb development (By similarity)",Widely expressed with the highest expression in peripheral blood leukocytes,,,Nucleus Cytoplasm Membrane,34711951,18066067,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
AKR1E2,ENSG00000165568,Unsafe,Protein,False,True,18.4,18.4,85,28,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 0.8 nTPM; positive ihc; cerebral cortex: 0.8 nTPM; positive ihc; colon: 1.2 nTPM; positive ihc; duodenum: 1.2 nTPM; positive ihc; kidney: 0.9 nTPM; positive ihc; rectum: 1.1 nTPM; positive ihc; retina: 3.3 nTPM; absolute ceiling; salivary gland: 1 nTPM; positive ihc; skin: 1.1 nTPM; positive ihc; small intestine: 1 nTPM; positive ihc; stomach: 1.5 nTPM; positive ihc; thyroid gland: 3.2 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",retina: 3.3 nTPM (limit 2),adrenal gland / glandular cells: Low (Enhanced); bronchus / respiratory epithelial cells: Low (Enhanced); cerebral cortex / glial cells: Low (Enhanced); cerebral cortex / neuronal cells: Low (Enhanced); colon / glandular cells: Low (Enhanced); duodenum / glandular cells: Low (Enhanced); kidney / cells in tubules: Low (Enhanced); nasopharynx / respiratory epithelial cells: Low (Enhanced); rectum / glandular cells: Low (Enhanced); salivary gland / glandular cells: Low (Enhanced); skin 1 / fibroblasts: Medium (Enhanced); small intestine / glandular cells: Low (Enhanced); stomach 2 / glandular cells: Low (Enhanced); thyroid gland / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 338/486 (69.5%); Breast Invasive Carcinoma (validation): 33/50 (66.0%); Rectum Adenocarcinoma (validation): 127/207 (61.4%),renal cancer: 3/11 (27.3%); breast cancer: 2/11 (18.2%),31,20,Q96JD6,https://www.uniprot.org/uniprotkb/Q96JD6/entry,"Catalyzes the NADPH-dependent reduction of 1,5-anhydro-D-fructose (AF) to 1,5-anhydro-D-glucitol (By similarity). Has low NADPH-dependent reductase activity towards 9,10-phenanthrenequinone (in vitro) (PubMed:12604216, PubMed:15118078)","Specifically expressed in testis (PubMed:12604216, PubMed:15118078). Expressed in testicular germ cells and testis interstitial cells (PubMed:15118078)",,,Cytoplasm,12604216|15118078,12604216|15118078,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
ALG10,ENSG00000139133,Unsafe,Protein,False,True,3.3,4.0,79,64,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 2.2 nTPM; continuous selectivity; adrenal gland: 2.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; bone marrow: 4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 0.6 nTPM; positive ihc; cerebral cortex: 1 nTPM; positive ihc;continuous selectivity; colon: 2.2 nTPM; positive ihc;continuous selectivity; duodenum: 1.6 nTPM; positive ihc;continuous selectivity; esophagus: 2.1 nTPM; positive ihc;continuous selectivity; heart muscle: 1 nTPM; positive ihc;continuous selectivity; kidney: 1.8 nTPM; positive ihc;continuous selectivity; liver: 2.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 1.8 nTPM; positive ihc;continuous selectivity; lymph node: 3.6 nTPM; positive ihc;continuous selectivity;reproductive not higher; pancreas: 1.5 nTPM; positive ihc;continuous selectivity; parathyroid gland: 2.2 nTPM; positive ihc;continuous selectivity; rectum: 1.9 nTPM; positive ihc;continuous selectivity; retina: 3.2 nTPM; absolute ceiling;continuous selectivity; salivary gland: 1.5 nTPM; positive ihc;continuous selectivity; skeletal muscle: 0.9 nTPM; positive ihc; skin: 1.9 nTPM; positive ihc;continuous selectivity; small intestine: 1.7 nTPM; positive ihc;continuous selectivity; smooth muscle: 2.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; spleen: 2.8 nTPM; positive ihc;continuous selectivity; stomach: 1.9 nTPM; positive ihc;continuous selectivity; thymus: 3.5 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 2.7 nTPM; positive ihc;continuous selectivity; urinary bladder: 1.2 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 2.6 nTPM (limit 2); bone marrow: 4 nTPM (limit 2); liver: 2.8 nTPM (limit 2); retina: 3.2 nTPM (limit 2); smooth muscle: 2.1 nTPM (limit 2),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: High (Approved); cerebellum / cells in molecular layer: High (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: High (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: Low (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Low (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: High (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: High (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Rectum Adenocarcinoma (validation): 188/207 (90.8%); Colon Adenocarcinoma (validation): 439/486 (90.3%),breast cancer: 10/11 (90.9%); cervical cancer: 10/12 (83.3%),31,20,Q5BKT4,https://www.uniprot.org/uniprotkb/Q5BKT4/entry,"Dol-P-Glc:Glc(2)Man(9)GlcNAc(2)-PP-Dol alpha-1,2-glucosyltransferase that operates in the biosynthetic pathway of dolichol-linked oligosaccharides, the glycan precursors employed in protein asparagine (N)-glycosylation. The assembly of dolichol-linked oligosaccharides begins on the cytosolic side of the endoplasmic reticulum membrane and finishes in its lumen. The sequential addition of sugars to dolichol pyrophosphate produces dolichol-linked oligosaccharides containing fourteen sugars, including two GlcNAcs, nine mannoses and three glucoses. Once assembled, the oligosaccharide is transferred from the lipid to nascent proteins by oligosaccharyltransferases. In the lumen of the endoplasmic reticulum, adds the third and last glucose residue from dolichyl phosphate glucose (Dol-P-Glc) onto the lipid-linked oligosaccharide intermediate Glc(2)Man(9)GlcNAc(2)-PP-Dol to produce Glc(3)Man(9)GlcNAc(2)-PP-Dol",,,,Endoplasmic reticulum membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ALG10B,ENSG00000175548,Unsafe,Protein,False,True,5.0,8.8,79,64,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 3.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; bone marrow: 4.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 1.3 nTPM; positive ihc; cerebral cortex: 2.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 2 nTPM; positive ihc;continuous selectivity; duodenum: 2.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 1.7 nTPM; positive ihc; heart muscle: 2.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; kidney: 3.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 3.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 2.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 4.5 nTPM; positive ihc;continuous selectivity; pancreas: 2.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 3.5 nTPM; positive ihc;continuous selectivity; rectum: 2.5 nTPM; positive ihc;continuous selectivity; retina: 8.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 2.7 nTPM; positive ihc;continuous selectivity; skeletal muscle: 1.4 nTPM; positive ihc;continuous selectivity; skin: 4.2 nTPM; positive ihc;continuous selectivity; small intestine: 2.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 2.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; spleen: 4.5 nTPM; positive ihc;continuous selectivity; stomach: 3.6 nTPM; positive ihc;continuous selectivity; thymus: 3.9 nTPM; continuous selectivity; thyroid gland: 4 nTPM; positive ihc;continuous selectivity; tongue: 2.3 nTPM; continuous selectivity; urinary bladder: 1.4 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 3.4 nTPM (limit 2); bone marrow: 4.2 nTPM (limit 2); cerebral cortex: 2.5 nTPM (limit 2); duodenum: 2.4 nTPM (limit 2); heart muscle: 2.1 nTPM (limit 2); kidney: 3.1 nTPM (limit 2); liver: 3.6 nTPM (limit 2); lung: 2.4 nTPM (limit 2); pancreas: 2.8 nTPM (limit 2); retina: 8.8 nTPM (limit 2); small intestine: 2.5 nTPM (limit 2); smooth muscle: 2.4 nTPM (limit 2),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: High (Approved); cerebellum / cells in molecular layer: High (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: High (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: Low (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Low (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: High (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: High (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 42/50 (84.0%); Pancreatic Adenocarcinoma (validation): 66/80 (82.5%),breast cancer: 10/11 (90.9%); cervical cancer: 10/12 (83.3%),31,20,Q5I7T1,https://www.uniprot.org/uniprotkb/Q5I7T1/entry,"Dol-P-Glc:Glc(2)Man(9)GlcNAc(2)-PP-Dol alpha-1,2-glucosyltransferase that operates in the biosynthetic pathway of dolichol-linked oligosaccharides, the glycan precursors employed in protein asparagine (N)-glycosylation. The assembly of dolichol-linked oligosaccharides begins on the cytosolic side of the endoplasmic reticulum membrane and finishes in its lumen. The sequential addition of sugars to dolichol pyrophosphate produces dolichol-linked oligosaccharides containing fourteen sugars, including two GlcNAcs, nine mannoses and three glucoses. Once assembled, the oligosaccharide is transferred from the lipid to nascent proteins by oligosaccharyltransferases. In the lumen of the endoplasmic reticulum, adds the third and last glucose residue from dolichyl phosphate glucose (Dol-P-Glc) onto the lipid-linked oligosaccharide intermediate Glc(2)Man(9)GlcNAc(2)-PP-Dol to produce Glc(3)Man(9)GlcNAc(2)-PP-Dol","Highly expressed in heart, placenta, liver, kidney and pancreas. Weakly expressed in lung, skeletal muscle and brain",,,Endoplasmic reticulum membrane,20950623,14525949,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ALK,ENSG00000171094,Unsafe,Protein,False,True,1.2,1.7,79,40,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 0.6 nTPM; positive ihc;continuous selectivity; amygdala: 0.5 nTPM; continuous selectivity; basal ganglia: 0.4 nTPM; continuous selectivity; bone marrow: 0 nTPM; positive ihc; cerebellum: 0.1 nTPM; positive ihc; cerebral cortex: 1.7 nTPM; positive ihc;continuous selectivity;reproductive not higher; colon: 0.6 nTPM; positive ihc;continuous selectivity; heart muscle: 0 nTPM; positive ihc; hypothalamus: 0.8 nTPM; continuous selectivity; lung: 0.1 nTPM; positive ihc; lymph node: 0 nTPM; positive ihc; midbrain: 0.4 nTPM; continuous selectivity; parathyroid gland: 0 nTPM; positive ihc; pituitary gland: 1.2 nTPM; continuous selectivity;reproductive not higher; rectum: 0.2 nTPM; positive ihc; retina: 0.7 nTPM; continuous selectivity; skeletal muscle: 0 nTPM; positive ihc; skin: 0.1 nTPM; positive ihc; thyroid gland: 0.3 nTPM; positive ihc; urinary bladder: 0 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,adrenal gland / glandular cells: Low (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Low (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / neuronal cells: High (Approved); cerebral cortex / neuropil: Medium (Approved); colon / glandular cells: Low (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / neuronal cells: High (Approved); lung / macrophages: Low (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); oral mucosa / squamous epithelial cells: Low (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Low (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: Low (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Low (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 32/58 (55.2%); Skin Cuteneous Melanoma (TCGA): 12/99 (12.1%); Glioblastoma Multiforme (TCGA): 17/141 (12.1%),prostate cancer: 7/12 (58.3%); skin cancer: 5/10 (50.0%),31,20,Q9UM73,https://www.uniprot.org/uniprotkb/Q9UM73/entry,"Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system (PubMed:11121404, PubMed:11387242, PubMed:16317043, PubMed:17274988, PubMed:30061385, PubMed:34646012, PubMed:34819673). Also acts as a key thinness protein involved in the resistance to weight gain: in hypothalamic neurons, controls energy expenditure acting as a negative regulator of white adipose tissue lipolysis and sympathetic tone to fine-tune energy homeostasis (By similarity). Following activation by ALKAL2 ligand at the cell surface, transduces an extracellular signal into an intracellular response (PubMed:30061385, PubMed:33411331, PubMed:34646012, PubMed:34819673). In contrast, ALKAL1 is not a potent physiological ligand for ALK (PubMed:34646012). Ligand-binding to the extracellular domain induces tyrosine kinase activation, leading to activation of the mitogen-activated protein kinase (MAPK) pathway (PubMed:34819673). Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif (PubMed:15226403, PubMed:16878150). Induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1 (PubMed:15226403, PubMed:16878150). ALK activation may also be regulated by pleiotrophin (PTN) and midkine (MDK) (PubMed:11278720, PubMed:11809760, PubMed:12107166, PubMed:12122009). PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation (PubMed:11278720, PubMed:11809760, PubMed:12107166). MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction (PubMed:12122009). Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase (PubMed:15226403, PubMed:16878150). Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK (PubMed:15226403, PubMed:16878150). May function as regulator of gastric epithelial differentiation (By similarity)","Expressed in brain and CNS. Also expressed in the small intestine and testis, but not in normal lymphoid cells",Neuroblastoma 3: A common neoplasm of early childhood arising from embryonic cells that form the primitive neural crest and give rise to the adrenal medulla and the sympathetic nervous system.,,Cell membrane,11121404|11278720|11387242|11809760|12107166|12122009|15226403|16317043|16878150|17274988|30061385|33411331|34646012|34819673,9174053,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ALPG,ENSG00000163286,Unsafe,Protein,False,True,0.9,0.9,125,7,Positive somewhere,True,False,False,True,Excluded,Normal,False,,Not assessed,,,positive normal IHC; positive ihc outside permitted; colon: 0.1 nTPM; positive ihc; duodenum: 0 nTPM; positive ihc; rectum: 0.1 nTPM; positive ihc; skin: 0 nTPM; positive ihc; small intestine: 0 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,colon / enterocytes - Microvilli: Medium (Approved); duodenum / enterocytes - Microvilli: High (Approved); rectum / enterocytes - Microvilli: High (Approved); skin 1 / fibrohistiocytic cells: Low (Approved); small intestine / enterocytes - Microvilli: High (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 118/133 (88.7%); Uterine Corpus Endometrial Carcinoma (TCGA): 63/176 (35.8%); Ovary Serous Cystadenocarcinoma (TCGA): 84/349 (24.1%),testis cancer: 9/11 (81.8%); endometrial cancer: 5/12 (41.7%),29,20,P10696,https://www.uniprot.org/uniprotkb/P10696/entry,Alkaline phosphatase that can hydrolyze various phosphate compounds,"Trace amounts in the testis and thymus, and in elevated amounts in germ cell tumors",,,Cell membrane,1939159,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Gong2021_reproductive_PC,No tumor-antigen validation in this source | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
ALPP,ENSG00000163283,Unsafe,Protein,False,True,33.6,33.6,129,10,Positive somewhere,True,False,False,True,Excluded,Normal,False,,Not assessed,,,positive normal IHC; positive ihc outside permitted; colon: 0 nTPM; positive ihc; duodenum: 0 nTPM; positive ihc; rectum: 0 nTPM; positive ihc; skin: 0 nTPM; positive ihc; small intestine: 0 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,colon / enterocytes - Microvilli: Medium (Enhanced); duodenum / enterocytes - Microvilli: High (Enhanced); rectum / enterocytes - Microvilli: High (Enhanced); skin 1 / fibrohistiocytic cells: Low (Enhanced); small intestine / enterocytes - Microvilli: High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 60/133 (45.1%); Uterine Corpus Endometrial Carcinoma (TCGA): 55/176 (31.2%); Ovary Serous Cystadenocarcinoma (validation): 20/81 (24.7%),testis cancer: 9/11 (81.8%); endometrial cancer: 5/12 (41.7%),31,20,P05187,https://www.uniprot.org/uniprotkb/P05187/entry,Alkaline phosphatase that can hydrolyze various phosphate compounds,Detected in placenta (at protein level),,,Cell membrane,1939159|25775211,20693656,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Gong2021_reproductive_PC,No tumor-antigen validation in this source | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
AMER1,ENSG00000184675,Unsafe,Protein,False,True,5.0,14.7,81,79,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 1.1 nTPM; positive ihc; adrenal gland: 1.4 nTPM; positive ihc;continuous selectivity; bone marrow: 1.1 nTPM; positive ihc; cerebellum: 1.9 nTPM; positive ihc;continuous selectivity; cerebral cortex: 1 nTPM; positive ihc; colon: 1.5 nTPM; positive ihc; duodenum: 1.4 nTPM; positive ihc;continuous selectivity; esophagus: 2.7 nTPM; positive ihc;continuous selectivity; heart muscle: 1.3 nTPM; positive ihc; kidney: 1.7 nTPM; positive ihc;continuous selectivity; liver: 2.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 1.2 nTPM; positive ihc; lymph node: 1.2 nTPM; positive ihc; pancreas: 2 nTPM; positive ihc;continuous selectivity; rectum: 1.3 nTPM; positive ihc; salivary gland: 2.1 nTPM; positive ihc;continuous selectivity; skeletal muscle: 3.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 2.1 nTPM; positive ihc; small intestine: 1.3 nTPM; positive ihc; smooth muscle: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; spleen: 1.3 nTPM; positive ihc; stomach: 1.6 nTPM; positive ihc; thyroid gland: 1.4 nTPM; positive ihc; tongue: 14.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 1.2 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",liver: 2.1 nTPM (limit 2); skeletal muscle: 3.9 nTPM (limit 2); smooth muscle: 2.7 nTPM (limit 2); tongue: 14.7 nTPM (limit 6),adipose tissue / adipocytes: High (Approved); adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: High (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / glial cells: High (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / endothelial cells: High (Approved); cerebral cortex / glial cells: High (Approved); cerebral cortex / neuronal cells: Medium (Approved); colon / endothelial cells: High (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: High (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: High (Approved); heart muscle / cardiomyocytes: High (Approved); hippocampus / glial cells: High (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: High (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: High (Approved); lung / macrophages: High (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: High (Approved); nasopharynx / respiratory epithelial cells: High (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: High (Approved); skeletal muscle / myocytes: High (Approved); skin 1 / fibroblasts: High (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: High (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: High (Approved); spleen / cells in red pulp: High (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Low (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: Low (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Rectum Adenocarcinoma (validation): 165/207 (79.7%); Colon Adenocarcinoma (validation): 372/486 (76.5%),lymphoma: 12/12 (100.0%); cervical cancer: 11/11 (100.0%),29,20,Q5JTC6,https://www.uniprot.org/uniprotkb/Q5JTC6/entry,"Regulator of the canonical Wnt signaling pathway. Acts by specifically binding phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2), translocating to the cell membrane and interacting with key regulators of the canonical Wnt signaling pathway, such as components of the beta-catenin destruction complex. Acts both as a positive and negative regulator of the Wnt signaling pathway, depending on the context: acts as a positive regulator by promoting LRP6 phosphorylation. Also acts as a negative regulator by acting as a scaffold protein for the beta-catenin destruction complex and promoting stabilization of Axin at the cell membrane. Promotes CTNNB1 ubiquitination and degradation. Involved in kidney development","Detected in fetal and adult kidney, brain and spleen","Osteopathia striata with cranial sclerosis: An X-linked dominant sclerosing bone dysplasia that presents in females with macrocephaly, cleft palate, facial palsy, conductive hearing loss, mild learning disabilities, sclerosis of the long bones and skull. Longitudinal striations are visible on radiographs of the long bones, pelvis, and scapulae (osteopathia striata). In males this entity is usually associated with fetal or neonatal lethality. Occasional surviving males have, in addition to hyperostosis, cardiac, intestinal, and genitourinary malformations.",,Cytoplasm Cell membrane Nucleus,17510365|17925383|19416806|21304492|21498506,19416806,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
AMIGO3,ENSG00000176020,Unsafe,RNA,False,True,1.7,3.3,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 0.8 nTPM; continuous selectivity; basal ganglia: 0.6 nTPM; continuous selectivity; bone marrow: 1.5 nTPM; continuous selectivity; cerebellum: 0.8 nTPM; continuous selectivity; esophagus: 0.9 nTPM; continuous selectivity; heart muscle: 0.9 nTPM; continuous selectivity; hypothalamus: 1 nTPM; continuous selectivity; kidney: 0.6 nTPM; continuous selectivity; liver: 1.8 nTPM; continuous selectivity;reproductive not higher; lung: 0.9 nTPM; continuous selectivity; pancreas: 1.5 nTPM; continuous selectivity; pituitary gland: 3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 0.9 nTPM; continuous selectivity; skeletal muscle: 3.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 2.9 nTPM; continuous selectivity;reproductive not higher; small intestine: 0.7 nTPM; continuous selectivity; spinal cord: 0.6 nTPM; continuous selectivity; spleen: 1 nTPM; continuous selectivity; stomach: 1 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,pituitary gland: 3 nTPM (limit 2); skeletal muscle: 3.3 nTPM (limit 2); pituitary gland: 3 nTPM (baseline 2); skeletal muscle: 3.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 37/50 (74.0%); Liver Hepatocellular Carcinoma (validation): 82/231 (35.5%); Uterine Corpus Endometrial Carcinoma (TCGA): 37/176 (21.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q86WK7,https://www.uniprot.org/uniprotkb/Q86WK7/entry,May mediate heterophilic cell-cell interaction. May contribute to signal transduction through its intracellular domain (By similarity),,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Gong2021_reproductive_PC,No tumor-antigen validation in this source | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
ANG,ENSG00000214274,Unsafe,RNA,False,True,56.2,2920.4,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 36.4 nTPM; absolute ceiling;continuous selectivity; adrenal gland: 2.9 nTPM; absolute ceiling; amygdala: 2.5 nTPM; absolute ceiling; basal ganglia: 2.7 nTPM; absolute ceiling; cerebral cortex: 2.2 nTPM; absolute ceiling; choroid plexus: 23.3 nTPM; absolute ceiling;continuous selectivity; colon: 31.5 nTPM; absolute ceiling;continuous selectivity; duodenum: 22.5 nTPM; absolute ceiling;continuous selectivity; esophagus: 9.5 nTPM; absolute ceiling; heart muscle: 16.3 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 3 nTPM; absolute ceiling; hypothalamus: 2.4 nTPM; absolute ceiling; kidney: 17.7 nTPM; absolute ceiling;continuous selectivity; liver: 2920.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 18 nTPM; absolute ceiling;continuous selectivity; midbrain: 2.9 nTPM; absolute ceiling; pancreas: 29.9 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 4.8 nTPM; absolute ceiling; rectum: 44.2 nTPM; absolute ceiling;continuous selectivity; retina: 2.1 nTPM; absolute ceiling; salivary gland: 51 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 6 nTPM; absolute ceiling; skin: 26.5 nTPM; absolute ceiling;continuous selectivity; small intestine: 26.3 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 10.1 nTPM; absolute ceiling; spinal cord: 3.9 nTPM; absolute ceiling; stomach: 56.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; tongue: 10.1 nTPM; absolute ceiling; urinary bladder: 24 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adipose tissue: 36.4 nTPM (limit 10); adrenal gland: 2.9 nTPM (limit 2); amygdala: 2.5 nTPM (limit 2); basal ganglia: 2.7 nTPM (limit 2); cerebral cortex: 2.2 nTPM (limit 2); choroid plexus: 23.3 nTPM (limit 2); colon: 31.5 nTPM (limit 6); duodenum: 22.5 nTPM (limit 2); esophagus: 9.5 nTPM (limit 6); heart muscle: 16.3 nTPM (limit 2); hippocampal formation: 3 nTPM (limit 2); hypothalamus: 2.4 nTPM (limit 2); kidney: 17.7 nTPM (limit 2); liver: 2920.4 nTPM (limit 2); lung: 18 nTPM (limit 2); midbrain: 2.9 nTPM (limit 2); pancreas: 29.9 nTPM (limit 2); pituitary gland: 4.8 nTPM (limit 2); rectum: 44.2 nTPM (limit 6); retina: 2.1 nTPM (limit 2); salivary gland: 51 nTPM (limit 6); skeletal muscle: 6 nTPM (limit 2); skin: 26.5 nTPM (limit 10); small intestine: 26.3 nTPM (limit 2); smooth muscle: 10.1 nTPM (limit 2); spinal cord: 3.9 nTPM (limit 2); stomach: 56.6 nTPM (limit 6); tongue: 10.1 nTPM (limit 6); urinary bladder: 24 nTPM (limit 6); adipose tissue: 36.4 nTPM (baseline 10); adrenal gland: 2.9 nTPM (baseline 2); amygdala: 2.5 nTPM (baseline 2); basal ganglia: 2.7 nTPM (baseline 2); cerebral cortex: 2.2 nTPM (baseline 2); choroid plexus: 23.3 nTPM (baseline 2); colon: 31.5 nTPM (baseline 6); duodenum: 22.5 nTPM (baseline 2); esophagus: 9.5 nTPM (baseline 6); heart muscle: 16.3 nTPM (baseline 2); hippocampal formation: 3 nTPM (baseline 2); hypothalamus: 2.4 nTPM (baseline 2); kidney: 17.7 nTPM (baseline 2); liver: 2920.4 nTPM (baseline 2); lung: 18 nTPM (baseline 2); midbrain: 2.9 nTPM (baseline 2); pancreas: 29.9 nTPM (baseline 2); pituitary gland: 4.8 nTPM (baseline 2); rectum: 44.2 nTPM (baseline 6); retina: 2.1 nTPM (baseline 2); salivary gland: 51 nTPM (baseline 6); skeletal muscle: 6 nTPM (baseline 2); skin: 26.5 nTPM (baseline 10); small intestine: 26.3 nTPM (baseline 2); smooth muscle: 10.1 nTPM (baseline 2); spinal cord: 3.9 nTPM (baseline 2); stomach: 56.6 nTPM (baseline 6); tongue: 10.1 nTPM (baseline 6); urinary bladder: 24 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (TCGA): 362/362 (100.0%); Kidney Renal Clear Cell Carcinoma (validation): 100/100 (100.0%); Rectum Adenocarcinoma (TCGA): 88/88 (100.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P03950,https://www.uniprot.org/uniprotkb/P03950/entry,"Secreted ribonuclease that can either promote or restrict cell proliferation of target cells, depending on the context (PubMed:12051708, PubMed:1400510, PubMed:19332886, PubMed:20129916, PubMed:21855800, PubMed:23047679, PubMed:23843625, PubMed:2424496, PubMed:2459697, PubMed:2730651, PubMed:27518564, PubMed:28176817, PubMed:29100074, PubMed:29748193, PubMed:3122207, PubMed:32510170, PubMed:38718836, PubMed:8159680, PubMed:8570639, PubMed:8622921, PubMed:9578571). Endocytosed in target cells via its receptor PLXNB2 and translocates to the cytoplasm or nucleus (PubMed:29100074, PubMed:32510170). Under stress conditions, localizes to the cytoplasm and promotes the assembly of stress granules (SGs): specifically cleaves a subset of tRNAs within anticodon loops to produce tRNA-derived stress-induced fragments (tiRNAs), resulting in translation repression and inhibition of cell proliferation (PubMed:1400510, PubMed:19332886, PubMed:20129916, PubMed:21855800, PubMed:23047679, PubMed:27518564, PubMed:29100074, PubMed:29748193, PubMed:32510170, PubMed:38718836). tiRNas also prevent formation of apoptosome, thereby promoting cell survival (By similarity). Preferentially cleaves RNAs between a pyrimidine and an adenosine residue, suggesting that it cleaves the anticodon loop of tRNA(Ala) (32-UUAGCAU-38) after positions 33 and 36 (PubMed:3289612, PubMed:38718836). Cleaves a subset of tRNAs, including tRNA(Ala), tRNA(Glu), tRNA(Gly), tRNA(Lys), tRNA(Val), tRNA(His), tRNA(Asp) and tRNA(Sec) (PubMed:31582561). Under growth conditions and in differentiated cells, translocates to the nucleus and stimulates ribosomal RNA (rRNA) transcription, including that containing the initiation site sequences of 45S rRNA, thereby promoting cell growth and proliferation (PubMed:12051708, PubMed:15735021, PubMed:27518564, PubMed:29100074, PubMed:8127865). Angiogenin induces vascularization of normal and malignant tissues via its ability to promote rRNA transcription (PubMed:19354288, PubMed:4074709, PubMed:8448182). Involved in hematopoietic stem and progenitor cell (HSPC) growth and survival by promoting rRNA transcription in growth conditions and inhibiting translation in response to stress, respectively (PubMed:27518564). Mediates the crosstalk between myeloid and intestinal epithelial cells to protect the intestinal epithelial barrier integrity: secreted by myeloid cells and promotes intestinal epithelial cells proliferation and survival (PubMed:32510170). Also mediates osteoclast-endothelial cell crosstalk in growing bone: produced by osteoclasts and protects the neighboring vascular cells against senescence by promoting rRNA transcription (By similarity)","Expressed predominantly in the liver (PubMed:2440105). Also detected in endothelial cells and spinal cord neurons (PubMed:17886298, PubMed:2440105)","Amyotrophic lateral sclerosis 9: A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.",,"Secreted Nucleus Nucleus, nucleolus Cytoplasm, Stress granule",12051708|1400510|15735021|19332886|19354288|20129916|21855800|23047679|23843625|2424496|2459697|2730651|27518564|28176817|29100074|29748193|3122207|31582561|32510170|3289612|38718836|4074709|8127865|8159680|8448182|8570639|8622921|9578571,17886298|2440105,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ANKAR,ENSG00000151687,Unsafe,High RNA,False,True,5.6,5.6,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 91/91 values ≥5 TPM, max 30.7367; DICE M2 (unstimulated): 15/90 values ≥5 TPM, max 6.4449; DICE NK (unstimulated): 75/90 values ≥5 TPM, max 12.5255; DICE TREG_MEM (unstimulated): 20/89 values ≥5 TPM, max 5.79492; DICE CD4_NAIVE (unstimulated): 87/88 values ≥5 TPM, max 9.82317; DICE TREG_NAIVE (unstimulated): 89/89 values ≥5 TPM, max 12.0264; DICE TFH (unstimulated): 21/89 values ≥5 TPM, max 7.08812; DICE TH1 (unstimulated): 41/81 values ≥5 TPM, max 8.3902; DICE THSTAR (unstimulated): 72/88 values ≥5 TPM, max 9.866; DICE TH17 (unstimulated): 31/89 values ≥5 TPM, max 7.08766; DICE TH2 (unstimulated): 64/89 values ≥5 TPM, max 8.39936; DICE CD8_NAIVE (unstimulated): 67/89 values ≥5 TPM, max 9.6101",True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA036168; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA036168; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA036168; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA036168; conflicting or uncurated primary profile; Caudate/Glial cells: Medium, HPA036168; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA036168; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: High, HPA036168; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA036168; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA036168; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA036168; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: High, HPA036168; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA036168; conflicting or uncurated primary profile; Colon/Endothelial cells: High, HPA036168; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA036168; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA036168; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA036168; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: High, HPA036168; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA036168; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA036168; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA036168; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: High, HPA036168; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA036168; conflicting or uncurated primary profile; Liver/Hepatocytes: High, HPA036168; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA036168; conflicting or uncurated primary profile; Lung/Macrophages: High, HPA036168; conflicting or uncurated primary profile; Lymph node/Germinal center cells: High, HPA036168; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: High, HPA036168; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA036168; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: High, HPA036168; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA036168; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA036168; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: High, HPA036168; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA036168; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA036168; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA036168; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Low, HPA036168; conflicting or uncurated primary profile; Skin 1/Keratinocytes: High, HPA036168; conflicting or uncurated primary profile; Skin 1/Langerhans: High, HPA036168; conflicting or uncurated primary profile; Skin 2/Epidermal cells: High, HPA036168; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA036168; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA036168; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA036168; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Low, HPA036168; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA036168; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA036168; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA036168; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: High, HPA036168; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,30.7366669063,81.6,"dice_b_cell_naive: blood/B_CELL_NAIVE, max 30.7367 TPM, 4 observations >30; hpa_single_cell: /Astrocytes, max 78.6 nTPM, 1 observations >30; hpa_single_cell: /Excitatory neurons, max 44.4 nTPM, 1 observations >30; hpa_single_cell: /Inhibitory neurons, max 57.9 nTPM, 1 observations >30; hpa_single_cell: /Microglial cells, max 45.6 nTPM, 1 observations >30; hpa_single_cell: /Oligodendrocyte precursor cells, max 81.6 nTPM, 1 observations >30; hpa_single_cell: /Oligodendrocytes, max 75 nTPM, 1 observations >30; hpa_single_cell: /Rod photoreceptor cells, max 49.8 nTPM, 1 observations >30; hpa_single_cell_tissue: brain/astrocytes, max 78.6 nTPM, 1 observations >30; hpa_single_cell_tissue: brain/excitatory neurons, max 57.4 nTPM, 26 observations >30; hpa_single_cell_tissue: brain/inhibitory neurons, max 73.5 nTPM, 14 observations >30; hpa_single_cell_tissue: brain/microglial cells, max 45.6 nTPM, 1 observations >30; hpa_single_cell_tissue: brain/oligodendrocyte precursor cells, max 81.6 nTPM, 1 observations >30; hpa_single_cell_tissue: brain/oligodendrocytes, max 75 nTPM, 2 observations >30; hpa_single_cell_tissue: eye/rod photoreceptor cells, max 57 nTPM, 2 observations >30; hpa_single_cell_tissue: heart muscle/endothelial cells, max 33.2 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,30.74 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,81.6 nTPM; unsited/Oligodendrocyte precursor cells; hpa_single_cell; unresolved,Glioblastoma Multiforme (validation): 57/58 (98.3%); Pancreatic Adenocarcinoma (validation): 52/80 (65.0%); Breast Invasive Carcinoma (validation): 24/50 (48.0%),colorectal cancer: 12/12 (100.0%); liver cancer: 11/11 (100.0%),31,20,Q7Z5J8,https://www.uniprot.org/uniprotkb/Q7Z5J8/entry,,Ubiquitously expressed with highest level in pancreas and lowest in skeletal muscle,,,Membrane,,15110750,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ANKRD33,ENSG00000167612,Unsafe,Protein,False,True,0.5,17.8,86,1,Positive somewhere,True,True,False,False,Excluded,Normal,False,,Not assessed,,,positive ihc outside permitted; parathyroid gland: 2 nTPM; continuous selectivity;reproductive not higher; retina: 17.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",retina: 17.8 nTPM (limit 2); retina: 17.8 nTPM (baseline 2),retina / photoreceptor cells: High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (validation): 6/231 (2.6%); Liver Hepatocellular Carcinoma (TCGA): 6/362 (1.7%); Ovary Serous Cystadenocarcinoma (validation): 1/81 (1.2%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q7Z3H0,https://www.uniprot.org/uniprotkb/Q7Z3H0/entry,Acts as a transcriptional repressor for CRX-activated photoreceptor gene regulation,,,,"Cytoplasm, cytosol Nucleus",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Gong2021_reproductive_PC,No tumor-antigen validation in this source | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
ANKRD36B,ENSG00000196912,Unsafe,RNA,False,True,3.8,8.9,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 2.9 nTPM; continuous selectivity; adrenal gland: 1.4 nTPM; continuous selectivity; amygdala: 2.2 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 2.5 nTPM; absolute ceiling;continuous selectivity; bone marrow: 7.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 8.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 2.5 nTPM; absolute ceiling;continuous selectivity; colon: 2.5 nTPM; continuous selectivity; esophagus: 1.4 nTPM; continuous selectivity; heart muscle: 1.9 nTPM; continuous selectivity; hippocampal formation: 2.6 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 2.1 nTPM; absolute ceiling;continuous selectivity; kidney: 1.5 nTPM; continuous selectivity; lung: 2.1 nTPM; absolute ceiling;continuous selectivity; lymph node: 2.1 nTPM; continuous selectivity; midbrain: 2.2 nTPM; absolute ceiling;continuous selectivity; pancreas: 4.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 2.4 nTPM; absolute ceiling;continuous selectivity; rectum: 2 nTPM; continuous selectivity; retina: 3 nTPM; absolute ceiling;continuous selectivity; salivary gland: 3.6 nTPM; continuous selectivity; skin: 3 nTPM; continuous selectivity; small intestine: 2.3 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 1.2 nTPM; continuous selectivity; spinal cord: 3 nTPM; absolute ceiling;continuous selectivity; spleen: 2.1 nTPM; continuous selectivity; stomach: 2.2 nTPM; continuous selectivity; thymus: 1.9 nTPM; continuous selectivity; thyroid gland: 2.3 nTPM; continuous selectivity; urinary bladder: 2.1 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 2.2 nTPM (limit 2); basal ganglia: 2.5 nTPM (limit 2); bone marrow: 7.5 nTPM (limit 2); cerebellum: 8.9 nTPM (limit 2); cerebral cortex: 2.5 nTPM (limit 2); hippocampal formation: 2.6 nTPM (limit 2); hypothalamus: 2.1 nTPM (limit 2); lung: 2.1 nTPM (limit 2); midbrain: 2.2 nTPM (limit 2); pancreas: 4.1 nTPM (limit 2); pituitary gland: 2.4 nTPM (limit 2); retina: 3 nTPM (limit 2); small intestine: 2.3 nTPM (limit 2); spinal cord: 3 nTPM (limit 2); amygdala: 2.2 nTPM (baseline 2); basal ganglia: 2.5 nTPM (baseline 2); bone marrow: 7.5 nTPM (baseline 2); cerebellum: 8.9 nTPM (baseline 2); cerebral cortex: 2.5 nTPM (baseline 2); hippocampal formation: 2.6 nTPM (baseline 2); hypothalamus: 2.1 nTPM (baseline 2); lung: 2.1 nTPM (baseline 2); midbrain: 2.2 nTPM (baseline 2); pancreas: 4.1 nTPM (baseline 2); pituitary gland: 2.4 nTPM (baseline 2); retina: 3 nTPM (baseline 2); small intestine: 2.3 nTPM (baseline 2); spinal cord: 3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Pancreatic Adenocarcinoma (validation): 79/80 (98.8%); Breast Invasive Carcinoma (validation): 45/50 (90.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8N2N9,https://www.uniprot.org/uniprotkb/Q8N2N9/entry,,,,,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ANKRD45,ENSG00000183831,Unsafe,Protein,False,True,12.3,12.3,99,11,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; amygdala: 2.6 nTPM; absolute ceiling; basal ganglia: 5.4 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 6.2 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 2.8 nTPM; absolute ceiling; hypothalamus: 2.8 nTPM; absolute ceiling; parathyroid gland: 9 nTPM; continuous selectivity; retina: 2.5 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 2.6 nTPM (limit 2); basal ganglia: 5.4 nTPM (limit 2); choroid plexus: 6.2 nTPM (limit 2); hippocampal formation: 2.8 nTPM (limit 2); hypothalamus: 2.8 nTPM (limit 2); retina: 2.5 nTPM (limit 2),bronchus / ciliated cells (cilia axoneme): High (Enhanced); bronchus / ciliated cells (tip of cilia): High (Enhanced); nasopharynx / ciliated cells (cilia axoneme): Medium (Enhanced); nasopharynx / ciliated cells (tip of cilia): Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 41/58 (70.7%); Ovary Serous Cystadenocarcinoma (validation): 20/81 (24.7%); Uterine Corpus Endometrial Carcinoma (TCGA): 34/176 (19.3%),colorectal cancer: 1/10 (10.0%); breast cancer: 0/11 (0.0%),31,20,Q5TZF3,https://www.uniprot.org/uniprotkb/Q5TZF3/entry,May play a role during cell division,,,,"Cytoplasm Midbody, Midbody ring Cleavage furrow",31208154,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
ANKRD55,ENSG00000164512,Unsafe,Protein,False,True,9.6,9.6,79,53,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; basal ganglia: 2.6 nTPM; absolute ceiling;continuous selectivity; bone marrow: 0.7 nTPM; positive ihc; cerebellum: 0.2 nTPM; positive ihc; cerebral cortex: 1.3 nTPM; positive ihc; colon: 0.1 nTPM; positive ihc; duodenum: 0.1 nTPM; positive ihc; esophagus: 0.2 nTPM; positive ihc; heart muscle: 0.1 nTPM; positive ihc; hypothalamus: 3.8 nTPM; absolute ceiling;continuous selectivity; kidney: 0.4 nTPM; positive ihc; liver: 3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 0.3 nTPM; positive ihc; lymph node: 3.5 nTPM; positive ihc;continuous selectivity; pancreas: 0 nTPM; positive ihc; parathyroid gland: 0 nTPM; positive ihc; rectum: 0.2 nTPM; positive ihc; salivary gland: 1 nTPM; positive ihc; skin: 0.4 nTPM; positive ihc; small intestine: 1.3 nTPM; positive ihc; spleen: 1.6 nTPM; positive ihc; stomach: 0.2 nTPM; positive ihc; thyroid gland: 0.2 nTPM; positive ihc; urinary bladder: 0.3 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",basal ganglia: 2.6 nTPM (limit 2); hypothalamus: 3.8 nTPM (limit 2); liver: 3 nTPM (limit 2); basal ganglia: 2.6 nTPM (baseline 2); hypothalamus: 3.8 nTPM (baseline 2); liver: 3 nTPM (baseline 2),bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Low (Uncertain); caudate / neuronal cells: Low (Uncertain); cerebellum / cells in granular layer: Low (Uncertain); cerebellum / Purkinje cells: Low (Uncertain); cerebral cortex / neuronal cells: Low (Uncertain); colon / endothelial cells: Low (Uncertain); colon / glandular cells: Low (Uncertain); duodenum / glandular cells: Low (Uncertain); esophagus / squamous epithelial cells: Low (Uncertain); heart muscle / cardiomyocytes: Low (Uncertain); hippocampus / neuronal cells: Low (Uncertain); kidney / cells in glomeruli: Low (Uncertain); kidney / cells in tubules: Low (Uncertain); liver / hepatocytes: Low (Uncertain); lung / alveolar cells: Low (Uncertain); lymph node / germinal center cells: Low (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); nasopharynx / respiratory epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Low (Uncertain); pancreas / pancreatic endocrine cells: Low (Uncertain); parathyroid gland / glandular cells: Low (Uncertain); rectum / glandular cells: Low (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skin 1 / keratinocytes: Low (Uncertain); skin 1 / Langerhans: Low (Uncertain); skin 2 / epidermal cells: Low (Uncertain); small intestine / glandular cells: Low (Uncertain); spleen / cells in red pulp: Low (Uncertain); spleen / cells in white pulp: Medium (Uncertain); stomach 1 / glandular cells: Low (Uncertain); stomach 2 / glandular cells: Low (Uncertain); thyroid gland / glandular cells: Low (Uncertain); urinary bladder / urothelial cells: Low (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 16/133 (12.0%); Breast Invasive Carcinoma (validation): 3/50 (6.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%),prostate cancer: 9/11 (81.8%); lung cancer: 6/11 (54.5%),31,20,Q3KP44,https://www.uniprot.org/uniprotkb/Q3KP44/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
ANKRD62,ENSG00000181626,Unsafe,High RNA,False,True,1.6,1.6,85,5,Positive somewhere,False,False,False,True,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,CTA,Pass,oncoref.target-sets.2026-10-23.1,False,False,,CTA → Unsafe,True,True,True,1.020455466,47.6,"hpa_single_cell_tissue: brain/excitatory neurons, max 47.6 nTPM, 5 observations >30",CTA,oncoref.target-sets.2026-10-23.2,1.02 TPM; blood/NK; dice_nk; vital,47.6 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Pancreatic Adenocarcinoma (validation): 2/80 (2.5%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),colorectal cancer: 3/10 (30.0%); endometrial cancer: 1/11 (9.1%),29,20,A6NC57,https://www.uniprot.org/uniprotkb/A6NC57/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Chang2019_TGCT,Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
ANKRD7,ENSG00000106013,Unsafe,High RNA,False,True,834.8,834.8,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,CTA,Pass,oncoref.target-sets.2026-10-23.1,False,False,,CTA → Unsafe,True,True,True,2.0496,34.1,"hpa_single_cell_tissue: testis/macrophages, max 34.1 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,2.05 TPM; blood/memory B-cell; hpa_immune_cell_samples; vital,34.1 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 30/58 (51.7%); Testicular Germ Cell Tumor (TCGA): 15/133 (11.3%); Skin Cuteneous Melanoma (TCGA): 8/99 (8.1%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q92527,https://www.uniprot.org/uniprotkb/Q92527/entry,,Testis specific,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
ANKS1B,ENSG00000185046,Unsafe,Protein,False,True,7.0,68.2,108,3,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; amygdala: 44.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 68.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 23.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 63.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 3.4 nTPM; absolute ceiling;continuous selectivity; colon: 3.8 nTPM; continuous selectivity; hippocampal formation: 60.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 37 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 4.3 nTPM; continuous selectivity; midbrain: 38.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 9.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; retina: 5.9 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 15.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 60.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 44.7 nTPM (limit 2); basal ganglia: 68.2 nTPM (limit 2); cerebellum: 23.8 nTPM (limit 12); cerebral cortex: 63.5 nTPM (limit 12); choroid plexus: 3.4 nTPM (limit 2); hippocampal formation: 60.3 nTPM (limit 2); hypothalamus: 37 nTPM (limit 2); midbrain: 38.2 nTPM (limit 2); pituitary gland: 9.8 nTPM (limit 2); retina: 5.9 nTPM (limit 2); skeletal muscle: 15.8 nTPM (limit 12); spinal cord: 60.2 nTPM (limit 2),caudate / neuronal cells: Medium (Enhanced); hippocampus / neuronal cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 40/50 (80.0%); Glioblastoma Multiforme (validation): 39/58 (67.2%); Glioblastoma Multiforme (TCGA): 92/141 (65.2%),breast cancer: 0/12 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q7Z6G8,https://www.uniprot.org/uniprotkb/Q7Z6G8/entry,Isoform 2 may participate in the regulation of nucleoplasmic coilin protein interactions in neuronal and transformed cells Isoform 3 can regulate global protein synthesis by altering nucleolar numbers Isoform 4 may play a role as a modulator of APP processing. Overexpression can down-regulate APP processing,Highly expressed in marrow from patients with pre-B ALL associated with the t(1;19) translocation. Strongly expressed in brain and testis. Expressed in fetal brain. Isoform 4 is highly expressed in brain (at protein level). Isoform 6 is expressed in brain and several cancer cell lines,,,"Cytoplasm Nucleus Postsynaptic density Cell projection, dendritic spine Nucleus, Cajal body",15347684|15862129,10490826|15347684,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
ANO2,ENSG00000047617,Unsafe,Protein,False,True,8.9,199.6,103,4,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; choroid plexus: 3.1 nTPM; absolute ceiling;continuous selectivity; retina: 199.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; tongue: 3.1 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 3.1 nTPM (limit 2); retina: 199.6 nTPM (limit 2),bronchus / ciliated cells (ciliary rootlets): High (Enhanced); nasopharynx / ciliated cells (ciliary rootlets): Medium (Enhanced); retina / outer plexiform layer: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 88/133 (66.2%); Glioblastoma Multiforme (validation): 8/58 (13.8%); Ovary Serous Cystadenocarcinoma (TCGA): 36/349 (10.3%),colorectal cancer: 1/12 (8.3%); breast cancer: 0/12 (0.0%),31,20,Q9NQ90,https://www.uniprot.org/uniprotkb/Q9NQ90/entry,"Calcium-activated chloride channel (CaCC) which may play a role in olfactory signal transduction. Odorant molecules bind to odor-sensing receptors (OSRs), leading to an increase in calcium entry that activates CaCC current which amplifies the depolarization of the OSR cells, ANO2 seems to be the underlying chloride channel involved in this process. May mediate light perception amplification in retina","Retina, especially in the photoreceptor synaptic terminals",,,Cell membrane,19474308|20056604,19474308,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination; inclusion depends on TGCT under this study's thresholds,,,,,,,,
AP3B2,ENSG00000103723,Unsafe,Protein,False,True,6.0,44.6,123,25,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 4.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 7.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 10.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 44.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 27.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 4.7 nTPM; absolute ceiling;continuous selectivity; colon: 1 nTPM; positive ihc; duodenum: 0.7 nTPM; positive ihc; hippocampal formation: 8.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 12.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 5.8 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 12.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 18.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 0.5 nTPM; positive ihc; retina: 31.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 0.8 nTPM; positive ihc; spinal cord: 4.6 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 1.9 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 4.3 nTPM (limit 2); amygdala: 7.5 nTPM (limit 2); basal ganglia: 10.3 nTPM (limit 2); cerebellum: 44.6 nTPM (limit 2); cerebral cortex: 27.6 nTPM (limit 2); choroid plexus: 4.7 nTPM (limit 2); hippocampal formation: 8.7 nTPM (limit 2); hypothalamus: 12.8 nTPM (limit 2); midbrain: 5.8 nTPM (limit 2); parathyroid gland: 12.3 nTPM (limit 6); pituitary gland: 18.3 nTPM (limit 2); retina: 31.8 nTPM (limit 2); spinal cord: 4.6 nTPM (limit 2),adrenal gland / glandular cells: Low (Enhanced); caudate / neuronal cells: Medium (Enhanced); cerebellum / GLUC cells - cytoplasm/membrane: High (Enhanced); cerebellum / granular cells - cytoplasm/membrane: Medium (Enhanced); cerebellum / molecular layer - neuropil: Medium (Enhanced); cerebellum / molecular layer cells - cytoplasm/membrane: High (Enhanced); cerebellum / Purkinje cells - cytoplasm/membrane: High (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); cerebral cortex / neuropil: Medium (Enhanced); colon / endocrine cells: High (Enhanced); colon / enterocytes: High (Enhanced); duodenum / endocrine cells: High (Enhanced); duodenum / enterocytes: High (Enhanced); hippocampus / neuronal cells: Medium (Enhanced); parathyroid gland / glandular cells: Low (Enhanced); rectum / endocrine cells: Medium (Enhanced); rectum / enterocytes: Medium (Enhanced); small intestine / endocrine cells: High (Enhanced); small intestine / enterocytes: High (Enhanced); thyroid gland / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 47/58 (81.0%); Glioblastoma Multiforme (TCGA): 111/141 (78.7%); Breast Invasive Carcinoma (validation): 29/50 (58.0%),colorectal cancer: 7/12 (58.3%); glioma: 1/11 (9.1%),31,20,Q13367,https://www.uniprot.org/uniprotkb/Q13367/entry,"Subunit of non-clathrin- and clathrin-associated adaptor protein complex 3 (AP-3) that plays a role in protein sorting in the late-Golgi/trans-Golgi network (TGN) and/or endosomes. The AP complexes mediate both the recruitment of clathrin to membranes and the recognition of sorting signals within the cytosolic tails of transmembrane cargo molecules. AP-3 appears to be involved in the sorting of a subset of transmembrane proteins targeted to lysosomes and lysosome-related organelles. In concert with the BLOC-1 complex, AP-3 is required to target cargos into vesicles assembled at cell bodies for delivery into neurites and nerve terminals","Isoform 1 expression is specific to nervous system. Expressed in nerve terminal and cell body, and is associated with nerve-terminal vesicles. Expression seen in Purkinje cells, cortical neurons, neuroectodermal tumors and graded in cerebral cortex (deeper layers exhibit stronger expression) (PubMed:1851215). Isoform 2 is expressed at high levels in brain and testis (PubMed:17453999)","Developmental and epileptic encephalopathy 48: A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE48 is an autosomal recessive form characterized by onset of seizures in the first year of life. Affected individuals manifest global developmental delay, intellectual disability, absent speech, and poor, if any, motor development.",,"Cytoplasmic vesicle, clathrin-coated vesicle membrane Golgi apparatus",,17453999|1851215,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
AP4S1,ENSG00000100478,Unsafe,Protein,False,True,14.4,16.2,84,77,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 4.4 nTPM; positive ihc; adrenal gland: 4.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 11.4 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 12.3 nTPM; absolute ceiling;continuous selectivity; bone marrow: 6.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 11.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 16.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 2.9 nTPM; absolute ceiling; colon: 8.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 3 nTPM; positive ihc;absolute ceiling; esophagus: 3.9 nTPM; positive ihc; heart muscle: 7 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 11.5 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 10.4 nTPM; absolute ceiling;continuous selectivity; kidney: 7.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 4.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 4.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 7.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 8.2 nTPM; absolute ceiling;continuous selectivity; pancreas: 6.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 4.3 nTPM; positive ihc; pituitary gland: 8.1 nTPM; absolute ceiling;continuous selectivity; rectum: 3.5 nTPM; positive ihc; retina: 9.9 nTPM; absolute ceiling;continuous selectivity; salivary gland: 4.9 nTPM; positive ihc; skeletal muscle: 11.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 4.8 nTPM; positive ihc; small intestine: 4.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 6.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 7.6 nTPM; absolute ceiling;continuous selectivity; spleen: 6.5 nTPM; positive ihc;continuous selectivity; stomach: 4.1 nTPM; positive ihc; thyroid gland: 7.1 nTPM; positive ihc;continuous selectivity; urinary bladder: 6 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 4.6 nTPM (limit 2); amygdala: 11.4 nTPM (limit 2); basal ganglia: 12.3 nTPM (limit 2); bone marrow: 6.4 nTPM (limit 2); cerebellum: 11.2 nTPM (limit 2); cerebral cortex: 16.2 nTPM (limit 2); choroid plexus: 2.9 nTPM (limit 2); colon: 8.2 nTPM (limit 6); duodenum: 3 nTPM (limit 2); heart muscle: 7 nTPM (limit 2); hippocampal formation: 11.5 nTPM (limit 2); hypothalamus: 10.4 nTPM (limit 2); kidney: 7.2 nTPM (limit 2); liver: 4.7 nTPM (limit 2); lung: 4.6 nTPM (limit 2); lymph node: 7.2 nTPM (limit 6); midbrain: 8.2 nTPM (limit 2); pancreas: 6.8 nTPM (limit 2); pituitary gland: 8.1 nTPM (limit 2); retina: 9.9 nTPM (limit 2); skeletal muscle: 11.1 nTPM (limit 2); small intestine: 4.1 nTPM (limit 2); smooth muscle: 6.3 nTPM (limit 2); spinal cord: 7.6 nTPM (limit 2),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: High (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: High (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: High (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: High (Approved); heart muscle / cardiomyocytes: High (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: High (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: High (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: High (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Adenocarcinoma (validation): 103/105 (98.1%); Rectum Adenocarcinoma (validation): 202/207 (97.6%); Glioblastoma Multiforme (validation): 56/58 (96.6%),liver cancer: 12/12 (100.0%); testis cancer: 12/12 (100.0%),31,20,Q9Y587,https://www.uniprot.org/uniprotkb/Q9Y587/entry,"Component of the adaptor protein complex 4 (AP-4). Adaptor protein complexes are vesicle coat components involved both in vesicle formation and cargo selection. They control the vesicular transport of proteins in different trafficking pathways (PubMed:10066790, PubMed:10436028). AP-4 forms a non clathrin-associated coat on vesicles departing the trans-Golgi network (TGN) and may be involved in the targeting of proteins from the trans-Golgi network (TGN) to the endosomal-lysosomal system. It is also involved in protein sorting to the basolateral membrane in epithelial cells and the proper asymmetric localization of somatodendritic proteins in neurons. AP-4 is involved in the recognition and binding of tyrosine-based sorting signals found in the cytoplasmic part of cargos, but may also recognize other types of sorting signal (Probable)",Widely expressed,"Spastic paraplegia 52, autosomal recessive: A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. SPG52 is characterized by neonatal hypotonia that progresses to hypertonia and spasticity, and severe intellectual disability with poor or absent speech development. Some patients may have seizures.",,"Golgi apparatus, trans-Golgi network membrane",10066790|10436028,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
APLF,ENSG00000169621,Unsafe,High RNA,False,True,1.7,2.3,82,0,Negative where measured,False,False,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 1.2 nTPM; continuous selectivity; adrenal gland: 0.9 nTPM; continuous selectivity; bone marrow: 0.7 nTPM; continuous selectivity; colon: 1 nTPM; continuous selectivity; duodenum: 0.6 nTPM; continuous selectivity; esophagus: 1.4 nTPM; continuous selectivity; heart muscle: 0.8 nTPM; continuous selectivity; kidney: 0.9 nTPM; continuous selectivity; liver: 1.5 nTPM; continuous selectivity; lung: 0.9 nTPM; continuous selectivity; lymph node: 1.2 nTPM; continuous selectivity; pancreas: 0.6 nTPM; continuous selectivity; parathyroid gland: 0.8 nTPM; continuous selectivity; rectum: 0.8 nTPM; continuous selectivity; salivary gland: 1.1 nTPM; continuous selectivity; skeletal muscle: 1 nTPM; continuous selectivity; skin: 2.3 nTPM; continuous selectivity;reproductive not higher; smooth muscle: 1.1 nTPM; continuous selectivity; stomach: 0.7 nTPM; continuous selectivity; thyroid gland: 1.1 nTPM; continuous selectivity; tongue: 1.2 nTPM; continuous selectivity; urinary bladder: 1 nTPM; continuous selectivity,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 50/91 values ≥5 TPM, max 7.31626; DICE TREG_MEM (unstimulated): 4/89 values ≥5 TPM, max 6.1164; DICE CD4_STIM (activated): 3/88 values ≥5 TPM, max 5.46455; DICE TREG_NAIVE (unstimulated): 3/89 values ≥5 TPM, max 5.68158; DICE THSTAR (unstimulated): 27/88 values ≥5 TPM, max 6.98734; DICE TH17 (unstimulated): 13/89 values ≥5 TPM, max 6.27459; hpa_immune_cell basophil: 7.1 nTPM; hpa_immune_monaco basophil: 5.3 TPM",True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA034642; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA034642; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: High, HPA034642; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA034642; conflicting or uncurated primary profile; Caudate/Glial cells: High, HPA034642; conflicting or uncurated primary profile; Caudate/Neuronal cells: High, HPA034642; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: High, HPA034642; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: High, HPA034642; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA034642; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA034642; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: High, HPA034642; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: High, HPA034642; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA034642; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA034642; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: High, HPA034642; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA034642; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: High, HPA034642; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA034642; conflicting or uncurated primary profile; Hippocampus/Glial cells: Medium, HPA034642; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: High, HPA034642; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA034642; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA034642; conflicting or uncurated primary profile; Liver/Cholangiocytes: Medium, HPA034642; conflicting or uncurated primary profile; Liver/Hepatocytes: High, HPA034642; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA034642; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA034642; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA034642; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: High, HPA034642; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA034642; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: High, HPA034642; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA034642; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: High, HPA034642; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: High, HPA034642; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA034642; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA034642; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA034642; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA034642; conflicting or uncurated primary profile; Skin 1/Keratinocytes: High, HPA034642; conflicting or uncurated primary profile; Skin 1/Langerhans: High, HPA034642; conflicting or uncurated primary profile; Skin 2/Epidermal cells: High, HPA034642; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA034642; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA034642; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA034642; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Medium, HPA034642; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA034642; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA034642; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA034642; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: High, HPA034642; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA034643; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA034643; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA034643; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA034643; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA034643; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA034643; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Low, HPA034643; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA034643; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA034643; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA034643; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA034643; conflicting or uncurated primary profile; Liver/Cholangiocytes: Medium, HPA034643; conflicting or uncurated primary profile; Liver/Hepatocytes: High, HPA034643; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA034643; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA034643; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA034643; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA034643; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA034643; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA034643; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA034643; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA034643; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA034643; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA034643; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA034643; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA034643; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA034643; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA034643; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,9.7088,32.0,"hpa_single_cell_tissue: brain/excitatory neurons, max 32 nTPM, 1 observations >30",Neither,oncoref.target-sets.2026-10-23.2,9.709 TPM; blood/basophil; hpa_immune_cell_samples; vital,32 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 53/58 (91.4%); Breast Invasive Carcinoma (validation): 36/50 (72.0%); Colon Adenocarcinoma (validation): 135/486 (27.8%),breast cancer: 12/12 (100.0%); colorectal cancer: 12/12 (100.0%),31,20,Q8IW19,https://www.uniprot.org/uniprotkb/Q8IW19/entry,"Histone chaperone involved in single-strand and double-strand DNA break repair (PubMed:17353262, PubMed:17396150, PubMed:21211721, PubMed:21211722, PubMed:29905837, PubMed:30104678). Recruited to sites of DNA damage through interaction with branched poly-ADP-ribose chains, a polymeric post-translational modification synthesized transiently at sites of chromosomal damage to accelerate DNA strand break repair reactions (PubMed:17353262, PubMed:17396150, PubMed:21211721, PubMed:30104678). Following recruitment to DNA damage sites, acts as a histone chaperone that mediates histone eviction during DNA repair and promotes recruitment of histone variant MACROH2A1 (PubMed:21211722, PubMed:29905837, PubMed:30104678). Also has a nuclease activity: displays apurinic-apyrimidinic (AP) endonuclease and 3'-5' exonuclease activities in vitro (PubMed:17353262, PubMed:17396150). Also able to introduce nicks at hydroxyuracil and other types of pyrimidine base damage (PubMed:17353262, PubMed:17396150). Together with PARP3, promotes the retention of the LIG4-XRCC4 complex on chromatin and accelerate DNA ligation during non-homologous end-joining (NHEJ) (PubMed:21211721, PubMed:23689425). Also acts as a negative regulator of cell pluripotency by promoting histone exchange (By similarity). Required for the embryo implantation during the epithelial to mesenchymal transition in females (By similarity)",,,,"Nucleus Chromosome Cytoplasm, cytosol",17353262|17396150|21211721|21211722|23689425|29905837|30104678,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,All audited maxima are within 10% above 30; other gates still require review,,,,
APOBEC3F,ENSG00000128394,Unsafe,RNA,False,True,8.6,15.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 6.1 nTPM; absolute ceiling;continuous selectivity; bone marrow: 3.1 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 5.9 nTPM; absolute ceiling;continuous selectivity; colon: 3.3 nTPM; continuous selectivity; duodenum: 3.5 nTPM; absolute ceiling;continuous selectivity; heart muscle: 5.3 nTPM; absolute ceiling;continuous selectivity; kidney: 3.3 nTPM; absolute ceiling;continuous selectivity; liver: 2.8 nTPM; absolute ceiling;continuous selectivity; lung: 3.3 nTPM; absolute ceiling;continuous selectivity; lymph node: 15.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 2.9 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 5 nTPM; continuous selectivity; pituitary gland: 3.3 nTPM; absolute ceiling;continuous selectivity; salivary gland: 4.7 nTPM; continuous selectivity; small intestine: 3.7 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 4.3 nTPM; absolute ceiling;continuous selectivity; spleen: 11.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; stomach: 4.6 nTPM; continuous selectivity; thymus: 5.2 nTPM; continuous selectivity; urinary bladder: 4.4 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 6.1 nTPM (limit 2); bone marrow: 3.1 nTPM (limit 2); choroid plexus: 5.9 nTPM (limit 2); duodenum: 3.5 nTPM (limit 2); heart muscle: 5.3 nTPM (limit 2); kidney: 3.3 nTPM (limit 2); liver: 2.8 nTPM (limit 2); lung: 3.3 nTPM (limit 2); lymph node: 15.2 nTPM (limit 6); pancreas: 2.9 nTPM (limit 2); pituitary gland: 3.3 nTPM (limit 2); small intestine: 3.7 nTPM (limit 2); smooth muscle: 4.3 nTPM (limit 2); spleen: 11.6 nTPM (limit 10); adrenal gland: 6.1 nTPM (baseline 2); bone marrow: 3.1 nTPM (baseline 2); choroid plexus: 5.9 nTPM (baseline 2); duodenum: 3.5 nTPM (baseline 2); heart muscle: 5.3 nTPM (baseline 2); kidney: 3.3 nTPM (baseline 2); liver: 2.8 nTPM (baseline 2); lung: 3.3 nTPM (baseline 2); lymph node: 15.2 nTPM (baseline 6); pancreas: 2.9 nTPM (baseline 2); pituitary gland: 3.3 nTPM (baseline 2); small intestine: 3.7 nTPM (baseline 2); smooth muscle: 4.3 nTPM (baseline 2); spleen: 11.6 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 477/486 (98.1%); Rectum Adenocarcinoma (validation): 203/207 (98.1%); Thyroid Carcinoma (TCGA): 440/495 (88.9%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8IUX4,https://www.uniprot.org/uniprotkb/Q8IUX4/entry,"DNA deaminase (cytidine deaminase) which acts as an inhibitor of retrovirus replication and retrotransposon mobility via deaminase-dependent and -independent mechanisms (PubMed:15141007, PubMed:17121840, PubMed:20062055, PubMed:22915799, PubMed:34774569). Exhibits antiviral activity against viruse such as HIV-1 or HIV-2 (PubMed:15141007, PubMed:15152192, PubMed:17121840, PubMed:20219927, PubMed:21835787, PubMed:22807680, PubMed:23001005, PubMed:23097438, PubMed:23152537, PubMed:34774569). After the penetration of retroviral nucleocapsids into target cells of infection and the initiation of reverse transcription, it can induce the conversion of cytosine to uracil in the minus-sense single-strand viral DNA, leading to G-to-A hypermutations in the subsequent plus-strand viral DNA (PubMed:15141007). The resultant detrimental levels of mutations in the proviral genome, along with a deamination-independent mechanism that works prior to the proviral integration, together exert efficient antiretroviral effects in infected target cells (PubMed:15141007). Selectively targets single-stranded DNA and does not deaminate double-stranded DNA or single- or double-stranded RNA (PubMed:15141007). Exhibits antiviral activity also against hepatitis B virus (HBV), equine infectious anemia virus (EIAV), xenotropic MuLV-related virus (XMRV) and simian foamy virus (SFV) and may inhibit the mobility of LTR and non-LTR retrotransposons (PubMed:16378963, PubMed:16527742, PubMed:19458006, PubMed:20062055, PubMed:20335265). May also play a role in the epigenetic regulation of gene expression through the process of active DNA demethylation (PubMed:21496894)",Widely expressed. Highly expressed in ovary,,,"Cytoplasm Cytoplasm, P-body",15141007|15152192|16378963|16527742|17121840|19458006|20062055|20219927|20335265|21496894|21835787|22807680|22915799|23001005|23097438|23152537|34774569,11863358|15152192|20308164,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
APOBEC4,ENSG00000173627,Unsafe,High RNA,False,True,11.2,11.2,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,CTA,Pass,oncoref.target-sets.2026-10-23.1,False,False,,CTA → Unsafe,True,True,True,0.510834550041,42.7,"hpa_single_cell: /Ciliated cells, max 32.6 nTPM, 1 observations >30; hpa_single_cell_tissue: bronchus/ciliated cells, max 32.7 nTPM, 1 observations >30; hpa_single_cell_tissue: lung/ciliated cells, max 42.7 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,0.5108 TPM; blood/CD4_NAIVE; dice_cd4_naive; vital,42.7 nTPM; lung/ciliated cells; hpa_single_cell_tissue; vital,Uterine Corpus Endometrial Carcinoma (TCGA): 16/176 (9.1%); Ovary Serous Cystadenocarcinoma (validation): 3/81 (3.7%); Lung Adenocarcinoma (TCGA): 10/497 (2.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8WW27,https://www.uniprot.org/uniprotkb/Q8WW27/entry,Putative deaminase whose physiological substrate is not yet known,Predominantly expressed in testis,,,,,16082223,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
AQP5,ENSG00000161798,Unsafe,Protein,False,True,215.9,604.8,86,13,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 3 nTPM; absolute ceiling; basal ganglia: 5.6 nTPM; absolute ceiling; duodenum: 14.9 nTPM; positive ihc;absolute ceiling; hippocampal formation: 2.1 nTPM; absolute ceiling; hypothalamus: 2.7 nTPM; absolute ceiling; midbrain: 4.1 nTPM; absolute ceiling; pancreas: 1.9 nTPM; positive ihc; salivary gland: 604.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 109 nTPM; absolute ceiling; stomach: 51 nTPM; positive ihc;absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 3 nTPM (limit 2); basal ganglia: 5.6 nTPM (limit 2); duodenum: 14.9 nTPM (limit 2); hippocampal formation: 2.1 nTPM (limit 2); hypothalamus: 2.7 nTPM (limit 2); midbrain: 4.1 nTPM (limit 2); salivary gland: 604.8 nTPM (limit 6); skin: 109 nTPM (limit 60); stomach: 51 nTPM (limit 6),bronchus / respiratory epithelial cells: Medium (Enhanced); duodenum / glandular cells: Low (Enhanced); nasopharynx / respiratory epithelial cells: Medium (Enhanced); pancreas / exocrine glandular cells: Low (Enhanced); salivary gland / glandular cells: High (Enhanced); stomach 1 / glandular cells: Low (Enhanced); stomach 2 / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Ovary Serous Cystadenocarcinoma (validation): 75/81 (92.6%); Ovary Serous Cystadenocarcinoma (TCGA): 318/349 (91.1%); Pancreatic Adenocarcinoma (TCGA): 150/176 (85.2%),endometrial cancer: 10/12 (83.3%); pancreatic cancer: 5/8 (62.5%),31,20,P55064,https://www.uniprot.org/uniprotkb/P55064/entry,"Aquaporins form homotetrameric transmembrane channels, with each monomer independently mediating water transport across the plasma membrane along its osmotic gradient (PubMed:18768791, PubMed:8621489). Plays an important role in fluid secretion in salivary glands (By similarity). Required for TRPV4 activation by hypotonicity. Together with TRPV4, controls regulatory volume decrease in salivary epithelial cells (PubMed:16571723). Seems to play a redundant role in water transport in the eye, lung and in sweat glands (By similarity)","Detected in skin eccrine sweat glands, at the apical cell membrane and at intercellular canaliculi (at protein level)","Keratoderma, palmoplantar, Bothnian type: A dermatological disorder characterized by diffuse non-epidermolytic hyperkeratosis of the skin of palms and soles. PPKB is frequently complicated by fungal infections.",,Apical cell membrane Cell membrane Cytoplasmic vesicle membrane,16571723|18768791|8621489,23473857,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
ARFGEF2,ENSG00000124198,Unsafe,Protein,False,True,15.4,78.8,86,83,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 8.8 nTPM; positive ihc;continuous selectivity; adrenal gland: 19.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 5.1 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 5.3 nTPM; absolute ceiling;continuous selectivity; bone marrow: 10.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 8.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 9.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 4.1 nTPM; absolute ceiling;continuous selectivity; colon: 13.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 13.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 10.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 13 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 6.3 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 6.2 nTPM; absolute ceiling;continuous selectivity; kidney: 14.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 12 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 7.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 9.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 6.5 nTPM; absolute ceiling;continuous selectivity; pancreas: 18.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 78.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 8.5 nTPM; absolute ceiling;continuous selectivity; rectum: 15.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 6.7 nTPM; absolute ceiling;continuous selectivity; salivary gland: 10.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 11.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 10.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 10.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 9.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 7.2 nTPM; absolute ceiling;continuous selectivity; spleen: 10.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 15.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; thymus: 11 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 23.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; tongue: 17.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 10.8 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 19.6 nTPM (limit 2); amygdala: 5.1 nTPM (limit 2); basal ganglia: 5.3 nTPM (limit 2); bone marrow: 10.3 nTPM (limit 2); cerebellum: 8.2 nTPM (limit 2); cerebral cortex: 9.3 nTPM (limit 2); choroid plexus: 4.1 nTPM (limit 2); colon: 13.7 nTPM (limit 6); duodenum: 13.3 nTPM (limit 2); esophagus: 10.7 nTPM (limit 6); heart muscle: 13 nTPM (limit 2); hippocampal formation: 6.3 nTPM (limit 2); hypothalamus: 6.2 nTPM (limit 2); kidney: 14.8 nTPM (limit 2); liver: 12 nTPM (limit 2); lung: 7.6 nTPM (limit 2); lymph node: 9.5 nTPM (limit 6); midbrain: 6.5 nTPM (limit 2); pancreas: 18.7 nTPM (limit 2); parathyroid gland: 78.8 nTPM (limit 6); pituitary gland: 8.5 nTPM (limit 2); rectum: 15.2 nTPM (limit 6); retina: 6.7 nTPM (limit 2); salivary gland: 10.7 nTPM (limit 6); skeletal muscle: 11.4 nTPM (limit 2); skin: 10.8 nTPM (limit 10); small intestine: 10.6 nTPM (limit 2); smooth muscle: 9.1 nTPM (limit 2); spinal cord: 7.2 nTPM (limit 2); spleen: 10.1 nTPM (limit 10); stomach: 15.8 nTPM (limit 6); thymus: 11 nTPM (limit 10); thyroid gland: 23.1 nTPM (limit 10); tongue: 17.5 nTPM (limit 6); urinary bladder: 10.8 nTPM (limit 6),adipose tissue / adipocytes: Low (Supported); adrenal gland / glandular cells: Medium (Supported); bone marrow / hematopoietic cells: Medium (Supported); bronchus / respiratory epithelial cells: Medium (Supported); caudate / glial cells: Low (Supported); caudate / neuronal cells: Low (Supported); cerebellum / cells in granular layer: Medium (Supported); cerebellum / cells in molecular layer: Medium (Supported); cerebellum / Purkinje cells: Medium (Supported); cerebral cortex / endothelial cells: Medium (Supported); cerebral cortex / glial cells: Medium (Supported); cerebral cortex / neuronal cells: Medium (Supported); cerebral cortex / neuropil: Medium (Supported); colon / endothelial cells: Medium (Supported); colon / glandular cells: Medium (Supported); colon / peripheral nerve/ganglion: Medium (Supported); duodenum / glandular cells: Medium (Supported); esophagus / squamous epithelial cells: Medium (Supported); heart muscle / cardiomyocytes: Medium (Supported); hippocampus / glial cells: Low (Supported); hippocampus / neuronal cells: Medium (Supported); kidney / cells in glomeruli: Medium (Supported); kidney / cells in tubules: Medium (Supported); liver / cholangiocytes: Low (Supported); liver / hepatocytes: Low (Supported); lung / alveolar cells type I: High (Supported); lung / alveolar cells type II: High (Supported); lung / endothelial cells: Medium (Supported); lung / macrophages: Medium (Supported); lymph node / germinal center cells: Medium (Supported); lymph node / non-germinal center cells: Medium (Supported); nasopharynx / respiratory epithelial cells: Medium (Supported); oral mucosa / squamous epithelial cells: Medium (Supported); pancreas / exocrine glandular cells: Medium (Supported); pancreas / pancreatic endocrine cells: Medium (Supported); parathyroid gland / glandular cells: Medium (Supported); rectum / glandular cells: Medium (Supported); salivary gland / glandular cells: Low (Supported); skeletal muscle / myocytes: Medium (Supported); skin 1 / fibroblasts: Medium (Supported); skin 1 / keratinocytes: Medium (Supported); skin 1 / Langerhans: Medium (Supported); skin 2 / epidermal cells: Medium (Supported); small intestine / glandular cells: Medium (Supported); smooth muscle / smooth muscle cells: Low (Supported); spleen / cells in red pulp: Medium (Supported); spleen / cells in white pulp: Low (Supported); stomach 1 / glandular cells: Medium (Supported); stomach 2 / glandular cells: Medium (Supported); thyroid gland / glandular cells: Medium (Supported); urinary bladder / urothelial cells: Medium (Supported),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 50/50 (100.0%),breast cancer: 12/12 (100.0%); pancreatic cancer: 12/12 (100.0%),31,20,Q9Y6D5,https://www.uniprot.org/uniprotkb/Q9Y6D5/entry,Promotes guanine-nucleotide exchange on ARF1 and ARF3 and to a lower extent on ARF5 and ARF6. Promotes the activation of ARF1/ARF5/ARF6 through replacement of GDP with GTP. Involved in the regulation of Golgi vesicular transport. Required for the integrity of the endosomal compartment. Involved in trafficking from the trans-Golgi network (TGN) to endosomes and is required for membrane association of the AP-1 complex and GGA1. Seems to be involved in recycling of the transferrin receptor from recycling endosomes to the plasma membrane. Probably is involved in the exit of GABA(A) receptors from the endoplasmic reticulum. Involved in constitutive release of tumor necrosis factor receptor 1 via exosome-like vesicles; the function seems to involve PKA and specifically PRKAR2B. Proposed to act as A kinase-anchoring protein (AKAP) and may mediate crosstalk between Arf and PKA pathways,"Expressed in placenta, lung, heart, brain, kidney and pancreas","Periventricular nodular heterotopia 2: A developmental disorder characterized by the presence of periventricular nodules of cerebral gray matter, resulting from a failure of neurons to migrate normally from the lateral ventricular proliferative zone, where they are formed, to the cerebral cortex. PVNH2 is an autosomal recessive form characterized by microcephaly (small brain), severe developmental delay and recurrent infections. No anomalies extrinsic to the central nervous system, such as dysmorphic features or grossly abnormal endocrine or other conditions, are associated with PVNH2.",,"Cytoplasm Membrane Golgi apparatus Cytoplasm, perinuclear region Golgi apparatus, trans-Golgi network Endosome Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Cell projection, dendrite Cytoplasmic vesicle Synapse Cytoplasm, cytoskeleton",12051703|12571360|15385626|16477018|17276987|18625701|20360857,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
ARHGAP11A,ENSG00000198826,Unsafe,Protein,False,True,7.9,25.3,72,43,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 0.9 nTPM; positive ihc; bone marrow: 23.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 0.3 nTPM; positive ihc; cerebral cortex: 0.8 nTPM; positive ihc; colon: 7.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 5.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 5 nTPM; positive ihc;continuous selectivity; heart muscle: 0.7 nTPM; positive ihc; lung: 1.6 nTPM; positive ihc; lymph node: 12.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 2.9 nTPM; absolute ceiling;continuous selectivity; pancreas: 2.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; rectum: 8.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 1.2 nTPM; positive ihc; skeletal muscle: 0.8 nTPM; positive ihc; skin: 4.1 nTPM; positive ihc;continuous selectivity; small intestine: 7.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 4.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 6.4 nTPM; absolute ceiling;continuous selectivity; stomach: 3.4 nTPM; positive ihc;continuous selectivity; thymus: 25.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 1.1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 23.5 nTPM (limit 2); colon: 7.2 nTPM (limit 6); duodenum: 5.7 nTPM (limit 2); lymph node: 12.9 nTPM (limit 6); midbrain: 2.9 nTPM (limit 2); pancreas: 2.3 nTPM (limit 2); rectum: 8.4 nTPM (limit 6); small intestine: 7.1 nTPM (limit 2); smooth muscle: 4.6 nTPM (limit 2); spinal cord: 6.4 nTPM (limit 2); thymus: 25.3 nTPM (limit 10),adrenal gland / glandular cells: Medium (Enhanced); bone marrow / hematopoietic cells: Medium (Enhanced); bronchus / respiratory epithelial cells: Low (Enhanced); caudate / neuronal cells: Medium (Enhanced); cerebellum / cells in molecular layer: Medium (Enhanced); cerebellum / Purkinje cells: Medium (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); cerebral cortex / neuropil: Medium (Enhanced); colon / endothelial cells: Low (Enhanced); colon / glandular cells: Medium (Enhanced); duodenum / glandular cells: Medium (Enhanced); esophagus / squamous epithelial cells: Medium (Enhanced); heart muscle / cardiomyocytes: Medium (Enhanced); lung / macrophages: Low (Enhanced); lymph node / germinal center cells: Medium (Enhanced); lymph node / non-germinal center cells: Medium (Enhanced); pancreas / pancreatic endocrine cells: Medium (Enhanced); rectum / glandular cells: Medium (Enhanced); salivary gland / glandular cells: Low (Enhanced); skeletal muscle / myocytes: Medium (Enhanced); skin 1 / keratinocytes: Medium (Enhanced); skin 1 / Langerhans: Low (Enhanced); skin 2 / epidermal cells: Low (Enhanced); small intestine / glandular cells: Medium (Enhanced); smooth muscle / smooth muscle cells: Low (Enhanced); stomach 1 / glandular cells: Low (Enhanced); stomach 2 / glandular cells: Low (Enhanced); thyroid gland / glandular cells: Medium (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Rectum Adenocarcinoma (validation): 205/207 (99.0%); Glioblastoma Multiforme (validation): 57/58 (98.3%),testis cancer: 11/11 (100.0%); melanoma: 10/11 (90.9%),31,20,Q6P4F7,https://www.uniprot.org/uniprotkb/Q6P4F7/entry,GTPase activator for the Rho-type GTPases by converting them to an inactive GDP-bound state,,,,Nucleus,27957544,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ARHGAP11B,ENSG00000285077,Unsafe,RNA,False,True,0.3,5.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,"incomplete routine rna; incomplete routine rna; missing normal RNA: amygdala, basal ganglia, cerebellum, hippocampal formation, hypothalamus, midbrain, pituitary gland, spinal cord; bone marrow: 5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 1.4 nTPM; continuous selectivity;reproductive not higher; rectum: 0.3 nTPM; continuous selectivity;reproductive not higher; skin: 0.5 nTPM; continuous selectivity;reproductive not higher; small intestine: 0.3 nTPM; continuous selectivity;reproductive not higher; smooth muscle: 0.2 nTPM; continuous selectivity; spleen: 0.3 nTPM; continuous selectivity;reproductive not higher; stomach: 0.4 nTPM; continuous selectivity;reproductive not higher; thymus: 1.4 nTPM; continuous selectivity;reproductive not higher",Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 5 nTPM (limit 2); bone marrow: 5 nTPM (baseline 2),,incomplete_routine_rna,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 36/50 (72.0%); Rectum Adenocarcinoma (validation): 5/207 (2.4%); Colon Adenocarcinoma (validation): 11/486 (2.3%),liver cancer: 2/11 (18.2%); breast cancer: 0/11 (0.0%),28,20,Q3KRB8,https://www.uniprot.org/uniprotkb/Q3KRB8/entry,"Hominin-specific protein that promotes development and evolutionary expansion of the brain neocortex (PubMed:25721503, PubMed:27957544, PubMed:30484771, PubMed:32554627, PubMed:33938018). Able to promote amplification of basal progenitors in the subventricular zone, producing more neurons during fetal corticogenesis, thereby playing a key role in neocortex expansion (PubMed:25721503). Promotes the proliferation of basal progenitors by inhibiting the mitochondrial permeability transition pore (mPTP): delays the opening of the mPTP via interaction with ADP:ATP translocase, thereby increasing mitochondrial Ca(2+) concentration and inducing glutamine catabolism, which is required for basal progenitor proliferation (PubMed:31883789). Does not possess GTPase activator activity: the absence of GTPase activator activity is required to promote amplification of basal progenitors during neocortex development (PubMed:25721503, PubMed:27957544)",,,"Although it contains a Rho-GAP domains, does not have GTPase activator activity (PubMed:25721503, PubMed:27957544). The absence of GTPase activator activity is required to promote amplification of basal progenitors (PubMed:27957544). Restoring this activity abolishes ability to promote amplification of basal progenitors during neocortex development (PubMed:27957544)",Mitochondrion matrix,25721503|27957544|30484771|31883789|32554627|33938018,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ARHGAP28,ENSG00000088756,Unsafe,Protein,False,True,75.1,75.1,93,17,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 1.9 nTPM; positive ihc; colon: 1.8 nTPM; positive ihc; heart muscle: 1.9 nTPM; positive ihc; kidney: 8.1 nTPM; positive ihc;absolute ceiling; lung: 4.4 nTPM; positive ihc;absolute ceiling; pancreas: 3.7 nTPM; positive ihc;absolute ceiling; skeletal muscle: 4.8 nTPM; positive ihc;absolute ceiling; skin: 2 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",kidney: 8.1 nTPM (limit 2); lung: 4.4 nTPM (limit 2); pancreas: 3.7 nTPM (limit 2); skeletal muscle: 4.8 nTPM (limit 2),adrenal gland / glandular cells: Low (Enhanced); colon / endothelial cells: Medium (Enhanced); colon / peripheral nerve/ganglion: Low (Enhanced); heart muscle / cardiomyocytes: Low (Enhanced); kidney / cells in glomeruli: High (Enhanced); kidney / proximal tubules (cell body): Low (Enhanced); lung / macrophages: Low (Enhanced); pancreas / exocrine glandular cells: Low (Enhanced); skeletal muscle / myocytes: Low (Enhanced); skin 1 / keratinocytes: Low (Enhanced); skin 2 / epidermal cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 38/50 (76.0%); Lung Squamous Cell Carcinoma (validation): 50/68 (73.5%); Testicular Germ Cell Tumor (TCGA): 86/133 (64.7%),testis cancer: 1/10 (10.0%); glioma: 1/11 (9.1%),31,20,Q9P2N2,https://www.uniprot.org/uniprotkb/Q9P2N2/entry,GTPase activator for the Rho-type GTPases by converting them to an inactive GDP-bound state,"Expressed in testis. Expressed at moderate level in kidney and ovary, and weakly expressed in spleen and skeletal muscle",,,,,10718198,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
ARHGEF18,ENSG00000104880,Unsafe,Protein,False,True,16.2,35.1,92,55,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 15.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 10.9 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 12 nTPM; absolute ceiling;continuous selectivity; bone marrow: 26.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 14.6 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 15.3 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 4.3 nTPM; absolute ceiling;continuous selectivity; colon: 21.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 13 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 19.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 6.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 12.7 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 10.1 nTPM; absolute ceiling;continuous selectivity; kidney: 23.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 12.7 nTPM; absolute ceiling;continuous selectivity; lung: 14.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 29 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 11.4 nTPM; absolute ceiling;continuous selectivity; pancreas: 20.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 10.8 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 15.4 nTPM; absolute ceiling;continuous selectivity; rectum: 7.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 4.8 nTPM; absolute ceiling;continuous selectivity; salivary gland: 10.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 5.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 13.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 30.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 13.4 nTPM; absolute ceiling;continuous selectivity; spinal cord: 11.8 nTPM; absolute ceiling;continuous selectivity; spleen: 35.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; stomach: 21.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; thymus: 32.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 10.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; urinary bladder: 13.5 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 15.4 nTPM (limit 2); amygdala: 10.9 nTPM (limit 2); basal ganglia: 12 nTPM (limit 2); bone marrow: 26.8 nTPM (limit 2); cerebellum: 14.6 nTPM (limit 4); cerebral cortex: 15.3 nTPM (limit 4); choroid plexus: 4.3 nTPM (limit 2); colon: 21.5 nTPM (limit 6); duodenum: 13 nTPM (limit 2); esophagus: 19.3 nTPM (limit 6); heart muscle: 6.9 nTPM (limit 2); hippocampal formation: 12.7 nTPM (limit 2); hypothalamus: 10.1 nTPM (limit 2); kidney: 23.4 nTPM (limit 2); liver: 12.7 nTPM (limit 4); lung: 14.1 nTPM (limit 2); lymph node: 29 nTPM (limit 6); midbrain: 11.4 nTPM (limit 2); pancreas: 20.4 nTPM (limit 2); parathyroid gland: 10.8 nTPM (limit 8); pituitary gland: 15.4 nTPM (limit 2); rectum: 7.5 nTPM (limit 6); retina: 4.8 nTPM (limit 2); salivary gland: 10.6 nTPM (limit 6); skeletal muscle: 5.1 nTPM (limit 2); skin: 13.3 nTPM (limit 10); small intestine: 30.3 nTPM (limit 2); smooth muscle: 13.4 nTPM (limit 4); spinal cord: 11.8 nTPM (limit 2); spleen: 35.1 nTPM (limit 10); stomach: 21.9 nTPM (limit 6); thymus: 32.2 nTPM (limit 10); thyroid gland: 10.5 nTPM (limit 10); urinary bladder: 13.5 nTPM (limit 6),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / ciliated cells (cell body): Low (Approved); bronchus / ciliated cells (cilia axoneme): Medium (Approved); bronchus / ciliated cells (ciliary rootlets): Medium (Approved); bronchus / ciliated cells (tip of cilia): High (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Medium (Approved); kidney / cells in tubules: Medium (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: High (Approved); nasopharynx / basal cells: Medium (Approved); nasopharynx / ciliated cells (cell body): Medium (Approved); nasopharynx / ciliated cells (cilia axoneme): Medium (Approved); nasopharynx / ciliated cells (ciliary rootlets): High (Approved); nasopharynx / ciliated cells (tip of cilia): Medium (Approved); nasopharynx / goblet cells: Medium (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / Langerhans: High (Approved); small intestine / glandular cells: Medium (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Low (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (TCGA): 254/254 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Bladder Urothelial Carcinoma (TCGA): 169/169 (100.0%),colorectal cancer: 7/11 (63.6%); lymphoma: 6/11 (54.5%),31,20,Q6ZSZ5,https://www.uniprot.org/uniprotkb/Q6ZSZ5/entry,"Acts as a guanine nucleotide exchange factor (GEF) for RhoA GTPases. Its activation induces formation of actin stress fibers. Also acts as a GEF for RAC1, inducing production of reactive oxygen species (ROS). Does not act as a GEF for CDC42. The G protein beta-gamma (Gbetagamma) subunits of heterotrimeric G proteins act as activators, explaining the integrated effects of LPA and other G protein-coupled receptor agonists on actin stress fiber formation, cell shape change and ROS production. Required for EPB41L4B-mediated regulation of the circumferential actomyosin belt in epithelial cells (PubMed:22006950)","Expressed in all tissues tested with highest expression in kidney and pancreas. Weakly or not expressed in liver, skeletal muscle and testis. Isoform 1: Expressed in eosinophils (PubMed:29601110). Isoform 2: Expressed in eosinophils (PubMed:29601110). Isoform 3: Expressed in eosinophils (PubMed:29601110). Isoform 4: Not detected in eosinophils (PubMed:29601110)","Retinitis pigmentosa 78: A form of retinitis pigmentosa, a retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. RP78 inheritance is autosomal recessive.",,"Cytoplasm Cytoplasm, cytoskeleton Cell membrane Apical cell membrane",11085924|14512443|15558029|22006950|28132693,11085924|14512443|15558029|29601110,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ARL17A,ENSG00000185829,Unsafe,Protein,False,True,39.0,39.0,75,54,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 13.4 nTPM; absolute ceiling; adrenal gland: 11.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 5.3 nTPM; absolute ceiling; basal ganglia: 6 nTPM; absolute ceiling; bone marrow: 18 nTPM; absolute ceiling;continuous selectivity; cerebellum: 14.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 9.5 nTPM; positive ihc;absolute ceiling; choroid plexus: 22.3 nTPM; absolute ceiling;continuous selectivity; colon: 12.5 nTPM; positive ihc;absolute ceiling; duodenum: 7.3 nTPM; positive ihc;absolute ceiling; esophagus: 9.8 nTPM; positive ihc;absolute ceiling; heart muscle: 10.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 6.4 nTPM; absolute ceiling; hypothalamus: 5.9 nTPM; absolute ceiling; kidney: 12.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 14.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 13.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 16.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 4.9 nTPM; absolute ceiling; pancreas: 9.2 nTPM; positive ihc;absolute ceiling; parathyroid gland: 21.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 13 nTPM; absolute ceiling;continuous selectivity; rectum: 18.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 33.6 nTPM; absolute ceiling;continuous selectivity; salivary gland: 11 nTPM; absolute ceiling; skeletal muscle: 17.3 nTPM; absolute ceiling;continuous selectivity; skin: 17.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 9.2 nTPM; positive ihc;absolute ceiling; smooth muscle: 18.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 6.4 nTPM; absolute ceiling; spleen: 14.4 nTPM; positive ihc;absolute ceiling; stomach: 10.3 nTPM; positive ihc;absolute ceiling; thymus: 19.5 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 18 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 19.8 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 10.4 nTPM; positive ihc;absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 13.4 nTPM (limit 10); adrenal gland: 11.5 nTPM (limit 2); amygdala: 5.3 nTPM (limit 2); basal ganglia: 6 nTPM (limit 2); bone marrow: 18 nTPM (limit 2); cerebellum: 14.1 nTPM (limit 2); cerebral cortex: 9.5 nTPM (limit 2); choroid plexus: 22.3 nTPM (limit 2); colon: 12.5 nTPM (limit 6); duodenum: 7.3 nTPM (limit 2); esophagus: 9.8 nTPM (limit 6); heart muscle: 10.5 nTPM (limit 2); hippocampal formation: 6.4 nTPM (limit 2); hypothalamus: 5.9 nTPM (limit 2); kidney: 12.8 nTPM (limit 2); liver: 14.2 nTPM (limit 2); lung: 13.1 nTPM (limit 2); lymph node: 16.1 nTPM (limit 6); midbrain: 4.9 nTPM (limit 2); pancreas: 9.2 nTPM (limit 2); parathyroid gland: 21.5 nTPM (limit 6); pituitary gland: 13 nTPM (limit 2); rectum: 18.1 nTPM (limit 6); retina: 33.6 nTPM (limit 2); salivary gland: 11 nTPM (limit 6); skeletal muscle: 17.3 nTPM (limit 2); skin: 17.6 nTPM (limit 10); small intestine: 9.2 nTPM (limit 2); smooth muscle: 18.9 nTPM (limit 2); spinal cord: 6.4 nTPM (limit 2); spleen: 14.4 nTPM (limit 10); stomach: 10.3 nTPM (limit 6); thymus: 19.5 nTPM (limit 10); thyroid gland: 18 nTPM (limit 10); tongue: 19.8 nTPM (limit 6); urinary bladder: 10.4 nTPM (limit 6); adipose tissue: 13.4 nTPM (baseline 10); adrenal gland: 11.5 nTPM (baseline 2); amygdala: 5.3 nTPM (baseline 2); basal ganglia: 6 nTPM (baseline 2); bone marrow: 18 nTPM (baseline 2); cerebellum: 14.1 nTPM (baseline 2); cerebral cortex: 9.5 nTPM (baseline 2); choroid plexus: 22.3 nTPM (baseline 2); colon: 12.5 nTPM (baseline 6); duodenum: 7.3 nTPM (baseline 2); esophagus: 9.8 nTPM (baseline 6); heart muscle: 10.5 nTPM (baseline 2); hippocampal formation: 6.4 nTPM (baseline 2); hypothalamus: 5.9 nTPM (baseline 2); kidney: 12.8 nTPM (baseline 2); liver: 14.2 nTPM (baseline 2); lung: 13.1 nTPM (baseline 2); lymph node: 16.1 nTPM (baseline 6); midbrain: 4.9 nTPM (baseline 2); pancreas: 9.2 nTPM (baseline 2); parathyroid gland: 21.5 nTPM (baseline 6); pituitary gland: 13 nTPM (baseline 2); rectum: 18.1 nTPM (baseline 6); retina: 33.6 nTPM (baseline 2); salivary gland: 11 nTPM (baseline 6); skeletal muscle: 17.3 nTPM (baseline 2); skin: 17.6 nTPM (baseline 10); small intestine: 9.2 nTPM (baseline 2); smooth muscle: 18.9 nTPM (baseline 2); spinal cord: 6.4 nTPM (baseline 2); spleen: 14.4 nTPM (baseline 10); stomach: 10.3 nTPM (baseline 6); thymus: 19.5 nTPM (baseline 10); thyroid gland: 18 nTPM (baseline 10); tongue: 19.8 nTPM (baseline 6); urinary bladder: 10.4 nTPM (baseline 6),adrenal gland / glandular cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / glial cells: High (Uncertain); caudate / neuronal cells: High (Uncertain); cerebellum / cells in molecular layer: High (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / endothelial cells: Medium (Uncertain); cerebral cortex / glial cells: Medium (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / glandular cells: Medium (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Low (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / glial cells: Low (Uncertain); kidney / cells in glomeruli: Low (Uncertain); kidney / cells in tubules: High (Uncertain); liver / cholangiocytes: Medium (Uncertain); liver / hepatocytes: High (Uncertain); lung / alveolar cells: Low (Uncertain); lymph node / germinal center cells: Low (Uncertain); oral mucosa / squamous epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Low (Uncertain); pancreas / pancreatic endocrine cells: Low (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: Medium (Uncertain); skin 1 / fibroblasts: Medium (Uncertain); skin 1 / keratinocytes: Low (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: High (Uncertain); smooth muscle / smooth muscle cells: Low (Uncertain); spleen / cells in white pulp: Medium (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Low (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Colon Adenocarcinoma (validation): 485/486 (99.8%); Breast Invasive Carcinoma (validation): 48/50 (96.0%),melanoma: 8/10 (80.0%); renal cancer: 9/12 (75.0%),31,20,Q8IVW1 | I3L3L1,https://www.uniprot.org/uniprotkb/Q8IVW1/entry | https://www.uniprot.org/uniprotkb/I3L3L1/entry,Putative small GTP-binding protein cycling between an inactive GDP-bound and an active GTP-bound form,,,,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ARL6,ENSG00000113966,Unsafe,Protein,False,True,6.8,36.8,78,64,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 5 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 4.1 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 6 nTPM; absolute ceiling;continuous selectivity; bone marrow: 0.8 nTPM; positive ihc; cerebellum: 5.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 7.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 2.8 nTPM; absolute ceiling;continuous selectivity; colon: 2.3 nTPM; positive ihc; duodenum: 1.2 nTPM; positive ihc; esophagus: 2.9 nTPM; positive ihc;continuous selectivity; heart muscle: 3.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 5 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 5 nTPM; absolute ceiling;continuous selectivity; kidney: 7.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 2.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 4.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 2.3 nTPM; positive ihc; midbrain: 3.6 nTPM; absolute ceiling;continuous selectivity; pancreas: 3.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 12.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 4 nTPM; absolute ceiling;continuous selectivity; rectum: 2.4 nTPM; positive ihc;continuous selectivity; retina: 36.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 5.6 nTPM; positive ihc;continuous selectivity; skeletal muscle: 1.4 nTPM; positive ihc; skin: 2.8 nTPM; positive ihc; small intestine: 1.7 nTPM; positive ihc; smooth muscle: 4.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 3.1 nTPM; absolute ceiling;continuous selectivity; spleen: 2.7 nTPM; positive ihc; stomach: 2.8 nTPM; positive ihc;continuous selectivity; thyroid gland: 5.3 nTPM; positive ihc;continuous selectivity; urinary bladder: 3.1 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 5 nTPM (limit 2); amygdala: 4.1 nTPM (limit 2); basal ganglia: 6 nTPM (limit 2); cerebellum: 5.1 nTPM (limit 2); cerebral cortex: 7.8 nTPM (limit 2); choroid plexus: 2.8 nTPM (limit 2); heart muscle: 3.3 nTPM (limit 2); hippocampal formation: 5 nTPM (limit 2); hypothalamus: 5 nTPM (limit 2); kidney: 7.3 nTPM (limit 2); liver: 2.5 nTPM (limit 2); lung: 4.9 nTPM (limit 2); midbrain: 3.6 nTPM (limit 2); pancreas: 3.3 nTPM (limit 2); parathyroid gland: 12.3 nTPM (limit 6); pituitary gland: 4 nTPM (limit 2); retina: 36.8 nTPM (limit 2); smooth muscle: 4.1 nTPM (limit 2); spinal cord: 3.1 nTPM (limit 2),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / neuronal cells: High (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / fibroblasts: Low (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 46/50 (92.0%); Kidney Chromophobe (TCGA): 54/64 (84.4%),liver cancer: 10/12 (83.3%); colorectal cancer: 7/11 (63.6%),31,20,Q9H0F7,https://www.uniprot.org/uniprotkb/Q9H0F7/entry,"Involved in membrane protein trafficking at the base of the ciliary organelle. Mediates recruitment onto plasma membrane of the BBSome complex which would constitute a coat complex required for sorting of specific membrane proteins to the primary cilia (PubMed:20603001). Together with BBS1, is necessary for correct trafficking of PKD1 to primary cilia (By similarity). Together with the BBSome complex and LTZL1, controls SMO ciliary trafficking and contributes to the sonic hedgehog (SHH) pathway regulation (PubMed:22072986). May regulate cilia assembly and disassembly and subsequent ciliary signaling events such as the Wnt signaling cascade (PubMed:20207729). Isoform 2 may be required for proper retinal function and organization (By similarity)",,"Bardet-Biedl syndrome 3: A syndrome characterized by usually severe pigmentary retinopathy, early-onset obesity, polydactyly, hypogenitalism, renal malformation and intellectual disability. Secondary features include diabetes mellitus, hypertension and congenital heart disease. Bardet-Biedl syndrome inheritance is autosomal recessive, but three mutated alleles (two at one locus, and a third at a second locus) may be required for clinical manifestation of some forms of the disease. Retinitis pigmentosa 55: A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.",,"Cell projection, cilium membrane Cytoplasm, cytoskeleton, cilium axoneme Cytoplasm, cytoskeleton, cilium basal body",20207729|20603001|22072986,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
ARMC12,ENSG00000157343,Unsafe,RNA,False,True,62.4,62.4,85,1,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,amygdala: 2.8 nTPM; absolute ceiling; basal ganglia: 3.6 nTPM; absolute ceiling; choroid plexus: 5.4 nTPM; absolute ceiling; hippocampal formation: 2.3 nTPM; absolute ceiling; hypothalamus: 2.8 nTPM; absolute ceiling; midbrain: 2.2 nTPM; absolute ceiling; pituitary gland: 10.9 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 2.8 nTPM (limit 2); basal ganglia: 3.6 nTPM (limit 2); choroid plexus: 5.4 nTPM (limit 2); hippocampal formation: 2.3 nTPM (limit 2); hypothalamus: 2.8 nTPM (limit 2); midbrain: 2.2 nTPM (limit 2); pituitary gland: 10.9 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 12/58 (20.7%); Glioblastoma Multiforme (TCGA): 19/141 (13.5%); Skin Cuteneous Melanoma (TCGA): 3/99 (3.0%),breast cancer: 0/12 (0.0%); cervical cancer: 0/11 (0.0%),29,20,Q5T9G4,https://www.uniprot.org/uniprotkb/Q5T9G4/entry,"Essential for male fertility and sperm mitochondrial sheath formation (By similarity). Required for proper mitochondrial elongation and coiling along the flagellum during the formation of the mitochondrial sheath (By similarity). Facilitates the growth and aggressiveness of neuroblastoma cells (PubMed:30026490). Increases the EZH2 activity and H3K27me3 levels in a RBBP4-dependent manner, and facilitates the enrichment of polycomb repressive complex 2 and H3K27me3 on gene promoters, resulting in transcriptional repression of tumor suppressors affecting the proliferation, invasion, and metastasis of tumor cells (PubMed:30026490)","Expressed in testis (PubMed:33536340, PubMed:35534203). Highly expressed in the mid-piece of the elongated and late spermatids (PubMed:35534203). Expressed at higher levels in neuroblastoma tissues and cell lines, than those of normal dorsal ganglia (at protein level) (PubMed:30026490). Expressed in breast cancer, colon cancer, hepatocellular carcinoma, lung cancer, pancreas cancer, prostate cancer, renal cancer and gastric cancer, but not in their normal counterparts (PubMed:30026490)",Spermatogenic failure 90: An autosomal recessive male infertility disorder due to severely reduced progressive motility of sperm.,,Nucleus Mitochondrion outer membrane,30026490,30026490|33536340|35534203,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
ARMC3,ENSG00000165309,Unsafe,Protein,False,True,43.1,50.1,102,11,Positive somewhere,True,True,False,True,Excluded,Normal,False,,Not assessed,,,positive ihc outside permitted; basal ganglia: 3.7 nTPM; absolute ceiling; choroid plexus: 50.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 3.2 nTPM; absolute ceiling; hypothalamus: 4 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",basal ganglia: 3.7 nTPM (limit 2); choroid plexus: 50.1 nTPM (limit 2); hippocampal formation: 3.2 nTPM (limit 2); hypothalamus: 4 nTPM (limit 2),bronchus / ciliated cells (cilia axoneme): High (Enhanced); bronchus / ciliated cells (tip of cilia): High (Enhanced); nasopharynx / ciliated cells (cilia axoneme): Medium (Enhanced); nasopharynx / ciliated cells (tip of cilia): Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 20/50 (40.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 70/176 (39.8%); Ovary Serous Cystadenocarcinoma (validation): 24/81 (29.6%),breast cancer: 0/11 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q5W041,https://www.uniprot.org/uniprotkb/Q5W041/entry,"Essential for male fertility and sperm motility (By similarity). During spermatogenesis, promotes the autophagic degradation of excessive ribosomes, providing energy resources for mitochondria and thus ensuring sperm flagellar motility (PubMed:34428398)","Expressed in skeletal muscle, brain, lung, kidney, prostate and testis Mainly expressed in skeletal muscle, liver, spleen and thymus Expressed only in the testis among normal tissues but is expressed frequently in various cancer tissues and, particularly, in pancreatic, lung and endometrial cancers",,,,34428398,16397042|16915934,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
ARMC8,ENSG00000114098,Unsafe,Protein,False,True,19.1,59.8,93,75,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 20.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; adrenal gland: 13.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 14 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 13.6 nTPM; absolute ceiling;continuous selectivity; bone marrow: 59.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 38.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 22.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 21.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 16.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 11.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 20.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 16.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 14 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 17.4 nTPM; absolute ceiling;continuous selectivity; kidney: 18.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 16.4 nTPM; absolute ceiling;continuous selectivity; lung: 15.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 20.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 14.5 nTPM; absolute ceiling;continuous selectivity; pancreas: 13.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 20.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 12 nTPM; absolute ceiling;continuous selectivity; rectum: 17.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 25.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 12.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 37.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 12.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 13.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 23.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 15.9 nTPM; absolute ceiling;continuous selectivity; spleen: 15.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 15 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 21.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 20.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; tongue: 33.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 21.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 20.1 nTPM (limit 20); adrenal gland: 13.9 nTPM (limit 2); amygdala: 14 nTPM (limit 2); basal ganglia: 13.6 nTPM (limit 2); bone marrow: 59.8 nTPM (limit 2); cerebellum: 38.1 nTPM (limit 2); cerebral cortex: 22.8 nTPM (limit 2); choroid plexus: 21.4 nTPM (limit 2); colon: 16.3 nTPM (limit 6); duodenum: 11.7 nTPM (limit 2); esophagus: 20.3 nTPM (limit 6); heart muscle: 16.8 nTPM (limit 2); hippocampal formation: 14 nTPM (limit 2); hypothalamus: 17.4 nTPM (limit 2); kidney: 18.2 nTPM (limit 2); liver: 16.4 nTPM (limit 4); lung: 15.8 nTPM (limit 2); lymph node: 20.7 nTPM (limit 8); midbrain: 14.5 nTPM (limit 2); pancreas: 13.8 nTPM (limit 2); parathyroid gland: 20.6 nTPM (limit 6); pituitary gland: 12 nTPM (limit 2); rectum: 17.8 nTPM (limit 6); retina: 25.4 nTPM (limit 2); salivary gland: 12.2 nTPM (limit 6); skeletal muscle: 37.4 nTPM (limit 2); skin: 12.4 nTPM (limit 10); small intestine: 13.1 nTPM (limit 2); smooth muscle: 23.5 nTPM (limit 2); spinal cord: 15.9 nTPM (limit 2); spleen: 15.5 nTPM (limit 10); stomach: 15 nTPM (limit 6); thymus: 21.6 nTPM (limit 10); thyroid gland: 20.7 nTPM (limit 10); tongue: 33.4 nTPM (limit 6); urinary bladder: 21.4 nTPM (limit 6),adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / ciliated cells (cell body): High (Approved); bronchus / ciliated cells (ciliary rootlets): High (Approved); bronchus / goblet cells: High (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Medium (Approved); nasopharynx / basal cells: High (Approved); nasopharynx / ciliated cells (cell body): High (Approved); nasopharynx / ciliated cells (ciliary rootlets): High (Approved); nasopharynx / goblet cells: High (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: High (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: High (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: High (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Low (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (TCGA): 141/141 (100.0%),testis cancer: 11/12 (91.7%); colorectal cancer: 9/11 (81.8%),31,20,Q8IUR7,https://www.uniprot.org/uniprotkb/Q8IUR7/entry,Component of the CTLH E3 ubiquitin-protein ligase complex that selectively accepts ubiquitin from UBE2H and mediates ubiquitination and subsequent proteasomal degradation of the transcription factor HBP1,,,,Nucleus Cytoplasm,29911972,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
ARRDC5,ENSG00000205784,Unsafe,High RNA,False,True,16.5,16.5,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 88/91 values ≥5 TPM, max 21.6396; DICE MONOCYTES (unstimulated): 19/91 values ≥5 TPM, max 7.91868; DICE M2 (unstimulated): 26/90 values ≥5 TPM, max 7.45969; DICE NK (unstimulated): 90/90 values ≥5 TPM, max 24.1957; DICE TREG_MEM (unstimulated): 89/89 values ≥5 TPM, max 22.5481; DICE CD4_NAIVE (unstimulated): 88/88 values ≥5 TPM, max 27.5726; DICE CD4_STIM (activated): 32/88 values ≥5 TPM, max 10.3669; DICE TREG_NAIVE (unstimulated): 89/89 values ≥5 TPM, max 38.6676; DICE TFH (unstimulated): 88/89 values ≥5 TPM, max 30.4905; DICE TH1 (unstimulated): 76/81 values ≥5 TPM, max 16.0536; DICE THSTAR (unstimulated): 47/88 values ≥5 TPM, max 11.0978; DICE TH17 (unstimulated): 38/89 values ≥5 TPM, max 9.54695; DICE TH2 (unstimulated): 78/89 values ≥5 TPM, max 14.7037; DICE CD8_NAIVE (unstimulated): 89/89 values ≥5 TPM, max 33.5284; DICE CD8_STIM (activated): 66/88 values ≥5 TPM, max 11.64; hpa_immune_monaco basophil: 8.5 TPM; hpa_immune_monaco Central memory CD8 T-cell: 14.4 TPM; hpa_immune_monaco Effector memory CD8 T-cell: 10.3 TPM; hpa_immune_monaco MAIT T-cell: 12.2 TPM; hpa_immune_monaco Memory CD4 T-cell TFH: 5.5 TPM; hpa_immune_monaco Memory CD4 T-cell Th1: 7 TPM; hpa_immune_monaco Memory CD4 T-cell Th17: 5.3 TPM; hpa_immune_monaco Memory CD4 T-cell Th2: 5.1 TPM; hpa_immune_monaco naive B-cell: 8.3 TPM; hpa_immune_monaco naive CD4 T-cell: 10.8 TPM; hpa_immune_monaco naive CD8 T-cell: 19 TPM; hpa_immune_monaco NK-cell: 10.1 TPM; hpa_immune_monaco Non-switched memory B-cell: 6.7 TPM; hpa_immune_monaco Non-Vd2 gdTCR: 8.2 TPM; hpa_immune_monaco plasmacytoid DC: 12.4 TPM; hpa_immune_monaco Progenitor cell: 8.8 TPM; hpa_immune_monaco T-reg: 9.1 TPM; hpa_immune_monaco Terminal effector memory CD8 T-cell: 7.8 TPM; hpa_immune_monaco Vd2 gdTCR: 13.2 TPM",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,38.6676393955,20.9,"dice_cd8_naive: blood/CD8_NAIVE, max 33.5284 TPM, 8 observations >30; dice_tfh: blood/TFH, max 30.4905 TPM, 1 observations >30; dice_treg_naive: blood/TREG_NAIVE, max 38.6676 TPM, 8 observations >30",CTA,oncoref.target-sets.2026-10-23.2,38.67 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,20.9 nTPM; pbmc/t-cells; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 2/58 (3.4%); Uterine Corpus Endometrial Carcinoma (TCGA): 5/176 (2.8%); Bladder Urothelial Carcinoma (TCGA): 3/169 (1.8%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,A6NEK1,https://www.uniprot.org/uniprotkb/A6NEK1/entry,Plays an essential role in spermatogenesis. May be involved in the anchoring of the sperm head to the tail during spermatogenesis by affecting SEC22A-mediated SUN5 and NDC1 transport and localization,Testis-enriched,,,Membrane,,37069147,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
ART5,ENSG00000167311,Unsafe,RNA,False,True,28.6,28.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,choroid plexus: 2.8 nTPM; absolute ceiling; skeletal muscle: 13 nTPM; absolute ceiling;continuous selectivity; tongue: 10 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 2.8 nTPM (limit 2); skeletal muscle: 13 nTPM (limit 2); tongue: 10 nTPM (limit 6); choroid plexus: 2.8 nTPM (baseline 2); skeletal muscle: 13 nTPM (baseline 2); tongue: 10 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 98/133 (73.7%); Kidney Chromophobe (TCGA): 34/64 (53.1%); Breast Invasive Carcinoma (validation): 7/50 (14.0%),breast cancer: 1/11 (9.1%); ovarian cancer: 1/11 (9.1%),31,20,Q96L15,https://www.uniprot.org/uniprotkb/Q96L15/entry,,,,,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ASB14,ENSG00000239388,Unsafe,RNA,False,True,0.6,27.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 0.6 nTPM; continuous selectivity;reproductive not higher; adrenal gland: 0.3 nTPM; continuous selectivity; bone marrow: 1.9 nTPM; continuous selectivity;reproductive not higher; cerebellum: 0.5 nTPM; continuous selectivity; cerebral cortex: 0.4 nTPM; continuous selectivity; colon: 0.4 nTPM; continuous selectivity; esophagus: 0.4 nTPM; continuous selectivity; heart muscle: 3.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 0.3 nTPM; continuous selectivity; liver: 0.3 nTPM; continuous selectivity; lung: 0.5 nTPM; continuous selectivity; lymph node: 0.7 nTPM; continuous selectivity;reproductive not higher; midbrain: 0.3 nTPM; continuous selectivity; pancreas: 1.5 nTPM; continuous selectivity;reproductive not higher; pituitary gland: 0.4 nTPM; continuous selectivity; retina: 1.6 nTPM; continuous selectivity;reproductive not higher; salivary gland: 0.6 nTPM; continuous selectivity;reproductive not higher; skeletal muscle: 27.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 0.8 nTPM; continuous selectivity;reproductive not higher; small intestine: 0.5 nTPM; continuous selectivity; spinal cord: 0.3 nTPM; continuous selectivity; spleen: 0.6 nTPM; continuous selectivity;reproductive not higher; stomach: 0.5 nTPM; continuous selectivity; thyroid gland: 0.4 nTPM; continuous selectivity; tongue: 17.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 0.4 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,heart muscle: 3.7 nTPM (limit 2); skeletal muscle: 27.1 nTPM (limit 2); tongue: 17.3 nTPM (limit 6); heart muscle: 3.7 nTPM (baseline 2); skeletal muscle: 27.1 nTPM (baseline 2); tongue: 17.3 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 12/50 (24.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 5/176 (2.8%); Pancreatic Adenocarcinoma (validation): 1/80 (1.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,A6NK59,https://www.uniprot.org/uniprotkb/A6NK59/entry,May be a substrate-recognition component of a SCF-like ECS (Elongin-Cullin-SOCS-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Plays a role in the inhibition of cardiomyocyte nuclear proliferation by mediating the ubiquitination and degradation of MAPRE2,,,Was originally derived from a readthrough transcript including ASB14 and DNAH12,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ASB3,ENSG00000115239,Unsafe,Protein,False,True,13.5,22.2,75,63,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 8.1 nTPM; continuous selectivity; adrenal gland: 11.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 19 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 19.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 14.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 9.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 18.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 14.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 7.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 6.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 8.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 9.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 15.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 16.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 8.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 9.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 9.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 10.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 20.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 7.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 10 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 14.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 7.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 22.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 8.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 6.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 9 nTPM; positive ihc;continuous selectivity; small intestine: 8.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 7.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 11.4 nTPM; absolute ceiling;continuous selectivity; spleen: 12.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 6.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 16.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 11.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 7.2 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 7.5 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 11.1 nTPM (limit 2); amygdala: 19 nTPM (limit 2); basal ganglia: 19.5 nTPM (limit 2); bone marrow: 14.6 nTPM (limit 2); cerebellum: 9.1 nTPM (limit 2); cerebral cortex: 18.7 nTPM (limit 2); choroid plexus: 14.6 nTPM (limit 2); colon: 7.3 nTPM (limit 6); duodenum: 6.4 nTPM (limit 2); esophagus: 8.2 nTPM (limit 6); heart muscle: 9.2 nTPM (limit 2); hippocampal formation: 15.5 nTPM (limit 2); hypothalamus: 16.9 nTPM (limit 2); kidney: 8.6 nTPM (limit 2); liver: 9.9 nTPM (limit 2); lung: 9.7 nTPM (limit 2); lymph node: 10.7 nTPM (limit 6); midbrain: 20.3 nTPM (limit 2); pancreas: 7.2 nTPM (limit 2); parathyroid gland: 10 nTPM (limit 6); pituitary gland: 14.1 nTPM (limit 2); rectum: 7.8 nTPM (limit 6); retina: 22.2 nTPM (limit 2); salivary gland: 8.6 nTPM (limit 6); skeletal muscle: 6.6 nTPM (limit 2); small intestine: 8.3 nTPM (limit 2); smooth muscle: 7.8 nTPM (limit 2); spinal cord: 11.4 nTPM (limit 2); spleen: 12.4 nTPM (limit 10); stomach: 6.9 nTPM (limit 6); thymus: 16.7 nTPM (limit 10); thyroid gland: 11.2 nTPM (limit 10); tongue: 7.2 nTPM (limit 6); urinary bladder: 7.5 nTPM (limit 6); adrenal gland: 11.1 nTPM (baseline 2); amygdala: 19 nTPM (baseline 2); basal ganglia: 19.5 nTPM (baseline 2); bone marrow: 14.6 nTPM (baseline 2); cerebellum: 9.1 nTPM (baseline 2); cerebral cortex: 18.7 nTPM (baseline 2); choroid plexus: 14.6 nTPM (baseline 2); colon: 7.3 nTPM (baseline 6); duodenum: 6.4 nTPM (baseline 2); esophagus: 8.2 nTPM (baseline 6); heart muscle: 9.2 nTPM (baseline 2); hippocampal formation: 15.5 nTPM (baseline 2); hypothalamus: 16.9 nTPM (baseline 2); kidney: 8.6 nTPM (baseline 2); liver: 9.9 nTPM (baseline 2); lung: 9.7 nTPM (baseline 2); lymph node: 10.7 nTPM (baseline 6); midbrain: 20.3 nTPM (baseline 2); pancreas: 7.2 nTPM (baseline 2); parathyroid gland: 10 nTPM (baseline 6); pituitary gland: 14.1 nTPM (baseline 2); rectum: 7.8 nTPM (baseline 6); retina: 22.2 nTPM (baseline 2); salivary gland: 8.6 nTPM (baseline 6); skeletal muscle: 6.6 nTPM (baseline 2); small intestine: 8.3 nTPM (baseline 2); smooth muscle: 7.8 nTPM (baseline 2); spinal cord: 11.4 nTPM (baseline 2); spleen: 12.4 nTPM (baseline 10); stomach: 6.9 nTPM (baseline 6); thymus: 16.7 nTPM (baseline 10); thyroid gland: 11.2 nTPM (baseline 10); tongue: 7.2 nTPM (baseline 6); urinary bladder: 7.5 nTPM (baseline 6),adrenal gland / glandular cells: High (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: High (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: High (Uncertain); cerebellum / cells in molecular layer: High (Uncertain); cerebellum / Purkinje cells: High (Uncertain); cerebral cortex / neuronal cells: Low (Uncertain); cerebral cortex / neuropil: Medium (Uncertain); colon / glandular cells: High (Uncertain); duodenum / glandular cells: High (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: High (Uncertain); hippocampus / glial cells: Low (Uncertain); hippocampus / neuronal cells: High (Uncertain); kidney / cells in tubules: High (Uncertain); liver / cholangiocytes: Medium (Uncertain); liver / hepatocytes: High (Uncertain); lung / alveolar cells: Low (Uncertain); lung / macrophages: High (Uncertain); lymph node / germinal center cells: Medium (Uncertain); lymph node / non-germinal center cells: Medium (Uncertain); nasopharynx / respiratory epithelial cells: High (Uncertain); oral mucosa / squamous epithelial cells: High (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: High (Uncertain); parathyroid gland / glandular cells: High (Uncertain); rectum / glandular cells: High (Uncertain); salivary gland / glandular cells: High (Uncertain); skeletal muscle / myocytes: Medium (Uncertain); skin 1 / keratinocytes: Low (Uncertain); skin 1 / Langerhans: Medium (Uncertain); skin 2 / epidermal cells: High (Uncertain); small intestine / glandular cells: High (Uncertain); smooth muscle / smooth muscle cells: Low (Uncertain); spleen / cells in red pulp: Medium (Uncertain); spleen / cells in white pulp: High (Uncertain); stomach 1 / glandular cells: High (Uncertain); stomach 2 / glandular cells: High (Uncertain); thyroid gland / glandular cells: High (Uncertain); urinary bladder / urothelial cells: High (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (TCGA): 141/141 (100.0%),endometrial cancer: 12/12 (100.0%); glioma: 12/12 (100.0%),31,20,Q9Y575,https://www.uniprot.org/uniprotkb/Q9Y575/entry,Probable substrate-recognition component of a SCF-like ECS (Elongin-Cullin-SOCS-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Recognizes TNFRSF1B (PubMed:15899873). Plays a role in the down-regulation of antiviral innate immunity by targeting MAVS for ubiquitin-proteasomal degradation (PubMed:39266719). Also destabilizes TRAF6 by enhancing its 'Lys-48'-linked polyubiquitination (PubMed:39162488),,,,Cytoplasm,15899873|39162488|39266719,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ASB9,ENSG00000102048,Unsafe,Protein,False,True,25.1,25.1,109,9,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; kidney: 16.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 16.9 nTPM; absolute ceiling;continuous selectivity; pancreas: 9.3 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",kidney: 16.2 nTPM (limit 2); liver: 16.9 nTPM (limit 12); pancreas: 9.3 nTPM (limit 2),kidney / collecting ducts: Low (Enhanced); kidney / distal tubules: Medium (Enhanced); pancreas / pancreatic endocrine cells: High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Skin Cuteneous Melanoma (TCGA): 77/99 (77.8%); Rectum Adenocarcinoma (TCGA): 55/88 (62.5%); Lung Adenocarcinoma (validation): 65/105 (61.9%),lymphoma: 1/12 (8.3%); breast cancer: 0/11 (0.0%),31,20,Q96DX5,https://www.uniprot.org/uniprotkb/Q96DX5/entry,"Substrate-recognition component of a cullin-5-RING E3 ubiquitin-protein ligase complex (ECS complex, also named CRL5 complex), which mediates the ubiquitination and subsequent proteasomal degradation of target proteins (PubMed:25654263, PubMed:33268465). The ECS(ASB9) complex catalyzes ubiquitination of creatine kinases CKB and CKMT1A (PubMed:20302626, PubMed:22418839, PubMed:25654263, PubMed:33268465) Does not interact with the Elongin BC complex, likely to be a negative regulator of isoform 1","Predominantly expressed in testis, kidney, and liver",,,Mitochondrion,20302626|22418839|25654263|33268465,20302626,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Jamin2021_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
ASF1B,ENSG00000105011,Unsafe,Protein,False,True,31.1,31.1,81,24,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 1.4 nTPM; positive ihc; cerebral cortex: 0.4 nTPM; positive ihc; colon: 7.2 nTPM; positive ihc;absolute ceiling; duodenum: 5.1 nTPM; positive ihc;absolute ceiling; heart muscle: 0.6 nTPM; positive ihc; kidney: 1 nTPM; positive ihc; lymph node: 12.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; rectum: 7.5 nTPM; positive ihc;absolute ceiling; salivary gland: 1.9 nTPM; positive ihc; small intestine: 5.8 nTPM; positive ihc;absolute ceiling; thymus: 22.6 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",colon: 7.2 nTPM (limit 6); duodenum: 5.1 nTPM (limit 2); lymph node: 12.2 nTPM (limit 6); rectum: 7.5 nTPM (limit 6); small intestine: 5.8 nTPM (limit 2); thymus: 22.6 nTPM (limit 10),adrenal gland / glandular cells: Low (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); colon / glandular cells: Low (Enhanced); duodenum / glandular cells: Medium (Enhanced); heart muscle / cardiomyocytes: Low (Enhanced); kidney / cells in tubules: Low (Enhanced); lymph node / non-germinal center cells: Low (Enhanced); oral mucosa / squamous epithelial cells: Medium (Enhanced); rectum / glandular cells: Low (Enhanced); salivary gland / glandular cells: Low (Enhanced); small intestine / glandular cells: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 283/283 (100.0%); Rectum Adenocarcinoma (TCGA): 88/88 (100.0%); Colon Adenocarcinoma (TCGA): 253/254 (99.6%),testis cancer: 2/12 (16.7%); urothelial cancer: 2/12 (16.7%),31,20,Q9NVP2,https://www.uniprot.org/uniprotkb/Q9NVP2/entry,"Histone chaperone that facilitates histone deposition and histone exchange and removal during nucleosome assembly and disassembly (PubMed:11897662, PubMed:14718166, PubMed:15664198, PubMed:16151251, PubMed:21454524, PubMed:26527279). Cooperates with chromatin assembly factor 1 (CAF-1) to promote replication-dependent chromatin assembly (PubMed:11897662, PubMed:14718166, PubMed:15664198, PubMed:16151251). Also involved in the nuclear import of the histone H3-H4 dimer together with importin-4 (IPO4): specifically recognizes and binds newly synthesized histones with the monomethylation of H3 'Lys-9' (H3K9me1) and diacetylation at 'Lys-5' and 'Lys-12' of H4 (H4K5K12ac) marks in the cytosol (PubMed:20953179, PubMed:21454524, PubMed:26527279). Does not participate in replication-independent nucleosome deposition which is mediated by ASF1A and HIRA (PubMed:11897662, PubMed:14718166, PubMed:15664198, PubMed:16151251). Required for gonad development (PubMed:12842904)","Highly expressed in testis and at lower levels in colon, small intestine and thymus",,,"Nucleus Cytoplasm, cytosol",11897662|12842904|14718166|15664198|16151251|20953179|21454524|26527279,12842904,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
ASGR1,ENSG00000141505,Unsafe,Protein,False,True,25.7,1065.6,75,4,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 6.7 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 4.9 nTPM; absolute ceiling; bone marrow: 2.4 nTPM; absolute ceiling; cerebellum: 21.2 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 14.6 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 4.4 nTPM; absolute ceiling; duodenum: 2.2 nTPM; absolute ceiling; hippocampal formation: 5.3 nTPM; absolute ceiling; hypothalamus: 7 nTPM; absolute ceiling;continuous selectivity; liver: 1065.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 3.8 nTPM; absolute ceiling; midbrain: 3.9 nTPM; absolute ceiling; parathyroid gland: 6.8 nTPM; absolute ceiling; pituitary gland: 2.8 nTPM; absolute ceiling; retina: 4.6 nTPM; absolute ceiling; spinal cord: 2.5 nTPM; absolute ceiling; stomach: 1.3 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 6.7 nTPM (limit 2); basal ganglia: 4.9 nTPM (limit 2); cerebellum: 21.2 nTPM (limit 12); cerebral cortex: 14.6 nTPM (limit 12); choroid plexus: 4.4 nTPM (limit 2); hippocampal formation: 5.3 nTPM (limit 2); hypothalamus: 7 nTPM (limit 2); liver: 1065.6 nTPM (limit 2); midbrain: 3.9 nTPM (limit 2); pituitary gland: 2.8 nTPM (limit 2); retina: 4.6 nTPM (limit 2); spinal cord: 2.5 nTPM (limit 2); amygdala: 6.7 nTPM (baseline 2); basal ganglia: 4.9 nTPM (baseline 2); bone marrow: 2.4 nTPM (baseline 2); cerebellum: 21.2 nTPM (baseline 2); cerebral cortex: 14.6 nTPM (baseline 2); choroid plexus: 4.4 nTPM (baseline 2); duodenum: 2.2 nTPM (baseline 2); hippocampal formation: 5.3 nTPM (baseline 2); hypothalamus: 7 nTPM (baseline 2); liver: 1065.6 nTPM (baseline 2); lung: 3.8 nTPM (baseline 2); midbrain: 3.9 nTPM (baseline 2); parathyroid gland: 6.8 nTPM (baseline 6); pituitary gland: 2.8 nTPM (baseline 2); retina: 4.6 nTPM (baseline 2); spinal cord: 2.5 nTPM (baseline 2),liver / hepatocytes: High (Enhanced); stomach 1 / glandular cells: Low (Enhanced); stomach 2 / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (TCGA): 359/362 (99.2%); Liver Hepatocellular Carcinoma (validation): 224/231 (97.0%); Glioblastoma Multiforme (TCGA): 103/141 (73.0%),liver cancer: 8/12 (66.7%); pancreatic cancer: 1/12 (8.3%),31,20,P07306,https://www.uniprot.org/uniprotkb/P07306/entry,"Transmembrane protein predominantly expressed on hepatocytes that plays a key role in endocytosis of plasma glycoproteins that lack terminal sialic acid residues. Specifically recognizes terminal galactose and N-acetylgalactosamine residues, facilitating the clearance of desialylated glycoproteins from circulation. Plays thereby a role in a variety of physiological processes, such as removal of desialylated platelets, elimination of activated lymphocytes and maintenance of serum glycoprotein homeostasis (PubMed:25485912). Plays a role in the removal of desialylated platelets by activating a feedback loop regulating thrombopoietin (TPO) expression via the JAK2-STAT3 signaling pathway (PubMed:25485912). Contributes also to recognition and elimination of activated lymphocytes by hepatocytes that can act as cytotoxic effectors (PubMed:21656538). May also play a physiological role in the regulatory network of lipid homeostasis (By similarity). Upon ligand binding, the receptor-ligand complex is internalized and trafficked to a sorting organelle, where dissociation occurs. The receptor is then recycled back to the cell surface (Microbial infection) Plays an essential role in ACE2-independent SARS-CoV-2 entry by acting as alternate receptor",Expressed exclusively in hepatic parenchymal cells,,,Cell membrane Secreted,12171918|21656538|25485912|34837059,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
ASPM,ENSG00000066279,Unsafe,RNA,False,True,3.1,16.5,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 10 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 1.6 nTPM; continuous selectivity; duodenum: 2 nTPM; continuous selectivity; esophagus: 1.5 nTPM; continuous selectivity; lymph node: 5.1 nTPM; continuous selectivity;reproductive not higher; rectum: 1.8 nTPM; continuous selectivity; skin: 2.6 nTPM; continuous selectivity; small intestine: 1.8 nTPM; continuous selectivity; thymus: 16.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 10 nTPM (limit 2); thymus: 16.5 nTPM (limit 10); bone marrow: 10 nTPM (baseline 2); thymus: 16.5 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 479/486 (98.6%); Glioblastoma Multiforme (validation): 57/58 (98.3%); Rectum Adenocarcinoma (validation): 196/207 (94.7%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8IZT6,https://www.uniprot.org/uniprotkb/Q8IZT6/entry,"Involved in mitotic spindle regulation and coordination of mitotic processes. The function in regulating microtubule dynamics at spindle poles including spindle orientation, astral microtubule density and poleward microtubule flux seems to depend on the association with the katanin complex formed by KATNA1 and KATNB1. Enhances the microtubule lattice severing activity of KATNA1 by recruiting the katanin complex to microtubules. Can block microtubule minus-end growth and reversely this function can be enhanced by the katanin complex (PubMed:28436967). May have a preferential role in regulating neurogenesis",,"Microcephaly 5, primary, autosomal recessive: A disease defined as a head circumference more than 3 standard deviations below the age-related mean. Brain weight is markedly reduced and the cerebral cortex is disproportionately small. Despite this marked reduction in size, the gyral pattern is relatively well preserved, with no major abnormality in cortical architecture. Affected individuals have mild to severe intellectual disability. Primary microcephaly is further defined by the absence of other syndromic features or significant neurological deficits due to degenerative brain disorder.",,"Cytoplasm Cytoplasm, cytoskeleton, spindle Nucleus",12355089|15972725|28436967,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ASXL3,ENSG00000141431,Unsafe,High RNA,False,True,1.7,1.7,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 0.8 nTPM; continuous selectivity; cerebral cortex: 1.5 nTPM; continuous selectivity; hippocampal formation: 0.7 nTPM; continuous selectivity; hypothalamus: 0.9 nTPM; continuous selectivity; kidney: 0.6 nTPM; continuous selectivity; midbrain: 0.6 nTPM; continuous selectivity; pituitary gland: 0.7 nTPM; continuous selectivity; spinal cord: 0.6 nTPM; continuous selectivity; stomach: 0.8 nTPM; continuous selectivity; thyroid gland: 0.9 nTPM; continuous selectivity,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,True,"brain/excitatory neurons cluster c-1: 162.3 nTPM, 20373 reads; reproductive-cell max 87.1; brain/excitatory neurons cluster c-2: 100.1 nTPM, 11403 reads; reproductive-cell max 87.1; brain/excitatory neurons cluster c-4: 98.7 nTPM, 13529 reads; reproductive-cell max 87.1; brain/inhibitory neurons cluster c-6: 160.5 nTPM, 8346 reads; reproductive-cell max 87.1; brain/excitatory neurons cluster c-7: 154.3 nTPM, 14422 reads; reproductive-cell max 87.1; brain/inhibitory neurons cluster c-8: 87.7 nTPM, 7293 reads; reproductive-cell max 87.1; brain/excitatory neurons cluster c-10: 177.9 nTPM, 9390 reads; reproductive-cell max 87.1; brain/excitatory neurons cluster c-11: 153 nTPM, 11209 reads; reproductive-cell max 87.1; brain/excitatory neurons cluster c-13: 150 nTPM, 7049 reads; reproductive-cell max 87.1; brain/inhibitory neurons cluster c-15: 152.1 nTPM, 4149 reads; reproductive-cell max 87.1; brain/excitatory neurons cluster c-16: 90.7 nTPM, 7165 reads; reproductive-cell max 87.1; brain/inhibitory neurons cluster c-17: 137 nTPM, 4419 reads; reproductive-cell max 87.1; brain/excitatory neurons cluster c-19: 120.2 nTPM, 5372 reads; reproductive-cell max 87.1; brain/excitatory neurons cluster c-22: 150.5 nTPM, 6510 reads; reproductive-cell max 87.1; brain/inhibitory neurons cluster c-23: 106.6 nTPM, 2476 reads; reproductive-cell max 87.1; brain/excitatory neurons cluster c-24: 142.4 nTPM, 3315 reads; reproductive-cell max 87.1; brain/excitatory neurons cluster c-27: 147.2 nTPM, 5237 reads; reproductive-cell max 87.1; brain/excitatory neurons cluster c-29: 280.5 nTPM, 7066 reads; reproductive-cell max 87.1; brain/excitatory neurons cluster c-31: 93.6 nTPM, 3717 reads; reproductive-cell max 87.1; brain/excitatory neurons cluster c-33: 144.9 nTPM, 3596 reads; reproductive-cell max 87.1; brain/excitatory neurons cluster c-36: 295.9 nTPM, 5056 reads; reproductive-cell max 87.1; brain/inhibitory neurons cluster c-38: 170.9 nTPM, 1777 reads; reproductive-cell max 87.1; brain/excitatory neurons cluster c-44: 101.2 nTPM, 288 reads; reproductive-cell max 87.1",True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Medium, HPA039539; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Low, HPA039539; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA039539; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA039539; conflicting or uncurated primary profile; Duodenum/Glandular cells: Low, HPA039539; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA039539; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA039539; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA039539; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA039539; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA039539; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA039539; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA039539; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA039539; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA039539; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA039539; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA039539; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA039539; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA039539; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Low, HPA039539; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA039539; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA039539; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA039539; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA039539; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA040034; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA040034; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA040034; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA040034; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA040034; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA040034; conflicting or uncurated primary profile; Liver/Cholangiocytes: High, HPA040034; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA040034; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA040034; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA040034; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Low, HPA040034; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA040034; conflicting or uncurated primary profile; Salivary gland/Glandular cells: High, HPA040034; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA040034; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA040034; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA040034; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA040034; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: High, HPA040034; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,0.565944691357,295.9,"hpa_single_cell: /Excitatory neurons, max 120.8 nTPM, 1 observations >30; hpa_single_cell: /Inhibitory neurons, max 96.8 nTPM, 1 observations >30; hpa_single_cell: /Oligodendrocyte precursor cells, max 83 nTPM, 1 observations >30; hpa_single_cell: /Oligodendrocytes, max 57.9 nTPM, 1 observations >30; hpa_single_cell_tissue: brain/excitatory neurons, max 295.9 nTPM, 26 observations >30; hpa_single_cell_tissue: brain/inhibitory neurons, max 170.9 nTPM, 11 observations >30; hpa_single_cell_tissue: brain/oligodendrocyte precursor cells, max 83 nTPM, 1 observations >30; hpa_single_cell_tissue: brain/oligodendrocytes, max 59 nTPM, 2 observations >30",Neither,oncoref.target-sets.2026-10-23.2,0.5659 TPM; blood/M2; dice_m2; vital,295.9 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 45/58 (77.6%); Pancreatic Adenocarcinoma (validation): 4/80 (5.0%); Kidney Renal Papillary Cell Carcinoma (TCGA): 4/282 (1.4%),cervical cancer: 12/12 (100.0%); breast cancer: 11/11 (100.0%),31,20,Q9C0F0,https://www.uniprot.org/uniprotkb/Q9C0F0/entry,"Putative Polycomb group (PcG) protein. PcG proteins act by forming multiprotein complexes, which are required to maintain the transcriptionally repressive state of homeotic genes throughout development. PcG proteins are not required to initiate repression, but to maintain it during later stages of development. They probably act via methylation of histones, rendering chromatin heritably changed in its expressibility (By similarity). Non-catalytic component of the PR-DUB complex, a complex that specifically mediates deubiquitination of histone H2A monoubiquitinated at 'Lys-119' (H2AK119ub1) (PubMed:30664650, PubMed:36180891). The PR-DUB complex is an epigenetic regulator of gene expression and acts as a transcriptional coactivator, affecting genes involved in development, cell communication, signaling, cell proliferation and cell viability (PubMed:30664650, PubMed:36180891). ASXL1, ASXL2 and ASXL3 function redundantly in the PR-DUB complex and are essential for chromatin recruitment and transcriptional activation of associated genes (By similarity)","Expressed in pancreatic islets, testis, neuroblastoma, head and neck tumor","Bainbridge-Ropers syndrome: A syndrome characterized by psychomotor retardation, feeding problems, severe postnatal growth retardation in some patients, arched eyebrows, anteverted nares, and ulnar deviation of the hands.",,Nucleus,30664650|36180891,15138607,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ATAD5,ENSG00000176208,Unsafe,RNA,False,True,1.9,12.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 12.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 1.8 nTPM; continuous selectivity; cerebral cortex: 0.6 nTPM; continuous selectivity; colon: 1.2 nTPM; continuous selectivity; duodenum: 1.4 nTPM; continuous selectivity; esophagus: 1.3 nTPM; continuous selectivity; lung: 0.7 nTPM; continuous selectivity; lymph node: 3.5 nTPM; continuous selectivity;reproductive not higher; rectum: 1.5 nTPM; continuous selectivity; retina: 2.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 2.4 nTPM; continuous selectivity;reproductive not higher; small intestine: 1.3 nTPM; continuous selectivity; smooth muscle: 0.6 nTPM; continuous selectivity; spleen: 1.3 nTPM; continuous selectivity; stomach: 1 nTPM; continuous selectivity; thymus: 5.2 nTPM; continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 12.2 nTPM (limit 2); retina: 2.4 nTPM (limit 2); bone marrow: 12.2 nTPM (baseline 2); retina: 2.4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 468/486 (96.3%); Glioblastoma Multiforme (validation): 55/58 (94.8%); Rectum Adenocarcinoma (validation): 188/207 (90.8%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q96QE3,https://www.uniprot.org/uniprotkb/Q96QE3/entry,"Has an important role in DNA replication and in maintaining genome integrity during replication stress (PubMed:15983387, PubMed:19755857). Involved in a RAD9A-related damage checkpoint, a pathway that is important in determining whether DNA damage is compatible with cell survival or whether it requires cell elimination by apoptosis (PubMed:15983387). Modulates the RAD9A interaction with BCL2 and thereby induces DNA damage-induced apoptosis (PubMed:15983387). Promotes PCNA deubiquitination by recruiting the ubiquitin-specific protease 1 (USP1) and WDR48 thereby down-regulating the error-prone damage bypass pathway (PubMed:20147293). As component of the ATAD5 RFC-like complex, regulates the function of the DNA polymerase processivity factor PCNA by unloading the ring-shaped PCNA homotrimer from DNA after replication during the S phase of the cell cycle (PubMed:23277426, PubMed:23937667). This seems to be dependent on its ATPase activity (PubMed:23277426). Plays important roles in restarting stalled replication forks under replication stress, by unloading the PCNA homotrimer from DNA and recruiting RAD51 possibly through an ATR-dependent manner (PubMed:31844045). Ultimately this enables replication fork regression, breakage, and eventual fork restart (PubMed:31844045). Both the PCNA unloading activity and the interaction with WDR48 are required to efficiently recruit RAD51 to stalled replication forks (PubMed:31844045). Promotes the generation of MUS81-mediated single-stranded DNA-associated breaks in response to replication stress, which is an alternative pathway to restart stalled/regressed replication forks (PubMed:31844045)",,,,Nucleus,15983387|19755857|20147293|23277426|23937667|31844045,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ATG10,ENSG00000152348,Unsafe,Protein,False,True,10.0,11.2,78,68,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 3.8 nTPM; positive ihc; adrenal gland: 5.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 3.4 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 3.2 nTPM; absolute ceiling;continuous selectivity; bone marrow: 5.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 2 nTPM; positive ihc; cerebral cortex: 3.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 5.9 nTPM; absolute ceiling;continuous selectivity; colon: 5.3 nTPM; positive ihc;continuous selectivity; duodenum: 3.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 4.8 nTPM; positive ihc;continuous selectivity; heart muscle: 4.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 3.3 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 3.2 nTPM; absolute ceiling;continuous selectivity; kidney: 5.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 6.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 3.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 3.4 nTPM; positive ihc; midbrain: 3.9 nTPM; absolute ceiling;continuous selectivity; pancreas: 4.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 11.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 3.9 nTPM; absolute ceiling;continuous selectivity; rectum: 5.9 nTPM; positive ihc;continuous selectivity; retina: 3.4 nTPM; absolute ceiling;continuous selectivity; salivary gland: 3.6 nTPM; positive ihc;continuous selectivity; skeletal muscle: 6.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 6.1 nTPM; positive ihc;continuous selectivity; small intestine: 3.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 5.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 4.4 nTPM; absolute ceiling;continuous selectivity; spleen: 3.8 nTPM; positive ihc; stomach: 4.5 nTPM; positive ihc;continuous selectivity; thymus: 7.6 nTPM; continuous selectivity; thyroid gland: 6.9 nTPM; positive ihc;continuous selectivity; urinary bladder: 3.8 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 5.1 nTPM (limit 2); amygdala: 3.4 nTPM (limit 2); basal ganglia: 3.2 nTPM (limit 2); bone marrow: 5.3 nTPM (limit 2); cerebral cortex: 3.8 nTPM (limit 2); choroid plexus: 5.9 nTPM (limit 2); duodenum: 3.2 nTPM (limit 2); heart muscle: 4.4 nTPM (limit 2); hippocampal formation: 3.3 nTPM (limit 2); hypothalamus: 3.2 nTPM (limit 2); kidney: 5.4 nTPM (limit 2); liver: 6.3 nTPM (limit 2); lung: 3.6 nTPM (limit 2); midbrain: 3.9 nTPM (limit 2); pancreas: 4.3 nTPM (limit 2); parathyroid gland: 11.2 nTPM (limit 8); pituitary gland: 3.9 nTPM (limit 2); retina: 3.4 nTPM (limit 2); skeletal muscle: 6.9 nTPM (limit 2); small intestine: 3.1 nTPM (limit 2); smooth muscle: 5.3 nTPM (limit 2); spinal cord: 4.4 nTPM (limit 2),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Low (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 47/50 (94.0%); Rectum Adenocarcinoma (validation): 193/207 (93.2%),colorectal cancer: 9/9 (100.0%); breast cancer: 7/11 (63.6%),31,20,Q9H0Y0,https://www.uniprot.org/uniprotkb/Q9H0Y0/entry,E2-like enzyme involved in autophagy. Acts as an E2-like enzyme that catalyzes the conjugation of ATG12 to ATG5. ATG12 conjugation to ATG5 is required for autophagy. Likely serves as an ATG5-recognition molecule. Not involved in ATG12 conjugation to ATG3 (By similarity). Plays a role in adenovirus-mediated cell lysis,,,,Cytoplasm,21367888,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | Jamin2021_CT,GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
ATP1A4,ENSG00000132681,Unsafe,RNA,False,True,15.8,15.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,retina: 2.4 nTPM; absolute ceiling; skeletal muscle: 2.9 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 2.4 nTPM (limit 2); skeletal muscle: 2.9 nTPM (limit 2); retina: 2.4 nTPM (baseline 2); skeletal muscle: 2.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 32/50 (64.0%); Bladder Urothelial Carcinoma (TCGA): 26/169 (15.4%); Breast Invasive Carcinoma (TCGA): 49/1022 (4.8%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q13733,https://www.uniprot.org/uniprotkb/Q13733/entry,"Sperm-specific catalytic alpha subunit of the Na(+)/K(+)-ATPase responsible for ATP-dependent Na(+)/K(+) exchange across the plasma membrane. Transports 3 Na(+) ions out of the cell and 2 K(+) ions into the cell for each ATP hydrolyze (PubMed:16861705). Plays an essential for sperm motility, capacitation, and male fertility by maintaining ionic gradients required for flagellar function and signaling (By similarity)","Specifically expressed in testis (PubMed:16175638, PubMed:16861705). Found in very low levels in skeletal muscle. Expressed in mature sperm (at protein level) (PubMed:16175638)",,,Cell membrane,16861705,16175638|16861705,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
ATP6V0C,ENSG00000185883,Unsafe,RNA,False,True,200.9,589.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 196.7 nTPM; absolute ceiling;continuous selectivity; adrenal gland: 239.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 365.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 389.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 180.3 nTPM; absolute ceiling;continuous selectivity; cerebellum: 459.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 589.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 220.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 167 nTPM; absolute ceiling;continuous selectivity; duodenum: 92.2 nTPM; absolute ceiling;continuous selectivity; esophagus: 327.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 204.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 387.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 409 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 402.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; liver: 201.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 223.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 49.6 nTPM; absolute ceiling; midbrain: 321.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 136.4 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 100.2 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 318.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 28.7 nTPM; absolute ceiling; retina: 107.1 nTPM; absolute ceiling;continuous selectivity; salivary gland: 207.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 290.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 272.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 159.8 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 28.8 nTPM; absolute ceiling; spinal cord: 269.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 216.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; stomach: 170.5 nTPM; absolute ceiling;continuous selectivity; thymus: 43.7 nTPM; absolute ceiling; thyroid gland: 161.7 nTPM; absolute ceiling;continuous selectivity; tongue: 51.8 nTPM; absolute ceiling; urinary bladder: 130 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adipose tissue: 196.7 nTPM (limit 10); adrenal gland: 239.5 nTPM (limit 2); amygdala: 365.6 nTPM (limit 2); basal ganglia: 389.1 nTPM (limit 2); bone marrow: 180.3 nTPM (limit 2); cerebellum: 459.3 nTPM (limit 2); cerebral cortex: 589.8 nTPM (limit 2); choroid plexus: 220.4 nTPM (limit 2); colon: 167 nTPM (limit 6); duodenum: 92.2 nTPM (limit 2); esophagus: 327.5 nTPM (limit 6); heart muscle: 204.8 nTPM (limit 2); hippocampal formation: 387.3 nTPM (limit 2); hypothalamus: 409 nTPM (limit 2); kidney: 402.9 nTPM (limit 2); liver: 201.9 nTPM (limit 2); lung: 223.5 nTPM (limit 2); lymph node: 49.6 nTPM (limit 6); midbrain: 321.7 nTPM (limit 2); pancreas: 136.4 nTPM (limit 2); parathyroid gland: 100.2 nTPM (limit 6); pituitary gland: 318.5 nTPM (limit 2); rectum: 28.7 nTPM (limit 6); retina: 107.1 nTPM (limit 2); salivary gland: 207.8 nTPM (limit 6); skeletal muscle: 290.4 nTPM (limit 2); skin: 272.5 nTPM (limit 10); small intestine: 159.8 nTPM (limit 2); smooth muscle: 28.8 nTPM (limit 2); spinal cord: 269.9 nTPM (limit 2); spleen: 216.6 nTPM (limit 10); stomach: 170.5 nTPM (limit 6); thymus: 43.7 nTPM (limit 10); thyroid gland: 161.7 nTPM (limit 10); tongue: 51.8 nTPM (limit 6); urinary bladder: 130 nTPM (limit 6); adipose tissue: 196.7 nTPM (baseline 10); adrenal gland: 239.5 nTPM (baseline 2); amygdala: 365.6 nTPM (baseline 2); basal ganglia: 389.1 nTPM (baseline 2); bone marrow: 180.3 nTPM (baseline 2); cerebellum: 459.3 nTPM (baseline 2); cerebral cortex: 589.8 nTPM (baseline 2); choroid plexus: 220.4 nTPM (baseline 2); colon: 167 nTPM (baseline 6); duodenum: 92.2 nTPM (baseline 2); esophagus: 327.5 nTPM (baseline 6); heart muscle: 204.8 nTPM (baseline 2); hippocampal formation: 387.3 nTPM (baseline 2); hypothalamus: 409 nTPM (baseline 2); kidney: 402.9 nTPM (baseline 2); liver: 201.9 nTPM (baseline 2); lung: 223.5 nTPM (baseline 2); lymph node: 49.6 nTPM (baseline 6); midbrain: 321.7 nTPM (baseline 2); pancreas: 136.4 nTPM (baseline 2); parathyroid gland: 100.2 nTPM (baseline 6); pituitary gland: 318.5 nTPM (baseline 2); rectum: 28.7 nTPM (baseline 6); retina: 107.1 nTPM (baseline 2); salivary gland: 207.8 nTPM (baseline 6); skeletal muscle: 290.4 nTPM (baseline 2); skin: 272.5 nTPM (baseline 10); small intestine: 159.8 nTPM (baseline 2); smooth muscle: 28.8 nTPM (baseline 2); spinal cord: 269.9 nTPM (baseline 2); spleen: 216.6 nTPM (baseline 10); stomach: 170.5 nTPM (baseline 6); thymus: 43.7 nTPM (baseline 10); thyroid gland: 161.7 nTPM (baseline 10); tongue: 51.8 nTPM (baseline 6); urinary bladder: 130 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%); Thyroid Carcinoma (TCGA): 495/495 (100.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P27449,https://www.uniprot.org/uniprotkb/P27449/entry,"Proton-conducting pore forming subunit of the V0 complex of vacuolar(H+)-ATPase (V-ATPase), a multisubunit enzyme composed of a peripheral complex (V1) that hydrolyzes ATP and a membrane integral complex (V0) that translocates protons (PubMed:33065002, PubMed:36074901). V-ATPase is responsible for acidifying and maintaining the pH of intracellular compartments, and in some cell types, it is targeted to the plasma membrane, where it promotes acidification of the extracellular environment (By similarity). The V-ATPase complex also acts as an activator for mTORC1 on lysosomal membrane by promoting the guanine nucleotide exchange factor (GEF) of the Ragulator complex, thereby enabling mTORC1 recruitment (PubMed:22053050)",,"Epilepsy, early-onset, 3, with or without developmental delay: An autosomal dominant neurologic disorder characterized by various types of seizures with onset in the first months or years of life. Many patients present with febrile seizures and later develop afebrile seizures. Some affected individuals have global developmental delay or regression, impaired intellectual development, poor or absent speech, and motor delay. Additional variable features include hypotonia, gait ataxia, behavioral abnormalities, and anomalies on brain imaging.",,"Cytoplasmic vesicle, clathrin-coated vesicle membrane Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane Lysosome membrane",22053050|33065002|36074901,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ATP6V1E2,ENSG00000250565,Unsafe,RNA,False,True,27.6,27.6,108,2,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,amygdala: 3.5 nTPM; absolute ceiling; basal ganglia: 4.2 nTPM; absolute ceiling; hippocampal formation: 3.3 nTPM; absolute ceiling; hypothalamus: 2.6 nTPM; absolute ceiling; midbrain: 3.6 nTPM; absolute ceiling; pituitary gland: 2.7 nTPM; absolute ceiling; retina: 2.3 nTPM; absolute ceiling; spinal cord: 3.8 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 3.5 nTPM (limit 2); basal ganglia: 4.2 nTPM (limit 2); hippocampal formation: 3.3 nTPM (limit 2); hypothalamus: 2.6 nTPM (limit 2); midbrain: 3.6 nTPM (limit 2); pituitary gland: 2.7 nTPM (limit 2); retina: 2.3 nTPM (limit 2); spinal cord: 3.8 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 48/58 (82.8%); Breast Invasive Carcinoma (validation): 40/50 (80.0%); Pancreatic Adenocarcinoma (validation): 29/80 (36.2%),prostate cancer: 1/11 (9.1%); liver cancer: 1/12 (8.3%),31,20,Q96A05,https://www.uniprot.org/uniprotkb/Q96A05/entry,"Subunit of the V1 complex of vacuolar(H+)-ATPase (V-ATPase), a multisubunit enzyme composed of a peripheral complex (V1) that hydrolyzes ATP and a membrane integral complex (V0) that translocates protons. V-ATPase is responsible for acidifying and maintaining the pH of intracellular compartments and in some cell types, is targeted to the plasma membrane, where it is responsible for acidifying the extracellular environment",Testis specific,,,,,12036578,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ATP8A2,ENSG00000132932,Unsafe,Protein,False,True,2.5,19.7,87,31,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 1.7 nTPM; positive ihc;continuous selectivity; amygdala: 4.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 4.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 0 nTPM; positive ihc; cerebellum: 19.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 14.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 0.1 nTPM; positive ihc; hippocampal formation: 5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 10.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 0.1 nTPM; positive ihc; midbrain: 5.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 0.2 nTPM; positive ihc; pituitary gland: 14.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; retina: 14.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 0 nTPM; positive ihc; small intestine: 0.3 nTPM; positive ihc; spinal cord: 1.9 nTPM; continuous selectivity; spleen: 0.1 nTPM; positive ihc; stomach: 0.6 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 4.7 nTPM (limit 2); basal ganglia: 4.9 nTPM (limit 2); cerebellum: 19.7 nTPM (limit 2); cerebral cortex: 14.6 nTPM (limit 2); hippocampal formation: 5 nTPM (limit 2); hypothalamus: 10.2 nTPM (limit 2); midbrain: 5.4 nTPM (limit 2); pituitary gland: 14.8 nTPM (limit 2); retina: 14.3 nTPM (limit 2),adrenal gland / glandular cells: Low (Enhanced); bone marrow / hematopoietic cells: Low (Enhanced); bronchus / respiratory epithelial cells: Low (Enhanced); caudate / neuronal cells: Low (Enhanced); cerebellum / Purkinje cells: Low (Enhanced); cerebral cortex / neuronal cells: Low (Enhanced); duodenum / glandular cells: Low (Enhanced); hippocampus / neuronal cells: Low (Enhanced); lymph node / germinal center cells: Low (Enhanced); lymph node / non-germinal center cells: Low (Enhanced); pancreas / exocrine glandular cells: Low (Enhanced); pituitary gland / cells in anterior : Medium (Enhanced); retina / ganglion cells : Medium (Enhanced); retina / photoreceptor cells: Medium (Enhanced); salivary gland / glandular cells: Low (Enhanced); small intestine / glandular cells: Low (Enhanced); spleen / cells in red pulp: Low (Enhanced); stomach 1 / glandular cells: Low (Enhanced); stomach 2 / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 18/58 (31.0%); Skin Cuteneous Melanoma (TCGA): 13/99 (13.1%); Prostate Adenocarcinoma (TCGA): 61/480 (12.7%),breast cancer: 3/11 (27.3%); prostate cancer: 3/11 (27.3%),31,20,Q9NTI2,https://www.uniprot.org/uniprotkb/Q9NTI2/entry,"Catalytic component of a P4-ATPase flippase complex which catalyzes the hydrolysis of ATP coupled to the transport of aminophospholipids from the outer to the inner leaflet of various membranes and ensures the maintenance of asymmetric distribution of phospholipids (By similarity). Able to translocate phosphatidylserine, but not phosphatidylcholine (PubMed:34403372). Phospholipid translocation also seems to be implicated in vesicle formation and in uptake of lipid signaling molecules (By similarity). Reconstituted to liposomes, the ATP8A2:CDC50A flippase complex predominantly transports phosphatidylserine (PS) and to a lesser extent phosphatidylethanolamine (PE) (By similarity). Phospholipid translocation is not associated with a countertransport of an inorganic ion or other charged substrate from the cytoplasmic side toward the exoplasm in connection with the phosphorylation from ATP (By similarity). ATP8A2:CDC50A may be involved in regulation of neurite outgrowth (By similarity). Proposed to function in the generation and maintenance of phospholipid asymmetry in photoreceptor disk membranes and neuronal axon membranes (By similarity). May be involved in vesicle trafficking in neuronal cells (By similarity). Required for normal visual and auditory function; involved in photoreceptor and inner ear spiral ganglion cell survival (By similarity)","Strongly expressed in the brain, cerebellum, retina and testis","Cerebellar ataxia, impaired intellectual development, and dysequilibrium syndrome 4: An autosomal recessive, congenital cerebellar ataxia associated with dysarthia, quadrupedal gait and intellectual disability.",,Membrane Golgi apparatus membrane Endosome membrane Cell membrane Photoreceptor outer segment membrane Photoreceptor inner segment membrane,31397519|34403372,20683487|22892528,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
ATP8B3,ENSG00000130270,Unsafe,RNA,False,True,21.3,21.3,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 5.8 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 5.8 nTPM (limit 2); bone marrow: 5.8 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 30/50 (60.0%); Kidney Renal Clear Cell Carcinoma (validation): 27/100 (27.0%); Pancreatic Adenocarcinoma (validation): 16/80 (20.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O60423,https://www.uniprot.org/uniprotkb/O60423/entry,P4-ATPase flippase which catalyzes the hydrolysis of ATP coupled to the transport of aminophospholipids from the outer to the inner leaflet of various membranes and ensures the maintenance of asymmetric distribution of phospholipids. Phospholipid translocation also seems to be implicated in vesicle formation and in uptake of lipid signaling molecules. May be responsible for the maintenance of asymmetric distribution of phosphatidylserine (PS) in spermatozoa membranes. Involved in acrosome reactions and binding of spermatozoa to zona pellucida,Isoform 3 was only detected in testis,,,"Cytoplasmic vesicle, secretory vesicle, acrosome membrane Endoplasmic reticulum membrane",,12880872,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
ATRNL1,ENSG00000107518,Unsafe,RNA,False,True,12.3,19.4,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 10.4 nTPM; absolute ceiling;continuous selectivity; amygdala: 6.3 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 5 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 19.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 4.7 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 6.8 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 4 nTPM; absolute ceiling;continuous selectivity; kidney: 2.7 nTPM; absolute ceiling; midbrain: 2.4 nTPM; absolute ceiling; pituitary gland: 5.6 nTPM; absolute ceiling;continuous selectivity; retina: 6.1 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 2.7 nTPM; absolute ceiling; smooth muscle: 5.6 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 10.4 nTPM (limit 2); amygdala: 6.3 nTPM (limit 2); basal ganglia: 5 nTPM (limit 2); cerebral cortex: 19.4 nTPM (limit 2); choroid plexus: 4.7 nTPM (limit 2); hippocampal formation: 6.8 nTPM (limit 2); hypothalamus: 4 nTPM (limit 2); kidney: 2.7 nTPM (limit 2); midbrain: 2.4 nTPM (limit 2); pituitary gland: 5.6 nTPM (limit 2); retina: 6.1 nTPM (limit 2); skeletal muscle: 2.7 nTPM (limit 2); smooth muscle: 5.6 nTPM (limit 2); adrenal gland: 10.4 nTPM (baseline 2); amygdala: 6.3 nTPM (baseline 2); basal ganglia: 5 nTPM (baseline 2); cerebral cortex: 19.4 nTPM (baseline 2); choroid plexus: 4.7 nTPM (baseline 2); hippocampal formation: 6.8 nTPM (baseline 2); hypothalamus: 4 nTPM (baseline 2); kidney: 2.7 nTPM (baseline 2); midbrain: 2.4 nTPM (baseline 2); pituitary gland: 5.6 nTPM (baseline 2); retina: 6.1 nTPM (baseline 2); skeletal muscle: 2.7 nTPM (baseline 2); smooth muscle: 5.6 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 54/58 (93.1%); Breast Invasive Carcinoma (validation): 24/50 (48.0%); Testicular Germ Cell Tumor (TCGA): 45/133 (33.8%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q5VV63,https://www.uniprot.org/uniprotkb/Q5VV63/entry,May play a role in melanocortin signaling pathways that regulate energy homeostasis,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
AUNIP,ENSG00000127423,Unsafe,RNA,False,True,15.5,15.5,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 6.1 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 6.1 nTPM (limit 2); bone marrow: 6.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 109/133 (82.0%); Colon Adenocarcinoma (validation): 385/486 (79.2%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 224/283 (79.2%),melanoma: 9/9 (100.0%); skin cancer: 1/8 (12.5%),29,20,Q9H7T9,https://www.uniprot.org/uniprotkb/Q9H7T9/entry,"DNA-binding protein that accumulates at DNA double-strand breaks (DSBs) following DNA damage and promotes DNA resection and homologous recombination (PubMed:29042561). Serves as a sensor of DNA damage: binds DNA with a strong preference for DNA substrates that mimic structures generated at stalled replication forks, and anchors RBBP8/CtIP to DSB sites to promote DNA end resection and ensuing homologous recombination repair (PubMed:29042561). Inhibits non-homologous end joining (NHEJ) (PubMed:29042561). Required for the dynamic movement of AURKA at the centrosomes and spindle apparatus during the cell cycle (PubMed:20596670)","Expressed in heart, skeletal muscles, placenta and testis",,,"Nucleus Chromosome Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Cytoplasm, cytoskeleton, spindle pole",20596670|29042561,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | Jamin2021_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
AURKA,ENSG00000087586,Unsafe,Protein,False,True,29.9,29.9,84,25,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 15.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 10.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 7.3 nTPM; positive ihc;absolute ceiling; kidney: 2.2 nTPM; positive ihc;absolute ceiling; liver: 4.9 nTPM; positive ihc;absolute ceiling; lung: 2.1 nTPM; positive ihc;absolute ceiling; lymph node: 20.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; rectum: 12.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 2.9 nTPM; absolute ceiling; stomach: 4.7 nTPM; positive ihc; thymus: 19.6 nTPM; absolute ceiling;continuous selectivity; tongue: 7.9 nTPM; absolute ceiling; urinary bladder: 2.9 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 15.1 nTPM (limit 2); colon: 10.4 nTPM (limit 6); esophagus: 7.3 nTPM (limit 6); kidney: 2.2 nTPM (limit 2); liver: 4.9 nTPM (limit 2); lung: 2.1 nTPM (limit 2); lymph node: 20.4 nTPM (limit 6); rectum: 12.5 nTPM (limit 6); retina: 2.9 nTPM (limit 2); thymus: 19.6 nTPM (limit 10); tongue: 7.9 nTPM (limit 6),bone marrow / hematopoietic cells: Low (Enhanced); bronchus / respiratory epithelial cells: Low (Enhanced); colon / glandular cells: Low (Enhanced); esophagus / squamous epithelial cells: Low (Enhanced); kidney / cells in tubules: Low (Enhanced); liver / hepatocytes: Low (Enhanced); lung / macrophages: Low (Enhanced); lymph node / germinal center cells: Low (Enhanced); lymph node / non-germinal center cells: Low (Enhanced); nasopharynx / respiratory epithelial cells: Low (Enhanced); oral mucosa / squamous epithelial cells: Low (Enhanced); rectum / glandular cells: Low (Enhanced); stomach 1 / glandular cells: Low (Enhanced); urinary bladder / urothelial cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 283/283 (100.0%); Colon Adenocarcinoma (TCGA): 254/254 (100.0%),lymphoma: 5/12 (41.7%); colorectal cancer: 4/12 (33.3%),31,20,O14965,https://www.uniprot.org/uniprotkb/O14965/entry,"Mitotic serine/threonine kinase that contributes to the regulation of cell cycle progression (PubMed:11039908, PubMed:12390251, PubMed:17125279, PubMed:17360485, PubMed:18615013, PubMed:26246606). Associates with the centrosome and the spindle microtubules during mitosis and plays a critical role in various mitotic events including the establishment of mitotic spindle, centrosome duplication, centrosome separation as well as maturation, chromosomal alignment, spindle assembly checkpoint, and cytokinesis (PubMed:14523000, PubMed:26246606). Required for normal spindle positioning during mitosis and for the localization of NUMA1 and DCTN1 to the cell cortex during metaphase (PubMed:27335426). Required for initial activation of CDK1 at centrosomes (PubMed:13678582, PubMed:15128871). Phosphorylates numerous target proteins, including ARHGEF2, BORA, BRCA1, CDC25B, DLGP5, HDAC6, KIF2A, LATS2, NDEL1, PARD3, PPP1R2, PLK1, RASSF1, TACC3, p53/TP53 and TPX2 (PubMed:11551964, PubMed:14702041, PubMed:15128871, PubMed:15147269, PubMed:15987997, PubMed:17604723, PubMed:18056443, PubMed:18615013). Phosphorylates MCRS1 which is required for MCRS1-mediated kinetochore fiber assembly and mitotic progression (PubMed:27192185). Regulates KIF2A tubulin depolymerase activity (PubMed:19351716). Important for microtubule formation and/or stabilization (PubMed:18056443). Required for normal axon formation (PubMed:19812038). Plays a role in microtubule remodeling during neurite extension (PubMed:19668197). Also acts as a key regulatory component of the p53/TP53 pathway, and particularly the checkpoint-response pathways critical for oncogenic transformation of cells, by phosphorylating and destabilizing p53/TP53 (PubMed:14702041). Phosphorylates its own inhibitors, the protein phosphatase type 1 (PP1) isoforms, to inhibit their activity (PubMed:11551964). Inhibits cilia outgrowth (By similarity). Required for cilia disassembly via phosphorylation of HDAC6 and subsequent deacetylation of alpha-tubulin (PubMed:17604723, PubMed:20643351). Regulates protein levels of the anti-apoptosis protein BIRC5 by suppressing the expression of the SCF(FBXL7) E3 ubiquitin-protein ligase substrate adapter FBXL7 through the phosphorylation of the transcription factor FOXP1 (PubMed:28218735)","Highly expressed in testis and weakly in skeletal muscle, thymus and spleen. Also highly expressed in colon, ovarian, prostate, neuroblastoma, breast and cervical cancer cell lines",,Authors initially considered AURKA/STK6 and STK15 as 2 different proteins (PubMed:9771714). It is clear that they are the same protein An article that concluded that AURKA-mediated phosphorylation of BRCA1 'Ser-308' plays a role in the normal cell cycle G2/M transition was withdrawn due to data manipulation of flow cytometry data,"Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Cytoplasm, cytoskeleton, spindle pole Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriole Cell projection, neuron projection Cell projection, cilium Cytoplasm, cytoskeleton, cilium basal body Basolateral cell membrane",11039908|11551964|12390251|13678582|14523000|14702041|15128871|15147269|15987997|17125279|17360485|17604723|18056443|18615013|19351716|19668197|19812038|20643351|26246606|27192185|27335426|28218735,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
AURKC,ENSG00000105146,Unsafe,RNA,False,True,45.2,45.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,cerebral cortex: 2.5 nTPM; absolute ceiling; choroid plexus: 3.6 nTPM; absolute ceiling; liver: 2.6 nTPM; absolute ceiling; spinal cord: 3.3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebral cortex: 2.5 nTPM (limit 2); choroid plexus: 3.6 nTPM (limit 2); liver: 2.6 nTPM (limit 2); spinal cord: 3.3 nTPM (limit 2); cerebral cortex: 2.5 nTPM (baseline 2); choroid plexus: 3.6 nTPM (baseline 2); liver: 2.6 nTPM (baseline 2); spinal cord: 3.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 30/50 (60.0%); Glioblastoma Multiforme (validation): 14/58 (24.1%); Testicular Germ Cell Tumor (TCGA): 26/133 (19.5%),liver cancer: 9/12 (75.0%); pancreatic cancer: 7/12 (58.3%),31,20,Q9UQB9,https://www.uniprot.org/uniprotkb/Q9UQB9/entry,"Serine/threonine-protein kinase component of the chromosomal passenger complex (CPC), a complex that acts as a key regulator of mitosis. The CPC complex has essential functions at the centromere in ensuring correct chromosome alignment and segregation and is required for chromatin-induced microtubule stabilization and spindle assembly. Also plays a role in meiosis and more particularly in spermatogenesis. Has redundant cellular functions with AURKB and can rescue an AURKB knockdown. Like AURKB, AURKC phosphorylates histone H3 at 'Ser-10' and 'Ser-28'. AURKC phosphorylates the CPC complex subunits BIRC5/survivin and INCENP leading to increased AURKC activity. Phosphorylates TACC1, another protein involved in cell division, at 'Ser-228'","Isoform 1 and isoform 2 are expressed in testis. Elevated expression levels were seen only in a subset of cancer cell lines such as Hep-G2, Huh-7 and HeLa. Expression is maximum at M phase","Spermatogenic failure 5: An infertility disorder caused by spermatogenesis defects. Semen from affected men show close to 100% morphologically abnormal multiflagellar spermatozoa with low motility, oversized irregular heads, and abnormal midpiece and acrosome.",,"Nucleus Chromosome Chromosome, centromere Cytoplasm, cytoskeleton, spindle",15316025|15499654|15670791|15938719|21493633|21531210|27332895,15670791,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
AXDND1,ENSG00000162779,Unsafe,Protein,False,True,15.3,15.3,84,8,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted,"Positive IHC in a Vital, Protected or Manageable compartment",,bronchus / respiratory epithelial cells: Low (Enhanced); nasopharynx / respiratory epithelial cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 11/80 (13.8%); Liver Hepatocellular Carcinoma (validation): 4/231 (1.7%); Testicular Germ Cell Tumor (TCGA): 2/133 (1.5%),breast cancer: 0/12 (0.0%); cervical cancer: 0/11 (0.0%),30,20,Q5T1B0,https://www.uniprot.org/uniprotkb/Q5T1B0/entry,"May be essential for spermiogenesis and male fertility probably by regulating the manchette dynamics, spermatid head shaping and sperm flagellum assembly",Highly expressed in testis. Highly expressed in the round and late spermatids,,,Cytoplasm,,34759295,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Loriot2025_S2 | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
AZI2,ENSG00000163512,Unsafe,Protein,False,True,16.0,26.1,79,69,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 26.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; adrenal gland: 11.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 14 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 14.4 nTPM; absolute ceiling;continuous selectivity; bone marrow: 20.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 10.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 17.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 14.3 nTPM; absolute ceiling;continuous selectivity; colon: 10 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 11.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 9.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 14.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 13.2 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 15.2 nTPM; absolute ceiling;continuous selectivity; kidney: 14.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 10.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 12.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 9.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 13.8 nTPM; absolute ceiling;continuous selectivity; pancreas: 10.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 12.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 13.5 nTPM; absolute ceiling;continuous selectivity; rectum: 9.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 13.2 nTPM; absolute ceiling;continuous selectivity; salivary gland: 17.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 13.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 9.6 nTPM; positive ihc;continuous selectivity; small intestine: 10.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 11.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 9.8 nTPM; absolute ceiling;continuous selectivity; spleen: 9.8 nTPM; positive ihc;continuous selectivity; stomach: 10.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 13.7 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 13.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 11.5 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 11.2 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 26.1 nTPM (limit 10); adrenal gland: 11.3 nTPM (limit 2); amygdala: 14 nTPM (limit 2); basal ganglia: 14.4 nTPM (limit 2); bone marrow: 20.6 nTPM (limit 2); cerebellum: 10.3 nTPM (limit 2); cerebral cortex: 17.1 nTPM (limit 2); choroid plexus: 14.3 nTPM (limit 2); colon: 10 nTPM (limit 6); duodenum: 11.6 nTPM (limit 2); esophagus: 9.3 nTPM (limit 6); heart muscle: 14.2 nTPM (limit 2); hippocampal formation: 13.2 nTPM (limit 2); hypothalamus: 15.2 nTPM (limit 2); kidney: 14.4 nTPM (limit 2); liver: 10.9 nTPM (limit 2); lung: 12.1 nTPM (limit 2); lymph node: 9.6 nTPM (limit 6); midbrain: 13.8 nTPM (limit 2); pancreas: 10.8 nTPM (limit 2); parathyroid gland: 12.4 nTPM (limit 6); pituitary gland: 13.5 nTPM (limit 2); rectum: 9.5 nTPM (limit 6); retina: 13.2 nTPM (limit 2); salivary gland: 17.3 nTPM (limit 6); skeletal muscle: 13.6 nTPM (limit 2); small intestine: 10.9 nTPM (limit 2); smooth muscle: 11.4 nTPM (limit 2); spinal cord: 9.8 nTPM (limit 2); stomach: 10.7 nTPM (limit 6); thymus: 13.7 nTPM (limit 10); thyroid gland: 13.6 nTPM (limit 10); tongue: 11.5 nTPM (limit 6); urinary bladder: 11.2 nTPM (limit 6),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: High (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / fibroblasts: Low (Approved); skin 1 / keratinocytes: Low (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in red pulp: Low (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (TCGA): 141/141 (100.0%),colorectal cancer: 12/12 (100.0%); melanoma: 12/12 (100.0%),31,20,Q9H6S1,https://www.uniprot.org/uniprotkb/Q9H6S1/entry,"Adapter protein which binds TBK1 and IKBKE playing a role in antiviral innate immunity (PubMed:14560022, PubMed:21931631). Activates serine/threonine-protein kinase TBK1 and facilitates its oligomerization (PubMed:14560022, PubMed:21931631). Enhances the phosphorylation of NF-kappa-B p65 subunit RELA by TBK1 (PubMed:14560022, PubMed:21931631). Promotes TBK1-induced as well as TNF or PMA-induced activation of NF-kappa-B (PubMed:14560022, PubMed:21931631). Participates in IFNB promoter activation via TICAM1 (PubMed:15611223)",Widely expressed (PubMed:14560022). Abundant expression seen in the pancreas and testis (PubMed:14560022),,,Cytoplasm,14560022|15611223|21931631,14560022,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
AZIN2,ENSG00000142920,Unsafe,RNA,False,True,31.2,31.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 3.7 nTPM; absolute ceiling; amygdala: 8.5 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 9.7 nTPM; absolute ceiling;continuous selectivity; cerebellum: 6.6 nTPM; absolute ceiling; cerebral cortex: 11.8 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 6.3 nTPM; absolute ceiling; heart muscle: 3.5 nTPM; absolute ceiling; hippocampal formation: 11.2 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 8.5 nTPM; absolute ceiling;continuous selectivity; kidney: 2.6 nTPM; absolute ceiling; midbrain: 11.6 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 3.4 nTPM; absolute ceiling; retina: 2.9 nTPM; absolute ceiling; spinal cord: 21.6 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 3.7 nTPM (limit 2); amygdala: 8.5 nTPM (limit 2); basal ganglia: 9.7 nTPM (limit 2); cerebellum: 6.6 nTPM (limit 2); cerebral cortex: 11.8 nTPM (limit 2); choroid plexus: 6.3 nTPM (limit 2); heart muscle: 3.5 nTPM (limit 2); hippocampal formation: 11.2 nTPM (limit 2); hypothalamus: 8.5 nTPM (limit 2); kidney: 2.6 nTPM (limit 2); midbrain: 11.6 nTPM (limit 2); pituitary gland: 3.4 nTPM (limit 2); retina: 2.9 nTPM (limit 2); spinal cord: 21.6 nTPM (limit 2); adrenal gland: 3.7 nTPM (baseline 2); amygdala: 8.5 nTPM (baseline 2); basal ganglia: 9.7 nTPM (baseline 2); cerebellum: 6.6 nTPM (baseline 2); cerebral cortex: 11.8 nTPM (baseline 2); choroid plexus: 6.3 nTPM (baseline 2); heart muscle: 3.5 nTPM (baseline 2); hippocampal formation: 11.2 nTPM (baseline 2); hypothalamus: 8.5 nTPM (baseline 2); kidney: 2.6 nTPM (baseline 2); midbrain: 11.6 nTPM (baseline 2); pituitary gland: 3.4 nTPM (baseline 2); retina: 2.9 nTPM (baseline 2); spinal cord: 21.6 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 49/58 (84.5%); Glioblastoma Multiforme (TCGA): 105/141 (74.5%); Breast Invasive Carcinoma (TCGA): 409/1022 (40.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q96A70,https://www.uniprot.org/uniprotkb/Q96A70/entry,"Antizyme inhibitor (AZI) protein that positively regulates ornithine decarboxylase (ODC) activity and polyamine uptake. AZI is an enzymatically inactive ODC homolog that counteracts the negative effect of ODC antizymes (AZs) OAZ1, OAZ2 and OAZ3 on ODC activity by competing with ODC for antizyme-binding (PubMed:17900240). Inhibits antizyme-dependent ODC degradation and releases ODC monomers from their inactive complex with antizymes, leading to formation of the catalytically active ODC homodimer and restoring polyamine production (PubMed:17900240). Participates in the morphological integrity of the trans-Golgi network (TGN) and functions as a regulator of intracellular secretory vesicle trafficking (PubMed:20188728)","Expressed in the neocortex, thalamus, hippocampus, cerebellum, medulla oblongata, gray and white matter. Expressed in neurons, oligodendrocytes, basket, Purkinje and pyramidal cells. Expressed in spermatocytes and Leydig cells of the testis. Expressed in luteal theca cells lining corpus luteum cysts and in hilus cells of the ovary. Expressed in primary and neoplastic mast cells (MC) (at protein level). Highly expressed in brain. Also expressed in testis",,"Was initially reported to have ornithine decarboxylase (PubMed:11587527) or arginine decarboxylase (PubMed:14738999) activities, but it was later found that the mouse ortholog does not possess either of them","Nucleus Cytoplasm Cytoplasm, perinuclear region Membrane Cytoplasmic vesicle Endoplasmic reticulum-Golgi intermediate compartment Golgi apparatus, cis-Golgi network Golgi apparatus, trans-Golgi network Cytoplasmic granule Cell projection, axon Cell projection, dendrite Perikaryon",17900240|20188728,11587527|14738999|19718454|19756694|19832840,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
B3GNT5,ENSG00000176597,Unsafe,Protein,False,True,13.4,75.7,79,43,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 11.5 nTPM; absolute ceiling;continuous selectivity; adrenal gland: 2.3 nTPM; positive ihc;absolute ceiling; amygdala: 2.1 nTPM; absolute ceiling; basal ganglia: 2.1 nTPM; absolute ceiling; bone marrow: 75.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 0.8 nTPM; positive ihc; cerebral cortex: 2.9 nTPM; positive ihc;absolute ceiling; colon: 21.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 37.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 36.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 3.4 nTPM; positive ihc;absolute ceiling; hippocampal formation: 2.4 nTPM; absolute ceiling; hypothalamus: 2.7 nTPM; absolute ceiling; kidney: 3.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 3.2 nTPM; positive ihc;absolute ceiling; lung: 14.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 1.1 nTPM; positive ihc; midbrain: 2.8 nTPM; absolute ceiling; pancreas: 7.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 3.4 nTPM; positive ihc; pituitary gland: 5.6 nTPM; absolute ceiling;continuous selectivity; rectum: 19 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 9.8 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 7.2 nTPM; absolute ceiling;continuous selectivity; skin: 10 nTPM; positive ihc;continuous selectivity; small intestine: 40.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 6.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 4.3 nTPM; absolute ceiling;continuous selectivity; spleen: 1.6 nTPM; positive ihc; stomach: 11 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 7.4 nTPM; continuous selectivity; thyroid gland: 5.1 nTPM; positive ihc; urinary bladder: 23.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 11.5 nTPM (limit 10); adrenal gland: 2.3 nTPM (limit 2); amygdala: 2.1 nTPM (limit 2); basal ganglia: 2.1 nTPM (limit 2); bone marrow: 75.7 nTPM (limit 2); cerebral cortex: 2.9 nTPM (limit 2); colon: 21.9 nTPM (limit 6); duodenum: 37.1 nTPM (limit 2); esophagus: 36.3 nTPM (limit 6); heart muscle: 3.4 nTPM (limit 2); hippocampal formation: 2.4 nTPM (limit 2); hypothalamus: 2.7 nTPM (limit 2); kidney: 3.6 nTPM (limit 2); liver: 3.2 nTPM (limit 2); lung: 14.5 nTPM (limit 2); midbrain: 2.8 nTPM (limit 2); pancreas: 7.2 nTPM (limit 2); pituitary gland: 5.6 nTPM (limit 2); rectum: 19 nTPM (limit 6); salivary gland: 9.8 nTPM (limit 6); skeletal muscle: 7.2 nTPM (limit 2); small intestine: 40.8 nTPM (limit 2); smooth muscle: 6.5 nTPM (limit 2); spinal cord: 4.3 nTPM (limit 2); stomach: 11 nTPM (limit 6); urinary bladder: 23.3 nTPM (limit 6); adipose tissue: 11.5 nTPM (baseline 10); adrenal gland: 2.3 nTPM (baseline 2); amygdala: 2.1 nTPM (baseline 2); basal ganglia: 2.1 nTPM (baseline 2); bone marrow: 75.7 nTPM (baseline 2); cerebral cortex: 2.9 nTPM (baseline 2); colon: 21.9 nTPM (baseline 6); duodenum: 37.1 nTPM (baseline 2); esophagus: 36.3 nTPM (baseline 6); heart muscle: 3.4 nTPM (baseline 2); hippocampal formation: 2.4 nTPM (baseline 2); hypothalamus: 2.7 nTPM (baseline 2); kidney: 3.6 nTPM (baseline 2); liver: 3.2 nTPM (baseline 2); lung: 14.5 nTPM (baseline 2); midbrain: 2.8 nTPM (baseline 2); pancreas: 7.2 nTPM (baseline 2); pituitary gland: 5.6 nTPM (baseline 2); rectum: 19 nTPM (baseline 6); salivary gland: 9.8 nTPM (baseline 6); skeletal muscle: 7.2 nTPM (baseline 2); small intestine: 40.8 nTPM (baseline 2); smooth muscle: 6.5 nTPM (baseline 2); spinal cord: 4.3 nTPM (baseline 2); stomach: 11 nTPM (baseline 6); urinary bladder: 23.3 nTPM (baseline 6),adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Low (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in molecular layer: Low (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / endothelial cells: Low (Uncertain); colon / glandular cells: Low (Uncertain); colon / peripheral nerve/ganglion: Low (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Low (Uncertain); heart muscle / cardiomyocytes: Low (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / macrophages: Low (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); parathyroid gland / glandular cells: Low (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: Low (Uncertain); smooth muscle / smooth muscle cells: Low (Uncertain); spleen / cells in red pulp: Medium (Uncertain); stomach 2 / glandular cells: Low (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Colon Adenocarcinoma (TCGA): 254/254 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%),liver cancer: 5/11 (45.5%); prostate cancer: 5/11 (45.5%),31,20,Q9BYG0,https://www.uniprot.org/uniprotkb/Q9BYG0/entry,"Beta-1,3-N-acetylglucosaminyltransferase that plays a key role in the synthesis of lacto- or neolacto-series carbohydrate chains on glycolipids, notably by participating in biosynthesis of HNK-1 and Lewis X carbohydrate structures. Has strong activity toward lactosylceramide (LacCer) and neolactotetraosylceramide (nLc(4)Cer; paragloboside), resulting in the synthesis of Lc(3)Cer and neolactopentaosylceramide (nLc(5)Cer), respectively. Probably plays a central role in regulating neolacto-series glycolipid synthesis during embryonic development","Widely expressed. Highly expressed in lung, colon, placenta, testis, pituitary gland and cerebellum. Weakly expressed in brain, liver, spleen, lymph node and thymus",,,Golgi apparatus membrane,11283017|11384981,11283017,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
BACH1,ENSG00000156273,Unsafe,Protein,False,True,48.9,88.2,96,26,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 11.7 nTPM; absolute ceiling; amygdala: 4.2 nTPM; absolute ceiling; basal ganglia: 3.6 nTPM; absolute ceiling; bone marrow: 88.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 9 nTPM; absolute ceiling; choroid plexus: 4.5 nTPM; absolute ceiling; colon: 12.9 nTPM; positive ihc;absolute ceiling; duodenum: 16.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 22.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 12.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 4.1 nTPM; absolute ceiling; hypothalamus: 3.9 nTPM; absolute ceiling; kidney: 15.3 nTPM; absolute ceiling; liver: 29.6 nTPM; absolute ceiling;continuous selectivity; lung: 20.7 nTPM; absolute ceiling;continuous selectivity; lymph node: 16.4 nTPM; absolute ceiling; midbrain: 5 nTPM; absolute ceiling; pancreas: 16.7 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 8.1 nTPM; absolute ceiling; pituitary gland: 3.3 nTPM; absolute ceiling; rectum: 12.7 nTPM; absolute ceiling; retina: 11.5 nTPM; absolute ceiling; salivary gland: 16.9 nTPM; absolute ceiling; skeletal muscle: 25.4 nTPM; absolute ceiling;continuous selectivity; skin: 22.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 16.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 15.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 5.6 nTPM; absolute ceiling; spleen: 20.1 nTPM; absolute ceiling; stomach: 13.1 nTPM; positive ihc;absolute ceiling; thymus: 13.8 nTPM; absolute ceiling; tongue: 12.3 nTPM; absolute ceiling; urinary bladder: 28.6 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 11.7 nTPM (limit 4); amygdala: 4.2 nTPM (limit 2); basal ganglia: 3.6 nTPM (limit 2); bone marrow: 88.2 nTPM (limit 2); cerebral cortex: 9 nTPM (limit 4); choroid plexus: 4.5 nTPM (limit 2); colon: 12.9 nTPM (limit 6); duodenum: 16.3 nTPM (limit 2); esophagus: 22.2 nTPM (limit 6); heart muscle: 12.7 nTPM (limit 2); hippocampal formation: 4.1 nTPM (limit 2); hypothalamus: 3.9 nTPM (limit 2); kidney: 15.3 nTPM (limit 4); liver: 29.6 nTPM (limit 4); lung: 20.7 nTPM (limit 4); lymph node: 16.4 nTPM (limit 8); midbrain: 5 nTPM (limit 2); pancreas: 16.7 nTPM (limit 4); parathyroid gland: 8.1 nTPM (limit 8); pituitary gland: 3.3 nTPM (limit 2); rectum: 12.7 nTPM (limit 8); retina: 11.5 nTPM (limit 2); salivary gland: 16.9 nTPM (limit 8); skeletal muscle: 25.4 nTPM (limit 4); skin: 22.6 nTPM (limit 10); small intestine: 16.9 nTPM (limit 2); smooth muscle: 15.4 nTPM (limit 2); spinal cord: 5.6 nTPM (limit 2); spleen: 20.1 nTPM (limit 20); stomach: 13.1 nTPM (limit 6); thymus: 13.8 nTPM (limit 10); tongue: 12.3 nTPM (limit 6); urinary bladder: 28.6 nTPM (limit 6),bone marrow / hematopoietic cells: Medium (Approved); bronchus / ciliated cells (cell body): Low (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Low (Approved); duodenum / glandular cells: Low (Approved); esophagus / squamous epithelial cells: High (Approved); heart muscle / cardiomyocytes: Low (Approved); oral mucosa / squamous epithelial cells: High (Approved); skin 1 / keratinocytes: Medium (Approved); skin 2 / epidermal cells: High (Approved); small intestine / glandular cells: Low (Approved); smooth muscle / smooth muscle cells: Low (Approved); stomach 2 / glandular cells: Low (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%),testis cancer: 9/12 (75.0%); cervical cancer: 8/12 (66.7%),31,20,O14867,https://www.uniprot.org/uniprotkb/O14867/entry,"Transcriptional regulator that acts as a repressor or activator, depending on the context. Binds to NF-E2 DNA binding sites. Plays important roles in coordinating transcription activation and repression by MAFK (By similarity). Together with MAF, represses the transcription of genes under the control of the NFE2L2 oxidative stress pathway (PubMed:24035498)",,,,Nucleus,24035498|39504958,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
BACH2,ENSG00000112182,Unsafe,Protein,False,True,2.7,17.1,104,57,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 1.3 nTPM; positive ihc;continuous selectivity; adrenal gland: 0.7 nTPM; positive ihc; bone marrow: 7.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 0.5 nTPM; positive ihc; cerebral cortex: 1.9 nTPM; positive ihc;continuous selectivity; colon: 0.5 nTPM; positive ihc; duodenum: 0.3 nTPM; positive ihc; heart muscle: 1.1 nTPM; positive ihc;continuous selectivity; kidney: 0.4 nTPM; positive ihc; lung: 0.9 nTPM; positive ihc;continuous selectivity; lymph node: 17.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 1.6 nTPM; positive ihc;continuous selectivity; rectum: 0.5 nTPM; positive ihc; retina: 1.3 nTPM; continuous selectivity; salivary gland: 1.1 nTPM; positive ihc;continuous selectivity; skeletal muscle: 2 nTPM; positive ihc;continuous selectivity; skin: 0.9 nTPM; positive ihc; small intestine: 1.2 nTPM; positive ihc;continuous selectivity; smooth muscle: 1.1 nTPM; positive ihc;continuous selectivity; spleen: 4.7 nTPM; continuous selectivity;reproductive not higher; stomach: 0.6 nTPM; positive ihc; thymus: 12.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 0.4 nTPM; positive ihc; tongue: 2.3 nTPM; continuous selectivity; urinary bladder: 1.3 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 7.2 nTPM (limit 2); lymph node: 17.1 nTPM (limit 6); thymus: 12.7 nTPM (limit 10),adipose tissue / adipocytes: Low (Enhanced); adrenal gland / glandular cells: Medium (Enhanced); bone marrow / hematopoietic cells: Medium (Enhanced); bronchus / ciliated cells (cell body): Low (Enhanced); bronchus / ciliated cells (ciliary rootlets): Low (Enhanced); bronchus / ciliated cells (tip of cilia): Low (Enhanced); cerebellum / cells in granular layer: Low (Enhanced); cerebellum / Purkinje cells: Low (Enhanced); cerebral cortex / neuronal cells: Low (Enhanced); cerebral cortex / neuropil: Low (Enhanced); colon / endothelial cells: Low (Enhanced); colon / glandular cells: Low (Enhanced); colon / peripheral nerve/ganglion: Low (Enhanced); duodenum / glandular cells: Medium (Enhanced); heart muscle / cardiomyocytes: Low (Enhanced); hippocampus / neuronal cells: Low (Enhanced); kidney / collecting ducts: Low (Enhanced); kidney / distal tubules: Medium (Enhanced); kidney / proximal tubules (cell body): Low (Enhanced); lung / macrophages: Low (Enhanced); lymph node / germinal center cells: Medium (Enhanced); lymph node / non-germinal center cells: Medium (Enhanced); nasopharynx / basal cells: Low (Enhanced); nasopharynx / ciliated cells (cell body): Medium (Enhanced); nasopharynx / goblet cells: Low (Enhanced); parathyroid gland / glandular cells: Medium (Enhanced); rectum / glandular cells: Low (Enhanced); salivary gland / glandular cells: Low (Enhanced); skeletal muscle / myocytes: Low (Enhanced); skin 1 / fibroblasts: Low (Enhanced); skin 1 / keratinocytes: Low (Enhanced); skin 1 / Langerhans: Low (Enhanced); small intestine / glandular cells: Medium (Enhanced); smooth muscle / smooth muscle cells: Low (Enhanced); stomach 1 / glandular cells: Low (Enhanced); stomach 2 / glandular cells: Medium (Enhanced); thyroid gland / glandular cells: Low (Enhanced); urinary bladder / urothelial cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 51/58 (87.9%); Breast Invasive Carcinoma (validation): 15/50 (30.0%); Pancreatic Adenocarcinoma (validation): 10/80 (12.5%),lymphoma: 5/12 (41.7%); testis cancer: 1/11 (9.1%),31,20,Q9BYV9,https://www.uniprot.org/uniprotkb/Q9BYV9/entry,"Transcriptional regulator that acts as a repressor or activator (By similarity). Binds to Maf recognition elements (MARE) (By similarity). Plays an important role in coordinating transcription activation and repression by MAFK (By similarity). Induces apoptosis in response to oxidative stress through repression of the antiapoptotic factor HMOX1 (PubMed:17018862). Positively regulates the nuclear import of actin (By similarity). Is a key regulator of adaptive immunity, crucial for the maintenance of regulatory T-cell function and B-cell maturation (PubMed:28530713)",B-cell specific,"Immunodeficiency 60 and autoimmunity: An autosomal dominant primary immunologic disorder characterized by intestinal inflammation, recurrent sino-pulmonary infections, impaired lymphocyte maturation, and variably decreased immunoglobulin production.",,Cytoplasm Nucleus,17018862|28530713,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
BANF2,ENSG00000125888,Unsafe,RNA,False,True,107.2,107.2,82,5,Positive somewhere,False,True,False,True,Excluded,Normal,False,,Not assessed,,,pancreas: 19.8 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,pancreas: 19.8 nTPM (limit 4),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (TCGA): 15/362 (4.1%); Pancreatic Adenocarcinoma (TCGA): 5/176 (2.8%); Thyroid Carcinoma (TCGA): 13/495 (2.6%),breast cancer: 0/11 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q9H503,https://www.uniprot.org/uniprotkb/Q9H503/entry,May play a role in BANF1 regulation and influence tissue-specific roles of BANF1,"Expressed strongly in testis and pancreas. Also detected in brain, colon, liver, lung, ovary, placenta, prostate, small intestine, spleen and thymus. Not detected in heart, kidney and skeletal muscle",,"In contrast to BANF1, it does not seem to bind DNA",Nucleus Cytoplasm,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
BARHL2,ENSG00000143032,Unsafe,RNA,False,True,2.2,43.9,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,cerebellum: 43.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 1.1 nTPM; continuous selectivity; retina: 2.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 0.7 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebellum: 43.9 nTPM (limit 2); retina: 2.7 nTPM (limit 2); cerebellum: 43.9 nTPM (baseline 2); retina: 2.7 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 4/133 (3.0%); Ovary Serous Cystadenocarcinoma (TCGA): 2/349 (0.6%); Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9NY43,https://www.uniprot.org/uniprotkb/Q9NY43/entry,Potential regulator of neural basic helix-loop-helix genes,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
BBS1,ENSG00000174483,Unsafe,Protein,False,True,27.1,36.7,80,25,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 10.2 nTPM; absolute ceiling; adrenal gland: 14.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 18.1 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 22.6 nTPM; absolute ceiling;continuous selectivity; bone marrow: 2.9 nTPM; absolute ceiling; cerebellum: 19.7 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 24.2 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 20.1 nTPM; absolute ceiling;continuous selectivity; colon: 17.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 6.4 nTPM; positive ihc;absolute ceiling; esophagus: 8.7 nTPM; absolute ceiling; heart muscle: 9.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 14.9 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 16.6 nTPM; absolute ceiling;continuous selectivity; kidney: 23.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 6.8 nTPM; positive ihc;absolute ceiling; lung: 10.1 nTPM; absolute ceiling;continuous selectivity; midbrain: 12.6 nTPM; absolute ceiling;continuous selectivity; pancreas: 13 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 36.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 17.4 nTPM; absolute ceiling;continuous selectivity; rectum: 7.1 nTPM; positive ihc;absolute ceiling; retina: 20.8 nTPM; absolute ceiling;continuous selectivity; salivary gland: 16.3 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 7.8 nTPM; absolute ceiling;continuous selectivity; skin: 9.3 nTPM; positive ihc; small intestine: 9.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 13.6 nTPM; absolute ceiling;continuous selectivity; spinal cord: 9.1 nTPM; absolute ceiling;continuous selectivity; stomach: 13.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; thyroid gland: 26.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 7.9 nTPM; absolute ceiling; urinary bladder: 14.9 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 10.2 nTPM (limit 10); adrenal gland: 14.8 nTPM (limit 2); amygdala: 18.1 nTPM (limit 2); basal ganglia: 22.6 nTPM (limit 2); bone marrow: 2.9 nTPM (limit 2); cerebellum: 19.7 nTPM (limit 2); cerebral cortex: 24.2 nTPM (limit 2); choroid plexus: 20.1 nTPM (limit 2); colon: 17.4 nTPM (limit 6); duodenum: 6.4 nTPM (limit 2); esophagus: 8.7 nTPM (limit 6); heart muscle: 9.8 nTPM (limit 2); hippocampal formation: 14.9 nTPM (limit 2); hypothalamus: 16.6 nTPM (limit 2); kidney: 23.3 nTPM (limit 2); liver: 6.8 nTPM (limit 2); lung: 10.1 nTPM (limit 2); midbrain: 12.6 nTPM (limit 2); pancreas: 13 nTPM (limit 2); parathyroid gland: 36.7 nTPM (limit 6); pituitary gland: 17.4 nTPM (limit 2); rectum: 7.1 nTPM (limit 6); retina: 20.8 nTPM (limit 2); salivary gland: 16.3 nTPM (limit 6); skeletal muscle: 7.8 nTPM (limit 2); small intestine: 9.1 nTPM (limit 2); smooth muscle: 13.6 nTPM (limit 2); spinal cord: 9.1 nTPM (limit 2); stomach: 13.4 nTPM (limit 6); thyroid gland: 26.4 nTPM (limit 10); tongue: 7.9 nTPM (limit 6); urinary bladder: 14.9 nTPM (limit 6); adipose tissue: 10.2 nTPM (baseline 10); adrenal gland: 14.8 nTPM (baseline 2); amygdala: 18.1 nTPM (baseline 2); basal ganglia: 22.6 nTPM (baseline 2); bone marrow: 2.9 nTPM (baseline 2); cerebellum: 19.7 nTPM (baseline 2); cerebral cortex: 24.2 nTPM (baseline 2); choroid plexus: 20.1 nTPM (baseline 2); colon: 17.4 nTPM (baseline 6); duodenum: 6.4 nTPM (baseline 2); esophagus: 8.7 nTPM (baseline 6); heart muscle: 9.8 nTPM (baseline 2); hippocampal formation: 14.9 nTPM (baseline 2); hypothalamus: 16.6 nTPM (baseline 2); kidney: 23.3 nTPM (baseline 2); liver: 6.8 nTPM (baseline 2); lung: 10.1 nTPM (baseline 2); midbrain: 12.6 nTPM (baseline 2); pancreas: 13 nTPM (baseline 2); parathyroid gland: 36.7 nTPM (baseline 6); pituitary gland: 17.4 nTPM (baseline 2); rectum: 7.1 nTPM (baseline 6); retina: 20.8 nTPM (baseline 2); salivary gland: 16.3 nTPM (baseline 6); skeletal muscle: 7.8 nTPM (baseline 2); small intestine: 9.1 nTPM (baseline 2); smooth muscle: 13.6 nTPM (baseline 2); spinal cord: 9.1 nTPM (baseline 2); stomach: 13.4 nTPM (baseline 6); thyroid gland: 26.4 nTPM (baseline 10); tongue: 7.9 nTPM (baseline 6); urinary bladder: 14.9 nTPM (baseline 6),adrenal gland / glandular cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); colon / glandular cells: Low (Uncertain); duodenum / glandular cells: Low (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / hepatocytes: Medium (Uncertain); nasopharynx / respiratory epithelial cells: Low (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: Medium (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: Low (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Low (Uncertain); thyroid gland / glandular cells: Medium (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 80/80 (100.0%); Rectum Adenocarcinoma (validation): 205/207 (99.0%); Kidney Renal Clear Cell Carcinoma (validation): 99/100 (99.0%),prostate cancer: 7/11 (63.6%); stomach cancer: 2/12 (16.7%),31,20,Q8NFJ9,https://www.uniprot.org/uniprotkb/Q8NFJ9/entry,"The BBSome complex is thought to function as a coat complex required for sorting of specific membrane proteins to the primary cilia. The BBSome complex is required for ciliogenesis but is dispensable for centriolar satellite function. This ciliogenic function is mediated in part by the Rab8 GDP/GTP exchange factor, which localizes to the basal body and contacts the BBSome. Rab8(GTP) enters the primary cilium and promotes extension of the ciliary membrane. Firstly the BBSome associates with the ciliary membrane and binds to RAB3IP/Rabin8, the guanosyl exchange factor (GEF) for Rab8 and then the Rab8-GTP localizes to the cilium and promotes docking and fusion of carrier vesicles to the base of the ciliary membrane. The BBSome complex, together with the LTZL1, controls SMO ciliary trafficking and contributes to the sonic hedgehog (SHH) pathway regulation. Required for proper BBSome complex assembly and its ciliary localization (PubMed:17574030, PubMed:22072986). Plays a role in olfactory cilium biogenesis/maintenance and trafficking (By similarity)","Highly expressed in the kidney. Also found in fetal tissue, testis, retina, adipose tissue, heart, skeletal muscle and pancreas","Bardet-Biedl syndrome 1: A syndrome characterized by usually severe pigmentary retinopathy, early-onset obesity, polydactyly, hypogenitalism, renal malformation and intellectual disability. Secondary features include diabetes mellitus, hypertension and congenital heart disease. Bardet-Biedl syndrome inheritance is autosomal recessive, but three mutated alleles (two at one locus, and a third at a second locus) may be required for clinical manifestation of some forms of the disease.",,"Cell projection, cilium membrane Cytoplasm Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriolar satellite",17574030|22072986,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
BCKDHA,ENSG00000248098,Unsafe,Protein,False,True,30.9,117.2,84,82,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 32.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; adrenal gland: 75.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 21.4 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 23.3 nTPM; absolute ceiling;continuous selectivity; bone marrow: 32 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 19.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 25.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 54.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 20.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 19.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 63.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 87.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 18.3 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 17.7 nTPM; absolute ceiling;continuous selectivity; kidney: 43 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 107.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 21.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 23.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 23.8 nTPM; absolute ceiling;continuous selectivity; pancreas: 44.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 54.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 23.4 nTPM; absolute ceiling;continuous selectivity; rectum: 14.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 21 nTPM; absolute ceiling;continuous selectivity; salivary gland: 39.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 106.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 30.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 18.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 12.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 18.8 nTPM; absolute ceiling;continuous selectivity; spleen: 23.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 51.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; thymus: 26.2 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 40.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; tongue: 117.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 21 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 32.6 nTPM (limit 10); adrenal gland: 75.9 nTPM (limit 2); amygdala: 21.4 nTPM (limit 2); basal ganglia: 23.3 nTPM (limit 2); bone marrow: 32 nTPM (limit 2); cerebellum: 19.3 nTPM (limit 2); cerebral cortex: 25.2 nTPM (limit 2); choroid plexus: 54.4 nTPM (limit 2); colon: 20.3 nTPM (limit 6); duodenum: 19.4 nTPM (limit 2); esophagus: 63.2 nTPM (limit 6); heart muscle: 87.5 nTPM (limit 2); hippocampal formation: 18.3 nTPM (limit 2); hypothalamus: 17.7 nTPM (limit 2); kidney: 43 nTPM (limit 2); liver: 107.3 nTPM (limit 2); lung: 21.7 nTPM (limit 2); lymph node: 23.9 nTPM (limit 6); midbrain: 23.8 nTPM (limit 2); pancreas: 44.8 nTPM (limit 2); parathyroid gland: 54.4 nTPM (limit 6); pituitary gland: 23.4 nTPM (limit 2); rectum: 14.5 nTPM (limit 6); retina: 21 nTPM (limit 2); salivary gland: 39.7 nTPM (limit 6); skeletal muscle: 106.1 nTPM (limit 2); skin: 30.9 nTPM (limit 10); small intestine: 18.2 nTPM (limit 2); smooth muscle: 12.2 nTPM (limit 2); spinal cord: 18.8 nTPM (limit 2); spleen: 23.7 nTPM (limit 10); stomach: 51.1 nTPM (limit 6); thymus: 26.2 nTPM (limit 10); thyroid gland: 40.4 nTPM (limit 10); tongue: 117.2 nTPM (limit 6); urinary bladder: 21 nTPM (limit 6),adipose tissue / adipocytes: Medium (Supported); adrenal gland / glandular cells: High (Supported); bone marrow / hematopoietic cells: High (Supported); bronchus / respiratory epithelial cells: High (Supported); caudate / glial cells: Medium (Supported); caudate / neuronal cells: Medium (Supported); cerebellum / cells in granular layer: High (Supported); cerebellum / cells in molecular layer: Low (Supported); cerebellum / Purkinje cells: High (Supported); cerebral cortex / endothelial cells: High (Supported); cerebral cortex / glial cells: Low (Supported); cerebral cortex / neuronal cells: Medium (Supported); cerebral cortex / neuropil: High (Supported); colon / endothelial cells: High (Supported); colon / glandular cells: High (Supported); colon / peripheral nerve/ganglion: Medium (Supported); duodenum / glandular cells: High (Supported); esophagus / squamous epithelial cells: High (Supported); heart muscle / cardiomyocytes: High (Supported); hippocampus / glial cells: Medium (Supported); hippocampus / neuronal cells: Medium (Supported); kidney / cells in glomeruli: High (Supported); kidney / cells in tubules: High (Supported); liver / cholangiocytes: Low (Supported); liver / hepatocytes: High (Supported); lung / alveolar cells: High (Supported); lung / macrophages: Medium (Supported); lymph node / germinal center cells: Medium (Supported); lymph node / non-germinal center cells: High (Supported); nasopharynx / respiratory epithelial cells: High (Supported); oral mucosa / squamous epithelial cells: High (Supported); pancreas / exocrine glandular cells: High (Supported); pancreas / pancreatic endocrine cells: High (Supported); parathyroid gland / glandular cells: High (Supported); rectum / glandular cells: High (Supported); salivary gland / glandular cells: High (Supported); skeletal muscle / myocytes: High (Supported); skin 1 / fibroblasts: High (Supported); skin 1 / keratinocytes: High (Supported); skin 1 / Langerhans: High (Supported); skin 2 / epidermal cells: High (Supported); small intestine / glandular cells: High (Supported); smooth muscle / smooth muscle cells: High (Supported); spleen / cells in red pulp: High (Supported); spleen / cells in white pulp: High (Supported); stomach 1 / glandular cells: High (Supported); stomach 2 / glandular cells: High (Supported); thyroid gland / glandular cells: High (Supported); urinary bladder / urothelial cells: High (Supported),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Kidney Renal Clear Cell Carcinoma (TCGA): 521/521 (100.0%); Thyroid Carcinoma (TCGA): 495/495 (100.0%),breast cancer: 12/12 (100.0%); cervical cancer: 12/12 (100.0%),31,20,P12694,https://www.uniprot.org/uniprotkb/P12694/entry,"Together with BCKDHB forms the heterotetrameric E1 subunit of the mitochondrial branched-chain alpha-ketoacid dehydrogenase (BCKD) complex. The BCKD complex catalyzes the multi-step oxidative decarboxylation of alpha-ketoacids derived from the branched-chain amino-acids valine, leucine and isoleucine producing CO2 and acyl-CoA which is subsequently utilized to produce energy. The E1 subunit catalyzes the first step with the decarboxylation of the alpha-ketoacid forming an enzyme-product intermediate. A reductive acylation mediated by the lipoylamide cofactor of E2 extracts the acyl group from the E1 active site for the next step of the reaction",,"Maple syrup urine disease 1A: A form of maple syrup urine disease, an autosomal recessive metabolic disorder due to an enzyme defect in the catabolic pathway of the branched-chain amino acids leucine, isoleucine, and valine. Accumulation of these 3 amino acids and their corresponding keto acids leads to encephalopathy and progressive neurodegeneration. Clinical features include mental and physical retardation, feeding problems, and a maple syrup odor to the urine. The keto acids of the branched-chain amino acids are present in the urine. If untreated, maple syrup urine disease can lead to seizures, coma, and death. The disease is often classified by its pattern of signs and symptoms. The most common and severe form of the disease is the classic type, which becomes apparent soon after birth. Variant forms of the disorder become apparent later in infancy or childhood and are typically milder, but they still involve developmental delay and other medical problems if not treated.",,Mitochondrion matrix,10745006|7883996|9582350,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
BCL2L14,ENSG00000121380,Unsafe,Protein,False,True,30.5,30.5,83,20,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 0 nTPM; positive ihc; cerebellum: 0 nTPM; positive ihc; cerebral cortex: 0 nTPM; positive ihc; duodenum: 13.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 0 nTPM; positive ihc; small intestine: 12.5 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",duodenum: 13.3 nTPM (limit 2); small intestine: 12.5 nTPM (limit 2),bone marrow / hematopoietic cells: Low (Enhanced); caudate / glial cells: Medium (Enhanced); caudate / neuronal cells: Medium (Enhanced); cerebellum / cells in granular layer: Medium (Enhanced); cerebral cortex / glial cells: Medium (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); cerebral cortex / neuropil: Low (Enhanced); duodenum / glandular cells: Low (Enhanced); hippocampus / glial cells: Medium (Enhanced); parathyroid gland / glandular cells: Low (Enhanced); small intestine / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 205/207 (99.0%); Colon Adenocarcinoma (validation): 478/486 (98.4%); Colon Adenocarcinoma (TCGA): 223/254 (87.8%),renal cancer: 8/12 (66.7%); glioma: 3/10 (30.0%),31,20,Q9BZR8,https://www.uniprot.org/uniprotkb/Q9BZR8/entry,Plays a role in apoptosis,Isoform 1 is widely expressed. Isoform 2 is testis-specific,,,"Cytoplasm Cytoplasm, cytosol Endomembrane system",,11054413,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
BEAN1,ENSG00000166546,Unsafe,RNA,False,True,1.4,2.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 0.8 nTPM; continuous selectivity; cerebellum: 0.8 nTPM; continuous selectivity; cerebral cortex: 2.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 0.6 nTPM; continuous selectivity; hippocampal formation: 1.4 nTPM; continuous selectivity;reproductive not higher; hypothalamus: 1.1 nTPM; continuous selectivity; retina: 1 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebral cortex: 2.2 nTPM (limit 2); cerebral cortex: 2.2 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 30/80 (37.5%); Pancreatic Adenocarcinoma (TCGA): 55/176 (31.2%); Lung Adenocarcinoma (TCGA): 153/497 (30.8%),liver cancer: 8/12 (66.7%); pancreatic cancer: 6/9 (66.7%),30,20,Q3B7T3,https://www.uniprot.org/uniprotkb/Q3B7T3/entry,,,"Spinocerebellar ataxia 31: A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCA31 belongs to the autosomal dominant cerebellar ataxias type III (ADCA III) which are characterized by pure cerebellar ataxia without additional signs.",,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
BEND2,ENSG00000177324,Unsafe,High RNA,False,True,5.2,5.2,86,2,Positive somewhere,False,False,False,True,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,True,"pbmc/platelets cluster c-9: 218.7 nTPM, 23 reads; reproductive-cell max 133.2",True,False,,True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,5.4423,218.7,"hpa_single_cell_tissue: pbmc/platelets, max 218.7 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,5.442 TPM; blood/basophil; hpa_immune_cell_samples; vital,218.7 nTPM; pbmc/platelets; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%); Pancreatic Adenocarcinoma (TCGA): 1/176 (0.6%),breast cancer: 0/11 (0.0%); cervical cancer: 0/9 (0.0%),31,20,Q8NDZ0,https://www.uniprot.org/uniprotkb/Q8NDZ0/entry,,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
BEND3,ENSG00000178409,Unsafe,Protein,False,True,1.8,1.9,79,69,Positive somewhere,True,False,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0.8 nTPM; positive ihc; adrenal gland: 0.6 nTPM; positive ihc;continuous selectivity; bone marrow: 0.9 nTPM; positive ihc;continuous selectivity; cerebellum: 1.3 nTPM; positive ihc;continuous selectivity; cerebral cortex: 0.9 nTPM; positive ihc;continuous selectivity; colon: 1.4 nTPM; positive ihc;continuous selectivity; duodenum: 1.2 nTPM; positive ihc;continuous selectivity; esophagus: 0.9 nTPM; positive ihc;continuous selectivity; heart muscle: 1 nTPM; positive ihc;continuous selectivity; kidney: 1.1 nTPM; positive ihc;continuous selectivity; liver: 0.7 nTPM; positive ihc;continuous selectivity; lung: 0.8 nTPM; positive ihc;continuous selectivity; lymph node: 0.8 nTPM; positive ihc;continuous selectivity; pancreas: 1.5 nTPM; positive ihc;continuous selectivity; parathyroid gland: 0.6 nTPM; positive ihc; pituitary gland: 0.8 nTPM; continuous selectivity; rectum: 1.5 nTPM; positive ihc;continuous selectivity; retina: 0.8 nTPM; continuous selectivity; salivary gland: 1.4 nTPM; positive ihc;continuous selectivity; skeletal muscle: 1.2 nTPM; continuous selectivity; skin: 0.6 nTPM; positive ihc; small intestine: 1 nTPM; positive ihc;continuous selectivity; smooth muscle: 0.7 nTPM; positive ihc;continuous selectivity; stomach: 1.9 nTPM; positive ihc;continuous selectivity;reproductive not higher; thymus: 1 nTPM; continuous selectivity; thyroid gland: 0.8 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,adipose tissue / adipocytes: Medium (Uncertain); adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / glial cells: Medium (Uncertain); caudate / neuronal cells: Low (Uncertain); cerebellum / cells in granular layer: Medium (Uncertain); cerebellum / cells in molecular layer: Low (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / endothelial cells: Low (Uncertain); cerebral cortex / glial cells: Medium (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / endothelial cells: Low (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: Low (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: Low (Uncertain); hippocampus / glial cells: Medium (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / cholangiocytes: Low (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / alveolar cells: Low (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / non-germinal center cells: Medium (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Low (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Low (Uncertain); skin 1 / fibroblasts: Low (Uncertain); skin 1 / keratinocytes: Low (Uncertain); skin 1 / Langerhans: Low (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: Medium (Uncertain); smooth muscle / smooth muscle cells: Low (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 457/486 (94.0%); Testicular Germ Cell Tumor (TCGA): 119/133 (89.5%); Rectum Adenocarcinoma (validation): 180/207 (87.0%),liver cancer: 11/12 (91.7%); prostate cancer: 9/10 (90.0%),31,20,Q5T5X7,https://www.uniprot.org/uniprotkb/Q5T5X7/entry,"Transcriptional repressor which associates with the NoRC (nucleolar remodeling complex) complex and plays a key role in repressing rDNA transcription. The sumoylated form modulates the stability of the NoRC complex component BAZ2A/TIP5 by controlling its USP21-mediated deubiquitination (PubMed:21914818, PubMed:26100909). Binds to unmethylated major satellite DNA and is involved in the recruitment of the Polycomb repressive complex 2 (PRC2) to major satellites (By similarity). Stimulates the ERCC6L translocase and ATPase activities (PubMed:28977671)","Expressed at least in heart, kidney, liver, ovary and spleen, with highest levels in spleen and lowest in heart. Expressed on the surface of T-cells",,,"Nucleus Nucleus, nucleolus",21914818|26100909|28977671,21914818|25400923,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
BEND4,ENSG00000188848,Unsafe,High RNA,False,True,9.1,9.1,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 91/91 values ≥5 TPM, max 41.0497; hpa_immune_monaco Progenitor cell: 5.7 TPM",True,True,False,,True,True,"Adipose tissue/Adipocytes: Low, HPA036850; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA036850; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA036850; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA036850; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA036850; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA036850; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: High, HPA036850; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA036850; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA036850; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA036850; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Medium, HPA036850; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA036850; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA036850; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA036850; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA036850; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA036850; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA036850; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: High, HPA036850; conflicting or uncurated primary profile; Hippocampus/Glial cells: Medium, HPA036850; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA036850; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA036850; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA036850; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA036850; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA036850; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA036850; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA036850; conflicting or uncurated primary profile; Lymph node/Germinal center cells: High, HPA036850; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: High, HPA036850; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA036850; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA036850; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA036850; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA036850; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: High, HPA036850; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA036850; conflicting or uncurated primary profile; Salivary gland/Glandular cells: High, HPA036850; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA036850; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA036850; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA036850; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA036850; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA036850; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA036850; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA036850; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA036850; conflicting or uncurated primary profile; Spleen/Cells in white pulp: High, HPA036850; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA036850; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA036850; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA036850; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA036850; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,41.0496623345,31.5,"dice_b_cell_naive: blood/B_CELL_NAIVE, max 41.0497 TPM, 29 observations >30; hpa_single_cell_tissue: eye/muller glia cells, max 31.5 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,41.05 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,31.5 nTPM; eye/muller glia cells; hpa_single_cell_tissue; vital,Prostate Adenocarcinoma (TCGA): 307/480 (64.0%); Testicular Germ Cell Tumor (TCGA): 67/133 (50.4%); Glioblastoma Multiforme (validation): 9/58 (15.5%),breast cancer: 12/12 (100.0%); endometrial cancer: 12/12 (100.0%),31,20,Q6ZU67,https://www.uniprot.org/uniprotkb/Q6ZU67/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Jamin2021_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
BFSP1,ENSG00000125864,Unsafe,Protein,False,True,3.7,5.2,83,1,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; adrenal gland: 1.3 nTPM; continuous selectivity; amygdala: 2.2 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 3.2 nTPM; absolute ceiling;continuous selectivity; cerebellum: 1.8 nTPM; continuous selectivity; cerebral cortex: 2.7 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 2.9 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 2.1 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 2.3 nTPM; absolute ceiling;continuous selectivity; kidney: 3.6 nTPM; absolute ceiling;continuous selectivity; lung: 1.6 nTPM; continuous selectivity; midbrain: 2.2 nTPM; absolute ceiling;continuous selectivity; pancreas: 1.9 nTPM; continuous selectivity; salivary gland: 1.4 nTPM; continuous selectivity; spinal cord: 5.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 2.4 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 2.2 nTPM (limit 2); basal ganglia: 3.2 nTPM (limit 2); choroid plexus: 2.9 nTPM (limit 2); hippocampal formation: 2.1 nTPM (limit 2); hypothalamus: 2.3 nTPM (limit 2); midbrain: 2.2 nTPM (limit 2); spinal cord: 5.2 nTPM (limit 2); amygdala: 2.2 nTPM (baseline 2); basal ganglia: 3.2 nTPM (baseline 2); cerebral cortex: 2.7 nTPM (baseline 2); choroid plexus: 2.9 nTPM (baseline 2); hippocampal formation: 2.1 nTPM (baseline 2); hypothalamus: 2.3 nTPM (baseline 2); kidney: 3.6 nTPM (baseline 2); midbrain: 2.2 nTPM (baseline 2); spinal cord: 5.2 nTPM (baseline 2),eye / lens fiber cells: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 34/50 (68.0%); Skin Cuteneous Melanoma (TCGA): 41/99 (41.4%); Testicular Germ Cell Tumor (TCGA): 45/133 (33.8%),breast cancer: 0/11 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q12934,https://www.uniprot.org/uniprotkb/Q12934/entry,"Required for the correct formation of lens intermediate filaments as part of a complex composed of BFSP1, BFSP2 and CRYAA (PubMed:28935373). Involved in altering the calcium regulation of MIP water permeability (PubMed:30790544)",Expressed in the cortex and nucleus of the retina lens (at protein level),"Cataract 33, multiple types: An opacification of the crystalline lens of the eye that frequently results in visual impairment or blindness. Opacities vary in morphology, are often confined to a portion of the lens, and may be static or progressive. In general, the more posteriorly located and dense an opacity, the greater the impact on visual function. CTRCT33 has juvenile-onset and the opacities are restricted to the cortex of the lens, not involving the nucleus.",,"Cell membrane Cytoplasm Cytoplasm, cytoskeleton Cytoplasm, cell cortex",28935373|30790544,30790544|7720401,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
BIRC5,ENSG00000089685,Unsafe,Protein,False,True,19.0,39.9,103,28,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,Trial registration,positive normal IHC; positive ihc outside permitted; bone marrow: 37.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; colon: 6.4 nTPM; positive ihc;absolute ceiling; duodenum: 7.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 12.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 15.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; rectum: 7.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 5.7 nTPM; positive ihc; small intestine: 7.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 3.6 nTPM; positive ihc; thymus: 39.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 2.5 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 37.4 nTPM (limit 2); colon: 6.4 nTPM (limit 6); duodenum: 7.6 nTPM (limit 2); esophagus: 12.4 nTPM (limit 6); lymph node: 15.9 nTPM (limit 6); rectum: 7.7 nTPM (limit 6); small intestine: 7.3 nTPM (limit 2); thymus: 39.9 nTPM (limit 10),bone marrow / hematopoietic cells: Medium (Enhanced); bronchus / respiratory epithelial cells: Low (Enhanced); colon / glandular cells: Low (Enhanced); duodenum / glandular cells: Low (Enhanced); esophagus / squamous epithelial cells: Medium (Enhanced); lymph node / germinal center cells: Medium (Enhanced); lymph node / non-germinal center cells: Low (Enhanced); oral mucosa / squamous epithelial cells: Medium (Enhanced); rectum / glandular cells: Low (Enhanced); skin 1 / cells in basal layer: Low (Enhanced); skin 2 / cells in basal layer: Medium (Enhanced); small intestine / glandular cells: Low (Enhanced); stomach 1 / glandular cells: Low (Enhanced); stomach 2 / glandular cells: Low (Enhanced); urinary bladder / urothelial cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE TREG_MEM (unstimulated): 21/89 values ≥5 TPM, max 11.1544; hpa_immune_cell T-reg: 14.1 nTPM; hpa_immune_monaco Effector memory CD8 T-cell: 6 TPM; hpa_immune_monaco Plasmablast: 11.7 TPM",True,True,False,,True,False,,False,True,True,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,True,26.1871,326.2,"hpa_rna_consensus: bone marrow/, max 37.4 nTPM, 1 observations >30; hpa_rna_consensus: thymus/, max 39.9 nTPM, 1 observations >30; hpa_single_cell: /Erythroid cells, max 142.8 nTPM, 1 observations >30; hpa_single_cell: /Pancreatic endocrine cells, max 47.5 nTPM, 1 observations >30; hpa_single_cell: /Plasma cells, max 64.4 nTPM, 1 observations >30; hpa_single_cell: /Squamous epithelial cells, max 31.3 nTPM, 1 observations >30; hpa_single_cell: /Undifferentiated cells, max 78.6 nTPM, 1 observations >30; hpa_single_cell_tissue: adipose tissue/t-cells, max 158 nTPM, 1 observations >30; hpa_single_cell_tissue: bone marrow/erythroid cells, max 68.8 nTPM, 1 observations >30; hpa_single_cell_tissue: bone marrow/plasma cells, max 83.1 nTPM, 1 observations >30; hpa_single_cell_tissue: bronchus/basal respiratory cells, max 31.2 nTPM, 1 observations >30; hpa_single_cell_tissue: colon/distal enterocytes, max 86.1 nTPM, 1 observations >30; hpa_single_cell_tissue: colon/undifferentiated cells, max 199 nTPM, 3 observations >30; hpa_single_cell_tissue: esophagus/squamous epithelial cells, max 48.3 nTPM, 1 observations >30; hpa_single_cell_tissue: liver/erythroid cells, max 216.8 nTPM, 1 observations >30; hpa_single_cell_tissue: liver/plasma cells, max 154.2 nTPM, 1 observations >30; hpa_single_cell_tissue: liver/t-cells, max 136.5 nTPM, 2 observations >30; hpa_single_cell_tissue: lung/alveolar cells type 2, max 32.1 nTPM, 1 observations >30; hpa_single_cell_tissue: lung/macrophages, max 78.6 nTPM, 1 observations >30; hpa_single_cell_tissue: pancreas/fibroblasts, max 116.2 nTPM, 1 observations >30; hpa_single_cell_tissue: pancreas/pancreatic endocrine cells, max 47.5 nTPM, 1 observations >30; hpa_single_cell_tissue: placenta/mixed immune cells, max 326.2 nTPM, 1 observations >30; hpa_single_cell_tissue: placenta/t-cells, max 37.1 nTPM, 1 observations >30; hpa_single_cell_tissue: rectum/mixed immune cells, max 277.8 nTPM, 1 observations >30; hpa_single_cell_tissue: rectum/undifferentiated cells, max 114.9 nTPM, 1 observations >30; hpa_single_cell_tissue: skin/b-cells, max 35.6 nTPM, 1 observations >30; hpa_single_cell_tissue: small intestine/intestinal goblet cells, max 72 nTPM, 1 observations >30; hpa_single_cell_tissue: small intestine/undifferentiated cells, max 74.4 nTPM, 2 observations >30; hpa_single_cell_tissue: spleen/b-cells, max 46.1 nTPM, 1 observations >30; hpa_single_cell_tissue: spleen/plasma cells, max 150.4 nTPM, 1 observations >30; hpa_single_cell_tissue: spleen/t-cells, max 38.9 nTPM, 1 observations >30; hpa_single_cell_tissue: thymus/plasma cells, max 124.7 nTPM, 3 observations >30; hpa_single_cell_tissue: tongue/basal keratinocytes, max 221.1 nTPM, 4 observations >30; hpa_single_cell_tissue: tongue/endothelial cells, max 39.8 nTPM, 1 observations >30; hpa_single_cell_tissue: tongue/suprabasal keratinocytes, max 56.2 nTPM, 1 observations >30; hpa_single_cell_tissue: vascular/fibroblasts, max 73 nTPM, 2 observations >30",Unsafe,oncoref.target-sets.2026-10-23.2,26.19 TPM; blood/T-reg; hpa_immune_cell_samples; vital,326.2 nTPM; placenta/mixed immune cells; hpa_single_cell_tissue; vital,Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 283/283 (100.0%); Colon Adenocarcinoma (TCGA): 254/254 (100.0%); Testicular Germ Cell Tumor (TCGA): 133/133 (100.0%),testis cancer: 9/12 (75.0%); urothelial cancer: 4/12 (33.3%),31,20,O15392,https://www.uniprot.org/uniprotkb/O15392/entry,"Multitasking protein that has dual roles in promoting cell proliferation and preventing apoptosis (PubMed:20627126, PubMed:21364656, PubMed:25778398, PubMed:28218735, PubMed:9859993). Component of a chromosome passage protein complex (CPC) which is essential for chromosome alignment and segregation during mitosis and cytokinesis (PubMed:16322459). Acts as an important regulator of the localization of this complex; directs CPC movement to different locations from the inner centromere during prometaphase to midbody during cytokinesis and participates in the organization of the center spindle by associating with polymerized microtubules (PubMed:20826784). Involved in the recruitment of CPC to centromeres during early mitosis via association with histone H3 phosphorylated at 'Thr-3' (H3pT3) during mitosis (PubMed:20929775). The complex with RAN plays a role in mitotic spindle formation by serving as a physical scaffold to help deliver the RAN effector molecule TPX2 to microtubules (PubMed:18591255). May counteract a default induction of apoptosis in G2/M phase (PubMed:9859993). The acetylated form represses STAT3 transactivation of target gene promoters (PubMed:20826784). May play a role in neoplasia (PubMed:10626797). Inhibitor of CASP3 and CASP7 (PubMed:21536684). Essential for the maintenance of mitochondrial integrity and function (PubMed:25778398). Isoform 2 and isoform 3 do not appear to play vital roles in mitosis (PubMed:12773388, PubMed:16291752). Isoform 3 shows a marked reduction in its anti-apoptotic effects when compared with the displayed wild-type isoform (PubMed:10626797)","Expressed only in fetal kidney and liver, and to lesser extent, lung and brain (PubMed:10626797). Abundantly expressed in adenocarcinoma (lung, pancreas, colon, breast, and prostate) and in high-grade lymphomas (PubMed:14741722, PubMed:16329164). Also expressed in various renal cell carcinoma cell lines (PubMed:10626797). Expressed in cochlea including the organ of Corti, the lateral wall, the interdental cells of the Limbus as well as in Schwann cells and cells of the cochlear nerve and the spiral ganglions (at protein level). Not expressed in cells of the inner and outer sulcus or the Reissner's membrane (at protein level) (PubMed:20627126, PubMed:21364656)",,,"Cytoplasm Nucleus Chromosome Chromosome, centromere Cytoplasm, cytoskeleton, spindle Chromosome, centromere, kinetochore Midbody",10626797|12773388|16291752|16322459|18591255|20627126|20826784|20929775|21364656|21536684|25778398|28218735|9859993,10626797|14741722|16329164|20627126|21364656,False,Reviewed UniProt annotation; not a new primary-paper review,Trial registration only,https://clinicaltrials.gov/study/NCT03093350,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
BLOC1S3,ENSG00000189114,Unsafe,Protein,False,True,7.0,12.8,98,63,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 6.5 nTPM; continuous selectivity; adrenal gland: 6.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 5.5 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 6.2 nTPM; absolute ceiling;continuous selectivity; bone marrow: 12.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 5.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 7.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 3.5 nTPM; absolute ceiling;continuous selectivity; colon: 5.6 nTPM; positive ihc;continuous selectivity; duodenum: 5.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 6.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 5 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 5.9 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 5.4 nTPM; absolute ceiling;continuous selectivity; kidney: 5.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 7.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 5.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 7.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 5.3 nTPM; absolute ceiling;continuous selectivity; pancreas: 5.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 4.6 nTPM; positive ihc;continuous selectivity; pituitary gland: 4.3 nTPM; absolute ceiling;continuous selectivity; rectum: 4.2 nTPM; positive ihc;continuous selectivity; retina: 3.2 nTPM; absolute ceiling;continuous selectivity; salivary gland: 5.5 nTPM; positive ihc;continuous selectivity; skeletal muscle: 4.2 nTPM; absolute ceiling;continuous selectivity; skin: 12.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 6.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 3.9 nTPM; continuous selectivity; spinal cord: 6.1 nTPM; absolute ceiling;continuous selectivity; spleen: 10.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; stomach: 7.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; thymus: 4.6 nTPM; continuous selectivity; thyroid gland: 4.5 nTPM; positive ihc;continuous selectivity; tongue: 3.2 nTPM; continuous selectivity; urinary bladder: 6.4 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 6.1 nTPM (limit 2); amygdala: 5.5 nTPM (limit 2); basal ganglia: 6.2 nTPM (limit 2); bone marrow: 12.2 nTPM (limit 2); cerebellum: 5.6 nTPM (limit 2); cerebral cortex: 7.4 nTPM (limit 4); choroid plexus: 3.5 nTPM (limit 2); duodenum: 5.2 nTPM (limit 2); esophagus: 6.2 nTPM (limit 6); heart muscle: 5 nTPM (limit 4); hippocampal formation: 5.9 nTPM (limit 2); hypothalamus: 5.4 nTPM (limit 2); kidney: 5.6 nTPM (limit 2); liver: 7.6 nTPM (limit 2); lung: 5.3 nTPM (limit 2); lymph node: 7.4 nTPM (limit 6); midbrain: 5.3 nTPM (limit 2); pancreas: 5.9 nTPM (limit 2); pituitary gland: 4.3 nTPM (limit 2); retina: 3.2 nTPM (limit 2); skeletal muscle: 4.2 nTPM (limit 4); skin: 12.8 nTPM (limit 10); small intestine: 6.5 nTPM (limit 2); spinal cord: 6.1 nTPM (limit 2); spleen: 10.7 nTPM (limit 10); stomach: 7.4 nTPM (limit 6); urinary bladder: 6.4 nTPM (limit 6),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / basal cells: Medium (Approved); bronchus / ciliated cells (cell body): Medium (Approved); cerebellum / Purkinje cells: Low (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Low (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: High (Approved); nasopharynx / basal cells: Medium (Approved); nasopharynx / ciliated cells (cell body): Low (Approved); nasopharynx / ciliated cells (ciliary rootlets): Medium (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: High (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skin 1 / keratinocytes: Low (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Medium (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: High (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%); Colon Adenocarcinoma (validation): 484/486 (99.6%),colorectal cancer: 11/12 (91.7%); lymphoma: 11/12 (91.7%),31,20,Q6QNY0,https://www.uniprot.org/uniprotkb/Q6QNY0/entry,"Component of the BLOC-1 complex, a complex that is required for normal biogenesis of lysosome-related organelles (LRO), such as platelet dense granules and melanosomes. In concert with the AP-3 complex, the BLOC-1 complex is required to target membrane protein cargos into vesicles assembled at cell bodies for delivery into neurites and nerve terminals. The BLOC-1 complex, in association with SNARE proteins, is also proposed to be involved in neurite extension. Plays a role in intracellular vesicle trafficking",,"Hermansky-Pudlak syndrome 8: A form of Hermansky-Pudlak syndrome, a genetically heterogeneous autosomal recessive disorder characterized by oculocutaneous albinism, bleeding due to platelet storage pool deficiency, and lysosomal storage defects. This syndrome results from defects of diverse cytoplasmic organelles including melanosomes, platelet dense granules and lysosomes. Ceroid storage in the lungs is associated with pulmonary fibrosis, a common cause of premature death in individuals with HPS.",,Cytoplasm,16385460|17182842,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
BLTP1,ENSG00000138688,Unsafe,Protein,False,True,40.2,60.4,97,40,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 28.1 nTPM; absolute ceiling;continuous selectivity; adrenal gland: 24 nTPM; absolute ceiling;continuous selectivity; amygdala: 32.6 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 39.2 nTPM; absolute ceiling;continuous selectivity; bone marrow: 38.3 nTPM; absolute ceiling;continuous selectivity; cerebellum: 42.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 36.6 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 33 nTPM; absolute ceiling;continuous selectivity; colon: 28.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 11.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 16.9 nTPM; absolute ceiling; heart muscle: 22.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 33 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 28.2 nTPM; absolute ceiling;continuous selectivity; kidney: 24.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 17.8 nTPM; absolute ceiling;continuous selectivity; lung: 27.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 11.6 nTPM; absolute ceiling; midbrain: 33.8 nTPM; absolute ceiling;continuous selectivity; pancreas: 24 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 40.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 45.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 14 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 60.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 21.7 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 40.1 nTPM; absolute ceiling;continuous selectivity; skin: 21.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 27.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 13.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 40.1 nTPM; absolute ceiling;continuous selectivity; spleen: 25.7 nTPM; absolute ceiling;continuous selectivity; stomach: 22.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 16.4 nTPM; absolute ceiling; thyroid gland: 30.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 32.9 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 23.7 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 28.1 nTPM (limit 20); adrenal gland: 24 nTPM (limit 4); amygdala: 32.6 nTPM (limit 2); basal ganglia: 39.2 nTPM (limit 2); bone marrow: 38.3 nTPM (limit 4); cerebellum: 42.4 nTPM (limit 4); cerebral cortex: 36.6 nTPM (limit 4); choroid plexus: 33 nTPM (limit 2); colon: 28.6 nTPM (limit 6); duodenum: 11.6 nTPM (limit 2); esophagus: 16.9 nTPM (limit 8); heart muscle: 22.1 nTPM (limit 2); hippocampal formation: 33 nTPM (limit 2); hypothalamus: 28.2 nTPM (limit 2); kidney: 24.6 nTPM (limit 2); liver: 17.8 nTPM (limit 4); lung: 27.1 nTPM (limit 2); lymph node: 11.6 nTPM (limit 8); midbrain: 33.8 nTPM (limit 2); pancreas: 24 nTPM (limit 2); parathyroid gland: 40.9 nTPM (limit 8); pituitary gland: 45.9 nTPM (limit 2); rectum: 14 nTPM (limit 6); retina: 60.4 nTPM (limit 2); salivary gland: 21.7 nTPM (limit 8); skeletal muscle: 40.1 nTPM (limit 4); skin: 21.5 nTPM (limit 10); small intestine: 27.4 nTPM (limit 2); smooth muscle: 13.8 nTPM (limit 2); spinal cord: 40.1 nTPM (limit 2); spleen: 25.7 nTPM (limit 20); stomach: 22.5 nTPM (limit 6); thymus: 16.4 nTPM (limit 10); thyroid gland: 30.3 nTPM (limit 10); tongue: 32.9 nTPM (limit 6); urinary bladder: 23.7 nTPM (limit 6),bronchus / ciliated cells (cilia axoneme): Medium (Approved); bronchus / ciliated cells (tip of cilia): Medium (Approved); caudate / neuronal cells: Low (Approved); colon / glandular cells: Low (Approved); duodenum / glandular cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); kidney / cells in tubules: Low (Approved); lung / macrophages: Medium (Approved); nasopharynx / ciliated cells (cell body): Medium (Approved); nasopharynx / ciliated cells (cilia axoneme): Medium (Approved); nasopharynx / ciliated cells (ciliary rootlets): Medium (Approved); nasopharynx / ciliated cells (tip of cilia): Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); skin 1 / keratinocytes: Low (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Low (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%),endometrial cancer: 2/12 (16.7%); prostate cancer: 2/12 (16.7%),31,20,Q2LD37,https://www.uniprot.org/uniprotkb/Q2LD37/entry,"Bridge-like lipid transfer protein that functions as molecular bridges between endoplasmic reticulum and the membranes targeted for lipid delivery (PubMed:35491307, PubMed:40269155). Forms a tunnel with multiple beta-grooves that allows the transport of phospholipids (By similarity). Provides phosphatidylethanolamine for glycosylphosphatidylinositol (GPI) anchor synthesis in the endoplasmic reticulum (PubMed:35015055). Plays a role in endosomal trafficking and endosome recycling (PubMed:30906834). Also involved in the actin cytoskeleton and cilia structural dynamics (PubMed:30906834). Acts as a regulator of phagocytosis (PubMed:31540829). Required for the formation of endoplasmic reticulum-plasma membrane junctions which are critical for lipid exchange (PubMed:40269155)",Highly expressed in testis and ovary. Weakly or not expressed in other tissues,"Alkuraya-Kucinskas syndrome: An autosomal recessive syndrome characterized by brain atrophy and arthrogryposis. Patients present with cerebral parenchymal underdevelopment, lissencephaly, severe to mild ventriculomegaly, and cerebellar hypoplasia with brainstem dysgenesis. Most affected individuals die in utero or soon after birth. The few patients who survive have variable intellectual disability and may have seizures. Facial dysmorphism, cardiac and ophthalmologic anomalies, such as microphthalmia and cataract, are additional features.",,Endoplasmic reticulum membrane Apical cell membrane Cell membrane Mitochondrion membrane,30906834|31540829|35015055|35491307|40269155,16545529,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
BLZF1,ENSG00000117475,Unsafe,Protein,False,True,34.0,34.0,85,80,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 12.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 7.6 nTPM; absolute ceiling; basal ganglia: 6.9 nTPM; absolute ceiling; bone marrow: 25.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 6.5 nTPM; positive ihc;absolute ceiling; cerebral cortex: 9.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 8 nTPM; absolute ceiling; colon: 13.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 12 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 31.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 15.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 7.5 nTPM; absolute ceiling; hypothalamus: 7.3 nTPM; absolute ceiling; kidney: 16.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 14.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 12.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 11.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 8 nTPM; absolute ceiling; pancreas: 9.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 14.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 8.5 nTPM; absolute ceiling; rectum: 15 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 22.1 nTPM; absolute ceiling;continuous selectivity; salivary gland: 12.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 10.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 17.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 12.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 17.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 9.5 nTPM; absolute ceiling;continuous selectivity; spleen: 12.1 nTPM; positive ihc;absolute ceiling; stomach: 12.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 13.4 nTPM; absolute ceiling; thyroid gland: 18.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 10.6 nTPM; absolute ceiling; urinary bladder: 16 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 12.7 nTPM (limit 2); amygdala: 7.6 nTPM (limit 2); basal ganglia: 6.9 nTPM (limit 2); bone marrow: 25.1 nTPM (limit 2); cerebellum: 6.5 nTPM (limit 2); cerebral cortex: 9.9 nTPM (limit 2); choroid plexus: 8 nTPM (limit 2); colon: 13.4 nTPM (limit 6); duodenum: 12 nTPM (limit 2); esophagus: 31.3 nTPM (limit 6); heart muscle: 15.4 nTPM (limit 2); hippocampal formation: 7.5 nTPM (limit 2); hypothalamus: 7.3 nTPM (limit 2); kidney: 16.4 nTPM (limit 2); liver: 14.5 nTPM (limit 2); lung: 12.5 nTPM (limit 2); lymph node: 11.5 nTPM (limit 6); midbrain: 8 nTPM (limit 2); pancreas: 9.2 nTPM (limit 2); parathyroid gland: 14.6 nTPM (limit 6); pituitary gland: 8.5 nTPM (limit 2); rectum: 15 nTPM (limit 6); retina: 22.1 nTPM (limit 2); salivary gland: 12.3 nTPM (limit 6); skeletal muscle: 10.8 nTPM (limit 2); skin: 17.4 nTPM (limit 10); small intestine: 12.3 nTPM (limit 2); smooth muscle: 17.2 nTPM (limit 2); spinal cord: 9.5 nTPM (limit 2); spleen: 12.1 nTPM (limit 10); stomach: 12.7 nTPM (limit 6); thymus: 13.4 nTPM (limit 10); thyroid gland: 18.1 nTPM (limit 10); tongue: 10.6 nTPM (limit 6); urinary bladder: 16 nTPM (limit 6),adrenal gland / glandular cells: Medium (Supported); bone marrow / hematopoietic cells: Medium (Supported); bronchus / respiratory epithelial cells: Medium (Supported); caudate / glial cells: Medium (Supported); caudate / neuronal cells: Medium (Supported); cerebellum / cells in granular layer: Medium (Supported); cerebellum / cells in molecular layer: Low (Supported); cerebral cortex / endothelial cells: Low (Supported); cerebral cortex / glial cells: Medium (Supported); cerebral cortex / neuronal cells: Medium (Supported); cerebral cortex / neuropil: High (Supported); colon / endothelial cells: Medium (Supported); colon / glandular cells: High (Supported); duodenum / glandular cells: High (Supported); esophagus / squamous epithelial cells: High (Supported); heart muscle / cardiomyocytes: Medium (Supported); hippocampus / glial cells: Medium (Supported); hippocampus / neuronal cells: Medium (Supported); kidney / cells in glomeruli: Medium (Supported); kidney / cells in tubules: High (Supported); liver / cholangiocytes: Medium (Supported); liver / hepatocytes: Medium (Supported); lung / alveolar cells type I: High (Supported); lung / alveolar cells type II: High (Supported); lung / endothelial cells: High (Supported); lymph node / germinal center cells: Low (Supported); lymph node / non-germinal center cells: Medium (Supported); nasopharynx / respiratory epithelial cells: Medium (Supported); oral mucosa / squamous epithelial cells: Medium (Supported); pancreas / exocrine glandular cells: Medium (Supported); pancreas / pancreatic endocrine cells: Medium (Supported); parathyroid gland / glandular cells: Medium (Supported); rectum / glandular cells: Medium (Supported); salivary gland / glandular cells: Medium (Supported); skeletal muscle / myocytes: Medium (Supported); skin 1 / fibroblasts: Medium (Supported); skin 1 / keratinocytes: Medium (Supported); skin 1 / Langerhans: Medium (Supported); skin 2 / epidermal cells: Medium (Supported); small intestine / glandular cells: Medium (Supported); smooth muscle / smooth muscle cells: Medium (Supported); spleen / cells in red pulp: Medium (Supported); spleen / cells in white pulp: Medium (Supported); stomach 1 / glandular cells: Medium (Supported); stomach 2 / glandular cells: Medium (Supported); thyroid gland / glandular cells: Medium (Supported); urinary bladder / urothelial cells: Medium (Supported),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Stomach Adenocarcinoma (TCGA): 346/346 (100.0%); Colon Adenocarcinoma (TCGA): 254/254 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%),breast cancer: 12/12 (100.0%); cervical cancer: 12/12 (100.0%),31,20,Q9H2G9,https://www.uniprot.org/uniprotkb/Q9H2G9/entry,Required for normal Golgi structure and for protein transport from the endoplasmic reticulum (ER) through the Golgi apparatus to the cell surface,Detected in adrenal gland (PubMed:9129147),,"Was originally identified as a potential transcription factor, because of the presence of a potential basic motif and leucine-zipper domain, and because isoform 1 is detected in the nucleus upon heterologous expression. However, homology at several typical position for basic or hydrophobic residues is missing. Besides, another publication showed it is important for normal Golgi apparatus structure and function",Golgi apparatus membrane Nucleus Cytoplasm,11739401,11056056|11739401|9129147,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
BNC1,ENSG00000169594,Unsafe,RNA,False,True,24.5,24.5,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 14.6 nTPM; absolute ceiling;continuous selectivity; esophagus: 12.2 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adipose tissue: 14.6 nTPM (limit 10); esophagus: 12.2 nTPM (limit 6); adipose tissue: 14.6 nTPM (baseline 10); esophagus: 12.2 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Head and Neck Squamous Cell Carcinoma (TCGA): 456/492 (92.7%); Lung Squamous Cell Carcinoma (validation): 52/68 (76.5%); Lung Squamous Cell Carcinoma (TCGA): 346/489 (70.8%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q01954,https://www.uniprot.org/uniprotkb/Q01954/entry,"Transcriptional activator (By similarity). It is likely involved in the regulation of keratinocytes terminal differentiation in squamous epithelia and hair follicles (PubMed:8034748). Required for the maintenance of spermatogenesis (By similarity). It is involved in the positive regulation of oocyte maturation, probably acting through the control of BMP15 levels and regulation of AKT signaling cascade (PubMed:30010909). May also play a role in the early development of embryos (By similarity)","In epidermis, primarily detected in cells of the basal or immediately suprabasal layers (at protein level) (PubMed:16891417). In hair follicles, mainly expressed in the outer root sheath (at protein level) (PubMed:8034748). Expressed in epidermis, testis and foreskin, and to a lower extent in thymus, spleen, mammary glands, placenta, brain and heart (PubMed:9687312). Expressed in the ovary, notably in oocytes (PubMed:30010909)","Premature ovarian failure 16: An autosomal dominant form of premature ovarian failure, an ovarian disorder defined as the cessation of ovarian function under the age of 40 years. It is characterized by oligomenorrhea or amenorrhea, in the presence of elevated levels of serum gonadotropins and low estradiol.",,"Nucleus Cytoplasm Nucleus, nucleoplasm",30010909|8034748,16891417|30010909|8034748|9687312,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
BOD1L2,ENSG00000228075,Unsafe,High RNA,False,True,268.7,268.7,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Low, HPA036293; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Low, HPA036293; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA036293; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Low, HPA036293; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA036293; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA036293; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA036293; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Low, HPA036293; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA036293; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA036293; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA036293; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA036293; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA036293; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA036293; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA036293; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA036293; conflicting or uncurated primary profile; Salivary gland/Glandular cells: High, HPA036293; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Low, HPA036293; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA036293; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA036293; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA036293; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA036293; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA036293; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA036293; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,0.218789850183,32.2,"hpa_single_cell_tissue: testis/macrophages, max 32.2 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,0.2188 TPM; blood/NK; dice_nk; vital,32.2 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 3/133 (2.3%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),prostate cancer: 12/12 (100.0%); pancreatic cancer: 8/10 (80.0%),29,20,Q8IYS8,https://www.uniprot.org/uniprotkb/Q8IYS8/entry,May play a role in proper chromosome biorientation through the detection or correction of syntelic attachments in mitotic spindles,,,,"Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Chromosome, centromere, kinetochore",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Chang2019_TGCT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,All audited maxima are within 10% above 30; other gates still require review,,,,
BPIFA1,ENSG00000198183,Unsafe,Protein,False,True,6.0,17.7,83,1,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; lung: 17.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 11.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 3.6 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",lung: 17.7 nTPM (limit 2); pituitary gland: 11.8 nTPM (limit 2); lung: 17.7 nTPM (baseline 2); pituitary gland: 11.8 nTPM (baseline 2),nasopharynx / respiratory epithelial cells: Medium (Supported),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Adenocarcinoma (validation): 74/105 (70.5%); Lung Adenocarcinoma (TCGA): 311/497 (62.6%); Lung Squamous Cell Carcinoma (validation): 35/68 (51.5%),ovarian cancer: 1/11 (9.1%); breast cancer: 0/11 (0.0%),29,20,Q9NP55,https://www.uniprot.org/uniprotkb/Q9NP55/entry,"Lipid-binding protein which shows high specificity for the surfactant phospholipid dipalmitoylphosphatidylcholine (DPPC) (PubMed:25223608). Plays a role in the innate immune responses of the upper airways (PubMed:23132494, PubMed:23499554). Reduces the surface tension in secretions from airway epithelia and inhibits the formation of biofilm by pathogenic Gram-negative bacteria, such as P.aeruginosa and K.pneumoniae (PubMed:23132494, PubMed:23499554, PubMed:27145151). Negatively regulates proteolytic cleavage of SCNN1G, an event that is required for activation of the epithelial sodium channel (ENaC), and thereby contributes to airway surface liquid homeostasis and proper clearance of mucus (PubMed:24043776, PubMed:24124190). Plays a role in the airway inflammatory response after exposure to irritants (PubMed:11425234). May attract macrophages and neutrophils (PubMed:23132494)","Highly expressed in lung, upper airways and nasopharyngeal regions, including trachea and nasal epithelium (at protein level) (PubMed:11018263, PubMed:11251963, PubMed:11425234, PubMed:12409287, PubMed:26559477). Specifically expressed in the secretory ducts and submucosal glands of tracheobronchial tissues (at protein level) (PubMed:11425234, PubMed:12409287). Also expressed in the eye where it is detected in lacrimal gland, eyelid, conjunctiva and cornea (at protein level) (PubMed:26559477). Specifically localizes to epithelial cell layers in cornea, eyelid (basal epithelium) and conjunctiva (at protein level) (PubMed:26559477). Detected within acinar cells and ducts in the lacrimal and Meibomian glands (at protein level) (PubMed:26559477). In lung, shows highest expression in the trachea and progressive decrease from proximal (bronchial) to distal (bronchiolar) airways (PubMed:12409287). Also expressed in lung cancers and some other types of cancer (PubMed:11251963)",,"Reported to bind to bacterial lipopolysaccharide (LPS) in vitro (PubMed:15158712, PubMed:27145151). However, the in vivo significance of this is uncertain since other studies indicate little or no specificity for LPS (PubMed:12920053, PubMed:25223608)",Secreted,11425234|23132494|23499554|24043776|24124190|25223608|27145151,11018263|11251963|11425234|12409287|26559477,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
BPIFA2,ENSG00000131050,Unsafe,Protein,False,True,4.1,6665.1,77,1,Positive somewhere,True,True,False,False,Excluded,Normal,False,,Not assessed,,,positive normal IHC; positive ihc outside permitted; pancreas: 3.8 nTPM; absolute ceiling;continuous selectivity; salivary gland: 6665.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",salivary gland: 6665.1 nTPM (limit 6); pancreas: 3.8 nTPM (baseline 2); salivary gland: 6665.1 nTPM (baseline 6),salivary gland / glandular cells: High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Chromophobe (TCGA): 19/64 (29.7%); Lung Adenocarcinoma (TCGA): 88/497 (17.7%); Lung Adenocarcinoma (validation): 16/105 (15.2%),breast cancer: 0/10 (0.0%); cervical cancer: 0/12 (0.0%),29,20,Q96DR5,https://www.uniprot.org/uniprotkb/Q96DR5/entry,Has strong antibacterial activity against P.aeruginosa,Detected in submandibular gland. Secreted into saliva,,,Secreted,24581853,11971875|24581853,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT,Cancer-associated RNA nomination; no antigen validation asserted,,,,,,,,
BPIFC,ENSG00000184459,Unsafe,RNA,False,True,2.2,44.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,skin: 44.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,skin: 44.2 nTPM (limit 10); skin: 44.2 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Head and Neck Squamous Cell Carcinoma (TCGA): 105/492 (21.3%); Skin Cuteneous Melanoma (TCGA): 19/99 (19.2%); Lung Squamous Cell Carcinoma (TCGA): 9/489 (1.8%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q8NFQ6,https://www.uniprot.org/uniprotkb/Q8NFQ6/entry,,"Detected in the basal layer of the epidermis from inflammatory skin from psoriasis patients, but not in normal skin",,,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
BRAP,ENSG00000089234,Unsafe,Protein,False,True,65.3,65.3,83,75,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 8.6 nTPM; positive ihc;absolute ceiling; amygdala: 7.3 nTPM; absolute ceiling; basal ganglia: 7.4 nTPM; absolute ceiling; bone marrow: 33.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 8 nTPM; positive ihc;absolute ceiling; cerebral cortex: 9.1 nTPM; positive ihc;absolute ceiling; choroid plexus: 9 nTPM; absolute ceiling; colon: 9.2 nTPM; positive ihc;absolute ceiling; duodenum: 8.9 nTPM; positive ihc;absolute ceiling; esophagus: 9.2 nTPM; positive ihc;absolute ceiling; heart muscle: 9.3 nTPM; positive ihc;absolute ceiling; hippocampal formation: 7.1 nTPM; absolute ceiling; hypothalamus: 7.1 nTPM; absolute ceiling; kidney: 8.2 nTPM; positive ihc;absolute ceiling; liver: 9.7 nTPM; positive ihc;absolute ceiling; lung: 7.8 nTPM; positive ihc;absolute ceiling; lymph node: 10.3 nTPM; positive ihc;absolute ceiling; midbrain: 7.8 nTPM; absolute ceiling; pancreas: 7.9 nTPM; positive ihc;absolute ceiling; parathyroid gland: 10.2 nTPM; positive ihc;absolute ceiling; pituitary gland: 6 nTPM; absolute ceiling; rectum: 8.9 nTPM; positive ihc;absolute ceiling; retina: 8.9 nTPM; absolute ceiling; salivary gland: 8.2 nTPM; positive ihc;absolute ceiling; skeletal muscle: 19.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 12.4 nTPM; positive ihc;absolute ceiling; small intestine: 8.6 nTPM; positive ihc;absolute ceiling; smooth muscle: 9 nTPM; positive ihc;absolute ceiling; spinal cord: 8.1 nTPM; absolute ceiling; spleen: 8.8 nTPM; positive ihc; stomach: 7.5 nTPM; positive ihc;absolute ceiling; thymus: 12.5 nTPM; absolute ceiling; thyroid gland: 9.7 nTPM; positive ihc; tongue: 13.4 nTPM; absolute ceiling; urinary bladder: 8.9 nTPM; positive ihc;absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 8.6 nTPM (limit 2); amygdala: 7.3 nTPM (limit 2); basal ganglia: 7.4 nTPM (limit 2); bone marrow: 33.2 nTPM (limit 2); cerebellum: 8 nTPM (limit 2); cerebral cortex: 9.1 nTPM (limit 2); choroid plexus: 9 nTPM (limit 2); colon: 9.2 nTPM (limit 6); duodenum: 8.9 nTPM (limit 2); esophagus: 9.2 nTPM (limit 6); heart muscle: 9.3 nTPM (limit 2); hippocampal formation: 7.1 nTPM (limit 2); hypothalamus: 7.1 nTPM (limit 2); kidney: 8.2 nTPM (limit 2); liver: 9.7 nTPM (limit 2); lung: 7.8 nTPM (limit 2); lymph node: 10.3 nTPM (limit 6); midbrain: 7.8 nTPM (limit 2); pancreas: 7.9 nTPM (limit 2); parathyroid gland: 10.2 nTPM (limit 6); pituitary gland: 6 nTPM (limit 2); rectum: 8.9 nTPM (limit 6); retina: 8.9 nTPM (limit 2); salivary gland: 8.2 nTPM (limit 6); skeletal muscle: 19.1 nTPM (limit 2); skin: 12.4 nTPM (limit 10); small intestine: 8.6 nTPM (limit 2); smooth muscle: 9 nTPM (limit 2); spinal cord: 8.1 nTPM (limit 2); stomach: 7.5 nTPM (limit 6); thymus: 12.5 nTPM (limit 10); tongue: 13.4 nTPM (limit 6); urinary bladder: 8.9 nTPM (limit 6),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: High (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%); Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%),colorectal cancer: 12/12 (100.0%); glioma: 12/12 (100.0%),31,20,Q7Z569,https://www.uniprot.org/uniprotkb/Q7Z569/entry,"Negatively regulates MAP kinase activation by limiting the formation of Raf/MEK complexes probably by inactivation of the KSR1 scaffold protein. Also acts as a Ras responsive E3 ubiquitin ligase that, on activation of Ras, is modified by auto-polyubiquitination resulting in the release of inhibition of Raf/MEK complex formation. May also act as a cytoplasmic retention protein with a role in regulating nuclear transport",Expressed in breast epithelial cell lines,,,Cytoplasm,10777491|14724641,9497340,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
BRCA2,ENSG00000139618,Unsafe,RNA,False,True,3.0,5.4,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 5.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 2.1 nTPM; continuous selectivity; thymus: 4.4 nTPM; continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 5.4 nTPM (limit 2); bone marrow: 5.4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Colon Adenocarcinoma (validation): 464/486 (95.5%); Rectum Adenocarcinoma (validation): 195/207 (94.2%),breast cancer: 10/11 (90.9%); colorectal cancer: 8/12 (66.7%),31,20,P51587,https://www.uniprot.org/uniprotkb/P51587/entry,"Tumor suppressor protein that maintains genome stability primarily by repairing damaged DNA through homologous recombination (HR) (PubMed:11239456, PubMed:12442171, PubMed:15115758, PubMed:15199141, PubMed:15671039, PubMed:15937124, PubMed:17515903, PubMed:17515904, PubMed:18317453, PubMed:19303847, PubMed:20729832, PubMed:20729858, PubMed:20729859, PubMed:21719596, PubMed:27941124, PubMed:37499663, PubMed:37515771). Facilitates the repair of double-strand breaks (DSBs) by binding and mediating the loading of the RAD51 protein onto single-stranded DNA (ssDNA), thereby promoting the activity of RAD51, which catalyzes DNA strand exchange (PubMed:11239456, PubMed:12442171, PubMed:15937124, PubMed:17515903, PubMed:17515904, PubMed:18317453, PubMed:19303847, PubMed:20729832, PubMed:20729858, PubMed:20729859, PubMed:27941124, PubMed:37499663). BRCA2 nucleates and stabilizes RAD51 on ssDNA directly and delivers RAD51 to ssDNA-double-stranded DNA (dsDNA) junctions by sliding along dsDNA backbone (PubMed:12442171, PubMed:19303847, PubMed:37499663). RAD51 targeting to ssDNA promotes removal of replication protein-A (RPA) from ssDNA and stabilization of RAD51-ssDNA filaments by blocking ATP hydrolysis (PubMed:20729859). May play a role in the extension step after strand invasion at replication-dependent DNA double-strand breaks; together with PALB2 is involved in both POLH localization at collapsed replication forks and DNA polymerization activity (PubMed:24485656). Required to prevent R-loop-associated DNA damage and thus transcription-associated genomic instability (PubMed:24896180). Silencing of BRCA2 promotes R-loop accumulation at actively transcribed genes in replicating and non-replicating cells, suggesting that BRCA2 mediates the control of R-loop associated genomic instability, independently of its known role in homologous recombination (PubMed:24896180). Also promotes RAD51 loading to telomeric regions, facilitating telomere replication and capping (PubMed:21076401). Also required for homologous recombination during meiosis by promoting the recruitment of RAD51 and DMC1 recombinases to meiotic DSB sites, enabling proper chromosome pairing and crossing over (PubMed:26976601). Also promotes homologous recombination by inactivating the FIGNL1-FIRRM complex to protect RAD51 filament from premature disassembly (PubMed:37515771). Together with NPM1, may also regulate centrosome duplication (PubMed:21084279)","Highest levels of expression in breast and thymus, with slightly lower levels in lung, ovary and spleen","Breast cancer: A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case. Pancreatic cancer 2: A malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue. Breast-ovarian cancer, familial, 2: A condition associated with familial predisposition to cancer of the breast and ovaries. Characteristic features in affected families are an early age of onset of breast cancer (often before age 50), increased chance of bilateral cancers (cancer that develop in both breasts, or both ovaries, independently), frequent occurrence of breast cancer among men, increased incidence of tumors of other specific organs, such as the prostate. Fanconi anemia complementation group D1: A disorder affecting all bone marrow elements and resulting in anemia, leukopenia and thrombopenia. It is associated with cardiac, renal and limb malformations, dermal pigmentary changes, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage) and defective DNA repair. Glioma 3: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Medulloblastoma: Malignant, invasive embryonal tumor of the cerebellum with a preferential manifestation in children.",,"Chromosome Chromosome, telomere Nucleus Cytoplasm, cytoskeleton, microtubule organizing center, centrosome",11239456|12442171|15115758|15199141|15671039|15937124|17515903|17515904|18317453|19303847|20729832|20729858|20729859|21076401|21084279|21719596|24485656|24896180|26976601|27941124|37499663|37515771,8589730,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
BRIP1,ENSG00000136492,Unsafe,Protein,False,True,4.7,4.7,78,75,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0.2 nTPM; positive ihc; bone marrow: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 0 nTPM; positive ihc; cerebral cortex: 0.1 nTPM; positive ihc; colon: 0.7 nTPM; positive ihc; duodenum: 0.7 nTPM; positive ihc; esophagus: 1.3 nTPM; positive ihc; heart muscle: 0 nTPM; positive ihc; kidney: 0.1 nTPM; positive ihc; liver: 0.7 nTPM; positive ihc; lung: 0.3 nTPM; positive ihc; lymph node: 1 nTPM; positive ihc; pancreas: 0.2 nTPM; positive ihc; parathyroid gland: 0 nTPM; positive ihc; rectum: 0.7 nTPM; positive ihc; salivary gland: 0.4 nTPM; positive ihc; skeletal muscle: 0.1 nTPM; positive ihc; skin: 0.7 nTPM; positive ihc; small intestine: 0.7 nTPM; positive ihc; spleen: 0.4 nTPM; positive ihc; stomach: 0.4 nTPM; positive ihc; thymus: 3.6 nTPM; continuous selectivity; thyroid gland: 0.1 nTPM; positive ihc; urinary bladder: 0.2 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 2.7 nTPM (limit 2),adipose tissue / adipocytes: Medium (Approved); bone marrow / hematopoietic cells: High (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / glial cells: High (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: High (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: High (Approved); cerebral cortex / neuronal cells: High (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: High (Approved); colon / peripheral nerve/ganglion: High (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: High (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / glial cells: High (Approved); hippocampus / neuronal cells: High (Approved); kidney / cells in glomeruli: High (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: High (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: High (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: High (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: High (Approved); small intestine / glandular cells: High (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 475/486 (97.7%); Rectum Adenocarcinoma (validation): 195/207 (94.2%); Glioblastoma Multiforme (validation): 51/58 (87.9%),colorectal cancer: 12/12 (100.0%); melanoma: 12/12 (100.0%),31,20,Q9BX63,https://www.uniprot.org/uniprotkb/Q9BX63/entry,"DNA-dependent ATPase and 5'-3' DNA helicase required for the maintenance of chromosomal stability (PubMed:11301010, PubMed:14983014, PubMed:16116421, PubMed:16153896, PubMed:17596542, PubMed:36608669). Acts late in the Fanconi anemia pathway, after FANCD2 ubiquitination (PubMed:14983014, PubMed:16153896). Involved in the repair of DNA double-strand breaks by homologous recombination in a manner that depends on its association with BRCA1 (PubMed:14983014, PubMed:16153896). Involved in the repair of abasic sites at replication forks by promoting the degradation of DNA-protein cross-links: acts by catalyzing unfolding of HMCES DNA-protein cross-link via its helicase activity, exposing the underlying DNA and enabling cleavage of the DNA-protein adduct by the SPRTN metalloprotease (PubMed:16116421, PubMed:36608669). Can unwind RNA:DNA substrates (PubMed:14983014). Unwinds G-quadruplex DNA; unwinding requires a 5'-single stranded tail (PubMed:18426915, PubMed:20639400)","Ubiquitously expressed, with highest levels in testis","Breast cancer: A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case. Fanconi anemia complementation group J: A disorder affecting all bone marrow elements and resulting in anemia, leukopenia and thrombopenia. It is associated with cardiac, renal and limb malformations, dermal pigmentary changes, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage) and defective DNA repair.",,Nucleus Cytoplasm,11301010|14983014|16116421|16153896|17596542|18426915|20639400|36608669,11301010,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
BRME1,ENSG00000132016,Unsafe,Protein,False,True,14.3,14.3,83,34,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 2.6 nTPM; absolute ceiling; cerebral cortex: 3 nTPM; positive ihc;absolute ceiling; choroid plexus: 3.1 nTPM; absolute ceiling; colon: 2.9 nTPM; positive ihc; duodenum: 1.2 nTPM; positive ihc; esophagus: 5.3 nTPM; positive ihc;continuous selectivity; hippocampal formation: 2.6 nTPM; absolute ceiling; hypothalamus: 2.3 nTPM; absolute ceiling; kidney: 1.1 nTPM; positive ihc; midbrain: 2.5 nTPM; absolute ceiling; pancreas: 5.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; rectum: 0.6 nTPM; positive ihc; salivary gland: 1.9 nTPM; positive ihc; skin: 5 nTPM; positive ihc; small intestine: 4 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 3 nTPM; absolute ceiling; stomach: 1.4 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 2.6 nTPM (limit 2); cerebral cortex: 3 nTPM (limit 2); choroid plexus: 3.1 nTPM (limit 2); hippocampal formation: 2.6 nTPM (limit 2); hypothalamus: 2.3 nTPM (limit 2); midbrain: 2.5 nTPM (limit 2); pancreas: 5.1 nTPM (limit 2); small intestine: 4 nTPM (limit 2); spinal cord: 3 nTPM (limit 2),cerebral cortex / neuronal cells: Low (Enhanced); colon / glandular cells: Medium (Enhanced); duodenum / glandular cells: Medium (Enhanced); esophagus / squamous epithelial cells: High (Enhanced); kidney / cells in glomeruli: Low (Enhanced); kidney / cells in tubules: Low (Enhanced); oral mucosa / squamous epithelial cells: Medium (Enhanced); pancreas / exocrine glandular cells: Low (Enhanced); rectum / glandular cells: Low (Enhanced); salivary gland / glandular cells: Medium (Enhanced); skin 1 / fibroblasts: Medium (Enhanced); skin 1 / keratinocytes: High (Enhanced); skin 2 / epidermal cells: Medium (Enhanced); small intestine / glandular cells: Medium (Enhanced); stomach 1 / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 201/283 (71.0%); Glioblastoma Multiforme (validation): 34/58 (58.6%); Rectum Adenocarcinoma (validation): 82/207 (39.6%),urothelial cancer: 6/10 (60.0%); skin cancer: 5/11 (45.5%),29,20,Q0VDD7,https://www.uniprot.org/uniprotkb/Q0VDD7/entry,"Meiotic recombination factor component of recombination bridges involved in meiotic double-strand break repair. Modulates the localization of recombinases DMC1:RAD51 to meiotic double-strand break (DSB) sites through the interaction with and stabilization of the BRCA2:HSF2BP complex during meiotic recombination. Indispensable for the DSB repair, homologous synapsis, and crossover formation that are needed for progression past metaphase I, is essential for spermatogenesis and male fertility",,,,Chromosome,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
BRWD1,ENSG00000185658,Unsafe,Protein,False,True,22.1,52.8,80,78,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 13.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 18.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 40.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 43.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 18.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 18.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 52.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 13.3 nTPM; absolute ceiling;continuous selectivity; colon: 12.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 9.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 11.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 15 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 35.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 40.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 15.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 25 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 12.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 15.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 29.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 19.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 12.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 12.9 nTPM; absolute ceiling;continuous selectivity; rectum: 11.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 37.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 11.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 21.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 14.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 11 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 10.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 21.2 nTPM; absolute ceiling;continuous selectivity; spleen: 10.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 11.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 14.5 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 19.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 23.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 12 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 13.1 nTPM (limit 10); adrenal gland: 18.3 nTPM (limit 2); amygdala: 40.3 nTPM (limit 2); basal ganglia: 43.5 nTPM (limit 2); bone marrow: 18.4 nTPM (limit 2); cerebellum: 18.7 nTPM (limit 2); cerebral cortex: 52.8 nTPM (limit 2); choroid plexus: 13.3 nTPM (limit 2); colon: 12.1 nTPM (limit 6); duodenum: 9.5 nTPM (limit 2); esophagus: 11.6 nTPM (limit 6); heart muscle: 15 nTPM (limit 2); hippocampal formation: 35.3 nTPM (limit 2); hypothalamus: 40.2 nTPM (limit 2); kidney: 15.2 nTPM (limit 2); liver: 25 nTPM (limit 2); lung: 12.8 nTPM (limit 2); lymph node: 15.4 nTPM (limit 6); midbrain: 29.8 nTPM (limit 2); pancreas: 19.3 nTPM (limit 2); parathyroid gland: 12.6 nTPM (limit 6); pituitary gland: 12.9 nTPM (limit 2); rectum: 11.9 nTPM (limit 6); retina: 37.4 nTPM (limit 2); salivary gland: 11.3 nTPM (limit 6); skeletal muscle: 21.1 nTPM (limit 2); skin: 14.2 nTPM (limit 10); small intestine: 11 nTPM (limit 2); smooth muscle: 10.7 nTPM (limit 2); spinal cord: 21.2 nTPM (limit 2); spleen: 10.7 nTPM (limit 10); stomach: 11.8 nTPM (limit 6); thymus: 14.5 nTPM (limit 10); thyroid gland: 19.1 nTPM (limit 10); tongue: 23.1 nTPM (limit 6); urinary bladder: 12 nTPM (limit 6),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: High (Approved); hippocampus / glial cells: Medium (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: High (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: High (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (TCGA): 141/141 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%),ovarian cancer: 12/12 (100.0%); colorectal cancer: 11/11 (100.0%),31,20,Q9NSI6,https://www.uniprot.org/uniprotkb/Q9NSI6/entry,May be a transcriptional activator. May be involved in chromatin remodeling (By similarity). Required for regulation of cell morphology and cytoskeletal organization (PubMed:21834987),Ubiquitously expressed (PubMed:12359327). Expressed in respiratory epithelial cells and testis spermatozoa,"Ciliary dyskinesia, primary, 51: A form of primary ciliary dyskinesia, a disorder characterized by abnormalities of motile cilia. Respiratory infections leading to chronic inflammation and bronchiectasis are recurrent, due to defects in the respiratory cilia. CILD51 is an autosomal recessive form characterized by male infertility due to multiple morphologic abnormalities of the sperm flagella, resulting in severely reduced progressive motility. Affected individuals have recurrent upper and lower respiratory infections, and some exhibit dextrocardia and/or situs inversus.",,"Cytoplasm Nucleus Cell projection, cilium membrane Cytoplasm, cytoskeleton, flagellum axoneme",21834987,12359327|33389130,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
BSPH1,ENSG00000188334,Unsafe,RNA,False,True,373.6,373.6,80,1,Positive somewhere,False,True,False,True,Excluded,Normal,False,,Not assessed,,,retina: 7.3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 7.3 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Liver Hepatocellular Carcinoma (validation): 1/231 (0.4%); Ovary Serous Cystadenocarcinoma (TCGA): 1/349 (0.3%),breast cancer: 0/11 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q075Z2,https://www.uniprot.org/uniprotkb/Q075Z2/entry,"Binds sperm in vitro and promotes sperm capacitation. Specifically promotes capacitation induced by high density lipoproteins (HDLs). Also binds heparin, phospholipid liposomes, and weakly to gelatin. Does not bind chondroitin sulfate B",Expressed only in the epididymis,,,Secreted,,17085770,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
BTG4,ENSG00000137707,Unsafe,RNA,False,True,22.0,22.0,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,choroid plexus: 4.3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 4.3 nTPM (limit 2); choroid plexus: 4.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 3/133 (2.3%); Uterine Corpus Endometrial Carcinoma (TCGA): 3/176 (1.7%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9NY30,https://www.uniprot.org/uniprotkb/Q9NY30/entry,"Adapter protein that bridges CNOT7, a catalytic subunit of the CCR4-NOT complex, to EIF4E (By similarity). Facilitates maternal mRNAs decay during the maturation of oocytes and in the fertilized egg, and is required for the maternal-zygotic transition (MZT), zygotic cleavage and initiation of embryonic development (PubMed:32502391)",Expressed in oocytes after germinal vesicle breakdown (PubMed:32502391). Expressed in testis and in olfactory epithelium,Oocyte/zygote/embryo maturation arrest 8: An autosomal recessive infertility disorder due to failure of the fertilized ovum to undergo zygotic cleavage.,,,32502391,32502391,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
BUB1,ENSG00000169679,Unsafe,RNA,False,True,29.4,29.4,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 11.7 nTPM; absolute ceiling;continuous selectivity; duodenum: 3.8 nTPM; absolute ceiling; lymph node: 15.6 nTPM; absolute ceiling;continuous selectivity; small intestine: 3.4 nTPM; absolute ceiling; smooth muscle: 2.1 nTPM; absolute ceiling; thymus: 26.8 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 11.7 nTPM (limit 2); duodenum: 3.8 nTPM (limit 2); lymph node: 15.6 nTPM (limit 6); small intestine: 3.4 nTPM (limit 2); smooth muscle: 2.1 nTPM (limit 2); thymus: 26.8 nTPM (limit 10); bone marrow: 11.7 nTPM (baseline 2); duodenum: 3.8 nTPM (baseline 2); lymph node: 15.6 nTPM (baseline 6); small intestine: 3.4 nTPM (baseline 2); smooth muscle: 2.1 nTPM (baseline 2); thymus: 26.8 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 482/486 (99.2%); Glioblastoma Multiforme (validation): 57/58 (98.3%); Rectum Adenocarcinoma (validation): 203/207 (98.1%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O43683,https://www.uniprot.org/uniprotkb/O43683/entry,"Serine/threonine-protein kinase that performs 2 crucial functions during mitosis: it is essential for spindle-assembly checkpoint signaling and for correct chromosome alignment. Has a key role in the assembly of checkpoint proteins at the kinetochore, being required for the subsequent localization of CENPF, BUB1B, CENPE and MAD2L1. Required for the kinetochore localization of PLK1. Required for centromeric enrichment of AUKRB in prometaphase. Plays an important role in defining SGO1 localization and thereby affects sister chromatid cohesion. Promotes the centromeric localization of TOP2A (PubMed:35044816). Acts as a substrate for anaphase-promoting complex or cyclosome (APC/C) in complex with its activator CDH1 (APC/C-Cdh1). Necessary for ensuring proper chromosome segregation and binding to BUB3 is essential for this function. Can regulate chromosome segregation in a kinetochore-independent manner. Can phosphorylate BUB3. The BUB1-BUB3 complex plays a role in the inhibition of APC/C when spindle-assembly checkpoint is activated and inhibits the ubiquitin ligase activity of APC/C by phosphorylating its activator CDC20. This complex can also phosphorylate MAD1L1. Kinase activity is essential for inhibition of APC/CCDC20 and for chromosome alignment but does not play a major role in the spindle-assembly checkpoint activity. Mediates cell death in response to chromosome missegregation and acts to suppress spontaneous tumorigenesis","High expression in testis and thymus, less in colon, spleen, lung and small intestine. Expressed in fetal thymus, bone marrow, heart, liver, spleen and thymus. Expression is associated with cells/tissues with a high mitotic index","Microcephaly 30, primary, autosomal recessive: A form of microcephaly, a disease defined as a head circumference more than 3 standard deviations below the age, sex and ethnically matched mean. Brain weight is markedly reduced and the cerebral cortex is disproportionately small. MCPH30 is characterized by small head, poor overall growth, and global developmental delay with variably impaired intellectual development. Affected individuals may also have variable congenital anomalies, including atrial septal defect, dysmorphic facial features, tracheal stenosis, and anomalies of the skin and teeth.",,"Nucleus Chromosome, centromere, kinetochore",10198256|15020684|15525512|15723797|16760428|17158872|19487456|20739936|35044816,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
BUB1B,ENSG00000156970,Unsafe,RNA,False,True,21.6,34.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 17.6 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 12.6 nTPM; absolute ceiling;continuous selectivity; duodenum: 4.5 nTPM; absolute ceiling; lymph node: 12.3 nTPM; absolute ceiling;continuous selectivity; small intestine: 4 nTPM; absolute ceiling; thymus: 34.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 17.6 nTPM (limit 2); choroid plexus: 12.6 nTPM (limit 2); duodenum: 4.5 nTPM (limit 2); lymph node: 12.3 nTPM (limit 6); small intestine: 4 nTPM (limit 2); thymus: 34.8 nTPM (limit 10); bone marrow: 17.6 nTPM (baseline 2); choroid plexus: 12.6 nTPM (baseline 2); duodenum: 4.5 nTPM (baseline 2); lymph node: 12.3 nTPM (baseline 6); small intestine: 4 nTPM (baseline 2); thymus: 34.8 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 132/133 (99.2%); Colon Adenocarcinoma (validation): 482/486 (99.2%); Rectum Adenocarcinoma (validation): 202/207 (97.6%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O60566,https://www.uniprot.org/uniprotkb/O60566/entry,"Kinase which is a component of the mitotic checkpoint complex (MCC), which inhibits APC/C and delays chromosome segregation until all chromosomes are properly attached to the mitotic spindle (PubMed:27509861, PubMed:31201382). The MCC, which consists of CDC20, MAD2L1/MAD2, BUB1B/BUBR1 and BUB3, is a key player of the spindle assembly checkpoint (PubMed:11702782, PubMed:14706340, PubMed:15020684, PubMed:27509861, PubMed:31201382). The MCC-bound APC/C complex is inactive and this delays the metaphase/anaphase transition (PubMed:10477750, PubMed:27509861). When the spindle assembly checkpoint is silenced, the MCC-APC/C complex recruits the E2 enzyme UBCH10 and triggers the auto-ubiquitination of CDC20 in the MCC, thereby reactivating APC/C for transition into anaphase (PubMed:27509861). MCC also monitors kinetochore activities that depend on the kinetochore motor CENPE (PubMed:15020684). Required for kinetochore localization of CENPE (PubMed:15020684). Negatively regulates PLK1 activity in interphase cells and suppresses centrosome amplification (PubMed:19503101). May play a role for tumor suppression (By similarity)",Highly expressed in thymus followed by spleen. Preferentially expressed in tissues with a high mitotic index,"Premature chromatid separation trait: Consists of separate and splayed chromatids with discernible centromeres and involves all or most chromosomes of a metaphase. It is found in up to 2% of metaphases in cultured lymphocytes from approximately 40% of normal individuals. When PCS is present in 5% or more of cells, it is known as the heterozygous PCS trait and has no obvious phenotypic effect, although some have reported decreased fertility. Inheritance is autosomal dominant. Mosaic variegated aneuploidy syndrome 1: A severe developmental disorder characterized by mosaic aneuploidies, predominantly trisomies and monosomies, involving multiple different chromosomes and tissues. Affected individuals typically present with severe intrauterine growth retardation and microcephaly. Eye anomalies, mild dysmorphism, variable developmental delay, and a broad spectrum of additional congenital abnormalities and medical conditions may also occur. The risk of malignancy is high, with rhabdomyosarcoma, Wilms tumor and leukemia reported in several cases.",,"Cytoplasm Nucleus Chromosome, centromere, kinetochore Cytoplasm, cytoskeleton, microtubule organizing center, centrosome",10477750|11702782|14706340|15020684|19411850|19503101|27509861|31201382,10593653,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
C10orf67,ENSG00000179133,Unsafe,Protein,False,True,12.0,12.0,98,15,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; choroid plexus: 5.5 nTPM; absolute ceiling;continuous selectivity; heart muscle: 0.6 nTPM; positive ihc; kidney: 3.4 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 5.5 nTPM (limit 2); kidney: 3.4 nTPM (limit 2),bronchus / ciliated cells (ciliary rootlets): Low (Approved); bronchus / ciliated cells (tip of cilia): Low (Approved); heart muscle / cardiomyocytes: Low (Approved); kidney / cells in tubules: Low (Approved); nasopharynx / ciliated cells (cell body): Low (Approved); nasopharynx / ciliated cells (ciliary rootlets): Low (Approved); nasopharynx / ciliated cells (tip of cilia): Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 12/133 (9.0%); Bladder Urothelial Carcinoma (TCGA): 8/169 (4.7%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 10/283 (3.5%),testis cancer: 2/10 (20.0%); breast cancer: 1/12 (8.3%),31,20,Q8IYJ2,https://www.uniprot.org/uniprotkb/Q8IYJ2/entry,,,,It is uncertain whether Met-1 or Met-2 is the initiator,Mitochondrion,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
C11orf65,ENSG00000166323,Unsafe,RNA,False,True,49.2,49.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,liver: 2.5 nTPM; absolute ceiling; retina: 2.7 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,liver: 2.5 nTPM (limit 2); retina: 2.7 nTPM (limit 2); liver: 2.5 nTPM (baseline 2); retina: 2.7 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 13/133 (9.8%); Kidney Renal Papillary Cell Carcinoma (TCGA): 15/282 (5.3%); Kidney Chromophobe (TCGA): 3/64 (4.7%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NCR3,https://www.uniprot.org/uniprotkb/Q8NCR3/entry,"Acts as an inhibitor of mitochondrial fission. Interacts with MFF and prevents DNM1L recruitment to mitochondria, promoting a more fused mitochondrial network",Enriched in the pancreatic beta cell and the testis and is expressed at low levels in other tissues tested,,,"Cytoplasm, cytosol Mitochondrion outer membrane",,30059978,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
C11orf71,ENSG00000180425,Unsafe,RNA,False,True,135.1,135.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 10.3 nTPM; absolute ceiling; amygdala: 11.7 nTPM; absolute ceiling; basal ganglia: 13.5 nTPM; absolute ceiling; bone marrow: 3.7 nTPM; absolute ceiling; cerebellum: 7.7 nTPM; absolute ceiling; cerebral cortex: 9.9 nTPM; absolute ceiling; choroid plexus: 7.1 nTPM; absolute ceiling; colon: 6.7 nTPM; absolute ceiling; duodenum: 7.4 nTPM; absolute ceiling; heart muscle: 9 nTPM; absolute ceiling; hippocampal formation: 12.3 nTPM; absolute ceiling; hypothalamus: 12.8 nTPM; absolute ceiling; kidney: 13.4 nTPM; absolute ceiling; liver: 21.6 nTPM; absolute ceiling; lung: 5.8 nTPM; absolute ceiling; lymph node: 6.5 nTPM; absolute ceiling; midbrain: 11.3 nTPM; absolute ceiling; pancreas: 8.5 nTPM; absolute ceiling; parathyroid gland: 8.6 nTPM; absolute ceiling; pituitary gland: 13.1 nTPM; absolute ceiling; retina: 15.4 nTPM; absolute ceiling; salivary gland: 9.5 nTPM; absolute ceiling; skeletal muscle: 14.5 nTPM; absolute ceiling; small intestine: 7.3 nTPM; absolute ceiling; smooth muscle: 2.8 nTPM; absolute ceiling; spinal cord: 11.2 nTPM; absolute ceiling; stomach: 7.1 nTPM; absolute ceiling; thyroid gland: 12.1 nTPM; absolute ceiling; tongue: 14.6 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 10.3 nTPM (limit 2); amygdala: 11.7 nTPM (limit 2); basal ganglia: 13.5 nTPM (limit 2); bone marrow: 3.7 nTPM (limit 2); cerebellum: 7.7 nTPM (limit 2); cerebral cortex: 9.9 nTPM (limit 2); choroid plexus: 7.1 nTPM (limit 2); colon: 6.7 nTPM (limit 6); duodenum: 7.4 nTPM (limit 2); heart muscle: 9 nTPM (limit 2); hippocampal formation: 12.3 nTPM (limit 2); hypothalamus: 12.8 nTPM (limit 2); kidney: 13.4 nTPM (limit 2); liver: 21.6 nTPM (limit 2); lung: 5.8 nTPM (limit 2); lymph node: 6.5 nTPM (limit 6); midbrain: 11.3 nTPM (limit 2); pancreas: 8.5 nTPM (limit 2); parathyroid gland: 8.6 nTPM (limit 6); pituitary gland: 13.1 nTPM (limit 2); retina: 15.4 nTPM (limit 2); salivary gland: 9.5 nTPM (limit 6); skeletal muscle: 14.5 nTPM (limit 2); small intestine: 7.3 nTPM (limit 2); smooth muscle: 2.8 nTPM (limit 2); spinal cord: 11.2 nTPM (limit 2); stomach: 7.1 nTPM (limit 6); thyroid gland: 12.1 nTPM (limit 10); tongue: 14.6 nTPM (limit 6); adrenal gland: 10.3 nTPM (baseline 2); amygdala: 11.7 nTPM (baseline 2); basal ganglia: 13.5 nTPM (baseline 2); bone marrow: 3.7 nTPM (baseline 2); cerebellum: 7.7 nTPM (baseline 2); cerebral cortex: 9.9 nTPM (baseline 2); choroid plexus: 7.1 nTPM (baseline 2); colon: 6.7 nTPM (baseline 6); duodenum: 7.4 nTPM (baseline 2); heart muscle: 9 nTPM (baseline 2); hippocampal formation: 12.3 nTPM (baseline 2); hypothalamus: 12.8 nTPM (baseline 2); kidney: 13.4 nTPM (baseline 2); liver: 21.6 nTPM (baseline 2); lung: 5.8 nTPM (baseline 2); lymph node: 6.5 nTPM (baseline 6); midbrain: 11.3 nTPM (baseline 2); pancreas: 8.5 nTPM (baseline 2); parathyroid gland: 8.6 nTPM (baseline 6); pituitary gland: 13.1 nTPM (baseline 2); retina: 15.4 nTPM (baseline 2); salivary gland: 9.5 nTPM (baseline 6); skeletal muscle: 14.5 nTPM (baseline 2); small intestine: 7.3 nTPM (baseline 2); smooth muscle: 2.8 nTPM (baseline 2); spinal cord: 11.2 nTPM (baseline 2); stomach: 7.1 nTPM (baseline 6); thyroid gland: 12.1 nTPM (baseline 10); tongue: 14.6 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (validation): 228/231 (98.7%); Thyroid Carcinoma (TCGA): 488/495 (98.6%); Breast Invasive Carcinoma (validation): 49/50 (98.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q6IPW1,https://www.uniprot.org/uniprotkb/Q6IPW1/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT,GC RNA nomination across cancer types; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
C11orf96,ENSG00000187479,Unsafe,Protein,False,True,725.1,725.1,77,57,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 462.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 192.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 42.2 nTPM; absolute ceiling; basal ganglia: 40.9 nTPM; absolute ceiling; bone marrow: 4.8 nTPM; absolute ceiling; cerebellum: 19.2 nTPM; positive ihc;absolute ceiling; cerebral cortex: 36.5 nTPM; positive ihc;absolute ceiling; choroid plexus: 31.3 nTPM; absolute ceiling; colon: 145.8 nTPM; positive ihc;absolute ceiling; duodenum: 19 nTPM; positive ihc;absolute ceiling; esophagus: 43.5 nTPM; absolute ceiling; heart muscle: 260.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 36.3 nTPM; absolute ceiling; hypothalamus: 78.3 nTPM; absolute ceiling; kidney: 219.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 174.8 nTPM; positive ihc;absolute ceiling; lung: 366 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 6.6 nTPM; absolute ceiling; midbrain: 64.7 nTPM; absolute ceiling; pancreas: 58.8 nTPM; positive ihc;absolute ceiling; parathyroid gland: 3.1 nTPM; positive ihc; pituitary gland: 123.1 nTPM; absolute ceiling; rectum: 8.1 nTPM; positive ihc;absolute ceiling; salivary gland: 21.5 nTPM; positive ihc;absolute ceiling; skeletal muscle: 107 nTPM; absolute ceiling; skin: 94 nTPM; positive ihc;absolute ceiling; small intestine: 126.4 nTPM; positive ihc;absolute ceiling; smooth muscle: 27.4 nTPM; positive ihc;absolute ceiling; spinal cord: 45.8 nTPM; absolute ceiling; spleen: 53.1 nTPM; positive ihc;absolute ceiling; stomach: 232.2 nTPM; positive ihc;absolute ceiling; thyroid gland: 115.7 nTPM; positive ihc;absolute ceiling; tongue: 9.9 nTPM; absolute ceiling; urinary bladder: 170.5 nTPM; positive ihc;absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 462.7 nTPM (limit 10); adrenal gland: 192.8 nTPM (limit 2); amygdala: 42.2 nTPM (limit 2); basal ganglia: 40.9 nTPM (limit 2); bone marrow: 4.8 nTPM (limit 2); cerebellum: 19.2 nTPM (limit 2); cerebral cortex: 36.5 nTPM (limit 2); choroid plexus: 31.3 nTPM (limit 2); colon: 145.8 nTPM (limit 6); duodenum: 19 nTPM (limit 2); esophagus: 43.5 nTPM (limit 6); heart muscle: 260.2 nTPM (limit 2); hippocampal formation: 36.3 nTPM (limit 2); hypothalamus: 78.3 nTPM (limit 2); kidney: 219.4 nTPM (limit 2); liver: 174.8 nTPM (limit 2); lung: 366 nTPM (limit 2); lymph node: 6.6 nTPM (limit 6); midbrain: 64.7 nTPM (limit 2); pancreas: 58.8 nTPM (limit 2); pituitary gland: 123.1 nTPM (limit 2); rectum: 8.1 nTPM (limit 6); salivary gland: 21.5 nTPM (limit 6); skeletal muscle: 107 nTPM (limit 2); skin: 94 nTPM (limit 10); small intestine: 126.4 nTPM (limit 2); smooth muscle: 27.4 nTPM (limit 2); spinal cord: 45.8 nTPM (limit 2); spleen: 53.1 nTPM (limit 10); stomach: 232.2 nTPM (limit 6); thyroid gland: 115.7 nTPM (limit 10); tongue: 9.9 nTPM (limit 6); urinary bladder: 170.5 nTPM (limit 6); adipose tissue: 462.7 nTPM (baseline 10); adrenal gland: 192.8 nTPM (baseline 2); amygdala: 42.2 nTPM (baseline 2); basal ganglia: 40.9 nTPM (baseline 2); bone marrow: 4.8 nTPM (baseline 2); cerebellum: 19.2 nTPM (baseline 2); cerebral cortex: 36.5 nTPM (baseline 2); choroid plexus: 31.3 nTPM (baseline 2); colon: 145.8 nTPM (baseline 6); duodenum: 19 nTPM (baseline 2); esophagus: 43.5 nTPM (baseline 6); heart muscle: 260.2 nTPM (baseline 2); hippocampal formation: 36.3 nTPM (baseline 2); hypothalamus: 78.3 nTPM (baseline 2); kidney: 219.4 nTPM (baseline 2); liver: 174.8 nTPM (baseline 2); lung: 366 nTPM (baseline 2); lymph node: 6.6 nTPM (baseline 6); midbrain: 64.7 nTPM (baseline 2); pancreas: 58.8 nTPM (baseline 2); pituitary gland: 123.1 nTPM (baseline 2); rectum: 8.1 nTPM (baseline 6); salivary gland: 21.5 nTPM (baseline 6); skeletal muscle: 107 nTPM (baseline 2); skin: 94 nTPM (baseline 10); small intestine: 126.4 nTPM (baseline 2); smooth muscle: 27.4 nTPM (baseline 2); spinal cord: 45.8 nTPM (baseline 2); spleen: 53.1 nTPM (baseline 10); stomach: 232.2 nTPM (baseline 6); thyroid gland: 115.7 nTPM (baseline 10); tongue: 9.9 nTPM (baseline 6); urinary bladder: 170.5 nTPM (baseline 6),adipose tissue / adipocytes: Low (Uncertain); adrenal gland / glandular cells: Medium (Uncertain); caudate / glial cells: Low (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: Medium (Uncertain); cerebellum / cells in molecular layer: Medium (Uncertain); cerebellum / Purkinje cells: Low (Uncertain); cerebral cortex / glial cells: Low (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); colon / glandular cells: High (Uncertain); colon / peripheral nerve/ganglion: Low (Uncertain); duodenum / glandular cells: High (Uncertain); heart muscle / cardiomyocytes: Low (Uncertain); hippocampus / glial cells: Low (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / cholangiocytes: Medium (Uncertain); lung / alveolar cells: High (Uncertain); lung / macrophages: High (Uncertain); nasopharynx / respiratory epithelial cells: High (Uncertain); pancreas / exocrine glandular cells: High (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: High (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skin 1 / fibroblasts: High (Uncertain); skin 2 / epidermal cells: Low (Uncertain); small intestine / glandular cells: High (Uncertain); smooth muscle / smooth muscle cells: Low (Uncertain); spleen / cells in red pulp: Low (Uncertain); stomach 1 / glandular cells: High (Uncertain); stomach 2 / glandular cells: High (Uncertain); thyroid gland / glandular cells: High (Uncertain); urinary bladder / urothelial cells: High (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (TCGA): 175/176 (99.4%); Stomach Adenocarcinoma (TCGA): 344/346 (99.4%); Glioblastoma Multiforme (TCGA): 140/141 (99.3%),breast cancer: 11/12 (91.7%); endometrial cancer: 11/12 (91.7%),30,20,Q7Z7L8,https://www.uniprot.org/uniprotkb/Q7Z7L8/entry,,,,,Cytoplasm,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
C12orf42,ENSG00000179088,Unsafe,High RNA,False,True,16.7,16.7,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 91/91 values ≥5 TPM, max 34.6357; DICE TREG_MEM (unstimulated): 35/89 values ≥5 TPM, max 7.66069; DICE CD4_NAIVE (unstimulated): 50/88 values ≥5 TPM, max 8.9831; DICE TREG_NAIVE (unstimulated): 89/89 values ≥5 TPM, max 16.923; DICE TFH (unstimulated): 64/89 values ≥5 TPM, max 9.39581; DICE TH1 (unstimulated): 27/81 values ≥5 TPM, max 7.6526; DICE TH2 (unstimulated): 26/89 values ≥5 TPM, max 7.99992; DICE CD8_NAIVE (unstimulated): 27/89 values ≥5 TPM, max 7.7861; hpa_immune_cell memory B-cell: 5.2 nTPM; hpa_immune_cell naive B-cell: 5.3 nTPM; hpa_immune_monaco naive B-cell: 6.8 TPM; hpa_immune_monaco Non-switched memory B-cell: 5 TPM",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,34.635688491399996,69.1,"dice_b_cell_naive: blood/B_CELL_NAIVE, max 34.6357 TPM, 8 observations >30; hpa_single_cell_tissue: brain/excitatory neurons, max 43.8 nTPM, 2 observations >30; hpa_single_cell_tissue: liver/b-cells, max 33.8 nTPM, 1 observations >30; hpa_single_cell_tissue: lymph node/b-cells, max 69.1 nTPM, 3 observations >30; hpa_single_cell_tissue: salivary gland/b-cells, max 36.3 nTPM, 1 observations >30; hpa_single_cell_tissue: spleen/b-cells, max 40.1 nTPM, 1 observations >30; hpa_single_cell_tissue: stomach/b-cells, max 36.7 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,34.64 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,69.1 nTPM; lymph node/b-cells; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q96LP6,https://www.uniprot.org/uniprotkb/Q96LP6/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
C12orf54,ENSG00000177627,Unsafe,High RNA,False,True,38.8,38.8,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE TREG_MEM (unstimulated): 29/89 values ≥5 TPM, max 9.54066; DICE TREG_NAIVE (unstimulated): 52/89 values ≥5 TPM, max 8.61503; DICE TFH (unstimulated): 13/89 values ≥5 TPM, max 6.769",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,9.5406551954,30.4,"hpa_single_cell_tissue: bronchus/basal respiratory cells, max 30.4 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,9.541 TPM; blood/TREG_MEM; dice_treg_mem; vital,30.4 nTPM; bronchus/basal respiratory cells; hpa_single_cell_tissue; vital,Lung Squamous Cell Carcinoma (validation): 16/68 (23.5%); Lung Squamous Cell Carcinoma (TCGA): 46/489 (9.4%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 15/283 (5.3%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q6X4T0,https://www.uniprot.org/uniprotkb/Q6X4T0/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,All audited maxima are within 10% above 30; other gates still require review,,,,
C12orf56,ENSG00000185306,Unsafe,RNA,False,True,7.3,7.3,86,2,Positive somewhere,False,True,False,True,Excluded,Normal,False,,Not assessed,,,choroid plexus: 2.4 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 2.4 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Ovary Serous Cystadenocarcinoma (validation): 19/81 (23.5%); Pancreatic Adenocarcinoma (validation): 9/80 (11.2%); Liver Hepatocellular Carcinoma (validation): 19/231 (8.2%),breast cancer: 0/10 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q8IXR9,https://www.uniprot.org/uniprotkb/Q8IXR9/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
C12orf60,ENSG00000182993,Unsafe,RNA,False,True,14.3,14.3,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 4.6 nTPM; absolute ceiling;continuous selectivity; heart muscle: 3.2 nTPM; absolute ceiling; kidney: 2.5 nTPM; absolute ceiling; liver: 5.8 nTPM; absolute ceiling;continuous selectivity; retina: 6.2 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 4.6 nTPM (limit 2); heart muscle: 3.2 nTPM (limit 2); kidney: 2.5 nTPM (limit 2); liver: 5.8 nTPM (limit 2); retina: 6.2 nTPM (limit 2); adrenal gland: 4.6 nTPM (baseline 2); heart muscle: 3.2 nTPM (baseline 2); kidney: 2.5 nTPM (baseline 2); liver: 5.8 nTPM (baseline 2); retina: 6.2 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 44/50 (88.0%); Testicular Germ Cell Tumor (TCGA): 52/133 (39.1%); Liver Hepatocellular Carcinoma (validation): 67/231 (29.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q5U649,https://www.uniprot.org/uniprotkb/Q5U649/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination; inclusion depends on TGCT under this study's thresholds | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
C14orf39,ENSG00000179008,Unsafe,RNA,False,True,10.5,10.5,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,pituitary gland: 4.7 nTPM; absolute ceiling;continuous selectivity; retina: 2.6 nTPM; absolute ceiling; salivary gland: 4.5 nTPM; continuous selectivity; skeletal muscle: 2.9 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,pituitary gland: 4.7 nTPM (limit 2); retina: 2.6 nTPM (limit 2); skeletal muscle: 2.9 nTPM (limit 2); pituitary gland: 4.7 nTPM (baseline 2); retina: 2.6 nTPM (baseline 2); skeletal muscle: 2.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 5/58 (8.6%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 16/283 (5.7%); Breast Invasive Carcinoma (validation): 2/50 (4.0%),lung cancer: 11/12 (91.7%); testis cancer: 11/12 (91.7%),31,20,Q8N1H7,https://www.uniprot.org/uniprotkb/Q8N1H7/entry,Meiotic protein that localizes to the central element of the synaptonemal complex and is required for chromosome synapsis during meiotic recombination. Required for the appropriate processing of intermediate recombination nodules before crossover formation,"Highest expression in retina, skeletal muscle, testis and colon","Spermatogenic failure 52: An autosomal recessive infertility disorder characterized by azoospermia due to meiotic arrest at the spermatocyte stage. Premature ovarian failure 18: A form of premature ovarian failure, an ovarian disorder defined as the cessation of ovarian function under the age of 40 years. It is characterized by oligomenorrhea or amenorrhea, in the presence of elevated levels of serum gonadotropins and low estradiol. POF18 is an autosomal recessive form characterized by irregular menstrual cycles and cessation of menstruation in the third decade of life. The uterus is small, ovaries may be small or rudimentary, and do not show follicular activity.",,Chromosome,,15703187|33508233,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
C16orf86,ENSG00000159761,Unsafe,RNA,False,True,38.7,38.7,83,3,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,amygdala: 2.4 nTPM; absolute ceiling; basal ganglia: 3.9 nTPM; absolute ceiling; choroid plexus: 4.9 nTPM; absolute ceiling; hippocampal formation: 2.3 nTPM; absolute ceiling; hypothalamus: 2.6 nTPM; absolute ceiling; midbrain: 3.2 nTPM; absolute ceiling; pituitary gland: 2.3 nTPM; absolute ceiling; spinal cord: 2.7 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 2.4 nTPM (limit 2); basal ganglia: 3.9 nTPM (limit 2); choroid plexus: 4.9 nTPM (limit 2); hippocampal formation: 2.3 nTPM (limit 2); hypothalamus: 2.6 nTPM (limit 2); midbrain: 3.2 nTPM (limit 2); pituitary gland: 2.3 nTPM (limit 2); spinal cord: 2.7 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 40/50 (80.0%); Kidney Renal Papillary Cell Carcinoma (TCGA): 106/282 (37.6%); Kidney Renal Clear Cell Carcinoma (validation): 16/100 (16.0%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q6ZW13,https://www.uniprot.org/uniprotkb/Q6ZW13/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
C16orf87,ENSG00000155330,Unsafe,Protein,False,True,17.8,17.8,80,19,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 4.6 nTPM; absolute ceiling;continuous selectivity; amygdala: 4 nTPM; absolute ceiling; basal ganglia: 5.8 nTPM; absolute ceiling;continuous selectivity; bone marrow: 11.6 nTPM; absolute ceiling;continuous selectivity; cerebellum: 3.4 nTPM; positive ihc;absolute ceiling; cerebral cortex: 5.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 2.8 nTPM; absolute ceiling; duodenum: 2.6 nTPM; absolute ceiling; esophagus: 4.5 nTPM; positive ihc; heart muscle: 6 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 4 nTPM; absolute ceiling; hypothalamus: 3.5 nTPM; absolute ceiling; kidney: 7.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 12.7 nTPM; absolute ceiling;continuous selectivity; lung: 3.9 nTPM; absolute ceiling; midbrain: 3 nTPM; absolute ceiling; pancreas: 2.4 nTPM; absolute ceiling; pituitary gland: 3.8 nTPM; absolute ceiling; rectum: 2.2 nTPM; positive ihc; retina: 2.3 nTPM; absolute ceiling; skeletal muscle: 13.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 3.6 nTPM; positive ihc; small intestine: 4.6 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 2.7 nTPM; absolute ceiling; spinal cord: 3.2 nTPM; absolute ceiling; stomach: 2.8 nTPM; positive ihc; tongue: 7.2 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 4 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 4.6 nTPM (limit 2); amygdala: 4 nTPM (limit 2); basal ganglia: 5.8 nTPM (limit 2); bone marrow: 11.6 nTPM (limit 2); cerebellum: 3.4 nTPM (limit 2); cerebral cortex: 5.7 nTPM (limit 2); choroid plexus: 2.8 nTPM (limit 2); duodenum: 2.6 nTPM (limit 2); heart muscle: 6 nTPM (limit 2); hippocampal formation: 4 nTPM (limit 2); hypothalamus: 3.5 nTPM (limit 2); kidney: 7.3 nTPM (limit 2); liver: 12.7 nTPM (limit 2); lung: 3.9 nTPM (limit 2); midbrain: 3 nTPM (limit 2); pancreas: 2.4 nTPM (limit 2); pituitary gland: 3.8 nTPM (limit 2); retina: 2.3 nTPM (limit 2); skeletal muscle: 13.2 nTPM (limit 2); small intestine: 4.6 nTPM (limit 2); smooth muscle: 2.7 nTPM (limit 2); spinal cord: 3.2 nTPM (limit 2); tongue: 7.2 nTPM (limit 6); adrenal gland: 4.6 nTPM (baseline 2); amygdala: 4 nTPM (baseline 2); basal ganglia: 5.8 nTPM (baseline 2); bone marrow: 11.6 nTPM (baseline 2); cerebellum: 3.4 nTPM (baseline 2); cerebral cortex: 5.7 nTPM (baseline 2); choroid plexus: 2.8 nTPM (baseline 2); duodenum: 2.6 nTPM (baseline 2); heart muscle: 6 nTPM (baseline 2); hippocampal formation: 4 nTPM (baseline 2); hypothalamus: 3.5 nTPM (baseline 2); kidney: 7.3 nTPM (baseline 2); liver: 12.7 nTPM (baseline 2); lung: 3.9 nTPM (baseline 2); midbrain: 3 nTPM (baseline 2); pancreas: 2.4 nTPM (baseline 2); pituitary gland: 3.8 nTPM (baseline 2); retina: 2.3 nTPM (baseline 2); skeletal muscle: 13.2 nTPM (baseline 2); small intestine: 4.6 nTPM (baseline 2); smooth muscle: 2.7 nTPM (baseline 2); spinal cord: 3.2 nTPM (baseline 2); tongue: 7.2 nTPM (baseline 6),caudate / glial cells: Medium (Uncertain); cerebellum / Purkinje cells: Low (Uncertain); cerebral cortex / glial cells: Medium (Uncertain); cerebral cortex / neuropil: Low (Uncertain); esophagus / squamous epithelial cells: Low (Uncertain); heart muscle / cardiomyocytes: Low (Uncertain); hippocampus / glial cells: Medium (Uncertain); kidney / cells in tubules: Low (Uncertain); oral mucosa / squamous epithelial cells: Low (Uncertain); rectum / glandular cells: Low (Uncertain); skeletal muscle / myocytes: Low (Uncertain); skin 1 / keratinocytes: Medium (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); stomach 1 / glandular cells: Low (Uncertain); stomach 2 / glandular cells: Low (Uncertain); urinary bladder / urothelial cells: Low (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 48/50 (96.0%); Liver Hepatocellular Carcinoma (validation): 219/231 (94.8%),urothelial cancer: 1/10 (10.0%); glioma: 1/12 (8.3%),31,20,Q6PH81,https://www.uniprot.org/uniprotkb/Q6PH81/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
C16orf92,ENSG00000167194,Unsafe,RNA,False,True,14.9,34.7,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,retina: 34.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 34.7 nTPM (limit 2); retina: 34.7 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 3/141 (2.1%); Lung Adenocarcinoma (validation): 1/105 (1.0%); Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q96LL3,https://www.uniprot.org/uniprotkb/Q96LL3/entry,May play a role in sperm-oocyte fusion during fertilization,Testis-specific,,,Cell membrane,,32295885,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
C16orf95,ENSG00000260456,Unsafe,Protein,False,True,98.6,98.6,109,10,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 3.9 nTPM; absolute ceiling; basal ganglia: 3.4 nTPM; absolute ceiling; colon: 1.6 nTPM; positive ihc; duodenum: 1.4 nTPM; positive ihc; hippocampal formation: 3.1 nTPM; absolute ceiling; hypothalamus: 3.1 nTPM; absolute ceiling; liver: 6.8 nTPM; absolute ceiling; midbrain: 4.3 nTPM; absolute ceiling; pituitary gland: 2.2 nTPM; absolute ceiling; rectum: 0.7 nTPM; positive ihc; small intestine: 1.5 nTPM; positive ihc; spinal cord: 3.1 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 3.9 nTPM (limit 2); basal ganglia: 3.4 nTPM (limit 2); hippocampal formation: 3.1 nTPM (limit 2); hypothalamus: 3.1 nTPM (limit 2); liver: 6.8 nTPM (limit 6); midbrain: 4.3 nTPM (limit 2); pituitary gland: 2.2 nTPM (limit 2); spinal cord: 3.1 nTPM (limit 2),colon / endocrine cells: High (Supported); duodenum / endocrine cells: High (Supported); duodenum / glands of Brunner: Medium (Supported); rectum / endocrine cells: High (Supported); small intestine / endocrine cells: High (Supported),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 66/141 (46.8%); Liver Hepatocellular Carcinoma (validation): 75/231 (32.5%); Kidney Renal Papillary Cell Carcinoma (TCGA): 85/282 (30.1%),stomach cancer: 1/8 (12.5%); pancreatic cancer: 1/10 (10.0%),30,20,Q9H693,https://www.uniprot.org/uniprotkb/Q9H693/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Chang2019_TGCT,Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
C17orf67,ENSG00000214226,Unsafe,Protein,False,True,1.9,5.3,79,15,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 1.3 nTPM; continuous selectivity; amygdala: 1 nTPM; continuous selectivity; basal ganglia: 0.8 nTPM; continuous selectivity; cerebellum: 0.9 nTPM; continuous selectivity; cerebral cortex: 0.9 nTPM; positive ihc;continuous selectivity; choroid plexus: 0.7 nTPM; continuous selectivity; colon: 1.3 nTPM; positive ihc;continuous selectivity; duodenum: 0.7 nTPM; positive ihc;continuous selectivity; esophagus: 0.8 nTPM; positive ihc;continuous selectivity; heart muscle: 0.9 nTPM; continuous selectivity; hippocampal formation: 1.1 nTPM; continuous selectivity; hypothalamus: 1.4 nTPM; continuous selectivity; kidney: 0.8 nTPM; continuous selectivity; liver: 2.2 nTPM; continuous selectivity;reproductive not higher; lung: 1.5 nTPM; continuous selectivity; lymph node: 1.5 nTPM; continuous selectivity; midbrain: 1 nTPM; continuous selectivity; pancreas: 1.6 nTPM; continuous selectivity; pituitary gland: 1.3 nTPM; continuous selectivity; rectum: 0.5 nTPM; positive ihc; retina: 0.8 nTPM; continuous selectivity; small intestine: 1.6 nTPM; positive ihc;continuous selectivity; smooth muscle: 1.1 nTPM; continuous selectivity; spinal cord: 1.4 nTPM; continuous selectivity; spleen: 2.6 nTPM; continuous selectivity;reproductive not higher; stomach: 0.9 nTPM; positive ihc;continuous selectivity; thymus: 5.3 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 1.3 nTPM; continuous selectivity; tongue: 0.8 nTPM; continuous selectivity; urinary bladder: 1.4 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",,caudate / glial cells: Medium (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuropil: Low (Approved); colon / glandular cells: High (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); hippocampus / glial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Low (Approved); rectum / glandular cells: High (Approved); small intestine / glandular cells: High (Approved); stomach 2 / glandular cells: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 35/50 (70.0%); Liver Hepatocellular Carcinoma (validation): 43/231 (18.6%); Ovary Serous Cystadenocarcinoma (TCGA): 26/349 (7.4%),glioma: 4/10 (40.0%); ovarian cancer: 2/11 (18.2%),31,20,Q0P5P2,https://www.uniprot.org/uniprotkb/Q0P5P2/entry,,,,,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
C17orf75,ENSG00000108666,Unsafe,Protein,False,True,25.5,26.9,96,70,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 15.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 9.7 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 10.4 nTPM; absolute ceiling;continuous selectivity; bone marrow: 7.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 15.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 15.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 18.7 nTPM; absolute ceiling;continuous selectivity; colon: 11.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 12.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 8.5 nTPM; positive ihc;absolute ceiling; heart muscle: 18.7 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 10 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 12.6 nTPM; absolute ceiling;continuous selectivity; kidney: 20.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 14 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 8.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 12.6 nTPM; absolute ceiling;continuous selectivity; midbrain: 11.2 nTPM; absolute ceiling;continuous selectivity; pancreas: 12.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 26.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 13.1 nTPM; absolute ceiling;continuous selectivity; rectum: 12.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 25.4 nTPM; absolute ceiling;continuous selectivity; salivary gland: 11.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 16.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 7 nTPM; positive ihc; small intestine: 10.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 10 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 10.3 nTPM; absolute ceiling;continuous selectivity; spleen: 9.3 nTPM; positive ihc; stomach: 12.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 15.6 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 13.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 13.7 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 9.3 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 15.4 nTPM (limit 2); amygdala: 9.7 nTPM (limit 2); basal ganglia: 10.4 nTPM (limit 2); bone marrow: 7.5 nTPM (limit 2); cerebellum: 15.6 nTPM (limit 2); cerebral cortex: 15.3 nTPM (limit 2); choroid plexus: 18.7 nTPM (limit 2); colon: 11.3 nTPM (limit 6); duodenum: 12.9 nTPM (limit 2); esophagus: 8.5 nTPM (limit 6); heart muscle: 18.7 nTPM (limit 4); hippocampal formation: 10 nTPM (limit 2); hypothalamus: 12.6 nTPM (limit 2); kidney: 20.5 nTPM (limit 2); liver: 14 nTPM (limit 2); lung: 8.5 nTPM (limit 2); lymph node: 12.6 nTPM (limit 6); midbrain: 11.2 nTPM (limit 2); pancreas: 12.7 nTPM (limit 2); parathyroid gland: 26.9 nTPM (limit 6); pituitary gland: 13.1 nTPM (limit 2); rectum: 12.2 nTPM (limit 6); retina: 25.4 nTPM (limit 2); salivary gland: 11.9 nTPM (limit 6); skeletal muscle: 16.9 nTPM (limit 2); small intestine: 10.5 nTPM (limit 2); smooth muscle: 10 nTPM (limit 2); spinal cord: 10.3 nTPM (limit 2); stomach: 12.6 nTPM (limit 6); thymus: 15.6 nTPM (limit 10); thyroid gland: 13.6 nTPM (limit 10); tongue: 13.7 nTPM (limit 6); urinary bladder: 9.3 nTPM (limit 6),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / basal cells: Medium (Approved); bronchus / ciliated cells (cell body): High (Approved); bronchus / ciliated cells (tip of cilia): Low (Approved); bronchus / goblet cells: High (Approved); caudate / glial cells: Medium (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / endothelial cells: High (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: High (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: Low (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in tubules: High (Approved); liver / hepatocytes: High (Approved); lung / macrophages: Medium (Approved); nasopharynx / basal cells: Low (Approved); nasopharynx / ciliated cells (cell body): Low (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: High (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Low (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Adenocarcinoma (TCGA): 497/497 (100.0%); Lung Squamous Cell Carcinoma (TCGA): 489/489 (100.0%); Colon Adenocarcinoma (TCGA): 254/254 (100.0%),prostate cancer: 11/11 (100.0%); renal cancer: 11/12 (91.7%),31,20,Q9HAS0,https://www.uniprot.org/uniprotkb/Q9HAS0/entry,As component of the WDR11 complex acts together with TBC1D23 to facilitate the golgin-mediated capture of vesicles generated using AP-1 (PubMed:29426865). May have a role in spermatogenesis,Highly expressed in testis and also expressed in fetal testis,,,"Golgi apparatus, trans-Golgi network Cytoplasmic vesicle",29426865,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
C18orf54,ENSG00000166845,Unsafe,RNA,False,True,16.8,16.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,spinal cord: 2.4 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,spinal cord: 2.4 nTPM (limit 2); spinal cord: 2.4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 32/50 (64.0%); Testicular Germ Cell Tumor (TCGA): 50/133 (37.6%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8IYD9,https://www.uniprot.org/uniprotkb/Q8IYD9/entry,Might play a role in cell proliferation,,,,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,Failed bulk numeric comparisons are within 20% of their cutoffs; not an automatic rescue,,,,
C19orf18,ENSG00000177025,Unsafe,Protein,False,True,12.0,15.6,81,4,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; basal ganglia: 2.2 nTPM; absolute ceiling; choroid plexus: 15.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 4.7 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 2.3 nTPM; absolute ceiling; hypothalamus: 2.4 nTPM; absolute ceiling; midbrain: 2.5 nTPM; absolute ceiling; pituitary gland: 3.8 nTPM; absolute ceiling;continuous selectivity; retina: 5 nTPM; absolute ceiling;continuous selectivity; spinal cord: 3 nTPM; absolute ceiling; thyroid gland: 1.7 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",basal ganglia: 2.2 nTPM (limit 2); choroid plexus: 15.6 nTPM (limit 2); heart muscle: 4.7 nTPM (limit 4); hippocampal formation: 2.3 nTPM (limit 2); hypothalamus: 2.4 nTPM (limit 2); midbrain: 2.5 nTPM (limit 2); pituitary gland: 3.8 nTPM (limit 2); retina: 5 nTPM (limit 2); spinal cord: 3 nTPM (limit 2),thyroid gland / glandular cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 50/58 (86.2%); Breast Invasive Carcinoma (validation): 32/50 (64.0%); Glioblastoma Multiforme (TCGA): 28/141 (19.9%),breast cancer: 0/12 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q8NEA5,https://www.uniprot.org/uniprotkb/Q8NEA5/entry,,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
C19orf25,ENSG00000119559,Unsafe,Protein,False,True,21.5,42.3,77,27,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 13.9 nTPM; continuous selectivity; adrenal gland: 22.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 41.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 36.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 7.7 nTPM; absolute ceiling;continuous selectivity; cerebellum: 28.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 42.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 18.1 nTPM; absolute ceiling;continuous selectivity; colon: 17.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 15.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 19.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 20.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 39.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 34.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 30.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 28.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 14.3 nTPM; absolute ceiling;continuous selectivity; lymph node: 14.5 nTPM; absolute ceiling;continuous selectivity; midbrain: 39.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 19.4 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 15 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 26.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 4.9 nTPM; positive ihc; retina: 6.7 nTPM; absolute ceiling;continuous selectivity; salivary gland: 17.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 15.6 nTPM; absolute ceiling;continuous selectivity; skin: 16.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 17.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 5.8 nTPM; absolute ceiling; spinal cord: 38.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 22.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; stomach: 17.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; thyroid gland: 23.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; tongue: 7.2 nTPM; absolute ceiling; urinary bladder: 16.9 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 22.8 nTPM (limit 4); amygdala: 41.8 nTPM (limit 2); basal ganglia: 36.5 nTPM (limit 2); bone marrow: 7.7 nTPM (limit 4); cerebellum: 28.3 nTPM (limit 4); cerebral cortex: 42.3 nTPM (limit 4); choroid plexus: 18.1 nTPM (limit 2); colon: 17.4 nTPM (limit 6); duodenum: 15.1 nTPM (limit 2); esophagus: 19.8 nTPM (limit 6); heart muscle: 20.6 nTPM (limit 2); hippocampal formation: 39.7 nTPM (limit 2); hypothalamus: 34.9 nTPM (limit 2); kidney: 30.1 nTPM (limit 2); liver: 28.7 nTPM (limit 2); lung: 14.3 nTPM (limit 4); lymph node: 14.5 nTPM (limit 8); midbrain: 39.4 nTPM (limit 2); pancreas: 19.4 nTPM (limit 4); parathyroid gland: 15 nTPM (limit 6); pituitary gland: 26.4 nTPM (limit 2); retina: 6.7 nTPM (limit 2); salivary gland: 17.1 nTPM (limit 6); skeletal muscle: 15.6 nTPM (limit 4); skin: 16.8 nTPM (limit 10); small intestine: 17.2 nTPM (limit 2); smooth muscle: 5.8 nTPM (limit 4); spinal cord: 38.4 nTPM (limit 2); spleen: 22.8 nTPM (limit 20); stomach: 17.3 nTPM (limit 6); thyroid gland: 23.1 nTPM (limit 10); tongue: 7.2 nTPM (limit 6); urinary bladder: 16.9 nTPM (limit 6),bronchus / respiratory epithelial cells: Medium (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Low (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Low (Approved); oral mucosa / squamous epithelial cells: High (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skin 1 / keratinocytes: Low (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Low (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Thyroid Carcinoma (TCGA): 495/495 (100.0%); Head and Neck Squamous Cell Carcinoma (TCGA): 492/492 (100.0%); Prostate Adenocarcinoma (TCGA): 480/480 (100.0%),skin cancer: 5/10 (50.0%); cervical cancer: 4/12 (33.3%),31,20,Q9UFG5,https://www.uniprot.org/uniprotkb/Q9UFG5/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
C19orf84,ENSG00000262874,Unsafe,Protein,False,True,21.4,21.4,79,21,Positive somewhere,True,False,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 0 nTPM; positive ihc; adrenal gland: 0 nTPM; positive ihc; cerebellum: 0 nTPM; positive ihc; cerebral cortex: 0.1 nTPM; positive ihc; duodenum: 0 nTPM; positive ihc; kidney: 0 nTPM; positive ihc; lung: 0.1 nTPM; positive ihc; pancreas: 0 nTPM; positive ihc; small intestine: 0 nTPM; positive ihc; spleen: 0.4 nTPM; positive ihc; stomach: 0 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,adipose tissue / adipocytes: Medium (Uncertain); adrenal gland / glandular cells: Low (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: Low (Uncertain); cerebral cortex / endothelial cells: Low (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); duodenum / glandular cells: Low (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in tubules: Low (Uncertain); lung / macrophages: Medium (Uncertain); pancreas / pancreatic endocrine cells: Low (Uncertain); small intestine / glandular cells: Low (Uncertain); spleen / cells in red pulp: Medium (Uncertain); spleen / cells in white pulp: Low (Uncertain); stomach 2 / glandular cells: Low (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 62/133 (46.6%); Ovary Serous Cystadenocarcinoma (TCGA): 35/349 (10.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 9/176 (5.1%),breast cancer: 0/10 (0.0%); cervical cancer: 0/9 (0.0%),29,20,I3L1E1,https://www.uniprot.org/uniprotkb/I3L1E1/entry,"Protein adapter involved in piRNA-directed transposon methylation by connecting PIWIL4-piRNA and DNA methylation machineries. The PIWIL4-piRNA pathway plays a central role during spermatogenesis by directing transposon DNA methylation and silencing, thereby preventing their mobilization, which is essential for the germline integrity",,,,"Nucleus, nucleoplasm",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Chang2019_TGCT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
C1orf105,ENSG00000180999,Unsafe,RNA,False,True,25.5,25.5,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,heart muscle: 16.8 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,heart muscle: 16.8 nTPM (limit 2); heart muscle: 16.8 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 3/58 (5.2%); Testicular Germ Cell Tumor (TCGA): 4/133 (3.0%); Rectum Adenocarcinoma (validation): 5/207 (2.4%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O95561,https://www.uniprot.org/uniprotkb/O95561/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
C1orf141,ENSG00000203963,Unsafe,RNA,False,True,14.9,14.9,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,choroid plexus: 2.7 nTPM; absolute ceiling; retina: 3.1 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 2.7 nTPM (limit 2); retina: 3.1 nTPM (limit 2); choroid plexus: 2.7 nTPM (baseline 2); retina: 3.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 3/133 (2.3%); Lung Adenocarcinoma (TCGA): 6/497 (1.2%); Bladder Urothelial Carcinoma (TCGA): 2/169 (1.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q5JVX7,https://www.uniprot.org/uniprotkb/Q5JVX7/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
C1orf167,ENSG00000215910,Unsafe,High RNA,False,True,27.4,27.4,99,3,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,True,"lung/alveolar cells type 2 cluster c-0: 46.4 nTPM, 3703 reads; reproductive-cell max 43.4; lung/alveolar cells type 1 cluster c-3: 79.5 nTPM, 2522 reads; reproductive-cell max 43.4; lung/alveolar cells type 1 cluster c-6: 95 nTPM, 210 reads; reproductive-cell max 43.4",True,False,,True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,2.9,95.0,"hpa_single_cell: /Alveolar cells type 1, max 85.3 nTPM, 1 observations >30; hpa_single_cell: /Alveolar cells type 2, max 39.4 nTPM, 1 observations >30; hpa_single_cell_tissue: lung/alveolar cells type 1, max 95 nTPM, 2 observations >30; hpa_single_cell_tissue: lung/alveolar cells type 2, max 46.4 nTPM, 3 observations >30",CTA,oncoref.target-sets.2026-10-23.2,2.9 TPM; blood/Plasmablast; hpa_immune_monaco; vital,95 nTPM; lung/alveolar cells type 1; hpa_single_cell_tissue; vital,Ovary Serous Cystadenocarcinoma (validation): 5/81 (6.2%); Pancreatic Adenocarcinoma (validation): 4/80 (5.0%); Testicular Germ Cell Tumor (TCGA): 4/133 (3.0%),prostate cancer: 1/12 (8.3%); breast cancer: 0/11 (0.0%),29,20,Q5SNV9,https://www.uniprot.org/uniprotkb/Q5SNV9/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Chang2019_TGCT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
C1orf226,ENSG00000239887,Unsafe,Protein,False,True,7.9,21.4,78,66,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 9.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 2 nTPM; positive ihc; cerebellum: 6.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 2.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 3.2 nTPM; absolute ceiling;continuous selectivity; colon: 9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 5.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 4 nTPM; positive ihc;continuous selectivity; heart muscle: 3.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 2.6 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 3.5 nTPM; absolute ceiling;continuous selectivity; kidney: 11 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 21.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 2.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 0.3 nTPM; positive ihc; midbrain: 2.8 nTPM; absolute ceiling;continuous selectivity; pancreas: 3.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 3.9 nTPM; positive ihc;continuous selectivity; pituitary gland: 9.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 9.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; retina: 6.8 nTPM; absolute ceiling;continuous selectivity; salivary gland: 8.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 0.6 nTPM; positive ihc; skin: 5.1 nTPM; positive ihc;continuous selectivity; small intestine: 7.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 2.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 3.3 nTPM; absolute ceiling;continuous selectivity; spleen: 0.6 nTPM; positive ihc; stomach: 8.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 0.7 nTPM; positive ihc; urinary bladder: 2.4 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 9.3 nTPM (limit 2); cerebellum: 6.5 nTPM (limit 2); cerebral cortex: 2.4 nTPM (limit 2); choroid plexus: 3.2 nTPM (limit 2); colon: 9 nTPM (limit 6); duodenum: 5.4 nTPM (limit 2); heart muscle: 3.3 nTPM (limit 2); hippocampal formation: 2.6 nTPM (limit 2); hypothalamus: 3.5 nTPM (limit 2); kidney: 11 nTPM (limit 2); liver: 21.4 nTPM (limit 2); lung: 2.4 nTPM (limit 2); midbrain: 2.8 nTPM (limit 2); pancreas: 3.5 nTPM (limit 2); pituitary gland: 9.6 nTPM (limit 2); rectum: 9.4 nTPM (limit 6); retina: 6.8 nTPM (limit 2); salivary gland: 8.3 nTPM (limit 6); small intestine: 7.7 nTPM (limit 2); smooth muscle: 2.4 nTPM (limit 2); spinal cord: 3.3 nTPM (limit 2); stomach: 8.4 nTPM (limit 6),adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: High (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: High (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: High (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Low (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: High (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: High (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 483/486 (99.4%); Rectum Adenocarcinoma (validation): 204/207 (98.6%); Breast Invasive Carcinoma (validation): 49/50 (98.0%),melanoma: 12/12 (100.0%); ovarian cancer: 11/11 (100.0%),31,20,A1L170,https://www.uniprot.org/uniprotkb/A1L170/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
C1orf56,ENSG00000143443,Unsafe,Protein,False,True,74.4,74.4,90,4,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 3.2 nTPM; absolute ceiling; basal ganglia: 3.4 nTPM; absolute ceiling; choroid plexus: 5.4 nTPM; absolute ceiling; hippocampal formation: 3.5 nTPM; absolute ceiling; hypothalamus: 3.3 nTPM; absolute ceiling; kidney: 6.4 nTPM; positive ihc;absolute ceiling; midbrain: 3.6 nTPM; absolute ceiling; pituitary gland: 9.7 nTPM; absolute ceiling; spinal cord: 3.6 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 3.2 nTPM (limit 2); basal ganglia: 3.4 nTPM (limit 2); choroid plexus: 5.4 nTPM (limit 2); hippocampal formation: 3.5 nTPM (limit 2); hypothalamus: 3.3 nTPM (limit 2); kidney: 6.4 nTPM (limit 2); midbrain: 3.6 nTPM (limit 2); pituitary gland: 9.7 nTPM (limit 2); spinal cord: 3.6 nTPM (limit 2),kidney / proximal tubules (cell body): Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Prostate Adenocarcinoma (TCGA): 480/480 (100.0%); Liver Hepatocellular Carcinoma (validation): 231/231 (100.0%); Thyroid Carcinoma (TCGA): 490/495 (99.0%),breast cancer: 0/12 (0.0%); cervical cancer: 0/10 (0.0%),31,20,Q9BUN1,https://www.uniprot.org/uniprotkb/Q9BUN1/entry,Involved in control of cellular proliferation. Onconcogenic modifier contributing to the tumor suppressor function of DNMT3B,Plasma. Overexpressed in lymphomas,,,Secreted,22133874,22133874,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
C22orf23,ENSG00000128346,Unsafe,RNA,False,True,92.8,92.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 2.5 nTPM; absolute ceiling; basal ganglia: 2.2 nTPM; absolute ceiling; bone marrow: 3 nTPM; absolute ceiling; cerebral cortex: 7.2 nTPM; absolute ceiling; choroid plexus: 10.8 nTPM; absolute ceiling; duodenum: 2.8 nTPM; absolute ceiling; esophagus: 13.5 nTPM; absolute ceiling; heart muscle: 5 nTPM; absolute ceiling; hippocampal formation: 2.2 nTPM; absolute ceiling; hypothalamus: 2.8 nTPM; absolute ceiling; kidney: 2.2 nTPM; absolute ceiling; lung: 4.8 nTPM; absolute ceiling; pancreas: 8.3 nTPM; absolute ceiling; pituitary gland: 4.7 nTPM; absolute ceiling; retina: 3.4 nTPM; absolute ceiling; salivary gland: 10 nTPM; absolute ceiling; skeletal muscle: 5.5 nTPM; absolute ceiling; skin: 25.2 nTPM; absolute ceiling; small intestine: 3.7 nTPM; absolute ceiling; spinal cord: 2.6 nTPM; absolute ceiling; stomach: 8.7 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 2.5 nTPM (limit 2); basal ganglia: 2.2 nTPM (limit 2); bone marrow: 3 nTPM (limit 2); cerebral cortex: 7.2 nTPM (limit 2); choroid plexus: 10.8 nTPM (limit 2); duodenum: 2.8 nTPM (limit 2); esophagus: 13.5 nTPM (limit 6); heart muscle: 5 nTPM (limit 2); hippocampal formation: 2.2 nTPM (limit 2); hypothalamus: 2.8 nTPM (limit 2); kidney: 2.2 nTPM (limit 2); lung: 4.8 nTPM (limit 2); pancreas: 8.3 nTPM (limit 2); pituitary gland: 4.7 nTPM (limit 2); retina: 3.4 nTPM (limit 2); salivary gland: 10 nTPM (limit 6); skeletal muscle: 5.5 nTPM (limit 2); skin: 25.2 nTPM (limit 10); small intestine: 3.7 nTPM (limit 2); spinal cord: 2.6 nTPM (limit 2); stomach: 8.7 nTPM (limit 6); adrenal gland: 2.5 nTPM (baseline 2); basal ganglia: 2.2 nTPM (baseline 2); bone marrow: 3 nTPM (baseline 2); cerebral cortex: 7.2 nTPM (baseline 2); choroid plexus: 10.8 nTPM (baseline 2); duodenum: 2.8 nTPM (baseline 2); esophagus: 13.5 nTPM (baseline 6); heart muscle: 5 nTPM (baseline 2); hippocampal formation: 2.2 nTPM (baseline 2); hypothalamus: 2.8 nTPM (baseline 2); kidney: 2.2 nTPM (baseline 2); lung: 4.8 nTPM (baseline 2); pancreas: 8.3 nTPM (baseline 2); pituitary gland: 4.7 nTPM (baseline 2); retina: 3.4 nTPM (baseline 2); salivary gland: 10 nTPM (baseline 6); skeletal muscle: 5.5 nTPM (baseline 2); skin: 25.2 nTPM (baseline 10); small intestine: 3.7 nTPM (baseline 2); spinal cord: 2.6 nTPM (baseline 2); stomach: 8.7 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Head and Neck Squamous Cell Carcinoma (TCGA): 469/492 (95.3%); Lung Squamous Cell Carcinoma (validation): 63/68 (92.6%); Glioblastoma Multiforme (TCGA): 128/141 (90.8%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9BZE7,https://www.uniprot.org/uniprotkb/Q9BZE7/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
C22orf42,ENSG00000205856,Unsafe,Protein,False,True,10.3,10.3,84,4,Positive somewhere,True,True,False,True,Excluded,Normal,False,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 0 nTPM; positive ihc; hypothalamus: 9.3 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",hypothalamus: 9.3 nTPM (limit 2),adrenal gland / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Prostate Adenocarcinoma (TCGA): 26/480 (5.4%); Pancreatic Adenocarcinoma (TCGA): 6/176 (3.4%); Testicular Germ Cell Tumor (TCGA): 3/133 (2.3%),colorectal cancer: 1/11 (9.1%); ovarian cancer: 1/11 (9.1%),31,20,Q6IC83,https://www.uniprot.org/uniprotkb/Q6IC83/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Jamin2021_CT | Jamin2021_core | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
C2CD6,ENSG00000155754,Unsafe,High RNA,False,True,38.7,38.7,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,False,False,,False,False,True,CTA,Pass,oncoref.target-sets.2026-10-23.1,False,False,,CTA → Unsafe,True,True,True,3.3288607225,32.2,"hpa_single_cell: /Oligodendrocytes, max 32.1 nTPM, 1 observations >30; hpa_single_cell_tissue: brain/oligodendrocytes, max 32.2 nTPM, 2 observations >30",CTA,oncoref.target-sets.2026-10-23.2,3.329 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,32.2 nTPM; brain/oligodendrocytes; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 40/133 (30.1%); Lung Adenocarcinoma (validation): 17/105 (16.2%); Skin Cuteneous Melanoma (TCGA): 7/99 (7.1%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q53TS8,https://www.uniprot.org/uniprotkb/Q53TS8/entry,"Auxiliary component of the CatSper complex, a complex involved in sperm cell hyperactivation. Sperm cell hyperactivation is needed for sperm motility which is essential late in the preparation of sperm for fertilization. Required for CatSper complex targeting and trafficking into the quadrilinear nanodomains. Targets the preassembled CatSper complexes to elongating flagella, where it links the channel-carrying vesicles and motor proteins",Expressed in testis (at protein level),"Spermatogenic failure 68: An autosomal recessive male infertility disorder characterized by globozoospermia. Affected individuals have a normal sperm count, but spermatozoa are round-headed and lack the acrosome. In addition to pure globozoospermia, some patients have a mixture of acrosomeless spermatozoa and spermatozoa with small or detached acrosomes, which is defined as acrosomal hypoplasia.",,"Cell projection, cilium, flagellum membrane",,34998468,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Loriot2025_S2,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct,,,,All audited maxima are within 10% above 30; other gates still require review,,,,
C4orf46,ENSG00000205208,Unsafe,Protein,False,True,12.4,14.3,79,15,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 2.3 nTPM; absolute ceiling; bone marrow: 14.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 2.3 nTPM; absolute ceiling; cerebral cortex: 2.2 nTPM; positive ihc;absolute ceiling; colon: 3.2 nTPM; positive ihc; duodenum: 2.9 nTPM; absolute ceiling; heart muscle: 3.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; kidney: 1.9 nTPM; positive ihc; lung: 2.5 nTPM; absolute ceiling; lymph node: 5.9 nTPM; positive ihc;continuous selectivity; pancreas: 2.3 nTPM; absolute ceiling; retina: 9.2 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 2 nTPM; positive ihc; skin: 2.8 nTPM; positive ihc; small intestine: 2.7 nTPM; positive ihc;absolute ceiling; smooth muscle: 3.9 nTPM; absolute ceiling;continuous selectivity; spinal cord: 2.7 nTPM; absolute ceiling; spleen: 3.1 nTPM; positive ihc; thymus: 9.9 nTPM; continuous selectivity; tongue: 5.8 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 2.3 nTPM (limit 2); bone marrow: 14.3 nTPM (limit 2); cerebellum: 2.3 nTPM (limit 2); cerebral cortex: 2.2 nTPM (limit 2); duodenum: 2.9 nTPM (limit 2); heart muscle: 3.5 nTPM (limit 2); lung: 2.5 nTPM (limit 2); pancreas: 2.3 nTPM (limit 2); retina: 9.2 nTPM (limit 2); small intestine: 2.7 nTPM (limit 2); smooth muscle: 3.9 nTPM (limit 2); spinal cord: 2.7 nTPM (limit 2); adrenal gland: 2.3 nTPM (baseline 2); bone marrow: 14.3 nTPM (baseline 2); cerebellum: 2.3 nTPM (baseline 2); cerebral cortex: 2.2 nTPM (baseline 2); duodenum: 2.9 nTPM (baseline 2); heart muscle: 3.5 nTPM (baseline 2); lung: 2.5 nTPM (baseline 2); pancreas: 2.3 nTPM (baseline 2); retina: 9.2 nTPM (baseline 2); small intestine: 2.7 nTPM (baseline 2); smooth muscle: 3.9 nTPM (baseline 2); spinal cord: 2.7 nTPM (baseline 2),bronchus / respiratory epithelial cells: Low (Uncertain); cerebral cortex / endothelial cells: Low (Uncertain); colon / glandular cells: Low (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); kidney / cells in tubules: High (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); skeletal muscle / myocytes: Low (Uncertain); skin 2 / epidermal cells: Low (Uncertain); small intestine / glandular cells: Low (Uncertain); spleen / cells in white pulp: Low (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 450/486 (92.6%); Breast Invasive Carcinoma (validation): 45/50 (90.0%),renal cancer: 4/12 (33.3%); breast cancer: 0/12 (0.0%),31,20,Q504U0,https://www.uniprot.org/uniprotkb/Q504U0/entry,,"Expressed in the kidney, in epithelial cells in both proximal tubules and distal convoluted tubules",,,Cytoplasm,,25059753,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
C5orf24,ENSG00000181904,Unsafe,Protein,False,True,28.1,41.9,77,66,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 23.2 nTPM; absolute ceiling;continuous selectivity; adrenal gland: 25.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 19.1 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 22.3 nTPM; absolute ceiling;continuous selectivity; bone marrow: 24.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 35.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 24.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 7.3 nTPM; absolute ceiling;continuous selectivity; colon: 20.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 21.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 20.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 18.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 20.3 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 19.6 nTPM; absolute ceiling;continuous selectivity; kidney: 39.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 41.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 22.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 15.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 18.1 nTPM; absolute ceiling;continuous selectivity; pancreas: 12.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 25.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 15 nTPM; absolute ceiling;continuous selectivity; rectum: 17.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 18.7 nTPM; absolute ceiling;continuous selectivity; salivary gland: 17.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 20.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 18.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 16.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 25.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 28 nTPM; absolute ceiling;continuous selectivity; spleen: 16.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 15.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 14.6 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 28.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; tongue: 25.6 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 21.4 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 23.2 nTPM (limit 20); adrenal gland: 25.1 nTPM (limit 2); amygdala: 19.1 nTPM (limit 2); basal ganglia: 22.3 nTPM (limit 2); bone marrow: 24.7 nTPM (limit 2); cerebellum: 35.8 nTPM (limit 2); cerebral cortex: 24.7 nTPM (limit 2); choroid plexus: 7.3 nTPM (limit 2); colon: 20.5 nTPM (limit 6); duodenum: 21.5 nTPM (limit 2); esophagus: 20.3 nTPM (limit 6); heart muscle: 18.8 nTPM (limit 2); hippocampal formation: 20.3 nTPM (limit 2); hypothalamus: 19.6 nTPM (limit 2); kidney: 39.6 nTPM (limit 2); liver: 41.9 nTPM (limit 2); lung: 22.2 nTPM (limit 2); lymph node: 15.9 nTPM (limit 6); midbrain: 18.1 nTPM (limit 2); pancreas: 12.8 nTPM (limit 2); parathyroid gland: 25.9 nTPM (limit 6); pituitary gland: 15 nTPM (limit 2); rectum: 17.8 nTPM (limit 6); retina: 18.7 nTPM (limit 2); salivary gland: 17.8 nTPM (limit 6); skeletal muscle: 20.7 nTPM (limit 2); skin: 18.6 nTPM (limit 10); small intestine: 16.7 nTPM (limit 2); smooth muscle: 25.7 nTPM (limit 2); spinal cord: 28 nTPM (limit 2); spleen: 16.2 nTPM (limit 10); stomach: 15.7 nTPM (limit 6); thymus: 14.6 nTPM (limit 10); thyroid gland: 28.9 nTPM (limit 10); tongue: 25.6 nTPM (limit 6); urinary bladder: 21.4 nTPM (limit 6),adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: High (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / glial cells: High (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: High (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebral cortex / glial cells: High (Approved); cerebral cortex / neuronal cells: High (Approved); colon / endothelial cells: High (Approved); colon / glandular cells: High (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: High (Approved); heart muscle / cardiomyocytes: High (Approved); hippocampus / glial cells: High (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: High (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: Medium (Approved); liver / hepatocytes: High (Approved); lung / alveolar cells: High (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: High (Approved); pancreas / exocrine glandular cells: High (Approved); pancreas / pancreatic endocrine cells: High (Approved); parathyroid gland / glandular cells: High (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: High (Approved); skeletal muscle / myocytes: High (Approved); skin 1 / fibroblasts: High (Approved); skin 1 / keratinocytes: High (Approved); skin 1 / Langerhans: High (Approved); skin 2 / epidermal cells: High (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: High (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: High (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Stomach Adenocarcinoma (TCGA): 346/346 (100.0%); Colon Adenocarcinoma (TCGA): 254/254 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%),glioma: 12/12 (100.0%); ovarian cancer: 12/12 (100.0%),31,20,Q7Z6I8,https://www.uniprot.org/uniprotkb/Q7Z6I8/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
C5orf34,ENSG00000172244,Unsafe,Protein,False,True,4.0,4.0,86,55,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 0.4 nTPM; positive ihc; bone marrow: 1.1 nTPM; positive ihc; cerebellum: 0.5 nTPM; positive ihc; cerebral cortex: 1.1 nTPM; positive ihc; colon: 1 nTPM; positive ihc; duodenum: 0.6 nTPM; positive ihc; esophagus: 1 nTPM; positive ihc; heart muscle: 0.5 nTPM; positive ihc; kidney: 0.8 nTPM; positive ihc; liver: 0.4 nTPM; positive ihc; lung: 0.6 nTPM; positive ihc; lymph node: 2.7 nTPM; positive ihc;continuous selectivity; pancreas: 0.3 nTPM; positive ihc; parathyroid gland: 0.4 nTPM; positive ihc; rectum: 1.2 nTPM; positive ihc; salivary gland: 1 nTPM; positive ihc; skeletal muscle: 0.4 nTPM; positive ihc; skin: 1.3 nTPM; positive ihc; small intestine: 0.7 nTPM; positive ihc; stomach: 0.7 nTPM; positive ihc; thymus: 3.5 nTPM; continuous selectivity; thyroid gland: 1.1 nTPM; positive ihc; urinary bladder: 1.4 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,adrenal gland / glandular cells: Low (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: High (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Medium (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: High (Approved); skin 1 / fibroblasts: Low (Approved); skin 1 / keratinocytes: Low (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: High (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 55/58 (94.8%); Breast Invasive Carcinoma (validation): 44/50 (88.0%); Lung Squamous Cell Carcinoma (validation): 21/68 (30.9%),breast cancer: 11/11 (100.0%); prostate cancer: 8/11 (72.7%),31,20,Q96MH7,https://www.uniprot.org/uniprotkb/Q96MH7/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | Jamin2021_CT,GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
C5orf58,ENSG00000234511,Unsafe,RNA,False,True,208.8,208.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 6.6 nTPM; absolute ceiling; lung: 4.8 nTPM; absolute ceiling; midbrain: 2.3 nTPM; absolute ceiling; spinal cord: 7.5 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 6.6 nTPM (limit 2); lung: 4.8 nTPM (limit 2); midbrain: 2.3 nTPM (limit 2); spinal cord: 7.5 nTPM (limit 2); bone marrow: 6.6 nTPM (baseline 2); lung: 4.8 nTPM (baseline 2); midbrain: 2.3 nTPM (baseline 2); spinal cord: 7.5 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 65/133 (48.9%); Liver Hepatocellular Carcinoma (validation): 53/231 (22.9%); Breast Invasive Carcinoma (validation): 11/50 (22.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,C9J3I9,https://www.uniprot.org/uniprotkb/C9J3I9/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
C5orf63,ENSG00000164241,Unsafe,RNA,False,True,12.0,12.7,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 2.9 nTPM; absolute ceiling; amygdala: 2.2 nTPM; absolute ceiling; basal ganglia: 2.5 nTPM; absolute ceiling; bone marrow: 3.5 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 4.7 nTPM; absolute ceiling;continuous selectivity; colon: 6.7 nTPM; absolute ceiling;continuous selectivity; duodenum: 5.5 nTPM; absolute ceiling;continuous selectivity; esophagus: 5.4 nTPM; continuous selectivity; heart muscle: 6.5 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 3.1 nTPM; absolute ceiling;continuous selectivity; kidney: 5.9 nTPM; absolute ceiling;continuous selectivity; liver: 5.1 nTPM; absolute ceiling;continuous selectivity; lung: 3.7 nTPM; absolute ceiling;continuous selectivity; lymph node: 8 nTPM; absolute ceiling;continuous selectivity; midbrain: 3.1 nTPM; absolute ceiling;continuous selectivity; pancreas: 5.1 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 5.8 nTPM; continuous selectivity; pituitary gland: 6.7 nTPM; absolute ceiling;continuous selectivity; rectum: 11.5 nTPM; absolute ceiling;continuous selectivity; retina: 12.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 4.4 nTPM; continuous selectivity; skeletal muscle: 4.9 nTPM; absolute ceiling;continuous selectivity; small intestine: 6.1 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 3 nTPM; absolute ceiling; stomach: 7.4 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 8.6 nTPM; continuous selectivity; tongue: 4.6 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 2.9 nTPM (limit 2); amygdala: 2.2 nTPM (limit 2); basal ganglia: 2.5 nTPM (limit 2); bone marrow: 3.5 nTPM (limit 2); choroid plexus: 4.7 nTPM (limit 2); colon: 6.7 nTPM (limit 6); duodenum: 5.5 nTPM (limit 2); heart muscle: 6.5 nTPM (limit 2); hypothalamus: 3.1 nTPM (limit 2); kidney: 5.9 nTPM (limit 2); liver: 5.1 nTPM (limit 2); lung: 3.7 nTPM (limit 2); lymph node: 8 nTPM (limit 6); midbrain: 3.1 nTPM (limit 2); pancreas: 5.1 nTPM (limit 2); pituitary gland: 6.7 nTPM (limit 2); rectum: 11.5 nTPM (limit 6); retina: 12.7 nTPM (limit 2); skeletal muscle: 4.9 nTPM (limit 2); small intestine: 6.1 nTPM (limit 2); smooth muscle: 3 nTPM (limit 2); stomach: 7.4 nTPM (limit 6); adrenal gland: 2.9 nTPM (baseline 2); amygdala: 2.2 nTPM (baseline 2); basal ganglia: 2.5 nTPM (baseline 2); bone marrow: 3.5 nTPM (baseline 2); choroid plexus: 4.7 nTPM (baseline 2); colon: 6.7 nTPM (baseline 6); duodenum: 5.5 nTPM (baseline 2); heart muscle: 6.5 nTPM (baseline 2); hypothalamus: 3.1 nTPM (baseline 2); kidney: 5.9 nTPM (baseline 2); liver: 5.1 nTPM (baseline 2); lung: 3.7 nTPM (baseline 2); lymph node: 8 nTPM (baseline 6); midbrain: 3.1 nTPM (baseline 2); pancreas: 5.1 nTPM (baseline 2); pituitary gland: 6.7 nTPM (baseline 2); rectum: 11.5 nTPM (baseline 6); retina: 12.7 nTPM (baseline 2); skeletal muscle: 4.9 nTPM (baseline 2); small intestine: 6.1 nTPM (baseline 2); smooth muscle: 3 nTPM (baseline 2); stomach: 7.4 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 190/207 (91.8%); Colon Adenocarcinoma (validation): 446/486 (91.8%); Lung Squamous Cell Carcinoma (validation): 58/68 (85.3%),No exact-ID IHC coverage in the HPA cancer snapshot,30,0,A6NC05,https://www.uniprot.org/uniprotkb/A6NC05/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
C6orf52,ENSG00000137434,Unsafe,RNA,False,True,13.3,13.3,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 4.3 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 3.2 nTPM; absolute ceiling; cerebral cortex: 3.3 nTPM; absolute ceiling; choroid plexus: 2.5 nTPM; absolute ceiling; hippocampal formation: 3.7 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 4.3 nTPM; absolute ceiling;continuous selectivity; kidney: 4.3 nTPM; absolute ceiling;continuous selectivity; midbrain: 3.9 nTPM; absolute ceiling;continuous selectivity; pancreas: 2.2 nTPM; absolute ceiling; spinal cord: 3.5 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 4.3 nTPM (limit 2); basal ganglia: 3.2 nTPM (limit 2); cerebral cortex: 3.3 nTPM (limit 2); choroid plexus: 2.5 nTPM (limit 2); hippocampal formation: 3.7 nTPM (limit 2); hypothalamus: 4.3 nTPM (limit 2); kidney: 4.3 nTPM (limit 2); midbrain: 3.9 nTPM (limit 2); pancreas: 2.2 nTPM (limit 2); spinal cord: 3.5 nTPM (limit 2); amygdala: 4.3 nTPM (baseline 2); basal ganglia: 3.2 nTPM (baseline 2); cerebral cortex: 3.3 nTPM (baseline 2); choroid plexus: 2.5 nTPM (baseline 2); hippocampal formation: 3.7 nTPM (baseline 2); hypothalamus: 4.3 nTPM (baseline 2); kidney: 4.3 nTPM (baseline 2); midbrain: 3.9 nTPM (baseline 2); pancreas: 2.2 nTPM (baseline 2); spinal cord: 3.5 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 41/50 (82.0%); Glioblastoma Multiforme (validation): 42/58 (72.4%); Ovary Serous Cystadenocarcinoma (TCGA): 106/349 (30.4%),breast cancer: 8/11 (72.7%); testis cancer: 8/11 (72.7%),31,20,Q5T4I8,https://www.uniprot.org/uniprotkb/Q5T4I8/entry,,,,,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
C7orf25,ENSG00000136197,Unsafe,Protein,False,True,3.2,3.2,78,69,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 1.5 nTPM; positive ihc;continuous selectivity; adrenal gland: 1.3 nTPM; positive ihc;continuous selectivity; amygdala: 1.8 nTPM; continuous selectivity; basal ganglia: 1.6 nTPM; continuous selectivity; bone marrow: 0.6 nTPM; positive ihc; cerebellum: 1.7 nTPM; positive ihc;continuous selectivity; cerebral cortex: 2 nTPM; positive ihc;continuous selectivity; choroid plexus: 1.7 nTPM; continuous selectivity; colon: 1.6 nTPM; positive ihc;continuous selectivity; duodenum: 0.3 nTPM; positive ihc; esophagus: 1.6 nTPM; positive ihc;continuous selectivity; heart muscle: 2 nTPM; positive ihc;continuous selectivity; hippocampal formation: 1.7 nTPM; continuous selectivity; hypothalamus: 2.1 nTPM; absolute ceiling;continuous selectivity; kidney: 2.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 1.4 nTPM; positive ihc;continuous selectivity; lung: 1.4 nTPM; positive ihc;continuous selectivity; lymph node: 1.6 nTPM; positive ihc;continuous selectivity; midbrain: 2.2 nTPM; absolute ceiling;continuous selectivity; pancreas: 1.6 nTPM; positive ihc;continuous selectivity; parathyroid gland: 2.7 nTPM; positive ihc;continuous selectivity; pituitary gland: 1.4 nTPM; continuous selectivity; rectum: 0.9 nTPM; positive ihc; retina: 1.5 nTPM; continuous selectivity; salivary gland: 1.5 nTPM; positive ihc;continuous selectivity; skeletal muscle: 1.6 nTPM; positive ihc;continuous selectivity; skin: 1.1 nTPM; positive ihc; small intestine: 1.2 nTPM; positive ihc;continuous selectivity; smooth muscle: 1.7 nTPM; continuous selectivity; spinal cord: 2.2 nTPM; absolute ceiling;continuous selectivity; spleen: 1.7 nTPM; positive ihc;continuous selectivity; stomach: 1.8 nTPM; positive ihc;continuous selectivity; thymus: 1.5 nTPM; continuous selectivity; thyroid gland: 2.7 nTPM; positive ihc;continuous selectivity; tongue: 1.9 nTPM; continuous selectivity; urinary bladder: 1.1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",hypothalamus: 2.1 nTPM (limit 2); kidney: 2.4 nTPM (limit 2); midbrain: 2.2 nTPM (limit 2); spinal cord: 2.2 nTPM (limit 2),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); colon / endothelial cells: High (Approved); colon / glandular cells: High (Approved); duodenum / glandular cells: Low (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: High (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: High (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: High (Approved); nasopharynx / respiratory epithelial cells: High (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: High (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: High (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: High (Approved); small intestine / glandular cells: High (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: High (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 50/50 (100.0%); Liver Hepatocellular Carcinoma (validation): 223/231 (96.5%); Glioblastoma Multiforme (validation): 23/58 (39.7%),lymphoma: 11/12 (91.7%); skin cancer: 10/11 (90.9%),31,20,Q9BPX7,https://www.uniprot.org/uniprotkb/Q9BPX7/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
C7orf57,ENSG00000164746,Unsafe,Protein,False,True,13.4,13.4,95,12,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; choroid plexus: 7.6 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 7.6 nTPM (limit 2),bronchus / ciliated cells (cell body): Low (Enhanced); bronchus / ciliated cells (cilia axoneme): High (Enhanced); bronchus / ciliated cells (tip of cilia): High (Enhanced); caudate / glial cells: Medium (Enhanced); nasopharynx / ciliated cells (cell body): Low (Enhanced); nasopharynx / ciliated cells (cilia axoneme): Medium (Enhanced); nasopharynx / ciliated cells (tip of cilia): Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 23/58 (39.7%); Kidney Chromophobe (TCGA): 21/64 (32.8%); Testicular Germ Cell Tumor (TCGA): 31/133 (23.3%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q8NEG2,https://www.uniprot.org/uniprotkb/Q8NEG2/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
C9orf153,ENSG00000187753,Unsafe,RNA,False,True,20.0,20.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 2.4 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 2.4 nTPM (limit 2); bone marrow: 2.4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 16/207 (7.7%); Uterine Corpus Endometrial Carcinoma (TCGA): 6/176 (3.4%); Colon Adenocarcinoma (validation): 15/486 (3.1%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q5TBE3,https://www.uniprot.org/uniprotkb/Q5TBE3/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,Failed bulk numeric comparisons are within 20% of their cutoffs; not an automatic rescue,,,,
C9orf85,ENSG00000155621,Unsafe,Protein,False,True,10.5,11.2,94,52,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 7.3 nTPM; continuous selectivity; adrenal gland: 6.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 7 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 7.1 nTPM; absolute ceiling;continuous selectivity; bone marrow: 5.8 nTPM; absolute ceiling;continuous selectivity; cerebellum: 3.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 5.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 3.6 nTPM; absolute ceiling;continuous selectivity; colon: 7.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 11.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 9.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 5.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 7.3 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 6.8 nTPM; absolute ceiling;continuous selectivity; kidney: 6.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 7.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 4.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 8.3 nTPM; absolute ceiling;continuous selectivity; midbrain: 8 nTPM; absolute ceiling;continuous selectivity; pancreas: 7.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 4.7 nTPM; positive ihc;continuous selectivity; pituitary gland: 5.8 nTPM; absolute ceiling;continuous selectivity; rectum: 7.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 6 nTPM; absolute ceiling;continuous selectivity; salivary gland: 8.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 8.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 10.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 7.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 6 nTPM; absolute ceiling;continuous selectivity; spinal cord: 10.2 nTPM; absolute ceiling;continuous selectivity; spleen: 6.3 nTPM; continuous selectivity; stomach: 6.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 8.2 nTPM; continuous selectivity; thyroid gland: 8.2 nTPM; positive ihc;continuous selectivity; tongue: 7.9 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 9.3 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 6.4 nTPM (limit 2); amygdala: 7 nTPM (limit 2); basal ganglia: 7.1 nTPM (limit 2); bone marrow: 5.8 nTPM (limit 4); cerebellum: 3.4 nTPM (limit 2); cerebral cortex: 5.9 nTPM (limit 2); choroid plexus: 3.6 nTPM (limit 2); colon: 7.4 nTPM (limit 6); duodenum: 11.2 nTPM (limit 2); esophagus: 9.6 nTPM (limit 6); heart muscle: 5.9 nTPM (limit 2); hippocampal formation: 7.3 nTPM (limit 2); hypothalamus: 6.8 nTPM (limit 2); kidney: 6.7 nTPM (limit 2); liver: 7.5 nTPM (limit 2); lung: 4.9 nTPM (limit 2); lymph node: 8.3 nTPM (limit 8); midbrain: 8 nTPM (limit 2); pancreas: 7.6 nTPM (limit 2); pituitary gland: 5.8 nTPM (limit 2); rectum: 7.2 nTPM (limit 6); retina: 6 nTPM (limit 2); salivary gland: 8.5 nTPM (limit 6); skeletal muscle: 8.3 nTPM (limit 2); skin: 10.7 nTPM (limit 10); small intestine: 7.9 nTPM (limit 2); smooth muscle: 6 nTPM (limit 4); spinal cord: 10.2 nTPM (limit 2); stomach: 6.6 nTPM (limit 6); tongue: 7.9 nTPM (limit 6); urinary bladder: 9.3 nTPM (limit 6),adrenal gland / glandular cells: Low (Approved); bronchus / ciliated cells (cell body): Low (Approved); caudate / glial cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Medium (Approved); colon / glandular cells: High (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: High (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells type II: High (Approved); lung / macrophages: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: High (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Low (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: High (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: High (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (TCGA): 254/254 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%),stomach cancer: 12/12 (100.0%); colorectal cancer: 11/12 (91.7%),31,20,Q96MD7,https://www.uniprot.org/uniprotkb/Q96MD7/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CABLES2,ENSG00000149679,Unsafe,RNA,False,True,30.2,30.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 2.9 nTPM; absolute ceiling; amygdala: 4.2 nTPM; absolute ceiling; basal ganglia: 3.9 nTPM; absolute ceiling; bone marrow: 8 nTPM; absolute ceiling;continuous selectivity; cerebellum: 13.8 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 8.6 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 2.1 nTPM; absolute ceiling; duodenum: 2.8 nTPM; absolute ceiling; heart muscle: 10.2 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 4.1 nTPM; absolute ceiling; hypothalamus: 5.1 nTPM; absolute ceiling; kidney: 2.5 nTPM; absolute ceiling; liver: 3.9 nTPM; absolute ceiling; lung: 2.8 nTPM; absolute ceiling; midbrain: 3.7 nTPM; absolute ceiling; pancreas: 3.1 nTPM; absolute ceiling; pituitary gland: 5.7 nTPM; absolute ceiling; retina: 5.5 nTPM; absolute ceiling; skeletal muscle: 5.6 nTPM; absolute ceiling; small intestine: 4.3 nTPM; absolute ceiling; smooth muscle: 3.2 nTPM; absolute ceiling; spinal cord: 3.5 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 2.9 nTPM (limit 2); amygdala: 4.2 nTPM (limit 2); basal ganglia: 3.9 nTPM (limit 2); bone marrow: 8 nTPM (limit 2); cerebellum: 13.8 nTPM (limit 2); cerebral cortex: 8.6 nTPM (limit 2); choroid plexus: 2.1 nTPM (limit 2); duodenum: 2.8 nTPM (limit 2); heart muscle: 10.2 nTPM (limit 2); hippocampal formation: 4.1 nTPM (limit 2); hypothalamus: 5.1 nTPM (limit 2); kidney: 2.5 nTPM (limit 2); liver: 3.9 nTPM (limit 2); lung: 2.8 nTPM (limit 2); midbrain: 3.7 nTPM (limit 2); pancreas: 3.1 nTPM (limit 2); pituitary gland: 5.7 nTPM (limit 2); retina: 5.5 nTPM (limit 2); skeletal muscle: 5.6 nTPM (limit 2); small intestine: 4.3 nTPM (limit 2); smooth muscle: 3.2 nTPM (limit 2); spinal cord: 3.5 nTPM (limit 2); adrenal gland: 2.9 nTPM (baseline 2); amygdala: 4.2 nTPM (baseline 2); basal ganglia: 3.9 nTPM (baseline 2); bone marrow: 8 nTPM (baseline 2); cerebellum: 13.8 nTPM (baseline 2); cerebral cortex: 8.6 nTPM (baseline 2); choroid plexus: 2.1 nTPM (baseline 2); duodenum: 2.8 nTPM (baseline 2); heart muscle: 10.2 nTPM (baseline 2); hippocampal formation: 4.1 nTPM (baseline 2); hypothalamus: 5.1 nTPM (baseline 2); kidney: 2.5 nTPM (baseline 2); liver: 3.9 nTPM (baseline 2); lung: 2.8 nTPM (baseline 2); midbrain: 3.7 nTPM (baseline 2); pancreas: 3.1 nTPM (baseline 2); pituitary gland: 5.7 nTPM (baseline 2); retina: 5.5 nTPM (baseline 2); skeletal muscle: 5.6 nTPM (baseline 2); small intestine: 4.3 nTPM (baseline 2); smooth muscle: 3.2 nTPM (baseline 2); spinal cord: 3.5 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 476/486 (97.9%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9BTV7,https://www.uniprot.org/uniprotkb/Q9BTV7/entry,Unknown. Probably involved in G1-S cell cycle transition,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CABP2,ENSG00000167791,Unsafe,RNA,False,True,0.0,7.1,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,existing nomination or manual review; insufficient positive reproductive evidence; nomination unresolved; reproductive expression not demonstrated; incomplete tissue evidence,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 7.1 nTPM (limit 2); retina: 7.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9NPB3,https://www.uniprot.org/uniprotkb/Q9NPB3/entry,"Required for sound encoding at inner hair cells (IHCs) synapses, likely via inhibition of the inactivation of voltage-gated calcium channel of type 1.3 (Cav1.3) in the IHCs (PubMed:28183797). Required for the normal transfer of light signals through the retina (By similarity)",Retina,"Deafness, autosomal recessive, 93: A form of non-syndromic deafness characterized by stable, bilateral, symmetric, prelingual moderate to severe deafness. Hearing impairment is slightly more pronounced in the mid-frequencies, resulting in a distinctive shallow U-shaped audiogram.",,"Cytoplasm, perinuclear region Cell membrane Golgi apparatus",28183797,11108966,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
CABYR,ENSG00000154040,Unsafe,RNA,False,True,295.1,295.1,86,2,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,amygdala: 5.1 nTPM; absolute ceiling; basal ganglia: 3 nTPM; absolute ceiling; choroid plexus: 12.7 nTPM; absolute ceiling; hippocampal formation: 7 nTPM; absolute ceiling; hypothalamus: 5.3 nTPM; absolute ceiling; midbrain: 5.2 nTPM; absolute ceiling; pituitary gland: 8 nTPM; absolute ceiling; retina: 5.4 nTPM; absolute ceiling; spinal cord: 6.7 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 5.1 nTPM (limit 2); basal ganglia: 3 nTPM (limit 2); choroid plexus: 12.7 nTPM (limit 2); hippocampal formation: 7 nTPM (limit 2); hypothalamus: 5.3 nTPM (limit 2); midbrain: 5.2 nTPM (limit 2); pituitary gland: 8 nTPM (limit 2); retina: 5.4 nTPM (limit 2); spinal cord: 6.7 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 47/50 (94.0%); Testicular Germ Cell Tumor (TCGA): 124/133 (93.2%); Breast Invasive Carcinoma (TCGA): 843/1022 (82.5%),breast cancer: 0/12 (0.0%); cervical cancer: 0/11 (0.0%),31,20,O75952,https://www.uniprot.org/uniprotkb/O75952/entry,May function as a regulator of both motility- and head-associated functions such as capacitation and the acrosome reaction. Isoform 1 binds calcium in vitro. Isoform 2 and isoform 6 probably bind calcium. Isoform 3 and isoform 5 do not bind calcium in vitro. Isoform 4 probably does not bind calcium,"Expressed in elongating spermatids and spermatozoa (at protein level). Isoform 1 is expressed in testis. Isoform 3 and isoform 5 are also expressed in brain, pancreas and numerous brain tumors",,,"Cytoplasm, cytoskeleton Cell projection, cilium, flagellum Nucleus Cytoplasm",,11820818|15752768|16139264,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
CACNA2D3,ENSG00000157445,Unsafe,RNA,False,True,1.6,16.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 3.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 16.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 2.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 16 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 2.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 7.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 6.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 1.2 nTPM; continuous selectivity; lung: 0.5 nTPM; continuous selectivity; midbrain: 2.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 0.8 nTPM; continuous selectivity; retina: 2.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 9.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 0.6 nTPM; continuous selectivity; spinal cord: 1 nTPM; continuous selectivity; tongue: 10.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 4 nTPM (limit 2); amygdala: 3.2 nTPM (limit 2); basal ganglia: 16.2 nTPM (limit 2); cerebellum: 2.2 nTPM (limit 2); cerebral cortex: 16 nTPM (limit 2); heart muscle: 2.5 nTPM (limit 2); hippocampal formation: 7.6 nTPM (limit 2); hypothalamus: 6.8 nTPM (limit 2); midbrain: 2.3 nTPM (limit 2); retina: 2.8 nTPM (limit 2); skeletal muscle: 9.5 nTPM (limit 2); tongue: 10.3 nTPM (limit 6); adrenal gland: 4 nTPM (baseline 2); amygdala: 3.2 nTPM (baseline 2); basal ganglia: 16.2 nTPM (baseline 2); cerebellum: 2.2 nTPM (baseline 2); cerebral cortex: 16 nTPM (baseline 2); heart muscle: 2.5 nTPM (baseline 2); hippocampal formation: 7.6 nTPM (baseline 2); hypothalamus: 6.8 nTPM (baseline 2); midbrain: 2.3 nTPM (baseline 2); retina: 2.8 nTPM (baseline 2); skeletal muscle: 9.5 nTPM (baseline 2); tongue: 10.3 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 24/58 (41.4%); Ovary Serous Cystadenocarcinoma (validation): 10/81 (12.3%); Testicular Germ Cell Tumor (TCGA): 8/133 (6.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8IZS8,https://www.uniprot.org/uniprotkb/Q8IZS8/entry,"The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-type calcium channel (CACNA1A), N-type (CACNA1B), L-type (CACNA1C OR CACNA1D) but not T-type (CACNA1G) (By similarity)","Only detected in brain. Not present in lung, testis, aorta, spleen, jejunum, ventricular muscle and kidney (at protein level). According to PubMed:11687876, it is brain-specific, while according to PubMed:11245980, it is widely expressed",,,Membrane,,11687876,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
CACNA2D4,ENSG00000151062,Unsafe,RNA,False,True,0.3,19.5,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 0.3 nTPM; continuous selectivity;reproductive not higher; duodenum: 0.3 nTPM; continuous selectivity;reproductive not higher; lung: 0.2 nTPM; continuous selectivity; pituitary gland: 0.2 nTPM; continuous selectivity; retina: 19.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 0.2 nTPM; continuous selectivity; spleen: 0.3 nTPM; continuous selectivity;reproductive not higher; tongue: 0.4 nTPM; continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 19.5 nTPM (limit 2); retina: 19.5 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 43/50 (86.0%); Pancreatic Adenocarcinoma (validation): 34/80 (42.5%); Glioblastoma Multiforme (validation): 6/58 (10.3%),colorectal cancer: 11/12 (91.7%); endometrial cancer: 10/12 (83.3%),31,20,Q7Z3S7,https://www.uniprot.org/uniprotkb/Q7Z3S7/entry,The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel,"Predominantly expressed in certain types of endocrine cells. Present in the Paneth cells of the small intestine. Also present in the erythroblasts in the fetal liver, in the cells of the zona reticularis of the adrenal gland and in the basophils of the pituitary. Present at low level in some brain regions such as the cerebellum (at protein level)",Retinal cone dystrophy 4: Characterized by minimal symptoms except for slowly progressive reduction in visual acuity.,,Membrane,12181424,12181424,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CALHM4,ENSG00000164451,Unsafe,RNA,False,True,22.5,22.5,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,choroid plexus: 3.2 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 3.2 nTPM (limit 2); choroid plexus: 3.2 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Ovary Serous Cystadenocarcinoma (TCGA): 2/349 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Thyroid Carcinoma (TCGA): 2/495 (0.4%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q5JW98,https://www.uniprot.org/uniprotkb/Q5JW98/entry,May assemble to form gap junction channel-like structures involved in intercellular communication. Channel gating and ion conductance are likely regulated by membrane lipids rather than by membrane depolarization or extracellular calcium levels,Placenta,,,Cell membrane,32374262,32374262,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
CALN1,ENSG00000183166,Unsafe,Protein,False,True,3.1,56.6,79,48,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 10.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 8.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 17.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 0.6 nTPM; positive ihc; cerebellum: 56.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 26.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; colon: 0 nTPM; positive ihc; heart muscle: 0 nTPM; positive ihc; hippocampal formation: 11.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 7.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 0 nTPM; positive ihc; lung: 0 nTPM; positive ihc; midbrain: 11.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 0.9 nTPM; continuous selectivity; rectum: 0.1 nTPM; positive ihc; retina: 1.8 nTPM; continuous selectivity; skeletal muscle: 0 nTPM; positive ihc; skin: 3.3 nTPM; positive ihc;continuous selectivity;reproductive not higher; small intestine: 0 nTPM; positive ihc; smooth muscle: 0 nTPM; positive ihc; spinal cord: 17.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 0 nTPM; positive ihc; stomach: 0 nTPM; positive ihc; thymus: 24.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 0.1 nTPM; positive ihc; urinary bladder: 0 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 10.9 nTPM (limit 2); amygdala: 8.4 nTPM (limit 2); basal ganglia: 17.9 nTPM (limit 2); cerebellum: 56.6 nTPM (limit 2); cerebral cortex: 26.4 nTPM (limit 2); hippocampal formation: 11.7 nTPM (limit 2); hypothalamus: 7.8 nTPM (limit 2); midbrain: 11.2 nTPM (limit 2); spinal cord: 17.3 nTPM (limit 2); thymus: 24.1 nTPM (limit 10),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Low (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Low (Approved); colon / peripheral nerve/ganglion: Low (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Low (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Low (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); rectum / glandular cells: Low (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / keratinocytes: Low (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Low (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Low (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Low (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 13/58 (22.4%); Testicular Germ Cell Tumor (TCGA): 12/133 (9.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 12/176 (6.8%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q9BXU9,https://www.uniprot.org/uniprotkb/Q9BXU9/entry,Negatively regulates Golgi-to-plasma membrane trafficking by interacting with PI4KB and inhibiting its activity. May play a role in the physiology of neurons and is potentially important in memory and learning,Brain specific,,,"Golgi apparatus, trans-Golgi network membrane Cytoplasm, perinuclear region Cell membrane",,11286509,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
CAMK4,ENSG00000152495,Unsafe,Protein,False,True,9.1,54.0,87,34,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 3.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 5.4 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 17.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 3.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 53.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 9.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; colon: 1.3 nTPM; positive ihc; duodenum: 1.3 nTPM; positive ihc; hippocampal formation: 5 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 3 nTPM; absolute ceiling;continuous selectivity; kidney: 0.6 nTPM; positive ihc; liver: 1.4 nTPM; positive ihc; lung: 1 nTPM; positive ihc; lymph node: 7.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; rectum: 1.3 nTPM; positive ihc; retina: 4.6 nTPM; absolute ceiling;continuous selectivity; small intestine: 2.3 nTPM; positive ihc;absolute ceiling; stomach: 1.5 nTPM; positive ihc; thymus: 54 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 1.7 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 3.7 nTPM (limit 2); amygdala: 5.4 nTPM (limit 2); basal ganglia: 17.1 nTPM (limit 2); bone marrow: 3.1 nTPM (limit 2); cerebellum: 53.5 nTPM (limit 2); cerebral cortex: 9.9 nTPM (limit 2); hippocampal formation: 5 nTPM (limit 2); hypothalamus: 3 nTPM (limit 2); lymph node: 7.9 nTPM (limit 6); retina: 4.6 nTPM (limit 2); small intestine: 2.3 nTPM (limit 2); thymus: 54 nTPM (limit 10),adrenal gland / glandular cells: Low (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Low (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: High (Approved); cerebellum / cells in granular layer: High (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: High (Approved); cerebral cortex / neuropil: Low (Approved); colon / glandular cells: Low (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Low (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: High (Approved); kidney / cells in tubules: Low (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Low (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); rectum / glandular cells: Low (Approved); small intestine / glandular cells: Low (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Low (Approved); urinary bladder / urothelial cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 31/58 (53.4%); Breast Invasive Carcinoma (validation): 18/50 (36.0%); Pancreatic Adenocarcinoma (validation): 28/80 (35.0%),lymphoma: 5/12 (41.7%); liver cancer: 3/11 (27.3%),31,20,Q16566,https://www.uniprot.org/uniprotkb/Q16566/entry,"Calcium/calmodulin-dependent protein kinase that operates in the calcium-triggered CaMKK-CaMK4 signaling cascade and regulates, mainly by phosphorylation, the activity of several transcription activators, such as CREB1, MEF2D, JUN and RORA, which play pivotal roles in immune response, inflammation, and memory consolidation. In the thymus, regulates the CD4(+)/CD8(+) double positive thymocytes selection threshold during T-cell ontogeny. In CD4 memory T-cells, is required to link T-cell antigen receptor (TCR) signaling to the production of IL2, IFNG and IL4 (through the regulation of CREB and MEF2). Regulates the differentiation and survival phases of osteoclasts and dendritic cells (DCs). Mediates DCs survival by linking TLR4 and the regulation of temporal expression of BCL2. Phosphorylates the transcription activator CREB1 on 'Ser-133' in hippocampal neuron nuclei and contribute to memory consolidation and long term potentiation (LTP) in the hippocampus. Can activate the MAP kinases MAPK1/ERK2, MAPK8/JNK1 and MAPK14/p38 and stimulate transcription through the phosphorylation of ELK1 and ATF2. Can also phosphorylate in vitro CREBBP, PRM2, MEF2A and STMN1/OP18","Expressed in brain, thymus, CD4 T-cells, testis and epithelial ovarian cancer tissue",,,Cytoplasm Nucleus,10617605|17909078|18829949|7961813|8065343|8855261|8980227|9154845,12065094|7961813|8397199,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
CAPN6,ENSG00000077274,Unsafe,RNA,False,True,207.7,207.7,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,kidney: 11.2 nTPM; absolute ceiling; pancreas: 7.2 nTPM; absolute ceiling; rectum: 8.3 nTPM; absolute ceiling; salivary gland: 13.7 nTPM; absolute ceiling; skeletal muscle: 2.9 nTPM; absolute ceiling; smooth muscle: 7.9 nTPM; absolute ceiling; stomach: 12.6 nTPM; absolute ceiling; tongue: 8.6 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,kidney: 11.2 nTPM (limit 2); pancreas: 7.2 nTPM (limit 2); rectum: 8.3 nTPM (limit 6); salivary gland: 13.7 nTPM (limit 6); skeletal muscle: 2.9 nTPM (limit 2); smooth muscle: 7.9 nTPM (limit 2); stomach: 12.6 nTPM (limit 6); tongue: 8.6 nTPM (limit 6); kidney: 11.2 nTPM (baseline 2); pancreas: 7.2 nTPM (baseline 2); rectum: 8.3 nTPM (baseline 6); salivary gland: 13.7 nTPM (baseline 6); skeletal muscle: 2.9 nTPM (baseline 2); smooth muscle: 7.9 nTPM (baseline 2); stomach: 12.6 nTPM (baseline 6); tongue: 8.6 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 30/50 (60.0%); Pancreatic Adenocarcinoma (TCGA): 100/176 (56.8%); Kidney Renal Papillary Cell Carcinoma (TCGA): 142/282 (50.4%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9Y6Q1,https://www.uniprot.org/uniprotkb/Q9Y6Q1/entry,Microtubule-stabilizing protein that may be involved in the regulation of microtubule dynamics and cytoskeletal organization. May act as a regulator of RAC1 activity through interaction with ARHGEF2 to control lamellipodial formation and cell mobility. Does not seem to have protease activity as it has lost the active site residues (By similarity),Expressed only in placenta,,,"Cytoplasm, perinuclear region Cytoplasm, cytoskeleton, spindle",17210638,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Bradley2020_CPA | Gong2021_reproductive_PC,No tumor-antigen validation in this source | Expression-nominated CPA; not newly validated by this study | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
CAPSL,ENSG00000152611,Unsafe,Protein,False,True,107.2,107.2,108,15,Positive somewhere,True,True,False,True,Excluded,Normal,False,,Not assessed,,,positive ihc outside permitted; amygdala: 4.4 nTPM; absolute ceiling; basal ganglia: 6.1 nTPM; absolute ceiling; choroid plexus: 88.5 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 7.1 nTPM; absolute ceiling; hypothalamus: 7.4 nTPM; absolute ceiling; pituitary gland: 13.2 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 4.4 nTPM (limit 2); basal ganglia: 6.1 nTPM (limit 2); choroid plexus: 88.5 nTPM (limit 2); hippocampal formation: 7.1 nTPM (limit 2); hypothalamus: 7.4 nTPM (limit 2); pituitary gland: 13.2 nTPM (limit 2),bronchus / ciliated cells (cell body): Medium (Enhanced); bronchus / ciliated cells (cilia axoneme): Medium (Enhanced); bronchus / ciliated cells (ciliary rootlets): Low (Enhanced); bronchus / ciliated cells (tip of cilia): High (Enhanced); nasopharynx / ciliated cells (cell body): Medium (Enhanced); nasopharynx / ciliated cells (ciliary rootlets): High (Enhanced); nasopharynx / ciliated cells (tip of cilia): Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 75/176 (42.6%); Breast Invasive Carcinoma (validation): 17/50 (34.0%); Ovary Serous Cystadenocarcinoma (validation): 22/81 (27.2%),melanoma: 6/11 (54.5%); stomach cancer: 5/11 (45.5%),31,20,Q8WWF8,https://www.uniprot.org/uniprotkb/Q8WWF8/entry,,,,,Cytoplasm,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
CARF,ENSG00000138380,Unsafe,Protein,False,True,20.9,20.9,78,75,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 4.3 nTPM; positive ihc; adrenal gland: 5.1 nTPM; positive ihc;absolute ceiling; amygdala: 3.8 nTPM; absolute ceiling; basal ganglia: 3.7 nTPM; absolute ceiling; bone marrow: 5.3 nTPM; positive ihc;absolute ceiling; cerebellum: 4.6 nTPM; positive ihc;absolute ceiling; cerebral cortex: 7.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 5 nTPM; absolute ceiling; colon: 5.1 nTPM; positive ihc; duodenum: 4.4 nTPM; positive ihc;absolute ceiling; esophagus: 5.3 nTPM; positive ihc; heart muscle: 4.8 nTPM; positive ihc;absolute ceiling; hippocampal formation: 4.3 nTPM; absolute ceiling; hypothalamus: 3.7 nTPM; absolute ceiling; kidney: 6.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 4.3 nTPM; positive ihc;absolute ceiling; lung: 4.9 nTPM; positive ihc;absolute ceiling; lymph node: 8.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 4.8 nTPM; absolute ceiling; pancreas: 3.8 nTPM; positive ihc;absolute ceiling; parathyroid gland: 7.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 5 nTPM; absolute ceiling; rectum: 5.8 nTPM; positive ihc; retina: 15.6 nTPM; absolute ceiling;continuous selectivity; salivary gland: 4.5 nTPM; positive ihc; skeletal muscle: 4.3 nTPM; positive ihc;absolute ceiling; skin: 7.1 nTPM; positive ihc; small intestine: 4.8 nTPM; positive ihc;absolute ceiling; smooth muscle: 6.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 7.1 nTPM; absolute ceiling;continuous selectivity; spleen: 7.3 nTPM; positive ihc; stomach: 5.8 nTPM; positive ihc; thymus: 9.2 nTPM; continuous selectivity; thyroid gland: 10.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; urinary bladder: 5.5 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 5.1 nTPM (limit 2); amygdala: 3.8 nTPM (limit 2); basal ganglia: 3.7 nTPM (limit 2); bone marrow: 5.3 nTPM (limit 2); cerebellum: 4.6 nTPM (limit 2); cerebral cortex: 7.3 nTPM (limit 2); choroid plexus: 5 nTPM (limit 2); duodenum: 4.4 nTPM (limit 2); heart muscle: 4.8 nTPM (limit 2); hippocampal formation: 4.3 nTPM (limit 2); hypothalamus: 3.7 nTPM (limit 2); kidney: 6.5 nTPM (limit 2); liver: 4.3 nTPM (limit 2); lung: 4.9 nTPM (limit 2); lymph node: 8.6 nTPM (limit 6); midbrain: 4.8 nTPM (limit 2); pancreas: 3.8 nTPM (limit 2); parathyroid gland: 7.6 nTPM (limit 6); pituitary gland: 5 nTPM (limit 2); retina: 15.6 nTPM (limit 2); skeletal muscle: 4.3 nTPM (limit 2); small intestine: 4.8 nTPM (limit 2); smooth muscle: 6.4 nTPM (limit 2); spinal cord: 7.1 nTPM (limit 2); thyroid gland: 10.3 nTPM (limit 10),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: High (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: High (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: High (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: High (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Rectum Adenocarcinoma (validation): 206/207 (99.5%); Colon Adenocarcinoma (validation): 475/486 (97.7%),breast cancer: 12/12 (100.0%); skin cancer: 12/12 (100.0%),29,20,Q8N187,https://www.uniprot.org/uniprotkb/Q8N187/entry,Acts as a transcriptional activator that mediates the calcium- and neuron-selective induction of BDNF exon III transcription. Binds to the consensus calcium-response element CaRE1 5'-CTATTTCGAG-3' sequence,,,,Nucleus,11832226|22174809,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
CATSPER1,ENSG00000175294,Unsafe,High RNA,False,True,16.8,16.8,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,True,"lung/granulocytes cluster c-14: 101.8 nTPM, 202 reads; reproductive-cell max 101.3",True,True,"DICE MONOCYTES (unstimulated): 91/91 values ≥5 TPM, max 24.1483; DICE NK (unstimulated): 89/90 values ≥5 TPM, max 32.8059; hpa_immune_cell basophil: 16.9 nTPM; hpa_immune_cell classical monocyte: 5.8 nTPM",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,32.8059173157,101.8,"dice_nk: blood/NK, max 32.8059 TPM, 1 observations >30; hpa_single_cell: /granulocytes, max 56.1 nTPM, 1 observations >30; hpa_single_cell_tissue: adipose tissue/macrophages, max 30.9 nTPM, 1 observations >30; hpa_single_cell_tissue: fallopian tube/granulocytes, max 42.1 nTPM, 1 observations >30; hpa_single_cell_tissue: kidney/macrophages, max 30.1 nTPM, 1 observations >30; hpa_single_cell_tissue: liver/kupffer cells, max 37.2 nTPM, 1 observations >30; hpa_single_cell_tissue: liver/t-cells, max 49.3 nTPM, 1 observations >30; hpa_single_cell_tissue: lung/granulocytes, max 101.8 nTPM, 1 observations >30; hpa_single_cell_tissue: lung/macrophages, max 54 nTPM, 3 observations >30; hpa_single_cell_tissue: pbmc/macrophages, max 60.9 nTPM, 1 observations >30; hpa_single_cell_tissue: pbmc/nk-cells, max 36.7 nTPM, 1 observations >30; hpa_single_cell_tissue: pbmc/platelets, max 66.6 nTPM, 1 observations >30; hpa_single_cell_tissue: skeletal muscle/macrophages, max 38.2 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,32.81 TPM; blood/NK; dice_nk; vital,101.8 nTPM; lung/granulocytes; hpa_single_cell_tissue; vital,Pancreatic Adenocarcinoma (validation): 12/80 (15.0%); Breast Invasive Carcinoma (validation): 1/50 (2.0%); Lung Adenocarcinoma (validation): 2/105 (1.9%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NEC5,https://www.uniprot.org/uniprotkb/Q8NEC5/entry,"Pore-forming subunit of the CatSper complex, a sperm-specific voltage-gated calcium channel that plays a central role in calcium-dependent physiological responses essential for successful fertilization, such as sperm hyperactivation, acrosome reaction and chemotaxis towards the oocyte",Testis-specific,"Spermatogenic failure 7: An infertility disorder characterized by non-motile sperm or sperm motility below the normal threshold, low sperm count, increased abnormally structured spermatozoa, and reduced semen volume.","In mouse, Slco6c1 is an additional auxiliary subunit of the CatSper complex. It is unclear if the related SLCO6A1 protein performs the same role in non-rodent species","Cell projection, cilium, flagellum membrane",21412338|21412339,11595941|16625279|17347248,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CATSPER3,ENSG00000152705,Unsafe,RNA,False,True,28.8,28.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,retina: 2.6 nTPM; absolute ceiling; skeletal muscle: 2.9 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 2.6 nTPM (limit 2); skeletal muscle: 2.9 nTPM (limit 2); retina: 2.6 nTPM (baseline 2); skeletal muscle: 2.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 27/50 (54.0%); Testicular Germ Cell Tumor (TCGA): 13/133 (9.8%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 8/283 (2.8%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q86XQ3,https://www.uniprot.org/uniprotkb/Q86XQ3/entry,"Pore-forming subunit of the CatSper complex, a sperm-specific voltage-gated calcium channel that plays a central role in calcium-dependent physiological responses essential for successful fertilization, such as sperm hyperactivation, acrosome reaction and chemotaxis towards the oocyte",Testis-specific,,"In mouse, Slco6c1 is an additional auxiliary subunit of the CatSper complex. It is unclear if the related SLCO6A1 protein performs the same role in non-rodent species","Cell projection, cilium, flagellum membrane",21412338|21412339,12646162|12932298|17347248,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CATSPERB,ENSG00000133962,Unsafe,RNA,False,True,1.0,10.4,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,colon: 0.6 nTPM; continuous selectivity; esophagus: 0.5 nTPM; continuous selectivity; heart muscle: 0.4 nTPM; continuous selectivity; lung: 0.6 nTPM; continuous selectivity; lymph node: 0.9 nTPM; continuous selectivity; pancreas: 10.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 0.5 nTPM; continuous selectivity; retina: 0.7 nTPM; continuous selectivity; salivary gland: 2.4 nTPM; continuous selectivity;reproductive not higher; skeletal muscle: 1.1 nTPM; continuous selectivity;reproductive not higher; skin: 2.2 nTPM; continuous selectivity;reproductive not higher; small intestine: 0.9 nTPM; continuous selectivity; spleen: 0.6 nTPM; continuous selectivity; stomach: 1.4 nTPM; continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,pancreas: 10.4 nTPM (limit 2); pancreas: 10.4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 43/80 (53.8%); Breast Invasive Carcinoma (validation): 26/50 (52.0%); Colon Adenocarcinoma (validation): 55/486 (11.3%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9H7T0,https://www.uniprot.org/uniprotkb/Q9H7T0/entry,"Auxiliary component of the CatSper complex, a complex involved in sperm cell hyperactivation. Sperm cell hyperactivation is needed for sperm motility which is essential late in the preparation of sperm for fertilization",,,"In mouse, Slco6c1 is an additional auxiliary subunit of the CatSper complex. It is unclear if the related SLCO6A1 protein performs the same role in non-rodent species","Cell projection, cilium, flagellum membrane",,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
CATSPERD,ENSG00000174898,Unsafe,High RNA,False,True,8.4,8.4,81,5,Positive somewhere,False,False,False,True,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,CTA,Pass,oncoref.target-sets.2026-10-23.1,False,False,,CTA → Unsafe,True,True,True,0.681222670461,177.1,"hpa_single_cell: /Ciliated cells, max 112.6 nTPM, 1 observations >30; hpa_single_cell_tissue: bronchus/ciliated cells, max 125.5 nTPM, 2 observations >30; hpa_single_cell_tissue: lung/ciliated cells, max 177.1 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,0.6812 TPM; blood/TH1; dice_th1; vital,177.1 nTPM; lung/ciliated cells; hpa_single_cell_tissue; vital,Pancreatic Adenocarcinoma (validation): 2/80 (2.5%); Ovary Serous Cystadenocarcinoma (validation): 2/81 (2.5%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),prostate cancer: 1/11 (9.1%); breast cancer: 0/11 (0.0%),29,20,Q86XM0,https://www.uniprot.org/uniprotkb/Q86XM0/entry,"Auxiliary component of the CatSper complex, a complex involved in sperm cell hyperactivation. Sperm cell hyperactivation is needed for sperm motility which is essential late in the preparation of sperm for fertilization. Required for CATSPER1 stability before intraflagellar transport and/or incorporation of the CatSper complex channel into the flagellar membrane",,,"It is uncertain whether Met-1 or Met-5 is the initiator In mouse, Slco6c1 is an additional auxiliary subunit of the CatSper complex. It is unclear if the related SLCO6A1 protein performs the same role in non-rodent species","Cell projection, cilium, flagellum membrane",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
CATSPERE,ENSG00000179397,Unsafe,High RNA,False,True,20.9,20.9,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 7/91 values ≥5 TPM, max 5.75145; DICE CD8_NAIVE (unstimulated): 12/89 values ≥5 TPM, max 6.07601",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,6.07601196518,40.0,"hpa_single_cell: /Oligodendrocytes, max 39.6 nTPM, 1 observations >30; hpa_single_cell_tissue: brain/oligodendrocytes, max 40 nTPM, 2 observations >30",CTA,oncoref.target-sets.2026-10-23.2,6.076 TPM; blood/CD8_NAIVE; dice_cd8_naive; vital,40 nTPM; brain/oligodendrocytes; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 13/58 (22.4%); Kidney Renal Papillary Cell Carcinoma (TCGA): 2/282 (0.7%); Glioblastoma Multiforme (TCGA): 1/141 (0.7%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q5SY80,https://www.uniprot.org/uniprotkb/Q5SY80/entry,"Auxiliary component of the CatSper complex, a complex involved in sperm cell hyperactivation. Sperm cell hyperactivation is needed for sperm motility which is essential late in the preparation of sperm for fertilization",,,"In mouse, Slco6c1 is an additional auxiliary subunit of the CatSper complex. It is unclear if the related SLCO6A1 protein performs the same role in non-rodent species","Cell projection, cilium, flagellum membrane",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CATSPERG,ENSG00000099338,Unsafe,RNA,False,True,30.5,30.5,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,cerebellum: 2.4 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebellum: 2.4 nTPM (limit 2); cerebellum: 2.4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 15/50 (30.0%); Pancreatic Adenocarcinoma (validation): 16/80 (20.0%); Ovary Serous Cystadenocarcinoma (validation): 13/81 (16.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q6ZRH7,https://www.uniprot.org/uniprotkb/Q6ZRH7/entry,"Auxiliary component of the CatSper complex, a complex involved in sperm cell hyperactivation. Sperm cell hyperactivation is needed for sperm motility which is essential late in the preparation of sperm for fertilization",,,"In mouse, Slco6c1 is an additional auxiliary subunit of the CatSper complex. It is unclear if the related SLCO6A1 protein performs the same role in non-rodent species","Cell projection, cilium, flagellum membrane",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,Failed bulk numeric comparisons are within 20% of their cutoffs; not an automatic rescue,,,,
CATSPERZ,ENSG00000219435,Unsafe,RNA,False,True,570.0,570.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 3.1 nTPM; absolute ceiling; basal ganglia: 2.7 nTPM; absolute ceiling; cerebral cortex: 2.9 nTPM; absolute ceiling; hippocampal formation: 3.3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 3.1 nTPM (limit 2); basal ganglia: 2.7 nTPM (limit 2); cerebral cortex: 2.9 nTPM (limit 2); hippocampal formation: 3.3 nTPM (limit 2); amygdala: 3.1 nTPM (baseline 2); basal ganglia: 2.7 nTPM (baseline 2); cerebral cortex: 2.9 nTPM (baseline 2); hippocampal formation: 3.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 10/133 (7.5%); Skin Cuteneous Melanoma (TCGA): 7/99 (7.1%); Kidney Renal Clear Cell Carcinoma (TCGA): 29/521 (5.6%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q9NTU4,https://www.uniprot.org/uniprotkb/Q9NTU4/entry,"Auxiliary component of the CatSper complex, a complex involved in sperm cell hyperactivation. Sperm cell hyperactivation is needed for sperm motility which is essential late in the preparation of sperm for fertilization. Required for a distribution of the CatSper complex in linear quadrilateral nanodomains along the flagellum, maximizing fertilization inside the mammalian female reproductive tract. Together with EFCAB9, associates with the CatSper channel pore and is required for the two-row structure of each single CatSper channel",,,"A report observed N-glycosylation at Asn-58 (PubMed:19139490). However, as the protein is not predicted to localize in an extracellular compartment of the cell, additional evidence is required to confirm this result In mouse, Slco6c1 is an additional auxiliary subunit of the CatSper complex. It is unclear if the related SLCO6A1 protein performs the same role in non-rodent species","Cell projection, cilium, flagellum membrane",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
CBLL1,ENSG00000105879,Unsafe,Protein,False,True,20.3,34.7,88,86,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 10.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 8.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 5.9 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 6.4 nTPM; absolute ceiling;continuous selectivity; bone marrow: 34.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 9.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 12.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 4.2 nTPM; absolute ceiling; colon: 11 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 9.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 10.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 9.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 6.2 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 5.4 nTPM; absolute ceiling;continuous selectivity; kidney: 9.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 10.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 9.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 14.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 5.9 nTPM; absolute ceiling;continuous selectivity; pancreas: 10 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 12.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 4.9 nTPM; absolute ceiling; rectum: 9.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 13.9 nTPM; absolute ceiling;continuous selectivity; salivary gland: 8.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 29.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 10.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 9.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 11.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 7.4 nTPM; absolute ceiling;continuous selectivity; spleen: 13.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 8.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 18 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 12.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 18.1 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 10.6 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 10.3 nTPM (limit 10); adrenal gland: 8.1 nTPM (limit 2); amygdala: 5.9 nTPM (limit 2); basal ganglia: 6.4 nTPM (limit 2); bone marrow: 34.7 nTPM (limit 2); cerebellum: 9.2 nTPM (limit 2); cerebral cortex: 12.5 nTPM (limit 2); choroid plexus: 4.2 nTPM (limit 2); colon: 11 nTPM (limit 6); duodenum: 9.3 nTPM (limit 2); esophagus: 10.1 nTPM (limit 6); heart muscle: 9.9 nTPM (limit 2); hippocampal formation: 6.2 nTPM (limit 2); hypothalamus: 5.4 nTPM (limit 2); kidney: 9.4 nTPM (limit 2); liver: 10.3 nTPM (limit 2); lung: 9.1 nTPM (limit 2); lymph node: 14.7 nTPM (limit 6); midbrain: 5.9 nTPM (limit 2); pancreas: 10 nTPM (limit 2); parathyroid gland: 12.3 nTPM (limit 6); pituitary gland: 4.9 nTPM (limit 2); rectum: 9.5 nTPM (limit 6); retina: 13.9 nTPM (limit 2); salivary gland: 8.4 nTPM (limit 6); skeletal muscle: 29.2 nTPM (limit 2); skin: 10.3 nTPM (limit 10); small intestine: 9.9 nTPM (limit 2); smooth muscle: 11.4 nTPM (limit 2); spinal cord: 7.4 nTPM (limit 2); spleen: 13.2 nTPM (limit 10); stomach: 8.7 nTPM (limit 6); thymus: 18 nTPM (limit 10); thyroid gland: 12.8 nTPM (limit 10); tongue: 18.1 nTPM (limit 6); urinary bladder: 10.6 nTPM (limit 6),adipose tissue / adipocytes: Medium (Enhanced); adrenal gland / glandular cells: High (Enhanced); bone marrow / hematopoietic cells: Medium (Enhanced); bronchus / respiratory epithelial cells: Medium (Enhanced); caudate / glial cells: Medium (Enhanced); caudate / neuronal cells: Medium (Enhanced); cerebellum / cells in granular layer: Medium (Enhanced); cerebellum / cells in molecular layer: Medium (Enhanced); cerebellum / Purkinje cells: Medium (Enhanced); cerebral cortex / endothelial cells: Medium (Enhanced); cerebral cortex / glial cells: Medium (Enhanced); cerebral cortex / neuronal cells: High (Enhanced); cerebral cortex / neuropil: Medium (Enhanced); colon / endothelial cells: Medium (Enhanced); colon / glandular cells: Medium (Enhanced); colon / peripheral nerve/ganglion: Medium (Enhanced); duodenum / glandular cells: Medium (Enhanced); esophagus / squamous epithelial cells: Medium (Enhanced); heart muscle / cardiomyocytes: Medium (Enhanced); hippocampus / glial cells: Medium (Enhanced); hippocampus / neuronal cells: Medium (Enhanced); kidney / cells in glomeruli: Medium (Enhanced); kidney / cells in tubules: Medium (Enhanced); liver / cholangiocytes: Low (Enhanced); liver / hepatocytes: Low (Enhanced); lung / alveolar cells type I: High (Enhanced); lung / alveolar cells type II: High (Enhanced); lung / endothelial cells: Medium (Enhanced); lung / macrophages: High (Enhanced); lymph node / germinal center cells: High (Enhanced); lymph node / non-germinal center cells: Medium (Enhanced); nasopharynx / respiratory epithelial cells: Medium (Enhanced); oral mucosa / squamous epithelial cells: Medium (Enhanced); pancreas / exocrine glandular cells: Medium (Enhanced); parathyroid gland / glandular cells: High (Enhanced); rectum / glandular cells: Medium (Enhanced); salivary gland / glandular cells: Medium (Enhanced); skeletal muscle / myocytes: Medium (Enhanced); skin 1 / fibroblasts: Medium (Enhanced); skin 1 / keratinocytes: Medium (Enhanced); skin 1 / Langerhans: Medium (Enhanced); skin 2 / epidermal cells: Medium (Enhanced); small intestine / glandular cells: Medium (Enhanced); smooth muscle / smooth muscle cells: Medium (Enhanced); spleen / cells in red pulp: Medium (Enhanced); spleen / cells in white pulp: Medium (Enhanced); stomach 1 / glandular cells: Medium (Enhanced); stomach 2 / glandular cells: Medium (Enhanced); thyroid gland / glandular cells: High (Enhanced); urinary bladder / urothelial cells: Medium (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Colon Adenocarcinoma (TCGA): 254/254 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%),cervical cancer: 12/12 (100.0%); endometrial cancer: 12/12 (100.0%),31,20,Q75N03,https://www.uniprot.org/uniprotkb/Q75N03/entry,"E3 ubiquitin-protein ligase that mediates ubiquitination of several tyrosine-phosphorylated Src substrates, including CDH1, CTTN and DOK1 (By similarity). Targets CDH1 for endocytosis and degradation (By similarity). Associated component of the WMM complex, a complex that mediates N6-methyladenosine (m6A) methylation of RNAs, a modification that plays a role in the efficiency of mRNA splicing and RNA processing (PubMed:29507755). Its function in the WMM complex is unknown (PubMed:29507755)",,,,"Nucleus speckle Nucleus, nucleoplasm Cytoplasm",29507755,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
CBLN1,ENSG00000102924,Unsafe,RNA,False,True,31.0,439.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 11.4 nTPM; absolute ceiling; basal ganglia: 3.9 nTPM; absolute ceiling; cerebellum: 439.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 5.5 nTPM; absolute ceiling; heart muscle: 4.4 nTPM; absolute ceiling; hypothalamus: 37.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 17.7 nTPM; absolute ceiling;continuous selectivity; pancreas: 2.7 nTPM; absolute ceiling; pituitary gland: 4.1 nTPM; absolute ceiling; retina: 3.4 nTPM; absolute ceiling; spinal cord: 9.7 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adipose tissue: 11.4 nTPM (limit 10); basal ganglia: 3.9 nTPM (limit 2); cerebellum: 439.8 nTPM (limit 2); cerebral cortex: 5.5 nTPM (limit 2); heart muscle: 4.4 nTPM (limit 2); hypothalamus: 37.4 nTPM (limit 2); midbrain: 17.7 nTPM (limit 2); pancreas: 2.7 nTPM (limit 2); pituitary gland: 4.1 nTPM (limit 2); retina: 3.4 nTPM (limit 2); spinal cord: 9.7 nTPM (limit 2); adipose tissue: 11.4 nTPM (baseline 10); basal ganglia: 3.9 nTPM (baseline 2); cerebellum: 439.8 nTPM (baseline 2); cerebral cortex: 5.5 nTPM (baseline 2); heart muscle: 4.4 nTPM (baseline 2); hypothalamus: 37.4 nTPM (baseline 2); midbrain: 17.7 nTPM (baseline 2); pancreas: 2.7 nTPM (baseline 2); pituitary gland: 4.1 nTPM (baseline 2); retina: 3.4 nTPM (baseline 2); spinal cord: 9.7 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Thyroid Carcinoma (TCGA): 254/495 (51.3%); Testicular Germ Cell Tumor (TCGA): 63/133 (47.4%); Glioblastoma Multiforme (validation): 17/58 (29.3%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P23435,https://www.uniprot.org/uniprotkb/P23435/entry,"Required for synapse integrity and synaptic plasticity. During cerebellar synapse formation, essential for the matching and maintenance of pre- and post-synaptic elements at parallel fiber-Purkinje cell synapses, the establishment of the proper pattern of climbing fiber-Purkinje cell innervation, and induction of long-term depression at parallel fiber-Purkinje cell synapses. Plays a role as a synaptic organizer that acts bidirectionally on both pre- and post-synaptic components. On the one hand induces accumulation of synaptic vesicles in the pre-synaptic part by binding with NRXN1 and in other hand induces clustering of GRID2 and its associated proteins at the post-synaptic site through association of GRID2. NRXN1-CBLN1-GRID2 complex directly induces parallel fiber protrusions that encapsulate spines of Purkinje cells leading to accumulation of GRID2 and synaptic vesicles. Required for CBLN3 export from the endoplasmic reticulum and secretion (By similarity). NRXN1-CBLN1-GRID2 complex mediates the D-Serine-dependent long term depression signals and AMPA receptor endocytosis (PubMed:27418511). Essential for long-term maintenance but not establishment of excitatory synapses (By similarity). Inhibits the formation and function of inhibitory GABAergic synapses in cerebellar Purkinje cells (By similarity) The cerebellin peptide exerts neuromodulatory functions. Directly stimulates norepinephrine release via the adenylate cyclase/PKA-dependent signaling pathway; and indirectly enhances adrenocortical secretion in vivo, through a paracrine mechanism involving medullary catecholamine release (By similarity)","In the Purkinje cells postsynaptic structures. In the cerebellum, cerebellin is much less abundant than [des-Ser1]-cerebellin",,,Secreted Postsynaptic cell membrane,27418511,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Jamin2021_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CBX2,ENSG00000173894,Unsafe,Protein,False,True,12.5,12.5,86,41,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; bone marrow: 2.2 nTPM; positive ihc;absolute ceiling; colon: 0.5 nTPM; positive ihc; duodenum: 0.3 nTPM; positive ihc; esophagus: 4.1 nTPM; positive ihc; lung: 1.2 nTPM; positive ihc; lymph node: 1.3 nTPM; positive ihc; parathyroid gland: 0.5 nTPM; positive ihc; rectum: 0.2 nTPM; positive ihc; skin: 2 nTPM; positive ihc; small intestine: 0.6 nTPM; positive ihc; spleen: 1.6 nTPM; positive ihc; stomach: 0.5 nTPM; positive ihc; thymus: 7.2 nTPM; continuous selectivity; urinary bladder: 0.9 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 2.2 nTPM (limit 2),bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Low (Approved); colon / glandular cells: Low (Approved); duodenum / glandular cells: Low (Approved); esophagus / squamous epithelial cells: Low (Approved); lung / alveolar cells: Low (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); oral mucosa / squamous epithelial cells: Low (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Low (Approved); skin 1 / keratinocytes: Low (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Low (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Low (Approved); urinary bladder / urothelial cells: Low (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 133/133 (100.0%); Breast Invasive Carcinoma (validation): 45/50 (90.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 129/176 (73.3%),glioma: 6/12 (50.0%); testis cancer: 4/10 (40.0%),31,20,Q14781,https://www.uniprot.org/uniprotkb/Q14781/entry,"Component of a Polycomb group (PcG) multiprotein PRC1-like complex, a complex class required to maintain the transcriptionally repressive state of many genes, including Hox genes, throughout development (PubMed:21282530). PcG PRC1 complex acts via chromatin remodeling and modification of histones; it mediates monoubiquitination of histone H2A 'Lys-119', rendering chromatin heritably changed in its expressibility (PubMed:21282530). Binds to histone H3 trimethylated at 'Lys-9' (H3K9me3) or at 'Lys-27' (H3K27me3) (By similarity). Plays a role in the lineage differentiation of the germ layers in embryonic development (By similarity). Involved in sexual development, acting as activator of NR5A1 expression (PubMed:19361780)",,"46,XY sex reversal 5: A disorder of sex development. Affected individuals have a 46,XY karyotype but present as phenotypically normal females.",,Nucleus Chromosome,19361780|21282530,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CBX5,ENSG00000094916,Unsafe,Protein,False,True,24.7,115.3,108,73,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 7.8 nTPM; positive ihc; adrenal gland: 13.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 19.5 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 18.1 nTPM; absolute ceiling;continuous selectivity; bone marrow: 16.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 16.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 25.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 115.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 10.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 7.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 9 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 20.1 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 16.9 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 21.5 nTPM; absolute ceiling;continuous selectivity; kidney: 16.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 9.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 18.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 18 nTPM; absolute ceiling;continuous selectivity; pancreas: 9.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 24.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 19.2 nTPM; absolute ceiling;continuous selectivity; rectum: 10.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 22.2 nTPM; absolute ceiling;continuous selectivity; salivary gland: 8.3 nTPM; positive ihc;absolute ceiling; skeletal muscle: 13.3 nTPM; absolute ceiling; skin: 16.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 8.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 20.3 nTPM; absolute ceiling;continuous selectivity; spleen: 10.4 nTPM; positive ihc;absolute ceiling; stomach: 10 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 30.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 23.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 7.4 nTPM; absolute ceiling; urinary bladder: 6.9 nTPM; positive ihc;absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 13.6 nTPM (limit 2); amygdala: 19.5 nTPM (limit 2); basal ganglia: 18.1 nTPM (limit 2); bone marrow: 16.9 nTPM (limit 2); cerebellum: 16.3 nTPM (limit 2); cerebral cortex: 25.9 nTPM (limit 2); choroid plexus: 115.3 nTPM (limit 2); colon: 10.2 nTPM (limit 6); duodenum: 7.3 nTPM (limit 2); esophagus: 9 nTPM (limit 6); heart muscle: 20.1 nTPM (limit 12); hippocampal formation: 16.9 nTPM (limit 2); hypothalamus: 21.5 nTPM (limit 2); kidney: 16.6 nTPM (limit 2); lung: 9.3 nTPM (limit 2); lymph node: 18.4 nTPM (limit 6); midbrain: 18 nTPM (limit 2); pancreas: 9.7 nTPM (limit 2); parathyroid gland: 24.8 nTPM (limit 6); pituitary gland: 19.2 nTPM (limit 2); rectum: 10.5 nTPM (limit 6); retina: 22.2 nTPM (limit 2); salivary gland: 8.3 nTPM (limit 6); skeletal muscle: 13.3 nTPM (limit 12); skin: 16.8 nTPM (limit 10); small intestine: 8.5 nTPM (limit 2); spinal cord: 20.3 nTPM (limit 2); spleen: 10.4 nTPM (limit 10); stomach: 10 nTPM (limit 6); thymus: 30.2 nTPM (limit 10); thyroid gland: 23.2 nTPM (limit 10); tongue: 7.4 nTPM (limit 6); urinary bladder: 6.9 nTPM (limit 6),adipose tissue / adipocytes: Low (Enhanced); adrenal gland / glandular cells: Medium (Enhanced); bone marrow / hematopoietic cells: Medium (Enhanced); bronchus / respiratory epithelial cells: Medium (Enhanced); caudate / glial cells: Medium (Enhanced); caudate / neuronal cells: Medium (Enhanced); cerebellum / cells in granular layer: Medium (Enhanced); cerebellum / cells in molecular layer: High (Enhanced); cerebellum / Purkinje cells: Medium (Enhanced); cerebral cortex / endothelial cells: Low (Enhanced); cerebral cortex / glial cells: Low (Enhanced); cerebral cortex / neuronal cells: High (Enhanced); cerebral cortex / neuropil: Low (Enhanced); colon / glandular cells: Medium (Enhanced); colon / peripheral nerve/ganglion: Medium (Enhanced); duodenum / glandular cells: Medium (Enhanced); esophagus / squamous epithelial cells: Low (Enhanced); hippocampus / glial cells: High (Enhanced); hippocampus / neuronal cells: Medium (Enhanced); kidney / cells in glomeruli: Medium (Enhanced); kidney / cells in tubules: Medium (Enhanced); lung / alveolar cells type II: Low (Enhanced); lung / macrophages: Low (Enhanced); lymph node / germinal center cells: Low (Enhanced); lymph node / non-germinal center cells: Low (Enhanced); nasopharynx / respiratory epithelial cells: Low (Enhanced); oral mucosa / squamous epithelial cells: Low (Enhanced); pancreas / exocrine glandular cells: Medium (Enhanced); pancreas / pancreatic endocrine cells: Medium (Enhanced); parathyroid gland / glandular cells: High (Enhanced); rectum / glandular cells: Medium (Enhanced); salivary gland / glandular cells: Medium (Enhanced); skin 1 / cells in basal layer: Low (Enhanced); skin 1 / cells in spinous layer: Low (Enhanced); skin 1 / endothelial cells: Low (Enhanced); skin 1 / fibrohistiocytic cells: Low (Enhanced); skin 1 / langerhans cells: Low (Enhanced); skin 1 / lymphocytes: Low (Enhanced); skin 2 / cells in basal layer: Low (Enhanced); skin 2 / cells in granular layer: Low (Enhanced); skin 2 / cells in spinous layer: Low (Enhanced); skin 2 / endothelial cells: Low (Enhanced); skin 2 / fibrohistiocytic cells: Low (Enhanced); skin 2 / langerhans cells: Low (Enhanced); skin 2 / lymphocytes: Low (Enhanced); skin 2 / sebaceous glands: Medium (Enhanced); small intestine / glandular cells: Medium (Enhanced); spleen / cells in red pulp: Low (Enhanced); spleen / cells in white pulp: Low (Enhanced); stomach 1 / glandular cells: Medium (Enhanced); stomach 2 / glandular cells: Medium (Enhanced); thyroid gland / glandular cells: Medium (Enhanced); urinary bladder / urothelial cells: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (TCGA): 141/141 (100.0%),cervical cancer: 11/11 (100.0%); prostate cancer: 9/9 (100.0%),31,20,P45973,https://www.uniprot.org/uniprotkb/P45973/entry,"Component of heterochromatin that recognizes and binds histone H3 tails methylated at 'Lys-9' (H3K9me), leading to epigenetic repression (PubMed:40440427). In contrast, it is excluded from chromatin when 'Tyr-41' of histone H3 is phosphorylated (H3Y41ph) (PubMed:19783980). Also recognizes and binds histone H1.4 methylated at 'Lys-26' (H1.4K26me) (PubMed:16127177). Excluded from chromatin when histone H1.4 is Simultaneously methylated at Lys-26 (H1.4K26me) and phosphorylated at Ser-27 (H1.4S27Ph) (PubMed:16127177). May contribute to the association of heterochromatin with the inner nuclear membrane by interactions with the lamin-B receptor (LBR) (PubMed:19783980). Involved in the formation of kinetochore through interaction with the MIS12 complex subunit NSL1 (PubMed:19783980, PubMed:20231385). Required for the formation of the inner centromere (PubMed:20231385)",,,"Was previously reported to interact with ASXL1. However, this publication has been retracted","Nucleus Chromosome Chromosome, centromere",16127177|19783980|20231385|40440427,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
CBY3,ENSG00000204659,Unsafe,RNA,False,True,15.0,15.0,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,midbrain: 2.8 nTPM; absolute ceiling; spinal cord: 3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,midbrain: 2.8 nTPM (limit 2); spinal cord: 3 nTPM (limit 2); midbrain: 2.8 nTPM (baseline 2); spinal cord: 3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 1/80 (1.2%); Bladder Urothelial Carcinoma (TCGA): 2/169 (1.2%); Skin Cuteneous Melanoma (TCGA): 1/99 (1.0%),glioma: 12/12 (100.0%); ovarian cancer: 12/12 (100.0%),30,20,A6NI87,https://www.uniprot.org/uniprotkb/A6NI87/entry,"Plays a key role in the correct positioning of the annulus, a septin-based ring structure in the sperm flagellum, serving both as a physical barrier and a membrane diffusion barrier that separates the midpiece (MP) from the principal piece (PP) (By similarity). This positioning is essential for proper sperm motility and function (By similarity). CBY3 interacts with CIBAR1 to form a complex which localizes to the curved membrane region of the flagellar pocket (By similarity). By doing so, may provide stability and rigidity to the periannular membrane to prevent membrane deformation (By similarity). This function is crucial for halting annulus migration at the proximal end of the fibrous sheath-containing PP (By similarity)",,,,"Cell projection, cilium, flagellum",,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Chang2019_TGCT,Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CCDC110,ENSG00000168491,Unsafe,RNA,False,True,97.1,97.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,kidney: 2.4 nTPM; absolute ceiling; pancreas: 29.7 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 2.8 nTPM; absolute ceiling; retina: 7.7 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,kidney: 2.4 nTPM (limit 2); pancreas: 29.7 nTPM (limit 2); pituitary gland: 2.8 nTPM (limit 2); retina: 7.7 nTPM (limit 2); kidney: 2.4 nTPM (baseline 2); pancreas: 29.7 nTPM (baseline 2); pituitary gland: 2.8 nTPM (baseline 2); retina: 7.7 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 39/50 (78.0%); Kidney Renal Clear Cell Carcinoma (validation): 42/100 (42.0%); Prostate Adenocarcinoma (TCGA): 159/480 (33.1%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8TBZ0,https://www.uniprot.org/uniprotkb/Q8TBZ0/entry,,Expressed specifically in testis. Also expressed in tumors of different origins,,,Nucleus,,15447989,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CCDC122,ENSG00000151773,Unsafe,Protein,False,True,5.3,5.3,83,66,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 2.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; basal ganglia: 1.6 nTPM; continuous selectivity; cerebellum: 0.6 nTPM; positive ihc; cerebral cortex: 1.6 nTPM; positive ihc;continuous selectivity; colon: 2.8 nTPM; positive ihc;continuous selectivity; duodenum: 1.6 nTPM; positive ihc;continuous selectivity; esophagus: 2 nTPM; positive ihc;continuous selectivity; heart muscle: 4.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 1.8 nTPM; continuous selectivity; hypothalamus: 1.5 nTPM; continuous selectivity; kidney: 2.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 2.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 2 nTPM; positive ihc;continuous selectivity; lymph node: 2.7 nTPM; positive ihc;continuous selectivity; midbrain: 1.8 nTPM; continuous selectivity; pancreas: 3.5 nTPM; continuous selectivity; parathyroid gland: 3.9 nTPM; continuous selectivity; pituitary gland: 3.1 nTPM; absolute ceiling;continuous selectivity; rectum: 3.4 nTPM; positive ihc;continuous selectivity; salivary gland: 3.1 nTPM; positive ihc;continuous selectivity; skeletal muscle: 1 nTPM; positive ihc; skin: 3.9 nTPM; positive ihc;continuous selectivity; small intestine: 2.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 3.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 1.9 nTPM; continuous selectivity; stomach: 3 nTPM; positive ihc;continuous selectivity; thyroid gland: 4.8 nTPM; positive ihc;continuous selectivity; urinary bladder: 2.8 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 2.8 nTPM (limit 2); heart muscle: 4.5 nTPM (limit 2); kidney: 2.9 nTPM (limit 2); liver: 2.3 nTPM (limit 2); pituitary gland: 3.1 nTPM (limit 2); small intestine: 2.4 nTPM (limit 2); smooth muscle: 3.2 nTPM (limit 2),adrenal gland / glandular cells: High (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: High (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: High (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells type I: Medium (Approved); lung / alveolar cells type II: Medium (Approved); lung / endothelial cells: Low (Approved); lung / macrophages: Low (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: High (Approved); oral mucosa / squamous epithelial cells: High (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: High (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Low (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Low (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Low (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: High (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 43/50 (86.0%); Pancreatic Adenocarcinoma (validation): 58/80 (72.5%); Thyroid Carcinoma (TCGA): 277/495 (56.0%),cervical cancer: 9/10 (90.0%); skin cancer: 10/12 (83.3%),31,20,Q5T0U0,https://www.uniprot.org/uniprotkb/Q5T0U0/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CCDC136,ENSG00000128596,Unsafe,Protein,False,True,180.5,180.5,100,11,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 26.9 nTPM; absolute ceiling; basal ganglia: 18.5 nTPM; absolute ceiling; cerebellum: 85.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 66.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 4.8 nTPM; absolute ceiling; hippocampal formation: 29.7 nTPM; absolute ceiling; hypothalamus: 46.2 nTPM; absolute ceiling;continuous selectivity; midbrain: 34 nTPM; absolute ceiling; pituitary gland: 6.3 nTPM; absolute ceiling; retina: 50.9 nTPM; absolute ceiling;continuous selectivity; spinal cord: 19 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 26.9 nTPM (limit 2); basal ganglia: 18.5 nTPM (limit 2); cerebellum: 85.4 nTPM (limit 2); cerebral cortex: 66.3 nTPM (limit 2); choroid plexus: 4.8 nTPM (limit 2); hippocampal formation: 29.7 nTPM (limit 2); hypothalamus: 46.2 nTPM (limit 2); midbrain: 34 nTPM (limit 2); pituitary gland: 6.3 nTPM (limit 2); retina: 50.9 nTPM (limit 2); spinal cord: 19 nTPM (limit 2),caudate / neuronal cells: Medium (Enhanced); cerebellum / molecular layer cells - cytoplasm/membrane: High (Enhanced); cerebellum / processes in molecular layer: Medium (Enhanced); cerebellum / Purkinje cells - cytoplasm/membrane: Medium (Enhanced); cerebellum / synaptic glomeruli - core: Low (Enhanced); cerebral cortex / neuronal cells: High (Enhanced); cerebral cortex / neuropil: Low (Enhanced); hippocampus / neuronal cells: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Glioblastoma Multiforme (TCGA): 121/141 (85.8%); Testicular Germ Cell Tumor (TCGA): 93/133 (69.9%),breast cancer: 0/12 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q96JN2,https://www.uniprot.org/uniprotkb/Q96JN2/entry,May play a role in acrosome formation in spermatogenesis and in fertilization,Expressed in gastric tissues. Down-regulated in gastric cancer,,,"Cytoplasmic vesicle, secretory vesicle, acrosome membrane",,15112360,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CCDC138,ENSG00000163006,Unsafe,Protein,False,True,10.6,10.6,85,50,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 0.9 nTPM; positive ihc; bone marrow: 3.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 1.9 nTPM; positive ihc; cerebral cortex: 1.4 nTPM; positive ihc; colon: 1.8 nTPM; positive ihc; duodenum: 0.9 nTPM; positive ihc; esophagus: 2 nTPM; positive ihc; hippocampal formation: 2.6 nTPM; absolute ceiling; kidney: 1.6 nTPM; positive ihc; liver: 2.7 nTPM; positive ihc;absolute ceiling; lung: 1.3 nTPM; positive ihc; pancreas: 1.6 nTPM; positive ihc; rectum: 2.2 nTPM; positive ihc; retina: 2.2 nTPM; absolute ceiling; salivary gland: 1.3 nTPM; positive ihc; skeletal muscle: 1 nTPM; positive ihc; skin: 2.3 nTPM; positive ihc; small intestine: 1.6 nTPM; positive ihc; smooth muscle: 1.5 nTPM; positive ihc; spinal cord: 2.5 nTPM; absolute ceiling; stomach: 1.8 nTPM; positive ihc; thymus: 6.2 nTPM; continuous selectivity; thyroid gland: 0.8 nTPM; positive ihc; urinary bladder: 1.5 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 3.4 nTPM (limit 2); hippocampal formation: 2.6 nTPM (limit 2); liver: 2.7 nTPM (limit 2); retina: 2.2 nTPM (limit 2); spinal cord: 2.5 nTPM (limit 2),adrenal gland / glandular cells: Low (Enhanced); bone marrow / hematopoietic cells: Low (Enhanced); bronchus / respiratory epithelial cells: Low (Enhanced); cerebellum / cells in molecular layer: Low (Enhanced); cerebral cortex / neuronal cells: Low (Enhanced); colon / endothelial cells: Low (Enhanced); colon / glandular cells: Low (Enhanced); colon / peripheral nerve/ganglion: Medium (Enhanced); duodenum / glandular cells: Low (Enhanced); esophagus / squamous epithelial cells: Low (Enhanced); hippocampus / neuronal cells: Low (Enhanced); kidney / cells in glomeruli: Low (Enhanced); kidney / cells in tubules: Low (Enhanced); liver / hepatocytes: Low (Enhanced); lung / alveolar cells: Low (Enhanced); lung / macrophages: Low (Enhanced); nasopharynx / respiratory epithelial cells: Low (Enhanced); oral mucosa / squamous epithelial cells: Low (Enhanced); pancreas / exocrine glandular cells: Low (Enhanced); pancreas / pancreatic endocrine cells: Low (Enhanced); rectum / glandular cells: Low (Enhanced); salivary gland / glandular cells: Low (Enhanced); skeletal muscle / myocytes: Low (Enhanced); skin 1 / Langerhans: Low (Enhanced); skin 2 / epidermal cells: Low (Enhanced); small intestine / glandular cells: Low (Enhanced); smooth muscle / smooth muscle cells: Low (Enhanced); stomach 1 / glandular cells: Low (Enhanced); stomach 2 / glandular cells: Low (Enhanced); thyroid gland / glandular cells: Low (Enhanced); urinary bladder / urothelial cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 56/58 (96.6%); Breast Invasive Carcinoma (validation): 42/50 (84.0%); Testicular Germ Cell Tumor (TCGA): 101/133 (75.9%),colorectal cancer: 2/9 (22.2%); testis cancer: 2/9 (22.2%),31,20,Q96M89,https://www.uniprot.org/uniprotkb/Q96M89/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | Jamin2021_CT | Jamin2021_core,GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
CCDC144A,ENSG00000170160,Unsafe,Protein,False,True,9.8,12.5,85,8,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 8 nTPM; continuous selectivity; cerebellum: 5.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; kidney: 0.7 nTPM; positive ihc; retina: 12.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; stomach: 1.8 nTPM; positive ihc; urinary bladder: 1.6 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",cerebellum: 5.9 nTPM (limit 2); retina: 12.5 nTPM (limit 2),cerebellum / cells in granular layer: Low (Enhanced); cerebellum / cells in molecular layer: Low (Enhanced); kidney / cells in tubules: Low (Enhanced); nasopharynx / respiratory epithelial cells: Low (Enhanced); stomach 2 / glandular cells: Low (Enhanced); urinary bladder / urothelial cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 203/486 (41.8%); Rectum Adenocarcinoma (validation): 85/207 (41.1%); Pancreatic Adenocarcinoma (validation): 32/80 (40.0%),breast cancer: 0/12 (0.0%); cervical cancer: 0/12 (0.0%),31,20,A2RUR9,https://www.uniprot.org/uniprotkb/A2RUR9/entry,"May play a role in preventing the formation of kidney stones through inhibition of calcium oxalate monohydrate (COM) crystallization, attenuating COM-induced apoptotic injury to renal epithelial cells (PubMed:32991878). May exhibit antilithiatic (preventing the formation of kidney stones) activity through crystal binding, hindering the crystal attachment to renal epithelial cells, a pre-requisite to initiate inflammatory response (PubMed:32991878)",,,,,32991878,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CCDC148,ENSG00000153237,Unsafe,RNA,False,True,4.8,4.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,choroid plexus: 2.9 nTPM; absolute ceiling;continuous selectivity; kidney: 3 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 3.1 nTPM; continuous selectivity; retina: 2.5 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 2.9 nTPM (limit 2); kidney: 3 nTPM (limit 2); retina: 2.5 nTPM (limit 2); choroid plexus: 2.9 nTPM (baseline 2); kidney: 3 nTPM (baseline 2); retina: 2.5 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 39/58 (67.2%); Breast Invasive Carcinoma (validation): 20/50 (40.0%); Pancreatic Adenocarcinoma (validation): 11/80 (13.8%),colorectal cancer: 2/11 (18.2%); breast cancer: 1/10 (10.0%),31,20,Q8NFR7,https://www.uniprot.org/uniprotkb/Q8NFR7/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CCDC15,ENSG00000149548,Unsafe,RNA,False,True,10.2,10.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 2.1 nTPM; absolute ceiling; salivary gland: 3.8 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 2.1 nTPM (limit 2); bone marrow: 2.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Breast Invasive Carcinoma (validation): 24/50 (48.0%); Pancreatic Adenocarcinoma (validation): 7/80 (8.8%),breast cancer: 11/11 (100.0%); endometrial cancer: 11/11 (100.0%),31,20,Q0P6D6,https://www.uniprot.org/uniprotkb/Q0P6D6/entry,"Plays an important role in primary cilium assembly, maintenance, and length regulation. Interacts with centriole inner scaffold proteins to promote proper centriole size and integrity and assembly of functional cilia. Required for the recruitment of both the inner scaffold protein POC1B and the distal SFI1/CETN2 complex to centrioles",,,,"Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriole Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriolar satellite",37934472,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Jamin2021_CT | Jamin2021_core | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,Failed bulk numeric comparisons are within 20% of their cutoffs; not an automatic rescue,,,,
CCDC150,ENSG00000144395,Unsafe,RNA,False,True,4.8,4.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,kidney: 2.5 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,kidney: 2.5 nTPM (limit 2); kidney: 2.5 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 26/50 (52.0%); Glioblastoma Multiforme (validation): 17/58 (29.3%); Pancreatic Adenocarcinoma (validation): 21/80 (26.2%),colorectal cancer: 11/12 (91.7%); liver cancer: 9/11 (81.8%),31,20,Q8NCX0,https://www.uniprot.org/uniprotkb/Q8NCX0/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Jamin2021_CT | Jamin2021_core | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CCDC152,ENSG00000198865,Unsafe,Protein,False,True,8.0,173.9,85,69,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 7.3 nTPM; positive ihc;continuous selectivity; adrenal gland: 5.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 5.2 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 5.7 nTPM; absolute ceiling;continuous selectivity; bone marrow: 1.5 nTPM; positive ihc; cerebellum: 1.2 nTPM; positive ihc; cerebral cortex: 3 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 2.7 nTPM; absolute ceiling;continuous selectivity; colon: 5.1 nTPM; positive ihc;continuous selectivity; duodenum: 3.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 2.2 nTPM; positive ihc; heart muscle: 7.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 6 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 7 nTPM; absolute ceiling;continuous selectivity; kidney: 8.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 173.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 5.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 7.2 nTPM; absolute ceiling;continuous selectivity; midbrain: 11.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 3.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 7.5 nTPM; absolute ceiling;continuous selectivity; rectum: 0.3 nTPM; positive ihc; retina: 2.2 nTPM; absolute ceiling;continuous selectivity; salivary gland: 2.6 nTPM; positive ihc; skeletal muscle: 1.7 nTPM; positive ihc; skin: 3.2 nTPM; positive ihc; small intestine: 13 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 0.4 nTPM; positive ihc; spinal cord: 18.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 14.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; stomach: 4.3 nTPM; positive ihc;continuous selectivity; thymus: 3.9 nTPM; continuous selectivity; thyroid gland: 3.2 nTPM; positive ihc; urinary bladder: 2.6 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 5.5 nTPM (limit 2); amygdala: 5.2 nTPM (limit 2); basal ganglia: 5.7 nTPM (limit 2); cerebral cortex: 3 nTPM (limit 2); choroid plexus: 2.7 nTPM (limit 2); duodenum: 3.8 nTPM (limit 2); heart muscle: 7.5 nTPM (limit 2); hippocampal formation: 6 nTPM (limit 2); hypothalamus: 7 nTPM (limit 2); kidney: 8.4 nTPM (limit 2); liver: 173.9 nTPM (limit 2); lung: 5.9 nTPM (limit 2); lymph node: 7.2 nTPM (limit 6); midbrain: 11.4 nTPM (limit 2); pancreas: 3.9 nTPM (limit 2); pituitary gland: 7.5 nTPM (limit 2); retina: 2.2 nTPM (limit 2); small intestine: 13 nTPM (limit 2); spinal cord: 18.7 nTPM (limit 2); spleen: 14.6 nTPM (limit 10),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Low (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Prostate Adenocarcinoma (TCGA): 480/480 (100.0%); Liver Hepatocellular Carcinoma (validation): 231/231 (100.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 168/176 (95.5%),pancreatic cancer: 6/11 (54.5%); colorectal cancer: 6/12 (50.0%),31,20,Q4G0S7,https://www.uniprot.org/uniprotkb/Q4G0S7/entry,,Detected in stomach,,,,,15809229,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CCDC157,ENSG00000187860,Unsafe,RNA,False,True,26.8,26.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 4 nTPM; absolute ceiling; basal ganglia: 4.5 nTPM; absolute ceiling; cerebral cortex: 4.4 nTPM; absolute ceiling; choroid plexus: 6.2 nTPM; absolute ceiling; hippocampal formation: 4.6 nTPM; absolute ceiling; hypothalamus: 6 nTPM; absolute ceiling; kidney: 2.9 nTPM; absolute ceiling; lung: 2.1 nTPM; absolute ceiling; midbrain: 2.5 nTPM; absolute ceiling; pituitary gland: 4.9 nTPM; absolute ceiling; retina: 2.2 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 4 nTPM (limit 2); basal ganglia: 4.5 nTPM (limit 2); cerebral cortex: 4.4 nTPM (limit 2); choroid plexus: 6.2 nTPM (limit 2); hippocampal formation: 4.6 nTPM (limit 2); hypothalamus: 6 nTPM (limit 2); kidney: 2.9 nTPM (limit 2); lung: 2.1 nTPM (limit 2); midbrain: 2.5 nTPM (limit 2); pituitary gland: 4.9 nTPM (limit 2); retina: 2.2 nTPM (limit 2); amygdala: 4 nTPM (baseline 2); basal ganglia: 4.5 nTPM (baseline 2); cerebral cortex: 4.4 nTPM (baseline 2); choroid plexus: 6.2 nTPM (baseline 2); hippocampal formation: 4.6 nTPM (baseline 2); hypothalamus: 6 nTPM (baseline 2); kidney: 2.9 nTPM (baseline 2); lung: 2.1 nTPM (baseline 2); midbrain: 2.5 nTPM (baseline 2); pituitary gland: 4.9 nTPM (baseline 2); retina: 2.2 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 40/50 (80.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 88/176 (50.0%); Kidney Renal Papillary Cell Carcinoma (TCGA): 89/282 (31.6%),skin cancer: 10/11 (90.9%); stomach cancer: 5/6 (83.3%),31,20,Q569K6,https://www.uniprot.org/uniprotkb/Q569K6/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CCDC169,ENSG00000242715,Unsafe,RNA,False,True,57.5,57.5,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 2.8 nTPM; absolute ceiling; retina: 2.5 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 2.8 nTPM (limit 2); retina: 2.5 nTPM (limit 2); bone marrow: 2.8 nTPM (baseline 2); retina: 2.5 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 19/58 (32.8%); Colon Adenocarcinoma (validation): 61/486 (12.6%); Rectum Adenocarcinoma (validation): 23/207 (11.1%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,A6NNP5,https://www.uniprot.org/uniprotkb/A6NNP5/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Loriot2025_S2,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct,,,,,,,,
CCDC170,ENSG00000120262,Unsafe,Protein,False,True,32.4,32.4,98,10,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; choroid plexus: 11.4 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 0.9 nTPM; positive ihc; thyroid gland: 5.4 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 11.4 nTPM (limit 2),bronchus / ciliated cells (cell body): Medium (Enhanced); bronchus / ciliated cells (ciliary rootlets): High (Enhanced); nasopharynx / ciliated cells (ciliary rootlets): Medium (Enhanced); smooth muscle / smooth muscle cells: Low (Enhanced); thyroid gland / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 542/1022 (53.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 53/176 (30.1%); Pancreatic Adenocarcinoma (validation): 23/80 (28.7%),breast cancer: 0/11 (0.0%); cervical cancer: 0/10 (0.0%),29,20,Q8IYT3,https://www.uniprot.org/uniprotkb/Q8IYT3/entry,Plays a role in Golgi-associated microtubules organization and stabilization,,,,Golgi apparatus,28687497,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CCDC171,ENSG00000164989,Unsafe,Protein,False,True,10.9,10.9,80,42,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 1 nTPM; positive ihc; bone marrow: 2 nTPM; positive ihc; cerebellum: 2.4 nTPM; positive ihc;absolute ceiling; cerebral cortex: 1.8 nTPM; positive ihc; colon: 0.9 nTPM; positive ihc; duodenum: 0.7 nTPM; positive ihc; esophagus: 0.9 nTPM; positive ihc; heart muscle: 1 nTPM; positive ihc; kidney: 1.1 nTPM; positive ihc; liver: 0.4 nTPM; positive ihc; lung: 1 nTPM; positive ihc; pancreas: 1.2 nTPM; positive ihc; parathyroid gland: 1.4 nTPM; positive ihc; rectum: 1 nTPM; positive ihc; retina: 5.2 nTPM; absolute ceiling;continuous selectivity; salivary gland: 0.7 nTPM; positive ihc; skeletal muscle: 0.8 nTPM; positive ihc; skin: 2.2 nTPM; positive ihc; small intestine: 0.9 nTPM; positive ihc; smooth muscle: 3.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; spleen: 0.6 nTPM; positive ihc; stomach: 1.3 nTPM; positive ihc; thyroid gland: 1.9 nTPM; positive ihc; urinary bladder: 0.7 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",cerebellum: 2.4 nTPM (limit 2); retina: 5.2 nTPM (limit 2); smooth muscle: 3.2 nTPM (limit 2); cerebellum: 2.4 nTPM (baseline 2); retina: 5.2 nTPM (baseline 2); smooth muscle: 3.2 nTPM (baseline 2),adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); cerebellum / Purkinje cells: Low (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / endothelial cells: Low (Uncertain); colon / glandular cells: Low (Uncertain); colon / peripheral nerve/ganglion: Low (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Low (Uncertain); heart muscle / cardiomyocytes: Low (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / alveolar cells: Low (Uncertain); lung / macrophages: Medium (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Low (Uncertain); pancreas / pancreatic endocrine cells: Low (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: Low (Uncertain); salivary gland / glandular cells: Low (Uncertain); skeletal muscle / myocytes: Low (Uncertain); skin 1 / fibroblasts: Low (Uncertain); skin 1 / keratinocytes: Low (Uncertain); skin 1 / Langerhans: Low (Uncertain); skin 2 / epidermal cells: Low (Uncertain); small intestine / glandular cells: Low (Uncertain); smooth muscle / smooth muscle cells: Low (Uncertain); spleen / cells in red pulp: Low (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Low (Uncertain); urinary bladder / urothelial cells: Low (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 39/58 (67.2%); Rectum Adenocarcinoma (validation): 80/207 (38.6%); Colon Adenocarcinoma (validation): 150/486 (30.9%),colorectal cancer: 4/12 (33.3%); breast cancer: 3/11 (27.3%),29,20,Q6TFL3,https://www.uniprot.org/uniprotkb/Q6TFL3/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CCDC172,ENSG00000182645,Unsafe,RNA,False,True,11.9,11.9,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,retina: 3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 3 nTPM (limit 2); retina: 3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 5/133 (3.8%); Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,P0C7W6,https://www.uniprot.org/uniprotkb/P0C7W6/entry,,,,,"Cytoplasm Cell projection, cilium",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Chang2019_TGCT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
CCDC18,ENSG00000122483,Unsafe,Protein,False,True,7.9,7.9,77,49,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 0.9 nTPM; positive ihc; bone marrow: 6.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 0.8 nTPM; positive ihc; cerebral cortex: 0.7 nTPM; positive ihc; colon: 1.4 nTPM; positive ihc; duodenum: 0.9 nTPM; positive ihc; esophagus: 1.2 nTPM; positive ihc; heart muscle: 0.9 nTPM; positive ihc; kidney: 0.6 nTPM; positive ihc; liver: 1.5 nTPM; positive ihc; lung: 1.1 nTPM; positive ihc; lymph node: 5.6 nTPM; positive ihc;continuous selectivity; pancreas: 0.4 nTPM; positive ihc; parathyroid gland: 0.3 nTPM; positive ihc; rectum: 1.8 nTPM; positive ihc; skeletal muscle: 1.9 nTPM; positive ihc; skin: 1.2 nTPM; positive ihc; small intestine: 1.5 nTPM; positive ihc; smooth muscle: 0.9 nTPM; positive ihc; stomach: 1.2 nTPM; positive ihc; thymus: 4.6 nTPM; continuous selectivity; thyroid gland: 0.7 nTPM; positive ihc; urinary bladder: 1.1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 6.3 nTPM (limit 2); bone marrow: 6.3 nTPM (baseline 2),adrenal gland / glandular cells: High (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / neuronal cells: Low (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / endothelial cells: Low (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / glandular cells: High (Uncertain); duodenum / glandular cells: High (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); kidney / cells in glomeruli: Low (Uncertain); kidney / cells in tubules: High (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / macrophages: Low (Uncertain); lymph node / germinal center cells: Low (Uncertain); lymph node / non-germinal center cells: Medium (Uncertain); nasopharynx / respiratory epithelial cells: Low (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Low (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: High (Uncertain); skeletal muscle / myocytes: Medium (Uncertain); skin 1 / Langerhans: Medium (Uncertain); skin 2 / epidermal cells: Low (Uncertain); small intestine / glandular cells: High (Uncertain); smooth muscle / smooth muscle cells: Low (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Low (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Breast Invasive Carcinoma (validation): 49/50 (98.0%); Colon Adenocarcinoma (validation): 369/486 (75.9%),colorectal cancer: 9/12 (75.0%); liver cancer: 7/12 (58.3%),31,20,Q5T9S5,https://www.uniprot.org/uniprotkb/Q5T9S5/entry,May promote pre-adipocyte differentiation,,,,"Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriolar satellite",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CCDC181,ENSG00000117477,Unsafe,Protein,False,True,25.5,38.7,106,14,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; amygdala: 6.7 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 8 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 31.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 7.4 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 11.1 nTPM; absolute ceiling;continuous selectivity; midbrain: 6 nTPM; absolute ceiling; pituitary gland: 17.6 nTPM; absolute ceiling;continuous selectivity; retina: 38.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 4.7 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 6.7 nTPM (limit 2); basal ganglia: 8 nTPM (limit 2); choroid plexus: 31.5 nTPM (limit 2); hippocampal formation: 7.4 nTPM (limit 2); hypothalamus: 11.1 nTPM (limit 2); midbrain: 6 nTPM (limit 2); pituitary gland: 17.6 nTPM (limit 2); retina: 38.7 nTPM (limit 2); spinal cord: 4.7 nTPM (limit 2),bronchus / ciliated cells (cilia axoneme): High (Enhanced); bronchus / ciliated cells (tip of cilia): High (Enhanced); nasopharynx / ciliated cells (cilia axoneme): High (Enhanced); nasopharynx / ciliated cells (tip of cilia): High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Glioblastoma Multiforme (TCGA): 90/141 (63.8%); Testicular Germ Cell Tumor (TCGA): 41/133 (30.8%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),29,20,Q5TID7,https://www.uniprot.org/uniprotkb/Q5TID7/entry,"Microtubule-binding protein that is essential for the integrity and function of the manchette, facilitating proper sperm head shaping and subsequent flagellum formation during spermatogenesis",,,,"Cytoplasm, cytoskeleton Cell projection, cilium, flagellum Cell projection, cilium Cytoplasm, cytoskeleton, cilium axoneme",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
CCDC188,ENSG00000234409,Unsafe,RNA,False,True,39.1,39.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,cerebellum: 2.5 nTPM; absolute ceiling; hypothalamus: 2.9 nTPM; absolute ceiling; pituitary gland: 9.3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebellum: 2.5 nTPM (limit 2); hypothalamus: 2.9 nTPM (limit 2); pituitary gland: 9.3 nTPM (limit 2); cerebellum: 2.5 nTPM (baseline 2); hypothalamus: 2.9 nTPM (baseline 2); pituitary gland: 9.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 8/176 (4.5%); Glioblastoma Multiforme (validation): 2/58 (3.4%); Pancreatic Adenocarcinoma (TCGA): 6/176 (3.4%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,H7C350,https://www.uniprot.org/uniprotkb/H7C350/entry,,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Chang2019_TGCT,Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CCDC196,ENSG00000196553,Unsafe,High RNA,False,True,5.3,5.3,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,CTA,Pass,oncoref.target-sets.2026-10-23.1,False,False,,CTA → Unsafe,True,True,True,2.4113438070599997,103.9,"hpa_single_cell: /Hepatocytes, max 66.4 nTPM, 1 observations >30; hpa_single_cell_tissue: liver/hepatocytes, max 103.9 nTPM, 5 observations >30; hpa_single_cell_tissue: rectum/intestinal goblet cells, max 103.3 nTPM, 3 observations >30",CTA,oncoref.target-sets.2026-10-23.2,2.411 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,103.9 nTPM; liver/hepatocytes; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (TCGA): 8/1022 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,A0A1B0GTZ2,https://www.uniprot.org/uniprotkb/A0A1B0GTZ2/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Loriot2025_S2 | Gong2021_reproductive_PC,Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
CCDC34,ENSG00000109881,Unsafe,RNA,False,True,47.4,47.4,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 5.1 nTPM; absolute ceiling; amygdala: 8.2 nTPM; absolute ceiling; basal ganglia: 10.1 nTPM; absolute ceiling; bone marrow: 13.6 nTPM; absolute ceiling;continuous selectivity; cerebellum: 2.9 nTPM; absolute ceiling; cerebral cortex: 8.9 nTPM; absolute ceiling; choroid plexus: 21.7 nTPM; absolute ceiling;continuous selectivity; colon: 8.5 nTPM; absolute ceiling; duodenum: 10.4 nTPM; absolute ceiling; heart muscle: 3.3 nTPM; absolute ceiling; hippocampal formation: 8.2 nTPM; absolute ceiling; hypothalamus: 6.7 nTPM; absolute ceiling; kidney: 4.8 nTPM; absolute ceiling; liver: 4.5 nTPM; absolute ceiling; lung: 2.3 nTPM; absolute ceiling; lymph node: 6.4 nTPM; absolute ceiling; midbrain: 4.9 nTPM; absolute ceiling; pancreas: 4.2 nTPM; absolute ceiling; parathyroid gland: 7.8 nTPM; absolute ceiling; pituitary gland: 5.4 nTPM; absolute ceiling; rectum: 9.8 nTPM; absolute ceiling; retina: 6 nTPM; absolute ceiling; skeletal muscle: 3 nTPM; absolute ceiling; small intestine: 8.7 nTPM; absolute ceiling; smooth muscle: 3.3 nTPM; absolute ceiling; spinal cord: 4.2 nTPM; absolute ceiling; stomach: 9 nTPM; absolute ceiling; thymus: 15.4 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 5.1 nTPM (limit 2); amygdala: 8.2 nTPM (limit 2); basal ganglia: 10.1 nTPM (limit 2); bone marrow: 13.6 nTPM (limit 2); cerebellum: 2.9 nTPM (limit 2); cerebral cortex: 8.9 nTPM (limit 2); choroid plexus: 21.7 nTPM (limit 2); colon: 8.5 nTPM (limit 6); duodenum: 10.4 nTPM (limit 2); heart muscle: 3.3 nTPM (limit 2); hippocampal formation: 8.2 nTPM (limit 2); hypothalamus: 6.7 nTPM (limit 2); kidney: 4.8 nTPM (limit 2); liver: 4.5 nTPM (limit 2); lung: 2.3 nTPM (limit 2); lymph node: 6.4 nTPM (limit 6); midbrain: 4.9 nTPM (limit 2); pancreas: 4.2 nTPM (limit 2); parathyroid gland: 7.8 nTPM (limit 6); pituitary gland: 5.4 nTPM (limit 2); rectum: 9.8 nTPM (limit 6); retina: 6 nTPM (limit 2); skeletal muscle: 3 nTPM (limit 2); small intestine: 8.7 nTPM (limit 2); smooth muscle: 3.3 nTPM (limit 2); spinal cord: 4.2 nTPM (limit 2); stomach: 9 nTPM (limit 6); thymus: 15.4 nTPM (limit 10); adrenal gland: 5.1 nTPM (baseline 2); amygdala: 8.2 nTPM (baseline 2); basal ganglia: 10.1 nTPM (baseline 2); bone marrow: 13.6 nTPM (baseline 2); cerebellum: 2.9 nTPM (baseline 2); cerebral cortex: 8.9 nTPM (baseline 2); choroid plexus: 21.7 nTPM (baseline 2); colon: 8.5 nTPM (baseline 6); duodenum: 10.4 nTPM (baseline 2); heart muscle: 3.3 nTPM (baseline 2); hippocampal formation: 8.2 nTPM (baseline 2); hypothalamus: 6.7 nTPM (baseline 2); kidney: 4.8 nTPM (baseline 2); liver: 4.5 nTPM (baseline 2); lung: 2.3 nTPM (baseline 2); lymph node: 6.4 nTPM (baseline 6); midbrain: 4.9 nTPM (baseline 2); pancreas: 4.2 nTPM (baseline 2); parathyroid gland: 7.8 nTPM (baseline 6); pituitary gland: 5.4 nTPM (baseline 2); rectum: 9.8 nTPM (baseline 6); retina: 6 nTPM (baseline 2); skeletal muscle: 3 nTPM (baseline 2); small intestine: 8.7 nTPM (baseline 2); smooth muscle: 3.3 nTPM (baseline 2); spinal cord: 4.2 nTPM (baseline 2); stomach: 9 nTPM (baseline 6); thymus: 15.4 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (TCGA): 254/254 (100.0%); Glioblastoma Multiforme (TCGA): 141/141 (100.0%); Rectum Adenocarcinoma (TCGA): 88/88 (100.0%),skin cancer: 8/11 (72.7%); urothelial cancer: 8/11 (72.7%),31,20,Q96HJ3,https://www.uniprot.org/uniprotkb/Q96HJ3/entry,Involved in spermatogenesis. Has a probable role in anterograde intraflagellar transport which is essential for the formation of sperm flagella,Expressed in sperm,"Spermatogenic failure 76: An autosomal recessive male infertility disorder characterized by oligoasthenoteratozoospermia, and abnormally shaped spermatozoa in the semen of affected individuals. Sperm flagella have multiple morphological abnormalities, including short, absent, and irregular caliber flagella.",,"Cell projection, cilium, flagellum",34348960,34348960,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CCDC38,ENSG00000165972,Unsafe,RNA,False,True,16.3,16.3,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,liver: 2.7 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,liver: 2.7 nTPM (limit 2); liver: 2.7 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 8/176 (4.5%); Testicular Germ Cell Tumor (TCGA): 5/133 (3.8%); Kidney Renal Papillary Cell Carcinoma (TCGA): 3/282 (1.1%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q502W7,https://www.uniprot.org/uniprotkb/Q502W7/entry,Essential for male fertility. Required for sperm flagellum biogenesis. Also required for acrosome biogenesis. Required for the attachment of developing acrosomes to the nucleus during spermiogenesis and may be involved in the transport of fibrous sheath components,,,,"Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Cytoplasm, perinuclear region Cell projection, cilium, flagellum Cytoplasm, cytoskeleton",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
CCDC63,ENSG00000173093,Unsafe,RNA,False,True,16.8,16.8,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,skeletal muscle: 2.6 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,skeletal muscle: 2.6 nTPM (limit 2); skeletal muscle: 2.6 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NA47,https://www.uniprot.org/uniprotkb/Q8NA47/entry,Plays a role in spermiogenesis. Involved in the elongation of flagella and the formation of sperm heads,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | Chang2019_TGCT | Gong2021_reproductive_PC | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
CCDC65,ENSG00000139537,Unsafe,RNA,False,True,36.2,36.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 2.1 nTPM; absolute ceiling; basal ganglia: 3.4 nTPM; absolute ceiling; cerebral cortex: 2.1 nTPM; absolute ceiling; choroid plexus: 18.9 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 3 nTPM; absolute ceiling; hypothalamus: 3.4 nTPM; absolute ceiling; lung: 2.8 nTPM; absolute ceiling; pituitary gland: 2.1 nTPM; absolute ceiling; retina: 6.9 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 2.1 nTPM (limit 2); basal ganglia: 3.4 nTPM (limit 2); cerebral cortex: 2.1 nTPM (limit 2); choroid plexus: 18.9 nTPM (limit 2); hippocampal formation: 3 nTPM (limit 2); hypothalamus: 3.4 nTPM (limit 2); lung: 2.8 nTPM (limit 2); pituitary gland: 2.1 nTPM (limit 2); retina: 6.9 nTPM (limit 2); amygdala: 2.1 nTPM (baseline 2); basal ganglia: 3.4 nTPM (baseline 2); cerebral cortex: 2.1 nTPM (baseline 2); choroid plexus: 18.9 nTPM (baseline 2); hippocampal formation: 3 nTPM (baseline 2); hypothalamus: 3.4 nTPM (baseline 2); lung: 2.8 nTPM (baseline 2); pituitary gland: 2.1 nTPM (baseline 2); retina: 6.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 22/50 (44.0%); Kidney Renal Papillary Cell Carcinoma (TCGA): 119/282 (42.2%); Glioblastoma Multiforme (validation): 19/58 (32.8%),colorectal cancer: 12/12 (100.0%); pancreatic cancer: 12/12 (100.0%),31,20,Q8IXS2,https://www.uniprot.org/uniprotkb/Q8IXS2/entry,"Component of the nexin-dynein regulatory complex (N-DRC), a key regulator of ciliary/flagellar motility which maintains the alignment and integrity of the distal axoneme and regulates microtubule sliding in motile axonemes (By similarity). Plays a critical role in the assembly of N-DRC and also stabilizes the assembly of multiple inner dynein arms and radial spokes. Coassembles with DRC1 to form a central scaffold needed for assembly of the N-DRC and its attachment to the outer doublet microtubules (PubMed:24094744)","Highly expressed in adult testis, in spermatocytes and spermatids. Also observed in spermatogonia. Not detected in Leydig cells, nor in fetal testis (at protein level)","Ciliary dyskinesia, primary, 27: A disorder characterized by abnormalities of motile cilia. Respiratory infections leading to chronic inflammation and bronchiectasis are recurrent, due to defects in the respiratory cilia. Patients may exhibit randomization of left-right body asymmetry and situs inversus, due to dysfunction of monocilia at the embryonic node. Primary ciliary dyskinesia associated with situs inversus is referred to as Kartagener syndrome.",,"Cytoplasm, cytoskeleton, flagellum basal body Cell projection, cilium, flagellum Cytoplasm, cytoskeleton, flagellum axoneme",24094744,17089017,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CCDC7,ENSG00000216937,Unsafe,RNA,False,True,76.9,76.9,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,retina: 2.6 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 2.6 nTPM (limit 2); retina: 2.6 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 52/58 (89.7%); Pancreatic Adenocarcinoma (validation): 68/80 (85.0%); Breast Invasive Carcinoma (validation): 26/50 (52.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q96M83,https://www.uniprot.org/uniprotkb/Q96M83/entry,May play a role in tumorigenesis,Expressed in epithelium of normal cervix and cervical cancer. Overexpressed in early and interim cervical cancer,,,,,21109960,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | Chang2019_TGCT,GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CCDC89,ENSG00000179071,Unsafe,Protein,False,True,42.4,42.4,92,29,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 0.9 nTPM; positive ihc; kidney: 1.1 nTPM; positive ihc; lymph node: 0.2 nTPM; positive ihc; skin: 0.4 nTPM; positive ihc; smooth muscle: 1.5 nTPM; positive ihc; urinary bladder: 0.7 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,adrenal gland / glandular cells: Low (Enhanced); hippocampus / neuronal cells: Low (Enhanced); kidney / cells in tubules: Low (Enhanced); lymph node / non-germinal center cells: Low (Enhanced); nasopharynx / basal cells: Low (Enhanced); nasopharynx / ciliated cells (cell body): Medium (Enhanced); skin 1 / keratinocytes: Low (Enhanced); skin 2 / epidermal cells: Low (Enhanced); smooth muscle / smooth muscle cells: Low (Enhanced); urinary bladder / urothelial cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 38/58 (65.5%); Breast Invasive Carcinoma (validation): 22/50 (44.0%); Kidney Renal Clear Cell Carcinoma (validation): 12/100 (12.0%),glioma: 1/12 (8.3%); prostate cancer: 1/12 (8.3%),31,20,Q8N998,https://www.uniprot.org/uniprotkb/Q8N998/entry,,,,,Cytoplasm Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CCDC93,ENSG00000125633,Unsafe,Protein,False,True,12.9,25.2,83,55,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 9.8 nTPM; continuous selectivity; adrenal gland: 14 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 7.2 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 8.7 nTPM; absolute ceiling;continuous selectivity; bone marrow: 21.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 15.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 8.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 14.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 10.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 11.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 7.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 20.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 6.9 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 8.1 nTPM; absolute ceiling;continuous selectivity; kidney: 9.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 7.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 11.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 10.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 7.4 nTPM; absolute ceiling;continuous selectivity; pancreas: 12.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 15.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 15.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 10.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 25.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 8.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 12.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 10.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 12.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 7.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 7.2 nTPM; absolute ceiling;continuous selectivity; spleen: 11.8 nTPM; continuous selectivity; stomach: 8.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 9.8 nTPM; continuous selectivity; thyroid gland: 11.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 9.9 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 8.3 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 14 nTPM (limit 2); amygdala: 7.2 nTPM (limit 2); basal ganglia: 8.7 nTPM (limit 2); bone marrow: 21.5 nTPM (limit 4); cerebellum: 15.7 nTPM (limit 2); cerebral cortex: 8.9 nTPM (limit 2); choroid plexus: 14.9 nTPM (limit 2); colon: 10.9 nTPM (limit 6); duodenum: 11.6 nTPM (limit 2); esophagus: 7.2 nTPM (limit 6); heart muscle: 20.6 nTPM (limit 2); hippocampal formation: 6.9 nTPM (limit 2); hypothalamus: 8.1 nTPM (limit 2); kidney: 9.5 nTPM (limit 2); liver: 7.6 nTPM (limit 2); lung: 11.4 nTPM (limit 2); lymph node: 10.1 nTPM (limit 6); midbrain: 7.4 nTPM (limit 2); pancreas: 12.7 nTPM (limit 2); parathyroid gland: 15.4 nTPM (limit 6); pituitary gland: 15.6 nTPM (limit 2); rectum: 10.3 nTPM (limit 6); retina: 25.2 nTPM (limit 2); salivary gland: 8.8 nTPM (limit 6); skeletal muscle: 12.4 nTPM (limit 2); skin: 10.7 nTPM (limit 10); small intestine: 12.4 nTPM (limit 2); smooth muscle: 7.8 nTPM (limit 2); spinal cord: 7.2 nTPM (limit 2); stomach: 8.8 nTPM (limit 6); thyroid gland: 11.5 nTPM (limit 10); tongue: 9.9 nTPM (limit 6); urinary bladder: 8.3 nTPM (limit 6),adrenal gland / glandular cells: High (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Medium (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: Medium (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Low (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Kidney Renal Clear Cell Carcinoma (validation): 100/100 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%),liver cancer: 12/12 (100.0%); colorectal cancer: 11/11 (100.0%),31,20,Q567U6,https://www.uniprot.org/uniprotkb/Q567U6/entry,"Component of the commander complex that is essential for endosomal recycling of transmembrane cargos; the commander complex is composed of composed of the CCC subcomplex and the retriever subcomplex (PubMed:37172566, PubMed:38459129). Component of the CCC complex, which is involved in the regulation of endosomal recycling of surface proteins, including integrins, signaling receptor and channels (PubMed:37172566, PubMed:38459129). The CCC complex associates with SNX17, retriever and WASH complexes to prevent lysosomal degradation and promote cell surface recycling of numerous cargos such as integrins ITGA5:ITGB1 (PubMed:25355947, PubMed:28892079). Involved in copper-dependent ATP7A trafficking between the trans-Golgi network and vesicles in the cell periphery; the function is proposed to depend on its association within the CCC complex and cooperation with the WASH complex on early endosomes and is dependent on its interaction with WASHC2C (PubMed:25355947) (Microbial infection) The CCC complex, in collaboration with the heterotrimeric retriever complex, mediates the exit of human papillomavirus to the cell surface",,,,Early endosome,25355947|28892079|37172566|38459129,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
CCHCR1,ENSG00000204536,Unsafe,RNA,False,True,135.1,135.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 10.1 nTPM; absolute ceiling; adrenal gland: 7.3 nTPM; absolute ceiling; amygdala: 9.3 nTPM; absolute ceiling; basal ganglia: 10.5 nTPM; absolute ceiling; cerebellum: 16.8 nTPM; absolute ceiling; cerebral cortex: 10.2 nTPM; absolute ceiling; colon: 15.7 nTPM; absolute ceiling; duodenum: 9.6 nTPM; absolute ceiling; esophagus: 14.7 nTPM; absolute ceiling; heart muscle: 11.3 nTPM; absolute ceiling; hippocampal formation: 8.7 nTPM; absolute ceiling; hypothalamus: 9.6 nTPM; absolute ceiling; kidney: 19.1 nTPM; absolute ceiling; liver: 11.9 nTPM; absolute ceiling; lung: 8.7 nTPM; absolute ceiling; lymph node: 6.8 nTPM; absolute ceiling; midbrain: 8.2 nTPM; absolute ceiling; pancreas: 14.1 nTPM; absolute ceiling; pituitary gland: 9 nTPM; absolute ceiling; salivary gland: 11.1 nTPM; absolute ceiling; skeletal muscle: 18.6 nTPM; absolute ceiling; skin: 16.9 nTPM; absolute ceiling; small intestine: 14.3 nTPM; absolute ceiling; spinal cord: 7.2 nTPM; absolute ceiling; spleen: 13 nTPM; absolute ceiling; stomach: 13.5 nTPM; absolute ceiling; thyroid gland: 15.6 nTPM; absolute ceiling; urinary bladder: 12.9 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adipose tissue: 10.1 nTPM (limit 10); adrenal gland: 7.3 nTPM (limit 2); amygdala: 9.3 nTPM (limit 2); basal ganglia: 10.5 nTPM (limit 2); cerebellum: 16.8 nTPM (limit 2); cerebral cortex: 10.2 nTPM (limit 2); colon: 15.7 nTPM (limit 6); duodenum: 9.6 nTPM (limit 2); esophagus: 14.7 nTPM (limit 6); heart muscle: 11.3 nTPM (limit 2); hippocampal formation: 8.7 nTPM (limit 2); hypothalamus: 9.6 nTPM (limit 2); kidney: 19.1 nTPM (limit 2); liver: 11.9 nTPM (limit 2); lung: 8.7 nTPM (limit 2); lymph node: 6.8 nTPM (limit 6); midbrain: 8.2 nTPM (limit 2); pancreas: 14.1 nTPM (limit 2); pituitary gland: 9 nTPM (limit 2); salivary gland: 11.1 nTPM (limit 6); skeletal muscle: 18.6 nTPM (limit 2); skin: 16.9 nTPM (limit 10); small intestine: 14.3 nTPM (limit 2); spinal cord: 7.2 nTPM (limit 2); spleen: 13 nTPM (limit 10); stomach: 13.5 nTPM (limit 6); thyroid gland: 15.6 nTPM (limit 10); urinary bladder: 12.9 nTPM (limit 6); adipose tissue: 10.1 nTPM (baseline 10); adrenal gland: 7.3 nTPM (baseline 2); amygdala: 9.3 nTPM (baseline 2); basal ganglia: 10.5 nTPM (baseline 2); cerebellum: 16.8 nTPM (baseline 2); cerebral cortex: 10.2 nTPM (baseline 2); colon: 15.7 nTPM (baseline 6); duodenum: 9.6 nTPM (baseline 2); esophagus: 14.7 nTPM (baseline 6); heart muscle: 11.3 nTPM (baseline 2); hippocampal formation: 8.7 nTPM (baseline 2); hypothalamus: 9.6 nTPM (baseline 2); kidney: 19.1 nTPM (baseline 2); liver: 11.9 nTPM (baseline 2); lung: 8.7 nTPM (baseline 2); lymph node: 6.8 nTPM (baseline 6); midbrain: 8.2 nTPM (baseline 2); pancreas: 14.1 nTPM (baseline 2); pituitary gland: 9 nTPM (baseline 2); salivary gland: 11.1 nTPM (baseline 6); skeletal muscle: 18.6 nTPM (baseline 2); skin: 16.9 nTPM (baseline 10); small intestine: 14.3 nTPM (baseline 2); spinal cord: 7.2 nTPM (baseline 2); spleen: 13 nTPM (baseline 10); stomach: 13.5 nTPM (baseline 6); thyroid gland: 15.6 nTPM (baseline 10); urinary bladder: 12.9 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Ovary Serous Cystadenocarcinoma (validation): 81/81 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Pancreatic Adenocarcinoma (validation): 79/80 (98.8%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8TD31,https://www.uniprot.org/uniprotkb/Q8TD31/entry,May be a regulator of keratinocyte proliferation or differentiation,"Found in all tissues tested, abundantly expressed in heart, liver, skeletal muscle, kidney and pancreas, and to a lesser extent in lung and placenta. Overexpressed in keratinocytes of psoriatic lesions",,,Cytoplasm Nucleus,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
CCL17,ENSG00000102970,Unsafe,Protein,False,True,1.9,20.5,77,57,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 1.1 nTPM; continuous selectivity; adrenal gland: 0.1 nTPM; positive ihc; bone marrow: 0 nTPM; positive ihc; cerebellum: 0.1 nTPM; positive ihc; cerebral cortex: 0.1 nTPM; positive ihc; colon: 1.4 nTPM; positive ihc;continuous selectivity; duodenum: 0.1 nTPM; positive ihc; esophagus: 3 nTPM; continuous selectivity;reproductive not higher; heart muscle: 1.3 nTPM; positive ihc;continuous selectivity; kidney: 0.6 nTPM; positive ihc;continuous selectivity; liver: 0.3 nTPM; positive ihc; lung: 4.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 8.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 0.4 nTPM; positive ihc; parathyroid gland: 0.1 nTPM; positive ihc; rectum: 2.6 nTPM; positive ihc;continuous selectivity;reproductive not higher; salivary gland: 2.5 nTPM; positive ihc;continuous selectivity;reproductive not higher; skeletal muscle: 0.1 nTPM; positive ihc; skin: 2.4 nTPM; positive ihc;continuous selectivity;reproductive not higher; small intestine: 3.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 2.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; stomach: 0.7 nTPM; positive ihc; thymus: 20.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 0.8 nTPM; positive ihc; urinary bladder: 3.3 nTPM; positive ihc;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",lung: 4.4 nTPM (limit 2); lymph node: 8.2 nTPM (limit 6); small intestine: 3.6 nTPM (limit 2); smooth muscle: 2.5 nTPM (limit 2); thymus: 20.5 nTPM (limit 10); lung: 4.4 nTPM (baseline 2); lymph node: 8.2 nTPM (baseline 6); small intestine: 3.6 nTPM (baseline 2); smooth muscle: 2.5 nTPM (baseline 2); thymus: 20.5 nTPM (baseline 10),adrenal gland / glandular cells: Low (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / neuronal cells: Low (Uncertain); cerebellum / cells in molecular layer: Low (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / neuronal cells: Low (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / glandular cells: Low (Uncertain); colon / peripheral nerve/ganglion: Low (Uncertain); duodenum / glandular cells: Medium (Uncertain); heart muscle / cardiomyocytes: Low (Uncertain); hippocampus / neuronal cells: Low (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / cholangiocytes: Low (Uncertain); liver / hepatocytes: Low (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / germinal center cells: Medium (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); oral mucosa / squamous epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Low (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: Low (Uncertain); salivary gland / glandular cells: Low (Uncertain); skeletal muscle / myocytes: Low (Uncertain); skin 1 / fibroblasts: Low (Uncertain); skin 1 / keratinocytes: Medium (Uncertain); skin 1 / Langerhans: Low (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: Medium (Uncertain); smooth muscle / smooth muscle cells: Low (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (TCGA): 101/176 (57.4%); Breast Invasive Carcinoma (validation): 25/50 (50.0%); Lung Adenocarcinoma (TCGA): 231/497 (46.5%),colorectal cancer: 10/11 (90.9%); endometrial cancer: 10/11 (90.9%),31,20,Q92583,https://www.uniprot.org/uniprotkb/Q92583/entry,"Chemokine, which displays chemotactic activity for T lymphocytes, preferentially Th2 cells, but not monocytes or granulocytes. Therefore plays an important role in a wide range of inflammatory and immunological processes (PubMed:8702936, PubMed:9169480). Acts by binding to CCR4 at T-cell surface (PubMed:10540332, PubMed:9169480). Mediates GM-CSF/CSF2-driven pain and inflammation (PubMed:27525438). In the brain, required to maintain the typical, highly branched morphology of hippocampal microglia under homeostatic conditions. May be important for the appropriate adaptation of microglial morphology and synaptic plasticity to acute lipopolysaccharide (LPS)-induced neuroinflammation (By similarity). Plays a role in wound healing, mainly by inducing fibroblast migration into the wound (By similarity)","Constitutively expressed in thymus. Detected at lower levels in the lung, colon and small intestine (PubMed:8702936). Expressed in stimulated peripheral blood mononuclear cells, but not in resting cells (PubMed:8702936)",,"Although CCL17 was shown to bind to CCR8, additional studies demonstrated that CCR4, not CCR8, was the bona fide CCL17 receptor Was originally thought to be a ligand for CCR8",Secreted,10540332|27525438|8702936|9169480,8702936,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CCL27,ENSG00000213927,Unsafe,Protein,False,True,26.6,470.5,95,7,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 1.6 nTPM; positive ihc; lymph node: 0.3 nTPM; positive ihc; skin: 470.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; spleen: 0.1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",skin: 470.5 nTPM (limit 10); skin: 470.5 nTPM (baseline 10),bone marrow / hematopoietic cells: Medium (Enhanced); lymph node / non-germinal center cells: Medium (Enhanced); skin 1 / cells in spinous layer: Medium (Enhanced); skin 2 / cells in spinous layer: Medium (Enhanced); skin 2 / fibrohistiocytic cells: High (Enhanced); spleen / cells in red pulp: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Head and Neck Squamous Cell Carcinoma (TCGA): 35/492 (7.1%); Bladder Urothelial Carcinoma (TCGA): 11/169 (6.5%); Skin Cuteneous Melanoma (TCGA): 6/99 (6.1%),renal cancer: 1/12 (8.3%); breast cancer: 0/11 (0.0%),31,20,Q9Y4X3,https://www.uniprot.org/uniprotkb/Q9Y4X3/entry,Chemotactic factor that attracts skin-associated memory T-lymphocytes. May play a role in mediating homing of lymphocytes to cutaneous sites. Binds to CCR10,"Testis, thymus, placenta, ovary and skin",,,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
CCN6,ENSG00000112761,Unsafe,RNA,False,True,9.9,9.9,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,cerebellum: 3.1 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebellum: 3.1 nTPM (limit 2); cerebellum: 3.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Ovary Serous Cystadenocarcinoma (validation): 33/81 (40.7%); Pancreatic Adenocarcinoma (validation): 25/80 (31.2%); Ovary Serous Cystadenocarcinoma (TCGA): 106/349 (30.4%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,O95389,https://www.uniprot.org/uniprotkb/O95389/entry,"Plays a role in mitochondrial electron transport and mitochondrial respiration (PubMed:27252383). Through its regulation of the mitochondrial function may play a role in normal postnatal skeletal growth and cartilage homeostasis (PubMed:10471507, PubMed:27252383)","Predominant expression in adult kidney and testis and fetal kidney. Weaker expression found in placenta, ovary, prostate and small intestine (PubMed:10471507, PubMed:9843955). Also expressed in skeletally-derived cells such as synoviocytes and articular cartilage chondrocytes (PubMed:10471507)","Progressive pseudorheumatoid dysplasia: An autosomal recessive disorder characterized by stiffness and swelling of joints, motor weakness and joint contractures. Signs and symptoms of the disease develop typically between three and eight years of age. This progressive disease is a primary disorder of articular cartilage with continued cartilage loss and destructive bone changes with aging.",,Secreted Mitochondrion,10471507|27252383,10471507|9843955,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
CCNA1,ENSG00000133101,Unsafe,Protein,False,True,79.0,79.0,102,7,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; amygdala: 6.1 nTPM; absolute ceiling; basal ganglia: 11.9 nTPM; absolute ceiling; choroid plexus: 8.2 nTPM; absolute ceiling; hippocampal formation: 7.4 nTPM; absolute ceiling; hypothalamus: 9.4 nTPM; absolute ceiling; midbrain: 3.2 nTPM; absolute ceiling; pituitary gland: 8 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 6.1 nTPM (limit 2); basal ganglia: 11.9 nTPM (limit 2); choroid plexus: 8.2 nTPM (limit 2); hippocampal formation: 7.4 nTPM (limit 2); hypothalamus: 9.4 nTPM (limit 2); midbrain: 3.2 nTPM (limit 2); pituitary gland: 8 nTPM (limit 2),bronchus / ciliated cells (cell body): High (Enhanced); nasopharynx / ciliated cells (cell body): Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Ovary Serous Cystadenocarcinoma (TCGA): 265/349 (75.9%); Ovary Serous Cystadenocarcinoma (validation): 58/81 (71.6%); Uterine Corpus Endometrial Carcinoma (TCGA): 111/176 (63.1%),breast cancer: 0/12 (0.0%); cervical cancer: 0/12 (0.0%),31,20,P78396,https://www.uniprot.org/uniprotkb/P78396/entry,May be involved in the control of the cell cycle at the G1/S (start) and G2/M (mitosis) transitions. May primarily function in the control of the germline meiotic cell cycle and additionally in the control of mitotic cell cycle in some somatic cells,Very high levels in testis and very low levels in brain. Also found in myeloid leukemia cell lines,,,Nucleus,10022926,9041194,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Jamin2021_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CCNB2,ENSG00000157456,Unsafe,Protein,False,True,67.4,73.6,128,54,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 1 nTPM; positive ihc; bone marrow: 73.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 0.9 nTPM; positive ihc; colon: 13.8 nTPM; positive ihc;absolute ceiling; duodenum: 13.7 nTPM; positive ihc;absolute ceiling; esophagus: 15.7 nTPM; positive ihc;absolute ceiling; kidney: 1.1 nTPM; positive ihc; lymph node: 32.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; pancreas: 0.7 nTPM; positive ihc; rectum: 16.3 nTPM; positive ihc;absolute ceiling; skeletal muscle: 0.6 nTPM; positive ihc; skin: 9.2 nTPM; positive ihc; small intestine: 11.7 nTPM; positive ihc;absolute ceiling; smooth muscle: 6.2 nTPM; positive ihc;absolute ceiling; spleen: 6.9 nTPM; positive ihc; stomach: 5.4 nTPM; positive ihc; thymus: 71.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 1 nTPM; positive ihc; urinary bladder: 3.5 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 73.6 nTPM (limit 2); colon: 13.8 nTPM (limit 6); duodenum: 13.7 nTPM (limit 2); esophagus: 15.7 nTPM (limit 6); lymph node: 32.2 nTPM (limit 6); rectum: 16.3 nTPM (limit 6); small intestine: 11.7 nTPM (limit 2); smooth muscle: 6.2 nTPM (limit 2); thymus: 71.2 nTPM (limit 10),adrenal gland / glandular cells: Medium (Enhanced); bone marrow / hematopoietic cells: High (Enhanced); bronchus / respiratory epithelial cells: Low (Enhanced); caudate / neuronal cells: Low (Enhanced); cerebral cortex / neuronal cells: Low (Enhanced); colon / endocrine cells: High (Enhanced); colon / goblet cells: Low (Enhanced); colon / mucosal lymphoid cells: Low (Enhanced); duodenum / endocrine cells: High (Enhanced); esophagus / squamous epithelial cells: Medium (Enhanced); hippocampus / neuronal cells: Low (Enhanced); kidney / cells in tubules: Low (Enhanced); lymph node / germinal center cells: Medium (Enhanced); lymph node / non-germinal center cells: Medium (Enhanced); nasopharynx / respiratory epithelial cells: Low (Enhanced); oral mucosa / squamous epithelial cells: Low (Enhanced); pancreas / exocrine glandular cells: Low (Enhanced); rectum / endocrine cells: High (Enhanced); rectum / enterocytes: Medium (Enhanced); rectum / mucosal lymphoid cells: Medium (Enhanced); skeletal muscle / myocytes: Low (Enhanced); skin 2 / cells in basal layer: Low (Enhanced); skin 2 / cells in spinous layer: Low (Enhanced); skin 2 / eccrine glands: Low (Enhanced); small intestine / endocrine cells: Medium (Enhanced); smooth muscle / smooth muscle cells: Low (Enhanced); spleen / cells in red pulp: Low (Enhanced); spleen / cells in white pulp: Low (Enhanced); stomach 1 / glandular cells: Low (Enhanced); stomach 2 / glandular cells: Low (Enhanced); thyroid gland / glandular cells: Low (Enhanced); urinary bladder / urothelial cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (TCGA): 88/88 (100.0%); Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%); Head and Neck Squamous Cell Carcinoma (TCGA): 491/492 (99.8%),colorectal cancer: 10/12 (83.3%); cervical cancer: 8/12 (66.7%),31,20,O95067,https://www.uniprot.org/uniprotkb/O95067/entry,Essential for the control of the cell cycle at the G2/M (mitosis) transition,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CCNB3,ENSG00000147082,Unsafe,RNA,False,True,5.7,5.7,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,spinal cord: 2.5 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,spinal cord: 2.5 nTPM (limit 2); spinal cord: 2.5 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 11/50 (22.0%); Glioblastoma Multiforme (validation): 2/58 (3.4%); Lung Squamous Cell Carcinoma (validation): 1/68 (1.5%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q8WWL7,https://www.uniprot.org/uniprotkb/Q8WWL7/entry,"Cyclins are positive regulatory subunits of the cyclin-dependent kinases (CDKs), and thereby play an essential role in the control of the cell cycle, notably via their destruction during cell division. Its tissue specificity suggest that it may be required during early meiotic prophase I","Testis specific. In testis, it is expressed in developing germ cells, but not in Leydig cells. Weakly or not expressed in other tissues",,,Nucleus,12185076,11846420|12185076,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Loriot2025_S2,Cancer-germline RNA nomination; strict and preferential classes remain distinct,,,,,,,,
CCNE2,ENSG00000175305,Unsafe,Protein,False,True,14.1,36.5,87,35,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 2.1 nTPM; absolute ceiling; basal ganglia: 2.1 nTPM; absolute ceiling; bone marrow: 36.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 2.2 nTPM; positive ihc;absolute ceiling; cerebral cortex: 7.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 5.3 nTPM; positive ihc;continuous selectivity; duodenum: 3.5 nTPM; positive ihc;absolute ceiling; esophagus: 4.5 nTPM; positive ihc; hippocampal formation: 4 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 2.4 nTPM; absolute ceiling; lung: 1.7 nTPM; positive ihc; lymph node: 10.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 5.4 nTPM; absolute ceiling;continuous selectivity; rectum: 5.5 nTPM; positive ihc;continuous selectivity; retina: 5 nTPM; absolute ceiling;continuous selectivity; skin: 5.7 nTPM; positive ihc; small intestine: 4.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 17.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; stomach: 3.9 nTPM; positive ihc; thymus: 14.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 2 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 2.1 nTPM (limit 2); basal ganglia: 2.1 nTPM (limit 2); bone marrow: 36.5 nTPM (limit 2); cerebellum: 2.2 nTPM (limit 2); cerebral cortex: 7.3 nTPM (limit 2); duodenum: 3.5 nTPM (limit 2); hippocampal formation: 4 nTPM (limit 2); hypothalamus: 2.4 nTPM (limit 2); lymph node: 10.6 nTPM (limit 6); midbrain: 5.4 nTPM (limit 2); retina: 5 nTPM (limit 2); small intestine: 4.2 nTPM (limit 2); spinal cord: 17.5 nTPM (limit 2); thymus: 14.7 nTPM (limit 10),bone marrow / hematopoietic cells: Medium (Enhanced); bronchus / respiratory epithelial cells: Low (Enhanced); caudate / glial cells: Medium (Enhanced); cerebellum / cells in granular layer: Low (Enhanced); cerebellum / cells in molecular layer: Medium (Enhanced); cerebral cortex / glial cells: Medium (Enhanced); colon / glandular cells: Low (Enhanced); duodenum / glandular cells: Low (Enhanced); esophagus / squamous epithelial cells: Low (Enhanced); hippocampus / glial cells: Low (Enhanced); lung / alveolar cells: Low (Enhanced); lung / macrophages: Low (Enhanced); lymph node / germinal center cells: Medium (Enhanced); lymph node / non-germinal center cells: Medium (Enhanced); nasopharynx / respiratory epithelial cells: Low (Enhanced); oral mucosa / squamous epithelial cells: Low (Enhanced); rectum / glandular cells: Low (Enhanced); skin 1 / keratinocytes: Medium (Enhanced); skin 1 / Langerhans: Low (Enhanced); skin 2 / epidermal cells: Medium (Enhanced); small intestine / glandular cells: Low (Enhanced); stomach 1 / glandular cells: Low (Enhanced); stomach 2 / glandular cells: Medium (Enhanced); urinary bladder / urothelial cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 480/486 (98.8%); Rectum Adenocarcinoma (validation): 199/207 (96.1%),glioma: 7/12 (58.3%); lymphoma: 7/12 (58.3%),31,20,O96020,https://www.uniprot.org/uniprotkb/O96020/entry,Essential for the control of the cell cycle at the late G1 and early S phase,"According to PubMed:9858585, highest levels of expression in adult testis, thymus and brain. Lower levels in placenta, spleen and colon. Consistently elevated levels in tumor-derived cells compared to non-transformed proliferating cells. According to PubMed:9840927: low levels in thymus, prostate, brain, skeletal muscle, and kidney. Elevated levels in lung. According to PubMed:9840943 highly expressed in testis, placenta, thymus and brain. In a lesser extent in small intestine and colon",,,Nucleus,9840927|9840943|9858585,9840927|9840943|9858585,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
CCSER1,ENSG00000184305,Unsafe,Protein,False,True,2.5,3.3,78,21,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 0.2 nTPM; positive ihc; adrenal gland: 1.1 nTPM; continuous selectivity; cerebral cortex: 0.8 nTPM; positive ihc;continuous selectivity; colon: 0.2 nTPM; positive ihc; duodenum: 0.3 nTPM; positive ihc; heart muscle: 0.9 nTPM; continuous selectivity; kidney: 0.9 nTPM; continuous selectivity; lung: 0.2 nTPM; positive ihc; rectum: 0.2 nTPM; positive ihc; retina: 3.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 0.5 nTPM; positive ihc; small intestine: 0.3 nTPM; positive ihc; smooth muscle: 0.1 nTPM; positive ihc; stomach: 0.4 nTPM; positive ihc; thyroid gland: 0.7 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",retina: 3.3 nTPM (limit 2); retina: 3.3 nTPM (baseline 2),adipose tissue / adipocytes: Medium (Uncertain); cerebral cortex / endothelial cells: Low (Uncertain); colon / endothelial cells: Medium (Uncertain); duodenum / glandular cells: Low (Uncertain); lung / alveolar cells: Medium (Uncertain); lung / macrophages: Medium (Uncertain); rectum / glandular cells: Low (Uncertain); skin 1 / fibroblasts: Medium (Uncertain); skin 2 / epidermal cells: Low (Uncertain); small intestine / glandular cells: Medium (Uncertain); smooth muscle / smooth muscle cells: Low (Uncertain); stomach 2 / glandular cells: Low (Uncertain); thyroid gland / glandular cells: Low (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 72/80 (90.0%); Colon Adenocarcinoma (validation): 55/486 (11.3%); Glioblastoma Multiforme (validation): 6/58 (10.3%),colorectal cancer: 11/12 (91.7%); prostate cancer: 8/11 (72.7%),29,20,Q9C0I3,https://www.uniprot.org/uniprotkb/Q9C0I3/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CCT6B,ENSG00000132141,Unsafe,Protein,False,True,122.5,122.5,83,57,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 3.2 nTPM; positive ihc;absolute ceiling; amygdala: 2.1 nTPM; absolute ceiling; basal ganglia: 2.2 nTPM; absolute ceiling; bone marrow: 3.8 nTPM; positive ihc;absolute ceiling; cerebellum: 1 nTPM; positive ihc; cerebral cortex: 1.9 nTPM; positive ihc; duodenum: 1.4 nTPM; positive ihc; esophagus: 1.7 nTPM; positive ihc; kidney: 3.9 nTPM; positive ihc;absolute ceiling; liver: 4.8 nTPM; positive ihc;absolute ceiling; lung: 1.2 nTPM; positive ihc; lymph node: 1.3 nTPM; positive ihc; midbrain: 2.8 nTPM; absolute ceiling; pancreas: 2.6 nTPM; positive ihc;absolute ceiling; pituitary gland: 2.7 nTPM; absolute ceiling; rectum: 1.1 nTPM; positive ihc; retina: 2.2 nTPM; absolute ceiling; salivary gland: 3.2 nTPM; positive ihc; skeletal muscle: 4.9 nTPM; absolute ceiling; skin: 2.7 nTPM; positive ihc; small intestine: 1.4 nTPM; positive ihc; spinal cord: 3.2 nTPM; absolute ceiling; spleen: 1.5 nTPM; positive ihc; stomach: 2 nTPM; positive ihc; thyroid gland: 2.8 nTPM; positive ihc; urinary bladder: 1.8 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 3.2 nTPM (limit 2); amygdala: 2.1 nTPM (limit 2); basal ganglia: 2.2 nTPM (limit 2); bone marrow: 3.8 nTPM (limit 2); kidney: 3.9 nTPM (limit 2); liver: 4.8 nTPM (limit 2); midbrain: 2.8 nTPM (limit 2); pancreas: 2.6 nTPM (limit 2); pituitary gland: 2.7 nTPM (limit 2); retina: 2.2 nTPM (limit 2); skeletal muscle: 4.9 nTPM (limit 2); spinal cord: 3.2 nTPM (limit 2); adrenal gland: 3.2 nTPM (baseline 2); amygdala: 2.1 nTPM (baseline 2); basal ganglia: 2.2 nTPM (baseline 2); bone marrow: 3.8 nTPM (baseline 2); kidney: 3.9 nTPM (baseline 2); liver: 4.8 nTPM (baseline 2); midbrain: 2.8 nTPM (baseline 2); pancreas: 2.6 nTPM (baseline 2); pituitary gland: 2.7 nTPM (baseline 2); retina: 2.2 nTPM (baseline 2); skeletal muscle: 4.9 nTPM (baseline 2); spinal cord: 3.2 nTPM (baseline 2),adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Low (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: Low (Uncertain); cerebellum / cells in molecular layer: Low (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / glial cells: Medium (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: Low (Uncertain); duodenum / glandular cells: High (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / macrophages: Low (Uncertain); lymph node / germinal center cells: Medium (Uncertain); lymph node / non-germinal center cells: Medium (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Low (Uncertain); skin 2 / epidermal cells: Low (Uncertain); small intestine / glandular cells: Medium (Uncertain); spleen / cells in white pulp: Low (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Low (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 47/50 (94.0%); Glioblastoma Multiforme (validation): 40/58 (69.0%); Prostate Adenocarcinoma (TCGA): 185/480 (38.5%),colorectal cancer: 12/12 (100.0%); testis cancer: 11/12 (91.7%),31,20,Q92526,https://www.uniprot.org/uniprotkb/Q92526/entry,"Could function as a component of a tissue-specific chaperonin-containing T-complex (TRiC), a molecular chaperone complex that assists the folding of actin, tubulin and other proteins upon ATP hydrolysis",Testis-specific,,,Cytoplasm,,8812458,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CD101,ENSG00000134256,Unsafe,Protein,False,True,0.6,6.5,79,47,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 0.7 nTPM; positive ihc;continuous selectivity;reproductive not higher; bone marrow: 4.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 0 nTPM; positive ihc; cerebral cortex: 0.3 nTPM; positive ihc;continuous selectivity; colon: 1.8 nTPM; positive ihc;continuous selectivity;reproductive not higher; duodenum: 3.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 0.9 nTPM; positive ihc;continuous selectivity;reproductive not higher; heart muscle: 0.4 nTPM; positive ihc;continuous selectivity; kidney: 0.2 nTPM; positive ihc; liver: 0.6 nTPM; positive ihc;continuous selectivity;reproductive not higher; lung: 6.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 1.9 nTPM; positive ihc;continuous selectivity;reproductive not higher; pancreas: 0.8 nTPM; positive ihc;continuous selectivity;reproductive not higher; parathyroid gland: 0 nTPM; positive ihc; rectum: 2.3 nTPM; positive ihc;continuous selectivity;reproductive not higher; salivary gland: 1.5 nTPM; positive ihc;continuous selectivity;reproductive not higher; skeletal muscle: 0.1 nTPM; positive ihc; skin: 0.9 nTPM; positive ihc;continuous selectivity;reproductive not higher; small intestine: 6.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 1.3 nTPM; positive ihc;continuous selectivity;reproductive not higher; spleen: 3.1 nTPM; continuous selectivity;reproductive not higher; stomach: 1.4 nTPM; positive ihc;continuous selectivity;reproductive not higher; thymus: 1.2 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 0.3 nTPM; positive ihc; urinary bladder: 1.2 nTPM; continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 4.7 nTPM (limit 2); duodenum: 3.5 nTPM (limit 2); lung: 6.5 nTPM (limit 2); small intestine: 6.1 nTPM (limit 2),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Low (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Low (Approved); colon / endothelial cells: Low (Approved); duodenum / glandular cells: Low (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in tubules: Low (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Low (Approved); lung / macrophages: Low (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Low (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Low (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Low (Approved); smooth muscle / smooth muscle cells: Medium (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Low (Approved); thyroid gland / glandular cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 47/58 (81.0%); Breast Invasive Carcinoma (validation): 23/50 (46.0%); Rectum Adenocarcinoma (validation): 35/207 (16.9%),melanoma: 7/12 (58.3%); urothelial cancer: 5/12 (41.7%),31,20,Q93033,https://www.uniprot.org/uniprotkb/Q93033/entry,Plays a role as inhibitor of T-cells proliferation induced by CD3. Inhibits expression of IL2RA on activated T-cells and secretion of IL2. Inhibits tyrosine kinases that are required for IL2 production and cellular proliferation. Inhibits phospholipase C-gamma-1/PLCG1 phosphorylation and subsequent CD3-induced changes in intracellular free calcium. Prevents nuclear translocation of nuclear factor of activated T-cell to the nucleus. Plays a role in the inhibition of T-cell proliferation via IL10 secretion by cutaneous dendritic cells. May be a marker of CD4(+) CD56(+) leukemic tumor cells,"Expressed in lung, thymus and small intestine. Detected in cutaneous dendritic cells, activated T-cells, monocytes and granulocytes as well as with epithelial cells with dendritic morphology. Expressed in some leukemic cells, the CD4(+) CD56(+) blastic tumor cells, as well as in Langerhans cells from LCH (Langerhans cell histiocytosis) patients",,,Membrane,11093127|15737213|7722299|9233604|9389317|9647226,10692025|15737213|7722299|7722300|9389317,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CD200R1L,ENSG00000206531,Unsafe,High RNA,False,True,2.7,2.7,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,hpa_immune_cell basophil: 85.4 nTPM; hpa_immune_monaco basophil: 167.4 TPM,True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,167.4,110.6663,"hpa_immune_cell: blood/basophil, max 85.4 nTPM, 1 observations >30; hpa_immune_cell_samples: blood/basophil, max 101.574 TPM, 3 observations >30; hpa_immune_cell_samples: blood/basophil, max 110.666 nTPM, 3 observations >30; hpa_immune_monaco: blood/basophil, max 167.4 TPM, 1 observations >30; hpa_single_cell_tissue: brain/excitatory neurons, max 33.1 nTPM, 1 observations >30",Neither,oncoref.target-sets.2026-10-23.2,167.4 TPM; blood/basophil; hpa_immune_monaco; vital,110.7 nTPM; blood/basophil; hpa_immune_cell_samples; vital,Testicular Germ Cell Tumor (TCGA): 2/133 (1.5%); Lung Squamous Cell Carcinoma (validation): 1/68 (1.5%); Colon Adenocarcinoma (validation): 4/486 (0.8%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q6Q8B3,https://www.uniprot.org/uniprotkb/Q6Q8B3/entry,May be a receptor for the CD200/OX2 cell surface glycoprotein,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
CDADC1,ENSG00000102543,Unsafe,Protein,False,True,7.6,9.2,77,8,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 4.8 nTPM; continuous selectivity; adrenal gland: 6.6 nTPM; absolute ceiling;continuous selectivity; amygdala: 4.1 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 3.6 nTPM; absolute ceiling;continuous selectivity; bone marrow: 6.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 6.2 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 4.7 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 4.5 nTPM; absolute ceiling;continuous selectivity; colon: 4.6 nTPM; continuous selectivity; duodenum: 3 nTPM; absolute ceiling;continuous selectivity; esophagus: 3.1 nTPM; continuous selectivity; heart muscle: 4.2 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 4 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 4.5 nTPM; absolute ceiling;continuous selectivity; kidney: 9.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; liver: 7.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 3.4 nTPM; absolute ceiling;continuous selectivity; lymph node: 3 nTPM; positive ihc;continuous selectivity; midbrain: 4 nTPM; absolute ceiling;continuous selectivity; pancreas: 2.6 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 5.3 nTPM; continuous selectivity; pituitary gland: 3.2 nTPM; absolute ceiling;continuous selectivity; rectum: 3.1 nTPM; continuous selectivity; retina: 5.1 nTPM; absolute ceiling;continuous selectivity; salivary gland: 3.3 nTPM; continuous selectivity; skeletal muscle: 4.3 nTPM; absolute ceiling;continuous selectivity; small intestine: 2.9 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 3.6 nTPM; absolute ceiling;continuous selectivity; spinal cord: 3.5 nTPM; absolute ceiling;continuous selectivity; spleen: 4 nTPM; positive ihc;continuous selectivity; stomach: 3.8 nTPM; continuous selectivity; thymus: 4.2 nTPM; continuous selectivity; thyroid gland: 9.1 nTPM; continuous selectivity;reproductive not higher; tongue: 5 nTPM; continuous selectivity; urinary bladder: 3.4 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 6.6 nTPM (limit 2); amygdala: 4.1 nTPM (limit 2); basal ganglia: 3.6 nTPM (limit 2); bone marrow: 6.2 nTPM (limit 2); cerebellum: 6.2 nTPM (limit 2); cerebral cortex: 4.7 nTPM (limit 2); choroid plexus: 4.5 nTPM (limit 2); duodenum: 3 nTPM (limit 2); heart muscle: 4.2 nTPM (limit 2); hippocampal formation: 4 nTPM (limit 2); hypothalamus: 4.5 nTPM (limit 2); kidney: 9.2 nTPM (limit 2); liver: 7.9 nTPM (limit 2); lung: 3.4 nTPM (limit 2); midbrain: 4 nTPM (limit 2); pancreas: 2.6 nTPM (limit 2); pituitary gland: 3.2 nTPM (limit 2); retina: 5.1 nTPM (limit 2); skeletal muscle: 4.3 nTPM (limit 2); small intestine: 2.9 nTPM (limit 2); smooth muscle: 3.6 nTPM (limit 2); spinal cord: 3.5 nTPM (limit 2); adrenal gland: 6.6 nTPM (baseline 2); amygdala: 4.1 nTPM (baseline 2); basal ganglia: 3.6 nTPM (baseline 2); bone marrow: 6.2 nTPM (baseline 2); cerebellum: 6.2 nTPM (baseline 2); cerebral cortex: 4.7 nTPM (baseline 2); choroid plexus: 4.5 nTPM (baseline 2); duodenum: 3 nTPM (baseline 2); heart muscle: 4.2 nTPM (baseline 2); hippocampal formation: 4 nTPM (baseline 2); hypothalamus: 4.5 nTPM (baseline 2); kidney: 9.2 nTPM (baseline 2); liver: 7.9 nTPM (baseline 2); lung: 3.4 nTPM (baseline 2); midbrain: 4 nTPM (baseline 2); pancreas: 2.6 nTPM (baseline 2); pituitary gland: 3.2 nTPM (baseline 2); retina: 5.1 nTPM (baseline 2); skeletal muscle: 4.3 nTPM (baseline 2); small intestine: 2.9 nTPM (baseline 2); smooth muscle: 3.6 nTPM (baseline 2); spinal cord: 3.5 nTPM (baseline 2),bone marrow / hematopoietic cells: Medium (Uncertain); lymph node / germinal center cells: Medium (Uncertain); lymph node / non-germinal center cells: Medium (Uncertain); spleen / cells in red pulp: Medium (Uncertain); spleen / cells in white pulp: Medium (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 46/50 (92.0%); Pancreatic Adenocarcinoma (validation): 51/80 (63.7%),breast cancer: 0/12 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q9BWV3,https://www.uniprot.org/uniprotkb/Q9BWV3/entry,"Catalyzes the deamination of dCTP to dUTP, exhibiting a strong substrate preference for dCTP over CTP (PubMed:40324085, PubMed:40504152). No deaminase activity toward 5-methyl-dCTP, cytidine, or deoxycytidine (PubMed:40324085, PubMed:40504152). May play an important role in testicular development and spermatogenesis (PubMed:16955368). In addition to its role on endogenous nucleotides, it deaminates the active triphosphate forms of the cytidine analog drugs, gemcitabine (dFdCTP) and decitabine (5-aza-dCTP), rendering them susceptible to inactivation by deoxyuridine triphosphatase (DUT). This process limits drug-induced cytotoxicity and contributes to cellular resistance to gemcitabine and decitabine (PubMed:40504152)",Widely expressed. Expressed at high levels in the testis,,"CDADC1 was initially reported to exhibit cytidine deaminase activity (PubMed:26945630). However, subsequent studies demonstrated that it specifically deaminates dCTP, with no activity toward cytidine or deoxycytidine (PubMed:40324085, PubMed:40504152). The initial attribution may have been an artifact of using partially purified recombinant protein. While one study reported weak activity on dCMP, another failed to detect any dCMP deamination (PubMed:40324085, PubMed:40504152)",Cytoplasm Nucleus,16955368|40324085|40504152,16955368,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
CDC25A,ENSG00000164045,Unsafe,RNA,False,True,12.9,15.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 15.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thymus: 8.6 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 15.1 nTPM (limit 2); bone marrow: 15.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 127/133 (95.5%); Colon Adenocarcinoma (validation): 462/486 (95.1%); Glioblastoma Multiforme (validation): 54/58 (93.1%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P30304,https://www.uniprot.org/uniprotkb/P30304/entry,"Tyrosine protein phosphatase which functions as a dosage-dependent inducer of mitotic progression (PubMed:12676925, PubMed:14559997, PubMed:1836978, PubMed:20360007). Directly dephosphorylates CDK1 and stimulates its kinase activity (PubMed:20360007). Also dephosphorylates CDK2 in complex with cyclin-E, in vitro (PubMed:20360007)",,,,,12676925|14559997|1836978|20360007,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Jamin2021_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CDC25C,ENSG00000158402,Unsafe,Protein,False,True,17.5,17.5,79,69,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 0.2 nTPM; positive ihc; adrenal gland: 0.2 nTPM; positive ihc; bone marrow: 5.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 0.1 nTPM; positive ihc; cerebral cortex: 0.2 nTPM; positive ihc; colon: 3.3 nTPM; positive ihc; duodenum: 2.9 nTPM; positive ihc;absolute ceiling; esophagus: 1.4 nTPM; positive ihc; heart muscle: 0.1 nTPM; positive ihc; kidney: 0.1 nTPM; positive ihc; lung: 0.3 nTPM; positive ihc; lymph node: 3.1 nTPM; positive ihc; pancreas: 0.3 nTPM; positive ihc; rectum: 3.9 nTPM; positive ihc; salivary gland: 0.3 nTPM; positive ihc; skeletal muscle: 0 nTPM; positive ihc; skin: 1.3 nTPM; positive ihc; small intestine: 2.9 nTPM; positive ihc;absolute ceiling; spleen: 0.9 nTPM; positive ihc; stomach: 1.1 nTPM; positive ihc; thymus: 8.6 nTPM; continuous selectivity; thyroid gland: 0.1 nTPM; positive ihc; urinary bladder: 0.5 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 5.7 nTPM (limit 2); duodenum: 2.9 nTPM (limit 2); small intestine: 2.9 nTPM (limit 2),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: High (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: High (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: High (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: High (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: High (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: High (Approved); oral mucosa / squamous epithelial cells: High (Approved); pancreas / exocrine glandular cells: High (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: High (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: High (Approved); small intestine / glandular cells: High (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 449/486 (92.4%); Rectum Adenocarcinoma (validation): 177/207 (85.5%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 236/283 (83.4%),cervical cancer: 12/12 (100.0%); lung cancer: 12/12 (100.0%),31,20,P30307,https://www.uniprot.org/uniprotkb/P30307/entry,"Functions as a dosage-dependent inducer in mitotic control. Tyrosine protein phosphatase required for progression of the cell cycle (PubMed:8119945). When phosphorylated, highly effective in activating G2 cells into prophase (PubMed:8119945). Directly dephosphorylates CDK1 and activates its kinase activity (PubMed:8119945)",,,,Nucleus,8119945,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Jamin2021_CT | Jamin2021_core | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CDC40,ENSG00000168438,Unsafe,RNA,False,True,14.2,37.7,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 10.7 nTPM; absolute ceiling;continuous selectivity; adrenal gland: 14.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 7.5 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 14.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 37.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 8.6 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 12.9 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 6.6 nTPM; absolute ceiling;continuous selectivity; colon: 10.7 nTPM; absolute ceiling;continuous selectivity; duodenum: 10.7 nTPM; absolute ceiling;continuous selectivity; esophagus: 10.4 nTPM; absolute ceiling;continuous selectivity; heart muscle: 10.1 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 10.6 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 6.5 nTPM; absolute ceiling;continuous selectivity; kidney: 15.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; liver: 16.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 10.6 nTPM; absolute ceiling;continuous selectivity; lymph node: 19.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 5.9 nTPM; absolute ceiling;continuous selectivity; pancreas: 12 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 13.5 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 9.2 nTPM; absolute ceiling;continuous selectivity; rectum: 11.7 nTPM; absolute ceiling;continuous selectivity; retina: 14.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 10.7 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 11.2 nTPM; absolute ceiling;continuous selectivity; skin: 10.3 nTPM; absolute ceiling;continuous selectivity; small intestine: 10.7 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 9.8 nTPM; absolute ceiling;continuous selectivity; spinal cord: 6.8 nTPM; absolute ceiling;continuous selectivity; spleen: 15.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; stomach: 11.1 nTPM; absolute ceiling;continuous selectivity; thymus: 18.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 15.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; tongue: 11.1 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 12.2 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adipose tissue: 10.7 nTPM (limit 10); adrenal gland: 14.2 nTPM (limit 2); amygdala: 7.5 nTPM (limit 2); basal ganglia: 14.2 nTPM (limit 2); bone marrow: 37.7 nTPM (limit 2); cerebellum: 8.6 nTPM (limit 2); cerebral cortex: 12.9 nTPM (limit 2); choroid plexus: 6.6 nTPM (limit 2); colon: 10.7 nTPM (limit 6); duodenum: 10.7 nTPM (limit 2); esophagus: 10.4 nTPM (limit 6); heart muscle: 10.1 nTPM (limit 2); hippocampal formation: 10.6 nTPM (limit 2); hypothalamus: 6.5 nTPM (limit 2); kidney: 15.7 nTPM (limit 2); liver: 16.3 nTPM (limit 2); lung: 10.6 nTPM (limit 2); lymph node: 19.1 nTPM (limit 6); midbrain: 5.9 nTPM (limit 2); pancreas: 12 nTPM (limit 2); parathyroid gland: 13.5 nTPM (limit 6); pituitary gland: 9.2 nTPM (limit 2); rectum: 11.7 nTPM (limit 6); retina: 14.3 nTPM (limit 2); salivary gland: 10.7 nTPM (limit 6); skeletal muscle: 11.2 nTPM (limit 2); skin: 10.3 nTPM (limit 10); small intestine: 10.7 nTPM (limit 2); smooth muscle: 9.8 nTPM (limit 2); spinal cord: 6.8 nTPM (limit 2); spleen: 15.6 nTPM (limit 10); stomach: 11.1 nTPM (limit 6); thymus: 18.1 nTPM (limit 10); thyroid gland: 15.4 nTPM (limit 10); tongue: 11.1 nTPM (limit 6); urinary bladder: 12.2 nTPM (limit 6); adipose tissue: 10.7 nTPM (baseline 10); adrenal gland: 14.2 nTPM (baseline 2); amygdala: 7.5 nTPM (baseline 2); basal ganglia: 14.2 nTPM (baseline 2); bone marrow: 37.7 nTPM (baseline 2); cerebellum: 8.6 nTPM (baseline 2); cerebral cortex: 12.9 nTPM (baseline 2); choroid plexus: 6.6 nTPM (baseline 2); colon: 10.7 nTPM (baseline 6); duodenum: 10.7 nTPM (baseline 2); esophagus: 10.4 nTPM (baseline 6); heart muscle: 10.1 nTPM (baseline 2); hippocampal formation: 10.6 nTPM (baseline 2); hypothalamus: 6.5 nTPM (baseline 2); kidney: 15.7 nTPM (baseline 2); liver: 16.3 nTPM (baseline 2); lung: 10.6 nTPM (baseline 2); lymph node: 19.1 nTPM (baseline 6); midbrain: 5.9 nTPM (baseline 2); pancreas: 12 nTPM (baseline 2); parathyroid gland: 13.5 nTPM (baseline 6); pituitary gland: 9.2 nTPM (baseline 2); rectum: 11.7 nTPM (baseline 6); retina: 14.3 nTPM (baseline 2); salivary gland: 10.7 nTPM (baseline 6); skeletal muscle: 11.2 nTPM (baseline 2); skin: 10.3 nTPM (baseline 10); small intestine: 10.7 nTPM (baseline 2); smooth muscle: 9.8 nTPM (baseline 2); spinal cord: 6.8 nTPM (baseline 2); spleen: 15.6 nTPM (baseline 10); stomach: 11.1 nTPM (baseline 6); thymus: 18.1 nTPM (baseline 10); thyroid gland: 15.4 nTPM (baseline 10); tongue: 11.1 nTPM (baseline 6); urinary bladder: 12.2 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%); Pancreatic Adenocarcinoma (validation): 80/80 (100.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O60508,https://www.uniprot.org/uniprotkb/O60508/entry,Required for pre-mRNA splicing as component of the activated spliceosome (PubMed:33220177). Plays an important role in embryonic brain development; this function does not require proline isomerization (PubMed:33220177),,"Pontocerebellar hypoplasia 15: A form of pontocerebellar hypoplasia, a disorder characterized by structural defects of the pons and cerebellum, evident upon brain imaging. PCH15 is a severe autosomal recessive form characterized by progressive microcephaly, and poor or absent psychomotor development with severely impaired intellectual development apparent from birth. Other features may include spastic quadriplegia, early-onset seizures, and chronic anemia and thrombocytopenia.",,Nucleus Nucleus speckle,28076346|28502770|29301961|29360106|29361316|30705154|33220177|9830021,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
CDC45,ENSG00000093009,Unsafe,Protein,False,True,22.7,25.1,105,38,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0.5 nTPM; positive ihc; bone marrow: 25.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; colon: 4.5 nTPM; positive ihc; kidney: 0.3 nTPM; positive ihc; lung: 0.9 nTPM; positive ihc; lymph node: 11.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 3.2 nTPM; positive ihc; stomach: 2.5 nTPM; positive ihc; thymus: 19.8 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 1.9 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 25.1 nTPM (limit 2); lymph node: 11.1 nTPM (limit 6); thymus: 19.8 nTPM (limit 10),adipose tissue / adipocytes: Low (Enhanced); bone marrow / hematopoietic cells: Low (Enhanced); bronchus / respiratory epithelial cells: Low (Enhanced); colon / endothelial cells: Low (Enhanced); hippocampus / glial cells: Low (Enhanced); kidney / cells in glomeruli: Low (Enhanced); kidney / cells in tubules: Low (Enhanced); lung / alveolar cells: Low (Enhanced); lung / macrophages: Low (Enhanced); lymph node / germinal center cells: Medium (Enhanced); nasopharynx / respiratory epithelial cells: Low (Enhanced); oral mucosa / squamous epithelial cells: Low (Enhanced); skin 1 / fibrohistiocytic cells: High (Enhanced); skin 2 / endothelial cells: Low (Enhanced); skin 2 / fibrohistiocytic cells: High (Enhanced); stomach 1 / glandular cells: Low (Enhanced); stomach 2 / glandular cells: Low (Enhanced); urinary bladder / urothelial cells: Low (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Squamous Cell Carcinoma (validation): 66/68 (97.1%); Lung Squamous Cell Carcinoma (TCGA): 474/489 (96.9%); Colon Adenocarcinoma (TCGA): 244/254 (96.1%),prostate cancer: 6/11 (54.5%); melanoma: 4/11 (36.4%),31,20,O75419,https://www.uniprot.org/uniprotkb/O75419/entry,"Required for initiation of chromosomal DNA replication. Core component of CDC45-MCM-GINS (CMG) helicase, the molecular machine that unwinds template DNA during replication, and around which the replisome is built","Widely expressed, highest levels are found in adult testis and thymus and in fetal liver","Meier-Gorlin syndrome 7: A form of Meier-Gorlin syndrome, a syndrome characterized by bilateral microtia, aplasia/hypoplasia of the patellae, and severe intrauterine and postnatal growth retardation with short stature and poor weight gain. Additional clinical findings include anomalies of cranial sutures, microcephaly, apparently low-set and simple ears, microstomia, full lips, highly arched or cleft palate, micrognathia, genitourinary tract anomalies, and various skeletal anomalies. While almost all cases have primordial dwarfism with substantial prenatal and postnatal growth retardation, not all cases have microcephaly, and microtia and absent/hypoplastic patella are absent in some. Despite the presence of microcephaly, intellect is usually normal. MGORS7 inheritance is autosomal recessive.",,Nucleus Chromosome,32453425|34694004|34700328|35585232,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CDC6,ENSG00000094804,Unsafe,Protein,False,True,9.8,26.9,80,68,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 1.8 nTPM; positive ihc; bone marrow: 26.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 0.7 nTPM; positive ihc; cerebral cortex: 1.5 nTPM; positive ihc; colon: 8.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 7.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 5.5 nTPM; positive ihc;continuous selectivity; heart muscle: 0.6 nTPM; positive ihc; kidney: 0.5 nTPM; positive ihc; liver: 2.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 1.3 nTPM; positive ihc; lymph node: 16 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 1.8 nTPM; positive ihc; rectum: 8.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; salivary gland: 1.3 nTPM; positive ihc; skeletal muscle: 0.3 nTPM; positive ihc; skin: 2.7 nTPM; positive ihc; small intestine: 6.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 3.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; spleen: 3.6 nTPM; positive ihc; stomach: 3.5 nTPM; positive ihc;continuous selectivity; thymus: 16.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 1.7 nTPM; positive ihc; urinary bladder: 4.2 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 26.9 nTPM (limit 2); colon: 8.1 nTPM (limit 6); duodenum: 7.3 nTPM (limit 2); liver: 2.9 nTPM (limit 2); lymph node: 16 nTPM (limit 6); rectum: 8.4 nTPM (limit 6); small intestine: 6.5 nTPM (limit 2); smooth muscle: 3.6 nTPM (limit 2); thymus: 16.2 nTPM (limit 10),adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Low (Approved); esophagus / squamous epithelial cells: High (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: High (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: High (Approved); spleen / cells in red pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Testicular Germ Cell Tumor (TCGA): 133/133 (100.0%); Colon Adenocarcinoma (TCGA): 253/254 (99.6%),testis cancer: 12/12 (100.0%); pancreatic cancer: 9/11 (81.8%),31,20,Q99741,https://www.uniprot.org/uniprotkb/Q99741/entry,Involved in the initiation of DNA replication. Also participates in checkpoint controls that ensure DNA replication is completed before mitosis is initiated,,"Meier-Gorlin syndrome 5: A syndrome characterized by bilateral microtia, aplasia/hypoplasia of the patellae, and severe intrauterine and postnatal growth retardation with short stature and poor weight gain. Additional clinical findings include anomalies of cranial sutures, microcephaly, apparently low-set and simple ears, microstomia, full lips, highly arched or cleft palate, micrognathia, genitourinary tract anomalies, and various skeletal anomalies. While almost all cases have primordial dwarfism with substantial prenatal and postnatal growth retardation, not all cases have microcephaly, and microtia and absent/hypoplastic patella are absent in some. Despite the presence of microcephaly, intellect is usually normal.",,Nucleus Cytoplasm,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
CDCA2,ENSG00000184661,Unsafe,Protein,False,True,18.9,18.9,136,53,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 6.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 0.1 nTPM; positive ihc; colon: 1.8 nTPM; positive ihc; duodenum: 1.5 nTPM; positive ihc; esophagus: 1.4 nTPM; positive ihc; kidney: 0 nTPM; positive ihc; lymph node: 5.1 nTPM; positive ihc; pancreas: 0 nTPM; positive ihc; rectum: 2.1 nTPM; positive ihc; salivary gland: 0.1 nTPM; positive ihc; skin: 1.1 nTPM; positive ihc; small intestine: 1.8 nTPM; positive ihc; stomach: 0.8 nTPM; positive ihc; thymus: 11.1 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 0.1 nTPM; positive ihc; urinary bladder: 0.5 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 6.4 nTPM (limit 2); thymus: 11.1 nTPM (limit 10),bone marrow / hematopoietic cells: Medium (Enhanced); bronchus / respiratory epithelial cells: Medium (Enhanced); caudate / neuronal cells: Medium (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); colon / endocrine cells: High (Enhanced); colon / enterocytes: High (Enhanced); colon / goblet cells: Medium (Enhanced); duodenum / endocrine cells: High (Enhanced); duodenum / enterocytes: Medium (Enhanced); duodenum / goblet cells: Medium (Enhanced); esophagus / squamous epithelial cells: Medium (Enhanced); kidney / cells in glomeruli: Low (Enhanced); kidney / cells in tubules: Medium (Enhanced); lymph node / non-germinal center cells: Low (Enhanced); nasopharynx / respiratory epithelial cells: Low (Enhanced); oral mucosa / squamous epithelial cells: Low (Enhanced); pancreas / exocrine glandular cells: Low (Enhanced); rectum / endocrine cells: High (Enhanced); rectum / enterocytes: Medium (Enhanced); rectum / goblet cells: Medium (Enhanced); salivary gland / glandular cells: Low (Enhanced); skin 1 / endothelial cells: Low (Enhanced); skin 2 / cells in basal layer: Low (Enhanced); small intestine / endocrine cells: High (Enhanced); small intestine / enterocytes: Medium (Enhanced); small intestine / goblet cells: Medium (Enhanced); stomach 1 / glandular cells: Medium (Enhanced); stomach 2 / glandular cells: Medium (Enhanced); thyroid gland / glandular cells: Medium (Enhanced); urinary bladder / urothelial cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 55/58 (94.8%); Colon Adenocarcinoma (validation): 434/486 (89.3%); Rectum Adenocarcinoma (validation): 170/207 (82.1%),colorectal cancer: 4/11 (36.4%); lung cancer: 3/11 (27.3%),31,20,Q69YH5,https://www.uniprot.org/uniprotkb/Q69YH5/entry,"Regulator of chromosome structure during mitosis required for condensin-depleted chromosomes to retain their compact architecture through anaphase. Acts by mediating the recruitment of phosphatase PP1-gamma subunit (PPP1CC) to chromatin at anaphase and into the following interphase. At anaphase onset, its association with chromatin targets a pool of PPP1CC to dephosphorylate substrates",Ubiquitously expressed,,,Nucleus,16492807|16998479,16492807,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CDCA5,ENSG00000146670,Unsafe,Protein,False,True,36.8,52.7,122,60,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 1.2 nTPM; positive ihc; bone marrow: 52.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 0.8 nTPM; positive ihc; cerebral cortex: 2.7 nTPM; positive ihc;absolute ceiling; colon: 6.6 nTPM; positive ihc;absolute ceiling; duodenum: 5.6 nTPM; positive ihc;absolute ceiling; esophagus: 9.1 nTPM; positive ihc;absolute ceiling; kidney: 0.9 nTPM; positive ihc; lymph node: 16.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; pancreas: 0.7 nTPM; positive ihc; parathyroid gland: 0.4 nTPM; positive ihc; rectum: 7.4 nTPM; positive ihc;absolute ceiling; salivary gland: 1.4 nTPM; positive ihc; skeletal muscle: 0.6 nTPM; positive ihc; skin: 4.1 nTPM; positive ihc; small intestine: 5.7 nTPM; positive ihc;absolute ceiling; spleen: 6.4 nTPM; positive ihc; stomach: 3.1 nTPM; positive ihc; thymus: 26.8 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 0.6 nTPM; positive ihc; urinary bladder: 2.1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 52.7 nTPM (limit 2); cerebral cortex: 2.7 nTPM (limit 2); colon: 6.6 nTPM (limit 6); duodenum: 5.6 nTPM (limit 2); esophagus: 9.1 nTPM (limit 6); lymph node: 16.6 nTPM (limit 6); rectum: 7.4 nTPM (limit 6); small intestine: 5.7 nTPM (limit 2); thymus: 26.8 nTPM (limit 10),adrenal gland / glandular cells: Medium (Enhanced); bone marrow / hematopoietic cells: High (Enhanced); bronchus / respiratory epithelial cells: Low (Enhanced); cerebellum / Purkinje cells: High (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); colon / endocrine cells: High (Enhanced); colon / enterocytes: Medium (Enhanced); colon / goblet cells: Medium (Enhanced); colon / mucosal lymphoid cells: Medium (Enhanced); duodenum / endocrine cells: High (Enhanced); duodenum / enterocytes: Medium (Enhanced); duodenum / goblet cells: Medium (Enhanced); esophagus / squamous epithelial cells: Medium (Enhanced); hippocampus / neuronal cells: Medium (Enhanced); kidney / cells in tubules: Medium (Enhanced); lymph node / germinal center cells: High (Enhanced); lymph node / non-germinal center cells: Medium (Enhanced); oral mucosa / squamous epithelial cells: Low (Enhanced); pancreas / exocrine glandular cells: Low (Enhanced); parathyroid gland / glandular cells: Medium (Enhanced); rectum / endocrine cells: High (Enhanced); rectum / enterocytes: High (Enhanced); rectum / goblet cells: Medium (Enhanced); rectum / mucosal lymphoid cells: Low (Enhanced); salivary gland / glandular cells: Low (Enhanced); skeletal muscle / myocytes: Low (Enhanced); skin 1 / cells in basal layer: Medium (Enhanced); skin 1 / cells in spinous layer: Medium (Enhanced); skin 2 / cells in basal layer: Medium (Enhanced); skin 2 / cells in spinous layer: Medium (Enhanced); small intestine / endocrine cells: High (Enhanced); small intestine / enterocytes: Medium (Enhanced); spleen / cells in red pulp: Medium (Enhanced); spleen / cells in white pulp: Medium (Enhanced); stomach 1 / glandular cells: Medium (Enhanced); stomach 2 / glandular cells: Medium (Enhanced); thyroid gland / glandular cells: Low (Enhanced); urinary bladder / urothelial cells: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 283/283 (100.0%); Rectum Adenocarcinoma (TCGA): 88/88 (100.0%); Colon Adenocarcinoma (TCGA): 253/254 (99.6%),liver cancer: 12/12 (100.0%); lung cancer: 12/12 (100.0%),31,20,Q96FF9,https://www.uniprot.org/uniprotkb/Q96FF9/entry,"Regulator of sister chromatid cohesion in mitosis, stabilizing cohesin complex association with chromatin. May antagonize the action of WAPL which stimulates cohesin dissociation from chromatin. Cohesion ensures that chromosome partitioning is accurate in both meiotic and mitotic cells and plays an important role in DNA repair. Required for efficient DNA double-stranded break repair",,,,Nucleus Chromosome Cytoplasm,15837422|17349791|21111234|41261216,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CDCA8,ENSG00000134690,Unsafe,Protein,False,True,21.9,37.8,125,60,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 1 nTPM; positive ihc; bone marrow: 33.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 0.5 nTPM; positive ihc; cerebral cortex: 0.8 nTPM; positive ihc; colon: 9.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 8.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 9 nTPM; positive ihc;absolute ceiling;continuous selectivity; kidney: 0.8 nTPM; positive ihc; liver: 1.3 nTPM; positive ihc; lymph node: 19 nTPM; positive ihc;absolute ceiling;continuous selectivity; pancreas: 0.8 nTPM; positive ihc; rectum: 10.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 6.2 nTPM; positive ihc; small intestine: 7.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 4.7 nTPM; positive ihc; thymus: 37.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 1.9 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 33.1 nTPM (limit 2); colon: 9.1 nTPM (limit 6); duodenum: 8.1 nTPM (limit 2); esophagus: 9 nTPM (limit 6); lymph node: 19 nTPM (limit 6); rectum: 10.9 nTPM (limit 6); small intestine: 7.1 nTPM (limit 2); thymus: 37.8 nTPM (limit 10),adrenal gland / glandular cells: Low (Enhanced); bone marrow / hematopoietic cells: Medium (Enhanced); caudate / neuronal cells: Low (Enhanced); cerebellum / cells in molecular layer: Low (Enhanced); cerebellum / Purkinje cells: Low (Enhanced); cerebral cortex / neuropil: Low (Enhanced); colon / endocrine cells: High (Enhanced); duodenum / endocrine cells: High (Enhanced); duodenum / enterocytes: Low (Enhanced); duodenum / goblet cells: Low (Enhanced); esophagus / squamous epithelial cells: Low (Enhanced); kidney / cells in tubules: Low (Enhanced); liver / hepatocytes: Low (Enhanced); lymph node / germinal center cells: Medium (Enhanced); lymph node / non-germinal center cells: Low (Enhanced); nasopharynx / respiratory epithelial cells: Low (Enhanced); oral mucosa / squamous epithelial cells: Low (Enhanced); pancreas / exocrine glandular cells: Low (Enhanced); rectum / endocrine cells: High (Enhanced); rectum / endothelial cells: Medium (Enhanced); rectum / enterocytes: Low (Enhanced); rectum / enterocytes - Microvilli: Low (Enhanced); rectum / goblet cells: Low (Enhanced); rectum / mucosal lymphoid cells: Medium (Enhanced); rectum / peripheral nerve/ganglion: Medium (Enhanced); skin 1 / cells in basal layer: Medium (Enhanced); skin 1 / cells in spinous layer: Medium (Enhanced); skin 1 / endothelial cells: Medium (Enhanced); skin 2 / cells in basal layer: Medium (Enhanced); skin 2 / cells in spinous layer: Medium (Enhanced); skin 2 / endothelial cells: Medium (Enhanced); skin 2 / fibrohistiocytic cells: High (Enhanced); skin 2 / lymphocytes: Medium (Enhanced); small intestine / enterocytes: Low (Enhanced); small intestine / enterocytes - Microvilli: Low (Enhanced); stomach 1 / glandular cells: Low (Enhanced); stomach 2 / glandular cells: Low (Enhanced); urinary bladder / urothelial cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (TCGA): 254/254 (100.0%); Rectum Adenocarcinoma (TCGA): 88/88 (100.0%); Colon Adenocarcinoma (validation): 485/486 (99.8%),colorectal cancer: 11/11 (100.0%); cervical cancer: 11/12 (91.7%),31,20,Q53HL2,https://www.uniprot.org/uniprotkb/Q53HL2/entry,"Component of the chromosomal passenger complex (CPC), a complex that acts as a key regulator of mitosis. The CPC complex has essential functions at the centromere in ensuring correct chromosome alignment and segregation and is required for chromatin-induced microtubule stabilization and spindle assembly. Major effector of the TTK kinase in the control of attachment-error-correction and chromosome alignment",,,,"Nucleus, nucleolus Cytoplasm Cytoplasm, cytoskeleton, spindle Chromosome, centromere",15249581|15260989|16571674|18243099,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CDK13,ENSG00000065883,Unsafe,Protein,False,True,17.1,27.3,79,20,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 10 nTPM; continuous selectivity; adrenal gland: 9 nTPM; absolute ceiling;continuous selectivity; amygdala: 5 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 5.8 nTPM; absolute ceiling;continuous selectivity; bone marrow: 27.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 11.6 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 9.8 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 7.9 nTPM; absolute ceiling;continuous selectivity; colon: 11.1 nTPM; absolute ceiling;continuous selectivity; duodenum: 10 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 12.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 9.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 5.3 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 5.4 nTPM; absolute ceiling;continuous selectivity; kidney: 11.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 14.7 nTPM; absolute ceiling;continuous selectivity; lung: 10.8 nTPM; absolute ceiling;continuous selectivity; lymph node: 19.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 4.9 nTPM; absolute ceiling;continuous selectivity; pancreas: 11.6 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 15.1 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 7.7 nTPM; absolute ceiling;continuous selectivity; rectum: 12.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 18.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 11.5 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 10.8 nTPM; absolute ceiling;continuous selectivity; skin: 11.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 11.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 10.6 nTPM; absolute ceiling;continuous selectivity; spinal cord: 5.7 nTPM; absolute ceiling;continuous selectivity; spleen: 15.5 nTPM; absolute ceiling;continuous selectivity; stomach: 11.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 16.8 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 18.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; tongue: 12.6 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 11.4 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 9 nTPM (limit 2); amygdala: 5 nTPM (limit 2); basal ganglia: 5.8 nTPM (limit 2); bone marrow: 27.3 nTPM (limit 2); cerebellum: 11.6 nTPM (limit 2); cerebral cortex: 9.8 nTPM (limit 2); choroid plexus: 7.9 nTPM (limit 2); colon: 11.1 nTPM (limit 6); duodenum: 10 nTPM (limit 2); esophagus: 12.5 nTPM (limit 6); heart muscle: 9.1 nTPM (limit 2); hippocampal formation: 5.3 nTPM (limit 2); hypothalamus: 5.4 nTPM (limit 2); kidney: 11.6 nTPM (limit 2); liver: 14.7 nTPM (limit 2); lung: 10.8 nTPM (limit 2); lymph node: 19.4 nTPM (limit 6); midbrain: 4.9 nTPM (limit 2); pancreas: 11.6 nTPM (limit 2); parathyroid gland: 15.1 nTPM (limit 6); pituitary gland: 7.7 nTPM (limit 2); rectum: 12.1 nTPM (limit 6); retina: 18.4 nTPM (limit 2); salivary gland: 11.5 nTPM (limit 6); skeletal muscle: 10.8 nTPM (limit 2); skin: 11.3 nTPM (limit 10); small intestine: 11.2 nTPM (limit 2); smooth muscle: 10.6 nTPM (limit 2); spinal cord: 5.7 nTPM (limit 2); spleen: 15.5 nTPM (limit 10); stomach: 11.7 nTPM (limit 6); thymus: 16.8 nTPM (limit 10); thyroid gland: 18.7 nTPM (limit 10); tongue: 12.6 nTPM (limit 6); urinary bladder: 11.4 nTPM (limit 6); adrenal gland: 9 nTPM (baseline 2); amygdala: 5 nTPM (baseline 2); basal ganglia: 5.8 nTPM (baseline 2); bone marrow: 27.3 nTPM (baseline 2); cerebellum: 11.6 nTPM (baseline 2); cerebral cortex: 9.8 nTPM (baseline 2); choroid plexus: 7.9 nTPM (baseline 2); colon: 11.1 nTPM (baseline 6); duodenum: 10 nTPM (baseline 2); esophagus: 12.5 nTPM (baseline 6); heart muscle: 9.1 nTPM (baseline 2); hippocampal formation: 5.3 nTPM (baseline 2); hypothalamus: 5.4 nTPM (baseline 2); kidney: 11.6 nTPM (baseline 2); liver: 14.7 nTPM (baseline 2); lung: 10.8 nTPM (baseline 2); lymph node: 19.4 nTPM (baseline 6); midbrain: 4.9 nTPM (baseline 2); pancreas: 11.6 nTPM (baseline 2); parathyroid gland: 15.1 nTPM (baseline 6); pituitary gland: 7.7 nTPM (baseline 2); rectum: 12.1 nTPM (baseline 6); retina: 18.4 nTPM (baseline 2); salivary gland: 11.5 nTPM (baseline 6); skeletal muscle: 10.8 nTPM (baseline 2); skin: 11.3 nTPM (baseline 10); small intestine: 11.2 nTPM (baseline 2); smooth muscle: 10.6 nTPM (baseline 2); spinal cord: 5.7 nTPM (baseline 2); spleen: 15.5 nTPM (baseline 10); stomach: 11.7 nTPM (baseline 6); thymus: 16.8 nTPM (baseline 10); thyroid gland: 18.7 nTPM (baseline 10); tongue: 12.6 nTPM (baseline 6); urinary bladder: 11.4 nTPM (baseline 6),bronchus / respiratory epithelial cells: Low (Uncertain); duodenum / glandular cells: High (Uncertain); esophagus / squamous epithelial cells: Low (Uncertain); heart muscle / cardiomyocytes: Low (Uncertain); kidney / cells in tubules: High (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); rectum / glandular cells: Medium (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: High (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Stomach Adenocarcinoma (TCGA): 346/346 (100.0%); Colon Adenocarcinoma (TCGA): 254/254 (100.0%),cervical cancer: 2/10 (20.0%); colorectal cancer: 2/10 (20.0%),31,20,Q14004,https://www.uniprot.org/uniprotkb/Q14004/entry,"Cyclin-dependent kinase which displays CTD kinase activity and is required for RNA splicing. Has CTD kinase activity by hyperphosphorylating the C-terminal heptapeptide repeat domain (CTD) of the largest RNA polymerase II subunit RPB1, thereby acting as a key regulator of transcription elongation. Required for RNA splicing, probably by phosphorylating SRSF1/SF2. Required during hematopoiesis. In case of infection by HIV-1 virus, interacts with HIV-1 Tat protein acetylated at 'Lys-50' and 'Lys-51', thereby increasing HIV-1 mRNA splicing and promoting the production of the doubly spliced HIV-1 protein Nef","Expressed in fetal brain, liver, muscle and in adult brain. Also expressed in neuroblastoma and glioblastoma tumors","Congenital heart defects, dysmorphic facial features, and intellectual developmental disorder: An autosomal dominant syndrome characterized by atrial and/or ventricular septal congenital heart defects, facial dysmorphism with hypertelorism, upslanted palpebral fissures, epicanthal folds, ptosis, strabismus, posteriorly rotated ears, thin upper lip, and small mouth. Patients manifest global developmental delay, delayed walking and speech acquisition, and intellectual disability. Some patients have mild microcephaly, a small cerebral cortex, and agenesis of corpus callosum. More variable features include clinodactyly and/or camptodactyly of the fingers, hypotonia, and joint hypermobility.",,Nucleus speckle,16721827|1731328|18480452|20952539,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
CDKL3,ENSG00000006837,Unsafe,RNA,False,True,14.2,14.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 2.8 nTPM; absolute ceiling; cerebral cortex: 2.4 nTPM; absolute ceiling; heart muscle: 2.4 nTPM; absolute ceiling; hippocampal formation: 2.6 nTPM; absolute ceiling; hypothalamus: 2.7 nTPM; absolute ceiling; midbrain: 3 nTPM; absolute ceiling; retina: 4.2 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 3.1 nTPM; absolute ceiling; spinal cord: 2.9 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 2.8 nTPM (limit 2); cerebral cortex: 2.4 nTPM (limit 2); heart muscle: 2.4 nTPM (limit 2); hippocampal formation: 2.6 nTPM (limit 2); hypothalamus: 2.7 nTPM (limit 2); midbrain: 3 nTPM (limit 2); retina: 4.2 nTPM (limit 2); skeletal muscle: 3.1 nTPM (limit 2); spinal cord: 2.9 nTPM (limit 2); amygdala: 2.8 nTPM (baseline 2); cerebral cortex: 2.4 nTPM (baseline 2); heart muscle: 2.4 nTPM (baseline 2); hippocampal formation: 2.6 nTPM (baseline 2); hypothalamus: 2.7 nTPM (baseline 2); midbrain: 3 nTPM (baseline 2); retina: 4.2 nTPM (baseline 2); skeletal muscle: 3.1 nTPM (baseline 2); spinal cord: 2.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 42/50 (84.0%); Glioblastoma Multiforme (validation): 35/58 (60.3%); Pancreatic Adenocarcinoma (validation): 36/80 (45.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8IVW4,https://www.uniprot.org/uniprotkb/Q8IVW4/entry,,,,,Cytoplasm,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CDKN3,ENSG00000100526,Unsafe,RNA,False,True,199.9,199.9,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 3.1 nTPM; absolute ceiling; basal ganglia: 2.7 nTPM; absolute ceiling; bone marrow: 42.3 nTPM; absolute ceiling; cerebellum: 2.9 nTPM; absolute ceiling; cerebral cortex: 4.4 nTPM; absolute ceiling; choroid plexus: 12 nTPM; absolute ceiling; colon: 13.5 nTPM; absolute ceiling; duodenum: 12.2 nTPM; absolute ceiling; esophagus: 9.9 nTPM; absolute ceiling; heart muscle: 5.1 nTPM; absolute ceiling; hippocampal formation: 2.6 nTPM; absolute ceiling; hypothalamus: 3.9 nTPM; absolute ceiling; liver: 2.3 nTPM; absolute ceiling; lymph node: 27.7 nTPM; absolute ceiling; midbrain: 3 nTPM; absolute ceiling; rectum: 16.4 nTPM; absolute ceiling; retina: 2.4 nTPM; absolute ceiling; skeletal muscle: 2.9 nTPM; absolute ceiling; small intestine: 12.1 nTPM; absolute ceiling; smooth muscle: 7.2 nTPM; absolute ceiling; thymus: 30.2 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 3.1 nTPM (limit 2); basal ganglia: 2.7 nTPM (limit 2); bone marrow: 42.3 nTPM (limit 2); cerebellum: 2.9 nTPM (limit 2); cerebral cortex: 4.4 nTPM (limit 2); choroid plexus: 12 nTPM (limit 2); colon: 13.5 nTPM (limit 6); duodenum: 12.2 nTPM (limit 2); esophagus: 9.9 nTPM (limit 6); heart muscle: 5.1 nTPM (limit 2); hippocampal formation: 2.6 nTPM (limit 2); hypothalamus: 3.9 nTPM (limit 2); liver: 2.3 nTPM (limit 2); lymph node: 27.7 nTPM (limit 6); midbrain: 3 nTPM (limit 2); rectum: 16.4 nTPM (limit 6); retina: 2.4 nTPM (limit 2); skeletal muscle: 2.9 nTPM (limit 2); small intestine: 12.1 nTPM (limit 2); smooth muscle: 7.2 nTPM (limit 2); thymus: 30.2 nTPM (limit 10); amygdala: 3.1 nTPM (baseline 2); basal ganglia: 2.7 nTPM (baseline 2); bone marrow: 42.3 nTPM (baseline 2); cerebellum: 2.9 nTPM (baseline 2); cerebral cortex: 4.4 nTPM (baseline 2); choroid plexus: 12 nTPM (baseline 2); colon: 13.5 nTPM (baseline 6); duodenum: 12.2 nTPM (baseline 2); esophagus: 9.9 nTPM (baseline 6); heart muscle: 5.1 nTPM (baseline 2); hippocampal formation: 2.6 nTPM (baseline 2); hypothalamus: 3.9 nTPM (baseline 2); liver: 2.3 nTPM (baseline 2); lymph node: 27.7 nTPM (baseline 6); midbrain: 3 nTPM (baseline 2); rectum: 16.4 nTPM (baseline 6); retina: 2.4 nTPM (baseline 2); skeletal muscle: 2.9 nTPM (baseline 2); small intestine: 12.1 nTPM (baseline 2); smooth muscle: 7.2 nTPM (baseline 2); thymus: 30.2 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Colon Adenocarcinoma (TCGA): 254/254 (100.0%); Rectum Adenocarcinoma (TCGA): 88/88 (100.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q16667,https://www.uniprot.org/uniprotkb/Q16667/entry,"May play a role in cell cycle regulation. Dual specificity CC phosphatase active toward substrates containing either phosphotyrosine or phosphoserine residues (PubMed:8127873, PubMed:8242750). Dephosphorylates CDK2 at 'Thr-160' in a cyclin-dependent manner (PubMed:7569954)",,"Hepatocellular carcinoma: A primary malignant neoplasm of epithelial liver cells. The major risk factors for HCC are chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, prolonged dietary aflatoxin exposure, alcoholic cirrhosis, and cirrhosis due to other causes.",,"Cytoplasm, perinuclear region",7569954|8127873|8242750,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CDRT15L2,ENSG00000214819,Unsafe,RNA,False,True,15.1,15.1,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,hippocampal formation: 2.2 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,hippocampal formation: 2.2 nTPM (limit 2); hippocampal formation: 2.2 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 10/283 (3.5%); Testicular Germ Cell Tumor (TCGA): 4/133 (3.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 3/176 (1.7%),No exact-ID IHC coverage in the HPA cancer snapshot,30,0,A8MXV6,https://www.uniprot.org/uniprotkb/A8MXV6/entry,,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Chang2019_TGCT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,Failed bulk numeric comparisons are within 20% of their cutoffs; not an automatic rescue,,,,
CDRT4,ENSG00000239704,Unsafe,Protein,False,True,15.3,30.1,78,30,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 11.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 7 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 9.7 nTPM; absolute ceiling;continuous selectivity; bone marrow: 3 nTPM; absolute ceiling; cerebellum: 11.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 7.8 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 15 nTPM; absolute ceiling;continuous selectivity; colon: 6.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 0.2 nTPM; positive ihc; esophagus: 6.5 nTPM; absolute ceiling;continuous selectivity; heart muscle: 3.2 nTPM; positive ihc;absolute ceiling; hippocampal formation: 7.5 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 10.1 nTPM; absolute ceiling;continuous selectivity; kidney: 10.6 nTPM; absolute ceiling;continuous selectivity; liver: 6.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 5 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 6.8 nTPM; absolute ceiling;continuous selectivity; pancreas: 12.1 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 0.5 nTPM; positive ihc; pituitary gland: 30.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 2.6 nTPM; positive ihc; retina: 5.9 nTPM; absolute ceiling;continuous selectivity; salivary gland: 9.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 0.7 nTPM; positive ihc; skin: 9.8 nTPM; continuous selectivity; small intestine: 7.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 1.1 nTPM; positive ihc; spinal cord: 6.3 nTPM; absolute ceiling;continuous selectivity; spleen: 10.4 nTPM; absolute ceiling;continuous selectivity; stomach: 7.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; thyroid gland: 14.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; urinary bladder: 5.4 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 11.6 nTPM (limit 2); amygdala: 7 nTPM (limit 2); basal ganglia: 9.7 nTPM (limit 2); bone marrow: 3 nTPM (limit 2); cerebellum: 11.1 nTPM (limit 2); cerebral cortex: 7.8 nTPM (limit 2); choroid plexus: 15 nTPM (limit 2); colon: 6.7 nTPM (limit 6); esophagus: 6.5 nTPM (limit 6); heart muscle: 3.2 nTPM (limit 2); hippocampal formation: 7.5 nTPM (limit 2); hypothalamus: 10.1 nTPM (limit 2); kidney: 10.6 nTPM (limit 2); liver: 6.5 nTPM (limit 2); lung: 5 nTPM (limit 2); midbrain: 6.8 nTPM (limit 2); pancreas: 12.1 nTPM (limit 2); pituitary gland: 30.1 nTPM (limit 2); retina: 5.9 nTPM (limit 2); salivary gland: 9.6 nTPM (limit 6); small intestine: 7.5 nTPM (limit 2); spinal cord: 6.3 nTPM (limit 2); spleen: 10.4 nTPM (limit 10); stomach: 7.2 nTPM (limit 6); thyroid gland: 14.5 nTPM (limit 10); adrenal gland: 11.6 nTPM (baseline 2); amygdala: 7 nTPM (baseline 2); basal ganglia: 9.7 nTPM (baseline 2); bone marrow: 3 nTPM (baseline 2); cerebellum: 11.1 nTPM (baseline 2); cerebral cortex: 7.8 nTPM (baseline 2); choroid plexus: 15 nTPM (baseline 2); colon: 6.7 nTPM (baseline 6); esophagus: 6.5 nTPM (baseline 6); heart muscle: 3.2 nTPM (baseline 2); hippocampal formation: 7.5 nTPM (baseline 2); hypothalamus: 10.1 nTPM (baseline 2); kidney: 10.6 nTPM (baseline 2); liver: 6.5 nTPM (baseline 2); lung: 5 nTPM (baseline 2); midbrain: 6.8 nTPM (baseline 2); pancreas: 12.1 nTPM (baseline 2); pituitary gland: 30.1 nTPM (baseline 2); retina: 5.9 nTPM (baseline 2); salivary gland: 9.6 nTPM (baseline 6); small intestine: 7.5 nTPM (baseline 2); spinal cord: 6.3 nTPM (baseline 2); spleen: 10.4 nTPM (baseline 10); stomach: 7.2 nTPM (baseline 6); thyroid gland: 14.5 nTPM (baseline 10),adrenal gland / glandular cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / neuronal cells: Low (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); colon / endothelial cells: Low (Uncertain); colon / glandular cells: Medium (Uncertain); duodenum / glandular cells: Medium (Uncertain); heart muscle / cardiomyocytes: Low (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / macrophages: Medium (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); parathyroid gland / glandular cells: High (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Low (Uncertain); skeletal muscle / myocytes: Low (Uncertain); small intestine / glandular cells: Low (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Low (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 44/50 (88.0%); Colon Adenocarcinoma (validation): 335/486 (68.9%); Rectum Adenocarcinoma (validation): 142/207 (68.6%),liver cancer: 5/12 (41.7%); pancreatic cancer: 3/10 (30.0%),31,20,Q8N9R6,https://www.uniprot.org/uniprotkb/Q8N9R6/entry,,Expressed in fetal skeletal muscle and kidney,,,,,11381029,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CELA3B,ENSG00000219073,Unsafe,Protein,False,True,9.9,48049.2,76,1,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 8.7 nTPM; continuous selectivity; cerebellum: 2.2 nTPM; absolute ceiling; duodenum: 6.3 nTPM; absolute ceiling;continuous selectivity; heart muscle: 8.1 nTPM; absolute ceiling;continuous selectivity; liver: 4.9 nTPM; absolute ceiling;continuous selectivity; pancreas: 48049.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 2.2 nTPM; absolute ceiling; salivary gland: 9.5 nTPM; absolute ceiling;continuous selectivity; small intestine: 2.6 nTPM; absolute ceiling;continuous selectivity; stomach: 16.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",duodenum: 6.3 nTPM (limit 6); heart muscle: 8.1 nTPM (limit 6); pancreas: 48049.2 nTPM (limit 2); pituitary gland: 2.2 nTPM (limit 2); stomach: 16.7 nTPM (limit 12); cerebellum: 2.2 nTPM (baseline 2); duodenum: 6.3 nTPM (baseline 2); heart muscle: 8.1 nTPM (baseline 2); liver: 4.9 nTPM (baseline 2); pancreas: 48049.2 nTPM (baseline 2); pituitary gland: 2.2 nTPM (baseline 2); salivary gland: 9.5 nTPM (baseline 6); small intestine: 2.6 nTPM (baseline 2); stomach: 16.7 nTPM (baseline 6),pancreas / exocrine glandular cells: High (Supported),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (TCGA): 97/176 (55.1%); Pancreatic Adenocarcinoma (validation): 24/80 (30.0%); Testicular Germ Cell Tumor (TCGA): 5/133 (3.8%),breast cancer: 0/12 (0.0%); cervical cancer: 0/11 (0.0%),31,20,P08861,https://www.uniprot.org/uniprotkb/P08861/entry,Efficient protease with alanine specificity but only little elastolytic activity,Pancreas. Not detectable in keratinocytes,,Was originally thought to be elastase 1,,,10620133,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
CENPA,ENSG00000115163,Unsafe,Protein,False,True,2.2,13.0,98,52,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; bone marrow: 3.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; colon: 2.9 nTPM; positive ihc;continuous selectivity;reproductive not higher; duodenum: 4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 3.5 nTPM; continuous selectivity;reproductive not higher; kidney: 0.1 nTPM; positive ihc; lymph node: 7.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; rectum: 2.6 nTPM; positive ihc;continuous selectivity;reproductive not higher; skin: 3.5 nTPM; positive ihc;continuous selectivity;reproductive not higher; small intestine: 2.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; spleen: 2 nTPM; positive ihc;continuous selectivity; stomach: 1.6 nTPM; positive ihc;continuous selectivity; thymus: 13 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 0.1 nTPM; positive ihc; urinary bladder: 0.7 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 3.7 nTPM (limit 2); duodenum: 4 nTPM (limit 2); lymph node: 7.2 nTPM (limit 6); small intestine: 2.8 nTPM (limit 2); thymus: 13 nTPM (limit 10),bone marrow / hematopoietic cells: Medium (Enhanced); colon / endothelial cells: Medium (Enhanced); colon / glandular cells: Medium (Enhanced); duodenum / glandular cells: Medium (Enhanced); kidney / cells in glomeruli: Low (Enhanced); kidney / cells in tubules: Low (Enhanced); lymph node / germinal center cells: Medium (Enhanced); lymph node / non-germinal center cells: Medium (Enhanced); oral mucosa / squamous epithelial cells: Medium (Enhanced); rectum / glandular cells: Medium (Enhanced); skin 1 / cells in basal layer: Medium (Enhanced); skin 1 / cells in granular layer: Medium (Enhanced); skin 1 / cells in spinous layer: Medium (Enhanced); skin 1 / eccrine glands: Medium (Enhanced); skin 1 / endothelial cells: Low (Enhanced); skin 1 / langerhans cells: Medium (Enhanced); skin 1 / lymphocytes: Medium (Enhanced); skin 2 / cells in basal layer: Medium (Enhanced); skin 2 / cells in granular layer: Medium (Enhanced); skin 2 / cells in spinous layer: Medium (Enhanced); skin 2 / endothelial cells: Medium (Enhanced); skin 2 / fibrohistiocytic cells: Medium (Enhanced); skin 2 / langerhans cells: Medium (Enhanced); skin 2 / lymphocytes: Medium (Enhanced); small intestine / glandular cells: Medium (Enhanced); spleen / cells in red pulp: Medium (Enhanced); spleen / cells in white pulp: Low (Enhanced); stomach 1 / glandular cells: Medium (Enhanced); stomach 2 / glandular cells: Medium (Enhanced); thyroid gland / glandular cells: Low (Enhanced); urinary bladder / urothelial cells: Low (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 52/58 (89.7%); Colon Adenocarcinoma (TCGA): 224/254 (88.2%); Ovary Serous Cystadenocarcinoma (TCGA): 307/349 (88.0%),cervical cancer: 6/12 (50.0%); colorectal cancer: 5/12 (41.7%),31,20,P49450,https://www.uniprot.org/uniprotkb/P49450/entry,"Histone H3-like nucleosomal protein that is specifically found in centromeric nucleosomes (PubMed:11756469, PubMed:14667408, PubMed:15282608, PubMed:15475964, PubMed:15702419, PubMed:17651496, PubMed:19114591, PubMed:20739937, PubMed:27499292, PubMed:7962047, PubMed:9024683). Replaces conventional H3 in the nucleosome core of centromeric chromatin that serves as an assembly site for the inner kinetochore (PubMed:18072184). The presence of CENPA subtly modifies the nucleosome structure and the way DNA is wrapped around the nucleosome and gives rise to protruding DNA ends that are less well-ordered and rigid compared to nucleosomes containing histone H3 (PubMed:26878239, PubMed:27499292). May serve as an epigenetic mark that propagates centromere identity through replication and cell division (PubMed:15282608, PubMed:15475964, PubMed:20739937, PubMed:21478274, PubMed:26878239). Required for recruitment and assembly of kinetochore proteins, and as a consequence required for progress through mitosis, chromosome segregation and cytokinesis (PubMed:11756469, PubMed:14667408, PubMed:18072184, PubMed:23818633, PubMed:25556658, PubMed:27499292)",,,,"Nucleus Chromosome, centromere",11756469|14667408|15282608|15475964|15702419|17651496|18072184|19114591|20739937|21478274|23818633|25556658|26878239|27499292|7962047|9024683,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CENPE,ENSG00000138778,Unsafe,Protein,False,True,4.0,9.9,107,59,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; bone marrow: 9.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 1.5 nTPM; positive ihc;continuous selectivity; esophagus: 1.9 nTPM; positive ihc;continuous selectivity; heart muscle: 0.2 nTPM; positive ihc; kidney: 0.2 nTPM; positive ihc; liver: 0.5 nTPM; positive ihc; lung: 0.7 nTPM; positive ihc; lymph node: 5.5 nTPM; positive ihc;continuous selectivity;reproductive not higher; rectum: 1.9 nTPM; positive ihc;continuous selectivity; salivary gland: 0.3 nTPM; positive ihc; skeletal muscle: 0 nTPM; positive ihc; skin: 1.9 nTPM; positive ihc;continuous selectivity; smooth muscle: 1.1 nTPM; positive ihc; stomach: 1 nTPM; positive ihc; thymus: 8.9 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 0.2 nTPM; positive ihc; urinary bladder: 0.7 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 9.9 nTPM (limit 2),bone marrow / hematopoietic cells: Medium (Enhanced); bronchus / respiratory epithelial cells: High (Enhanced); duodenum / glandular cells: Low (Enhanced); esophagus / squamous epithelial cells: Medium (Enhanced); heart muscle / cardiomyocytes: Medium (Enhanced); kidney / distal tubules: High (Enhanced); kidney / proximal tubules (cell body): Low (Enhanced); liver / hepatocytes: Low (Enhanced); lung / alveolar cells: Low (Enhanced); lymph node / non-germinal center cells: Medium (Enhanced); nasopharynx / respiratory epithelial cells: High (Enhanced); oral mucosa / squamous epithelial cells: High (Enhanced); rectum / glandular cells: High (Enhanced); salivary gland / glandular cells: Medium (Enhanced); skeletal muscle / myocytes: Medium (Enhanced); skin 1 / cells in basal layer: Medium (Enhanced); skin 1 / cells in granular layer: Low (Enhanced); skin 1 / cells in spinous layer: Medium (Enhanced); skin 1 / eccrine glands: High (Enhanced); skin 1 / endothelial cells: Low (Enhanced); skin 1 / fibrohistiocytic cells: Low (Enhanced); skin 1 / langerhans cells: Medium (Enhanced); skin 1 / lymphocytes: Medium (Enhanced); skin 2 / cells in basal layer: Medium (Enhanced); skin 2 / cells in spinous layer: Medium (Enhanced); skin 2 / endothelial cells: Low (Enhanced); skin 2 / fibrohistiocytic cells: Low (Enhanced); skin 2 / langerhans cells: Medium (Enhanced); skin 2 / lymphocytes: Medium (Enhanced); smooth muscle / smooth muscle cells: Medium (Enhanced); stomach 1 / glandular cells: Low (Enhanced); stomach 2 / glandular cells: Low (Enhanced); thyroid gland / glandular cells: Low (Enhanced); urinary bladder / urothelial cells: Low (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Colon Adenocarcinoma (validation): 455/486 (93.6%); Breast Invasive Carcinoma (validation): 43/50 (86.0%),skin cancer: 9/12 (75.0%); testis cancer: 7/11 (63.6%),31,20,Q02224,https://www.uniprot.org/uniprotkb/Q02224/entry,"Microtubule plus-end-directed kinetochore motor which plays an important role in chromosome congression, microtubule-kinetochore conjugation and spindle assembly checkpoint activation. Drives chromosome congression (alignment of chromosomes at the spindle equator resulting in the formation of the metaphase plate) by mediating the lateral sliding of polar chromosomes along spindle microtubules towards the spindle equator and by aiding the establishment and maintenance of connections between kinetochores and spindle microtubules (PubMed:23891108, PubMed:25395579, PubMed:7889940). The transport of pole-proximal chromosomes towards the spindle equator is favored by microtubule tracks that are detyrosinated (PubMed:25908662). Acts as a processive bi-directional tracker of dynamic microtubule tips; after chromosomes have congressed, continues to play an active role at kinetochores, enhancing their links with dynamic microtubule ends (PubMed:23955301). Suppresses chromosome congression in NDC80-depleted cells and contributes positively to congression only when microtubules are stabilized (PubMed:25743205). Plays an important role in the formation of stable attachments between kinetochores and spindle microtubules (PubMed:17535814) The stabilization of kinetochore-microtubule attachment also requires CENPE-dependent localization of other proteins to the kinetochore including BUB1B, MAD1 and MAD2. Plays a role in spindle assembly checkpoint activation (SAC) via its interaction with BUB1B resulting in the activation of its kinase activity, which is important for activating SAC. Necessary for the mitotic checkpoint signal at individual kinetochores to prevent aneuploidy due to single chromosome loss (By similarity)",,"Microcephaly 13, primary, autosomal recessive: A form of microcephaly, a disease defined as a head circumference more than 3 standard deviations below the age-related mean. Brain weight is markedly reduced and the cerebral cortex is disproportionately small.",,"Chromosome, centromere, kinetochore Cytoplasm, cytoskeleton, spindle Chromosome, centromere",17535814|23891108|23955301|25395579|25743205|25908662|7889940,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CENPH,ENSG00000153044,Unsafe,Protein,False,True,28.8,33.2,85,38,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 1.9 nTPM; positive ihc; amygdala: 2.5 nTPM; absolute ceiling; basal ganglia: 2.8 nTPM; absolute ceiling; bone marrow: 33.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 1.7 nTPM; positive ihc; cerebral cortex: 2.2 nTPM; positive ihc;absolute ceiling; colon: 7.1 nTPM; positive ihc;absolute ceiling; duodenum: 6.4 nTPM; positive ihc;absolute ceiling; esophagus: 7.3 nTPM; positive ihc;absolute ceiling; heart muscle: 3.8 nTPM; positive ihc;absolute ceiling; hippocampal formation: 2.2 nTPM; absolute ceiling; kidney: 1.5 nTPM; positive ihc; liver: 3.5 nTPM; positive ihc;absolute ceiling; lung: 2.7 nTPM; positive ihc;absolute ceiling; lymph node: 17.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 2.5 nTPM; absolute ceiling; pancreas: 1.5 nTPM; positive ihc; parathyroid gland: 1.9 nTPM; positive ihc; rectum: 7.8 nTPM; positive ihc;absolute ceiling; retina: 2.4 nTPM; absolute ceiling; salivary gland: 2.8 nTPM; positive ihc; skeletal muscle: 3.9 nTPM; positive ihc;absolute ceiling; skin: 8.9 nTPM; positive ihc; small intestine: 5.7 nTPM; positive ihc;absolute ceiling; smooth muscle: 3.6 nTPM; positive ihc;absolute ceiling; spinal cord: 2.5 nTPM; absolute ceiling; stomach: 3.6 nTPM; positive ihc; thymus: 18 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 3.7 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 2.5 nTPM (limit 2); basal ganglia: 2.8 nTPM (limit 2); bone marrow: 33.2 nTPM (limit 4); cerebral cortex: 2.2 nTPM (limit 2); colon: 7.1 nTPM (limit 6); duodenum: 6.4 nTPM (limit 2); esophagus: 7.3 nTPM (limit 6); heart muscle: 3.8 nTPM (limit 2); hippocampal formation: 2.2 nTPM (limit 2); liver: 3.5 nTPM (limit 2); lung: 2.7 nTPM (limit 2); lymph node: 17.3 nTPM (limit 6); midbrain: 2.5 nTPM (limit 2); rectum: 7.8 nTPM (limit 6); retina: 2.4 nTPM (limit 2); skeletal muscle: 3.9 nTPM (limit 2); small intestine: 5.7 nTPM (limit 2); smooth muscle: 3.6 nTPM (limit 2); spinal cord: 2.5 nTPM (limit 2); thymus: 18 nTPM (limit 10),adrenal gland / glandular cells: Medium (Approved); caudate / neuronal cells: Low (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / neuronal cells: Low (Approved); cerebral cortex / neuropil: Low (Approved); colon / glandular cells: Low (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells type II: Low (Approved); lymph node / non-germinal center cells: Low (Approved); pancreas / exocrine glandular cells: Low (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Low (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / keratinocytes: Low (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Low (Approved); urinary bladder / urothelial cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (TCGA): 253/254 (99.6%); Rectum Adenocarcinoma (TCGA): 87/88 (98.9%); Colon Adenocarcinoma (validation): 480/486 (98.8%),colorectal cancer: 4/9 (44.4%); stomach cancer: 3/11 (27.3%),31,20,Q9H3R5,https://www.uniprot.org/uniprotkb/Q9H3R5/entry,"Component of the CENPA-NAC (nucleosome-associated) complex, a complex that plays a central role in assembly of kinetochore proteins, mitotic progression and chromosome segregation. The CENPA-NAC complex recruits the CENPA-CAD (nucleosome distal) complex and may be involved in incorporation of newly synthesized CENPA into centromeres. Required for chromosome congression and efficiently align the chromosomes on a metaphase plate",,,,"Nucleus Chromosome, centromere, kinetochore",14536089|16875666|18007590,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CENPI,ENSG00000102384,Unsafe,RNA,False,True,1.9,5.5,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 5.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 0.8 nTPM; continuous selectivity; colon: 2 nTPM; continuous selectivity;reproductive not higher; duodenum: 2.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 2 nTPM; continuous selectivity;reproductive not higher; liver: 0.7 nTPM; continuous selectivity; lung: 0.7 nTPM; continuous selectivity; lymph node: 4.3 nTPM; continuous selectivity;reproductive not higher; rectum: 2.7 nTPM; continuous selectivity;reproductive not higher; retina: 2 nTPM; continuous selectivity;reproductive not higher; skin: 3.2 nTPM; continuous selectivity;reproductive not higher; small intestine: 1.9 nTPM; continuous selectivity;reproductive not higher; smooth muscle: 1.8 nTPM; continuous selectivity; spleen: 1.5 nTPM; continuous selectivity; stomach: 1.2 nTPM; continuous selectivity; thymus: 5.2 nTPM; continuous selectivity;reproductive not higher; urinary bladder: 1 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 5.5 nTPM (limit 2); duodenum: 2.4 nTPM (limit 2); bone marrow: 5.5 nTPM (baseline 2); duodenum: 2.4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Rectum Adenocarcinoma (validation): 205/207 (99.0%); Lung Squamous Cell Carcinoma (validation): 66/68 (97.1%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q92674,https://www.uniprot.org/uniprotkb/Q92674/entry,"Component of the CENPA-CAD (nucleosome distal) complex, a complex recruited to centromeres which is involved in assembly of kinetochore proteins, mitotic progression and chromosome segregation. May be involved in incorporation of newly synthesized CENPA into centromeres via its interaction with the CENPA-NAC complex. Required for the localization of CENPF, MAD1L1 and MAD2 (MAD2L1 or MAD2L2) to kinetochores. Involved in the response of gonadal tissues to follicle-stimulating hormone",,,,"Nucleus Chromosome, centromere",12640463|16622420,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CENPK,ENSG00000123219,Unsafe,RNA,False,True,13.2,24.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 24.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 8.7 nTPM; absolute ceiling;continuous selectivity; duodenum: 8.1 nTPM; absolute ceiling;continuous selectivity; esophagus: 5.5 nTPM; continuous selectivity; lymph node: 14.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 11.5 nTPM; absolute ceiling;continuous selectivity; skin: 8.5 nTPM; continuous selectivity; small intestine: 8.4 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 3.3 nTPM; absolute ceiling; stomach: 5.4 nTPM; continuous selectivity; thymus: 21.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 24.6 nTPM (limit 2); colon: 8.7 nTPM (limit 6); duodenum: 8.1 nTPM (limit 2); lymph node: 14.4 nTPM (limit 6); rectum: 11.5 nTPM (limit 6); small intestine: 8.4 nTPM (limit 2); smooth muscle: 3.3 nTPM (limit 2); thymus: 21.7 nTPM (limit 10); bone marrow: 24.6 nTPM (baseline 2); colon: 8.7 nTPM (baseline 6); duodenum: 8.1 nTPM (baseline 2); lymph node: 14.4 nTPM (baseline 6); rectum: 11.5 nTPM (baseline 6); small intestine: 8.4 nTPM (baseline 2); smooth muscle: 3.3 nTPM (baseline 2); thymus: 21.7 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 484/486 (99.6%); Rectum Adenocarcinoma (validation): 206/207 (99.5%); Lung Squamous Cell Carcinoma (validation): 67/68 (98.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9BS16,https://www.uniprot.org/uniprotkb/Q9BS16/entry,"Component of the CENPA-CAD (nucleosome distal) complex, a complex recruited to centromeres which is involved in assembly of kinetochore proteins, mitotic progression and chromosome segregation. May be involved in incorporation of newly synthesized CENPA into centromeres via its interaction with the CENPA-NAC complex. Acts in coordination with KNL1 to recruit the NDC80 complex to the outer kinetochore","Detected in several fetal organs with highest levels in fetal liver. In adults, it is weakly expressed in lung and placenta",,,"Nucleus Chromosome, centromere Chromosome, centromere, kinetochore",16622420|16716197|18045986,8950979,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CENPL,ENSG00000120334,Unsafe,Protein,False,True,9.4,9.4,80,63,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 2 nTPM; positive ihc; adrenal gland: 1.2 nTPM; positive ihc; bone marrow: 9.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 0.8 nTPM; positive ihc; cerebral cortex: 1.4 nTPM; positive ihc; colon: 2.3 nTPM; positive ihc; duodenum: 2.1 nTPM; positive ihc;absolute ceiling; esophagus: 2.2 nTPM; positive ihc; heart muscle: 1.6 nTPM; positive ihc; kidney: 1.4 nTPM; positive ihc; liver: 0.9 nTPM; positive ihc; lung: 1.3 nTPM; positive ihc; lymph node: 6.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; pancreas: 0.7 nTPM; positive ihc; rectum: 2.8 nTPM; positive ihc; salivary gland: 1.3 nTPM; positive ihc; skeletal muscle: 1.4 nTPM; positive ihc; skin: 2.1 nTPM; positive ihc; small intestine: 1.7 nTPM; positive ihc; smooth muscle: 2.2 nTPM; positive ihc;absolute ceiling; stomach: 2.1 nTPM; positive ihc; thymus: 8.5 nTPM; continuous selectivity; thyroid gland: 1.6 nTPM; positive ihc; urinary bladder: 1.8 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 9.3 nTPM (limit 2); duodenum: 2.1 nTPM (limit 2); lymph node: 6.3 nTPM (limit 6); smooth muscle: 2.2 nTPM (limit 2); bone marrow: 9.3 nTPM (baseline 2); duodenum: 2.1 nTPM (baseline 2); lymph node: 6.3 nTPM (baseline 6); smooth muscle: 2.2 nTPM (baseline 2),adipose tissue / adipocytes: Low (Uncertain); adrenal gland / glandular cells: High (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / Purkinje cells: Low (Uncertain); cerebral cortex / glial cells: Low (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / glandular cells: High (Uncertain); colon / peripheral nerve/ganglion: Medium (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / glial cells: Low (Uncertain); hippocampus / neuronal cells: Low (Uncertain); kidney / cells in tubules: Low (Uncertain); liver / hepatocytes: Low (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: High (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Low (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: Medium (Uncertain); skin 1 / fibroblasts: Medium (Uncertain); skin 1 / keratinocytes: Medium (Uncertain); skin 1 / Langerhans: High (Uncertain); skin 2 / epidermal cells: High (Uncertain); small intestine / glandular cells: Medium (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Low (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Lung Squamous Cell Carcinoma (validation): 63/68 (92.6%); Colon Adenocarcinoma (validation): 435/486 (89.5%),breast cancer: 6/12 (50.0%); ovarian cancer: 4/10 (40.0%),31,20,Q8N0S6,https://www.uniprot.org/uniprotkb/Q8N0S6/entry,"Component of the CENPA-CAD (nucleosome distal) complex, a complex recruited to centromeres which is involved in assembly of kinetochore proteins, mitotic progression and chromosome segregation. May be involved in incorporation of newly synthesized CENPA into centromeres via its interaction with the CENPA-NAC complex",,,,"Nucleus Chromosome, centromere",16716197,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CENPO,ENSG00000138092,Unsafe,RNA,False,True,8.1,11.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 5.1 nTPM; continuous selectivity; adrenal gland: 3.9 nTPM; absolute ceiling;continuous selectivity; amygdala: 4.2 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 4.2 nTPM; absolute ceiling;continuous selectivity; bone marrow: 9.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 4 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 4.8 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 2.3 nTPM; absolute ceiling;continuous selectivity; colon: 3.2 nTPM; continuous selectivity; duodenum: 3.1 nTPM; absolute ceiling;continuous selectivity; esophagus: 4.4 nTPM; continuous selectivity; heart muscle: 2.7 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 4.3 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 4 nTPM; absolute ceiling;continuous selectivity; kidney: 2.8 nTPM; absolute ceiling;continuous selectivity; liver: 2.5 nTPM; absolute ceiling;continuous selectivity; lung: 3.5 nTPM; absolute ceiling;continuous selectivity; lymph node: 4.8 nTPM; continuous selectivity; midbrain: 4 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 3.5 nTPM; absolute ceiling;continuous selectivity; rectum: 3.6 nTPM; continuous selectivity; skeletal muscle: 2.9 nTPM; absolute ceiling;continuous selectivity; skin: 3.7 nTPM; continuous selectivity; small intestine: 3.8 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 2.1 nTPM; absolute ceiling; spinal cord: 3.7 nTPM; absolute ceiling;continuous selectivity; spleen: 4.2 nTPM; continuous selectivity; thymus: 11.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 3.9 nTPM (limit 2); amygdala: 4.2 nTPM (limit 2); basal ganglia: 4.2 nTPM (limit 2); bone marrow: 9.1 nTPM (limit 2); cerebellum: 4 nTPM (limit 2); cerebral cortex: 4.8 nTPM (limit 2); choroid plexus: 2.3 nTPM (limit 2); duodenum: 3.1 nTPM (limit 2); heart muscle: 2.7 nTPM (limit 2); hippocampal formation: 4.3 nTPM (limit 2); hypothalamus: 4 nTPM (limit 2); kidney: 2.8 nTPM (limit 2); liver: 2.5 nTPM (limit 2); lung: 3.5 nTPM (limit 2); midbrain: 4 nTPM (limit 2); pituitary gland: 3.5 nTPM (limit 2); skeletal muscle: 2.9 nTPM (limit 2); small intestine: 3.8 nTPM (limit 2); smooth muscle: 2.1 nTPM (limit 2); spinal cord: 3.7 nTPM (limit 2); thymus: 11.1 nTPM (limit 10); adrenal gland: 3.9 nTPM (baseline 2); amygdala: 4.2 nTPM (baseline 2); basal ganglia: 4.2 nTPM (baseline 2); bone marrow: 9.1 nTPM (baseline 2); cerebellum: 4 nTPM (baseline 2); cerebral cortex: 4.8 nTPM (baseline 2); choroid plexus: 2.3 nTPM (baseline 2); duodenum: 3.1 nTPM (baseline 2); heart muscle: 2.7 nTPM (baseline 2); hippocampal formation: 4.3 nTPM (baseline 2); hypothalamus: 4 nTPM (baseline 2); kidney: 2.8 nTPM (baseline 2); liver: 2.5 nTPM (baseline 2); lung: 3.5 nTPM (baseline 2); midbrain: 4 nTPM (baseline 2); pituitary gland: 3.5 nTPM (baseline 2); skeletal muscle: 2.9 nTPM (baseline 2); small intestine: 3.8 nTPM (baseline 2); smooth muscle: 2.1 nTPM (baseline 2); spinal cord: 3.7 nTPM (baseline 2); thymus: 11.1 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 482/486 (99.2%); Rectum Adenocarcinoma (validation): 205/207 (99.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9BU64,https://www.uniprot.org/uniprotkb/Q9BU64/entry,"Component of the CENPA-CAD (nucleosome distal) complex, a complex recruited to centromeres which is involved in assembly of kinetochore proteins, mitotic progression and chromosome segregation. May be involved in incorporation of newly synthesized CENPA into centromeres via its interaction with the CENPA-NAC complex. Modulates the kinetochore-bound levels of NDC80 complex",,,,"Nucleus Chromosome, centromere Chromosome, centromere, kinetochore",16622420|16716197|16932742|18007590,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CENPP,ENSG00000188312,Unsafe,Protein,False,True,4.3,20.9,78,60,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 3.2 nTPM; continuous selectivity; adrenal gland: 2.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 2.6 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 3 nTPM; absolute ceiling;continuous selectivity; bone marrow: 12.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 2.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 3.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 2.3 nTPM; positive ihc;continuous selectivity; duodenum: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 4.3 nTPM; positive ihc;continuous selectivity;reproductive not higher; heart muscle: 2.7 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 2.9 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 2.5 nTPM; absolute ceiling;continuous selectivity; kidney: 1.9 nTPM; positive ihc;continuous selectivity; liver: 1.8 nTPM; positive ihc;continuous selectivity; lung: 1.9 nTPM; positive ihc;continuous selectivity; lymph node: 5.5 nTPM; continuous selectivity;reproductive not higher; midbrain: 2.4 nTPM; absolute ceiling;continuous selectivity; pancreas: 2.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 2.3 nTPM; positive ihc;continuous selectivity; pituitary gland: 1.7 nTPM; continuous selectivity; rectum: 2.6 nTPM; positive ihc;continuous selectivity; retina: 2.3 nTPM; absolute ceiling;continuous selectivity; salivary gland: 2.2 nTPM; positive ihc;continuous selectivity; skeletal muscle: 8.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 20.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 1.8 nTPM; positive ihc;continuous selectivity; smooth muscle: 2.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 2.1 nTPM; absolute ceiling;continuous selectivity; spleen: 2.7 nTPM; continuous selectivity; stomach: 1.8 nTPM; positive ihc;continuous selectivity; thymus: 6.9 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 1.3 nTPM; positive ihc; tongue: 4.3 nTPM; continuous selectivity;reproductive not higher; urinary bladder: 2.2 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 2.9 nTPM (limit 2); amygdala: 2.6 nTPM (limit 2); basal ganglia: 3 nTPM (limit 2); bone marrow: 12.1 nTPM (limit 2); cerebellum: 2.3 nTPM (limit 2); cerebral cortex: 3.3 nTPM (limit 2); duodenum: 2.7 nTPM (limit 2); heart muscle: 2.7 nTPM (limit 2); hippocampal formation: 2.9 nTPM (limit 2); hypothalamus: 2.5 nTPM (limit 2); midbrain: 2.4 nTPM (limit 2); pancreas: 2.1 nTPM (limit 2); retina: 2.3 nTPM (limit 2); skeletal muscle: 8.7 nTPM (limit 2); skin: 20.9 nTPM (limit 10); smooth muscle: 2.9 nTPM (limit 2); spinal cord: 2.1 nTPM (limit 2); adrenal gland: 2.9 nTPM (baseline 2); amygdala: 2.6 nTPM (baseline 2); basal ganglia: 3 nTPM (baseline 2); bone marrow: 12.1 nTPM (baseline 2); cerebellum: 2.3 nTPM (baseline 2); cerebral cortex: 3.3 nTPM (baseline 2); duodenum: 2.7 nTPM (baseline 2); heart muscle: 2.7 nTPM (baseline 2); hippocampal formation: 2.9 nTPM (baseline 2); hypothalamus: 2.5 nTPM (baseline 2); midbrain: 2.4 nTPM (baseline 2); pancreas: 2.1 nTPM (baseline 2); retina: 2.3 nTPM (baseline 2); skeletal muscle: 8.7 nTPM (baseline 2); skin: 20.9 nTPM (baseline 10); smooth muscle: 2.9 nTPM (baseline 2); spinal cord: 2.1 nTPM (baseline 2),adrenal gland / glandular cells: High (Uncertain); bone marrow / hematopoietic cells: Low (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / glial cells: Medium (Uncertain); cerebellum / cells in granular layer: Low (Uncertain); cerebellum / cells in molecular layer: High (Uncertain); cerebellum / Purkinje cells: High (Uncertain); cerebral cortex / glial cells: Medium (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: Low (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); hippocampus / glial cells: Medium (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in glomeruli: Low (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / cholangiocytes: Medium (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / alveolar cells: Low (Uncertain); lung / macrophages: Low (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: Low (Uncertain); skin 1 / fibroblasts: Low (Uncertain); skin 1 / keratinocytes: Low (Uncertain); skin 1 / Langerhans: Low (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: Medium (Uncertain); smooth muscle / smooth muscle cells: Low (Uncertain); stomach 1 / glandular cells: Low (Uncertain); stomach 2 / glandular cells: Low (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 191/207 (92.3%); Colon Adenocarcinoma (validation): 447/486 (92.0%); Head and Neck Squamous Cell Carcinoma (TCGA): 443/492 (90.0%),pancreatic cancer: 8/10 (80.0%); testis cancer: 8/10 (80.0%),31,20,Q6IPU0,https://www.uniprot.org/uniprotkb/Q6IPU0/entry,"Component of the CENPA-CAD (nucleosome distal) complex, a complex recruited to centromeres which is involved in assembly of kinetochore proteins, mitotic progression and chromosome segregation. May be involved in incorporation of newly synthesized CENPA into centromeres via its interaction with the CENPA-NAC complex",,,,"Nucleus Chromosome, centromere",16622420,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CENPS-CORT,ENSG00000251503,Unsafe,RNA,False,True,35.2,35.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,existing nomination or manual review; nomination unresolved; amygdala: 4 nTPM; absolute ceiling; basal ganglia: 4.5 nTPM; absolute ceiling; bone marrow: 8.3 nTPM; absolute ceiling; cerebral cortex: 3.8 nTPM; absolute ceiling; hippocampal formation: 3.2 nTPM; absolute ceiling; hypothalamus: 3.5 nTPM; absolute ceiling; kidney: 2.2 nTPM; absolute ceiling; midbrain: 2.9 nTPM; absolute ceiling; pituitary gland: 2.4 nTPM; absolute ceiling; retina: 2.4 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 4 nTPM (limit 2); basal ganglia: 4.5 nTPM (limit 2); bone marrow: 8.3 nTPM (limit 2); cerebral cortex: 3.8 nTPM (limit 2); hippocampal formation: 3.2 nTPM (limit 2); hypothalamus: 3.5 nTPM (limit 2); kidney: 2.2 nTPM (limit 2); midbrain: 2.9 nTPM (limit 2); pituitary gland: 2.4 nTPM (limit 2); retina: 2.4 nTPM (limit 2); amygdala: 4 nTPM (baseline 2); basal ganglia: 4.5 nTPM (baseline 2); bone marrow: 8.3 nTPM (baseline 2); cerebral cortex: 3.8 nTPM (baseline 2); hippocampal formation: 3.2 nTPM (baseline 2); hypothalamus: 3.5 nTPM (baseline 2); kidney: 2.2 nTPM (baseline 2); midbrain: 2.9 nTPM (baseline 2); pituitary gland: 2.4 nTPM (baseline 2); retina: 2.4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 91/133 (68.4%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 155/283 (54.8%); Uterine Corpus Endometrial Carcinoma (TCGA): 68/176 (38.6%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q8N2Z9,https://www.uniprot.org/uniprotkb/Q8N2Z9/entry,"DNA-binding component of the Fanconi anemia (FA) core complex. Required for the normal activation of the FA pathway, leading to monoubiquitination of the FANCI-FANCD2 complex in response to DNA damage, cellular resistance to DNA cross-linking drugs, and prevention of chromosomal breakage (PubMed:20347428, PubMed:20347429). In complex with CENPX (MHF heterodimer), crucial cofactor for FANCM in both binding and ATP-dependent remodeling of DNA. Stabilizes FANCM (PubMed:20347428, PubMed:20347429). In complex with CENPX and FANCM (but not other FANC proteins), rapidly recruited to blocked forks and promotes gene conversion at blocked replication forks (PubMed:20347428). In complex with CENPT, CENPW and CENPX (CENP-T-W-S-X heterotetramer), involved in the formation of a functional kinetochore outer plate, which is essential for kinetochore-microtubule attachment and faithful mitotic progression (PubMed:19620631). As a component of MHF and CENP-T-W-S-X complexes, binds DNA and bends it to form a nucleosome-like structure (PubMed:20347428, PubMed:22304917). DNA-binding function is fulfilled in the presence of CENPX, with the following preference for DNA substates: Holliday junction > double-stranded > splay arm > single-stranded. Does not bind DNA on its own (PubMed:20347428, PubMed:20347429)",Ubiquitously expressed,,,"Nucleus Chromosome, centromere Chromosome, centromere, kinetochore",19620631|20347428|20347429|22304917,15328517,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
CENPU,ENSG00000151725,Unsafe,RNA,False,True,28.6,61.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 61.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 7.5 nTPM; absolute ceiling; duodenum: 4.9 nTPM; absolute ceiling; esophagus: 10.1 nTPM; absolute ceiling;continuous selectivity; liver: 3.6 nTPM; absolute ceiling; lymph node: 15.8 nTPM; absolute ceiling;continuous selectivity; rectum: 7.8 nTPM; absolute ceiling; skin: 14.9 nTPM; absolute ceiling;continuous selectivity; small intestine: 5.2 nTPM; absolute ceiling; smooth muscle: 2.6 nTPM; absolute ceiling; thymus: 12.5 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 61.8 nTPM (limit 2); colon: 7.5 nTPM (limit 6); duodenum: 4.9 nTPM (limit 2); esophagus: 10.1 nTPM (limit 6); liver: 3.6 nTPM (limit 2); lymph node: 15.8 nTPM (limit 6); rectum: 7.8 nTPM (limit 6); skin: 14.9 nTPM (limit 10); small intestine: 5.2 nTPM (limit 2); smooth muscle: 2.6 nTPM (limit 2); thymus: 12.5 nTPM (limit 10); bone marrow: 61.8 nTPM (baseline 2); colon: 7.5 nTPM (baseline 6); duodenum: 4.9 nTPM (baseline 2); esophagus: 10.1 nTPM (baseline 6); liver: 3.6 nTPM (baseline 2); lymph node: 15.8 nTPM (baseline 6); rectum: 7.8 nTPM (baseline 6); skin: 14.9 nTPM (baseline 10); small intestine: 5.2 nTPM (baseline 2); smooth muscle: 2.6 nTPM (baseline 2); thymus: 12.5 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Lung Squamous Cell Carcinoma (validation): 66/68 (97.1%); Colon Adenocarcinoma (validation): 464/486 (95.5%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q71F23,https://www.uniprot.org/uniprotkb/Q71F23/entry,"Component of the CENPA-NAC (nucleosome-associated) complex, a complex that plays a central role in assembly of kinetochore proteins, mitotic progression and chromosome segregation. The CENPA-NAC complex recruits the CENPA-CAD (nucleosome distal) complex and may be involved in incorporation of newly synthesized CENPA into centromeres. Plays an important role in the correct PLK1 localization to the mitotic kinetochores. A scaffold protein responsible for the initial recruitment and maintenance of the kinetochore PLK1 population until its degradation. Involved in transcriptional repression","Expressed at high levels in the testis, fetal liver, thymus, bone marrow and at lower levels in the lymph nodes, placenta, colon and spleen. Present in all cell lines examined, including B-cells, T-cells, epithelial cells and fibroblast cells. Expressed at high levels in glioblastoma cell lines",,,"Cytoplasm Nucleus Chromosome, centromere, kinetochore",12941884|16716197|17081991,12941884|15116101|15893739,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Jamin2021_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CENPVL1,ENSG00000223591,Unsafe,RNA,False,True,1.1,3.9,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,amygdala: 0.9 nTPM; continuous selectivity; basal ganglia: 3.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 0.6 nTPM; continuous selectivity; hippocampal formation: 0.5 nTPM; continuous selectivity; hypothalamus: 3.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 0.6 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,basal ganglia: 3.9 nTPM (limit 2); hypothalamus: 3.9 nTPM (limit 2); basal ganglia: 3.9 nTPM (baseline 2); hypothalamus: 3.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (TCGA): 3/362 (0.8%); Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,30,0,A0A0U1RR11 | P0DPI3,https://www.uniprot.org/uniprotkb/A0A0U1RR11/entry | https://www.uniprot.org/uniprotkb/P0DPI3/entry,,,,,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Loriot2025_S1,Cancer-germline RNA nomination; strict and preferential classes remain distinct,,,,,,,,
CENPVL2,ENSG00000283093,Unsafe,RNA,False,True,0.7,4.7,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,amygdala: 0.8 nTPM; continuous selectivity;reproductive not higher; basal ganglia: 4.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 0.6 nTPM; continuous selectivity; hippocampal formation: 0.5 nTPM; continuous selectivity; hypothalamus: 4.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 0.6 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,basal ganglia: 4.7 nTPM (limit 2); hypothalamus: 4.6 nTPM (limit 2); basal ganglia: 4.7 nTPM (baseline 2); hypothalamus: 4.6 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (TCGA): 3/362 (0.8%); Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,26,0,A0A0U1RR11 | P0DPI3,https://www.uniprot.org/uniprotkb/A0A0U1RR11/entry | https://www.uniprot.org/uniprotkb/P0DPI3/entry,,,,,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Loriot2025_S1,Cancer-germline RNA nomination; strict and preferential classes remain distinct,,,,,,,,
CEP120,ENSG00000168944,Unsafe,RNA,False,True,13.4,13.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 8 nTPM; continuous selectivity; adrenal gland: 6.8 nTPM; absolute ceiling;continuous selectivity; amygdala: 4.5 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 4.9 nTPM; absolute ceiling;continuous selectivity; bone marrow: 2.9 nTPM; absolute ceiling; cerebellum: 11.2 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 4.2 nTPM; absolute ceiling;continuous selectivity; colon: 6.9 nTPM; absolute ceiling;continuous selectivity; duodenum: 4.7 nTPM; absolute ceiling;continuous selectivity; heart muscle: 6 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 5.2 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 6.1 nTPM; absolute ceiling;continuous selectivity; kidney: 6.7 nTPM; absolute ceiling;continuous selectivity; liver: 7.7 nTPM; absolute ceiling;continuous selectivity; lung: 7.1 nTPM; absolute ceiling;continuous selectivity; lymph node: 9.1 nTPM; absolute ceiling;continuous selectivity; midbrain: 5.2 nTPM; absolute ceiling;continuous selectivity; pancreas: 6.1 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 7.3 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 6.4 nTPM; absolute ceiling;continuous selectivity; rectum: 5 nTPM; continuous selectivity; retina: 11.2 nTPM; absolute ceiling;continuous selectivity; salivary gland: 5 nTPM; continuous selectivity; skeletal muscle: 4.2 nTPM; absolute ceiling;continuous selectivity; small intestine: 7.1 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 7.7 nTPM; absolute ceiling;continuous selectivity; spinal cord: 6.7 nTPM; absolute ceiling;continuous selectivity; spleen: 8.8 nTPM; continuous selectivity; stomach: 4.9 nTPM; continuous selectivity; thymus: 13.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 8 nTPM; continuous selectivity; tongue: 5.9 nTPM; continuous selectivity; urinary bladder: 6.4 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 6.8 nTPM (limit 2); amygdala: 4.5 nTPM (limit 2); basal ganglia: 4.9 nTPM (limit 2); bone marrow: 2.9 nTPM (limit 2); cerebellum: 11.2 nTPM (limit 2); cerebral cortex: 4.2 nTPM (limit 2); colon: 6.9 nTPM (limit 6); duodenum: 4.7 nTPM (limit 2); heart muscle: 6 nTPM (limit 2); hippocampal formation: 5.2 nTPM (limit 2); hypothalamus: 6.1 nTPM (limit 2); kidney: 6.7 nTPM (limit 2); liver: 7.7 nTPM (limit 2); lung: 7.1 nTPM (limit 2); lymph node: 9.1 nTPM (limit 6); midbrain: 5.2 nTPM (limit 2); pancreas: 6.1 nTPM (limit 2); parathyroid gland: 7.3 nTPM (limit 6); pituitary gland: 6.4 nTPM (limit 2); retina: 11.2 nTPM (limit 2); skeletal muscle: 4.2 nTPM (limit 2); small intestine: 7.1 nTPM (limit 2); smooth muscle: 7.7 nTPM (limit 2); spinal cord: 6.7 nTPM (limit 2); thymus: 13.6 nTPM (limit 10); urinary bladder: 6.4 nTPM (limit 6); adrenal gland: 6.8 nTPM (baseline 2); amygdala: 4.5 nTPM (baseline 2); basal ganglia: 4.9 nTPM (baseline 2); bone marrow: 2.9 nTPM (baseline 2); cerebellum: 11.2 nTPM (baseline 2); cerebral cortex: 4.2 nTPM (baseline 2); colon: 6.9 nTPM (baseline 6); duodenum: 4.7 nTPM (baseline 2); heart muscle: 6 nTPM (baseline 2); hippocampal formation: 5.2 nTPM (baseline 2); hypothalamus: 6.1 nTPM (baseline 2); kidney: 6.7 nTPM (baseline 2); liver: 7.7 nTPM (baseline 2); lung: 7.1 nTPM (baseline 2); lymph node: 9.1 nTPM (baseline 6); midbrain: 5.2 nTPM (baseline 2); pancreas: 6.1 nTPM (baseline 2); parathyroid gland: 7.3 nTPM (baseline 6); pituitary gland: 6.4 nTPM (baseline 2); retina: 11.2 nTPM (baseline 2); skeletal muscle: 4.2 nTPM (baseline 2); small intestine: 7.1 nTPM (baseline 2); smooth muscle: 7.7 nTPM (baseline 2); spinal cord: 6.7 nTPM (baseline 2); thymus: 13.6 nTPM (baseline 10); urinary bladder: 6.4 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Pancreatic Adenocarcinoma (validation): 79/80 (98.8%); Lung Adenocarcinoma (validation): 102/105 (97.1%),cervical cancer: 2/12 (16.7%); endometrial cancer: 2/12 (16.7%),31,20,Q8N960,https://www.uniprot.org/uniprotkb/Q8N960/entry,Plays a role in the microtubule-dependent coupling of the nucleus and the centrosome. Involved in the processes that regulate centrosome-mediated interkinetic nuclear migration (INM) of neural progenitors and for proper positioning of neurons during brain development. Also implicated in the migration and selfrenewal of neural progenitors. Required for centriole duplication and maturation during mitosis and subsequent ciliogenesis (By similarity). Required for the recruitment of CEP295 to the proximal end of new-born centrioles at the centriolar microtubule wall during early S phase in a PLK4-dependent manner (PubMed:27185865),,"Short-rib thoracic dysplasia 13 with or without polydactyly: A form of short-rib thoracic dysplasia, a group of autosomal recessive ciliopathies that are characterized by a constricted thoracic cage, short ribs, shortened tubular bones, and a 'trident' appearance of the acetabular roof. Polydactyly is variably present. Non-skeletal involvement can include cleft lip/palate as well as anomalies of major organs such as the brain, eye, heart, kidneys, liver, pancreas, intestines, and genitalia. Some forms of the disease are lethal in the neonatal period due to respiratory insufficiency secondary to a severely restricted thoracic cage, whereas others are compatible with life. Disease spectrum encompasses Ellis-van Creveld syndrome, asphyxiating thoracic dystrophy (Jeune syndrome), Mainzer-Saldino syndrome, and short rib-polydactyly syndrome. Joubert syndrome 31: A form of Joubert syndrome, a disorder presenting with cerebellar ataxia, oculomotor apraxia, hypotonia, neonatal breathing abnormalities and psychomotor delay. Neuroradiologically, it is characterized by cerebellar vermian hypoplasia/aplasia, thickened and reoriented superior cerebellar peduncles, and an abnormally large interpeduncular fossa, giving the appearance of a molar tooth on transaxial slices (molar tooth sign). Additional variable features include retinal dystrophy, renal disease, liver fibrosis, and polydactyly. JBTS31 inheritance is autosomal recessive.",,"Cytoplasm, cytoskeleton, microtubule organizing center, centrosome",27185865,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
CEP128,ENSG00000100629,Unsafe,Protein,False,True,5.0,24.2,80,66,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 2 nTPM; positive ihc; adrenal gland: 0.8 nTPM; positive ihc; bone marrow: 6.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 0.7 nTPM; positive ihc; cerebral cortex: 0.8 nTPM; positive ihc; colon: 1.9 nTPM; positive ihc;continuous selectivity; duodenum: 1.4 nTPM; positive ihc;continuous selectivity; esophagus: 1.6 nTPM; positive ihc; heart muscle: 1.2 nTPM; positive ihc; kidney: 0.8 nTPM; positive ihc; lung: 1.4 nTPM; positive ihc;continuous selectivity; lymph node: 4.6 nTPM; positive ihc;continuous selectivity; pancreas: 0.6 nTPM; positive ihc; parathyroid gland: 1.6 nTPM; positive ihc; rectum: 1.6 nTPM; positive ihc; retina: 1.5 nTPM; continuous selectivity; salivary gland: 1.7 nTPM; positive ihc; skeletal muscle: 1.8 nTPM; positive ihc;continuous selectivity; skin: 2.3 nTPM; positive ihc;continuous selectivity; small intestine: 1 nTPM; positive ihc; smooth muscle: 1.9 nTPM; positive ihc;continuous selectivity; spleen: 2.3 nTPM; continuous selectivity; stomach: 1.6 nTPM; positive ihc; thymus: 24.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 1.6 nTPM; positive ihc; urinary bladder: 2.2 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 6.1 nTPM (limit 2); thymus: 24.2 nTPM (limit 10); bone marrow: 6.1 nTPM (baseline 2); thymus: 24.2 nTPM (baseline 10),adipose tissue / adipocytes: Low (Uncertain); adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Low (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / glial cells: Low (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: Medium (Uncertain); cerebellum / cells in molecular layer: Medium (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / endothelial cells: Low (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: Medium (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in tubules: Low (Uncertain); lung / alveolar cells: Low (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Low (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: Low (Uncertain); skin 1 / fibroblasts: Medium (Uncertain); skin 1 / keratinocytes: Medium (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: Medium (Uncertain); smooth muscle / smooth muscle cells: Low (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 54/58 (93.1%); Colon Adenocarcinoma (validation): 432/486 (88.9%); Rectum Adenocarcinoma (validation): 181/207 (87.4%),liver cancer: 12/12 (100.0%); endometrial cancer: 11/12 (91.7%),30,20,Q6ZU80,https://www.uniprot.org/uniprotkb/Q6ZU80/entry,"Is involved in the negative regulation of ciliogenesis and plays a role in spermatogenesis (PubMed:29514088, PubMed:35296684). Contributes to the regulation of the TGFB/BMP signaling pathway at the primary cilium, where it is required for ciliary localization of RAB11A, likely affecting the trafficking and regulation of TGFB/BMP pathway components (PubMed:29514088). Required, together with ODF2, for the formation of the subdistal appendage of the centriole (By similarity)",,,,"Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriole Cytoplasm, cytoskeleton, cilium basal body Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Cytoplasm, cytoskeleton, spindle pole",29514088|35296684,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | Jamin2021_CT,GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
CEP152,ENSG00000103995,Unsafe,Protein,False,True,9.6,16.2,84,39,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 16.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 1.1 nTPM; positive ihc; cerebral cortex: 0.8 nTPM; positive ihc; colon: 2.2 nTPM; positive ihc; duodenum: 2.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; pancreas: 2.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; rectum: 3 nTPM; positive ihc; salivary gland: 2.3 nTPM; positive ihc; skin: 2.9 nTPM; positive ihc; small intestine: 2.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 2.2 nTPM; positive ihc; thymus: 5.5 nTPM; continuous selectivity; urinary bladder: 1.3 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 16.2 nTPM (limit 4); duodenum: 2.8 nTPM (limit 2); pancreas: 2.9 nTPM (limit 2); small intestine: 2.9 nTPM (limit 2),bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Low (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); hippocampus / glial cells: Medium (Approved); hippocampus / neuronal cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skin 1 / keratinocytes: Low (Approved); small intestine / glandular cells: Medium (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Low (Approved); urinary bladder / urothelial cells: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 56/58 (96.6%); Colon Adenocarcinoma (validation): 457/486 (94.0%); Rectum Adenocarcinoma (validation): 190/207 (91.8%),ovarian cancer: 4/11 (36.4%); pancreatic cancer: 3/11 (27.3%),31,20,O94986,https://www.uniprot.org/uniprotkb/O94986/entry,"Necessary for centrosome duplication; the function also seems to involve CEP63, CDK5RAP2 and WDR62 through a stepwise assembled complex at the centrosome that recruits CDK2 required for centriole duplication (PubMed:26297806). Acts as a molecular scaffold facilitating the interaction of PLK4 and CPAP, 2 molecules involved in centriole formation (PubMed:20852615, PubMed:21059844). Proposed to snatch PLK4 away from PLK4:CEP92 complexes in early G1 daughter centriole and to reposition PLK4 at the outer boundary of a newly forming CEP152 ring structure (PubMed:24997597). Also plays a key role in deuterosome-mediated centriole amplification in multiciliated that can generate more than 100 centrioles (By similarity). Overexpression of CEP152 can drive amplification of centrioles (PubMed:20852615)",,"Microcephaly 9, primary, autosomal recessive: A disease defined as a head circumference more than 3 standard deviations below the age-related mean. Brain weight is markedly reduced and the cerebral cortex is disproportionately small. Despite this marked reduction in size, the gyral pattern is relatively well preserved, with no major abnormality in cortical architecture. Affected individuals have intellectual disability. Primary microcephaly is further defined by the absence of other syndromic features or significant neurological deficits due to degenerative brain disorder. Seckel syndrome 5: A rare autosomal recessive disorder characterized by proportionate dwarfism of prenatal onset associated with low birth weight, growth retardation, severe microcephaly with a bird-headed like appearance, and intellectual disability.",,"Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriole",20852615|21059844|21131973,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CEP170,ENSG00000143702,Unsafe,Protein,False,True,87.3,87.3,84,32,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 4.9 nTPM; absolute ceiling; amygdala: 6.5 nTPM; absolute ceiling; basal ganglia: 6.5 nTPM; absolute ceiling; bone marrow: 52 nTPM; absolute ceiling;continuous selectivity; cerebellum: 24.6 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 16.9 nTPM; positive ihc;absolute ceiling; choroid plexus: 3 nTPM; absolute ceiling; colon: 5.3 nTPM; positive ihc; duodenum: 3 nTPM; positive ihc;absolute ceiling; heart muscle: 7.2 nTPM; absolute ceiling; hippocampal formation: 7.8 nTPM; absolute ceiling; hypothalamus: 8.8 nTPM; absolute ceiling; kidney: 2.6 nTPM; absolute ceiling; liver: 6.2 nTPM; absolute ceiling; lung: 8.3 nTPM; positive ihc;absolute ceiling; lymph node: 6.3 nTPM; absolute ceiling; midbrain: 9.7 nTPM; absolute ceiling; pancreas: 2 nTPM; positive ihc; pituitary gland: 4.2 nTPM; absolute ceiling; rectum: 2.9 nTPM; positive ihc; retina: 10.6 nTPM; absolute ceiling; salivary gland: 3.6 nTPM; positive ihc; skeletal muscle: 9.9 nTPM; positive ihc;absolute ceiling; skin: 3.6 nTPM; positive ihc; small intestine: 4.2 nTPM; positive ihc;absolute ceiling; smooth muscle: 6 nTPM; absolute ceiling; spinal cord: 23.7 nTPM; absolute ceiling;continuous selectivity; stomach: 3.2 nTPM; positive ihc; thymus: 10.5 nTPM; absolute ceiling; thyroid gland: 12 nTPM; positive ihc;absolute ceiling; urinary bladder: 6.3 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 4.9 nTPM (limit 2); amygdala: 6.5 nTPM (limit 2); basal ganglia: 6.5 nTPM (limit 2); bone marrow: 52 nTPM (limit 2); cerebellum: 24.6 nTPM (limit 2); cerebral cortex: 16.9 nTPM (limit 2); choroid plexus: 3 nTPM (limit 2); duodenum: 3 nTPM (limit 2); heart muscle: 7.2 nTPM (limit 2); hippocampal formation: 7.8 nTPM (limit 2); hypothalamus: 8.8 nTPM (limit 2); kidney: 2.6 nTPM (limit 2); liver: 6.2 nTPM (limit 2); lung: 8.3 nTPM (limit 2); lymph node: 6.3 nTPM (limit 6); midbrain: 9.7 nTPM (limit 2); pituitary gland: 4.2 nTPM (limit 2); retina: 10.6 nTPM (limit 2); skeletal muscle: 9.9 nTPM (limit 2); small intestine: 4.2 nTPM (limit 2); smooth muscle: 6 nTPM (limit 2); spinal cord: 23.7 nTPM (limit 2); thymus: 10.5 nTPM (limit 10); thyroid gland: 12 nTPM (limit 10); urinary bladder: 6.3 nTPM (limit 6); adrenal gland: 4.9 nTPM (baseline 2); amygdala: 6.5 nTPM (baseline 2); basal ganglia: 6.5 nTPM (baseline 2); bone marrow: 52 nTPM (baseline 2); cerebellum: 24.6 nTPM (baseline 2); cerebral cortex: 16.9 nTPM (baseline 2); choroid plexus: 3 nTPM (baseline 2); duodenum: 3 nTPM (baseline 2); heart muscle: 7.2 nTPM (baseline 2); hippocampal formation: 7.8 nTPM (baseline 2); hypothalamus: 8.8 nTPM (baseline 2); kidney: 2.6 nTPM (baseline 2); liver: 6.2 nTPM (baseline 2); lung: 8.3 nTPM (baseline 2); lymph node: 6.3 nTPM (baseline 6); midbrain: 9.7 nTPM (baseline 2); pituitary gland: 4.2 nTPM (baseline 2); retina: 10.6 nTPM (baseline 2); skeletal muscle: 9.9 nTPM (baseline 2); small intestine: 4.2 nTPM (baseline 2); smooth muscle: 6 nTPM (baseline 2); spinal cord: 23.7 nTPM (baseline 2); thymus: 10.5 nTPM (baseline 10); thyroid gland: 12 nTPM (baseline 10); urinary bladder: 6.3 nTPM (baseline 6),bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / glandular cells: Low (Uncertain); duodenum / glandular cells: Low (Uncertain); hippocampus / neuronal cells: Low (Uncertain); lung / macrophages: Low (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); rectum / glandular cells: Low (Uncertain); salivary gland / glandular cells: Low (Uncertain); skeletal muscle / myocytes: Low (Uncertain); skin 1 / keratinocytes: Low (Uncertain); small intestine / glandular cells: Medium (Uncertain); stomach 1 / glandular cells: Low (Uncertain); stomach 2 / glandular cells: Low (Uncertain); thyroid gland / glandular cells: Low (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Pancreatic Adenocarcinoma (validation): 80/80 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%),colorectal cancer: 7/11 (63.6%); testis cancer: 4/10 (40.0%),31,20,Q5SW79,https://www.uniprot.org/uniprotkb/Q5SW79/entry,Plays a role in microtubule organization (PubMed:15616186). Required for centriole subdistal appendage assembly (PubMed:28422092),,,,"Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriole Cytoplasm, cytoskeleton, spindle",15616186|28422092,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
CEP19,ENSG00000174007,Unsafe,Protein,False,True,9.6,9.6,85,21,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 4.7 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 6.2 nTPM; absolute ceiling;continuous selectivity; cerebellum: 3.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 6.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 3.2 nTPM; absolute ceiling;continuous selectivity; colon: 1.4 nTPM; positive ihc; duodenum: 0.9 nTPM; positive ihc; hippocampal formation: 4.7 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 5.3 nTPM; absolute ceiling;continuous selectivity; lung: 1.6 nTPM; positive ihc; midbrain: 3.8 nTPM; absolute ceiling;continuous selectivity; pancreas: 0.7 nTPM; positive ihc; pituitary gland: 3.7 nTPM; absolute ceiling;continuous selectivity; rectum: 0.9 nTPM; positive ihc; retina: 6.4 nTPM; absolute ceiling;continuous selectivity; small intestine: 1.1 nTPM; positive ihc; spinal cord: 2.5 nTPM; absolute ceiling; thymus: 7.4 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 4.7 nTPM (limit 2); basal ganglia: 6.2 nTPM (limit 2); cerebellum: 3.6 nTPM (limit 2); cerebral cortex: 6.4 nTPM (limit 2); choroid plexus: 3.2 nTPM (limit 2); hippocampal formation: 4.7 nTPM (limit 2); hypothalamus: 5.3 nTPM (limit 2); midbrain: 3.8 nTPM (limit 2); pituitary gland: 3.7 nTPM (limit 2); retina: 6.4 nTPM (limit 2); spinal cord: 2.5 nTPM (limit 2),bronchus / respiratory epithelial cells: Low (Enhanced); caudate / glial cells: Medium (Enhanced); cerebellum / cells in molecular layer: Medium (Enhanced); cerebral cortex / glial cells: Medium (Enhanced); cerebral cortex / neuropil: Low (Enhanced); colon / glandular cells: Low (Enhanced); duodenum / glandular cells: Low (Enhanced); hippocampus / glial cells: Medium (Enhanced); lung / macrophages: Low (Enhanced); nasopharynx / respiratory epithelial cells: Low (Enhanced); pancreas / exocrine glandular cells: Low (Enhanced); rectum / glandular cells: Low (Enhanced); small intestine / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Glioblastoma Multiforme (TCGA): 88/141 (62.4%); Testicular Germ Cell Tumor (TCGA): 73/133 (54.9%),endometrial cancer: 3/10 (30.0%); testis cancer: 2/9 (22.2%),30,20,Q96LK0,https://www.uniprot.org/uniprotkb/Q96LK0/entry,"Required for ciliation (PubMed:28428259, PubMed:28625565, PubMed:28659385). Recruits the RABL2B GTPase to the ciliary base to initiate ciliation. After specifically capturing the activated GTP-bound RABL2B, the CEP19-RABL2B complex binds intraflagellar transport (IFT) complex B from the large pool pre-docked at the base of the cilium and thus triggers its entry into the cilia (PubMed:28428259, PubMed:28625565). Involved in the early steps in cilia formation by recruiting the ciliary vesicles (CVs) to the distal end of the mother centriole where they fuse to initiate cilium assembly. Involved in microtubule (MT) anchoring to the centrosomes (PubMed:28659385)",,"Morbid obesity and spermatogenic failure: An autosomal recessive morbid obesity syndrome characterized by hypertension, fatty liver disease, insulin resistance, and decreased sperm counts. Variable clinical manifestations are early coronary artery disease with myocardial infarction before 45 years of age, type II diabetes mellitus, and intellectual disability. Morbid obese individuals are defined as having a BMI greater than 40.","The region that interacts with CEP43 is conflicting: According to a report, interacts via N-terminus (PubMed:28428259). According to another report, interacts via C-terminus (PubMed:28659385)","Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriole Cytoplasm, cytoskeleton, spindle pole Cytoplasm, cytoskeleton, cilium basal body",28428259|28625565|28659385,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
CEP57L1,ENSG00000183137,Unsafe,Protein,False,True,25.3,25.3,78,78,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 10.2 nTPM; positive ihc;absolute ceiling; adrenal gland: 7.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 5.3 nTPM; absolute ceiling; basal ganglia: 4.6 nTPM; absolute ceiling; bone marrow: 10 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 3.9 nTPM; positive ihc;absolute ceiling; cerebral cortex: 6.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 11.2 nTPM; absolute ceiling;continuous selectivity; colon: 8.2 nTPM; positive ihc;absolute ceiling; duodenum: 8.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 6 nTPM; positive ihc; heart muscle: 7.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 5.3 nTPM; absolute ceiling; hypothalamus: 4.8 nTPM; absolute ceiling; kidney: 7.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 9.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 6.4 nTPM; positive ihc;absolute ceiling; lymph node: 8.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 5.9 nTPM; absolute ceiling; pancreas: 7.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 16.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 5.4 nTPM; absolute ceiling; rectum: 10.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 10.8 nTPM; absolute ceiling;continuous selectivity; salivary gland: 5.1 nTPM; positive ihc; skeletal muscle: 5.8 nTPM; positive ihc;absolute ceiling; skin: 6.5 nTPM; positive ihc; small intestine: 7.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 10.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 8.4 nTPM; absolute ceiling;continuous selectivity; spleen: 7.5 nTPM; positive ihc; stomach: 7.1 nTPM; positive ihc;absolute ceiling; thymus: 14 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 8.4 nTPM; positive ihc; tongue: 6.3 nTPM; absolute ceiling; urinary bladder: 6.2 nTPM; positive ihc;absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 10.2 nTPM (limit 10); adrenal gland: 7.3 nTPM (limit 2); amygdala: 5.3 nTPM (limit 2); basal ganglia: 4.6 nTPM (limit 2); bone marrow: 10 nTPM (limit 2); cerebellum: 3.9 nTPM (limit 2); cerebral cortex: 6.9 nTPM (limit 2); choroid plexus: 11.2 nTPM (limit 2); colon: 8.2 nTPM (limit 6); duodenum: 8.4 nTPM (limit 2); heart muscle: 7.4 nTPM (limit 2); hippocampal formation: 5.3 nTPM (limit 2); hypothalamus: 4.8 nTPM (limit 2); kidney: 7.7 nTPM (limit 2); liver: 9.7 nTPM (limit 2); lung: 6.4 nTPM (limit 2); lymph node: 8.6 nTPM (limit 6); midbrain: 5.9 nTPM (limit 2); pancreas: 7.1 nTPM (limit 2); parathyroid gland: 16.3 nTPM (limit 6); pituitary gland: 5.4 nTPM (limit 2); rectum: 10.5 nTPM (limit 6); retina: 10.8 nTPM (limit 2); skeletal muscle: 5.8 nTPM (limit 2); small intestine: 7.6 nTPM (limit 2); smooth muscle: 10.4 nTPM (limit 2); spinal cord: 8.4 nTPM (limit 2); stomach: 7.1 nTPM (limit 6); thymus: 14 nTPM (limit 10); tongue: 6.3 nTPM (limit 6); urinary bladder: 6.2 nTPM (limit 6),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Medium (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: High (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: High (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 485/486 (99.8%),endometrial cancer: 12/12 (100.0%); glioma: 12/12 (100.0%),30,20,Q8IYX8,https://www.uniprot.org/uniprotkb/Q8IYX8/entry,Centrosomal protein which may be required for microtubule attachment to centrosomes,,,,"Cytoplasm, cytoskeleton, microtubule organizing center, centrosome",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CEP78,ENSG00000148019,Unsafe,Protein,False,True,14.7,14.7,86,49,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 2.8 nTPM; positive ihc;absolute ceiling; amygdala: 4 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 3.8 nTPM; absolute ceiling;continuous selectivity; bone marrow: 12.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 5.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 4.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 2.2 nTPM; absolute ceiling; colon: 3.4 nTPM; positive ihc; esophagus: 3.4 nTPM; positive ihc; heart muscle: 1.5 nTPM; positive ihc; hippocampal formation: 4.1 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 3.5 nTPM; absolute ceiling; kidney: 3.5 nTPM; positive ihc;absolute ceiling; liver: 3.4 nTPM; positive ihc;absolute ceiling; lung: 3.2 nTPM; positive ihc;absolute ceiling; lymph node: 6 nTPM; positive ihc;continuous selectivity; midbrain: 4.1 nTPM; absolute ceiling;continuous selectivity; pancreas: 2.5 nTPM; positive ihc;absolute ceiling; pituitary gland: 2.6 nTPM; absolute ceiling; rectum: 3.8 nTPM; positive ihc; retina: 9 nTPM; absolute ceiling;continuous selectivity; salivary gland: 3.2 nTPM; positive ihc; skeletal muscle: 1.6 nTPM; positive ihc; skin: 3.5 nTPM; positive ihc; small intestine: 2.8 nTPM; positive ihc;absolute ceiling; smooth muscle: 4.6 nTPM; absolute ceiling; spinal cord: 4.5 nTPM; absolute ceiling;continuous selectivity; stomach: 2.9 nTPM; positive ihc; thymus: 11.2 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 3.6 nTPM; positive ihc; urinary bladder: 3.1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 2.8 nTPM (limit 2); amygdala: 4 nTPM (limit 2); basal ganglia: 3.8 nTPM (limit 2); bone marrow: 12.2 nTPM (limit 2); cerebellum: 5.9 nTPM (limit 2); cerebral cortex: 4.5 nTPM (limit 2); choroid plexus: 2.2 nTPM (limit 2); hippocampal formation: 4.1 nTPM (limit 2); hypothalamus: 3.5 nTPM (limit 2); kidney: 3.5 nTPM (limit 2); liver: 3.4 nTPM (limit 2); lung: 3.2 nTPM (limit 2); midbrain: 4.1 nTPM (limit 2); pancreas: 2.5 nTPM (limit 2); pituitary gland: 2.6 nTPM (limit 2); retina: 9 nTPM (limit 2); small intestine: 2.8 nTPM (limit 2); smooth muscle: 4.6 nTPM (limit 4); spinal cord: 4.5 nTPM (limit 2); thymus: 11.2 nTPM (limit 10),adrenal gland / glandular cells: Low (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Medium (Approved); kidney / cells in tubules: High (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Low (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: High (Approved); pancreas / exocrine glandular cells: Medium (Approved); rectum / glandular cells: Low (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: High (Approved); small intestine / glandular cells: Medium (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 48/50 (96.0%); Pancreatic Adenocarcinoma (validation): 75/80 (93.8%),cervical cancer: 8/11 (72.7%); urothelial cancer: 8/12 (66.7%),31,20,Q5JTW2,https://www.uniprot.org/uniprotkb/Q5JTW2/entry,"Centriole wall protein that localizes to mature centrioles and regulates centriole and cilia biogenesis (PubMed:27246242, PubMed:27588451, PubMed:28242748, PubMed:34259627). Involved in centrosome duplication: required for efficient PLK4 centrosomal localization and PLK4-induced overduplication of centrioles (PubMed:27246242). Involved in cilium biogenesis and controls cilium length (PubMed:27588451). Acts as a regulator of protein stability by preventing ubiquitination of centrosomal proteins, such as CCP110 and tektins (PubMed:28242748, PubMed:34259627). Associates with the EDVP complex, preventing ubiquitination and degradation of CCP110 (PubMed:28242748, PubMed:34259627). Promotes deubiquitination of tektin proteins (TEKT1, TEKT2, TEK3, TEKT4 and TEKT5) via its interaction with USP16 (By similarity)","Widely expressed (PubMed:27588451, PubMed:27588452). Expressed in different retinal cell types with higher expression in cone compared to rod cells (at protein level) (PubMed:27588452)","Cone-rod dystrophy and hearing loss 1: An autosomal recessive disease defined by the association of progressive cone-rod dystrophy with sensorineural hearing loss. Cone-rod dystrophy is characterized by retinal pigment deposits visible on fundus examination, predominantly in the macular region, and initial loss of cone photoreceptors followed by rod degeneration. This leads to decreased visual acuity and sensitivity in the central visual field, followed by loss of peripheral vision. Severe loss of vision occurs earlier than in retinitis pigmentosa, due to cone photoreceptors degenerating at a higher rate than rod photoreceptors.",,"Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriole Cytoplasm, cytoskeleton, cilium basal body",27246242|27588451|28242748|34259627,27588451|27588452,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
CERS1,ENSG00000223802,Unsafe,Protein,False,True,28.5,166.6,110,15,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 135.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 166.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 57.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 139.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 14.4 nTPM; absolute ceiling;continuous selectivity; colon: 3.4 nTPM; positive ihc; heart muscle: 4.2 nTPM; positive ihc;absolute ceiling; hippocampal formation: 141.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 106.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 0 nTPM; positive ihc; midbrain: 158.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 12.4 nTPM; absolute ceiling;continuous selectivity; rectum: 0.2 nTPM; positive ihc; retina: 4.6 nTPM; absolute ceiling; skeletal muscle: 17.5 nTPM; absolute ceiling;continuous selectivity; small intestine: 0.9 nTPM; positive ihc; spinal cord: 161.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; tongue: 11.3 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 135.2 nTPM (limit 2); basal ganglia: 166.6 nTPM (limit 2); cerebellum: 57.8 nTPM (limit 12); cerebral cortex: 139.9 nTPM (limit 2); choroid plexus: 14.4 nTPM (limit 2); heart muscle: 4.2 nTPM (limit 2); hippocampal formation: 141.6 nTPM (limit 2); hypothalamus: 106.2 nTPM (limit 2); midbrain: 158.9 nTPM (limit 2); pituitary gland: 12.4 nTPM (limit 2); retina: 4.6 nTPM (limit 2); skeletal muscle: 17.5 nTPM (limit 12); spinal cord: 161.8 nTPM (limit 2); tongue: 11.3 nTPM (limit 6),caudate / glial cells: Low (Enhanced); caudate / neuronal cells: Medium (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); colon / endocrine cells: Medium (Enhanced); colon / enterocytes: Low (Enhanced); heart muscle / cardiomyocytes: Low (Enhanced); hippocampus / neuronal cells: Low (Enhanced); lymph node / germinal center cells: Low (Enhanced); rectum / endocrine cells: Medium (Enhanced); small intestine / endocrine cells: Medium (Enhanced); small intestine / enterocytes: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 141/141 (100.0%); Skin Cuteneous Melanoma (TCGA): 96/99 (97.0%); Testicular Germ Cell Tumor (TCGA): 124/133 (93.2%),glioma: 2/10 (20.0%); colorectal cancer: 2/12 (16.7%),29,20,P27544,https://www.uniprot.org/uniprotkb/P27544/entry,"Ceramide synthase that catalyzes the transfer of the acyl chain from acyl-CoA to a sphingoid base, with high selectivity toward stearoyl-CoA (octadecanoyl-CoA; C18:0-CoA) (PubMed:17977534, PubMed:23530041, PubMed:26887952, PubMed:31916624). N-acylates sphinganine and sphingosine bases to form dihydroceramides and ceramides in de novo synthesis and salvage pathways, respectively (PubMed:17977534, PubMed:23530041, PubMed:24782409, PubMed:26887952, PubMed:31916624). Plays a predominant role in skeletal muscle in regulating C18 ceramide and dihydroceramide levels with an impact on whole-body glucose metabolism and insulin sensitivity. Protects from diet-induced obesity by suppressing the uptake of glucose in multiple organs in a FGF21-dependent way (By similarity). Generates C18 ceramides in the brain, playing a critical role in cerebellar development and Purkinje cell function (By similarity). In response to cellular stress mediates mitophagy, a known defense mechanism against cell transformation and aging. Upon mitochondria fission, generates C18 ceramides that anchor lipidated MAP1LC3B/LC3B-II autophagolysosomes to outer mitochondrial membranes to eliminate damaged mitochondria (PubMed:22922758)",,"Epilepsy, progressive myoclonic 8: A form of progressive myoclonic epilepsy, a clinically and genetically heterogeneous group of disorders defined by the combination of action and reflex myoclonus, other types of epileptic seizures, and progressive neurodegeneration and neurocognitive impairment. EPM8 is an autosomal recessive form characterized by myoclonus, generalized tonic-clonic seizures and moderate to severe cognitive impairment.",,Endoplasmic reticulum membrane,17977534|22922758|23530041|24782409|26887952|31916624,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CERS3,ENSG00000154227,Unsafe,Protein,False,True,29.4,62.0,85,38,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 0 nTPM; positive ihc; bone marrow: 0.2 nTPM; positive ihc; cerebellum: 0.2 nTPM; positive ihc; cerebral cortex: 0.1 nTPM; positive ihc; colon: 0 nTPM; positive ihc; duodenum: 0 nTPM; positive ihc; esophagus: 53.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 0.1 nTPM; positive ihc; kidney: 0 nTPM; positive ihc; parathyroid gland: 0 nTPM; positive ihc; salivary gland: 8.2 nTPM; absolute ceiling; skeletal muscle: 0.6 nTPM; positive ihc; skin: 62 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; stomach: 0.1 nTPM; positive ihc; thyroid gland: 0.1 nTPM; positive ihc; urinary bladder: 0.2 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",esophagus: 53.6 nTPM (limit 6); salivary gland: 8.2 nTPM (limit 8); skin: 62 nTPM (limit 10),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Low (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: Low (Approved); colon / glandular cells: Low (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Low (Approved); kidney / cells in tubules: Medium (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); parathyroid gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / keratinocytes: Low (Approved); skin 2 / epidermal cells: Medium (Approved); stomach 1 / glandular cells: Low (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Head and Neck Squamous Cell Carcinoma (TCGA): 459/492 (93.3%); Lung Squamous Cell Carcinoma (validation): 50/68 (73.5%); Lung Squamous Cell Carcinoma (TCGA): 331/489 (67.7%),cervical cancer: 7/12 (58.3%); colorectal cancer: 5/12 (41.7%),29,20,Q8IU89,https://www.uniprot.org/uniprotkb/Q8IU89/entry,"Ceramide synthase that catalyzes the transfer of the acyl chain from acyl-CoA to a sphingoid base, with high selectivity toward very- and ultra-long-chain fatty acyl-CoA (chain length greater than C22) (PubMed:17977534, PubMed:22038835, PubMed:26887952). N-acylates sphinganine and sphingosine bases to form dihydroceramides and ceramides in de novo synthesis and salvage pathways, respectively (PubMed:17977534, PubMed:22038835, PubMed:26887952). It is crucial for the synthesis of ultra-long-chain ceramides in the epidermis, to maintain epidermal lipid homeostasis and terminal differentiation (PubMed:23754960)","Expressed in the epidermis, where it localizes at the interface between the stratum granulosum and the stratum corneum (at protein level)","Ichthyosis, congenital, autosomal recessive 9: A form of autosomal recessive congenital ichthyosis, a disorder of keratinization with abnormal differentiation and desquamation of the epidermis, resulting in abnormal skin scaling over the whole body. The main skin phenotypes are lamellar ichthyosis (LI) and non-bullous congenital ichthyosiform erythroderma (NCIE), although phenotypic overlap within the same patient or among patients from the same family can occur. Lamellar ichthyosis is a condition often associated with an embedment in a collodion-like membrane at birth; skin scales later develop, covering the entire body surface. Non-bullous congenital ichthyosiform erythroderma characterized by fine whitish scaling on an erythrodermal background; larger brownish scales are present on the buttocks, neck and legs.","Contains a predicted homeobox domain which is degenerated, lacking residues important for DNA-binding. Moreover, the protein localizes in the endoplasmic reticulum and not in the nucleus, which also argues against homeobox function (By similarity)",Endoplasmic reticulum membrane,17977534|22038835|23754960|26887952,23754960,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | daSilva2017_tumor_proteomics,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
CFAP100,ENSG00000163885,Unsafe,Protein,False,True,31.5,31.5,102,5,Positive somewhere,True,True,False,True,Excluded,Normal,False,,Not assessed,,,positive ihc outside permitted; basal ganglia: 3.6 nTPM; absolute ceiling; choroid plexus: 13 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 3.1 nTPM; absolute ceiling; hypothalamus: 3.4 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",basal ganglia: 3.6 nTPM (limit 2); choroid plexus: 13 nTPM (limit 2); hippocampal formation: 3.1 nTPM (limit 2); hypothalamus: 3.4 nTPM (limit 2),bronchus / ciliated cells (tip of cilia): Medium (Enhanced); nasopharynx / ciliated cells (tip of cilia): Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 33/176 (18.8%); Ovary Serous Cystadenocarcinoma (validation): 12/81 (14.8%); Glioblastoma Multiforme (validation): 6/58 (10.3%),testis cancer: 1/12 (8.3%); breast cancer: 0/12 (0.0%),29,20,Q494V2,https://www.uniprot.org/uniprotkb/Q494V2/entry,"Microtubule-associated protein that promotes microtubule polymerization and regulates microtubule organization (PubMed:37192300). Plays a critical role in ensuring proper epidermal development and function by regulating mitosis in keratinocytes (PubMed:40593606). Maintains spindle pole integrity during keratinocyte division through the recruitment of the microtubule glutamylase TTLL13 to spindle poles, thereby enhancing localized microtubule glutamylation (PubMed:40593606). This modification stabilizes spindle microtubules, ensuring accurate spindle assembly, faithful chromosome segregation, and efficient mitotic progression (PubMed:40593606). May play a role in ciliary/flagellar motility by regulating the assembly and the activity of axonemal inner dynein arm",,,,"Cytoplasm, cytoskeleton, cilium axoneme Cytoplasm, cytoskeleton, spindle pole Cytoplasm, cytoskeleton",40593606,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CFAP107,ENSG00000157330,Unsafe,RNA,False,True,47.5,47.5,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,basal ganglia: 2.1 nTPM; absolute ceiling; choroid plexus: 45.3 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 2.6 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,basal ganglia: 2.1 nTPM (limit 2); choroid plexus: 45.3 nTPM (limit 2); hypothalamus: 2.6 nTPM (limit 2); basal ganglia: 2.1 nTPM (baseline 2); choroid plexus: 45.3 nTPM (baseline 2); hypothalamus: 2.6 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 43/176 (24.4%); Glioblastoma Multiforme (TCGA): 27/141 (19.1%); Glioblastoma Multiforme (validation): 10/58 (17.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8N1D5,https://www.uniprot.org/uniprotkb/Q8N1D5/entry,"Microtubule inner protein (MIP) part of the dynein-decorated doublet microtubules (DMTs) in cilia axoneme, which is required for motile cilia beating",Expressed in airway epithelial cells,,,"Cytoplasm, cytoskeleton, cilium axoneme Cytoplasm, cytoskeleton, flagellum axoneme",36191189,36191189,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
CFAP126,ENSG00000188931,Unsafe,Protein,False,True,146.7,207.8,94,11,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; adrenal gland: 12.9 nTPM; absolute ceiling; amygdala: 8.5 nTPM; absolute ceiling; basal ganglia: 12.5 nTPM; absolute ceiling; cerebral cortex: 28 nTPM; absolute ceiling; choroid plexus: 207.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 38.2 nTPM; absolute ceiling; hippocampal formation: 11.1 nTPM; absolute ceiling; hypothalamus: 14.9 nTPM; absolute ceiling; kidney: 16.1 nTPM; absolute ceiling; lung: 13.5 nTPM; absolute ceiling; midbrain: 8.5 nTPM; absolute ceiling; pituitary gland: 3.5 nTPM; absolute ceiling; retina: 31.8 nTPM; absolute ceiling; skeletal muscle: 81.3 nTPM; absolute ceiling;continuous selectivity; spinal cord: 4.3 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 12.9 nTPM (limit 12); amygdala: 8.5 nTPM (limit 2); basal ganglia: 12.5 nTPM (limit 2); cerebral cortex: 28 nTPM (limit 12); choroid plexus: 207.8 nTPM (limit 2); heart muscle: 38.2 nTPM (limit 12); hippocampal formation: 11.1 nTPM (limit 2); hypothalamus: 14.9 nTPM (limit 2); kidney: 16.1 nTPM (limit 12); lung: 13.5 nTPM (limit 12); midbrain: 8.5 nTPM (limit 2); pituitary gland: 3.5 nTPM (limit 2); retina: 31.8 nTPM (limit 2); skeletal muscle: 81.3 nTPM (limit 12); spinal cord: 4.3 nTPM (limit 2),bronchus / ciliated cells (cilia axoneme): High (Enhanced); bronchus / ciliated cells (ciliary rootlets): Low (Enhanced); bronchus / ciliated cells (tip of cilia): High (Enhanced); nasopharynx / ciliated cells (cilia axoneme): High (Enhanced); nasopharynx / ciliated cells (ciliary rootlets): Low (Enhanced); nasopharynx / ciliated cells (tip of cilia): High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Colon Adenocarcinoma (validation): 485/486 (99.8%); Lung Adenocarcinoma (validation): 104/105 (99.0%),breast cancer: 1/10 (10.0%); urothelial cancer: 1/11 (9.1%),29,20,Q5VTH2,https://www.uniprot.org/uniprotkb/Q5VTH2/entry,Microtubule inner protein (MIP) part of the dynein-decorated doublet microtubules (DMTs) in cilia axoneme (PubMed:36191189). Acts as a regulator of cilium basal body docking and positioning in mono- and multiciliated cells (By similarity). Regulates basal body docking and cilia formation in multiciliated lung cells (By similarity). Regulates kinocilium positioning and stereocilia bundle morphogenesis in the inner ear (By similarity),Expressed in airway epithelial cells,,,"Cytoplasm, cytoskeleton, cilium basal body Cell projection, cilium Apical cell membrane Cytoplasm, cytoskeleton, cilium axoneme Cytoplasm, cytoskeleton, flagellum axoneme",36191189,36191189,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
CFAP141,ENSG00000163263,Unsafe,High RNA,False,True,29.5,29.5,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE CD4_STIM (activated): 32/88 values ≥5 TPM, max 11.3571; DICE CD8_STIM (activated): 35/88 values ≥5 TPM, max 10.1025",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,11.3570634565,143.4,"hpa_single_cell: /Ciliated cells, max 100 nTPM, 1 observations >30; hpa_single_cell_tissue: bronchus/ciliated cells, max 136.1 nTPM, 2 observations >30; hpa_single_cell_tissue: bronchus/club cells, max 45.4 nTPM, 1 observations >30; hpa_single_cell_tissue: lung/ciliated cells, max 143.4 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,11.36 TPM; blood/CD4_STIM; dice_cd4_stim; vital,143.4 nTPM; lung/ciliated cells; hpa_single_cell_tissue; vital,Uterine Corpus Endometrial Carcinoma (TCGA): 31/176 (17.6%); Glioblastoma Multiforme (validation): 7/58 (12.1%); Breast Invasive Carcinoma (validation): 6/50 (12.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q5VU69,https://www.uniprot.org/uniprotkb/Q5VU69/entry,"Microtubule inner protein (MIP) part of the dynein-decorated doublet microtubules (DMTs) in cilia axoneme, which is required for motile cilia beating",Expressed in airway epithelial cells,,,"Cytoplasm, cytoskeleton, cilium axoneme Cytoplasm, cytoskeleton, flagellum axoneme",36191189,36191189,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
CFAP144P1,ENSG00000164556,Unsafe,High RNA,False,True,,,0,0,Missing,False,False,False,False,Excluded,Unassessed,False,,Not assessed,,,"incomplete routine rna; insufficient positive reproductive evidence; reproductive expression not demonstrated; incomplete routine rna; missing normal RNA: adipose tissue, adrenal gland, amygdala, basal ganglia, bone marrow, cerebellum, cerebral cortex, choroid plexus, colon, duodenum, esophagus, heart muscle, hippocampal formation, hypothalamus, kidney, liver, lung, lymph node, midbrain, pancreas, parathyroid gland, pituitary gland, rectum, retina, salivary gland, skeletal muscle, skin, small intestine, smooth muscle, spinal cord, spleen, stomach, thymus, thyroid gland, tongue, urinary bladder; incomplete tissue evidence","Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,incomplete_routine_rna,oncoref.target-sets.2026-10-24.1,False,,False,True,"DICE B_CELL_NAIVE (unstimulated): 91/91 values ≥5 TPM, max 31.6857; DICE NK (unstimulated): 12/90 values ≥5 TPM, max 6.97692; DICE TREG_MEM (unstimulated): 27/89 values ≥5 TPM, max 9.77892; DICE CD4_NAIVE (unstimulated): 11/88 values ≥5 TPM, max 14.182; DICE TREG_NAIVE (unstimulated): 11/89 values ≥5 TPM, max 9.82924; DICE TFH (unstimulated): 58/89 values ≥5 TPM, max 16.919; DICE TH1 (unstimulated): 27/81 values ≥5 TPM, max 8.99027; DICE THSTAR (unstimulated): 6/88 values ≥5 TPM, max 6.64371; DICE TH17 (unstimulated): 19/89 values ≥5 TPM, max 10.856; DICE TH2 (unstimulated): 37/89 values ≥5 TPM, max 9.92285; DICE CD8_NAIVE (unstimulated): 30/89 values ≥5 TPM, max 10.4197",True,False,False,,False,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,31.6857257099,,"dice_b_cell_naive: blood/B_CELL_NAIVE, max 31.6857 TPM, 2 observations >30",Neither,oncoref.target-sets.2026-10-23.2,31.69 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,,No exact-ID RNA coverage in the HPA cancer snapshot,No exact-ID IHC coverage in the HPA cancer snapshot,0,0,Q6ZVS7,https://www.uniprot.org/uniprotkb/Q6ZVS7/entry,,,,Could be the product of a pseudogene,"Cytoplasm, cytoskeleton, cilium basal body",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Chang2019_TGCT,Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,All audited maxima are within 10% above 30; other gates still require review,,,,
CFAP20DC,ENSG00000163689,Unsafe,RNA,False,True,21.7,21.7,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,esophagus: 7.7 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,esophagus: 7.7 nTPM (limit 6); esophagus: 7.7 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 50/133 (37.6%); Lung Squamous Cell Carcinoma (validation): 24/68 (35.3%); Rectum Adenocarcinoma (validation): 61/207 (29.5%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q6ZVT6,https://www.uniprot.org/uniprotkb/Q6ZVT6/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CFAP210,ENSG00000154479,Unsafe,Protein,False,True,77.8,77.8,82,5,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; amygdala: 3.3 nTPM; absolute ceiling; basal ganglia: 4 nTPM; absolute ceiling; choroid plexus: 45.9 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 4.4 nTPM; absolute ceiling; hypothalamus: 4.3 nTPM; absolute ceiling; pituitary gland: 2.5 nTPM; absolute ceiling; retina: 6.5 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 3.3 nTPM (limit 2); basal ganglia: 4 nTPM (limit 2); choroid plexus: 45.9 nTPM (limit 2); hippocampal formation: 4.4 nTPM (limit 2); hypothalamus: 4.3 nTPM (limit 2); pituitary gland: 2.5 nTPM (limit 2); retina: 6.5 nTPM (limit 2),bronchus / respiratory epithelial cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 48/58 (82.8%); Uterine Corpus Endometrial Carcinoma (TCGA): 29/176 (16.5%); Glioblastoma Multiforme (TCGA): 17/141 (12.1%),liver cancer: 6/12 (50.0%); breast cancer: 5/12 (41.7%),29,20,Q0VFZ6,https://www.uniprot.org/uniprotkb/Q0VFZ6/entry,"Microtubule inner protein (MIP) part of the dynein-decorated doublet microtubules (DMTs) in cilia axoneme, which is required for motile cilia beating",Expressed in airway epithelial cells,,It is uncertain whether Met-1 or Met-7 is the initiator,"Cytoplasm, cytoskeleton, cilium axoneme Cytoplasm, cytoskeleton, flagellum axoneme",36191189,36191189,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CFAP263,ENSG00000103021,Unsafe,RNA,False,True,30.2,30.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 2.4 nTPM; absolute ceiling; amygdala: 5.6 nTPM; absolute ceiling; basal ganglia: 6.7 nTPM; absolute ceiling; cerebellum: 2.1 nTPM; absolute ceiling; cerebral cortex: 6.4 nTPM; absolute ceiling; choroid plexus: 9.3 nTPM; absolute ceiling;continuous selectivity; heart muscle: 3.2 nTPM; absolute ceiling; hippocampal formation: 6.2 nTPM; absolute ceiling; hypothalamus: 5.7 nTPM; absolute ceiling; lung: 3.5 nTPM; absolute ceiling; midbrain: 4.4 nTPM; absolute ceiling; parathyroid gland: 6.6 nTPM; absolute ceiling; pituitary gland: 3.1 nTPM; absolute ceiling; retina: 9.1 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 2.6 nTPM; absolute ceiling; spinal cord: 3.4 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 2.4 nTPM (limit 2); amygdala: 5.6 nTPM (limit 2); basal ganglia: 6.7 nTPM (limit 2); cerebellum: 2.1 nTPM (limit 2); cerebral cortex: 6.4 nTPM (limit 2); choroid plexus: 9.3 nTPM (limit 2); heart muscle: 3.2 nTPM (limit 2); hippocampal formation: 6.2 nTPM (limit 2); hypothalamus: 5.7 nTPM (limit 2); lung: 3.5 nTPM (limit 2); midbrain: 4.4 nTPM (limit 2); parathyroid gland: 6.6 nTPM (limit 6); pituitary gland: 3.1 nTPM (limit 2); retina: 9.1 nTPM (limit 2); skeletal muscle: 2.6 nTPM (limit 2); spinal cord: 3.4 nTPM (limit 2); adrenal gland: 2.4 nTPM (baseline 2); amygdala: 5.6 nTPM (baseline 2); basal ganglia: 6.7 nTPM (baseline 2); cerebellum: 2.1 nTPM (baseline 2); cerebral cortex: 6.4 nTPM (baseline 2); choroid plexus: 9.3 nTPM (baseline 2); heart muscle: 3.2 nTPM (baseline 2); hippocampal formation: 6.2 nTPM (baseline 2); hypothalamus: 5.7 nTPM (baseline 2); lung: 3.5 nTPM (baseline 2); midbrain: 4.4 nTPM (baseline 2); parathyroid gland: 6.6 nTPM (baseline 6); pituitary gland: 3.1 nTPM (baseline 2); retina: 9.1 nTPM (baseline 2); skeletal muscle: 2.6 nTPM (baseline 2); spinal cord: 3.4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Rectum Adenocarcinoma (validation): 176/207 (85.0%); Breast Invasive Carcinoma (validation): 42/50 (84.0%),melanoma: 12/12 (100.0%); lung cancer: 5/10 (50.0%),31,20,Q9H0I3,https://www.uniprot.org/uniprotkb/Q9H0I3/entry,"Component of centriolar satellites contributing to primary cilium formation (PubMed:25074808). In complex with CFAP263, acts as a regulator of ciliary beating that connects radial spoke 3 (RS3) to the inner dynein arm (IDA) and the nexin-dynein regulatory complex (N-DRC). The complex is positioned parallel to N-DRC and forms a connection between the arch at the base of RS3, the IDA tail and N-DRC (By similarity)",,,,"Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriolar satellite Cell projection, cilium",25074808,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CFAP298,ENSG00000159079,Unsafe,Protein,False,True,60.4,67.7,93,52,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 22.6 nTPM; positive ihc;absolute ceiling; adrenal gland: 28.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 34.6 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 33.2 nTPM; absolute ceiling;continuous selectivity; bone marrow: 13.9 nTPM; absolute ceiling; cerebellum: 48.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 34.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 67.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 25.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 13.6 nTPM; positive ihc;absolute ceiling; esophagus: 29.8 nTPM; absolute ceiling; heart muscle: 25.9 nTPM; absolute ceiling; hippocampal formation: 37.7 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 43.6 nTPM; absolute ceiling;continuous selectivity; kidney: 36.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 28.3 nTPM; absolute ceiling; lung: 24.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 16.1 nTPM; positive ihc;absolute ceiling; midbrain: 29.9 nTPM; absolute ceiling;continuous selectivity; pancreas: 35.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 47.5 nTPM; absolute ceiling;continuous selectivity; rectum: 13.3 nTPM; positive ihc;absolute ceiling; retina: 26.8 nTPM; absolute ceiling;continuous selectivity; salivary gland: 27.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 34 nTPM; absolute ceiling;continuous selectivity; skin: 26.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 22.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 11 nTPM; positive ihc;absolute ceiling; spinal cord: 27.5 nTPM; absolute ceiling;continuous selectivity; stomach: 28.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 15.6 nTPM; absolute ceiling; thyroid gland: 32.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 11.3 nTPM; absolute ceiling; urinary bladder: 23.9 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 22.6 nTPM (limit 10); adrenal gland: 28.2 nTPM (limit 2); amygdala: 34.6 nTPM (limit 2); basal ganglia: 33.2 nTPM (limit 2); bone marrow: 13.9 nTPM (limit 12); cerebellum: 48.9 nTPM (limit 2); cerebral cortex: 34.1 nTPM (limit 2); choroid plexus: 67.7 nTPM (limit 2); colon: 25.6 nTPM (limit 6); duodenum: 13.6 nTPM (limit 2); esophagus: 29.8 nTPM (limit 24); heart muscle: 25.9 nTPM (limit 12); hippocampal formation: 37.7 nTPM (limit 2); hypothalamus: 43.6 nTPM (limit 2); kidney: 36.7 nTPM (limit 2); liver: 28.3 nTPM (limit 12); lung: 24.3 nTPM (limit 2); lymph node: 16.1 nTPM (limit 6); midbrain: 29.9 nTPM (limit 2); pancreas: 35.2 nTPM (limit 2); pituitary gland: 47.5 nTPM (limit 2); rectum: 13.3 nTPM (limit 6); retina: 26.8 nTPM (limit 2); salivary gland: 27.9 nTPM (limit 6); skeletal muscle: 34 nTPM (limit 12); skin: 26.9 nTPM (limit 10); small intestine: 22.3 nTPM (limit 2); smooth muscle: 11 nTPM (limit 2); spinal cord: 27.5 nTPM (limit 2); stomach: 28.4 nTPM (limit 6); thymus: 15.6 nTPM (limit 10); thyroid gland: 32.5 nTPM (limit 10); tongue: 11.3 nTPM (limit 6); urinary bladder: 23.9 nTPM (limit 6),adipose tissue / adipocytes: Low (Enhanced); adrenal gland / glandular cells: Low (Enhanced); bronchus / respiratory epithelial cells: High (Enhanced); cerebellum / Purkinje cells: Low (Enhanced); cerebral cortex / neuronal cells: Low (Enhanced); colon / glandular cells: Medium (Enhanced); duodenum / glandular cells: Medium (Enhanced); kidney / collecting ducts: Low (Enhanced); kidney / distal tubules: Low (Enhanced); kidney / proximal tubules (cell body): Medium (Enhanced); lung / macrophages: Low (Enhanced); lymph node / germinal center cells: Low (Enhanced); lymph node / non-germinal center cells: Low (Enhanced); nasopharynx / respiratory epithelial cells: Medium (Enhanced); oral mucosa / squamous epithelial cells: Low (Enhanced); pancreas / exocrine glandular cells: Medium (Enhanced); pancreas / pancreatic endocrine cells: Medium (Enhanced); rectum / glandular cells: Medium (Enhanced); salivary gland / glandular cells: Low (Enhanced); skin 1 / keratinocytes: Low (Enhanced); skin 2 / epidermal cells: Medium (Enhanced); small intestine / glandular cells: Medium (Enhanced); smooth muscle / smooth muscle cells: Low (Enhanced); stomach 1 / glandular cells: Medium (Enhanced); stomach 2 / glandular cells: Medium (Enhanced); thyroid gland / glandular cells: Low (Enhanced); urinary bladder / urothelial cells: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%); Thyroid Carcinoma (TCGA): 495/495 (100.0%),testis cancer: 7/10 (70.0%); colorectal cancer: 6/10 (60.0%),29,20,P57076,https://www.uniprot.org/uniprotkb/P57076/entry,"Plays a role in motile cilium function, possibly by acting on outer dynein arm assembly (PubMed:24094744). Seems to be important for initiation rather than maintenance of cilium motility (By similarity). Required for correct positioning of the cilium at the apical cell surface, suggesting an additional role in the planar cell polarity (PCP) pathway (By similarity). May suppress canonical Wnt signaling activity (By similarity)",,"Ciliary dyskinesia, primary, 26: A disorder characterized by abnormalities of motile cilia. Respiratory infections leading to chronic inflammation and bronchiectasis are recurrent, due to defects in the respiratory cilia. Patients may exhibit randomization of left-right body asymmetry and situs inversus, due to dysfunction of monocilia at the embryonic node. Primary ciliary dyskinesia associated with situs inversus is referred to as Kartagener syndrome.",,"Cytoplasm Cytoplasm, cytoskeleton, cilium basal body",24094744,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CFAP299,ENSG00000197826,Unsafe,Protein,False,True,26.6,26.6,92,11,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; basal ganglia: 2.4 nTPM; absolute ceiling; choroid plexus: 5.1 nTPM; absolute ceiling; hippocampal formation: 2.8 nTPM; absolute ceiling; hypothalamus: 2.9 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",basal ganglia: 2.4 nTPM (limit 2); choroid plexus: 5.1 nTPM (limit 2); hippocampal formation: 2.8 nTPM (limit 2); hypothalamus: 2.9 nTPM (limit 2),nasopharynx / ciliated cells (ciliary rootlets): Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 15/176 (8.5%); Lung Adenocarcinoma (TCGA): 15/497 (3.0%); Ovary Serous Cystadenocarcinoma (validation): 2/81 (2.5%),testis cancer: 8/9 (88.9%); melanoma: 8/12 (66.7%),29,20,Q6V702,https://www.uniprot.org/uniprotkb/Q6V702/entry,May be involved in spermatogenesis,,,,Cytoplasm Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CFAP300,ENSG00000137691,Unsafe,Protein,False,True,29.3,29.3,95,9,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; basal ganglia: 2.9 nTPM; absolute ceiling; choroid plexus: 23.6 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 2.6 nTPM; absolute ceiling; hypothalamus: 3.4 nTPM; absolute ceiling; pituitary gland: 3.9 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",basal ganglia: 2.9 nTPM (limit 2); choroid plexus: 23.6 nTPM (limit 2); hippocampal formation: 2.6 nTPM (limit 2); hypothalamus: 3.4 nTPM (limit 2); pituitary gland: 3.9 nTPM (limit 2),bronchus / ciliated cells (cell body): Low (Enhanced); bronchus / ciliated cells (cilia axoneme): Medium (Enhanced); bronchus / ciliated cells (ciliary rootlets): Low (Enhanced); bronchus / ciliated cells (tip of cilia): Medium (Enhanced); nasopharynx / ciliated cells (ciliary rootlets): Low (Enhanced); nasopharynx / ciliated cells (tip of cilia): Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Adenocarcinoma (validation): 51/105 (48.6%); Glioblastoma Multiforme (validation): 25/58 (43.1%); Ovary Serous Cystadenocarcinoma (TCGA): 141/349 (40.4%),breast cancer: 0/12 (0.0%); cervical cancer: 0/11 (0.0%),29,20,Q9BRQ4,https://www.uniprot.org/uniprotkb/Q9BRQ4/entry,Cilium- and flagellum-specific protein that plays a role in axonemal structure organization and motility. May play a role in outer and inner dynein arm assembly,Expressed in nasal epithelial cells,"Ciliary dyskinesia, primary, 38: A form of primary ciliary dyskinesia, a disorder characterized by abnormalities of motile cilia. Respiratory infections leading to chronic inflammation and bronchiectasis are recurrent, due to defects in the respiratory cilia. Some patients exhibit randomization of left-right body asymmetry and situs inversus. Primary ciliary dyskinesia associated with situs inversus is referred to as Kartagener syndrome. CILD38 inheritance is autosomal recessive.",,"Cytoplasm Cytoplasm, cytoskeleton, cilium axoneme",,29727693,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CFAP418,ENSG00000156172,Unsafe,Protein,False,True,3.8,4.9,81,53,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 1.7 nTPM; positive ihc; adrenal gland: 1.7 nTPM; positive ihc;continuous selectivity; amygdala: 2.2 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 2.7 nTPM; absolute ceiling;continuous selectivity; bone marrow: 0.8 nTPM; positive ihc; cerebellum: 1.8 nTPM; continuous selectivity; cerebral cortex: 2.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 2.6 nTPM; absolute ceiling;continuous selectivity; colon: 1 nTPM; positive ihc; duodenum: 0.9 nTPM; positive ihc; esophagus: 1 nTPM; positive ihc; heart muscle: 2.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 2.1 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 2.2 nTPM; absolute ceiling;continuous selectivity; kidney: 2.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 1.7 nTPM; positive ihc;continuous selectivity; lung: 1.5 nTPM; positive ihc;continuous selectivity; lymph node: 2.1 nTPM; positive ihc;continuous selectivity; midbrain: 2.1 nTPM; absolute ceiling;continuous selectivity; pancreas: 1.2 nTPM; positive ihc;continuous selectivity; parathyroid gland: 3.3 nTPM; positive ihc;continuous selectivity; pituitary gland: 2.2 nTPM; absolute ceiling;continuous selectivity; rectum: 0.9 nTPM; positive ihc; retina: 4.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 1 nTPM; positive ihc; small intestine: 1 nTPM; positive ihc; smooth muscle: 2.2 nTPM; continuous selectivity; spinal cord: 1.8 nTPM; continuous selectivity; spleen: 1.6 nTPM; positive ihc; stomach: 1.1 nTPM; positive ihc; thymus: 2.3 nTPM; continuous selectivity; thyroid gland: 2.4 nTPM; positive ihc;continuous selectivity; tongue: 1.8 nTPM; continuous selectivity; urinary bladder: 1.1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 2.2 nTPM (limit 2); basal ganglia: 2.7 nTPM (limit 2); cerebral cortex: 2.4 nTPM (limit 2); choroid plexus: 2.6 nTPM (limit 2); heart muscle: 2.6 nTPM (limit 2); hippocampal formation: 2.1 nTPM (limit 2); hypothalamus: 2.2 nTPM (limit 2); kidney: 2.3 nTPM (limit 2); midbrain: 2.1 nTPM (limit 2); pituitary gland: 2.2 nTPM (limit 2); retina: 4.9 nTPM (limit 2),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Medium (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / neuronal cells: Low (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Medium (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: Low (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Low (Approved); liver / hepatocytes: Low (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: High (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Low (Approved); skeletal muscle / myocytes: Low (Approved); small intestine / glandular cells: Low (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Low (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 46/50 (92.0%); Glioblastoma Multiforme (TCGA): 49/141 (34.8%),lymphoma: 5/11 (45.5%); melanoma: 3/10 (30.0%),31,20,Q96NL8,https://www.uniprot.org/uniprotkb/Q96NL8/entry,May be involved in photoreceptor outer segment disk morphogenesis (By similarity),"Widely expressed, with highest levels in heart and brain. Also expressed in the retina (at protein level)","Cone-rod dystrophy 16: An inherited retinal dystrophy characterized by retinal pigment deposits visible on fundus examination, predominantly in the macular region, and initial loss of cone photoreceptors followed by rod degeneration. This leads to decreased visual acuity and sensitivity in the central visual field, followed by loss of peripheral vision. Severe loss of vision occurs earlier than in retinitis pigmentosa, due to cone photoreceptors degenerating at a higher rate than rod photoreceptors. Retinitis pigmentosa 64: A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. Bardet-Biedl syndrome 21: A form of Bardet-Biedl syndrome, a syndrome characterized by usually severe pigmentary retinopathy, early-onset obesity, polydactyly, hypogenitalism, renal malformation and intellectual disability. Secondary features include diabetes mellitus, hypertension and congenital heart disease. Bardet-Biedl syndrome inheritance is autosomal recessive, but three mutated alleles (two at one locus, and a third at a second locus) may be required for clinical manifestation of some forms of the disease.",,Cytoplasm Photoreceptor inner segment,,22177090,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CFAP43,ENSG00000197748,Unsafe,RNA,False,True,55.6,96.9,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 5.2 nTPM; absolute ceiling; basal ganglia: 9.9 nTPM; absolute ceiling; choroid plexus: 96.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 9.3 nTPM; absolute ceiling; hypothalamus: 11.9 nTPM; absolute ceiling; kidney: 5.7 nTPM; absolute ceiling; lung: 7.9 nTPM; absolute ceiling; midbrain: 2.7 nTPM; absolute ceiling; pancreas: 2.1 nTPM; absolute ceiling; pituitary gland: 9.8 nTPM; absolute ceiling; retina: 10.4 nTPM; absolute ceiling; spinal cord: 2.6 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 5.2 nTPM (limit 2); basal ganglia: 9.9 nTPM (limit 2); choroid plexus: 96.9 nTPM (limit 2); hippocampal formation: 9.3 nTPM (limit 2); hypothalamus: 11.9 nTPM (limit 2); kidney: 5.7 nTPM (limit 2); lung: 7.9 nTPM (limit 2); midbrain: 2.7 nTPM (limit 2); pancreas: 2.1 nTPM (limit 2); pituitary gland: 9.8 nTPM (limit 2); retina: 10.4 nTPM (limit 2); spinal cord: 2.6 nTPM (limit 2); amygdala: 5.2 nTPM (baseline 2); basal ganglia: 9.9 nTPM (baseline 2); choroid plexus: 96.9 nTPM (baseline 2); hippocampal formation: 9.3 nTPM (baseline 2); hypothalamus: 11.9 nTPM (baseline 2); kidney: 5.7 nTPM (baseline 2); lung: 7.9 nTPM (baseline 2); midbrain: 2.7 nTPM (baseline 2); pancreas: 2.1 nTPM (baseline 2); pituitary gland: 9.8 nTPM (baseline 2); retina: 10.4 nTPM (baseline 2); spinal cord: 2.6 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 23/58 (39.7%); Kidney Renal Papillary Cell Carcinoma (TCGA): 106/282 (37.6%); Uterine Corpus Endometrial Carcinoma (TCGA): 61/176 (34.7%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q8NDM7,https://www.uniprot.org/uniprotkb/Q8NDM7/entry,Flagellar protein involved in sperm flagellum axoneme organization and function (By similarity). Involved in the regulation of the beating frequency of motile cilia on the epithelial cells of the respiratory tract (By similarity),Testis-specific,"Spermatogenic failure 19: An infertility disorder caused by spermatogenesis defects and characterized by abnormally shaped spermatozoa in the semen of affected individuals. SPGF19 patients have spermatozoa with absent, short, coiled, bent, and/or irregular-caliber flagella, which impair sperm motility. Hydrocephalus, normal pressure, 1: An autosomal dominant neurologic disorder characterized by a slowly progressive gait disorder, urinary incontinence, progressive intellectual decline, and ventricular enlargement on brain imaging. Cerebrospinal fluid pressure tends to be in the high normal range.",,"Cell projection, cilium, flagellum Cytoplasm, cytoskeleton, flagellum axoneme Cytoplasm, cytoskeleton, cilium axoneme",,29449551,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CFAP44,ENSG00000206530,Unsafe,Protein,False,True,6.6,8.4,80,3,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; cerebellum: 2.7 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 1 nTPM; positive ihc; choroid plexus: 5.9 nTPM; absolute ceiling;continuous selectivity; colon: 2.6 nTPM; continuous selectivity; kidney: 1.8 nTPM; continuous selectivity; liver: 2 nTPM; continuous selectivity; lung: 2.4 nTPM; absolute ceiling;continuous selectivity; pancreas: 3.6 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 6.1 nTPM; absolute ceiling;continuous selectivity; retina: 8.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 4.8 nTPM; continuous selectivity; skin: 2.3 nTPM; positive ihc; small intestine: 2.8 nTPM; absolute ceiling;continuous selectivity; spleen: 1.9 nTPM; positive ihc; stomach: 2.9 nTPM; continuous selectivity; thyroid gland: 3.1 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",cerebellum: 2.7 nTPM (limit 2); choroid plexus: 5.9 nTPM (limit 2); lung: 2.4 nTPM (limit 2); pancreas: 3.6 nTPM (limit 2); pituitary gland: 6.1 nTPM (limit 2); retina: 8.4 nTPM (limit 2); small intestine: 2.8 nTPM (limit 2); cerebellum: 2.7 nTPM (baseline 2); choroid plexus: 5.9 nTPM (baseline 2); lung: 2.4 nTPM (baseline 2); pancreas: 3.6 nTPM (baseline 2); pituitary gland: 6.1 nTPM (baseline 2); retina: 8.4 nTPM (baseline 2); small intestine: 2.8 nTPM (baseline 2),cerebral cortex / neuronal cells: Low (Uncertain); skin 2 / epidermal cells: Low (Uncertain); spleen / cells in red pulp: Low (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 54/58 (93.1%); Pancreatic Adenocarcinoma (validation): 55/80 (68.8%); Rectum Adenocarcinoma (validation): 79/207 (38.2%),breast cancer: 0/12 (0.0%); cervical cancer: 0/11 (0.0%),29,20,Q96MT7,https://www.uniprot.org/uniprotkb/Q96MT7/entry,Flagellar protein involved in sperm flagellum axoneme organization and function,Testis-specific,"Spermatogenic failure 20: An infertility disorder caused by spermatogenesis defects and characterized by abnormally shaped spermatozoa in the semen of affected individuals. SPGF20 patients have spermatozoa with absent, short, coiled, bent, and/or irregular-caliber flagella, which impair sperm motility.",,"Cell projection, cilium, flagellum Cytoplasm, cytoskeleton, flagellum axoneme",,29449551,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
CFAP53,ENSG00000172361,Unsafe,Protein,False,True,77.4,77.4,101,14,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; amygdala: 3 nTPM; absolute ceiling; basal ganglia: 5.8 nTPM; absolute ceiling; choroid plexus: 19.9 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 4.2 nTPM; absolute ceiling; hypothalamus: 5.1 nTPM; absolute ceiling; pituitary gland: 3.2 nTPM; absolute ceiling; retina: 3.4 nTPM; absolute ceiling; spinal cord: 2.1 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 3 nTPM (limit 2); basal ganglia: 5.8 nTPM (limit 2); choroid plexus: 19.9 nTPM (limit 2); hippocampal formation: 4.2 nTPM (limit 2); hypothalamus: 5.1 nTPM (limit 2); pituitary gland: 3.2 nTPM (limit 2); retina: 3.4 nTPM (limit 2); spinal cord: 2.1 nTPM (limit 2),bronchus / ciliated cells (cell body): Low (Enhanced); bronchus / ciliated cells (ciliary rootlets): Medium (Enhanced); bronchus / ciliated cells (tip of cilia): High (Enhanced); caudate / glial cells: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 47/58 (81.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 63/176 (35.8%); Kidney Renal Papillary Cell Carcinoma (TCGA): 95/282 (33.7%),breast cancer: 0/12 (0.0%); cervical cancer: 0/12 (0.0%),29,20,Q96M91,https://www.uniprot.org/uniprotkb/Q96M91/entry,"Microtubule inner protein (MIP) part of the dynein-decorated doublet microtubules (DMTs) in cilia axoneme, which is required for motile cilia beating (PubMed:36191189). Regulates motility patterns of both 9+0 and 9+2 motile cilia through differential localization and recruitment of axonemal dynein components (By similarity). Required for centriolar satellite integrity and non-motile cilium assembly (PubMed:26538025). Required for motile cilium formation (PubMed:26538025). Through its role in the beating of primary cilia, involved in the establishment of organ laterality during embryogenesis (PubMed:26531781). Required for sperm flagellum biogenesis and is essential for male fertility (By similarity)","Expressed in skin fibroblasts (at protein level) (PubMed:22577226, PubMed:28621423). Expressed in nasal respiratory epithelial cells (at protein level) (PubMed:25504577). Expressed in airway epithelial cells (PubMed:36191189)","Heterotaxy, visceral, 6, autosomal: A form of visceral heterotaxy, a complex disorder due to disruption of the normal left-right asymmetry of the thoracoabdominal organs. Visceral heterotaxy or situs ambiguus results in randomization of the placement of visceral organs, including the heart, lungs, liver, spleen, and stomach. The organs are oriented randomly with respect to the left-right axis and with respect to one another. It can be associated with a variety of congenital defects including cardiac malformations. HTX6 clinical features are situs inversus totalis and severe complex cardiac malformations including unbalanced atrioventricular canal defects, transposition of the great arteries with severe pulmonary stenosis, right aortic arch, abnormal systemic venous return and total anomalous pulmonary venous drainage.",,"Cytoplasm, cytoskeleton, cilium axoneme Cytoplasm, cytoskeleton, flagellum axoneme Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriole Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriolar satellite Cytoplasm, cytoskeleton, spindle pole Cytoplasm, cytoskeleton Cell projection, cilium",26531781|26538025|36191189,22577226|25504577|28621423|36191189,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CFAP57,ENSG00000243710,Unsafe,Protein,False,True,22.7,22.7,104,17,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; basal ganglia: 2.3 nTPM; absolute ceiling; choroid plexus: 13.6 nTPM; absolute ceiling;continuous selectivity; lung: 2.4 nTPM; positive ihc;absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",basal ganglia: 2.3 nTPM (limit 2); choroid plexus: 13.6 nTPM (limit 2); lung: 2.4 nTPM (limit 2),bronchus / ciliated cells (cell body): Medium (Enhanced); bronchus / ciliated cells (cilia axoneme): High (Enhanced); bronchus / ciliated cells (tip of cilia): High (Enhanced); caudate / glial cells: Low (Enhanced); lung / alveolar cells type I: High (Enhanced); lung / macrophages: Medium (Enhanced); nasopharynx / ciliated cells (cell body): Medium (Enhanced); nasopharynx / ciliated cells (cilia axoneme): Medium (Enhanced); nasopharynx / ciliated cells (tip of cilia): Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 32/176 (18.2%); Glioblastoma Multiforme (validation): 7/58 (12.1%); Lung Adenocarcinoma (validation): 10/105 (9.5%),colorectal cancer: 2/11 (18.2%); endometrial cancer: 2/11 (18.2%),29,20,Q96MR6,https://www.uniprot.org/uniprotkb/Q96MR6/entry,"Associates with components of the nexin-dynein regulatory complex (N-DRC), a key regulator of ciliary/flagellar motility, and might act as an inner dynein arm (IDA) hub or linkage",Expressed in nasal epithelial cells,"Spermatogenic failure 95: An autosomal recessive, male infertility disorder characterized by markedly reduced progressive sperm motility and multiple morphologic abnormalities of the flagella, including irregularly shaped, short, absent, coiled, and bent flagella.",,"Cytoplasm, cytoskeleton, cilium axoneme",32764743,32764743,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CFAP58,ENSG00000120051,Unsafe,RNA,False,True,13.0,13.0,79,3,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,choroid plexus: 3.2 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 3.2 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 4/58 (6.9%); Uterine Corpus Endometrial Carcinoma (TCGA): 8/176 (4.5%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 5/283 (1.8%),prostate cancer: 7/12 (58.3%); testis cancer: 2/11 (18.2%),29,20,Q5T655,https://www.uniprot.org/uniprotkb/Q5T655/entry,Has an essential role in the assembly and organization of the sperm flagellar axoneme (PubMed:32791035). Required for the elongation of the primary cilium and sperm flagellar midpiece via modulation of the Notch signaling pathway (By similarity),,"Spermatogenic failure 49: An autosomal recessive infertility disorder characterized by asthenoteratozoospermia and multiple morphologic abnormalities of the sperm flagella, primarily coiled and short flagella, with markedly reduced or absent motility.",,"Cell projection, cilium Cell projection, cilium, flagellum Cytoplasm, cytoskeleton, microtubule organizing center, centrosome",32791035,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CFAP70,ENSG00000156042,Unsafe,Protein,False,True,19.4,58.6,103,11,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 4.3 nTPM; positive ihc;absolute ceiling; amygdala: 3.1 nTPM; absolute ceiling; basal ganglia: 4.3 nTPM; absolute ceiling; choroid plexus: 58.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 3.9 nTPM; absolute ceiling; hypothalamus: 4.8 nTPM; absolute ceiling; lung: 2.9 nTPM; positive ihc;absolute ceiling; pituitary gland: 13.1 nTPM; absolute ceiling;continuous selectivity; retina: 10 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 4.3 nTPM (limit 2); amygdala: 3.1 nTPM (limit 2); basal ganglia: 4.3 nTPM (limit 2); choroid plexus: 58.6 nTPM (limit 2); hippocampal formation: 3.9 nTPM (limit 2); hypothalamus: 4.8 nTPM (limit 2); lung: 2.9 nTPM (limit 2); pituitary gland: 13.1 nTPM (limit 2); retina: 10 nTPM (limit 2),adrenal gland / glandular cells: Low (Enhanced); bronchus / ciliated cells (cilia axoneme): High (Enhanced); bronchus / ciliated cells (tip of cilia): High (Enhanced); lung / macrophages: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 29/58 (50.0%); Ovary Serous Cystadenocarcinoma (validation): 29/81 (35.8%); Kidney Renal Papillary Cell Carcinoma (TCGA): 66/282 (23.4%),endometrial cancer: 1/12 (8.3%); breast cancer: 0/11 (0.0%),29,20,Q5T0N1,https://www.uniprot.org/uniprotkb/Q5T0N1/entry,"Axoneme-binding protein that plays a role in the regulation of ciliary motility and cilium length. Essential for the assembly of the sperm flagellum and the correct shaping of the sperm head, during spermiogenesis.Contributes in part to flagellar biogenesis by stabilizing QRICH2, promoting the cytoplasmic preassembly of CFAP61 and CFAP91, and regulating the manchette localization of axoneme-associated proteins such as IFT88, DNAI1 and CFAP61",Expressed in testis,"Spermatogenic failure 41: An autosomal recessive infertility disorder characterized by oligozoospermia, severe asthenozoospermia and flagellar abnormalities such as short, absent, coiled, and irregular-caliber flagella. Some sperm show tapered heads and acrosomal abnormalities.",,"Cell projection, cilium, flagellum Cytoplasm, cytoskeleton, flagellum basal body Cell projection, cilium Cytoplasm, cytoskeleton, cilium axoneme Cytoplasm, cytoskeleton, flagellum axoneme",,31621862|37352829,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
CFAP91,ENSG00000183833,Unsafe,Protein,False,True,13.7,15.8,87,4,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; choroid plexus: 15.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 2.3 nTPM; absolute ceiling; pituitary gland: 7 nTPM; absolute ceiling;continuous selectivity; retina: 4 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 15.8 nTPM (limit 2); hypothalamus: 2.3 nTPM (limit 2); pituitary gland: 7 nTPM (limit 2); retina: 4 nTPM (limit 2),bronchus / ciliated cells (cilia axoneme): High (Supported); bronchus / ciliated cells (ciliary rootlets): Medium (Supported); bronchus / ciliated cells (tip of cilia): High (Supported),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 40/58 (69.0%); Ovary Serous Cystadenocarcinoma (validation): 27/81 (33.3%); Kidney Renal Clear Cell Carcinoma (validation): 29/100 (29.0%),breast cancer: 0/12 (0.0%); cervical cancer: 0/11 (0.0%),29,20,Q7Z4T9,https://www.uniprot.org/uniprotkb/Q7Z4T9/entry,"Involved in sperm flagellum axonemal organization and function (PubMed:12223483, PubMed:32161152). May regulate cilium motility through its role in the assembly of the axonemal radial spokes (By similarity)","Strongly expressed in the liver Widely expressed, but strongly expressed in all spermatogenesis-related tissues, including the testis, the epithelium of cauda and the corpus epididymis, as well as the spermatid and mature sperm. Also expressed in Leydig cells","Spermatogenic failure 51: An autosomal recessive infertility disorder characterized by asthenoteratozoospermia. Spermatozoa exhibit multiple morphologic abnormalities, including absent, short, bent, coiled and irregular-caliber flagella. Abnormalities of the sperm head, base, and acrosome have also been observed.",,"Mitochondrion Cytoplasm Cytoplasm, cytoskeleton, cilium axoneme",12223483|32161152,15863901|32161152,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
CFAP92,ENSG00000114656,Unsafe,RNA,False,True,21.4,21.4,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 2.1 nTPM; absolute ceiling; choroid plexus: 4.5 nTPM; absolute ceiling; retina: 2.8 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 2.1 nTPM (limit 2); choroid plexus: 4.5 nTPM (limit 2); retina: 2.8 nTPM (limit 2); bone marrow: 2.1 nTPM (baseline 2); choroid plexus: 4.5 nTPM (baseline 2); retina: 2.8 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 182/207 (87.9%); Colon Adenocarcinoma (validation): 425/486 (87.4%); Rectum Adenocarcinoma (TCGA): 34/88 (38.6%),glioma: 3/12 (25.0%); testis cancer: 1/10 (10.0%),29,20,Q9ULG3,https://www.uniprot.org/uniprotkb/Q9ULG3/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Loriot2025_S2,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct,,,,,,,,
CFAP96,ENSG00000205129,Unsafe,Protein,False,True,11.6,30.8,101,12,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; basal ganglia: 4.6 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 30.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 2.9 nTPM; absolute ceiling; hypothalamus: 3.1 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 2.8 nTPM; absolute ceiling; retina: 13.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 0.1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",basal ganglia: 4.6 nTPM (limit 2); choroid plexus: 30.8 nTPM (limit 2); hippocampal formation: 2.9 nTPM (limit 2); hypothalamus: 3.1 nTPM (limit 2); pituitary gland: 2.8 nTPM (limit 2); retina: 13.1 nTPM (limit 2),bronchus / ciliated cells (cilia axoneme): High (Enhanced); bronchus / ciliated cells (tip of cilia): High (Enhanced); nasopharynx / ciliated cells (cilia axoneme): High (Enhanced); nasopharynx / ciliated cells (tip of cilia): High (Enhanced); skeletal muscle / myocytes: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 50/58 (86.2%); Kidney Renal Clear Cell Carcinoma (validation): 77/100 (77.0%); Breast Invasive Carcinoma (validation): 33/50 (66.0%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),31,20,A7E2U8,https://www.uniprot.org/uniprotkb/A7E2U8/entry,,Detected in testis and fetal liver,,,"Cytoplasm, cytoskeleton, microtubule organizing center, centrosome",,15809229,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Jamin2021_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CFAP99,ENSG00000206113,Unsafe,RNA,False,True,5.1,5.1,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,choroid plexus: 2.5 nTPM; absolute ceiling;continuous selectivity; retina: 1.4 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 2.5 nTPM (limit 2); choroid plexus: 2.5 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 4/58 (6.9%); Uterine Corpus Endometrial Carcinoma (TCGA): 11/176 (6.2%); Glioblastoma Multiforme (TCGA): 3/141 (2.1%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,D6REC4,https://www.uniprot.org/uniprotkb/D6REC4/entry,,,,,"Cell projection, cilium, flagellum",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Chang2019_TGCT,Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CFHR5,ENSG00000134389,Unsafe,RNA,False,True,0.0,162.0,81,0,Negative where measured,False,True,False,False,Excluded,Normal,False,,Not assessed,,,insufficient positive reproductive evidence; reproductive expression not demonstrated; incomplete tissue evidence,Measured normal RNA exceeds its applicable category/IHC ceiling,liver: 162 nTPM (limit 6); liver: 162 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (validation): 192/231 (83.1%); Liver Hepatocellular Carcinoma (TCGA): 285/362 (78.7%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),liver cancer: 3/12 (25.0%); pancreatic cancer: 1/10 (10.0%),31,20,Q9BXR6,https://www.uniprot.org/uniprotkb/Q9BXR6/entry,Involved in complement regulation. The dimerized forms have avidity for tissue-bound complement fragments and efficiently compete with the physiological complement inhibitor CFH,Expressed by the liver and secreted in plasma,"CFHR5 deficiency: A progressive disease characterized by glomerulonephritis, hematuria, renal failure, end-stage renal disease, subendothelial and mesangial glomerular C3 deposits, mesangial matrix expansion, increased glomerular cellularity, and segmental capillary wall thickening. Hematuria may become apparent after respiratory infections.",,Secreted,23487775,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | daSilva2017_tumor_proteomics,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
CGB1,ENSG00000267631,Unsafe,Protein,False,True,0.3,4.1,87,4,Positive somewhere,True,True,False,True,Excluded,Normal,False,,Not assessed,,,positive ihc outside permitted; pancreas: 2.6 nTPM; continuous selectivity;reproductive not higher; pituitary gland: 4.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",pituitary gland: 4.1 nTPM (limit 2),pituitary gland / cells in anterior : High (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Chromophobe (TCGA): 1/64 (1.6%); Testicular Germ Cell Tumor (TCGA): 2/133 (1.5%); Ovary Serous Cystadenocarcinoma (TCGA): 4/349 (1.1%),lung cancer: 3/12 (25.0%); endometrial cancer: 1/12 (8.3%),31,20,A6NKQ9,https://www.uniprot.org/uniprotkb/A6NKQ9/entry,,"Expressed in placenta, testis and pituitary",,,Secreted,,16123088|18048458,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
CGB5,ENSG00000189052,Unsafe,RNA,False,True,24.9,24.9,87,3,Positive somewhere,False,True,False,True,Excluded,Normal,False,,Not assessed,,,pituitary gland: 8.4 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,pituitary gland: 8.4 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (TCGA): 84/176 (47.7%); Pancreatic Adenocarcinoma (validation): 19/80 (23.8%); Testicular Germ Cell Tumor (TCGA): 25/133 (18.8%),urothelial cancer: 1/10 (10.0%); breast cancer: 0/10 (0.0%),31,20,P0DN86,https://www.uniprot.org/uniprotkb/P0DN86/entry,"Beta subunit of the human chorionic gonadotropin (hCG). hCG is a complex glycoprotein composed of two glycosylated subunits alpha and beta which are non-covalently associated. The alpha subunit is identical to those in the pituitary gonadotropin hormones (LH, FSH and TSH). The beta subunits are distinct in each of the hormones and confer receptor and biological specificity. Has an essential role in pregnancy and maternal adaptation. Stimulates the ovaries to synthesize the steroids that are essential for the maintenance of pregnancy",High expression in the placenta throughout pregnancy,,,Secreted,,16123088,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Bradley2020_CPA | daSilva2017_testis_biased | daSilva2017_CT | Gong2021_reproductive_PC,No tumor-antigen validation in this source | Expression-nominated CPA; not newly validated by this study | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
CGB8,ENSG00000213030,Unsafe,RNA,False,True,18.1,18.1,87,3,Positive somewhere,False,True,False,True,Excluded,Normal,False,,Not assessed,,,pituitary gland: 2.3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,pituitary gland: 2.3 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 50/133 (37.6%); Pancreatic Adenocarcinoma (TCGA): 59/176 (33.5%); Pancreatic Adenocarcinoma (validation): 13/80 (16.2%),urothelial cancer: 1/10 (10.0%); breast cancer: 0/10 (0.0%),31,20,P0DN86,https://www.uniprot.org/uniprotkb/P0DN86/entry,"Beta subunit of the human chorionic gonadotropin (hCG). hCG is a complex glycoprotein composed of two glycosylated subunits alpha and beta which are non-covalently associated. The alpha subunit is identical to those in the pituitary gonadotropin hormones (LH, FSH and TSH). The beta subunits are distinct in each of the hormones and confer receptor and biological specificity. Has an essential role in pregnancy and maternal adaptation. Stimulates the ovaries to synthesize the steroids that are essential for the maintenance of pregnancy",High expression in the placenta throughout pregnancy,,,Secreted,,16123088,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | daSilva2017_testis_biased | daSilva2017_CT | Gong2021_reproductive_PC,No tumor-antigen validation in this source | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Normal reproductive-tissue enrichment; no tumor validation,,,,Failed bulk numeric comparisons are within 20% of their cutoffs; not an automatic rescue,,,,
CHEK1,ENSG00000149554,Unsafe,RNA,False,True,29.4,29.4,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 26 nTPM; absolute ceiling;continuous selectivity; colon: 8 nTPM; absolute ceiling; duodenum: 6.6 nTPM; absolute ceiling; kidney: 2.3 nTPM; absolute ceiling; liver: 2.1 nTPM; absolute ceiling; lymph node: 14.7 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 12.8 nTPM; absolute ceiling;continuous selectivity; rectum: 8.6 nTPM; absolute ceiling; small intestine: 7.3 nTPM; absolute ceiling; smooth muscle: 3.3 nTPM; absolute ceiling; thymus: 20.4 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 26 nTPM (limit 2); colon: 8 nTPM (limit 6); duodenum: 6.6 nTPM (limit 2); kidney: 2.3 nTPM (limit 2); liver: 2.1 nTPM (limit 2); lymph node: 14.7 nTPM (limit 6); parathyroid gland: 12.8 nTPM (limit 6); rectum: 8.6 nTPM (limit 6); small intestine: 7.3 nTPM (limit 2); smooth muscle: 3.3 nTPM (limit 2); thymus: 20.4 nTPM (limit 10); bone marrow: 26 nTPM (baseline 2); colon: 8 nTPM (baseline 6); duodenum: 6.6 nTPM (baseline 2); kidney: 2.3 nTPM (baseline 2); liver: 2.1 nTPM (baseline 2); lymph node: 14.7 nTPM (baseline 6); parathyroid gland: 12.8 nTPM (baseline 6); rectum: 8.6 nTPM (baseline 6); small intestine: 7.3 nTPM (baseline 2); smooth muscle: 3.3 nTPM (baseline 2); thymus: 20.4 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%); Colon Adenocarcinoma (validation): 485/486 (99.8%); Rectum Adenocarcinoma (validation): 205/207 (99.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O14757,https://www.uniprot.org/uniprotkb/O14757/entry,"Serine/threonine-protein kinase which is required for checkpoint-mediated cell cycle arrest and activation of DNA repair in response to the presence of DNA damage or unreplicated DNA (PubMed:11535615, PubMed:12399544, PubMed:12446774, PubMed:14559997, PubMed:14988723, PubMed:15311285, PubMed:15650047, PubMed:15665856, PubMed:32357935). May also negatively regulate cell cycle progression during unperturbed cell cycles (PubMed:11535615, PubMed:12399544, PubMed:12446774, PubMed:14559997, PubMed:14988723, PubMed:15311285, PubMed:15650047, PubMed:15665856). This regulation is achieved by a number of mechanisms that together help to preserve the integrity of the genome (PubMed:11535615, PubMed:12399544, PubMed:12446774, PubMed:14559997, PubMed:14988723, PubMed:15311285, PubMed:15650047, PubMed:15665856). Recognizes the substrate consensus sequence [R-X-X-S/T] (PubMed:11535615, PubMed:12399544, PubMed:12446774, PubMed:14559997, PubMed:14988723, PubMed:15311285, PubMed:15650047, PubMed:15665856). Binds to and phosphorylates CDC25A, CDC25B and CDC25C (PubMed:12676583, PubMed:12676925, PubMed:12759351, PubMed:14559997, PubMed:14681206, PubMed:19734889, PubMed:9278511). Phosphorylation of CDC25A at 'Ser-178' and 'Thr-507' and phosphorylation of CDC25C at 'Ser-216' creates binding sites for 14-3-3 proteins which inhibit CDC25A and CDC25C (PubMed:9278511). Phosphorylation of CDC25A at 'Ser-76', 'Ser-124', 'Ser-178', 'Ser-279' and 'Ser-293' promotes proteolysis of CDC25A (PubMed:12676583, PubMed:12676925, PubMed:12759351, PubMed:14681206, PubMed:19734889, PubMed:9278511). Phosphorylation of CDC25A at 'Ser-76' primes the protein for subsequent phosphorylation at 'Ser-79', 'Ser-82' and 'Ser-88' by NEK11, which is required for polyubiquitination and degradation of CDCD25A (PubMed:19734889, PubMed:20090422, PubMed:9278511). Inhibition of CDC25 leads to increased inhibitory tyrosine phosphorylation of CDK-cyclin complexes and blocks cell cycle progression (PubMed:9278511). Also phosphorylates NEK6 (PubMed:18728393). Binds to and phosphorylates RAD51 at 'Thr-309', which promotes the release of RAD51 from BRCA2 and enhances the association of RAD51 with chromatin, thereby promoting DNA repair by homologous recombination (PubMed:15665856). Phosphorylates multiple sites within the C-terminus of TP53, which promotes activation of TP53 by acetylation and promotes cell cycle arrest and suppression of cellular proliferation (PubMed:10673501, PubMed:15659650, PubMed:16511572). Also promotes repair of DNA cross-links through phosphorylation of FANCE (PubMed:17296736). Binds to and phosphorylates TLK1 at 'Ser-743', which prevents the TLK1-dependent phosphorylation of the chromatin assembly factor ASF1A (PubMed:12660173, PubMed:12955071). This may enhance chromatin assembly both in the presence or absence of DNA damage (PubMed:12660173, PubMed:12955071). May also play a role in replication fork maintenance through regulation of PCNA (PubMed:18451105). May regulate the transcription of genes that regulate cell-cycle progression through the phosphorylation of histones (By similarity). Phosphorylates histone H3.1 (to form H3T11ph), which leads to epigenetic inhibition of a subset of genes (By similarity). May also phosphorylate RB1 to promote its interaction with the E2F family of transcription factors and subsequent cell cycle arrest (PubMed:17380128). Phosphorylates SPRTN, promoting SPRTN recruitment to chromatin (PubMed:31316063). Reduces replication stress and activates the G2/M checkpoint, by phosphorylating and inactivating PABIR1/FAM122A and promoting the serine/threonine-protein phosphatase 2A-mediated dephosphorylation and stabilization of WEE1 levels and activity (PubMed:33108758) Endogenous repressor of isoform 1, interacts with, and antagonizes CHK1 to promote the S to G2/M phase transition","Expressed ubiquitously with the most abundant expression in thymus, testis, small intestine and colon","Oocyte/zygote/embryo maturation arrest 21: An autosomal dominant, female infertility disorder characterized by zygote development arrest due to failure of pronuclei fusion.",,"Nucleus Chromosome Cytoplasm Cytoplasm, cytoskeleton, microtubule organizing center, centrosome",10673501|11535615|12399544|12446774|12660173|12676583|12676925|12759351|12955071|14559997|14681206|14988723|15311285|15650047|15659650|15665856|16511572|17296736|17380128|18451105|18728393|19734889|20090422|22184239|31316063|32357935|33108758|9278511,9278511|9382850,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | Jamin2021_CT,GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
CHODL,ENSG00000154645,Unsafe,Protein,False,True,30.1,30.1,86,10,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; colon: 2.7 nTPM; positive ihc; duodenum: 1.6 nTPM; positive ihc; hypothalamus: 7.9 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 2.4 nTPM; absolute ceiling; rectum: 3.4 nTPM; positive ihc; small intestine: 0.9 nTPM; positive ihc; spinal cord: 2.2 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",hypothalamus: 7.9 nTPM (limit 2); pituitary gland: 2.4 nTPM (limit 2); spinal cord: 2.2 nTPM (limit 2),colon / glandular cells: Low (Enhanced); duodenum / glandular cells: Low (Enhanced); rectum / glandular cells: Low (Enhanced); small intestine / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Ovary Serous Cystadenocarcinoma (TCGA): 254/349 (72.8%); Ovary Serous Cystadenocarcinoma (validation): 48/81 (59.3%); Testicular Germ Cell Tumor (TCGA): 61/133 (45.9%),breast cancer: 0/12 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q9H9P2,https://www.uniprot.org/uniprotkb/Q9H9P2/entry,May play a role in the development of the nervous system such as in neurite outgrowth and elongation. May be involved in motor axon growth and guidance,"Found in spleen, testis, prostate and fetal liver. Expression limited to vascular muscle of testis, smooth muscle of prostate stroma, heart muscle, skeletal muscle, crypts of small intestine, and red pulp of spleen. B lymphocytes express isoform 2 only; peripheral blood T lymphocytes express isoform 3 only; granulocytes and monocytes express neither isoform 2 nor isoform 3. During development of T lymphocytes, bone marrow progenitor cells express isoform 2 only; thymocytes at different stages of maturation express predominantly isoform 2 and weakly isoform 3, and mature thymocytes express only isoform 2",,,Cytoplasm Membrane Endoplasmic reticulum Endoplasmic reticulum membrane,,11707072|12079284|12621022,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CHRM3,ENSG00000133019,Unsafe,Protein,False,True,4.3,17.0,85,47,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0.2 nTPM; positive ihc; adrenal gland: 0.4 nTPM; positive ihc; amygdala: 1.7 nTPM; continuous selectivity; basal ganglia: 1.5 nTPM; continuous selectivity; cerebral cortex: 9.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; colon: 6.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 1.4 nTPM; positive ihc;continuous selectivity; esophagus: 7.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 2.1 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 1.4 nTPM; continuous selectivity; kidney: 1.1 nTPM; positive ihc; liver: 0.4 nTPM; positive ihc; lung: 1.1 nTPM; positive ihc; lymph node: 0.1 nTPM; positive ihc; pancreas: 10.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; rectum: 2.8 nTPM; positive ihc;continuous selectivity; retina: 1.6 nTPM; continuous selectivity; salivary gland: 17 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 0 nTPM; positive ihc; skin: 1.2 nTPM; positive ihc; small intestine: 1.4 nTPM; positive ihc;continuous selectivity; smooth muscle: 4 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 4.9 nTPM; positive ihc;continuous selectivity;reproductive not higher; thyroid gland: 1.9 nTPM; positive ihc; urinary bladder: 6.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",cerebral cortex: 9.7 nTPM (limit 2); colon: 6.7 nTPM (limit 6); esophagus: 7.2 nTPM (limit 6); hippocampal formation: 2.1 nTPM (limit 2); pancreas: 10.3 nTPM (limit 2); salivary gland: 17 nTPM (limit 6); smooth muscle: 4 nTPM (limit 2); urinary bladder: 6.8 nTPM (limit 6),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Low (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Medium (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); colon / endothelial cells: Low (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in tubules: Low (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Low (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); rectum / glandular cells: Low (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / fibroblasts: High (Approved); skin 1 / keratinocytes: Low (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Low (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Low (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 174/207 (84.1%); Colon Adenocarcinoma (validation): 375/486 (77.2%); Glioblastoma Multiforme (validation): 33/58 (56.9%),renal cancer: 7/10 (70.0%); liver cancer: 4/12 (33.3%),31,20,P20309,https://www.uniprot.org/uniprotkb/P20309/entry,"The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover",,"Prune belly syndrome: A syndrome characterized by thin abdominal musculature with overlying lax skin, cryptorchism, megacystis with disorganized detrusor muscle, and urinary tract abnormalities.",,Cell membrane Postsynaptic cell membrane Basolateral cell membrane Endoplasmic reticulum membrane,7565628,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CHRNA5,ENSG00000169684,Unsafe,Protein,False,True,3.0,4.6,82,7,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 1.9 nTPM; continuous selectivity; cerebral cortex: 0.8 nTPM; positive ihc; choroid plexus: 1.1 nTPM; continuous selectivity; colon: 3.9 nTPM; continuous selectivity;reproductive not higher; duodenum: 4.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 1.5 nTPM; continuous selectivity; heart muscle: 1.2 nTPM; continuous selectivity; pancreas: 1.8 nTPM; continuous selectivity; rectum: 4.1 nTPM; continuous selectivity;reproductive not higher; retina: 2.5 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 3.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 2.3 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 2 nTPM; positive ihc;continuous selectivity; stomach: 2.7 nTPM; continuous selectivity; urinary bladder: 1.7 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",duodenum: 4.6 nTPM (limit 4); retina: 2.5 nTPM (limit 2); duodenum: 4.6 nTPM (baseline 2); retina: 2.5 nTPM (baseline 2); skeletal muscle: 3.8 nTPM (baseline 2); small intestine: 2.3 nTPM (baseline 2),cerebral cortex / glial cells: High (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Medium (Approved); cerebral cortex / synapses: Low (Approved); hippocampus / glial cells: High (Approved); hippocampus / synapses: Low (Approved); smooth muscle / smooth muscle cells: High (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 389/486 (80.0%); Pancreatic Adenocarcinoma (validation): 64/80 (80.0%); Testicular Germ Cell Tumor (TCGA): 100/133 (75.2%),skin cancer: 1/12 (8.3%); urothelial cancer: 1/12 (8.3%),31,20,P30532,https://www.uniprot.org/uniprotkb/P30532/entry,"Component of neuronal acetylcholine receptors (nAChRs) that function as pentameric, ligand-gated cation channels with high calcium permeability among other activities. nAChRs are excitatory neurotrasnmitter receptors formed by a collection of nAChR subunits known to mediate synaptic transmission in the nervous system and the neuromuscular junction. Each nAchR subunit confers differential attributes to channel properties, including activation, deactivation and desensitization kinetics, pH sensitivity, cation permeability, and binding to allosteric modulators (PubMed:20881005, PubMed:8663494). Has an accessory rather than functional role and is only able to form functional nAChRs when co-assembled with another beta subunit (PubMed:20881005, PubMed:8663494). Participates in pentameric assemblies along with CHRNA3, CHRNA4, CHRNB2 and CHRNB4 (PubMed:20881005, PubMed:8663494). Increases receptor sensitivity to acetylcholine and nicotine when associated with CHRNA4 and CHRNB2 (PubMed:8663494). Plays a role in nicotine addiction (PubMed:20881005)",,,,Synaptic cell membrane Cell membrane,20881005|8663494,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CHRNA7,ENSG00000175344,Unsafe,Protein,False,True,2.4,9.4,112,76,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 7.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 1 nTPM; continuous selectivity; bone marrow: 0.9 nTPM; positive ihc;continuous selectivity; cerebellum: 0.2 nTPM; positive ihc; cerebral cortex: 1.7 nTPM; positive ihc;continuous selectivity; choroid plexus: 3.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 1.4 nTPM; positive ihc;continuous selectivity; duodenum: 4.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 0.2 nTPM; positive ihc; heart muscle: 0.4 nTPM; positive ihc; hippocampal formation: 0.8 nTPM; continuous selectivity; hypothalamus: 1.9 nTPM; continuous selectivity; kidney: 0.4 nTPM; positive ihc; liver: 0.1 nTPM; positive ihc; lymph node: 0.6 nTPM; positive ihc; midbrain: 0.8 nTPM; continuous selectivity; pancreas: 2.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 6.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 1 nTPM; continuous selectivity; rectum: 2.2 nTPM; positive ihc;continuous selectivity; retina: 2.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 0.5 nTPM; positive ihc; skeletal muscle: 0.4 nTPM; positive ihc; skin: 0.3 nTPM; positive ihc; small intestine: 9.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 0.4 nTPM; positive ihc; spleen: 1.2 nTPM; positive ihc;continuous selectivity; stomach: 6.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 2.1 nTPM; positive ihc;continuous selectivity; urinary bladder: 1.4 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 7.5 nTPM (limit 2); choroid plexus: 3.8 nTPM (limit 2); duodenum: 4.3 nTPM (limit 2); pancreas: 2.3 nTPM (limit 2); parathyroid gland: 6.2 nTPM (limit 6); retina: 2.5 nTPM (limit 2); small intestine: 9.4 nTPM (limit 2); stomach: 6.4 nTPM (limit 6),adrenal gland / glandular cells: High (Enhanced); bone marrow / hematopoietic cells: Low (Enhanced); bronchus / respiratory epithelial cells: Medium (Enhanced); caudate / glial cells: Low (Enhanced); caudate / neuronal cells: Medium (Enhanced); cerebellum / cells in granular layer: Medium (Enhanced); cerebellum / cells in molecular layer: Medium (Enhanced); cerebellum / Purkinje cells: Medium (Enhanced); cerebral cortex / glial cells: Medium (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); cerebral cortex / neuropil: Medium (Enhanced); colon / endocrine cells: High (Enhanced); colon / enterocytes: High (Enhanced); colon / goblet cells: High (Enhanced); colon / mucosal lymphoid cells: Medium (Enhanced); colon / peripheral nerve/ganglion: Low (Enhanced); duodenum / endocrine cells: High (Enhanced); duodenum / enterocytes: High (Enhanced); duodenum / glands of Brunner: Low (Enhanced); duodenum / goblet cells: High (Enhanced); esophagus / squamous epithelial cells: Medium (Enhanced); heart muscle / cardiomyocytes: Medium (Enhanced); hippocampus / glial cells: Medium (Enhanced); hippocampus / neuronal cells: Medium (Enhanced); kidney / cells in tubules: Medium (Enhanced); liver / cholangiocytes: Low (Enhanced); liver / hepatocytes: Low (Enhanced); lymph node / germinal center cells: Low (Enhanced); lymph node / non-germinal center cells: Medium (Enhanced); nasopharynx / respiratory epithelial cells: Medium (Enhanced); oral mucosa / squamous epithelial cells: Low (Enhanced); pancreas / exocrine glandular cells: Low (Enhanced); parathyroid gland / glandular cells: High (Enhanced); rectum / endocrine cells: High (Enhanced); rectum / enterocytes: High (Enhanced); rectum / goblet cells: High (Enhanced); rectum / mucosal lymphoid cells: Medium (Enhanced); rectum / peripheral nerve/ganglion: Medium (Enhanced); salivary gland / glandular cells: Medium (Enhanced); skeletal muscle / myocytes: Medium (Enhanced); skin 1 / keratinocytes: Low (Enhanced); skin 2 / epidermal cells: Medium (Enhanced); small intestine / endocrine cells: High (Enhanced); small intestine / enterocytes: Medium (Enhanced); smooth muscle / smooth muscle cells: Low (Enhanced); spleen / cells in red pulp: Low (Enhanced); spleen / cells in white pulp: Low (Enhanced); stomach 1 / glandular cells: Medium (Enhanced); stomach 2 / glandular cells: Medium (Enhanced); thyroid gland / glandular cells: Medium (Enhanced); urinary bladder / urothelial cells: Low (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 15/80 (18.8%); Stomach Adenocarcinoma (TCGA): 47/346 (13.6%); Colon Adenocarcinoma (validation): 59/486 (12.1%),colorectal cancer: 10/11 (90.9%); prostate cancer: 9/10 (90.0%),31,20,P36544,https://www.uniprot.org/uniprotkb/P36544/entry,"Component of neuronal acetylcholine receptors (nAChRs) that function as pentameric, ligand-gated cation channels with high calcium permeability among other activities. nAChRs are excitatory neurotrasnmitter receptors formed by a collection of nAChR subunits known to mediate synaptic transmission in the nervous system and the neuromuscular junction. Each nAchR subunit confers differential attributes to channel properties, including activation, deactivation and desensitization kinetics, pH sensitivity, cation permeability, and binding to allosteric modulators (PubMed:15609996, PubMed:33735609, PubMed:8145738). CHRNA7 forms homopentameric neuronal acetylcholine receptors abundantly expressed in the central nervous system, characterized by fast desensitization and high calcium permeability (PubMed:31560909, PubMed:33735609, PubMed:38382524, PubMed:8145738). Also forms heteropentamers with CHRNB2, mainly expressed in basal forebrain cholinergic neurons. Involved in the modulation of calcium-dependent signaling pathways and influences the release of neurotransmitters, including dopamine, glutamate and GABA (PubMed:33239400). Also expressed in non-neuronal cells such as immune cells like lymphocytes, monocytes and macrophages (PubMed:12508119, PubMed:16968406, PubMed:25259522). In T cells, activation induces metabotropic signaling that results in an increase of intracellular Ca2+ concentrations, independent of ionotropic receptor functions (PubMed:17709503). In macrophages, required for acetylcholine-mediated inhibition of TNF and other inflammatory cytokine release (PubMed:12508119). Once activated by acetylcholine, nicotine or other agonists, selectively inhibits production of pro-inflammatory cytokines while leaving anti-inflammatory cytokines undisturbed (PubMed:12508119, PubMed:25259522). Stimulates the cholinergic anti-inflammatory pathway, controlling inflammation by inhibiting NFKB nuclear translocation and activating the JAK2-STAT3 pathway, independently of ion channel activity (PubMed:16968406, PubMed:25259522). Also expressed in the urothelium where it modulates reflex bladder activity by increasing intracellular calcium through internal stores and decreasing basal ATP release (By similarity)",Expressed in neuronal cells (PubMed:8145738). Expressed in macrophages (at protein level) (PubMed:12508119),,,Postsynaptic cell membrane Cell membrane,12508119|15609996|16968406|17709503|18723036|25259522|31560909|33239400|33735609|38382524|8145738,12508119|8145738,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CHRNB4,ENSG00000117971,Unsafe,RNA,False,True,5.6,5.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 2.4 nTPM; absolute ceiling;continuous selectivity; retina: 2.7 nTPM; absolute ceiling;continuous selectivity; thymus: 2.9 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 2.4 nTPM (limit 2); retina: 2.7 nTPM (limit 2); adrenal gland: 2.4 nTPM (baseline 2); retina: 2.7 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 58/133 (43.6%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 56/283 (19.8%); Lung Squamous Cell Carcinoma (TCGA): 29/489 (5.9%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P30926,https://www.uniprot.org/uniprotkb/P30926/entry,"Component of neuronal acetylcholine receptors (nAChRs) that function as pentameric, ligand-gated cation channels with high calcium permeability among other activities. nAChRs are excitatory neurotrasnmitter receptors formed by a collection of nAChR subunits known to mediate synaptic transmission in the nervous system and the neuromuscular junction. Each nAchR subunit confers differential attributes to channel properties, including activation, deactivation and desensitization kinetics, pH sensitivity, cation permeability, and binding to allosteric modulators (PubMed:20881005, PubMed:31488329, PubMed:8663494, PubMed:8906617, PubMed:9203638). CHRNB4 forms heteropentameric neuronal acetylcholine receptors with CHRNA2, CHRNA3 and CHRNA4, as well as CHRNA5 and CHRNB3 as accesory subunits (PubMed:11118490, PubMed:20881005, PubMed:8663494). CHRNA3:CHRNB4 being predominant in neurons of the autonomic ganglia, it is known as ganglionic nicotinic receptor (PubMed:31488329). CHRNA3:CHRNB4 or CHRNA3:CHRNA5:CHRNB4 play also an important role in the habenulo-interpeduncular tract, modulating the mesolimbic dopamine system and affecting reward circuits and addiction (By similarity). Hypothalamic CHRNA3:CHRNB4 nAChR activation by nicotine leads to activation of POMC neurons and a decrease in food intake (By similarity)",,,,Synaptic cell membrane Cell membrane,11118490|20881005|31488329|8663494|8906617|9203638,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | Loriot2025_S2,GC RNA nomination across cancer types; no antigen validation asserted | Cancer-germline RNA nomination; strict and preferential classes remain distinct,,,,,,,,
CHURC1,ENSG00000258289,Unsafe,Protein,False,True,54.5,80.0,91,77,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 46.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 40.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 32.7 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 28.9 nTPM; absolute ceiling;continuous selectivity; bone marrow: 42.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 18.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 31.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 40.4 nTPM; absolute ceiling;continuous selectivity; colon: 42.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 29.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 32.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 56.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 30.8 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 30.7 nTPM; absolute ceiling;continuous selectivity; kidney: 33.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 51.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 28.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 41.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 37.4 nTPM; absolute ceiling;continuous selectivity; pancreas: 29.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 44.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 24.6 nTPM; absolute ceiling;continuous selectivity; rectum: 35.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 35.8 nTPM; absolute ceiling;continuous selectivity; salivary gland: 25.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 80 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 29.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 31.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 44.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 49 nTPM; absolute ceiling;continuous selectivity; spleen: 40.9 nTPM; absolute ceiling;continuous selectivity; stomach: 32.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 59.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 30.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 51.8 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 37 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 46.7 nTPM (limit 10); adrenal gland: 40.9 nTPM (limit 2); amygdala: 32.7 nTPM (limit 2); basal ganglia: 28.9 nTPM (limit 2); bone marrow: 42.8 nTPM (limit 2); cerebellum: 18.5 nTPM (limit 2); cerebral cortex: 31.6 nTPM (limit 2); choroid plexus: 40.4 nTPM (limit 2); colon: 42.3 nTPM (limit 6); duodenum: 29.6 nTPM (limit 2); esophagus: 32.7 nTPM (limit 6); heart muscle: 56.9 nTPM (limit 2); hippocampal formation: 30.8 nTPM (limit 2); hypothalamus: 30.7 nTPM (limit 2); kidney: 33.1 nTPM (limit 2); liver: 51.1 nTPM (limit 2); lung: 28.4 nTPM (limit 2); lymph node: 41.8 nTPM (limit 6); midbrain: 37.4 nTPM (limit 2); pancreas: 29.3 nTPM (limit 2); parathyroid gland: 44.2 nTPM (limit 6); pituitary gland: 24.6 nTPM (limit 2); rectum: 35.5 nTPM (limit 6); retina: 35.8 nTPM (limit 2); salivary gland: 25.7 nTPM (limit 6); skeletal muscle: 80 nTPM (limit 2); skin: 29.2 nTPM (limit 10); small intestine: 31.9 nTPM (limit 2); smooth muscle: 44.9 nTPM (limit 2); spinal cord: 49 nTPM (limit 2); spleen: 40.9 nTPM (limit 20); stomach: 32.7 nTPM (limit 6); thymus: 59.2 nTPM (limit 10); thyroid gland: 30.8 nTPM (limit 10); tongue: 51.8 nTPM (limit 6); urinary bladder: 37 nTPM (limit 6),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: Low (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / basal cells: Medium (Approved); bronchus / ciliated cells (cell body): Medium (Approved); bronchus / ciliated cells (cilia axoneme): Low (Approved); bronchus / ciliated cells (tip of cilia): Low (Approved); bronchus / goblet cells: Medium (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / basal cells: Medium (Approved); nasopharynx / ciliated cells (cell body): Medium (Approved); nasopharynx / ciliated cells (tip of cilia): Medium (Approved); nasopharynx / goblet cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Low (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Kidney Renal Clear Cell Carcinoma (TCGA): 521/521 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%),breast cancer: 8/11 (72.7%); melanoma: 6/11 (54.5%),31,20,Q8WUH1,https://www.uniprot.org/uniprotkb/Q8WUH1/entry,Transcriptional activator that mediates FGF signaling during neural development (By similarity). Plays a role in the regulation of cell movement (By similarity) Does not bind DNA by itself,,,,,17610897,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CILP2,ENSG00000160161,Unsafe,High RNA,False,True,5.4,5.4,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,True,"skeletal muscle/fibroblasts cluster c-18: 159 nTPM, 102 reads; reproductive-cell max 98.1",True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Medium, HPA041847; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA041847; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA041847; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA041847; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA041847; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA041847; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA041847; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA041847; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA041847; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA041847; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA041847; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA041847; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA041847; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA041847; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA041847; conflicting or uncurated primary profile; Liver/Hepatocytes: High, HPA041847; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA041847; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA041847; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA041847; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA041847; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Low, HPA041847; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA041847; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA041847; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA041847; conflicting or uncurated primary profile; Rectum/Glandular cells: Low, HPA041847; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA041847; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA041847; conflicting or uncurated primary profile; Small intestine/Glandular cells: Low, HPA041847; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Low, HPA041847; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Low, HPA041847; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA041847; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA041847; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA041847; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,5.36067552726,159.0,"hpa_single_cell_tissue: skeletal muscle/fibroblasts, max 159 nTPM, 2 observations >30",CTA,oncoref.target-sets.2026-10-23.2,5.361 TPM; blood/CD8_STIM; dice_cd8_stim; vital,159 nTPM; skeletal muscle/fibroblasts; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (validation): 43/50 (86.0%); Ovary Serous Cystadenocarcinoma (TCGA): 179/349 (51.3%); Breast Invasive Carcinoma (TCGA): 435/1022 (42.6%),liver cancer: 8/12 (66.7%); lung cancer: 3/10 (30.0%),31,20,Q8IUL8,https://www.uniprot.org/uniprotkb/Q8IUL8/entry,May play a role in cartilage scaffolding,Expressed in articular chondrocytes but not in knee meniscal cartilage cells (PubMed:12746903). Localizes to the intermediate to deep zone of articular cartilage (PubMed:21880736),,,"Secreted, extracellular space, extracellular matrix",,12746903|21880736,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CIMAP1C,ENSG00000182950,Unsafe,RNA,False,True,21.9,21.9,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,choroid plexus: 2.9 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 2.9 nTPM (limit 2); choroid plexus: 2.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Skin Cuteneous Melanoma (TCGA): 8/99 (8.1%); Breast Invasive Carcinoma (validation): 4/50 (8.0%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 20/283 (7.1%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8IXM7,https://www.uniprot.org/uniprotkb/Q8IXM7/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CIMAP1D,ENSG00000181781,Unsafe,RNA,False,True,22.8,22.8,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,skeletal muscle: 8 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,skeletal muscle: 8 nTPM (limit 2); skeletal muscle: 8 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Skin Cuteneous Melanoma (TCGA): 2/99 (2.0%); Kidney Chromophobe (TCGA): 1/64 (1.6%); Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%),melanoma: 9/12 (75.0%); testis cancer: 7/12 (58.3%),31,20,Q3SX64,https://www.uniprot.org/uniprotkb/Q3SX64/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
CIMIP1,ENSG00000124237,Unsafe,Protein,False,True,440.1,440.1,101,14,Positive somewhere,True,True,False,True,Excluded,Normal,False,,Not assessed,,,existing nomination or manual review; nomination unresolved; positive ihc outside permitted; choroid plexus: 5.4 nTPM; absolute ceiling; hypothalamus: 2.1 nTPM; absolute ceiling; lung: 24.7 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 5.4 nTPM (limit 2); hypothalamus: 2.1 nTPM (limit 2); lung: 24.7 nTPM (limit 12),bronchus / ciliated cells (cell body): High (Enhanced); bronchus / ciliated cells (cilia axoneme): High (Enhanced); bronchus / ciliated cells (tip of cilia): High (Enhanced); nasopharynx / ciliated cells (cell body): High (Enhanced); nasopharynx / ciliated cells (cilia axoneme): Medium (Enhanced); nasopharynx / ciliated cells (ciliary rootlets): Low (Enhanced); nasopharynx / ciliated cells (tip of cilia): Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 68/176 (38.6%); Lung Squamous Cell Carcinoma (validation): 26/68 (38.2%); Lung Adenocarcinoma (validation): 40/105 (38.1%),breast cancer: 0/10 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q9H1P6,https://www.uniprot.org/uniprotkb/Q9H1P6/entry,,"Expressed in airway epithelial cells, renal tubular cells, pancreatic acinar cells and epithelial cells of the stomach, duodenum, and gallbladder (at protein level)",,,"Cell projection, cilium",,25786037,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
CIMIP2C,ENSG00000173557,Unsafe,RNA,False,True,25.8,25.8,84,6,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,choroid plexus: 8.5 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 2.3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 8.5 nTPM (limit 2); hypothalamus: 2.3 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (TCGA): 51/88 (58.0%); Colon Adenocarcinoma (TCGA): 123/254 (48.4%); Rectum Adenocarcinoma (validation): 86/207 (41.5%),melanoma: 2/12 (16.7%); testis cancer: 1/11 (9.1%),29,20,A6NJV1,https://www.uniprot.org/uniprotkb/A6NJV1/entry,"Microtubule inner protein (MIP) part of the dynein-decorated doublet microtubules (DMTs) in cilia axoneme, which is required for motile cilia beating (PubMed:36191189). Binds to the intra-tubulin interfaces (By similarity)",Expressed in airway epithelial cells,,,"Cytoplasm, cytoskeleton, cilium axoneme Cytoplasm, cytoskeleton, flagellum axoneme",36191189,36191189,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CIMIP6,ENSG00000177994,Unsafe,RNA,False,True,49.2,49.2,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,choroid plexus: 3.8 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 3.8 nTPM (limit 2); choroid plexus: 3.8 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 6/58 (10.3%); Breast Invasive Carcinoma (validation): 3/50 (6.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 8/176 (4.5%),melanoma: 5/12 (41.7%); ovarian cancer: 2/10 (20.0%),31,20,Q8N5S3,https://www.uniprot.org/uniprotkb/Q8N5S3/entry,,,,,"Cell projection, cilium",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CIP2A,ENSG00000163507,Unsafe,Protein,False,True,2.4,3.9,77,72,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0.6 nTPM; positive ihc; adrenal gland: 0.7 nTPM; positive ihc; bone marrow: 3.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 0.8 nTPM; positive ihc;continuous selectivity; cerebral cortex: 1.1 nTPM; positive ihc;continuous selectivity; colon: 1.1 nTPM; positive ihc;continuous selectivity; duodenum: 1 nTPM; positive ihc;continuous selectivity; esophagus: 1.1 nTPM; positive ihc;continuous selectivity; heart muscle: 0.6 nTPM; positive ihc; kidney: 0.7 nTPM; positive ihc; liver: 0.3 nTPM; positive ihc; lung: 0.9 nTPM; positive ihc;continuous selectivity; lymph node: 3.7 nTPM; positive ihc;continuous selectivity;reproductive not higher; pancreas: 0.3 nTPM; positive ihc; parathyroid gland: 0.4 nTPM; positive ihc; rectum: 1.6 nTPM; positive ihc;continuous selectivity; retina: 1.4 nTPM; continuous selectivity; salivary gland: 0.3 nTPM; positive ihc; skeletal muscle: 0.3 nTPM; positive ihc; skin: 1 nTPM; positive ihc; small intestine: 1.1 nTPM; positive ihc;continuous selectivity; smooth muscle: 0.9 nTPM; positive ihc;continuous selectivity; stomach: 0.7 nTPM; positive ihc; thymus: 3.2 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 0.9 nTPM; positive ihc; urinary bladder: 0.8 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 3.9 nTPM (limit 2),adipose tissue / adipocytes: High (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / endothelial cells: High (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: High (Approved); colon / glandular cells: High (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: High (Approved); skeletal muscle / myocytes: High (Approved); skin 1 / fibroblasts: High (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: High (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Lung Squamous Cell Carcinoma (validation): 60/68 (88.2%); Pancreatic Adenocarcinoma (validation): 66/80 (82.5%),breast cancer: 12/12 (100.0%); cervical cancer: 12/12 (100.0%),29,20,Q8TCG1,https://www.uniprot.org/uniprotkb/Q8TCG1/entry,"Acts as an inhibitor of protein phosphatase PP2A (PubMed:17632056). Promotes anchorage-independent cell growth and tumor formation by preventing dephosphorylation of MYC, thereby stabilizing MYC in human malignancies (PubMed:17632056). Together with TOPBP1, plays an essential role in the response to genome instability generated by the presence of acentric chromosome fragments derived from shattered chromosomes within micronuclei (PubMed:35121901, PubMed:35842428, PubMed:37165191, PubMed:37316668). Micronuclei, which are frequently found in cancer cells, consist of chromatin surrounded by their own nuclear membrane: following breakdown of the micronuclear envelope, a process associated with chromothripsis, the CIP2A-TOPBP1 complex tethers chromosome fragments during mitosis to ensure clustered segregation of the fragments to a single daughter cell nucleus, facilitating re-ligation with limited chromosome scattering and loss (PubMed:37165191, PubMed:37316668)",Expressed at low levels in most of the tissues. Overexpressed in head-and-neck squamous cell carcinomas (HNSCC). Present in liver cancer cells (at protein level),,,Cytoplasm Chromosome,17632056|35121901|35842428|37165191|37316668,12118381|17632056,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CKAP2L,ENSG00000169607,Unsafe,Protein,False,True,4.4,13.0,78,48,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 0.1 nTPM; positive ihc; bone marrow: 13 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 0.4 nTPM; positive ihc; colon: 1.5 nTPM; positive ihc; duodenum: 1.5 nTPM; positive ihc;continuous selectivity; esophagus: 2.3 nTPM; positive ihc;continuous selectivity; heart muscle: 0 nTPM; positive ihc; kidney: 0.1 nTPM; positive ihc; lung: 0.3 nTPM; positive ihc; lymph node: 4.9 nTPM; positive ihc;continuous selectivity;reproductive not higher; pancreas: 0 nTPM; positive ihc; rectum: 2.1 nTPM; positive ihc;continuous selectivity; salivary gland: 0.3 nTPM; positive ihc; skeletal muscle: 0 nTPM; positive ihc; skin: 1.5 nTPM; positive ihc; small intestine: 1.1 nTPM; positive ihc; smooth muscle: 1 nTPM; positive ihc; stomach: 1 nTPM; positive ihc; thymus: 11.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 0.3 nTPM; positive ihc; urinary bladder: 0.7 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 13 nTPM (limit 2); thymus: 11.7 nTPM (limit 10); bone marrow: 13 nTPM (baseline 2); thymus: 11.7 nTPM (baseline 10),adrenal gland / glandular cells: Low (Uncertain); bone marrow / hematopoietic cells: Low (Uncertain); bronchus / respiratory epithelial cells: Low (Uncertain); cerebral cortex / neuronal cells: Low (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / endothelial cells: Low (Uncertain); colon / glandular cells: High (Uncertain); colon / peripheral nerve/ganglion: Low (Uncertain); duodenum / glandular cells: High (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: Low (Uncertain); kidney / cells in tubules: Low (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / germinal center cells: Low (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Low (Uncertain); rectum / glandular cells: High (Uncertain); salivary gland / glandular cells: Low (Uncertain); skeletal muscle / myocytes: Medium (Uncertain); skin 1 / fibroblasts: Medium (Uncertain); skin 1 / keratinocytes: Medium (Uncertain); skin 2 / epidermal cells: Low (Uncertain); small intestine / glandular cells: High (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Low (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 56/58 (96.6%); Colon Adenocarcinoma (validation): 461/486 (94.9%); Rectum Adenocarcinoma (validation): 179/207 (86.5%),ovarian cancer: 6/12 (50.0%); colorectal cancer: 5/11 (45.5%),31,20,Q8IYA6,https://www.uniprot.org/uniprotkb/Q8IYA6/entry,Microtubule-associated protein required for mitotic spindle formation and cell-cycle progression in neural progenitor cells,,"Filippi syndrome: A rare disorder characterized by microcephaly, pre- and postnatal growth failure, syndactyly, and distinctive facial features, including a broad nasal bridge and underdeveloped alae nasi. Some affected individuals have intellectual disability, seizures, undescended testicles in males, and teeth and hair abnormalities.",,"Cytoplasm, cytoskeleton, spindle pole",25439729,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CKS2,ENSG00000123975,Unsafe,Protein,False,True,180.6,180.6,81,81,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 13.2 nTPM; positive ihc;absolute ceiling; adrenal gland: 80.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 10.5 nTPM; absolute ceiling; basal ganglia: 9.7 nTPM; absolute ceiling; bone marrow: 174.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 9.1 nTPM; positive ihc;absolute ceiling; cerebral cortex: 10.3 nTPM; positive ihc;absolute ceiling; choroid plexus: 11.2 nTPM; absolute ceiling; colon: 42.6 nTPM; positive ihc;absolute ceiling; duodenum: 42 nTPM; positive ihc;absolute ceiling; esophagus: 51.7 nTPM; positive ihc;absolute ceiling; heart muscle: 9.9 nTPM; positive ihc;absolute ceiling; hippocampal formation: 10.7 nTPM; absolute ceiling; hypothalamus: 7.6 nTPM; absolute ceiling; kidney: 34.6 nTPM; positive ihc;absolute ceiling; liver: 30.2 nTPM; positive ihc;absolute ceiling; lung: 23.3 nTPM; positive ihc;absolute ceiling; lymph node: 100.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 7.9 nTPM; absolute ceiling; pancreas: 4.1 nTPM; positive ihc;absolute ceiling; parathyroid gland: 19.1 nTPM; positive ihc;absolute ceiling; pituitary gland: 4.7 nTPM; absolute ceiling; rectum: 39.6 nTPM; positive ihc;absolute ceiling; retina: 27 nTPM; absolute ceiling; salivary gland: 10.5 nTPM; positive ihc;absolute ceiling; skeletal muscle: 9.1 nTPM; positive ihc;absolute ceiling; skin: 19.3 nTPM; positive ihc;absolute ceiling; small intestine: 32.1 nTPM; positive ihc;absolute ceiling; smooth muscle: 16.9 nTPM; positive ihc;absolute ceiling; spinal cord: 8.6 nTPM; absolute ceiling; spleen: 31.8 nTPM; positive ihc;absolute ceiling; stomach: 19.8 nTPM; positive ihc;absolute ceiling; thymus: 117.8 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 12.4 nTPM; positive ihc;absolute ceiling; urinary bladder: 25.6 nTPM; positive ihc;absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 13.2 nTPM (limit 10); adrenal gland: 80.2 nTPM (limit 2); amygdala: 10.5 nTPM (limit 2); basal ganglia: 9.7 nTPM (limit 2); bone marrow: 174.7 nTPM (limit 2); cerebellum: 9.1 nTPM (limit 2); cerebral cortex: 10.3 nTPM (limit 2); choroid plexus: 11.2 nTPM (limit 2); colon: 42.6 nTPM (limit 6); duodenum: 42 nTPM (limit 2); esophagus: 51.7 nTPM (limit 6); heart muscle: 9.9 nTPM (limit 2); hippocampal formation: 10.7 nTPM (limit 2); hypothalamus: 7.6 nTPM (limit 2); kidney: 34.6 nTPM (limit 2); liver: 30.2 nTPM (limit 2); lung: 23.3 nTPM (limit 2); lymph node: 100.3 nTPM (limit 6); midbrain: 7.9 nTPM (limit 2); pancreas: 4.1 nTPM (limit 2); parathyroid gland: 19.1 nTPM (limit 6); pituitary gland: 4.7 nTPM (limit 2); rectum: 39.6 nTPM (limit 6); retina: 27 nTPM (limit 2); salivary gland: 10.5 nTPM (limit 6); skeletal muscle: 9.1 nTPM (limit 2); skin: 19.3 nTPM (limit 10); small intestine: 32.1 nTPM (limit 2); smooth muscle: 16.9 nTPM (limit 2); spinal cord: 8.6 nTPM (limit 2); spleen: 31.8 nTPM (limit 10); stomach: 19.8 nTPM (limit 6); thymus: 117.8 nTPM (limit 10); thyroid gland: 12.4 nTPM (limit 10); urinary bladder: 25.6 nTPM (limit 6),adipose tissue / adipocytes: High (Approved); adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: High (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / glial cells: High (Approved); caudate / neuronal cells: High (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: High (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / endothelial cells: High (Approved); cerebral cortex / glial cells: High (Approved); cerebral cortex / neuronal cells: High (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: High (Approved); colon / glandular cells: High (Approved); colon / peripheral nerve/ganglion: High (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: High (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Medium (Approved); hippocampus / neuronal cells: High (Approved); kidney / cells in glomeruli: High (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: High (Approved); lung / macrophages: High (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: High (Approved); nasopharynx / respiratory epithelial cells: High (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: High (Approved); pancreas / pancreatic endocrine cells: High (Approved); parathyroid gland / glandular cells: High (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: High (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: High (Approved); skin 1 / keratinocytes: High (Approved); skin 1 / Langerhans: High (Approved); skin 2 / epidermal cells: High (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: High (Approved); spleen / cells in red pulp: High (Approved); spleen / cells in white pulp: High (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: High (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Kidney Renal Clear Cell Carcinoma (TCGA): 521/521 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%),cervical cancer: 12/12 (100.0%); lung cancer: 12/12 (100.0%),31,20,P33552,https://www.uniprot.org/uniprotkb/P33552/entry,Binds to the catalytic subunit of the cyclin dependent kinases and is essential for their biological function,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CLDN6,ENSG00000184697,Unsafe,High RNA,False,True,0.9,1.0,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,Trial registration,basal ganglia: 1 nTPM; continuous selectivity;reproductive not higher; cerebellum: 0.7 nTPM; continuous selectivity; kidney: 0.7 nTPM; continuous selectivity; pancreas: 0.9 nTPM; continuous selectivity;reproductive not higher,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,0.67142199259,64.8,"hpa_single_cell: /Fibroblasts, max 44.4 nTPM, 1 observations >30; hpa_single_cell_tissue: pancreas/ductal cells, max 64.8 nTPM, 2 observations >30",Neither,oncoref.target-sets.2026-10-23.2,0.6714 TPM; blood/CD8_STIM; dice_cd8_stim; vital,64.8 nTPM; pancreas/ductal cells; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 132/133 (99.2%); Ovary Serous Cystadenocarcinoma (TCGA): 277/349 (79.4%); Ovary Serous Cystadenocarcinoma (validation): 50/81 (61.7%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P56747,https://www.uniprot.org/uniprotkb/P56747/entry,Plays a major role in tight junction-specific obliteration of the intercellular space (Microbial infection) Acts as a receptor for hepatitis C virus (HCV) entry into hepatic cells,"Expressed in the liver, in peripheral blood mononuclear cells and hepatocarcinoma cell lines",,,"Cell junction, tight junction Cell membrane",17804490|20375010,17804490,False,Reviewed UniProt annotation; not a new primary-paper review,Trial registration only,https://clinicaltrials.gov/study/NCT04503278,"Initial report: 7/21 unconfirmed responses (33%); CRS 10/22, including one grade 3 event; one grade 1 ICANS. Oncofetal surface-target experience does not validate unrestricted targeting of all developmental tissues.",https://www.nature.com/articles/s41591-023-02612-0,Clinical outcomes,,,,,,,,,,
CLDND2,ENSG00000160318,Unsafe,RNA,False,True,43.7,43.7,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 4.4 nTPM; absolute ceiling; amygdala: 5.5 nTPM; absolute ceiling; basal ganglia: 5.5 nTPM; absolute ceiling; bone marrow: 9.5 nTPM; absolute ceiling; cerebellum: 4.9 nTPM; absolute ceiling; cerebral cortex: 6.2 nTPM; absolute ceiling; choroid plexus: 7.3 nTPM; absolute ceiling; duodenum: 4.4 nTPM; absolute ceiling; heart muscle: 3.2 nTPM; absolute ceiling; hippocampal formation: 5.8 nTPM; absolute ceiling; hypothalamus: 5.9 nTPM; absolute ceiling; kidney: 4.2 nTPM; absolute ceiling; liver: 4.6 nTPM; absolute ceiling; lung: 3.1 nTPM; absolute ceiling; midbrain: 6.6 nTPM; absolute ceiling; pancreas: 5.1 nTPM; absolute ceiling; pituitary gland: 3.3 nTPM; absolute ceiling; skeletal muscle: 2.4 nTPM; absolute ceiling; small intestine: 4.2 nTPM; absolute ceiling; spinal cord: 3.8 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 4.4 nTPM (limit 2); amygdala: 5.5 nTPM (limit 2); basal ganglia: 5.5 nTPM (limit 2); bone marrow: 9.5 nTPM (limit 2); cerebellum: 4.9 nTPM (limit 2); cerebral cortex: 6.2 nTPM (limit 2); choroid plexus: 7.3 nTPM (limit 2); duodenum: 4.4 nTPM (limit 2); heart muscle: 3.2 nTPM (limit 2); hippocampal formation: 5.8 nTPM (limit 2); hypothalamus: 5.9 nTPM (limit 2); kidney: 4.2 nTPM (limit 2); liver: 4.6 nTPM (limit 2); lung: 3.1 nTPM (limit 2); midbrain: 6.6 nTPM (limit 2); pancreas: 5.1 nTPM (limit 2); pituitary gland: 3.3 nTPM (limit 2); skeletal muscle: 2.4 nTPM (limit 2); small intestine: 4.2 nTPM (limit 2); spinal cord: 3.8 nTPM (limit 2); adrenal gland: 4.4 nTPM (baseline 2); amygdala: 5.5 nTPM (baseline 2); basal ganglia: 5.5 nTPM (baseline 2); bone marrow: 9.5 nTPM (baseline 2); cerebellum: 4.9 nTPM (baseline 2); cerebral cortex: 6.2 nTPM (baseline 2); choroid plexus: 7.3 nTPM (baseline 2); duodenum: 4.4 nTPM (baseline 2); heart muscle: 3.2 nTPM (baseline 2); hippocampal formation: 5.8 nTPM (baseline 2); hypothalamus: 5.9 nTPM (baseline 2); kidney: 4.2 nTPM (baseline 2); liver: 4.6 nTPM (baseline 2); lung: 3.1 nTPM (baseline 2); midbrain: 6.6 nTPM (baseline 2); pancreas: 5.1 nTPM (baseline 2); pituitary gland: 3.3 nTPM (baseline 2); skeletal muscle: 2.4 nTPM (baseline 2); small intestine: 4.2 nTPM (baseline 2); spinal cord: 3.8 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 79/141 (56.0%); Prostate Adenocarcinoma (TCGA): 218/480 (45.4%); Kidney Renal Clear Cell Carcinoma (validation): 45/100 (45.0%),breast cancer: 10/12 (83.3%); cervical cancer: 9/12 (75.0%),31,20,Q8NHS1,https://www.uniprot.org/uniprotkb/Q8NHS1/entry,,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CLEC12B,ENSG00000256660,Unsafe,RNA,False,True,13.0,13.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 5.4 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 5.4 nTPM (limit 2); bone marrow: 5.4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 2/133 (1.5%); Rectum Adenocarcinoma (validation): 2/207 (1.0%); Liver Hepatocellular Carcinoma (validation): 2/231 (0.9%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q2HXU8,https://www.uniprot.org/uniprotkb/Q2HXU8/entry,"Inhibitory receptor postulated to negatively regulate immune and non-immune functions (PubMed:17562706, PubMed:34310951). Upon phosphorylation, recruits SH2 domain-containing PTPN6 and PTPN11 phosphatases to its ITIM motif and antagonizes activation signals (PubMed:17562706, PubMed:34310951). Although it inhibits KLRK1/NKG2D-mediated signaling, it does not bind known ligands of KLRK1/NKG2D and therefore is not its inhibitory counterpart (PubMed:17562706). May limit activation of myeloid cell subsets in response to infection or tissue inflammation (PubMed:17562706). May protect target cells against natural killer cell-mediated lysis (PubMed:17562706). May negatively regulate cell cycle and differentiation of melanocytes via inactivation of STAT3 (PubMed:34310951). Plays an important function in the skin immunity by modulating melanocytes immune function through the phosphorylation of its ITIM domain. Mechanistically, senses exogenous ligands present on S. aureus and E. coli but not gut Listeria monocytogenes and modulates the IFNgamma-induced production of chemokines and subsequent chemoattraction of immune cells through the STAT1/IRF1/CXCL9 axis (PubMed:39736308)","Detected in colon, heart, kidney, liver, lung, mammary gland, ovary, spleen and testis (PubMed:17562706). Expressed in melanocytes (at protein level) (PubMed:34310951)",,,Cell membrane,17562706|34310951|39736308,17562706|34310951,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CLEC18A,ENSG00000157322,Unsafe,RNA,False,True,3.1,23.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 0.9 nTPM; continuous selectivity; choroid plexus: 15.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 23.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 1.1 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 15.9 nTPM (limit 2); kidney: 23.2 nTPM (limit 2); choroid plexus: 15.9 nTPM (baseline 2); kidney: 23.2 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Renal Clear Cell Carcinoma (validation): 84/100 (84.0%); Kidney Renal Clear Cell Carcinoma (TCGA): 433/521 (83.1%); Glioblastoma Multiforme (TCGA): 38/141 (27.0%),prostate cancer: 5/10 (50.0%); colorectal cancer: 5/12 (41.7%),31,20,A5D8T8,https://www.uniprot.org/uniprotkb/A5D8T8/entry,"Binds polysaccharides in a Ca(2+)-independent manner with a preferentially binding to fucoidan, beta-glucans and galactans (PubMed:26170455)",Dectected in all cell lines tested and in peripheral blood cells,,,Secreted Endoplasmic reticulum Golgi apparatus Endosome,26170455,26170455,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
CLEC2D,ENSG00000069493,Unsafe,Protein,False,True,12.2,52.7,79,64,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 5.9 nTPM; continuous selectivity; adrenal gland: 1.8 nTPM; positive ihc; bone marrow: 16.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 0.7 nTPM; positive ihc; cerebral cortex: 1.4 nTPM; positive ihc; choroid plexus: 4.3 nTPM; absolute ceiling;continuous selectivity; colon: 4.6 nTPM; positive ihc;continuous selectivity; duodenum: 3.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 3.1 nTPM; positive ihc; heart muscle: 5.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; kidney: 3.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 3.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 8.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 52.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 2.5 nTPM; absolute ceiling; pancreas: 2.3 nTPM; positive ihc;absolute ceiling; parathyroid gland: 0.8 nTPM; positive ihc; pituitary gland: 2.2 nTPM; absolute ceiling; rectum: 3.9 nTPM; positive ihc; retina: 3.5 nTPM; absolute ceiling;continuous selectivity; salivary gland: 6.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 3.1 nTPM; positive ihc;absolute ceiling; skin: 3.7 nTPM; positive ihc; small intestine: 19.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 2.1 nTPM; positive ihc;absolute ceiling; spinal cord: 3.3 nTPM; absolute ceiling;continuous selectivity; spleen: 26 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; stomach: 5.4 nTPM; positive ihc;continuous selectivity; thymus: 30.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 4.3 nTPM; positive ihc; urinary bladder: 5.6 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 16.5 nTPM (limit 2); choroid plexus: 4.3 nTPM (limit 2); duodenum: 3.8 nTPM (limit 2); heart muscle: 5.1 nTPM (limit 2); kidney: 3.8 nTPM (limit 2); liver: 3.2 nTPM (limit 2); lung: 8.3 nTPM (limit 2); lymph node: 52.7 nTPM (limit 6); midbrain: 2.5 nTPM (limit 2); pancreas: 2.3 nTPM (limit 2); pituitary gland: 2.2 nTPM (limit 2); retina: 3.5 nTPM (limit 2); salivary gland: 6.4 nTPM (limit 6); skeletal muscle: 3.1 nTPM (limit 2); small intestine: 19.8 nTPM (limit 2); smooth muscle: 2.1 nTPM (limit 2); spinal cord: 3.3 nTPM (limit 2); spleen: 26 nTPM (limit 10); thymus: 30.9 nTPM (limit 10); bone marrow: 16.5 nTPM (baseline 2); choroid plexus: 4.3 nTPM (baseline 2); duodenum: 3.8 nTPM (baseline 2); heart muscle: 5.1 nTPM (baseline 2); kidney: 3.8 nTPM (baseline 2); liver: 3.2 nTPM (baseline 2); lung: 8.3 nTPM (baseline 2); lymph node: 52.7 nTPM (baseline 6); midbrain: 2.5 nTPM (baseline 2); pancreas: 2.3 nTPM (baseline 2); pituitary gland: 2.2 nTPM (baseline 2); retina: 3.5 nTPM (baseline 2); salivary gland: 6.4 nTPM (baseline 6); skeletal muscle: 3.1 nTPM (baseline 2); small intestine: 19.8 nTPM (baseline 2); smooth muscle: 2.1 nTPM (baseline 2); spinal cord: 3.3 nTPM (baseline 2); spleen: 26 nTPM (baseline 10); thymus: 30.9 nTPM (baseline 10),adrenal gland / glandular cells: High (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: Low (Uncertain); cerebellum / cells in molecular layer: Low (Uncertain); cerebellum / Purkinje cells: High (Uncertain); cerebral cortex / endothelial cells: Low (Uncertain); cerebral cortex / neuronal cells: Low (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / endothelial cells: Low (Uncertain); colon / glandular cells: High (Uncertain); colon / peripheral nerve/ganglion: Medium (Uncertain); duodenum / glandular cells: High (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in glomeruli: Medium (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / cholangiocytes: Low (Uncertain); liver / hepatocytes: Low (Uncertain); lung / alveolar cells: Low (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / germinal center cells: Medium (Uncertain); lymph node / non-germinal center cells: Medium (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Low (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: High (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: Medium (Uncertain); skin 1 / keratinocytes: Medium (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: High (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); spleen / cells in red pulp: Low (Uncertain); stomach 1 / glandular cells: High (Uncertain); stomach 2 / glandular cells: High (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Lung Squamous Cell Carcinoma (validation): 63/68 (92.6%); Breast Invasive Carcinoma (validation): 46/50 (92.0%),lymphoma: 11/12 (91.7%); colorectal cancer: 9/12 (75.0%),31,20,Q9UHP7,https://www.uniprot.org/uniprotkb/Q9UHP7/entry,"Receptor for KLRB1 that protects target cells against natural killer cell-mediated lysis (PubMed:16339513, PubMed:20843815). Inhibits osteoclast formation (PubMed:14753741, PubMed:15123656). Inhibits bone resorption (PubMed:14753741). Modulates the release of interferon-gamma (PubMed:15104121). Binds high molecular weight sulfated glycosaminoglycans (PubMed:15123656)","Detected in peripheral blood leukocytes, osteoblasts, lymph node, thymus and spleen. Isoform 1, isoform 2 and isoform 4 are expressed in T- and B-lymphocytes, and at lower levels in NK cells. They are also expressed in B-cell lines and LPS-matured monocyte-derived dendritic cells",,,Cell membrane Endoplasmic reticulum,14753741|15104121|15123656|16339513|20843815,10541800|20843815,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
CLEC4C,ENSG00000198178,Unsafe,Protein,False,True,1.3,5.3,78,77,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0.3 nTPM; positive ihc; adrenal gland: 0 nTPM; positive ihc; bone marrow: 1.5 nTPM; positive ihc;continuous selectivity;reproductive not higher; cerebellum: 0 nTPM; positive ihc; cerebral cortex: 0 nTPM; positive ihc; colon: 0.1 nTPM; positive ihc; duodenum: 0 nTPM; positive ihc; esophagus: 0.2 nTPM; positive ihc; heart muscle: 0 nTPM; positive ihc; kidney: 0 nTPM; positive ihc; liver: 0.2 nTPM; positive ihc; lung: 0.6 nTPM; positive ihc;continuous selectivity; lymph node: 5.3 nTPM; positive ihc;continuous selectivity;reproductive not higher; pancreas: 0 nTPM; positive ihc; parathyroid gland: 0 nTPM; positive ihc; rectum: 0.1 nTPM; positive ihc; salivary gland: 0 nTPM; positive ihc; skeletal muscle: 0.1 nTPM; positive ihc; skin: 0.1 nTPM; positive ihc; small intestine: 0.2 nTPM; positive ihc; smooth muscle: 0.1 nTPM; positive ihc; spleen: 3.7 nTPM; positive ihc;continuous selectivity;reproductive not higher; stomach: 0.2 nTPM; positive ihc; thymus: 2 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 0 nTPM; positive ihc; urinary bladder: 1 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",,adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: High (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: High (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: High (Approved); nasopharynx / respiratory epithelial cells: High (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: High (Approved); skeletal muscle / myocytes: High (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 8/133 (6.0%); Breast Invasive Carcinoma (validation): 3/50 (6.0%); Bladder Urothelial Carcinoma (TCGA): 4/169 (2.4%),liver cancer: 12/12 (100.0%); renal cancer: 12/12 (100.0%),31,20,Q8WTT0,https://www.uniprot.org/uniprotkb/Q8WTT0/entry,"Lectin-type cell surface receptor which may play a role in antigen capturing by dendritic cells (PubMed:11748283, PubMed:21880719, PubMed:25995448). Specifically recognizes non-sialylated galactose-terminated biantennary glycans containing the trisaccharide epitope Gal(beta1-3/4)GlcNAc(beta1-2)Man (PubMed:21880719, PubMed:25995448). Binds to serum IgG (PubMed:25995448). Efficiently targets ligand into antigen-processing and peptide-loading compartments for presentation to T-cells (PubMed:11748283). May mediate potent inhibition of induction of IFN-alpha/beta expression in plasmacytoid dendritic cells (PubMed:11748283, PubMed:21880719). May act as a signaling receptor that activates protein-tyrosine kinases and mobilizes intracellular calcium (PubMed:11748283)",Expressed in plasmacytoid dendritic cells (PDCs). Constitutively expressed in immature monocyte-derived dendritic cells (iMDDC) and is significantly down-regulated upon maturation with LPS but not with TNF,,,Cell membrane,11748283|21880719|25995448,11031109|11536172|11748283,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT,Cancer-associated RNA nomination; no antigen validation asserted,,,,,,,,
CLGN,ENSG00000153132,Unsafe,RNA,False,True,110.3,110.3,95,6,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,choroid plexus: 7.9 nTPM; absolute ceiling; heart muscle: 57.4 nTPM; absolute ceiling; hypothalamus: 4.8 nTPM; absolute ceiling; pituitary gland: 10.9 nTPM; absolute ceiling; retina: 16.7 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 7.9 nTPM (limit 2); heart muscle: 57.4 nTPM (limit 12); hypothalamus: 4.8 nTPM (limit 2); pituitary gland: 10.9 nTPM (limit 2); retina: 16.7 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Prostate Adenocarcinoma (TCGA): 447/480 (93.1%); Breast Invasive Carcinoma (validation): 39/50 (78.0%); Ovary Serous Cystadenocarcinoma (TCGA): 218/349 (62.5%),breast cancer: 0/10 (0.0%); cervical cancer: 0/10 (0.0%),31,20,O14967,https://www.uniprot.org/uniprotkb/O14967/entry,Functions during spermatogenesis as a chaperone for a range of client proteins that are important for sperm adhesion onto the egg zona pellucida and for subsequent penetration of the zona pellucida. Required for normal sperm migration from the uterus into the oviduct. Required for normal male fertility. Binds calcium ions (By similarity),Detected in testis (at protein level). Detected in testis,,,Endoplasmic reticulum membrane,,9434179,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
CLHC1,ENSG00000162994,Unsafe,RNA,False,True,14.6,14.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 2.7 nTPM; absolute ceiling; bone marrow: 2.1 nTPM; absolute ceiling; cerebellum: 2.3 nTPM; absolute ceiling; cerebral cortex: 2.5 nTPM; absolute ceiling; choroid plexus: 4.2 nTPM; absolute ceiling;continuous selectivity; heart muscle: 2.3 nTPM; absolute ceiling; kidney: 3.5 nTPM; absolute ceiling; lung: 2.4 nTPM; absolute ceiling; pancreas: 2.5 nTPM; absolute ceiling; parathyroid gland: 5.2 nTPM; continuous selectivity; pituitary gland: 5.7 nTPM; absolute ceiling;continuous selectivity; retina: 7.5 nTPM; absolute ceiling;continuous selectivity; small intestine: 2.7 nTPM; absolute ceiling; smooth muscle: 3.3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 2.7 nTPM (limit 2); bone marrow: 2.1 nTPM (limit 2); cerebellum: 2.3 nTPM (limit 2); cerebral cortex: 2.5 nTPM (limit 2); choroid plexus: 4.2 nTPM (limit 2); heart muscle: 2.3 nTPM (limit 2); kidney: 3.5 nTPM (limit 2); lung: 2.4 nTPM (limit 2); pancreas: 2.5 nTPM (limit 2); pituitary gland: 5.7 nTPM (limit 2); retina: 7.5 nTPM (limit 2); small intestine: 2.7 nTPM (limit 2); smooth muscle: 3.3 nTPM (limit 2); adrenal gland: 2.7 nTPM (baseline 2); bone marrow: 2.1 nTPM (baseline 2); cerebellum: 2.3 nTPM (baseline 2); cerebral cortex: 2.5 nTPM (baseline 2); choroid plexus: 4.2 nTPM (baseline 2); heart muscle: 2.3 nTPM (baseline 2); kidney: 3.5 nTPM (baseline 2); lung: 2.4 nTPM (baseline 2); pancreas: 2.5 nTPM (baseline 2); pituitary gland: 5.7 nTPM (baseline 2); retina: 7.5 nTPM (baseline 2); small intestine: 2.7 nTPM (baseline 2); smooth muscle: 3.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Rectum Adenocarcinoma (validation): 165/207 (79.7%); Colon Adenocarcinoma (validation): 351/486 (72.2%),liver cancer: 4/11 (36.4%); ovarian cancer: 4/12 (33.3%),29,20,Q8NHS4,https://www.uniprot.org/uniprotkb/Q8NHS4/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
CLIP3,ENSG00000105270,Unsafe,RNA,False,True,64.0,215.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 15.8 nTPM; absolute ceiling; adrenal gland: 13.1 nTPM; absolute ceiling; amygdala: 151.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 132.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 215.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 213.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 29.7 nTPM; absolute ceiling;continuous selectivity; colon: 72.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 6.3 nTPM; absolute ceiling; esophagus: 15.7 nTPM; absolute ceiling; heart muscle: 12.3 nTPM; absolute ceiling; hippocampal formation: 138.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 149.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 11.2 nTPM; absolute ceiling; liver: 2.8 nTPM; absolute ceiling; lung: 9.7 nTPM; absolute ceiling; lymph node: 6.8 nTPM; absolute ceiling; midbrain: 118.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 3.5 nTPM; absolute ceiling; pituitary gland: 45.7 nTPM; absolute ceiling;continuous selectivity; rectum: 8.3 nTPM; absolute ceiling; retina: 53.2 nTPM; absolute ceiling;continuous selectivity; salivary gland: 6.1 nTPM; absolute ceiling; skeletal muscle: 3.2 nTPM; absolute ceiling; small intestine: 20.8 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 36.6 nTPM; absolute ceiling;continuous selectivity; spinal cord: 90 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; stomach: 24.8 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 66 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,adipose tissue: 15.8 nTPM (limit 10); adrenal gland: 13.1 nTPM (limit 2); amygdala: 151.5 nTPM (limit 2); basal ganglia: 132.8 nTPM (limit 2); cerebellum: 215.1 nTPM (limit 2); cerebral cortex: 213.9 nTPM (limit 2); choroid plexus: 29.7 nTPM (limit 2); colon: 72.7 nTPM (limit 6); duodenum: 6.3 nTPM (limit 2); esophagus: 15.7 nTPM (limit 6); heart muscle: 12.3 nTPM (limit 2); hippocampal formation: 138.3 nTPM (limit 2); hypothalamus: 149.6 nTPM (limit 2); kidney: 11.2 nTPM (limit 2); liver: 2.8 nTPM (limit 2); lung: 9.7 nTPM (limit 2); lymph node: 6.8 nTPM (limit 6); midbrain: 118.1 nTPM (limit 2); pancreas: 3.5 nTPM (limit 2); pituitary gland: 45.7 nTPM (limit 2); rectum: 8.3 nTPM (limit 6); retina: 53.2 nTPM (limit 2); salivary gland: 6.1 nTPM (limit 6); skeletal muscle: 3.2 nTPM (limit 2); small intestine: 20.8 nTPM (limit 2); smooth muscle: 36.6 nTPM (limit 2); spinal cord: 90 nTPM (limit 2); stomach: 24.8 nTPM (limit 6); urinary bladder: 66 nTPM (limit 6); adipose tissue: 15.8 nTPM (baseline 10); adrenal gland: 13.1 nTPM (baseline 2); amygdala: 151.5 nTPM (baseline 2); basal ganglia: 132.8 nTPM (baseline 2); cerebellum: 215.1 nTPM (baseline 2); cerebral cortex: 213.9 nTPM (baseline 2); choroid plexus: 29.7 nTPM (baseline 2); colon: 72.7 nTPM (baseline 6); duodenum: 6.3 nTPM (baseline 2); esophagus: 15.7 nTPM (baseline 6); heart muscle: 12.3 nTPM (baseline 2); hippocampal formation: 138.3 nTPM (baseline 2); hypothalamus: 149.6 nTPM (baseline 2); kidney: 11.2 nTPM (baseline 2); liver: 2.8 nTPM (baseline 2); lung: 9.7 nTPM (baseline 2); lymph node: 6.8 nTPM (baseline 6); midbrain: 118.1 nTPM (baseline 2); pancreas: 3.5 nTPM (baseline 2); pituitary gland: 45.7 nTPM (baseline 2); rectum: 8.3 nTPM (baseline 6); retina: 53.2 nTPM (baseline 2); salivary gland: 6.1 nTPM (baseline 6); skeletal muscle: 3.2 nTPM (baseline 2); small intestine: 20.8 nTPM (baseline 2); smooth muscle: 36.6 nTPM (baseline 2); spinal cord: 90 nTPM (baseline 2); stomach: 24.8 nTPM (baseline 6); urinary bladder: 66 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 141/141 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Ovary Serous Cystadenocarcinoma (TCGA): 326/349 (93.4%),glioma: 5/11 (45.5%); liver cancer: 1/12 (8.3%),31,20,Q96DZ5,https://www.uniprot.org/uniprotkb/Q96DZ5/entry,"Functions as a cytoplasmic linker protein. Involved in TGN-endosome dynamics. May modulate the cellular compartmentalization of AKT kinase family and promote its cell membrane localization, thereby playing a role in glucose transport in adipocytes",,,,"Cell membrane Cytoplasm Golgi apparatus, Golgi stack",19139280,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
CLNK,ENSG00000109684,Unsafe,Protein,False,True,1.1,6.1,79,4,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 0.4 nTPM; continuous selectivity; duodenum: 0.5 nTPM; continuous selectivity; kidney: 6.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 0.7 nTPM; continuous selectivity; lung: 0.5 nTPM; continuous selectivity; lymph node: 2.6 nTPM; positive ihc;continuous selectivity;reproductive not higher; pituitary gland: 1.2 nTPM; continuous selectivity;reproductive not higher; skin: 0.8 nTPM; continuous selectivity; small intestine: 0.8 nTPM; continuous selectivity; spleen: 1.4 nTPM; continuous selectivity;reproductive not higher; stomach: 1.1 nTPM; continuous selectivity;reproductive not higher; thymus: 1.2 nTPM; continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",kidney: 6.1 nTPM (limit 2); kidney: 6.1 nTPM (baseline 2),kidney / cells in tubules: Low (Uncertain); lymph node / non-germinal center cells: High (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Chromophobe (TCGA): 57/64 (89.1%); Uterine Corpus Endometrial Carcinoma (TCGA): 9/176 (5.1%); Pancreatic Adenocarcinoma (validation): 4/80 (5.0%),testis cancer: 3/11 (27.3%); lung cancer: 2/9 (22.2%),31,20,Q7Z7G1,https://www.uniprot.org/uniprotkb/Q7Z7G1/entry,"An adapter protein which plays a role in the regulation of immunoreceptor signaling, including PLC-gamma-mediated B-cell antigen receptor (BCR) signaling and FC-epsilon R1-mediated mast cell degranulation (By similarity). Together with FGR, it acts as a negative regulator of natural killer cell-activating receptors and inhibits interferon-gamma production (By similarity). Acts as a positive regulator of both T-cell receptor and natural killer T (NKT) cell receptor signaling in CD4-positive NKT cells (By similarity). Together with MAP4K1, it enhances CD3-triggered activation of T-cells and subsequent IL2 production (By similarity). May be involved in tumor necrosis factor induced cell death by promoting reactive oxidative species generation, and MLKL oligomerization, ultimately leading to necrosis (By similarity). Involved in phosphorylation of LAT (By similarity). May be involved in high affinity immunoglobulin epsilon receptor signaling in mast cells (By similarity)",,,,Cytoplasm,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CLPB,ENSG00000162129,Unsafe,Protein,False,True,107.2,107.2,84,68,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 5.3 nTPM; positive ihc; adrenal gland: 6.5 nTPM; positive ihc;absolute ceiling; amygdala: 3.6 nTPM; absolute ceiling; basal ganglia: 3.7 nTPM; absolute ceiling; bone marrow: 9 nTPM; positive ihc;absolute ceiling; cerebellum: 3.2 nTPM; positive ihc;absolute ceiling; cerebral cortex: 6.8 nTPM; positive ihc;absolute ceiling; choroid plexus: 2.9 nTPM; absolute ceiling; colon: 3.2 nTPM; positive ihc; duodenum: 3.5 nTPM; positive ihc;absolute ceiling; esophagus: 3.4 nTPM; positive ihc; heart muscle: 5.4 nTPM; positive ihc;absolute ceiling; hippocampal formation: 3.1 nTPM; absolute ceiling; hypothalamus: 3.3 nTPM; absolute ceiling; kidney: 8.3 nTPM; positive ihc;absolute ceiling; liver: 10 nTPM; positive ihc;absolute ceiling; lung: 3.3 nTPM; positive ihc;absolute ceiling; lymph node: 3.1 nTPM; positive ihc; midbrain: 3.8 nTPM; absolute ceiling; pancreas: 5.6 nTPM; positive ihc;absolute ceiling; parathyroid gland: 7.5 nTPM; positive ihc;absolute ceiling; pituitary gland: 2.1 nTPM; absolute ceiling; rectum: 2.9 nTPM; positive ihc; retina: 6.1 nTPM; absolute ceiling; salivary gland: 5.5 nTPM; positive ihc; skeletal muscle: 8.3 nTPM; positive ihc;absolute ceiling; skin: 2.3 nTPM; positive ihc; small intestine: 2.5 nTPM; positive ihc;absolute ceiling; smooth muscle: 5.1 nTPM; positive ihc;absolute ceiling; spinal cord: 3.2 nTPM; absolute ceiling; spleen: 3.5 nTPM; positive ihc; stomach: 3.5 nTPM; positive ihc; thyroid gland: 4.9 nTPM; positive ihc; urinary bladder: 3.2 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 6.5 nTPM (limit 2); amygdala: 3.6 nTPM (limit 2); basal ganglia: 3.7 nTPM (limit 2); bone marrow: 9 nTPM (limit 2); cerebellum: 3.2 nTPM (limit 2); cerebral cortex: 6.8 nTPM (limit 2); choroid plexus: 2.9 nTPM (limit 2); duodenum: 3.5 nTPM (limit 2); heart muscle: 5.4 nTPM (limit 2); hippocampal formation: 3.1 nTPM (limit 2); hypothalamus: 3.3 nTPM (limit 2); kidney: 8.3 nTPM (limit 2); liver: 10 nTPM (limit 2); lung: 3.3 nTPM (limit 2); midbrain: 3.8 nTPM (limit 2); pancreas: 5.6 nTPM (limit 2); parathyroid gland: 7.5 nTPM (limit 6); pituitary gland: 2.1 nTPM (limit 2); retina: 6.1 nTPM (limit 2); skeletal muscle: 8.3 nTPM (limit 2); small intestine: 2.5 nTPM (limit 2); smooth muscle: 5.1 nTPM (limit 2); spinal cord: 3.2 nTPM (limit 2),adipose tissue / adipocytes: Low (Enhanced); adrenal gland / glandular cells: Medium (Enhanced); bone marrow / hematopoietic cells: Low (Enhanced); bronchus / respiratory epithelial cells: Low (Enhanced); caudate / neuronal cells: Medium (Enhanced); cerebellum / cells in granular layer: Low (Enhanced); cerebellum / Purkinje cells: Medium (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); cerebral cortex / neuropil: Low (Enhanced); colon / endothelial cells: Medium (Enhanced); colon / glandular cells: Medium (Enhanced); colon / peripheral nerve/ganglion: High (Enhanced); duodenum / glandular cells: Medium (Enhanced); esophagus / squamous epithelial cells: Medium (Enhanced); heart muscle / cardiomyocytes: Low (Enhanced); hippocampus / glial cells: Low (Enhanced); hippocampus / neuronal cells: Low (Enhanced); kidney / cells in tubules: High (Enhanced); liver / cholangiocytes: Low (Enhanced); liver / hepatocytes: Medium (Enhanced); lung / macrophages: Medium (Enhanced); lymph node / non-germinal center cells: Low (Enhanced); nasopharynx / respiratory epithelial cells: Low (Enhanced); oral mucosa / squamous epithelial cells: Low (Enhanced); pancreas / exocrine glandular cells: Medium (Enhanced); pancreas / pancreatic endocrine cells: Medium (Enhanced); parathyroid gland / glandular cells: Medium (Enhanced); rectum / glandular cells: Medium (Enhanced); salivary gland / glandular cells: Medium (Enhanced); skeletal muscle / myocytes: Low (Enhanced); skin 1 / fibroblasts: Medium (Enhanced); skin 1 / keratinocytes: Medium (Enhanced); skin 1 / Langerhans: Medium (Enhanced); skin 2 / epidermal cells: Medium (Enhanced); small intestine / glandular cells: Medium (Enhanced); smooth muscle / smooth muscle cells: Medium (Enhanced); spleen / cells in red pulp: Low (Enhanced); spleen / cells in white pulp: Low (Enhanced); stomach 1 / glandular cells: Medium (Enhanced); stomach 2 / glandular cells: Medium (Enhanced); thyroid gland / glandular cells: Medium (Enhanced); urinary bladder / urothelial cells: Medium (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 484/486 (99.6%),breast cancer: 12/12 (100.0%); colorectal cancer: 12/12 (100.0%),31,20,Q9H078,https://www.uniprot.org/uniprotkb/Q9H078/entry,"Functions as a regulatory ATPase and participates in secretion/protein trafficking process. Has ATP-dependent protein disaggregase activity and is required to maintain the solubility of key mitochondrial proteins (PubMed:32573439, PubMed:34115842, PubMed:35247700, PubMed:36170828, PubMed:36745679). Involved in mitochondrial-mediated antiviral innate immunity, activates RIG-I-mediated signal transduction and production of IFNB1 and pro-inflammatory cytokine IL6 (PubMed:31522117). Plays a role in granulocyte differentiation (PubMed:34115842)","Widely expressed (at protein level) (PubMed:25597511). Expressed in fetal, as well as in adult tissues, with highest levels in adult brain, including thalamus, hippocampus, occipital cortex and parietal cortex. Low expression in granulocytes (PubMed:25597510)","3-methylglutaconic aciduria 7B: An autosomal recessive inborn error of metabolism with a highly variable phenotype. Primary disease symptoms are increased levels of 3-methylglutaconic acid, neurologic deterioration and neutropenia. Other common features include progressive encephalopathy, movement abnormalities, delayed psychomotor development,impaired intellectual development, cataracts, seizures, and recurrent infections. 3-methylglutaconic aciduria 7A: An autosomal dominant inborn error of metabolism with a highly variable phenotype. Primary disease symptoms are increased levels of 3-methylglutaconic acid, neurologic deterioration and neutropenia. Other common features include progressive encephalopathy, movement abnormalities, delayed psychomotor development, impaired intellectual development, cataracts, seizures, and recurrent infections. Neutropenia, severe congenital 9, autosomal dominant: A form of severe congenital neutropenia, a disorder of hematopoiesis characterized by maturation arrest of granulopoiesis at the level of promyelocytes with peripheral blood absolute neutrophil counts below 0.5 x 10(9)/l and early onset of severe bacterial infections. SCN9 is characterized by onset of neutropenia in the first years of life. Rare patients may exhibit additional features such as seizures, learning difficulties, or cataracts. Patients with SCN9 do not have 3-methylglutaconic aciduria.","Despite its gene name, this protein differs in domain structure from bacterial clpB. Bacterial clpB contains two AAA modules, one in the N-terminal part of the protein and one in the C-terminal part, separated by a coiled coil, while vertebrate CLPB contains a single C-terminal AAA region and an N-terminal ANK repeat region which is absent from bacterial clpB",Mitochondrion intermembrane space,31522117|32573439|34115842|35247700|36170828|36745679,25597510|25597511,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CLPSL1,ENSG00000204140,Unsafe,RNA,False,True,592.0,592.0,79,1,Positive somewhere,False,True,False,True,Excluded,Normal,False,,Not assessed,,,hippocampal formation: 2.8 nTPM; absolute ceiling; pancreas: 173.3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,hippocampal formation: 2.8 nTPM (limit 2); pancreas: 173.3 nTPM (limit 12),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 559/1022 (54.7%); Uterine Corpus Endometrial Carcinoma (TCGA): 59/176 (33.5%); Ovary Serous Cystadenocarcinoma (TCGA): 73/349 (20.9%),renal cancer: 6/12 (50.0%); endometrial cancer: 2/12 (16.7%),29,20,A2RUU4,https://www.uniprot.org/uniprotkb/A2RUU4/entry,,"Exclusively expressed in epididymis, in the corpus region",,,Secreted,,18390568,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
CLPSL2,ENSG00000196748,Unsafe,Protein,False,True,518.4,518.4,78,20,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 0 nTPM; positive ihc; bone marrow: 0.1 nTPM; positive ihc; cerebellum: 0 nTPM; positive ihc; colon: 0 nTPM; positive ihc; kidney: 0 nTPM; positive ihc; lung: 0 nTPM; positive ihc; lymph node: 0 nTPM; positive ihc; pancreas: 5 nTPM; absolute ceiling; parathyroid gland: 0 nTPM; positive ihc; salivary gland: 1.6 nTPM; positive ihc; skin: 0.1 nTPM; positive ihc; urinary bladder: 0 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",pancreas: 5 nTPM (limit 4),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Medium (Approved); colon / glandular cells: Low (Approved); kidney / cells in tubules: Low (Approved); lung / macrophages: Low (Approved); lymph node / non-germinal center cells: Low (Approved); parathyroid gland / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skin 2 / epidermal cells: Low (Approved); urinary bladder / urothelial cells: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 450/1022 (44.0%); Lung Adenocarcinoma (TCGA): 52/497 (10.5%); Uterine Corpus Endometrial Carcinoma (TCGA): 12/176 (6.8%),prostate cancer: 4/11 (36.4%); breast cancer: 3/11 (27.3%),29,20,Q6UWE3,https://www.uniprot.org/uniprotkb/Q6UWE3/entry,,,,,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
CLRN1,ENSG00000163646,Unsafe,RNA,False,True,0.3,12.4,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,adrenal gland: 4.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 1.3 nTPM; continuous selectivity;reproductive not higher; pituitary gland: 0.2 nTPM; continuous selectivity; retina: 12.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 0.2 nTPM; continuous selectivity; spinal cord: 0.2 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 4.8 nTPM (limit 2); retina: 12.4 nTPM (limit 2); adrenal gland: 4.8 nTPM (baseline 2); retina: 12.4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 2/141 (1.4%); Bladder Urothelial Carcinoma (TCGA): 2/169 (1.2%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P58418,https://www.uniprot.org/uniprotkb/P58418/entry,May have a role in the excitatory ribbon synapse junctions between hair cells and cochlear ganglion cells and presumably also in analogous synapses within the retina,Widely expressed. Found in the retina,"Usher syndrome 3A: USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH3 is characterized by postlingual, progressive hearing loss, variable vestibular dysfunction, and onset of retinitis pigmentosa symptoms, including nyctalopia, constriction of the visual fields, and loss of central visual acuity, usually by the second decade of life. Retinitis pigmentosa 61: A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.",,Cell membrane,12080385,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
CLSPN,ENSG00000092853,Unsafe,RNA,False,True,5.6,11.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 11.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 4.8 nTPM; continuous selectivity; rectum: 2 nTPM; continuous selectivity; retina: 6.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thymus: 7.7 nTPM; continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 11.1 nTPM (limit 2); retina: 6.6 nTPM (limit 2); bone marrow: 11.1 nTPM (baseline 2); retina: 6.6 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 56/58 (96.6%); Colon Adenocarcinoma (validation): 447/486 (92.0%); Rectum Adenocarcinoma (validation): 169/207 (81.6%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9HAW4,https://www.uniprot.org/uniprotkb/Q9HAW4/entry,"Required for checkpoint mediated cell cycle arrest in response to inhibition of DNA replication or to DNA damage induced by both ionizing and UV irradiation (PubMed:12766152, PubMed:15190204, PubMed:15707391, PubMed:16123041). Adapter protein which binds to BRCA1 and the checkpoint kinase CHEK1 and facilitates the ATR-dependent phosphorylation of both proteins (PubMed:12766152, PubMed:15096610, PubMed:15707391, PubMed:16123041). Also required to maintain normal rates of replication fork progression during unperturbed DNA replication. Binds directly to DNA, with particular affinity for branched or forked molecules and interacts with multiple protein components of the replisome such as the MCM2-7 complex and TIMELESS (PubMed:15226314, PubMed:34694004, PubMed:35585232). Important for initiation of DNA replication, recruits kinase CDC7 to phosphorylate MCM2-7 components (PubMed:27401717)",,,,Nucleus,12766152|15096610|15190204|15226314|15707391|16123041|27401717|34694004|35585232,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CLUL1,ENSG00000079101,Unsafe,Protein,False,True,8.1,288.9,87,1,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; amygdala: 2.7 nTPM; absolute ceiling;continuous selectivity; bone marrow: 3.8 nTPM; absolute ceiling;continuous selectivity; cerebellum: 2.3 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 4.3 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 27.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 3.2 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 3.5 nTPM; absolute ceiling;continuous selectivity; kidney: 5 nTPM; absolute ceiling;continuous selectivity; midbrain: 2.8 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 3.3 nTPM; continuous selectivity; pituitary gland: 3.6 nTPM; absolute ceiling;continuous selectivity; retina: 288.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 3.5 nTPM; absolute ceiling;continuous selectivity; stomach: 2.9 nTPM; continuous selectivity; thyroid gland: 5.9 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 2.7 nTPM (limit 2); choroid plexus: 27.9 nTPM (limit 2); hippocampal formation: 3.2 nTPM (limit 2); hypothalamus: 3.5 nTPM (limit 2); midbrain: 2.8 nTPM (limit 2); pituitary gland: 3.6 nTPM (limit 2); retina: 288.9 nTPM (limit 2); spinal cord: 3.5 nTPM (limit 2); amygdala: 2.7 nTPM (baseline 2); bone marrow: 3.8 nTPM (baseline 2); cerebellum: 2.3 nTPM (baseline 2); cerebral cortex: 4.3 nTPM (baseline 2); choroid plexus: 27.9 nTPM (baseline 2); hippocampal formation: 3.2 nTPM (baseline 2); hypothalamus: 3.5 nTPM (baseline 2); kidney: 5 nTPM (baseline 2); midbrain: 2.8 nTPM (baseline 2); pituitary gland: 3.6 nTPM (baseline 2); retina: 288.9 nTPM (baseline 2); spinal cord: 3.5 nTPM (baseline 2),retina / photoreceptor cells: High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Prostate Adenocarcinoma (TCGA): 387/480 (80.6%); Ovary Serous Cystadenocarcinoma (TCGA): 202/349 (57.9%); Kidney Renal Clear Cell Carcinoma (validation): 53/100 (53.0%),endometrial cancer: 4/12 (33.3%); prostate cancer: 1/12 (8.3%),31,20,Q15846,https://www.uniprot.org/uniprotkb/Q15846/entry,,,,,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CMTM1,ENSG00000089505,Unsafe,RNA,False,True,30.4,30.4,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,cerebellum: 2.3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebellum: 2.3 nTPM (limit 2); cerebellum: 2.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 48/50 (96.0%); Colon Adenocarcinoma (validation): 460/486 (94.7%); Rectum Adenocarcinoma (validation): 191/207 (92.3%),testis cancer: 5/10 (50.0%); prostate cancer: 5/11 (45.5%),31,20,Q8IZ96,https://www.uniprot.org/uniprotkb/Q8IZ96/entry,,Highly expressed in testis,,,Membrane,,12782130|15147728,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | Jamin2021_CT | Jamin2021_core | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,Failed bulk numeric comparisons are within 20% of their cutoffs; not an automatic rescue,,,,
CMTM2,ENSG00000140932,Unsafe,High RNA,False,True,630.9,630.9,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE MONOCYTES (unstimulated): 78/91 values ≥5 TPM, max 19.114",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,19.1139986452,1248.8,"hpa_single_cell_tissue: fallopian tube/neutrophils, max 1248.8 nTPM, 1 observations >30; hpa_single_cell_tissue: pbmc/platelets, max 38 nTPM, 1 observations >30; hpa_single_cell_tissue: salivary gland/serous glandular cells, max 389.6 nTPM, 1 observations >30; hpa_single_cell_tissue: testis/macrophages, max 39.7 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,19.11 TPM; blood/MONOCYTES; dice_monocytes; vital,1249 nTPM; fallopian tube/neutrophils; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (validation): 3/50 (6.0%); Testicular Germ Cell Tumor (TCGA): 4/133 (3.0%); Pancreatic Adenocarcinoma (validation): 1/80 (1.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8TAZ6,https://www.uniprot.org/uniprotkb/Q8TAZ6/entry,,Highly expressed in testis,,,Membrane,,12782130,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
CNBD1,ENSG00000176571,Unsafe,High RNA,False,True,4.9,4.9,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: High, HPA025037; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA025037; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA025037; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA025037; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA025037; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA025037; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA025037; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA025037; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA025037; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA025037; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA025037; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA025037; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA025037; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA025037; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA025037; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA025037; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA025037; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA025037; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA025037; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA025037; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA025037; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA025037; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA025037; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA025037; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA025037; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Low, HPA025037; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA025037; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA025037; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA025037; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: High, HPA027469; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA027469; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA027469; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA027469; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA027469; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA027469; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA027469; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA027469; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: High, HPA027469; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA027469; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Low, HPA027469; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA027469; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA027469; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA027469; conflicting or uncurated primary profile; Small intestine/Glandular cells: Low, HPA027469; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA027469; conflicting or uncurated primary profile; Adipose tissue/Adipocytes: Medium, HPA027786; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA027786; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA027786; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA027786; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA027786; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA027786; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA027786; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA027786; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA027786; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA027786; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA027786; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA027786; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA027786; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA027786; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA027786; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA027786; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA027786; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA027786; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA027786; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA027786; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Low, HPA027786; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA027786; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA027786; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA027786; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA027786; conflicting or uncurated primary profile; Skin 1/Langerhans: Low, HPA027786; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA027786; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA027786; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA027786; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Low, HPA027786; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, HPA027786; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA027786; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA027786; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,0.479761624671,40.1,"hpa_single_cell_tissue: brain/inhibitory neurons, max 40.1 nTPM, 1 observations >30",Neither,oncoref.target-sets.2026-10-23.2,0.4798 TPM; blood/MONOCYTES; dice_monocytes; vital,40.1 nTPM; brain/inhibitory neurons; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Lung Adenocarcinoma (TCGA): 1/497 (0.2%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),prostate cancer: 2/12 (16.7%); testis cancer: 2/12 (16.7%),31,20,Q8NA66,https://www.uniprot.org/uniprotkb/Q8NA66/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
CNBD2,ENSG00000149646,Unsafe,Protein,False,True,25.2,25.2,74,65,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 2.4 nTPM; positive ihc; adrenal gland: 4.3 nTPM; positive ihc;absolute ceiling; amygdala: 4 nTPM; absolute ceiling; basal ganglia: 4.5 nTPM; absolute ceiling; bone marrow: 8.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 8.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 3.8 nTPM; positive ihc;absolute ceiling; choroid plexus: 6.4 nTPM; absolute ceiling;continuous selectivity; colon: 4.1 nTPM; positive ihc; duodenum: 3.7 nTPM; positive ihc;absolute ceiling; esophagus: 3 nTPM; positive ihc; heart muscle: 3.8 nTPM; positive ihc;absolute ceiling; hippocampal formation: 3.9 nTPM; absolute ceiling; hypothalamus: 4.4 nTPM; absolute ceiling; kidney: 7.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 5.4 nTPM; positive ihc;absolute ceiling; lung: 2.3 nTPM; positive ihc;absolute ceiling; midbrain: 4.3 nTPM; absolute ceiling; pancreas: 6.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 5.5 nTPM; positive ihc; pituitary gland: 4.8 nTPM; absolute ceiling; rectum: 2.7 nTPM; positive ihc; retina: 15.3 nTPM; absolute ceiling;continuous selectivity; salivary gland: 4 nTPM; positive ihc; skeletal muscle: 22.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 5.6 nTPM; positive ihc; small intestine: 4.5 nTPM; positive ihc;absolute ceiling; smooth muscle: 1.8 nTPM; positive ihc; spinal cord: 3.3 nTPM; absolute ceiling; spleen: 5.6 nTPM; positive ihc; stomach: 3.7 nTPM; positive ihc; thyroid gland: 4.5 nTPM; positive ihc; tongue: 16.1 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 2.7 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 4.3 nTPM (limit 2); amygdala: 4 nTPM (limit 2); basal ganglia: 4.5 nTPM (limit 2); bone marrow: 8.7 nTPM (limit 2); cerebellum: 8.4 nTPM (limit 2); cerebral cortex: 3.8 nTPM (limit 2); choroid plexus: 6.4 nTPM (limit 2); duodenum: 3.7 nTPM (limit 2); heart muscle: 3.8 nTPM (limit 2); hippocampal formation: 3.9 nTPM (limit 2); hypothalamus: 4.4 nTPM (limit 2); kidney: 7.5 nTPM (limit 2); liver: 5.4 nTPM (limit 2); lung: 2.3 nTPM (limit 2); midbrain: 4.3 nTPM (limit 2); pancreas: 6.8 nTPM (limit 2); pituitary gland: 4.8 nTPM (limit 2); retina: 15.3 nTPM (limit 2); skeletal muscle: 22.9 nTPM (limit 2); small intestine: 4.5 nTPM (limit 2); spinal cord: 3.3 nTPM (limit 2); tongue: 16.1 nTPM (limit 6); adrenal gland: 4.3 nTPM (baseline 2); amygdala: 4 nTPM (baseline 2); basal ganglia: 4.5 nTPM (baseline 2); bone marrow: 8.7 nTPM (baseline 2); cerebellum: 8.4 nTPM (baseline 2); cerebral cortex: 3.8 nTPM (baseline 2); choroid plexus: 6.4 nTPM (baseline 2); duodenum: 3.7 nTPM (baseline 2); heart muscle: 3.8 nTPM (baseline 2); hippocampal formation: 3.9 nTPM (baseline 2); hypothalamus: 4.4 nTPM (baseline 2); kidney: 7.5 nTPM (baseline 2); liver: 5.4 nTPM (baseline 2); lung: 2.3 nTPM (baseline 2); midbrain: 4.3 nTPM (baseline 2); pancreas: 6.8 nTPM (baseline 2); pituitary gland: 4.8 nTPM (baseline 2); retina: 15.3 nTPM (baseline 2); skeletal muscle: 22.9 nTPM (baseline 2); small intestine: 4.5 nTPM (baseline 2); spinal cord: 3.3 nTPM (baseline 2); tongue: 16.1 nTPM (baseline 6),adipose tissue / adipocytes: Medium (Uncertain); adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / glial cells: Low (Uncertain); caudate / neuronal cells: Low (Uncertain); cerebellum / cells in granular layer: Medium (Uncertain); cerebellum / cells in molecular layer: Low (Uncertain); cerebral cortex / endothelial cells: Medium (Uncertain); cerebral cortex / glial cells: Low (Uncertain); cerebral cortex / neuropil: Medium (Uncertain); colon / endothelial cells: Medium (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: Medium (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / glial cells: Low (Uncertain); kidney / cells in glomeruli: Medium (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / cholangiocytes: Low (Uncertain); liver / hepatocytes: Low (Uncertain); lung / alveolar cells: Medium (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: Medium (Uncertain); skin 1 / fibroblasts: Medium (Uncertain); skin 1 / keratinocytes: Medium (Uncertain); skin 1 / Langerhans: Medium (Uncertain); skin 2 / epidermal cells: Low (Uncertain); small intestine / glandular cells: Medium (Uncertain); smooth muscle / smooth muscle cells: Low (Uncertain); spleen / cells in white pulp: Low (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 114/141 (80.9%); Prostate Adenocarcinoma (TCGA): 388/480 (80.8%); Uterine Corpus Endometrial Carcinoma (TCGA): 100/176 (56.8%),liver cancer: 12/12 (100.0%); stomach cancer: 12/12 (100.0%),29,20,Q96M20,https://www.uniprot.org/uniprotkb/Q96M20/entry,Essential for male fertility. Plays an important role in spermatogenesis and regulates sperm motility by controlling the development of the flagellar bending of sperm,,,,"Cytoplasm, cytosol",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
CNKSR3,ENSG00000153721,Unsafe,Protein,False,True,7.4,18.3,80,65,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 1.1 nTPM; positive ihc; amygdala: 2 nTPM; continuous selectivity; bone marrow: 0.8 nTPM; positive ihc; cerebellum: 0.6 nTPM; positive ihc; cerebral cortex: 1.2 nTPM; positive ihc; choroid plexus: 6.7 nTPM; absolute ceiling;continuous selectivity; colon: 6.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 5.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 12.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 6.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 2.4 nTPM; absolute ceiling;continuous selectivity; kidney: 7.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 9.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 3.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 1.4 nTPM; positive ihc; midbrain: 2.3 nTPM; absolute ceiling;continuous selectivity; pancreas: 18.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 0.7 nTPM; positive ihc; pituitary gland: 2.2 nTPM; absolute ceiling;continuous selectivity; rectum: 3.3 nTPM; positive ihc;continuous selectivity; retina: 2.5 nTPM; absolute ceiling;continuous selectivity; salivary gland: 5.5 nTPM; continuous selectivity; skeletal muscle: 1.1 nTPM; positive ihc; skin: 3.8 nTPM; positive ihc;continuous selectivity; small intestine: 6.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 6.3 nTPM; absolute ceiling;continuous selectivity; spinal cord: 3.9 nTPM; absolute ceiling;continuous selectivity; spleen: 4.4 nTPM; positive ihc;continuous selectivity; stomach: 3.9 nTPM; positive ihc;continuous selectivity; thyroid gland: 2 nTPM; positive ihc; urinary bladder: 4.2 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 6.7 nTPM (limit 2); colon: 6.3 nTPM (limit 6); duodenum: 5.6 nTPM (limit 2); esophagus: 12.8 nTPM (limit 6); heart muscle: 6.1 nTPM (limit 2); hippocampal formation: 2.4 nTPM (limit 2); kidney: 7.3 nTPM (limit 2); liver: 9.3 nTPM (limit 2); lung: 3.6 nTPM (limit 2); midbrain: 2.3 nTPM (limit 2); pancreas: 18.3 nTPM (limit 2); pituitary gland: 2.2 nTPM (limit 2); retina: 2.5 nTPM (limit 2); small intestine: 6.2 nTPM (limit 2); smooth muscle: 6.3 nTPM (limit 4); spinal cord: 3.9 nTPM (limit 2),adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: High (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Low (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: High (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: High (Approved); nasopharynx / respiratory epithelial cells: High (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Low (Approved); skin 1 / Langerhans: Medium (Approved); small intestine / glandular cells: Medium (Approved); spleen / cells in red pulp: High (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (validation): 222/231 (96.1%); Colon Adenocarcinoma (validation): 461/486 (94.9%); Kidney Renal Clear Cell Carcinoma (validation): 93/100 (93.0%),breast cancer: 12/12 (100.0%); lung cancer: 12/12 (100.0%),31,20,Q6P9H4,https://www.uniprot.org/uniprotkb/Q6P9H4/entry,Involved in transepithelial sodium transport. Regulates aldosterone-induced and epithelial sodium channel (ENaC)-mediated sodium transport through regulation of ENaC cell surface expression. Acts as a scaffold protein coordinating the assembly of an ENaC-regulatory complex (ERC),,,"The gene name MAGI1, shown in this entry as a synonym, is an obsolete human gene nomenclature committee-approved name. It should be noted that MAGI1 currently is the official name for the unrelated membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1",Cytoplasm Apical cell membrane,22851176,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CNST,ENSG00000162852,Unsafe,Protein,False,True,12.5,37.4,78,59,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 12.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; adrenal gland: 18.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 6 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 8.9 nTPM; absolute ceiling;continuous selectivity; bone marrow: 23.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 16.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 15.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 13.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 13.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 9.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 16.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 8.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 6.3 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 11.6 nTPM; absolute ceiling;continuous selectivity; kidney: 8.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 22.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 9.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 16.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 7.2 nTPM; absolute ceiling;continuous selectivity; pancreas: 9.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 10.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 7.3 nTPM; absolute ceiling;continuous selectivity; rectum: 11.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 16.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 7 nTPM; continuous selectivity; skeletal muscle: 30.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 9.9 nTPM; positive ihc;continuous selectivity; small intestine: 12.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 9.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 5.1 nTPM; absolute ceiling;continuous selectivity; spleen: 10.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 8.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 13.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 13.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; tongue: 37.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 10.9 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 12.6 nTPM (limit 10); adrenal gland: 18.7 nTPM (limit 2); amygdala: 6 nTPM (limit 2); basal ganglia: 8.9 nTPM (limit 2); bone marrow: 23.2 nTPM (limit 2); cerebellum: 16.9 nTPM (limit 2); cerebral cortex: 15.5 nTPM (limit 2); choroid plexus: 13.1 nTPM (limit 2); colon: 13.3 nTPM (limit 6); duodenum: 9.9 nTPM (limit 2); esophagus: 16.1 nTPM (limit 6); heart muscle: 8.5 nTPM (limit 2); hippocampal formation: 6.3 nTPM (limit 2); hypothalamus: 11.6 nTPM (limit 2); kidney: 8.3 nTPM (limit 2); liver: 22.8 nTPM (limit 2); lung: 9.6 nTPM (limit 2); lymph node: 16.3 nTPM (limit 6); midbrain: 7.2 nTPM (limit 2); pancreas: 9.9 nTPM (limit 2); parathyroid gland: 10.9 nTPM (limit 6); pituitary gland: 7.3 nTPM (limit 2); rectum: 11.6 nTPM (limit 6); retina: 16.2 nTPM (limit 2); skeletal muscle: 30.7 nTPM (limit 2); small intestine: 12.8 nTPM (limit 2); smooth muscle: 9.7 nTPM (limit 2); spinal cord: 5.1 nTPM (limit 2); spleen: 10.2 nTPM (limit 10); stomach: 8.2 nTPM (limit 6); thymus: 13.9 nTPM (limit 10); thyroid gland: 13.5 nTPM (limit 10); tongue: 37.4 nTPM (limit 6); urinary bladder: 10.9 nTPM (limit 6),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Low (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: High (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Low (Approved); skin 1 / keratinocytes: High (Approved); skin 2 / epidermal cells: High (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: High (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%); Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%),skin cancer: 9/11 (81.8%); prostate cancer: 6/11 (54.5%),31,20,Q6PJW8,https://www.uniprot.org/uniprotkb/Q6PJW8/entry,Required for targeting of connexins to the plasma membrane,,,,"Cell membrane Golgi apparatus, trans-Golgi network membrane Cytoplasmic vesicle, secretory vesicle",19864490,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
CNTD1,ENSG00000176563,Unsafe,High RNA,False,True,41.1,41.1,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 91/91 values ≥5 TPM, max 14.1993; DICE M2 (unstimulated): 25/90 values ≥5 TPM, max 7.62136; DICE NK (unstimulated): 56/90 values ≥5 TPM, max 11.3566; DICE TREG_MEM (unstimulated): 14/89 values ≥5 TPM, max 7.736; DICE CD4_NAIVE (unstimulated): 76/88 values ≥5 TPM, max 10.2954; DICE CD4_STIM (activated): 34/88 values ≥5 TPM, max 7.55155; DICE TREG_NAIVE (unstimulated): 17/89 values ≥5 TPM, max 6.63014; DICE TFH (unstimulated): 28/89 values ≥5 TPM, max 7.01995; DICE TH1 (unstimulated): 34/81 values ≥5 TPM, max 8.35583; DICE THSTAR (unstimulated): 34/88 values ≥5 TPM, max 7.70855; DICE TH17 (unstimulated): 26/89 values ≥5 TPM, max 8.31899; DICE TH2 (unstimulated): 37/89 values ≥5 TPM, max 7.82593; DICE CD8_NAIVE (unstimulated): 71/89 values ≥5 TPM, max 10.5874; DICE CD8_STIM (activated): 41/88 values ≥5 TPM, max 7.08137",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,14.1992535817,43.2,"hpa_single_cell_tissue: lung/ciliated cells, max 43.2 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,14.2 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,43.2 nTPM; lung/ciliated cells; hpa_single_cell_tissue; vital,Liver Hepatocellular Carcinoma (validation): 231/231 (100.0%); Breast Invasive Carcinoma (validation): 37/50 (74.0%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 40/283 (14.1%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8N815,https://www.uniprot.org/uniprotkb/Q8N815/entry,"Plays a role in the different steps of crossover formation during meiotic recombination. Participates in the crossover differentiation step of crossover-specific recombination intermediates through its interaction with PRR19. In addition, stimulates crossover formation through the interactions with RFC3 and RFC4 and simultaneously regulates cell-cycle progression through interactions with CDC34 and subsequent ubiquitination of WEE1. May also participates in an active deselection process that destabilizes or removes excess pre-CO intermediates",,,,Nucleus Cytoplasm Chromosome,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CNTLN,ENSG00000044459,Unsafe,Protein,False,True,7.4,10.2,79,63,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 4.3 nTPM; continuous selectivity; adrenal gland: 2.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; bone marrow: 7.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 3.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 1.7 nTPM; positive ihc; colon: 4.3 nTPM; positive ihc;continuous selectivity; duodenum: 1.2 nTPM; positive ihc; esophagus: 2.6 nTPM; positive ihc;continuous selectivity; heart muscle: 2.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; kidney: 2.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 10.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 2.6 nTPM; positive ihc;continuous selectivity; pancreas: 1.7 nTPM; positive ihc; parathyroid gland: 4.2 nTPM; positive ihc;continuous selectivity; pituitary gland: 2.1 nTPM; absolute ceiling;continuous selectivity; rectum: 2.1 nTPM; positive ihc; retina: 2.1 nTPM; absolute ceiling;continuous selectivity; salivary gland: 1.6 nTPM; positive ihc; skeletal muscle: 1.5 nTPM; positive ihc; skin: 1.9 nTPM; positive ihc; small intestine: 2.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 4.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; spleen: 3.8 nTPM; positive ihc;continuous selectivity; stomach: 1.9 nTPM; positive ihc; thyroid gland: 3 nTPM; positive ihc; urinary bladder: 3.3 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 2.3 nTPM (limit 2); bone marrow: 7.2 nTPM (limit 2); cerebellum: 3.5 nTPM (limit 2); heart muscle: 2.2 nTPM (limit 2); kidney: 2.3 nTPM (limit 2); liver: 10.2 nTPM (limit 2); lung: 2.7 nTPM (limit 2); pituitary gland: 2.1 nTPM (limit 2); retina: 2.1 nTPM (limit 2); small intestine: 2.1 nTPM (limit 2); smooth muscle: 4.3 nTPM (limit 2); adrenal gland: 2.3 nTPM (baseline 2); bone marrow: 7.2 nTPM (baseline 2); cerebellum: 3.5 nTPM (baseline 2); heart muscle: 2.2 nTPM (baseline 2); kidney: 2.3 nTPM (baseline 2); liver: 10.2 nTPM (baseline 2); lung: 2.7 nTPM (baseline 2); pituitary gland: 2.1 nTPM (baseline 2); retina: 2.1 nTPM (baseline 2); small intestine: 2.1 nTPM (baseline 2); smooth muscle: 4.3 nTPM (baseline 2),adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: High (Uncertain); bronchus / respiratory epithelial cells: High (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: Medium (Uncertain); cerebellum / cells in molecular layer: Medium (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / glial cells: Medium (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: Medium (Uncertain); colon / endothelial cells: Low (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: Low (Uncertain); duodenum / glandular cells: High (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / cholangiocytes: Medium (Uncertain); liver / hepatocytes: Low (Uncertain); lung / alveolar cells: Low (Uncertain); lung / macrophages: Low (Uncertain); lymph node / germinal center cells: Medium (Uncertain); nasopharynx / respiratory epithelial cells: High (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: High (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: High (Uncertain); skeletal muscle / myocytes: Medium (Uncertain); skin 1 / fibroblasts: High (Uncertain); skin 1 / keratinocytes: Medium (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: Medium (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); spleen / cells in red pulp: Low (Uncertain); stomach 1 / glandular cells: High (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 45/50 (90.0%); Pancreatic Adenocarcinoma (validation): 55/80 (68.8%),prostate cancer: 12/12 (100.0%); breast cancer: 11/12 (91.7%),31,20,Q9NXG0,https://www.uniprot.org/uniprotkb/Q9NXG0/entry,Required for centrosome cohesion and recruitment of CEP68 to centrosomes,,,,"Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriole",24554434,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CNTN4,ENSG00000144619,Unsafe,RNA,False,True,13.1,21.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,cerebellum: 4.7 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 7.5 nTPM; absolute ceiling;continuous selectivity; colon: 4.5 nTPM; continuous selectivity; heart muscle: 2.4 nTPM; absolute ceiling; kidney: 4 nTPM; absolute ceiling;continuous selectivity; liver: 2.8 nTPM; absolute ceiling; lung: 2.3 nTPM; absolute ceiling; parathyroid gland: 21.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; retina: 19.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 3.9 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 4.3 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 10 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebellum: 4.7 nTPM (limit 2); cerebral cortex: 7.5 nTPM (limit 2); heart muscle: 2.4 nTPM (limit 2); kidney: 4 nTPM (limit 2); liver: 2.8 nTPM (limit 2); lung: 2.3 nTPM (limit 2); parathyroid gland: 21.8 nTPM (limit 6); retina: 19.2 nTPM (limit 2); small intestine: 3.9 nTPM (limit 2); smooth muscle: 4.3 nTPM (limit 2); cerebellum: 4.7 nTPM (baseline 2); cerebral cortex: 7.5 nTPM (baseline 2); heart muscle: 2.4 nTPM (baseline 2); kidney: 4 nTPM (baseline 2); liver: 2.8 nTPM (baseline 2); lung: 2.3 nTPM (baseline 2); parathyroid gland: 21.8 nTPM (baseline 6); retina: 19.2 nTPM (baseline 2); small intestine: 3.9 nTPM (baseline 2); smooth muscle: 4.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 36/50 (72.0%); Pancreatic Adenocarcinoma (validation): 41/80 (51.2%); Thyroid Carcinoma (TCGA): 190/495 (38.4%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8IWV2,https://www.uniprot.org/uniprotkb/Q8IWV2/entry,Contactins mediate cell surface interactions during nervous system development. Has some neurite outgrowth-promoting activity. May be involved in synaptogenesis,"Mainly expressed in brain. Highly expressed in cerebellum and weakly expressed in corpus callosum, caudate nucleus, amygdala and spinal cord. Also expressed in testis, pancreas, thyroid, uterus, small intestine and kidney. Not expressed in skeletal muscle. Isoform 2 is weakly expressed in cerebral cortex",,,Cell membrane Secreted,,11013081|14571131,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
COL10A1,ENSG00000123500,Unsafe,RNA,False,True,5.7,8.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,lung: 2.8 nTPM; absolute ceiling;continuous selectivity; pancreas: 3.2 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 2.4 nTPM; continuous selectivity; salivary gland: 2.6 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,lung: 2.8 nTPM (limit 2); pancreas: 3.2 nTPM (limit 2); lung: 2.8 nTPM (baseline 2); pancreas: 3.2 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Adenocarcinoma (validation): 104/105 (99.0%); Lung Squamous Cell Carcinoma (validation): 67/68 (98.5%); Pancreatic Adenocarcinoma (validation): 76/80 (95.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q03692,https://www.uniprot.org/uniprotkb/Q03692/entry,Type X collagen is a product of hypertrophic chondrocytes and has been localized to presumptive mineralization zones of hyaline cartilage,,"Schmid type metaphyseal chondrodysplasia: Dominantly inherited disorder of the osseous skeleton. The cardinal features of the phenotype are mild short stature, coxa vara and a waddling gait. Radiography usually shows sclerosis of the ribs, flaring of the metaphyses, and a wide irregular growth plate, especially of the knees. A variant form of SMCD is spondylometaphyseal dysplasia Japanese type. It is characterized by spinal involvement comprising mild platyspondyly, vertebral body abnormalities, and end-plate irregularity.",,"Secreted, extracellular space, extracellular matrix",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
COL20A1,ENSG00000101203,Unsafe,RNA,False,True,2.4,9.0,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,amygdala: 7.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 4.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 1.9 nTPM; continuous selectivity; cerebral cortex: 9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 0.8 nTPM; continuous selectivity; hippocampal formation: 6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 3.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 1 nTPM; continuous selectivity; spinal cord: 4.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 7.5 nTPM (limit 2); basal ganglia: 4.3 nTPM (limit 2); cerebral cortex: 9 nTPM (limit 2); hippocampal formation: 6 nTPM (limit 2); hypothalamus: 3.2 nTPM (limit 2); midbrain: 5 nTPM (limit 2); spinal cord: 4.2 nTPM (limit 2); amygdala: 7.5 nTPM (baseline 2); basal ganglia: 4.3 nTPM (baseline 2); cerebral cortex: 9 nTPM (baseline 2); hippocampal formation: 6 nTPM (baseline 2); hypothalamus: 3.2 nTPM (baseline 2); midbrain: 5 nTPM (baseline 2); spinal cord: 4.2 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 85/141 (60.3%); Glioblastoma Multiforme (validation): 29/58 (50.0%); Skin Cuteneous Melanoma (TCGA): 8/99 (8.1%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9P218,https://www.uniprot.org/uniprotkb/Q9P218/entry,Probable collagen protein,"High expression in heart, lung, liver, skeletal muscle, kidney, pancreas, spleen, testis, ovary, subthalamic nucleus and fetal liver. Weak expression in other tissues tested",,,"Secreted, extracellular space",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CORO7,ENSG00000262246,Unsafe,Protein,False,True,26.7,68.7,79,22,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 15 nTPM; absolute ceiling;continuous selectivity; adrenal gland: 15.3 nTPM; absolute ceiling;continuous selectivity; amygdala: 13.8 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 24.1 nTPM; absolute ceiling;continuous selectivity; bone marrow: 68.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 12.4 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 17.5 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 6.1 nTPM; absolute ceiling; colon: 19.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 14.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 10.6 nTPM; absolute ceiling;continuous selectivity; heart muscle: 11.3 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 20.6 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 13 nTPM; absolute ceiling;continuous selectivity; kidney: 15.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 8.6 nTPM; absolute ceiling;continuous selectivity; lung: 26.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 23.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 15.5 nTPM; absolute ceiling;continuous selectivity; pancreas: 10.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 13.1 nTPM; absolute ceiling;continuous selectivity; rectum: 4.5 nTPM; positive ihc; salivary gland: 13 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 6.2 nTPM; positive ihc;absolute ceiling; skin: 11.3 nTPM; positive ihc;absolute ceiling; small intestine: 30.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 5.3 nTPM; positive ihc;absolute ceiling; spinal cord: 20.3 nTPM; absolute ceiling;continuous selectivity; spleen: 55.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; stomach: 14.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 10.6 nTPM; absolute ceiling; thyroid gland: 14 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 14.1 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 15 nTPM (limit 10); adrenal gland: 15.3 nTPM (limit 2); amygdala: 13.8 nTPM (limit 2); basal ganglia: 24.1 nTPM (limit 2); bone marrow: 68.7 nTPM (limit 2); cerebellum: 12.4 nTPM (limit 2); cerebral cortex: 17.5 nTPM (limit 2); choroid plexus: 6.1 nTPM (limit 2); colon: 19.8 nTPM (limit 6); duodenum: 14.7 nTPM (limit 2); esophagus: 10.6 nTPM (limit 6); heart muscle: 11.3 nTPM (limit 2); hippocampal formation: 20.6 nTPM (limit 2); hypothalamus: 13 nTPM (limit 2); kidney: 15.1 nTPM (limit 2); liver: 8.6 nTPM (limit 2); lung: 26.7 nTPM (limit 2); lymph node: 23.7 nTPM (limit 6); midbrain: 15.5 nTPM (limit 2); pancreas: 10.5 nTPM (limit 2); pituitary gland: 13.1 nTPM (limit 2); salivary gland: 13 nTPM (limit 6); skeletal muscle: 6.2 nTPM (limit 2); skin: 11.3 nTPM (limit 10); small intestine: 30.2 nTPM (limit 2); smooth muscle: 5.3 nTPM (limit 2); spinal cord: 20.3 nTPM (limit 2); spleen: 55.2 nTPM (limit 10); stomach: 14.9 nTPM (limit 6); thymus: 10.6 nTPM (limit 10); thyroid gland: 14 nTPM (limit 10); urinary bladder: 14.1 nTPM (limit 6); adipose tissue: 15 nTPM (baseline 10); adrenal gland: 15.3 nTPM (baseline 2); amygdala: 13.8 nTPM (baseline 2); basal ganglia: 24.1 nTPM (baseline 2); bone marrow: 68.7 nTPM (baseline 2); cerebellum: 12.4 nTPM (baseline 2); cerebral cortex: 17.5 nTPM (baseline 2); choroid plexus: 6.1 nTPM (baseline 2); colon: 19.8 nTPM (baseline 6); duodenum: 14.7 nTPM (baseline 2); esophagus: 10.6 nTPM (baseline 6); heart muscle: 11.3 nTPM (baseline 2); hippocampal formation: 20.6 nTPM (baseline 2); hypothalamus: 13 nTPM (baseline 2); kidney: 15.1 nTPM (baseline 2); liver: 8.6 nTPM (baseline 2); lung: 26.7 nTPM (baseline 2); lymph node: 23.7 nTPM (baseline 6); midbrain: 15.5 nTPM (baseline 2); pancreas: 10.5 nTPM (baseline 2); pituitary gland: 13.1 nTPM (baseline 2); salivary gland: 13 nTPM (baseline 6); skeletal muscle: 6.2 nTPM (baseline 2); skin: 11.3 nTPM (baseline 10); small intestine: 30.2 nTPM (baseline 2); smooth muscle: 5.3 nTPM (baseline 2); spinal cord: 20.3 nTPM (baseline 2); spleen: 55.2 nTPM (baseline 10); stomach: 14.9 nTPM (baseline 6); thymus: 10.6 nTPM (baseline 10); thyroid gland: 14 nTPM (baseline 10); urinary bladder: 14.1 nTPM (baseline 6),bone marrow / hematopoietic cells: Low (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); colon / glandular cells: High (Uncertain); duodenum / glandular cells: High (Uncertain); kidney / cells in glomeruli: Medium (Uncertain); kidney / cells in tubules: Low (Uncertain); lung / macrophages: Low (Uncertain); lymph node / non-germinal center cells: Medium (Uncertain); pancreas / exocrine glandular cells: Low (Uncertain); rectum / glandular cells: High (Uncertain); skeletal muscle / myocytes: Medium (Uncertain); skin 2 / epidermal cells: Low (Uncertain); small intestine / glandular cells: High (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); spleen / cells in red pulp: Medium (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Low (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Rectum Adenocarcinoma (TCGA): 88/88 (100.0%); Colon Adenocarcinoma (TCGA): 252/254 (99.2%),colorectal cancer: 4/12 (33.3%); liver cancer: 2/10 (20.0%),31,20,P57737,https://www.uniprot.org/uniprotkb/P57737/entry,"F-actin regulator involved in anterograde Golgi to endosome transport: upon ubiquitination via 'Lys-33'-linked ubiquitin chains by the BCR(KLHL20) E3 ubiquitin ligase complex, interacts with EPS15 and localizes to the trans-Golgi network, where it promotes actin polymerization, thereby facilitating post-Golgi trafficking. May play a role in the maintenance of the Golgi apparatus morphology","Widely expressed. Expressed in the spleen, peripheral leukocytes, testes, brain, thymus and small intestine",,Reported to form a E3 ubiquitin-ligase complex and promote degradation of TOB1 (PubMed:21130766). Additional evidence is however required to confirm these data,"Golgi apparatus membrane Golgi apparatus, trans-Golgi network Cytoplasmic vesicle Cytoplasm, cytosol",16905771|24768539,21130766,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
COX6B2,ENSG00000160471,Unsafe,RNA,False,True,88.0,88.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,colon: 6.5 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,colon: 6.5 nTPM (limit 6); colon: 6.5 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 142/283 (50.2%); Pancreatic Adenocarcinoma (TCGA): 85/176 (48.3%); Pancreatic Adenocarcinoma (validation): 34/80 (42.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q6YFQ2,https://www.uniprot.org/uniprotkb/Q6YFQ2/entry,"Component of the cytochrome c oxidase, the last enzyme in the mitochondrial electron transport chain which drives oxidative phosphorylation. The respiratory chain contains 3 multisubunit complexes succinate dehydrogenase (complex II, CII), ubiquinol-cytochrome c oxidoreductase (cytochrome b-c1 complex, complex III, CIII) and cytochrome c oxidase (complex IV, CIV), that cooperate to transfer electrons derived from NADH and succinate to molecular oxygen, creating an electrochemical gradient over the inner membrane that drives transmembrane transport and the ATP synthase. Cytochrome c oxidase is the component of the respiratory chain that catalyzes the reduction of oxygen to water. Electrons originating from reduced cytochrome c in the intermembrane space (IMS) are transferred via the dinuclear copper A center (CU(A)) of subunit 2 and heme A of subunit 1 to the active site in subunit 1, a binuclear center (BNC) formed by heme A3 and copper B (CU(B)). The BNC reduces molecular oxygen to 2 water molecules using 4 electrons from cytochrome c in the IMS and 4 protons from the mitochondrial matrix",Testis specific. Weak expression in thymus and heart. Expressed in cancer cell lines,,,Mitochondrion inner membrane,,12874793|15905330,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,Failed bulk numeric comparisons are within 20% of their cutoffs; not an automatic rescue,,,,
COX8C,ENSG00000187581,Unsafe,Protein,False,True,74.1,74.1,83,32,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; bone marrow: 0 nTPM; positive ihc; cerebral cortex: 0.1 nTPM; positive ihc; colon: 0.1 nTPM; positive ihc; duodenum: 0 nTPM; positive ihc; esophagus: 0 nTPM; positive ihc; kidney: 0.2 nTPM; positive ihc; lung: 0 nTPM; positive ihc; lymph node: 0 nTPM; positive ihc; pancreas: 0.1 nTPM; positive ihc; skeletal muscle: 0.2 nTPM; positive ihc; skin: 0 nTPM; positive ihc; small intestine: 0 nTPM; positive ihc; urinary bladder: 0.1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,bone marrow / hematopoietic cells: Low (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); colon / endothelial cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Low (Approved); esophagus / squamous epithelial cells: Low (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: High (Approved); lung / macrophages: High (Approved); lymph node / germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Medium (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / fibroblasts: Medium (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: High (Approved); urinary bladder / urothelial cells: Low (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 27/133 (20.3%); Ovary Serous Cystadenocarcinoma (TCGA): 30/349 (8.6%); Ovary Serous Cystadenocarcinoma (validation): 4/81 (4.9%),glioma: 11/12 (91.7%); melanoma: 10/11 (90.9%),31,20,Q7Z4L0,https://www.uniprot.org/uniprotkb/Q7Z4L0/entry,"Component of the cytochrome c oxidase, the last enzyme in the mitochondrial electron transport chain which drives oxidative phosphorylation. The respiratory chain contains 3 multisubunit complexes succinate dehydrogenase (complex II, CII), ubiquinol-cytochrome c oxidoreductase (cytochrome b-c1 complex, complex III, CIII) and cytochrome c oxidase (complex IV, CIV), that cooperate to transfer electrons derived from NADH and succinate to molecular oxygen, creating an electrochemical gradient over the inner membrane that drives transmembrane transport and the ATP synthase. Cytochrome c oxidase is the component of the respiratory chain that catalyzes the reduction of oxygen to water. Electrons originating from reduced cytochrome c in the intermembrane space (IMS) are transferred via the dinuclear copper A center (CU(A)) of subunit 2 and heme A of subunit 1 to the active site in subunit 1, a binuclear center (BNC) formed by heme A3 and copper B (CU(B)). The BNC reduces molecular oxygen to 2 water molecules using 4 electrons from cytochrome c in the IMS and 4 protons from the mitochondrial matrix",It is not yet known where COX8C is expressed,,,Mitochondrion inner membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
CPA5,ENSG00000158525,Unsafe,High RNA,False,True,32.7,32.7,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE TREG_MEM (unstimulated): 33/89 values ≥5 TPM, max 41.2711; DICE CD4_NAIVE (unstimulated): 5/88 values ≥5 TPM, max 11.9908; DICE TREG_NAIVE (unstimulated): 38/89 values ≥5 TPM, max 52.2711; DICE TFH (unstimulated): 19/89 values ≥5 TPM, max 21.6476; DICE TH1 (unstimulated): 5/81 values ≥5 TPM, max 13.1213; DICE THSTAR (unstimulated): 4/88 values ≥5 TPM, max 5.84849; DICE TH17 (unstimulated): 12/89 values ≥5 TPM, max 13.3994; DICE TH2 (unstimulated): 10/89 values ≥5 TPM, max 15.3129; DICE CD8_NAIVE (unstimulated): 33/89 values ≥5 TPM, max 78.3194; DICE CD8_STIM (activated): 4/88 values ≥5 TPM, max 8.78523; hpa_immune_cell memory CD4 T-cell: 16.9 nTPM; hpa_immune_cell memory CD8 T-cell: 8.6 nTPM; hpa_immune_cell naive CD8 T-cell: 42.6 nTPM; hpa_immune_cell T-reg: 56.6 nTPM; hpa_immune_cell total PBMC: 5.8 nTPM",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,82.5412,106.6,"dice_cd8_naive: blood/CD8_NAIVE, max 78.3194 TPM, 6 observations >30; dice_treg_mem: blood/TREG_MEM, max 41.2711 TPM, 3 observations >30; dice_treg_naive: blood/TREG_NAIVE, max 52.2711 TPM, 3 observations >30; hpa_immune_cell: blood/T-reg, max 56.6 nTPM, 1 observations >30; hpa_immune_cell: blood/naive CD8 T-cell, max 42.6 nTPM, 1 observations >30; hpa_immune_cell_samples: blood/T-reg, max 82.5412 TPM, 5 observations >30; hpa_immune_cell_samples: blood/memory CD4 T-cell, max 32.0841 TPM, 1 observations >30; hpa_immune_cell_samples: blood/naive CD8 T-cell, max 66.286 TPM, 4 observations >30; hpa_immune_cell_samples: blood/T-reg, max 99.4516 nTPM, 5 observations >30; hpa_immune_cell_samples: blood/memory CD4 T-cell, max 39.018 nTPM, 1 observations >30; hpa_immune_cell_samples: blood/naive CD8 T-cell, max 64.9796 nTPM, 4 observations >30; hpa_single_cell_tissue: pbmc/t-cells, max 106.6 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,82.54 TPM; blood/T-reg; hpa_immune_cell_samples; vital,106.6 nTPM; pbmc/t-cells; hpa_single_cell_tissue; vital,Pancreatic Adenocarcinoma (TCGA): 6/176 (3.4%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 8/283 (2.8%); Bladder Urothelial Carcinoma (TCGA): 4/169 (2.4%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8WXQ8,https://www.uniprot.org/uniprotkb/Q8WXQ8/entry,,Expression is very low or not detectable,,,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
CPT1A,ENSG00000110090,Unsafe,Protein,False,True,24.6,69.3,100,82,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 23.5 nTPM; continuous selectivity; adrenal gland: 26.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 12.5 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 18.1 nTPM; absolute ceiling;continuous selectivity; bone marrow: 38.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 4.8 nTPM; positive ihc;absolute ceiling; cerebral cortex: 13.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 18.9 nTPM; absolute ceiling;continuous selectivity; colon: 65.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 68.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 21.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 24.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 9.6 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 9.3 nTPM; absolute ceiling;continuous selectivity; kidney: 37.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 65.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 24.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 15.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 13.7 nTPM; absolute ceiling;continuous selectivity; pancreas: 22.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 26.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 14 nTPM; absolute ceiling;continuous selectivity; rectum: 43.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; retina: 21.9 nTPM; absolute ceiling;continuous selectivity; salivary gland: 25.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 9.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 16.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 69.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 33.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 6 nTPM; absolute ceiling; spleen: 26.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; stomach: 34.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; thymus: 13.6 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 15 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 13.7 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 18.1 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 26.8 nTPM (limit 2); amygdala: 12.5 nTPM (limit 2); basal ganglia: 18.1 nTPM (limit 2); bone marrow: 38.4 nTPM (limit 2); cerebellum: 4.8 nTPM (limit 2); cerebral cortex: 13.3 nTPM (limit 2); choroid plexus: 18.9 nTPM (limit 2); colon: 65.2 nTPM (limit 6); duodenum: 68.7 nTPM (limit 2); esophagus: 21.3 nTPM (limit 6); heart muscle: 24.6 nTPM (limit 2); hippocampal formation: 9.6 nTPM (limit 2); hypothalamus: 9.3 nTPM (limit 2); kidney: 37.1 nTPM (limit 2); liver: 65.9 nTPM (limit 2); lung: 24.6 nTPM (limit 2); lymph node: 15.5 nTPM (limit 6); midbrain: 13.7 nTPM (limit 2); pancreas: 22.9 nTPM (limit 2); parathyroid gland: 26.7 nTPM (limit 6); pituitary gland: 14 nTPM (limit 2); rectum: 43.2 nTPM (limit 6); retina: 21.9 nTPM (limit 2); salivary gland: 25.2 nTPM (limit 6); skeletal muscle: 9.6 nTPM (limit 2); skin: 16.4 nTPM (limit 10); small intestine: 69.3 nTPM (limit 2); smooth muscle: 33.6 nTPM (limit 2); spinal cord: 6 nTPM (limit 2); spleen: 26.7 nTPM (limit 10); stomach: 34.7 nTPM (limit 6); thymus: 13.6 nTPM (limit 10); thyroid gland: 15 nTPM (limit 10); tongue: 13.7 nTPM (limit 6); urinary bladder: 18.1 nTPM (limit 6),adrenal gland / glandular cells: High (Supported); bone marrow / hematopoietic cells: Low (Supported); bronchus / basal cells: High (Supported); bronchus / ciliated cells (cell body): High (Supported); bronchus / goblet cells: High (Supported); caudate / glial cells: Low (Supported); caudate / neuronal cells: Medium (Supported); cerebellum / cells in granular layer: Low (Supported); cerebellum / cells in molecular layer: Low (Supported); cerebellum / Purkinje cells: Medium (Supported); cerebral cortex / endothelial cells: Medium (Supported); cerebral cortex / glial cells: Low (Supported); cerebral cortex / neuronal cells: Low (Supported); cerebral cortex / neuropil: Low (Supported); colon / endothelial cells: Medium (Supported); colon / glandular cells: High (Supported); colon / peripheral nerve/ganglion: Medium (Supported); duodenum / glandular cells: High (Supported); esophagus / squamous epithelial cells: Low (Supported); heart muscle / cardiomyocytes: Medium (Supported); hippocampus / glial cells: Low (Supported); hippocampus / neuronal cells: Medium (Supported); kidney / cells in glomeruli: Low (Supported); kidney / cells in tubules: High (Supported); liver / cholangiocytes: Low (Supported); liver / hepatocytes: Medium (Supported); lung / alveolar cells type I: Low (Supported); lung / alveolar cells type II: Low (Supported); lung / macrophages: Low (Supported); lymph node / germinal center cells: Low (Supported); lymph node / non-germinal center cells: Low (Supported); nasopharynx / basal cells: Medium (Supported); nasopharynx / ciliated cells (cell body): Medium (Supported); oral mucosa / squamous epithelial cells: Low (Supported); pancreas / exocrine glandular cells: Low (Supported); pancreas / pancreatic endocrine cells: Low (Supported); parathyroid gland / glandular cells: Medium (Supported); rectum / glandular cells: High (Supported); salivary gland / glandular cells: High (Supported); skeletal muscle / myocytes: Medium (Supported); skin 1 / fibroblasts: Medium (Supported); skin 1 / keratinocytes: Low (Supported); skin 1 / Langerhans: Low (Supported); skin 2 / epidermal cells: Low (Supported); small intestine / glandular cells: High (Supported); smooth muscle / smooth muscle cells: Low (Supported); spleen / cells in red pulp: Low (Supported); spleen / cells in white pulp: Low (Supported); stomach 1 / glandular cells: Medium (Supported); stomach 2 / glandular cells: Low (Supported); thyroid gland / glandular cells: Low (Supported); urinary bladder / urothelial cells: Low (Supported),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Stomach Adenocarcinoma (TCGA): 346/346 (100.0%); Colon Adenocarcinoma (TCGA): 254/254 (100.0%),liver cancer: 10/11 (90.9%); ovarian cancer: 9/10 (90.0%),31,20,P50416,https://www.uniprot.org/uniprotkb/P50416/entry,"Catalyzes the transfer of the acyl group of long-chain fatty acid-CoA conjugates onto carnitine, an essential step for the mitochondrial uptake of long-chain fatty acids and their subsequent beta-oxidation in the mitochondrion (PubMed:11350182, PubMed:14517221, PubMed:16651524, PubMed:9691089). Also possesses a lysine succinyltransferase activity that can regulate enzymatic activity of substrate proteins such as ENO1 and metabolism independent of its classical carnitine O-palmitoyltransferase activity (PubMed:29425493). Plays an important role in hepatic triglyceride metabolism (By similarity). Also plays a role in inducible regulatory T-cell (iTreg) differentiation once activated by butyryl-CoA that antagonizes malonyl-CoA-mediated CPT1A repression (By similarity). Sustains the IFN-I response by recruiting ZDHCC4 to palmitoylate MAVS at the mitochondria leading to MAVS stabilization and activation (PubMed:38016475). Promotes ROS-induced oxidative stress in liver injury via modulation of NFE2L2 and NLRP3-mediated signaling pathways (By similarity)","Strong expression in kidney and heart, and lower in liver and skeletal muscle",Carnitine palmitoyltransferase 1A deficiency: Rare autosomal recessive metabolic disorder of long-chain fatty acid oxidation characterized by severe episodes of hypoketotic hypoglycemia usually occurring after fasting or illness. Onset is in infancy or early childhood.,,Mitochondrion outer membrane,11350182|14517221|16651524|29425493|38016475|9691089,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
CPT1C,ENSG00000169169,Unsafe,Protein,False,True,7.8,28.5,79,9,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 5.2 nTPM; absolute ceiling;continuous selectivity; amygdala: 18.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 23.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 26.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 25.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 28.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 3.7 nTPM; continuous selectivity; hippocampal formation: 20.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 20.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 1.6 nTPM; positive ihc; midbrain: 12.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 27.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; retina: 12.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 0.9 nTPM; positive ihc; smooth muscle: 4.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 11.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 4.8 nTPM; continuous selectivity; stomach: 1.5 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 5.2 nTPM (limit 4); amygdala: 18.1 nTPM (limit 2); basal ganglia: 23.6 nTPM (limit 2); cerebellum: 26.8 nTPM (limit 2); cerebral cortex: 25.2 nTPM (limit 2); choroid plexus: 28.5 nTPM (limit 2); hippocampal formation: 20.7 nTPM (limit 2); hypothalamus: 20.4 nTPM (limit 2); midbrain: 12.1 nTPM (limit 2); pituitary gland: 27.6 nTPM (limit 2); retina: 12.1 nTPM (limit 2); smooth muscle: 4.4 nTPM (limit 2); spinal cord: 11.7 nTPM (limit 2),caudate / neuronal cells: Low (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in tubules: Low (Approved); salivary gland / glandular cells: Low (Approved); smooth muscle / smooth muscle cells: Low (Approved); stomach 1 / glandular cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 140/141 (99.3%); Glioblastoma Multiforme (validation): 57/58 (98.3%); Breast Invasive Carcinoma (validation): 42/50 (84.0%),breast cancer: 0/12 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q8TCG5,https://www.uniprot.org/uniprotkb/Q8TCG5/entry,"Palmitoyl thioesterase specifically expressed in the endoplasmic reticulum of neurons. Modulates the trafficking of the glutamate receptor, AMPAR, to plasma membrane through depalmitoylation of GRIA1 (PubMed:30135643). Also regulates AMPR trafficking through the regulation of SACM1L phosphatidylinositol-3-phosphatase activity by interaction in a malonyl-CoA dependent manner (By similarity). Binds malonyl-CoA and couples malonyl-CoA to ceramide levels, necessary for proper spine maturation and contributing to systemic energy homeostasis and appetite control (PubMed:16651524). Binds to palmitoyl-CoA, but does not have carnitine palmitoyltransferase 1 catalytic activity or at very low levels (PubMed:25751282, PubMed:30135643)",Expressed predominantly in brain and testis. Expressed in motor neurons,"Spastic paraplegia 73, autosomal dominant: A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body.","In contrast to its paralogs, CPT1A and CPT1B, does not have, or at very low levels, carnitine O-palmitoyltransferase activity (EC:2.3.1.21) in vivo, being unable to catalyze the transfer of the acyl group of long-chain fatty acid-CoA conjugates onto carnitine. This is in agreement with its expression specific to neurons which is a cell-type that does not use fatty acids as fuel to any major extent and the fact that it locates to endoplasmic reticulum instead of mitochondria","Cell projection, dendrite Cell projection, axon Endoplasmic reticulum membrane",16651524|25751282|30135643,12376098|25751282,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
CRACD,ENSG00000109265,Unsafe,Protein,False,True,28.4,28.4,81,52,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0.4 nTPM; positive ihc; adrenal gland: 2.1 nTPM; positive ihc;absolute ceiling; amygdala: 2.3 nTPM; absolute ceiling; bone marrow: 3.9 nTPM; positive ihc;absolute ceiling; cerebellum: 2.5 nTPM; positive ihc;absolute ceiling; cerebral cortex: 5.7 nTPM; positive ihc;absolute ceiling; colon: 8.8 nTPM; positive ihc;absolute ceiling; duodenum: 12.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 0.5 nTPM; positive ihc; heart muscle: 0.8 nTPM; positive ihc; hippocampal formation: 2.2 nTPM; absolute ceiling; hypothalamus: 4.1 nTPM; absolute ceiling; kidney: 0.7 nTPM; positive ihc; midbrain: 3.5 nTPM; absolute ceiling; pancreas: 1.3 nTPM; positive ihc; parathyroid gland: 5.8 nTPM; positive ihc; rectum: 7.5 nTPM; positive ihc;absolute ceiling; retina: 4.1 nTPM; absolute ceiling; salivary gland: 1 nTPM; positive ihc; skin: 0.5 nTPM; positive ihc; small intestine: 18.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 4.1 nTPM; positive ihc;absolute ceiling; spinal cord: 2.4 nTPM; absolute ceiling; stomach: 2.6 nTPM; positive ihc; thyroid gland: 0.1 nTPM; positive ihc; urinary bladder: 1.2 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 2.1 nTPM (limit 2); amygdala: 2.3 nTPM (limit 2); bone marrow: 3.9 nTPM (limit 2); cerebellum: 2.5 nTPM (limit 2); cerebral cortex: 5.7 nTPM (limit 2); colon: 8.8 nTPM (limit 6); duodenum: 12.9 nTPM (limit 2); hippocampal formation: 2.2 nTPM (limit 2); hypothalamus: 4.1 nTPM (limit 2); midbrain: 3.5 nTPM (limit 2); rectum: 7.5 nTPM (limit 6); retina: 4.1 nTPM (limit 2); small intestine: 18.8 nTPM (limit 2); smooth muscle: 4.1 nTPM (limit 2); spinal cord: 2.4 nTPM (limit 2); adrenal gland: 2.1 nTPM (baseline 2); amygdala: 2.3 nTPM (baseline 2); bone marrow: 3.9 nTPM (baseline 2); cerebellum: 2.5 nTPM (baseline 2); cerebral cortex: 5.7 nTPM (baseline 2); colon: 8.8 nTPM (baseline 6); duodenum: 12.9 nTPM (baseline 2); hippocampal formation: 2.2 nTPM (baseline 2); hypothalamus: 4.1 nTPM (baseline 2); midbrain: 3.5 nTPM (baseline 2); rectum: 7.5 nTPM (baseline 6); retina: 4.1 nTPM (baseline 2); small intestine: 18.8 nTPM (baseline 2); smooth muscle: 4.1 nTPM (baseline 2); spinal cord: 2.4 nTPM (baseline 2),adipose tissue / adipocytes: Low (Uncertain); adrenal gland / glandular cells: Low (Uncertain); bone marrow / hematopoietic cells: Low (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / glial cells: Low (Uncertain); caudate / neuronal cells: Low (Uncertain); cerebellum / cells in granular layer: Low (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / neuronal cells: Low (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / endothelial cells: Low (Uncertain); colon / glandular cells: High (Uncertain); colon / peripheral nerve/ganglion: Low (Uncertain); duodenum / glandular cells: High (Uncertain); esophagus / squamous epithelial cells: Low (Uncertain); heart muscle / cardiomyocytes: Low (Uncertain); hippocampus / glial cells: Low (Uncertain); hippocampus / neuronal cells: Low (Uncertain); kidney / cells in glomeruli: Medium (Uncertain); kidney / cells in tubules: Medium (Uncertain); nasopharynx / respiratory epithelial cells: Low (Uncertain); oral mucosa / squamous epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Low (Uncertain); pancreas / pancreatic endocrine cells: Low (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: High (Uncertain); salivary gland / glandular cells: Low (Uncertain); skin 1 / fibroblasts: Low (Uncertain); skin 1 / keratinocytes: Low (Uncertain); skin 2 / epidermal cells: Low (Uncertain); small intestine / glandular cells: High (Uncertain); smooth muscle / smooth muscle cells: Low (Uncertain); stomach 1 / glandular cells: High (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Rectum Adenocarcinoma (validation): 200/207 (96.6%); Colon Adenocarcinoma (validation): 468/486 (96.3%),melanoma: 6/8 (75.0%); pancreatic cancer: 6/9 (66.7%),29,20,Q6ZU35,https://www.uniprot.org/uniprotkb/Q6ZU35/entry,"Involved in epithelial cell integrity by acting on the maintenance of the actin cytoskeleton. Positively regulates the actin polymerization, by inhibiting the interaction of actin-capping proteins with actin",Expressed in intestinal epithelial cells (at protein level),,,"Cytoplasm, cytosol",30361697,30361697,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Jamin2021_CT | Jamin2021_core | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CRB1,ENSG00000134376,Unsafe,Protein,False,True,2.8,72.4,90,2,Positive somewhere,True,True,False,False,Excluded,Normal,False,,Not assessed,,,positive ihc outside permitted; amygdala: 11.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 11.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 9.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 11.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 9.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 6.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 4.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 2.1 nTPM; absolute ceiling;continuous selectivity; retina: 72.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 3.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 11.6 nTPM (limit 2); basal ganglia: 11.8 nTPM (limit 2); cerebellum: 9.5 nTPM (limit 4); cerebral cortex: 11.8 nTPM (limit 4); hippocampal formation: 9.7 nTPM (limit 2); hypothalamus: 6.5 nTPM (limit 2); midbrain: 4.4 nTPM (limit 2); pituitary gland: 2.1 nTPM (limit 2); retina: 72.4 nTPM (limit 2); spinal cord: 3.6 nTPM (limit 2); amygdala: 11.6 nTPM (baseline 2); basal ganglia: 11.8 nTPM (baseline 2); cerebellum: 9.5 nTPM (baseline 2); cerebral cortex: 11.8 nTPM (baseline 2); hippocampal formation: 9.7 nTPM (baseline 2); hypothalamus: 6.5 nTPM (baseline 2); midbrain: 4.4 nTPM (baseline 2); pituitary gland: 2.1 nTPM (baseline 2); retina: 72.4 nTPM (baseline 2); spinal cord: 3.6 nTPM (baseline 2),retina / outer plexiform layer: Low (Approved); retina / photoreceptor cells: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 55/58 (94.8%); Glioblastoma Multiforme (TCGA): 123/141 (87.2%); Skin Cuteneous Melanoma (TCGA): 6/99 (6.1%),liver cancer: 1/12 (8.3%); pancreatic cancer: 1/12 (8.3%),31,20,P82279,https://www.uniprot.org/uniprotkb/P82279/entry,Plays a role in photoreceptor morphogenesis in the retina (By similarity). May maintain cell polarization and adhesion (By similarity),"Preferential expression in retina, also expressed in brain, testis, fetal brain and fetal eye (PubMed:15914641). Expressed at the outer limiting membrane and apical to adherens junctions in the retina (PubMed:15914641)","Retinitis pigmentosa 12: A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. RP12 is an autosomal recessive, severe form often manifesting in early childhood. Patients experiment progressive visual field loss with severe visual impairment before the age of twenty. Some patients have a preserved paraarteriolar retinal pigment epithelium (PPRPE) and hypermetropia. Leber congenital amaurosis 8: A severe dystrophy of the retina, typically becoming evident in the first years of life. Visual function is usually poor and often accompanied by nystagmus, sluggish or near-absent pupillary responses, photophobia, high hyperopia and keratoconus. Pigmented paravenous chorioretinal atrophy: Unusual retinal degeneration characterized by accumulation of pigmentation along retinal veins. PPCRA is dominantly inherited, but exhibited variable expressivity. Males are more likely to exhibit a severe phenotype, whereas females may remain virtually asymptomatic even in later years. The PPCRA phenotype is associated with a mutation in CRB1 gene which is likely to affect the structure of the CRB1 protein.",,"Apical cell membrane Secreted Cell projection, cilium, photoreceptor outer segment Photoreceptor inner segment",,15914641,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CRCP,ENSG00000241258,Unsafe,Protein,False,True,17.0,36.7,94,74,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 13 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 14.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 13.3 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 13.5 nTPM; absolute ceiling;continuous selectivity; bone marrow: 36.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 14.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 17.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 8.5 nTPM; absolute ceiling;continuous selectivity; colon: 17.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 16.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 19.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 16.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 12.7 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 14.5 nTPM; absolute ceiling;continuous selectivity; kidney: 15.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 25.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 14.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 15.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 13.9 nTPM; absolute ceiling;continuous selectivity; pancreas: 19.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 20.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 10.8 nTPM; absolute ceiling;continuous selectivity; rectum: 18.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; retina: 13.8 nTPM; absolute ceiling;continuous selectivity; salivary gland: 15.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 14.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 15.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 14.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 17.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 13.7 nTPM; absolute ceiling;continuous selectivity; spleen: 16.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 17.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; thymus: 14.6 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 19.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; tongue: 13 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 15.9 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 13 nTPM (limit 10); adrenal gland: 14.7 nTPM (limit 2); amygdala: 13.3 nTPM (limit 2); basal ganglia: 13.5 nTPM (limit 2); bone marrow: 36.7 nTPM (limit 4); cerebellum: 14.6 nTPM (limit 2); cerebral cortex: 17.8 nTPM (limit 2); choroid plexus: 8.5 nTPM (limit 2); colon: 17.7 nTPM (limit 6); duodenum: 16.2 nTPM (limit 2); esophagus: 19.3 nTPM (limit 8); heart muscle: 16.8 nTPM (limit 2); hippocampal formation: 12.7 nTPM (limit 2); hypothalamus: 14.5 nTPM (limit 2); kidney: 15.9 nTPM (limit 2); liver: 25.8 nTPM (limit 2); lung: 14.1 nTPM (limit 2); lymph node: 15.9 nTPM (limit 6); midbrain: 13.9 nTPM (limit 2); pancreas: 19.9 nTPM (limit 2); parathyroid gland: 20.4 nTPM (limit 6); pituitary gland: 10.8 nTPM (limit 2); rectum: 18.9 nTPM (limit 6); retina: 13.8 nTPM (limit 2); salivary gland: 15.6 nTPM (limit 6); skeletal muscle: 14.2 nTPM (limit 2); skin: 15.6 nTPM (limit 10); small intestine: 14.3 nTPM (limit 2); smooth muscle: 17.5 nTPM (limit 2); spinal cord: 13.7 nTPM (limit 2); spleen: 16.9 nTPM (limit 10); stomach: 17.3 nTPM (limit 6); thymus: 14.6 nTPM (limit 10); thyroid gland: 19.4 nTPM (limit 10); tongue: 13 nTPM (limit 6); urinary bladder: 15.9 nTPM (limit 6),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: Low (Approved); bronchus / ciliated cells (cell body): Medium (Approved); bronchus / ciliated cells (cilia axoneme): High (Approved); bronchus / ciliated cells (ciliary rootlets): High (Approved); bronchus / ciliated cells (tip of cilia): High (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: High (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Low (Approved); lymph node / germinal center cells: Low (Approved); nasopharynx / basal cells: Medium (Approved); nasopharynx / ciliated cells (cell body): High (Approved); nasopharynx / ciliated cells (cilia axoneme): High (Approved); nasopharynx / ciliated cells (ciliary rootlets): High (Approved); nasopharynx / ciliated cells (tip of cilia): High (Approved); nasopharynx / goblet cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: High (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Low (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Low (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Low (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Lung Squamous Cell Carcinoma (TCGA): 489/489 (100.0%); Ovary Serous Cystadenocarcinoma (TCGA): 349/349 (100.0%),breast cancer: 4/11 (36.4%); lung cancer: 4/11 (36.4%),31,20,O75575,https://www.uniprot.org/uniprotkb/O75575/entry,"DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates (PubMed:20413673, PubMed:33558764, PubMed:34675218). Specific peripheric component of RNA polymerase III (Pol III) which synthesizes small non-coding RNAs including 5S rRNA, snRNAs, tRNAs and miRNAs from at least 500 distinct genomic loci. With POLR3H/RPC8 forms a mobile stalk that protrudes from Pol III core and functions primarily in transcription initiation (By similarity) (PubMed:20413673, PubMed:33558764, PubMed:33558766, PubMed:34675218). Pol III plays a key role in sensing and limiting infection by intracellular bacteria and DNA viruses. Acts as nuclear and cytosolic DNA sensor involved in innate immune response. Can sense non-self dsDNA that serves as template for transcription into dsRNA. The non-self RNA polymerase III transcripts, such as Epstein-Barr virus-encoded RNAs (EBERs) induce type I interferon and NF-kappa-B through the RIG-I pathway (PubMed:19609254, PubMed:19631370) Accessory protein for the calcitonin gene-related peptide (CGRP) receptor. It modulates CGRP responsiveness in a variety of tissues",Ubiquitous. Most prevalent in testis,,,Nucleus Cell membrane,19609254|19631370|20413673|33558764|33558766|34675218,10067875,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CREM,ENSG00000095794,Unsafe,Protein,False,True,203.3,203.3,150,43,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 131.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 38.6 nTPM; absolute ceiling; basal ganglia: 37 nTPM; absolute ceiling; bone marrow: 21.5 nTPM; positive ihc;absolute ceiling; cerebellum: 14.1 nTPM; positive ihc;absolute ceiling; cerebral cortex: 39.3 nTPM; absolute ceiling; choroid plexus: 55.7 nTPM; absolute ceiling;continuous selectivity; colon: 23.3 nTPM; positive ihc;absolute ceiling; duodenum: 8.5 nTPM; positive ihc;absolute ceiling; heart muscle: 47.7 nTPM; positive ihc;absolute ceiling; hippocampal formation: 34.4 nTPM; absolute ceiling; hypothalamus: 41.1 nTPM; absolute ceiling; kidney: 56.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 57.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 29.1 nTPM; positive ihc;absolute ceiling; midbrain: 34.7 nTPM; absolute ceiling; pancreas: 15.1 nTPM; positive ihc;absolute ceiling; parathyroid gland: 22.9 nTPM; positive ihc;absolute ceiling; pituitary gland: 57.7 nTPM; absolute ceiling;continuous selectivity; rectum: 13 nTPM; positive ihc;absolute ceiling; retina: 21.7 nTPM; absolute ceiling; salivary gland: 13.2 nTPM; positive ihc;absolute ceiling; skeletal muscle: 28.1 nTPM; positive ihc;absolute ceiling; skin: 8.5 nTPM; positive ihc; small intestine: 15.1 nTPM; positive ihc;absolute ceiling; smooth muscle: 23.4 nTPM; absolute ceiling; spinal cord: 35.1 nTPM; absolute ceiling; stomach: 19.7 nTPM; positive ihc;absolute ceiling; thymus: 28.4 nTPM; absolute ceiling; tongue: 29.4 nTPM; absolute ceiling; urinary bladder: 58 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 131.7 nTPM (limit 2); amygdala: 38.6 nTPM (limit 2); basal ganglia: 37 nTPM (limit 2); bone marrow: 21.5 nTPM (limit 2); cerebellum: 14.1 nTPM (limit 2); cerebral cortex: 39.3 nTPM (limit 12); choroid plexus: 55.7 nTPM (limit 2); colon: 23.3 nTPM (limit 6); duodenum: 8.5 nTPM (limit 2); heart muscle: 47.7 nTPM (limit 2); hippocampal formation: 34.4 nTPM (limit 2); hypothalamus: 41.1 nTPM (limit 2); kidney: 56.3 nTPM (limit 2); liver: 57.9 nTPM (limit 2); lung: 29.1 nTPM (limit 2); midbrain: 34.7 nTPM (limit 2); pancreas: 15.1 nTPM (limit 2); parathyroid gland: 22.9 nTPM (limit 6); pituitary gland: 57.7 nTPM (limit 2); rectum: 13 nTPM (limit 6); retina: 21.7 nTPM (limit 2); salivary gland: 13.2 nTPM (limit 6); skeletal muscle: 28.1 nTPM (limit 2); small intestine: 15.1 nTPM (limit 2); smooth muscle: 23.4 nTPM (limit 12); spinal cord: 35.1 nTPM (limit 2); stomach: 19.7 nTPM (limit 6); thymus: 28.4 nTPM (limit 10); tongue: 29.4 nTPM (limit 6); urinary bladder: 58 nTPM (limit 24),adrenal gland / glandular cells: Medium (Enhanced); bone marrow / hematopoietic cells: Low (Enhanced); bronchus / respiratory epithelial cells: Medium (Enhanced); cerebellum / Purkinje cells - cytoplasm/membrane: Low (Enhanced); colon / goblet cells: Medium (Enhanced); colon / mucosal lymphoid cells: Low (Enhanced); duodenum / glands of Brunner: Low (Enhanced); duodenum / goblet cells: Medium (Enhanced); heart muscle / cardiomyocytes: Low (Enhanced); kidney / proximal tubules (cell body): Medium (Enhanced); liver / hepatocytes: Low (Enhanced); lung / macrophages: Medium (Enhanced); nasopharynx / respiratory epithelial cells: Low (Enhanced); pancreas / exocrine glandular cells: Low (Enhanced); parathyroid gland / glandular cells: Low (Enhanced); rectum / endothelial cells: Low (Enhanced); rectum / goblet cells: Low (Enhanced); rectum / mucosal lymphoid cells: Low (Enhanced); salivary gland / glandular cells: Low (Enhanced); skeletal muscle / myocytes: Medium (Enhanced); skin 1 / endothelial cells: Low (Enhanced); skin 1 / extracellular matrix: Low (Enhanced); skin 1 / fibrohistiocytic cells: Low (Enhanced); skin 2 / extracellular matrix: Low (Enhanced); skin 2 / fibrohistiocytic cells: Low (Enhanced); small intestine / goblet cells: Medium (Enhanced); stomach 1 / glandular cells: Low (Enhanced); stomach 2 / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Renal Clear Cell Carcinoma (TCGA): 521/521 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%); Lung Squamous Cell Carcinoma (TCGA): 489/489 (100.0%),pancreatic cancer: 4/11 (36.4%); prostate cancer: 3/10 (30.0%),31,20,Q03060,https://www.uniprot.org/uniprotkb/Q03060/entry,"Transcriptional regulator that binds the cAMP response element (CRE), a sequence present in many viral and cellular promoters. Isoforms are either transcriptional activators or repressors. Plays a role in spermatogenesis and is involved in spermatid maturation (PubMed:10373550) May play a role in the regulation of the circadian clock: acts as a transcriptional repressor of the core circadian component PER1 by directly binding to cAMP response elements in its promoter",Expressed in testes (round spermatids) (at protein level). Isoform 14 is the major activator form in testes,,,Nucleus Cytoplasm,10373550,11044457|14511788|16143638,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
CRH,ENSG00000147571,Unsafe,RNA,False,True,6.3,46.0,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,amygdala: 5.7 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 3.4 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 11.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 3.9 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 46 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 1.7 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 5.7 nTPM (limit 2); basal ganglia: 3.4 nTPM (limit 2); cerebral cortex: 11.5 nTPM (limit 2); hippocampal formation: 3.9 nTPM (limit 2); hypothalamus: 46 nTPM (limit 2); amygdala: 5.7 nTPM (baseline 2); basal ganglia: 3.4 nTPM (baseline 2); cerebral cortex: 11.5 nTPM (baseline 2); hippocampal formation: 3.9 nTPM (baseline 2); hypothalamus: 46 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Bladder Urothelial Carcinoma (TCGA): 43/169 (25.4%); Kidney Chromophobe (TCGA): 15/64 (23.4%); Pancreatic Adenocarcinoma (TCGA): 17/176 (9.7%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P06850,https://www.uniprot.org/uniprotkb/P06850/entry,"Hormone that plays a central role in whole body adaptation to stress (By similarity). Released by the hypothalamus primarily in response to physical or psychological stress and acts by binding to CRH receptor CRHR1, and to a lower extent, CRHR2 (PubMed:18801728, PubMed:3003585, PubMed:32004469). CRH-dependent signaling is a primary mediator of the neuroendocrine, autonomic (fight-or-flight) and behavioral responses to stress, acting as a key regulator of adaptation by activating the hypothalamus-pituitary-adrenal axis, leading to corticotropin hormone (ACTH) production (By similarity). Acts as a 'placental clock' during pregnancy, regulating gestational length, fetal development and the timing of labor (PubMed:7585095). Also acts as a regulator of blastocyst implantation by promoting decidualization, regulating trophoblast invasion and facilitating maternal immune tolerance (PubMed:11590404)",Produced by the hypothalamus and placenta,,,Secreted,11590404|18801728|3003585|32004469|7585095,2783917|3262120,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Gong2021_reproductive_PC,No tumor-antigen validation in this source | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
CRIP1,ENSG00000213145,Unsafe,Protein,False,True,201.6,303.5,97,45,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 256.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; adrenal gland: 21 nTPM; absolute ceiling; amygdala: 24.8 nTPM; absolute ceiling; basal ganglia: 29.7 nTPM; absolute ceiling; bone marrow: 29 nTPM; absolute ceiling; cerebellum: 7.3 nTPM; absolute ceiling; cerebral cortex: 15.5 nTPM; positive ihc;absolute ceiling; choroid plexus: 44.8 nTPM; absolute ceiling; colon: 129.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 118 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 115.4 nTPM; absolute ceiling;continuous selectivity; heart muscle: 253.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 28 nTPM; absolute ceiling; hypothalamus: 29.2 nTPM; absolute ceiling; kidney: 106.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 17.4 nTPM; absolute ceiling; lung: 246.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 81.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 30.6 nTPM; absolute ceiling; pancreas: 17.7 nTPM; absolute ceiling; parathyroid gland: 20.5 nTPM; absolute ceiling; pituitary gland: 40.4 nTPM; absolute ceiling; rectum: 53.5 nTPM; positive ihc;absolute ceiling; salivary gland: 131.6 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 43.2 nTPM; absolute ceiling; skin: 291.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 303.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 40.8 nTPM; positive ihc;absolute ceiling; spinal cord: 21.9 nTPM; absolute ceiling; spleen: 92.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 91.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 77.5 nTPM; absolute ceiling; thyroid gland: 176.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 48.1 nTPM; absolute ceiling; urinary bladder: 110 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 256.4 nTPM (limit 10); adrenal gland: 21 nTPM (limit 4); amygdala: 24.8 nTPM (limit 2); basal ganglia: 29.7 nTPM (limit 2); bone marrow: 29 nTPM (limit 4); cerebellum: 7.3 nTPM (limit 4); cerebral cortex: 15.5 nTPM (limit 2); choroid plexus: 44.8 nTPM (limit 2); colon: 129.9 nTPM (limit 6); duodenum: 118 nTPM (limit 2); esophagus: 115.4 nTPM (limit 8); heart muscle: 253.9 nTPM (limit 4); hippocampal formation: 28 nTPM (limit 2); hypothalamus: 29.2 nTPM (limit 2); kidney: 106.5 nTPM (limit 2); liver: 17.4 nTPM (limit 4); lung: 246.8 nTPM (limit 2); lymph node: 81.8 nTPM (limit 6); midbrain: 30.6 nTPM (limit 2); pancreas: 17.7 nTPM (limit 4); parathyroid gland: 20.5 nTPM (limit 8); pituitary gland: 40.4 nTPM (limit 2); rectum: 53.5 nTPM (limit 6); salivary gland: 131.6 nTPM (limit 8); skeletal muscle: 43.2 nTPM (limit 4); skin: 291.8 nTPM (limit 10); small intestine: 303.5 nTPM (limit 2); smooth muscle: 40.8 nTPM (limit 2); spinal cord: 21.9 nTPM (limit 2); spleen: 92.2 nTPM (limit 10); stomach: 91.6 nTPM (limit 6); thymus: 77.5 nTPM (limit 10); thyroid gland: 176.6 nTPM (limit 10); tongue: 48.1 nTPM (limit 6); urinary bladder: 110 nTPM (limit 8),adipose tissue / adipocytes: Medium (Approved); bronchus / ciliated cells (cell body): High (Approved); bronchus / goblet cells: Medium (Approved); cerebral cortex / glial cells: Low (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Low (Approved); duodenum / glandular cells: Low (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Low (Approved); lung / macrophages: High (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / ciliated cells (cell body): Medium (Approved); oral mucosa / squamous epithelial cells: Low (Approved); rectum / glandular cells: Medium (Approved); skin 1 / fibroblasts: High (Approved); skin 1 / keratinocytes: Low (Approved); skin 1 / Langerhans: High (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Low (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%); Thyroid Carcinoma (TCGA): 495/495 (100.0%),breast cancer: 8/10 (80.0%); ovarian cancer: 9/12 (75.0%),31,20,P50238,https://www.uniprot.org/uniprotkb/P50238/entry,Seems to have a role in zinc absorption and may function as an intracellular zinc transport protein,,,,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CRISP2,ENSG00000124490,Unsafe,RNA,False,True,490.9,490.9,86,5,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,bone marrow: 16.5 nTPM; absolute ceiling; choroid plexus: 4.1 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 16.5 nTPM (limit 12); choroid plexus: 4.1 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (TCGA): 20/176 (11.4%); Breast Invasive Carcinoma (validation): 4/50 (8.0%); Lung Adenocarcinoma (validation): 7/105 (6.7%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),31,20,P16562,https://www.uniprot.org/uniprotkb/P16562/entry,May regulate some ion channels' activity and thereby regulate calcium fluxes during sperm capacitation,Testis and epididymis,,,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
CRYBA4,ENSG00000196431,Unsafe,Protein,False,True,1.4,1.4,84,1,Positive somewhere,True,False,False,False,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted,"Positive IHC in a Vital, Protected or Manageable compartment",,eye / lens fiber cells: High (Supported),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 11/133 (8.3%); Uterine Corpus Endometrial Carcinoma (TCGA): 8/176 (4.5%); Glioblastoma Multiforme (validation): 1/58 (1.7%),breast cancer: 0/10 (0.0%); cervical cancer: 0/12 (0.0%),31,20,P53673,https://www.uniprot.org/uniprotkb/P53673/entry,Crystallins are the dominant structural components of the vertebrate eye lens,,"Cataract 23, multiple types: An opacification of the crystalline lens of the eye that frequently results in visual impairment or blindness. Opacities vary in morphology, are often confined to a portion of the lens, and may be static or progressive. In general, the more posteriorly located and dense an opacity, the greater the impact on visual function. CTRCT23 is a zonular cataract. Zonular or lamellar cataracts are opacities, broad or narrow, usually consisting of powdery white dots affecting only certain layers or zones between the cortex and nucleus of an otherwise clear lens. The opacity may be so dense as to render the entire central region of the lens completely opaque, or so translucent that vision is hardly if at all impeded. Zonular cataracts generally do not involve the embryonic nucleus, though sometimes they involve the fetal nucleus. Usually sharply separated from a clear cortex outside them, they may have projections from their outer edges known as riders or spokes.",,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
CRYGC,ENSG00000163254,Unsafe,Protein,False,True,1.6,1.6,86,1,Positive somewhere,True,False,False,False,Excluded,Normal,False,,Not assessed,,,positive ihc outside permitted,"Positive IHC in a Vital, Protected or Manageable compartment",,eye / lens fiber cells: High (Supported),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Ovary Serous Cystadenocarcinoma (TCGA): 14/349 (4.0%); Ovary Serous Cystadenocarcinoma (validation): 3/81 (3.7%); Testicular Germ Cell Tumor (TCGA): 3/133 (2.3%),liver cancer: 1/11 (9.1%); renal cancer: 1/12 (8.3%),31,20,P07315,https://www.uniprot.org/uniprotkb/P07315/entry,Crystallins are the dominant structural components of the vertebrate eye lens,,"Cataract 2, multiple types: An opacification of the crystalline lens of the eye that frequently results in visual impairment or blindness. Opacities vary in morphology, are often confined to a portion of the lens, and may be static or progressive. CTRCT2 includes Coppock-like cataract, among others. Coppock-like cataract is a congenital pulverulent disk-like opacity involving the embryonic nucleus with many tiny white dots in the lamellar portion of the lens. It is usually bilateral and dominantly inherited. In some cases, CTRCT2 is associated with microcornea without any other systemic anomaly or dysmorphism. Microcornea is defined by a corneal diameter inferior to 10 mm in both meridians in an otherwise normal eye.",,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
CSH1,ENSG00000136488,Unsafe,Protein,False,True,9508.4,9508.4,84,3,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; smooth muscle: 38.3 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",smooth muscle: 38.3 nTPM (limit 12),pituitary gland / cells in anterior : High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 26/133 (19.5%); Breast Invasive Carcinoma (validation): 1/50 (2.0%); Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%),breast cancer: 0/12 (0.0%); cervical cancer: 0/12 (0.0%),31,20,P0DML2,https://www.uniprot.org/uniprotkb/P0DML2/entry,"Produced only during pregnancy and is involved in stimulating lactation, fetal growth and metabolism. Does not interact with GHR but only activates PRLR through zinc-induced dimerization",,,,Secreted,16546209,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | daSilva2017_testis_biased | Gong2021_reproductive_PC,No tumor-antigen validation in this source | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
CSH2,ENSG00000213218,Unsafe,RNA,False,True,3198.1,3198.1,80,1,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,smooth muscle: 14.6 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,smooth muscle: 14.6 nTPM (limit 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 15/133 (11.3%); Breast Invasive Carcinoma (validation): 1/50 (2.0%); Rectum Adenocarcinoma (validation): 2/207 (1.0%),breast cancer: 0/12 (0.0%); cervical cancer: 0/12 (0.0%),31,20,P0DML3,https://www.uniprot.org/uniprotkb/P0DML3/entry,"Produced only during pregnancy and is involved in stimulating lactation, fetal growth and metabolism. Does not interact with GHR but only activates PRLR through zinc-induced dimerization",,,,Secreted,16546209,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Gong2021_reproductive_PC,No tumor-antigen validation in this source | Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
CSHL1,ENSG00000204414,Unsafe,Protein,False,True,145.3,145.3,84,3,Positive somewhere,True,False,False,True,Excluded,Normal,False,,Not assessed,,,positive ihc outside permitted,"Positive IHC in a Vital, Protected or Manageable compartment",,pituitary gland / cells in anterior : High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),breast cancer: 0/12 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q14406,https://www.uniprot.org/uniprotkb/Q14406/entry,May be a novel gestational hormone required to compensate for absence of other members of the GH/CS cluster during gestation,,,,Secreted,8083227,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | daSilva2017_testis_biased | Gong2021_reproductive_PC | daSilva2017_tumor_proteomics,No tumor-antigen validation in this source | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Normal reproductive-tissue enrichment; no tumor validation | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
CSMD2,ENSG00000121904,Unsafe,RNA,False,True,0.3,2.5,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 0.4 nTPM; continuous selectivity;reproductive not higher; amygdala: 1.6 nTPM; continuous selectivity;reproductive not higher; basal ganglia: 2.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 1.9 nTPM; continuous selectivity;reproductive not higher; cerebral cortex: 2.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 0.2 nTPM; continuous selectivity; duodenum: 0.9 nTPM; continuous selectivity;reproductive not higher; heart muscle: 0.2 nTPM; continuous selectivity; hippocampal formation: 1.9 nTPM; continuous selectivity;reproductive not higher; hypothalamus: 2.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 1.4 nTPM; continuous selectivity;reproductive not higher; pancreas: 1.3 nTPM; continuous selectivity;reproductive not higher; retina: 0.8 nTPM; continuous selectivity;reproductive not higher; smooth muscle: 0.2 nTPM; continuous selectivity; spinal cord: 0.7 nTPM; continuous selectivity;reproductive not higher; spleen: 0.3 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 0.5 nTPM; continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,basal ganglia: 2.5 nTPM (limit 2); cerebral cortex: 2.3 nTPM (limit 2); hypothalamus: 2.4 nTPM (limit 2); basal ganglia: 2.5 nTPM (baseline 2); cerebral cortex: 2.3 nTPM (baseline 2); hypothalamus: 2.4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 50/58 (86.2%); Pancreatic Adenocarcinoma (validation): 15/80 (18.8%); Glioblastoma Multiforme (TCGA): 24/141 (17.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q7Z408,https://www.uniprot.org/uniprotkb/Q7Z408/entry,,"Weakly expressed in most tissues, except in brain. Expressed at intermediate level in brain, including cerebellum, substantia nigra, hippocampus and fetal brain. Overexpressed in some head and neck cancer cell lines",,,Cell membrane,,11572484|12906867,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CSMD3,ENSG00000164796,Unsafe,RNA,False,True,0.9,2.7,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,amygdala: 1.7 nTPM; continuous selectivity;reproductive not higher; basal ganglia: 2 nTPM; continuous selectivity;reproductive not higher; cerebellum: 0.5 nTPM; continuous selectivity; cerebral cortex: 2.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 1.6 nTPM; continuous selectivity;reproductive not higher; hypothalamus: 2.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 0.8 nTPM; continuous selectivity; retina: 0.6 nTPM; continuous selectivity; spinal cord: 0.5 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebral cortex: 2.7 nTPM (limit 2); hypothalamus: 2.1 nTPM (limit 2); cerebral cortex: 2.7 nTPM (baseline 2); hypothalamus: 2.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 30/58 (51.7%); Breast Invasive Carcinoma (validation): 6/50 (12.0%); Lung Squamous Cell Carcinoma (validation): 1/68 (1.5%),testis cancer: 11/12 (91.7%); endometrial cancer: 9/12 (75.0%),31,20,Q7Z407,https://www.uniprot.org/uniprotkb/Q7Z407/entry,Involved in dendrite development,"Weakly expressed in most tissues, except in brain. Expressed at intermediate level in brain, including cerebellum, substantia nigra, thalamus, spinal cord, hippocampus and fetal brain. Also expressed in testis",,,Cell membrane,,11572484|12943675,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CSN2,ENSG00000135222,Unsafe,High RNA,False,True,560.3,560.3,84,3,Positive somewhere,False,False,False,True,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,CTA,Pass,oncoref.target-sets.2026-10-23.1,False,False,,CTA → Unsafe,True,True,True,0.319491192337,683.2,"hpa_single_cell: /Adipocytes, max 121.2 nTPM, 1 observations >30; hpa_single_cell_tissue: breast/macrophages, max 683.2 nTPM, 3 observations >30; hpa_single_cell_tissue: breast/t-cells, max 321.1 nTPM, 3 observations >30",CTA,oncoref.target-sets.2026-10-23.2,0.3195 TPM; blood/TH1; dice_th1; vital,683.2 nTPM; breast/macrophages; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (validation): 3/50 (6.0%); Liver Hepatocellular Carcinoma (validation): 4/231 (1.7%); Ovary Serous Cystadenocarcinoma (validation): 1/81 (1.2%),colorectal cancer: 7/12 (58.3%); testis cancer: 5/12 (41.7%),31,20,P05814,https://www.uniprot.org/uniprotkb/P05814/entry,Important role in determination of the surface properties of the casein micelles,Mammary gland specific. Secreted in milk,,,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT,Cancer-associated RNA nomination; no antigen validation asserted,,,,,,,,
CSN3,ENSG00000171209,Unsafe,RNA,False,True,350.7,350.7,82,2,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,salivary gland: 65.7 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,salivary gland: 65.7 nTPM (limit 24),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 9/50 (18.0%); Lung Squamous Cell Carcinoma (validation): 5/68 (7.4%); Breast Invasive Carcinoma (TCGA): 42/1022 (4.1%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),31,20,P07498,https://www.uniprot.org/uniprotkb/P07498/entry,"Kappa-casein stabilizes micelle formation, preventing casein precipitation in milk",Mammary gland specific. Secreted in milk,,,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
CSPP1,ENSG00000104218,Unsafe,RNA,False,True,12.5,13.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 2.8 nTPM; absolute ceiling; amygdala: 4 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 5 nTPM; absolute ceiling;continuous selectivity; cerebellum: 7 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 4 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 3.8 nTPM; absolute ceiling;continuous selectivity; duodenum: 2.2 nTPM; absolute ceiling; heart muscle: 3.6 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 4.8 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 5 nTPM; absolute ceiling;continuous selectivity; kidney: 5.3 nTPM; absolute ceiling;continuous selectivity; liver: 5.3 nTPM; absolute ceiling;continuous selectivity; lung: 5.6 nTPM; absolute ceiling;continuous selectivity; midbrain: 3.6 nTPM; absolute ceiling;continuous selectivity; pancreas: 5.8 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 3.2 nTPM; absolute ceiling; retina: 2.2 nTPM; absolute ceiling; skeletal muscle: 13.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 3.8 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 2.5 nTPM; absolute ceiling; spinal cord: 4.3 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 2.8 nTPM (limit 2); amygdala: 4 nTPM (limit 2); basal ganglia: 5 nTPM (limit 2); cerebellum: 7 nTPM (limit 2); cerebral cortex: 4 nTPM (limit 2); choroid plexus: 3.8 nTPM (limit 2); duodenum: 2.2 nTPM (limit 2); heart muscle: 3.6 nTPM (limit 2); hippocampal formation: 4.8 nTPM (limit 2); hypothalamus: 5 nTPM (limit 2); kidney: 5.3 nTPM (limit 2); liver: 5.3 nTPM (limit 2); lung: 5.6 nTPM (limit 2); midbrain: 3.6 nTPM (limit 2); pancreas: 5.8 nTPM (limit 2); pituitary gland: 3.2 nTPM (limit 2); retina: 2.2 nTPM (limit 2); skeletal muscle: 13.1 nTPM (limit 2); small intestine: 3.8 nTPM (limit 2); smooth muscle: 2.5 nTPM (limit 2); spinal cord: 4.3 nTPM (limit 2); adrenal gland: 2.8 nTPM (baseline 2); amygdala: 4 nTPM (baseline 2); basal ganglia: 5 nTPM (baseline 2); cerebellum: 7 nTPM (baseline 2); cerebral cortex: 4 nTPM (baseline 2); choroid plexus: 3.8 nTPM (baseline 2); duodenum: 2.2 nTPM (baseline 2); heart muscle: 3.6 nTPM (baseline 2); hippocampal formation: 4.8 nTPM (baseline 2); hypothalamus: 5 nTPM (baseline 2); kidney: 5.3 nTPM (baseline 2); liver: 5.3 nTPM (baseline 2); lung: 5.6 nTPM (baseline 2); midbrain: 3.6 nTPM (baseline 2); pancreas: 5.8 nTPM (baseline 2); pituitary gland: 3.2 nTPM (baseline 2); retina: 2.2 nTPM (baseline 2); skeletal muscle: 13.1 nTPM (baseline 2); small intestine: 3.8 nTPM (baseline 2); smooth muscle: 2.5 nTPM (baseline 2); spinal cord: 4.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 49/50 (98.0%); Pancreatic Adenocarcinoma (validation): 77/80 (96.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q1MSJ5,https://www.uniprot.org/uniprotkb/Q1MSJ5/entry,May play a role in cell-cycle-dependent microtubule organization,Expressed in adult and fetal brain with enrichment in the cerebellum. Detected in testis,"Joubert syndrome 21: A disorder presenting with cerebellar ataxia, oculomotor apraxia, hypotonia, neonatal breathing abnormalities and psychomotor delay. Neuroradiologically, it is characterized by cerebellar vermian hypoplasia/aplasia, thickened and reoriented superior cerebellar peduncles, and an abnormally large interpeduncular fossa, giving the appearance of a molar tooth on transaxial slices (molar tooth sign). Additional variable features include retinal dystrophy, renal disease, liver fibrosis, and polydactyly.",,"Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Cytoplasm, cytoskeleton, spindle Cytoplasm, cytoskeleton, spindle pole Cell projection, cilium",16826565,15580290|24360807,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
CT45A1,ENSG00000268940,Unsafe,Protein,False,True,11.6,11.6,85,4,Positive somewhere,True,False,False,True,Excluded,Normal,False,,Not assessed,,,existing nomination or manual review; nomination unresolved; positive normal IHC; positive ihc outside permitted; skin: 0 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,skin 2 / epidermal cells: Low (Supported),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Squamous Cell Carcinoma (TCGA): 98/489 (20.0%); Ovary Serous Cystadenocarcinoma (TCGA): 61/349 (17.5%); Lung Squamous Cell Carcinoma (validation): 10/68 (14.7%),ovarian cancer: 4/10 (40.0%); testis cancer: 3/12 (25.0%),28,20,Q5HYN5,https://www.uniprot.org/uniprotkb/Q5HYN5/entry,,Testis specific. Expressed in cancer cell lines,,,Nucleus,,15905330,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Jamin2021_CT | Jamin2021_core | Loriot2025_S1 | Gong2021_reproductive_PC | daSilva2017_tumor_proteomics,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
CT45A3,ENSG00000269096,Unsafe,Protein,False,True,9.2,9.2,84,4,Positive somewhere,True,True,False,True,Excluded,Normal,False,,Not assessed,,,existing nomination or manual review; nomination unresolved; positive normal IHC; positive ihc outside permitted; amygdala: 2.1 nTPM; absolute ceiling; heart muscle: 0 nTPM; positive ihc; hippocampal formation: 2.3 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 2.1 nTPM (limit 2); hippocampal formation: 2.3 nTPM (limit 2),heart muscle / cardiomyocytes: Low (Supported),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Squamous Cell Carcinoma (TCGA): 94/489 (19.2%); Ovary Serous Cystadenocarcinoma (TCGA): 64/349 (18.3%); Lung Squamous Cell Carcinoma (validation): 11/68 (16.2%),ovarian cancer: 4/10 (40.0%); testis cancer: 3/12 (25.0%),28,20,Q8NHU0,https://www.uniprot.org/uniprotkb/Q8NHU0/entry,,Testis specific. Expressed in cancer cell lines,,,Nucleus,,15905330,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Jamin2021_CT | Jamin2021_core | Loriot2025_S1 | Gong2021_reproductive_PC | daSilva2017_tumor_proteomics,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
CT45A5,ENSG00000228836,Unsafe,RNA,False,True,5.0,5.0,87,3,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,existing nomination or manual review; nomination unresolved; basal ganglia: 4.8 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 1.6 nTPM; continuous selectivity; pituitary gland: 1.9 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,basal ganglia: 4.8 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Ovary Serous Cystadenocarcinoma (TCGA): 82/349 (23.5%); Lung Squamous Cell Carcinoma (TCGA): 114/489 (23.3%); Lung Squamous Cell Carcinoma (validation): 11/68 (16.2%),ovarian cancer: 4/10 (40.0%); testis cancer: 3/12 (25.0%),31,20,P0DMU7 | P0DMU8 | P0DMV0,https://www.uniprot.org/uniprotkb/P0DMU7/entry | https://www.uniprot.org/uniprotkb/P0DMU8/entry | https://www.uniprot.org/uniprotkb/P0DMV0/entry,,Testis specific. Expressed in cancer cell lines,,,Nucleus,,15905330,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Jamin2021_CT | Jamin2021_core | Loriot2025_S1,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci | Cancer-germline RNA nomination; strict and preferential classes remain distinct,,,,,,,,
CT45A6,ENSG00000278289,Unsafe,RNA,False,True,0.1,3.9,85,3,Positive somewhere,False,True,False,True,Excluded,Normal,False,,Not assessed,,,amygdala: 0.6 nTPM; continuous selectivity;reproductive not higher; basal ganglia: 3.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 0.2 nTPM; continuous selectivity;reproductive not higher; hippocampal formation: 0.4 nTPM; continuous selectivity;reproductive not higher; hypothalamus: 1.2 nTPM; continuous selectivity;reproductive not higher; midbrain: 0.2 nTPM; continuous selectivity;reproductive not higher; pituitary gland: 1.2 nTPM; continuous selectivity;reproductive not higher; retina: 0.2 nTPM; continuous selectivity;reproductive not higher; spinal cord: 0.4 nTPM; continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,basal ganglia: 3.9 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 6/133 (4.5%); Ovary Serous Cystadenocarcinoma (TCGA): 14/349 (4.0%); Lung Squamous Cell Carcinoma (TCGA): 16/489 (3.3%),ovarian cancer: 4/10 (40.0%); testis cancer: 3/12 (25.0%),28,20,P0DMU7 | P0DMU8 | P0DMV0,https://www.uniprot.org/uniprotkb/P0DMU7/entry | https://www.uniprot.org/uniprotkb/P0DMU8/entry | https://www.uniprot.org/uniprotkb/P0DMV0/entry,,Testis specific. Expressed in cancer cell lines,,,Nucleus,,15905330,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Jamin2021_CT | Jamin2021_core | Loriot2025_S1,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci | Cancer-germline RNA nomination; strict and preferential classes remain distinct,,,,,,,,
CTDSPL2,ENSG00000137770,Unsafe,Protein,False,True,20.4,24.6,79,45,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 7.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 3.3 nTPM; absolute ceiling; basal ganglia: 3.3 nTPM; absolute ceiling; bone marrow: 20.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 9 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 10.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 3.2 nTPM; absolute ceiling; colon: 10.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 9.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 12.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 9.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 3.4 nTPM; absolute ceiling; hypothalamus: 3.1 nTPM; absolute ceiling; kidney: 10.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 10 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 10.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 18.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 2.8 nTPM; absolute ceiling; pancreas: 11.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 10.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 3.9 nTPM; absolute ceiling; rectum: 10.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 14.7 nTPM; absolute ceiling;continuous selectivity; salivary gland: 8.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 5.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 7.9 nTPM; positive ihc; small intestine: 12.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 13.4 nTPM; absolute ceiling;continuous selectivity; spinal cord: 3.7 nTPM; absolute ceiling; spleen: 12.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 9.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 24.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 14.6 nTPM; continuous selectivity; tongue: 9.1 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 11.8 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 7.2 nTPM (limit 2); amygdala: 3.3 nTPM (limit 2); basal ganglia: 3.3 nTPM (limit 2); bone marrow: 20.2 nTPM (limit 2); cerebellum: 9 nTPM (limit 4); cerebral cortex: 10.2 nTPM (limit 2); choroid plexus: 3.2 nTPM (limit 2); colon: 10.5 nTPM (limit 6); duodenum: 9.7 nTPM (limit 2); esophagus: 12.1 nTPM (limit 6); heart muscle: 9.2 nTPM (limit 2); hippocampal formation: 3.4 nTPM (limit 2); hypothalamus: 3.1 nTPM (limit 2); kidney: 10.4 nTPM (limit 2); liver: 10 nTPM (limit 2); lung: 10.1 nTPM (limit 2); lymph node: 18.9 nTPM (limit 6); midbrain: 2.8 nTPM (limit 2); pancreas: 11.2 nTPM (limit 2); parathyroid gland: 10.7 nTPM (limit 6); pituitary gland: 3.9 nTPM (limit 2); rectum: 10.9 nTPM (limit 6); retina: 14.7 nTPM (limit 2); salivary gland: 8.9 nTPM (limit 6); skeletal muscle: 5.2 nTPM (limit 2); small intestine: 12.4 nTPM (limit 2); smooth muscle: 13.4 nTPM (limit 4); spinal cord: 3.7 nTPM (limit 2); spleen: 12.9 nTPM (limit 10); stomach: 9.5 nTPM (limit 6); thymus: 24.6 nTPM (limit 10); tongue: 9.1 nTPM (limit 6); urinary bladder: 11.8 nTPM (limit 6),adrenal gland / glandular cells: Low (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: High (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuropil: Low (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Low (Approved); esophagus / squamous epithelial cells: High (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Medium (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells type I: High (Approved); lung / macrophages: Low (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: High (Approved); oral mucosa / squamous epithelial cells: High (Approved); pancreas / exocrine glandular cells: Medium (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / keratinocytes: High (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Low (Approved); spleen / cells in red pulp: High (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%),skin cancer: 10/12 (83.3%); cervical cancer: 8/11 (72.7%),31,20,Q05D32,https://www.uniprot.org/uniprotkb/Q05D32/entry,"Serine/threonine phosphatase that promotes gluconeogenesis by dephosphorylating FOXO1 and FOXO3A, promoting their nuclear retention and enhancing their transcriptional activity on PCK1 and G6PC1, key enzymes in hepatic gluconeogenesis (PubMed:28851713). Essential for proper embryonic skeletal development by regulating chondrocyte survival through dephosphorylation of FOXO3 (By similarity). By maintaining FOXO3 in its active, dephosphorylated form, inhibits excessive apoptosis of chondrocytes, which is essential for normal endochondral ossification and cartilage formation (By similarity)",,,,Nucleus,28851713,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
CTNNA2,ENSG00000066032,Unsafe,Protein,False,True,65.5,91.6,77,6,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 82.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 60.4 nTPM; absolute ceiling;continuous selectivity; cerebellum: 12.2 nTPM; absolute ceiling; cerebral cortex: 91.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 6.5 nTPM; absolute ceiling; hippocampal formation: 55.9 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 38.3 nTPM; absolute ceiling;continuous selectivity; midbrain: 29.9 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 6.9 nTPM; absolute ceiling; retina: 78 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 10.7 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 82.4 nTPM (limit 2); basal ganglia: 60.4 nTPM (limit 2); cerebellum: 12.2 nTPM (limit 12); cerebral cortex: 91.6 nTPM (limit 2); choroid plexus: 6.5 nTPM (limit 2); hippocampal formation: 55.9 nTPM (limit 2); hypothalamus: 38.3 nTPM (limit 2); midbrain: 29.9 nTPM (limit 2); pituitary gland: 6.9 nTPM (limit 2); retina: 78 nTPM (limit 2); spinal cord: 10.7 nTPM (limit 2),cerebral cortex / glial cells: Low (Enhanced); cerebral cortex / neuronal cells: Low (Enhanced); cerebral cortex / neuropil: Medium (Enhanced); hippocampus / neuronal cells: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Glioblastoma Multiforme (TCGA): 137/141 (97.2%); Kidney Chromophobe (TCGA): 34/64 (53.1%),ovarian cancer: 3/10 (30.0%); colorectal cancer: 3/11 (27.3%),31,20,P26232,https://www.uniprot.org/uniprotkb/P26232/entry,May function as a linker between cadherin adhesion receptors and the cytoskeleton to regulate cell-cell adhesion and differentiation in the nervous system (By similarity). Required for proper regulation of cortical neuronal migration and neurite growth (PubMed:30013181). It acts as a negative regulator of Arp2/3 complex activity and Arp2/3-mediated actin polymerization (PubMed:30013181). It thereby suppresses excessive actin branching which would impair neurite growth and stability (PubMed:30013181). Regulates morphological plasticity of synapses and cerebellar and hippocampal lamination during development. Functions in the control of startle modulation (By similarity),"Expressed in neural tissues, with strongest expression in fetal and adult brain. Expressed in the developing cortical plate and marginal zone of 20-week-old human fetal brain","Cortical dysplasia, complex, with other brain malformations 9: An autosomal recessive disorder characterized by neurodevelopmental delay apparent from early infancy, acquired microcephaly, hypotonic cerebral palsy, inability to ambulate or speak, and intractable seizures. Brain imaging shows pachygyria with severe cortical gray matter thickening, paucity of gyri without an obvious posterior-anterior gradient or focal dysplasias, hypogenesis of the corpus callosum, and cerebellar hypoplasia.",,"Cell membrane Cytoplasm Cytoplasm, cytoskeleton Cell junction, adherens junction Cell projection, axon Nucleus",30013181,30013181,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
CXCL11,ENSG00000169248,Unsafe,RNA,False,True,5.0,11.6,82,0,Negative where measured,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 1.9 nTPM; continuous selectivity; cerebral cortex: 5.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 3.1 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 3.6 nTPM; absolute ceiling;continuous selectivity; liver: 2.3 nTPM; absolute ceiling;continuous selectivity; lung: 5.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 11.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 2.7 nTPM; absolute ceiling;continuous selectivity; pancreas: 8.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 4.2 nTPM; continuous selectivity; salivary gland: 3 nTPM; continuous selectivity; smooth muscle: 1.6 nTPM; continuous selectivity; spinal cord: 5.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 5.6 nTPM; continuous selectivity;reproductive not higher; stomach: 6.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thymus: 6.2 nTPM; continuous selectivity;reproductive not higher; urinary bladder: 4.5 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 9 nTPM (limit 2); cerebral cortex: 5.4 nTPM (limit 2); hippocampal formation: 3.1 nTPM (limit 2); hypothalamus: 3.6 nTPM (limit 2); liver: 2.3 nTPM (limit 2); lung: 5.8 nTPM (limit 2); lymph node: 11.6 nTPM (limit 6); midbrain: 2.7 nTPM (limit 2); pancreas: 8.6 nTPM (limit 2); spinal cord: 5.4 nTPM (limit 2); stomach: 6.1 nTPM (limit 6); amygdala: 9 nTPM (baseline 2); cerebral cortex: 5.4 nTPM (baseline 2); hippocampal formation: 3.1 nTPM (baseline 2); hypothalamus: 3.6 nTPM (baseline 2); liver: 2.3 nTPM (baseline 2); lung: 5.8 nTPM (baseline 2); lymph node: 11.6 nTPM (baseline 6); midbrain: 2.7 nTPM (baseline 2); pancreas: 8.6 nTPM (baseline 2); spinal cord: 5.4 nTPM (baseline 2); stomach: 6.1 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 42/50 (84.0%); Lung Squamous Cell Carcinoma (validation): 56/68 (82.4%); Testicular Germ Cell Tumor (TCGA): 89/133 (66.9%),colorectal cancer: 9/9 (100.0%); renal cancer: 11/12 (91.7%),31,20,O14625,https://www.uniprot.org/uniprotkb/O14625/entry,"Chemotactic for interleukin-activated T-cells but not unstimulated T-cells, neutrophils or monocytes. Induces calcium release in activated T-cells. Binds to CXCR3. May play an important role in CNS diseases which involve T-cell recruitment. May play a role in skin immune responses","High levels in peripheral blood leukocytes, pancreas and liver astrocytes. Moderate levels in thymus, spleen and lung. Low levels in placenta, prostate and small intestine. Also found in epidermal basal layer keratinocytes in skin disorders",,,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CXorf65,ENSG00000204165,Unsafe,High RNA,False,True,21.8,21.8,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 91/91 values ≥5 TPM, max 149.349; DICE MONOCYTES (unstimulated): 68/91 values ≥5 TPM, max 10.9993; DICE M2 (unstimulated): 46/90 values ≥5 TPM, max 14.3729; DICE NK (unstimulated): 90/90 values ≥5 TPM, max 198.804; DICE TREG_MEM (unstimulated): 89/89 values ≥5 TPM, max 157.391; DICE CD4_NAIVE (unstimulated): 88/88 values ≥5 TPM, max 180.917; DICE CD4_STIM (activated): 88/88 values ≥5 TPM, max 117.162; DICE TREG_NAIVE (unstimulated): 89/89 values ≥5 TPM, max 154.857; DICE TFH (unstimulated): 89/89 values ≥5 TPM, max 166.791; DICE TH1 (unstimulated): 81/81 values ≥5 TPM, max 192.048; DICE THSTAR (unstimulated): 88/88 values ≥5 TPM, max 190.964; DICE TH17 (unstimulated): 89/89 values ≥5 TPM, max 154.542; DICE TH2 (unstimulated): 89/89 values ≥5 TPM, max 178.193; DICE CD8_NAIVE (unstimulated): 89/89 values ≥5 TPM, max 139.384; DICE CD8_STIM (activated): 88/88 values ≥5 TPM, max 104.791",True,True,False,,True,True,"Bronchus/Respiratory epithelial cells: Low, HPA047396; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA047396; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA047396; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA047396; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA047396; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA047396; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA047396; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA047396; conflicting or uncurated primary profile; Rectum/Glandular cells: Low, HPA047396; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: High, HPA047396; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA047396; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA047396; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Low, HPA047396; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, HPA047396; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA047396; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,198.803910789,3.7,"dice_b_cell_naive: blood/B_CELL_NAIVE, max 149.349 TPM, 91 observations >30; dice_cd4_naive: blood/CD4_NAIVE, max 180.917 TPM, 88 observations >30; dice_cd4_stim: blood/CD4_STIM, max 117.162 TPM, 88 observations >30; dice_cd8_naive: blood/CD8_NAIVE, max 139.384 TPM, 89 observations >30; dice_cd8_stim: blood/CD8_STIM, max 104.791 TPM, 88 observations >30; dice_nk: blood/NK, max 198.804 TPM, 90 observations >30; dice_tfh: blood/TFH, max 166.791 TPM, 89 observations >30; dice_th1: blood/TH1, max 192.048 TPM, 81 observations >30; dice_th17: blood/TH17, max 154.542 TPM, 89 observations >30; dice_th2: blood/TH2, max 178.193 TPM, 89 observations >30; dice_thstar: blood/THSTAR, max 190.964 TPM, 88 observations >30; dice_treg_mem: blood/TREG_MEM, max 157.391 TPM, 89 observations >30; dice_treg_naive: blood/TREG_NAIVE, max 154.857 TPM, 89 observations >30; hpa_immune_schmiedel: blood/Memory CD4 T-cell TFH, max 119.8 TPM, 1 observations >30; hpa_immune_schmiedel: blood/Memory CD4 T-cell Th1, max 141.5 TPM, 1 observations >30; hpa_immune_schmiedel: blood/Memory CD4 T-cell Th1/Th17, max 140.3 TPM, 1 observations >30; hpa_immune_schmiedel: blood/Memory CD4 T-cell Th17, max 120.3 TPM, 1 observations >30; hpa_immune_schmiedel: blood/Memory CD4 T-cell Th2, max 123.6 TPM, 1 observations >30; hpa_immune_schmiedel: blood/Memory T-reg, max 109 TPM, 1 observations >30; hpa_immune_schmiedel: blood/NK-cell, max 145 TPM, 1 observations >30; hpa_immune_schmiedel: blood/Naive CD4 T-cell activated, max 71.1 TPM, 1 observations >30; hpa_immune_schmiedel: blood/Naive CD8 T-cell activated, max 76.1 TPM, 1 observations >30; hpa_immune_schmiedel: blood/Naive T-reg, max 110 TPM, 1 observations >30; hpa_immune_schmiedel: blood/naive B-cell, max 104.3 TPM, 1 observations >30; hpa_immune_schmiedel: blood/naive CD4 T-cell, max 137 TPM, 1 observations >30; hpa_immune_schmiedel: blood/naive CD8 T-cell, max 103.2 TPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,198.8 TPM; blood/NK; dice_nk; vital,3.7 nTPM; pbmc/t-cells; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (validation): 10/50 (20.0%); Skin Cuteneous Melanoma (TCGA): 4/99 (4.0%); Liver Hepatocellular Carcinoma (validation): 9/231 (3.9%),testis cancer: 6/11 (54.5%); breast cancer: 1/12 (8.3%),31,20,A6NEN9,https://www.uniprot.org/uniprotkb/A6NEN9/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
CYB5RL,ENSG00000215883,Unsafe,Protein,False,True,3.0,4.3,84,47,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 2 nTPM; continuous selectivity; adrenal gland: 4.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 1.9 nTPM; continuous selectivity; basal ganglia: 1.8 nTPM; continuous selectivity; bone marrow: 2.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 1.9 nTPM; positive ihc;continuous selectivity; cerebral cortex: 2.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 2.1 nTPM; absolute ceiling;continuous selectivity; colon: 2.2 nTPM; positive ihc;continuous selectivity; duodenum: 2.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 1.9 nTPM; positive ihc;continuous selectivity; heart muscle: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 2.1 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 1.6 nTPM; continuous selectivity; kidney: 2.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 2.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 1.7 nTPM; positive ihc;continuous selectivity; lymph node: 2.3 nTPM; continuous selectivity; midbrain: 2 nTPM; continuous selectivity; pancreas: 4.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 3.1 nTPM; positive ihc;continuous selectivity;reproductive not higher; pituitary gland: 3.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 2.3 nTPM; positive ihc;continuous selectivity; retina: 2.5 nTPM; absolute ceiling;continuous selectivity; salivary gland: 2.6 nTPM; positive ihc;continuous selectivity; skeletal muscle: 3.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 3.2 nTPM; positive ihc;continuous selectivity;reproductive not higher; small intestine: 2 nTPM; positive ihc;continuous selectivity; smooth muscle: 1.5 nTPM; positive ihc;continuous selectivity; spinal cord: 2 nTPM; continuous selectivity; spleen: 3 nTPM; continuous selectivity;reproductive not higher; stomach: 3 nTPM; positive ihc;continuous selectivity;reproductive not higher; thymus: 1.4 nTPM; continuous selectivity; thyroid gland: 2.4 nTPM; continuous selectivity; tongue: 2.7 nTPM; continuous selectivity; urinary bladder: 1.9 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 4.3 nTPM (limit 2); bone marrow: 2.1 nTPM (limit 2); cerebral cortex: 2.1 nTPM (limit 2); choroid plexus: 2.1 nTPM (limit 2); duodenum: 2.4 nTPM (limit 2); heart muscle: 2.7 nTPM (limit 2); hippocampal formation: 2.1 nTPM (limit 2); kidney: 2.4 nTPM (limit 2); liver: 2.9 nTPM (limit 2); pancreas: 4.1 nTPM (limit 2); pituitary gland: 3.6 nTPM (limit 2); retina: 2.5 nTPM (limit 2); skeletal muscle: 3.9 nTPM (limit 2),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Medium (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells type I: Medium (Approved); lung / alveolar cells type II: Medium (Approved); lung / macrophages: Medium (Approved); nasopharynx / respiratory epithelial cells: High (Approved); pancreas / exocrine glandular cells: Low (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / keratinocytes: Low (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Low (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 40/50 (80.0%); Glioblastoma Multiforme (validation): 45/58 (77.6%); Rectum Adenocarcinoma (validation): 119/207 (57.5%),ovarian cancer: 2/9 (22.2%); glioma: 2/12 (16.7%),31,20,Q6IPT4,https://www.uniprot.org/uniprotkb/Q6IPT4/entry,"Putative NADH-cytochrome b5 reductases family protein. May participate in fatty acid desaturation and elongation, cholesterol biosynthesis, drug metabolism, and, in erythrocyte, methemoglobin reduction",,,It is uncertain whether Met-1 or Met-2 is the initiator,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
CYP11B1,ENSG00000160882,Unsafe,Protein,False,True,4.0,3571.8,86,4,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 3571.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 4.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 3571.8 nTPM (limit 2); adrenal gland: 3571.8 nTPM (baseline 2); cerebellum: 4.2 nTPM (baseline 2),adrenal gland / cells in zona fasciculata: High (Supported); adrenal gland / cells in zona glomerulosa: High (Supported); adrenal gland / cells in zona reticularis: High (Supported); adrenal gland / glandular cells: High (Supported),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Kidney Renal Papillary Cell Carcinoma (TCGA): 1/282 (0.4%); Lung Adenocarcinoma (TCGA): 1/497 (0.2%),breast cancer: 0/9 (0.0%); cervical cancer: 0/7 (0.0%),31,20,P15538,https://www.uniprot.org/uniprotkb/P15538/entry,"A cytochrome P450 monooxygenase mainly involved in the biosynthesis of adrenal corticoids (PubMed:12530636, PubMed:1518866, PubMed:1775135, PubMed:18215163, PubMed:23322723, PubMed:23685396, PubMed:29277707). Catalyzes a variety of reactions that are essential for many species, including detoxification, defense, and the formation of endogenous chemicals like steroid hormones. Steroid 11beta, 18- and 19-hydroxylase with preferred regioselectivity at 11beta, then 18, and lastly 19 (By similarity). Catalyzes the hydroxylation of 11-deoxycortisol and 11-deoxycorticosterone (21-hydroxyprogesterone) at 11beta position, yielding cortisol or corticosterone, respectively, but cannot produce aldosterone (PubMed:12530636, PubMed:1518866, PubMed:1775135, PubMed:18215163, PubMed:23322723, PubMed:23685396, PubMed:29277707). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate for hydroxylation and reducing the second into a water molecule. Two electrons are provided by NADPH via a two-protein mitochondrial transfer system comprising flavoprotein FDXR (adrenodoxin/ferredoxin reductase) and nonheme iron-sulfur protein FDX1 or FDX2 (adrenodoxin/ferredoxin) (PubMed:18215163, PubMed:23685396). Due to its lack of 18-oxidation activity, it is incapable of generating aldosterone (PubMed:23322723). Besides its role in the biosynthesis of mineralocorticoids and glucocorticoids, it can also participate in the androgen metabolic pathway, converting androst-4-ene-3,17-dione to 11beta-hydroxyandrost-4-ene-3,17-dione, and testosterone (17beta-hydroxy-4-androsten-3-one) to 11beta,17beta-dihydroxyandrost-4-ene-3-one (PubMed:23685396, PubMed:29277707)",Expressed in the zona fasciculata/reticularis of the adrenal cortex,"Adrenal hyperplasia 4: A form of congenital adrenal hyperplasia, a common recessive disease due to defective synthesis of cortisol. Congenital adrenal hyperplasia is characterized by androgen excess leading to ambiguous genitalia in affected females, rapid somatic growth during childhood in both sexes with premature closure of the epiphyses and short adult stature. Four clinical types: 'salt wasting' (SW, the most severe type), 'simple virilizing' (SV, less severely affected patients), with normal aldosterone biosynthesis, 'non-classic form' or late-onset (NC or LOAH) and 'cryptic' (asymptomatic). Hyperaldosteronism, familial, 1: A disorder characterized by hypertension, variable hyperaldosteronism, and abnormal adrenal steroid production, including 18-oxocortisol and 18-hydroxycortisol. There is significant phenotypic heterogeneity, and some individuals never develop hypertension.",,Mitochondrion inner membrane,12530636|1518866|1775135|18215163|23322723|23685396|29277707,20200334,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | daSilva2017_tumor_proteomics,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
CYP11B2,ENSG00000179142,Unsafe,Protein,False,True,0.0,173.3,86,4,Positive somewhere,True,True,False,False,Excluded,Normal,False,,Not assessed,,,existing nomination or manual review; insufficient positive reproductive evidence; nomination unresolved; positive normal IHC; positive ihc outside permitted; reproductive expression not demonstrated; incomplete tissue evidence; adrenal gland: 173.3 nTPM; positive ihc;incomplete expression evidence,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 173.3 nTPM (limit 2); adrenal gland: 173.3 nTPM (baseline 2),adrenal gland / cells in zona fasciculata: High (Supported); adrenal gland / cells in zona glomerulosa: High (Supported); adrenal gland / cells in zona reticularis: High (Supported); adrenal gland / glandular cells: High (Supported),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (TCGA): 3/362 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),breast cancer: 0/9 (0.0%); cervical cancer: 0/7 (0.0%),31,20,P19099,https://www.uniprot.org/uniprotkb/P19099/entry,"A cytochrome P450 monooxygenase that catalyzes the biosynthesis of aldosterone, the main mineralocorticoid in the human body responsible for salt and water homeostasis, thus involved in blood pressure regulation, arterial hypertension, and the development of heart failure (PubMed:11856349, PubMed:12530636, PubMed:1518866, PubMed:15356073, PubMed:1594605, PubMed:1775135, PubMed:22446688, PubMed:23322723, PubMed:9814482, PubMed:9814506). Catalyzes three sequential oxidative reactions of 11-deoxycorticosterone (21-hydroxyprogesterone), namely 11-beta hydroxylation, followed by two successive oxidations at C18 yielding 18-hydroxy and then 18-oxo intermediates (that would not leave the enzyme active site during the consecutive hydroxylation reactions), ending with the formation of aldosterone (PubMed:11856349, PubMed:12530636, PubMed:1518866, PubMed:1594605, PubMed:1775135, PubMed:22446688, PubMed:23322723, PubMed:9814506). Can also produce 18-hydroxycortisol and 18-oxocortisol, derived from successive oxidations of cortisol at C18, normally found at very low levels, but significantly increased in primary aldosteronism, the most common form of secondary hypertension (PubMed:15356073, PubMed:9814482). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate and reducing the second into a water molecule. Two electrons are provided by NADPH via a two-protein mitochondrial transfer system comprising flavoprotein FDXR (adrenodoxin/ferredoxin reductase) and nonheme iron-sulfur protein FDX1 or FDX2 (adrenodoxin/ferredoxin) (PubMed:11856349, PubMed:1594605, PubMed:23322723, PubMed:23685396, PubMed:9814506). Besides its role in the biosynthesis of mineralocorticoids and glucocorticoids, it can also participate in the androgen metabolic pathway, converting testosterone (17beta-hydroxy-4-androsten-3-one) to 11beta,17beta-dihydroxyandrost-4-ene-3-one (PubMed:23685396). Can also use progesterone as substrate (PubMed:33189850)","Expressed sporadically in the zona glomerulosa (zG) of the adrenal cortex (conventional zonation), as well as in aldosterone-producing cell clusters (APCCs) composed of morphological zG cells in contact with the capsule (variegated zonation)","Corticosterone methyloxidase 1 deficiency: Autosomal recessive disorder of aldosterone biosynthesis. There are two biochemically different forms of selective aldosterone deficiency be termed corticosterone methyloxidase (CMO) deficiency type 1 and type 2. In CMO-1 deficiency, aldosterone is undetectable in plasma, while its immediate precursor, 18-hydroxycorticosterone, is low or normal. Corticosterone methyloxidase 2 deficiency: Autosomal recessive disorder of aldosterone biosynthesis. In CMO-2 deficiency, aldosterone can be low or normal, but at the expense of increased secretion of 18-hydroxycorticosterone. Consequently, patients have a greatly increased ratio of 18-hydroxycorticosterone to aldosterone and a low ratio of corticosterone to 18-hydroxycorticosterone in serum.",,Mitochondrion inner membrane,11856349|12530636|1518866|15356073|1594605|1775135|22446688|23322723|23685396|33189850|9814482|9814506,20200334,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
CYP19A1,ENSG00000137869,Unsafe,High RNA,False,True,120.5,120.5,85,2,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,CTA,Pass,oncoref.target-sets.2026-10-23.1,False,False,,CTA → Unsafe,True,True,True,0.7468,33.4,"hpa_single_cell_tissue: skeletal muscle/fibroblasts, max 33.4 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,0.7468 TPM; blood/neutrophil; hpa_immune_cell_samples; vital,33.4 nTPM; skeletal muscle/fibroblasts; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 13/58 (22.4%); Colon Adenocarcinoma (validation): 62/486 (12.8%); Rectum Adenocarcinoma (validation): 23/207 (11.1%),breast cancer: 0/12 (0.0%); cervical cancer: 0/12 (0.0%),31,20,P11511,https://www.uniprot.org/uniprotkb/P11511/entry,"A cytochrome P450 monooxygenase that catalyzes the conversion of C19 androgens, androst-4-ene-3,17-dione (androstenedione) and testosterone to the C18 estrogens, estrone and estradiol, respectively (PubMed:27702664, PubMed:2848247). Catalyzes three successive oxidations of C19 androgens: two conventional oxidations at C19 yielding 19-hydroxy and 19-oxo/19-aldehyde derivatives, followed by a third oxidative aromatization step that involves C1-beta hydrogen abstraction combined with cleavage of the C10-C19 bond to yield a phenolic A ring and formic acid (PubMed:20385561). Alternatively, the third oxidative reaction yields a 19-norsteroid and formic acid. Converts dihydrotestosterone to delta1,10-dehydro 19-nordihydrotestosterone and may play a role in homeostasis of this potent androgen (PubMed:22773874). Also displays 2-hydroxylase activity toward estrone (PubMed:22773874). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase) (PubMed:20385561, PubMed:22773874)","Widely expressed, including in adult and fetal brain, placenta, skin fibroblasts, adipose tissue and gonads","Aromatase excess syndrome: An autosomal dominant disorder characterized by increased extraglandular aromatization of steroids that presents with heterosexual precocity in males and isosexual precocity in females. Aromatase deficiency: A rare disease in which fetal androgens are not converted into estrogens due to placental aromatase deficiency. Thus, pregnant women exhibit a hirsutism, which spontaneously resolves after post-partum. At birth, female babies present with pseudohermaphroditism due to virilization of extern genital organs. In adult females, manifestations include delay of puberty, breast hypoplasia and primary amenorrhoea with multicystic ovaries.",,Endoplasmic reticulum membrane Microsome membrane,20385561|22773874|27702664|2848247,2040633|3018730|7690033|8117272,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Gong2021_reproductive_PC,No tumor-antigen validation in this source | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
CYP2C8,ENSG00000138115,Unsafe,Protein,False,True,3.9,2088.7,99,4,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 1.7 nTPM; continuous selectivity; amygdala: 1.3 nTPM; continuous selectivity; basal ganglia: 2.3 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 1.9 nTPM; continuous selectivity; colon: 0.4 nTPM; positive ihc; hippocampal formation: 1.4 nTPM; continuous selectivity; hypothalamus: 2.5 nTPM; absolute ceiling;continuous selectivity; kidney: 1.4 nTPM; continuous selectivity; liver: 2088.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 1.6 nTPM; continuous selectivity; pituitary gland: 3 nTPM; absolute ceiling;continuous selectivity; retina: 3 nTPM; absolute ceiling;continuous selectivity; small intestine: 1.1 nTPM; positive ihc;continuous selectivity; spinal cord: 1.1 nTPM; continuous selectivity; stomach: 5.8 nTPM; continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",basal ganglia: 2.3 nTPM (limit 2); hypothalamus: 2.5 nTPM (limit 2); liver: 2088.7 nTPM (limit 2); pituitary gland: 3 nTPM (limit 2); retina: 3 nTPM (limit 2); basal ganglia: 2.3 nTPM (baseline 2); hypothalamus: 2.5 nTPM (baseline 2); liver: 2088.7 nTPM (baseline 2); pituitary gland: 3 nTPM (baseline 2); retina: 3 nTPM (baseline 2),colon / enterocytes: Low (Enhanced); liver / hepatocytes: High (Enhanced); small intestine / enterocytes: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (validation): 214/231 (92.6%); Liver Hepatocellular Carcinoma (TCGA): 313/362 (86.5%); Breast Invasive Carcinoma (validation): 18/50 (36.0%),liver cancer: 2/10 (20.0%); breast cancer: 0/11 (0.0%),31,20,P10632,https://www.uniprot.org/uniprotkb/P10632/entry,"A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids, steroid hormones and vitamins (PubMed:11093772, PubMed:14559847, PubMed:15766564, PubMed:19965576, PubMed:7574697). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:11093772, PubMed:14559847, PubMed:15766564, PubMed:19965576, PubMed:7574697). Primarily catalyzes the epoxidation of double bonds of polyunsaturated fatty acids (PUFA) with a preference for the last double bond (PubMed:15766564, PubMed:19965576, PubMed:7574697). Catalyzes the hydroxylation of carbon-hydrogen bonds. Metabolizes all trans-retinoic acid toward its 4-hydroxylated form (PubMed:11093772). Displays 16-alpha hydroxylase activity toward estrogen steroid hormones, 17beta-estradiol (E2) and estrone (E1) (PubMed:14559847). Plays a role in the oxidative metabolism of xenobiotics. It is the principal enzyme responsible for the metabolism of the anti-cancer drug paclitaxel (taxol) (PubMed:26427316)",,,Alternative splicing has been shown to occur but the shorter forms are believed to be non-functional,Endoplasmic reticulum membrane Microsome membrane,11093772|14559847|15766564|19965576|26427316|7574697,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
CYTH3,ENSG00000008256,Unsafe,Protein,False,True,30.7,30.7,75,49,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 27.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 9.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 14.3 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 19.3 nTPM; absolute ceiling;continuous selectivity; bone marrow: 7.5 nTPM; positive ihc;absolute ceiling; cerebellum: 18.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 22.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 4.3 nTPM; absolute ceiling; colon: 17.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 16 nTPM; absolute ceiling;continuous selectivity; esophagus: 13.6 nTPM; absolute ceiling;continuous selectivity; heart muscle: 27.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 16.2 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 10.2 nTPM; absolute ceiling;continuous selectivity; kidney: 13.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 4 nTPM; absolute ceiling; lung: 19.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 5.2 nTPM; positive ihc; midbrain: 13.1 nTPM; absolute ceiling;continuous selectivity; pancreas: 7.3 nTPM; absolute ceiling; parathyroid gland: 11.1 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 9.6 nTPM; absolute ceiling;continuous selectivity; rectum: 6.7 nTPM; absolute ceiling; retina: 5.5 nTPM; absolute ceiling; salivary gland: 11.5 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 14.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 20.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 16.2 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 11.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 7 nTPM; absolute ceiling; spleen: 10.7 nTPM; absolute ceiling; stomach: 13.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; thyroid gland: 26.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 19 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 13.4 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 27.9 nTPM (limit 10); adrenal gland: 9.2 nTPM (limit 2); amygdala: 14.3 nTPM (limit 2); basal ganglia: 19.3 nTPM (limit 2); bone marrow: 7.5 nTPM (limit 2); cerebellum: 18.8 nTPM (limit 2); cerebral cortex: 22.4 nTPM (limit 2); choroid plexus: 4.3 nTPM (limit 2); colon: 17.6 nTPM (limit 6); duodenum: 16 nTPM (limit 2); esophagus: 13.6 nTPM (limit 6); heart muscle: 27.6 nTPM (limit 2); hippocampal formation: 16.2 nTPM (limit 2); hypothalamus: 10.2 nTPM (limit 2); kidney: 13.8 nTPM (limit 2); liver: 4 nTPM (limit 2); lung: 19.1 nTPM (limit 2); midbrain: 13.1 nTPM (limit 2); pancreas: 7.3 nTPM (limit 2); parathyroid gland: 11.1 nTPM (limit 6); pituitary gland: 9.6 nTPM (limit 2); rectum: 6.7 nTPM (limit 6); retina: 5.5 nTPM (limit 2); salivary gland: 11.5 nTPM (limit 6); skeletal muscle: 14.6 nTPM (limit 2); skin: 20.9 nTPM (limit 10); small intestine: 16.2 nTPM (limit 2); smooth muscle: 11.6 nTPM (limit 2); spinal cord: 7 nTPM (limit 2); spleen: 10.7 nTPM (limit 10); stomach: 13.5 nTPM (limit 6); thyroid gland: 26.9 nTPM (limit 10); tongue: 19 nTPM (limit 6); urinary bladder: 13.4 nTPM (limit 6); adipose tissue: 27.9 nTPM (baseline 10); adrenal gland: 9.2 nTPM (baseline 2); amygdala: 14.3 nTPM (baseline 2); basal ganglia: 19.3 nTPM (baseline 2); bone marrow: 7.5 nTPM (baseline 2); cerebellum: 18.8 nTPM (baseline 2); cerebral cortex: 22.4 nTPM (baseline 2); choroid plexus: 4.3 nTPM (baseline 2); colon: 17.6 nTPM (baseline 6); duodenum: 16 nTPM (baseline 2); esophagus: 13.6 nTPM (baseline 6); heart muscle: 27.6 nTPM (baseline 2); hippocampal formation: 16.2 nTPM (baseline 2); hypothalamus: 10.2 nTPM (baseline 2); kidney: 13.8 nTPM (baseline 2); liver: 4 nTPM (baseline 2); lung: 19.1 nTPM (baseline 2); midbrain: 13.1 nTPM (baseline 2); pancreas: 7.3 nTPM (baseline 2); parathyroid gland: 11.1 nTPM (baseline 6); pituitary gland: 9.6 nTPM (baseline 2); rectum: 6.7 nTPM (baseline 6); retina: 5.5 nTPM (baseline 2); salivary gland: 11.5 nTPM (baseline 6); skeletal muscle: 14.6 nTPM (baseline 2); skin: 20.9 nTPM (baseline 10); small intestine: 16.2 nTPM (baseline 2); smooth muscle: 11.6 nTPM (baseline 2); spinal cord: 7 nTPM (baseline 2); spleen: 10.7 nTPM (baseline 10); stomach: 13.5 nTPM (baseline 6); thyroid gland: 26.9 nTPM (baseline 10); tongue: 19 nTPM (baseline 6); urinary bladder: 13.4 nTPM (baseline 6),adipose tissue / adipocytes: Medium (Uncertain); adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Low (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: Medium (Uncertain); cerebellum / cells in molecular layer: Low (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / endothelial cells: Medium (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / endothelial cells: Medium (Uncertain); colon / peripheral nerve/ganglion: Medium (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in glomeruli: Medium (Uncertain); kidney / cells in tubules: Low (Uncertain); lung / alveolar cells: Medium (Uncertain); lung / macrophages: High (Uncertain); lymph node / germinal center cells: Low (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); nasopharynx / respiratory epithelial cells: Low (Uncertain); skeletal muscle / myocytes: Low (Uncertain); skin 1 / fibroblasts: High (Uncertain); skin 1 / keratinocytes: Medium (Uncertain); skin 1 / Langerhans: High (Uncertain); skin 2 / epidermal cells: Low (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); stomach 1 / glandular cells: Low (Uncertain); thyroid gland / glandular cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 141/141 (100.0%); Skin Cuteneous Melanoma (TCGA): 99/99 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%),melanoma: 12/12 (100.0%); glioma: 6/12 (50.0%),31,20,O43739,https://www.uniprot.org/uniprotkb/O43739/entry,Promotes guanine-nucleotide exchange on ARF1 and ARF6. Promotes the activation of ARF factors through replacement of GDP with GTP. Plays a role in the epithelial polarization (By similarity),"Almost absent from liver, thymus and peripheral blood lymphocytes",,,"Cytoplasm, cytosol Cell membrane Cell junction, adherens junction Cell junction, tight junction",23940353|9707577,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
DAW1,ENSG00000123977,Unsafe,Protein,False,True,50.1,57.1,95,18,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; amygdala: 2.5 nTPM; absolute ceiling; basal ganglia: 6.8 nTPM; absolute ceiling; choroid plexus: 57.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 4 nTPM; absolute ceiling; hypothalamus: 3.3 nTPM; absolute ceiling; skeletal muscle: 8.6 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 2.5 nTPM (limit 2); basal ganglia: 6.8 nTPM (limit 2); choroid plexus: 57.1 nTPM (limit 2); hippocampal formation: 4 nTPM (limit 2); hypothalamus: 3.3 nTPM (limit 2); skeletal muscle: 8.6 nTPM (limit 4),bronchus / ciliated cells (cell body): High (Approved); bronchus / ciliated cells (cilia axoneme): High (Approved); bronchus / ciliated cells (ciliary rootlets): High (Approved); bronchus / ciliated cells (tip of cilia): High (Approved); nasopharynx / ciliated cells (cell body): High (Approved); nasopharynx / ciliated cells (cilia axoneme): High (Approved); nasopharynx / ciliated cells (ciliary rootlets): High (Approved); nasopharynx / ciliated cells (tip of cilia): High (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Adenocarcinoma (TCGA): 55/497 (11.1%); Lung Adenocarcinoma (validation): 9/105 (8.6%); Kidney Renal Papillary Cell Carcinoma (TCGA): 23/282 (8.2%),prostate cancer: 11/11 (100.0%); pancreatic cancer: 11/12 (91.7%),29,20,Q8N136,https://www.uniprot.org/uniprotkb/Q8N136/entry,"Required for axonemal dynein assembly and ciliary motility in ciliated organs, including Kupffer's vesicle, during embryogenesis (PubMed:36074124). Facilitates the onset of robust cilia motility during development (PubMed:36074124)",,"Ciliary dyskinesia, primary, 52: A form of primary ciliary dyskinesia, a disorder characterized by abnormalities of motile cilia. Respiratory infections leading to chronic inflammation and bronchiectasis are recurrent, due to defects in the respiratory cilia. CILD52 is an autosomal recessive form characterized by laterality defects, and mild respiratory symptoms.",,"Cytoplasm, cytoskeleton, flagellum basal body Cytoplasm, cytoskeleton, flagellum axoneme",36074124,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
DAZ4,ENSG00000205916,Unsafe,RNA,False,True,11.2,25.2,88,3,Positive somewhere,False,True,False,True,Excluded,Normal,False,,Not assessed,,,stomach: 25.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,stomach: 25.2 nTPM (limit 8),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Stomach Adenocarcinoma (TCGA): 46/346 (13.3%); Pancreatic Adenocarcinoma (validation): 8/80 (10.0%); Glioblastoma Multiforme (TCGA): 5/141 (3.5%),liver cancer: 1/12 (8.3%); testis cancer: 1/12 (8.3%),31,20,Q86SG3,https://www.uniprot.org/uniprotkb/Q86SG3/entry,RNA-binding protein that plays an essential role in spermatogenesis. May act by binding to the 3'-UTR of mRNAs and regulating their translation,"Testis-specific. Expression restricted to premeiotic germ cells, particularly in spermatogonia (at protein level)","Spermatogenic failure Y-linked 2: A disorder resulting in the absence (azoospermia) or reduction (oligozoospermia) of sperm in the semen, leading to male infertility.",,Cytoplasm Nucleus,,10936047|18385127|19223287,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Jamin2021_CT | Jamin2021_core,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
DBF4,ENSG00000006634,Unsafe,High RNA,False,True,14.7,14.7,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 91/91 values ≥5 TPM, max 113.214; DICE MONOCYTES (unstimulated): 80/91 values ≥5 TPM, max 9.51479; DICE M2 (unstimulated): 89/90 values ≥5 TPM, max 24.7187; DICE NK (unstimulated): 90/90 values ≥5 TPM, max 59.62; DICE TREG_MEM (unstimulated): 89/89 values ≥5 TPM, max 45.9555; DICE CD4_NAIVE (unstimulated): 88/88 values ≥5 TPM, max 52.5573; DICE CD4_STIM (activated): 88/88 values ≥5 TPM, max 30.5917; DICE TREG_NAIVE (unstimulated): 89/89 values ≥5 TPM, max 51.781; DICE TFH (unstimulated): 89/89 values ≥5 TPM, max 55.5058; DICE TH1 (unstimulated): 81/81 values ≥5 TPM, max 68.3694; DICE THSTAR (unstimulated): 88/88 values ≥5 TPM, max 74.4922; DICE TH17 (unstimulated): 89/89 values ≥5 TPM, max 55.3092; DICE TH2 (unstimulated): 89/89 values ≥5 TPM, max 64.8193; DICE CD8_NAIVE (unstimulated): 89/89 values ≥5 TPM, max 53.4284; DICE CD8_STIM (activated): 88/88 values ≥5 TPM, max 28.9363",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,113.214279848,120.1,"dice_b_cell_naive: blood/B_CELL_NAIVE, max 113.214 TPM, 89 observations >30; dice_cd4_naive: blood/CD4_NAIVE, max 52.5573 TPM, 49 observations >30; dice_cd4_stim: blood/CD4_STIM, max 30.5917 TPM, 1 observations >30; dice_cd8_naive: blood/CD8_NAIVE, max 53.4284 TPM, 26 observations >30; dice_nk: blood/NK, max 59.62 TPM, 31 observations >30; dice_tfh: blood/TFH, max 55.5058 TPM, 24 observations >30; dice_th1: blood/TH1, max 68.3694 TPM, 50 observations >30; dice_th17: blood/TH17, max 55.3092 TPM, 71 observations >30; dice_th2: blood/TH2, max 64.8193 TPM, 82 observations >30; dice_thstar: blood/THSTAR, max 74.4922 TPM, 82 observations >30; dice_treg_mem: blood/TREG_MEM, max 45.9555 TPM, 26 observations >30; dice_treg_naive: blood/TREG_NAIVE, max 51.781 TPM, 46 observations >30; hpa_immune_schmiedel: blood/Memory CD4 T-cell Th1, max 34.1 TPM, 1 observations >30; hpa_immune_schmiedel: blood/Memory CD4 T-cell Th1/Th17, max 49 TPM, 1 observations >30; hpa_immune_schmiedel: blood/Memory CD4 T-cell Th17, max 36.7 TPM, 1 observations >30; hpa_immune_schmiedel: blood/Memory CD4 T-cell Th2, max 43.9 TPM, 1 observations >30; hpa_immune_schmiedel: blood/Naive T-reg, max 30.9 TPM, 1 observations >30; hpa_immune_schmiedel: blood/naive B-cell, max 52.8 TPM, 1 observations >30; hpa_immune_schmiedel: blood/naive CD4 T-cell, max 31.3 TPM, 1 observations >30; hpa_single_cell: /Erythroid cells, max 43.2 nTPM, 1 observations >30; hpa_single_cell: /NK-cells, max 56.7 nTPM, 1 observations >30; hpa_single_cell: /Plasma cells, max 46.7 nTPM, 1 observations >30; hpa_single_cell: /T-cells, max 45.4 nTPM, 1 observations >30; hpa_single_cell: /Undifferentiated cells, max 31 nTPM, 1 observations >30; hpa_single_cell: /dendritic cells, max 44 nTPM, 1 observations >30; hpa_single_cell: /monocytes, max 47.3 nTPM, 1 observations >30; hpa_single_cell_tissue: adipose tissue/b-cells, max 65 nTPM, 1 observations >30; hpa_single_cell_tissue: adipose tissue/dendritic cells, max 59.2 nTPM, 1 observations >30; hpa_single_cell_tissue: adipose tissue/macrophages, max 37.7 nTPM, 2 observations >30; hpa_single_cell_tissue: adipose tissue/monocytes, max 47.3 nTPM, 1 observations >30; hpa_single_cell_tissue: adipose tissue/nk-cells, max 91.2 nTPM, 2 observations >30; hpa_single_cell_tissue: adipose tissue/schwann cells, max 32.4 nTPM, 1 observations >30; hpa_single_cell_tissue: adipose tissue/t-cells, max 120.1 nTPM, 7 observations >30; hpa_single_cell_tissue: bone marrow/erythroid cells, max 37.4 nTPM, 1 observations >30; hpa_single_cell_tissue: bone marrow/plasma cells, max 42.3 nTPM, 1 observations >30; hpa_single_cell_tissue: bone marrow/t-cells, max 31.7 nTPM, 1 observations >30; hpa_single_cell_tissue: breast/macrophages, max 36.3 nTPM, 1 observations >30; hpa_single_cell_tissue: breast/t-cells, max 74.4 nTPM, 5 observations >30; hpa_single_cell_tissue: colon/intestinal goblet cells, max 34.4 nTPM, 1 observations >30; hpa_single_cell_tissue: colon/t-cells, max 64.3 nTPM, 1 observations >30; hpa_single_cell_tissue: colon/undifferentiated cells, max 55.6 nTPM, 2 observations >30; hpa_single_cell_tissue: endometrium/macrophages, max 49.8 nTPM, 1 observations >30; hpa_single_cell_tissue: endometrium/t-cells, max 67.7 nTPM, 1 observations >30; hpa_single_cell_tissue: esophagus/t-cells, max 38.9 nTPM, 1 observations >30; hpa_single_cell_tissue: fallopian tube/granulocytes, max 36.9 nTPM, 1 observations >30; hpa_single_cell_tissue: fallopian tube/macrophages, max 50.2 nTPM, 1 observations >30; hpa_single_cell_tissue: fallopian tube/plasma cells, max 40.2 nTPM, 1 observations >30; hpa_single_cell_tissue: fallopian tube/t-cells, max 98.5 nTPM, 4 observations >30; hpa_single_cell_tissue: liver/erythroid cells, max 48.9 nTPM, 1 observations >30; hpa_single_cell_tissue: liver/plasma cells, max 49.6 nTPM, 1 observations >30; hpa_single_cell_tissue: liver/t-cells, max 46.6 nTPM, 2 observations >30; hpa_single_cell_tissue: lymph node/b-cells, max 66.8 nTPM, 3 observations >30; hpa_single_cell_tissue: lymph node/t-cells, max 58.4 nTPM, 3 observations >30; hpa_single_cell_tissue: placenta/mixed immune cells, max 82.7 nTPM, 1 observations >30; hpa_single_cell_tissue: prostate/t-cells, max 46.4 nTPM, 1 observations >30; hpa_single_cell_tissue: rectum/mixed immune cells, max 98.8 nTPM, 1 observations >30; hpa_single_cell_tissue: rectum/undifferentiated cells, max 38.5 nTPM, 1 observations >30; hpa_single_cell_tissue: salivary gland/b-cells, max 40.7 nTPM, 2 observations >30; hpa_single_cell_tissue: salivary gland/mixed immune cells, max 42.6 nTPM, 1 observations >30; hpa_single_cell_tissue: salivary gland/plasma cells, max 32.7 nTPM, 1 observations >30; hpa_single_cell_tissue: salivary gland/serous glandular cells, max 33.6 nTPM, 1 observations >30; hpa_single_cell_tissue: salivary gland/t-cells, max 46.3 nTPM, 1 observations >30; hpa_single_cell_tissue: skeletal muscle/t-cells, max 48.4 nTPM, 1 observations >30; hpa_single_cell_tissue: spleen/b-cells, max 32.9 nTPM, 2 observations >30; hpa_single_cell_tissue: spleen/plasma cells, max 74.3 nTPM, 1 observations >30; hpa_single_cell_tissue: spleen/t-cells, max 51.3 nTPM, 4 observations >30; hpa_single_cell_tissue: stomach/b-cells, max 41.8 nTPM, 1 observations >30; hpa_single_cell_tissue: stomach/plasma cells, max 43.6 nTPM, 1 observations >30; hpa_single_cell_tissue: stomach/t-cells, max 49.8 nTPM, 4 observations >30; hpa_single_cell_tissue: thymus/b-cells, max 41.5 nTPM, 1 observations >30; hpa_single_cell_tissue: thymus/plasma cells, max 82 nTPM, 3 observations >30; hpa_single_cell_tissue: thymus/t-cells, max 49.1 nTPM, 4 observations >30; hpa_single_cell_tissue: tongue/basal keratinocytes, max 67.7 nTPM, 1 observations >30; hpa_single_cell_tissue: tongue/granulocytes, max 34 nTPM, 1 observations >30; hpa_single_cell_tissue: tongue/t-cells, max 39.2 nTPM, 2 observations >30",CTA,oncoref.target-sets.2026-10-23.2,113.2 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,120.1 nTPM; adipose tissue/t-cells; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 58/58 (100.0%); Pancreatic Adenocarcinoma (validation): 78/80 (97.5%); Breast Invasive Carcinoma (validation): 44/50 (88.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9UBU7,https://www.uniprot.org/uniprotkb/Q9UBU7/entry,Regulatory subunit for CDC7 which activates its kinase activity thereby playing a central role in DNA replication and cell proliferation. Required for progression of S phase. The complex CDC7-DBF4A selectively phosphorylates MCM2 subunit at 'Ser-40' and 'Ser-53' and then is involved in regulating the initiation of DNA replication during cell cycle,Highly expressed in testis and thymus. Expressed also in most cancer cells lines,,,Nucleus,10373557|10523313|17062569,10373557,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
DCAF12L1,ENSG00000198889,Unsafe,Protein,False,True,6.0,6.0,83,49,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 0.1 nTPM; positive ihc; cerebellum: 0 nTPM; positive ihc; cerebral cortex: 0 nTPM; positive ihc; colon: 0 nTPM; positive ihc; duodenum: 0 nTPM; positive ihc; esophagus: 0 nTPM; positive ihc; heart muscle: 0 nTPM; positive ihc; kidney: 1.5 nTPM; positive ihc; liver: 0 nTPM; positive ihc; lung: 0 nTPM; positive ihc; lymph node: 0 nTPM; positive ihc; pancreas: 0 nTPM; positive ihc; parathyroid gland: 0 nTPM; positive ihc; rectum: 0 nTPM; positive ihc; salivary gland: 0 nTPM; positive ihc; skeletal muscle: 0 nTPM; positive ihc; skin: 0 nTPM; positive ihc; small intestine: 0 nTPM; positive ihc; stomach: 0.8 nTPM; positive ihc; urinary bladder: 0.2 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,adrenal gland / glandular cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / keratinocytes: Low (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Renal Papillary Cell Carcinoma (TCGA): 68/282 (24.1%); Kidney Renal Clear Cell Carcinoma (validation): 19/100 (19.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 22/176 (12.5%),breast cancer: 11/11 (100.0%); colorectal cancer: 11/12 (91.7%),31,20,Q5VU92,https://www.uniprot.org/uniprotkb/Q5VU92/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Jamin2021_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
DCAF8L1,ENSG00000226372,Unsafe,Protein,False,True,0.9,0.9,85,5,Positive somewhere,True,False,False,True,Excluded,Normal,False,,Not assessed,,,positive ihc outside permitted,"Positive IHC in a Vital, Protected or Manageable compartment",,bronchus / respiratory epithelial cells: Low (Enhanced); nasopharynx / respiratory epithelial cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (validation): 11/231 (4.8%); Testicular Germ Cell Tumor (TCGA): 2/133 (1.5%); Liver Hepatocellular Carcinoma (TCGA): 3/362 (0.8%),breast cancer: 0/12 (0.0%); cervical cancer: 0/10 (0.0%),31,20,A6NGE4,https://www.uniprot.org/uniprotkb/A6NGE4/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
DCHS2,ENSG00000197410,Unsafe,RNA,False,True,1.3,2.2,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,amygdala: 0.5 nTPM; continuous selectivity; basal ganglia: 2.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 1.7 nTPM; continuous selectivity;reproductive not higher; colon: 1.7 nTPM; continuous selectivity;reproductive not higher; hippocampal formation: 0.6 nTPM; continuous selectivity; hypothalamus: 0.8 nTPM; continuous selectivity; midbrain: 0.6 nTPM; continuous selectivity; pituitary gland: 0.5 nTPM; continuous selectivity; stomach: 1.2 nTPM; continuous selectivity; urinary bladder: 0.6 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,basal ganglia: 2.2 nTPM (limit 2); basal ganglia: 2.2 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 28/58 (48.3%); Pancreatic Adenocarcinoma (validation): 16/80 (20.0%); Breast Invasive Carcinoma (validation): 2/50 (4.0%),skin cancer: 11/12 (91.7%); renal cancer: 10/12 (83.3%),31,20,Q6V1P9,https://www.uniprot.org/uniprotkb/Q6V1P9/entry,Calcium-dependent cell-adhesion protein,Cerebral cortex and testis,,,Membrane,,15003449,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
DCST1,ENSG00000163357,Unsafe,RNA,False,True,6.5,6.5,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,retina: 2.5 nTPM; absolute ceiling;continuous selectivity; skin: 3 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 2.5 nTPM (limit 2); retina: 2.5 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (validation): 4/231 (1.7%); Lung Squamous Cell Carcinoma (validation): 1/68 (1.5%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 4/283 (1.4%),glioma: 9/10 (90.0%); colorectal cancer: 6/10 (60.0%),31,20,Q5T197,https://www.uniprot.org/uniprotkb/Q5T197/entry,E3 ubiquitin-protein ligase which mediates 'Lys-48'-linked ubiquitination of STAT2 and induces its proteasomal degradation thereby negatively regulating type-I-interferon signaling. Essential sperm cell-surface protein required for sperm-egg fusion and fertilization (By similarity),,,,"Cell membrane Cytoplasmic vesicle, secretory vesicle, acrosome membrane",27782195,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
DCUN1D4,ENSG00000109184,Unsafe,Protein,False,True,16.5,28.0,77,65,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 13.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 17.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 12.6 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 13.2 nTPM; absolute ceiling;continuous selectivity; bone marrow: 2.8 nTPM; positive ihc;absolute ceiling; cerebellum: 12.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 14.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 5.7 nTPM; absolute ceiling;continuous selectivity; colon: 14.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 5.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 10 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 11.7 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 13.2 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 18.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 14.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 28 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 8.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 7.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 15 nTPM; absolute ceiling;continuous selectivity; pancreas: 8.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 9.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 15.3 nTPM; absolute ceiling;continuous selectivity; rectum: 8.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 15.2 nTPM; absolute ceiling;continuous selectivity; salivary gland: 13.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 11.4 nTPM; absolute ceiling;continuous selectivity; skin: 7.5 nTPM; positive ihc;continuous selectivity; small intestine: 9.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 16.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 14.2 nTPM; absolute ceiling;continuous selectivity; spleen: 9.2 nTPM; positive ihc;continuous selectivity; stomach: 12.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; thyroid gland: 12.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 10.9 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 16.4 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 13.5 nTPM (limit 10); adrenal gland: 17.2 nTPM (limit 2); amygdala: 12.6 nTPM (limit 2); basal ganglia: 13.2 nTPM (limit 2); bone marrow: 2.8 nTPM (limit 2); cerebellum: 12.9 nTPM (limit 2); cerebral cortex: 14.7 nTPM (limit 2); choroid plexus: 5.7 nTPM (limit 2); colon: 14.5 nTPM (limit 6); duodenum: 5.7 nTPM (limit 2); esophagus: 10 nTPM (limit 6); heart muscle: 11.7 nTPM (limit 2); hippocampal formation: 13.2 nTPM (limit 2); hypothalamus: 18.6 nTPM (limit 2); kidney: 14.3 nTPM (limit 2); liver: 28 nTPM (limit 2); lung: 8.8 nTPM (limit 2); lymph node: 7.3 nTPM (limit 6); midbrain: 15 nTPM (limit 2); pancreas: 8.8 nTPM (limit 2); parathyroid gland: 9.2 nTPM (limit 6); pituitary gland: 15.3 nTPM (limit 2); rectum: 8.2 nTPM (limit 6); retina: 15.2 nTPM (limit 2); salivary gland: 13.1 nTPM (limit 6); skeletal muscle: 11.4 nTPM (limit 2); small intestine: 9.4 nTPM (limit 2); smooth muscle: 16.6 nTPM (limit 2); spinal cord: 14.2 nTPM (limit 2); stomach: 12.9 nTPM (limit 6); thyroid gland: 12.8 nTPM (limit 10); tongue: 10.9 nTPM (limit 6); urinary bladder: 16.4 nTPM (limit 6); adipose tissue: 13.5 nTPM (baseline 10); adrenal gland: 17.2 nTPM (baseline 2); amygdala: 12.6 nTPM (baseline 2); basal ganglia: 13.2 nTPM (baseline 2); bone marrow: 2.8 nTPM (baseline 2); cerebellum: 12.9 nTPM (baseline 2); cerebral cortex: 14.7 nTPM (baseline 2); choroid plexus: 5.7 nTPM (baseline 2); colon: 14.5 nTPM (baseline 6); duodenum: 5.7 nTPM (baseline 2); esophagus: 10 nTPM (baseline 6); heart muscle: 11.7 nTPM (baseline 2); hippocampal formation: 13.2 nTPM (baseline 2); hypothalamus: 18.6 nTPM (baseline 2); kidney: 14.3 nTPM (baseline 2); liver: 28 nTPM (baseline 2); lung: 8.8 nTPM (baseline 2); lymph node: 7.3 nTPM (baseline 6); midbrain: 15 nTPM (baseline 2); pancreas: 8.8 nTPM (baseline 2); parathyroid gland: 9.2 nTPM (baseline 6); pituitary gland: 15.3 nTPM (baseline 2); rectum: 8.2 nTPM (baseline 6); retina: 15.2 nTPM (baseline 2); salivary gland: 13.1 nTPM (baseline 6); skeletal muscle: 11.4 nTPM (baseline 2); small intestine: 9.4 nTPM (baseline 2); smooth muscle: 16.6 nTPM (baseline 2); spinal cord: 14.2 nTPM (baseline 2); stomach: 12.9 nTPM (baseline 6); thyroid gland: 12.8 nTPM (baseline 10); tongue: 10.9 nTPM (baseline 6); urinary bladder: 16.4 nTPM (baseline 6),adipose tissue / adipocytes: Low (Uncertain); adrenal gland / glandular cells: High (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: Medium (Uncertain); cerebellum / cells in molecular layer: Low (Uncertain); cerebellum / Purkinje cells: Low (Uncertain); cerebral cortex / endothelial cells: Medium (Uncertain); cerebral cortex / glial cells: Medium (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); colon / endothelial cells: Medium (Uncertain); colon / glandular cells: Medium (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); hippocampus / glial cells: Low (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in glomeruli: Medium (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / cholangiocytes: Low (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / alveolar cells: Low (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / non-germinal center cells: Medium (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skin 1 / fibroblasts: Medium (Uncertain); skin 1 / keratinocytes: Low (Uncertain); skin 1 / Langerhans: Low (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: Medium (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); spleen / cells in red pulp: Low (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (validation): 231/231 (100.0%); Glioblastoma Multiforme (TCGA): 141/141 (100.0%); Kidney Renal Clear Cell Carcinoma (validation): 100/100 (100.0%),testis cancer: 9/11 (81.8%); renal cancer: 8/10 (80.0%),31,20,Q92564,https://www.uniprot.org/uniprotkb/Q92564/entry,Contributes to the neddylation of all cullins by transferring NEDD8 from N-terminally acetylated NEDD8-conjugating E2s enzyme to different cullin C-terminal domain-RBX complexes which are necessary for the activation of cullin-RING E3 ubiquitin ligases (CRLs),,,,Nucleus,23201271|26906416,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
DCX,ENSG00000077279,Unsafe,Protein,False,True,1.4,6.0,91,22,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 1.9 nTPM; continuous selectivity;reproductive not higher; basal ganglia: 1.8 nTPM; continuous selectivity;reproductive not higher; cerebral cortex: 6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; colon: 0 nTPM; positive ihc; hippocampal formation: 1.1 nTPM; continuous selectivity; hypothalamus: 1.9 nTPM; continuous selectivity;reproductive not higher; kidney: 0 nTPM; positive ihc; midbrain: 0.7 nTPM; continuous selectivity; rectum: 0 nTPM; positive ihc; retina: 2.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 0 nTPM; positive ihc; small intestine: 0 nTPM; positive ihc; spinal cord: 1.1 nTPM; continuous selectivity; stomach: 0.2 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",cerebral cortex: 6 nTPM (limit 2); retina: 2.1 nTPM (limit 2),bronchus / respiratory epithelial cells: Low (Enhanced); caudate / neuronal cells: Medium (Enhanced); caudate / synapses: Low (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); cerebral cortex / neuronal projections: Low (Enhanced); colon / glandular cells: Low (Enhanced); hippocampus / neuronal cells: Medium (Enhanced); kidney / cells in tubules: Low (Enhanced); oral mucosa / squamous epithelial cells: Low (Enhanced); rectum / glandular cells: Low (Enhanced); skin 1 / keratinocytes: Low (Enhanced); skin 2 / epidermal cells: Low (Enhanced); small intestine / glandular cells: Low (Enhanced); stomach 1 / glandular cells: Low (Enhanced); stomach 2 / glandular cells: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 44/58 (75.9%); Glioblastoma Multiforme (TCGA): 66/141 (46.8%); Breast Invasive Carcinoma (validation): 9/50 (18.0%),glioma: 3/11 (27.3%); pancreatic cancer: 2/11 (18.2%),31,20,O43602,https://www.uniprot.org/uniprotkb/O43602/entry,"Microtubule-associated protein required for initial steps of neuronal dispersion and cortex lamination during cerebral cortex development. May act by competing with the putative neuronal protein kinase DCLK1 in binding to a target protein. May in that way participate in a signaling pathway that is crucial for neuronal interaction before and during migration, possibly as part of a calcium ion-dependent signal transduction pathway. May be part with PAFAH1B1/LIS-1 of overlapping, but distinct, signaling pathways that promote neuronal migration","Highly expressed in neuronal cells of fetal brain (in the majority of cells of the cortical plate, intermediate zone and ventricular zone), but not expressed in other fetal tissues. In the adult, highly expressed in the brain frontal lobe, but very low expression in other regions of brain, and not detected in heart, placenta, lung, liver, skeletal muscles, kidney and pancreas","Lissencephaly, X-linked 1: A classic lissencephaly characterized by intellectual disability and seizures that are more severe in male patients. Affected boys show an abnormally thick cortex with absent or severely reduced gyri. Clinical manifestations include feeding problems, abnormal muscular tone, seizures and severe to profound psychomotor retardation. Female patients display a less severe phenotype referred to as 'doublecortex'. Subcortical band heterotopia X-linked: SBHX is a mild brain malformation of the lissencephaly spectrum. It is characterized by bilateral and symmetric plates or bands of gray matter found in the central white matter between the cortex and cerebral ventricles, cerebral convolutions usually appearing normal.",,"Cytoplasm Cell projection, neuron projection",22359282,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
DDHD1,ENSG00000100523,Unsafe,Protein,False,True,29.9,29.9,84,37,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 3.5 nTPM; positive ihc;absolute ceiling; amygdala: 5.9 nTPM; absolute ceiling; basal ganglia: 5.7 nTPM; absolute ceiling; cerebellum: 8.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 7 nTPM; positive ihc;absolute ceiling; choroid plexus: 2.1 nTPM; absolute ceiling; colon: 3.7 nTPM; positive ihc; duodenum: 2.5 nTPM; positive ihc;absolute ceiling; heart muscle: 4.9 nTPM; positive ihc;absolute ceiling; hippocampal formation: 6.7 nTPM; absolute ceiling; hypothalamus: 6.1 nTPM; absolute ceiling; kidney: 2.2 nTPM; positive ihc;absolute ceiling; liver: 2.6 nTPM; positive ihc;absolute ceiling; lung: 5.1 nTPM; positive ihc;absolute ceiling; midbrain: 7.5 nTPM; absolute ceiling; pancreas: 2.8 nTPM; positive ihc;absolute ceiling; parathyroid gland: 4.3 nTPM; positive ihc; pituitary gland: 5.2 nTPM; absolute ceiling; rectum: 4.5 nTPM; positive ihc; retina: 16.1 nTPM; absolute ceiling;continuous selectivity; salivary gland: 2.4 nTPM; positive ihc; skin: 3.3 nTPM; positive ihc; small intestine: 4.6 nTPM; positive ihc;absolute ceiling; spinal cord: 9.4 nTPM; absolute ceiling;continuous selectivity; stomach: 3.7 nTPM; positive ihc; thyroid gland: 3.4 nTPM; positive ihc; urinary bladder: 5.3 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 3.5 nTPM (limit 2); amygdala: 5.9 nTPM (limit 2); basal ganglia: 5.7 nTPM (limit 2); cerebellum: 8.5 nTPM (limit 2); cerebral cortex: 7 nTPM (limit 2); choroid plexus: 2.1 nTPM (limit 2); duodenum: 2.5 nTPM (limit 2); heart muscle: 4.9 nTPM (limit 2); hippocampal formation: 6.7 nTPM (limit 2); hypothalamus: 6.1 nTPM (limit 2); kidney: 2.2 nTPM (limit 2); liver: 2.6 nTPM (limit 2); lung: 5.1 nTPM (limit 2); midbrain: 7.5 nTPM (limit 2); pancreas: 2.8 nTPM (limit 2); pituitary gland: 5.2 nTPM (limit 2); retina: 16.1 nTPM (limit 2); small intestine: 4.6 nTPM (limit 2); spinal cord: 9.4 nTPM (limit 2),adrenal gland / glandular cells: Low (Enhanced); bronchus / respiratory epithelial cells: Low (Enhanced); cerebellum / cells in granular layer: Medium (Enhanced); cerebellum / Purkinje cells: Medium (Enhanced); cerebral cortex / neuropil: Medium (Enhanced); colon / glandular cells: Low (Enhanced); colon / peripheral nerve/ganglion: Low (Enhanced); duodenum / glandular cells: Medium (Enhanced); heart muscle / cardiomyocytes: Low (Enhanced); kidney / cells in tubules: Medium (Enhanced); liver / hepatocytes: Low (Enhanced); lung / macrophages: Medium (Enhanced); pancreas / exocrine glandular cells: Medium (Enhanced); parathyroid gland / glandular cells: Medium (Enhanced); rectum / glandular cells: Medium (Enhanced); salivary gland / glandular cells: Medium (Enhanced); skin 1 / keratinocytes: Medium (Enhanced); skin 1 / Langerhans: Medium (Enhanced); small intestine / glandular cells: Medium (Enhanced); stomach 1 / glandular cells: Medium (Enhanced); stomach 2 / glandular cells: Medium (Enhanced); thyroid gland / glandular cells: Low (Enhanced); urinary bladder / urothelial cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 485/486 (99.8%),melanoma: 4/12 (33.3%); testis cancer: 4/12 (33.3%),31,20,Q8NEL9,https://www.uniprot.org/uniprotkb/Q8NEL9/entry,"Phospholipase A1 (PLA1) that hydrolyzes ester bonds at the sn-1 position of glycerophospholipids producing a free fatty acid and a lysophospholipid (Probable) (PubMed:20359546, PubMed:22922100). Prefers phosphatidate (1,2-diacyl-sn-glycero-3-phosphate, PA) as substrate in vitro, but can efficiently hydrolyze phosphatidylinositol (1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol), PI), as well as a range of other glycerophospholipid substrates such as phosphatidylcholine (1,2-diacyl-sn-glycero-3-phosphocholine, PC), phosphatidylethanolamine (1,2-diacyl-sn-glycero-3-phosphoethanolamine, PE), phosphatidylserine (1,2-diacyl-sn-glycero-3-phospho-L-serine, PS) and phosphatidylglycerol (1,2-diacyl-sn-glycero-3-phospho-(1'-sn-glycerol), PG) (Probable) (PubMed:20359546). Involved in the regulation of the endogenous content of polyunsaturated PI and PS lipids in the nervous system. Changes in these lipids extend to downstream metabolic products like PI phosphates PIP and PIP2, which play fundamental roles in cell biology (By similarity). Regulates mitochondrial morphology (PubMed:24599962). These dynamic changes may be due to PA hydrolysis at the mitochondrial surface (PubMed:24599962). May play a regulatory role in spermatogenesis or sperm function (PubMed:24599962)","Highly expressed in testis. Also expressed in brain, spleen and lung. Only expressed in cerebellum in fetal brain","Spastic paraplegia 28, autosomal recessive: A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. Some SPG28 patients also have distal sensory impairment.",,Cytoplasm,20359546|22922100|24599962|37189713,9488669,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
DDIAS,ENSG00000165490,Unsafe,Protein,False,True,10.6,10.6,75,50,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0.9 nTPM; positive ihc; bone marrow: 7.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 1.8 nTPM; positive ihc; duodenum: 1.5 nTPM; positive ihc; esophagus: 2.8 nTPM; positive ihc; lung: 3.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 4.3 nTPM; positive ihc;continuous selectivity; rectum: 2.1 nTPM; positive ihc; skin: 2.2 nTPM; positive ihc; small intestine: 1.5 nTPM; positive ihc; smooth muscle: 1.8 nTPM; positive ihc; spleen: 2.8 nTPM; positive ihc; stomach: 0.9 nTPM; positive ihc; thymus: 5.2 nTPM; continuous selectivity; urinary bladder: 3.3 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 7.7 nTPM (limit 2); lung: 3.3 nTPM (limit 2),adipose tissue / adipocytes: Low (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Low (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: High (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); rectum / glandular cells: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Low (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 459/486 (94.4%); Rectum Adenocarcinoma (validation): 189/207 (91.3%); Lung Squamous Cell Carcinoma (validation): 59/68 (86.8%),breast cancer: 12/12 (100.0%); colorectal cancer: 12/12 (100.0%),29,20,Q8IXT1,https://www.uniprot.org/uniprotkb/Q8IXT1/entry,May be an anti-apoptotic protein involved in DNA repair or cell survival,Highly expressed in colorectal and lung cancer tissues,,,Cytoplasm Nucleus,24214091,24214091,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
DDX11,ENSG00000013573,Unsafe,Protein,False,True,10.7,28.8,89,73,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 5.7 nTPM; positive ihc;continuous selectivity; adrenal gland: 6.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 3 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 2.9 nTPM; absolute ceiling;continuous selectivity; bone marrow: 28.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 8.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 3.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 4.7 nTPM; absolute ceiling;continuous selectivity; colon: 9.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 7.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 9.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 5.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 3.2 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 3.1 nTPM; absolute ceiling;continuous selectivity; kidney: 9 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 9.1 nTPM; absolute ceiling;continuous selectivity; lung: 5.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 12.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 3.3 nTPM; absolute ceiling;continuous selectivity; pancreas: 17 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 9.2 nTPM; absolute ceiling;continuous selectivity; rectum: 9.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 6.4 nTPM; absolute ceiling;continuous selectivity; salivary gland: 8.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 10.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 16.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 13 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 3.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 3.4 nTPM; absolute ceiling;continuous selectivity; spleen: 13.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; stomach: 9.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 23.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 7.8 nTPM; positive ihc;continuous selectivity; tongue: 6.2 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 6.7 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 6.2 nTPM (limit 2); amygdala: 3 nTPM (limit 2); basal ganglia: 2.9 nTPM (limit 2); bone marrow: 28.8 nTPM (limit 2); cerebellum: 8.8 nTPM (limit 2); cerebral cortex: 3.9 nTPM (limit 2); choroid plexus: 4.7 nTPM (limit 2); colon: 9.3 nTPM (limit 6); duodenum: 7.7 nTPM (limit 2); esophagus: 9.3 nTPM (limit 6); heart muscle: 5.1 nTPM (limit 2); hippocampal formation: 3.2 nTPM (limit 2); hypothalamus: 3.1 nTPM (limit 2); kidney: 9 nTPM (limit 2); liver: 9.1 nTPM (limit 6); lung: 5.9 nTPM (limit 2); lymph node: 12.9 nTPM (limit 6); midbrain: 3.3 nTPM (limit 2); pancreas: 17 nTPM (limit 2); pituitary gland: 9.2 nTPM (limit 2); rectum: 9.7 nTPM (limit 6); retina: 6.4 nTPM (limit 2); salivary gland: 8.3 nTPM (limit 6); skeletal muscle: 10.3 nTPM (limit 2); skin: 16.3 nTPM (limit 10); small intestine: 13 nTPM (limit 2); smooth muscle: 3.4 nTPM (limit 2); spinal cord: 3.4 nTPM (limit 2); spleen: 13.5 nTPM (limit 10); stomach: 9.3 nTPM (limit 6); thymus: 23.4 nTPM (limit 10); tongue: 6.2 nTPM (limit 6); urinary bladder: 6.7 nTPM (limit 6),adipose tissue / adipocytes: Low (Supported); adrenal gland / glandular cells: Medium (Supported); bone marrow / hematopoietic cells: Low (Supported); bronchus / respiratory epithelial cells: Medium (Supported); caudate / glial cells: Medium (Supported); cerebellum / cells in granular layer: Medium (Supported); cerebellum / Purkinje cells: Low (Supported); cerebral cortex / endothelial cells: Low (Supported); cerebral cortex / glial cells: Low (Supported); cerebral cortex / neuronal cells: Low (Supported); cerebral cortex / neuropil: Low (Supported); colon / glandular cells: Low (Supported); duodenum / glandular cells: Low (Supported); esophagus / squamous epithelial cells: Medium (Supported); heart muscle / cardiomyocytes: Low (Supported); hippocampus / glial cells: Low (Supported); kidney / cells in glomeruli: Low (Supported); kidney / cells in tubules: Medium (Supported); lung / alveolar cells type I: High (Supported); lung / alveolar cells type II: High (Supported); lung / macrophages: High (Supported); lymph node / germinal center cells: Low (Supported); lymph node / non-germinal center cells: Medium (Supported); nasopharynx / respiratory epithelial cells: Medium (Supported); oral mucosa / squamous epithelial cells: Medium (Supported); pancreas / exocrine glandular cells: Medium (Supported); pancreas / pancreatic endocrine cells: Medium (Supported); rectum / glandular cells: Medium (Supported); salivary gland / glandular cells: Medium (Supported); skeletal muscle / myocytes: Low (Supported); skin 1 / fibroblasts: Medium (Supported); skin 1 / keratinocytes: Medium (Supported); skin 1 / Langerhans: Medium (Supported); skin 2 / epidermal cells: Medium (Supported); small intestine / glandular cells: Medium (Supported); smooth muscle / smooth muscle cells: Low (Supported); spleen / cells in red pulp: Medium (Supported); spleen / cells in white pulp: Medium (Supported); stomach 1 / glandular cells: Medium (Supported); stomach 2 / glandular cells: Medium (Supported); thyroid gland / glandular cells: Medium (Supported); urinary bladder / urothelial cells: Medium (Supported),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 133/133 (100.0%); Pancreatic Adenocarcinoma (validation): 80/80 (100.0%); Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%),testis cancer: 8/10 (80.0%); breast cancer: 6/11 (54.5%),31,20,Q96FC9,https://www.uniprot.org/uniprotkb/Q96FC9/entry,"DNA-dependent ATPase and ATP-dependent DNA helicase that participates in various functions in genomic stability, including DNA replication, DNA repair and heterochromatin organization as well as in ribosomal RNA synthesis (PubMed:10648783, PubMed:21854770, PubMed:23797032, PubMed:26089203, PubMed:26503245). Its double-stranded DNA helicase activity requires either a minimal 5'-single-stranded tail length of approximately 15 nt (flap substrates) or 10 nt length single-stranded gapped DNA substrates of a partial duplex DNA structure for helicase loading and translocation along DNA in a 5' to 3' direction (PubMed:10648783, PubMed:18499658, PubMed:22102414). The helicase activity is capable of displacing duplex regions up to 100 bp, which can be extended up to 500 bp by the replication protein A (RPA) or the cohesion CTF18-replication factor C (Ctf18-RFC) complex activities (PubMed:18499658). Also shows ATPase- and helicase activities on substrates that mimic key DNA intermediates of replication, repair and homologous recombination reactions, including forked duplex, anti-parallel G-quadruplex and three-stranded D-loop DNA molecules (PubMed:22102414, PubMed:26503245). Plays a role in DNA double-strand break (DSB) repair at the DNA replication fork during DNA replication recovery from DNA damage (PubMed:23797032). Recruited with TIMELESS factor upon DNA-replication stress response at DNA replication fork to preserve replication fork progression, and hence ensure DNA replication fidelity (PubMed:26503245). Also cooperates with TIMELESS factor during DNA replication to regulate proper sister chromatid cohesion and mitotic chromosome segregation (PubMed:17105772, PubMed:18499658, PubMed:20124417, PubMed:23116066, PubMed:23797032). Stimulates 5'-single-stranded DNA flap endonuclease activity of FEN1 in an ATP- and helicase-independent manner; and hence it may contribute in Okazaki fragment processing at DNA replication fork during lagging strand DNA synthesis (PubMed:18499658). Its ability to function at DNA replication fork is modulated by its binding to long non-coding RNA (lncRNA) cohesion regulator non-coding RNA DDX11-AS1/CONCR, which is able to increase both DDX11 ATPase activity and binding to DNA replicating regions (PubMed:27477908). Also plays a role in heterochromatin organization (PubMed:21854770). Involved in rRNA transcription activation through binding to active hypomethylated rDNA gene loci by recruiting UBTF and the RNA polymerase Pol I transcriptional machinery (PubMed:26089203). Plays a role in embryonic development and prevention of aneuploidy (By similarity). Involved in melanoma cell proliferation and survival (PubMed:23116066). Associates with chromatin at DNA replication fork regions (PubMed:27477908). Binds to single- and double-stranded DNAs (PubMed:18499658, PubMed:22102414, PubMed:9013641) (Microbial infection) Required for bovine papillomavirus type 1 regulatory protein E2 loading onto mitotic chromosomes during DNA replication for the viral genome to be maintained and segregated","Expressed in melanoma cells. Not detected in epidermal melanocytes of normal skin (at protein level) (PubMed:23116066). Highly expressed in spleen, B-cells, thymus, testis, ovary, small intestine and pancreas (PubMed:9013641). Very low expression seen in brain (PubMed:9013641). Expressed in dividing cells and/or cells undergoing high levels of recombination (PubMed:9013641). No expression detected in cells signaled to terminally differentiate (PubMed:9013641). Expressed weakly in keratinocytes (PubMed:8798685)","Warsaw breakage syndrome: A syndrome characterized by severe microcephaly, pre- and postnatal growth retardation, facial dysmorphism and abnormal skin pigmentation. Additional features include high arched palate, coloboma of the right optic disk, deafness, ventricular septal defect, toes and fingers abnormalities. At cellular level, drug-induced chromosomal breakage, a feature of Fanconi anemia, and sister chromatid cohesion defects, a feature of Roberts syndrome, coexist.",,"Nucleus Nucleus, nucleolus Cytoplasm, cytoskeleton, spindle pole Midbody Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Chromosome",10648783|17105772|17189189|18499658|20124417|21854770|22102414|23116066|23797032|26089203|26503245|27477908,23116066|8798685|9013641,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
DDX20,ENSG00000064703,Unsafe,Protein,False,True,51.3,51.3,87,19,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 2.2 nTPM; absolute ceiling; basal ganglia: 2.3 nTPM; absolute ceiling; colon: 3.8 nTPM; positive ihc; duodenum: 0.5 nTPM; positive ihc; esophagus: 3.2 nTPM; positive ihc; hippocampal formation: 2.1 nTPM; absolute ceiling; hypothalamus: 2.1 nTPM; absolute ceiling; lymph node: 2.9 nTPM; positive ihc; rectum: 1.9 nTPM; positive ihc; small intestine: 4.2 nTPM; positive ihc;absolute ceiling; stomach: 3.7 nTPM; positive ihc; urinary bladder: 3.8 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 2.2 nTPM (limit 2); basal ganglia: 2.3 nTPM (limit 2); hippocampal formation: 2.1 nTPM (limit 2); hypothalamus: 2.1 nTPM (limit 2); small intestine: 4.2 nTPM (limit 2),bronchus / respiratory epithelial cells: Low (Enhanced); colon / glandular cells: Low (Enhanced); colon / peripheral nerve/ganglion: Low (Enhanced); duodenum / glandular cells: Low (Enhanced); esophagus / squamous epithelial cells: Low (Enhanced); lymph node / germinal center cells: Low (Enhanced); rectum / glandular cells: Low (Enhanced); small intestine / glandular cells: Low (Enhanced); stomach 1 / glandular cells: Low (Enhanced); urinary bladder / urothelial cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 49/50 (98.0%); Pancreatic Adenocarcinoma (validation): 76/80 (95.0%),testis cancer: 8/12 (66.7%); colorectal cancer: 5/12 (41.7%),31,20,Q9UHI6,https://www.uniprot.org/uniprotkb/Q9UHI6/entry,"The SMN complex catalyzes the assembly of small nuclear ribonucleoproteins (snRNPs), the building blocks of the spliceosome, and thereby plays an important role in the splicing of cellular pre-mRNAs. Most spliceosomal snRNPs contain a common set of Sm proteins SNRPB, SNRPD1, SNRPD2, SNRPD3, SNRPE, SNRPF and SNRPG that assemble in a heptameric protein ring on the Sm site of the small nuclear RNA to form the core snRNP (Sm core). In the cytosol, the Sm proteins SNRPD1, SNRPD2, SNRPE, SNRPF and SNRPG are trapped in an inactive 6S pICln-Sm complex by the chaperone CLNS1A that controls the assembly of the core snRNP. To assemble core snRNPs, the SMN complex accepts the trapped 5Sm proteins from CLNS1A forming an intermediate. Binding of snRNA inside 5Sm triggers eviction of the SMN complex, thereby allowing binding of SNRPD3 and SNRPB to complete assembly of the core snRNP. May also play a role in the metabolism of small nucleolar ribonucleoprotein (snoRNPs)",Ubiquitous,,,"Cytoplasm Nucleus, gem",18984161,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Jamin2021_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
DDX25,ENSG00000109832,Unsafe,Protein,False,True,88.8,88.8,90,13,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 13.2 nTPM; absolute ceiling; basal ganglia: 21.6 nTPM; absolute ceiling; cerebellum: 15.7 nTPM; absolute ceiling; cerebral cortex: 22 nTPM; positive ihc;absolute ceiling; hippocampal formation: 12.4 nTPM; absolute ceiling; hypothalamus: 18.8 nTPM; absolute ceiling; midbrain: 11.6 nTPM; absolute ceiling; pituitary gland: 14.5 nTPM; absolute ceiling; retina: 21.2 nTPM; absolute ceiling; spinal cord: 4.7 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 13.2 nTPM (limit 2); basal ganglia: 21.6 nTPM (limit 2); cerebellum: 15.7 nTPM (limit 12); cerebral cortex: 22 nTPM (limit 2); hippocampal formation: 12.4 nTPM (limit 2); hypothalamus: 18.8 nTPM (limit 2); midbrain: 11.6 nTPM (limit 2); pituitary gland: 14.5 nTPM (limit 2); retina: 21.2 nTPM (limit 2); spinal cord: 4.7 nTPM (limit 2),cerebral cortex / glial cells: High (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); cerebral cortex / neuronal projections: Medium (Enhanced); hypothalamus / glial cells: Medium (Enhanced); hypothalamus / neuronal cells: Low (Enhanced); hypothalamus / neuronal projections: High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 42/58 (72.4%); Glioblastoma Multiforme (TCGA): 71/141 (50.4%); Testicular Germ Cell Tumor (TCGA): 41/133 (30.8%),liver cancer: 1/10 (10.0%); prostate cancer: 1/12 (8.3%),31,20,Q9UHL0,https://www.uniprot.org/uniprotkb/Q9UHL0/entry,ATP-dependent RNA helicase. Required for mRNA export and translation regulation during spermatid development (By similarity),Highly expressed in the Leydig and germ cells of the testis and weakly expressed in the pituitary and hypothalamus,,,Cytoplasm Nucleus,10608860,10608860,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Jamin2021_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
DDX43,ENSG00000080007,Unsafe,Protein,False,True,19.0,19.0,88,8,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; lung: 1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,lung / macrophages: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 97/133 (72.9%); Kidney Renal Clear Cell Carcinoma (validation): 12/100 (12.0%); Lung Adenocarcinoma (validation): 12/105 (11.4%),testis cancer: 9/12 (75.0%); liver cancer: 3/12 (25.0%),31,20,Q9NXZ2,https://www.uniprot.org/uniprotkb/Q9NXZ2/entry,,Expressed in testis. Expressed in many tumors of various histological types at a level that is 100-fold higher than the level observed in normal tissues except testis,,,,,10919659,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination; inclusion depends on TGCT under this study's thresholds | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
DDX47,ENSG00000213782,Unsafe,Protein,False,True,35.5,45.9,87,61,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 27.9 nTPM; absolute ceiling;continuous selectivity; adrenal gland: 23.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 18.5 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 19.1 nTPM; absolute ceiling;continuous selectivity; bone marrow: 40.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 21.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 19.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 35.1 nTPM; absolute ceiling;continuous selectivity; colon: 28.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 17.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 28.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 22.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 18.7 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 18.5 nTPM; absolute ceiling;continuous selectivity; kidney: 30.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 36.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 24.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 31.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 19.4 nTPM; absolute ceiling;continuous selectivity; pancreas: 29.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 35.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 17.1 nTPM; absolute ceiling;continuous selectivity; rectum: 25.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 16.4 nTPM; absolute ceiling;continuous selectivity; salivary gland: 23.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 43 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 29.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 21.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 32.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 20.1 nTPM; absolute ceiling;continuous selectivity; spleen: 22.8 nTPM; absolute ceiling;continuous selectivity; stomach: 28.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 34.6 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 32.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 40 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 45.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 27.9 nTPM (limit 20); adrenal gland: 23.4 nTPM (limit 2); amygdala: 18.5 nTPM (limit 2); basal ganglia: 19.1 nTPM (limit 2); bone marrow: 40.6 nTPM (limit 2); cerebellum: 21.2 nTPM (limit 2); cerebral cortex: 19.4 nTPM (limit 2); choroid plexus: 35.1 nTPM (limit 2); colon: 28.4 nTPM (limit 6); duodenum: 17.7 nTPM (limit 2); esophagus: 28.3 nTPM (limit 6); heart muscle: 22.3 nTPM (limit 2); hippocampal formation: 18.7 nTPM (limit 2); hypothalamus: 18.5 nTPM (limit 2); kidney: 30.9 nTPM (limit 2); liver: 36.7 nTPM (limit 2); lung: 24.1 nTPM (limit 2); lymph node: 31.9 nTPM (limit 6); midbrain: 19.4 nTPM (limit 2); pancreas: 29.9 nTPM (limit 2); parathyroid gland: 35.3 nTPM (limit 6); pituitary gland: 17.1 nTPM (limit 2); rectum: 25.5 nTPM (limit 6); retina: 16.4 nTPM (limit 2); salivary gland: 23.7 nTPM (limit 6); skeletal muscle: 43 nTPM (limit 2); skin: 29.6 nTPM (limit 10); small intestine: 21.1 nTPM (limit 2); smooth muscle: 32.2 nTPM (limit 2); spinal cord: 20.1 nTPM (limit 2); spleen: 22.8 nTPM (limit 20); stomach: 28.5 nTPM (limit 6); thymus: 34.6 nTPM (limit 10); thyroid gland: 32.3 nTPM (limit 10); tongue: 40 nTPM (limit 6); urinary bladder: 45.9 nTPM (limit 6),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Low (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: High (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: High (Approved); pancreas / exocrine glandular cells: Low (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Low (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: High (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%); Thyroid Carcinoma (TCGA): 495/495 (100.0%),skin cancer: 11/12 (91.7%); melanoma: 8/9 (88.9%),31,20,Q9H0S4,https://www.uniprot.org/uniprotkb/Q9H0S4/entry,Required for efficient ribosome biogenesis (By similarity). May have a role in mRNA splicing (PubMed:16963496). Involved in apoptosis (PubMed:15977068),"Expressed in skin, lung and breast. Also expressed in the brain",,,"Nucleus, nucleolus",15977068|16963496,31256877,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
DEFB119,ENSG00000180483,Unsafe,RNA,False,True,1870.7,1870.7,84,2,Positive somewhere,False,True,False,True,Excluded,Normal,False,,Not assessed,,,retina: 150.8 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 150.8 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 22/133 (16.5%); Glioblastoma Multiforme (validation): 3/58 (5.2%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),stomach cancer: 1/12 (8.3%); breast cancer: 0/11 (0.0%),31,20,Q8N690,https://www.uniprot.org/uniprotkb/Q8N690/entry,Has antibacterial activity,"Abundant expression in the male reproductive tract only. Abundant expressed in testis and the caput region of epididymis, but low in the corpus region",,,Secreted,,15772680,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Carter2023_CT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
DEPDC1,ENSG00000024526,Unsafe,Protein,False,True,7.8,7.9,81,45,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,Trial registration,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; bone marrow: 4.9 nTPM; absolute ceiling;continuous selectivity; cerebellum: 0 nTPM; positive ihc; cerebral cortex: 0.2 nTPM; positive ihc; colon: 2.8 nTPM; positive ihc;continuous selectivity; duodenum: 2.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 2.3 nTPM; positive ihc; kidney: 0 nTPM; positive ihc; lymph node: 4.7 nTPM; continuous selectivity; rectum: 3.4 nTPM; positive ihc;continuous selectivity; skin: 1.5 nTPM; positive ihc; small intestine: 2.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 1.4 nTPM; positive ihc; spleen: 0.5 nTPM; positive ihc; stomach: 1.2 nTPM; positive ihc; thymus: 7.9 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 0.3 nTPM; positive ihc; urinary bladder: 0.9 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 4.9 nTPM (limit 4); duodenum: 2.4 nTPM (limit 2); small intestine: 2.3 nTPM (limit 2),bronchus / respiratory epithelial cells: Low (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Low (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Medium (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); oral mucosa / squamous epithelial cells: Low (Approved); rectum / glandular cells: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in red pulp: Low (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Low (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Low (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,True,1.8,82.9,"hpa_single_cell: /Erythroid cells, max 30.2 nTPM, 1 observations >30; hpa_single_cell_tissue: colon/undifferentiated cells, max 54.6 nTPM, 2 observations >30; hpa_single_cell_tissue: liver/erythroid cells, max 35 nTPM, 1 observations >30; hpa_single_cell_tissue: placenta/mixed immune cells, max 74.1 nTPM, 1 observations >30; hpa_single_cell_tissue: rectum/mixed immune cells, max 44.2 nTPM, 1 observations >30; hpa_single_cell_tissue: rectum/undifferentiated cells, max 36.1 nTPM, 1 observations >30; hpa_single_cell_tissue: tongue/basal keratinocytes, max 82.9 nTPM, 1 observations >30",Unsafe,oncoref.target-sets.2026-10-23.2,1.8 TPM; blood/Plasmablast; hpa_immune_monaco; vital,82.9 nTPM; tongue/basal keratinocytes; hpa_single_cell_tissue; protected,Colon Adenocarcinoma (validation): 465/486 (95.7%); Glioblastoma Multiforme (validation): 53/58 (91.4%); Rectum Adenocarcinoma (validation): 174/207 (84.1%),urothelial cancer: 9/10 (90.0%); melanoma: 8/11 (72.7%),31,20,Q5TB30,https://www.uniprot.org/uniprotkb/Q5TB30/entry,"May be involved in transcriptional regulation as a transcriptional corepressor. The DEPDC1A-ZNF224 complex may play a critical role in bladder carcinogenesis by repressing the transcription of the A20 gene, leading to transport of NF-KB protein into the nucleus, resulting in suppression of apoptosis of bladder cancer cells",Expressed in testis. Up-regulated in bladder cancer cells (at protein level),,,Nucleus,20587513,17452976,False,Reviewed UniProt annotation; not a new primary-paper review,Trial registration only,https://clinicaltrials.gov/study/NCT00676949,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
DEPDC1B,ENSG00000035499,Unsafe,Protein,False,True,12.3,20.3,85,35,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 11 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 0.8 nTPM; positive ihc; colon: 3.9 nTPM; positive ihc; duodenum: 5.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 2.4 nTPM; positive ihc; kidney: 2.8 nTPM; positive ihc;absolute ceiling; lung: 0.3 nTPM; positive ihc; lymph node: 8.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; pancreas: 0.1 nTPM; positive ihc; rectum: 5.4 nTPM; positive ihc;continuous selectivity; small intestine: 6.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 0.8 nTPM; positive ihc; spleen: 1.5 nTPM; positive ihc; thymus: 20.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 1.2 nTPM; positive ihc; urinary bladder: 1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 11 nTPM (limit 2); duodenum: 5.9 nTPM (limit 2); kidney: 2.8 nTPM (limit 2); lymph node: 8.8 nTPM (limit 6); small intestine: 6.2 nTPM (limit 2); thymus: 20.2 nTPM (limit 10),bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Low (Approved); caudate / neuronal cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Low (Approved); duodenum / glandular cells: Low (Approved); esophagus / squamous epithelial cells: Low (Approved); kidney / cells in tubules: Low (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Low (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Low (Approved); pancreas / pancreatic endocrine cells: Low (Approved); rectum / glandular cells: Low (Approved); small intestine / glandular cells: Low (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in red pulp: Low (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (TCGA): 228/254 (89.8%); Colon Adenocarcinoma (validation): 435/486 (89.5%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 244/283 (86.2%),liver cancer: 7/10 (70.0%); endometrial cancer: 5/12 (41.7%),31,20,Q8WUY9,https://www.uniprot.org/uniprotkb/Q8WUY9/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bradley2020_CPA | Bruggeman2018_GC | Jamin2021_CT,Expression-nominated CPA; not newly validated by this study | GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
DEPDC7,ENSG00000121690,Unsafe,RNA,False,True,27.4,71.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 2.4 nTPM; absolute ceiling; cerebral cortex: 2.1 nTPM; absolute ceiling; choroid plexus: 2.8 nTPM; absolute ceiling; duodenum: 23.9 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 3.3 nTPM; absolute ceiling; kidney: 18.8 nTPM; absolute ceiling;continuous selectivity; liver: 71.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 2.8 nTPM; absolute ceiling; pancreas: 3.7 nTPM; absolute ceiling; skeletal muscle: 4.7 nTPM; absolute ceiling; small intestine: 28.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 4.5 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 2.4 nTPM (limit 2); cerebral cortex: 2.1 nTPM (limit 2); choroid plexus: 2.8 nTPM (limit 2); duodenum: 23.9 nTPM (limit 2); hippocampal formation: 3.3 nTPM (limit 2); kidney: 18.8 nTPM (limit 2); liver: 71.8 nTPM (limit 2); midbrain: 2.8 nTPM (limit 2); pancreas: 3.7 nTPM (limit 2); skeletal muscle: 4.7 nTPM (limit 2); small intestine: 28.2 nTPM (limit 2); spinal cord: 4.5 nTPM (limit 2); amygdala: 2.4 nTPM (baseline 2); cerebral cortex: 2.1 nTPM (baseline 2); choroid plexus: 2.8 nTPM (baseline 2); duodenum: 23.9 nTPM (baseline 2); hippocampal formation: 3.3 nTPM (baseline 2); kidney: 18.8 nTPM (baseline 2); liver: 71.8 nTPM (baseline 2); midbrain: 2.8 nTPM (baseline 2); pancreas: 3.7 nTPM (baseline 2); skeletal muscle: 4.7 nTPM (baseline 2); small intestine: 28.2 nTPM (baseline 2); spinal cord: 4.5 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (validation): 219/231 (94.8%); Kidney Renal Clear Cell Carcinoma (validation): 86/100 (86.0%); Liver Hepatocellular Carcinoma (TCGA): 304/362 (84.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q96QD5,https://www.uniprot.org/uniprotkb/Q96QD5/entry,,Expressed in liver,,,,,10568747,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
DEUP1,ENSG00000165325,Unsafe,High RNA,False,True,15.9,15.9,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,CTA,Pass,oncoref.target-sets.2026-10-23.1,False,False,,CTA → Unsafe,True,True,True,1.0,38.3,"hpa_single_cell_tissue: lung/ciliated cells, max 38.3 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,1 TPM; blood/myeloid DC; hpa_immune_monaco; vital,38.3 nTPM; lung/ciliated cells; hpa_single_cell_tissue; vital,Uterine Corpus Endometrial Carcinoma (TCGA): 6/176 (3.4%); Lung Squamous Cell Carcinoma (validation): 2/68 (2.9%); Ovary Serous Cystadenocarcinoma (TCGA): 10/349 (2.9%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q05D60,https://www.uniprot.org/uniprotkb/Q05D60/entry,"Key structural component of the deuterosome, a structure that promotes de novo centriole amplification in multiciliated cells. Deuterosome-mediated centriole amplification occurs in terminally differentiated multiciliated cells and can generate more than 100 centrioles. Probably sufficient for the specification and formation of the deuterosome inner core. Interacts with CEP152 and recruits PLK4 to activate centriole biogenesis (By similarity)",,,It is uncertain whether Met-1 or Met-9 is the initiator,Cytoplasm,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
DGKH,ENSG00000102780,Unsafe,Protein,False,True,6.8,7.5,78,74,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 3.6 nTPM; positive ihc;continuous selectivity; adrenal gland: 1.3 nTPM; positive ihc; basal ganglia: 7.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 1.3 nTPM; positive ihc; cerebellum: 5.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 2 nTPM; positive ihc;continuous selectivity; colon: 3.6 nTPM; positive ihc;continuous selectivity; duodenum: 1.5 nTPM; positive ihc; esophagus: 4 nTPM; positive ihc;continuous selectivity; heart muscle: 2.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 1.9 nTPM; continuous selectivity; hypothalamus: 1.8 nTPM; continuous selectivity; kidney: 3.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 1 nTPM; positive ihc; lung: 7.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 2.1 nTPM; positive ihc; pancreas: 1 nTPM; positive ihc; parathyroid gland: 0.6 nTPM; positive ihc; pituitary gland: 2.5 nTPM; absolute ceiling;continuous selectivity; rectum: 3.2 nTPM; positive ihc;continuous selectivity; retina: 2.5 nTPM; absolute ceiling;continuous selectivity; salivary gland: 2.9 nTPM; positive ihc;continuous selectivity; skeletal muscle: 1.5 nTPM; positive ihc; skin: 3.2 nTPM; positive ihc;continuous selectivity; small intestine: 2.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 3.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; spleen: 1.6 nTPM; positive ihc; stomach: 2.5 nTPM; positive ihc;continuous selectivity; thyroid gland: 2.4 nTPM; positive ihc; urinary bladder: 5.1 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",basal ganglia: 7.5 nTPM (limit 2); cerebellum: 5.9 nTPM (limit 2); heart muscle: 2.9 nTPM (limit 2); kidney: 3.2 nTPM (limit 2); lung: 7.5 nTPM (limit 2); pituitary gland: 2.5 nTPM (limit 2); retina: 2.5 nTPM (limit 2); small intestine: 2.6 nTPM (limit 2); smooth muscle: 3.9 nTPM (limit 2); basal ganglia: 7.5 nTPM (baseline 2); cerebellum: 5.9 nTPM (baseline 2); heart muscle: 2.9 nTPM (baseline 2); kidney: 3.2 nTPM (baseline 2); lung: 7.5 nTPM (baseline 2); pituitary gland: 2.5 nTPM (baseline 2); retina: 2.5 nTPM (baseline 2); small intestine: 2.6 nTPM (baseline 2); smooth muscle: 3.9 nTPM (baseline 2),adipose tissue / adipocytes: Low (Uncertain); adrenal gland / glandular cells: High (Uncertain); bone marrow / hematopoietic cells: High (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / neuronal cells: Low (Uncertain); cerebellum / cells in granular layer: Low (Uncertain); cerebellum / cells in molecular layer: Low (Uncertain); cerebellum / Purkinje cells: High (Uncertain); cerebral cortex / endothelial cells: Medium (Uncertain); cerebral cortex / glial cells: Medium (Uncertain); cerebral cortex / neuronal cells: High (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / endothelial cells: Medium (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: High (Uncertain); duodenum / glandular cells: High (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: High (Uncertain); hippocampus / neuronal cells: Low (Uncertain); kidney / cells in glomeruli: Medium (Uncertain); kidney / cells in tubules: High (Uncertain); liver / hepatocytes: Low (Uncertain); lung / alveolar cells: Low (Uncertain); lung / macrophages: High (Uncertain); lymph node / germinal center cells: Medium (Uncertain); lymph node / non-germinal center cells: Medium (Uncertain); nasopharynx / respiratory epithelial cells: High (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: High (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: High (Uncertain); skin 1 / fibroblasts: Medium (Uncertain); skin 1 / keratinocytes: Medium (Uncertain); skin 1 / Langerhans: Medium (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: High (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); spleen / cells in red pulp: High (Uncertain); spleen / cells in white pulp: Medium (Uncertain); stomach 1 / glandular cells: High (Uncertain); stomach 2 / glandular cells: High (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 485/486 (99.8%),colorectal cancer: 11/11 (100.0%); breast cancer: 10/11 (90.9%),31,20,Q86XP1,https://www.uniprot.org/uniprotkb/Q86XP1/entry,"Diacylglycerol kinase that converts diacylglycerol/DAG into phosphatidic acid/phosphatidate/PA and regulates the respective levels of these two bioactive lipids (PubMed:12810723, PubMed:23949095). Thereby, acts as a central switch between the signaling pathways activated by these second messengers with different cellular targets and opposite effects in numerous biological processes (Probable) (PubMed:12810723, PubMed:23949095). Plays a key role in promoting cell growth (PubMed:19710016). Activates the Ras/B-Raf/C-Raf/MEK/ERK signaling pathway induced by EGF (PubMed:19710016). Regulates the recruitment of RAF1 and BRAF from cytoplasm to membranes and their heterodimerization (PubMed:19710016)","Expressed only in testis, kidney and colon Ubiquitously expressed",,,Cytoplasm Cell membrane,12810723|19710016|23949095,12810723,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
DHH,ENSG00000139549,Unsafe,High RNA,False,True,16.2,16.2,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,True,"vascular/schwann cells cluster c-18: 56.9 nTPM, 109 reads; reproductive-cell max 32.1",True,False,,True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,1.01440826579,56.9,"hpa_single_cell_tissue: lung/endothelial cells, max 30.5 nTPM, 1 observations >30; hpa_single_cell_tissue: vascular/schwann cells, max 56.9 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,1.014 TPM; blood/NK; dice_nk; vital,56.9 nTPM; vascular/schwann cells; hpa_single_cell_tissue; vital,Skin Cuteneous Melanoma (TCGA): 4/99 (4.0%); Testicular Germ Cell Tumor (TCGA): 2/133 (1.5%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O43323,https://www.uniprot.org/uniprotkb/O43323/entry,"Precursor of desert hedgehog, a morphogen that activates the smoothened signaling pathway, and which is essential for a variety of patterning events during development (By similarity). The C-terminal part of the precursor displays an autoproteolysis and a cholesterol transferase activity, resulting (1) in the cleavage of the full-length protein into two parts, desert hedgehog protein N-product and C-product and (2) covalent attachment of a cholesterol moiety to the C-terminus of the newly generated N-product (DHH-N) (By similarity). Both autoproteolysis and a cholesterol transferase activities occur in the endoplasmic reticulum (By similarity). Following additional lipidation, DHH-N acts as a morphogen, while the C-product is degraded in the endoplasmic reticulum (By similarity) The dually lipidated desert hedgehog protein N-product is a morphogen that activates the smoothened signaling pathway, and which is essential for a variety of patterning events during development (By similarity). Acts by binding to the patched receptor (PTCH1 or PTCH2), relieving smoothened (SMO) inhibition by patched, activating the smoothened signaling pathway and transcription of target genes (PubMed:11472839, PubMed:33063110). In the absence of DHH, patched represses the constitutive signaling activity of SMO (By similarity). DHH plays a key role in male gonad development (spermatogenesis) and the formation of Schwann cells (By similarity). Required for normal testis development and spermatogenesis, namely for the formation of adult-type Leydig cells and normal development of peritubular cells and seminiferous tubules (By similarity). In Schwann cells, controls the development of the peripheral nerve sheath and the transition of mesenchymal cells to form the epithelium-like structure of the perineurial tube (By similarity). May induce motor neurons in lateral neural tube and may have a polarizing activity (PubMed:11472839). Involved in tissue regeneration: secreted from epithelial neuroendocrine cells and elicits a regenerative response from mesenchymal cells (By similarity). Functions in cell-cell mediated juxtacrine signaling (PubMed:24342078). Activates primary cilia signaling on neighboring valve interstitial cells through a paracrine mechanism (By similarity). Promotes endothelium integrity (PubMed:33063110)",,"46,XY gonadal dysgenesis with minifascicular neuropathy: An autosomal recessive disorder characterized by gonadal dysgenesis associated with polyneuropathy. Genital anomalies include the presence of a testis on one side and a streak or an absent gonad at the other, persistence of Muellerian duct structures, and a variable degree of genital ambiguity. 46,XY sex reversal 7: A disorder of sex development. Affected individuals have a 46,XY karyotype but present as phenotypically normal females. SRXY7 patients have no functional gonads.",,Endoplasmic reticulum membrane Golgi apparatus membrane Secreted Cell membrane,11472839|24342078|33063110,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
DHX9,ENSG00000135829,Unsafe,Protein,False,True,51.5,129.8,92,87,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 37.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 29.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 18.4 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 21.6 nTPM; absolute ceiling;continuous selectivity; bone marrow: 129.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 36.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 37.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 21.5 nTPM; absolute ceiling;continuous selectivity; colon: 38.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 31.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 31.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 27.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 17.1 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 19 nTPM; absolute ceiling;continuous selectivity; kidney: 48.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 35.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 37.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 55.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 17.8 nTPM; absolute ceiling;continuous selectivity; pancreas: 29.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 66 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 20.5 nTPM; absolute ceiling;continuous selectivity; rectum: 45.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 64.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 31.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 29.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 30.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 35.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 48.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 22.3 nTPM; absolute ceiling;continuous selectivity; spleen: 39.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 33.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 86.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 46.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 36.3 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 52 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 37.3 nTPM (limit 10); adrenal gland: 29.6 nTPM (limit 2); amygdala: 18.4 nTPM (limit 2); basal ganglia: 21.6 nTPM (limit 2); bone marrow: 129.8 nTPM (limit 2); cerebellum: 36.1 nTPM (limit 2); cerebral cortex: 37.2 nTPM (limit 2); choroid plexus: 21.5 nTPM (limit 2); colon: 38.9 nTPM (limit 6); duodenum: 31.7 nTPM (limit 2); esophagus: 31.2 nTPM (limit 6); heart muscle: 27.5 nTPM (limit 2); hippocampal formation: 17.1 nTPM (limit 2); hypothalamus: 19 nTPM (limit 2); kidney: 48.2 nTPM (limit 2); liver: 35.8 nTPM (limit 2); lung: 37.4 nTPM (limit 2); lymph node: 55.6 nTPM (limit 6); midbrain: 17.8 nTPM (limit 2); pancreas: 29.6 nTPM (limit 2); parathyroid gland: 66 nTPM (limit 6); pituitary gland: 20.5 nTPM (limit 2); rectum: 45.7 nTPM (limit 6); retina: 64.4 nTPM (limit 2); salivary gland: 31.6 nTPM (limit 6); skeletal muscle: 29.2 nTPM (limit 2); skin: 30.3 nTPM (limit 10); small intestine: 35.3 nTPM (limit 2); smooth muscle: 48.9 nTPM (limit 2); spinal cord: 22.3 nTPM (limit 2); spleen: 39.8 nTPM (limit 10); stomach: 33.6 nTPM (limit 6); thymus: 86.3 nTPM (limit 10); thyroid gland: 46.6 nTPM (limit 10); tongue: 36.3 nTPM (limit 6); urinary bladder: 52 nTPM (limit 6),adipose tissue / adipocytes: Medium (Supported); adrenal gland / glandular cells: High (Supported); bone marrow / hematopoietic cells: High (Supported); bronchus / respiratory epithelial cells: Medium (Supported); caudate / glial cells: High (Supported); caudate / neuronal cells: High (Supported); cerebellum / cells in granular layer: High (Supported); cerebellum / cells in molecular layer: High (Supported); cerebellum / Purkinje cells: High (Supported); cerebral cortex / endothelial cells: Low (Supported); cerebral cortex / glial cells: High (Supported); cerebral cortex / neuronal cells: High (Supported); colon / endothelial cells: High (Supported); colon / glandular cells: High (Supported); colon / peripheral nerve/ganglion: High (Supported); duodenum / glandular cells: High (Supported); esophagus / squamous epithelial cells: High (Supported); heart muscle / cardiomyocytes: Medium (Supported); hippocampus / glial cells: Medium (Supported); hippocampus / neuronal cells: High (Supported); kidney / cells in glomeruli: High (Supported); kidney / cells in tubules: High (Supported); liver / cholangiocytes: Low (Supported); liver / hepatocytes: Medium (Supported); lung / alveolar cells type I: High (Supported); lung / alveolar cells type II: High (Supported); lung / endothelial cells: Low (Supported); lung / macrophages: Medium (Supported); lymph node / germinal center cells: Medium (Supported); lymph node / non-germinal center cells: Medium (Supported); nasopharynx / respiratory epithelial cells: High (Supported); oral mucosa / squamous epithelial cells: Medium (Supported); pancreas / exocrine glandular cells: High (Supported); pancreas / pancreatic endocrine cells: High (Supported); parathyroid gland / glandular cells: High (Supported); rectum / glandular cells: High (Supported); salivary gland / glandular cells: High (Supported); skeletal muscle / myocytes: High (Supported); skin 1 / fibroblasts: Medium (Supported); skin 1 / keratinocytes: Medium (Supported); skin 1 / Langerhans: Medium (Supported); skin 2 / epidermal cells: High (Supported); small intestine / glandular cells: High (Supported); smooth muscle / smooth muscle cells: Medium (Supported); spleen / cells in red pulp: Medium (Supported); spleen / cells in white pulp: Medium (Supported); stomach 1 / glandular cells: High (Supported); stomach 2 / glandular cells: High (Supported); thyroid gland / glandular cells: High (Supported); urinary bladder / urothelial cells: High (Supported),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Squamous Cell Carcinoma (TCGA): 489/489 (100.0%); Colon Adenocarcinoma (validation): 486/486 (100.0%); Ovary Serous Cystadenocarcinoma (TCGA): 349/349 (100.0%),breast cancer: 12/12 (100.0%); cervical cancer: 12/12 (100.0%),31,20,Q08211,https://www.uniprot.org/uniprotkb/Q08211/entry,"Multifunctional ATP-dependent nucleic acid helicase that unwinds DNA and RNA in a 3' to 5' direction and that plays important roles in many processes, such as DNA replication, transcriptional activation, post-transcriptional RNA regulation, mRNA translation and RNA-mediated gene silencing (PubMed:11416126, PubMed:12711669, PubMed:15355351, PubMed:16680162, PubMed:17531811, PubMed:20669935, PubMed:21561811, PubMed:24049074, PubMed:24990949, PubMed:25062910, PubMed:28221134, PubMed:9111062, PubMed:37467750). Requires a 3'-single-stranded tail as entry site for acid nuclei unwinding activities as well as the binding and hydrolyzing of any of the four ribo- or deoxyribo-nucleotide triphosphates (NTPs) (PubMed:1537828). Unwinds numerous nucleic acid substrates such as double-stranded (ds) DNA and RNA, DNA:RNA hybrids, DNA and RNA forks composed of either partially complementary DNA duplexes or DNA:RNA hybrids, respectively, and also DNA and RNA displacement loops (D- and R-loops), triplex-helical DNA (H-DNA) structure and DNA and RNA-based G-quadruplexes (PubMed:20669935, PubMed:21561811, PubMed:24049074). Binds dsDNA, single-stranded DNA (ssDNA), dsRNA, ssRNA and poly(A)-containing RNA (PubMed:10198287, PubMed:9111062). Also binds to circular dsDNA or dsRNA of either linear and/or circular forms and stimulates the relaxation of supercoiled DNAs catalyzed by topoisomerase TOP2A (PubMed:12711669). Plays a role in DNA replication at origins of replication and cell cycle progression (PubMed:24990949). Plays a role as a transcriptional coactivator acting as a bridging factor between polymerase II holoenzyme and transcription factors or cofactors, such as BRCA1, CREBBP, RELA and SMN1 (PubMed:11038348, PubMed:11149922, PubMed:11416126, PubMed:15355351, PubMed:28221134, PubMed:9323138, PubMed:9662397). Binds to the CDKN2A promoter (PubMed:11038348). Plays several roles in post-transcriptional regulation of gene expression (PubMed:28221134, PubMed:28355180). In cooperation with NUP98, promotes pre-mRNA alternative splicing activities of a subset of genes (PubMed:11402034, PubMed:16680162, PubMed:28221134, PubMed:28355180). As component of a large PER complex, is involved in the negative regulation of 3' transcriptional termination of circadian target genes such as PER1 and NR1D1 and the control of the circadian rhythms (By similarity). Also acts as a nuclear resolvase that is able to bind and neutralize harmful massive secondary double-stranded RNA structures formed by inverted-repeat Alu retrotransposon elements that are inserted and transcribed as parts of genes during the process of gene transposition (PubMed:28355180). Involved in the positive regulation of nuclear export of constitutive transport element (CTE)-containing unspliced mRNA (PubMed:10924507, PubMed:11402034, PubMed:9162007). Component of the coding region determinant (CRD)-mediated complex that promotes cytoplasmic MYC mRNA stability (PubMed:19029303). Plays a role in mRNA translation (PubMed:28355180). Positively regulates translation of selected mRNAs through its binding to post-transcriptional control element (PCE) in the 5'-untranslated region (UTR) (PubMed:16680162). Involved with LARP6 in the translation stimulation of type I collagen mRNAs for CO1A1 and CO1A2 through binding of a specific stem-loop structure in their 5'-UTRs (PubMed:22190748). Stimulates LIN28A-dependent mRNA translation probably by facilitating ribonucleoprotein remodeling during the process of translation (PubMed:21247876). Plays also a role as a small interfering (siRNA)-loading factor involved in the RNA-induced silencing complex (RISC) loading complex (RLC) assembly, and hence functions in the RISC-mediated gene silencing process (PubMed:17531811). Binds preferentially to short double-stranded RNA, such as those produced during rotavirus intestinal infection (PubMed:28636595). This interaction may mediate NLRP9 inflammasome activation and trigger inflammatory response, including IL18 release and pyroptosis (PubMed:28636595). Finally, mediates the attachment of heterogeneous nuclear ribonucleoproteins (hnRNPs) to actin filaments in the nucleus (PubMed:11687588) (Microbial infection) Plays a role in HIV-1 replication and virion infectivity (PubMed:11096080, PubMed:19229320, PubMed:25149208, PubMed:27107641). Enhances HIV-1 transcription by facilitating the binding of RNA polymerase II holoenzyme to the proviral DNA (PubMed:11096080, PubMed:25149208). Binds (via DRBM domain 2) to the HIV-1 TAR RNA and stimulates HIV-1 transcription of transactivation response element (TAR)-containing mRNAs (PubMed:11096080, PubMed:9892698). Involved also in HIV-1 mRNA splicing and transport (PubMed:25149208). Positively regulates HIV-1 gag mRNA translation, through its binding to post-transcriptional control element (PCE) in the 5'-untranslated region (UTR) (PubMed:16680162). Binds (via DRBM domains) to a HIV-1 double-stranded RNA region of the primer binding site (PBS)-segment of the 5'-UTR, and hence stimulates DHX9 incorporation into virions and virion infectivity (PubMed:27107641). Also plays a role as a cytosolic viral MyD88-dependent DNA and RNA sensors in plasmacytoid dendritic cells (pDCs), and hence induce antiviral innate immune responses (PubMed:20696886, PubMed:21957149). Binds (via the OB-fold region) to viral single-stranded DNA unmethylated C-phosphate-G (CpG) oligonucleotide (PubMed:20696886)",,"Intellectual developmental disorder, autosomal dominant 75: An autosomal dominant neurodevelopmental disorder characterized by developmental delay, mild to severe impaired intellectual development, and neuropsychiatric manifestations including autism spectrum disorder, anxiety, and obsessive compulsive disorder. Disease features are highly variable and may include hypotonia, seizures, non-specific dysmorphism, poor overall growth with small head circumference, abnormal brain imaging, and heart disease.",,"Nucleus Nucleus, nucleoplasm Nucleus, nucleolus Cytoplasm Cytoplasm, cytoskeleton, microtubule organizing center, centrosome",10198287|10924507|11038348|11096080|11149922|11402034|11416126|11687588|12711669|15355351|1537828|16680162|17531811|19029303|19229320|20669935|20696886|21247876|21561811|21957149|22190748|24049074|24990949|25062910|25149208|27107641|28221134|28355180|28636595|37467750|9111062|9162007|9323138|9662397|9892698,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
DIAPH3,ENSG00000139734,Unsafe,RNA,False,True,18.3,18.3,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 7 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 2.5 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 7 nTPM (limit 2); smooth muscle: 2.5 nTPM (limit 2); bone marrow: 7 nTPM (baseline 2); smooth muscle: 2.5 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 478/486 (98.4%); Rectum Adenocarcinoma (validation): 196/207 (94.7%); Glioblastoma Multiforme (validation): 53/58 (91.4%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9NSV4,https://www.uniprot.org/uniprotkb/Q9NSV4/entry,"Actin nucleation and elongation factor required for the assembly of F-actin structures, such as actin cables and stress fibers. Required for cytokinesis, stress fiber formation and transcriptional activation of the serum response factor. Binds to GTP-bound form of Rho and to profilin: acts in a Rho-dependent manner to recruit profilin to the membrane, where it promotes actin polymerization. DFR proteins couple Rho and Src tyrosine kinase during signaling and the regulation of actin dynamics. Also acts as an actin nucleation and elongation factor in the nucleus by promoting nuclear actin polymerization inside the nucleus to drive serum-dependent SRF-MRTFA activity",,"Auditory neuropathy, autosomal dominant 1: A form of sensorineural hearing loss with absent or severely abnormal auditory brainstem response, in the presence of normal cochlear outer hair cell function and normal otoacoustic emissions. Auditory neuropathies result from a lesion in the area including the inner hair cells, connections between the inner hair cells and the cochlear branch of the auditory nerve, the auditory nerve itself and auditory pathways of the brainstem. Affected individuals typically respond to sound but have difficulties in speech discrimination.",,Cytoplasm Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Jamin2021_CT | Jamin2021_core | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
DLGAP5,ENSG00000126787,Unsafe,Protein,False,True,16.9,40.9,126,49,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 29.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 0.4 nTPM; positive ihc; duodenum: 4.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 5 nTPM; positive ihc; kidney: 0.2 nTPM; positive ihc; lung: 0.7 nTPM; positive ihc; lymph node: 17.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; rectum: 6.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 0.1 nTPM; positive ihc; skin: 3.1 nTPM; positive ihc; small intestine: 4.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 2.6 nTPM; positive ihc;absolute ceiling; spleen: 2.6 nTPM; positive ihc; stomach: 2.9 nTPM; positive ihc; thymus: 40.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 2 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 29.3 nTPM (limit 2); duodenum: 4.9 nTPM (limit 2); lymph node: 17.4 nTPM (limit 6); rectum: 6.5 nTPM (limit 6); small intestine: 4.5 nTPM (limit 2); smooth muscle: 2.6 nTPM (limit 2); thymus: 40.9 nTPM (limit 10),bone marrow / hematopoietic cells: High (Enhanced); bronchus / respiratory epithelial cells: Low (Enhanced); cerebral cortex / neuropil: Low (Enhanced); duodenum / endocrine cells: Medium (Enhanced); esophagus / squamous epithelial cells: Low (Enhanced); kidney / cells in glomeruli: Low (Enhanced); kidney / cells in tubules: Low (Enhanced); lung / macrophages: Low (Enhanced); lymph node / germinal center cells: High (Enhanced); nasopharynx / respiratory epithelial cells: Low (Enhanced); oral mucosa / squamous epithelial cells: Low (Enhanced); rectum / endocrine cells: Medium (Enhanced); rectum / mucosal lymphoid cells: Low (Enhanced); skeletal muscle / myocytes: Low (Enhanced); skin 1 / cells in basal layer: Low (Enhanced); skin 1 / endothelial cells: Medium (Enhanced); skin 1 / fibrohistiocytic cells: Low (Enhanced); skin 2 / cells in basal layer: Low (Enhanced); skin 2 / cells in spinous layer: Low (Enhanced); skin 2 / endothelial cells: Medium (Enhanced); skin 2 / fibrohistiocytic cells: Low (Enhanced); small intestine / endocrine cells: Medium (Enhanced); smooth muscle / smooth muscle cells: Low (Enhanced); spleen / cells in red pulp: Low (Enhanced); stomach 2 / glandular cells: Low (Enhanced); urinary bladder / urothelial cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 483/486 (99.4%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 279/283 (98.6%); Glioblastoma Multiforme (validation): 57/58 (98.3%),testis cancer: 11/12 (91.7%); cervical cancer: 8/11 (72.7%),31,20,Q15398,https://www.uniprot.org/uniprotkb/Q15398/entry,Potential cell cycle regulator that may play a role in carcinogenesis of cancer cells. Mitotic phosphoprotein regulated by the ubiquitin-proteasome pathway. Key regulator of adherens junction integrity and differentiation that may be involved in CDH1-mediated adhesion and signaling in epithelial cells,"Abundantly expressed in fetal liver. Expressed at lower levels in bone marrow, testis, colon, and placenta",,It was localized to the spindle and the spindle pole (PubMed:12527899) but was later found to be localized to the spindle and to be excluded from the spindle pole (PubMed:15561729),"Nucleus Cytoplasm Cytoplasm, cytoskeleton, spindle",12527899|14699157|15145941,12527899,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
DMC1,ENSG00000100206,Unsafe,Protein,False,True,11.5,11.5,86,2,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; heart muscle: 2.2 nTPM; positive ihc;absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",heart muscle: 2.2 nTPM (limit 2),heart muscle / cardiomyocytes: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 46/133 (34.6%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 85/283 (30.0%); Breast Invasive Carcinoma (validation): 9/50 (18.0%),breast cancer: 0/11 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q14565,https://www.uniprot.org/uniprotkb/Q14565/entry,"Homologous DNA recombinase that catalyzes strand exchange during meiotic recombination (PubMed:15164066, PubMed:21307306, PubMed:26976601). Specifically required for meiotic recombination, facilitating the search and repair of DNA using the homolog rather than the sister chromatid, and can tolerate mismatches in heteroduplex DNA, unlike the higher-fidelity RAD51 (PubMed:15164066, PubMed:26976601)",,,,Chromosome Nucleus,15164066|21307306|26976601,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination; inclusion depends on TGCT under this study's thresholds | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
DMP1,ENSG00000152592,Unsafe,Protein,False,True,0.8,0.8,77,70,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0 nTPM; positive ihc; adrenal gland: 0 nTPM; positive ihc; bone marrow: 0 nTPM; positive ihc; cerebellum: 0 nTPM; positive ihc; cerebral cortex: 0 nTPM; positive ihc; colon: 0 nTPM; positive ihc; duodenum: 0 nTPM; positive ihc; esophagus: 0 nTPM; positive ihc; heart muscle: 0 nTPM; positive ihc; kidney: 0 nTPM; positive ihc; liver: 0 nTPM; positive ihc; lung: 0 nTPM; positive ihc; lymph node: 0 nTPM; positive ihc; pancreas: 0 nTPM; positive ihc; parathyroid gland: 0 nTPM; positive ihc; rectum: 0 nTPM; positive ihc; salivary gland: 0 nTPM; positive ihc; skeletal muscle: 0 nTPM; positive ihc; skin: 0 nTPM; positive ihc; small intestine: 0 nTPM; positive ihc; smooth muscle: 0 nTPM; positive ihc; spleen: 0 nTPM; positive ihc; stomach: 0 nTPM; positive ihc; thyroid gland: 0 nTPM; positive ihc; urinary bladder: 0.1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 1/58 (1.7%); Pancreatic Adenocarcinoma (validation): 1/80 (1.2%); Kidney Renal Clear Cell Carcinoma (TCGA): 4/521 (0.8%),pancreatic cancer: 12/12 (100.0%); colorectal cancer: 11/11 (100.0%),31,20,Q13316,https://www.uniprot.org/uniprotkb/Q13316/entry,"May have a dual function during osteoblast differentiation. In the nucleus of undifferentiated osteoblasts, unphosphorylated form acts as a transcriptional component for activation of osteoblast-specific genes like osteocalcin. During the osteoblast to osteocyte transition phase it is phosphorylated and exported into the extracellular matrix, where it regulates nucleation of hydroxyapatite","Expressed in tooth particularly in odontoblast, ameloblast and cementoblast","Hypophosphatemic rickets, autosomal recessive, 1: A hereditary form of hypophosphatemic rickets, a disorder of proximal renal tubule function that causes phosphate loss, hypophosphatemia and skeletal deformities, including rickets and osteomalacia unresponsive to vitamin D. Symptoms are bone pain, fractures and growth abnormalities.",,"Nucleus Cytoplasm Secreted, extracellular space, extracellular matrix",12615915,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT,Cancer-associated RNA nomination; no antigen validation asserted,,,,,,,,
DMRTC1,ENSG00000269502,Unsafe,RNA,False,True,2.5,3.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 0.9 nTPM; continuous selectivity; basal ganglia: 1.8 nTPM; continuous selectivity; cerebellum: 0.9 nTPM; continuous selectivity; cerebral cortex: 3.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 1.1 nTPM; continuous selectivity; pituitary gland: 1.7 nTPM; continuous selectivity; retina: 2.3 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 2.1 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebral cortex: 3.2 nTPM (limit 2); retina: 2.3 nTPM (limit 2); cerebral cortex: 3.2 nTPM (baseline 2); retina: 2.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 4/50 (8.0%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Stomach Adenocarcinoma (TCGA): 1/346 (0.3%),urothelial cancer: 2/11 (18.2%); pancreatic cancer: 1/8 (12.5%),28,20,Q5HYR2,https://www.uniprot.org/uniprotkb/Q5HYR2/entry,,"Predominantly expressed in kidney, pancreas, ovary and testis. Detected in brain and in many other tissues",,"Although related to other DMRT proteins, it does not contain a canonical DM DNA-binding domain",,,11863363,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
DMRTC1B,ENSG00000184911,Unsafe,RNA,False,True,8.7,28.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 2.4 nTPM; absolute ceiling;continuous selectivity; amygdala: 21 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 28.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 9.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 23.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 4.3 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 17.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 27 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 9.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 3 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 24.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; retina: 8 nTPM; absolute ceiling;continuous selectivity; spinal cord: 3.9 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 2.4 nTPM (limit 2); amygdala: 21 nTPM (limit 2); basal ganglia: 28.2 nTPM (limit 2); cerebellum: 9.4 nTPM (limit 2); cerebral cortex: 23.2 nTPM (limit 2); choroid plexus: 4.3 nTPM (limit 2); hippocampal formation: 17.3 nTPM (limit 2); hypothalamus: 27 nTPM (limit 2); midbrain: 9.2 nTPM (limit 2); pancreas: 3 nTPM (limit 2); pituitary gland: 24.6 nTPM (limit 2); retina: 8 nTPM (limit 2); spinal cord: 3.9 nTPM (limit 2); adrenal gland: 2.4 nTPM (baseline 2); amygdala: 21 nTPM (baseline 2); basal ganglia: 28.2 nTPM (baseline 2); cerebellum: 9.4 nTPM (baseline 2); cerebral cortex: 23.2 nTPM (baseline 2); choroid plexus: 4.3 nTPM (baseline 2); hippocampal formation: 17.3 nTPM (baseline 2); hypothalamus: 27 nTPM (baseline 2); midbrain: 9.2 nTPM (baseline 2); pancreas: 3 nTPM (baseline 2); pituitary gland: 24.6 nTPM (baseline 2); retina: 8 nTPM (baseline 2); spinal cord: 3.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Thyroid Carcinoma (TCGA): 164/495 (33.1%); Glioblastoma Multiforme (TCGA): 42/141 (29.8%); Breast Invasive Carcinoma (validation): 13/50 (26.0%),colorectal cancer: 4/12 (33.3%); urothelial cancer: 3/11 (27.3%),31,20,Q5HYR2,https://www.uniprot.org/uniprotkb/Q5HYR2/entry,,"Predominantly expressed in kidney, pancreas, ovary and testis. Detected in brain and in many other tissues",,"Although related to other DMRT proteins, it does not contain a canonical DM DNA-binding domain",,,11863363,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
DNAAF1,ENSG00000154099,Unsafe,Protein,False,True,43.9,43.9,102,12,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; amygdala: 3.5 nTPM; absolute ceiling; basal ganglia: 5.4 nTPM; absolute ceiling; choroid plexus: 23.7 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 5.2 nTPM; absolute ceiling; hypothalamus: 8.1 nTPM; absolute ceiling; pituitary gland: 2.3 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 3.5 nTPM (limit 2); basal ganglia: 5.4 nTPM (limit 2); choroid plexus: 23.7 nTPM (limit 2); hippocampal formation: 5.2 nTPM (limit 2); hypothalamus: 8.1 nTPM (limit 2); pituitary gland: 2.3 nTPM (limit 2),bronchus / ciliated cells (cell body): High (Enhanced); bronchus / ciliated cells (ciliary rootlets): Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Prostate Adenocarcinoma (TCGA): 453/480 (94.4%); Uterine Corpus Endometrial Carcinoma (TCGA): 161/176 (91.5%); Kidney Renal Papillary Cell Carcinoma (TCGA): 87/282 (30.9%),ovarian cancer: 2/11 (18.2%); breast cancer: 0/11 (0.0%),30,20,Q8NEP3,https://www.uniprot.org/uniprotkb/Q8NEP3/entry,Cilium-specific protein required for the stability of the ciliary architecture. Plays a role in cytoplasmic preassembly of dynein arms. Involved in regulation of microtubule-based cilia and actin-based brush border microvilli,Mainly expressed in trachea and testis,"Ciliary dyskinesia, primary, 13: A disorder characterized by abnormalities of motile cilia. Respiratory infections leading to chronic inflammation and bronchiectasis are recurrent, due to defects in the respiratory cilia; reduced fertility is often observed in male patients due to abnormalities of sperm tails. Half of the patients exhibit randomization of left-right body asymmetry and situs inversus, due to dysfunction of monocilia at the embryonic node. Primary ciliary dyskinesia associated with situs inversus is referred to as Kartagener syndrome. At ultrastructural level, CILD13 is characterized by a marked reduction or absence of both dynein arms from the patients cilia.",,"Cell projection, cilium Cytoplasm Cytoplasm, cytoskeleton, spindle pole",18385425|19944400|19944405,19944405,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
DNAAF10,ENSG00000243667,Unsafe,Protein,False,True,15.6,15.6,79,46,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 6.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 4.4 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 6 nTPM; absolute ceiling;continuous selectivity; bone marrow: 3.6 nTPM; positive ihc;absolute ceiling; cerebellum: 5 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 5.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 8.9 nTPM; absolute ceiling;continuous selectivity; colon: 5.9 nTPM; positive ihc;continuous selectivity; duodenum: 6.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 6.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 8.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 5.2 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 4.7 nTPM; absolute ceiling;continuous selectivity; kidney: 5.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 5 nTPM; absolute ceiling; lung: 5.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 9.5 nTPM; absolute ceiling;continuous selectivity; midbrain: 4 nTPM; absolute ceiling;continuous selectivity; pancreas: 4.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 7 nTPM; continuous selectivity; pituitary gland: 4.6 nTPM; absolute ceiling;continuous selectivity; rectum: 7.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 6.7 nTPM; absolute ceiling;continuous selectivity; salivary gland: 6.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 11 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 10.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 5.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 7.2 nTPM; absolute ceiling;continuous selectivity; spinal cord: 4.4 nTPM; absolute ceiling;continuous selectivity; stomach: 5.8 nTPM; positive ihc;continuous selectivity; thymus: 7.9 nTPM; continuous selectivity; thyroid gland: 8.1 nTPM; positive ihc;continuous selectivity; tongue: 8.7 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 4.8 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 6.8 nTPM (limit 2); amygdala: 4.4 nTPM (limit 2); basal ganglia: 6 nTPM (limit 2); bone marrow: 3.6 nTPM (limit 2); cerebellum: 5 nTPM (limit 2); cerebral cortex: 5.1 nTPM (limit 2); choroid plexus: 8.9 nTPM (limit 2); duodenum: 6.1 nTPM (limit 2); esophagus: 6.8 nTPM (limit 6); heart muscle: 8.7 nTPM (limit 2); hippocampal formation: 5.2 nTPM (limit 2); hypothalamus: 4.7 nTPM (limit 2); kidney: 5.3 nTPM (limit 2); liver: 5 nTPM (limit 4); lung: 5.6 nTPM (limit 2); lymph node: 9.5 nTPM (limit 8); midbrain: 4 nTPM (limit 2); pancreas: 4.2 nTPM (limit 2); pituitary gland: 4.6 nTPM (limit 2); rectum: 7.7 nTPM (limit 6); retina: 6.7 nTPM (limit 2); salivary gland: 6.1 nTPM (limit 6); skeletal muscle: 11 nTPM (limit 2); skin: 10.3 nTPM (limit 10); small intestine: 5.1 nTPM (limit 2); smooth muscle: 7.2 nTPM (limit 4); spinal cord: 4.4 nTPM (limit 2); tongue: 8.7 nTPM (limit 6),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); lung / macrophages: Low (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / keratinocytes: Low (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%); Lung Adenocarcinoma (validation): 104/105 (99.0%); Rectum Adenocarcinoma (validation): 204/207 (98.6%),prostate cancer: 9/9 (100.0%); pancreatic cancer: 2/11 (18.2%),31,20,Q96MX6,https://www.uniprot.org/uniprotkb/Q96MX6/entry,Key assembly factor specifically required for the stability of axonemal dynein heavy chains in cytoplasm,Widely expressed with the highest expression in testis,,,Dynein axonemal particle,,16487927,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
DNAAF4,ENSG00000256061,Unsafe,Protein,False,True,11.7,28.7,77,65,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 2.3 nTPM; positive ihc;absolute ceiling; amygdala: 2.4 nTPM; absolute ceiling; basal ganglia: 3 nTPM; absolute ceiling; bone marrow: 1.9 nTPM; positive ihc; cerebellum: 0.4 nTPM; positive ihc; cerebral cortex: 3 nTPM; positive ihc;absolute ceiling; choroid plexus: 17.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 1 nTPM; positive ihc; duodenum: 0.9 nTPM; positive ihc; esophagus: 1.2 nTPM; positive ihc; heart muscle: 1.6 nTPM; positive ihc; hippocampal formation: 2.5 nTPM; absolute ceiling; hypothalamus: 3.7 nTPM; absolute ceiling;continuous selectivity; kidney: 5 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 0.6 nTPM; positive ihc; lung: 4.4 nTPM; absolute ceiling;continuous selectivity; lymph node: 1.3 nTPM; positive ihc; pancreas: 2 nTPM; positive ihc; parathyroid gland: 8.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 3.5 nTPM; absolute ceiling;continuous selectivity; rectum: 1.2 nTPM; positive ihc; retina: 28.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 1.7 nTPM; positive ihc; skeletal muscle: 1 nTPM; positive ihc; skin: 2.5 nTPM; positive ihc; small intestine: 1 nTPM; positive ihc; smooth muscle: 2.1 nTPM; positive ihc;absolute ceiling; spleen: 1.4 nTPM; positive ihc; stomach: 1.2 nTPM; positive ihc; thyroid gland: 8.5 nTPM; positive ihc;continuous selectivity; urinary bladder: 1.4 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 2.3 nTPM (limit 2); amygdala: 2.4 nTPM (limit 2); basal ganglia: 3 nTPM (limit 2); cerebral cortex: 3 nTPM (limit 2); choroid plexus: 17.4 nTPM (limit 2); hippocampal formation: 2.5 nTPM (limit 2); hypothalamus: 3.7 nTPM (limit 2); kidney: 5 nTPM (limit 2); lung: 4.4 nTPM (limit 2); parathyroid gland: 8.4 nTPM (limit 6); pituitary gland: 3.5 nTPM (limit 2); retina: 28.7 nTPM (limit 2); smooth muscle: 2.1 nTPM (limit 2); adrenal gland: 2.3 nTPM (baseline 2); amygdala: 2.4 nTPM (baseline 2); basal ganglia: 3 nTPM (baseline 2); cerebral cortex: 3 nTPM (baseline 2); choroid plexus: 17.4 nTPM (baseline 2); hippocampal formation: 2.5 nTPM (baseline 2); hypothalamus: 3.7 nTPM (baseline 2); kidney: 5 nTPM (baseline 2); lung: 4.4 nTPM (baseline 2); parathyroid gland: 8.4 nTPM (baseline 6); pituitary gland: 3.5 nTPM (baseline 2); retina: 28.7 nTPM (baseline 2); smooth muscle: 2.1 nTPM (baseline 2),adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Low (Uncertain); bronchus / respiratory epithelial cells: High (Uncertain); caudate / glial cells: Medium (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in molecular layer: Medium (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / endothelial cells: Low (Uncertain); cerebral cortex / glial cells: Low (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); colon / endothelial cells: Low (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: Low (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: High (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in glomeruli: Low (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / hepatocytes: Medium (Uncertain); lymph node / germinal center cells: Low (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); nasopharynx / respiratory epithelial cells: High (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: High (Uncertain); pancreas / pancreatic endocrine cells: Low (Uncertain); parathyroid gland / glandular cells: Low (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: Low (Uncertain); skin 1 / fibroblasts: Low (Uncertain); skin 1 / keratinocytes: Medium (Uncertain); skin 1 / Langerhans: Medium (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: Medium (Uncertain); smooth muscle / smooth muscle cells: Low (Uncertain); spleen / cells in white pulp: Low (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: High (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Thyroid Carcinoma (TCGA): 427/495 (86.3%); Kidney Renal Papillary Cell Carcinoma (TCGA): 205/282 (72.7%); Glioblastoma Multiforme (TCGA): 99/141 (70.2%),colorectal cancer: 11/12 (91.7%); pancreatic cancer: 10/12 (83.3%),29,20,Q8WXU2,https://www.uniprot.org/uniprotkb/Q8WXU2/entry,"Axonemal dynein assembly factor required for ciliary motility. Involved in neuronal migration during development of the cerebral neocortex. May regulate the stability and proteasomal degradation of the estrogen receptors that play an important role in neuronal differentiation, survival and plasticity","Expressed in several tissues, including brain, lung, kidney and testis. In brain localizes to a fraction of cortical neurons and white matter glial cells","Dyslexia 1: A relatively common, complex cognitive disorder characterized by an impairment of reading performance despite adequate motivational, educational and intellectual opportunities. It is a multifactorial trait, with evidence for familial clustering and heritability. Ciliary dyskinesia, primary, 25: A disorder characterized by abnormalities of motile cilia. Respiratory infections leading to chronic inflammation and bronchiectasis are recurrent, due to defects in the respiratory cilia. Patients may exhibit randomization of left-right body asymmetry and situs inversus, due to dysfunction of monocilia at the embryonic node. Primary ciliary dyskinesia associated with situs inversus is referred to as Kartagener syndrome.",,"Nucleus Cytoplasm Dynein axonemal particle Cell projection, neuron projection",19423554|23872636,12954984,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
DNAAF6,ENSG00000080572,Unsafe,Protein,False,True,11.6,11.6,92,9,Positive somewhere,True,True,False,True,Excluded,Normal,False,,Not assessed,,,positive ihc outside permitted; choroid plexus: 3.9 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 3.9 nTPM (limit 2),bronchus / ciliated cells (cell body): High (Enhanced); bronchus / ciliated cells (ciliary rootlets): High (Enhanced); bronchus / goblet cells: High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 21/176 (11.9%); Glioblastoma Multiforme (validation): 2/58 (3.4%); Lung Adenocarcinoma (TCGA): 14/497 (2.8%),endometrial cancer: 1/12 (8.3%); breast cancer: 0/10 (0.0%),29,20,Q9NQM4,https://www.uniprot.org/uniprotkb/Q9NQM4/entry,Plays a role in cytoplasmic pre-assembly of axonemal dynein,"Expressed in testis, small intestine, prostate, adrenal gland, spleen, lung, bladder, breast and ovary. Expressed in ciliated epithelial cells (PubMed:28176794)","Ciliary dyskinesia, primary, 36, X-linked: A form of primary ciliary dyskinesia, a disorder characterized by abnormalities of motile cilia. Respiratory infections leading to chronic inflammation and bronchiectasis are recurrent, due to defects in the respiratory cilia. Some patients exhibit randomization of left-right body asymmetry and situs inversus. Primary ciliary dyskinesia associated with situs inversus is referred to as Kartagener syndrome. CILD36 inheritance is X-linked recessive. About half of CILD36 patients have laterality defects due to ciliary dysfunction at the embryonic node.",,"Cytoplasm Golgi apparatus, trans-Golgi network",28041644|28176794,12601173|28176794,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
DNAAF8,ENSG00000166246,Unsafe,Protein,False,True,71.9,71.9,103,10,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; basal ganglia: 2.4 nTPM; absolute ceiling; choroid plexus: 11.2 nTPM; absolute ceiling; hippocampal formation: 2.3 nTPM; absolute ceiling; hypothalamus: 2.7 nTPM; absolute ceiling; kidney: 1.7 nTPM; positive ihc; pituitary gland: 4 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",basal ganglia: 2.4 nTPM (limit 2); choroid plexus: 11.2 nTPM (limit 2); hippocampal formation: 2.3 nTPM (limit 2); hypothalamus: 2.7 nTPM (limit 2); pituitary gland: 4 nTPM (limit 2),bronchus / ciliated cells (cell body): Medium (Enhanced); bronchus / ciliated cells (ciliary rootlets): Medium (Enhanced); kidney / proximal tubules (cell body): Low (Enhanced); nasopharynx / ciliated cells (cell body): Medium (Enhanced); nasopharynx / ciliated cells (ciliary rootlets): Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 24/50 (48.0%); Breast Invasive Carcinoma (TCGA): 465/1022 (45.5%); Kidney Renal Papillary Cell Carcinoma (TCGA): 125/282 (44.3%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q8IYS4,https://www.uniprot.org/uniprotkb/Q8IYS4/entry,"In cyliated cells, dynein axonemal particle-specific protein required for deployment of ODA to the axoneme. Interacts with outer dynein arm (ODA) subunits",Expressed in respiratory ciliated cells (at protein level),,,Dynein axonemal particle Cytoplasm,,33263282,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
DNAH10,ENSG00000197653,Unsafe,Protein,False,True,4.0,4.0,102,12,Positive somewhere,True,False,False,True,Excluded,Normal,False,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 0 nTPM; positive ihc; kidney: 0.1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,adrenal gland / glandular cells: Low (Enhanced); bronchus / ciliated cells (cilia axoneme): Medium (Enhanced); bronchus / ciliated cells (tip of cilia): Medium (Enhanced); choroid plexus / ependymal cells: Medium (Enhanced); kidney / cells in tubules: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 7/50 (14.0%); Glioblastoma Multiforme (validation): 1/58 (1.7%); Uterine Corpus Endometrial Carcinoma (TCGA): 3/176 (1.7%),breast cancer: 0/11 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q8IVF4,https://www.uniprot.org/uniprotkb/Q8IVF4/entry,Force generating protein of respiratory cilia. Produces force towards the minus ends of microtubules. Dynein has ATPase activity; the force-producing power stroke is thought to occur on release of ADP. Involved in sperm motility; implicated in sperm flagellar assembly (PubMed:34237282). Probable inner arm dynein heavy chain,"Expressed primarily in trachea and testis, 2 tissues containing axonemal structures. Also expressed in brain but not in adult heart","Spermatogenic failure 56: An autosomal recessive male infertility disorder characterized by severely reduced sperm motility, due to multiple morphologic abnormalities of the flagella.",,"Cytoplasm, cytoskeleton, cilium axoneme",34237282,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination; inclusion depends on TGCT under this study's thresholds,,,,,,,,
DNAH11,ENSG00000105877,Unsafe,Protein,False,True,5.1,68.9,95,4,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; choroid plexus: 7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 68.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 7 nTPM (limit 2); parathyroid gland: 68.9 nTPM (limit 8),bronchus / ciliated cells (cell body): Medium (Approved); bronchus / ciliated cells (ciliary rootlets): Medium (Approved); nasopharynx / ciliated cells (ciliary rootlets): Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Renal Clear Cell Carcinoma (validation): 63/100 (63.0%); Glioblastoma Multiforme (validation): 31/58 (53.4%); Kidney Renal Clear Cell Carcinoma (TCGA): 152/521 (29.2%),breast cancer: 0/12 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q96DT5,https://www.uniprot.org/uniprotkb/Q96DT5/entry,"Force generating protein required for cilia beating in respiratory epithelia (By similarity). Produces force towards the minus ends of microtubules (By similarity). Key component of dynein, a family of motor proteins essential for movement along microtubules (By similarity). Dynein has ATPase activity; the force-producing power stroke is thought to occur on release of ADP (By similarity). Required for structural and functional integrity of cilia (By similarity)","Expressed in airway ciliated epithelial cells (at protein level) (PubMed:31178125, PubMed:33139725). Not detected in spermatozoa (at protein level) (PubMed:31178125)","Ciliary dyskinesia, primary, 7: A disorder characterized by abnormalities of motile cilia. Respiratory infections leading to chronic inflammation and bronchiectasis are recurrent, due to defects in the respiratory cilia; reduced fertility is often observed in male patients due to abnormalities of sperm tails. Half of the patients exhibit randomization of left-right body asymmetry and situs inversus, due to dysfunction of monocilia at the embryonic node. Primary ciliary dyskinesia associated with situs inversus is referred to as Kartagener syndrome.",,"Cytoplasm, cytoskeleton, cilium axoneme",,31178125|33139725,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
DNAH14,ENSG00000185842,Unsafe,Protein,False,True,21.5,21.5,78,8,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 3.1 nTPM; positive ihc;absolute ceiling; choroid plexus: 2.4 nTPM; absolute ceiling; colon: 1.8 nTPM; positive ihc; hypothalamus: 4 nTPM; absolute ceiling; kidney: 5.3 nTPM; positive ihc;absolute ceiling; liver: 5.5 nTPM; absolute ceiling;continuous selectivity; lung: 2.2 nTPM; absolute ceiling; pancreas: 5.5 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 6.4 nTPM; absolute ceiling;continuous selectivity; retina: 2.6 nTPM; absolute ceiling; spinal cord: 3.1 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 3.1 nTPM (limit 2); choroid plexus: 2.4 nTPM (limit 2); hypothalamus: 4 nTPM (limit 2); kidney: 5.3 nTPM (limit 2); liver: 5.5 nTPM (limit 2); lung: 2.2 nTPM (limit 2); pancreas: 5.5 nTPM (limit 2); pituitary gland: 6.4 nTPM (limit 2); retina: 2.6 nTPM (limit 2); spinal cord: 3.1 nTPM (limit 2); adrenal gland: 3.1 nTPM (baseline 2); choroid plexus: 2.4 nTPM (baseline 2); hypothalamus: 4 nTPM (baseline 2); kidney: 5.3 nTPM (baseline 2); liver: 5.5 nTPM (baseline 2); lung: 2.2 nTPM (baseline 2); pancreas: 5.5 nTPM (baseline 2); pituitary gland: 6.4 nTPM (baseline 2); retina: 2.6 nTPM (baseline 2); spinal cord: 3.1 nTPM (baseline 2),adrenal gland / glandular cells: Low (Uncertain); bronchus / respiratory epithelial cells: Low (Uncertain); colon / endothelial cells: Low (Uncertain); kidney / cells in tubules: Low (Uncertain); nasopharynx / respiratory epithelial cells: Low (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 78/80 (97.5%); Lung Adenocarcinoma (validation): 95/105 (90.5%); Rectum Adenocarcinoma (validation): 183/207 (88.4%),testis cancer: 1/10 (10.0%); liver cancer: 1/12 (8.3%),31,20,Q0VDD8,https://www.uniprot.org/uniprotkb/Q0VDD8/entry,Force generating protein of respiratory cilia. Produces force towards the minus ends of microtubules. Dynein has ATPase activity; the force-producing power stroke is thought to occur on release of ADP. Involved in sperm motility; implicated in sperm flagellar assembly (By similarity),,,,"Cytoplasm, cytoskeleton, cilium axoneme",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | Jamin2021_CT,GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
DNAH17,ENSG00000187775,Unsafe,RNA,False,True,5.4,5.4,87,1,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,retina: 2.4 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 2.4 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 33/50 (66.0%); Liver Hepatocellular Carcinoma (validation): 35/231 (15.2%); Head and Neck Squamous Cell Carcinoma (TCGA): 64/492 (13.0%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q9UFH2,https://www.uniprot.org/uniprotkb/Q9UFH2/entry,"Force generating protein component of the outer dynein arms (ODAs) in the sperm flagellum (By similarity). Produces force towards the minus ends of microtubules (By similarity). Key component of dynein, a family of motor proteins essential for movement along microtubules (By similarity). Dynein has ATPase activity; the force-producing power stroke is thought to occur on release of ADP (By similarity). Required for structural and functional integrity of cilia (By similarity). Plays a major role in sperm motility, implicated in sperm flagellar assembly and beating (PubMed:31178125)",Expressed in testis (PubMed:9545504). Expressed in spermatozoa (at protein level). Not detected in airway epithelial cells (at protein level) (PubMed:31178125),"Spermatogenic failure 39: An autosomal recessive infertility disorder characterized by asthenoteratozoospermia. Spermatozoa exhibit multiple morphologic anomalies including short, absent, irregularly shaped and coiled flagella, and abnormalities of the head and midpiece.",,"Cytoplasm, cytoskeleton, flagellum axoneme Cell projection, cilium, flagellum",31178125,31178125|9545504,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
DNAH2,ENSG00000183914,Unsafe,Protein,False,True,12.6,20.1,101,12,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; basal ganglia: 3.1 nTPM; absolute ceiling; choroid plexus: 2.9 nTPM; absolute ceiling; parathyroid gland: 10.2 nTPM; continuous selectivity; retina: 20.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",basal ganglia: 3.1 nTPM (limit 2); choroid plexus: 2.9 nTPM (limit 2); retina: 20.1 nTPM (limit 2),bronchus / ciliated cells (cilia axoneme): Medium (Enhanced); bronchus / ciliated cells (ciliary rootlets): Medium (Enhanced); bronchus / ciliated cells (tip of cilia): Medium (Enhanced); nasopharynx / ciliated cells (cilia axoneme): Medium (Enhanced); nasopharynx / ciliated cells (ciliary rootlets): High (Enhanced); nasopharynx / ciliated cells (tip of cilia): High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Adenocarcinoma (validation): 43/105 (41.0%); Lung Adenocarcinoma (TCGA): 183/497 (36.8%); Colon Adenocarcinoma (validation): 164/486 (33.7%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q9P225,https://www.uniprot.org/uniprotkb/Q9P225/entry,"As part of the axonemal inner dynein arm complex plays a central role in ciliary beat (PubMed:30811583). Expressed in sperm flagellum, it is required for sperm motility (PubMed:30811583). Dyneins are microtubule-based molecular motors possessing ATPase activities that can convert the chemical energy of ATP into relative sliding between adjacent microtubule doublets to generate ciliary bending (PubMed:30811583)","Expressed primarily in trachea and testis, 2 tissues containing axonemal structures. Also expressed in lung. Expressed in spermatozoa (at protein level) (PubMed:31178125)",Spermatogenic failure 45: An autosomal recessive infertility disorder caused by spermatogenesis defects resulting in severe teratozoospermia. SPGF45 is characterized by multiple morphologic abnormalities of spermatozoa flagella. Some spermatozoa also show abnormalities of the head.,,"Cytoplasm, cytoskeleton, cilium axoneme Cytoplasm, cytoskeleton, flagellum axoneme",30811583,31178125|9256245,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
DNAH5,ENSG00000039139,Unsafe,Protein,False,True,3.4,3.4,97,9,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; choroid plexus: 2.8 nTPM; absolute ceiling;continuous selectivity; lung: 1.6 nTPM; positive ihc;continuous selectivity; pituitary gland: 2 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 2.8 nTPM (limit 2),bronchus / ciliated cells (cilia axoneme): Medium (Enhanced); bronchus / ciliated cells (tip of cilia): Medium (Enhanced); lung / macrophages: Medium (Enhanced); nasopharynx / ciliated cells (cilia axoneme): High (Enhanced); nasopharynx / ciliated cells (tip of cilia): High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 35/50 (70.0%); Glioblastoma Multiforme (validation): 21/58 (36.2%); Pancreatic Adenocarcinoma (validation): 25/80 (31.2%),testis cancer: 3/11 (27.3%); pancreatic cancer: 2/9 (22.2%),31,20,Q8TE73,https://www.uniprot.org/uniprotkb/Q8TE73/entry,"Force generating protein of respiratory cilia (By similarity). Produces force towards the minus ends of microtubules (By similarity). Key component of dynein, a family of motor proteins essential for movement along microtubules (By similarity). Dynein has ATPase activity; the force-producing power stroke is thought to occur on release of ADP (By similarity). Required for structural and functional integrity of the cilia of ependymal cells lining the brain ventricles (By similarity)",Expressed in airway epithelial cells (at protein level). Not detected in spermatozoa (at protein level),"Ciliary dyskinesia, primary, 3: A disorder characterized by abnormalities of motile cilia. Respiratory infections leading to chronic inflammation and bronchiectasis are recurrent, due to defects in the respiratory cilia; reduced fertility is often observed in male patients due to abnormalities of sperm tails. Half of the patients exhibit randomization of left-right body asymmetry and situs inversus, due to dysfunction of monocilia at the embryonic node. Primary ciliary dyskinesia associated with situs inversus is referred to as Kartagener syndrome.",,"Cytoplasm, cytoskeleton, cilium axoneme",,31178125,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
DNAH7,ENSG00000118997,Unsafe,Protein,False,True,10.5,20.4,99,16,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 0.9 nTPM; positive ihc; amygdala: 5.4 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 8.5 nTPM; absolute ceiling;continuous selectivity; bone marrow: 0 nTPM; positive ihc; cerebral cortex: 6.3 nTPM; continuous selectivity; choroid plexus: 20.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 4.6 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 4.7 nTPM; absolute ceiling;continuous selectivity; midbrain: 2.9 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 7 nTPM; absolute ceiling;continuous selectivity; retina: 8.7 nTPM; absolute ceiling;continuous selectivity; stomach: 0.6 nTPM; positive ihc; thyroid gland: 3.1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 5.4 nTPM (limit 2); basal ganglia: 8.5 nTPM (limit 2); choroid plexus: 20.4 nTPM (limit 2); hippocampal formation: 4.6 nTPM (limit 2); hypothalamus: 4.7 nTPM (limit 2); midbrain: 2.9 nTPM (limit 2); pituitary gland: 7 nTPM (limit 2); retina: 8.7 nTPM (limit 2),adrenal gland / glandular cells: Low (Enhanced); bone marrow / hematopoietic cells: Low (Enhanced); bronchus / ciliated cells (cilia axoneme): Medium (Enhanced); bronchus / ciliated cells (tip of cilia): High (Enhanced); nasopharynx / ciliated cells (cilia axoneme): Medium (Enhanced); nasopharynx / ciliated cells (tip of cilia): High (Enhanced); stomach 2 / glandular cells: Low (Enhanced); thyroid gland / glandular cells: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 43/58 (74.1%); Breast Invasive Carcinoma (validation): 26/50 (52.0%); Kidney Renal Papillary Cell Carcinoma (TCGA): 83/282 (29.4%),lymphoma: 2/12 (16.7%); melanoma: 1/10 (10.0%),31,20,Q8WXX0,https://www.uniprot.org/uniprotkb/Q8WXX0/entry,Force generating protein that plays an important role in respiratory cilia and sperm flagella beating (PubMed:34476482). Produces force towards the minus ends of microtubules. Dynein has ATPase activity; the force-producing power stroke is thought to occur on release of ADP (By similarity),"Detected in brain, testis and trachea. Detected in bronchial cells (at protein level)","Ciliary dyskinesia, primary, 50: A form of primary ciliary dyskinesia, a disorder characterized by abnormalities of motile cilia. Respiratory infections leading to chronic inflammation and bronchiectasis are recurrent, due to defects in the respiratory cilia. CILD50 is an autosomal recessive form characterized by chronic sinusitis and bronchitis as well as male infertility. Patient sperm have markedly reduced progressive motility, and multiple morphologic abnormalities of the flagella.",,"Cytoplasm, cytoskeleton, cilium axoneme Cell projection, cilium, flagellum",34476482,11175280|11877439,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
DNAH9,ENSG00000007174,Unsafe,Protein,False,True,34.1,34.1,93,12,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 8 nTPM; absolute ceiling; basal ganglia: 8.5 nTPM; absolute ceiling; choroid plexus: 12.2 nTPM; absolute ceiling;continuous selectivity; heart muscle: 0.2 nTPM; positive ihc; hippocampal formation: 13 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 11.5 nTPM; absolute ceiling;continuous selectivity; midbrain: 4.3 nTPM; absolute ceiling; pituitary gland: 3.1 nTPM; absolute ceiling; retina: 6.4 nTPM; absolute ceiling; spinal cord: 3.2 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 8 nTPM (limit 2); basal ganglia: 8.5 nTPM (limit 2); choroid plexus: 12.2 nTPM (limit 2); hippocampal formation: 13 nTPM (limit 2); hypothalamus: 11.5 nTPM (limit 2); midbrain: 4.3 nTPM (limit 2); pituitary gland: 3.1 nTPM (limit 2); retina: 6.4 nTPM (limit 2); spinal cord: 3.2 nTPM (limit 2),bronchus / ciliated cells (cell body): Medium (Enhanced); bronchus / ciliated cells (cilia axoneme): High (Enhanced); bronchus / ciliated cells (tip of cilia): High (Enhanced); heart muscle / cardiomyocytes: Low (Enhanced); nasopharynx / ciliated cells (cell body): Low (Enhanced); nasopharynx / ciliated cells (cilia axoneme): High (Enhanced); nasopharynx / ciliated cells (ciliary rootlets): Medium (Enhanced); nasopharynx / ciliated cells (tip of cilia): High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 114/141 (80.9%); Glioblastoma Multiforme (validation): 38/58 (65.5%); Uterine Corpus Endometrial Carcinoma (TCGA): 50/176 (28.4%),breast cancer: 0/11 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q9NYC9,https://www.uniprot.org/uniprotkb/Q9NYC9/entry,"Force generating protein required for cilia beating in respiratory epithelia (PubMed:30471717, PubMed:30471718). Produces force towards the minus ends of microtubules (PubMed:30471717, PubMed:30471718). Key component of dynein, a family of motor proteins essential for movement along microtubules (By similarity). Dynein has ATPase activity; the force-producing power stroke is thought to occur on release of ADP (PubMed:30471717, PubMed:30471718). Required for structural and functional integrity of cilia (PubMed:30471717, PubMed:30471718)",Expressed in upper and lower respiratory airway epithelia (at protein level). Not detected in spermatozoa (at protein level) (PubMed:31178125),"Ciliary dyskinesia, primary, 40: A form of primary ciliary dyskinesia, a disorder characterized by abnormalities of motile cilia. Respiratory infections leading to chronic inflammation and bronchiectasis are recurrent, due to defects in the respiratory cilia. Some patients exhibit randomization of left-right body asymmetry and situs inversus. Primary ciliary dyskinesia associated with situs inversus is referred to as Kartagener syndrome. CILD40 inheritance is autosomal recessive.",,"Cytoplasm, cytoskeleton, cilium axoneme Cell projection, cilium, flagellum",30471717|30471718,30471717|31178125,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
DNAI4,ENSG00000152763,Unsafe,RNA,False,True,34.2,34.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,basal ganglia: 2.6 nTPM; absolute ceiling; choroid plexus: 20 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 2.6 nTPM; absolute ceiling; hypothalamus: 3 nTPM; absolute ceiling; kidney: 6.1 nTPM; absolute ceiling; lung: 4.1 nTPM; absolute ceiling; parathyroid gland: 6.7 nTPM; absolute ceiling; pituitary gland: 2.7 nTPM; absolute ceiling; retina: 3.9 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,basal ganglia: 2.6 nTPM (limit 2); choroid plexus: 20 nTPM (limit 2); hippocampal formation: 2.6 nTPM (limit 2); hypothalamus: 3 nTPM (limit 2); kidney: 6.1 nTPM (limit 2); lung: 4.1 nTPM (limit 2); parathyroid gland: 6.7 nTPM (limit 6); pituitary gland: 2.7 nTPM (limit 2); retina: 3.9 nTPM (limit 2); basal ganglia: 2.6 nTPM (baseline 2); choroid plexus: 20 nTPM (baseline 2); hippocampal formation: 2.6 nTPM (baseline 2); hypothalamus: 3 nTPM (baseline 2); kidney: 6.1 nTPM (baseline 2); lung: 4.1 nTPM (baseline 2); parathyroid gland: 6.7 nTPM (baseline 6); pituitary gland: 2.7 nTPM (baseline 2); retina: 3.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Pancreatic Adenocarcinoma (validation): 53/80 (66.2%); Kidney Renal Papillary Cell Carcinoma (TCGA): 127/282 (45.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q5VTH9,https://www.uniprot.org/uniprotkb/Q5VTH9/entry,"Plays a critical role in the assembly of axonemal dynein complex, thereby playing a role in ciliary motility",,,,"Cytoplasm, cytoskeleton, flagellum axoneme Cytoplasm, cytoskeleton, cilium axoneme Dynein axonemal particle",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
DNAI7,ENSG00000118307,Unsafe,Protein,False,True,22.3,22.3,100,14,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; choroid plexus: 13.9 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 2.5 nTPM; absolute ceiling; lung: 1.8 nTPM; positive ihc; pituitary gland: 3.9 nTPM; absolute ceiling; retina: 5 nTPM; absolute ceiling; thyroid gland: 4 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 13.9 nTPM (limit 2); hypothalamus: 2.5 nTPM (limit 2); pituitary gland: 3.9 nTPM (limit 2); retina: 5 nTPM (limit 2),bronchus / ciliated cells (cilia axoneme): Medium (Enhanced); bronchus / ciliated cells (tip of cilia): Medium (Enhanced); lung / macrophages: Medium (Enhanced); nasopharynx / ciliated cells (cell body): Medium (Enhanced); nasopharynx / ciliated cells (tip of cilia): High (Enhanced); thyroid gland / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 39/58 (67.2%); Uterine Corpus Endometrial Carcinoma (TCGA): 47/176 (26.7%); Kidney Renal Papillary Cell Carcinoma (TCGA): 68/282 (24.1%),breast cancer: 0/12 (0.0%); cervical cancer: 0/11 (0.0%),29,20,Q6TDU7,https://www.uniprot.org/uniprotkb/Q6TDU7/entry,"Via its association with the multisubunit axonemal dynein complex, is potentially involved in the regulation of cilia function. May also act as a cell cycle regulator",,,,"Cell projection, cilium Cytoplasm",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
DNAJB13,ENSG00000187726,Unsafe,Protein,False,True,51.5,51.5,99,16,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; basal ganglia: 2.2 nTPM; absolute ceiling; choroid plexus: 26.1 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 2.3 nTPM; absolute ceiling; hypothalamus: 2.5 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",basal ganglia: 2.2 nTPM (limit 2); choroid plexus: 26.1 nTPM (limit 2); hippocampal formation: 2.3 nTPM (limit 2); hypothalamus: 2.5 nTPM (limit 2),bronchus / ciliated cells (cell body): Medium (Enhanced); bronchus / ciliated cells (cilia axoneme): High (Enhanced); bronchus / ciliated cells (tip of cilia): High (Enhanced); nasopharynx / ciliated cells (cell body): Medium (Enhanced); nasopharynx / ciliated cells (cilia axoneme): High (Enhanced); nasopharynx / ciliated cells (tip of cilia): High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Ovary Serous Cystadenocarcinoma (TCGA): 270/349 (77.4%); Uterine Corpus Endometrial Carcinoma (TCGA): 113/176 (64.2%); Ovary Serous Cystadenocarcinoma (validation): 52/81 (64.2%),cervical cancer: 1/9 (11.1%); endometrial cancer: 1/11 (9.1%),31,20,P59910,https://www.uniprot.org/uniprotkb/P59910/entry,Functions as part of axonemal radial spoke complexes that play an important part in the motility of sperm and cilia,Specifically expressed in testis and trachea,"Ciliary dyskinesia, primary, 34: A form of primary ciliary dyskinesia, a disorder characterized by abnormalities of motile cilia. Respiratory infections leading to chronic inflammation and bronchiectasis are recurrent, due to defects in the respiratory cilia. CILD34 inheritance is autosomal recessive.",,"Cell projection, cilium, flagellum",27486783,27486783,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
DNAJC24,ENSG00000170946,Unsafe,Protein,False,True,6.5,16.4,98,42,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 7 nTPM; continuous selectivity;reproductive not higher; adrenal gland: 6.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 5.5 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 5.5 nTPM; absolute ceiling;continuous selectivity; cerebellum: 7.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 6.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 2.6 nTPM; absolute ceiling;continuous selectivity; colon: 4.6 nTPM; continuous selectivity; duodenum: 4.3 nTPM; absolute ceiling;continuous selectivity; esophagus: 5.1 nTPM; positive ihc;continuous selectivity; heart muscle: 11.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 5.6 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 5.9 nTPM; absolute ceiling;continuous selectivity; kidney: 6.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 5.8 nTPM; absolute ceiling;continuous selectivity; lung: 4.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 6.6 nTPM; continuous selectivity;reproductive not higher; midbrain: 5.7 nTPM; absolute ceiling;continuous selectivity; pancreas: 7.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 4.6 nTPM; positive ihc;continuous selectivity; pituitary gland: 4.5 nTPM; absolute ceiling;continuous selectivity; rectum: 4.2 nTPM; continuous selectivity; retina: 7.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 5.6 nTPM; positive ihc;continuous selectivity; skeletal muscle: 16.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 8.5 nTPM; positive ihc;continuous selectivity;reproductive not higher; small intestine: 4.3 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 6.1 nTPM; absolute ceiling;continuous selectivity; spinal cord: 5.9 nTPM; absolute ceiling;continuous selectivity; spleen: 5.7 nTPM; continuous selectivity; stomach: 4.9 nTPM; positive ihc;continuous selectivity; thymus: 5 nTPM; continuous selectivity; thyroid gland: 6.3 nTPM; positive ihc;continuous selectivity; tongue: 10.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 5.4 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 6.1 nTPM (limit 2); amygdala: 5.5 nTPM (limit 2); basal ganglia: 5.5 nTPM (limit 2); cerebellum: 7.2 nTPM (limit 4); cerebral cortex: 6.4 nTPM (limit 2); choroid plexus: 2.6 nTPM (limit 2); duodenum: 4.3 nTPM (limit 4); heart muscle: 11.3 nTPM (limit 2); hippocampal formation: 5.6 nTPM (limit 2); hypothalamus: 5.9 nTPM (limit 2); kidney: 6.1 nTPM (limit 2); liver: 5.8 nTPM (limit 4); lung: 4.2 nTPM (limit 2); midbrain: 5.7 nTPM (limit 2); pancreas: 7.1 nTPM (limit 2); pituitary gland: 4.5 nTPM (limit 2); retina: 7.8 nTPM (limit 2); skeletal muscle: 16.4 nTPM (limit 4); small intestine: 4.3 nTPM (limit 4); smooth muscle: 6.1 nTPM (limit 4); spinal cord: 5.9 nTPM (limit 2); tongue: 10.9 nTPM (limit 6),adrenal gland / glandular cells: Medium (Approved); bronchus / basal cells: Medium (Approved); bronchus / ciliated cells (ciliary rootlets): Medium (Approved); bronchus / ciliated cells (tip of cilia): Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / glial cells: Low (Approved); kidney / cells in tubules: Low (Approved); lung / macrophages: Medium (Approved); nasopharynx / basal cells: Medium (Approved); nasopharynx / ciliated cells (ciliary rootlets): Medium (Approved); nasopharynx / ciliated cells (tip of cilia): Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Low (Approved); parathyroid gland / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skin 1 / keratinocytes: Low (Approved); skin 2 / epidermal cells: Low (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Low (Approved); thyroid gland / glandular cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Glioblastoma Multiforme (TCGA): 138/141 (97.9%); Pancreatic Adenocarcinoma (validation): 78/80 (97.5%),melanoma: 7/11 (63.6%); prostate cancer: 4/12 (33.3%),31,20,Q6P3W2,https://www.uniprot.org/uniprotkb/Q6P3W2/entry,"Stimulates the ATPase activity of several Hsp70-type chaperones. This ability is enhanced by iron-binding. The iron-bound form is redox-active and can function as electron carrier. Plays a role in the diphthamide biosynthesis, a post-translational modification of histidine which occurs in translation elongation factor 2 (EEF2) which can be ADP-ribosylated by diphtheria toxin and by Pseudomonas exotoxin A (Eta)",,,It is uncertain whether Met-1 or Met-2 is the initiator,"Cytoplasm, cytoskeleton",22367199|22509046,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
DNAJC28,ENSG00000177692,Unsafe,Protein,False,True,6.8,6.8,81,75,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0.6 nTPM; positive ihc; adrenal gland: 2.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 1.8 nTPM; continuous selectivity; basal ganglia: 2.1 nTPM; absolute ceiling;continuous selectivity; bone marrow: 0.4 nTPM; positive ihc; cerebellum: 2.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 1.1 nTPM; positive ihc; duodenum: 0.3 nTPM; positive ihc; esophagus: 1.1 nTPM; positive ihc; heart muscle: 2.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 2.1 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 2 nTPM; continuous selectivity; kidney: 2.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 2.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 0.6 nTPM; positive ihc; lymph node: 0.2 nTPM; positive ihc; midbrain: 1.9 nTPM; continuous selectivity; pancreas: 1.3 nTPM; positive ihc; parathyroid gland: 1.3 nTPM; positive ihc; rectum: 0.6 nTPM; positive ihc; salivary gland: 1.4 nTPM; positive ihc; skeletal muscle: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 0.6 nTPM; positive ihc; small intestine: 1.1 nTPM; positive ihc; smooth muscle: 0.3 nTPM; positive ihc; spleen: 1.1 nTPM; positive ihc; stomach: 1.5 nTPM; positive ihc; thyroid gland: 2.4 nTPM; positive ihc; urinary bladder: 0.6 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 2.2 nTPM (limit 2); basal ganglia: 2.1 nTPM (limit 2); cerebellum: 2.6 nTPM (limit 2); cerebral cortex: 2.7 nTPM (limit 2); heart muscle: 2.8 nTPM (limit 2); hippocampal formation: 2.1 nTPM (limit 2); kidney: 2.5 nTPM (limit 2); liver: 2.5 nTPM (limit 2); skeletal muscle: 2.7 nTPM (limit 2),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: High (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / glial cells: Medium (Approved); caudate / neuronal cells: High (Approved); cerebellum / cells in granular layer: High (Approved); cerebellum / cells in molecular layer: High (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / neuronal cells: High (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: High (Approved); colon / peripheral nerve/ganglion: High (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Medium (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: High (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: High (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: High (Approved); pancreas / pancreatic endocrine cells: High (Approved); parathyroid gland / glandular cells: High (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: High (Approved); skeletal muscle / myocytes: High (Approved); skin 1 / keratinocytes: Low (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: High (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: High (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 54/58 (93.1%); Breast Invasive Carcinoma (validation): 41/50 (82.0%); Kidney Chromophobe (TCGA): 2/64 (3.1%),cervical cancer: 10/12 (83.3%); pancreatic cancer: 9/11 (81.8%),31,20,Q9NX36,https://www.uniprot.org/uniprotkb/Q9NX36/entry,May have a role in protein folding or as a chaperone,"Expressed in the fetal and adult brain, testis, uterus, spleen and liver",,,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination; inclusion depends on TGCT under this study's thresholds,,,,,,,,
DNAJC5B,ENSG00000147570,Unsafe,RNA,False,True,63.6,63.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,lung: 5.9 nTPM; absolute ceiling; lymph node: 7.5 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,lung: 5.9 nTPM (limit 2); lymph node: 7.5 nTPM (limit 6); lung: 5.9 nTPM (baseline 2); lymph node: 7.5 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Adenocarcinoma (validation): 75/105 (71.4%); Lung Squamous Cell Carcinoma (validation): 31/68 (45.6%); Lung Adenocarcinoma (TCGA): 182/497 (36.6%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9UF47,https://www.uniprot.org/uniprotkb/Q9UF47/entry,,Testis specific,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
DNAL1,ENSG00000119661,Unsafe,Protein,False,True,53.0,53.0,98,42,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 7.1 nTPM; positive ihc; adrenal gland: 6 nTPM; absolute ceiling; amygdala: 6.9 nTPM; absolute ceiling; basal ganglia: 7.4 nTPM; absolute ceiling; bone marrow: 5.1 nTPM; positive ihc;absolute ceiling; cerebellum: 5.1 nTPM; absolute ceiling; cerebral cortex: 11 nTPM; positive ihc;absolute ceiling; choroid plexus: 15.1 nTPM; absolute ceiling;continuous selectivity; heart muscle: 8.7 nTPM; positive ihc;absolute ceiling; hippocampal formation: 7.4 nTPM; absolute ceiling; hypothalamus: 7.4 nTPM; absolute ceiling; kidney: 10.8 nTPM; positive ihc;absolute ceiling; liver: 3.5 nTPM; positive ihc;absolute ceiling; lung: 7.1 nTPM; absolute ceiling; lymph node: 4.7 nTPM; positive ihc; midbrain: 5.8 nTPM; absolute ceiling; pancreas: 5.5 nTPM; positive ihc;absolute ceiling; parathyroid gland: 14 nTPM; positive ihc;absolute ceiling; pituitary gland: 8.2 nTPM; absolute ceiling; rectum: 5 nTPM; positive ihc; retina: 17.3 nTPM; absolute ceiling;continuous selectivity; salivary gland: 4.3 nTPM; positive ihc; skeletal muscle: 4.8 nTPM; absolute ceiling; smooth muscle: 8.9 nTPM; absolute ceiling; spinal cord: 4.7 nTPM; absolute ceiling; stomach: 5.4 nTPM; positive ihc; thyroid gland: 15.6 nTPM; positive ihc;absolute ceiling; urinary bladder: 5.9 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 6 nTPM (limit 4); amygdala: 6.9 nTPM (limit 2); basal ganglia: 7.4 nTPM (limit 2); bone marrow: 5.1 nTPM (limit 2); cerebellum: 5.1 nTPM (limit 4); cerebral cortex: 11 nTPM (limit 2); choroid plexus: 15.1 nTPM (limit 2); heart muscle: 8.7 nTPM (limit 2); hippocampal formation: 7.4 nTPM (limit 2); hypothalamus: 7.4 nTPM (limit 2); kidney: 10.8 nTPM (limit 2); liver: 3.5 nTPM (limit 2); lung: 7.1 nTPM (limit 4); midbrain: 5.8 nTPM (limit 2); pancreas: 5.5 nTPM (limit 2); parathyroid gland: 14 nTPM (limit 6); pituitary gland: 8.2 nTPM (limit 2); retina: 17.3 nTPM (limit 2); skeletal muscle: 4.8 nTPM (limit 4); smooth muscle: 8.9 nTPM (limit 4); spinal cord: 4.7 nTPM (limit 2); thyroid gland: 15.6 nTPM (limit 10),adipose tissue / adipocytes: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / basal cells: Medium (Approved); bronchus / ciliated cells (cell body): High (Approved); bronchus / ciliated cells (ciliary rootlets): High (Approved); bronchus / ciliated cells (tip of cilia): High (Approved); bronchus / goblet cells: Medium (Approved); caudate / glial cells: Medium (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuropil: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Medium (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Low (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / ciliated cells (cilia axoneme): High (Approved); nasopharynx / ciliated cells (tip of cilia): High (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Low (Approved); salivary gland / glandular cells: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Pancreatic Adenocarcinoma (validation): 80/80 (100.0%); Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%),glioma: 6/9 (66.7%); testis cancer: 6/10 (60.0%),31,20,Q4LDG9,https://www.uniprot.org/uniprotkb/Q4LDG9/entry,Part of the multisubunit axonemal ATPase complexes that generate the force for cilia motility and govern beat frequency (By similarity). Component of the outer arm dynein (ODA). May be involved in a mechanosensory feedback mechanism controlling ODA activity based on external conformational cues by tethering the outer arm dynein heavy chain (DNAH5) to the microtubule within the axoneme (By similarity). Important for ciliary function in the airways and for the function of the cilia that produce the nodal flow essential for the determination of the left-right asymmetry (PubMed:21496787),"Expressed in tissues carrying motile cilia such as respiratory epithelia, ependyma and testis","Ciliary dyskinesia, primary, 16: A disorder characterized by abnormalities of motile cilia. Respiratory infections leading to chronic inflammation and bronchiectasis are recurrent, due to defects in the respiratory cilia; reduced fertility is often observed in male patients due to abnormalities of sperm tails. Half of the patients exhibit randomization of left-right body asymmetry and situs inversus, due to dysfunction of monocilia at the embryonic node. Primary ciliary dyskinesia associated with situs inversus is referred to as Kartagener syndrome.",,"Cytoplasm, cytoskeleton, cilium axoneme",21496787,15845866,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
DNALI1,ENSG00000163879,Unsafe,Protein,False,True,52.7,77.1,129,20,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 10.4 nTPM; absolute ceiling; basal ganglia: 12.6 nTPM; absolute ceiling; choroid plexus: 77.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 5.1 nTPM; positive ihc; duodenum: 1.2 nTPM; positive ihc; hippocampal formation: 11.3 nTPM; absolute ceiling; hypothalamus: 15.6 nTPM; absolute ceiling;continuous selectivity; midbrain: 11.3 nTPM; absolute ceiling; pituitary gland: 12.3 nTPM; absolute ceiling; rectum: 2.2 nTPM; positive ihc; retina: 11.5 nTPM; absolute ceiling; salivary gland: 4.4 nTPM; positive ihc; small intestine: 2.2 nTPM; absolute ceiling; spinal cord: 11.3 nTPM; absolute ceiling; stomach: 6.2 nTPM; positive ihc;absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 10.4 nTPM (limit 2); basal ganglia: 12.6 nTPM (limit 2); choroid plexus: 77.1 nTPM (limit 2); hippocampal formation: 11.3 nTPM (limit 2); hypothalamus: 15.6 nTPM (limit 2); midbrain: 11.3 nTPM (limit 2); pituitary gland: 12.3 nTPM (limit 2); retina: 11.5 nTPM (limit 2); small intestine: 2.2 nTPM (limit 2); spinal cord: 11.3 nTPM (limit 2); stomach: 6.2 nTPM (limit 6),bronchus / ciliated cells (cell body): Low (Enhanced); bronchus / ciliated cells (cilia axoneme): High (Enhanced); bronchus / ciliated cells (tip of cilia): High (Enhanced); colon / enterocytes: Low (Enhanced); duodenum / enterocytes: Medium (Enhanced); duodenum / enterocytes - Gradient: Ascending (Enhanced); rectum / enterocytes: Low (Enhanced); rectum / enterocytes - Gradient: Ascending (Enhanced); salivary gland / glandular cells: Low (Enhanced); stomach 1 / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Glioblastoma Multiforme (TCGA): 138/141 (97.9%); Breast Invasive Carcinoma (validation): 47/50 (94.0%),endometrial cancer: 1/12 (8.3%); ovarian cancer: 1/12 (8.3%),31,20,O14645,https://www.uniprot.org/uniprotkb/O14645/entry,Involved in sperm flagellum assembly,"Expressed in many tissues. A smaller 0.9 kb and a larger 2.5 kb transcripts were detected at the highest level in the testis, at medium levels in the prostate, heart, liver, lung and pancreas, at low levels in the ovary, skeletal muscle and small intestine. Not detected in spleen, colon epithelium, thymus or peripheral blood leukocytes. The 0.9 kb transcript is expressed at a 20-fold higher level than the 2.5 kb transcript in the testis. Expressed in spermatozoa and airway epithelial cells (at protein level) (PubMed:31178125)",Spermatogenic failure 83: An autosomal recessive male infertility disorder characterized by asthenoteratozoospermia. Patient sperm exhibit an asymmetric fibrous sheath of the flagella.,,"Cell projection, cilium Cell projection, cilium, flagellum Dynein axonemal particle Cytoplasm",36792588,31178125,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
DNASE2B,ENSG00000137976,Unsafe,RNA,False,True,6.5,165.3,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,lung: 2.3 nTPM; absolute ceiling;continuous selectivity; salivary gland: 165.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,lung: 2.3 nTPM (limit 2); salivary gland: 165.3 nTPM (limit 6); lung: 2.3 nTPM (baseline 2); salivary gland: 165.3 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Prostate Adenocarcinoma (TCGA): 360/480 (75.0%); Skin Cuteneous Melanoma (TCGA): 18/99 (18.2%); Breast Invasive Carcinoma (validation): 4/50 (8.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8WZ79,https://www.uniprot.org/uniprotkb/Q8WZ79/entry,Hydrolyzes DNA under acidic conditions. Does not require divalent cations for activity. Participates in the degradation of nuclear DNA during lens cell differentiation,"Highly expressed in the eye lens and in salivary gland. Detected at lower levels in lung, prostate and lymph node. Isoform 2 is lung specific",,,Lysosome,11700027|12944971,11376952|11700027|12944971,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
DND1,ENSG00000256453,Unsafe,RNA,False,True,11.8,11.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,cerebellum: 3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebellum: 3 nTPM (limit 2); cerebellum: 3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (validation): 216/231 (93.5%); Breast Invasive Carcinoma (validation): 44/50 (88.0%); Prostate Adenocarcinoma (TCGA): 389/480 (81.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8IYX4,https://www.uniprot.org/uniprotkb/Q8IYX4/entry,"RNA-binding factor that positively regulates gene expression by prohibiting miRNA-mediated gene suppression. Relieves miRNA repression in germline cells (By similarity). Prohibits the function of several miRNAs by blocking the accessibility of target mRNAs. Sequence-specific RNA-binding factor that binds specifically to U-rich regions (URRs) in the 3' untranslated region (3'-UTR) of several mRNAs. Does not bind to miRNAs. May play a role during primordial germ cell (PGC) survival (By similarity). However, does not seem to be essential for PGC migration (By similarity)",,,,Nucleus Cytoplasm,18155131,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
DOCK1,ENSG00000150760,Unsafe,Protein,False,True,24.5,35.5,80,57,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 19.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 7.9 nTPM; absolute ceiling; amygdala: 32.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 31 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 0.7 nTPM; positive ihc; cerebellum: 5.8 nTPM; positive ihc;absolute ceiling; cerebral cortex: 19.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 10.2 nTPM; absolute ceiling;continuous selectivity; colon: 17.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 13 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 15.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 13.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 28.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 21.7 nTPM; absolute ceiling;continuous selectivity; kidney: 18.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 9.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 13.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 35.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 13.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 24.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 5.5 nTPM; absolute ceiling; rectum: 13.4 nTPM; absolute ceiling;continuous selectivity; retina: 2.2 nTPM; absolute ceiling; salivary gland: 17.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 5 nTPM; absolute ceiling; skin: 32.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 14.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 18.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 29.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 9.7 nTPM; positive ihc; stomach: 12.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; thyroid gland: 25.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; tongue: 10.1 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 15.9 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 19.3 nTPM (limit 10); adrenal gland: 7.9 nTPM (limit 4); amygdala: 32.9 nTPM (limit 2); basal ganglia: 31 nTPM (limit 2); cerebellum: 5.8 nTPM (limit 2); cerebral cortex: 19.4 nTPM (limit 2); choroid plexus: 10.2 nTPM (limit 2); colon: 17.1 nTPM (limit 6); duodenum: 13 nTPM (limit 2); esophagus: 15.7 nTPM (limit 6); heart muscle: 13.7 nTPM (limit 2); hippocampal formation: 28.7 nTPM (limit 2); hypothalamus: 21.7 nTPM (limit 2); kidney: 18.6 nTPM (limit 2); liver: 9.3 nTPM (limit 2); lung: 13.3 nTPM (limit 2); midbrain: 35.5 nTPM (limit 2); pancreas: 13.7 nTPM (limit 2); parathyroid gland: 24.7 nTPM (limit 6); pituitary gland: 5.5 nTPM (limit 2); rectum: 13.4 nTPM (limit 8); retina: 2.2 nTPM (limit 2); salivary gland: 17.2 nTPM (limit 6); skeletal muscle: 5 nTPM (limit 4); skin: 32.5 nTPM (limit 10); small intestine: 14.6 nTPM (limit 2); smooth muscle: 18.5 nTPM (limit 2); spinal cord: 29.7 nTPM (limit 2); stomach: 12.9 nTPM (limit 6); thyroid gland: 25.8 nTPM (limit 10); tongue: 10.1 nTPM (limit 6); urinary bladder: 15.9 nTPM (limit 6),adipose tissue / adipocytes: Low (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Medium (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Low (Approved); colon / endothelial cells: High (Approved); colon / glandular cells: Low (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Low (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Low (Approved); salivary gland / glandular cells: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in red pulp: Low (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%),glioma: 9/11 (81.8%); skin cancer: 8/11 (72.7%),31,20,Q14185,https://www.uniprot.org/uniprotkb/Q14185/entry,"Involved in cytoskeletal rearrangements required for phagocytosis of apoptotic cells and cell motility. Along with DOCK1, mediates CRK/CRKL regulation of epithelial and endothelial cell spreading and migration on type IV collagen (PubMed:19004829). Functions as a guanine nucleotide exchange factor (GEF), which activates Rac Rho small GTPases by exchanging bound GDP for free GTP. Its GEF activity may be enhanced by ELMO1 (PubMed:8657152)","Highly expressed in placenta, lung, kidney, pancreas and ovary. Expressed at intermediate level in thymus, testes and colon",,,Cytoplasm Membrane,19004829|8657152,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
DOK6,ENSG00000206052,Unsafe,Protein,False,True,5.7,21.6,80,26,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 0.6 nTPM; positive ihc; amygdala: 16.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 5.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 17.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; colon: 0.6 nTPM; positive ihc; heart muscle: 6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 13.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 7.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 4.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 2.3 nTPM; continuous selectivity; lung: 2.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 0.5 nTPM; positive ihc; midbrain: 9.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 12.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; retina: 21.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 0.4 nTPM; positive ihc; smooth muscle: 2.4 nTPM; continuous selectivity; spinal cord: 1.9 nTPM; continuous selectivity; spleen: 0.9 nTPM; positive ihc; urinary bladder: 3 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 16.3 nTPM (limit 2); basal ganglia: 7 nTPM (limit 2); cerebellum: 5.1 nTPM (limit 2); cerebral cortex: 17.7 nTPM (limit 2); heart muscle: 6 nTPM (limit 2); hippocampal formation: 13.2 nTPM (limit 2); hypothalamus: 7.1 nTPM (limit 2); kidney: 4.7 nTPM (limit 2); lung: 2.3 nTPM (limit 2); midbrain: 9.2 nTPM (limit 2); parathyroid gland: 12.1 nTPM (limit 8); retina: 21.6 nTPM (limit 2),adrenal gland / glandular cells: Low (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Low (Approved); colon / peripheral nerve/ganglion: Low (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Low (Approved); lung / macrophages: Low (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); skin 1 / keratinocytes: Low (Approved); spleen / cells in white pulp: Low (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 32/58 (55.2%); Kidney Renal Clear Cell Carcinoma (validation): 23/100 (23.0%); Lung Squamous Cell Carcinoma (validation): 8/68 (11.8%),lymphoma: 4/11 (36.4%); liver cancer: 1/10 (10.0%),31,20,Q6PKX4,https://www.uniprot.org/uniprotkb/Q6PKX4/entry,DOK proteins are enzymatically inert adaptor or scaffolding proteins. They provide a docking platform for the assembly of multimolecular signaling complexes. DOK6 promotes Ret-mediated neurite growth. May have a role in brain development and/or maintenance,"Highly expressed in fetal and adult brain. Highly expressed in the cerebellum. Weak expression in kidney, spinal cord and testis",,,,15286081,15286081,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
DPH6,ENSG00000134146,Unsafe,Protein,False,True,10.7,13.8,86,36,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 8.3 nTPM; positive ihc;continuous selectivity; adrenal gland: 7.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 4.1 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 4.3 nTPM; absolute ceiling;continuous selectivity; bone marrow: 5.4 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 5.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 4.9 nTPM; absolute ceiling;continuous selectivity; colon: 6.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 6.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 9.2 nTPM; absolute ceiling;continuous selectivity; heart muscle: 9.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 3.8 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 3.9 nTPM; absolute ceiling;continuous selectivity; kidney: 10.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 7.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 5.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 5.1 nTPM; continuous selectivity; midbrain: 4.9 nTPM; absolute ceiling;continuous selectivity; pancreas: 13.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 8.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 5.7 nTPM; absolute ceiling;continuous selectivity; rectum: 6.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 8.6 nTPM; absolute ceiling;continuous selectivity; salivary gland: 6.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 10.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 9.4 nTPM; continuous selectivity; small intestine: 6.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 6.2 nTPM; absolute ceiling;continuous selectivity; spinal cord: 6.1 nTPM; absolute ceiling;continuous selectivity; spleen: 6.2 nTPM; continuous selectivity; stomach: 6.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 6.8 nTPM; continuous selectivity; thyroid gland: 10.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 6.6 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 7.8 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 7.2 nTPM (limit 2); amygdala: 4.1 nTPM (limit 2); basal ganglia: 4.3 nTPM (limit 2); bone marrow: 5.4 nTPM (limit 4); cerebral cortex: 5.3 nTPM (limit 2); choroid plexus: 4.9 nTPM (limit 2); colon: 6.5 nTPM (limit 6); duodenum: 6.1 nTPM (limit 2); esophagus: 9.2 nTPM (limit 8); heart muscle: 9.8 nTPM (limit 2); hippocampal formation: 3.8 nTPM (limit 2); hypothalamus: 3.9 nTPM (limit 2); kidney: 10.1 nTPM (limit 2); liver: 7.8 nTPM (limit 2); lung: 5.2 nTPM (limit 2); midbrain: 4.9 nTPM (limit 2); pancreas: 13.8 nTPM (limit 2); parathyroid gland: 8.4 nTPM (limit 6); pituitary gland: 5.7 nTPM (limit 2); rectum: 6.8 nTPM (limit 6); retina: 8.6 nTPM (limit 2); salivary gland: 6.5 nTPM (limit 6); skeletal muscle: 10.4 nTPM (limit 2); small intestine: 6.4 nTPM (limit 2); smooth muscle: 6.2 nTPM (limit 4); spinal cord: 6.1 nTPM (limit 2); stomach: 6.5 nTPM (limit 6); thyroid gland: 10.5 nTPM (limit 10); tongue: 6.6 nTPM (limit 6); urinary bladder: 7.8 nTPM (limit 6),adipose tissue / adipocytes: High (Approved); adrenal gland / glandular cells: High (Approved); bronchus / respiratory epithelial cells: Low (Approved); caudate / neuronal cells: Low (Approved); cerebral cortex / glial cells: Low (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Low (Approved); duodenum / glandular cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in tubules: High (Approved); liver / hepatocytes: Medium (Approved); lung / macrophages: Low (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: High (Approved); parathyroid gland / glandular cells: High (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Low (Approved); small intestine / glandular cells: Medium (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 140/141 (99.3%); Colon Adenocarcinoma (validation): 479/486 (98.6%); Lung Adenocarcinoma (validation): 103/105 (98.1%),liver cancer: 9/12 (75.0%); testis cancer: 5/10 (50.0%),29,20,Q7L8W6,https://www.uniprot.org/uniprotkb/Q7L8W6/entry,Amidase that may catalyze the last step of diphthamide biosynthesis using ammonium and ATP (PubMed:23169644). Diphthamide biosynthesis consists in the conversion of an L-histidine residue in the translation elongation factor (EEF2) to diphthamide (By similarity),,,,,23169644,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
DPPA4,ENSG00000121570,Unsafe,RNA,False,True,4.1,12.1,87,6,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,bone marrow: 4.7 nTPM; continuous selectivity;reproductive not higher; thymus: 12.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,thymus: 12.1 nTPM (limit 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 121/133 (91.0%); Pancreatic Adenocarcinoma (validation): 6/80 (7.5%); Glioblastoma Multiforme (validation): 1/58 (1.7%),testis cancer: 12/12 (100.0%); urothelial cancer: 4/12 (33.3%),31,20,Q7L190,https://www.uniprot.org/uniprotkb/Q7L190/entry,May be involved in the maintenance of active epigenetic status of target genes. May inhibit differentiation of embryonic cells into a primitive ectoderm lineage,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
DRC7,ENSG00000159625,Unsafe,RNA,False,True,44.7,44.7,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,basal ganglia: 2.3 nTPM; absolute ceiling; choroid plexus: 12 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 2.1 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,basal ganglia: 2.3 nTPM (limit 2); choroid plexus: 12 nTPM (limit 2); hypothalamus: 2.1 nTPM (limit 2); basal ganglia: 2.3 nTPM (baseline 2); choroid plexus: 12 nTPM (baseline 2); hypothalamus: 2.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Renal Papillary Cell Carcinoma (TCGA): 175/282 (62.1%); Uterine Corpus Endometrial Carcinoma (TCGA): 51/176 (29.0%); Ovary Serous Cystadenocarcinoma (TCGA): 36/349 (10.3%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q8IY82,https://www.uniprot.org/uniprotkb/Q8IY82/entry,"Component of the nexin-dynein regulatory complex (N-DRC) a key regulator of ciliary/flagellar motility which maintains the alignment and integrity of the distal axoneme and regulates microtubule sliding in motile axonemes (By similarity). Involved in the regulation of flagellar motility (By similarity). Essential for male fertility, sperm head morphogenesis and sperm flagellum formation (By similarity)",,,,"Cell projection, cilium, flagellum Cytoplasm, cytoskeleton, cilium axoneme Cytoplasm, cytoskeleton, flagellum axoneme",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
DRD3,ENSG00000151577,Unsafe,RNA,False,True,0.6,3.2,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,basal ganglia: 3.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,basal ganglia: 3.2 nTPM (limit 2); basal ganglia: 3.2 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P35462,https://www.uniprot.org/uniprotkb/P35462/entry,"G protein-coupled receptor for dopamine, a catecholamine neurotransmitter hormone that functions as the brain's 'reward chemical', driving motivation, reinforcement learning and pleasure (PubMed:19520868, PubMed:33548201, PubMed:37221270, PubMed:39237617, PubMed:39984436, PubMed:8301582). Dopamine binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase (PubMed:10578130, PubMed:33548201, PubMed:37221270, PubMed:39237617). Dopamine receptors can be classified in two categories: (1) DRD3 (together with DRD2 and DRD4) is a D2-type receptor and is coupled to G(i)/G(o) G proteins, mediating inhibition of adenylate cyclase activity, while D1-type receptors (DRD1 and DRD5) are coupled to G(s) G proteins and promote activation of adenylate cyclase activity (PubMed:10578130, PubMed:33548201, PubMed:37221270, PubMed:39237617). D1- and D2-type dopamine receptors have antagonistic effects, particularly in the brain's striatum, where they govern voluntary movement and reward: D1-type receptors generally stimulate neural activity and promotes action, while D2-type receptors tend to inhibit neural activity and suppress movement (PubMed:10578130, PubMed:33548201, PubMed:37221270, PubMed:39237617). DRD3 is primarily expressed in limbic areas of the brain and is involved in the modulation of cognitive, emotional and motor functions: plays a key role in regulating neuronal signaling pathways associated with motivation, reward and behavior (PubMed:39984436). Involved in the incentive salience of drugs: controls responses to drug-related stimuli, making it a key target for reducing addiction to substances like cocaine, morphine, and alcohol (PubMed:10432116, PubMed:39984436). Forms heterotetramers with DRD1 to potentiate beta-arrestin recruitment and mediate locomotor activity (By similarity). Also involved in autophagy regulation: receptor activation stimulates AMPK, which phosphorylates RPTOR and enhances its interaction with MTOR, thereby inhibiting mTORC1 signaling and its downstream target RPS6KB1 (PubMed:31538542). This leads to activation of ULK1 and initiation of the autophagy cascade (PubMed:31538542)",Brain,"Tremor, hereditary essential 1: A common movement disorder mainly characterized by postural tremor of the arms. Head, legs, trunk, voice, jaw, and facial muscles may also be involved. The condition can be aggravated by emotions, hunger, fatigue and temperature extremes, and may cause a functional disability or even incapacitation. Inheritance is autosomal dominant. Schizophrenia: A complex, multifactorial psychotic disorder or group of disorders characterized by disturbances in the form and content of thought (e.g. delusions, hallucinations), in mood (e.g. inappropriate affect), in sense of self and relationship to the external world (e.g. loss of ego boundaries, withdrawal), and in behavior (e.g bizarre or apparently purposeless behavior). Although it affects emotions, it is distinguished from mood disorders in which such disturbances are primary. Similarly, there may be mild impairment of cognitive function, and it is distinguished from the dementias in which disturbed cognitive function is considered primary. Some patients manifest schizophrenic as well as bipolar disorder symptoms and are often given the diagnosis of schizoaffective disorder.",,Cell membrane,10432116|10578130|19520868|31538542|33548201|37221270|39237617|39984436|8301582,8415635,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
DRICH1,ENSG00000189269,Unsafe,RNA,False,True,45.1,45.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 3.7 nTPM; absolute ceiling; kidney: 2.5 nTPM; absolute ceiling; pancreas: 2.3 nTPM; absolute ceiling; parathyroid gland: 8.9 nTPM; absolute ceiling; retina: 3.8 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 3.7 nTPM (limit 2); kidney: 2.5 nTPM (limit 2); pancreas: 2.3 nTPM (limit 2); parathyroid gland: 8.9 nTPM (limit 6); retina: 3.8 nTPM (limit 2); bone marrow: 3.7 nTPM (baseline 2); kidney: 2.5 nTPM (baseline 2); pancreas: 2.3 nTPM (baseline 2); parathyroid gland: 8.9 nTPM (baseline 6); retina: 3.8 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 8/58 (13.8%); Kidney Renal Papillary Cell Carcinoma (TCGA): 35/282 (12.4%); Testicular Germ Cell Tumor (TCGA): 14/133 (10.5%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q6PGQ1,https://www.uniprot.org/uniprotkb/Q6PGQ1/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
DTL,ENSG00000143476,Unsafe,Protein,False,True,13.3,14.4,78,15,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 14.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 1.9 nTPM; positive ihc; lung: 1.4 nTPM; positive ihc; lymph node: 5.4 nTPM; positive ihc;continuous selectivity; skin: 2.1 nTPM; positive ihc; smooth muscle: 1.8 nTPM; positive ihc; thymus: 13.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 14.4 nTPM (limit 2); thymus: 13.8 nTPM (limit 10),bone marrow / hematopoietic cells: High (Supported); esophagus / squamous epithelial cells: Low (Supported); lung / macrophages: Low (Supported); lymph node / germinal center cells: Medium (Supported); lymph node / non-germinal center cells: Low (Supported); skin 2 / epidermal cells: Low (Supported); smooth muscle / smooth muscle cells: Low (Supported),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 479/486 (98.6%); Glioblastoma Multiforme (validation): 57/58 (98.3%); Lung Squamous Cell Carcinoma (validation): 65/68 (95.6%),colorectal cancer: 2/12 (16.7%); melanoma: 1/11 (9.1%),31,20,Q9NZJ0,https://www.uniprot.org/uniprotkb/Q9NZJ0/entry,"Substrate-specific adapter of a DCX (DDB1-CUL4-X-box) E3 ubiquitin-protein ligase complex required for cell cycle control, DNA damage response and translesion DNA synthesis. The DCX(DTL) complex, also named CRL4(CDT2) complex, mediates the polyubiquitination and subsequent degradation of CDT1, CDKN1A/p21(CIP1), FBH1, KMT5A and SDE2 (PubMed:16861906, PubMed:16949367, PubMed:16964240, PubMed:17085480, PubMed:18703516, PubMed:18794347, PubMed:18794348, PubMed:19332548, PubMed:20129063, PubMed:23478441, PubMed:23478445, PubMed:23677613, PubMed:27906959). CDT1 degradation in response to DNA damage is necessary to ensure proper cell cycle regulation of DNA replication (PubMed:16861906, PubMed:16949367, PubMed:17085480). CDKN1A/p21(CIP1) degradation during S phase or following UV irradiation is essential to control replication licensing (PubMed:18794348, PubMed:19332548). KMT5A degradation is also important for a proper regulation of mechanisms such as TGF-beta signaling, cell cycle progression, DNA repair and cell migration (PubMed:23478445). Most substrates require their interaction with PCNA for their polyubiquitination: substrates interact with PCNA via their PIP-box, and those containing the 'K+4' motif in the PIP box, recruit the DCX(DTL) complex, leading to their degradation. In undamaged proliferating cells, the DCX(DTL) complex also promotes the 'Lys-164' monoubiquitination of PCNA, thereby being involved in PCNA-dependent translesion DNA synthesis (PubMed:20129063, PubMed:23478441, PubMed:23478445, PubMed:23677613). The DDB1-CUL4A-DTL E3 ligase complex regulates the circadian clock function by mediating the ubiquitination and degradation of CRY1 (PubMed:26431207)","Expressed in placenta and testis, very low expression seen in skeletal muscle. Detected in all hematopoietic tissues examined, with highest expression in thymus and bone marrow. A low level detected in the spleen and lymph node, and barely detectable level in the peripheral leukocytes. RA treatment down-regulated the expression in NT2 cell",,,"Nucleus Nucleus membrane Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Chromosome",16861906|16949367|16964240|17085480|18703516|18794347|18794348|19332548|20129063|23478441|23478445|23677613|26431207|27906959,11278750|17106265,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
DTWD2,ENSG00000169570,Unsafe,Protein,False,True,4.9,10.0,93,30,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 3 nTPM; continuous selectivity; adrenal gland: 3.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 1.4 nTPM; continuous selectivity; basal ganglia: 1.5 nTPM; continuous selectivity; bone marrow: 1.2 nTPM; positive ihc; cerebellum: 2.8 nTPM; continuous selectivity; cerebral cortex: 2.5 nTPM; continuous selectivity; colon: 3.1 nTPM; positive ihc;continuous selectivity; duodenum: 3 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 4.1 nTPM; positive ihc;continuous selectivity; heart muscle: 6.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 1.5 nTPM; continuous selectivity; kidney: 6.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 4.3 nTPM; absolute ceiling;continuous selectivity; lung: 2.3 nTPM; continuous selectivity; midbrain: 1.4 nTPM; continuous selectivity; pancreas: 2.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 4.5 nTPM; continuous selectivity; rectum: 3.2 nTPM; positive ihc;continuous selectivity; retina: 3.3 nTPM; absolute ceiling;continuous selectivity; salivary gland: 3.1 nTPM; positive ihc;continuous selectivity; skeletal muscle: 10 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 3.2 nTPM; positive ihc;continuous selectivity; small intestine: 2.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 3 nTPM; continuous selectivity; spinal cord: 1.9 nTPM; continuous selectivity; spleen: 2.9 nTPM; positive ihc;continuous selectivity; stomach: 2.6 nTPM; positive ihc;continuous selectivity; thyroid gland: 8.7 nTPM; continuous selectivity;reproductive not higher; tongue: 6.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 2.8 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 3.2 nTPM (limit 2); duodenum: 3 nTPM (limit 2); heart muscle: 6.3 nTPM (limit 2); kidney: 6.2 nTPM (limit 2); liver: 4.3 nTPM (limit 4); pancreas: 2.9 nTPM (limit 2); retina: 3.3 nTPM (limit 2); skeletal muscle: 10 nTPM (limit 4); small intestine: 2.6 nTPM (limit 2); tongue: 6.1 nTPM (limit 6),adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: High (Approved); bronchus / ciliated cells (cell body): Medium (Approved); colon / glandular cells: High (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Low (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Low (Approved); nasopharynx / ciliated cells (cell body): Medium (Approved); pancreas / exocrine glandular cells: Low (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: Medium (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Medium (Approved); spleen / cells in red pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 45/50 (90.0%); Pancreatic Adenocarcinoma (validation): 68/80 (85.0%),pancreatic cancer: 7/10 (70.0%); breast cancer: 7/12 (58.3%),31,20,Q8NBA8,https://www.uniprot.org/uniprotkb/Q8NBA8/entry,"Catalyzes the formation of 3-(3-amino-3-carboxypropyl)uridine (acp3U) at position 20a in the D-loop of several cytoplasmic tRNAs (acp3U(20a)) (PubMed:31804502, PubMed:39173631). Also has a weak activity to form acp3U at position 20 in the D-loop of tRNAs (acp3U(20)) (PubMed:31804502). Involved in glycoRNA biosynthesis by mediating formation of acp3U, which acts as an attachment site for N-glycans on tRNAs (PubMed:39173631). GlycoRNAs consist of RNAs modified with secretory N-glycans that are presented on the cell surface (PubMed:39173631)",,,,Cytoplasm Nucleus,31804502|39173631,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
DUSP19,ENSG00000162999,Unsafe,Protein,False,True,3.6,3.8,78,33,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 1.4 nTPM; positive ihc;continuous selectivity; amygdala: 1.4 nTPM; continuous selectivity; basal ganglia: 2 nTPM; continuous selectivity; cerebral cortex: 1.7 nTPM; positive ihc;continuous selectivity; colon: 1.4 nTPM; positive ihc;continuous selectivity; duodenum: 1.3 nTPM; positive ihc;continuous selectivity; esophagus: 1.3 nTPM; positive ihc; heart muscle: 3 nTPM; continuous selectivity; hippocampal formation: 1.7 nTPM; continuous selectivity; kidney: 1.7 nTPM; positive ihc;continuous selectivity; liver: 1.1 nTPM; positive ihc;continuous selectivity; lymph node: 0.9 nTPM; positive ihc; pancreas: 0.9 nTPM; positive ihc; pituitary gland: 1.1 nTPM; continuous selectivity; rectum: 1 nTPM; positive ihc; retina: 1.1 nTPM; continuous selectivity; skeletal muscle: 1.6 nTPM; continuous selectivity; small intestine: 1.1 nTPM; positive ihc;continuous selectivity; smooth muscle: 1.8 nTPM; continuous selectivity; stomach: 3.8 nTPM; positive ihc;continuous selectivity;reproductive not higher; tongue: 1.6 nTPM; continuous selectivity; urinary bladder: 1.1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,adrenal gland / glandular cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); cerebral cortex / neuronal cells: Low (Approved); colon / glandular cells: High (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: Medium (Approved); kidney / cells in tubules: High (Approved); liver / hepatocytes: Low (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); rectum / glandular cells: High (Approved); small intestine / glandular cells: High (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: Low (Approved); urinary bladder / urothelial cells: High (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Breast Invasive Carcinoma (validation): 14/50 (28.0%); Pancreatic Adenocarcinoma (validation): 10/80 (12.5%),renal cancer: 5/12 (41.7%); colorectal cancer: 4/11 (36.4%),31,20,Q8WTR2,https://www.uniprot.org/uniprotkb/Q8WTR2/entry,Has a dual specificity toward Ser/Thr and Tyr-containing proteins,"Expressed in the heart, lung, liver, and pancreas. The expression level in the pancreas is the highest",,,,12479873,12479873,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
DYNLRB2,ENSG00000168589,Unsafe,RNA,False,True,220.8,220.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 2.4 nTPM; absolute ceiling; amygdala: 8.8 nTPM; absolute ceiling; basal ganglia: 11.3 nTPM; absolute ceiling; cerebral cortex: 3.3 nTPM; absolute ceiling; choroid plexus: 56.3 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 11.5 nTPM; absolute ceiling; hypothalamus: 11.4 nTPM; absolute ceiling; kidney: 5.6 nTPM; absolute ceiling; lung: 5.9 nTPM; absolute ceiling; midbrain: 6.4 nTPM; absolute ceiling; pituitary gland: 4.2 nTPM; absolute ceiling; retina: 4 nTPM; absolute ceiling; spinal cord: 5.6 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 2.4 nTPM (limit 2); amygdala: 8.8 nTPM (limit 2); basal ganglia: 11.3 nTPM (limit 2); cerebral cortex: 3.3 nTPM (limit 2); choroid plexus: 56.3 nTPM (limit 2); hippocampal formation: 11.5 nTPM (limit 2); hypothalamus: 11.4 nTPM (limit 2); kidney: 5.6 nTPM (limit 2); lung: 5.9 nTPM (limit 2); midbrain: 6.4 nTPM (limit 2); pituitary gland: 4.2 nTPM (limit 2); retina: 4 nTPM (limit 2); spinal cord: 5.6 nTPM (limit 2); adrenal gland: 2.4 nTPM (baseline 2); amygdala: 8.8 nTPM (baseline 2); basal ganglia: 11.3 nTPM (baseline 2); cerebral cortex: 3.3 nTPM (baseline 2); choroid plexus: 56.3 nTPM (baseline 2); hippocampal formation: 11.5 nTPM (baseline 2); hypothalamus: 11.4 nTPM (baseline 2); kidney: 5.6 nTPM (baseline 2); lung: 5.9 nTPM (baseline 2); midbrain: 6.4 nTPM (baseline 2); pituitary gland: 4.2 nTPM (baseline 2); retina: 4 nTPM (baseline 2); spinal cord: 5.6 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 45/50 (90.0%); Breast Invasive Carcinoma (TCGA): 466/1022 (45.6%); Kidney Renal Papillary Cell Carcinoma (TCGA): 112/282 (39.7%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8TF09,https://www.uniprot.org/uniprotkb/Q8TF09/entry,Acts as one of several non-catalytic accessory components of the cytoplasmic dynein 1 complex that are thought to be involved in linking dynein to cargos and to adapter proteins that regulate dynein function. Cytoplasmic dynein 1 acts as a motor for the intracellular retrograde motility of vesicles and organelles along microtubules,"High expression in heart, brain, placenta, skeletal muscle, prostate and small intestine; moderate in kidney, pancreas, spleen, testis, ovary and colon; low in lung, liver, thymus and leukocyte",,,"Cytoplasm, cytoskeleton",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Jamin2021_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
DYNLT2,ENSG00000184786,Unsafe,High RNA,False,True,17.7,17.7,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 89/91 values ≥5 TPM, max 16.2735; DICE NK (unstimulated): 51/90 values ≥5 TPM, max 11.0377; DICE TREG_MEM (unstimulated): 30/89 values ≥5 TPM, max 7.68898; DICE CD4_NAIVE (unstimulated): 87/88 values ≥5 TPM, max 15.557; DICE CD4_STIM (activated): 88/88 values ≥5 TPM, max 41.5246; DICE TREG_NAIVE (unstimulated): 86/89 values ≥5 TPM, max 15.0208; DICE TFH (unstimulated): 35/89 values ≥5 TPM, max 8.46354; DICE TH1 (unstimulated): 34/81 values ≥5 TPM, max 8.27644; DICE THSTAR (unstimulated): 73/88 values ≥5 TPM, max 10.3658; DICE TH17 (unstimulated): 48/89 values ≥5 TPM, max 9.03342; DICE TH2 (unstimulated): 70/89 values ≥5 TPM, max 11.256; DICE CD8_NAIVE (unstimulated): 84/89 values ≥5 TPM, max 13.0367; DICE CD8_STIM (activated): 88/88 values ≥5 TPM, max 23.8553",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,41.5245892994,18.3,"dice_cd4_stim: blood/CD4_STIM, max 41.5246 TPM, 4 observations >30",CTA,oncoref.target-sets.2026-10-23.2,41.52 TPM; blood/CD4_STIM; dice_cd4_stim; vital,18.3 nTPM; fallopian tube/t-cells; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 2/58 (3.4%); Pancreatic Adenocarcinoma (validation): 1/80 (1.2%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q8IZS6,https://www.uniprot.org/uniprotkb/Q8IZS6/entry,"Component of dynein, a family of motor proteins essential for movement along microtubules (PubMed:11278908, PubMed:12584439). Required for structural and functional integrity of cilia (By similarity). Candidate for involvement in male sterility (By similarity)","Expressed predominantly in testis. Also expressed in brain, lung and trachea",,,"Cytoplasm, cytoskeleton Cytoplasmic granule Membrane",11278908|12584439,11278908|12584439,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
DYRK3,ENSG00000143479,Unsafe,RNA,False,True,46.5,46.5,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 2.3 nTPM; absolute ceiling; bone marrow: 8.7 nTPM; absolute ceiling; cerebral cortex: 2.5 nTPM; absolute ceiling; choroid plexus: 8.1 nTPM; absolute ceiling; heart muscle: 8 nTPM; absolute ceiling; hippocampal formation: 2.7 nTPM; absolute ceiling; hypothalamus: 2.5 nTPM; absolute ceiling; kidney: 3.2 nTPM; absolute ceiling; liver: 4 nTPM; absolute ceiling; lung: 5.3 nTPM; absolute ceiling; pancreas: 3.7 nTPM; absolute ceiling; pituitary gland: 6.3 nTPM; absolute ceiling; retina: 6.2 nTPM; absolute ceiling; smooth muscle: 7.9 nTPM; absolute ceiling; urinary bladder: 7.2 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 2.3 nTPM (limit 2); bone marrow: 8.7 nTPM (limit 2); cerebral cortex: 2.5 nTPM (limit 2); choroid plexus: 8.1 nTPM (limit 2); heart muscle: 8 nTPM (limit 2); hippocampal formation: 2.7 nTPM (limit 2); hypothalamus: 2.5 nTPM (limit 2); kidney: 3.2 nTPM (limit 2); liver: 4 nTPM (limit 2); lung: 5.3 nTPM (limit 2); pancreas: 3.7 nTPM (limit 2); pituitary gland: 6.3 nTPM (limit 2); retina: 6.2 nTPM (limit 2); smooth muscle: 7.9 nTPM (limit 2); urinary bladder: 7.2 nTPM (limit 6); adrenal gland: 2.3 nTPM (baseline 2); bone marrow: 8.7 nTPM (baseline 2); cerebral cortex: 2.5 nTPM (baseline 2); choroid plexus: 8.1 nTPM (baseline 2); heart muscle: 8 nTPM (baseline 2); hippocampal formation: 2.7 nTPM (baseline 2); hypothalamus: 2.5 nTPM (baseline 2); kidney: 3.2 nTPM (baseline 2); liver: 4 nTPM (baseline 2); lung: 5.3 nTPM (baseline 2); pancreas: 3.7 nTPM (baseline 2); pituitary gland: 6.3 nTPM (baseline 2); retina: 6.2 nTPM (baseline 2); smooth muscle: 7.9 nTPM (baseline 2); urinary bladder: 7.2 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 50/50 (100.0%); Glioblastoma Multiforme (validation): 57/58 (98.3%); Pancreatic Adenocarcinoma (validation): 75/80 (93.8%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O43781,https://www.uniprot.org/uniprotkb/O43781/entry,"Dual-specificity protein kinase that promotes disassembly of several types of membraneless organelles during mitosis, such as stress granules, nuclear speckles and pericentriolar material (PubMed:29973724). Dual-specificity tyrosine-regulated kinases (DYRKs) autophosphorylate a critical tyrosine residue in their activation loop and phosphorylate their substrate on serine and threonine residues (PubMed:29634919, PubMed:9748265). Acts as a central dissolvase of membraneless organelles during the G2-to-M transition, after the nuclear-envelope breakdown: acts by mediating phosphorylation of multiple serine and threonine residues in unstructured domains of proteins, such as SRRM1 and PCM1 (PubMed:29973724). Does not mediate disassembly of all membraneless organelles: disassembly of P-body and nucleolus is not regulated by DYRK3 (PubMed:29973724). Dissolution of membraneless organelles at the onset of mitosis is also required to release mitotic regulators, such as ZNF207, from liquid-unmixed organelles where they are sequestered and keep them dissolved during mitosis (PubMed:29973724). Regulates mTORC1 by mediating the dissolution of stress granules: during stressful conditions, DYRK3 partitions from the cytosol to the stress granule, together with mTORC1 components, which prevents mTORC1 signaling (PubMed:23415227). When stress signals are gone, the kinase activity of DYRK3 is required for the dissolution of stress granule and mTORC1 relocation to the cytosol: acts by mediating the phosphorylation of the mTORC1 inhibitor AKT1S1, allowing full reactivation of mTORC1 signaling (PubMed:23415227). Also acts as a negative regulator of EPO-dependent erythropoiesis: may place an upper limit on red cell production during stress erythropoiesis (PubMed:10779429). Inhibits cell death due to cytokine withdrawal in hematopoietic progenitor cells (PubMed:10779429). Promotes cell survival upon genotoxic stress through phosphorylation of SIRT1: this in turn inhibits p53/TP53 activity and apoptosis (PubMed:20167603)","Isoform 1: Highly expressed in testis and in hematopoietic tissue such as fetal liver, and bone marrow (PubMed:10779429). Isoform 1: Predominant form in fetal liver and bone marrow (PubMed:10779429). Isoform 1: Present at low levels in heart, pancreas, lymph node and thymus (PubMed:10779429). Isoform 2: Highly expressed in testis and in hematopoietic tissue such as fetal liver, and bone marrow (PubMed:10779429). Isoform 2: Predominant form in testis. Isoform 2: Present at low levels in heart, pancreas, lymph node and thymus (PubMed:10779429)",,,"Nucleus Cytoplasm Nucleus speckle Cytoplasmic granule Cytoplasm, cytoskeleton, microtubule organizing center, centrosome",10779429|20167603|23415227|29634919|29973724|9748265,10779429,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
DZIP3,ENSG00000198919,Unsafe,Protein,False,True,33.6,33.6,91,55,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 9.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 11.4 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 15.9 nTPM; absolute ceiling;continuous selectivity; bone marrow: 3.8 nTPM; positive ihc;absolute ceiling; cerebellum: 14.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 22.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 21.7 nTPM; absolute ceiling;continuous selectivity; colon: 5 nTPM; positive ihc; duodenum: 3 nTPM; positive ihc;absolute ceiling; esophagus: 3.7 nTPM; positive ihc; heart muscle: 11.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 12.8 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 17.8 nTPM; absolute ceiling;continuous selectivity; kidney: 10.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 4.1 nTPM; absolute ceiling; lung: 6.3 nTPM; positive ihc;absolute ceiling; lymph node: 9.9 nTPM; positive ihc;absolute ceiling; midbrain: 10.1 nTPM; absolute ceiling;continuous selectivity; pancreas: 5.2 nTPM; positive ihc;absolute ceiling; pituitary gland: 23.9 nTPM; absolute ceiling;continuous selectivity; rectum: 4.5 nTPM; positive ihc; retina: 28.9 nTPM; absolute ceiling;continuous selectivity; salivary gland: 3.4 nTPM; positive ihc; skeletal muscle: 11.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 3.5 nTPM; positive ihc; small intestine: 3.8 nTPM; positive ihc;absolute ceiling; smooth muscle: 5 nTPM; positive ihc;absolute ceiling; spinal cord: 8.2 nTPM; absolute ceiling; stomach: 6.4 nTPM; positive ihc;absolute ceiling; thyroid gland: 12.4 nTPM; positive ihc;absolute ceiling; tongue: 15.6 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 9.4 nTPM (limit 2); amygdala: 11.4 nTPM (limit 2); basal ganglia: 15.9 nTPM (limit 2); bone marrow: 3.8 nTPM (limit 2); cerebellum: 14.2 nTPM (limit 2); cerebral cortex: 22.6 nTPM (limit 2); choroid plexus: 21.7 nTPM (limit 2); duodenum: 3 nTPM (limit 2); heart muscle: 11.2 nTPM (limit 2); hippocampal formation: 12.8 nTPM (limit 2); hypothalamus: 17.8 nTPM (limit 2); kidney: 10.5 nTPM (limit 2); liver: 4.1 nTPM (limit 4); lung: 6.3 nTPM (limit 2); lymph node: 9.9 nTPM (limit 6); midbrain: 10.1 nTPM (limit 2); pancreas: 5.2 nTPM (limit 2); pituitary gland: 23.9 nTPM (limit 2); retina: 28.9 nTPM (limit 2); skeletal muscle: 11.9 nTPM (limit 2); small intestine: 3.8 nTPM (limit 2); smooth muscle: 5 nTPM (limit 2); spinal cord: 8.2 nTPM (limit 2); stomach: 6.4 nTPM (limit 6); thyroid gland: 12.4 nTPM (limit 10); tongue: 15.6 nTPM (limit 6),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / ciliated cells (cell body): Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in tubules: High (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / ciliated cells (cell body): Medium (Approved); nasopharynx / ciliated cells (cilia axoneme): High (Approved); nasopharynx / ciliated cells (tip of cilia): High (Approved); pancreas / exocrine glandular cells: Low (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); rectum / glandular cells: Low (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Low (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Low (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Rectum Adenocarcinoma (validation): 203/207 (98.1%); Colon Adenocarcinoma (validation): 473/486 (97.3%),melanoma: 5/9 (55.6%); ovarian cancer: 4/12 (33.3%),31,20,Q86Y13,https://www.uniprot.org/uniprotkb/Q86Y13/entry,E3 Ubiquitin ligase proteins mediate ubiquitination and subsequent proteasomal degradation of target proteins. E3 ubiquitin ligases accept ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates. Able to specifically bind RNA,"Widely expressed at low level. Highly expressed in skeletal muscle, kidney and heart. Expressed at low level in placenta, lung, brain, liver and pancreas",,,Cytoplasm,12538761,12538761,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
E2F7,ENSG00000165891,Unsafe,RNA,False,True,2.8,8.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 4.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 1.4 nTPM; continuous selectivity; lymph node: 1.5 nTPM; continuous selectivity; rectum: 1.4 nTPM; continuous selectivity; small intestine: 0.8 nTPM; continuous selectivity; thymus: 8 nTPM; continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 4.9 nTPM (limit 2); bone marrow: 4.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 50/58 (86.2%); Colon Adenocarcinoma (validation): 414/486 (85.2%); Rectum Adenocarcinoma (validation): 155/207 (74.9%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q96AV8,https://www.uniprot.org/uniprotkb/Q96AV8/entry,"Atypical E2F transcription factor that participates in various processes such as angiogenesis, polyploidization of specialized cells and DNA damage response. Mainly acts as a transcription repressor that binds DNA independently of DP proteins and specifically recognizes the E2 recognition site 5'-TTTC[CG]CGC-3'. Directly represses transcription of classical E2F transcription factors such as E2F1. Acts as a regulator of S-phase by recognizing and binding the E2-related site 5'-TTCCCGCC-3' and mediating repression of G1/S-regulated genes. Plays a key role in polyploidization of cells in placenta and liver by regulating the endocycle, probably by repressing genes promoting cytokinesis and antagonizing action of classical E2F proteins (E2F1, E2F2 and/or E2F3). Required for placental development by promoting polyploidization of trophoblast giant cells. Also involved in DNA damage response: up-regulated by p53/TP53 following genotoxic stress and acts as a downstream effector of p53/TP53-dependent repression by mediating repression of indirect p53/TP53 target genes involved in DNA replication. Acts as a promoter of sprouting angiogenesis, possibly by acting as a transcription activator: associates with HIF1A, recognizes and binds the VEGFA promoter, which is different from canonical E2 recognition site, and activates expression of the VEGFA gene. Acts as a negative regulator of keratinocyte differentiation",,,,Nucleus,14633988|15133492|18202719|19223542|21248772|22802528|22802529|22903062,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
EBI3,ENSG00000105246,Unsafe,RNA,False,True,142.7,142.7,83,3,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,amygdala: 2.8 nTPM; absolute ceiling; choroid plexus: 4.4 nTPM; absolute ceiling; hippocampal formation: 2.5 nTPM; absolute ceiling; hypothalamus: 2.2 nTPM; absolute ceiling; midbrain: 3.8 nTPM; absolute ceiling; spinal cord: 5 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 2.8 nTPM (limit 2); choroid plexus: 4.4 nTPM (limit 2); hippocampal formation: 2.5 nTPM (limit 2); hypothalamus: 2.2 nTPM (limit 2); midbrain: 3.8 nTPM (limit 2); spinal cord: 5 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 47/50 (94.0%); Kidney Renal Clear Cell Carcinoma (validation): 79/100 (79.0%); Glioblastoma Multiforme (TCGA): 108/141 (76.6%),skin cancer: 1/10 (10.0%); stomach cancer: 1/11 (9.1%),31,20,Q14213,https://www.uniprot.org/uniprotkb/Q14213/entry,"Associates with IL27 to form the IL-27 interleukin, a heterodimeric cytokine which functions in innate immunity. IL-27 has pro- and anti-inflammatory properties, that can regulate T-helper cell development, suppress T-cell proliferation, stimulate cytotoxic T-cell activity, induce isotype switching in B-cells, and that has diverse effects on innate immune cells. Among its target cells are CD4 T-helper cells which can differentiate in type 1 effector cells (TH1), type 2 effector cells (TH2) and IL17 producing helper T-cells (TH17). It drives rapid clonal expansion of naive but not memory CD4 T-cells. It also strongly synergizes with IL-12 to trigger interferon-gamma/IFN-gamma production of naive CD4 T-cells, binds to the cytokine receptor WSX-1/TCCR. Another important role of IL-27 is its antitumor activity as well as its antiangiogenic activity with activation of production of antiangiogenic chemokines",,,,Secreted,12121660,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Gong2021_reproductive_PC,No tumor-antigen validation in this source | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
EDAR,ENSG00000135960,Unsafe,Protein,False,True,1.4,3.5,77,65,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 0 nTPM; positive ihc; bone marrow: 0.3 nTPM; positive ihc; cerebellum: 0 nTPM; positive ihc; cerebral cortex: 0 nTPM; positive ihc; colon: 1.2 nTPM; positive ihc;continuous selectivity; duodenum: 1 nTPM; positive ihc;continuous selectivity; esophagus: 3.5 nTPM; positive ihc;continuous selectivity;reproductive not higher; heart muscle: 0 nTPM; positive ihc; kidney: 0.6 nTPM; positive ihc;continuous selectivity; liver: 0.9 nTPM; positive ihc;continuous selectivity; lung: 0.2 nTPM; positive ihc; lymph node: 1.5 nTPM; positive ihc;continuous selectivity;reproductive not higher; pancreas: 0.1 nTPM; positive ihc; parathyroid gland: 0 nTPM; positive ihc; rectum: 1.9 nTPM; positive ihc;continuous selectivity;reproductive not higher; salivary gland: 0.5 nTPM; positive ihc; skeletal muscle: 0 nTPM; positive ihc; skin: 1.4 nTPM; positive ihc;continuous selectivity;reproductive not higher; small intestine: 1 nTPM; positive ihc;continuous selectivity; smooth muscle: 0 nTPM; positive ihc; spleen: 0.2 nTPM; positive ihc; stomach: 0.8 nTPM; positive ihc;continuous selectivity; thymus: 1.1 nTPM; continuous selectivity; thyroid gland: 0 nTPM; positive ihc; urinary bladder: 1.4 nTPM; positive ihc;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",,adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: High (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in tubules: High (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: High (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: High (Approved); parathyroid gland / glandular cells: High (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: High (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 116/207 (56.0%); Colon Adenocarcinoma (validation): 249/486 (51.2%); Rectum Adenocarcinoma (TCGA): 38/88 (43.2%),colorectal cancer: 10/12 (83.3%); stomach cancer: 10/12 (83.3%),31,20,Q9UNE0,https://www.uniprot.org/uniprotkb/Q9UNE0/entry,"Receptor for EDA isoform A1, but not for EDA isoform A2. Mediates the activation of NF-kappa-B and JNK. May promote caspase-independent cell death","Detected in fetal kidney, lung, skin and cultured neonatal epidermal keratinocytes. Not detected in lymphoblast and fibroblast cell lines","Ectodermal dysplasia 10A, hypohidrotic/hair/nail type, autosomal dominant: A form of ectodermal dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. It is an autosomal dominant condition characterized by hypotrichosis, abnormal or missing teeth, and hypohidrosis due to the absence of sweat glands. Ectodermal dysplasia 10B, hypohidrotic/hair/tooth type, autosomal recessive: A disorder due to abnormal development of two or more ectodermal structures, and characterized by sparse hair (atrichosis or hypotrichosis), abnormal or missing teeth and the inability to sweat due to the absence of sweat glands.",,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
EDDM3A,ENSG00000181562,Unsafe,High RNA,False,True,620.9,620.9,84,4,Positive somewhere,False,False,False,True,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,CTA,Pass,oncoref.target-sets.2026-10-23.1,False,False,,CTA → Unsafe,True,True,True,5.1823573891,31.1,"hpa_single_cell: /Collecting duct cells, max 31.1 nTPM, 1 observations >30; hpa_single_cell_tissue: kidney/collecting duct cells, max 31.1 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,5.182 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,31.1 nTPM; unsited/Collecting duct cells; hpa_single_cell; unresolved,Breast Invasive Carcinoma (validation): 3/50 (6.0%); Kidney Chromophobe (TCGA): 2/64 (3.1%); Liver Hepatocellular Carcinoma (TCGA): 6/362 (1.7%),breast cancer: 0/12 (0.0%); cervical cancer: 0/10 (0.0%),31,20,Q14507,https://www.uniprot.org/uniprotkb/Q14507/entry,Possible function in sperm maturation,"Epididymis, with predominant expression in the corpus region. Moderately expressed in the vas deferens; only low levels are detectable in the caput and cauda regions",,,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,All audited maxima are within 10% above 30; other gates still require review,,,,
EFCAB10,ENSG00000185055,Unsafe,RNA,False,True,28.7,28.7,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,basal ganglia: 3.4 nTPM; absolute ceiling; bone marrow: 2.3 nTPM; absolute ceiling; choroid plexus: 12.4 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 2.7 nTPM; absolute ceiling; hypothalamus: 3.3 nTPM; absolute ceiling; lung: 3.1 nTPM; absolute ceiling; pituitary gland: 2.1 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,basal ganglia: 3.4 nTPM (limit 2); bone marrow: 2.3 nTPM (limit 2); choroid plexus: 12.4 nTPM (limit 2); hippocampal formation: 2.7 nTPM (limit 2); hypothalamus: 3.3 nTPM (limit 2); lung: 3.1 nTPM (limit 2); pituitary gland: 2.1 nTPM (limit 2); basal ganglia: 3.4 nTPM (baseline 2); bone marrow: 2.3 nTPM (baseline 2); choroid plexus: 12.4 nTPM (baseline 2); hippocampal formation: 2.7 nTPM (baseline 2); hypothalamus: 3.3 nTPM (baseline 2); lung: 3.1 nTPM (baseline 2); pituitary gland: 2.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Prostate Adenocarcinoma (TCGA): 342/480 (71.2%); Uterine Corpus Endometrial Carcinoma (TCGA): 117/176 (66.5%); Liver Hepatocellular Carcinoma (validation): 151/231 (65.4%),melanoma: 12/12 (100.0%); renal cancer: 12/12 (100.0%),31,20,A6NFE3,https://www.uniprot.org/uniprotkb/A6NFE3/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Chang2019_TGCT,Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
EFCAB11,ENSG00000140025,Unsafe,RNA,False,True,35.7,35.7,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 4 nTPM; absolute ceiling; amygdala: 7.6 nTPM; absolute ceiling; basal ganglia: 6.3 nTPM; absolute ceiling; bone marrow: 5.9 nTPM; absolute ceiling; cerebellum: 2.1 nTPM; absolute ceiling; cerebral cortex: 4.9 nTPM; absolute ceiling; choroid plexus: 5.5 nTPM; absolute ceiling; duodenum: 4.9 nTPM; absolute ceiling; heart muscle: 2.5 nTPM; absolute ceiling; hippocampal formation: 5.9 nTPM; absolute ceiling; hypothalamus: 5 nTPM; absolute ceiling; kidney: 7.3 nTPM; absolute ceiling; liver: 5.8 nTPM; absolute ceiling; lung: 3 nTPM; absolute ceiling; midbrain: 7.4 nTPM; absolute ceiling; pancreas: 4.7 nTPM; absolute ceiling; parathyroid gland: 7.9 nTPM; absolute ceiling; pituitary gland: 3.2 nTPM; absolute ceiling; retina: 6 nTPM; absolute ceiling; small intestine: 3.7 nTPM; absolute ceiling; smooth muscle: 3.7 nTPM; absolute ceiling; spinal cord: 6.6 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 4 nTPM (limit 2); amygdala: 7.6 nTPM (limit 2); basal ganglia: 6.3 nTPM (limit 2); bone marrow: 5.9 nTPM (limit 2); cerebellum: 2.1 nTPM (limit 2); cerebral cortex: 4.9 nTPM (limit 2); choroid plexus: 5.5 nTPM (limit 2); duodenum: 4.9 nTPM (limit 2); heart muscle: 2.5 nTPM (limit 2); hippocampal formation: 5.9 nTPM (limit 2); hypothalamus: 5 nTPM (limit 2); kidney: 7.3 nTPM (limit 2); liver: 5.8 nTPM (limit 2); lung: 3 nTPM (limit 2); midbrain: 7.4 nTPM (limit 2); pancreas: 4.7 nTPM (limit 2); parathyroid gland: 7.9 nTPM (limit 6); pituitary gland: 3.2 nTPM (limit 2); retina: 6 nTPM (limit 2); small intestine: 3.7 nTPM (limit 2); smooth muscle: 3.7 nTPM (limit 2); spinal cord: 6.6 nTPM (limit 2); adrenal gland: 4 nTPM (baseline 2); amygdala: 7.6 nTPM (baseline 2); basal ganglia: 6.3 nTPM (baseline 2); bone marrow: 5.9 nTPM (baseline 2); cerebellum: 2.1 nTPM (baseline 2); cerebral cortex: 4.9 nTPM (baseline 2); choroid plexus: 5.5 nTPM (baseline 2); duodenum: 4.9 nTPM (baseline 2); heart muscle: 2.5 nTPM (baseline 2); hippocampal formation: 5.9 nTPM (baseline 2); hypothalamus: 5 nTPM (baseline 2); kidney: 7.3 nTPM (baseline 2); liver: 5.8 nTPM (baseline 2); lung: 3 nTPM (baseline 2); midbrain: 7.4 nTPM (baseline 2); pancreas: 4.7 nTPM (baseline 2); parathyroid gland: 7.9 nTPM (baseline 6); pituitary gland: 3.2 nTPM (baseline 2); retina: 6 nTPM (baseline 2); small intestine: 3.7 nTPM (baseline 2); smooth muscle: 3.7 nTPM (baseline 2); spinal cord: 6.6 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (TCGA): 87/88 (98.9%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 276/283 (97.5%); Breast Invasive Carcinoma (TCGA): 980/1022 (95.9%),No exact-ID IHC coverage in the HPA cancer snapshot,30,0,Q9BUY7,https://www.uniprot.org/uniprotkb/Q9BUY7/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
EFCAB12,ENSG00000172771,Unsafe,RNA,False,True,19.0,19.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,basal ganglia: 2.8 nTPM; absolute ceiling; choroid plexus: 10.5 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 3 nTPM; absolute ceiling; pituitary gland: 3.5 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,basal ganglia: 2.8 nTPM (limit 2); choroid plexus: 10.5 nTPM (limit 2); hypothalamus: 3 nTPM (limit 2); pituitary gland: 3.5 nTPM (limit 2); basal ganglia: 2.8 nTPM (baseline 2); choroid plexus: 10.5 nTPM (baseline 2); hypothalamus: 3 nTPM (baseline 2); pituitary gland: 3.5 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 44/176 (25.0%); Kidney Renal Papillary Cell Carcinoma (TCGA): 55/282 (19.5%); Prostate Adenocarcinoma (TCGA): 47/480 (9.8%),colorectal cancer: 10/10 (100.0%); endometrial cancer: 10/11 (90.9%),29,20,Q6NXP0,https://www.uniprot.org/uniprotkb/Q6NXP0/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
EFCAB13,ENSG00000178852,Unsafe,RNA,False,True,19.8,19.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 2.5 nTPM; absolute ceiling; bone marrow: 3.8 nTPM; absolute ceiling; duodenum: 4.6 nTPM; absolute ceiling; heart muscle: 2.4 nTPM; absolute ceiling; kidney: 5.2 nTPM; absolute ceiling;continuous selectivity; liver: 3.3 nTPM; absolute ceiling; lung: 3 nTPM; absolute ceiling; pituitary gland: 2.5 nTPM; absolute ceiling; retina: 3.8 nTPM; absolute ceiling; small intestine: 3.3 nTPM; absolute ceiling; smooth muscle: 2.4 nTPM; absolute ceiling; thyroid gland: 13.6 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 2.5 nTPM (limit 2); bone marrow: 3.8 nTPM (limit 2); duodenum: 4.6 nTPM (limit 2); heart muscle: 2.4 nTPM (limit 2); kidney: 5.2 nTPM (limit 2); liver: 3.3 nTPM (limit 2); lung: 3 nTPM (limit 2); pituitary gland: 2.5 nTPM (limit 2); retina: 3.8 nTPM (limit 2); small intestine: 3.3 nTPM (limit 2); smooth muscle: 2.4 nTPM (limit 2); thyroid gland: 13.6 nTPM (limit 10); adrenal gland: 2.5 nTPM (baseline 2); bone marrow: 3.8 nTPM (baseline 2); duodenum: 4.6 nTPM (baseline 2); heart muscle: 2.4 nTPM (baseline 2); kidney: 5.2 nTPM (baseline 2); liver: 3.3 nTPM (baseline 2); lung: 3 nTPM (baseline 2); pituitary gland: 2.5 nTPM (baseline 2); retina: 3.8 nTPM (baseline 2); small intestine: 3.3 nTPM (baseline 2); smooth muscle: 2.4 nTPM (baseline 2); thyroid gland: 13.6 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 164/207 (79.2%); Thyroid Carcinoma (TCGA): 366/495 (73.9%); Colon Adenocarcinoma (validation): 346/486 (71.2%),pancreatic cancer: 8/10 (80.0%); testis cancer: 6/11 (54.5%),29,20,Q8IY85,https://www.uniprot.org/uniprotkb/Q8IY85/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
EFCAB2,ENSG00000203666,Unsafe,Protein,False,True,22.5,22.5,81,79,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 9.5 nTPM; positive ihc; adrenal gland: 8 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 7.4 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 6.8 nTPM; absolute ceiling;continuous selectivity; bone marrow: 13.4 nTPM; absolute ceiling;continuous selectivity; cerebellum: 2.8 nTPM; positive ihc;absolute ceiling; cerebral cortex: 7.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 20.3 nTPM; absolute ceiling;continuous selectivity; colon: 5.2 nTPM; positive ihc; duodenum: 3.2 nTPM; positive ihc;absolute ceiling; esophagus: 9 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 10 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 8.2 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 6.8 nTPM; absolute ceiling;continuous selectivity; kidney: 7.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 3.8 nTPM; positive ihc;absolute ceiling; lung: 10 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 8.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 9.4 nTPM; absolute ceiling;continuous selectivity; pancreas: 7.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 10 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 5.9 nTPM; absolute ceiling;continuous selectivity; rectum: 10.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 15.5 nTPM; absolute ceiling;continuous selectivity; salivary gland: 7.2 nTPM; positive ihc;absolute ceiling; skeletal muscle: 18.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 6 nTPM; positive ihc; small intestine: 5.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 8.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 10.1 nTPM; absolute ceiling;continuous selectivity; spleen: 6.5 nTPM; positive ihc; stomach: 9.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; thyroid gland: 21.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; urinary bladder: 6.1 nTPM; positive ihc;absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 8 nTPM (limit 2); amygdala: 7.4 nTPM (limit 2); basal ganglia: 6.8 nTPM (limit 2); bone marrow: 13.4 nTPM (limit 4); cerebellum: 2.8 nTPM (limit 2); cerebral cortex: 7.7 nTPM (limit 2); choroid plexus: 20.3 nTPM (limit 2); duodenum: 3.2 nTPM (limit 2); esophagus: 9 nTPM (limit 6); heart muscle: 10 nTPM (limit 2); hippocampal formation: 8.2 nTPM (limit 2); hypothalamus: 6.8 nTPM (limit 2); kidney: 7.7 nTPM (limit 2); liver: 3.8 nTPM (limit 2); lung: 10 nTPM (limit 2); lymph node: 8.4 nTPM (limit 6); midbrain: 9.4 nTPM (limit 2); pancreas: 7.2 nTPM (limit 2); parathyroid gland: 10 nTPM (limit 6); pituitary gland: 5.9 nTPM (limit 2); rectum: 10.8 nTPM (limit 6); retina: 15.5 nTPM (limit 2); salivary gland: 7.2 nTPM (limit 6); skeletal muscle: 18.1 nTPM (limit 2); small intestine: 5.9 nTPM (limit 2); smooth muscle: 8.9 nTPM (limit 2); spinal cord: 10.1 nTPM (limit 2); stomach: 9.2 nTPM (limit 6); thyroid gland: 21.4 nTPM (limit 10); urinary bladder: 6.1 nTPM (limit 6),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Medium (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / glial cells: Medium (Approved); caudate / neuronal cells: High (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: High (Approved); hippocampus / glial cells: Medium (Approved); hippocampus / neuronal cells: High (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: High (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: High (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: High (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Adenocarcinoma (validation): 105/105 (100.0%); Lung Squamous Cell Carcinoma (validation): 67/68 (98.5%); Glioblastoma Multiforme (TCGA): 137/141 (97.2%),endometrial cancer: 11/12 (91.7%); colorectal cancer: 10/12 (83.3%),31,20,Q5VUJ9,https://www.uniprot.org/uniprotkb/Q5VUJ9/entry,"Component of the nexin-dynein regulatory complex (N-DRC), a key regulator of ciliary/flagellar motility which maintains the alignment and integrity of the distal axoneme and regulates microtubule sliding in motile axonemes",,,,"Cytoplasm, cytoskeleton, flagellum axoneme",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
EFCAB5,ENSG00000176927,Unsafe,High RNA,False,True,8.3,8.3,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 6/91 values ≥5 TPM, max 6.52002",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,6.841,34.1,"hpa_single_cell_tissue: brain/excitatory neurons, max 34.1 nTPM, 3 observations >30",CTA,oncoref.target-sets.2026-10-23.2,6.841 TPM; blood/eosinophil; hpa_immune_cell_samples; vital,34.1 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (validation): 3/50 (6.0%); Rectum Adenocarcinoma (validation): 10/207 (4.8%); Colon Adenocarcinoma (validation): 19/486 (3.9%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,A4FU69,https://www.uniprot.org/uniprotkb/A4FU69/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
EFCAB6,ENSG00000186976,Unsafe,RNA,False,True,23.6,23.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,choroid plexus: 3.1 nTPM; absolute ceiling; retina: 3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 3.1 nTPM (limit 2); retina: 3 nTPM (limit 2); choroid plexus: 3.1 nTPM (baseline 2); retina: 3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 30/50 (60.0%); Glioblastoma Multiforme (validation): 28/58 (48.3%); Pancreatic Adenocarcinoma (validation): 8/80 (10.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q5THR3,https://www.uniprot.org/uniprotkb/Q5THR3/entry,"Negatively regulates the androgen receptor by recruiting histone deacetylase complex, and protein DJ-1 antagonizes this inhibition by abrogation of this complex (PubMed:12612053). Microtubule inner protein (MIP) part of the dynein-decorated doublet microtubules (DMTs) in cilia axoneme, which is required for motile cilia beating (By similarity)",Specifically expressed in the testis,,,"Nucleus Cytoplasm, cytoskeleton, flagellum axoneme",12612053,12612053,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
EGFL6,ENSG00000198759,Unsafe,RNA,False,True,623.7,623.7,80,1,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,lung: 24.8 nTPM; absolute ceiling; pituitary gland: 2.5 nTPM; absolute ceiling; retina: 2.2 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,lung: 24.8 nTPM (limit 12); pituitary gland: 2.5 nTPM (limit 2); retina: 2.2 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Adenocarcinoma (validation): 105/105 (100.0%); Lung Squamous Cell Carcinoma (validation): 67/68 (98.5%); Lung Squamous Cell Carcinoma (TCGA): 441/489 (90.2%),prostate cancer: 3/11 (27.3%); stomach cancer: 1/11 (9.1%),31,20,Q8IUX8,https://www.uniprot.org/uniprotkb/Q8IUX8/entry,May bind integrin alpha-8/beta-1 and play a role in hair follicle morphogenesis. Promotes matrix assembly (By similarity),,,,"Secreted, extracellular space, extracellular matrix, basement membrane",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bai2016_EGFL6,Ovarian-tumor and vascular expression/function; no normal-tissue exclusivity claim,,,,,,,,
EGR4,ENSG00000135625,Unsafe,Protein,False,True,3.8,18.6,83,5,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 5.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 11.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 18.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 6.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 9.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 2.9 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 3.4 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 5.2 nTPM (limit 2); basal ganglia: 11.2 nTPM (limit 2); cerebellum: 18.6 nTPM (limit 2); cerebral cortex: 6.9 nTPM (limit 2); hippocampal formation: 9.7 nTPM (limit 2); hypothalamus: 2.9 nTPM (limit 2); pituitary gland: 3.4 nTPM (limit 2); amygdala: 5.2 nTPM (baseline 2); basal ganglia: 11.2 nTPM (baseline 2); cerebellum: 18.6 nTPM (baseline 2); cerebral cortex: 6.9 nTPM (baseline 2); hippocampal formation: 9.7 nTPM (baseline 2); hypothalamus: 2.9 nTPM (baseline 2); pituitary gland: 3.4 nTPM (baseline 2),caudate / glial cells: Low (Enhanced); cerebellum / cells in granular layer: Low (Enhanced); cerebral cortex / glial cells: Low (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); hippocampus / glial cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Stomach Adenocarcinoma (TCGA): 13/346 (3.8%); Breast Invasive Carcinoma (validation): 1/50 (2.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 3/176 (1.7%),melanoma: 2/10 (20.0%); glioma: 1/10 (10.0%),31,20,Q05215,https://www.uniprot.org/uniprotkb/Q05215/entry,Transcriptional regulator. Recognizes and binds to the DNA sequence 5'-GCGGGGGCG-3' (GSG). Activates the transcription of target genes whose products are required for mitogenesis and differentiation (By similarity),,,It is uncertain whether Met-1 or Met-104 is the initiator. Some orthologous sequences cannot be extended,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
EID2B,ENSG00000176401,Unsafe,Protein,False,True,5.0,15.9,77,41,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 3.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 8.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 11.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 15.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 11.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 5.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 3.6 nTPM; positive ihc;continuous selectivity; duodenum: 1.3 nTPM; positive ihc; heart muscle: 2.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 7.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 13.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 2.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 2.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 3.2 nTPM; continuous selectivity; midbrain: 5.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 1.4 nTPM; positive ihc;continuous selectivity; pituitary gland: 10 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 0.9 nTPM; positive ihc; retina: 9.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 2 nTPM; continuous selectivity; skin: 0.9 nTPM; positive ihc; small intestine: 2.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 1.5 nTPM; positive ihc;continuous selectivity; spinal cord: 4.7 nTPM; absolute ceiling;continuous selectivity; spleen: 3.3 nTPM; continuous selectivity; stomach: 1.9 nTPM; positive ihc;continuous selectivity; thymus: 2.5 nTPM; continuous selectivity; thyroid gland: 3.6 nTPM; positive ihc;continuous selectivity; urinary bladder: 2.9 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 3.5 nTPM (limit 2); amygdala: 8.5 nTPM (limit 2); basal ganglia: 11.8 nTPM (limit 2); cerebellum: 15.9 nTPM (limit 4); cerebral cortex: 11.1 nTPM (limit 2); choroid plexus: 5.1 nTPM (limit 2); heart muscle: 2.9 nTPM (limit 2); hippocampal formation: 7.8 nTPM (limit 2); hypothalamus: 13.5 nTPM (limit 2); kidney: 2.5 nTPM (limit 2); lung: 2.1 nTPM (limit 2); midbrain: 5.6 nTPM (limit 2); pituitary gland: 10 nTPM (limit 2); retina: 9.2 nTPM (limit 2); small intestine: 2.4 nTPM (limit 2); spinal cord: 4.7 nTPM (limit 2),adrenal gland / glandular cells: Low (Approved); bronchus / respiratory epithelial cells: High (Approved); cerebral cortex / endothelial cells: Low (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); lung / alveolar cells type II: Medium (Approved); lung / macrophages: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Low (Approved); rectum / glandular cells: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Low (Approved); skin 1 / Langerhans: Low (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: High (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 39/50 (78.0%); Glioblastoma Multiforme (TCGA): 84/141 (59.6%),urothelial cancer: 10/12 (83.3%); skin cancer: 8/10 (80.0%),31,20,Q96D98,https://www.uniprot.org/uniprotkb/Q96D98/entry,"Acts as a repressor of MYOD-dependent transcription, glucocorticoid receptor-dependent transcription, and muscle differentiation",,,,Nucleus,15970276,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
EID3,ENSG00000255150,Unsafe,Protein,False,True,59.4,59.4,79,10,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 3 nTPM; absolute ceiling; basal ganglia: 2.4 nTPM; absolute ceiling; bone marrow: 5.2 nTPM; absolute ceiling; cerebellum: 2.8 nTPM; positive ihc;absolute ceiling; cerebral cortex: 2.2 nTPM; absolute ceiling; colon: 3 nTPM; positive ihc; heart muscle: 1.9 nTPM; positive ihc; hippocampal formation: 2.3 nTPM; absolute ceiling; hypothalamus: 2.5 nTPM; absolute ceiling; kidney: 1.7 nTPM; positive ihc; lung: 2.9 nTPM; absolute ceiling; pancreas: 2.4 nTPM; absolute ceiling; pituitary gland: 3.6 nTPM; absolute ceiling; rectum: 0.9 nTPM; positive ihc; retina: 6.4 nTPM; absolute ceiling; skin: 2.6 nTPM; positive ihc; small intestine: 2.6 nTPM; absolute ceiling; smooth muscle: 2.2 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 3 nTPM (limit 2); basal ganglia: 2.4 nTPM (limit 2); bone marrow: 5.2 nTPM (limit 2); cerebellum: 2.8 nTPM (limit 2); cerebral cortex: 2.2 nTPM (limit 2); hippocampal formation: 2.3 nTPM (limit 2); hypothalamus: 2.5 nTPM (limit 2); lung: 2.9 nTPM (limit 2); pancreas: 2.4 nTPM (limit 2); pituitary gland: 3.6 nTPM (limit 2); retina: 6.4 nTPM (limit 2); small intestine: 2.6 nTPM (limit 2); smooth muscle: 2.2 nTPM (limit 2); adrenal gland: 3 nTPM (baseline 2); basal ganglia: 2.4 nTPM (baseline 2); bone marrow: 5.2 nTPM (baseline 2); cerebellum: 2.8 nTPM (baseline 2); cerebral cortex: 2.2 nTPM (baseline 2); hippocampal formation: 2.3 nTPM (baseline 2); hypothalamus: 2.5 nTPM (baseline 2); lung: 2.9 nTPM (baseline 2); pancreas: 2.4 nTPM (baseline 2); pituitary gland: 3.6 nTPM (baseline 2); retina: 6.4 nTPM (baseline 2); small intestine: 2.6 nTPM (baseline 2); smooth muscle: 2.2 nTPM (baseline 2),cerebellum / Purkinje cells: Low (Uncertain); colon / glandular cells: Low (Uncertain); heart muscle / cardiomyocytes: Low (Uncertain); kidney / cells in tubules: Low (Uncertain); rectum / glandular cells: Low (Uncertain); skin 1 / keratinocytes: Medium (Uncertain); skin 2 / epidermal cells: Low (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 54/58 (93.1%); Breast Invasive Carcinoma (validation): 40/50 (80.0%); Testicular Germ Cell Tumor (TCGA): 78/133 (58.6%),melanoma: 1/12 (8.3%); breast cancer: 0/11 (0.0%),31,20,Q8N140,https://www.uniprot.org/uniprotkb/Q8N140/entry,"Tissue-specific component of the SMC5-SMC6 complex, a complex involved in repair of DNA double-strand breaks by homologous recombination. The complex may promote sister chromatid homologous recombination by recruiting the SMC1-SMC3 cohesin complex to double-strand breaks. The complex is required for telomere maintenance via recombination and mediates sumoylation of shelterin complex (telosome) components Acts as a repressor of nuclear receptor-dependent transcription possibly by interfering with CREBBP-dependent coactivation. May function as a coinhibitor of other CREBBP/EP300-dependent transcription factors",Highly expressed in testis,,,"Nucleus Cytoplasm Chromosome, telomere",15987788,15987788,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
EIF4E,ENSG00000151247,Unsafe,Protein,False,True,60.7,60.7,123,98,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 36.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 36.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 25.6 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 24.2 nTPM; absolute ceiling;continuous selectivity; bone marrow: 56.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 21.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 36.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 30.7 nTPM; absolute ceiling;continuous selectivity; colon: 43.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 35 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 50 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 36.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 22.6 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 30.3 nTPM; absolute ceiling;continuous selectivity; kidney: 45.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 42 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 26.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 43.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 29.3 nTPM; absolute ceiling;continuous selectivity; pancreas: 26.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 43.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 16.6 nTPM; absolute ceiling;continuous selectivity; rectum: 50.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 52.4 nTPM; absolute ceiling;continuous selectivity; salivary gland: 30.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 37.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 23.4 nTPM; positive ihc;absolute ceiling; small intestine: 33.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 37.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 35.7 nTPM; absolute ceiling;continuous selectivity; spleen: 30.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 34.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 51.8 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 51 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 46.3 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 52.4 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 36.6 nTPM (limit 10); adrenal gland: 36.3 nTPM (limit 2); amygdala: 25.6 nTPM (limit 2); basal ganglia: 24.2 nTPM (limit 2); bone marrow: 56.6 nTPM (limit 2); cerebellum: 21.9 nTPM (limit 2); cerebral cortex: 36.4 nTPM (limit 2); choroid plexus: 30.7 nTPM (limit 2); colon: 43.6 nTPM (limit 6); duodenum: 35 nTPM (limit 2); esophagus: 50 nTPM (limit 6); heart muscle: 36.2 nTPM (limit 2); hippocampal formation: 22.6 nTPM (limit 2); hypothalamus: 30.3 nTPM (limit 2); kidney: 45.7 nTPM (limit 2); liver: 42 nTPM (limit 2); lung: 26.2 nTPM (limit 2); lymph node: 43.6 nTPM (limit 6); midbrain: 29.3 nTPM (limit 2); pancreas: 26.3 nTPM (limit 2); parathyroid gland: 43.5 nTPM (limit 6); pituitary gland: 16.6 nTPM (limit 2); rectum: 50.6 nTPM (limit 6); retina: 52.4 nTPM (limit 2); salivary gland: 30.3 nTPM (limit 6); skeletal muscle: 37.8 nTPM (limit 2); skin: 23.4 nTPM (limit 10); small intestine: 33.5 nTPM (limit 2); smooth muscle: 37.9 nTPM (limit 2); spinal cord: 35.7 nTPM (limit 2); spleen: 30.6 nTPM (limit 10); stomach: 34.9 nTPM (limit 6); thymus: 51.8 nTPM (limit 10); thyroid gland: 51 nTPM (limit 10); tongue: 46.3 nTPM (limit 6); urinary bladder: 52.4 nTPM (limit 6),adipose tissue / adipocytes: Low (Supported); adrenal gland / glandular cells: Medium (Supported); bone marrow / hematopoietic cells: Medium (Supported); bronchus / respiratory epithelial cells: Medium (Supported); caudate / glial cells: Low (Supported); caudate / neuronal cells: Low (Supported); cerebellum / GLUC cells - cytoplasm/membrane: High (Supported); cerebellum / molecular layer cells - cytoplasm/membrane: High (Supported); cerebellum / Purkinje cells - cytoplasm/membrane: High (Supported); cerebellum / synaptic glomeruli - core: Low (Supported); cerebral cortex / endothelial cells: Low (Supported); cerebral cortex / glial cells: Medium (Supported); cerebral cortex / neuronal cells: High (Supported); colon / endothelial cells: Medium (Supported); colon / glandular cells: Medium (Supported); colon / peripheral nerve/ganglion: Medium (Supported); duodenum / glandular cells: Medium (Supported); esophagus / squamous epithelial cells: Medium (Supported); heart muscle / cardiomyocytes: Low (Supported); hippocampus / glial cells: Low (Supported); hippocampus / neuronal cells: Medium (Supported); kidney / cells in glomeruli: Medium (Supported); kidney / cells in tubules: Medium (Supported); liver / cholangiocytes: Low (Supported); liver / hepatocytes: Low (Supported); lung / alveolar cells type I: High (Supported); lung / alveolar cells type II: High (Supported); lung / endothelial cells: Low (Supported); lung / macrophages: Medium (Supported); lymph node / germinal center cells: High (Supported); lymph node / non-germinal center cells: Low (Supported); nasopharynx / respiratory epithelial cells: Medium (Supported); oral mucosa / squamous epithelial cells: Medium (Supported); pancreas / exocrine glandular cells: High (Supported); pancreas / pancreatic endocrine cells: Low (Supported); parathyroid gland / glandular cells: Medium (Supported); rectum / glandular cells: Medium (Supported); salivary gland / glandular cells: Medium (Supported); skeletal muscle / myocytes: Low (Supported); skin 1 / cells in basal layer: Medium (Supported); skin 1 / cells in granular layer: High (Supported); skin 1 / cells in spinous layer: Medium (Supported); skin 1 / eccrine glands: Medium (Supported); skin 1 / endothelial cells: Medium (Supported); skin 1 / fibrohistiocytic cells: High (Supported); skin 1 / langerhans cells: Medium (Supported); skin 1 / lymphocytes: Medium (Supported); skin 2 / cells in basal layer: Medium (Supported); skin 2 / cells in granular layer: Medium (Supported); skin 2 / cells in spinous layer: Medium (Supported); skin 2 / endothelial cells: Medium (Supported); skin 2 / fibrohistiocytic cells: High (Supported); skin 2 / langerhans cells: Medium (Supported); skin 2 / lymphocytes: High (Supported); small intestine / glandular cells: Medium (Supported); smooth muscle / smooth muscle cells: Low (Supported); spleen / cells in red pulp: Low (Supported); spleen / cells in white pulp: Low (Supported); stomach 1 / glandular cells: Medium (Supported); stomach 2 / glandular cells: Medium (Supported); thyroid gland / glandular cells: Medium (Supported); urinary bladder / urothelial cells: Medium (Supported),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%); Head and Neck Squamous Cell Carcinoma (TCGA): 492/492 (100.0%),breast cancer: 12/12 (100.0%); glioma: 12/12 (100.0%),31,20,P06730,https://www.uniprot.org/uniprotkb/P06730/entry,"Acts in the cytoplasm to initiate and regulate protein synthesis and is required in the nucleus for export of a subset of mRNAs from the nucleus to the cytoplasm which promotes processes such as RNA capping, processing and splicing (PubMed:11606200, PubMed:22578813, PubMed:22684010, PubMed:24335285, PubMed:29987188). Component of the protein complex eIF4F, which is involved in the recognition of the mRNA cap, ATP-dependent unwinding of 5'-terminal secondary structure and recruitment of mRNA to the ribosome (By similarity). This protein recognizes and binds the 7-methylguanosine (m7G)-containing mRNA cap during an early step in the initiation of protein synthesis and facilitates ribosome binding by inducing the unwinding of the mRNAs secondary structures (PubMed:16271312, PubMed:22578813). Together with EIF4G1, antagonizes the scanning promoted by EIF1-EIF4G1 and is required for TISU translation, a process where the TISU element recognition makes scanning unnecessary (PubMed:29987188). In addition to its role in translation initiation, also acts as a regulator of translation and stability in the cytoplasm (PubMed:24335285). Component of the CYFIP1-EIF4E-FMR1 complex which binds to the mRNA cap and mediates translational repression: in the complex, EIF4E mediates the binding to the mRNA cap (By similarity). Component of a multiprotein complex that sequesters and represses translation of proneurogenic factors during neurogenesis (By similarity). In P-bodies, component of a complex that mediates the storage of translationally inactive mRNAs in the cytoplasm and prevents their degradation (PubMed:24335285). May play an important role in spermatogenesis through translational regulation of stage-specific mRNAs during germ cell development (By similarity). As well as its roles in translation, also involved in mRNA nucleocytoplasmic transport (By similarity). Its role in mRNA export from the nucleus to the cytoplasm relies on its ability to bind the m7G cap of RNAs and on the presence of the 50-nucleotide EIF4E sensitivity element (4ESE) in the 3'UTR of sensitive transcripts (By similarity). Interaction with the 4ESE is mediated by LRPPRC which binds simultaneously to both EIF4E and the 4ESE, thereby acting as a platform for assembly for the RNA export complex (By similarity). EIF4E-dependent mRNA export is independent of ongoing protein or RNA synthesis and is also NFX1-independent but is XPO1-dependent with LRPPRC interacting with XPO1 to form an EIF4E-dependent mRNA export complex (By similarity). Alters the composition of the cytoplasmic face of the nuclear pore to promote RNA export by reducing RANBP2 expression, relocalizing nucleoporin NUP214 and increasing expression of RANBP1 and RNA export factors DDX19 and GLE1 (By similarity). Promotes the nuclear export of cyclin CCND1 mRNA (By similarity). Promotes the nuclear export of NOS2/iNOS mRNA (PubMed:23471078). Promotes the nuclear export of MDM2 mRNA (PubMed:22684010). Promotes the export of additional mRNAs, including others involved in the cell cycle (By similarity). In the nucleus, binds to capped splice factor-encoding mRNAs and stimulates their nuclear export to enhance splice factor production by increasing their cytoplasmic availability to the translation machinery (By similarity). May also regulate splicing through interaction with the spliceosome in an RNA and m7G cap-dependent manner (By similarity). Also binds to some pre-mRNAs and may play a role in their recruitment to the spliceosome (By similarity). Promotes steady-state capping of a subset of coding and non-coding RNAs by mediating nuclear export of capping machinery mRNAs including RNMT, RNGTT and RAMAC to enhance their translation (By similarity). Stimulates mRNA 3'-end processing by promoting the expression of several core cleavage complex factors required for mRNA cleavage and polyadenylation, and may also have a direct effect through its interaction with the CPSF3 cleavage enzyme (By similarity). Rescues cells from apoptosis by promoting activation of serine/threonine-protein kinase AKT1 through mRNA export of NBS1 which potentiates AKT1 phosphorylation and also through mRNA export of AKT1 effectors, allowing for increased production of these proteins (By similarity)",,"Autism 19: A complex multifactorial, pervasive developmental disorder characterized by impairments in reciprocal social interaction and communication, restricted and stereotyped patterns of interests and activities, and the presence of developmental abnormalities by 3 years of age. Most individuals with autism also manifest moderate intellectual disability.","Was originally thought to be phosphorylated on Ser-53 (PubMed:3112145). However, it was later shown that the major phosphorylation site is Ser-209 (By similarity)","Cytoplasm, P-body Cytoplasm Cytoplasm, Stress granule Nucleus Nucleus speckle Nucleus, nuclear body",11606200|16271312|22578813|22684010|23471078|24335285|29987188,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
ELAVL2,ENSG00000107105,Unsafe,Protein,False,True,41.8,41.8,104,23,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 8.2 nTPM; absolute ceiling; basal ganglia: 4.7 nTPM; absolute ceiling; cerebellum: 13 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 24.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 0.4 nTPM; positive ihc; duodenum: 0.1 nTPM; positive ihc; hippocampal formation: 7.9 nTPM; absolute ceiling; hypothalamus: 21.3 nTPM; absolute ceiling;continuous selectivity; kidney: 0.5 nTPM; positive ihc; midbrain: 17.2 nTPM; absolute ceiling;continuous selectivity; rectum: 0.5 nTPM; positive ihc; retina: 4.8 nTPM; absolute ceiling; small intestine: 0.2 nTPM; positive ihc; spinal cord: 2.8 nTPM; absolute ceiling; stomach: 0.1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 8.2 nTPM (limit 2); basal ganglia: 4.7 nTPM (limit 2); cerebellum: 13 nTPM (limit 2); cerebral cortex: 24.2 nTPM (limit 2); hippocampal formation: 7.9 nTPM (limit 2); hypothalamus: 21.3 nTPM (limit 2); midbrain: 17.2 nTPM (limit 2); retina: 4.8 nTPM (limit 2); spinal cord: 2.8 nTPM (limit 2),caudate / neuronal cells: Medium (Enhanced); cerebellum / GLUC cells - cytoplasm/membrane: High (Enhanced); cerebellum / GLUC cells - nucleus: High (Enhanced); cerebellum / granular cells - cytoplasm/membrane: Low (Enhanced); cerebellum / molecular layer cells - cytoplasm/membrane: Low (Enhanced); cerebral cortex / glial cells: Low (Enhanced); cerebral cortex / neuronal cells: High (Enhanced); colon / endothelial cells: Low (Enhanced); colon / glandular cells: Low (Enhanced); duodenum / glandular cells: Low (Enhanced); hippocampus / neuronal cells: Medium (Enhanced); kidney / collecting ducts: High (Enhanced); kidney / distal tubules: Low (Enhanced); kidney / proximal tubules (cell body): Low (Enhanced); rectum / glandular cells: Low (Enhanced); small intestine / glandular cells: Low (Enhanced); stomach 1 / glandular cells: Low (Enhanced); stomach 2 / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Chromophobe (TCGA): 41/64 (64.1%); Glioblastoma Multiforme (validation): 36/58 (62.1%); Testicular Germ Cell Tumor (TCGA): 75/133 (56.4%),colorectal cancer: 3/12 (25.0%); urothelial cancer: 3/12 (25.0%),31,20,Q12926,https://www.uniprot.org/uniprotkb/Q12926/entry,"RNA-binding protein that binds to the 3' untranslated region (3'UTR) of target mRNAs (By similarity). Seems to recognize a GAAA motif (By similarity). Can bind to its own 3'UTR, the FOS 3'UTR and the ID 3'UTR (By similarity)",Brain; neural-specific,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
ELL3,ENSG00000128886,Unsafe,Protein,False,True,16.5,56.1,100,22,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; cerebellum: 1.2 nTPM; positive ihc; cerebral cortex: 0.3 nTPM; positive ihc; choroid plexus: 15.3 nTPM; absolute ceiling;continuous selectivity; colon: 8.3 nTPM; absolute ceiling;continuous selectivity; duodenum: 16.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 50.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; rectum: 11.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 25.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 14.7 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 15.3 nTPM (limit 2); colon: 8.3 nTPM (limit 8); duodenum: 16.7 nTPM (limit 2); lymph node: 50.1 nTPM (limit 6); rectum: 11.9 nTPM (limit 6); skin: 25.8 nTPM (limit 10); small intestine: 14.7 nTPM (limit 4),bronchus / ciliated cells (cell body): High (Approved); bronchus / ciliated cells (ciliary rootlets): High (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / neuronal cells: Low (Approved); duodenum / glandular cells: Medium (Approved); hippocampus / neuronal cells: Medium (Approved); lymph node / germinal center cells: High (Approved); nasopharynx / basal cells: Medium (Approved); nasopharynx / ciliated cells (cell body): Medium (Approved); nasopharynx / ciliated cells (ciliary rootlets): Medium (Approved); oral mucosa / squamous epithelial cells: Low (Approved); rectum / glandular cells: Low (Approved); skin 1 / keratinocytes: Low (Approved); skin 2 / epidermal cells: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 48/50 (96.0%); Prostate Adenocarcinoma (TCGA): 421/480 (87.7%); Pancreatic Adenocarcinoma (validation): 48/80 (60.0%),colorectal cancer: 8/12 (66.7%); ovarian cancer: 5/10 (50.0%),31,20,Q9HB65,https://www.uniprot.org/uniprotkb/Q9HB65/entry,"Enhancer-binding elongation factor that specifically binds enhancers in embryonic stem cells (ES cells), marks them, and is required for their future activation during stem cell specification. Does not only bind to enhancer regions of active genes, but also marks the enhancers that are in a poised or inactive state in ES cells and is required for establishing proper RNA polymerase II occupancy at developmentally regulated genes in a cohesin-dependent manner. Probably required for priming developmentally regulated genes for later recruitment of the super elongation complex (SEC), for transcriptional activation during differentiation. Required for recruitment of P-TEFb within SEC during differentiation. Probably preloaded on germ cell chromatin, suggesting that it may prime gene activation by marking enhancers as early as in the germ cells. Promoting epithelial-mesenchymal transition (EMT) (By similarity). Elongation factor component of the super elongation complex (SEC), a complex required to increase the catalytic rate of RNA polymerase II transcription by suppressing transient pausing by the polymerase at multiple sites along the DNA. Component of the little elongation complex (LEC), a complex required to regulate small nuclear RNA (snRNA) gene transcription by RNA polymerase II and III (PubMed:22195968)",Testis specific,,,Nucleus,10882741|22195968,10882741,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ELOA2,ENSG00000206181,Unsafe,Protein,False,True,3.9,3.9,78,34,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; cerebellum: 0 nTPM; positive ihc; cerebral cortex: 0 nTPM; positive ihc; colon: 0 nTPM; positive ihc; duodenum: 0 nTPM; positive ihc; esophagus: 0 nTPM; positive ihc; heart muscle: 0 nTPM; positive ihc; kidney: 0 nTPM; positive ihc; liver: 0 nTPM; positive ihc; lymph node: 0 nTPM; positive ihc; pancreas: 0 nTPM; positive ihc; rectum: 0 nTPM; positive ihc; skeletal muscle: 0 nTPM; positive ihc; skin: 0 nTPM; positive ihc; small intestine: 0 nTPM; positive ihc; stomach: 0 nTPM; positive ihc; urinary bladder: 0 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Low (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / neuronal cells: Low (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Medium (Approved); lymph node / germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Low (Approved); rectum / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),liver cancer: 5/12 (41.7%); melanoma: 4/10 (40.0%),29,20,Q8IYF1,https://www.uniprot.org/uniprotkb/Q8IYF1/entry,"SIII, also known as elongin, is a general transcription elongation factor that increases the RNA polymerase II transcription elongation past template-encoded arresting sites. Subunit A2 is transcriptionally active but its transcription activity is not enhanced by binding to the dimeric complex of the SIII regulatory subunits B and C (elongin BC complex)",Specifically expressed in testis,,,Nucleus,10692460,10692460,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
ELOVL2,ENSG00000197977,Unsafe,RNA,False,True,34.1,50.9,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 10.9 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 12.6 nTPM; absolute ceiling;continuous selectivity; cerebellum: 5.8 nTPM; absolute ceiling; cerebral cortex: 13.1 nTPM; absolute ceiling;continuous selectivity; heart muscle: 3.1 nTPM; absolute ceiling; hippocampal formation: 7.1 nTPM; absolute ceiling; hypothalamus: 5.3 nTPM; absolute ceiling; liver: 50.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 7.8 nTPM; absolute ceiling; pancreas: 2.5 nTPM; absolute ceiling; parathyroid gland: 9.4 nTPM; absolute ceiling; pituitary gland: 2.9 nTPM; absolute ceiling; retina: 27 nTPM; absolute ceiling;continuous selectivity; spinal cord: 20.4 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 10.9 nTPM (limit 2); basal ganglia: 12.6 nTPM (limit 2); cerebellum: 5.8 nTPM (limit 2); cerebral cortex: 13.1 nTPM (limit 2); heart muscle: 3.1 nTPM (limit 2); hippocampal formation: 7.1 nTPM (limit 2); hypothalamus: 5.3 nTPM (limit 2); liver: 50.9 nTPM (limit 2); midbrain: 7.8 nTPM (limit 2); pancreas: 2.5 nTPM (limit 2); parathyroid gland: 9.4 nTPM (limit 6); pituitary gland: 2.9 nTPM (limit 2); retina: 27 nTPM (limit 2); spinal cord: 20.4 nTPM (limit 2); amygdala: 10.9 nTPM (baseline 2); basal ganglia: 12.6 nTPM (baseline 2); cerebellum: 5.8 nTPM (baseline 2); cerebral cortex: 13.1 nTPM (baseline 2); heart muscle: 3.1 nTPM (baseline 2); hippocampal formation: 7.1 nTPM (baseline 2); hypothalamus: 5.3 nTPM (baseline 2); liver: 50.9 nTPM (baseline 2); midbrain: 7.8 nTPM (baseline 2); pancreas: 2.5 nTPM (baseline 2); parathyroid gland: 9.4 nTPM (baseline 6); pituitary gland: 2.9 nTPM (baseline 2); retina: 27 nTPM (baseline 2); spinal cord: 20.4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 53/58 (91.4%); Liver Hepatocellular Carcinoma (validation): 209/231 (90.5%); Glioblastoma Multiforme (TCGA): 123/141 (87.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9NXB9,https://www.uniprot.org/uniprotkb/Q9NXB9/entry,"Catalyzes the first and rate-limiting reaction of the four reactions that constitute the long-chain fatty acids elongation cycle. This endoplasmic reticulum-bound enzymatic process allows the addition of 2 carbons to the chain of long- and very long-chain fatty acids (VLCFAs) per cycle. Condensing enzyme that catalyzes the synthesis of polyunsaturated very long chain fatty acid (C20- and C22-PUFA), acting specifically toward polyunsaturated acyl-CoA with the higher activity toward C20:4(n-6) acyl-CoA. May participate in the production of polyunsaturated VLCFAs of different chain lengths that are involved in multiple biological processes as precursors of membrane lipids and lipid mediators",Liver and testis,,,Endoplasmic reticulum membrane,11734209|12371743|19575253|20937905,20937905,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
ELSPBP1,ENSG00000169393,Unsafe,RNA,False,True,2760.0,2760.0,79,1,Positive somewhere,False,True,False,True,Excluded,Normal,False,,Not assessed,,,retina: 72.3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 72.3 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Skin Cuteneous Melanoma (TCGA): 7/99 (7.1%); Kidney Renal Papillary Cell Carcinoma (TCGA): 19/282 (6.7%); Kidney Chromophobe (TCGA): 4/64 (6.2%),testis cancer: 1/12 (8.3%); breast cancer: 0/10 (0.0%),31,20,Q96BH3,https://www.uniprot.org/uniprotkb/Q96BH3/entry,Binds to spermatozoa upon ejaculation and may play a role in sperm capacitation. Has phosphorylcholine-binding activity (By similarity),Detected in cauda epididymidal fluid and on sperm membrane (at protein level),,,Secreted,,11144225|17307309,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
EME1,ENSG00000154920,Unsafe,Protein,False,True,6.2,6.2,86,77,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0.5 nTPM; positive ihc; adrenal gland: 0.3 nTPM; positive ihc; bone marrow: 4.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 0.1 nTPM; positive ihc; cerebral cortex: 0.3 nTPM; positive ihc; colon: 0.9 nTPM; positive ihc; duodenum: 0.7 nTPM; positive ihc; esophagus: 1 nTPM; positive ihc; heart muscle: 0.2 nTPM; positive ihc; kidney: 0.2 nTPM; positive ihc; liver: 0.4 nTPM; positive ihc; lung: 0.4 nTPM; positive ihc; lymph node: 2.2 nTPM; positive ihc;continuous selectivity; pancreas: 0.2 nTPM; positive ihc; parathyroid gland: 0.1 nTPM; positive ihc; rectum: 1.2 nTPM; positive ihc; salivary gland: 0.4 nTPM; positive ihc; skeletal muscle: 0.2 nTPM; positive ihc; skin: 1 nTPM; positive ihc; small intestine: 0.7 nTPM; positive ihc; smooth muscle: 0.6 nTPM; positive ihc; spleen: 0.9 nTPM; positive ihc; stomach: 0.4 nTPM; positive ihc; thymus: 3.2 nTPM; continuous selectivity; thyroid gland: 0.2 nTPM; positive ihc; urinary bladder: 0.4 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 4.3 nTPM (limit 2),adipose tissue / adipocytes: High (Supported); adrenal gland / glandular cells: High (Supported); bone marrow / hematopoietic cells: High (Supported); bronchus / respiratory epithelial cells: High (Supported); caudate / glial cells: High (Supported); cerebellum / cells in granular layer: High (Supported); cerebellum / cells in molecular layer: High (Supported); cerebellum / Purkinje cells: Medium (Supported); cerebral cortex / endothelial cells: Medium (Supported); cerebral cortex / glial cells: High (Supported); cerebral cortex / neuronal cells: Low (Supported); cerebral cortex / neuropil: Low (Supported); colon / endothelial cells: High (Supported); colon / glandular cells: High (Supported); colon / peripheral nerve/ganglion: High (Supported); duodenum / glandular cells: High (Supported); esophagus / squamous epithelial cells: High (Supported); heart muscle / cardiomyocytes: Medium (Supported); hippocampus / glial cells: High (Supported); kidney / cells in glomeruli: High (Supported); kidney / cells in tubules: Medium (Supported); liver / cholangiocytes: Medium (Supported); liver / hepatocytes: Medium (Supported); lung / alveolar cells: High (Supported); lung / macrophages: Medium (Supported); lymph node / germinal center cells: High (Supported); lymph node / non-germinal center cells: High (Supported); nasopharynx / respiratory epithelial cells: High (Supported); oral mucosa / squamous epithelial cells: High (Supported); pancreas / exocrine glandular cells: High (Supported); parathyroid gland / glandular cells: Medium (Supported); rectum / glandular cells: High (Supported); salivary gland / glandular cells: High (Supported); skeletal muscle / myocytes: High (Supported); skin 1 / keratinocytes: Low (Supported); skin 1 / Langerhans: Medium (Supported); skin 2 / epidermal cells: High (Supported); small intestine / glandular cells: High (Supported); smooth muscle / smooth muscle cells: Medium (Supported); spleen / cells in red pulp: High (Supported); spleen / cells in white pulp: High (Supported); stomach 1 / glandular cells: High (Supported); stomach 2 / glandular cells: High (Supported); thyroid gland / glandular cells: High (Supported); urinary bladder / urothelial cells: High (Supported),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 44/50 (88.0%); Liver Hepatocellular Carcinoma (validation): 201/231 (87.0%); Testicular Germ Cell Tumor (TCGA): 99/133 (74.4%),breast cancer: 12/12 (100.0%); lymphoma: 12/12 (100.0%),31,20,Q96AY2,https://www.uniprot.org/uniprotkb/Q96AY2/entry,"Non-catalytic subunit of the structure-specific, heterodimeric DNA endonuclease MUS81-EME1 which is involved in the maintenance of genome stability. In the complex, EME1 is required for DNA cleavage, participating in DNA recognition and bending (PubMed:12686547, PubMed:12721304, PubMed:14617801, PubMed:17289582, PubMed:24733841, PubMed:24813886, PubMed:35290797, PubMed:39015284). MUS81-EME1 cleaves 3'-flaps and nicked Holliday junctions, and exhibit limited endonuclease activity with 5' flaps and nicked double-stranded DNAs (PubMed:24733841, PubMed:35290797). Active during prometaphase, MUS81-EME1 resolves mitotic recombination intermediates, including Holliday junctions, which form during homologous recombination (PubMed:14617801, PubMed:24813886)",,,,"Nucleus, nucleolus",12686547|12721304|14617801|17289582|24733841|24813886|35290797|39015284,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
ENAM,ENSG00000132464,Unsafe,RNA,False,True,7.3,8.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,heart muscle: 6.3 nTPM; absolute ceiling;continuous selectivity; kidney: 8.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 3.5 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 4.7 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,heart muscle: 6.3 nTPM (limit 2); kidney: 8.6 nTPM (limit 2); pancreas: 3.5 nTPM (limit 2); skeletal muscle: 4.7 nTPM (limit 2); heart muscle: 6.3 nTPM (baseline 2); kidney: 8.6 nTPM (baseline 2); pancreas: 3.5 nTPM (baseline 2); skeletal muscle: 4.7 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Chromophobe (TCGA): 35/64 (54.7%); Kidney Renal Papillary Cell Carcinoma (TCGA): 93/282 (33.0%); Kidney Renal Clear Cell Carcinoma (validation): 23/100 (23.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9NRM1,https://www.uniprot.org/uniprotkb/Q9NRM1/entry,Involved in the mineralization and structural organization of enamel. Involved in the extension of enamel during the secretory stage of dental enamel formation,"Expressed in tooth particularly in odontoblast, ameloblast and cementoblast","Amelogenesis imperfecta 1B: An autosomal dominant defect of enamel formation. Clinical manifestations may be variable. Some cases present with generalized enamel hypoplasia resulting in small, smooth, yellow and widely spaced teeth (smooth hypoplastic AI). Others show horizontal rows of pits, grooves or a hypoplastic area in the enamel (local hypoplastic AI). Amelogenesis imperfecta 1C: An autosomal recessive defect of dental enamel formation. Teeth show local hypoplastic and unmineralized enamel, and a yellow-brown discoloration. Enamel defects can be associated with facial and oral features including vertical dysgnathia and anterior openbite malocclusion.",,"Secreted, extracellular space, extracellular matrix",,11487571,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ENDOV,ENSG00000173818,Unsafe,RNA,False,True,23.1,25.5,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 8.1 nTPM; absolute ceiling;continuous selectivity; amygdala: 10.2 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 12.9 nTPM; absolute ceiling;continuous selectivity; bone marrow: 4.9 nTPM; absolute ceiling; cerebellum: 11.4 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 12.1 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 8.8 nTPM; absolute ceiling;continuous selectivity; colon: 10.6 nTPM; absolute ceiling;continuous selectivity; duodenum: 6.1 nTPM; absolute ceiling;continuous selectivity; esophagus: 9 nTPM; absolute ceiling;continuous selectivity; heart muscle: 6.5 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 10.2 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 10.5 nTPM; absolute ceiling;continuous selectivity; kidney: 15.2 nTPM; absolute ceiling;continuous selectivity; liver: 14.7 nTPM; absolute ceiling;continuous selectivity; lung: 9.4 nTPM; absolute ceiling;continuous selectivity; midbrain: 8.2 nTPM; absolute ceiling;continuous selectivity; pancreas: 10.2 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 9 nTPM; absolute ceiling;continuous selectivity; retina: 25.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 10.1 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 12.2 nTPM; absolute ceiling;continuous selectivity; skin: 14.5 nTPM; absolute ceiling;continuous selectivity; small intestine: 8.9 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 4.8 nTPM; absolute ceiling; spinal cord: 9.3 nTPM; absolute ceiling;continuous selectivity; spleen: 13.1 nTPM; absolute ceiling;continuous selectivity; stomach: 9.2 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 9 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 8.1 nTPM (limit 2); amygdala: 10.2 nTPM (limit 2); basal ganglia: 12.9 nTPM (limit 2); bone marrow: 4.9 nTPM (limit 2); cerebellum: 11.4 nTPM (limit 2); cerebral cortex: 12.1 nTPM (limit 2); choroid plexus: 8.8 nTPM (limit 2); colon: 10.6 nTPM (limit 6); duodenum: 6.1 nTPM (limit 2); esophagus: 9 nTPM (limit 6); heart muscle: 6.5 nTPM (limit 2); hippocampal formation: 10.2 nTPM (limit 2); hypothalamus: 10.5 nTPM (limit 2); kidney: 15.2 nTPM (limit 2); liver: 14.7 nTPM (limit 2); lung: 9.4 nTPM (limit 2); midbrain: 8.2 nTPM (limit 2); pancreas: 10.2 nTPM (limit 2); pituitary gland: 9 nTPM (limit 2); retina: 25.5 nTPM (limit 2); salivary gland: 10.1 nTPM (limit 6); skeletal muscle: 12.2 nTPM (limit 2); skin: 14.5 nTPM (limit 10); small intestine: 8.9 nTPM (limit 2); smooth muscle: 4.8 nTPM (limit 2); spinal cord: 9.3 nTPM (limit 2); spleen: 13.1 nTPM (limit 10); stomach: 9.2 nTPM (limit 6); urinary bladder: 9 nTPM (limit 6); adrenal gland: 8.1 nTPM (baseline 2); amygdala: 10.2 nTPM (baseline 2); basal ganglia: 12.9 nTPM (baseline 2); bone marrow: 4.9 nTPM (baseline 2); cerebellum: 11.4 nTPM (baseline 2); cerebral cortex: 12.1 nTPM (baseline 2); choroid plexus: 8.8 nTPM (baseline 2); colon: 10.6 nTPM (baseline 6); duodenum: 6.1 nTPM (baseline 2); esophagus: 9 nTPM (baseline 6); heart muscle: 6.5 nTPM (baseline 2); hippocampal formation: 10.2 nTPM (baseline 2); hypothalamus: 10.5 nTPM (baseline 2); kidney: 15.2 nTPM (baseline 2); liver: 14.7 nTPM (baseline 2); lung: 9.4 nTPM (baseline 2); midbrain: 8.2 nTPM (baseline 2); pancreas: 10.2 nTPM (baseline 2); pituitary gland: 9 nTPM (baseline 2); retina: 25.5 nTPM (baseline 2); salivary gland: 10.1 nTPM (baseline 6); skeletal muscle: 12.2 nTPM (baseline 2); skin: 14.5 nTPM (baseline 10); small intestine: 8.9 nTPM (baseline 2); smooth muscle: 4.8 nTPM (baseline 2); spinal cord: 9.3 nTPM (baseline 2); spleen: 13.1 nTPM (baseline 10); stomach: 9.2 nTPM (baseline 6); urinary bladder: 9 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 141/141 (100.0%); Kidney Renal Clear Cell Carcinoma (validation): 100/100 (100.0%); Prostate Adenocarcinoma (TCGA): 475/480 (99.0%),No exact-ID IHC coverage in the HPA cancer snapshot,30,0,Q8N8Q3,https://www.uniprot.org/uniprotkb/Q8N8Q3/entry,"Endoribonuclease that specifically cleaves inosine-containing RNAs: cleaves RNA at the second phosphodiester bond 3' to inosine (PubMed:23912683, PubMed:23912718, PubMed:25195743, PubMed:27573237, PubMed:31703097). Active against both single-stranded and double-stranded RNAs (PubMed:25195743, PubMed:31703097). Has strong preference for single-stranded RNAs (ssRNAs) toward double-stranded RNAs (dsRNAs) (PubMed:23912718). Cleaves mRNAs and tRNAs containing inosine (PubMed:23912683, PubMed:31703097). Also able to cleave structure-specific dsRNA substrates containing the specific sites 5'-IIUI-3' and 5'-UIUU-3' (PubMed:23912718, PubMed:27573237). Inosine is present in a number of RNAs following editing; the function of inosine-specific endoribonuclease is still unclear: it could either play a regulatory role in edited RNAs, or be involved in antiviral response by removing the hyperedited long viral dsRNA genome that has undergone A-to-I editing (Probable). Binds branched DNA structures (PubMed:23139746) Endoribonuclease that specifically cleaves inosine-containing RNAs: cleaves RNA at the second phosphodiester bond 3' to inosine (PubMed:31703097). Active against both single-stranded and double-stranded RNAs (PubMed:31703097). Cleaves tRNAs containing inosine (PubMed:31703097)",,,"Was initially characterized as an endodeoxyribonuclease involved in DNA repair (PubMed:22664237). While it shows some weak endodeoxyribonuclease activity in vitro, such activity probably does not exist in vivo","Cytoplasm Nucleus, nucleolus Cytoplasm, Stress granule",23139746|23912683|23912718|25195743|27573237|31703097,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | daSilva2017_tumor_proteomics,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
ENPP5,ENSG00000112796,Unsafe,Protein,False,True,237.9,237.9,76,40,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 8.4 nTPM; positive ihc;absolute ceiling; amygdala: 6.2 nTPM; absolute ceiling; basal ganglia: 8.6 nTPM; absolute ceiling; cerebellum: 7 nTPM; positive ihc;absolute ceiling; cerebral cortex: 14.2 nTPM; positive ihc;absolute ceiling; choroid plexus: 8.4 nTPM; absolute ceiling; colon: 2.5 nTPM; positive ihc; heart muscle: 4.3 nTPM; positive ihc;absolute ceiling; hippocampal formation: 6.3 nTPM; absolute ceiling; hypothalamus: 9.2 nTPM; absolute ceiling; kidney: 23.4 nTPM; positive ihc;absolute ceiling; lung: 8.5 nTPM; positive ihc;absolute ceiling; midbrain: 15.5 nTPM; absolute ceiling; parathyroid gland: 44.7 nTPM; absolute ceiling; pituitary gland: 19.3 nTPM; absolute ceiling; rectum: 3.1 nTPM; positive ihc; retina: 29.7 nTPM; absolute ceiling; salivary gland: 13.9 nTPM; positive ihc;absolute ceiling; skeletal muscle: 10.3 nTPM; positive ihc;absolute ceiling; small intestine: 1.8 nTPM; positive ihc; spinal cord: 5.8 nTPM; absolute ceiling; spleen: 5.5 nTPM; positive ihc; stomach: 6.5 nTPM; positive ihc;absolute ceiling; thyroid gland: 49.5 nTPM; positive ihc;absolute ceiling; tongue: 9.9 nTPM; absolute ceiling; urinary bladder: 5.3 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 8.4 nTPM (limit 2); amygdala: 6.2 nTPM (limit 2); basal ganglia: 8.6 nTPM (limit 2); cerebellum: 7 nTPM (limit 2); cerebral cortex: 14.2 nTPM (limit 2); choroid plexus: 8.4 nTPM (limit 2); heart muscle: 4.3 nTPM (limit 2); hippocampal formation: 6.3 nTPM (limit 2); hypothalamus: 9.2 nTPM (limit 2); kidney: 23.4 nTPM (limit 2); lung: 8.5 nTPM (limit 2); midbrain: 15.5 nTPM (limit 2); parathyroid gland: 44.7 nTPM (limit 6); pituitary gland: 19.3 nTPM (limit 2); retina: 29.7 nTPM (limit 2); salivary gland: 13.9 nTPM (limit 6); skeletal muscle: 10.3 nTPM (limit 2); spinal cord: 5.8 nTPM (limit 2); stomach: 6.5 nTPM (limit 6); thyroid gland: 49.5 nTPM (limit 10); tongue: 9.9 nTPM (limit 6),adrenal gland / glandular cells: Low (Enhanced); bronchus / respiratory epithelial cells: Low (Enhanced); caudate / glial cells: Low (Enhanced); caudate / neuronal cells: Low (Enhanced); cerebellum / cells in granular layer: Low (Enhanced); cerebellum / cells in molecular layer: Low (Enhanced); cerebellum / Purkinje cells: Low (Enhanced); cerebral cortex / neuronal cells: Low (Enhanced); cerebral cortex / neuropil: Medium (Enhanced); colon / glandular cells: Low (Enhanced); colon / peripheral nerve/ganglion: Low (Enhanced); heart muscle / cardiomyocytes: Low (Enhanced); hippocampus / glial cells: Low (Enhanced); hippocampus / neuronal cells: Medium (Enhanced); kidney / cells in glomeruli: Low (Enhanced); kidney / cells in tubules: Medium (Enhanced); lung / macrophages: Low (Enhanced); nasopharynx / respiratory epithelial cells: Medium (Enhanced); rectum / glandular cells: Low (Enhanced); salivary gland / glandular cells: Low (Enhanced); skeletal muscle / myocytes: Low (Enhanced); small intestine / glandular cells: Low (Enhanced); spleen / cells in red pulp: Low (Enhanced); stomach 1 / glandular cells: Low (Enhanced); stomach 2 / glandular cells: Low (Enhanced); thyroid gland / glandular cells: Low (Enhanced); urinary bladder / urothelial cells: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Thyroid Carcinoma (TCGA): 492/495 (99.4%); Prostate Adenocarcinoma (TCGA): 472/480 (98.3%); Lung Adenocarcinoma (validation): 102/105 (97.1%),prostate cancer: 12/12 (100.0%); testis cancer: 11/11 (100.0%),31,20,Q9UJA9,https://www.uniprot.org/uniprotkb/Q9UJA9/entry,Can hydrolyze NAD but cannot hydrolyze nucleotide di- and triphosphates. Lacks lysopholipase D activity. May play a role in neuronal cell communication,,,,Secreted Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
ENTPD4,ENSG00000197217,Unsafe,Protein,False,True,19.3,31.7,114,67,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 15.7 nTPM; continuous selectivity; adrenal gland: 11.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 9 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 8.8 nTPM; absolute ceiling;continuous selectivity; bone marrow: 30.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 16.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 20 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 9.6 nTPM; absolute ceiling;continuous selectivity; colon: 19.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 17.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 12.2 nTPM; absolute ceiling;continuous selectivity; heart muscle: 20.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 11 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 10.3 nTPM; absolute ceiling;continuous selectivity; kidney: 11.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 13.4 nTPM; absolute ceiling;continuous selectivity; lung: 19.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 28.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 10.7 nTPM; absolute ceiling;continuous selectivity; pancreas: 20.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 26.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 17.8 nTPM; absolute ceiling;continuous selectivity; rectum: 19.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; retina: 31.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 21.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 14.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 12.1 nTPM; absolute ceiling;continuous selectivity; small intestine: 25.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 15.9 nTPM; absolute ceiling;continuous selectivity; spinal cord: 10.8 nTPM; absolute ceiling;continuous selectivity; spleen: 24.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; stomach: 19.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; thymus: 14.1 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 14.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 15.3 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 16.1 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 11.1 nTPM (limit 2); amygdala: 9 nTPM (limit 2); basal ganglia: 8.8 nTPM (limit 2); bone marrow: 30.2 nTPM (limit 2); cerebellum: 16.4 nTPM (limit 2); cerebral cortex: 20 nTPM (limit 2); choroid plexus: 9.6 nTPM (limit 2); colon: 19.1 nTPM (limit 6); duodenum: 17.5 nTPM (limit 2); esophagus: 12.2 nTPM (limit 12); heart muscle: 20.4 nTPM (limit 6); hippocampal formation: 11 nTPM (limit 2); hypothalamus: 10.3 nTPM (limit 2); kidney: 11.8 nTPM (limit 2); liver: 13.4 nTPM (limit 6); lung: 19.3 nTPM (limit 2); lymph node: 28.6 nTPM (limit 6); midbrain: 10.7 nTPM (limit 2); pancreas: 20.8 nTPM (limit 2); parathyroid gland: 26.2 nTPM (limit 6); pituitary gland: 17.8 nTPM (limit 2); rectum: 19.6 nTPM (limit 6); retina: 31.7 nTPM (limit 2); salivary gland: 21.4 nTPM (limit 6); skeletal muscle: 14.7 nTPM (limit 2); skin: 12.1 nTPM (limit 10); small intestine: 25.5 nTPM (limit 2); smooth muscle: 15.9 nTPM (limit 6); spinal cord: 10.8 nTPM (limit 2); spleen: 24.8 nTPM (limit 10); stomach: 19.7 nTPM (limit 6); thymus: 14.1 nTPM (limit 10); thyroid gland: 14.2 nTPM (limit 10); tongue: 15.3 nTPM (limit 6); urinary bladder: 16.1 nTPM (limit 6),adrenal gland / glandular cells: High (Supported); bronchus / basal cells: Medium (Supported); bronchus / ciliated cells (cell body): High (Supported); caudate / neuronal cells: Medium (Supported); cerebellum / cells in molecular layer: Medium (Supported); cerebellum / Purkinje cells: High (Supported); cerebral cortex / neuronal cells: High (Supported); colon / endocrine cells: High (Supported); colon / enterocytes: High (Supported); colon / goblet cells: High (Supported); colon / mucosal lymphoid cells: High (Supported); duodenum / endocrine cells: High (Supported); duodenum / enterocytes: High (Supported); duodenum / goblet cells: High (Supported); duodenum / paneth cells: High (Supported); hippocampus / neuronal cells: Medium (Supported); kidney / cells in glomeruli: Medium (Supported); kidney / cells in tubules: Low (Supported); lung / macrophages: Low (Supported); lymph node / germinal center cells: High (Supported); lymph node / non-germinal center cells: High (Supported); nasopharynx / basal cells: High (Supported); nasopharynx / ciliated cells (cell body): High (Supported); pancreas / exocrine glandular cells: High (Supported); pancreas / pancreatic endocrine cells: High (Supported); parathyroid gland / glandular cells: High (Supported); rectum / endocrine cells: High (Supported); rectum / enterocytes: High (Supported); rectum / goblet cells: High (Supported); rectum / mucosal lymphoid cells: High (Supported); salivary gland / glandular cells: High (Supported); skeletal muscle / myocytes: Low (Supported); small intestine / endocrine cells: High (Supported); small intestine / enterocytes: High (Supported); small intestine / goblet cells: High (Supported); small intestine / paneth cells: High (Supported); spleen / cells in red pulp: High (Supported); spleen / cells in white pulp: High (Supported); stomach 1 / glandular cells: High (Supported); stomach 2 / glandular cells: High (Supported); thyroid gland / glandular cells: Medium (Supported); urinary bladder / urothelial cells: High (Supported),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%); Pancreatic Adenocarcinoma (validation): 80/80 (100.0%),endometrial cancer: 12/12 (100.0%); prostate cancer: 12/12 (100.0%),31,20,Q9Y227,https://www.uniprot.org/uniprotkb/Q9Y227/entry,"Catalyzes the hydrolysis of nucleoside triphosphates and diphosphates in a calcium- or magnesium-dependent manner, with a preference for pyrimidines. Preferentially hydrolyzes UTP and TTP. AMP, ADP, ATP and UMP are not substrates (PubMed:10858452, PubMed:9556635). Preferentially activated by Ca(2+) over Mg(2+) (PubMed:10858452) Has a broad substrate specificity with the ability of cleaving all nucleotide di- and triphosphates with the exception of adenosine di- and triphosphate (ADP and ATP). Preferentially hydrolyzes CTP, UDP, CDP, GTP and GDP. Can use either Ca(2+) or Mg(2+) equally",Ubiquitous. Highest expression in testis and lowest in bladder,,,"Cytoplasmic vesicle, autophagosome membrane Lysosome membrane Golgi apparatus membrane",10858452|9556635,10393803|9556635,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
EPC1,ENSG00000120616,Unsafe,RNA,False,True,20.6,147.7,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 13.9 nTPM; absolute ceiling;continuous selectivity; adrenal gland: 9.3 nTPM; absolute ceiling;continuous selectivity; amygdala: 7.9 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 8.5 nTPM; absolute ceiling;continuous selectivity; bone marrow: 147.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 21.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 9.6 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 9.9 nTPM; absolute ceiling;continuous selectivity; colon: 15.4 nTPM; absolute ceiling;continuous selectivity; duodenum: 11.1 nTPM; absolute ceiling;continuous selectivity; esophagus: 10.8 nTPM; absolute ceiling;continuous selectivity; heart muscle: 11.5 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 8.3 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 7.7 nTPM; absolute ceiling;continuous selectivity; kidney: 11.5 nTPM; absolute ceiling;continuous selectivity; liver: 13.4 nTPM; absolute ceiling;continuous selectivity; lung: 14.3 nTPM; absolute ceiling;continuous selectivity; lymph node: 21 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 7.4 nTPM; absolute ceiling;continuous selectivity; pancreas: 13.9 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 14.1 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 10.1 nTPM; absolute ceiling;continuous selectivity; rectum: 15.6 nTPM; absolute ceiling;continuous selectivity; retina: 18.7 nTPM; absolute ceiling;continuous selectivity; salivary gland: 14.6 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 21.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 13.4 nTPM; absolute ceiling;continuous selectivity; small intestine: 12.6 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 16.2 nTPM; absolute ceiling;continuous selectivity; spinal cord: 8.5 nTPM; absolute ceiling;continuous selectivity; spleen: 18.1 nTPM; absolute ceiling;continuous selectivity; stomach: 13.6 nTPM; absolute ceiling;continuous selectivity; thymus: 31 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 16.3 nTPM; absolute ceiling;continuous selectivity; tongue: 22.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 14.7 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adipose tissue: 13.9 nTPM (limit 10); adrenal gland: 9.3 nTPM (limit 2); amygdala: 7.9 nTPM (limit 2); basal ganglia: 8.5 nTPM (limit 2); bone marrow: 147.7 nTPM (limit 2); cerebellum: 21.4 nTPM (limit 2); cerebral cortex: 9.6 nTPM (limit 2); choroid plexus: 9.9 nTPM (limit 2); colon: 15.4 nTPM (limit 6); duodenum: 11.1 nTPM (limit 2); esophagus: 10.8 nTPM (limit 6); heart muscle: 11.5 nTPM (limit 2); hippocampal formation: 8.3 nTPM (limit 2); hypothalamus: 7.7 nTPM (limit 2); kidney: 11.5 nTPM (limit 2); liver: 13.4 nTPM (limit 2); lung: 14.3 nTPM (limit 2); lymph node: 21 nTPM (limit 6); midbrain: 7.4 nTPM (limit 2); pancreas: 13.9 nTPM (limit 2); parathyroid gland: 14.1 nTPM (limit 6); pituitary gland: 10.1 nTPM (limit 2); rectum: 15.6 nTPM (limit 6); retina: 18.7 nTPM (limit 2); salivary gland: 14.6 nTPM (limit 6); skeletal muscle: 21.9 nTPM (limit 2); skin: 13.4 nTPM (limit 10); small intestine: 12.6 nTPM (limit 2); smooth muscle: 16.2 nTPM (limit 2); spinal cord: 8.5 nTPM (limit 2); spleen: 18.1 nTPM (limit 10); stomach: 13.6 nTPM (limit 6); thymus: 31 nTPM (limit 10); thyroid gland: 16.3 nTPM (limit 10); tongue: 22.5 nTPM (limit 6); urinary bladder: 14.7 nTPM (limit 6); adipose tissue: 13.9 nTPM (baseline 10); adrenal gland: 9.3 nTPM (baseline 2); amygdala: 7.9 nTPM (baseline 2); basal ganglia: 8.5 nTPM (baseline 2); bone marrow: 147.7 nTPM (baseline 2); cerebellum: 21.4 nTPM (baseline 2); cerebral cortex: 9.6 nTPM (baseline 2); choroid plexus: 9.9 nTPM (baseline 2); colon: 15.4 nTPM (baseline 6); duodenum: 11.1 nTPM (baseline 2); esophagus: 10.8 nTPM (baseline 6); heart muscle: 11.5 nTPM (baseline 2); hippocampal formation: 8.3 nTPM (baseline 2); hypothalamus: 7.7 nTPM (baseline 2); kidney: 11.5 nTPM (baseline 2); liver: 13.4 nTPM (baseline 2); lung: 14.3 nTPM (baseline 2); lymph node: 21 nTPM (baseline 6); midbrain: 7.4 nTPM (baseline 2); pancreas: 13.9 nTPM (baseline 2); parathyroid gland: 14.1 nTPM (baseline 6); pituitary gland: 10.1 nTPM (baseline 2); rectum: 15.6 nTPM (baseline 6); retina: 18.7 nTPM (baseline 2); salivary gland: 14.6 nTPM (baseline 6); skeletal muscle: 21.9 nTPM (baseline 2); skin: 13.4 nTPM (baseline 10); small intestine: 12.6 nTPM (baseline 2); smooth muscle: 16.2 nTPM (baseline 2); spinal cord: 8.5 nTPM (baseline 2); spleen: 18.1 nTPM (baseline 10); stomach: 13.6 nTPM (baseline 6); thymus: 31 nTPM (baseline 10); thyroid gland: 16.3 nTPM (baseline 10); tongue: 22.5 nTPM (baseline 6); urinary bladder: 14.7 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%); Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9H2F5,https://www.uniprot.org/uniprotkb/Q9H2F5/entry,"Component of the NuA4 histone acetyltransferase (HAT) complex, a multiprotein complex involved in transcriptional activation of select genes principally by acetylation of nucleosomal histones H4 and H2A (PubMed:14966270). The NuA4 complex plays a direct role in repair of DNA double-strand breaks (DSBs) by promoting homologous recombination (HR) (PubMed:27153538). The NuA4 complex is also required for spermatid development by promoting acetylation of histones: histone acetylation is required for histone replacement during the transition from round to elongating spermatids (By similarity). In the NuA4 complex, EPC1 is required to recruit MBTD1 into the complex (PubMed:32209463)",,,,Nucleus Cytoplasm,14966270|27153538|32209463,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
EPHA6,ENSG00000080224,Unsafe,RNA,False,True,8.0,8.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,cerebral cortex: 2.1 nTPM; absolute ceiling; colon: 3.1 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebral cortex: 2.1 nTPM (limit 2); cerebral cortex: 2.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Prostate Adenocarcinoma (TCGA): 86/480 (17.9%); Kidney Renal Clear Cell Carcinoma (validation): 15/100 (15.0%); Glioblastoma Multiforme (validation): 8/58 (13.8%),colorectal cancer: 9/11 (81.8%); endometrial cancer: 7/11 (63.6%),31,20,Q9UF33,https://www.uniprot.org/uniprotkb/Q9UF33/entry,"Receptor tyrosine kinase which binds promiscuously GPI-anchored ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling (By similarity)",Expressed in brain and testis,,,Membrane,,14726470,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,Failed bulk numeric comparisons are within 20% of their cutoffs; not an automatic rescue,,,,
EPHA8,ENSG00000070886,Unsafe,RNA,False,True,2.1,32.4,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,adrenal gland: 3.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 1 nTPM; continuous selectivity; basal ganglia: 1.2 nTPM; continuous selectivity; cerebellum: 1.1 nTPM; continuous selectivity; cerebral cortex: 1.8 nTPM; continuous selectivity; choroid plexus: 32.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 0.8 nTPM; continuous selectivity; hypothalamus: 2.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 2.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 3.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 1.5 nTPM; continuous selectivity; retina: 2.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 0.8 nTPM; continuous selectivity; spleen: 4.5 nTPM; continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 3.4 nTPM (limit 2); choroid plexus: 32.4 nTPM (limit 2); hypothalamus: 2.7 nTPM (limit 2); midbrain: 2.1 nTPM (limit 2); pancreas: 3.2 nTPM (limit 2); retina: 2.1 nTPM (limit 2); adrenal gland: 3.4 nTPM (baseline 2); choroid plexus: 32.4 nTPM (baseline 2); hypothalamus: 2.7 nTPM (baseline 2); midbrain: 2.1 nTPM (baseline 2); pancreas: 3.2 nTPM (baseline 2); retina: 2.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 11/50 (22.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 12/176 (6.8%); Testicular Germ Cell Tumor (TCGA): 7/133 (5.3%),liver cancer: 4/11 (36.4%); urothelial cancer: 2/11 (18.2%),31,20,P29322,https://www.uniprot.org/uniprotkb/P29322/entry,"Receptor tyrosine kinase which binds promiscuously GPI-anchored ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. The GPI-anchored ephrin-A EFNA2, EFNA3, and EFNA5 are able to activate EPHA8 through phosphorylation. With EFNA5 may regulate integrin-mediated cell adhesion and migration on fibronectin substrate but also neurite outgrowth. During development of the nervous system also plays a role in axon guidance. Downstream effectors of the EPHA8 signaling pathway include FYN which promotes cell adhesion upon activation by EPHA8 and the MAP kinases in the stimulation of neurite outgrowth (By similarity)",,,,Cell membrane Cell projection Early endosome membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
EPHB1,ENSG00000154928,Unsafe,Protein,False,True,10.4,20.2,115,26,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; amygdala: 7.3 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 14.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 20.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 13.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 5.1 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 3.9 nTPM; absolute ceiling;continuous selectivity; kidney: 1.3 nTPM; positive ihc; retina: 4 nTPM; absolute ceiling;continuous selectivity; stomach: 0.6 nTPM; positive ihc; thyroid gland: 6.8 nTPM; positive ihc;continuous selectivity; tongue: 9.9 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 1.4 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 7.3 nTPM (limit 2); basal ganglia: 14.8 nTPM (limit 2); cerebellum: 20.2 nTPM (limit 2); cerebral cortex: 13.5 nTPM (limit 12); hippocampal formation: 5.1 nTPM (limit 2); hypothalamus: 3.9 nTPM (limit 2); retina: 4 nTPM (limit 2); tongue: 9.9 nTPM (limit 6),bronchus / ciliated cells (ciliary rootlets): Medium (Enhanced); cerebellum / granular cells - cytoplasm/membrane: Low (Enhanced); cerebellum / processes in granular layer: Low (Enhanced); cerebellum / processes in molecular layer: Medium (Enhanced); cerebellum / white matter cells - cytoplasm/membrane: Low (Enhanced); hippocampus / glial cells: Low (Enhanced); kidney / cells in tubules: Low (Enhanced); nasopharynx / ciliated cells (ciliary rootlets): Medium (Enhanced); stomach 1 / glandular cells: Low (Enhanced); stomach 2 / glandular cells: Low (Enhanced); thyroid gland / glandular cells: Low (Enhanced); urinary bladder / urothelial cells: Low (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 50/58 (86.2%); Glioblastoma Multiforme (TCGA): 93/141 (66.0%); Colon Adenocarcinoma (validation): 161/486 (33.1%),renal cancer: 1/11 (9.1%); ovarian cancer: 1/12 (8.3%),31,20,P54762,https://www.uniprot.org/uniprotkb/P54762/entry,"Receptor tyrosine kinase which binds promiscuously transmembrane ephrin-B family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Cognate/functional ephrin ligands for this receptor include EFNB1, EFNB2 and EFNB3. During nervous system development, regulates retinal axon guidance redirecting ipsilaterally ventrotemporal retinal ganglion cells axons at the optic chiasm midline. This probably requires repulsive interaction with EFNB2. In the adult nervous system together with EFNB3, regulates chemotaxis, proliferation and polarity of the hippocampus neural progenitors. In addition to its role in axon guidance also plays an important redundant role with other ephrin-B receptors in development and maturation of dendritic spines and synapse formation. May also regulate angiogenesis. More generally, may play a role in targeted cell migration and adhesion. Upon activation by EFNB1 and probably other ephrin-B ligands activates the MAPK/ERK and the JNK signaling cascades to regulate cell migration and adhesion respectively. Involved in the maintenance of the pool of satellite cells (muscle stem cells) by promoting their self-renewal and reducing their activation and differentiation (By similarity)",Preferentially expressed in brain,,,"Cell membrane Early endosome membrane Cell projection, dendrite",12223469|12925710|18034775|9430661|9499402,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
EPPIN,ENSG00000101448,Unsafe,High RNA,False,True,319.7,319.7,87,1,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,CTA,Pass,oncoref.target-sets.2026-10-23.1,False,False,,CTA → Unsafe,True,True,True,4.7,30.9,"hpa_single_cell_tissue: lung/ciliated cells, max 30.9 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,4.7 TPM; blood/Progenitor cell; hpa_immune_monaco; vital,30.9 nTPM; lung/ciliated cells; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 55/207 (26.6%); Colon Adenocarcinoma (validation): 103/486 (21.2%); Pancreatic Adenocarcinoma (validation): 9/80 (11.2%),breast cancer: 0/12 (0.0%); cervical cancer: 0/11 (0.0%),29,20,O95925,https://www.uniprot.org/uniprotkb/O95925/entry,"Serine protease inhibitor that plays an essential role in male reproduction and fertility. Modulates the hydrolysis of SEMG1 by KLK3/PSA (a serine protease), provides antimicrobial protection for spermatozoa in the ejaculate coagulum, and binds SEMG1 thereby inhibiting sperm motility","In testis, expressed and secreted by Sertoli cells, appearing on the surface of testicular and ejaculate spermatozoa. Expressed in the spermatogonia and the earliest preleptotene spermatocytes. In the epididymis, is expressed and secreted by epithelial cells and covers the surface of epididymal spermatozoa and ciliated epithelial cells (at protein level). Expressed specifically in epididymis and testis. Isoform 2 is expressed only in the epididymis. Weak expression is detected in myoid cells as well as spermatogenic cells",,,Secreted Cell surface,15229136|17644992,11404006|21461566,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,All audited maxima are within 10% above 30; other gates still require review,,,,
ERCC6L,ENSG00000186871,Unsafe,Protein,False,True,0.7,3.5,78,57,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 0.1 nTPM; positive ihc; bone marrow: 3.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 0.1 nTPM; positive ihc; colon: 0.9 nTPM; positive ihc;continuous selectivity;reproductive not higher; duodenum: 0.7 nTPM; positive ihc;continuous selectivity;reproductive not higher; esophagus: 1.1 nTPM; positive ihc;continuous selectivity;reproductive not higher; heart muscle: 0.1 nTPM; positive ihc; kidney: 0.1 nTPM; positive ihc; lung: 0.1 nTPM; positive ihc; lymph node: 2.3 nTPM; positive ihc;continuous selectivity;reproductive not higher; pancreas: 0.1 nTPM; positive ihc; rectum: 1.1 nTPM; positive ihc;continuous selectivity;reproductive not higher; retina: 0.4 nTPM; continuous selectivity; salivary gland: 0.3 nTPM; positive ihc; skeletal muscle: 0.1 nTPM; positive ihc; skin: 0.6 nTPM; positive ihc;continuous selectivity; small intestine: 0.6 nTPM; positive ihc;continuous selectivity; smooth muscle: 0.3 nTPM; positive ihc;continuous selectivity; spleen: 0.5 nTPM; continuous selectivity; stomach: 0.7 nTPM; positive ihc;continuous selectivity;reproductive not higher; thymus: 3.5 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 0.1 nTPM; positive ihc; urinary bladder: 0.2 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 3.2 nTPM (limit 2),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in tubules: Low (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Low (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Low (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 114/133 (85.7%); Colon Adenocarcinoma (validation): 361/486 (74.3%); Breast Invasive Carcinoma (validation): 36/50 (72.0%),prostate cancer: 9/10 (90.0%); breast cancer: 8/9 (88.9%),31,20,Q2NKX8,https://www.uniprot.org/uniprotkb/Q2NKX8/entry,"DNA helicase that acts as a tension sensor that associates with catenated DNA which is stretched under tension until it is resolved during anaphase (PubMed:17218258, PubMed:23973328). Functions as ATP-dependent DNA translocase (PubMed:23973328, PubMed:28977671). Can promote Holliday junction branch migration (in vitro) (PubMed:23973328)",,,"Was initially thought to play a role in the spindle checkpoint. However, it was later shown that phenotypes initially observed are due to off-target effects of the siRNA used which results in MAD2L1 down-regulation and mis-localization","Chromosome, centromere Chromosome, centromere, kinetochore Chromosome",17218258|23973328|28977671,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ERCC8,ENSG00000049167,Unsafe,RNA,False,True,4.0,4.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 3.7 nTPM; continuous selectivity; adrenal gland: 3 nTPM; absolute ceiling;continuous selectivity; amygdala: 3.4 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 3.3 nTPM; absolute ceiling;continuous selectivity; bone marrow: 2.6 nTPM; absolute ceiling;continuous selectivity; cerebellum: 1.5 nTPM; continuous selectivity; cerebral cortex: 2.8 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 1.7 nTPM; continuous selectivity; colon: 3.2 nTPM; continuous selectivity; duodenum: 2.5 nTPM; absolute ceiling;continuous selectivity; esophagus: 2.7 nTPM; continuous selectivity; heart muscle: 3.4 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 3 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 3.2 nTPM; absolute ceiling;continuous selectivity; kidney: 4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; liver: 3.4 nTPM; absolute ceiling;continuous selectivity; lung: 2.1 nTPM; absolute ceiling;continuous selectivity; lymph node: 2.4 nTPM; continuous selectivity; midbrain: 3.7 nTPM; absolute ceiling;continuous selectivity; pancreas: 2.6 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 3.5 nTPM; continuous selectivity; pituitary gland: 2.4 nTPM; absolute ceiling;continuous selectivity; rectum: 3.4 nTPM; continuous selectivity; retina: 3.6 nTPM; absolute ceiling;continuous selectivity; salivary gland: 2.6 nTPM; continuous selectivity; skeletal muscle: 2.9 nTPM; absolute ceiling;continuous selectivity; skin: 2.3 nTPM; continuous selectivity; small intestine: 2.2 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 3.3 nTPM; absolute ceiling;continuous selectivity; spinal cord: 4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 3 nTPM; continuous selectivity; stomach: 2.5 nTPM; continuous selectivity; thymus: 4 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 2.9 nTPM; continuous selectivity; tongue: 4 nTPM; continuous selectivity;reproductive not higher; urinary bladder: 3 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 3 nTPM (limit 2); amygdala: 3.4 nTPM (limit 2); basal ganglia: 3.3 nTPM (limit 2); bone marrow: 2.6 nTPM (limit 2); cerebral cortex: 2.8 nTPM (limit 2); duodenum: 2.5 nTPM (limit 2); heart muscle: 3.4 nTPM (limit 2); hippocampal formation: 3 nTPM (limit 2); hypothalamus: 3.2 nTPM (limit 2); kidney: 4 nTPM (limit 2); liver: 3.4 nTPM (limit 2); lung: 2.1 nTPM (limit 2); midbrain: 3.7 nTPM (limit 2); pancreas: 2.6 nTPM (limit 2); pituitary gland: 2.4 nTPM (limit 2); retina: 3.6 nTPM (limit 2); skeletal muscle: 2.9 nTPM (limit 2); small intestine: 2.2 nTPM (limit 2); smooth muscle: 3.3 nTPM (limit 2); spinal cord: 4 nTPM (limit 2); adrenal gland: 3 nTPM (baseline 2); amygdala: 3.4 nTPM (baseline 2); basal ganglia: 3.3 nTPM (baseline 2); bone marrow: 2.6 nTPM (baseline 2); cerebral cortex: 2.8 nTPM (baseline 2); duodenum: 2.5 nTPM (baseline 2); heart muscle: 3.4 nTPM (baseline 2); hippocampal formation: 3 nTPM (baseline 2); hypothalamus: 3.2 nTPM (baseline 2); kidney: 4 nTPM (baseline 2); liver: 3.4 nTPM (baseline 2); lung: 2.1 nTPM (baseline 2); midbrain: 3.7 nTPM (baseline 2); pancreas: 2.6 nTPM (baseline 2); pituitary gland: 2.4 nTPM (baseline 2); retina: 3.6 nTPM (baseline 2); skeletal muscle: 2.9 nTPM (baseline 2); small intestine: 2.2 nTPM (baseline 2); smooth muscle: 3.3 nTPM (baseline 2); spinal cord: 4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Pancreatic Adenocarcinoma (validation): 76/80 (95.0%); Breast Invasive Carcinoma (validation): 46/50 (92.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q13216,https://www.uniprot.org/uniprotkb/Q13216/entry,"Substrate-recognition component of the CSA complex, a DCX (DDB1-CUL4-X-box) E3 ubiquitin-protein ligase complex, involved in transcription-coupled nucleotide excision repair (TC-NER), a process during which RNA polymerase II-blocking lesions are rapidly removed from the transcribed strand of active genes (PubMed:12732143, PubMed:16751180, PubMed:16964240, PubMed:32142649, PubMed:34526721, PubMed:38316879, PubMed:38600235, PubMed:38600236). Following recruitment to lesion-stalled RNA polymerase II (Pol II), the CSA complex mediates ubiquitination of Pol II subunit POLR2A/RPB1 at 'Lys-1268', a critical TC-NER checkpoint, governing RNA Pol II stability and initiating DNA damage excision by TFIIH recruitment (PubMed:12732143, PubMed:16751180, PubMed:16964240, PubMed:32142649, PubMed:32355176, PubMed:34526721, PubMed:38316879, PubMed:38600235, PubMed:38600236). The CSA complex also promotes the ubiquitination and subsequent proteasomal degradation of ERCC6/CSB in a UV-dependent manner; ERCC6 degradation is essential for the recovery of RNA synthesis after transcription-coupled repair (PubMed:16751180). Also plays a role in DNA double-strand breaks (DSSBs) repair by non-homologous end joining (NHEJ) (PubMed:29545921)",,"Cockayne syndrome A: A rare disorder characterized by cutaneous sensitivity to sunlight, abnormal and slow growth, cachectic dwarfism, progeroid appearance, progressive pigmentary retinopathy and sensorineural deafness. There is delayed neural development and severe progressive neurologic degeneration resulting in intellectual disability. Two clinical forms are recognized: in the classical form or Cockayne syndrome type 1, the symptoms are progressive and typically become apparent within the first few years or life; the less common Cockayne syndrome type 2 is characterized by more severe symptoms that manifest prenatally. Cockayne syndrome shows some overlap with certain forms of xeroderma pigmentosum. Unlike xeroderma pigmentosum, patients with Cockayne syndrome do not manifest increased freckling and other pigmentation abnormalities in the skin and have no significant increase in skin cancer. UV-sensitive syndrome 2: An autosomal recessive disorder characterized by cutaneous photosensitivity and mild freckling in the absence of neurological abnormalities or skin tumors.",PubMed:16916636 was retracted due to image manipulations,Nucleus Chromosome Nucleus matrix,12732143|16751180|16964240|29545921|32142649|32355176|34526721|38316879|38600235|38600236,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | Jamin2021_CT,GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
ERICH2,ENSG00000204334,Unsafe,RNA,False,True,159.4,159.4,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 2.2 nTPM; absolute ceiling; amygdala: 4 nTPM; absolute ceiling; basal ganglia: 3.4 nTPM; absolute ceiling; cerebral cortex: 3.9 nTPM; absolute ceiling; choroid plexus: 46.7 nTPM; absolute ceiling;continuous selectivity; heart muscle: 2.7 nTPM; absolute ceiling; hippocampal formation: 2.9 nTPM; absolute ceiling; hypothalamus: 4.4 nTPM; absolute ceiling; kidney: 3.7 nTPM; absolute ceiling; liver: 3.3 nTPM; absolute ceiling; lung: 9.3 nTPM; absolute ceiling; midbrain: 3.7 nTPM; absolute ceiling; pancreas: 3.9 nTPM; absolute ceiling; parathyroid gland: 6.3 nTPM; absolute ceiling; retina: 5.5 nTPM; absolute ceiling; spinal cord: 2.2 nTPM; absolute ceiling; thyroid gland: 10.4 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 2.2 nTPM (limit 2); amygdala: 4 nTPM (limit 2); basal ganglia: 3.4 nTPM (limit 2); cerebral cortex: 3.9 nTPM (limit 2); choroid plexus: 46.7 nTPM (limit 2); heart muscle: 2.7 nTPM (limit 2); hippocampal formation: 2.9 nTPM (limit 2); hypothalamus: 4.4 nTPM (limit 2); kidney: 3.7 nTPM (limit 2); liver: 3.3 nTPM (limit 2); lung: 9.3 nTPM (limit 2); midbrain: 3.7 nTPM (limit 2); pancreas: 3.9 nTPM (limit 2); parathyroid gland: 6.3 nTPM (limit 6); retina: 5.5 nTPM (limit 2); spinal cord: 2.2 nTPM (limit 2); thyroid gland: 10.4 nTPM (limit 10); adrenal gland: 2.2 nTPM (baseline 2); amygdala: 4 nTPM (baseline 2); basal ganglia: 3.4 nTPM (baseline 2); cerebral cortex: 3.9 nTPM (baseline 2); choroid plexus: 46.7 nTPM (baseline 2); heart muscle: 2.7 nTPM (baseline 2); hippocampal formation: 2.9 nTPM (baseline 2); hypothalamus: 4.4 nTPM (baseline 2); kidney: 3.7 nTPM (baseline 2); liver: 3.3 nTPM (baseline 2); lung: 9.3 nTPM (baseline 2); midbrain: 3.7 nTPM (baseline 2); pancreas: 3.9 nTPM (baseline 2); parathyroid gland: 6.3 nTPM (baseline 6); retina: 5.5 nTPM (baseline 2); spinal cord: 2.2 nTPM (baseline 2); thyroid gland: 10.4 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 51/58 (87.9%); Lung Adenocarcinoma (validation): 87/105 (82.9%); Glioblastoma Multiforme (TCGA): 101/141 (71.6%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,A1L162,https://www.uniprot.org/uniprotkb/A1L162/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Chang2019_TGCT,Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
ERO1B,ENSG00000086619,Unsafe,Protein,False,True,32.6,177.1,78,65,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 5.2 nTPM; positive ihc; adrenal gland: 5 nTPM; positive ihc;absolute ceiling; amygdala: 4.5 nTPM; absolute ceiling; basal ganglia: 5.7 nTPM; absolute ceiling; bone marrow: 5.4 nTPM; positive ihc;absolute ceiling; cerebellum: 11.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 4.8 nTPM; positive ihc;absolute ceiling; choroid plexus: 6.9 nTPM; absolute ceiling; colon: 4.7 nTPM; positive ihc; duodenum: 10.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 2.6 nTPM; positive ihc; heart muscle: 4.6 nTPM; positive ihc;absolute ceiling; hippocampal formation: 4.9 nTPM; absolute ceiling; hypothalamus: 4.6 nTPM; absolute ceiling; kidney: 7.5 nTPM; positive ihc;absolute ceiling; liver: 20.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 4.5 nTPM; positive ihc;absolute ceiling; lymph node: 6 nTPM; positive ihc; midbrain: 3.9 nTPM; absolute ceiling; pancreas: 177.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 17 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 9.2 nTPM; absolute ceiling;continuous selectivity; rectum: 3.4 nTPM; positive ihc; retina: 4.2 nTPM; absolute ceiling; salivary gland: 7.9 nTPM; positive ihc;absolute ceiling; skeletal muscle: 3 nTPM; positive ihc;absolute ceiling; skin: 2.7 nTPM; positive ihc; small intestine: 5 nTPM; positive ihc;absolute ceiling; smooth muscle: 4.7 nTPM; positive ihc;absolute ceiling; spinal cord: 5 nTPM; absolute ceiling; spleen: 7.7 nTPM; positive ihc; stomach: 43.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 29.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; urinary bladder: 4.8 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 5 nTPM (limit 2); amygdala: 4.5 nTPM (limit 2); basal ganglia: 5.7 nTPM (limit 2); bone marrow: 5.4 nTPM (limit 2); cerebellum: 11.2 nTPM (limit 2); cerebral cortex: 4.8 nTPM (limit 2); choroid plexus: 6.9 nTPM (limit 2); duodenum: 10.7 nTPM (limit 2); heart muscle: 4.6 nTPM (limit 2); hippocampal formation: 4.9 nTPM (limit 2); hypothalamus: 4.6 nTPM (limit 2); kidney: 7.5 nTPM (limit 2); liver: 20.9 nTPM (limit 2); lung: 4.5 nTPM (limit 2); midbrain: 3.9 nTPM (limit 2); pancreas: 177.1 nTPM (limit 2); parathyroid gland: 17 nTPM (limit 6); pituitary gland: 9.2 nTPM (limit 2); retina: 4.2 nTPM (limit 2); salivary gland: 7.9 nTPM (limit 6); skeletal muscle: 3 nTPM (limit 2); small intestine: 5 nTPM (limit 2); smooth muscle: 4.7 nTPM (limit 2); spinal cord: 5 nTPM (limit 2); stomach: 43.3 nTPM (limit 6); thyroid gland: 29.7 nTPM (limit 10),adipose tissue / adipocytes: Low (Enhanced); adrenal gland / glandular cells: Medium (Enhanced); bone marrow / hematopoietic cells: Low (Enhanced); bronchus / respiratory epithelial cells: Medium (Enhanced); caudate / glial cells: Low (Enhanced); caudate / neuronal cells: Medium (Enhanced); cerebellum / cells in granular layer: Low (Enhanced); cerebellum / Purkinje cells: Medium (Enhanced); cerebral cortex / endothelial cells: Medium (Enhanced); cerebral cortex / neuronal cells: Low (Enhanced); cerebral cortex / neuropil: Medium (Enhanced); colon / endothelial cells: Low (Enhanced); colon / glandular cells: Medium (Enhanced); duodenum / glandular cells: Medium (Enhanced); esophagus / squamous epithelial cells: Medium (Enhanced); heart muscle / cardiomyocytes: Low (Enhanced); hippocampus / glial cells: Low (Enhanced); hippocampus / neuronal cells: Low (Enhanced); kidney / cells in glomeruli: Low (Enhanced); kidney / cells in tubules: Medium (Enhanced); liver / cholangiocytes: Low (Enhanced); liver / hepatocytes: Medium (Enhanced); lung / alveolar cells: Low (Enhanced); lung / macrophages: Low (Enhanced); lymph node / germinal center cells: Low (Enhanced); lymph node / non-germinal center cells: Medium (Enhanced); nasopharynx / respiratory epithelial cells: Medium (Enhanced); oral mucosa / squamous epithelial cells: Low (Enhanced); pancreas / exocrine glandular cells: High (Enhanced); parathyroid gland / glandular cells: Low (Enhanced); rectum / glandular cells: Medium (Enhanced); salivary gland / glandular cells: Low (Enhanced); skeletal muscle / myocytes: Low (Enhanced); skin 1 / keratinocytes: Low (Enhanced); skin 2 / epidermal cells: Low (Enhanced); small intestine / glandular cells: Medium (Enhanced); smooth muscle / smooth muscle cells: Low (Enhanced); spleen / cells in red pulp: Low (Enhanced); stomach 1 / glandular cells: High (Enhanced); stomach 2 / glandular cells: High (Enhanced); thyroid gland / glandular cells: Medium (Enhanced); urinary bladder / urothelial cells: Low (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Kidney Renal Clear Cell Carcinoma (validation): 96/100 (96.0%); Lung Squamous Cell Carcinoma (validation): 62/68 (91.2%),testis cancer: 12/12 (100.0%); prostate cancer: 9/10 (90.0%),29,20,Q86YB8,https://www.uniprot.org/uniprotkb/Q86YB8/entry,"Oxidoreductase involved in disulfide bond formation in the endoplasmic reticulum. Efficiently reoxidizes P4HB/PDI, the enzyme catalyzing protein disulfide formation, in order to allow P4HB to sustain additional rounds of disulfide formation. Other protein disulfide isomerase family members can also be reoxidized, but at lower rates compared to P4HB, including PDIA2 (50% of P4HB reoxidation rate), as well as PDIA3, PDIA4, PDIA6 and NXNDC12 (<10%). Following P4HB reoxidation, passes its electrons to molecular oxygen via FAD, leading to the production of reactive oxygen species (ROS) in the cell. May be involved in oxidative proinsulin folding in pancreatic cells, hence may play a role in glucose homeostasis","Highly expressed in the digestive tract, including the duodenum and lower digestive tract. In the stomach, highly expressed in enzyme-producing chief cells (at protein level). In the pancreas, expressed in islets of Langerhans and, at lower levels, in enzyme-secreting cells (at protein level). Detected at low level in many other tissues",,,Endoplasmic reticulum membrane,11707400|21091435,10818100|16012172,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
ERVFRD-1,ENSG00000244476,Unsafe,RNA,False,True,35.8,35.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,parathyroid gland: 7.2 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,parathyroid gland: 7.2 nTPM (limit 6); parathyroid gland: 7.2 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Chromophobe (TCGA): 7/64 (10.9%); Testicular Germ Cell Tumor (TCGA): 4/133 (3.0%); Bladder Urothelial Carcinoma (TCGA): 3/169 (1.8%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,P60508,https://www.uniprot.org/uniprotkb/P60508/entry,"This endogenous retroviral envelope protein has retained its original fusogenic properties and participates in trophoblast fusion and the formation of a syncytium during placenta morphogenesis. The interaction with MFSD2A is apparently important for this process (PubMed:18988732) Endogenous envelope proteins may have kept, lost or modified their original function during evolution but this one can still make pseudotypes with MLV, HIV-1 or SIV-1 virions and confer infectivity. Retroviral envelope proteins mediate receptor recognition and membrane fusion during early infection. The surface protein mediates receptor recognition, while the transmembrane protein anchors the envelope heterodimer to the viral membrane through one transmembrane domain. The other hydrophobic domain, called fusion peptide, mediates fusion of the viral membrane with the target cell membrane (PubMed:14694139)","Expressed at higher level in placenta. Expressed at lower level in adrenal, bone marrow, brain, breast, colon, kidney, lung, ovary, peripheral blood lymphocytes, prostate, skin, spleen, testis, thymus, thyroid, trachea",,CKS-17 sequence does not match the minimal active consensus,Virion Cell membrane,14694139|18988732,12970426,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Gong2021_reproductive_PC,No tumor-antigen validation in this source | Normal reproductive-tissue enrichment; no tumor validation,,,,Failed bulk numeric comparisons are within 20% of their cutoffs; not an automatic rescue,,,,
ERVW-1,ENSG00000242950,Unsafe,RNA,False,True,52.8,52.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,choroid plexus: 2.4 nTPM; absolute ceiling; retina: 6.7 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 2.4 nTPM (limit 2); retina: 6.7 nTPM (limit 2); choroid plexus: 2.4 nTPM (baseline 2); retina: 6.7 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 80/133 (60.2%); Rectum Adenocarcinoma (validation): 109/207 (52.7%); Colon Adenocarcinoma (validation): 240/486 (49.4%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q9UQF0,https://www.uniprot.org/uniprotkb/Q9UQF0/entry,"This endogenous retroviral envelope protein has retained its original fusogenic properties and participates in trophoblast fusion and the formation of a syncytium during placenta morphogenesis. May induce fusion through binding of SLC1A4 and SLC1A5 (PubMed:10708449, PubMed:12050356, PubMed:23492904) Endogenous envelope proteins may have kept, lost or modified their original function during evolution. Retroviral envelope proteins mediate receptor recognition and membrane fusion during early infection. The surface protein (SU) mediates receptor recognition, while the transmembrane protein (TM) acts as a class I viral fusion protein. The protein may have at least 3 conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During viral and target cell membrane fusion, the coiled coil regions (heptad repeats) assume a trimer-of-hairpins structure, positioning the fusion peptide in close proximity to the C-terminal region of the ectodomain. The formation of this structure appears to drive apposition and subsequent fusion of membranes","Expressed at higher level in placental syncytiotrophoblast. Expressed at intermediate level in testis. Seems also to be found at low level in adrenal tissue, bone marrow, breast, colon, kidney, ovary, prostate, skin, spleen, thymus, thyroid, brain and trachea. Both mRNA and protein levels are significantly increased in the brain of individuals with multiple sclerosis, particularly in astrocytes and microglia",,,Cell membrane Virion,10708449|12050356|23492904,10693809|10708449|12970426|15452578,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Jamin2021_CT | Loriot2025_S2 | Gong2021_reproductive_PC,No tumor-antigen validation in this source | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
ESCO2,ENSG00000171320,Unsafe,RNA,False,True,5.6,10.7,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 5.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 3.6 nTPM; continuous selectivity; duodenum: 10.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 2.3 nTPM; continuous selectivity; lymph node: 4.5 nTPM; continuous selectivity; rectum: 4.1 nTPM; continuous selectivity; small intestine: 7.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; stomach: 2.5 nTPM; continuous selectivity; thymus: 8.3 nTPM; continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 5.9 nTPM (limit 2); duodenum: 10.7 nTPM (limit 2); small intestine: 7.6 nTPM (limit 2); bone marrow: 5.9 nTPM (baseline 2); duodenum: 10.7 nTPM (baseline 2); small intestine: 7.6 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 450/486 (92.6%); Rectum Adenocarcinoma (validation): 176/207 (85.0%); Glioblastoma Multiforme (validation): 46/58 (79.3%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q56NI9,https://www.uniprot.org/uniprotkb/Q56NI9/entry,"Acetyltransferase required for the establishment of sister chromatid cohesion (PubMed:15821733, PubMed:15958495). Couples the processes of cohesion and DNA replication to ensure that only sister chromatids become paired together. In contrast to the structural cohesins, the deposition and establishment factors are required only during the S phase. Acetylates the cohesin component SMC3 (PubMed:21111234)","Widely expressed in fetal tissues. In adult, it is expressed in thymus, placenta and small intestine","Roberts-SC phocomelia syndrome: An autosomal recessive disorder characterized by pre- and postnatal growth retardation, intellectual disability, microcephaly, bilateral cleft lip and cleft palate, and mesomelic symmetric limb reduction. Severely affected infants may be stillborn or die shortly after birth. Patient chromosomes have a lack of cohesion involving heterochromatic C-banding regions around centromeres and the heterochromatin regions on the 1, 9, 16, and Y chromosomes. These findings are referred to as premature centromere separation (PCS) and heterochromatin repulsion (HR), and they are important for the diagnosis of the syndrome. Juberg-Hayward syndrome: An autosomal recessive syndrome characterized by cleft lip/palate, microcephaly, ptosis, hypoplasia or aplasia of thumbs, short stature, dislocation of radial head, and fusion of humerus and radius leading to elbow restriction.",,Nucleus Chromosome,15821733|15958495|19907496|21111234,15821733,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ESPN,ENSG00000187017,Unsafe,Protein,False,True,140.9,140.9,85,22,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 5.5 nTPM; positive ihc;absolute ceiling; bone marrow: 27.6 nTPM; absolute ceiling; cerebellum: 20.5 nTPM; positive ihc;absolute ceiling; cerebral cortex: 0.7 nTPM; positive ihc; colon: 27.3 nTPM; positive ihc;absolute ceiling; duodenum: 88.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 33.3 nTPM; positive ihc;absolute ceiling; kidney: 61.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 125.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 26 nTPM; absolute ceiling; pituitary gland: 40.9 nTPM; absolute ceiling;continuous selectivity; rectum: 6.6 nTPM; positive ihc;absolute ceiling; retina: 114.4 nTPM; absolute ceiling;continuous selectivity; skin: 89.6 nTPM; absolute ceiling; small intestine: 87.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 2.6 nTPM; positive ihc; urinary bladder: 1.2 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 5.5 nTPM (limit 2); bone marrow: 27.6 nTPM (limit 12); cerebellum: 20.5 nTPM (limit 2); colon: 27.3 nTPM (limit 6); duodenum: 88.3 nTPM (limit 2); esophagus: 33.3 nTPM (limit 6); kidney: 61.5 nTPM (limit 2); liver: 125.7 nTPM (limit 2); parathyroid gland: 26 nTPM (limit 6); pituitary gland: 40.9 nTPM (limit 2); rectum: 6.6 nTPM (limit 6); retina: 114.4 nTPM (limit 2); skin: 89.6 nTPM (limit 60); small intestine: 87.2 nTPM (limit 2),adrenal gland / glandular cells: Medium (Enhanced); caudate / neuronal cells: Low (Enhanced); cerebellum / Purkinje cells: Medium (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); colon / glandular cells: High (Enhanced); duodenum / glandular cells: High (Enhanced); esophagus / squamous epithelial cells: Medium (Enhanced); hippocampus / neuronal cells: Low (Enhanced); kidney / cells in tubules: High (Enhanced); liver / hepatocytes: Medium (Enhanced); rectum / glandular cells: High (Enhanced); small intestine / glandular cells: High (Enhanced); stomach 1 / glandular cells: Medium (Enhanced); stomach 2 / glandular cells: Medium (Enhanced); urinary bladder / urothelial cells: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 205/207 (99.0%); Liver Hepatocellular Carcinoma (TCGA): 355/362 (98.1%); Ovary Serous Cystadenocarcinoma (TCGA): 342/349 (98.0%),liver cancer: 4/10 (40.0%); pancreatic cancer: 2/11 (18.2%),31,20,B1AK53,https://www.uniprot.org/uniprotkb/B1AK53/entry,"Multifunctional actin-bundling protein. Plays a major role in regulating the organization, dimension, dynamics and signaling capacities of the actin filament-rich microvilli in the mechanosensory and chemosensory cells (PubMed:29572253). Required for the assembly and stabilization of the stereociliary parallel actin bundles. Plays a crucial role in the formation and maintenance of inner ear hair cell stereocilia (By similarity). Involved in the elongation of actin in stereocilia (PubMed:29572253). In extrastriolar hair cells, required for targeting MYO3B to stereocilia tips, and for regulation of stereocilia diameter and staircase formation",,"Deafness, autosomal recessive, 36, with or without vestibular involvement: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. DFNB36 is characterized by prelingual, profound hearing loss, and vestibular areflexia in some patients. Deafness, autosomal dominant, 91: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. DFNA91 is a mild-to-severe form characterized by hearing loss without vestibular involvement. Onset ranges from the first to the fifth decades of life. Usher syndrome 1M: A form of Usher syndrome, a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH1M is an autosomal recessive disease characterized by prelingual sensorineural hearing loss, vestibular dysfunction, night blindness, and progressive impairment of vision.",,"Cytoplasm, cytoskeleton Cell projection, stereocilium Cell projection, microvillus",29572253,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
ESPNL,ENSG00000144488,Unsafe,RNA,False,True,2.1,4.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,cerebellum: 4.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; liver: 1.6 nTPM; continuous selectivity; pituitary gland: 2 nTPM; continuous selectivity; small intestine: 3.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 1.1 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebellum: 4.1 nTPM (limit 2); small intestine: 3.4 nTPM (limit 2); cerebellum: 4.1 nTPM (baseline 2); small intestine: 3.4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 6/50 (12.0%); Ovary Serous Cystadenocarcinoma (TCGA): 36/349 (10.3%); Thyroid Carcinoma (TCGA): 42/495 (8.5%),breast cancer: 5/11 (45.5%); lung cancer: 3/12 (25.0%),31,20,Q6ZVH7,https://www.uniprot.org/uniprotkb/Q6ZVH7/entry,Binds to but does not cross-link actin. Required for the formation and maintenance of inner ear hair cell stereocilia and staircase formation. Essential for normal hearing,,,,"Cell projection, stereocilium",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ESR2,ENSG00000140009,Unsafe,Protein,False,True,5.5,5.9,83,10,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 5.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 2 nTPM; positive ihc;continuous selectivity; rectum: 0.9 nTPM; positive ihc; retina: 1.8 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 5.9 nTPM (limit 2),adrenal gland / cells in zona glomerulosa: Medium (Enhanced); adrenal gland / glandular cells: Low (Enhanced); adrenal gland / medullary cells: Low (Enhanced); lymph node / non-germinal center cells: Low (Enhanced); rectum / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 42/207 (20.3%); Colon Adenocarcinoma (validation): 81/486 (16.7%); Glioblastoma Multiforme (validation): 6/58 (10.3%),colorectal cancer: 2/12 (16.7%); cervical cancer: 1/11 (9.1%),31,20,Q92731,https://www.uniprot.org/uniprotkb/Q92731/entry,"Nuclear hormone receptor. Binds estrogens with an affinity similar to that of ESR1/ER-alpha, and activates expression of reporter genes containing estrogen response elements (ERE) in an estrogen-dependent manner (PubMed:20074560) Lacks ligand binding ability and has no or only very low ERE binding activity resulting in the loss of ligand-dependent transactivation ability","Expressed in testis and ovary, and at a lower level in heart, brain, placenta, liver, skeletal muscle, spleen, thymus, prostate, colon, bone marrow, mammary gland and uterus. Also found in uterine bone, breast, and ovarian tumor cell lines, but not in colon and liver tumors Expressed in spleen, thymus, testis and ovary and at a lower level in skeletal muscle, prostate, colon, small intestine, leukocytes, bone marrow, mammary gland and uterus Expressed in the testis Expressed in testis, and at a lower level in spleen, thymus, ovary, mammary gland and uterus Expressed in testis, placenta, skeletal muscle, spleen and leukocytes, and at a lower level in heart, lung, liver, kidney, pancreas, thymus, prostate, colon, small intestine, bone marrow, mammary gland and uterus. Not expressed in brain","Ovarian dysgenesis 8: An autosomal dominant form of ovarian dysgenesis, a disorder characterized by lack of spontaneous pubertal development, primary amenorrhea, uterine hypoplasia, and hypergonadotropic hypogonadism as a result of streak gonads.",Had previously been shown to interact with PELP1. However this paper was retracted as cell-based data was viewed as unreliable,Nucleus,20074560|29261182|30113650|9325313|9671811,9636657,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ESYT2,ENSG00000117868,Unsafe,Protein,False,True,46.6,49.2,78,52,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 49.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; adrenal gland: 33.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 15 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 19.5 nTPM; absolute ceiling;continuous selectivity; bone marrow: 29.3 nTPM; absolute ceiling;continuous selectivity; cerebellum: 22.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 19.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 16.3 nTPM; absolute ceiling;continuous selectivity; colon: 37.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 20.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 39.3 nTPM; absolute ceiling;continuous selectivity; heart muscle: 33.6 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 17.7 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 18.6 nTPM; absolute ceiling;continuous selectivity; kidney: 25.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 22.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 31.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 25.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 16.5 nTPM; absolute ceiling;continuous selectivity; pancreas: 25.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 29.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 20 nTPM; absolute ceiling;continuous selectivity; rectum: 26.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 13.5 nTPM; absolute ceiling;continuous selectivity; salivary gland: 31.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 43.3 nTPM; absolute ceiling;continuous selectivity; skin: 30 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 24.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 34.9 nTPM; absolute ceiling;continuous selectivity; spinal cord: 15.8 nTPM; absolute ceiling;continuous selectivity; spleen: 20.2 nTPM; absolute ceiling; stomach: 22.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 34.8 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 37.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 40.2 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 33.7 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 49.2 nTPM (limit 20); adrenal gland: 33.4 nTPM (limit 2); amygdala: 15 nTPM (limit 2); basal ganglia: 19.5 nTPM (limit 2); bone marrow: 29.3 nTPM (limit 4); cerebellum: 22.6 nTPM (limit 2); cerebral cortex: 19.1 nTPM (limit 2); choroid plexus: 16.3 nTPM (limit 2); colon: 37.1 nTPM (limit 6); duodenum: 20.6 nTPM (limit 2); esophagus: 39.3 nTPM (limit 8); heart muscle: 33.6 nTPM (limit 4); hippocampal formation: 17.7 nTPM (limit 2); hypothalamus: 18.6 nTPM (limit 2); kidney: 25.1 nTPM (limit 2); liver: 22.3 nTPM (limit 2); lung: 31.1 nTPM (limit 2); lymph node: 25.7 nTPM (limit 6); midbrain: 16.5 nTPM (limit 2); pancreas: 25.1 nTPM (limit 2); parathyroid gland: 29.7 nTPM (limit 6); pituitary gland: 20 nTPM (limit 2); rectum: 26.9 nTPM (limit 6); retina: 13.5 nTPM (limit 2); salivary gland: 31.2 nTPM (limit 6); skeletal muscle: 43.3 nTPM (limit 4); skin: 30 nTPM (limit 10); small intestine: 24.6 nTPM (limit 2); smooth muscle: 34.9 nTPM (limit 4); spinal cord: 15.8 nTPM (limit 2); spleen: 20.2 nTPM (limit 20); stomach: 22.1 nTPM (limit 6); thymus: 34.8 nTPM (limit 10); thyroid gland: 37.3 nTPM (limit 10); tongue: 40.2 nTPM (limit 6); urinary bladder: 33.7 nTPM (limit 6),adrenal gland / glandular cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Low (Approved); liver / cholangiocytes: Low (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Low (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Medium (Approved); pancreas / exocrine glandular cells: Low (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Adenocarcinoma (TCGA): 497/497 (100.0%); Colon Adenocarcinoma (TCGA): 254/254 (100.0%); Liver Hepatocellular Carcinoma (validation): 231/231 (100.0%),colorectal cancer: 8/12 (66.7%); prostate cancer: 4/10 (40.0%),31,20,A0FGR8,https://www.uniprot.org/uniprotkb/A0FGR8/entry,Tethers the endoplasmic reticulum to the cell membrane and promotes the formation of appositions between the endoplasmic reticulum and the cell membrane. Binds glycerophospholipids in a barrel-like domain and may play a role in cellular lipid transport. Plays a role in FGF signaling via its role in the rapid internalization of FGFR1 that has been activated by FGF1 binding; this occurs most likely via the AP-2 complex. Promotes the localization of SACM1L at endoplasmic reticulum-plasma membrane contact sites (EPCS) (PubMed:27044890),Widely expressed with high level in cerebellum,,,Cell membrane Endoplasmic reticulum membrane,17360437|20833364|23791178|24847877|27044890,17360437,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
ETFBKMT,ENSG00000139160,Unsafe,Protein,False,True,5.1,9.4,79,45,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 2.3 nTPM; continuous selectivity; adrenal gland: 3.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 2 nTPM; continuous selectivity; basal ganglia: 2.4 nTPM; absolute ceiling;continuous selectivity; bone marrow: 2.2 nTPM; absolute ceiling;continuous selectivity; cerebellum: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 2.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 2.7 nTPM; absolute ceiling;continuous selectivity; colon: 2.3 nTPM; positive ihc;continuous selectivity; duodenum: 2.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 2.3 nTPM; positive ihc;continuous selectivity; heart muscle: 3.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 2 nTPM; continuous selectivity; hypothalamus: 2 nTPM; continuous selectivity; kidney: 5.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 9.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 2 nTPM; positive ihc;continuous selectivity; midbrain: 2 nTPM; continuous selectivity; pancreas: 3.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 4.6 nTPM; positive ihc;continuous selectivity; pituitary gland: 2.5 nTPM; absolute ceiling;continuous selectivity; rectum: 2.4 nTPM; positive ihc;continuous selectivity; retina: 5.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 2.2 nTPM; positive ihc;continuous selectivity; skeletal muscle: 7.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 2.3 nTPM; positive ihc;continuous selectivity; small intestine: 2 nTPM; positive ihc;continuous selectivity; smooth muscle: 2.9 nTPM; absolute ceiling;continuous selectivity; spinal cord: 2.3 nTPM; absolute ceiling;continuous selectivity; spleen: 2.4 nTPM; continuous selectivity; stomach: 2.6 nTPM; positive ihc;continuous selectivity; thyroid gland: 3.5 nTPM; positive ihc;continuous selectivity; tongue: 7.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 2 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 3.7 nTPM (limit 2); basal ganglia: 2.4 nTPM (limit 2); bone marrow: 2.2 nTPM (limit 2); cerebellum: 2.7 nTPM (limit 2); cerebral cortex: 2.3 nTPM (limit 2); choroid plexus: 2.7 nTPM (limit 2); duodenum: 2.8 nTPM (limit 2); heart muscle: 3.5 nTPM (limit 2); kidney: 5.9 nTPM (limit 2); liver: 9.4 nTPM (limit 2); pancreas: 3.3 nTPM (limit 2); pituitary gland: 2.5 nTPM (limit 2); retina: 5.9 nTPM (limit 2); skeletal muscle: 7.3 nTPM (limit 2); smooth muscle: 2.9 nTPM (limit 2); spinal cord: 2.3 nTPM (limit 2); tongue: 7.5 nTPM (limit 6); adrenal gland: 3.7 nTPM (baseline 2); basal ganglia: 2.4 nTPM (baseline 2); bone marrow: 2.2 nTPM (baseline 2); cerebellum: 2.7 nTPM (baseline 2); cerebral cortex: 2.3 nTPM (baseline 2); choroid plexus: 2.7 nTPM (baseline 2); duodenum: 2.8 nTPM (baseline 2); heart muscle: 3.5 nTPM (baseline 2); kidney: 5.9 nTPM (baseline 2); liver: 9.4 nTPM (baseline 2); pancreas: 3.3 nTPM (baseline 2); pituitary gland: 2.5 nTPM (baseline 2); retina: 5.9 nTPM (baseline 2); skeletal muscle: 7.3 nTPM (baseline 2); smooth muscle: 2.9 nTPM (baseline 2); spinal cord: 2.3 nTPM (baseline 2); tongue: 7.5 nTPM (baseline 6),adrenal gland / glandular cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / neuronal cells: Low (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / glial cells: Low (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); colon / endothelial cells: Low (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: Low (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Low (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / macrophages: Medium (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Low (Uncertain); pancreas / pancreatic endocrine cells: Low (Uncertain); parathyroid gland / glandular cells: Low (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Low (Uncertain); skeletal muscle / myocytes: Medium (Uncertain); skin 1 / keratinocytes: Low (Uncertain); small intestine / glandular cells: Low (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 54/58 (93.1%); Testicular Germ Cell Tumor (TCGA): 71/133 (53.4%); Prostate Adenocarcinoma (TCGA): 169/480 (35.2%),renal cancer: 10/12 (83.3%); prostate cancer: 8/11 (72.7%),29,20,Q8IXQ9,https://www.uniprot.org/uniprotkb/Q8IXQ9/entry,"Protein-lysine methyltransferase that selectively trimethylates the flavoprotein ETFB in mitochondria (PubMed:25023281, PubMed:25416781). Thereby, may negatively regulate the function of ETFB in electron transfer from Acyl-CoA dehydrogenases to the main respiratory chain (PubMed:25416781)",,,,Cytoplasm Mitochondrion matrix,25023281|25416781,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ETFRF1,ENSG00000205707,Unsafe,Protein,False,True,54.6,117.6,78,13,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 27.2 nTPM; absolute ceiling; adrenal gland: 44.8 nTPM; absolute ceiling;continuous selectivity; amygdala: 31.9 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 28.8 nTPM; absolute ceiling;continuous selectivity; bone marrow: 12.8 nTPM; absolute ceiling; cerebellum: 10.1 nTPM; absolute ceiling; cerebral cortex: 30.7 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 13.6 nTPM; absolute ceiling; colon: 17.3 nTPM; positive ihc;absolute ceiling; duodenum: 32.5 nTPM; absolute ceiling;continuous selectivity; esophagus: 21.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 51.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 31.3 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 26.1 nTPM; absolute ceiling;continuous selectivity; kidney: 53.8 nTPM; absolute ceiling;continuous selectivity; liver: 117.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 21 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 17.5 nTPM; absolute ceiling; midbrain: 38.6 nTPM; absolute ceiling;continuous selectivity; pancreas: 23.3 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 36 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 14.7 nTPM; absolute ceiling;continuous selectivity; rectum: 18.8 nTPM; absolute ceiling; retina: 29.5 nTPM; absolute ceiling;continuous selectivity; salivary gland: 29.5 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 85.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 23.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 23.2 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 17.6 nTPM; absolute ceiling; spinal cord: 70.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; stomach: 29.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 18.4 nTPM; absolute ceiling; thyroid gland: 41.9 nTPM; absolute ceiling;continuous selectivity; tongue: 97.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 17.4 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 27.2 nTPM (limit 20); adrenal gland: 44.8 nTPM (limit 4); amygdala: 31.9 nTPM (limit 2); basal ganglia: 28.8 nTPM (limit 2); bone marrow: 12.8 nTPM (limit 4); cerebellum: 10.1 nTPM (limit 4); cerebral cortex: 30.7 nTPM (limit 4); choroid plexus: 13.6 nTPM (limit 2); colon: 17.3 nTPM (limit 6); duodenum: 32.5 nTPM (limit 4); esophagus: 21.8 nTPM (limit 6); heart muscle: 51.2 nTPM (limit 2); hippocampal formation: 31.3 nTPM (limit 2); hypothalamus: 26.1 nTPM (limit 2); kidney: 53.8 nTPM (limit 4); liver: 117.6 nTPM (limit 4); lung: 21 nTPM (limit 2); lymph node: 17.5 nTPM (limit 8); midbrain: 38.6 nTPM (limit 2); pancreas: 23.3 nTPM (limit 4); parathyroid gland: 36 nTPM (limit 8); pituitary gland: 14.7 nTPM (limit 2); rectum: 18.8 nTPM (limit 8); retina: 29.5 nTPM (limit 2); salivary gland: 29.5 nTPM (limit 8); skeletal muscle: 85.9 nTPM (limit 2); skin: 23.6 nTPM (limit 10); small intestine: 23.2 nTPM (limit 4); smooth muscle: 17.6 nTPM (limit 4); spinal cord: 70.3 nTPM (limit 2); stomach: 29.5 nTPM (limit 6); thymus: 18.4 nTPM (limit 10); thyroid gland: 41.9 nTPM (limit 20); tongue: 97.6 nTPM (limit 6); urinary bladder: 17.4 nTPM (limit 8),colon / endothelial cells: Medium (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Medium (Approved); lung / alveolar cells: Low (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / keratinocytes: Low (Approved); skin 2 / epidermal cells: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Renal Clear Cell Carcinoma (TCGA): 521/521 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%); Prostate Adenocarcinoma (TCGA): 480/480 (100.0%),breast cancer: 0/12 (0.0%); cervical cancer: 0/12 (0.0%),29,20,Q6IPR1,https://www.uniprot.org/uniprotkb/Q6IPR1/entry,Acts as a regulator of the electron transfer flavoprotein by promoting the removal of flavin from the ETF holoenzyme (composed of ETFA and ETFB),,,,Mitochondrion,27499296,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ETNK1,ENSG00000139163,Unsafe,Protein,False,True,19.1,43.9,83,43,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 9.8 nTPM; positive ihc;continuous selectivity; adrenal gland: 14 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 9.1 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 9.4 nTPM; absolute ceiling;continuous selectivity; bone marrow: 12 nTPM; absolute ceiling;continuous selectivity; cerebellum: 12 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 16.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 7.1 nTPM; absolute ceiling;continuous selectivity; colon: 26.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 22.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 10.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 7.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 9.4 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 14.5 nTPM; absolute ceiling;continuous selectivity; kidney: 17.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 17.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 12.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 17 nTPM; absolute ceiling;continuous selectivity; midbrain: 9.9 nTPM; absolute ceiling;continuous selectivity; pancreas: 10.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 10.5 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 13.3 nTPM; absolute ceiling;continuous selectivity; rectum: 14.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 17.6 nTPM; absolute ceiling;continuous selectivity; salivary gland: 12.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 6 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 14.9 nTPM; absolute ceiling;continuous selectivity; small intestine: 15 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 7.3 nTPM; absolute ceiling;continuous selectivity; spinal cord: 11.1 nTPM; absolute ceiling;continuous selectivity; spleen: 16.3 nTPM; continuous selectivity; stomach: 43.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; thymus: 22.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 14.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; urinary bladder: 10.4 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 14 nTPM (limit 2); amygdala: 9.1 nTPM (limit 2); basal ganglia: 9.4 nTPM (limit 2); bone marrow: 12 nTPM (limit 4); cerebellum: 12 nTPM (limit 2); cerebral cortex: 16.4 nTPM (limit 2); choroid plexus: 7.1 nTPM (limit 2); colon: 26.3 nTPM (limit 6); duodenum: 22.7 nTPM (limit 2); esophagus: 10.5 nTPM (limit 6); heart muscle: 7.1 nTPM (limit 2); hippocampal formation: 9.4 nTPM (limit 2); hypothalamus: 14.5 nTPM (limit 2); kidney: 17.8 nTPM (limit 2); liver: 17.7 nTPM (limit 2); lung: 12.2 nTPM (limit 2); lymph node: 17 nTPM (limit 6); midbrain: 9.9 nTPM (limit 2); pancreas: 10.4 nTPM (limit 2); parathyroid gland: 10.5 nTPM (limit 8); pituitary gland: 13.3 nTPM (limit 2); rectum: 14.9 nTPM (limit 6); retina: 17.6 nTPM (limit 2); salivary gland: 12.1 nTPM (limit 6); skeletal muscle: 6 nTPM (limit 2); skin: 14.9 nTPM (limit 10); small intestine: 15 nTPM (limit 2); smooth muscle: 7.3 nTPM (limit 4); spinal cord: 11.1 nTPM (limit 2); stomach: 43.9 nTPM (limit 6); thymus: 22.5 nTPM (limit 10); thyroid gland: 14.1 nTPM (limit 10); urinary bladder: 10.4 nTPM (limit 6),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Low (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Low (Approved); colon / glandular cells: Low (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / macrophages: Low (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Low (Approved); rectum / glandular cells: Low (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Medium (Approved); small intestine / glandular cells: Low (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Low (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Stomach Adenocarcinoma (TCGA): 346/346 (100.0%); Colon Adenocarcinoma (TCGA): 254/254 (100.0%),cervical cancer: 3/12 (25.0%); ovarian cancer: 3/12 (25.0%),31,20,Q9HBU6,https://www.uniprot.org/uniprotkb/Q9HBU6/entry,Highly specific for ethanolamine phosphorylation. May be a rate-controlling step in phosphatidylethanolamine biosynthesis,"Expressed in kidney, liver, placenta, heart, leukocyte, ovary and testis",,,Cytoplasm,11044454,11044454,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
ETV2,ENSG00000105672,Unsafe,RNA,False,True,18.5,18.5,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,pancreas: 2.3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,pancreas: 2.3 nTPM (limit 2); pancreas: 2.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Skin Cuteneous Melanoma (TCGA): 51/99 (51.5%); Ovary Serous Cystadenocarcinoma (TCGA): 117/349 (33.5%); Bladder Urothelial Carcinoma (TCGA): 45/169 (26.6%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O00321,https://www.uniprot.org/uniprotkb/O00321/entry,Binds to DNA sequences containing the consensus pentanucleotide 5'-CGGA[AT]-3',,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,Failed bulk numeric comparisons are within 20% of their cutoffs; not an automatic rescue,,,,
EXO1,ENSG00000174371,Unsafe,RNA,False,True,5.5,17.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 17.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 3.1 nTPM; continuous selectivity; duodenum: 2.8 nTPM; absolute ceiling;continuous selectivity; esophagus: 2.4 nTPM; continuous selectivity; lymph node: 5.7 nTPM; continuous selectivity;reproductive not higher; rectum: 3.6 nTPM; continuous selectivity; small intestine: 2.4 nTPM; absolute ceiling;continuous selectivity; thymus: 10.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 17.1 nTPM (limit 2); duodenum: 2.8 nTPM (limit 2); small intestine: 2.4 nTPM (limit 2); thymus: 10.8 nTPM (limit 10); bone marrow: 17.1 nTPM (baseline 2); duodenum: 2.8 nTPM (baseline 2); small intestine: 2.4 nTPM (baseline 2); thymus: 10.8 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 476/486 (97.9%); Testicular Germ Cell Tumor (TCGA): 128/133 (96.2%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 269/283 (95.1%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9UQ84,https://www.uniprot.org/uniprotkb/Q9UQ84/entry,5'->3' double-stranded DNA exonuclease which may also possess a cryptic 3'->5' double-stranded DNA exonuclease activity. Functions in DNA mismatch repair (MMR) to excise mismatch-containing DNA tracts directed by strand breaks located either 5' or 3' to the mismatch. Also exhibits endonuclease activity against 5'-overhanging flap structures similar to those generated by displacement synthesis when DNA polymerase encounters the 5'-end of a downstream Okazaki fragment. Required for somatic hypermutation (SHM) and class switch recombination (CSR) of immunoglobulin genes. Essential for male and female meiosis,"Highly expressed in bone marrow, testis and thymus. Expressed at lower levels in colon, lymph nodes, ovary, placenta, prostate, small intestine, spleen and stomach",,,Nucleus,10364235|10608837|11809771|11842105|12414623|12704184|14636568|14676842|15225546|15886194|16143102|9685493,10856833|9685493|9788596|9823303,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
F11R,ENSG00000158769,Unsafe,Protein,False,True,49.0,83.1,104,60,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 23.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 5.3 nTPM; absolute ceiling; basal ganglia: 5.4 nTPM; absolute ceiling; bone marrow: 21.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 4.6 nTPM; positive ihc;absolute ceiling; choroid plexus: 12.7 nTPM; absolute ceiling;continuous selectivity; colon: 51 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 54.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 83.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 12.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 5.8 nTPM; absolute ceiling; hypothalamus: 5.2 nTPM; absolute ceiling; kidney: 39.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 71.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 65.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 12.9 nTPM; positive ihc;absolute ceiling; midbrain: 6.4 nTPM; absolute ceiling; pancreas: 40.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 35.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 18.3 nTPM; absolute ceiling;continuous selectivity; rectum: 50.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; retina: 2.1 nTPM; absolute ceiling; salivary gland: 47.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 46.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 62 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 6.3 nTPM; absolute ceiling; spleen: 21 nTPM; positive ihc;absolute ceiling; stomach: 51.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; thymus: 16 nTPM; absolute ceiling; thyroid gland: 38.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; urinary bladder: 50.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 23.7 nTPM (limit 2); amygdala: 5.3 nTPM (limit 2); basal ganglia: 5.4 nTPM (limit 2); bone marrow: 21.1 nTPM (limit 2); cerebral cortex: 4.6 nTPM (limit 2); choroid plexus: 12.7 nTPM (limit 2); colon: 51 nTPM (limit 6); duodenum: 54.3 nTPM (limit 2); esophagus: 83.1 nTPM (limit 6); heart muscle: 12.4 nTPM (limit 2); hippocampal formation: 5.8 nTPM (limit 2); hypothalamus: 5.2 nTPM (limit 2); kidney: 39.2 nTPM (limit 2); liver: 71.4 nTPM (limit 2); lung: 65.1 nTPM (limit 2); lymph node: 12.9 nTPM (limit 6); midbrain: 6.4 nTPM (limit 2); pancreas: 40.5 nTPM (limit 2); parathyroid gland: 35.1 nTPM (limit 6); pituitary gland: 18.3 nTPM (limit 2); rectum: 50.1 nTPM (limit 6); retina: 2.1 nTPM (limit 2); salivary gland: 47.9 nTPM (limit 6); skin: 46.8 nTPM (limit 10); small intestine: 62 nTPM (limit 2); spinal cord: 6.3 nTPM (limit 2); spleen: 21 nTPM (limit 10); stomach: 51.3 nTPM (limit 6); thymus: 16 nTPM (limit 10); thyroid gland: 38.1 nTPM (limit 10); urinary bladder: 50.3 nTPM (limit 6),adrenal gland / glandular cells: High (Enhanced); bone marrow / hematopoietic cells: Medium (Enhanced); bronchus / ciliated cells (cell body): Medium (Enhanced); bronchus / ciliated cells (ciliary rootlets): Medium (Enhanced); caudate / neuronal cells: Medium (Enhanced); cerebral cortex / endothelial cells: Medium (Enhanced); colon / endothelial cells: Low (Enhanced); colon / glandular cells: Medium (Enhanced); duodenum / glandular cells: High (Enhanced); esophagus / squamous epithelial cells: Medium (Enhanced); heart muscle / cardiomyocytes: Low (Enhanced); kidney / collecting ducts: High (Enhanced); kidney / distal tubules: High (Enhanced); kidney / proximal tubules (cell body): Medium (Enhanced); liver / cholangiocytes: Medium (Enhanced); liver / hepatocytes: Medium (Enhanced); lung / alveolar cells: Low (Enhanced); lung / macrophages: Low (Enhanced); lymph node / germinal center cells: Medium (Enhanced); lymph node / non-germinal center cells: Medium (Enhanced); nasopharynx / ciliated cells (cell body): Medium (Enhanced); oral mucosa / squamous epithelial cells: Medium (Enhanced); pancreas / exocrine glandular cells: Medium (Enhanced); pancreas / pancreatic endocrine cells: Low (Enhanced); parathyroid gland / glandular cells: Low (Enhanced); rectum / glandular cells: High (Enhanced); salivary gland / glandular cells: Medium (Enhanced); skin 1 / keratinocytes: Medium (Enhanced); skin 2 / epidermal cells: Medium (Enhanced); small intestine / glandular cells: High (Enhanced); spleen / cells in red pulp: Low (Enhanced); spleen / cells in white pulp: Medium (Enhanced); stomach 1 / glandular cells: Medium (Enhanced); stomach 2 / glandular cells: Low (Enhanced); thyroid gland / glandular cells: Medium (Enhanced); urinary bladder / urothelial cells: High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%); Thyroid Carcinoma (TCGA): 495/495 (100.0%),lung cancer: 12/12 (100.0%); urothelial cancer: 10/10 (100.0%),31,20,Q9Y624,https://www.uniprot.org/uniprotkb/Q9Y624/entry,"Seems to play a role in epithelial tight junction formation. Appears early in primordial forms of cell junctions and recruits PARD3 (PubMed:11489913). The association of the PARD6-PARD3 complex may prevent the interaction of PARD3 with JAM1, thereby preventing tight junction assembly (By similarity). Plays a role in regulating monocyte transmigration involved in integrity of epithelial barrier (By similarity). Ligand for integrin alpha-L/beta-2 involved in memory T-cell and neutrophil transmigration (PubMed:11812992). Involved in platelet activation (PubMed:10753840) (Microbial infection) Acts as a receptor for Mammalian reovirus sigma-1 (Microbial infection) Acts as a receptor for Human Rotavirus strain Wa","Expressed in endothelium, epithelium and leukocytes (at protein level)",,,"Cell junction, tight junction Cell membrane",10753840|11239401|11489913|11812992|25481868,11812992,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
F2RL2,ENSG00000164220,Unsafe,RNA,False,True,3.7,6.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,colon: 3.4 nTPM; continuous selectivity; duodenum: 1.6 nTPM; continuous selectivity; heart muscle: 1.7 nTPM; continuous selectivity; hypothalamus: 1.7 nTPM; continuous selectivity; liver: 1.9 nTPM; continuous selectivity; midbrain: 2.6 nTPM; absolute ceiling;continuous selectivity; rectum: 1.6 nTPM; continuous selectivity; retina: 4.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 3.6 nTPM; continuous selectivity; skin: 2.2 nTPM; continuous selectivity; small intestine: 2.2 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 3.6 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,midbrain: 2.6 nTPM (limit 2); retina: 4.8 nTPM (limit 2); small intestine: 2.2 nTPM (limit 2); smooth muscle: 3.6 nTPM (limit 2); midbrain: 2.6 nTPM (baseline 2); retina: 4.8 nTPM (baseline 2); small intestine: 2.2 nTPM (baseline 2); smooth muscle: 3.6 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 193/207 (93.2%); Breast Invasive Carcinoma (validation): 46/50 (92.0%); Colon Adenocarcinoma (validation): 416/486 (85.6%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O00254,https://www.uniprot.org/uniprotkb/O00254/entry,Receptor for activated thrombin coupled to G proteins that stimulate phosphoinositide hydrolysis,"Highest expression in the megakaryocytes of the bone marrow, lower in mature megakaryocytes, in platelets and in a variety of other tissues such as heart and gut",,,Cell membrane,10079109,9614115,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
FABP12,ENSG00000197416,Unsafe,Protein,False,True,7.2,54.5,85,14,Positive somewhere,True,True,False,True,Excluded,Normal,False,,Not assessed,,,positive normal IHC; positive ihc outside permitted; cerebral cortex: 0 nTPM; positive ihc; retina: 54.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 0 nTPM; positive ihc; thyroid gland: 0 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",retina: 54.5 nTPM (limit 2),bronchus / respiratory epithelial cells: Medium (Enhanced); caudate / neuronal cells: Low (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); hippocampus / neuronal cells: Low (Enhanced); nasopharynx / respiratory epithelial cells: Low (Enhanced); skeletal muscle / myocytes: Medium (Enhanced); thyroid gland / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 15/283 (5.3%); Head and Neck Squamous Cell Carcinoma (TCGA): 6/492 (1.2%); Lung Squamous Cell Carcinoma (TCGA): 4/489 (0.8%),lung cancer: 3/12 (25.0%); cervical cancer: 1/9 (11.1%),31,20,A6NFH5,https://www.uniprot.org/uniprotkb/A6NFH5/entry,May play a role in lipid transport,Expressed in a number of retinoblastoma cell lines,,,,,18786628,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
FAF1,ENSG00000185104,Unsafe,Protein,False,True,5.9,11.8,73,57,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 2.6 nTPM; positive ihc; adrenal gland: 2.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 3 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 3.4 nTPM; absolute ceiling;continuous selectivity; bone marrow: 3.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 5.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 4.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 2.5 nTPM; absolute ceiling;continuous selectivity; colon: 4 nTPM; positive ihc;continuous selectivity; duodenum: 2.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 3.9 nTPM; positive ihc;continuous selectivity; heart muscle: 6.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 3.1 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 3.4 nTPM; absolute ceiling;continuous selectivity; kidney: 3.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 3.1 nTPM; continuous selectivity; lung: 2.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 2.9 nTPM; positive ihc;continuous selectivity; midbrain: 2.7 nTPM; absolute ceiling;continuous selectivity; pancreas: 3.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 5.8 nTPM; positive ihc;continuous selectivity; pituitary gland: 2.8 nTPM; absolute ceiling;continuous selectivity; rectum: 3.6 nTPM; positive ihc;continuous selectivity; retina: 6.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 3 nTPM; positive ihc;continuous selectivity; skeletal muscle: 11.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 4 nTPM; positive ihc;continuous selectivity; small intestine: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 4 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 2.7 nTPM; absolute ceiling;continuous selectivity; spleen: 2.3 nTPM; positive ihc; stomach: 2.5 nTPM; positive ihc;continuous selectivity; thymus: 4.6 nTPM; continuous selectivity; thyroid gland: 4.6 nTPM; positive ihc;continuous selectivity; tongue: 9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 3.3 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 2.6 nTPM (limit 2); amygdala: 3 nTPM (limit 2); basal ganglia: 3.4 nTPM (limit 2); bone marrow: 3.9 nTPM (limit 2); cerebellum: 5.8 nTPM (limit 2); cerebral cortex: 4.3 nTPM (limit 2); choroid plexus: 2.5 nTPM (limit 2); duodenum: 2.4 nTPM (limit 2); heart muscle: 6.6 nTPM (limit 2); hippocampal formation: 3.1 nTPM (limit 2); hypothalamus: 3.4 nTPM (limit 2); kidney: 3.9 nTPM (limit 2); lung: 2.8 nTPM (limit 2); midbrain: 2.7 nTPM (limit 2); pancreas: 3.9 nTPM (limit 2); pituitary gland: 2.8 nTPM (limit 2); retina: 6.9 nTPM (limit 2); skeletal muscle: 11.8 nTPM (limit 2); small intestine: 2.7 nTPM (limit 2); smooth muscle: 4 nTPM (limit 2); spinal cord: 2.7 nTPM (limit 2); tongue: 9 nTPM (limit 6),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); lung / macrophages: Low (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: High (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / keratinocytes: Low (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Kidney Renal Clear Cell Carcinoma (TCGA): 521/521 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%),cervical cancer: 9/9 (100.0%); colorectal cancer: 9/9 (100.0%),31,20,Q9UNN5,https://www.uniprot.org/uniprotkb/Q9UNN5/entry,Ubiquitin-binding protein (PubMed:19722279). Required for the progression of DNA replication forks by targeting DNA replication licensing factor CDT1 for degradation (PubMed:26842564). Potentiates but cannot initiate FAS-induced apoptosis (By similarity),"Most abundant in testis, slightly less abundant in skeletal muscle and heart, followed by prostate, thymus, ovary, small intestine, and colon. Not detected in the peripheral blood leukocytes",,,Nucleus,19722279|26842564,10462485,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
FAHD1,ENSG00000180185,Unsafe,Protein,False,True,11.9,71.2,150,81,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 12.2 nTPM; continuous selectivity;reproductive not higher; adrenal gland: 19.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 11.5 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 9.3 nTPM; absolute ceiling;continuous selectivity; bone marrow: 10.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 8.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 14.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 10.4 nTPM; absolute ceiling;continuous selectivity; colon: 22.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 39.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 17.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 19.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 12 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 12.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 71.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 62.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 7.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 8.1 nTPM; continuous selectivity; midbrain: 11.3 nTPM; absolute ceiling;continuous selectivity; pancreas: 15.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 13.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 9 nTPM; absolute ceiling;continuous selectivity; rectum: 16.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; retina: 7.3 nTPM; absolute ceiling;continuous selectivity; salivary gland: 10.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 29.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 16.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 29.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 9.7 nTPM; continuous selectivity; spinal cord: 10.7 nTPM; absolute ceiling;continuous selectivity; spleen: 8.4 nTPM; positive ihc;continuous selectivity; stomach: 19.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; thymus: 8.8 nTPM; continuous selectivity; thyroid gland: 8.7 nTPM; positive ihc;continuous selectivity; tongue: 26.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 10.5 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 19.1 nTPM (limit 2); amygdala: 11.5 nTPM (limit 2); basal ganglia: 9.3 nTPM (limit 2); bone marrow: 10.3 nTPM (limit 2); cerebellum: 8.4 nTPM (limit 2); cerebral cortex: 14.8 nTPM (limit 2); choroid plexus: 10.4 nTPM (limit 2); colon: 22.5 nTPM (limit 6); duodenum: 39.4 nTPM (limit 2); esophagus: 17.9 nTPM (limit 6); heart muscle: 19.6 nTPM (limit 2); hippocampal formation: 12 nTPM (limit 2); hypothalamus: 12.9 nTPM (limit 2); kidney: 71.2 nTPM (limit 2); liver: 62.3 nTPM (limit 2); lung: 7.7 nTPM (limit 2); midbrain: 11.3 nTPM (limit 2); pancreas: 15.7 nTPM (limit 2); parathyroid gland: 13.5 nTPM (limit 6); pituitary gland: 9 nTPM (limit 2); rectum: 16.2 nTPM (limit 6); retina: 7.3 nTPM (limit 2); salivary gland: 10.1 nTPM (limit 6); skeletal muscle: 29.2 nTPM (limit 12); skin: 16.3 nTPM (limit 10); small intestine: 29.8 nTPM (limit 2); spinal cord: 10.7 nTPM (limit 2); stomach: 19.3 nTPM (limit 6); tongue: 26.8 nTPM (limit 6); urinary bladder: 10.5 nTPM (limit 6),adrenal gland / glandular cells: High (Enhanced); bone marrow / hematopoietic cells: Low (Enhanced); bronchus / respiratory epithelial cells: Medium (Enhanced); caudate / neuronal cells: Low (Enhanced); cerebellum / molecular layer cells - cytoplasm/membrane: High (Enhanced); cerebellum / processes in granular layer: High (Enhanced); cerebellum / processes in molecular layer: High (Enhanced); cerebellum / synaptic glomeruli - core: High (Enhanced); cerebral cortex / endothelial cells: Low (Enhanced); cerebral cortex / neuronal cells: Low (Enhanced); cerebral cortex / neuropil: Medium (Enhanced); colon / endocrine cells: High (Enhanced); colon / endothelial cells: High (Enhanced); colon / enterocytes: High (Enhanced); colon / goblet cells: High (Enhanced); colon / mucosal lymphoid cells: Low (Enhanced); colon / peripheral nerve/ganglion: Medium (Enhanced); duodenum / endocrine cells: High (Enhanced); duodenum / enterocytes: High (Enhanced); duodenum / glands of Brunner: Low (Enhanced); duodenum / goblet cells: High (Enhanced); duodenum / paneth cells: Medium (Enhanced); esophagus / squamous epithelial cells: Medium (Enhanced); heart muscle / cardiomyocytes: Medium (Enhanced); hippocampus / neuronal cells: Low (Enhanced); kidney / collecting ducts: Medium (Enhanced); kidney / distal tubules: High (Enhanced); kidney / proximal tubules (cell body): High (Enhanced); liver / cholangiocytes: Medium (Enhanced); liver / hepatocytes: Medium (Enhanced); lung / alveolar cells type I: High (Enhanced); lung / endothelial cells: Medium (Enhanced); nasopharynx / respiratory epithelial cells: High (Enhanced); oral mucosa / squamous epithelial cells: Low (Enhanced); pancreas / exocrine glandular cells: Medium (Enhanced); pancreas / pancreatic endocrine cells: Medium (Enhanced); parathyroid gland / glandular cells: High (Enhanced); rectum / endocrine cells: High (Enhanced); rectum / endothelial cells: High (Enhanced); rectum / enterocytes: High (Enhanced); rectum / goblet cells: High (Enhanced); rectum / mucosal lymphoid cells: Low (Enhanced); salivary gland / glandular cells: Medium (Enhanced); skin 1 / endothelial cells: Medium (Enhanced); skin 2 / cells in basal layer: Medium (Enhanced); skin 2 / endothelial cells: High (Enhanced); small intestine / endocrine cells: High (Enhanced); small intestine / enterocytes: High (Enhanced); small intestine / goblet cells: High (Enhanced); small intestine / paneth cells: High (Enhanced); spleen / cells in red pulp: Low (Enhanced); spleen / cells in white pulp: Low (Enhanced); stomach 1 / glandular cells: High (Enhanced); stomach 2 / glandular cells: Medium (Enhanced); thyroid gland / glandular cells: Medium (Enhanced); urinary bladder / urothelial cells: High (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Kidney Renal Clear Cell Carcinoma (TCGA): 521/521 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%),colorectal cancer: 12/12 (100.0%); breast cancer: 11/12 (91.7%),31,20,Q6P587,https://www.uniprot.org/uniprotkb/Q6P587/entry,"Tautomerase that converts enol-oxaloacetate, a strong inhibitor of succinate dehydrogenase, to the physiological keto form of oxaloacetate (PubMed:38287013). It is thereby required to maximize aerobic respiration efficiency by preventing succinate dehydrogenase inhibition (PubMed:38287013). Also acts as a weak oxaloacetate decarboxylase (ODx), catalyzing the decarboxylation of oxaloacetate (OAA) to pyruvate and CO(2), and as such is likely a regulatory enzyme in the TCA cycle (PubMed:25575590, PubMed:30348641). Also displays acylpyruvase activity, being able to hydrolyze acetylpyruvate and fumarylpyruvate in vitro (PubMed:21878618, PubMed:30348641). Exhibits only a weak hydrolase activity on methylacetopyruvate and acetylacetone, and no activity toward acetoacetyl-CoA (PubMed:21878618)",Ubiquitous (at protein level),,,"Mitochondrion Cytoplasm, cytosol",21878618|25575590|30348641|38287013,21878618,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
FAM118B,ENSG00000197798,Unsafe,Protein,False,True,20.8,29.8,101,69,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 10.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 14.2 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 23 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 4.2 nTPM; positive ihc;absolute ceiling; cerebellum: 5.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 15.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 29.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 23.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 18 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 7.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 17.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 11.9 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 10.8 nTPM; absolute ceiling;continuous selectivity; kidney: 10 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 8.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 15.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 12.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 11.7 nTPM; absolute ceiling;continuous selectivity; pancreas: 5.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 7.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 8.8 nTPM; absolute ceiling;continuous selectivity; rectum: 22.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; retina: 8.8 nTPM; absolute ceiling;continuous selectivity; salivary gland: 7.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 21.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 5.2 nTPM; positive ihc; small intestine: 12.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 13.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 12.2 nTPM; absolute ceiling;continuous selectivity; spleen: 10.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 14.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 13.7 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 9.9 nTPM; positive ihc;continuous selectivity; tongue: 15.7 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 13.1 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 10.2 nTPM (limit 2); amygdala: 14.2 nTPM (limit 2); basal ganglia: 23 nTPM (limit 2); bone marrow: 4.2 nTPM (limit 2); cerebellum: 5.6 nTPM (limit 2); cerebral cortex: 15.1 nTPM (limit 2); choroid plexus: 29.8 nTPM (limit 2); colon: 23.2 nTPM (limit 6); duodenum: 18 nTPM (limit 2); esophagus: 7.4 nTPM (limit 6); heart muscle: 17.6 nTPM (limit 2); hippocampal formation: 11.9 nTPM (limit 2); hypothalamus: 10.8 nTPM (limit 2); kidney: 10 nTPM (limit 2); liver: 8.7 nTPM (limit 2); lung: 15.7 nTPM (limit 2); lymph node: 12.4 nTPM (limit 6); midbrain: 11.7 nTPM (limit 2); pancreas: 5.5 nTPM (limit 2); parathyroid gland: 7.4 nTPM (limit 6); pituitary gland: 8.8 nTPM (limit 2); rectum: 22.9 nTPM (limit 6); retina: 8.8 nTPM (limit 2); salivary gland: 7.8 nTPM (limit 6); skeletal muscle: 21.2 nTPM (limit 2); small intestine: 12.7 nTPM (limit 2); smooth muscle: 13.7 nTPM (limit 2); spinal cord: 12.2 nTPM (limit 2); spleen: 10.2 nTPM (limit 10); stomach: 14.5 nTPM (limit 6); thymus: 13.7 nTPM (limit 10); tongue: 15.7 nTPM (limit 6); urinary bladder: 13.1 nTPM (limit 6),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: High (Approved); caudate / glial cells: Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / glial cells: High (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: High (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / glial cells: Medium (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells type II: High (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / ciliated cells (cell body): Medium (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / keratinocytes: Low (Approved); skin 1 / Langerhans: Low (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: High (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (TCGA): 254/254 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (TCGA): 141/141 (100.0%),glioma: 9/11 (81.8%); stomach cancer: 7/11 (63.6%),31,20,Q9BPY3,https://www.uniprot.org/uniprotkb/Q9BPY3/entry,May play a role in Cajal bodies formation,,,,"Nucleus, Cajal body",24569877,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
FAM133A,ENSG00000179083,Unsafe,RNA,False,True,7.5,7.5,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 2.7 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 4.7 nTPM; absolute ceiling;continuous selectivity; cerebellum: 2.2 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 3.1 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 2.3 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 4.6 nTPM; absolute ceiling;continuous selectivity; midbrain: 2.3 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 2.1 nTPM; absolute ceiling;continuous selectivity; spinal cord: 2.4 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 2.7 nTPM (limit 2); basal ganglia: 4.7 nTPM (limit 2); cerebellum: 2.2 nTPM (limit 2); cerebral cortex: 3.1 nTPM (limit 2); hippocampal formation: 2.3 nTPM (limit 2); hypothalamus: 4.6 nTPM (limit 2); midbrain: 2.3 nTPM (limit 2); pituitary gland: 2.1 nTPM (limit 2); spinal cord: 2.4 nTPM (limit 2); amygdala: 2.7 nTPM (baseline 2); basal ganglia: 4.7 nTPM (baseline 2); cerebellum: 2.2 nTPM (baseline 2); cerebral cortex: 3.1 nTPM (baseline 2); hippocampal formation: 2.3 nTPM (baseline 2); hypothalamus: 4.6 nTPM (baseline 2); midbrain: 2.3 nTPM (baseline 2); pituitary gland: 2.1 nTPM (baseline 2); spinal cord: 2.4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 21/58 (36.2%); Testicular Germ Cell Tumor (TCGA): 27/133 (20.3%); Liver Hepatocellular Carcinoma (validation): 36/231 (15.6%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8N9E0,https://www.uniprot.org/uniprotkb/Q8N9E0/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
FAM161A,ENSG00000170264,Unsafe,Protein,False,True,5.4,28.1,96,17,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 1.6 nTPM; continuous selectivity; basal ganglia: 2.2 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 2 nTPM; positive ihc;continuous selectivity; choroid plexus: 3.6 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 1.6 nTPM; continuous selectivity; hypothalamus: 2 nTPM; continuous selectivity; kidney: 1.9 nTPM; positive ihc;continuous selectivity; lung: 1 nTPM; positive ihc; pancreas: 2.2 nTPM; continuous selectivity; pituitary gland: 2.4 nTPM; absolute ceiling;continuous selectivity; retina: 28.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 1.6 nTPM; continuous selectivity; stomach: 2.5 nTPM; positive ihc;continuous selectivity; thyroid gland: 3.5 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",basal ganglia: 2.2 nTPM (limit 2); choroid plexus: 3.6 nTPM (limit 2); pituitary gland: 2.4 nTPM (limit 2); retina: 28.1 nTPM (limit 2),bronchus / ciliated cells (cilia axoneme): Medium (Approved); bronchus / ciliated cells (ciliary rootlets): High (Approved); bronchus / ciliated cells (tip of cilia): High (Approved); cerebral cortex / endothelial cells: Low (Approved); kidney / cells in glomeruli: Low (Approved); lung / alveolar cells type II: Medium (Approved); nasopharynx / ciliated cells (cilia axoneme): Medium (Approved); nasopharynx / ciliated cells (ciliary rootlets): High (Approved); nasopharynx / ciliated cells (tip of cilia): High (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 42/50 (84.0%); Ovary Serous Cystadenocarcinoma (validation): 23/81 (28.4%),colorectal cancer: 5/12 (41.7%); pancreatic cancer: 2/12 (16.7%),31,20,Q3B820,https://www.uniprot.org/uniprotkb/Q3B820/entry,Involved in ciliogenesis,"Isoform 1 and isoform 3 are widely expressed with highest levels in retina and testis, with isoform 1 being the most abundant in all tissues tested","Retinitis pigmentosa 28: A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.",,"Cytoplasm, cytoskeleton, cilium basal body Cell projection, cilium Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriole",22940612,20705278|20705279|36233334,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
FAM163A,ENSG00000143340,Unsafe,RNA,False,True,12.3,28.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 5.8 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 2.4 nTPM; absolute ceiling; pituitary gland: 28.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thymus: 15.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 5.8 nTPM (limit 2); cerebral cortex: 2.4 nTPM (limit 2); pituitary gland: 28.8 nTPM (limit 2); thymus: 15.6 nTPM (limit 10); adrenal gland: 5.8 nTPM (baseline 2); cerebral cortex: 2.4 nTPM (baseline 2); pituitary gland: 28.8 nTPM (baseline 2); thymus: 15.6 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Skin Cuteneous Melanoma (TCGA): 8/99 (8.1%); Uterine Corpus Endometrial Carcinoma (TCGA): 9/176 (5.1%); Pancreatic Adenocarcinoma (TCGA): 7/176 (4.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q96GL9,https://www.uniprot.org/uniprotkb/Q96GL9/entry,,"Highly expressed in neuroblastoma compared to other tissues, suggesting that it may be used as a marker for metastasis in bone marrow",,,Membrane,,17208556,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
FAM168B,ENSG00000152102,Unsafe,Protein,False,True,49.6,69.2,79,12,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 32.6 nTPM; absolute ceiling;continuous selectivity; amygdala: 54.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 69.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 45.7 nTPM; absolute ceiling;continuous selectivity; cerebellum: 63.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 68.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 21 nTPM; absolute ceiling;continuous selectivity; colon: 52.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 25.6 nTPM; absolute ceiling; esophagus: 33.3 nTPM; absolute ceiling;continuous selectivity; heart muscle: 42 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 54.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 45.1 nTPM; absolute ceiling;continuous selectivity; kidney: 37.1 nTPM; absolute ceiling;continuous selectivity; liver: 30.1 nTPM; absolute ceiling;continuous selectivity; lung: 26.7 nTPM; absolute ceiling; lymph node: 27.1 nTPM; absolute ceiling;continuous selectivity; midbrain: 54.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 29.2 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 45.2 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 19.8 nTPM; absolute ceiling;continuous selectivity; rectum: 30.9 nTPM; absolute ceiling; retina: 47.1 nTPM; absolute ceiling;continuous selectivity; salivary gland: 27.3 nTPM; absolute ceiling; skeletal muscle: 67.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 33.4 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 39.4 nTPM; absolute ceiling;continuous selectivity; spinal cord: 54.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; stomach: 35.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 37.5 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 35.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 50.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 46.1 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 32.6 nTPM (limit 12); amygdala: 54.9 nTPM (limit 2); basal ganglia: 69.2 nTPM (limit 2); bone marrow: 45.7 nTPM (limit 12); cerebellum: 63.9 nTPM (limit 2); cerebral cortex: 68.2 nTPM (limit 2); choroid plexus: 21 nTPM (limit 2); colon: 52.4 nTPM (limit 24); duodenum: 25.6 nTPM (limit 12); esophagus: 33.3 nTPM (limit 24); heart muscle: 42 nTPM (limit 2); hippocampal formation: 54.7 nTPM (limit 2); hypothalamus: 45.1 nTPM (limit 2); kidney: 37.1 nTPM (limit 12); liver: 30.1 nTPM (limit 12); lung: 26.7 nTPM (limit 12); lymph node: 27.1 nTPM (limit 6); midbrain: 54.7 nTPM (limit 2); pancreas: 29.2 nTPM (limit 12); parathyroid gland: 45.2 nTPM (limit 24); pituitary gland: 19.8 nTPM (limit 2); rectum: 30.9 nTPM (limit 24); retina: 47.1 nTPM (limit 2); salivary gland: 27.3 nTPM (limit 24); skeletal muscle: 67.4 nTPM (limit 2); small intestine: 33.4 nTPM (limit 12); smooth muscle: 39.4 nTPM (limit 12); spinal cord: 54.9 nTPM (limit 2); stomach: 35.2 nTPM (limit 6); thymus: 37.5 nTPM (limit 10); thyroid gland: 35.1 nTPM (limit 10); tongue: 50.9 nTPM (limit 6); urinary bladder: 46.1 nTPM (limit 6),caudate / neuronal cells: Low (Enhanced); cerebellum / cells in granular layer: Low (Enhanced); cerebellum / cells in molecular layer: Low (Enhanced); cerebral cortex / neuronal cells: Low (Enhanced); heart muscle / cardiomyocytes: High (Enhanced); hippocampus / neuronal cells: Low (Enhanced); skeletal muscle / myocytes: High (Enhanced); stomach 1 / glandular cells: Low (Enhanced); thyroid gland / glandular cells: Low (Enhanced); urinary bladder / urothelial cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Prostate Adenocarcinoma (TCGA): 480/480 (100.0%); Stomach Adenocarcinoma (TCGA): 346/346 (100.0%),breast cancer: 0/9 (0.0%); cervical cancer: 0/12 (0.0%),31,20,A1KXE4,https://www.uniprot.org/uniprotkb/A1KXE4/entry,Inhibitor of neuronal axonal outgrowth. Acts as a negative regulator of CDC42 and STAT3 and a positive regulator of STMN2. Positive regulator of CDC27,"Expressed in the brain, within neuronal axonal fibers and associated with myelin sheets (at protein level). Expression tends to be lower in the brain of Alzheimer disease patients compared to healthy individuals (at protein level)",,,"Cytoplasm, perinuclear region Cell membrane Cell projection, axon",,20716133,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
FAM181A,ENSG00000140067,Unsafe,RNA,False,True,31.6,31.6,86,3,Positive somewhere,False,True,False,True,Excluded,Normal,False,,Not assessed,,,amygdala: 13.5 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 9.9 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 8.9 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 9.2 nTPM; absolute ceiling;continuous selectivity; midbrain: 8.1 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 2.2 nTPM; absolute ceiling; spinal cord: 4.4 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 13.5 nTPM (limit 2); basal ganglia: 9.9 nTPM (limit 2); hippocampal formation: 8.9 nTPM (limit 2); hypothalamus: 9.2 nTPM (limit 2); midbrain: 8.1 nTPM (limit 2); pituitary gland: 2.2 nTPM (limit 2); spinal cord: 4.4 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 116/141 (82.3%); Glioblastoma Multiforme (validation): 39/58 (67.2%); Ovary Serous Cystadenocarcinoma (validation): 46/81 (56.8%),ovarian cancer: 1/11 (9.1%); breast cancer: 0/9 (0.0%),31,20,Q8N9Y4,https://www.uniprot.org/uniprotkb/Q8N9Y4/entry,,,,,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
FAM209A,ENSG00000124103,Unsafe,RNA,False,True,101.3,101.3,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 16.5 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 16.5 nTPM (limit 2); bone marrow: 16.5 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 1/80 (1.2%); Bladder Urothelial Carcinoma (TCGA): 2/169 (1.2%); Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q5JX71,https://www.uniprot.org/uniprotkb/Q5JX71/entry,May play a role in sperm acrosome biogenesis,,,,Nucleus inner membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
FAM209B,ENSG00000213714,Unsafe,High RNA,False,True,111.2,111.2,84,5,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 86/91 values ≥5 TPM, max 17.3053; DICE MONOCYTES (unstimulated): 69/91 values ≥5 TPM, max 10.6148; DICE M2 (unstimulated): 23/90 values ≥5 TPM, max 9.2192; DICE NK (unstimulated): 87/90 values ≥5 TPM, max 30.9086; DICE TREG_MEM (unstimulated): 88/89 values ≥5 TPM, max 22.5464; DICE CD4_NAIVE (unstimulated): 88/88 values ≥5 TPM, max 22.4565; DICE CD4_STIM (activated): 18/88 values ≥5 TPM, max 9.05377; DICE TREG_NAIVE (unstimulated): 87/89 values ≥5 TPM, max 18.2327; DICE TFH (unstimulated): 88/89 values ≥5 TPM, max 24.4307; DICE TH1 (unstimulated): 81/81 values ≥5 TPM, max 21.1944; DICE THSTAR (unstimulated): 87/88 values ≥5 TPM, max 15.1581; DICE TH17 (unstimulated): 89/89 values ≥5 TPM, max 22.3159; DICE TH2 (unstimulated): 89/89 values ≥5 TPM, max 24.8485; DICE CD8_NAIVE (unstimulated): 89/89 values ≥5 TPM, max 18.752; DICE CD8_STIM (activated): 41/88 values ≥5 TPM, max 8.84382; hpa_immune_monaco Effector memory CD8 T-cell: 6.7 TPM; hpa_immune_monaco naive CD4 T-cell: 6.3 TPM; hpa_immune_monaco naive CD8 T-cell: 5.2 TPM; hpa_immune_monaco neutrophil: 8 TPM; hpa_immune_monaco T-reg: 5.1 TPM",True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,30.9085923112,11.6,"dice_nk: blood/NK, max 30.9086 TPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,30.91 TPM; blood/NK; dice_nk; vital,11.6 nTPM; bone marrow/bulk; hpa_rna_consensus; vital,Testicular Germ Cell Tumor (TCGA): 4/133 (3.0%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 7/283 (2.5%); Kidney Chromophobe (TCGA): 1/64 (1.6%),breast cancer: 0/11 (0.0%); cervical cancer: 0/11 (0.0%),29,20,Q5JX69,https://www.uniprot.org/uniprotkb/Q5JX69/entry,May play a role in sperm acrosome biogenesis,,,,"Nucleus inner membrane Cytoplasmic vesicle, secretory vesicle, acrosome",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Chang2019_TGCT | Gong2021_reproductive_PC,Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,All audited maxima are within 10% above 30; other gates still require review,,,,
FAM221B,ENSG00000204930,Unsafe,Protein,False,True,9.5,9.5,83,6,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; kidney: 0 nTPM; positive ihc; lung: 0.1 nTPM; positive ihc; parathyroid gland: 0.1 nTPM; positive ihc; spleen: 0.3 nTPM; positive ihc; stomach: 0.3 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,kidney / cells in tubules: Low (Enhanced); lung / alveolar cells: Low (Enhanced); parathyroid gland / glandular cells: Low (Enhanced); spleen / cells in red pulp: Low (Enhanced); stomach 2 / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Chromophobe (TCGA): 17/64 (26.6%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 20/283 (7.1%); Skin Cuteneous Melanoma (TCGA): 4/99 (4.0%),prostate cancer: 8/12 (66.7%); renal cancer: 2/11 (18.2%),29,20,A6H8Z2,https://www.uniprot.org/uniprotkb/A6H8Z2/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
FAM229A,ENSG00000225828,Unsafe,RNA,False,True,116.4,116.4,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 6.5 nTPM; absolute ceiling; amygdala: 7.4 nTPM; absolute ceiling; basal ganglia: 6.2 nTPM; absolute ceiling; bone marrow: 2.1 nTPM; absolute ceiling; cerebellum: 8 nTPM; absolute ceiling; cerebral cortex: 5.6 nTPM; absolute ceiling; heart muscle: 3.2 nTPM; absolute ceiling; hippocampal formation: 5.7 nTPM; absolute ceiling; hypothalamus: 5.5 nTPM; absolute ceiling; kidney: 8.5 nTPM; absolute ceiling; liver: 9.7 nTPM; absolute ceiling; lung: 4.2 nTPM; absolute ceiling; midbrain: 6.1 nTPM; absolute ceiling; pancreas: 3.4 nTPM; absolute ceiling; pituitary gland: 3.9 nTPM; absolute ceiling; small intestine: 5.4 nTPM; absolute ceiling; spinal cord: 4.9 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 6.5 nTPM (limit 2); amygdala: 7.4 nTPM (limit 2); basal ganglia: 6.2 nTPM (limit 2); bone marrow: 2.1 nTPM (limit 2); cerebellum: 8 nTPM (limit 2); cerebral cortex: 5.6 nTPM (limit 2); heart muscle: 3.2 nTPM (limit 2); hippocampal formation: 5.7 nTPM (limit 2); hypothalamus: 5.5 nTPM (limit 2); kidney: 8.5 nTPM (limit 2); liver: 9.7 nTPM (limit 2); lung: 4.2 nTPM (limit 2); midbrain: 6.1 nTPM (limit 2); pancreas: 3.4 nTPM (limit 2); pituitary gland: 3.9 nTPM (limit 2); small intestine: 5.4 nTPM (limit 2); spinal cord: 4.9 nTPM (limit 2); adrenal gland: 6.5 nTPM (baseline 2); amygdala: 7.4 nTPM (baseline 2); basal ganglia: 6.2 nTPM (baseline 2); bone marrow: 2.1 nTPM (baseline 2); cerebellum: 8 nTPM (baseline 2); cerebral cortex: 5.6 nTPM (baseline 2); heart muscle: 3.2 nTPM (baseline 2); hippocampal formation: 5.7 nTPM (baseline 2); hypothalamus: 5.5 nTPM (baseline 2); kidney: 8.5 nTPM (baseline 2); liver: 9.7 nTPM (baseline 2); lung: 4.2 nTPM (baseline 2); midbrain: 6.1 nTPM (baseline 2); pancreas: 3.4 nTPM (baseline 2); pituitary gland: 3.9 nTPM (baseline 2); small intestine: 5.4 nTPM (baseline 2); spinal cord: 4.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 58/141 (41.1%); Glioblastoma Multiforme (validation): 20/58 (34.5%); Ovary Serous Cystadenocarcinoma (TCGA): 118/349 (33.8%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,H3BQW9,https://www.uniprot.org/uniprotkb/H3BQW9/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Chang2019_TGCT,Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
FAM229B,ENSG00000203778,Unsafe,RNA,False,True,435.6,435.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 17.6 nTPM; absolute ceiling; adrenal gland: 21 nTPM; absolute ceiling; amygdala: 74.3 nTPM; absolute ceiling; basal ganglia: 72 nTPM; absolute ceiling; bone marrow: 3.7 nTPM; absolute ceiling; cerebellum: 23.4 nTPM; absolute ceiling; cerebral cortex: 58.9 nTPM; absolute ceiling; choroid plexus: 101.6 nTPM; absolute ceiling; colon: 20.4 nTPM; absolute ceiling; duodenum: 3.4 nTPM; absolute ceiling; esophagus: 7 nTPM; absolute ceiling; heart muscle: 67.7 nTPM; absolute ceiling; hippocampal formation: 64.9 nTPM; absolute ceiling; hypothalamus: 70.2 nTPM; absolute ceiling; kidney: 28.4 nTPM; absolute ceiling; liver: 24.2 nTPM; absolute ceiling; lung: 14.8 nTPM; absolute ceiling; midbrain: 90.3 nTPM; absolute ceiling; pancreas: 8.3 nTPM; absolute ceiling; parathyroid gland: 42 nTPM; absolute ceiling; pituitary gland: 64.3 nTPM; absolute ceiling; retina: 34.3 nTPM; absolute ceiling; salivary gland: 8.7 nTPM; absolute ceiling; skeletal muscle: 13.2 nTPM; absolute ceiling; small intestine: 7.2 nTPM; absolute ceiling; smooth muscle: 17.7 nTPM; absolute ceiling; spinal cord: 100.2 nTPM; absolute ceiling; stomach: 18.1 nTPM; absolute ceiling; thymus: 10.6 nTPM; absolute ceiling; thyroid gland: 20.4 nTPM; absolute ceiling; tongue: 14.7 nTPM; absolute ceiling; urinary bladder: 18.4 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adipose tissue: 17.6 nTPM (limit 10); adrenal gland: 21 nTPM (limit 2); amygdala: 74.3 nTPM (limit 2); basal ganglia: 72 nTPM (limit 2); bone marrow: 3.7 nTPM (limit 2); cerebellum: 23.4 nTPM (limit 2); cerebral cortex: 58.9 nTPM (limit 2); choroid plexus: 101.6 nTPM (limit 2); colon: 20.4 nTPM (limit 6); duodenum: 3.4 nTPM (limit 2); esophagus: 7 nTPM (limit 6); heart muscle: 67.7 nTPM (limit 2); hippocampal formation: 64.9 nTPM (limit 2); hypothalamus: 70.2 nTPM (limit 2); kidney: 28.4 nTPM (limit 2); liver: 24.2 nTPM (limit 2); lung: 14.8 nTPM (limit 2); midbrain: 90.3 nTPM (limit 2); pancreas: 8.3 nTPM (limit 2); parathyroid gland: 42 nTPM (limit 6); pituitary gland: 64.3 nTPM (limit 2); retina: 34.3 nTPM (limit 2); salivary gland: 8.7 nTPM (limit 6); skeletal muscle: 13.2 nTPM (limit 2); small intestine: 7.2 nTPM (limit 2); smooth muscle: 17.7 nTPM (limit 2); spinal cord: 100.2 nTPM (limit 2); stomach: 18.1 nTPM (limit 6); thymus: 10.6 nTPM (limit 10); thyroid gland: 20.4 nTPM (limit 10); tongue: 14.7 nTPM (limit 6); urinary bladder: 18.4 nTPM (limit 6); adipose tissue: 17.6 nTPM (baseline 10); adrenal gland: 21 nTPM (baseline 2); amygdala: 74.3 nTPM (baseline 2); basal ganglia: 72 nTPM (baseline 2); bone marrow: 3.7 nTPM (baseline 2); cerebellum: 23.4 nTPM (baseline 2); cerebral cortex: 58.9 nTPM (baseline 2); choroid plexus: 101.6 nTPM (baseline 2); colon: 20.4 nTPM (baseline 6); duodenum: 3.4 nTPM (baseline 2); esophagus: 7 nTPM (baseline 6); heart muscle: 67.7 nTPM (baseline 2); hippocampal formation: 64.9 nTPM (baseline 2); hypothalamus: 70.2 nTPM (baseline 2); kidney: 28.4 nTPM (baseline 2); liver: 24.2 nTPM (baseline 2); lung: 14.8 nTPM (baseline 2); midbrain: 90.3 nTPM (baseline 2); pancreas: 8.3 nTPM (baseline 2); parathyroid gland: 42 nTPM (baseline 6); pituitary gland: 64.3 nTPM (baseline 2); retina: 34.3 nTPM (baseline 2); salivary gland: 8.7 nTPM (baseline 6); skeletal muscle: 13.2 nTPM (baseline 2); small intestine: 7.2 nTPM (baseline 2); smooth muscle: 17.7 nTPM (baseline 2); spinal cord: 100.2 nTPM (baseline 2); stomach: 18.1 nTPM (baseline 6); thymus: 10.6 nTPM (baseline 10); thyroid gland: 20.4 nTPM (baseline 10); tongue: 14.7 nTPM (baseline 6); urinary bladder: 18.4 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Thyroid Carcinoma (TCGA): 495/495 (100.0%); Glioblastoma Multiforme (TCGA): 141/141 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q4G0N7,https://www.uniprot.org/uniprotkb/Q4G0N7/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
FAM25C,ENSG00000276430,Unsafe,RNA,False,True,14.3,42.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,esophagus: 29.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 14.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 42.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,esophagus: 29.3 nTPM (limit 6); salivary gland: 14.9 nTPM (limit 6); skin: 42.2 nTPM (limit 10); esophagus: 29.3 nTPM (baseline 6); salivary gland: 14.9 nTPM (baseline 6); skin: 42.2 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Head and Neck Squamous Cell Carcinoma (TCGA): 251/492 (51.0%); Skin Cuteneous Melanoma (TCGA): 17/99 (17.2%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 40/283 (14.1%),liver cancer: 12/12 (100.0%); testis cancer: 12/12 (100.0%),27,20,B3EWG3 | B3EWG5 | B3EWG6,https://www.uniprot.org/uniprotkb/B3EWG3/entry | https://www.uniprot.org/uniprotkb/B3EWG5/entry | https://www.uniprot.org/uniprotkb/B3EWG6/entry,,,,,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_tumor_proteomics,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
FAM25G,ENSG00000189090,Unsafe,RNA,False,True,10.1,41.9,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,esophagus: 18.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 8.6 nTPM; absolute ceiling;continuous selectivity; skin: 41.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,esophagus: 18.1 nTPM (limit 6); salivary gland: 8.6 nTPM (limit 6); skin: 41.9 nTPM (limit 10); esophagus: 18.1 nTPM (baseline 6); salivary gland: 8.6 nTPM (baseline 6); skin: 41.9 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Head and Neck Squamous Cell Carcinoma (TCGA): 50/492 (10.2%); Pancreatic Adenocarcinoma (validation): 1/80 (1.2%); Bladder Urothelial Carcinoma (TCGA): 2/169 (1.2%),liver cancer: 12/12 (100.0%); testis cancer: 12/12 (100.0%),30,20,B3EWG3 | B3EWG5 | B3EWG6,https://www.uniprot.org/uniprotkb/B3EWG3/entry | https://www.uniprot.org/uniprotkb/B3EWG5/entry | https://www.uniprot.org/uniprotkb/B3EWG6/entry,,,,,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_tumor_proteomics,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
FAM72A,ENSG00000196550,Unsafe,RNA,False,True,6.9,10.7,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 3.9 nTPM; continuous selectivity; adrenal gland: 3.1 nTPM; absolute ceiling;continuous selectivity; amygdala: 2.1 nTPM; absolute ceiling;continuous selectivity; bone marrow: 8.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 5.5 nTPM; absolute ceiling;continuous selectivity; duodenum: 2.9 nTPM; absolute ceiling;continuous selectivity; esophagus: 2.5 nTPM; continuous selectivity; hippocampal formation: 2.4 nTPM; absolute ceiling;continuous selectivity; liver: 2 nTPM; continuous selectivity; lung: 2.6 nTPM; absolute ceiling;continuous selectivity; lymph node: 10.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 2.6 nTPM; absolute ceiling;continuous selectivity; skin: 5.9 nTPM; continuous selectivity; small intestine: 2.9 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 1.9 nTPM; continuous selectivity; spinal cord: 2.7 nTPM; absolute ceiling;continuous selectivity; spleen: 6.1 nTPM; continuous selectivity; thymus: 8.4 nTPM; continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 3.1 nTPM (limit 2); amygdala: 2.1 nTPM (limit 2); bone marrow: 8.5 nTPM (limit 2); cerebellum: 5.5 nTPM (limit 2); duodenum: 2.9 nTPM (limit 2); hippocampal formation: 2.4 nTPM (limit 2); lung: 2.6 nTPM (limit 2); lymph node: 10.7 nTPM (limit 6); midbrain: 2.6 nTPM (limit 2); small intestine: 2.9 nTPM (limit 2); spinal cord: 2.7 nTPM (limit 2); adrenal gland: 3.1 nTPM (baseline 2); amygdala: 2.1 nTPM (baseline 2); bone marrow: 8.5 nTPM (baseline 2); cerebellum: 5.5 nTPM (baseline 2); duodenum: 2.9 nTPM (baseline 2); hippocampal formation: 2.4 nTPM (baseline 2); lung: 2.6 nTPM (baseline 2); lymph node: 10.7 nTPM (baseline 6); midbrain: 2.6 nTPM (baseline 2); small intestine: 2.9 nTPM (baseline 2); spinal cord: 2.7 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 440/486 (90.5%); Rectum Adenocarcinoma (validation): 184/207 (88.9%); Lung Squamous Cell Carcinoma (validation): 54/68 (79.4%),breast cancer: 0/12 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q5TYM5,https://www.uniprot.org/uniprotkb/Q5TYM5/entry,May play a role in the regulation of cellular reactive oxygen species metabolism. May participate in cell growth regulation,"May be up-regulated in malignant colon cancers, compared to normal colon and colon adenomas. Expression is also elevated in other common cancer types, including breast, lung, uterus, and ovary",,,Cytoplasm Mitochondrion,21317926,18676834,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
FAM76B,ENSG00000077458,Unsafe,Protein,False,True,17.2,39.0,82,3,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 4.9 nTPM; absolute ceiling;continuous selectivity; bone marrow: 39 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 3.7 nTPM; absolute ceiling; cerebral cortex: 3.6 nTPM; absolute ceiling; duodenum: 8.9 nTPM; absolute ceiling;continuous selectivity; heart muscle: 3.8 nTPM; absolute ceiling; kidney: 3 nTPM; absolute ceiling; liver: 8 nTPM; absolute ceiling;continuous selectivity; lung: 4.9 nTPM; absolute ceiling;continuous selectivity; lymph node: 16.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; pancreas: 5.9 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 2.3 nTPM; absolute ceiling; retina: 5.2 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 3.8 nTPM; absolute ceiling; small intestine: 6.2 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 4.3 nTPM; absolute ceiling; spinal cord: 2.6 nTPM; absolute ceiling; spleen: 8.2 nTPM; continuous selectivity; thymus: 13.8 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 4.9 nTPM (limit 4); bone marrow: 39 nTPM (limit 4); duodenum: 8.9 nTPM (limit 4); liver: 8 nTPM (limit 4); lung: 4.9 nTPM (limit 4); lymph node: 16.7 nTPM (limit 6); pancreas: 5.9 nTPM (limit 4); pituitary gland: 2.3 nTPM (limit 2); retina: 5.2 nTPM (limit 2); small intestine: 6.2 nTPM (limit 4); smooth muscle: 4.3 nTPM (limit 4); spinal cord: 2.6 nTPM (limit 2); thymus: 13.8 nTPM (limit 10); adrenal gland: 4.9 nTPM (baseline 2); bone marrow: 39 nTPM (baseline 2); cerebellum: 3.7 nTPM (baseline 2); cerebral cortex: 3.6 nTPM (baseline 2); duodenum: 8.9 nTPM (baseline 2); heart muscle: 3.8 nTPM (baseline 2); kidney: 3 nTPM (baseline 2); liver: 8 nTPM (baseline 2); lung: 4.9 nTPM (baseline 2); lymph node: 16.7 nTPM (baseline 6); pancreas: 5.9 nTPM (baseline 2); pituitary gland: 2.3 nTPM (baseline 2); retina: 5.2 nTPM (baseline 2); skeletal muscle: 3.8 nTPM (baseline 2); small intestine: 6.2 nTPM (baseline 2); smooth muscle: 4.3 nTPM (baseline 2); spinal cord: 2.6 nTPM (baseline 2); thymus: 13.8 nTPM (baseline 10),lymph node / germinal center cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Rectum Adenocarcinoma (validation): 206/207 (99.5%); Colon Adenocarcinoma (validation): 479/486 (98.6%),glioma: 4/12 (33.3%); breast cancer: 0/12 (0.0%),31,20,Q5HYJ3,https://www.uniprot.org/uniprotkb/Q5HYJ3/entry,"Negatively regulates the NF-kappa-B-mediated inflammatory pathway by preventing the translocation of HNRNPA2B1 from the nucleus to the cytoplasm (PubMed:37643469). Inhibits the PI3K/Akt/NF-kappa-B pathway-mediated polarization of M1 macrophages by binding to and stabilizing PIK3CD mRNA, resulting in increased levels of PIK3CD protein and increased levels of phosphorylated downstream target AKT which leads to decreased NF-kappa-B signaling (PubMed:38421448)",,,,Nucleus speckle,37643469|38421448,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
FAM78B,ENSG00000188859,Unsafe,High RNA,False,True,1.1,1.1,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 0.6 nTPM; continuous selectivity; colon: 0.5 nTPM; continuous selectivity; heart muscle: 0.6 nTPM; continuous selectivity; liver: 0.7 nTPM; continuous selectivity; pancreas: 0.4 nTPM; continuous selectivity; pituitary gland: 0.5 nTPM; continuous selectivity; retina: 0.8 nTPM; continuous selectivity; skeletal muscle: 0.7 nTPM; continuous selectivity; urinary bladder: 0.7 nTPM; continuous selectivity,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,True,"heart muscle/cardiomyocytes cluster c-5: 14 nTPM, 29 reads; reproductive-cell max 11.1; heart muscle/cardiomyocytes cluster c-8: 21.6 nTPM, 63 reads; reproductive-cell max 11.1; brain/excitatory neurons cluster c-0: 67.3 nTPM, 10111 reads; reproductive-cell max 11.1; brain/excitatory neurons cluster c-1: 51.4 nTPM, 6458 reads; reproductive-cell max 11.1; brain/excitatory neurons cluster c-2: 38.4 nTPM, 4378 reads; reproductive-cell max 11.1; brain/excitatory neurons cluster c-3: 62 nTPM, 7135 reads; reproductive-cell max 11.1; brain/excitatory neurons cluster c-4: 40.3 nTPM, 5523 reads; reproductive-cell max 11.1; brain/inhibitory neurons cluster c-5: 171.5 nTPM, 15256 reads; reproductive-cell max 11.1; brain/inhibitory neurons cluster c-6: 27.8 nTPM, 1444 reads; reproductive-cell max 11.1; brain/excitatory neurons cluster c-7: 47.2 nTPM, 4410 reads; reproductive-cell max 11.1; brain/inhibitory neurons cluster c-8: 161.9 nTPM, 13459 reads; reproductive-cell max 11.1; brain/excitatory neurons cluster c-9: 86 nTPM, 5992 reads; reproductive-cell max 11.1; brain/excitatory neurons cluster c-10: 81.9 nTPM, 4320 reads; reproductive-cell max 11.1; brain/excitatory neurons cluster c-11: 30.3 nTPM, 2219 reads; reproductive-cell max 11.1; brain/excitatory neurons cluster c-13: 65.3 nTPM, 3070 reads; reproductive-cell max 11.1; brain/inhibitory neurons cluster c-14: 42.1 nTPM, 1667 reads; reproductive-cell max 11.1; brain/inhibitory neurons cluster c-15: 71.4 nTPM, 1949 reads; reproductive-cell max 11.1; brain/excitatory neurons cluster c-16: 50.1 nTPM, 3958 reads; reproductive-cell max 11.1; brain/inhibitory neurons cluster c-17: 24.4 nTPM, 787 reads; reproductive-cell max 11.1; brain/excitatory neurons cluster c-18: 87.8 nTPM, 4347 reads; reproductive-cell max 11.1; brain/excitatory neurons cluster c-19: 77.4 nTPM, 3459 reads; reproductive-cell max 11.1; brain/excitatory neurons cluster c-20: 24.5 nTPM, 1195 reads; reproductive-cell max 11.1; brain/inhibitory neurons cluster c-21: 45.7 nTPM, 1389 reads; reproductive-cell max 11.1; brain/excitatory neurons cluster c-22: 33.2 nTPM, 1435 reads; reproductive-cell max 11.1; brain/inhibitory neurons cluster c-23: 70.2 nTPM, 1632 reads; reproductive-cell max 11.1; brain/excitatory neurons cluster c-24: 57.1 nTPM, 1330 reads; reproductive-cell max 11.1; brain/inhibitory neurons cluster c-25: 45.4 nTPM, 849 reads; reproductive-cell max 11.1; brain/inhibitory neurons cluster c-26: 27 nTPM, 605 reads; reproductive-cell max 11.1; brain/excitatory neurons cluster c-27: 38 nTPM, 1352 reads; reproductive-cell max 11.1; brain/inhibitory neurons cluster c-28: 29.3 nTPM, 595 reads; reproductive-cell max 11.1; brain/excitatory neurons cluster c-29: 25.4 nTPM, 641 reads; reproductive-cell max 11.1; brain/inhibitory neurons cluster c-30: 168.1 nTPM, 4032 reads; reproductive-cell max 11.1; brain/excitatory neurons cluster c-31: 25.6 nTPM, 1017 reads; reproductive-cell max 11.1; brain/excitatory neurons cluster c-32: 79 nTPM, 2289 reads; reproductive-cell max 11.1; brain/excitatory neurons cluster c-33: 34.1 nTPM, 846 reads; reproductive-cell max 11.1; brain/excitatory neurons cluster c-34: 25.1 nTPM, 628 reads; reproductive-cell max 11.1; brain/excitatory neurons cluster c-36: 25.3 nTPM, 432 reads; reproductive-cell max 11.1; brain/inhibitory neurons cluster c-38: 16.4 nTPM, 171 reads; reproductive-cell max 11.1; brain/excitatory neurons cluster c-39: 46.3 nTPM, 519 reads; reproductive-cell max 11.1; brain/excitatory neurons cluster c-40: 45.4 nTPM, 458 reads; reproductive-cell max 11.1; brain/inhibitory neurons cluster c-41: 139.4 nTPM, 734 reads; reproductive-cell max 11.1; brain/oligodendrocyte precursor cells cluster c-42: 42.9 nTPM, 91 reads; reproductive-cell max 11.1; brain/excitatory neurons cluster c-44: 40.8 nTPM, 116 reads; reproductive-cell max 11.1; eye/rod photoreceptor cells cluster c-0: 19.9 nTPM, 52 reads; reproductive-cell max 11.1; eye/bipolar cells cluster c-1: 16.7 nTPM, 48 reads; reproductive-cell max 11.1; eye/horizontal cells cluster c-5: 25.8 nTPM, 41 reads; reproductive-cell max 11.1; eye/cone photoreceptor cells cluster c-10: 44.2 nTPM, 26 reads; reproductive-cell max 11.1",True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Medium, HPA052789; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA052789; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA052789; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA052789; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA052789; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: High, HPA052789; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Medium, HPA052789; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA052789; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA052789; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA052789; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA052789; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA052789; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA052789; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA052789; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: High, HPA052789; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: High, HPA052789; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: High, HPA052789; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA052789; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA052789; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA052789; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA052789; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA052789; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: High, HPA052789; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA052789; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA052789; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: High, HPA052789; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA052789; conflicting or uncurated primary profile; Salivary gland/Glandular cells: High, HPA052789; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA052789; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA052789; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA052789; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA052789; conflicting or uncurated primary profile; Skin 2/Epidermal cells: High, HPA052789; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA052789; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Medium, HPA052789; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA052789; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA052789; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA052789; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA052789; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,3.4956145116000004,171.5,"hpa_single_cell: /Cone photoreceptor cells, max 44.2 nTPM, 1 observations >30; hpa_single_cell: /Excitatory neurons, max 53.6 nTPM, 1 observations >30; hpa_single_cell: /Inhibitory neurons, max 81.8 nTPM, 1 observations >30; hpa_single_cell: /Oligodendrocyte precursor cells, max 42.9 nTPM, 1 observations >30; hpa_single_cell_tissue: brain/excitatory neurons, max 87.8 nTPM, 21 observations >30; hpa_single_cell_tissue: brain/inhibitory neurons, max 171.5 nTPM, 9 observations >30; hpa_single_cell_tissue: brain/oligodendrocyte precursor cells, max 42.9 nTPM, 1 observations >30; hpa_single_cell_tissue: eye/cone photoreceptor cells, max 44.2 nTPM, 1 observations >30",Neither,oncoref.target-sets.2026-10-23.2,3.496 TPM; blood/TFH; dice_tfh; vital,171.5 nTPM; brain/inhibitory neurons; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 31/58 (53.4%); Breast Invasive Carcinoma (validation): 22/50 (44.0%); Skin Cuteneous Melanoma (TCGA): 16/99 (16.2%),melanoma: 8/8 (100.0%); colorectal cancer: 9/10 (90.0%),31,20,Q5VT40,https://www.uniprot.org/uniprotkb/Q5VT40/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
FAM81B,ENSG00000153347,Unsafe,RNA,False,True,81.1,81.1,86,2,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,amygdala: 3.2 nTPM; absolute ceiling; basal ganglia: 4.2 nTPM; absolute ceiling; choroid plexus: 60.6 nTPM; absolute ceiling;continuous selectivity; heart muscle: 7.3 nTPM; absolute ceiling; hippocampal formation: 5.1 nTPM; absolute ceiling; hypothalamus: 6.7 nTPM; absolute ceiling; lung: 4.2 nTPM; absolute ceiling; pituitary gland: 3.6 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 3.2 nTPM (limit 2); basal ganglia: 4.2 nTPM (limit 2); choroid plexus: 60.6 nTPM (limit 2); heart muscle: 7.3 nTPM (limit 4); hippocampal formation: 5.1 nTPM (limit 2); hypothalamus: 6.7 nTPM (limit 2); lung: 4.2 nTPM (limit 4); pituitary gland: 3.6 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Renal Papillary Cell Carcinoma (TCGA): 97/282 (34.4%); Uterine Corpus Endometrial Carcinoma (TCGA): 45/176 (25.6%); Lung Adenocarcinoma (TCGA): 124/497 (24.9%),breast cancer: 0/12 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q96LP2,https://www.uniprot.org/uniprotkb/Q96LP2/entry,,,,It is uncertain whether Met-1 or Met-39 is the initiator. Met-1 does not seem to exist in orthologs,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Jamin2021_CT | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
FAM83F,ENSG00000133477,Unsafe,Protein,False,True,39.7,39.7,85,25,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; colon: 5.2 nTPM; positive ihc; duodenum: 3.1 nTPM; positive ihc;absolute ceiling; heart muscle: 1.9 nTPM; positive ihc; kidney: 3.9 nTPM; positive ihc;absolute ceiling; pancreas: 13.1 nTPM; absolute ceiling; rectum: 3.1 nTPM; positive ihc; skeletal muscle: 0.1 nTPM; positive ihc; small intestine: 7.4 nTPM; positive ihc;absolute ceiling; stomach: 6.6 nTPM; positive ihc;absolute ceiling; urinary bladder: 2.5 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",duodenum: 3.1 nTPM (limit 2); kidney: 3.9 nTPM (limit 2); pancreas: 13.1 nTPM (limit 12); small intestine: 7.4 nTPM (limit 2); stomach: 6.6 nTPM (limit 6),colon / endothelial cells: Medium (Enhanced); colon / glandular cells: Medium (Enhanced); colon / peripheral nerve/ganglion: Low (Enhanced); duodenum / glandular cells: High (Enhanced); heart muscle / cardiomyocytes: Low (Enhanced); kidney / cells in glomeruli: Low (Enhanced); kidney / cells in tubules: Medium (Enhanced); rectum / glandular cells: Medium (Enhanced); skeletal muscle / myocytes: Low (Enhanced); small intestine / glandular cells: High (Enhanced); stomach 1 / glandular cells: Medium (Enhanced); stomach 2 / glandular cells: Medium (Enhanced); urinary bladder / urothelial cells: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 205/207 (99.0%); Colon Adenocarcinoma (validation): 481/486 (99.0%); Head and Neck Squamous Cell Carcinoma (TCGA): 478/492 (97.2%),colorectal cancer: 6/11 (54.5%); ovarian cancer: 3/12 (25.0%),31,20,Q8NEG4,https://www.uniprot.org/uniprotkb/Q8NEG4/entry,,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
FAM90A1,ENSG00000171847,Unsafe,RNA,False,True,2.0,6.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 1.8 nTPM; continuous selectivity; amygdala: 1.2 nTPM; continuous selectivity; basal ganglia: 2 nTPM; continuous selectivity;reproductive not higher; cerebellum: 2.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 6.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 0.7 nTPM; continuous selectivity; esophagus: 1.1 nTPM; continuous selectivity; heart muscle: 1.5 nTPM; continuous selectivity; hippocampal formation: 1.3 nTPM; continuous selectivity; hypothalamus: 1.4 nTPM; continuous selectivity; kidney: 0.7 nTPM; continuous selectivity; lung: 1.3 nTPM; continuous selectivity; lymph node: 1 nTPM; continuous selectivity; midbrain: 1.3 nTPM; continuous selectivity; pancreas: 1.7 nTPM; continuous selectivity; pituitary gland: 1.8 nTPM; continuous selectivity; retina: 4.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 2 nTPM; continuous selectivity;reproductive not higher; skeletal muscle: 0.7 nTPM; continuous selectivity; skin: 2.2 nTPM; continuous selectivity;reproductive not higher; spinal cord: 1 nTPM; continuous selectivity; thyroid gland: 2.4 nTPM; continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebellum: 2.2 nTPM (limit 2); cerebral cortex: 6.8 nTPM (limit 2); retina: 4.5 nTPM (limit 2); cerebellum: 2.2 nTPM (baseline 2); cerebral cortex: 6.8 nTPM (baseline 2); retina: 4.5 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Ovary Serous Cystadenocarcinoma (TCGA): 174/349 (49.9%); Glioblastoma Multiforme (TCGA): 70/141 (49.6%); Testicular Germ Cell Tumor (TCGA): 47/133 (35.3%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q86YD7,https://www.uniprot.org/uniprotkb/Q86YD7/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination; inclusion depends on TGCT under this study's thresholds,,,,,,,,
FAM9B,ENSG00000177138,Unsafe,RNA,False,True,5.7,5.7,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,liver: 3 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,liver: 3 nTPM (limit 2); liver: 3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (validation): 22/231 (9.5%); Testicular Germ Cell Tumor (TCGA): 12/133 (9.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 7/176 (4.0%),colorectal cancer: 11/11 (100.0%); ovarian cancer: 11/12 (91.7%),31,20,Q8IZU0,https://www.uniprot.org/uniprotkb/Q8IZU0/entry,May play a role in meiosis,Expressed in testis and ovary (at protein level),,,Nucleus Cytoplasm Chromosome,34507348,34507348,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
FAM9C,ENSG00000187268,Unsafe,RNA,False,True,4.2,37.2,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,spleen: 37.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,spleen: 37.2 nTPM (limit 10); spleen: 37.2 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 67/133 (50.4%); Bladder Urothelial Carcinoma (TCGA): 8/169 (4.7%); Pancreatic Adenocarcinoma (validation): 2/80 (2.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8IZT9,https://www.uniprot.org/uniprotkb/Q8IZT9/entry,,Expressed exclusively in testis,,,Nucleus,,12213195,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination; inclusion depends on TGCT under this study's thresholds | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
FANCA,ENSG00000187741,Unsafe,RNA,False,True,21.0,21.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,basal ganglia: 2.1 nTPM; absolute ceiling; bone marrow: 11.3 nTPM; absolute ceiling;continuous selectivity; cerebellum: 5.2 nTPM; absolute ceiling; cerebral cortex: 3.3 nTPM; absolute ceiling; duodenum: 3.4 nTPM; absolute ceiling; esophagus: 6.4 nTPM; absolute ceiling; kidney: 2.8 nTPM; absolute ceiling; liver: 5.9 nTPM; absolute ceiling;continuous selectivity; lung: 3.2 nTPM; absolute ceiling; lymph node: 7.7 nTPM; absolute ceiling;continuous selectivity; small intestine: 5.5 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,basal ganglia: 2.1 nTPM (limit 2); bone marrow: 11.3 nTPM (limit 2); cerebellum: 5.2 nTPM (limit 2); cerebral cortex: 3.3 nTPM (limit 2); duodenum: 3.4 nTPM (limit 2); esophagus: 6.4 nTPM (limit 6); kidney: 2.8 nTPM (limit 2); liver: 5.9 nTPM (limit 2); lung: 3.2 nTPM (limit 2); lymph node: 7.7 nTPM (limit 6); small intestine: 5.5 nTPM (limit 2); basal ganglia: 2.1 nTPM (baseline 2); bone marrow: 11.3 nTPM (baseline 2); cerebellum: 5.2 nTPM (baseline 2); cerebral cortex: 3.3 nTPM (baseline 2); duodenum: 3.4 nTPM (baseline 2); esophagus: 6.4 nTPM (baseline 6); kidney: 2.8 nTPM (baseline 2); liver: 5.9 nTPM (baseline 2); lung: 3.2 nTPM (baseline 2); lymph node: 7.7 nTPM (baseline 6); small intestine: 5.5 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 485/486 (99.8%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 279/283 (98.6%); Rectum Adenocarcinoma (validation): 203/207 (98.1%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O15360,https://www.uniprot.org/uniprotkb/O15360/entry,DNA repair protein that may operate in a postreplication repair or a cell cycle checkpoint function. May be involved in interstrand DNA cross-link repair and in the maintenance of normal chromosome stability,,"Fanconi anemia, complementation group A: A disorder affecting all bone marrow elements and resulting in anemia, leukopenia and thrombopenia. It is associated with cardiac, renal and limb malformations, dermal pigmentary changes, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage) and defective DNA repair.",,Nucleus Cytoplasm,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | daSilva2017_tumor_proteomics,GC RNA nomination across cancer types; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
FANCM,ENSG00000187790,Unsafe,RNA,False,True,6.5,6.5,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 3.3 nTPM; absolute ceiling;continuous selectivity; retina: 2 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 3.3 nTPM (limit 2); bone marrow: 3.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Breast Invasive Carcinoma (validation): 46/50 (92.0%); Colon Adenocarcinoma (validation): 219/486 (45.1%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8IYD8,https://www.uniprot.org/uniprotkb/Q8IYD8/entry,"DNA-dependent ATPase component of the Fanconi anemia (FA) core complex (PubMed:16116422). Required for the normal activation of the FA pathway, leading to monoubiquitination of the FANCI-FANCD2 complex in response to DNA damage, cellular resistance to DNA cross-linking drugs, and prevention of chromosomal breakage (PubMed:16116422, PubMed:19423727, PubMed:20347428, PubMed:20347429, PubMed:29231814). In complex with CENPS and CENPX, binds double-stranded DNA (dsDNA), fork-structured DNA (fsDNA) and Holliday junction substrates (PubMed:20347428, PubMed:20347429). Its ATP-dependent DNA branch migration activity can process branched DNA structures such as a movable replication fork. This activity is strongly stimulated in the presence of CENPS and CENPX (PubMed:20347429). In complex with FAAP24, efficiently binds to single-strand DNA (ssDNA), splayed-arm DNA, and 3'-flap substrates (PubMed:17289582). In vitro, on its own, strongly binds ssDNA oligomers and weakly fsDNA, but does not bind to dsDNA (PubMed:16116434)","Expressed in germ cells of fetal and adult ovaries. In fetal ovaries, it is present in oogonia but expression is stronger in pachytene stage oocytes. Expressed in oocytes arrested at the diplotene stage of prophase I during the last trimester of pregnancy and in adults (PubMed:29231814). Expressed in the testis (PubMed:30075111)","Spermatogenic failure 28: An autosomal recessive infertility disorder caused by spermatogenesis defects that result in oligoasthenospermia or non-obstructive azoospermia. Premature ovarian failure 15: An ovarian disorder defined as the cessation of ovarian function under the age of 40 years. It is characterized by oligomenorrhea or amenorrhea, in the presence of elevated levels of serum gonadotropins and low estradiol.",,Nucleus,16116422|16116434|17289582|19423727|20347428|20347429|29231814,29231814|30075111,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | Jamin2021_CT,GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
FANK1,ENSG00000203780,Unsafe,RNA,False,True,54.9,66.4,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 3.5 nTPM; absolute ceiling; amygdala: 5.2 nTPM; absolute ceiling; basal ganglia: 7.4 nTPM; absolute ceiling; cerebral cortex: 2.9 nTPM; absolute ceiling; choroid plexus: 66.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 2.3 nTPM; absolute ceiling; hippocampal formation: 6.9 nTPM; absolute ceiling; hypothalamus: 9.5 nTPM; absolute ceiling; kidney: 5.7 nTPM; absolute ceiling; lung: 5.5 nTPM; absolute ceiling; midbrain: 4.3 nTPM; absolute ceiling; pancreas: 4.1 nTPM; absolute ceiling; pituitary gland: 7.2 nTPM; absolute ceiling; retina: 15.3 nTPM; absolute ceiling;continuous selectivity; spinal cord: 3.2 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 3.5 nTPM (limit 2); amygdala: 5.2 nTPM (limit 2); basal ganglia: 7.4 nTPM (limit 2); cerebral cortex: 2.9 nTPM (limit 2); choroid plexus: 66.4 nTPM (limit 2); duodenum: 2.3 nTPM (limit 2); hippocampal formation: 6.9 nTPM (limit 2); hypothalamus: 9.5 nTPM (limit 2); kidney: 5.7 nTPM (limit 2); lung: 5.5 nTPM (limit 2); midbrain: 4.3 nTPM (limit 2); pancreas: 4.1 nTPM (limit 2); pituitary gland: 7.2 nTPM (limit 2); retina: 15.3 nTPM (limit 2); spinal cord: 3.2 nTPM (limit 2); adrenal gland: 3.5 nTPM (baseline 2); amygdala: 5.2 nTPM (baseline 2); basal ganglia: 7.4 nTPM (baseline 2); cerebral cortex: 2.9 nTPM (baseline 2); choroid plexus: 66.4 nTPM (baseline 2); duodenum: 2.3 nTPM (baseline 2); hippocampal formation: 6.9 nTPM (baseline 2); hypothalamus: 9.5 nTPM (baseline 2); kidney: 5.7 nTPM (baseline 2); lung: 5.5 nTPM (baseline 2); midbrain: 4.3 nTPM (baseline 2); pancreas: 4.1 nTPM (baseline 2); pituitary gland: 7.2 nTPM (baseline 2); retina: 15.3 nTPM (baseline 2); spinal cord: 3.2 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Thyroid Carcinoma (TCGA): 474/495 (95.8%); Breast Invasive Carcinoma (validation): 46/50 (92.0%); Kidney Renal Papillary Cell Carcinoma (TCGA): 207/282 (73.4%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8TC84,https://www.uniprot.org/uniprotkb/Q8TC84/entry,"Through the activation of JUN and AP-1-mediated transcription, may regulate apoptosis",Mostly restricted to testis,,,"Nucleus Cytoplasm, cytosol Cytoplasm, cytoskeleton, cilium basal body Cell projection, cilium",20978819|27060496,17604233,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
FATE1,ENSG00000147378,Unsafe,High RNA,False,True,232.3,232.3,86,2,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,CTA,Pass,oncoref.target-sets.2026-10-23.1,False,False,,CTA → Unsafe,True,True,True,0.0064,41.2,"hpa_single_cell_tissue: small intestine/enteroendocrine cells, max 41.2 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,0.0064 TPM; blood/naive CD8 T-cell; hpa_immune_cell_samples; vital,41.2 nTPM; small intestine/enteroendocrine cells; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 27/133 (20.3%); Kidney Renal Clear Cell Carcinoma (TCGA): 102/521 (19.6%); Kidney Renal Clear Cell Carcinoma (validation): 14/100 (14.0%),ovarian cancer: 1/12 (8.3%); breast cancer: 0/12 (0.0%),31,20,Q969F0,https://www.uniprot.org/uniprotkb/Q969F0/entry,Involved in the regulation of endoplasmic reticulum (ER)-mitochondria coupling. Negatively regulates the ER-mitochondria distance and Ca(2+) transfer from ER to mitochondria possibly implicating it in the regulation of apoptosis (PubMed:27402544). May collaborate with RNF183 to restrain BIK protein levels thus regulating apoptotic signaling (PubMed:26567849),"Testis-specific in fetus (aged from 6 to 11 weeks). In adult, expressed predominantly in testis, with some expression in lung, heart, kidney, adrenal gland and whole brain (PubMed:11694338). Highly expressed in certain types of cancer tissues such as hepatocellular carcinoma, colon and gastric cancer. Weakly expressed in normal pancreas (PubMed:12865919)",,,Mitochondrion Mitochondrion outer membrane Endoplasmic reticulum membrane,26567849|27402544,11694338|12865919,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
FBXL13,ENSG00000161040,Unsafe,Protein,False,True,3.8,4.9,79,38,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 1.5 nTPM; positive ihc;continuous selectivity; bone marrow: 0.7 nTPM; positive ihc; cerebellum: 0 nTPM; positive ihc; cerebral cortex: 0.4 nTPM; positive ihc; choroid plexus: 1.4 nTPM; continuous selectivity; colon: 0.2 nTPM; positive ihc; duodenum: 0.4 nTPM; positive ihc; esophagus: 0.4 nTPM; positive ihc; heart muscle: 0.3 nTPM; positive ihc; kidney: 0.4 nTPM; positive ihc; liver: 0.2 nTPM; positive ihc; lung: 0.5 nTPM; positive ihc; lymph node: 0.3 nTPM; positive ihc; pancreas: 0.4 nTPM; positive ihc; parathyroid gland: 0.8 nTPM; positive ihc; retina: 2.6 nTPM; absolute ceiling;continuous selectivity; skin: 0.6 nTPM; positive ihc; small intestine: 0.3 nTPM; positive ihc; smooth muscle: 0.3 nTPM; positive ihc; spleen: 0.5 nTPM; positive ihc; stomach: 4.9 nTPM; positive ihc;continuous selectivity;reproductive not higher; urinary bladder: 0.3 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",retina: 2.6 nTPM (limit 2); retina: 2.6 nTPM (baseline 2),adrenal gland / glandular cells: Low (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Low (Uncertain); caudate / glial cells: Low (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / glial cells: Medium (Uncertain); cerebral cortex / neuronal cells: Low (Uncertain); cerebral cortex / neuropil: Medium (Uncertain); colon / endothelial cells: High (Uncertain); colon / glandular cells: Low (Uncertain); colon / peripheral nerve/ganglion: Low (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Low (Uncertain); heart muscle / cardiomyocytes: Low (Uncertain); hippocampus / glial cells: Medium (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / non-germinal center cells: Medium (Uncertain); nasopharynx / respiratory epithelial cells: Low (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); parathyroid gland / glandular cells: Low (Uncertain); skin 2 / epidermal cells: Low (Uncertain); small intestine / glandular cells: Medium (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); spleen / cells in red pulp: Low (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 50/58 (86.2%); Pancreatic Adenocarcinoma (validation): 17/80 (21.2%); Breast Invasive Carcinoma (validation): 3/50 (6.0%),liver cancer: 3/11 (27.3%); glioma: 1/8 (12.5%),31,20,Q8NEE6,https://www.uniprot.org/uniprotkb/Q8NEE6/entry,"Substrate-recognition component of the SCF (SKP1-CUL1-F-box protein)-type E3 ubiquitin ligase complex. Component of the nexin-dynein regulatory complex (N-DRC), a key regulator of ciliary/flagellar motility which maintains the alignment and integrity of the distal axoneme and regulates microtubule sliding in motile axonemes. Specifically targets CEP192 isoform 3 for ubiquitin-mediated proteolysis and thereby acts as a regulator of microtubule nucleation activity (PubMed:29348145)",,,,"Cytoplasm, cytoskeleton, flagellum axoneme Cytoplasm, cytoskeleton, microtubule organizing center, centrosome",29348145,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
FBXL17,ENSG00000145743,Unsafe,Protein,False,True,10.2,42.0,74,48,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 11.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; adrenal gland: 10.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 4.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 1.2 nTPM; positive ihc; cerebral cortex: 16.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 3.1 nTPM; absolute ceiling;continuous selectivity; colon: 7.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 8 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 8.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 19.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; kidney: 12.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 10.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 6.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 6.4 nTPM; absolute ceiling;continuous selectivity; pancreas: 7.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 19 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 7.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 18.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 7.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 42 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 6.6 nTPM; positive ihc;continuous selectivity; small intestine: 8.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 8.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; spleen: 8.2 nTPM; positive ihc;continuous selectivity; stomach: 7.7 nTPM; absolute ceiling;continuous selectivity; thymus: 7.4 nTPM; continuous selectivity; thyroid gland: 18.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; tongue: 30.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 6.2 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 11.9 nTPM (limit 10); adrenal gland: 10.2 nTPM (limit 2); bone marrow: 4.6 nTPM (limit 2); cerebral cortex: 16.8 nTPM (limit 2); choroid plexus: 3.1 nTPM (limit 2); colon: 7.6 nTPM (limit 6); duodenum: 8 nTPM (limit 2); esophagus: 8.7 nTPM (limit 6); heart muscle: 19.8 nTPM (limit 2); kidney: 12.6 nTPM (limit 2); liver: 10.6 nTPM (limit 2); lung: 6.6 nTPM (limit 2); lymph node: 6.4 nTPM (limit 6); pancreas: 7.4 nTPM (limit 2); parathyroid gland: 19 nTPM (limit 6); rectum: 7.7 nTPM (limit 6); retina: 18.9 nTPM (limit 2); salivary gland: 7.4 nTPM (limit 6); skeletal muscle: 42 nTPM (limit 2); small intestine: 8.1 nTPM (limit 2); smooth muscle: 8.5 nTPM (limit 2); stomach: 7.7 nTPM (limit 6); thyroid gland: 18.1 nTPM (limit 10); tongue: 30.5 nTPM (limit 6); urinary bladder: 6.2 nTPM (limit 6); adipose tissue: 11.9 nTPM (baseline 10); adrenal gland: 10.2 nTPM (baseline 2); bone marrow: 4.6 nTPM (baseline 2); cerebral cortex: 16.8 nTPM (baseline 2); choroid plexus: 3.1 nTPM (baseline 2); colon: 7.6 nTPM (baseline 6); duodenum: 8 nTPM (baseline 2); esophagus: 8.7 nTPM (baseline 6); heart muscle: 19.8 nTPM (baseline 2); kidney: 12.6 nTPM (baseline 2); liver: 10.6 nTPM (baseline 2); lung: 6.6 nTPM (baseline 2); lymph node: 6.4 nTPM (baseline 6); pancreas: 7.4 nTPM (baseline 2); parathyroid gland: 19 nTPM (baseline 6); rectum: 7.7 nTPM (baseline 6); retina: 18.9 nTPM (baseline 2); salivary gland: 7.4 nTPM (baseline 6); skeletal muscle: 42 nTPM (baseline 2); small intestine: 8.1 nTPM (baseline 2); smooth muscle: 8.5 nTPM (baseline 2); stomach: 7.7 nTPM (baseline 6); thyroid gland: 18.1 nTPM (baseline 10); tongue: 30.5 nTPM (baseline 6); urinary bladder: 6.2 nTPM (baseline 6),adipose tissue / adipocytes: Medium (Uncertain); adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Low (Uncertain); caudate / glial cells: Low (Uncertain); caudate / neuronal cells: Low (Uncertain); cerebellum / cells in molecular layer: Low (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / glial cells: Medium (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / endothelial cells: Medium (Uncertain); colon / glandular cells: Medium (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Low (Uncertain); heart muscle / cardiomyocytes: Low (Uncertain); hippocampus / glial cells: Low (Uncertain); hippocampus / neuronal cells: Low (Uncertain); kidney / cells in glomeruli: Medium (Uncertain); kidney / cells in tubules: Low (Uncertain); lung / macrophages: Low (Uncertain); nasopharynx / respiratory epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Low (Uncertain); skeletal muscle / myocytes: Medium (Uncertain); skin 1 / keratinocytes: Low (Uncertain); small intestine / glandular cells: Medium (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); spleen / cells in red pulp: Low (Uncertain); urinary bladder / urothelial cells: Low (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Adenocarcinoma (validation): 105/105 (100.0%); Kidney Chromophobe (TCGA): 64/64 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%),breast cancer: 12/12 (100.0%); skin cancer: 12/12 (100.0%),31,20,Q9UF56,https://www.uniprot.org/uniprotkb/Q9UF56/entry,"Substrate-recognition component of the SCF(FBXL17) E3 ubiquitin ligase complex, a key component of a quality control pathway required to ensure functional dimerization of BTB domain-containing proteins (dimerization quality control, DQC) (PubMed:30190310). FBXL17 specifically recognizes and binds a conserved degron of non-consecutive residues present at the interface of BTB dimers of aberrant composition: aberrant BTB dimer are then ubiquitinated by the SCF(FBXL17) complex and degraded by the proteasome (PubMed:30190310). The ability of the SCF(FBXL17) complex to eliminate compromised BTB dimers is required for the differentiation and survival of neural crest and neuronal cells (By similarity). The SCF(FBXL17) complex mediates ubiquitination and degradation of BACH1 (PubMed:24035498, PubMed:30190310). The SCF(FBXL17) complex is also involved in the regulation of the hedgehog/smoothened (Hh) signaling pathway by mediating the ubiquitination and degradation of SUFU, allowing the release of GLI1 from SUFU for proper Hh signal transduction (PubMed:27234298). The SCF(FBXL17) complex mediates ubiquitination and degradation of PRMT1 (By similarity)",,,,Cytoplasm Nucleus,24035498|27234298|30190310,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
FBXO10,ENSG00000147912,Unsafe,Protein,False,True,10.5,28.7,77,12,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 7.7 nTPM; absolute ceiling;continuous selectivity; amygdala: 4 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 5.8 nTPM; absolute ceiling;continuous selectivity; cerebellum: 3.8 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 7.7 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 2.2 nTPM; absolute ceiling; colon: 7.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 1.7 nTPM; positive ihc; heart muscle: 3.8 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 5.4 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 4.9 nTPM; absolute ceiling;continuous selectivity; kidney: 3.7 nTPM; absolute ceiling;continuous selectivity; liver: 3.5 nTPM; absolute ceiling;continuous selectivity; lung: 2.2 nTPM; positive ihc;absolute ceiling; lymph node: 5.4 nTPM; continuous selectivity; midbrain: 3.2 nTPM; absolute ceiling;continuous selectivity; pancreas: 6.4 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 3.7 nTPM; continuous selectivity; pituitary gland: 16 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 1.7 nTPM; positive ihc; salivary gland: 8.3 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 28.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 4.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 3.1 nTPM; absolute ceiling;continuous selectivity; spinal cord: 2.5 nTPM; absolute ceiling; spleen: 9.8 nTPM; continuous selectivity; thyroid gland: 7.4 nTPM; continuous selectivity; tongue: 13.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 7.7 nTPM (limit 2); amygdala: 4 nTPM (limit 2); basal ganglia: 5.8 nTPM (limit 2); cerebellum: 3.8 nTPM (limit 2); cerebral cortex: 7.7 nTPM (limit 2); choroid plexus: 2.2 nTPM (limit 2); colon: 7.2 nTPM (limit 6); heart muscle: 3.8 nTPM (limit 2); hippocampal formation: 5.4 nTPM (limit 2); hypothalamus: 4.9 nTPM (limit 2); kidney: 3.7 nTPM (limit 2); liver: 3.5 nTPM (limit 2); lung: 2.2 nTPM (limit 2); midbrain: 3.2 nTPM (limit 2); pancreas: 6.4 nTPM (limit 2); pituitary gland: 16 nTPM (limit 2); salivary gland: 8.3 nTPM (limit 6); skeletal muscle: 28.7 nTPM (limit 2); small intestine: 4.6 nTPM (limit 2); smooth muscle: 3.1 nTPM (limit 2); spinal cord: 2.5 nTPM (limit 2); tongue: 13.4 nTPM (limit 6); adrenal gland: 7.7 nTPM (baseline 2); amygdala: 4 nTPM (baseline 2); basal ganglia: 5.8 nTPM (baseline 2); cerebellum: 3.8 nTPM (baseline 2); cerebral cortex: 7.7 nTPM (baseline 2); choroid plexus: 2.2 nTPM (baseline 2); colon: 7.2 nTPM (baseline 6); heart muscle: 3.8 nTPM (baseline 2); hippocampal formation: 5.4 nTPM (baseline 2); hypothalamus: 4.9 nTPM (baseline 2); kidney: 3.7 nTPM (baseline 2); liver: 3.5 nTPM (baseline 2); lung: 2.2 nTPM (baseline 2); midbrain: 3.2 nTPM (baseline 2); pancreas: 6.4 nTPM (baseline 2); pituitary gland: 16 nTPM (baseline 2); salivary gland: 8.3 nTPM (baseline 6); skeletal muscle: 28.7 nTPM (baseline 2); small intestine: 4.6 nTPM (baseline 2); smooth muscle: 3.1 nTPM (baseline 2); spinal cord: 2.5 nTPM (baseline 2); tongue: 13.4 nTPM (baseline 6),colon / glandular cells: Medium (Uncertain); duodenum / glandular cells: Medium (Uncertain); lung / macrophages: Low (Uncertain); rectum / glandular cells: Medium (Uncertain); small intestine / glandular cells: Medium (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 49/58 (84.5%); Breast Invasive Carcinoma (validation): 40/50 (80.0%); Testicular Germ Cell Tumor (TCGA): 105/133 (78.9%),renal cancer: 4/12 (33.3%); liver cancer: 2/10 (20.0%),31,20,Q9UK96,https://www.uniprot.org/uniprotkb/Q9UK96/entry,"Substrate-recognition component of the SCF (SKP1-CUL1-F-box protein)-type E3 ubiquitin ligase complex. Mediates the ubiquitination and degradation of BCL2, an antiapoptotic protein, thereby playing a role in apoptosis by controlling the stability of BCL2. Targets also the receptor for advanced glycation end products RAGE for ubiquitination and subsequent lysosomal degradation (PubMed:28515150). Directly controls HGAL/GCSAM ubiquitination and degradation and thereby decreases BCR signaling (PubMed:31570756)",,,,Cytoplasm,23431138|28515150|31570756,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
FBXO15,ENSG00000141665,Unsafe,RNA,False,True,6.9,6.9,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,choroid plexus: 2.9 nTPM; absolute ceiling;continuous selectivity; retina: 3.3 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 2.9 nTPM (limit 2); retina: 3.3 nTPM (limit 2); choroid plexus: 2.9 nTPM (baseline 2); retina: 3.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 35/50 (70.0%); Pancreatic Adenocarcinoma (validation): 6/80 (7.5%); Kidney Renal Papillary Cell Carcinoma (TCGA): 21/282 (7.4%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NCQ5,https://www.uniprot.org/uniprotkb/Q8NCQ5/entry,Substrate-recognition component of the SCF (SKP1-CUL1-F-box protein)-type E3 ubiquitin ligase complex,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
FBXO38,ENSG00000145868,Unsafe,Protein,False,True,14.1,19.7,84,57,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 12.4 nTPM; continuous selectivity; adrenal gland: 11.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 6.8 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 7.4 nTPM; absolute ceiling;continuous selectivity; bone marrow: 9.7 nTPM; absolute ceiling;continuous selectivity; cerebellum: 11 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 9.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 7.8 nTPM; absolute ceiling;continuous selectivity; colon: 12.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 9.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 10.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 16.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 7.6 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 7.3 nTPM; absolute ceiling;continuous selectivity; kidney: 12.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 17.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 14.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 14.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 7.7 nTPM; absolute ceiling;continuous selectivity; pancreas: 9.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 17.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 9.9 nTPM; absolute ceiling;continuous selectivity; rectum: 12.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 10.6 nTPM; absolute ceiling;continuous selectivity; salivary gland: 11.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 18 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 11.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 11.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 11.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 9.3 nTPM; absolute ceiling;continuous selectivity; spleen: 14 nTPM; continuous selectivity; stomach: 12.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 19.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 11.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 16.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 13.3 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 11.1 nTPM (limit 2); amygdala: 6.8 nTPM (limit 2); basal ganglia: 7.4 nTPM (limit 2); bone marrow: 9.7 nTPM (limit 4); cerebellum: 11 nTPM (limit 2); cerebral cortex: 9.1 nTPM (limit 2); choroid plexus: 7.8 nTPM (limit 2); colon: 12.1 nTPM (limit 6); duodenum: 9.4 nTPM (limit 2); esophagus: 10.2 nTPM (limit 6); heart muscle: 16.8 nTPM (limit 2); hippocampal formation: 7.6 nTPM (limit 2); hypothalamus: 7.3 nTPM (limit 2); kidney: 12.5 nTPM (limit 2); liver: 17.5 nTPM (limit 2); lung: 14.1 nTPM (limit 2); lymph node: 14.2 nTPM (limit 8); midbrain: 7.7 nTPM (limit 2); pancreas: 9.2 nTPM (limit 2); parathyroid gland: 17.9 nTPM (limit 6); pituitary gland: 9.9 nTPM (limit 2); rectum: 12.6 nTPM (limit 6); retina: 10.6 nTPM (limit 2); salivary gland: 11.2 nTPM (limit 6); skeletal muscle: 18 nTPM (limit 4); skin: 11.8 nTPM (limit 10); small intestine: 11.3 nTPM (limit 2); smooth muscle: 11.8 nTPM (limit 2); spinal cord: 9.3 nTPM (limit 2); stomach: 12.1 nTPM (limit 6); thymus: 19.7 nTPM (limit 10); thyroid gland: 11.9 nTPM (limit 10); tongue: 16.2 nTPM (limit 6); urinary bladder: 13.3 nTPM (limit 6),adrenal gland / glandular cells: Low (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Low (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Medium (Approved); liver / hepatocytes: Low (Approved); lung / macrophages: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skin 1 / fibroblasts: Low (Approved); skin 1 / keratinocytes: Low (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%); Kidney Renal Clear Cell Carcinoma (validation): 100/100 (100.0%),colorectal cancer: 11/11 (100.0%); pancreatic cancer: 8/10 (80.0%),31,20,Q6PIJ6,https://www.uniprot.org/uniprotkb/Q6PIJ6/entry,"Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of PDCD1/PD-1, thereby regulating T-cells-mediated immunity (PubMed:30487606). Required for anti-tumor activity of T-cells by promoting the degradation of PDCD1/PD-1; the PDCD1-mediated inhibitory pathway being exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival (PubMed:30487606). May indirectly stimulate the activity of transcription factor KLF7, a regulator of neuronal differentiation, without promoting KLF7 ubiquitination (By similarity)",,"Neuronopathy, distal hereditary motor, autosomal dominant 6: A form of distal hereditary motor neuronopathy, a heterogeneous group of neuromuscular disorders caused by selective degeneration of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. The overall clinical picture consists of a classical distal muscular atrophy syndrome in the legs without clinical sensory loss. The disease starts with weakness and wasting of distal muscles of the anterior tibial and peroneal compartments of the legs. Later on, weakness and atrophy may expand to the proximal muscles of the lower limbs and/or to the distal upper limbs.",,"Cytoplasm, cytosol Nucleus",30487606,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
FBXO5,ENSG00000112029,Unsafe,Protein,False,True,6.1,43.5,80,76,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 3 nTPM; positive ihc;continuous selectivity; adrenal gland: 3 nTPM; positive ihc;absolute ceiling;continuous selectivity; bone marrow: 43.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 3.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 2.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 1.9 nTPM; continuous selectivity; colon: 4.8 nTPM; positive ihc;continuous selectivity; duodenum: 4.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 3.6 nTPM; positive ihc;continuous selectivity; heart muscle: 1.7 nTPM; positive ihc;continuous selectivity; kidney: 3 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 4.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 3.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 14.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 2.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 2.2 nTPM; positive ihc;continuous selectivity; pituitary gland: 2 nTPM; continuous selectivity; rectum: 5 nTPM; positive ihc;continuous selectivity; retina: 3.2 nTPM; absolute ceiling;continuous selectivity; salivary gland: 2.6 nTPM; positive ihc;continuous selectivity; skeletal muscle: 0.9 nTPM; positive ihc; skin: 4.2 nTPM; positive ihc;continuous selectivity; small intestine: 4.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 4.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; spleen: 5.4 nTPM; positive ihc;continuous selectivity; stomach: 4.5 nTPM; positive ihc;continuous selectivity; thymus: 26.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 4.2 nTPM; positive ihc;continuous selectivity; tongue: 2.5 nTPM; continuous selectivity; urinary bladder: 3.8 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 3 nTPM (limit 2); bone marrow: 43.5 nTPM (limit 2); cerebellum: 3.5 nTPM (limit 2); cerebral cortex: 2.5 nTPM (limit 2); duodenum: 4.5 nTPM (limit 2); kidney: 3 nTPM (limit 2); liver: 4.3 nTPM (limit 2); lung: 3.3 nTPM (limit 2); lymph node: 14.5 nTPM (limit 6); pancreas: 2.9 nTPM (limit 2); retina: 3.2 nTPM (limit 2); small intestine: 4.2 nTPM (limit 2); smooth muscle: 4.8 nTPM (limit 2); thymus: 26.6 nTPM (limit 10),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Low (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Low (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Low (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Low (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 482/486 (99.2%),pancreatic cancer: 7/9 (77.8%); ovarian cancer: 7/11 (63.6%),31,20,Q9UKT4,https://www.uniprot.org/uniprotkb/Q9UKT4/entry,"Regulator of APC activity during mitotic and meiotic cell cycle (PubMed:16921029, PubMed:17234884, PubMed:17485488, PubMed:17875940, PubMed:23708001, PubMed:23708605). During mitotic cell cycle plays a role as both substrate and inhibitor of APC-FZR1 complex (PubMed:16921029, PubMed:17234884, PubMed:17485488, PubMed:17875940, PubMed:23708001, PubMed:23708605, PubMed:29875408). During G1 phase, plays a role as substrate of APC-FZR1 complex E3 ligase (PubMed:29875408). Then switches as an inhibitor of APC-FZR1 complex during S and G2 leading to cell-cycle commitment (PubMed:29875408). As APC inhibitor, prevents the degradation of APC substrates at multiple levels: by interacting with APC and blocking access of APC substrates to the D-box coreceptor, formed by FZR1 and ANAPC10; by suppressing ubiquitin ligation and chain elongation by APC by preventing the UBE2C and UBE2S activities (PubMed:16921029, PubMed:23708001, PubMed:23708605). Plays a role in genome integrity preservation by coordinating DNA replication with mitosis through APC inhibition in interphase to stabilize CCNA2 and GMNN in order to promote mitosis and prevent rereplication and DNA damage-induced cellular senescence (PubMed:17234884, PubMed:17485488, PubMed:17875940). During oocyte maturation, plays a role in meiosis through inactivation of APC-FZR1 complex. Inhibits APC through RPS6KA2 interaction that increases FBXO5 affiniy for CDC20 leading to the metaphase arrest of the second meiotic division before fertilization (By similarity). Controls entry into the first meiotic division through inactivation of APC-FZR1 complex (By similarity). Promotes migration and osteogenic differentiation of mesenchymal stem cells (PubMed:29850565)",,,,"Nucleus Cytoplasm Cytoplasm, cytoskeleton, spindle",16921029|17234884|17485488|17875940|23708001|23708605|29850565|29875408,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
FER1L6,ENSG00000214814,Unsafe,Protein,False,True,2.4,42.0,101,13,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 0 nTPM; positive ihc; colon: 4.9 nTPM; positive ihc;continuous selectivity;reproductive not higher; duodenum: 2.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; kidney: 3.1 nTPM; continuous selectivity;reproductive not higher; rectum: 10.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 0.1 nTPM; positive ihc; small intestine: 4.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; stomach: 42 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 2.2 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",duodenum: 2.8 nTPM (limit 2); rectum: 10.4 nTPM (limit 6); small intestine: 4.4 nTPM (limit 2); stomach: 42 nTPM (limit 6),adrenal gland / glandular cells: Low (Enhanced); bronchus / respiratory epithelial cells: Low (Enhanced); colon / goblet cells: Low (Enhanced); duodenum / goblet cells: Medium (Enhanced); rectum / goblet cells: Medium (Enhanced); skeletal muscle / myocytes: Low (Enhanced); small intestine / goblet cells: High (Enhanced); stomach 1 / glandular cells: High (Enhanced); stomach 2 / glandular cells: High (Enhanced); thyroid gland / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 51/80 (63.7%); Colon Adenocarcinoma (validation): 219/486 (45.1%); Rectum Adenocarcinoma (validation): 92/207 (44.4%),stomach cancer: 8/12 (66.7%); pancreatic cancer: 7/12 (58.3%),31,20,Q2WGJ9,https://www.uniprot.org/uniprotkb/Q2WGJ9/entry,Calcium/phospholipid-binding protein which is essential for proper development of skeletal and cardiac muscle,,,,"Cell membrane Cytoplasm, perinuclear region Golgi apparatus, trans-Golgi network Recycling endosome",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
FEZF1,ENSG00000128610,Unsafe,Protein,False,True,4.4,13.4,82,5,Positive somewhere,True,True,False,False,Excluded,Normal,False,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 2.9 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 3.6 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 0.2 nTPM; positive ihc; hypothalamus: 13.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 2 nTPM; continuous selectivity; pituitary gland: 2.9 nTPM; absolute ceiling;continuous selectivity; retina: 2.4 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 2.9 nTPM (limit 2); basal ganglia: 3.6 nTPM (limit 2); hypothalamus: 13.4 nTPM (limit 2); pituitary gland: 2.9 nTPM (limit 2); retina: 2.4 nTPM (limit 2); amygdala: 2.9 nTPM (baseline 2); basal ganglia: 3.6 nTPM (baseline 2); hypothalamus: 13.4 nTPM (baseline 2); pituitary gland: 2.9 nTPM (baseline 2); retina: 2.4 nTPM (baseline 2),caudate / neuronal cells: Low (Approved); cerebral cortex / neuropil: Medium (Approved); hippocampus / neuronal cells: Low (Approved); hypothalamus / neuronal cells: Low (Approved); hypothalamus / neuronal projections: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 178/486 (36.6%); Lung Squamous Cell Carcinoma (TCGA): 153/489 (31.3%); Lung Adenocarcinoma (TCGA): 133/497 (26.8%),breast cancer: 0/10 (0.0%); cervical cancer: 0/12 (0.0%),31,20,A0PJY2,https://www.uniprot.org/uniprotkb/A0PJY2/entry,Transcription repressor. Involved in the axonal projection and proper termination of olfactory sensory neurons (OSN). Plays a role in rostro-caudal patterning of the diencephalon and in prethalamic formation. Expression is required in OSN to cell-autonomously regulate OSN axon projections. Regulates non-cell-autonomously the layer formation of the olfactory bulb development and the interneurons. May be required for correct rostral migration of the interneuron progenitors (By similarity),Expressed in brain. Little or no expression in other tissues. Overexpressed specifically in gastric cancers. A 2- to 20-fold increase is found in over 50% of gastric cancer tissues,"Hypogonadotropic hypogonadism 22 with or without anosmia: A disorder characterized by absent or incomplete sexual maturation by the age of 18 years, in conjunction with low levels of circulating gonadotropins and testosterone and no other abnormalities of the hypothalamic-pituitary axis. In some cases, it is associated with non-reproductive phenotypes, such as anosmia, cleft palate, and sensorineural hearing loss. Anosmia or hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts. Hypogonadism is due to deficiency in gonadotropin-releasing hormone and probably results from a failure of embryonic migration of gonadotropin-releasing hormone-synthesizing neurons. In the presence of anosmia, idiopathic hypogonadotropic hypogonadism is referred to as Kallmann syndrome, whereas in the presence of a normal sense of smell, it has been termed normosmic idiopathic hypogonadotropic hypogonadism (nIHH).",,Nucleus,,19318583,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
FHAD1,ENSG00000142621,Unsafe,Protein,False,True,15.0,15.0,97,15,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; choroid plexus: 10.2 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 10.2 nTPM (limit 2),bronchus / ciliated cells (cilia axoneme): High (Enhanced); bronchus / ciliated cells (ciliary rootlets): High (Enhanced); bronchus / ciliated cells (tip of cilia): High (Enhanced); nasopharynx / ciliated cells (cell body): Medium (Enhanced); nasopharynx / ciliated cells (cilia axoneme): Medium (Enhanced); nasopharynx / ciliated cells (ciliary rootlets): High (Enhanced); nasopharynx / ciliated cells (tip of cilia): High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 34/50 (68.0%); Pancreatic Adenocarcinoma (validation): 37/80 (46.2%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 55/283 (19.4%),ovarian cancer: 1/11 (9.1%); breast cancer: 0/11 (0.0%),31,20,B1AJZ9,https://www.uniprot.org/uniprotkb/B1AJZ9/entry,Regulator of sperm motility and spermatocyte meiosis,Testis (at protein level),,,"Cell projection, cilium, flagellum",,31429579,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
FIGNL1,ENSG00000132436,Unsafe,Protein,False,True,10.2,12.7,87,69,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 4 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 3.3 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 4.5 nTPM; absolute ceiling;continuous selectivity; bone marrow: 8.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 6.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 6.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 5.9 nTPM; positive ihc;continuous selectivity; duodenum: 6.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 8.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 3.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 3.7 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 3.6 nTPM; absolute ceiling;continuous selectivity; kidney: 3.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 4.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 3.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 9.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 3.5 nTPM; absolute ceiling;continuous selectivity; pancreas: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 3.6 nTPM; positive ihc;continuous selectivity; pituitary gland: 2.5 nTPM; absolute ceiling; rectum: 6.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 9.2 nTPM; absolute ceiling;continuous selectivity; salivary gland: 3.6 nTPM; positive ihc;continuous selectivity; skeletal muscle: 6.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 8.3 nTPM; positive ihc;continuous selectivity; small intestine: 6 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 9.4 nTPM; absolute ceiling;continuous selectivity; spinal cord: 3.8 nTPM; absolute ceiling;continuous selectivity; spleen: 7.4 nTPM; positive ihc;continuous selectivity; stomach: 4.1 nTPM; positive ihc;continuous selectivity; thymus: 9.7 nTPM; continuous selectivity; thyroid gland: 3.5 nTPM; positive ihc; tongue: 7.7 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 3.4 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 4 nTPM (limit 2); amygdala: 3.3 nTPM (limit 2); basal ganglia: 4.5 nTPM (limit 2); bone marrow: 8.5 nTPM (limit 2); cerebellum: 6.5 nTPM (limit 2); cerebral cortex: 6.1 nTPM (limit 2); duodenum: 6.6 nTPM (limit 2); esophagus: 8.6 nTPM (limit 6); heart muscle: 3.6 nTPM (limit 2); hippocampal formation: 3.7 nTPM (limit 2); hypothalamus: 3.6 nTPM (limit 2); kidney: 3.3 nTPM (limit 2); liver: 4.5 nTPM (limit 2); lung: 3.2 nTPM (limit 2); lymph node: 9.9 nTPM (limit 6); midbrain: 3.5 nTPM (limit 2); pancreas: 2.7 nTPM (limit 2); pituitary gland: 2.5 nTPM (limit 2); rectum: 6.1 nTPM (limit 6); retina: 9.2 nTPM (limit 2); skeletal muscle: 6.1 nTPM (limit 2); small intestine: 6 nTPM (limit 2); smooth muscle: 9.4 nTPM (limit 4); spinal cord: 3.8 nTPM (limit 2); tongue: 7.7 nTPM (limit 6),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: High (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Low (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Low (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Medium (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%),liver cancer: 8/11 (72.7%); breast cancer: 6/11 (54.5%),31,20,Q6PIW4,https://www.uniprot.org/uniprotkb/Q6PIW4/entry,"ATPase that maintains genome stability by acting as a key regulator of DNA double-strand break (DSB) repair via homologous recombination (HR) (PubMed:23754376, PubMed:37256941, PubMed:37347663, PubMed:37515771, PubMed:37556550, PubMed:38286805, PubMed:38597669, PubMed:39636933, PubMed:41166468). Regulates HR by mediating disassembly of RAD51 filaments from DNA and chromatin, thereby preventing DNA damage-independent RAD51 loading and persistent DNA accumulation of RAD51 recombinases (PubMed:37256941, PubMed:37347663, PubMed:37515771, PubMed:37556550, PubMed:38286805, PubMed:38597669, PubMed:39636933, PubMed:41166468). Also regulates HR during meiosis by mediating dissociation of DMC1 filaments from DNA (By similarity). May regulate osteoblast proliferation and differentiation (By similarity)",,,,"Chromosome Nucleus Cytoplasm Cytoplasm, perinuclear region",23754376|37256941|37347663|37515771|37556550|38286805|38597669|39636933|41166468,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
FIP1L1,ENSG00000145216,Unsafe,Protein,False,True,30.6,30.6,101,78,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 18.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 15.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 11 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 10.2 nTPM; absolute ceiling;continuous selectivity; bone marrow: 27.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 12.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 13.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 7.1 nTPM; absolute ceiling; colon: 13.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 11 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 15.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 12.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 10.2 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 10.1 nTPM; absolute ceiling;continuous selectivity; kidney: 12.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 13 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 13.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 18.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 10.4 nTPM; absolute ceiling;continuous selectivity; pancreas: 9.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 16.7 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 9.4 nTPM; absolute ceiling;continuous selectivity; rectum: 14.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 16.3 nTPM; absolute ceiling;continuous selectivity; salivary gland: 14.2 nTPM; absolute ceiling; skeletal muscle: 24.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 17.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 14 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 14.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 12.4 nTPM; absolute ceiling;continuous selectivity; stomach: 13.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 28.9 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 14.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 11.9 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 16.9 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 18.4 nTPM (limit 10); adrenal gland: 15.2 nTPM (limit 2); amygdala: 11 nTPM (limit 2); basal ganglia: 10.2 nTPM (limit 2); bone marrow: 27.8 nTPM (limit 2); cerebellum: 12.7 nTPM (limit 2); cerebral cortex: 13.3 nTPM (limit 2); choroid plexus: 7.1 nTPM (limit 2); colon: 13.9 nTPM (limit 6); duodenum: 11 nTPM (limit 2); esophagus: 15.4 nTPM (limit 6); heart muscle: 12.5 nTPM (limit 2); hippocampal formation: 10.2 nTPM (limit 2); hypothalamus: 10.1 nTPM (limit 2); kidney: 12.9 nTPM (limit 2); liver: 13 nTPM (limit 2); lung: 13.8 nTPM (limit 2); lymph node: 18.9 nTPM (limit 6); midbrain: 10.4 nTPM (limit 2); pancreas: 9.7 nTPM (limit 2); parathyroid gland: 16.7 nTPM (limit 12); pituitary gland: 9.4 nTPM (limit 2); rectum: 14.3 nTPM (limit 6); retina: 16.3 nTPM (limit 2); salivary gland: 14.2 nTPM (limit 12); skeletal muscle: 24.9 nTPM (limit 2); skin: 17.3 nTPM (limit 10); small intestine: 14 nTPM (limit 2); smooth muscle: 14.8 nTPM (limit 2); spinal cord: 12.4 nTPM (limit 2); stomach: 13.4 nTPM (limit 6); thymus: 28.9 nTPM (limit 10); thyroid gland: 14.9 nTPM (limit 10); tongue: 11.9 nTPM (limit 6); urinary bladder: 16.9 nTPM (limit 6),adipose tissue / adipocytes: Medium (Supported); adrenal gland / glandular cells: Medium (Supported); bone marrow / hematopoietic cells: Medium (Supported); bronchus / ciliated cells (cell body): Medium (Supported); caudate / glial cells: Low (Supported); caudate / neuronal cells: Medium (Supported); cerebellum / cells in granular layer: Medium (Supported); cerebellum / cells in molecular layer: High (Supported); cerebellum / Purkinje cells: High (Supported); cerebral cortex / endothelial cells: Low (Supported); cerebral cortex / glial cells: Low (Supported); cerebral cortex / neuronal cells: High (Supported); colon / endothelial cells: Medium (Supported); colon / glandular cells: High (Supported); colon / peripheral nerve/ganglion: High (Supported); duodenum / glandular cells: High (Supported); esophagus / squamous epithelial cells: High (Supported); heart muscle / cardiomyocytes: Low (Supported); hippocampus / neuronal cells: Low (Supported); kidney / cells in glomeruli: Medium (Supported); kidney / cells in tubules: High (Supported); liver / hepatocytes: Medium (Supported); lung / alveolar cells type I: Low (Supported); lung / alveolar cells type II: Low (Supported); lung / macrophages: Low (Supported); lymph node / germinal center cells: Medium (Supported); lymph node / non-germinal center cells: Low (Supported); nasopharynx / basal cells: High (Supported); nasopharynx / ciliated cells (cell body): High (Supported); nasopharynx / goblet cells: High (Supported); oral mucosa / squamous epithelial cells: Medium (Supported); pancreas / exocrine glandular cells: Medium (Supported); pancreas / pancreatic endocrine cells: Medium (Supported); rectum / glandular cells: High (Supported); skeletal muscle / myocytes: Low (Supported); skin 1 / fibroblasts: Medium (Supported); skin 1 / keratinocytes: Medium (Supported); skin 1 / Langerhans: Medium (Supported); skin 2 / epidermal cells: High (Supported); small intestine / glandular cells: Medium (Supported); smooth muscle / smooth muscle cells: Medium (Supported); stomach 1 / glandular cells: Medium (Supported); stomach 2 / glandular cells: Medium (Supported); thyroid gland / glandular cells: High (Supported); urinary bladder / urothelial cells: High (Supported),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%); Ovary Serous Cystadenocarcinoma (validation): 81/81 (100.0%),breast cancer: 12/12 (100.0%); cervical cancer: 12/12 (100.0%),31,20,Q6UN15,https://www.uniprot.org/uniprotkb/Q6UN15/entry,"Component of the cleavage and polyadenylation specificity factor (CPSF) complex that plays a key role in pre-mRNA 3'-end formation, recognizing the AAUAAA signal sequence and interacting with poly(A) polymerase and other factors to bring about cleavage and poly(A) addition. FIP1L1 contributes to poly(A) site recognition and stimulates poly(A) addition. Binds to U-rich RNA sequence elements surrounding the poly(A) site. May act to tether poly(A) polymerase to the CPSF complex",,,,Nucleus,14749727,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
FIRRM,ENSG00000000460,Unsafe,Protein,False,True,10.0,13.0,80,67,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 1.8 nTPM; positive ihc; adrenal gland: 1.1 nTPM; positive ihc; bone marrow: 8.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 3 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 1 nTPM; positive ihc; colon: 2.5 nTPM; positive ihc; esophagus: 2 nTPM; positive ihc; heart muscle: 0.9 nTPM; positive ihc; kidney: 1 nTPM; positive ihc; liver: 2.5 nTPM; positive ihc;absolute ceiling; lung: 1.6 nTPM; positive ihc; lymph node: 6.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; pancreas: 1.4 nTPM; positive ihc; parathyroid gland: 13 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; rectum: 4 nTPM; continuous selectivity; retina: 5.3 nTPM; absolute ceiling;continuous selectivity; salivary gland: 1.5 nTPM; positive ihc; skeletal muscle: 0.9 nTPM; positive ihc; skin: 2.4 nTPM; positive ihc; smooth muscle: 2.6 nTPM; positive ihc;absolute ceiling; spleen: 2.7 nTPM; positive ihc; stomach: 1.8 nTPM; positive ihc; thymus: 11.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 1.6 nTPM; positive ihc; urinary bladder: 2.9 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 8.9 nTPM (limit 2); cerebellum: 3 nTPM (limit 2); liver: 2.5 nTPM (limit 2); lymph node: 6.2 nTPM (limit 6); parathyroid gland: 13 nTPM (limit 6); retina: 5.3 nTPM (limit 2); smooth muscle: 2.6 nTPM (limit 2); thymus: 11.3 nTPM (limit 10); bone marrow: 8.9 nTPM (baseline 2); cerebellum: 3 nTPM (baseline 2); liver: 2.5 nTPM (baseline 2); lymph node: 6.2 nTPM (baseline 6); parathyroid gland: 13 nTPM (baseline 6); retina: 5.3 nTPM (baseline 2); smooth muscle: 2.6 nTPM (baseline 2); thymus: 11.3 nTPM (baseline 10),adipose tissue / adipocytes: Medium (Uncertain); adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Low (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / glial cells: Low (Uncertain); caudate / neuronal cells: Low (Uncertain); cerebellum / cells in granular layer: Low (Uncertain); cerebellum / cells in molecular layer: Low (Uncertain); cerebellum / Purkinje cells: Low (Uncertain); cerebral cortex / endothelial cells: Medium (Uncertain); cerebral cortex / glial cells: Low (Uncertain); cerebral cortex / neuronal cells: Low (Uncertain); colon / peripheral nerve/ganglion: Medium (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / glial cells: Medium (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in glomeruli: Medium (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / alveolar cells: Medium (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / germinal center cells: Low (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Low (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: Medium (Uncertain); skin 1 / fibroblasts: Medium (Uncertain); skin 1 / keratinocytes: Medium (Uncertain); skin 1 / Langerhans: Medium (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); spleen / cells in red pulp: Medium (Uncertain); stomach 1 / glandular cells: Low (Uncertain); stomach 2 / glandular cells: Low (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 46/50 (92.0%); Rectum Adenocarcinoma (validation): 186/207 (89.9%),cervical cancer: 10/10 (100.0%); skin cancer: 11/12 (91.7%),31,20,Q9NSG2,https://www.uniprot.org/uniprotkb/Q9NSG2/entry,"Forms a complex with FIGL1, which regulates DNA double-strand break (DSB) repair via homologous recombination (HR) (PubMed:29608566, PubMed:37256941, PubMed:37347663, PubMed:37515771, PubMed:37556550, PubMed:38286805). The FIGNL1-FIRRM complex is essential for resolution of homologous recombination intermediates in response to DNA interstrand cross-links (ICLs) (PubMed:37256941, PubMed:37347663, PubMed:37515771, PubMed:37556550, PubMed:38286805). The complex regulates HR by promoting disassembly of RAD51 filaments from DNA and chromatin, thereby preventing DNA damage-independent RAD51 loading and persistent DNA accumulation of RAD51 recombinases (PubMed:37256941, PubMed:37347663, PubMed:37515771, PubMed:37556550, PubMed:38286805). It also regulates HR during meiosis by promoting dissociation of DMC1 filaments from DNA (By similarity). Within the complex, provides the ATPase activity to disassemble DMC1 and RAD51 filaments, while FIRRM directly binds single-stranded DNA to facilitate this unloading (PubMed:37556550). Independently of FIRRM, slso acts as a regulator of PLK1 kinase activity at kinetochores that promotes faithful chromosome segregation in prometaphase by bridging kinase and phosphatase activities (PubMed:34260926). Phosphorylation of FIRRM by PLK1 negatively regulates its interaction with the phosphatase, PPP1CC, thus creating a negative feedback loop for maintaining proper PLK1 kinase activity during mitosis (PubMed:34260926)",,,,"Chromosome Nucleus Chromosome, centromere, kinetochore Chromosome, centromere Midbody Cytoplasm, cytoskeleton, spindle",29608566|34260926|37256941|37347663|37515771|37556550|38286805,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | Jamin2021_CT,GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
FLACC1,ENSG00000155749,Unsafe,RNA,False,True,16.6,16.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 5 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 8.7 nTPM; absolute ceiling;continuous selectivity; heart muscle: 4.1 nTPM; absolute ceiling; lung: 2.4 nTPM; absolute ceiling; retina: 3.2 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 5 nTPM (limit 2); choroid plexus: 8.7 nTPM (limit 2); heart muscle: 4.1 nTPM (limit 2); lung: 2.4 nTPM (limit 2); retina: 3.2 nTPM (limit 2); bone marrow: 5 nTPM (baseline 2); choroid plexus: 8.7 nTPM (baseline 2); heart muscle: 4.1 nTPM (baseline 2); lung: 2.4 nTPM (baseline 2); retina: 3.2 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 50/58 (86.2%); Rectum Adenocarcinoma (validation): 13/207 (6.3%); Uterine Corpus Endometrial Carcinoma (TCGA): 10/176 (5.7%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q96Q35,https://www.uniprot.org/uniprotkb/Q96Q35/entry,,,,,"Cytoplasm Cytoplasmic granule Cell projection, cilium, flagellum",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
FMC1,ENSG00000164898,Unsafe,Protein,False,True,11.3,37.1,94,53,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 8.2 nTPM; continuous selectivity; adrenal gland: 11.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 12.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 13.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 5.9 nTPM; absolute ceiling;continuous selectivity; cerebellum: 6.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 11 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 24 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 9.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 6.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 5.4 nTPM; positive ihc;continuous selectivity; heart muscle: 27.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 12.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 12.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 15.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 17.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 5 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 5.3 nTPM; continuous selectivity; midbrain: 13.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 10 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 10.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 11.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 4.9 nTPM; positive ihc;continuous selectivity; retina: 3 nTPM; absolute ceiling;continuous selectivity; salivary gland: 12.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 29 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 4.8 nTPM; positive ihc; small intestine: 6.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 11.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 6.3 nTPM; continuous selectivity; stomach: 11 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 7.3 nTPM; continuous selectivity; thyroid gland: 10.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 37.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 8.3 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 11.1 nTPM (limit 2); amygdala: 12.9 nTPM (limit 2); basal ganglia: 13.9 nTPM (limit 2); bone marrow: 5.9 nTPM (limit 4); cerebellum: 6.5 nTPM (limit 2); cerebral cortex: 11 nTPM (limit 2); choroid plexus: 24 nTPM (limit 2); colon: 9.4 nTPM (limit 6); duodenum: 6.7 nTPM (limit 2); heart muscle: 27.6 nTPM (limit 2); hippocampal formation: 12.1 nTPM (limit 2); hypothalamus: 12.5 nTPM (limit 2); kidney: 15.8 nTPM (limit 2); liver: 17.3 nTPM (limit 2); lung: 5 nTPM (limit 2); midbrain: 13.1 nTPM (limit 2); pancreas: 10 nTPM (limit 2); parathyroid gland: 10.7 nTPM (limit 6); pituitary gland: 11.7 nTPM (limit 2); retina: 3 nTPM (limit 2); salivary gland: 12.2 nTPM (limit 6); skeletal muscle: 29 nTPM (limit 4); small intestine: 6.8 nTPM (limit 2); spinal cord: 11.3 nTPM (limit 2); stomach: 11 nTPM (limit 6); thyroid gland: 10.4 nTPM (limit 10); tongue: 37.1 nTPM (limit 6); urinary bladder: 8.3 nTPM (limit 6),adrenal gland / glandular cells: Medium (Approved); bronchus / basal cells: Low (Approved); bronchus / ciliated cells (cell body): Medium (Approved); caudate / glial cells: Medium (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / glial cells: Low (Approved); colon / glandular cells: High (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: High (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Low (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: High (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Prostate Adenocarcinoma (TCGA): 480/480 (100.0%); Glioblastoma Multiforme (TCGA): 141/141 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%),prostate cancer: 9/10 (90.0%); colorectal cancer: 10/12 (83.3%),29,20,Q96HJ9,https://www.uniprot.org/uniprotkb/Q96HJ9/entry,Plays a role in the assembly/stability of the mitochondrial membrane ATP synthase (F(1)F(0) ATP synthase or Complex V) (PubMed:28719601),,,,Mitochondrion,28719601,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
FMN1,ENSG00000248905,Unsafe,Protein,False,True,9.9,29.1,130,60,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 0.7 nTPM; positive ihc; choroid plexus: 2.6 nTPM; absolute ceiling;continuous selectivity; colon: 5.5 nTPM; positive ihc;continuous selectivity; duodenum: 1.3 nTPM; positive ihc; esophagus: 1.9 nTPM; positive ihc; heart muscle: 0.8 nTPM; positive ihc; kidney: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 3.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; pancreas: 1.2 nTPM; positive ihc; parathyroid gland: 1.4 nTPM; positive ihc; pituitary gland: 3.6 nTPM; absolute ceiling;continuous selectivity; rectum: 4.2 nTPM; positive ihc;continuous selectivity; retina: 29.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 4.1 nTPM; positive ihc;continuous selectivity; skeletal muscle: 0.7 nTPM; positive ihc; skin: 4 nTPM; positive ihc; small intestine: 1.8 nTPM; positive ihc; smooth muscle: 2.1 nTPM; positive ihc;absolute ceiling; stomach: 7.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; urinary bladder: 1.3 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 2.6 nTPM (limit 2); kidney: 2.7 nTPM (limit 2); lung: 3.3 nTPM (limit 2); pituitary gland: 3.6 nTPM (limit 2); retina: 29.1 nTPM (limit 2); smooth muscle: 2.1 nTPM (limit 2); stomach: 7.7 nTPM (limit 6),adrenal gland / glandular cells: Medium (Supported); bronchus / ciliated cells (cell body): Medium (Supported); colon / endothelial cells: Medium (Supported); colon / glandular cells: Medium (Supported); duodenum / glandular cells: Medium (Supported); esophagus / squamous epithelial cells: Medium (Supported); heart muscle / cardiomyocytes: Medium (Supported); kidney / bowman's capsule: Medium (Supported); kidney / cells in glomeruli: Low (Supported); kidney / collecting ducts: High (Supported); kidney / distal tubules: High (Supported); kidney / proximal tubules (cell body): Low (Supported); lung / macrophages: Low (Supported); nasopharynx / basal cells: Low (Supported); oral mucosa / squamous epithelial cells: Medium (Supported); pancreas / exocrine glandular cells: Medium (Supported); parathyroid gland / glandular cells: Medium (Supported); rectum / glandular cells: Medium (Supported); retina / outer plexiform layer: High (Supported); retina / photoreceptor cells: High (Supported); salivary gland / glandular cells: Low (Supported); skeletal muscle / myocytes: Medium (Supported); skin 1 / cells in basal layer: Low (Supported); skin 1 / cells in granular layer: Low (Supported); skin 1 / cells in spinous layer: Low (Supported); skin 1 / endothelial cells: Low (Supported); skin 1 / langerhans cells: Low (Supported); skin 2 / cells in basal layer: Low (Supported); skin 2 / cells in corneal layer: Low (Supported); skin 2 / cells in granular layer: Low (Supported); skin 2 / cells in spinous layer: Low (Supported); skin 2 / endothelial cells: High (Supported); skin 2 / fibrohistiocytic cells: Medium (Supported); skin 2 / langerhans cells: Low (Supported); skin 2 / lymphocytes: Low (Supported); small intestine / glandular cells: Medium (Supported); smooth muscle / smooth muscle cells: Medium (Supported); stomach 1 / glandular cells: Medium (Supported); stomach 2 / glandular cells: Medium (Supported); urinary bladder / urothelial cells: Medium (Supported),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Pancreatic Adenocarcinoma (validation): 80/80 (100.0%); Colon Adenocarcinoma (validation): 485/486 (99.8%),colorectal cancer: 10/12 (83.3%); pancreatic cancer: 10/12 (83.3%),31,20,Q68DA7,https://www.uniprot.org/uniprotkb/Q68DA7/entry,Plays a role in the formation of adherens junction and the polymerization of linear actin cables,,,,"Nucleus Cytoplasm Cell junction, adherens junction Cell membrane",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
FNDC11,ENSG00000125531,Unsafe,High RNA,False,True,105.0,105.0,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 15/91 values ≥5 TPM, max 8.12904; DICE TREG_MEM (unstimulated): 3/89 values ≥5 TPM, max 5.7252",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,8.12904239804,37.4,"hpa_single_cell_tissue: bronchus/ciliated cells, max 37.4 nTPM, 1 observations >30; hpa_single_cell_tissue: lung/ciliated cells, max 31.1 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,8.129 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,37.4 nTPM; bronchus/ciliated cells; hpa_single_cell_tissue; vital,Ovary Serous Cystadenocarcinoma (TCGA): 52/349 (14.9%); Bladder Urothelial Carcinoma (TCGA): 22/169 (13.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 16/176 (9.1%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q9BVV2,https://www.uniprot.org/uniprotkb/Q9BVV2/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
FOXB1,ENSG00000171956,Unsafe,RNA,False,True,0.6,4.1,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,hypothalamus: 3.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 4.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 1.3 nTPM; continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,hypothalamus: 3.3 nTPM (limit 2); midbrain: 4.1 nTPM (limit 2); hypothalamus: 3.3 nTPM (baseline 2); midbrain: 4.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 18/176 (10.2%); Ovary Serous Cystadenocarcinoma (TCGA): 21/349 (6.0%); Ovary Serous Cystadenocarcinoma (validation): 3/81 (3.7%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q99853,https://www.uniprot.org/uniprotkb/Q99853/entry,"Transcription factor expressed by neural progenitor cells in specific regions of the embryonic neuroepithelium. Essential for the mammillary nuclei maintenance. Negatively regulates the proliferation of oligodendrocyte progenitors and promotes oligodendrocyte maturation. Also expressed in mammary glands, plays a role in lactation, controls development of mammary glands and the inferior colliculi of the midbrain in the central nervous system that regulates the milk-ejection reflex",,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT,Cancer-associated RNA nomination; no antigen validation asserted,,,,,,,,
FOXD1,ENSG00000251493,Unsafe,RNA,False,True,3.2,3.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 1.8 nTPM; continuous selectivity; amygdala: 1.1 nTPM; continuous selectivity; basal ganglia: 1.8 nTPM; continuous selectivity; cerebral cortex: 1.3 nTPM; continuous selectivity; choroid plexus: 1.5 nTPM; continuous selectivity; esophagus: 1.7 nTPM; continuous selectivity; hippocampal formation: 1.1 nTPM; continuous selectivity; hypothalamus: 2.7 nTPM; absolute ceiling;continuous selectivity; kidney: 2.1 nTPM; absolute ceiling;continuous selectivity; midbrain: 1.8 nTPM; continuous selectivity; pituitary gland: 1.9 nTPM; continuous selectivity; small intestine: 1.2 nTPM; continuous selectivity; tongue: 1.9 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,hypothalamus: 2.7 nTPM (limit 2); kidney: 2.1 nTPM (limit 2); hypothalamus: 2.7 nTPM (baseline 2); kidney: 2.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 108/141 (76.6%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 177/283 (62.5%); Head and Neck Squamous Cell Carcinoma (TCGA): 248/492 (50.4%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q16676,https://www.uniprot.org/uniprotkb/Q16676/entry,"Transcription factor involved in regulation of gene expression in a variety of processes, including formation of positional identity in the developing retina, regionalization of the optic chiasm, morphogenesis of the kidney, and neuralization of ectodermal cells (By similarity). Involved in transcriptional activation of PGF and C3 genes (PubMed:27805902)",,,,Nucleus,27805902,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
FOXG1,ENSG00000176165,Unsafe,RNA,False,True,3.8,20.6,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,amygdala: 15 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 18.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 20.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 15.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 2.3 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 2.7 nTPM; absolute ceiling;continuous selectivity; thymus: 3 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 15 nTPM (limit 2); basal ganglia: 18.7 nTPM (limit 2); cerebral cortex: 20.6 nTPM (limit 2); hippocampal formation: 15.4 nTPM (limit 2); hypothalamus: 2.3 nTPM (limit 2); pituitary gland: 2.7 nTPM (limit 2); amygdala: 15 nTPM (baseline 2); basal ganglia: 18.7 nTPM (baseline 2); cerebral cortex: 20.6 nTPM (baseline 2); hippocampal formation: 15.4 nTPM (baseline 2); hypothalamus: 2.3 nTPM (baseline 2); pituitary gland: 2.7 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 55/58 (94.8%); Glioblastoma Multiforme (TCGA): 128/141 (90.8%); Uterine Corpus Endometrial Carcinoma (TCGA): 32/176 (18.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P55316,https://www.uniprot.org/uniprotkb/P55316/entry,Transcription repression factor which plays an important role in the establishment of the regional subdivision of the developing brain and in the development of the telencephalon,Expression is restricted to the neurons of the developing telencephalon,"Rett syndrome congenital variant: A severe neurodevelopmental disorder with features of classic Rett syndrome but earlier onset in the first months of life. Clinical features include progressive microcephaly, hypotonia, irresponsiveness and irritability in the neonatal period, intellectual disability, psychomotor regression and stereotypical movements.","PubMed:7959731 claims that there are 3 different FOXG1 proteins, FOXG1A, FOXG1B, and FOXG1C. It was latter found that there is only one gene and the differences between these three may be sequencing errors since the protein is coded in a unique exon",Nucleus,12657635,7959731,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
FOXJ3,ENSG00000198815,Unsafe,RNA,False,True,21.8,40.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 22.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; adrenal gland: 12.5 nTPM; absolute ceiling;continuous selectivity; amygdala: 14.7 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 18 nTPM; absolute ceiling;continuous selectivity; bone marrow: 29.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 28.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 18.5 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 12.1 nTPM; absolute ceiling;continuous selectivity; colon: 17.2 nTPM; absolute ceiling;continuous selectivity; duodenum: 15.3 nTPM; absolute ceiling;continuous selectivity; esophagus: 15 nTPM; absolute ceiling;continuous selectivity; heart muscle: 19.4 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 16.9 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 15.7 nTPM; absolute ceiling;continuous selectivity; kidney: 13 nTPM; absolute ceiling;continuous selectivity; liver: 15.8 nTPM; absolute ceiling;continuous selectivity; lung: 18 nTPM; absolute ceiling;continuous selectivity; lymph node: 17.4 nTPM; absolute ceiling;continuous selectivity; midbrain: 11.9 nTPM; absolute ceiling;continuous selectivity; pancreas: 18.4 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 20.7 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 16.6 nTPM; absolute ceiling;continuous selectivity; rectum: 17.6 nTPM; absolute ceiling;continuous selectivity; retina: 18.8 nTPM; absolute ceiling;continuous selectivity; salivary gland: 16.4 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 40.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 22.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 17.1 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 17.1 nTPM; absolute ceiling;continuous selectivity; spinal cord: 12.4 nTPM; absolute ceiling;continuous selectivity; spleen: 16.7 nTPM; absolute ceiling;continuous selectivity; stomach: 17 nTPM; absolute ceiling;continuous selectivity; thymus: 21.6 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 18.6 nTPM; absolute ceiling;continuous selectivity; tongue: 28 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 17.7 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adipose tissue: 22.4 nTPM (limit 10); adrenal gland: 12.5 nTPM (limit 2); amygdala: 14.7 nTPM (limit 2); basal ganglia: 18 nTPM (limit 2); bone marrow: 29.8 nTPM (limit 2); cerebellum: 28.8 nTPM (limit 2); cerebral cortex: 18.5 nTPM (limit 2); choroid plexus: 12.1 nTPM (limit 2); colon: 17.2 nTPM (limit 6); duodenum: 15.3 nTPM (limit 2); esophagus: 15 nTPM (limit 6); heart muscle: 19.4 nTPM (limit 2); hippocampal formation: 16.9 nTPM (limit 2); hypothalamus: 15.7 nTPM (limit 2); kidney: 13 nTPM (limit 2); liver: 15.8 nTPM (limit 2); lung: 18 nTPM (limit 2); lymph node: 17.4 nTPM (limit 6); midbrain: 11.9 nTPM (limit 2); pancreas: 18.4 nTPM (limit 2); parathyroid gland: 20.7 nTPM (limit 6); pituitary gland: 16.6 nTPM (limit 2); rectum: 17.6 nTPM (limit 6); retina: 18.8 nTPM (limit 2); salivary gland: 16.4 nTPM (limit 6); skeletal muscle: 40.6 nTPM (limit 2); skin: 22.2 nTPM (limit 10); small intestine: 17.1 nTPM (limit 2); smooth muscle: 17.1 nTPM (limit 2); spinal cord: 12.4 nTPM (limit 2); spleen: 16.7 nTPM (limit 10); stomach: 17 nTPM (limit 6); thymus: 21.6 nTPM (limit 10); thyroid gland: 18.6 nTPM (limit 10); tongue: 28 nTPM (limit 6); urinary bladder: 17.7 nTPM (limit 6); adipose tissue: 22.4 nTPM (baseline 10); adrenal gland: 12.5 nTPM (baseline 2); amygdala: 14.7 nTPM (baseline 2); basal ganglia: 18 nTPM (baseline 2); bone marrow: 29.8 nTPM (baseline 2); cerebellum: 28.8 nTPM (baseline 2); cerebral cortex: 18.5 nTPM (baseline 2); choroid plexus: 12.1 nTPM (baseline 2); colon: 17.2 nTPM (baseline 6); duodenum: 15.3 nTPM (baseline 2); esophagus: 15 nTPM (baseline 6); heart muscle: 19.4 nTPM (baseline 2); hippocampal formation: 16.9 nTPM (baseline 2); hypothalamus: 15.7 nTPM (baseline 2); kidney: 13 nTPM (baseline 2); liver: 15.8 nTPM (baseline 2); lung: 18 nTPM (baseline 2); lymph node: 17.4 nTPM (baseline 6); midbrain: 11.9 nTPM (baseline 2); pancreas: 18.4 nTPM (baseline 2); parathyroid gland: 20.7 nTPM (baseline 6); pituitary gland: 16.6 nTPM (baseline 2); rectum: 17.6 nTPM (baseline 6); retina: 18.8 nTPM (baseline 2); salivary gland: 16.4 nTPM (baseline 6); skeletal muscle: 40.6 nTPM (baseline 2); skin: 22.2 nTPM (baseline 10); small intestine: 17.1 nTPM (baseline 2); smooth muscle: 17.1 nTPM (baseline 2); spinal cord: 12.4 nTPM (baseline 2); spleen: 16.7 nTPM (baseline 10); stomach: 17 nTPM (baseline 6); thymus: 21.6 nTPM (baseline 10); thyroid gland: 18.6 nTPM (baseline 10); tongue: 28 nTPM (baseline 6); urinary bladder: 17.7 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (TCGA): 141/141 (100.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9UPW0,https://www.uniprot.org/uniprotkb/Q9UPW0/entry,Transcriptional activator of MEF2C involved in the regulation of adult muscle fiber type identity and skeletal muscle regeneration (By similarity). Plays an important role in spermatogenesis (By similarity). Required for the survival of spermatogonia and participates in spermatocyte meiosis (By similarity),,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
FOXO3B,ENSG00000240445,Unsafe,RNA,False,True,4.5,4.5,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,"incomplete routine rna; incomplete routine rna; missing normal RNA: amygdala, basal ganglia, cerebellum, hippocampal formation, hypothalamus, midbrain, pituitary gland, spinal cord; cerebral cortex: 2.2 nTPM; absolute ceiling;continuous selectivity; heart muscle: 1.5 nTPM; continuous selectivity; lymph node: 1.7 nTPM; continuous selectivity; retina: 1.7 nTPM; continuous selectivity; smooth muscle: 1.6 nTPM; continuous selectivity; thymus: 2.3 nTPM; continuous selectivity",Measured normal RNA exceeds its applicable category/IHC ceiling,cerebral cortex: 2.2 nTPM (limit 2); cerebral cortex: 2.2 nTPM (baseline 2),,incomplete_routine_rna,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 55/58 (94.8%); Breast Invasive Carcinoma (validation): 47/50 (94.0%); Colon Adenocarcinoma (validation): 92/486 (18.9%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,A0A2Z4LIS9,https://www.uniprot.org/uniprotkb/A0A2Z4LIS9/entry,Transcription factor,,,,"Cytoplasm, cytosol",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
FOXP3,ENSG00000049768,Unsafe,Protein,False,True,5.0,6.8,82,6,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; lung: 0.8 nTPM; positive ihc; lymph node: 5.6 nTPM; positive ihc;continuous selectivity;reproductive not higher; spleen: 2.3 nTPM; positive ihc;continuous selectivity; thymus: 6.6 nTPM; continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",,lung / macrophages: Medium (Enhanced); lymph node / non-germinal center cells: Medium (Enhanced); spleen / cells in white pulp: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 36/50 (72.0%); Rectum Adenocarcinoma (validation): 138/207 (66.7%); Colon Adenocarcinoma (validation): 310/486 (63.8%),breast cancer: 0/12 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q9BZS1,https://www.uniprot.org/uniprotkb/Q9BZS1/entry,"Transcriptional regulator which is crucial for the development and inhibitory function of regulatory T-cells (Treg) (PubMed:17377532, PubMed:21458306, PubMed:23947341, PubMed:24354325, PubMed:24722479, PubMed:24835996, PubMed:30513302, PubMed:32644293). Plays an essential role in maintaining homeostasis of the immune system by allowing the acquisition of full suppressive function and stability of the Treg lineage, and by directly modulating the expansion and function of conventional T-cells (PubMed:23169781). Can act either as a transcriptional repressor or a transcriptional activator depending on its interactions with other transcription factors, histone acetylases and deacetylases (PubMed:17377532, PubMed:21458306, PubMed:23947341, PubMed:24354325, PubMed:24722479). The suppressive activity of Treg involves the coordinate activation of many genes, including CTLA4 and TNFRSF18 by FOXP3 along with repression of genes encoding cytokines such as interleukin-2 (IL2) and interferon-gamma (IFNG) (PubMed:17377532, PubMed:21458306, PubMed:23947341, PubMed:24354325, PubMed:24722479). Inhibits cytokine production and T-cell effector function by repressing the activity of two key transcription factors, RELA and NFATC2 (PubMed:15790681). Mediates transcriptional repression of IL2 via its association with histone acetylase KAT5 and histone deacetylase HDAC7 (PubMed:17360565). Can activate the expression of TNFRSF18, IL2RA and CTLA4 and repress the expression of IL2 and IFNG via its association with transcription factor RUNX1 (PubMed:17377532). Inhibits the differentiation of IL17 producing helper T-cells (Th17) by antagonizing RORC function, leading to down-regulation of IL17 expression, favoring Treg development (PubMed:18368049). Inhibits the transcriptional activator activity of RORA (PubMed:18354202). Can repress the expression of IL2 and IFNG via its association with transcription factor IKZF4 (By similarity)",,"Immunodeficiency polyendocrinopathy, enteropathy, X-linked syndrome: Characterized by neonatal onset insulin-dependent diabetes mellitus, infections, secretory diarrhea, thrombocytopenia, anemia and eczema. It is usually lethal in infancy.",,Nucleus Cytoplasm,15790681|17360565|17377532|18354202|18368049|21458306|23169781|23947341|24354325|24722479|24835996|30513302|32644293,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
FRMPD1,ENSG00000070601,Unsafe,Protein,False,True,9.1,66.8,79,61,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0.4 nTPM; positive ihc; adrenal gland: 0.5 nTPM; positive ihc; bone marrow: 2.2 nTPM; positive ihc;absolute ceiling; cerebellum: 0.8 nTPM; positive ihc; cerebral cortex: 1.8 nTPM; positive ihc; colon: 0.5 nTPM; positive ihc; duodenum: 0.7 nTPM; positive ihc; esophagus: 1.5 nTPM; positive ihc; heart muscle: 0.7 nTPM; positive ihc; kidney: 0.5 nTPM; positive ihc; liver: 0.5 nTPM; positive ihc; lung: 0.6 nTPM; positive ihc; lymph node: 1.3 nTPM; positive ihc; pancreas: 0.8 nTPM; positive ihc; parathyroid gland: 0.7 nTPM; positive ihc; rectum: 0.5 nTPM; positive ihc; retina: 66.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 3.9 nTPM; positive ihc;continuous selectivity; skeletal muscle: 4 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 6.1 nTPM; positive ihc;continuous selectivity; small intestine: 1.1 nTPM; positive ihc; smooth muscle: 0.4 nTPM; positive ihc; spleen: 0.4 nTPM; positive ihc; stomach: 0.5 nTPM; positive ihc; thyroid gland: 1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 2.2 nTPM (limit 2); retina: 66.8 nTPM (limit 2); skeletal muscle: 4 nTPM (limit 2); bone marrow: 2.2 nTPM (baseline 2); retina: 66.8 nTPM (baseline 2); skeletal muscle: 4 nTPM (baseline 2),adipose tissue / adipocytes: Low (Uncertain); adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); cerebellum / cells in granular layer: High (Uncertain); cerebellum / cells in molecular layer: Low (Uncertain); cerebellum / Purkinje cells: Low (Uncertain); cerebral cortex / neuronal cells: Low (Uncertain); cerebral cortex / neuropil: Medium (Uncertain); colon / glandular cells: High (Uncertain); duodenum / glandular cells: High (Uncertain); esophagus / squamous epithelial cells: High (Uncertain); heart muscle / cardiomyocytes: Low (Uncertain); kidney / cells in glomeruli: Medium (Uncertain); kidney / cells in tubules: High (Uncertain); liver / cholangiocytes: Low (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / macrophages: Low (Uncertain); lymph node / germinal center cells: Medium (Uncertain); lymph node / non-germinal center cells: Medium (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Low (Uncertain); skeletal muscle / myocytes: Medium (Uncertain); skin 1 / fibroblasts: Low (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: High (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); spleen / cells in red pulp: Medium (Uncertain); spleen / cells in white pulp: Medium (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 55/80 (68.8%); Kidney Chromophobe (TCGA): 13/64 (20.3%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 45/283 (15.9%),colorectal cancer: 11/11 (100.0%); stomach cancer: 9/9 (100.0%),31,20,Q5SYB0,https://www.uniprot.org/uniprotkb/Q5SYB0/entry,"Stabilizes membrane-bound GPSM1, and thereby promotes its interaction with GNAI1",,,,"Cytoplasm, cytosol Cell membrane",18566450,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Jamin2021_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
FSHR,ENSG00000170820,Unsafe,High RNA,False,True,2.7,2.7,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,True,"brain/excitatory neurons cluster c-10: 26.1 nTPM, 1375 reads; reproductive-cell max 19.8; brain/excitatory neurons cluster c-18: 33.5 nTPM, 1661 reads; reproductive-cell max 19.8; brain/excitatory neurons cluster c-19: 67.6 nTPM, 3020 reads; reproductive-cell max 19.8; brain/excitatory neurons cluster c-29: 21.1 nTPM, 532 reads; reproductive-cell max 19.8; brain/excitatory neurons cluster c-32: 28.9 nTPM, 838 reads; reproductive-cell max 19.8",True,False,,True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,0.0898084061333999,67.6,"hpa_single_cell_tissue: brain/excitatory neurons, max 67.6 nTPM, 2 observations >30",Neither,oncoref.target-sets.2026-10-23.2,0.08981 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,67.6 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Kidney Renal Papillary Cell Carcinoma (TCGA): 2/282 (0.7%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P23945,https://www.uniprot.org/uniprotkb/P23945/entry,"G protein-coupled receptor for follitropin, the follicle-stimulating hormone (PubMed:11847099, PubMed:24058690, PubMed:24692546). Mediates FSH signaling through cAMP/protein kinase A (PKA) and phosphatidylinositol-3 kinase (PI3K)/protein kinase B (AKT) pathways to regulate ovarian follicular development and steroidogenesis (PubMed:24058690). Has diverse extragonadal functions: signals via a GNAI2-coupled FSHR on osteoclasts and their precursors, resulting in activation of MEK/ERK, NF-kappa-B, and AKT pathways and thus increases osteoclastogenesis and bone resorption (By similarity). Regulates glucose-stimulated insulin secretion in pancreatic beta-cells in a bell curve manner, with moderate FSH levels promoting insulin secretion via Galphas/cAMP/PKA pathways while high FSH levels inhibit this effect through Galphai coupling (By similarity). In adipose tissue, inhibits thermogenesis by suppressing UCP1 expression and promotes lipogenesis via CREB/PPARgamma pathways (By similarity). Also affects hepatic cholesterol metabolism by increasing serum total and low-density-lipoprotein cholesterol (LDL-C) by inhibiting the expression of LDL receptor (LDLR) (PubMed:26583582)",Sertoli cells and ovarian granulosa cells,"Ovarian dysgenesis 1: An autosomal recessive disease characterized by primary amenorrhea, variable development of secondary sex characteristics, poorly developed streak ovaries, and high serum levels of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Ovarian hyperstimulation syndrome: Disorder which occurs either spontaneously or most often as an iatrogenic complication of ovarian stimulation treatments for in vitro fertilization. The clinical manifestations vary from abdominal distention and discomfort to potentially life-threatening, massive ovarian enlargement and capillary leak with fluid sequestration. Pathologic features of this syndrome include the presence of multiple serous and hemorrhagic follicular cysts lined by luteinized cells, a condition called hyperreactio luteinalis.",,Cell membrane,11847099|24058690|24692546|26583582,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
FSIP1,ENSG00000150667,Unsafe,RNA,False,True,7.0,10.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,choroid plexus: 2 nTPM; continuous selectivity; colon: 7.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 10.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,colon: 7.1 nTPM (limit 6); rectum: 10.6 nTPM (limit 6); colon: 7.1 nTPM (baseline 6); rectum: 10.6 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 54/58 (93.1%); Breast Invasive Carcinoma (validation): 45/50 (90.0%); Breast Invasive Carcinoma (TCGA): 482/1022 (47.2%),breast cancer: 12/12 (100.0%); endometrial cancer: 12/12 (100.0%),31,20,Q8NA03,https://www.uniprot.org/uniprotkb/Q8NA03/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Jamin2021_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
FSIP2,ENSG00000188738,Unsafe,High RNA,False,True,5.2,5.2,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,stomach: 2.5 nTPM; continuous selectivity,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Selectivity,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,3.40914738773,71.8,"hpa_single_cell: /Gastric mucus-secreting cells, max 59 nTPM, 1 observations >30; hpa_single_cell_tissue: colon/distal enterocytes, max 71.8 nTPM, 2 observations >30; hpa_single_cell_tissue: small intestine/intestinal goblet cells, max 60.1 nTPM, 1 observations >30; hpa_single_cell_tissue: stomach/gastric mucus-secreting cells, max 59 nTPM, 1 observations >30",Neither,oncoref.target-sets.2026-10-23.2,3.409 TPM; blood/CD8_NAIVE; dice_cd8_naive; vital,71.8 nTPM; colon/distal enterocytes; hpa_single_cell_tissue; protected,Pancreatic Adenocarcinoma (validation): 80/80 (100.0%); Ovary Serous Cystadenocarcinoma (validation): 58/81 (71.6%); Colon Adenocarcinoma (validation): 21/486 (4.3%),No exact-ID IHC coverage in the HPA cancer snapshot,30,0,Q5CZC0,https://www.uniprot.org/uniprotkb/Q5CZC0/entry,Plays a role in spermatogenesis,Predominantly expressed in testis,"Spermatogenic failure 34: An autosomal recessive infertility disorder caused by spermatogenesis defects that result in multiple abnormalities of sperm flagellum, including irregular-caliber, short, coiled, or absent flagella.",,,30137358,30137358,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Chang2019_TGCT | Loriot2025_S2,Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct,,,,,,,,
GABPA,ENSG00000154727,Unsafe,Protein,False,True,23.7,23.7,89,71,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 16.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 13.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 6.2 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 8.7 nTPM; absolute ceiling;continuous selectivity; bone marrow: 15.8 nTPM; absolute ceiling;continuous selectivity; cerebellum: 8.3 nTPM; absolute ceiling; cerebral cortex: 8.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 2.8 nTPM; absolute ceiling; colon: 12.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 12.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 10.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 12.5 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 6.4 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 5.3 nTPM; absolute ceiling; kidney: 13.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 18.7 nTPM; absolute ceiling;continuous selectivity; lung: 12.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 19.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 6.8 nTPM; absolute ceiling;continuous selectivity; pancreas: 9.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 14.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 6.5 nTPM; absolute ceiling;continuous selectivity; rectum: 13.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 11.1 nTPM; absolute ceiling;continuous selectivity; salivary gland: 10.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 10.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 10 nTPM; positive ihc; small intestine: 13 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 14.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 8.7 nTPM; absolute ceiling;continuous selectivity; spleen: 18.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 11.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 21.5 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 20.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 15.9 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 12.5 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 16.4 nTPM (limit 10); adrenal gland: 13.4 nTPM (limit 2); amygdala: 6.2 nTPM (limit 2); basal ganglia: 8.7 nTPM (limit 2); bone marrow: 15.8 nTPM (limit 6); cerebellum: 8.3 nTPM (limit 6); cerebral cortex: 8.5 nTPM (limit 2); choroid plexus: 2.8 nTPM (limit 2); colon: 12.1 nTPM (limit 6); duodenum: 12.6 nTPM (limit 2); esophagus: 10.9 nTPM (limit 6); heart muscle: 12.5 nTPM (limit 6); hippocampal formation: 6.4 nTPM (limit 2); hypothalamus: 5.3 nTPM (limit 2); kidney: 13.3 nTPM (limit 2); liver: 18.7 nTPM (limit 6); lung: 12.9 nTPM (limit 2); lymph node: 19.9 nTPM (limit 6); midbrain: 6.8 nTPM (limit 2); pancreas: 9.9 nTPM (limit 2); parathyroid gland: 14.8 nTPM (limit 6); pituitary gland: 6.5 nTPM (limit 2); rectum: 13.3 nTPM (limit 6); retina: 11.1 nTPM (limit 2); salivary gland: 10.1 nTPM (limit 6); skeletal muscle: 10.2 nTPM (limit 2); small intestine: 13 nTPM (limit 2); smooth muscle: 14.8 nTPM (limit 2); spinal cord: 8.7 nTPM (limit 2); spleen: 18.2 nTPM (limit 10); stomach: 11.5 nTPM (limit 6); thymus: 21.5 nTPM (limit 10); thyroid gland: 20.6 nTPM (limit 10); tongue: 15.9 nTPM (limit 6); urinary bladder: 12.5 nTPM (limit 6),adipose tissue / adipocytes: Low (Supported); adrenal gland / glandular cells: Medium (Supported); bronchus / respiratory epithelial cells: Medium (Supported); cerebral cortex / endothelial cells: Low (Supported); cerebral cortex / glial cells: Low (Supported); cerebral cortex / neuropil: Medium (Supported); colon / endothelial cells: Medium (Supported); colon / glandular cells: Medium (Supported); colon / peripheral nerve/ganglion: Low (Supported); duodenum / glandular cells: Medium (Supported); esophagus / squamous epithelial cells: Medium (Supported); kidney / cells in glomeruli: Medium (Supported); kidney / cells in tubules: Medium (Supported); lung / alveolar cells type I: High (Supported); lung / alveolar cells type II: High (Supported); lung / endothelial cells: Medium (Supported); lymph node / germinal center cells: Medium (Supported); lymph node / non-germinal center cells: Medium (Supported); nasopharynx / respiratory epithelial cells: Medium (Supported); oral mucosa / squamous epithelial cells: Medium (Supported); pancreas / exocrine glandular cells: Medium (Supported); pancreas / pancreatic endocrine cells: Medium (Supported); parathyroid gland / glandular cells: Medium (Supported); rectum / glandular cells: Medium (Supported); salivary gland / glandular cells: Medium (Supported); skeletal muscle / myocytes: Medium (Supported); skin 1 / fibroblasts: Low (Supported); skin 1 / keratinocytes: Medium (Supported); skin 1 / Langerhans: Medium (Supported); skin 2 / epidermal cells: Medium (Supported); small intestine / glandular cells: Medium (Supported); smooth muscle / smooth muscle cells: Medium (Supported); spleen / cells in red pulp: Low (Supported); stomach 1 / glandular cells: Medium (Supported); thyroid gland / glandular cells: Medium (Supported); urinary bladder / urothelial cells: Medium (Supported),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%); Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%),lymphoma: 10/12 (83.3%); breast cancer: 5/11 (45.5%),31,20,Q06546,https://www.uniprot.org/uniprotkb/Q06546/entry,Transcription factor capable of interacting with purine rich repeats (GA repeats). Positively regulates transcription of transcriptional repressor RHIT/ZNF205 (PubMed:22306510) (Microbial infection) Necessary for the expression of the Adenovirus E4 gene,,,,Nucleus,22306510,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
GABRB3,ENSG00000166206,Unsafe,RNA,False,True,4.6,45.7,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 5.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 3.2 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 9.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 9.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 45.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 5.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 4 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 5.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 1.6 nTPM; continuous selectivity; pancreas: 3.2 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 2 nTPM; continuous selectivity; pituitary gland: 5.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; retina: 29.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; stomach: 5.5 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 8.3 nTPM; continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 5.2 nTPM (limit 2); amygdala: 3.2 nTPM (limit 2); basal ganglia: 9.4 nTPM (limit 2); cerebellum: 9.8 nTPM (limit 2); cerebral cortex: 45.7 nTPM (limit 2); heart muscle: 5.1 nTPM (limit 2); hippocampal formation: 4 nTPM (limit 2); hypothalamus: 5.9 nTPM (limit 2); kidney: 7 nTPM (limit 2); pancreas: 3.2 nTPM (limit 2); pituitary gland: 5.6 nTPM (limit 2); retina: 29.3 nTPM (limit 2); adrenal gland: 5.2 nTPM (baseline 2); amygdala: 3.2 nTPM (baseline 2); basal ganglia: 9.4 nTPM (baseline 2); cerebellum: 9.8 nTPM (baseline 2); cerebral cortex: 45.7 nTPM (baseline 2); heart muscle: 5.1 nTPM (baseline 2); hippocampal formation: 4 nTPM (baseline 2); hypothalamus: 5.9 nTPM (baseline 2); kidney: 7 nTPM (baseline 2); pancreas: 3.2 nTPM (baseline 2); pituitary gland: 5.6 nTPM (baseline 2); retina: 29.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Prostate Adenocarcinoma (TCGA): 332/480 (69.2%); Glioblastoma Multiforme (validation): 36/58 (62.1%); Testicular Germ Cell Tumor (TCGA): 76/133 (57.1%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P28472,https://www.uniprot.org/uniprotkb/P28472/entry,"Beta subunit of the heteropentameric ligand-gated chloride channel gated by gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the brain (PubMed:14993607, PubMed:18514161, PubMed:22243422, PubMed:22303015, PubMed:24909990, PubMed:26950270, PubMed:30602789). GABA-gated chloride channels, also named GABA(A) receptors (GABAAR), consist of five subunits arranged around a central pore and contain GABA active binding site(s) located at the alpha and beta subunit interface(s) (PubMed:24909990, PubMed:30140029, PubMed:30602789). GABAARs containing beta-3/GABRB3 subunit are found at both synaptic and extrasynaptic sites (By similarity). When activated by GABA, GABAARs selectively allow the flow of chloride anions across the cell membrane down their electrochemical gradient (PubMed:14993607, PubMed:22303015, PubMed:26950270, PubMed:30602789). Chloride influx into the postsynaptic neuron following GABAAR opening decreases the neuron ability to generate a new action potential, thereby reducing nerve transmission (PubMed:22303015, PubMed:26950270). GABAARs containing alpha-1 and beta-3 subunits exhibit synaptogenic activity; the gamma-2 subunit being necessary but not sufficient to induce rapid synaptic contacts formation (PubMed:25489750). Extrasynaptic beta-3 receptors contribute to the tonic GABAergic inhibition (By similarity). GABAARs containing alpha-1, beta-3 and epsilon subunits may also permit spontaneous chloride channel activity while preserving the structural information required for GABA-gated openings (By similarity). Beta-containing GABAARs can simultaneously bind GABA and histamine where histamine binds at the interface of two neighboring beta subunits, which may be involved in the regulation of sleep and wakefulness (PubMed:18281286, PubMed:24909990, PubMed:35355020). Plays an important role in somatosensation and in the production of antinociception (By similarity)",,"Epilepsy, childhood absence 5: A subtype of idiopathic generalized epilepsy characterized by an onset at age 6-7 years, frequent absence seizures (several per day) and bilateral, synchronous, symmetric 3-Hz spike waves on EEG. Tonic-clonic seizures often develop in adolescence. Absence seizures may either remit or persist into adulthood. Developmental and epileptic encephalopathy 43: A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE43 inheritance is autosomal dominant.",,Postsynaptic cell membrane Cell membrane Cytoplasmic vesicle membrane,14993607|18281286|18514161|22243422|22303015|24909990|25489750|26950270|30140029|30602789|35355020,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
GABRG3,ENSG00000182256,Unsafe,Protein,False,True,9.0,26.3,97,24,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 0 nTPM; positive ihc; cerebellum: 1.3 nTPM; positive ihc; cerebral cortex: 2.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; hypothalamus: 3.3 nTPM; absolute ceiling;continuous selectivity; lung: 0 nTPM; positive ihc; lymph node: 0.6 nTPM; positive ihc; pancreas: 0 nTPM; positive ihc; pituitary gland: 2.9 nTPM; absolute ceiling;continuous selectivity; retina: 26.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 0.3 nTPM; positive ihc; spleen: 1 nTPM; positive ihc; stomach: 0 nTPM; positive ihc; thyroid gland: 1.4 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",cerebral cortex: 2.4 nTPM (limit 2); hypothalamus: 3.3 nTPM (limit 2); pituitary gland: 2.9 nTPM (limit 2); retina: 26.3 nTPM (limit 2),bone marrow / hematopoietic cells: Low (Approved); caudate / neuronal cells: Low (Approved); cerebellum / processes in white matter: Low (Approved); cerebellum / Purkinje cells - cytoplasm/membrane: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); hippocampus / neuronal cells: Low (Approved); lung / macrophages: Low (Approved); lymph node / non-germinal center cells: Low (Approved); pancreas / exocrine glandular cells: Low (Approved); skin 1 / keratinocytes: Low (Approved); spleen / cells in red pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Low (Approved); thyroid gland / glandular cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Prostate Adenocarcinoma (TCGA): 310/480 (64.6%); Thyroid Carcinoma (TCGA): 96/495 (19.4%); Ovary Serous Cystadenocarcinoma (TCGA): 39/349 (11.2%),prostate cancer: 2/10 (20.0%); endometrial cancer: 1/12 (8.3%),31,20,Q99928,https://www.uniprot.org/uniprotkb/Q99928/entry,"Gamma subunit of the heteropentameric ligand-gated chloride channel gated by gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the brain (By similarity). GABA-gated chloride channels, also named GABA(A) receptors (GABAAR), consist of five subunits arranged around a central pore and contain GABA active binding site(s) located at the alpha and beta subunit interface(s) (By similarity). When activated by GABA, GABAARs selectively allow the flow of chloride across the cell membrane down their electrochemical gradient (By similarity)",Expressed in brain,,,Postsynaptic cell membrane Cell membrane,,8719414,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
GABRR1,ENSG00000146276,Unsafe,RNA,False,True,0.9,23.9,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,retina: 23.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 23.9 nTPM (limit 2); retina: 23.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Squamous Cell Carcinoma (TCGA): 32/489 (6.5%); Lung Squamous Cell Carcinoma (validation): 4/68 (5.9%); Testicular Germ Cell Tumor (TCGA): 6/133 (4.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P24046,https://www.uniprot.org/uniprotkb/P24046/entry,"Rho subunit of the pentameric ligand-gated chloride channels responsible for mediating the effects of gamma-aminobutyric acid (GABA), the major inhibitory neurotransmitter in the brain (PubMed:37659407). Rho-containing GABA-gated chloride channels are a subclass of GABA(A) receptors (GABAARs) entirely composed of rho subunits, where GABA molecules bind at the rho intersubunit interfaces (PubMed:37659407). When activated by GABA, rho-GABAARs selectively allow the flow of chloride anions across the cell membrane down their electrochemical gradient (PubMed:37659407). Rho-1 subunits are primarily expressed in retina where rho-1-containing GABAARs may play a role in retinal neurotransmission (PubMed:1849271). Rho-1 GABAARs are also involved in neuronal tonic (extrasynaptic) and phasic (synaptic) transmission in the Purkinje neurons of the cerebellum (By similarity). Rho-1 GABAARs may also contribute to the regulation of glial development in the cerebellum by controlling extrasynaptic transmission (By similarity)","Highly expressed in the retina (PubMed:1849271). Expressed in a lesser extent in brain, lung and thymus (PubMed:1849271)",,,Postsynaptic cell membrane Cell membrane,1849271|37659407,1849271,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT,Cancer-associated RNA nomination; no antigen validation asserted,,,,,,,,
GABRR3,ENSG00000183185,Unsafe,RNA,False,True,0.1,8.5,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,existing nomination or manual review; nomination unresolved; retina: 8.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 8.5 nTPM (limit 2); retina: 8.5 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Liver Hepatocellular Carcinoma (validation): 1/231 (0.4%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,A8MPY1,https://www.uniprot.org/uniprotkb/A8MPY1/entry,"Rho subunit of the pentameric ligand-gated chloride channels responsible for mediating the effects of gamma-aminobutyric acid (GABA), the major inhibitory neurotransmitter in the brain (By similarity). Rho-containing GABA-gated chloride channels are a subclass of GABA(A) receptors (GABAARs) entirely composed of rho subunits, where GABA molecules bind at the rho intersubunit interfaces (By similarity). When activated by GABA, rho-GABAARs selectively allow the flow of chloride anions across the cell membrane down their electrochemical gradient (By similarity)",,,The sequence shown in this entry differs from the translation of the reference genome assembly (GRCh38/hg38) due to a nonsense variant creating stop codon at position 205 in the reference genome,Postsynaptic cell membrane Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
GAGE12B,ENSG00000236737,Unsafe,RNA,False,True,137.7,137.7,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,basal ganglia: 3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,basal ganglia: 3 nTPM (limit 2); basal ganglia: 3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Ovary Serous Cystadenocarcinoma (TCGA): 18/349 (5.2%); Stomach Adenocarcinoma (TCGA): 16/346 (4.6%); Thyroid Carcinoma (TCGA): 15/495 (3.0%),No exact-ID IHC coverage in the HPA cancer snapshot,30,0,,,,,,,,,,False,No exact Ensembl mapping to a reviewed UniProt entry,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
GAGE12F,ENSG00000236362,Unsafe,High RNA,False,True,103.3,103.3,83,3,Positive somewhere,False,False,False,True,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,hpa_immune_cell classical monocyte: 7.7 nTPM; hpa_immune_cell intermediate monocyte: 7.8 nTPM; hpa_immune_cell memory B-cell: 5.6 nTPM; hpa_immune_cell memory CD4 T-cell: 8.1 nTPM; hpa_immune_cell memory CD8 T-cell: 5.5 nTPM; hpa_immune_cell naive B-cell: 5.3 nTPM; hpa_immune_cell naive CD4 T-cell: 6.2 nTPM; hpa_immune_cell naive CD8 T-cell: 5.3 nTPM; hpa_immune_cell NK-cell: 8.9 nTPM; hpa_immune_cell non-classical monocyte: 6.2 nTPM; hpa_immune_cell plasmacytoid DC: 8.3 nTPM; hpa_immune_cell T-reg: 13.8 nTPM; hpa_immune_cell total PBMC: 7.7 nTPM,True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,71.6653,83.0695,"hpa_immune_cell_samples: blood/NK-cell, max 51.8037 TPM, 1 observations >30; hpa_immune_cell_samples: blood/T-reg, max 71.6653 TPM, 1 observations >30; hpa_immune_cell_samples: blood/classical monocyte, max 38.8727 TPM, 1 observations >30; hpa_immune_cell_samples: blood/intermediate monocyte, max 32.0759 TPM, 1 observations >30; hpa_immune_cell_samples: blood/memory CD4 T-cell, max 46.1675 TPM, 1 observations >30; hpa_immune_cell_samples: blood/naive CD4 T-cell, max 35.4421 TPM, 1 observations >30; hpa_immune_cell_samples: blood/naive CD8 T-cell, max 33.0234 TPM, 1 observations >30; hpa_immune_cell_samples: blood/plasmacytoid DC, max 41.922 TPM, 1 observations >30; hpa_immune_cell_samples: blood/total PBMC, max 40.9921 TPM, 1 observations >30; hpa_immune_cell_samples: blood/NK-cell, max 53.5002 nTPM, 1 observations >30; hpa_immune_cell_samples: blood/T-reg, max 83.0695 nTPM, 1 observations >30; hpa_immune_cell_samples: blood/classical monocyte, max 46.6655 nTPM, 1 observations >30; hpa_immune_cell_samples: blood/intermediate monocyte, max 47.1668 nTPM, 1 observations >30; hpa_immune_cell_samples: blood/memory B-cell, max 33.8287 nTPM, 1 observations >30; hpa_immune_cell_samples: blood/memory CD4 T-cell, max 49.0849 nTPM, 1 observations >30; hpa_immune_cell_samples: blood/naive B-cell, max 32.1517 nTPM, 1 observations >30; hpa_immune_cell_samples: blood/naive CD4 T-cell, max 37.4272 nTPM, 1 observations >30; hpa_immune_cell_samples: blood/naive CD8 T-cell, max 32.3725 nTPM, 1 observations >30; hpa_immune_cell_samples: blood/non-classical monocyte, max 31.2073 nTPM, 1 observations >30; hpa_immune_cell_samples: blood/plasmacytoid DC, max 50.2688 nTPM, 1 observations >30; hpa_immune_cell_samples: blood/total PBMC, max 46.4602 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,71.67 TPM; blood/T-reg; hpa_immune_cell_samples; vital,83.07 nTPM; blood/T-reg; hpa_immune_cell_samples; vital,Testicular Germ Cell Tumor (TCGA): 32/133 (24.1%); Lung Squamous Cell Carcinoma (TCGA): 115/489 (23.5%); Lung Squamous Cell Carcinoma (validation): 13/68 (19.1%),breast cancer: 0/10 (0.0%); cervical cancer: 0/12 (0.0%),31,20,O76087 | P0CL82 | P0CL80 | P0CL81,https://www.uniprot.org/uniprotkb/O76087/entry | https://www.uniprot.org/uniprotkb/P0CL82/entry | https://www.uniprot.org/uniprotkb/P0CL80/entry | https://www.uniprot.org/uniprotkb/P0CL81/entry,,Expressed in some prostate cancer tissues but not in normal prostate tissue,,"The first GAGE nomenclature was based on identified mRNA sequences, but the high identity of the GAGE members made impossible to separate products of paralogous genes from polymorph products. PubMed:18179644 presented a new GAGE gene nomenclature based on the identified genes and their products",,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Jamin2021_CT | Jamin2021_core | Loriot2025_S2 | daSilva2017_tumor_proteomics,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,Is the immune signal correctly assigned within the GAGE family?,Review uniquely assigning reads and exact gene/protein identity before reconsidering local expression.,Highly related paralogs can complicate attribution; no paralog substitution or RNA-to-protein inference is permitted.,,,,,
GAGE12G,ENSG00000215269,Unsafe,High RNA,False,True,60.1,60.1,83,3,Positive somewhere,False,False,False,True,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,hpa_immune_cell classical monocyte: 5.9 nTPM; hpa_immune_cell intermediate monocyte: 6.1 nTPM; hpa_immune_cell memory CD4 T-cell: 6.8 nTPM; hpa_immune_cell naive CD4 T-cell: 5 nTPM; hpa_immune_cell naive CD8 T-cell: 5 nTPM; hpa_immune_cell NK-cell: 7.1 nTPM; hpa_immune_cell non-classical monocyte: 6 nTPM; hpa_immune_cell plasmacytoid DC: 6.1 nTPM; hpa_immune_cell T-reg: 11 nTPM; hpa_immune_cell total PBMC: 6 nTPM,True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,56.9784,66.0454,"hpa_immune_cell_samples: blood/NK-cell, max 41.4415 TPM, 1 observations >30; hpa_immune_cell_samples: blood/T-reg, max 56.9784 TPM, 1 observations >30; hpa_immune_cell_samples: blood/memory CD4 T-cell, max 38.3827 TPM, 1 observations >30; hpa_immune_cell_samples: blood/naive CD8 T-cell, max 31.1559 TPM, 1 observations >30; hpa_immune_cell_samples: blood/plasmacytoid DC, max 30.9988 TPM, 1 observations >30; hpa_immune_cell_samples: blood/total PBMC, max 31.8705 TPM, 1 observations >30; hpa_immune_cell_samples: blood/NK-cell, max 42.7987 nTPM, 1 observations >30; hpa_immune_cell_samples: blood/T-reg, max 66.0454 nTPM, 1 observations >30; hpa_immune_cell_samples: blood/classical monocyte, max 35.7077 nTPM, 1 observations >30; hpa_immune_cell_samples: blood/intermediate monocyte, max 36.9895 nTPM, 1 observations >30; hpa_immune_cell_samples: blood/memory CD4 T-cell, max 40.8081 nTPM, 1 observations >30; hpa_immune_cell_samples: blood/naive CD4 T-cell, max 30.3976 nTPM, 1 observations >30; hpa_immune_cell_samples: blood/naive CD8 T-cell, max 30.5419 nTPM, 1 observations >30; hpa_immune_cell_samples: blood/non-classical monocyte, max 30.2294 nTPM, 1 observations >30; hpa_immune_cell_samples: blood/plasmacytoid DC, max 37.1707 nTPM, 1 observations >30; hpa_immune_cell_samples: blood/total PBMC, max 36.1219 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,56.98 TPM; blood/T-reg; hpa_immune_cell_samples; vital,66.05 nTPM; blood/T-reg; hpa_immune_cell_samples; vital,Ovary Serous Cystadenocarcinoma (validation): 6/81 (7.4%); Skin Cuteneous Melanoma (TCGA): 5/99 (5.1%); Ovary Serous Cystadenocarcinoma (TCGA): 16/349 (4.6%),breast cancer: 0/10 (0.0%); cervical cancer: 0/12 (0.0%),30,20,O76087 | P0CL82 | P0CL80 | P0CL81,https://www.uniprot.org/uniprotkb/O76087/entry | https://www.uniprot.org/uniprotkb/P0CL82/entry | https://www.uniprot.org/uniprotkb/P0CL80/entry | https://www.uniprot.org/uniprotkb/P0CL81/entry,,Expressed in some prostate cancer tissues but not in normal prostate tissue,,"The first GAGE nomenclature was based on identified mRNA sequences, but the high identity of the GAGE members made impossible to separate products of paralogous genes from polymorph products. PubMed:18179644 presented a new GAGE gene nomenclature based on the identified genes and their products",,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Jamin2021_CT | Jamin2021_core | daSilva2017_tumor_proteomics,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
GAGE12J,ENSG00000224659,Unsafe,RNA,False,True,22.5,22.5,83,3,Positive somewhere,False,True,False,True,Excluded,Normal,False,,Not assessed,,,retina: 2.2 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 2.2 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Squamous Cell Carcinoma (validation): 10/68 (14.7%); Lung Squamous Cell Carcinoma (TCGA): 65/489 (13.3%); Skin Cuteneous Melanoma (TCGA): 10/99 (10.1%),breast cancer: 0/10 (0.0%); cervical cancer: 0/12 (0.0%),31,20,A6NER3,https://www.uniprot.org/uniprotkb/A6NER3/entry,,,,"The first GAGE nomenclature was based on identified mRNA sequences, but the high identity of the GAGE members made impossible to separate products of paralogous genes from polymorph products. PubMed:18179644 presented a new GAGE gene nomenclature based on the identified genes and their products",,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Jamin2021_CT | Jamin2021_core | Chang2019_TGCT | Seager2024_CTA | Loriot2025_S2 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Member of the published 17-target CTA profiling panel; includes differentiation antigen MLANA | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,Failed bulk numeric comparisons are within 20% of their cutoffs; not an automatic rescue,,,,
GAGE2E,ENSG00000275113,Unsafe,RNA,False,True,25.4,25.4,83,3,Positive somewhere,False,True,False,True,Excluded,Normal,False,,Not assessed,,,retina: 2.4 nTPM; absolute ceiling; stomach: 14.9 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 2.4 nTPM (limit 2); stomach: 14.9 nTPM (limit 8),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 28/133 (21.1%); Lung Squamous Cell Carcinoma (TCGA): 102/489 (20.9%); Skin Cuteneous Melanoma (TCGA): 17/99 (17.2%),breast cancer: 0/10 (0.0%); cervical cancer: 0/12 (0.0%),28,20,Q4V326,https://www.uniprot.org/uniprotkb/Q4V326/entry,,,,"The first GAGE nomenclature was based on identified mRNA sequences, but the high identity of the GAGE members made impossible to separate products of paralogous genes from polymorph products. PubMed:18179644 presented a new GAGE gene nomenclature based on the identified genes and their products",,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Jamin2021_CT | Jamin2021_core | Loriot2025_S2 | daSilva2017_tumor_proteomics,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
GALNTL5,ENSG00000106648,Unsafe,Protein,False,True,10.5,10.5,85,7,Positive somewhere,True,False,False,True,Excluded,Normal,False,,Not assessed,,,positive normal IHC; positive ihc outside permitted; cerebral cortex: 1.4 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,cerebral cortex / neuronal cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),breast cancer: 0/11 (0.0%); cervical cancer: 0/10 (0.0%),31,20,Q7Z4T8,https://www.uniprot.org/uniprotkb/Q7Z4T8/entry,Probable inactive glycosyltransferase required during spermatid development. May participate in protein loading into the acrosomes and accumulation of ubiquitin-proteasome systems around the head-tail coupling apparatus region,Mainly expressed in testis. Weakly or not expressed in other tissues,,"In contrast to other members of the family, lacks the C-terminal ricin B-type lectin domain, which contributes to the glycopeptide specificity. No glycosyltransferase activity has been detected in an in vitro assay (PubMed:24398516)",Late endosome membrane,,24398516,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Jamin2021_CT | Jamin2021_core | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
GAPDHS,ENSG00000105679,Unsafe,RNA,False,True,262.3,262.3,86,1,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,retina: 3.4 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 3.4 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Skin Cuteneous Melanoma (TCGA): 89/99 (89.9%); Rectum Adenocarcinoma (validation): 172/207 (83.1%); Colon Adenocarcinoma (validation): 316/486 (65.0%),melanoma: 7/12 (58.3%); prostate cancer: 1/12 (8.3%),31,20,O14556,https://www.uniprot.org/uniprotkb/O14556/entry,Catalyzes the conversion of D-glyceraldehyde 3-phosphate (G3P) into 3-phospho-D-glyceroyl phosphate in glycolysis and the reverse reaction in gluconeogenesis (By similarity). May play an important role in regulating the switch between different pathways for energy production during spermiogenesis and in the spermatozoon. Required for sperm motility and male fertility (By similarity),Testis specific,,,Cytoplasm,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
GARIN1A,ENSG00000205085,Unsafe,RNA,False,True,35.4,35.4,88,4,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,basal ganglia: 2.2 nTPM; absolute ceiling; pituitary gland: 4.3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,basal ganglia: 2.2 nTPM (limit 2); pituitary gland: 4.3 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 48/58 (82.8%); Breast Invasive Carcinoma (validation): 20/50 (40.0%); Pancreatic Adenocarcinoma (validation): 15/80 (18.8%),breast cancer: 0/12 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q6NXP2,https://www.uniprot.org/uniprotkb/Q6NXP2/entry,RAB2B effector protein required for accurate acrosome formation and normal male fertility,,,,Golgi apparatus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
GARIN4,ENSG00000162771,Unsafe,High RNA,False,True,76.5,76.5,83,4,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,CTA,Pass,oncoref.target-sets.2026-10-23.1,False,False,,CTA → Unsafe,True,True,True,1.01673883126,39.0,"hpa_single_cell_tissue: salivary gland/serous glandular cells, max 39 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,1.017 TPM; blood/MONOCYTES; dice_monocytes; vital,39 nTPM; salivary gland/serous glandular cells; hpa_single_cell_tissue; protected,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),breast cancer: 0/12 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q8IYT1,https://www.uniprot.org/uniprotkb/Q8IYT1/entry,"RAB2B effector protein required for the compacted Golgi morphology, probably through interaction with small GTPase RAB2B",,,,Golgi apparatus,26209634,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
GARIN5A,ENSG00000142530,Unsafe,RNA,False,True,74.5,74.5,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 7.4 nTPM; absolute ceiling; basal ganglia: 9 nTPM; absolute ceiling; cerebellum: 4.3 nTPM; absolute ceiling; cerebral cortex: 7.9 nTPM; absolute ceiling; choroid plexus: 2.6 nTPM; absolute ceiling; hippocampal formation: 5.2 nTPM; absolute ceiling; hypothalamus: 8.4 nTPM; absolute ceiling; kidney: 3.4 nTPM; absolute ceiling; liver: 2.6 nTPM; absolute ceiling; midbrain: 8.9 nTPM; absolute ceiling; pancreas: 2.3 nTPM; absolute ceiling; pituitary gland: 3.9 nTPM; absolute ceiling; skeletal muscle: 3.6 nTPM; absolute ceiling; spinal cord: 4 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 7.4 nTPM (limit 2); basal ganglia: 9 nTPM (limit 2); cerebellum: 4.3 nTPM (limit 2); cerebral cortex: 7.9 nTPM (limit 2); choroid plexus: 2.6 nTPM (limit 2); hippocampal formation: 5.2 nTPM (limit 2); hypothalamus: 8.4 nTPM (limit 2); kidney: 3.4 nTPM (limit 2); liver: 2.6 nTPM (limit 2); midbrain: 8.9 nTPM (limit 2); pancreas: 2.3 nTPM (limit 2); pituitary gland: 3.9 nTPM (limit 2); skeletal muscle: 3.6 nTPM (limit 2); spinal cord: 4 nTPM (limit 2); amygdala: 7.4 nTPM (baseline 2); basal ganglia: 9 nTPM (baseline 2); cerebellum: 4.3 nTPM (baseline 2); cerebral cortex: 7.9 nTPM (baseline 2); choroid plexus: 2.6 nTPM (baseline 2); hippocampal formation: 5.2 nTPM (baseline 2); hypothalamus: 8.4 nTPM (baseline 2); kidney: 3.4 nTPM (baseline 2); liver: 2.6 nTPM (baseline 2); midbrain: 8.9 nTPM (baseline 2); pancreas: 2.3 nTPM (baseline 2); pituitary gland: 3.9 nTPM (baseline 2); skeletal muscle: 3.6 nTPM (baseline 2); spinal cord: 4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 46/50 (92.0%); Ovary Serous Cystadenocarcinoma (TCGA): 320/349 (91.7%); Prostate Adenocarcinoma (TCGA): 386/480 (80.4%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q6IPT2,https://www.uniprot.org/uniprotkb/Q6IPT2/entry,RAB2B effector protein which promotes cytosolic DNA-induced innate immune responses. Regulates IFN responses against DNA viruses by regulating the CGAS-STING signaling axis,,,,Golgi apparatus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
GART,ENSG00000159131,Unsafe,Protein,False,True,28.5,37.5,80,78,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 23.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 19.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 11.4 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 12.5 nTPM; absolute ceiling;continuous selectivity; bone marrow: 18.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 10.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 18.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 10.7 nTPM; absolute ceiling;continuous selectivity; colon: 22.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 21.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 24.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 20 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 10.1 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 11.4 nTPM; absolute ceiling;continuous selectivity; kidney: 20.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 28.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 15.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 29.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 12.6 nTPM; absolute ceiling;continuous selectivity; pancreas: 21.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 19.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 12.4 nTPM; absolute ceiling;continuous selectivity; rectum: 28.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 20.1 nTPM; absolute ceiling;continuous selectivity; salivary gland: 16.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 28 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 16.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 18.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 25.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 13.3 nTPM; absolute ceiling;continuous selectivity; spleen: 19.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 19.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 33.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 20.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 20.9 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 31 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 23.3 nTPM (limit 10); adrenal gland: 19.6 nTPM (limit 2); amygdala: 11.4 nTPM (limit 2); basal ganglia: 12.5 nTPM (limit 2); bone marrow: 18.5 nTPM (limit 2); cerebellum: 10.4 nTPM (limit 2); cerebral cortex: 18.5 nTPM (limit 2); choroid plexus: 10.7 nTPM (limit 2); colon: 22.4 nTPM (limit 6); duodenum: 21.5 nTPM (limit 2); esophagus: 24.1 nTPM (limit 6); heart muscle: 20 nTPM (limit 4); hippocampal formation: 10.1 nTPM (limit 2); hypothalamus: 11.4 nTPM (limit 2); kidney: 20.2 nTPM (limit 2); liver: 28.7 nTPM (limit 2); lung: 15.5 nTPM (limit 2); lymph node: 29.5 nTPM (limit 6); midbrain: 12.6 nTPM (limit 2); pancreas: 21.7 nTPM (limit 2); parathyroid gland: 19.2 nTPM (limit 6); pituitary gland: 12.4 nTPM (limit 2); rectum: 28.1 nTPM (limit 6); retina: 20.1 nTPM (limit 2); salivary gland: 16.3 nTPM (limit 6); skeletal muscle: 28 nTPM (limit 2); skin: 16.8 nTPM (limit 10); small intestine: 18.8 nTPM (limit 2); smooth muscle: 25.3 nTPM (limit 2); spinal cord: 13.3 nTPM (limit 2); spleen: 19.5 nTPM (limit 10); stomach: 19.2 nTPM (limit 6); thymus: 33.5 nTPM (limit 10); thyroid gland: 20.2 nTPM (limit 10); tongue: 20.9 nTPM (limit 6); urinary bladder: 31 nTPM (limit 6),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Medium (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / fibroblasts: Low (Approved); skin 1 / keratinocytes: Low (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Squamous Cell Carcinoma (TCGA): 489/489 (100.0%); Stomach Adenocarcinoma (TCGA): 346/346 (100.0%); Colon Adenocarcinoma (TCGA): 254/254 (100.0%),cervical cancer: 12/12 (100.0%); melanoma: 11/11 (100.0%),31,20,P22102,https://www.uniprot.org/uniprotkb/P22102/entry,Trifunctional enzyme that catalyzes three distinct reactions as part of the 'de novo' inosine monophosphate biosynthetic pathway,,,,,12450384|12755606|20631005|2183217,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
GAST,ENSG00000184502,Unsafe,Protein,False,True,4.0,9294.1,74,1,Positive somewhere,True,True,False,False,Excluded,Normal,False,,Not assessed,,,positive normal IHC; positive ihc outside permitted; duodenum: 55.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 3.5 nTPM; absolute ceiling;continuous selectivity; spleen: 9.1 nTPM; continuous selectivity;reproductive not higher; stomach: 9294.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; thymus: 4.2 nTPM; continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",duodenum: 55.5 nTPM (limit 12); stomach: 9294.1 nTPM (limit 6); duodenum: 55.5 nTPM (baseline 2); lung: 3.5 nTPM (baseline 2); stomach: 9294.1 nTPM (baseline 6),stomach 2 / glandular cells: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Head and Neck Squamous Cell Carcinoma (TCGA): 211/492 (42.9%); Lung Squamous Cell Carcinoma (TCGA): 138/489 (28.2%); Lung Squamous Cell Carcinoma (validation): 13/68 (19.1%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),31,20,P01350,https://www.uniprot.org/uniprotkb/P01350/entry,Gastrin stimulates the stomach mucosa to produce and secrete hydrochloric acid and the pancreas to secrete its digestive enzymes. It also stimulates smooth muscle contraction and increases blood circulation and water secretion in the stomach and intestine,,,,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
GATC,ENSG00000257218,Unsafe,RNA,False,True,11.6,36.7,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 9.7 nTPM; continuous selectivity; adrenal gland: 10 nTPM; absolute ceiling;continuous selectivity; amygdala: 9.9 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 9.1 nTPM; absolute ceiling;continuous selectivity; bone marrow: 7.3 nTPM; absolute ceiling;continuous selectivity; cerebellum: 15 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 11.3 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 8.1 nTPM; absolute ceiling;continuous selectivity; colon: 9.8 nTPM; absolute ceiling;continuous selectivity; duodenum: 11.4 nTPM; absolute ceiling;continuous selectivity; esophagus: 8.5 nTPM; absolute ceiling;continuous selectivity; heart muscle: 6.4 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 11 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 10 nTPM; absolute ceiling;continuous selectivity; kidney: 14.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; liver: 15.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 8.3 nTPM; absolute ceiling;continuous selectivity; lymph node: 9.9 nTPM; absolute ceiling;continuous selectivity; midbrain: 11.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 36.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 12.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 7.7 nTPM; absolute ceiling;continuous selectivity; rectum: 10.3 nTPM; absolute ceiling;continuous selectivity; retina: 12.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 10.1 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 8.2 nTPM; absolute ceiling;continuous selectivity; skin: 9.2 nTPM; continuous selectivity; small intestine: 9.9 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 7.5 nTPM; absolute ceiling;continuous selectivity; spinal cord: 15.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 9 nTPM; continuous selectivity; stomach: 9.3 nTPM; absolute ceiling;continuous selectivity; thymus: 11.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 11.2 nTPM; absolute ceiling;continuous selectivity; tongue: 7.7 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 9.6 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 10 nTPM (limit 2); amygdala: 9.9 nTPM (limit 2); basal ganglia: 9.1 nTPM (limit 2); bone marrow: 7.3 nTPM (limit 2); cerebellum: 15 nTPM (limit 2); cerebral cortex: 11.3 nTPM (limit 2); choroid plexus: 8.1 nTPM (limit 2); colon: 9.8 nTPM (limit 6); duodenum: 11.4 nTPM (limit 2); esophagus: 8.5 nTPM (limit 6); heart muscle: 6.4 nTPM (limit 2); hippocampal formation: 11 nTPM (limit 2); hypothalamus: 10 nTPM (limit 2); kidney: 14.7 nTPM (limit 2); liver: 15.8 nTPM (limit 2); lung: 8.3 nTPM (limit 2); lymph node: 9.9 nTPM (limit 6); midbrain: 11.6 nTPM (limit 2); pancreas: 36.7 nTPM (limit 2); parathyroid gland: 12.6 nTPM (limit 6); pituitary gland: 7.7 nTPM (limit 2); rectum: 10.3 nTPM (limit 6); retina: 12.4 nTPM (limit 2); salivary gland: 10.1 nTPM (limit 6); skeletal muscle: 8.2 nTPM (limit 2); small intestine: 9.9 nTPM (limit 2); smooth muscle: 7.5 nTPM (limit 2); spinal cord: 15.2 nTPM (limit 2); stomach: 9.3 nTPM (limit 6); thymus: 11.6 nTPM (limit 10); thyroid gland: 11.2 nTPM (limit 10); tongue: 7.7 nTPM (limit 6); urinary bladder: 9.6 nTPM (limit 6); adrenal gland: 10 nTPM (baseline 2); amygdala: 9.9 nTPM (baseline 2); basal ganglia: 9.1 nTPM (baseline 2); bone marrow: 7.3 nTPM (baseline 2); cerebellum: 15 nTPM (baseline 2); cerebral cortex: 11.3 nTPM (baseline 2); choroid plexus: 8.1 nTPM (baseline 2); colon: 9.8 nTPM (baseline 6); duodenum: 11.4 nTPM (baseline 2); esophagus: 8.5 nTPM (baseline 6); heart muscle: 6.4 nTPM (baseline 2); hippocampal formation: 11 nTPM (baseline 2); hypothalamus: 10 nTPM (baseline 2); kidney: 14.7 nTPM (baseline 2); liver: 15.8 nTPM (baseline 2); lung: 8.3 nTPM (baseline 2); lymph node: 9.9 nTPM (baseline 6); midbrain: 11.6 nTPM (baseline 2); pancreas: 36.7 nTPM (baseline 2); parathyroid gland: 12.6 nTPM (baseline 6); pituitary gland: 7.7 nTPM (baseline 2); rectum: 10.3 nTPM (baseline 6); retina: 12.4 nTPM (baseline 2); salivary gland: 10.1 nTPM (baseline 6); skeletal muscle: 8.2 nTPM (baseline 2); small intestine: 9.9 nTPM (baseline 2); smooth muscle: 7.5 nTPM (baseline 2); spinal cord: 15.2 nTPM (baseline 2); stomach: 9.3 nTPM (baseline 6); thymus: 11.6 nTPM (baseline 10); thyroid gland: 11.2 nTPM (baseline 10); tongue: 7.7 nTPM (baseline 6); urinary bladder: 9.6 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Prostate Adenocarcinoma (TCGA): 480/480 (100.0%); Stomach Adenocarcinoma (TCGA): 346/346 (100.0%); Colon Adenocarcinoma (TCGA): 254/254 (100.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O43716,https://www.uniprot.org/uniprotkb/O43716/entry,Structural subunit of the mitochondrial Glu-tRNA(Gln) amidotransferase complex GatCAB. GatCAB allows the formation of correctly charged Gln-tRNA(Gln) through the transamidation of misacylated Glu-tRNA(Gln) in the mitochondria (PubMed:19805282). The reaction takes place in the presence of glutamine and ATP through an activated gamma-phospho-Glu-tRNA(Gln) (By similarity). This subunit probably forms a belt that wraps around the interface of the catalytic subunits A and B to stabilize the complex (Probable),,"Combined oxidative phosphorylation deficiency 42: An autosomal recessive mitochondrial disorder characterized by onset in the first months of life, cardiomyopathy, respiratory insufficiency, lactic acidosis, anemia, and variable impairment of mitochondrial respiratory complexes I, III, and IV. Death occurs in infancy.",,Mitochondrion,19805282,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
GBX1,ENSG00000164900,Unsafe,RNA,False,True,5.0,10.9,84,2,Positive somewhere,False,True,False,True,Excluded,Normal,False,,Not assessed,,,skeletal muscle: 10.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,skeletal muscle: 10.9 nTPM (limit 4),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 30/283 (10.6%); Head and Neck Squamous Cell Carcinoma (TCGA): 10/492 (2.0%); Lung Squamous Cell Carcinoma (validation): 1/68 (1.5%),breast cancer: 0/11 (0.0%); cervical cancer: 0/10 (0.0%),31,20,Q14549,https://www.uniprot.org/uniprotkb/Q14549/entry,,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
GCM1,ENSG00000137270,Unsafe,High RNA,False,True,19.5,19.5,81,2,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 51/91 values ≥5 TPM, max 10.9641",True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,10.9641299005,48.1,"hpa_single_cell_tissue: kidney/proximal tubular cells, max 48.1 nTPM, 2 observations >30",CTA,oncoref.target-sets.2026-10-23.2,10.96 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,48.1 nTPM; kidney/proximal tubular cells; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (validation): 7/50 (14.0%); Kidney Renal Papillary Cell Carcinoma (TCGA): 16/282 (5.7%); Testicular Germ Cell Tumor (TCGA): 6/133 (4.5%),lymphoma: 2/12 (16.7%); breast cancer: 0/12 (0.0%),31,20,Q9NP62,https://www.uniprot.org/uniprotkb/Q9NP62/entry,"Transcription factor involved in the control of expression of placental growth factor (PGF) and other placenta-specific genes (PubMed:10542267, PubMed:18160678). Binds to the trophoblast-specific element 2 (TSE2) of the aromatase gene enhancer (PubMed:10542267). Binds to the SYDE1 promoter (PubMed:27917469). Has a central role in mediating the differentiation of trophoblast cells along both the villous and extravillous pathways in placental development (PubMed:19219068)",Highly expressed in the placenta (PubMed:10542267). Expressed in trophoblast cells of the villi (PubMed:27917469),,,Nucleus,10542267|18160678|19219068|27917469,10542267|27917469,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Gong2021_reproductive_PC,No tumor-antigen validation in this source | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
GDAP2,ENSG00000196505,Unsafe,Protein,False,True,4.6,7.9,80,48,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 2.9 nTPM; positive ihc;continuous selectivity; adrenal gland: 2.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 1.3 nTPM; continuous selectivity; basal ganglia: 1.3 nTPM; continuous selectivity; bone marrow: 7.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 1.4 nTPM; positive ihc;continuous selectivity; cerebral cortex: 1.6 nTPM; positive ihc;continuous selectivity; choroid plexus: 2 nTPM; continuous selectivity; colon: 3.6 nTPM; positive ihc;continuous selectivity; duodenum: 3.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 3 nTPM; positive ihc;continuous selectivity; heart muscle: 2.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 1.3 nTPM; continuous selectivity; hypothalamus: 1.4 nTPM; continuous selectivity; kidney: 4.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 4.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 3.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 3.5 nTPM; continuous selectivity; midbrain: 1.4 nTPM; continuous selectivity; pancreas: 4.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 4.7 nTPM; continuous selectivity;reproductive not higher; pituitary gland: 2.3 nTPM; absolute ceiling;continuous selectivity; rectum: 4.3 nTPM; positive ihc;continuous selectivity; retina: 2.8 nTPM; absolute ceiling;continuous selectivity; salivary gland: 2.9 nTPM; positive ihc;continuous selectivity; skeletal muscle: 1.8 nTPM; continuous selectivity; skin: 2.8 nTPM; positive ihc;continuous selectivity; small intestine: 4.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 2.8 nTPM; continuous selectivity; spinal cord: 1.5 nTPM; continuous selectivity; spleen: 4.1 nTPM; continuous selectivity; stomach: 4.2 nTPM; positive ihc;continuous selectivity; thymus: 3.9 nTPM; continuous selectivity; thyroid gland: 4.5 nTPM; positive ihc;continuous selectivity; tongue: 2 nTPM; continuous selectivity; urinary bladder: 4.3 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 2.3 nTPM (limit 2); bone marrow: 7.9 nTPM (limit 2); duodenum: 3.9 nTPM (limit 2); heart muscle: 2.4 nTPM (limit 2); kidney: 4.6 nTPM (limit 2); liver: 4.9 nTPM (limit 4); lung: 3.3 nTPM (limit 2); pancreas: 4.3 nTPM (limit 2); pituitary gland: 2.3 nTPM (limit 2); retina: 2.8 nTPM (limit 2); small intestine: 4.5 nTPM (limit 2),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: High (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: High (Approved); cerebral cortex / neuronal cells: Medium (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / glial cells: Medium (Approved); kidney / cells in tubules: Low (Approved); lung / alveolar cells type II: High (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Low (Approved); pancreas / pancreatic endocrine cells: High (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: High (Approved); skin 1 / fibroblasts: Medium (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Medium (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: High (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 485/486 (99.8%),breast cancer: 8/9 (88.9%); urothelial cancer: 8/11 (72.7%),31,20,Q9NXN4,https://www.uniprot.org/uniprotkb/Q9NXN4/entry,,,"Spinocerebellar ataxia, autosomal recessive, 27: A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCAR27 is a progressive disease characterized by gait difficulties, eye movement abnormalities, dysarthria, and difficulty writing. Some patients may lose independent ambulation. Additional features include spasticity of the lower limbs and cognitive impairment.",,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
GDF5,ENSG00000125965,Unsafe,RNA,False,True,1.1,9.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 0.9 nTPM; continuous selectivity; basal ganglia: 0.6 nTPM; continuous selectivity; choroid plexus: 0.5 nTPM; continuous selectivity; colon: 1.5 nTPM; continuous selectivity;reproductive not higher; heart muscle: 0.4 nTPM; continuous selectivity; lung: 2.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 1.7 nTPM; continuous selectivity;reproductive not higher; salivary gland: 9.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 0.6 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,lung: 2.2 nTPM (limit 2); salivary gland: 9.6 nTPM (limit 6); lung: 2.2 nTPM (baseline 2); salivary gland: 9.6 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 55/176 (31.2%); Breast Invasive Carcinoma (validation): 5/50 (10.0%); Kidney Renal Papillary Cell Carcinoma (TCGA): 19/282 (6.7%),colorectal cancer: 11/11 (100.0%); lung cancer: 10/10 (100.0%),31,20,P43026,https://www.uniprot.org/uniprotkb/P43026/entry,"Growth factor involved in bone and cartilage formation. During cartilage development regulates differentiation of chondrogenic tissue through two pathways. Firstly, positively regulates differentiation of chondrogenic tissue through its binding of high affinity with BMPR1B and of less affinity with BMPR1A, leading to induction of SMAD1-SMAD5-SMAD8 complex phosphorylation and then SMAD protein signaling transduction (PubMed:15530414, PubMed:21976273, PubMed:24098149, PubMed:25092592). Secondly, negatively regulates chondrogenic differentiation through its interaction with NOG (PubMed:21976273). Required to prevent excessive muscle loss upon denervation. This function requires SMAD4 and is mediated by phosphorylated SMAD1/5/8 (By similarity). Binds bacterial lipopolysaccharide (LPS) and mediates LPS-induced inflammatory response, including TNF secretion by monocytes (PubMed:11276205)",Predominantly expressed in long bones during embryonic development. Expressed in monocytes (at protein level),"Acromesomelic dysplasia 2A: A form of acromesomelic dysplasia, a skeletal disorder characterized by short stature, very short limbs and hand/foot malformations. The severity of limb abnormalities increases from proximal to distal with profoundly affected hands and feet showing brachydactyly and/or rudimentary fingers (knob-like fingers). AMD2A is an autosomal recessive form characterized by normal axial skeletons and missing or fused skeletal elements within the hands and feet. Acromesomelic dysplasia 2C: A form of acromesomelic dysplasia, a skeletal disorder characterized by short stature, very short limbs and hand/foot malformations. The severity of limb abnormalities increases from proximal to distal with profoundly affected hands and feet showing brachydactyly and/or rudimentary fingers (knob-like fingers). AMD2C is an autosomal recessive form characterized by skeletal abnormalities restricted to the limbs. The craniofacial skeleton and axial skeletal structures are normal. Brachydactyly C: A form of brachydactyly. Brachydactyly defines a group of inherited malformations characterized by shortening of the digits due to abnormal development of the phalanges and/or the metacarpals. Brachydactyly type C is characterized by deformity of the middle and proximal phalanges of the second and third fingers, sometimes with hypersegmentation of the proximal phalanx. The ring finger may be essentially normal and project beyond the others. Acromesomelic dysplasia 2B: A form of acromesomelic dysplasia, a skeletal disorder characterized by short stature, very short limbs and hand/foot malformations. The severity of limb abnormalities increases from proximal to distal with profoundly affected hands and feet showing brachydactyly and/or rudimentary fingers (knob-like fingers). AMD2B is an autosomal recessive form characterized by acromesomelic limb shortening with severe reduction or absence of the fibula, and severe hand and feet abnormalities including complex brachydactyly. Symphalangism, proximal 1B: A disease characterized by the hereditary absence of the proximal interphalangeal joints. Distal interphalangeal joints are less frequently involved and metacarpophalangeal joints are rarely affected whereas carpal bone malformation and fusion are common. In the lower extremities, tarsal bone coalition is common. Conductive hearing loss is seen and is due to fusion of the stapes to the petrous part of the temporal bone. Multiple synostoses syndrome 2: A bone disease characterized by multiple progressive joint fusions that commonly involve proximal interphalangeal, tarsal-carpal, humeroradial and cervical spine joints. Additional features can include progressive conductive deafness and facial dysmorphism. Brachydactyly A2: A form of brachydactyly. Brachydactyly defines a group of inherited malformations characterized by shortening of the digits due to abnormal development of the phalanges and/or the metacarpals. In brachydactyly type A2 shortening of the middle phalanges is confined to the index finger and the second toe, all other digits being more or less normal. Because of a rhomboid or triangular shape of the affected middle phalanx, the end of the second finger usually deviates radially. Osteoarthritis 5: A degenerative disease of the joints characterized by degradation of the hyaline articular cartilage and remodeling of the subchondral bone with sclerosis. Clinical symptoms include pain and joint stiffness often leading to significant disability and joint replacement. Brachydactyly A1, C: A form of brachydactyly type A1. Brachydactyly defines a group of inherited malformations characterized by shortening of the digits due to abnormal development of the phalanges and/or the metacarpals. Brachydactyly type A1 is characterized by middle phalanges of all the digits rudimentary or fused with the terminal phalanges. The proximal phalanges of the thumbs and big toes are short. BDA1C inheritance can be autosomal dominant or autosomal recessive. Autosomal dominant BDA1C has a milder phenotype.",,Secreted Cell membrane,11276205|15530414|19229295|19956691|21976273|24098149|25092592,11276205,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
GDF6,ENSG00000156466,Unsafe,RNA,False,True,10.5,10.5,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,heart muscle: 2.7 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,heart muscle: 2.7 nTPM (limit 2); heart muscle: 2.7 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Renal Clear Cell Carcinoma (validation): 47/100 (47.0%); Kidney Renal Clear Cell Carcinoma (TCGA): 227/521 (43.6%); Testicular Germ Cell Tumor (TCGA): 11/133 (8.3%),melanoma: 11/12 (91.7%); prostate cancer: 3/12 (25.0%),31,20,Q6KF10,https://www.uniprot.org/uniprotkb/Q6KF10/entry,"Growth factor that controls proliferation and cellular differentiation in the retina and bone formation. Plays a key role in regulating apoptosis during retinal development. Establishes dorsal-ventral positional information in the retina and controls the formation of the retinotectal map (PubMed:23307924). Required for normal formation of bones and joints in the limbs, skull, digits and axial skeleton. Plays a key role in establishing boundaries between skeletal elements during development. Regulation of GDF6 expression seems to be a mechanism for evolving species-specific changes in skeletal structures. Seems to positively regulate differentiation of chondrogenic tissue through the growth factor receptors subunits BMPR1A, BMPR1B, BMPR2 and ACVR2A, leading to the activation of SMAD1-SMAD5-SMAD8 complex. The regulation of chondrogenic differentiation is inhibited by NOG (PubMed:26643732). Also involved in the induction of adipogenesis from mesenchymal stem cells. This mechanism acts through the growth factor receptors subunits BMPR1A, BMPR2 and ACVR2A and the activation of SMAD1-SMAD5-SMAD8 complex and MAPK14/p38 (By similarity)",,"Klippel-Feil syndrome 1, autosomal dominant: A skeletal disorder characterized by congenital fusion of cervical vertebrae. It is due to a failure in the normal segmentation of vertebrae during the early weeks of fetal development. The clinical triad consists of short neck, low posterior hairline, and limited neck movement. Deafness is a feature in some cases and may be of sensorineural, conductive, or mixed type. Microphthalmia, isolated, 4: A disorder of eye formation, ranging from small size of a single eye to complete bilateral absence of ocular tissues. Ocular abnormalities like opacities of the cornea and lens, scaring of the retina and choroid, and other abnormalities may also be present. Leber congenital amaurosis 17: A severe dystrophy of the retina, typically becoming evident in the first years of life. Visual function is usually poor and often accompanied by nystagmus, sluggish or almost absent pupillary responses, photophobia, high hyperopia and keratoconus. Multiple synostoses syndrome 4: A bone disease characterized by multiple progressive joint fusions that commonly involve proximal interphalangeal, tarsal-carpal, humeroradial and cervical spine joints. Additional features can include progressive conductive deafness and facial dysmorphism. SYNS4 inheritance is autosomal dominant. Deafness, autosomal recessive, 118, with cochlear aplasia: A form of non-syndromic deafness characterized by congenital profound sensorineural hearing loss and cochlear aplasia. Sensorineural hearing loss results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information.",,Secreted,23307924|26643732,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
GDPD1,ENSG00000153982,Unsafe,RNA,False,True,8.3,11.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 5.2 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 5.8 nTPM; absolute ceiling;continuous selectivity; cerebellum: 10 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 11.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 2.9 nTPM; absolute ceiling;continuous selectivity; duodenum: 5.6 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 6 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 7.6 nTPM; absolute ceiling;continuous selectivity; lung: 2.2 nTPM; absolute ceiling;continuous selectivity; midbrain: 4.9 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 5.7 nTPM; continuous selectivity; retina: 5.6 nTPM; absolute ceiling;continuous selectivity; small intestine: 4.1 nTPM; absolute ceiling;continuous selectivity; spinal cord: 4.3 nTPM; absolute ceiling;continuous selectivity; stomach: 5 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 5.2 nTPM (limit 2); basal ganglia: 5.8 nTPM (limit 2); cerebellum: 10 nTPM (limit 2); cerebral cortex: 11.6 nTPM (limit 2); choroid plexus: 2.9 nTPM (limit 2); duodenum: 5.6 nTPM (limit 2); hippocampal formation: 6 nTPM (limit 2); hypothalamus: 7.6 nTPM (limit 2); lung: 2.2 nTPM (limit 2); midbrain: 4.9 nTPM (limit 2); retina: 5.6 nTPM (limit 2); small intestine: 4.1 nTPM (limit 2); spinal cord: 4.3 nTPM (limit 2); amygdala: 5.2 nTPM (baseline 2); basal ganglia: 5.8 nTPM (baseline 2); cerebellum: 10 nTPM (baseline 2); cerebral cortex: 11.6 nTPM (baseline 2); choroid plexus: 2.9 nTPM (baseline 2); duodenum: 5.6 nTPM (baseline 2); hippocampal formation: 6 nTPM (baseline 2); hypothalamus: 7.6 nTPM (baseline 2); lung: 2.2 nTPM (baseline 2); midbrain: 4.9 nTPM (baseline 2); retina: 5.6 nTPM (baseline 2); small intestine: 4.1 nTPM (baseline 2); spinal cord: 4.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 56/58 (96.6%); Breast Invasive Carcinoma (validation): 43/50 (86.0%); Glioblastoma Multiforme (TCGA): 95/141 (67.4%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8N9F7,https://www.uniprot.org/uniprotkb/Q8N9F7/entry,"Hydrolyzes lysoglycerophospholipids to produce lysophosphatidic acid (LPA) and the corresponding amines (PubMed:25596343, PubMed:27637550). Shows a preference for 1-O-alkyl-sn-glycero-3-phosphocholine (lyso-PAF), lysophosphatidylethanolamine (lyso-PE) and lysophosphatidylcholine (lyso-PC) (PubMed:25596343, PubMed:27637550). May be involved in bioactive N-acylethanolamine biosynthesis from both N-acyl-lysoplasmenylethanolamin (N-acyl-lysoPlsEt) and N-acyl-lysophosphatidylethanolamin (N-acyl-lysoPE) (PubMed:25596343, PubMed:27637550). In addition, hydrolyzes glycerophospho-N-acylethanolamine to N-acylethanolamine (PubMed:27637550). Does not display glycerophosphodiester phosphodiesterase activity, since it cannot hydrolyze either glycerophosphoinositol or glycerophosphocholine (By similarity)",Widely expressed with high expression level in testis,,,"Cytoplasm Membrane Cytoplasm, perinuclear region Endoplasmic reticulum",25596343|27637550,16147865|27637550,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
GEN1,ENSG00000178295,Unsafe,Protein,False,True,9.0,15.0,79,66,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 1.7 nTPM; positive ihc; bone marrow: 15 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 1.1 nTPM; positive ihc; cerebral cortex: 1.3 nTPM; positive ihc; choroid plexus: 4.2 nTPM; absolute ceiling;continuous selectivity; colon: 5 nTPM; positive ihc;continuous selectivity; duodenum: 3.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 5.4 nTPM; positive ihc;continuous selectivity; heart muscle: 2.2 nTPM; positive ihc;absolute ceiling; kidney: 1.7 nTPM; positive ihc; liver: 8.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 1.9 nTPM; positive ihc; lymph node: 10.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 2.2 nTPM; positive ihc;absolute ceiling; parathyroid gland: 1 nTPM; positive ihc; pituitary gland: 2.9 nTPM; absolute ceiling;continuous selectivity; rectum: 6.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 2.4 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 1.7 nTPM; positive ihc; skin: 7.3 nTPM; positive ihc;continuous selectivity; small intestine: 4.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 1.3 nTPM; positive ihc; spleen: 5 nTPM; positive ihc;continuous selectivity; stomach: 2.9 nTPM; positive ihc; thymus: 5.3 nTPM; continuous selectivity; thyroid gland: 1.8 nTPM; positive ihc; urinary bladder: 1.5 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 15 nTPM (limit 2); choroid plexus: 4.2 nTPM (limit 2); duodenum: 3.1 nTPM (limit 2); heart muscle: 2.2 nTPM (limit 2); liver: 8.4 nTPM (limit 2); lymph node: 10.5 nTPM (limit 6); pancreas: 2.2 nTPM (limit 2); pituitary gland: 2.9 nTPM (limit 2); rectum: 6.7 nTPM (limit 6); retina: 2.4 nTPM (limit 2); small intestine: 4.4 nTPM (limit 2),adrenal gland / glandular cells: Medium (Enhanced); bone marrow / hematopoietic cells: Medium (Enhanced); bronchus / respiratory epithelial cells: Medium (Enhanced); cerebellum / cells in granular layer: Medium (Enhanced); cerebellum / Purkinje cells: Medium (Enhanced); cerebral cortex / glial cells: Low (Enhanced); cerebral cortex / neuropil: Medium (Enhanced); colon / endothelial cells: Medium (Enhanced); colon / glandular cells: Medium (Enhanced); colon / peripheral nerve/ganglion: Medium (Enhanced); duodenum / glandular cells: Medium (Enhanced); esophagus / squamous epithelial cells: Medium (Enhanced); heart muscle / cardiomyocytes: Medium (Enhanced); hippocampus / neuronal cells: Medium (Enhanced); kidney / cells in glomeruli: Low (Enhanced); kidney / cells in tubules: Medium (Enhanced); liver / hepatocytes: Medium (Enhanced); lung / alveolar cells: Low (Enhanced); lung / macrophages: Medium (Enhanced); lymph node / germinal center cells: Medium (Enhanced); lymph node / non-germinal center cells: Medium (Enhanced); nasopharynx / respiratory epithelial cells: Low (Enhanced); oral mucosa / squamous epithelial cells: Medium (Enhanced); pancreas / exocrine glandular cells: Medium (Enhanced); pancreas / pancreatic endocrine cells: Low (Enhanced); parathyroid gland / glandular cells: Medium (Enhanced); rectum / glandular cells: Medium (Enhanced); skeletal muscle / myocytes: Medium (Enhanced); skin 1 / fibroblasts: Medium (Enhanced); skin 1 / keratinocytes: Low (Enhanced); skin 1 / Langerhans: Low (Enhanced); skin 2 / epidermal cells: Medium (Enhanced); small intestine / glandular cells: Medium (Enhanced); smooth muscle / smooth muscle cells: Low (Enhanced); spleen / cells in red pulp: Medium (Enhanced); spleen / cells in white pulp: Medium (Enhanced); stomach 1 / glandular cells: Medium (Enhanced); stomach 2 / glandular cells: Medium (Enhanced); thyroid gland / glandular cells: Medium (Enhanced); urinary bladder / urothelial cells: Medium (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 483/486 (99.4%); Rectum Adenocarcinoma (validation): 204/207 (98.6%),pancreatic cancer: 6/7 (85.7%); liver cancer: 9/12 (75.0%),31,20,Q17RS7,https://www.uniprot.org/uniprotkb/Q17RS7/entry,"Endonuclease which resolves Holliday junctions (HJs) by the introduction of symmetrically related cuts across the junction point, to produce nicked duplex products in which the nicks can be readily ligated. Four-way DNA intermediates, also known as Holliday junctions, are formed during homologous recombination and DNA repair, and their resolution is necessary for proper chromosome segregation (PubMed:19020614, PubMed:26682650). Cleaves HJs by a nick and counter-nick mechanism involving dual coordinated incisions that lead to the formation of ligatable nicked duplex products. Cleavage of the first strand is rate limiting, while second strand cleavage is rapid. Largely monomeric, dimerizes on the HJ and the first nick occurs upon dimerization at the junction (PubMed:26578604). Efficiently cleaves both single and double HJs contained within large recombination intermediates. Exhibits a weak sequence preference for incision between two G residues that reside in a T-rich region of DNA (PubMed:28049850). Also has endonuclease activity on 5'-flap and replication fork (RF) DNA substrates (PubMed:26578604)",,,,Nucleus,19020614|26578604|26682650|28049850,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
GGN,ENSG00000179168,Unsafe,RNA,False,True,93.6,93.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,cerebral cortex: 2.1 nTPM; absolute ceiling; duodenum: 2.7 nTPM; absolute ceiling; small intestine: 2.8 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebral cortex: 2.1 nTPM (limit 2); duodenum: 2.7 nTPM (limit 2); small intestine: 2.8 nTPM (limit 2); cerebral cortex: 2.1 nTPM (baseline 2); duodenum: 2.7 nTPM (baseline 2); small intestine: 2.8 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 6/50 (12.0%); Glioblastoma Multiforme (TCGA): 8/141 (5.7%); Ovary Serous Cystadenocarcinoma (TCGA): 17/349 (4.9%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q86UU5,https://www.uniprot.org/uniprotkb/Q86UU5/entry,May be involved in spermatogenesis,,"Spermatogenic failure 69: An autosomal recessive male infertility disorder characterized by low sperm concentrations, globozoospermia, and absence of sperm acrosome.",,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
GGTLC2,ENSG00000100121,Unsafe,RNA,False,True,24.1,24.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 2.2 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 2.2 nTPM (limit 2); bone marrow: 2.2 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Renal Papillary Cell Carcinoma (TCGA): 24/282 (8.5%); Thyroid Carcinoma (TCGA): 36/495 (7.3%); Lung Adenocarcinoma (TCGA): 20/497 (4.0%),renal cancer: 5/12 (41.7%); liver cancer: 4/11 (36.4%),31,20,Q14390,https://www.uniprot.org/uniprotkb/Q14390/entry,,Placenta and sigmoid tissues,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | Loriot2025_S2 | Gong2021_reproductive_PC,GC RNA nomination across cancer types; no antigen validation asserted | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,Failed bulk numeric comparisons are within 20% of their cutoffs; not an automatic rescue,,,,
GH2,ENSG00000136487,Unsafe,Protein,False,True,123.9,123.9,80,2,Positive somewhere,True,True,False,True,Excluded,Normal,False,,Not assessed,,,positive ihc outside permitted; pituitary gland: 99.7 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",pituitary gland: 99.7 nTPM (limit 2),pituitary gland / cells in anterior : High (Supported),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 3/133 (2.3%); Uterine Corpus Endometrial Carcinoma (TCGA): 2/176 (1.1%); Lung Adenocarcinoma (TCGA): 3/497 (0.6%),breast cancer: 0/12 (0.0%); cervical cancer: 0/12 (0.0%),31,20,P01242,https://www.uniprot.org/uniprotkb/P01242/entry,Plays an important role in growth control. Its major role in stimulating body growth is to stimulate the liver and other tissues to secrete IGF1. It stimulates both the differentiation and proliferation of myoblasts. It also stimulates amino acid uptake and protein synthesis in muscle and other tissues,Expressed in the placenta,,,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Gong2021_reproductive_PC,No tumor-antigen validation in this source | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
GINS1,ENSG00000101003,Unsafe,Protein,False,True,8.8,8.8,76,43,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 0.6 nTPM; positive ihc; bone marrow: 3.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 3.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 1.3 nTPM; positive ihc; colon: 3.3 nTPM; positive ihc;continuous selectivity; duodenum: 2.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 4.1 nTPM; positive ihc;continuous selectivity; kidney: 1.1 nTPM; positive ihc; liver: 1.2 nTPM; positive ihc; lung: 0.5 nTPM; positive ihc; lymph node: 5 nTPM; positive ihc;continuous selectivity; pancreas: 0.4 nTPM; positive ihc; rectum: 3.4 nTPM; positive ihc;continuous selectivity; small intestine: 2.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; spleen: 1.4 nTPM; positive ihc; stomach: 1.9 nTPM; positive ihc; thymus: 7.1 nTPM; continuous selectivity; thyroid gland: 0.6 nTPM; positive ihc; urinary bladder: 1.2 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 3.8 nTPM (limit 2); cerebellum: 3.1 nTPM (limit 2); duodenum: 2.9 nTPM (limit 2); small intestine: 2.8 nTPM (limit 2); bone marrow: 3.8 nTPM (baseline 2); cerebellum: 3.1 nTPM (baseline 2); duodenum: 2.9 nTPM (baseline 2); small intestine: 2.8 nTPM (baseline 2),adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / Purkinje cells: Low (Uncertain); cerebral cortex / neuronal cells: Low (Uncertain); colon / glandular cells: Medium (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); hippocampus / neuronal cells: Low (Uncertain); kidney / cells in glomeruli: Low (Uncertain); kidney / cells in tubules: High (Uncertain); liver / hepatocytes: Low (Uncertain); lung / alveolar cells: Low (Uncertain); lymph node / germinal center cells: Medium (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); oral mucosa / squamous epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); rectum / glandular cells: Medium (Uncertain); small intestine / glandular cells: Medium (Uncertain); spleen / cells in red pulp: Low (Uncertain); spleen / cells in white pulp: Low (Uncertain); stomach 1 / glandular cells: Low (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: High (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 280/283 (98.9%); Glioblastoma Multiforme (validation): 57/58 (98.3%); Colon Adenocarcinoma (validation): 473/486 (97.3%),renal cancer: 11/12 (91.7%); testis cancer: 8/9 (88.9%),31,20,Q14691,https://www.uniprot.org/uniprotkb/Q14691/entry,"Required for correct functioning of the GINS complex, a complex that plays an essential role in the initiation of DNA replication, and progression of DNA replication forks (PubMed:17417653, PubMed:28414293). GINS complex is a core component of CDC45-MCM-GINS (CMG) helicase, the molecular machine that unwinds template DNA during replication, and around which the replisome is built (PubMed:32453425, PubMed:34694004, PubMed:34700328, PubMed:35585232)",,"Immunodeficiency 55: An autosomal recessive primary immunodeficiency characterized by chronic neutropenia, natural killer cell deficiency, recurrent viral and bacterial infections, and intrauterine growth retardation. Postnatal growth retardation is present in most patients.",,Nucleus Chromosome,17417653|28414293|32453425|34694004|34700328|35585232,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
GINS4,ENSG00000147536,Unsafe,Protein,False,True,2.8,6.0,80,79,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0.8 nTPM; positive ihc; adrenal gland: 0.7 nTPM; positive ihc; bone marrow: 5.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 0.3 nTPM; positive ihc; cerebral cortex: 0.9 nTPM; positive ihc;continuous selectivity; colon: 2 nTPM; positive ihc;continuous selectivity; duodenum: 1.5 nTPM; positive ihc;continuous selectivity; esophagus: 1.6 nTPM; positive ihc;continuous selectivity; heart muscle: 0.7 nTPM; positive ihc; kidney: 0.6 nTPM; positive ihc; liver: 1.3 nTPM; positive ihc;continuous selectivity; lung: 0.7 nTPM; positive ihc; lymph node: 5 nTPM; positive ihc;continuous selectivity;reproductive not higher; pancreas: 0.8 nTPM; positive ihc;continuous selectivity; parathyroid gland: 0.6 nTPM; positive ihc; rectum: 2.9 nTPM; positive ihc;continuous selectivity;reproductive not higher; retina: 0.8 nTPM; continuous selectivity; salivary gland: 0.7 nTPM; positive ihc; skeletal muscle: 0.5 nTPM; positive ihc; skin: 2 nTPM; positive ihc;continuous selectivity; small intestine: 1.6 nTPM; positive ihc;continuous selectivity; smooth muscle: 1.4 nTPM; positive ihc;continuous selectivity; spinal cord: 1 nTPM; continuous selectivity; spleen: 1.6 nTPM; positive ihc;continuous selectivity; stomach: 1.2 nTPM; positive ihc;continuous selectivity; thymus: 6 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 1.2 nTPM; positive ihc; urinary bladder: 1.1 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 5.7 nTPM (limit 2); bone marrow: 5.7 nTPM (baseline 2),adipose tissue / adipocytes: Low (Uncertain); adrenal gland / glandular cells: High (Uncertain); bone marrow / hematopoietic cells: High (Uncertain); bronchus / respiratory epithelial cells: High (Uncertain); caudate / glial cells: Medium (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: Medium (Uncertain); cerebellum / cells in molecular layer: Medium (Uncertain); cerebellum / Purkinje cells: Low (Uncertain); cerebral cortex / endothelial cells: Low (Uncertain); cerebral cortex / glial cells: Medium (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); colon / endothelial cells: Medium (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: Medium (Uncertain); duodenum / glandular cells: High (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / glial cells: Medium (Uncertain); hippocampus / neuronal cells: Low (Uncertain); kidney / cells in glomeruli: Low (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / cholangiocytes: Low (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / alveolar cells: Medium (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / germinal center cells: Medium (Uncertain); lymph node / non-germinal center cells: Medium (Uncertain); nasopharynx / respiratory epithelial cells: High (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Low (Uncertain); parathyroid gland / glandular cells: High (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: Low (Uncertain); skin 1 / fibroblasts: Low (Uncertain); skin 1 / keratinocytes: Low (Uncertain); skin 1 / Langerhans: Medium (Uncertain); skin 2 / epidermal cells: High (Uncertain); small intestine / glandular cells: Medium (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); spleen / cells in red pulp: Medium (Uncertain); spleen / cells in white pulp: Low (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 441/486 (90.7%); Testicular Germ Cell Tumor (TCGA): 120/133 (90.2%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 248/283 (87.6%),melanoma: 9/9 (100.0%); prostate cancer: 10/11 (90.9%),31,20,Q9BRT9,https://www.uniprot.org/uniprotkb/Q9BRT9/entry,"Required for correct functioning of the GINS complex, a complex that plays an essential role in the initiation of DNA replication, and progression of DNA replication forks (PubMed:17417653, PubMed:28414293). GINS complex is a core component of CDC45-MCM-GINS (CMG) helicase, the molecular machine that unwinds template DNA during replication, and around which the replisome is built (PubMed:32453425, PubMed:34694004, PubMed:34700328, PubMed:35585232)",,,,Nucleus Chromosome Cytoplasm,17417653|28414293|32453425|34694004|34700328|35585232,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
GIP,ENSG00000159224,Unsafe,Protein,False,True,0.5,251.8,102,2,Positive somewhere,True,True,False,False,Excluded,Normal,False,,Not assessed,,,positive normal IHC; positive ihc outside permitted; colon: 0.3 nTPM; continuous selectivity; duodenum: 251.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 91.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; stomach: 1.2 nTPM; continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",duodenum: 251.8 nTPM (limit 2); small intestine: 91.2 nTPM (limit 2); duodenum: 251.8 nTPM (baseline 2); small intestine: 91.2 nTPM (baseline 2),duodenum / endocrine cells: High (Enhanced); small intestine / endocrine cells: High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 94/133 (70.7%); Pancreatic Adenocarcinoma (TCGA): 6/176 (3.4%); Stomach Adenocarcinoma (TCGA): 10/346 (2.9%),breast cancer: 0/11 (0.0%); cervical cancer: 0/11 (0.0%),31,20,P09681,https://www.uniprot.org/uniprotkb/P09681/entry,Potent stimulator of insulin secretion and relatively poor inhibitor of gastric acid secretion,,,,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
GJA8,ENSG00000121634,Unsafe,Protein,False,True,5.7,5.7,86,1,Positive somewhere,True,False,False,False,Excluded,Normal,False,,Not assessed,,,positive ihc outside permitted,"Positive IHC in a Vital, Protected or Manageable compartment",,eye / lens fiber cells: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Ovary Serous Cystadenocarcinoma (TCGA): 7/349 (2.0%); Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Kidney Renal Papillary Cell Carcinoma (TCGA): 2/282 (0.7%),breast cancer: 0/10 (0.0%); cervical cancer: 0/12 (0.0%),31,20,P48165,https://www.uniprot.org/uniprotkb/P48165/entry,"Structural component of eye lens gap junctions (PubMed:18006672, PubMed:19756179). Gap junctions are dodecameric channels that connect the cytoplasm of adjoining cells. They are formed by the docking of two hexameric hemichannels, one from each cell membrane (By similarity). Small molecules and ions diffuse from one cell to a neighboring cell via the central pore (PubMed:18006672, PubMed:19756179)",Eye lens,"Cataract 1, multiple types: An opacification of the crystalline lens of the eye that frequently results in visual impairment or blindness. Opacities vary in morphology, are often confined to a portion of the lens, and may be static or progressive. CTRCT1 includes congenital, zonular pulverulent, nuclear progressive, nuclear pulverulent, nuclear total, total, and posterior subcapsular types of cataract. Zonular or lamellar cataracts are opacities, broad or narrow, usually consisting of powdery white dots affecting only certain layers or zones between the cortex and nucleus of an otherwise clear lens. The opacity may be so dense as to render the entire central region of the lens completely opaque, or so translucent that vision is hardly if at all impeded. Zonular cataracts generally do not involve the embryonic nucleus, though sometimes they involve the fetal nucleus. Usually sharply separated from a clear cortex outside them, they may have projections from their outer edges known as riders or spokes. In some cases cataract is associated with microcornea without any other systemic anomaly or dysmorphism. Microcornea is defined by a corneal diameter inferior to 10 mm in both meridians in an otherwise normal eye.",,"Cell membrane Cell junction, gap junction",16397066|18006672|19756179|35531093,19756179,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Carter2023_CT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
GKAP1,ENSG00000165113,Unsafe,Protein,False,True,194.6,194.6,119,6,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 12.2 nTPM; absolute ceiling; basal ganglia: 10.4 nTPM; absolute ceiling; cerebellum: 18.6 nTPM; positive ihc;absolute ceiling; choroid plexus: 14.6 nTPM; absolute ceiling; colon: 11.7 nTPM; absolute ceiling; duodenum: 4.5 nTPM; absolute ceiling; heart muscle: 14.4 nTPM; absolute ceiling; hippocampal formation: 10.6 nTPM; absolute ceiling; hypothalamus: 14.1 nTPM; absolute ceiling; midbrain: 14.4 nTPM; absolute ceiling; pituitary gland: 12.2 nTPM; absolute ceiling; retina: 22.1 nTPM; absolute ceiling; skeletal muscle: 48.5 nTPM; absolute ceiling; small intestine: 5.2 nTPM; absolute ceiling; spinal cord: 13.1 nTPM; absolute ceiling; tongue: 25.5 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 12.2 nTPM (limit 2); basal ganglia: 10.4 nTPM (limit 2); cerebellum: 18.6 nTPM (limit 2); choroid plexus: 14.6 nTPM (limit 2); colon: 11.7 nTPM (limit 6); duodenum: 4.5 nTPM (limit 2); heart muscle: 14.4 nTPM (limit 12); hippocampal formation: 10.6 nTPM (limit 2); hypothalamus: 14.1 nTPM (limit 2); midbrain: 14.4 nTPM (limit 2); pituitary gland: 12.2 nTPM (limit 2); retina: 22.1 nTPM (limit 2); skeletal muscle: 48.5 nTPM (limit 12); small intestine: 5.2 nTPM (limit 2); spinal cord: 13.1 nTPM (limit 2); tongue: 25.5 nTPM (limit 6),cerebellum / Purkinje cells - cytoplasm/membrane: Low (Enhanced); cerebellum / Purkinje cells - dendrites: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Prostate Adenocarcinoma (TCGA): 447/480 (93.1%); Breast Invasive Carcinoma (validation): 46/50 (92.0%),breast cancer: 0/12 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q5VSY0,https://www.uniprot.org/uniprotkb/Q5VSY0/entry,Regulates insulin-dependent IRS1 tyrosine phosphorylation in adipocytes by modulating the availability of IRS1 to IR tyrosine kinase. Its association with IRS1 is required for insulin-induced translocation of SLC2A4 to the cell membrane. Involved in TNF-induced impairment of insulin-dependent IRS1 tyrosine phosphorylation,,,,Golgi apparatus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
GLIPR1L2,ENSG00000180481,Unsafe,Protein,False,True,45.3,45.3,90,7,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 3.9 nTPM; absolute ceiling; basal ganglia: 3.9 nTPM; absolute ceiling; bone marrow: 0.3 nTPM; positive ihc; hippocampal formation: 3.7 nTPM; absolute ceiling; hypothalamus: 3.4 nTPM; absolute ceiling; kidney: 1.9 nTPM; positive ihc; lymph node: 0.7 nTPM; positive ihc; midbrain: 5.3 nTPM; absolute ceiling; pituitary gland: 2.5 nTPM; absolute ceiling; retina: 2.7 nTPM; absolute ceiling; spinal cord: 6.4 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 3.9 nTPM (limit 2); basal ganglia: 3.9 nTPM (limit 2); hippocampal formation: 3.7 nTPM (limit 2); hypothalamus: 3.4 nTPM (limit 2); midbrain: 5.3 nTPM (limit 2); pituitary gland: 2.5 nTPM (limit 2); retina: 2.7 nTPM (limit 2); spinal cord: 6.4 nTPM (limit 2),bone marrow / hematopoietic cells: Low (Enhanced); kidney / cells in tubules: Low (Enhanced); lymph node / non-germinal center cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 74/80 (92.5%); Glioblastoma Multiforme (validation): 29/58 (50.0%); Breast Invasive Carcinoma (validation): 19/50 (38.0%),breast cancer: 0/12 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q4G1C9,https://www.uniprot.org/uniprotkb/Q4G1C9/entry,,"Highly expressed in testis. Detected in prostate, kidney, bladder, lung and bone marrow",,,Membrane,,16714093,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
GLUD2,ENSG00000182890,Unsafe,Protein,False,True,15.0,15.0,88,82,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 1.6 nTPM; positive ihc; adrenal gland: 1.7 nTPM; positive ihc; bone marrow: 0 nTPM; positive ihc; cerebellum: 0.3 nTPM; positive ihc; cerebral cortex: 1.7 nTPM; positive ihc; colon: 0.4 nTPM; positive ihc; duodenum: 0 nTPM; positive ihc; esophagus: 0.5 nTPM; positive ihc; heart muscle: 0.8 nTPM; positive ihc; kidney: 1.6 nTPM; positive ihc; liver: 3.8 nTPM; positive ihc;absolute ceiling; lung: 0.5 nTPM; positive ihc; lymph node: 0.1 nTPM; positive ihc; pancreas: 1 nTPM; positive ihc; parathyroid gland: 0.5 nTPM; positive ihc; rectum: 0 nTPM; positive ihc; salivary gland: 0.6 nTPM; positive ihc; skeletal muscle: 0.5 nTPM; positive ihc; skin: 0.5 nTPM; positive ihc; small intestine: 0.4 nTPM; positive ihc; smooth muscle: 0.1 nTPM; positive ihc; spleen: 0.1 nTPM; positive ihc; stomach: 0.6 nTPM; positive ihc; thyroid gland: 0.4 nTPM; positive ihc; urinary bladder: 0.4 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",liver: 3.8 nTPM (limit 2); liver: 3.8 nTPM (baseline 2),adipose tissue / adipocytes: Medium (Uncertain); adrenal gland / glandular cells: High (Uncertain); bone marrow / hematopoietic cells: Low (Uncertain); bronchus / respiratory epithelial cells: High (Uncertain); caudate / glial cells: High (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: Medium (Uncertain); cerebellum / cells in molecular layer: Medium (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / endothelial cells: High (Uncertain); cerebral cortex / glial cells: High (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: High (Uncertain); colon / endothelial cells: Medium (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: Low (Uncertain); duodenum / glandular cells: High (Uncertain); esophagus / squamous epithelial cells: High (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / glial cells: High (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in glomeruli: Low (Uncertain); kidney / cells in tubules: High (Uncertain); liver / cholangiocytes: Low (Uncertain); liver / hepatocytes: High (Uncertain); lung / alveolar cells: Low (Uncertain); lung / macrophages: High (Uncertain); lymph node / germinal center cells: High (Uncertain); lymph node / non-germinal center cells: High (Uncertain); nasopharynx / respiratory epithelial cells: High (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: High (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); parathyroid gland / glandular cells: High (Uncertain); rectum / glandular cells: High (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: Low (Uncertain); skin 1 / fibroblasts: Medium (Uncertain); skin 1 / keratinocytes: Low (Uncertain); skin 1 / Langerhans: Medium (Uncertain); skin 2 / epidermal cells: High (Uncertain); small intestine / glandular cells: High (Uncertain); smooth muscle / smooth muscle cells: High (Uncertain); spleen / cells in red pulp: High (Uncertain); spleen / cells in white pulp: High (Uncertain); stomach 1 / glandular cells: High (Uncertain); stomach 2 / glandular cells: High (Uncertain); thyroid gland / glandular cells: High (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 46/50 (92.0%); Glioblastoma Multiforme (validation): 29/58 (50.0%); Liver Hepatocellular Carcinoma (validation): 89/231 (38.5%),breast cancer: 12/12 (100.0%); colorectal cancer: 12/12 (100.0%),31,20,P49448,https://www.uniprot.org/uniprotkb/P49448/entry,Catalyzes the oxidative deamination of glutamate to alpha-ketoglutarate and ammonia (PubMed:11032875). Plays a key role in glutamate metabolism and energy production via the TCA cycle in neural and testicular tissues (PubMed:11032875). Important for recycling glutamate during neurotransmission (By similarity),"Expressed in retina, testis and, at a lower level, brain",,,Mitochondrion matrix,11032875,8207021,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
GMCL1,ENSG00000087338,Unsafe,Protein,False,True,15.9,18.5,99,69,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 9 nTPM; positive ihc;continuous selectivity; adrenal gland: 6.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 5 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 4.7 nTPM; absolute ceiling;continuous selectivity; bone marrow: 13.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 7.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 5.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 11.7 nTPM; absolute ceiling;continuous selectivity; colon: 10.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 15.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 8 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 4.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 5.5 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 5.2 nTPM; absolute ceiling;continuous selectivity; kidney: 11.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 10.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 7.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 11.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 5.6 nTPM; absolute ceiling;continuous selectivity; pancreas: 8.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 18.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 6.3 nTPM; absolute ceiling;continuous selectivity; rectum: 11.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 6 nTPM; absolute ceiling;continuous selectivity; salivary gland: 9.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 4 nTPM; positive ihc;absolute ceiling; skin: 8.5 nTPM; positive ihc;continuous selectivity; small intestine: 12.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 6.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 5.5 nTPM; absolute ceiling;continuous selectivity; spleen: 8.9 nTPM; positive ihc;continuous selectivity; stomach: 8.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 18 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 8.9 nTPM; positive ihc;continuous selectivity; urinary bladder: 8 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 6.2 nTPM (limit 2); amygdala: 5 nTPM (limit 2); basal ganglia: 4.7 nTPM (limit 2); bone marrow: 13.5 nTPM (limit 2); cerebellum: 7.2 nTPM (limit 2); cerebral cortex: 5.6 nTPM (limit 2); choroid plexus: 11.7 nTPM (limit 2); colon: 10.4 nTPM (limit 6); duodenum: 15.5 nTPM (limit 2); esophagus: 8 nTPM (limit 6); heart muscle: 4.6 nTPM (limit 2); hippocampal formation: 5.5 nTPM (limit 2); hypothalamus: 5.2 nTPM (limit 2); kidney: 11.1 nTPM (limit 2); liver: 10.3 nTPM (limit 2); lung: 7.5 nTPM (limit 2); lymph node: 11.7 nTPM (limit 6); midbrain: 5.6 nTPM (limit 2); pancreas: 8.7 nTPM (limit 2); parathyroid gland: 18.5 nTPM (limit 8); pituitary gland: 6.3 nTPM (limit 2); rectum: 11.8 nTPM (limit 6); retina: 6 nTPM (limit 2); salivary gland: 9.1 nTPM (limit 6); skeletal muscle: 4 nTPM (limit 2); small intestine: 12.7 nTPM (limit 2); smooth muscle: 6.1 nTPM (limit 2); spinal cord: 5.5 nTPM (limit 2); stomach: 8.3 nTPM (limit 6); thymus: 18 nTPM (limit 10); urinary bladder: 8 nTPM (limit 6),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / basal cells: High (Approved); bronchus / ciliated cells (cell body): High (Approved); bronchus / goblet cells: High (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: High (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / basal cells: Medium (Approved); nasopharynx / ciliated cells (cell body): Low (Approved); nasopharynx / goblet cells: Low (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: High (Approved); pancreas / pancreatic endocrine cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: High (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (TCGA): 254/254 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%),lung cancer: 8/10 (80.0%); melanoma: 9/12 (75.0%),31,20,Q96IK5,https://www.uniprot.org/uniprotkb/Q96IK5/entry,Possible function in spermatogenesis. Enhances the degradation of MDM2 and increases the amount of p53 probably by modulating the nucleocytoplasmic transport (By similarity),,,,Nucleus matrix,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
GMCL2,ENSG00000244234,Unsafe,Protein,False,True,18.6,18.6,99,69,Positive somewhere,True,False,False,False,Excluded,Normal,True,,Not assessed,,,"incomplete routine rna; positive normal IHC; positive ihc outside permitted; incomplete routine rna; missing normal RNA: amygdala, basal ganglia, cerebellum, hippocampal formation, hypothalamus, midbrain, pituitary gland, spinal cord; adipose tissue: 0 nTPM; positive ihc; adrenal gland: 0 nTPM; positive ihc; bone marrow: 0 nTPM; positive ihc; cerebral cortex: 0 nTPM; positive ihc; colon: 0 nTPM; positive ihc; duodenum: 0 nTPM; positive ihc; esophagus: 0 nTPM; positive ihc; heart muscle: 0 nTPM; positive ihc; kidney: 0 nTPM; positive ihc; liver: 0 nTPM; positive ihc; lung: 0 nTPM; positive ihc; lymph node: 0 nTPM; positive ihc; pancreas: 0 nTPM; positive ihc; rectum: 0 nTPM; positive ihc; salivary gland: 0 nTPM; positive ihc; skeletal muscle: 0 nTPM; positive ihc; skin: 0 nTPM; positive ihc; small intestine: 0 nTPM; positive ihc; smooth muscle: 0 nTPM; positive ihc; spleen: 0 nTPM; positive ihc; stomach: 0 nTPM; positive ihc; thyroid gland: 0 nTPM; positive ihc; urinary bladder: 0 nTPM; positive ihc","Positive IHC in a Vital, Protected or Manageable compartment",,adipose tissue / adipocytes: Low (Uncertain); adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / basal cells: High (Uncertain); bronchus / ciliated cells (cell body): High (Uncertain); bronchus / goblet cells: High (Uncertain); caudate / neuronal cells: Low (Uncertain); cerebellum / cells in molecular layer: Low (Uncertain); cerebellum / Purkinje cells: Low (Uncertain); cerebral cortex / endothelial cells: Medium (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / endothelial cells: Medium (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: Low (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: High (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in tubules: High (Uncertain); liver / cholangiocytes: Medium (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / alveolar cells: Low (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / germinal center cells: Low (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); nasopharynx / basal cells: Medium (Uncertain); nasopharynx / ciliated cells (cell body): Low (Uncertain); nasopharynx / goblet cells: Low (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: High (Uncertain); pancreas / pancreatic endocrine cells: Low (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: High (Uncertain); skeletal muscle / myocytes: Medium (Uncertain); skin 1 / keratinocytes: Medium (Uncertain); skin 1 / Langerhans: Low (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: High (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); spleen / cells in red pulp: Low (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: High (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),incomplete_routine_rna,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (TCGA): 2/362 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Kidney Renal Papillary Cell Carcinoma (TCGA): 1/282 (0.4%),lung cancer: 8/10 (80.0%); melanoma: 9/12 (75.0%),29,20,Q8NEA9,https://www.uniprot.org/uniprotkb/Q8NEA9/entry,Possible function in spermatogenesis. Probable substrate-specific adapter of an E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins (PubMed:14528312),Expressed predominantly in testis,,,Nucleus matrix,14528312,16201836,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
GML,ENSG00000104499,Unsafe,RNA,False,True,3.3,187.3,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 187.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 187.3 nTPM (limit 2); adrenal gland: 187.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Liver Hepatocellular Carcinoma (TCGA): 1/362 (0.3%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q99445,https://www.uniprot.org/uniprotkb/Q99445/entry,May play a role in the apoptotic pathway or cell-cycle regulation induced by p53/TP53 after DNA damage,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Chang2019_TGCT | Gong2021_reproductive_PC,Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
GMNC,ENSG00000205835,Unsafe,RNA,False,True,7.8,7.8,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,choroid plexus: 2.9 nTPM; absolute ceiling;continuous selectivity; liver: 4 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 2.9 nTPM (limit 2); liver: 4 nTPM (limit 2); choroid plexus: 2.9 nTPM (baseline 2); liver: 4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Ovary Serous Cystadenocarcinoma (TCGA): 102/349 (29.2%); Ovary Serous Cystadenocarcinoma (validation): 21/81 (25.9%); Glioblastoma Multiforme (validation): 7/58 (12.1%),cervical cancer: 4/9 (44.4%); pancreatic cancer: 2/11 (18.2%),29,20,A6NCL1,https://www.uniprot.org/uniprotkb/A6NCL1/entry,Regulator of DNA replication. Promotes initiation of chromosomal DNA replication by mediating TOPBP1- and CDK2-dependent recruitment of CDC45L onto replication origins (By similarity),,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
GNAL,ENSG00000141404,Unsafe,Protein,False,True,16.4,61.7,115,30,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 1.4 nTPM; positive ihc; amygdala: 17.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 61.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 4.1 nTPM; positive ihc;absolute ceiling; cerebral cortex: 15.8 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 5 nTPM; absolute ceiling;continuous selectivity; colon: 6.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 1.5 nTPM; positive ihc; hippocampal formation: 11.3 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 12.3 nTPM; absolute ceiling;continuous selectivity; kidney: 3.9 nTPM; positive ihc;absolute ceiling; lung: 2.6 nTPM; positive ihc;absolute ceiling; lymph node: 4.7 nTPM; positive ihc; midbrain: 9.4 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 15.8 nTPM; absolute ceiling;continuous selectivity; rectum: 3.5 nTPM; positive ihc; retina: 4 nTPM; absolute ceiling; skeletal muscle: 21 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 3.1 nTPM; positive ihc;absolute ceiling; spinal cord: 4.4 nTPM; absolute ceiling;continuous selectivity; spleen: 2.9 nTPM; positive ihc; tongue: 12.6 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 12.8 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 17.1 nTPM (limit 2); basal ganglia: 61.7 nTPM (limit 2); cerebellum: 4.1 nTPM (limit 2); cerebral cortex: 15.8 nTPM (limit 12); choroid plexus: 5 nTPM (limit 2); colon: 6.9 nTPM (limit 6); hippocampal formation: 11.3 nTPM (limit 2); hypothalamus: 12.3 nTPM (limit 2); kidney: 3.9 nTPM (limit 2); lung: 2.6 nTPM (limit 2); midbrain: 9.4 nTPM (limit 2); pituitary gland: 15.8 nTPM (limit 2); retina: 4 nTPM (limit 2); skeletal muscle: 21 nTPM (limit 12); small intestine: 3.1 nTPM (limit 2); spinal cord: 4.4 nTPM (limit 2); tongue: 12.6 nTPM (limit 6); urinary bladder: 12.8 nTPM (limit 6),adrenal gland / glandular cells: Medium (Enhanced); bronchus / ciliated cells (cell body): Low (Enhanced); caudate / neuronal cells: Low (Enhanced); caudate / synapses: High (Enhanced); cerebellum / granular cells - cytoplasm/membrane: Low (Enhanced); cerebellum / synaptic glomeruli - core: Medium (Enhanced); cerebellum / white matter cells - cytoplasm/membrane: Low (Enhanced); colon / endothelial cells: High (Enhanced); colon / glandular cells: Low (Enhanced); duodenum / glandular cells: Low (Enhanced); kidney / cells in glomeruli: Low (Enhanced); lung / alveolar cells type I: Low (Enhanced); lung / macrophages: Medium (Enhanced); lymph node / non-germinal center cells: Low (Enhanced); rectum / glandular cells: Low (Enhanced); small intestine / glandular cells: Medium (Enhanced); spleen / cells in red pulp: Low (Enhanced); spleen / cells in white pulp: Medium (Enhanced); urinary bladder / urothelial cells: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Prostate Adenocarcinoma (TCGA): 285/480 (59.4%); Rectum Adenocarcinoma (validation): 121/207 (58.5%); Kidney Renal Papillary Cell Carcinoma (TCGA): 154/282 (54.6%),pancreatic cancer: 3/10 (30.0%); cervical cancer: 2/12 (16.7%),31,20,P38405,https://www.uniprot.org/uniprotkb/P38405/entry,"Guanine nucleotide-binding protein (G protein) involved as transducer in olfactory signal transduction controlled by G protein-coupled receptors (GPCRs) (By similarity). Contains the guanine nucleotide binding site and alternates between an active, GTP-bound state and an inactive, GDP-bound state (By similarity). Signaling by an activated GPCR promotes GDP release and GTP binding (By similarity). The alpha subunit has a low GTPase activity that converts bound GTP to GDP, thereby terminating the signal (By similarity). Both GDP release and GTP hydrolysis are modulated by numerous regulatory proteins (By similarity). GNAL/G(olf) alpha specifically mediates olfactory signal transduction within the olfactory neuroepithelium and the basal ganglia following GPCRs activation (By similarity). Acts by promoting the specific activation of adenylyl cyclase ADCY3, resulting in increased levels of the signaling molecule cAMP (By similarity)","Detected in olfactory neuroepithelium, brain, testis, and to a lower extent in retina, lung alveoli, spleen (PubMed:8243272). Trace amounts where seen in kidney, adrenal gland and liver (PubMed:8243272). Found to be expressed in all the insulinomas examined (PubMed:8243272)","Dystonia 25: A form of dystonia, a disorder defined by the presence of sustained involuntary muscle contraction, often leading to abnormal postures. DYT25 is an autosomal dominant neurologic disorder characterized by adult onset of focal dystonia, usually involving the neck. The dystonia most often progresses to involve other regions, particularly the face and laryngeal muscles, and less commonly the trunk and limbs.",,Cell membrane,,8243272,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
GNAT1,ENSG00000114349,Unsafe,Protein,False,True,1.2,1086.0,90,1,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; bone marrow: 0.7 nTPM; continuous selectivity; retina: 1086 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",retina: 1086 nTPM (limit 2); retina: 1086 nTPM (baseline 2),retina / photoreceptor cells: High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Chromophobe (TCGA): 1/64 (1.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Kidney Renal Papillary Cell Carcinoma (TCGA): 1/282 (0.4%),testis cancer: 4/12 (33.3%); lung cancer: 2/11 (18.2%),31,20,P11488,https://www.uniprot.org/uniprotkb/P11488/entry,"Alpha subunit of the heterotrimeric guanine nucleotide-binding protein (G protein) that transduces signals from the G protein-coupled photoreceptor rhodopsin (RHO). Essential for normal RHO-mediated light perception in retinal rod photoreceptors (PubMed:22190596). Functions as a GTPase, cycling between an active GTP-bound state and an inactive GDP-bound state. Under dim light conditions, photoactivated RHO promotes GDP release and GTP binding. In its active state, GNAT1 stimulates downstream effectors, including rod cGMP-phosphodiesterase (PDE6) complex, to mediate the phototransduction cascade (By similarity). Activation of the PDE6 complex occurs through binding and repositioning of the inhibitory PDE6 gamma subunits (PDE6G), thereby promoting catalytic activity (By similarity)","Rod photoreceptor cells (PubMed:1614872). Predominantly expressed in the retina followed by the ciliary body, iris and retinal pigment epithelium (PubMed:22190596)","Night blindness, congenital stationary, autosomal dominant 3: A non-progressive retinal disorder characterized by impaired night vision, often associated with nystagmus and myopia. Night blindness, congenital stationary, 1G: An autosomal recessive form of congenital stationary night blindness, a non-progressive retinal disorder characterized by impaired night vision or in dim light, with good vision only on bright days.",,Photoreceptor outer segment membrane Membrane Photoreceptor inner segment,22190596,1614872|22190596,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT,Cancer-associated RNA nomination; no antigen validation asserted,,,,,,,,
GNAT3,ENSG00000214415,Unsafe,Protein,False,True,0.3,1.7,98,2,Positive somewhere,True,False,False,False,Excluded,Normal,False,,Not assessed,,,positive normal IHC; positive ihc outside permitted; duodenum: 1.7 nTPM; positive ihc;continuous selectivity;reproductive not higher; small intestine: 1.2 nTPM; positive ihc;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",,duodenum / endocrine cells: High (Enhanced); small intestine / endocrine cells: High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 2/50 (4.0%); Bladder Urothelial Carcinoma (TCGA): 6/169 (3.6%); Pancreatic Adenocarcinoma (validation): 2/80 (2.5%),testis cancer: 1/12 (8.3%); breast cancer: 0/9 (0.0%),31,20,A8MTJ3,https://www.uniprot.org/uniprotkb/A8MTJ3/entry,"Guanine nucleotide-binding protein (G protein) alpha subunit playing a prominent role in bitter and sweet taste transduction as well as in umami (monosodium glutamate, monopotassium glutamate, and inosine monophosphate) taste transduction (PubMed:40339580, PubMed:38600377, PubMed:38776963). Transduction by this alpha subunit involves coupling of specific cell-surface receptors with a cGMP-phosphodiesterase; Activation of phosphodiesterase lowers intracellular levels of cAMP and cGMP which may open a cyclic nucleotide-suppressible cation channel leading to influx of calcium, ultimately leading to release of neurotransmitter. Indeed, denatonium and strychnine induce transient reduction in cAMP and cGMP in taste tissue, whereas this decrease is inhibited by GNAT3 antibody. Gustducin heterotrimer transduces response to bitter and sweet compounds via regulation of phosphodiesterase for alpha subunit, as well as via activation of phospholipase C for beta and gamma subunits, with ultimate increase inositol trisphosphate and increase of intracellular Calcium. GNAT3 can functionally couple to taste receptors to transmit intracellular signal: receptor heterodimer TAS1R2/TAS1R3 senses sweetness and TAS1R1/TAS1R3 transduces umami taste, whereas the T2R family GPCRs such as TAS2R14 act as bitter sensors (PubMed:40339580, PubMed:38600377, PubMed:38776963). Also functions as lumenal sugar sensors in the gut to control the expression of the Na+-glucose transporter SGLT1 in response to dietaty sugar, as well as the secretion of Glucagon-like peptide-1, GLP-1 and glucose-dependent insulinotropic polypeptide, GIP. Thus, may modulate the gut capacity to absorb sugars, with implications in malabsorption syndromes and diet-related disorders including diabetes and obesity",Expressed in taste buds (sensory organs of clustered epithelial cells) of the circumvallate and foliate papillae of the tongue at protein level. Expressed in enteroendocrine L cells of the gut. Detected also in spermatozoa,,,Cytoplasm,11917125|17724330|38600377|38776963|40339580,16728727|17021831|17724332|8015379,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT,Cancer-associated RNA nomination; no antigen validation asserted,,,,,,,,
GNG2,ENSG00000186469,Unsafe,Protein,False,True,110.3,110.3,76,43,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 44 nTPM; positive ihc;absolute ceiling; adrenal gland: 19.2 nTPM; absolute ceiling; amygdala: 74.4 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 13 nTPM; absolute ceiling; bone marrow: 57.1 nTPM; absolute ceiling;continuous selectivity; cerebellum: 5.8 nTPM; positive ihc;absolute ceiling; cerebral cortex: 83.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 27.3 nTPM; absolute ceiling; colon: 23.3 nTPM; positive ihc;absolute ceiling; duodenum: 12.7 nTPM; absolute ceiling; esophagus: 11.9 nTPM; positive ihc;absolute ceiling; heart muscle: 11.2 nTPM; absolute ceiling; hippocampal formation: 44.1 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 72.3 nTPM; absolute ceiling;continuous selectivity; kidney: 6.4 nTPM; positive ihc;absolute ceiling; liver: 10.8 nTPM; absolute ceiling; lung: 16.7 nTPM; absolute ceiling; lymph node: 40.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 13.8 nTPM; absolute ceiling; pancreas: 6.5 nTPM; positive ihc;absolute ceiling; pituitary gland: 14.5 nTPM; absolute ceiling; rectum: 16.2 nTPM; absolute ceiling; retina: 13.3 nTPM; absolute ceiling; salivary gland: 6.7 nTPM; positive ihc;absolute ceiling; skeletal muscle: 4.9 nTPM; absolute ceiling; skin: 6.9 nTPM; positive ihc; small intestine: 18 nTPM; absolute ceiling; smooth muscle: 16.5 nTPM; positive ihc;absolute ceiling; spinal cord: 11.8 nTPM; absolute ceiling; spleen: 52.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 13.8 nTPM; positive ihc;absolute ceiling; thymus: 57.2 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 4.9 nTPM; positive ihc; tongue: 12.5 nTPM; absolute ceiling; urinary bladder: 19.9 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 44 nTPM (limit 10); adrenal gland: 19.2 nTPM (limit 2); amygdala: 74.4 nTPM (limit 2); basal ganglia: 13 nTPM (limit 2); bone marrow: 57.1 nTPM (limit 2); cerebellum: 5.8 nTPM (limit 2); cerebral cortex: 83.4 nTPM (limit 2); choroid plexus: 27.3 nTPM (limit 2); colon: 23.3 nTPM (limit 6); duodenum: 12.7 nTPM (limit 2); esophagus: 11.9 nTPM (limit 6); heart muscle: 11.2 nTPM (limit 2); hippocampal formation: 44.1 nTPM (limit 2); hypothalamus: 72.3 nTPM (limit 2); kidney: 6.4 nTPM (limit 2); liver: 10.8 nTPM (limit 2); lung: 16.7 nTPM (limit 2); lymph node: 40.3 nTPM (limit 6); midbrain: 13.8 nTPM (limit 2); pancreas: 6.5 nTPM (limit 2); pituitary gland: 14.5 nTPM (limit 2); rectum: 16.2 nTPM (limit 6); retina: 13.3 nTPM (limit 2); salivary gland: 6.7 nTPM (limit 6); skeletal muscle: 4.9 nTPM (limit 2); small intestine: 18 nTPM (limit 2); smooth muscle: 16.5 nTPM (limit 2); spinal cord: 11.8 nTPM (limit 2); spleen: 52.3 nTPM (limit 10); stomach: 13.8 nTPM (limit 6); thymus: 57.2 nTPM (limit 10); tongue: 12.5 nTPM (limit 6); urinary bladder: 19.9 nTPM (limit 6); adipose tissue: 44 nTPM (baseline 10); adrenal gland: 19.2 nTPM (baseline 2); amygdala: 74.4 nTPM (baseline 2); basal ganglia: 13 nTPM (baseline 2); bone marrow: 57.1 nTPM (baseline 2); cerebellum: 5.8 nTPM (baseline 2); cerebral cortex: 83.4 nTPM (baseline 2); choroid plexus: 27.3 nTPM (baseline 2); colon: 23.3 nTPM (baseline 6); duodenum: 12.7 nTPM (baseline 2); esophagus: 11.9 nTPM (baseline 6); heart muscle: 11.2 nTPM (baseline 2); hippocampal formation: 44.1 nTPM (baseline 2); hypothalamus: 72.3 nTPM (baseline 2); kidney: 6.4 nTPM (baseline 2); liver: 10.8 nTPM (baseline 2); lung: 16.7 nTPM (baseline 2); lymph node: 40.3 nTPM (baseline 6); midbrain: 13.8 nTPM (baseline 2); pancreas: 6.5 nTPM (baseline 2); pituitary gland: 14.5 nTPM (baseline 2); rectum: 16.2 nTPM (baseline 6); retina: 13.3 nTPM (baseline 2); salivary gland: 6.7 nTPM (baseline 6); skeletal muscle: 4.9 nTPM (baseline 2); small intestine: 18 nTPM (baseline 2); smooth muscle: 16.5 nTPM (baseline 2); spinal cord: 11.8 nTPM (baseline 2); spleen: 52.3 nTPM (baseline 10); stomach: 13.8 nTPM (baseline 6); thymus: 57.2 nTPM (baseline 10); tongue: 12.5 nTPM (baseline 6); urinary bladder: 19.9 nTPM (baseline 6),adipose tissue / adipocytes: High (Uncertain); bronchus / respiratory epithelial cells: Low (Uncertain); caudate / glial cells: Low (Uncertain); caudate / neuronal cells: Low (Uncertain); cerebellum / cells in granular layer: Low (Uncertain); cerebellum / cells in molecular layer: Low (Uncertain); cerebral cortex / endothelial cells: Medium (Uncertain); cerebral cortex / glial cells: Low (Uncertain); cerebral cortex / neuronal cells: Low (Uncertain); cerebral cortex / neuropil: High (Uncertain); colon / endothelial cells: High (Uncertain); esophagus / squamous epithelial cells: Low (Uncertain); hippocampus / glial cells: Low (Uncertain); hippocampus / neuronal cells: Low (Uncertain); kidney / cells in tubules: Medium (Uncertain); lymph node / germinal center cells: Low (Uncertain); oral mucosa / squamous epithelial cells: Low (Uncertain); pancreas / pancreatic endocrine cells: Low (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skin 1 / fibroblasts: Medium (Uncertain); skin 1 / keratinocytes: Low (Uncertain); skin 2 / epidermal cells: Low (Uncertain); smooth muscle / smooth muscle cells: High (Uncertain); spleen / cells in red pulp: Low (Uncertain); spleen / cells in white pulp: Low (Uncertain); stomach 1 / glandular cells: Low (Uncertain); thyroid gland / glandular cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 141/141 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%); Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%),melanoma: 7/12 (58.3%); breast cancer: 4/11 (36.4%),31,20,P59768,https://www.uniprot.org/uniprotkb/P59768/entry,"Guanine nucleotide-binding proteins (G proteins) are involved as a modulator or transducer in various transmembrane signaling systems (PubMed:29925951, PubMed:33762731, PubMed:34239069, PubMed:35610220, PubMed:35714614, PubMed:35835867, PubMed:36087581, PubMed:36989299, PubMed:37327704, PubMed:37935376, PubMed:37935377, PubMed:37963465, PubMed:38168118, PubMed:38552625, PubMed:39103320). The beta and gamma chains are required for the GTPase activity, for replacement of GDP by GTP, and for G protein-effector interaction (PubMed:29925951, PubMed:33762731, PubMed:34239069, PubMed:35610220, PubMed:35714614, PubMed:35835867, PubMed:36087581, PubMed:36989299, PubMed:37327704, PubMed:37935376, PubMed:37935377, PubMed:37963465, PubMed:38168118, PubMed:38552625, PubMed:39103320). Involved in bitter and sweet taste transduction as well as in umami (monosodium glutamate, monopotassium glutamate, and inosine monophosphate) taste transduction (PubMed:40339580, PubMed:38600377, PubMed:38776963)","Expressed in fetal tissues, including testis, adrenal gland, brain, white blood cells and brain",,,Cell membrane,29925951|33762731|34239069|35610220|35714614|35835867|36087581|36989299|37327704|37935376|37935377|37963465|38168118|38552625|38600377|38776963|39103320|40339580,10833460,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
GNGT1,ENSG00000127928,Unsafe,Protein,False,True,2.8,1842.8,90,1,Positive somewhere,True,True,False,False,Excluded,Normal,False,,Not assessed,,,positive ihc outside permitted; choroid plexus: 11.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; retina: 1842.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 11.1 nTPM (limit 2); retina: 1842.8 nTPM (limit 2); choroid plexus: 11.1 nTPM (baseline 2); retina: 1842.8 nTPM (baseline 2),retina / photoreceptor cells: High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Renal Clear Cell Carcinoma (validation): 21/100 (21.0%); Kidney Chromophobe (TCGA): 9/64 (14.1%); Breast Invasive Carcinoma (validation): 5/50 (10.0%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),31,20,P63211,https://www.uniprot.org/uniprotkb/P63211/entry,"Guanine nucleotide-binding proteins (G proteins) are involved as a modulator or transducer in various transmembrane signaling systems. The beta and gamma chains are required for the GTPase activity, for replacement of GDP by GTP, and for G protein-effector interaction",Retinal rod outer segment,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Gong2021_reproductive_PC,No tumor-antigen validation in this source | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
GOPC,ENSG00000047932,Unsafe,Protein,False,True,22.8,23.2,93,69,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 14.9 nTPM; continuous selectivity; adrenal gland: 13.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 11.5 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 11.4 nTPM; absolute ceiling;continuous selectivity; bone marrow: 7 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 20.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 17.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 5.1 nTPM; absolute ceiling; colon: 18.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 11.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 11.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 21.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 13 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 12.3 nTPM; absolute ceiling;continuous selectivity; kidney: 14 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 15.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 13.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 19.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 11.8 nTPM; absolute ceiling;continuous selectivity; pancreas: 12.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 21.4 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 15.7 nTPM; absolute ceiling;continuous selectivity; rectum: 19.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 13.1 nTPM; absolute ceiling;continuous selectivity; salivary gland: 13.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 15.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 18.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 14.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 17.7 nTPM; absolute ceiling;continuous selectivity; spinal cord: 13.3 nTPM; absolute ceiling;continuous selectivity; spleen: 16.5 nTPM; continuous selectivity; stomach: 14.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 20.4 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 23.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; tongue: 16.7 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 14.6 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 13.8 nTPM (limit 2); amygdala: 11.5 nTPM (limit 2); basal ganglia: 11.4 nTPM (limit 2); bone marrow: 7 nTPM (limit 2); cerebellum: 20.1 nTPM (limit 2); cerebral cortex: 17.8 nTPM (limit 2); choroid plexus: 5.1 nTPM (limit 2); colon: 18.1 nTPM (limit 6); duodenum: 11.9 nTPM (limit 2); esophagus: 11.7 nTPM (limit 6); heart muscle: 21.3 nTPM (limit 2); hippocampal formation: 13 nTPM (limit 2); hypothalamus: 12.3 nTPM (limit 2); kidney: 14 nTPM (limit 2); liver: 15.9 nTPM (limit 2); lung: 13.1 nTPM (limit 2); lymph node: 19.5 nTPM (limit 6); midbrain: 11.8 nTPM (limit 2); pancreas: 12.3 nTPM (limit 2); parathyroid gland: 21.4 nTPM (limit 8); pituitary gland: 15.7 nTPM (limit 2); rectum: 19.7 nTPM (limit 6); retina: 13.1 nTPM (limit 2); salivary gland: 13.9 nTPM (limit 6); skeletal muscle: 15.2 nTPM (limit 2); skin: 18.2 nTPM (limit 10); small intestine: 14.6 nTPM (limit 2); smooth muscle: 17.7 nTPM (limit 4); spinal cord: 13.3 nTPM (limit 2); stomach: 14.5 nTPM (limit 6); thymus: 20.4 nTPM (limit 10); thyroid gland: 23.2 nTPM (limit 10); tongue: 16.7 nTPM (limit 6); urinary bladder: 14.6 nTPM (limit 6),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / basal cells: Low (Approved); bronchus / ciliated cells (cell body): Medium (Approved); bronchus / ciliated cells (tip of cilia): Low (Approved); bronchus / goblet cells: Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Low (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / basal cells: Low (Approved); nasopharynx / ciliated cells (cell body): Medium (Approved); nasopharynx / goblet cells: Low (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / fibroblasts: Low (Approved); skin 1 / keratinocytes: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (TCGA): 254/254 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%),glioma: 2/11 (18.2%); liver cancer: 2/12 (16.7%),31,20,Q9HD26,https://www.uniprot.org/uniprotkb/Q9HD26/entry,"Plays a role in intracellular protein trafficking and degradation (PubMed:11707463, PubMed:14570915, PubMed:15358775). May regulate CFTR chloride currents and acid-induced ASIC3 currents by modulating cell surface expression of both channels (By similarity). May also regulate the intracellular trafficking of the ADR1B receptor (PubMed:15358775). May play a role in autophagy (By similarity). Together with MARCHF2 mediates the ubiquitination and lysosomal degradation of CFTR (PubMed:23818989). Overexpression results in CFTR intracellular retention and lysosomaldegradation in the lysosomes (PubMed:11707463, PubMed:14570915)",Ubiquitously expressed,,,"Cytoplasm Golgi apparatus membrane Golgi apparatus, trans-Golgi network membrane Synapse Postsynaptic density Cell projection, dendrite",11707463|14570915|15358775|23818989,11162552|11384996|11707463,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
GP1BA,ENSG00000185245,Unsafe,Protein,False,True,0.3,14.3,80,2,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 0.4 nTPM; continuous selectivity;reproductive not higher; basal ganglia: 0.2 nTPM; continuous selectivity; bone marrow: 4.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 0.3 nTPM; continuous selectivity;reproductive not higher; cerebral cortex: 0.5 nTPM; continuous selectivity;reproductive not higher; colon: 0.4 nTPM; continuous selectivity;reproductive not higher; duodenum: 1.2 nTPM; continuous selectivity;reproductive not higher; esophagus: 0.3 nTPM; continuous selectivity;reproductive not higher; heart muscle: 0.5 nTPM; continuous selectivity;reproductive not higher; kidney: 0.4 nTPM; continuous selectivity;reproductive not higher; liver: 0.4 nTPM; continuous selectivity;reproductive not higher; lung: 1.2 nTPM; continuous selectivity;reproductive not higher; lymph node: 14.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 0.4 nTPM; continuous selectivity;reproductive not higher; retina: 2.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 0.9 nTPM; continuous selectivity;reproductive not higher; skeletal muscle: 2.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 2.3 nTPM; continuous selectivity;reproductive not higher; small intestine: 1.2 nTPM; continuous selectivity;reproductive not higher; spleen: 3.6 nTPM; positive ihc;continuous selectivity;reproductive not higher; stomach: 0.7 nTPM; continuous selectivity;reproductive not higher; thymus: 0.6 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 0.3 nTPM; continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 4.9 nTPM (limit 2); lymph node: 14.3 nTPM (limit 12); retina: 2.3 nTPM (limit 2); bone marrow: 4.9 nTPM (baseline 2); lymph node: 14.3 nTPM (baseline 6); retina: 2.3 nTPM (baseline 2); skeletal muscle: 2.6 nTPM (baseline 2),bone marrow / hematopoietic cells: Medium (Supported); spleen / cells in red pulp: Medium (Supported),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 11/50 (22.0%); Testicular Germ Cell Tumor (TCGA): 24/133 (18.0%); Rectum Adenocarcinoma (validation): 13/207 (6.3%),ovarian cancer: 1/11 (9.1%); glioma: 1/12 (8.3%),31,20,P07359,https://www.uniprot.org/uniprotkb/P07359/entry,"GP-Ib, a surface membrane protein of platelets, participates in the formation of platelet plugs by binding to the A1 domain of vWF, which is already bound to the subendothelium",,"Non-arteritic anterior ischemic optic neuropathy: An autosomal recessive ocular disease due to ischemic injury to the optic nerve. It usually affects the optic disk and leads to visual loss and optic disk swelling of a pallid nature. Visual loss is usually sudden, or over a few days at most and is usually permanent, with some recovery possibly occurring within the first weeks or months. Patients with small disks having smaller or non-existent cups have an anatomical predisposition for non-arteritic anterior ischemic optic neuropathy. As an ischemic episode evolves, the swelling compromises circulation, with a spiral of ischemia resulting in further neuronal damage. Bernard-Soulier syndrome: An autosomal recessive coagulation disorder characterized by a prolonged bleeding time, unusually large platelets, thrombocytopenia, and impaired prothrombin consumption. Bernard-Soulier syndrome A2, autosomal dominant: A coagulation disorder characterized by mild to moderate bleeding tendency, thrombocytopenia, and an increased mean platelet volume. Some individuals have no symptoms. Mild bleeding tendencies manifest as epistaxis, gingival bleeding, menorrhagia, easy bruising, or prolonged bleeding after dental surgery. von Willebrand disease, platelet-type: An autosomal dominant bleeding disorder characterized by abnormally enhanced binding of von Willebrand factor by the platelet glycoprotein Ib (GP Ib) receptor complex. Hemostatic function is impaired due to the removal of VWF multimers from the circulation.",,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
GPD2,ENSG00000115159,Unsafe,Protein,False,True,17.6,23.8,106,82,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 7.9 nTPM; positive ihc;continuous selectivity; adrenal gland: 5.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 14.9 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 16.1 nTPM; absolute ceiling;continuous selectivity; bone marrow: 13.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 17.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 15 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 3.9 nTPM; absolute ceiling; colon: 18 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 14 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 19.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 6 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 14.6 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 9.6 nTPM; absolute ceiling;continuous selectivity; kidney: 7.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 3.3 nTPM; positive ihc;absolute ceiling; lung: 11.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 6.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 8.8 nTPM; absolute ceiling;continuous selectivity; pancreas: 6.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 19.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 5.3 nTPM; absolute ceiling;continuous selectivity; rectum: 17.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 9.3 nTPM; absolute ceiling;continuous selectivity; salivary gland: 14.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 23.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 12.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 15.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 5.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 6.9 nTPM; absolute ceiling;continuous selectivity; spleen: 8.3 nTPM; positive ihc;continuous selectivity; stomach: 17 nTPM; positive ihc;absolute ceiling;continuous selectivity; thyroid gland: 11.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 13.7 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 13.8 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 5.5 nTPM (limit 2); amygdala: 14.9 nTPM (limit 2); basal ganglia: 16.1 nTPM (limit 2); bone marrow: 13.2 nTPM (limit 2); cerebellum: 17.7 nTPM (limit 2); cerebral cortex: 15 nTPM (limit 2); choroid plexus: 3.9 nTPM (limit 2); colon: 18 nTPM (limit 6); duodenum: 14 nTPM (limit 2); esophagus: 19.7 nTPM (limit 6); heart muscle: 6 nTPM (limit 2); hippocampal formation: 14.6 nTPM (limit 2); hypothalamus: 9.6 nTPM (limit 2); kidney: 7.7 nTPM (limit 2); liver: 3.3 nTPM (limit 2); lung: 11.1 nTPM (limit 2); lymph node: 6.8 nTPM (limit 6); midbrain: 8.8 nTPM (limit 2); pancreas: 6.6 nTPM (limit 2); parathyroid gland: 19.8 nTPM (limit 6); pituitary gland: 5.3 nTPM (limit 2); rectum: 17.4 nTPM (limit 6); retina: 9.3 nTPM (limit 2); salivary gland: 14.5 nTPM (limit 6); skeletal muscle: 23.8 nTPM (limit 2); skin: 12.1 nTPM (limit 10); small intestine: 15.3 nTPM (limit 2); smooth muscle: 5.9 nTPM (limit 2); spinal cord: 6.9 nTPM (limit 2); stomach: 17 nTPM (limit 6); thyroid gland: 11.9 nTPM (limit 10); tongue: 13.7 nTPM (limit 6); urinary bladder: 13.8 nTPM (limit 6),adipose tissue / adipocytes: Medium (Enhanced); adrenal gland / glandular cells: High (Enhanced); bone marrow / hematopoietic cells: Medium (Enhanced); bronchus / respiratory epithelial cells: High (Enhanced); caudate / neuronal cells: Medium (Enhanced); cerebellum / granular cells - cytoplasm/membrane: Low (Enhanced); cerebellum / molecular layer - neuropil: Low (Enhanced); cerebellum / synaptic glomeruli - core: High (Enhanced); cerebral cortex / endothelial cells: Medium (Enhanced); cerebral cortex / glial cells: Low (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); cerebral cortex / neuropil: Medium (Enhanced); colon / endothelial cells: Medium (Enhanced); colon / glandular cells: High (Enhanced); colon / peripheral nerve/ganglion: Medium (Enhanced); duodenum / glandular cells: High (Enhanced); esophagus / squamous epithelial cells: High (Enhanced); heart muscle / cardiomyocytes: Medium (Enhanced); hippocampus / glial cells: Low (Enhanced); hippocampus / neuronal cells: High (Enhanced); kidney / cells in glomeruli: Medium (Enhanced); kidney / cells in tubules: High (Enhanced); liver / cholangiocytes: Medium (Enhanced); liver / hepatocytes: Low (Enhanced); lung / alveolar cells type I: High (Enhanced); lung / alveolar cells type II: High (Enhanced); lung / macrophages: High (Enhanced); lymph node / germinal center cells: Low (Enhanced); lymph node / non-germinal center cells: Medium (Enhanced); nasopharynx / respiratory epithelial cells: High (Enhanced); oral mucosa / squamous epithelial cells: High (Enhanced); pancreas / exocrine glandular cells: High (Enhanced); parathyroid gland / glandular cells: High (Enhanced); rectum / glandular cells: High (Enhanced); salivary gland / glandular cells: High (Enhanced); skeletal muscle / myocytes: Medium (Enhanced); skin 1 / fibroblasts: Medium (Enhanced); skin 1 / keratinocytes: High (Enhanced); skin 1 / Langerhans: High (Enhanced); skin 2 / epidermal cells: High (Enhanced); small intestine / glandular cells: High (Enhanced); smooth muscle / smooth muscle cells: Low (Enhanced); spleen / cells in red pulp: Medium (Enhanced); spleen / cells in white pulp: Medium (Enhanced); stomach 1 / glandular cells: High (Enhanced); stomach 2 / glandular cells: High (Enhanced); thyroid gland / glandular cells: Medium (Enhanced); urinary bladder / urothelial cells: High (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (TCGA): 254/254 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (TCGA): 141/141 (100.0%),breast cancer: 12/12 (100.0%); endometrial cancer: 12/12 (100.0%),31,20,P43304,https://www.uniprot.org/uniprotkb/P43304/entry,Calcium-responsive mitochondrial glycerol-3-phosphate dehydrogenase which seems to be a key component of the pancreatic beta-cell glucose-sensing device,,,,Mitochondrion,9070847,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
GPR18,ENSG00000125245,Unsafe,Protein,False,True,12.7,38.0,82,4,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 9.6 nTPM; absolute ceiling;continuous selectivity; lymph node: 38 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 3.9 nTPM; absolute ceiling;continuous selectivity; spleen: 10.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 7.7 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",lymph node: 38 nTPM (limit 6); spleen: 10.2 nTPM (limit 10); bone marrow: 9.6 nTPM (baseline 2); lymph node: 38 nTPM (baseline 6); small intestine: 3.9 nTPM (baseline 2); spleen: 10.2 nTPM (baseline 10),lymph node / germinal center cells: Low (Enhanced); lymph node / non-germinal center cells: Medium (Enhanced); spleen / cells in red pulp: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 27/50 (54.0%); Rectum Adenocarcinoma (validation): 77/207 (37.2%); Colon Adenocarcinoma (validation): 169/486 (34.8%),lymphoma: 3/12 (25.0%); glioma: 1/11 (9.1%),31,20,Q14330,https://www.uniprot.org/uniprotkb/Q14330/entry,"G protein-coupled receptor (GPCR) that plays a role in diverse physiological processes particularly within the immune and nervous systems (PubMed:21732409, PubMed:26195725). Becomes active when triggered by various endogenous ligands including endocannabinoid N-arachidonyl glycine (NAGly), delta-9-tetrahydrocannabinol or resolvin D2/RvD2 derived from the omega-3 fatty acid docosahexaenoic acid (DHA) (PubMed:16844083, PubMed:24762058, PubMed:26195725, PubMed:27572937). Upon RvD2 binding, facilitates the resolution of inflammation, aiding in tissue repair and homeostasis. Mechanistically, RvD2 ligation initiates Galphas protein coupling, activation of cAMP-PKA signaling pathway and phosphorylation of STAT3, leading to RvD2-stimulated macrophage phagocytosis (PubMed:27994074). Mediates NAGly-induced process of reorganization of actin filaments and induction of acrosomal exocytosis (PubMed:27572937). Activation by N-arachidonoyl glycine (NAGly) can also induce apoptosis in macrophages (By similarity). Plays a role in homeostasis of CD8+ subsets of intraepithelial lymphocytes (IELs) (CD8alphaalpha and CD8alphabeta IELs) in small intestine by supporting preferential migration of CD8alphaalpha T-cells to intraepithelial compartment over lamina propria compartment, and by mediating their reconstitution into small intestine after bone marrow transplant (By similarity). Also participates in hypotensive responses, mediating reduction in intraocular and blood pressure (By similarity)",Expressed in midpiece of spermatozoon (at protein level) (PubMed:27572937). Most abundant in testis and spleen (PubMed:16844083). Highly expressed in CD4 and CD8-positive T-cells as well as CD19-positive B-cells (PubMed:16844083),,,Cell membrane Cytoplasmic vesicle membrane,16844083|21732409|24762058|26195725|27572937|27994074,16844083|27572937,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
GPR32,ENSG00000142511,Unsafe,RNA,False,True,1.7,56.2,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,parathyroid gland: 56.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,parathyroid gland: 56.2 nTPM (limit 6); parathyroid gland: 56.2 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Bladder Urothelial Carcinoma (TCGA): 2/169 (1.2%); Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O75388,https://www.uniprot.org/uniprotkb/O75388/entry,"G protein-coupled receptor that binds to several ligands including resolvin D1 (RvD1) with high affinity, leading to rapid and transient activation of numerous intracellular signaling pathways. In macrophages, enhances the RvD1-stimulated phagocytic and clearance functions (PubMed:20080636). Macrophages migrate less toward different chemoattractant stimuli but phagocytose more microbial particles (PubMed:26969756). Prevents the increase in Ca(2+) and activation of ERK1/2 used by histamine and its H1 receptor subtype to induce goblet cell secretion by activating PKC and GRK2 to counter-regulate the histamine receptor (PubMed:23462912)",Expressed in resting primary human macrophages,,,Cell membrane,20080636|23462912|26969756,26969756,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
GPR39,ENSG00000183840,Unsafe,Protein,False,True,4.2,6.5,79,21,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 0.2 nTPM; positive ihc; adrenal gland: 0 nTPM; positive ihc; bone marrow: 0 nTPM; positive ihc; cerebellum: 0.1 nTPM; positive ihc; cerebral cortex: 0.2 nTPM; positive ihc; choroid plexus: 1.4 nTPM; continuous selectivity; colon: 6.5 nTPM; continuous selectivity;reproductive not higher; duodenum: 4.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 0.8 nTPM; positive ihc; heart muscle: 0 nTPM; positive ihc; kidney: 2.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 3.2 nTPM; continuous selectivity; lung: 3.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 0 nTPM; positive ihc; pancreas: 3.8 nTPM; continuous selectivity; parathyroid gland: 4.9 nTPM; continuous selectivity;reproductive not higher; rectum: 5.5 nTPM; continuous selectivity;reproductive not higher; skin: 1 nTPM; positive ihc; small intestine: 3.6 nTPM; continuous selectivity; stomach: 5.9 nTPM; continuous selectivity;reproductive not higher; urinary bladder: 2.5 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",duodenum: 4.5 nTPM (limit 4); kidney: 2.6 nTPM (limit 2); lung: 3.8 nTPM (limit 2),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Low (Approved); bone marrow / hematopoietic cells: Low (Approved); caudate / glial cells: High (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Low (Approved); cerebral cortex / glial cells: Low (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / glial cells: Medium (Approved); kidney / cells in tubules: Low (Approved); lung / macrophages: Low (Approved); lymph node / non-germinal center cells: Low (Approved); skin 1 / keratinocytes: Low (Approved); skin 2 / epidermal cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 199/207 (96.1%); Colon Adenocarcinoma (validation): 449/486 (92.4%); Lung Adenocarcinoma (TCGA): 444/497 (89.3%),endometrial cancer: 2/11 (18.2%); colorectal cancer: 1/11 (9.1%),31,20,O43194,https://www.uniprot.org/uniprotkb/O43194/entry,"Zinc-sensing receptor that can sense changes in extracellular Zn(2+), mediate Zn(2+) signal transmission, and participates in the regulation of numerous physiological processes including glucose homeostasis regulation, gastrointestinal mobility, hormone secretion and cell death (PubMed:18180304). Activation by Zn(2+) in keratinocytes increases the intracellular concentration of Ca(2+) and activates the ERK/MAPK and PI3K/AKT signaling pathways leading to epithelial repair (PubMed:20522546). Plays an essential role in normal wound healing by inducing the production of cytokines including the major inflammatory cytokine IL6 via the PKC/MAPK/CEBPB pathway (By similarity). Regulates adipose tissue metabolism, especially lipolysis, and regulates the function of lipases, such as hormone-sensitive lipase and adipose triglyceride lipase (By similarity). Plays a role in the inhibition of cell death and protects against oxidative, endoplasmic reticulum and mitochondrial stress by inducing secretion of the cytoprotective pigment epithelium-derived growth factor (PEDF) and probably other protective transcripts in a GNA13/RHOA/SRE-dependent manner (PubMed:18180304). Forms dynamic heteroreceptor complexes with HTR1A and GALR1 depending on cell type or specific physiological states, resulting in signaling diversity: HTR1A-GPR39 shows additive increase in signaling along the serum response element (SRE) and NF-kappa-B pathways while GALR1 acts as an antagonist blocking SRE (PubMed:26365466)","Expressed in many tissues, including the stomach, intestine and hypothalamus",,,Cell membrane,18180304|20522546|26365466,9441746,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
GPR55,ENSG00000135898,Unsafe,RNA,False,True,4.5,4.5,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,basal ganglia: 3.5 nTPM; absolute ceiling;continuous selectivity; duodenum: 1.3 nTPM; continuous selectivity; lymph node: 2.8 nTPM; continuous selectivity; small intestine: 2.1 nTPM; absolute ceiling;continuous selectivity; spleen: 4 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,basal ganglia: 3.5 nTPM (limit 2); small intestine: 2.1 nTPM (limit 2); basal ganglia: 3.5 nTPM (baseline 2); small intestine: 2.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 9/133 (6.8%); Rectum Adenocarcinoma (validation): 9/207 (4.3%); Breast Invasive Carcinoma (validation): 2/50 (4.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9Y2T6,https://www.uniprot.org/uniprotkb/Q9Y2T6/entry,"G protein-coupled receptor that binds to several ligands including 2-arachidonoyl lysophosphatidylinositol or lysophosphatidylglucoside with high affinity, leading to rapid and transient activation of numerous intracellular signaling pathways (PubMed:36142844, PubMed:36523570, PubMed:37544935). Induces the Ca(2+) release from intracellular stores via ERK, the heterotrimeric G protein GNA13 and RHOA leading to morphological changes including cell rounding and stress fiber formation (PubMed:36142844). In macrophages, acts downstream of lysophosphatidylglucoside to inhibit the translocation of the phospholipid-transporting ABCA1 to plasma membrane and subsequent cholesterol efflux leading to lipid accumulation and foam cell formation (PubMed:37544935)","Expressed in the caudate nucleus and putamen, but not detected in the hippocampus, thalamus, pons cerebellum, frontal cortex of the brain or in the liver. Expressed in osteoclasts and osteoblasts. Highly expressed in macrophages and B-cells (PubMed:36523570, PubMed:37544935)",,,Cell membrane,19805329|36142844|36523570|37544935,19805329|36523570|37544935|9931487,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
GPR89B,ENSG00000188092,Unsafe,RNA,False,True,10.2,12.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 5.9 nTPM; continuous selectivity; adrenal gland: 6.8 nTPM; absolute ceiling;continuous selectivity; amygdala: 5 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 5 nTPM; absolute ceiling;continuous selectivity; bone marrow: 3 nTPM; absolute ceiling;continuous selectivity; cerebellum: 6.8 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 6.5 nTPM; absolute ceiling;continuous selectivity; colon: 5.2 nTPM; continuous selectivity; esophagus: 5.5 nTPM; continuous selectivity; heart muscle: 5.5 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 4.8 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 6.8 nTPM; absolute ceiling;continuous selectivity; kidney: 12 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; liver: 7 nTPM; absolute ceiling;continuous selectivity; lung: 5.3 nTPM; absolute ceiling;continuous selectivity; midbrain: 5.8 nTPM; absolute ceiling;continuous selectivity; pancreas: 4.3 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 4.7 nTPM; absolute ceiling;continuous selectivity; salivary gland: 7.1 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 8.5 nTPM; absolute ceiling;continuous selectivity; skin: 8.2 nTPM; continuous selectivity; small intestine: 6.9 nTPM; absolute ceiling;continuous selectivity; spinal cord: 7.7 nTPM; absolute ceiling;continuous selectivity; spleen: 4.9 nTPM; continuous selectivity; stomach: 6.2 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 4.6 nTPM; continuous selectivity; tongue: 5.7 nTPM; continuous selectivity; urinary bladder: 6.1 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 6.8 nTPM (limit 2); amygdala: 5 nTPM (limit 2); basal ganglia: 5 nTPM (limit 2); bone marrow: 3 nTPM (limit 2); cerebellum: 6.8 nTPM (limit 2); cerebral cortex: 6.5 nTPM (limit 2); heart muscle: 5.5 nTPM (limit 2); hippocampal formation: 4.8 nTPM (limit 2); hypothalamus: 6.8 nTPM (limit 2); kidney: 12 nTPM (limit 2); liver: 7 nTPM (limit 2); lung: 5.3 nTPM (limit 2); midbrain: 5.8 nTPM (limit 2); pancreas: 4.3 nTPM (limit 2); pituitary gland: 4.7 nTPM (limit 2); salivary gland: 7.1 nTPM (limit 6); skeletal muscle: 8.5 nTPM (limit 2); small intestine: 6.9 nTPM (limit 2); spinal cord: 7.7 nTPM (limit 2); stomach: 6.2 nTPM (limit 6); urinary bladder: 6.1 nTPM (limit 6); adrenal gland: 6.8 nTPM (baseline 2); amygdala: 5 nTPM (baseline 2); basal ganglia: 5 nTPM (baseline 2); bone marrow: 3 nTPM (baseline 2); cerebellum: 6.8 nTPM (baseline 2); cerebral cortex: 6.5 nTPM (baseline 2); heart muscle: 5.5 nTPM (baseline 2); hippocampal formation: 4.8 nTPM (baseline 2); hypothalamus: 6.8 nTPM (baseline 2); kidney: 12 nTPM (baseline 2); liver: 7 nTPM (baseline 2); lung: 5.3 nTPM (baseline 2); midbrain: 5.8 nTPM (baseline 2); pancreas: 4.3 nTPM (baseline 2); pituitary gland: 4.7 nTPM (baseline 2); salivary gland: 7.1 nTPM (baseline 6); skeletal muscle: 8.5 nTPM (baseline 2); small intestine: 6.9 nTPM (baseline 2); spinal cord: 7.7 nTPM (baseline 2); stomach: 6.2 nTPM (baseline 6); urinary bladder: 6.1 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Pancreatic Adenocarcinoma (validation): 79/80 (98.8%); Colon Adenocarcinoma (validation): 479/486 (98.6%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,B7ZAQ6 | P0CG08,https://www.uniprot.org/uniprotkb/B7ZAQ6/entry | https://www.uniprot.org/uniprotkb/P0CG08/entry,"Voltage-gated channel that enables the transfer of monoatomic anions such as iodide, chloride, bromide and fluoride which may function in counter-ion conductance and participates in Golgi acidification (PubMed:18794847). Plays a role in lymphocyte development, probably by acting as a RABL3 effector in hematopoietic cells (By similarity). Essential for maintaining the acidic luminal pH of the Golgi apparatus in neurons, which is important for preserving Golgi structural integrity (By similarity). This integrity supports proper axonal transport and synaptic maintenance in cerebellar inhibitory neurons, including Purkinje and basket cells (By similarity). Additionally, Golgi acidification facilitates the activation of SREBP2, thereby ensuring sufficient cholesterol biosynthesis necessary for normal neuronal morphology and function (By similarity) | Voltage-gated channel that enables the transfer of anions such as iodide, chloride, bromide and fluoride which may function in counter-ion conductance and participates in Golgi acidification (PubMed:18794847). Plays a role in lymphocyte development, probably by acting as a RABL3 effector in hematopoietic cells (By similarity). Essential for maintaining the acidic luminal pH of the Golgi apparatus in neurons, which is important for preserving Golgi structural integrity (By similarity). This integrity supports proper axonal transport and synaptic maintenance in cerebellar inhibitory neurons, including Purkinje and basket cells (By similarity). Additionally, Golgi acidification facilitates the activation of SREBP2, thereby ensuring sufficient cholesterol biosynthesis necessary for normal neuronal morphology and function (By similarity)",Ubiquitous,,,Golgi apparatus membrane,18794847,18794847,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
GRID2,ENSG00000152208,Unsafe,Protein,False,True,33.0,33.0,102,5,Positive somewhere,True,True,False,True,Excluded,Normal,False,,Not assessed,,,positive normal IHC; positive ihc outside permitted; basal ganglia: 3.5 nTPM; absolute ceiling; cerebellum: 11.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; hypothalamus: 3.3 nTPM; absolute ceiling; retina: 4.7 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",basal ganglia: 3.5 nTPM (limit 2); cerebellum: 11.2 nTPM (limit 2); hypothalamus: 3.3 nTPM (limit 2); retina: 4.7 nTPM (limit 2),cerebellum / processes in molecular layer: High (Enhanced); cerebellum / Purkinje cells - cytoplasm/membrane: Medium (Enhanced); cerebellum / synaptic glomeruli - core: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 43/58 (74.1%); Glioblastoma Multiforme (TCGA): 45/141 (31.9%); Testicular Germ Cell Tumor (TCGA): 6/133 (4.5%),stomach cancer: 1/12 (8.3%); breast cancer: 0/11 (0.0%),31,20,O43424,https://www.uniprot.org/uniprotkb/O43424/entry,"Member of the ionotropic glutamate receptor family, which plays a crucial role in synaptic organization and signal transduction in the central nervous system (PubMed:34936451, PubMed:27418511, PubMed:40957579). Although it shares structural features with ionotropic glutamate receptors, does not bind glutamate as a primary ligand (PubMed:34936451). Promotes synaptogenesis and mediates the D-serine-dependent long term depression signals and AMPA receptor endocytosis of cerebellar parallel fiber-Purkinje cell (PF-PC) synapses through the NRX1B-CBLN1-GRID2 triad complex (PubMed:27418511). In the presence of neurexins and cerebellins, forms cation-selective channels that are proposed to be gated by glycine and D-serine (PubMed:34936451). Cation-selective ion channel activity can be triggered by GRM1 in Purkinje cells (PubMed:24357660, PubMed:27276689)",,"Spinocerebellar ataxia, autosomal recessive, 18: A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCAR18 features include progressive cerebellar atrophy, delayed psychomotor development, severely impaired gait, ocular movement abnormalities, and intellectual disability.","The ligand-gated cation channel activity was previously disputed due to a lack of evidence for direct ligand-gated ion channel activity (PubMed:39052831). However, structural studies have shown an asymmetric opening of the ion channel upon D-serine binding, and this would explain the lack of activity in the absence of D-serine (PubMed:40957579)",Postsynaptic cell membrane,24357660|27276689|27418511|34936451|40957579,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
GRIK5,ENSG00000105737,Unsafe,RNA,False,True,32.0,32.7,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 3.4 nTPM; absolute ceiling; amygdala: 16.9 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 20.6 nTPM; absolute ceiling;continuous selectivity; bone marrow: 2.7 nTPM; absolute ceiling; cerebellum: 32.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 27.3 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 7 nTPM; absolute ceiling; colon: 15.9 nTPM; absolute ceiling;continuous selectivity; heart muscle: 4.8 nTPM; absolute ceiling; hippocampal formation: 20 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 15.4 nTPM; absolute ceiling;continuous selectivity; kidney: 6.8 nTPM; absolute ceiling; midbrain: 8.9 nTPM; absolute ceiling;continuous selectivity; pancreas: 2.3 nTPM; absolute ceiling; parathyroid gland: 13.8 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 17.8 nTPM; absolute ceiling;continuous selectivity; retina: 11.9 nTPM; absolute ceiling;continuous selectivity; small intestine: 3.3 nTPM; absolute ceiling; smooth muscle: 4.8 nTPM; absolute ceiling; spinal cord: 3.6 nTPM; absolute ceiling; thyroid gland: 11 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 3.4 nTPM (limit 2); amygdala: 16.9 nTPM (limit 2); basal ganglia: 20.6 nTPM (limit 2); bone marrow: 2.7 nTPM (limit 2); cerebellum: 32.7 nTPM (limit 2); cerebral cortex: 27.3 nTPM (limit 2); choroid plexus: 7 nTPM (limit 2); colon: 15.9 nTPM (limit 6); heart muscle: 4.8 nTPM (limit 2); hippocampal formation: 20 nTPM (limit 2); hypothalamus: 15.4 nTPM (limit 2); kidney: 6.8 nTPM (limit 2); midbrain: 8.9 nTPM (limit 2); pancreas: 2.3 nTPM (limit 2); parathyroid gland: 13.8 nTPM (limit 6); pituitary gland: 17.8 nTPM (limit 2); retina: 11.9 nTPM (limit 2); small intestine: 3.3 nTPM (limit 2); smooth muscle: 4.8 nTPM (limit 2); spinal cord: 3.6 nTPM (limit 2); thyroid gland: 11 nTPM (limit 10); adrenal gland: 3.4 nTPM (baseline 2); amygdala: 16.9 nTPM (baseline 2); basal ganglia: 20.6 nTPM (baseline 2); bone marrow: 2.7 nTPM (baseline 2); cerebellum: 32.7 nTPM (baseline 2); cerebral cortex: 27.3 nTPM (baseline 2); choroid plexus: 7 nTPM (baseline 2); colon: 15.9 nTPM (baseline 6); heart muscle: 4.8 nTPM (baseline 2); hippocampal formation: 20 nTPM (baseline 2); hypothalamus: 15.4 nTPM (baseline 2); kidney: 6.8 nTPM (baseline 2); midbrain: 8.9 nTPM (baseline 2); pancreas: 2.3 nTPM (baseline 2); parathyroid gland: 13.8 nTPM (baseline 6); pituitary gland: 17.8 nTPM (baseline 2); retina: 11.9 nTPM (baseline 2); small intestine: 3.3 nTPM (baseline 2); smooth muscle: 4.8 nTPM (baseline 2); spinal cord: 3.6 nTPM (baseline 2); thyroid gland: 11 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Glioblastoma Multiforme (TCGA): 137/141 (97.2%); Thyroid Carcinoma (TCGA): 402/495 (81.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q16478,https://www.uniprot.org/uniprotkb/Q16478/entry,"Ionotropic glutamate receptor that functions as a cation-permeable ligand-gated ion channel, gated by L-glutamate and the glutamatergic agonist kainic acid. Cannot form functional channels on its own and produces channel activity only in heteromeric assembly with GRIK1 and GRIK2 subunits (PubMed:1321949, PubMed:14511640, PubMed:8730589). Can form functional heteromeric receptors with GRIK3 (By similarity)",,,,Cell membrane Postsynaptic cell membrane Presynaptic cell membrane,1321949|14511640|8730589,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
GRIN3A,ENSG00000198785,Unsafe,RNA,False,True,1.4,7.4,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 1.1 nTPM; continuous selectivity; cerebral cortex: 7.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 0.6 nTPM; continuous selectivity; hippocampal formation: 1 nTPM; continuous selectivity; hypothalamus: 1.9 nTPM; continuous selectivity;reproductive not higher; midbrain: 1 nTPM; continuous selectivity; retina: 0.8 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebral cortex: 7.4 nTPM (limit 2); cerebral cortex: 7.4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Prostate Adenocarcinoma (TCGA): 85/480 (17.7%); Glioblastoma Multiforme (validation): 3/58 (5.2%); Breast Invasive Carcinoma (validation): 1/50 (2.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8TCU5,https://www.uniprot.org/uniprotkb/Q8TCU5/entry,"Component of a non-conventional N-methyl-D-aspartate (NMDA) receptors (NMDARs) that function as heterotetrameric, ligand-gated cation channels with low calcium permeability and low voltage-dependent block by Mg(2+) (By similarity). During the development of neural circuits, participates in the synaptic refinement period, restricting spine maturation and growth (By similarity). Forms glutamatergic receptor complexes with GluN1 and GluN2 subunits which are activated by glycine binding to the GluN1 and GluN3 subunits and L-glutamate binding to GluN2 subunits (By similarity). Forms excitatory glycinergic receptor complexes with GluN1 alone which are activated by glycine binding to the GluN1 and GluN3 subunits (PubMed:38598639). GluN3A subunit also binds D-serine (By similarity). Each GluN3 subunit confers differential attributes to channel properties, including activation, deactivation and desensitization kinetics, pH sensitivity, Ca2(+) permeability, and binding to allosteric modulators (By similarity). By competing with GIT1 interaction with ARHGEF7/beta-PIX, may reduce GIT1/ARHGEF7-regulated local activation of RAC1, hence affecting signaling and limiting the maturation and growth of inactive synapses (By similarity)",,,,Cell membrane Postsynaptic cell membrane Postsynaptic density,38598639,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
GRK4,ENSG00000125388,Unsafe,Protein,False,True,41.1,41.1,97,7,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 5.5 nTPM; absolute ceiling; basal ganglia: 4.7 nTPM; absolute ceiling; cerebellum: 12.1 nTPM; absolute ceiling; cerebral cortex: 5.9 nTPM; positive ihc;absolute ceiling; choroid plexus: 2.7 nTPM; absolute ceiling; heart muscle: 4.7 nTPM; absolute ceiling; hippocampal formation: 5.8 nTPM; absolute ceiling; hypothalamus: 5.3 nTPM; absolute ceiling; midbrain: 5.7 nTPM; absolute ceiling; pancreas: 5.2 nTPM; absolute ceiling; pituitary gland: 6 nTPM; absolute ceiling; retina: 9.8 nTPM; absolute ceiling; skeletal muscle: 4.6 nTPM; absolute ceiling; spinal cord: 6.5 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 5.5 nTPM (limit 2); basal ganglia: 4.7 nTPM (limit 2); cerebellum: 12.1 nTPM (limit 4); cerebral cortex: 5.9 nTPM (limit 2); choroid plexus: 2.7 nTPM (limit 2); heart muscle: 4.7 nTPM (limit 4); hippocampal formation: 5.8 nTPM (limit 2); hypothalamus: 5.3 nTPM (limit 2); midbrain: 5.7 nTPM (limit 2); pancreas: 5.2 nTPM (limit 4); pituitary gland: 6 nTPM (limit 2); retina: 9.8 nTPM (limit 2); skeletal muscle: 4.6 nTPM (limit 4); spinal cord: 6.5 nTPM (limit 2),bronchus / ciliated cells (ciliary rootlets): High (Approved); cerebral cortex / neuronal cells: Low (Approved); nasopharynx / ciliated cells (ciliary rootlets): High (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 43/50 (86.0%); Glioblastoma Multiforme (TCGA): 107/141 (75.9%),liver cancer: 6/12 (50.0%); colorectal cancer: 2/12 (16.7%),31,20,P32298,https://www.uniprot.org/uniprotkb/P32298/entry,"Specifically phosphorylates the activated forms of G protein-coupled receptors, such as ADRB2, DRD1 and DRD3 (PubMed:16338988, PubMed:19520868). Such receptor phosphorylation initiates beta-arrestin-mediated receptor internalization, and signaling events leading to their desensitization (PubMed:16338988, PubMed:19520868). Mediates phosphorylation of DRD1 in the absence of dopamine activation, resulting in constitutive desensitization (PubMed:16338988) Phosphorylates rhodopsin and its activity is inhibited by calmodulin In contrast to isoform 1, does not phosphorylate rhodopsin and does not interact with calmodulin","Isoform 1, isoform 2, isoform 3, and isoform 4 are expressed in testis. Isoform 4 is expressed in myometrium",,,"Cytoplasm Cytoplasm, cell cortex",16338988|19520868|8626439,16636192|8626439,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Jamin2021_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
GRM8,ENSG00000179603,Unsafe,RNA,False,True,1.3,21.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 0.5 nTPM; continuous selectivity; amygdala: 0.5 nTPM; continuous selectivity; basal ganglia: 1.1 nTPM; continuous selectivity; cerebral cortex: 2.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 21 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 1.5 nTPM; continuous selectivity;reproductive not higher; hippocampal formation: 0.6 nTPM; continuous selectivity; hypothalamus: 0.9 nTPM; continuous selectivity; kidney: 0.6 nTPM; continuous selectivity; liver: 2.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 0.6 nTPM; continuous selectivity; rectum: 1.9 nTPM; continuous selectivity;reproductive not higher; retina: 1.9 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 0.7 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebral cortex: 2.1 nTPM (limit 2); choroid plexus: 21 nTPM (limit 2); liver: 2.7 nTPM (limit 2); cerebral cortex: 2.1 nTPM (baseline 2); choroid plexus: 21 nTPM (baseline 2); liver: 2.7 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 155/207 (74.9%); Colon Adenocarcinoma (validation): 276/486 (56.8%); Rectum Adenocarcinoma (TCGA): 43/88 (48.9%),breast cancer: 2/12 (16.7%); testis cancer: 2/12 (16.7%),31,20,O00222,https://www.uniprot.org/uniprotkb/O00222/entry,"G protein-coupled receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity",,,,Cell membrane,9473604,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
GRXCR1,ENSG00000215203,Unsafe,High RNA,False,True,2.4,2.4,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA040824; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Low, HPA040824; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA040824; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA040824; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA040824; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Low, HPA040824; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA040824; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA040824; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: High, HPA040824; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA040824; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA040824; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA040824; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA040824; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA040824; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA040824; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA040824; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA040824; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA040824; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA040824; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA040824; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA040824; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA040824; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA040824; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA040824; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA040824; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA040824; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA040824; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA040824; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Low, HPA040824; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA040824; conflicting or uncurated primary profile; Skin 1/Langerhans: Low, HPA040824; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA040824; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA040824; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA040824; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA040824; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA040824; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA040824; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,0.3137311471819999,95.4,"hpa_single_cell_tissue: prostate/t-cells, max 95.4 nTPM, 1 observations >30",Neither,oncoref.target-sets.2026-10-23.2,0.3137 TPM; blood/TH2; dice_th2; vital,95.4 nTPM; prostate/t-cells; hpa_single_cell_tissue; vital,Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),colorectal cancer: 8/11 (72.7%); breast cancer: 8/12 (66.7%),31,20,A8MXD5,https://www.uniprot.org/uniprotkb/A8MXD5/entry,May play a role in actin filament architecture in developing stereocilia of sensory cells,"Expressed at low levels in adult lung, brain and duodenum with moderate levels in testis. Highly expressed in fetal cochlea","Deafness, autosomal recessive, 25: A form of non-syndromic sensorineural deafness characterized by moderate to severe or profound hearing loss which is progressive in some individuals but not in others. Speech development is impaired in some but not all affected individuals, and vestibular dysfunction is observed in some affected individuals. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information.",,"Cell projection, stereocilium Cell projection, microvillus Cell projection, kinocilium",,20137778,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
GSG1,ENSG00000111305,Unsafe,RNA,False,True,418.0,418.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,choroid plexus: 11.5 nTPM; absolute ceiling; pancreas: 4.8 nTPM; absolute ceiling; retina: 29.5 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 11.5 nTPM (limit 2); pancreas: 4.8 nTPM (limit 2); retina: 29.5 nTPM (limit 2); choroid plexus: 11.5 nTPM (baseline 2); pancreas: 4.8 nTPM (baseline 2); retina: 29.5 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 30/133 (22.6%); Kidney Renal Papillary Cell Carcinoma (TCGA): 44/282 (15.6%); Uterine Corpus Endometrial Carcinoma (TCGA): 16/176 (9.1%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q2KHT4,https://www.uniprot.org/uniprotkb/Q2KHT4/entry,May cause the redistribution of PAPOLB from the cytosol to the endoplasmic reticulum,,,,Endoplasmic reticulum membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
GSTA5,ENSG00000182793,Unsafe,High RNA,False,True,0.0,0.0,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,insufficient positive reproductive evidence; reproductive expression not demonstrated; incomplete tissue evidence,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,True,"bronchus/smooth muscle cells cluster c-13: 102.9 nTPM, 122 reads; reproductive-cell max 1.5",True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA004342; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA004342; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA004342; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA004342; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA004342; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA004342; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA004342; conflicting or uncurated primary profile; Colon/Glandular cells: Low, HPA004342; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA004342; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: High, HPA004342; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA004342; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA004342; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA004342; conflicting or uncurated primary profile; Liver/Hepatocytes: High, HPA004342; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA004342; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA004342; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA004342; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA004342; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA004342; conflicting or uncurated primary profile; Rectum/Glandular cells: Low, HPA004342; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: High, HPA004342; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA004342; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA004342; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: High, HPA004342; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA004342; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA004342; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA004342; conflicting or uncurated primary profile; Adipose tissue/Adipocytes: Low, HPA048934; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA048934; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA048934; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA048934; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA048934; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA048934; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA048934; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA048934; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA048934; conflicting or uncurated primary profile; Duodenum/Endocrine cells: High, HPA048934; conflicting or uncurated primary profile; Duodenum/Enterocytes: Medium, HPA048934; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA048934; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA048934; conflicting or uncurated primary profile; Liver/Hepatocytes: High, HPA048934; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA048934; conflicting or uncurated primary profile; Lung/Macrophages: High, HPA048934; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA048934; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA048934; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Low, HPA048934; conflicting or uncurated primary profile; Rectum/Endothelial cells: Low, HPA048934; conflicting or uncurated primary profile; Rectum/Mucosal lymphoid cells: Low, HPA048934; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA048934; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA048934; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA048934; conflicting or uncurated primary profile; Small intestine/Enterocytes: Low, HPA048934; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA048934; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA048934; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA048934; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA048934; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA053817; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA053817; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA053817; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA053817; conflicting or uncurated primary profile; Liver/Hepatocytes: High, HPA053817; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA053817; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA053817; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA053817; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA053817; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA053817; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,0.0,102.9,"hpa_single_cell_tissue: bronchus/smooth muscle cells, max 102.9 nTPM, 1 observations >30",Neither,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,102.9 nTPM; bronchus/smooth muscle cells; hpa_single_cell_tissue; vital,Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%); Breast Invasive Carcinoma (validation): 0/50 (0.0%),liver cancer: 8/10 (80.0%); stomach cancer: 7/9 (77.8%),31,20,Q7RTV2,https://www.uniprot.org/uniprotkb/Q7RTV2/entry,,Expression not detected,,,Cytoplasm,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
GSTCD,ENSG00000138780,Unsafe,Protein,False,True,10.5,10.5,83,62,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 2.5 nTPM; positive ihc; adrenal gland: 2.3 nTPM; positive ihc;absolute ceiling; bone marrow: 5.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 2.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 3.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 2.9 nTPM; absolute ceiling;continuous selectivity; colon: 3.6 nTPM; positive ihc; duodenum: 2.5 nTPM; positive ihc;absolute ceiling; esophagus: 4.8 nTPM; positive ihc;continuous selectivity; heart muscle: 2.2 nTPM; positive ihc;absolute ceiling; kidney: 4.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 2.4 nTPM; positive ihc;absolute ceiling; lung: 2.6 nTPM; positive ihc;absolute ceiling; lymph node: 4.5 nTPM; positive ihc;continuous selectivity; midbrain: 2.1 nTPM; absolute ceiling; pancreas: 3.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 3.4 nTPM; positive ihc; pituitary gland: 2.3 nTPM; absolute ceiling; rectum: 3.9 nTPM; positive ihc;continuous selectivity; retina: 7.1 nTPM; absolute ceiling;continuous selectivity; salivary gland: 2.1 nTPM; positive ihc; skeletal muscle: 2 nTPM; positive ihc; skin: 3.3 nTPM; positive ihc; small intestine: 2.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 3.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 2.4 nTPM; absolute ceiling; spleen: 2.7 nTPM; positive ihc; stomach: 3.2 nTPM; positive ihc; thyroid gland: 5.2 nTPM; positive ihc;continuous selectivity; urinary bladder: 2.3 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 2.3 nTPM (limit 2); bone marrow: 5.2 nTPM (limit 2); cerebellum: 2.8 nTPM (limit 2); cerebral cortex: 3.5 nTPM (limit 2); choroid plexus: 2.9 nTPM (limit 2); duodenum: 2.5 nTPM (limit 2); heart muscle: 2.2 nTPM (limit 2); kidney: 4.2 nTPM (limit 2); liver: 2.4 nTPM (limit 2); lung: 2.6 nTPM (limit 2); midbrain: 2.1 nTPM (limit 2); pancreas: 3.1 nTPM (limit 2); pituitary gland: 2.3 nTPM (limit 2); retina: 7.1 nTPM (limit 2); small intestine: 2.9 nTPM (limit 2); smooth muscle: 3.9 nTPM (limit 2); spinal cord: 2.4 nTPM (limit 2),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: High (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Medium (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: High (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Low (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: High (Approved); liver / hepatocytes: High (Approved); lung / macrophages: Medium (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: High (Approved); pancreas / exocrine glandular cells: High (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: High (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: High (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 485/486 (99.8%),colorectal cancer: 10/10 (100.0%); liver cancer: 10/12 (83.3%),31,20,Q8NEC7,https://www.uniprot.org/uniprotkb/Q8NEC7/entry,,"Widely expressed in cell types relevant to airway function, including airway smooth muscle cells and epithelial cells",,,Cytoplasm,,24058608,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
GTF2A1L,ENSG00000242441,Unsafe,RNA,False,True,58.2,58.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,colon: 8.4 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,colon: 8.4 nTPM (limit 6); colon: 8.4 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 1/50 (2.0%); Glioblastoma Multiforme (validation): 1/58 (1.7%); Testicular Germ Cell Tumor (TCGA): 2/133 (1.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9UNN4,https://www.uniprot.org/uniprotkb/Q9UNN4/entry,"May function as a testis specific transcription factor. Binds DNA in conjunction with GTF2A2 and TBP (the TATA-binding protein) and together with GTF2A2, allows mRNA transcription",Testis specific. Detected in adult testis mostly in round and elongating spermatids (at protein level). Detected in testis,,,Nucleus,10364255,10364255|16525715,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
GTPBP10,ENSG00000105793,Unsafe,Protein,False,True,10.9,18.1,90,58,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 8.2 nTPM; continuous selectivity; adrenal gland: 7 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 3.6 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 3.7 nTPM; absolute ceiling;continuous selectivity; bone marrow: 6.4 nTPM; absolute ceiling;continuous selectivity; cerebellum: 5.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 7.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 4 nTPM; absolute ceiling;continuous selectivity; colon: 8.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 8.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 8 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 9.7 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 3.9 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 4.2 nTPM; absolute ceiling;continuous selectivity; kidney: 12.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 18.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 5.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 10.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 4.3 nTPM; absolute ceiling;continuous selectivity; pancreas: 7.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 7.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 4.4 nTPM; absolute ceiling;continuous selectivity; rectum: 9.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 7 nTPM; absolute ceiling;continuous selectivity; salivary gland: 5.9 nTPM; positive ihc;continuous selectivity; skeletal muscle: 11.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 6.6 nTPM; positive ihc;continuous selectivity; small intestine: 6.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 6.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 4.5 nTPM; absolute ceiling;continuous selectivity; spleen: 7.2 nTPM; positive ihc;continuous selectivity; stomach: 10.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 12.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 9.5 nTPM; positive ihc;continuous selectivity; tongue: 9.7 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 9.2 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 7 nTPM (limit 2); amygdala: 3.6 nTPM (limit 2); basal ganglia: 3.7 nTPM (limit 2); bone marrow: 6.4 nTPM (limit 4); cerebellum: 5.2 nTPM (limit 2); cerebral cortex: 7.2 nTPM (limit 2); choroid plexus: 4 nTPM (limit 2); colon: 8.5 nTPM (limit 6); duodenum: 8.5 nTPM (limit 2); esophagus: 8 nTPM (limit 6); heart muscle: 9.7 nTPM (limit 4); hippocampal formation: 3.9 nTPM (limit 2); hypothalamus: 4.2 nTPM (limit 2); kidney: 12.1 nTPM (limit 2); liver: 18.1 nTPM (limit 4); lung: 5.6 nTPM (limit 2); lymph node: 10.6 nTPM (limit 6); midbrain: 4.3 nTPM (limit 2); pancreas: 7.4 nTPM (limit 2); parathyroid gland: 7.8 nTPM (limit 6); pituitary gland: 4.4 nTPM (limit 2); rectum: 9.3 nTPM (limit 6); retina: 7 nTPM (limit 2); skeletal muscle: 11.8 nTPM (limit 2); small intestine: 6.9 nTPM (limit 2); smooth muscle: 6.9 nTPM (limit 2); spinal cord: 4.5 nTPM (limit 2); stomach: 10.4 nTPM (limit 6); thymus: 12.4 nTPM (limit 10); tongue: 9.7 nTPM (limit 6); urinary bladder: 9.2 nTPM (limit 6),adrenal gland / glandular cells: Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: High (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Medium (Approved); colon / glandular cells: High (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: High (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: High (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / basal cells: High (Approved); nasopharynx / ciliated cells (cell body): High (Approved); oral mucosa / squamous epithelial cells: High (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: High (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / keratinocytes: High (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: High (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (TCGA): 141/141 (100.0%); Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%),skin cancer: 11/11 (100.0%); cervical cancer: 6/11 (54.5%),31,20,A4D1E9,https://www.uniprot.org/uniprotkb/A4D1E9/entry,"May be involved in the ribosome maturation process. Complements an ObgE(CgtA) function in E.coli ribosome maturation. Plays a role of GTPase in vitro. When missing, disorganization of the nucleolar architecture is observed",,,,"Nucleus, nucleolus Chromosome",17054726,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
GTSE1,ENSG00000075218,Unsafe,RNA,False,True,7.0,19.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 11 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 4 nTPM; absolute ceiling;continuous selectivity; esophagus: 3.5 nTPM; continuous selectivity; lymph node: 9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 2.5 nTPM; continuous selectivity; small intestine: 2.8 nTPM; absolute ceiling;continuous selectivity; thymus: 19.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 11 nTPM (limit 2); duodenum: 4 nTPM (limit 2); lymph node: 9 nTPM (limit 6); small intestine: 2.8 nTPM (limit 2); thymus: 19.1 nTPM (limit 10); bone marrow: 11 nTPM (baseline 2); duodenum: 4 nTPM (baseline 2); lymph node: 9 nTPM (baseline 6); small intestine: 2.8 nTPM (baseline 2); thymus: 19.1 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 131/133 (98.5%); Colon Adenocarcinoma (validation): 473/486 (97.3%); Breast Invasive Carcinoma (validation): 47/50 (94.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9NYZ3,https://www.uniprot.org/uniprotkb/Q9NYZ3/entry,May be involved in p53-induced cell cycle arrest in G2/M phase by interfering with microtubule rearrangements that are required to enter mitosis. Overexpression delays G2/M phase progression,,,It is uncertain whether Met-1 or Met-20 is the initiator,"Cytoplasm, cytoskeleton",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
GTSF1,ENSG00000170627,Unsafe,RNA,False,True,180.5,180.5,87,6,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,bone marrow: 6 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 6 nTPM (limit 4),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 102/133 (76.7%); Liver Hepatocellular Carcinoma (validation): 65/231 (28.1%); Lung Squamous Cell Carcinoma (validation): 18/68 (26.5%),testis cancer: 7/11 (63.6%); lymphoma: 4/12 (33.3%),31,20,Q8WW33,https://www.uniprot.org/uniprotkb/Q8WW33/entry,Required for spermatogenesis and is involved in the suppression of retrotransposon transcription in male germ cells,,,,Cytoplasm,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
GUCA1A,ENSG00000048545,Unsafe,Protein,False,True,8.4,734.2,90,1,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; choroid plexus: 2.4 nTPM; absolute ceiling;continuous selectivity; retina: 734.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 2.4 nTPM (limit 2); retina: 734.2 nTPM (limit 2); choroid plexus: 2.4 nTPM (baseline 2); retina: 734.2 nTPM (baseline 2),retina / photoreceptor cells: High (Supported),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 80/133 (60.2%); Uterine Corpus Endometrial Carcinoma (TCGA): 12/176 (6.8%); Bladder Urothelial Carcinoma (TCGA): 5/169 (3.0%),breast cancer: 0/11 (0.0%); cervical cancer: 0/11 (0.0%),31,20,P43080,https://www.uniprot.org/uniprotkb/P43080/entry,"Stimulates retinal guanylyl cyclase when free calcium ions concentration is low and inhibits guanylyl cyclase when free calcium ions concentration is elevated (PubMed:18706439, PubMed:19459154, PubMed:30184081, PubMed:30622141). This Ca(2+)-sensitive regulation of retinal guanylyl cyclase is a key event in recovery of the dark state of rod photoreceptors following light exposure (By similarity). May be involved in cone photoreceptor light response and recovery of response in bright light (By similarity)","In the retina, it is expressed in rod and cone photoreceptors","Cone dystrophy 3: An autosomal dominant cone dystrophy. Cone dystrophies are retinal dystrophies characterized by progressive degeneration of the cone photoreceptors with preservation of rod function, as indicated by electroretinogram. However, some rod involvement may be present in some cone dystrophies, particularly at late stage. Affected individuals suffer from photophobia, loss of visual acuity, color vision and central visual field. Another sign is the absence of macular lesions for many years. Cone dystrophies are distinguished from the cone-rod dystrophies in which some loss of peripheral vision also occurs. Cone-rod dystrophy 14: An autosomal dominant form of cone-rod dystrophy, a retinal disease characterized by retinal pigment deposits visible on fundus examination, predominantly in the macular region, and initial loss of cone photoreceptors followed by rod degeneration. This leads to decreased visual acuity and sensitivity in the central visual field, followed by loss of peripheral vision. Severe loss of vision occurs earlier than in retinitis pigmentosa, due to cone photoreceptors degenerating at a higher rate than rod photoreceptors.",,"Membrane Photoreceptor inner segment Cell projection, cilium, photoreceptor outer segment",18706439|30184081|30622141,9620085,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
GUCY2F,ENSG00000101890,Unsafe,RNA,False,True,0.2,40.9,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,retina: 40.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thymus: 0.2 nTPM; continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 40.9 nTPM (limit 2); retina: 40.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P51841,https://www.uniprot.org/uniprotkb/P51841/entry,"Responsible for the synthesis of cyclic GMP (cGMP) in rods and cones of photoreceptors (PubMed:7777544). Plays an essential role in phototransduction, by mediating cGMP replenishment (By similarity). May also participate in the trafficking of membrane-associated proteins to the photoreceptor outer segment membrane (By similarity)",Retina. Localized exclusively in the outer nuclear layer and inner segments of the rod and cone photoreceptor cells,,,Photoreceptor outer segment membrane,7777544,7777544,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT,Cancer-associated RNA nomination; no antigen validation asserted,,,,,,,,
H1-1,ENSG00000124610,Unsafe,Protein,False,True,0.1,0.1,88,18,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,family exclusion; family exclusion; positive normal IHC; positive ihc outside permitted; esophagus: 0 nTPM; positive ihc; kidney: 0 nTPM; positive ihc; skin: 0 nTPM; positive ihc; thyroid gland: 0.1 nTPM; reproductive not higher; urinary bladder: 0 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,esophagus / squamous epithelial cells: Low (Enhanced); kidney / distal tubules: Medium (Enhanced); nasopharynx / respiratory epithelial cells: Low (Enhanced); oral mucosa / squamous epithelial cells: Low (Enhanced); skin 1 / keratinocytes: Low (Enhanced); urinary bladder / urothelial cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 44/58 (75.9%); Pancreatic Adenocarcinoma (validation): 21/80 (26.2%); Colon Adenocarcinoma (validation): 97/486 (20.0%),testis cancer: 3/11 (27.3%); endometrial cancer: 3/12 (25.0%),29,20,Q02539,https://www.uniprot.org/uniprotkb/Q02539/entry,"Histone H1 protein binds to linker DNA between nucleosomes forming the macromolecular structure known as the chromatin fiber (PubMed:11130728). Histones H1 are necessary for the condensation of nucleosome chains into higher-order structured fibers and promote formation of the H3K27me3 mark by the PRC2/EED-EZH2 complex (PubMed:11130728). Also acts as a regulator of individual gene transcription through chromatin remodeling, nucleosome spacing and DNA methylation (By similarity)",,,,Nucleus Chromosome,11130728,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | daSilva2017_tumor_proteomics,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
H1-7,ENSG00000187166,Unsafe,Protein,False,True,211.0,211.0,79,41,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,family exclusion; family exclusion; positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0.2 nTPM; positive ihc; bone marrow: 0.1 nTPM; positive ihc; cerebellum: 0.7 nTPM; positive ihc; colon: 0.3 nTPM; positive ihc; duodenum: 0 nTPM; positive ihc; esophagus: 0 nTPM; positive ihc; heart muscle: 0.1 nTPM; positive ihc; kidney: 0.1 nTPM; positive ihc; liver: 0.1 nTPM; positive ihc; lung: 0.2 nTPM; positive ihc; parathyroid gland: 0 nTPM; positive ihc; salivary gland: 0.1 nTPM; positive ihc; skin: 0.2 nTPM; positive ihc; smooth muscle: 0 nTPM; positive ihc; stomach: 0.1 nTPM; positive ihc; urinary bladder: 0.4 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,adipose tissue / adipocytes: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Low (Approved); cerebellum / Purkinje cells: Low (Approved); colon / endothelial cells: Medium (Approved); duodenum / glandular cells: Low (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: High (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: High (Approved); parathyroid gland / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: Low (Approved); smooth muscle / smooth muscle cells: Low (Approved); stomach 2 / glandular cells: Low (Approved); urinary bladder / urothelial cells: High (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 1/283 (0.4%),testis cancer: 7/11 (63.6%); urothelial cancer: 4/9 (44.4%),29,20,Q75WM6,https://www.uniprot.org/uniprotkb/Q75WM6/entry,"Essential for normal spermatogenesis and male fertility (PubMed:16533358). Required for proper cell restructuring and DNA condensation during the elongation phase of spermiogenesis. Involved in the histone-protamine transition of sperm chromatin and the subsequent production of functional sperm. Binds both double-stranded and single-stranded DNA, ATP and protamine-1",Testis-specific,,It is uncertain whether Met-1 or Met-22 is the initiator,Nucleus Chromosome,16533358,16533358,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
H1-8,ENSG00000178804,Unsafe,Protein,False,True,7.1,7.1,85,5,Positive somewhere,True,False,False,True,Excluded,Normal,False,,Not assessed,,,family exclusion; family exclusion; positive normal IHC; positive ihc outside permitted; cerebellum: 0 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,cerebellum / cells in molecular layer: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),breast cancer: 0/10 (0.0%); cervical cancer: 0/12 (0.0%),29,20,Q8IZA3,https://www.uniprot.org/uniprotkb/Q8IZA3/entry,"May play a key role in the control of gene expression during oogenesis and early embryogenesis, presumably through the perturbation of chromatin structure. Essential for meiotic maturation of germinal vesicle-stage oocytes. The somatic type linker histone H1c is rapidly replaced by H1oo in a donor nucleus transplanted into an oocyte. The greater mobility of H1oo as compared to H1c may contribute to this rapid replacement and increased instability of the embryonic chromatin structure. The rapid replacement of H1c with H1oo may play an important role in nuclear remodeling (By similarity)",Oocyte-specific,,,Cytoplasm Nucleus Chromosome,,12711322,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
H2AC1,ENSG00000164508,Unsafe,Protein,False,True,5.5,5.5,86,78,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,family exclusion; family exclusion; positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0 nTPM; positive ihc; adrenal gland: 0 nTPM; positive ihc; bone marrow: 0 nTPM; positive ihc; cerebellum: 0 nTPM; positive ihc; cerebral cortex: 0 nTPM; positive ihc; colon: 0 nTPM; positive ihc; duodenum: 0 nTPM; positive ihc; esophagus: 0 nTPM; positive ihc; heart muscle: 0 nTPM; positive ihc; kidney: 0.2 nTPM; positive ihc; liver: 0.1 nTPM; positive ihc; lung: 0 nTPM; positive ihc; lymph node: 0 nTPM; positive ihc; pancreas: 0.3 nTPM; positive ihc; parathyroid gland: 0 nTPM; positive ihc; rectum: 0 nTPM; positive ihc; salivary gland: 0 nTPM; positive ihc; skeletal muscle: 0 nTPM; positive ihc; skin: 0 nTPM; positive ihc; small intestine: 0 nTPM; positive ihc; smooth muscle: 0 nTPM; positive ihc; spleen: 0 nTPM; positive ihc; stomach: 0 nTPM; positive ihc; thyroid gland: 0 nTPM; positive ihc; urinary bladder: 0 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,adipose tissue / adipocytes: Medium (Supported); adrenal gland / glandular cells: Medium (Supported); bone marrow / hematopoietic cells: High (Supported); bronchus / respiratory epithelial cells: Medium (Supported); caudate / glial cells: High (Supported); caudate / neuronal cells: High (Supported); cerebellum / cells in granular layer: High (Supported); cerebellum / cells in molecular layer: High (Supported); cerebellum / Purkinje cells: Low (Supported); cerebral cortex / glial cells: High (Supported); cerebral cortex / neuronal cells: High (Supported); colon / endothelial cells: Medium (Supported); colon / glandular cells: Medium (Supported); colon / peripheral nerve/ganglion: Medium (Supported); duodenum / glandular cells: High (Supported); esophagus / squamous epithelial cells: Medium (Supported); heart muscle / cardiomyocytes: Medium (Supported); hippocampus / glial cells: High (Supported); hippocampus / neuronal cells: High (Supported); kidney / cells in glomeruli: Medium (Supported); kidney / cells in tubules: Medium (Supported); liver / cholangiocytes: Low (Supported); liver / hepatocytes: Medium (Supported); lung / alveolar cells: High (Supported); lung / macrophages: High (Supported); lymph node / germinal center cells: Medium (Supported); lymph node / non-germinal center cells: Medium (Supported); nasopharynx / respiratory epithelial cells: Medium (Supported); oral mucosa / squamous epithelial cells: Medium (Supported); pancreas / exocrine glandular cells: High (Supported); pancreas / pancreatic endocrine cells: Medium (Supported); parathyroid gland / glandular cells: Low (Supported); rectum / glandular cells: Medium (Supported); salivary gland / glandular cells: Low (Supported); skeletal muscle / myocytes: Medium (Supported); skin 1 / fibroblasts: Medium (Supported); skin 1 / keratinocytes: Medium (Supported); skin 1 / Langerhans: Medium (Supported); skin 2 / epidermal cells: Medium (Supported); small intestine / glandular cells: Medium (Supported); smooth muscle / smooth muscle cells: Medium (Supported); spleen / cells in red pulp: Medium (Supported); stomach 1 / glandular cells: High (Supported); stomach 2 / glandular cells: High (Supported); thyroid gland / glandular cells: High (Supported); urinary bladder / urothelial cells: Medium (Supported),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Colon Adenocarcinoma (validation): 1/486 (0.2%); Lung Adenocarcinoma (TCGA): 1/497 (0.2%),glioma: 12/12 (100.0%); lung cancer: 11/11 (100.0%),29,20,Q96QV6,https://www.uniprot.org/uniprotkb/Q96QV6/entry,"Core component of nucleosome. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. DNA accessibility is regulated via a complex set of post-translational modifications of histones, also called histone code, and nucleosome remodeling",,,,Nucleus Chromosome,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Chang2019_TGCT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
H2BC12L,ENSG00000234289,Unsafe,Protein,False,True,1.4,1.9,84,82,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,family exclusion; family exclusion; positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0.9 nTPM; positive ihc;continuous selectivity; adrenal gland: 0.6 nTPM; positive ihc;continuous selectivity; bone marrow: 0.1 nTPM; positive ihc; cerebellum: 0 nTPM; positive ihc; cerebral cortex: 0.1 nTPM; positive ihc; colon: 0.7 nTPM; positive ihc;continuous selectivity; duodenum: 0.1 nTPM; positive ihc; esophagus: 1.3 nTPM; positive ihc;continuous selectivity; heart muscle: 0.5 nTPM; positive ihc;continuous selectivity; kidney: 0.2 nTPM; positive ihc; liver: 1.9 nTPM; positive ihc;continuous selectivity;reproductive not higher; lung: 0.9 nTPM; positive ihc;continuous selectivity; lymph node: 1.4 nTPM; positive ihc;continuous selectivity;reproductive not higher; pancreas: 1 nTPM; positive ihc;continuous selectivity; parathyroid gland: 0 nTPM; positive ihc; rectum: 0 nTPM; positive ihc; salivary gland: 0.6 nTPM; positive ihc;continuous selectivity; skeletal muscle: 0.1 nTPM; positive ihc; skin: 0.6 nTPM; positive ihc; small intestine: 0.8 nTPM; positive ihc;continuous selectivity; smooth muscle: 0 nTPM; positive ihc; spleen: 1.5 nTPM; positive ihc;continuous selectivity;reproductive not higher; stomach: 0.6 nTPM; positive ihc;continuous selectivity; thyroid gland: 0.7 nTPM; positive ihc; urinary bladder: 0.3 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,adipose tissue / adipocytes: High (Supported); adrenal gland / glandular cells: High (Supported); bone marrow / hematopoietic cells: High (Supported); bronchus / respiratory epithelial cells: High (Supported); caudate / glial cells: High (Supported); caudate / neuronal cells: Medium (Supported); cerebellum / cells in granular layer: High (Supported); cerebellum / cells in molecular layer: High (Supported); cerebellum / Purkinje cells: Medium (Supported); cerebral cortex / endothelial cells: Medium (Supported); cerebral cortex / glial cells: High (Supported); cerebral cortex / neuronal cells: Medium (Supported); colon / glandular cells: High (Supported); duodenum / glandular cells: High (Supported); esophagus / squamous epithelial cells: High (Supported); heart muscle / cardiomyocytes: High (Supported); hippocampus / glial cells: High (Supported); hippocampus / neuronal cells: High (Supported); kidney / cells in glomeruli: High (Supported); kidney / cells in tubules: High (Supported); liver / cholangiocytes: High (Supported); liver / hepatocytes: High (Supported); lung / alveolar cells: High (Supported); lung / macrophages: High (Supported); lymph node / germinal center cells: High (Supported); lymph node / non-germinal center cells: High (Supported); nasopharynx / respiratory epithelial cells: High (Supported); oral mucosa / squamous epithelial cells: High (Supported); pancreas / exocrine glandular cells: High (Supported); pancreas / pancreatic endocrine cells: High (Supported); parathyroid gland / glandular cells: High (Supported); rectum / glandular cells: High (Supported); salivary gland / glandular cells: High (Supported); skeletal muscle / myocytes: High (Supported); skin 1 / fibroblasts: High (Supported); skin 1 / keratinocytes: High (Supported); skin 1 / Langerhans: High (Supported); skin 2 / epidermal cells: High (Supported); small intestine / glandular cells: High (Supported); smooth muscle / smooth muscle cells: Medium (Supported); spleen / cells in red pulp: High (Supported); spleen / cells in white pulp: High (Supported); stomach 1 / glandular cells: High (Supported); stomach 2 / glandular cells: High (Supported); thyroid gland / glandular cells: High (Supported); urinary bladder / urothelial cells: High (Supported),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 15/58 (25.9%); Pancreatic Adenocarcinoma (validation): 6/80 (7.5%); Ovary Serous Cystadenocarcinoma (validation): 6/81 (7.4%),breast cancer: 12/12 (100.0%); cervical cancer: 12/12 (100.0%),29,20,P57053,https://www.uniprot.org/uniprotkb/P57053/entry,"Core component of nucleosome. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. DNA accessibility is regulated via a complex set of post-translational modifications of histones, also called histone code, and nucleosome remodeling Has broad antibacterial activity. May contribute to the formation of the functional antimicrobial barrier of the colonic epithelium, and to the bactericidal activity of amniotic fluid",,,,Nucleus Chromosome,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Gong2021_reproductive_PC,No tumor-antigen validation in this source | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
H2BC3,ENSG00000276410,Unsafe,Protein,False,True,1.3,1.3,85,83,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,family exclusion; family exclusion; positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0 nTPM; positive ihc; adrenal gland: 0 nTPM; positive ihc; bone marrow: 1 nTPM; positive ihc;continuous selectivity; cerebellum: 0 nTPM; positive ihc; cerebral cortex: 0 nTPM; positive ihc; choroid plexus: 0.5 nTPM; continuous selectivity; colon: 0.1 nTPM; positive ihc; duodenum: 0.1 nTPM; positive ihc; esophagus: 0.1 nTPM; positive ihc; heart muscle: 0 nTPM; positive ihc; kidney: 0 nTPM; positive ihc; liver: 0 nTPM; positive ihc; lung: 0 nTPM; positive ihc; lymph node: 0.2 nTPM; positive ihc; pancreas: 0 nTPM; positive ihc; parathyroid gland: 0 nTPM; positive ihc; rectum: 0 nTPM; positive ihc; salivary gland: 0 nTPM; positive ihc; skeletal muscle: 0.2 nTPM; positive ihc; skin: 0 nTPM; positive ihc; small intestine: 0.1 nTPM; positive ihc; smooth muscle: 0 nTPM; positive ihc; spleen: 0.1 nTPM; positive ihc; stomach: 0 nTPM; positive ihc; thymus: 1 nTPM; continuous selectivity; thyroid gland: 0 nTPM; positive ihc; urinary bladder: 0 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,adipose tissue / adipocytes: High (Supported); adrenal gland / glandular cells: High (Supported); bone marrow / hematopoietic cells: High (Supported); bronchus / respiratory epithelial cells: High (Supported); caudate / glial cells: High (Supported); caudate / neuronal cells: High (Supported); cerebellum / cells in granular layer: High (Supported); cerebellum / cells in molecular layer: High (Supported); cerebellum / Purkinje cells: Low (Supported); cerebral cortex / endothelial cells: Medium (Supported); cerebral cortex / glial cells: Medium (Supported); cerebral cortex / neuronal cells: High (Supported); colon / glandular cells: High (Supported); duodenum / glandular cells: High (Supported); esophagus / squamous epithelial cells: High (Supported); heart muscle / cardiomyocytes: High (Supported); hippocampus / glial cells: High (Supported); hippocampus / neuronal cells: High (Supported); kidney / cells in glomeruli: High (Supported); kidney / cells in tubules: High (Supported); liver / cholangiocytes: High (Supported); liver / hepatocytes: High (Supported); lung / alveolar cells: High (Supported); lung / macrophages: High (Supported); lymph node / germinal center cells: Medium (Supported); lymph node / non-germinal center cells: Medium (Supported); nasopharynx / respiratory epithelial cells: High (Supported); oral mucosa / squamous epithelial cells: High (Supported); pancreas / exocrine glandular cells: High (Supported); pancreas / pancreatic endocrine cells: High (Supported); parathyroid gland / glandular cells: High (Supported); rectum / glandular cells: High (Supported); salivary gland / glandular cells: High (Supported); skeletal muscle / myocytes: High (Supported); skin 1 / fibroblasts: High (Supported); skin 1 / keratinocytes: High (Supported); skin 1 / Langerhans: High (Supported); skin 2 / epidermal cells: High (Supported); small intestine / glandular cells: High (Supported); smooth muscle / smooth muscle cells: Medium (Supported); spleen / cells in red pulp: High (Supported); spleen / cells in white pulp: High (Supported); stomach 1 / glandular cells: High (Supported); stomach 2 / glandular cells: High (Supported); thyroid gland / glandular cells: High (Supported); urinary bladder / urothelial cells: High (Supported),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 477/486 (98.1%); Rectum Adenocarcinoma (validation): 193/207 (93.2%); Colon Adenocarcinoma (TCGA): 6/254 (2.4%),breast cancer: 12/12 (100.0%); cervical cancer: 12/12 (100.0%),26,20,P33778,https://www.uniprot.org/uniprotkb/P33778/entry,"Core component of nucleosome. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. DNA accessibility is regulated via a complex set of post-translational modifications of histones, also called histone code, and nucleosome remodeling",,,,Nucleus Chromosome,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | daSilva2017_tumor_proteomics,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
H3-4,ENSG00000168148,Unsafe,Protein,False,True,3.0,3.0,105,100,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,family exclusion; family exclusion; positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0 nTPM; positive ihc; adrenal gland: 0 nTPM; positive ihc; bone marrow: 0 nTPM; positive ihc; cerebellum: 0.2 nTPM; positive ihc; cerebral cortex: 0 nTPM; positive ihc; colon: 0.1 nTPM; positive ihc; duodenum: 0 nTPM; positive ihc; esophagus: 0 nTPM; positive ihc; heart muscle: 0 nTPM; positive ihc; kidney: 0 nTPM; positive ihc; liver: 0 nTPM; positive ihc; lung: 0 nTPM; positive ihc; lymph node: 0 nTPM; positive ihc; pancreas: 0 nTPM; positive ihc; parathyroid gland: 0 nTPM; positive ihc; rectum: 0 nTPM; positive ihc; salivary gland: 0.1 nTPM; positive ihc; skeletal muscle: 0 nTPM; positive ihc; skin: 0 nTPM; positive ihc; small intestine: 0.1 nTPM; positive ihc; smooth muscle: 0 nTPM; positive ihc; spleen: 0 nTPM; positive ihc; stomach: 0 nTPM; positive ihc; thyroid gland: 0 nTPM; positive ihc; urinary bladder: 0.1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,adipose tissue / adipocytes: High (Approved); adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: High (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / glial cells: High (Approved); caudate / neuronal cells: High (Approved); cerebellum / cells in granular layer: High (Approved); cerebellum / cells in molecular layer: High (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / endothelial cells: High (Approved); cerebral cortex / glial cells: High (Approved); cerebral cortex / neuronal cells: High (Approved); colon / endothelial cells: High (Approved); colon / glandular cells: High (Approved); colon / peripheral nerve/ganglion: High (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: High (Approved); heart muscle / cardiomyocytes: High (Approved); hippocampus / glial cells: High (Approved); hippocampus / neuronal cells: High (Approved); kidney / cells in glomeruli: High (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: High (Approved); liver / hepatocytes: High (Approved); lung / alveolar cells: High (Approved); lung / macrophages: High (Approved); lymph node / germinal center cells: High (Approved); lymph node / non-germinal center cells: High (Approved); nasopharynx / respiratory epithelial cells: High (Approved); oral mucosa / squamous epithelial cells: High (Approved); pancreas / exocrine glandular cells: High (Approved); pancreas / pancreatic endocrine cells: High (Approved); parathyroid gland / glandular cells: High (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: High (Approved); skeletal muscle / myocytes: High (Approved); skin 1 / cells in basal layer: High (Approved); skin 1 / cells in granular layer: High (Approved); skin 1 / cells in spinous layer: High (Approved); skin 1 / endothelial cells: High (Approved); skin 1 / fibrohistiocytic cells: High (Approved); skin 1 / langerhans cells: High (Approved); skin 1 / lymphocytes: High (Approved); skin 1 / vascular mural cells: High (Approved); skin 2 / cells in basal layer: High (Approved); skin 2 / cells in granular layer: High (Approved); skin 2 / cells in spinous layer: High (Approved); skin 2 / endothelial cells: High (Approved); skin 2 / fibrohistiocytic cells: High (Approved); skin 2 / langerhans cells: High (Approved); skin 2 / lymphocytes: High (Approved); skin 2 / vascular mural cells: High (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: High (Approved); spleen / cells in red pulp: High (Approved); spleen / cells in white pulp: High (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: High (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 0/283 (0.0%),glioma: 12/12 (100.0%); lymphoma: 12/12 (100.0%),29,20,Q16695,https://www.uniprot.org/uniprotkb/Q16695/entry,"Core component of nucleosome. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. DNA accessibility is regulated via a complex set of post-translational modifications of histones, also called histone code, and nucleosome remodeling",Expressed in testicular cells,,,Nucleus Chromosome,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Carter2023_CT,Cancer-associated RNA nomination; no antigen validation asserted | Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene,,,,,,,,
H3C12,ENSG00000197153,Unsafe,Protein,False,True,0.3,1.2,104,99,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,family exclusion; family exclusion; positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0 nTPM; positive ihc; adrenal gland: 0 nTPM; positive ihc; amygdala: 0.3 nTPM; continuous selectivity;reproductive not higher; bone marrow: 1.2 nTPM; positive ihc;continuous selectivity;reproductive not higher; cerebellum: 0 nTPM; positive ihc; cerebral cortex: 0 nTPM; positive ihc; colon: 0.1 nTPM; positive ihc; duodenum: 0 nTPM; positive ihc; esophagus: 0.1 nTPM; positive ihc; heart muscle: 0 nTPM; positive ihc; kidney: 0 nTPM; positive ihc; liver: 0.1 nTPM; positive ihc; lung: 0.1 nTPM; positive ihc; lymph node: 1 nTPM; positive ihc;continuous selectivity;reproductive not higher; pancreas: 0 nTPM; positive ihc; parathyroid gland: 0 nTPM; positive ihc; rectum: 0 nTPM; positive ihc; salivary gland: 0 nTPM; positive ihc; skeletal muscle: 0 nTPM; positive ihc; skin: 0.1 nTPM; positive ihc; small intestine: 0.1 nTPM; positive ihc; smooth muscle: 0 nTPM; positive ihc; spleen: 0.4 nTPM; positive ihc;continuous selectivity;reproductive not higher; stomach: 0 nTPM; positive ihc; thymus: 1.1 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 0 nTPM; positive ihc; urinary bladder: 0.1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,adipose tissue / adipocytes: High (Approved); adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: High (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / glial cells: High (Approved); caudate / neuronal cells: High (Approved); cerebellum / cells in granular layer: High (Approved); cerebellum / cells in molecular layer: High (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: High (Approved); cerebral cortex / glial cells: High (Approved); cerebral cortex / neuronal cells: High (Approved); colon / endothelial cells: High (Approved); colon / glandular cells: High (Approved); colon / peripheral nerve/ganglion: High (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: High (Approved); heart muscle / cardiomyocytes: High (Approved); hippocampus / glial cells: High (Approved); hippocampus / neuronal cells: High (Approved); kidney / cells in glomeruli: High (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: High (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: High (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: High (Approved); lymph node / non-germinal center cells: High (Approved); nasopharynx / respiratory epithelial cells: High (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: High (Approved); pancreas / pancreatic endocrine cells: High (Approved); parathyroid gland / glandular cells: High (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: High (Approved); skeletal muscle / myocytes: High (Approved); skin 1 / cells in basal layer: High (Approved); skin 1 / cells in granular layer: High (Approved); skin 1 / cells in spinous layer: High (Approved); skin 1 / endothelial cells: High (Approved); skin 1 / fibrohistiocytic cells: High (Approved); skin 1 / langerhans cells: High (Approved); skin 1 / lymphocytes: High (Approved); skin 1 / vascular mural cells: High (Approved); skin 2 / cells in basal layer: High (Approved); skin 2 / cells in granular layer: High (Approved); skin 2 / cells in spinous layer: High (Approved); skin 2 / endothelial cells: High (Approved); skin 2 / fibrohistiocytic cells: High (Approved); skin 2 / langerhans cells: High (Approved); skin 2 / lymphocytes: High (Approved); skin 2 / vascular mural cells: High (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: High (Approved); spleen / cells in red pulp: High (Approved); spleen / cells in white pulp: High (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: High (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 485/486 (99.8%); Rectum Adenocarcinoma (validation): 203/207 (98.1%); Glioblastoma Multiforme (validation): 53/58 (91.4%),glioma: 12/12 (100.0%); lymphoma: 12/12 (100.0%),29,20,P68431,https://www.uniprot.org/uniprotkb/P68431/entry,"Core component of nucleosome. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. DNA accessibility is regulated via a complex set of post-translational modifications of histones, also called histone code, and nucleosome remodeling",,"Glioma: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes.","The original paper reporting lysine deamination at Lys-5 by LOXL2 has been retracted due to inappropriate manipulation of figure data (PubMed:22483618, PubMed:27392148). However, this modification was confirmed in a subsequent publication (PubMed:27735137)",Nucleus Chromosome,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
H4C6,ENSG00000274618,Unsafe,Protein,False,True,0.2,0.8,84,63,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,family exclusion; family exclusion; positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0 nTPM; positive ihc; bone marrow: 0.8 nTPM; positive ihc;continuous selectivity;reproductive not higher; cerebellum: 0 nTPM; positive ihc; cerebral cortex: 0 nTPM; positive ihc; choroid plexus: 0.3 nTPM; continuous selectivity;reproductive not higher; colon: 0.1 nTPM; positive ihc; duodenum: 0 nTPM; positive ihc; esophagus: 0.1 nTPM; positive ihc; heart muscle: 0 nTPM; positive ihc; kidney: 0 nTPM; positive ihc; liver: 0 nTPM; positive ihc; lung: 0 nTPM; positive ihc; lymph node: 0.2 nTPM; positive ihc;continuous selectivity;reproductive not higher; pancreas: 0 nTPM; positive ihc; parathyroid gland: 0 nTPM; positive ihc; rectum: 0 nTPM; positive ihc; salivary gland: 0 nTPM; positive ihc; skeletal muscle: 0 nTPM; positive ihc; skin: 0 nTPM; positive ihc; small intestine: 0 nTPM; positive ihc; smooth muscle: 0 nTPM; positive ihc; spleen: 0 nTPM; positive ihc; stomach: 0 nTPM; positive ihc; thymus: 0.7 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 0 nTPM; positive ihc; urinary bladder: 0 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,adipose tissue / adipocytes: Low (Supported); bone marrow / hematopoietic cells: High (Supported); bronchus / respiratory epithelial cells: Medium (Supported); caudate / glial cells: High (Supported); cerebellum / cells in granular layer: Low (Supported); cerebellum / cells in molecular layer: Medium (Supported); cerebral cortex / glial cells: High (Supported); cerebral cortex / neuronal cells: Low (Supported); colon / glandular cells: High (Supported); duodenum / glandular cells: High (Supported); esophagus / squamous epithelial cells: Medium (Supported); heart muscle / cardiomyocytes: Medium (Supported); hippocampus / glial cells: Medium (Supported); kidney / cells in glomeruli: Medium (Supported); kidney / cells in tubules: Medium (Supported); liver / cholangiocytes: Low (Supported); liver / hepatocytes: Medium (Supported); lung / alveolar cells: Low (Supported); lymph node / germinal center cells: Medium (Supported); lymph node / non-germinal center cells: Medium (Supported); nasopharynx / respiratory epithelial cells: Medium (Supported); oral mucosa / squamous epithelial cells: High (Supported); pancreas / exocrine glandular cells: Medium (Supported); parathyroid gland / glandular cells: Medium (Supported); rectum / glandular cells: High (Supported); salivary gland / glandular cells: Medium (Supported); skeletal muscle / myocytes: Medium (Supported); skin 1 / keratinocytes: Medium (Supported); skin 2 / epidermal cells: Medium (Supported); small intestine / glandular cells: High (Supported); smooth muscle / smooth muscle cells: Low (Supported); spleen / cells in red pulp: Low (Supported); spleen / cells in white pulp: Medium (Supported); stomach 1 / glandular cells: High (Supported); stomach 2 / glandular cells: Medium (Supported); thyroid gland / glandular cells: Medium (Supported); urinary bladder / urothelial cells: Medium (Supported),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 483/486 (99.4%); Rectum Adenocarcinoma (validation): 202/207 (97.6%); Ovary Serous Cystadenocarcinoma (TCGA): 18/349 (5.2%),breast cancer: 12/12 (100.0%); endometrial cancer: 12/12 (100.0%),26,20,P62805,https://www.uniprot.org/uniprotkb/P62805/entry,"Core component of nucleosome. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. DNA accessibility is regulated via a complex set of post-translational modifications of histones, also called histone code, and nucleosome remodeling",,"Tessadori-Bicknell-Van Haaften neurodevelopmental syndrome 1: An autosomal dominant disorder with onset in infancy, characterized by poor overall growth, microcephaly, hypotonia, profound global developmental delay, impaired intellectual development, poor or absent speech, and characteristic dysmorphic facial features, including hypertelorism and abnormal nose. Other variable neurologic and systemic features may also occur. Tessadori-Bicknell-Van Haaften neurodevelopmental syndrome 2: An autosomal dominant disorder characterized by poor overall growth, microcephaly, hypotonia, profound global developmental delay, impaired intellectual development, absent speech, and characteristic dysmorphic facial features, including hypertelorism, abnormal nose, and wide mouth. Tessadori-Bicknell-Van Haaften neurodevelopmental syndrome 3: An autosomal dominant disorder characterized by global developmental delay with poor overall growth, impaired intellectual development, and speech difficulties. More variable features include hypotonia, microcephaly, and dysmorphic facies. Tessadori-Bicknell-Van Haaften neurodevelopmental syndrome 4: An autosomal dominant disorder characterized by global developmental delay with poor overall growth, variably impaired intellectual development, learning difficulties, distal skeletal anomalies, and dysmorphic facies. Some patients have visual or hearing deficits.",,Nucleus Chromosome,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | daSilva2017_tumor_proteomics,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
HARBI1,ENSG00000180423,Unsafe,Protein,False,True,11.7,11.7,83,4,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; basal ganglia: 2.2 nTPM; absolute ceiling; bone marrow: 5.4 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 2.1 nTPM; absolute ceiling; midbrain: 2.4 nTPM; absolute ceiling; pituitary gland: 2.4 nTPM; absolute ceiling; retina: 2.6 nTPM; absolute ceiling; spinal cord: 2.8 nTPM; absolute ceiling; stomach: 3.9 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",basal ganglia: 2.2 nTPM (limit 2); bone marrow: 5.4 nTPM (limit 4); hippocampal formation: 2.1 nTPM (limit 2); midbrain: 2.4 nTPM (limit 2); pituitary gland: 2.4 nTPM (limit 2); retina: 2.6 nTPM (limit 2); spinal cord: 2.8 nTPM (limit 2),stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 44/50 (88.0%); Prostate Adenocarcinoma (TCGA): 414/480 (86.2%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q96MB7,https://www.uniprot.org/uniprotkb/Q96MB7/entry,Transposase-derived protein that may have nuclease activity (Potential). Does not have transposase activity,"Detected in brain, eye, nerve tissue, kidney and lung",,,Nucleus Cytoplasm,15169610|18339812,15169610,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
HAUS6,ENSG00000147874,Unsafe,Protein,False,True,23.3,23.3,83,74,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 5.1 nTPM; positive ihc; adrenal gland: 6.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 4.7 nTPM; absolute ceiling; basal ganglia: 4.6 nTPM; absolute ceiling; bone marrow: 16.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 5.2 nTPM; positive ihc;absolute ceiling; cerebral cortex: 7.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 2.8 nTPM; absolute ceiling; colon: 5.6 nTPM; positive ihc; duodenum: 3.9 nTPM; positive ihc;absolute ceiling; esophagus: 5 nTPM; positive ihc; heart muscle: 5 nTPM; positive ihc;absolute ceiling; hippocampal formation: 4.8 nTPM; absolute ceiling; hypothalamus: 4 nTPM; absolute ceiling; kidney: 3.9 nTPM; positive ihc;absolute ceiling; liver: 6.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 4.6 nTPM; positive ihc;absolute ceiling; lymph node: 11.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 5.7 nTPM; absolute ceiling; pancreas: 3.8 nTPM; positive ihc;absolute ceiling; parathyroid gland: 5.9 nTPM; positive ihc; pituitary gland: 2.9 nTPM; absolute ceiling; rectum: 6 nTPM; positive ihc; retina: 8.7 nTPM; absolute ceiling;continuous selectivity; salivary gland: 4.3 nTPM; positive ihc; skeletal muscle: 4.2 nTPM; positive ihc;absolute ceiling; skin: 7.9 nTPM; positive ihc; small intestine: 5.1 nTPM; positive ihc;absolute ceiling; smooth muscle: 6.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 7.6 nTPM; absolute ceiling;continuous selectivity; spleen: 6.7 nTPM; positive ihc; stomach: 4.2 nTPM; positive ihc; thymus: 14.7 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 5.1 nTPM; positive ihc; tongue: 6.9 nTPM; absolute ceiling; urinary bladder: 5.9 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 6.3 nTPM (limit 2); amygdala: 4.7 nTPM (limit 2); basal ganglia: 4.6 nTPM (limit 2); bone marrow: 16.8 nTPM (limit 2); cerebellum: 5.2 nTPM (limit 2); cerebral cortex: 7.1 nTPM (limit 2); choroid plexus: 2.8 nTPM (limit 2); duodenum: 3.9 nTPM (limit 2); heart muscle: 5 nTPM (limit 2); hippocampal formation: 4.8 nTPM (limit 2); hypothalamus: 4 nTPM (limit 2); kidney: 3.9 nTPM (limit 2); liver: 6.7 nTPM (limit 2); lung: 4.6 nTPM (limit 2); lymph node: 11.1 nTPM (limit 6); midbrain: 5.7 nTPM (limit 2); pancreas: 3.8 nTPM (limit 2); pituitary gland: 2.9 nTPM (limit 2); retina: 8.7 nTPM (limit 2); skeletal muscle: 4.2 nTPM (limit 2); small intestine: 5.1 nTPM (limit 2); smooth muscle: 6.9 nTPM (limit 2); spinal cord: 7.6 nTPM (limit 2); thymus: 14.7 nTPM (limit 10); tongue: 6.9 nTPM (limit 6),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: High (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: High (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Low (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: High (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%),colorectal cancer: 9/11 (81.8%); skin cancer: 9/12 (75.0%),31,20,Q7Z4H7,https://www.uniprot.org/uniprotkb/Q7Z4H7/entry,"Contributes to mitotic spindle assembly, maintenance of centrosome integrity and completion of cytokinesis as part of the HAUS augmin-like complex. Promotes the nucleation of microtubules from the spindle through recruitment of NEDD1 and gamma-tubulin",,,,"Cytoplasm, cytoskeleton Cytoplasm, cytoskeleton, spindle Cytoplasm, cytoskeleton, microtubule organizing center, centrosome",19029337|19369198|19427217,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
HBG2,ENSG00000196565,Unsafe,Protein,False,True,9951.4,9951.4,79,6,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 4.7 nTPM; absolute ceiling; basal ganglia: 3.7 nTPM; absolute ceiling; bone marrow: 77 nTPM; positive ihc;absolute ceiling; cerebellum: 2.1 nTPM; positive ihc;absolute ceiling; cerebral cortex: 2.6 nTPM; absolute ceiling; choroid plexus: 9.1 nTPM; absolute ceiling; heart muscle: 8 nTPM; absolute ceiling; hippocampal formation: 3.7 nTPM; absolute ceiling; hypothalamus: 3.3 nTPM; absolute ceiling; kidney: 5.7 nTPM; absolute ceiling; liver: 6 nTPM; positive ihc;absolute ceiling; lung: 15.9 nTPM; positive ihc;absolute ceiling; midbrain: 8.1 nTPM; absolute ceiling; pancreas: 9 nTPM; absolute ceiling; pituitary gland: 3.1 nTPM; absolute ceiling; skeletal muscle: 4 nTPM; absolute ceiling; smooth muscle: 4.2 nTPM; absolute ceiling; spinal cord: 4.8 nTPM; absolute ceiling; spleen: 26.7 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 4.7 nTPM (limit 2); basal ganglia: 3.7 nTPM (limit 2); bone marrow: 77 nTPM (limit 2); cerebellum: 2.1 nTPM (limit 2); choroid plexus: 9.1 nTPM (limit 2); heart muscle: 8 nTPM (limit 4); hippocampal formation: 3.7 nTPM (limit 2); hypothalamus: 3.3 nTPM (limit 2); kidney: 5.7 nTPM (limit 4); liver: 6 nTPM (limit 2); lung: 15.9 nTPM (limit 2); midbrain: 8.1 nTPM (limit 2); pancreas: 9 nTPM (limit 4); pituitary gland: 3.1 nTPM (limit 2); smooth muscle: 4.2 nTPM (limit 4); spinal cord: 4.8 nTPM (limit 2); spleen: 26.7 nTPM (limit 20); amygdala: 4.7 nTPM (baseline 2); basal ganglia: 3.7 nTPM (baseline 2); bone marrow: 77 nTPM (baseline 2); cerebellum: 2.1 nTPM (baseline 2); cerebral cortex: 2.6 nTPM (baseline 2); choroid plexus: 9.1 nTPM (baseline 2); heart muscle: 8 nTPM (baseline 2); hippocampal formation: 3.7 nTPM (baseline 2); hypothalamus: 3.3 nTPM (baseline 2); kidney: 5.7 nTPM (baseline 2); liver: 6 nTPM (baseline 2); lung: 15.9 nTPM (baseline 2); midbrain: 8.1 nTPM (baseline 2); pancreas: 9 nTPM (baseline 2); pituitary gland: 3.1 nTPM (baseline 2); skeletal muscle: 4 nTPM (baseline 2); smooth muscle: 4.2 nTPM (baseline 2); spinal cord: 4.8 nTPM (baseline 2); spleen: 26.7 nTPM (baseline 10),bone marrow / hematopoietic cells: Low (Approved); cerebellum / Purkinje cells: Low (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 48/141 (34.0%); Kidney Renal Clear Cell Carcinoma (TCGA): 57/521 (10.9%); Breast Invasive Carcinoma (validation): 3/50 (6.0%),liver cancer: 4/11 (36.4%); breast cancer: 0/12 (0.0%),31,20,P69892,https://www.uniprot.org/uniprotkb/P69892/entry,"Gamma chains make up the fetal hemoglobin F, in combination with alpha chains",Red blood cells,"Cyanosis transient neonatal: A disorder characterized by cyanosis in the fetus and neonate, due to a defect in the fetal hemoglobin chain which has reduced affinity for oxygen. Some patients develop anemia resulting from increased destruction of red cells containing abnormal or unstable hemoglobin. The cyanosis resolves spontaneously by 5 to 6 months of age or earlier, as the adult beta-globin chain is produced and replaces the fetal gamma-globin chain.",,,19065339|21561349|24502349,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Gong2021_reproductive_PC,No tumor-antigen validation in this source | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
HBZ,ENSG00000130656,Unsafe,Protein,False,True,7.1,7.1,78,2,Positive somewhere,True,True,False,False,Excluded,Normal,False,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 3.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; spleen: 0.3 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 3.9 nTPM (limit 2); bone marrow: 3.9 nTPM (baseline 2),bone marrow / hematopoietic cells: Medium (Approved); spleen / cells in red pulp: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Kidney Renal Clear Cell Carcinoma (TCGA): 2/521 (0.4%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),breast cancer: 0/12 (0.0%); cervical cancer: 0/11 (0.0%),31,20,P02008,https://www.uniprot.org/uniprotkb/P02008/entry,The zeta chain is an alpha-type chain of mammalian embryonic hemoglobin,Detected in fetal erythrocytes (at protein level),,,,,6171809|6539334,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
HEATR4,ENSG00000187105,Unsafe,Protein,False,True,11.1,11.1,92,10,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; colon: 0.4 nTPM; positive ihc; kidney: 0.4 nTPM; positive ihc; parathyroid gland: 0.2 nTPM; positive ihc; retina: 2.8 nTPM; absolute ceiling; smooth muscle: 0.1 nTPM; positive ihc; stomach: 0.7 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",retina: 2.8 nTPM (limit 2),colon / peripheral nerve/ganglion: Low (Enhanced); kidney / proximal tubules (microvilli): High (Enhanced); parathyroid gland / glandular cells: Low (Enhanced); smooth muscle / smooth muscle cells: Low (Enhanced); stomach 1 / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 77/486 (15.8%); Rectum Adenocarcinoma (validation): 31/207 (15.0%); Kidney Chromophobe (TCGA): 5/64 (7.8%),stomach cancer: 1/12 (8.3%); breast cancer: 0/12 (0.0%),31,20,Q86WZ0,https://www.uniprot.org/uniprotkb/Q86WZ0/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
HEATR9,ENSG00000270379,Unsafe,High RNA,False,True,9.8,9.8,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE NK (unstimulated): 90/90 values ≥5 TPM, max 55.9302; DICE TH1 (unstimulated): 66/81 values ≥5 TPM, max 23.5162; DICE THSTAR (unstimulated): 31/88 values ≥5 TPM, max 12.6836",True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA023129; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA023129; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: High, HPA023129; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA023129; conflicting or uncurated primary profile; Caudate/Glial cells: Medium, HPA023129; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: High, HPA023129; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: High, HPA023129; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA023129; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: High, HPA023129; conflicting or uncurated primary profile; Colon/Endothelial cells: High, HPA023129; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA023129; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: High, HPA023129; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA023129; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: High, HPA023129; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: High, HPA023129; conflicting or uncurated primary profile; Hippocampus/Glial cells: Medium, HPA023129; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: High, HPA023129; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA023129; conflicting or uncurated primary profile; Liver/Cholangiocytes: High, HPA023129; conflicting or uncurated primary profile; Liver/Hepatocytes: High, HPA023129; conflicting or uncurated primary profile; Lung/Alveolar cells: High, HPA023129; conflicting or uncurated primary profile; Lung/Macrophages: High, HPA023129; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA023129; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA023129; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: High, HPA023129; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA023129; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: High, HPA023129; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: High, HPA023129; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA023129; conflicting or uncurated primary profile; Salivary gland/Glandular cells: High, HPA023129; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: High, HPA023129; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA023129; conflicting or uncurated primary profile; Skin 1/Keratinocytes: High, HPA023129; conflicting or uncurated primary profile; Skin 1/Langerhans: High, HPA023129; conflicting or uncurated primary profile; Skin 2/Epidermal cells: High, HPA023129; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA023129; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: High, HPA023129; conflicting or uncurated primary profile; Spleen/Cells in red pulp: High, HPA023129; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Medium, HPA023129; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA023129; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA023129; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA023129; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: High, HPA023129; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,55.9302364928,4.8,"dice_nk: blood/NK, max 55.9302 TPM, 47 observations >30; hpa_immune_schmiedel: blood/NK-cell, max 32.4 TPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,55.93 TPM; blood/NK; dice_nk; vital,4.8 nTPM; liver/b-cells; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),breast cancer: 12/12 (100.0%); cervical cancer: 12/12 (100.0%),26,20,A2RTY3,https://www.uniprot.org/uniprotkb/A2RTY3/entry,,,,"Despite its name, the presence of HEAT repeat is unsure and is not confirmed by repeat-detection programs",,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
HELB,ENSG00000127311,Unsafe,High RNA,False,True,0.8,1.7,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 0.7 nTPM; continuous selectivity; bone marrow: 0.9 nTPM; continuous selectivity;reproductive not higher; colon: 0.7 nTPM; continuous selectivity; esophagus: 0.5 nTPM; continuous selectivity; heart muscle: 0.4 nTPM; continuous selectivity; kidney: 0.7 nTPM; continuous selectivity; liver: 1.2 nTPM; continuous selectivity;reproductive not higher; lung: 1 nTPM; continuous selectivity;reproductive not higher; lymph node: 0.5 nTPM; continuous selectivity; midbrain: 0.4 nTPM; continuous selectivity; pancreas: 0.8 nTPM; continuous selectivity;reproductive not higher; pituitary gland: 1.2 nTPM; continuous selectivity;reproductive not higher; salivary gland: 0.7 nTPM; continuous selectivity; skin: 0.5 nTPM; continuous selectivity; small intestine: 1.2 nTPM; continuous selectivity;reproductive not higher; spinal cord: 0.6 nTPM; continuous selectivity; spleen: 1.7 nTPM; continuous selectivity;reproductive not higher; stomach: 0.7 nTPM; continuous selectivity; thyroid gland: 0.7 nTPM; continuous selectivity; urinary bladder: 0.5 nTPM; continuous selectivity,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,True,"endometrium/t-cells cluster c-2: 38.8 nTPM, 322 reads; reproductive-cell max 21.1; brain/excitatory neurons cluster c-39: 22.7 nTPM, 255 reads; reproductive-cell max 21.1; skeletal muscle/t-cells cluster c-5: 21.2 nTPM, 56 reads; reproductive-cell max 21.1; adipose tissue/t-cells cluster c-1: 36.9 nTPM, 804 reads; reproductive-cell max 21.1; adipose tissue/t-cells cluster c-2: 54.8 nTPM, 865 reads; reproductive-cell max 21.1; adipose tissue/t-cells cluster c-3: 36.3 nTPM, 624 reads; reproductive-cell max 21.1; adipose tissue/t-cells cluster c-11: 32.9 nTPM, 207 reads; reproductive-cell max 21.1; adipose tissue/nk-cells cluster c-14: 56.3 nTPM, 228 reads; reproductive-cell max 21.1; adipose tissue/t-cells cluster c-16: 45.5 nTPM, 141 reads; reproductive-cell max 21.1; lymph node/t-cells cluster c-2: 43.2 nTPM, 159 reads; reproductive-cell max 21.1; lymph node/t-cells cluster c-3: 45 nTPM, 117 reads; reproductive-cell max 21.1; lymph node/b-cells cluster c-4: 21.7 nTPM, 29 reads; reproductive-cell max 21.1; lymph node/t-cells cluster c-5: 50.4 nTPM, 25 reads; reproductive-cell max 21.1; bone marrow/t-cells cluster c-0: 29 nTPM, 89 reads; reproductive-cell max 21.1; bone marrow/t-cells cluster c-1: 39.7 nTPM, 79 reads; reproductive-cell max 21.1; bone marrow/t-cells cluster c-4: 36.8 nTPM, 31 reads; reproductive-cell max 21.1; spleen/t-cells cluster c-1: 27.7 nTPM, 55 reads; reproductive-cell max 21.1; spleen/t-cells cluster c-2: 30.7 nTPM, 56 reads; reproductive-cell max 21.1; spleen/t-cells cluster c-6: 29.9 nTPM, 28 reads; reproductive-cell max 21.1; stomach/t-cells cluster c-3: 22.7 nTPM, 36 reads; reproductive-cell max 21.1; lung/t-cells cluster c-10: 24.9 nTPM, 63 reads; reproductive-cell max 21.1; prostate/t-cells cluster c-4: 23.9 nTPM, 102 reads; reproductive-cell max 21.1; salivary gland/serous glandular cells cluster c-1: 25.1 nTPM, 266 reads; reproductive-cell max 21.1; salivary gland/t-cells cluster c-7: 29.5 nTPM, 144 reads; reproductive-cell max 21.1; thymus/t-cells cluster c-0: 51.6 nTPM, 1222 reads; reproductive-cell max 21.1; thymus/t-cells cluster c-1: 33.2 nTPM, 614 reads; reproductive-cell max 21.1; thymus/t-cells cluster c-4: 50.3 nTPM, 788 reads; reproductive-cell max 21.1; thymus/t-cells cluster c-18: 53.8 nTPM, 90 reads; reproductive-cell max 21.1; tongue/t-cells cluster c-6: 35.1 nTPM, 209 reads; reproductive-cell max 21.1; vascular/t-cells cluster c-10: 43 nTPM, 107 reads; reproductive-cell max 21.1; breast/t-cells cluster c-0: 42.2 nTPM, 434 reads; reproductive-cell max 21.1; breast/t-cells cluster c-2: 44.6 nTPM, 358 reads; reproductive-cell max 21.1; breast/t-cells cluster c-10: 24.6 nTPM, 39 reads; reproductive-cell max 21.1; breast/t-cells cluster c-15: 28.2 nTPM, 71 reads; reproductive-cell max 21.1; fallopian tube/t-cells cluster c-8: 33.7 nTPM, 182 reads; reproductive-cell max 21.1; fallopian tube/t-cells cluster c-9: 31.1 nTPM, 155 reads; reproductive-cell max 21.1; fallopian tube/t-cells cluster c-20: 45.4 nTPM, 229 reads; reproductive-cell max 21.1; fallopian tube/t-cells cluster c-22: 22 nTPM, 30 reads; reproductive-cell max 21.1",True,True,"DICE B_CELL_NAIVE (unstimulated): 91/91 values ≥5 TPM, max 13.3197; DICE MONOCYTES (unstimulated): 58/91 values ≥5 TPM, max 9.22807; DICE M2 (unstimulated): 21/90 values ≥5 TPM, max 8.91509; DICE NK (unstimulated): 90/90 values ≥5 TPM, max 25.9692; DICE TREG_MEM (unstimulated): 89/89 values ≥5 TPM, max 62.5551; DICE CD4_NAIVE (unstimulated): 88/88 values ≥5 TPM, max 85.1694; DICE CD4_STIM (activated): 88/88 values ≥5 TPM, max 47.5103; DICE TREG_NAIVE (unstimulated): 89/89 values ≥5 TPM, max 70.0101; DICE TFH (unstimulated): 89/89 values ≥5 TPM, max 73.5812; DICE TH1 (unstimulated): 81/81 values ≥5 TPM, max 61.2736; DICE THSTAR (unstimulated): 88/88 values ≥5 TPM, max 78.9404; DICE TH17 (unstimulated): 89/89 values ≥5 TPM, max 68.7396; DICE TH2 (unstimulated): 89/89 values ≥5 TPM, max 87.4433; DICE CD8_NAIVE (unstimulated): 89/89 values ≥5 TPM, max 66.3288; DICE CD8_STIM (activated): 88/88 values ≥5 TPM, max 35.4718; hpa_immune_cell eosinophil: 5.8 nTPM; hpa_immune_cell memory CD4 T-cell: 5 nTPM; hpa_immune_cell naive CD4 T-cell: 5.1 nTPM; hpa_immune_cell T-reg: 5.6 nTPM; hpa_immune_monaco basophil: 9.6 TPM; hpa_immune_monaco Central memory CD8 T-cell: 11.9 TPM; hpa_immune_monaco Effector memory CD8 T-cell: 9.7 TPM; hpa_immune_monaco MAIT T-cell: 8.2 TPM; hpa_immune_monaco Memory CD4 T-cell TFH: 17.3 TPM; hpa_immune_monaco Memory CD4 T-cell Th1: 15.9 TPM; hpa_immune_monaco Memory CD4 T-cell Th1/Th17: 13.1 TPM; hpa_immune_monaco Memory CD4 T-cell Th17: 12.8 TPM; hpa_immune_monaco Memory CD4 T-cell Th2: 12.5 TPM; hpa_immune_monaco naive CD4 T-cell: 12.8 TPM; hpa_immune_monaco naive CD8 T-cell: 8.5 TPM; hpa_immune_monaco T-reg: 10.4 TPM; hpa_immune_monaco Terminal effector memory CD4 T-cell: 6.3 TPM; hpa_immune_monaco Terminal effector memory CD8 T-cell: 6.1 TPM; hpa_immune_monaco Vd2 gdTCR: 5.6 TPM",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,87.44328070479999,56.3,"dice_cd4_naive: blood/CD4_NAIVE, max 85.1694 TPM, 88 observations >30; dice_cd4_stim: blood/CD4_STIM, max 47.5103 TPM, 38 observations >30; dice_cd8_naive: blood/CD8_NAIVE, max 66.3288 TPM, 88 observations >30; dice_cd8_stim: blood/CD8_STIM, max 35.4718 TPM, 18 observations >30; dice_tfh: blood/TFH, max 73.5812 TPM, 89 observations >30; dice_th1: blood/TH1, max 61.2736 TPM, 78 observations >30; dice_th17: blood/TH17, max 68.7396 TPM, 89 observations >30; dice_th2: blood/TH2, max 87.4433 TPM, 89 observations >30; dice_thstar: blood/THSTAR, max 78.9404 TPM, 88 observations >30; dice_treg_mem: blood/TREG_MEM, max 62.5551 TPM, 88 observations >30; dice_treg_naive: blood/TREG_NAIVE, max 70.0101 TPM, 89 observations >30; hpa_immune_schmiedel: blood/Memory CD4 T-cell TFH, max 49.4 TPM, 1 observations >30; hpa_immune_schmiedel: blood/Memory CD4 T-cell Th1, max 45 TPM, 1 observations >30; hpa_immune_schmiedel: blood/Memory CD4 T-cell Th1/Th17, max 55 TPM, 1 observations >30; hpa_immune_schmiedel: blood/Memory CD4 T-cell Th17, max 46.6 TPM, 1 observations >30; hpa_immune_schmiedel: blood/Memory CD4 T-cell Th2, max 60.8 TPM, 1 observations >30; hpa_immune_schmiedel: blood/Memory T-reg, max 45.2 TPM, 1 observations >30; hpa_immune_schmiedel: blood/Naive T-reg, max 48.8 TPM, 1 observations >30; hpa_immune_schmiedel: blood/naive CD4 T-cell, max 56.8 TPM, 1 observations >30; hpa_immune_schmiedel: blood/naive CD8 T-cell, max 43.3 TPM, 1 observations >30; hpa_single_cell_tissue: adipose tissue/nk-cells, max 56.3 nTPM, 1 observations >30; hpa_single_cell_tissue: adipose tissue/t-cells, max 54.8 nTPM, 5 observations >30; hpa_single_cell_tissue: bone marrow/t-cells, max 39.7 nTPM, 2 observations >30; hpa_single_cell_tissue: breast/t-cells, max 44.6 nTPM, 2 observations >30; hpa_single_cell_tissue: endometrium/t-cells, max 38.8 nTPM, 1 observations >30; hpa_single_cell_tissue: esophagus/t-cells, max 36.5 nTPM, 1 observations >30; hpa_single_cell_tissue: fallopian tube/t-cells, max 45.4 nTPM, 3 observations >30; hpa_single_cell_tissue: lymph node/t-cells, max 50.4 nTPM, 3 observations >30; hpa_single_cell_tissue: spleen/t-cells, max 30.7 nTPM, 1 observations >30; hpa_single_cell_tissue: thymus/t-cells, max 53.8 nTPM, 4 observations >30; hpa_single_cell_tissue: tongue/t-cells, max 35.1 nTPM, 1 observations >30; hpa_single_cell_tissue: vascular/t-cells, max 43 nTPM, 1 observations >30",Neither,oncoref.target-sets.2026-10-23.2,87.44 TPM; blood/TH2; dice_th2; vital,56.3 nTPM; adipose tissue/nk-cells; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 50/58 (86.2%); Pancreatic Adenocarcinoma (validation): 59/80 (73.8%); Breast Invasive Carcinoma (validation): 22/50 (44.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NG08,https://www.uniprot.org/uniprotkb/Q8NG08/entry,"5'-3' DNA helicase involved in DNA damage response by acting as an inhibitor of DNA end resection (PubMed:25617833, PubMed:26774285). Recruitment to single-stranded DNA (ssDNA) following DNA damage leads to inhibit the nucleases catalyzing resection, such as EXO1, BLM and DNA2, possibly via the 5'-3' ssDNA translocase activity of HELB (PubMed:26774285). As cells approach S phase, DNA end resection is promoted by the nuclear export of HELB following phosphorylation (PubMed:26774285). Acts independently of TP53BP1 (PubMed:26774285). Unwinds duplex DNA with 5'-3' polarity. Has single-strand DNA-dependent ATPase and DNA helicase activities. Prefers ATP and dATP as substrates (PubMed:12181327). During S phase, may facilitate cellular recovery from replication stress (PubMed:22194613)","Highly expressed in testis and thymus and weakly in liver, spleen, kidney and brain",,,Nucleus Cytoplasm Chromosome,12181327|22194613|25617833|26774285,12181327,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
HELQ,ENSG00000163312,Unsafe,Protein,False,True,7.2,9.1,78,65,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 4.7 nTPM; positive ihc;continuous selectivity; adrenal gland: 8.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 2.1 nTPM; absolute ceiling;continuous selectivity; bone marrow: 4.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 3.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 2.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 5.5 nTPM; absolute ceiling;continuous selectivity; colon: 3.8 nTPM; positive ihc;continuous selectivity; duodenum: 3.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 3.3 nTPM; positive ihc;continuous selectivity; heart muscle: 4.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; hypothalamus: 2 nTPM; continuous selectivity; kidney: 5.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 5.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 3.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 9.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 2 nTPM; continuous selectivity; pancreas: 3.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 5.4 nTPM; continuous selectivity; pituitary gland: 4.3 nTPM; absolute ceiling;continuous selectivity; rectum: 3.8 nTPM; positive ihc;continuous selectivity; retina: 5.3 nTPM; absolute ceiling;continuous selectivity; salivary gland: 4.5 nTPM; positive ihc;continuous selectivity; skeletal muscle: 6.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 3.8 nTPM; positive ihc;continuous selectivity; small intestine: 4.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 4.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 2.3 nTPM; absolute ceiling;continuous selectivity; spleen: 6.1 nTPM; positive ihc;continuous selectivity; stomach: 3.6 nTPM; positive ihc;continuous selectivity; thymus: 7.8 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 5.6 nTPM; positive ihc;continuous selectivity; tongue: 7.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 4.2 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 8.8 nTPM (limit 2); basal ganglia: 2.1 nTPM (limit 2); bone marrow: 4.5 nTPM (limit 2); cerebellum: 3.3 nTPM (limit 2); cerebral cortex: 2.3 nTPM (limit 2); choroid plexus: 5.5 nTPM (limit 2); duodenum: 3.1 nTPM (limit 2); heart muscle: 4.9 nTPM (limit 2); kidney: 5.2 nTPM (limit 2); liver: 5.3 nTPM (limit 2); lung: 3.8 nTPM (limit 2); lymph node: 9.1 nTPM (limit 6); pancreas: 3.6 nTPM (limit 2); pituitary gland: 4.3 nTPM (limit 2); retina: 5.3 nTPM (limit 2); skeletal muscle: 6.9 nTPM (limit 2); small intestine: 4.3 nTPM (limit 2); smooth muscle: 4.2 nTPM (limit 2); spinal cord: 2.3 nTPM (limit 2); tongue: 7.8 nTPM (limit 6),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Medium (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Low (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: Low (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Low (Approved); pancreas / pancreatic endocrine cells: Low (Approved); rectum / glandular cells: Low (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Low (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Low (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Low (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Pancreatic Adenocarcinoma (validation): 77/80 (96.2%); Breast Invasive Carcinoma (validation): 45/50 (90.0%),colorectal cancer: 12/12 (100.0%); melanoma: 12/12 (100.0%),31,20,Q8TDG4,https://www.uniprot.org/uniprotkb/Q8TDG4/entry,"Single-stranded 3'-5' DNA helicase that plays a key role in homology-driven double-strand break (DSB) repair (PubMed:11751861, PubMed:19995904, PubMed:21398521, PubMed:24005041, PubMed:24005565, PubMed:34316696, PubMed:34937945). Involved in different DSB repair mechanisms that are guided by annealing of extensive stretches of complementary bases at break ends, such as microhomology-mediated end-joining (MMEJ), single-strand annealing (SSA) or synthesis-dependent strand annealing (SDSA) (PubMed:34937945). Possesses both DNA unwinding and annealing activities (PubMed:34937945). Forms a complex with RAD51, stimulating HELQ DNA helicase activity and ability to unwing DNA (PubMed:34937945). Efficiently unwinds substrates containing 3' overhangs or a D-loop (PubMed:21398521, PubMed:34937945). In contrast, interaction with the replication protein A (RPA/RP-A) complex inhibits DNA unwinding by HELQ but strongly stimulates DNA strand annealing (PubMed:34937945). Triggers displacement of RPA from single-stranded DNA to facilitate annealing of complementary sequences (PubMed:34316696, PubMed:34937945)",,,,Nucleus Chromosome,11751861|19995904|21398521|24005041|24005565|34316696|34937945,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
HEMGN,ENSG00000136929,Unsafe,Protein,False,True,49.1,243.6,91,9,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 243.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; thymus: 12.5 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 243.6 nTPM (limit 2); thymus: 12.5 nTPM (limit 10),bone marrow / hematopoietic cells: High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 3/133 (2.3%); Skin Cuteneous Melanoma (TCGA): 1/99 (1.0%); Kidney Renal Clear Cell Carcinoma (validation): 1/100 (1.0%),cervical cancer: 1/12 (8.3%); colorectal cancer: 1/12 (8.3%),31,20,Q9BXL5,https://www.uniprot.org/uniprotkb/Q9BXL5/entry,Regulates the proliferation and differentiation of hematopoietic cells. Overexpression block the TPA-induced megakaryocytic differentiation in the K562 cell model. May also prevent cell apoptosis through the activation of the nuclear factor-kappa B (NF-kB),"Expressed in hematopoietic precursor cells, thyroid and spermatids (at protein level). Expressed in bone marrow, testis, thymus. Expressed in prostate cancer and ovarian cancer. Also expressed in thymus and thyroid tumors, non-Hodgkin lymphoma, various leukemia cell lines, peripheral blood mononuclear cells (PBMCs) and bone marrow mononuclear cells (BMMCs) of patients with leukemia",,,Nucleus,14730214|15332117|15920494,11404085|14648837|14730214|15332117|15920494|23436708,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
HENMT1,ENSG00000162639,Unsafe,Protein,False,True,69.9,69.9,79,55,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 2.9 nTPM; positive ihc;absolute ceiling; amygdala: 7.9 nTPM; absolute ceiling; basal ganglia: 10.2 nTPM; absolute ceiling; bone marrow: 13.1 nTPM; absolute ceiling; cerebellum: 4.2 nTPM; positive ihc;absolute ceiling; cerebral cortex: 11.3 nTPM; positive ihc;absolute ceiling; colon: 6.3 nTPM; positive ihc;absolute ceiling; duodenum: 4.8 nTPM; positive ihc;absolute ceiling; esophagus: 2.6 nTPM; positive ihc; hippocampal formation: 7.4 nTPM; absolute ceiling; hypothalamus: 12.4 nTPM; absolute ceiling; kidney: 3.3 nTPM; positive ihc;absolute ceiling; lung: 4.6 nTPM; positive ihc;absolute ceiling; lymph node: 13.1 nTPM; positive ihc;absolute ceiling; midbrain: 9.7 nTPM; absolute ceiling; pancreas: 2 nTPM; positive ihc; parathyroid gland: 0.9 nTPM; positive ihc; pituitary gland: 5.1 nTPM; absolute ceiling; rectum: 9.2 nTPM; positive ihc;absolute ceiling; retina: 2.9 nTPM; absolute ceiling; salivary gland: 2.9 nTPM; positive ihc; skeletal muscle: 3.1 nTPM; positive ihc;absolute ceiling; skin: 3.7 nTPM; positive ihc; small intestine: 7.4 nTPM; positive ihc;absolute ceiling; smooth muscle: 3.4 nTPM; positive ihc;absolute ceiling; spinal cord: 9.3 nTPM; absolute ceiling; spleen: 10.8 nTPM; positive ihc;absolute ceiling; stomach: 4.6 nTPM; positive ihc; thymus: 18.2 nTPM; absolute ceiling; thyroid gland: 2.1 nTPM; positive ihc; urinary bladder: 6 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 2.9 nTPM (limit 2); amygdala: 7.9 nTPM (limit 2); basal ganglia: 10.2 nTPM (limit 2); bone marrow: 13.1 nTPM (limit 2); cerebellum: 4.2 nTPM (limit 2); cerebral cortex: 11.3 nTPM (limit 2); colon: 6.3 nTPM (limit 6); duodenum: 4.8 nTPM (limit 2); hippocampal formation: 7.4 nTPM (limit 2); hypothalamus: 12.4 nTPM (limit 2); kidney: 3.3 nTPM (limit 2); lung: 4.6 nTPM (limit 2); lymph node: 13.1 nTPM (limit 6); midbrain: 9.7 nTPM (limit 2); pituitary gland: 5.1 nTPM (limit 2); rectum: 9.2 nTPM (limit 6); retina: 2.9 nTPM (limit 2); skeletal muscle: 3.1 nTPM (limit 2); small intestine: 7.4 nTPM (limit 2); smooth muscle: 3.4 nTPM (limit 2); spinal cord: 9.3 nTPM (limit 2); spleen: 10.8 nTPM (limit 10); thymus: 18.2 nTPM (limit 10); adrenal gland: 2.9 nTPM (baseline 2); amygdala: 7.9 nTPM (baseline 2); basal ganglia: 10.2 nTPM (baseline 2); bone marrow: 13.1 nTPM (baseline 2); cerebellum: 4.2 nTPM (baseline 2); cerebral cortex: 11.3 nTPM (baseline 2); colon: 6.3 nTPM (baseline 6); duodenum: 4.8 nTPM (baseline 2); hippocampal formation: 7.4 nTPM (baseline 2); hypothalamus: 12.4 nTPM (baseline 2); kidney: 3.3 nTPM (baseline 2); lung: 4.6 nTPM (baseline 2); lymph node: 13.1 nTPM (baseline 6); midbrain: 9.7 nTPM (baseline 2); pituitary gland: 5.1 nTPM (baseline 2); rectum: 9.2 nTPM (baseline 6); retina: 2.9 nTPM (baseline 2); skeletal muscle: 3.1 nTPM (baseline 2); small intestine: 7.4 nTPM (baseline 2); smooth muscle: 3.4 nTPM (baseline 2); spinal cord: 9.3 nTPM (baseline 2); spleen: 10.8 nTPM (baseline 10); thymus: 18.2 nTPM (baseline 10),adrenal gland / glandular cells: Medium (Uncertain); caudate / neuronal cells: Low (Uncertain); cerebellum / Purkinje cells: Low (Uncertain); cerebral cortex / neuropil: High (Uncertain); colon / endothelial cells: Low (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: Low (Uncertain); duodenum / glandular cells: High (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); kidney / cells in glomeruli: Medium (Uncertain); kidney / cells in tubules: Low (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / germinal center cells: High (Uncertain); lymph node / non-germinal center cells: High (Uncertain); nasopharynx / respiratory epithelial cells: Low (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Low (Uncertain); pancreas / pancreatic endocrine cells: Low (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: High (Uncertain); salivary gland / glandular cells: High (Uncertain); skeletal muscle / myocytes: Medium (Uncertain); skin 1 / fibroblasts: Medium (Uncertain); skin 1 / keratinocytes: Low (Uncertain); skin 1 / Langerhans: Low (Uncertain); skin 2 / epidermal cells: High (Uncertain); small intestine / glandular cells: High (Uncertain); smooth muscle / smooth muscle cells: Low (Uncertain); spleen / cells in white pulp: Low (Uncertain); stomach 1 / glandular cells: Low (Uncertain); stomach 2 / glandular cells: Low (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Low (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 205/207 (99.0%); Testicular Germ Cell Tumor (TCGA): 128/133 (96.2%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 272/283 (96.1%),lymphoma: 10/12 (83.3%); testis cancer: 10/12 (83.3%),30,20,Q5T8I9,https://www.uniprot.org/uniprotkb/Q5T8I9/entry,"Methyltransferase that adds a 2'-O-methyl group at the 3'-end of piRNAs, a class of 24 to 30 nucleotide RNAs that are generated by a Dicer-independent mechanism and are primarily derived from transposons and other repeated sequence elements. This probably protects the 3'-end of piRNAs from uridylation activity and subsequent degradation. Stabilization of piRNAs is essential for gametogenesis",,,,Cytoplasm,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
HERC5,ENSG00000138646,Unsafe,Protein,False,True,56.2,56.2,86,13,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 5.8 nTPM; positive ihc;absolute ceiling; amygdala: 3.6 nTPM; absolute ceiling; basal ganglia: 3.4 nTPM; absolute ceiling; bone marrow: 18.6 nTPM; absolute ceiling; choroid plexus: 9.9 nTPM; absolute ceiling; colon: 3.8 nTPM; positive ihc; hippocampal formation: 3 nTPM; absolute ceiling; hypothalamus: 2.9 nTPM; absolute ceiling; kidney: 6.2 nTPM; positive ihc;absolute ceiling; liver: 9.4 nTPM; positive ihc;absolute ceiling; lung: 6.3 nTPM; absolute ceiling; midbrain: 3.5 nTPM; absolute ceiling; pancreas: 7.5 nTPM; absolute ceiling; pituitary gland: 4 nTPM; absolute ceiling; rectum: 2.5 nTPM; positive ihc; retina: 3.6 nTPM; absolute ceiling; small intestine: 4.5 nTPM; positive ihc;absolute ceiling; smooth muscle: 13 nTPM; absolute ceiling; spinal cord: 3 nTPM; absolute ceiling; stomach: 4.7 nTPM; positive ihc; thymus: 13.5 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 5.8 nTPM (limit 2); amygdala: 3.6 nTPM (limit 2); basal ganglia: 3.4 nTPM (limit 2); bone marrow: 18.6 nTPM (limit 6); choroid plexus: 9.9 nTPM (limit 2); hippocampal formation: 3 nTPM (limit 2); hypothalamus: 2.9 nTPM (limit 2); kidney: 6.2 nTPM (limit 2); liver: 9.4 nTPM (limit 2); lung: 6.3 nTPM (limit 6); midbrain: 3.5 nTPM (limit 2); pancreas: 7.5 nTPM (limit 6); pituitary gland: 4 nTPM (limit 2); retina: 3.6 nTPM (limit 2); small intestine: 4.5 nTPM (limit 2); smooth muscle: 13 nTPM (limit 6); spinal cord: 3 nTPM (limit 2); thymus: 13.5 nTPM (limit 10),adrenal gland / glandular cells: Low (Supported); colon / glandular cells: Low (Supported); hippocampus / neuronal cells: Low (Supported); kidney / cells in tubules: Low (Supported); liver / hepatocytes: Low (Supported); rectum / glandular cells: Low (Supported); small intestine / glandular cells: Low (Supported); stomach 2 / glandular cells: Low (Supported),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Breast Invasive Carcinoma (validation): 46/50 (92.0%); Lung Squamous Cell Carcinoma (validation): 61/68 (89.7%),testis cancer: 6/11 (54.5%); ovarian cancer: 1/12 (8.3%),31,20,Q9UII4,https://www.uniprot.org/uniprotkb/Q9UII4/entry,"Major E3 ligase for ISG15 conjugation (PubMed:16407192, PubMed:16815975, PubMed:16884686, PubMed:20308324, PubMed:20542004, PubMed:26355087, PubMed:27534820, PubMed:27564865, PubMed:37279284, PubMed:38421872, PubMed:38652662, PubMed:40184173). Functions as part of the ISGylation machinery that recognizes target proteins in a broad and relatively non-specific manner (PubMed:16407192, PubMed:16815975, PubMed:16884686, PubMed:20308324, PubMed:20542004, PubMed:26355087, PubMed:27534820, PubMed:27564865, PubMed:37279284). Physically associated with polyribosomes, broadly modifies newly synthesized proteins in a cotranslational manner (PubMed:20542004). Acts as a positive regulator of innate antiviral response in cells induced by interferon by mediating ISGylation of proteins involved in innate immunity, such as CGAS, IRF3, IFIH1/MDA5 and STING1 (PubMed:16815975, PubMed:20308324, PubMed:38421872, PubMed:38652662, PubMed:40184173). Catalyzes ISGylation of IRF3 which results in sustained activation, it attenuates IRF3-PIN1 interaction, which antagonizes IRF3 ubiquitination and degradation, and boosts the antiviral response (PubMed:20308324). Also regulates innate antiviral response by mediating ISGylation of CGAS and STING1, thereby promoting activation of cGAS-STING signaling (PubMed:38421872, PubMed:38652662). Catalyzes ISGylation of IFIH1/MDA5, promoting IFIH1/MDA5 oligomerization and immune signal transduction (PubMed:40184173). Also regulates innate immunity by catalyzing ISGylation of viral proteins: newly translated viral proteins are primary targets of ISG15 in interferon-stimulated cells (PubMed:20133869, PubMed:20385878, PubMed:20542004, PubMed:22093708, PubMed:34572049). Interferes with the function of key viral structural proteins such as ebolavirus structural protein VP40 or HIV-1 protein GAG (PubMed:22093708, PubMed:34572049). Catalyzes ISGylation of influenza A viral NS1 which attenuates virulence; ISGylated NS1 fails to form homodimers and thus to interact with its RNA targets (PubMed:20133869, PubMed:20385878). Catalyzes ISGylation of papillomavirus type 16 L1 protein which results in dominant-negative effect on virus infectivity (PubMed:20542004). Mediates ISGylation of the phosphatase PTEN leading to its degradation, thus alleviating its suppression of the PI3K-AKT signaling pathway and promoting the production of cytokines that facilitate bacterial clearance (PubMed:37279284). Promotes parkin/PRKN ubiquitin E3 ligase activity by suppressing the intramolecular interaction that maintains its autoinhibited conformation (PubMed:27534820) (Microbial infection) Functions as an E3 ligase for ISGylation of hepatitis B virus protein X leading to enhanced viral replication due to increased interferon resistance","Expressed in testis and to a lesser degree in brain, ovary and placenta. Found in most tissues at low levels",,"Was thought to be a ubiquitin ligase ubiquitinated by UBE2D1, but was confirmed by numerous studies that its main function is as E3 ISG15 ligase","Cytoplasm, perinuclear region Cytoplasm",16407192|16815975|16884686|20133869|20308324|20385878|20542004|22093708|26355087|27534820|27564865|34572049|34661519|37279284|38421872|38652662|40184173,10581175|15331633,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
HINT3,ENSG00000111911,Unsafe,Protein,False,True,28.7,108.6,99,63,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 17.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 22.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 35.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 30.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 12 nTPM; absolute ceiling;continuous selectivity; cerebellum: 23.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 31.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 9.7 nTPM; absolute ceiling;continuous selectivity; colon: 19 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 15.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 21.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 27.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 36.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 30.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 21.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 27.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 20.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 10.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 39.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 18.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 29.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 14 nTPM; absolute ceiling;continuous selectivity; rectum: 17 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 14.5 nTPM; absolute ceiling;continuous selectivity; salivary gland: 24.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 108.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 16.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 15.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 16.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 57.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; stomach: 24.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 13.3 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 22.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 81.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 17.7 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 17.4 nTPM (limit 10); adrenal gland: 22.7 nTPM (limit 2); amygdala: 35.8 nTPM (limit 2); basal ganglia: 30.8 nTPM (limit 2); bone marrow: 12 nTPM (limit 4); cerebellum: 23.4 nTPM (limit 2); cerebral cortex: 31.7 nTPM (limit 2); choroid plexus: 9.7 nTPM (limit 2); colon: 19 nTPM (limit 6); duodenum: 15.2 nTPM (limit 2); esophagus: 21.5 nTPM (limit 6); heart muscle: 27.3 nTPM (limit 2); hippocampal formation: 36.1 nTPM (limit 2); hypothalamus: 30.4 nTPM (limit 2); kidney: 21.4 nTPM (limit 2); liver: 27.4 nTPM (limit 2); lung: 20.3 nTPM (limit 2); lymph node: 10.9 nTPM (limit 6); midbrain: 39.7 nTPM (limit 2); pancreas: 18.6 nTPM (limit 2); parathyroid gland: 29.6 nTPM (limit 6); pituitary gland: 14 nTPM (limit 2); rectum: 17 nTPM (limit 6); retina: 14.5 nTPM (limit 2); salivary gland: 24.8 nTPM (limit 6); skeletal muscle: 108.6 nTPM (limit 2); skin: 16.9 nTPM (limit 10); small intestine: 15.5 nTPM (limit 2); smooth muscle: 16.7 nTPM (limit 2); spinal cord: 57.2 nTPM (limit 2); stomach: 24.2 nTPM (limit 6); thymus: 13.3 nTPM (limit 10); thyroid gland: 22.7 nTPM (limit 10); tongue: 81.2 nTPM (limit 6); urinary bladder: 17.7 nTPM (limit 6),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: High (Approved); bronchus / ciliated cells (cell body): Medium (Approved); bronchus / ciliated cells (ciliary rootlets): Medium (Approved); bronchus / ciliated cells (tip of cilia): Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuropil: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Low (Approved); lymph node / germinal center cells: Low (Approved); nasopharynx / ciliated cells (cell body): Medium (Approved); nasopharynx / ciliated cells (cilia axoneme): Medium (Approved); nasopharynx / ciliated cells (tip of cilia): Medium (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / keratinocytes: Low (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Low (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Prostate Adenocarcinoma (TCGA): 480/480 (100.0%); Colon Adenocarcinoma (TCGA): 254/254 (100.0%),breast cancer: 12/12 (100.0%); prostate cancer: 11/11 (100.0%),31,20,Q9NQE9,https://www.uniprot.org/uniprotkb/Q9NQE9/entry,"Exhibits adenosine 5'-monophosphoramidase activity, hydrolyzing purine nucleotide phosphoramidates with a single phosphate group such as adenosine 5'monophosphoramidate (AMP-NH2) to yield AMP and NH2 (PubMed:17870088). Hydrolyzes lysyl-AMP (AMP-N-epsilon-(N-alpha-acetyl lysine methyl ester)) generated by lysine tRNA ligase (PubMed:17870088). Hydrolyzes 3-indolepropionic acyl-adenylate and fluorogenic purine nucleoside tryptamine phosphoramidates in vitro (PubMed:17870088)",,,,Cytoplasm Nucleus,17870088,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
HIPK3,ENSG00000110422,Unsafe,Protein,False,True,33.9,82.0,84,62,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 55.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; adrenal gland: 20.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 10.6 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 9.8 nTPM; absolute ceiling;continuous selectivity; bone marrow: 23.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 11.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 13.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 19 nTPM; absolute ceiling;continuous selectivity; colon: 29.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 16.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 29.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 51.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 10.6 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 11.9 nTPM; absolute ceiling;continuous selectivity; kidney: 36.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 28.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 26.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 22.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 11.8 nTPM; absolute ceiling;continuous selectivity; pancreas: 25 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 45.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 12.5 nTPM; absolute ceiling;continuous selectivity; rectum: 19.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 21.7 nTPM; absolute ceiling;continuous selectivity; salivary gland: 22.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 66.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 21.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 19.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 37.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 16.3 nTPM; absolute ceiling;continuous selectivity; spleen: 29.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 21.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 24.8 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 32.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 82 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 31.2 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 55.8 nTPM (limit 20); adrenal gland: 20.8 nTPM (limit 2); amygdala: 10.6 nTPM (limit 2); basal ganglia: 9.8 nTPM (limit 2); bone marrow: 23.1 nTPM (limit 2); cerebellum: 11.4 nTPM (limit 2); cerebral cortex: 13.2 nTPM (limit 2); choroid plexus: 19 nTPM (limit 2); colon: 29.7 nTPM (limit 6); duodenum: 16.2 nTPM (limit 2); esophagus: 29.8 nTPM (limit 6); heart muscle: 51.8 nTPM (limit 2); hippocampal formation: 10.6 nTPM (limit 2); hypothalamus: 11.9 nTPM (limit 2); kidney: 36.8 nTPM (limit 2); liver: 28.9 nTPM (limit 2); lung: 26.1 nTPM (limit 2); lymph node: 22.3 nTPM (limit 6); midbrain: 11.8 nTPM (limit 2); pancreas: 25 nTPM (limit 2); parathyroid gland: 45.2 nTPM (limit 6); pituitary gland: 12.5 nTPM (limit 2); rectum: 19.9 nTPM (limit 6); retina: 21.7 nTPM (limit 2); salivary gland: 22.3 nTPM (limit 6); skeletal muscle: 66.5 nTPM (limit 2); skin: 21.7 nTPM (limit 10); small intestine: 19.7 nTPM (limit 2); smooth muscle: 37.9 nTPM (limit 2); spinal cord: 16.3 nTPM (limit 2); spleen: 29.8 nTPM (limit 10); stomach: 21.4 nTPM (limit 6); thymus: 24.8 nTPM (limit 10); thyroid gland: 32.7 nTPM (limit 10); tongue: 82 nTPM (limit 6); urinary bladder: 31.2 nTPM (limit 6),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Medium (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Medium (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%),colorectal cancer: 9/12 (75.0%); liver cancer: 7/12 (58.3%),31,20,Q9H422,https://www.uniprot.org/uniprotkb/Q9H422/entry,"Serine/threonine-protein kinase involved in transcription regulation, apoptosis and steroidogenic gene expression. Phosphorylates JUN and RUNX2. Seems to negatively regulate apoptosis by promoting FADD phosphorylation. Enhances androgen receptor-mediated transcription. May act as a transcriptional corepressor for NK homeodomain transcription factors. The phosphorylation of NR5A1 activates SF1 leading to increased steroidogenic gene expression upon cAMP signaling pathway stimulation. In osteoblasts, supports transcription activation: phosphorylates RUNX2 that synergizes with SPEN/MINT to enhance FGFR2-mediated activation of the osteocalcin FGF-responsive element (OCFRE)","Overexpressed in multidrug resistant cells. Highly expressed in heart and skeletal muscle, and at lower levels in placenta, pancreas, brain, spleen, prostate, thymus, testis, small intestine, colon and leukocytes. Not found in liver and lung",,,Cytoplasm Nucleus,14766760|17210646,11034606|9373137|9725910,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
HIPK4,ENSG00000160396,Unsafe,RNA,False,True,17.6,17.6,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,amygdala: 2.9 nTPM; absolute ceiling; basal ganglia: 8.8 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 4.9 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 4.1 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 2.9 nTPM (limit 2); basal ganglia: 8.8 nTPM (limit 2); cerebral cortex: 4.9 nTPM (limit 2); hippocampal formation: 4.1 nTPM (limit 2); amygdala: 2.9 nTPM (baseline 2); basal ganglia: 8.8 nTPM (baseline 2); cerebral cortex: 4.9 nTPM (baseline 2); hippocampal formation: 4.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Chromophobe (TCGA): 1/64 (1.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Kidney Renal Papillary Cell Carcinoma (TCGA): 1/282 (0.4%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NE63,https://www.uniprot.org/uniprotkb/Q8NE63/entry,"Protein kinase that phosphorylates human TP53 at Ser-9, and thus induces TP53 repression of BIRC5 promoter (By similarity). May act as a corepressor of transcription factors (Potential)",,,,Cytoplasm,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
HJURP,ENSG00000123485,Unsafe,Protein,False,True,10.8,46.8,80,51,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0.6 nTPM; positive ihc; bone marrow: 46.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 0 nTPM; positive ihc; cerebral cortex: 0.4 nTPM; positive ihc; colon: 3.8 nTPM; positive ihc;continuous selectivity; duodenum: 3.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 5.4 nTPM; continuous selectivity; heart muscle: 0.3 nTPM; positive ihc; kidney: 0.4 nTPM; positive ihc; liver: 0.8 nTPM; positive ihc; lung: 1.3 nTPM; positive ihc; lymph node: 12.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 0.2 nTPM; positive ihc; rectum: 5.1 nTPM; positive ihc;continuous selectivity; salivary gland: 0.9 nTPM; positive ihc; skeletal muscle: 0.2 nTPM; positive ihc; small intestine: 3.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 1.9 nTPM; positive ihc; spleen: 4 nTPM; positive ihc; stomach: 2.3 nTPM; positive ihc; thymus: 29.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 0.3 nTPM; positive ihc; urinary bladder: 1.4 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 46.8 nTPM (limit 2); duodenum: 3.9 nTPM (limit 2); lymph node: 12.3 nTPM (limit 6); small intestine: 3.7 nTPM (limit 2); thymus: 29.6 nTPM (limit 10); bone marrow: 46.8 nTPM (baseline 2); duodenum: 3.9 nTPM (baseline 2); lymph node: 12.3 nTPM (baseline 6); small intestine: 3.7 nTPM (baseline 2); thymus: 29.6 nTPM (baseline 10),adipose tissue / adipocytes: Low (Uncertain); bone marrow / hematopoietic cells: High (Uncertain); bronchus / respiratory epithelial cells: Low (Uncertain); cerebellum / Purkinje cells: Low (Uncertain); cerebral cortex / endothelial cells: Low (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); colon / endothelial cells: Low (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: Low (Uncertain); duodenum / glandular cells: Medium (Uncertain); heart muscle / cardiomyocytes: Low (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / cholangiocytes: Low (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / alveolar cells: Low (Uncertain); lung / macrophages: Low (Uncertain); lymph node / germinal center cells: Low (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); nasopharynx / respiratory epithelial cells: Low (Uncertain); oral mucosa / squamous epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Low (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Low (Uncertain); skeletal muscle / myocytes: Low (Uncertain); small intestine / glandular cells: Medium (Uncertain); smooth muscle / smooth muscle cells: Low (Uncertain); spleen / cells in red pulp: Medium (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Low (Uncertain); thyroid gland / glandular cells: Low (Uncertain); urinary bladder / urothelial cells: Low (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 483/486 (99.4%); Testicular Germ Cell Tumor (TCGA): 131/133 (98.5%); Rectum Adenocarcinoma (validation): 203/207 (98.1%),colorectal cancer: 7/12 (58.3%); stomach cancer: 7/12 (58.3%),31,20,Q8NCD3,https://www.uniprot.org/uniprotkb/Q8NCD3/entry,Centromeric protein that plays a central role in the incorporation and maintenance of histone H3-like variant CENPA at centromeres. Acts as a specific chaperone for CENPA and is required for the incorporation of newly synthesized CENPA molecules into nucleosomes at replicated centromeres. Prevents CENPA-H4 tetramerization and prevents premature DNA binding by the CENPA-H4 tetramer. Directly binds Holliday junctions,"According to PubMed:17256767, highly expressed in the thymus with lower levels in the placenta, small intestine, liver, skeletal muscle, and colon. According to PubMed:17823411, highly expressed in testis, and at a relatively lower level in thymus and bone marrow. Significantly overexpressed in many lung cancer samples, compared with normal lung",,,"Nucleus, nucleolus Chromosome, centromere",19410544|19410545,17256767|17823411,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
HMGA2,ENSG00000149948,Unsafe,Protein,False,True,3.7,4.8,84,63,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 0 nTPM; positive ihc; bone marrow: 4.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 0 nTPM; positive ihc; cerebral cortex: 0.1 nTPM; positive ihc; colon: 2 nTPM; positive ihc;continuous selectivity; duodenum: 1.3 nTPM; positive ihc;continuous selectivity; esophagus: 0.3 nTPM; positive ihc; heart muscle: 0.1 nTPM; positive ihc; kidney: 0.2 nTPM; positive ihc; liver: 0.2 nTPM; positive ihc; lung: 0.1 nTPM; positive ihc; lymph node: 0.1 nTPM; positive ihc; pancreas: 0.9 nTPM; positive ihc; parathyroid gland: 0 nTPM; positive ihc; rectum: 2.3 nTPM; positive ihc;continuous selectivity; salivary gland: 0.1 nTPM; positive ihc; skeletal muscle: 1.6 nTPM; positive ihc;continuous selectivity; skin: 0.4 nTPM; positive ihc; small intestine: 1 nTPM; positive ihc; smooth muscle: 0.1 nTPM; positive ihc; spleen: 0.1 nTPM; positive ihc; stomach: 1.1 nTPM; positive ihc; thyroid gland: 0.6 nTPM; positive ihc; urinary bladder: 0.1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 4.8 nTPM (limit 2),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Medium (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Low (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Low (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Low (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Low (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Low (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Low (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 192/207 (92.8%); Colon Adenocarcinoma (validation): 435/486 (89.5%); Thyroid Carcinoma (TCGA): 390/495 (78.8%),stomach cancer: 9/12 (75.0%); testis cancer: 8/11 (72.7%),31,20,P52926,https://www.uniprot.org/uniprotkb/P52926/entry,"Functions as a transcriptional regulator. Functions in cell cycle regulation through CCNA2. Plays an important role in chromosome condensation during the meiotic G2/M transition of spermatocytes. Plays a role in postnatal myogenesis, is involved in satellite cell activation (By similarity). Positively regulates IGF2 expression through PLAG1 and in a PLAG1-independent manner (PubMed:28796236)",,"Silver-Russell syndrome 5: A form of Silver-Russell syndrome, a clinically heterogeneous condition characterized by severe intrauterine growth retardation, poor postnatal growth, craniofacial features such as a triangular shaped face and a broad forehead, body asymmetry, and a variety of minor malformations. The phenotypic expression changes during childhood and adolescence, with the facial features and asymmetry usually becoming more subtle with age. SRS5 inheritance is autosomal dominant.",,Nucleus,14645522|28796236,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
HMGB4,ENSG00000176256,Unsafe,High RNA,False,True,361.1,361.1,84,3,Positive somewhere,False,False,False,True,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,CTA,Pass,oncoref.target-sets.2026-10-23.1,False,False,,CTA → Unsafe,True,True,True,0.116456013709,63.9,"hpa_single_cell_tissue: testis/macrophages, max 63.9 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,0.1165 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,63.9 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 2/133 (1.5%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),breast cancer: 0/11 (0.0%); cervical cancer: 0/9 (0.0%),31,20,Q8WW32,https://www.uniprot.org/uniprotkb/Q8WW32/entry,,,,,Nucleus Chromosome,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | Chang2019_TGCT | Gong2021_reproductive_PC | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
HMHB1,ENSG00000158497,Unsafe,High RNA,False,True,1.3,2.3,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 0.9 nTPM; continuous selectivity; lymph node: 0.6 nTPM; continuous selectivity; thymus: 2.3 nTPM; continuous selectivity;reproductive not higher,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,hpa_immune_cell plasmacytoid DC: 20.1 nTPM,True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,30.0832,31.8998,"hpa_immune_cell_samples: blood/plasmacytoid DC, max 30.0832 TPM, 1 observations >30; hpa_immune_cell_samples: blood/plasmacytoid DC, max 31.8998 nTPM, 1 observations >30",Neither,oncoref.target-sets.2026-10-23.2,30.08 TPM; blood/plasmacytoid DC; hpa_immune_cell_samples; vital,31.9 nTPM; blood/plasmacytoid DC; hpa_immune_cell_samples; vital,Breast Invasive Carcinoma (validation): 1/50 (2.0%); Glioblastoma Multiforme (TCGA): 1/141 (0.7%); Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O97980,https://www.uniprot.org/uniprotkb/O97980/entry,"Precursor of the histocompatibility antigen HB-1. More generally, minor histocompatibility antigens (mHags) refer to immunogenic peptide which, when complexed with MHC, can generate an immune response after recognition by specific T-cells. The peptides are derived from polymorphic intracellular proteins, which are cleaved by normal pathways of antigen processing. The binding of these peptides to MHC class I or class II molecules and its expression on the cell surface can stimulate T-cell responses and thereby trigger graft rejection or graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation from HLA-identical sibling donor. GVHD is a frequent complication after bone marrow transplantation (BMT), due to mismatch of minor histocompatibility antigen in HLA-matched sibling marrow transplants. HB-1 is presented on the cell surface by MHC class I HLA-B44. This complex specifically elicits donor-cytotoxic T lymphocyte (CTL) reactivity in B-cell acute lymphoblastic leukemia (B-ALL) after treatment by HLA-identical allogenic bone marrow transplantation (BMT). It induces cell recognition and lysis by CTL. However, HB-1 restricted expression in B-ALL cells and not in normal tissues may allow a specific CTL reactivity against B-ALL without the risk of evoking graft-versus-host disease",Expressed in acute lymphoblastic leukemia B-cells and Epstein-Barr virus-transformed B-cells,,"This sequence containing mHag HB-1 may not represent the full-length protein, because functional domains are absent in this short gene product PubMed:9892612 postulated that the initiator methionine is coded by a non-canonical CTG leucine codon",,15102363|8992968|9892612,8992968|9892612,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,All audited maxima are within 10% above 30; other gates still require review,,,,
HMMR,ENSG00000072571,Unsafe,Protein,False,True,26.7,26.7,110,24,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 20.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 1.1 nTPM; positive ihc; colon: 6.3 nTPM; positive ihc;absolute ceiling; duodenum: 7.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 17.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; rectum: 8.5 nTPM; positive ihc;absolute ceiling; skin: 4.1 nTPM; positive ihc; stomach: 3.5 nTPM; positive ihc; thymus: 26.5 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 20.3 nTPM (limit 2); colon: 6.3 nTPM (limit 6); duodenum: 7.2 nTPM (limit 2); lymph node: 17.7 nTPM (limit 6); rectum: 8.5 nTPM (limit 6); thymus: 26.5 nTPM (limit 10),bone marrow / hematopoietic cells: Low (Enhanced); caudate / glial cells: Low (Enhanced); caudate / neuronal cells: Low (Enhanced); cerebral cortex / neuronal cells: Low (Enhanced); colon / glandular cells: Low (Enhanced); duodenum / glandular cells: Low (Enhanced); hippocampus / neuronal cells: Low (Enhanced); lymph node / non-germinal center cells: Low (Enhanced); rectum / glandular cells: Low (Enhanced); skin 1 / sebaceous glands: Low (Enhanced); skin 2 / cells in spinous layer: Low (Enhanced); stomach 1 / glandular cells: Low (Enhanced); stomach 2 / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 482/486 (99.2%); Colon Adenocarcinoma (TCGA): 246/254 (96.9%); Glioblastoma Multiforme (validation): 56/58 (96.6%),breast cancer: 3/12 (25.0%); colorectal cancer: 1/10 (10.0%),31,20,O75330,https://www.uniprot.org/uniprotkb/O75330/entry,"Receptor for hyaluronic acid (HA) (By similarity). Involved in cell motility (By similarity). When hyaluronan binds to HMMR, the phosphorylation of a number of proteins, including PTK2/FAK1 occurs. May also be involved in cellular transformation and metastasis formation, and in regulating extracellular-regulated kinase (ERK) activity. May act as a regulator of adipogenisis (By similarity)",Expressed in testis (PubMed:22965910). Expressed in the breast (PubMed:8890751),,,"Cell surface Cytoplasm Cytoplasm, cytoskeleton, spindle",,22965910|8890751,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
HROB,ENSG00000125319,Unsafe,Protein,False,True,11.1,11.1,81,68,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 1.4 nTPM; positive ihc; adrenal gland: 0.4 nTPM; positive ihc; bone marrow: 9.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 0.7 nTPM; positive ihc; cerebral cortex: 0.3 nTPM; positive ihc; colon: 0.9 nTPM; positive ihc; duodenum: 0.8 nTPM; positive ihc; esophagus: 2.7 nTPM; positive ihc; heart muscle: 0.7 nTPM; positive ihc; kidney: 0.4 nTPM; positive ihc; liver: 0.6 nTPM; positive ihc; lung: 0.6 nTPM; positive ihc; lymph node: 1.6 nTPM; positive ihc; pancreas: 0.3 nTPM; positive ihc; parathyroid gland: 0.4 nTPM; positive ihc; rectum: 1 nTPM; positive ihc; salivary gland: 0.7 nTPM; positive ihc; skeletal muscle: 0.9 nTPM; positive ihc; skin: 1.7 nTPM; positive ihc; small intestine: 0.9 nTPM; positive ihc; spleen: 1.2 nTPM; positive ihc; stomach: 0.6 nTPM; positive ihc; thyroid gland: 0.3 nTPM; positive ihc; urinary bladder: 0.6 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 9.2 nTPM (limit 2); bone marrow: 9.2 nTPM (baseline 2),adipose tissue / adipocytes: Medium (Uncertain); adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / glial cells: Medium (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: Medium (Uncertain); cerebellum / cells in molecular layer: Low (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / neuronal cells: Low (Uncertain); cerebral cortex / neuropil: Medium (Uncertain); colon / endothelial cells: Low (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: Medium (Uncertain); duodenum / glandular cells: High (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / glial cells: Low (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / cholangiocytes: Low (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / germinal center cells: Medium (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: Low (Uncertain); skin 1 / keratinocytes: Low (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: Medium (Uncertain); spleen / cells in red pulp: Medium (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Low (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 114/133 (85.7%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 219/283 (77.4%); Lung Squamous Cell Carcinoma (TCGA): 297/489 (60.7%),prostate cancer: 11/12 (91.7%); colorectal cancer: 9/11 (81.8%),29,20,Q8N3J3,https://www.uniprot.org/uniprotkb/Q8N3J3/entry,DNA-binding protein involved in homologous recombination that acts by recruiting the MCM8-MCM9 helicase complex to sites of DNA damage to promote DNA repair synthesis (PubMed:31467087). A C-terminal region including the OB-fold stimulates the helicase activity of MCM8-MCM9 probably by altering its conformation (PubMed:37535404),,"Ovarian dysgenesis 11: An autosomal recessive form of ovarian dysgenesis, a disorder characterized by lack of spontaneous pubertal development, primary amenorrhea, uterine hypoplasia, and hypergonadotropic hypogonadism as a result of streak gonads.",,Nucleus Chromosome,31467087|37535404,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
HS6ST3,ENSG00000185352,Unsafe,RNA,False,True,2.0,16.7,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 1.3 nTPM; continuous selectivity; adrenal gland: 4.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 5.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 5.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 1.5 nTPM; continuous selectivity; cerebral cortex: 16.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 0.9 nTPM; continuous selectivity; hippocampal formation: 10.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 6.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 0.8 nTPM; continuous selectivity; midbrain: 3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 2.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 2 nTPM; continuous selectivity;reproductive not higher; pituitary gland: 1.9 nTPM; continuous selectivity; retina: 2.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 1 nTPM; continuous selectivity; smooth muscle: 1.5 nTPM; continuous selectivity; spinal cord: 1.5 nTPM; continuous selectivity; stomach: 0.8 nTPM; continuous selectivity; thyroid gland: 2.3 nTPM; continuous selectivity;reproductive not higher; urinary bladder: 2.6 nTPM; continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 4.1 nTPM (limit 2); amygdala: 5.2 nTPM (limit 2); basal ganglia: 5.9 nTPM (limit 2); cerebral cortex: 16.7 nTPM (limit 2); hippocampal formation: 10.9 nTPM (limit 2); hypothalamus: 6.7 nTPM (limit 2); midbrain: 3 nTPM (limit 2); pancreas: 2.1 nTPM (limit 2); retina: 2.2 nTPM (limit 2); adrenal gland: 4.1 nTPM (baseline 2); amygdala: 5.2 nTPM (baseline 2); basal ganglia: 5.9 nTPM (baseline 2); cerebral cortex: 16.7 nTPM (baseline 2); hippocampal formation: 10.9 nTPM (baseline 2); hypothalamus: 6.7 nTPM (baseline 2); midbrain: 3 nTPM (baseline 2); pancreas: 2.1 nTPM (baseline 2); retina: 2.2 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Chromophobe (TCGA): 55/64 (85.9%); Breast Invasive Carcinoma (validation): 24/50 (48.0%); Glioblastoma Multiforme (validation): 16/58 (27.6%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8IZP7,https://www.uniprot.org/uniprotkb/Q8IZP7/entry,6-O-sulfation enzyme which catalyzes the transfer of sulfate from 3'-phosphoadenosine 5'-phosphosulfate (PAPS) to position 6 of the N-sulfoglucosamine residue (GlcNS) of heparan sulfate,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
HSD17B1,ENSG00000108786,Unsafe,RNA,False,True,79.7,79.7,85,2,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,amygdala: 3 nTPM; absolute ceiling; basal ganglia: 3.1 nTPM; absolute ceiling; choroid plexus: 3 nTPM; absolute ceiling; hippocampal formation: 3.4 nTPM; absolute ceiling; hypothalamus: 2.4 nTPM; absolute ceiling; midbrain: 3.4 nTPM; absolute ceiling; pituitary gland: 2.3 nTPM; absolute ceiling; spinal cord: 3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 3 nTPM (limit 2); basal ganglia: 3.1 nTPM (limit 2); choroid plexus: 3 nTPM (limit 2); hippocampal formation: 3.4 nTPM (limit 2); hypothalamus: 2.4 nTPM (limit 2); midbrain: 3.4 nTPM (limit 2); pituitary gland: 2.3 nTPM (limit 2); spinal cord: 3 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 48/50 (96.0%); Head and Neck Squamous Cell Carcinoma (TCGA): 457/492 (92.9%); Ovary Serous Cystadenocarcinoma (TCGA): 310/349 (88.8%),breast cancer: 0/12 (0.0%); cervical cancer: 0/10 (0.0%),31,20,P14061,https://www.uniprot.org/uniprotkb/P14061/entry,"Favors the reduction of estrogens and androgens. Converts estrone (E1) to a more potent estrogen, 17beta-estradiol (E2) (PubMed:8994190). Also has 20-alpha-HSD activity. Uses preferentially NADH",,,,Cytoplasm,8994190,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Gong2021_reproductive_PC,No tumor-antigen validation in this source | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
HSD17B3,ENSG00000130948,Unsafe,RNA,False,True,35.7,35.7,79,1,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,amygdala: 2.8 nTPM; absolute ceiling; basal ganglia: 3.2 nTPM; absolute ceiling; hippocampal formation: 4.1 nTPM; absolute ceiling; hypothalamus: 2.2 nTPM; absolute ceiling; liver: 14.8 nTPM; absolute ceiling; midbrain: 4.2 nTPM; absolute ceiling; spinal cord: 5 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 2.8 nTPM (limit 2); basal ganglia: 3.2 nTPM (limit 2); hippocampal formation: 4.1 nTPM (limit 2); hypothalamus: 2.2 nTPM (limit 2); liver: 14.8 nTPM (limit 12); midbrain: 4.2 nTPM (limit 2); spinal cord: 5 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (validation): 172/231 (74.5%); Glioblastoma Multiforme (validation): 26/58 (44.8%); Breast Invasive Carcinoma (validation): 8/50 (16.0%),liver cancer: 5/12 (41.7%); lung cancer: 4/12 (33.3%),31,20,P37058,https://www.uniprot.org/uniprotkb/P37058/entry,"Catalyzes the conversion of 17-oxosteroids to 17beta-hydroxysteroids (PubMed:16216911, PubMed:23856005, PubMed:26545797, PubMed:27927697, PubMed:8075637). Favors the reduction of androstenedione to testosterone (PubMed:16216911, PubMed:23856005, PubMed:26545797, PubMed:27927697). Testosterone is the key androgen driving male development and function (PubMed:8075637). Uses NADPH while the two other EDH17B enzymes use NADH (PubMed:16216911, PubMed:26545797, PubMed:8075637). Androgens such as epiandrosterone, dehydroepiandrosterone, androsterone and androstanedione are accepted as substrates and reduced at C-17 (PubMed:16216911). Can reduce 11-ketoandrostenedione as well as 11beta-hydroxyandrostenedione at C-17 to the respective testosterone forms (PubMed:16216911, PubMed:27927697)",Testis,"Male pseudohermaphrodism with gynecomastia: An autosomal recessive disorder that manifests, in males, as undermasculinization characterized by hypoplastic-to-normal internal genitalia (epididymis, vas deferens, seminal vesicles, and ejaculatory ducts) but female external genitalia and the absence of a prostate. This phenotype is caused by inadequate testicular synthesis of testosterone, which, in turn, results in insufficient formation of dihydrotestosterone in the anlage of the external genitalia and prostate during fetal development. At the expected time of puberty, there is a marked increase in plasma leuteinizing hormone and, consequently, in testicular secretion of androstenedione. Hence, a diagnostic hallmark of this disorder is a decreased plasma testosterone-to-androstenedione ratio. Significant amounts of the circulating androstenedione are, however, converted to testosterone, in peripheral tissues, thereby causing virilization.",,Endoplasmic reticulum,16216911|23856005|26545797|27927697|8075637,8075637,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
HSD3B1,ENSG00000203857,Unsafe,Protein,False,True,75.2,75.2,87,5,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 1.2 nTPM; positive ihc; small intestine: 8.4 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",small intestine: 8.4 nTPM (limit 6),adrenal gland / cells in zona fasciculata: Low (Supported); adrenal gland / cells in zona glomerulosa: Low (Supported); adrenal gland / glandular cells: Low (Supported),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Bladder Urothelial Carcinoma (TCGA): 13/169 (7.7%); Testicular Germ Cell Tumor (TCGA): 6/133 (4.5%); Liver Hepatocellular Carcinoma (TCGA): 11/362 (3.0%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),31,20,P14060,https://www.uniprot.org/uniprotkb/P14060/entry,"A bifunctional enzyme responsible for the oxidation and isomerization of 3beta-hydroxy-Delta(5)-steroid precursors to 3-oxo-Delta(4)-steroids, an essential step in steroid hormone biosynthesis. Specifically catalyzes the conversion of pregnenolone to progesterone, 17alpha-hydroxypregnenolone to 17alpha-hydroxyprogesterone, dehydroepiandrosterone (DHEA) to 4-androstenedione, and androstenediol to testosterone. Additionally, catalyzes the interconversion between 3beta-hydroxy and 3-oxo-5alpha-androstane steroids controlling the bioavalability of the active forms. Specifically converts dihydrotestosterone to its inactive form 5alpha-androstanediol, that does not bind androgen receptor/AR. Also converts androstanedione, a precursor of testosterone and estrone, to epiandrosterone (PubMed:1401999, PubMed:2139411). Expected to use NAD(+) as preferred electron donor for the 3beta-hydroxy-steroid dehydrogenase activity and NADPH for the 3-ketosteroid reductase activity (Probable)",Placenta and skin (PubMed:1401999). Predominantly expressed in mammary gland tissue,,,Endoplasmic reticulum membrane Mitochondrion membrane,1401999|2139411,1401999,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Gong2021_reproductive_PC,No tumor-antigen validation in this source | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
HSF2,ENSG00000025156,Unsafe,RNA,False,True,36.8,61.7,100,4,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,adrenal gland: 14.7 nTPM; absolute ceiling;continuous selectivity; amygdala: 8.5 nTPM; absolute ceiling; basal ganglia: 8.7 nTPM; absolute ceiling; bone marrow: 29.2 nTPM; absolute ceiling;continuous selectivity; cerebellum: 17.9 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 11.5 nTPM; absolute ceiling; choroid plexus: 16.1 nTPM; absolute ceiling;continuous selectivity; colon: 11.2 nTPM; absolute ceiling; duodenum: 6.7 nTPM; absolute ceiling; heart muscle: 22.4 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 8.9 nTPM; absolute ceiling; hypothalamus: 11.1 nTPM; absolute ceiling;continuous selectivity; kidney: 6.5 nTPM; absolute ceiling; liver: 5.3 nTPM; absolute ceiling; lung: 8.5 nTPM; absolute ceiling; lymph node: 12.4 nTPM; absolute ceiling; midbrain: 8.4 nTPM; absolute ceiling; pancreas: 6.2 nTPM; absolute ceiling; parathyroid gland: 13.6 nTPM; absolute ceiling; pituitary gland: 10.3 nTPM; absolute ceiling;continuous selectivity; retina: 43.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 8.2 nTPM; absolute ceiling; skeletal muscle: 46.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 8.8 nTPM; absolute ceiling; smooth muscle: 13.5 nTPM; absolute ceiling;continuous selectivity; spinal cord: 8.6 nTPM; absolute ceiling; stomach: 9.1 nTPM; absolute ceiling; thymus: 17.4 nTPM; absolute ceiling;continuous selectivity; tongue: 61.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 9.3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 14.7 nTPM (limit 4); amygdala: 8.5 nTPM (limit 2); basal ganglia: 8.7 nTPM (limit 2); bone marrow: 29.2 nTPM (limit 4); cerebellum: 17.9 nTPM (limit 4); cerebral cortex: 11.5 nTPM (limit 4); choroid plexus: 16.1 nTPM (limit 2); colon: 11.2 nTPM (limit 8); duodenum: 6.7 nTPM (limit 4); heart muscle: 22.4 nTPM (limit 4); hippocampal formation: 8.9 nTPM (limit 2); hypothalamus: 11.1 nTPM (limit 2); kidney: 6.5 nTPM (limit 4); liver: 5.3 nTPM (limit 4); lung: 8.5 nTPM (limit 4); lymph node: 12.4 nTPM (limit 8); midbrain: 8.4 nTPM (limit 2); pancreas: 6.2 nTPM (limit 4); parathyroid gland: 13.6 nTPM (limit 8); pituitary gland: 10.3 nTPM (limit 2); retina: 43.1 nTPM (limit 2); salivary gland: 8.2 nTPM (limit 8); skeletal muscle: 46.8 nTPM (limit 4); small intestine: 8.8 nTPM (limit 4); smooth muscle: 13.5 nTPM (limit 4); spinal cord: 8.6 nTPM (limit 2); stomach: 9.1 nTPM (limit 8); thymus: 17.4 nTPM (limit 10); tongue: 61.7 nTPM (limit 6); urinary bladder: 9.3 nTPM (limit 8),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Adenocarcinoma (validation): 105/105 (100.0%); Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%),testis cancer: 5/11 (45.5%); breast cancer: 0/12 (0.0%),31,20,Q03933,https://www.uniprot.org/uniprotkb/Q03933/entry,"DNA-binding protein that specifically binds heat shock promoter elements (HSE) and activates transcription. In higher eukaryotes, HSF is unable to bind to the HSE unless the cells are heat shocked",,,,Cytoplasm Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
HSF2BP,ENSG00000160207,Unsafe,Protein,False,True,23.4,23.4,89,9,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; cerebral cortex: 2.4 nTPM; positive ihc;absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",cerebral cortex: 2.4 nTPM (limit 2),caudate / neuronal cells: Low (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); hippocampus / neuronal cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 37/58 (63.8%); Breast Invasive Carcinoma (validation): 31/50 (62.0%); Bladder Urothelial Carcinoma (TCGA): 14/169 (8.3%),breast cancer: 1/12 (8.3%); cervical cancer: 0/11 (0.0%),31,20,O75031,https://www.uniprot.org/uniprotkb/O75031/entry,"Meiotic recombination factor component of recombination bridges involved in meiotic double-strand break repair. Modulates the localization of recombinases DMC1:RAD51 to meiotic double-strand break (DSB) sites through the interaction with BRCA2 and its recruitment during meiotic recombination (By similarity) (PubMed:31242413). Indispensable for the DSB repair, homologous synapsis, and crossover formation that are needed for progression past metaphase I, is essential for spermatogenesis and male fertility (By similarity). Required for proper recombinase recruitment in female meiosis (By similarity). Inhibits BNC1 transcriptional activity during spermatogenesis, probably by sequestering it in the cytoplasm (By similarity). May be involved in modulating HSF2 activation in testis (PubMed:9651507)",Testis specific. Overexpressed in some tumors (PubMed:31242413),"Premature ovarian failure 19: A form of premature ovarian failure, an ovarian disorder defined as the cessation of ovarian function under the age of 40 years. It is characterized by oligomenorrhea or amenorrhea, in the presence of elevated levels of serum gonadotropins and low estradiol. POF19 is an autosomal recessive form characterized by irregular menstrual cycles and cessation of menstruation in the third decade of life.",,Cytoplasm Chromosome,31242413|9651507,31242413|9651507,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
HSFX4,ENSG00000283463,Unsafe,RNA,False,True,14.6,14.6,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,existing nomination or manual review; nomination unresolved; adrenal gland: 2.7 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 2.7 nTPM (limit 2); adrenal gland: 2.7 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 9/176 (5.1%); Kidney Chromophobe (TCGA): 1/64 (1.6%); Prostate Adenocarcinoma (TCGA): 5/480 (1.0%),No exact-ID IHC coverage in the HPA cancer snapshot,26,0,A0A1B0GTS1,https://www.uniprot.org/uniprotkb/A0A1B0GTS1/entry,,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
HSPA1L,ENSG00000204390,Unsafe,Protein,False,True,61.4,61.4,102,8,Positive somewhere,True,True,False,True,Excluded,Normal,False,,Not assessed,,,positive ihc outside permitted; amygdala: 2.9 nTPM; absolute ceiling; basal ganglia: 3.2 nTPM; absolute ceiling; hippocampal formation: 2.5 nTPM; absolute ceiling; hypothalamus: 2.4 nTPM; absolute ceiling; midbrain: 2.7 nTPM; absolute ceiling; spinal cord: 3 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 2.9 nTPM (limit 2); basal ganglia: 3.2 nTPM (limit 2); hippocampal formation: 2.5 nTPM (limit 2); hypothalamus: 2.4 nTPM (limit 2); midbrain: 2.7 nTPM (limit 2); spinal cord: 3 nTPM (limit 2),bronchus / ciliated cells (cell body): Medium (Enhanced); nasopharynx / ciliated cells (cell body): Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 45/50 (90.0%); Glioblastoma Multiforme (validation): 50/58 (86.2%); Kidney Chromophobe (TCGA): 1/64 (1.6%),ovarian cancer: 1/11 (9.1%); breast cancer: 0/10 (0.0%),31,20,P34931,https://www.uniprot.org/uniprotkb/P34931/entry,"Molecular chaperone implicated in a wide variety of cellular processes, including protection of the proteome from stress, folding and transport of newly synthesized polypeptides, activation of proteolysis of misfolded proteins and the formation and dissociation of protein complexes. Plays a pivotal role in the protein quality control system, ensuring the correct folding of proteins, the re-folding of misfolded proteins and controlling the targeting of proteins for subsequent degradation. This is achieved through cycles of ATP binding, ATP hydrolysis and ADP release, mediated by co-chaperones. The affinity for polypeptides is regulated by its nucleotide bound state. In the ATP-bound form, it has a low affinity for substrate proteins. However, upon hydrolysis of the ATP to ADP, it undergoes a conformational change that increases its affinity for substrate proteins. It goes through repeated cycles of ATP hydrolysis and nucleotide exchange, which permits cycles of substrate binding and release (PubMed:26865365). Positive regulator of PRKN translocation to damaged mitochondria (PubMed:24270810)",Expressed in spermatids,,,,24270810|26865365,9685725,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
HSPA4L,ENSG00000164070,Unsafe,Protein,False,True,105.6,105.6,105,8,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 4.7 nTPM; absolute ceiling; basal ganglia: 5.5 nTPM; absolute ceiling; cerebellum: 8.3 nTPM; positive ihc;absolute ceiling; choroid plexus: 8.1 nTPM; absolute ceiling; hippocampal formation: 4.4 nTPM; absolute ceiling; hypothalamus: 9.4 nTPM; absolute ceiling; kidney: 12.9 nTPM; absolute ceiling; lung: 1.5 nTPM; positive ihc; midbrain: 6.1 nTPM; absolute ceiling; pituitary gland: 7.8 nTPM; absolute ceiling; retina: 26.1 nTPM; absolute ceiling; spinal cord: 3.1 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 4.7 nTPM (limit 2); basal ganglia: 5.5 nTPM (limit 2); cerebellum: 8.3 nTPM (limit 2); choroid plexus: 8.1 nTPM (limit 2); hippocampal formation: 4.4 nTPM (limit 2); hypothalamus: 9.4 nTPM (limit 2); kidney: 12.9 nTPM (limit 12); midbrain: 6.1 nTPM (limit 2); pituitary gland: 7.8 nTPM (limit 2); retina: 26.1 nTPM (limit 2); spinal cord: 3.1 nTPM (limit 2),cerebellum / Purkinje cells - cytoplasm/membrane: Medium (Enhanced); cerebellum / Purkinje cells - dendrites: Medium (Enhanced); lung / macrophages: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Kidney Renal Clear Cell Carcinoma (validation): 95/100 (95.0%); Kidney Chromophobe (TCGA): 59/64 (92.2%),breast cancer: 0/10 (0.0%); cervical cancer: 0/9 (0.0%),31,20,O95757,https://www.uniprot.org/uniprotkb/O95757/entry,Possesses chaperone activity in vitro where it inhibits aggregation of citrate synthase,,,,Cytoplasm Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
HTN1,ENSG00000126550,Unsafe,RNA,False,True,5.3,47123.7,84,1,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,heart muscle: 4.3 nTPM; absolute ceiling;continuous selectivity; pancreas: 18 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 47123.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,heart muscle: 4.3 nTPM (limit 4); pancreas: 18 nTPM (limit 4); salivary gland: 47123.7 nTPM (limit 8),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 20/80 (25.0%); Lung Squamous Cell Carcinoma (validation): 1/68 (1.5%); Ovary Serous Cystadenocarcinoma (validation): 1/81 (1.2%),skin cancer: 9/12 (75.0%); urothelial cancer: 5/12 (41.7%),31,20,P15515,https://www.uniprot.org/uniprotkb/P15515/entry,"Histatins (Hsts) are cationic and histidine-rich secreted peptides mainly synthesized by saliva glands of humans and higher primates (PubMed:3286634, PubMed:3944083). Hsts are considered to be major precursors of the protective proteinaceous structure on tooth surfaces (enamel pellicle). Hsts can be divided into two major groups according to their biological functions: antimicrobial Hsts (e.g. Hst 5/HTN3) and cell-activating Hsts (e.g. Hst 1/HTN1 and Hst 2/HTN1) (PubMed:32225006). Hst 1/HTN1 and Hst 2/HTN1 act in different cell types (epithelium, fibroblasts and endothelium) in oral and non-oral mucosa (PubMed:25903106, PubMed:28542418, PubMed:28751526, PubMed:32225006) Hst 1 functions primarily as a wound healing factor by activating cell-surface and cell-cell adhesions, cell spreading and migration and it can also stimulate cellular metabolic activity (PubMed:18650243, PubMed:25903106, PubMed:28542418, PubMed:28751526, PubMed:32225006, PubMed:35970844). Hst 1 is internalized in host cells in a stereospecific and energy-dependent process, which is partially mediated by the G protein-coupled receptors (GPCR)-activated endocytosis (PubMed:35970844). Internalized Hst 1 is targeted and released via early endosomes trafficking to the mitochondria, where it significantly enhances mitochondrial energy metabolism (PubMed:32225006, PubMed:35970844). At the mitochondria, Hst 1 increases mitochondria-ER contacts through binding with ER receptor TMEM97, which also stimulates metabolic activity and cell migration and may as well regulate calcium homeostasis of the cell (PubMed:32225006, PubMed:34233061, PubMed:35970844). Also activates the ERK1/2 signaling pathway to promote cell migration, possibly upon interaction with GPRCs at the plasma membrane (PubMed:28751526). Also triggers the RIN2/Rab5/Rac1 signaling cascade which activates endothelial cell adhesion, spreading and migration required for angiogenesis in the oral wound healing process, however the receptor that transduces Hst 1 signal has not yet been identified (PubMed:28751526). Also displays antimicrobial functions against pathogenic yeast Candida albicans, although with less effectiveness than Hst 5 (PubMed:28751526, PubMed:3286634, PubMed:3944083) Hst 2 consists of the fragment sequence 12-28 of Hst 1. Similar to Hst 1, actively and stereospecifically internalized in host cells and targeted to the mitochondria and the ER and promotes cell metabolic activity (PubMed:18650243, PubMed:32225006). Also activates the ERK1/2 signaling pathway to promote cell migration and wound closure (PubMed:18650243). In contrast with Hst 1, not able to promote cell-substrate and cell-cell adhesion (PubMed:25903106)",Submandibular and parotid glands,,"Has been reported to promote cell proliferation (PubMed:18650243). However other studies were unable to demonstrate any cell proliferation activity (PubMed:25903106, PubMed:28542418, PubMed:28751526, PubMed:32225006). The peptide named histatin 2 was mistakenly described as the non-phosphorylated form of histatin 1 by some authors (PubMed:17503797)",Secreted Mitochondrion Endoplasmic reticulum membrane,18650243|25903106|28542418|28751526|32225006|3286634|34233061|35970844|3944083,17503797,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
HTN3,ENSG00000205649,Unsafe,Protein,False,True,12.6,131918.0,80,1,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 18.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 25.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 119.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 131918 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 9.7 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 18.7 nTPM (limit 12); heart muscle: 25.2 nTPM (limit 12); pancreas: 119.5 nTPM (limit 12); salivary gland: 131918 nTPM (limit 6); bone marrow: 18.7 nTPM (baseline 2); heart muscle: 25.2 nTPM (baseline 2); pancreas: 119.5 nTPM (baseline 2); salivary gland: 131918 nTPM (baseline 6),salivary gland / glandular cells: High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 50/207 (24.2%); Colon Adenocarcinoma (validation): 70/486 (14.4%); Pancreatic Adenocarcinoma (validation): 5/80 (6.2%),breast cancer: 0/11 (0.0%); cervical cancer: 0/11 (0.0%),31,20,P15516,https://www.uniprot.org/uniprotkb/P15516/entry,"Histatins are cationic and histidine-rich peptides mainly found in the saliva of higher primates (PubMed:3286634). They are considered to be major precursors of the protective proteinaceous structure on tooth surfaces (enamel pellicle). Hsts can be divided into two major groups according to their biological functions: antimicrobial Hsts (e.g. Hst 5/HTN3) and cell-activating Hsts (e.g. Hst 1/HTN1, Hst 2/HTN1 and Hst 3/HTN3) (PubMed:32225006) Histatin 3 (Hst 3) is mostly involved in cell migration and wound healing in the oral cavity (PubMed:18650243). Also stimulates cell proliferation after binding to heat shock protein HSC70, which enhances HSC70-CDKN1B complex formation and subsequent ubiquitination during G1/S transition (PubMed:26775844). Also displays antifungal activity against pathogenic yeast Candida albicans, however with less effectiveness than Hst 5 (PubMed:11083804, PubMed:3286634) Histatin 5 (Hst 5), a fragment of Hst 3, is the major histatin exhibiting antifungal and antibacterial activities (PubMed:10066791, PubMed:11083804, PubMed:11179305, PubMed:11717389, PubMed:12939362, PubMed:15485849, PubMed:2372245, PubMed:8945538). It is effective against pathogenic yeast C.albicans, C.neoformans, C.glabrata and S.cerevisiae as well as ESKAPE bacterial pathogens (PubMed:18974864, PubMed:23613860, PubMed:2372245, PubMed:28261570, PubMed:8945538). Secreted Hst 5 mediates a multi-step intracellular mechanism of action against the pathogen. Depending on peptide concentration and pathogen, uptake across the membrane can occur through transporters, direct interaction with plasma membrane and/or receptor-mediated endocytosis (PubMed:18974864, PubMed:20487276, PubMed:28261570). Binds C.albicans cell wall proteins SSA1 and SSA2 and glycans in an energy-independent manner, then is taken up by the cells through fungal polyamine transporters DUR3 and DUR31 in an energy-dependent manner (PubMed:12761219, PubMed:20487276, PubMed:22033918, PubMed:23613860). Internalized Hst5 is then targeted to the energized mitochondrion to induce reactive oxygen species (ROS) formation and subsequent release of intracellular non-lytic ATP which ultimately leads to fungal cell death (PubMed:10066791, PubMed:11083804, PubMed:11717389). In addition, inhibits C.albicans TRK1 potassium-transporter which causes exudation of intracellular K(+), generating an osmotic imbalance leading to delayed membrane lysis and cell death (PubMed:15485849). Also acts as a potent inhibitor of bacterial proteases such as Lys-gingipain and Arg-gingipain (rgpB) from P.gingivalis as well as human metalloproteases MMP2 and MMP9 (PubMed:11179305). The binding of metals such as zinc, copper or nickel with Hst 5 results in the protection of the enamel and antimicrobial activities such as the inhibition of microbial growth by decreasing the metal concentration, the formation of ROS commonly associated with redox-active metals, the induction of membrane disruption mediated by zinc binding (PubMed:19846304, PubMed:28261570, PubMed:28763199, PubMed:32751915). Also involved in coating oral surfaces in the form of a salivary film which reduces colonization by C.albicans on epithelial cell surfaces (PubMed:26379655). Secreted Hst 5 can also internalize mammalian epithelial cells and target the mitochondria although it does not exert cytotoxic effects in these cells (PubMed:32225006). In contrast with Hst 3, not able to promote wound healing in mammalian host cells (PubMed:18650243)",,,"Hst 5 uptake into the pathogen cell by direct transfer across the membrane causing cell death has been questioned (PubMed:20487276). Moreover, endocytic vacuolar uptake was showed to be insignificant in terms of Hst 5 toxicity (PubMed:20487276)",Secreted Mitochondrion,10066791|11083804|11179305|11717389|12761219|12939362|15485849|18650243|18974864|19846304|20487276|22033918|23613860|2372245|26379655|26775844|28261570|28763199|32225006|32751915|3286634|8945538,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
HTR7,ENSG00000148680,Unsafe,Protein,False,True,8.5,12.7,91,28,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 0.2 nTPM; positive ihc; cerebral cortex: 1.4 nTPM; positive ihc; colon: 0.6 nTPM; positive ihc; kidney: 0 nTPM; positive ihc; lung: 0.2 nTPM; positive ihc; lymph node: 0.6 nTPM; positive ihc; pancreas: 0.1 nTPM; positive ihc; parathyroid gland: 12.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; spleen: 1.1 nTPM; positive ihc; stomach: 0.7 nTPM; positive ihc; thyroid gland: 0.1 nTPM; positive ihc; urinary bladder: 2.2 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",parathyroid gland: 12.7 nTPM (limit 6),adrenal gland / glandular cells: Medium (Approved); bronchus / respiratory epithelial cells: Low (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuronal projections: Medium (Approved); colon / glandular cells: Low (Approved); hypothalamus / neuronal cells: Medium (Approved); hypothalamus / neuronal projections: High (Approved); kidney / cells in glomeruli: Low (Approved); lung / macrophages: Low (Approved); lymph node / germinal center cells: Low (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Medium (Approved); spleen / cells in white pulp: Low (Approved); stomach 2 / glandular cells: Low (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Low (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Head and Neck Squamous Cell Carcinoma (TCGA): 182/492 (37.0%); Lung Squamous Cell Carcinoma (validation): 13/68 (19.1%); Bladder Urothelial Carcinoma (TCGA): 31/169 (18.3%),liver cancer: 4/11 (36.4%); endometrial cancer: 4/12 (33.3%),31,20,P34969,https://www.uniprot.org/uniprotkb/P34969/entry,"G protein-coupled receptor for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone and a mitogen (PubMed:35714614, PubMed:8226867). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors (PubMed:35714614, PubMed:8226867). HTR7 is coupled to G(s) G alpha proteins and mediates activation of adenylate cyclase activity (PubMed:35714614)","Predominant isoform in spleen, caudate and hippocampus Expressed at lower levels Minor isoform in terms of expression",,,Cell membrane,35714614|8226867,9084407,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
HUNK,ENSG00000142149,Unsafe,Protein,False,True,4.5,9.5,80,80,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0.7 nTPM; positive ihc; adrenal gland: 1 nTPM; positive ihc; bone marrow: 0.2 nTPM; positive ihc; cerebellum: 1.2 nTPM; positive ihc; cerebral cortex: 2.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 3.5 nTPM; positive ihc;continuous selectivity; duodenum: 1.4 nTPM; positive ihc;continuous selectivity; esophagus: 0.4 nTPM; positive ihc; heart muscle: 0.4 nTPM; positive ihc; hippocampal formation: 1.4 nTPM; continuous selectivity; kidney: 3.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 0.5 nTPM; positive ihc; lung: 0.9 nTPM; positive ihc; lymph node: 0.3 nTPM; positive ihc; pancreas: 9.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 0.1 nTPM; positive ihc; rectum: 3.6 nTPM; positive ihc;continuous selectivity; retina: 2.9 nTPM; absolute ceiling;continuous selectivity; salivary gland: 0.5 nTPM; positive ihc; skeletal muscle: 0.3 nTPM; positive ihc; skin: 2.9 nTPM; positive ihc;continuous selectivity; small intestine: 2.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 2.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; spleen: 0.1 nTPM; positive ihc; stomach: 1.2 nTPM; positive ihc; thyroid gland: 0.5 nTPM; positive ihc; urinary bladder: 1.4 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",cerebral cortex: 2.8 nTPM (limit 2); kidney: 3.6 nTPM (limit 2); pancreas: 9.5 nTPM (limit 2); retina: 2.9 nTPM (limit 2); small intestine: 2.6 nTPM (limit 2); smooth muscle: 2.3 nTPM (limit 2),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 178/207 (86.0%); Colon Adenocarcinoma (validation): 351/486 (72.2%); Testicular Germ Cell Tumor (TCGA): 86/133 (64.7%),testis cancer: 8/9 (88.9%); endometrial cancer: 6/12 (50.0%),31,20,P57058,https://www.uniprot.org/uniprotkb/P57058/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
HYCC1,ENSG00000122591,Unsafe,Protein,False,True,14.3,24.2,98,69,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 14.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; adrenal gland: 4.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 5.8 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 4.6 nTPM; absolute ceiling;continuous selectivity; bone marrow: 4.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 0.8 nTPM; positive ihc; cerebral cortex: 3.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 3.5 nTPM; absolute ceiling; colon: 9.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 9.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 11.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 10.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 7.8 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 4.4 nTPM; absolute ceiling;continuous selectivity; kidney: 4.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 8.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 13.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 11.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 5.7 nTPM; absolute ceiling;continuous selectivity; pancreas: 6 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 2.2 nTPM; positive ihc; pituitary gland: 4.8 nTPM; absolute ceiling;continuous selectivity; rectum: 4.2 nTPM; positive ihc; retina: 4.7 nTPM; absolute ceiling;continuous selectivity; salivary gland: 6.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 24.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 4.8 nTPM; positive ihc; small intestine: 6.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 11.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 5.4 nTPM; absolute ceiling;continuous selectivity; spleen: 11.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 4.4 nTPM; positive ihc; thyroid gland: 6.4 nTPM; positive ihc;continuous selectivity; tongue: 14.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 9 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 14.4 nTPM (limit 10); adrenal gland: 4.6 nTPM (limit 2); amygdala: 5.8 nTPM (limit 2); basal ganglia: 4.6 nTPM (limit 2); bone marrow: 4.2 nTPM (limit 2); cerebral cortex: 3.8 nTPM (limit 2); choroid plexus: 3.5 nTPM (limit 2); colon: 9.4 nTPM (limit 6); duodenum: 9.2 nTPM (limit 2); esophagus: 11.8 nTPM (limit 6); heart muscle: 10.1 nTPM (limit 2); hippocampal formation: 7.8 nTPM (limit 2); hypothalamus: 4.4 nTPM (limit 2); kidney: 4.5 nTPM (limit 2); liver: 8.3 nTPM (limit 2); lung: 13.3 nTPM (limit 2); lymph node: 11.2 nTPM (limit 6); midbrain: 5.7 nTPM (limit 2); pancreas: 6 nTPM (limit 2); pituitary gland: 4.8 nTPM (limit 2); retina: 4.7 nTPM (limit 2); salivary gland: 6.6 nTPM (limit 6); skeletal muscle: 24.2 nTPM (limit 2); small intestine: 6.7 nTPM (limit 2); smooth muscle: 11.2 nTPM (limit 2); spinal cord: 5.4 nTPM (limit 2); spleen: 11.5 nTPM (limit 10); tongue: 14.6 nTPM (limit 6); urinary bladder: 9 nTPM (limit 6),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / basal cells: Medium (Approved); bronchus / ciliated cells (cell body): High (Approved); bronchus / goblet cells: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Medium (Approved); kidney / cells in tubules: High (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Low (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / basal cells: Medium (Approved); nasopharynx / ciliated cells (cell body): High (Approved); nasopharynx / goblet cells: Medium (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Low (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Lung Adenocarcinoma (validation): 104/105 (99.0%); Lung Squamous Cell Carcinoma (validation): 65/68 (95.6%),colorectal cancer: 5/11 (45.5%); testis cancer: 5/12 (41.7%),31,20,Q9BYI3,https://www.uniprot.org/uniprotkb/Q9BYI3/entry,"Component of a complex required to localize phosphatidylinositol 4-kinase (PI4K) to the plasma membrane (PubMed:26571211). The complex acts as a regulator of phosphatidylinositol 4-phosphate (PtdIns(4)P) synthesis (PubMed:26571211). HYCC1 plays a key role in oligodendrocytes formation, a cell type with expanded plasma membrane that requires generation of PtdIns(4)P (PubMed:26571211). Its role in oligodendrocytes formation probably explains its importance in myelination of the central and peripheral nervous system (PubMed:16951682, PubMed:26571211). May also have a role in the beta-catenin/Lef signaling pathway (Probable)","Widely expressed. Highest levels in heart, brain, placenta, spleen and testis","Leukodystrophy, hypomyelinating, 5: A hypomyelinating leukodystrophy associated with congenital cataract. It is clinically characterized by congenital cataract, progressive neurologic impairment, and diffuse myelin deficiency. Affected individuals experience progressive pyramidal and cerebellar dysfunction, muscle weakness and wasting prevailingly in the lower limbs. Mental deficiency ranges from mild to moderate. HLD5 shows clinical variability, but features of hypomyelination combined with increased periventricular white matter water content are consistently observed.",,"Cytoplasm, cytosol Cell membrane",10910037|16951682|26571211,10910037,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
HYDIN,ENSG00000157423,Unsafe,Protein,False,True,5.2,6.6,115,8,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; basal ganglia: 1.9 nTPM; continuous selectivity; choroid plexus: 3.2 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 1.8 nTPM; continuous selectivity; hypothalamus: 2.1 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 4.2 nTPM; absolute ceiling;continuous selectivity; retina: 6.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 3.2 nTPM (limit 2); hypothalamus: 2.1 nTPM (limit 2); pituitary gland: 4.2 nTPM (limit 2); retina: 6.6 nTPM (limit 2),nasopharynx / ciliated cells (tip of cilia): Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 54/58 (93.1%); Breast Invasive Carcinoma (validation): 37/50 (74.0%); Pancreatic Adenocarcinoma (validation): 28/80 (35.0%),breast cancer: 0/12 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q4G0P3,https://www.uniprot.org/uniprotkb/Q4G0P3/entry,Required for ciliary motility (By similarity). Required for localization of SPEF2 to the ciliary axoneme in ciliated respiratory epithelial cells (PubMed:31545650),,"Ciliary dyskinesia, primary, 5: An autosomal recessive form of primary dyskinesia, a disorder characterized by abnormalities of motile cilia. Respiratory infections leading to chronic inflammation and bronchiectasis are recurrent, due to defects in the respiratory cilia; reduced fertility is often observed in male patients due to abnormalities of sperm tails. Half of the patients exhibit randomization of left-right body asymmetry and situs inversus, due to dysfunction of monocilia at the embryonic node. Primary ciliary dyskinesia associated with situs inversus is referred to as Kartagener syndrome. CILD5 is characterized by early onset of a progressive decline in lung function due to an inability to clear mucus and particles from the airways. Affected individuals have recurrent infections of the sinuses, ears, airways, and lungs. Sperm motility is also decreased. Individuals with CILD5 do not have situs inversus.",,"Cell projection, cilium Cytoplasm, cytoskeleton, cilium axoneme Cell projection, cilium, flagellum",31545650,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
IBA57,ENSG00000181873,Unsafe,Protein,False,True,1.8,5.8,86,38,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 1.9 nTPM; continuous selectivity;reproductive not higher; adrenal gland: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 1.2 nTPM; continuous selectivity; basal ganglia: 1.3 nTPM; continuous selectivity; bone marrow: 4.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 2.3 nTPM; continuous selectivity;reproductive not higher; cerebral cortex: 1.6 nTPM; continuous selectivity; choroid plexus: 1.5 nTPM; continuous selectivity; colon: 1.7 nTPM; positive ihc;continuous selectivity; duodenum: 1.6 nTPM; continuous selectivity; esophagus: 1.6 nTPM; continuous selectivity; heart muscle: 3.2 nTPM; continuous selectivity;reproductive not higher; hippocampal formation: 1.1 nTPM; continuous selectivity; hypothalamus: 0.9 nTPM; continuous selectivity; kidney: 1.9 nTPM; positive ihc;continuous selectivity;reproductive not higher; liver: 2.7 nTPM; continuous selectivity;reproductive not higher; lung: 1.9 nTPM; positive ihc;continuous selectivity;reproductive not higher; lymph node: 1.6 nTPM; positive ihc;continuous selectivity; midbrain: 1.1 nTPM; continuous selectivity; pancreas: 2.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 2.1 nTPM; positive ihc;continuous selectivity;reproductive not higher; pituitary gland: 0.9 nTPM; continuous selectivity; rectum: 1.3 nTPM; positive ihc;continuous selectivity; retina: 1.2 nTPM; continuous selectivity; salivary gland: 1.7 nTPM; positive ihc;continuous selectivity; skeletal muscle: 5.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 2.9 nTPM; positive ihc;continuous selectivity;reproductive not higher; small intestine: 1.6 nTPM; positive ihc;continuous selectivity; smooth muscle: 1.6 nTPM; continuous selectivity; spinal cord: 0.9 nTPM; continuous selectivity; spleen: 1.7 nTPM; positive ihc;continuous selectivity; stomach: 1.9 nTPM; positive ihc;continuous selectivity;reproductive not higher; thymus: 1.3 nTPM; continuous selectivity; thyroid gland: 1.3 nTPM; continuous selectivity; tongue: 3.8 nTPM; continuous selectivity;reproductive not higher; urinary bladder: 1.3 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 2.7 nTPM (limit 2); bone marrow: 4.1 nTPM (limit 2); pancreas: 2.8 nTPM (limit 2); skeletal muscle: 5.8 nTPM (limit 4),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Low (Approved); colon / peripheral nerve/ganglion: Low (Approved); kidney / cells in tubules: Medium (Approved); lung / macrophages: Low (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: High (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Low (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Low (Approved); salivary gland / glandular cells: Low (Approved); skin 1 / fibroblasts: Low (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Medium (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Low (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 45/58 (77.6%); Colon Adenocarcinoma (validation): 187/486 (38.5%); Pancreatic Adenocarcinoma (validation): 30/80 (37.5%),prostate cancer: 11/11 (100.0%); melanoma: 7/10 (70.0%),30,20,Q5T440,https://www.uniprot.org/uniprotkb/Q5T440/entry,"Mitochondrial protein involved in the maturation of mitochondrial [4Fe-4S]-proteins in the late stage of the iron-sulfur cluster assembly pathway (PubMed:22323289, PubMed:23462291). Operates in cooperation with ISCA2 in the maturation of [4Fe-4S] proteins (PubMed:30269484) Involved in the maturation of mitochondrial 2Fe-2S proteins in the late stage of the iron-sulfur cluster assembly pathway",Expressed in skin fibroblasts and skeletal muscle (at protein level),"Multiple mitochondrial dysfunctions syndrome 3: A severe disorder of systemic energy metabolism, resulting in weakness, respiratory failure, lack of neurologic development, lactic acidosis, hyperglycinemia and early death. Some patients show failure to thrive, pulmonary hypertension, hypotonia and irritability. Biochemical features include severe combined deficiency of the 2-oxoacid dehydrogenases, defective lipoic acid synthesis and reduction in activity of mitochondrial respiratory chain complexes. Spastic paraplegia 74, autosomal recessive: A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. SPG74 is characterized by a combination of spastic paraplegia, optic atrophy, and peripheral neuropathy with childhood-onset and slow progression into late adulthood.",,Mitochondrion,22323289|23462291|30269484,23462291,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
IER3IP1,ENSG00000134049,Unsafe,Protein,False,True,13.7,30.3,134,86,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 13.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 16.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 7.7 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 7.6 nTPM; absolute ceiling;continuous selectivity; bone marrow: 14.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 14.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 8.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 15.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 13.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 16.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 11.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 16.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 7.5 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 9.5 nTPM; absolute ceiling;continuous selectivity; kidney: 30.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 18.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 11.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 11.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 7.7 nTPM; absolute ceiling;continuous selectivity; pancreas: 13.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 18.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 15.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 12.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 13.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 14.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 30 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 13.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 15.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 9.2 nTPM; absolute ceiling;continuous selectivity; spinal cord: 7.4 nTPM; absolute ceiling;continuous selectivity; spleen: 10.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 15.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; thymus: 10.8 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 15.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; tongue: 20.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 13.4 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 13.2 nTPM (limit 10); adrenal gland: 16.7 nTPM (limit 2); amygdala: 7.7 nTPM (limit 2); basal ganglia: 7.6 nTPM (limit 2); bone marrow: 14.3 nTPM (limit 2); cerebellum: 14.3 nTPM (limit 2); cerebral cortex: 8.3 nTPM (limit 2); choroid plexus: 15.1 nTPM (limit 2); colon: 13.6 nTPM (limit 6); duodenum: 16.5 nTPM (limit 2); esophagus: 11.7 nTPM (limit 6); heart muscle: 16.3 nTPM (limit 2); hippocampal formation: 7.5 nTPM (limit 2); hypothalamus: 9.5 nTPM (limit 2); kidney: 30.3 nTPM (limit 2); liver: 18.9 nTPM (limit 2); lung: 11.9 nTPM (limit 2); lymph node: 11.1 nTPM (limit 6); midbrain: 7.7 nTPM (limit 2); pancreas: 13.2 nTPM (limit 2); parathyroid gland: 18.5 nTPM (limit 6); pituitary gland: 15.1 nTPM (limit 2); rectum: 12.6 nTPM (limit 6); retina: 13.7 nTPM (limit 2); salivary gland: 14.6 nTPM (limit 6); skeletal muscle: 30 nTPM (limit 2); skin: 13.4 nTPM (limit 10); small intestine: 15.3 nTPM (limit 2); smooth muscle: 9.2 nTPM (limit 6); spinal cord: 7.4 nTPM (limit 2); spleen: 10.8 nTPM (limit 10); stomach: 15.5 nTPM (limit 6); thymus: 10.8 nTPM (limit 10); thyroid gland: 15.4 nTPM (limit 10); tongue: 20.9 nTPM (limit 6); urinary bladder: 13.4 nTPM (limit 6),adipose tissue / adipocytes: Low (Supported); adrenal gland / glandular cells: High (Supported); bone marrow / hematopoietic cells: Low (Supported); bronchus / basal cells: Medium (Supported); bronchus / ciliated cells (cell body): Medium (Supported); bronchus / goblet cells: Medium (Supported); caudate / neuronal cells: Medium (Supported); cerebellum / GLUC cells - cytoplasm/membrane: Medium (Supported); cerebellum / molecular layer cells - cytoplasm/membrane: High (Supported); cerebellum / Purkinje cells - cytoplasm/membrane: High (Supported); cerebellum / Purkinje cells - dendrites: High (Supported); cerebellum / synaptic glomeruli - core: Low (Supported); cerebellum / white matter cells - cytoplasm/membrane: Medium (Supported); cerebral cortex / endothelial cells: Low (Supported); cerebral cortex / neuronal cells: Medium (Supported); cerebral cortex / neuropil: Low (Supported); colon / endothelial cells: Low (Supported); colon / glandular cells: Medium (Supported); colon / peripheral nerve/ganglion: Low (Supported); duodenum / glandular cells: High (Supported); esophagus / squamous epithelial cells: Medium (Supported); heart muscle / cardiomyocytes: Low (Supported); hippocampus / neuronal cells: Medium (Supported); kidney / cells in tubules: Medium (Supported); liver / cholangiocytes: Low (Supported); liver / hepatocytes: High (Supported); lung / alveolar cells type I: Low (Supported); lung / alveolar cells type II: Medium (Supported); lung / macrophages: Medium (Supported); lymph node / germinal center cells: Medium (Supported); nasopharynx / basal cells: Medium (Supported); nasopharynx / ciliated cells (cell body): Medium (Supported); oral mucosa / squamous epithelial cells: Medium (Supported); pancreas / exocrine glandular cells: High (Supported); pancreas / pancreatic endocrine cells: Medium (Supported); parathyroid gland / glandular cells: Medium (Supported); rectum / glandular cells: Medium (Supported); salivary gland / glandular cells: Medium (Supported); skeletal muscle / myocytes: Low (Supported); skin 1 / cells in basal layer: Medium (Supported); skin 1 / cells in granular layer: Medium (Supported); skin 1 / cells in spinous layer: Medium (Supported); skin 1 / endothelial cells: Medium (Supported); skin 1 / fibrohistiocytic cells: Medium (Supported); skin 1 / langerhans cells: Medium (Supported); skin 1 / lymphocytes: Medium (Supported); skin 2 / cells in basal layer: Medium (Supported); skin 2 / cells in granular layer: Medium (Supported); skin 2 / cells in spinous layer: Medium (Supported); skin 2 / endothelial cells: Medium (Supported); skin 2 / fibrohistiocytic cells: Medium (Supported); skin 2 / langerhans cells: Medium (Supported); skin 2 / lymphocytes: Medium (Supported); small intestine / glandular cells: Medium (Supported); spleen / cells in red pulp: Low (Supported); stomach 1 / glandular cells: High (Supported); stomach 2 / glandular cells: Medium (Supported); thyroid gland / glandular cells: Medium (Supported); urinary bladder / urothelial cells: Medium (Supported),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Kidney Renal Clear Cell Carcinoma (TCGA): 521/521 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%),breast cancer: 12/12 (100.0%); endometrial cancer: 10/11 (90.9%),31,20,Q9Y5U9,https://www.uniprot.org/uniprotkb/Q9Y5U9/entry,Regulator of endoplasmic reticulum secretion that acts as a key determinant of brain size (PubMed:33122427). Required for secretion of extracellular matrix proteins (PubMed:33122427). Required for correct brain development by depositing sufficient extracellular matrix proteins for tissue integrity and the proliferation of neural progenitors (PubMed:33122427). Acts as a regulator of the unfolded protein response (UPR) (By similarity),"Highest levels in heart, skeletal muscle, and kidney","Microcephaly, epilepsy, and diabetes syndrome 1: An autosomal recessive disorder characterized by microcephaly, simplified gyral pattern, severe epilepsy, and infantile diabetes.",,Endoplasmic reticulum membrane,33122427,15276200,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
IFT56,ENSG00000105948,Unsafe,Protein,False,True,13.7,13.7,120,15,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; basal ganglia: 2.2 nTPM; absolute ceiling; cerebral cortex: 1.4 nTPM; positive ihc; choroid plexus: 11.1 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 2.2 nTPM; absolute ceiling; pituitary gland: 3.6 nTPM; absolute ceiling;continuous selectivity; retina: 4.5 nTPM; absolute ceiling;continuous selectivity; small intestine: 1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",basal ganglia: 2.2 nTPM (limit 2); choroid plexus: 11.1 nTPM (limit 2); hypothalamus: 2.2 nTPM (limit 2); pituitary gland: 3.6 nTPM (limit 2); retina: 4.5 nTPM (limit 2),bronchus / ciliated cells (cell body): Low (Enhanced); bronchus / ciliated cells (cilia axoneme): Medium (Enhanced); bronchus / ciliated cells (ciliary rootlets): Medium (Enhanced); bronchus / ciliated cells (tip of cilia): Medium (Enhanced); cerebral cortex / neuropil: Low (Enhanced); nasopharynx / ciliated cells (ciliary rootlets): High (Enhanced); small intestine / enterocytes - Microvilli: Medium (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 45/50 (90.0%); Kidney Renal Clear Cell Carcinoma (validation): 82/100 (82.0%),breast cancer: 0/12 (0.0%); cervical cancer: 0/11 (0.0%),31,20,A0AVF1,https://www.uniprot.org/uniprotkb/A0AVF1/entry,"Component of the intraflagellar transport (IFT) complex B required for transport of proteins in the motile cilium. Required for transport of specific ciliary cargo proteins related to motility, while it is neither required for IFT complex B assembly or motion nor for cilium assembly. Required for efficient coupling between the accumulation of GLI2 and GLI3 at the ciliary tips and their dissociation from the negative regulator SUFU. Plays a key role in maintaining the integrity of the IFT complex B and the proper ciliary localization of the IFT complex B components. Not required for IFT complex A ciliary localization or function. Essential for maintaining proper microtubule organization within the ciliary axoneme",,"Biliary, renal, neurologic, and skeletal syndrome: An autosomal recessive ciliopathy with multisystemic manifestations including severe neonatal cholestasis that progresses to liver fibrosis and cirrhosis, postaxial polydactyly, hydrocephalus, retinal abnormalities, and situs inversus. Additional features may include congenital cardiac defects, echogenic kidneys with renal failure, ocular abnormalities, joint hyperextensibility, and dysmorphic facial features. Some patients have global developmental delay. Brain imaging typically shows dilated ventricles, hypomyelination, and white matter abnormalities, although some patients have been described with abnormal pituitary development.",,"Cell projection, cilium",31595528,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
IFT70A,ENSG00000197557,Unsafe,Protein,False,True,9.6,9.6,109,9,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; choroid plexus: 3.1 nTPM; absolute ceiling;continuous selectivity; kidney: 4.8 nTPM; continuous selectivity; parathyroid gland: 5.5 nTPM; continuous selectivity; retina: 8 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 6.9 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 3.1 nTPM (limit 2); retina: 8 nTPM (limit 2),bronchus / respiratory epithelial cells: Medium (Supported); nasopharynx / respiratory epithelial cells: Medium (Supported),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 45/50 (90.0%); Pancreatic Adenocarcinoma (validation): 63/80 (78.8%),liver cancer: 2/11 (18.2%); lung cancer: 2/12 (16.7%),31,20,Q86WT1,https://www.uniprot.org/uniprotkb/Q86WT1/entry,"Required for polyglutamylation of axonemal tubulin. Plays a role in anterograde intraflagellar transport (IFT), the process by which cilia precursors are transported from the base of the cilium to the site of their incorporation at the tip",,,,"Cell projection, cilium",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | Jamin2021_CT | Jamin2021_core,GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
IFT70B,ENSG00000196659,Unsafe,Protein,False,True,10.0,10.0,109,9,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; choroid plexus: 4 nTPM; absolute ceiling;continuous selectivity; duodenum: 2.5 nTPM; absolute ceiling; kidney: 4.7 nTPM; continuous selectivity; retina: 5.1 nTPM; absolute ceiling;continuous selectivity; small intestine: 2.8 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 7.9 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 4 nTPM (limit 2); duodenum: 2.5 nTPM (limit 2); retina: 5.1 nTPM (limit 2); small intestine: 2.8 nTPM (limit 2),bronchus / respiratory epithelial cells: High (Supported); nasopharynx / respiratory epithelial cells: Medium (Supported),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 47/50 (94.0%); Ovary Serous Cystadenocarcinoma (TCGA): 270/349 (77.4%),liver cancer: 2/11 (18.2%); lung cancer: 2/12 (16.7%),31,20,Q8N4P2,https://www.uniprot.org/uniprotkb/Q8N4P2/entry,"Required for polyglutamylation of axonemal tubulin. Plays a role in anterograde intraflagellar transport (IFT), the process by which cilia precursors are transported from the base of the cilium to the site of their incorporation at the tip",,,,"Cell projection, cilium",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_core,Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
IGF2BP1,ENSG00000159217,Unsafe,Protein,False,True,5.3,5.3,89,8,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; kidney: 1.2 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,bronchus / respiratory epithelial cells: Low (Enhanced); kidney / collecting ducts: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 129/133 (97.0%); Liver Hepatocellular Carcinoma (validation): 59/231 (25.5%); Lung Squamous Cell Carcinoma (TCGA): 101/489 (20.7%),testis cancer: 12/12 (100.0%); colorectal cancer: 4/9 (44.4%),31,20,Q9NZI8,https://www.uniprot.org/uniprotkb/Q9NZI8/entry,"RNA-binding factor that recruits target transcripts to cytoplasmic protein-RNA complexes (mRNPs). This transcript 'caging' into mRNPs allows mRNA transport and transient storage. It also modulates the rate and location at which target transcripts encounter the translational apparatus and shields them from endonuclease attacks or microRNA-mediated degradation. Preferentially binds to N6-methyladenosine (m6A)-containing mRNAs and increases their stability (PubMed:29476152, PubMed:32245947). Plays a direct role in the transport and translation of transcripts required for axonal regeneration in adult sensory neurons (By similarity). Regulates localized beta-actin/ACTB mRNA translation, a crucial process for cell polarity, cell migration and neurite outgrowth. Co-transcriptionally associates with the ACTB mRNA in the nucleus. This binding involves a conserved 54-nucleotide element in the ACTB mRNA 3'-UTR, known as the 'zipcode'. The RNP thus formed is exported to the cytoplasm, binds to a motor protein and is transported along the cytoskeleton to the cell periphery. During transport, prevents ACTB mRNA from being translated into protein. When the RNP complex reaches its destination near the plasma membrane, IGF2BP1 is phosphorylated. This releases the mRNA, allowing ribosomal 40S and 60S subunits to assemble and initiate ACTB protein synthesis. Monomeric ACTB then assembles into the subcortical actin cytoskeleton (By similarity). During neuronal development, key regulator of neurite outgrowth, growth cone guidance and neuronal cell migration, presumably through the spatiotemporal fine tuning of protein synthesis, such as that of ACTB (By similarity). May regulate mRNA transport to activated synapses (By similarity). Binds to and stabilizes ABCB1/MDR-1 mRNA (By similarity). During interstinal wound repair, interacts with and stabilizes PTGS2 transcript. PTGS2 mRNA stabilization may be crucial for colonic mucosal wound healing (By similarity). Binds to the 3'-UTR of IGF2 mRNA by a mechanism of cooperative and sequential dimerization and regulates IGF2 mRNA subcellular localization and translation. Binds to MYC mRNA, in the coding region instability determinant (CRD) of the open reading frame (ORF), hence preventing MYC cleavage by endonucleases and possibly microRNA targeting to MYC-CRD (PubMed:29476152). Binding to MYC mRNA is enhanced by m6A-modification of the CRD (PubMed:29476152). Binds to the 3'-UTR of CD44 mRNA and stabilizes it, hence promotes cell adhesion and invadopodia formation in cancer cells. Binds to the oncofetal H19 transcript and to the neuron-specific TAU mRNA and regulates their localizations. Binds to and stabilizes BTRC/FBW1A mRNA. Binds to the adenine-rich autoregulatory sequence (ARS) located in PABPC1 mRNA and represses its translation. PABPC1 mRNA-binding is stimulated by PABPC1 protein. Prevents BTRC/FBW1A mRNA degradation by disrupting microRNA-dependent interaction with AGO2. Promotes the directed movement of tumor-derived cells by fine-tuning intracellular signaling networks. Binds to MAPK4 3'-UTR and inhibits its translation. Interacts with PTEN transcript open reading frame (ORF) and prevents mRNA decay. This combined action on MAPK4 (down-regulation) and PTEN (up-regulation) antagonizes HSPB1 phosphorylation, consequently it prevents G-actin sequestration by phosphorylated HSPB1, allowing F-actin polymerization. Hence enhances the velocity of cell migration and stimulates directed cell migration by PTEN-modulated polarization. Interacts with Hepatitis C virus (HCV) 5'-UTR and 3'-UTR and specifically enhances translation at the HCV IRES, but not 5'-cap-dependent translation, possibly by recruiting eIF3. Interacts with HIV-1 GAG protein and blocks the formation of infectious HIV-1 particles. Reduces HIV-1 assembly by inhibiting viral RNA packaging, as well as assembly and processing of GAG protein on cellular membranes. During cellular stress, such as oxidative stress or heat shock, stabilizes target mRNAs that are recruited to stress granules, including CD44, IGF2, MAPK4, MYC, PTEN, RAPGEF2 and RPS6KA5 transcripts","Mainly expressed in the embryo, including in fetal liver, fetal lung, fetal kidney, fetal thymus (at protein level). Also expressed follicles of ovary, as well as in gonocytes of testis, spermatogonia, semen, oocytes and placenta (at protein level). Expressed in various cancers, including testis and lung cancers (at protein level), as well as kidney, prostate and trachea cancers",,,"Nucleus Cytoplasm Cytoplasm, perinuclear region Cytoplasm, P-body Cytoplasm, Stress granule Cell projection, lamellipodium Cell projection, dendrite Cell projection, dendritic spine Cell projection, growth cone Cell projection, filopodium Cell projection, axon",10875929|16356927|16541107|16778892|17101699|17255263|17893325|18385235|19029303|19541769|19647520|20080952|22279049|29476152|32245947|8132663|9891060,12921532|16049158|17255263|9891060,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
IGF2BP3,ENSG00000136231,Unsafe,Protein,False,True,27.9,27.9,81,20,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,Published clinical study,positive normal IHC; positive ihc outside permitted; adrenal gland: 0 nTPM; positive ihc; cerebellum: 0 nTPM; positive ihc; colon: 0.1 nTPM; positive ihc; kidney: 0 nTPM; positive ihc; lymph node: 4.1 nTPM; positive ihc; rectum: 0.1 nTPM; positive ihc; salivary gland: 0.2 nTPM; positive ihc; urinary bladder: 0.2 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,adrenal gland / glandular cells: Low (Enhanced); bronchus / respiratory epithelial cells: Low (Enhanced); cerebellum / Purkinje cells: Low (Enhanced); colon / peripheral nerve/ganglion: Low (Enhanced); kidney / cells in tubules: Low (Enhanced); lymph node / germinal center cells: Medium (Enhanced); lymph node / non-germinal center cells: Low (Enhanced); rectum / glandular cells: Low (Enhanced); salivary gland / glandular cells: Low (Enhanced); urinary bladder / urothelial cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,True,"pbmc/platelets cluster c-9: 209.2 nTPM, 22 reads; reproductive-cell max 128.7",True,False,,True,True,False,,True,False,,False,True,True,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,True,2.6,209.2,"hpa_single_cell_tissue: brain/inhibitory neurons, max 54.4 nTPM, 1 observations >30; hpa_single_cell_tissue: bronchus/smooth muscle cells, max 73.4 nTPM, 1 observations >30; hpa_single_cell_tissue: colon/undifferentiated cells, max 41.9 nTPM, 1 observations >30; hpa_single_cell_tissue: pbmc/platelets, max 209.2 nTPM, 1 observations >30; hpa_single_cell_tissue: placenta/mixed immune cells, max 32.1 nTPM, 1 observations >30",Unsafe,oncoref.target-sets.2026-10-23.2,2.6 TPM; blood/Progenitor cell; hpa_immune_monaco; vital,209.2 nTPM; pbmc/platelets; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 50/58 (86.2%); Pancreatic Adenocarcinoma (validation): 67/80 (83.8%); Lung Squamous Cell Carcinoma (validation): 53/68 (77.9%),lung cancer: 7/12 (58.3%); pancreatic cancer: 6/12 (50.0%),31,20,O00425,https://www.uniprot.org/uniprotkb/O00425/entry,"RNA-binding factor that may recruit target transcripts to cytoplasmic protein-RNA complexes (mRNPs). This transcript 'caging' into mRNPs allows mRNA transport and transient storage. It also modulates the rate and location at which target transcripts encounter the translational apparatus and shields them from endonuclease attacks or microRNA-mediated degradation. Preferentially binds to N6-methyladenosine (m6A)-containing mRNAs and increases their stability (PubMed:29476152). Binds to the 3'-UTR of CD44 mRNA and stabilizes it, hence promotes cell adhesion and invadopodia formation in cancer cells. Binds to beta-actin/ACTB and MYC transcripts. Increases MYC mRNA stability by binding to the coding region instability determinant (CRD) and binding is enhanced by m6A-modification of the CRD (PubMed:29476152). Binds to the 5'-UTR of the insulin-like growth factor 2 (IGF2) mRNAs","Expressed in fetal liver, fetal lung, fetal kidney, fetal thymus, fetal placenta, fetal follicles of ovary and gonocytes of testis, growing oocytes, spermatogonia and semen (at protein level). Expressed in cervix adenocarcinoma, in testicular, pancreatic and renal-cell carcinomas (at protein level). Expressed ubiquitously during fetal development at 8 and 14 weeks of gestation. Expressed in ovary, testis, brain, placenta, pancreatic cancer tissues and pancreatic cancer cell lines",,,"Nucleus Cytoplasm Cytoplasm, P-body Cytoplasm, Stress granule",16541107|23640942|29476152,10525192|12161597|15644775|16049158|16814207|17192788|9178771|9891060,False,Reviewed UniProt annotation; not a new primary-paper review,Clinical publication,https://pmc.ncbi.nlm.nih.gov/articles/PMC4203508/,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bradley2020_CPA | Wang2016_CT | Bruggeman2018_GC | Jamin2021_CT | Chang2019_TGCT,Expression-nominated CPA; not newly validated by this study | Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
IGFLR1,ENSG00000126246,Unsafe,Protein,False,True,6.5,48.7,80,40,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 7.4 nTPM; positive ihc;continuous selectivity;reproductive not higher; adrenal gland: 10.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 5.8 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 5 nTPM; absolute ceiling;continuous selectivity; bone marrow: 13.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 4 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 4.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 5.4 nTPM; absolute ceiling;continuous selectivity; colon: 6.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 5.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 3.8 nTPM; continuous selectivity; heart muscle: 4.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 4.9 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 5.2 nTPM; absolute ceiling;continuous selectivity; kidney: 13.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 48.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 11 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 32.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 6.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 1.4 nTPM; positive ihc; pituitary gland: 5.4 nTPM; absolute ceiling;continuous selectivity; rectum: 6.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 4.2 nTPM; absolute ceiling;continuous selectivity; salivary gland: 7.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 4.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 4.1 nTPM; continuous selectivity; small intestine: 12.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 4.2 nTPM; absolute ceiling;continuous selectivity; spinal cord: 7.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 27.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; stomach: 7.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; thymus: 12.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 6.9 nTPM; positive ihc;continuous selectivity;reproductive not higher; urinary bladder: 6.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 10.6 nTPM (limit 2); amygdala: 5.8 nTPM (limit 2); basal ganglia: 5 nTPM (limit 2); bone marrow: 13.7 nTPM (limit 2); cerebellum: 4 nTPM (limit 2); cerebral cortex: 4.5 nTPM (limit 2); choroid plexus: 5.4 nTPM (limit 2); colon: 6.2 nTPM (limit 6); duodenum: 5.7 nTPM (limit 2); heart muscle: 4.3 nTPM (limit 2); hippocampal formation: 4.9 nTPM (limit 2); hypothalamus: 5.2 nTPM (limit 2); kidney: 13.6 nTPM (limit 2); liver: 48.7 nTPM (limit 2); lung: 11 nTPM (limit 2); lymph node: 32.3 nTPM (limit 6); midbrain: 6.8 nTPM (limit 2); pancreas: 9 nTPM (limit 2); pituitary gland: 5.4 nTPM (limit 2); rectum: 6.2 nTPM (limit 6); retina: 4.2 nTPM (limit 2); salivary gland: 7.6 nTPM (limit 6); skeletal muscle: 4.3 nTPM (limit 2); small intestine: 12.8 nTPM (limit 2); smooth muscle: 4.2 nTPM (limit 2); spinal cord: 7.5 nTPM (limit 2); spleen: 27.9 nTPM (limit 10); stomach: 7.6 nTPM (limit 6); thymus: 12.2 nTPM (limit 10); urinary bladder: 6.9 nTPM (limit 6); adrenal gland: 10.6 nTPM (baseline 2); amygdala: 5.8 nTPM (baseline 2); basal ganglia: 5 nTPM (baseline 2); bone marrow: 13.7 nTPM (baseline 2); cerebellum: 4 nTPM (baseline 2); cerebral cortex: 4.5 nTPM (baseline 2); choroid plexus: 5.4 nTPM (baseline 2); colon: 6.2 nTPM (baseline 6); duodenum: 5.7 nTPM (baseline 2); heart muscle: 4.3 nTPM (baseline 2); hippocampal formation: 4.9 nTPM (baseline 2); hypothalamus: 5.2 nTPM (baseline 2); kidney: 13.6 nTPM (baseline 2); liver: 48.7 nTPM (baseline 2); lung: 11 nTPM (baseline 2); lymph node: 32.3 nTPM (baseline 6); midbrain: 6.8 nTPM (baseline 2); pancreas: 9 nTPM (baseline 2); pituitary gland: 5.4 nTPM (baseline 2); rectum: 6.2 nTPM (baseline 6); retina: 4.2 nTPM (baseline 2); salivary gland: 7.6 nTPM (baseline 6); skeletal muscle: 4.3 nTPM (baseline 2); small intestine: 12.8 nTPM (baseline 2); smooth muscle: 4.2 nTPM (baseline 2); spinal cord: 7.5 nTPM (baseline 2); spleen: 27.9 nTPM (baseline 10); stomach: 7.6 nTPM (baseline 6); thymus: 12.2 nTPM (baseline 10); urinary bladder: 6.9 nTPM (baseline 6),adipose tissue / adipocytes: Low (Uncertain); adrenal gland / glandular cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Low (Uncertain); caudate / glial cells: Low (Uncertain); caudate / neuronal cells: High (Uncertain); cerebellum / cells in granular layer: Low (Uncertain); cerebellum / cells in molecular layer: Low (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / glial cells: Low (Uncertain); cerebral cortex / neuronal cells: High (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / glandular cells: Low (Uncertain); duodenum / glandular cells: Low (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / glial cells: Low (Uncertain); hippocampus / neuronal cells: High (Uncertain); kidney / cells in tubules: Low (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); nasopharynx / respiratory epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Low (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: Low (Uncertain); skeletal muscle / myocytes: Low (Uncertain); small intestine / glandular cells: Low (Uncertain); spleen / cells in red pulp: Low (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Adenocarcinoma (TCGA): 490/497 (98.6%); Glioblastoma Multiforme (TCGA): 139/141 (98.6%); Liver Hepatocellular Carcinoma (validation): 219/231 (94.8%),liver cancer: 2/8 (25.0%); glioma: 1/11 (9.1%),30,20,Q9H665,https://www.uniprot.org/uniprotkb/Q9H665/entry,Probable cell membrane receptor for the IGF-like family proteins. Binds IGFL1 and IGFL3 with a higher affinity. May also bind IGFL2,,,,Cell membrane,21454693,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
IGLL1,ENSG00000128322,Unsafe,Protein,False,True,24.5,69.3,86,4,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 69.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 69.3 nTPM (limit 2),bone marrow / hematopoietic cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 8/133 (6.0%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 15/283 (5.3%); Kidney Renal Papillary Cell Carcinoma (TCGA): 9/282 (3.2%),breast cancer: 0/12 (0.0%); cervical cancer: 0/10 (0.0%),31,20,P15814,https://www.uniprot.org/uniprotkb/P15814/entry,Critical for B-cell development,Expressed only in pre-B-cells and a special B-cell line (which is surface Ig negative),"Agammaglobulinemia 2, autosomal recessive: A primary immunodeficiency characterized by profoundly low or absent serum antibodies and low or absent circulating B cells due to an early block of B-cell development. Affected individuals develop severe infections in the first years of life.",,Endoplasmic reticulum Secreted,9419212,2128466,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | Loriot2025_S2 | Gong2021_reproductive_PC | daSilva2017_tumor_proteomics,GC RNA nomination across cancer types; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
IKZF3,ENSG00000161405,Unsafe,Protein,False,True,1.8,39.9,111,12,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 5.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; colon: 3.2 nTPM; positive ihc;continuous selectivity;reproductive not higher; duodenum: 3.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 1.5 nTPM; continuous selectivity; liver: 1.9 nTPM; continuous selectivity;reproductive not higher; lung: 3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 35.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; rectum: 3 nTPM; positive ihc;continuous selectivity;reproductive not higher; salivary gland: 2.1 nTPM; continuous selectivity;reproductive not higher; small intestine: 11.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 21.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; stomach: 6 nTPM; continuous selectivity;reproductive not higher; thymus: 22.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 4.3 nTPM; continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 5.8 nTPM (limit 2); duodenum: 3.4 nTPM (limit 2); lung: 3 nTPM (limit 2); lymph node: 35.6 nTPM (limit 6); small intestine: 11.8 nTPM (limit 2); spleen: 21.8 nTPM (limit 10); thymus: 22.4 nTPM (limit 10),bone marrow / hematopoietic cells: Medium (Enhanced); colon / mucosal lymphoid cells: High (Enhanced); lung / alveolar cells: Low (Enhanced); lymph node / non-germinal center cells: High (Enhanced); rectum / mucosal lymphoid cells: High (Enhanced); spleen / cells in white pulp: High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 447/486 (92.0%); Rectum Adenocarcinoma (validation): 186/207 (89.9%); Lung Adenocarcinoma (validation): 82/105 (78.1%),lymphoma: 11/12 (91.7%); glioma: 1/11 (9.1%),31,20,Q9UKT9,https://www.uniprot.org/uniprotkb/Q9UKT9/entry,"Transcription factor that plays an important role in the regulation of lymphocyte differentiation. Plays an essential role in regulation of B-cell differentiation, proliferation and maturation to an effector state. Involved in regulating BCL2 expression and controlling apoptosis in T-cells in an IL2-dependent manner","Expressed most strongly in peripheral blood leukocytes, the spleen, and the thymus",Immunodeficiency 84: An autosomal recessive immunologic disorder characterized by recurrent sinopulmonary infections from childhood associated with low levels of B cells and impaired early B-cell development. There may also be variable T-cell abnormalities. Patients have increased susceptibility to infection with Epstein-Barr virus and a propensity for the development of lymphoma in adulthood.,,Nucleus Cytoplasm,10369681|34155405,17646674,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
IL12RB2,ENSG00000081985,Unsafe,RNA,False,True,6.4,6.4,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,cerebral cortex: 2 nTPM; continuous selectivity; pancreas: 2.5 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 3.4 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,pancreas: 2.5 nTPM (limit 2); skeletal muscle: 3.4 nTPM (limit 2); pancreas: 2.5 nTPM (baseline 2); skeletal muscle: 3.4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Skin Cuteneous Melanoma (TCGA): 71/99 (71.7%); Head and Neck Squamous Cell Carcinoma (TCGA): 216/492 (43.9%); Kidney Renal Papillary Cell Carcinoma (TCGA): 107/282 (37.9%),stomach cancer: 10/12 (83.3%); liver cancer: 7/12 (58.3%),31,20,Q99665,https://www.uniprot.org/uniprotkb/Q99665/entry,Receptor for interleukin-12. This subunit is the signaling component coupling to the JAK2/STAT4 pathway. Promotes the proliferation of T-cells as well as NK cells. Induces the promotion of T-cells towards the Th1 phenotype by strongly enhancing IFN-gamma production,Isoform 2 is expressed at similar levels in both naive and activated T-cells,,,Membrane,,9120388,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
IL13,ENSG00000169194,Unsafe,Normal,False,True,23.6,23.6,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Published protein production by nonmalignant cells outside permitted reproductive/disposable compartments,,,,oncoref.target-sets.2026-10-24.1,True,"fallopian tube/granulocytes cluster c-18: 336.5 nTPM, 1614 reads; reproductive-cell max 310.7",True,True,"DICE CD4_STIM (activated): 21/88 values ≥5 TPM, max 15.1541; DICE TH2 (unstimulated): 8/89 values ≥5 TPM, max 7.94458; DICE CD8_STIM (activated): 3/88 values ≥5 TPM, max 18.2779; hpa_immune_monaco basophil: 10.7 TPM",True,True,False,,True,False,,False,False,True,Unsafe,Normal,oncoref.target-sets.2026-10-23.1,False,True,https://pubmed.ncbi.nlm.nih.gov/8605923/,Unchanged,True,True,True,18.2778865708,336.5,"hpa_single_cell: /granulocytes, max 122.5 nTPM, 1 observations >30; hpa_single_cell_tissue: fallopian tube/granulocytes, max 336.5 nTPM, 1 observations >30; hpa_single_cell_tissue: skin/t-cells, max 226.4 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,18.28 TPM; blood/CD8_STIM; dice_cd8_stim; vital,336.5 nTPM; fallopian tube/granulocytes; hpa_single_cell_tissue; vital,Lung Squamous Cell Carcinoma (validation): 1/68 (1.5%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Liver Hepatocellular Carcinoma (TCGA): 1/362 (0.3%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P35225,https://www.uniprot.org/uniprotkb/P35225/entry,"Cytokine that plays important roles in allergic inflammation and immune response to parasite infection (PubMed:8096327, PubMed:8097324). Synergizes with IL2 in regulating interferon-gamma synthesis (PubMed:8096327). Stimulates B-cell proliferation, and activation of eosinophils, basophils, and mast cells (PubMed:7903680, PubMed:8759755). Plays an important role in controlling IL33 activity by modulating the production of transmembrane and soluble forms of interleukin-1 receptor-like 1/IL1RL1 (By similarity). Displays the capacity to antagonize Th1-driven proinflammatory immune response and down-regulates synthesis of many proinflammatory cytokines including IL1, IL6, IL10, IL12 and TNF through a mechanism that partially involves suppression of NF-kappa-B (By similarity). Also functions on nonhematopoietic cells, including endothelial cells where it induces vascular cell adhesion protein 1/VCAM1, which is important in the recruitment of eosinophils (PubMed:8639787). Exerts its biological effects through its receptors which comprises the IL4R chain and the IL13RA1 chain, to activate JAK1 and TYK2, leading to the activation of STAT6 (PubMed:9013879). Aside from IL13RA1, another receptor IL13RA2 acts as a high affinity decoy for IL13 and mediates internalization and depletion of extracellular IL13 (PubMed:21622864). Induces inflammatory response in esophageal epithelium which results in a dysregulation of desmosome intercellular adhesion junctions, via down-regulation of DSG1 (PubMed:24220297)",,Allergic rhinitis: A common disease with complex inheritance characterized by mucosal inflammation caused by allergen exposure.,It is uncertain whether Met-1 or Met-15 is the initiator,Secreted,21622864|24220297|7903680|8096327|8097324|8639787|8759755|9013879,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,Activated nonmalignant T cells produce IL-13. State-dependent cytokine expression defeats a reproductive-restricted label even if resting bulk-tissue RNA is low.,https://pubmed.ncbi.nlm.nih.gov/8605923/,Normal function,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
IL13RA2,ENSG00000123496,Unsafe,RNA,False,True,29.1,29.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 4.6 nTPM; absolute ceiling; amygdala: 2.8 nTPM; absolute ceiling; basal ganglia: 5.6 nTPM; absolute ceiling; cerebral cortex: 2.3 nTPM; absolute ceiling; choroid plexus: 8.7 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 4 nTPM; absolute ceiling; hypothalamus: 11.7 nTPM; absolute ceiling;continuous selectivity; kidney: 3.5 nTPM; absolute ceiling; liver: 9.7 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 11.7 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 4.6 nTPM (limit 2); amygdala: 2.8 nTPM (limit 2); basal ganglia: 5.6 nTPM (limit 2); cerebral cortex: 2.3 nTPM (limit 2); choroid plexus: 8.7 nTPM (limit 2); hippocampal formation: 4 nTPM (limit 2); hypothalamus: 11.7 nTPM (limit 2); kidney: 3.5 nTPM (limit 2); liver: 9.7 nTPM (limit 2); pituitary gland: 11.7 nTPM (limit 2); adrenal gland: 4.6 nTPM (baseline 2); amygdala: 2.8 nTPM (baseline 2); basal ganglia: 5.6 nTPM (baseline 2); cerebral cortex: 2.3 nTPM (baseline 2); choroid plexus: 8.7 nTPM (baseline 2); hippocampal formation: 4 nTPM (baseline 2); hypothalamus: 11.7 nTPM (baseline 2); kidney: 3.5 nTPM (baseline 2); liver: 9.7 nTPM (baseline 2); pituitary gland: 11.7 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 47/58 (81.0%); Glioblastoma Multiforme (TCGA): 111/141 (78.7%); Skin Cuteneous Melanoma (TCGA): 30/99 (30.3%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q14627,https://www.uniprot.org/uniprotkb/Q14627/entry,"Cell surface receptor that plays a role in the regulation of IL-13-mediated responses (PubMed:11861389, PubMed:17030238). Functions as a decoy receptor that inhibits IL-13- and IL-4-mediated signal transduction via the JAK-STAT pathway and thereby modulates immune responses and inflammation (PubMed:11861389, PubMed:17030238). Serves as a functional signaling receptor for IL-13 in an alternative pathway involving AP-1 ultimately leading to the production of TGFB1 (PubMed:16327802)",,,,Cell membrane,11861389|16327802|17030238|20223216,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
IL17F,ENSG00000112116,Unsafe,High RNA,False,True,0.0,2.1,0,0,Missing,False,False,False,False,Excluded,Other,True,Disposable,Not assessed,,,insufficient positive reproductive evidence; reproductive expression not demonstrated; incomplete tissue evidence,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,True,"skin/t-cells cluster c-2: 7.7 nTPM, 22 reads; reproductive-cell max 0.3; tongue/t-cells cluster c-6: 107.2 nTPM, 638 reads; reproductive-cell max 0.3; tongue/macrophages cluster c-12: 5.1 nTPM, 29 reads; reproductive-cell max 0.3; fallopian tube/t-cells cluster c-8: 16.3 nTPM, 88 reads; reproductive-cell max 0.3",True,False,,True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,4.08341269938,107.2,"hpa_single_cell_tissue: tongue/t-cells, max 107.2 nTPM, 1 observations >30",Neither,oncoref.target-sets.2026-10-23.2,4.083 TPM; blood/CD4_STIM; dice_cd4_stim; vital,107.2 nTPM; tongue/t-cells; hpa_single_cell_tissue; vital,Bladder Urothelial Carcinoma (TCGA): 2/169 (1.2%); Rectum Adenocarcinoma (validation): 2/207 (1.0%); Stomach Adenocarcinoma (TCGA): 2/346 (0.6%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q96PD4,https://www.uniprot.org/uniprotkb/Q96PD4/entry,"Effector cytokine of innate and adaptive immune system involved in antimicrobial host defense and maintenance of tissue integrity (PubMed:21350122). IL17A-IL17F signals via IL17RA-IL17RC heterodimeric receptor complex, triggering homotypic interaction of IL17RA and IL17RC chains with TRAF3IP2 adapter through SEFIR domains. This leads to downstream TRAF6-mediated activation of NF-kappa-B and MAPkinase pathways ultimately resulting in transcriptional activation of cytokines, chemokines, antimicrobial peptides and matrix metalloproteinases, with potential strong immune inflammation (PubMed:11574464, PubMed:11591732, PubMed:11591768, PubMed:17911633, PubMed:18684971, PubMed:21350122, PubMed:28827714). IL17A-IL17F is primarily involved in host defense against extracellular bacteria and fungi by inducing neutrophilic inflammation (By similarity). As signature effector cytokine of T-helper 17 cells (Th17), primarily induces neutrophil activation and recruitment at infection and inflammatory sites (By similarity). Stimulates the production of antimicrobial beta-defensins DEFB1, DEFB103A, and DEFB104A by mucosal epithelial cells, limiting the entry of microbes through the epithelial barriers (By similarity). IL17F homodimer can signal via IL17RC homodimeric receptor complex, triggering downstream activation of TRAF6 and NF-kappa-B signaling pathway (PubMed:32187518). Via IL17RC induces transcriptional activation of IL33, a potent cytokine that stimulates group 2 innate lymphoid cells and adaptive T-helper 2 cells involved in pulmonary allergic response to fungi. Likely via IL17RC, promotes sympathetic innervation of peripheral organs by coordinating the communication between gamma-delta T cells and parenchymal cells. Stimulates sympathetic innervation of thermogenic adipose tissue by driving TGFB1 expression (By similarity). Regulates the composition of intestinal microbiota and immune tolerance by inducing antimicrobial proteins that specifically control the growth of commensal Firmicutes and Bacteroidetes (By similarity)","Expressed in T-helper 1 and T-helper 2 cells, basophils and mast cells","Candidiasis, familial, 6: A primary immunodeficiency disorder with altered immune responses and impaired clearance of fungal infections, selective against Candida. It is characterized by persistent and/or recurrent infections of the skin, nails and mucous membranes caused by organisms of the genus Candida, mainly Candida albicans.",,Secreted,11574464|11591732|11591768|17911633|18684971|21350122|28827714|32187518,11591768,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
IL1A,ENSG00000115008,Unsafe,RNA,False,True,10.1,25.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,esophagus: 12.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 2.3 nTPM; absolute ceiling; urinary bladder: 25 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,esophagus: 12.9 nTPM (limit 6); lung: 2.3 nTPM (limit 2); urinary bladder: 25 nTPM (limit 6); esophagus: 12.9 nTPM (baseline 6); lung: 2.3 nTPM (baseline 2); urinary bladder: 25 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Head and Neck Squamous Cell Carcinoma (TCGA): 371/492 (75.4%); Lung Squamous Cell Carcinoma (validation): 43/68 (63.2%); Glioblastoma Multiforme (validation): 31/58 (53.4%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P01583,https://www.uniprot.org/uniprotkb/P01583/entry,"Cytokine constitutively present intracellularly in nearly all resting non-hematopoietic cells that plays an important role in inflammation and bridges the innate and adaptive immune systems (PubMed:26439902). After binding to its receptor IL1R1 together with its accessory protein IL1RAP, forms the high affinity interleukin-1 receptor complex (PubMed:17507369, PubMed:2950091). Signaling involves the recruitment of adapter molecules such as MYD88, IRAK1 or IRAK4 (PubMed:17507369). In turn, mediates the activation of NF-kappa-B and the three MAPK pathways p38, p42/p44 and JNK pathways (PubMed:14687581). Within the cell, acts as an alarmin and cell death results in its liberation in the extracellular space after disruption of the cell membrane to induce inflammation and alert the host to injury or damage (PubMed:15679580). In addition to its role as a danger signal, which occurs when the cytokine is passively released by cell necrosis, directly senses DNA damage and acts as a signal for genotoxic stress without loss of cell integrity (PubMed:26439902)",,,,Nucleus Cytoplasm Secreted,14687581|15679580|17507369|26439902|2950091|3258335,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
IL21,ENSG00000138684,Unsafe,High RNA,False,True,0.7,5.8,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,lymph node: 5.8 nTPM; continuous selectivity;reproductive not higher,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE CD4_STIM (activated): 88/88 values ≥5 TPM, max 247.982",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,247.981711804,15.8,"dice_cd4_stim: blood/CD4_STIM, max 247.982 TPM, 77 observations >30; hpa_immune_schmiedel: blood/Naive CD4 T-cell activated, max 68.1 TPM, 1 observations >30",Neither,oncoref.target-sets.2026-10-23.2,248 TPM; blood/CD4_STIM; dice_cd4_stim; vital,15.8 nTPM; stomach/t-cells; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (validation): 1/50 (2.0%); Testicular Germ Cell Tumor (TCGA): 2/133 (1.5%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9HBE4,https://www.uniprot.org/uniprotkb/Q9HBE4/entry,"Cytokine with immunoregulatory activity. May promote the transition between innate and adaptive immunity. Induces the production of IgG(1) and IgG(3) in B-cells (By similarity). Implicated in the generation and maintenance of T follicular helper (Tfh) cells and the formation of germinal-centers. Together with IL6, control the early generation of Tfh cells and are critical for an effective antibody response to acute viral infection (By similarity). May play a role in proliferation and maturation of natural killer (NK) cells in synergy with IL15. May regulate proliferation of mature B- and T-cells in response to activating stimuli. In synergy with IL15 and IL18 stimulates interferon gamma production in T-cells and NK cells (PubMed:11081504, PubMed:15178704). During T-cell mediated immune response may inhibit dendritic cells (DC) activation and maturation (By similarity)","Expressed in activated CD4-positive T-cells but not in CD8-positive T-cells, B-cells, or monocytes","Immunodeficiency, common variable, 11: A primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B-cells is usually in the normal range, but can be low.",It is uncertain whether Met-1 or Met-8 is the initiator,Secreted,11081504|15178704,11081504,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
IL3,ENSG00000164399,Unsafe,High RNA,False,True,0.1,0.3,0,0,Missing,False,False,False,False,Excluded,Normal,False,,Not assessed,,,existing nomination or manual review; nomination unresolved; bone marrow: 0.3 nTPM; continuous selectivity;reproductive not higher; retina: 0.1 nTPM; reproductive not higher,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE CD4_STIM (activated): 48/88 values ≥5 TPM, max 78.673; DICE CD8_STIM (activated): 24/88 values ≥5 TPM, max 55.1332",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,78.67296556560001,12.4,"dice_cd4_stim: blood/CD4_STIM, max 78.673 TPM, 3 observations >30; dice_cd8_stim: blood/CD8_STIM, max 55.1332 TPM, 2 observations >30",Neither,oncoref.target-sets.2026-10-23.2,78.67 TPM; blood/CD4_STIM; dice_cd4_stim; vital,12.4 nTPM; breast/t-cells; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P08700,https://www.uniprot.org/uniprotkb/P08700/entry,"Cytokine secreted predominantly by activated T-lymphocytes as well as mast cells and osteoblastic cells that controls the production and differentiation of hematopoietic progenitor cells into lineage-restricted cells (PubMed:2556442). Also stimulates mature basophils, eosinophils, and monocytes to become functionally activated (PubMed:10779277, PubMed:32889153). In addition, plays an important role in neural cell proliferation and survival (PubMed:23226269). Participates as well in bone homeostasis and inhibits osteoclast differentiation by preventing NF-kappa-B nuclear translocation and activation (PubMed:12816992). Mechanistically, exerts its biological effects through a receptor composed of IL3RA subunit and a signal transducing subunit IL3RB (PubMed:29374162). Receptor stimulation results in the rapid activation of JAK2 kinase activity leading to STAT5-mediated transcriptional program (By similarity). Alternatively, contributes to cell survival under oxidative stress in non-hematopoietic systems by activating pathways mediated by PI3K/AKT and ERK (PubMed:27862234)","Activated T-cells, mast cells, natural killer cells",,,Secreted,10779277|12816992|23226269|2556442|27862234|29374162|32889153,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
IL4I1,ENSG00000104951,Unsafe,Protein,False,True,26.0,26.0,126,51,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 4 nTPM; positive ihc;absolute ceiling; cerebellum: 0.3 nTPM; positive ihc; colon: 1.5 nTPM; positive ihc; duodenum: 3.5 nTPM; positive ihc;absolute ceiling; kidney: 4.7 nTPM; positive ihc;absolute ceiling; lung: 2.3 nTPM; positive ihc;absolute ceiling; lymph node: 9 nTPM; positive ihc;absolute ceiling;continuous selectivity; rectum: 1.3 nTPM; positive ihc; skin: 1.2 nTPM; positive ihc; small intestine: 2.6 nTPM; positive ihc;absolute ceiling; spleen: 3.9 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 4 nTPM (limit 2); duodenum: 3.5 nTPM (limit 2); kidney: 4.7 nTPM (limit 2); lung: 2.3 nTPM (limit 2); lymph node: 9 nTPM (limit 6); small intestine: 2.6 nTPM (limit 2),bone marrow / hematopoietic cells: Medium (Enhanced); bronchus / basal cells: Medium (Enhanced); bronchus / ciliated cells (cell body): Medium (Enhanced); bronchus / ciliated cells (tip of cilia): Medium (Enhanced); bronchus / goblet cells: Medium (Enhanced); cerebellum / Purkinje cells: Low (Enhanced); colon / endothelial cells: Low (Enhanced); colon / glandular cells: Low (Enhanced); colon / peripheral nerve/ganglion: Low (Enhanced); duodenum / glandular cells: Low (Enhanced); kidney / cells in glomeruli: Low (Enhanced); kidney / collecting ducts: High (Enhanced); kidney / distal tubules: High (Enhanced); lung / macrophages: High (Enhanced); lymph node / germinal center cells: Medium (Enhanced); lymph node / non-germinal center cells: High (Enhanced); nasopharynx / ciliated cells (cell body): Medium (Enhanced); nasopharynx / goblet cells: Medium (Enhanced); rectum / glandular cells: Medium (Enhanced); skin 1 / cells in basal layer: Medium (Enhanced); skin 1 / cells in corneal layer: High (Enhanced); skin 1 / cells in granular layer: High (Enhanced); skin 1 / cells in spinous layer: High (Enhanced); skin 1 / eccrine glands: Low (Enhanced); skin 1 / fibrohistiocytic cells: Medium (Enhanced); skin 1 / langerhans cells: High (Enhanced); skin 1 / lymphocytes: High (Enhanced); skin 1 / sebaceous glands: High (Enhanced); skin 2 / cells in basal layer: Medium (Enhanced); skin 2 / cells in corneal layer: Medium (Enhanced); skin 2 / cells in granular layer: High (Enhanced); skin 2 / cells in spinous layer: High (Enhanced); skin 2 / endothelial cells: Low (Enhanced); skin 2 / fibrohistiocytic cells: High (Enhanced); skin 2 / langerhans cells: High (Enhanced); small intestine / glandular cells: Low (Enhanced); spleen / cells in red pulp: High (Enhanced); spleen / cells in white pulp: High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Ovary Serous Cystadenocarcinoma (TCGA): 328/349 (94.0%); Ovary Serous Cystadenocarcinoma (validation): 71/81 (87.7%); Kidney Renal Clear Cell Carcinoma (TCGA): 452/521 (86.8%),lymphoma: 9/12 (75.0%); glioma: 6/12 (50.0%),31,20,Q96RQ9,https://www.uniprot.org/uniprotkb/Q96RQ9/entry,"Secreted L-amino-acid oxidase that acts as a key immunoregulator (PubMed:17356132, PubMed:32818467, PubMed:32866000). Has preference for L-aromatic amino acids: converts phenylalanine (Phe), tyrosine (Tyr) and tryptophan (Trp) to phenylpyruvic acid (PP), hydroxyphenylpyruvic acid (HPP), and indole-3-pyruvic acid (I3P), respectively (PubMed:17356132, PubMed:32818467, PubMed:32866000). Also has weak L-arginine oxidase activity (PubMed:26673964). Acts as a negative regulator of anti-tumor immunity by mediating Trp degradation via an indole pyruvate pathway that activates the transcription factor AHR (PubMed:32818467, PubMed:32866000). IL4I1-mediated Trp catabolism generates I3P, giving rise to indole metabolites (indole-3-acetic acid (IAA) and indole-3-aldehyde (I3A)) and kynurenic acid, which act as ligands for AHR, a ligand-activated transcription factor that plays important roles in immunity and cancer (PubMed:32818467, PubMed:32866000). AHR activation by indoles following IL4I1-mediated Trp degradation enhances tumor progression by promoting cancer cell motility and suppressing adaptive immunity (PubMed:32818467). Also has an immunoregulatory function in some immune cells, probably by mediating Trp degradation and promoting downstream AHR activation: inhibits T-cell activation and proliferation, promotes the differentiation of naive CD4(+) T-cells into FOXP3(+) regulatory T-cells (Treg) and regulates the development and function of B-cells (PubMed:17356132, PubMed:25446972, PubMed:25778793, PubMed:28891065). Also regulates M2 macrophage polarization by inhibiting T-cell activation (By similarity). Also has antibacterial properties by inhibiting growth of Gram negative and Gram positive bacteria through the production of NH4(+) and H2O2 (PubMed:23355881)","Primarily found in immune tissues, with the highest expression in lymph nodes and spleen (PubMed:12031486, PubMed:12446450). Present in germinal center macrophages and inflammatory myeloid cells and antigen-presenting cells (at protein level) (PubMed:17356132). Also present in spermatozoa (at protein level) (PubMed:25767141). Highly expressed in primary mediastinal large B-cell lymphoma, a specific subtype of diffuse large B-cell lymphoma (PubMed:12446450). Expressed by neoplastic cells of several B-cell lymphomas and by tumor-associated macrophages (PubMed:19436310)",,"According to a report, acts as a negative regulator of T-cell activation independently of its enzymatic activity (PubMed:28891065). However, authors of this study only tested enzyme activity via phenylalanine (Phe) deprivation and not via tryptophan (Trp). As IL4I1 immunoregulator activity is mediated via Trp degradation and subsequent activation of the transcription factor AHR, additional experiments are required to confirm this statement (PubMed:32818467, PubMed:32866000)","Secreted Lysosome Cytoplasmic vesicle, secretory vesicle, acrosome",17356132|23355881|25446972|25778793|26673964|28891065|32818467|32866000,12031486|12446450|17356132|19436310|25767141,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | daSilva2017_tumor_proteomics,GC RNA nomination across cancer types; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
IL5,ENSG00000113525,Unsafe,Normal,False,True,4.9,4.9,74,0,Negative where measured,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Published protein production by nonmalignant cells outside permitted reproductive/disposable compartments,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,Unsafe,Normal,oncoref.target-sets.2026-10-23.1,False,True,https://pmc.ncbi.nlm.nih.gov/articles/PMC3445433/,Unchanged,True,True,False,10.1706862506,22.4,,Neither,oncoref.target-sets.2026-10-23.2,10.17 TPM; blood/CD8_STIM; dice_cd8_stim; vital,22.4 nTPM; skin/t-cells; hpa_single_cell_tissue; vital,Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 5/283 (1.8%); Lung Squamous Cell Carcinoma (validation): 1/68 (1.5%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),breast cancer: 0/12 (0.0%); cervical cancer: 0/12 (0.0%),31,20,P05113,https://www.uniprot.org/uniprotkb/P05113/entry,"Homodimeric cytokine expressed predominantly by T-lymphocytes and NK cells that plays an important role in the survival, differentiation, and chemotaxis of eosinophils (PubMed:2653458, PubMed:9010276). Also acts on activated and resting B-cells to induce immunoglobulin production, growth, and differentiation (By similarity). Mechanistically, exerts its biological effects through a receptor composed of IL5RA subunit and the cytokine receptor common subunit beta/CSF2RB (PubMed:1495999, PubMed:22528658). Binding to the receptor leads to activation of various kinases including LYN, SYK and JAK2 and thereby propagates signals through the RAS-MAPK and JAK-STAT5 pathways respectively (PubMed:7613138)",Present in peripheral blood mononuclear cells,,,Secreted,1495999|22528658|2653458|7613138|9010276,32211550,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,IL-5 is produced by normal activated immune cells. Baseline tissue silence cannot establish reproductive restriction; neutralizing a secreted cytokine is different from destroying every cell that produces it.,https://pmc.ncbi.nlm.nih.gov/articles/PMC3445433/,Normal function,Wang2016_CT | Chang2019_TGCT | Carter2023_CT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene,,,,,,,,
IL7,ENSG00000104432,Unsafe,Protein,False,True,4.6,8.5,99,12,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; bone marrow: 2.1 nTPM; continuous selectivity; colon: 4.9 nTPM; continuous selectivity;reproductive not higher; duodenum: 6.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 3.4 nTPM; continuous selectivity; liver: 4 nTPM; continuous selectivity; lung: 3.2 nTPM; continuous selectivity; lymph node: 8.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 4.3 nTPM; continuous selectivity; skin: 8.5 nTPM; continuous selectivity;reproductive not higher; small intestine: 8.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 3.4 nTPM; continuous selectivity; stomach: 3.7 nTPM; continuous selectivity; urinary bladder: 2.7 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",duodenum: 6.5 nTPM (limit 4); lymph node: 8.5 nTPM (limit 8); small intestine: 8.5 nTPM (limit 4),bronchus / basal cells: High (Approved); bronchus / ciliated cells (cell body): High (Approved); bronchus / goblet cells: High (Approved); nasopharynx / basal cells: High (Approved); nasopharynx / ciliated cells (cell body): High (Approved); nasopharynx / ciliated cells (tip of cilia): Low (Approved); nasopharynx / goblet cells: High (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 63/80 (78.8%); Colon Adenocarcinoma (validation): 329/486 (67.7%); Kidney Renal Clear Cell Carcinoma (validation): 67/100 (67.0%),colorectal cancer: 12/12 (100.0%); breast cancer: 11/11 (100.0%),31,20,P13232,https://www.uniprot.org/uniprotkb/P13232/entry,"Hematopoietic cytokine that plays an essential role in the development, expansion, and survival of naive and memory T-cells and B-cells thereby regulating the number of mature lymphocytes and maintaining lymphoid homeostasis (PubMed:25870237, PubMed:7527823). Mechanistically, exerts its biological effects through a receptor composed of IL7RA subunit and the cytokine receptor common subunit gamma/CSF2RG (PubMed:8128231). Binding to the receptor leads to activation of various kinases including JAK1 or JAK3 depending on the cell type and subsequently propagation of signals through activation of several downstream signaling pathways including the PI3K/Akt/mTOR or the JAK-STAT5 (PubMed:18523275, PubMed:20974963)",,"Immunodeficiency 130 with HPV-related verrucosis: An autosomal recessive immunologic disorder characterized by susceptibility to human papillomavirus (HPV) infections that lead to the development of warts and verrucous or plaque-like skin lesions. There is an increased risk of skin malignancy. Some patients may also suffer from mycobacterial, herpes simplex virus (HSV), or fungal infections. Immunologic workup shows T-cell lymphopenia, particularly affecting CD4+ T cells.",,Secreted,18523275|20974963|25870237|7527823|8128231,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | Jamin2021_CT,GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
IMMP1L,ENSG00000148950,Unsafe,Protein,False,True,29.0,48.3,83,63,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 15.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 39.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 44.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 11 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 44.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 35.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 35.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 12.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 8.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 11.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 25.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 33.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 29.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 26.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 18.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 8.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 9.3 nTPM; positive ihc;absolute ceiling; midbrain: 26.2 nTPM; absolute ceiling;continuous selectivity; pancreas: 16 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 17.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 22.7 nTPM; absolute ceiling;continuous selectivity; rectum: 9.7 nTPM; positive ihc;absolute ceiling; retina: 36.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 11.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 48.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 12.1 nTPM; positive ihc;absolute ceiling; small intestine: 9.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 10.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 22.6 nTPM; absolute ceiling;continuous selectivity; spleen: 10.6 nTPM; positive ihc;absolute ceiling; stomach: 14.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 24.1 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 12.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 41 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 10.5 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 15.1 nTPM (limit 2); amygdala: 39.7 nTPM (limit 2); basal ganglia: 44.7 nTPM (limit 2); bone marrow: 11 nTPM (limit 2); cerebellum: 44.6 nTPM (limit 2); cerebral cortex: 35.6 nTPM (limit 2); choroid plexus: 35.7 nTPM (limit 2); colon: 12.3 nTPM (limit 6); duodenum: 8.4 nTPM (limit 2); esophagus: 11.4 nTPM (limit 6); heart muscle: 25.4 nTPM (limit 2); hippocampal formation: 33.7 nTPM (limit 2); hypothalamus: 29.6 nTPM (limit 2); kidney: 26.4 nTPM (limit 2); liver: 18.1 nTPM (limit 2); lung: 8.7 nTPM (limit 2); lymph node: 9.3 nTPM (limit 6); midbrain: 26.2 nTPM (limit 2); pancreas: 16 nTPM (limit 2); parathyroid gland: 17.2 nTPM (limit 6); pituitary gland: 22.7 nTPM (limit 2); rectum: 9.7 nTPM (limit 6); retina: 36.5 nTPM (limit 2); salivary gland: 11.4 nTPM (limit 6); skeletal muscle: 48.3 nTPM (limit 2); skin: 12.1 nTPM (limit 10); small intestine: 9.2 nTPM (limit 2); smooth muscle: 10.3 nTPM (limit 2); spinal cord: 22.6 nTPM (limit 2); spleen: 10.6 nTPM (limit 10); stomach: 14.7 nTPM (limit 6); thymus: 24.1 nTPM (limit 10); thyroid gland: 12.8 nTPM (limit 10); tongue: 41 nTPM (limit 6); urinary bladder: 10.5 nTPM (limit 6),adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / neuronal cells: Low (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: High (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); pancreas / exocrine glandular cells: High (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / fibroblasts: High (Approved); skin 1 / Langerhans: High (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in red pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: Low (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (validation): 231/231 (100.0%); Pancreatic Adenocarcinoma (TCGA): 176/176 (100.0%); Glioblastoma Multiforme (TCGA): 141/141 (100.0%),liver cancer: 7/8 (87.5%); melanoma: 7/10 (70.0%),31,20,Q96LU5,https://www.uniprot.org/uniprotkb/Q96LU5/entry,"Catalyzes the removal of transit peptides required for the targeting of proteins from the mitochondrial matrix, across the inner membrane, into the inter-membrane space. Known to process the nuclear encoded protein DIABLO",,,,Mitochondrion inner membrane,15814844,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
IMPACT,ENSG00000154059,Unsafe,Protein,False,True,33.4,33.4,85,62,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 18.7 nTPM; continuous selectivity; adrenal gland: 20.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 11.8 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 13.3 nTPM; absolute ceiling;continuous selectivity; bone marrow: 15.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 3.3 nTPM; positive ihc;absolute ceiling; cerebral cortex: 14.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 8.9 nTPM; absolute ceiling;continuous selectivity; colon: 17.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 15.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 21 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 18.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 9.7 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 17.4 nTPM; absolute ceiling;continuous selectivity; kidney: 23.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 21.6 nTPM; absolute ceiling;continuous selectivity; lung: 15.2 nTPM; absolute ceiling;continuous selectivity; lymph node: 11.2 nTPM; positive ihc;absolute ceiling; midbrain: 13.3 nTPM; absolute ceiling;continuous selectivity; pancreas: 19.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 26.9 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 9.7 nTPM; absolute ceiling;continuous selectivity; rectum: 14.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 9.8 nTPM; absolute ceiling;continuous selectivity; salivary gland: 24.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 19.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 11.1 nTPM; positive ihc;absolute ceiling; small intestine: 16 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 12.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 15.2 nTPM; absolute ceiling;continuous selectivity; stomach: 15.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 10.9 nTPM; absolute ceiling; thyroid gland: 31.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 12.6 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 12.2 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 20.3 nTPM (limit 2); amygdala: 11.8 nTPM (limit 2); basal ganglia: 13.3 nTPM (limit 2); bone marrow: 15.6 nTPM (limit 2); cerebellum: 3.3 nTPM (limit 2); cerebral cortex: 14.3 nTPM (limit 2); choroid plexus: 8.9 nTPM (limit 2); colon: 17.4 nTPM (limit 6); duodenum: 15.6 nTPM (limit 2); esophagus: 21 nTPM (limit 6); heart muscle: 18.6 nTPM (limit 2); hippocampal formation: 9.7 nTPM (limit 2); hypothalamus: 17.4 nTPM (limit 2); kidney: 23.5 nTPM (limit 2); liver: 21.6 nTPM (limit 4); lung: 15.2 nTPM (limit 4); lymph node: 11.2 nTPM (limit 6); midbrain: 13.3 nTPM (limit 2); pancreas: 19.9 nTPM (limit 2); parathyroid gland: 26.9 nTPM (limit 8); pituitary gland: 9.7 nTPM (limit 2); rectum: 14.4 nTPM (limit 6); retina: 9.8 nTPM (limit 2); salivary gland: 24.2 nTPM (limit 6); skeletal muscle: 19.6 nTPM (limit 2); skin: 11.1 nTPM (limit 10); small intestine: 16 nTPM (limit 2); smooth muscle: 12.5 nTPM (limit 2); spinal cord: 15.2 nTPM (limit 2); stomach: 15.4 nTPM (limit 6); thymus: 10.9 nTPM (limit 10); thyroid gland: 31.5 nTPM (limit 10); tongue: 12.6 nTPM (limit 6); urinary bladder: 12.2 nTPM (limit 6),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Low (Approved); caudate / neuronal cells: Low (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: High (Approved); colon / peripheral nerve/ganglion: High (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Low (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Adenocarcinoma (validation): 105/105 (100.0%); Kidney Renal Clear Cell Carcinoma (validation): 100/100 (100.0%); Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%),breast cancer: 9/11 (81.8%); testis cancer: 9/11 (81.8%),31,20,Q9P2X3,https://www.uniprot.org/uniprotkb/Q9P2X3/entry,"Translational regulator that ensures constant high levels of translation upon a variety of stress conditions, such as amino acid starvation, UV-C irradiation, proteasome inhibitor treatment and glucose deprivation. Plays a role as a negative regulator of the EIF2AK4/GCN2 kinase activity; impairs GCN1-mediated EIF2AK4/GCN2 activation, and hence EIF2AK4/GCN2-mediated eIF-2-alpha phosphorylation and subsequent down-regulation of protein synthesis. May be required to regulate translation in specific neuronal cells under amino acid starvation conditions by preventing GCN2 activation and therefore ATF4 synthesis. Through its inhibitory action on EIF2AK4/GCN2, plays a role in differentiation of neuronal cells by stimulating neurite outgrowth",Widely expressed. Expressed at high level in brain,,,Cytoplasm,,11116084|11244491,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
INCA1,ENSG00000196388,Unsafe,RNA,False,True,46.4,46.4,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 3.6 nTPM; absolute ceiling; amygdala: 2.9 nTPM; absolute ceiling; basal ganglia: 3 nTPM; absolute ceiling; cerebellum: 2.6 nTPM; absolute ceiling; cerebral cortex: 6.9 nTPM; absolute ceiling; choroid plexus: 3.3 nTPM; absolute ceiling; duodenum: 10.4 nTPM; absolute ceiling; heart muscle: 6.2 nTPM; absolute ceiling; hippocampal formation: 4 nTPM; absolute ceiling; hypothalamus: 2.6 nTPM; absolute ceiling; kidney: 3.9 nTPM; absolute ceiling; liver: 3.7 nTPM; absolute ceiling; lung: 4.4 nTPM; absolute ceiling; lymph node: 8.3 nTPM; absolute ceiling; midbrain: 3.3 nTPM; absolute ceiling; pancreas: 3.8 nTPM; absolute ceiling; pituitary gland: 2.2 nTPM; absolute ceiling; retina: 4.3 nTPM; absolute ceiling; skeletal muscle: 10.4 nTPM; absolute ceiling; small intestine: 7.6 nTPM; absolute ceiling; smooth muscle: 2.1 nTPM; absolute ceiling; spinal cord: 3.7 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 3.6 nTPM (limit 2); amygdala: 2.9 nTPM (limit 2); basal ganglia: 3 nTPM (limit 2); cerebellum: 2.6 nTPM (limit 2); cerebral cortex: 6.9 nTPM (limit 2); choroid plexus: 3.3 nTPM (limit 2); duodenum: 10.4 nTPM (limit 2); heart muscle: 6.2 nTPM (limit 2); hippocampal formation: 4 nTPM (limit 2); hypothalamus: 2.6 nTPM (limit 2); kidney: 3.9 nTPM (limit 2); liver: 3.7 nTPM (limit 2); lung: 4.4 nTPM (limit 2); lymph node: 8.3 nTPM (limit 6); midbrain: 3.3 nTPM (limit 2); pancreas: 3.8 nTPM (limit 2); pituitary gland: 2.2 nTPM (limit 2); retina: 4.3 nTPM (limit 2); skeletal muscle: 10.4 nTPM (limit 2); small intestine: 7.6 nTPM (limit 2); smooth muscle: 2.1 nTPM (limit 2); spinal cord: 3.7 nTPM (limit 2); adrenal gland: 3.6 nTPM (baseline 2); amygdala: 2.9 nTPM (baseline 2); basal ganglia: 3 nTPM (baseline 2); cerebellum: 2.6 nTPM (baseline 2); cerebral cortex: 6.9 nTPM (baseline 2); choroid plexus: 3.3 nTPM (baseline 2); duodenum: 10.4 nTPM (baseline 2); heart muscle: 6.2 nTPM (baseline 2); hippocampal formation: 4 nTPM (baseline 2); hypothalamus: 2.6 nTPM (baseline 2); kidney: 3.9 nTPM (baseline 2); liver: 3.7 nTPM (baseline 2); lung: 4.4 nTPM (baseline 2); lymph node: 8.3 nTPM (baseline 6); midbrain: 3.3 nTPM (baseline 2); pancreas: 3.8 nTPM (baseline 2); pituitary gland: 2.2 nTPM (baseline 2); retina: 4.3 nTPM (baseline 2); skeletal muscle: 10.4 nTPM (baseline 2); small intestine: 7.6 nTPM (baseline 2); smooth muscle: 2.1 nTPM (baseline 2); spinal cord: 3.7 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Adenocarcinoma (validation): 92/105 (87.6%); Rectum Adenocarcinoma (validation): 181/207 (87.4%); Kidney Renal Clear Cell Carcinoma (validation): 85/100 (85.0%),colorectal cancer: 11/12 (91.7%); testis cancer: 9/10 (90.0%),31,20,Q0VD86,https://www.uniprot.org/uniprotkb/Q0VD86/entry,"Binds to CDK2-bound cyclins and inhibits the kinase activity of CDK2; binding to cyclins is critical for its function as CDK inhibitor (PubMed:21540187). Inhibits cell growth and cell proliferation and may play a role in cell cycle control (By similarity). Required for ING5-mediated regulation of S-phase progression, enhancement of Fas-induced apoptosis and inhibition of cell growth (By similarity)","Detected in testis, and at lower levels in ovary. Detected at very low levels in testis tumors (PubMed:15159402). Down-regulated in bone marrow cells in acute myeloid and lymphoid leukemia patients as compared with normal bone marrow cells (PubMed:21540187)",,,Nucleus Cytoplasm,21540187,15159402|21540187,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
INHA,ENSG00000123999,Unsafe,Protein,False,True,101.1,101.1,87,6,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 73.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 4.3 nTPM; absolute ceiling; basal ganglia: 10.4 nTPM; absolute ceiling; heart muscle: 15.8 nTPM; absolute ceiling; hippocampal formation: 4.4 nTPM; absolute ceiling; hypothalamus: 4.6 nTPM; absolute ceiling; pituitary gland: 6.4 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 73.2 nTPM (limit 2); amygdala: 4.3 nTPM (limit 2); basal ganglia: 10.4 nTPM (limit 2); heart muscle: 15.8 nTPM (limit 12); hippocampal formation: 4.4 nTPM (limit 2); hypothalamus: 4.6 nTPM (limit 2); pituitary gland: 6.4 nTPM (limit 2),adrenal gland / glandular cells: High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 33/50 (66.0%); Testicular Germ Cell Tumor (TCGA): 36/133 (27.1%); Lung Adenocarcinoma (TCGA): 100/497 (20.1%),lung cancer: 1/12 (8.3%); breast cancer: 0/12 (0.0%),31,20,P05111,https://www.uniprot.org/uniprotkb/P05111/entry,"Inhibins and activins inhibit and activate, respectively, the secretion of follitropin by the pituitary gland. Inhibins/activins are involved in regulating a number of diverse functions such as hypothalamic and pituitary hormone secretion, gonadal hormone secretion, germ cell development and maturation, erythroid differentiation, insulin secretion, nerve cell survival, embryonic axial development or bone growth, depending on their subunit composition. Inhibins appear to oppose the functions of activins Inhibin A is a dimer of alpha/INHA and beta-A/INHBA that functions as a feedback regulator in the hypothalamic-pituitary-gonadal (HPG) axis. Inhibits the secretion of FSH from the anterior pituitary gland by acting on pituitary gonadotrope cells. Antagonizes activin A by binding to the proteoglycan, betaglycan, and forming a stable complex with and, thereby, sequestering type II activin receptors while excluding type I receptor Inhibin B is a dimer of alpha and beta-B that plays a crucial role in the regulation of the reproductive system by inhibiting the secretion of follicle-stimulating hormone (FSH) from the anterior pituitary gland. Thereby, maintains reproductive homeostasis in both males and females. Acts as a more potent suppressor of FSH release than inhibin A (By similarity). Functions as competitive receptor antagonist binding activin type II receptors with high affinity in the presence of the TGF-beta type III coreceptor/TGFBR3L (PubMed:34910520)","Originally found in ovary (granulosa cells) and testis (Sertoli cells), but widely distributed in many tissues including brain and placenta. In adrenal cortex expression is limited to the zona reticularis and the innermost zona fasciculata in the normal gland, extending centripetally into the zona fasciculata in hyperplasia. Also found in adrenocortical tumors. Also expressed in prostate epithelium of benign prostatic hyperplasia, in regions of basal cell hyperplasia and in nonmalignant regions of high grade prostate cancer. Only circulating inhibin B is found in male, whereas circulating inhibins A and B are found in female",,,Secreted,11786387|34910520,9506758,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
INO80B,ENSG00000115274,Unsafe,RNA,False,True,46.6,46.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 25.5 nTPM; absolute ceiling;continuous selectivity; adrenal gland: 29.5 nTPM; absolute ceiling;continuous selectivity; amygdala: 26.7 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 26.2 nTPM; absolute ceiling;continuous selectivity; bone marrow: 20.3 nTPM; absolute ceiling;continuous selectivity; cerebellum: 36.4 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 29 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 15.5 nTPM; absolute ceiling;continuous selectivity; colon: 23.3 nTPM; absolute ceiling;continuous selectivity; duodenum: 18.8 nTPM; absolute ceiling;continuous selectivity; esophagus: 30.2 nTPM; absolute ceiling;continuous selectivity; heart muscle: 19.5 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 24.5 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 24.5 nTPM; absolute ceiling;continuous selectivity; kidney: 26.6 nTPM; absolute ceiling;continuous selectivity; liver: 31.3 nTPM; absolute ceiling;continuous selectivity; lung: 25.1 nTPM; absolute ceiling;continuous selectivity; lymph node: 18.4 nTPM; absolute ceiling;continuous selectivity; midbrain: 20.4 nTPM; absolute ceiling;continuous selectivity; pancreas: 40.7 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 18.9 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 40.9 nTPM; absolute ceiling;continuous selectivity; rectum: 11.9 nTPM; absolute ceiling; retina: 18.1 nTPM; absolute ceiling;continuous selectivity; salivary gland: 29 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 29 nTPM; absolute ceiling;continuous selectivity; skin: 39.6 nTPM; absolute ceiling;continuous selectivity; small intestine: 23.3 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 14.2 nTPM; absolute ceiling;continuous selectivity; spinal cord: 19.7 nTPM; absolute ceiling;continuous selectivity; spleen: 23.9 nTPM; absolute ceiling;continuous selectivity; stomach: 31.8 nTPM; absolute ceiling;continuous selectivity; thymus: 12.5 nTPM; absolute ceiling; thyroid gland: 38.1 nTPM; absolute ceiling;continuous selectivity; tongue: 8.8 nTPM; absolute ceiling; urinary bladder: 26.2 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adipose tissue: 25.5 nTPM (limit 10); adrenal gland: 29.5 nTPM (limit 2); amygdala: 26.7 nTPM (limit 2); basal ganglia: 26.2 nTPM (limit 2); bone marrow: 20.3 nTPM (limit 2); cerebellum: 36.4 nTPM (limit 2); cerebral cortex: 29 nTPM (limit 2); choroid plexus: 15.5 nTPM (limit 2); colon: 23.3 nTPM (limit 6); duodenum: 18.8 nTPM (limit 2); esophagus: 30.2 nTPM (limit 6); heart muscle: 19.5 nTPM (limit 2); hippocampal formation: 24.5 nTPM (limit 2); hypothalamus: 24.5 nTPM (limit 2); kidney: 26.6 nTPM (limit 2); liver: 31.3 nTPM (limit 2); lung: 25.1 nTPM (limit 2); lymph node: 18.4 nTPM (limit 6); midbrain: 20.4 nTPM (limit 2); pancreas: 40.7 nTPM (limit 2); parathyroid gland: 18.9 nTPM (limit 6); pituitary gland: 40.9 nTPM (limit 2); rectum: 11.9 nTPM (limit 6); retina: 18.1 nTPM (limit 2); salivary gland: 29 nTPM (limit 6); skeletal muscle: 29 nTPM (limit 2); skin: 39.6 nTPM (limit 10); small intestine: 23.3 nTPM (limit 2); smooth muscle: 14.2 nTPM (limit 2); spinal cord: 19.7 nTPM (limit 2); spleen: 23.9 nTPM (limit 10); stomach: 31.8 nTPM (limit 6); thymus: 12.5 nTPM (limit 10); thyroid gland: 38.1 nTPM (limit 10); tongue: 8.8 nTPM (limit 6); urinary bladder: 26.2 nTPM (limit 6); adipose tissue: 25.5 nTPM (baseline 10); adrenal gland: 29.5 nTPM (baseline 2); amygdala: 26.7 nTPM (baseline 2); basal ganglia: 26.2 nTPM (baseline 2); bone marrow: 20.3 nTPM (baseline 2); cerebellum: 36.4 nTPM (baseline 2); cerebral cortex: 29 nTPM (baseline 2); choroid plexus: 15.5 nTPM (baseline 2); colon: 23.3 nTPM (baseline 6); duodenum: 18.8 nTPM (baseline 2); esophagus: 30.2 nTPM (baseline 6); heart muscle: 19.5 nTPM (baseline 2); hippocampal formation: 24.5 nTPM (baseline 2); hypothalamus: 24.5 nTPM (baseline 2); kidney: 26.6 nTPM (baseline 2); liver: 31.3 nTPM (baseline 2); lung: 25.1 nTPM (baseline 2); lymph node: 18.4 nTPM (baseline 6); midbrain: 20.4 nTPM (baseline 2); pancreas: 40.7 nTPM (baseline 2); parathyroid gland: 18.9 nTPM (baseline 6); pituitary gland: 40.9 nTPM (baseline 2); rectum: 11.9 nTPM (baseline 6); retina: 18.1 nTPM (baseline 2); salivary gland: 29 nTPM (baseline 6); skeletal muscle: 29 nTPM (baseline 2); skin: 39.6 nTPM (baseline 10); small intestine: 23.3 nTPM (baseline 2); smooth muscle: 14.2 nTPM (baseline 2); spinal cord: 19.7 nTPM (baseline 2); spleen: 23.9 nTPM (baseline 10); stomach: 31.8 nTPM (baseline 6); thymus: 12.5 nTPM (baseline 10); thyroid gland: 38.1 nTPM (baseline 10); tongue: 8.8 nTPM (baseline 6); urinary bladder: 26.2 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Adenocarcinoma (TCGA): 497/497 (100.0%); Thyroid Carcinoma (TCGA): 495/495 (100.0%); Head and Neck Squamous Cell Carcinoma (TCGA): 492/492 (100.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9C086,https://www.uniprot.org/uniprotkb/Q9C086/entry,"Induces growth and cell cycle arrests at the G1 phase of the cell cycle Proposed core component of the chromatin remodeling INO80 complex which is involved in transcriptional regulation, DNA replication and probably DNA repair",,,,"Nucleus Nucleus, nucleolus",15556297,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
INSL3,ENSG00000248099,Unsafe,High RNA,False,True,397.1,397.1,86,1,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 34/91 values ≥5 TPM, max 10.0825; DICE NK (unstimulated): 42/90 values ≥5 TPM, max 12.5615; DICE TREG_MEM (unstimulated): 89/89 values ≥5 TPM, max 37.3594; DICE CD4_NAIVE (unstimulated): 87/88 values ≥5 TPM, max 34.7943; DICE CD4_STIM (activated): 79/88 values ≥5 TPM, max 22.7148; DICE TREG_NAIVE (unstimulated): 89/89 values ≥5 TPM, max 33.6474; DICE TFH (unstimulated): 89/89 values ≥5 TPM, max 43.7348; DICE TH1 (unstimulated): 80/81 values ≥5 TPM, max 33.3347; DICE THSTAR (unstimulated): 78/88 values ≥5 TPM, max 18.2345; DICE TH17 (unstimulated): 88/89 values ≥5 TPM, max 31.1571; DICE TH2 (unstimulated): 88/89 values ≥5 TPM, max 37.8101; DICE CD8_NAIVE (unstimulated): 87/89 values ≥5 TPM, max 27.4673; DICE CD8_STIM (activated): 65/88 values ≥5 TPM, max 16.7825; hpa_immune_monaco Effector memory CD8 T-cell: 6.1 TPM; hpa_immune_monaco MAIT T-cell: 5.8 TPM; hpa_immune_monaco Memory CD4 T-cell TFH: 12.3 TPM; hpa_immune_monaco Memory CD4 T-cell Th1: 11.2 TPM; hpa_immune_monaco Memory CD4 T-cell Th1/Th17: 7.8 TPM; hpa_immune_monaco Memory CD4 T-cell Th17: 12.4 TPM; hpa_immune_monaco Memory CD4 T-cell Th2: 8.8 TPM; hpa_immune_monaco naive CD4 T-cell: 10.8 TPM; hpa_immune_monaco naive CD8 T-cell: 7.2 TPM; hpa_immune_monaco neutrophil: 10.3 TPM; hpa_immune_monaco T-reg: 8.2 TPM; hpa_immune_monaco Terminal effector memory CD4 T-cell: 9.7 TPM",True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,43.7347852895,11.8,"dice_cd4_naive: blood/CD4_NAIVE, max 34.7943 TPM, 2 observations >30; dice_tfh: blood/TFH, max 43.7348 TPM, 18 observations >30; dice_th1: blood/TH1, max 33.3347 TPM, 1 observations >30; dice_th17: blood/TH17, max 31.1571 TPM, 1 observations >30; dice_th2: blood/TH2, max 37.8101 TPM, 3 observations >30; dice_treg_mem: blood/TREG_MEM, max 37.3594 TPM, 5 observations >30; dice_treg_naive: blood/TREG_NAIVE, max 33.6474 TPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,43.73 TPM; blood/TFH; dice_tfh; vital,11.8 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Colon Adenocarcinoma (validation): 207/486 (42.6%); Rectum Adenocarcinoma (validation): 84/207 (40.6%); Testicular Germ Cell Tumor (TCGA): 36/133 (27.1%),breast cancer: 0/12 (0.0%); cervical cancer: 0/10 (0.0%),31,20,P51460,https://www.uniprot.org/uniprotkb/P51460/entry,Seems to play a role in testicular function. May be a trophic hormone with a role in testicular descent in fetal life. Is a ligand for LGR8 receptor,"Expressed in prenatal and postnatal Leydig cells. Found as well in the corpus luteum, trophoblast, fetal membranes and breast","Cryptorchidism: One of the most frequent congenital abnormalities in humans, involving 2-5% of male births. Cryptorchidism is associated with increased risk of infertility and testicular cancer.",,Secreted,,7852540,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
INSL6,ENSG00000120210,Unsafe,RNA,False,True,14.4,14.4,85,2,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,retina: 6.4 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 6.4 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Ovary Serous Cystadenocarcinoma (TCGA): 17/349 (4.9%); Lung Squamous Cell Carcinoma (validation): 3/68 (4.4%); Stomach Adenocarcinoma (TCGA): 11/346 (3.2%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q9Y581,https://www.uniprot.org/uniprotkb/Q9Y581/entry,May have a role in sperm development and fertilization,Testis specific,,,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
INSRR,ENSG00000027644,Unsafe,RNA,False,True,1.9,3.7,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 1.3 nTPM; continuous selectivity; cerebellum: 0.7 nTPM; continuous selectivity; kidney: 3.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; stomach: 1.7 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,kidney: 3.7 nTPM (limit 2); kidney: 3.7 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Chromophobe (TCGA): 4/64 (6.2%); Glioblastoma Multiforme (validation): 3/58 (5.2%); Glioblastoma Multiforme (TCGA): 2/141 (1.4%),cervical cancer: 12/12 (100.0%); stomach cancer: 12/12 (100.0%),31,20,P14616,https://www.uniprot.org/uniprotkb/P14616/entry,Receptor with tyrosine-protein kinase activity. Functions as a pH sensing receptor which is activated by increased extracellular pH. Activates an intracellular signaling pathway that involves IRS1 and AKT1/PKB,,,,Membrane,21641549,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
IPO11,ENSG00000086200,Unsafe,Protein,False,True,20.8,20.8,95,65,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 15.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 8.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 7.5 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 7.6 nTPM; absolute ceiling;continuous selectivity; bone marrow: 6.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 5.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 8.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 10 nTPM; absolute ceiling;continuous selectivity; colon: 8.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 6.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 11.6 nTPM; absolute ceiling;continuous selectivity; heart muscle: 14.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 8.7 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 7.6 nTPM; absolute ceiling;continuous selectivity; kidney: 11.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 11.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 7.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 10.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 8.9 nTPM; absolute ceiling;continuous selectivity; pancreas: 8.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 13 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 5.8 nTPM; absolute ceiling;continuous selectivity; rectum: 8.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 6.1 nTPM; absolute ceiling;continuous selectivity; salivary gland: 8.2 nTPM; absolute ceiling; skeletal muscle: 12.1 nTPM; absolute ceiling;continuous selectivity; skin: 8.5 nTPM; positive ihc; small intestine: 7.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 10.6 nTPM; absolute ceiling;continuous selectivity; spinal cord: 8.6 nTPM; absolute ceiling;continuous selectivity; spleen: 13 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 8.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 9.8 nTPM; continuous selectivity; thyroid gland: 13.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 13.9 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 12.9 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 15.5 nTPM (limit 10); adrenal gland: 8.8 nTPM (limit 2); amygdala: 7.5 nTPM (limit 2); basal ganglia: 7.6 nTPM (limit 2); bone marrow: 6.5 nTPM (limit 2); cerebellum: 5.7 nTPM (limit 2); cerebral cortex: 8.5 nTPM (limit 2); choroid plexus: 10 nTPM (limit 2); colon: 8.9 nTPM (limit 6); duodenum: 6.7 nTPM (limit 2); esophagus: 11.6 nTPM (limit 8); heart muscle: 14.2 nTPM (limit 2); hippocampal formation: 8.7 nTPM (limit 2); hypothalamus: 7.6 nTPM (limit 2); kidney: 11.5 nTPM (limit 2); liver: 11.1 nTPM (limit 2); lung: 7.5 nTPM (limit 2); lymph node: 10.1 nTPM (limit 6); midbrain: 8.9 nTPM (limit 2); pancreas: 8.4 nTPM (limit 2); parathyroid gland: 13 nTPM (limit 8); pituitary gland: 5.8 nTPM (limit 2); rectum: 8.3 nTPM (limit 6); retina: 6.1 nTPM (limit 2); salivary gland: 8.2 nTPM (limit 8); skeletal muscle: 12.1 nTPM (limit 4); small intestine: 7.6 nTPM (limit 2); smooth muscle: 10.6 nTPM (limit 4); spinal cord: 8.6 nTPM (limit 2); spleen: 13 nTPM (limit 10); stomach: 8.2 nTPM (limit 6); thyroid gland: 13.6 nTPM (limit 10); tongue: 13.9 nTPM (limit 6); urinary bladder: 12.9 nTPM (limit 8),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / basal cells: Medium (Approved); bronchus / ciliated cells (cell body): High (Approved); bronchus / goblet cells: Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: High (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / glial cells: Medium (Approved); hippocampus / neuronal cells: High (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: High (Approved); lung / macrophages: High (Approved); lymph node / germinal center cells: Medium (Approved); nasopharynx / basal cells: Medium (Approved); nasopharynx / ciliated cells (cell body): High (Approved); nasopharynx / goblet cells: Medium (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Medium (Approved); rectum / glandular cells: High (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Medium (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Low (Approved); thyroid gland / glandular cells: High (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (TCGA): 141/141 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%),prostate cancer: 8/11 (72.7%); liver cancer: 6/11 (54.5%),31,20,Q9UI26,https://www.uniprot.org/uniprotkb/Q9UI26/entry,"Functions in nuclear protein import as nuclear transport receptor. Serves as receptor for nuclear localization signals (NLS) in cargo substrates. Is thought to mediate docking of the importin/substrate complex to the nuclear pore complex (NPC) through binding to nucleoporin and the complex is subsequently translocated through the pore by an energy requiring, Ran-dependent mechanism. At the nucleoplasmic side of the NPC, Ran binds to the importin, the importin/substrate complex dissociates and importin is re-exported from the nucleus to the cytoplasm where GTP hydrolysis releases Ran. The directionality of nuclear import is thought to be conferred by an asymmetric distribution of the GTP- and GDP-bound forms of Ran between the cytoplasm and nucleus (By similarity). Mediates the nuclear import of UBE2E3, and of RPL12 (By similarity)",,,,Cytoplasm Nucleus,11032817,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
IQCD,ENSG00000166578,Unsafe,RNA,False,True,43.0,43.0,84,1,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,amygdala: 2.2 nTPM; absolute ceiling; basal ganglia: 3.2 nTPM; absolute ceiling; choroid plexus: 21.4 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 2.6 nTPM; absolute ceiling; hypothalamus: 3 nTPM; absolute ceiling; midbrain: 2.2 nTPM; absolute ceiling; pituitary gland: 3.8 nTPM; absolute ceiling; retina: 3.6 nTPM; absolute ceiling; spinal cord: 2.5 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 2.2 nTPM (limit 2); basal ganglia: 3.2 nTPM (limit 2); choroid plexus: 21.4 nTPM (limit 2); hippocampal formation: 2.6 nTPM (limit 2); hypothalamus: 3 nTPM (limit 2); midbrain: 2.2 nTPM (limit 2); pituitary gland: 3.8 nTPM (limit 2); retina: 3.6 nTPM (limit 2); spinal cord: 2.5 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 44/50 (88.0%); Kidney Renal Papillary Cell Carcinoma (TCGA): 209/282 (74.1%); Uterine Corpus Endometrial Carcinoma (TCGA): 108/176 (61.4%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q96DY2,https://www.uniprot.org/uniprotkb/Q96DY2/entry,"Component of the nexin-dynein regulatory complex (N-DRC), a key regulator of ciliary/flagellar motility which maintains the alignment and integrity of the distal axoneme and regulates microtubule sliding in motile axonemes",,,,"Cytoplasm, cytoskeleton, flagellum axoneme",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
IQCH,ENSG00000103599,Unsafe,RNA,False,True,11.2,11.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,kidney: 2.1 nTPM; absolute ceiling; retina: 4.8 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,kidney: 2.1 nTPM (limit 2); retina: 4.8 nTPM (limit 2); kidney: 2.1 nTPM (baseline 2); retina: 4.8 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 39/50 (78.0%); Glioblastoma Multiforme (validation): 26/58 (44.8%); Pancreatic Adenocarcinoma (validation): 15/80 (18.8%),breast cancer: 12/12 (100.0%); liver cancer: 12/12 (100.0%),31,20,Q86VS3,https://www.uniprot.org/uniprotkb/Q86VS3/entry,May play a regulatory role in spermatogenesis,"Expressed in fetal and adult testis, in germ cells but not somatic cells",,,,15897968,15897968,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
IQCN,ENSG00000130518,Unsafe,Protein,False,True,27.4,27.4,96,6,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; cerebellum: 1.8 nTPM; positive ihc; choroid plexus: 3.4 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 3.4 nTPM (limit 2),cerebellum / Bergmann glia - nucleus: High (Enhanced); cerebellum / GLUC cells - nucleus: Low (Enhanced); cerebellum / Purkinje cells - nucleus: High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 81/207 (39.1%); Colon Adenocarcinoma (validation): 148/486 (30.5%); Ovary Serous Cystadenocarcinoma (validation): 24/81 (29.6%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),29,20,Q9H0B3,https://www.uniprot.org/uniprotkb/Q9H0B3/entry,Essential for spermiogenesis and fertilization (PubMed:36321563). May be required for manchette assembly in elongating spermatids (By similarity),,"Spermatogenic failure 78: An autosomal recessive, male infertility disorder characterized by a high proportion of sperm head anomalies, primarily tapered and microcephalic heads, and an abnormal acrosome structure.",,,36321563,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
IQUB,ENSG00000164675,Unsafe,RNA,False,True,32.5,32.5,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,choroid plexus: 2.3 nTPM; absolute ceiling; kidney: 2.9 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 2.3 nTPM (limit 2); kidney: 2.9 nTPM (limit 2); choroid plexus: 2.3 nTPM (baseline 2); kidney: 2.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 27/58 (46.6%); Breast Invasive Carcinoma (validation): 18/50 (36.0%); Kidney Renal Clear Cell Carcinoma (validation): 14/100 (14.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NA54,https://www.uniprot.org/uniprotkb/Q8NA54/entry,"Adapter protein that anchors the radial spoke 1 (RS1) complex to the A microtubule of outer doublet microtubules in axonemes (PubMed:36355624). The triple radial spokes (RS1, RS2 and RS3) are required to modulate beating of the sperm flagellum (PubMed:36355624). May play a role in inhibiting signaling via MAPK1/ERK2 and MAPK3/ERK1 (PubMed:36355624). Additionally, may play a role in the functioning of cilia (By similarity). Not required for the functioning of tracheal or ependymal cilia (By similarity)",,,,"Cytoplasm, cytoskeleton, flagellum axoneme Cell projection, cilium",36355624,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Jamin2021_CT | Jamin2021_core | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
IRAK1BP1,ENSG00000146243,Unsafe,RNA,False,True,4.3,5.4,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 1.7 nTPM; continuous selectivity; amygdala: 1.2 nTPM; continuous selectivity; basal ganglia: 1.8 nTPM; continuous selectivity; bone marrow: 5.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 1.5 nTPM; continuous selectivity; cerebral cortex: 1.6 nTPM; continuous selectivity; choroid plexus: 1.9 nTPM; continuous selectivity; colon: 1.6 nTPM; continuous selectivity; heart muscle: 1.6 nTPM; continuous selectivity; hippocampal formation: 1.3 nTPM; continuous selectivity; hypothalamus: 1.5 nTPM; continuous selectivity; kidney: 2.8 nTPM; absolute ceiling;continuous selectivity; lung: 2.1 nTPM; absolute ceiling;continuous selectivity; lymph node: 1.8 nTPM; continuous selectivity; pancreas: 3.1 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 3.5 nTPM; continuous selectivity; pituitary gland: 3.3 nTPM; absolute ceiling;continuous selectivity; retina: 5.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 2.6 nTPM; continuous selectivity; skin: 2.2 nTPM; continuous selectivity; small intestine: 1.4 nTPM; continuous selectivity; smooth muscle: 2 nTPM; continuous selectivity; stomach: 3.3 nTPM; continuous selectivity; thymus: 2.9 nTPM; continuous selectivity; thyroid gland: 3.2 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 5.3 nTPM (limit 2); kidney: 2.8 nTPM (limit 2); lung: 2.1 nTPM (limit 2); pancreas: 3.1 nTPM (limit 2); pituitary gland: 3.3 nTPM (limit 2); retina: 5.4 nTPM (limit 2); bone marrow: 5.3 nTPM (baseline 2); kidney: 2.8 nTPM (baseline 2); lung: 2.1 nTPM (baseline 2); pancreas: 3.1 nTPM (baseline 2); pituitary gland: 3.3 nTPM (baseline 2); retina: 5.4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Breast Invasive Carcinoma (validation): 47/50 (94.0%); Rectum Adenocarcinoma (validation): 147/207 (71.0%),colorectal cancer: 10/11 (90.9%); renal cancer: 10/12 (83.3%),31,20,Q5VVH5,https://www.uniprot.org/uniprotkb/Q5VVH5/entry,Component of the IRAK1-dependent TNFRSF1A signaling pathway that leads to NF-kappa-B activation and is required for cell survival. Acts by enhancing RELA transcriptional activity (By similarity),,,,Cytoplasm Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | Jamin2021_CT,GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
ISM2,ENSG00000100593,Unsafe,Protein,False,True,206.2,206.2,90,9,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; basal ganglia: 2.1 nTPM; absolute ceiling; cerebral cortex: 0.4 nTPM; positive ihc; colon: 0.2 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",basal ganglia: 2.1 nTPM (limit 2),cerebral cortex / endothelial cells: Low (Supported); colon / endothelial cells: Low (Supported),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Chromophobe (TCGA): 27/64 (42.2%); Testicular Germ Cell Tumor (TCGA): 19/133 (14.3%); Rectum Adenocarcinoma (TCGA): 10/88 (11.4%),colorectal cancer: 3/10 (30.0%); pancreatic cancer: 1/11 (9.1%),31,20,Q6H9L7,https://www.uniprot.org/uniprotkb/Q6H9L7/entry,,"Expressed at high levels in the placenta and at moderate levels in the pancreas, kidney, heart, liver, lung, brain and skeletal muscle",,,Secreted,,15194193,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Gong2021_reproductive_PC,No tumor-antigen validation in this source | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
ISY1,ENSG00000240682,Unsafe,Protein,False,True,21.3,50.4,84,79,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 18.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 13.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 10.4 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 10.7 nTPM; absolute ceiling;continuous selectivity; bone marrow: 50.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 11.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 12.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 10.3 nTPM; absolute ceiling;continuous selectivity; colon: 20.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 14.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 21.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 20.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 9.9 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 10.1 nTPM; absolute ceiling;continuous selectivity; kidney: 14.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 10.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 13.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 31.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 10.5 nTPM; absolute ceiling;continuous selectivity; pancreas: 15.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 10.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 8.5 nTPM; absolute ceiling;continuous selectivity; rectum: 16.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 10.1 nTPM; absolute ceiling;continuous selectivity; salivary gland: 14.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 33.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 19.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 15.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 19.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 10.8 nTPM; absolute ceiling;continuous selectivity; spleen: 17.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 14.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 22.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 14.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 20.4 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 17.7 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 18.1 nTPM (limit 10); adrenal gland: 13.3 nTPM (limit 2); amygdala: 10.4 nTPM (limit 2); basal ganglia: 10.7 nTPM (limit 2); bone marrow: 50.4 nTPM (limit 2); cerebellum: 11.6 nTPM (limit 2); cerebral cortex: 12.8 nTPM (limit 2); choroid plexus: 10.3 nTPM (limit 2); colon: 20.9 nTPM (limit 6); duodenum: 14.9 nTPM (limit 2); esophagus: 21.5 nTPM (limit 6); heart muscle: 20.6 nTPM (limit 2); hippocampal formation: 9.9 nTPM (limit 2); hypothalamus: 10.1 nTPM (limit 2); kidney: 14.6 nTPM (limit 2); liver: 10.6 nTPM (limit 2); lung: 13.7 nTPM (limit 2); lymph node: 31.2 nTPM (limit 6); midbrain: 10.5 nTPM (limit 2); pancreas: 15.3 nTPM (limit 2); parathyroid gland: 10.8 nTPM (limit 6); pituitary gland: 8.5 nTPM (limit 2); rectum: 16.3 nTPM (limit 6); retina: 10.1 nTPM (limit 2); salivary gland: 14.4 nTPM (limit 6); skeletal muscle: 33.6 nTPM (limit 2); skin: 19.7 nTPM (limit 10); small intestine: 15.7 nTPM (limit 2); smooth muscle: 19.5 nTPM (limit 2); spinal cord: 10.8 nTPM (limit 2); spleen: 17.8 nTPM (limit 10); stomach: 14.4 nTPM (limit 6); thymus: 22.1 nTPM (limit 10); thyroid gland: 14.4 nTPM (limit 10); tongue: 20.4 nTPM (limit 6); urinary bladder: 17.7 nTPM (limit 6),adipose tissue / adipocytes: High (Supported); adrenal gland / glandular cells: High (Supported); bone marrow / hematopoietic cells: High (Supported); bronchus / respiratory epithelial cells: High (Supported); caudate / glial cells: High (Supported); caudate / neuronal cells: High (Supported); cerebellum / cells in granular layer: Low (Supported); cerebellum / cells in molecular layer: Medium (Supported); cerebellum / Purkinje cells: High (Supported); cerebral cortex / endothelial cells: Medium (Supported); cerebral cortex / glial cells: High (Supported); cerebral cortex / neuronal cells: High (Supported); colon / endothelial cells: High (Supported); colon / glandular cells: High (Supported); duodenum / glandular cells: High (Supported); esophagus / squamous epithelial cells: High (Supported); heart muscle / cardiomyocytes: Medium (Supported); hippocampus / glial cells: High (Supported); hippocampus / neuronal cells: High (Supported); kidney / cells in glomeruli: High (Supported); kidney / cells in tubules: High (Supported); liver / cholangiocytes: High (Supported); liver / hepatocytes: High (Supported); lung / alveolar cells: High (Supported); lung / macrophages: High (Supported); lymph node / germinal center cells: Medium (Supported); lymph node / non-germinal center cells: Medium (Supported); nasopharynx / respiratory epithelial cells: High (Supported); oral mucosa / squamous epithelial cells: High (Supported); pancreas / exocrine glandular cells: High (Supported); pancreas / pancreatic endocrine cells: Medium (Supported); parathyroid gland / glandular cells: High (Supported); rectum / glandular cells: High (Supported); salivary gland / glandular cells: High (Supported); skeletal muscle / myocytes: High (Supported); skin 1 / fibroblasts: Medium (Supported); skin 1 / keratinocytes: High (Supported); skin 1 / Langerhans: High (Supported); skin 2 / epidermal cells: High (Supported); small intestine / glandular cells: High (Supported); smooth muscle / smooth muscle cells: High (Supported); spleen / cells in red pulp: High (Supported); spleen / cells in white pulp: Low (Supported); stomach 1 / glandular cells: High (Supported); stomach 2 / glandular cells: High (Supported); thyroid gland / glandular cells: High (Supported); urinary bladder / urothelial cells: High (Supported),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Adenocarcinoma (TCGA): 497/497 (100.0%); Head and Neck Squamous Cell Carcinoma (TCGA): 492/492 (100.0%); Lung Squamous Cell Carcinoma (TCGA): 489/489 (100.0%),cervical cancer: 12/12 (100.0%); colorectal cancer: 12/12 (100.0%),31,20,Q9ULR0,https://www.uniprot.org/uniprotkb/Q9ULR0/entry,"Component of the spliceosome C complex required for the selective processing of microRNAs during embryonic stem cell differentiation (By similarity). Required for the biogenesis of all miRNAs from the pri-miR-17-92 primary transcript except miR-92a (By similarity). Only required for the biogenesis of miR-290 and miR-96 from the pri-miR-290-295 and pri-miR-96-183 primary transcripts, respectively (By similarity). Required during the transition of embryonic stem cells (ESCs) from the naive to primed state (By similarity). By enhancing miRNA biogenesis, promotes exit of ESCs from the naive state to an intermediate state of poised pluripotency, which precedes transition to the primed state (By similarity). Involved in pre-mRNA splicing as component of the spliceosome",,,,Nucleus,11991638|25599396|29301961,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ITIH4,ENSG00000055955,Unsafe,RNA,False,True,4.1,1807.4,81,0,Negative where measured,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 4 nTPM; continuous selectivity; adrenal gland: 17.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 1.9 nTPM; continuous selectivity; basal ganglia: 2.7 nTPM; absolute ceiling;continuous selectivity; bone marrow: 9.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 3.5 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 3.2 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 2.7 nTPM; absolute ceiling;continuous selectivity; colon: 3.5 nTPM; continuous selectivity; heart muscle: 3.1 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 1.8 nTPM; continuous selectivity; hypothalamus: 1.7 nTPM; continuous selectivity; kidney: 5.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; liver: 1807.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 4.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 1.6 nTPM; continuous selectivity; midbrain: 2 nTPM; continuous selectivity; pancreas: 47.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 4.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; retina: 3.2 nTPM; absolute ceiling;continuous selectivity; salivary gland: 2 nTPM; continuous selectivity; skeletal muscle: 38.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 2.4 nTPM; continuous selectivity; small intestine: 3.3 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 1.4 nTPM; continuous selectivity; spinal cord: 1.4 nTPM; continuous selectivity; spleen: 7.2 nTPM; continuous selectivity;reproductive not higher; stomach: 3.7 nTPM; continuous selectivity; thymus: 2.1 nTPM; continuous selectivity; thyroid gland: 5.1 nTPM; continuous selectivity;reproductive not higher; tongue: 2.7 nTPM; continuous selectivity; urinary bladder: 5.1 nTPM; continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 17.9 nTPM (limit 12); basal ganglia: 2.7 nTPM (limit 2); choroid plexus: 2.7 nTPM (limit 2); liver: 1807.4 nTPM (limit 12); pancreas: 47.5 nTPM (limit 12); pituitary gland: 4.2 nTPM (limit 2); retina: 3.2 nTPM (limit 2); skeletal muscle: 38.8 nTPM (limit 12); adrenal gland: 17.9 nTPM (baseline 2); basal ganglia: 2.7 nTPM (baseline 2); bone marrow: 9.9 nTPM (baseline 2); cerebellum: 3.5 nTPM (baseline 2); cerebral cortex: 3.2 nTPM (baseline 2); choroid plexus: 2.7 nTPM (baseline 2); heart muscle: 3.1 nTPM (baseline 2); kidney: 5.2 nTPM (baseline 2); liver: 1807.4 nTPM (baseline 2); lung: 4.7 nTPM (baseline 2); pancreas: 47.5 nTPM (baseline 2); pituitary gland: 4.2 nTPM (baseline 2); retina: 3.2 nTPM (baseline 2); skeletal muscle: 38.8 nTPM (baseline 2); small intestine: 3.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (validation): 228/231 (98.7%); Liver Hepatocellular Carcinoma (TCGA): 356/362 (98.3%); Breast Invasive Carcinoma (validation): 42/50 (84.0%),liver cancer: 5/12 (41.7%); breast cancer: 2/12 (16.7%),31,20,Q14624,https://www.uniprot.org/uniprotkb/Q14624/entry,Type II acute-phase protein (APP) involved in inflammatory responses to trauma. May also play a role in liver development or regeneration,Liver specific,,,Secreted,19263524,7775381|7805892,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ITPRIPL1,ENSG00000198885,Unsafe,RNA,False,True,27.0,27.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,cerebellum: 3.2 nTPM; absolute ceiling; salivary gland: 7.3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebellum: 3.2 nTPM (limit 2); salivary gland: 7.3 nTPM (limit 6); cerebellum: 3.2 nTPM (baseline 2); salivary gland: 7.3 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 55/58 (94.8%); Glioblastoma Multiforme (TCGA): 94/141 (66.7%); Testicular Germ Cell Tumor (TCGA): 40/133 (30.1%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q6GPH6,https://www.uniprot.org/uniprotkb/Q6GPH6/entry,"Functions as a ligand of CD3E, inhibiting TCR-CD3 complex signaling to regulate T cell activation. Induces stable CD3E-NCK1 binding, thereby preventing the CD3E-ZAP70 interaction and subsequently inhibiting the activation of the downstream ERK-NFkB signaling cascade and calcium influx",Expressed in testis and tumoral cells,,,Cell membrane,38614099,38614099,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
IZUMO4,ENSG00000099840,Unsafe,Protein,False,True,430.8,430.8,92,7,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 17.8 nTPM; absolute ceiling; basal ganglia: 15.3 nTPM; absolute ceiling; cerebral cortex: 15.5 nTPM; absolute ceiling; choroid plexus: 12.6 nTPM; absolute ceiling; hippocampal formation: 13.4 nTPM; absolute ceiling; hypothalamus: 11.7 nTPM; absolute ceiling; kidney: 4.1 nTPM; positive ihc;absolute ceiling; midbrain: 14.4 nTPM; absolute ceiling; pituitary gland: 9.9 nTPM; absolute ceiling; retina: 2.8 nTPM; absolute ceiling; spinal cord: 16.3 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 17.8 nTPM (limit 2); basal ganglia: 15.3 nTPM (limit 2); cerebral cortex: 15.5 nTPM (limit 12); choroid plexus: 12.6 nTPM (limit 2); hippocampal formation: 13.4 nTPM (limit 2); hypothalamus: 11.7 nTPM (limit 2); kidney: 4.1 nTPM (limit 2); midbrain: 14.4 nTPM (limit 2); pituitary gland: 9.9 nTPM (limit 2); retina: 2.8 nTPM (limit 2); spinal cord: 16.3 nTPM (limit 2),kidney / proximal tubules (cell body): Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Prostate Adenocarcinoma (TCGA): 293/480 (61.0%); Glioblastoma Multiforme (TCGA): 83/141 (58.9%); Glioblastoma Multiforme (validation): 15/58 (25.9%),testis cancer: 11/12 (91.7%); glioma: 4/11 (36.4%),30,20,Q1ZYL8,https://www.uniprot.org/uniprotkb/Q1ZYL8/entry,,Detected in sperm,,,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
JAM3,ENSG00000166086,Unsafe,Protein,False,True,100.0,100.0,91,37,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 22.9 nTPM; absolute ceiling; adrenal gland: 19 nTPM; positive ihc;absolute ceiling; amygdala: 33.1 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 45.5 nTPM; absolute ceiling;continuous selectivity; cerebellum: 12.9 nTPM; positive ihc;absolute ceiling; cerebral cortex: 34.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 48.3 nTPM; absolute ceiling;continuous selectivity; colon: 52.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 7.2 nTPM; positive ihc;absolute ceiling; esophagus: 21.3 nTPM; positive ihc;absolute ceiling; heart muscle: 30.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 51.3 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 31.8 nTPM; absolute ceiling;continuous selectivity; kidney: 11.1 nTPM; positive ihc;absolute ceiling; liver: 3.2 nTPM; positive ihc;absolute ceiling; lung: 28.7 nTPM; absolute ceiling; lymph node: 8.4 nTPM; positive ihc;absolute ceiling; midbrain: 51.2 nTPM; absolute ceiling;continuous selectivity; pancreas: 5 nTPM; positive ihc;absolute ceiling; parathyroid gland: 17.1 nTPM; absolute ceiling; pituitary gland: 32.4 nTPM; absolute ceiling;continuous selectivity; rectum: 12.5 nTPM; absolute ceiling; retina: 46.8 nTPM; absolute ceiling;continuous selectivity; salivary gland: 12.9 nTPM; absolute ceiling; skeletal muscle: 6.8 nTPM; absolute ceiling; small intestine: 21.9 nTPM; absolute ceiling; smooth muscle: 41.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 77 nTPM; absolute ceiling;continuous selectivity; spleen: 13.2 nTPM; positive ihc;absolute ceiling; stomach: 21.7 nTPM; positive ihc;absolute ceiling; thymus: 17.1 nTPM; absolute ceiling; thyroid gland: 15.3 nTPM; positive ihc;absolute ceiling; tongue: 14.1 nTPM; absolute ceiling; urinary bladder: 40.3 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 22.9 nTPM (limit 20); adrenal gland: 19 nTPM (limit 2); amygdala: 33.1 nTPM (limit 2); basal ganglia: 45.5 nTPM (limit 2); cerebellum: 12.9 nTPM (limit 2); cerebral cortex: 34.6 nTPM (limit 2); choroid plexus: 48.3 nTPM (limit 2); colon: 52.8 nTPM (limit 6); duodenum: 7.2 nTPM (limit 2); esophagus: 21.3 nTPM (limit 6); heart muscle: 30.5 nTPM (limit 2); hippocampal formation: 51.3 nTPM (limit 2); hypothalamus: 31.8 nTPM (limit 2); kidney: 11.1 nTPM (limit 2); liver: 3.2 nTPM (limit 2); lung: 28.7 nTPM (limit 4); lymph node: 8.4 nTPM (limit 6); midbrain: 51.2 nTPM (limit 2); pancreas: 5 nTPM (limit 2); parathyroid gland: 17.1 nTPM (limit 8); pituitary gland: 32.4 nTPM (limit 2); rectum: 12.5 nTPM (limit 8); retina: 46.8 nTPM (limit 2); salivary gland: 12.9 nTPM (limit 8); skeletal muscle: 6.8 nTPM (limit 4); small intestine: 21.9 nTPM (limit 4); smooth muscle: 41.3 nTPM (limit 2); spinal cord: 77 nTPM (limit 2); spleen: 13.2 nTPM (limit 10); stomach: 21.7 nTPM (limit 6); thymus: 17.1 nTPM (limit 10); thyroid gland: 15.3 nTPM (limit 10); tongue: 14.1 nTPM (limit 6); urinary bladder: 40.3 nTPM (limit 6),adrenal gland / glandular cells: Low (Approved); bronchus / ciliated cells (cilia axoneme): High (Approved); bronchus / ciliated cells (tip of cilia): High (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Low (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: Low (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Low (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Low (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / ciliated cells (tip of cilia): Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: Low (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 141/141 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Pancreatic Adenocarcinoma (validation): 78/80 (97.5%),glioma: 11/11 (100.0%); testis cancer: 8/12 (66.7%),31,20,Q9BX67,https://www.uniprot.org/uniprotkb/Q9BX67/entry,"Junctional adhesion protein that mediates heterotypic cell-cell interactions with its cognate receptor JAM2 to regulate different cellular processes (PubMed:11590146, PubMed:11823489). Plays a role in homing and mobilization of hematopoietic stem and progenitor cells within the bone marrow. At the surface of bone marrow stromal cells, it contributes to the retention of the hematopoietic stem and progenitor cells expressing JAM3 (PubMed:11590146, PubMed:24357068). Plays a central role in leukocytes extravasation by facilitating transmigration through the endothelium (By similarity). Plays a role in spermatogenesis where JAM2 and JAM3, which are respectively expressed by Sertoli and germ cells, mediate an interaction between both cell types and play an essential role in the anchorage of germ cells onto Sertoli cells and the assembly of cell polarity complexes during spermatid differentiation (By similarity). Also functions as a counter-receptor for ITGAM, mediating leukocyte-platelet interactions and is involved in the regulation of transepithelial migration of polymorphonuclear neutrophils (PMN) (PubMed:12208882, PubMed:15194813). Plays a role in angiogenesis (PubMed:23255084). Plays a role in the regulation of cell migration (Probable). During myogenesis, it is involved in myocyte fusion (By similarity) Promotes chemotaxis of vascular endothelial cells and stimulates angiogenesis","Detected on round and elongated spermatids (at protein level) (PubMed:15372036). Highest expression in placenta, brain and kidney. Significant expression is detected on platelets. Expressed in intestinal mucosa cells. Expressed in the vascular endothelium. Found in serum (at protein level). Also detected in the synovial fluid of patients with rheumatoid arthritis, psoriatic arthritis or ostearthritis (at protein level)","Hemorrhagic destruction of the brain with subependymal calcification and cataracts: A syndrome characterized by congenital cataracts and severe brain abnormalities apparently resulting from hemorrhagic destruction of the brain parenchyma, including the cerebral white matter and basal ganglia. Patients manifest profound developmental delay, and other neurologic features included seizures, spasticity, and hyperreflexia. The clinical course is very severe resulting in death in infancy. Brain imaging shows multifocal intraparenchymal hemorrhage with associated liquefaction and massive cystic degeneration, and calcification in the subependymal region and in brain tissue.",,"Cell membrane Cell junction Cell junction, desmosome Cell junction, tight junction Secreted",11590146|11823489|12208882|15194813|20592283|23255084|24357068|28196865,11590146|11944976|12208882|15194813|15372036|15994945|20592283,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
JMJD1C,ENSG00000171988,Unsafe,Protein,False,True,22.2,38.3,80,65,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 14.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 11.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 2.2 nTPM; absolute ceiling; basal ganglia: 2.5 nTPM; absolute ceiling; bone marrow: 36.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 10.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 12.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 6.3 nTPM; absolute ceiling;continuous selectivity; colon: 10.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 15.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 11.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 11.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 2.3 nTPM; absolute ceiling; hypothalamus: 2.2 nTPM; absolute ceiling; kidney: 14.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 20.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 14.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 20.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 2.2 nTPM; absolute ceiling; pancreas: 12.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 20.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 2.3 nTPM; absolute ceiling; rectum: 11.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 38.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 12.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 6.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 10.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 17.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 14.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 2.2 nTPM; absolute ceiling; spleen: 19.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 13.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 18.7 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 19.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 12.4 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 14.5 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 14.9 nTPM (limit 10); adrenal gland: 11.5 nTPM (limit 2); amygdala: 2.2 nTPM (limit 2); basal ganglia: 2.5 nTPM (limit 2); bone marrow: 36.2 nTPM (limit 2); cerebellum: 10.6 nTPM (limit 2); cerebral cortex: 12.3 nTPM (limit 2); choroid plexus: 6.3 nTPM (limit 2); colon: 10.4 nTPM (limit 6); duodenum: 15.9 nTPM (limit 2); esophagus: 11.8 nTPM (limit 6); heart muscle: 11.1 nTPM (limit 2); hippocampal formation: 2.3 nTPM (limit 2); hypothalamus: 2.2 nTPM (limit 2); kidney: 14.2 nTPM (limit 2); liver: 20.5 nTPM (limit 2); lung: 14.6 nTPM (limit 2); lymph node: 20.7 nTPM (limit 6); midbrain: 2.2 nTPM (limit 2); pancreas: 12.1 nTPM (limit 2); parathyroid gland: 20.1 nTPM (limit 6); pituitary gland: 2.3 nTPM (limit 2); rectum: 11.4 nTPM (limit 6); retina: 38.3 nTPM (limit 2); salivary gland: 12.1 nTPM (limit 6); skeletal muscle: 6.8 nTPM (limit 2); skin: 10.4 nTPM (limit 10); small intestine: 17.6 nTPM (limit 2); smooth muscle: 14.3 nTPM (limit 2); spinal cord: 2.2 nTPM (limit 2); spleen: 19.6 nTPM (limit 10); stomach: 13.5 nTPM (limit 6); thymus: 18.7 nTPM (limit 10); thyroid gland: 19.1 nTPM (limit 10); tongue: 12.4 nTPM (limit 6); urinary bladder: 14.5 nTPM (limit 6),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%),testis cancer: 12/12 (100.0%); urothelial cancer: 12/12 (100.0%),31,20,Q15652,https://www.uniprot.org/uniprotkb/Q15652/entry,"Demethylates lysine in proteins, such as STAT3 or MDC1 (By similarity) (PubMed:24240613). Demethylates MDC1, thereby promoting MDC1-RNF8 interaction and facilitating RNF8-dependent MDC1 ubiquitination essential for double-strand break (DSB) repair (PubMed:24240613). Demethylation of STAT3 at 'Lys-140' facilitates its interactions with the phosphatase PTPN6 and restrains STAT3 activation (By similarity). It is uncertain whether JMJD1C removes methyl groups from histone proteins as the other JMJD1/KDM3 proteins do (PubMed:23593242, PubMed:24240613, PubMed:32034158). Nevertheless, JMJD1C may act as a context-specific histone demethylase. Implicated in lipogenic gene transcription in the liver, where USF1 recruits JMJD1C to lipogenic promoters in response to insulin or feeding stimuli, thereby potentially promoting H3K9me2 demethylation and enhancing chromatin accessibility (PubMed:32034158). Post-translational modifications may regulate JMJD1C's enzymatic activity, contributing to its context-specific functions (PubMed:32034158). Alternatively, JMJD1C may influence chromatin regulation indirectly, acting as a scaffold or co-regulator that recruits or stabilizes other active demethylase complexes modifying histone marks (PubMed:24240613). Plays an indispensable role in spermatogenesis (By similarity) Coactivator of androgen receptor",,,"It is uncertain whether JMJD1C removes methyl groups from histone proteins as the other JMJD/KDM3 proteins do. Independent studies show conflicting conclusions that either succeeded or failed to substantiate the existence of histone demethylase activity of JMJD1C (PubMed:23593242, PubMed:24240613, PubMed:32034158). This conflicting data suggests JMJD1C's role may be context-dependent. It may be possible that JMJD1C contributes to H3K9 demethylation in the very restricted regions of the genome",Nucleus,17353003|23593242|24240613|32034158,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
JMY,ENSG00000152409,Unsafe,Protein,False,True,12.9,12.9,79,61,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 4.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 4.1 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 5.1 nTPM; absolute ceiling;continuous selectivity; bone marrow: 10.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 7.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 6.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 3.1 nTPM; absolute ceiling; colon: 10.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 3.1 nTPM; positive ihc;absolute ceiling; esophagus: 4.8 nTPM; positive ihc;continuous selectivity; heart muscle: 4.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 4.2 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 4.3 nTPM; absolute ceiling;continuous selectivity; kidney: 6.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 5.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 3.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 4.1 nTPM; positive ihc; midbrain: 4.3 nTPM; absolute ceiling;continuous selectivity; pancreas: 9.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 11.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 4.7 nTPM; absolute ceiling;continuous selectivity; rectum: 4.2 nTPM; positive ihc; retina: 11.4 nTPM; absolute ceiling;continuous selectivity; salivary gland: 7.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 8.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 6.5 nTPM; positive ihc;continuous selectivity; small intestine: 4.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 7 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 4.8 nTPM; absolute ceiling;continuous selectivity; spleen: 4.8 nTPM; positive ihc; stomach: 5 nTPM; positive ihc;continuous selectivity; thyroid gland: 9.9 nTPM; positive ihc;continuous selectivity; tongue: 7.4 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 5.8 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 4.8 nTPM (limit 2); amygdala: 4.1 nTPM (limit 2); basal ganglia: 5.1 nTPM (limit 2); bone marrow: 10.2 nTPM (limit 2); cerebellum: 7.6 nTPM (limit 2); cerebral cortex: 6.3 nTPM (limit 2); choroid plexus: 3.1 nTPM (limit 2); colon: 10.5 nTPM (limit 6); duodenum: 3.1 nTPM (limit 2); heart muscle: 4.8 nTPM (limit 2); hippocampal formation: 4.2 nTPM (limit 2); hypothalamus: 4.3 nTPM (limit 2); kidney: 6.2 nTPM (limit 2); liver: 5.1 nTPM (limit 2); lung: 3.8 nTPM (limit 2); midbrain: 4.3 nTPM (limit 2); pancreas: 9.1 nTPM (limit 2); parathyroid gland: 11.1 nTPM (limit 6); pituitary gland: 4.7 nTPM (limit 2); retina: 11.4 nTPM (limit 2); salivary gland: 7.2 nTPM (limit 6); skeletal muscle: 8.6 nTPM (limit 2); small intestine: 4.3 nTPM (limit 2); smooth muscle: 7 nTPM (limit 2); spinal cord: 4.8 nTPM (limit 2); tongue: 7.4 nTPM (limit 6); adrenal gland: 4.8 nTPM (baseline 2); amygdala: 4.1 nTPM (baseline 2); basal ganglia: 5.1 nTPM (baseline 2); bone marrow: 10.2 nTPM (baseline 2); cerebellum: 7.6 nTPM (baseline 2); cerebral cortex: 6.3 nTPM (baseline 2); choroid plexus: 3.1 nTPM (baseline 2); colon: 10.5 nTPM (baseline 6); duodenum: 3.1 nTPM (baseline 2); heart muscle: 4.8 nTPM (baseline 2); hippocampal formation: 4.2 nTPM (baseline 2); hypothalamus: 4.3 nTPM (baseline 2); kidney: 6.2 nTPM (baseline 2); liver: 5.1 nTPM (baseline 2); lung: 3.8 nTPM (baseline 2); midbrain: 4.3 nTPM (baseline 2); pancreas: 9.1 nTPM (baseline 2); parathyroid gland: 11.1 nTPM (baseline 6); pituitary gland: 4.7 nTPM (baseline 2); retina: 11.4 nTPM (baseline 2); salivary gland: 7.2 nTPM (baseline 6); skeletal muscle: 8.6 nTPM (baseline 2); small intestine: 4.3 nTPM (baseline 2); smooth muscle: 7 nTPM (baseline 2); spinal cord: 4.8 nTPM (baseline 2); tongue: 7.4 nTPM (baseline 6),adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: High (Uncertain); caudate / glial cells: Low (Uncertain); cerebellum / cells in granular layer: Medium (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / endothelial cells: Medium (Uncertain); cerebral cortex / glial cells: Medium (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); colon / endothelial cells: High (Uncertain); colon / glandular cells: High (Uncertain); colon / peripheral nerve/ganglion: Medium (Uncertain); duodenum / glandular cells: High (Uncertain); esophagus / squamous epithelial cells: High (Uncertain); heart muscle / cardiomyocytes: Low (Uncertain); hippocampus / glial cells: Low (Uncertain); hippocampus / neuronal cells: Low (Uncertain); kidney / cells in glomeruli: Low (Uncertain); kidney / cells in tubules: High (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / alveolar cells: Low (Uncertain); lung / macrophages: Low (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); nasopharynx / respiratory epithelial cells: High (Uncertain); oral mucosa / squamous epithelial cells: High (Uncertain); pancreas / exocrine glandular cells: High (Uncertain); pancreas / pancreatic endocrine cells: Low (Uncertain); parathyroid gland / glandular cells: Low (Uncertain); rectum / glandular cells: High (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: Medium (Uncertain); skin 1 / keratinocytes: High (Uncertain); skin 1 / Langerhans: Medium (Uncertain); skin 2 / epidermal cells: High (Uncertain); small intestine / glandular cells: High (Uncertain); smooth muscle / smooth muscle cells: Low (Uncertain); spleen / cells in red pulp: Medium (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: High (Uncertain); thyroid gland / glandular cells: High (Uncertain); urinary bladder / urothelial cells: High (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 476/486 (97.9%); Pancreatic Adenocarcinoma (validation): 76/80 (95.0%),colorectal cancer: 11/11 (100.0%); cervical cancer: 10/11 (90.9%),31,20,Q8N9B5,https://www.uniprot.org/uniprotkb/Q8N9B5/entry,"Acts both as a nuclear p53/TP53-cofactor and a cytoplasmic regulator of actin dynamics depending on conditions (PubMed:30420355). In nucleus, acts as a cofactor that increases p53/TP53 response via its interaction with p300/EP300. Increases p53/TP53-dependent transcription and apoptosis, suggesting an important role in p53/TP53 stress response such as DNA damage. In cytoplasm, acts as a nucleation-promoting factor for both branched and unbranched actin filaments (PubMed:30420355). Activates the Arp2/3 complex to induce branched actin filament networks. Also catalyzes actin polymerization in the absence of Arp2/3, creating unbranched filaments (PubMed:30420355). Contributes to cell motility by controlling actin dynamics. May promote the rapid formation of a branched actin network by first nucleating new mother filaments and then activating Arp2/3 to branch off these filaments. Upon nutrient stress, directly recruited by MAP1LC3B to the phagophore membrane surfaces to promote actin assembly during autophagy (PubMed:30420355). The p53/TP53-cofactor and actin activator activities are regulated via its subcellular location (By similarity)",,,,"Nucleus Cytoplasmic vesicle Cytoplasm, cytoskeleton Endomembrane system Cytoplasmic vesicle, autophagosome membrane",30420355,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
KANSL1L,ENSG00000144445,Unsafe,Protein,False,True,24.6,192.4,77,53,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 11.2 nTPM; absolute ceiling;continuous selectivity; adrenal gland: 8 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 5.5 nTPM; absolute ceiling; basal ganglia: 5.9 nTPM; absolute ceiling; bone marrow: 5.5 nTPM; positive ihc;absolute ceiling; cerebellum: 8 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 5.2 nTPM; positive ihc;absolute ceiling; choroid plexus: 4.8 nTPM; absolute ceiling; colon: 9.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 6.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 6.7 nTPM; positive ihc;absolute ceiling; heart muscle: 9.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 5.9 nTPM; absolute ceiling; hypothalamus: 5.9 nTPM; absolute ceiling; kidney: 21.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 9.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 11.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 6.5 nTPM; positive ihc;absolute ceiling; midbrain: 5.7 nTPM; absolute ceiling; pancreas: 14.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 192.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 9.7 nTPM; absolute ceiling;continuous selectivity; rectum: 6.6 nTPM; positive ihc;absolute ceiling; retina: 12.2 nTPM; absolute ceiling;continuous selectivity; salivary gland: 9.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 11.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 12.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 6.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 12.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 6.9 nTPM; absolute ceiling;continuous selectivity; stomach: 12.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 26 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 19.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 17.7 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 13.2 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 11.2 nTPM (limit 10); adrenal gland: 8 nTPM (limit 2); amygdala: 5.5 nTPM (limit 2); basal ganglia: 5.9 nTPM (limit 2); bone marrow: 5.5 nTPM (limit 2); cerebellum: 8 nTPM (limit 2); cerebral cortex: 5.2 nTPM (limit 2); choroid plexus: 4.8 nTPM (limit 2); colon: 9.6 nTPM (limit 6); duodenum: 6.3 nTPM (limit 2); esophagus: 6.7 nTPM (limit 6); heart muscle: 9.4 nTPM (limit 2); hippocampal formation: 5.9 nTPM (limit 2); hypothalamus: 5.9 nTPM (limit 2); kidney: 21.9 nTPM (limit 2); liver: 9.1 nTPM (limit 2); lung: 11.5 nTPM (limit 2); lymph node: 6.5 nTPM (limit 6); midbrain: 5.7 nTPM (limit 2); pancreas: 14.7 nTPM (limit 2); parathyroid gland: 192.4 nTPM (limit 6); pituitary gland: 9.7 nTPM (limit 2); rectum: 6.6 nTPM (limit 6); retina: 12.2 nTPM (limit 2); salivary gland: 9.7 nTPM (limit 6); skeletal muscle: 11.6 nTPM (limit 2); skin: 12.9 nTPM (limit 10); small intestine: 6.6 nTPM (limit 2); smooth muscle: 12.8 nTPM (limit 2); spinal cord: 6.9 nTPM (limit 2); stomach: 12.2 nTPM (limit 6); thymus: 26 nTPM (limit 10); thyroid gland: 19.1 nTPM (limit 10); tongue: 17.7 nTPM (limit 6); urinary bladder: 13.2 nTPM (limit 6); adipose tissue: 11.2 nTPM (baseline 10); adrenal gland: 8 nTPM (baseline 2); amygdala: 5.5 nTPM (baseline 2); basal ganglia: 5.9 nTPM (baseline 2); bone marrow: 5.5 nTPM (baseline 2); cerebellum: 8 nTPM (baseline 2); cerebral cortex: 5.2 nTPM (baseline 2); choroid plexus: 4.8 nTPM (baseline 2); colon: 9.6 nTPM (baseline 6); duodenum: 6.3 nTPM (baseline 2); esophagus: 6.7 nTPM (baseline 6); heart muscle: 9.4 nTPM (baseline 2); hippocampal formation: 5.9 nTPM (baseline 2); hypothalamus: 5.9 nTPM (baseline 2); kidney: 21.9 nTPM (baseline 2); liver: 9.1 nTPM (baseline 2); lung: 11.5 nTPM (baseline 2); lymph node: 6.5 nTPM (baseline 6); midbrain: 5.7 nTPM (baseline 2); pancreas: 14.7 nTPM (baseline 2); parathyroid gland: 192.4 nTPM (baseline 6); pituitary gland: 9.7 nTPM (baseline 2); rectum: 6.6 nTPM (baseline 6); retina: 12.2 nTPM (baseline 2); salivary gland: 9.7 nTPM (baseline 6); skeletal muscle: 11.6 nTPM (baseline 2); skin: 12.9 nTPM (baseline 10); small intestine: 6.6 nTPM (baseline 2); smooth muscle: 12.8 nTPM (baseline 2); spinal cord: 6.9 nTPM (baseline 2); stomach: 12.2 nTPM (baseline 6); thymus: 26 nTPM (baseline 10); thyroid gland: 19.1 nTPM (baseline 10); tongue: 17.7 nTPM (baseline 6); urinary bladder: 13.2 nTPM (baseline 6),adrenal gland / glandular cells: High (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: Medium (Uncertain); cerebellum / cells in molecular layer: Medium (Uncertain); cerebellum / Purkinje cells: High (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: Medium (Uncertain); colon / glandular cells: High (Uncertain); duodenum / glandular cells: High (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in tubules: High (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / alveolar cells: Medium (Uncertain); lung / macrophages: High (Uncertain); lymph node / non-germinal center cells: Medium (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Low (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: High (Uncertain); salivary gland / glandular cells: Low (Uncertain); skeletal muscle / myocytes: Medium (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: High (Uncertain); smooth muscle / smooth muscle cells: High (Uncertain); stomach 1 / glandular cells: High (Uncertain); stomach 2 / glandular cells: High (Uncertain); thyroid gland / glandular cells: High (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%); Kidney Renal Clear Cell Carcinoma (validation): 100/100 (100.0%),colorectal cancer: 5/12 (41.7%); pancreatic cancer: 4/12 (33.3%),29,20,A0AUZ9,https://www.uniprot.org/uniprotkb/A0AUZ9/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
KANSL3,ENSG00000114982,Unsafe,Protein,False,True,14.5,32.7,96,60,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 11.4 nTPM; continuous selectivity; adrenal gland: 9.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 2.7 nTPM; absolute ceiling; basal ganglia: 3.6 nTPM; absolute ceiling; bone marrow: 14.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 2.9 nTPM; positive ihc;absolute ceiling; cerebral cortex: 7.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 7.1 nTPM; absolute ceiling;continuous selectivity; colon: 11.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 7 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 8.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 10.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 2.2 nTPM; absolute ceiling; hypothalamus: 2.2 nTPM; absolute ceiling; kidney: 8.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 6.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 9.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 8 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 2.9 nTPM; absolute ceiling; pancreas: 9.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 14.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 8.5 nTPM; absolute ceiling;continuous selectivity; rectum: 6.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 6.1 nTPM; absolute ceiling;continuous selectivity; salivary gland: 12.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 32.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 10.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 11.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 10.2 nTPM; absolute ceiling;continuous selectivity; spinal cord: 2.4 nTPM; absolute ceiling; spleen: 9.9 nTPM; positive ihc;continuous selectivity; stomach: 9.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 12.7 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 12.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 20.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 12.6 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 9.6 nTPM (limit 2); amygdala: 2.7 nTPM (limit 2); basal ganglia: 3.6 nTPM (limit 2); bone marrow: 14.7 nTPM (limit 2); cerebellum: 2.9 nTPM (limit 2); cerebral cortex: 7.9 nTPM (limit 2); choroid plexus: 7.1 nTPM (limit 2); colon: 11.4 nTPM (limit 6); duodenum: 7 nTPM (limit 2); esophagus: 8.6 nTPM (limit 6); heart muscle: 10.3 nTPM (limit 2); hippocampal formation: 2.2 nTPM (limit 2); hypothalamus: 2.2 nTPM (limit 2); kidney: 8.6 nTPM (limit 2); liver: 6.2 nTPM (limit 2); lung: 9.6 nTPM (limit 2); lymph node: 8 nTPM (limit 6); midbrain: 2.9 nTPM (limit 2); pancreas: 9.5 nTPM (limit 2); parathyroid gland: 14.6 nTPM (limit 6); pituitary gland: 8.5 nTPM (limit 2); rectum: 6.6 nTPM (limit 6); retina: 6.1 nTPM (limit 2); salivary gland: 12.2 nTPM (limit 6); skeletal muscle: 32.7 nTPM (limit 4); skin: 10.5 nTPM (limit 10); small intestine: 11.6 nTPM (limit 2); smooth muscle: 10.2 nTPM (limit 4); spinal cord: 2.4 nTPM (limit 2); stomach: 9.5 nTPM (limit 6); thymus: 12.7 nTPM (limit 10); thyroid gland: 12.5 nTPM (limit 10); tongue: 20.3 nTPM (limit 6); urinary bladder: 12.6 nTPM (limit 8),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / basal cells: Medium (Approved); bronchus / ciliated cells (cell body): Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuropil: Low (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / glial cells: Low (Approved); kidney / cells in tubules: High (Approved); liver / hepatocytes: Medium (Approved); lung / macrophages: Low (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / basal cells: Low (Approved); nasopharynx / ciliated cells (cell body): Medium (Approved); nasopharynx / goblet cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skin 1 / fibroblasts: Low (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 80/80 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Kidney Renal Clear Cell Carcinoma (validation): 97/100 (97.0%),prostate cancer: 11/12 (91.7%); liver cancer: 9/11 (81.8%),29,20,Q9P2N6,https://www.uniprot.org/uniprotkb/Q9P2N6/entry,"Non-catalytic component of the NSL histone acetyltransferase complex, a multiprotein complex that mediates histone H4 acetylation at 'Lys-5'- and 'Lys-8' (H4K5ac and H4K8ac) at transcription start sites and promotes transcription initiation (PubMed:20018852, PubMed:33657400). The NSL complex also acts as a regulator of gene expression in mitochondria (PubMed:27768893). Within the NSL complex, KANSL3 is required to promote KAT8 association with mitochondrial DNA (PubMed:27768893). Required for transcription of intraciliary transport genes in both ciliated and non-ciliated cells (By similarity). This is necessary for cilium assembly in ciliated cells and for organization of the microtubule cytoskeleton in non-ciliated cells (By similarity). Also required within the NSL complex to maintain nuclear architecture stability by promoting KAT8-mediated acetylation of lamin LMNA (By similarity). Plays an essential role in spindle assembly during mitosis (PubMed:26243146). Acts as a microtubule minus-end binding protein which stabilizes microtubules and promotes their assembly (PubMed:26243146). Indispensable during early embryonic development where it is required for proper lineage specification and maintenance during peri-implantation development and is essential for implantation (By similarity)",,,,"Nucleus Mitochondrion Cytoplasm, cytoskeleton, spindle pole",20018852|26243146|27768893|33657400,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
KASH5,ENSG00000161609,Unsafe,Protein,False,True,53.0,53.0,86,66,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 0 nTPM; positive ihc; bone marrow: 0 nTPM; positive ihc; cerebellum: 11.5 nTPM; positive ihc;absolute ceiling; cerebral cortex: 0 nTPM; positive ihc; colon: 0 nTPM; positive ihc; duodenum: 0 nTPM; positive ihc; esophagus: 0 nTPM; positive ihc; heart muscle: 0 nTPM; positive ihc; kidney: 0 nTPM; positive ihc; liver: 0 nTPM; positive ihc; lung: 0.1 nTPM; positive ihc; lymph node: 0 nTPM; positive ihc; pancreas: 1.9 nTPM; positive ihc; parathyroid gland: 0 nTPM; positive ihc; rectum: 0 nTPM; positive ihc; retina: 7.2 nTPM; absolute ceiling; salivary gland: 0 nTPM; positive ihc; skeletal muscle: 0 nTPM; positive ihc; skin: 0 nTPM; positive ihc; small intestine: 0 nTPM; positive ihc; smooth muscle: 0 nTPM; positive ihc; stomach: 0 nTPM; positive ihc; thyroid gland: 0 nTPM; positive ihc; urinary bladder: 0 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",cerebellum: 11.5 nTPM (limit 2); retina: 7.2 nTPM (limit 2),adrenal gland / glandular cells: Medium (Enhanced); bone marrow / hematopoietic cells: Low (Enhanced); bronchus / respiratory epithelial cells: Medium (Enhanced); caudate / neuronal cells: Low (Enhanced); cerebellum / cells in granular layer: Medium (Enhanced); cerebellum / cells in molecular layer: Medium (Enhanced); cerebellum / Purkinje cells: Medium (Enhanced); cerebral cortex / endothelial cells: Low (Enhanced); cerebral cortex / glial cells: Low (Enhanced); cerebral cortex / neuronal cells: High (Enhanced); colon / endothelial cells: Medium (Enhanced); colon / glandular cells: Medium (Enhanced); colon / peripheral nerve/ganglion: Medium (Enhanced); duodenum / glandular cells: Medium (Enhanced); esophagus / squamous epithelial cells: Low (Enhanced); heart muscle / cardiomyocytes: Medium (Enhanced); hippocampus / glial cells: Low (Enhanced); hippocampus / neuronal cells: Medium (Enhanced); kidney / cells in glomeruli: Medium (Enhanced); kidney / cells in tubules: Medium (Enhanced); liver / hepatocytes: Medium (Enhanced); lung / macrophages: Medium (Enhanced); lymph node / non-germinal center cells: Low (Enhanced); nasopharynx / respiratory epithelial cells: Medium (Enhanced); pancreas / exocrine glandular cells: Low (Enhanced); pancreas / pancreatic endocrine cells: Medium (Enhanced); parathyroid gland / glandular cells: High (Enhanced); rectum / glandular cells: High (Enhanced); salivary gland / glandular cells: Low (Enhanced); skeletal muscle / myocytes: Medium (Enhanced); skin 1 / fibroblasts: Low (Enhanced); skin 1 / keratinocytes: Low (Enhanced); skin 1 / Langerhans: Medium (Enhanced); skin 2 / epidermal cells: Medium (Enhanced); small intestine / glandular cells: Medium (Enhanced); smooth muscle / smooth muscle cells: Medium (Enhanced); stomach 1 / glandular cells: Medium (Enhanced); stomach 2 / glandular cells: Medium (Enhanced); thyroid gland / glandular cells: Medium (Enhanced); urinary bladder / urothelial cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 13/133 (9.8%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 11/283 (3.9%); Uterine Corpus Endometrial Carcinoma (TCGA): 3/176 (1.7%),ovarian cancer: 5/12 (41.7%); renal cancer: 5/12 (41.7%),29,20,Q8N6L0,https://www.uniprot.org/uniprotkb/Q8N6L0/entry,"As a component of the LINC (LInker of Nucleoskeleton and Cytoskeleton) complex, involved in the connection between the nuclear lamina and the cytoskeleton. The nucleocytoplasmic interactions established by the LINC complex play an important role in the transmission of mechanical forces across the nuclear envelope and in nuclear movement and positioning. Required for telomere attachment to nuclear envelope in the prophase of meiosis (PubMed:35587281). Required for rapid telomere prophase movements implicating a SUN1/2:KASH5 LINC complex in which SUN1 and SUN2 seem to act at least partial redundantly. Required for homolog pairing during meiotic prophase in spermatocytes and probably oocytes. Essential for male and female gametogenesis (PubMed:35587281). Recruits cytoplasmic dynein to telomere attachment sites at the nuclear envelope in spermatocytes. In oocytes is involved in meiotic resumption and spindle formation",Expressed in testis (at protein level),"Spermatogenic failure 88: An autosomal recessive male infertility disorder characterized by non-obstructive azoospermia due to primary spermatogenic arrest. Premature ovarian failure 22: A form of premature ovarian failure, an ovarian disorder defined as the cessation of ovarian function under the age of 40 years. It is characterized by oligomenorrhea or amenorrhea, in the presence of elevated levels of serum gonadotropins and low estradiol. POF22 is an autosomal recessive form characterized by infertility, and small to atrophic ovaries and no visible ovarian follicles.",,"Nucleus outer membrane Nucleus Chromosome, telomere Nucleus envelope",35587281,35587281|35674372,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
KATNAL1,ENSG00000102781,Unsafe,RNA,False,True,20.2,20.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 3.7 nTPM; absolute ceiling; amygdala: 4.7 nTPM; absolute ceiling; basal ganglia: 4.3 nTPM; absolute ceiling; bone marrow: 6.4 nTPM; absolute ceiling;continuous selectivity; cerebellum: 5.8 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 9.6 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 2.5 nTPM; absolute ceiling; colon: 8.4 nTPM; absolute ceiling;continuous selectivity; heart muscle: 17.3 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 5.2 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 6 nTPM; absolute ceiling;continuous selectivity; kidney: 3.9 nTPM; absolute ceiling; liver: 3.8 nTPM; absolute ceiling; lung: 4.8 nTPM; absolute ceiling; lymph node: 6.4 nTPM; absolute ceiling; midbrain: 5.6 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 2.9 nTPM; absolute ceiling; retina: 7.6 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 4.9 nTPM; absolute ceiling; small intestine: 2.7 nTPM; absolute ceiling; smooth muscle: 14.4 nTPM; absolute ceiling;continuous selectivity; spinal cord: 7.2 nTPM; absolute ceiling;continuous selectivity; thymus: 9 nTPM; continuous selectivity; tongue: 6.3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 3.7 nTPM (limit 2); amygdala: 4.7 nTPM (limit 2); basal ganglia: 4.3 nTPM (limit 2); bone marrow: 6.4 nTPM (limit 2); cerebellum: 5.8 nTPM (limit 2); cerebral cortex: 9.6 nTPM (limit 2); choroid plexus: 2.5 nTPM (limit 2); colon: 8.4 nTPM (limit 6); heart muscle: 17.3 nTPM (limit 2); hippocampal formation: 5.2 nTPM (limit 2); hypothalamus: 6 nTPM (limit 2); kidney: 3.9 nTPM (limit 2); liver: 3.8 nTPM (limit 2); lung: 4.8 nTPM (limit 2); lymph node: 6.4 nTPM (limit 6); midbrain: 5.6 nTPM (limit 2); pituitary gland: 2.9 nTPM (limit 2); retina: 7.6 nTPM (limit 2); skeletal muscle: 4.9 nTPM (limit 2); small intestine: 2.7 nTPM (limit 2); smooth muscle: 14.4 nTPM (limit 2); spinal cord: 7.2 nTPM (limit 2); tongue: 6.3 nTPM (limit 6); adrenal gland: 3.7 nTPM (baseline 2); amygdala: 4.7 nTPM (baseline 2); basal ganglia: 4.3 nTPM (baseline 2); bone marrow: 6.4 nTPM (baseline 2); cerebellum: 5.8 nTPM (baseline 2); cerebral cortex: 9.6 nTPM (baseline 2); choroid plexus: 2.5 nTPM (baseline 2); colon: 8.4 nTPM (baseline 6); heart muscle: 17.3 nTPM (baseline 2); hippocampal formation: 5.2 nTPM (baseline 2); hypothalamus: 6 nTPM (baseline 2); kidney: 3.9 nTPM (baseline 2); liver: 3.8 nTPM (baseline 2); lung: 4.8 nTPM (baseline 2); lymph node: 6.4 nTPM (baseline 6); midbrain: 5.6 nTPM (baseline 2); pituitary gland: 2.9 nTPM (baseline 2); retina: 7.6 nTPM (baseline 2); skeletal muscle: 4.9 nTPM (baseline 2); small intestine: 2.7 nTPM (baseline 2); smooth muscle: 14.4 nTPM (baseline 2); spinal cord: 7.2 nTPM (baseline 2); tongue: 6.3 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 46/50 (92.0%); Pancreatic Adenocarcinoma (validation): 70/80 (87.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9BW62,https://www.uniprot.org/uniprotkb/Q9BW62/entry,"Regulates microtubule dynamics in Sertoli cells, a process that is essential for spermiogenesis and male fertility. Severs microtubules in an ATP-dependent manner, promoting rapid reorganization of cellular microtubule arrays (By similarity). Has microtubule-severing activity in vitro (PubMed:26929214)","Expressed in testis, restricted to Sertoli cells (at protein level)",,,"Cytoplasm, cytoskeleton Cytoplasm Cytoplasm, cytoskeleton, spindle pole Cytoplasm, cytoskeleton, spindle",26929214,22654668,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
KBTBD8,ENSG00000163376,Unsafe,Protein,False,True,7.6,20.1,81,39,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 1.1 nTPM; positive ihc; bone marrow: 13.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 1.2 nTPM; positive ihc; colon: 2.3 nTPM; positive ihc; duodenum: 1.7 nTPM; positive ihc; heart muscle: 3.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; kidney: 0.6 nTPM; positive ihc; lung: 2.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 19.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 0.3 nTPM; positive ihc; rectum: 1.9 nTPM; positive ihc; salivary gland: 0.8 nTPM; positive ihc; skin: 0.5 nTPM; positive ihc; small intestine: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; spleen: 5.6 nTPM; positive ihc;continuous selectivity; stomach: 2.1 nTPM; positive ihc; thymus: 3.5 nTPM; continuous selectivity; thyroid gland: 0.8 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 13.7 nTPM (limit 2); heart muscle: 3.7 nTPM (limit 2); lung: 2.1 nTPM (limit 2); lymph node: 19.9 nTPM (limit 6); small intestine: 2.7 nTPM (limit 2),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Low (Approved); caudate / glial cells: Low (Approved); cerebellum / cells in granular layer: Medium (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); heart muscle / cardiomyocytes: Low (Approved); kidney / cells in tubules: Low (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Medium (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Low (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 56/58 (96.6%); Breast Invasive Carcinoma (validation): 15/50 (30.0%); Rectum Adenocarcinoma (validation): 52/207 (25.1%),lymphoma: 7/11 (63.6%); stomach cancer: 7/11 (63.6%),31,20,Q8NFY9,https://www.uniprot.org/uniprotkb/Q8NFY9/entry,"Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin ligase complex that acts as a regulator of neural crest specification (PubMed:26399832). The BCR(KBTBD8) complex acts by mediating monoubiquitination of NOLC1 and TCOF1: monoubiquitination promotes the formation of a NOLC1-TCOF1 complex that acts as a platform to connect RNA polymerase I with enzymes responsible for ribosomal processing and modification, leading to remodel the translational program of differentiating cells in favor of neural crest specification (PubMed:26399832)",,,,"Cytoplasm, cytoskeleton, spindle Golgi apparatus",26399832,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
KCNA3,ENSG00000177272,Unsafe,Protein,False,True,0.3,2.5,81,4,Positive somewhere,True,True,False,False,Excluded,Normal,False,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 0.4 nTPM; continuous selectivity;reproductive not higher; amygdala: 0.3 nTPM; continuous selectivity;reproductive not higher; basal ganglia: 0.9 nTPM; continuous selectivity;reproductive not higher; cerebellum: 0.6 nTPM; positive ihc;continuous selectivity;reproductive not higher; cerebral cortex: 0.5 nTPM; positive ihc;continuous selectivity;reproductive not higher; colon: 0.6 nTPM; continuous selectivity;reproductive not higher; heart muscle: 0.2 nTPM; continuous selectivity; hippocampal formation: 0.3 nTPM; continuous selectivity;reproductive not higher; hypothalamus: 1.1 nTPM; continuous selectivity;reproductive not higher; kidney: 0.2 nTPM; continuous selectivity; liver: 0.2 nTPM; continuous selectivity; lung: 2.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 0.2 nTPM; continuous selectivity; pituitary gland: 0.4 nTPM; continuous selectivity;reproductive not higher; salivary gland: 0.8 nTPM; continuous selectivity;reproductive not higher; small intestine: 1.9 nTPM; continuous selectivity;reproductive not higher; spinal cord: 0.3 nTPM; continuous selectivity;reproductive not higher; spleen: 2.5 nTPM; continuous selectivity;reproductive not higher; stomach: 0.4 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 0.5 nTPM; continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",; lung: 2.1 nTPM (baseline 2),caudate / glial cells: Medium (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebral cortex / glial cells: Medium (Approved); hippocampus / glial cells: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 31/58 (53.4%); Rectum Adenocarcinoma (validation): 108/207 (52.2%); Lung Adenocarcinoma (validation): 51/105 (48.6%),glioma: 4/11 (36.4%); cervical cancer: 1/12 (8.3%),31,20,P22001,https://www.uniprot.org/uniprotkb/P22001/entry,"Mediates the voltage-dependent potassium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a potassium-selective channel through which potassium ions may pass in accordance with their electrochemical gradient Lacks voltage-gated potassium channel activity",,,,"Cell membrane Cytoplasm, perinuclear region",1373731|1547020|1986382|36852591,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
KCNH5,ENSG00000140015,Unsafe,RNA,False,True,0.3,4.3,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,adrenal gland: 1 nTPM; continuous selectivity;reproductive not higher; amygdala: 0.6 nTPM; continuous selectivity;reproductive not higher; cerebral cortex: 2.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 0.5 nTPM; continuous selectivity;reproductive not higher; hippocampal formation: 0.3 nTPM; continuous selectivity;reproductive not higher; hypothalamus: 1 nTPM; continuous selectivity;reproductive not higher; midbrain: 0.3 nTPM; continuous selectivity;reproductive not higher; pituitary gland: 0.3 nTPM; continuous selectivity;reproductive not higher; retina: 4.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 0.2 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebral cortex: 2.3 nTPM (limit 2); retina: 4.3 nTPM (limit 2); cerebral cortex: 2.3 nTPM (baseline 2); retina: 4.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 6/58 (10.3%); Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%); Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%),lung cancer: 2/11 (18.2%); ovarian cancer: 2/11 (18.2%),31,20,Q8NCM2,https://www.uniprot.org/uniprotkb/Q8NCM2/entry,"Pore-forming (alpha) subunit of a voltage-gated delayed rectifier potassium channel that mediates outward-rectifying potassium currents which, on depolarization, reaches a steady-state level and do not inactivate (PubMed:11943152, PubMed:12135768, PubMed:24133262, PubMed:36928654). The kinetic is characterized by a slow activation time course and a small voltage dependence of the activation time constants, therefore, starts to open at more negative voltages (PubMed:11943152, PubMed:12135768). The activation kinetics depend on the prepulse potential and external divalent cation concentration (PubMed:11943152, PubMed:24133262). The time course of activation is biphasic with a fast and a slowly activating current component (PubMed:11943152, PubMed:12135768, PubMed:36928654). With negative prepulses, the current activation is delayed and slowed down several fold, whereas more positive prepulses speed up activation, therefore the activation rate depends on holding potential (PubMed:11943152, PubMed:12135768, PubMed:36928654)","Detected in brain, skeletal muscle, heart, placenta, lung and liver, and at low levels in kidney","Developmental and epileptic encephalopathy 112: A form of epileptic encephalopathy, a heterogeneous group of early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE112 is an autosomal dominant form characterized by onset in infancy, and a wide range of seizure types including focal and generalized seizures. Cognitive outcomes range from normal intellect to profound intellectual development impairment.",,Membrane,11943152|12135768|24133262|36928654,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
KCNJ14,ENSG00000182324,Unsafe,RNA,False,True,1.3,56.9,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 0.8 nTPM; continuous selectivity; amygdala: 1 nTPM; continuous selectivity; basal ganglia: 4.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 2 nTPM; continuous selectivity;reproductive not higher; cerebellum: 1.7 nTPM; continuous selectivity;reproductive not higher; cerebral cortex: 1.7 nTPM; continuous selectivity;reproductive not higher; esophagus: 1.2 nTPM; continuous selectivity; hippocampal formation: 1.3 nTPM; continuous selectivity;reproductive not higher; hypothalamus: 1.1 nTPM; continuous selectivity; kidney: 0.8 nTPM; continuous selectivity; liver: 0.9 nTPM; continuous selectivity; lung: 0.7 nTPM; continuous selectivity; midbrain: 1.2 nTPM; continuous selectivity; pancreas: 0.6 nTPM; continuous selectivity; pituitary gland: 0.9 nTPM; continuous selectivity; retina: 56.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 0.6 nTPM; continuous selectivity; skeletal muscle: 1.6 nTPM; continuous selectivity;reproductive not higher; skin: 2.1 nTPM; continuous selectivity;reproductive not higher; small intestine: 0.5 nTPM; continuous selectivity; spinal cord: 0.6 nTPM; continuous selectivity; thyroid gland: 1.2 nTPM; continuous selectivity; urinary bladder: 0.6 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,basal ganglia: 4.5 nTPM (limit 2); retina: 56.9 nTPM (limit 2); basal ganglia: 4.5 nTPM (baseline 2); retina: 56.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 16/50 (32.0%); Glioblastoma Multiforme (validation): 16/58 (27.6%); Uterine Corpus Endometrial Carcinoma (TCGA): 18/176 (10.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9UNX9,https://www.uniprot.org/uniprotkb/Q9UNX9/entry,"Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages",Expressed preferentially in retina,,,Membrane,10942728,10942728,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
KCNK13,ENSG00000152315,Unsafe,Protein,False,True,9.0,9.0,82,3,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; cerebral cortex: 1.3 nTPM; positive ihc; choroid plexus: 4.3 nTPM; absolute ceiling;continuous selectivity; kidney: 3.8 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 5.8 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 4.3 nTPM (limit 2); choroid plexus: 4.3 nTPM (baseline 2); kidney: 3.8 nTPM (baseline 2),caudate / glial cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); hippocampus / glial cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 28/58 (48.3%); Testicular Germ Cell Tumor (TCGA): 64/133 (48.1%); Thyroid Carcinoma (TCGA): 185/495 (37.4%),glioma: 1/12 (8.3%); breast cancer: 0/12 (0.0%),31,20,Q9HB14,https://www.uniprot.org/uniprotkb/Q9HB14/entry,"K(+) channel that conducts outward rectifying tonic currents potentiated by purinergic signals (PubMed:24163367, PubMed:25148687, PubMed:30472253, PubMed:38409076). Homo- and heterodimerizes to form functional channels with distinct regulatory and gating properties (PubMed:25148687, PubMed:40011745, PubMed:40011746, PubMed:40307591, PubMed:40178898). Contributes most of K(+) currents at the plasma membrane of resting microglia (PubMed:38409076). Maintains a depolarized membrane potential required for proper ramified microglia morphology and phagocytosis, selectively mediating microglial pruning of presynaptic compartments at hippocampal excitatory synapses (PubMed:38409076). Upon local release of ATP caused by neuronal injury or infection, it is potentiated by P2RY12 and P2RX7 receptor signaling and contributes to ATP-triggered K(+) efflux underlying microglial NLRP3 inflammasome assembly and IL1B release (PubMed:38409076)",Expressed in microglia (at protein level),,,Cell membrane,24163367|25148687|30472253|38409076|40011745|40011746|40178898|40307591,38409076,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
KCNMB2,ENSG00000197584,Unsafe,Protein,False,True,34.5,34.5,81,54,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 5 nTPM; positive ihc;absolute ceiling; amygdala: 3.7 nTPM; absolute ceiling; bone marrow: 0 nTPM; positive ihc; cerebellum: 0.6 nTPM; positive ihc; cerebral cortex: 4.8 nTPM; positive ihc;absolute ceiling; colon: 1.1 nTPM; positive ihc; duodenum: 0.5 nTPM; positive ihc; esophagus: 0.4 nTPM; positive ihc; heart muscle: 5.6 nTPM; positive ihc;absolute ceiling; hippocampal formation: 4.9 nTPM; absolute ceiling; hypothalamus: 2.6 nTPM; absolute ceiling; kidney: 3.3 nTPM; positive ihc;absolute ceiling; liver: 0.2 nTPM; positive ihc; lung: 1.1 nTPM; positive ihc; lymph node: 0 nTPM; positive ihc; midbrain: 2.4 nTPM; absolute ceiling; pancreas: 3.9 nTPM; positive ihc;absolute ceiling; rectum: 0.3 nTPM; positive ihc; salivary gland: 0.2 nTPM; positive ihc; skin: 0.3 nTPM; positive ihc; small intestine: 0.5 nTPM; positive ihc; stomach: 2.9 nTPM; positive ihc; thyroid gland: 0.2 nTPM; positive ihc; urinary bladder: 0.1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 5 nTPM (limit 2); amygdala: 3.7 nTPM (limit 2); cerebral cortex: 4.8 nTPM (limit 2); heart muscle: 5.6 nTPM (limit 2); hippocampal formation: 4.9 nTPM (limit 2); hypothalamus: 2.6 nTPM (limit 2); kidney: 3.3 nTPM (limit 2); midbrain: 2.4 nTPM (limit 2); pancreas: 3.9 nTPM (limit 2); adrenal gland: 5 nTPM (baseline 2); amygdala: 3.7 nTPM (baseline 2); cerebral cortex: 4.8 nTPM (baseline 2); heart muscle: 5.6 nTPM (baseline 2); hippocampal formation: 4.9 nTPM (baseline 2); hypothalamus: 2.6 nTPM (baseline 2); kidney: 3.3 nTPM (baseline 2); midbrain: 2.4 nTPM (baseline 2); pancreas: 3.9 nTPM (baseline 2),adrenal gland / glandular cells: Low (Uncertain); bone marrow / hematopoietic cells: Low (Uncertain); bronchus / respiratory epithelial cells: Low (Uncertain); caudate / glial cells: Low (Uncertain); cerebellum / cells in molecular layer: Low (Uncertain); cerebral cortex / glial cells: Low (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / endothelial cells: Low (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: Low (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: Low (Uncertain); hippocampus / neuronal cells: Low (Uncertain); kidney / cells in tubules: Low (Uncertain); liver / cholangiocytes: Low (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / germinal center cells: Low (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Low (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skin 1 / keratinocytes: Low (Uncertain); skin 1 / Langerhans: Low (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: Medium (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Low (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 24/58 (41.4%); Pancreatic Adenocarcinoma (TCGA): 37/176 (21.0%); Ovary Serous Cystadenocarcinoma (TCGA): 73/349 (20.9%),prostate cancer: 8/12 (66.7%); breast cancer: 6/12 (50.0%),31,20,Q9Y691,https://www.uniprot.org/uniprotkb/Q9Y691/entry,"Regulatory subunit of the calcium activated potassium KCNMA1 (maxiK) channel. Modulates the calcium sensitivity and gating kinetics of KCNMA1, thereby contributing to KCNMA1 channel diversity. Acts as a negative regulator that confers rapid and complete inactivation of KCNMA1 channel complex. May participate in KCNMA1 inactivation in chromaffin cells of the adrenal gland or in hippocampal CA1 neurons","Expressed in kidney, heart and brain. Highly expressed in ovary. Expressed at low level in other tissues",,,Membrane,10097176|10377337,10097176|10377337|10692449,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
KCNMB3,ENSG00000171121,Unsafe,Protein,False,True,4.5,7.6,77,26,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 4.7 nTPM; continuous selectivity;reproductive not higher; adrenal gland: 3.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 4.3 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 4.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 7.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 6.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 2.2 nTPM; absolute ceiling;continuous selectivity; colon: 3.9 nTPM; positive ihc;continuous selectivity; duodenum: 1.6 nTPM; positive ihc;continuous selectivity; esophagus: 2 nTPM; positive ihc;continuous selectivity; heart muscle: 3.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 5.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 4.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 4.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 5.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 2.9 nTPM; continuous selectivity; lymph node: 2.4 nTPM; continuous selectivity; midbrain: 4.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 5.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 3.2 nTPM; absolute ceiling;continuous selectivity; rectum: 1.7 nTPM; positive ihc;continuous selectivity; retina: 2.8 nTPM; absolute ceiling;continuous selectivity; salivary gland: 3 nTPM; continuous selectivity; skin: 2.3 nTPM; positive ihc;continuous selectivity; small intestine: 3.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 4 nTPM; absolute ceiling;continuous selectivity; spleen: 7.3 nTPM; continuous selectivity;reproductive not higher; stomach: 3.6 nTPM; positive ihc;continuous selectivity; thyroid gland: 3.1 nTPM; continuous selectivity; urinary bladder: 3.6 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 3.5 nTPM (limit 2); amygdala: 4.3 nTPM (limit 2); basal ganglia: 4.6 nTPM (limit 2); cerebellum: 7.6 nTPM (limit 4); cerebral cortex: 6.6 nTPM (limit 4); choroid plexus: 2.2 nTPM (limit 2); heart muscle: 3.4 nTPM (limit 2); hippocampal formation: 5.5 nTPM (limit 2); hypothalamus: 4.8 nTPM (limit 2); kidney: 4.6 nTPM (limit 2); liver: 5.4 nTPM (limit 2); midbrain: 4.8 nTPM (limit 2); pancreas: 5.1 nTPM (limit 2); pituitary gland: 3.2 nTPM (limit 2); retina: 2.8 nTPM (limit 2); small intestine: 3.4 nTPM (limit 2); spinal cord: 4 nTPM (limit 2),adrenal gland / glandular cells: Medium (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: High (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Low (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); rectum / glandular cells: High (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: High (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: High (Approved); urinary bladder / urothelial cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 43/50 (86.0%); Liver Hepatocellular Carcinoma (validation): 84/231 (36.4%); Pancreatic Adenocarcinoma (validation): 17/80 (21.2%),colorectal cancer: 8/11 (72.7%); stomach cancer: 7/10 (70.0%),31,20,Q9NPA1,https://www.uniprot.org/uniprotkb/Q9NPA1/entry,"Regulatory subunit of the calcium activated potassium KCNMA1 (maxiK) channel. Modulates the calcium sensitivity and gating kinetics of KCNMA1, thereby contributing to KCNMA1 channel diversity. Alters the functional properties of the current expressed by the KCNMA1 channel. Isoform 2, isoform 3 and isoform 4 partially inactivate the current of KCNBMA. Isoform 4 induces a fast and incomplete inactivation of KCNMA1 channel that is detectable only at large depolarizations. In contrast, isoform 1 does not induce detectable inactivation of KCNMA1. Two or more subunits of KCNMB3 are required to block the KCNMA1 tetramer","Isoform 1, isoform 3 and isoform 4 are widely expressed. Isoform 2 is expressed placenta, pancreas, kidney and heart. Isoform 1 and isoform 3 are highly expressed in pancreas and testis",,,Membrane,10766764|10864947,10585773|10692449|10766764,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
KCNV2,ENSG00000168263,Unsafe,Protein,False,True,4.7,280.3,87,1,Positive somewhere,True,True,False,False,Excluded,Normal,False,,Not assessed,,,positive ihc outside permitted; retina: 280.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",retina: 280.3 nTPM (limit 2); retina: 280.3 nTPM (baseline 2),retina / photoreceptor cells: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 62/133 (46.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Ovary Serous Cystadenocarcinoma (TCGA): 1/349 (0.3%),pancreatic cancer: 1/10 (10.0%); breast cancer: 0/8 (0.0%),31,20,Q8TDN2,https://www.uniprot.org/uniprotkb/Q8TDN2/entry,Potassium channel subunit. Modulates channel activity by shifting the threshold and the half-maximal activation to more negative values,"Detected in lung, liver, kidney, pancreas, spleen, thymus, prostate, testis, ovary and colon","Cone dystrophy with supernormal rod responses: An autosomal recessive ocular disorder characterized by macular dysfunction, reduced and delayed cone responses, and supernormal and delayed rod responses. The onset of symptoms is in the first and second decades of life, and patients have reduced central vision, marked photophobia, reduced color discrimination predominantly along the red-green axes while tritan color vision is relatively well preserved. Nyctalopia is a later feature of the disorder.",,Cell membrane,,12060745,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Jamin2021_CT | Jamin2021_core | Chang2019_TGCT | Carter2023_CT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene,,,,,,,,
KCTD19,ENSG00000168676,Unsafe,RNA,False,True,32.0,32.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 3.3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 3.3 nTPM (limit 2); bone marrow: 3.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 27/283 (9.5%); Testicular Germ Cell Tumor (TCGA): 12/133 (9.0%); Pancreatic Adenocarcinoma (validation): 5/80 (6.2%),pancreatic cancer: 4/10 (40.0%); melanoma: 4/11 (36.4%),31,20,Q17RG1,https://www.uniprot.org/uniprotkb/Q17RG1/entry,Transcription regulator which is essential for male fertility and for the completion of meiotic prophase in spermatocytes. Regulates progression of the pachytene stage of meiotic prophase and promotes the transcriptional activation activity ZNF541. Required for the organization of chromosomes during metaphase I,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
KDM4C,ENSG00000107077,Unsafe,RNA,False,True,11.6,38.3,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 9.7 nTPM; continuous selectivity; adrenal gland: 9.3 nTPM; absolute ceiling;continuous selectivity; amygdala: 6.8 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 7.6 nTPM; absolute ceiling;continuous selectivity; bone marrow: 29.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 38.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 7.6 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 16.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 13.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 12.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 9.9 nTPM; absolute ceiling;continuous selectivity; heart muscle: 7.5 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 8 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 8.5 nTPM; absolute ceiling;continuous selectivity; kidney: 8.4 nTPM; absolute ceiling;continuous selectivity; liver: 10.7 nTPM; absolute ceiling;continuous selectivity; lung: 10.3 nTPM; absolute ceiling;continuous selectivity; lymph node: 18.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 7.2 nTPM; absolute ceiling;continuous selectivity; pancreas: 15.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 17.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 11.5 nTPM; absolute ceiling;continuous selectivity; rectum: 15.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; retina: 28 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 11.3 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 8 nTPM; absolute ceiling;continuous selectivity; skin: 14.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 14 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 10.4 nTPM; absolute ceiling;continuous selectivity; spinal cord: 9.6 nTPM; absolute ceiling;continuous selectivity; spleen: 13.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; stomach: 14.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thymus: 23 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 13 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; tongue: 5.8 nTPM; continuous selectivity; urinary bladder: 9.9 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 9.3 nTPM (limit 2); amygdala: 6.8 nTPM (limit 2); basal ganglia: 7.6 nTPM (limit 2); bone marrow: 29.7 nTPM (limit 2); cerebellum: 38.3 nTPM (limit 2); cerebral cortex: 7.6 nTPM (limit 2); choroid plexus: 16.3 nTPM (limit 2); colon: 13.3 nTPM (limit 6); duodenum: 12.7 nTPM (limit 2); esophagus: 9.9 nTPM (limit 6); heart muscle: 7.5 nTPM (limit 2); hippocampal formation: 8 nTPM (limit 2); hypothalamus: 8.5 nTPM (limit 2); kidney: 8.4 nTPM (limit 2); liver: 10.7 nTPM (limit 2); lung: 10.3 nTPM (limit 2); lymph node: 18.7 nTPM (limit 6); midbrain: 7.2 nTPM (limit 2); pancreas: 15.6 nTPM (limit 2); parathyroid gland: 17.2 nTPM (limit 6); pituitary gland: 11.5 nTPM (limit 2); rectum: 15.6 nTPM (limit 6); retina: 28 nTPM (limit 2); salivary gland: 11.3 nTPM (limit 6); skeletal muscle: 8 nTPM (limit 2); skin: 14.7 nTPM (limit 10); small intestine: 14 nTPM (limit 2); smooth muscle: 10.4 nTPM (limit 2); spinal cord: 9.6 nTPM (limit 2); spleen: 13.5 nTPM (limit 10); stomach: 14.7 nTPM (limit 6); thymus: 23 nTPM (limit 10); thyroid gland: 13 nTPM (limit 10); urinary bladder: 9.9 nTPM (limit 6); adrenal gland: 9.3 nTPM (baseline 2); amygdala: 6.8 nTPM (baseline 2); basal ganglia: 7.6 nTPM (baseline 2); bone marrow: 29.7 nTPM (baseline 2); cerebellum: 38.3 nTPM (baseline 2); cerebral cortex: 7.6 nTPM (baseline 2); choroid plexus: 16.3 nTPM (baseline 2); colon: 13.3 nTPM (baseline 6); duodenum: 12.7 nTPM (baseline 2); esophagus: 9.9 nTPM (baseline 6); heart muscle: 7.5 nTPM (baseline 2); hippocampal formation: 8 nTPM (baseline 2); hypothalamus: 8.5 nTPM (baseline 2); kidney: 8.4 nTPM (baseline 2); liver: 10.7 nTPM (baseline 2); lung: 10.3 nTPM (baseline 2); lymph node: 18.7 nTPM (baseline 6); midbrain: 7.2 nTPM (baseline 2); pancreas: 15.6 nTPM (baseline 2); parathyroid gland: 17.2 nTPM (baseline 6); pituitary gland: 11.5 nTPM (baseline 2); rectum: 15.6 nTPM (baseline 6); retina: 28 nTPM (baseline 2); salivary gland: 11.3 nTPM (baseline 6); skeletal muscle: 8 nTPM (baseline 2); skin: 14.7 nTPM (baseline 10); small intestine: 14 nTPM (baseline 2); smooth muscle: 10.4 nTPM (baseline 2); spinal cord: 9.6 nTPM (baseline 2); spleen: 13.5 nTPM (baseline 10); stomach: 14.7 nTPM (baseline 6); thymus: 23 nTPM (baseline 10); thyroid gland: 13 nTPM (baseline 10); urinary bladder: 9.9 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9H3R0,https://www.uniprot.org/uniprotkb/Q9H3R0/entry,"Histone demethylase that specifically demethylates 'Lys-9' and 'Lys-36' residues of histone H3, thereby playing a central role in histone code. Does not demethylate histone H3 'Lys-4', H3 'Lys-27' nor H4 'Lys-20'. Demethylates trimethylated H3 'Lys-9' and H3 'Lys-36' residue, while it has no activity on mono- and dimethylated residues. Demethylation of Lys residue generates formaldehyde and succinate",Overexpressed in several esophageal squamous cell carcinomas (ESCs),,,Nucleus,16603238|28262558,10987278,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
KDM4D,ENSG00000186280,Unsafe,Protein,False,True,32.3,32.3,87,27,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; cerebellum: 0.9 nTPM; positive ihc; cerebral cortex: 0.9 nTPM; positive ihc; colon: 0.2 nTPM; positive ihc; duodenum: 0.1 nTPM; positive ihc; esophagus: 0.3 nTPM; positive ihc; kidney: 0.5 nTPM; positive ihc; parathyroid gland: 0.9 nTPM; positive ihc; rectum: 0.3 nTPM; positive ihc; salivary gland: 0.6 nTPM; positive ihc; skin: 0.7 nTPM; positive ihc; small intestine: 0.2 nTPM; positive ihc; stomach: 0.3 nTPM; positive ihc; thyroid gland: 0.7 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,bronchus / respiratory epithelial cells: Low (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); colon / glandular cells: Low (Approved); duodenum / glandular cells: Low (Approved); esophagus / squamous epithelial cells: Low (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in tubules: Medium (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); oral mucosa / squamous epithelial cells: Low (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skin 1 / keratinocytes: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Low (Approved); stomach 2 / glandular cells: Low (Approved); thyroid gland / glandular cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 32/58 (55.2%); Testicular Germ Cell Tumor (TCGA): 14/133 (10.5%); Breast Invasive Carcinoma (validation): 4/50 (8.0%),cervical cancer: 2/12 (16.7%); lung cancer: 1/9 (11.1%),31,20,Q6B0I6,https://www.uniprot.org/uniprotkb/Q6B0I6/entry,"Histone demethylase that specifically demethylates 'Lys-9' of histone H3, thereby playing a central role in histone code. Does not demethylate histone H3 'Lys-4', H3 'Lys-27', H3 'Lys-36' nor H4 'Lys-20'. Demethylates both di- and trimethylated H3 'Lys-9' residue, while it has no activity on monomethylated residues. Demethylation of Lys residue generates formaldehyde and succinate",,,It is uncertain whether Met-1 or Met-4 is the initiator,Nucleus,16603238|35145029,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
KDM7A,ENSG00000006459,Unsafe,Protein,False,True,9.2,16.2,79,64,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 6.3 nTPM; positive ihc;continuous selectivity; adrenal gland: 2.1 nTPM; positive ihc;absolute ceiling; bone marrow: 16.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 2.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 3.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 8.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 8 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 6.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 3.9 nTPM; absolute ceiling;continuous selectivity; kidney: 3.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 6.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 4.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 6.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; pancreas: 4.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 4 nTPM; positive ihc;continuous selectivity; rectum: 9 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 5.7 nTPM; absolute ceiling;continuous selectivity; salivary gland: 4.9 nTPM; positive ihc;continuous selectivity; skeletal muscle: 12.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 7.3 nTPM; positive ihc;continuous selectivity; small intestine: 8.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 4.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; spleen: 5.4 nTPM; positive ihc;continuous selectivity; stomach: 9.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 6.5 nTPM; continuous selectivity; thyroid gland: 2.7 nTPM; positive ihc; tongue: 12.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 5.5 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 2.1 nTPM (limit 2); bone marrow: 16.2 nTPM (limit 2); cerebellum: 2.6 nTPM (limit 2); cerebral cortex: 3.4 nTPM (limit 2); colon: 8.1 nTPM (limit 6); duodenum: 8 nTPM (limit 2); esophagus: 6.7 nTPM (limit 6); heart muscle: 3.9 nTPM (limit 2); kidney: 3.5 nTPM (limit 2); liver: 6.5 nTPM (limit 2); lung: 4.6 nTPM (limit 2); lymph node: 6.8 nTPM (limit 6); pancreas: 4.4 nTPM (limit 2); rectum: 9 nTPM (limit 6); retina: 5.7 nTPM (limit 2); skeletal muscle: 12.2 nTPM (limit 2); small intestine: 8.1 nTPM (limit 2); smooth muscle: 4.2 nTPM (limit 2); stomach: 9.1 nTPM (limit 6); tongue: 12.7 nTPM (limit 6); adrenal gland: 2.1 nTPM (baseline 2); bone marrow: 16.2 nTPM (baseline 2); cerebellum: 2.6 nTPM (baseline 2); cerebral cortex: 3.4 nTPM (baseline 2); colon: 8.1 nTPM (baseline 6); duodenum: 8 nTPM (baseline 2); esophagus: 6.7 nTPM (baseline 6); heart muscle: 3.9 nTPM (baseline 2); kidney: 3.5 nTPM (baseline 2); liver: 6.5 nTPM (baseline 2); lung: 4.6 nTPM (baseline 2); lymph node: 6.8 nTPM (baseline 6); pancreas: 4.4 nTPM (baseline 2); rectum: 9 nTPM (baseline 6); retina: 5.7 nTPM (baseline 2); skeletal muscle: 12.2 nTPM (baseline 2); small intestine: 8.1 nTPM (baseline 2); smooth muscle: 4.2 nTPM (baseline 2); stomach: 9.1 nTPM (baseline 6); tongue: 12.7 nTPM (baseline 6),adipose tissue / adipocytes: Low (Uncertain); adrenal gland / glandular cells: High (Uncertain); bone marrow / hematopoietic cells: High (Uncertain); bronchus / respiratory epithelial cells: High (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: Low (Uncertain); cerebellum / cells in molecular layer: Medium (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / endothelial cells: Medium (Uncertain); cerebral cortex / glial cells: Low (Uncertain); cerebral cortex / neuronal cells: High (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / endothelial cells: Medium (Uncertain); colon / glandular cells: High (Uncertain); colon / peripheral nerve/ganglion: Medium (Uncertain); duodenum / glandular cells: High (Uncertain); esophagus / squamous epithelial cells: High (Uncertain); hippocampus / neuronal cells: High (Uncertain); kidney / cells in glomeruli: Medium (Uncertain); kidney / cells in tubules: High (Uncertain); liver / hepatocytes: High (Uncertain); lung / alveolar cells: Medium (Uncertain); lung / macrophages: Low (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); nasopharynx / respiratory epithelial cells: High (Uncertain); oral mucosa / squamous epithelial cells: High (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); parathyroid gland / glandular cells: High (Uncertain); rectum / glandular cells: High (Uncertain); salivary gland / glandular cells: High (Uncertain); skeletal muscle / myocytes: Medium (Uncertain); skin 1 / keratinocytes: High (Uncertain); skin 1 / Langerhans: High (Uncertain); skin 2 / epidermal cells: High (Uncertain); small intestine / glandular cells: High (Uncertain); smooth muscle / smooth muscle cells: High (Uncertain); spleen / cells in red pulp: Medium (Uncertain); spleen / cells in white pulp: Low (Uncertain); stomach 1 / glandular cells: Low (Uncertain); stomach 2 / glandular cells: High (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: High (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 485/486 (99.8%),colorectal cancer: 12/12 (100.0%); skin cancer: 12/12 (100.0%),29,20,Q6ZMT4,https://www.uniprot.org/uniprotkb/Q6ZMT4/entry,"Histone demethylase required for brain development. Specifically demethylates dimethylated 'Lys-9', 'Lys-27' and 'Lys-36' (H3K9me2, H3K27me2, H3K36me2, respectively) of histone H3 and monomethylated histone H4 'Lys-20' residue (H4K20Me1), thereby playing a central role in histone code (PubMed:20023638, PubMed:20622853). Specifically binds trimethylated 'Lys-4' of histone H3 (H3K4me3), affecting histone demethylase specificity: in presence of H3K4me3, it has no demethylase activity toward H3K9me2, while it has high activity toward H3K27me2. Demethylates H3K9me2 in absence of H3K4me3 (PubMed:20023638). Has activity toward H4K20Me1 only when nucleosome is used as a substrate and when not histone octamer is used as substrate (PubMed:20622853)",,,,Nucleus,20023638|20622853,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
KHDC1,ENSG00000135314,Unsafe,RNA,False,True,8.1,14.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 11 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 14.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 9.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 13.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 4 nTPM; absolute ceiling;continuous selectivity; heart muscle: 3.7 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 9.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 9.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 9.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 2.6 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 7.3 nTPM; absolute ceiling;continuous selectivity; retina: 3.6 nTPM; absolute ceiling;continuous selectivity; spinal cord: 7.1 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 11 nTPM (limit 2); basal ganglia: 14.2 nTPM (limit 2); cerebellum: 9.2 nTPM (limit 2); cerebral cortex: 13.7 nTPM (limit 2); choroid plexus: 4 nTPM (limit 2); heart muscle: 3.7 nTPM (limit 2); hippocampal formation: 9.2 nTPM (limit 2); hypothalamus: 9.4 nTPM (limit 2); midbrain: 9.9 nTPM (limit 2); pancreas: 2.6 nTPM (limit 2); pituitary gland: 7.3 nTPM (limit 2); retina: 3.6 nTPM (limit 2); spinal cord: 7.1 nTPM (limit 2); amygdala: 11 nTPM (baseline 2); basal ganglia: 14.2 nTPM (baseline 2); cerebellum: 9.2 nTPM (baseline 2); cerebral cortex: 13.7 nTPM (baseline 2); choroid plexus: 4 nTPM (baseline 2); heart muscle: 3.7 nTPM (baseline 2); hippocampal formation: 9.2 nTPM (baseline 2); hypothalamus: 9.4 nTPM (baseline 2); midbrain: 9.9 nTPM (baseline 2); pancreas: 2.6 nTPM (baseline 2); pituitary gland: 7.3 nTPM (baseline 2); retina: 3.6 nTPM (baseline 2); spinal cord: 7.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 135/141 (95.7%); Glioblastoma Multiforme (validation): 36/58 (62.1%); Breast Invasive Carcinoma (validation): 29/50 (58.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q4VXA5,https://www.uniprot.org/uniprotkb/Q4VXA5/entry,,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
KHDC1L,ENSG00000256980,Unsafe,RNA,False,True,5.4,8.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,basal ganglia: 8.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 1.8 nTPM; continuous selectivity; pituitary gland: 1.5 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,basal ganglia: 8.1 nTPM (limit 2); basal ganglia: 8.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 92/133 (69.2%); Head and Neck Squamous Cell Carcinoma (TCGA): 279/492 (56.7%); Lung Squamous Cell Carcinoma (TCGA): 93/489 (19.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q5JSQ8,https://www.uniprot.org/uniprotkb/Q5JSQ8/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
KHDRBS3,ENSG00000131773,Unsafe,Protein,False,True,152.8,152.8,111,82,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 16.2 nTPM; positive ihc;absolute ceiling; adrenal gland: 15.9 nTPM; positive ihc;absolute ceiling; amygdala: 29.7 nTPM; absolute ceiling; basal ganglia: 14.4 nTPM; absolute ceiling; bone marrow: 2.6 nTPM; positive ihc;absolute ceiling; cerebellum: 12.6 nTPM; positive ihc;absolute ceiling; cerebral cortex: 51.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 4.7 nTPM; absolute ceiling; colon: 12 nTPM; positive ihc;absolute ceiling; duodenum: 4 nTPM; positive ihc;absolute ceiling; heart muscle: 10 nTPM; positive ihc;absolute ceiling; hippocampal formation: 29.1 nTPM; absolute ceiling; hypothalamus: 18.1 nTPM; absolute ceiling; kidney: 18.5 nTPM; positive ihc;absolute ceiling; lymph node: 2.9 nTPM; positive ihc; midbrain: 17.8 nTPM; absolute ceiling; pancreas: 9 nTPM; positive ihc;absolute ceiling; parathyroid gland: 7.3 nTPM; positive ihc;absolute ceiling; pituitary gland: 6.6 nTPM; absolute ceiling; rectum: 8.6 nTPM; positive ihc;absolute ceiling; retina: 20.3 nTPM; absolute ceiling; salivary gland: 10.7 nTPM; positive ihc;absolute ceiling; skeletal muscle: 31.4 nTPM; positive ihc;absolute ceiling; skin: 6.2 nTPM; positive ihc; small intestine: 5.7 nTPM; positive ihc;absolute ceiling; smooth muscle: 8.4 nTPM; positive ihc;absolute ceiling; spinal cord: 24.4 nTPM; absolute ceiling; stomach: 6.7 nTPM; positive ihc;absolute ceiling; thyroid gland: 5.4 nTPM; positive ihc; tongue: 29.9 nTPM; absolute ceiling; urinary bladder: 10.2 nTPM; positive ihc;absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 16.2 nTPM (limit 10); adrenal gland: 15.9 nTPM (limit 2); amygdala: 29.7 nTPM (limit 2); basal ganglia: 14.4 nTPM (limit 2); bone marrow: 2.6 nTPM (limit 2); cerebellum: 12.6 nTPM (limit 2); cerebral cortex: 51.4 nTPM (limit 2); choroid plexus: 4.7 nTPM (limit 2); colon: 12 nTPM (limit 6); duodenum: 4 nTPM (limit 2); heart muscle: 10 nTPM (limit 2); hippocampal formation: 29.1 nTPM (limit 2); hypothalamus: 18.1 nTPM (limit 2); kidney: 18.5 nTPM (limit 2); midbrain: 17.8 nTPM (limit 2); pancreas: 9 nTPM (limit 2); parathyroid gland: 7.3 nTPM (limit 6); pituitary gland: 6.6 nTPM (limit 2); rectum: 8.6 nTPM (limit 6); retina: 20.3 nTPM (limit 2); salivary gland: 10.7 nTPM (limit 6); skeletal muscle: 31.4 nTPM (limit 2); small intestine: 5.7 nTPM (limit 2); smooth muscle: 8.4 nTPM (limit 2); spinal cord: 24.4 nTPM (limit 2); stomach: 6.7 nTPM (limit 6); tongue: 29.9 nTPM (limit 6); urinary bladder: 10.2 nTPM (limit 6),adipose tissue / adipocytes: Medium (Enhanced); adrenal gland / glandular cells: Medium (Enhanced); bone marrow / hematopoietic cells: Low (Enhanced); bronchus / respiratory epithelial cells: Medium (Enhanced); caudate / glial cells: Medium (Enhanced); caudate / neuronal cells: High (Enhanced); cerebellum / cells in granular layer: High (Enhanced); cerebellum / cells in molecular layer: Medium (Enhanced); cerebellum / Purkinje cells: High (Enhanced); cerebral cortex / neuronal cells: High (Enhanced); colon / endocrine cells: Medium (Enhanced); colon / endothelial cells: Low (Enhanced); colon / enterocytes: Low (Enhanced); colon / fibroblasts: Medium (Enhanced); colon / goblet cells: Low (Enhanced); colon / mucosal lymphoid cells: Medium (Enhanced); colon / peripheral nerve/ganglion: Low (Enhanced); duodenum / endocrine cells: Medium (Enhanced); duodenum / enterocytes: Medium (Enhanced); duodenum / goblet cells: Medium (Enhanced); heart muscle / cardiomyocytes: Medium (Enhanced); hippocampus / neuronal cells: High (Enhanced); kidney / bowman's capsule: Low (Enhanced); kidney / cells in glomeruli: Medium (Enhanced); kidney / collecting ducts: High (Enhanced); kidney / distal tubules: High (Enhanced); kidney / proximal tubules (cell body): High (Enhanced); lymph node / germinal center cells: Low (Enhanced); nasopharynx / respiratory epithelial cells: Medium (Enhanced); oral mucosa / squamous epithelial cells: Low (Enhanced); pancreas / exocrine glandular cells: Low (Enhanced); pancreas / pancreatic endocrine cells: Medium (Enhanced); parathyroid gland / glandular cells: Medium (Enhanced); rectum / endocrine cells: Medium (Enhanced); rectum / endothelial cells: Low (Enhanced); rectum / enterocytes: Low (Enhanced); rectum / fibroblasts: Medium (Enhanced); rectum / goblet cells: Low (Enhanced); rectum / mucosal lymphoid cells: Medium (Enhanced); rectum / peripheral nerve/ganglion: High (Enhanced); salivary gland / glandular cells: Medium (Enhanced); skeletal muscle / myocytes: Medium (Enhanced); skin 1 / fibroblasts: Medium (Enhanced); skin 1 / keratinocytes: Low (Enhanced); skin 2 / epidermal cells: Low (Enhanced); small intestine / endocrine cells: Medium (Enhanced); small intestine / enterocytes: Low (Enhanced); small intestine / goblet cells: Low (Enhanced); small intestine / paneth cells: Medium (Enhanced); smooth muscle / smooth muscle cells: Medium (Enhanced); stomach 1 / glandular cells: Medium (Enhanced); stomach 2 / glandular cells: Medium (Enhanced); thyroid gland / glandular cells: Low (Enhanced); urinary bladder / urothelial cells: High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 141/141 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Kidney Renal Papillary Cell Carcinoma (TCGA): 266/282 (94.3%),glioma: 11/11 (100.0%); colorectal cancer: 10/11 (90.9%),31,20,O75525,https://www.uniprot.org/uniprotkb/O75525/entry,"RNA-binding protein that plays a role in the regulation of alternative splicing and influences mRNA splice site selection and exon inclusion. Binds preferentially to the 5'-[AU]UAAA-3' motif in vitro. Binds optimally to RNA containing 5'-[AU]UAA-3' as a bipartite motif spaced by more than 15 nucleotides. Binds poly(A). RNA-binding abilities are down-regulated by tyrosine kinase PTK6 (PubMed:10564820, PubMed:19561594, PubMed:26758068). Involved in splice site selection of vascular endothelial growth factor (PubMed:15901763). In vitro regulates CD44 alternative splicing by direct binding to purine-rich exonic enhancer (By similarity). Can regulate alternative splicing of neurexins NRXN1-3 in the laminin G-like domain 6 containing the evolutionary conserved neurexin alternative spliced segment 4 (AS4) involved in neurexin selective targeting to postsynaptic partners such as neuroligins and LRRTM family members (PubMed:26758068). Targeted, cell-type specific splicing regulation of NRXN1 at AS4 is involved in neuronal glutamatergic synapse function and plasticity (By similarity). May regulate expression of KHDRBS2/SLIM-1 in defined brain neuron populations by modifying its alternative splicing (By similarity). Can bind FABP9 mRNA (By similarity). May play a role as a negative regulator of cell growth. Inhibits cell proliferation (Microbial infection) Involved in post-transcriptional regulation of HIV-1 gene expression","Ubiquitous with higher expression in testis, skeletal muscle and brain. Expressed in the kidney only in podocytes, the glomerular epithelial cells of the kidney. Strongly expressed after meiosis",,,Nucleus,10564820|11741900|15901763|19561594|26758068,10077576|10332027|10564820,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
KIAA0825,ENSG00000185261,Unsafe,Protein,False,True,2.7,3.2,78,53,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 1 nTPM; positive ihc;continuous selectivity; amygdala: 0.9 nTPM; continuous selectivity; basal ganglia: 1.7 nTPM; continuous selectivity; bone marrow: 1.1 nTPM; continuous selectivity; cerebellum: 1.6 nTPM; positive ihc;continuous selectivity; cerebral cortex: 1.6 nTPM; positive ihc;continuous selectivity; colon: 0.6 nTPM; positive ihc; duodenum: 0.5 nTPM; positive ihc; esophagus: 1 nTPM; positive ihc; heart muscle: 0.8 nTPM; positive ihc;continuous selectivity; hippocampal formation: 0.9 nTPM; continuous selectivity; hypothalamus: 0.9 nTPM; continuous selectivity; kidney: 1.3 nTPM; positive ihc;continuous selectivity; liver: 1 nTPM; positive ihc;continuous selectivity; lung: 0.9 nTPM; positive ihc;continuous selectivity; lymph node: 0.8 nTPM; positive ihc; pancreas: 0.8 nTPM; positive ihc;continuous selectivity; parathyroid gland: 1.3 nTPM; positive ihc;continuous selectivity; pituitary gland: 1 nTPM; continuous selectivity; rectum: 0.6 nTPM; positive ihc; retina: 3.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 0.7 nTPM; positive ihc; skeletal muscle: 1.4 nTPM; positive ihc;continuous selectivity; skin: 0.8 nTPM; positive ihc; small intestine: 0.5 nTPM; positive ihc; smooth muscle: 0.8 nTPM; positive ihc;continuous selectivity; stomach: 0.6 nTPM; positive ihc; thyroid gland: 1.7 nTPM; positive ihc;continuous selectivity; urinary bladder: 1.1 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",retina: 3.2 nTPM (limit 2); retina: 3.2 nTPM (baseline 2),adrenal gland / glandular cells: High (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / neuronal cells: Low (Uncertain); cerebellum / cells in granular layer: Medium (Uncertain); cerebellum / Purkinje cells: Low (Uncertain); cerebral cortex / neuronal cells: Low (Uncertain); cerebral cortex / neuropil: Medium (Uncertain); colon / endothelial cells: Medium (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: Medium (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: High (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); kidney / cells in glomeruli: Medium (Uncertain); kidney / cells in tubules: High (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / alveolar cells: Low (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: High (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Low (Uncertain); skeletal muscle / myocytes: High (Uncertain); skin 1 / fibroblasts: Medium (Uncertain); skin 1 / keratinocytes: Medium (Uncertain); skin 1 / Langerhans: Medium (Uncertain); skin 2 / epidermal cells: High (Uncertain); small intestine / glandular cells: Medium (Uncertain); smooth muscle / smooth muscle cells: Low (Uncertain); stomach 1 / glandular cells: Low (Uncertain); stomach 2 / glandular cells: Low (Uncertain); thyroid gland / glandular cells: Low (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 51/58 (87.9%); Pancreatic Adenocarcinoma (validation): 29/80 (36.2%); Kidney Renal Papillary Cell Carcinoma (TCGA): 5/282 (1.8%),liver cancer: 7/10 (70.0%); pancreatic cancer: 4/9 (44.4%),30,20,Q8IV33,https://www.uniprot.org/uniprotkb/Q8IV33/entry,,,"Polydactyly, postaxial, A10: A form of postaxial polydactyly, a condition characterized by the occurrence of supernumerary digits in the upper and/or lower extremities. In postaxial polydactyly type A, the extra digit is well-formed and articulates with the fifth or a sixth metacarpal/metatarsal. PAPA10 is an autosomal recessive condition characterized by one or more postaxial digits of the hands and/or feet. A rudimentary digit (PAP type B) may also be present. Intrafamilial variability has been observed.",,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
KIAA1328,ENSG00000150477,Unsafe,Protein,False,True,12.0,20.5,79,71,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 4.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 3 nTPM; absolute ceiling; basal ganglia: 2.7 nTPM; absolute ceiling; bone marrow: 14.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 2.3 nTPM; positive ihc;absolute ceiling; cerebral cortex: 6.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 5.8 nTPM; absolute ceiling;continuous selectivity; colon: 3.8 nTPM; positive ihc; duodenum: 4.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 3.9 nTPM; positive ihc; heart muscle: 4.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 2.9 nTPM; absolute ceiling; hypothalamus: 2.6 nTPM; absolute ceiling; kidney: 5 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 4.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 5.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 5.3 nTPM; positive ihc;continuous selectivity; midbrain: 3.6 nTPM; absolute ceiling;continuous selectivity; pancreas: 3.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 3.7 nTPM; positive ihc; pituitary gland: 2.7 nTPM; absolute ceiling; rectum: 3.3 nTPM; positive ihc; retina: 20.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 6.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 7 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 8.4 nTPM; positive ihc;continuous selectivity; small intestine: 5.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 4 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 4.3 nTPM; absolute ceiling;continuous selectivity; spleen: 5.4 nTPM; positive ihc;continuous selectivity; stomach: 5.3 nTPM; positive ihc;continuous selectivity; thyroid gland: 4.8 nTPM; positive ihc; urinary bladder: 3.1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 4.6 nTPM (limit 2); amygdala: 3 nTPM (limit 2); basal ganglia: 2.7 nTPM (limit 2); bone marrow: 14.3 nTPM (limit 2); cerebellum: 2.3 nTPM (limit 2); cerebral cortex: 6.4 nTPM (limit 2); choroid plexus: 5.8 nTPM (limit 2); duodenum: 4.8 nTPM (limit 2); heart muscle: 4.8 nTPM (limit 2); hippocampal formation: 2.9 nTPM (limit 2); hypothalamus: 2.6 nTPM (limit 2); kidney: 5 nTPM (limit 2); liver: 4.4 nTPM (limit 2); lung: 5.3 nTPM (limit 2); midbrain: 3.6 nTPM (limit 2); pancreas: 3.8 nTPM (limit 2); pituitary gland: 2.7 nTPM (limit 2); retina: 20.5 nTPM (limit 2); salivary gland: 6.7 nTPM (limit 6); skeletal muscle: 7 nTPM (limit 2); small intestine: 5.5 nTPM (limit 2); smooth muscle: 4 nTPM (limit 2); spinal cord: 4.3 nTPM (limit 2),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / neuronal cells: Low (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Low (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: High (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Low (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Pancreatic Adenocarcinoma (validation): 80/80 (100.0%),colorectal cancer: 11/11 (100.0%); breast cancer: 11/12 (91.7%),31,20,Q86T90,https://www.uniprot.org/uniprotkb/Q86T90/entry,Competes with SMC1 for binding to SMC3. May affect the availability of SMC3 to engage in the formation of multimeric protein complexes,Widely expressed,,,,15656913,15656913,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
KIAA1549,ENSG00000122778,Unsafe,Protein,False,True,5.3,6.2,77,77,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0.6 nTPM; positive ihc; adrenal gland: 1.7 nTPM; positive ihc;continuous selectivity; amygdala: 1.7 nTPM; continuous selectivity; basal ganglia: 1.9 nTPM; continuous selectivity; bone marrow: 0.3 nTPM; positive ihc; cerebellum: 0.6 nTPM; positive ihc; cerebral cortex: 4.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 0.8 nTPM; positive ihc; duodenum: 0.7 nTPM; positive ihc; esophagus: 0.5 nTPM; positive ihc; heart muscle: 1.1 nTPM; positive ihc; hippocampal formation: 2 nTPM; continuous selectivity; hypothalamus: 2 nTPM; continuous selectivity; kidney: 3.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 0.4 nTPM; positive ihc; lung: 1.8 nTPM; positive ihc;continuous selectivity; lymph node: 0.1 nTPM; positive ihc; pancreas: 6.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 2.4 nTPM; positive ihc;continuous selectivity; pituitary gland: 1.7 nTPM; continuous selectivity; rectum: 0.7 nTPM; positive ihc; retina: 5.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 2.3 nTPM; positive ihc;continuous selectivity; skeletal muscle: 0.5 nTPM; positive ihc; skin: 0.8 nTPM; positive ihc; small intestine: 0.7 nTPM; positive ihc; smooth muscle: 1.2 nTPM; positive ihc; spleen: 0.3 nTPM; positive ihc; stomach: 1.3 nTPM; positive ihc; thyroid gland: 0.7 nTPM; positive ihc; urinary bladder: 1.1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",cerebral cortex: 4.2 nTPM (limit 2); kidney: 3.8 nTPM (limit 2); pancreas: 6.2 nTPM (limit 2); retina: 5.6 nTPM (limit 2); cerebral cortex: 4.2 nTPM (baseline 2); kidney: 3.8 nTPM (baseline 2); pancreas: 6.2 nTPM (baseline 2); retina: 5.6 nTPM (baseline 2),adipose tissue / adipocytes: High (Uncertain); adrenal gland / glandular cells: High (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: High (Uncertain); caudate / glial cells: Medium (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: High (Uncertain); cerebellum / cells in molecular layer: Medium (Uncertain); cerebellum / Purkinje cells: High (Uncertain); cerebral cortex / endothelial cells: Medium (Uncertain); cerebral cortex / glial cells: Medium (Uncertain); cerebral cortex / neuronal cells: High (Uncertain); cerebral cortex / neuropil: High (Uncertain); colon / endothelial cells: Medium (Uncertain); colon / glandular cells: High (Uncertain); colon / peripheral nerve/ganglion: Medium (Uncertain); duodenum / glandular cells: High (Uncertain); esophagus / squamous epithelial cells: High (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / glial cells: Medium (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in glomeruli: Medium (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / cholangiocytes: Low (Uncertain); liver / hepatocytes: Low (Uncertain); lung / alveolar cells: Low (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / germinal center cells: Medium (Uncertain); lymph node / non-germinal center cells: Medium (Uncertain); nasopharynx / respiratory epithelial cells: High (Uncertain); oral mucosa / squamous epithelial cells: High (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); parathyroid gland / glandular cells: High (Uncertain); rectum / glandular cells: High (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: High (Uncertain); skin 1 / fibroblasts: High (Uncertain); skin 1 / keratinocytes: Medium (Uncertain); skin 1 / Langerhans: Medium (Uncertain); skin 2 / epidermal cells: High (Uncertain); small intestine / glandular cells: High (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); spleen / cells in red pulp: Medium (Uncertain); spleen / cells in white pulp: Medium (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: High (Uncertain); thyroid gland / glandular cells: High (Uncertain); urinary bladder / urothelial cells: High (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Rectum Adenocarcinoma (validation): 191/207 (92.3%); Breast Invasive Carcinoma (validation): 46/50 (92.0%),breast cancer: 12/12 (100.0%); cervical cancer: 12/12 (100.0%),31,20,Q9HCM3,https://www.uniprot.org/uniprotkb/Q9HCM3/entry,May play a role in photoreceptor function,"Expression is low to moderate in retina and tissues, such as heart and kidney, and is predominantly expressed in brain Abundantly expressed in the retina, compared with only minimal expression in brain and other tissues","Retinitis pigmentosa 86: A form of retinitis pigmentosa, a retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. RP86 is an autosomal recessive form.",,"Membrane Cell projection, cilium",30120214,30120214,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
KIAA1586,ENSG00000168116,Unsafe,Protein,False,True,9.1,9.1,83,40,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 4.6 nTPM; absolute ceiling;continuous selectivity; amygdala: 2.3 nTPM; absolute ceiling; basal ganglia: 2.4 nTPM; absolute ceiling;continuous selectivity; bone marrow: 8.4 nTPM; absolute ceiling;continuous selectivity; cerebellum: 4.4 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 5.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 2.8 nTPM; positive ihc; duodenum: 2.1 nTPM; positive ihc;absolute ceiling; esophagus: 3.2 nTPM; positive ihc;continuous selectivity; heart muscle: 3.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 2.4 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 3.1 nTPM; absolute ceiling;continuous selectivity; kidney: 3.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 4.8 nTPM; absolute ceiling;continuous selectivity; lymph node: 4.5 nTPM; continuous selectivity; midbrain: 2.2 nTPM; absolute ceiling; pancreas: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 5.1 nTPM; continuous selectivity; pituitary gland: 3.6 nTPM; absolute ceiling;continuous selectivity; rectum: 2.5 nTPM; positive ihc; retina: 3.8 nTPM; absolute ceiling;continuous selectivity; salivary gland: 2.6 nTPM; positive ihc; skeletal muscle: 1.5 nTPM; positive ihc; skin: 2.4 nTPM; positive ihc; smooth muscle: 4.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 2.3 nTPM; absolute ceiling; stomach: 2 nTPM; positive ihc; thymus: 5.7 nTPM; continuous selectivity; thyroid gland: 5.5 nTPM; continuous selectivity; tongue: 3.2 nTPM; continuous selectivity; urinary bladder: 4.6 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 4.6 nTPM (limit 4); amygdala: 2.3 nTPM (limit 2); basal ganglia: 2.4 nTPM (limit 2); bone marrow: 8.4 nTPM (limit 4); cerebellum: 4.4 nTPM (limit 4); cerebral cortex: 5.9 nTPM (limit 2); duodenum: 2.1 nTPM (limit 2); heart muscle: 3.4 nTPM (limit 2); hippocampal formation: 2.4 nTPM (limit 2); hypothalamus: 3.1 nTPM (limit 2); kidney: 3.5 nTPM (limit 2); liver: 4.8 nTPM (limit 4); midbrain: 2.2 nTPM (limit 2); pancreas: 2.7 nTPM (limit 2); pituitary gland: 3.6 nTPM (limit 2); retina: 3.8 nTPM (limit 2); smooth muscle: 4.2 nTPM (limit 2); spinal cord: 2.3 nTPM (limit 2),bronchus / respiratory epithelial cells: Medium (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 45/50 (90.0%); Lung Squamous Cell Carcinoma (validation): 56/68 (82.4%),urothelial cancer: 5/8 (62.5%); pancreatic cancer: 6/10 (60.0%),31,20,Q9HCI6,https://www.uniprot.org/uniprotkb/Q9HCI6/entry,E3 SUMO-protein ligase; facilitates UBE2I/UBC9-mediated SUMO2 modification of target proteins (PubMed:26524493),,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
KICS2,ENSG00000174206,Unsafe,Protein,False,True,5.3,8.3,76,31,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 2.8 nTPM; continuous selectivity; adrenal gland: 4 nTPM; absolute ceiling;continuous selectivity; amygdala: 2.8 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 4.4 nTPM; absolute ceiling;continuous selectivity; bone marrow: 1.7 nTPM; positive ihc;continuous selectivity; cerebellum: 1.8 nTPM; continuous selectivity; cerebral cortex: 3.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 1.8 nTPM; continuous selectivity; colon: 2.7 nTPM; positive ihc;continuous selectivity; duodenum: 3 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 4.1 nTPM; continuous selectivity; heart muscle: 2.2 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 3.2 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 2.9 nTPM; absolute ceiling;continuous selectivity; kidney: 5.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 8.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 4.8 nTPM; continuous selectivity; midbrain: 3.3 nTPM; absolute ceiling;continuous selectivity; pancreas: 5 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 5.5 nTPM; continuous selectivity;reproductive not higher; pituitary gland: 2.5 nTPM; absolute ceiling;continuous selectivity; rectum: 3 nTPM; positive ihc;continuous selectivity; retina: 1.5 nTPM; continuous selectivity; salivary gland: 2.8 nTPM; continuous selectivity; skeletal muscle: 4.3 nTPM; absolute ceiling;continuous selectivity; skin: 5.4 nTPM; continuous selectivity;reproductive not higher; small intestine: 2.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 2.2 nTPM; absolute ceiling;continuous selectivity; spinal cord: 3.6 nTPM; absolute ceiling;continuous selectivity; spleen: 4.8 nTPM; continuous selectivity; stomach: 3 nTPM; positive ihc;continuous selectivity; thymus: 3.2 nTPM; continuous selectivity; thyroid gland: 5.4 nTPM; positive ihc;continuous selectivity;reproductive not higher; tongue: 3.1 nTPM; continuous selectivity; urinary bladder: 2.5 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 4 nTPM (limit 2); amygdala: 2.8 nTPM (limit 2); basal ganglia: 4.4 nTPM (limit 2); cerebral cortex: 3.7 nTPM (limit 2); duodenum: 3 nTPM (limit 2); heart muscle: 2.2 nTPM (limit 2); hippocampal formation: 3.2 nTPM (limit 2); hypothalamus: 2.9 nTPM (limit 2); kidney: 5.3 nTPM (limit 2); liver: 8.3 nTPM (limit 2); lung: 2.7 nTPM (limit 2); midbrain: 3.3 nTPM (limit 2); pancreas: 5 nTPM (limit 2); pituitary gland: 2.5 nTPM (limit 2); skeletal muscle: 4.3 nTPM (limit 2); small intestine: 2.4 nTPM (limit 2); smooth muscle: 2.2 nTPM (limit 2); spinal cord: 3.6 nTPM (limit 2); adrenal gland: 4 nTPM (baseline 2); amygdala: 2.8 nTPM (baseline 2); basal ganglia: 4.4 nTPM (baseline 2); cerebral cortex: 3.7 nTPM (baseline 2); duodenum: 3 nTPM (baseline 2); heart muscle: 2.2 nTPM (baseline 2); hippocampal formation: 3.2 nTPM (baseline 2); hypothalamus: 2.9 nTPM (baseline 2); kidney: 5.3 nTPM (baseline 2); liver: 8.3 nTPM (baseline 2); lung: 2.7 nTPM (baseline 2); midbrain: 3.3 nTPM (baseline 2); pancreas: 5 nTPM (baseline 2); pituitary gland: 2.5 nTPM (baseline 2); skeletal muscle: 4.3 nTPM (baseline 2); small intestine: 2.4 nTPM (baseline 2); smooth muscle: 2.2 nTPM (baseline 2); spinal cord: 3.6 nTPM (baseline 2),bone marrow / hematopoietic cells: Low (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / endothelial cells: Low (Uncertain); colon / glandular cells: High (Uncertain); colon / peripheral nerve/ganglion: Medium (Uncertain); duodenum / glandular cells: Medium (Uncertain); kidney / cells in tubules: Medium (Uncertain); lung / macrophages: Low (Uncertain); nasopharynx / respiratory epithelial cells: High (Uncertain); oral mucosa / squamous epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Low (Uncertain); rectum / glandular cells: Medium (Uncertain); small intestine / glandular cells: High (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Low (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Rectum Adenocarcinoma (validation): 205/207 (99.0%); Colon Adenocarcinoma (validation): 476/486 (97.9%),cervical cancer: 2/11 (18.2%); ovarian cancer: 2/11 (18.2%),31,20,Q96MD2,https://www.uniprot.org/uniprotkb/Q96MD2/entry,"As part of the KICSTOR complex functions in the amino acid-sensing branch of the TORC1 signaling pathway. Recruits, in an amino acid-independent manner, the GATOR1 complex to the lysosomal membranes and allows its interaction with GATOR2 and the RAG GTPases. Functions upstream of the RAG GTPases and is required to negatively regulate mTORC1 signaling in absence of amino acids. In absence of the KICSTOR complex mTORC1 is constitutively localized to the lysosome and activated. The KICSTOR complex is also probably involved in the regulation of mTORC1 by glucose",,"Intellectual developmental disorder, autosomal recessive 83: An autosomal recessive disorder characterized by developmental delay, mild to moderate intellectual disability, and poor or absent speech. Additional variable features include seizures, hearing impairment, hypotonia, and non-specific facial dysmorphism.",,Lysosome membrane,28199306,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
KIF14,ENSG00000118193,Unsafe,RNA,False,True,2.4,10.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 6.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 1.2 nTPM; continuous selectivity; esophagus: 1 nTPM; continuous selectivity; lymph node: 3.1 nTPM; continuous selectivity;reproductive not higher; rectum: 1.2 nTPM; continuous selectivity; small intestine: 1 nTPM; continuous selectivity; thymus: 10.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 6.5 nTPM (limit 2); thymus: 10.6 nTPM (limit 10); bone marrow: 6.5 nTPM (baseline 2); thymus: 10.6 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 56/58 (96.6%); Colon Adenocarcinoma (validation): 409/486 (84.2%); Rectum Adenocarcinoma (validation): 149/207 (72.0%),cervical cancer: 12/12 (100.0%); ovarian cancer: 12/12 (100.0%),31,20,Q15058,https://www.uniprot.org/uniprotkb/Q15058/entry,"Microtubule motor protein that binds to microtubules with high affinity through each tubulin heterodimer and has an ATPase activity (By similarity). Plays a role in many processes like cell division, cytokinesis and also in cell proliferation and apoptosis (PubMed:16648480, PubMed:24784001). During cytokinesis, targets to central spindle and midbody through its interaction with PRC1 and CIT respectively (PubMed:16431929). Regulates cell growth through regulation of cell cycle progression and cytokinesis (PubMed:24854087). During cell cycle progression acts through SCF-dependent proteasomal ubiquitin-dependent protein catabolic process which controls CDKN1B degradation, resulting in positive regulation of cyclins, including CCNE1, CCND1 and CCNB1 (PubMed:24854087). During late neurogenesis, regulates the cerebellar, cerebral cortex and olfactory bulb development through regulation of apoptosis, cell proliferation and cell division (By similarity). Also is required for chromosome congression and alignment during mitotic cell cycle process (PubMed:15843429). Regulates cell spreading, focal adhesion dynamics, and cell migration through its interaction with RADIL resulting in regulation of RAP1A-mediated inside-out integrin activation by tethering RADIL on microtubules (PubMed:23209302)",,"Meckel syndrome 12: A form of Meckel syndrome, a disorder characterized by a combination of renal cysts and variably associated features including developmental anomalies of the central nervous system (typically encephalocele), hepatic ductal dysplasia and cysts, and polydactyly. Microcephaly 20, primary, autosomal recessive: A form of microcephaly, a disease defined as a head circumference more than 3 standard deviations below the age, sex and ethnically matched mean. Brain weight is markedly reduced and the cerebral cortex is disproportionately small. MCPH20 features include mild to moderate intellectual disability, autistic features, poor speech. Disease severity is highly variable.",,"Nucleus Cytoplasm Cytoplasm, cytoskeleton, spindle Midbody",15843429|16431929|16648480|23209302|24784001|24854087,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
KIF15,ENSG00000163808,Unsafe,Protein,False,True,7.1,9.0,84,33,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 0 nTPM; positive ihc; bone marrow: 5.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 0.3 nTPM; positive ihc; colon: 1.4 nTPM; positive ihc; duodenum: 1.3 nTPM; positive ihc; heart muscle: 0 nTPM; positive ihc; kidney: 0 nTPM; positive ihc; lymph node: 2.2 nTPM; positive ihc; rectum: 1.5 nTPM; positive ihc; skeletal muscle: 0 nTPM; positive ihc; small intestine: 1.4 nTPM; positive ihc; smooth muscle: 0.4 nTPM; positive ihc; spleen: 0.4 nTPM; positive ihc; stomach: 0.8 nTPM; positive ihc; thymus: 9 nTPM; continuous selectivity;reproductive not higher; urinary bladder: 0.3 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 5.1 nTPM (limit 2),adrenal gland / glandular cells: Low (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); cerebral cortex / neuropil: Low (Approved); colon / glandular cells: High (Approved); duodenum / glandular cells: High (Approved); heart muscle / cardiomyocytes: Medium (Approved); kidney / cells in tubules: Medium (Approved); lymph node / germinal center cells: High (Approved); lymph node / non-germinal center cells: Medium (Approved); oral mucosa / squamous epithelial cells: Low (Approved); rectum / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Low (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Low (Approved); thymus / cortical cells: High (Approved); thymus / medullary cells: Medium (Approved); urinary bladder / urothelial cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Breast Invasive Carcinoma (validation): 41/50 (82.0%); Colon Adenocarcinoma (validation): 297/486 (61.1%),lymphoma: 8/12 (66.7%); cervical cancer: 6/11 (54.5%),31,20,Q9NS87,https://www.uniprot.org/uniprotkb/Q9NS87/entry,Plus-end directed kinesin-like motor enzyme involved in mitotic spindle assembly,"Expressed in testis, colon, thymus and in breast cancer","Braddock-Carey syndrome 2: An autosomal recessive disease characterized by microcephaly, congenital thrombocytopenia, and facial dysmorphisms including Pierre-Robin sequence.",,"Cytoplasm Cytoplasm, cytoskeleton, spindle",,12747765,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
KIF18A,ENSG00000121621,Unsafe,Protein,False,True,13.3,13.3,77,76,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0.2 nTPM; positive ihc; adrenal gland: 0.1 nTPM; positive ihc; bone marrow: 8.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 0 nTPM; positive ihc; cerebral cortex: 0.1 nTPM; positive ihc; colon: 1.5 nTPM; positive ihc; duodenum: 1.4 nTPM; positive ihc; esophagus: 1.3 nTPM; positive ihc; heart muscle: 0 nTPM; positive ihc; kidney: 0.3 nTPM; positive ihc; liver: 0.3 nTPM; positive ihc; lung: 1 nTPM; positive ihc; lymph node: 4.5 nTPM; positive ihc; pancreas: 0.1 nTPM; positive ihc; parathyroid gland: 0.1 nTPM; positive ihc; rectum: 2 nTPM; positive ihc; salivary gland: 0.3 nTPM; positive ihc; skeletal muscle: 0.1 nTPM; positive ihc; skin: 1.2 nTPM; positive ihc; small intestine: 1.3 nTPM; positive ihc; smooth muscle: 0.7 nTPM; positive ihc; spleen: 0.7 nTPM; positive ihc; stomach: 0.6 nTPM; positive ihc; thymus: 9.3 nTPM; continuous selectivity; thyroid gland: 1.1 nTPM; positive ihc; urinary bladder: 0.7 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 8.1 nTPM (limit 2),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: High (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: High (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: High (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: High (Approved); oral mucosa / squamous epithelial cells: High (Approved); pancreas / exocrine glandular cells: Low (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: High (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Breast Invasive Carcinoma (validation): 43/50 (86.0%); Colon Adenocarcinoma (validation): 415/486 (85.4%),breast cancer: 12/12 (100.0%); colorectal cancer: 12/12 (100.0%),31,20,Q8NI77,https://www.uniprot.org/uniprotkb/Q8NI77/entry,"Microtubule-depolymerizing kinesin which plays a role in chromosome congression by reducing the amplitude of preanaphase oscillations and slowing poleward movement during anaphase, thus suppressing chromosome movements. May stabilize the CENPE-BUB1B complex at the kinetochores during early mitosis and maintains CENPE levels at kinetochores during chromosome congression",,,,"Cell projection, ruffle Cytoplasm Nucleus Cytoplasm, cytoskeleton, microtubule organizing center, centrosome",17346968|18267093|18513970|19625775,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Jamin2021_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
KIF20A,ENSG00000112984,Unsafe,Protein,False,True,11.3,23.9,77,68,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,Trial registration,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0.7 nTPM; positive ihc; adrenal gland: 0.8 nTPM; positive ihc; bone marrow: 13.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 0 nTPM; positive ihc; cerebral cortex: 0.5 nTPM; positive ihc; colon: 3.2 nTPM; positive ihc; duodenum: 3.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 6.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; kidney: 0.3 nTPM; positive ihc; liver: 0.8 nTPM; positive ihc; lung: 0.9 nTPM; positive ihc; lymph node: 8.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; pancreas: 0.2 nTPM; positive ihc; parathyroid gland: 0.1 nTPM; positive ihc; rectum: 5 nTPM; positive ihc;continuous selectivity; salivary gland: 1 nTPM; positive ihc; skin: 4.3 nTPM; positive ihc; small intestine: 2.7 nTPM; positive ihc;absolute ceiling; smooth muscle: 5.6 nTPM; absolute ceiling;continuous selectivity; spleen: 1.9 nTPM; positive ihc; stomach: 2.1 nTPM; positive ihc; thymus: 23.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 0.5 nTPM; positive ihc; urinary bladder: 1.6 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 13.9 nTPM (limit 2); duodenum: 3.4 nTPM (limit 2); esophagus: 6.4 nTPM (limit 6); lymph node: 8.4 nTPM (limit 6); small intestine: 2.7 nTPM (limit 2); smooth muscle: 5.6 nTPM (limit 4); thymus: 23.9 nTPM (limit 10),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Low (Approved); bone marrow / hematopoietic cells: High (Approved); bronchus / respiratory epithelial cells: Low (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Low (Approved); duodenum / glandular cells: Low (Approved); esophagus / squamous epithelial cells: Medium (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Low (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Low (Approved); lymph node / germinal center cells: High (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Low (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Low (Approved); salivary gland / glandular cells: Low (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: High (Approved); small intestine / glandular cells: Low (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: High (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,True,True,hpa_immune_cell NK-cell: 6.7 nTPM,True,True,False,,True,False,,False,True,True,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,True,42.9471,42.7,"hpa_immune_cell_samples: blood/NK-cell, max 42.9471 TPM, 1 observations >30; hpa_immune_cell_samples: blood/NK-cell, max 35.3399 nTPM, 1 observations >30; hpa_single_cell_tissue: placenta/mixed immune cells, max 42.7 nTPM, 1 observations >30; hpa_single_cell_tissue: tongue/basal keratinocytes, max 32.6 nTPM, 1 observations >30",Unsafe,oncoref.target-sets.2026-10-23.2,42.95 TPM; blood/NK-cell; hpa_immune_cell_samples; vital,42.7 nTPM; placenta/mixed immune cells; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 132/133 (99.2%); Colon Adenocarcinoma (validation): 480/486 (98.8%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 279/283 (98.6%),colorectal cancer: 11/11 (100.0%); stomach cancer: 11/11 (100.0%),31,20,O95235,https://www.uniprot.org/uniprotkb/O95235/entry,"Mitotic kinesin required for chromosome passenger complex (CPC)-mediated cytokinesis. Following phosphorylation by PLK1, involved in recruitment of PLK1 to the central spindle. Interacts with guanosine triphosphate (GTP)-bound forms of RAB6A and RAB6B. May act as a motor required for the retrograde RAB6 regulated transport of Golgi membranes and associated vesicles along microtubules. Has a microtubule plus end-directed motility",,"Cardiomyopathy, familial restrictive 6: A heart disorder characterized by impaired filling of the ventricles with reduced diastolic volume, in the presence of normal or near normal wall thickness and systolic function. RCM6 is an autosomal recessive, severe form characterized by prenatal onset, irreversible heart failure and early death.",,"Golgi apparatus Cytoplasm, cytoskeleton, spindle",12939256,,False,Reviewed UniProt annotation; not a new primary-paper review,Trial registration only,https://clinicaltrials.gov/study/NCT01069575,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,,,,,,,,,,
KIF20B,ENSG00000138182,Unsafe,Protein,False,True,6.7,10.1,98,43,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,Trial registration,positive normal IHC; positive ihc outside permitted; adrenal gland: 0.7 nTPM; positive ihc; bone marrow: 10.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 0.8 nTPM; positive ihc; colon: 3.1 nTPM; positive ihc;continuous selectivity; duodenum: 3.5 nTPM; continuous selectivity; esophagus: 3.1 nTPM; positive ihc;continuous selectivity; kidney: 1.2 nTPM; positive ihc; liver: 1.3 nTPM; positive ihc; lymph node: 7.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 0.7 nTPM; positive ihc; rectum: 3.9 nTPM; positive ihc;continuous selectivity; salivary gland: 1 nTPM; positive ihc; skin: 2.4 nTPM; positive ihc; small intestine: 3.3 nTPM; continuous selectivity; spleen: 3.2 nTPM; positive ihc;continuous selectivity; stomach: 2.4 nTPM; positive ihc;continuous selectivity; thymus: 9.6 nTPM; continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 10.1 nTPM (limit 2); lymph node: 7.8 nTPM (limit 6),adrenal gland / glandular cells: Medium (Supported); bone marrow / hematopoietic cells: High (Supported); bronchus / respiratory epithelial cells: Low (Supported); caudate / neuronal cells: Low (Supported); cerebral cortex / neuronal cells: Medium (Supported); colon / endothelial cells: Low (Supported); colon / glandular cells: Low (Supported); esophagus / squamous epithelial cells: Low (Supported); hippocampus / glial cells: Low (Supported); hippocampus / neuronal cells: Low (Supported); kidney / cells in glomeruli: Low (Supported); liver / hepatocytes: Low (Supported); pancreas / exocrine glandular cells: Medium (Supported); rectum / glandular cells: Low (Supported); salivary gland / glandular cells: Medium (Supported); skin 1 / cells in basal layer: Medium (Supported); skin 1 / cells in spinous layer: Medium (Supported); skin 1 / endothelial cells: Low (Supported); skin 1 / fibrohistiocytic cells: Low (Supported); skin 1 / lymphocytes: Low (Supported); skin 2 / cells in basal layer: Low (Supported); skin 2 / cells in spinous layer: Low (Supported); skin 2 / endothelial cells: Low (Supported); skin 2 / fibrohistiocytic cells: Low (Supported); skin 2 / lymphocytes: Low (Supported); spleen / cells in red pulp: Medium (Supported); stomach 1 / glandular cells: Medium (Supported); stomach 2 / glandular cells: Medium (Supported),,oncoref.target-sets.2026-10-24.1,True,"tongue/basal keratinocytes cluster c-7: 198.9 nTPM, 5764 reads; reproductive-cell max 191.7",True,True,"DICE B_CELL_NAIVE (unstimulated): 91/91 values ≥5 TPM, max 50.8326; DICE M2 (unstimulated): 77/90 values ≥5 TPM, max 10.2814; DICE NK (unstimulated): 90/90 values ≥5 TPM, max 17.3926; DICE TREG_MEM (unstimulated): 89/89 values ≥5 TPM, max 24.2471; DICE CD4_NAIVE (unstimulated): 88/88 values ≥5 TPM, max 19.3386; DICE CD4_STIM (activated): 88/88 values ≥5 TPM, max 59.5048; DICE TREG_NAIVE (unstimulated): 89/89 values ≥5 TPM, max 24.0252; DICE TFH (unstimulated): 89/89 values ≥5 TPM, max 17.1833; DICE TH1 (unstimulated): 81/81 values ≥5 TPM, max 16.9227; DICE THSTAR (unstimulated): 88/88 values ≥5 TPM, max 20.9465; DICE TH17 (unstimulated): 89/89 values ≥5 TPM, max 27.6873; DICE TH2 (unstimulated): 89/89 values ≥5 TPM, max 22.2963; DICE CD8_NAIVE (unstimulated): 89/89 values ≥5 TPM, max 17.3481; DICE CD8_STIM (activated): 88/88 values ≥5 TPM, max 47.2883; hpa_immune_cell basophil: 13.1 nTPM; hpa_immune_cell gdT-cell: 5.5 nTPM; hpa_immune_cell MAIT T-cell: 6.8 nTPM; hpa_immune_cell memory B-cell: 13.1 nTPM; hpa_immune_cell memory CD4 T-cell: 7.4 nTPM; hpa_immune_cell memory CD8 T-cell: 6.1 nTPM; hpa_immune_cell naive B-cell: 16.1 nTPM; hpa_immune_cell naive CD4 T-cell: 8.6 nTPM; hpa_immune_cell naive CD8 T-cell: 8 nTPM; hpa_immune_cell plasmacytoid DC: 5.2 nTPM; hpa_immune_cell T-reg: 9.5 nTPM; hpa_immune_monaco basophil: 20.2 TPM; hpa_immune_monaco Central memory CD8 T-cell: 24.3 TPM; hpa_immune_monaco classical monocyte: 5.1 TPM; hpa_immune_monaco Effector memory CD8 T-cell: 30 TPM; hpa_immune_monaco Exhausted memory B-cell: 15.6 TPM; hpa_immune_monaco intermediate monocyte: 5.7 TPM; hpa_immune_monaco MAIT T-cell: 16.1 TPM; hpa_immune_monaco Memory CD4 T-cell TFH: 27.2 TPM; hpa_immune_monaco Memory CD4 T-cell Th1: 22.4 TPM; hpa_immune_monaco Memory CD4 T-cell Th1/Th17: 23.1 TPM; hpa_immune_monaco Memory CD4 T-cell Th17: 29.2 TPM; hpa_immune_monaco Memory CD4 T-cell Th2: 16.5 TPM; hpa_immune_monaco myeloid DC: 5.6 TPM; hpa_immune_monaco naive B-cell: 24.6 TPM; hpa_immune_monaco naive CD4 T-cell: 21.6 TPM; hpa_immune_monaco naive CD8 T-cell: 16.1 TPM; hpa_immune_monaco NK-cell: 14.7 TPM; hpa_immune_monaco non-classical monocyte: 10.2 TPM; hpa_immune_monaco Non-switched memory B-cell: 24.2 TPM; hpa_immune_monaco Non-Vd2 gdTCR: 21.1 TPM; hpa_immune_monaco Plasmablast: 8.9 TPM; hpa_immune_monaco plasmacytoid DC: 19.7 TPM; hpa_immune_monaco Progenitor cell: 14.5 TPM; hpa_immune_monaco Switched memory B-cell: 23.2 TPM; hpa_immune_monaco T-reg: 33 TPM; hpa_immune_monaco Terminal effector memory CD4 T-cell: 26.2 TPM; hpa_immune_monaco Terminal effector memory CD8 T-cell: 25.3 TPM; hpa_immune_monaco total PBMC: 9.5 TPM; hpa_immune_monaco Vd2 gdTCR: 24.4 TPM",True,True,False,,True,False,,False,True,True,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,True,59.504781356,198.9,"dice_b_cell_naive: blood/B_CELL_NAIVE, max 50.8326 TPM, 21 observations >30; dice_cd4_stim: blood/CD4_STIM, max 59.5048 TPM, 31 observations >30; dice_cd8_stim: blood/CD8_STIM, max 47.2883 TPM, 18 observations >30; hpa_immune_cell_samples: blood/basophil, max 34.643 nTPM, 1 observations >30; hpa_immune_cell_samples: blood/naive B-cell, max 39.5753 nTPM, 1 observations >30; hpa_immune_monaco: blood/T-reg, max 33 TPM, 1 observations >30; hpa_single_cell: /B-cells, max 30.3 nTPM, 1 observations >30; hpa_single_cell: /Erythroid cells, max 97.2 nTPM, 1 observations >30; hpa_single_cell: /NK-cells, max 36.7 nTPM, 1 observations >30; hpa_single_cell: /Plasma cells, max 44.7 nTPM, 1 observations >30; hpa_single_cell: /T-cells, max 35.3 nTPM, 1 observations >30; hpa_single_cell: /Undifferentiated cells, max 41.6 nTPM, 1 observations >30; hpa_single_cell: /dendritic cells, max 38.1 nTPM, 1 observations >30; hpa_single_cell_tissue: adipose tissue/b-cells, max 46.5 nTPM, 1 observations >30; hpa_single_cell_tissue: adipose tissue/dendritic cells, max 51.1 nTPM, 1 observations >30; hpa_single_cell_tissue: adipose tissue/nk-cells, max 51.9 nTPM, 2 observations >30; hpa_single_cell_tissue: adipose tissue/t-cells, max 145.5 nTPM, 7 observations >30; hpa_single_cell_tissue: bone marrow/erythroid cells, max 54.6 nTPM, 1 observations >30; hpa_single_cell_tissue: bone marrow/plasma cells, max 68 nTPM, 1 observations >30; hpa_single_cell_tissue: bronchus/basal respiratory cells, max 51.9 nTPM, 1 observations >30; hpa_single_cell_tissue: colon/t-cells, max 49.7 nTPM, 1 observations >30; hpa_single_cell_tissue: colon/undifferentiated cells, max 62.4 nTPM, 3 observations >30; hpa_single_cell_tissue: endometrium/t-cells, max 41.3 nTPM, 1 observations >30; hpa_single_cell_tissue: esophagus/squamous epithelial cells, max 35.5 nTPM, 1 observations >30; hpa_single_cell_tissue: esophagus/t-cells, max 34.1 nTPM, 1 observations >30; hpa_single_cell_tissue: fallopian tube/t-cells, max 43.3 nTPM, 3 observations >30; hpa_single_cell_tissue: kidney/b-cells, max 31.2 nTPM, 1 observations >30; hpa_single_cell_tissue: liver/erythroid cells, max 139.8 nTPM, 1 observations >30; hpa_single_cell_tissue: liver/plasma cells, max 60.6 nTPM, 1 observations >30; hpa_single_cell_tissue: liver/t-cells, max 44.2 nTPM, 2 observations >30; hpa_single_cell_tissue: lung/alveolar cells type 2, max 51.9 nTPM, 1 observations >30; hpa_single_cell_tissue: lung/b-cells, max 34.9 nTPM, 1 observations >30; hpa_single_cell_tissue: lung/macrophages, max 59.7 nTPM, 1 observations >30; hpa_single_cell_tissue: lung/t-cells, max 37.6 nTPM, 1 observations >30; hpa_single_cell_tissue: lymph node/b-cells, max 32 nTPM, 1 observations >30; hpa_single_cell_tissue: lymph node/t-cells, max 30.4 nTPM, 1 observations >30; hpa_single_cell_tissue: ovary/mixed immune cells, max 48.2 nTPM, 1 observations >30; hpa_single_cell_tissue: pancreas/fibroblasts, max 36.4 nTPM, 1 observations >30; hpa_single_cell_tissue: pbmc/b-cells, max 50.8 nTPM, 1 observations >30; hpa_single_cell_tissue: pbmc/t-cells, max 41.6 nTPM, 1 observations >30; hpa_single_cell_tissue: placenta/mixed immune cells, max 134.6 nTPM, 1 observations >30; hpa_single_cell_tissue: rectum/mixed immune cells, max 79 nTPM, 1 observations >30; hpa_single_cell_tissue: rectum/undifferentiated cells, max 63.5 nTPM, 1 observations >30; hpa_single_cell_tissue: salivary gland/b-cells, max 49.1 nTPM, 2 observations >30; hpa_single_cell_tissue: salivary gland/mixed immune cells, max 43.7 nTPM, 1 observations >30; hpa_single_cell_tissue: salivary gland/serous glandular cells, max 30.2 nTPM, 1 observations >30; hpa_single_cell_tissue: salivary gland/t-cells, max 36.8 nTPM, 2 observations >30; hpa_single_cell_tissue: skeletal muscle/macrophages, max 33.8 nTPM, 1 observations >30; hpa_single_cell_tissue: skeletal muscle/t-cells, max 42 nTPM, 1 observations >30; hpa_single_cell_tissue: skin/langerhans cells, max 35.7 nTPM, 1 observations >30; hpa_single_cell_tissue: skin/t-cells, max 53.3 nTPM, 1 observations >30; hpa_single_cell_tissue: small intestine/mixed immune cells, max 48.3 nTPM, 1 observations >30; hpa_single_cell_tissue: small intestine/undifferentiated cells, max 40.7 nTPM, 1 observations >30; hpa_single_cell_tissue: spleen/b-cells, max 47.8 nTPM, 1 observations >30; hpa_single_cell_tissue: spleen/plasma cells, max 90.7 nTPM, 1 observations >30; hpa_single_cell_tissue: spleen/t-cells, max 33.8 nTPM, 1 observations >30; hpa_single_cell_tissue: stomach/b-cells, max 32.9 nTPM, 1 observations >30; hpa_single_cell_tissue: stomach/t-cells, max 37.8 nTPM, 2 observations >30; hpa_single_cell_tissue: testis/macrophages, max 31 nTPM, 1 observations >30; hpa_single_cell_tissue: thymus/b-cells, max 36.8 nTPM, 1 observations >30; hpa_single_cell_tissue: thymus/plasma cells, max 113.1 nTPM, 3 observations >30; hpa_single_cell_tissue: thymus/t-cells, max 31.4 nTPM, 1 observations >30; hpa_single_cell_tissue: tongue/basal keratinocytes, max 198.9 nTPM, 3 observations >30; hpa_single_cell_tissue: tongue/macrophages, max 36.3 nTPM, 1 observations >30; hpa_single_cell_tissue: tongue/t-cells, max 59.7 nTPM, 2 observations >30; hpa_single_cell_tissue: vascular/t-cells, max 34.6 nTPM, 1 observations >30",Unsafe,oncoref.target-sets.2026-10-23.2,59.5 TPM; blood/CD4_STIM; dice_cd4_stim; vital,198.9 nTPM; tongue/basal keratinocytes; hpa_single_cell_tissue; protected,Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 483/486 (99.4%); Rectum Adenocarcinoma (validation): 204/207 (98.6%),colorectal cancer: 4/12 (33.3%); ovarian cancer: 4/12 (33.3%),31,20,Q96Q89,https://www.uniprot.org/uniprotkb/Q96Q89/entry,"Plus-end-directed motor enzyme that is required for completion of cytokinesis (PubMed:11470801, PubMed:12740395). Required for proper midbody organization and abscission in polarized cortical stem cells. Plays a role in the regulation of neuronal polarization by mediating the transport of specific cargos. Participates in the mobilization of SHTN1 and in the accumulation of PIP3 in the growth cone of primary hippocampal neurons in a tubulin and actin-dependent manner. In the developing telencephalon, cooperates with SHTN1 to promote both the transition from the multipolar to the bipolar stage and the radial migration of cortical neurons from the ventricular zone toward the superficial layer of the neocortex. Involved in cerebral cortex growth (By similarity). Acts as an oncogene for promoting bladder cancer cells proliferation, apoptosis inhibition and carcinogenic progression (PubMed:17409436)","Brain, ovary, kidney and testis (at protein level) (PubMed:12740395). Overexpressed in bladder cancer cells (at protein level) (PubMed:17409436). Expressed in testis. Overexpressed in bladder cancer cells (PubMed:17409436)",,,"Nucleus Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Nucleus, nucleolus Nucleus, nucleoplasm Cytoplasm, cytoskeleton, spindle Cytoplasm, cytoskeleton, spindle pole Midbody Cell projection, axon Cell projection, growth cone",11470801|12740395|17409436,12740395|17409436,False,Reviewed UniProt annotation; not a new primary-paper review,Trial registration only,https://clinicaltrials.gov/study/NCT00676949,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
KIF24,ENSG00000186638,Unsafe,RNA,False,True,10.9,10.9,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 2.1 nTPM; absolute ceiling; choroid plexus: 3.5 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 2.1 nTPM (limit 2); choroid plexus: 3.5 nTPM (limit 2); bone marrow: 2.1 nTPM (baseline 2); choroid plexus: 3.5 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 49/58 (84.5%); Breast Invasive Carcinoma (validation): 37/50 (74.0%); Colon Adenocarcinoma (validation): 325/486 (66.9%),melanoma: 5/11 (45.5%); testis cancer: 4/9 (44.4%),31,20,Q5T7B8,https://www.uniprot.org/uniprotkb/Q5T7B8/entry,"Microtubule-dependent motor protein that acts as a negative regulator of ciliogenesis by mediating recruitment of CCP110 to mother centriole in cycling cells, leading to restrict nucleation of cilia at centrioles. Mediates depolymerization of microtubules of centriolar origin, possibly to suppress aberrant cilia formation (PubMed:21620453). Following activation by NEK2 involved in disassembly of primary cilium during G2/M phase but does not disassemble fully formed ciliary axonemes. As cilium assembly and disassembly is proposed to coexist in a dynamic equilibrium may suppress nascent cilium assembly and, potentially, ciliar re-assembly in cells that have already disassembled their cilia ensuring the completion of cilium removal in the later stages of the cell cycle (PubMed:26290419). Plays an important role in recruiting MPHOSPH9, a negative regulator of cilia formation to the distal end of mother centriole (PubMed:30375385)",,,,"Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriole Cytoplasm, cytoskeleton, microtubule organizing center, centrosome",21620453|26290419|30375385,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
KIF2A,ENSG00000068796,Unsafe,Protein,False,True,47.7,47.7,83,54,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 11.5 nTPM; positive ihc;absolute ceiling; adrenal gland: 7.5 nTPM; positive ihc;absolute ceiling; amygdala: 15.3 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 12.2 nTPM; absolute ceiling;continuous selectivity; bone marrow: 12.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 8.2 nTPM; positive ihc;absolute ceiling; cerebral cortex: 36.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 6.9 nTPM; absolute ceiling; colon: 13.3 nTPM; positive ihc;absolute ceiling; duodenum: 11.1 nTPM; positive ihc;absolute ceiling; esophagus: 12.1 nTPM; positive ihc;absolute ceiling; heart muscle: 6 nTPM; absolute ceiling; hippocampal formation: 15.7 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 14.7 nTPM; absolute ceiling;continuous selectivity; kidney: 7.8 nTPM; absolute ceiling; liver: 5.2 nTPM; absolute ceiling; lung: 9.5 nTPM; positive ihc;absolute ceiling; lymph node: 32.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 15.9 nTPM; absolute ceiling;continuous selectivity; pancreas: 9.9 nTPM; positive ihc;absolute ceiling; parathyroid gland: 11.9 nTPM; positive ihc;absolute ceiling; pituitary gland: 8.3 nTPM; absolute ceiling; rectum: 14.2 nTPM; positive ihc;absolute ceiling; retina: 41.4 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 4.6 nTPM; absolute ceiling; skin: 5.7 nTPM; positive ihc; small intestine: 15.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 12.6 nTPM; absolute ceiling; spinal cord: 17.3 nTPM; absolute ceiling;continuous selectivity; spleen: 18 nTPM; positive ihc;absolute ceiling; stomach: 9.3 nTPM; positive ihc;absolute ceiling; thymus: 42.4 nTPM; absolute ceiling;continuous selectivity; tongue: 6.5 nTPM; absolute ceiling; urinary bladder: 19.5 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 11.5 nTPM (limit 10); adrenal gland: 7.5 nTPM (limit 2); amygdala: 15.3 nTPM (limit 2); basal ganglia: 12.2 nTPM (limit 2); bone marrow: 12.6 nTPM (limit 2); cerebellum: 8.2 nTPM (limit 2); cerebral cortex: 36.1 nTPM (limit 2); choroid plexus: 6.9 nTPM (limit 2); colon: 13.3 nTPM (limit 6); duodenum: 11.1 nTPM (limit 2); esophagus: 12.1 nTPM (limit 6); heart muscle: 6 nTPM (limit 4); hippocampal formation: 15.7 nTPM (limit 2); hypothalamus: 14.7 nTPM (limit 2); kidney: 7.8 nTPM (limit 4); liver: 5.2 nTPM (limit 4); lung: 9.5 nTPM (limit 2); lymph node: 32.1 nTPM (limit 6); midbrain: 15.9 nTPM (limit 2); pancreas: 9.9 nTPM (limit 2); parathyroid gland: 11.9 nTPM (limit 6); pituitary gland: 8.3 nTPM (limit 2); rectum: 14.2 nTPM (limit 6); retina: 41.4 nTPM (limit 2); skeletal muscle: 4.6 nTPM (limit 4); small intestine: 15.5 nTPM (limit 2); smooth muscle: 12.6 nTPM (limit 4); spinal cord: 17.3 nTPM (limit 2); spleen: 18 nTPM (limit 10); stomach: 9.3 nTPM (limit 6); thymus: 42.4 nTPM (limit 10); tongue: 6.5 nTPM (limit 6); urinary bladder: 19.5 nTPM (limit 6),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: High (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / glial cells: High (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: High (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); hippocampus / glial cells: Medium (Approved); hippocampus / neuronal cells: Low (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: High (Approved); lymph node / non-germinal center cells: High (Approved); nasopharynx / respiratory epithelial cells: High (Approved); pancreas / exocrine glandular cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); skin 1 / keratinocytes: Low (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: High (Approved); small intestine / glandular cells: Medium (Approved); spleen / cells in red pulp: Medium (Approved); stomach 1 / glandular cells: Low (Approved); urinary bladder / urothelial cells: High (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%),lymphoma: 11/12 (91.7%); glioma: 10/11 (90.9%),31,20,O00139,https://www.uniprot.org/uniprotkb/O00139/entry,Plus end-directed microtubule-dependent motor required for normal brain development. May regulate microtubule dynamics during axonal growth. Required for normal progression through mitosis. Required for normal congress of chromosomes at the metaphase plate. Required for normal spindle dynamics during mitosis. Promotes spindle turnover. Implicated in formation of bipolar mitotic spindles. Has microtubule depolymerization activity,,"Cortical dysplasia, complex, with other brain malformations 3: A disorder of aberrant neuronal migration and disturbed axonal guidance. Clinical features include early-onset epilepsy, and various malformations of cortical development such as agyria, posterior or frontal pachygyria, subcortical band heterotopia, and thin corpus callosum.",,"Cytoplasm Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Cytoplasm, cytoskeleton, spindle pole Cytoplasm, cytoskeleton, spindle",15843429|17538014|18411309|30785839,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
KIF2B,ENSG00000141200,Unsafe,Protein,False,True,73.2,73.2,82,69,Positive somewhere,True,False,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0 nTPM; positive ihc; adrenal gland: 0 nTPM; positive ihc; bone marrow: 0 nTPM; positive ihc; cerebellum: 0 nTPM; positive ihc; cerebral cortex: 0 nTPM; positive ihc; colon: 0 nTPM; positive ihc; duodenum: 0 nTPM; positive ihc; esophagus: 0 nTPM; positive ihc; heart muscle: 0 nTPM; positive ihc; kidney: 0 nTPM; positive ihc; liver: 0 nTPM; positive ihc; lung: 0 nTPM; positive ihc; lymph node: 0 nTPM; positive ihc; pancreas: 0 nTPM; positive ihc; parathyroid gland: 0 nTPM; positive ihc; rectum: 0 nTPM; positive ihc; salivary gland: 0 nTPM; positive ihc; skeletal muscle: 0 nTPM; positive ihc; skin: 0 nTPM; positive ihc; small intestine: 0 nTPM; positive ihc; smooth muscle: 0 nTPM; positive ihc; stomach: 0 nTPM; positive ihc; thyroid gland: 0 nTPM; positive ihc; urinary bladder: 0 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,adipose tissue / adipocytes: Low (Uncertain); adrenal gland / glandular cells: Low (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / glial cells: Low (Uncertain); caudate / neuronal cells: Low (Uncertain); cerebellum / cells in molecular layer: Low (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / endothelial cells: Low (Uncertain); cerebral cortex / neuronal cells: Low (Uncertain); cerebral cortex / neuropil: Medium (Uncertain); colon / endothelial cells: Low (Uncertain); colon / glandular cells: High (Uncertain); colon / peripheral nerve/ganglion: Low (Uncertain); duodenum / glandular cells: High (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / glial cells: Low (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in glomeruli: Low (Uncertain); kidney / cells in tubules: High (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / alveolar cells: Low (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / germinal center cells: Low (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: Medium (Uncertain); skin 1 / fibroblasts: Low (Uncertain); skin 1 / keratinocytes: Medium (Uncertain); skin 1 / Langerhans: Medium (Uncertain); skin 2 / epidermal cells: High (Uncertain); small intestine / glandular cells: High (Uncertain); smooth muscle / smooth muscle cells: Low (Uncertain); stomach 1 / glandular cells: High (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),renal cancer: 7/11 (63.6%); ovarian cancer: 6/12 (50.0%),31,20,Q8N4N8,https://www.uniprot.org/uniprotkb/Q8N4N8/entry,Plus end-directed microtubule-dependent motor required for spindle assembly and chromosome movement. Has microtubule depolymerization activity (PubMed:17538014). Plays a role in chromosome congression (PubMed:23891108),"Highest level in lung. High level in ovary, moderate levels in heart, kidney, placenta, skeletal muscle and spleen (at protein level). Pancreas and spleen express a shorter isoform (at protein level)",,,"Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Cytoplasm, cytoskeleton, spindle Chromosome, centromere, kinetochore",17538014|23891108,17538014,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
KIF2C,ENSG00000142945,Unsafe,Protein,False,True,74.3,74.3,109,14,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 32.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 5.3 nTPM; positive ihc;absolute ceiling; lymph node: 16.1 nTPM; positive ihc;absolute ceiling; rectum: 7.4 nTPM; positive ihc;absolute ceiling; small intestine: 5 nTPM; positive ihc;absolute ceiling; thymus: 36.4 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 32.6 nTPM (limit 2); duodenum: 5.3 nTPM (limit 2); lymph node: 16.1 nTPM (limit 6); rectum: 7.4 nTPM (limit 6); small intestine: 5 nTPM (limit 2); thymus: 36.4 nTPM (limit 10),bone marrow / hematopoietic cells: Low (Enhanced); duodenum / endocrine cells: Low (Enhanced); lymph node / germinal center cells: Low (Enhanced); rectum / endocrine cells: Low (Enhanced); small intestine / enterocytes: Low (Enhanced); thymus / cortical cells: Medium (Enhanced); thymus / medullary cells: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 283/283 (100.0%); Testicular Germ Cell Tumor (TCGA): 133/133 (100.0%); Colon Adenocarcinoma (validation): 484/486 (99.6%),cervical cancer: 1/12 (8.3%); breast cancer: 0/12 (0.0%),31,20,Q99661,https://www.uniprot.org/uniprotkb/Q99661/entry,"In complex with KIF18B, constitutes the major microtubule plus-end depolymerizing activity in mitotic cells (PubMed:21820309). Regulates the turnover of microtubules at the kinetochore and functions in chromosome segregation during mitosis (PubMed:19060894). Plays a role in chromosome congression and is required for the lateral to end-on conversion of the chromosome-microtubule attachment (PubMed:23891108)","Expressed at high levels in thymus and testis, at low levels in small intestine, the mucosal lining of colon, and placenta, and at very low levels in spleen and ovary; expression is not detected in prostate, peripheral blood Leukocytes, heart, brain, lung, liver, skeletal muscle, kidney or pancreas. Isoform 2 is testis-specific",,,"Cytoplasm, cytoskeleton Nucleus Chromosome, centromere Chromosome, centromere, kinetochore",19060894|21820309|23891108,12383881|9434124,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
KIF4A,ENSG00000090889,Unsafe,Protein,False,True,2.2,12.3,77,67,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0.3 nTPM; positive ihc; adrenal gland: 0.2 nTPM; positive ihc; bone marrow: 11.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 0 nTPM; positive ihc; cerebral cortex: 0.4 nTPM; positive ihc; colon: 3.6 nTPM; positive ihc;continuous selectivity;reproductive not higher; duodenum: 3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 3.5 nTPM; positive ihc;continuous selectivity;reproductive not higher; heart muscle: 0.2 nTPM; positive ihc; kidney: 0.2 nTPM; positive ihc; liver: 0.5 nTPM; positive ihc; lung: 0.5 nTPM; positive ihc; lymph node: 5.3 nTPM; positive ihc;continuous selectivity;reproductive not higher; pancreas: 0.1 nTPM; positive ihc; parathyroid gland: 0 nTPM; positive ihc; rectum: 4.4 nTPM; positive ihc;continuous selectivity;reproductive not higher; salivary gland: 0.5 nTPM; positive ihc; skeletal muscle: 0 nTPM; positive ihc; skin: 2.1 nTPM; positive ihc;continuous selectivity; small intestine: 3.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 1.2 nTPM; continuous selectivity; spleen: 2.3 nTPM; positive ihc;continuous selectivity;reproductive not higher; stomach: 1.7 nTPM; positive ihc;continuous selectivity; thymus: 12.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 0.2 nTPM; positive ihc; urinary bladder: 0.9 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 11.1 nTPM (limit 2); duodenum: 3 nTPM (limit 2); small intestine: 3.2 nTPM (limit 2); thymus: 12.3 nTPM (limit 10),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Low (Approved); bone marrow / hematopoietic cells: High (Approved); bronchus / respiratory epithelial cells: Low (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: High (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: High (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in tubules: Low (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Low (Approved); lymph node / germinal center cells: High (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / keratinocytes: Low (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: High (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Colon Adenocarcinoma (validation): 476/486 (97.9%); Colon Adenocarcinoma (TCGA): 244/254 (96.1%),prostate cancer: 12/12 (100.0%); breast cancer: 11/11 (100.0%),31,20,O95239,https://www.uniprot.org/uniprotkb/O95239/entry,"Iron-sulfur (Fe-S) cluster binding motor protein that has a role in chromosome segregation during mitosis (PubMed:29848660). Translocates PRC1 to the plus ends of interdigitating spindle microtubules during the metaphase to anaphase transition, an essential step for the formation of an organized central spindle midzone and midbody and for successful cytokinesis (PubMed:15297875, PubMed:15625105). May play a role in mitotic chromosomal positioning and bipolar spindle stabilization (By similarity)","Highly expressed in hematopoietic tissues, fetal liver, spleen, thymus and adult thymus and bone marrow. Lower levels are found in heart, testis, kidney, colon and lung","Intellectual developmental disorder, X-linked 100: A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. Intellectual deficiency is the only primary symptom of non-syndromic X-linked forms, while syndromic forms present with associated physical, neurological and/or psychiatric manifestations. XLID100 clinical features include intellectual disability, epilepsy, microcephaly and cortical malformations. Taurodontism, microdontia, and dens invaginatus: An X-linked recessive disorder characterized by the triad of taurodontism, microdontia, and dens invaginatus. Taurodontism is a rare developmental dental condition that largely affects the molar teeth and may be associated with hypodontia. In taurodontism, the crown of the molar tooth and pulp chamber are disproportionately longer than the roots. Microdontia, a mild form of hypodontia, is defined as smaller than normal teeth with shortened crowns (vertically or mesio-distally) and loss of contact areas between the teeth. Dens invaginatus or dens invagination is a tooth developmental anomaly that results from either the dental papilla folding into the developing tooth or the entire enamel organ folding into the dental papilla. In both instances, this leads to the formation of a tooth within a tooth.",,"Nucleus matrix Cytoplasm Cytoplasm, cytoskeleton, spindle Midbody Chromosome",15297875|15625105|29848660,10978527,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
KIF6,ENSG00000164627,Unsafe,Protein,False,True,5.1,8.9,95,19,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 3.4 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 4.1 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 3.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 2.1 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 5.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 5 nTPM; absolute ceiling;continuous selectivity; midbrain: 8.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; retina: 2.9 nTPM; absolute ceiling;continuous selectivity; spinal cord: 7.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 0.5 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 3.4 nTPM (limit 2); basal ganglia: 4.1 nTPM (limit 2); cerebral cortex: 3.9 nTPM (limit 2); choroid plexus: 2.1 nTPM (limit 2); hippocampal formation: 5.1 nTPM (limit 2); hypothalamus: 5 nTPM (limit 2); midbrain: 8.9 nTPM (limit 2); retina: 2.9 nTPM (limit 2); spinal cord: 7.4 nTPM (limit 2),bronchus / ciliated cells (cell body): Medium (Enhanced); bronchus / ciliated cells (cilia axoneme): Low (Enhanced); bronchus / ciliated cells (ciliary rootlets): High (Enhanced); bronchus / ciliated cells (tip of cilia): Low (Enhanced); caudate / glial cells: Medium (Enhanced); cerebral cortex / endothelial cells: Low (Enhanced); hippocampus / glial cells: Medium (Enhanced); hippocampus / neuronal cells: Low (Enhanced); nasopharynx / ciliated cells (cell body): Medium (Enhanced); thyroid gland / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Skin Cuteneous Melanoma (TCGA): 24/99 (24.2%); Breast Invasive Carcinoma (validation): 10/50 (20.0%); Glioblastoma Multiforme (TCGA): 22/141 (15.6%),glioma: 3/12 (25.0%); breast cancer: 0/12 (0.0%),31,20,Q6ZMV9,https://www.uniprot.org/uniprotkb/Q6ZMV9/entry,,,,,"Cytoplasm, cytoskeleton",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
KIF9,ENSG00000088727,Unsafe,Protein,False,True,66.5,110.4,81,81,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 6.3 nTPM; positive ihc; adrenal gland: 7.2 nTPM; positive ihc;absolute ceiling; amygdala: 13 nTPM; absolute ceiling; basal ganglia: 11.6 nTPM; absolute ceiling; bone marrow: 11.7 nTPM; positive ihc;absolute ceiling; cerebellum: 4.6 nTPM; positive ihc;absolute ceiling; cerebral cortex: 12.9 nTPM; positive ihc;absolute ceiling; choroid plexus: 110.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 8.8 nTPM; positive ihc;absolute ceiling; duodenum: 5.9 nTPM; positive ihc;absolute ceiling; esophagus: 5.7 nTPM; positive ihc; heart muscle: 13.7 nTPM; positive ihc;absolute ceiling; hippocampal formation: 11.7 nTPM; absolute ceiling; hypothalamus: 19.5 nTPM; absolute ceiling;continuous selectivity; kidney: 26.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 5.8 nTPM; positive ihc;absolute ceiling; lung: 8.4 nTPM; positive ihc;absolute ceiling; lymph node: 2.5 nTPM; positive ihc; midbrain: 17.7 nTPM; absolute ceiling;continuous selectivity; pancreas: 12.4 nTPM; positive ihc;absolute ceiling; parathyroid gland: 9.7 nTPM; positive ihc;absolute ceiling; pituitary gland: 16 nTPM; absolute ceiling; rectum: 7.8 nTPM; positive ihc;absolute ceiling; retina: 18.3 nTPM; absolute ceiling;continuous selectivity; salivary gland: 8.7 nTPM; positive ihc;absolute ceiling; skeletal muscle: 9.1 nTPM; positive ihc;absolute ceiling; skin: 8.2 nTPM; positive ihc; small intestine: 5.4 nTPM; positive ihc;absolute ceiling; smooth muscle: 4.4 nTPM; positive ihc;absolute ceiling; spinal cord: 9.2 nTPM; absolute ceiling; spleen: 5.5 nTPM; positive ihc; stomach: 9.1 nTPM; positive ihc;absolute ceiling; thyroid gland: 20.3 nTPM; positive ihc;absolute ceiling; urinary bladder: 6.6 nTPM; positive ihc;absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 7.2 nTPM (limit 2); amygdala: 13 nTPM (limit 2); basal ganglia: 11.6 nTPM (limit 2); bone marrow: 11.7 nTPM (limit 2); cerebellum: 4.6 nTPM (limit 2); cerebral cortex: 12.9 nTPM (limit 2); choroid plexus: 110.4 nTPM (limit 2); colon: 8.8 nTPM (limit 6); duodenum: 5.9 nTPM (limit 2); heart muscle: 13.7 nTPM (limit 2); hippocampal formation: 11.7 nTPM (limit 2); hypothalamus: 19.5 nTPM (limit 2); kidney: 26.1 nTPM (limit 2); liver: 5.8 nTPM (limit 2); lung: 8.4 nTPM (limit 2); midbrain: 17.7 nTPM (limit 2); pancreas: 12.4 nTPM (limit 2); parathyroid gland: 9.7 nTPM (limit 6); pituitary gland: 16 nTPM (limit 2); rectum: 7.8 nTPM (limit 6); retina: 18.3 nTPM (limit 2); salivary gland: 8.7 nTPM (limit 6); skeletal muscle: 9.1 nTPM (limit 2); small intestine: 5.4 nTPM (limit 2); smooth muscle: 4.4 nTPM (limit 2); spinal cord: 9.2 nTPM (limit 2); stomach: 9.1 nTPM (limit 6); thyroid gland: 20.3 nTPM (limit 10); urinary bladder: 6.6 nTPM (limit 6),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Low (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: High (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Thyroid Carcinoma (TCGA): 495/495 (100.0%); Prostate Adenocarcinoma (TCGA): 480/480 (100.0%); Rectum Adenocarcinoma (TCGA): 88/88 (100.0%),colorectal cancer: 12/12 (100.0%); endometrial cancer: 12/12 (100.0%),31,20,Q9HAQ2,https://www.uniprot.org/uniprotkb/Q9HAQ2/entry,Essential for normal male fertility and for progressive motility of spermatozoa,,,,"Cytoplasm, cytoskeleton Cell projection, cilium, flagellum Cytoplasm, cytoskeleton, flagellum axoneme",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
KISS1,ENSG00000170498,Unsafe,RNA,False,True,226.4,226.4,89,4,Positive somewhere,False,True,False,True,Excluded,Normal,False,,Not assessed,,,basal ganglia: 4.4 nTPM; absolute ceiling; hypothalamus: 4 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,basal ganglia: 4.4 nTPM (limit 2); hypothalamus: 4 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (TCGA): 144/362 (39.8%); Liver Hepatocellular Carcinoma (validation): 67/231 (29.0%); Bladder Urothelial Carcinoma (TCGA): 49/169 (29.0%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q15726,https://www.uniprot.org/uniprotkb/Q15726/entry,"Kisspeptins are ligands for the G protein-coupled receptor KISS1R/GPR54 (PubMed:11385580, PubMed:11457843, PubMed:11527393, PubMed:12879005, PubMed:15020672, PubMed:15596153). The hypothalamic KISS1/KISS1R signaling system plays a central role in the regulation of the hypothalamic-pituitary-gonadal reproductive axis by modulating the secretion of gonadotropin-releasing hormone (GnRH) from GnRH neurons (PubMed:15219839, PubMed:15598687, PubMed:22335740). In these neurons, kisspeptin binding to its receptor activates G(q)-dependent signaling, leading to phospholipase C (PLC) activation, and hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) (PubMed:15598687, PubMed:22335740). The subsequent rise in intracellular calcium levels results in the inhibition of inward rectifier potassium channels and activation of TRPC-like cation channels, leading to GnRH neurons depolarization and stimulation (By similarity). In addition to this pathway, kisspeptin also triggers G(q)-independent signaling via beta-arrestin, leading to MAPK cascade activation and ERK1/ERK2 phosphorylation (PubMed:25147978). Kisspeptins are also involved in the regulation of other processes including cell growth, cell proliferation and cell migration (PubMed:11385580, PubMed:11457843, PubMed:11527393, PubMed:12879005, PubMed:15020672, PubMed:15596153) Binds the G protein-coupled receptor KISS1R/GPR54 and triggers G protein-coupled receptor signaling via activation of G(q) and phosphatidylinositol 4,5-bisphosphate (PIP2) hydrolysis by phospholipase C (PubMed:11457843, PubMed:22335740). Binding to the receptor also activates beta-arrestin-dependent signaling resulting in ERK1/2 phosphorylation (PubMed:11457843, PubMed:25147978). Activation of the receptor inhibits cell proliferation and cell migration, and is involved in the regulation of trophoblast invasion during early stages of pregnancy. Is also involved in the modulation of airway smooth muscle cells migration (PubMed:11457843, PubMed:15020672, PubMed:38512807). In bone tissue, activation of KISS1R by kisspeptin-10 recruits phosphatase DUSP18 and SRC to the KISS1R C-terminus through a G(q)-dependent signaling pathway. This leads to DUSP18-mediated dephosphorylation of SRC, down-regulation of osteoclast differentiation and activity, and consequently suppression of bone resorption (By similarity) Receptor binding triggers G protein-coupled receptor signaling via activation of G(q) and phosphatidylinositol 4,5-bisphosphate (PIP2) hydrolysis by phospholipase C","High expression in placenta (PubMed:8944003, PubMed:11385580, PubMed:11457843, PubMed:12574233). Expression levels increased in both early placentas and molar pregnancies and are reduced in choriocarcinoma cells. In first trimester trophoblasts is expressed at higher levels than at term of gestation, but only expressed in the villous trophoblast (PubMed:15020672). Also expressed in testis, pancreas, liver, small intestine","Hypogonadotropic hypogonadism 13 with or without anosmia: A disorder characterized by absent or incomplete sexual maturation by the age of 18 years, in conjunction with low levels of circulating gonadotropins and testosterone and no other abnormalities of the hypothalamic-pituitary axis. In some cases, it is associated with non-reproductive phenotypes, such as anosmia, cleft palate, and sensorineural hearing loss. Anosmia or hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts. Hypogonadism is due to deficiency in gonadotropin-releasing hormone and probably results from a failure of embryonic migration of gonadotropin-releasing hormone-synthesizing neurons. In the presence of anosmia, idiopathic hypogonadotropic hypogonadism is referred to as Kallmann syndrome, whereas in the presence of a normal sense of smell, it has been termed normosmic idiopathic hypogonadotropic hypogonadism (nIHH).",,Secreted,11385580|11457843|11527393|12879005|15020672|15219839|15596153|15598687|22335740|25147978|38512807|39151001,11385580|11457843|12414911|12574233|15020672|8944003,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Gong2021_reproductive_PC,No tumor-antigen validation in this source | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
KLHL11,ENSG00000178502,Unsafe,Protein,False,True,9.4,9.4,80,47,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 2.4 nTPM; positive ihc;absolute ceiling; bone marrow: 8.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 1.9 nTPM; positive ihc; cerebral cortex: 6.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 1.9 nTPM; positive ihc; duodenum: 1.7 nTPM; positive ihc; heart muscle: 1.9 nTPM; positive ihc; kidney: 2.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 2.4 nTPM; positive ihc;absolute ceiling; lung: 2.2 nTPM; absolute ceiling; pancreas: 2.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 4.4 nTPM; positive ihc;continuous selectivity; rectum: 1.7 nTPM; positive ihc; retina: 6.8 nTPM; absolute ceiling;continuous selectivity; salivary gland: 2.2 nTPM; positive ihc; skeletal muscle: 4.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 3.1 nTPM; positive ihc; small intestine: 1.7 nTPM; positive ihc; spleen: 2.7 nTPM; positive ihc; stomach: 2.2 nTPM; positive ihc; thyroid gland: 4.3 nTPM; positive ihc;continuous selectivity; urinary bladder: 1.5 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 2.4 nTPM (limit 2); bone marrow: 8.9 nTPM (limit 2); cerebral cortex: 6.4 nTPM (limit 2); kidney: 2.5 nTPM (limit 2); liver: 2.4 nTPM (limit 2); lung: 2.2 nTPM (limit 2); pancreas: 2.9 nTPM (limit 2); retina: 6.8 nTPM (limit 2); skeletal muscle: 4.1 nTPM (limit 2); adrenal gland: 2.4 nTPM (baseline 2); bone marrow: 8.9 nTPM (baseline 2); cerebral cortex: 6.4 nTPM (baseline 2); kidney: 2.5 nTPM (baseline 2); liver: 2.4 nTPM (baseline 2); lung: 2.2 nTPM (baseline 2); pancreas: 2.9 nTPM (baseline 2); retina: 6.8 nTPM (baseline 2); skeletal muscle: 4.1 nTPM (baseline 2),adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Low (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / glial cells: Medium (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: Medium (Uncertain); cerebellum / cells in molecular layer: Medium (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / glial cells: Low (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: Medium (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: Low (Uncertain); duodenum / glandular cells: Medium (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / glial cells: Medium (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / hepatocytes: Low (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Low (Uncertain); pancreas / pancreatic endocrine cells: Low (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: Low (Uncertain); salivary gland / glandular cells: Low (Uncertain); skeletal muscle / myocytes: Low (Uncertain); skin 2 / epidermal cells: Low (Uncertain); small intestine / glandular cells: Medium (Uncertain); spleen / cells in red pulp: Low (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Low (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Rectum Adenocarcinoma (validation): 206/207 (99.5%); Colon Adenocarcinoma (validation): 480/486 (98.8%),testis cancer: 7/8 (87.5%); renal cancer: 8/11 (72.7%),31,20,Q9NVR0,https://www.uniprot.org/uniprotkb/Q9NVR0/entry,"Component of a cullin-RING-based BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex that mediates the ubiquitination of target proteins, leading most often to their proteasomal degradation",,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | Jamin2021_CT | Jamin2021_core,GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
KLHL35,ENSG00000149243,Unsafe,RNA,False,True,9.0,10.4,84,2,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,amygdala: 3.6 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 10.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 5 nTPM; continuous selectivity; hippocampal formation: 3.7 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 5.8 nTPM; absolute ceiling;continuous selectivity; midbrain: 2.6 nTPM; absolute ceiling;continuous selectivity; spinal cord: 4.7 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 3.6 nTPM (limit 2); basal ganglia: 10.4 nTPM (limit 2); hippocampal formation: 3.7 nTPM (limit 2); hypothalamus: 5.8 nTPM (limit 2); midbrain: 2.6 nTPM (limit 2); spinal cord: 4.7 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 41/50 (82.0%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 177/283 (62.5%); Ovary Serous Cystadenocarcinoma (TCGA): 176/349 (50.4%),breast cancer: 0/12 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q6PF15,https://www.uniprot.org/uniprotkb/Q6PF15/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
KLHL7,ENSG00000122550,Unsafe,Protein,False,True,40.9,49.0,78,63,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 9.2 nTPM; positive ihc; adrenal gland: 18.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 14.3 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 13.8 nTPM; absolute ceiling;continuous selectivity; bone marrow: 12.2 nTPM; absolute ceiling;continuous selectivity; cerebellum: 14.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 15.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 7.7 nTPM; absolute ceiling; colon: 8.8 nTPM; positive ihc;absolute ceiling; duodenum: 7.5 nTPM; positive ihc;absolute ceiling; esophagus: 8.8 nTPM; positive ihc;absolute ceiling; heart muscle: 49 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 13.6 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 15.7 nTPM; absolute ceiling;continuous selectivity; kidney: 11.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 10.1 nTPM; positive ihc;absolute ceiling; lung: 7.4 nTPM; positive ihc;absolute ceiling; lymph node: 8.2 nTPM; positive ihc;absolute ceiling; midbrain: 14.7 nTPM; absolute ceiling;continuous selectivity; pancreas: 7.6 nTPM; positive ihc;absolute ceiling; parathyroid gland: 10.7 nTPM; positive ihc;absolute ceiling; pituitary gland: 7.1 nTPM; absolute ceiling; rectum: 7.6 nTPM; positive ihc;absolute ceiling; retina: 14.6 nTPM; absolute ceiling;continuous selectivity; salivary gland: 8.3 nTPM; positive ihc;absolute ceiling; skeletal muscle: 8.7 nTPM; positive ihc;absolute ceiling; skin: 10.5 nTPM; positive ihc;absolute ceiling; small intestine: 6.7 nTPM; positive ihc;absolute ceiling; smooth muscle: 10.1 nTPM; absolute ceiling; spinal cord: 13.6 nTPM; absolute ceiling;continuous selectivity; stomach: 6.2 nTPM; positive ihc;absolute ceiling; thymus: 12.1 nTPM; absolute ceiling; thyroid gland: 9 nTPM; positive ihc; tongue: 9.4 nTPM; absolute ceiling; urinary bladder: 8.5 nTPM; positive ihc;absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 18.3 nTPM (limit 2); amygdala: 14.3 nTPM (limit 2); basal ganglia: 13.8 nTPM (limit 2); bone marrow: 12.2 nTPM (limit 2); cerebellum: 14.5 nTPM (limit 2); cerebral cortex: 15.3 nTPM (limit 2); choroid plexus: 7.7 nTPM (limit 2); colon: 8.8 nTPM (limit 6); duodenum: 7.5 nTPM (limit 2); esophagus: 8.8 nTPM (limit 6); heart muscle: 49 nTPM (limit 2); hippocampal formation: 13.6 nTPM (limit 2); hypothalamus: 15.7 nTPM (limit 2); kidney: 11.5 nTPM (limit 2); liver: 10.1 nTPM (limit 2); lung: 7.4 nTPM (limit 2); lymph node: 8.2 nTPM (limit 6); midbrain: 14.7 nTPM (limit 2); pancreas: 7.6 nTPM (limit 2); parathyroid gland: 10.7 nTPM (limit 6); pituitary gland: 7.1 nTPM (limit 2); rectum: 7.6 nTPM (limit 6); retina: 14.6 nTPM (limit 2); salivary gland: 8.3 nTPM (limit 6); skeletal muscle: 8.7 nTPM (limit 2); skin: 10.5 nTPM (limit 10); small intestine: 6.7 nTPM (limit 2); smooth muscle: 10.1 nTPM (limit 2); spinal cord: 13.6 nTPM (limit 2); stomach: 6.2 nTPM (limit 6); thymus: 12.1 nTPM (limit 10); tongue: 9.4 nTPM (limit 6); urinary bladder: 8.5 nTPM (limit 6); adrenal gland: 18.3 nTPM (baseline 2); amygdala: 14.3 nTPM (baseline 2); basal ganglia: 13.8 nTPM (baseline 2); bone marrow: 12.2 nTPM (baseline 2); cerebellum: 14.5 nTPM (baseline 2); cerebral cortex: 15.3 nTPM (baseline 2); choroid plexus: 7.7 nTPM (baseline 2); colon: 8.8 nTPM (baseline 6); duodenum: 7.5 nTPM (baseline 2); esophagus: 8.8 nTPM (baseline 6); heart muscle: 49 nTPM (baseline 2); hippocampal formation: 13.6 nTPM (baseline 2); hypothalamus: 15.7 nTPM (baseline 2); kidney: 11.5 nTPM (baseline 2); liver: 10.1 nTPM (baseline 2); lung: 7.4 nTPM (baseline 2); lymph node: 8.2 nTPM (baseline 6); midbrain: 14.7 nTPM (baseline 2); pancreas: 7.6 nTPM (baseline 2); parathyroid gland: 10.7 nTPM (baseline 6); pituitary gland: 7.1 nTPM (baseline 2); rectum: 7.6 nTPM (baseline 6); retina: 14.6 nTPM (baseline 2); salivary gland: 8.3 nTPM (baseline 6); skeletal muscle: 8.7 nTPM (baseline 2); skin: 10.5 nTPM (baseline 10); small intestine: 6.7 nTPM (baseline 2); smooth muscle: 10.1 nTPM (baseline 2); spinal cord: 13.6 nTPM (baseline 2); stomach: 6.2 nTPM (baseline 6); thymus: 12.1 nTPM (baseline 10); tongue: 9.4 nTPM (baseline 6); urinary bladder: 8.5 nTPM (baseline 6),adipose tissue / adipocytes: Medium (Uncertain); adrenal gland / glandular cells: High (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / glial cells: Low (Uncertain); caudate / neuronal cells: Low (Uncertain); cerebellum / cells in granular layer: Medium (Uncertain); cerebellum / cells in molecular layer: Low (Uncertain); cerebral cortex / glial cells: Medium (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: Low (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: High (Uncertain); hippocampus / glial cells: Medium (Uncertain); hippocampus / neuronal cells: Low (Uncertain); kidney / cells in glomeruli: Low (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / cholangiocytes: Low (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / alveolar cells: Medium (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / germinal center cells: Low (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Low (Uncertain); parathyroid gland / glandular cells: Low (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: Medium (Uncertain); skin 1 / fibroblasts: Low (Uncertain); skin 1 / keratinocytes: Medium (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: Medium (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Low (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 141/141 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%); Kidney Renal Clear Cell Carcinoma (validation): 100/100 (100.0%),colorectal cancer: 11/12 (91.7%); liver cancer: 10/12 (83.3%),31,20,Q8IXQ5,https://www.uniprot.org/uniprotkb/Q8IXQ5/entry,Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin ligase complex. The BCR(KLHL7) complex acts by mediating ubiquitination and subsequent degradation of substrate proteins. Probably mediates 'Lys-48'-linked ubiquitination,"Widely expressed, with highest levels in adult and fetal heart, CNS and adult testis","Perching syndrome: An autosomal recessive multisystem disorder characterized by global developmental delay, dysmorphic facial features, feeding and respiratory difficulties with poor overall growth, axial hypotonia, and joint contractures. The features are variable, even within families, and may also include retinitis pigmentosa, cardiac or genitourinary anomalies, and abnormal sweating. Retinitis pigmentosa 42: A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.",,Nucleus Cytoplasm,21828050,16918702,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
KLK15,ENSG00000174562,Unsafe,High RNA,False,True,1.1,3.9,82,0,Negative where measured,False,False,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 0.8 nTPM; continuous selectivity; colon: 2.2 nTPM; continuous selectivity;reproductive not higher; rectum: 0.9 nTPM; continuous selectivity; salivary gland: 3.9 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 0.7 nTPM; continuous selectivity,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,True,"colon/intestinal goblet cells cluster c-4: 28 nTPM, 114 reads; reproductive-cell max 24.6; rectum/intestinal goblet cells cluster c-1: 109.2 nTPM, 221 reads; reproductive-cell max 24.6; rectum/intestinal goblet cells cluster c-6: 75.1 nTPM, 84 reads; reproductive-cell max 24.6",True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: High, HPA019802; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA019802; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA019802; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA019802; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA019802; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA019802; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA019802; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, HPA019802; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA019802; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,0.285741019037,109.2,"hpa_single_cell: /Intestinal goblet cells, max 33.8 nTPM, 1 observations >30; hpa_single_cell_tissue: rectum/intestinal goblet cells, max 109.2 nTPM, 2 observations >30",Neither,oncoref.target-sets.2026-10-23.2,0.2857 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,109.2 nTPM; rectum/intestinal goblet cells; hpa_single_cell_tissue; protected,Kidney Chromophobe (TCGA): 56/64 (87.5%); Prostate Adenocarcinoma (TCGA): 215/480 (44.8%); Rectum Adenocarcinoma (validation): 30/207 (14.5%),prostate cancer: 3/10 (30.0%); skin cancer: 1/11 (9.1%),31,20,Q9H2R5,https://www.uniprot.org/uniprotkb/Q9H2R5/entry,Protease whose physiological substrate is not yet known,"Highest expression in the thyroid gland. Also expressed in the prostate, salivary, and adrenal glands and in the colon testis and kidney",,,Secreted,,11010966,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
KNL1,ENSG00000137812,Unsafe,Protein,False,True,16.4,16.4,91,17,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 5.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 1.2 nTPM; positive ihc; duodenum: 1.5 nTPM; positive ihc; esophagus: 0.9 nTPM; positive ihc; lymph node: 3.5 nTPM; positive ihc; rectum: 1.3 nTPM; positive ihc; skin: 0.7 nTPM; positive ihc; small intestine: 1.6 nTPM; positive ihc; thymus: 7.2 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 5.1 nTPM (limit 2),bone marrow / hematopoietic cells: Medium (Enhanced); colon / glandular cells: Low (Enhanced); duodenum / glandular cells: Low (Enhanced); esophagus / squamous epithelial cells: Low (Enhanced); lymph node / non-germinal center cells: Low (Enhanced); rectum / glandular cells: Low (Enhanced); skin 1 / keratinocytes: Low (Enhanced); small intestine / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 472/486 (97.1%); Glioblastoma Multiforme (validation): 56/58 (96.6%); Rectum Adenocarcinoma (validation): 191/207 (92.3%),cervical cancer: 9/12 (75.0%); colorectal cancer: 4/11 (36.4%),29,20,Q8NG31,https://www.uniprot.org/uniprotkb/Q8NG31/entry,"Acts as a component of the outer kinetochore KNL1 complex that serves as a docking point for spindle assembly checkpoint components and mediates microtubule-kinetochore interactions (PubMed:15502821, PubMed:17981135, PubMed:18045986, PubMed:19893618, PubMed:21199919, PubMed:22000412, PubMed:22331848, PubMed:27881301, PubMed:30100357). Kinetochores, consisting of a centromere-associated inner segment and a microtubule-contacting outer segment, play a crucial role in chromosome segregation by mediating the physical connection between centromeric DNA and spindle microtubules (PubMed:18045986, PubMed:19893618, PubMed:27881301). The outer kinetochore is made up of the ten-subunit KMN network, comprising the MIS12, NDC80 and KNL1 complexes, and auxiliary microtubule-associated components; together they connect the outer kinetochore with the inner kinetochore, bind microtubules, and mediate interactions with mitotic checkpoint proteins that delay anaphase until chromosomes are bioriented on the spindle (PubMed:17981135, PubMed:19893618, PubMed:22000412, PubMed:38459127, PubMed:38459128). Required for kinetochore binding by a distinct subset of kMAPs (kinetochore-bound microtubule-associated proteins) and motors (PubMed:19893618). Acts in coordination with CENPK to recruit the NDC80 complex to the outer kinetochore (PubMed:18045986, PubMed:27881301). Can bind either to microtubules or to the protein phosphatase 1 (PP1) catalytic subunits PPP1CA and PPP1CC (via overlapping binding sites), it has higher affinity for PP1 (PubMed:30100357). Recruits MAD2L1 to the kinetochore and also directly links BUB1 and BUB1B to the kinetochore (PubMed:17981135, PubMed:19893618, PubMed:22000412, PubMed:22331848, PubMed:25308863). In addition to orienting mitotic chromosomes, it is also essential for alignment of homologous chromosomes during meiotic metaphase I (By similarity). In meiosis I, required to activate the spindle assembly checkpoint at unattached kinetochores to correct erroneous kinetochore-microtubule attachments (By similarity)","Highly expressed in testis, where it is localized in germ cells, in particular in spermatocytes and in the pre-acrosome of round spermatids. Detected in the acrosome of ejaculated spermatozoa. Detected in adult thymus, bone marrow, colon, small intestine, appendix and placenta, and in fetal liver and thymus","Microcephaly 4, primary, autosomal recessive: A disease defined as a head circumference more than 3 standard deviations below the age-related mean. Brain weight is markedly reduced and the cerebral cortex is disproportionately small. Despite this marked reduction in size, the gyral pattern is relatively well preserved, with no major abnormality in cortical architecture. Affected individuals have mild to moderate intellectual disability. Primary microcephaly is further defined by the absence of other syndromic features or significant neurological deficits due to degenerative brain disorder.",,"Nucleus Chromosome, centromere, kinetochore Cytoplasm",15502821|17981135|18045986|19893618|21199919|22000412|22331848|25308863|27881301|30100357|38459127|38459128,10980622|12087463|12618768,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Jamin2021_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
KPNA2,ENSG00000182481,Unsafe,Protein,False,True,203.2,203.2,125,63,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 15.4 nTPM; positive ihc;absolute ceiling; amygdala: 17.8 nTPM; absolute ceiling; basal ganglia: 15.2 nTPM; absolute ceiling; bone marrow: 98 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 10.3 nTPM; positive ihc;absolute ceiling; cerebral cortex: 26.4 nTPM; positive ihc;absolute ceiling; choroid plexus: 9.6 nTPM; absolute ceiling; colon: 29.7 nTPM; positive ihc;absolute ceiling; duodenum: 25.4 nTPM; positive ihc;absolute ceiling; esophagus: 40.2 nTPM; positive ihc;absolute ceiling; heart muscle: 23.1 nTPM; positive ihc;absolute ceiling; hippocampal formation: 20 nTPM; absolute ceiling; hypothalamus: 23 nTPM; absolute ceiling; kidney: 15.7 nTPM; positive ihc;absolute ceiling; liver: 22.4 nTPM; positive ihc;absolute ceiling; lung: 17.3 nTPM; positive ihc;absolute ceiling; lymph node: 70.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 16.4 nTPM; absolute ceiling; pancreas: 9.7 nTPM; positive ihc;absolute ceiling; parathyroid gland: 10.3 nTPM; positive ihc;absolute ceiling; pituitary gland: 15.2 nTPM; absolute ceiling; rectum: 34.7 nTPM; positive ihc;absolute ceiling; retina: 21.5 nTPM; absolute ceiling; salivary gland: 15 nTPM; positive ihc;absolute ceiling; skeletal muscle: 14.3 nTPM; positive ihc;absolute ceiling; skin: 20.5 nTPM; positive ihc;absolute ceiling; small intestine: 22.7 nTPM; positive ihc;absolute ceiling; smooth muscle: 33.3 nTPM; absolute ceiling; spinal cord: 15.6 nTPM; absolute ceiling; spleen: 27.6 nTPM; positive ihc;absolute ceiling; stomach: 18.5 nTPM; positive ihc;absolute ceiling; thymus: 92.3 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 10.6 nTPM; positive ihc;absolute ceiling; tongue: 16.1 nTPM; absolute ceiling; urinary bladder: 37.2 nTPM; positive ihc;absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 15.4 nTPM (limit 2); amygdala: 17.8 nTPM (limit 2); basal ganglia: 15.2 nTPM (limit 2); bone marrow: 98 nTPM (limit 2); cerebellum: 10.3 nTPM (limit 2); cerebral cortex: 26.4 nTPM (limit 2); choroid plexus: 9.6 nTPM (limit 2); colon: 29.7 nTPM (limit 6); duodenum: 25.4 nTPM (limit 2); esophagus: 40.2 nTPM (limit 6); heart muscle: 23.1 nTPM (limit 2); hippocampal formation: 20 nTPM (limit 2); hypothalamus: 23 nTPM (limit 2); kidney: 15.7 nTPM (limit 2); liver: 22.4 nTPM (limit 2); lung: 17.3 nTPM (limit 2); lymph node: 70.4 nTPM (limit 6); midbrain: 16.4 nTPM (limit 2); pancreas: 9.7 nTPM (limit 2); parathyroid gland: 10.3 nTPM (limit 6); pituitary gland: 15.2 nTPM (limit 2); rectum: 34.7 nTPM (limit 6); retina: 21.5 nTPM (limit 2); salivary gland: 15 nTPM (limit 6); skeletal muscle: 14.3 nTPM (limit 2); skin: 20.5 nTPM (limit 10); small intestine: 22.7 nTPM (limit 2); smooth muscle: 33.3 nTPM (limit 12); spinal cord: 15.6 nTPM (limit 2); spleen: 27.6 nTPM (limit 10); stomach: 18.5 nTPM (limit 6); thymus: 92.3 nTPM (limit 10); thyroid gland: 10.6 nTPM (limit 10); tongue: 16.1 nTPM (limit 6); urinary bladder: 37.2 nTPM (limit 6),adrenal gland / glandular cells: Medium (Enhanced); bone marrow / hematopoietic cells: Medium (Enhanced); bronchus / ciliated cells (cell body): Medium (Enhanced); caudate / neuronal cells: Medium (Enhanced); cerebellum / Purkinje cells: Medium (Enhanced); cerebral cortex / glial cells: Low (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); colon / glandular cells: Medium (Enhanced); duodenum / glandular cells: Medium (Enhanced); esophagus / squamous epithelial cells: Medium (Enhanced); heart muscle / cardiomyocytes: High (Enhanced); hippocampus / glial cells: Low (Enhanced); hippocampus / neuronal cells: Medium (Enhanced); kidney / distal tubules: Medium (Enhanced); kidney / proximal tubules (cell body): Low (Enhanced); liver / hepatocytes: Medium (Enhanced); lung / macrophages: Medium (Enhanced); lymph node / germinal center cells: High (Enhanced); lymph node / non-germinal center cells: Medium (Enhanced); nasopharynx / ciliated cells (cell body): Medium (Enhanced); oral mucosa / squamous epithelial cells: Low (Enhanced); pancreas / exocrine glandular cells: Medium (Enhanced); pancreas / pancreatic endocrine cells: Low (Enhanced); parathyroid gland / glandular cells: Low (Enhanced); rectum / glandular cells: Medium (Enhanced); salivary gland / glandular cells: Low (Enhanced); skeletal muscle / myocytes: Low (Enhanced); skin 1 / cells in basal layer: Low (Enhanced); skin 1 / cells in spinous layer: Low (Enhanced); skin 1 / fibrohistiocytic cells: High (Enhanced); skin 2 / cells in basal layer: Low (Enhanced); skin 2 / cells in spinous layer: Medium (Enhanced); skin 2 / fibrohistiocytic cells: Low (Enhanced); skin 2 / lymphocytes: Low (Enhanced); small intestine / glandular cells: Medium (Enhanced); spleen / cells in red pulp: Medium (Enhanced); spleen / cells in white pulp: Medium (Enhanced); stomach 1 / glandular cells: Medium (Enhanced); stomach 2 / glandular cells: Low (Enhanced); thyroid gland / glandular cells: Medium (Enhanced); urinary bladder / urothelial cells: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%); Head and Neck Squamous Cell Carcinoma (TCGA): 492/492 (100.0%),cervical cancer: 12/12 (100.0%); colorectal cancer: 12/12 (100.0%),31,20,P52292,https://www.uniprot.org/uniprotkb/P52292/entry,"Functions in nuclear protein import as an adapter protein for nuclear receptor KPNB1 (PubMed:28991411, PubMed:32130408, PubMed:7604027, PubMed:7754385). Binds specifically and directly to substrates containing either a simple or bipartite NLS motif (PubMed:28991411, PubMed:32130408, PubMed:7604027, PubMed:7754385). Docking of the importin/substrate complex to the nuclear pore complex (NPC) is mediated by KPNB1 through binding to nucleoporin FxFG repeats and the complex is subsequently translocated through the pore by an energy requiring, Ran-dependent mechanism (PubMed:7604027, PubMed:7754385). At the nucleoplasmic side of the NPC, Ran binds to importin-beta and the three components separate and importin-alpha and -beta are re-exported from the nucleus to the cytoplasm where GTP hydrolysis releases Ran from importin. The directionality of nuclear import is thought to be conferred by an asymmetric distribution of the GTP- and GDP-bound forms of Ran between the cytoplasm and nucleus. Mediator of PR-DUB complex component BAP1 nuclear import; acts redundantly with KPNA1 and Transportin-1/TNPO1 (PubMed:35446349)",Expressed ubiquitously,,,Cytoplasm Nucleus Endoplasmic reticulum membrane Golgi apparatus membrane,28991411|32130408|35446349|7604027|7754385,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
KPNA5,ENSG00000196911,Unsafe,Protein,False,True,40.7,40.7,108,47,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 5.6 nTPM; positive ihc;absolute ceiling; amygdala: 3 nTPM; absolute ceiling; basal ganglia: 3 nTPM; absolute ceiling; bone marrow: 4.5 nTPM; positive ihc;absolute ceiling; cerebellum: 7.4 nTPM; positive ihc;absolute ceiling; cerebral cortex: 10.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 3.2 nTPM; positive ihc; duodenum: 2.8 nTPM; positive ihc;absolute ceiling; esophagus: 4.2 nTPM; positive ihc; heart muscle: 4.4 nTPM; positive ihc;absolute ceiling; hippocampal formation: 3 nTPM; absolute ceiling; hypothalamus: 3 nTPM; absolute ceiling; kidney: 5.3 nTPM; positive ihc;absolute ceiling; midbrain: 3.1 nTPM; absolute ceiling; parathyroid gland: 7 nTPM; positive ihc;absolute ceiling; pituitary gland: 4.5 nTPM; absolute ceiling; rectum: 3.3 nTPM; positive ihc; retina: 19.5 nTPM; absolute ceiling;continuous selectivity; salivary gland: 4.2 nTPM; positive ihc; skeletal muscle: 12.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 4.1 nTPM; positive ihc; small intestine: 3.2 nTPM; positive ihc;absolute ceiling; spinal cord: 3.1 nTPM; absolute ceiling; stomach: 3.7 nTPM; positive ihc; thyroid gland: 11.1 nTPM; positive ihc;absolute ceiling; tongue: 12.4 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 5.6 nTPM (limit 2); amygdala: 3 nTPM (limit 2); basal ganglia: 3 nTPM (limit 2); bone marrow: 4.5 nTPM (limit 2); cerebellum: 7.4 nTPM (limit 2); cerebral cortex: 10.4 nTPM (limit 2); duodenum: 2.8 nTPM (limit 2); heart muscle: 4.4 nTPM (limit 2); hippocampal formation: 3 nTPM (limit 2); hypothalamus: 3 nTPM (limit 2); kidney: 5.3 nTPM (limit 2); midbrain: 3.1 nTPM (limit 2); parathyroid gland: 7 nTPM (limit 6); pituitary gland: 4.5 nTPM (limit 2); retina: 19.5 nTPM (limit 2); skeletal muscle: 12.7 nTPM (limit 2); small intestine: 3.2 nTPM (limit 2); spinal cord: 3.1 nTPM (limit 2); thyroid gland: 11.1 nTPM (limit 10); tongue: 12.4 nTPM (limit 6),adrenal gland / glandular cells: Low (Enhanced); bone marrow / hematopoietic cells: Medium (Enhanced); bronchus / respiratory epithelial cells: Low (Enhanced); caudate / glial cells: Low (Enhanced); caudate / neuronal cells: Low (Enhanced); cerebellum / cells in granular layer: Low (Enhanced); cerebellum / cells in molecular layer: Low (Enhanced); cerebellum / Purkinje cells: Medium (Enhanced); cerebral cortex / glial cells: Low (Enhanced); cerebral cortex / neuronal cells: Low (Enhanced); colon / endothelial cells: Low (Enhanced); colon / glandular cells: Low (Enhanced); duodenum / glandular cells: Low (Enhanced); esophagus / squamous epithelial cells: Low (Enhanced); heart muscle / cardiomyocytes: Medium (Enhanced); hippocampus / neuronal cells: Medium (Enhanced); kidney / distal tubules: Medium (Enhanced); kidney / proximal tubules (cell body): Low (Enhanced); nasopharynx / respiratory epithelial cells: Low (Enhanced); oral mucosa / squamous epithelial cells: Low (Enhanced); parathyroid gland / glandular cells: Medium (Enhanced); rectum / glandular cells: Medium (Enhanced); salivary gland / glandular cells: Low (Enhanced); skeletal muscle / myocytes: Low (Enhanced); skin 1 / cells in granular layer: Low (Enhanced); skin 1 / endothelial cells: Medium (Enhanced); skin 1 / fibrohistiocytic cells: Medium (Enhanced); skin 2 / cells in granular layer: Low (Enhanced); skin 2 / cells in spinous layer: Low (Enhanced); skin 2 / endothelial cells: Medium (Enhanced); skin 2 / fibrohistiocytic cells: Medium (Enhanced); small intestine / glandular cells: Low (Enhanced); stomach 1 / glandular cells: Medium (Enhanced); stomach 2 / glandular cells: Medium (Enhanced); thyroid gland / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 485/486 (99.8%),endometrial cancer: 2/12 (16.7%); colorectal cancer: 1/10 (10.0%),31,20,O15131,https://www.uniprot.org/uniprotkb/O15131/entry,"Functions in nuclear protein import as an adapter protein for nuclear receptor KPNB1. Binds specifically and directly to substrates containing either a simple or bipartite NLS motif. Docking of the importin/substrate complex to the nuclear pore complex (NPC) is mediated by KPNB1 through binding to nucleoporin FxFG repeats and the complex is subsequently translocated through the pore by an energy requiring, Ran-dependent mechanism. At the nucleoplasmic side of the NPC, Ran binds to importin-beta and the three components separate and importin-alpha and -beta are re-exported from the nucleus to the cytoplasm where GTP hydrolysis releases Ran from importin. The directionality of nuclear import is thought to be conferred by an asymmetric distribution of the GTP- and GDP-bound forms of Ran between the cytoplasm and nucleus. Mediates nuclear import of STAT1 homodimers and STAT1/STAT2 heterodimers by recognizing non-classical NLSs of STAT1 and STAT2 through ARM repeats 8-9. Recognizes influenza A virus nucleoprotein through ARM repeat 7-9 In vitro, mediates the nuclear import of human cytomegalovirus UL84 by recognizing a non-classical NLS",Testis,,,Cytoplasm,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
KRBOX1,ENSG00000240747,Unsafe,RNA,False,True,192.1,192.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 4.5 nTPM; absolute ceiling; amygdala: 3.9 nTPM; absolute ceiling; basal ganglia: 3.2 nTPM; absolute ceiling; cerebellum: 2.2 nTPM; absolute ceiling; cerebral cortex: 3.2 nTPM; absolute ceiling; choroid plexus: 2.3 nTPM; absolute ceiling; heart muscle: 3.6 nTPM; absolute ceiling; hippocampal formation: 3.3 nTPM; absolute ceiling; hypothalamus: 3.2 nTPM; absolute ceiling; kidney: 5.3 nTPM; absolute ceiling; midbrain: 3.5 nTPM; absolute ceiling; pancreas: 3.9 nTPM; absolute ceiling; pituitary gland: 3.6 nTPM; absolute ceiling; retina: 2.7 nTPM; absolute ceiling; smooth muscle: 5.2 nTPM; absolute ceiling; spinal cord: 4.6 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 4.5 nTPM (limit 2); amygdala: 3.9 nTPM (limit 2); basal ganglia: 3.2 nTPM (limit 2); cerebellum: 2.2 nTPM (limit 2); cerebral cortex: 3.2 nTPM (limit 2); choroid plexus: 2.3 nTPM (limit 2); heart muscle: 3.6 nTPM (limit 2); hippocampal formation: 3.3 nTPM (limit 2); hypothalamus: 3.2 nTPM (limit 2); kidney: 5.3 nTPM (limit 2); midbrain: 3.5 nTPM (limit 2); pancreas: 3.9 nTPM (limit 2); pituitary gland: 3.6 nTPM (limit 2); retina: 2.7 nTPM (limit 2); smooth muscle: 5.2 nTPM (limit 2); spinal cord: 4.6 nTPM (limit 2); adrenal gland: 4.5 nTPM (baseline 2); amygdala: 3.9 nTPM (baseline 2); basal ganglia: 3.2 nTPM (baseline 2); cerebellum: 2.2 nTPM (baseline 2); cerebral cortex: 3.2 nTPM (baseline 2); choroid plexus: 2.3 nTPM (baseline 2); heart muscle: 3.6 nTPM (baseline 2); hippocampal formation: 3.3 nTPM (baseline 2); hypothalamus: 3.2 nTPM (baseline 2); kidney: 5.3 nTPM (baseline 2); midbrain: 3.5 nTPM (baseline 2); pancreas: 3.9 nTPM (baseline 2); pituitary gland: 3.6 nTPM (baseline 2); retina: 2.7 nTPM (baseline 2); smooth muscle: 5.2 nTPM (baseline 2); spinal cord: 4.6 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 69/141 (48.9%); Thyroid Carcinoma (TCGA): 240/495 (48.5%); Ovary Serous Cystadenocarcinoma (TCGA): 159/349 (45.6%),No exact-ID IHC coverage in the HPA cancer snapshot,30,0,C9JBD0,https://www.uniprot.org/uniprotkb/C9JBD0/entry,,,,,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Chang2019_TGCT,Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
KRIT1,ENSG00000001631,Unsafe,Protein,False,True,12.0,15.8,106,5,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 8 nTPM; continuous selectivity; adrenal gland: 8.4 nTPM; absolute ceiling;continuous selectivity; amygdala: 5.4 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 6.2 nTPM; absolute ceiling;continuous selectivity; cerebellum: 10.4 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 6.9 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 5.9 nTPM; absolute ceiling;continuous selectivity; colon: 8.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 6.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 7.7 nTPM; absolute ceiling;continuous selectivity; heart muscle: 12 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 5.5 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 6.2 nTPM; absolute ceiling;continuous selectivity; kidney: 9.1 nTPM; absolute ceiling;continuous selectivity; liver: 8.1 nTPM; absolute ceiling;continuous selectivity; lung: 6.3 nTPM; absolute ceiling;continuous selectivity; lymph node: 6 nTPM; continuous selectivity; midbrain: 5.7 nTPM; absolute ceiling;continuous selectivity; pancreas: 7.9 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 15.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 9.2 nTPM; absolute ceiling;continuous selectivity; rectum: 6 nTPM; positive ihc;continuous selectivity; retina: 4.1 nTPM; absolute ceiling;continuous selectivity; salivary gland: 8.1 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 12.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 6.1 nTPM; continuous selectivity; small intestine: 7.1 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 7.6 nTPM; absolute ceiling;continuous selectivity; spinal cord: 6.3 nTPM; absolute ceiling;continuous selectivity; spleen: 6.8 nTPM; continuous selectivity; stomach: 7.9 nTPM; absolute ceiling;continuous selectivity; thymus: 10.7 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 12.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; tongue: 13 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 8.4 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 8.4 nTPM (limit 6); amygdala: 5.4 nTPM (limit 2); basal ganglia: 6.2 nTPM (limit 2); cerebellum: 10.4 nTPM (limit 6); cerebral cortex: 6.9 nTPM (limit 6); choroid plexus: 5.9 nTPM (limit 2); colon: 8.5 nTPM (limit 6); duodenum: 6.1 nTPM (limit 2); heart muscle: 12 nTPM (limit 6); hippocampal formation: 5.5 nTPM (limit 2); hypothalamus: 6.2 nTPM (limit 2); kidney: 9.1 nTPM (limit 6); liver: 8.1 nTPM (limit 6); lung: 6.3 nTPM (limit 6); midbrain: 5.7 nTPM (limit 2); pancreas: 7.9 nTPM (limit 6); parathyroid gland: 15.8 nTPM (limit 12); pituitary gland: 9.2 nTPM (limit 2); retina: 4.1 nTPM (limit 2); skeletal muscle: 12.4 nTPM (limit 6); small intestine: 7.1 nTPM (limit 2); smooth muscle: 7.6 nTPM (limit 6); spinal cord: 6.3 nTPM (limit 2); thymus: 10.7 nTPM (limit 10); tongue: 13 nTPM (limit 6); adrenal gland: 8.4 nTPM (baseline 2); amygdala: 5.4 nTPM (baseline 2); basal ganglia: 6.2 nTPM (baseline 2); cerebellum: 10.4 nTPM (baseline 2); cerebral cortex: 6.9 nTPM (baseline 2); choroid plexus: 5.9 nTPM (baseline 2); colon: 8.5 nTPM (baseline 6); duodenum: 6.1 nTPM (baseline 2); esophagus: 7.7 nTPM (baseline 6); heart muscle: 12 nTPM (baseline 2); hippocampal formation: 5.5 nTPM (baseline 2); hypothalamus: 6.2 nTPM (baseline 2); kidney: 9.1 nTPM (baseline 2); liver: 8.1 nTPM (baseline 2); lung: 6.3 nTPM (baseline 2); midbrain: 5.7 nTPM (baseline 2); pancreas: 7.9 nTPM (baseline 2); parathyroid gland: 15.8 nTPM (baseline 6); pituitary gland: 9.2 nTPM (baseline 2); retina: 4.1 nTPM (baseline 2); salivary gland: 8.1 nTPM (baseline 6); skeletal muscle: 12.4 nTPM (baseline 2); small intestine: 7.1 nTPM (baseline 2); smooth muscle: 7.6 nTPM (baseline 2); spinal cord: 6.3 nTPM (baseline 2); stomach: 7.9 nTPM (baseline 6); thymus: 10.7 nTPM (baseline 10); thyroid gland: 12.6 nTPM (baseline 10); tongue: 13 nTPM (baseline 6); urinary bladder: 8.4 nTPM (baseline 6),colon / enterocytes: Low (Supported); colon / goblet cells: Low (Supported); duodenum / enterocytes: Low (Supported); rectum / endothelial cells: Low (Supported),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Pancreatic Adenocarcinoma (validation): 80/80 (100.0%),colorectal cancer: 1/12 (8.3%); ovarian cancer: 1/12 (8.3%),31,20,O00522,https://www.uniprot.org/uniprotkb/O00522/entry,"Component of the CCM signaling pathway which is a crucial regulator of heart and vessel formation and integrity (By similarity). Negative regulator of angiogenesis. Inhibits endothelial proliferation, apoptosis, migration, lumen formation and sprouting angiogenesis in primary endothelial cells. Promotes AKT phosphorylation in a NOTCH-dependent and independent manner, and inhibits ERK1/2 phosphorylation indirectly through activation of the DELTA-NOTCH cascade. Acts in concert with CDH5 to establish and maintain correct endothelial cell polarity and vascular lumen and these effects are mediated by recruitment and activation of the Par polarity complex and RAP1B. Required for the localization of phosphorylated PRKCZ, PARD3, TIAM1 and RAP1B to the cell junction, and cell junction stabilization. Plays a role in integrin signaling via its interaction with ITGB1BP1; this prevents the interaction between ITGB1 and ITGB1BP1. Microtubule-associated protein that binds to phosphatidylinositol 4,5-bisphosphate (PIP2)-containing membranes in a GTP-bound RAP1-dependent manner. Plays an important role in the maintenance of the intracellular reactive oxygen species (ROS) homeostasis to prevent oxidative cellular damage. Regulates the homeostasis of intracellular ROS through an antioxidant pathway involving FOXO1 and SOD2. Facilitates the down-regulation of cyclin-D1 (CCND1) levels required for cell transition from proliferative growth to quiescence by preventing the accumulation of intracellular ROS through the modulation of FOXO1 and SOD2 levels. May play a role in the regulation of macroautophagy through the down-regulation of the mTOR pathway (PubMed:26417067)",Low levels in brain. Very weak expression found in heart and muscle,"Cerebral cavernous malformations 1: A form of cerebral cavernous malformations, a congenital vascular anomaly of the central nervous system that can result in hemorrhagic stroke, seizures, recurrent headaches, and focal neurologic deficits. The lesions are characterized by grossly enlarged blood vessels consisting of a single layer of endothelium and without any intervening neural tissue, ranging in diameter from a few millimeters to several centimeters. CCM1 inheritance is autosomal dominant.",,"Cytoplasm, cytoskeleton Cell membrane Cell junction",11741838|17916086|20332120|20616044|20668652|21633110|23317506|26417067,9285558,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
KRT25,ENSG00000204897,Unsafe,RNA,False,True,2.6,108.8,104,1,Positive somewhere,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 2.6 nTPM; continuous selectivity;reproductive not higher; skin: 108.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,skin: 108.8 nTPM (limit 10); skin: 108.8 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Skin Cuteneous Melanoma (TCGA): 3/99 (3.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 4/176 (2.3%); Kidney Renal Clear Cell Carcinoma (validation): 1/100 (1.0%),breast cancer: 0/12 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q7Z3Z0,https://www.uniprot.org/uniprotkb/Q7Z3Z0/entry,Essential for the proper assembly of type I and type II keratin protein complexes and formation of keratin intermediate filaments in the inner root sheath (irs) (By similarity). Plays a role in the cytoskeleton organization (PubMed:26902920),"Strongly expressed in skin and scalp, and weak expression observed in thymus and tongue. In the hair follicle, expressed in Henle layer, Huxley layer and in the inner root sheath cuticle of the hair follicle. Expression extends from the bulb region up to the point of differentiation into the three layers. Also present in the medulla of beard hair (at protein level)","Woolly hair autosomal recessive 3: A hair shaft disorder characterized by fine and tightly curled hair. Compared to normal curly hair that is observed in some populations, woolly hair grows slowly and stops growing after a few inches. Under light microscopy, woolly hair shows some structural anomalies, including trichorrhexis nodosa and tapered ends. Some individuals may present with hypotrichosis.",,Cytoplasm,26902920,15617563|16874310,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
KRT28,ENSG00000173908,Unsafe,RNA,False,True,0.7,11.3,100,1,Positive somewhere,False,True,False,False,Excluded,Normal,True,,Not assessed,,,skin: 11.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,skin: 11.3 nTPM (limit 10); skin: 11.3 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 5/176 (2.8%); Bladder Urothelial Carcinoma (TCGA): 2/169 (1.2%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 3/283 (1.1%),breast cancer: 0/10 (0.0%); cervical cancer: 0/9 (0.0%),31,20,Q7Z3Y7,https://www.uniprot.org/uniprotkb/Q7Z3Y7/entry,Essential for the proper assembly of types I and II keratin protein complexes and the formation of keratin intermediate filaments in the inner root sheath (irs),"Strongly expressed in skin and scalp, and weak expression observed in thymus. In the hair follicle, expressed in Henle layer, Huxley layer and in the irs cuticle. Expression extends from the bulb region up to the point of differentiation into the three layers. Also present in the medulla of beard hair (at protein level)",,,Cytoplasm,,15617563|16874310,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
KRT33A,ENSG00000006059,Unsafe,RNA,False,True,2.4,46.0,99,1,Positive somewhere,False,True,False,False,Excluded,Normal,True,,Not assessed,,,skin: 46 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,skin: 46 nTPM (limit 10); skin: 46 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 1/50 (2.0%); Lung Squamous Cell Carcinoma (TCGA): 9/489 (1.8%); Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%),testis cancer: 1/12 (8.3%); breast cancer: 0/11 (0.0%),31,20,O76009,https://www.uniprot.org/uniprotkb/O76009/entry,,Expressed in the hair follicles,,,,,9756910,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
KRT33B,ENSG00000131738,Unsafe,RNA,False,True,0.2,80.2,99,1,Positive somewhere,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 0.7 nTPM; continuous selectivity;reproductive not higher; cerebral cortex: 0.4 nTPM; continuous selectivity;reproductive not higher; hippocampal formation: 0.2 nTPM; continuous selectivity;reproductive not higher; skin: 80.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thymus: 1.3 nTPM; continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,skin: 80.2 nTPM (limit 10); skin: 80.2 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Colon Adenocarcinoma (validation): 1/486 (0.2%),testis cancer: 1/12 (8.3%); breast cancer: 0/11 (0.0%),31,20,Q14525,https://www.uniprot.org/uniprotkb/Q14525/entry,,,,,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
KRT35,ENSG00000197079,Unsafe,RNA,False,True,0.1,56.3,79,1,Positive somewhere,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 1.9 nTPM; continuous selectivity;reproductive not higher; salivary gland: 0.6 nTPM; continuous selectivity;reproductive not higher; skin: 56.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 0.1 nTPM; reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,; skin: 56.3 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 1/50 (2.0%); Rectum Adenocarcinoma (validation): 4/207 (1.9%); Colon Adenocarcinoma (validation): 9/486 (1.9%),breast cancer: 0/10 (0.0%); cervical cancer: 0/9 (0.0%),31,20,Q92764,https://www.uniprot.org/uniprotkb/Q92764/entry,,"Early expression in the hair follicle, mainly found in supramatricial cells and lowermost cortical cells of the hair bulb",,,,,8823373,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
KRT72,ENSG00000170486,Unsafe,RNA,False,True,23.0,23.0,101,1,Positive somewhere,False,True,False,False,Excluded,Normal,True,,Not assessed,,,skin: 10.2 nTPM; absolute ceiling;continuous selectivity; small intestine: 2.1 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,skin: 10.2 nTPM (limit 10); skin: 10.2 nTPM (baseline 10); small intestine: 2.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 2/50 (4.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 3/176 (1.7%); Lung Squamous Cell Carcinoma (validation): 1/68 (1.5%),breast cancer: 0/12 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q14CN4,https://www.uniprot.org/uniprotkb/Q14CN4/entry,Has a role in hair formation. Specific component of keratin intermediate filaments in the inner root sheath (IRS) of the hair follicle (Probable),"Highly expressed in hair follicles from scalp and eyebrow. Also expressed in palmoplantar epidermis. Not expressed in face skin despite the presence of fine hairs histologically. In hair, it is specifically present in the inner root sheath (IRS) of the hair follicle. Present in the IRS cuticle, but not in Henle or Huxley layers of the IRS. In the IRS cuticle, its presence is delayed up to the height of the apex of the dermal papilla (at protein level)",,Was initially thought to be the ortholog of mouse KRT71,,,11703281|12648212|16874310,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,Failed bulk numeric comparisons are within 20% of their cutoffs; not an automatic rescue,,,,
KRT82,ENSG00000161850,Unsafe,RNA,False,True,0.1,12.3,82,1,Positive somewhere,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 0.3 nTPM; continuous selectivity;reproductive not higher; skin: 12.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,; skin: 12.3 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),breast cancer: 0/12 (0.0%); cervical cancer: 0/10 (0.0%),31,20,Q9NSB4,https://www.uniprot.org/uniprotkb/Q9NSB4/entry,"Structural component of intermediate filaments in the hair follicle. As a type II hair keratin, forms obligate heterodimers with type I hair keratins that assemble into keratin intermediate filaments. Expressed specifically in cuticle-forming cells of the hair shaft during the anagen phase, where it contributes to the formation and structural integrity of the hair cuticle","Expressed in the hair follicle, specifically in hair shaft cuticle during the anagen phase of the hair cycle",,,Cytoplasm,35145093,11445569|35145093,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
KRTAP10-1,ENSG00000215455,Unsafe,RNA,False,True,0.0,10.1,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,existing nomination or manual review; insufficient positive reproductive evidence; nomination unresolved; reproductive expression not demonstrated; incomplete tissue evidence,Measured normal RNA exceeds its applicable category/IHC ceiling,skin: 10.1 nTPM (limit 10); skin: 10.1 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,P60331,https://www.uniprot.org/uniprotkb/P60331/entry,"In the hair cortex, hair keratin intermediate filaments are embedded in an interfilamentous matrix, consisting of hair keratin-associated proteins (KRTAP), which are essential for the formation of a rigid and resistant hair shaft through their extensive disulfide bond cross-linking with abundant cysteine residues of hair keratins. The matrix proteins include the high-sulfur and high-glycine-tyrosine keratins","Restricted to a narrow region of the hair fiber cuticle, lying approximately 20 cell layers above the apex of the dermal papilla of the hair root; not detected in any other tissues",,,,,14962103|15028290,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,Failed bulk numeric comparisons are within 20% of their cutoffs; not an automatic rescue,,,,
KRTAP10-2,ENSG00000205445,Unsafe,RNA,False,True,0.0,14.6,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,insufficient positive reproductive evidence; reproductive expression not demonstrated; incomplete tissue evidence,Measured normal RNA exceeds its applicable category/IHC ceiling,skin: 14.6 nTPM (limit 10); skin: 14.6 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,P60368,https://www.uniprot.org/uniprotkb/P60368/entry,"In the hair cortex, hair keratin intermediate filaments are embedded in an interfilamentous matrix, consisting of hair keratin-associated proteins (KRTAP), which are essential for the formation of a rigid and resistant hair shaft through their extensive disulfide bond cross-linking with abundant cysteine residues of hair keratins. The matrix proteins include the high-sulfur and high-glycine-tyrosine keratins","Restricted to a narrow region of the hair fiber cuticle, lying approximately 20 cell layers above the apex of the dermal papilla of the hair root; not detected in any other tissues",,,,,14962103|15028290,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
KRTAP10-7,ENSG00000272804,Unsafe,RNA,False,True,0.0,13.8,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,existing nomination or manual review; insufficient positive reproductive evidence; nomination unresolved; reproductive expression not demonstrated; incomplete tissue evidence,Measured normal RNA exceeds its applicable category/IHC ceiling,skin: 13.8 nTPM (limit 10); skin: 13.8 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,26,0,P60409,https://www.uniprot.org/uniprotkb/P60409/entry,"In the hair cortex, hair keratin intermediate filaments are embedded in an interfilamentous matrix, consisting of hair keratin-associated proteins (KRTAP), which are essential for the formation of a rigid and resistant hair shaft through their extensive disulfide bond cross-linking with abundant cysteine residues of hair keratins. The matrix proteins include the high-sulfur and high-glycine-tyrosine keratins","Restricted to a narrow region of the hair fiber cuticle, lying approximately 20 cell layers above the apex of the dermal papilla of the hair root; not detected in any other tissues",,,,,14962103|15028290,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
KRTAP26-1,ENSG00000197683,Unsafe,RNA,False,True,1.3,18.7,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,existing nomination or manual review; nomination unresolved; skin: 18.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,skin: 18.7 nTPM (limit 10); skin: 18.7 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Prostate Adenocarcinoma (TCGA): 1/480 (0.2%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q6PEX3,https://www.uniprot.org/uniprotkb/Q6PEX3/entry,"In the hair cortex, hair keratin intermediate filaments are embedded in an interfilamentous matrix, consisting of hair keratin-associated proteins (KRTAP), which are essential for the formation of a rigid and resistant hair shaft through their extensive disulfide bond cross-linking with abundant cysteine residues of hair keratins. The matrix proteins include the high-sulfur and high-glycine-tyrosine keratins",Localized high up in the well differentiated portion of the hair follicle cuticle (about 10-15 cell layers above the apex of the dermal papilla),,,,,18647308,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
KRTAP5-8,ENSG00000241233,Unsafe,RNA,False,True,1.4,7.3,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,basal ganglia: 0.5 nTPM; continuous selectivity; cerebral cortex: 0.5 nTPM; continuous selectivity; kidney: 5.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 7.3 nTPM; continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,kidney: 5.8 nTPM (limit 2); kidney: 5.8 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Chromophobe (TCGA): 52/64 (81.2%); Bladder Urothelial Carcinoma (TCGA): 6/169 (3.6%); Kidney Renal Clear Cell Carcinoma (TCGA): 16/521 (3.1%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,O75690,https://www.uniprot.org/uniprotkb/O75690/entry,"In the hair cortex, hair keratin intermediate filaments are embedded in an interfilamentous matrix, consisting of hair keratin-associated protein (KRTAP), which are essential for the formation of a rigid and resistant hair shaft through their extensive disulfide bond cross-linking with abundant cysteine residues of hair keratins. The matrix proteins include the high-sulfur and high-glycine-tyrosine keratins","Restricted to hair root, not detected in any other tissues. Expressed in cuticle layers of differentiating hair follicles",,,,,15144888,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
KRTAP8-1,ENSG00000183640,Unsafe,RNA,False,True,0.2,59.4,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,existing nomination or manual review; nomination unresolved; adipose tissue: 0.6 nTPM; continuous selectivity;reproductive not higher; skin: 59.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,skin: 59.4 nTPM (limit 10); skin: 59.4 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Skin Cuteneous Melanoma (TCGA): 1/99 (1.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q8IUC2,https://www.uniprot.org/uniprotkb/Q8IUC2/entry,"In the hair cortex, hair keratin intermediate filaments are embedded in an interfilamentous matrix, consisting of hair keratin-associated proteins (KRTAP), which are essential for the formation of a rigid and resistant hair shaft through their extensive disulfide bond cross-linking with abundant cysteine residues of hair keratins. The matrix proteins include the high-sulfur and high-glycine-tyrosine keratins",Is essentially restricted to only one vertical half of the hair forming compartment and in beard hairs is absent from the central medulla,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
KRTAP9-2,ENSG00000239886,Unsafe,RNA,False,True,0.1,31.7,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,skin: 31.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,skin: 31.7 nTPM (limit 10); skin: 31.7 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 0/283 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q9BYQ4,https://www.uniprot.org/uniprotkb/Q9BYQ4/entry,"In the hair cortex, hair keratin intermediate filaments are embedded in an interfilamentous matrix, consisting of hair keratin-associated proteins (KRTAP), which are essential for the formation of a rigid and resistant hair shaft through their extensive disulfide bond cross-linking with abundant cysteine residues of hair keratins. The matrix proteins include the high-sulfur and high-glycine-tyrosine keratins",,,,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | daSilva2017_tumor_proteomics,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
L1TD1,ENSG00000240563,Unsafe,High RNA,False,True,11.2,11.2,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,colon: 5.2 nTPM; continuous selectivity,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE M2 (unstimulated): 87/90 values ≥5 TPM, max 57.2226; hpa_immune_cell non-classical monocyte: 5.1 nTPM; hpa_immune_monaco non-classical monocyte: 13.6 TPM",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,57.2225886155,57.6,"dice_m2: blood/M2, max 57.2226 TPM, 31 observations >30; hpa_single_cell_tissue: colon/intestinal goblet cells, max 57.6 nTPM, 1 observations >30; hpa_single_cell_tissue: colon/undifferentiated cells, max 32.1 nTPM, 1 observations >30; hpa_single_cell_tissue: vascular/fibroblasts, max 32.8 nTPM, 1 observations >30",Neither,oncoref.target-sets.2026-10-23.2,57.22 TPM; blood/M2; dice_m2; vital,57.6 nTPM; colon/intestinal goblet cells; hpa_single_cell_tissue; protected,Testicular Germ Cell Tumor (TCGA): 125/133 (94.0%); Colon Adenocarcinoma (validation): 222/486 (45.7%); Colon Adenocarcinoma (TCGA): 96/254 (37.8%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q5T7N2,https://www.uniprot.org/uniprotkb/Q5T7N2/entry,"RNA-binding protein which plays a role in the regulation of pluripotency. Preferentially binds to 5'-GAGCGU-3' sequences. Binds to the 3'-UTR of the pluripotency regulator TFCP2L1, stabilizing transcripts and resulting in increased TFCP2L1 mRNA levels",,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Jamin2021_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
L3MBTL4,ENSG00000154655,Unsafe,Protein,False,True,12.3,12.3,86,40,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 4.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 3.3 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 2.6 nTPM; absolute ceiling; bone marrow: 1.4 nTPM; positive ihc; cerebellum: 0.3 nTPM; positive ihc; cerebral cortex: 3.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 2.2 nTPM; absolute ceiling; colon: 2 nTPM; positive ihc; esophagus: 3.4 nTPM; positive ihc; heart muscle: 4.8 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 3.5 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 2.4 nTPM; absolute ceiling; kidney: 6.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 8.5 nTPM; absolute ceiling;continuous selectivity; lung: 3.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 1.9 nTPM; positive ihc; midbrain: 3.2 nTPM; absolute ceiling;continuous selectivity; pancreas: 6.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 8.2 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 3.1 nTPM; absolute ceiling; salivary gland: 3.2 nTPM; positive ihc; skeletal muscle: 0.9 nTPM; positive ihc; skin: 7 nTPM; positive ihc;continuous selectivity; small intestine: 3.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 1.2 nTPM; positive ihc; spinal cord: 2.3 nTPM; absolute ceiling; stomach: 3.1 nTPM; positive ihc; thyroid gland: 5.6 nTPM; positive ihc;continuous selectivity; urinary bladder: 1.4 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 4.2 nTPM (limit 2); amygdala: 3.3 nTPM (limit 2); basal ganglia: 2.6 nTPM (limit 2); cerebral cortex: 3.2 nTPM (limit 2); choroid plexus: 2.2 nTPM (limit 2); heart muscle: 4.8 nTPM (limit 4); hippocampal formation: 3.5 nTPM (limit 2); hypothalamus: 2.4 nTPM (limit 2); kidney: 6.9 nTPM (limit 2); liver: 8.5 nTPM (limit 4); lung: 3.7 nTPM (limit 2); midbrain: 3.2 nTPM (limit 2); pancreas: 6.3 nTPM (limit 2); parathyroid gland: 8.2 nTPM (limit 8); pituitary gland: 3.1 nTPM (limit 2); small intestine: 3.4 nTPM (limit 2); spinal cord: 2.3 nTPM (limit 2),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Medium (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebral cortex / glial cells: Low (Approved); colon / peripheral nerve/ganglion: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); hippocampus / glial cells: Medium (Approved); kidney / cells in tubules: Medium (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Low (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Low (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Low (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Low (Approved); smooth muscle / smooth muscle cells: Medium (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 46/58 (79.3%); Kidney Renal Clear Cell Carcinoma (validation): 70/100 (70.0%); Liver Hepatocellular Carcinoma (validation): 160/231 (69.3%),lung cancer: 5/12 (41.7%); liver cancer: 3/10 (30.0%),31,20,Q8NA19,https://www.uniprot.org/uniprotkb/Q8NA19/entry,"Putative Polycomb group (PcG) protein. PcG proteins maintain the transcriptionally repressive state of genes, probably via a modification of chromatin, rendering it heritably changed in its expressibility (By similarity)",,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
LACTB,ENSG00000103642,Unsafe,Protein,False,True,21.4,56.5,116,79,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 16.7 nTPM; continuous selectivity; adrenal gland: 24.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 7.1 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 8.1 nTPM; absolute ceiling;continuous selectivity; bone marrow: 56.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 5.1 nTPM; positive ihc;absolute ceiling; cerebral cortex: 6.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 12 nTPM; absolute ceiling;continuous selectivity; colon: 17.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 19 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 14.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 21.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 6.5 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 6.7 nTPM; absolute ceiling;continuous selectivity; kidney: 22.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 41.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 18.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 19.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 7.4 nTPM; absolute ceiling;continuous selectivity; pancreas: 10.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 9.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 6.5 nTPM; absolute ceiling;continuous selectivity; rectum: 15.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 4.5 nTPM; absolute ceiling; salivary gland: 9.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 47.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 11.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 16.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 8.7 nTPM; absolute ceiling; spinal cord: 6.6 nTPM; absolute ceiling;continuous selectivity; spleen: 17.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 12.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; thyroid gland: 9 nTPM; positive ihc; tongue: 34.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 19 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 24.6 nTPM (limit 2); amygdala: 7.1 nTPM (limit 2); basal ganglia: 8.1 nTPM (limit 2); bone marrow: 56.5 nTPM (limit 2); cerebellum: 5.1 nTPM (limit 2); cerebral cortex: 6.6 nTPM (limit 2); choroid plexus: 12 nTPM (limit 2); colon: 17.9 nTPM (limit 6); duodenum: 19 nTPM (limit 2); esophagus: 14.4 nTPM (limit 6); heart muscle: 21.5 nTPM (limit 2); hippocampal formation: 6.5 nTPM (limit 2); hypothalamus: 6.7 nTPM (limit 2); kidney: 22.7 nTPM (limit 2); liver: 41.1 nTPM (limit 2); lung: 18.4 nTPM (limit 2); lymph node: 19.3 nTPM (limit 6); midbrain: 7.4 nTPM (limit 2); pancreas: 10.3 nTPM (limit 2); parathyroid gland: 9.5 nTPM (limit 6); pituitary gland: 6.5 nTPM (limit 2); rectum: 15.4 nTPM (limit 6); retina: 4.5 nTPM (limit 2); salivary gland: 9.6 nTPM (limit 6); skeletal muscle: 47.5 nTPM (limit 2); skin: 11.6 nTPM (limit 10); small intestine: 16.4 nTPM (limit 2); smooth muscle: 8.7 nTPM (limit 6); spinal cord: 6.6 nTPM (limit 2); spleen: 17.8 nTPM (limit 10); stomach: 12.4 nTPM (limit 6); tongue: 34.9 nTPM (limit 6); urinary bladder: 19 nTPM (limit 6),adrenal gland / glandular cells: Medium (Supported); bone marrow / hematopoietic cells: Medium (Supported); bronchus / ciliated cells (cell body): Medium (Supported); caudate / glial cells: Low (Supported); caudate / neuronal cells: Medium (Supported); cerebellum / cells in granular layer: Low (Supported); cerebellum / cells in molecular layer: Low (Supported); cerebellum / Purkinje cells: Medium (Supported); cerebral cortex / endothelial cells: Low (Supported); cerebral cortex / neuronal cells: Medium (Supported); cerebral cortex / neuropil: Medium (Supported); colon / endothelial cells: Low (Supported); colon / glandular cells: Medium (Supported); colon / peripheral nerve/ganglion: Low (Supported); duodenum / glandular cells: Medium (Supported); esophagus / squamous epithelial cells: Medium (Supported); heart muscle / cardiomyocytes: Low (Supported); hippocampus / neuronal cells: Medium (Supported); kidney / cells in glomeruli: Low (Supported); kidney / cells in tubules: Medium (Supported); liver / hepatocytes: Medium (Supported); lung / alveolar cells type II: Low (Supported); lung / macrophages: Medium (Supported); lymph node / germinal center cells: Medium (Supported); lymph node / non-germinal center cells: Medium (Supported); nasopharynx / ciliated cells (cell body): Medium (Supported); oral mucosa / squamous epithelial cells: Medium (Supported); pancreas / exocrine glandular cells: Medium (Supported); pancreas / pancreatic endocrine cells: Low (Supported); parathyroid gland / glandular cells: Medium (Supported); rectum / glandular cells: Medium (Supported); salivary gland / glandular cells: Medium (Supported); skeletal muscle / myocytes: Low (Supported); skin 1 / cells in basal layer: Medium (Supported); skin 2 / cells in basal layer: Medium (Supported); skin 2 / cells in granular layer: Medium (Supported); skin 2 / cells in spinous layer: Medium (Supported); skin 2 / endothelial cells: Medium (Supported); skin 2 / fibrohistiocytic cells: Medium (Supported); skin 2 / langerhans cells: Medium (Supported); skin 2 / lymphocytes: Low (Supported); small intestine / glandular cells: Medium (Supported); spleen / cells in red pulp: Low (Supported); spleen / cells in white pulp: Medium (Supported); stomach 1 / glandular cells: Medium (Supported); stomach 2 / glandular cells: Medium (Supported); thyroid gland / glandular cells: Medium (Supported); urinary bladder / urothelial cells: Medium (Supported),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Colon Adenocarcinoma (TCGA): 254/254 (100.0%); Liver Hepatocellular Carcinoma (validation): 231/231 (100.0%),liver cancer: 11/11 (100.0%); melanoma: 11/12 (91.7%),31,20,P83111,https://www.uniprot.org/uniprotkb/P83111/entry,"Mitochondrial serine protease that acts as a regulator of mitochondrial lipid metabolism (PubMed:28329758). Acts by decreasing protein levels of PISD, a mitochondrial enzyme that converts phosphatidylserine (PtdSer) to phosphatidylethanolamine (PtdEtn), thereby affecting mitochondrial lipid metabolism (PubMed:28329758). It is unclear whether it acts directly by mediating proteolysis of PISD or by mediating proteolysis of another lipid metabolism protein (PubMed:28329758). Acts as a tumor suppressor that has the ability to inhibit proliferation of multiple types of breast cancer cells: probably by promoting decreased levels of PISD, thereby affecting mitochondrial lipid metabolism (PubMed:28329758)",Expressed predominantly in skeletal muscle,,"Was originally identified as mitochondrial large ribosomal subunit protein mL56 (MRP-L56) (PubMed:11551941), but has since been shown to localize to the mitochondrial intermembrane space where it forms filaments (PubMed:19858488)",Mitochondrion,28329758,11707067,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
LACTBL1,ENSG00000215906,Unsafe,RNA,False,True,0.2,3.8,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,existing nomination or manual review; nomination unresolved; retina: 3.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 3.8 nTPM (limit 2); retina: 3.8 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,A8MY62,https://www.uniprot.org/uniprotkb/A8MY62/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
LALBA,ENSG00000167531,Unsafe,High RNA,False,True,2109.2,2109.2,79,2,Positive somewhere,False,False,False,True,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,CTA,Pass,oncoref.target-sets.2026-10-23.1,False,False,,CTA → Unsafe,True,True,True,0.5688161284409999,1302.6,"hpa_single_cell: /Adipocytes, max 139 nTPM, 1 observations >30; hpa_single_cell: /Macrophages, max 54.4 nTPM, 1 observations >30; hpa_single_cell_tissue: breast/macrophages, max 1302.6 nTPM, 3 observations >30; hpa_single_cell_tissue: breast/t-cells, max 555.5 nTPM, 4 observations >30",CTA,oncoref.target-sets.2026-10-23.2,0.5688 TPM; blood/TH17; dice_th17; vital,1303 nTPM; breast/macrophages; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (validation): 5/50 (10.0%); Breast Invasive Carcinoma (TCGA): 28/1022 (2.7%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),breast cancer: 0/12 (0.0%); cervical cancer: 0/11 (0.0%),31,20,P00709,https://www.uniprot.org/uniprotkb/P00709/entry,"Regulatory subunit of lactose synthase, changes the substrate specificity of galactosyltransferase in the mammary gland making glucose a good acceptor substrate for this enzyme. This enables LS to synthesize lactose, the major carbohydrate component of milk. In other tissues, galactosyltransferase transfers galactose onto the N-acetylglucosamine of the oligosaccharide chains in glycoproteins",Mammary gland specific. Secreted in milk,,,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
LCA5,ENSG00000135338,Unsafe,Protein,False,True,9.3,16.7,103,45,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 1.8 nTPM; positive ihc; amygdala: 4.3 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 4.2 nTPM; absolute ceiling;continuous selectivity; bone marrow: 3.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 4.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 13.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 2.4 nTPM; positive ihc; duodenum: 1 nTPM; positive ihc; esophagus: 2.9 nTPM; positive ihc; heart muscle: 2.3 nTPM; positive ihc;absolute ceiling; hippocampal formation: 4.5 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 4 nTPM; absolute ceiling;continuous selectivity; kidney: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 1.1 nTPM; positive ihc; lung: 3.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 4 nTPM; absolute ceiling;continuous selectivity; pancreas: 2.4 nTPM; positive ihc;absolute ceiling; parathyroid gland: 16.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 3.5 nTPM; absolute ceiling;continuous selectivity; rectum: 1.5 nTPM; positive ihc; retina: 13.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 5.4 nTPM; positive ihc;continuous selectivity; skeletal muscle: 1.1 nTPM; positive ihc; small intestine: 1.3 nTPM; positive ihc; spinal cord: 6 nTPM; absolute ceiling;continuous selectivity; stomach: 1.5 nTPM; positive ihc; thyroid gland: 6.1 nTPM; positive ihc;continuous selectivity; urinary bladder: 3.3 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 4.3 nTPM (limit 2); basal ganglia: 4.2 nTPM (limit 2); bone marrow: 3.5 nTPM (limit 2); cerebral cortex: 4.2 nTPM (limit 2); choroid plexus: 13.9 nTPM (limit 2); heart muscle: 2.3 nTPM (limit 2); hippocampal formation: 4.5 nTPM (limit 2); hypothalamus: 4 nTPM (limit 2); kidney: 2.7 nTPM (limit 2); lung: 3.9 nTPM (limit 2); midbrain: 4 nTPM (limit 2); pancreas: 2.4 nTPM (limit 2); parathyroid gland: 16.7 nTPM (limit 6); pituitary gland: 3.5 nTPM (limit 2); retina: 13.3 nTPM (limit 2); spinal cord: 6 nTPM (limit 2),adrenal gland / glandular cells: Low (Supported); bone marrow / hematopoietic cells: Medium (Supported); bronchus / ciliated cells (tip of cilia): High (Supported); caudate / glial cells: Medium (Supported); cerebral cortex / glial cells: Medium (Supported); cerebral cortex / neuropil: Medium (Supported); colon / glandular cells: Low (Supported); duodenum / glandular cells: Low (Supported); esophagus / squamous epithelial cells: Low (Supported); heart muscle / cardiomyocytes: Medium (Supported); hippocampus / glial cells: Medium (Supported); kidney / cells in tubules: Medium (Supported); liver / hepatocytes: Low (Supported); lung / alveolar cells type II: Low (Supported); lung / macrophages: Medium (Supported); nasopharynx / ciliated cells (tip of cilia): High (Supported); oral mucosa / squamous epithelial cells: Low (Supported); pancreas / exocrine glandular cells: Low (Supported); parathyroid gland / glandular cells: Low (Supported); rectum / glandular cells: Low (Supported); salivary gland / glandular cells: Low (Supported); skeletal muscle / myocytes: Low (Supported); small intestine / glandular cells: Low (Supported); stomach 1 / glandular cells: Medium (Supported); stomach 2 / glandular cells: Medium (Supported); thyroid gland / glandular cells: Medium (Supported); urinary bladder / urothelial cells: Low (Supported),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 43/50 (86.0%); Thyroid Carcinoma (TCGA): 373/495 (75.4%),prostate cancer: 11/11 (100.0%); breast cancer: 8/12 (66.7%),31,20,Q86VQ0,https://www.uniprot.org/uniprotkb/Q86VQ0/entry,Involved in intraflagellar protein (IFT) transport in photoreceptor cilia. Plays a role in the ciliary transport of photoreceptors outer segment proteins,Widely expressed,"Leber congenital amaurosis 5: A severe dystrophy of the retina, typically becoming evident in the first years of life. Visual function is usually poor and often accompanied by nystagmus, sluggish or near-absent pupillary responses, photophobia, high hyperopia and keratoconus.",,"Cytoplasm, cytoskeleton Cytoplasm, cytoskeleton, cilium axoneme Cytoplasm, cytoskeleton, cilium basal body Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Cell projection, cilium",,17546029,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
LCA5L,ENSG00000157578,Unsafe,Protein,False,True,107.2,107.2,101,11,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; choroid plexus: 2.4 nTPM; absolute ceiling; kidney: 2.3 nTPM; positive ihc;absolute ceiling; retina: 10.5 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 2.4 nTPM (limit 2); kidney: 2.3 nTPM (limit 2); retina: 10.5 nTPM (limit 2),bronchus / ciliated cells (cilia axoneme): High (Enhanced); kidney / cells in glomeruli: Medium (Enhanced); kidney / distal tubules: Low (Enhanced); kidney / proximal tubules (microvilli): Medium (Enhanced); nasopharynx / ciliated cells (ciliary rootlets): Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 46/50 (92.0%); Glioblastoma Multiforme (validation): 11/58 (19.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 21/176 (11.9%),glioma: 7/12 (58.3%); melanoma: 3/9 (33.3%),31,20,O95447,https://www.uniprot.org/uniprotkb/O95447/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | Jamin2021_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
LCE2D,ENSG00000187223,Unsafe,RNA,False,True,6.8,147.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,skeletal muscle: 2.1 nTPM; absolute ceiling;continuous selectivity; skin: 147.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,skeletal muscle: 2.1 nTPM (limit 2); skin: 147.2 nTPM (limit 10); skeletal muscle: 2.1 nTPM (baseline 2); skin: 147.2 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Skin Cuteneous Melanoma (TCGA): 24/99 (24.2%); Head and Neck Squamous Cell Carcinoma (TCGA): 48/492 (9.8%); Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q5TA82,https://www.uniprot.org/uniprotkb/Q5TA82/entry,Precursors of the cornified envelope of the stratum corneum,"Skin-specific. Expression was readily detected in adult trunk skin, adult arm skin, fetal skin, penal skin, vulva, esophagus and tongue. Not expressed in the cervix, rectum, lung, colon, or placenta",,,,,15854049,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
LCOR,ENSG00000196233,Unsafe,Protein,False,True,5.3,25.2,78,74,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 3.6 nTPM; positive ihc;continuous selectivity; adrenal gland: 3 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 2.9 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 2.9 nTPM; absolute ceiling;continuous selectivity; bone marrow: 25.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 6.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 3.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 1.7 nTPM; continuous selectivity; colon: 8.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 10.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 6.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 3.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 3.4 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 3.2 nTPM; absolute ceiling;continuous selectivity; kidney: 5.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 5.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 4.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 6.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 3.4 nTPM; absolute ceiling;continuous selectivity; pancreas: 7.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 4.2 nTPM; positive ihc;continuous selectivity; pituitary gland: 5.1 nTPM; absolute ceiling;continuous selectivity; rectum: 8.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; retina: 15.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 5.4 nTPM; positive ihc;continuous selectivity;reproductive not higher; skeletal muscle: 8.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 4 nTPM; positive ihc;continuous selectivity; small intestine: 10.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 3.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 5 nTPM; absolute ceiling;continuous selectivity; spleen: 5.4 nTPM; positive ihc;continuous selectivity;reproductive not higher; stomach: 8.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; thymus: 5.8 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 5.3 nTPM; positive ihc;continuous selectivity;reproductive not higher; tongue: 4.9 nTPM; continuous selectivity; urinary bladder: 6.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 3 nTPM (limit 2); amygdala: 2.9 nTPM (limit 2); basal ganglia: 2.9 nTPM (limit 2); bone marrow: 25.2 nTPM (limit 2); cerebellum: 6.4 nTPM (limit 2); cerebral cortex: 3.7 nTPM (limit 2); colon: 8.4 nTPM (limit 6); duodenum: 10.9 nTPM (limit 2); esophagus: 6.8 nTPM (limit 6); heart muscle: 3.6 nTPM (limit 2); hippocampal formation: 3.4 nTPM (limit 2); hypothalamus: 3.2 nTPM (limit 2); kidney: 5.1 nTPM (limit 2); liver: 5.7 nTPM (limit 2); lung: 4.7 nTPM (limit 2); lymph node: 6.1 nTPM (limit 6); midbrain: 3.4 nTPM (limit 2); pancreas: 7.9 nTPM (limit 2); pituitary gland: 5.1 nTPM (limit 2); rectum: 8.3 nTPM (limit 6); retina: 15.3 nTPM (limit 2); skeletal muscle: 8.9 nTPM (limit 2); small intestine: 10.4 nTPM (limit 2); smooth muscle: 3.2 nTPM (limit 2); spinal cord: 5 nTPM (limit 2); stomach: 8.1 nTPM (limit 6); urinary bladder: 6.5 nTPM (limit 6),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: High (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Medium (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: High (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: High (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Low (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%),breast cancer: 11/11 (100.0%); colorectal cancer: 11/11 (100.0%),31,20,Q96JN0,https://www.uniprot.org/uniprotkb/Q96JN0/entry,"May act as transcription activator that binds DNA elements with the sequence 5'-CCCTATCGATCGATCTCTACCT-3' (By similarity). Repressor of ligand-dependent transcription activation by target nuclear receptors. Repressor of ligand-dependent transcription activation by ESR1, ESR2, NR3C1, PGR, RARA, RARB, RARG, RXRA and VDR",Ubiquitous,,,Nucleus,12535528,12535528,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
LCORL,ENSG00000178177,Unsafe,Protein,False,True,5.7,6.8,80,63,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 2.5 nTPM; positive ihc; adrenal gland: 3.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 2.3 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 1.7 nTPM; continuous selectivity; bone marrow: 3.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 3.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 2.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 3.1 nTPM; positive ihc;continuous selectivity; duodenum: 5.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 2.4 nTPM; positive ihc;continuous selectivity; heart muscle: 1.6 nTPM; positive ihc;continuous selectivity; hippocampal formation: 2.4 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 3 nTPM; absolute ceiling;continuous selectivity; kidney: 3.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 3.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 3.5 nTPM; continuous selectivity; midbrain: 2.5 nTPM; absolute ceiling;continuous selectivity; pancreas: 3.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 4.4 nTPM; continuous selectivity; pituitary gland: 1.6 nTPM; continuous selectivity; rectum: 3.5 nTPM; positive ihc;continuous selectivity; retina: 6.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 2.2 nTPM; positive ihc;continuous selectivity; skeletal muscle: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 4.7 nTPM; positive ihc;continuous selectivity; small intestine: 6.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 2.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 3.1 nTPM; absolute ceiling;continuous selectivity; spleen: 3.3 nTPM; continuous selectivity; stomach: 4.4 nTPM; positive ihc;continuous selectivity; thymus: 3.8 nTPM; continuous selectivity; thyroid gland: 3.6 nTPM; positive ihc;continuous selectivity; tongue: 2.8 nTPM; continuous selectivity; urinary bladder: 2.7 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 3.6 nTPM (limit 2); amygdala: 2.3 nTPM (limit 2); bone marrow: 3.6 nTPM (limit 2); cerebellum: 3.4 nTPM (limit 2); cerebral cortex: 2.6 nTPM (limit 2); duodenum: 5.6 nTPM (limit 2); hippocampal formation: 2.4 nTPM (limit 2); hypothalamus: 3 nTPM (limit 2); kidney: 3.9 nTPM (limit 2); liver: 3.3 nTPM (limit 2); lung: 2.7 nTPM (limit 2); midbrain: 2.5 nTPM (limit 2); pancreas: 3.2 nTPM (limit 2); retina: 6.4 nTPM (limit 2); skeletal muscle: 2.7 nTPM (limit 2); small intestine: 6.8 nTPM (limit 2); smooth muscle: 2.6 nTPM (limit 2); spinal cord: 3.1 nTPM (limit 2); adrenal gland: 3.6 nTPM (baseline 2); amygdala: 2.3 nTPM (baseline 2); bone marrow: 3.6 nTPM (baseline 2); cerebellum: 3.4 nTPM (baseline 2); cerebral cortex: 2.6 nTPM (baseline 2); duodenum: 5.6 nTPM (baseline 2); hippocampal formation: 2.4 nTPM (baseline 2); hypothalamus: 3 nTPM (baseline 2); kidney: 3.9 nTPM (baseline 2); liver: 3.3 nTPM (baseline 2); lung: 2.7 nTPM (baseline 2); midbrain: 2.5 nTPM (baseline 2); pancreas: 3.2 nTPM (baseline 2); retina: 6.4 nTPM (baseline 2); skeletal muscle: 2.7 nTPM (baseline 2); small intestine: 6.8 nTPM (baseline 2); smooth muscle: 2.6 nTPM (baseline 2); spinal cord: 3.1 nTPM (baseline 2),adipose tissue / adipocytes: Low (Uncertain); adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Low (Uncertain); bronchus / respiratory epithelial cells: Low (Uncertain); caudate / glial cells: Low (Uncertain); caudate / neuronal cells: Low (Uncertain); cerebellum / cells in granular layer: Medium (Uncertain); cerebellum / cells in molecular layer: Low (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / endothelial cells: Low (Uncertain); cerebral cortex / glial cells: Low (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / endothelial cells: Low (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: Low (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Low (Uncertain); heart muscle / cardiomyocytes: Low (Uncertain); hippocampus / glial cells: Low (Uncertain); hippocampus / neuronal cells: Low (Uncertain); kidney / cells in glomeruli: Low (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / hepatocytes: High (Uncertain); lung / macrophages: Low (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Low (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Low (Uncertain); skeletal muscle / myocytes: Low (Uncertain); skin 1 / fibroblasts: Low (Uncertain); skin 1 / keratinocytes: Low (Uncertain); skin 2 / epidermal cells: Low (Uncertain); small intestine / glandular cells: Medium (Uncertain); smooth muscle / smooth muscle cells: Low (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Low (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 80/80 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 479/486 (98.6%),liver cancer: 4/12 (33.3%); pancreatic cancer: 2/11 (18.2%),31,20,Q8N3X6,https://www.uniprot.org/uniprotkb/Q8N3X6/entry,May act as transcription activator that binds DNA elements with the sequence 5'-CCCTATCGATCGATCTCTACCT-3'. May play a role in spermatogenesis (By similarity),,,"A report observed N-glycosylation at Asn-493 (PubMed:19139490). However, as the protein is predicted to act as a DNA-binding transcription activator, additional evidence is required to confirm this result",Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | Jamin2021_CT,GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
LELP1,ENSG00000203784,Unsafe,High RNA,False,True,1086.6,1086.6,88,1,Positive somewhere,False,False,False,True,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,CTA,Pass,oncoref.target-sets.2026-10-23.1,False,False,,CTA → Unsafe,True,True,True,0.0,65.7,"hpa_single_cell_tissue: testis/macrophages, max 65.7 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,65.7 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 2/133 (1.5%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Lung Squamous Cell Carcinoma (TCGA): 1/489 (0.2%),breast cancer: 0/11 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q5T871,https://www.uniprot.org/uniprotkb/Q5T871/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
LEMD1,ENSG00000186007,Unsafe,RNA,False,True,53.6,53.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,cerebellum: 3.6 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebellum: 3.6 nTPM (limit 2); cerebellum: 3.6 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Ovary Serous Cystadenocarcinoma (TCGA): 284/349 (81.4%); Ovary Serous Cystadenocarcinoma (validation): 65/81 (80.2%); Pancreatic Adenocarcinoma (validation): 61/80 (76.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q68G75,https://www.uniprot.org/uniprotkb/Q68G75/entry,,Testis-specific. Isoform 6 is detected in 17 of 18 colon cancer tissues examined,,,Membrane,,15254688,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | Jamin2021_CT | Jamin2021_core | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
LGALS8,ENSG00000116977,Unsafe,Protein,False,True,55.5,55.5,83,63,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 27.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 13.8 nTPM; positive ihc;absolute ceiling; amygdala: 11.2 nTPM; absolute ceiling; basal ganglia: 14.4 nTPM; absolute ceiling;continuous selectivity; bone marrow: 44.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 17.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 15.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 10.9 nTPM; absolute ceiling; colon: 19.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 21 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 20.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 53 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 12.6 nTPM; absolute ceiling; hypothalamus: 12.5 nTPM; absolute ceiling; kidney: 22.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 47.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 26.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 23.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 11 nTPM; absolute ceiling; pancreas: 21.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 33.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 12.3 nTPM; absolute ceiling; rectum: 19.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 22.2 nTPM; absolute ceiling;continuous selectivity; salivary gland: 21.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 6.5 nTPM; positive ihc;absolute ceiling; skin: 31.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 23.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 21.1 nTPM; absolute ceiling;continuous selectivity; spinal cord: 14.2 nTPM; absolute ceiling;continuous selectivity; spleen: 41.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 18.4 nTPM; positive ihc;absolute ceiling; thymus: 25.7 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 16.7 nTPM; positive ihc;absolute ceiling; tongue: 9 nTPM; absolute ceiling; urinary bladder: 31.6 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 27.6 nTPM (limit 10); adrenal gland: 13.8 nTPM (limit 2); amygdala: 11.2 nTPM (limit 2); basal ganglia: 14.4 nTPM (limit 2); bone marrow: 44.5 nTPM (limit 2); cerebellum: 17.1 nTPM (limit 2); cerebral cortex: 15.8 nTPM (limit 2); choroid plexus: 10.9 nTPM (limit 2); colon: 19.3 nTPM (limit 6); duodenum: 21 nTPM (limit 2); esophagus: 20.5 nTPM (limit 6); heart muscle: 53 nTPM (limit 2); hippocampal formation: 12.6 nTPM (limit 2); hypothalamus: 12.5 nTPM (limit 2); kidney: 22.7 nTPM (limit 2); liver: 47.9 nTPM (limit 2); lung: 26.2 nTPM (limit 2); lymph node: 23.4 nTPM (limit 6); midbrain: 11 nTPM (limit 2); pancreas: 21.1 nTPM (limit 2); parathyroid gland: 33.9 nTPM (limit 6); pituitary gland: 12.3 nTPM (limit 2); rectum: 19.3 nTPM (limit 6); retina: 22.2 nTPM (limit 2); salivary gland: 21.5 nTPM (limit 6); skeletal muscle: 6.5 nTPM (limit 2); skin: 31.5 nTPM (limit 10); small intestine: 23.4 nTPM (limit 2); smooth muscle: 21.1 nTPM (limit 4); spinal cord: 14.2 nTPM (limit 2); spleen: 41.6 nTPM (limit 10); stomach: 18.4 nTPM (limit 6); thymus: 25.7 nTPM (limit 10); thyroid gland: 16.7 nTPM (limit 10); tongue: 9 nTPM (limit 6); urinary bladder: 31.6 nTPM (limit 6),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Medium (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Low (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Medium (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: High (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); spleen / cells in red pulp: Low (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Adenocarcinoma (TCGA): 497/497 (100.0%); Lung Squamous Cell Carcinoma (TCGA): 489/489 (100.0%); Stomach Adenocarcinoma (TCGA): 346/346 (100.0%),breast cancer: 11/11 (100.0%); colorectal cancer: 11/12 (91.7%),31,20,O00214,https://www.uniprot.org/uniprotkb/O00214/entry,"Beta-galactoside-binding lectin that acts as a sensor of membrane damage caused by infection and restricts the proliferation of infecting pathogens by targeting them for autophagy (PubMed:22246324, PubMed:28077878). Detects membrane rupture by binding beta-galactoside ligands located on the lumenal side of the endosome membrane; these ligands becoming exposed to the cytoplasm following rupture (PubMed:22246324, PubMed:28077878). Restricts infection by initiating autophagy via interaction with CALCOCO2/NDP52 (PubMed:22246324, PubMed:28077878). Required to restrict infection of bacterial invasion such as S.typhimurium (PubMed:22246324). Also required to restrict infection of Picornaviridae viruses (PubMed:28077878). Has a marked preference for 3'-O-sialylated and 3'-O-sulfated glycans (PubMed:21288902)",Ubiquitous. Selective expression by prostate carcinomas versus normal prostate and benign prostatic hypertrophy,,,"Cytoplasmic vesicle Cytoplasm, cytosol",21288902|22246324|28077878,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
LHX9,ENSG00000143355,Unsafe,RNA,False,True,18.3,18.3,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,retina: 3.6 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 3.6 nTPM (limit 2); retina: 3.6 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Chromophobe (TCGA): 37/64 (57.8%); Glioblastoma Multiforme (validation): 22/58 (37.9%); Glioblastoma Multiforme (TCGA): 21/141 (14.9%),cervical cancer: 2/11 (18.2%); colorectal cancer: 2/12 (16.7%),31,20,Q9NQ69,https://www.uniprot.org/uniprotkb/Q9NQ69/entry,Involved in gonadal development,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
LIAT1,ENSG00000187624,Unsafe,Protein,False,True,57.2,57.2,84,48,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 5 nTPM; positive ihc;absolute ceiling; amygdala: 6.5 nTPM; absolute ceiling; basal ganglia: 9.8 nTPM; absolute ceiling; cerebral cortex: 8.4 nTPM; positive ihc;absolute ceiling; choroid plexus: 4.9 nTPM; absolute ceiling; colon: 3.9 nTPM; positive ihc; duodenum: 0.7 nTPM; positive ihc; esophagus: 3.1 nTPM; positive ihc; heart muscle: 3.6 nTPM; positive ihc;absolute ceiling; hippocampal formation: 6.7 nTPM; absolute ceiling; hypothalamus: 8 nTPM; absolute ceiling; kidney: 8.2 nTPM; positive ihc;absolute ceiling; liver: 2.6 nTPM; positive ihc;absolute ceiling; lung: 2.7 nTPM; positive ihc;absolute ceiling; lymph node: 1.2 nTPM; positive ihc; midbrain: 5 nTPM; absolute ceiling; pancreas: 2.8 nTPM; positive ihc;absolute ceiling; parathyroid gland: 1.9 nTPM; positive ihc; pituitary gland: 6.8 nTPM; absolute ceiling; rectum: 1.1 nTPM; positive ihc; retina: 2.6 nTPM; absolute ceiling; salivary gland: 3 nTPM; positive ihc; skeletal muscle: 4.5 nTPM; absolute ceiling; small intestine: 2.4 nTPM; positive ihc;absolute ceiling; spinal cord: 3.3 nTPM; absolute ceiling; stomach: 2.9 nTPM; positive ihc; thyroid gland: 6.7 nTPM; positive ihc; urinary bladder: 2.6 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 5 nTPM (limit 2); amygdala: 6.5 nTPM (limit 2); basal ganglia: 9.8 nTPM (limit 2); cerebral cortex: 8.4 nTPM (limit 2); choroid plexus: 4.9 nTPM (limit 2); heart muscle: 3.6 nTPM (limit 2); hippocampal formation: 6.7 nTPM (limit 2); hypothalamus: 8 nTPM (limit 2); kidney: 8.2 nTPM (limit 2); liver: 2.6 nTPM (limit 2); lung: 2.7 nTPM (limit 2); midbrain: 5 nTPM (limit 2); pancreas: 2.8 nTPM (limit 2); pituitary gland: 6.8 nTPM (limit 2); retina: 2.6 nTPM (limit 2); skeletal muscle: 4.5 nTPM (limit 4); small intestine: 2.4 nTPM (limit 2); spinal cord: 3.3 nTPM (limit 2),adrenal gland / glandular cells: Low (Approved); bronchus / respiratory epithelial cells: Medium (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); cerebral cortex / neuropil: Low (Approved); colon / glandular cells: Low (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Low (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Low (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Low (Approved); salivary gland / glandular cells: Low (Approved); small intestine / glandular cells: Low (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Low (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 45/50 (90.0%); Kidney Renal Papillary Cell Carcinoma (TCGA): 243/282 (86.2%); Glioblastoma Multiforme (validation): 37/58 (63.8%),breast cancer: 9/12 (75.0%); endometrial cancer: 8/12 (66.7%),31,20,Q6ZQX7,https://www.uniprot.org/uniprotkb/Q6ZQX7/entry,Participates in nucleolar liquid-liquid phase separation (LLPS) through its N-terminal intrinsically disordered region (IDR). May be involved in ATE1-mediated N-terminal arginylation,,,,"Nucleus, nucleolus Cytoplasm",,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
LIG4,ENSG00000174405,Unsafe,Protein,False,True,9.7,25.4,79,75,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 7.1 nTPM; positive ihc;continuous selectivity; adrenal gland: 8.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 6.5 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 6.8 nTPM; absolute ceiling;continuous selectivity; bone marrow: 4.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 6.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 11.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 6.3 nTPM; absolute ceiling;continuous selectivity; colon: 5.6 nTPM; positive ihc;continuous selectivity; duodenum: 7 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 4.3 nTPM; positive ihc;continuous selectivity; heart muscle: 6.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 7.7 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 8.4 nTPM; absolute ceiling;continuous selectivity; kidney: 8 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 12.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 11 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 7.4 nTPM; absolute ceiling;continuous selectivity; pancreas: 5.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 11.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 7.1 nTPM; absolute ceiling;continuous selectivity; rectum: 6.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 25.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 4.4 nTPM; positive ihc;continuous selectivity; skeletal muscle: 7 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 5.1 nTPM; positive ihc;continuous selectivity; small intestine: 6.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 6.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 8.5 nTPM; absolute ceiling;continuous selectivity; spleen: 8.2 nTPM; positive ihc;continuous selectivity; stomach: 7.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 21.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 7.6 nTPM; positive ihc;continuous selectivity; tongue: 6.3 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 6.8 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 8.1 nTPM (limit 2); amygdala: 6.5 nTPM (limit 2); basal ganglia: 6.8 nTPM (limit 2); bone marrow: 4.2 nTPM (limit 2); cerebellum: 6.6 nTPM (limit 2); cerebral cortex: 11.8 nTPM (limit 2); choroid plexus: 6.3 nTPM (limit 2); duodenum: 7 nTPM (limit 2); heart muscle: 6.5 nTPM (limit 2); hippocampal formation: 7.7 nTPM (limit 2); hypothalamus: 8.4 nTPM (limit 2); kidney: 8 nTPM (limit 2); liver: 12.6 nTPM (limit 2); lung: 7 nTPM (limit 2); lymph node: 11 nTPM (limit 6); midbrain: 7.4 nTPM (limit 2); pancreas: 5.1 nTPM (limit 2); parathyroid gland: 11.1 nTPM (limit 6); pituitary gland: 7.1 nTPM (limit 2); rectum: 6.6 nTPM (limit 6); retina: 25.4 nTPM (limit 2); skeletal muscle: 7 nTPM (limit 2); small intestine: 6.8 nTPM (limit 2); smooth muscle: 6.7 nTPM (limit 2); spinal cord: 8.5 nTPM (limit 2); stomach: 7.7 nTPM (limit 6); thymus: 21.6 nTPM (limit 10); tongue: 6.3 nTPM (limit 6); urinary bladder: 6.8 nTPM (limit 6),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Low (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Lung Adenocarcinoma (validation): 104/105 (99.0%); Rectum Adenocarcinoma (validation): 199/207 (96.1%),prostate cancer: 10/12 (83.3%); glioma: 9/12 (75.0%),31,20,P49917,https://www.uniprot.org/uniprotkb/P49917/entry,"DNA ligase involved in DNA non-homologous end joining (NHEJ); required for double-strand break (DSB) repair and V(D)J recombination (PubMed:12517771, PubMed:17290226, PubMed:23523427, PubMed:29980672, PubMed:33586762, PubMed:8798671, PubMed:9242410, PubMed:9809069). Catalyzes the NHEJ ligation step of the broken DNA during DSB repair by resealing the DNA breaks after the gap filling is completed (PubMed:12517771, PubMed:17290226, PubMed:9242410, PubMed:9809069). Joins single-strand breaks in a double-stranded polydeoxynucleotide in an ATP-dependent reaction (PubMed:12517771, PubMed:17290226, PubMed:9242410, PubMed:9809069). LIG4 is mechanistically flexible: it can ligate nicks as well as compatible DNA overhangs alone, while in the presence of XRCC4, it can ligate ends with 2-nucleotides (nt) microhomology and 1-nt gaps (PubMed:17290226). Forms a subcomplex with XRCC4; the LIG4-XRCC4 subcomplex is responsible for the NHEJ ligation step and XRCC4 enhances the joining activity of LIG4 (PubMed:9242410, PubMed:9809069). Binding of the LIG4-XRCC4 complex to DNA ends is dependent on the assembly of the DNA-dependent protein kinase complex DNA-PK to these DNA ends (PubMed:10854421). LIG4 regulates nuclear localization of XRCC4 (PubMed:24984242)","Testis, thymus, prostate and heart","LIG4 syndrome: Characterized by immunodeficiency and developmental and growth delay. Patients display unusual facial features, microcephaly, growth and/or developmental delay, pancytopenia, and various skin abnormalities. Severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-negative/NK-cell-positive with sensitivity to ionizing radiation: A form of severe combined immunodeficiency, a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy with recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development. Individuals affected by RS-SCID show defects in the DNA repair machinery necessary for coding joint formation and the completion of V(D)J recombination. A subset of cells from such patients show increased radiosensitivity.",,Nucleus,10854421|12517771|17290226|23523427|24984242|29980672|33586762|8798671|9242410|9809069,7760816,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
LIN28A,ENSG00000131914,Unsafe,Protein,False,True,5.0,5.0,85,18,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; colon: 0 nTPM; positive ihc; duodenum: 0.1 nTPM; positive ihc; heart muscle: 0 nTPM; positive ihc; kidney: 0 nTPM; positive ihc; lung: 0.1 nTPM; positive ihc; rectum: 0 nTPM; positive ihc; small intestine: 0 nTPM; positive ihc; urinary bladder: 0 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,bronchus / respiratory epithelial cells: Low (Enhanced); colon / glandular cells: Low (Enhanced); duodenum / glandular cells: Low (Enhanced); heart muscle / cardiomyocytes: Low (Enhanced); kidney / cells in tubules: Low (Enhanced); lung / alveolar cells: Low (Enhanced); rectum / glandular cells: Low (Enhanced); small intestine / glandular cells: Low (Enhanced); urinary bladder / urothelial cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 126/133 (94.7%); Breast Invasive Carcinoma (validation): 8/50 (16.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 8/176 (4.5%),testis cancer: 11/12 (91.7%); skin cancer: 3/10 (30.0%),31,20,Q9H9Z2,https://www.uniprot.org/uniprotkb/Q9H9Z2/entry,"RNA-binding protein that inhibits processing of pre-let-7 miRNAs and regulates translation of mRNAs that control developmental timing, pluripotency and metabolism (PubMed:21247876). Seems to recognize a common structural G-quartet (G4) feature in its miRNA and mRNA targets (Probable). 'Translational enhancer' that drives specific mRNAs to polysomes and increases the efficiency of protein synthesis. Its association with the translational machinery and target mRNAs results in an increased number of initiation events per molecule of mRNA and, indirectly, in mRNA stabilization. Binds IGF2 mRNA, MYOD1 mRNA, ARBP/36B4 ribosomal protein mRNA and its own mRNA. Essential for skeletal muscle differentiation program through the translational up-regulation of IGF2 expression. Suppressor of microRNA (miRNA) biogenesis, including that of let-7, miR107, miR-143 and miR-200c. Specifically binds the miRNA precursors (pre-miRNAs), recognizing an 5'-GGAG-3' motif found in pre-miRNA terminal loop, and recruits TUT4 and TUT7 uridylyltransferases (PubMed:18951094, PubMed:19703396, PubMed:22118463, PubMed:22898984). This results in the terminal uridylation of target pre-miRNAs (PubMed:18951094, PubMed:19703396, PubMed:22118463, PubMed:22898984). Uridylated pre-miRNAs fail to be processed by Dicer and undergo degradation. The repression of let-7 expression is required for normal development and contributes to maintain the pluripotent state by preventing let-7-mediated differentiation of embryonic stem cells (PubMed:18951094, PubMed:19703396, PubMed:22118463, PubMed:22898984). Localized to the periendoplasmic reticulum area, binds to a large number of spliced mRNAs and inhibits the translation of mRNAs destined for the ER, reducing the synthesis of transmembrane proteins, ER or Golgi lumen proteins, and secretory proteins. Binds to and enhances the translation of mRNAs for several metabolic enzymes, such as PFKP, PDHA1 or SDHA, increasing glycolysis and oxidative phosphorylation. Which, with the let-7 repression may enhance tissue repair in adult tissue (By similarity)","Expressed in embryonic stem cells, placenta and testis. Tends to be up-regulated in HER2-overexpressing breast tumors",,,"Cytoplasm Rough endoplasmic reticulum Cytoplasm, P-body Cytoplasm, Stress granule Nucleus, nucleolus",18951094|19703396|21247876|22118463|22898984,14688391|15614775|15722555|22118463,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT | Carter2023_CT | Loriot2025_S1 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination; inclusion depends on TGCT under this study's thresholds | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
LIN28B,ENSG00000187772,Unsafe,High RNA,False,True,63.2,63.2,77,1,Positive somewhere,False,False,False,True,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,CTA,Pass,oncoref.target-sets.2026-10-23.1,False,False,,CTA → Unsafe,True,True,True,0.9,65.8,"hpa_single_cell: /Excitatory neurons, max 38.9 nTPM, 1 observations >30; hpa_single_cell_tissue: brain/excitatory neurons, max 65.8 nTPM, 16 observations >30",CTA,oncoref.target-sets.2026-10-23.2,0.9 TPM; blood/Exhausted memory B-cell; hpa_immune_monaco; vital,65.8 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 113/133 (85.0%); Glioblastoma Multiforme (validation): 7/58 (12.1%); Liver Hepatocellular Carcinoma (validation): 27/231 (11.7%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q6ZN17,https://www.uniprot.org/uniprotkb/Q6ZN17/entry,"Suppressor of microRNA (miRNA) biogenesis, including that of let-7 and possibly of miR107, miR-143 and miR-200c. Binds primary let-7 transcripts (pri-let-7), including pri-let-7g and pri-let-7a-1, and sequester them in the nucleolus, away from the microprocessor complex, hence preventing their processing into mature miRNA (PubMed:22118463). Does not act on pri-miR21 (PubMed:22118463). The repression of let-7 expression is required for normal development and contributes to maintain the pluripotent state of embryonic stem cells by preventing let-7-mediated differentiation. When overexpressed, recruits ZCCHC11/TUT4 uridylyltransferase to pre-let-7 transcripts, leading to their terminal uridylation and degradation (PubMed:19703396). This activity might not be relevant in vivo, as LIN28B-mediated inhibition of let-7 miRNA maturation appears to be ZCCHC11-independent (PubMed:22118463). Interaction with target pre-miRNAs occurs via an 5'-GGAG-3' motif in the pre-miRNA terminal loop. Mediates MYC-induced let-7 repression (By similarity). When overexpressed, isoform 1 stimulates growth of the breast adenocarcinoma cell line MCF-7. Isoform 2 has no effect on cell growth","Expressed at high levels in the placenta and, at mucher lower, in testis and fetal liver (PubMed:16971064). Isoform 1 is only detected in placenta and in moderately and poorly differentiated hepatocellular carcinoma cells (at protein level). Isoform 2 is detected in fetal liver, non-tumor liver tissues, as well as well-differentiated tumor tissues (at protein level). Tends to be up-regulated in triple-negative (ER-,PR-,HER2-) breast tumors, as well as in liver, ovarian, and thyroid carcinomas (PubMed:22118463)",,,"Nucleus Nucleus, nucleolus Cytoplasm",16971064|18951094|19703396|22118463,16971064|22118463,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Wang2016_CT | Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | Jamin2021_CT | Jamin2021_core | Chang2019_TGCT | Carter2023_CT | Gong2021_reproductive_PC | daSilva2017_tumor_proteomics,No tumor-antigen validation in this source | Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene | Normal reproductive-tissue enrichment; no tumor validation | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
LIN7A,ENSG00000111052,Unsafe,Protein,False,True,8.2,27.6,84,17,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 4.9 nTPM; continuous selectivity; adrenal gland: 3 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 5 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 4.3 nTPM; absolute ceiling;continuous selectivity; bone marrow: 27.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 19.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 8 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 2.5 nTPM; absolute ceiling;continuous selectivity; colon: 1.9 nTPM; positive ihc; duodenum: 0.5 nTPM; positive ihc; heart muscle: 6.1 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 4.8 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 5.6 nTPM; absolute ceiling;continuous selectivity; kidney: 8.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 17.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 4.9 nTPM; absolute ceiling;continuous selectivity; midbrain: 4.7 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 5.8 nTPM; absolute ceiling;continuous selectivity; rectum: 0.5 nTPM; positive ihc; retina: 25.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 0.8 nTPM; positive ihc; small intestine: 2 nTPM; positive ihc; smooth muscle: 4.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; spleen: 4.5 nTPM; positive ihc;continuous selectivity; thyroid gland: 4.1 nTPM; positive ihc;continuous selectivity; urinary bladder: 3.8 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 3 nTPM (limit 2); amygdala: 5 nTPM (limit 2); basal ganglia: 4.3 nTPM (limit 2); bone marrow: 27.6 nTPM (limit 2); cerebellum: 19.2 nTPM (limit 4); cerebral cortex: 8 nTPM (limit 4); choroid plexus: 2.5 nTPM (limit 2); heart muscle: 6.1 nTPM (limit 4); hippocampal formation: 4.8 nTPM (limit 2); hypothalamus: 5.6 nTPM (limit 2); kidney: 8.4 nTPM (limit 2); liver: 17.1 nTPM (limit 2); lung: 4.9 nTPM (limit 4); midbrain: 4.7 nTPM (limit 2); pituitary gland: 5.8 nTPM (limit 2); retina: 25.8 nTPM (limit 2); smooth muscle: 4.4 nTPM (limit 2),adrenal gland / glandular cells: Low (Approved); bone marrow / hematopoietic cells: Low (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: Low (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Low (Approved); rectum / glandular cells: Low (Approved); salivary gland / glandular cells: Low (Approved); small intestine / glandular cells: Low (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in red pulp: Low (Approved); thyroid gland / glandular cells: Low (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Kidney Chromophobe (TCGA): 61/64 (95.3%); Liver Hepatocellular Carcinoma (validation): 203/231 (87.9%),breast cancer: 0/12 (0.0%); cervical cancer: 0/11 (0.0%),31,20,O14910,https://www.uniprot.org/uniprotkb/O14910/entry,"Plays a role in establishing and maintaining the asymmetric distribution of channels and receptors at the plasma membrane of polarized cells. Forms membrane-associated multiprotein complexes that may regulate delivery and recycling of proteins to the correct membrane domains. The tripartite complex composed of LIN7 (LIN7A, LIN7B or LIN7C), CASK and APBA1 associates with the motor protein KIF17 to transport vesicles containing N-methyl-D-aspartate (NMDA) receptor subunit NR2B along microtubules (By similarity). This complex may have the potential to couple synaptic vesicle exocytosis to cell adhesion in brain. Ensures the proper localization of GRIN2B (subunit 2B of the NMDA receptor) to neuronal postsynaptic density and may function in localizing synaptic vesicles at synapses where it is recruited by beta-catenin and cadherin. Required to localize Kir2 channels, GABA transporter (SLC6A12) and EGFR/ERBB1, ERBB2, ERBB3 and ERBB4 to the basolateral membrane of epithelial cells","Expressed in brain, testis, kidney, placenta and liver",,,"Cell membrane Basolateral cell membrane Cell junction Postsynaptic density membrane Cell junction, tight junction",12967566,11311936,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
LIPT1,ENSG00000144182,Unsafe,Protein,False,True,13.7,13.7,97,27,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 6.9 nTPM; positive ihc;continuous selectivity; adrenal gland: 7.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 5.3 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 6 nTPM; absolute ceiling;continuous selectivity; bone marrow: 12.2 nTPM; absolute ceiling;continuous selectivity; cerebellum: 5.4 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 4.6 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 3.9 nTPM; absolute ceiling;continuous selectivity; colon: 6.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 8.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 8.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 6 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 5.2 nTPM; absolute ceiling;continuous selectivity; kidney: 10.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 7.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 5.5 nTPM; absolute ceiling;continuous selectivity; lymph node: 10.4 nTPM; absolute ceiling;continuous selectivity; midbrain: 6.9 nTPM; absolute ceiling;continuous selectivity; pancreas: 7 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 6.1 nTPM; continuous selectivity; pituitary gland: 6.5 nTPM; absolute ceiling;continuous selectivity; rectum: 7 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 7.3 nTPM; absolute ceiling;continuous selectivity; salivary gland: 8.7 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 8.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 6.8 nTPM; positive ihc;continuous selectivity; small intestine: 8.1 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 5.4 nTPM; absolute ceiling;continuous selectivity; spinal cord: 7.2 nTPM; absolute ceiling;continuous selectivity; spleen: 11.6 nTPM; continuous selectivity; stomach: 6.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; thyroid gland: 11 nTPM; continuous selectivity; tongue: 8.6 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 6.1 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 7.5 nTPM (limit 2); amygdala: 5.3 nTPM (limit 2); basal ganglia: 6 nTPM (limit 2); bone marrow: 12.2 nTPM (limit 4); cerebellum: 5.4 nTPM (limit 4); cerebral cortex: 4.6 nTPM (limit 2); choroid plexus: 3.9 nTPM (limit 2); colon: 6.5 nTPM (limit 6); duodenum: 8.1 nTPM (limit 2); heart muscle: 8.2 nTPM (limit 2); hippocampal formation: 6 nTPM (limit 2); hypothalamus: 5.2 nTPM (limit 2); kidney: 10.9 nTPM (limit 2); liver: 7.9 nTPM (limit 2); lung: 5.5 nTPM (limit 4); lymph node: 10.4 nTPM (limit 8); midbrain: 6.9 nTPM (limit 2); pancreas: 7 nTPM (limit 2); pituitary gland: 6.5 nTPM (limit 2); rectum: 7 nTPM (limit 6); retina: 7.3 nTPM (limit 2); salivary gland: 8.7 nTPM (limit 8); skeletal muscle: 8.8 nTPM (limit 2); small intestine: 8.1 nTPM (limit 4); smooth muscle: 5.4 nTPM (limit 4); spinal cord: 7.2 nTPM (limit 2); stomach: 6.7 nTPM (limit 6); tongue: 8.6 nTPM (limit 6); urinary bladder: 6.1 nTPM (limit 6),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: Medium (Approved); bronchus / ciliated cells (ciliary rootlets): Medium (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Low (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: Low (Approved); heart muscle / cardiomyocytes: Low (Approved); kidney / cells in tubules: Low (Approved); liver / hepatocytes: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); rectum / glandular cells: Low (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Low (Approved); skin 2 / epidermal cells: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Low (Approved); urinary bladder / urothelial cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 141/141 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Lung Squamous Cell Carcinoma (validation): 67/68 (98.5%),endometrial cancer: 1/11 (9.1%); melanoma: 1/11 (9.1%),31,20,Q9Y234,https://www.uniprot.org/uniprotkb/Q9Y234/entry,"Lipoyl amidotransferase that catalyzes the transfer of lipoyl moieties from lipoyl-protein H of the glycine cleavage system (lipoyl-GCSH) to E2 subunits of the pyruvate dehydrogenase complex (PDCE2) (PubMed:29987032). Unable to catalyze the transfer of octanoyl from octanoyl-GCSH to PDCE2 (PubMed:29987032). In vitro, it is also able to catalyze the transfer of the lipoyl group from lipoyl-AMP to the specific lysine residue of lipoyl domains of lipoate-dependent enzymes but this reaction may not be physiologically relevant (Probable)","Highly expressed in skeletal muscle and heart, moderately in kidney and pancreas, and detected at lower levels in liver, brain, placenta and lung","Lipoyltransferase 1 deficiency: An autosomal recessive disorder due to a defect in lipoic acid metabolism, resulting in severe lactic acidosis and metabolic decompensation. Variable clinical manifestations include delayed psychomotor development, severe hypotonia, dystonia, loss of head control, coma, bradycardia, and pulmonary hypertension.",,Mitochondrion,29987032,10103005,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
LIPT2,ENSG00000175536,Unsafe,Protein,False,True,12.0,12.0,79,69,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 1.3 nTPM; positive ihc; adrenal gland: 1.9 nTPM; positive ihc; bone marrow: 2 nTPM; positive ihc; cerebral cortex: 1.1 nTPM; positive ihc; choroid plexus: 2.4 nTPM; absolute ceiling; colon: 2 nTPM; positive ihc; duodenum: 3.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 1.8 nTPM; positive ihc; heart muscle: 1.4 nTPM; positive ihc; kidney: 4.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 3.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 1.7 nTPM; positive ihc; lymph node: 2.1 nTPM; positive ihc; pancreas: 2.8 nTPM; positive ihc;absolute ceiling; parathyroid gland: 2 nTPM; positive ihc; pituitary gland: 2.1 nTPM; absolute ceiling; rectum: 2.2 nTPM; positive ihc; salivary gland: 2 nTPM; positive ihc; skeletal muscle: 7.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 1.6 nTPM; positive ihc; small intestine: 3.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 0.5 nTPM; positive ihc; stomach: 3.4 nTPM; positive ihc; thyroid gland: 2.9 nTPM; positive ihc; tongue: 6.8 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 1.7 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 2.4 nTPM (limit 2); duodenum: 3.6 nTPM (limit 2); kidney: 4.4 nTPM (limit 2); liver: 3.1 nTPM (limit 2); pancreas: 2.8 nTPM (limit 2); pituitary gland: 2.1 nTPM (limit 2); skeletal muscle: 7.8 nTPM (limit 2); small intestine: 3.5 nTPM (limit 2); tongue: 6.8 nTPM (limit 6),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: High (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: High (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: High (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: High (Approved); hippocampus / neuronal cells: High (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: High (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: High (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: High (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: High (Approved); skin 1 / keratinocytes: Low (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Medium (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 43/50 (86.0%); Ovary Serous Cystadenocarcinoma (TCGA): 242/349 (69.3%); Kidney Renal Clear Cell Carcinoma (validation): 55/100 (55.0%),breast cancer: 11/12 (91.7%); colorectal cancer: 11/12 (91.7%),31,20,A6NK58,https://www.uniprot.org/uniprotkb/A6NK58/entry,Catalyzes the transfer of endogenously produced octanoic acid from octanoyl-acyl-carrier-protein (octanoyl-ACP) onto the lipoyl domains of lipoate-dependent enzymes such as the protein H of the glycine cleavage system (GCSH) (PubMed:28757203). Lipoyl-ACP can also act as a substrate although octanoyl-ACP is likely to be the physiological substrate (By similarity),,"Encephalopathy, neonatal severe, with lactic acidosis and brain abnormalities: An autosomal recessive disorder characterized by severe encephalopathy with neonatal onset, metabolic features including lactic acidosis, little or no psychomotor development, and brain abnormalities including cerebral atrophy, cysts, and white matter abnormalities.",,Mitochondrion,28757203,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
LMX1B,ENSG00000136944,Unsafe,RNA,False,True,4.0,18.0,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,heart muscle: 1.9 nTPM; continuous selectivity; kidney: 3.5 nTPM; absolute ceiling;continuous selectivity; midbrain: 3.6 nTPM; absolute ceiling;continuous selectivity; salivary gland: 18 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 2 nTPM; continuous selectivity; spinal cord: 1.3 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,kidney: 3.5 nTPM (limit 2); midbrain: 3.6 nTPM (limit 2); salivary gland: 18 nTPM (limit 6); kidney: 3.5 nTPM (baseline 2); midbrain: 3.6 nTPM (baseline 2); salivary gland: 18 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 49/50 (98.0%); Breast Invasive Carcinoma (TCGA): 822/1022 (80.4%); Skin Cuteneous Melanoma (TCGA): 6/99 (6.1%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O60663,https://www.uniprot.org/uniprotkb/O60663/entry,"Transcription factor involved in the regulation of podocyte-expressed genes (PubMed:24042019, PubMed:28059119). Essential for the specification of dorsal limb fate at both the zeugopodal and autopodal levels","Expressed in most tissues. Highest levels in testis, thyroid, duodenum, skeletal muscle, and pancreatic islets","Nail-patella syndrome: Disease that cause abnormal skeletal patterning and renal dysplasia. Focal segmental glomerulosclerosis 10: An autosomal dominant form of focal segmental glomerulosclerosis, a renal pathology defined by the presence of segmental sclerosis in glomeruli and resulting in proteinuria, reduced glomerular filtration rate and progressive decline in renal function. Renal insufficiency often progresses to end-stage renal disease, a highly morbid state requiring either dialysis therapy or kidney transplantation.",,Nucleus,24042019|28059119,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
LOXHD1,ENSG00000167210,Unsafe,RNA,False,True,22.3,22.3,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 2.8 nTPM; absolute ceiling; kidney: 6.7 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 2.8 nTPM (limit 2); kidney: 6.7 nTPM (limit 2); bone marrow: 2.8 nTPM (baseline 2); kidney: 6.7 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Chromophobe (TCGA): 7/64 (10.9%); Testicular Germ Cell Tumor (TCGA): 11/133 (8.3%); Breast Invasive Carcinoma (validation): 2/50 (4.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8IVV2,https://www.uniprot.org/uniprotkb/Q8IVV2/entry,Involved in hearing. Required for normal function of hair cells in the inner ear (By similarity),,"Deafness, autosomal recessive, 77: A form of non-syndromic deafness characterized by preserved low-frequency hearing, and a trend toward mild to moderate mid-frequency and high-frequency hearing loss during childhood and adolescence. Hearing loss progresses to become moderate to severe at mid and high frequencies during adulthood.",,"Cell projection, stereocilium",19732867,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
LRAT,ENSG00000121207,Unsafe,RNA,False,True,0.8,2.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 0.5 nTPM; continuous selectivity; basal ganglia: 1.1 nTPM; continuous selectivity;reproductive not higher; bone marrow: 0.5 nTPM; continuous selectivity; cerebral cortex: 0.4 nTPM; continuous selectivity; colon: 0.5 nTPM; continuous selectivity; duodenum: 1.1 nTPM; continuous selectivity;reproductive not higher; hippocampal formation: 0.6 nTPM; continuous selectivity; hypothalamus: 1.3 nTPM; continuous selectivity;reproductive not higher; liver: 2.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 0.8 nTPM; continuous selectivity;reproductive not higher; pancreas: 0.8 nTPM; continuous selectivity;reproductive not higher; retina: 0.9 nTPM; continuous selectivity;reproductive not higher; skeletal muscle: 0.8 nTPM; continuous selectivity;reproductive not higher; small intestine: 1.5 nTPM; continuous selectivity;reproductive not higher; spinal cord: 1.7 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 1.5 nTPM; continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,liver: 2.1 nTPM (limit 2); liver: 2.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 20/58 (34.5%); Pancreatic Adenocarcinoma (validation): 13/80 (16.2%); Breast Invasive Carcinoma (validation): 6/50 (12.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O95237,https://www.uniprot.org/uniprotkb/O95237/entry,"Transfers the acyl group from the sn-1 position of phosphatidylcholine to all-trans retinol, producing all-trans retinyl esters (PubMed:9920938). Retinyl esters are storage forms of vitamin A (Probable). LRAT plays a critical role in vision (Probable). It provides the all-trans retinyl ester substrates for the isomerohydrolase which processes the esters into 11-cis-retinol in the retinal pigment epithelium; due to a membrane-associated alcohol dehydrogenase, 11 cis-retinol is oxidized and converted into 11-cis-retinaldehyde which is the chromophore for rhodopsin and the cone photopigments (Probable). Required for the survival of cone photoreceptors and correct rod photoreceptor cell morphology (By similarity)","Hepatic stellate cells and endothelial cells (at protein level). Found at high levels in testis and liver, followed by retinal pigment epithelium, small intestine, prostate, pancreas and colon. Low expression observed in brain. In fetal tissues, expressed in retinal pigment epithelium and liver, and barely in the brain","Leber congenital amaurosis 14: A severe dystrophy of the retina, typically becoming evident in the first years of life. Visual function is usually poor and often accompanied by nystagmus, sluggish or near-absent pupillary responses, photophobia, high hyperopia and keratoconus.",,"Endoplasmic reticulum membrane Rough endoplasmic reticulum Endosome, multivesicular body Cytoplasm, perinuclear region",9920938,18544127|9920938,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
LRFN4,ENSG00000173621,Unsafe,Protein,False,True,22.2,40.1,84,18,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 13 nTPM; absolute ceiling;continuous selectivity; amygdala: 19.2 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 14.2 nTPM; absolute ceiling;continuous selectivity; cerebellum: 40.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 24 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 19.1 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 13.9 nTPM; absolute ceiling;continuous selectivity; kidney: 11.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 8.4 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 7.7 nTPM; absolute ceiling;continuous selectivity; spinal cord: 7.7 nTPM; absolute ceiling;continuous selectivity; stomach: 8.1 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 13 nTPM (limit 12); amygdala: 19.2 nTPM (limit 2); basal ganglia: 14.2 nTPM (limit 2); cerebellum: 40.1 nTPM (limit 2); cerebral cortex: 24 nTPM (limit 2); hippocampal formation: 19.1 nTPM (limit 2); hypothalamus: 13.9 nTPM (limit 2); kidney: 11.7 nTPM (limit 2); midbrain: 8.4 nTPM (limit 2); pituitary gland: 7.7 nTPM (limit 2); spinal cord: 7.7 nTPM (limit 2); stomach: 8.1 nTPM (limit 6),caudate / glial cells: High (Enhanced); caudate / neuronal cells: Medium (Enhanced); cerebellum / cells in molecular layer: Medium (Enhanced); cerebellum / Purkinje cells: High (Enhanced); cerebral cortex / glial cells: Medium (Enhanced); cerebral cortex / neuronal cells: High (Enhanced); hippocampus / glial cells: Medium (Enhanced); hippocampus / neuronal cells: High (Enhanced); kidney / cells in tubules: Medium (Enhanced); stomach 1 / glandular cells: Low (Enhanced); stomach 2 / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (TCGA): 88/88 (100.0%); Ovary Serous Cystadenocarcinoma (validation): 81/81 (100.0%); Breast Invasive Carcinoma (validation): 50/50 (100.0%),glioma: 8/11 (72.7%); liver cancer: 2/12 (16.7%),31,20,Q6PJG9,https://www.uniprot.org/uniprotkb/Q6PJG9/entry,Promotes neurite outgrowth in hippocampal neurons. May play a role in redistributing DLG4 to the cell periphery (By similarity),,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
LRGUK,ENSG00000155530,Unsafe,RNA,False,True,5.0,5.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,choroid plexus: 3.2 nTPM; absolute ceiling;continuous selectivity; retina: 2.5 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 3.2 nTPM (limit 2); retina: 2.5 nTPM (limit 2); choroid plexus: 3.2 nTPM (baseline 2); retina: 2.5 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 51/58 (87.9%); Breast Invasive Carcinoma (validation): 17/50 (34.0%); Skin Cuteneous Melanoma (TCGA): 13/99 (13.1%),breast cancer: 8/12 (66.7%); prostate cancer: 7/12 (58.3%),31,20,Q96M69,https://www.uniprot.org/uniprotkb/Q96M69/entry,"Involved in multiple aspects of sperm assembly including acrosome attachment, shaping of the sperm head and in the early aspects of axoneme development. Not essential for primary cilium biogenesis",,,,"Cytoplasmic vesicle, secretory vesicle, acrosome Cytoplasm, cytoskeleton Cytoplasm, cytoskeleton, cilium basal body",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
LRIT1,ENSG00000148602,Unsafe,RNA,False,True,6.0,24.9,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,retina: 24.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 24.9 nTPM (limit 2); retina: 24.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9P2V4,https://www.uniprot.org/uniprotkb/Q9P2V4/entry,Photoreceptor synaptic protein essential for normal vision (By similarity). Involved in synapse formation in cone photoreceptor cells (By similarity),,,,"Endoplasmic reticulum membrane Cell projection, dendrite",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Chang2019_TGCT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
LRP1B,ENSG00000168702,Unsafe,Protein,False,True,2.2,9.7,88,10,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 3 nTPM; positive ihc;continuous selectivity;reproductive not higher; adrenal gland: 1.3 nTPM; positive ihc;continuous selectivity; amygdala: 8.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 5.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 9.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 1 nTPM; continuous selectivity; hippocampal formation: 6.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 6.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 7.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 1.9 nTPM; continuous selectivity; retina: 2.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 4.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 4.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 5.5 nTPM; positive ihc;continuous selectivity;reproductive not higher; tongue: 3.4 nTPM; continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 8.4 nTPM (limit 2); basal ganglia: 8 nTPM (limit 2); cerebellum: 5.4 nTPM (limit 2); cerebral cortex: 9.7 nTPM (limit 2); hippocampal formation: 6.7 nTPM (limit 2); hypothalamus: 6.6 nTPM (limit 2); midbrain: 7.7 nTPM (limit 2); retina: 2.5 nTPM (limit 2); skeletal muscle: 4.3 nTPM (limit 2); spinal cord: 4.7 nTPM (limit 2),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Low (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Medium (Approved); skeletal muscle / myocytes: Low (Approved); thyroid gland / glandular cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Glioblastoma Multiforme (TCGA): 71/141 (50.4%); Breast Invasive Carcinoma (validation): 12/50 (24.0%),liver cancer: 8/11 (72.7%); colorectal cancer: 3/12 (25.0%),31,20,Q9NZR2,https://www.uniprot.org/uniprotkb/Q9NZR2/entry,Potential cell surface proteins that bind and internalize ligands in the process of receptor-mediated endocytosis,"Expressed in thyroid gland and in salivary gland, as well as in adult and fetal brain",,,Membrane,,11384978,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
LRP2BP,ENSG00000109771,Unsafe,Protein,False,True,10.4,28.0,80,18,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; amygdala: 7.5 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 8 nTPM; absolute ceiling;continuous selectivity; cerebellum: 12.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 7.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 3.6 nTPM; absolute ceiling;continuous selectivity; colon: 3.5 nTPM; positive ihc; heart muscle: 3.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 8.2 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 8.9 nTPM; absolute ceiling;continuous selectivity; kidney: 4.7 nTPM; absolute ceiling;continuous selectivity; lung: 4.3 nTPM; absolute ceiling;continuous selectivity; midbrain: 5.1 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 16.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; retina: 28 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 2.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 1.5 nTPM; positive ihc; smooth muscle: 0.3 nTPM; positive ihc; spinal cord: 5.7 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 7.5 nTPM (limit 2); basal ganglia: 8 nTPM (limit 2); cerebellum: 12.6 nTPM (limit 2); cerebral cortex: 7.3 nTPM (limit 2); choroid plexus: 3.6 nTPM (limit 2); heart muscle: 3.5 nTPM (limit 2); hippocampal formation: 8.2 nTPM (limit 2); hypothalamus: 8.9 nTPM (limit 2); kidney: 4.7 nTPM (limit 4); lung: 4.3 nTPM (limit 4); midbrain: 5.1 nTPM (limit 2); pituitary gland: 16.9 nTPM (limit 2); retina: 28 nTPM (limit 2); skeletal muscle: 2.9 nTPM (limit 2); spinal cord: 5.7 nTPM (limit 2),bronchus / respiratory epithelial cells: Low (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); colon / endothelial cells: Low (Approved); colon / peripheral nerve/ganglion: Low (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / neuronal cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / fibroblasts: Low (Approved); skin 1 / keratinocytes: Low (Approved); skin 2 / epidermal cells: Low (Approved); smooth muscle / smooth muscle cells: Low (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 36/58 (62.1%); Breast Invasive Carcinoma (validation): 17/50 (34.0%); Glioblastoma Multiforme (TCGA): 27/141 (19.1%),breast cancer: 0/12 (0.0%); cervical cancer: 0/10 (0.0%),31,20,Q9P2M1,https://www.uniprot.org/uniprotkb/Q9P2M1/entry,May act as an adapter that regulates LRP2 function,,,,Cytoplasm,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
LRRC18,ENSG00000165383,Unsafe,Protein,False,True,13.2,23.9,102,7,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; choroid plexus: 23.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 23.9 nTPM (limit 2),bronchus / ciliated cells (ciliary rootlets): Low (Enhanced); bronchus / ciliated cells (tip of cilia): Medium (Enhanced); nasopharynx / basal cells: Medium (Enhanced); nasopharynx / ciliated cells (tip of cilia): Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 10/176 (5.7%); Testicular Germ Cell Tumor (TCGA): 3/133 (2.3%); Lung Adenocarcinoma (TCGA): 8/497 (1.6%),urothelial cancer: 1/11 (9.1%); breast cancer: 0/12 (0.0%),31,20,Q8N456,https://www.uniprot.org/uniprotkb/Q8N456/entry,May be involved in the regulation of spermatogenesis and sperm maturation,,,,Cytoplasm,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
LRRC27,ENSG00000148814,Unsafe,Protein,False,True,73.5,73.5,114,14,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 13.3 nTPM; absolute ceiling; basal ganglia: 14.2 nTPM; absolute ceiling; cerebellum: 4.5 nTPM; positive ihc;absolute ceiling; cerebral cortex: 13.6 nTPM; positive ihc;absolute ceiling; choroid plexus: 15.3 nTPM; absolute ceiling; duodenum: 2.5 nTPM; absolute ceiling; hippocampal formation: 14.1 nTPM; absolute ceiling; hypothalamus: 12.1 nTPM; absolute ceiling; kidney: 6.9 nTPM; positive ihc;absolute ceiling; midbrain: 10.1 nTPM; absolute ceiling; parathyroid gland: 7.7 nTPM; positive ihc;absolute ceiling; pituitary gland: 7.8 nTPM; absolute ceiling; rectum: 2.5 nTPM; positive ihc; retina: 10.6 nTPM; absolute ceiling; small intestine: 3.2 nTPM; absolute ceiling; smooth muscle: 4.1 nTPM; positive ihc;absolute ceiling; spinal cord: 8.2 nTPM; absolute ceiling; stomach: 3.8 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 13.3 nTPM (limit 2); basal ganglia: 14.2 nTPM (limit 2); cerebellum: 4.5 nTPM (limit 2); cerebral cortex: 13.6 nTPM (limit 2); choroid plexus: 15.3 nTPM (limit 2); duodenum: 2.5 nTPM (limit 2); hippocampal formation: 14.1 nTPM (limit 2); hypothalamus: 12.1 nTPM (limit 2); kidney: 6.9 nTPM (limit 2); midbrain: 10.1 nTPM (limit 2); parathyroid gland: 7.7 nTPM (limit 6); pituitary gland: 7.8 nTPM (limit 2); retina: 10.6 nTPM (limit 2); small intestine: 3.2 nTPM (limit 2); smooth muscle: 4.1 nTPM (limit 2); spinal cord: 8.2 nTPM (limit 2),caudate / neuronal cells: Low (Enhanced); cerebellum / Purkinje cells: Low (Enhanced); cerebral cortex / neuronal cells: Low (Enhanced); hippocampus / neuronal cells: Low (Enhanced); kidney / distal tubules: Medium (Enhanced); kidney / proximal tubules (cell body): High (Enhanced); parathyroid gland / glandular cells: Low (Enhanced); rectum / peripheral nerve/ganglion: Low (Enhanced); smooth muscle / smooth muscle cells: Low (Enhanced); stomach 2 / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 47/50 (94.0%); Kidney Renal Clear Cell Carcinoma (validation): 92/100 (92.0%); Thyroid Carcinoma (TCGA): 444/495 (89.7%),breast cancer: 0/10 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q9C0I9,https://www.uniprot.org/uniprotkb/Q9C0I9/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
LRRC28,ENSG00000168904,Unsafe,Protein,False,True,27.6,45.6,83,76,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 7.8 nTPM; positive ihc; adrenal gland: 7.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 4.1 nTPM; absolute ceiling; basal ganglia: 3.8 nTPM; absolute ceiling; bone marrow: 8.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 5.5 nTPM; positive ihc;absolute ceiling; cerebral cortex: 4.7 nTPM; positive ihc;absolute ceiling; choroid plexus: 11.7 nTPM; absolute ceiling;continuous selectivity; colon: 7.7 nTPM; positive ihc;absolute ceiling; duodenum: 16.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 9.3 nTPM; positive ihc;absolute ceiling; heart muscle: 9.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 4.1 nTPM; absolute ceiling; hypothalamus: 4.3 nTPM; absolute ceiling; kidney: 18.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 45.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 5.1 nTPM; positive ihc;absolute ceiling; lymph node: 6.7 nTPM; positive ihc;absolute ceiling; midbrain: 4.2 nTPM; absolute ceiling; pancreas: 18.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 9.1 nTPM; positive ihc;absolute ceiling; pituitary gland: 4 nTPM; absolute ceiling; rectum: 9.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 6.6 nTPM; absolute ceiling; salivary gland: 6 nTPM; positive ihc; skeletal muscle: 17.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 10.1 nTPM; positive ihc;absolute ceiling; small intestine: 16 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 7.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 4.8 nTPM; absolute ceiling; spleen: 4.8 nTPM; positive ihc; stomach: 7.9 nTPM; positive ihc;absolute ceiling; thymus: 22 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 6.4 nTPM; positive ihc; tongue: 17.6 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 6.3 nTPM; positive ihc;absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 7.6 nTPM (limit 2); amygdala: 4.1 nTPM (limit 2); basal ganglia: 3.8 nTPM (limit 2); bone marrow: 8.5 nTPM (limit 2); cerebellum: 5.5 nTPM (limit 2); cerebral cortex: 4.7 nTPM (limit 2); choroid plexus: 11.7 nTPM (limit 2); colon: 7.7 nTPM (limit 6); duodenum: 16.4 nTPM (limit 2); esophagus: 9.3 nTPM (limit 6); heart muscle: 9.4 nTPM (limit 2); hippocampal formation: 4.1 nTPM (limit 2); hypothalamus: 4.3 nTPM (limit 2); kidney: 18.7 nTPM (limit 2); liver: 45.6 nTPM (limit 2); lung: 5.1 nTPM (limit 2); lymph node: 6.7 nTPM (limit 6); midbrain: 4.2 nTPM (limit 2); pancreas: 18.9 nTPM (limit 2); parathyroid gland: 9.1 nTPM (limit 6); pituitary gland: 4 nTPM (limit 2); rectum: 9.4 nTPM (limit 6); retina: 6.6 nTPM (limit 2); skeletal muscle: 17.7 nTPM (limit 2); skin: 10.1 nTPM (limit 10); small intestine: 16 nTPM (limit 2); smooth muscle: 7.6 nTPM (limit 2); spinal cord: 4.8 nTPM (limit 2); stomach: 7.9 nTPM (limit 6); thymus: 22 nTPM (limit 10); tongue: 17.6 nTPM (limit 6); urinary bladder: 6.3 nTPM (limit 6),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: High (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: High (Approved); cerebellum / cells in granular layer: High (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: High (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: High (Approved); heart muscle / cardiomyocytes: High (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: High (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: High (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: High (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: High (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: High (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: High (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (validation): 231/231 (100.0%); Glioblastoma Multiforme (TCGA): 141/141 (100.0%); Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%),breast cancer: 12/12 (100.0%); colorectal cancer: 12/12 (100.0%),31,20,Q86X40,https://www.uniprot.org/uniprotkb/Q86X40/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
LRRC34,ENSG00000171757,Unsafe,Protein,False,True,12.4,12.4,92,38,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 0.3 nTPM; positive ihc; basal ganglia: 2.3 nTPM; absolute ceiling; bone marrow: 1.4 nTPM; positive ihc; cerebellum: 0.2 nTPM; positive ihc; cerebral cortex: 1.8 nTPM; positive ihc; choroid plexus: 5.6 nTPM; absolute ceiling;continuous selectivity; colon: 0.4 nTPM; positive ihc; duodenum: 0.2 nTPM; positive ihc; hypothalamus: 2.1 nTPM; absolute ceiling; kidney: 0.7 nTPM; positive ihc; pancreas: 0.1 nTPM; positive ihc; pituitary gland: 2.7 nTPM; absolute ceiling; rectum: 0 nTPM; positive ihc; retina: 5.4 nTPM; absolute ceiling;continuous selectivity; skin: 0.4 nTPM; positive ihc; small intestine: 0.4 nTPM; positive ihc; stomach: 0.4 nTPM; positive ihc; thyroid gland: 0.9 nTPM; positive ihc; urinary bladder: 0.4 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",basal ganglia: 2.3 nTPM (limit 2); choroid plexus: 5.6 nTPM (limit 2); hypothalamus: 2.1 nTPM (limit 2); pituitary gland: 2.7 nTPM (limit 2); retina: 5.4 nTPM (limit 2),adrenal gland / glandular cells: Low (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / ciliated cells (cell body): Medium (Approved); bronchus / ciliated cells (cilia axoneme): Medium (Approved); bronchus / ciliated cells (tip of cilia): High (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Low (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); nasopharynx / ciliated cells (cell body): Medium (Approved); nasopharynx / ciliated cells (tip of cilia): High (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); rectum / glandular cells: Medium (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Low (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 47/58 (81.0%); Breast Invasive Carcinoma (validation): 28/50 (56.0%); Ovary Serous Cystadenocarcinoma (validation): 6/81 (7.4%),pancreatic cancer: 2/12 (16.7%); colorectal cancer: 1/11 (9.1%),31,20,Q8IZ02,https://www.uniprot.org/uniprotkb/Q8IZ02/entry,"Highly expressed in stem cells where it may be involved in regulation of pluripotency. In embryonic stem cells (ESCs), important for normal expression of the pluripotency regulators POU5F1/OCT4 and KLF4. Also important for expression of the ectodermal marker gene NES and the endodermal marker gene GATA4. Promotes stem cell proliferation in vitro",,,It is uncertain whether Met-1 or Met-14 is the initiator,"Nucleus Nucleus, nucleolus Cytoplasm",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
LRRC36,ENSG00000159708,Unsafe,High RNA,False,True,34.3,34.3,85,3,Positive somewhere,False,False,False,True,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,hpa_immune_cell plasmacytoid DC: 9.8 nTPM; hpa_immune_monaco plasmacytoid DC: 19.7 TPM,True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,19.7,105.6,"hpa_single_cell_tissue: lung/alveolar cells type 2, max 105.6 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,19.7 TPM; blood/plasmacytoid DC; hpa_immune_monaco; vital,105.6 nTPM; lung/alveolar cells type 2; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (validation): 8/50 (16.0%); Glioblastoma Multiforme (validation): 6/58 (10.3%); Pancreatic Adenocarcinoma (validation): 4/80 (5.0%),breast cancer: 0/12 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q1X8D7,https://www.uniprot.org/uniprotkb/Q1X8D7/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Loriot2025_S2,Cancer-germline RNA nomination; strict and preferential classes remain distinct,,,,,,,,
LRRC37A2,ENSG00000238083,Unsafe,Protein,False,True,6.7,6.7,108,3,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; small intestine: 0.3 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,small intestine / enterocytes - Gradient: Ascending (Supported),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 48/50 (96.0%); Pancreatic Adenocarcinoma (validation): 69/80 (86.2%); Ovary Serous Cystadenocarcinoma (validation): 67/81 (82.7%),liver cancer: 3/10 (30.0%); endometrial cancer: 1/11 (9.1%),31,20,A6NM11,https://www.uniprot.org/uniprotkb/A6NM11/entry,,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
LRRC3B,ENSG00000179796,Unsafe,Protein,False,True,7.0,24.5,88,9,Positive somewhere,True,True,False,True,Excluded,Normal,False,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 24.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 24 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 21.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 24 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 15.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 11.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 13.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 9.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 4.6 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 4.6 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 24.5 nTPM (limit 2); basal ganglia: 24 nTPM (limit 2); cerebellum: 21.5 nTPM (limit 4); cerebral cortex: 24 nTPM (limit 2); hippocampal formation: 15.5 nTPM (limit 2); hypothalamus: 11.5 nTPM (limit 2); midbrain: 13.1 nTPM (limit 2); skeletal muscle: 9.1 nTPM (limit 2); spinal cord: 4.6 nTPM (limit 2),cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Medium (Approved); skeletal muscle / myocytes: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 42/58 (72.4%); Glioblastoma Multiforme (TCGA): 77/141 (54.6%); Ovary Serous Cystadenocarcinoma (TCGA): 50/349 (14.3%),breast cancer: 11/11 (100.0%); endometrial cancer: 11/11 (100.0%),31,20,Q96PB8,https://www.uniprot.org/uniprotkb/Q96PB8/entry,,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
LRRC52,ENSG00000162763,Unsafe,RNA,False,True,16.2,16.2,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,choroid plexus: 3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 3 nTPM (limit 2); choroid plexus: 3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Chromophobe (TCGA): 4/64 (6.2%); Lung Adenocarcinoma (TCGA): 7/497 (1.4%); Thyroid Carcinoma (TCGA): 5/495 (1.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8N7C0,https://www.uniprot.org/uniprotkb/Q8N7C0/entry,"Auxiliary protein of the large-conductance, voltage and calcium-activated potassium channel (BK alpha). Modulates gating properties by producing a marked shift in the BK channel's voltage dependence of activation in the hyperpolarizing direction, and in the absence of calcium. KCNU1 channel auxiliary protein. Modulates KCNU1 gating properties",Mainly expressed in testis and skeletal muscle,,,Cell membrane,22547800|23129643,22547800,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
LRRC63,ENSG00000173988,Unsafe,RNA,False,True,3.3,4.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,cerebral cortex: 1.2 nTPM; continuous selectivity; midbrain: 1.5 nTPM; continuous selectivity; retina: 2.3 nTPM; absolute ceiling;continuous selectivity; spinal cord: 4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 2.3 nTPM (limit 2); spinal cord: 4 nTPM (limit 2); retina: 2.3 nTPM (baseline 2); spinal cord: 4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 7/58 (12.1%); Testicular Germ Cell Tumor (TCGA): 3/133 (2.3%); Skin Cuteneous Melanoma (TCGA): 2/99 (2.0%),testis cancer: 11/12 (91.7%); melanoma: 5/12 (41.7%),29,19,Q05C16,https://www.uniprot.org/uniprotkb/Q05C16/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Chang2019_TGCT,Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
LRRC71,ENSG00000160838,Unsafe,RNA,False,True,24.7,24.7,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,choroid plexus: 11.1 nTPM; absolute ceiling;continuous selectivity; lung: 2.3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 11.1 nTPM (limit 2); lung: 2.3 nTPM (limit 2); choroid plexus: 11.1 nTPM (baseline 2); lung: 2.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 23/176 (13.1%); Glioblastoma Multiforme (validation): 3/58 (5.2%); Lung Adenocarcinoma (TCGA): 15/497 (3.0%),No exact-ID IHC coverage in the HPA cancer snapshot,30,0,Q8N4P6,https://www.uniprot.org/uniprotkb/Q8N4P6/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Loriot2025_S2,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct,,,,,,,,
LRRC73,ENSG00000204052,Unsafe,Protein,False,True,43.0,43.0,106,12,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 7.1 nTPM; absolute ceiling; basal ganglia: 9.8 nTPM; absolute ceiling; cerebellum: 2.3 nTPM; positive ihc;absolute ceiling; cerebral cortex: 12.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 6 nTPM; absolute ceiling; hippocampal formation: 8.4 nTPM; absolute ceiling; hypothalamus: 5.5 nTPM; absolute ceiling; midbrain: 2.8 nTPM; absolute ceiling; pituitary gland: 4.6 nTPM; absolute ceiling; rectum: 0.1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 7.1 nTPM (limit 2); basal ganglia: 9.8 nTPM (limit 2); cerebellum: 2.3 nTPM (limit 2); cerebral cortex: 12.5 nTPM (limit 2); choroid plexus: 6 nTPM (limit 2); hippocampal formation: 8.4 nTPM (limit 2); hypothalamus: 5.5 nTPM (limit 2); midbrain: 2.8 nTPM (limit 2); pituitary gland: 4.6 nTPM (limit 2),bronchus / ciliated cells (ciliary rootlets): High (Enhanced); caudate / glial cells: Low (Enhanced); cerebellum / Purkinje cells - cytoplasm/membrane: Low (Enhanced); cerebellum / Purkinje cells - dendrites: Low (Enhanced); cerebellum / synaptic glomeruli - core: High (Enhanced); cerebral cortex / neuronal cells: Low (Enhanced); hippocampus / neuronal cells: Low (Enhanced); rectum / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 42/176 (23.9%); Kidney Renal Papillary Cell Carcinoma (TCGA): 56/282 (19.9%); Ovary Serous Cystadenocarcinoma (TCGA): 51/349 (14.6%),cervical cancer: 2/10 (20.0%); prostate cancer: 2/11 (18.2%),29,20,Q5JTD7,https://www.uniprot.org/uniprotkb/Q5JTD7/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
LRRC8D,ENSG00000171492,Unsafe,RNA,False,True,12.5,42.5,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 5.7 nTPM; continuous selectivity; adrenal gland: 26 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 15 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 17.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 14 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 8.2 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 20.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 7.7 nTPM; absolute ceiling;continuous selectivity; colon: 17.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 18.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 7.6 nTPM; absolute ceiling;continuous selectivity; heart muscle: 7.3 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 24.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 16.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 25 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; liver: 22.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 9.5 nTPM; absolute ceiling;continuous selectivity; lymph node: 24.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 21.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 12.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 7.4 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 15.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 17.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; retina: 11.6 nTPM; absolute ceiling;continuous selectivity; salivary gland: 23.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 8.3 nTPM; absolute ceiling;continuous selectivity; skin: 5.5 nTPM; continuous selectivity; small intestine: 17.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 11 nTPM; absolute ceiling;continuous selectivity; spinal cord: 42.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 23.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; stomach: 11.2 nTPM; absolute ceiling;continuous selectivity; thymus: 27 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 15.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 10.8 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 26 nTPM (limit 2); amygdala: 15 nTPM (limit 2); basal ganglia: 17.1 nTPM (limit 2); bone marrow: 14 nTPM (limit 2); cerebellum: 8.2 nTPM (limit 2); cerebral cortex: 20.7 nTPM (limit 2); choroid plexus: 7.7 nTPM (limit 2); colon: 17.3 nTPM (limit 6); duodenum: 18.5 nTPM (limit 2); esophagus: 7.6 nTPM (limit 6); heart muscle: 7.3 nTPM (limit 2); hippocampal formation: 24.9 nTPM (limit 2); hypothalamus: 16.8 nTPM (limit 2); kidney: 25 nTPM (limit 2); liver: 22.8 nTPM (limit 2); lung: 9.5 nTPM (limit 2); lymph node: 24.3 nTPM (limit 6); midbrain: 21.6 nTPM (limit 2); pancreas: 12.6 nTPM (limit 2); parathyroid gland: 7.4 nTPM (limit 6); pituitary gland: 15.8 nTPM (limit 2); rectum: 17.6 nTPM (limit 6); retina: 11.6 nTPM (limit 2); salivary gland: 23.8 nTPM (limit 6); skeletal muscle: 8.3 nTPM (limit 2); small intestine: 17.5 nTPM (limit 2); smooth muscle: 11 nTPM (limit 2); spinal cord: 42.5 nTPM (limit 2); spleen: 23.3 nTPM (limit 10); stomach: 11.2 nTPM (limit 6); thymus: 27 nTPM (limit 10); thyroid gland: 15.4 nTPM (limit 10); urinary bladder: 10.8 nTPM (limit 6); adrenal gland: 26 nTPM (baseline 2); amygdala: 15 nTPM (baseline 2); basal ganglia: 17.1 nTPM (baseline 2); bone marrow: 14 nTPM (baseline 2); cerebellum: 8.2 nTPM (baseline 2); cerebral cortex: 20.7 nTPM (baseline 2); choroid plexus: 7.7 nTPM (baseline 2); colon: 17.3 nTPM (baseline 6); duodenum: 18.5 nTPM (baseline 2); esophagus: 7.6 nTPM (baseline 6); heart muscle: 7.3 nTPM (baseline 2); hippocampal formation: 24.9 nTPM (baseline 2); hypothalamus: 16.8 nTPM (baseline 2); kidney: 25 nTPM (baseline 2); liver: 22.8 nTPM (baseline 2); lung: 9.5 nTPM (baseline 2); lymph node: 24.3 nTPM (baseline 6); midbrain: 21.6 nTPM (baseline 2); pancreas: 12.6 nTPM (baseline 2); parathyroid gland: 7.4 nTPM (baseline 6); pituitary gland: 15.8 nTPM (baseline 2); rectum: 17.6 nTPM (baseline 6); retina: 11.6 nTPM (baseline 2); salivary gland: 23.8 nTPM (baseline 6); skeletal muscle: 8.3 nTPM (baseline 2); small intestine: 17.5 nTPM (baseline 2); smooth muscle: 11 nTPM (baseline 2); spinal cord: 42.5 nTPM (baseline 2); spleen: 23.3 nTPM (baseline 10); stomach: 11.2 nTPM (baseline 6); thymus: 27 nTPM (baseline 10); thyroid gland: 15.4 nTPM (baseline 10); urinary bladder: 10.8 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (TCGA): 254/254 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (TCGA): 141/141 (100.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q7L1W4,https://www.uniprot.org/uniprotkb/Q7L1W4/entry,"Non-essential component of the volume-regulated anion channel (VRAC, also named VSOAC channel), an anion channel required to maintain a constant cell volume in response to extracellular or intracellular osmotic changes (PubMed:24790029, PubMed:26530471, PubMed:26824658, PubMed:28193731, PubMed:32415200). The VRAC channel conducts iodide better than chloride and can also conduct organic osmolytes like taurine (PubMed:24790029, PubMed:26824658, PubMed:28193731). Plays a redundant role in the efflux of amino acids, such as aspartate, in response to osmotic stress (PubMed:28193731). LRRC8A and LRRC8D are required for the uptake of the drug cisplatin (PubMed:26530471). Channel activity requires LRRC8A plus at least one other family member (LRRC8B, LRRC8C, LRRC8D or LRRC8E); channel characteristics depend on the precise subunit composition (PubMed:24782309, PubMed:24790029, PubMed:26824658, PubMed:28193731). Also acts as a regulator of glucose-sensing in pancreatic beta cells: VRAC currents, generated in response to hypotonicity- or glucose-induced beta cell swelling, depolarize cells, thereby causing electrical excitation, leading to increase glucose sensitivity and insulin secretion (By similarity). VRAC channels containing LRRC8D inhibit transport of immunoreactive cyclic dinucleotide GMP-AMP (2'-3'-cGAMP), an immune messenger produced in response to DNA virus in the cytosol (PubMed:33171122). Mediates the import of the antibiotic blasticidin-S into the cell (PubMed:24782309)",,,,Cell membrane Endoplasmic reticulum membrane,24782309|24790029|26530471|26824658|28193731|32415200|33171122,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
LRRC9,ENSG00000131951,Unsafe,RNA,False,True,5.6,5.6,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,choroid plexus: 2.6 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 2.6 nTPM (limit 2); choroid plexus: 2.6 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 8/58 (13.8%); Prostate Adenocarcinoma (TCGA): 32/480 (6.7%); Kidney Chromophobe (TCGA): 4/64 (6.2%),lung cancer: 2/12 (16.7%); prostate cancer: 1/10 (10.0%),29,20,Q6ZRR7,https://www.uniprot.org/uniprotkb/Q6ZRR7/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Chang2019_TGCT,Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
LRRIQ1,ENSG00000133640,Unsafe,RNA,False,True,15.0,15.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,choroid plexus: 13.6 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 2.2 nTPM; absolute ceiling; lung: 2.5 nTPM; absolute ceiling; retina: 8.5 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 13.6 nTPM (limit 2); hypothalamus: 2.2 nTPM (limit 2); lung: 2.5 nTPM (limit 2); retina: 8.5 nTPM (limit 2); choroid plexus: 13.6 nTPM (baseline 2); hypothalamus: 2.2 nTPM (baseline 2); lung: 2.5 nTPM (baseline 2); retina: 8.5 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Renal Papillary Cell Carcinoma (TCGA): 66/282 (23.4%); Breast Invasive Carcinoma (validation): 8/50 (16.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 25/176 (14.2%),breast cancer: 12/12 (100.0%); colorectal cancer: 12/12 (100.0%),31,20,Q96JM4,https://www.uniprot.org/uniprotkb/Q96JM4/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
LRRIQ3,ENSG00000162620,Unsafe,Protein,False,True,19.8,19.8,99,8,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; kidney: 1.9 nTPM; positive ihc; parathyroid gland: 1.2 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,bronchus / ciliated cells (ciliary rootlets): High (Approved); kidney / cells in tubules: Low (Approved); nasopharynx / ciliated cells (ciliary rootlets): High (Approved); parathyroid gland / glandular cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Skin Cuteneous Melanoma (TCGA): 4/99 (4.0%); Kidney Renal Papillary Cell Carcinoma (TCGA): 11/282 (3.9%); Bladder Urothelial Carcinoma (TCGA): 6/169 (3.6%),breast cancer: 0/12 (0.0%); cervical cancer: 0/11 (0.0%),31,20,A6PVS8,https://www.uniprot.org/uniprotkb/A6PVS8/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Loriot2025_S2,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct,,,,,,,,
LRWD1,ENSG00000161036,Unsafe,Protein,False,True,267.6,267.6,89,7,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 16.2 nTPM; absolute ceiling; amygdala: 11.7 nTPM; absolute ceiling; basal ganglia: 13.5 nTPM; absolute ceiling; bone marrow: 14.8 nTPM; absolute ceiling; cerebellum: 26.8 nTPM; absolute ceiling; cerebral cortex: 13.8 nTPM; absolute ceiling; choroid plexus: 11 nTPM; absolute ceiling; hippocampal formation: 12.5 nTPM; absolute ceiling; hypothalamus: 13.8 nTPM; absolute ceiling; liver: 14.6 nTPM; absolute ceiling; lung: 9.8 nTPM; positive ihc;absolute ceiling; midbrain: 10.3 nTPM; absolute ceiling; pituitary gland: 17.1 nTPM; absolute ceiling; retina: 3.3 nTPM; absolute ceiling; skeletal muscle: 12.7 nTPM; absolute ceiling; small intestine: 16.6 nTPM; absolute ceiling; spinal cord: 8.9 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 16.2 nTPM (limit 12); amygdala: 11.7 nTPM (limit 2); basal ganglia: 13.5 nTPM (limit 2); bone marrow: 14.8 nTPM (limit 12); cerebellum: 26.8 nTPM (limit 12); cerebral cortex: 13.8 nTPM (limit 12); choroid plexus: 11 nTPM (limit 2); hippocampal formation: 12.5 nTPM (limit 2); hypothalamus: 13.8 nTPM (limit 2); liver: 14.6 nTPM (limit 12); lung: 9.8 nTPM (limit 2); midbrain: 10.3 nTPM (limit 2); pituitary gland: 17.1 nTPM (limit 2); retina: 3.3 nTPM (limit 2); skeletal muscle: 12.7 nTPM (limit 12); small intestine: 16.6 nTPM (limit 12); spinal cord: 8.9 nTPM (limit 2),lung / macrophages: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 141/141 (100.0%); Ovary Serous Cystadenocarcinoma (TCGA): 348/349 (99.7%); Colon Adenocarcinoma (TCGA): 253/254 (99.6%),breast cancer: 0/10 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q9UFC0,https://www.uniprot.org/uniprotkb/Q9UFC0/entry,"Required for G1/S transition. Recruits and stabilizes the origin recognition complex (ORC) onto chromatin during G1 to establish pre-replication complex (preRC) and to heterochromatic sites in post-replicated cells. Binds a combination of DNA and histone methylation repressive marks on heterochromatin. Binds histone H3 and H4 trimethylation marks H3K9me3, H3K27me3 and H4K20me3 in a cooperative manner with DNA methylation. Required for silencing of major satellite repeats. May be important ORC2, ORC3 and ORC4 stability",Testis-specific. Drastically down-regulated in testis from patients with Sertoli cell-only syndrome (SCOS),,,"Nucleus Chromosome, centromere Chromosome, telomere Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Chromosome, centromere, kinetochore",20850016|20932478|21029866|22427655|22645314,17074343,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
LSM12,ENSG00000161654,Unsafe,Protein,False,True,24.4,35.8,89,72,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 19.3 nTPM; continuous selectivity; adrenal gland: 21.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 20.1 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 16.7 nTPM; absolute ceiling;continuous selectivity; bone marrow: 29.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 16.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 20.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 16 nTPM; absolute ceiling;continuous selectivity; colon: 19.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 16.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 27.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 21.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 18.9 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 22.1 nTPM; absolute ceiling;continuous selectivity; kidney: 20.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 28.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 16.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 20.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 19.9 nTPM; absolute ceiling;continuous selectivity; pancreas: 23.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 20.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 13.8 nTPM; absolute ceiling;continuous selectivity; rectum: 22.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 30.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 17.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 35.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 16.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 16.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 19.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 18.6 nTPM; absolute ceiling;continuous selectivity; spleen: 16.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 19.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 19.4 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 17.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 22.8 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 22 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 21.2 nTPM (limit 2); amygdala: 20.1 nTPM (limit 2); basal ganglia: 16.7 nTPM (limit 2); bone marrow: 29.2 nTPM (limit 2); cerebellum: 16.5 nTPM (limit 2); cerebral cortex: 20.9 nTPM (limit 2); choroid plexus: 16 nTPM (limit 2); colon: 19.1 nTPM (limit 6); duodenum: 16.7 nTPM (limit 2); esophagus: 27.3 nTPM (limit 6); heart muscle: 21.9 nTPM (limit 2); hippocampal formation: 18.9 nTPM (limit 2); hypothalamus: 22.1 nTPM (limit 2); kidney: 20.2 nTPM (limit 2); liver: 28.5 nTPM (limit 2); lung: 16.3 nTPM (limit 2); lymph node: 20.3 nTPM (limit 6); midbrain: 19.9 nTPM (limit 2); pancreas: 23.2 nTPM (limit 2); parathyroid gland: 20.8 nTPM (limit 6); pituitary gland: 13.8 nTPM (limit 2); rectum: 22.9 nTPM (limit 6); retina: 30.3 nTPM (limit 2); salivary gland: 17.6 nTPM (limit 6); skeletal muscle: 35.8 nTPM (limit 2); skin: 16.2 nTPM (limit 10); small intestine: 16.4 nTPM (limit 2); smooth muscle: 19.6 nTPM (limit 2); spinal cord: 18.6 nTPM (limit 2); spleen: 16.8 nTPM (limit 10); stomach: 19.3 nTPM (limit 6); thymus: 19.4 nTPM (limit 10); thyroid gland: 17.7 nTPM (limit 10); tongue: 22.8 nTPM (limit 6); urinary bladder: 22 nTPM (limit 6),adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: High (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: High (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: High (Approved); colon / glandular cells: High (Approved); colon / peripheral nerve/ganglion: High (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: High (Approved); heart muscle / cardiomyocytes: Medium (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: High (Approved); lung / alveolar cells type II: High (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: High (Approved); lymph node / non-germinal center cells: High (Approved); nasopharynx / respiratory epithelial cells: High (Approved); oral mucosa / squamous epithelial cells: High (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: High (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: High (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: High (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%); Thyroid Carcinoma (TCGA): 495/495 (100.0%),cervical cancer: 12/12 (100.0%); testis cancer: 12/12 (100.0%),31,20,Q3MHD2,https://www.uniprot.org/uniprotkb/Q3MHD2/entry,Nicotinic acid adenine dinucleotide phosphate (NAADP) binding protein (PubMed:34362892). Confers NAADP sensitivity to the two pore channel complex (TPCs) by acting as TPC accessory protein necessary for NAADP-evoked Ca(2+) release (PubMed:34362892),,,,Cytoplasm,34362892,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
LY6K,ENSG00000160886,Unsafe,RNA,False,True,35.0,35.0,86,3,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,Trial registration,basal ganglia: 2.2 nTPM; absolute ceiling; hypothalamus: 2.3 nTPM; absolute ceiling; midbrain: 2.4 nTPM; absolute ceiling; retina: 2.3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,basal ganglia: 2.2 nTPM (limit 2); hypothalamus: 2.3 nTPM (limit 2); midbrain: 2.4 nTPM (limit 2); retina: 2.3 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,True,3.4002,106.2,"hpa_single_cell: /Basal keratinocytes, max 32.5 nTPM, 1 observations >30; hpa_single_cell: /Langerhans cells, max 31.7 nTPM, 1 observations >30; hpa_single_cell: /Squamous epithelial cells, max 33.3 nTPM, 1 observations >30; hpa_single_cell: /Suprabasal keratinocytes, max 64.5 nTPM, 1 observations >30; hpa_single_cell_tissue: adipose tissue/smooth muscle cells, max 34.3 nTPM, 1 observations >30; hpa_single_cell_tissue: esophagus/squamous epithelial cells, max 43.4 nTPM, 1 observations >30; hpa_single_cell_tissue: placenta/mixed immune cells, max 35.3 nTPM, 1 observations >30; hpa_single_cell_tissue: skin/basal keratinocytes, max 41.3 nTPM, 1 observations >30; hpa_single_cell_tissue: skin/langerhans cells, max 38.8 nTPM, 1 observations >30; hpa_single_cell_tissue: skin/suprabasal keratinocytes, max 42.4 nTPM, 1 observations >30; hpa_single_cell_tissue: tongue/basal keratinocytes, max 51 nTPM, 1 observations >30; hpa_single_cell_tissue: tongue/suprabasal keratinocytes, max 106.2 nTPM, 3 observations >30",Unsafe,oncoref.target-sets.2026-10-23.2,3.4 TPM; blood/neutrophil; hpa_immune_cell_samples; vital,106.2 nTPM; tongue/suprabasal keratinocytes; hpa_single_cell_tissue; protected,Head and Neck Squamous Cell Carcinoma (TCGA): 475/492 (96.5%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 266/283 (94.0%); Lung Squamous Cell Carcinoma (TCGA): 378/489 (77.3%),breast cancer: 0/12 (0.0%); cervical cancer: 0/10 (0.0%),31,20,Q17RY6,https://www.uniprot.org/uniprotkb/Q17RY6/entry,Required for sperm migration into the oviduct and male fertility by controlling binding of sperm to zona pellucida (By similarity). May play a role in cell growth (PubMed:18089789),Specifically expressed in testis (at protein level),,,"Secreted Cytoplasm Cell membrane Cytoplasmic vesicle, secretory vesicle, acrosome Membrane raft",18089789,12516096|18089789,False,Reviewed UniProt annotation; not a new primary-paper review,Trial registration only,https://clinicaltrials.gov/study/NCT00669292,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,Failed bulk numeric comparisons are within 20% of their cutoffs; not an automatic rescue,,,,
M1AP,ENSG00000159374,Unsafe,RNA,False,True,6.3,6.3,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 2.4 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 1.7 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 2.4 nTPM (limit 2); bone marrow: 2.4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Ovary Serous Cystadenocarcinoma (TCGA): 150/349 (43.0%); Testicular Germ Cell Tumor (TCGA): 49/133 (36.8%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 78/283 (27.6%),prostate cancer: 12/12 (100.0%); lymphoma: 11/12 (91.7%),29,20,Q8TC57,https://www.uniprot.org/uniprotkb/Q8TC57/entry,Required for meiosis I progression during spermatogenesis,,Spermatogenic failure 48: An autosomal recessive infertility disorder caused by spermatogenesis defects resulting in non-obstructive azoospermia.,,Cytoplasm,32673564,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
MAEL,ENSG00000143194,Unsafe,RNA,False,True,154.6,154.6,82,1,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,heart muscle: 5.4 nTPM; absolute ceiling; retina: 4.2 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,heart muscle: 5.4 nTPM (limit 4); retina: 4.2 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 61/133 (45.9%); Glioblastoma Multiforme (validation): 24/58 (41.4%); Glioblastoma Multiforme (TCGA): 51/141 (36.2%),prostate cancer: 1/10 (10.0%); breast cancer: 1/11 (9.1%),31,20,Q96JY0,https://www.uniprot.org/uniprotkb/Q96JY0/entry,"Plays a central role during spermatogenesis by repressing transposable elements and preventing their mobilization, which is essential for the germline integrity. Acts via the piRNA metabolic process, which mediates the repression of transposable elements during meiosis by forming complexes composed of piRNAs and Piwi proteins and governs the methylation and subsequent repression of transposons. Its association with piP-bodies suggests a participation in the secondary piRNAs metabolic process. Required for the localization of germ-cell factors to the meiotic nuage (By similarity)","Testis-specific. Expressed in various cancer cell lines, probably due to demethylation of its promoter",,,Cytoplasm Nucleus,,19693694,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
MAF,ENSG00000178573,Unsafe,Protein,False,True,37.5,80.7,81,72,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 26.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 15 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 9.3 nTPM; absolute ceiling; basal ganglia: 7.1 nTPM; absolute ceiling; bone marrow: 4 nTPM; positive ihc;absolute ceiling; cerebellum: 10.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 10.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 5.1 nTPM; absolute ceiling; colon: 11 nTPM; positive ihc;absolute ceiling; duodenum: 68.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 22 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 6.6 nTPM; positive ihc;absolute ceiling; hippocampal formation: 7.6 nTPM; absolute ceiling; hypothalamus: 6.2 nTPM; absolute ceiling; kidney: 46.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 25 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 18.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 30.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 8.7 nTPM; absolute ceiling; pancreas: 3.1 nTPM; positive ihc;absolute ceiling; parathyroid gland: 49.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 5.1 nTPM; absolute ceiling; rectum: 10.4 nTPM; positive ihc;absolute ceiling; retina: 4.5 nTPM; absolute ceiling; salivary gland: 11.5 nTPM; positive ihc;absolute ceiling; skeletal muscle: 47.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 56.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 80.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 17.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 11.8 nTPM; absolute ceiling;continuous selectivity; spleen: 25.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 12.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 17.4 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 22.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 19 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 17.1 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 26.9 nTPM (limit 10); adrenal gland: 15 nTPM (limit 2); amygdala: 9.3 nTPM (limit 2); basal ganglia: 7.1 nTPM (limit 2); bone marrow: 4 nTPM (limit 2); cerebellum: 10.1 nTPM (limit 2); cerebral cortex: 10.7 nTPM (limit 2); choroid plexus: 5.1 nTPM (limit 2); colon: 11 nTPM (limit 6); duodenum: 68.4 nTPM (limit 2); esophagus: 22 nTPM (limit 6); heart muscle: 6.6 nTPM (limit 2); hippocampal formation: 7.6 nTPM (limit 2); hypothalamus: 6.2 nTPM (limit 2); kidney: 46.5 nTPM (limit 2); liver: 25 nTPM (limit 2); lung: 18.2 nTPM (limit 2); lymph node: 30.2 nTPM (limit 6); midbrain: 8.7 nTPM (limit 2); pancreas: 3.1 nTPM (limit 2); parathyroid gland: 49.2 nTPM (limit 6); pituitary gland: 5.1 nTPM (limit 2); rectum: 10.4 nTPM (limit 6); retina: 4.5 nTPM (limit 2); salivary gland: 11.5 nTPM (limit 6); skeletal muscle: 47.8 nTPM (limit 2); skin: 56.3 nTPM (limit 10); small intestine: 80.7 nTPM (limit 2); smooth muscle: 17.2 nTPM (limit 2); spinal cord: 11.8 nTPM (limit 2); spleen: 25.3 nTPM (limit 10); stomach: 12.7 nTPM (limit 6); thymus: 17.4 nTPM (limit 10); thyroid gland: 22.4 nTPM (limit 10); tongue: 19 nTPM (limit 6); urinary bladder: 17.1 nTPM (limit 6),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: High (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: High (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / glial cells: High (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: High (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: Medium (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: High (Approved); oral mucosa / squamous epithelial cells: High (Approved); pancreas / exocrine glandular cells: High (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: High (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Medium (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Adenocarcinoma (validation): 105/105 (100.0%); Kidney Renal Clear Cell Carcinoma (validation): 100/100 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%),breast cancer: 12/12 (100.0%); renal cancer: 11/11 (100.0%),31,20,O75444,https://www.uniprot.org/uniprotkb/O75444/entry,"Acts as a transcriptional activator or repressor. Involved in embryonic lens fiber cell development. Recruits the transcriptional coactivators CREBBP and/or EP300 to crystallin promoters leading to up-regulation of crystallin gene during lens fiber cell differentiation. Activates the expression of IL4 in T helper 2 (Th2) cells. Increases T-cell susceptibility to apoptosis by interacting with MYB and decreasing BCL2 expression. Together with PAX6, transactivates strongly the glucagon gene promoter through the G1 element. Activates transcription of the CD13 proximal promoter in endothelial cells. Represses transcription of the CD13 promoter in early stages of myelopoiesis by affecting the ETS1 and MYB cooperative interaction. Involved in the initial chondrocyte terminal differentiation and the disappearance of hypertrophic chondrocytes during endochondral bone development. Binds to the sequence 5'-[GT]G[GC]N[GT]NCTCAGNN-3' in the L7 promoter. Binds to the T-MARE (Maf response element) sites of lens-specific alpha- and beta-crystallin gene promoters. Binds element G1 on the glucagon promoter. Binds an AT-rich region adjacent to the TGC motif (atypical Maf response element) in the CD13 proximal promoter in endothelial cells (By similarity). When overexpressed, represses anti-oxidant response element (ARE)-mediated transcription. Involved either as an oncogene or as a tumor suppressor, depending on the cell context. Binds to the ARE sites of detoxifying enzyme gene promoters",Expressed in endothelial cells,"Cataract 21, multiple types: An opacification of the crystalline lens of the eye that frequently results in visual impairment or blindness. Opacities vary in morphology, are often confined to a portion of the lens, and may be static or progressive. In general, the more posteriorly located and dense an opacity, the greater the impact on visual function. CTRCT21 includes cerulean and pulverulent cataracts. Cerulean cataracts are characterized by peripheral bluish and white opacifications organized in concentric layers with occasional central lesions arranged radially. The opacities are observed in the superficial layers of the fetal nucleus as well as the adult nucleus of the lens. Involvement is usually bilateral. Visual acuity is only mildly reduced in childhood. In adulthood, the opacifications may progress, making lens extraction necessary. Histologically the lesions are described as fusiform cavities between lens fibers which contain a deeply staining granular material. Although the lesions may take on various colors, a dull blue is the most common appearance and is responsible for the designation cerulean cataract. Pulverulent cataracts are characterized by a dust-like, 'pulverised' appearance of the opacities which can be found in any part of the lens. In some cases cataract is associated with microcornea without any other systemic anomaly or dysmorphism. Microcornea is defined by a corneal diameter inferior to 10 mm in both meridians in an otherwise normal eye. Ayme-Gripp syndrome: A multisystem disorder characterized by congenital cataracts, sensorineural deafness, intellectual disability, seizures, brachycephaly, distinctive flat facial appearance, skeletal anomalies, mammary gland hypoplasia, and reduced growth.",,Nucleus,12149651|14998494|15007382|16247450|19143053,17897790,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
MAGEA12,ENSG00000213401,Unsafe,Safety,False,True,2.7,2.7,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,Published safety findings,external safety hold; external safety hold,Independent reviewed normal-tissue safety hold,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Unsafe,Safety,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,False,0.0,1.9,,Unsafe,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,1.9 nTPM; placenta/mixed immune cells; hpa_single_cell_tissue; vital,Skin Cuteneous Melanoma (TCGA): 46/99 (46.5%); Stomach Adenocarcinoma (TCGA): 88/346 (25.4%); Lung Squamous Cell Carcinoma (TCGA): 110/489 (22.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P43365,https://www.uniprot.org/uniprotkb/P43365/entry,"Not known, though may play a role tumor transformation or progression. In vitro promotes cell viability in melanoma cell lines","Expressed in many tumors of several types, such as melanoma, head and neck squamous cell carcinoma, lung carcinoma and breast carcinoma, but not in normal tissues except for testes",,,,17942928,,True,Reviewed UniProt annotation; not a new primary-paper review,Clinical safety concern,https://pubmed.ncbi.nlm.nih.gov/23377668/,"Five of nine patients had tumor regression; three developed neurological toxicity and two died. The receptor cross-recognized MAGE-A12, with brain RNA evidence; pan-MAGE neuronal staining did not uniquely establish the causal paralog.",https://pubmed.ncbi.nlm.nih.gov/23377668/,Clinical safety signal,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Jamin2021_CT | Jamin2021_core | Chang2019_TGCT | Carter2023_CT | Seager2024_CTA | Loriot2025_S1,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene | Member of the published 17-target CTA profiling panel; includes differentiation antigen MLANA | Cancer-germline RNA nomination; strict and preferential classes remain distinct,,,,,,,,
MAGEA3,ENSG00000221867,Unsafe,High RNA,False,True,7.8,7.8,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,Trial registration,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,CTA,Pass,oncoref.target-sets.2026-10-23.1,False,False,,CTA → Unsafe,True,True,True,0.166407249537,53.1,"hpa_single_cell_tissue: colon/undifferentiated cells, max 53.1 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,0.1664 TPM; blood/CD8_STIM; dice_cd8_stim; vital,53.1 nTPM; colon/undifferentiated cells; hpa_single_cell_tissue; protected,Skin Cuteneous Melanoma (TCGA): 55/99 (55.6%); Lung Squamous Cell Carcinoma (TCGA): 223/489 (45.6%); Bladder Urothelial Carcinoma (TCGA): 68/169 (40.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P43357,https://www.uniprot.org/uniprotkb/P43357/entry,"Activator of ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases that acts as a repressor of autophagy (PubMed:20864041, PubMed:31267705). May enhance ubiquitin ligase activity of TRIM28 and stimulate p53/TP53 ubiquitination by TRIM28. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzyme (E2) at the E3:substrate complex (PubMed:17942928, PubMed:20864041). May play a role in embryonal development and tumor transformation or aspects of tumor progression (PubMed:17942928, PubMed:20864041). In vitro promotes cell viability in melanoma cell lines (PubMed:17942928). Antigen recognized on a melanoma by autologous cytolytic T-lymphocytes (PubMed:8113684)","Expressed in many tumors of several types, such as melanoma, head and neck squamous cell carcinoma, lung carcinoma and breast carcinoma, but not in normal tissues except for testes and placenta. Never expressed in kidney tumors, Leukemias and lymphomas",,In vitro experiments measuring cell viability in melanoma cell lines used siRNA specific for MAGEA3 and MAGEA6,,17942928|20864041|31267705|8113684,8113684,True,Reviewed UniProt annotation; not a new primary-paper review,Trial registration only,https://clinicaltrials.gov/study/NCT00480025,"Two fatal cardiac events followed affinity-enhanced MAGE-A3 TCR treatment. Cross-recognition of unrelated cardiac titin explains the hazard; it does not demonstrate native MAGEA3 expression in heart. | Five of nine patients had tumor regression; three developed neurological toxicity and two died. The receptor cross-recognized MAGE-A12, with brain RNA evidence; pan-MAGE neuronal staining did not uniquely establish the causal paralog. | MAGE-A3 vaccination did not improve disease-free survival after NSCLC resection (hazard ratio 1.02; 95% CI 0.89-1.18). Trial nomination is therefore not evidence of benefit.",https://pubmed.ncbi.nlm.nih.gov/23770775/ | https://pubmed.ncbi.nlm.nih.gov/23377668/ | https://pubmed.ncbi.nlm.nih.gov/27132212/,Clinical safety signal | Negative randomized trial,Wang2016_CT | Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | Jamin2021_CT | Jamin2021_core | Chang2019_TGCT | Carter2023_CT | Seager2024_CTA | Loriot2025_S1 | Gong2021_reproductive_PC | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene | Member of the published 17-target CTA profiling panel; includes differentiation antigen MLANA | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,Is the colonic undifferentiated-cell RNA correctly attributed and endogenous?,Resolve the pinned high normal-cell signal and exact locus/protein identity before reconsideration.,Clinical interest does not create a gene exception; RNA does not by itself establish protein or peptide display.,,,,,
MAGEB2,ENSG00000099399,Unsafe,High RNA,False,True,28.2,28.2,85,1,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,CTA,Pass,oncoref.target-sets.2026-10-23.1,False,False,,CTA → Unsafe,True,True,True,2.15352119748,118.4,"hpa_single_cell_tissue: colon/undifferentiated cells, max 118.4 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,2.154 TPM; blood/NK; dice_nk; vital,118.4 nTPM; colon/undifferentiated cells; hpa_single_cell_tissue; protected,Testicular Germ Cell Tumor (TCGA): 98/133 (73.7%); Lung Squamous Cell Carcinoma (TCGA): 105/489 (21.5%); Skin Cuteneous Melanoma (TCGA): 14/99 (14.1%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),31,20,O15479,https://www.uniprot.org/uniprotkb/O15479/entry,May enhance ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzyme (E2) at the E3:substrate complex,"Expressed in testis and placenta, and in a significant fraction of tumors of various histologic types",,,,20864041,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | Jamin2021_CT | Jamin2021_core | Chang2019_TGCT | Carter2023_CT | Loriot2025_S1 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination; inclusion depends on TGCT under this study's thresholds | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
MAGEB4,ENSG00000120289,Unsafe,Protein,False,True,26.6,26.6,84,20,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 0 nTPM; positive ihc; duodenum: 0 nTPM; positive ihc; lymph node: 0 nTPM; positive ihc; rectum: 0 nTPM; positive ihc; salivary gland: 0 nTPM; positive ihc; small intestine: 0 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,adrenal gland / glandular cells: Low (Enhanced); bronchus / respiratory epithelial cells: Low (Enhanced); duodenum / glandular cells: Low (Enhanced); lymph node / germinal center cells: Low (Enhanced); nasopharynx / respiratory epithelial cells: Low (Enhanced); rectum / glandular cells: Low (Enhanced); salivary gland / glandular cells: Low (Enhanced); small intestine / glandular cells: Low (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 1/50 (2.0%); Breast Invasive Carcinoma (TCGA): 11/1022 (1.1%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),breast cancer: 0/12 (0.0%); cervical cancer: 0/12 (0.0%),31,20,O15481,https://www.uniprot.org/uniprotkb/O15481/entry,,Expressed in testis,,,Cytoplasm,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
MAK,ENSG00000111837,Unsafe,RNA,False,True,5.2,115.3,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,choroid plexus: 6.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 4.5 nTPM; continuous selectivity; retina: 115.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 6.9 nTPM (limit 2); retina: 115.3 nTPM (limit 2); choroid plexus: 6.9 nTPM (baseline 2); retina: 115.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 10/50 (20.0%); Glioblastoma Multiforme (validation): 10/58 (17.2%); Uterine Corpus Endometrial Carcinoma (TCGA): 16/176 (9.1%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P20794,https://www.uniprot.org/uniprotkb/P20794/entry,Essential for the regulation of ciliary length and required for the long-term survival of photoreceptors (By similarity). Phosphorylates FZR1 in a cell cycle-dependent manner. Plays a role in the transcriptional coactivation of AR. Could play an important function in spermatogenesis. May play a role in chromosomal stability in prostate cancer cells,"Expressed in prostate cancer cell lines at generally higher levels than in normal prostate epithelial cell lines. Isoform 1 is expressed in kidney, testis, lung, trachea, and retina. Isoform 2 is retina-specific where it is expressed in rod and cone photoreceptors","Retinitis pigmentosa 62: A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.",,"Nucleus Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Cytoplasm, cytoskeleton, spindle Midbody Cell projection, cilium, photoreceptor outer segment Photoreceptor inner segment",12084720|16951154|21986944,12084720|21825139,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Jamin2021_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
MAP10,ENSG00000212916,Unsafe,Protein,False,True,2.6,3.1,79,57,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 0.8 nTPM; positive ihc;continuous selectivity; basal ganglia: 1.2 nTPM; continuous selectivity; bone marrow: 0.6 nTPM; positive ihc; cerebellum: 0.8 nTPM; positive ihc;continuous selectivity; cerebral cortex: 2.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 0.8 nTPM; positive ihc; duodenum: 1.1 nTPM; positive ihc;continuous selectivity; esophagus: 0.4 nTPM; positive ihc; heart muscle: 2.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 0.8 nTPM; continuous selectivity; hypothalamus: 0.9 nTPM; continuous selectivity; kidney: 0.9 nTPM; positive ihc;continuous selectivity; liver: 2.2 nTPM; continuous selectivity; lung: 1 nTPM; positive ihc;continuous selectivity; lymph node: 2.2 nTPM; continuous selectivity; pancreas: 1.7 nTPM; positive ihc;continuous selectivity; parathyroid gland: 0.6 nTPM; positive ihc; rectum: 0.7 nTPM; positive ihc; retina: 2.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 1.3 nTPM; positive ihc;continuous selectivity; skeletal muscle: 2.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 0.3 nTPM; positive ihc; small intestine: 1.5 nTPM; positive ihc;continuous selectivity; smooth muscle: 1 nTPM; positive ihc;continuous selectivity; stomach: 1.3 nTPM; positive ihc;continuous selectivity; thymus: 3.1 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 1.8 nTPM; positive ihc;continuous selectivity; tongue: 1.2 nTPM; continuous selectivity; urinary bladder: 0.8 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",cerebral cortex: 2.1 nTPM (limit 2); heart muscle: 2.1 nTPM (limit 2); retina: 2.8 nTPM (limit 2); skeletal muscle: 2.1 nTPM (limit 2),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / glial cells: Low (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: High (Approved); heart muscle / cardiomyocytes: Medium (Approved); kidney / cells in tubules: Medium (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: High (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: High (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: High (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Low (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 53/58 (91.4%); Lung Adenocarcinoma (validation): 24/105 (22.9%); Pancreatic Adenocarcinoma (validation): 9/80 (11.2%),pancreatic cancer: 12/12 (100.0%); prostate cancer: 6/7 (85.7%),29,20,Q9P2G4,https://www.uniprot.org/uniprotkb/Q9P2G4/entry,Microtubule-associated protein (MAP) that plays a role in the regulation of cell division; promotes microtubule stability and participates in the organization of the spindle midzone and normal progress of cytokinesis,Expressed in different cell lines (at protein level),,,"Cytoplasm, cytoskeleton Cytoplasm, cytoskeleton, spindle pole Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Midbody",23264731,23264731,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
MAP6,ENSG00000171533,Unsafe,Protein,False,True,39.4,93.1,160,34,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 18.4 nTPM; absolute ceiling; amygdala: 67.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 75.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 43.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 84.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 89 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 22.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 63.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 75.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 16.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 47.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 74.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 3.4 nTPM; positive ihc; retina: 93.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 7.8 nTPM; positive ihc; small intestine: 4.6 nTPM; absolute ceiling; smooth muscle: 12.6 nTPM; absolute ceiling; spinal cord: 43.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 18.4 nTPM (limit 12); amygdala: 67.2 nTPM (limit 2); basal ganglia: 75.4 nTPM (limit 2); cerebellum: 43.4 nTPM (limit 2); cerebral cortex: 84.9 nTPM (limit 2); choroid plexus: 89 nTPM (limit 2); colon: 22.2 nTPM (limit 6); hippocampal formation: 63.8 nTPM (limit 2); hypothalamus: 75.6 nTPM (limit 2); kidney: 16.5 nTPM (limit 2); midbrain: 47.7 nTPM (limit 2); pituitary gland: 74.8 nTPM (limit 2); retina: 93.1 nTPM (limit 2); small intestine: 4.6 nTPM (limit 2); smooth muscle: 12.6 nTPM (limit 12); spinal cord: 43.5 nTPM (limit 2),bronchus / ciliated cells (cell body): Medium (Enhanced); bronchus / ciliated cells (cilia axoneme): Low (Enhanced); bronchus / ciliated cells (tip of cilia): Low (Enhanced); caudate / glial cells: Low (Enhanced); caudate / neuronal cells: High (Enhanced); cerebellum / molecular layer cells - cytoplasm/membrane: High (Enhanced); cerebellum / processes in granular layer: High (Enhanced); cerebellum / processes in molecular layer: High (Enhanced); cerebellum / processes in white matter: High (Enhanced); cerebellum / Purkinje cells - cytoplasm/membrane: High (Enhanced); cerebellum / Purkinje cells - dendrites: High (Enhanced); cerebral cortex / glial cells: Low (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); cerebral cortex / neuropil: High (Enhanced); colon / peripheral nerve/ganglion: High (Enhanced); hippocampus / glial cells: Low (Enhanced); hippocampus / neuronal cells: High (Enhanced); kidney / cells in glomeruli: High (Enhanced); nasopharynx / ciliated cells (cilia axoneme): Low (Enhanced); nasopharynx / ciliated cells (ciliary rootlets): Low (Enhanced); nasopharynx / ciliated cells (tip of cilia): Low (Enhanced); rectum / peripheral nerve/ganglion: High (Enhanced); skin 1 / cells in corneal layer: High (Enhanced); skin 1 / cells in granular layer: High (Enhanced); skin 1 / eccrine glands: Low (Enhanced); skin 2 / cells in corneal layer: Medium (Enhanced); skin 2 / cells in granular layer: Medium (Enhanced); skin 2 / eccrine glands: Low (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Glioblastoma Multiforme (TCGA): 139/141 (98.6%); Prostate Adenocarcinoma (TCGA): 444/480 (92.5%),breast cancer: 0/11 (0.0%); cervical cancer: 0/10 (0.0%),31,20,Q96JE9,https://www.uniprot.org/uniprotkb/Q96JE9/entry,"Involved in microtubule stabilization in many cell types, including neuronal cells (By similarity). Specifically has microtubule cold stabilizing activity (By similarity). Involved in dendrite morphogenesis and maintenance by regulating lysosomal trafficking via its interaction with TMEM106B (PubMed:24357581). Regulates KIF5A-mediated axonal cargo transport (By similarity). Regulates axonal growth during neuron polarization (By similarity)",Expressed in brain (at protein level). Expressed in spinal cord. Isoform 2 expression is up-regulated in the prefrontal cortex (Brodmann's area 46) of patients with schizophrenia (postmortem brain study),,,"Cytoplasm, cytoskeleton Golgi apparatus Cell projection, axon Cell projection, dendrite Cytoplasmic vesicle, secretory vesicle membrane",24357581,14692697|16624526,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
MAP7D2,ENSG00000184368,Unsafe,Protein,False,True,35.5,35.5,96,31,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; amygdala: 13.6 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 21.1 nTPM; absolute ceiling;continuous selectivity; cerebellum: 23.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 31.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 0.7 nTPM; positive ihc; hippocampal formation: 14.2 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 20.9 nTPM; absolute ceiling;continuous selectivity; kidney: 3.4 nTPM; positive ihc;absolute ceiling; midbrain: 14.1 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 3.8 nTPM; absolute ceiling; rectum: 0.8 nTPM; positive ihc; retina: 14.1 nTPM; absolute ceiling;continuous selectivity; skin: 0.9 nTPM; positive ihc; spinal cord: 6 nTPM; absolute ceiling; stomach: 8.5 nTPM; positive ihc;absolute ceiling; thyroid gland: 0.1 nTPM; positive ihc; urinary bladder: 0.1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 13.6 nTPM (limit 2); basal ganglia: 21.1 nTPM (limit 2); cerebellum: 23.7 nTPM (limit 2); cerebral cortex: 31.3 nTPM (limit 2); hippocampal formation: 14.2 nTPM (limit 2); hypothalamus: 20.9 nTPM (limit 2); kidney: 3.4 nTPM (limit 2); midbrain: 14.1 nTPM (limit 2); pituitary gland: 3.8 nTPM (limit 2); retina: 14.1 nTPM (limit 2); spinal cord: 6 nTPM (limit 2); stomach: 8.5 nTPM (limit 6),bronchus / respiratory epithelial cells: Low (Enhanced); caudate / neuronal cells: Low (Enhanced); cerebellum / Bergmann glia - cytoplasm/membrane: High (Enhanced); cerebellum / GLUC cells - cytoplasm/membrane: High (Enhanced); cerebellum / granular cells - cytoplasm/membrane: Medium (Enhanced); cerebellum / molecular layer cells - cytoplasm/membrane: High (Enhanced); cerebellum / Purkinje cells - cytoplasm/membrane: High (Enhanced); cerebellum / Purkinje cells - dendrites: High (Enhanced); cerebral cortex / endothelial cells: Low (Enhanced); cerebral cortex / glial cells: Low (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); cerebral cortex / neuropil: Low (Enhanced); colon / endothelial cells: Low (Enhanced); colon / glandular cells: Low (Enhanced); colon / peripheral nerve/ganglion: Low (Enhanced); hippocampus / neuronal cells: Medium (Enhanced); kidney / cells in tubules: Low (Enhanced); nasopharynx / respiratory epithelial cells: Low (Enhanced); rectum / glandular cells: Low (Enhanced); skin 2 / epidermal cells: Low (Enhanced); stomach 1 / glandular cells: Medium (Enhanced); stomach 2 / glandular cells: Low (Enhanced); thyroid gland / glandular cells: Low (Enhanced); urinary bladder / urothelial cells: Low (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Renal Clear Cell Carcinoma (validation): 70/100 (70.0%); Testicular Germ Cell Tumor (TCGA): 81/133 (60.9%); Kidney Renal Clear Cell Carcinoma (TCGA): 264/521 (50.7%),colorectal cancer: 3/8 (37.5%); stomach cancer: 2/11 (18.2%),31,20,Q96T17,https://www.uniprot.org/uniprotkb/Q96T17/entry,"Microtubule-stabilizing protein that plays a role in the control of cell motility and neurite outgrowth via direct binding to the microtubule (By similarity). Acts as a critical cofactor for kinesin transport. In the proximal axon, regulates kinesin-1 family members, KIF5A, KIF5B and KIF5C recruitment to microtubules and contributes to kinesin-1-mediated transport in the axons (By similarity)",,,,"Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Midbody Cytoplasm, cytoskeleton Cell projection, neuron projection Cell projection, axon",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
MARCHF10,ENSG00000173838,Unsafe,RNA,False,True,133.7,133.7,88,5,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,basal ganglia: 4.1 nTPM; absolute ceiling; choroid plexus: 17.8 nTPM; absolute ceiling; hippocampal formation: 2.8 nTPM; absolute ceiling; hypothalamus: 2.9 nTPM; absolute ceiling; pituitary gland: 12.3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,basal ganglia: 4.1 nTPM (limit 2); choroid plexus: 17.8 nTPM (limit 2); hippocampal formation: 2.8 nTPM (limit 2); hypothalamus: 2.9 nTPM (limit 2); pituitary gland: 12.3 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 28/141 (19.9%); Uterine Corpus Endometrial Carcinoma (TCGA): 29/176 (16.5%); Kidney Chromophobe (TCGA): 10/64 (15.6%),glioma: 5/12 (41.7%); breast cancer: 1/12 (8.3%),29,20,Q8NA82,https://www.uniprot.org/uniprotkb/Q8NA82/entry,E3 ubiquitin-protein ligase (Probable). E3 ubiquitin ligases accept ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfer the ubiquitin to targeted substrates,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
MARCHF11,ENSG00000183654,Unsafe,RNA,False,True,80.1,80.1,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,amygdala: 3.3 nTPM; absolute ceiling; basal ganglia: 4.3 nTPM; absolute ceiling; cerebellum: 5.9 nTPM; absolute ceiling; cerebral cortex: 6 nTPM; absolute ceiling; heart muscle: 4.8 nTPM; absolute ceiling; hippocampal formation: 2.6 nTPM; absolute ceiling; hypothalamus: 5.9 nTPM; absolute ceiling; midbrain: 2.6 nTPM; absolute ceiling; pituitary gland: 9.7 nTPM; absolute ceiling; retina: 3.5 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 3.3 nTPM (limit 2); basal ganglia: 4.3 nTPM (limit 2); cerebellum: 5.9 nTPM (limit 2); cerebral cortex: 6 nTPM (limit 2); heart muscle: 4.8 nTPM (limit 2); hippocampal formation: 2.6 nTPM (limit 2); hypothalamus: 5.9 nTPM (limit 2); midbrain: 2.6 nTPM (limit 2); pituitary gland: 9.7 nTPM (limit 2); retina: 3.5 nTPM (limit 2); amygdala: 3.3 nTPM (baseline 2); basal ganglia: 4.3 nTPM (baseline 2); cerebellum: 5.9 nTPM (baseline 2); cerebral cortex: 6 nTPM (baseline 2); heart muscle: 4.8 nTPM (baseline 2); hippocampal formation: 2.6 nTPM (baseline 2); hypothalamus: 5.9 nTPM (baseline 2); midbrain: 2.6 nTPM (baseline 2); pituitary gland: 9.7 nTPM (baseline 2); retina: 3.5 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Chromophobe (TCGA): 24/64 (37.5%); Lung Adenocarcinoma (validation): 6/105 (5.7%); Testicular Germ Cell Tumor (TCGA): 7/133 (5.3%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,A6NNE9,https://www.uniprot.org/uniprotkb/A6NNE9/entry,E3 ubiquitin-protein ligase that mediates polyubiquitination of CD4. E3 ubiquitin ligases accept ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfer the ubiquitin to targeted substrates. May play a role in ubuquitin-dependent protein sorting in developmenting spermatids,,,,Cytoplasmic vesicle membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Jamin2021_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
MATCAP2,ENSG00000164542,Unsafe,RNA,False,True,21.6,21.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 7.8 nTPM; absolute ceiling;continuous selectivity; amygdala: 3.6 nTPM; absolute ceiling; basal ganglia: 4.6 nTPM; absolute ceiling; bone marrow: 2.4 nTPM; absolute ceiling; cerebellum: 17.4 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 5 nTPM; absolute ceiling; choroid plexus: 6.4 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 3.7 nTPM; absolute ceiling; hypothalamus: 5.7 nTPM; absolute ceiling;continuous selectivity; kidney: 8.8 nTPM; absolute ceiling;continuous selectivity; liver: 5.3 nTPM; absolute ceiling; lung: 2.9 nTPM; absolute ceiling; midbrain: 2.7 nTPM; absolute ceiling; pancreas: 8.8 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 11.3 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 6.2 nTPM; absolute ceiling;continuous selectivity; retina: 14.5 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 2.8 nTPM; absolute ceiling; spinal cord: 3.5 nTPM; absolute ceiling; stomach: 10.8 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 7.8 nTPM (limit 2); amygdala: 3.6 nTPM (limit 2); basal ganglia: 4.6 nTPM (limit 2); bone marrow: 2.4 nTPM (limit 2); cerebellum: 17.4 nTPM (limit 2); cerebral cortex: 5 nTPM (limit 2); choroid plexus: 6.4 nTPM (limit 2); hippocampal formation: 3.7 nTPM (limit 2); hypothalamus: 5.7 nTPM (limit 2); kidney: 8.8 nTPM (limit 2); liver: 5.3 nTPM (limit 2); lung: 2.9 nTPM (limit 2); midbrain: 2.7 nTPM (limit 2); pancreas: 8.8 nTPM (limit 2); parathyroid gland: 11.3 nTPM (limit 6); pituitary gland: 6.2 nTPM (limit 2); retina: 14.5 nTPM (limit 2); smooth muscle: 2.8 nTPM (limit 2); spinal cord: 3.5 nTPM (limit 2); stomach: 10.8 nTPM (limit 6); adrenal gland: 7.8 nTPM (baseline 2); amygdala: 3.6 nTPM (baseline 2); basal ganglia: 4.6 nTPM (baseline 2); bone marrow: 2.4 nTPM (baseline 2); cerebellum: 17.4 nTPM (baseline 2); cerebral cortex: 5 nTPM (baseline 2); choroid plexus: 6.4 nTPM (baseline 2); hippocampal formation: 3.7 nTPM (baseline 2); hypothalamus: 5.7 nTPM (baseline 2); kidney: 8.8 nTPM (baseline 2); liver: 5.3 nTPM (baseline 2); lung: 2.9 nTPM (baseline 2); midbrain: 2.7 nTPM (baseline 2); pancreas: 8.8 nTPM (baseline 2); parathyroid gland: 11.3 nTPM (baseline 6); pituitary gland: 6.2 nTPM (baseline 2); retina: 14.5 nTPM (baseline 2); smooth muscle: 2.8 nTPM (baseline 2); spinal cord: 3.5 nTPM (baseline 2); stomach: 10.8 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Breast Invasive Carcinoma (validation): 45/50 (90.0%); Pancreatic Adenocarcinoma (validation): 71/80 (88.8%),glioma: 10/12 (83.3%); breast cancer: 9/12 (75.0%),31,20,Q8NCT3,https://www.uniprot.org/uniprotkb/Q8NCT3/entry,Putative tyrosine carboxypeptidase,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
MBD1,ENSG00000141644,Unsafe,Protein,False,True,85.6,85.6,83,61,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 27.6 nTPM; absolute ceiling; adrenal gland: 38.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 23.9 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 26.1 nTPM; absolute ceiling;continuous selectivity; bone marrow: 43.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 36.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 34.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 21.2 nTPM; absolute ceiling; colon: 34.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 24 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 38.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 34.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 25.2 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 22.8 nTPM; absolute ceiling;continuous selectivity; kidney: 31.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 34.8 nTPM; absolute ceiling;continuous selectivity; lung: 29 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 29.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 21.1 nTPM; absolute ceiling; pancreas: 33.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 31.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 41.6 nTPM; absolute ceiling;continuous selectivity; rectum: 17.4 nTPM; positive ihc;absolute ceiling; retina: 23.4 nTPM; absolute ceiling;continuous selectivity; salivary gland: 29.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 49.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 42.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 32.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 20.3 nTPM; absolute ceiling; spinal cord: 21.4 nTPM; absolute ceiling; spleen: 40 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 32.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 29.2 nTPM; absolute ceiling; thyroid gland: 34.3 nTPM; positive ihc;absolute ceiling; tongue: 28 nTPM; absolute ceiling; urinary bladder: 34.2 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 27.6 nTPM (limit 20); adrenal gland: 38.5 nTPM (limit 2); amygdala: 23.9 nTPM (limit 2); basal ganglia: 26.1 nTPM (limit 2); bone marrow: 43.9 nTPM (limit 2); cerebellum: 36.3 nTPM (limit 2); cerebral cortex: 34.3 nTPM (limit 2); choroid plexus: 21.2 nTPM (limit 2); colon: 34.5 nTPM (limit 6); duodenum: 24 nTPM (limit 2); esophagus: 38.1 nTPM (limit 6); heart muscle: 34.5 nTPM (limit 2); hippocampal formation: 25.2 nTPM (limit 2); hypothalamus: 22.8 nTPM (limit 2); kidney: 31.6 nTPM (limit 2); liver: 34.8 nTPM (limit 4); lung: 29 nTPM (limit 2); lymph node: 29.9 nTPM (limit 6); midbrain: 21.1 nTPM (limit 2); pancreas: 33.5 nTPM (limit 2); parathyroid gland: 31.5 nTPM (limit 6); pituitary gland: 41.6 nTPM (limit 2); rectum: 17.4 nTPM (limit 6); retina: 23.4 nTPM (limit 2); salivary gland: 29.6 nTPM (limit 6); skeletal muscle: 49.2 nTPM (limit 2); skin: 42.1 nTPM (limit 10); small intestine: 32.7 nTPM (limit 2); smooth muscle: 20.3 nTPM (limit 4); spinal cord: 21.4 nTPM (limit 2); spleen: 40 nTPM (limit 10); stomach: 32.6 nTPM (limit 6); thymus: 29.2 nTPM (limit 10); thyroid gland: 34.3 nTPM (limit 10); tongue: 28 nTPM (limit 6); urinary bladder: 34.2 nTPM (limit 6),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Low (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / keratinocytes: Low (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Medium (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Low (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Adenocarcinoma (TCGA): 497/497 (100.0%); Head and Neck Squamous Cell Carcinoma (TCGA): 492/492 (100.0%); Lung Squamous Cell Carcinoma (TCGA): 489/489 (100.0%),pancreatic cancer: 8/11 (72.7%); breast cancer: 8/12 (66.7%),31,20,Q9UIS9,https://www.uniprot.org/uniprotkb/Q9UIS9/entry,"Transcriptional repressor that binds CpG islands in promoters where the DNA is methylated at position 5 of cytosine within CpG dinucleotides. Binding is abolished by the presence of 7-mG that is produced by DNA damage by methylmethanesulfonate (MMS). Acts as transcriptional repressor and plays a role in gene silencing by recruiting ATF7IP, which in turn recruits factors such as the histone methyltransferase SETDB1. Probably forms a complex with SETDB1 and ATF7IP that represses transcription and couples DNA methylation and histone 'Lys-9' trimethylation. Isoform 1 and isoform 2 can also repress transcription from unmethylated promoters",Widely expressed,,"Was reported to recruit SETDB1 during DNA replication, to form a S phase-specific complex that would facilitate methylation of H3 'Lys-9' during replication-coupled chromatin assembly and vould be at least composed of the CAF-1 subunit CHAF1A, MBD1 and SETDB1 (PubMed:15327775). The interaction with SETDB1 was also reported to be inhibited by sumoylation at Lys-499 and Lys-538 (PubMed:17066076). However, these papers have been retracted because some data, results and conclusions are not reliable (PubMed:30849389, PubMed:31612521)",Nucleus Nucleus matrix Nucleus speckle Chromosome,10454587|10648624|12665582|12697822|12711603|14555760|14610093|9207790|9774669,9207790,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
MBD2,ENSG00000134046,Unsafe,Protein,False,True,30.6,34.3,83,64,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 25.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 10.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 7.8 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 9.5 nTPM; absolute ceiling;continuous selectivity; bone marrow: 20.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 10.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 8.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 7.7 nTPM; absolute ceiling; colon: 16.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 11.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 28.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 14.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 7.4 nTPM; absolute ceiling; hypothalamus: 7.8 nTPM; absolute ceiling;continuous selectivity; kidney: 16.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 16.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 15.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 31.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 9.5 nTPM; absolute ceiling;continuous selectivity; pancreas: 16.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 15.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 9 nTPM; absolute ceiling;continuous selectivity; rectum: 15.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 13.8 nTPM; absolute ceiling;continuous selectivity; salivary gland: 18.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 14.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 24.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 15.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 11.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 9.1 nTPM; absolute ceiling;continuous selectivity; spleen: 20.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 13.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 19.5 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 30.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 16.1 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 20.2 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 25.9 nTPM (limit 10); adrenal gland: 10.2 nTPM (limit 2); amygdala: 7.8 nTPM (limit 2); basal ganglia: 9.5 nTPM (limit 2); bone marrow: 20.1 nTPM (limit 2); cerebellum: 10.1 nTPM (limit 2); cerebral cortex: 8.4 nTPM (limit 2); choroid plexus: 7.7 nTPM (limit 2); colon: 16.7 nTPM (limit 6); duodenum: 11.7 nTPM (limit 2); esophagus: 28.7 nTPM (limit 6); heart muscle: 14.4 nTPM (limit 2); hippocampal formation: 7.4 nTPM (limit 2); hypothalamus: 7.8 nTPM (limit 2); kidney: 16.2 nTPM (limit 2); liver: 16.4 nTPM (limit 2); lung: 15.9 nTPM (limit 2); lymph node: 31.3 nTPM (limit 6); midbrain: 9.5 nTPM (limit 2); pancreas: 16.9 nTPM (limit 2); parathyroid gland: 15.9 nTPM (limit 6); pituitary gland: 9 nTPM (limit 2); rectum: 15.9 nTPM (limit 6); retina: 13.8 nTPM (limit 2); salivary gland: 18.8 nTPM (limit 6); skeletal muscle: 14.9 nTPM (limit 2); skin: 24.8 nTPM (limit 10); small intestine: 15.1 nTPM (limit 2); smooth muscle: 11.5 nTPM (limit 2); spinal cord: 9.1 nTPM (limit 2); spleen: 20.6 nTPM (limit 10); stomach: 13.6 nTPM (limit 6); thymus: 19.5 nTPM (limit 10); thyroid gland: 30.1 nTPM (limit 10); tongue: 16.1 nTPM (limit 6); urinary bladder: 20.2 nTPM (limit 6),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / neuronal cells: Low (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / neuronal cells: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: High (Approved); heart muscle / cardiomyocytes: Low (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Low (Approved); lung / macrophages: Low (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: High (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: High (Approved); skin 2 / epidermal cells: High (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in red pulp: Low (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: High (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Squamous Cell Carcinoma (TCGA): 489/489 (100.0%); Colon Adenocarcinoma (validation): 486/486 (100.0%); Stomach Adenocarcinoma (TCGA): 346/346 (100.0%),urothelial cancer: 9/11 (81.8%); lung cancer: 6/12 (50.0%),31,20,Q9UBB5,https://www.uniprot.org/uniprotkb/Q9UBB5/entry,"Binds CpG islands in promoters where the DNA is methylated at position 5 of cytosine within CpG dinucleotides (PubMed:9774669). Binds hemimethylated DNA as well (PubMed:10947852, PubMed:24307175). Recruits histone deacetylases and DNA methyltransferases to chromatin (PubMed:10471499, PubMed:10947852). Acts as a component of the histone deacetylase NuRD complex which participates in the remodeling of chromatin (PubMed:16428440, PubMed:28977666). Acts as a transcriptional repressor and plays a role in gene silencing (PubMed:10471499, PubMed:10947852, PubMed:16415179). Functions as a scaffold protein, targeting GATAD2A and GATAD2B to chromatin to promote repression (PubMed:16415179). May enhance the activation of some unmethylated cAMP-responsive promoters (PubMed:12665568)","Highly expressed in brain, heart, kidney, stomach, testis and placenta",,"Functional studies (PubMed:10050851, PubMed:10950960, PubMed:12665568) have used a C-terminal fragment of isoform 1 which has been described originally as isoform MBD2b but cannot however be proven by supporting cDNA sequences",Nucleus Chromosome,10471499|10947852|12665568|16415179|16428440|24307175|28977666|9774669,10050851,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
MBD3,ENSG00000071655,Unsafe,Protein,False,True,53.2,83.9,84,54,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 38.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 44.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 75.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 55 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 12.6 nTPM; positive ihc;absolute ceiling; cerebellum: 51.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 83.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 4 nTPM; absolute ceiling; colon: 44.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 7.4 nTPM; positive ihc;absolute ceiling; esophagus: 41.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 58.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 75.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 46.1 nTPM; absolute ceiling;continuous selectivity; kidney: 44.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 57.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 37.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 9.4 nTPM; positive ihc;absolute ceiling; midbrain: 48.1 nTPM; absolute ceiling;continuous selectivity; pancreas: 31.8 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 7.2 nTPM; positive ihc;absolute ceiling; pituitary gland: 48.6 nTPM; absolute ceiling;continuous selectivity; rectum: 6.2 nTPM; positive ihc;absolute ceiling; retina: 3.9 nTPM; absolute ceiling; salivary gland: 29.5 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 71.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 39 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 33.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 7.1 nTPM; positive ihc;absolute ceiling; spinal cord: 38.9 nTPM; absolute ceiling;continuous selectivity; spleen: 48.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 37.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; thyroid gland: 43.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; urinary bladder: 39.7 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 38.8 nTPM (limit 10); adrenal gland: 44.7 nTPM (limit 2); amygdala: 75.4 nTPM (limit 2); basal ganglia: 55 nTPM (limit 2); bone marrow: 12.6 nTPM (limit 2); cerebellum: 51.2 nTPM (limit 2); cerebral cortex: 83.9 nTPM (limit 2); choroid plexus: 4 nTPM (limit 2); colon: 44.2 nTPM (limit 6); duodenum: 7.4 nTPM (limit 2); esophagus: 41.2 nTPM (limit 6); heart muscle: 58.4 nTPM (limit 2); hippocampal formation: 75.9 nTPM (limit 2); hypothalamus: 46.1 nTPM (limit 2); kidney: 44.1 nTPM (limit 2); liver: 57.8 nTPM (limit 6); lung: 37.1 nTPM (limit 2); lymph node: 9.4 nTPM (limit 6); midbrain: 48.1 nTPM (limit 2); pancreas: 31.8 nTPM (limit 6); parathyroid gland: 7.2 nTPM (limit 6); pituitary gland: 48.6 nTPM (limit 2); rectum: 6.2 nTPM (limit 6); retina: 3.9 nTPM (limit 2); salivary gland: 29.5 nTPM (limit 12); skeletal muscle: 71.4 nTPM (limit 2); skin: 39 nTPM (limit 10); small intestine: 33.6 nTPM (limit 2); smooth muscle: 7.1 nTPM (limit 2); spinal cord: 38.9 nTPM (limit 2); spleen: 48.6 nTPM (limit 10); stomach: 37.8 nTPM (limit 6); thyroid gland: 43.9 nTPM (limit 10); urinary bladder: 39.7 nTPM (limit 6),adipose tissue / adipocytes: Medium (Supported); adrenal gland / glandular cells: Medium (Supported); bone marrow / hematopoietic cells: High (Supported); bronchus / respiratory epithelial cells: Low (Supported); caudate / glial cells: Low (Supported); caudate / neuronal cells: Low (Supported); cerebellum / cells in granular layer: Medium (Supported); cerebellum / cells in molecular layer: Medium (Supported); cerebellum / Purkinje cells: Low (Supported); cerebral cortex / endothelial cells: Medium (Supported); cerebral cortex / glial cells: Low (Supported); cerebral cortex / neuronal cells: High (Supported); colon / endothelial cells: Medium (Supported); colon / glandular cells: Low (Supported); colon / peripheral nerve/ganglion: High (Supported); duodenum / glandular cells: Low (Supported); esophagus / squamous epithelial cells: Low (Supported); heart muscle / cardiomyocytes: Low (Supported); hippocampus / glial cells: Low (Supported); hippocampus / neuronal cells: Low (Supported); kidney / cells in tubules: Low (Supported); lung / alveolar cells: Low (Supported); lung / macrophages: Low (Supported); lymph node / germinal center cells: Low (Supported); lymph node / non-germinal center cells: Low (Supported); nasopharynx / respiratory epithelial cells: Low (Supported); oral mucosa / squamous epithelial cells: Low (Supported); parathyroid gland / glandular cells: Low (Supported); rectum / glandular cells: Medium (Supported); skeletal muscle / myocytes: Low (Supported); skin 1 / keratinocytes: Low (Supported); skin 2 / epidermal cells: Low (Supported); small intestine / glandular cells: Low (Supported); smooth muscle / smooth muscle cells: Low (Supported); spleen / cells in red pulp: Low (Supported); stomach 1 / glandular cells: Low (Supported); stomach 2 / glandular cells: Medium (Supported); thyroid gland / glandular cells: Medium (Supported); urinary bladder / urothelial cells: Medium (Supported),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (validation): 231/231 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Ovary Serous Cystadenocarcinoma (validation): 81/81 (100.0%),colorectal cancer: 11/12 (91.7%); glioma: 11/12 (91.7%),31,20,O95983,https://www.uniprot.org/uniprotkb/O95983/entry,"Acts as a component of the histone deacetylase NuRD complex which participates in the remodeling of chromatin (PubMed:12124384, PubMed:16428440, PubMed:28977666). Acts as transcriptional repressor and plays a role in gene silencing (PubMed:10947852, PubMed:18644863). Does not bind to methylated DNA by itself (PubMed:12124384, PubMed:16428440). Binds to a lesser degree DNA containing unmethylated CpG dinucleotides (PubMed:24307175). Recruits histone deacetylases and DNA methyltransferases",,,,Nucleus Chromosome,10947852|12124384|16428440|18644863|23361464|24307175|28977666|9774669,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
MBD3L1,ENSG00000170948,Unsafe,Protein,False,True,26.3,26.3,86,4,Positive somewhere,True,False,False,True,Excluded,Normal,False,,Not assessed,,,positive normal IHC; positive ihc outside permitted; kidney: 0 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,kidney / proximal tubules (cell body): Medium (Supported),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Chromophobe (TCGA): 1/64 (1.6%); Ovary Serous Cystadenocarcinoma (validation): 1/81 (1.2%); Uterine Corpus Endometrial Carcinoma (TCGA): 2/176 (1.1%),breast cancer: 0/10 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q8WWY6,https://www.uniprot.org/uniprotkb/Q8WWY6/entry,Transcriptional repressor,Highly expressed in testis. Detected at low levels in pancreas. Not detected in the other tissues tested,,,Nucleus,12504854,12504854,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
MC3R,ENSG00000124089,Unsafe,Protein,False,True,0.1,1.4,83,3,Positive somewhere,True,False,False,False,Excluded,Normal,False,,Not assessed,,,positive ihc outside permitted; hypothalamus: 1.4 nTPM; continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",,hypothalamus / neuronal cells: Medium (Uncertain); hypothalamus / neuronal projections: Low (Uncertain); hypothalamus / synapses: Medium (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Chromophobe (TCGA): 1/64 (1.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Lung Squamous Cell Carcinoma (TCGA): 1/489 (0.2%),colorectal cancer: 6/12 (50.0%); stomach cancer: 5/11 (45.5%),31,20,P41968,https://www.uniprot.org/uniprotkb/P41968/entry,"G protein-coupled receptor for melanocyte-stimulating hormones (alpha, beta, and gamma-MSH) and corticotropin/ACTH, which are peptide products of the POMC precursor (PubMed:37524700, PubMed:8463333). Upon activation, couples to G(s) protein, stimulating adenylate cyclase and the cAMP-dependent signaling pathway, which contributes to the regulation of energy homeostasis (PubMed:18231126, PubMed:37524700, PubMed:8463333). Required for expression of anticipatory patterns of activity and wakefulness during periods of limited nutrient availability and for the normal regulation of circadian clock activity in the brain (By similarity). Binding of the Agouti-related protein/AGPR antagonist precludes alpha-MSH-induced signaling, blocking cAMP production (PubMed:9311920)","Brain, placental, and gut tissues",,,Cell membrane,18231126|37524700|8463333|9311920,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
MCF2,ENSG00000101977,Unsafe,RNA,False,True,14.7,23.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 23.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 5.3 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 7.4 nTPM; absolute ceiling;continuous selectivity; cerebellum: 3.4 nTPM; absolute ceiling; cerebral cortex: 9 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 5.7 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 11.6 nTPM; absolute ceiling;continuous selectivity; midbrain: 9.1 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 3.3 nTPM; absolute ceiling; retina: 8.9 nTPM; absolute ceiling;continuous selectivity; spinal cord: 7.2 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 23.2 nTPM (limit 2); amygdala: 5.3 nTPM (limit 2); basal ganglia: 7.4 nTPM (limit 2); cerebellum: 3.4 nTPM (limit 2); cerebral cortex: 9 nTPM (limit 2); hippocampal formation: 5.7 nTPM (limit 2); hypothalamus: 11.6 nTPM (limit 2); midbrain: 9.1 nTPM (limit 2); pituitary gland: 3.3 nTPM (limit 2); retina: 8.9 nTPM (limit 2); spinal cord: 7.2 nTPM (limit 2); adrenal gland: 23.2 nTPM (baseline 2); amygdala: 5.3 nTPM (baseline 2); basal ganglia: 7.4 nTPM (baseline 2); cerebellum: 3.4 nTPM (baseline 2); cerebral cortex: 9 nTPM (baseline 2); hippocampal formation: 5.7 nTPM (baseline 2); hypothalamus: 11.6 nTPM (baseline 2); midbrain: 9.1 nTPM (baseline 2); pituitary gland: 3.3 nTPM (baseline 2); retina: 8.9 nTPM (baseline 2); spinal cord: 7.2 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 15/58 (25.9%); Skin Cuteneous Melanoma (TCGA): 4/99 (4.0%); Kidney Renal Clear Cell Carcinoma (validation): 3/100 (3.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P10911,https://www.uniprot.org/uniprotkb/P10911/entry,"Guanine nucleotide exchange factor (GEF) that modulates the Rho family of GTPases. Promotes the conversion of some member of the Rho family GTPase from the GDP-bound to the GTP-bound form. Isoform 1 exhibits no activity toward RHOA, RAC1 or CDC42. Isoform 2 exhibits decreased GEF activity toward CDC42. Isoform 3 exhibits a weak but significant activity toward RAC1 and CDC42. Isoform 4 exhibits significant activity toward RHOA and CDC42. The truncated DBL oncogene is active toward RHOA, RAC1 and CDC42","Isoform 1 is expressed only in brain. Isoform 3 is expressed in heart, kidney, spleen, liver and testis. Isoform 4 is expressed in brain, heart, kidney, testis, placenta, stomach and peripheral blood. The protein is detectable in brain, heart, kidney, intestine, muscle, lung and testis",,,Cytoplasm Membrane,,12445822,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
MCM10,ENSG00000065328,Unsafe,Protein,False,True,2.0,9.1,82,5,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 1.2 nTPM; continuous selectivity; bone marrow: 9.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; colon: 1.7 nTPM; continuous selectivity; duodenum: 1.5 nTPM; continuous selectivity; esophagus: 1.9 nTPM; continuous selectivity; liver: 0.7 nTPM; continuous selectivity; lymph node: 4.7 nTPM; positive ihc;continuous selectivity;reproductive not higher; rectum: 2.1 nTPM; continuous selectivity;reproductive not higher; skin: 1.1 nTPM; continuous selectivity; small intestine: 1.2 nTPM; continuous selectivity; smooth muscle: 0.8 nTPM; continuous selectivity; spleen: 0.9 nTPM; positive ihc; stomach: 0.8 nTPM; continuous selectivity; thymus: 7.9 nTPM; continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 9.1 nTPM (limit 2); bone marrow: 9.1 nTPM (baseline 2),bone marrow / hematopoietic cells: High (Approved); lymph node / non-germinal center cells: Medium (Approved); spleen / cells in red pulp: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 458/486 (94.2%); Rectum Adenocarcinoma (validation): 178/207 (86.0%); Glioblastoma Multiforme (validation): 47/58 (81.0%),skin cancer: 4/11 (36.4%); cervical cancer: 3/12 (25.0%),31,20,Q7L590,https://www.uniprot.org/uniprotkb/Q7L590/entry,"Acts as a replication initiation factor that brings together the MCM2-7 helicase and the DNA polymerase alpha/primase complex in order to initiate DNA replication. Additionally, plays a role in preventing DNA damage during replication. Key effector of the RBBP6 and ZBTB38-mediated regulation of DNA-replication and common fragile sites stability; acts as a direct target of transcriptional repression by ZBTB38 (PubMed:24726359)",,"Immunodeficiency 80 with or without congenital cardiomyopathy: An autosomal recessive immunologic disorder with variable manifestations including decreased B and T cells, reduced effector and memory T cells, NK cell deficiency, chronic cytomegalovirus infection. Restrictive cardiomyopathy and hypoplasia of the spleen and thymus have also been reported in some patients.",,Nucleus,11095689|15136575|17699597|19608746|24726359|32865517,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
MCMDC2,ENSG00000178460,Unsafe,RNA,False,True,11.6,11.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 4.1 nTPM; absolute ceiling;continuous selectivity; heart muscle: 2.4 nTPM; absolute ceiling; retina: 4.3 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 5.8 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 4.1 nTPM (limit 2); heart muscle: 2.4 nTPM (limit 2); retina: 4.3 nTPM (limit 2); skeletal muscle: 5.8 nTPM (limit 2); bone marrow: 4.1 nTPM (baseline 2); heart muscle: 2.4 nTPM (baseline 2); retina: 4.3 nTPM (baseline 2); skeletal muscle: 5.8 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Ovary Serous Cystadenocarcinoma (TCGA): 200/349 (57.3%); Stomach Adenocarcinoma (TCGA): 170/346 (49.1%); Rectum Adenocarcinoma (TCGA): 27/88 (30.7%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q4G0Z9,https://www.uniprot.org/uniprotkb/Q4G0Z9/entry,Plays an important role in meiotic recombination and associated DNA double-strand break repair,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
MCOLN2,ENSG00000153898,Unsafe,RNA,False,True,3.9,14.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 8.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 2.7 nTPM; absolute ceiling;continuous selectivity; colon: 9.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 1.6 nTPM; continuous selectivity; lung: 5.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 12.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 14.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 2 nTPM; continuous selectivity; small intestine: 5.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 6.6 nTPM; continuous selectivity;reproductive not higher; stomach: 2.1 nTPM; continuous selectivity; thymus: 2.2 nTPM; continuous selectivity; urinary bladder: 1.5 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 8.5 nTPM (limit 2); bone marrow: 2.7 nTPM (limit 2); colon: 9.8 nTPM (limit 6); lung: 5.3 nTPM (limit 2); lymph node: 12.5 nTPM (limit 6); rectum: 14.6 nTPM (limit 6); small intestine: 5.3 nTPM (limit 2); adrenal gland: 8.5 nTPM (baseline 2); bone marrow: 2.7 nTPM (baseline 2); colon: 9.8 nTPM (baseline 6); lung: 5.3 nTPM (baseline 2); lymph node: 12.5 nTPM (baseline 6); rectum: 14.6 nTPM (baseline 6); small intestine: 5.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 30/50 (60.0%); Rectum Adenocarcinoma (validation): 121/207 (58.5%); Colon Adenocarcinoma (validation): 268/486 (55.1%),prostate cancer: 9/10 (90.0%); breast cancer: 5/11 (45.5%),31,20,Q8IZK6,https://www.uniprot.org/uniprotkb/Q8IZK6/entry,"Nonselective cation channel probably playing a role in the regulation of membrane trafficking events. Acts as a Ca(2+)-permeable cation channel with inwardly rectifying activity (PubMed:19885840, PubMed:19940139). May activate ARF6 and be involved in the trafficking of GPI-anchored cargo proteins to the cell surface via the ARF6-regulated recycling pathway (PubMed:17662026). May play a role in immune processes. In adaptive immunity, TRPML2 and TRPML1 may play redundant roles in the function of the specialized lysosomes of B cells (By similarity). In the innate immune response, may play a role in the regulation of chemokine secretion and macrophage migration (By similarity). Through a possible and probably tissue-specific heteromerization with MCOLN1 may be at least in part involved in many lysosome-dependent cellular events (PubMed:19885840). Also functions as a Fe(2+) permeable channel (By similarity)",,,,Cell membrane Late endosome membrane Lysosome membrane Recycling endosome membrane,17662026|19885840|19940139,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
MCPH1,ENSG00000147316,Unsafe,Protein,False,True,6.1,16.2,86,76,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 5.5 nTPM; positive ihc;continuous selectivity; adrenal gland: 3.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 3.6 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 3.9 nTPM; absolute ceiling;continuous selectivity; bone marrow: 13.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 4.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 4.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 2.9 nTPM; absolute ceiling;continuous selectivity; colon: 4.8 nTPM; positive ihc;continuous selectivity; duodenum: 3.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 4.6 nTPM; positive ihc;continuous selectivity; heart muscle: 4.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 3.8 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 3.4 nTPM; absolute ceiling;continuous selectivity; kidney: 4.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 3.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 4.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 5.2 nTPM; positive ihc;continuous selectivity; midbrain: 3.9 nTPM; absolute ceiling;continuous selectivity; pancreas: 5 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 4 nTPM; positive ihc;continuous selectivity; pituitary gland: 3.7 nTPM; absolute ceiling;continuous selectivity; rectum: 3 nTPM; positive ihc;continuous selectivity; retina: 4.4 nTPM; absolute ceiling;continuous selectivity; salivary gland: 5.7 nTPM; positive ihc;continuous selectivity; skeletal muscle: 9.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 5 nTPM; positive ihc;continuous selectivity; small intestine: 4.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 2.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 4.6 nTPM; absolute ceiling;continuous selectivity; spleen: 4.9 nTPM; positive ihc;continuous selectivity; stomach: 4.5 nTPM; positive ihc;continuous selectivity; thymus: 16.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 4.5 nTPM; positive ihc;continuous selectivity; tongue: 3.7 nTPM; continuous selectivity; urinary bladder: 5.2 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 3.6 nTPM (limit 2); amygdala: 3.6 nTPM (limit 2); basal ganglia: 3.9 nTPM (limit 2); bone marrow: 13.1 nTPM (limit 2); cerebellum: 4.8 nTPM (limit 2); cerebral cortex: 4.4 nTPM (limit 2); choroid plexus: 2.9 nTPM (limit 2); duodenum: 3.8 nTPM (limit 2); heart muscle: 4.1 nTPM (limit 2); hippocampal formation: 3.8 nTPM (limit 2); hypothalamus: 3.4 nTPM (limit 2); kidney: 4.2 nTPM (limit 2); liver: 3.8 nTPM (limit 2); lung: 4.3 nTPM (limit 2); midbrain: 3.9 nTPM (limit 2); pancreas: 5 nTPM (limit 2); pituitary gland: 3.7 nTPM (limit 2); retina: 4.4 nTPM (limit 2); skeletal muscle: 9.5 nTPM (limit 2); small intestine: 4.5 nTPM (limit 2); smooth muscle: 2.8 nTPM (limit 2); spinal cord: 4.6 nTPM (limit 2); thymus: 16.2 nTPM (limit 10),adipose tissue / adipocytes: Medium (Supported); adrenal gland / glandular cells: Medium (Supported); bone marrow / hematopoietic cells: Medium (Supported); bronchus / respiratory epithelial cells: High (Supported); caudate / neuronal cells: Medium (Supported); cerebellum / cells in granular layer: Medium (Supported); cerebellum / cells in molecular layer: Medium (Supported); cerebellum / Purkinje cells: Medium (Supported); cerebral cortex / endothelial cells: Low (Supported); cerebral cortex / glial cells: Medium (Supported); cerebral cortex / neuronal cells: High (Supported); cerebral cortex / neuropil: Low (Supported); colon / endothelial cells: Medium (Supported); colon / glandular cells: Medium (Supported); colon / peripheral nerve/ganglion: Medium (Supported); duodenum / glandular cells: Medium (Supported); esophagus / squamous epithelial cells: Low (Supported); heart muscle / cardiomyocytes: Low (Supported); hippocampus / glial cells: Medium (Supported); hippocampus / neuronal cells: Medium (Supported); kidney / cells in glomeruli: High (Supported); kidney / cells in tubules: High (Supported); liver / hepatocytes: Medium (Supported); lung / alveolar cells type II: Medium (Supported); lung / endothelial cells: Medium (Supported); lung / macrophages: Medium (Supported); lymph node / germinal center cells: Low (Supported); lymph node / non-germinal center cells: Medium (Supported); nasopharynx / respiratory epithelial cells: Medium (Supported); oral mucosa / squamous epithelial cells: Medium (Supported); pancreas / exocrine glandular cells: Medium (Supported); pancreas / pancreatic endocrine cells: Medium (Supported); parathyroid gland / glandular cells: High (Supported); rectum / glandular cells: High (Supported); salivary gland / glandular cells: Medium (Supported); skeletal muscle / myocytes: Medium (Supported); skin 1 / fibroblasts: Low (Supported); skin 1 / keratinocytes: Low (Supported); skin 2 / epidermal cells: Low (Supported); small intestine / glandular cells: Medium (Supported); smooth muscle / smooth muscle cells: Low (Supported); spleen / cells in red pulp: Low (Supported); spleen / cells in white pulp: Low (Supported); stomach 1 / glandular cells: Medium (Supported); stomach 2 / glandular cells: Medium (Supported); thyroid gland / glandular cells: Medium (Supported); urinary bladder / urothelial cells: Medium (Supported),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Pancreatic Adenocarcinoma (validation): 79/80 (98.8%); Colon Adenocarcinoma (validation): 443/486 (91.2%),cervical cancer: 12/12 (100.0%); skin cancer: 12/12 (100.0%),31,20,Q8NEM0,https://www.uniprot.org/uniprotkb/Q8NEM0/entry,Implicated in chromosome condensation and DNA damage induced cellular responses. May play a role in neurogenesis and regulation of the size of the cerebral cortex,"Expressed in fetal brain, liver and kidney","Microcephaly 1, primary, autosomal recessive: A disease defined as a head circumference more than 3 standard deviations below the age-related mean. Brain weight is markedly reduced and the cerebral cortex is disproportionately small. Despite this marked reduction in size, the gyral pattern is relatively well preserved, with no major abnormality in cortical architecture. Affected individuals have mild to severe intellectual disability. Primary microcephaly is further defined by the absence of other syndromic features or significant neurological deficits due to degenerative brain disorder. Some MCHP1 patients also present growth retardation, short stature, and misregulated chromosome condensation as indicated by a high number of prophase-like cells detected in routine cytogenetic preparations and poor-quality metaphase G-banding.",,"Cytoplasm, cytoskeleton, microtubule organizing center, centrosome",12046007|15199523|15220350,12046007,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
MDGA2,ENSG00000139915,Unsafe,RNA,False,True,3.7,4.3,76,2,Positive somewhere,False,True,False,False,Excluded,Normal,False,,Not assessed,,,cerebral cortex: 3.5 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 1.3 nTPM; continuous selectivity; retina: 4.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 1.7 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebral cortex: 3.5 nTPM (limit 2); retina: 4.3 nTPM (limit 2); cerebral cortex: 3.5 nTPM (baseline 2); retina: 4.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 22/58 (37.9%); Skin Cuteneous Melanoma (TCGA): 8/99 (8.1%); Testicular Germ Cell Tumor (TCGA): 4/133 (3.0%),breast cancer: 1/11 (9.1%); glioma: 1/11 (9.1%),31,20,Q7Z553,https://www.uniprot.org/uniprotkb/Q7Z553/entry,May be involved in cell-cell interactions,"Detected in Leydig cells, syncytiotrophoblast, duodenal villi epithelial cells and neutrophils from kidney and cutaneous squamous cell carcinoma (at protein level)",,,Cell membrane,,19997561,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
MDH1B,ENSG00000138400,Unsafe,Protein,False,True,23.8,23.8,98,10,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; amygdala: 2.3 nTPM; absolute ceiling; basal ganglia: 4.1 nTPM; absolute ceiling; choroid plexus: 20.3 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 2.6 nTPM; absolute ceiling; hypothalamus: 3.4 nTPM; absolute ceiling; midbrain: 2.3 nTPM; absolute ceiling; pituitary gland: 9 nTPM; absolute ceiling;continuous selectivity; retina: 8.3 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 2.3 nTPM (limit 2); basal ganglia: 4.1 nTPM (limit 2); choroid plexus: 20.3 nTPM (limit 2); hippocampal formation: 2.6 nTPM (limit 2); hypothalamus: 3.4 nTPM (limit 2); midbrain: 2.3 nTPM (limit 2); pituitary gland: 9 nTPM (limit 2); retina: 8.3 nTPM (limit 2),bronchus / ciliated cells (cilia axoneme): High (Approved); bronchus / ciliated cells (ciliary rootlets): Medium (Approved); bronchus / ciliated cells (tip of cilia): High (Approved); nasopharynx / ciliated cells (cilia axoneme): Medium (Approved); nasopharynx / ciliated cells (tip of cilia): Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 45/58 (77.6%); Breast Invasive Carcinoma (validation): 35/50 (70.0%); Ovary Serous Cystadenocarcinoma (validation): 24/81 (29.6%),breast cancer: 0/12 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q5I0G3,https://www.uniprot.org/uniprotkb/Q5I0G3/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
MED12L,ENSG00000144893,Unsafe,Protein,False,True,4.0,4.0,79,25,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 1.7 nTPM; positive ihc;continuous selectivity; amygdala: 3.2 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 2.8 nTPM; absolute ceiling;continuous selectivity; bone marrow: 3.8 nTPM; continuous selectivity; cerebellum: 2.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 3.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 2.7 nTPM; absolute ceiling;continuous selectivity; colon: 0.2 nTPM; positive ihc; duodenum: 0.8 nTPM; positive ihc; hippocampal formation: 2.5 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 2.5 nTPM; absolute ceiling;continuous selectivity; liver: 0 nTPM; positive ihc; lung: 0.2 nTPM; positive ihc; midbrain: 3 nTPM; absolute ceiling;continuous selectivity; pancreas: 0.1 nTPM; positive ihc; pituitary gland: 1.6 nTPM; continuous selectivity; rectum: 0 nTPM; positive ihc; retina: 2.7 nTPM; absolute ceiling;continuous selectivity; skin: 0.1 nTPM; positive ihc; smooth muscle: 0.3 nTPM; positive ihc; spinal cord: 2.5 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 3.2 nTPM (limit 2); basal ganglia: 2.8 nTPM (limit 2); cerebellum: 2.5 nTPM (limit 2); cerebral cortex: 3.6 nTPM (limit 2); choroid plexus: 2.7 nTPM (limit 2); hippocampal formation: 2.5 nTPM (limit 2); hypothalamus: 2.5 nTPM (limit 2); midbrain: 3 nTPM (limit 2); retina: 2.7 nTPM (limit 2); spinal cord: 2.5 nTPM (limit 2),adrenal gland / glandular cells: Low (Enhanced); caudate / glial cells: Medium (Enhanced); cerebellum / cells in granular layer: Low (Enhanced); cerebellum / cells in molecular layer: Low (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); cerebral cortex / neuropil: Low (Enhanced); colon / peripheral nerve/ganglion: Low (Enhanced); duodenum / glandular cells: Low (Enhanced); hippocampus / neuronal cells: Low (Enhanced); liver / hepatocytes: Low (Enhanced); lung / alveolar cells: Low (Enhanced); pancreas / pancreatic endocrine cells: Low (Enhanced); rectum / glandular cells: Low (Enhanced); skin 1 / keratinocytes: Low (Enhanced); skin 1 / Langerhans: Low (Enhanced); smooth muscle / smooth muscle cells: Low (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Testicular Germ Cell Tumor (TCGA): 12/133 (9.0%); Breast Invasive Carcinoma (validation): 2/50 (4.0%),glioma: 6/12 (50.0%); skin cancer: 1/10 (10.0%),31,20,Q86YW9,https://www.uniprot.org/uniprotkb/Q86YW9/entry,"May be a component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional preinitiation complex with RNA polymerase II and the general transcription factors (By similarity)",,"Nizon-Isidor syndrome: An autosomal dominant neurodevelopmental disorder characterized by intellectual disability, global developmental delay, speech impairment, and behavioral abnormalities including autism spectrum disorder and aggressive behavior. Other features include a thin corpus callosum, and mild facial dysmorphism. Disease onset is in infancy or early childhood.",,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
MED23,ENSG00000112282,Unsafe,RNA,False,True,13.8,21.7,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 7.4 nTPM; continuous selectivity; adrenal gland: 10.2 nTPM; absolute ceiling;continuous selectivity; amygdala: 2.4 nTPM; absolute ceiling; basal ganglia: 3.1 nTPM; absolute ceiling; bone marrow: 21.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 11.7 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 7.1 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 3.5 nTPM; absolute ceiling; colon: 10.2 nTPM; absolute ceiling;continuous selectivity; duodenum: 11.1 nTPM; absolute ceiling;continuous selectivity; esophagus: 8.2 nTPM; absolute ceiling;continuous selectivity; heart muscle: 6.3 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 2.7 nTPM; absolute ceiling; hypothalamus: 3 nTPM; absolute ceiling; kidney: 10 nTPM; absolute ceiling;continuous selectivity; liver: 7.6 nTPM; absolute ceiling;continuous selectivity; lung: 9.6 nTPM; absolute ceiling;continuous selectivity; lymph node: 14.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 2.4 nTPM; absolute ceiling; pancreas: 10.3 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 17.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 5.9 nTPM; absolute ceiling;continuous selectivity; rectum: 12.1 nTPM; absolute ceiling;continuous selectivity; retina: 11.1 nTPM; absolute ceiling;continuous selectivity; salivary gland: 12.4 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 7.2 nTPM; absolute ceiling;continuous selectivity; skin: 11.2 nTPM; absolute ceiling;continuous selectivity; small intestine: 10.3 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 10 nTPM; absolute ceiling;continuous selectivity; spinal cord: 3.2 nTPM; absolute ceiling; spleen: 12.5 nTPM; absolute ceiling;continuous selectivity; stomach: 11.3 nTPM; absolute ceiling;continuous selectivity; thymus: 17.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 14 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; tongue: 9.7 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 9.8 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 10.2 nTPM (limit 2); amygdala: 2.4 nTPM (limit 2); basal ganglia: 3.1 nTPM (limit 2); bone marrow: 21.7 nTPM (limit 2); cerebellum: 11.7 nTPM (limit 2); cerebral cortex: 7.1 nTPM (limit 2); choroid plexus: 3.5 nTPM (limit 2); colon: 10.2 nTPM (limit 6); duodenum: 11.1 nTPM (limit 2); esophagus: 8.2 nTPM (limit 6); heart muscle: 6.3 nTPM (limit 2); hippocampal formation: 2.7 nTPM (limit 2); hypothalamus: 3 nTPM (limit 2); kidney: 10 nTPM (limit 2); liver: 7.6 nTPM (limit 2); lung: 9.6 nTPM (limit 2); lymph node: 14.5 nTPM (limit 6); midbrain: 2.4 nTPM (limit 2); pancreas: 10.3 nTPM (limit 2); parathyroid gland: 17.7 nTPM (limit 6); pituitary gland: 5.9 nTPM (limit 2); rectum: 12.1 nTPM (limit 6); retina: 11.1 nTPM (limit 2); salivary gland: 12.4 nTPM (limit 6); skeletal muscle: 7.2 nTPM (limit 2); skin: 11.2 nTPM (limit 10); small intestine: 10.3 nTPM (limit 2); smooth muscle: 10 nTPM (limit 2); spinal cord: 3.2 nTPM (limit 2); spleen: 12.5 nTPM (limit 10); stomach: 11.3 nTPM (limit 6); thymus: 17.5 nTPM (limit 10); thyroid gland: 14 nTPM (limit 10); tongue: 9.7 nTPM (limit 6); urinary bladder: 9.8 nTPM (limit 6); adrenal gland: 10.2 nTPM (baseline 2); amygdala: 2.4 nTPM (baseline 2); basal ganglia: 3.1 nTPM (baseline 2); bone marrow: 21.7 nTPM (baseline 2); cerebellum: 11.7 nTPM (baseline 2); cerebral cortex: 7.1 nTPM (baseline 2); choroid plexus: 3.5 nTPM (baseline 2); colon: 10.2 nTPM (baseline 6); duodenum: 11.1 nTPM (baseline 2); esophagus: 8.2 nTPM (baseline 6); heart muscle: 6.3 nTPM (baseline 2); hippocampal formation: 2.7 nTPM (baseline 2); hypothalamus: 3 nTPM (baseline 2); kidney: 10 nTPM (baseline 2); liver: 7.6 nTPM (baseline 2); lung: 9.6 nTPM (baseline 2); lymph node: 14.5 nTPM (baseline 6); midbrain: 2.4 nTPM (baseline 2); pancreas: 10.3 nTPM (baseline 2); parathyroid gland: 17.7 nTPM (baseline 6); pituitary gland: 5.9 nTPM (baseline 2); rectum: 12.1 nTPM (baseline 6); retina: 11.1 nTPM (baseline 2); salivary gland: 12.4 nTPM (baseline 6); skeletal muscle: 7.2 nTPM (baseline 2); skin: 11.2 nTPM (baseline 10); small intestine: 10.3 nTPM (baseline 2); smooth muscle: 10 nTPM (baseline 2); spinal cord: 3.2 nTPM (baseline 2); spleen: 12.5 nTPM (baseline 10); stomach: 11.3 nTPM (baseline 6); thymus: 17.5 nTPM (baseline 10); thyroid gland: 14 nTPM (baseline 10); tongue: 9.7 nTPM (baseline 6); urinary bladder: 9.8 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9ULK4,https://www.uniprot.org/uniprotkb/Q9ULK4/entry,"Required for transcriptional activation subsequent to the assembly of the pre-initiation complex (By similarity). Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional pre-initiation complex with RNA polymerase II and the general transcription factors. Required for transcriptional activation by adenovirus E1A protein. Required for ELK1-dependent transcriptional activation in response to activated Ras signaling",,"Intellectual developmental disorder, autosomal recessive 18, with or without epilepsy: A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period.",,Nucleus,10353252|14759369|16595664,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
MED26,ENSG00000105085,Unsafe,Protein,False,True,34.9,34.9,94,6,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; amygdala: 2.9 nTPM; absolute ceiling; basal ganglia: 3 nTPM; absolute ceiling; choroid plexus: 3 nTPM; absolute ceiling; hippocampal formation: 2.9 nTPM; absolute ceiling; hypothalamus: 3.1 nTPM; absolute ceiling; midbrain: 2.5 nTPM; absolute ceiling; pituitary gland: 3.5 nTPM; absolute ceiling; spinal cord: 3.3 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 2.9 nTPM (limit 2); basal ganglia: 3 nTPM (limit 2); choroid plexus: 3 nTPM (limit 2); hippocampal formation: 2.9 nTPM (limit 2); hypothalamus: 3.1 nTPM (limit 2); midbrain: 2.5 nTPM (limit 2); pituitary gland: 3.5 nTPM (limit 2); spinal cord: 3.3 nTPM (limit 2),bronchus / ciliated cells (cell body): Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 206/207 (99.5%); Colon Adenocarcinoma (validation): 483/486 (99.4%); Testicular Germ Cell Tumor (TCGA): 125/133 (94.0%),skin cancer: 1/10 (10.0%); melanoma: 1/11 (9.1%),31,20,O95402,https://www.uniprot.org/uniprotkb/O95402/entry,"Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional pre-initiation complex with RNA polymerase II and the general transcription factors",,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
MEIG1,ENSG00000197889,Unsafe,High RNA,False,True,9.9,9.9,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,CTA,Pass,oncoref.target-sets.2026-10-23.1,False,False,,CTA → Unsafe,True,True,True,6.29158162101,47.8,"hpa_single_cell: /Ciliated cells, max 31.8 nTPM, 1 observations >30; hpa_single_cell_tissue: bronchus/ciliated cells, max 38.5 nTPM, 1 observations >30; hpa_single_cell_tissue: lung/ciliated cells, max 47.8 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,6.292 TPM; blood/TFH; dice_tfh; vital,47.8 nTPM; lung/ciliated cells; hpa_single_cell_tissue; vital,Uterine Corpus Endometrial Carcinoma (TCGA): 11/176 (6.2%); Ovary Serous Cystadenocarcinoma (TCGA): 16/349 (4.6%); Breast Invasive Carcinoma (validation): 2/50 (4.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q5JSS6,https://www.uniprot.org/uniprotkb/Q5JSS6/entry,Essential for spermiogenesis,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
METTL21A,ENSG00000144401,Unsafe,Protein,False,True,11.8,23.1,80,70,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 9.8 nTPM; positive ihc;continuous selectivity; adrenal gland: 8.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 16 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 17.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 22.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 12.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 17.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 14.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 8.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 7.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 6.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 13.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 15 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 15.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 10.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 23.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 8 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 16 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 18.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 8.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 9.5 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 9.6 nTPM; absolute ceiling;continuous selectivity; rectum: 8.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 14.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 7.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 15 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 4.2 nTPM; positive ihc; small intestine: 8.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 7.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 19.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 14.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; stomach: 10.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 17.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 11.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; tongue: 8.5 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 8.2 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 8.7 nTPM (limit 2); amygdala: 16 nTPM (limit 2); basal ganglia: 17.6 nTPM (limit 2); bone marrow: 22.1 nTPM (limit 2); cerebellum: 12.9 nTPM (limit 2); cerebral cortex: 17.1 nTPM (limit 2); choroid plexus: 14.1 nTPM (limit 2); colon: 8.9 nTPM (limit 6); duodenum: 7.1 nTPM (limit 2); esophagus: 6.5 nTPM (limit 6); heart muscle: 13.2 nTPM (limit 2); hippocampal formation: 15 nTPM (limit 2); hypothalamus: 15.5 nTPM (limit 2); kidney: 10.9 nTPM (limit 2); liver: 23.1 nTPM (limit 2); lung: 8 nTPM (limit 2); lymph node: 16 nTPM (limit 6); midbrain: 18.8 nTPM (limit 2); pancreas: 8.6 nTPM (limit 2); parathyroid gland: 9.5 nTPM (limit 6); pituitary gland: 9.6 nTPM (limit 2); rectum: 8.6 nTPM (limit 6); retina: 14.2 nTPM (limit 2); salivary gland: 7.8 nTPM (limit 6); skeletal muscle: 15 nTPM (limit 2); small intestine: 8.6 nTPM (limit 2); smooth muscle: 7.4 nTPM (limit 2); spinal cord: 19.8 nTPM (limit 2); spleen: 14.4 nTPM (limit 10); stomach: 10.6 nTPM (limit 6); thymus: 17.2 nTPM (limit 10); thyroid gland: 11.9 nTPM (limit 10); tongue: 8.5 nTPM (limit 6); urinary bladder: 8.2 nTPM (limit 6); adrenal gland: 8.7 nTPM (baseline 2); amygdala: 16 nTPM (baseline 2); basal ganglia: 17.6 nTPM (baseline 2); bone marrow: 22.1 nTPM (baseline 2); cerebellum: 12.9 nTPM (baseline 2); cerebral cortex: 17.1 nTPM (baseline 2); choroid plexus: 14.1 nTPM (baseline 2); colon: 8.9 nTPM (baseline 6); duodenum: 7.1 nTPM (baseline 2); esophagus: 6.5 nTPM (baseline 6); heart muscle: 13.2 nTPM (baseline 2); hippocampal formation: 15 nTPM (baseline 2); hypothalamus: 15.5 nTPM (baseline 2); kidney: 10.9 nTPM (baseline 2); liver: 23.1 nTPM (baseline 2); lung: 8 nTPM (baseline 2); lymph node: 16 nTPM (baseline 6); midbrain: 18.8 nTPM (baseline 2); pancreas: 8.6 nTPM (baseline 2); parathyroid gland: 9.5 nTPM (baseline 6); pituitary gland: 9.6 nTPM (baseline 2); rectum: 8.6 nTPM (baseline 6); retina: 14.2 nTPM (baseline 2); salivary gland: 7.8 nTPM (baseline 6); skeletal muscle: 15 nTPM (baseline 2); small intestine: 8.6 nTPM (baseline 2); smooth muscle: 7.4 nTPM (baseline 2); spinal cord: 19.8 nTPM (baseline 2); spleen: 14.4 nTPM (baseline 10); stomach: 10.6 nTPM (baseline 6); thymus: 17.2 nTPM (baseline 10); thyroid gland: 11.9 nTPM (baseline 10); tongue: 8.5 nTPM (baseline 6); urinary bladder: 8.2 nTPM (baseline 6),adipose tissue / adipocytes: Low (Uncertain); adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / glial cells: Low (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in molecular layer: Low (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / endothelial cells: Medium (Uncertain); cerebral cortex / glial cells: Medium (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / endothelial cells: Medium (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: Low (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in glomeruli: Medium (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / cholangiocytes: Low (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / germinal center cells: Medium (Uncertain); lymph node / non-germinal center cells: Medium (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skin 1 / fibroblasts: Medium (Uncertain); skin 1 / keratinocytes: Low (Uncertain); skin 1 / Langerhans: Low (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: Medium (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); spleen / cells in white pulp: Low (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%); Thyroid Carcinoma (TCGA): 495/495 (100.0%),melanoma: 12/12 (100.0%); breast cancer: 11/11 (100.0%),30,20,Q8WXB1,https://www.uniprot.org/uniprotkb/Q8WXB1/entry,"Protein-lysine methyltransferase that selectively trimethylates residues in heat shock protein 70 (HSP70) family members. Contributes to the in vivo trimethylation of Lys residues in HSPA1 and HSPA8. In vitro methylates 'Lys-561' in HSPA1, 'Lys-564' in HSPA2, 'Lys-585' in HSPA5, 'Lys-563' in HSPA6 and 'Lys-561' in HSPA8",,,,Cytoplasm,22948820|23349634|23921388,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
MEX3A,ENSG00000254726,Unsafe,RNA,False,True,5.7,5.7,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,cerebral cortex: 2.1 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebral cortex: 2.1 nTPM (limit 2); cerebral cortex: 2.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 54/58 (93.1%); Uterine Corpus Endometrial Carcinoma (TCGA): 156/176 (88.6%); Breast Invasive Carcinoma (validation): 43/50 (86.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,A1L020,https://www.uniprot.org/uniprotkb/A1L020/entry,"RNA binding protein, may be involved in post-transcriptional regulatory mechanisms","Highest levels found in fetal brain and testis. Detected also in thymus, salivary gland and uterus",,,"Cytoplasm Nucleus Cytoplasm, P-body",,17267406,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
MFAP3L,ENSG00000198948,Unsafe,Protein,False,True,45.0,45.0,85,18,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 3.3 nTPM; positive ihc;absolute ceiling; amygdala: 19.6 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 26.4 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 21.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 41.1 nTPM; absolute ceiling;continuous selectivity; heart muscle: 1.7 nTPM; positive ihc; hippocampal formation: 20.5 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 15.1 nTPM; absolute ceiling;continuous selectivity; kidney: 29 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 36.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 23.6 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 4 nTPM; absolute ceiling; retina: 24.2 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 4.9 nTPM; positive ihc;absolute ceiling; small intestine: 0.9 nTPM; positive ihc; spinal cord: 22.4 nTPM; absolute ceiling;continuous selectivity; stomach: 1.3 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 3.3 nTPM (limit 2); amygdala: 19.6 nTPM (limit 2); basal ganglia: 26.4 nTPM (limit 2); cerebral cortex: 21.4 nTPM (limit 2); choroid plexus: 41.1 nTPM (limit 2); hippocampal formation: 20.5 nTPM (limit 2); hypothalamus: 15.1 nTPM (limit 2); kidney: 29 nTPM (limit 2); liver: 36.3 nTPM (limit 2); midbrain: 23.6 nTPM (limit 2); pituitary gland: 4 nTPM (limit 2); retina: 24.2 nTPM (limit 2); skeletal muscle: 4.9 nTPM (limit 2); spinal cord: 22.4 nTPM (limit 2),adrenal gland / glandular cells: Low (Enhanced); caudate / neuronal cells: Low (Enhanced); cerebral cortex / neuronal cells: Low (Enhanced); heart muscle / cardiomyocytes: Medium (Enhanced); hippocampus / neuronal cells: Low (Enhanced); kidney / cells in tubules: Low (Enhanced); liver / hepatocytes: Medium (Enhanced); skeletal muscle / myocytes: Medium (Enhanced); small intestine / glandular cells: Low (Enhanced); stomach 1 / glandular cells: Low (Enhanced); stomach 2 / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Glioblastoma Multiforme (TCGA): 137/141 (97.2%); Kidney Renal Papillary Cell Carcinoma (TCGA): 241/282 (85.5%),liver cancer: 2/10 (20.0%); breast cancer: 0/11 (0.0%),31,20,O75121,https://www.uniprot.org/uniprotkb/O75121/entry,May participate in the nuclear signaling of EGFR and MAPK1/ERK2. May a have a role in metastasis,Highly expressed in testis,,"Protein kinase activity is reported (PubMed:24735981). However, no protein kinase domain is detected by any prediction method (PROSITE, Pfam). Its enzyme activity is therefore unsure",Cell membrane Nucleus Cytoplasm,24735981,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
MFSD2B,ENSG00000205639,Unsafe,Protein,False,True,0.5,11.7,84,9,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 11.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 0 nTPM; positive ihc; cerebral cortex: 0 nTPM; positive ihc; spleen: 0.3 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 11.7 nTPM (limit 2),bone marrow / hematopoietic cells: High (Enhanced); caudate / neuronal cells: Medium (Enhanced); cerebellum / Purkinje cells: Medium (Enhanced); cerebral cortex / neuronal cells: Low (Enhanced); hippocampus / neuronal cells: Low (Enhanced); spleen / cells in red pulp: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 1/80 (1.2%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Liver Hepatocellular Carcinoma (validation): 1/231 (0.4%),testis cancer: 3/10 (30.0%); prostate cancer: 3/12 (25.0%),31,20,A6NFX1,https://www.uniprot.org/uniprotkb/A6NFX1/entry,"Lipid transporter that specifically mediates export of sphingosine-1-phosphate in red blood cells and platelets (PubMed:29045386). Sphingosine-1-phosphate is a signaling sphingolipid and its export from red blood cells into in the plasma is required for red blood cell morphology (By similarity). Sphingosine-1-phosphate export from platelets is required for platelet aggregation and thrombus formation (By similarity). Mediates the export of different sphingosine-1-phosphate (S1P) species, including S1P(d18:0) (sphinganine 1-phosphate), S1P (d18:1) (sphing-4-enine 1-phosphate) and S1P (d18:2) (sphinga-4E,14Z-dienine-1-phosphate) (Probable). Release of sphingosine-1-phosphate is facilitated by a proton gradient (By similarity). In contrast, cations, such as sodium, are not required to drive sphingosine-1-phosphate transport (Probable). In addition to export, also able to mediate S1P import (By similarity). Does not transport lysophosphatidylcholine (LPC) (Probable)",,,,Cell membrane,29045386|29563527,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
MFSD6L,ENSG00000185156,Unsafe,RNA,False,True,24.8,24.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,duodenum: 2.3 nTPM; absolute ceiling; pancreas: 9.1 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 4.7 nTPM; absolute ceiling; salivary gland: 6.6 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,duodenum: 2.3 nTPM (limit 2); pancreas: 9.1 nTPM (limit 2); pituitary gland: 4.7 nTPM (limit 2); salivary gland: 6.6 nTPM (limit 6); duodenum: 2.3 nTPM (baseline 2); pancreas: 9.1 nTPM (baseline 2); pituitary gland: 4.7 nTPM (baseline 2); salivary gland: 6.6 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Thyroid Carcinoma (TCGA): 392/495 (79.2%); Breast Invasive Carcinoma (validation): 26/50 (52.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 71/176 (40.3%),ovarian cancer: 7/11 (63.6%); lung cancer: 6/11 (54.5%),31,20,Q8IWD5,https://www.uniprot.org/uniprotkb/Q8IWD5/entry,,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
MGAT4C,ENSG00000182050,Unsafe,Protein,False,True,4.6,5.8,77,16,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; amygdala: 2.7 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 4.4 nTPM; absolute ceiling;continuous selectivity; bone marrow: 0 nTPM; positive ihc; cerebral cortex: 3.5 nTPM; continuous selectivity; colon: 0.4 nTPM; positive ihc; heart muscle: 1.6 nTPM; positive ihc;continuous selectivity; hippocampal formation: 1.7 nTPM; continuous selectivity; hypothalamus: 2.3 nTPM; absolute ceiling;continuous selectivity; kidney: 0.1 nTPM; positive ihc; midbrain: 2 nTPM; continuous selectivity; pituitary gland: 3.1 nTPM; absolute ceiling;continuous selectivity; rectum: 0 nTPM; positive ihc; skeletal muscle: 0 nTPM; positive ihc; skin: 0 nTPM; positive ihc; small intestine: 0.1 nTPM; positive ihc; stomach: 0.1 nTPM; positive ihc; thyroid gland: 5.8 nTPM; continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 2.7 nTPM (limit 2); basal ganglia: 4.4 nTPM (limit 2); hypothalamus: 2.3 nTPM (limit 2); pituitary gland: 3.1 nTPM (limit 2),bone marrow / hematopoietic cells: Medium (Approved); colon / glandular cells: Low (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Low (Approved); rectum / glandular cells: Low (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / keratinocytes: Low (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Low (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Low (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Thyroid Carcinoma (TCGA): 291/495 (58.8%); Glioblastoma Multiforme (validation): 21/58 (36.2%); Glioblastoma Multiforme (TCGA): 2/141 (1.4%),breast cancer: 1/9 (11.1%); colorectal cancer: 1/9 (11.1%),31,20,Q9UBM8,https://www.uniprot.org/uniprotkb/Q9UBM8/entry,Glycosyltransferase that participates in the transfer of N-acetylglucosamine (GlcNAc) to the core mannose residues of N-linked glycans. Catalyzes the formation of the GlcNAcbeta1-4 branch on the GlcNAcbeta1-2Manalpha1-3 arm of the core structure of N-linked glycans. Essential for the production of tri- and tetra-antennary N-linked sugar chains (By similarity). Does not catalyze the transfer of GlcNAc to the Manalpha1-6 arm to form GlcNAcBeta1-4Manalpha1-6 linkage ('GnT-VI' activity),"Expressed in heart, adrenal gland, testis, liver, brain and fetal brain. Not expressed in pancreas",,,Golgi apparatus membrane,10962001,10570912,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
MIA2,ENSG00000150527,Unsafe,Protein,False,True,38.4,131.0,76,59,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 25.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 5.3 nTPM; absolute ceiling; basal ganglia: 6.5 nTPM; absolute ceiling; bone marrow: 23.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 6.1 nTPM; positive ihc;absolute ceiling; cerebral cortex: 9.1 nTPM; positive ihc;absolute ceiling; choroid plexus: 84 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 29.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 76.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 26.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 15.9 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 6 nTPM; absolute ceiling; hypothalamus: 7 nTPM; absolute ceiling; kidney: 73.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 131 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 14.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 15.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 5.9 nTPM; absolute ceiling; pancreas: 41.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 37.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 15.1 nTPM; absolute ceiling;continuous selectivity; rectum: 33.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 12.4 nTPM; absolute ceiling;continuous selectivity; salivary gland: 51 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 52.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 9.6 nTPM; positive ihc; small intestine: 74.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 11.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 7.2 nTPM; absolute ceiling; spleen: 14.1 nTPM; positive ihc;absolute ceiling; stomach: 43.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; thymus: 13.9 nTPM; absolute ceiling; thyroid gland: 45.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; tongue: 19.9 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 15.6 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 25.6 nTPM (limit 2); amygdala: 5.3 nTPM (limit 2); basal ganglia: 6.5 nTPM (limit 2); bone marrow: 23.2 nTPM (limit 2); cerebellum: 6.1 nTPM (limit 2); cerebral cortex: 9.1 nTPM (limit 2); choroid plexus: 84 nTPM (limit 2); colon: 29.6 nTPM (limit 6); duodenum: 76.8 nTPM (limit 2); esophagus: 26.2 nTPM (limit 6); heart muscle: 15.9 nTPM (limit 4); hippocampal formation: 6 nTPM (limit 2); hypothalamus: 7 nTPM (limit 2); kidney: 73.8 nTPM (limit 2); liver: 131 nTPM (limit 2); lung: 14.8 nTPM (limit 2); lymph node: 15.8 nTPM (limit 6); midbrain: 5.9 nTPM (limit 2); pancreas: 41.7 nTPM (limit 2); parathyroid gland: 37.1 nTPM (limit 6); pituitary gland: 15.1 nTPM (limit 2); rectum: 33.4 nTPM (limit 6); retina: 12.4 nTPM (limit 2); salivary gland: 51 nTPM (limit 6); skeletal muscle: 52.6 nTPM (limit 4); small intestine: 74.7 nTPM (limit 2); smooth muscle: 11.9 nTPM (limit 2); spinal cord: 7.2 nTPM (limit 2); spleen: 14.1 nTPM (limit 10); stomach: 43.6 nTPM (limit 6); thymus: 13.9 nTPM (limit 10); thyroid gland: 45.2 nTPM (limit 10); tongue: 19.9 nTPM (limit 6); urinary bladder: 15.6 nTPM (limit 6),adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: High (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: High (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: Low (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: High (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: High (Approved); lymph node / germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: High (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: High (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Low (Approved); salivary gland / glandular cells: High (Approved); skin 1 / keratinocytes: Low (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (TCGA): 254/254 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%),stomach cancer: 11/11 (100.0%); endometrial cancer: 10/10 (100.0%),31,20,Q96PC5,https://www.uniprot.org/uniprotkb/Q96PC5/entry,"Plays a role in the transport of cargos that are too large to fit into COPII-coated vesicles and require specific mechanisms to be incorporated into membrane-bound carriers and exported from the endoplasmic reticulum (PubMed:21525241, PubMed:25202031, PubMed:27138255, PubMed:27170179). Plays a role in the secretion of lipoproteins, pre-chylomicrons and pre-VLDLs, by participating in their export from the endoplasmic reticulum (PubMed:27138255). Thereby, may play a role in cholesterol and triglyceride homeostasis (By similarity). Required for collagen VII (COL7A1) secretion by loading COL7A1 into transport carriers and recruiting PREB/SEC12 at the endoplasmic reticulum exit sites (PubMed:21525241, PubMed:25202031, PubMed:27170179)","Highly expressed in liver and weakly in testis. Expression was higher in patients with severe fibrosis or inflammation and chronic hepatitis (PubMed:12586826). Isoform 1 is specifically expressed in lung, testis, small intestine, colon, pancreas, kidney, liver and prostate (PubMed:27138255). Isoform 8 is expressed only in testis (at the protein level). Isoform 8 (at protein level) and isoform 9 are expressed in cutaneous T-cell lymphoma (CTCL) cell lines, colorectal carcinomas, breast carcinomas and melanoma. Isoform 9, but not isoform 5A, is expressed in head and neck squamous cell carcinoma (PubMed:12839582)",,,Endoplasmic reticulum membrane,21525241|25202031|27138255|27170179,12586826|12839582|27138255,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
MICAL2,ENSG00000133816,Unsafe,Protein,False,True,44.4,199.5,80,62,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 7.4 nTPM; positive ihc; adrenal gland: 6.2 nTPM; positive ihc;absolute ceiling; amygdala: 16.7 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 8.2 nTPM; absolute ceiling; bone marrow: 14.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 199.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 54.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 13.8 nTPM; absolute ceiling;continuous selectivity; colon: 28.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 13.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 23.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 47.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 27.6 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 6.3 nTPM; absolute ceiling; kidney: 3.7 nTPM; positive ihc;absolute ceiling; liver: 5.2 nTPM; positive ihc;absolute ceiling; lung: 24.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 4.5 nTPM; positive ihc; midbrain: 3.6 nTPM; absolute ceiling; pancreas: 6.8 nTPM; positive ihc;absolute ceiling; parathyroid gland: 1.7 nTPM; positive ihc; rectum: 26.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 4.1 nTPM; absolute ceiling; salivary gland: 2.1 nTPM; positive ihc; skeletal muscle: 22.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 15.1 nTPM; positive ihc;absolute ceiling; small intestine: 18.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 45.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 8.4 nTPM; absolute ceiling; stomach: 11 nTPM; positive ihc;absolute ceiling; thyroid gland: 8.7 nTPM; positive ihc; urinary bladder: 17.8 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 6.2 nTPM (limit 2); amygdala: 16.7 nTPM (limit 2); basal ganglia: 8.2 nTPM (limit 2); bone marrow: 14.7 nTPM (limit 2); cerebellum: 199.5 nTPM (limit 2); cerebral cortex: 54.3 nTPM (limit 2); choroid plexus: 13.8 nTPM (limit 2); colon: 28.6 nTPM (limit 6); duodenum: 13.4 nTPM (limit 2); esophagus: 23.3 nTPM (limit 6); heart muscle: 47.9 nTPM (limit 4); hippocampal formation: 27.6 nTPM (limit 2); hypothalamus: 6.3 nTPM (limit 2); kidney: 3.7 nTPM (limit 2); liver: 5.2 nTPM (limit 2); lung: 24.7 nTPM (limit 2); midbrain: 3.6 nTPM (limit 2); pancreas: 6.8 nTPM (limit 2); rectum: 26.1 nTPM (limit 6); retina: 4.1 nTPM (limit 2); skeletal muscle: 22.3 nTPM (limit 2); skin: 15.1 nTPM (limit 10); small intestine: 18.1 nTPM (limit 2); smooth muscle: 45.5 nTPM (limit 2); spinal cord: 8.4 nTPM (limit 2); stomach: 11 nTPM (limit 6); urinary bladder: 17.8 nTPM (limit 6),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / keratinocytes: Low (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Pancreatic Adenocarcinoma (validation): 80/80 (100.0%),testis cancer: 11/11 (100.0%); colorectal cancer: 10/11 (90.9%),31,20,O94851,https://www.uniprot.org/uniprotkb/O94851/entry,"Methionine monooxygenase that promotes depolymerization of F-actin by mediating oxidation of residues 'Met-44' and 'Met-47' on actin to form methionine-sulfoxide, resulting in actin filament disassembly and preventing repolymerization (PubMed:24440334, PubMed:29343822). Regulates the disassembly of branched actin networks also by oxidizing ARP3B-containing ARP2/3 complexes leading to ARP3B dissociation from the network (PubMed:34106209). Acts as a key regulator of the SRF signaling pathway elicited by nerve growth factor and serum: mediates oxidation and subsequent depolymerization of nuclear actin, leading to increase MKL1/MRTF-A presence in the nucleus and promote SRF:MKL1/MRTF-A-dependent gene transcription. Does not activate SRF:MKL1/MRTF-A through RhoA (PubMed:24440334)",,,,Nucleus Cytoplasm,24440334|29343822|34106209,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
MINDY4,ENSG00000106125,Unsafe,Protein,False,True,11.1,11.8,87,45,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 6.4 nTPM; continuous selectivity; adrenal gland: 3.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; basal ganglia: 3.8 nTPM; absolute ceiling;continuous selectivity; cerebellum: 0.9 nTPM; positive ihc; cerebral cortex: 2.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 11.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 4.4 nTPM; positive ihc;continuous selectivity; duodenum: 1.3 nTPM; positive ihc; esophagus: 2.8 nTPM; positive ihc; heart muscle: 4.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; hypothalamus: 2.6 nTPM; absolute ceiling; kidney: 4.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 2.1 nTPM; positive ihc;absolute ceiling; lung: 9.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 1.2 nTPM; positive ihc; midbrain: 2.3 nTPM; absolute ceiling; pancreas: 3.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 4.6 nTPM; positive ihc;continuous selectivity; pituitary gland: 5.4 nTPM; absolute ceiling;continuous selectivity; rectum: 2 nTPM; positive ihc; salivary gland: 3 nTPM; positive ihc; skin: 3.1 nTPM; positive ihc; small intestine: 2.1 nTPM; positive ihc;absolute ceiling; smooth muscle: 5.7 nTPM; absolute ceiling;continuous selectivity; stomach: 3.1 nTPM; positive ihc; thyroid gland: 6.5 nTPM; positive ihc;continuous selectivity; urinary bladder: 4.2 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 3.6 nTPM (limit 2); basal ganglia: 3.8 nTPM (limit 2); cerebral cortex: 2.9 nTPM (limit 2); choroid plexus: 11.8 nTPM (limit 2); heart muscle: 4.5 nTPM (limit 2); hypothalamus: 2.6 nTPM (limit 2); kidney: 4.8 nTPM (limit 2); liver: 2.1 nTPM (limit 2); lung: 9.2 nTPM (limit 2); midbrain: 2.3 nTPM (limit 2); pancreas: 3.3 nTPM (limit 2); pituitary gland: 5.4 nTPM (limit 2); small intestine: 2.1 nTPM (limit 2); smooth muscle: 5.7 nTPM (limit 4),adrenal gland / glandular cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Low (Approved); lung / macrophages: Low (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Low (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 198/207 (95.7%); Pancreatic Adenocarcinoma (validation): 71/80 (88.8%); Colon Adenocarcinoma (validation): 422/486 (86.8%),renal cancer: 7/12 (58.3%); colorectal cancer: 5/12 (41.7%),29,20,Q4G0A6,https://www.uniprot.org/uniprotkb/Q4G0A6/entry,Probable hydrolase that can remove 'Lys-48'-linked conjugated ubiquitin from proteins,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
MIPOL1,ENSG00000151338,Unsafe,Protein,False,True,8.2,8.2,77,64,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 2.4 nTPM; positive ihc; adrenal gland: 2.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 0.4 nTPM; positive ihc; cerebral cortex: 2 nTPM; positive ihc; colon: 2.5 nTPM; positive ihc; duodenum: 1.6 nTPM; positive ihc; esophagus: 3 nTPM; positive ihc;continuous selectivity; heart muscle: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; kidney: 4.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 1.7 nTPM; positive ihc; lung: 2.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 0.4 nTPM; positive ihc; pancreas: 4.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 6.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 2.6 nTPM; absolute ceiling;continuous selectivity; rectum: 2 nTPM; positive ihc; retina: 3 nTPM; absolute ceiling;continuous selectivity; salivary gland: 3.1 nTPM; positive ihc;continuous selectivity; skeletal muscle: 1.9 nTPM; positive ihc; skin: 1.6 nTPM; positive ihc; small intestine: 1.5 nTPM; positive ihc; smooth muscle: 3.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; spleen: 1.4 nTPM; positive ihc; stomach: 3.5 nTPM; positive ihc;continuous selectivity; thyroid gland: 5.6 nTPM; positive ihc;continuous selectivity; urinary bladder: 3.2 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 2.9 nTPM (limit 2); heart muscle: 2.7 nTPM (limit 2); kidney: 4.1 nTPM (limit 2); lung: 2.5 nTPM (limit 2); pancreas: 4.2 nTPM (limit 2); parathyroid gland: 6.7 nTPM (limit 6); pituitary gland: 2.6 nTPM (limit 2); retina: 3 nTPM (limit 2); smooth muscle: 3.3 nTPM (limit 2),adipose tissue / adipocytes: Low (Enhanced); adrenal gland / glandular cells: Low (Enhanced); bronchus / respiratory epithelial cells: Medium (Enhanced); caudate / neuronal cells: Medium (Enhanced); cerebellum / cells in molecular layer: Medium (Enhanced); cerebellum / Purkinje cells: Medium (Enhanced); cerebral cortex / endothelial cells: Medium (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); cerebral cortex / neuropil: Low (Enhanced); colon / endothelial cells: Medium (Enhanced); colon / glandular cells: Medium (Enhanced); colon / peripheral nerve/ganglion: Medium (Enhanced); duodenum / glandular cells: Medium (Enhanced); esophagus / squamous epithelial cells: Low (Enhanced); heart muscle / cardiomyocytes: Medium (Enhanced); hippocampus / neuronal cells: Medium (Enhanced); kidney / cells in glomeruli: High (Enhanced); kidney / cells in tubules: Medium (Enhanced); liver / cholangiocytes: Medium (Enhanced); liver / hepatocytes: Medium (Enhanced); lung / alveolar cells: Low (Enhanced); lung / macrophages: Medium (Enhanced); lymph node / germinal center cells: Low (Enhanced); lymph node / non-germinal center cells: Low (Enhanced); nasopharynx / respiratory epithelial cells: Low (Enhanced); oral mucosa / squamous epithelial cells: Medium (Enhanced); pancreas / exocrine glandular cells: Medium (Enhanced); pancreas / pancreatic endocrine cells: Medium (Enhanced); parathyroid gland / glandular cells: High (Enhanced); rectum / glandular cells: Medium (Enhanced); salivary gland / glandular cells: Medium (Enhanced); skeletal muscle / myocytes: Low (Enhanced); skin 1 / fibroblasts: Medium (Enhanced); small intestine / glandular cells: Medium (Enhanced); smooth muscle / smooth muscle cells: Low (Enhanced); spleen / cells in red pulp: Low (Enhanced); spleen / cells in white pulp: Low (Enhanced); stomach 1 / glandular cells: Low (Enhanced); stomach 2 / glandular cells: Medium (Enhanced); thyroid gland / glandular cells: Low (Enhanced); urinary bladder / urothelial cells: Low (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 79/80 (98.8%); Breast Invasive Carcinoma (validation): 45/50 (90.0%); Lung Adenocarcinoma (validation): 70/105 (66.7%),prostate cancer: 9/9 (100.0%); breast cancer: 10/12 (83.3%),31,20,Q8TD10,https://www.uniprot.org/uniprotkb/Q8TD10/entry,,"Expressed very weakly in heart, liver, skeletal muscle, kidney, pancreas and fetal kidney. Not detected in brain, placenta and lung",,,,,11954550,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | Jamin2021_CT,GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
MLANA,ENSG00000120215,Unsafe,Protein,False,True,1.3,41.8,114,5,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; salivary gland: 1 nTPM; continuous selectivity; skin: 41.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",skin: 41.8 nTPM (limit 10),retina / pigment epithelial cells: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Skin Cuteneous Melanoma (TCGA): 97/99 (98.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 9/176 (5.1%); Pancreatic Adenocarcinoma (validation): 4/80 (5.0%),melanoma: 9/12 (75.0%); breast cancer: 0/11 (0.0%),31,20,Q16655,https://www.uniprot.org/uniprotkb/Q16655/entry,"Involved in melanosome biogenesis by ensuring the stability of GPR143. Plays a vital role in the expression, stability, trafficking, and processing of melanocyte protein PMEL, which is critical to the formation of stage II melanosomes",Expression is restricted to melanoma and melanocyte cell lines and retina,,,"Endoplasmic reticulum membrane Golgi apparatus Golgi apparatus, trans-Golgi network membrane Melanosome",15695812|19717472,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Seager2024_CTA,Member of the published 17-target CTA profiling panel; includes differentiation antigen MLANA,,,,,,,,
MLF1,ENSG00000178053,Unsafe,Protein,False,True,382.7,382.7,80,11,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 18 nTPM; absolute ceiling; basal ganglia: 29.7 nTPM; absolute ceiling; cerebellum: 7.4 nTPM; positive ihc;absolute ceiling; cerebral cortex: 15.8 nTPM; absolute ceiling; choroid plexus: 93.2 nTPM; absolute ceiling; colon: 9.6 nTPM; absolute ceiling; heart muscle: 134.3 nTPM; absolute ceiling; hippocampal formation: 18.9 nTPM; absolute ceiling; hypothalamus: 20.2 nTPM; absolute ceiling; kidney: 20.4 nTPM; absolute ceiling; lung: 17.3 nTPM; absolute ceiling; midbrain: 16.6 nTPM; absolute ceiling; pituitary gland: 17.6 nTPM; absolute ceiling; retina: 45.4 nTPM; absolute ceiling; skeletal muscle: 175.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 13.6 nTPM; absolute ceiling; spinal cord: 15.3 nTPM; absolute ceiling; tongue: 103.1 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 18 nTPM (limit 2); basal ganglia: 29.7 nTPM (limit 2); cerebellum: 7.4 nTPM (limit 2); cerebral cortex: 15.8 nTPM (limit 12); choroid plexus: 93.2 nTPM (limit 2); colon: 9.6 nTPM (limit 6); heart muscle: 134.3 nTPM (limit 12); hippocampal formation: 18.9 nTPM (limit 2); hypothalamus: 20.2 nTPM (limit 2); kidney: 20.4 nTPM (limit 12); lung: 17.3 nTPM (limit 12); midbrain: 16.6 nTPM (limit 2); pituitary gland: 17.6 nTPM (limit 2); retina: 45.4 nTPM (limit 2); skeletal muscle: 175.9 nTPM (limit 2); smooth muscle: 13.6 nTPM (limit 12); spinal cord: 15.3 nTPM (limit 2); tongue: 103.1 nTPM (limit 6),bronchus / respiratory epithelial cells: High (Enhanced); caudate / neuronal cells: Low (Enhanced); cerebellum / Purkinje cells: Low (Enhanced); nasopharynx / respiratory epithelial cells: High (Enhanced); skeletal muscle / myocytes: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 141/141 (100.0%); Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%),endometrial cancer: 3/12 (25.0%); lung cancer: 2/12 (16.7%),31,20,P58340,https://www.uniprot.org/uniprotkb/P58340/entry,Involved in lineage commitment of primary hemopoietic progenitors by restricting erythroid formation and enhancing myeloid formation. Interferes with erythropoietin-induced erythroid terminal differentiation by preventing cells from exiting the cell cycle through suppression of CDKN1B/p27Kip1 levels. Suppresses COP1 activity via CSN3 which activates p53 and induces cell cycle arrest. Binds DNA and affects the expression of a number of genes so may function as a transcription factor in the nucleus,"Most abundant in testis, ovary, skeletal muscle, heart, kidney and colon. Low expression in spleen, thymus and peripheral blood leukocytes",,,"Cytoplasm Nucleus Cell projection, cilium Cytoplasm, cytoskeleton, cilium basal body",15861129,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
MMP11,ENSG00000099953,Unsafe,Protein,False,True,138.5,138.5,81,17,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 3.2 nTPM; positive ihc; adrenal gland: 1.6 nTPM; positive ihc; duodenum: 6.6 nTPM; absolute ceiling; heart muscle: 7 nTPM; positive ihc;absolute ceiling; kidney: 2.5 nTPM; positive ihc;absolute ceiling; parathyroid gland: 3.2 nTPM; positive ihc; salivary gland: 5.1 nTPM; positive ihc; small intestine: 5.9 nTPM; positive ihc;absolute ceiling; smooth muscle: 9.1 nTPM; absolute ceiling; stomach: 2.5 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",duodenum: 6.6 nTPM (limit 4); heart muscle: 7 nTPM (limit 2); kidney: 2.5 nTPM (limit 2); small intestine: 5.9 nTPM (limit 2); smooth muscle: 9.1 nTPM (limit 4),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Low (Approved); bronchus / respiratory epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Low (Approved); kidney / cells in tubules: Low (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); parathyroid gland / glandular cells: Low (Approved); salivary gland / glandular cells: Low (Approved); small intestine / glandular cells: Low (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 50/50 (100.0%); Breast Invasive Carcinoma (TCGA): 1014/1022 (99.2%); Pancreatic Adenocarcinoma (validation): 79/80 (98.8%),testis cancer: 10/11 (90.9%); prostate cancer: 9/10 (90.0%),31,20,P24347,https://www.uniprot.org/uniprotkb/P24347/entry,May play an important role in the progression of epithelial malignancies,Specifically expressed in stromal cells of breast carcinomas,,,"Secreted, extracellular space, extracellular matrix",,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Bradley2020_CPA | Gong2021_reproductive_PC,No tumor-antigen validation in this source | Expression-nominated CPA; not newly validated by this study | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
MMS22L,ENSG00000146263,Unsafe,RNA,False,True,6.6,7.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 3.4 nTPM; continuous selectivity; retina: 2.3 nTPM; absolute ceiling;continuous selectivity; spinal cord: 1.8 nTPM; continuous selectivity; thymus: 5.1 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 7 nTPM (limit 2); retina: 2.3 nTPM (limit 2); bone marrow: 7 nTPM (baseline 2); retina: 2.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 467/486 (96.1%); Rectum Adenocarcinoma (validation): 193/207 (93.2%); Glioblastoma Multiforme (validation): 53/58 (91.4%),No exact-ID IHC coverage in the HPA cancer snapshot,30,0,Q6ZRQ5,https://www.uniprot.org/uniprotkb/Q6ZRQ5/entry,"Component of the MMS22L-TONSL complex, a complex that promotes homologous recombination-mediated repair of double-strand breaks (DSBs) at stalled or collapsed replication forks (PubMed:21055983, PubMed:21055984, PubMed:21055985, PubMed:21113133, PubMed:26527279, PubMed:27338793, PubMed:29478807). The MMS22L-TONSL complex is required to maintain genome integrity during DNA replication (PubMed:21055983, PubMed:21055984, PubMed:21055985, PubMed:27797818). It mediates the assembly of RAD51 filaments on single-stranded DNA (ssDNA): the MMS22L-TONSL complex is recruited to DSBs following histone replacement by histone chaperones and eviction of the replication protein A complex (RPA/RP-A) from DSBs (PubMed:21055983, PubMed:21055984, PubMed:21055985, PubMed:29478807). Following recruitment to DSBs, the TONSL-MMS22L complex promotes recruitment of RAD51 filaments and subsequent homologous recombination (PubMed:27797818, PubMed:29478807). Within the complex, MMS22L acts by binding ssDNA (PubMed:27797818)",,,,Nucleus Chromosome,21055983|21055984|21055985|21113133|26527279|27338793|27797818|29478807,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
MND1,ENSG00000121211,Unsafe,Protein,False,True,15.4,26.0,80,12,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 13.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 0.7 nTPM; positive ihc; lymph node: 11.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; spleen: 1.7 nTPM; positive ihc; thymus: 26 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 13.1 nTPM (limit 2); lymph node: 11.7 nTPM (limit 6); thymus: 26 nTPM (limit 10),bone marrow / hematopoietic cells: Medium (Supported); lung / macrophages: Medium (Supported); lymph node / germinal center cells: Medium (Supported); lymph node / non-germinal center cells: Medium (Supported); spleen / cells in red pulp: Medium (Supported); spleen / cells in white pulp: Medium (Supported); thymus / cortical cells: High (Supported); thymus / medullary cells: High (Supported),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 55/58 (94.8%); Colon Adenocarcinoma (TCGA): 236/254 (92.9%); Rectum Adenocarcinoma (TCGA): 80/88 (90.9%),lymphoma: 3/11 (27.3%); breast cancer: 2/9 (22.2%),31,20,Q9BWT6,https://www.uniprot.org/uniprotkb/Q9BWT6/entry,"Required for proper homologous chromosome pairing and efficient cross-over and intragenic recombination during meiosis (By similarity). Stimulates both DMC1- and RAD51-mediated homologous strand assimilation, which is required for the resolution of meiotic double-strand breaks",,,,Nucleus,16407260,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Jamin2021_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
MNS1,ENSG00000138587,Unsafe,RNA,False,True,46.8,46.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 3 nTPM; absolute ceiling; basal ganglia: 4.3 nTPM; absolute ceiling; bone marrow: 4.5 nTPM; absolute ceiling; cerebellum: 7.5 nTPM; absolute ceiling; cerebral cortex: 2.1 nTPM; absolute ceiling; choroid plexus: 22 nTPM; absolute ceiling;continuous selectivity; duodenum: 2.2 nTPM; absolute ceiling; heart muscle: 2.4 nTPM; absolute ceiling; hippocampal formation: 4.1 nTPM; absolute ceiling; hypothalamus: 4.1 nTPM; absolute ceiling; kidney: 10.2 nTPM; absolute ceiling; lung: 3.3 nTPM; absolute ceiling; midbrain: 2.5 nTPM; absolute ceiling; pancreas: 2.3 nTPM; absolute ceiling; pituitary gland: 3.4 nTPM; absolute ceiling; retina: 4.5 nTPM; absolute ceiling; spinal cord: 3.2 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 3 nTPM (limit 2); basal ganglia: 4.3 nTPM (limit 2); bone marrow: 4.5 nTPM (limit 2); cerebellum: 7.5 nTPM (limit 2); cerebral cortex: 2.1 nTPM (limit 2); choroid plexus: 22 nTPM (limit 2); duodenum: 2.2 nTPM (limit 2); heart muscle: 2.4 nTPM (limit 2); hippocampal formation: 4.1 nTPM (limit 2); hypothalamus: 4.1 nTPM (limit 2); kidney: 10.2 nTPM (limit 2); lung: 3.3 nTPM (limit 2); midbrain: 2.5 nTPM (limit 2); pancreas: 2.3 nTPM (limit 2); pituitary gland: 3.4 nTPM (limit 2); retina: 4.5 nTPM (limit 2); spinal cord: 3.2 nTPM (limit 2); amygdala: 3 nTPM (baseline 2); basal ganglia: 4.3 nTPM (baseline 2); bone marrow: 4.5 nTPM (baseline 2); cerebellum: 7.5 nTPM (baseline 2); cerebral cortex: 2.1 nTPM (baseline 2); choroid plexus: 22 nTPM (baseline 2); duodenum: 2.2 nTPM (baseline 2); heart muscle: 2.4 nTPM (baseline 2); hippocampal formation: 4.1 nTPM (baseline 2); hypothalamus: 4.1 nTPM (baseline 2); kidney: 10.2 nTPM (baseline 2); lung: 3.3 nTPM (baseline 2); midbrain: 2.5 nTPM (baseline 2); pancreas: 2.3 nTPM (baseline 2); pituitary gland: 3.4 nTPM (baseline 2); retina: 4.5 nTPM (baseline 2); spinal cord: 3.2 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 45/50 (90.0%); Kidney Renal Clear Cell Carcinoma (validation): 83/100 (83.0%),breast cancer: 12/12 (100.0%); liver cancer: 12/12 (100.0%),31,20,Q8NEH6,https://www.uniprot.org/uniprotkb/Q8NEH6/entry,"Microtubule inner protein (MIP) part of the dynein-decorated doublet microtubules (DMTs) in cilia axoneme, which is required for motile cilia beating (PubMed:36191189). May play a role in the control of meiotic division and germ cell differentiation through regulation of pairing and recombination during meiosis. Required for sperm flagella assembly (By similarity). May play a role in the assembly and function of the outer dynein arm-docking complex (ODA-DC). ODA-DC mediates outer dynein arms (ODA) binding onto the axonemal doublet microtubules (PubMed:30148830)",Expressed in nasal respiratory epithelium and in the sperm,"Heterotaxy, visceral, 9, autosomal, with male infertility: A form of visceral heterotaxy, a complex disorder due to disruption of the normal left-right asymmetry of the thoracoabdominal organs. Visceral heterotaxy or situs ambiguus results in randomization of the placement of visceral organs, including the heart, lungs, liver, spleen, and stomach. The organs are oriented randomly with respect to the left-right axis and with respect to one another. It can be associated with a variety of congenital defects including cardiac malformations. HTX9 is an autosomal recessive form associated with male infertility, mainly due to defective sperm motility.",,"Nucleus Cytoplasm, cytoskeleton, cilium axoneme Cytoplasm, cytoskeleton, flagellum axoneme",30148830|36191189,30148830|36191189,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Jamin2021_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
MOBP,ENSG00000168314,Unsafe,Protein,False,True,5.3,1086.6,79,1,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 179.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 126.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 20.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 102.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 51.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 261.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 178.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 428.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 2.3 nTPM; continuous selectivity; spinal cord: 1086.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 179.3 nTPM (limit 2); basal ganglia: 126.9 nTPM (limit 2); cerebellum: 20.8 nTPM (limit 12); cerebral cortex: 102.5 nTPM (limit 2); choroid plexus: 51.2 nTPM (limit 2); hippocampal formation: 261.9 nTPM (limit 2); hypothalamus: 178.5 nTPM (limit 2); midbrain: 428.9 nTPM (limit 2); spinal cord: 1086.6 nTPM (limit 2); amygdala: 179.3 nTPM (baseline 2); basal ganglia: 126.9 nTPM (baseline 2); cerebellum: 20.8 nTPM (baseline 2); cerebral cortex: 102.5 nTPM (baseline 2); choroid plexus: 51.2 nTPM (baseline 2); hippocampal formation: 261.9 nTPM (baseline 2); hypothalamus: 178.5 nTPM (baseline 2); midbrain: 428.9 nTPM (baseline 2); spinal cord: 1086.6 nTPM (baseline 2),cerebral cortex / neuropil: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 71/141 (50.4%); Glioblastoma Multiforme (validation): 27/58 (46.6%); Lung Squamous Cell Carcinoma (validation): 2/68 (2.9%),breast cancer: 0/10 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q13875,https://www.uniprot.org/uniprotkb/Q13875/entry,"May play a role in compacting or stabilizing the myelin sheath, possibly by binding the negatively charged acidic phospholipids of the cytoplasmic membrane",,,,"Cytoplasm, perinuclear region",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
MORN3,ENSG00000139714,Unsafe,RNA,False,True,4.4,6.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 2.1 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 2.2 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 2.4 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 2.5 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 2 nTPM; continuous selectivity; parathyroid gland: 2.2 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 2.1 nTPM (limit 2); basal ganglia: 2.2 nTPM (limit 2); cerebral cortex: 2.4 nTPM (limit 2); choroid plexus: 6 nTPM (limit 2); hippocampal formation: 2.5 nTPM (limit 2); amygdala: 2.1 nTPM (baseline 2); basal ganglia: 2.2 nTPM (baseline 2); cerebral cortex: 2.4 nTPM (baseline 2); choroid plexus: 6 nTPM (baseline 2); hippocampal formation: 2.5 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 37/50 (74.0%); Glioblastoma Multiforme (validation): 29/58 (50.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 47/176 (26.7%),endometrial cancer: 12/12 (100.0%); ovarian cancer: 12/12 (100.0%),31,20,Q6PF18,https://www.uniprot.org/uniprotkb/Q6PF18/entry,"Assembles a suppression complex (suppresome) by tethering SIRT1 and MDM2 to regulate composite modifications of p53/TP53. Confers both deacetylation-mediated functional inactivation, by SIRT1, and ubiquitination-dependent degradation, by MDM2, of p53/TP53, promoting a proliferative and cell survival behaviors (PubMed:29681526). May play a role in the regulation of spermatogenesis (By similarity)",,,,"Cytoplasmic vesicle, secretory vesicle, acrosome",29681526,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
MPL,ENSG00000117400,Unsafe,High RNA,False,True,2.0,2.0,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 1.7 nTPM; continuous selectivity; cerebral cortex: 0.8 nTPM; continuous selectivity; heart muscle: 1 nTPM; continuous selectivity; pancreas: 0.7 nTPM; continuous selectivity; retina: 1.5 nTPM; continuous selectivity; smooth muscle: 0.7 nTPM; continuous selectivity,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,True,"brain/excitatory neurons cluster c-1: 6.6 nTPM, 829 reads; reproductive-cell max 3.9; brain/excitatory neurons cluster c-7: 5.5 nTPM, 515 reads; reproductive-cell max 3.9; brain/excitatory neurons cluster c-13: 5.6 nTPM, 265 reads; reproductive-cell max 3.9",True,True,hpa_immune_monaco Progenitor cell: 133.7 TPM; hpa_immune_monaco total PBMC: 9.9 TPM,True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,133.7,104.6,"hpa_immune_monaco: blood/Progenitor cell, max 133.7 TPM, 1 observations >30; hpa_single_cell_tissue: pbmc/platelets, max 104.6 nTPM, 1 observations >30",Neither,oncoref.target-sets.2026-10-23.2,133.7 TPM; blood/Progenitor cell; hpa_immune_monaco; vital,104.6 nTPM; pbmc/platelets; hpa_single_cell_tissue; vital,Uterine Corpus Endometrial Carcinoma (TCGA): 9/176 (5.1%); Kidney Renal Papillary Cell Carcinoma (TCGA): 10/282 (3.5%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 9/283 (3.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P40238,https://www.uniprot.org/uniprotkb/P40238/entry,"Receptor for thrombopoietin that regulates hematopoietic stem cell renewal, megakaryocyte differentiation, and platelet formation. Upon activation by THPO, induces rapid tyrosine phosphorylation and activation of JAK2, providing docking sites for many signaling proteins such as STAT5, SHIP/INPP5D, GRB2, SOS1 and PI3K (PubMed:15899890, PubMed:37633268). In turn, These signaling cascades lead to the proliferation, survival, and differentiation of megakaryocytes, ultimately leading to increased platelet production",Expressed at a low level in a large number of cells of hematopoietic origin. Isoform 1 and isoform 2 are always found to be coexpressed,"Amegakaryocytic thrombocytopenia, congenital, 1: An autosomal recessive form of congenital amegakaryocytic thrombocytopenia, a hematologic disorder characterized by severe reduction of megakaryocytes and platelets at birth, and evolving into generalized bone marrow aplasia during childhood. Thrombocythemia 2: A myeloproliferative disorder characterized by excessive platelet production, resulting in increased numbers of circulating platelets. It can be associated with spontaneous hemorrhages and thrombotic episodes. Myelofibrosis with myeloid metaplasia: A chronic myeloproliferative disorder characterized by replacement of the bone marrow by fibrous tissue, extramedullary hematopoiesis, anemia, leukoerythroblastosis and hepatosplenomegaly.",It is uncertain whether Met-1 or Met-8 is the initiator,Cell membrane Golgi apparatus Cell surface,15899890|37633268,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
MROH8,ENSG00000101353,Unsafe,Protein,False,True,18.1,18.1,79,21,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 1.3 nTPM; positive ihc; cerebellum: 1.3 nTPM; positive ihc; cerebral cortex: 1.4 nTPM; positive ihc; choroid plexus: 2.8 nTPM; absolute ceiling; colon: 1.2 nTPM; positive ihc; duodenum: 0.8 nTPM; positive ihc; heart muscle: 2.1 nTPM; positive ihc;absolute ceiling; kidney: 1.7 nTPM; positive ihc; retina: 3.9 nTPM; absolute ceiling; salivary gland: 1 nTPM; positive ihc; skeletal muscle: 5.6 nTPM; absolute ceiling; thyroid gland: 1.9 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 2.8 nTPM (limit 2); heart muscle: 2.1 nTPM (limit 2); retina: 3.9 nTPM (limit 2); skeletal muscle: 5.6 nTPM (limit 4),adrenal gland / glandular cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); colon / glandular cells: Low (Approved); duodenum / glandular cells: Low (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Low (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); salivary gland / glandular cells: Low (Approved); thyroid gland / glandular cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 44/58 (75.9%); Testicular Germ Cell Tumor (TCGA): 12/133 (9.0%); Kidney Chromophobe (TCGA): 4/64 (6.2%),renal cancer: 3/11 (27.3%); prostate cancer: 1/11 (9.1%),29,20,,,,,,,,,,False,No exact Ensembl mapping to a reviewed UniProt entry,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
MRPL30,ENSG00000185414,Unsafe,Protein,False,True,9.8,28.5,84,53,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 9.6 nTPM; continuous selectivity; adrenal gland: 12.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 10.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 9.3 nTPM; absolute ceiling;continuous selectivity; bone marrow: 3.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 9.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 12.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 3.4 nTPM; absolute ceiling;continuous selectivity; colon: 9.5 nTPM; absolute ceiling;continuous selectivity; duodenum: 6.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 14.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 16.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 9.6 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 11.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 12.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 13.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 5.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 5.1 nTPM; continuous selectivity; midbrain: 10.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 10.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 7.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 7 nTPM; absolute ceiling;continuous selectivity; rectum: 6.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 5.8 nTPM; absolute ceiling;continuous selectivity; salivary gland: 9.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 28.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 10.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 7.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 5.1 nTPM; absolute ceiling;continuous selectivity; spinal cord: 12.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 6.9 nTPM; positive ihc;continuous selectivity; stomach: 9.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; thymus: 7.2 nTPM; continuous selectivity; thyroid gland: 6.8 nTPM; positive ihc;continuous selectivity; tongue: 20.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 9 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 12.1 nTPM (limit 4); amygdala: 10.8 nTPM (limit 2); basal ganglia: 9.3 nTPM (limit 2); bone marrow: 3.3 nTPM (limit 2); cerebellum: 9.9 nTPM (limit 2); cerebral cortex: 12.3 nTPM (limit 2); choroid plexus: 3.4 nTPM (limit 2); colon: 9.5 nTPM (limit 8); duodenum: 6.8 nTPM (limit 2); esophagus: 14.2 nTPM (limit 6); heart muscle: 16.2 nTPM (limit 4); hippocampal formation: 9.6 nTPM (limit 2); hypothalamus: 11.3 nTPM (limit 2); kidney: 12.1 nTPM (limit 2); liver: 13.3 nTPM (limit 2); lung: 5.8 nTPM (limit 2); midbrain: 10.5 nTPM (limit 2); pancreas: 10.9 nTPM (limit 2); parathyroid gland: 7.1 nTPM (limit 6); pituitary gland: 7 nTPM (limit 2); rectum: 6.5 nTPM (limit 6); retina: 5.8 nTPM (limit 2); salivary gland: 9.6 nTPM (limit 6); skeletal muscle: 28.5 nTPM (limit 4); skin: 10.3 nTPM (limit 10); small intestine: 7.8 nTPM (limit 2); smooth muscle: 5.1 nTPM (limit 4); spinal cord: 12.1 nTPM (limit 2); stomach: 9.8 nTPM (limit 6); tongue: 20.2 nTPM (limit 6); urinary bladder: 9 nTPM (limit 6),bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: Medium (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells type II: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: High (Approved); pancreas / pancreatic endocrine cells: High (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: High (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: High (Approved); spleen / cells in red pulp: Medium (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (validation): 231/231 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (TCGA): 141/141 (100.0%),prostate cancer: 10/10 (100.0%); endometrial cancer: 10/12 (83.3%),31,20,Q8TCC3,https://www.uniprot.org/uniprotkb/Q8TCC3/entry,,,,,Mitochondrion,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
MRPS17,ENSG00000239789,Unsafe,Protein,False,True,11.5,31.7,77,46,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 9.3 nTPM; continuous selectivity; adrenal gland: 13.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 13.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 13.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 9.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 12.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 16.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 7.5 nTPM; absolute ceiling;continuous selectivity; colon: 12.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 8.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 13.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 19.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 13.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 12.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 16.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 21.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 6.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 8.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 9.7 nTPM; absolute ceiling;continuous selectivity; pancreas: 13.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 9.3 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 8.1 nTPM; absolute ceiling;continuous selectivity; rectum: 9.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 5.4 nTPM; absolute ceiling;continuous selectivity; salivary gland: 8.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 31.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 8 nTPM; positive ihc;continuous selectivity; small intestine: 8.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 9 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 7.7 nTPM; absolute ceiling;continuous selectivity; spleen: 9.9 nTPM; continuous selectivity; stomach: 11.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 8.9 nTPM; continuous selectivity; thyroid gland: 7.9 nTPM; positive ihc;continuous selectivity; tongue: 31.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 10.6 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 13.1 nTPM (limit 2); amygdala: 13.2 nTPM (limit 2); basal ganglia: 13.8 nTPM (limit 2); bone marrow: 9.9 nTPM (limit 2); cerebellum: 12.5 nTPM (limit 2); cerebral cortex: 16.1 nTPM (limit 2); choroid plexus: 7.5 nTPM (limit 2); colon: 12.6 nTPM (limit 6); duodenum: 8.6 nTPM (limit 2); esophagus: 13.1 nTPM (limit 6); heart muscle: 19.4 nTPM (limit 2); hippocampal formation: 13.3 nTPM (limit 2); hypothalamus: 12.5 nTPM (limit 2); kidney: 16.3 nTPM (limit 2); liver: 21.6 nTPM (limit 2); lung: 6.7 nTPM (limit 2); lymph node: 8.8 nTPM (limit 6); midbrain: 9.7 nTPM (limit 2); pancreas: 13.2 nTPM (limit 2); parathyroid gland: 9.3 nTPM (limit 8); pituitary gland: 8.1 nTPM (limit 2); rectum: 9.5 nTPM (limit 6); retina: 5.4 nTPM (limit 2); salivary gland: 8.7 nTPM (limit 6); skeletal muscle: 31.7 nTPM (limit 2); small intestine: 8.9 nTPM (limit 2); smooth muscle: 9 nTPM (limit 2); spinal cord: 7.7 nTPM (limit 2); stomach: 11.2 nTPM (limit 6); tongue: 31.3 nTPM (limit 6); urinary bladder: 10.6 nTPM (limit 6),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Low (Approved); colon / glandular cells: Low (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / macrophages: Low (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); rectum / glandular cells: Low (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%); Head and Neck Squamous Cell Carcinoma (TCGA): 492/492 (100.0%),melanoma: 7/12 (58.3%); endometrial cancer: 6/12 (50.0%),31,20,Q9Y2R5,https://www.uniprot.org/uniprotkb/Q9Y2R5/entry,,,,,Mitochondrion,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
MS4A14,ENSG00000166928,Unsafe,RNA,False,True,71.0,71.0,88,2,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,choroid plexus: 4.7 nTPM; absolute ceiling; hippocampal formation: 2.2 nTPM; absolute ceiling; hypothalamus: 2.1 nTPM; absolute ceiling; midbrain: 2.5 nTPM; absolute ceiling; spinal cord: 4 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 4.7 nTPM (limit 2); hippocampal formation: 2.2 nTPM (limit 2); hypothalamus: 2.1 nTPM (limit 2); midbrain: 2.5 nTPM (limit 2); spinal cord: 4 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 32/50 (64.0%); Glioblastoma Multiforme (validation): 16/58 (27.6%); Breast Invasive Carcinoma (TCGA): 192/1022 (18.8%),ovarian cancer: 2/11 (18.2%); colorectal cancer: 1/11 (9.1%),31,20,Q96JA4,https://www.uniprot.org/uniprotkb/Q96JA4/entry,May be involved in signal transduction as a component of a multimeric receptor complex,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
MS4A18,ENSG00000214782,Unsafe,Protein,False,True,5.8,18.1,85,5,Positive somewhere,True,True,False,True,Excluded,Normal,False,,Not assessed,,,existing nomination or manual review; nomination unresolved; positive normal IHC; positive ihc outside permitted; colon: 0 nTPM; positive ihc; duodenum: 18.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; rectum: 0 nTPM; positive ihc; small intestine: 3 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",duodenum: 18.1 nTPM (limit 2); small intestine: 3 nTPM (limit 2),colon / glandular cells: Low (Approved); duodenum / glandular cells: Medium (Approved); rectum / glandular cells: Low (Approved); small intestine / glandular cells: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 11/1022 (1.1%); Pancreatic Adenocarcinoma (TCGA): 1/176 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),liver cancer: 3/12 (25.0%); breast cancer: 1/7 (14.3%),29,20,Q3C1V0,https://www.uniprot.org/uniprotkb/Q3C1V0/entry,,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
MSANTD4,ENSG00000170903,Unsafe,Protein,False,True,11.6,32.1,90,36,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 8 nTPM; continuous selectivity; adrenal gland: 9.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 10.6 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 9.6 nTPM; absolute ceiling;continuous selectivity; cerebellum: 10.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 15.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 7.4 nTPM; absolute ceiling;continuous selectivity; colon: 6.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 5.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 7.7 nTPM; continuous selectivity; heart muscle: 15.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 10 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 9.8 nTPM; absolute ceiling;continuous selectivity; kidney: 9.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 6.8 nTPM; absolute ceiling;continuous selectivity; lung: 8.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 9.5 nTPM; absolute ceiling;continuous selectivity; midbrain: 10.4 nTPM; absolute ceiling;continuous selectivity; pancreas: 9.1 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 7.9 nTPM; continuous selectivity; pituitary gland: 9.4 nTPM; absolute ceiling;continuous selectivity; rectum: 6.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 32.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 7 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 11.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 5.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 10.1 nTPM; absolute ceiling;continuous selectivity; spinal cord: 9.3 nTPM; absolute ceiling;continuous selectivity; spleen: 8.2 nTPM; continuous selectivity; stomach: 7 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 8.1 nTPM; continuous selectivity; thyroid gland: 12.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; tongue: 16.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 8.5 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 9.8 nTPM (limit 2); amygdala: 10.6 nTPM (limit 2); basal ganglia: 9.6 nTPM (limit 2); cerebellum: 10.6 nTPM (limit 2); cerebral cortex: 15.8 nTPM (limit 2); choroid plexus: 7.4 nTPM (limit 2); colon: 6.9 nTPM (limit 6); duodenum: 5.1 nTPM (limit 2); heart muscle: 15.1 nTPM (limit 2); hippocampal formation: 10 nTPM (limit 2); hypothalamus: 9.8 nTPM (limit 2); kidney: 9.2 nTPM (limit 2); liver: 6.8 nTPM (limit 4); lung: 8.2 nTPM (limit 2); lymph node: 9.5 nTPM (limit 8); midbrain: 10.4 nTPM (limit 2); pancreas: 9.1 nTPM (limit 4); pituitary gland: 9.4 nTPM (limit 2); rectum: 6.1 nTPM (limit 6); retina: 32.1 nTPM (limit 2); salivary gland: 7 nTPM (limit 6); skeletal muscle: 11.4 nTPM (limit 2); small intestine: 5.6 nTPM (limit 2); smooth muscle: 10.1 nTPM (limit 4); spinal cord: 9.3 nTPM (limit 2); stomach: 7 nTPM (limit 6); thyroid gland: 12.8 nTPM (limit 10); tongue: 16.1 nTPM (limit 6); urinary bladder: 8.5 nTPM (limit 8),adrenal gland / glandular cells: Medium (Approved); bronchus / ciliated cells (cilia axoneme): High (Approved); bronchus / ciliated cells (ciliary rootlets): High (Approved); bronchus / ciliated cells (tip of cilia): High (Approved); caudate / glial cells: Medium (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebral cortex / endothelial cells: High (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuropil: High (Approved); colon / glandular cells: Low (Approved); duodenum / glandular cells: Low (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Medium (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in tubules: Low (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Low (Approved); nasopharynx / ciliated cells (cilia axoneme): High (Approved); nasopharynx / ciliated cells (ciliary rootlets): High (Approved); nasopharynx / ciliated cells (tip of cilia): High (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Medium (Approved); small intestine / glandular cells: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 141/141 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%); Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%),glioma: 9/12 (75.0%); lung cancer: 1/12 (8.3%),29,20,Q8NCY6,https://www.uniprot.org/uniprotkb/Q8NCY6/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
MSH4,ENSG00000057468,Unsafe,High RNA,False,True,4.1,4.1,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,True,"brain/excitatory neurons cluster c-0: 24.9 nTPM, 3741 reads; reproductive-cell max 20.7; brain/excitatory neurons cluster c-1: 23.1 nTPM, 2903 reads; reproductive-cell max 20.7; brain/excitatory neurons cluster c-4: 24.2 nTPM, 3317 reads; reproductive-cell max 20.7; brain/inhibitory neurons cluster c-5: 26 nTPM, 2313 reads; reproductive-cell max 20.7; brain/inhibitory neurons cluster c-6: 26 nTPM, 1353 reads; reproductive-cell max 20.7; brain/inhibitory neurons cluster c-8: 26.9 nTPM, 2233 reads; reproductive-cell max 20.7; brain/excitatory neurons cluster c-11: 24.6 nTPM, 1800 reads; reproductive-cell max 20.7; brain/excitatory neurons cluster c-13: 27.2 nTPM, 1278 reads; reproductive-cell max 20.7; brain/inhibitory neurons cluster c-15: 25.5 nTPM, 696 reads; reproductive-cell max 20.7; brain/excitatory neurons cluster c-18: 31 nTPM, 1538 reads; reproductive-cell max 20.7; brain/excitatory neurons cluster c-19: 25.3 nTPM, 1132 reads; reproductive-cell max 20.7; brain/excitatory neurons cluster c-20: 26.8 nTPM, 1310 reads; reproductive-cell max 20.7; brain/inhibitory neurons cluster c-21: 21 nTPM, 638 reads; reproductive-cell max 20.7; brain/excitatory neurons cluster c-22: 37.1 nTPM, 1605 reads; reproductive-cell max 20.7; brain/inhibitory neurons cluster c-26: 22.2 nTPM, 496 reads; reproductive-cell max 20.7; brain/inhibitory neurons cluster c-28: 25.6 nTPM, 521 reads; reproductive-cell max 20.7; brain/inhibitory neurons cluster c-30: 22.8 nTPM, 547 reads; reproductive-cell max 20.7; brain/excitatory neurons cluster c-33: 23 nTPM, 572 reads; reproductive-cell max 20.7; brain/excitatory neurons cluster c-34: 37.7 nTPM, 943 reads; reproductive-cell max 20.7; brain/excitatory neurons cluster c-36: 23 nTPM, 393 reads; reproductive-cell max 20.7; brain/excitatory neurons cluster c-40: 24.9 nTPM, 251 reads; reproductive-cell max 20.7; brain/inhibitory neurons cluster c-41: 24.7 nTPM, 130 reads; reproductive-cell max 20.7",True,False,,True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,3.82643871985,37.7,"hpa_single_cell_tissue: brain/excitatory neurons, max 37.7 nTPM, 3 observations >30",Neither,oncoref.target-sets.2026-10-23.2,3.826 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,37.7 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 10/58 (17.2%); Colon Adenocarcinoma (validation): 9/486 (1.9%); Testicular Germ Cell Tumor (TCGA): 2/133 (1.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O15457,https://www.uniprot.org/uniprotkb/O15457/entry,Involved in meiotic recombination. Required for reciprocal recombination and proper segregation of homologous chromosomes at meiosis,"Highly expressed in testis (PubMed:33437391, PubMed:9299235). Also expressed in the ovary (PubMed:9299235)","Spermatogenic failure 2: An autosomal recessive disorder characterized by male infertility due to non-obstructive azoospermia. Testicular histopathology reveals no round spermatids or spermatozoa in the seminiferous tubules of SPGF2 patients, consistent with meiotic arrest. Premature ovarian failure 20: A form of premature ovarian failure, an ovarian disorder defined as the cessation of ovarian function under the age of 40 years. It is characterized by oligomenorrhea or amenorrhea, in the presence of elevated levels of serum gonadotropins and low estradiol. POF20 inheritance is autosomal recessive.",,Chromosome,,33437391|9299235,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
MSTN,ENSG00000138379,Unsafe,RNA,False,True,1.2,14.7,80,0,Negative where measured,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 0.9 nTPM; continuous selectivity; amygdala: 0.7 nTPM; continuous selectivity; basal ganglia: 0.6 nTPM; continuous selectivity; cerebellum: 0.8 nTPM; continuous selectivity; cerebral cortex: 0.7 nTPM; continuous selectivity; colon: 0.6 nTPM; continuous selectivity; esophagus: 1 nTPM; continuous selectivity; hippocampal formation: 0.7 nTPM; continuous selectivity; hypothalamus: 0.7 nTPM; continuous selectivity; kidney: 0.5 nTPM; continuous selectivity; midbrain: 0.6 nTPM; continuous selectivity; pituitary gland: 0.6 nTPM; continuous selectivity; retina: 3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 9.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; tongue: 14.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 3 nTPM (limit 2); skeletal muscle: 9.7 nTPM (limit 4); tongue: 14.7 nTPM (limit 6); retina: 3 nTPM (baseline 2); skeletal muscle: 9.7 nTPM (baseline 2); tongue: 14.7 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 46/58 (79.3%); Glioblastoma Multiforme (TCGA): 56/141 (39.7%); Breast Invasive Carcinoma (validation): 3/50 (6.0%),breast cancer: 1/11 (9.1%); renal cancer: 1/12 (8.3%),31,20,O14793,https://www.uniprot.org/uniprotkb/O14793/entry,Acts specifically as a negative regulator of skeletal muscle growth,,Muscle hypertrophy: A condition characterized by increased muscle bulk and strength. Affected individuals are exceptionally strong.,,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
MTCL3,ENSG00000214338,Unsafe,RNA,False,True,1.1,8.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 1.5 nTPM; continuous selectivity;reproductive not higher; amygdala: 0.6 nTPM; continuous selectivity; cerebellum: 0.4 nTPM; continuous selectivity; cerebral cortex: 8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 0.4 nTPM; continuous selectivity; colon: 0.6 nTPM; continuous selectivity; duodenum: 0.6 nTPM; continuous selectivity; esophagus: 1.2 nTPM; continuous selectivity;reproductive not higher; hippocampal formation: 0.7 nTPM; continuous selectivity; hypothalamus: 0.7 nTPM; continuous selectivity; lung: 2.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 0.5 nTPM; continuous selectivity; midbrain: 1.8 nTPM; continuous selectivity;reproductive not higher; pancreas: 0.9 nTPM; continuous selectivity; pituitary gland: 1.9 nTPM; continuous selectivity;reproductive not higher; rectum: 0.6 nTPM; continuous selectivity; retina: 3.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 0.5 nTPM; continuous selectivity; skin: 0.6 nTPM; continuous selectivity; small intestine: 1.2 nTPM; continuous selectivity;reproductive not higher; spinal cord: 3.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 1 nTPM; continuous selectivity; stomach: 2.2 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 0.9 nTPM; continuous selectivity; urinary bladder: 0.6 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebral cortex: 8 nTPM (limit 2); lung: 2.3 nTPM (limit 2); retina: 3.3 nTPM (limit 2); spinal cord: 3.6 nTPM (limit 2); cerebral cortex: 8 nTPM (baseline 2); lung: 2.3 nTPM (baseline 2); retina: 3.3 nTPM (baseline 2); spinal cord: 3.6 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Renal Clear Cell Carcinoma (validation): 12/100 (12.0%); Kidney Renal Papillary Cell Carcinoma (TCGA): 32/282 (11.3%); Glioblastoma Multiforme (TCGA): 10/141 (7.1%),breast cancer: 12/12 (100.0%); colorectal cancer: 12/12 (100.0%),29,20,Q5TF21,https://www.uniprot.org/uniprotkb/Q5TF21/entry,,,,,Membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
MTFR2,ENSG00000146410,Unsafe,Protein,False,True,6.8,16.1,82,18,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 16.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; colon: 2.8 nTPM; positive ihc;continuous selectivity; duodenum: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 6.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; rectum: 3.6 nTPM; positive ihc;continuous selectivity; small intestine: 2.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 1.1 nTPM; positive ihc; thymus: 6 nTPM; continuous selectivity; urinary bladder: 0.8 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 16.1 nTPM (limit 2); duodenum: 2.7 nTPM (limit 2); lymph node: 6.2 nTPM (limit 6); small intestine: 2.2 nTPM (limit 2),bone marrow / hematopoietic cells: Low (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Low (Approved); lymph node / non-germinal center cells: Low (Approved); rectum / glandular cells: Medium (Approved); small intestine / glandular cells: Low (Approved); stomach 2 / glandular cells: Low (Approved); urinary bladder / urothelial cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 442/486 (90.9%); Rectum Adenocarcinoma (validation): 178/207 (86.0%); Lung Squamous Cell Carcinoma (validation): 56/68 (82.4%),colorectal cancer: 7/10 (70.0%); prostate cancer: 4/10 (40.0%),29,20,Q6P444,https://www.uniprot.org/uniprotkb/Q6P444/entry,May play a role in mitochondrial aerobic respiration essentially in the testis. Can also promote mitochondrial fission (By similarity),,,,Mitochondrion,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Jamin2021_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
MTNAP1,ENSG00000141219,Unsafe,Protein,False,True,38.5,38.5,79,76,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 8.2 nTPM; positive ihc; adrenal gland: 9.6 nTPM; positive ihc;absolute ceiling; amygdala: 8.3 nTPM; absolute ceiling; basal ganglia: 8.7 nTPM; absolute ceiling; bone marrow: 3.1 nTPM; positive ihc;absolute ceiling; cerebellum: 13 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 9.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 7.4 nTPM; absolute ceiling; colon: 11.2 nTPM; positive ihc;absolute ceiling; duodenum: 10.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 8.3 nTPM; positive ihc;absolute ceiling; heart muscle: 15 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 7.9 nTPM; absolute ceiling; hypothalamus: 8.4 nTPM; absolute ceiling; kidney: 12.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 9.4 nTPM; positive ihc;absolute ceiling; lung: 8.7 nTPM; positive ihc;absolute ceiling; lymph node: 13.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 8.7 nTPM; absolute ceiling; pancreas: 9 nTPM; positive ihc;absolute ceiling; parathyroid gland: 15.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 10.3 nTPM; absolute ceiling;continuous selectivity; rectum: 9.7 nTPM; positive ihc;absolute ceiling; retina: 22.3 nTPM; absolute ceiling;continuous selectivity; salivary gland: 10.3 nTPM; positive ihc;absolute ceiling; skeletal muscle: 22.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 8.2 nTPM; positive ihc; small intestine: 9.2 nTPM; positive ihc;absolute ceiling; smooth muscle: 12.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 8.2 nTPM; absolute ceiling; spleen: 10.4 nTPM; positive ihc;absolute ceiling; stomach: 9.8 nTPM; positive ihc;absolute ceiling; thymus: 17.1 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 15.4 nTPM; positive ihc;absolute ceiling; tongue: 20.7 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 8.8 nTPM; positive ihc;absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 9.6 nTPM (limit 2); amygdala: 8.3 nTPM (limit 2); basal ganglia: 8.7 nTPM (limit 2); bone marrow: 3.1 nTPM (limit 2); cerebellum: 13 nTPM (limit 2); cerebral cortex: 9.8 nTPM (limit 2); choroid plexus: 7.4 nTPM (limit 2); colon: 11.2 nTPM (limit 6); duodenum: 10.1 nTPM (limit 2); esophagus: 8.3 nTPM (limit 6); heart muscle: 15 nTPM (limit 2); hippocampal formation: 7.9 nTPM (limit 2); hypothalamus: 8.4 nTPM (limit 2); kidney: 12.1 nTPM (limit 2); liver: 9.4 nTPM (limit 2); lung: 8.7 nTPM (limit 2); lymph node: 13.2 nTPM (limit 6); midbrain: 8.7 nTPM (limit 2); pancreas: 9 nTPM (limit 2); parathyroid gland: 15.8 nTPM (limit 6); pituitary gland: 10.3 nTPM (limit 2); rectum: 9.7 nTPM (limit 6); retina: 22.3 nTPM (limit 2); salivary gland: 10.3 nTPM (limit 6); skeletal muscle: 22.9 nTPM (limit 2); small intestine: 9.2 nTPM (limit 2); smooth muscle: 12.1 nTPM (limit 2); spinal cord: 8.2 nTPM (limit 2); spleen: 10.4 nTPM (limit 10); stomach: 9.8 nTPM (limit 6); thymus: 17.1 nTPM (limit 10); thyroid gland: 15.4 nTPM (limit 10); tongue: 20.7 nTPM (limit 6); urinary bladder: 8.8 nTPM (limit 6); adrenal gland: 9.6 nTPM (baseline 2); amygdala: 8.3 nTPM (baseline 2); basal ganglia: 8.7 nTPM (baseline 2); bone marrow: 3.1 nTPM (baseline 2); cerebellum: 13 nTPM (baseline 2); cerebral cortex: 9.8 nTPM (baseline 2); choroid plexus: 7.4 nTPM (baseline 2); colon: 11.2 nTPM (baseline 6); duodenum: 10.1 nTPM (baseline 2); esophagus: 8.3 nTPM (baseline 6); heart muscle: 15 nTPM (baseline 2); hippocampal formation: 7.9 nTPM (baseline 2); hypothalamus: 8.4 nTPM (baseline 2); kidney: 12.1 nTPM (baseline 2); liver: 9.4 nTPM (baseline 2); lung: 8.7 nTPM (baseline 2); lymph node: 13.2 nTPM (baseline 6); midbrain: 8.7 nTPM (baseline 2); pancreas: 9 nTPM (baseline 2); parathyroid gland: 15.8 nTPM (baseline 6); pituitary gland: 10.3 nTPM (baseline 2); rectum: 9.7 nTPM (baseline 6); retina: 22.3 nTPM (baseline 2); salivary gland: 10.3 nTPM (baseline 6); skeletal muscle: 22.9 nTPM (baseline 2); small intestine: 9.2 nTPM (baseline 2); smooth muscle: 12.1 nTPM (baseline 2); spinal cord: 8.2 nTPM (baseline 2); spleen: 10.4 nTPM (baseline 10); stomach: 9.8 nTPM (baseline 6); thymus: 17.1 nTPM (baseline 10); thyroid gland: 15.4 nTPM (baseline 10); tongue: 20.7 nTPM (baseline 6); urinary bladder: 8.8 nTPM (baseline 6),adipose tissue / adipocytes: Medium (Uncertain); adrenal gland / glandular cells: High (Uncertain); bone marrow / hematopoietic cells: High (Uncertain); bronchus / respiratory epithelial cells: High (Uncertain); caudate / glial cells: Low (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: High (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / endothelial cells: Low (Uncertain); cerebral cortex / glial cells: Low (Uncertain); cerebral cortex / neuronal cells: High (Uncertain); cerebral cortex / neuropil: Medium (Uncertain); colon / endothelial cells: Medium (Uncertain); colon / glandular cells: High (Uncertain); colon / peripheral nerve/ganglion: Medium (Uncertain); duodenum / glandular cells: High (Uncertain); esophagus / squamous epithelial cells: High (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / glial cells: Low (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in glomeruli: Low (Uncertain); kidney / cells in tubules: High (Uncertain); liver / cholangiocytes: Medium (Uncertain); liver / hepatocytes: High (Uncertain); lung / alveolar cells: Low (Uncertain); lung / macrophages: High (Uncertain); lymph node / germinal center cells: Medium (Uncertain); lymph node / non-germinal center cells: Medium (Uncertain); nasopharynx / respiratory epithelial cells: High (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); parathyroid gland / glandular cells: High (Uncertain); rectum / glandular cells: High (Uncertain); salivary gland / glandular cells: High (Uncertain); skeletal muscle / myocytes: Medium (Uncertain); skin 1 / fibroblasts: Medium (Uncertain); skin 1 / keratinocytes: Medium (Uncertain); skin 1 / Langerhans: Medium (Uncertain); skin 2 / epidermal cells: High (Uncertain); small intestine / glandular cells: High (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); spleen / cells in red pulp: Medium (Uncertain); spleen / cells in white pulp: High (Uncertain); stomach 1 / glandular cells: High (Uncertain); stomach 2 / glandular cells: High (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (TCGA): 141/141 (100.0%); Testicular Germ Cell Tumor (TCGA): 133/133 (100.0%),breast cancer: 12/12 (100.0%); cervical cancer: 12/12 (100.0%),31,20,Q9BSJ5,https://www.uniprot.org/uniprotkb/Q9BSJ5/entry,Critical regulator of mitochondrial DNA (mtDNA) abundance (PubMed:37676315). Binds dsDNA throughout the mitochondrial genome without sequence specificity and controls mtDNA copy number by promoting its replication (PubMed:37676315). Also plays important roles in mitochondrial metabolism and cell proliferation (PubMed:37676315),,,,"Mitochondrion inner membrane Mitochondrion matrix, mitochondrion nucleoid",37676315,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | Jamin2021_CT | Jamin2021_core,GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
MTNR1B,ENSG00000134640,Unsafe,Protein,False,True,1.0,1.0,92,12,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; cerebellum: 0 nTPM; positive ihc; cerebral cortex: 0.1 nTPM; positive ihc; skin: 0 nTPM; positive ihc; thyroid gland: 0 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,caudate / glial cells: High (Supported); caudate / neuronal cells: Medium (Supported); cerebellum / cells in molecular layer: Medium (Supported); cerebral cortex / glial cells: Low (Supported); cerebral cortex / neuronal cells: High (Supported); hippocampus / glial cells: High (Supported); retina / nerve fiber layer: High (Supported); skin 1 / fibroblasts: Medium (Supported); thyroid gland / glandular cells: Medium (Supported),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (TCGA): 16/362 (4.4%); Bladder Urothelial Carcinoma (TCGA): 6/169 (3.6%); Liver Hepatocellular Carcinoma (validation): 5/231 (2.2%),endometrial cancer: 2/12 (16.7%); melanoma: 2/12 (16.7%),31,20,P49286,https://www.uniprot.org/uniprotkb/P49286/entry,High affinity receptor for melatonin. Likely to mediate the reproductive and circadian actions of melatonin. The activity of this receptor is mediated by pertussis toxin sensitive G proteins that inhibit adenylate cyclase activity,Expressed in retina and less in brain and hippocampus,,,Cell membrane,,7568007,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Wang2016_CT | Gong2021_reproductive_PC,No tumor-antigen validation in this source | Cancer-associated RNA nomination; no antigen validation asserted | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
MTSS1,ENSG00000170873,Unsafe,Protein,False,True,34.5,70.7,85,57,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 23.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 35.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 20.1 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 15.9 nTPM; absolute ceiling;continuous selectivity; bone marrow: 12.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 42.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 23.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 10.4 nTPM; absolute ceiling;continuous selectivity; colon: 10.7 nTPM; positive ihc;absolute ceiling; duodenum: 6.3 nTPM; positive ihc;absolute ceiling; esophagus: 43.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 16.5 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 20 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 19.7 nTPM; absolute ceiling;continuous selectivity; kidney: 23.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 70.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 15.9 nTPM; absolute ceiling;continuous selectivity; lymph node: 15.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 20.4 nTPM; absolute ceiling;continuous selectivity; pancreas: 27.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 3.6 nTPM; positive ihc; pituitary gland: 10.7 nTPM; absolute ceiling;continuous selectivity; rectum: 8.8 nTPM; positive ihc;absolute ceiling; retina: 14.6 nTPM; absolute ceiling;continuous selectivity; salivary gland: 13.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 31.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 29.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 7.7 nTPM; positive ihc;absolute ceiling; smooth muscle: 9.3 nTPM; absolute ceiling; spinal cord: 31.6 nTPM; absolute ceiling;continuous selectivity; spleen: 33.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 11.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 17.9 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 5.9 nTPM; positive ihc; tongue: 23.7 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 15 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 23.7 nTPM (limit 10); adrenal gland: 35.1 nTPM (limit 2); amygdala: 20.1 nTPM (limit 2); basal ganglia: 15.9 nTPM (limit 2); bone marrow: 12.3 nTPM (limit 2); cerebellum: 42.6 nTPM (limit 2); cerebral cortex: 23.2 nTPM (limit 2); choroid plexus: 10.4 nTPM (limit 2); colon: 10.7 nTPM (limit 6); duodenum: 6.3 nTPM (limit 2); esophagus: 43.7 nTPM (limit 6); heart muscle: 16.5 nTPM (limit 4); hippocampal formation: 20 nTPM (limit 2); hypothalamus: 19.7 nTPM (limit 2); kidney: 23.3 nTPM (limit 2); liver: 70.7 nTPM (limit 2); lung: 15.9 nTPM (limit 4); lymph node: 15.6 nTPM (limit 6); midbrain: 20.4 nTPM (limit 2); pancreas: 27.6 nTPM (limit 2); pituitary gland: 10.7 nTPM (limit 2); rectum: 8.8 nTPM (limit 6); retina: 14.6 nTPM (limit 2); salivary gland: 13.5 nTPM (limit 6); skeletal muscle: 31.2 nTPM (limit 2); skin: 29.8 nTPM (limit 10); small intestine: 7.7 nTPM (limit 2); smooth muscle: 9.3 nTPM (limit 4); spinal cord: 31.6 nTPM (limit 2); spleen: 33.6 nTPM (limit 10); stomach: 11.7 nTPM (limit 6); thymus: 17.9 nTPM (limit 10); tongue: 23.7 nTPM (limit 6); urinary bladder: 15 nTPM (limit 6),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / glial cells: Low (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: Medium (Approved); hippocampus / glial cells: Low (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: High (Approved); liver / hepatocytes: Medium (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Low (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / fibroblasts: High (Approved); skin 1 / keratinocytes: Low (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: High (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Low (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Liver Hepatocellular Carcinoma (TCGA): 360/362 (99.4%); Pancreatic Adenocarcinoma (validation): 79/80 (98.8%),lung cancer: 12/12 (100.0%); testis cancer: 10/10 (100.0%),31,20,O43312,https://www.uniprot.org/uniprotkb/O43312/entry,"May be related to cancer progression or tumor metastasis in a variety of organ sites, most likely through an interaction with the actin cytoskeleton","Expressed in many tissues, including spleen, thymus, prostate, testis, uterus, colon, and peripheral blood",,,"Cytoplasm, cytoskeleton",,12082544,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
MYBL1,ENSG00000185697,Unsafe,Protein,False,True,11.4,19.7,77,19,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 0.7 nTPM; positive ihc; bone marrow: 2.5 nTPM; absolute ceiling; cerebellum: 1.4 nTPM; positive ihc; cerebral cortex: 1.5 nTPM; positive ihc; colon: 1 nTPM; positive ihc; duodenum: 1.2 nTPM; positive ihc; heart muscle: 3.3 nTPM; absolute ceiling;continuous selectivity; kidney: 0.4 nTPM; positive ihc; lung: 2.3 nTPM; absolute ceiling; lymph node: 19.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 0.2 nTPM; positive ihc; rectum: 1.4 nTPM; positive ihc; retina: 5.7 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 0.9 nTPM; positive ihc; small intestine: 1.8 nTPM; positive ihc; smooth muscle: 2.2 nTPM; absolute ceiling; spinal cord: 2.9 nTPM; absolute ceiling; spleen: 7.4 nTPM; continuous selectivity; stomach: 1.3 nTPM; positive ihc; thyroid gland: 0.6 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 2.5 nTPM (limit 2); heart muscle: 3.3 nTPM (limit 2); lung: 2.3 nTPM (limit 2); lymph node: 19.7 nTPM (limit 6); retina: 5.7 nTPM (limit 2); smooth muscle: 2.2 nTPM (limit 2); spinal cord: 2.9 nTPM (limit 2); bone marrow: 2.5 nTPM (baseline 2); heart muscle: 3.3 nTPM (baseline 2); lung: 2.3 nTPM (baseline 2); lymph node: 19.7 nTPM (baseline 6); retina: 5.7 nTPM (baseline 2); smooth muscle: 2.2 nTPM (baseline 2); spinal cord: 2.9 nTPM (baseline 2),adrenal gland / glandular cells: Low (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / neuronal cells: Low (Uncertain); colon / glandular cells: Medium (Uncertain); duodenum / glandular cells: Medium (Uncertain); kidney / cells in tubules: Medium (Uncertain); pancreas / exocrine glandular cells: Low (Uncertain); rectum / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: Low (Uncertain); small intestine / glandular cells: Medium (Uncertain); stomach 1 / glandular cells: Low (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Low (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Breast Invasive Carcinoma (validation): 46/50 (92.0%); Breast Invasive Carcinoma (TCGA): 341/1022 (33.4%),breast cancer: 0/10 (0.0%); cervical cancer: 0/11 (0.0%),31,20,P10243,https://www.uniprot.org/uniprotkb/P10243/entry,"Transcription factor that specifically recognizes the sequence 5'-YAAC[GT]G-3' (PubMed:7987850, PubMed:8058310). Acts as a master regulator of male meiosis by promoting expression of piRNAs: activates expression of both piRNA precursor RNAs and expression of protein-coding genes involved in piRNA metabolism (By similarity). The piRNA metabolic process mediates the repression of transposable elements during meiosis by forming complexes composed of piRNAs and Piwi proteins and governs the methylation and subsequent repression of transposons, which is essential for the germline integrity (By similarity). Transcriptional activator of SOX30 (By similarity)",Expressed in a variety of lymphoid and solid tumor lines cultured in vitro,,,Nucleus,7987850|8058310,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
MYBL2,ENSG00000101057,Unsafe,Protein,False,True,15.1,90.6,80,73,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 1.6 nTPM; positive ihc; adrenal gland: 0.6 nTPM; positive ihc; bone marrow: 90.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 0 nTPM; positive ihc; cerebral cortex: 0.5 nTPM; positive ihc; colon: 8.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 6.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 9.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 0.4 nTPM; positive ihc; kidney: 0.6 nTPM; positive ihc; liver: 1.1 nTPM; positive ihc; lung: 1.7 nTPM; positive ihc; lymph node: 54.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 10.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 0.1 nTPM; positive ihc; rectum: 6.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; salivary gland: 1.5 nTPM; positive ihc; skeletal muscle: 0.1 nTPM; positive ihc; skin: 4.1 nTPM; positive ihc; small intestine: 7.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 2 nTPM; positive ihc; spleen: 27.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; stomach: 5.9 nTPM; positive ihc;continuous selectivity; thymus: 32.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 0.5 nTPM; positive ihc; urinary bladder: 3.4 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 90.6 nTPM (limit 2); colon: 8.3 nTPM (limit 6); duodenum: 6.8 nTPM (limit 2); esophagus: 9.8 nTPM (limit 6); lymph node: 54.2 nTPM (limit 6); pancreas: 10.9 nTPM (limit 2); rectum: 6.7 nTPM (limit 6); small intestine: 7.6 nTPM (limit 2); spleen: 27.2 nTPM (limit 10); thymus: 32.4 nTPM (limit 10); bone marrow: 90.6 nTPM (baseline 2); colon: 8.3 nTPM (baseline 6); duodenum: 6.8 nTPM (baseline 2); esophagus: 9.8 nTPM (baseline 6); lymph node: 54.2 nTPM (baseline 6); pancreas: 10.9 nTPM (baseline 2); rectum: 6.7 nTPM (baseline 6); small intestine: 7.6 nTPM (baseline 2); spleen: 27.2 nTPM (baseline 10); thymus: 32.4 nTPM (baseline 10),adipose tissue / adipocytes: Medium (Uncertain); adrenal gland / glandular cells: High (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: High (Uncertain); caudate / glial cells: Medium (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: Low (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / endothelial cells: Low (Uncertain); cerebral cortex / glial cells: Medium (Uncertain); cerebral cortex / neuronal cells: Low (Uncertain); cerebral cortex / neuropil: Medium (Uncertain); colon / endothelial cells: Medium (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: Medium (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: Low (Uncertain); hippocampus / glial cells: Low (Uncertain); hippocampus / neuronal cells: Low (Uncertain); kidney / cells in glomeruli: Medium (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / cholangiocytes: Low (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / alveolar cells: Medium (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / non-germinal center cells: Medium (Uncertain); nasopharynx / respiratory epithelial cells: High (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: Medium (Uncertain); skin 1 / fibroblasts: Medium (Uncertain); skin 1 / keratinocytes: Medium (Uncertain); skin 1 / Langerhans: Medium (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: High (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); spleen / cells in red pulp: High (Uncertain); spleen / cells in white pulp: Medium (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: High (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 283/283 (100.0%); Colon Adenocarcinoma (TCGA): 254/254 (100.0%),pancreatic cancer: 10/11 (90.9%); testis cancer: 9/10 (90.0%),31,20,P10244,https://www.uniprot.org/uniprotkb/P10244/entry,"Transcription factor involved in the regulation of cell survival, proliferation, and differentiation. Transactivates the expression of the CLU gene",,,,Nucleus,10770937,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
MYCBPAP,ENSG00000136449,Unsafe,Protein,False,True,63.2,63.2,99,12,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; choroid plexus: 5 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 5 nTPM (limit 2),bronchus / ciliated cells (cell body): Low (Enhanced); bronchus / ciliated cells (cilia axoneme): High (Enhanced); bronchus / ciliated cells (tip of cilia): High (Enhanced); nasopharynx / ciliated cells (cilia axoneme): Medium (Enhanced); nasopharynx / ciliated cells (tip of cilia): Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 15/50 (30.0%); Glioblastoma Multiforme (validation): 5/58 (8.6%); Uterine Corpus Endometrial Carcinoma (TCGA): 12/176 (6.8%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q8TBZ2,https://www.uniprot.org/uniprotkb/Q8TBZ2/entry,"Plays a crucial role in centrosome-nuclear envelope docking during spermiogenesis, a key step for anchoring the centrosome to the nucleus that is essential for proper sperm flagellum biogenesis. Also required for acrosome biogenesis, manchette organization, and spermatid head morphogenesis, contributing to the complete and functional assembly of the sperm flagellum",Expressed specifically in testis,,,"Membrane Cytoplasm, cytoskeleton, flagellum axoneme Cell projection, cilium, flagellum Cytoplasmic vesicle, secretory vesicle, acrosome Cytoplasm",,12151104,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
MYH15,ENSG00000144821,Unsafe,Protein,False,True,0.6,3.1,79,16,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 0.3 nTPM; positive ihc;continuous selectivity; amygdala: 1.4 nTPM; continuous selectivity;reproductive not higher; basal ganglia: 1.2 nTPM; continuous selectivity;reproductive not higher; bone marrow: 0.1 nTPM; positive ihc; cerebellum: 0.6 nTPM; positive ihc;continuous selectivity;reproductive not higher; cerebral cortex: 1.2 nTPM; positive ihc;continuous selectivity;reproductive not higher; colon: 0.4 nTPM; continuous selectivity; duodenum: 0.4 nTPM; continuous selectivity; heart muscle: 0.4 nTPM; positive ihc;continuous selectivity; hippocampal formation: 1.4 nTPM; continuous selectivity;reproductive not higher; hypothalamus: 1.2 nTPM; continuous selectivity;reproductive not higher; liver: 0 nTPM; positive ihc; lung: 0.3 nTPM; positive ihc;continuous selectivity; midbrain: 1.8 nTPM; continuous selectivity;reproductive not higher; parathyroid gland: 0 nTPM; positive ihc; pituitary gland: 0.8 nTPM; continuous selectivity;reproductive not higher; retina: 3.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 0.2 nTPM; positive ihc; skin: 0.5 nTPM; positive ihc;continuous selectivity; small intestine: 0.6 nTPM; positive ihc;continuous selectivity;reproductive not higher; spinal cord: 1.7 nTPM; continuous selectivity;reproductive not higher; tongue: 2 nTPM; continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",retina: 3.1 nTPM (limit 2); retina: 3.1 nTPM (baseline 2),adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Low (Uncertain); caudate / glial cells: Low (Uncertain); cerebellum / cells in granular layer: Low (Uncertain); cerebellum / cells in molecular layer: Low (Uncertain); cerebral cortex / glial cells: Low (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / glial cells: Low (Uncertain); hippocampus / neuronal cells: Low (Uncertain); liver / hepatocytes: Low (Uncertain); lung / macrophages: Medium (Uncertain); parathyroid gland / glandular cells: Low (Uncertain); skeletal muscle / myocytes: Medium (Uncertain); skin 1 / Langerhans: Low (Uncertain); skin 2 / epidermal cells: Low (Uncertain); small intestine / glandular cells: Low (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 8/58 (13.8%); Pancreatic Adenocarcinoma (validation): 2/80 (2.5%); Lung Adenocarcinoma (validation): 2/105 (1.9%),glioma: 1/11 (9.1%); urothelial cancer: 1/11 (9.1%),31,20,Q9Y2K3,https://www.uniprot.org/uniprotkb/Q9Y2K3/entry,Muscle contraction,,,Represents a conventional myosin. This protein should not be confused with the unconventional myosin-15 (MYO15),"Cytoplasm, myofibril",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
MYO16,ENSG00000041515,Unsafe,RNA,False,True,1.0,2.5,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 1.4 nTPM; continuous selectivity;reproductive not higher; adrenal gland: 0.6 nTPM; continuous selectivity; amygdala: 0.7 nTPM; continuous selectivity; cerebellum: 0.4 nTPM; continuous selectivity; cerebral cortex: 2.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 0.8 nTPM; continuous selectivity; hippocampal formation: 0.9 nTPM; continuous selectivity; hypothalamus: 0.5 nTPM; continuous selectivity; liver: 1.8 nTPM; continuous selectivity;reproductive not higher; pituitary gland: 1.7 nTPM; continuous selectivity;reproductive not higher; retina: 0.4 nTPM; continuous selectivity; smooth muscle: 0.4 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebral cortex: 2.5 nTPM (limit 2); cerebral cortex: 2.5 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 45/58 (77.6%); Glioblastoma Multiforme (TCGA): 12/141 (8.5%); Breast Invasive Carcinoma (validation): 4/50 (8.0%),liver cancer: 2/12 (16.7%); renal cancer: 1/12 (8.3%),31,20,Q9Y6X6,https://www.uniprot.org/uniprotkb/Q9Y6X6/entry,"Myosins are actin-based motor molecules with ATPase activity. Unconventional myosins serve in intracellular movements. Their highly divergent tails are presumed to bind to membranous compartments, which would be moved relative to actin filaments. May be involved in targeting of the catalytic subunit of protein phosphatase 1 during brain development. Activates PI3K and concomitantly recruits the WAVE1 complex to the close vicinity of PI3K and regulates neuronal morphogenesis (By similarity)",,,,Cytoplasm,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
MYO3A,ENSG00000095777,Unsafe,Protein,False,True,5.0,15.0,87,28,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 0.1 nTPM; positive ihc; basal ganglia: 1.8 nTPM; continuous selectivity; colon: 0.1 nTPM; positive ihc; esophagus: 0.3 nTPM; positive ihc; kidney: 0.3 nTPM; positive ihc; lymph node: 0 nTPM; positive ihc; retina: 15 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 0 nTPM; positive ihc; skin: 0.7 nTPM; positive ihc; stomach: 0.2 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",retina: 15 nTPM (limit 2),adrenal gland / glandular cells: Medium (Enhanced); colon / glandular cells: Low (Enhanced); colon / peripheral nerve/ganglion: Medium (Enhanced); esophagus / squamous epithelial cells: Low (Enhanced); kidney / cells in glomeruli: Low (Enhanced); kidney / cells in tubules: Low (Enhanced); lymph node / non-germinal center cells: Low (Enhanced); oral mucosa / squamous epithelial cells: Low (Enhanced); pituitary gland / cells in anterior : High (Enhanced); retina / ganglion cells : Low (Enhanced); retina / nerve fiber layer: High (Enhanced); retina / outer plexiform layer: High (Enhanced); retina / photoreceptor cells: Medium (Enhanced); salivary gland / glandular cells: Low (Enhanced); skin 1 / keratinocytes: Low (Enhanced); stomach 2 / glandular cells: Low (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Renal Clear Cell Carcinoma (validation): 41/100 (41.0%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 91/283 (32.2%); Kidney Renal Clear Cell Carcinoma (TCGA): 105/521 (20.2%),renal cancer: 5/12 (41.7%); melanoma: 4/10 (40.0%),31,20,Q8NEV4,https://www.uniprot.org/uniprotkb/Q8NEV4/entry,"Actin-dependent motor protein with a protein kinase activity, playing an essential role in hearing (PubMed:12032315, PubMed:29880844, PubMed:34788109). Probably also plays a role in vision. Required for normal cochlear hair bundle development and hearing. Plays an important role in the early steps of cochlear hair bundle morphogenesis. Influences the number and lengths of stereocilia to be produced and limits the growth of microvilli within the forming auditory hair bundles thereby contributing to the architecture of the hair bundle, including its staircase pattern. Involved in the elongation of actin in stereocilia tips by transporting the actin regulatory factor ESPN to the plus ends of actin filaments (PubMed:29880844, PubMed:34788109)","Strongest expression in retina, retinal pigment epithelial cells, cochlea and pancreas","Deafness, autosomal recessive, 30: A form of non-syndromic deafness characterized by bilateral progressive hearing loss, which first affects the high frequencies. Hearing loss begins in the second decade, and by age 50 is severe in high and middle frequencies and moderate at low frequencies. Deafness, autosomal dominant, 90: A form of non-syndromic, sensorineural hearing loss. Sensorineural hearing loss results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. DFNA90 is characterized by bilateral progressive hearing loss that affects all frequencies.",,"Cytoplasm, cytoskeleton Cytoplasm Cell projection, filopodium tip Cell projection, stereocilium",12032315|29880844|34788109,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
MYO3B,ENSG00000071909,Unsafe,Protein,False,True,13.7,13.7,80,9,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; cerebral cortex: 0 nTPM; positive ihc; kidney: 5.1 nTPM; absolute ceiling;continuous selectivity; lung: 0 nTPM; positive ihc; parathyroid gland: 8.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 5.7 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",kidney: 5.1 nTPM (limit 4); parathyroid gland: 8.5 nTPM (limit 6); retina: 5.7 nTPM (limit 2),caudate / neuronal cells: Low (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); hippocampus / neuronal cells: Low (Approved); lung / macrophages: Low (Approved); parathyroid gland / glandular cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Adenocarcinoma (validation): 12/105 (11.4%); Kidney Chromophobe (TCGA): 6/64 (9.4%); Uterine Corpus Endometrial Carcinoma (TCGA): 16/176 (9.1%),renal cancer: 3/11 (27.3%); breast cancer: 2/12 (16.7%),31,20,Q8WXR4,https://www.uniprot.org/uniprotkb/Q8WXR4/entry,"Probable actin-based motor with a protein kinase activity. Required for normal cochlear hair bundle development and hearing. Plays an important role in the early steps of cochlear hair bundle morphogenesis. Influences the number and lengths of stereocilia to be produced and limits the growth of microvilli within the forming auditory hair bundles thereby contributing to the architecture of the hair bundle, including its staircase pattern. Involved in the elongation of actin in stereocilia tips by transporting the actin regulatory factor ESPN to the plus ends of actin filaments","Expressed in retina, kidney and testis",,,"Cytoplasm, cytoskeleton Cell projection, stereocilium",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
MYT1L,ENSG00000186487,Unsafe,RNA,False,True,5.4,39.4,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 17.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 28.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 36.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 39.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 23.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 18.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 7.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 14.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; retina: 4.6 nTPM; absolute ceiling;continuous selectivity; spinal cord: 3 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 17.4 nTPM (limit 2); basal ganglia: 28.7 nTPM (limit 2); cerebellum: 36.2 nTPM (limit 2); cerebral cortex: 39.4 nTPM (limit 2); hippocampal formation: 23.4 nTPM (limit 2); hypothalamus: 18.5 nTPM (limit 2); midbrain: 7.3 nTPM (limit 2); pituitary gland: 14.4 nTPM (limit 2); retina: 4.6 nTPM (limit 2); spinal cord: 3 nTPM (limit 2); amygdala: 17.4 nTPM (baseline 2); basal ganglia: 28.7 nTPM (baseline 2); cerebellum: 36.2 nTPM (baseline 2); cerebral cortex: 39.4 nTPM (baseline 2); hippocampal formation: 23.4 nTPM (baseline 2); hypothalamus: 18.5 nTPM (baseline 2); midbrain: 7.3 nTPM (baseline 2); pituitary gland: 14.4 nTPM (baseline 2); retina: 4.6 nTPM (baseline 2); spinal cord: 3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 18/58 (31.0%); Testicular Germ Cell Tumor (TCGA): 13/133 (9.8%); Uterine Corpus Endometrial Carcinoma (TCGA): 16/176 (9.1%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9UL68,https://www.uniprot.org/uniprotkb/Q9UL68/entry,"Transcription factor that plays a key role in neuronal differentiation by specifically repressing expression of non-neuronal genes during neuron differentiation. In contrast to other transcription repressors that inhibit specific lineages, mediates repression of multiple differentiation programs. Also represses expression of negative regulators of neurogenesis, such as members of the Notch signaling pathway, including HES1. The combination of three transcription factors, ASCL1, POU3F2/BRN2 and MYT1L, is sufficient to reprogram fibroblasts and other somatic cells into induced neuronal (iN) cells in vitro. Directly binds the 5'-AAGTT-3' core motif present on the promoter of target genes and represses transcription by recruiting a multiprotein complex containing SIN3B. The 5'-AAGTT-3' core motif is absent from the promoter of neural genes",,"Intellectual developmental disorder, autosomal dominant 39: A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRD39 patients show delayed psychomotor development and autistic features.",,Nucleus Chromosome,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
N4BP2,ENSG00000078177,Unsafe,Protein,False,True,3.4,11.0,86,66,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0.9 nTPM; positive ihc; adrenal gland: 0.7 nTPM; positive ihc; bone marrow: 4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 0.4 nTPM; positive ihc; cerebral cortex: 0.8 nTPM; positive ihc; colon: 2 nTPM; positive ihc;continuous selectivity; duodenum: 2.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 1.6 nTPM; positive ihc;continuous selectivity; heart muscle: 1.1 nTPM; positive ihc;continuous selectivity; kidney: 1.4 nTPM; positive ihc;continuous selectivity; liver: 5.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 1.6 nTPM; positive ihc;continuous selectivity; lymph node: 3.5 nTPM; positive ihc;continuous selectivity;reproductive not higher; pancreas: 4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 1.3 nTPM; positive ihc;continuous selectivity; pituitary gland: 1.2 nTPM; continuous selectivity; rectum: 2.1 nTPM; positive ihc;continuous selectivity; retina: 2 nTPM; continuous selectivity; salivary gland: 3.2 nTPM; positive ihc;continuous selectivity; skeletal muscle: 0.7 nTPM; positive ihc; skin: 1.8 nTPM; positive ihc;continuous selectivity; small intestine: 2 nTPM; positive ihc;continuous selectivity; smooth muscle: 0.7 nTPM; positive ihc; spleen: 1.8 nTPM; positive ihc;continuous selectivity; stomach: 1.8 nTPM; positive ihc;continuous selectivity; thymus: 11 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 3.2 nTPM; positive ihc;continuous selectivity; urinary bladder: 1.9 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 4 nTPM (limit 2); duodenum: 2.1 nTPM (limit 2); liver: 5.4 nTPM (limit 2); pancreas: 4 nTPM (limit 2); thymus: 11 nTPM (limit 10),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Low (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Medium (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Low (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Pancreatic Adenocarcinoma (validation): 74/80 (92.5%); Breast Invasive Carcinoma (validation): 38/50 (76.0%),ovarian cancer: 5/12 (41.7%); colorectal cancer: 4/10 (40.0%),31,20,Q86UW6,https://www.uniprot.org/uniprotkb/Q86UW6/entry,"Has 5'-polynucleotide kinase and nicking endonuclease activity. May play a role in DNA repair or recombination (PubMed:12730195). May play a role in the non-stop mRNA decay pathway (NSD), which specifically targets and degrades mRNAs that lack a proper stop codon (PubMed:40441874)",,,,Cytoplasm,12730195|40441874,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
NAALADL2,ENSG00000177694,Unsafe,Protein,False,True,6.1,9.9,89,30,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 2.3 nTPM; positive ihc; cerebral cortex: 1 nTPM; positive ihc; colon: 2.9 nTPM; positive ihc;continuous selectivity; heart muscle: 2.5 nTPM; continuous selectivity; kidney: 3.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 2.8 nTPM; continuous selectivity; lung: 1.9 nTPM; positive ihc;continuous selectivity; pancreas: 2.1 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 9.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; rectum: 2.3 nTPM; positive ihc;continuous selectivity; salivary gland: 5.6 nTPM; positive ihc;continuous selectivity; skeletal muscle: 0.9 nTPM; positive ihc; skin: 0.7 nTPM; positive ihc; smooth muscle: 3.4 nTPM; continuous selectivity; urinary bladder: 3.7 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",kidney: 3.2 nTPM (limit 2); pancreas: 2.1 nTPM (limit 2); parathyroid gland: 9.9 nTPM (limit 6),adipose tissue / adipocytes: Low (Approved); bronchus / ciliated cells (cell body): Medium (Approved); cerebral cortex / neuronal cells: Low (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Low (Approved); colon / peripheral nerve/ganglion: Low (Approved); kidney / cells in tubules: Low (Approved); lung / macrophages: Low (Approved); nasopharynx / ciliated cells (cell body): Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Low (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / keratinocytes: Low (Approved); skin 2 / epidermal cells: Low (Approved); urinary bladder / urothelial cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 199/207 (96.1%); Pancreatic Adenocarcinoma (validation): 75/80 (93.8%); Glioblastoma Multiforme (validation): 53/58 (91.4%),prostate cancer: 11/11 (100.0%); endometrial cancer: 9/11 (81.8%),31,20,Q58DX5,https://www.uniprot.org/uniprotkb/Q58DX5/entry,May be catalytically inactive,"Expressed at higher level in kidney and placenta. In embryo, it is mainly confined to duodenal and stomach endoderm, mesonephros, metanephros and pancreas",,"Although related to the peptidase M28 family, it lacks the conserved zinc-binding and active sites and therefore has probably lost hydrolase activity",Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
NACA2,ENSG00000253506,Unsafe,High RNA,False,True,62.4,62.4,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 85/91 values ≥5 TPM, max 22.8848; DICE MONOCYTES (unstimulated): 49/91 values ≥5 TPM, max 13.1908; DICE M2 (unstimulated): 46/90 values ≥5 TPM, max 10.4026; DICE NK (unstimulated): 23/90 values ≥5 TPM, max 10.2957; DICE TREG_MEM (unstimulated): 36/89 values ≥5 TPM, max 9.60467; DICE CD4_NAIVE (unstimulated): 67/88 values ≥5 TPM, max 28.3405; DICE CD4_STIM (activated): 59/88 values ≥5 TPM, max 14.5424; DICE TREG_NAIVE (unstimulated): 15/89 values ≥5 TPM, max 12.2987; DICE TFH (unstimulated): 66/89 values ≥5 TPM, max 12.6563; DICE TH1 (unstimulated): 55/81 values ≥5 TPM, max 14.0755; DICE THSTAR (unstimulated): 74/88 values ≥5 TPM, max 19.1347; DICE TH17 (unstimulated): 88/89 values ≥5 TPM, max 17.679; DICE TH2 (unstimulated): 66/89 values ≥5 TPM, max 18.598; DICE CD8_NAIVE (unstimulated): 89/89 values ≥5 TPM, max 19.2424; DICE CD8_STIM (activated): 55/88 values ≥5 TPM, max 9.54639",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,28.3404782871,289.4,"hpa_single_cell_tissue: bronchus/smooth muscle cells, max 289.4 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,28.34 TPM; blood/CD4_NAIVE; dice_cd4_naive; vital,289.4 nTPM; bronchus/smooth muscle cells; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (validation): 10/50 (20.0%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 10/283 (3.5%); Uterine Corpus Endometrial Carcinoma (TCGA): 4/176 (2.3%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9H009,https://www.uniprot.org/uniprotkb/Q9H009/entry,"Prevents inappropriate targeting of non-secretory polypeptides to the endoplasmic reticulum (ER). Binds to nascent polypeptide chains as they emerge from the ribosome and blocks their interaction with the signal recognition particle (SRP), which normally targets nascent secretory peptides to the ER. Also reduces the inherent affinity of ribosomes for protein translocation sites in the ER membrane (M sites) (By similarity)",Expressed specifically in testis and skeletal muscle,,,Cytoplasm Nucleus,,16201836,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | Gong2021_reproductive_PC,GC RNA nomination across cancer types; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
NBPF6,ENSG00000186086,Unsafe,RNA,False,True,2.6,2.7,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,liver: 2.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 0.8 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,liver: 2.7 nTPM (limit 2); liver: 2.7 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 31/50 (62.0%); Breast Invasive Carcinoma (TCGA): 231/1022 (22.6%); Rectum Adenocarcinoma (validation): 9/207 (4.3%),melanoma: 6/12 (50.0%); urothelial cancer: 4/12 (33.3%),31,20,Q5VWK0,https://www.uniprot.org/uniprotkb/Q5VWK0/entry,,,,,Cytoplasm,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
NCAPG2,ENSG00000146918,Unsafe,Protein,False,True,14.4,27.2,79,71,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 2.4 nTPM; positive ihc;absolute ceiling; amygdala: 2.4 nTPM; absolute ceiling; basal ganglia: 2.6 nTPM; absolute ceiling; bone marrow: 24.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 2.5 nTPM; positive ihc;absolute ceiling; cerebral cortex: 3.3 nTPM; positive ihc;absolute ceiling; colon: 6.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 4.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 6.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 2.8 nTPM; positive ihc;absolute ceiling; hippocampal formation: 2.6 nTPM; absolute ceiling; kidney: 2.5 nTPM; positive ihc;absolute ceiling; liver: 4 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 3 nTPM; positive ihc;absolute ceiling; lymph node: 12.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 2.3 nTPM; absolute ceiling; pancreas: 2.1 nTPM; positive ihc;absolute ceiling; parathyroid gland: 4.5 nTPM; positive ihc; pituitary gland: 3.4 nTPM; absolute ceiling; rectum: 7.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 2.7 nTPM; absolute ceiling; salivary gland: 3.4 nTPM; positive ihc; skeletal muscle: 3.3 nTPM; positive ihc;absolute ceiling; skin: 6.6 nTPM; positive ihc;continuous selectivity; small intestine: 5.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 4.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 3 nTPM; absolute ceiling; spleen: 4.4 nTPM; positive ihc; stomach: 5.4 nTPM; positive ihc;continuous selectivity; thymus: 27.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 3.1 nTPM; positive ihc; urinary bladder: 3.9 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 2.4 nTPM (limit 2); amygdala: 2.4 nTPM (limit 2); basal ganglia: 2.6 nTPM (limit 2); bone marrow: 24.1 nTPM (limit 2); cerebellum: 2.5 nTPM (limit 2); cerebral cortex: 3.3 nTPM (limit 2); colon: 6.7 nTPM (limit 6); duodenum: 4.3 nTPM (limit 2); esophagus: 6.7 nTPM (limit 6); heart muscle: 2.8 nTPM (limit 2); hippocampal formation: 2.6 nTPM (limit 2); kidney: 2.5 nTPM (limit 2); liver: 4 nTPM (limit 2); lung: 3 nTPM (limit 2); lymph node: 12.1 nTPM (limit 6); midbrain: 2.3 nTPM (limit 2); pancreas: 2.1 nTPM (limit 2); pituitary gland: 3.4 nTPM (limit 2); rectum: 7.4 nTPM (limit 6); retina: 2.7 nTPM (limit 2); skeletal muscle: 3.3 nTPM (limit 2); small intestine: 5.6 nTPM (limit 2); smooth muscle: 4.7 nTPM (limit 2); spinal cord: 3 nTPM (limit 2); thymus: 27.2 nTPM (limit 10),adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: High (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / glial cells: Medium (Approved); caudate / neuronal cells: High (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: High (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / glial cells: High (Approved); cerebral cortex / neuronal cells: High (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: High (Approved); hippocampus / glial cells: Medium (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: High (Approved); oral mucosa / squamous epithelial cells: High (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: High (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: High (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 485/486 (99.8%),breast cancer: 12/12 (100.0%); ovarian cancer: 12/12 (100.0%),31,20,Q86XI2,https://www.uniprot.org/uniprotkb/Q86XI2/entry,"Regulatory subunit of the condensin-2 complex, a complex which establishes mitotic chromosome architecture and is involved in physical rigidity of the chromatid axis",,"Khan-Khan-Katsanis syndrome: An autosomal recessive neurodevelopmental disorder characterized by multiple congenital anomalies affecting the ocular, renal, skeletal, and sometimes cardiac systems, defects in urogenital and limb morphogenesis, poor overall growth, microcephaly, and global developmental delay.",,Nucleus,14532007|30609410,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
NCAPH,ENSG00000121152,Unsafe,Protein,False,True,34.3,36.4,104,23,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 34.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 0.4 nTPM; positive ihc; lymph node: 19.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; rectum: 9 nTPM; positive ihc;absolute ceiling; skin: 4.6 nTPM; positive ihc; spleen: 3.6 nTPM; positive ihc; stomach: 3.5 nTPM; positive ihc; thymus: 36.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 2.5 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 34.8 nTPM (limit 2); lymph node: 19.9 nTPM (limit 6); rectum: 9 nTPM (limit 6); thymus: 36.4 nTPM (limit 10),bone marrow / hematopoietic cells: Medium (Enhanced); heart muscle / cardiomyocytes: Low (Enhanced); lymph node / germinal center cells: Medium (Enhanced); rectum / glandular cells: Low (Enhanced); skin 1 / cells in basal layer: Low (Enhanced); skin 1 / cells in spinous layer: Low (Enhanced); skin 1 / eccrine glands: Medium (Enhanced); skin 2 / cells in basal layer: Medium (Enhanced); skin 2 / cells in spinous layer: High (Enhanced); skin 2 / lymphocytes: Medium (Enhanced); spleen / cells in red pulp: Low (Enhanced); stomach 1 / glandular cells: Low (Enhanced); urinary bladder / urothelial cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (TCGA): 253/254 (99.6%); Colon Adenocarcinoma (validation): 483/486 (99.4%); Testicular Germ Cell Tumor (TCGA): 132/133 (99.2%),lymphoma: 9/12 (75.0%); endometrial cancer: 8/11 (72.7%),31,20,Q15003,https://www.uniprot.org/uniprotkb/Q15003/entry,"Regulatory subunit of the condensin complex, a complex required for conversion of interphase chromatin into mitotic-like condense chromosomes. The condensin complex probably introduces positive supercoils into relaxed DNA in the presence of type I topoisomerases and converts nicked DNA into positive knotted forms in the presence of type II topoisomerases (PubMed:11136719). Early in neurogenesis, may play an essential role to ensure accurate mitotic chromosome condensation in neuron stem cells, ultimately affecting neuron pool and cortex size (PubMed:27737959)",Widely expressed at low level. Expressed in proliferating cells,"Microcephaly 23, primary, autosomal recessive: A form of microcephaly, a disease defined as a head circumference more than 3 standard deviations below the age, sex and ethnically matched mean. Brain weight is markedly reduced and the cerebral cortex is disproportionately small.",,Nucleus Cytoplasm Chromosome,11136719|27737959,11694586,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
NCKAP5,ENSG00000176771,Unsafe,RNA,False,True,2.9,11.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 1.7 nTPM; continuous selectivity; adrenal gland: 1 nTPM; continuous selectivity; amygdala: 3.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 4.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 0.9 nTPM; continuous selectivity; cerebral cortex: 2.5 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 1.9 nTPM; continuous selectivity; colon: 1.1 nTPM; continuous selectivity; duodenum: 2.1 nTPM; absolute ceiling;continuous selectivity; esophagus: 3.8 nTPM; continuous selectivity;reproductive not higher; heart muscle: 2.5 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 4.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 2.8 nTPM; absolute ceiling;continuous selectivity; kidney: 3.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; liver: 3.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 11.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 1.3 nTPM; continuous selectivity; midbrain: 5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 1 nTPM; continuous selectivity; retina: 4.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 2 nTPM; continuous selectivity; skin: 2 nTPM; continuous selectivity; small intestine: 3.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 4.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 1.7 nTPM; continuous selectivity; stomach: 1.7 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 3.6 nTPM (limit 2); basal ganglia: 4.1 nTPM (limit 2); cerebral cortex: 2.5 nTPM (limit 2); duodenum: 2.1 nTPM (limit 2); heart muscle: 2.5 nTPM (limit 2); hippocampal formation: 4.2 nTPM (limit 2); hypothalamus: 2.8 nTPM (limit 2); kidney: 3.9 nTPM (limit 2); liver: 3.9 nTPM (limit 2); lung: 11.1 nTPM (limit 2); midbrain: 5 nTPM (limit 2); retina: 4.6 nTPM (limit 2); small intestine: 3.1 nTPM (limit 2); spinal cord: 4.9 nTPM (limit 2); amygdala: 3.6 nTPM (baseline 2); basal ganglia: 4.1 nTPM (baseline 2); cerebral cortex: 2.5 nTPM (baseline 2); duodenum: 2.1 nTPM (baseline 2); heart muscle: 2.5 nTPM (baseline 2); hippocampal formation: 4.2 nTPM (baseline 2); hypothalamus: 2.8 nTPM (baseline 2); kidney: 3.9 nTPM (baseline 2); liver: 3.9 nTPM (baseline 2); lung: 11.1 nTPM (baseline 2); midbrain: 5 nTPM (baseline 2); retina: 4.6 nTPM (baseline 2); small intestine: 3.1 nTPM (baseline 2); spinal cord: 4.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Breast Invasive Carcinoma (validation): 36/50 (72.0%); Lung Squamous Cell Carcinoma (validation): 28/68 (41.2%),liver cancer: 7/12 (58.3%); prostate cancer: 7/12 (58.3%),31,20,O14513,https://www.uniprot.org/uniprotkb/O14513/entry,,"Expressed in fetal and adult brain, leukocytes and fetal fibroblasts",,It is uncertain whether Met-1 or Met-26 is the initiator,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
NDUFA11,ENSG00000174886,Unsafe,RNA,False,True,221.3,664.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 192.6 nTPM; absolute ceiling;continuous selectivity; adrenal gland: 416.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 296.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 250.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 155.9 nTPM; absolute ceiling;continuous selectivity; cerebellum: 172.8 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 266.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 271.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 301.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 121.1 nTPM; absolute ceiling;continuous selectivity; esophagus: 275.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 664.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 249.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 275 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 282.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; liver: 371.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 150.4 nTPM; absolute ceiling;continuous selectivity; lymph node: 141.6 nTPM; absolute ceiling;continuous selectivity; midbrain: 295.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 199.8 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 133.6 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 200.5 nTPM; absolute ceiling;continuous selectivity; rectum: 54.2 nTPM; absolute ceiling; retina: 30.7 nTPM; absolute ceiling; salivary gland: 224.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 410.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 181.8 nTPM; absolute ceiling;continuous selectivity; small intestine: 180.3 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 86.1 nTPM; absolute ceiling;continuous selectivity; spinal cord: 258 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 191.7 nTPM; absolute ceiling;continuous selectivity; stomach: 242.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thymus: 117.3 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 183.2 nTPM; absolute ceiling;continuous selectivity; tongue: 317.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 202.5 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adipose tissue: 192.6 nTPM (limit 10); adrenal gland: 416.4 nTPM (limit 2); amygdala: 296.9 nTPM (limit 2); basal ganglia: 250.5 nTPM (limit 2); bone marrow: 155.9 nTPM (limit 2); cerebellum: 172.8 nTPM (limit 2); cerebral cortex: 266.3 nTPM (limit 2); choroid plexus: 271.5 nTPM (limit 2); colon: 301.7 nTPM (limit 6); duodenum: 121.1 nTPM (limit 2); esophagus: 275.4 nTPM (limit 6); heart muscle: 664.8 nTPM (limit 2); hippocampal formation: 249.6 nTPM (limit 2); hypothalamus: 275 nTPM (limit 2); kidney: 282.2 nTPM (limit 2); liver: 371.2 nTPM (limit 2); lung: 150.4 nTPM (limit 2); lymph node: 141.6 nTPM (limit 6); midbrain: 295.2 nTPM (limit 2); pancreas: 199.8 nTPM (limit 2); parathyroid gland: 133.6 nTPM (limit 6); pituitary gland: 200.5 nTPM (limit 2); rectum: 54.2 nTPM (limit 6); retina: 30.7 nTPM (limit 2); salivary gland: 224.1 nTPM (limit 6); skeletal muscle: 410.6 nTPM (limit 2); skin: 181.8 nTPM (limit 10); small intestine: 180.3 nTPM (limit 2); smooth muscle: 86.1 nTPM (limit 2); spinal cord: 258 nTPM (limit 2); spleen: 191.7 nTPM (limit 10); stomach: 242.9 nTPM (limit 6); thymus: 117.3 nTPM (limit 10); thyroid gland: 183.2 nTPM (limit 10); tongue: 317.1 nTPM (limit 6); urinary bladder: 202.5 nTPM (limit 6); adipose tissue: 192.6 nTPM (baseline 10); adrenal gland: 416.4 nTPM (baseline 2); amygdala: 296.9 nTPM (baseline 2); basal ganglia: 250.5 nTPM (baseline 2); bone marrow: 155.9 nTPM (baseline 2); cerebellum: 172.8 nTPM (baseline 2); cerebral cortex: 266.3 nTPM (baseline 2); choroid plexus: 271.5 nTPM (baseline 2); colon: 301.7 nTPM (baseline 6); duodenum: 121.1 nTPM (baseline 2); esophagus: 275.4 nTPM (baseline 6); heart muscle: 664.8 nTPM (baseline 2); hippocampal formation: 249.6 nTPM (baseline 2); hypothalamus: 275 nTPM (baseline 2); kidney: 282.2 nTPM (baseline 2); liver: 371.2 nTPM (baseline 2); lung: 150.4 nTPM (baseline 2); lymph node: 141.6 nTPM (baseline 6); midbrain: 295.2 nTPM (baseline 2); pancreas: 199.8 nTPM (baseline 2); parathyroid gland: 133.6 nTPM (baseline 6); pituitary gland: 200.5 nTPM (baseline 2); rectum: 54.2 nTPM (baseline 6); retina: 30.7 nTPM (baseline 2); salivary gland: 224.1 nTPM (baseline 6); skeletal muscle: 410.6 nTPM (baseline 2); skin: 181.8 nTPM (baseline 10); small intestine: 180.3 nTPM (baseline 2); smooth muscle: 86.1 nTPM (baseline 2); spinal cord: 258 nTPM (baseline 2); spleen: 191.7 nTPM (baseline 10); stomach: 242.9 nTPM (baseline 6); thymus: 117.3 nTPM (baseline 10); thyroid gland: 183.2 nTPM (baseline 10); tongue: 317.1 nTPM (baseline 6); urinary bladder: 202.5 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%); Thyroid Carcinoma (TCGA): 495/495 (100.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q86Y39,https://www.uniprot.org/uniprotkb/Q86Y39/entry,"Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone",,"Mitochondrial complex I deficiency, nuclear type 14: A form of mitochondrial complex I deficiency, the most common biochemical signature of mitochondrial disorders, a group of highly heterogeneous conditions characterized by defective oxidative phosphorylation, which collectively affects 1 in 5-10000 live births. Clinical disorders have variable severity, ranging from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. MC1DN14 transmission pattern is consistent with autosomal recessive inheritance.",,Mitochondrion inner membrane,27626371,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
NDUFA2,ENSG00000131495,Unsafe,Protein,False,True,77.5,274.0,76,73,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 73.4 nTPM; absolute ceiling;continuous selectivity; adrenal gland: 124 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 124.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 119.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 94.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 68.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 115.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 241.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 78.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 87.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 71.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 191.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 103.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 108 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 141 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 141.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 51.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 64.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 124.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 78.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 96.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 77 nTPM; absolute ceiling;continuous selectivity; rectum: 59 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 50.2 nTPM; absolute ceiling;continuous selectivity; salivary gland: 99 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 274 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 50.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 83.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 30.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 95.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 70.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 88.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; thymus: 76 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 62.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 223.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 53.4 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 73.4 nTPM (limit 10); adrenal gland: 124 nTPM (limit 2); amygdala: 124.6 nTPM (limit 2); basal ganglia: 119.7 nTPM (limit 2); bone marrow: 94.6 nTPM (limit 2); cerebellum: 68.6 nTPM (limit 2); cerebral cortex: 115.7 nTPM (limit 2); choroid plexus: 241.3 nTPM (limit 2); colon: 78.2 nTPM (limit 6); duodenum: 87.5 nTPM (limit 2); esophagus: 71.4 nTPM (limit 6); heart muscle: 191.1 nTPM (limit 2); hippocampal formation: 103.5 nTPM (limit 2); hypothalamus: 108 nTPM (limit 2); kidney: 141 nTPM (limit 2); liver: 141.5 nTPM (limit 2); lung: 51.7 nTPM (limit 2); lymph node: 64.4 nTPM (limit 6); midbrain: 124.2 nTPM (limit 2); pancreas: 78.9 nTPM (limit 2); parathyroid gland: 96.2 nTPM (limit 6); pituitary gland: 77 nTPM (limit 2); rectum: 59 nTPM (limit 6); retina: 50.2 nTPM (limit 2); salivary gland: 99 nTPM (limit 6); skeletal muscle: 274 nTPM (limit 2); skin: 50.7 nTPM (limit 10); small intestine: 83.6 nTPM (limit 2); smooth muscle: 30.4 nTPM (limit 2); spinal cord: 95.2 nTPM (limit 2); spleen: 70.9 nTPM (limit 10); stomach: 88.2 nTPM (limit 6); thymus: 76 nTPM (limit 10); thyroid gland: 62.2 nTPM (limit 10); tongue: 223.4 nTPM (limit 6); urinary bladder: 53.4 nTPM (limit 6),adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Medium (Approved); caudate / neuronal cells: High (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: High (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: High (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: High (Approved); hippocampus / glial cells: Medium (Approved); hippocampus / neuronal cells: High (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / non-germinal center cells: High (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: High (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: High (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Low (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Kidney Renal Clear Cell Carcinoma (TCGA): 521/521 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%),prostate cancer: 10/12 (83.3%); breast cancer: 9/11 (81.8%),31,20,O43678,https://www.uniprot.org/uniprotkb/O43678/entry,"Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone",,"Mitochondrial complex I deficiency, nuclear type 13: A form of mitochondrial complex I deficiency, the most common biochemical signature of mitochondrial disorders, a group of highly heterogeneous conditions characterized by defective oxidative phosphorylation, which collectively affects 1 in 5-10000 live births. Clinical disorders have variable severity, ranging from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. MC1DN13 transmission pattern is consistent with autosomal recessive inheritance.",,Mitochondrion inner membrane,27626371,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
NDUFA7,ENSG00000267855,Unsafe,Protein,False,True,52.5,237.0,110,91,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 84.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 80.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 86 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 33.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 36.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 71.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 174.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 45.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 23.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 56 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 162.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 61.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 62.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 85.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 81.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 30.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 28.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 77.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 35.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 99.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 84.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 32.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 31.2 nTPM; absolute ceiling;continuous selectivity; salivary gland: 42.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 237 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 29.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 33 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 21.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 43.9 nTPM; absolute ceiling;continuous selectivity; spleen: 41 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 53.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; thymus: 39.7 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 40.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 232.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 34.4 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 84.8 nTPM (limit 2); amygdala: 80.3 nTPM (limit 2); basal ganglia: 86 nTPM (limit 2); bone marrow: 33.7 nTPM (limit 2); cerebellum: 36.9 nTPM (limit 2); cerebral cortex: 71.5 nTPM (limit 2); choroid plexus: 174.9 nTPM (limit 2); colon: 45.2 nTPM (limit 6); duodenum: 23.4 nTPM (limit 2); esophagus: 56 nTPM (limit 6); heart muscle: 162.7 nTPM (limit 2); hippocampal formation: 61.2 nTPM (limit 2); hypothalamus: 62.4 nTPM (limit 2); kidney: 85.9 nTPM (limit 2); liver: 81.4 nTPM (limit 2); lung: 30.1 nTPM (limit 2); lymph node: 28.8 nTPM (limit 6); midbrain: 77.6 nTPM (limit 2); pancreas: 35.9 nTPM (limit 2); parathyroid gland: 99.6 nTPM (limit 6); pituitary gland: 84.1 nTPM (limit 2); rectum: 32.4 nTPM (limit 6); retina: 31.2 nTPM (limit 2); salivary gland: 42.2 nTPM (limit 6); skeletal muscle: 237 nTPM (limit 2); skin: 29.8 nTPM (limit 10); small intestine: 33 nTPM (limit 2); smooth muscle: 21.9 nTPM (limit 2); spinal cord: 43.9 nTPM (limit 2); spleen: 41 nTPM (limit 10); stomach: 53.2 nTPM (limit 6); thymus: 39.7 nTPM (limit 10); thyroid gland: 40.1 nTPM (limit 10); tongue: 232.8 nTPM (limit 6); urinary bladder: 34.4 nTPM (limit 6),adrenal gland / glandular cells: High (Enhanced); bone marrow / hematopoietic cells: Low (Enhanced); bronchus / respiratory epithelial cells: High (Enhanced); caudate / glial cells: Low (Enhanced); caudate / neuronal cells: High (Enhanced); cerebellum / cells in granular layer: High (Enhanced); cerebellum / cells in molecular layer: Medium (Enhanced); cerebellum / Purkinje cells: High (Enhanced); cerebral cortex / glial cells: Medium (Enhanced); cerebral cortex / neuronal cells: High (Enhanced); cerebral cortex / neuropil: Medium (Enhanced); colon / endothelial cells: Medium (Enhanced); colon / glandular cells: High (Enhanced); duodenum / glandular cells: High (Enhanced); esophagus / squamous epithelial cells: Medium (Enhanced); heart muscle / cardiomyocytes: High (Enhanced); hippocampus / glial cells: Low (Enhanced); hippocampus / neuronal cells: High (Enhanced); kidney / cells in glomeruli: Medium (Enhanced); kidney / cells in tubules: High (Enhanced); liver / cholangiocytes: Medium (Enhanced); liver / hepatocytes: Medium (Enhanced); lung / alveolar cells type I: Medium (Enhanced); lung / alveolar cells type II: Medium (Enhanced); lung / macrophages: Medium (Enhanced); lymph node / germinal center cells: Medium (Enhanced); lymph node / non-germinal center cells: Low (Enhanced); nasopharynx / respiratory epithelial cells: Medium (Enhanced); oral mucosa / squamous epithelial cells: Medium (Enhanced); pancreas / exocrine glandular cells: Medium (Enhanced); pancreas / pancreatic endocrine cells: Medium (Enhanced); parathyroid gland / glandular cells: Medium (Enhanced); rectum / glandular cells: High (Enhanced); salivary gland / glandular cells: Medium (Enhanced); skeletal muscle / myocytes: Medium (Enhanced); skin 1 / cells in basal layer: Medium (Enhanced); skin 1 / cells in granular layer: Medium (Enhanced); skin 1 / cells in spinous layer: Medium (Enhanced); skin 1 / endothelial cells: Low (Enhanced); skin 1 / langerhans cells: Medium (Enhanced); skin 1 / lymphocytes: Low (Enhanced); skin 1 / vascular mural cells: Low (Enhanced); skin 2 / arrector pili muscle cells: Low (Enhanced); skin 2 / cells in basal layer: Medium (Enhanced); skin 2 / cells in granular layer: Medium (Enhanced); skin 2 / cells in spinous layer: Medium (Enhanced); skin 2 / endothelial cells: Low (Enhanced); skin 2 / langerhans cells: Medium (Enhanced); skin 2 / lymphocytes: Low (Enhanced); skin 2 / sebaceous glands: Medium (Enhanced); skin 2 / vascular mural cells: Low (Enhanced); small intestine / glandular cells: High (Enhanced); smooth muscle / smooth muscle cells: Medium (Enhanced); spleen / cells in red pulp: Low (Enhanced); spleen / cells in white pulp: Low (Enhanced); stomach 1 / glandular cells: High (Enhanced); stomach 2 / glandular cells: High (Enhanced); thyroid gland / glandular cells: High (Enhanced); urinary bladder / urothelial cells: High (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Kidney Renal Clear Cell Carcinoma (TCGA): 521/521 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%),breast cancer: 12/12 (100.0%); lymphoma: 11/12 (91.7%),31,20,O95182,https://www.uniprot.org/uniprotkb/O95182/entry,"Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone",,,,Mitochondrion inner membrane,27626371,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
NEBL,ENSG00000078114,Unsafe,Protein,False,True,12.5,301.0,87,30,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 2.5 nTPM; positive ihc;absolute ceiling; amygdala: 40.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 42.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 42.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 39.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 1.3 nTPM; positive ihc; duodenum: 0 nTPM; positive ihc; esophagus: 15.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 301 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 31.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 34.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 12.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 1.2 nTPM; positive ihc; lung: 15.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 0.2 nTPM; positive ihc; midbrain: 36.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 6.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 1.2 nTPM; positive ihc; pituitary gland: 21.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 0.9 nTPM; positive ihc; retina: 2.5 nTPM; absolute ceiling; salivary gland: 17.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 14.4 nTPM; continuous selectivity;reproductive not higher; small intestine: 1.3 nTPM; positive ihc; spinal cord: 24.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 0.2 nTPM; positive ihc; stomach: 3.1 nTPM; positive ihc; thyroid gland: 20.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 2 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 2.5 nTPM (limit 2); amygdala: 40.7 nTPM (limit 2); basal ganglia: 42.1 nTPM (limit 2); cerebellum: 42.7 nTPM (limit 4); cerebral cortex: 39.2 nTPM (limit 4); esophagus: 15.6 nTPM (limit 8); heart muscle: 301 nTPM (limit 2); hippocampal formation: 31.7 nTPM (limit 2); hypothalamus: 34.3 nTPM (limit 2); kidney: 12.7 nTPM (limit 2); lung: 15.7 nTPM (limit 2); midbrain: 36.8 nTPM (limit 2); pancreas: 6.8 nTPM (limit 2); pituitary gland: 21.5 nTPM (limit 2); retina: 2.5 nTPM (limit 2); salivary gland: 17.5 nTPM (limit 8); spinal cord: 24.4 nTPM (limit 2); thyroid gland: 20.8 nTPM (limit 10),adrenal gland / glandular cells: Low (Approved); bronchus / respiratory epithelial cells: Low (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); heart muscle / cardiomyocytes: High (Approved); kidney / cells in tubules: Low (Approved); liver / hepatocytes: Medium (Approved); lung / macrophages: Low (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); spleen / cells in red pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 50/50 (100.0%); Glioblastoma Multiforme (validation): 57/58 (98.3%); Rectum Adenocarcinoma (validation): 203/207 (98.1%),pancreatic cancer: 11/12 (91.7%); colorectal cancer: 10/11 (90.9%),31,20,O76041,https://www.uniprot.org/uniprotkb/O76041/entry,Binds to actin and plays an important role in the assembly of the Z-disk. May functionally link sarcomeric actin to the desmin intermediate filaments in the heart muscle sarcomeres (PubMed:27733623) May play a role in the assembly of focal adhesions,"Abundantly expressed in cardiac muscle, but not in skeletal or smooth muscle. Localized to Z-lines in cardiac cells and to dense bodies in nonmuscle cells. Isoform 2 is expressed in non-muscle cells such as in fibroblasts",,,Cytoplasm,15004028|27733623,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Jamin2021_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
NEDD1,ENSG00000139350,Unsafe,Protein,False,True,22.9,36.7,79,78,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 8.8 nTPM; positive ihc; adrenal gland: 5.6 nTPM; positive ihc;absolute ceiling; amygdala: 2.5 nTPM; absolute ceiling; basal ganglia: 2.7 nTPM; absolute ceiling; bone marrow: 15.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 1.1 nTPM; positive ihc; cerebral cortex: 3.4 nTPM; positive ihc;absolute ceiling; choroid plexus: 3.9 nTPM; absolute ceiling; colon: 8 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 6.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 9.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 8.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 2.7 nTPM; absolute ceiling; hypothalamus: 2.4 nTPM; absolute ceiling; kidney: 8.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 6.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 8.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 15 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 2.6 nTPM; absolute ceiling; pancreas: 6.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 14.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 3.7 nTPM; absolute ceiling; rectum: 9.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 7 nTPM; absolute ceiling;continuous selectivity; salivary gland: 6.6 nTPM; positive ihc;absolute ceiling; skeletal muscle: 36.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 8 nTPM; positive ihc; small intestine: 6.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 12.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 3.5 nTPM; absolute ceiling; spleen: 13 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 7 nTPM; positive ihc;absolute ceiling; thymus: 21.9 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 10.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 24.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 9.2 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 5.6 nTPM (limit 2); amygdala: 2.5 nTPM (limit 2); basal ganglia: 2.7 nTPM (limit 2); bone marrow: 15.1 nTPM (limit 2); cerebral cortex: 3.4 nTPM (limit 2); choroid plexus: 3.9 nTPM (limit 2); colon: 8 nTPM (limit 6); duodenum: 6.9 nTPM (limit 2); esophagus: 9.7 nTPM (limit 6); heart muscle: 8.9 nTPM (limit 2); hippocampal formation: 2.7 nTPM (limit 2); hypothalamus: 2.4 nTPM (limit 2); kidney: 8.6 nTPM (limit 2); liver: 6.1 nTPM (limit 2); lung: 8.5 nTPM (limit 2); lymph node: 15 nTPM (limit 6); midbrain: 2.6 nTPM (limit 2); pancreas: 6.9 nTPM (limit 2); parathyroid gland: 14.4 nTPM (limit 6); pituitary gland: 3.7 nTPM (limit 2); rectum: 9.4 nTPM (limit 6); retina: 7 nTPM (limit 2); salivary gland: 6.6 nTPM (limit 6); skeletal muscle: 36.7 nTPM (limit 2); small intestine: 6.7 nTPM (limit 2); smooth muscle: 12.6 nTPM (limit 2); spinal cord: 3.5 nTPM (limit 2); spleen: 13 nTPM (limit 10); stomach: 7 nTPM (limit 6); thymus: 21.9 nTPM (limit 10); thyroid gland: 10.2 nTPM (limit 10); tongue: 24.6 nTPM (limit 6); urinary bladder: 9.2 nTPM (limit 6),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / glial cells: High (Approved); caudate / neuronal cells: High (Approved); cerebellum / cells in granular layer: High (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: High (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: High (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: High (Approved); hippocampus / glial cells: High (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: High (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: High (Approved); oral mucosa / squamous epithelial cells: High (Approved); pancreas / exocrine glandular cells: High (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: High (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: High (Approved); skin 1 / Langerhans: High (Approved); skin 2 / epidermal cells: High (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: High (Approved); spleen / cells in red pulp: High (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%),breast cancer: 12/12 (100.0%); liver cancer: 12/12 (100.0%),31,20,Q8NHV4,https://www.uniprot.org/uniprotkb/Q8NHV4/entry,Required for mitosis progression. Promotes the nucleation of microtubules from the spindle,,,,"Cytoplasm, cytoskeleton, microtubule organizing center, centrosome",19029337|19509060,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
NEDD8,ENSG00000129559,Unsafe,Protein,False,True,152.5,290.2,80,77,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 163.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; adrenal gland: 217.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 239 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 254 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 89.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 149.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 286.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 176 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 167.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 54.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 196.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 290.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 205.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 219.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 190.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 171.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 143.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 79.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 216.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 107.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 278.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 140.1 nTPM; absolute ceiling;continuous selectivity; rectum: 85.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 72.2 nTPM; absolute ceiling;continuous selectivity; salivary gland: 135.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 283.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 176.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 125.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 94 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 168 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 160.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; stomach: 142.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 122.3 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 128.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 189.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 147 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 163.6 nTPM (limit 10); adrenal gland: 217.3 nTPM (limit 2); amygdala: 239 nTPM (limit 2); basal ganglia: 254 nTPM (limit 2); bone marrow: 89.8 nTPM (limit 2); cerebellum: 149.3 nTPM (limit 2); cerebral cortex: 286.6 nTPM (limit 2); choroid plexus: 176 nTPM (limit 2); colon: 167.1 nTPM (limit 6); duodenum: 54.2 nTPM (limit 2); esophagus: 196.4 nTPM (limit 6); heart muscle: 290.2 nTPM (limit 2); hippocampal formation: 205.9 nTPM (limit 2); hypothalamus: 219.7 nTPM (limit 2); kidney: 190.4 nTPM (limit 2); liver: 171.3 nTPM (limit 2); lung: 143.2 nTPM (limit 2); lymph node: 79.1 nTPM (limit 6); midbrain: 216.3 nTPM (limit 2); pancreas: 107.7 nTPM (limit 2); parathyroid gland: 278.8 nTPM (limit 6); pituitary gland: 140.1 nTPM (limit 2); rectum: 85.7 nTPM (limit 6); retina: 72.2 nTPM (limit 2); salivary gland: 135.1 nTPM (limit 6); skeletal muscle: 283.9 nTPM (limit 2); skin: 176.3 nTPM (limit 10); small intestine: 125.2 nTPM (limit 2); smooth muscle: 94 nTPM (limit 2); spinal cord: 168 nTPM (limit 2); spleen: 160.6 nTPM (limit 10); stomach: 142.4 nTPM (limit 6); thymus: 122.3 nTPM (limit 10); thyroid gland: 128.8 nTPM (limit 10); tongue: 189.3 nTPM (limit 6); urinary bladder: 147 nTPM (limit 6); adipose tissue: 163.6 nTPM (baseline 10); adrenal gland: 217.3 nTPM (baseline 2); amygdala: 239 nTPM (baseline 2); basal ganglia: 254 nTPM (baseline 2); bone marrow: 89.8 nTPM (baseline 2); cerebellum: 149.3 nTPM (baseline 2); cerebral cortex: 286.6 nTPM (baseline 2); choroid plexus: 176 nTPM (baseline 2); colon: 167.1 nTPM (baseline 6); duodenum: 54.2 nTPM (baseline 2); esophagus: 196.4 nTPM (baseline 6); heart muscle: 290.2 nTPM (baseline 2); hippocampal formation: 205.9 nTPM (baseline 2); hypothalamus: 219.7 nTPM (baseline 2); kidney: 190.4 nTPM (baseline 2); liver: 171.3 nTPM (baseline 2); lung: 143.2 nTPM (baseline 2); lymph node: 79.1 nTPM (baseline 6); midbrain: 216.3 nTPM (baseline 2); pancreas: 107.7 nTPM (baseline 2); parathyroid gland: 278.8 nTPM (baseline 6); pituitary gland: 140.1 nTPM (baseline 2); rectum: 85.7 nTPM (baseline 6); retina: 72.2 nTPM (baseline 2); salivary gland: 135.1 nTPM (baseline 6); skeletal muscle: 283.9 nTPM (baseline 2); skin: 176.3 nTPM (baseline 10); small intestine: 125.2 nTPM (baseline 2); smooth muscle: 94 nTPM (baseline 2); spinal cord: 168 nTPM (baseline 2); spleen: 160.6 nTPM (baseline 10); stomach: 142.4 nTPM (baseline 6); thymus: 122.3 nTPM (baseline 10); thyroid gland: 128.8 nTPM (baseline 10); tongue: 189.3 nTPM (baseline 6); urinary bladder: 147 nTPM (baseline 6),adipose tissue / adipocytes: Low (Uncertain); adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: High (Uncertain); caudate / glial cells: Low (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: Low (Uncertain); cerebellum / cells in molecular layer: Medium (Uncertain); cerebellum / Purkinje cells: High (Uncertain); cerebral cortex / endothelial cells: Low (Uncertain); cerebral cortex / glial cells: Low (Uncertain); cerebral cortex / neuronal cells: High (Uncertain); cerebral cortex / neuropil: Medium (Uncertain); colon / endothelial cells: Low (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: Low (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: Low (Uncertain); hippocampus / glial cells: Low (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in glomeruli: Low (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / cholangiocytes: Low (Uncertain); lung / alveolar cells: Low (Uncertain); lung / macrophages: Low (Uncertain); lymph node / germinal center cells: Medium (Uncertain); lymph node / non-germinal center cells: Medium (Uncertain); nasopharynx / respiratory epithelial cells: High (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Low (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); parathyroid gland / glandular cells: High (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: Low (Uncertain); skin 1 / fibroblasts: High (Uncertain); skin 1 / keratinocytes: Medium (Uncertain); skin 1 / Langerhans: Medium (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: Medium (Uncertain); smooth muscle / smooth muscle cells: Low (Uncertain); spleen / cells in red pulp: Low (Uncertain); spleen / cells in white pulp: Low (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Kidney Renal Clear Cell Carcinoma (TCGA): 521/521 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%),glioma: 11/12 (91.7%); prostate cancer: 11/12 (91.7%),31,20,Q15843,https://www.uniprot.org/uniprotkb/Q15843/entry,"Ubiquitin-like protein which plays an important role in cell cycle control and embryogenesis via its conjugation to a limited number of cellular proteins, such as cullins or p53/TP53 (PubMed:10318914, PubMed:10597293, PubMed:11953428, PubMed:14690597, PubMed:15242646, PubMed:9694792, PubMed:38605244, PubMed:38316879). Attachment of NEDD8 to cullins is critical for the recruitment of E2 to the cullin-RING-based E3 ubiquitin-protein ligase complex, thus facilitating polyubiquitination and proteasomal degradation of cyclins and other regulatory proteins (PubMed:10318914, PubMed:10597293, PubMed:11953428, PubMed:20688984, PubMed:9694792, PubMed:38605244, PubMed:38316879). Attachment of NEDD8 to p53/TP53 inhibits p53/TP53 transcriptional activity (PubMed:15242646). Covalent attachment to its substrates requires prior activation by the E1 complex UBE1C-APPBP1 and linkage to the E2 enzyme UBE2M (PubMed:14690597). Neddylates EGFR resulting in protein stabilization and translocation to the cell membrane (PubMed:28891468)","Highly expressed in heart, skeletal muscle, spleen, thymus, prostate, testis, ovary, colon and leukocytes",,,Nucleus,10318914|10597293|11953428|14690597|15242646|20688984|28891468|38316879|38605244|9694792,10597293|9353319,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
NEIL3,ENSG00000109674,Unsafe,RNA,False,True,1.5,23.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 6.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 1 nTPM; continuous selectivity; duodenum: 1.1 nTPM; continuous selectivity; esophagus: 1.5 nTPM; continuous selectivity;reproductive not higher; lymph node: 3.5 nTPM; continuous selectivity;reproductive not higher; rectum: 1.4 nTPM; continuous selectivity; skin: 2.3 nTPM; continuous selectivity;reproductive not higher; small intestine: 1.2 nTPM; continuous selectivity; smooth muscle: 0.5 nTPM; continuous selectivity; thymus: 23 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 6.5 nTPM (limit 2); thymus: 23 nTPM (limit 10); bone marrow: 6.5 nTPM (baseline 2); thymus: 23 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 46/58 (79.3%); Breast Invasive Carcinoma (validation): 34/50 (68.0%); Colon Adenocarcinoma (validation): 292/486 (60.1%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8TAT5,https://www.uniprot.org/uniprotkb/Q8TAT5/entry,"DNA glycosylase which prefers single-stranded DNA (ssDNA), or partially ssDNA structures such as bubble and fork structures, to double-stranded DNA (dsDNA) (PubMed:12433996, PubMed:19170771, PubMed:22569481, PubMed:23755964). Mediates interstrand cross-link repair in response to replication stress: acts by mediating DNA glycosylase activity, cleaving one of the two N-glycosyl bonds comprising the interstrand cross-link, which avoids the formation of a double-strand break but generates an abasic site that is bypassed by translesion synthesis polymerases (By similarity). In vitro, displays strong glycosylase activity towards the hydantoin lesions spiroiminodihydantoin (Sp) and guanidinohydantoin (Gh) in both ssDNA and dsDNA; also recognizes FapyA, FapyG, 5-OHU, 5-OHC, 5-OHMH, Tg and 8-oxoA lesions in ssDNA (PubMed:12433996, PubMed:19170771, PubMed:22569481, PubMed:23755964). No activity on 8-oxoG detected (PubMed:12433996, PubMed:19170771, PubMed:22569481, PubMed:23755964). Also shows weak DNA-(apurinic or apyrimidinic site) lyase activity (PubMed:12433996, PubMed:19170771, PubMed:22569481, PubMed:23755964). In vivo, appears to be the primary enzyme involved in removing Sp and Gh from ssDNA in neonatal tissues (PubMed:12433996, PubMed:19170771, PubMed:22569481, PubMed:23755964)","Expressed in keratinocytes and embryonic fibroblasts (at protein level). Also detected in thymus, testis and fetal lung primary fibroblasts",,"Was originally thought to be inactive as a glycosylase (PMID:12200441,PMID:19121397), but recent reports (PMID:22569481, PMID:20185759) demonstrate that cleavage of the initiator methionine is essential for catalytic activity",Nucleus Chromosome,12433996|19170771|22569481|23755964,12433996|16428305|19426544|22365498,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
NEK10,ENSG00000163491,Unsafe,RNA,False,True,34.3,34.3,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,basal ganglia: 3.1 nTPM; absolute ceiling; choroid plexus: 2.7 nTPM; absolute ceiling; heart muscle: 3.1 nTPM; absolute ceiling; hippocampal formation: 2.6 nTPM; absolute ceiling; hypothalamus: 2.9 nTPM; absolute ceiling; lung: 2.2 nTPM; absolute ceiling; pituitary gland: 3.3 nTPM; absolute ceiling; retina: 4.6 nTPM; absolute ceiling; skeletal muscle: 9.4 nTPM; absolute ceiling;continuous selectivity; tongue: 14.1 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,basal ganglia: 3.1 nTPM (limit 2); choroid plexus: 2.7 nTPM (limit 2); heart muscle: 3.1 nTPM (limit 2); hippocampal formation: 2.6 nTPM (limit 2); hypothalamus: 2.9 nTPM (limit 2); lung: 2.2 nTPM (limit 2); pituitary gland: 3.3 nTPM (limit 2); retina: 4.6 nTPM (limit 2); skeletal muscle: 9.4 nTPM (limit 2); tongue: 14.1 nTPM (limit 6); basal ganglia: 3.1 nTPM (baseline 2); choroid plexus: 2.7 nTPM (baseline 2); heart muscle: 3.1 nTPM (baseline 2); hippocampal formation: 2.6 nTPM (baseline 2); hypothalamus: 2.9 nTPM (baseline 2); lung: 2.2 nTPM (baseline 2); pituitary gland: 3.3 nTPM (baseline 2); retina: 4.6 nTPM (baseline 2); skeletal muscle: 9.4 nTPM (baseline 2); tongue: 14.1 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 39/50 (78.0%); Breast Invasive Carcinoma (TCGA): 442/1022 (43.2%); Glioblastoma Multiforme (validation): 17/58 (29.3%),ovarian cancer: 1/11 (9.1%); pancreatic cancer: 1/11 (9.1%),31,20,Q6ZWH5,https://www.uniprot.org/uniprotkb/Q6ZWH5/entry,"Plays a role in the cellular response to UV irradiation. Mediates G2/M cell cycle arrest, MEK autoactivation and ERK1/2-signaling pathway activation in response to UV irradiation. In ciliated cells of airways, it is involved in the regulation of mucociliary transport (PubMed:31959991)",Expressed in the lung,"Ciliary dyskinesia, primary, 44: A form of primary ciliary dyskinesia, a disorder characterized by abnormalities of motile cilia. Respiratory infections leading to chronic inflammation and bronchiectasis are recurrent, due to defects in the respiratory cilia. CILD44 inheritance is autosomal recessive.",,,20956560|31959991,31959991,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
NEK2,ENSG00000117650,Unsafe,Protein,False,True,65.2,65.2,85,10,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 17.5 nTPM; absolute ceiling; lymph node: 8.8 nTPM; positive ihc;absolute ceiling; rectum: 7.4 nTPM; positive ihc;absolute ceiling; small intestine: 6.7 nTPM; positive ihc;absolute ceiling; thymus: 18.7 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 17.5 nTPM (limit 12); lymph node: 8.8 nTPM (limit 6); rectum: 7.4 nTPM (limit 6); small intestine: 6.7 nTPM (limit 2); thymus: 18.7 nTPM (limit 10),lymph node / germinal center cells: Medium (Enhanced); lymph node / non-germinal center cells: Medium (Enhanced); rectum / glandular cells: Low (Enhanced); small intestine / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (TCGA): 88/88 (100.0%); Colon Adenocarcinoma (TCGA): 253/254 (99.6%); Colon Adenocarcinoma (validation): 482/486 (99.2%),lymphoma: 5/12 (41.7%); cervical cancer: 2/11 (18.2%),31,20,P51955,https://www.uniprot.org/uniprotkb/P51955/entry,"Protein kinase which is involved in the control of centrosome separation and bipolar spindle formation in mitotic cells and chromatin condensation in meiotic cells. Regulates centrosome separation (essential for the formation of bipolar spindles and high-fidelity chromosome separation) by phosphorylating centrosomal proteins such as CROCC, CEP250 and NINL, resulting in their displacement from the centrosomes. Regulates kinetochore microtubule attachment stability in mitosis via phosphorylation of NDC80. Involved in regulation of mitotic checkpoint protein complex via phosphorylation of CDC20 and MAD2L1. Plays an active role in chromatin condensation during the first meiotic division through phosphorylation of HMGA2. Phosphorylates: PPP1CC; SGO1; NECAB3 and NPM1. Essential for localization of MAD2L1 to kinetochore and MAPK1 and NPM1 to the centrosome. Phosphorylates CEP68 and CNTLN directly or indirectly (PubMed:24554434). NEK2-mediated phosphorylation of CEP68 promotes CEP68 dissociation from the centrosome and its degradation at the onset of mitosis (PubMed:25704143). Involved in the regulation of centrosome disjunction (PubMed:26220856). Phosphorylates CCDC102B either directly or indirectly which causes CCDC102B to dissociate from the centrosome and allows for centrosome separation (PubMed:30404835) Phosphorylates and activates NEK11 in G1/S-arrested cells Not present in the nucleolus and, in contrast to isoform 1, does not phosphorylate and activate NEK11 in G1/S-arrested cells","Isoform 1 and isoform 2 are expressed in peripheral blood T-cells and a wide variety of transformed cell types. Isoform 1 and isoform 4 are expressed in the testis. Up-regulated in various cancer cell lines, as well as primary breast tumors","Retinitis pigmentosa 67: A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.",,"Nucleus Nucleus, nucleolus Cytoplasm Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Cytoplasm, cytoskeleton, spindle pole Chromosome, centromere, kinetochore Chromosome, centromere",11742531|12857871|14978040|15161910|15358203|15388344|17283141|17621308|17626005|18086858|18297113|20034488|21076410|24554434|25704143|26220856|30404835,11742531|15659832,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Jamin2021_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
NEMP2,ENSG00000189362,Unsafe,RNA,False,True,2.9,4.5,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 1.4 nTPM; continuous selectivity; adrenal gland: 1.6 nTPM; continuous selectivity; amygdala: 0.9 nTPM; continuous selectivity; basal ganglia: 0.9 nTPM; continuous selectivity; bone marrow: 1.9 nTPM; continuous selectivity; cerebellum: 2.3 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 1.2 nTPM; continuous selectivity; colon: 1.3 nTPM; continuous selectivity; duodenum: 0.9 nTPM; continuous selectivity; esophagus: 1.5 nTPM; continuous selectivity; heart muscle: 0.9 nTPM; continuous selectivity; hippocampal formation: 1.1 nTPM; continuous selectivity; hypothalamus: 0.9 nTPM; continuous selectivity; kidney: 1.3 nTPM; continuous selectivity; liver: 1.7 nTPM; continuous selectivity; lung: 1.6 nTPM; continuous selectivity; lymph node: 3.6 nTPM; continuous selectivity;reproductive not higher; midbrain: 1.2 nTPM; continuous selectivity; pancreas: 1.1 nTPM; continuous selectivity; pituitary gland: 1.2 nTPM; continuous selectivity; retina: 1.2 nTPM; continuous selectivity; salivary gland: 2 nTPM; continuous selectivity; skin: 2 nTPM; continuous selectivity; small intestine: 1.6 nTPM; continuous selectivity; smooth muscle: 1.1 nTPM; continuous selectivity; spinal cord: 1.1 nTPM; continuous selectivity; spleen: 2.3 nTPM; continuous selectivity; stomach: 1.8 nTPM; continuous selectivity; thymus: 4.5 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 1.9 nTPM; continuous selectivity; urinary bladder: 1.2 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebellum: 2.3 nTPM (limit 2); cerebellum: 2.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 53/58 (91.4%); Pancreatic Adenocarcinoma (validation): 49/80 (61.3%); Colon Adenocarcinoma (validation): 211/486 (43.4%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,A6NFY4,https://www.uniprot.org/uniprotkb/A6NFY4/entry,,,,,Nucleus inner membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
NEUROG2,ENSG00000178403,Unsafe,RNA,False,True,1.6,2.1,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,amygdala: 1.5 nTPM; continuous selectivity; basal ganglia: 2.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 1.9 nTPM; continuous selectivity;reproductive not higher; cerebral cortex: 0.5 nTPM; continuous selectivity; hippocampal formation: 2 nTPM; continuous selectivity;reproductive not higher; retina: 0.5 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,basal ganglia: 2.1 nTPM (limit 2); basal ganglia: 2.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 8/50 (16.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 9/176 (5.1%); Testicular Germ Cell Tumor (TCGA): 5/133 (3.8%),cervical cancer: 12/12 (100.0%); glioma: 12/12 (100.0%),31,20,Q9H2A3,https://www.uniprot.org/uniprotkb/Q9H2A3/entry,Transcriptional regulator. Involved in neuronal differentiation. Activates transcription by binding to the E box (5'-CANNTG-3'),,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
NEXMIF,ENSG00000050030,Unsafe,RNA,False,True,0.9,3.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 0.9 nTPM; continuous selectivity;reproductive not higher; amygdala: 1.1 nTPM; continuous selectivity;reproductive not higher; basal ganglia: 1.5 nTPM; continuous selectivity;reproductive not higher; cerebellum: 1.8 nTPM; continuous selectivity;reproductive not higher; cerebral cortex: 3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 0.4 nTPM; continuous selectivity; colon: 0.8 nTPM; continuous selectivity; hippocampal formation: 1 nTPM; continuous selectivity;reproductive not higher; hypothalamus: 2.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 0.7 nTPM; continuous selectivity; midbrain: 0.5 nTPM; continuous selectivity; pancreas: 1.4 nTPM; continuous selectivity;reproductive not higher; parathyroid gland: 1.8 nTPM; continuous selectivity;reproductive not higher; pituitary gland: 1.7 nTPM; continuous selectivity;reproductive not higher; retina: 0.9 nTPM; continuous selectivity;reproductive not higher; small intestine: 0.4 nTPM; continuous selectivity; smooth muscle: 0.7 nTPM; continuous selectivity; stomach: 0.6 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebral cortex: 3 nTPM (limit 2); hypothalamus: 2.1 nTPM (limit 2); cerebral cortex: 3 nTPM (baseline 2); hypothalamus: 2.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 44/58 (75.9%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 2/283 (0.7%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),29,20,Q5QGS0,https://www.uniprot.org/uniprotkb/Q5QGS0/entry,"Involved in neurite outgrowth by regulating cell-cell adhesion via the N-cadherin signaling pathway. May act by regulating expression of protein-coding genes, such as N-cadherins and integrin beta-1 (ITGB1)","Highly expressed in fetal and adult brain, predominantly in the cerebral cortex and the cerebellum. Also expressed in other tissues but to a lesser extent","Intellectual developmental disorder, X-linked 98: A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. XLID98 patients show delayed psychomotor development, absent or poor speech development, and postnatal growth retardation, often with microcephaly. Some patients show autistic behavioral features, such as stereotypic hand movements and repetitive behaviors. Additional, more variable features include spasticity, axial hypotonia, seizures, drooling, gastroesophageal reflux, and lack of sphincter control.",,Nucleus Cytoplasm,,15466006,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
NF1,ENSG00000196712,Unsafe,Protein,False,True,15.2,26.1,74,51,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 9 nTPM; continuous selectivity; adrenal gland: 11.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 9.4 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 9.6 nTPM; absolute ceiling;continuous selectivity; bone marrow: 3.5 nTPM; positive ihc;absolute ceiling; cerebellum: 12.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 19.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 9.5 nTPM; absolute ceiling;continuous selectivity; colon: 9.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 8 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 6.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 12.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 9.4 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 9.2 nTPM; absolute ceiling;continuous selectivity; kidney: 13.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 12 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 8.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 9.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 9.3 nTPM; absolute ceiling;continuous selectivity; pancreas: 10.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 18.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 7.6 nTPM; absolute ceiling;continuous selectivity; rectum: 10.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 26.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 11.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 9.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 10.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 8.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 9.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 10.6 nTPM; absolute ceiling;continuous selectivity; spleen: 8.5 nTPM; positive ihc;continuous selectivity; stomach: 9.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 16.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 20.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; tongue: 12.3 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 11.6 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 11.1 nTPM (limit 2); amygdala: 9.4 nTPM (limit 2); basal ganglia: 9.6 nTPM (limit 2); bone marrow: 3.5 nTPM (limit 2); cerebellum: 12.5 nTPM (limit 2); cerebral cortex: 19.1 nTPM (limit 2); choroid plexus: 9.5 nTPM (limit 2); colon: 9.9 nTPM (limit 6); duodenum: 8 nTPM (limit 2); esophagus: 6.4 nTPM (limit 6); heart muscle: 12.5 nTPM (limit 2); hippocampal formation: 9.4 nTPM (limit 2); hypothalamus: 9.2 nTPM (limit 2); kidney: 13.7 nTPM (limit 2); liver: 12 nTPM (limit 2); lung: 8.1 nTPM (limit 2); lymph node: 9.6 nTPM (limit 6); midbrain: 9.3 nTPM (limit 2); pancreas: 10.8 nTPM (limit 2); parathyroid gland: 18.3 nTPM (limit 6); pituitary gland: 7.6 nTPM (limit 2); rectum: 10.1 nTPM (limit 6); retina: 26.1 nTPM (limit 2); salivary gland: 11.3 nTPM (limit 6); skeletal muscle: 9.2 nTPM (limit 2); skin: 10.9 nTPM (limit 10); small intestine: 8.7 nTPM (limit 2); smooth muscle: 9.7 nTPM (limit 2); spinal cord: 10.6 nTPM (limit 2); stomach: 9.1 nTPM (limit 6); thymus: 16.6 nTPM (limit 10); thyroid gland: 20.2 nTPM (limit 10); tongue: 12.3 nTPM (limit 6); urinary bladder: 11.6 nTPM (limit 6); adrenal gland: 11.1 nTPM (baseline 2); amygdala: 9.4 nTPM (baseline 2); basal ganglia: 9.6 nTPM (baseline 2); bone marrow: 3.5 nTPM (baseline 2); cerebellum: 12.5 nTPM (baseline 2); cerebral cortex: 19.1 nTPM (baseline 2); choroid plexus: 9.5 nTPM (baseline 2); colon: 9.9 nTPM (baseline 6); duodenum: 8 nTPM (baseline 2); esophagus: 6.4 nTPM (baseline 6); heart muscle: 12.5 nTPM (baseline 2); hippocampal formation: 9.4 nTPM (baseline 2); hypothalamus: 9.2 nTPM (baseline 2); kidney: 13.7 nTPM (baseline 2); liver: 12 nTPM (baseline 2); lung: 8.1 nTPM (baseline 2); lymph node: 9.6 nTPM (baseline 6); midbrain: 9.3 nTPM (baseline 2); pancreas: 10.8 nTPM (baseline 2); parathyroid gland: 18.3 nTPM (baseline 6); pituitary gland: 7.6 nTPM (baseline 2); rectum: 10.1 nTPM (baseline 6); retina: 26.1 nTPM (baseline 2); salivary gland: 11.3 nTPM (baseline 6); skeletal muscle: 9.2 nTPM (baseline 2); skin: 10.9 nTPM (baseline 10); small intestine: 8.7 nTPM (baseline 2); smooth muscle: 9.7 nTPM (baseline 2); spinal cord: 10.6 nTPM (baseline 2); stomach: 9.1 nTPM (baseline 6); thymus: 16.6 nTPM (baseline 10); thyroid gland: 20.2 nTPM (baseline 10); tongue: 12.3 nTPM (baseline 6); urinary bladder: 11.6 nTPM (baseline 6),adrenal gland / glandular cells: High (Uncertain); bone marrow / hematopoietic cells: Low (Uncertain); bronchus / respiratory epithelial cells: High (Uncertain); cerebellum / cells in granular layer: Medium (Uncertain); cerebellum / cells in molecular layer: Medium (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / endothelial cells: Medium (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / endothelial cells: Low (Uncertain); colon / glandular cells: Medium (Uncertain); duodenum / glandular cells: High (Uncertain); esophagus / squamous epithelial cells: Low (Uncertain); heart muscle / cardiomyocytes: High (Uncertain); kidney / cells in tubules: High (Uncertain); liver / hepatocytes: High (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / non-germinal center cells: Medium (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: High (Uncertain); parathyroid gland / glandular cells: High (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: High (Uncertain); skeletal muscle / myocytes: Low (Uncertain); skin 1 / fibroblasts: High (Uncertain); skin 1 / keratinocytes: Low (Uncertain); small intestine / glandular cells: High (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); spleen / cells in red pulp: Medium (Uncertain); spleen / cells in white pulp: Medium (Uncertain); stomach 1 / glandular cells: High (Uncertain); stomach 2 / glandular cells: High (Uncertain); thyroid gland / glandular cells: High (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Pancreatic Adenocarcinoma (validation): 80/80 (100.0%),colorectal cancer: 10/10 (100.0%); prostate cancer: 11/12 (91.7%),31,20,P21359,https://www.uniprot.org/uniprotkb/P21359/entry,"Stimulates the GTPase activity of Ras. NF1 shows greater affinity for Ras GAP, but lower specific activity. May be a regulator of Ras activity","Detected in brain, peripheral nerve, lung, colon and muscle","Neurofibromatosis 1: A disease characterized by patches of skin pigmentation (cafe-au-lait spots), Lisch nodules of the iris, tumors in the peripheral nervous system and fibromatous skin tumors. Individuals with the disorder have increased susceptibility to the development of benign and malignant tumors. Leukemia, juvenile myelomonocytic: An aggressive pediatric myelodysplastic syndrome/myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Patients have splenomegaly, enlarged lymph nodes, rashes, and hemorrhages. Watson syndrome: A syndrome characterized by the presence of pulmonary stenosis, cafe-au-lait spots, and intellectual disability. It is considered as an atypical form of neurofibromatosis. Familial spinal neurofibromatosis: Considered to be an alternative form of neurofibromatosis, showing multiple spinal tumors. Neurofibromatosis-Noonan syndrome: Characterized by manifestations of both NF1 and Noonan syndrome (NS). NS is a disorder characterized by dysmorphic facial features, short stature, hypertelorism, cardiac anomalies, deafness, motor delay, and a bleeding diathesis. Colorectal cancer: A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history.","Was originally thought to be associated with LEOPARD (LS), an autosomal dominant syndrome","Nucleus Nucleus, nucleolus Cell membrane",2121371|8417346,8417346,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
NHEJ1,ENSG00000187736,Unsafe,Protein,False,True,16.0,16.5,80,77,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 9.9 nTPM; positive ihc;continuous selectivity; adrenal gland: 8.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 2.5 nTPM; absolute ceiling; basal ganglia: 2.9 nTPM; absolute ceiling; bone marrow: 3.2 nTPM; positive ihc;absolute ceiling; cerebellum: 6.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 3 nTPM; positive ihc;absolute ceiling; colon: 13.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 6.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 7 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 6 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 2.9 nTPM; absolute ceiling; hypothalamus: 3.1 nTPM; absolute ceiling; kidney: 12.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 7.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 6.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 5.3 nTPM; positive ihc; midbrain: 2.8 nTPM; absolute ceiling; pancreas: 8.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 3.1 nTPM; positive ihc; pituitary gland: 2.7 nTPM; absolute ceiling; rectum: 8.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 2.8 nTPM; absolute ceiling; salivary gland: 5.5 nTPM; positive ihc;continuous selectivity; skeletal muscle: 16.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 8.2 nTPM; positive ihc;continuous selectivity; small intestine: 11.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 6.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 3.7 nTPM; absolute ceiling; spleen: 6.7 nTPM; positive ihc; stomach: 8.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; thyroid gland: 4.5 nTPM; positive ihc; tongue: 6.2 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 10.1 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 8.1 nTPM (limit 2); amygdala: 2.5 nTPM (limit 2); basal ganglia: 2.9 nTPM (limit 2); bone marrow: 3.2 nTPM (limit 2); cerebellum: 6.5 nTPM (limit 2); cerebral cortex: 3 nTPM (limit 2); colon: 13.6 nTPM (limit 6); duodenum: 6.8 nTPM (limit 2); esophagus: 7 nTPM (limit 6); heart muscle: 6 nTPM (limit 2); hippocampal formation: 2.9 nTPM (limit 2); hypothalamus: 3.1 nTPM (limit 2); kidney: 12.5 nTPM (limit 2); liver: 7.9 nTPM (limit 2); lung: 6.7 nTPM (limit 2); midbrain: 2.8 nTPM (limit 2); pancreas: 8.2 nTPM (limit 2); pituitary gland: 2.7 nTPM (limit 2); rectum: 8.7 nTPM (limit 6); retina: 2.8 nTPM (limit 2); skeletal muscle: 16.5 nTPM (limit 2); small intestine: 11.8 nTPM (limit 2); smooth muscle: 6.2 nTPM (limit 2); spinal cord: 3.7 nTPM (limit 2); stomach: 8.7 nTPM (limit 6); tongue: 6.2 nTPM (limit 6); urinary bladder: 10.1 nTPM (limit 6),adipose tissue / adipocytes: High (Approved); adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: High (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / glial cells: Medium (Approved); cerebellum / cells in granular layer: High (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebral cortex / endothelial cells: High (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Low (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: High (Approved); colon / glandular cells: High (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: High (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / glial cells: High (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: High (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: High (Approved); lung / macrophages: Low (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: High (Approved); nasopharynx / respiratory epithelial cells: High (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: High (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: High (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: High (Approved); skin 1 / keratinocytes: High (Approved); skin 1 / Langerhans: High (Approved); skin 2 / epidermal cells: High (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: High (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: High (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Colon Adenocarcinoma (validation): 485/486 (99.8%); Colon Adenocarcinoma (TCGA): 245/254 (96.5%),melanoma: 12/12 (100.0%); cervical cancer: 11/11 (100.0%),31,20,Q9H9Q4,https://www.uniprot.org/uniprotkb/Q9H9Q4/entry,"DNA repair protein involved in DNA non-homologous end joining (NHEJ); it is required for double-strand break (DSB) repair and V(D)J recombination and is also involved in telomere maintenance (PubMed:16439204, PubMed:16439205, PubMed:17317666, PubMed:17470781, PubMed:17717001, PubMed:18158905, PubMed:18644470, PubMed:20558749, PubMed:26100018, PubMed:28369633). Plays a key role in NHEJ by promoting the ligation of various mismatched and non-cohesive ends (PubMed:17470781, PubMed:17717001, PubMed:19056826). Together with PAXX, collaborates with DNA polymerase lambda (POLL) to promote joining of non-cohesive DNA ends (PubMed:25670504, PubMed:30250067). May act in concert with XRCC5-XRCC6 (Ku) to stimulate XRCC4-mediated joining of blunt ends and several types of mismatched ends that are non-complementary or partially complementary (PubMed:16439204, PubMed:16439205, PubMed:17317666, PubMed:17470781). In some studies, has been shown to associate with XRCC4 to form alternating helical filaments that bridge DNA and act like a bandage, holding together the broken DNA until it is repaired (PubMed:21768349, PubMed:21775435, PubMed:22228831, PubMed:22287571, PubMed:26100018, PubMed:27437582, PubMed:28500754). Alternatively, it has also been shown that rather than forming filaments, a single NHEJ1 dimer interacts through both head domains with XRCC4 to promote the close alignment of DNA ends (By similarity). The XRCC4-NHEJ1/XLF subcomplex binds to the DNA fragments of a DSB in a highly diffusive manner and robustly bridges two independent DNA molecules, holding the broken DNA fragments in close proximity to one other (PubMed:27437582, PubMed:28500754). The mobility of the bridges ensures that the ends remain accessible for further processing by other repair factors (PubMed:27437582). Binds DNA in a length-dependent manner (PubMed:17317666, PubMed:18158905)",Ubiquitously expressed,"Immunodeficiency 124, severe combined: A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia and low or absent antibody levels. Patients with SCID present in infancy with recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T- cell development. IMD124 is characterized by a profound T- and B- lymphocytopenia associated with increased cellular sensitivity to ionizing radiation, shortened telomeres and premature senescence of hematopoietic stem cells, microcephaly and growth retardation. Some patients may manifest SCID with sensitivity to ionizing radiation without microcephaly and mild growth retardation, probably due to hypomorphic NHEJ1 variants. Microphthalmia/coloboma 13: A form of colobomatous microphthalmia, a disorder of eye formation, ranging from small size of a single eye to complete bilateral absence of ocular tissues. Ocular abnormalities like coloboma, opacities of the cornea and lens, scaring of the retina and choroid, and other abnormalities may also be present. Ocular colobomas are a set of malformations resulting from abnormal morphogenesis of the optic cup and stalk, and the fusion of the fetal fissure (optic fissure). MCOPCB13 is an autosomal recessive form characterized by variable ocular anomalies, even between eyes within the same patient. Patients may also exhibit high myopia, strabismus, nystagmus, and/or retinal pigmentary changes and atrophy.",,Nucleus Chromosome,16439204|16439205|17317666|17470781|17717001|18158905|18644470|19056826|20558749|21768349|21775435|22228831|22287571|25670504|26100018|27437582|28369633|28500754|30250067,16439204,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
NKAPD1,ENSG00000150776,Unsafe,Protein,False,True,19.8,32.4,86,65,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 13.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 11 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 13.1 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 11.9 nTPM; absolute ceiling;continuous selectivity; bone marrow: 12.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 21.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 14.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 7.6 nTPM; absolute ceiling;continuous selectivity; colon: 11.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 11 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 13.4 nTPM; absolute ceiling;continuous selectivity; heart muscle: 12.6 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 12.9 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 13.9 nTPM; absolute ceiling;continuous selectivity; kidney: 14.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 11.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 10.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 13.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 13.5 nTPM; absolute ceiling;continuous selectivity; pancreas: 11.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 13.6 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 7.5 nTPM; absolute ceiling;continuous selectivity; rectum: 11.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 32.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 13.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 17.9 nTPM; absolute ceiling;continuous selectivity; skin: 11.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 10.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 12 nTPM; absolute ceiling;continuous selectivity; spinal cord: 13.6 nTPM; absolute ceiling;continuous selectivity; spleen: 12.3 nTPM; continuous selectivity; stomach: 11.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 16.5 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 15.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 9.7 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 11.1 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 13.7 nTPM (limit 10); adrenal gland: 11 nTPM (limit 2); amygdala: 13.1 nTPM (limit 2); basal ganglia: 11.9 nTPM (limit 2); bone marrow: 12.8 nTPM (limit 2); cerebellum: 21.9 nTPM (limit 2); cerebral cortex: 14.1 nTPM (limit 2); choroid plexus: 7.6 nTPM (limit 2); colon: 11.8 nTPM (limit 6); duodenum: 11 nTPM (limit 2); esophagus: 13.4 nTPM (limit 8); heart muscle: 12.6 nTPM (limit 4); hippocampal formation: 12.9 nTPM (limit 2); hypothalamus: 13.9 nTPM (limit 2); kidney: 14.1 nTPM (limit 2); liver: 11.4 nTPM (limit 2); lung: 10.7 nTPM (limit 2); lymph node: 13.8 nTPM (limit 6); midbrain: 13.5 nTPM (limit 2); pancreas: 11.9 nTPM (limit 2); parathyroid gland: 13.6 nTPM (limit 8); pituitary gland: 7.5 nTPM (limit 2); rectum: 11.3 nTPM (limit 6); retina: 32.4 nTPM (limit 2); salivary gland: 13.3 nTPM (limit 6); skeletal muscle: 17.9 nTPM (limit 4); skin: 11.8 nTPM (limit 10); small intestine: 10.8 nTPM (limit 2); smooth muscle: 12 nTPM (limit 4); spinal cord: 13.6 nTPM (limit 2); stomach: 11.2 nTPM (limit 6); thymus: 16.5 nTPM (limit 10); thyroid gland: 15.5 nTPM (limit 10); tongue: 9.7 nTPM (limit 6); urinary bladder: 11.1 nTPM (limit 6),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / ciliated cells (cilia axoneme): Medium (Approved); bronchus / ciliated cells (ciliary rootlets): Medium (Approved); bronchus / ciliated cells (tip of cilia): High (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in tubules: Low (Approved); liver / hepatocytes: Low (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Medium (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Low (Approved); pancreas / pancreatic endocrine cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Low (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (TCGA): 254/254 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (TCGA): 141/141 (100.0%),pancreatic cancer: 7/10 (70.0%); prostate cancer: 7/11 (63.6%),29,20,Q6ZUT1,https://www.uniprot.org/uniprotkb/Q6ZUT1/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
NKAPL,ENSG00000189134,Unsafe,RNA,False,True,31.4,31.4,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 2.5 nTPM; absolute ceiling; basal ganglia: 2.8 nTPM; absolute ceiling; cerebral cortex: 2.3 nTPM; absolute ceiling; heart muscle: 4.9 nTPM; absolute ceiling; hippocampal formation: 2.3 nTPM; absolute ceiling; hypothalamus: 2.4 nTPM; absolute ceiling; midbrain: 3.6 nTPM; absolute ceiling; retina: 12.2 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 5.4 nTPM; absolute ceiling; spinal cord: 3.9 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 2.5 nTPM (limit 2); basal ganglia: 2.8 nTPM (limit 2); cerebral cortex: 2.3 nTPM (limit 2); heart muscle: 4.9 nTPM (limit 2); hippocampal formation: 2.3 nTPM (limit 2); hypothalamus: 2.4 nTPM (limit 2); midbrain: 3.6 nTPM (limit 2); retina: 12.2 nTPM (limit 2); skeletal muscle: 5.4 nTPM (limit 2); spinal cord: 3.9 nTPM (limit 2); amygdala: 2.5 nTPM (baseline 2); basal ganglia: 2.8 nTPM (baseline 2); cerebral cortex: 2.3 nTPM (baseline 2); heart muscle: 4.9 nTPM (baseline 2); hippocampal formation: 2.3 nTPM (baseline 2); hypothalamus: 2.4 nTPM (baseline 2); midbrain: 3.6 nTPM (baseline 2); retina: 12.2 nTPM (baseline 2); skeletal muscle: 5.4 nTPM (baseline 2); spinal cord: 3.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 10/58 (17.2%); Breast Invasive Carcinoma (validation): 4/50 (8.0%); Kidney Chromophobe (TCGA): 3/64 (4.7%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q5M9Q1,https://www.uniprot.org/uniprotkb/Q5M9Q1/entry,Transcriptional repressor of Notch-mediated signaling. Required for spermatogenesis,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
NKX2-8,ENSG00000136327,Unsafe,RNA,False,True,7.7,7.7,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,spinal cord: 7.6 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,spinal cord: 7.6 nTPM (limit 2); spinal cord: 7.6 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Thyroid Carcinoma (TCGA): 29/495 (5.9%); Lung Adenocarcinoma (TCGA): 23/497 (4.6%); Lung Squamous Cell Carcinoma (TCGA): 20/489 (4.1%),prostate cancer: 12/12 (100.0%); breast cancer: 10/11 (90.9%),29,20,O15522,https://www.uniprot.org/uniprotkb/O15522/entry,,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
NLGN1,ENSG00000169760,Unsafe,Protein,False,True,4.6,12.3,78,33,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 0.8 nTPM; positive ihc; amygdala: 4.2 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 3.7 nTPM; absolute ceiling;continuous selectivity; bone marrow: 0 nTPM; positive ihc; cerebellum: 4.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 12.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 1.3 nTPM; continuous selectivity; colon: 1.8 nTPM; continuous selectivity; duodenum: 0.2 nTPM; positive ihc; heart muscle: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 4.5 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 4.4 nTPM; absolute ceiling;continuous selectivity; kidney: 2.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 0.2 nTPM; positive ihc; midbrain: 3 nTPM; absolute ceiling;continuous selectivity; pancreas: 0.6 nTPM; positive ihc; parathyroid gland: 0.5 nTPM; positive ihc; pituitary gland: 1.7 nTPM; continuous selectivity; retina: 10.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 0.2 nTPM; positive ihc; small intestine: 0.5 nTPM; positive ihc; spinal cord: 2.4 nTPM; absolute ceiling;continuous selectivity; stomach: 0.7 nTPM; positive ihc; thyroid gland: 0.8 nTPM; positive ihc; urinary bladder: 2.2 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 4.2 nTPM (limit 2); basal ganglia: 3.7 nTPM (limit 2); cerebellum: 4.8 nTPM (limit 2); cerebral cortex: 12.3 nTPM (limit 2); heart muscle: 2.7 nTPM (limit 2); hippocampal formation: 4.5 nTPM (limit 2); hypothalamus: 4.4 nTPM (limit 2); kidney: 2.2 nTPM (limit 2); midbrain: 3 nTPM (limit 2); retina: 10.7 nTPM (limit 2); spinal cord: 2.4 nTPM (limit 2),adrenal gland / glandular cells: Medium (Enhanced); bone marrow / hematopoietic cells: Low (Enhanced); caudate / glial cells: Low (Enhanced); caudate / neuronal cells: Medium (Enhanced); cerebellum / cells in granular layer: Low (Enhanced); cerebellum / Purkinje cells: Low (Enhanced); cerebral cortex / glial cells: Medium (Enhanced); cerebral cortex / neuronal cells: High (Enhanced); duodenum / glandular cells: Low (Enhanced); heart muscle / cardiomyocytes: Low (Enhanced); hippocampus / glial cells: Medium (Enhanced); hippocampus / neuronal cells: High (Enhanced); kidney / cells in tubules: Low (Enhanced); lymph node / germinal center cells: Low (Enhanced); lymph node / non-germinal center cells: Low (Enhanced); nasopharynx / respiratory epithelial cells: Low (Enhanced); pancreas / pancreatic endocrine cells: Medium (Enhanced); parathyroid gland / glandular cells: Low (Enhanced); salivary gland / glandular cells: Medium (Enhanced); small intestine / glandular cells: Low (Enhanced); stomach 1 / glandular cells: Medium (Enhanced); stomach 2 / glandular cells: Low (Enhanced); thyroid gland / glandular cells: Medium (Enhanced); urinary bladder / urothelial cells: Medium (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Kidney Renal Clear Cell Carcinoma (validation): 89/100 (89.0%); Glioblastoma Multiforme (TCGA): 121/141 (85.8%),testis cancer: 5/10 (50.0%); colorectal cancer: 5/11 (45.5%),31,20,Q8N2Q7,https://www.uniprot.org/uniprotkb/Q8N2Q7/entry,"Cell surface protein involved in cell-cell-interactions via its interactions with neurexin family members. Plays a role in synapse function and synaptic signal transmission, and probably mediates its effects by recruiting and clustering other synaptic proteins. May promote the initial formation of synapses, but is not essential for this. In vitro, triggers the de novo formation of presynaptic structures. May be involved in specification of excitatory synapses. Required to maintain wakefulness quality and normal synchrony of cerebral cortex activity during wakefulness and sleep (By similarity). The protein is involved in nervous system development","Expressed in the blood vessel walls (at protein level). Highly expressed in brain through prenatal stages, and at lower levels in pancreas islet beta cells","Autism 20: A complex multifactorial, pervasive developmental disorder characterized by impairments in reciprocal social interaction and communication, restricted and stereotyped patterns of interests and activities, and the presence of developmental abnormalities by 3 years of age. Most individuals with autism also manifest moderate intellectual disability. The transmission pattern of AUTS20 is consistent with autosomal dominant inheritance.",,"Cell membrane Postsynaptic density Synaptic cleft Synaptic cell membrane Cell projection, dendrite Synapse",28841651,18755801|19926856|28841651,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
NLRP10,ENSG00000182261,Unsafe,Protein,False,True,1.4,4.8,79,70,Positive somewhere,True,False,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0 nTPM; positive ihc; adrenal gland: 0 nTPM; positive ihc; bone marrow: 0.1 nTPM; positive ihc; cerebellum: 0 nTPM; positive ihc; cerebral cortex: 0 nTPM; positive ihc; colon: 0 nTPM; positive ihc; duodenum: 0 nTPM; positive ihc; esophagus: 0 nTPM; positive ihc; heart muscle: 0 nTPM; positive ihc; kidney: 0 nTPM; positive ihc; liver: 0 nTPM; positive ihc; lung: 0 nTPM; positive ihc; lymph node: 0 nTPM; positive ihc; pancreas: 0 nTPM; positive ihc; parathyroid gland: 0 nTPM; positive ihc; rectum: 0 nTPM; positive ihc; salivary gland: 0 nTPM; positive ihc; skeletal muscle: 0.1 nTPM; positive ihc; skin: 4.8 nTPM; positive ihc;continuous selectivity;reproductive not higher; small intestine: 0 nTPM; positive ihc; spleen: 0 nTPM; positive ihc; stomach: 0 nTPM; positive ihc; thyroid gland: 0 nTPM; positive ihc; urinary bladder: 0 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,adipose tissue / adipocytes: Medium (Uncertain); adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Low (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / glial cells: Low (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: Low (Uncertain); cerebellum / cells in molecular layer: Low (Uncertain); cerebellum / Purkinje cells: Low (Uncertain); cerebral cortex / endothelial cells: Medium (Uncertain); cerebral cortex / glial cells: Medium (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: High (Uncertain); colon / endothelial cells: Medium (Uncertain); colon / glandular cells: High (Uncertain); colon / peripheral nerve/ganglion: Medium (Uncertain); duodenum / glandular cells: High (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: High (Uncertain); hippocampus / glial cells: Low (Uncertain); hippocampus / neuronal cells: Low (Uncertain); kidney / cells in glomeruli: Low (Uncertain); kidney / cells in tubules: High (Uncertain); liver / cholangiocytes: Medium (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / alveolar cells: Low (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / non-germinal center cells: Medium (Uncertain); nasopharynx / respiratory epithelial cells: Low (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); parathyroid gland / glandular cells: High (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: High (Uncertain); skin 1 / fibroblasts: Low (Uncertain); skin 1 / keratinocytes: Low (Uncertain); skin 1 / Langerhans: Medium (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: Medium (Uncertain); spleen / cells in red pulp: High (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: High (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Head and Neck Squamous Cell Carcinoma (TCGA): 7/492 (1.4%); Uterine Corpus Endometrial Carcinoma (TCGA): 2/176 (1.1%); Skin Cuteneous Melanoma (TCGA): 1/99 (1.0%),melanoma: 10/10 (100.0%); breast cancer: 10/11 (90.9%),31,20,Q86W26,https://www.uniprot.org/uniprotkb/Q86W26/entry,"Inhibits autoprocessing of CASP1, CASP1-dependent IL1B secretion, PYCARD aggregation and PYCARD-mediated apoptosis but not apoptosis induced by FAS or BID (PubMed:15096476). Displays anti-inflammatory activity (PubMed:20393137). Required for immunity against C.albicans infection (By similarity). Involved in the innate immune response by contributing to pro-inflammatory cytokine release in response to invasive bacterial infection (PubMed:22672233). Contributes to T-cell-mediated inflammatory responses in the skin (By similarity). Plays a role in protection against periodontitis through its involvement in induction of IL1A via ERK activation in oral epithelial cells infected with periodontal pathogens (PubMed:28766990). Exhibits both ATPase and GTPase activities (PubMed:23861819)","Highly expressed in basal and suprabasal epidermal cell layers with lower levels in dermal fibroblast cells (at protein level) (PubMed:22672233). Widely expressed with highest levels in heart, brain and skeletal muscle (PubMed:15096476). Also expressed in liver, colon, dermis and epidermis (PubMed:15096476). Little expression detected in myeloid cells or peripheral blood mononuclear cells (PubMed:15096476)",,"Despite its official name, does not contain LRR repeats Was originally thought to play a role in adaptive immunity through control of dendritic cell-mediated antigen transport to lymph nodes from peripheral sites. However, this was later shown to be dependent on DOCK8",Cytoplasm Cell membrane,15096476|20393137|22672233|23861819,15096476|22672233,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | daSilva2017_tumor_proteomics,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
NLRP5,ENSG00000171487,Unsafe,RNA,False,True,6.4,21.7,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,parathyroid gland: 21.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,parathyroid gland: 21.7 nTPM (limit 6); parathyroid gland: 21.7 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 2/50 (4.0%); Breast Invasive Carcinoma (TCGA): 21/1022 (2.1%); Lung Adenocarcinoma (validation): 1/105 (1.0%),colorectal cancer: 9/11 (81.8%); prostate cancer: 8/10 (80.0%),31,20,P59047,https://www.uniprot.org/uniprotkb/P59047/entry,"Component of the subcortical maternal complex (SCMC), a multiprotein complex that plays a key role in early embryonic development (PubMed:38868925). The SCMC complex is a structural constituent of cytoplasmic lattices, which consist in fibrous structures found in the cytoplasm of oocytes and preimplantation embryos (PubMed:41118754). They are required to store maternal proteins critical for embryonic development, such as ribosomal proteins, cytoskeletal tubulins and proteins controlling epigenetic reprogramming of the preimplantation embryo, in a poised but restrained state, regulating their availability for early embryonic development (PubMed:24374158, PubMed:38868925). Cytoplasmic lattices also tightly control ubiquitination during the oocyte-to-embryo transition by trapping E3 ubiquitin-protein ligase UHRF1 in a compact autoinhibited conformation and maintaining SCF ubiquitin ligase complexes inactive (PubMed:38868925). Required for the localization of cortical granules to the cortex of oocytes, via association with the cortical actin scaffold (By similarity). Required for cortical actin clearance prior to oocyte exocytosis and prevention of polyspermy (By similarity). Involved in regulating post-fertilization Ca(2+) release and endoplasmic reticulum storage (ER) storage via regulation of cellular localization (By similarity). May be involved in the localization of mitochondria to the cytoplasm and perinuclear region in oocytes and early stage embryos, independent of its role in CPL formation (By similarity)","Expressed in cumulus cells (at protein level) (PubMed:19542546). Highly abundant in oocytes and early embryos, however poorly expressed in somatic tissues such as the liver and spinal cord (PubMed:11925379, PubMed:30877238)","Oocyte/zygote/embryo maturation arrest 19: An autosomal recessive female infertility disorder characterized by reduced fertilization rate, oocyte maturation arrest at germinal vesicle stage, and early embryonic arrest.",,"Cytoplasm Cytoplasmic vesicle, secretory vesicle, Cortical granule Mitochondrion Nucleus, nucleolus Golgi apparatus",24374158|38868925|41118754,11925379|19542546|30877238,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
NLRP7,ENSG00000167634,Unsafe,High RNA,False,True,3.8,3.8,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,True,"thymus/plasma cells cluster c-19: 34.8 nTPM, 63 reads; reproductive-cell max 30.1",True,True,"DICE NK (unstimulated): 90/90 values ≥5 TPM, max 21.442",True,True,False,,True,True,"Adipose tissue/Adipocytes: High, HPA051382; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA051382; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: High, HPA051382; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA051382; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA051382; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: High, HPA051382; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA051382; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: High, HPA051382; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA051382; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA051382; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA051382; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA051382; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA051382; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA051382; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA051382; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: High, HPA051382; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA051382; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: High, HPA051382; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA051382; conflicting or uncurated primary profile; Liver/Cholangiocytes: Medium, HPA051382; conflicting or uncurated primary profile; Liver/Hepatocytes: High, HPA051382; conflicting or uncurated primary profile; Lung/Alveolar cells: High, HPA051382; conflicting or uncurated primary profile; Lung/Macrophages: High, HPA051382; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA051382; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: High, HPA051382; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA051382; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA051382; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA051382; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA051382; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: High, HPA051382; conflicting or uncurated primary profile; Rectum/Glandular cells: High, HPA051382; conflicting or uncurated primary profile; Salivary gland/Glandular cells: High, HPA051382; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: High, HPA051382; conflicting or uncurated primary profile; Skin 1/Fibroblasts: High, HPA051382; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA051382; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA051382; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA051382; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA051382; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: High, HPA051382; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA051382; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA051382; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA051382; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA051382; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA051382; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,21.4419572385,34.8,"hpa_single_cell_tissue: thymus/plasma cells, max 34.8 nTPM, 1 observations >30",Neither,oncoref.target-sets.2026-10-23.2,21.44 TPM; blood/NK; dice_nk; vital,34.8 nTPM; thymus/plasma cells; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 45/133 (33.8%); Ovary Serous Cystadenocarcinoma (validation): 11/81 (13.6%); Bladder Urothelial Carcinoma (TCGA): 5/169 (3.0%),liver cancer: 11/11 (100.0%); testis cancer: 11/11 (100.0%),31,20,Q8WX94,https://www.uniprot.org/uniprotkb/Q8WX94/entry,"Component of cytoplasmic lattices, which consist in fibrous structures found in the cytoplasm of oocytes and preimplantation embryos (PubMed:41118754). Cytoplasmic lattices are required to store maternal proteins critical for embryonic development, such as ribosomal proteins, cytoskeletal tubulins and proteins controlling epigenetic reprogramming of the preimplantation embryo, in a poised but restrained state, regulating their availability for early embryonic development (PubMed:41118754). Inhibits CASP1/caspase-1-dependent IL1B secretion (PubMed:15817483)","Expressed in numerous tissues including uterus and ovary, with low levels in heart and brain. Not detected in skeletal muscle","Hydatidiform mole, recurrent, 1: A disorder characterized by excessive trophoblast development that produces a growing mass of tissue inside the uterus at the beginning of a pregnancy. It leads to abnormal pregnancies with no embryo, and cystic degeneration of the chorionic villi. Oocyte/zygote/embryo maturation arrest 25: An autosomal dominant, female infertility disorder due to early embryo maturation arrest.",,"Cytoplasm, cell cortex",15817483|41118754,15817483|16462743,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Jamin2021_CT | Jamin2021_core | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination; inclusion depends on TGCT under this study's thresholds | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
NME8,ENSG00000086288,Unsafe,RNA,False,True,10.1,12.2,86,7,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,bone marrow: 12.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 12.2 nTPM (limit 12),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 2/58 (3.4%); Uterine Corpus Endometrial Carcinoma (TCGA): 5/176 (2.8%); Testicular Germ Cell Tumor (TCGA): 3/133 (2.3%),colorectal cancer: 1/12 (8.3%); breast cancer: 0/12 (0.0%),29,20,Q8N427,https://www.uniprot.org/uniprotkb/Q8N427/entry,"Possesses an intrinsic kinase activity (PubMed:16313181). In vitro, does not exhibit nucleoside diphosphate kinase (NDPK) activity or disulfide bond-reducing activity (PubMed:11737268, PubMed:16313181). Additionally, exhibits a 3'-5'-DNA exonuclease activity that removes single nucleotides from the 3' terminus of single-stranded DNA substrates and digests overhanging mismatched 3' termini from double-stranded DNA substrates, suggesting a role in DNA nucleolytic processing (PubMed:16313181). May be required during the final stages of sperm tail maturation in the testis and/or epididymis, where extensive disulfide bonding of fibrous sheath (FS) proteins occurs (By similarity)",Testis-specific. Expressed only in primary spermatocytes and round spermatids,"Ciliary dyskinesia, primary, 6: A disorder characterized by abnormalities of motile cilia. Respiratory infections leading to chronic inflammation and bronchiectasis are recurrent, due to defects in the respiratory cilia; reduced fertility is often observed in male patients due to abnormalities of sperm tails. Half of the patients exhibit randomization of left-right body asymmetry and situs inversus, due to dysfunction of monocilia at the embryonic node. Primary ciliary dyskinesia associated with situs inversus is referred to as Kartagener syndrome.",,Cytoplasm,11737268|16313181,11737268,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Jamin2021_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
NME9,ENSG00000181322,Unsafe,Protein,False,True,17.0,20.1,123,18,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 0.7 nTPM; positive ihc; amygdala: 4.2 nTPM; absolute ceiling; basal ganglia: 5.4 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 20.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 4.7 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 6.6 nTPM; absolute ceiling;continuous selectivity; midbrain: 3.5 nTPM; absolute ceiling; pituitary gland: 3.6 nTPM; absolute ceiling; retina: 7.2 nTPM; absolute ceiling;continuous selectivity; spinal cord: 3.7 nTPM; absolute ceiling; thyroid gland: 1.1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 4.2 nTPM (limit 2); basal ganglia: 5.4 nTPM (limit 2); choroid plexus: 20.1 nTPM (limit 2); hippocampal formation: 4.7 nTPM (limit 2); hypothalamus: 6.6 nTPM (limit 2); midbrain: 3.5 nTPM (limit 2); pituitary gland: 3.6 nTPM (limit 2); retina: 7.2 nTPM (limit 2); spinal cord: 3.7 nTPM (limit 2),adrenal gland / glandular cells: Low (Enhanced); bronchus / ciliated cells (cell body): Low (Enhanced); bronchus / ciliated cells (cilia axoneme): High (Enhanced); bronchus / ciliated cells (tip of cilia): High (Enhanced); caudate / glial cells: Low (Enhanced); caudate / neuronal cells: Low (Enhanced); hippocampus / glial cells: Low (Enhanced); nasopharynx / ciliated cells (cell body): Medium (Enhanced); nasopharynx / ciliated cells (cilia axoneme): High (Enhanced); nasopharynx / ciliated cells (tip of cilia): High (Enhanced); thyroid gland / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 31/176 (17.6%); Glioblastoma Multiforme (validation): 9/58 (15.5%); Kidney Renal Papillary Cell Carcinoma (TCGA): 29/282 (10.3%),breast cancer: 0/12 (0.0%); cervical cancer: 0/12 (0.0%),29,20,Q86XW9,https://www.uniprot.org/uniprotkb/Q86XW9/entry,May be a regulator of microtubule physiology,"Detected at very low levels in testis, lung and brain",,,"Cytoplasm, cytoskeleton, cilium axoneme Dynein axonemal particle",12569107,12569107,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
NOL4,ENSG00000101746,Unsafe,RNA,False,True,12.2,12.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 6.9 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 8.7 nTPM; absolute ceiling;continuous selectivity; cerebellum: 10.4 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 10 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 5.6 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 7.7 nTPM; absolute ceiling;continuous selectivity; liver: 2.1 nTPM; absolute ceiling; midbrain: 2.7 nTPM; absolute ceiling; pituitary gland: 7.8 nTPM; absolute ceiling;continuous selectivity; retina: 6.1 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 6.9 nTPM (limit 2); basal ganglia: 8.7 nTPM (limit 2); cerebellum: 10.4 nTPM (limit 2); cerebral cortex: 10 nTPM (limit 2); hippocampal formation: 5.6 nTPM (limit 2); hypothalamus: 7.7 nTPM (limit 2); liver: 2.1 nTPM (limit 2); midbrain: 2.7 nTPM (limit 2); pituitary gland: 7.8 nTPM (limit 2); retina: 6.1 nTPM (limit 2); amygdala: 6.9 nTPM (baseline 2); basal ganglia: 8.7 nTPM (baseline 2); cerebellum: 10.4 nTPM (baseline 2); cerebral cortex: 10 nTPM (baseline 2); hippocampal formation: 5.6 nTPM (baseline 2); hypothalamus: 7.7 nTPM (baseline 2); liver: 2.1 nTPM (baseline 2); midbrain: 2.7 nTPM (baseline 2); pituitary gland: 7.8 nTPM (baseline 2); retina: 6.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Glioblastoma Multiforme (TCGA): 46/141 (32.6%); Kidney Renal Papillary Cell Carcinoma (TCGA): 41/282 (14.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O94818,https://www.uniprot.org/uniprotkb/O94818/entry,,"Expressed predominantly in fetal brain, adult brain and testis",,,"Nucleus, nucleolus",,9813152,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
NOL4L,ENSG00000197183,Unsafe,Protein,False,True,42.8,48.0,86,59,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 9.9 nTPM; positive ihc; amygdala: 13 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 9.3 nTPM; absolute ceiling; bone marrow: 20.9 nTPM; absolute ceiling; cerebellum: 19.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 12.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 9.1 nTPM; absolute ceiling; colon: 16.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 18.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 2.4 nTPM; positive ihc; hippocampal formation: 14.6 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 12 nTPM; absolute ceiling;continuous selectivity; kidney: 14 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 12.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 8.1 nTPM; positive ihc;absolute ceiling; midbrain: 12 nTPM; absolute ceiling;continuous selectivity; pancreas: 10.7 nTPM; positive ihc;absolute ceiling; pituitary gland: 21.6 nTPM; absolute ceiling;continuous selectivity; rectum: 13.2 nTPM; positive ihc;absolute ceiling; retina: 48 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 9.5 nTPM; positive ihc;absolute ceiling; skin: 3.3 nTPM; positive ihc; small intestine: 19.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 6.3 nTPM; positive ihc;absolute ceiling; spinal cord: 20.7 nTPM; absolute ceiling;continuous selectivity; spleen: 12.6 nTPM; positive ihc;absolute ceiling; stomach: 13 nTPM; positive ihc;absolute ceiling; thymus: 15.4 nTPM; absolute ceiling; thyroid gland: 9.3 nTPM; positive ihc; urinary bladder: 9.3 nTPM; positive ihc;absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 13 nTPM (limit 2); basal ganglia: 9.3 nTPM (limit 2); bone marrow: 20.9 nTPM (limit 12); cerebellum: 19.1 nTPM (limit 2); cerebral cortex: 12.3 nTPM (limit 2); choroid plexus: 9.1 nTPM (limit 2); colon: 16.6 nTPM (limit 6); duodenum: 18.6 nTPM (limit 2); hippocampal formation: 14.6 nTPM (limit 2); hypothalamus: 12 nTPM (limit 2); kidney: 14 nTPM (limit 2); lung: 12.7 nTPM (limit 2); lymph node: 8.1 nTPM (limit 6); midbrain: 12 nTPM (limit 2); pancreas: 10.7 nTPM (limit 2); pituitary gland: 21.6 nTPM (limit 2); rectum: 13.2 nTPM (limit 6); retina: 48 nTPM (limit 2); salivary gland: 9.5 nTPM (limit 6); small intestine: 19.6 nTPM (limit 2); smooth muscle: 6.3 nTPM (limit 2); spinal cord: 20.7 nTPM (limit 2); spleen: 12.6 nTPM (limit 10); stomach: 13 nTPM (limit 6); thymus: 15.4 nTPM (limit 10); urinary bladder: 9.3 nTPM (limit 6),adipose tissue / adipocytes: Low (Enhanced); bronchus / respiratory epithelial cells: Low (Enhanced); caudate / glial cells: Low (Enhanced); caudate / neuronal cells: Low (Enhanced); cerebellum / cells in granular layer: Low (Enhanced); cerebellum / cells in molecular layer: Low (Enhanced); cerebellum / Purkinje cells: Medium (Enhanced); cerebral cortex / endothelial cells: Low (Enhanced); cerebral cortex / glial cells: Medium (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); colon / endothelial cells: High (Enhanced); colon / glandular cells: High (Enhanced); colon / peripheral nerve/ganglion: Medium (Enhanced); duodenum / glandular cells: High (Enhanced); esophagus / squamous epithelial cells: Low (Enhanced); hippocampus / glial cells: Low (Enhanced); hippocampus / neuronal cells: Low (Enhanced); kidney / cells in glomeruli: Medium (Enhanced); kidney / cells in tubules: Medium (Enhanced); lung / alveolar cells type II: Medium (Enhanced); lung / macrophages: Medium (Enhanced); lymph node / non-germinal center cells: Low (Enhanced); nasopharynx / respiratory epithelial cells: Medium (Enhanced); pancreas / exocrine glandular cells: Medium (Enhanced); pancreas / pancreatic endocrine cells: Medium (Enhanced); rectum / glandular cells: High (Enhanced); salivary gland / glandular cells: Medium (Enhanced); skin 1 / keratinocytes: Low (Enhanced); skin 1 / Langerhans: Low (Enhanced); skin 2 / epidermal cells: Low (Enhanced); small intestine / glandular cells: High (Enhanced); smooth muscle / smooth muscle cells: Low (Enhanced); spleen / cells in red pulp: Medium (Enhanced); stomach 1 / glandular cells: High (Enhanced); stomach 2 / glandular cells: High (Enhanced); thyroid gland / glandular cells: Low (Enhanced); urinary bladder / urothelial cells: Medium (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Ovary Serous Cystadenocarcinoma (TCGA): 348/349 (99.7%),colorectal cancer: 11/12 (91.7%); pancreatic cancer: 10/11 (90.9%),29,20,Q96MY1,https://www.uniprot.org/uniprotkb/Q96MY1/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
NOTUM,ENSG00000185269,Unsafe,RNA,False,True,131.0,131.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,liver: 9.7 nTPM; absolute ceiling; lung: 2.1 nTPM; absolute ceiling; skeletal muscle: 7.9 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,liver: 9.7 nTPM (limit 2); lung: 2.1 nTPM (limit 2); skeletal muscle: 7.9 nTPM (limit 2); liver: 9.7 nTPM (baseline 2); lung: 2.1 nTPM (baseline 2); skeletal muscle: 7.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (TCGA): 59/88 (67.0%); Rectum Adenocarcinoma (validation): 111/207 (53.6%); Colon Adenocarcinoma (TCGA): 124/254 (48.8%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q6P988,https://www.uniprot.org/uniprotkb/Q6P988/entry,Carboxylesterase that acts as a key negative regulator of the Wnt signaling pathway by specifically mediating depalmitoleoylation of WNT proteins. Serine palmitoleoylation of WNT proteins is required for efficient binding to frizzled receptors (PubMed:25731175),Rarely expressed in adult normal tissues,,"The molecular function of NOTUM has remained unclear for many years. It was initially thought to hydrolyze glycosaminoglycan (GAG) chains of glypicans, thereby affecting glypicans ability to interact with Wnt ligands. It was later reported to trigger glypican shedding, by mediating cleavage of their GPI-anchor. However, while NOTUM specifically inhibit the Wnt signaling pathway, more pleiotropic effects would be expected from an enzyme affecting glypicans. It was finally shown that it requires glypicans to suppress Wnt signaling, but does not cleave their GPI-anchor. It acts by mediating depalmitoleoylation of WNT proteins, impairing WNT binding to frizzled receptors (PubMed:25731175)",Secreted,25731175,18429952,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
NOXRED1,ENSG00000165555,Unsafe,RNA,False,True,6.7,6.7,85,2,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,retina: 4.2 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 4.2 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 4/58 (6.9%); Kidney Chromophobe (TCGA): 2/64 (3.1%); Testicular Germ Cell Tumor (TCGA): 4/133 (3.0%),liver cancer: 2/12 (16.7%); breast cancer: 0/12 (0.0%),29,20,Q6NXP6,https://www.uniprot.org/uniprotkb/Q6NXP6/entry,Probable oxidoreductase,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
NPFFR2,ENSG00000056291,Unsafe,High RNA,False,True,3.1,7.0,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,thymus: 7 nTPM; continuous selectivity;reproductive not higher,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Selectivity,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,0.4645,194.4,"hpa_single_cell_tissue: brain/excitatory neurons, max 194.4 nTPM, 4 observations >30",Neither,oncoref.target-sets.2026-10-23.2,0.4645 TPM; blood/NK-cell; hpa_immune_cell_samples; vital,194.4 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (validation): 8/50 (16.0%); Liver Hepatocellular Carcinoma (validation): 24/231 (10.4%); Bladder Urothelial Carcinoma (TCGA): 11/169 (6.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9Y5X5,https://www.uniprot.org/uniprotkb/Q9Y5X5/entry,"Receptor for NPAF (A-18-F-amide) and NPFF (F-8-F-amide) neuropeptides, also known as morphine-modulating peptides. Can also be activated by a variety of naturally occurring or synthetic FMRF-amide like ligands. This receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system","Isoform 1 is abundant in placenta. Relatively highly expressed in thymus, testis, and small intestine. Expressed at low levels in several tissues including spleen, prostate, brain, heart, ovary, colon, kidney, lung, liver and pancreas and not expressed in skeletal muscle and leukocytes. Isoform 2 expression is highest in placenta (but at relatively low level compared to isoform 1). Very low level of expression in numerous tissues including adipose tissue and many brain regions. Isoform 3 is expressed in brain and heart and, at lower levels, in kidney, liver, lung and pancreas",,,Cell membrane,11024015,10079187,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Gong2021_reproductive_PC,No tumor-antigen validation in this source | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
NPHP1,ENSG00000144061,Unsafe,Protein,False,True,24.1,37.1,95,69,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 3.6 nTPM; positive ihc;absolute ceiling; amygdala: 4.9 nTPM; absolute ceiling; basal ganglia: 7 nTPM; absolute ceiling;continuous selectivity; bone marrow: 0.1 nTPM; positive ihc; cerebellum: 1 nTPM; positive ihc; cerebral cortex: 4.3 nTPM; positive ihc;absolute ceiling; choroid plexus: 37.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 5.1 nTPM; positive ihc; duodenum: 0.9 nTPM; positive ihc; esophagus: 1.3 nTPM; positive ihc; heart muscle: 4.7 nTPM; positive ihc;absolute ceiling; hippocampal formation: 5.5 nTPM; absolute ceiling; hypothalamus: 7.5 nTPM; absolute ceiling;continuous selectivity; kidney: 7.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 0.8 nTPM; positive ihc; lung: 4.2 nTPM; positive ihc;absolute ceiling; lymph node: 0.8 nTPM; positive ihc; midbrain: 3.8 nTPM; absolute ceiling; pancreas: 3.1 nTPM; positive ihc;absolute ceiling; parathyroid gland: 16.4 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 11.4 nTPM; absolute ceiling;continuous selectivity; rectum: 1.7 nTPM; positive ihc; retina: 10.4 nTPM; absolute ceiling;continuous selectivity; salivary gland: 2.4 nTPM; positive ihc; skeletal muscle: 35 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 1.7 nTPM; positive ihc; small intestine: 1.8 nTPM; positive ihc; smooth muscle: 4.5 nTPM; positive ihc;absolute ceiling; spinal cord: 3.6 nTPM; absolute ceiling; spleen: 1.8 nTPM; positive ihc; stomach: 3.5 nTPM; positive ihc; thyroid gland: 7.2 nTPM; positive ihc; tongue: 10.3 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 4 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 3.6 nTPM (limit 2); amygdala: 4.9 nTPM (limit 2); basal ganglia: 7 nTPM (limit 2); cerebral cortex: 4.3 nTPM (limit 2); choroid plexus: 37.1 nTPM (limit 2); heart muscle: 4.7 nTPM (limit 2); hippocampal formation: 5.5 nTPM (limit 2); hypothalamus: 7.5 nTPM (limit 2); kidney: 7.8 nTPM (limit 2); lung: 4.2 nTPM (limit 2); midbrain: 3.8 nTPM (limit 2); pancreas: 3.1 nTPM (limit 2); parathyroid gland: 16.4 nTPM (limit 8); pituitary gland: 11.4 nTPM (limit 2); retina: 10.4 nTPM (limit 2); skeletal muscle: 35 nTPM (limit 2); smooth muscle: 4.5 nTPM (limit 2); spinal cord: 3.6 nTPM (limit 2); tongue: 10.3 nTPM (limit 6),adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / ciliated cells (ciliary rootlets): High (Approved); caudate / neuronal cells: Low (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / endothelial cells: Medium (Approved); colon / endothelial cells: High (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / ciliated cells (cell body): Low (Approved); nasopharynx / ciliated cells (ciliary rootlets): High (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pituitary gland / cells in anterior : Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 46/50 (92.0%); Kidney Renal Clear Cell Carcinoma (validation): 90/100 (90.0%); Thyroid Carcinoma (TCGA): 420/495 (84.8%),pancreatic cancer: 10/12 (83.3%); colorectal cancer: 9/12 (75.0%),31,20,O15259,https://www.uniprot.org/uniprotkb/O15259/entry,"Together with BCAR1 it may play a role in the control of epithelial cell polarity (By similarity). Involved in the organization of apical junctions in kidney cells together with NPHP4 and RPGRIP1L/NPHP8 (By similarity). Does not seem to be strictly required for ciliogenesis (By similarity). Seems to help to recruit PTK2B/PYK2 to cell matrix adhesions, thereby initiating phosphorylation of PTK2B/PYK2 and PTK2B/PYK2-dependent signaling (By similarity). May play a role in the regulation of intraflagellar transport (IFT) during cilia assembly. Required for normal retina development (By similarity). In connecting photoreceptor cilia influences the movement of some IFT proteins such as IFT88 and WDR19. Involved in spermatogenesis (By similarity)","Widespread expression, with highest levels in pituitary gland, spinal cord, thyroid gland, testis, skeletal muscle, lymph node and trachea. Weakly expressed in heart, kidney and pancreas. Expressed in nasal epithelial cells (at protein level) (PubMed:16308564). Expressed in the renal collecting duct (at protein level) (PubMed:18477472)","Nephronophthisis 1: An autosomal recessive inherited disease characterized by anemia, polyuria, polydipsia, isosthenuria and death in uremia. Symmetrical destruction of the kidneys involving both tubules and glomeruli occurs. The underlying pathology is a chronic tubulo-interstitial nephropathy with characteristic tubular basement membrane thickening and medullary cyst formation. Associations with extrarenal symptoms, especially ocular lesions, are frequent. The age at death ranges from about 4 to 15 years. Senior-Loken syndrome 1: A renal-retinal disorder characterized by progressive wasting of the filtering unit of the kidney (nephronophthisis), with or without medullary cystic renal disease, and progressive eye disease. Typically this disorder becomes apparent during the first year of life. Joubert syndrome 4: A disorder presenting with cerebellar ataxia, oculomotor apraxia, hypotonia, neonatal breathing abnormalities and psychomotor delay. Neuroradiologically, it is characterized by cerebellar vermian hypoplasia/aplasia, thickened and reoriented superior cerebellar peduncles, and an abnormally large interpeduncular fossa, giving the appearance of a molar tooth on transaxial slices (molar tooth sign). Additional variable features include retinal dystrophy and renal disease. Joubert syndrome type 4 is a phenotypically mild form.",,"Cell junction Cell junction, adherens junction Cell projection, cilium Cytoplasm, cytoskeleton, cilium axoneme Cell junction, tight junction",,16308564|18477472,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
NR6A1,ENSG00000148200,Unsafe,RNA,False,True,22.2,22.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 4.3 nTPM; absolute ceiling; liver: 2.6 nTPM; absolute ceiling; pancreas: 2.8 nTPM; absolute ceiling; retina: 3 nTPM; absolute ceiling; small intestine: 2.5 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 4.3 nTPM (limit 2); liver: 2.6 nTPM (limit 2); pancreas: 2.8 nTPM (limit 2); retina: 3 nTPM (limit 2); small intestine: 2.5 nTPM (limit 2); bone marrow: 4.3 nTPM (baseline 2); liver: 2.6 nTPM (baseline 2); pancreas: 2.8 nTPM (baseline 2); retina: 3 nTPM (baseline 2); small intestine: 2.5 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 125/133 (94.0%); Rectum Adenocarcinoma (validation): 180/207 (87.0%); Colon Adenocarcinoma (validation): 351/486 (72.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q15406,https://www.uniprot.org/uniprotkb/Q15406/entry,Orphan nuclear receptor that binds to a response element containing the sequence 5'-TCAAGGTCA-3' (PubMed:26769970). Acts as a regulator of embryonic stem cell pluripotency by mediating repression of POU5F1/OCT4: binds to the DR0 element within the POU5F1/OCT4 promoter and inhibits POU5F1/OCT4 expression during embryonic stem cell differentiation (PubMed:26769970). Involved in the regulation of gene expression in germ cell development during gametogenesis (By similarity),Shows highest expression in the germ cells of the adult testis,"Oculovertebral syndrome: An autosomal dominant syndrome characterized by missing vertebrae in the thoracic and/or lumbar spine and uveal coloboma, a congenital ocular malformation caused by failure of the ventral optic fissure to close during early eye morphogenesis and usually considered on a phenotypic continuum with microphthalmia and anophthalmia. Some patients have congenital kidney abnormalities. OVS shows incomplete penetrance and variable expressivity.",,Nucleus,26769970,8982251|9134503|9177477|9493564|9537518,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
NRG1,ENSG00000157168,Unsafe,Protein,False,True,7.4,16.5,78,19,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 2.9 nTPM; absolute ceiling;continuous selectivity; bone marrow: 1.3 nTPM; positive ihc; cerebellum: 3.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 5.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 3 nTPM; absolute ceiling;continuous selectivity; colon: 2.8 nTPM; continuous selectivity; duodenum: 2.1 nTPM; absolute ceiling;continuous selectivity; esophagus: 2.6 nTPM; continuous selectivity; hippocampal formation: 2.1 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 11.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; liver: 16.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 3.4 nTPM; absolute ceiling;continuous selectivity; lymph node: 0.3 nTPM; positive ihc; midbrain: 4.2 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 0.6 nTPM; positive ihc; pituitary gland: 3.6 nTPM; absolute ceiling;continuous selectivity; rectum: 2.9 nTPM; continuous selectivity; retina: 11.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 4.7 nTPM; positive ihc;continuous selectivity; small intestine: 2.3 nTPM; absolute ceiling;continuous selectivity; spinal cord: 2 nTPM; continuous selectivity; spleen: 1.5 nTPM; positive ihc; thyroid gland: 9.4 nTPM; continuous selectivity;reproductive not higher; urinary bladder: 8.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 2.9 nTPM (limit 2); cerebellum: 3.4 nTPM (limit 2); cerebral cortex: 5.5 nTPM (limit 2); choroid plexus: 3 nTPM (limit 2); duodenum: 2.1 nTPM (limit 2); hippocampal formation: 2.1 nTPM (limit 2); hypothalamus: 11.7 nTPM (limit 2); kidney: 8 nTPM (limit 2); liver: 16.5 nTPM (limit 2); lung: 3.4 nTPM (limit 2); midbrain: 4.2 nTPM (limit 2); pituitary gland: 3.6 nTPM (limit 2); retina: 11.3 nTPM (limit 2); small intestine: 2.3 nTPM (limit 2); urinary bladder: 8.9 nTPM (limit 6); amygdala: 2.9 nTPM (baseline 2); cerebellum: 3.4 nTPM (baseline 2); cerebral cortex: 5.5 nTPM (baseline 2); choroid plexus: 3 nTPM (baseline 2); duodenum: 2.1 nTPM (baseline 2); hippocampal formation: 2.1 nTPM (baseline 2); hypothalamus: 11.7 nTPM (baseline 2); kidney: 8 nTPM (baseline 2); liver: 16.5 nTPM (baseline 2); lung: 3.4 nTPM (baseline 2); midbrain: 4.2 nTPM (baseline 2); pituitary gland: 3.6 nTPM (baseline 2); retina: 11.3 nTPM (baseline 2); small intestine: 2.3 nTPM (baseline 2); urinary bladder: 8.9 nTPM (baseline 6),bone marrow / hematopoietic cells: Low (Uncertain); caudate / glial cells: Low (Uncertain); cerebellum / cells in granular layer: Low (Uncertain); cerebellum / cells in molecular layer: Low (Uncertain); cerebellum / Purkinje cells: Low (Uncertain); cerebral cortex / glial cells: Low (Uncertain); hippocampus / glial cells: Low (Uncertain); lymph node / germinal center cells: Medium (Uncertain); lymph node / non-germinal center cells: Medium (Uncertain); nasopharynx / respiratory epithelial cells: Low (Uncertain); parathyroid gland / glandular cells: Low (Uncertain); skin 1 / Langerhans: Medium (Uncertain); spleen / cells in red pulp: Low (Uncertain); spleen / cells in white pulp: Medium (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Head and Neck Squamous Cell Carcinoma (TCGA): 404/492 (82.1%); Rectum Adenocarcinoma (validation): 164/207 (79.2%); Kidney Renal Papillary Cell Carcinoma (TCGA): 209/282 (74.1%),lymphoma: 7/12 (58.3%); breast cancer: 0/12 (0.0%),31,20,Q02297,https://www.uniprot.org/uniprotkb/Q02297/entry,"Direct ligand for ERBB3 and ERBB4 tyrosine kinase receptors. Concomitantly recruits ERBB1 and ERBB2 coreceptors, resulting in ligand-stimulated tyrosine phosphorylation and activation of the ERBB receptors. The multiple isoforms perform diverse functions such as inducing growth and differentiation of epithelial, glial, neuronal, and skeletal muscle cells; inducing expression of acetylcholine receptor in synaptic vesicles during the formation of the neuromuscular junction; stimulating lobuloalveolar budding and milk production in the mammary gland and inducing differentiation of mammary tumor cells; stimulating Schwann cell proliferation; implication in the development of the myocardium such as trabeculation of the developing heart. Isoform 10 may play a role in motor and sensory neuron development. Binds to ERBB4 (PubMed:10867024, PubMed:7902537). Binds to ERBB3 (PubMed:20682778). Acts as a ligand for integrins and binds (via EGF domain) to integrins ITGAV:ITGB3 or ITGA6:ITGB4. Its binding to integrins and subsequent ternary complex formation with integrins and ERRB3 are essential for NRG1-ERBB signaling. Induces the phosphorylation and activation of MAPK3/ERK1, MAPK1/ERK2 and AKT1 (PubMed:20682778). Ligand-dependent ERBB4 endocytosis is essential for the NRG1-mediated activation of these kinases in neurons (By similarity)","Type I isoforms are the predominant forms expressed in the endocardium. Isoform alpha is expressed in breast, ovary, testis, prostate, heart, skeletal muscle, lung, placenta liver, kidney, salivary gland, small intestine and brain, but not in uterus, stomach, pancreas, and spleen. Isoform 3 is the predominant form in mesenchymal cells and in non-neuronal organs, whereas isoform 6 is the major neuronal form. Isoform 8 is expressed in spinal cord and brain. Isoform 9 is the major form in skeletal muscle cells; in the nervous system it is expressed in spinal cord and brain. Also detected in adult heart, placenta, lung, liver, kidney, and pancreas. Isoform 10 is expressed in nervous system: spinal cord motor neurons, dorsal root ganglion neurons, and brain. Predominant isoform expressed in sensory and motor neurons. Not detected in adult heart, placenta, lung, liver, skeletal muscle, kidney, and pancreas. Not expressed in fetal lung, liver and kidney. Type IV isoforms are brain-specific",,,Cell membrane Secreted Nucleus Membrane,10867024|1348215|20682778|7902537,17565985,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
NRL,ENSG00000129535,Unsafe,Protein,False,True,4.1,307.1,88,1,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; adrenal gland: 2.4 nTPM; absolute ceiling;continuous selectivity; amygdala: 3.6 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 3.7 nTPM; absolute ceiling;continuous selectivity; cerebellum: 1.8 nTPM; continuous selectivity; cerebral cortex: 3.3 nTPM; absolute ceiling;continuous selectivity; heart muscle: 1.7 nTPM; continuous selectivity; hippocampal formation: 3.1 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 2.6 nTPM; absolute ceiling;continuous selectivity; kidney: 3 nTPM; absolute ceiling;continuous selectivity; liver: 3.5 nTPM; absolute ceiling;continuous selectivity; midbrain: 3.4 nTPM; absolute ceiling;continuous selectivity; pancreas: 1.6 nTPM; continuous selectivity; parathyroid gland: 1.9 nTPM; continuous selectivity; pituitary gland: 2.3 nTPM; absolute ceiling;continuous selectivity; retina: 307.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 2.1 nTPM; absolute ceiling;continuous selectivity; small intestine: 1.3 nTPM; continuous selectivity; spinal cord: 3.7 nTPM; absolute ceiling;continuous selectivity; spleen: 2 nTPM; continuous selectivity; thyroid gland: 2.3 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 3.6 nTPM (limit 2); basal ganglia: 3.7 nTPM (limit 2); hippocampal formation: 3.1 nTPM (limit 2); hypothalamus: 2.6 nTPM (limit 2); midbrain: 3.4 nTPM (limit 2); pituitary gland: 2.3 nTPM (limit 2); retina: 307.1 nTPM (limit 2); spinal cord: 3.7 nTPM (limit 2); adrenal gland: 2.4 nTPM (baseline 2); amygdala: 3.6 nTPM (baseline 2); basal ganglia: 3.7 nTPM (baseline 2); cerebral cortex: 3.3 nTPM (baseline 2); hippocampal formation: 3.1 nTPM (baseline 2); hypothalamus: 2.6 nTPM (baseline 2); kidney: 3 nTPM (baseline 2); liver: 3.5 nTPM (baseline 2); midbrain: 3.4 nTPM (baseline 2); pituitary gland: 2.3 nTPM (baseline 2); retina: 307.1 nTPM (baseline 2); skeletal muscle: 2.1 nTPM (baseline 2); spinal cord: 3.7 nTPM (baseline 2),retina / photoreceptor cells: High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 29/50 (58.0%); Kidney Chromophobe (TCGA): 11/64 (17.2%); Testicular Germ Cell Tumor (TCGA): 12/133 (9.0%),breast cancer: 0/11 (0.0%); cervical cancer: 0/10 (0.0%),31,20,P54845,https://www.uniprot.org/uniprotkb/P54845/entry,"Acts as a transcriptional activator which regulates the expression of several rod-specific genes, including RHO and PDE6B (PubMed:21981118). Also functions as a transcriptional coactivator, stimulating transcription mediated by the transcription factor CRX and NR2E3 (PubMed:17335001). Binds to the rhodopsin promoter in a sequence-specific manner (PubMed:17335001)",Expressed in the brain and the retina (PubMed:11477108). Expressed strongly in rod and cone cells (at protein level) (PubMed:11477108),"Retinitis pigmentosa 27: A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. Enhanced S-cone syndrome 2: A form of enhanced S-cone syndrome, an autosomal recessive retinopathy characterized by increased sensitivity to blue light due to an increase in the number of cone photoreceptors for short wavelength light. Affected individuals experience early-onset night blindness, visual loss, varying degrees of L (long, red)- and M (middle, green)-cone vision, and retinal degeneration.",,Cytoplasm Nucleus,17335001|21981118,11477108,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
NSUN3,ENSG00000178694,Unsafe,RNA,False,True,3.2,3.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 2.4 nTPM; continuous selectivity; adrenal gland: 2.7 nTPM; absolute ceiling;continuous selectivity; amygdala: 1.9 nTPM; continuous selectivity; basal ganglia: 2.8 nTPM; absolute ceiling;continuous selectivity; bone marrow: 3.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 1.6 nTPM; continuous selectivity; cerebral cortex: 2.1 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 1.2 nTPM; continuous selectivity; colon: 3.4 nTPM; continuous selectivity;reproductive not higher; duodenum: 3 nTPM; absolute ceiling;continuous selectivity; esophagus: 2.2 nTPM; continuous selectivity; heart muscle: 2.3 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 2.1 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 2.2 nTPM; absolute ceiling;continuous selectivity; kidney: 2.3 nTPM; absolute ceiling;continuous selectivity; liver: 3 nTPM; absolute ceiling;continuous selectivity; lung: 2.6 nTPM; absolute ceiling;continuous selectivity; lymph node: 3.1 nTPM; continuous selectivity; midbrain: 2.1 nTPM; absolute ceiling;continuous selectivity; pancreas: 3 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 2.2 nTPM; continuous selectivity; pituitary gland: 2.2 nTPM; absolute ceiling;continuous selectivity; rectum: 3.8 nTPM; continuous selectivity;reproductive not higher; retina: 3.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 2.6 nTPM; continuous selectivity; skeletal muscle: 1.1 nTPM; continuous selectivity; skin: 3.1 nTPM; continuous selectivity; small intestine: 2.9 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 2.4 nTPM; absolute ceiling;continuous selectivity; spinal cord: 2.3 nTPM; absolute ceiling;continuous selectivity; spleen: 3.4 nTPM; continuous selectivity;reproductive not higher; stomach: 3.1 nTPM; continuous selectivity; thymus: 3.2 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 2.9 nTPM; continuous selectivity; tongue: 1.3 nTPM; continuous selectivity; urinary bladder: 2.5 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 2.7 nTPM (limit 2); basal ganglia: 2.8 nTPM (limit 2); bone marrow: 3.6 nTPM (limit 2); cerebral cortex: 2.1 nTPM (limit 2); duodenum: 3 nTPM (limit 2); heart muscle: 2.3 nTPM (limit 2); hippocampal formation: 2.1 nTPM (limit 2); hypothalamus: 2.2 nTPM (limit 2); kidney: 2.3 nTPM (limit 2); liver: 3 nTPM (limit 2); lung: 2.6 nTPM (limit 2); midbrain: 2.1 nTPM (limit 2); pancreas: 3 nTPM (limit 2); pituitary gland: 2.2 nTPM (limit 2); retina: 3.3 nTPM (limit 2); small intestine: 2.9 nTPM (limit 2); smooth muscle: 2.4 nTPM (limit 2); spinal cord: 2.3 nTPM (limit 2); adrenal gland: 2.7 nTPM (baseline 2); basal ganglia: 2.8 nTPM (baseline 2); bone marrow: 3.6 nTPM (baseline 2); cerebral cortex: 2.1 nTPM (baseline 2); duodenum: 3 nTPM (baseline 2); heart muscle: 2.3 nTPM (baseline 2); hippocampal formation: 2.1 nTPM (baseline 2); hypothalamus: 2.2 nTPM (baseline 2); kidney: 2.3 nTPM (baseline 2); liver: 3 nTPM (baseline 2); lung: 2.6 nTPM (baseline 2); midbrain: 2.1 nTPM (baseline 2); pancreas: 3 nTPM (baseline 2); pituitary gland: 2.2 nTPM (baseline 2); retina: 3.3 nTPM (baseline 2); small intestine: 2.9 nTPM (baseline 2); smooth muscle: 2.4 nTPM (baseline 2); spinal cord: 2.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 479/486 (98.6%); Rectum Adenocarcinoma (validation): 204/207 (98.6%),lymphoma: 6/11 (54.5%); prostate cancer: 6/12 (50.0%),31,20,Q9H649,https://www.uniprot.org/uniprotkb/Q9H649/entry,"Mitochondrial tRNA methyltransferase that mediates methylation of cytosine to 5-methylcytosine (m5C) at position 34 of mt-tRNA(Met) (PubMed:27214402, PubMed:27356879, PubMed:27497299). mt-tRNA(Met) methylation at cytosine(34) takes place at the wobble position of the anticodon and initiates the formation of 5-formylcytosine (f(5)c) at this position (PubMed:27214402, PubMed:27356879, PubMed:27497299). mt-tRNA(Met) containing the f(5)c modification at the wobble position enables recognition of the AUA codon in addition to the AUG codon, expanding codon recognition in mitochondrial translation (PubMed:27356879, PubMed:27497299)",,"Combined oxidative phosphorylation deficiency 48: An autosomal recessive, mitochondrial encephalomyopathy characterized by global developmental delay, microcephaly, failure to thrive, hypotonia, muscle weakness, external ophthalmoplegia, and seizures. Laboratory studies show metabolic acidosis, increased serum lactate, and combined oxidative phosphorylation deficiency in skeletal muscle.",,Mitochondrion matrix,27214402|27356879|27497299,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
NSUN7,ENSG00000179299,Unsafe,Protein,False,True,16.0,16.0,74,48,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 0.9 nTPM; positive ihc; bone marrow: 0.6 nTPM; positive ihc; cerebral cortex: 0.3 nTPM; positive ihc; choroid plexus: 9.7 nTPM; absolute ceiling;continuous selectivity; colon: 2.7 nTPM; positive ihc; duodenum: 1.7 nTPM; positive ihc; esophagus: 1.8 nTPM; positive ihc; heart muscle: 2 nTPM; positive ihc; kidney: 4.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 3.2 nTPM; positive ihc;absolute ceiling; lymph node: 0.3 nTPM; positive ihc; pancreas: 7 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 3.5 nTPM; absolute ceiling; rectum: 2.3 nTPM; positive ihc; salivary gland: 4.7 nTPM; positive ihc; skeletal muscle: 0 nTPM; positive ihc; skin: 1.5 nTPM; positive ihc; small intestine: 2 nTPM; positive ihc; smooth muscle: 1.1 nTPM; positive ihc; stomach: 3.1 nTPM; positive ihc; thyroid gland: 4.6 nTPM; positive ihc; urinary bladder: 1.3 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 9.7 nTPM (limit 2); kidney: 4.5 nTPM (limit 2); lung: 3.2 nTPM (limit 2); pancreas: 7 nTPM (limit 2); pituitary gland: 3.5 nTPM (limit 2); choroid plexus: 9.7 nTPM (baseline 2); kidney: 4.5 nTPM (baseline 2); lung: 3.2 nTPM (baseline 2); pancreas: 7 nTPM (baseline 2); pituitary gland: 3.5 nTPM (baseline 2),adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Low (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); cerebral cortex / endothelial cells: Low (Uncertain); colon / glandular cells: Medium (Uncertain); duodenum / glandular cells: Low (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: Low (Uncertain); kidney / cells in glomeruli: Low (Uncertain); kidney / cells in tubules: Low (Uncertain); lung / alveolar cells: Low (Uncertain); lung / macrophages: Low (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Low (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Low (Uncertain); skeletal muscle / myocytes: Low (Uncertain); skin 1 / keratinocytes: Medium (Uncertain); skin 1 / Langerhans: Medium (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: Low (Uncertain); smooth muscle / smooth muscle cells: Low (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Low (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 42/50 (84.0%); Kidney Chromophobe (TCGA): 48/64 (75.0%); Prostate Adenocarcinoma (TCGA): 315/480 (65.6%),melanoma: 5/10 (50.0%); skin cancer: 4/8 (50.0%),31,20,Q8NE18,https://www.uniprot.org/uniprotkb/Q8NE18/entry,Plays an essential for sperm flagellum assembly,,,"In contrast to other NSUN family members, NSUN7 lacks RNA cytosine C5-methyltransferase activity, due to sequence variations in S-adenosyl-L-methionine(SAM)-binding residues. Substitution of the conserved SAM-binding Asp-373 with Leu-373 abolishes SAM binding and likely renders the enzyme catalytically inactive","Cytoplasm Cell projection, cilium, flagellum",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
NT5DC4,ENSG00000144130,Unsafe,High RNA,False,True,2.5,2.5,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 1.2 nTPM; continuous selectivity,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE M2 (unstimulated): 9/90 values ≥5 TPM, max 137.193; hpa_immune_monaco intermediate monocyte: 8.3 TPM; hpa_immune_monaco non-classical monocyte: 13.3 TPM",True,True,False,,True,True,"Adrenal gland/Glandular cells: High, HPA046856; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA046856; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA046856; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA046856; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Medium, HPA046856; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA046856; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA046856; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Medium, HPA046856; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA046856; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA046856; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA046856; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA046856; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA046856; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA046856; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA046856; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: High, HPA046856; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA046856; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA046856; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA046856; conflicting or uncurated primary profile; Liver/Hepatocytes: High, HPA046856; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA046856; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA046856; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA046856; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: High, HPA046856; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA046856; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Medium, HPA046856; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA046856; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA046856; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA046856; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: High, HPA046856; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA046856; conflicting or uncurated primary profile; Skin 1/Keratinocytes: High, HPA046856; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA046856; conflicting or uncurated primary profile; Skin 2/Epidermal cells: High, HPA046856; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA046856; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Low, HPA046856; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Low, HPA046856; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA046856; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA046856; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA046856; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA046856; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,137.19317547100002,6.0,"dice_m2: blood/M2, max 137.193 TPM, 8 observations >30",Neither,oncoref.target-sets.2026-10-23.2,137.2 TPM; blood/M2; dice_m2; vital,6 nTPM; placenta/mixed immune cells; hpa_single_cell_tissue; vital,Kidney Chromophobe (TCGA): 2/64 (3.1%); Pancreatic Adenocarcinoma (validation): 1/80 (1.2%); Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%),colorectal cancer: 9/12 (75.0%); liver cancer: 9/12 (75.0%),29,20,Q86YG4,https://www.uniprot.org/uniprotkb/Q86YG4/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Chang2019_TGCT,Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
NUF2,ENSG00000143228,Unsafe,RNA,False,True,52.0,52.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,Published clinical study,bone marrow: 28 nTPM; absolute ceiling;continuous selectivity; duodenum: 4.2 nTPM; absolute ceiling; lymph node: 17.8 nTPM; absolute ceiling;continuous selectivity; small intestine: 4.2 nTPM; absolute ceiling; smooth muscle: 2.2 nTPM; absolute ceiling; thymus: 25.3 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 28 nTPM (limit 2); duodenum: 4.2 nTPM (limit 2); lymph node: 17.8 nTPM (limit 6); small intestine: 4.2 nTPM (limit 2); smooth muscle: 2.2 nTPM (limit 2); thymus: 25.3 nTPM (limit 10); bone marrow: 28 nTPM (baseline 2); duodenum: 4.2 nTPM (baseline 2); lymph node: 17.8 nTPM (baseline 6); small intestine: 4.2 nTPM (baseline 2); smooth muscle: 2.2 nTPM (baseline 2); thymus: 25.3 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 7/91 values ≥5 TPM, max 6.37002; DICE NK (unstimulated): 38/90 values ≥5 TPM, max 9.43146; DICE TREG_MEM (unstimulated): 23/89 values ≥5 TPM, max 9.89993; DICE TREG_NAIVE (unstimulated): 7/89 values ≥5 TPM, max 6.07641; DICE TH1 (unstimulated): 3/81 values ≥5 TPM, max 8.05195; DICE TH2 (unstimulated): 3/89 values ≥5 TPM, max 5.98424",True,True,False,,True,False,,False,False,True,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,True,9.89992849944,90.9,"hpa_single_cell: /Erythroid cells, max 57.9 nTPM, 1 observations >30; hpa_single_cell_tissue: adipose tissue/t-cells, max 79 nTPM, 1 observations >30; hpa_single_cell_tissue: bone marrow/erythroid cells, max 38.9 nTPM, 1 observations >30; hpa_single_cell_tissue: colon/undifferentiated cells, max 32.8 nTPM, 2 observations >30; hpa_single_cell_tissue: liver/erythroid cells, max 76.9 nTPM, 1 observations >30; hpa_single_cell_tissue: liver/plasma cells, max 38.6 nTPM, 1 observations >30; hpa_single_cell_tissue: placenta/mixed immune cells, max 84 nTPM, 1 observations >30; hpa_single_cell_tissue: rectum/mixed immune cells, max 89.5 nTPM, 1 observations >30; hpa_single_cell_tissue: spleen/plasma cells, max 53.4 nTPM, 1 observations >30; hpa_single_cell_tissue: thymus/plasma cells, max 48.1 nTPM, 3 observations >30; hpa_single_cell_tissue: tongue/basal keratinocytes, max 90.9 nTPM, 1 observations >30",Unsafe,oncoref.target-sets.2026-10-23.2,9.9 TPM; blood/TREG_MEM; dice_treg_mem; vital,90.9 nTPM; tongue/basal keratinocytes; hpa_single_cell_tissue; protected,Lung Squamous Cell Carcinoma (validation): 67/68 (98.5%); Glioblastoma Multiforme (validation): 57/58 (98.3%); Colon Adenocarcinoma (validation): 473/486 (97.3%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9BZD4,https://www.uniprot.org/uniprotkb/Q9BZD4/entry,"Acts as a component of the essential kinetochore-associated NDC80 complex, which is required for chromosome segregation and spindle checkpoint activity (PubMed:12438418, PubMed:14654001, PubMed:15062103, PubMed:15235793, PubMed:15239953, PubMed:15548592, PubMed:17535814). Required for kinetochore integrity and the organization of stable microtubule binding sites in the outer plate of the kinetochore (PubMed:15548592). The NDC80 complex synergistically enhances the affinity of the SKA1 complex for microtubules and may allow the NDC80 complex to track depolymerizing microtubules (PubMed:23085020)",,,,"Nucleus Chromosome, centromere, kinetochore",12438418|14654001|15062103|15235793|15239953|15548592|17535814|23085020,,False,Reviewed UniProt annotation; not a new primary-paper review,Clinical publication,https://pmc.ncbi.nlm.nih.gov/articles/PMC4203508/,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
NUP58,ENSG00000139496,Unsafe,Protein,False,True,43.9,43.9,81,47,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 11.4 nTPM; absolute ceiling; amygdala: 10.2 nTPM; absolute ceiling; basal ganglia: 11 nTPM; absolute ceiling; bone marrow: 19.2 nTPM; absolute ceiling;continuous selectivity; cerebellum: 16.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 14 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 4.2 nTPM; absolute ceiling; colon: 10.7 nTPM; positive ihc;absolute ceiling; duodenum: 11.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 12.4 nTPM; positive ihc;absolute ceiling; heart muscle: 13.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 10.9 nTPM; absolute ceiling; hypothalamus: 12.6 nTPM; absolute ceiling;continuous selectivity; kidney: 14 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 13.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 16.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 19.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 9.9 nTPM; absolute ceiling; pancreas: 10.5 nTPM; positive ihc;absolute ceiling; parathyroid gland: 9.7 nTPM; positive ihc;absolute ceiling; pituitary gland: 20.3 nTPM; absolute ceiling;continuous selectivity; rectum: 12.4 nTPM; positive ihc;absolute ceiling; retina: 25.4 nTPM; absolute ceiling;continuous selectivity; salivary gland: 10.4 nTPM; positive ihc;absolute ceiling; skeletal muscle: 18.8 nTPM; absolute ceiling;continuous selectivity; skin: 11.3 nTPM; positive ihc;absolute ceiling; small intestine: 10.8 nTPM; positive ihc;absolute ceiling; smooth muscle: 12.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 10.9 nTPM; absolute ceiling; spleen: 11.3 nTPM; positive ihc;absolute ceiling; stomach: 11.8 nTPM; positive ihc;absolute ceiling; thymus: 25.8 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 18.3 nTPM; positive ihc;absolute ceiling; tongue: 22.5 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 17.9 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 11.4 nTPM (limit 4); amygdala: 10.2 nTPM (limit 2); basal ganglia: 11 nTPM (limit 2); bone marrow: 19.2 nTPM (limit 4); cerebellum: 16.2 nTPM (limit 2); cerebral cortex: 14 nTPM (limit 2); choroid plexus: 4.2 nTPM (limit 2); colon: 10.7 nTPM (limit 6); duodenum: 11.1 nTPM (limit 2); esophagus: 12.4 nTPM (limit 6); heart muscle: 13.1 nTPM (limit 2); hippocampal formation: 10.9 nTPM (limit 2); hypothalamus: 12.6 nTPM (limit 2); kidney: 14 nTPM (limit 2); liver: 13.7 nTPM (limit 2); lung: 16.9 nTPM (limit 2); lymph node: 19.8 nTPM (limit 6); midbrain: 9.9 nTPM (limit 2); pancreas: 10.5 nTPM (limit 2); parathyroid gland: 9.7 nTPM (limit 6); pituitary gland: 20.3 nTPM (limit 2); rectum: 12.4 nTPM (limit 6); retina: 25.4 nTPM (limit 2); salivary gland: 10.4 nTPM (limit 6); skeletal muscle: 18.8 nTPM (limit 4); skin: 11.3 nTPM (limit 10); small intestine: 10.8 nTPM (limit 2); smooth muscle: 12.3 nTPM (limit 2); spinal cord: 10.9 nTPM (limit 2); spleen: 11.3 nTPM (limit 10); stomach: 11.8 nTPM (limit 6); thymus: 25.8 nTPM (limit 10); thyroid gland: 18.3 nTPM (limit 10); tongue: 22.5 nTPM (limit 6); urinary bladder: 17.9 nTPM (limit 6),caudate / neuronal cells: Low (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in tubules: High (Approved); liver / hepatocytes: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: High (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: Low (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 2 / epidermal cells: High (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in red pulp: Medium (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Low (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Colon Adenocarcinoma (TCGA): 254/254 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%),skin cancer: 8/12 (66.7%); lymphoma: 5/11 (45.5%),29,20,Q9BVL2,https://www.uniprot.org/uniprotkb/Q9BVL2/entry,"Component of the nuclear pore complex, a complex required for the trafficking across the nuclear membrane",,,,"Nucleus, nuclear pore complex Nucleus membrane",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
NUP62,ENSG00000213024,Unsafe,Protein,False,True,47.8,47.8,107,87,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 19.2 nTPM; positive ihc;absolute ceiling; adrenal gland: 28.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 12.4 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 12.6 nTPM; absolute ceiling;continuous selectivity; bone marrow: 25.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 28.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 14.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 11.5 nTPM; absolute ceiling; colon: 21.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 22.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 24.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 19.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 12.7 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 14.7 nTPM; absolute ceiling;continuous selectivity; kidney: 17.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 30.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 18.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 37.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 12.3 nTPM; absolute ceiling;continuous selectivity; pancreas: 20.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 17.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 22.2 nTPM; absolute ceiling;continuous selectivity; rectum: 19.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 9.8 nTPM; absolute ceiling; salivary gland: 21.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 32.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 22.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 23.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 26.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 14.3 nTPM; absolute ceiling;continuous selectivity; spleen: 28.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 18.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 39.7 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 15.8 nTPM; positive ihc;absolute ceiling; tongue: 20.8 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 23.4 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 19.2 nTPM (limit 10); adrenal gland: 28.4 nTPM (limit 2); amygdala: 12.4 nTPM (limit 2); basal ganglia: 12.6 nTPM (limit 2); bone marrow: 25.9 nTPM (limit 2); cerebellum: 28.1 nTPM (limit 2); cerebral cortex: 14.3 nTPM (limit 2); choroid plexus: 11.5 nTPM (limit 2); colon: 21.7 nTPM (limit 6); duodenum: 22.8 nTPM (limit 2); esophagus: 24.2 nTPM (limit 6); heart muscle: 19.7 nTPM (limit 2); hippocampal formation: 12.7 nTPM (limit 2); hypothalamus: 14.7 nTPM (limit 2); kidney: 17.9 nTPM (limit 2); liver: 30.9 nTPM (limit 2); lung: 18.5 nTPM (limit 2); lymph node: 37.3 nTPM (limit 6); midbrain: 12.3 nTPM (limit 2); pancreas: 20.3 nTPM (limit 2); parathyroid gland: 17.1 nTPM (limit 6); pituitary gland: 22.2 nTPM (limit 2); rectum: 19.8 nTPM (limit 6); retina: 9.8 nTPM (limit 2); salivary gland: 21.1 nTPM (limit 6); skeletal muscle: 32.4 nTPM (limit 2); skin: 22.5 nTPM (limit 10); small intestine: 23.6 nTPM (limit 2); smooth muscle: 26.6 nTPM (limit 2); spinal cord: 14.3 nTPM (limit 2); spleen: 28.7 nTPM (limit 10); stomach: 18.8 nTPM (limit 6); thymus: 39.7 nTPM (limit 10); thyroid gland: 15.8 nTPM (limit 10); tongue: 20.8 nTPM (limit 6); urinary bladder: 23.4 nTPM (limit 6),adipose tissue / adipocytes: Low (Supported); adrenal gland / glandular cells: Low (Supported); bone marrow / hematopoietic cells: Medium (Supported); bronchus / ciliated cells (cell body): Medium (Supported); bronchus / ciliated cells (ciliary rootlets): Low (Supported); bronchus / ciliated cells (tip of cilia): Low (Supported); caudate / glial cells: Low (Supported); caudate / neuronal cells: High (Supported); cerebellum / cells in granular layer: Low (Supported); cerebellum / cells in molecular layer: Medium (Supported); cerebellum / Purkinje cells: Medium (Supported); cerebral cortex / endothelial cells: Low (Supported); cerebral cortex / glial cells: Low (Supported); cerebral cortex / neuronal cells: Medium (Supported); cerebral cortex / neuropil: Low (Supported); colon / endothelial cells: Medium (Supported); colon / glandular cells: Medium (Supported); colon / peripheral nerve/ganglion: Medium (Supported); duodenum / glandular cells: Medium (Supported); esophagus / squamous epithelial cells: Low (Supported); heart muscle / cardiomyocytes: Medium (Supported); hippocampus / glial cells: Low (Supported); hippocampus / neuronal cells: Medium (Supported); kidney / cells in glomeruli: Low (Supported); kidney / cells in tubules: Medium (Supported); liver / cholangiocytes: Low (Supported); liver / hepatocytes: Low (Supported); lung / alveolar cells type II: Low (Supported); lung / macrophages: Medium (Supported); lymph node / germinal center cells: Medium (Supported); lymph node / non-germinal center cells: Medium (Supported); nasopharynx / ciliated cells (cell body): Medium (Supported); oral mucosa / squamous epithelial cells: Low (Supported); pancreas / exocrine glandular cells: Medium (Supported); pancreas / pancreatic endocrine cells: Low (Supported); parathyroid gland / glandular cells: Low (Supported); rectum / glandular cells: High (Supported); salivary gland / glandular cells: Low (Supported); skeletal muscle / myocytes: Medium (Supported); skin 1 / fibroblasts: Low (Supported); skin 1 / keratinocytes: Low (Supported); skin 1 / Langerhans: Low (Supported); skin 2 / epidermal cells: Medium (Supported); small intestine / glandular cells: Medium (Supported); smooth muscle / smooth muscle cells: Low (Supported); spleen / cells in red pulp: Medium (Supported); spleen / cells in white pulp: Low (Supported); stomach 1 / glandular cells: Medium (Supported); stomach 2 / glandular cells: Medium (Supported); thyroid gland / glandular cells: Medium (Supported); urinary bladder / urothelial cells: Medium (Supported),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%); Head and Neck Squamous Cell Carcinoma (TCGA): 492/492 (100.0%),ovarian cancer: 5/11 (45.5%); renal cancer: 4/12 (33.3%),31,20,P37198,https://www.uniprot.org/uniprotkb/P37198/entry,"Essential component of the nuclear pore complex (PubMed:1915414). The N-terminal is probably involved in nucleocytoplasmic transport (PubMed:1915414). The C-terminal is involved in protein-protein interaction probably via coiled-coil formation, promotes its association with centrosomes and may function in anchorage of p62 to the pore complex (PubMed:1915414, PubMed:24107630). Plays a role in mitotic cell cycle progression by regulating centrosome segregation, centriole maturation and spindle orientation (PubMed:24107630). It might be involved in protein recruitment to the centrosome after nuclear breakdown (PubMed:24107630)",,"Infantile striatonigral degeneration: Neurological disorder characterized by symmetrical degeneration of the caudate nucleus, putamen, and occasionally the globus pallidus, with little involvement of the rest of the brain. The clinical features include developmental regression, choreoathetosis, dystonia, spasticity, dysphagia, failure to thrive, nystagmus, optic atrophy, and intellectual disability.",,"Nucleus, nuclear pore complex Cytoplasm, cytoskeleton, spindle pole Nucleus envelope Cytoplasm, cytoskeleton, microtubule organizing center, centrosome",1915414|24107630,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
NUP62CL,ENSG00000198088,Unsafe,Protein,False,True,16.9,16.9,84,32,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 13.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 10.4 nTPM; absolute ceiling;continuous selectivity; colon: 2.6 nTPM; positive ihc; duodenum: 2.9 nTPM; positive ihc;absolute ceiling; kidney: 5.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 1.6 nTPM; positive ihc; pancreas: 4.2 nTPM; absolute ceiling; parathyroid gland: 4 nTPM; positive ihc; pituitary gland: 2.5 nTPM; absolute ceiling; rectum: 3.1 nTPM; positive ihc; small intestine: 2.9 nTPM; positive ihc;absolute ceiling; stomach: 1.7 nTPM; positive ihc; thyroid gland: 9.7 nTPM; positive ihc;continuous selectivity; urinary bladder: 0.9 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 13.4 nTPM (limit 2); choroid plexus: 10.4 nTPM (limit 2); duodenum: 2.9 nTPM (limit 2); kidney: 5.7 nTPM (limit 2); pancreas: 4.2 nTPM (limit 4); pituitary gland: 2.5 nTPM (limit 2); small intestine: 2.9 nTPM (limit 2),adrenal gland / glandular cells: Medium (Approved); bronchus / ciliated cells (cell body): Low (Approved); bronchus / ciliated cells (tip of cilia): Low (Approved); colon / endothelial cells: Low (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: Low (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Low (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Low (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Low (Approved); small intestine / glandular cells: Low (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Low (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Low (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 409/486 (84.2%); Rectum Adenocarcinoma (validation): 165/207 (79.7%); Breast Invasive Carcinoma (validation): 36/50 (72.0%),melanoma: 9/12 (75.0%); glioma: 8/12 (66.7%),31,20,Q9H1M0,https://www.uniprot.org/uniprotkb/Q9H1M0/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
NUPR2,ENSG00000185290,Unsafe,RNA,False,True,345.0,345.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 3.3 nTPM; absolute ceiling; amygdala: 7 nTPM; absolute ceiling; basal ganglia: 6.3 nTPM; absolute ceiling; cerebellum: 6.2 nTPM; absolute ceiling; cerebral cortex: 5 nTPM; absolute ceiling; choroid plexus: 3.4 nTPM; absolute ceiling; hippocampal formation: 2.4 nTPM; absolute ceiling; hypothalamus: 4.9 nTPM; absolute ceiling; kidney: 17.7 nTPM; absolute ceiling; liver: 2.2 nTPM; absolute ceiling; midbrain: 2.7 nTPM; absolute ceiling; pancreas: 3.8 nTPM; absolute ceiling; pituitary gland: 12.4 nTPM; absolute ceiling; retina: 2.5 nTPM; absolute ceiling; salivary gland: 7.5 nTPM; absolute ceiling; thyroid gland: 15 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 3.3 nTPM (limit 2); amygdala: 7 nTPM (limit 2); basal ganglia: 6.3 nTPM (limit 2); cerebellum: 6.2 nTPM (limit 2); cerebral cortex: 5 nTPM (limit 2); choroid plexus: 3.4 nTPM (limit 2); hippocampal formation: 2.4 nTPM (limit 2); hypothalamus: 4.9 nTPM (limit 2); kidney: 17.7 nTPM (limit 2); liver: 2.2 nTPM (limit 2); midbrain: 2.7 nTPM (limit 2); pancreas: 3.8 nTPM (limit 2); pituitary gland: 12.4 nTPM (limit 2); retina: 2.5 nTPM (limit 2); salivary gland: 7.5 nTPM (limit 6); thyroid gland: 15 nTPM (limit 10); adrenal gland: 3.3 nTPM (baseline 2); amygdala: 7 nTPM (baseline 2); basal ganglia: 6.3 nTPM (baseline 2); cerebellum: 6.2 nTPM (baseline 2); cerebral cortex: 5 nTPM (baseline 2); choroid plexus: 3.4 nTPM (baseline 2); hippocampal formation: 2.4 nTPM (baseline 2); hypothalamus: 4.9 nTPM (baseline 2); kidney: 17.7 nTPM (baseline 2); liver: 2.2 nTPM (baseline 2); midbrain: 2.7 nTPM (baseline 2); pancreas: 3.8 nTPM (baseline 2); pituitary gland: 12.4 nTPM (baseline 2); retina: 2.5 nTPM (baseline 2); salivary gland: 7.5 nTPM (baseline 6); thyroid gland: 15 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Chromophobe (TCGA): 56/64 (87.5%); Ovary Serous Cystadenocarcinoma (TCGA): 304/349 (87.1%); Thyroid Carcinoma (TCGA): 415/495 (83.8%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,A6NF83,https://www.uniprot.org/uniprotkb/A6NF83/entry,"Acts as a transcriptional repressor by inhibiting gene expression at the NUPR1 promoter in a p53/TP53-dependent manner in cancer cells (PubMed:25899918). Involved in the G1 cell cycle arrest, and in a decrease in cell viability and cell proliferation (PubMed:25899918). Plays a role as a negative regulator of the protumoral factor NUPR1 (PubMed:25899918)",,,,Nucleus,25899918,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
NUTM2F,ENSG00000130950,Unsafe,High RNA,False,True,1.8,1.8,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,True,"brain/excitatory neurons cluster c-0: 36.6 nTPM, 5496 reads; reproductive-cell max 0.4; brain/excitatory neurons cluster c-1: 41.8 nTPM, 5241 reads; reproductive-cell max 0.4; brain/excitatory neurons cluster c-2: 41.3 nTPM, 4702 reads; reproductive-cell max 0.4; brain/excitatory neurons cluster c-3: 33.9 nTPM, 3896 reads; reproductive-cell max 0.4; brain/excitatory neurons cluster c-4: 64.1 nTPM, 8788 reads; reproductive-cell max 0.4; brain/inhibitory neurons cluster c-5: 33.5 nTPM, 2984 reads; reproductive-cell max 0.4; brain/inhibitory neurons cluster c-6: 21.7 nTPM, 1126 reads; reproductive-cell max 0.4; brain/excitatory neurons cluster c-7: 37.5 nTPM, 3503 reads; reproductive-cell max 0.4; brain/inhibitory neurons cluster c-8: 27.6 nTPM, 2295 reads; reproductive-cell max 0.4; brain/excitatory neurons cluster c-9: 30.7 nTPM, 2135 reads; reproductive-cell max 0.4; brain/excitatory neurons cluster c-10: 34.9 nTPM, 1841 reads; reproductive-cell max 0.4; brain/excitatory neurons cluster c-11: 34 nTPM, 2491 reads; reproductive-cell max 0.4; brain/oligodendrocytes cluster c-12: 29.8 nTPM, 361 reads; reproductive-cell max 0.4; brain/excitatory neurons cluster c-13: 30.2 nTPM, 1421 reads; reproductive-cell max 0.4; brain/inhibitory neurons cluster c-14: 29.9 nTPM, 1186 reads; reproductive-cell max 0.4; brain/inhibitory neurons cluster c-15: 25.1 nTPM, 684 reads; reproductive-cell max 0.4; brain/excitatory neurons cluster c-16: 74.5 nTPM, 5886 reads; reproductive-cell max 0.4; brain/inhibitory neurons cluster c-17: 31 nTPM, 1000 reads; reproductive-cell max 0.4; brain/excitatory neurons cluster c-18: 36.6 nTPM, 1812 reads; reproductive-cell max 0.4; brain/excitatory neurons cluster c-19: 40.6 nTPM, 1813 reads; reproductive-cell max 0.4; brain/excitatory neurons cluster c-20: 56.3 nTPM, 2748 reads; reproductive-cell max 0.4; brain/inhibitory neurons cluster c-21: 25.2 nTPM, 765 reads; reproductive-cell max 0.4; brain/excitatory neurons cluster c-22: 41.6 nTPM, 1801 reads; reproductive-cell max 0.4; brain/inhibitory neurons cluster c-23: 28.2 nTPM, 655 reads; reproductive-cell max 0.4; brain/excitatory neurons cluster c-24: 31.7 nTPM, 738 reads; reproductive-cell max 0.4; brain/inhibitory neurons cluster c-25: 27.6 nTPM, 515 reads; reproductive-cell max 0.4; brain/inhibitory neurons cluster c-26: 29.3 nTPM, 655 reads; reproductive-cell max 0.4; brain/excitatory neurons cluster c-27: 37.6 nTPM, 1337 reads; reproductive-cell max 0.4; brain/inhibitory neurons cluster c-28: 22.7 nTPM, 461 reads; reproductive-cell max 0.4; brain/excitatory neurons cluster c-29: 30.8 nTPM, 777 reads; reproductive-cell max 0.4; brain/inhibitory neurons cluster c-30: 31 nTPM, 744 reads; reproductive-cell max 0.4; brain/excitatory neurons cluster c-31: 38.7 nTPM, 1539 reads; reproductive-cell max 0.4; brain/excitatory neurons cluster c-32: 42.6 nTPM, 1236 reads; reproductive-cell max 0.4; brain/excitatory neurons cluster c-33: 39.5 nTPM, 980 reads; reproductive-cell max 0.4; brain/excitatory neurons cluster c-34: 81.5 nTPM, 2038 reads; reproductive-cell max 0.4; brain/astrocytes cluster c-35: 9.9 nTPM, 32 reads; reproductive-cell max 0.4; brain/excitatory neurons cluster c-36: 32.6 nTPM, 557 reads; reproductive-cell max 0.4; brain/oligodendrocytes cluster c-37: 26.8 nTPM, 94 reads; reproductive-cell max 0.4; brain/inhibitory neurons cluster c-38: 25.7 nTPM, 267 reads; reproductive-cell max 0.4; brain/excitatory neurons cluster c-39: 46.4 nTPM, 520 reads; reproductive-cell max 0.4; brain/excitatory neurons cluster c-40: 33.4 nTPM, 337 reads; reproductive-cell max 0.4; brain/inhibitory neurons cluster c-41: 29.8 nTPM, 157 reads; reproductive-cell max 0.4; brain/oligodendrocyte precursor cells cluster c-42: 25.5 nTPM, 54 reads; reproductive-cell max 0.4; brain/excitatory neurons cluster c-44: 28.5 nTPM, 81 reads; reproductive-cell max 0.4",True,False,,True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,0.9006418786310001,81.5,"hpa_single_cell: /Excitatory neurons, max 41.4 nTPM, 1 observations >30; hpa_single_cell_tissue: brain/excitatory neurons, max 81.5 nTPM, 25 observations >30; hpa_single_cell_tissue: brain/inhibitory neurons, max 33.5 nTPM, 3 observations >30",Neither,oncoref.target-sets.2026-10-23.2,0.9006 TPM; blood/TFH; dice_tfh; vital,81.5 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Ovary Serous Cystadenocarcinoma (TCGA): 1/349 (0.3%); Prostate Adenocarcinoma (TCGA): 1/480 (0.2%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,A1L443,https://www.uniprot.org/uniprotkb/A1L443/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Gong2021_reproductive_PC | daSilva2017_tumor_proteomics,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Normal reproductive-tissue enrichment; no tumor validation | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
NXF2,ENSG00000269405,Unsafe,RNA,False,True,14.8,14.8,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,pituitary gland: 3.2 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,pituitary gland: 3.2 nTPM (limit 2); pituitary gland: 3.2 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 20/176 (11.4%); Lung Squamous Cell Carcinoma (TCGA): 49/489 (10.0%); Lung Squamous Cell Carcinoma (validation): 6/68 (8.8%),testis cancer: 12/12 (100.0%); colorectal cancer: 10/10 (100.0%),28,20,Q9GZY0,https://www.uniprot.org/uniprotkb/Q9GZY0/entry,Involved in the export of mRNA from the nucleus to the cytoplasm,Expressed almost exclusively in testis. Also expressed in several cancers,,,"Nucleus, nucleoplasm Cytoplasm",,12704671,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core | Loriot2025_S1,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci | Cancer-germline RNA nomination; strict and preferential classes remain distinct,,,,,,,,
NXF2B,ENSG00000269437,Unsafe,RNA,False,True,14.8,14.8,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,pituitary gland: 2.4 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,pituitary gland: 2.4 nTPM (limit 2); pituitary gland: 2.4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 20/176 (11.4%); Lung Squamous Cell Carcinoma (validation): 5/68 (7.4%); Stomach Adenocarcinoma (TCGA): 25/346 (7.2%),testis cancer: 12/12 (100.0%); colorectal cancer: 10/10 (100.0%),28,20,Q9GZY0,https://www.uniprot.org/uniprotkb/Q9GZY0/entry,Involved in the export of mRNA from the nucleus to the cytoplasm,Expressed almost exclusively in testis. Also expressed in several cancers,,,"Nucleus, nucleoplasm Cytoplasm",,12704671,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,Failed bulk numeric comparisons are within 20% of their cutoffs; not an automatic rescue,,,,
NXF3,ENSG00000147206,Unsafe,Protein,False,True,56.2,56.2,79,8,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,existing nomination or manual review; nomination unresolved; positive normal IHC; positive ihc outside permitted; duodenum: 0.6 nTPM; positive ihc; lung: 4.8 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",lung: 4.8 nTPM (limit 4),duodenum / glandular cells: Low (Approved); oral mucosa / squamous epithelial cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 19/80 (23.8%); Pancreatic Adenocarcinoma (TCGA): 34/176 (19.3%); Colon Adenocarcinoma (validation): 55/486 (11.3%),testis cancer: 9/10 (90.0%); urothelial cancer: 6/10 (60.0%),31,20,Q9H4D5,https://www.uniprot.org/uniprotkb/Q9H4D5/entry,May function as a tissue-specific nuclear mRNA export factor,Expressed at high level in testis and at low level in a small number of tissues,,,Nucleus Cytoplasm,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
OAZ3,ENSG00000143450,Unsafe,RNA,False,True,189.5,189.5,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,retina: 2.6 nTPM; absolute ceiling; salivary gland: 7.5 nTPM; absolute ceiling; skeletal muscle: 2.8 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 2.6 nTPM (limit 2); salivary gland: 7.5 nTPM (limit 6); skeletal muscle: 2.8 nTPM (limit 2); retina: 2.6 nTPM (baseline 2); salivary gland: 7.5 nTPM (baseline 6); skeletal muscle: 2.8 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Prostate Adenocarcinoma (TCGA): 479/480 (99.8%); Breast Invasive Carcinoma (validation): 46/50 (92.0%); Thyroid Carcinoma (TCGA): 440/495 (88.9%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9UMX2,https://www.uniprot.org/uniprotkb/Q9UMX2/entry,"Ornithine decarboxylase (ODC) antizyme protein that negatively regulates ODC activity and intracellular polyamine biosynthesis and uptake in response to increased intracellular polyamine levels. Binds to ODC monomers, inhibiting the assembly of the functional ODC homodimers. Does not target the ODC monomers for degradation, which allows a protein synthesis-independent restoration of ODC activity (PubMed:17900240). Stabilizes AZIN2 by interfering with its ubiquitination. Involved in the translocation of AZNI2 from ER-Golgi intermediate compartment (ERGIC) to the cytosol. Probably plays a key role in spermatogenesis by regulating the intracellular concentration of polyamines in haploid germ cells (By similarity)",Testis specific,,,Nucleus Cytoplasm,17900240,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
ODAD1,ENSG00000105479,Unsafe,Protein,False,True,24.7,28.3,100,12,Positive somewhere,True,True,False,True,Excluded,Normal,False,,Not assessed,,,positive ihc outside permitted; choroid plexus: 28.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 28.3 nTPM (limit 2),bronchus / ciliated cells (cilia axoneme): High (Approved); bronchus / ciliated cells (ciliary rootlets): Low (Approved); bronchus / ciliated cells (tip of cilia): High (Approved); nasopharynx / ciliated cells (ciliary rootlets): High (Approved); nasopharynx / ciliated cells (tip of cilia): High (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 38/50 (76.0%); Ovary Serous Cystadenocarcinoma (validation): 20/81 (24.7%); Uterine Corpus Endometrial Carcinoma (TCGA): 35/176 (19.9%),colorectal cancer: 9/9 (100.0%); breast cancer: 6/11 (54.5%),31,20,Q96M63,https://www.uniprot.org/uniprotkb/Q96M63/entry,Component of the outer dynein arm-docking complex (ODA-DC) that mediates outer dynein arms (ODA) binding onto the doublet microtubule. Involved in mediating assembly of both ODAs and their axonemal docking complex onto ciliary microtubules (By similarity),"Expressed in nasal epithelial cells (PubMed:23261302, PubMed:23261303). Highly expressed in testis and also detected in lung, brain and kidney (PubMed:23261302)","Ciliary dyskinesia, primary, 20: A disorder characterized by abnormalities of motile cilia. Respiratory infections leading to chronic inflammation and bronchiectasis are recurrent, due to defects in the respiratory cilia. Patients may exhibit randomization of left-right body asymmetry and situs inversus, due to dysfunction of monocilia at the embryonic node. Primary ciliary dyskinesia associated with situs inversus is referred to as Kartagener syndrome. Unlike other forms of CILD characterized by reduced fertility, patients with CILD20 do not appear to be infertile.",,"Cytoplasm, cytoskeleton, cilium axoneme",23261302|23261303|27486780,23261302|23261303,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
ODAD2,ENSG00000169126,Unsafe,Protein,False,True,39.5,39.5,96,10,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; choroid plexus: 7.8 nTPM; absolute ceiling; pituitary gland: 3.1 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 7.8 nTPM (limit 2); pituitary gland: 3.1 nTPM (limit 2),bronchus / ciliated cells (cilia axoneme): Medium (Enhanced); bronchus / ciliated cells (ciliary rootlets): Medium (Enhanced); bronchus / ciliated cells (tip of cilia): Medium (Enhanced); nasopharynx / ciliated cells (cilia axoneme): Medium (Enhanced); nasopharynx / ciliated cells (ciliary rootlets): Medium (Enhanced); nasopharynx / ciliated cells (tip of cilia): Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 31/176 (17.6%); Breast Invasive Carcinoma (validation): 8/50 (16.0%); Glioblastoma Multiforme (validation): 8/58 (13.8%),breast cancer: 0/10 (0.0%); cervical cancer: 0/10 (0.0%),31,20,Q5T2S8,https://www.uniprot.org/uniprotkb/Q5T2S8/entry,Component of the outer dynein arm-docking complex (ODA-DC) that mediates outer dynein arms (ODA) binding onto the doublet microtubule (PubMed:27486780). Involved in mediating assembly of both ODAs and their axonemal docking complex onto ciliary microtubules (PubMed:23849778),Expressed in respiratory epithelial cells (at protein level),"Ciliary dyskinesia, primary, 23: A disorder characterized by abnormalities of motile cilia. Respiratory infections leading to chronic inflammation and bronchiectasis are recurrent, due to defects in the respiratory cilia. Patients may exhibit randomization of left-right body asymmetry and situs inversus, due to dysfunction of monocilia at the embryonic node. Primary ciliary dyskinesia associated with situs inversus is referred to as Kartagener syndrome.",,"Cytoplasm, cytoskeleton, cilium axoneme Cytoplasm, cytoskeleton, cilium basal body",23849778|27486780,23849778,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
ODF2,ENSG00000136811,Unsafe,Protein,False,True,308.7,308.7,124,12,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 7.9 nTPM; absolute ceiling; basal ganglia: 8.7 nTPM; absolute ceiling; bone marrow: 22.3 nTPM; absolute ceiling; cerebellum: 30.3 nTPM; absolute ceiling; choroid plexus: 36.6 nTPM; absolute ceiling; colon: 14.6 nTPM; absolute ceiling; duodenum: 7.4 nTPM; absolute ceiling; heart muscle: 12.5 nTPM; absolute ceiling; hippocampal formation: 9.6 nTPM; absolute ceiling; hypothalamus: 10.9 nTPM; absolute ceiling; kidney: 13.7 nTPM; absolute ceiling; liver: 16 nTPM; absolute ceiling; lung: 13.6 nTPM; positive ihc;absolute ceiling; midbrain: 8.6 nTPM; absolute ceiling; pituitary gland: 29.8 nTPM; absolute ceiling; rectum: 10 nTPM; absolute ceiling; retina: 9.4 nTPM; absolute ceiling; small intestine: 13 nTPM; absolute ceiling; smooth muscle: 13.8 nTPM; absolute ceiling; spinal cord: 9.4 nTPM; absolute ceiling; thymus: 24.1 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 7.9 nTPM (limit 2); basal ganglia: 8.7 nTPM (limit 2); bone marrow: 22.3 nTPM (limit 12); cerebellum: 30.3 nTPM (limit 12); choroid plexus: 36.6 nTPM (limit 2); colon: 14.6 nTPM (limit 6); duodenum: 7.4 nTPM (limit 2); heart muscle: 12.5 nTPM (limit 12); hippocampal formation: 9.6 nTPM (limit 2); hypothalamus: 10.9 nTPM (limit 2); kidney: 13.7 nTPM (limit 12); liver: 16 nTPM (limit 12); lung: 13.6 nTPM (limit 2); midbrain: 8.6 nTPM (limit 2); pituitary gland: 29.8 nTPM (limit 2); rectum: 10 nTPM (limit 6); retina: 9.4 nTPM (limit 2); small intestine: 13 nTPM (limit 2); smooth muscle: 13.8 nTPM (limit 12); spinal cord: 9.4 nTPM (limit 2); thymus: 24.1 nTPM (limit 10),bronchus / ciliated cells (cilia axoneme): High (Enhanced); bronchus / ciliated cells (tip of cilia): High (Enhanced); lung / macrophages: Medium (Enhanced); nasopharynx / ciliated cells (cilia axoneme): High (Enhanced); nasopharynx / ciliated cells (tip of cilia): High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Colon Adenocarcinoma (validation): 486/486 (100.0%); Prostate Adenocarcinoma (TCGA): 480/480 (100.0%),colorectal cancer: 5/12 (41.7%); ovarian cancer: 4/11 (36.4%),31,20,Q5BJF6,https://www.uniprot.org/uniprotkb/Q5BJF6/entry,Seems to be a major component of sperm tail outer dense fibers (ODF). ODFs are filamentous structures located on the outside of the axoneme in the midpiece and principal piece of the mammalian sperm tail and may help to maintain the passive elastic structures and elastic recoil of the sperm tail. May have a modulating influence on sperm motility. Functions as a general scaffold protein that is specifically localized at the distal/subdistal appendages of mother centrioles. Component of the centrosome matrix required for the localization of PLK1 and NIN to the centrosomes. Required for the formation and/or maintenance of normal CETN1 assembly,Testis-specific (at protein level). Highly expressed in cytoplasm of step 2 round spermatids. Detected in the middle piece and extends to about half the principal piece of the sperm tails,,,"Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Cell projection, cilium Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriole Cytoplasm, cytoskeleton, spindle pole Cell projection, cilium, flagellum",16966375,10381817,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
OIP5,ENSG00000104147,Unsafe,Protein,False,True,20.3,20.3,84,4,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; pancreas: 0.3 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,pancreas / exocrine glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 125/133 (94.0%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 264/283 (93.3%); Breast Invasive Carcinoma (validation): 46/50 (92.0%),breast cancer: 0/12 (0.0%); cervical cancer: 0/12 (0.0%),31,20,O43482,https://www.uniprot.org/uniprotkb/O43482/entry,Required for recruitment of CENPA to centromeres and normal chromosome segregation during mitosis,,,,"Nucleus Chromosome Chromosome, centromere",17199038,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
OLAH,ENSG00000152463,Unsafe,Protein,False,True,26.1,26.1,85,6,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 0.9 nTPM; positive ihc; salivary gland: 2.6 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,adrenal gland / glandular cells: Low (Enhanced); salivary gland / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 52/133 (39.1%); Thyroid Carcinoma (TCGA): 39/495 (7.9%); Uterine Corpus Endometrial Carcinoma (TCGA): 10/176 (5.7%),liver cancer: 4/12 (33.3%); stomach cancer: 2/9 (22.2%),31,20,Q9NV23,https://www.uniprot.org/uniprotkb/Q9NV23/entry,"Contributes to the release of free fatty acids from fatty acid synthase (FASN). Has broad substrate specificity, giving rise to a range of free fatty acids with chain lengths between 10 and 16 carbon atoms (C10 - C16)",Detected both in lactating and non-lactating breast epithelium (at protein level) (PubMed:6589427). Isoform 2 is up-regulated in bone marrow-derived mononuclear cells of rheumatoid arthritis patients (PubMed:17082220),,,"Cytoplasm, cytosol",26663084,17082220|6589427,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
ONECUT2,ENSG00000119547,Unsafe,Protein,False,True,0.1,9.9,78,2,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 0.1 nTPM; reproductive not higher; basal ganglia: 3.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 0.7 nTPM; continuous selectivity;reproductive not higher; cerebral cortex: 0.4 nTPM; continuous selectivity;reproductive not higher; duodenum: 9.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 0.1 nTPM; reproductive not higher; hypothalamus: 0.3 nTPM; continuous selectivity;reproductive not higher; kidney: 0.1 nTPM; reproductive not higher; liver: 8.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 2.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 0.8 nTPM; continuous selectivity;reproductive not higher; pituitary gland: 0.8 nTPM; continuous selectivity;reproductive not higher; retina: 5.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 2.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; stomach: 0.1 nTPM; reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",basal ganglia: 3.3 nTPM (limit 2); retina: 5.3 nTPM (limit 2); small intestine: 2.1 nTPM (limit 2); basal ganglia: 3.3 nTPM (baseline 2); duodenum: 9.9 nTPM (baseline 2); liver: 8.2 nTPM (baseline 2); pancreas: 2.3 nTPM (baseline 2); retina: 5.3 nTPM (baseline 2); small intestine: 2.1 nTPM (baseline 2),small intestine / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (validation): 196/231 (84.8%); Pancreatic Adenocarcinoma (validation): 60/80 (75.0%); Stomach Adenocarcinoma (TCGA): 151/346 (43.6%),breast cancer: 0/11 (0.0%); cervical cancer: 0/10 (0.0%),31,20,O95948,https://www.uniprot.org/uniprotkb/O95948/entry,Transcriptional activator. Activates the transcription of a number of liver genes such as HNF3B,,,It is uncertain whether Met-1 or Met-20 is the initiator,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
OOSP2,ENSG00000149507,Unsafe,Protein,False,True,17.4,17.4,84,12,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 0 nTPM; positive ihc; duodenum: 0 nTPM; positive ihc; heart muscle: 0 nTPM; positive ihc; skin: 0 nTPM; positive ihc; small intestine: 0 nTPM; positive ihc; stomach: 0 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,adrenal gland / glandular cells: Low (Enhanced); duodenum / glandular cells: Low (Enhanced); heart muscle / cardiomyocytes: Low (Enhanced); skin 1 / keratinocytes: Low (Enhanced); small intestine / glandular cells: Low (Enhanced); stomach 2 / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),breast cancer: 0/12 (0.0%); cervical cancer: 0/10 (0.0%),29,20,Q86WS3,https://www.uniprot.org/uniprotkb/Q86WS3/entry,Involved in oocyte maturation,Highly expressed in oocytes,,"Unlike human OOSP2, mouse OOSP2 seems not participate in folliculogenesis and oocyte maturation",Secreted Cytoplasm,36042231,36042231,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
OPN1LW,ENSG00000102076,Unsafe,RNA,False,True,0.0,248.2,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,insufficient positive reproductive evidence; reproductive expression not demonstrated; incomplete tissue evidence,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 248.2 nTPM (limit 2); retina: 248.2 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P04000,https://www.uniprot.org/uniprotkb/P04000/entry,"G protein-coupled photoreceptor that selectively activates transducin G alpha protein (G(t)) in response to long-wavelength (red) light (PubMed:21314100, PubMed:2937147, PubMed:6140680). This activation leads to increased cGMP phosphodiesterase activity, resulting in decreased intracellular cGMP and subsequent closure of cGMP-gated ion channels (PubMed:21314100, PubMed:2937147, PubMed:6140680). The process is initiated when the opsin-bound cis-retinal chromophore absorbs a photon and isomerizes to all-trans-retinal, inducing a conformational change in the opsin that triggers the G protein-mediated phototransduction cascade (PubMed:21314100, PubMed:2937147, PubMed:6140680). Mediates visual perception of red light in cone photoreceptor cells (PubMed:12051694, PubMed:8213841, PubMed:8666378)","The red (OPN1LW), green (OPN1MW), and blue (OPN1SW) photoreceptor pigments are found in cone cells","Colorblindness, partial, protan series: An X-linked color vision defect characterized by a dichromasy in which red and green are confused, with loss of luminance and shift of brightness and hue curves toward the short wave end of the spectrum. Dichromasy is due to the use of only two types of photoreceptors, blue plus red in deuteranopia and blue plus green in protanopia. Blue cone monochromacy: A rare X-linked congenital stationary cone dysfunction syndrome characterized by the absence of functional long wavelength-sensitive and medium wavelength-sensitive cones in the retina. Color discrimination is severely impaired from birth, and vision is derived from the remaining preserved blue (S) cones and rod photoreceptors. BCM typically presents with reduced visual acuity, pendular nystagmus, and photophobia. Patients often have myopia.",,Membrane Photoreceptor outer segment membrane,12051694|21314100|2937147|6140680|8213841|8666378,2937147,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OPN5,ENSG00000124818,Unsafe,Protein,False,True,2.5,2.5,89,1,Positive somewhere,True,False,False,False,Excluded,Normal,False,,Not assessed,,,positive ihc outside permitted,"Positive IHC in a Vital, Protected or Manageable compartment",,retina / photoreceptor cells: High (Supported),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Skin Cuteneous Melanoma (TCGA): 1/99 (1.0%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),testis cancer: 6/12 (50.0%); lung cancer: 4/12 (33.3%),31,20,Q6U736,https://www.uniprot.org/uniprotkb/Q6U736/entry,"G protein-coupled photoreceptor that selectively activates G(i) protein in response to light in the retina (By similarity). Activation occurs when the opsin-bound cis-retinal chromophore absorbs a photon and isomerizes to all-trans-retinal, inducing a conformational change in the opsin that triggers a G protein-mediated phototransduction cascade (PubMed:22043319). Acts as a bistable protein with absorption peaks at 380 nm (UVA light) and 470 nm (blue light), allowing photoreversible regeneration of the cis-retinal chromophore after stimulation (PubMed:22043319). Required for the light-response in the inner plexiform layer, and contributes to the regulation of the light-response in the nerve fiber layer, via phosphorylated DAT/SLC6A3 dopamine uptake. Involved in local corneal and retinal circadian rhythm photoentrainment via modulation of the UVA light-induced phase-shift of the retina clock. Acts as a circadian photoreceptor in the outer ear and vibrissal pads, via modulation of circadian clock-gene expression in response to violet light during the light-to-dark transition phase and night phase of the circadian cycle. Required in the retina to negatively regulate hyaloid vessel regression during postnatal development via light-dependent OPN5-SLC32A1-DRD2-VEGFR2 signaling. Involved in the light-dependent regulation of retina and vitreous compartment dopamine levels. Mediates violet light-accelerated wound healing in corneas, being transiently expressed following physical injury (By similarity)",Detected in brain and retina and cell lines derived from neural retina,,,Cell membrane,22043319,14623103,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
OPRM1,ENSG00000112038,Unsafe,High RNA,False,True,2.8,2.8,84,3,Positive somewhere,False,False,False,True,Excluded,Normal,True,,Not assessed,,,cerebellum: 2.1 nTPM; continuous selectivity; retina: 0.9 nTPM; continuous selectivity,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,True,"brain/inhibitory neurons cluster c-6: 71.8 nTPM, 3734 reads; reproductive-cell max 70",True,False,,True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,1.8,71.8,"hpa_single_cell: /Excitatory neurons, max 39.8 nTPM, 1 observations >30; hpa_single_cell_tissue: brain/excitatory neurons, max 69.8 nTPM, 17 observations >30; hpa_single_cell_tissue: brain/inhibitory neurons, max 71.8 nTPM, 4 observations >30",Neither,oncoref.target-sets.2026-10-23.2,1.8 TPM; blood/basophil; hpa_immune_monaco; vital,71.8 nTPM; brain/inhibitory neurons; hpa_single_cell_tissue; vital,Uterine Corpus Endometrial Carcinoma (TCGA): 8/176 (4.5%); Testicular Germ Cell Tumor (TCGA): 2/133 (1.5%); Pancreatic Adenocarcinoma (validation): 1/80 (1.2%),melanoma: 1/12 (8.3%); breast cancer: 0/10 (0.0%),31,20,P35372,https://www.uniprot.org/uniprotkb/P35372/entry,"Receptor for endogenous opioids such as beta-endorphin and endomorphin (PubMed:10529478, PubMed:12589820, PubMed:7891175, PubMed:7905839, PubMed:7957926, PubMed:9689128). Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone (PubMed:10529478, PubMed:10836142, PubMed:12589820, PubMed:19300905, PubMed:7891175, PubMed:7905839, PubMed:7957926, PubMed:9689128). Also activated by enkephalin peptides, such as Met-enkephalin or Met-enkephalin-Arg-Phe, with higher affinity for Met-enkephalin-Arg-Phe (By similarity). Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G protein complex and subsequent exchange of GDP for GTP in the G protein alpha subunit leading to dissociation of the G protein complex with the free GTP-bound G protein alpha and the G protein beta-gamma dimer activating downstream cellular effectors (PubMed:7905839). The agonist- and cell type-specific activity is predominantly coupled to pertussis toxin-sensitive G(i) and G(o) G alpha proteins, GNAI1, GNAI2, GNAI3 and GNAO1 isoforms Alpha-1 and Alpha-2, and to a lesser extent to pertussis toxin-insensitive G alpha proteins GNAZ and GNA15 (PubMed:12068084). They mediate an array of downstream cellular responses, including inhibition of adenylate cyclase activity and both N-type and L-type calcium channels, activation of inward rectifying potassium channels, mitogen-activated protein kinase (MAPK), phospholipase C (PLC), phosphoinositide/protein kinase (PKC), phosphoinositide 3-kinase (PI3K) and regulation of NF-kappa-B (By similarity). Also couples to adenylate cyclase stimulatory G alpha proteins (By similarity). The selective temporal coupling to G proteins and subsequent signaling can be regulated by RGSZ proteins, such as RGS9, RGS17 and RGS4 (By similarity). Phosphorylation by members of the GPRK subfamily of Ser/Thr protein kinases and association with beta-arrestins is involved in short-term receptor desensitization (By similarity). Beta-arrestins associate with the GPRK-phosphorylated receptor and uncouple it from the G protein thus terminating signal transduction (By similarity). The phosphorylated receptor is internalized through endocytosis via clathrin-coated pits which involves beta-arrestins (By similarity). The activation of the ERK pathway occurs either in a G protein-dependent or a beta-arrestin-dependent manner and is regulated by agonist-specific receptor phosphorylation (By similarity). Acts as a class A G protein-coupled receptor (GPCR) which dissociates from beta-arrestin at or near the plasma membrane and undergoes rapid recycling (By similarity). Receptor down-regulation pathways are varying with the agonist and occur dependent or independent of G protein coupling (By similarity). Endogenous ligands induce rapid desensitization, endocytosis and recycling (By similarity). Heterooligomerization with other GPCRs can modulate agonist binding, signaling and trafficking properties (By similarity) Couples to GNAS and is proposed to be involved in excitatory effects Does not bind agonists but may act through oligomerization with binding-competent OPRM1 isoforms and reduce their ligand binding activity",Expressed in brain. Isoform 16 and isoform 17 are detected in brain,,,"Cell membrane Cell projection, axon Perikaryon Cell projection, dendrite Endosome Cytoplasm",10529478|10836142|12068084|12589820|16580639|19300905|20525224|7891175|7905839|7957926|9689128,16580639,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT,Cancer-associated RNA nomination; no antigen validation asserted,,,,,,,,
OR1D2,ENSG00000184166,Unsafe,RNA,False,True,1.0,2.3,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,existing nomination or manual review; nomination unresolved; bone marrow: 1.5 nTPM; continuous selectivity;reproductive not higher; cerebral cortex: 0.8 nTPM; continuous selectivity; choroid plexus: 1 nTPM; continuous selectivity;reproductive not higher; duodenum: 0.4 nTPM; continuous selectivity; kidney: 0.7 nTPM; continuous selectivity; liver: 0.7 nTPM; continuous selectivity; lung: 0.4 nTPM; continuous selectivity; lymph node: 0.8 nTPM; continuous selectivity; retina: 2.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 0.6 nTPM; continuous selectivity; skeletal muscle: 0.6 nTPM; continuous selectivity; skin: 1.1 nTPM; continuous selectivity;reproductive not higher; small intestine: 0.4 nTPM; continuous selectivity; spleen: 0.8 nTPM; continuous selectivity; thyroid gland: 1.2 nTPM; continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 2.3 nTPM (limit 2); retina: 2.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 54/207 (26.1%); Colon Adenocarcinoma (validation): 115/486 (23.7%); Testicular Germ Cell Tumor (TCGA): 19/133 (14.3%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P34982,https://www.uniprot.org/uniprotkb/P34982/entry,Odorant receptor which may be involved in sperm chemotaxis. Bourgeonal is a strong chemoattractant for sperm in vitro and is shown to be a strong agonist for OR1D2 in vitro. May also function in olfactory reception,Expressed in testis. Expressed in spermatozoa (at protein level). Expressed in olfactory epithelium,,,Cell membrane,12663925|15458659|16820410,12663925|15458659|16820410,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
OR1J2,ENSG00000197233,Unsafe,High RNA,False,True,0.1,0.1,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,True,"brain/excitatory neurons cluster c-1: 6.9 nTPM, 871 reads; reproductive-cell max 0; brain/excitatory neurons cluster c-2: 28.2 nTPM, 3211 reads; reproductive-cell max 0; brain/excitatory neurons cluster c-3: 7.2 nTPM, 823 reads; reproductive-cell max 0; brain/excitatory neurons cluster c-4: 36.8 nTPM, 5043 reads; reproductive-cell max 0; brain/excitatory neurons cluster c-7: 5.8 nTPM, 546 reads; reproductive-cell max 0; brain/excitatory neurons cluster c-10: 30.7 nTPM, 1622 reads; reproductive-cell max 0; brain/excitatory neurons cluster c-11: 18.7 nTPM, 1371 reads; reproductive-cell max 0; brain/excitatory neurons cluster c-16: 38 nTPM, 3002 reads; reproductive-cell max 0; brain/excitatory neurons cluster c-19: 29.5 nTPM, 1319 reads; reproductive-cell max 0; brain/excitatory neurons cluster c-20: 13.2 nTPM, 646 reads; reproductive-cell max 0; brain/excitatory neurons cluster c-22: 15.5 nTPM, 672 reads; reproductive-cell max 0; brain/excitatory neurons cluster c-24: 16.6 nTPM, 386 reads; reproductive-cell max 0; brain/excitatory neurons cluster c-27: 15.1 nTPM, 536 reads; reproductive-cell max 0; brain/excitatory neurons cluster c-32: 17.4 nTPM, 505 reads; reproductive-cell max 0; brain/excitatory neurons cluster c-33: 6.3 nTPM, 156 reads; reproductive-cell max 0; brain/excitatory neurons cluster c-34: 9.6 nTPM, 241 reads; reproductive-cell max 0; brain/excitatory neurons cluster c-39: 17.6 nTPM, 197 reads; reproductive-cell max 0; brain/excitatory neurons cluster c-40: 20.5 nTPM, 207 reads; reproductive-cell max 0",True,False,,True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,4.127924406030001,38.0,"hpa_single_cell_tissue: brain/excitatory neurons, max 38 nTPM, 3 observations >30",Neither,oncoref.target-sets.2026-10-23.2,4.128 TPM; blood/TH17; dice_th17; vital,38 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 2/283 (0.7%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NGS2,https://www.uniprot.org/uniprotkb/Q8NGS2/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR2A4,ENSG00000180658,Unsafe,High RNA,False,True,0.3,0.3,0,0,Missing,False,False,False,False,Retained,Normal,False,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,hpa_immune_cell basophil: 11.9 nTPM; hpa_immune_monaco basophil: 25.2 TPM,True,True,False,,True,True,"Bone marrow/Hematopoietic cells: Low, HPA058272; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA058272; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA058272; conflicting or uncurated primary profile; Skin 1/Fibroblasts: High, HPA058272; conflicting or uncurated primary profile; Small intestine/Glandular cells: Low, HPA058272; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,25.2,37.3643,"hpa_immune_cell_samples: blood/basophil, max 37.3643 nTPM, 1 observations >30",Neither,oncoref.target-sets.2026-10-23.2,25.2 TPM; blood/basophil; hpa_immune_monaco; vital,37.36 nTPM; blood/basophil; hpa_immune_cell_samples; vital,Breast Invasive Carcinoma (validation): 45/50 (90.0%); Kidney Renal Clear Cell Carcinoma (TCGA): 104/521 (20.0%); Kidney Renal Clear Cell Carcinoma (validation): 18/100 (18.0%),breast cancer: 0/12 (0.0%); cervical cancer: 0/11 (0.0%),31,20,O95047,https://www.uniprot.org/uniprotkb/O95047/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OR3A1,ENSG00000180090,Unsafe,High RNA,False,True,0.7,0.7,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,True,"brain/excitatory neurons cluster c-2: 6.9 nTPM, 786 reads; reproductive-cell max 3; brain/excitatory neurons cluster c-4: 7.6 nTPM, 1039 reads; reproductive-cell max 3; brain/excitatory neurons cluster c-10: 8.2 nTPM, 433 reads; reproductive-cell max 3; brain/excitatory neurons cluster c-11: 11.9 nTPM, 875 reads; reproductive-cell max 3; brain/oligodendrocytes cluster c-12: 5.3 nTPM, 64 reads; reproductive-cell max 3; brain/excitatory neurons cluster c-16: 9.7 nTPM, 770 reads; reproductive-cell max 3; brain/excitatory neurons cluster c-19: 5.5 nTPM, 244 reads; reproductive-cell max 3; brain/excitatory neurons cluster c-20: 32.5 nTPM, 1588 reads; reproductive-cell max 3; brain/excitatory neurons cluster c-22: 17.3 nTPM, 748 reads; reproductive-cell max 3; brain/excitatory neurons cluster c-27: 5.6 nTPM, 198 reads; reproductive-cell max 3; brain/excitatory neurons cluster c-29: 9.4 nTPM, 238 reads; reproductive-cell max 3; brain/excitatory neurons cluster c-31: 9.4 nTPM, 375 reads; reproductive-cell max 3; brain/excitatory neurons cluster c-32: 6.3 nTPM, 184 reads; reproductive-cell max 3; brain/excitatory neurons cluster c-34: 29.5 nTPM, 737 reads; reproductive-cell max 3; brain/astrocytes cluster c-35: 6.2 nTPM, 20 reads; reproductive-cell max 3; brain/excitatory neurons cluster c-36: 11.3 nTPM, 193 reads; reproductive-cell max 3; brain/excitatory neurons cluster c-39: 8.6 nTPM, 96 reads; reproductive-cell max 3; brain/microglial cells cluster c-43: 17.9 nTPM, 20 reads; reproductive-cell max 3",True,False,,True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,3.50467865251,32.5,"hpa_single_cell_tissue: brain/excitatory neurons, max 32.5 nTPM, 1 observations >30",Neither,oncoref.target-sets.2026-10-23.2,3.505 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,32.5 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 5/133 (3.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P47881,https://www.uniprot.org/uniprotkb/P47881/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,All audited maxima are within 10% above 30; other gates still require review,,,,
OR6C2,ENSG00000179695,Unsafe,High RNA,False,True,0.1,0.1,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,Neither,Low,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,30.923577747600003,0.2,"dice_m2: blood/M2, max 30.9236 TPM, 1 observations >30",Neither,oncoref.target-sets.2026-10-23.2,30.92 TPM; blood/M2; dice_m2; vital,0.2 nTPM; salivary gland/serous glandular cells; hpa_single_cell_tissue; protected,Testicular Germ Cell Tumor (TCGA): 3/133 (2.3%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9NZP2,https://www.uniprot.org/uniprotkb/Q9NZP2/entry,Odorant receptor,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,All audited maxima are within 10% above 30; other gates still require review,,,,
OR9A2,ENSG00000179468,Unsafe,High RNA,False,True,0.0,0.3,0,0,Missing,False,False,False,False,Excluded,Other,False,Silent,Not assessed,,,insufficient positive reproductive evidence; reproductive expression not demonstrated; incomplete tissue evidence,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,True,"brain/oligodendrocytes cluster c-12: 70.3 nTPM, 852 reads; reproductive-cell max 0; brain/oligodendrocytes cluster c-37: 75.4 nTPM, 265 reads; reproductive-cell max 0; brain/excitatory neurons cluster c-44: 10.5 nTPM, 30 reads; reproductive-cell max 0",True,False,,True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,0.811971775641,75.4,"hpa_single_cell: /Oligodendrocytes, max 71.2 nTPM, 1 observations >30; hpa_single_cell_tissue: brain/oligodendrocytes, max 75.4 nTPM, 2 observations >30",Neither,oncoref.target-sets.2026-10-23.2,0.812 TPM; blood/TH2; dice_th2; vital,75.4 nTPM; brain/oligodendrocytes; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 3/58 (5.2%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NGT5,https://www.uniprot.org/uniprotkb/Q8NGT5/entry,Odorant receptor,,,,Cell membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Gong2021_reproductive_PC,No tumor-antigen validation in this source | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
ORC1,ENSG00000085840,Unsafe,Protein,False,True,5.0,28.6,75,60,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0.4 nTPM; positive ihc; adrenal gland: 0.6 nTPM; positive ihc; bone marrow: 28.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 0.6 nTPM; positive ihc; cerebral cortex: 0.3 nTPM; positive ihc; colon: 3.3 nTPM; positive ihc;continuous selectivity; duodenum: 1.6 nTPM; positive ihc;continuous selectivity; esophagus: 2.7 nTPM; positive ihc;continuous selectivity; heart muscle: 0.2 nTPM; positive ihc; kidney: 0.5 nTPM; positive ihc; liver: 0.6 nTPM; positive ihc; lung: 0.6 nTPM; positive ihc; lymph node: 6.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 0.3 nTPM; positive ihc; parathyroid gland: 0.2 nTPM; positive ihc; rectum: 3.9 nTPM; positive ihc;continuous selectivity; skeletal muscle: 0.5 nTPM; positive ihc; skin: 1.9 nTPM; positive ihc; small intestine: 2.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 0.9 nTPM; positive ihc; stomach: 1 nTPM; positive ihc; thymus: 11.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 0.3 nTPM; positive ihc; urinary bladder: 0.9 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 28.6 nTPM (limit 2); lymph node: 6.5 nTPM (limit 6); small intestine: 2.3 nTPM (limit 2); thymus: 11.3 nTPM (limit 10),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: High (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: High (Approved); cerebral cortex / neuronal cells: High (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Low (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / glial cells: Medium (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in tubules: Low (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Low (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: High (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: High (Approved); rectum / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Low (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Low (Approved); smooth muscle / smooth muscle cells: Low (Approved); stomach 1 / glandular cells: Low (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Low (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 465/486 (95.7%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 262/283 (92.6%); Testicular Germ Cell Tumor (TCGA): 122/133 (91.7%),renal cancer: 3/12 (25.0%); ovarian cancer: 2/11 (18.2%),30,20,Q13415,https://www.uniprot.org/uniprotkb/Q13415/entry,Component of the origin recognition complex (ORC) that binds origins of replication. DNA-binding is ATP-dependent. The DNA sequences that define origins of replication have not been identified yet. ORC is required to assemble the pre-replication complex necessary to initiate DNA replication,,"Meier-Gorlin syndrome 1: A syndrome characterized by bilateral microtia, aplasia/hypoplasia of the patellae, and severe intrauterine and postnatal growth retardation with short stature and poor weight gain. Additional clinical findings include anomalies of cranial sutures, microcephaly, apparently low-set and simple ears, microstomia, full lips, highly arched or cleft palate, micrognathia, genitourinary tract anomalies, and various skeletal anomalies. While almost all cases have primordial dwarfism with substantial prenatal and postnatal growth retardation, not all cases have microcephaly, and microtia and absent/hypoplastic patella are absent in some. Despite the presence of microcephaly, intellect is usually normal.",,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ORC5,ENSG00000164815,Unsafe,Protein,False,True,18.8,18.8,81,74,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 9.4 nTPM; positive ihc;continuous selectivity; adrenal gland: 9.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 6.6 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 9.4 nTPM; absolute ceiling;continuous selectivity; bone marrow: 5.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 12.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 10.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 5.4 nTPM; absolute ceiling;continuous selectivity; colon: 11.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 8.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 10.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 6.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 8.1 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 8.6 nTPM; absolute ceiling;continuous selectivity; kidney: 10 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 16.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 6.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 11.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 6.6 nTPM; absolute ceiling;continuous selectivity; pancreas: 14 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 9.8 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 7.3 nTPM; absolute ceiling;continuous selectivity; rectum: 12.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 13.7 nTPM; absolute ceiling;continuous selectivity; salivary gland: 8.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 8.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 11.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 7.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 10.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 6.1 nTPM; absolute ceiling;continuous selectivity; spleen: 8.8 nTPM; positive ihc;continuous selectivity; stomach: 10 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 12.9 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 9.9 nTPM; positive ihc;continuous selectivity; tongue: 7.6 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 10.6 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 9.5 nTPM (limit 2); amygdala: 6.6 nTPM (limit 2); basal ganglia: 9.4 nTPM (limit 2); bone marrow: 5.7 nTPM (limit 2); cerebellum: 12.7 nTPM (limit 2); cerebral cortex: 10.8 nTPM (limit 2); choroid plexus: 5.4 nTPM (limit 2); colon: 11.6 nTPM (limit 6); duodenum: 8.2 nTPM (limit 2); esophagus: 10.3 nTPM (limit 6); heart muscle: 6.1 nTPM (limit 2); hippocampal formation: 8.1 nTPM (limit 2); hypothalamus: 8.6 nTPM (limit 2); kidney: 10 nTPM (limit 2); liver: 16.9 nTPM (limit 2); lung: 6.2 nTPM (limit 2); lymph node: 11.9 nTPM (limit 6); midbrain: 6.6 nTPM (limit 2); pancreas: 14 nTPM (limit 2); parathyroid gland: 9.8 nTPM (limit 8); pituitary gland: 7.3 nTPM (limit 2); rectum: 12.4 nTPM (limit 6); retina: 13.7 nTPM (limit 2); salivary gland: 8.6 nTPM (limit 6); skeletal muscle: 8.7 nTPM (limit 2); skin: 11.2 nTPM (limit 10); small intestine: 7.3 nTPM (limit 2); smooth muscle: 10.5 nTPM (limit 2); spinal cord: 6.1 nTPM (limit 2); stomach: 10 nTPM (limit 6); thymus: 12.9 nTPM (limit 10); tongue: 7.6 nTPM (limit 6); urinary bladder: 10.6 nTPM (limit 6),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: High (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Low (Approved); skin 1 / keratinocytes: Low (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Prostate Adenocarcinoma (TCGA): 480/480 (100.0%); Colon Adenocarcinoma (TCGA): 254/254 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%),testis cancer: 10/11 (90.9%); urothelial cancer: 8/11 (72.7%),30,20,O43913,https://www.uniprot.org/uniprotkb/O43913/entry,Component of the origin recognition complex (ORC) that binds origins of replication. DNA-binding is ATP-dependent. The specific DNA sequences that define origins of replication have not been identified yet. ORC is required to assemble the pre-replication complex necessary to initiate DNA replication,"Abundant in spleen, ovary, prostate, testis, and colon mucosa",,,Nucleus Chromosome,31160578,9765232,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
ORC6,ENSG00000091651,Unsafe,Protein,False,True,9.3,10.1,90,41,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 2.1 nTPM; absolute ceiling; basal ganglia: 2.4 nTPM; absolute ceiling; bone marrow: 10.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 2 nTPM; positive ihc; cerebral cortex: 3.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 1.6 nTPM; positive ihc; duodenum: 1.5 nTPM; positive ihc; esophagus: 3.9 nTPM; positive ihc;continuous selectivity; heart muscle: 1.4 nTPM; positive ihc; hippocampal formation: 2.3 nTPM; absolute ceiling; kidney: 0.4 nTPM; positive ihc; liver: 0.9 nTPM; positive ihc; lung: 0.6 nTPM; positive ihc; lymph node: 7.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; pancreas: 0.3 nTPM; positive ihc; parathyroid gland: 0.7 nTPM; positive ihc; rectum: 1.8 nTPM; positive ihc; salivary gland: 0.7 nTPM; positive ihc; skin: 1.1 nTPM; positive ihc; small intestine: 1.4 nTPM; positive ihc; stomach: 0.8 nTPM; positive ihc; thymus: 6 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 2.1 nTPM (limit 2); basal ganglia: 2.4 nTPM (limit 2); bone marrow: 10.1 nTPM (limit 2); cerebral cortex: 3.2 nTPM (limit 2); hippocampal formation: 2.3 nTPM (limit 2); lymph node: 7.2 nTPM (limit 6),bone marrow / hematopoietic cells: High (Enhanced); cerebellum / Purkinje cells: Low (Enhanced); cerebral cortex / neuronal cells: Low (Enhanced); colon / glandular cells: High (Enhanced); duodenum / glandular cells: High (Enhanced); esophagus / squamous epithelial cells: Medium (Enhanced); heart muscle / cardiomyocytes: Low (Enhanced); hippocampus / neuronal cells: Low (Enhanced); kidney / cells in tubules: Medium (Enhanced); liver / hepatocytes: Low (Enhanced); lung / macrophages: Low (Enhanced); lymph node / non-germinal center cells: High (Enhanced); nasopharynx / respiratory epithelial cells: Low (Enhanced); oral mucosa / squamous epithelial cells: Medium (Enhanced); pancreas / exocrine glandular cells: High (Enhanced); parathyroid gland / glandular cells: Low (Enhanced); rectum / glandular cells: Medium (Enhanced); salivary gland / glandular cells: Medium (Enhanced); skin 2 / cells in basal layer: Low (Enhanced); skin 2 / cells in spinous layer: Low (Enhanced); skin 2 / lymphocytes: Medium (Enhanced); small intestine / glandular cells: Medium (Enhanced); stomach 1 / glandular cells: Medium (Enhanced); stomach 2 / glandular cells: High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 80/80 (100.0%); Ovary Serous Cystadenocarcinoma (validation): 77/81 (95.1%); Testicular Germ Cell Tumor (TCGA): 116/133 (87.2%),testis cancer: 11/11 (100.0%); cervical cancer: 10/12 (83.3%),30,20,Q9Y5N6,https://www.uniprot.org/uniprotkb/Q9Y5N6/entry,"Component of the origin recognition complex (ORC) that binds origins of replication. DNA-binding is ATP-dependent. The specific DNA sequences that define origins of replication have not been identified yet. ORC is required to assemble the pre-replication complex necessary to initiate DNA replication. Does not bind histone H3 and H4 trimethylation marks H3K9me3, H3K27me3 and H4K20me3",,"Meier-Gorlin syndrome 3: A syndrome characterized by bilateral microtia, aplasia/hypoplasia of the patellae, and severe intrauterine and postnatal growth retardation with short stature and poor weight gain. Additional clinical findings include anomalies of cranial sutures, microcephaly, apparently low-set and simple ears, microstomia, full lips, highly arched or cleft palate, micrognathia, genitourinary tract anomalies, and various skeletal anomalies. While almost all cases have primordial dwarfism with substantial prenatal and postnatal growth retardation, not all cases have microcephaly, and microtia and absent/hypoplastic patella are absent in some. Despite the presence of microcephaly, intellect is usually normal.",,Nucleus,22427655,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
OTOA,ENSG00000155719,Unsafe,Protein,False,True,3.9,3.9,81,1,Positive somewhere,True,False,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; spleen: 2 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",,spleen / cells in red pulp: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Renal Papillary Cell Carcinoma (TCGA): 12/282 (4.3%); Skin Cuteneous Melanoma (TCGA): 3/99 (3.0%); Breast Invasive Carcinoma (validation): 1/50 (2.0%),cervical cancer: 1/12 (8.3%); breast cancer: 0/12 (0.0%),31,20,Q7RTW8,https://www.uniprot.org/uniprotkb/Q7RTW8/entry,May act as an adhesion molecule,,"Deafness, autosomal recessive, 22: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information.",,"Apical cell membrane Secreted, extracellular space, extracellular matrix",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
OTOP2,ENSG00000183034,Unsafe,RNA,False,True,4.1,19.4,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,colon: 19.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 10.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 1.3 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,colon: 19.4 nTPM (limit 6); rectum: 10.3 nTPM (limit 6); colon: 19.4 nTPM (baseline 6); rectum: 10.3 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 18/486 (3.7%); Rectum Adenocarcinoma (TCGA): 2/88 (2.3%); Colon Adenocarcinoma (TCGA): 2/254 (0.8%),colorectal cancer: 6/9 (66.7%); urothelial cancer: 7/11 (63.6%),31,20,Q7RTS6,https://www.uniprot.org/uniprotkb/Q7RTS6/entry,"Proton-selective ion channel open at neutral pH. Active at neutral and alkaline extracellular pH, likely participates in some alkali-related physiological activities",,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OTP,ENSG00000171540,Unsafe,Protein,False,True,0.2,12.9,82,1,Positive somewhere,True,True,False,False,Excluded,Normal,False,,Not assessed,,,positive ihc outside permitted; basal ganglia: 0.2 nTPM; continuous selectivity;reproductive not higher; hypothalamus: 12.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 0.2 nTPM; continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",hypothalamus: 12.9 nTPM (limit 2); hypothalamus: 12.9 nTPM (baseline 2),hypothalamus / neuronal cells: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 26/141 (18.4%); Glioblastoma Multiforme (validation): 4/58 (6.9%); Testicular Germ Cell Tumor (TCGA): 2/133 (1.5%),renal cancer: 3/12 (25.0%); liver cancer: 1/10 (10.0%),31,20,Q5XKR4,https://www.uniprot.org/uniprotkb/Q5XKR4/entry,Probably involved in the differentiation of hypothalamic neuroendocrine cells,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
OTUD7A,ENSG00000169918,Unsafe,RNA,False,True,4.0,12.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 6.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 5.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 12 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 7.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 1.2 nTPM; continuous selectivity; hippocampal formation: 8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 5.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 6.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 1.3 nTPM; continuous selectivity; pituitary gland: 1.5 nTPM; continuous selectivity; retina: 1.5 nTPM; continuous selectivity; skin: 2.5 nTPM; continuous selectivity; spinal cord: 9.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 6.1 nTPM (limit 2); basal ganglia: 5.6 nTPM (limit 2); cerebellum: 12 nTPM (limit 2); cerebral cortex: 7.8 nTPM (limit 2); hippocampal formation: 8 nTPM (limit 2); hypothalamus: 5.3 nTPM (limit 2); midbrain: 6.7 nTPM (limit 2); spinal cord: 9.8 nTPM (limit 2); amygdala: 6.1 nTPM (baseline 2); basal ganglia: 5.6 nTPM (baseline 2); cerebellum: 12 nTPM (baseline 2); cerebral cortex: 7.8 nTPM (baseline 2); hippocampal formation: 8 nTPM (baseline 2); hypothalamus: 5.3 nTPM (baseline 2); midbrain: 6.7 nTPM (baseline 2); spinal cord: 9.8 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 6/58 (10.3%); Kidney Chromophobe (TCGA): 5/64 (7.8%); Breast Invasive Carcinoma (validation): 2/50 (4.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8TE49,https://www.uniprot.org/uniprotkb/Q8TE49/entry,"Deubiquitinase, which cleaves 'Lys-11'-linked polyubiquitin chains. Might be required for PA28-20S proteasome assembly (Probable)",,"Neurodevelopmental disorder with hypotonia and seizures: An autosomal recessive, severe disorder characterized by global developmental delay, language impairment, impaired intellectual development, hypotonia, and early-onset seizures.",,Cytoplasm Nucleus,20622874|23827681|31997314,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
OXCT2,ENSG00000198754,Unsafe,Protein,False,True,71.0,71.0,93,5,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; kidney: 0.4 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,kidney / distal tubules: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 13/50 (26.0%); Kidney Renal Papillary Cell Carcinoma (TCGA): 25/282 (8.9%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 11/283 (3.9%),colorectal cancer: 2/12 (16.7%); breast cancer: 0/11 (0.0%),31,20,Q9BYC2,https://www.uniprot.org/uniprotkb/Q9BYC2/entry,Key enzyme for ketone body catabolism. Transfers the CoA moiety from succinate to acetoacetate. Formation of the enzyme-CoA intermediate proceeds via an unstable anhydride species formed between the carboxylate groups of the enzyme and substrate (By similarity),Testis specific,,,Mitochondrion,,11756565,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
PABIR3,ENSG00000156500,Unsafe,Protein,False,True,10.3,10.3,84,48,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 1.7 nTPM; positive ihc; bone marrow: 5.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 0.4 nTPM; positive ihc; choroid plexus: 7.1 nTPM; absolute ceiling;continuous selectivity; colon: 1.7 nTPM; positive ihc; duodenum: 0.9 nTPM; positive ihc; esophagus: 1.7 nTPM; positive ihc; heart muscle: 1.3 nTPM; positive ihc; kidney: 1.5 nTPM; positive ihc; liver: 1.8 nTPM; positive ihc; lung: 2.1 nTPM; positive ihc;absolute ceiling; lymph node: 4.1 nTPM; positive ihc;continuous selectivity; pancreas: 0.7 nTPM; positive ihc; parathyroid gland: 1.5 nTPM; positive ihc; rectum: 1.5 nTPM; positive ihc; retina: 5.5 nTPM; absolute ceiling;continuous selectivity; salivary gland: 4 nTPM; positive ihc;continuous selectivity; skin: 1.4 nTPM; positive ihc; small intestine: 1.3 nTPM; positive ihc; spleen: 3.9 nTPM; positive ihc; stomach: 2.7 nTPM; positive ihc; thyroid gland: 1.5 nTPM; positive ihc; urinary bladder: 1.9 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 5.9 nTPM (limit 2); choroid plexus: 7.1 nTPM (limit 2); lung: 2.1 nTPM (limit 2); retina: 5.5 nTPM (limit 2),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Low (Approved); cerebellum / cells in molecular layer: Low (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Low (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: High (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Medium (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Low (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Medium (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Low (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 71/80 (88.8%); Breast Invasive Carcinoma (validation): 39/50 (78.0%); Ovary Serous Cystadenocarcinoma (validation): 63/81 (77.8%),melanoma: 10/11 (90.9%); prostate cancer: 10/11 (90.9%),31,20,Q6P4D5,https://www.uniprot.org/uniprotkb/Q6P4D5/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
PABPC3,ENSG00000151846,Unsafe,Protein,False,True,35.7,35.7,84,26,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 0 nTPM; positive ihc; cerebellum: 0.2 nTPM; positive ihc; cerebral cortex: 0.2 nTPM; positive ihc; colon: 0.3 nTPM; positive ihc; duodenum: 0 nTPM; positive ihc; esophagus: 0.8 nTPM; positive ihc; lymph node: 0 nTPM; positive ihc; rectum: 0 nTPM; positive ihc; salivary gland: 0.6 nTPM; positive ihc; skin: 0.5 nTPM; positive ihc; small intestine: 0.3 nTPM; positive ihc; stomach: 0.3 nTPM; positive ihc; urinary bladder: 0.3 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,bone marrow / hematopoietic cells: Low (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Low (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); colon / glandular cells: Low (Approved); duodenum / glandular cells: Low (Approved); esophagus / squamous epithelial cells: Low (Approved); hippocampus / neuronal cells: Low (Approved); lymph node / non-germinal center cells: Low (Approved); rectum / glandular cells: Low (Approved); salivary gland / glandular cells: Low (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Low (Approved); stomach 1 / glandular cells: Low (Approved); urinary bladder / urothelial cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 44/50 (88.0%); Glioblastoma Multiforme (validation): 13/58 (22.4%); Uterine Corpus Endometrial Carcinoma (TCGA): 9/176 (5.1%),testis cancer: 11/12 (91.7%); stomach cancer: 8/11 (72.7%),31,20,Q9H361,https://www.uniprot.org/uniprotkb/Q9H361/entry,Binds the poly(A) tail of mRNA. May be involved in cytoplasmic regulatory processes of mRNA metabolism. Binds poly(A) with a slightly lower affinity as compared to PABPC1,Testis specific,,,Cytoplasm,,11328870,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Carter2023_CT | Loriot2025_S2 | Gong2021_reproductive_PC | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
PABPC4L,ENSG00000254535,Unsafe,RNA,False,True,9.9,9.9,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,parathyroid gland: 5.2 nTPM; continuous selectivity; smooth muscle: 2.3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,smooth muscle: 2.3 nTPM (limit 2); smooth muscle: 2.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Renal Clear Cell Carcinoma (validation): 40/100 (40.0%); Kidney Chromophobe (TCGA): 20/64 (31.2%); Glioblastoma Multiforme (validation): 16/58 (27.6%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P0CB38,https://www.uniprot.org/uniprotkb/P0CB38/entry,May bind RNA,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
PAGE2B,ENSG00000238269,Unsafe,High RNA,False,True,55.0,55.0,86,1,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 3/91 values ≥5 TPM, max 8.04323",True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,8.04323471611,35.0,"hpa_single_cell_tissue: liver/erythroid cells, max 35 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,8.043 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,35 nTPM; liver/erythroid cells; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 22/133 (16.5%); Liver Hepatocellular Carcinoma (validation): 30/231 (13.0%); Liver Hepatocellular Carcinoma (TCGA): 39/362 (10.8%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q5JRK9,https://www.uniprot.org/uniprotkb/Q5JRK9/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,Are borderline DICE B-cell RNA and other cell-context signals genuine?,Review exact loci and source-specific normal-cell signals; reliable protein evidence must address implicated cells.,A borderline immune summary must not hide a higher signal elsewhere; complete RNA audit accompanies this record.,,,,,
PAGE4,ENSG00000101951,Unsafe,RNA,False,True,987.1,987.1,82,2,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,smooth muscle: 23.3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,smooth muscle: 23.3 nTPM (limit 12),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Prostate Adenocarcinoma (TCGA): 422/480 (87.9%); Liver Hepatocellular Carcinoma (TCGA): 105/362 (29.0%); Liver Hepatocellular Carcinoma (validation): 59/231 (25.5%),liver cancer: 4/9 (44.4%); melanoma: 5/12 (41.7%),31,20,O60829,https://www.uniprot.org/uniprotkb/O60829/entry,"Intrinsically disordered protein that potentiates the transcriptional activator activity of JUN (PubMed:24263171, PubMed:28289210). Protects cells from stress-induced apoptosis by inhibiting reactive oxygen species (ROS) production and via regulation of the MAPK signaling pathway (PubMed:21357425, PubMed:25374899, PubMed:30658679)","Expressed at basal lvels in the adult normal prostate gland but is highly up-regulated in the fetal prostate and prostate cancer cells (PubMed:12489849, PubMed:24263171, PubMed:24559171, PubMed:25374899). Preferentially expressed in normal male and female reproductive tissues, testis, fallopian tube, uterus, and placenta, as well as in testicular cancer, uterine cancer, cervical cancer and kidney cancer (PubMed:12489849, PubMed:9724777)",,,Cytoplasm Nucleus Mitochondrion,21357425|24263171|25374899|28289210|30658679,12489849|24263171|24559171|25374899|9724777,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Gong2021_reproductive_PC,No tumor-antigen validation in this source | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
PAK6,ENSG00000137843,Unsafe,Protein,False,True,17.2,31.8,88,15,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 8 nTPM; absolute ceiling;continuous selectivity; amygdala: 22.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 22.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 20 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 31.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 2.3 nTPM; absolute ceiling; esophagus: 24.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 8 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 17.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 8.1 nTPM; absolute ceiling;continuous selectivity; kidney: 4.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 3.3 nTPM; absolute ceiling; pancreas: 7.8 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 7.7 nTPM; continuous selectivity; pituitary gland: 11.8 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 4.3 nTPM; absolute ceiling; skin: 27.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 7.2 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 8 nTPM (limit 4); amygdala: 22.3 nTPM (limit 2); basal ganglia: 22.7 nTPM (limit 2); cerebellum: 20 nTPM (limit 4); cerebral cortex: 31.8 nTPM (limit 2); choroid plexus: 2.3 nTPM (limit 2); esophagus: 24.9 nTPM (limit 6); heart muscle: 8 nTPM (limit 2); hippocampal formation: 17.6 nTPM (limit 2); hypothalamus: 8.1 nTPM (limit 2); kidney: 4.6 nTPM (limit 2); midbrain: 3.3 nTPM (limit 2); pancreas: 7.8 nTPM (limit 4); pituitary gland: 11.8 nTPM (limit 2); skeletal muscle: 4.3 nTPM (limit 4); skin: 27.3 nTPM (limit 10),cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); cerebral cortex / neuropil: Low (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Low (Approved); kidney / cells in tubules: Low (Approved); skin 1 / keratinocytes: High (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: High (Approved); thyroid gland / glandular cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Thyroid Carcinoma (TCGA): 477/495 (96.4%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 272/283 (96.1%); Head and Neck Squamous Cell Carcinoma (TCGA): 458/492 (93.1%),pancreatic cancer: 5/12 (41.7%); skin cancer: 4/12 (33.3%),31,20,Q9NQU5,https://www.uniprot.org/uniprotkb/Q9NQU5/entry,Serine/threonine protein kinase that plays a role in the regulation of gene transcription. The kinase activity is induced by various effectors including AR or MAP2K6/MAPKK6. Phosphorylates the DNA-binding domain of androgen receptor/AR and thereby inhibits AR-mediated transcription. Also inhibits ESR1-mediated transcription. May play a role in cytoskeleton regulation by interacting with IQGAP1. May protect cells from apoptosis through phosphorylation of BAD,"Selectively expressed in brain and testis, with lower levels in multiple tissues including prostate and breast",,,Cytoplasm Nucleus,14573606|20054820,11278661|11773441,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | daSilva2017_testis_biased,GC RNA nomination across cancer types; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
PAOX,ENSG00000148832,Unsafe,RNA,False,True,26.6,26.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 2.2 nTPM; absolute ceiling; amygdala: 2.4 nTPM; absolute ceiling; basal ganglia: 2.4 nTPM; absolute ceiling; cerebellum: 2.9 nTPM; absolute ceiling; cerebral cortex: 2.6 nTPM; absolute ceiling; esophagus: 6.1 nTPM; absolute ceiling; hippocampal formation: 2.8 nTPM; absolute ceiling; kidney: 3.3 nTPM; absolute ceiling; liver: 7.5 nTPM; absolute ceiling;continuous selectivity; midbrain: 2.4 nTPM; absolute ceiling; pancreas: 2.4 nTPM; absolute ceiling; skeletal muscle: 2.9 nTPM; absolute ceiling; small intestine: 4.3 nTPM; absolute ceiling; spinal cord: 4 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 2.2 nTPM (limit 2); amygdala: 2.4 nTPM (limit 2); basal ganglia: 2.4 nTPM (limit 2); cerebellum: 2.9 nTPM (limit 2); cerebral cortex: 2.6 nTPM (limit 2); esophagus: 6.1 nTPM (limit 6); hippocampal formation: 2.8 nTPM (limit 2); kidney: 3.3 nTPM (limit 2); liver: 7.5 nTPM (limit 2); midbrain: 2.4 nTPM (limit 2); pancreas: 2.4 nTPM (limit 2); skeletal muscle: 2.9 nTPM (limit 2); small intestine: 4.3 nTPM (limit 2); spinal cord: 4 nTPM (limit 2); adrenal gland: 2.2 nTPM (baseline 2); amygdala: 2.4 nTPM (baseline 2); basal ganglia: 2.4 nTPM (baseline 2); cerebellum: 2.9 nTPM (baseline 2); cerebral cortex: 2.6 nTPM (baseline 2); esophagus: 6.1 nTPM (baseline 6); hippocampal formation: 2.8 nTPM (baseline 2); kidney: 3.3 nTPM (baseline 2); liver: 7.5 nTPM (baseline 2); midbrain: 2.4 nTPM (baseline 2); pancreas: 2.4 nTPM (baseline 2); skeletal muscle: 2.9 nTPM (baseline 2); small intestine: 4.3 nTPM (baseline 2); spinal cord: 4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (validation): 213/231 (92.2%); Breast Invasive Carcinoma (validation): 46/50 (92.0%); Kidney Renal Clear Cell Carcinoma (validation): 74/100 (74.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q6QHF9,https://www.uniprot.org/uniprotkb/Q6QHF9/entry,"Flavoenzyme which catalyzes the oxidation of N(1)-acetylspermine to spermidine and is thus involved in the polyamine back-conversion (PubMed:12477380). Can also oxidize N(1)-acetylspermidine to putrescine. Substrate specificity: N(1)-acetylspermine = N(1)-acetylspermidine > N(1),N(12)-diacylspermine >> spermine. Does not oxidize spermidine. Plays an important role in the regulation of polyamine intracellular concentration and has the potential to act as a determinant of cellular sensitivity to the antitumor polyamine analogs (PubMed:12477380)",Widely expressed. Not detected in spleen. Expressed at lower level in neoplastic tissues,,,Peroxisome Cytoplasm,12477380,12477380,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
PAPOLB,ENSG00000218823,Unsafe,High RNA,False,True,29.0,29.0,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,CTA,Pass,oncoref.target-sets.2026-10-23.1,False,False,,CTA → Unsafe,True,True,True,0.3376515692,30.4,"hpa_single_cell_tissue: bronchus/smooth muscle cells, max 30.4 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,0.3377 TPM; blood/CD8_STIM; dice_cd8_stim; vital,30.4 nTPM; bronchus/smooth muscle cells; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9NRJ5,https://www.uniprot.org/uniprotkb/Q9NRJ5/entry,,Testis specific,,,Cytoplasm Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,All audited maxima are within 10% above 30; other gates still require review,,,,
PAPPA,ENSG00000182752,Unsafe,Normal,False,True,70.0,70.0,83,3,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,Published protein production by nonmalignant cells outside permitted reproductive/disposable compartments,,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,Unsafe,Normal,oncoref.target-sets.2026-10-23.1,False,True,https://pubmed.ncbi.nlm.nih.gov/17936662/,Unchanged,True,True,True,1.04016544656,277.6,"hpa_single_cell: /Basal squamous epithelial cells, max 61.8 nTPM, 1 observations >30; hpa_single_cell: /Collecting duct cells, max 134.2 nTPM, 1 observations >30; hpa_single_cell: /Fibroblasts, max 44.8 nTPM, 1 observations >30; hpa_single_cell: /Horizontal cells, max 57.9 nTPM, 1 observations >30; hpa_single_cell: /Mesothelial cells, max 93.4 nTPM, 1 observations >30; hpa_single_cell: /Proximal tubular cells, max 53.8 nTPM, 1 observations >30; hpa_single_cell: /Schwann cells, max 43.4 nTPM, 1 observations >30; hpa_single_cell_tissue: brain/excitatory neurons, max 71.6 nTPM, 4 observations >30; hpa_single_cell_tissue: esophagus/basal squamous epithelial cells, max 61.8 nTPM, 1 observations >30; hpa_single_cell_tissue: esophagus/fibroblasts, max 277.6 nTPM, 1 observations >30; hpa_single_cell_tissue: esophagus/schwann cells, max 107.8 nTPM, 1 observations >30; hpa_single_cell_tissue: eye/horizontal cells, max 57.9 nTPM, 1 observations >30; hpa_single_cell_tissue: kidney/collecting duct cells, max 134.2 nTPM, 1 observations >30; hpa_single_cell_tissue: kidney/proximal tubular cells, max 141.3 nTPM, 6 observations >30; hpa_single_cell_tissue: lung/fibroblasts, max 78.2 nTPM, 1 observations >30; hpa_single_cell_tissue: pancreas/fibroblasts, max 44.9 nTPM, 1 observations >30; hpa_single_cell_tissue: skeletal muscle/fibroblasts, max 123.1 nTPM, 4 observations >30; hpa_single_cell_tissue: skin/fibroblasts, max 71.9 nTPM, 2 observations >30; hpa_single_cell_tissue: thymus/fibroblasts, max 58.1 nTPM, 1 observations >30; hpa_single_cell_tissue: thymus/mesothelial cells, max 93.4 nTPM, 1 observations >30; hpa_single_cell_tissue: tongue/basal keratinocytes, max 84.8 nTPM, 2 observations >30; hpa_single_cell_tissue: tongue/smooth muscle cells, max 59 nTPM, 1 observations >30; hpa_single_cell_tissue: vascular/fibroblasts, max 82.4 nTPM, 3 observations >30; hpa_single_cell_tissue: vascular/smooth muscle cells, max 39.7 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,1.04 TPM; blood/TREG_MEM; dice_treg_mem; vital,277.6 nTPM; esophagus/fibroblasts; hpa_single_cell_tissue; protected,Rectum Adenocarcinoma (validation): 93/207 (44.9%); Pancreatic Adenocarcinoma (validation): 33/80 (41.2%); Colon Adenocarcinoma (validation): 177/486 (36.4%),breast cancer: 0/12 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q13219,https://www.uniprot.org/uniprotkb/Q13219/entry,"Metalloproteinase which specifically cleaves IGFBP-4 and IGFBP-5, resulting in release of bound IGF. Cleavage of IGFBP-4 is dramatically enhanced by the presence of IGF, whereas cleavage of IGFBP-5 is slightly inhibited by the presence of IGF","High levels in placenta and pregnancy serum. In placenta, expressed in X cells in septa and anchoring villi, and in syncytiotrophoblasts in the chorionic villi. Lower levels are found in a variety of other tissues including kidney, myometrium, endometrium, ovaries, breast, prostate, bone marrow, colon, fibroblasts and osteoblasts",,,Secreted,10077652|10913121|11522292,10077652|10491647|7508748|7526035,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,Activated human coronary vascular cells can produce PAPP-A. Placental association does not imply exclusive reproductive expression.,https://pubmed.ncbi.nlm.nih.gov/17936662/,Normal function,Gong2021_placenta_PC | Bruggeman2018_GC | Gong2021_reproductive_PC,No tumor-antigen validation in this source | GC RNA nomination across cancer types; no antigen validation asserted | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
PAPPA2,ENSG00000116183,Unsafe,RNA,False,True,54.9,54.9,90,4,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,retina: 3.6 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 3.6 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Chromophobe (TCGA): 33/64 (51.6%); Glioblastoma Multiforme (validation): 21/58 (36.2%); Pancreatic Adenocarcinoma (validation): 6/80 (7.5%),breast cancer: 0/9 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q9BXP8,https://www.uniprot.org/uniprotkb/Q9BXP8/entry,Metalloproteinase which specifically cleaves insulin-like growth factor binding protein (IGFBP)-5 at the '163-Ser-|-Lys-164' bond. Shows limited proteolysis toward IGFBP-3,"Expressed abundantly in placenta, and non-pregnant mammary gland with low expression in the kidney, fetal brain and pancreas","Short stature, Dauber-Argente type: An autosomal recessive disorder characterized by progressive postnatal growth failure, moderate microcephaly, thin long bones, mildly decreased bone density, and elevated serum levels of total IGF1, IGFBP3 and IGFBP5. Levels of circulating free IGF1 are reduced.",,Secreted,11264294|26902202,11264294|11597188,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Bruggeman2018_GC | Gong2021_reproductive_PC,No tumor-antigen validation in this source | GC RNA nomination across cancer types; no antigen validation asserted | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
PARPBP,ENSG00000185480,Unsafe,Protein,False,True,3.8,9.2,72,49,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 0.6 nTPM; positive ihc; bone marrow: 9.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 0.4 nTPM; positive ihc; cerebral cortex: 0.6 nTPM; positive ihc; colon: 2.9 nTPM; continuous selectivity; duodenum: 2.2 nTPM; continuous selectivity; esophagus: 3.5 nTPM; positive ihc;continuous selectivity; heart muscle: 0.3 nTPM; positive ihc; hypothalamus: 1.1 nTPM; continuous selectivity; kidney: 0.8 nTPM; positive ihc; lung: 0.6 nTPM; positive ihc; lymph node: 4.1 nTPM; continuous selectivity;reproductive not higher; pancreas: 0.3 nTPM; positive ihc; parathyroid gland: 0.3 nTPM; positive ihc; rectum: 3.7 nTPM; positive ihc;continuous selectivity; salivary gland: 0.9 nTPM; positive ihc; skeletal muscle: 0.3 nTPM; positive ihc; skin: 1.9 nTPM; positive ihc;continuous selectivity; small intestine: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 1.6 nTPM; positive ihc;continuous selectivity; stomach: 1.8 nTPM; positive ihc;continuous selectivity; thymus: 7.4 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 0.5 nTPM; positive ihc; urinary bladder: 1.8 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 9.2 nTPM (limit 2); small intestine: 2.7 nTPM (limit 2),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); lung / macrophages: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Low (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Low (Approved); smooth muscle / smooth muscle cells: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Low (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 53/58 (91.4%); Colon Adenocarcinoma (validation): 427/486 (87.9%); Lung Squamous Cell Carcinoma (validation): 55/68 (80.9%),breast cancer: 12/12 (100.0%); cervical cancer: 12/12 (100.0%),29,20,Q9NWS1,https://www.uniprot.org/uniprotkb/Q9NWS1/entry,"Required to suppress inappropriate homologous recombination, thereby playing a central role DNA repair and in the maintenance of genomic stability. Antagonizes homologous recombination by interfering with the formation of the RAD51-DNA homologous recombination structure. Binds single-strand DNA and poly(A) homopolymers. Positively regulate the poly(ADP-ribosyl)ation activity of PARP1; however such function may be indirect",Restricted to testis. Overexpressed in multiple cancer cells,,,Cytoplasm Nucleus,20931645|22153967,20931645,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
PBK,ENSG00000168078,Unsafe,Protein,False,True,68.2,68.2,89,6,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; lymph node: 12.5 nTPM; positive ihc;absolute ceiling; thymus: 22.2 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",lymph node: 12.5 nTPM (limit 6); thymus: 22.2 nTPM (limit 10),lymph node / germinal center cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Colon Adenocarcinoma (validation): 474/486 (97.5%); Lung Squamous Cell Carcinoma (validation): 66/68 (97.1%),lymphoma: 1/11 (9.1%); breast cancer: 0/11 (0.0%),31,20,Q96KB5,https://www.uniprot.org/uniprotkb/Q96KB5/entry,"Phosphorylates MAP kinase p38. Seems to be active only in mitosis. May also play a role in the activation of lymphoid cells. When phosphorylated, forms a complex with TP53, leading to TP53 destabilization and attenuation of G2/M checkpoint during doxorubicin-induced DNA damage","Expressed in the testis and placenta. In the testis, restrictedly expressed in outer cell layer of seminiferous tubules",,,,10781613|17482142,10781613|11378444,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
PCDH15,ENSG00000150275,Unsafe,RNA,False,True,3.2,59.9,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 18.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 6.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 3.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 6.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 5.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 5.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 7.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 2.4 nTPM; absolute ceiling;continuous selectivity; midbrain: 5.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 4.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; retina: 59.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 2.8 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 18.4 nTPM (limit 2); amygdala: 6.8 nTPM (limit 2); basal ganglia: 3.5 nTPM (limit 2); cerebral cortex: 6.6 nTPM (limit 2); hippocampal formation: 5.9 nTPM (limit 2); hypothalamus: 5.1 nTPM (limit 2); kidney: 7.7 nTPM (limit 2); lung: 2.4 nTPM (limit 2); midbrain: 5.1 nTPM (limit 2); pituitary gland: 4.6 nTPM (limit 2); retina: 59.9 nTPM (limit 2); spinal cord: 2.8 nTPM (limit 2); adrenal gland: 18.4 nTPM (baseline 2); amygdala: 6.8 nTPM (baseline 2); basal ganglia: 3.5 nTPM (baseline 2); cerebral cortex: 6.6 nTPM (baseline 2); hippocampal formation: 5.9 nTPM (baseline 2); hypothalamus: 5.1 nTPM (baseline 2); kidney: 7.7 nTPM (baseline 2); lung: 2.4 nTPM (baseline 2); midbrain: 5.1 nTPM (baseline 2); pituitary gland: 4.6 nTPM (baseline 2); retina: 59.9 nTPM (baseline 2); spinal cord: 2.8 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 37/58 (63.8%); Glioblastoma Multiforme (TCGA): 37/141 (26.2%); Ovary Serous Cystadenocarcinoma (TCGA): 20/349 (5.7%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q96QU1,https://www.uniprot.org/uniprotkb/Q96QU1/entry,Calcium-dependent cell-adhesion protein. Essential for maintenance of normal retinal and cochlear function,"Expressed in brain, lung, kidney, spleen and testis. Found also in the inner and outer synaptic layers, and the nerve fiber layer in adult and fetal retinas. Found in the supporting cells, outer sulcus cells and spiral ganglion of fetal cochlea. Expressed in cytotoxic tumor-derived T- and NK-cell lines as well as biopsies of nasal NK/T-cell lymphomas. Not detected in normal or in vitro activated peripheral blood cells, CD4 or CD8 lymphocytes or NK cells. Isoform 3 is expressed in brain, heart, cerebellum and kidney. CD1 isoforms, such as isoform 1, have a limited pattern of expression and is detected in testis, retina and cochlea. CD2 isoforms, such as isoforms 4 and 5, are expressed in heart, kidney, thymus, spleen, testis, retina and cochlea. CD3 isoforms, such as isoform 6, are widely expressed","Usher syndrome 1F: USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH1 is characterized by profound congenital sensorineural deafness, absent vestibular function and prepubertal onset of progressive retinitis pigmentosa leading to blindness. Usher syndrome 1D/F: A digenic recessive form of Usher syndrome, a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH1 is characterized by profound congenital sensorineural deafness, absent vestibular function and prepubertal onset of progressive retinitis pigmentosa leading to blindness. Deafness, autosomal recessive, 23: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information.",,Cell membrane Secreted,,11487575|16369489|18719945,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
PCDHA1,ENSG00000204970,Unsafe,Protein,False,True,1.0,2.8,79,4,Positive somewhere,True,True,False,False,Excluded,Normal,False,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 1.5 nTPM; continuous selectivity;reproductive not higher; basal ganglia: 2.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 2.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 2.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 1.8 nTPM; continuous selectivity;reproductive not higher; hypothalamus: 1.8 nTPM; continuous selectivity;reproductive not higher; midbrain: 1.4 nTPM; continuous selectivity;reproductive not higher; pituitary gland: 1 nTPM; continuous selectivity;reproductive not higher; spinal cord: 2.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",basal ganglia: 2.1 nTPM (limit 2); cerebral cortex: 2.2 nTPM (limit 2); spinal cord: 2.8 nTPM (limit 2); basal ganglia: 2.1 nTPM (baseline 2); cerebellum: 2.3 nTPM (baseline 2); cerebral cortex: 2.2 nTPM (baseline 2); spinal cord: 2.8 nTPM (baseline 2),caudate / neuronal cells: Low (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); cerebral cortex / neuropil: Low (Enhanced); hippocampus / neuronal cells: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (validation): 33/231 (14.3%); Glioblastoma Multiforme (validation): 6/58 (10.3%); Breast Invasive Carcinoma (validation): 5/50 (10.0%),endometrial cancer: 2/12 (16.7%); urothelial cancer: 1/10 (10.0%),31,20,Q9Y5I3,https://www.uniprot.org/uniprotkb/Q9Y5I3/entry,Potential calcium-dependent cell-adhesion protein. May be involved in the establishment and maintenance of specific neuronal connections in the brain,,,,Cell membrane Secreted,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT,GC RNA nomination across cancer types; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
PCDHA10,ENSG00000250120,Unsafe,RNA,False,True,1.9,8.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 1.4 nTPM; continuous selectivity; basal ganglia: 1.5 nTPM; continuous selectivity; cerebellum: 2.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 1.4 nTPM; continuous selectivity; hypothalamus: 1 nTPM; continuous selectivity; kidney: 1.4 nTPM; continuous selectivity; lung: 0.7 nTPM; continuous selectivity; midbrain: 1.3 nTPM; continuous selectivity; pancreas: 4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 1.4 nTPM; continuous selectivity; retina: 2.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 0.7 nTPM; continuous selectivity; smooth muscle: 1.5 nTPM; continuous selectivity; spinal cord: 2.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 2 nTPM; continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebellum: 2.9 nTPM (limit 2); cerebral cortex: 8 nTPM (limit 2); pancreas: 4 nTPM (limit 2); retina: 2.3 nTPM (limit 2); spinal cord: 2.6 nTPM (limit 2); cerebellum: 2.9 nTPM (baseline 2); cerebral cortex: 8 nTPM (baseline 2); pancreas: 4 nTPM (baseline 2); retina: 2.3 nTPM (baseline 2); spinal cord: 2.6 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 15/58 (25.9%); Thyroid Carcinoma (TCGA): 101/495 (20.4%); Glioblastoma Multiforme (TCGA): 27/141 (19.1%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9Y5I2,https://www.uniprot.org/uniprotkb/Q9Y5I2/entry,Potential calcium-dependent cell-adhesion protein. May be involved in the establishment and maintenance of specific neuronal connections in the brain,,,,Cell membrane Secreted,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
PCDHA2,ENSG00000204969,Unsafe,RNA,False,True,0.8,2.4,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 0.7 nTPM; continuous selectivity; basal ganglia: 0.6 nTPM; continuous selectivity; cerebellum: 2.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 0.8 nTPM; continuous selectivity;reproductive not higher; hippocampal formation: 0.7 nTPM; continuous selectivity; hypothalamus: 0.6 nTPM; continuous selectivity; midbrain: 0.4 nTPM; continuous selectivity; pituitary gland: 1.7 nTPM; continuous selectivity;reproductive not higher; retina: 0.5 nTPM; continuous selectivity; spinal cord: 0.5 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebellum: 2.4 nTPM (limit 2); cerebellum: 2.4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 10/58 (17.2%); Liver Hepatocellular Carcinoma (validation): 30/231 (13.0%); Breast Invasive Carcinoma (validation): 6/50 (12.0%),melanoma: 9/11 (81.8%); ovarian cancer: 6/11 (54.5%),31,20,Q9Y5H9,https://www.uniprot.org/uniprotkb/Q9Y5H9/entry,Potential calcium-dependent cell-adhesion protein. May be involved in the establishment and maintenance of specific neuronal connections in the brain,,,,Cell membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
PCDHA4,ENSG00000204967,Unsafe,Protein,False,True,0.5,2.0,77,23,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 0.8 nTPM; continuous selectivity;reproductive not higher; basal ganglia: 1 nTPM; continuous selectivity;reproductive not higher; bone marrow: 0.8 nTPM; continuous selectivity;reproductive not higher; cerebellum: 1.7 nTPM; positive ihc;continuous selectivity;reproductive not higher; cerebral cortex: 2 nTPM; positive ihc;continuous selectivity;reproductive not higher; colon: 0.2 nTPM; positive ihc; duodenum: 0.2 nTPM; positive ihc; hippocampal formation: 0.8 nTPM; continuous selectivity;reproductive not higher; hypothalamus: 0.9 nTPM; continuous selectivity;reproductive not higher; kidney: 0.4 nTPM; positive ihc;continuous selectivity; lung: 0.4 nTPM; continuous selectivity; midbrain: 0.5 nTPM; continuous selectivity;reproductive not higher; pancreas: 1.2 nTPM; positive ihc;continuous selectivity;reproductive not higher; pituitary gland: 0.3 nTPM; continuous selectivity; rectum: 0.2 nTPM; positive ihc; retina: 0.8 nTPM; continuous selectivity;reproductive not higher; skin: 0.4 nTPM; continuous selectivity; small intestine: 0.2 nTPM; positive ihc; smooth muscle: 0.3 nTPM; continuous selectivity; spinal cord: 0.5 nTPM; continuous selectivity;reproductive not higher; stomach: 0.2 nTPM; positive ihc; urinary bladder: 0.2 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,bronchus / respiratory epithelial cells: Low (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); colon / glandular cells: Low (Approved); duodenum / glandular cells: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in tubules: Low (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Low (Approved); rectum / glandular cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); stomach 2 / glandular cells: Low (Approved); urinary bladder / urothelial cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 19/58 (32.8%); Breast Invasive Carcinoma (validation): 11/50 (22.0%); Glioblastoma Multiforme (TCGA): 23/141 (16.3%),pancreatic cancer: 1/10 (10.0%); glioma: 1/11 (9.1%),31,20,Q9UN74,https://www.uniprot.org/uniprotkb/Q9UN74/entry,"Calcium-dependent cell-adhesion protein involved in cells self-recognition and non-self discrimination. Thereby, it is involved in the establishment and maintenance of specific neuronal connections in the brain",,,,Cell membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | daSilva2017_tumor_proteomics,GC RNA nomination across cancer types; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
PCDHA5,ENSG00000204965,Unsafe,Protein,False,True,0.3,2.8,82,11,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 0.8 nTPM; continuous selectivity;reproductive not higher; basal ganglia: 0.5 nTPM; continuous selectivity;reproductive not higher; cerebellum: 2.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 2.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 0.7 nTPM; continuous selectivity;reproductive not higher; hypothalamus: 0.7 nTPM; continuous selectivity;reproductive not higher; midbrain: 0.5 nTPM; continuous selectivity;reproductive not higher; pancreas: 0.2 nTPM; continuous selectivity; pituitary gland: 0.5 nTPM; continuous selectivity;reproductive not higher; retina: 0.3 nTPM; continuous selectivity;reproductive not higher; spinal cord: 0.4 nTPM; continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",cerebellum: 2.8 nTPM (limit 2); cerebral cortex: 2.1 nTPM (limit 2); cerebellum: 2.8 nTPM (baseline 2); cerebral cortex: 2.1 nTPM (baseline 2),caudate / glial cells: Low (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Medium (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (validation): 29/231 (12.6%); Glioblastoma Multiforme (validation): 6/58 (10.3%); Pancreatic Adenocarcinoma (validation): 4/80 (5.0%),glioma: 5/9 (55.6%); colorectal cancer: 2/11 (18.2%),31,20,Q9Y5H7,https://www.uniprot.org/uniprotkb/Q9Y5H7/entry,Potential calcium-dependent cell-adhesion protein. May be involved in the establishment and maintenance of specific neuronal connections in the brain,,,,Cell membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | daSilva2017_tumor_proteomics,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
PCDHA6,ENSG00000081842,Unsafe,Protein,False,True,0.6,3.0,78,6,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 0.8 nTPM; continuous selectivity;reproductive not higher; basal ganglia: 1.3 nTPM; continuous selectivity;reproductive not higher; cerebellum: 3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 2.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 1 nTPM; continuous selectivity;reproductive not higher; hypothalamus: 1.4 nTPM; continuous selectivity;reproductive not higher; midbrain: 0.8 nTPM; continuous selectivity;reproductive not higher; pancreas: 1 nTPM; continuous selectivity;reproductive not higher; parathyroid gland: 1.4 nTPM; continuous selectivity;reproductive not higher; pituitary gland: 1.5 nTPM; continuous selectivity;reproductive not higher; retina: 1.1 nTPM; continuous selectivity;reproductive not higher; spinal cord: 1.3 nTPM; continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",cerebellum: 3 nTPM (limit 2); cerebral cortex: 2.4 nTPM (limit 2),caudate / neuronal cells: Low (Enhanced); cerebellum / cells in molecular layer: Medium (Enhanced); cerebral cortex / neuronal cells: Low (Enhanced); cerebral cortex / neuropil: Medium (Enhanced); hippocampus / neuronal cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 13/58 (22.4%); Breast Invasive Carcinoma (validation): 8/50 (16.0%); Liver Hepatocellular Carcinoma (validation): 31/231 (13.4%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q9UN73,https://www.uniprot.org/uniprotkb/Q9UN73/entry,Potential calcium-dependent cell-adhesion protein. May be involved in the establishment and maintenance of specific neuronal connections in the brain,,,,Cell membrane Secreted,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
PCDHAC1,ENSG00000248383,Unsafe,RNA,False,True,0.7,28.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 0.4 nTPM; continuous selectivity; amygdala: 0.4 nTPM; continuous selectivity; basal ganglia: 0.3 nTPM; continuous selectivity; cerebellum: 0.6 nTPM; continuous selectivity; cerebral cortex: 1 nTPM; continuous selectivity;reproductive not higher; hippocampal formation: 0.4 nTPM; continuous selectivity; hypothalamus: 0.5 nTPM; continuous selectivity; lung: 0.6 nTPM; continuous selectivity; lymph node: 1.2 nTPM; continuous selectivity;reproductive not higher; midbrain: 0.4 nTPM; continuous selectivity; pancreas: 1.1 nTPM; continuous selectivity;reproductive not higher; parathyroid gland: 28.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 0.7 nTPM; continuous selectivity;reproductive not higher; retina: 0.7 nTPM; continuous selectivity;reproductive not higher; salivary gland: 0.4 nTPM; continuous selectivity; thyroid gland: 0.9 nTPM; continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,parathyroid gland: 28.8 nTPM (limit 6); parathyroid gland: 28.8 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 27/58 (46.6%); Liver Hepatocellular Carcinoma (validation): 28/231 (12.1%); Pancreatic Adenocarcinoma (validation): 8/80 (10.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9H158,https://www.uniprot.org/uniprotkb/Q9H158/entry,Potential calcium-dependent cell-adhesion protein. May be involved in the establishment and maintenance of specific neuronal connections in the brain,,,,Cell membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT,GC RNA nomination across cancer types; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
PCDHB2,ENSG00000112852,Unsafe,Protein,False,True,5.4,5.4,82,11,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; cerebellum: 1.2 nTPM; positive ihc; cerebral cortex: 4.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; kidney: 0.9 nTPM; positive ihc; lung: 2.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 1.7 nTPM; continuous selectivity; thyroid gland: 1.3 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",cerebral cortex: 4.4 nTPM (limit 2); lung: 2.1 nTPM (limit 2),caudate / glial cells: Low (Enhanced); cerebellum / cells in molecular layer: Medium (Enhanced); cerebral cortex / glial cells: Low (Enhanced); hippocampus / glial cells: Low (Enhanced); hippocampus / neuronal cells: Low (Enhanced); kidney / cells in tubules: Low (Enhanced); lung / macrophages: Low (Enhanced); thyroid gland / glandular cells: Low (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 49/58 (84.5%); Breast Invasive Carcinoma (validation): 37/50 (74.0%); Ovary Serous Cystadenocarcinoma (TCGA): 175/349 (50.1%),glioma: 5/12 (41.7%); endometrial cancer: 1/11 (9.1%),31,20,Q9Y5E7,https://www.uniprot.org/uniprotkb/Q9Y5E7/entry,Potential calcium-dependent cell-adhesion protein. May be involved in the establishment and maintenance of specific neuronal connections in the brain,,,,Cell membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | Jamin2021_CT | Jamin2021_core,GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
PCDHB5,ENSG00000113209,Unsafe,Protein,False,True,6.3,6.3,78,55,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; amygdala: 2.7 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 2.8 nTPM; absolute ceiling;continuous selectivity; bone marrow: 0 nTPM; positive ihc; cerebellum: 1.7 nTPM; positive ihc;continuous selectivity; cerebral cortex: 4 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 1.4 nTPM; positive ihc; duodenum: 0.2 nTPM; positive ihc; heart muscle: 1.9 nTPM; positive ihc;continuous selectivity; hippocampal formation: 2.3 nTPM; absolute ceiling;continuous selectivity; kidney: 2.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 1.7 nTPM; positive ihc;continuous selectivity; lymph node: 0.1 nTPM; positive ihc; pancreas: 4.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 2.6 nTPM; positive ihc;continuous selectivity; pituitary gland: 3.1 nTPM; absolute ceiling;continuous selectivity; rectum: 0.3 nTPM; positive ihc; retina: 2.3 nTPM; absolute ceiling;continuous selectivity; salivary gland: 2.2 nTPM; positive ihc; skeletal muscle: 1.1 nTPM; positive ihc; skin: 0.6 nTPM; positive ihc; small intestine: 0.6 nTPM; positive ihc; smooth muscle: 2.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 2 nTPM; continuous selectivity; spleen: 0.7 nTPM; positive ihc; stomach: 1 nTPM; positive ihc; thyroid gland: 2.5 nTPM; positive ihc; urinary bladder: 1.5 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 2.7 nTPM (limit 2); basal ganglia: 2.8 nTPM (limit 2); cerebral cortex: 4 nTPM (limit 2); hippocampal formation: 2.3 nTPM (limit 2); kidney: 2.3 nTPM (limit 2); pancreas: 4.6 nTPM (limit 2); pituitary gland: 3.1 nTPM (limit 2); retina: 2.3 nTPM (limit 2); smooth muscle: 2.1 nTPM (limit 2),bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Medium (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Low (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Low (Approved); heart muscle / cardiomyocytes: Medium (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: High (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Low (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); small intestine / glandular cells: Low (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in red pulp: High (Approved); spleen / cells in white pulp: High (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Low (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Low (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 49/58 (84.5%); Prostate Adenocarcinoma (TCGA): 264/480 (55.0%); Breast Invasive Carcinoma (validation): 25/50 (50.0%),lymphoma: 10/12 (83.3%); glioma: 4/11 (36.4%),31,20,Q9Y5E4,https://www.uniprot.org/uniprotkb/Q9Y5E4/entry,Potential calcium-dependent cell-adhesion protein. May be involved in the establishment and maintenance of specific neuronal connections in the brain,,,,Cell membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
PCDHB9,ENSG00000177839,Unsafe,Protein,False,True,1.9,4.2,74,71,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0.9 nTPM; positive ihc; adrenal gland: 0.7 nTPM; positive ihc;continuous selectivity; amygdala: 1 nTPM; continuous selectivity; basal ganglia: 0.7 nTPM; continuous selectivity; bone marrow: 0.1 nTPM; positive ihc; cerebellum: 1 nTPM; positive ihc;continuous selectivity; cerebral cortex: 4.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; colon: 1 nTPM; positive ihc;continuous selectivity; duodenum: 0.1 nTPM; positive ihc; esophagus: 0.3 nTPM; positive ihc; heart muscle: 1.1 nTPM; positive ihc;continuous selectivity; hippocampal formation: 0.9 nTPM; continuous selectivity; hypothalamus: 0.7 nTPM; continuous selectivity; kidney: 0.5 nTPM; positive ihc; liver: 0.2 nTPM; positive ihc; lung: 1.1 nTPM; positive ihc;continuous selectivity; lymph node: 0.1 nTPM; positive ihc; midbrain: 0.6 nTPM; continuous selectivity; pancreas: 0.7 nTPM; positive ihc;continuous selectivity; parathyroid gland: 1.1 nTPM; positive ihc;continuous selectivity; pituitary gland: 2.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; retina: 1.2 nTPM; continuous selectivity; salivary gland: 1 nTPM; positive ihc;continuous selectivity; skeletal muscle: 0.4 nTPM; positive ihc; skin: 0.7 nTPM; positive ihc; small intestine: 0.4 nTPM; positive ihc; smooth muscle: 1.1 nTPM; positive ihc;continuous selectivity; spinal cord: 0.7 nTPM; continuous selectivity; spleen: 0.3 nTPM; positive ihc; stomach: 0.4 nTPM; positive ihc; thyroid gland: 0.6 nTPM; positive ihc; tongue: 0.9 nTPM; continuous selectivity; urinary bladder: 0.8 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",cerebral cortex: 4.2 nTPM (limit 2); pituitary gland: 2.4 nTPM (limit 2); cerebral cortex: 4.2 nTPM (baseline 2); pituitary gland: 2.4 nTPM (baseline 2),adipose tissue / adipocytes: Medium (Uncertain); adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); caudate / glial cells: Low (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: Low (Uncertain); cerebellum / cells in molecular layer: Medium (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / endothelial cells: Medium (Uncertain); cerebral cortex / glial cells: Low (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / endothelial cells: Medium (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: High (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / glial cells: Low (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in glomeruli: Medium (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / cholangiocytes: Low (Uncertain); liver / hepatocytes: Low (Uncertain); lung / alveolar cells: Medium (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); nasopharynx / respiratory epithelial cells: High (Uncertain); oral mucosa / squamous epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: High (Uncertain); skin 1 / fibroblasts: Medium (Uncertain); skin 1 / keratinocytes: Low (Uncertain); skin 1 / Langerhans: Low (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: Medium (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); spleen / cells in red pulp: Medium (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Glioblastoma Multiforme (TCGA): 103/141 (73.0%); Breast Invasive Carcinoma (validation): 16/50 (32.0%),liver cancer: 10/10 (100.0%); testis cancer: 9/11 (81.8%),31,20,Q9Y5E1,https://www.uniprot.org/uniprotkb/Q9Y5E1/entry,Potential calcium-dependent cell-adhesion protein. May be involved in the establishment and maintenance of specific neuronal connections in the brain,,,,Cell membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
PCDHGA4,ENSG00000262576,Unsafe,RNA,False,True,1.5,3.3,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 1.7 nTPM; continuous selectivity;reproductive not higher; adrenal gland: 1.3 nTPM; continuous selectivity; amygdala: 1.5 nTPM; continuous selectivity;reproductive not higher; basal ganglia: 2.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 1.9 nTPM; continuous selectivity;reproductive not higher; cerebral cortex: 3.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 0.8 nTPM; continuous selectivity; heart muscle: 1.4 nTPM; continuous selectivity; hippocampal formation: 1.2 nTPM; continuous selectivity; hypothalamus: 1.2 nTPM; continuous selectivity; lung: 1 nTPM; continuous selectivity; midbrain: 1.1 nTPM; continuous selectivity; pancreas: 2 nTPM; continuous selectivity;reproductive not higher; parathyroid gland: 2.2 nTPM; continuous selectivity;reproductive not higher; pituitary gland: 1 nTPM; continuous selectivity; retina: 1.5 nTPM; continuous selectivity;reproductive not higher; salivary gland: 0.7 nTPM; continuous selectivity; skeletal muscle: 0.7 nTPM; continuous selectivity; smooth muscle: 1.4 nTPM; continuous selectivity; spinal cord: 1.3 nTPM; continuous selectivity; tongue: 0.9 nTPM; continuous selectivity; urinary bladder: 0.7 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,basal ganglia: 2.2 nTPM (limit 2); cerebral cortex: 3.3 nTPM (limit 2); basal ganglia: 2.2 nTPM (baseline 2); cerebral cortex: 3.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 46/58 (79.3%); Liver Hepatocellular Carcinoma (validation): 170/231 (73.6%); Breast Invasive Carcinoma (validation): 9/50 (18.0%),glioma: 12/12 (100.0%); melanoma: 11/12 (91.7%),31,20,Q9Y5G9,https://www.uniprot.org/uniprotkb/Q9Y5G9/entry,Potential calcium-dependent cell-adhesion protein. May be involved in the establishment and maintenance of specific neuronal connections in the brain,,,It is uncertain whether Met-1 or Met-32 is the initiator,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
PCDHGB1,ENSG00000254221,Unsafe,RNA,False,True,1.1,12.4,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 0.7 nTPM; continuous selectivity; amygdala: 1.9 nTPM; continuous selectivity;reproductive not higher; basal ganglia: 1.9 nTPM; continuous selectivity;reproductive not higher; cerebellum: 1 nTPM; continuous selectivity; cerebral cortex: 12.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 0.5 nTPM; continuous selectivity; hippocampal formation: 1.4 nTPM; continuous selectivity;reproductive not higher; hypothalamus: 1.1 nTPM; continuous selectivity;reproductive not higher; kidney: 0.4 nTPM; continuous selectivity; lung: 0.6 nTPM; continuous selectivity; midbrain: 1.1 nTPM; continuous selectivity;reproductive not higher; pancreas: 0.7 nTPM; continuous selectivity; parathyroid gland: 2.1 nTPM; continuous selectivity;reproductive not higher; pituitary gland: 1 nTPM; continuous selectivity; retina: 1.5 nTPM; continuous selectivity;reproductive not higher; smooth muscle: 0.8 nTPM; continuous selectivity; spinal cord: 1.2 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 0.6 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebral cortex: 12.4 nTPM (limit 2); cerebral cortex: 12.4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (validation): 175/231 (75.8%); Glioblastoma Multiforme (validation): 41/58 (70.7%); Glioblastoma Multiforme (TCGA): 37/141 (26.2%),glioma: 12/12 (100.0%); melanoma: 11/12 (91.7%),31,20,Q9Y5G3,https://www.uniprot.org/uniprotkb/Q9Y5G3/entry,Potential calcium-dependent cell-adhesion protein. May be involved in the establishment and maintenance of specific neuronal connections in the brain,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
PCDHGB2,ENSG00000253910,Unsafe,RNA,False,True,2.8,3.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 1.4 nTPM; continuous selectivity; adrenal gland: 0.9 nTPM; continuous selectivity; amygdala: 3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 3.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 3.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 1.7 nTPM; continuous selectivity; hippocampal formation: 2.1 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 1.7 nTPM; continuous selectivity; lung: 1.6 nTPM; continuous selectivity; midbrain: 1.6 nTPM; continuous selectivity; pancreas: 0.8 nTPM; continuous selectivity; parathyroid gland: 1.1 nTPM; continuous selectivity; pituitary gland: 0.9 nTPM; continuous selectivity; retina: 1.5 nTPM; continuous selectivity; skeletal muscle: 0.8 nTPM; continuous selectivity; smooth muscle: 1.4 nTPM; continuous selectivity; spinal cord: 1.5 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 3 nTPM (limit 2); basal ganglia: 3 nTPM (limit 2); cerebellum: 3.2 nTPM (limit 2); cerebral cortex: 3.6 nTPM (limit 2); hippocampal formation: 2.1 nTPM (limit 2); amygdala: 3 nTPM (baseline 2); basal ganglia: 3 nTPM (baseline 2); cerebellum: 3.2 nTPM (baseline 2); cerebral cortex: 3.6 nTPM (baseline 2); hippocampal formation: 2.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 56/58 (96.6%); Liver Hepatocellular Carcinoma (validation): 171/231 (74.0%); Glioblastoma Multiforme (TCGA): 94/141 (66.7%),glioma: 12/12 (100.0%); melanoma: 11/12 (91.7%),31,20,Q9Y5G2,https://www.uniprot.org/uniprotkb/Q9Y5G2/entry,Potential calcium-dependent cell-adhesion protein. May be involved in the establishment and maintenance of specific neuronal connections in the brain,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
PCGF5,ENSG00000180628,Unsafe,Protein,False,True,15.3,27.3,98,30,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 13.2 nTPM; continuous selectivity; adrenal gland: 21.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 15.1 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 13.2 nTPM; absolute ceiling;continuous selectivity; bone marrow: 5.7 nTPM; absolute ceiling;continuous selectivity; cerebellum: 9.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 18 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 4.7 nTPM; absolute ceiling;continuous selectivity; colon: 14.8 nTPM; absolute ceiling;continuous selectivity; duodenum: 17.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 12.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 27.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 12.6 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 14.9 nTPM; absolute ceiling;continuous selectivity; kidney: 22.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 25.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 12.7 nTPM; absolute ceiling;continuous selectivity; lymph node: 16.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 15.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 15.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 19.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 7 nTPM; absolute ceiling;continuous selectivity; rectum: 13.7 nTPM; absolute ceiling;continuous selectivity; retina: 15.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 17.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 14.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 10.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 20.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 11.5 nTPM; absolute ceiling;continuous selectivity; spinal cord: 16.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 17.4 nTPM; continuous selectivity;reproductive not higher; stomach: 14.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 18.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 23.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; tongue: 16 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 11.8 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 21.1 nTPM (limit 4); amygdala: 15.1 nTPM (limit 2); basal ganglia: 13.2 nTPM (limit 2); bone marrow: 5.7 nTPM (limit 4); cerebellum: 9.7 nTPM (limit 2); cerebral cortex: 18 nTPM (limit 2); choroid plexus: 4.7 nTPM (limit 2); colon: 14.8 nTPM (limit 8); duodenum: 17.1 nTPM (limit 2); esophagus: 12.4 nTPM (limit 6); heart muscle: 27.3 nTPM (limit 4); hippocampal formation: 12.6 nTPM (limit 2); hypothalamus: 14.9 nTPM (limit 2); kidney: 22.6 nTPM (limit 2); liver: 25.4 nTPM (limit 2); lung: 12.7 nTPM (limit 4); lymph node: 16.4 nTPM (limit 8); midbrain: 15.8 nTPM (limit 2); pancreas: 15.6 nTPM (limit 2); parathyroid gland: 19.2 nTPM (limit 8); pituitary gland: 7 nTPM (limit 2); rectum: 13.7 nTPM (limit 8); retina: 15.7 nTPM (limit 2); salivary gland: 17.1 nTPM (limit 8); skeletal muscle: 14.6 nTPM (limit 2); skin: 10.9 nTPM (limit 10); small intestine: 20.4 nTPM (limit 2); smooth muscle: 11.5 nTPM (limit 4); spinal cord: 16.7 nTPM (limit 2); stomach: 14.3 nTPM (limit 6); thymus: 18.9 nTPM (limit 10); thyroid gland: 23.4 nTPM (limit 20); tongue: 16 nTPM (limit 6); urinary bladder: 11.8 nTPM (limit 6),bronchus / ciliated cells (cell body): Medium (Approved); bronchus / ciliated cells (tip of cilia): Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / neuronal cells: Low (Approved); duodenum / glandular cells: Low (Approved); esophagus / squamous epithelial cells: Medium (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Low (Approved); pancreas / exocrine glandular cells: Low (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / keratinocytes: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Low (Approved); stomach 2 / glandular cells: Low (Approved); urinary bladder / urothelial cells: Low (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%); Kidney Renal Clear Cell Carcinoma (validation): 100/100 (100.0%),stomach cancer: 6/10 (60.0%); lung cancer: 6/11 (54.5%),31,20,Q86SE9,https://www.uniprot.org/uniprotkb/Q86SE9/entry,"Component of a Polycomb group (PcG) multiprotein PRC1-like complex, a complex class required to maintain the transcriptionally repressive state of many genes, including Hox genes, throughout development. PcG PRC1 complex acts via chromatin remodeling and modification of histones; it mediates monoubiquitination of histone H2A 'Lys-119', rendering chromatin heritably changed in its expressibility (PubMed:26151332). Within the PRC1-like complex, regulates RNF2 ubiquitin ligase activity (PubMed:26151332). Plays a redundant role with PCGF3 as part of a PRC1-like complex that mediates monoubiquitination of histone H2A 'Lys-119' on the X chromosome and is required for normal silencing of one copy of the X chromosome in XX females (By similarity)",,,,"Nucleus Nucleus, nucleoplasm",26151332,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
PCP2,ENSG00000174788,Unsafe,RNA,False,True,109.3,116.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 3.7 nTPM; absolute ceiling; cerebellum: 116.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 2.1 nTPM; absolute ceiling; hypothalamus: 6.6 nTPM; absolute ceiling; kidney: 7.8 nTPM; absolute ceiling; liver: 3.6 nTPM; absolute ceiling; lung: 2.2 nTPM; absolute ceiling; pancreas: 5.2 nTPM; absolute ceiling; retina: 32.3 nTPM; absolute ceiling;continuous selectivity; salivary gland: 15.8 nTPM; absolute ceiling; spinal cord: 5.3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 3.7 nTPM (limit 2); cerebellum: 116.2 nTPM (limit 2); heart muscle: 2.1 nTPM (limit 2); hypothalamus: 6.6 nTPM (limit 2); kidney: 7.8 nTPM (limit 2); liver: 3.6 nTPM (limit 2); lung: 2.2 nTPM (limit 2); pancreas: 5.2 nTPM (limit 2); retina: 32.3 nTPM (limit 2); salivary gland: 15.8 nTPM (limit 6); spinal cord: 5.3 nTPM (limit 2); bone marrow: 3.7 nTPM (baseline 2); cerebellum: 116.2 nTPM (baseline 2); heart muscle: 2.1 nTPM (baseline 2); hypothalamus: 6.6 nTPM (baseline 2); kidney: 7.8 nTPM (baseline 2); liver: 3.6 nTPM (baseline 2); lung: 2.2 nTPM (baseline 2); pancreas: 5.2 nTPM (baseline 2); retina: 32.3 nTPM (baseline 2); salivary gland: 15.8 nTPM (baseline 6); spinal cord: 5.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 47/50 (94.0%); Breast Invasive Carcinoma (TCGA): 577/1022 (56.5%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 125/283 (44.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8IVA1,https://www.uniprot.org/uniprotkb/Q8IVA1/entry,May function as a cell-type specific modulator for G protein-mediated cell signaling,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
PCSK4,ENSG00000115257,Unsafe,RNA,False,True,64.1,64.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 2.4 nTPM; absolute ceiling; basal ganglia: 3 nTPM; absolute ceiling; cerebral cortex: 2.8 nTPM; absolute ceiling; hippocampal formation: 2.5 nTPM; absolute ceiling; hypothalamus: 3.5 nTPM; absolute ceiling; kidney: 3.6 nTPM; absolute ceiling; liver: 3.9 nTPM; absolute ceiling; pancreas: 2.7 nTPM; absolute ceiling; pituitary gland: 6.9 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 2.4 nTPM (limit 2); basal ganglia: 3 nTPM (limit 2); cerebral cortex: 2.8 nTPM (limit 2); hippocampal formation: 2.5 nTPM (limit 2); hypothalamus: 3.5 nTPM (limit 2); kidney: 3.6 nTPM (limit 2); liver: 3.9 nTPM (limit 2); pancreas: 2.7 nTPM (limit 2); pituitary gland: 6.9 nTPM (limit 2); amygdala: 2.4 nTPM (baseline 2); basal ganglia: 3 nTPM (baseline 2); cerebral cortex: 2.8 nTPM (baseline 2); hippocampal formation: 2.5 nTPM (baseline 2); hypothalamus: 3.5 nTPM (baseline 2); kidney: 3.6 nTPM (baseline 2); liver: 3.9 nTPM (baseline 2); pancreas: 2.7 nTPM (baseline 2); pituitary gland: 6.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 42/50 (84.0%); Kidney Renal Papillary Cell Carcinoma (TCGA): 111/282 (39.4%); Liver Hepatocellular Carcinoma (validation): 40/231 (17.3%),breast cancer: 12/12 (100.0%); cervical cancer: 12/12 (100.0%),31,20,Q6UW60,https://www.uniprot.org/uniprotkb/Q6UW60/entry,"Proprotein convertase involved in the processing of hormone and other protein precursors at sites comprised of pairs of basic amino acid residues (By similarity). In males, important for ADAM2 processing as well as other acrosomal proteins with roles in fertilization and critical for normal fertilization events such as sperm capacitation, acrosome reaction and binding of sperm to zona pellucida (By similarity). Also plays a role in female fertility, involved in the regulation of trophoblast migration and placental development, may be through the proteolytical processing and activation of proteins such as IGF2 (PubMed:16040806). May also participate in folliculogenesis in the ovaries (By similarity)",Placenta,,,"Membrane Cytoplasmic vesicle, secretory vesicle, acrosome membrane",16040806,16040806,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
PCYT1A,ENSG00000161217,Unsafe,Protein,False,True,21.8,71.2,87,79,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 30.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; adrenal gland: 23.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 13 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 13 nTPM; absolute ceiling;continuous selectivity; bone marrow: 45 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 12.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 15.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 15.9 nTPM; absolute ceiling;continuous selectivity; colon: 24.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 58.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 29.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 44.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 12.5 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 13.6 nTPM; absolute ceiling;continuous selectivity; kidney: 17.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 20 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 21.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 22.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 15.3 nTPM; absolute ceiling;continuous selectivity; pancreas: 16.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 21.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 12.6 nTPM; absolute ceiling;continuous selectivity; rectum: 22.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; retina: 13.9 nTPM; absolute ceiling;continuous selectivity; salivary gland: 18.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 71.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 41.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 47.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 22.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 15.7 nTPM; absolute ceiling;continuous selectivity; spleen: 25.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; stomach: 23.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; thymus: 17.8 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 16.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 40.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 20.2 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 30.3 nTPM (limit 10); adrenal gland: 23.7 nTPM (limit 2); amygdala: 13 nTPM (limit 2); basal ganglia: 13 nTPM (limit 2); bone marrow: 45 nTPM (limit 2); cerebellum: 12.8 nTPM (limit 2); cerebral cortex: 15.6 nTPM (limit 2); choroid plexus: 15.9 nTPM (limit 2); colon: 24.8 nTPM (limit 6); duodenum: 58.6 nTPM (limit 2); esophagus: 29.9 nTPM (limit 6); heart muscle: 44.8 nTPM (limit 2); hippocampal formation: 12.5 nTPM (limit 2); hypothalamus: 13.6 nTPM (limit 2); kidney: 17.7 nTPM (limit 2); liver: 20 nTPM (limit 2); lung: 21.8 nTPM (limit 2); lymph node: 22.3 nTPM (limit 6); midbrain: 15.3 nTPM (limit 2); pancreas: 16.3 nTPM (limit 2); parathyroid gland: 21.9 nTPM (limit 6); pituitary gland: 12.6 nTPM (limit 2); rectum: 22.2 nTPM (limit 6); retina: 13.9 nTPM (limit 2); salivary gland: 18.7 nTPM (limit 6); skeletal muscle: 71.2 nTPM (limit 2); skin: 41.8 nTPM (limit 10); small intestine: 47.7 nTPM (limit 2); smooth muscle: 22.2 nTPM (limit 2); spinal cord: 15.7 nTPM (limit 2); spleen: 25.3 nTPM (limit 10); stomach: 23.6 nTPM (limit 6); thymus: 17.8 nTPM (limit 10); thyroid gland: 16.6 nTPM (limit 10); tongue: 40.4 nTPM (limit 6); urinary bladder: 20.2 nTPM (limit 6),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); colon / endothelial cells: High (Approved); colon / glandular cells: High (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: High (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: High (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: High (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: High (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: High (Approved); skeletal muscle / myocytes: High (Approved); skin 1 / fibroblasts: High (Approved); skin 1 / keratinocytes: High (Approved); skin 1 / Langerhans: High (Approved); skin 2 / epidermal cells: High (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Head and Neck Squamous Cell Carcinoma (TCGA): 492/492 (100.0%); Lung Squamous Cell Carcinoma (TCGA): 489/489 (100.0%),breast cancer: 12/12 (100.0%); colorectal cancer: 12/12 (100.0%),31,20,P49585,https://www.uniprot.org/uniprotkb/P49585/entry,Catalyzes the key rate-limiting step in the CDP-choline pathway for phosphatidylcholine biosynthesis,"Brain, placenta, liver, fetal and adult lung","Spondylometaphyseal dysplasia with cone-rod dystrophy: An autosomal recessive disorder characterized by postnatal growth deficiency resulting in profound short stature, rhizomelia with bowing of the lower extremities, platyspondyly with anterior vertebral protrusions, progressive metaphyseal irregularity and cupping with shortened tubular bones, and early-onset progressive visual impairment associated with a pigmentary maculopathy and electroretinographic evidence of cone-rod dysfunction. Lipodystrophy, congenital generalized, 5: A form of congenital generalized lipodystrophy, a metabolic disorder characterized by a near complete absence of adipose tissue, extreme insulin resistance, hypertriglyceridemia, hepatic steatosis and diabetes mellitus. CGL5 is an autosomal recessive form with onset in early childhood. Affected individuals also have short stature.",,"Cytoplasm, cytosol Membrane Endoplasmic reticulum membrane Nucleus",10480912|30559292|7918629,10480912,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
PDE10A,ENSG00000112541,Unsafe,Protein,False,True,3.3,22.2,94,2,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 2.5 nTPM; continuous selectivity; amygdala: 1.4 nTPM; continuous selectivity; basal ganglia: 22.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 4.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 1.5 nTPM; continuous selectivity; heart muscle: 3.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 1.9 nTPM; continuous selectivity; hypothalamus: 2.1 nTPM; absolute ceiling;continuous selectivity; kidney: 2.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 1 nTPM; continuous selectivity; midbrain: 1.4 nTPM; continuous selectivity; pituitary gland: 2.6 nTPM; absolute ceiling;continuous selectivity; retina: 1.9 nTPM; continuous selectivity; smooth muscle: 1.6 nTPM; continuous selectivity; thyroid gland: 3.4 nTPM; continuous selectivity;reproductive not higher; urinary bladder: 2.2 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",basal ganglia: 22.2 nTPM (limit 2); cerebellum: 4.2 nTPM (limit 2); hypothalamus: 2.1 nTPM (limit 2); kidney: 2.9 nTPM (limit 2); pituitary gland: 2.6 nTPM (limit 2); basal ganglia: 22.2 nTPM (baseline 2); cerebellum: 4.2 nTPM (baseline 2); heart muscle: 3.5 nTPM (baseline 2); hypothalamus: 2.1 nTPM (baseline 2); kidney: 2.9 nTPM (baseline 2); pituitary gland: 2.6 nTPM (baseline 2),cerebellum / white matter cells - cytoplasm/membrane: Low (Supported); kidney / proximal tubules (cell body): Medium (Supported),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 40/58 (69.0%); Breast Invasive Carcinoma (validation): 27/50 (54.0%); Kidney Renal Clear Cell Carcinoma (validation): 32/100 (32.0%),colorectal cancer: 2/11 (18.2%); pancreatic cancer: 1/10 (10.0%),31,20,Q9Y233,https://www.uniprot.org/uniprotkb/Q9Y233/entry,"Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides (PubMed:10373451, PubMed:10393245, PubMed:16330539, PubMed:17389385, PubMed:27058447). Can hydrolyze both cAMP and cGMP, but has higher affinity for cAMP and is more efficient with cAMP as substrate (PubMed:10373451, PubMed:10393245, PubMed:17389385, PubMed:27058447). May play a critical role in regulating cAMP and cGMP levels in the striatum, a region of the brain that contributes to the control of movement and cognition (PubMed:27058447)","Abundant in the putamen and caudate nucleus regions of brain and testis, moderately expressed in the thyroid gland, pituitary gland, thalamus and cerebellum","Dyskinesia, limb and orofacial, infantile-onset: An autosomal recessive, early-onset hyperkinetic movement disorder characterized by axial hypotonia, dyskinesia of the limbs and trunk, orofacial dyskinesia, drooling, and dysarthria. The severity of the hyperkinesis is variable. Striatal degeneration, autosomal dominant 2: An autosomal dominant disorder characterized by striatal degeneration and dysfunction of basal ganglia, resulting in hyperkinesis.",,"Cytoplasm, cytosol",10373451|10393245|16330539|17389385|27058447,10373451|27058447,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
PDE11A,ENSG00000128655,Unsafe,Protein,False,True,5.3,9.9,78,76,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 2.2 nTPM; positive ihc; adrenal gland: 0.3 nTPM; positive ihc; bone marrow: 0.2 nTPM; positive ihc; cerebellum: 0 nTPM; positive ihc; cerebral cortex: 0.5 nTPM; positive ihc; colon: 0.5 nTPM; positive ihc; duodenum: 0.8 nTPM; positive ihc; esophagus: 0 nTPM; positive ihc; heart muscle: 0.3 nTPM; positive ihc; kidney: 0.5 nTPM; positive ihc; liver: 6.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 0 nTPM; positive ihc; lymph node: 0 nTPM; positive ihc; midbrain: 1.6 nTPM; continuous selectivity; pancreas: 1.1 nTPM; positive ihc; parathyroid gland: 9.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; rectum: 0.4 nTPM; positive ihc; salivary gland: 1.3 nTPM; positive ihc; skeletal muscle: 4.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 0.1 nTPM; positive ihc; small intestine: 0.5 nTPM; positive ihc; smooth muscle: 1 nTPM; positive ihc; spinal cord: 2.8 nTPM; absolute ceiling;continuous selectivity; spleen: 0 nTPM; positive ihc; stomach: 0.4 nTPM; positive ihc; thyroid gland: 1.6 nTPM; positive ihc; urinary bladder: 0 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",liver: 6.1 nTPM (limit 2); parathyroid gland: 9.9 nTPM (limit 6); skeletal muscle: 4.2 nTPM (limit 2); spinal cord: 2.8 nTPM (limit 2),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: High (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: High (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: High (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Medium (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Medium (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: High (Approved); oral mucosa / squamous epithelial cells: High (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: High (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in red pulp: High (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 27/80 (33.8%); Prostate Adenocarcinoma (TCGA): 107/480 (22.3%); Kidney Chromophobe (TCGA): 13/64 (20.3%),skin cancer: 12/12 (100.0%); pancreatic cancer: 11/11 (100.0%),31,20,Q9HCR9,https://www.uniprot.org/uniprotkb/Q9HCR9/entry,"Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides cAMP and cGMP (PubMed:10725373, PubMed:10906126, PubMed:11050148, PubMed:16330539). Catalyzes the hydrolysis of both cAMP and cGMP to 5'-AMP and 5'-GMP, respectively (PubMed:10725373, PubMed:10906126, PubMed:11050148)","Isoform 1 is present in prostate, pituitary, heart and liver. It is however not present in testis nor in penis, suggesting that weak inhibition by Tadalafil (Cialis) is not relevant (at protein level). Isoform 2 may be expressed in testis. Isoform 4 is expressed in adrenal cortex","Primary pigmented nodular adrenocortical disease 2: A rare bilateral adrenal defect causing ACTH-independent Cushing syndrome. Macroscopic appearance of the adrenals is characteristic with small pigmented micronodules observed in the cortex. Adrenal glands show overall normal size and weight, and multiple small yellow-to-dark brown nodules surrounded by a cortex with a uniform appearance. Microscopically, there are moderate diffuse cortical hyperplasia with mostly nonpigmented nodules, multiple capsular deficits and massive circumscribed and infiltrating extra-adrenal cortical excrescences with micronodules. Clinical manifestations of Cushing syndrome include facial and truncal obesity, abdominal striae, muscular weakness, osteoporosis, arterial hypertension, diabetes.",,"Cytoplasm, cytosol",10725373|10906126|11050148|16330539,10725373|11121118|15800651|16079899|16767104,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
PDE1A,ENSG00000115252,Unsafe,Protein,False,True,34.3,41.6,78,66,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 10.1 nTPM; positive ihc;absolute ceiling; adrenal gland: 3.9 nTPM; positive ihc;absolute ceiling; amygdala: 13.2 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 3.7 nTPM; absolute ceiling; cerebellum: 37.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 21.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 3.7 nTPM; absolute ceiling; colon: 11.4 nTPM; positive ihc;absolute ceiling; duodenum: 2.7 nTPM; positive ihc;absolute ceiling; heart muscle: 13.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 16.8 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 7.4 nTPM; absolute ceiling; kidney: 40.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 3.3 nTPM; positive ihc;absolute ceiling; lung: 3.5 nTPM; positive ihc;absolute ceiling; lymph node: 1.8 nTPM; positive ihc; midbrain: 7.4 nTPM; absolute ceiling; pancreas: 1.8 nTPM; positive ihc; parathyroid gland: 1.9 nTPM; positive ihc; pituitary gland: 2.6 nTPM; absolute ceiling; rectum: 6 nTPM; positive ihc; skeletal muscle: 2.7 nTPM; positive ihc;absolute ceiling; skin: 2.1 nTPM; positive ihc; small intestine: 5.6 nTPM; positive ihc;absolute ceiling; smooth muscle: 11.2 nTPM; absolute ceiling; spinal cord: 15.5 nTPM; absolute ceiling;continuous selectivity; spleen: 2.5 nTPM; positive ihc; stomach: 5.4 nTPM; positive ihc; thyroid gland: 41.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 9.4 nTPM; positive ihc;absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 10.1 nTPM (limit 10); adrenal gland: 3.9 nTPM (limit 2); amygdala: 13.2 nTPM (limit 2); basal ganglia: 3.7 nTPM (limit 2); cerebellum: 37.1 nTPM (limit 2); cerebral cortex: 21.8 nTPM (limit 2); choroid plexus: 3.7 nTPM (limit 2); colon: 11.4 nTPM (limit 6); duodenum: 2.7 nTPM (limit 2); heart muscle: 13.9 nTPM (limit 2); hippocampal formation: 16.8 nTPM (limit 2); hypothalamus: 7.4 nTPM (limit 2); kidney: 40.2 nTPM (limit 2); liver: 3.3 nTPM (limit 2); lung: 3.5 nTPM (limit 2); midbrain: 7.4 nTPM (limit 2); pituitary gland: 2.6 nTPM (limit 2); skeletal muscle: 2.7 nTPM (limit 2); small intestine: 5.6 nTPM (limit 2); smooth muscle: 11.2 nTPM (limit 4); spinal cord: 15.5 nTPM (limit 2); thyroid gland: 41.6 nTPM (limit 10); urinary bladder: 9.4 nTPM (limit 6),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Medium (Approved); bronchus / respiratory epithelial cells: Low (Approved); caudate / glial cells: Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Low (Approved); duodenum / glandular cells: Low (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / glial cells: Medium (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Low (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Low (Approved); skeletal muscle / myocytes: Low (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Low (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Low (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Thyroid Carcinoma (TCGA): 486/495 (98.2%); Kidney Chromophobe (TCGA): 61/64 (95.3%); Breast Invasive Carcinoma (validation): 42/50 (84.0%),breast cancer: 12/12 (100.0%); colorectal cancer: 11/11 (100.0%),31,20,P54750,https://www.uniprot.org/uniprotkb/P54750/entry,"Calcium/calmodulin-dependent cyclic nucleotide phosphodiesterase with a dual specificity for the second messengers cGMP and cAMP, which are key regulators of many important physiological processes. Has a higher efficiency with cGMP compared to cAMP","Several tissues, including brain, kidney, testes and heart",,,,8557689,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
PDILT,ENSG00000169340,Unsafe,Protein,False,True,18.0,119.4,88,5,Positive somewhere,True,True,False,True,Excluded,Normal,False,,Not assessed,,,positive normal IHC; positive ihc outside permitted; stomach: 119.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",stomach: 119.4 nTPM (limit 6),stomach 2 / glandular cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (TCGA): 4/88 (4.5%); Testicular Germ Cell Tumor (TCGA): 4/133 (3.0%); Bladder Urothelial Carcinoma (TCGA): 4/169 (2.4%),melanoma: 4/12 (33.3%); lung cancer: 2/12 (16.7%),31,20,Q8N807,https://www.uniprot.org/uniprotkb/Q8N807/entry,Probable redox-inactive chaperone involved in spermatogenesis,Testis-specific,,,Endoplasmic reticulum,17507649,15475357|17507649,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
PDP2,ENSG00000172840,Unsafe,Protein,False,True,5.3,9.0,84,77,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 5.8 nTPM; positive ihc;continuous selectivity;reproductive not higher; adrenal gland: 2.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 2.9 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 2.7 nTPM; absolute ceiling;continuous selectivity; bone marrow: 1.4 nTPM; positive ihc; cerebellum: 4.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 4.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 3.9 nTPM; absolute ceiling;continuous selectivity; colon: 3.7 nTPM; positive ihc;continuous selectivity; duodenum: 5.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 3.6 nTPM; positive ihc;continuous selectivity; heart muscle: 1.7 nTPM; positive ihc;continuous selectivity; hippocampal formation: 2.8 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 2.8 nTPM; absolute ceiling;continuous selectivity; kidney: 8.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 8.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 3.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 2.5 nTPM; positive ihc;continuous selectivity; midbrain: 3.2 nTPM; absolute ceiling;continuous selectivity; pancreas: 4.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 5.9 nTPM; positive ihc;continuous selectivity;reproductive not higher; pituitary gland: 2.9 nTPM; absolute ceiling;continuous selectivity; rectum: 3.9 nTPM; positive ihc;continuous selectivity; retina: 4.8 nTPM; absolute ceiling;continuous selectivity; salivary gland: 3.5 nTPM; positive ihc;continuous selectivity; skeletal muscle: 2.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 1.9 nTPM; positive ihc; small intestine: 3.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 2 nTPM; positive ihc;continuous selectivity; spinal cord: 2.3 nTPM; absolute ceiling;continuous selectivity; spleen: 1.9 nTPM; positive ihc; stomach: 2.9 nTPM; positive ihc;continuous selectivity; thymus: 2.5 nTPM; continuous selectivity; thyroid gland: 9 nTPM; positive ihc;continuous selectivity;reproductive not higher; tongue: 3.9 nTPM; continuous selectivity; urinary bladder: 2 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 2.5 nTPM (limit 2); amygdala: 2.9 nTPM (limit 2); basal ganglia: 2.7 nTPM (limit 2); cerebellum: 4.4 nTPM (limit 2); cerebral cortex: 4.9 nTPM (limit 2); choroid plexus: 3.9 nTPM (limit 2); duodenum: 5.3 nTPM (limit 2); hippocampal formation: 2.8 nTPM (limit 2); hypothalamus: 2.8 nTPM (limit 2); kidney: 8.9 nTPM (limit 2); liver: 8.3 nTPM (limit 2); lung: 3.3 nTPM (limit 2); midbrain: 3.2 nTPM (limit 2); pancreas: 4.4 nTPM (limit 2); pituitary gland: 2.9 nTPM (limit 2); retina: 4.8 nTPM (limit 2); skeletal muscle: 2.5 nTPM (limit 2); small intestine: 3.1 nTPM (limit 2); spinal cord: 2.3 nTPM (limit 2),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: High (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: High (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Medium (Approved); lung / macrophages: Low (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: High (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Low (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: High (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Low (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 485/486 (99.8%),ovarian cancer: 12/12 (100.0%); cervical cancer: 11/11 (100.0%),31,20,Q9P2J9,https://www.uniprot.org/uniprotkb/Q9P2J9/entry,"Mitochondrial enzyme that catalyzes the dephosphorylation and concomitant reactivation of the alpha subunit of the E1 component of the pyruvate dehydrogenase complex (PDC), thereby stimulating the conversion of pyruvate into acetyl-CoA (By similarity). Acts as a crucial regulator of T cell metabolism and function, with a particular focus on T-helper Th17 (By similarity)",,,,Mitochondrion,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
PENK,ENSG00000181195,Unsafe,Protein,False,True,125.4,738.6,115,4,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 365.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 20.2 nTPM; absolute ceiling; basal ganglia: 738.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 31.6 nTPM; absolute ceiling; choroid plexus: 2.4 nTPM; absolute ceiling; colon: 22.3 nTPM; absolute ceiling; heart muscle: 24.7 nTPM; absolute ceiling; hippocampal formation: 4.6 nTPM; absolute ceiling; hypothalamus: 82.3 nTPM; absolute ceiling;continuous selectivity; midbrain: 3.5 nTPM; absolute ceiling; pituitary gland: 16.6 nTPM; absolute ceiling; small intestine: 4.1 nTPM; absolute ceiling; spinal cord: 25.5 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 365.1 nTPM (limit 2); amygdala: 20.2 nTPM (limit 2); basal ganglia: 738.6 nTPM (limit 2); cerebellum: 31.6 nTPM (limit 12); choroid plexus: 2.4 nTPM (limit 2); colon: 22.3 nTPM (limit 6); heart muscle: 24.7 nTPM (limit 12); hippocampal formation: 4.6 nTPM (limit 2); hypothalamus: 82.3 nTPM (limit 2); midbrain: 3.5 nTPM (limit 2); pituitary gland: 16.6 nTPM (limit 2); small intestine: 4.1 nTPM (limit 2); spinal cord: 25.5 nTPM (limit 2),adrenal gland / glandular cells: Medium (Enhanced); adrenal gland / medullary cells: High (Enhanced); caudate / neuronal cells: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Squamous Cell Carcinoma (TCGA): 130/489 (26.6%); Breast Invasive Carcinoma (validation): 13/50 (26.0%); Glioblastoma Multiforme (TCGA): 36/141 (25.5%),breast cancer: 0/11 (0.0%); cervical cancer: 0/11 (0.0%),31,20,P01210,https://www.uniprot.org/uniprotkb/P01210/entry,"Neuropeptide that competes with and mimic the effects of opiate drugs. They play a role in a number of physiologic functions, including pain perception and responses to stress Met-enkephalin-Arg-Phe neuropeptide acts as a strong ligand of Mu-type opioid receptor OPRM1. Met-enkephalin-Arg-Phe-binding to OPRM1 in the nucleus accumbens of the brain increases activation of OPRM1, leading to long-term synaptic depression of glutamate release Increases glutamate release in the striatum and decreases GABA concentration in the striatum Neuropeptide that mediates stress-induced opioid analgesia (By similarity). Also possesses non-opioid action by acting as a ligand for MRGPRX1 receptor to induce itch in a histamine-independent manner (PubMed:11850634) Neuropeptide that induces itch in a histamine-independent manner as well as nociceptive sensations (PubMed:11850634, PubMed:28223516). Acts as a ligand for MRGPRX1 receptor in sensory neurons of dorsal root ganglion: MRGPRX1-binding in the peripheral nervous system elicits itch and scratching, while MRGPRX1-binding in the central nervous system dampens chronic pain (PubMed:11850634, PubMed:21593341, PubMed:28223516, PubMed:36302898, PubMed:37591889, PubMed:39725036) Increases glutamate release in the striatum",,,,"Cytoplasmic vesicle, secretory vesicle, chromaffin granule lumen Secreted",11850634|21593341|28223516|36302898|37591889|39725036|7057924,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
PEX13,ENSG00000162928,Unsafe,Protein,False,True,14.5,24.3,105,86,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 9.2 nTPM; positive ihc;continuous selectivity; adrenal gland: 7.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 7.3 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 7 nTPM; absolute ceiling;continuous selectivity; bone marrow: 7.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 6 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 6.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 7.5 nTPM; absolute ceiling;continuous selectivity; colon: 9.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 9.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 9.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 11.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 6.6 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 7 nTPM; absolute ceiling;continuous selectivity; kidney: 13.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 24.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 9 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 6.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 6.9 nTPM; absolute ceiling;continuous selectivity; pancreas: 11.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 9.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 7.2 nTPM; absolute ceiling;continuous selectivity; rectum: 10.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 8.5 nTPM; absolute ceiling;continuous selectivity; salivary gland: 8.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 14.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 7.6 nTPM; positive ihc;continuous selectivity; small intestine: 9.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 7.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 7.7 nTPM; absolute ceiling;continuous selectivity; spleen: 6.5 nTPM; positive ihc;continuous selectivity; stomach: 9.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 7.2 nTPM; continuous selectivity; thyroid gland: 13.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 13.1 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 13.3 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 7.8 nTPM (limit 2); amygdala: 7.3 nTPM (limit 2); basal ganglia: 7 nTPM (limit 2); bone marrow: 7.3 nTPM (limit 2); cerebellum: 6 nTPM (limit 2); cerebral cortex: 6.6 nTPM (limit 2); choroid plexus: 7.5 nTPM (limit 2); colon: 9.9 nTPM (limit 6); duodenum: 9.9 nTPM (limit 2); esophagus: 9.9 nTPM (limit 6); heart muscle: 11.5 nTPM (limit 2); hippocampal formation: 6.6 nTPM (limit 2); hypothalamus: 7 nTPM (limit 2); kidney: 13.1 nTPM (limit 2); liver: 24.3 nTPM (limit 2); lung: 9 nTPM (limit 2); lymph node: 6.6 nTPM (limit 6); midbrain: 6.9 nTPM (limit 2); pancreas: 11.4 nTPM (limit 2); parathyroid gland: 9.2 nTPM (limit 6); pituitary gland: 7.2 nTPM (limit 2); rectum: 10.3 nTPM (limit 6); retina: 8.5 nTPM (limit 2); salivary gland: 8.4 nTPM (limit 6); skeletal muscle: 14.1 nTPM (limit 2); small intestine: 9.5 nTPM (limit 2); smooth muscle: 7.8 nTPM (limit 2); spinal cord: 7.7 nTPM (limit 2); stomach: 9.8 nTPM (limit 6); thyroid gland: 13.3 nTPM (limit 10); tongue: 13.1 nTPM (limit 6); urinary bladder: 13.3 nTPM (limit 6),adipose tissue / adipocytes: Low (Enhanced); adrenal gland / glandular cells: High (Enhanced); bone marrow / hematopoietic cells: Low (Enhanced); bronchus / respiratory epithelial cells: Medium (Enhanced); caudate / glial cells: Low (Enhanced); caudate / neuronal cells: High (Enhanced); cerebellum / GLUC cells - cytoplasm/membrane: High (Enhanced); cerebellum / granular cells - cytoplasm/membrane: Medium (Enhanced); cerebellum / molecular layer - neuropil: Low (Enhanced); cerebellum / molecular layer cells - cytoplasm/membrane: High (Enhanced); cerebellum / processes in granular layer: High (Enhanced); cerebellum / processes in molecular layer: High (Enhanced); cerebellum / Purkinje cells - cytoplasm/membrane: High (Enhanced); cerebellum / synaptic glomeruli - core: Medium (Enhanced); cerebral cortex / endothelial cells: Low (Enhanced); cerebral cortex / glial cells: Medium (Enhanced); cerebral cortex / neuronal cells: High (Enhanced); cerebral cortex / neuropil: Low (Enhanced); colon / endothelial cells: Low (Enhanced); colon / glandular cells: High (Enhanced); colon / peripheral nerve/ganglion: Medium (Enhanced); duodenum / glandular cells: High (Enhanced); esophagus / squamous epithelial cells: Medium (Enhanced); heart muscle / cardiomyocytes: Medium (Enhanced); hippocampus / glial cells: Medium (Enhanced); hippocampus / neuronal cells: Medium (Enhanced); kidney / cells in tubules: High (Enhanced); liver / cholangiocytes: Low (Enhanced); liver / hepatocytes: Medium (Enhanced); lung / macrophages: High (Enhanced); lymph node / germinal center cells: Medium (Enhanced); lymph node / non-germinal center cells: Medium (Enhanced); nasopharynx / respiratory epithelial cells: High (Enhanced); oral mucosa / squamous epithelial cells: Medium (Enhanced); pancreas / exocrine glandular cells: Medium (Enhanced); pancreas / pancreatic endocrine cells: Medium (Enhanced); parathyroid gland / glandular cells: High (Enhanced); rectum / glandular cells: Medium (Enhanced); salivary gland / glandular cells: High (Enhanced); skeletal muscle / myocytes: Medium (Enhanced); skin 1 / fibroblasts: Medium (Enhanced); skin 1 / keratinocytes: Medium (Enhanced); skin 1 / Langerhans: Medium (Enhanced); skin 2 / epidermal cells: Medium (Enhanced); small intestine / glandular cells: Medium (Enhanced); smooth muscle / smooth muscle cells: Low (Enhanced); spleen / cells in white pulp: Low (Enhanced); stomach 1 / glandular cells: Medium (Enhanced); stomach 2 / glandular cells: Medium (Enhanced); thyroid gland / glandular cells: High (Enhanced); urinary bladder / urothelial cells: High (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Adenocarcinoma (TCGA): 497/497 (100.0%); Lung Squamous Cell Carcinoma (TCGA): 489/489 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%),cervical cancer: 12/12 (100.0%); lung cancer: 12/12 (100.0%),31,20,Q92968,https://www.uniprot.org/uniprotkb/Q92968/entry,"Component of the PEX13-PEX14 docking complex, a translocon channel that specifically mediates the import of peroxisomal cargo proteins bound to PEX5 receptor (PubMed:28765278, PubMed:8858165, PubMed:9653144). The PEX13-PEX14 docking complex forms a large import pore which can be opened to a diameter of about 9 nm (By similarity). Mechanistically, PEX5 receptor along with cargo proteins associates with the PEX14 subunit of the PEX13-PEX14 docking complex in the cytosol, leading to the insertion of the receptor into the organelle membrane with the concomitant translocation of the cargo into the peroxisome matrix (PubMed:28765278, PubMed:8858165, PubMed:9653144). Involved in the import of PTS1- and PTS2-type containing proteins (PubMed:8858165, PubMed:9653144)",,"Peroxisome biogenesis disorder complementation group 13: A peroxisomal disorder arising from a failure of protein import into the peroxisomal membrane or matrix. The peroxisome biogenesis disorders (PBD group) are genetically heterogeneous with at least 14 distinct genetic groups as concluded from complementation studies. Include disorders are: Zellweger syndrome (ZWS), neonatal adrenoleukodystrophy (NALD), infantile Refsum disease (IRD), and classical rhizomelic chondrodysplasia punctata (RCDP). ZWS, NALD and IRD are distinct from RCDP and constitute a clinical continuum of overlapping phenotypes known as the Zellweger spectrum (PBD-ZSS). Peroxisome biogenesis disorder 11A: A fatal peroxisome biogenesis disorder belonging to the Zellweger disease spectrum and clinically characterized by severe neurologic dysfunction with profound psychomotor retardation, severe hypotonia and neonatal seizures, craniofacial abnormalities, liver dysfunction, and biochemically by the absence of peroxisomes. Additional features include cardiovascular and skeletal defects, renal cysts, ocular abnormalities, and hearing impairment. Most severely affected individuals with the classic form of the disease (classic Zellweger syndrome) die within the first year of life. Peroxisome biogenesis disorder 11B: A peroxisome biogenesis disorder that includes neonatal adrenoleukodystrophy (NALD) and infantile Refsum disease (IRD), two milder manifestations of the Zellweger disease spectrum. The clinical course of patients with the NALD and IRD presentation is variable and may include developmental delay, hypotonia, liver dysfunction, sensorineural hearing loss, retinal dystrophy and vision impairment. Children with the NALD presentation may reach their teens, while patients with the IRD presentation may reach adulthood. The clinical conditions are often slowly progressive in particular with respect to loss of hearing and vision. The biochemical abnormalities include accumulation of phytanic acid, very long chain fatty acids (VLCFA), di- and trihydroxycholestanoic acid and pipecolic acid.","It is uncertain whether Met-1 or Met-40 is the initiator There are conflicting reports regarding PEX13 topology, with one report placing the C-terminus in the cytosol",Peroxisome membrane,28765278|8858165|9653144,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
PEX5L,ENSG00000114757,Unsafe,Protein,False,True,4.7,48.8,85,31,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 0.3 nTPM; positive ihc; amygdala: 14.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 12.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 2.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 39.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 1.3 nTPM; continuous selectivity; colon: 0 nTPM; positive ihc; duodenum: 0.1 nTPM; positive ihc; heart muscle: 0.2 nTPM; positive ihc; hippocampal formation: 24.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 11.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 0.1 nTPM; positive ihc; lung: 0.1 nTPM; positive ihc; midbrain: 26.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 9.9 nTPM; continuous selectivity;reproductive not higher; parathyroid gland: 29.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 5.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 0 nTPM; positive ihc; retina: 14.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 0.2 nTPM; positive ihc; small intestine: 0.1 nTPM; positive ihc; spinal cord: 48.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; stomach: 0.1 nTPM; positive ihc; thymus: 2.6 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 14.3 nTPM (limit 2); basal ganglia: 12.5 nTPM (limit 2); cerebellum: 2.1 nTPM (limit 2); cerebral cortex: 39.4 nTPM (limit 2); hippocampal formation: 24.7 nTPM (limit 2); hypothalamus: 11.8 nTPM (limit 2); midbrain: 26.7 nTPM (limit 2); parathyroid gland: 29.2 nTPM (limit 6); pituitary gland: 5.1 nTPM (limit 2); retina: 14.8 nTPM (limit 2); spinal cord: 48.8 nTPM (limit 2),adrenal gland / glandular cells: Low (Enhanced); bronchus / respiratory epithelial cells: Medium (Enhanced); caudate / glial cells: High (Enhanced); caudate / neuronal cells: Low (Enhanced); cerebellum / cells in granular layer: Medium (Enhanced); cerebral cortex / glial cells: High (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); cerebral cortex / neuropil: Medium (Enhanced); colon / glandular cells: Low (Enhanced); duodenum / glandular cells: Low (Enhanced); heart muscle / cardiomyocytes: Low (Enhanced); hippocampus / glial cells: High (Enhanced); hippocampus / neuronal cells: Medium (Enhanced); kidney / cells in tubules: Low (Enhanced); lung / macrophages: Medium (Enhanced); nasopharynx / respiratory epithelial cells: Low (Enhanced); parathyroid gland / glandular cells: High (Enhanced); pituitary gland / cells in anterior : Medium (Enhanced); rectum / glandular cells: Low (Enhanced); salivary gland / glandular cells: Low (Enhanced); small intestine / glandular cells: Low (Enhanced); stomach 1 / glandular cells: Low (Enhanced); stomach 2 / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 32/58 (55.2%); Glioblastoma Multiforme (TCGA): 15/141 (10.6%); Skin Cuteneous Melanoma (TCGA): 7/99 (7.1%),colorectal cancer: 4/12 (33.3%); glioma: 3/11 (27.3%),31,20,Q8IYB4,https://www.uniprot.org/uniprotkb/Q8IYB4/entry,"Accessory subunit of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, regulating their cell-surface expression and cyclic nucleotide dependence","Mainly expressed in brain. Also expressed in pancreas, testis and pituitary",,,Cytoplasm Membrane,,11463335,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
PFN4,ENSG00000176732,Unsafe,RNA,False,True,78.8,78.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,retina: 2.9 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 2.9 nTPM (limit 2); retina: 2.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 37/58 (63.8%); Breast Invasive Carcinoma (validation): 13/50 (26.0%); Glioblastoma Multiforme (TCGA): 8/141 (5.7%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NHR9,https://www.uniprot.org/uniprotkb/Q8NHR9/entry,"Involved in male fertility. Required for manchette development and acrosome biogenesis during spermiogenesis (By similarity). Binds in vitro to phospholipids, including phosphatidylinositol 3-phosphate (PtdIns(3)P), phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2), phosphatidylinositol 4-phosphate (PtdIns(4)P) and phosphatidic acid (PA) (PubMed:19419568). Contrary to other profilin family members, does not bind to actin in vitro (PubMed:19419568)","Expressed in testis, in germ cells in seminiferous tubules (at protein level) (PubMed:15591451, PubMed:19419568). Prominently expressed in pachytene/diplotene stage spematocytes (PubMed:33438010)",,,Cytoplasm,19419568,15591451|19419568|33438010,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
PGAM5,ENSG00000247077,Unsafe,Protein,False,True,16.1,32.0,91,80,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 10.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 17.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 11.6 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 11.4 nTPM; absolute ceiling;continuous selectivity; bone marrow: 16.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 14.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 17.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 8.7 nTPM; absolute ceiling;continuous selectivity; colon: 16 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 14.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 23.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 19.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 14.4 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 11.9 nTPM; absolute ceiling;continuous selectivity; kidney: 13.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 28.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 9 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 20.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 9.7 nTPM; absolute ceiling;continuous selectivity; pancreas: 25.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 9.6 nTPM; absolute ceiling;continuous selectivity; rectum: 11.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 5.8 nTPM; absolute ceiling;continuous selectivity; salivary gland: 15.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 32 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 17.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 12.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 10.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 7.7 nTPM; absolute ceiling;continuous selectivity; spleen: 12.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 13.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 14.1 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 11.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 18.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 15 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 10.5 nTPM (limit 10); adrenal gland: 17.1 nTPM (limit 2); amygdala: 11.6 nTPM (limit 2); basal ganglia: 11.4 nTPM (limit 2); bone marrow: 16.6 nTPM (limit 2); cerebellum: 14.4 nTPM (limit 2); cerebral cortex: 17.7 nTPM (limit 2); choroid plexus: 8.7 nTPM (limit 2); colon: 16 nTPM (limit 6); duodenum: 14.8 nTPM (limit 2); esophagus: 23.1 nTPM (limit 6); heart muscle: 19.4 nTPM (limit 2); hippocampal formation: 14.4 nTPM (limit 2); hypothalamus: 11.9 nTPM (limit 2); kidney: 13.8 nTPM (limit 2); liver: 28.2 nTPM (limit 2); lung: 9 nTPM (limit 2); lymph node: 20.9 nTPM (limit 6); midbrain: 9.7 nTPM (limit 2); pancreas: 25.1 nTPM (limit 2); pituitary gland: 9.6 nTPM (limit 2); rectum: 11.2 nTPM (limit 6); retina: 5.8 nTPM (limit 2); salivary gland: 15.4 nTPM (limit 6); skeletal muscle: 32 nTPM (limit 12); skin: 17.5 nTPM (limit 10); small intestine: 12.8 nTPM (limit 2); smooth muscle: 10.6 nTPM (limit 2); spinal cord: 7.7 nTPM (limit 2); spleen: 12.8 nTPM (limit 10); stomach: 13.3 nTPM (limit 6); thymus: 14.1 nTPM (limit 10); thyroid gland: 11.2 nTPM (limit 10); tongue: 18.1 nTPM (limit 6); urinary bladder: 15 nTPM (limit 6),adipose tissue / adipocytes: Low (Enhanced); adrenal gland / glandular cells: High (Enhanced); bone marrow / hematopoietic cells: Medium (Enhanced); bronchus / respiratory epithelial cells: Medium (Enhanced); caudate / glial cells: Medium (Enhanced); caudate / neuronal cells: Medium (Enhanced); cerebellum / cells in granular layer: Medium (Enhanced); cerebellum / cells in molecular layer: Low (Enhanced); cerebral cortex / endothelial cells: Medium (Enhanced); cerebral cortex / glial cells: Medium (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); cerebral cortex / neuropil: Low (Enhanced); colon / endothelial cells: Medium (Enhanced); colon / glandular cells: Medium (Enhanced); colon / peripheral nerve/ganglion: Medium (Enhanced); duodenum / glandular cells: Medium (Enhanced); esophagus / squamous epithelial cells: High (Enhanced); heart muscle / cardiomyocytes: Low (Enhanced); hippocampus / glial cells: Low (Enhanced); hippocampus / neuronal cells: Medium (Enhanced); kidney / cells in glomeruli: Low (Enhanced); kidney / cells in tubules: Medium (Enhanced); liver / hepatocytes: Medium (Enhanced); lung / macrophages: Medium (Enhanced); lymph node / germinal center cells: Medium (Enhanced); lymph node / non-germinal center cells: Medium (Enhanced); nasopharynx / respiratory epithelial cells: Medium (Enhanced); oral mucosa / squamous epithelial cells: Medium (Enhanced); pancreas / exocrine glandular cells: Medium (Enhanced); pancreas / pancreatic endocrine cells: Low (Enhanced); rectum / glandular cells: Medium (Enhanced); salivary gland / glandular cells: Medium (Enhanced); skin 1 / fibroblasts: Medium (Enhanced); skin 1 / keratinocytes: Medium (Enhanced); skin 1 / Langerhans: Medium (Enhanced); skin 2 / epidermal cells: Medium (Enhanced); small intestine / glandular cells: Medium (Enhanced); smooth muscle / smooth muscle cells: Low (Enhanced); spleen / cells in red pulp: Medium (Enhanced); spleen / cells in white pulp: High (Enhanced); stomach 1 / glandular cells: Low (Enhanced); stomach 2 / glandular cells: Medium (Enhanced); thyroid gland / glandular cells: Medium (Enhanced); urinary bladder / urothelial cells: Medium (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%); Head and Neck Squamous Cell Carcinoma (TCGA): 492/492 (100.0%),breast cancer: 12/12 (100.0%); colorectal cancer: 12/12 (100.0%),31,20,Q96HS1,https://www.uniprot.org/uniprotkb/Q96HS1/entry,"Mitochondrial serine/threonine phosphatase that dephosphorylates various substrates and thus plays a role in different biological processes including cellular senescence or mitophagy (PubMed:24746696, PubMed:32439975). Modulates cellular senescence by regulating mitochondrial dynamics. Mechanistically, participates in mitochondrial fission through dephosphorylating DNM1L/DRP1 (PubMed:32439975). Additionally, dephosphorylates MFN2 in a stress-sensitive manner and consequently protects it from ubiquitination and degradation to promote mitochondrial network formation (PubMed:37498743). Regulates mitophagy independent of PARKIN by interacting with and dephosphorylating FUNDC1, which interacts with LC3 (PubMed:24746696). Regulates anti-oxidative response by forming a tertiary complex with KEAP1 and NRF2 (PubMed:18387606). Regulates necroptosis by acting as a RIPK3 target and recruiting the RIPK1-RIPK3-MLKL necrosis 'attack' complex to mitochondria (PubMed:22265414)",,,,Mitochondrion outer membrane Mitochondrion inner membrane,18387606|19590015|22265414|24746696|32439975|37498743,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | Jamin2021_CT,GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
PGBD4,ENSG00000182405,Unsafe,RNA,False,True,1.7,5.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 0.8 nTPM; continuous selectivity; amygdala: 0.8 nTPM; continuous selectivity; basal ganglia: 1 nTPM; continuous selectivity; bone marrow: 2.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 1.1 nTPM; continuous selectivity; cerebral cortex: 2 nTPM; continuous selectivity;reproductive not higher; choroid plexus: 0.8 nTPM; continuous selectivity; colon: 0.9 nTPM; continuous selectivity; duodenum: 1.1 nTPM; continuous selectivity; esophagus: 0.7 nTPM; continuous selectivity; heart muscle: 1.4 nTPM; continuous selectivity; hippocampal formation: 0.9 nTPM; continuous selectivity; hypothalamus: 1.1 nTPM; continuous selectivity; kidney: 1 nTPM; continuous selectivity; liver: 1.3 nTPM; continuous selectivity; lung: 0.7 nTPM; continuous selectivity; lymph node: 2 nTPM; continuous selectivity;reproductive not higher; midbrain: 1 nTPM; continuous selectivity; pancreas: 0.9 nTPM; continuous selectivity; parathyroid gland: 1.5 nTPM; continuous selectivity; pituitary gland: 0.6 nTPM; continuous selectivity; rectum: 1.1 nTPM; continuous selectivity; retina: 2.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 0.7 nTPM; continuous selectivity; skeletal muscle: 5.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 1.5 nTPM; continuous selectivity; small intestine: 1.1 nTPM; continuous selectivity; smooth muscle: 0.6 nTPM; continuous selectivity; spinal cord: 1 nTPM; continuous selectivity; spleen: 1.4 nTPM; continuous selectivity; stomach: 1.4 nTPM; continuous selectivity; thymus: 1.3 nTPM; continuous selectivity; thyroid gland: 1 nTPM; continuous selectivity; tongue: 1.2 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 2.7 nTPM (limit 2); retina: 2.3 nTPM (limit 2); skeletal muscle: 5.1 nTPM (limit 2); bone marrow: 2.7 nTPM (baseline 2); retina: 2.3 nTPM (baseline 2); skeletal muscle: 5.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 43/50 (86.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 15/176 (8.5%),urothelial cancer: 3/10 (30.0%); colorectal cancer: 2/11 (18.2%),31,20,Q96DM1,https://www.uniprot.org/uniprotkb/Q96DM1/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
PHC3,ENSG00000173889,Unsafe,Protein,False,True,11.9,50.3,77,73,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 8.8 nTPM; positive ihc;continuous selectivity; adrenal gland: 7.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 2.8 nTPM; absolute ceiling; basal ganglia: 3.1 nTPM; absolute ceiling;continuous selectivity; bone marrow: 50.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 5.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 5.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 4.9 nTPM; absolute ceiling;continuous selectivity; colon: 10.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 10.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 12 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 7.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 3 nTPM; absolute ceiling; hypothalamus: 2.9 nTPM; absolute ceiling; kidney: 9.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 8.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 9.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 17.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 2.9 nTPM; absolute ceiling; pancreas: 10.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 14.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 5.3 nTPM; absolute ceiling;continuous selectivity; rectum: 10.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 40.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 8.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 8.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 8.3 nTPM; positive ihc;continuous selectivity; small intestine: 12 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 12.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 4 nTPM; absolute ceiling;continuous selectivity; spleen: 13.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; stomach: 11.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 16.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 16.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; tongue: 13.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 11.4 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 7.2 nTPM (limit 2); amygdala: 2.8 nTPM (limit 2); basal ganglia: 3.1 nTPM (limit 2); bone marrow: 50.3 nTPM (limit 2); cerebellum: 5.1 nTPM (limit 2); cerebral cortex: 5.8 nTPM (limit 2); choroid plexus: 4.9 nTPM (limit 2); colon: 10.1 nTPM (limit 6); duodenum: 10.9 nTPM (limit 2); esophagus: 12 nTPM (limit 6); heart muscle: 7.8 nTPM (limit 2); hippocampal formation: 3 nTPM (limit 2); hypothalamus: 2.9 nTPM (limit 2); kidney: 9.4 nTPM (limit 2); liver: 8.4 nTPM (limit 2); lung: 9.4 nTPM (limit 2); lymph node: 17.6 nTPM (limit 6); midbrain: 2.9 nTPM (limit 2); pancreas: 10.9 nTPM (limit 2); parathyroid gland: 14.6 nTPM (limit 6); pituitary gland: 5.3 nTPM (limit 2); rectum: 10.9 nTPM (limit 6); retina: 40.7 nTPM (limit 2); salivary gland: 8.6 nTPM (limit 6); skeletal muscle: 8.4 nTPM (limit 2); small intestine: 12 nTPM (limit 2); smooth muscle: 12.9 nTPM (limit 2); spinal cord: 4 nTPM (limit 2); spleen: 13.6 nTPM (limit 10); stomach: 11.5 nTPM (limit 6); thymus: 16.3 nTPM (limit 10); thyroid gland: 16.1 nTPM (limit 10); tongue: 13.4 nTPM (limit 6); urinary bladder: 11.4 nTPM (limit 6),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Kidney Renal Clear Cell Carcinoma (validation): 100/100 (100.0%),breast cancer: 12/12 (100.0%); cervical cancer: 12/12 (100.0%),31,20,Q8NDX5,https://www.uniprot.org/uniprotkb/Q8NDX5/entry,"Component of a Polycomb group (PcG) multiprotein PRC1-like complex, a complex class required to maintain the transcriptionally repressive state of many genes, including Hox genes, throughout development. PcG PRC1 complex acts via chromatin remodeling and modification of histones; it mediates monoubiquitination of histone H2A 'Lys-119', rendering chromatin heritably changed in its expressibility",,,,Nucleus,12167701,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
PHF7,ENSG00000010318,Unsafe,RNA,False,True,1181.3,1181.3,85,1,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,choroid plexus: 2.7 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 2.7 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 46/50 (92.0%); Glioblastoma Multiforme (validation): 49/58 (84.5%); Testicular Germ Cell Tumor (TCGA): 68/133 (51.1%),colorectal cancer: 7/12 (58.3%); endometrial cancer: 3/11 (27.3%),31,20,Q9BWX1,https://www.uniprot.org/uniprotkb/Q9BWX1/entry,"E3 ubiquitin-protein ligase which ubiquitinates histone H3 at 'Lys-14' (By similarity). Required for male fertility, via inhibition of SPOP-mediated BRDT degradation when in the presence of acetylated histone H4 in early condensing spermatids (By similarity). Stabilization of BRDT allows it to facilitate histone removal in early condensing spermatids and promote the progression of histone-to-protamine exchange (By similarity). Promotes the expression of steroidogenesis proteins in the testes, and as a result plays a role in maintaining testosterone levels and repressing osteoclastogenesis (By similarity). Promotes transcription of cardiac enhancer genes by facilitating binding of cardiac transcription factors such as MEF2C and GATA4 to target gene promoters (By similarity). Ubiquitinates histone H4 (PubMed:32726616). Ubiquitinates histone H2A and H3 as part of the nucleosome core particle (By similarity)","Highly expressed in Sertoli cells, but not in germ cells in adult testis. Expression in embryonic testis is 30-times lower. Highly expressed in colon, spleen, white blood cells, pancreas, lung, liver, placenta and brain. Detected at lower levels in thymus, small intestine, ovary and kidney",,,Nucleus,32726616,11829468,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
PHOSPHO1,ENSG00000173868,Unsafe,RNA,False,True,100.1,100.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 18.7 nTPM; absolute ceiling; cerebral cortex: 3.8 nTPM; absolute ceiling; duodenum: 2.8 nTPM; absolute ceiling; lung: 2.3 nTPM; absolute ceiling; midbrain: 2.5 nTPM; absolute ceiling; skeletal muscle: 3.3 nTPM; absolute ceiling; small intestine: 2.9 nTPM; absolute ceiling; spleen: 13.8 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 18.7 nTPM (limit 2); cerebral cortex: 3.8 nTPM (limit 2); duodenum: 2.8 nTPM (limit 2); lung: 2.3 nTPM (limit 2); midbrain: 2.5 nTPM (limit 2); skeletal muscle: 3.3 nTPM (limit 2); small intestine: 2.9 nTPM (limit 2); spleen: 13.8 nTPM (limit 10); bone marrow: 18.7 nTPM (baseline 2); cerebral cortex: 3.8 nTPM (baseline 2); duodenum: 2.8 nTPM (baseline 2); lung: 2.3 nTPM (baseline 2); midbrain: 2.5 nTPM (baseline 2); skeletal muscle: 3.3 nTPM (baseline 2); small intestine: 2.9 nTPM (baseline 2); spleen: 13.8 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 110/207 (53.1%); Colon Adenocarcinoma (validation): 185/486 (38.1%); Ovary Serous Cystadenocarcinoma (TCGA): 86/349 (24.6%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8TCT1,https://www.uniprot.org/uniprotkb/Q8TCT1/entry,"Phosphatase that has a high activity toward phosphoethanolamine (PEA) and phosphocholine (PCho) (PubMed:15175005). Involved in the generation of inorganic phosphate for bone mineralization (By similarity). Acts in a non-redundant manner with PHOSPHO1 in skeletal mineralization: while PHOSPHO1 mediates the initiation of hydroxyapatite crystallization in the matrix vesicles (MVs), ALPL/TNAP catalyzes the spread of hydroxyapatite crystallization in the extracellular matrix (By similarity)","Expressed at sites of mineralization in bone and cartilage. Highly expressed in osteoblast cell line SaOS-2 which produces a mineralized matrix, but not in MG-63 cell line, which do not mineralize",,,Extracellular vesicle,15175005,15050893,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
PHTF1,ENSG00000116793,Unsafe,RNA,False,True,29.5,29.5,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 7.8 nTPM; absolute ceiling;continuous selectivity; amygdala: 5.4 nTPM; absolute ceiling; basal ganglia: 5.9 nTPM; absolute ceiling; bone marrow: 18.5 nTPM; absolute ceiling;continuous selectivity; cerebellum: 13.9 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 7.4 nTPM; absolute ceiling; choroid plexus: 28.2 nTPM; absolute ceiling;continuous selectivity; duodenum: 3.4 nTPM; absolute ceiling; heart muscle: 5.4 nTPM; absolute ceiling; hippocampal formation: 6.1 nTPM; absolute ceiling; hypothalamus: 8.6 nTPM; absolute ceiling;continuous selectivity; kidney: 8.4 nTPM; absolute ceiling;continuous selectivity; liver: 7.9 nTPM; absolute ceiling;continuous selectivity; lung: 7.9 nTPM; absolute ceiling;continuous selectivity; midbrain: 5.8 nTPM; absolute ceiling; pancreas: 6.6 nTPM; absolute ceiling; parathyroid gland: 11.1 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 11.7 nTPM; absolute ceiling;continuous selectivity; retina: 13.7 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 4.4 nTPM; absolute ceiling; small intestine: 3.9 nTPM; absolute ceiling; smooth muscle: 6.4 nTPM; absolute ceiling; spinal cord: 3.8 nTPM; absolute ceiling; stomach: 6.5 nTPM; absolute ceiling; urinary bladder: 6.1 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 7.8 nTPM (limit 2); amygdala: 5.4 nTPM (limit 2); basal ganglia: 5.9 nTPM (limit 2); bone marrow: 18.5 nTPM (limit 2); cerebellum: 13.9 nTPM (limit 2); cerebral cortex: 7.4 nTPM (limit 2); choroid plexus: 28.2 nTPM (limit 2); duodenum: 3.4 nTPM (limit 2); heart muscle: 5.4 nTPM (limit 2); hippocampal formation: 6.1 nTPM (limit 2); hypothalamus: 8.6 nTPM (limit 2); kidney: 8.4 nTPM (limit 2); liver: 7.9 nTPM (limit 2); lung: 7.9 nTPM (limit 2); midbrain: 5.8 nTPM (limit 2); pancreas: 6.6 nTPM (limit 2); parathyroid gland: 11.1 nTPM (limit 6); pituitary gland: 11.7 nTPM (limit 2); retina: 13.7 nTPM (limit 2); skeletal muscle: 4.4 nTPM (limit 2); small intestine: 3.9 nTPM (limit 2); smooth muscle: 6.4 nTPM (limit 2); spinal cord: 3.8 nTPM (limit 2); stomach: 6.5 nTPM (limit 6); urinary bladder: 6.1 nTPM (limit 6); adrenal gland: 7.8 nTPM (baseline 2); amygdala: 5.4 nTPM (baseline 2); basal ganglia: 5.9 nTPM (baseline 2); bone marrow: 18.5 nTPM (baseline 2); cerebellum: 13.9 nTPM (baseline 2); cerebral cortex: 7.4 nTPM (baseline 2); choroid plexus: 28.2 nTPM (baseline 2); duodenum: 3.4 nTPM (baseline 2); heart muscle: 5.4 nTPM (baseline 2); hippocampal formation: 6.1 nTPM (baseline 2); hypothalamus: 8.6 nTPM (baseline 2); kidney: 8.4 nTPM (baseline 2); liver: 7.9 nTPM (baseline 2); lung: 7.9 nTPM (baseline 2); midbrain: 5.8 nTPM (baseline 2); pancreas: 6.6 nTPM (baseline 2); parathyroid gland: 11.1 nTPM (baseline 6); pituitary gland: 11.7 nTPM (baseline 2); retina: 13.7 nTPM (baseline 2); skeletal muscle: 4.4 nTPM (baseline 2); small intestine: 3.9 nTPM (baseline 2); smooth muscle: 6.4 nTPM (baseline 2); spinal cord: 3.8 nTPM (baseline 2); stomach: 6.5 nTPM (baseline 6); urinary bladder: 6.1 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 80/80 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Glioblastoma Multiforme (TCGA): 140/141 (99.3%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9UMS5,https://www.uniprot.org/uniprotkb/Q9UMS5/entry,,Widely expressed with highest levels in testis,,"The PHTF domain was initially defined as an atypical homeodomain, suggesting that this protein could act as a transcription regulator (PubMed:10395808). However, the protein is not found in the nucleus and mainly localizes in the endoplasmic reticulum membrane, suggesting that it does not act as a transcription factor (By similarity)","Endoplasmic reticulum membrane Golgi apparatus, cis-Golgi network membrane",,10729229,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
PIAS2,ENSG00000078043,Unsafe,Protein,False,True,65.3,65.3,91,36,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 5.2 nTPM; positive ihc;absolute ceiling; amygdala: 6.2 nTPM; absolute ceiling; basal ganglia: 6.9 nTPM; absolute ceiling; cerebellum: 13.8 nTPM; absolute ceiling; cerebral cortex: 8 nTPM; positive ihc;absolute ceiling; choroid plexus: 5 nTPM; absolute ceiling; esophagus: 3.6 nTPM; positive ihc; heart muscle: 6.6 nTPM; positive ihc;absolute ceiling; hippocampal formation: 6.1 nTPM; absolute ceiling; hypothalamus: 6.6 nTPM; absolute ceiling; kidney: 6.2 nTPM; positive ihc;absolute ceiling; lung: 4.2 nTPM; positive ihc;absolute ceiling; lymph node: 6 nTPM; positive ihc; midbrain: 6 nTPM; absolute ceiling; pancreas: 4.1 nTPM; positive ihc;absolute ceiling; parathyroid gland: 11.4 nTPM; absolute ceiling; pituitary gland: 5.5 nTPM; absolute ceiling; retina: 10.5 nTPM; absolute ceiling; salivary gland: 5.3 nTPM; positive ihc; skeletal muscle: 15.6 nTPM; positive ihc;absolute ceiling; skin: 7.4 nTPM; positive ihc; smooth muscle: 4.5 nTPM; positive ihc;absolute ceiling; spinal cord: 5 nTPM; absolute ceiling; thyroid gland: 8 nTPM; positive ihc; tongue: 9.8 nTPM; absolute ceiling; urinary bladder: 4 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 5.2 nTPM (limit 2); amygdala: 6.2 nTPM (limit 2); basal ganglia: 6.9 nTPM (limit 2); cerebellum: 13.8 nTPM (limit 12); cerebral cortex: 8 nTPM (limit 2); choroid plexus: 5 nTPM (limit 2); heart muscle: 6.6 nTPM (limit 2); hippocampal formation: 6.1 nTPM (limit 2); hypothalamus: 6.6 nTPM (limit 2); kidney: 6.2 nTPM (limit 2); lung: 4.2 nTPM (limit 2); midbrain: 6 nTPM (limit 2); pancreas: 4.1 nTPM (limit 2); parathyroid gland: 11.4 nTPM (limit 6); pituitary gland: 5.5 nTPM (limit 2); retina: 10.5 nTPM (limit 2); skeletal muscle: 15.6 nTPM (limit 2); smooth muscle: 4.5 nTPM (limit 2); spinal cord: 5 nTPM (limit 2); tongue: 9.8 nTPM (limit 6),adrenal gland / glandular cells: Medium (Enhanced); caudate / neuronal cells: Medium (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); esophagus / squamous epithelial cells: Low (Enhanced); heart muscle / cardiomyocytes: Low (Enhanced); hippocampus / neuronal cells: Medium (Enhanced); kidney / cells in glomeruli: Medium (Enhanced); lung / alveolar cells type I: Low (Enhanced); lung / alveolar cells type II: Low (Enhanced); lung / macrophages: Medium (Enhanced); lymph node / non-germinal center cells: Low (Enhanced); pancreas / pancreatic endocrine cells: Low (Enhanced); salivary gland / glandular cells: Low (Enhanced); skeletal muscle / myocytes: Medium (Enhanced); skin 1 / fibroblasts: Low (Enhanced); skin 1 / keratinocytes: Low (Enhanced); skin 1 / Langerhans: Low (Enhanced); skin 2 / epidermal cells: Medium (Enhanced); smooth muscle / smooth muscle cells: Low (Enhanced); thyroid gland / glandular cells: Low (Enhanced); urinary bladder / urothelial cells: Low (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Rectum Adenocarcinoma (validation): 206/207 (99.5%); Colon Adenocarcinoma (validation): 479/486 (98.6%),glioma: 10/10 (100.0%); melanoma: 8/12 (66.7%),31,20,O75928,https://www.uniprot.org/uniprotkb/O75928/entry,"Functions as an E3-type small ubiquitin-like modifier (SUMO) ligase, stabilizing the interaction between UBE2I and the substrate, and as a SUMO-tethering factor. Plays a crucial role as a transcriptional coregulator in various cellular pathways, including the STAT pathway, the p53 pathway and the steroid hormone signaling pathway. The effects of this transcriptional coregulation, transactivation or silencing may vary depending upon the biological context and the PIAS2 isoform studied. However, it seems to be mostly involved in gene silencing. Binds to sumoylated ELK1 and enhances its transcriptional activity by preventing recruitment of HDAC2 by ELK1, thus reversing SUMO-mediated repression of ELK1 transactivation activity. Isoform PIAS2-beta, but not isoform PIAS2-alpha, promotes MDM2 sumoylation. Isoform PIAS2-alpha promotes PARK7 sumoylation. Isoform PIAS2-beta promotes NCOA2 sumoylation more efficiently than isoform PIAS2-alpha. Isoform PIAS2-alpha sumoylates PML at'Lys-65' and 'Lys-160'","Mainly expressed in testis. Isoform 3 is expressed predominantly in adult testis, weakly in pancreas, embryonic testis and sperm, and at very low levels in other organs",,,"Nucleus speckle Nucleus, PML body Nucleus",15920481|15976810|22406621,11439351|15301740|9920921,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
PIH1D2,ENSG00000150773,Unsafe,RNA,False,True,64.5,64.5,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,basal ganglia: 2.1 nTPM; absolute ceiling; choroid plexus: 9.3 nTPM; absolute ceiling; hypothalamus: 2.1 nTPM; absolute ceiling; kidney: 3.7 nTPM; absolute ceiling; lung: 2.8 nTPM; absolute ceiling; pituitary gland: 3.2 nTPM; absolute ceiling; retina: 12 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,basal ganglia: 2.1 nTPM (limit 2); choroid plexus: 9.3 nTPM (limit 2); hypothalamus: 2.1 nTPM (limit 2); kidney: 3.7 nTPM (limit 2); lung: 2.8 nTPM (limit 2); pituitary gland: 3.2 nTPM (limit 2); retina: 12 nTPM (limit 2); basal ganglia: 2.1 nTPM (baseline 2); choroid plexus: 9.3 nTPM (baseline 2); hypothalamus: 2.1 nTPM (baseline 2); kidney: 3.7 nTPM (baseline 2); lung: 2.8 nTPM (baseline 2); pituitary gland: 3.2 nTPM (baseline 2); retina: 12 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 52/58 (89.7%); Breast Invasive Carcinoma (validation): 43/50 (86.0%); Prostate Adenocarcinoma (TCGA): 406/480 (84.6%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8WWB5,https://www.uniprot.org/uniprotkb/Q8WWB5/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
PIK3CG,ENSG00000105851,Unsafe,Protein,False,True,5.0,43.1,84,38,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 1.8 nTPM; positive ihc;continuous selectivity; bone marrow: 43.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 1.8 nTPM; positive ihc;continuous selectivity; colon: 4 nTPM; positive ihc;continuous selectivity; duodenum: 4 nTPM; positive ihc;absolute ceiling;continuous selectivity; kidney: 1 nTPM; positive ihc; liver: 1.9 nTPM; positive ihc;continuous selectivity; lung: 4.7 nTPM; continuous selectivity; lymph node: 18.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; rectum: 3.7 nTPM; positive ihc;continuous selectivity; skin: 0.7 nTPM; positive ihc; small intestine: 4.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; spleen: 10.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; stomach: 3.8 nTPM; positive ihc;continuous selectivity; thymus: 16 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 1 nTPM; positive ihc; urinary bladder: 4.2 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 43.1 nTPM (limit 2); duodenum: 4 nTPM (limit 2); lymph node: 18.5 nTPM (limit 6); small intestine: 4.2 nTPM (limit 2); spleen: 10.7 nTPM (limit 10); thymus: 16 nTPM (limit 10),adrenal gland / glandular cells: Medium (Enhanced); bone marrow / hematopoietic cells: Medium (Enhanced); caudate / neuronal cells: Low (Enhanced); cerebral cortex / neuronal cells: Low (Enhanced); colon / glandular cells: Low (Enhanced); duodenum / glandular cells: Medium (Enhanced); kidney / cells in tubules: Medium (Enhanced); liver / hepatocytes: Low (Enhanced); lymph node / germinal center cells: Low (Enhanced); lymph node / non-germinal center cells: Medium (Enhanced); rectum / glandular cells: Medium (Enhanced); skin 1 / keratinocytes: Low (Enhanced); skin 2 / epidermal cells: Medium (Enhanced); small intestine / glandular cells: Medium (Enhanced); spleen / cells in red pulp: Medium (Enhanced); stomach 1 / glandular cells: Medium (Enhanced); stomach 2 / glandular cells: Medium (Enhanced); thyroid gland / glandular cells: Low (Enhanced); urinary bladder / urothelial cells: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 56/58 (96.6%); Colon Adenocarcinoma (validation): 451/486 (92.8%); Rectum Adenocarcinoma (validation): 184/207 (88.9%),breast cancer: 9/12 (75.0%); pancreatic cancer: 5/12 (41.7%),31,20,P48736,https://www.uniprot.org/uniprotkb/P48736/entry,"Phosphoinositide-3-kinase (PI3K) that phosphorylates PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Links G protein coupled receptor activation to PIP3 production. Involved in immune, inflammatory and allergic responses. Modulates leukocyte chemotaxis to inflammatory sites and in response to chemoattractant agents. May control leukocyte polarization and migration by regulating the spatial accumulation of PIP3 and by regulating the organization of F-actin formation and integrin-based adhesion at the leading edge. Controls motility of dendritic cells. Together with PIK3CD is involved in natural killer (NK) cell development and migration towards the sites of inflammation. Participates in T-lymphocyte migration. Regulates T-lymphocyte proliferation, activation, and cytokine production. Together with PIK3CD participates in T-lymphocyte development. Required for B-lymphocyte development and signaling. Together with PIK3CD participates in neutrophil respiratory burst. Together with PIK3CD is involved in neutrophil chemotaxis and extravasation. Together with PIK3CB promotes platelet aggregation and thrombosis. Regulates alpha-IIb/beta-3 integrins (ITGA2B/ ITGB3) adhesive function in platelets downstream of P2Y12 through a lipid kinase activity-independent mechanism. May have also a lipid kinase activity-dependent function in platelet aggregation. Involved in endothelial progenitor cell migration. Negative regulator of cardiac contractility. Modulates cardiac contractility by anchoring protein kinase A (PKA) and PDE3B activation, reducing cAMP levels. Regulates cardiac contractility also by promoting beta-adrenergic receptor internalization by binding to GRK2 and by non-muscle tropomyosin phosphorylation. Also has serine/threonine protein kinase activity: both lipid and protein kinase activities are required for beta-adrenergic receptor endocytosis. May also have a scaffolding role in modulating cardiac contractility. Contributes to cardiac hypertrophy under pathological stress. Through simultaneous binding of PDE3B to RAPGEF3 and PIK3R6 is assembled in a signaling complex in which the PI3K gamma complex is activated by RAPGEF3 and which is involved in angiogenesis. In neutrophils, participates in a phospholipase C-activating N-formyl peptide-activated GPCR (G protein-coupled receptor) signaling pathway downstream of RASGRP4-mediated Ras-activation, to promote neutrophil functional responses (By similarity)","Pancreas, skeletal muscle, liver and heart","Immunodeficiency 97 with autoinflammation: An autosomal recessive disorder with variable features. Affected individuals have childhood-onset antibody defects, cytopenias, and T lymphocytic pneumonitis and colitis. Some patients may have features of hemophagocytic lymphohistiocytosis.",,Cytoplasm Cell membrane,11277933|12163475|15135396|15294162|16094730|16123124|21393242|31554793|33054089|7624799,7624799,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
PIK3R2,ENSG00000105647,Unsafe,Protein,False,True,20.8,42.4,80,73,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 7 nTPM; positive ihc; adrenal gland: 24.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 30.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 33.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 9.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 17.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 39.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 5.8 nTPM; absolute ceiling;continuous selectivity; colon: 13 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 20 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 25.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 12.3 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 42.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 13 nTPM; absolute ceiling;continuous selectivity; kidney: 9.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 10.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 8.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 5.1 nTPM; positive ihc; midbrain: 9.2 nTPM; absolute ceiling;continuous selectivity; pancreas: 10.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 20.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 20.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 9.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 7.6 nTPM; absolute ceiling;continuous selectivity; salivary gland: 14.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 12 nTPM; absolute ceiling;continuous selectivity; skin: 25.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 16.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 9.4 nTPM; absolute ceiling;continuous selectivity; spinal cord: 8.6 nTPM; absolute ceiling;continuous selectivity; spleen: 8.5 nTPM; positive ihc; stomach: 14.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 11.3 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 10.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 9.5 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 14.8 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 24.8 nTPM (limit 2); amygdala: 30.7 nTPM (limit 2); basal ganglia: 33.3 nTPM (limit 2); bone marrow: 9.6 nTPM (limit 2); cerebellum: 17.5 nTPM (limit 2); cerebral cortex: 39.6 nTPM (limit 2); choroid plexus: 5.8 nTPM (limit 2); colon: 13 nTPM (limit 6); duodenum: 20 nTPM (limit 2); esophagus: 25.3 nTPM (limit 6); heart muscle: 12.3 nTPM (limit 4); hippocampal formation: 42.4 nTPM (limit 2); hypothalamus: 13 nTPM (limit 2); kidney: 9.3 nTPM (limit 2); liver: 10.3 nTPM (limit 2); lung: 8.8 nTPM (limit 2); midbrain: 9.2 nTPM (limit 2); pancreas: 10.7 nTPM (limit 2); parathyroid gland: 20.1 nTPM (limit 6); pituitary gland: 20.9 nTPM (limit 2); rectum: 9.3 nTPM (limit 6); retina: 7.6 nTPM (limit 2); salivary gland: 14.5 nTPM (limit 6); skeletal muscle: 12 nTPM (limit 4); skin: 25.7 nTPM (limit 10); small intestine: 16.2 nTPM (limit 2); smooth muscle: 9.4 nTPM (limit 4); spinal cord: 8.6 nTPM (limit 2); stomach: 14.7 nTPM (limit 6); thymus: 11.3 nTPM (limit 10); thyroid gland: 10.2 nTPM (limit 10); tongue: 9.5 nTPM (limit 6); urinary bladder: 14.8 nTPM (limit 6),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: High (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: Medium (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: High (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Low (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: High (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: High (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Ovary Serous Cystadenocarcinoma (TCGA): 349/349 (100.0%); Stomach Adenocarcinoma (TCGA): 346/346 (100.0%); Colon Adenocarcinoma (TCGA): 254/254 (100.0%),breast cancer: 12/12 (100.0%); colorectal cancer: 12/12 (100.0%),31,20,O00459,https://www.uniprot.org/uniprotkb/O00459/entry,"Regulatory subunit of phosphoinositide-3-kinase (PI3K), a kinase that phosphorylates PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Binds to activated (phosphorylated) protein-tyrosine kinases, through its SH2 domain, and acts as an adapter, mediating the association of the p110 catalytic unit to the plasma membrane. Indirectly regulates autophagy (PubMed:23604317). Promotes nuclear translocation of XBP1 isoform 2 in a ER stress- and/or insulin-dependent manner during metabolic overloading in the liver and hence plays a role in glucose tolerance improvement (By similarity)",,"Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 1: A syndrome characterized by megalencephaly, hydrocephalus, and polymicrogyria; polydactyly may also be seen. There is considerable phenotypic similarity between this disorder and the megalencephaly-capillary malformation syndrome.",,,23604317,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
PIK3R3,ENSG00000117461,Unsafe,Protein,False,True,27.1,45.2,83,67,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 30.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; adrenal gland: 11.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 10.5 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 9.6 nTPM; absolute ceiling;continuous selectivity; bone marrow: 0.7 nTPM; positive ihc; cerebellum: 45.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 11.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 13.8 nTPM; absolute ceiling;continuous selectivity; colon: 7.2 nTPM; positive ihc;absolute ceiling; duodenum: 3.1 nTPM; positive ihc;absolute ceiling; heart muscle: 34.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 8.5 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 11.8 nTPM; absolute ceiling;continuous selectivity; kidney: 15.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 3.9 nTPM; positive ihc;absolute ceiling; lung: 18 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 6.1 nTPM; positive ihc;absolute ceiling; midbrain: 11.6 nTPM; absolute ceiling;continuous selectivity; pancreas: 4.5 nTPM; positive ihc;absolute ceiling; parathyroid gland: 11.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 8.3 nTPM; absolute ceiling;continuous selectivity; rectum: 4.7 nTPM; positive ihc; retina: 17.3 nTPM; absolute ceiling;continuous selectivity; salivary gland: 12.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 11.6 nTPM; absolute ceiling;continuous selectivity; skin: 6.1 nTPM; positive ihc; small intestine: 8.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 11.1 nTPM; absolute ceiling;continuous selectivity; spinal cord: 8.8 nTPM; absolute ceiling;continuous selectivity; spleen: 10.9 nTPM; positive ihc;absolute ceiling; stomach: 9.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 10.5 nTPM; absolute ceiling; thyroid gland: 13.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 17.7 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 14.3 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 30.2 nTPM (limit 10); adrenal gland: 11.8 nTPM (limit 2); amygdala: 10.5 nTPM (limit 2); basal ganglia: 9.6 nTPM (limit 2); cerebellum: 45.2 nTPM (limit 2); cerebral cortex: 11.5 nTPM (limit 2); choroid plexus: 13.8 nTPM (limit 2); colon: 7.2 nTPM (limit 6); duodenum: 3.1 nTPM (limit 2); heart muscle: 34.2 nTPM (limit 4); hippocampal formation: 8.5 nTPM (limit 2); hypothalamus: 11.8 nTPM (limit 2); kidney: 15.7 nTPM (limit 2); liver: 3.9 nTPM (limit 2); lung: 18 nTPM (limit 2); lymph node: 6.1 nTPM (limit 6); midbrain: 11.6 nTPM (limit 2); pancreas: 4.5 nTPM (limit 2); parathyroid gland: 11.7 nTPM (limit 6); pituitary gland: 8.3 nTPM (limit 2); retina: 17.3 nTPM (limit 2); salivary gland: 12.2 nTPM (limit 6); skeletal muscle: 11.6 nTPM (limit 4); small intestine: 8.3 nTPM (limit 2); smooth muscle: 11.1 nTPM (limit 4); spinal cord: 8.8 nTPM (limit 2); spleen: 10.9 nTPM (limit 10); stomach: 9.6 nTPM (limit 6); thymus: 10.5 nTPM (limit 10); thyroid gland: 13.8 nTPM (limit 10); tongue: 17.7 nTPM (limit 6); urinary bladder: 14.3 nTPM (limit 6),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / glial cells: Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: High (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: Medium (Approved); hippocampus / glial cells: Medium (Approved); hippocampus / neuronal cells: High (Approved); kidney / cells in glomeruli: High (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Low (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: High (Approved); lymph node / non-germinal center cells: High (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: High (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: High (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Low (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (TCGA): 1019/1022 (99.7%); Colon Adenocarcinoma (validation): 477/486 (98.1%),lung cancer: 7/12 (58.3%); melanoma: 7/12 (58.3%),31,20,Q92569,https://www.uniprot.org/uniprotkb/Q92569/entry,"Binds to activated (phosphorylated) protein-tyrosine kinases through its SH2 domain and regulates their kinase activity. During insulin stimulation, it also binds to IRS-1","Highest levels in brain and testis. Lower levels in adipose tissue, kidney, heart, lung and skeletal muscle",,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | daSilva2017_tumor_proteomics,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
PIWIL1,ENSG00000125207,Unsafe,High RNA,False,True,41.5,41.5,85,2,Positive somewhere,False,False,False,True,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,CTA,Pass,oncoref.target-sets.2026-10-23.1,False,False,,CTA → Unsafe,True,True,True,0.512280239349,161.1,"hpa_single_cell: /Cone photoreceptor cells, max 98.6 nTPM, 1 observations >30; hpa_single_cell: /Rod photoreceptor cells, max 154.2 nTPM, 1 observations >30; hpa_single_cell_tissue: eye/bipolar cells, max 31.9 nTPM, 1 observations >30; hpa_single_cell_tissue: eye/cone photoreceptor cells, max 98.6 nTPM, 1 observations >30; hpa_single_cell_tissue: eye/rod photoreceptor cells, max 161.1 nTPM, 3 observations >30",CTA,oncoref.target-sets.2026-10-23.2,0.5123 TPM; blood/TFH; dice_tfh; vital,161.1 nTPM; eye/rod photoreceptor cells; hpa_single_cell_tissue; vital,Colon Adenocarcinoma (validation): 70/486 (14.4%); Pancreatic Adenocarcinoma (validation): 6/80 (7.5%); Rectum Adenocarcinoma (validation): 15/207 (7.2%),breast cancer: 0/11 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q96J94,https://www.uniprot.org/uniprotkb/Q96J94/entry,"Endoribonuclease that plays a central role in postnatal germ cells by repressing transposable elements and preventing their mobilization, which is essential for the germline integrity. Acts via the piRNA metabolic process, which mediates the repression of transposable elements during meiosis by forming complexes composed of piRNAs and Piwi proteins and governs the methylation and subsequent repression of transposons. Directly binds methylated piRNAs, a class of 24 to 30 nucleotide RNAs that are generated by a Dicer-independent mechanism and are primarily derived from transposons and other repeated sequence elements. Strongly prefers a uridine in the first position of their guide (g1U preference, also named 1U-bias). Not involved in the piRNA amplification loop, also named ping-pong amplification cycle. Acts as an endoribonuclease that cleaves transposon messenger RNAs. Besides their function in transposable elements repression, piRNAs are probably involved in other processes during meiosis such as translation regulation. Probable component of some RISC complex, which mediates RNA cleavage and translational silencing. Also plays a role in the formation of chromatoid bodies and is required for some miRNAs stability. Required to sequester RNF8 in the cytoplasm until late spermatogenesis; RNF8 being released upon ubiquitination and degradation of PIWIL1 May be a negative developmental regulator (PubMed:12037681, PubMed:16287078)","Expressed in spermatocytes and spermatids. Also detected in prostate cancer (at protein level). Detected in most fetal and adult tissues. Expressed in testes, specifically in germline cells; detected in spermatocytes and spermatids during spermatogenesis. Increased expression in testicular tumors originating from embryonic germ cells with retention of germ cells phenotype. No expression in testicular tumors of somatic origin, such as Sertoli cell and Leydig cell tumors. Overexpressed in gastric cancer cells. Isoform 3: Ubiquitously expressed, and specifically in CD34(+) hematopoietic progenitor cells but not in more differentiated cells",,,Cytoplasm,12037681|16287078,11154219|12037681|12906857|23436708,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Jamin2021_CT | Jamin2021_core | Chang2019_TGCT | Gong2021_reproductive_PC | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
PIWIL2,ENSG00000197181,Unsafe,RNA,False,True,27.9,27.9,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,duodenum: 5.8 nTPM; absolute ceiling; pancreas: 2.3 nTPM; absolute ceiling; skeletal muscle: 2.4 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,duodenum: 5.8 nTPM (limit 2); pancreas: 2.3 nTPM (limit 2); skeletal muscle: 2.4 nTPM (limit 2); duodenum: 5.8 nTPM (baseline 2); pancreas: 2.3 nTPM (baseline 2); skeletal muscle: 2.4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 70/133 (52.6%); Pancreatic Adenocarcinoma (validation): 13/80 (16.2%); Head and Neck Squamous Cell Carcinoma (TCGA): 42/492 (8.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8TC59,https://www.uniprot.org/uniprotkb/Q8TC59/entry,"Endoribonuclease that plays a central role during spermatogenesis by repressing transposable elements and preventing their mobilization, which is essential for the germline integrity (By similarity). Plays an essential role in meiotic differentiation of spermatocytes, germ cell differentiation and in self-renewal of spermatogonial stem cells (By similarity). Acts via the piRNA metabolic process, which mediates the repression of transposable elements during meiosis by forming complexes composed of piRNAs and Piwi proteins and govern the methylation and subsequent repression of transposons (By similarity). During piRNA biosynthesis, plays a key role in the piRNA amplification loop, also named ping-pong amplification cycle, by acting as a 'slicer-competent' piRNA endoribonuclease that cleaves primary piRNAs, which are then loaded onto 'slicer-incompetent' PIWIL4 (By similarity). PIWIL2 slicing produces a pre-miRNA intermediate, which is then processed in mature piRNAs, and as well as a 16 nucleotide by-product that is degraded (By similarity). Required for PIWIL4/MIWI2 nuclear localization and association with secondary piRNAs antisense (By similarity). Besides their function in transposable elements repression, piRNAs are probably involved in other processes during meiosis such as translation regulation (By similarity). Indirectly modulates expression of genes such as PDGFRB, SLC2A1, ITGA6, GJA7, THY1, CD9 and STRA8 (By similarity). When overexpressed, acts as an oncogene by inhibition of apoptosis and promotion of proliferation in tumors (PubMed:16377660). Represses circadian rhythms by promoting the stability and activity of core clock components BMAL1 and CLOCK by inhibiting GSK3B-mediated phosphorylation and ubiquitination-dependent degradation of these proteins (PubMed:28903391)",Expressed in adult testis and in most tumors,,,Cytoplasm,16377660|28903391,16377660,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination; inclusion depends on TGCT under this study's thresholds | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
PJVK,ENSG00000204311,Unsafe,RNA,False,True,26.6,26.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 2.5 nTPM; absolute ceiling; amygdala: 3.5 nTPM; absolute ceiling; basal ganglia: 4.4 nTPM; absolute ceiling; cerebral cortex: 3.2 nTPM; absolute ceiling; choroid plexus: 5.2 nTPM; absolute ceiling; hippocampal formation: 3.7 nTPM; absolute ceiling; hypothalamus: 3.5 nTPM; absolute ceiling; kidney: 4.1 nTPM; absolute ceiling; liver: 4 nTPM; absolute ceiling; midbrain: 4.3 nTPM; absolute ceiling; pituitary gland: 5.7 nTPM; absolute ceiling; retina: 6.2 nTPM; absolute ceiling; skeletal muscle: 3.3 nTPM; absolute ceiling; spinal cord: 3.8 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 2.5 nTPM (limit 2); amygdala: 3.5 nTPM (limit 2); basal ganglia: 4.4 nTPM (limit 2); cerebral cortex: 3.2 nTPM (limit 2); choroid plexus: 5.2 nTPM (limit 2); hippocampal formation: 3.7 nTPM (limit 2); hypothalamus: 3.5 nTPM (limit 2); kidney: 4.1 nTPM (limit 2); liver: 4 nTPM (limit 2); midbrain: 4.3 nTPM (limit 2); pituitary gland: 5.7 nTPM (limit 2); retina: 6.2 nTPM (limit 2); skeletal muscle: 3.3 nTPM (limit 2); spinal cord: 3.8 nTPM (limit 2); adrenal gland: 2.5 nTPM (baseline 2); amygdala: 3.5 nTPM (baseline 2); basal ganglia: 4.4 nTPM (baseline 2); cerebral cortex: 3.2 nTPM (baseline 2); choroid plexus: 5.2 nTPM (baseline 2); hippocampal formation: 3.7 nTPM (baseline 2); hypothalamus: 3.5 nTPM (baseline 2); kidney: 4.1 nTPM (baseline 2); liver: 4 nTPM (baseline 2); midbrain: 4.3 nTPM (baseline 2); pituitary gland: 5.7 nTPM (baseline 2); retina: 6.2 nTPM (baseline 2); skeletal muscle: 3.3 nTPM (baseline 2); spinal cord: 3.8 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 32/58 (55.2%); Kidney Renal Papillary Cell Carcinoma (TCGA): 137/282 (48.6%); Uterine Corpus Endometrial Carcinoma (TCGA): 28/176 (15.9%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q0ZLH3,https://www.uniprot.org/uniprotkb/Q0ZLH3/entry,"Peroxisome-associated protein required to protect auditory hair cells against noise-induced damage. Acts by regulating noise-induced peroxisome proliferation in auditory hair cells and neurons, and promoting autophagic degradation of damaged peroxisomes (pexophagy). Noise overexposure increases reactive oxygen species (ROS) levels, causing oxidative damage to auditory hair cells and resulting in hearing loss. PJVK acts as a ROS sensor that recruits the autophagy machinery to trigger pexophagy of peroxisomes damaged by oxidative stress. In addition to pexophagy, also required to promote peroxisome proliferation in response to sound overstimulation",,"Deafness, autosomal recessive, 59: A form of sensorineural hearing impairment with absent or severely abnormal auditory brainstem response but normal otoacoustic emissions (auditory neuropathy or auditory dys-synchrony). Auditory neuropathies result from a lesion in the area including the inner hair cells, connections between the inner hair cells and the cochlear branch of the auditory nerve, the auditory nerve itself and auditory pathways of the brainstem.",,"Peroxisome membrane Cell projection, cilium",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
PKD1L1,ENSG00000158683,Unsafe,RNA,False,True,1.2,2.7,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 1.4 nTPM; continuous selectivity;reproductive not higher; basal ganglia: 0.5 nTPM; continuous selectivity; bone marrow: 1 nTPM; continuous selectivity; cerebellum: 0.4 nTPM; continuous selectivity; duodenum: 0.6 nTPM; continuous selectivity; heart muscle: 2.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 0.4 nTPM; continuous selectivity; liver: 0.5 nTPM; continuous selectivity; lung: 0.4 nTPM; continuous selectivity; lymph node: 0.8 nTPM; continuous selectivity; retina: 1.7 nTPM; continuous selectivity;reproductive not higher; skeletal muscle: 2.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thymus: 1.2 nTPM; continuous selectivity;reproductive not higher; tongue: 2.5 nTPM; continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,heart muscle: 2.6 nTPM (limit 2); skeletal muscle: 2.7 nTPM (limit 2); heart muscle: 2.6 nTPM (baseline 2); skeletal muscle: 2.7 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 51/133 (38.3%); Rectum Adenocarcinoma (validation): 21/207 (10.1%); Colon Adenocarcinoma (TCGA): 20/254 (7.9%),colorectal cancer: 12/12 (100.0%); stomach cancer: 12/12 (100.0%),31,20,Q8TDX9,https://www.uniprot.org/uniprotkb/Q8TDX9/entry,"Component of a calcium-permeant ion channel formed by PKD1L2 and PKD1L1 in primary cilia, where it controls cilium calcium concentration, without affecting cytoplasmic calcium concentration, and regulates sonic hedgehog/SHH signaling and GLI2 transcription (PubMed:24336289). The PKD1L1:PKD2L1 channel complex is mechanosensitive only at high pressures and is highly temperature sensitive (PubMed:24336289). Also involved in left/right axis specification downstream of nodal flow by forming a complex with PKD2 in cilia to facilitate flow detection in left/right patterning (By similarity). May function as a G protein-coupled receptor (PubMed:15203210)",Detected in testis and in fetal and adult heart,"Heterotaxy, visceral, 8, autosomal: A form of visceral heterotaxy, a complex disorder due to disruption of the normal left-right asymmetry of the thoracoabdominal organs. Visceral heterotaxy or situs ambiguus results in randomization of the placement of visceral organs, including the heart, lungs, liver, spleen, and stomach. The organs are oriented randomly with respect to the left-right axis and with respect to one another. It can be associated with a variety of congenital defects including cardiac malformations. HTX8 inheritance is autosomal recessive.",,"Cell projection, cilium membrane",15203210|24336289,11863367,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination; inclusion depends on TGCT under this study's thresholds,,,,,,,,
PKD2L2,ENSG00000078795,Unsafe,Protein,False,True,7.9,7.9,86,73,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 0.9 nTPM; positive ihc; bone marrow: 1.4 nTPM; positive ihc; cerebellum: 0.1 nTPM; positive ihc; cerebral cortex: 0.5 nTPM; positive ihc; colon: 0.1 nTPM; positive ihc; duodenum: 0.3 nTPM; positive ihc; esophagus: 0.4 nTPM; positive ihc; heart muscle: 1.1 nTPM; positive ihc; kidney: 0.1 nTPM; positive ihc; liver: 0.1 nTPM; positive ihc; lung: 0.1 nTPM; positive ihc; lymph node: 0.8 nTPM; positive ihc; pancreas: 0.9 nTPM; positive ihc; parathyroid gland: 0 nTPM; positive ihc; rectum: 0.1 nTPM; positive ihc; salivary gland: 0.4 nTPM; positive ihc; skeletal muscle: 2.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 0.5 nTPM; positive ihc; small intestine: 0.2 nTPM; positive ihc; spleen: 0.7 nTPM; positive ihc; stomach: 0.4 nTPM; positive ihc; thyroid gland: 0.6 nTPM; positive ihc; urinary bladder: 0.1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",skeletal muscle: 2.2 nTPM (limit 2),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Low (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Medium (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Low (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Medium (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (validation): 70/231 (30.3%); Kidney Chromophobe (TCGA): 12/64 (18.8%); Prostate Adenocarcinoma (TCGA): 73/480 (15.2%),liver cancer: 10/12 (83.3%); prostate cancer: 9/12 (75.0%),31,20,Q9NZM6,https://www.uniprot.org/uniprotkb/Q9NZM6/entry,Exhibits a lower single conductance but no spontaneous channel activity (PubMed:16883570). May function as a regulator of calcium channels or a channel component involving Ca2(+) homeostasis (By similarity),Expressed only in testis (PubMed:10602361). Expressed also in brain and kidney (PubMed:10756092) Expressed only in transformed lymphoblasts,,,Membrane,16883570,10602361|10756092,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
PKMYT1,ENSG00000127564,Unsafe,RNA,False,True,55.3,55.3,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 27.3 nTPM; absolute ceiling;continuous selectivity; cerebellum: 3.8 nTPM; absolute ceiling; duodenum: 2.7 nTPM; absolute ceiling; esophagus: 11.2 nTPM; absolute ceiling; lymph node: 7.8 nTPM; absolute ceiling; retina: 16.9 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 2.3 nTPM; absolute ceiling; small intestine: 3.9 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 27.3 nTPM (limit 2); cerebellum: 3.8 nTPM (limit 2); duodenum: 2.7 nTPM (limit 2); esophagus: 11.2 nTPM (limit 6); lymph node: 7.8 nTPM (limit 6); retina: 16.9 nTPM (limit 2); skeletal muscle: 2.3 nTPM (limit 2); small intestine: 3.9 nTPM (limit 2); bone marrow: 27.3 nTPM (baseline 2); cerebellum: 3.8 nTPM (baseline 2); duodenum: 2.7 nTPM (baseline 2); esophagus: 11.2 nTPM (baseline 6); lymph node: 7.8 nTPM (baseline 6); retina: 16.9 nTPM (baseline 2); skeletal muscle: 2.3 nTPM (baseline 2); small intestine: 3.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Head and Neck Squamous Cell Carcinoma (TCGA): 492/492 (100.0%); Prostate Adenocarcinoma (TCGA): 480/480 (100.0%); Colon Adenocarcinoma (TCGA): 254/254 (100.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q99640,https://www.uniprot.org/uniprotkb/Q99640/entry,"Acts as a negative regulator of entry into mitosis (G2 to M transition) by phosphorylation of the CDK1 kinase specifically when CDK1 is complexed to cyclins (PubMed:10373560, PubMed:10504341, PubMed:9001210, PubMed:9268380). Mediates phosphorylation of CDK1 predominantly on 'Thr-14'. Also involved in Golgi fragmentation (PubMed:9001210, PubMed:9268380). May be involved in phosphorylation of CDK1 on 'Tyr-15' to a lesser degree, however tyrosine kinase activity is unclear and may be indirect (PubMed:9001210, PubMed:9268380)",,,,Endoplasmic reticulum membrane Golgi apparatus membrane,10373560|10504341|9001210|9268380,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
PLAAT1,ENSG00000127252,Unsafe,RNA,False,True,71.6,86.9,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 2.4 nTPM; absolute ceiling; amygdala: 8.5 nTPM; absolute ceiling; basal ganglia: 6.4 nTPM; absolute ceiling; cerebral cortex: 6.9 nTPM; absolute ceiling; choroid plexus: 3.5 nTPM; absolute ceiling; esophagus: 6.3 nTPM; absolute ceiling; heart muscle: 9 nTPM; absolute ceiling; hippocampal formation: 6.3 nTPM; absolute ceiling; hypothalamus: 5.9 nTPM; absolute ceiling; midbrain: 7 nTPM; absolute ceiling; pituitary gland: 2.2 nTPM; absolute ceiling; retina: 8.7 nTPM; absolute ceiling; skeletal muscle: 86.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 2.4 nTPM; absolute ceiling; tongue: 42.8 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 2.4 nTPM (limit 2); amygdala: 8.5 nTPM (limit 2); basal ganglia: 6.4 nTPM (limit 2); cerebral cortex: 6.9 nTPM (limit 2); choroid plexus: 3.5 nTPM (limit 2); esophagus: 6.3 nTPM (limit 6); heart muscle: 9 nTPM (limit 2); hippocampal formation: 6.3 nTPM (limit 2); hypothalamus: 5.9 nTPM (limit 2); midbrain: 7 nTPM (limit 2); pituitary gland: 2.2 nTPM (limit 2); retina: 8.7 nTPM (limit 2); skeletal muscle: 86.9 nTPM (limit 2); spinal cord: 2.4 nTPM (limit 2); tongue: 42.8 nTPM (limit 6); adrenal gland: 2.4 nTPM (baseline 2); amygdala: 8.5 nTPM (baseline 2); basal ganglia: 6.4 nTPM (baseline 2); cerebral cortex: 6.9 nTPM (baseline 2); choroid plexus: 3.5 nTPM (baseline 2); esophagus: 6.3 nTPM (baseline 6); heart muscle: 9 nTPM (baseline 2); hippocampal formation: 6.3 nTPM (baseline 2); hypothalamus: 5.9 nTPM (baseline 2); midbrain: 7 nTPM (baseline 2); pituitary gland: 2.2 nTPM (baseline 2); retina: 8.7 nTPM (baseline 2); skeletal muscle: 86.9 nTPM (baseline 2); spinal cord: 2.4 nTPM (baseline 2); tongue: 42.8 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 55/58 (94.8%); Glioblastoma Multiforme (TCGA): 119/141 (84.4%); Lung Squamous Cell Carcinoma (TCGA): 237/489 (48.5%),liver cancer: 9/10 (90.0%); pancreatic cancer: 6/7 (85.7%),29,20,Q9HDD0,https://www.uniprot.org/uniprotkb/Q9HDD0/entry,"Exhibits both phospholipase A1/2 and acyltransferase activities (PubMed:21880860, PubMed:26503625). Shows phospholipase A1 (PLA1) and A2 (PLA2) activity, catalyzing the calcium-independent release of fatty acids from the sn-1 or sn-2 position of glycerophospholipids (PubMed:21880860, PubMed:22825852, PubMed:27623847). Shows O-acyltransferase activity, catalyzing the transfer of a fatty acyl group from glycerophospholipid to the hydroxyl group of lysophospholipid (PubMed:21880860). Shows N-acyltransferase activity, catalyzing the calcium-independent transfer of a fatty acyl group at the sn-1 position of phosphatidylcholine (PC) and other glycerophospholipids to the primary amine of phosphatidylethanolamine (PE), forming N-acylphosphatidylethanolamine (NAPE) which serves as precursor for N-acylethanolamines (NAEs) (PubMed:21880860, PubMed:22825852, PubMed:27623847)","Abundantly expressed in testis, skeletal muscle, brain, and heart Highly expressed in the testis, skeletal muscle, brain, heart, and thyroid",,,Membrane Cytoplasm Nucleus,21880860|22825852|26503625|27623847,21880860|27623847,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Jamin2021_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
PLAC8L1,ENSG00000173261,Unsafe,RNA,False,True,17.9,17.9,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,spinal cord: 2.4 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,spinal cord: 2.4 nTPM (limit 2); spinal cord: 2.4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 20/58 (34.5%); Breast Invasive Carcinoma (validation): 8/50 (16.0%); Liver Hepatocellular Carcinoma (validation): 16/231 (6.9%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,A1L4L8,https://www.uniprot.org/uniprotkb/A1L4L8/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,Failed bulk numeric comparisons are within 20% of their cutoffs; not an automatic rescue,,,,
PLD6,ENSG00000179598,Unsafe,Protein,False,True,20.6,21.6,76,57,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; amygdala: 5.9 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 9.2 nTPM; absolute ceiling;continuous selectivity; cerebellum: 21.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 7.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 5.9 nTPM; absolute ceiling;continuous selectivity; colon: 8.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 1.6 nTPM; positive ihc; esophagus: 1.5 nTPM; positive ihc; heart muscle: 5 nTPM; positive ihc;absolute ceiling; hippocampal formation: 6.2 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 9.5 nTPM; absolute ceiling;continuous selectivity; kidney: 2.8 nTPM; positive ihc;absolute ceiling; liver: 5.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 2.7 nTPM; positive ihc;absolute ceiling; lymph node: 2.9 nTPM; positive ihc; midbrain: 6 nTPM; absolute ceiling;continuous selectivity; pancreas: 4.8 nTPM; positive ihc;absolute ceiling; parathyroid gland: 5.5 nTPM; positive ihc; pituitary gland: 7.9 nTPM; absolute ceiling;continuous selectivity; retina: 3.4 nTPM; absolute ceiling; salivary gland: 3.1 nTPM; positive ihc; skeletal muscle: 5 nTPM; positive ihc;absolute ceiling; skin: 4.3 nTPM; positive ihc; small intestine: 3.1 nTPM; positive ihc;absolute ceiling; smooth muscle: 2.3 nTPM; positive ihc;absolute ceiling; spinal cord: 5.3 nTPM; absolute ceiling;continuous selectivity; stomach: 4.3 nTPM; positive ihc; thyroid gland: 3.2 nTPM; positive ihc; urinary bladder: 4.1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 5.9 nTPM (limit 2); basal ganglia: 9.2 nTPM (limit 2); cerebellum: 21.6 nTPM (limit 2); cerebral cortex: 7.6 nTPM (limit 2); choroid plexus: 5.9 nTPM (limit 2); colon: 8.7 nTPM (limit 6); heart muscle: 5 nTPM (limit 2); hippocampal formation: 6.2 nTPM (limit 2); hypothalamus: 9.5 nTPM (limit 2); kidney: 2.8 nTPM (limit 2); liver: 5.7 nTPM (limit 2); lung: 2.7 nTPM (limit 2); midbrain: 6 nTPM (limit 2); pancreas: 4.8 nTPM (limit 2); pituitary gland: 7.9 nTPM (limit 2); retina: 3.4 nTPM (limit 2); skeletal muscle: 5 nTPM (limit 2); small intestine: 3.1 nTPM (limit 2); smooth muscle: 2.3 nTPM (limit 2); spinal cord: 5.3 nTPM (limit 2),bronchus / respiratory epithelial cells: High (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: High (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Low (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: High (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: High (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); salivary gland / glandular cells: High (Approved); skeletal muscle / myocytes: Medium (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 47/50 (94.0%); Prostate Adenocarcinoma (TCGA): 435/480 (90.6%); Glioblastoma Multiforme (validation): 38/58 (65.5%),prostate cancer: 12/12 (100.0%); pancreatic cancer: 10/10 (100.0%),31,20,Q8N2A8,https://www.uniprot.org/uniprotkb/Q8N2A8/entry,"Presents phospholipase and nuclease activities, depending on the different physiological conditions (PubMed:17028579, PubMed:21397847, PubMed:28063496). Interaction with Mitoguardin (MIGA1 or MIGA2) affects the dimer conformation, facilitating the lipase activity over the nuclease activity (PubMed:26711011). Plays a key role in mitochondrial fusion and fission via its phospholipase activity (PubMed:17028579, PubMed:24599962, PubMed:26678338). In its phospholipase role, it uses the mitochondrial lipid cardiolipin as substrate to generate phosphatidate (PA or 1,2-diacyl-sn-glycero-3-phosphate), a second messenger signaling lipid (PubMed:17028579, PubMed:26711011). Production of PA facilitates Mitofusin-mediated fusion, whereas the cleavage of PA by the Lipin family of phosphatases produces diacylgycerol (DAG) which promotes mitochondrial fission (PubMed:24599962). Both Lipin and DAG regulate mitochondrial dynamics and membrane fusion/fission, important processes for adapting mitochondrial metabolism to changes in cell physiology. Mitochondrial fusion enables cells to cope with the increased nucleotide demand during DNA synthesis (PubMed:26678338). Mitochondrial function and dynamics are closely associated with biological processes such as cell growth, proliferation, and differentiation (PubMed:21397848). Mediator of MYC activity, promotes mitochondrial fusion and activates AMPK which in turn inhibits YAP/TAZ, thereby inducing cell growth and proliferation (PubMed:26678338). The endonuclease activity plays a critical role in PIWI-interacting RNA (piRNA) biogenesis during spermatogenesis (PubMed:21397847, PubMed:21397848). Implicated in spermatogenesis and sperm fertility in testicular germ cells, its single strand-specific nuclease activity is critical for the biogenesis/maturation of PIWI-interacting RNA (piRNA). MOV10L1 selectively binds to piRNA precursors and funnels them to the endonuclease that catalyzes the first cleavage step of piRNA processing to generate piRNA intermediate fragments that are subsequently loaded to Piwi proteins. Cleaves either DNA or RNA substrates with similar affinity, producing a 5' phosphate end, in this way it participates in the processing of primary piRNA transcripts. piRNAs provide essential protection against the activity of mobile genetic elements. piRNA-mediated transposon silencing is thus critical for maintaining genome stability, in particular in germline cells when transposons are mobilized as a consequence of wide-spread genomic demethylation (By similarity). PA may act as signaling molecule in the recognition/transport of the precursor RNAs of primary piRNAs (PubMed:21397847). Interacts with tesmin in testes, suggesting a role in spermatogenesis via association with its interacting partner (By similarity)","Predominantly expressed in testis and ovary, but not limited to gonads (at protein level) (PubMed:17028579, PubMed:21397847). It is also found in brain, heart, pituitary gland, prostate, pancreas, thyroid, bone marrow, lung and muscle (PubMed:21397847)",,"Evidence for subcellular location in the Golgi was determined in pachytene spermatocytes and spermatids in mouse testes. They observe that the ectopically expressed PLD6 protein was localized to the mitochondria in PLD6-transfected cells. Authors claim a possible explanation for the contradictory results is that previous studies have reported the localization of exogenous PLD6, but not endogenous PLD6, in cultured cells. The reason for differences observed in subcellular localization of exogenous and endogenous PLD6 is not clear but one attributable reason may be that different types of anti-PLD6 antibodies have been used in previous studies",Mitochondrion outer membrane Golgi apparatus,17028579|21397847|21397848|24599962|26678338|26711011|28063496,17028579|21397847,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
PLEKHM3,ENSG00000178385,Unsafe,Protein,False,True,3.0,8.1,79,67,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 2.8 nTPM; positive ihc;continuous selectivity; adrenal gland: 4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 2.5 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 3.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 4.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 4.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 5.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; colon: 3 nTPM; positive ihc;continuous selectivity;reproductive not higher; duodenum: 0.9 nTPM; positive ihc;continuous selectivity; esophagus: 1.5 nTPM; positive ihc;continuous selectivity; heart muscle: 2.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 3.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 1.8 nTPM; positive ihc;continuous selectivity; liver: 3.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 2.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 1.4 nTPM; positive ihc;continuous selectivity; midbrain: 3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 2.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 3.9 nTPM; positive ihc;continuous selectivity;reproductive not higher; pituitary gland: 2.4 nTPM; absolute ceiling;continuous selectivity; rectum: 1.4 nTPM; positive ihc;continuous selectivity; retina: 8.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 2.1 nTPM; positive ihc;continuous selectivity; skeletal muscle: 2.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 2.5 nTPM; positive ihc;continuous selectivity; small intestine: 1.8 nTPM; positive ihc;continuous selectivity; smooth muscle: 1.8 nTPM; positive ihc;continuous selectivity; spinal cord: 3.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 1.8 nTPM; positive ihc;continuous selectivity; stomach: 2.2 nTPM; positive ihc;continuous selectivity; thymus: 2.1 nTPM; continuous selectivity; thyroid gland: 3.5 nTPM; positive ihc;continuous selectivity;reproductive not higher; tongue: 1.5 nTPM; continuous selectivity; urinary bladder: 1.9 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 4 nTPM (limit 2); amygdala: 2.5 nTPM (limit 2); basal ganglia: 3.1 nTPM (limit 2); bone marrow: 4.2 nTPM (limit 2); cerebellum: 4.7 nTPM (limit 2); cerebral cortex: 5.2 nTPM (limit 2); heart muscle: 2.8 nTPM (limit 2); hippocampal formation: 3 nTPM (limit 2); hypothalamus: 3.9 nTPM (limit 2); liver: 3.1 nTPM (limit 2); lung: 2.9 nTPM (limit 2); midbrain: 3 nTPM (limit 2); pancreas: 2.2 nTPM (limit 2); pituitary gland: 2.4 nTPM (limit 2); retina: 8.1 nTPM (limit 2); skeletal muscle: 2.3 nTPM (limit 2); spinal cord: 3.7 nTPM (limit 2); adrenal gland: 4 nTPM (baseline 2); amygdala: 2.5 nTPM (baseline 2); basal ganglia: 3.1 nTPM (baseline 2); bone marrow: 4.2 nTPM (baseline 2); cerebellum: 4.7 nTPM (baseline 2); cerebral cortex: 5.2 nTPM (baseline 2); heart muscle: 2.8 nTPM (baseline 2); hippocampal formation: 3 nTPM (baseline 2); hypothalamus: 3.9 nTPM (baseline 2); liver: 3.1 nTPM (baseline 2); lung: 2.9 nTPM (baseline 2); midbrain: 3 nTPM (baseline 2); pancreas: 2.2 nTPM (baseline 2); pituitary gland: 2.4 nTPM (baseline 2); retina: 8.1 nTPM (baseline 2); skeletal muscle: 2.3 nTPM (baseline 2); spinal cord: 3.7 nTPM (baseline 2),adipose tissue / adipocytes: Low (Uncertain); adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: Medium (Uncertain); cerebellum / cells in molecular layer: Low (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / endothelial cells: Low (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / endothelial cells: Low (Uncertain); colon / glandular cells: Low (Uncertain); colon / peripheral nerve/ganglion: Medium (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: Low (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / cholangiocytes: Low (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / macrophages: Low (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: Low (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: Low (Uncertain); skin 1 / fibroblasts: Medium (Uncertain); skin 1 / keratinocytes: Low (Uncertain); skin 1 / Langerhans: Low (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: Medium (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); spleen / cells in red pulp: Low (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Low (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Pancreatic Adenocarcinoma (validation): 78/80 (97.5%); Breast Invasive Carcinoma (validation): 39/50 (78.0%),colorectal cancer: 9/12 (75.0%); liver cancer: 8/11 (72.7%),31,20,Q6ZWE6,https://www.uniprot.org/uniprotkb/Q6ZWE6/entry,Involved in skeletal muscle differentiation. May act as a scaffold protein for AKT1 during muscle differentiation,,,,Cytoplasm Golgi apparatus Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
PLK1,ENSG00000166851,Unsafe,Protein,False,True,32.1,42.7,84,57,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 1.5 nTPM; positive ihc; basal ganglia: 2.2 nTPM; absolute ceiling; bone marrow: 31.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 3 nTPM; positive ihc;absolute ceiling; cerebral cortex: 1.8 nTPM; positive ihc; colon: 9.3 nTPM; positive ihc;absolute ceiling; duodenum: 10.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 13.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 1 nTPM; positive ihc; kidney: 1.4 nTPM; positive ihc; liver: 1.8 nTPM; positive ihc; lung: 1.9 nTPM; positive ihc; lymph node: 27.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; pancreas: 1.1 nTPM; positive ihc; rectum: 9.8 nTPM; positive ihc;absolute ceiling; salivary gland: 2.3 nTPM; positive ihc; skeletal muscle: 0.9 nTPM; positive ihc; skin: 5.6 nTPM; positive ihc; small intestine: 8.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 3.8 nTPM; positive ihc;absolute ceiling; stomach: 6 nTPM; positive ihc; thymus: 42.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 0.9 nTPM; positive ihc; urinary bladder: 2.7 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",basal ganglia: 2.2 nTPM (limit 2); bone marrow: 31.6 nTPM (limit 2); cerebellum: 3 nTPM (limit 2); colon: 9.3 nTPM (limit 6); duodenum: 10.1 nTPM (limit 2); esophagus: 13.5 nTPM (limit 6); lymph node: 27.2 nTPM (limit 6); rectum: 9.8 nTPM (limit 6); small intestine: 8.9 nTPM (limit 2); smooth muscle: 3.8 nTPM (limit 2); thymus: 42.7 nTPM (limit 10),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Low (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Low (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Low (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 283/283 (100.0%); Colon Adenocarcinoma (TCGA): 254/254 (100.0%),liver cancer: 4/12 (33.3%); cervical cancer: 3/12 (25.0%),31,20,P53350,https://www.uniprot.org/uniprotkb/P53350/entry,"Serine/threonine-protein kinase that performs several important functions throughout M phase of the cell cycle, including the regulation of centrosome maturation and spindle assembly, the removal of cohesins from chromosome arms, the inactivation of anaphase-promoting complex/cyclosome (APC/C) inhibitors, and the regulation of mitotic exit and cytokinesis (PubMed:11202906, PubMed:12207013, PubMed:12447691, PubMed:12524548, PubMed:12738781, PubMed:12852856, PubMed:12939256, PubMed:14532005, PubMed:14734534, PubMed:15070733, PubMed:15148369, PubMed:15469984, PubMed:16198290, PubMed:16247472, PubMed:16980960, PubMed:17081991, PubMed:17351640, PubMed:17376779, PubMed:17617734, PubMed:18174154, PubMed:18331714, PubMed:18418051, PubMed:18477460, PubMed:18521620, PubMed:18615013, PubMed:19160488, PubMed:19351716, PubMed:19468300, PubMed:19468302, PubMed:19473992, PubMed:19509060, PubMed:19597481, PubMed:23455478, PubMed:23509069, PubMed:28512243, PubMed:8991084). Polo-like kinase proteins act by binding and phosphorylating proteins that are already phosphorylated on a specific motif recognized by the POLO box domains (PubMed:11202906, PubMed:12207013, PubMed:12447691, PubMed:12524548, PubMed:12738781, PubMed:12852856, PubMed:12939256, PubMed:14532005, PubMed:14734534, PubMed:15070733, PubMed:15148369, PubMed:15469984, PubMed:16198290, PubMed:16247472, PubMed:16980960, PubMed:17081991, PubMed:17351640, PubMed:17376779, PubMed:17617734, PubMed:18174154, PubMed:18331714, PubMed:18418051, PubMed:18477460, PubMed:18521620, PubMed:18615013, PubMed:19160488, PubMed:19351716, PubMed:19468300, PubMed:19468302, PubMed:19473992, PubMed:19509060, PubMed:19597481, PubMed:23455478, PubMed:23509069, PubMed:28512243, PubMed:8991084). Phosphorylates BORA, BUB1B/BUBR1, CCNB1, CDC25C, CEP55, ECT2, ERCC6L, FBXO5/EMI1, FOXM1, KIF20A/MKLP2, CENPU, NEDD1, NINL, NPM1, NUDC, PKMYT1/MYT1, KIZ, MRE11, PPP1R12A/MYPT1, POLQ, PRC1, RACGAP1/CYK4, RAD51, RHNO1, SGO1, STAG2/SA2, TEX14, TOPORS, p73/TP73, TPT1, WEE1 and HNRNPU (PubMed:11202906, PubMed:12207013, PubMed:12447691, PubMed:12524548, PubMed:12738781, PubMed:12852856, PubMed:12939256, PubMed:14532005, PubMed:14734534, PubMed:15070733, PubMed:15148369, PubMed:15469984, PubMed:16198290, PubMed:16247472, PubMed:16980960, PubMed:17081991, PubMed:17218258, PubMed:17351640, PubMed:17376779, PubMed:17617734, PubMed:18174154, PubMed:18331714, PubMed:18418051, PubMed:18477460, PubMed:18521620, PubMed:18615013, PubMed:19160488, PubMed:19351716, PubMed:19468300, PubMed:19468302, PubMed:19473992, PubMed:19509060, PubMed:19597481, PubMed:22325354, PubMed:23455478, PubMed:23509069, PubMed:25986610, PubMed:26811421, PubMed:28512243, PubMed:37440612, PubMed:37674080, PubMed:8991084). Plays a key role in centrosome functions and the assembly of bipolar spindles by phosphorylating KIZ, NEDD1 and NINL (PubMed:16980960, PubMed:19509060). NEDD1 phosphorylation promotes subsequent targeting of the gamma-tubulin ring complex (gTuRC) to the centrosome, an important step for spindle formation (PubMed:19509060). Phosphorylation of NINL component of the centrosome leads to NINL dissociation from other centrosomal proteins (PubMed:12852856). Involved in mitosis exit and cytokinesis by phosphorylating CEP55, ECT2, KIF20A/MKLP2, CENPU, PRC1 and RACGAP1 (PubMed:12939256, PubMed:16247472, PubMed:17351640, PubMed:19468300, PubMed:19468302). Recruited at the central spindle by phosphorylating and docking PRC1 and KIF20A/MKLP2; creates its own docking sites on PRC1 and KIF20A/MKLP2 by mediating phosphorylation of sites subsequently recognized by the POLO box domains (PubMed:12939256, PubMed:17351640). Phosphorylates RACGAP1, thereby creating a docking site for the Rho GTP exchange factor ECT2 that is essential for the cleavage furrow formation (PubMed:19468300, PubMed:19468302). Promotes the central spindle recruitment of ECT2 (PubMed:16247472). Plays a central role in G2/M transition of mitotic cell cycle by phosphorylating CCNB1, CDC25C, FOXM1, CENPU, PKMYT1/MYT1, PPP1R12A/MYPT1 and WEE1 (PubMed:11202906, PubMed:12447691, PubMed:12524548, PubMed:19160488). Part of a regulatory circuit that promotes the activation of CDK1 by phosphorylating the positive regulator CDC25C and inhibiting the negative regulators WEE1 and PKMYT1/MYT1 (PubMed:11202906). Also acts by mediating phosphorylation of cyclin-B1 (CCNB1) on centrosomes in prophase (PubMed:12447691, PubMed:12524548). Phosphorylates FOXM1, a key mitotic transcription regulator, leading to enhance FOXM1 transcriptional activity (PubMed:19160488). Involved in kinetochore functions and sister chromatid cohesion by phosphorylating BUB1B/BUBR1, FBXO5/EMI1 and STAG2/SA2 (PubMed:15148369, PubMed:15469984, PubMed:17376779, PubMed:18331714). PLK1 is high on non-attached kinetochores suggesting a role of PLK1 in kinetochore attachment or in spindle assembly checkpoint (SAC) regulation (PubMed:17617734). Required for kinetochore localization of BUB1B (PubMed:17376779). Regulates the dissociation of cohesin from chromosomes by phosphorylating cohesin subunits such as STAG2/SA2 (By similarity). Phosphorylates SGO1: required for spindle pole localization of isoform 3 of SGO1 and plays a role in regulating its centriole cohesion function (PubMed:18331714). Mediates phosphorylation of FBXO5/EMI1, a negative regulator of the APC/C complex during prophase, leading to FBXO5/EMI1 ubiquitination and degradation by the proteasome (PubMed:15148369, PubMed:15469984). Acts as a negative regulator of p53 family members: phosphorylates TOPORS, leading to inhibit the sumoylation of p53/TP53 and simultaneously enhance the ubiquitination and subsequent degradation of p53/TP53 (PubMed:19473992). Phosphorylates the transactivation domain of the transcription factor p73/TP73, leading to inhibit p73/TP73-mediated transcriptional activation and pro-apoptotic functions. Phosphorylates BORA, and thereby promotes the degradation of BORA (PubMed:18521620). Contributes to the regulation of AURKA function (PubMed:18615013, PubMed:18662541). Also required for recovery after DNA damage checkpoint and entry into mitosis (PubMed:18615013, PubMed:18662541). Phosphorylates MISP, leading to stabilization of cortical and astral microtubule attachments required for proper spindle positioning (PubMed:23509069). Together with MEIKIN, acts as a regulator of kinetochore function during meiosis I: required both for mono-orientation of kinetochores on sister chromosomes and protection of centromeric cohesin from separase-mediated cleavage (By similarity). Phosphorylates CEP68 and is required for its degradation (PubMed:25503564). Regulates nuclear envelope breakdown during prophase by phosphorylating DCTN1 resulting in its localization in the nuclear envelope (PubMed:20679239). Phosphorylates the heat shock transcription factor HSF1, promoting HSF1 nuclear translocation upon heat shock (PubMed:15661742). Phosphorylates HSF1 also in the early mitotic period; this phosphorylation regulates HSF1 localization to the spindle pole, the recruitment of the SCF(BTRC) ubiquitin ligase complex induicing HSF1 degradation, and hence mitotic progression (PubMed:18794143). Regulates mitotic progression by phosphorylating RIOK2 (PubMed:21880710). Through the phosphorylation of DZIP1 regulates the localization during mitosis of the BBSome, a ciliary protein complex involved in cilium biogenesis (PubMed:27979967). Regulates DNA repair during mitosis by mediating phosphorylation of POLQ and RHNO1, thereby promoting POLQ recruitment to DNA damage sites (PubMed:37440612, PubMed:37674080). Phosphorylates ATXN10 which may play a role in the regulation of cytokinesis and may stimulate the proteasome-mediated degradation of ATXN10 (PubMed:21857149)",Placenta and colon,,,"Nucleus Chromosome, centromere, kinetochore Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Cytoplasm, cytoskeleton, spindle Midbody",11202906|12207013|12447691|12524548|12738781|12852856|12939256|14532005|14734534|15070733|15148369|15469984|15661742|16198290|16247472|16980960|17081991|17218258|17351640|17376779|17617734|18174154|18331714|18418051|18477460|18521620|18615013|18662541|18794143|19160488|19351716|19468300|19468302|19473992|19509060|19597481|20679239|21857149|21880710|22325354|23455478|23509069|25503564|25986610|26811421|27979967|37440612|37674080|8991084,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
PLK4,ENSG00000142731,Unsafe,Protein,False,True,22.0,22.3,87,48,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 22.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 0.9 nTPM; positive ihc; colon: 3.4 nTPM; positive ihc; duodenum: 2.7 nTPM; positive ihc;absolute ceiling; esophagus: 3.2 nTPM; positive ihc; kidney: 0.6 nTPM; positive ihc; liver: 0.8 nTPM; positive ihc; lung: 0.9 nTPM; positive ihc; lymph node: 7.3 nTPM; positive ihc;absolute ceiling; pancreas: 0.4 nTPM; positive ihc; rectum: 4.1 nTPM; positive ihc; salivary gland: 0.9 nTPM; positive ihc; skin: 2.3 nTPM; positive ihc; small intestine: 2.8 nTPM; positive ihc;absolute ceiling; spleen: 1.6 nTPM; positive ihc; stomach: 1.9 nTPM; positive ihc; thymus: 14 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 0.8 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 22.3 nTPM (limit 2); duodenum: 2.7 nTPM (limit 2); lymph node: 7.3 nTPM (limit 6); small intestine: 2.8 nTPM (limit 2); thymus: 14 nTPM (limit 10),bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Low (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Medium (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 482/486 (99.2%); Breast Invasive Carcinoma (validation): 49/50 (98.0%); Glioblastoma Multiforme (validation): 56/58 (96.6%),prostate cancer: 9/12 (75.0%); cervical cancer: 8/12 (66.7%),31,20,O00444,https://www.uniprot.org/uniprotkb/O00444/entry,"Serine/threonine-protein kinase that plays a central role in centriole duplication. Able to trigger procentriole formation on the surface of the parental centriole cylinder, leading to the recruitment of centriole biogenesis proteins such as SASS6, CPAP, CCP110, CEP135 and gamma-tubulin. When overexpressed, it is able to induce centrosome amplification through the simultaneous generation of multiple procentrioles adjoining each parental centriole during S phase. Phosphorylates 'Ser-151' of FBXW5 during the G1/S transition, leading to inhibit FBXW5 ability to ubiquitinate SASS6. Its central role in centriole replication suggests a possible role in tumorigenesis, centrosome aberrations being frequently observed in tumors. Also involved in deuterosome-mediated centriole amplification in multiciliated that can generate more than 100 centrioles. Also involved in trophoblast differentiation by phosphorylating HAND1, leading to disrupt the interaction between HAND1 and MDFIC and activate HAND1. Phosphorylates CDC25C and CHEK2. Required for the recruitment of STIL to the centriole and for STIL-mediated centriole amplification (PubMed:22020124). Phosphorylates CEP131 at 'Ser-78' and PCM1 at 'Ser-372' which is essential for proper organization and integrity of centriolar satellites (PubMed:30804208)",,"Microcephaly and chorioretinopathy, autosomal recessive, 2: A severe disorder characterized by microcephaly, delayed psychomotor development, growth retardation with dwarfism, and ocular abnormalities.",,"Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriole Nucleus, nucleolus Cleavage furrow Cytoplasm, cytoskeleton, microtubule organizing center, centrosome",16244668|16326102|17681131|18239451|19164942|21725316|22020124|27796307|30804208,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
PNLDC1,ENSG00000146453,Unsafe,Protein,False,True,7.9,7.9,80,36,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 0.2 nTPM; positive ihc; basal ganglia: 3.6 nTPM; absolute ceiling;continuous selectivity; cerebellum: 0.3 nTPM; positive ihc; cerebral cortex: 1.8 nTPM; positive ihc; colon: 0.3 nTPM; positive ihc; duodenum: 0 nTPM; positive ihc; esophagus: 0.2 nTPM; positive ihc; kidney: 0.2 nTPM; positive ihc; lung: 0.2 nTPM; positive ihc; pancreas: 1.6 nTPM; positive ihc; rectum: 0 nTPM; positive ihc; skin: 1 nTPM; positive ihc; small intestine: 0.1 nTPM; positive ihc; stomach: 0.2 nTPM; positive ihc; thyroid gland: 0.2 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",basal ganglia: 3.6 nTPM (limit 2); basal ganglia: 3.6 nTPM (baseline 2),adrenal gland / glandular cells: Low (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / glial cells: Low (Uncertain); cerebellum / cells in granular layer: Low (Uncertain); cerebellum / Purkinje cells: Low (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / glandular cells: Low (Uncertain); duodenum / glandular cells: Low (Uncertain); esophagus / squamous epithelial cells: Low (Uncertain); kidney / cells in tubules: Low (Uncertain); lung / alveolar cells: Low (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Low (Uncertain); rectum / glandular cells: Low (Uncertain); skin 1 / fibroblasts: Low (Uncertain); skin 1 / keratinocytes: Low (Uncertain); skin 1 / Langerhans: Low (Uncertain); skin 2 / epidermal cells: Low (Uncertain); small intestine / glandular cells: Low (Uncertain); stomach 2 / glandular cells: Low (Uncertain); thyroid gland / glandular cells: Low (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 34/133 (25.6%); Lung Squamous Cell Carcinoma (validation): 12/68 (17.6%); Head and Neck Squamous Cell Carcinoma (TCGA): 74/492 (15.0%),renal cancer: 11/12 (91.7%); pancreatic cancer: 4/9 (44.4%),31,20,Q8NA58,https://www.uniprot.org/uniprotkb/Q8NA58/entry,"3'-exoribonuclease that has a preference for poly(A) tails of mRNAs, thereby efficiently degrading poly(A) tails (PubMed:27515512). Exonucleolytic degradation of the poly(A) tail is often the first step in the decay of eukaryotic mRNAs and is also used to silence certain maternal mRNAs translationally during oocyte maturation and early embryonic development (PubMed:27515512). May act as a regulator of multipotency in embryonic stem cells (By similarity). Is a critical factor for proper spermatogenesis, involved in pre-piRNAs processing to generate mature piRNAs (PubMed:34347949)",,"Spermatogenic failure 57: An autosomal recessive male infertility disorder characterized by non-obstructive azoospermia, due to error-prone meiosis and spermatogenic arrest at the late pachytene stage.",,Endoplasmic reticulum membrane,27515512|34347949,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Loriot2025_S2,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct,,,,,,,,
PNMA5,ENSG00000198883,Unsafe,Protein,False,True,8.5,21.7,86,8,Positive somewhere,True,True,False,True,Excluded,Normal,False,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 7.2 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 16.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 9.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 4.5 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 21.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; stomach: 0.1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 7.2 nTPM (limit 2); basal ganglia: 16.7 nTPM (limit 2); cerebral cortex: 9.1 nTPM (limit 2); hippocampal formation: 4.5 nTPM (limit 2); hypothalamus: 21.7 nTPM (limit 2),caudate / neuronal cells: Medium (Enhanced); cerebral cortex / neuronal cells: High (Enhanced); hippocampus / neuronal cells: Medium (Enhanced); stomach 1 / glandular cells: Low (Enhanced); stomach 2 / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 46/133 (34.6%); Bladder Urothelial Carcinoma (TCGA): 10/169 (5.9%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 16/283 (5.7%),testis cancer: 3/12 (25.0%); urothelial cancer: 2/12 (16.7%),31,20,Q96PV4,https://www.uniprot.org/uniprotkb/Q96PV4/entry,,Expressed in the brain,,,Nucleus,,19366867,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
POLE2,ENSG00000100479,Unsafe,Protein,False,True,4.1,18.1,80,17,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 18.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; colon: 3.7 nTPM; continuous selectivity; duodenum: 2.4 nTPM; absolute ceiling;continuous selectivity; esophagus: 3.6 nTPM; positive ihc;continuous selectivity; liver: 3.2 nTPM; absolute ceiling;continuous selectivity; lymph node: 5.2 nTPM; positive ihc;continuous selectivity;reproductive not higher; pancreas: 1.2 nTPM; continuous selectivity; rectum: 4.6 nTPM; continuous selectivity;reproductive not higher; retina: 3.5 nTPM; absolute ceiling;continuous selectivity; skin: 3.5 nTPM; positive ihc;continuous selectivity; small intestine: 3.6 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 2.2 nTPM; absolute ceiling;continuous selectivity; stomach: 2.2 nTPM; continuous selectivity; thymus: 5.6 nTPM; continuous selectivity;reproductive not higher; urinary bladder: 1.3 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 18.1 nTPM (limit 2); duodenum: 2.4 nTPM (limit 2); liver: 3.2 nTPM (limit 2); retina: 3.5 nTPM (limit 2); small intestine: 3.6 nTPM (limit 2); smooth muscle: 2.2 nTPM (limit 2); bone marrow: 18.1 nTPM (baseline 2); duodenum: 2.4 nTPM (baseline 2); liver: 3.2 nTPM (baseline 2); retina: 3.5 nTPM (baseline 2); small intestine: 3.6 nTPM (baseline 2); smooth muscle: 2.2 nTPM (baseline 2),bone marrow / hematopoietic cells: Low (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); urinary bladder / urothelial cells: Low (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 46/50 (92.0%); Colon Adenocarcinoma (validation): 443/486 (91.2%); Glioblastoma Multiforme (validation): 51/58 (87.9%),liver cancer: 6/10 (60.0%); renal cancer: 7/12 (58.3%),31,20,P56282,https://www.uniprot.org/uniprotkb/P56282/entry,Accessory component of the DNA polymerase epsilon complex (PubMed:10801849). Participates in DNA repair and in chromosomal DNA replication (By similarity),,,,Nucleus,10801849,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
POLH,ENSG00000170734,Unsafe,Protein,False,True,10.3,13.8,79,71,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 3.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; bone marrow: 4.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 3.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 3.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 4.1 nTPM; absolute ceiling;continuous selectivity; colon: 6.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 4.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 5.3 nTPM; positive ihc;continuous selectivity; heart muscle: 3.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; kidney: 4.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 5.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 5.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 12.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 5.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 3.6 nTPM; positive ihc;continuous selectivity; pituitary gland: 3.1 nTPM; absolute ceiling;continuous selectivity; rectum: 6.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 7.2 nTPM; absolute ceiling;continuous selectivity; salivary gland: 3.9 nTPM; positive ihc;continuous selectivity; skeletal muscle: 8.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 8.2 nTPM; positive ihc;continuous selectivity; small intestine: 4.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 6 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 2.2 nTPM; absolute ceiling; spleen: 5.4 nTPM; positive ihc;continuous selectivity; stomach: 4.4 nTPM; positive ihc;continuous selectivity; thymus: 12.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 6.6 nTPM; positive ihc;continuous selectivity; tongue: 4.5 nTPM; continuous selectivity; urinary bladder: 4.6 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 3.7 nTPM (limit 2); bone marrow: 4.1 nTPM (limit 2); cerebellum: 3.2 nTPM (limit 2); cerebral cortex: 3.2 nTPM (limit 2); choroid plexus: 4.1 nTPM (limit 2); colon: 6.7 nTPM (limit 6); duodenum: 4.4 nTPM (limit 2); heart muscle: 3.5 nTPM (limit 2); kidney: 4.5 nTPM (limit 2); liver: 5.4 nTPM (limit 2); lung: 5.5 nTPM (limit 2); lymph node: 12.6 nTPM (limit 6); pancreas: 5.2 nTPM (limit 2); pituitary gland: 3.1 nTPM (limit 2); rectum: 6.9 nTPM (limit 6); retina: 7.2 nTPM (limit 2); skeletal muscle: 8.2 nTPM (limit 2); small intestine: 4.3 nTPM (limit 2); smooth muscle: 6 nTPM (limit 2); spinal cord: 2.2 nTPM (limit 2); thymus: 12.5 nTPM (limit 10),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Medium (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Low (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Medium (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: High (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: High (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 485/486 (99.8%),breast cancer: 10/12 (83.3%); colorectal cancer: 10/12 (83.3%),31,20,Q9Y253,https://www.uniprot.org/uniprotkb/Q9Y253/entry,"DNA polymerase specifically involved in the DNA repair by translesion synthesis (TLS) (PubMed:10385124, PubMed:11743006, PubMed:16357261, PubMed:20388628, PubMed:24449906, PubMed:24553286, PubMed:38212351). Due to low processivity on both damaged and normal DNA, cooperates with the heterotetrameric (REV3L, REV7, POLD2 and POLD3) POLZ complex for complete bypass of DNA lesions. Inserts one or 2 nucleotide(s) opposite the lesion, the primer is further extended by the tetrameric POLZ complex. In the case of 1,2-intrastrand d(GpG)-cisplatin cross-link, inserts dCTP opposite the 3' guanine (PubMed:24449906). Particularly important for the repair of UV-induced pyrimidine dimers (PubMed:10385124, PubMed:11743006). Although inserts the correct base, may cause base transitions and transversions depending upon the context. May play a role in hypermutation at immunoglobulin genes (PubMed:11376341, PubMed:14734526). Forms a Schiff base with 5'-deoxyribose phosphate at abasic sites, but does not have any lyase activity, preventing the release of the 5'-deoxyribose phosphate (5'-dRP) residue. This covalent trapping of the enzyme by the 5'-dRP residue inhibits its DNA synthetic activity during base excision repair, thereby avoiding high incidence of mutagenesis (PubMed:14630940). Targets POLI to replication foci (PubMed:12606586)",,"Xeroderma pigmentosum variant type: An autosomal recessive pigmentary skin disorder characterized by solar hypersensitivity of the skin, high predisposition for developing cancers on areas exposed to sunlight and, in some cases, neurological abnormalities. XPV shows normal nucleotide excision repair, but an exaggerated delay in recovery of replicative DNA synthesis. Most patients with the variant type of xeroderma pigmentosum do not develop clinical symptoms and skin neoplasias until a later age. Clinical manifestations are limited to photo-induced deterioration of the skin and eyes.",,Nucleus,10385124|11376341|11743006|12606586|14630940|14734526|16357261|20388628|24449906|24553286|38212351,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
POLQ,ENSG00000051341,Unsafe,RNA,False,True,2.1,5.9,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 5.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 1.2 nTPM; continuous selectivity; duodenum: 1.1 nTPM; continuous selectivity; esophagus: 1.9 nTPM; continuous selectivity; lymph node: 2.7 nTPM; continuous selectivity;reproductive not higher; rectum: 1.9 nTPM; continuous selectivity; skin: 1.4 nTPM; continuous selectivity; small intestine: 0.9 nTPM; continuous selectivity; thymus: 4.3 nTPM; continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 5.9 nTPM (limit 2); bone marrow: 5.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 398/486 (81.9%); Glioblastoma Multiforme (validation): 47/58 (81.0%); Rectum Adenocarcinoma (validation): 151/207 (72.9%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O75417,https://www.uniprot.org/uniprotkb/O75417/entry,"Low-fidelity DNA polymerase with a putative helicase activity that promotes microhomology-mediated end-joining (MMEJ), an alternative non-homologous end-joining (NHEJ) machinery required to repair double-strand breaks in DNA during mitosis (PubMed:14576298, PubMed:18503084, PubMed:24648516, PubMed:25642963, PubMed:25643323, PubMed:25775267, PubMed:26636256, PubMed:27311885, PubMed:27591252, PubMed:30655289, PubMed:31562312, PubMed:32873648, PubMed:34140467, PubMed:34179826, PubMed:36455556, PubMed:37440612, PubMed:37674080). MMEJ is an error-prone repair pathway that produces deletions of sequences from the strand being repaired and promotes genomic rearrangements, such as telomere fusions, some of them leading to cellular transformation (PubMed:25642963, PubMed:25643323, PubMed:25775267, PubMed:27311885, PubMed:27591252, PubMed:31562312, PubMed:32873648). MMEJ is required during mitosis to repair persistent double-strand breaks that originate in S-phase (PubMed:37440612, PubMed:37674080). Although error-prone, MMEJ protects against chromosomal instability and tumorigenesis (By similarity). The polymerase acts by binding directly the 2 ends of resected double-strand breaks, allowing microhomologous sequences in the overhangs to form base pairs (PubMed:25643323, PubMed:25775267, PubMed:27311885, PubMed:27591252). It then extends each strand from the base-paired region using the opposing overhang as a template (PubMed:25643323, PubMed:25775267, PubMed:27311885, PubMed:27591252). Requires partially resected DNA containing 2 to 6 base pairs of microhomology to perform MMEJ (PubMed:25643323, PubMed:25775267, PubMed:27311885, PubMed:27591252). The polymerase lacks proofreading activity and is highly promiscuous: unlike most polymerases, promotes extension of ssDNA and partial ssDNA (pssDNA) substrates (PubMed:18503084, PubMed:21050863, PubMed:22135286). When the ends of a break do not contain terminal microhomology must identify embedded complementary sequences through a scanning step (PubMed:32234782). Promotes dissociation of the replication protein A complex (RPA/RP-A), composed of RPA1, RPA2 and RPA3, from resected double-strand breaks to allow their annealing and subsequent joining by MMEJ (PubMed:36455556). Removal of RPA/RP-A complex proteins prevents RAD51 accumulation at resected ends, thereby inhibiting homology-recombination repair (HR) pathway (PubMed:25642963, PubMed:28695890). Also shows RNA-directed DNA polymerase activity to mediate DNA repair in vitro; however this activity needs additional evidence in vivo (PubMed:34117057). May also have lyase activity (PubMed:19188258). Involved in somatic hypermutation of immunoglobulin genes, a process that requires the activity of DNA polymerases to ultimately introduce mutations at both A/T and C/G base pairs (By similarity). POLQ-mediated end joining activity is involved in random integration of exogenous DNA hampers (PubMed:28695890). DNA helicase activity has been examined and has (PubMed:29444826) and has not (PubMed:14576298, PubMed:36455556) been demonstrated (PubMed:14576298, PubMed:29444826, PubMed:36455556)",Highly expressed in testis,Breast cancer: A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.,"A publication reported some endonuclease activity required to trim the 3' ends before synthesis can occur. However, subsequent research from the same group showed that DNA synthesis products generated by POLQ that migrate more quickly on denaturing polyacrylamide gels arise by production of stable stem-loop structures rather than from nuclease activity (PubMed:38640889). The original publication was therefore retracted Was wrongly named DNA polymerase eta (POLH) by some authors (Ref.4). This protein corresponds to DNA polymerase theta (POLQ) and should not be confused with DNA polymerase eta (POLH) (AC Q9Y253)",Nucleus Chromosome,14576298|18503084|19188258|21050863|22135286|24648516|25642963|25643323|25775267|26636256|27311885|27591252|28695890|29444826|30655289|31562312|32234782|32873648|34117057|34140467|34179826|36455556|37440612|37674080,14576298,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
POLR2M,ENSG00000255529,Unsafe,RNA,False,True,33.6,37.4,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 18.7 nTPM; absolute ceiling;continuous selectivity; adrenal gland: 19.4 nTPM; absolute ceiling;continuous selectivity; amygdala: 20.2 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 18.1 nTPM; absolute ceiling;continuous selectivity; bone marrow: 16.7 nTPM; absolute ceiling;continuous selectivity; cerebellum: 11.1 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 18.7 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 9.5 nTPM; absolute ceiling;continuous selectivity; colon: 15 nTPM; absolute ceiling;continuous selectivity; duodenum: 11.9 nTPM; absolute ceiling;continuous selectivity; esophagus: 14.8 nTPM; absolute ceiling;continuous selectivity; heart muscle: 28.1 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 19.5 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 19.8 nTPM; absolute ceiling;continuous selectivity; kidney: 19.4 nTPM; absolute ceiling;continuous selectivity; liver: 14.9 nTPM; absolute ceiling;continuous selectivity; lung: 13.8 nTPM; absolute ceiling;continuous selectivity; lymph node: 18.7 nTPM; absolute ceiling;continuous selectivity; midbrain: 24.3 nTPM; absolute ceiling;continuous selectivity; pancreas: 15.6 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 24.7 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 8.8 nTPM; absolute ceiling;continuous selectivity; rectum: 14.6 nTPM; absolute ceiling;continuous selectivity; retina: 12.3 nTPM; absolute ceiling;continuous selectivity; salivary gland: 15.6 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 34.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 14.9 nTPM; absolute ceiling;continuous selectivity; small intestine: 12.8 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 26.1 nTPM; absolute ceiling;continuous selectivity; spinal cord: 24.3 nTPM; absolute ceiling;continuous selectivity; spleen: 20.7 nTPM; absolute ceiling;continuous selectivity; stomach: 14.6 nTPM; absolute ceiling;continuous selectivity; thymus: 20.8 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 23.4 nTPM; absolute ceiling;continuous selectivity; tongue: 37.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 14.6 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adipose tissue: 18.7 nTPM (limit 10); adrenal gland: 19.4 nTPM (limit 2); amygdala: 20.2 nTPM (limit 2); basal ganglia: 18.1 nTPM (limit 2); bone marrow: 16.7 nTPM (limit 2); cerebellum: 11.1 nTPM (limit 2); cerebral cortex: 18.7 nTPM (limit 2); choroid plexus: 9.5 nTPM (limit 2); colon: 15 nTPM (limit 6); duodenum: 11.9 nTPM (limit 2); esophagus: 14.8 nTPM (limit 6); heart muscle: 28.1 nTPM (limit 2); hippocampal formation: 19.5 nTPM (limit 2); hypothalamus: 19.8 nTPM (limit 2); kidney: 19.4 nTPM (limit 2); liver: 14.9 nTPM (limit 2); lung: 13.8 nTPM (limit 2); lymph node: 18.7 nTPM (limit 6); midbrain: 24.3 nTPM (limit 2); pancreas: 15.6 nTPM (limit 2); parathyroid gland: 24.7 nTPM (limit 6); pituitary gland: 8.8 nTPM (limit 2); rectum: 14.6 nTPM (limit 6); retina: 12.3 nTPM (limit 2); salivary gland: 15.6 nTPM (limit 6); skeletal muscle: 34.7 nTPM (limit 2); skin: 14.9 nTPM (limit 10); small intestine: 12.8 nTPM (limit 2); smooth muscle: 26.1 nTPM (limit 2); spinal cord: 24.3 nTPM (limit 2); spleen: 20.7 nTPM (limit 10); stomach: 14.6 nTPM (limit 6); thymus: 20.8 nTPM (limit 10); thyroid gland: 23.4 nTPM (limit 10); tongue: 37.4 nTPM (limit 6); urinary bladder: 14.6 nTPM (limit 6); adipose tissue: 18.7 nTPM (baseline 10); adrenal gland: 19.4 nTPM (baseline 2); amygdala: 20.2 nTPM (baseline 2); basal ganglia: 18.1 nTPM (baseline 2); bone marrow: 16.7 nTPM (baseline 2); cerebellum: 11.1 nTPM (baseline 2); cerebral cortex: 18.7 nTPM (baseline 2); choroid plexus: 9.5 nTPM (baseline 2); colon: 15 nTPM (baseline 6); duodenum: 11.9 nTPM (baseline 2); esophagus: 14.8 nTPM (baseline 6); heart muscle: 28.1 nTPM (baseline 2); hippocampal formation: 19.5 nTPM (baseline 2); hypothalamus: 19.8 nTPM (baseline 2); kidney: 19.4 nTPM (baseline 2); liver: 14.9 nTPM (baseline 2); lung: 13.8 nTPM (baseline 2); lymph node: 18.7 nTPM (baseline 6); midbrain: 24.3 nTPM (baseline 2); pancreas: 15.6 nTPM (baseline 2); parathyroid gland: 24.7 nTPM (baseline 6); pituitary gland: 8.8 nTPM (baseline 2); rectum: 14.6 nTPM (baseline 6); retina: 12.3 nTPM (baseline 2); salivary gland: 15.6 nTPM (baseline 6); skeletal muscle: 34.7 nTPM (baseline 2); skin: 14.9 nTPM (baseline 10); small intestine: 12.8 nTPM (baseline 2); smooth muscle: 26.1 nTPM (baseline 2); spinal cord: 24.3 nTPM (baseline 2); spleen: 20.7 nTPM (baseline 10); stomach: 14.6 nTPM (baseline 6); thymus: 20.8 nTPM (baseline 10); thyroid gland: 23.4 nTPM (baseline 10); tongue: 37.4 nTPM (baseline 6); urinary bladder: 14.6 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Stomach Adenocarcinoma (TCGA): 346/346 (100.0%); Colon Adenocarcinoma (TCGA): 254/254 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,P0CAP2 | Q6EEV4,https://www.uniprot.org/uniprotkb/P0CAP2/entry | https://www.uniprot.org/uniprotkb/Q6EEV4/entry,"Appears to be a stable component of the Pol II(G) complex form of RNA polymerase II (Pol II). Pol II synthesizes mRNA precursors and many functional non-coding RNAs and is the central component of the basal RNA polymerase II transcription machinery. May play a role in the Mediator complex-dependent regulation of transcription activation. Acts as a negative regulator of transcriptional activation; this repression is relieved by the Mediator complex, which restores Pol II(G) activator-dependent transcription to a level equivalent to that of Pol II","Detected in adult an fetal brain. Detected in heart, kidney, skeletal muscle, small intestine, lung, prostate and testis",,,Nucleus,16769904|30190596,15233991,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
POTEG,ENSG00000187537,Unsafe,High RNA,False,True,1.1,1.1,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,hpa_immune_cell basophil: 8.6 nTPM; hpa_immune_cell classical monocyte: 7.6 nTPM; hpa_immune_cell eosinophil: 15 nTPM; hpa_immune_cell intermediate monocyte: 11.1 nTPM; hpa_immune_cell myeloid DC: 10.6 nTPM; hpa_immune_cell naive CD8 T-cell: 5 nTPM; hpa_immune_cell neutrophil: 7.6 nTPM; hpa_immune_cell non-classical monocyte: 11.4 nTPM; hpa_immune_cell T-reg: 7 nTPM; hpa_immune_cell total PBMC: 18 nTPM,True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,22.3615,47.1005,"hpa_immune_cell_samples: blood/total PBMC, max 47.1005 nTPM, 1 observations >30",Neither,oncoref.target-sets.2026-10-23.2,22.36 TPM; blood/eosinophil; hpa_immune_cell_samples; vital,47.1 nTPM; blood/total PBMC; hpa_immune_cell_samples; vital,Pancreatic Adenocarcinoma (validation): 1/80 (1.2%); Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q6S5H5,https://www.uniprot.org/uniprotkb/Q6S5H5/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
POU4F1,ENSG00000152192,Unsafe,Protein,False,True,0.9,2.5,96,5,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; retina: 2.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 0.5 nTPM; continuous selectivity; thymus: 0.7 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",retina: 2.5 nTPM (limit 2),retina / inner nuclear layer: Medium (Enhanced); retina / inner plexiform layer: High (Enhanced); retina / nerve fiber layer: High (Enhanced); retina / outer plexiform layer: High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 19/58 (32.8%); Glioblastoma Multiforme (TCGA): 9/141 (6.4%); Kidney Renal Clear Cell Carcinoma (validation): 4/100 (4.0%),urothelial cancer: 1/10 (10.0%); breast cancer: 0/11 (0.0%),31,20,Q01851,https://www.uniprot.org/uniprotkb/Q01851/entry,"Multifunctional transcription factor with different regions mediating its different effects. Acts by binding (via its C-terminal domain) to sequences related to the consensus octamer motif 5'-ATGCAAAT-3' in the regulatory regions of its target genes. Regulates the expression of specific genes involved in differentiation and survival within a subset of neuronal lineages. It has been shown that activation of some of these genes requires its N-terminal domain, maybe through a neuronal-specific cofactor. Activates BCL2 expression and protects neuronal cells from apoptosis (via the N-terminal domain). Induces neuronal process outgrowth and the coordinate expression of genes encoding synaptic proteins. Exerts its major developmental effects in somatosensory neurons and in brainstem nuclei involved in motor control. Stimulates the binding affinity of the nuclear estrogene receptor ESR1 to DNA estrogen response element (ERE), and hence modulates ESR1-induced transcriptional activity. May positively regulate POU4F2 and POU4F3. Regulates dorsal root ganglion sensory neuron specification and axonal projection into the spinal cord. Plays a role in TNFSF11-mediated terminal osteoclast differentiation. Negatively regulates its own expression interacting directly with a highly conserved autoregulatory domain surrounding the transcription initiation site Able to act as transcription factor, cannot regulate the expression of the same subset of genes than isoform 1. Does not have antiapoptotic effect on neuronal cells","Expressed in the brain and the retina. Present in the developing brain, spinal cord and eye","Ataxia, intention tremor, and hypotonia syndrome, childhood-onset: An autosomal dominant neurodevelopmental disorder characterized by global developmental delay, mildly impaired intellectual development with speech delay or learning disabilities, delayed walking due to ataxia, intention tremor, and hypotonia apparent from early childhood. Brain imaging shows cerebellar atrophy in some patients.",,Nucleus Cytoplasm,,1357630|7623109,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
POU5F2,ENSG00000248483,Unsafe,Protein,False,True,1.9,1.9,83,6,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; kidney: 0.1 nTPM; positive ihc; retina: 1 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",,kidney / cells in tubules: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 21/58 (36.2%); Pancreatic Adenocarcinoma (validation): 6/80 (7.5%); Colon Adenocarcinoma (validation): 8/486 (1.6%),testis cancer: 5/12 (41.7%); urothelial cancer: 1/11 (9.1%),31,20,Q8N7G0,https://www.uniprot.org/uniprotkb/Q8N7G0/entry,Transcription factor that binds preferentially to the octamer motif (5'-ATGTTAAT-3'). May exert a regulatory function in meiotic events that are required for terminal differentiation of male germ cell (By similarity),"Expressed in skeletal and cardiac muscles, brain, heart and lung. Little or no detectable expression found in pancreas, kidney, liver or placenta",,,Nucleus,,7908264,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
PPAN,ENSG00000130810,Unsafe,Protein,False,True,19.9,31.6,86,80,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 22.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; adrenal gland: 19.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 12 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 12.9 nTPM; absolute ceiling;continuous selectivity; bone marrow: 11.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 16.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 15 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 13.7 nTPM; absolute ceiling;continuous selectivity; colon: 18.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 11.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 27 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 17.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 13 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 11.8 nTPM; absolute ceiling;continuous selectivity; kidney: 18.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 23.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 14.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 17.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 10.9 nTPM; absolute ceiling;continuous selectivity; pancreas: 22.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 8 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 13.4 nTPM; absolute ceiling;continuous selectivity; rectum: 5 nTPM; positive ihc; retina: 4.3 nTPM; absolute ceiling; salivary gland: 16.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 31.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 27.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 19.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 6.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 10.6 nTPM; absolute ceiling;continuous selectivity; spleen: 25.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; stomach: 17.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 9.6 nTPM; continuous selectivity; thyroid gland: 15.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 10.4 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 19.8 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 22.5 nTPM (limit 10); adrenal gland: 19.8 nTPM (limit 2); amygdala: 12 nTPM (limit 2); basal ganglia: 12.9 nTPM (limit 2); bone marrow: 11.5 nTPM (limit 2); cerebellum: 16.9 nTPM (limit 2); cerebral cortex: 15 nTPM (limit 2); choroid plexus: 13.7 nTPM (limit 2); colon: 18.1 nTPM (limit 6); duodenum: 11.8 nTPM (limit 2); esophagus: 27 nTPM (limit 6); heart muscle: 17.1 nTPM (limit 2); hippocampal formation: 13 nTPM (limit 2); hypothalamus: 11.8 nTPM (limit 2); kidney: 18.3 nTPM (limit 2); liver: 23.9 nTPM (limit 2); lung: 14.4 nTPM (limit 2); lymph node: 17.2 nTPM (limit 6); midbrain: 10.9 nTPM (limit 2); pancreas: 22.5 nTPM (limit 2); parathyroid gland: 8 nTPM (limit 6); pituitary gland: 13.4 nTPM (limit 2); retina: 4.3 nTPM (limit 2); salivary gland: 16.2 nTPM (limit 6); skeletal muscle: 31.6 nTPM (limit 2); skin: 27.3 nTPM (limit 10); small intestine: 19.4 nTPM (limit 2); smooth muscle: 6.4 nTPM (limit 2); spinal cord: 10.6 nTPM (limit 2); spleen: 25.9 nTPM (limit 10); stomach: 17.8 nTPM (limit 6); thyroid gland: 15.5 nTPM (limit 10); tongue: 10.4 nTPM (limit 6); urinary bladder: 19.8 nTPM (limit 6),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: High (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: High (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: High (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: High (Approved); lung / alveolar cells: High (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: High (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Low (Approved); skin 1 / keratinocytes: Low (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Head and Neck Squamous Cell Carcinoma (TCGA): 492/492 (100.0%); Prostate Adenocarcinoma (TCGA): 480/480 (100.0%); Ovary Serous Cystadenocarcinoma (TCGA): 349/349 (100.0%),testis cancer: 11/11 (100.0%); ovarian cancer: 10/11 (90.9%),31,20,Q9NQ55,https://www.uniprot.org/uniprotkb/Q9NQ55/entry,May have a role in cell growth,Widely expressed,,,"Nucleus, nucleolus",,10944437|11278528,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
PPAT,ENSG00000128059,Unsafe,Protein,False,True,8.4,8.4,78,41,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 2.7 nTPM; positive ihc; adrenal gland: 5.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 3.3 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 3.4 nTPM; absolute ceiling;continuous selectivity; bone marrow: 5.5 nTPM; absolute ceiling;continuous selectivity; cerebellum: 3.8 nTPM; continuous selectivity; cerebral cortex: 5.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 3.5 nTPM; absolute ceiling;continuous selectivity; colon: 3.8 nTPM; positive ihc;continuous selectivity; duodenum: 3.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 4.3 nTPM; positive ihc;continuous selectivity; heart muscle: 2.2 nTPM; positive ihc;absolute ceiling; hippocampal formation: 3 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 3.4 nTPM; absolute ceiling;continuous selectivity; kidney: 5.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 6 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 2.1 nTPM; positive ihc;absolute ceiling; lymph node: 8.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 3.5 nTPM; absolute ceiling;continuous selectivity; pancreas: 5.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 3.8 nTPM; continuous selectivity; pituitary gland: 2.4 nTPM; absolute ceiling;continuous selectivity; rectum: 4.6 nTPM; positive ihc;continuous selectivity; retina: 4.3 nTPM; absolute ceiling;continuous selectivity; salivary gland: 5.5 nTPM; positive ihc;continuous selectivity; skeletal muscle: 2.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 3.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 3.5 nTPM; continuous selectivity; spinal cord: 2.7 nTPM; absolute ceiling;continuous selectivity; spleen: 4.2 nTPM; positive ihc;continuous selectivity; stomach: 3.5 nTPM; positive ihc;continuous selectivity; thymus: 8.1 nTPM; continuous selectivity; thyroid gland: 5.8 nTPM; continuous selectivity; urinary bladder: 6.5 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 5.9 nTPM (limit 2); amygdala: 3.3 nTPM (limit 2); basal ganglia: 3.4 nTPM (limit 2); bone marrow: 5.5 nTPM (limit 4); cerebral cortex: 5.5 nTPM (limit 2); choroid plexus: 3.5 nTPM (limit 2); duodenum: 3.9 nTPM (limit 2); heart muscle: 2.2 nTPM (limit 2); hippocampal formation: 3 nTPM (limit 2); hypothalamus: 3.4 nTPM (limit 2); kidney: 5.8 nTPM (limit 2); liver: 6 nTPM (limit 2); lung: 2.1 nTPM (limit 2); lymph node: 8.2 nTPM (limit 6); midbrain: 3.5 nTPM (limit 2); pancreas: 5.7 nTPM (limit 2); pituitary gland: 2.4 nTPM (limit 2); retina: 4.3 nTPM (limit 2); skeletal muscle: 2.8 nTPM (limit 2); small intestine: 3.1 nTPM (limit 2); spinal cord: 2.7 nTPM (limit 2),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Medium (Approved); caudate / glial cells: Medium (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Medium (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Low (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: Low (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Medium (Approved); small intestine / glandular cells: Medium (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Adenocarcinoma (validation): 105/105 (100.0%); Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%),colorectal cancer: 9/11 (81.8%); testis cancer: 7/12 (58.3%),31,20,Q06203,https://www.uniprot.org/uniprotkb/Q06203/entry,Catalyzes the formation of phosphoribosylamine from phosphoribosylpyrophosphate (PRPP) and glutamine,Ubiquitously expressed,,,,,8380692,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
PPEF1,ENSG00000086717,Unsafe,RNA,False,True,13.6,13.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,cerebral cortex: 3.5 nTPM; absolute ceiling;continuous selectivity; spinal cord: 10.3 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebral cortex: 3.5 nTPM (limit 2); spinal cord: 10.3 nTPM (limit 2); cerebral cortex: 3.5 nTPM (baseline 2); spinal cord: 10.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 30/50 (60.0%); Glioblastoma Multiforme (validation): 8/58 (13.8%); Skin Cuteneous Melanoma (TCGA): 4/99 (4.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O14829,https://www.uniprot.org/uniprotkb/O14829/entry,Dephosphorylates and destabilises PDCD5 to inhibit TP53/p53-mediated signaling (PubMed:28051100). May have a role in the recovery or adaptation response of photoreceptors (By similarity),Detected in retina and retinal derived Y-79 retinoblastoma cells (PubMed:9430683). Also found in fetal brain (PubMed:9430683),,,,28051100,9430683,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Jamin2021_CT | Chang2019_TGCT | Loriot2025_S2,Cancer-associated RNA nomination; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct,,,,,,,,
PPEF2,ENSG00000156194,Unsafe,RNA,False,True,0.5,231.4,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,cerebellum: 0.6 nTPM; continuous selectivity;reproductive not higher; choroid plexus: 0.8 nTPM; continuous selectivity;reproductive not higher; retina: 231.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 231.4 nTPM (limit 2); retina: 231.4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 15/176 (8.5%); Testicular Germ Cell Tumor (TCGA): 9/133 (6.8%); Kidney Renal Papillary Cell Carcinoma (TCGA): 18/282 (6.4%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O14830,https://www.uniprot.org/uniprotkb/O14830/entry,"May play a role in phototransduction. May dephosphorylate photoactivated rhodopsin. May function as a calcium sensing regulator of ionic currents, energy production or synaptic transmission",Retinal specific,,,"Cytoplasm Cell projection, cilium, photoreceptor outer segment Photoreceptor inner segment",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
PPM1E,ENSG00000175175,Unsafe,Protein,False,True,6.5,21.6,80,18,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 5.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 3.5 nTPM; absolute ceiling;continuous selectivity; cerebellum: 6.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 12.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 10.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 5.5 nTPM; absolute ceiling;continuous selectivity; midbrain: 3.4 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 0.3 nTPM; positive ihc; retina: 21.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 2.2 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 5.3 nTPM (limit 2); amygdala: 3.5 nTPM (limit 2); cerebellum: 6.4 nTPM (limit 2); cerebral cortex: 12.1 nTPM (limit 2); hippocampal formation: 10.3 nTPM (limit 2); hypothalamus: 5.5 nTPM (limit 2); midbrain: 3.4 nTPM (limit 2); retina: 21.6 nTPM (limit 2); spinal cord: 2.2 nTPM (limit 2),adrenal gland / glandular cells: Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: High (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: High (Approved); cerebral cortex / neuropil: High (Approved); hippocampus / glial cells: Medium (Approved); hippocampus / neuronal cells: High (Approved); parathyroid gland / glandular cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Glioblastoma Multiforme (TCGA): 43/141 (30.5%); Prostate Adenocarcinoma (TCGA): 134/480 (27.9%),breast cancer: 12/12 (100.0%); colorectal cancer: 12/12 (100.0%),31,20,Q8WY54,https://www.uniprot.org/uniprotkb/Q8WY54/entry,Protein phosphatase that inactivates multifunctional CaM kinases such as CAMK4 and CAMK2 (By similarity). Dephosphorylates and inactivates PAK. May play a role in the inhibition of actin fiber stress breakdown and in morphological changes driven by TNK2/CDC42. Dephosphorylates PRKAA2 (By similarity),,,,Nucleus Cytoplasm,11864573,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
PPM1J,ENSG00000155367,Unsafe,Protein,False,True,62.0,73.1,75,52,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 2.7 nTPM; positive ihc;absolute ceiling; amygdala: 7.8 nTPM; absolute ceiling; basal ganglia: 4.4 nTPM; absolute ceiling; cerebellum: 15.5 nTPM; positive ihc;absolute ceiling; cerebral cortex: 8 nTPM; positive ihc;absolute ceiling; choroid plexus: 3.5 nTPM; absolute ceiling; colon: 1.1 nTPM; positive ihc; duodenum: 0.7 nTPM; positive ihc; esophagus: 4.4 nTPM; positive ihc; heart muscle: 8.4 nTPM; positive ihc;absolute ceiling; hippocampal formation: 5.1 nTPM; absolute ceiling; hypothalamus: 6.1 nTPM; absolute ceiling; kidney: 7.5 nTPM; positive ihc;absolute ceiling; lung: 1.5 nTPM; positive ihc; lymph node: 3.5 nTPM; positive ihc; midbrain: 4.7 nTPM; absolute ceiling; pancreas: 1.6 nTPM; positive ihc; parathyroid gland: 5.9 nTPM; positive ihc; pituitary gland: 2.5 nTPM; absolute ceiling; rectum: 0.6 nTPM; positive ihc; retina: 7.4 nTPM; absolute ceiling; salivary gland: 2.7 nTPM; positive ihc; skeletal muscle: 73.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 19.4 nTPM; positive ihc;absolute ceiling; small intestine: 1.4 nTPM; positive ihc; spleen: 1.5 nTPM; positive ihc; stomach: 1.2 nTPM; positive ihc; thyroid gland: 3 nTPM; positive ihc; tongue: 27.1 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 1.1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 2.7 nTPM (limit 2); amygdala: 7.8 nTPM (limit 2); basal ganglia: 4.4 nTPM (limit 2); cerebellum: 15.5 nTPM (limit 2); cerebral cortex: 8 nTPM (limit 2); choroid plexus: 3.5 nTPM (limit 2); heart muscle: 8.4 nTPM (limit 2); hippocampal formation: 5.1 nTPM (limit 2); hypothalamus: 6.1 nTPM (limit 2); kidney: 7.5 nTPM (limit 2); midbrain: 4.7 nTPM (limit 2); pituitary gland: 2.5 nTPM (limit 2); retina: 7.4 nTPM (limit 2); skeletal muscle: 73.1 nTPM (limit 2); skin: 19.4 nTPM (limit 10); tongue: 27.1 nTPM (limit 6); adrenal gland: 2.7 nTPM (baseline 2); amygdala: 7.8 nTPM (baseline 2); basal ganglia: 4.4 nTPM (baseline 2); cerebellum: 15.5 nTPM (baseline 2); cerebral cortex: 8 nTPM (baseline 2); choroid plexus: 3.5 nTPM (baseline 2); heart muscle: 8.4 nTPM (baseline 2); hippocampal formation: 5.1 nTPM (baseline 2); hypothalamus: 6.1 nTPM (baseline 2); kidney: 7.5 nTPM (baseline 2); midbrain: 4.7 nTPM (baseline 2); pituitary gland: 2.5 nTPM (baseline 2); retina: 7.4 nTPM (baseline 2); skeletal muscle: 73.1 nTPM (baseline 2); skin: 19.4 nTPM (baseline 10); tongue: 27.1 nTPM (baseline 6),adrenal gland / glandular cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Low (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: Medium (Uncertain); cerebellum / cells in molecular layer: Medium (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / endothelial cells: Low (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / endothelial cells: Medium (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: Low (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Low (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in glomeruli: Low (Uncertain); kidney / cells in tubules: Medium (Uncertain); lung / macrophages: Low (Uncertain); lymph node / germinal center cells: Low (Uncertain); oral mucosa / squamous epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Low (Uncertain); pancreas / pancreatic endocrine cells: Low (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: Low (Uncertain); skin 1 / fibroblasts: Low (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: Medium (Uncertain); spleen / cells in red pulp: Low (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Low (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 48/50 (96.0%); Breast Invasive Carcinoma (TCGA): 679/1022 (66.4%); Ovary Serous Cystadenocarcinoma (validation): 34/81 (42.0%),breast cancer: 6/11 (54.5%); prostate cancer: 5/10 (50.0%),31,20,Q5JR12,https://www.uniprot.org/uniprotkb/Q5JR12/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
PPP1R2C,ENSG00000102055,Unsafe,High RNA,False,True,69.0,69.0,0,0,Missing,False,False,False,False,Excluded,Reproductive,True,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE NK (unstimulated): 10/90 values ≥5 TPM, max 20.8484; DICE TREG_MEM (unstimulated): 35/89 values ≥5 TPM, max 86.5482; DICE CD4_NAIVE (unstimulated): 20/88 values ≥5 TPM, max 23.4734; DICE CD4_STIM (activated): 10/88 values ≥5 TPM, max 8.29252; DICE TREG_NAIVE (unstimulated): 31/89 values ≥5 TPM, max 38.5474; DICE TFH (unstimulated): 34/89 values ≥5 TPM, max 37.2909; DICE TH1 (unstimulated): 30/81 values ≥5 TPM, max 53.1601; DICE THSTAR (unstimulated): 34/88 values ≥5 TPM, max 60.1355; DICE TH17 (unstimulated): 35/89 values ≥5 TPM, max 53.8348; DICE TH2 (unstimulated): 32/89 values ≥5 TPM, max 30.4212; DICE CD8_NAIVE (unstimulated): 34/89 values ≥5 TPM, max 70.0835; DICE CD8_STIM (activated): 28/88 values ≥5 TPM, max 14.991; hpa_immune_monaco MAIT T-cell: 6 TPM; hpa_immune_monaco Memory CD4 T-cell Th1/Th17: 5 TPM; hpa_immune_monaco Vd2 gdTCR: 6.5 TPM",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,86.54816028280001,222.4,"dice_cd8_naive: blood/CD8_NAIVE, max 70.0835 TPM, 4 observations >30; dice_tfh: blood/TFH, max 37.2909 TPM, 2 observations >30; dice_th1: blood/TH1, max 53.1601 TPM, 13 observations >30; dice_th17: blood/TH17, max 53.8348 TPM, 11 observations >30; dice_th2: blood/TH2, max 30.4212 TPM, 1 observations >30; dice_thstar: blood/THSTAR, max 60.1355 TPM, 16 observations >30; dice_treg_mem: blood/TREG_MEM, max 86.5482 TPM, 27 observations >30; dice_treg_naive: blood/TREG_NAIVE, max 38.5474 TPM, 2 observations >30; hpa_single_cell_tissue: adipose tissue/t-cells, max 33.2 nTPM, 1 observations >30; hpa_single_cell_tissue: breast/macrophages, max 88.7 nTPM, 1 observations >30; hpa_single_cell_tissue: breast/t-cells, max 222.4 nTPM, 5 observations >30; hpa_single_cell_tissue: endometrium/t-cells, max 95.9 nTPM, 1 observations >30; hpa_single_cell_tissue: fallopian tube/t-cells, max 156.2 nTPM, 4 observations >30; hpa_single_cell_tissue: ovary/mixed immune cells, max 36.2 nTPM, 1 observations >30",Neither,oncoref.target-sets.2026-10-23.2,86.55 TPM; blood/TREG_MEM; dice_treg_mem; vital,222.4 nTPM; breast/t-cells; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 17/133 (12.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,O14990,https://www.uniprot.org/uniprotkb/O14990/entry,Functions as a protein phosphatase inhibitor. It inhibits activity of the catalytic subunit of PP1 and weakly inhibits the activity of myosin-associated phosphates,Detected in sperm (at protein level),,,,11076525,24195737,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
PPP1R36,ENSG00000165807,Unsafe,Protein,False,True,36.0,36.0,113,9,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 0 nTPM; positive ihc; choroid plexus: 4.8 nTPM; absolute ceiling; colon: 6.3 nTPM; positive ihc;absolute ceiling; duodenum: 6.4 nTPM; positive ihc;absolute ceiling; small intestine: 4.5 nTPM; positive ihc;absolute ceiling; spinal cord: 3 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 4.8 nTPM (limit 2); colon: 6.3 nTPM (limit 6); duodenum: 6.4 nTPM (limit 2); small intestine: 4.5 nTPM (limit 2); spinal cord: 3 nTPM (limit 2),bone marrow / hematopoietic cells: Low (Enhanced); bronchus / ciliated cells (ciliary rootlets): Medium (Enhanced); bronchus / ciliated cells (tip of cilia): Low (Enhanced); colon / enterocytes - Microvilli: High (Enhanced); duodenum / enterocytes - Microvilli: Low (Enhanced); small intestine / enterocytes - Microvilli: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 34/80 (42.5%); Pancreatic Adenocarcinoma (TCGA): 55/176 (31.2%); Colon Adenocarcinoma (TCGA): 52/254 (20.5%),testis cancer: 4/12 (33.3%); breast cancer: 0/12 (0.0%),29,20,Q96LQ0,https://www.uniprot.org/uniprotkb/Q96LQ0/entry,Inhibits phosphatase activity of protein phosphatase 1 (PP1) complexes,,,,,19389623,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
PPP1R42,ENSG00000178125,Unsafe,High RNA,False,True,8.9,8.9,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA024313; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA024313; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA024313; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: High, HPA024313; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA024313; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Low, HPA024313; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA024313; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA024313; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA024313; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA024313; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA024313; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA024313; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA024313; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA024313; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA024313; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA024313; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA024313; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA024313; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA024313; conflicting or uncurated primary profile; Lung/Macrophages: High, HPA024313; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA024313; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA024313; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA024313; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA024313; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA024313; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: High, HPA024313; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA024313; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Low, HPA024313; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA024313; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Low, HPA024313; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA024313; conflicting or uncurated primary profile; Skin 1/Langerhans: Low, HPA024313; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA024313; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA024313; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA024313; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA024313; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA024313; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA024313; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA024313; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA027983; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA027983; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA027983; conflicting or uncurated primary profile; Caudate/Glial cells: Medium, HPA027983; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA027983; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Low, HPA027983; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA027983; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA027983; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA027983; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Medium, HPA027983; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA027983; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA027983; conflicting or uncurated primary profile; Colon/Endothelial cells: Low, HPA027983; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA027983; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA027983; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA027983; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA027983; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA027983; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA027983; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA027983; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA027983; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA027983; conflicting or uncurated primary profile; Liver/Cholangiocytes: Low, HPA027983; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA027983; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA027983; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA027983; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Medium, HPA027983; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Medium, HPA027983; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA027983; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA027983; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA027983; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA027983; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA027983; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA027983; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA027983; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA027983; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA027983; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA027983; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA027983; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA027983; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA027983; conflicting or uncurated primary profile; Adipose tissue/Adipocytes: Low, HPA028628; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA028628; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA028628; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA028628; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA028628; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA028628; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Medium, HPA028628; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Medium, HPA028628; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA028628; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA028628; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA028628; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA028628; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: High, HPA028628; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA028628; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA028628; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA028628; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA028628; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA028628; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Low, HPA028628; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA028628; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA028628; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA028628; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA028628; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA028628; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA028628; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Low, HPA028628; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA028628; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA028628; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,0.756099823204,107.7,"hpa_single_cell: /Ciliated cells, max 78.4 nTPM, 1 observations >30; hpa_single_cell_tissue: bronchus/ciliated cells, max 100.3 nTPM, 2 observations >30; hpa_single_cell_tissue: bronchus/club cells, max 31.4 nTPM, 1 observations >30; hpa_single_cell_tissue: lung/ciliated cells, max 107.7 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,0.7561 TPM; blood/NK; dice_nk; vital,107.7 nTPM; lung/ciliated cells; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 12/58 (20.7%); Ovary Serous Cystadenocarcinoma (validation): 2/81 (2.5%); Uterine Corpus Endometrial Carcinoma (TCGA): 4/176 (2.3%),liver cancer: 2/12 (16.7%); endometrial cancer: 1/11 (9.1%),29,20,Q7Z4L9,https://www.uniprot.org/uniprotkb/Q7Z4L9/entry,Regulates phosphatase activity of protein phosphatase 1 (PP1) complexes in the testis,,,,"Cytoplasm, cytoskeleton Cytoplasm, cytoskeleton, microtubule organizing center, centrosome",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
PRAMEF9,ENSG00000204505,Unsafe,RNA,False,True,0.4,32.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,esophagus: 0.5 nTPM; continuous selectivity;reproductive not higher; heart muscle: 0.6 nTPM; continuous selectivity;reproductive not higher; lymph node: 0.4 nTPM; continuous selectivity;reproductive not higher; retina: 0.3 nTPM; continuous selectivity; skeletal muscle: 32.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 0.3 nTPM; continuous selectivity; thyroid gland: 0.3 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,skeletal muscle: 32.1 nTPM (limit 2); skeletal muscle: 32.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 5/176 (2.8%); Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,,,,,,,,,,False,No exact Ensembl mapping to a reviewed UniProt entry,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
PRAP1,ENSG00000165828,Unsafe,Protein,False,True,11.9,1103.8,94,6,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; choroid plexus: 58.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 72.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 1022.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; kidney: 139.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 653.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; rectum: 34.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 1103.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 58.9 nTPM (limit 2); colon: 72.1 nTPM (limit 6); duodenum: 1022.9 nTPM (limit 2); kidney: 139.8 nTPM (limit 2); liver: 653.6 nTPM (limit 2); rectum: 34.5 nTPM (limit 6); small intestine: 1103.8 nTPM (limit 2); choroid plexus: 58.9 nTPM (baseline 2); colon: 72.1 nTPM (baseline 6); duodenum: 1022.9 nTPM (baseline 2); kidney: 139.8 nTPM (baseline 2); liver: 653.6 nTPM (baseline 2); rectum: 34.5 nTPM (baseline 6); small intestine: 1103.8 nTPM (baseline 2),duodenum / glandular cells: Medium (Supported); kidney / cells in tubules: Medium (Supported); liver / hepatocytes: Medium (Supported); small intestine / endocrine cells: High (Supported); small intestine / enterocytes: Medium (Supported),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (TCGA): 87/88 (98.9%); Rectum Adenocarcinoma (validation): 203/207 (98.1%); Liver Hepatocellular Carcinoma (validation): 225/231 (97.4%),colorectal cancer: 6/12 (50.0%); liver cancer: 5/12 (41.7%),31,20,Q96NZ9,https://www.uniprot.org/uniprotkb/Q96NZ9/entry,Lipid-binding protein which promotes lipid absorption by facilitating MTTP-mediated lipid transfer (mainly triglycerides and phospholipids) and MTTP-mediated apoB lipoprotein assembly and secretion (By similarity). Protects the gastrointestinal epithelium from irradiation-induced apoptosis (By similarity). May play an important role in maintaining normal growth homeostasis in epithelial cells (PubMed:14583459). Involved in p53/TP53-dependent cell survival after DNA damage (PubMed:23235459). May down-regulate the expression of MAD1L1 and exert a suppressive role in mitotic spindle assembly checkpoint in hepatocellular carcinomas (PubMed:24374861),"Highly expressed in the intestinal epithelial cells (at protein level) (PubMed:32629119). Abundantly expressed in the epithelial cells of the liver, kidney and cervix. Significantly down-regulated in hepatocellular carcinoma and right colon adenocarcinoma compared with the respective adjacent normal tissues. Expressed in epididymis (at protein level)",,,Secreted Endoplasmic reticulum,14583459|23235459|24374861,14583459|20736409|24374861|32629119,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
PRH1,ENSG00000231887,Unsafe,RNA,False,True,57.4,229.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,esophagus: 10.7 nTPM; absolute ceiling; pituitary gland: 3.8 nTPM; absolute ceiling; salivary gland: 229.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,esophagus: 10.7 nTPM (limit 6); pituitary gland: 3.8 nTPM (limit 2); salivary gland: 229.6 nTPM (limit 6); esophagus: 10.7 nTPM (baseline 6); pituitary gland: 3.8 nTPM (baseline 2); salivary gland: 229.6 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 38/50 (76.0%); Skin Cuteneous Melanoma (TCGA): 2/99 (2.0%); Lung Squamous Cell Carcinoma (validation): 1/68 (1.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,,,,,,,,,,False,No exact Ensembl mapping to a reviewed UniProt entry,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | daSilva2017_tumor_proteomics,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
PRKG2,ENSG00000138669,Unsafe,Protein,False,True,9.6,13.3,80,77,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 1 nTPM; positive ihc; adrenal gland: 0.2 nTPM; positive ihc; bone marrow: 0.5 nTPM; positive ihc; cerebellum: 0.1 nTPM; positive ihc; cerebral cortex: 2 nTPM; positive ihc; colon: 2.4 nTPM; positive ihc; duodenum: 9.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 2.8 nTPM; positive ihc; heart muscle: 4.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; kidney: 0.4 nTPM; positive ihc; liver: 0.1 nTPM; positive ihc; lung: 3.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 0.2 nTPM; positive ihc; pancreas: 1.3 nTPM; positive ihc; parathyroid gland: 0 nTPM; positive ihc; pituitary gland: 2.1 nTPM; absolute ceiling; rectum: 2.9 nTPM; positive ihc; salivary gland: 0.3 nTPM; positive ihc; skeletal muscle: 0 nTPM; positive ihc; skin: 1.1 nTPM; positive ihc; small intestine: 13.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 0.5 nTPM; positive ihc; spleen: 0 nTPM; positive ihc; stomach: 0.9 nTPM; positive ihc; thyroid gland: 0.9 nTPM; positive ihc; urinary bladder: 0.5 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",duodenum: 9.8 nTPM (limit 2); heart muscle: 4.3 nTPM (limit 2); lung: 3.4 nTPM (limit 2); pituitary gland: 2.1 nTPM (limit 2); small intestine: 13.3 nTPM (limit 2),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / glial cells: Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: High (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Skin Cuteneous Melanoma (TCGA): 38/99 (38.4%); Glioblastoma Multiforme (validation): 15/58 (25.9%); Prostate Adenocarcinoma (TCGA): 87/480 (18.1%),liver cancer: 12/12 (100.0%); pancreatic cancer: 10/10 (100.0%),31,20,Q13237,https://www.uniprot.org/uniprotkb/Q13237/entry,"Crucial regulator of intestinal secretion and bone growth. Phosphorylates and activates CFTR on the plasma membrane. Plays a key role in intestinal secretion by regulating cGMP-dependent translocation of CFTR in jejunum (PubMed:33106379). Acts downstream of NMDAR to activate the plasma membrane accumulation of GRIA1/GLUR1 in synapse and increase synaptic plasticity. Phosphorylates GRIA1/GLUR1 at Ser-863 (By similarity). Acts as a regulator of gene expression and activator of the extracellular signal-regulated kinases MAPK3/ERK1 and MAPK1/ERK2 in mechanically stimulated osteoblasts. Under fluid shear stress, mediates ERK activation and subsequent induction of FOS, FOSL1/FRA1, FOSL2/FRA2 and FOSB that play a key role in the osteoblast anabolic response to mechanical stimulation (By similarity)","Highly concentrated in brain, lung and intestinal mucosa","Spondylometaphyseal dysplasia, Pagnamenta type: A form of spondylometaphyseal dysplasia, a group of short stature disorders distinguished by abnormalities in the vertebrae and the metaphyses of the tubular bones. SMDP is an autosomal recessive form characterized by short stature and mild platyspondyly with no disproportion between the limbs. Mild metaphyseal changes are present. Acromesomelic dysplasia 4: A form of acromesomelic dysplasia, a skeletal disorder characterized by short stature, very short limbs and hand/foot malformations. The severity of limb abnormalities increases from proximal to distal with profoundly affected hands and feet showing brachydactyly and/or rudimentary fingers (knob-like fingers). AMD4 radiographic hallmarks include mild to moderate platyspondyly, moderate brachydactyly, iliac flaring, and metaphyseal alterations of the long bones that progressively increase with age. AMD4 inheritance is autosomal recessive.",,Apical cell membrane,33106379,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
PRM1,ENSG00000175646,Unsafe,High RNA,False,True,13722.9,13722.9,88,1,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,CTA,Pass,oncoref.target-sets.2026-10-23.1,False,False,,CTA → Unsafe,True,True,True,2.17032529228,1360.2,"hpa_single_cell: /Endothelial cells, max 43.3 nTPM, 1 observations >30; hpa_single_cell: /Macrophages, max 71.6 nTPM, 1 observations >30; hpa_single_cell_tissue: testis/macrophages, max 1360.2 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,2.17 TPM; blood/TREG_MEM; dice_treg_mem; vital,1360 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 19/133 (14.3%); Glioblastoma Multiforme (TCGA): 1/141 (0.7%); Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%),colorectal cancer: 4/12 (33.3%); skin cancer: 2/12 (16.7%),31,20,P04553,https://www.uniprot.org/uniprotkb/P04553/entry,"Protamines substitute for histones in the chromatin of sperm during the haploid phase of spermatogenesis. They compact sperm DNA into a highly condensed, stable and inactive complex",Testis,,,Nucleus Chromosome,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Chang2019_TGCT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
PRM2,ENSG00000122304,Unsafe,High RNA,False,True,11371.6,11371.6,87,1,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,CTA,Pass,oncoref.target-sets.2026-10-23.1,False,False,,CTA → Unsafe,True,True,True,1.0520064018000002,1073.7,"hpa_single_cell: /Endothelial cells, max 46.5 nTPM, 1 observations >30; hpa_single_cell: /Macrophages, max 56.5 nTPM, 1 observations >30; hpa_single_cell_tissue: testis/macrophages, max 1073.7 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,1.052 TPM; blood/TH17; dice_th17; vital,1074 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 19/133 (14.3%); Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),breast cancer: 0/12 (0.0%); cervical cancer: 0/12 (0.0%),31,20,P04554,https://www.uniprot.org/uniprotkb/P04554/entry,"Protamines substitute for histones in the chromatin of sperm during the haploid phase of spermatogenesis. They compact sperm DNA into a highly condensed, stable and inactive complex",Testis,,,Nucleus Chromosome,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
PRM3,ENSG00000178257,Unsafe,RNA,False,True,86.4,86.4,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,bone marrow: 2.6 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 2.6 nTPM (limit 2); bone marrow: 2.6 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Kidney Renal Papillary Cell Carcinoma (TCGA): 1/282 (0.4%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9NNZ6,https://www.uniprot.org/uniprotkb/Q9NNZ6/entry,"Protamines substitute for histones in the chromatin of sperm during the haploid phase of spermatogenesis. They compact sperm DNA into a highly condensed, stable and inactive complex (By similarity)",,,,Nucleus Chromosome,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Chang2019_TGCT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
PRND,ENSG00000171864,Unsafe,RNA,False,True,68.8,68.8,80,1,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,choroid plexus: 39.4 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 39.4 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 35/133 (26.3%); Breast Invasive Carcinoma (validation): 11/50 (22.0%); Kidney Renal Clear Cell Carcinoma (TCGA): 60/521 (11.5%),breast cancer: 0/11 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q9UKY0,https://www.uniprot.org/uniprotkb/Q9UKY0/entry,"Required for normal acrosome reaction and for normal male fertility (By similarity). Can bind Cu(2+) (PubMed:15218028, PubMed:20411530)","Expressed in testis, in Sertoli cells, ejaculated spermatozoa and in seminal fluid (at protein level)",,,Cell membrane,15218028|20411530,12200435,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
PROCA1,ENSG00000167525,Unsafe,RNA,False,True,172.5,172.5,83,1,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,amygdala: 4 nTPM; absolute ceiling; basal ganglia: 5.1 nTPM; absolute ceiling; cerebellum: 7.2 nTPM; absolute ceiling; cerebral cortex: 4.6 nTPM; absolute ceiling; choroid plexus: 4.8 nTPM; absolute ceiling; hippocampal formation: 4 nTPM; absolute ceiling; hypothalamus: 4.9 nTPM; absolute ceiling; kidney: 8 nTPM; absolute ceiling; midbrain: 4.3 nTPM; absolute ceiling; pituitary gland: 2.9 nTPM; absolute ceiling; spinal cord: 3.9 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 4 nTPM (limit 2); basal ganglia: 5.1 nTPM (limit 2); cerebellum: 7.2 nTPM (limit 4); cerebral cortex: 4.6 nTPM (limit 4); choroid plexus: 4.8 nTPM (limit 2); hippocampal formation: 4 nTPM (limit 2); hypothalamus: 4.9 nTPM (limit 2); kidney: 8 nTPM (limit 4); midbrain: 4.3 nTPM (limit 2); pituitary gland: 2.9 nTPM (limit 2); spinal cord: 3.9 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 41/50 (82.0%); Testicular Germ Cell Tumor (TCGA): 93/133 (69.9%); Kidney Renal Papillary Cell Carcinoma (TCGA): 80/282 (28.4%),liver cancer: 1/12 (8.3%); renal cancer: 1/12 (8.3%),31,20,Q8NCQ7,https://www.uniprot.org/uniprotkb/Q8NCQ7/entry,,High expressed in testis,,"Was originally thought to interact with CCNA1 and found in a complex with CCNA1 and CDK2 (PubMed:15159402). However the amino acid sequence described in this paper contains several frameshifts and a wrong choice of frame, so results from this paper need to be validated",,,15159402,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
PROK2,ENSG00000163421,Unsafe,RNA,False,True,11.1,63.7,79,0,Negative where measured,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 7 nTPM; continuous selectivity; bone marrow: 63.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; liver: 2.4 nTPM; absolute ceiling; lung: 12.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 21.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; tongue: 4.1 nTPM; continuous selectivity; urinary bladder: 5.8 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 63.7 nTPM (limit 4); lung: 12.7 nTPM (limit 4); spleen: 21.9 nTPM (limit 20); bone marrow: 63.7 nTPM (baseline 2); liver: 2.4 nTPM (baseline 2); lung: 12.7 nTPM (baseline 2); spleen: 21.9 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 91/486 (18.7%); Rectum Adenocarcinoma (validation): 32/207 (15.5%); Ovary Serous Cystadenocarcinoma (TCGA): 35/349 (10.0%),breast cancer: 0/12 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q9HC23,https://www.uniprot.org/uniprotkb/Q9HC23/entry,May function as an output molecule from the suprachiasmatic nucleus (SCN) that transmits behavioral circadian rhythm. May also function locally within the SCN to synchronize output. Potently contracts gastrointestinal (GI) smooth muscle,"Expressed in the testis and, at low levels, in the small intestine","Hypogonadotropic hypogonadism 4 with or without anosmia: A disorder characterized by absent or incomplete sexual maturation by the age of 18 years, in conjunction with low levels of circulating gonadotropins and testosterone and no other abnormalities of the hypothalamic-pituitary axis. In some cases, it is associated with non-reproductive phenotypes, such as anosmia, cleft palate, and sensorineural hearing loss. Anosmia or hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts. Hypogonadism is due to deficiency in gonadotropin-releasing hormone and probably results from a failure of embryonic migration of gonadotropin-releasing hormone-synthesizing neurons. In the presence of anosmia, idiopathic hypogonadotropic hypogonadism is referred to as Kallmann syndrome, whereas in the presence of a normal sense of smell, it has been termed normosmic idiopathic hypogonadotropic hypogonadism (nIHH).",,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
PRORP,ENSG00000100890,Unsafe,Protein,False,True,16.4,30.2,92,81,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 10.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 16.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 11.4 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 12.7 nTPM; absolute ceiling;continuous selectivity; bone marrow: 12 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 7.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 11.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 22.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 19.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 14.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 18.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 13.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 10.4 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 10.3 nTPM; absolute ceiling;continuous selectivity; kidney: 24 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 24.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 12.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 20.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 13.3 nTPM; absolute ceiling;continuous selectivity; pancreas: 10.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 18.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 9.4 nTPM; absolute ceiling;continuous selectivity; rectum: 20.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; retina: 6 nTPM; absolute ceiling;continuous selectivity; salivary gland: 12.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 14.6 nTPM; absolute ceiling;continuous selectivity; skin: 16.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 14.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 11.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 15 nTPM; absolute ceiling;continuous selectivity; spleen: 13.2 nTPM; continuous selectivity; stomach: 13.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 30.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 15.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 16.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 14.8 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 10.9 nTPM (limit 10); adrenal gland: 16.5 nTPM (limit 2); amygdala: 11.4 nTPM (limit 2); basal ganglia: 12.7 nTPM (limit 2); bone marrow: 12 nTPM (limit 2); cerebellum: 7.3 nTPM (limit 2); cerebral cortex: 11.1 nTPM (limit 2); choroid plexus: 22.8 nTPM (limit 2); colon: 19.3 nTPM (limit 6); duodenum: 14.9 nTPM (limit 2); esophagus: 18.6 nTPM (limit 6); heart muscle: 13.3 nTPM (limit 2); hippocampal formation: 10.4 nTPM (limit 2); hypothalamus: 10.3 nTPM (limit 2); kidney: 24 nTPM (limit 2); liver: 24.1 nTPM (limit 2); lung: 12.1 nTPM (limit 2); lymph node: 20.7 nTPM (limit 6); midbrain: 13.3 nTPM (limit 2); pancreas: 10.3 nTPM (limit 2); parathyroid gland: 18.6 nTPM (limit 6); pituitary gland: 9.4 nTPM (limit 2); rectum: 20.1 nTPM (limit 6); retina: 6 nTPM (limit 2); salivary gland: 12.7 nTPM (limit 6); skeletal muscle: 14.6 nTPM (limit 4); skin: 16.8 nTPM (limit 10); small intestine: 14.1 nTPM (limit 2); smooth muscle: 11.4 nTPM (limit 2); spinal cord: 15 nTPM (limit 2); stomach: 13.3 nTPM (limit 6); thymus: 30.2 nTPM (limit 10); thyroid gland: 15.1 nTPM (limit 10); tongue: 16.5 nTPM (limit 6); urinary bladder: 14.8 nTPM (limit 6),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / basal cells: High (Approved); bronchus / ciliated cells (cell body): High (Approved); bronchus / ciliated cells (tip of cilia): Medium (Approved); bronchus / goblet cells: Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: High (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: High (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: High (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / basal cells: Medium (Approved); nasopharynx / ciliated cells (cell body): High (Approved); nasopharynx / ciliated cells (tip of cilia): Medium (Approved); nasopharynx / goblet cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: High (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Low (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: High (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Lung Squamous Cell Carcinoma (TCGA): 489/489 (100.0%); Stomach Adenocarcinoma (TCGA): 346/346 (100.0%),colorectal cancer: 12/12 (100.0%); ovarian cancer: 12/12 (100.0%),29,20,O15091,https://www.uniprot.org/uniprotkb/O15091/entry,"Catalytic ribonuclease component of mitochondrial ribonuclease P, a complex composed of TRMT10C/MRPP1, HSD17B10/MRPP2 and PRORP/MRPP3, which cleaves tRNA molecules in their 5'-ends (PubMed:18984158, PubMed:25953853, PubMed:34715011). The presence of TRMT10C/MRPP1, HSD17B10/MRPP2 is required to catalyze tRNA molecules in their 5'-ends (PubMed:25953853)",,"Combined oxidative phosphorylation deficiency 54: An autosomal recessive, multisystem disorder with highly variable manifestations resulting from defective mitochondrial transcription and translation. Clinical features include early-onset sensorineural hearing loss, sometimes associated with global developmental delay or primary ovarian failure, peripheral hypertonia, seizures, muscle weakness, behavioral abnormalities, and leukoencephalopathy on brain imaging. Serum lactate may or may not be elevated.",,Mitochondrion,18984158|25953853|34715011,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
PRPH2,ENSG00000112619,Unsafe,Protein,False,True,3.5,621.9,87,1,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; amygdala: 1.3 nTPM; continuous selectivity; basal ganglia: 1 nTPM; continuous selectivity; cerebral cortex: 3.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 2.2 nTPM; continuous selectivity; heart muscle: 1.5 nTPM; continuous selectivity; hippocampal formation: 1.1 nTPM; continuous selectivity; hypothalamus: 2.3 nTPM; absolute ceiling;continuous selectivity; kidney: 1.3 nTPM; continuous selectivity; lung: 1.4 nTPM; continuous selectivity; midbrain: 1 nTPM; continuous selectivity; pancreas: 2.2 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 4.1 nTPM; continuous selectivity;reproductive not higher; pituitary gland: 2.4 nTPM; absolute ceiling;continuous selectivity; retina: 621.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 12.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 1.4 nTPM; continuous selectivity; smooth muscle: 1.8 nTPM; continuous selectivity; thyroid gland: 4 nTPM; continuous selectivity;reproductive not higher; tongue: 2.8 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",hypothalamus: 2.3 nTPM (limit 2); pituitary gland: 2.4 nTPM (limit 2); retina: 621.9 nTPM (limit 2); skeletal muscle: 12.8 nTPM (limit 12); cerebral cortex: 3.7 nTPM (baseline 2); hypothalamus: 2.3 nTPM (baseline 2); pancreas: 2.2 nTPM (baseline 2); pituitary gland: 2.4 nTPM (baseline 2); retina: 621.9 nTPM (baseline 2); skeletal muscle: 12.8 nTPM (baseline 2),retina / photoreceptor cells: High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 9/50 (18.0%); Kidney Chromophobe (TCGA): 3/64 (4.7%); Thyroid Carcinoma (TCGA): 21/495 (4.2%),breast cancer: 0/11 (0.0%); cervical cancer: 0/11 (0.0%),31,20,P23942,https://www.uniprot.org/uniprotkb/P23942/entry,"Essential for retina photoreceptor outer segment disk morphogenesis, may also play a role with ROM1 in the maintenance of outer segment disk structure (By similarity). Required for the maintenance of retinal outer nuclear layer thickness (By similarity). Required for the correct development and organization of the photoreceptor inner segment (By similarity)",Retina (photoreceptor). In rim region of ROS (rod outer segment) disks,"Retinitis pigmentosa 7: A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. Retinitis punctata albescens: A form of fleck retina disease characterized by aggregation of white flecks posteriorly in the retina, causing night blindness and delayed dark adaptation. It differs from fundus albipunctatus in being progressive and evolving to generalized atrophy of the retina. Macular dystrophy, vitelliform, 3: A form of vitelliform macular dystrophy, a retinal disease characterized by yellow, lipofuscin-containing deposits, usually localized at the center of the macula. Patients usually become symptomatic in the fourth or fifth decade of life with a protracted disease of decreased visual acuity. Macular dystrophy, patterned, 1: A form of retinal patterned dystrophy, a heterogeneous group of macular disorders that includes reticular (fishnet-like) dystrophy, macroreticular (spider-shaped) dystrophy and butterfly-shaped pigment dystrophy. Choroidal dystrophy, central areolar 2: A form of central areolar choroidal dystrophy, a retinal disease that affects the macula and results in a well-demarcated circumscribed area of atrophy of the pigment epithelium and choriocapillaris.",,"Membrane Cell projection, cilium, photoreceptor outer segment Photoreceptor inner segment",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
PRR11,ENSG00000068489,Unsafe,RNA,False,True,4.1,20.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 17.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 1.8 nTPM; continuous selectivity; colon: 4.5 nTPM; continuous selectivity;reproductive not higher; duodenum: 6.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 3.6 nTPM; continuous selectivity; liver: 1.3 nTPM; continuous selectivity; lung: 2.2 nTPM; absolute ceiling;continuous selectivity; lymph node: 10 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 5.3 nTPM; continuous selectivity;reproductive not higher; retina: 1.6 nTPM; continuous selectivity; skin: 3 nTPM; continuous selectivity; small intestine: 4.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 3.5 nTPM; absolute ceiling;continuous selectivity; spleen: 3.1 nTPM; continuous selectivity; stomach: 2.2 nTPM; continuous selectivity; thymus: 20 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 2 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 17.8 nTPM (limit 2); duodenum: 6.3 nTPM (limit 2); lung: 2.2 nTPM (limit 2); lymph node: 10 nTPM (limit 6); small intestine: 4.8 nTPM (limit 2); smooth muscle: 3.5 nTPM (limit 2); thymus: 20 nTPM (limit 10); bone marrow: 17.8 nTPM (baseline 2); duodenum: 6.3 nTPM (baseline 2); lung: 2.2 nTPM (baseline 2); lymph node: 10 nTPM (baseline 6); small intestine: 4.8 nTPM (baseline 2); smooth muscle: 3.5 nTPM (baseline 2); thymus: 20 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Rectum Adenocarcinoma (validation): 204/207 (98.6%),cervical cancer: 12/12 (100.0%); skin cancer: 11/11 (100.0%),31,20,Q96HE9,https://www.uniprot.org/uniprotkb/Q96HE9/entry,Plays a critical role in cell cycle progression,Ubiquitously expressed,,,Cytoplasm Nucleus,23246489,23246489,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
PRR19,ENSG00000188368,Unsafe,RNA,False,True,21.0,21.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 2.1 nTPM; absolute ceiling; basal ganglia: 4.1 nTPM; absolute ceiling; bone marrow: 2.2 nTPM; absolute ceiling; cerebellum: 2.2 nTPM; absolute ceiling; cerebral cortex: 2.3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 2.1 nTPM (limit 2); basal ganglia: 4.1 nTPM (limit 2); bone marrow: 2.2 nTPM (limit 2); cerebellum: 2.2 nTPM (limit 2); cerebral cortex: 2.3 nTPM (limit 2); amygdala: 2.1 nTPM (baseline 2); basal ganglia: 4.1 nTPM (baseline 2); bone marrow: 2.2 nTPM (baseline 2); cerebellum: 2.2 nTPM (baseline 2); cerebral cortex: 2.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 42/50 (84.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 129/176 (73.3%); Testicular Germ Cell Tumor (TCGA): 83/133 (62.4%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,A6NJB7,https://www.uniprot.org/uniprotkb/A6NJB7/entry,Promotes meiotic crossing over formation through its interaction with CNTD1 by participating in the crossover differentiation step of crossover-specific recombination intermediates,,,,Nucleus Chromosome,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
PRR22,ENSG00000212123,Unsafe,RNA,False,True,48.7,48.7,83,1,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,amygdala: 3.1 nTPM; absolute ceiling; basal ganglia: 4.2 nTPM; absolute ceiling; hippocampal formation: 3.5 nTPM; absolute ceiling; hypothalamus: 2.7 nTPM; absolute ceiling; midbrain: 2.5 nTPM; absolute ceiling; pancreas: 6.1 nTPM; absolute ceiling; pituitary gland: 3.7 nTPM; absolute ceiling; spinal cord: 2.8 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 3.1 nTPM (limit 2); basal ganglia: 4.2 nTPM (limit 2); hippocampal formation: 3.5 nTPM (limit 2); hypothalamus: 2.7 nTPM (limit 2); midbrain: 2.5 nTPM (limit 2); pancreas: 6.1 nTPM (limit 2); pituitary gland: 3.7 nTPM (limit 2); spinal cord: 2.8 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 43/50 (86.0%); Testicular Germ Cell Tumor (TCGA): 108/133 (81.2%); Uterine Corpus Endometrial Carcinoma (TCGA): 78/176 (44.3%),glioma: 1/11 (9.1%); breast cancer: 0/9 (0.0%),31,20,Q8IZ63,https://www.uniprot.org/uniprotkb/Q8IZ63/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT,Cancer-associated RNA nomination; no antigen validation asserted,,,,,,,,
PRR27,ENSG00000187533,Unsafe,Protein,False,True,0.5,1071.7,79,1,Positive somewhere,True,True,False,False,Excluded,Normal,False,,Not assessed,,,positive normal IHC; positive ihc outside permitted; pancreas: 1.1 nTPM; continuous selectivity;reproductive not higher; salivary gland: 1071.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",salivary gland: 1071.7 nTPM (limit 6); salivary gland: 1071.7 nTPM (baseline 6),salivary gland / glandular cells: High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 3/176 (1.7%); Lung Squamous Cell Carcinoma (validation): 1/68 (1.5%); Breast Invasive Carcinoma (TCGA): 13/1022 (1.3%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),29,20,Q6MZM9,https://www.uniprot.org/uniprotkb/Q6MZM9/entry,,,,,Secreted,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT,Cancer-associated RNA nomination; no antigen validation asserted,,,,,,,,
PRSS21,ENSG00000007038,Unsafe,Protein,False,True,82.3,82.3,87,6,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; lung: 2.4 nTPM; positive ihc;absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",lung: 2.4 nTPM (limit 2),lung / macrophages: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Ovary Serous Cystadenocarcinoma (validation): 69/81 (85.2%); Ovary Serous Cystadenocarcinoma (TCGA): 270/349 (77.4%); Lung Squamous Cell Carcinoma (TCGA): 276/489 (56.4%),breast cancer: 1/12 (8.3%); cervical cancer: 0/12 (0.0%),31,20,Q9Y6M0,https://www.uniprot.org/uniprotkb/Q9Y6M0/entry,Could regulate proteolytic events associated with testicular germ cell maturation,"Expressed predominantly in premeiotic testicular germ cells, mostly late pachytene and diplotene spermatocytes",,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
PSEN1,ENSG00000080815,Unsafe,Protein,False,True,32.1,81.0,92,74,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 21.6 nTPM; absolute ceiling;continuous selectivity; adrenal gland: 18.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 25.3 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 29.8 nTPM; absolute ceiling;continuous selectivity; bone marrow: 13.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 14.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 27.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 19 nTPM; absolute ceiling;continuous selectivity; colon: 36 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 38.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 25.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 12.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 35.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 22.9 nTPM; absolute ceiling;continuous selectivity; kidney: 26.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 22 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 24.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 14.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 39.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 15.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 25.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 10.9 nTPM; absolute ceiling;continuous selectivity; rectum: 33.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; retina: 10.9 nTPM; absolute ceiling;continuous selectivity; salivary gland: 21.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 17.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 33 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 39.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 20.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 81 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 18.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 23.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 19.2 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 26.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 16.3 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 25 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 21.6 nTPM (limit 20); adrenal gland: 18.4 nTPM (limit 2); amygdala: 25.3 nTPM (limit 2); basal ganglia: 29.8 nTPM (limit 2); bone marrow: 13.5 nTPM (limit 2); cerebellum: 14.5 nTPM (limit 2); cerebral cortex: 27.6 nTPM (limit 2); choroid plexus: 19 nTPM (limit 2); colon: 36 nTPM (limit 6); duodenum: 38.9 nTPM (limit 2); esophagus: 25.6 nTPM (limit 6); heart muscle: 12.4 nTPM (limit 2); hippocampal formation: 35.7 nTPM (limit 2); hypothalamus: 22.9 nTPM (limit 2); kidney: 26.1 nTPM (limit 2); liver: 22 nTPM (limit 2); lung: 24.3 nTPM (limit 2); lymph node: 14.4 nTPM (limit 6); midbrain: 39.5 nTPM (limit 2); pancreas: 15.9 nTPM (limit 2); parathyroid gland: 25.7 nTPM (limit 6); pituitary gland: 10.9 nTPM (limit 2); rectum: 33.2 nTPM (limit 6); retina: 10.9 nTPM (limit 2); salivary gland: 21.3 nTPM (limit 6); skeletal muscle: 17.3 nTPM (limit 2); skin: 33 nTPM (limit 10); small intestine: 39.7 nTPM (limit 2); smooth muscle: 20.4 nTPM (limit 2); spinal cord: 81 nTPM (limit 2); spleen: 18.2 nTPM (limit 10); stomach: 23.1 nTPM (limit 6); thymus: 19.2 nTPM (limit 10); thyroid gland: 26.8 nTPM (limit 10); tongue: 16.3 nTPM (limit 6); urinary bladder: 25 nTPM (limit 6),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: High (Approved); bronchus / basal cells: High (Approved); bronchus / ciliated cells (cell body): High (Approved); bronchus / goblet cells: High (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: High (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: High (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Low (Approved); lung / macrophages: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / basal cells: Low (Approved); nasopharynx / ciliated cells (cell body): Low (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%); Thyroid Carcinoma (TCGA): 495/495 (100.0%),prostate cancer: 10/12 (83.3%); colorectal cancer: 8/12 (66.7%),31,20,P49768,https://www.uniprot.org/uniprotkb/P49768/entry,"Catalytic subunit of the gamma-secretase complex, an endoprotease complex that catalyzes the intramembrane cleavage of integral membrane proteins such as Notch receptors and APP (amyloid-beta precursor protein) (PubMed:10206644, PubMed:10545183, PubMed:10593990, PubMed:10811883, PubMed:10899933, PubMed:12679784, PubMed:12740439, PubMed:15274632, PubMed:20460383, PubMed:25043039, PubMed:26280335, PubMed:28269784, PubMed:30598546, PubMed:30630874). Requires the presence of the other members of the gamma-secretase complex for protease activity (PubMed:15274632, PubMed:25043039, PubMed:26280335, PubMed:30598546, PubMed:30630874). Plays a role in Notch and Wnt signaling cascades and regulation of downstream processes via its role in processing key regulatory proteins, and by regulating cytosolic CTNNB1 levels (PubMed:10593990, PubMed:10811883, PubMed:10899933, PubMed:9738936). Stimulates cell-cell adhesion via its interaction with CDH1; this stabilizes the complexes between CDH1 (E-cadherin) and its interaction partners CTNNB1 (beta-catenin), CTNND1 and JUP (gamma-catenin) (PubMed:11953314). Under conditions of apoptosis or calcium influx, cleaves CDH1 (PubMed:11953314). This promotes the disassembly of the complexes between CDH1 and CTNND1, JUP and CTNNB1, increases the pool of cytoplasmic CTNNB1, and thereby negatively regulates Wnt signaling (PubMed:11953314, PubMed:9738936). Required for normal embryonic brain and skeleton development, and for normal angiogenesis (By similarity). Mediates the proteolytic cleavage of EphB2/CTF1 into EphB2/CTF2 (PubMed:17428795, PubMed:28269784). The holoprotein functions as a calcium-leak channel that allows the passive movement of calcium from endoplasmic reticulum to cytosol and is therefore involved in calcium homeostasis (PubMed:16959576, PubMed:25394380). Involved in the regulation of neurite outgrowth (PubMed:15004326, PubMed:20460383). Is a regulator of presynaptic facilitation, spike transmission and synaptic vesicles replenishment in a process that depends on gamma-secretase activity. It acts through the control of SYT7 presynaptic expression (By similarity)","Detected in azurophile granules in neutrophils and in platelet cytoplasmic granules (at protein level) (PubMed:11987239). Expressed in a wide range of tissues including various regions of the brain, liver, spleen and lymph nodes (PubMed:7596406, PubMed:8574969, PubMed:8641442)","Alzheimer disease 3: A familial early-onset form of Alzheimer disease. Alzheimer disease is a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituents of these plaques are neurotoxic amyloid-beta protein 40 and amyloid-beta protein 42, that are produced by the proteolysis of the transmembrane APP protein. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products, such as C31, are also implicated in neuronal death. Frontotemporal dementia 1: A form of dementia characterized by pathologic finding of frontotemporal lobar degeneration, presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. In some cases, parkinsonian symptoms are prominent. Neuropathological changes include frontotemporal atrophy often associated with atrophy of the basal ganglia, substantia nigra, amygdala. In most cases, protein tau deposits are found in glial cells and/or neurons. Cardiomyopathy, dilated, 1U: A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. Acne inversa, familial, 3: A chronic relapsing inflammatory disease of the hair follicles characterized by recurrent draining sinuses, painful skin abscesses, and disfiguring scars. Manifestations typically appear after puberty. Pick disease of the brain: A rare form of dementia pathologically defined by severe atrophy, neuronal loss and gliosis. It is characterized by the occurrence of tau-positive inclusions, swollen neurons (Pick cells) and argentophilic neuronal inclusions known as Pick bodies that disproportionally affect the frontal and temporal cortical regions. Clinical features include aphasia, apraxia, confusion, anomia, memory loss and personality deterioration.",,"Endoplasmic reticulum Endoplasmic reticulum membrane Golgi apparatus membrane Cytoplasmic granule Cell membrane Cell projection, growth cone Early endosome Early endosome membrane Cell projection, neuron projection Cell projection, axon Synapse",10206644|10545183|10593990|10811883|10899933|11953314|12679784|12740439|15004326|15274632|15341515|16305624|16959576|17428795|20460383|25043039|25394380|26280335|28269784|30598546|30630874|9738936,11987239|7596406|8574969|8641442,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
PSG4,ENSG00000243137,Unsafe,RNA,False,True,139.5,139.5,85,3,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,parathyroid gland: 53.8 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,parathyroid gland: 53.8 nTPM (limit 12),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Chromophobe (TCGA): 26/64 (40.6%); Bladder Urothelial Carcinoma (TCGA): 17/169 (10.1%); Head and Neck Squamous Cell Carcinoma (TCGA): 37/492 (7.5%),liver cancer: 1/11 (9.1%); melanoma: 1/12 (8.3%),31,20,Q00888,https://www.uniprot.org/uniprotkb/Q00888/entry,,,,,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Gong2021_reproductive_PC,No tumor-antigen validation in this source | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
PSG5,ENSG00000204941,Unsafe,High RNA,False,True,108.6,108.6,85,3,Positive somewhere,False,False,False,True,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,CTA,Pass,oncoref.target-sets.2026-10-23.1,False,False,,CTA → Unsafe,True,True,True,0.7,31.6,"hpa_single_cell_tissue: placenta/mixed immune cells, max 31.6 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,0.7 TPM; blood/NK-cell; hpa_immune_monaco; vital,31.6 nTPM; placenta/mixed immune cells; hpa_single_cell_tissue; vital,Kidney Chromophobe (TCGA): 30/64 (46.9%); Lung Squamous Cell Carcinoma (validation): 5/68 (7.4%); Bladder Urothelial Carcinoma (TCGA): 9/169 (5.3%),liver cancer: 1/11 (9.1%); melanoma: 1/12 (8.3%),31,20,Q15238,https://www.uniprot.org/uniprotkb/Q15238/entry,,Synthesized by syncytiotrophoblast of the placenta,,,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Gong2021_reproductive_PC,No tumor-antigen validation in this source | Normal reproductive-tissue enrichment; no tumor validation,,,,All audited maxima are within 10% above 30; other gates still require review,,,,
PSKH2,ENSG00000147613,Unsafe,Protein,False,True,0.1,2.4,81,15,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; cerebral cortex: 0 nTPM; positive ihc; colon: 0 nTPM; positive ihc; kidney: 0.2 nTPM; positive ihc;continuous selectivity;reproductive not higher; lung: 0 nTPM; positive ihc; retina: 2.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 0 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",retina: 2.4 nTPM (limit 2),cerebral cortex / endothelial cells: Medium (Approved); colon / endothelial cells: Medium (Approved); kidney / cells in glomeruli: Medium (Approved); lung / macrophages: High (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 2 / epidermal cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 13/133 (9.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 1/283 (0.4%),melanoma: 3/10 (30.0%); endometrial cancer: 2/12 (16.7%),31,20,Q96QS6,https://www.uniprot.org/uniprotkb/Q96QS6/entry,,,,Asn-183 is present instead of the conserved Asp which is expected to be an active site residue,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
PSMA2,ENSG00000106588,Unsafe,Protein,False,True,96.6,308.9,77,62,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 97.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; adrenal gland: 109.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 63.8 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 66 nTPM; absolute ceiling;continuous selectivity; bone marrow: 118.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 50.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 56.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 104.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 87.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 101 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 106.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 115.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 58.6 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 59.8 nTPM; absolute ceiling;continuous selectivity; kidney: 113.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 308.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 83.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 98.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 72.1 nTPM; absolute ceiling;continuous selectivity; pancreas: 88.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 67.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 62.1 nTPM; absolute ceiling;continuous selectivity; rectum: 83.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 40.4 nTPM; absolute ceiling;continuous selectivity; salivary gland: 73.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 219.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 84.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 93.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 64.5 nTPM; absolute ceiling;continuous selectivity; spinal cord: 78.8 nTPM; absolute ceiling;continuous selectivity; spleen: 91.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 101.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; thymus: 133.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 65.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 115.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 88.9 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 97.5 nTPM (limit 10); adrenal gland: 109.9 nTPM (limit 2); amygdala: 63.8 nTPM (limit 2); basal ganglia: 66 nTPM (limit 2); bone marrow: 118.5 nTPM (limit 2); cerebellum: 50.8 nTPM (limit 2); cerebral cortex: 56.6 nTPM (limit 2); choroid plexus: 104.6 nTPM (limit 2); colon: 87.8 nTPM (limit 6); duodenum: 101 nTPM (limit 2); esophagus: 106.9 nTPM (limit 6); heart muscle: 115.4 nTPM (limit 2); hippocampal formation: 58.6 nTPM (limit 2); hypothalamus: 59.8 nTPM (limit 2); kidney: 113.7 nTPM (limit 2); liver: 308.9 nTPM (limit 2); lung: 83.3 nTPM (limit 2); lymph node: 98.8 nTPM (limit 6); midbrain: 72.1 nTPM (limit 2); pancreas: 88.3 nTPM (limit 2); parathyroid gland: 67.9 nTPM (limit 6); pituitary gland: 62.1 nTPM (limit 2); rectum: 83.7 nTPM (limit 6); retina: 40.4 nTPM (limit 2); salivary gland: 73.7 nTPM (limit 6); skeletal muscle: 219.5 nTPM (limit 2); skin: 84.2 nTPM (limit 10); small intestine: 93.9 nTPM (limit 2); smooth muscle: 64.5 nTPM (limit 2); spinal cord: 78.8 nTPM (limit 2); spleen: 91.9 nTPM (limit 10); stomach: 101.7 nTPM (limit 6); thymus: 133.5 nTPM (limit 10); thyroid gland: 65.4 nTPM (limit 10); tongue: 115.4 nTPM (limit 6); urinary bladder: 88.9 nTPM (limit 6); adipose tissue: 97.5 nTPM (baseline 10); adrenal gland: 109.9 nTPM (baseline 2); amygdala: 63.8 nTPM (baseline 2); basal ganglia: 66 nTPM (baseline 2); bone marrow: 118.5 nTPM (baseline 2); cerebellum: 50.8 nTPM (baseline 2); cerebral cortex: 56.6 nTPM (baseline 2); choroid plexus: 104.6 nTPM (baseline 2); colon: 87.8 nTPM (baseline 6); duodenum: 101 nTPM (baseline 2); esophagus: 106.9 nTPM (baseline 6); heart muscle: 115.4 nTPM (baseline 2); hippocampal formation: 58.6 nTPM (baseline 2); hypothalamus: 59.8 nTPM (baseline 2); kidney: 113.7 nTPM (baseline 2); liver: 308.9 nTPM (baseline 2); lung: 83.3 nTPM (baseline 2); lymph node: 98.8 nTPM (baseline 6); midbrain: 72.1 nTPM (baseline 2); pancreas: 88.3 nTPM (baseline 2); parathyroid gland: 67.9 nTPM (baseline 6); pituitary gland: 62.1 nTPM (baseline 2); rectum: 83.7 nTPM (baseline 6); retina: 40.4 nTPM (baseline 2); salivary gland: 73.7 nTPM (baseline 6); skeletal muscle: 219.5 nTPM (baseline 2); skin: 84.2 nTPM (baseline 10); small intestine: 93.9 nTPM (baseline 2); smooth muscle: 64.5 nTPM (baseline 2); spinal cord: 78.8 nTPM (baseline 2); spleen: 91.9 nTPM (baseline 10); stomach: 101.7 nTPM (baseline 6); thymus: 133.5 nTPM (baseline 10); thyroid gland: 65.4 nTPM (baseline 10); tongue: 115.4 nTPM (baseline 6); urinary bladder: 88.9 nTPM (baseline 6),adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Low (Uncertain); bronchus / respiratory epithelial cells: Low (Uncertain); caudate / glial cells: Low (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: Low (Uncertain); cerebellum / cells in molecular layer: Medium (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / neuronal cells: Low (Uncertain); colon / endothelial cells: Low (Uncertain); colon / glandular cells: Low (Uncertain); colon / peripheral nerve/ganglion: Low (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Low (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in glomeruli: Low (Uncertain); kidney / cells in tubules: Low (Uncertain); liver / cholangiocytes: Medium (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / alveolar cells: Low (Uncertain); lung / macrophages: Low (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Low (Uncertain); parathyroid gland / glandular cells: Low (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Low (Uncertain); skin 1 / keratinocytes: Low (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: Medium (Uncertain); spleen / cells in red pulp: Medium (Uncertain); spleen / cells in white pulp: Low (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Low (Uncertain); thyroid gland / glandular cells: Low (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Kidney Renal Clear Cell Carcinoma (TCGA): 521/521 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%),prostate cancer: 9/11 (81.8%); renal cancer: 9/12 (75.0%),31,20,P25787,https://www.uniprot.org/uniprotkb/P25787/entry,"Component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. This complex plays numerous essential roles within the cell by associating with different regulatory particles. Associated with two 19S regulatory particles, forms the 26S proteasome and thus participates in the ATP-dependent degradation of ubiquitinated proteins. The 26S proteasome plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins that could impair cellular functions, and by removing proteins whose functions are no longer required. Associated with the PA200 or PA28, the 20S proteasome mediates ubiquitin-independent protein degradation. This type of proteolysis is required in several pathways including spermatogenesis (20S-PA200 complex) or generation of a subset of MHC class I-presented antigenic peptides (20S-PA28 complex)",,,,Cytoplasm Nucleus,15244466|27176742|8610016,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
PSMB11,ENSG00000222028,Unsafe,Protein,False,True,0.3,29.8,78,1,Positive somewhere,True,True,False,False,Excluded,Normal,False,,Not assessed,,,positive ihc outside permitted; thymus: 29.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",thymus: 29.8 nTPM (limit 10); thymus: 29.8 nTPM (baseline 10),thymus / cortical cells: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),breast cancer: 0/10 (0.0%); cervical cancer: 0/11 (0.0%),31,20,A5LHX3,https://www.uniprot.org/uniprotkb/A5LHX3/entry,"The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. Incorporated instead of PSMB5 or PSMB8, this unit reduces the chymotrypsin-like activity of the proteasome (By similarity). Plays a pivotal role in development of CD8-positive T cells (By similarity)",,,,Cytoplasm Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
PSORS1C1,ENSG00000204540,Unsafe,High RNA,False,True,106.8,106.8,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,CTA,Pass,oncoref.target-sets.2026-10-23.1,False,False,,CTA → Unsafe,True,True,True,0.238790654548,44.6,"hpa_single_cell_tissue: colon/distal enterocytes, max 44.6 nTPM, 2 observations >30; hpa_single_cell_tissue: esophagus/endothelial cells, max 32.3 nTPM, 1 observations >30; hpa_single_cell_tissue: placenta/mixed immune cells, max 31.6 nTPM, 1 observations >30; hpa_single_cell_tissue: skin/endothelial cells, max 40.2 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,0.2388 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,44.6 nTPM; colon/distal enterocytes; hpa_single_cell_tissue; protected,Breast Invasive Carcinoma (validation): 32/50 (64.0%); Pancreatic Adenocarcinoma (validation): 31/80 (38.8%); Ovary Serous Cystadenocarcinoma (validation): 31/81 (38.3%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9UIG5,https://www.uniprot.org/uniprotkb/Q9UIG5/entry,,"Expressed in skin. Also found in heart, placenta, liver, skeletal muscle and pancreas",,,,,12930300,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
PSPC1,ENSG00000121390,Unsafe,Protein,False,True,24.3,53.1,87,85,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 10.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 12.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 13.2 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 13.5 nTPM; absolute ceiling;continuous selectivity; bone marrow: 53.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 18.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 19.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 8.1 nTPM; absolute ceiling;continuous selectivity; colon: 14.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 12.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 13.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 10.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 14.3 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 15.1 nTPM; absolute ceiling;continuous selectivity; kidney: 11.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 8.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 9.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 20.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 11 nTPM; absolute ceiling;continuous selectivity; pancreas: 9.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 9.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 10.1 nTPM; absolute ceiling;continuous selectivity; rectum: 15 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 16.9 nTPM; absolute ceiling;continuous selectivity; salivary gland: 9.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 20.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 14 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 12 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 12.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 10.5 nTPM; absolute ceiling;continuous selectivity; spleen: 10.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 11.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 22.5 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 11.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 12.3 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 19.7 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 10.6 nTPM (limit 10); adrenal gland: 12.6 nTPM (limit 2); amygdala: 13.2 nTPM (limit 2); basal ganglia: 13.5 nTPM (limit 2); bone marrow: 53.1 nTPM (limit 2); cerebellum: 18.9 nTPM (limit 2); cerebral cortex: 19.7 nTPM (limit 2); choroid plexus: 8.1 nTPM (limit 2); colon: 14.4 nTPM (limit 6); duodenum: 12.1 nTPM (limit 2); esophagus: 13.6 nTPM (limit 6); heart muscle: 10.7 nTPM (limit 2); hippocampal formation: 14.3 nTPM (limit 2); hypothalamus: 15.1 nTPM (limit 2); kidney: 11.8 nTPM (limit 2); liver: 8.6 nTPM (limit 2); lung: 9.6 nTPM (limit 2); lymph node: 20.3 nTPM (limit 6); midbrain: 11 nTPM (limit 2); pancreas: 9.3 nTPM (limit 2); parathyroid gland: 9.1 nTPM (limit 6); pituitary gland: 10.1 nTPM (limit 2); rectum: 15 nTPM (limit 6); retina: 16.9 nTPM (limit 2); salivary gland: 9.7 nTPM (limit 6); skeletal muscle: 20.2 nTPM (limit 2); skin: 14 nTPM (limit 10); small intestine: 12 nTPM (limit 2); smooth muscle: 12.2 nTPM (limit 2); spinal cord: 10.5 nTPM (limit 2); spleen: 10.9 nTPM (limit 10); stomach: 11.7 nTPM (limit 6); thymus: 22.5 nTPM (limit 10); thyroid gland: 11.9 nTPM (limit 10); tongue: 12.3 nTPM (limit 6); urinary bladder: 19.7 nTPM (limit 6),adipose tissue / adipocytes: Medium (Supported); adrenal gland / glandular cells: Medium (Supported); bone marrow / hematopoietic cells: Medium (Supported); caudate / glial cells: High (Supported); caudate / neuronal cells: High (Supported); cerebellum / cells in granular layer: High (Supported); cerebellum / cells in molecular layer: High (Supported); cerebellum / Purkinje cells: High (Supported); cerebral cortex / endothelial cells: High (Supported); cerebral cortex / glial cells: Medium (Supported); cerebral cortex / neuronal cells: High (Supported); colon / endothelial cells: High (Supported); colon / glandular cells: High (Supported); colon / peripheral nerve/ganglion: High (Supported); duodenum / glandular cells: High (Supported); esophagus / squamous epithelial cells: High (Supported); heart muscle / cardiomyocytes: Low (Supported); hippocampus / glial cells: Low (Supported); hippocampus / neuronal cells: High (Supported); kidney / cells in glomeruli: Low (Supported); kidney / cells in tubules: High (Supported); liver / cholangiocytes: Medium (Supported); liver / hepatocytes: Medium (Supported); lung / alveolar cells type I: High (Supported); lung / alveolar cells type II: High (Supported); lung / endothelial cells: Low (Supported); lung / macrophages: Medium (Supported); lymph node / germinal center cells: Medium (Supported); lymph node / non-germinal center cells: Medium (Supported); nasopharynx / respiratory epithelial cells: High (Supported); oral mucosa / squamous epithelial cells: Medium (Supported); pancreas / exocrine glandular cells: Medium (Supported); pancreas / pancreatic endocrine cells: Medium (Supported); parathyroid gland / glandular cells: Medium (Supported); rectum / glandular cells: High (Supported); salivary gland / glandular cells: High (Supported); skeletal muscle / myocytes: High (Supported); skin 1 / fibroblasts: High (Supported); skin 1 / keratinocytes: Medium (Supported); skin 1 / Langerhans: High (Supported); skin 2 / epidermal cells: Medium (Supported); small intestine / glandular cells: High (Supported); smooth muscle / smooth muscle cells: Medium (Supported); spleen / cells in red pulp: Medium (Supported); spleen / cells in white pulp: Medium (Supported); stomach 1 / glandular cells: High (Supported); stomach 2 / glandular cells: High (Supported); thyroid gland / glandular cells: High (Supported); urinary bladder / urothelial cells: High (Supported),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (TCGA): 254/254 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (TCGA): 141/141 (100.0%),breast cancer: 12/12 (100.0%); colorectal cancer: 12/12 (100.0%),31,20,Q8WXF1,https://www.uniprot.org/uniprotkb/Q8WXF1/entry,"RNA-binding protein required for the formation of nuclear paraspeckles (PubMed:22416126). Binds to poly(A), poly(G) and poly(U) RNA homopolymers (PubMed:22416126). Regulates, cooperatively with NONO and SFPQ, androgen receptor-mediated gene transcription activity in Sertoli cell line (By similarity). Regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-BMAL1 heterodimer (By similarity). Plays a role in the regulation of DNA virus-mediated innate immune response by assembling into the HDP-RNP complex, a complex that serves as a platform for IRF3 phosphorylation and subsequent innate immune response activation through the cGAS-STING pathway (PubMed:28712728)","Expressed in pancreas, kidney, skeletal muscle, liver, lung, placenta, brain and heart",,,"Nucleus speckle Nucleus, nucleolus Nucleus matrix Cytoplasm",22416126|28712728,11790299,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
PSPH,ENSG00000146733,Unsafe,Protein,False,True,15.9,15.9,95,38,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 9.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 10.5 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 12.3 nTPM; absolute ceiling;continuous selectivity; cerebellum: 6.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 10.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 13 nTPM; absolute ceiling;continuous selectivity; colon: 4.8 nTPM; positive ihc; duodenum: 4.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 8.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 7.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 9.6 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 9.4 nTPM; absolute ceiling;continuous selectivity; kidney: 9.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 6.6 nTPM; absolute ceiling;continuous selectivity; lung: 3.4 nTPM; positive ihc;absolute ceiling; midbrain: 9.8 nTPM; absolute ceiling;continuous selectivity; pancreas: 6.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 6.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 9.2 nTPM; absolute ceiling;continuous selectivity; rectum: 4.3 nTPM; positive ihc; retina: 4.2 nTPM; absolute ceiling;continuous selectivity; salivary gland: 4.3 nTPM; positive ihc; skeletal muscle: 4.5 nTPM; absolute ceiling; skin: 4.1 nTPM; positive ihc; small intestine: 4 nTPM; positive ihc;absolute ceiling; smooth muscle: 4.9 nTPM; absolute ceiling; spinal cord: 11.8 nTPM; absolute ceiling;continuous selectivity; stomach: 6 nTPM; positive ihc;continuous selectivity; thyroid gland: 6.8 nTPM; positive ihc; tongue: 6.4 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 5 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 9.2 nTPM (limit 2); amygdala: 10.5 nTPM (limit 2); basal ganglia: 12.3 nTPM (limit 2); cerebellum: 6.8 nTPM (limit 2); cerebral cortex: 10.5 nTPM (limit 2); choroid plexus: 13 nTPM (limit 2); duodenum: 4.2 nTPM (limit 2); esophagus: 8.5 nTPM (limit 6); heart muscle: 7.9 nTPM (limit 2); hippocampal formation: 9.6 nTPM (limit 2); hypothalamus: 9.4 nTPM (limit 2); kidney: 9.7 nTPM (limit 2); liver: 6.6 nTPM (limit 4); lung: 3.4 nTPM (limit 2); midbrain: 9.8 nTPM (limit 2); pancreas: 6.5 nTPM (limit 2); parathyroid gland: 6.6 nTPM (limit 6); pituitary gland: 9.2 nTPM (limit 2); retina: 4.2 nTPM (limit 2); skeletal muscle: 4.5 nTPM (limit 4); small intestine: 4 nTPM (limit 2); smooth muscle: 4.9 nTPM (limit 4); spinal cord: 11.8 nTPM (limit 2); tongue: 6.4 nTPM (limit 6),adrenal gland / glandular cells: Medium (Approved); bronchus / basal cells: Low (Approved); bronchus / ciliated cells (cell body): Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); colon / glandular cells: High (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Low (Approved); kidney / cells in tubules: High (Approved); lung / macrophages: Medium (Approved); nasopharynx / ciliated cells (cell body): Medium (Approved); pancreas / exocrine glandular cells: Low (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: Low (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 141/141 (100.0%); Testicular Germ Cell Tumor (TCGA): 133/133 (100.0%); Kidney Renal Clear Cell Carcinoma (validation): 100/100 (100.0%),colorectal cancer: 12/12 (100.0%); ovarian cancer: 11/12 (91.7%),31,20,P78330,https://www.uniprot.org/uniprotkb/P78330/entry,"Catalyzes the last irreversible step in the biosynthesis of L-serine from carbohydrates, the dephosphorylation of O-phospho-L-serine to L-serine (PubMed:12213811, PubMed:14673469, PubMed:15291819, PubMed:25080166, PubMed:9222972). L-serine can then be used in protein synthesis, to produce other amino acids, in nucleotide metabolism or in glutathione synthesis, or can be racemized to D-serine, a neuromodulator (PubMed:14673469). May also act on O-phospho-D-serine (Probable)",,"Phosphoserine phosphatase deficiency: An autosomal recessive disorder that results in pre- and postnatal growth retardation, moderate psychomotor retardation and facial features suggestive of Williams syndrome.",,"Cytoplasm, cytosol",12213811|14673469|15291819|1965857|25080166|9222972,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
PSTK,ENSG00000179988,Unsafe,Protein,False,True,3.4,6.1,84,74,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0.9 nTPM; positive ihc; adrenal gland: 2.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 2.4 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 2.4 nTPM; absolute ceiling;continuous selectivity; bone marrow: 6.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 1.3 nTPM; positive ihc;continuous selectivity; cerebral cortex: 3 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 1.3 nTPM; continuous selectivity; colon: 1.5 nTPM; positive ihc;continuous selectivity; duodenum: 1.8 nTPM; positive ihc;continuous selectivity; esophagus: 1.5 nTPM; positive ihc;continuous selectivity; heart muscle: 1.6 nTPM; positive ihc;continuous selectivity; hippocampal formation: 2.7 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 2.8 nTPM; absolute ceiling;continuous selectivity; kidney: 1.9 nTPM; positive ihc;continuous selectivity; liver: 4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 1 nTPM; positive ihc;continuous selectivity; lymph node: 0.9 nTPM; positive ihc; midbrain: 2.4 nTPM; absolute ceiling;continuous selectivity; pancreas: 2 nTPM; positive ihc;continuous selectivity; parathyroid gland: 1 nTPM; positive ihc; pituitary gland: 2.6 nTPM; absolute ceiling;continuous selectivity; rectum: 1.4 nTPM; positive ihc;continuous selectivity; salivary gland: 1.9 nTPM; positive ihc;continuous selectivity; skeletal muscle: 3.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 1.6 nTPM; positive ihc;continuous selectivity; small intestine: 1 nTPM; positive ihc;continuous selectivity; smooth muscle: 1.8 nTPM; positive ihc;continuous selectivity; spinal cord: 3.2 nTPM; absolute ceiling;continuous selectivity; spleen: 1.1 nTPM; positive ihc; stomach: 1.3 nTPM; positive ihc;continuous selectivity; thymus: 1.7 nTPM; continuous selectivity; thyroid gland: 2.3 nTPM; positive ihc;continuous selectivity; urinary bladder: 1.3 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 2.2 nTPM (limit 2); amygdala: 2.4 nTPM (limit 2); basal ganglia: 2.4 nTPM (limit 2); bone marrow: 6.1 nTPM (limit 2); cerebral cortex: 3 nTPM (limit 2); hippocampal formation: 2.7 nTPM (limit 2); hypothalamus: 2.8 nTPM (limit 2); liver: 4 nTPM (limit 2); midbrain: 2.4 nTPM (limit 2); pituitary gland: 2.6 nTPM (limit 2); skeletal muscle: 3.3 nTPM (limit 2); spinal cord: 3.2 nTPM (limit 2),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Medium (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 44/50 (88.0%); Ovary Serous Cystadenocarcinoma (validation): 40/81 (49.4%); Testicular Germ Cell Tumor (TCGA): 61/133 (45.9%),ovarian cancer: 12/12 (100.0%); liver cancer: 11/11 (100.0%),31,20,Q8IV42,https://www.uniprot.org/uniprotkb/Q8IV42/entry,"Specifically phosphorylates seryl-tRNA(Sec) to O-phosphoseryl-tRNA(Sec), an activated intermediate for selenocysteine biosynthesis. No activity with other tRNAs has been detected",,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
PTBP2,ENSG00000117569,Unsafe,Protein,False,True,23.0,32.3,81,4,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 14.3 nTPM; absolute ceiling;continuous selectivity; adrenal gland: 7.7 nTPM; absolute ceiling;continuous selectivity; amygdala: 16.9 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 15 nTPM; absolute ceiling;continuous selectivity; bone marrow: 11.4 nTPM; absolute ceiling;continuous selectivity; cerebellum: 19 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 15.9 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 2.3 nTPM; absolute ceiling; colon: 32.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 3.8 nTPM; absolute ceiling; esophagus: 7.7 nTPM; positive ihc;absolute ceiling; heart muscle: 7.6 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 18.9 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 18.6 nTPM; absolute ceiling;continuous selectivity; kidney: 10.4 nTPM; absolute ceiling;continuous selectivity; liver: 7.3 nTPM; absolute ceiling;continuous selectivity; lung: 8.4 nTPM; absolute ceiling;continuous selectivity; midbrain: 18.6 nTPM; absolute ceiling;continuous selectivity; pancreas: 6.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 11.1 nTPM; absolute ceiling;continuous selectivity; rectum: 6.3 nTPM; absolute ceiling; retina: 13.1 nTPM; absolute ceiling;continuous selectivity; salivary gland: 8 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 10.9 nTPM; absolute ceiling;continuous selectivity; small intestine: 12.5 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 12.6 nTPM; absolute ceiling;continuous selectivity; spinal cord: 20.3 nTPM; absolute ceiling;continuous selectivity; spleen: 11.2 nTPM; absolute ceiling;continuous selectivity; stomach: 11.8 nTPM; absolute ceiling;continuous selectivity; thymus: 10.2 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 11.6 nTPM; absolute ceiling;continuous selectivity; tongue: 8.6 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 16.9 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 14.3 nTPM (limit 10); adrenal gland: 7.7 nTPM (limit 2); amygdala: 16.9 nTPM (limit 2); basal ganglia: 15 nTPM (limit 2); bone marrow: 11.4 nTPM (limit 2); cerebellum: 19 nTPM (limit 2); cerebral cortex: 15.9 nTPM (limit 2); choroid plexus: 2.3 nTPM (limit 2); colon: 32.3 nTPM (limit 6); duodenum: 3.8 nTPM (limit 2); esophagus: 7.7 nTPM (limit 6); heart muscle: 7.6 nTPM (limit 2); hippocampal formation: 18.9 nTPM (limit 2); hypothalamus: 18.6 nTPM (limit 2); kidney: 10.4 nTPM (limit 2); liver: 7.3 nTPM (limit 2); lung: 8.4 nTPM (limit 2); midbrain: 18.6 nTPM (limit 2); pancreas: 6.9 nTPM (limit 2); pituitary gland: 11.1 nTPM (limit 2); rectum: 6.3 nTPM (limit 6); retina: 13.1 nTPM (limit 2); salivary gland: 8 nTPM (limit 6); skeletal muscle: 10.9 nTPM (limit 2); small intestine: 12.5 nTPM (limit 2); smooth muscle: 12.6 nTPM (limit 2); spinal cord: 20.3 nTPM (limit 2); spleen: 11.2 nTPM (limit 10); stomach: 11.8 nTPM (limit 6); thymus: 10.2 nTPM (limit 10); thyroid gland: 11.6 nTPM (limit 10); tongue: 8.6 nTPM (limit 6); urinary bladder: 16.9 nTPM (limit 6); adipose tissue: 14.3 nTPM (baseline 10); adrenal gland: 7.7 nTPM (baseline 2); amygdala: 16.9 nTPM (baseline 2); basal ganglia: 15 nTPM (baseline 2); bone marrow: 11.4 nTPM (baseline 2); cerebellum: 19 nTPM (baseline 2); cerebral cortex: 15.9 nTPM (baseline 2); choroid plexus: 2.3 nTPM (baseline 2); colon: 32.3 nTPM (baseline 6); duodenum: 3.8 nTPM (baseline 2); esophagus: 7.7 nTPM (baseline 6); heart muscle: 7.6 nTPM (baseline 2); hippocampal formation: 18.9 nTPM (baseline 2); hypothalamus: 18.6 nTPM (baseline 2); kidney: 10.4 nTPM (baseline 2); liver: 7.3 nTPM (baseline 2); lung: 8.4 nTPM (baseline 2); midbrain: 18.6 nTPM (baseline 2); pancreas: 6.9 nTPM (baseline 2); pituitary gland: 11.1 nTPM (baseline 2); rectum: 6.3 nTPM (baseline 6); retina: 13.1 nTPM (baseline 2); salivary gland: 8 nTPM (baseline 6); skeletal muscle: 10.9 nTPM (baseline 2); small intestine: 12.5 nTPM (baseline 2); smooth muscle: 12.6 nTPM (baseline 2); spinal cord: 20.3 nTPM (baseline 2); spleen: 11.2 nTPM (baseline 10); stomach: 11.8 nTPM (baseline 6); thymus: 10.2 nTPM (baseline 10); thyroid gland: 11.6 nTPM (baseline 10); tongue: 8.6 nTPM (baseline 6); urinary bladder: 16.9 nTPM (baseline 6),esophagus / squamous epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Glioblastoma Multiforme (TCGA): 134/141 (95.0%); Pancreatic Adenocarcinoma (validation): 76/80 (95.0%),renal cancer: 5/12 (41.7%); liver cancer: 1/10 (10.0%),31,20,Q9UKA9,https://www.uniprot.org/uniprotkb/Q9UKA9/entry,"RNA-binding protein which binds to intronic polypyrimidine tracts and mediates negative regulation of exons splicing. May antagonize in a tissue-specific manner the ability of NOVA1 to activate exon selection. In addition to its function in pre-mRNA splicing, plays also a role in the regulation of translation Reduced affinity for RNA",Mainly expressed in brain although also detected in other tissues like heart and skeletal muscle. Isoform 1 and isoform 2 are specifically expressed in neuronal tissues. Isoform 3 and isoform 4 are expressed in non-neuronal tissues. Isoform 5 and isoform 6 are truncated forms expressed in non-neuronal tissues,,,Nucleus,11003644|12213192|12667457,11003644|12213192,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
PTCH1,ENSG00000185920,Unsafe,Protein,False,True,35.5,35.5,77,74,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 2.9 nTPM; positive ihc; adrenal gland: 3.9 nTPM; positive ihc;absolute ceiling; bone marrow: 0.7 nTPM; positive ihc; cerebellum: 5.9 nTPM; positive ihc;absolute ceiling; cerebral cortex: 7.4 nTPM; positive ihc;absolute ceiling; colon: 14.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 9.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 3.9 nTPM; positive ihc; heart muscle: 2.7 nTPM; positive ihc;absolute ceiling; kidney: 5.6 nTPM; positive ihc;absolute ceiling; liver: 2.5 nTPM; positive ihc;absolute ceiling; lung: 7.1 nTPM; positive ihc;absolute ceiling; lymph node: 2.8 nTPM; positive ihc; pancreas: 7.6 nTPM; positive ihc;absolute ceiling; parathyroid gland: 3.3 nTPM; positive ihc; rectum: 16 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 8.1 nTPM; absolute ceiling; salivary gland: 8.4 nTPM; positive ihc;absolute ceiling; skeletal muscle: 2.7 nTPM; positive ihc;absolute ceiling; skin: 3.5 nTPM; positive ihc; small intestine: 14.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 2.8 nTPM; positive ihc;absolute ceiling; spleen: 3.8 nTPM; positive ihc; stomach: 16.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; thyroid gland: 6.4 nTPM; positive ihc; tongue: 6.2 nTPM; absolute ceiling; urinary bladder: 6.2 nTPM; positive ihc;absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 3.9 nTPM (limit 2); cerebellum: 5.9 nTPM (limit 2); cerebral cortex: 7.4 nTPM (limit 2); colon: 14.9 nTPM (limit 6); duodenum: 9.3 nTPM (limit 2); heart muscle: 2.7 nTPM (limit 2); kidney: 5.6 nTPM (limit 2); liver: 2.5 nTPM (limit 2); lung: 7.1 nTPM (limit 2); pancreas: 7.6 nTPM (limit 2); rectum: 16 nTPM (limit 6); retina: 8.1 nTPM (limit 2); salivary gland: 8.4 nTPM (limit 6); skeletal muscle: 2.7 nTPM (limit 2); small intestine: 14.4 nTPM (limit 2); smooth muscle: 2.8 nTPM (limit 2); stomach: 16.2 nTPM (limit 6); tongue: 6.2 nTPM (limit 6); urinary bladder: 6.2 nTPM (limit 6); adrenal gland: 3.9 nTPM (baseline 2); cerebellum: 5.9 nTPM (baseline 2); cerebral cortex: 7.4 nTPM (baseline 2); colon: 14.9 nTPM (baseline 6); duodenum: 9.3 nTPM (baseline 2); heart muscle: 2.7 nTPM (baseline 2); kidney: 5.6 nTPM (baseline 2); liver: 2.5 nTPM (baseline 2); lung: 7.1 nTPM (baseline 2); pancreas: 7.6 nTPM (baseline 2); rectum: 16 nTPM (baseline 6); retina: 8.1 nTPM (baseline 2); salivary gland: 8.4 nTPM (baseline 6); skeletal muscle: 2.7 nTPM (baseline 2); small intestine: 14.4 nTPM (baseline 2); smooth muscle: 2.8 nTPM (baseline 2); stomach: 16.2 nTPM (baseline 6); tongue: 6.2 nTPM (baseline 6); urinary bladder: 6.2 nTPM (baseline 6),adipose tissue / adipocytes: Medium (Uncertain); adrenal gland / glandular cells: High (Uncertain); bone marrow / hematopoietic cells: High (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / neuronal cells: High (Uncertain); cerebellum / cells in granular layer: High (Uncertain); cerebellum / cells in molecular layer: Medium (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / endothelial cells: High (Uncertain); cerebral cortex / glial cells: Low (Uncertain); cerebral cortex / neuronal cells: High (Uncertain); cerebral cortex / neuropil: High (Uncertain); colon / endothelial cells: High (Uncertain); colon / glandular cells: High (Uncertain); colon / peripheral nerve/ganglion: High (Uncertain); duodenum / glandular cells: High (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: High (Uncertain); hippocampus / glial cells: Low (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in glomeruli: High (Uncertain); kidney / cells in tubules: High (Uncertain); liver / cholangiocytes: Medium (Uncertain); liver / hepatocytes: Low (Uncertain); lung / alveolar cells: Medium (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / germinal center cells: High (Uncertain); lymph node / non-germinal center cells: Medium (Uncertain); nasopharynx / respiratory epithelial cells: High (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); parathyroid gland / glandular cells: High (Uncertain); rectum / glandular cells: High (Uncertain); salivary gland / glandular cells: High (Uncertain); skeletal muscle / myocytes: High (Uncertain); skin 1 / fibroblasts: Medium (Uncertain); skin 1 / keratinocytes: Medium (Uncertain); skin 1 / Langerhans: Medium (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: High (Uncertain); smooth muscle / smooth muscle cells: Low (Uncertain); spleen / cells in red pulp: High (Uncertain); spleen / cells in white pulp: Medium (Uncertain); stomach 1 / glandular cells: High (Uncertain); stomach 2 / glandular cells: High (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: High (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Colon Adenocarcinoma (validation): 484/486 (99.6%); Glioblastoma Multiforme (validation): 54/58 (93.1%),breast cancer: 12/12 (100.0%); colorectal cancer: 12/12 (100.0%),31,20,Q13635,https://www.uniprot.org/uniprotkb/Q13635/entry,"Negative regulator of the smoothened signaling pathway, which acts as a receptor for hedgehog (SHH, IHH and DHH) morphogens (PubMed:21537345, PubMed:29954986, PubMed:29995851, PubMed:30139912, PubMed:31127104, PubMed:31555730, PubMed:37611095, PubMed:40128518, PubMed:9811851). In absence of hedgehog, acts as an inhibitor of smoothened protein (SMO) by preventing SMO access to cholesterol: mechanistically, acts as a cholesterol transporter, which depeletes cholesterol from the outer leaflet of plasma membrane, thereby preventing cholesterol-binding to the extracellular CRD region of SMO (PubMed:31555730, PubMed:37611095). Hedgehog-binding inhibits PTCH1 cholesterol transporter activity, promoting SMO activation by cholesterol and transduction of the smoothened signaling pathway (PubMed:31548691). Molecular mechanism governing cholesterol transport are still unclear: may move cholesterol from the outer to the inner leaflet of the membrane in exchange for potassium or sodium ion export in the opposite direction (PubMed:37611095). Seems to have a tumor suppressor function, as inactivation of this protein is probably a necessary, if not sufficient step for tumorigenesis (PubMed:8658145)","In the adult, expressed in brain, lung, liver, heart, placenta, skeletal muscle, pancreas and kidney. Expressed in tumor cells but not in normal skin","Basal cell nevus syndrome 1: A form of basal cell nevus syndrome, a disease characterized by nevoid basal cell carcinomas and developmental abnormalities such as rib and craniofacial alterations, polydactyly, syndactyly, and spina bifida. In addition, the patients suffer from a multitude of tumors like fibromas of the ovaries and heart, cysts of the skin, jaws and mesentery, as well as medulloblastomas and meningiomas. BCNS1 inheritance is autosomal dominant. Basal cell carcinoma: A common malignant skin neoplasm that typically appears on hair-bearing skin, most commonly on sun-exposed areas. BCC is slow growing and rarely metastasizes, but has potentialities for local invasion and destruction. It usually develops as a flat, firm, pale area that is small, raised, pink or red, translucent, shiny, and waxy, and the area may bleed following minor injury. Tumor size can vary from a few millimeters to several centimeters in diameter. Holoprosencephaly 7: A form of holoprosencephaly, a structural anomaly of the brain in which the developing forebrain fails to correctly separate into right and left hemispheres. It is a genetically and clinically heterogeneous disorder with a wide spectrum of severity, ranging from alobar holoprosencephaly with severe facial abnormalities, such as cyclopia and proboscis, to mild forms that include lobar or microform holoprosencephaly, without cerebral malformations and with mild craniofacial defects. HPE7 inheritance is autosomal dominant.",,"Cell membrane Cell projection, cilium membrane",21537345|29954986|29995851|30139912|31127104|31548691|31555730|37611095|40128518|8658145|9811851,8647801,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
PTF1A,ENSG00000168267,Unsafe,RNA,False,True,2.1,101.2,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,basal ganglia: 0.7 nTPM; continuous selectivity; cerebral cortex: 0.7 nTPM; continuous selectivity; pancreas: 101.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; stomach: 1.9 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,pancreas: 101.2 nTPM (limit 2); pancreas: 101.2 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (TCGA): 29/176 (16.5%); Rectum Adenocarcinoma (TCGA): 5/88 (5.7%); Rectum Adenocarcinoma (validation): 7/207 (3.4%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q7RTS3,https://www.uniprot.org/uniprotkb/Q7RTS3/entry,"Transcription factor implicated in the cell fate determination in various organs. Binds to the E-box consensus sequence 5'-CANNTG-3'. Plays a role in early and late pancreas development and differentiation. Important for determining whether cells allocated to the pancreatic buds continue towards pancreatic organogenesis or revert back to duodenal fates. May be involved in the maintenance of exocrine pancreas-specific gene expression including ELA1 and amylase. Required for the formation of pancreatic acinar and ductal cells. Plays an important role in cerebellar development. Directly regulated by FOXN4 and RORC during retinal development, FOXN4-PTF1A pathway plays a central role in directing the differentiation of retinal progenitors towards horizontal and amacrine fates",Pancreas-specific (at protein level). Loss of expression is seen in ductal type pancreas cancers,"Pancreatic and cerebellar agenesis: A disease characterized by neonatal diabetes mellitus, cerebellar agenesis or hypoplasia, severe intrauterine growth retardation, the presence of very little subcutaneous fat, and dysmorphic facial features. Pancreatic agenesis 2: A disease characterized by isolated hypoplasia or agenesis of the pancreas, pancreatic beta-cell failure resulting in neonatal insulin-dependent diabetes mellitus, and exocrine pancreatic insufficiency.",,Nucleus Cytoplasm,10768861|15543146,10768861,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
PTGR2,ENSG00000140043,Unsafe,Protein,False,True,16.8,31.7,78,57,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 11.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 13.4 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 13.6 nTPM; absolute ceiling;continuous selectivity; cerebellum: 5.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 12.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 16.2 nTPM; absolute ceiling;continuous selectivity; colon: 7 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 11.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 26.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 11.3 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 11.1 nTPM; absolute ceiling;continuous selectivity; kidney: 18.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 18.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 5.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 3 nTPM; positive ihc; midbrain: 14.6 nTPM; absolute ceiling;continuous selectivity; pancreas: 5.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 10.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 7.4 nTPM; absolute ceiling;continuous selectivity; rectum: 5.5 nTPM; positive ihc; retina: 10.5 nTPM; absolute ceiling;continuous selectivity; salivary gland: 6.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 31.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 6.8 nTPM; positive ihc; small intestine: 8.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 12.4 nTPM; absolute ceiling;continuous selectivity; spleen: 3.3 nTPM; positive ihc; stomach: 6.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; thyroid gland: 12.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 31.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 4.1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 11.8 nTPM (limit 2); amygdala: 13.4 nTPM (limit 2); basal ganglia: 13.6 nTPM (limit 2); cerebellum: 5.8 nTPM (limit 2); cerebral cortex: 12.5 nTPM (limit 2); choroid plexus: 16.2 nTPM (limit 2); colon: 7 nTPM (limit 6); duodenum: 11.8 nTPM (limit 2); heart muscle: 26.4 nTPM (limit 2); hippocampal formation: 11.3 nTPM (limit 2); hypothalamus: 11.1 nTPM (limit 2); kidney: 18.2 nTPM (limit 2); liver: 18.5 nTPM (limit 2); lung: 5.4 nTPM (limit 2); midbrain: 14.6 nTPM (limit 2); pancreas: 5.1 nTPM (limit 2); parathyroid gland: 10.2 nTPM (limit 6); pituitary gland: 7.4 nTPM (limit 2); retina: 10.5 nTPM (limit 2); salivary gland: 6.6 nTPM (limit 6); skeletal muscle: 31.7 nTPM (limit 2); small intestine: 8.7 nTPM (limit 2); spinal cord: 12.4 nTPM (limit 2); stomach: 6.1 nTPM (limit 6); thyroid gland: 12.3 nTPM (limit 10); tongue: 31.1 nTPM (limit 6),adrenal gland / glandular cells: Medium (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Low (Approved); colon / glandular cells: Low (Approved); duodenum / glandular cells: Low (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Low (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / macrophages: High (Approved); lymph node / germinal center cells: High (Approved); lymph node / non-germinal center cells: Low (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: High (Approved); parathyroid gland / glandular cells: High (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / fibroblasts: Low (Approved); skin 1 / keratinocytes: Medium (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Medium (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: High (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (validation): 229/231 (99.1%); Kidney Chromophobe (TCGA): 63/64 (98.4%); Prostate Adenocarcinoma (TCGA): 472/480 (98.3%),prostate cancer: 11/11 (100.0%); breast cancer: 6/9 (66.7%),31,20,Q8N8N7,https://www.uniprot.org/uniprotkb/Q8N8N7/entry,"Functions as 15-oxo-prostaglandin 13-reductase and acts on 15-keto-PGE1, 15-keto-PGE2, 15-keto-PGE1-alpha and 15-keto-PGE2-alpha with highest activity towards 15-keto-PGE2 (PubMed:19000823). Overexpression represses transcriptional activity of PPARG and inhibits adipocyte differentiation (By similarity)",Widely expressed,,,Cytoplasm,19000823,15004468,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
PTPN11,ENSG00000179295,Unsafe,Protein,False,True,40.5,94.8,68,66,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 56 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; adrenal gland: 31.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 73.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 72.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 41.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 30.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 67.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 23 nTPM; absolute ceiling;continuous selectivity; colon: 31.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 26 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 37.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 64.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 71.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 63.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 36.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 45.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 31.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 31.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 94.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 29.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 51 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 15.7 nTPM; absolute ceiling;continuous selectivity; rectum: 29.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 45.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 22.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 72.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 25.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 24.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 42.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 94.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 24.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 28.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 33.4 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 44.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; tongue: 60.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 38.2 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 56 nTPM (limit 10); adrenal gland: 31.2 nTPM (limit 2); amygdala: 73.7 nTPM (limit 2); basal ganglia: 72.3 nTPM (limit 2); bone marrow: 41.4 nTPM (limit 2); cerebellum: 30.3 nTPM (limit 2); cerebral cortex: 67.2 nTPM (limit 2); choroid plexus: 23 nTPM (limit 2); colon: 31.4 nTPM (limit 6); duodenum: 26 nTPM (limit 2); esophagus: 37.2 nTPM (limit 6); heart muscle: 64.6 nTPM (limit 2); hippocampal formation: 71.3 nTPM (limit 2); hypothalamus: 63.5 nTPM (limit 2); kidney: 36.1 nTPM (limit 2); liver: 45.8 nTPM (limit 2); lung: 31.7 nTPM (limit 2); lymph node: 31.8 nTPM (limit 6); midbrain: 94.8 nTPM (limit 2); pancreas: 29.2 nTPM (limit 2); parathyroid gland: 51 nTPM (limit 6); pituitary gland: 15.7 nTPM (limit 2); rectum: 29.1 nTPM (limit 6); retina: 45.7 nTPM (limit 2); salivary gland: 22.1 nTPM (limit 6); skeletal muscle: 72.5 nTPM (limit 4); skin: 25.3 nTPM (limit 10); small intestine: 24.4 nTPM (limit 2); smooth muscle: 42.9 nTPM (limit 2); spinal cord: 94.6 nTPM (limit 2); spleen: 24.6 nTPM (limit 10); stomach: 28.1 nTPM (limit 6); thymus: 33.4 nTPM (limit 10); thyroid gland: 44.9 nTPM (limit 10); tongue: 60.5 nTPM (limit 6); urinary bladder: 38.2 nTPM (limit 6),adipose tissue / adipocytes: High (Approved); adrenal gland / glandular cells: Low (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: High (Approved); cerebellum / cells in granular layer: High (Approved); cerebellum / cells in molecular layer: High (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: High (Approved); cerebral cortex / neuronal cells: High (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: High (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); hippocampus / glial cells: High (Approved); hippocampus / neuronal cells: High (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Low (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: High (Approved); lymph node / germinal center cells: High (Approved); lymph node / non-germinal center cells: High (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: High (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: High (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Squamous Cell Carcinoma (TCGA): 489/489 (100.0%); Colon Adenocarcinoma (validation): 486/486 (100.0%); Stomach Adenocarcinoma (TCGA): 346/346 (100.0%),prostate cancer: 11/11 (100.0%); urothelial cancer: 11/11 (100.0%),31,20,Q06124,https://www.uniprot.org/uniprotkb/Q06124/entry,"Acts downstream of various receptor and cytoplasmic protein tyrosine kinases to participate in the signal transduction from the cell surface to the nucleus (PubMed:10655584, PubMed:14739280, PubMed:18559669, PubMed:18829466, PubMed:26742426, PubMed:28074573, PubMed:32184441). Positively regulates MAPK signal transduction pathway (PubMed:28074573). Dephosphorylates GAB1, ARHGAP35 and EGFR (PubMed:28074573). Dephosphorylates ROCK2 at 'Tyr-722' resulting in stimulation of its RhoA binding activity (PubMed:18559669). Dephosphorylates CDC73 (PubMed:26742426). Dephosphorylates SOX9 on tyrosine residues, leading to inactivate SOX9 and promote ossification (By similarity). Dephosphorylates tyrosine-phosphorylated NEDD9/CAS-L (PubMed:19275884). Acts as an effector of PDCD1-mediated inhibition of T-cell response: recruited by phosphorylated PDCD1, mediating dephosphorylation of key T-cell receptor (TCR) proximal signaling molecules, leading to TCR signaling inhibition (PubMed:32184441)","Widely expressed, with highest levels in heart, brain, and skeletal muscle","LEOPARD syndrome 1: A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness. Noonan syndrome 1: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. Some patients with NS1 develop multiple giant cell lesions of the jaw or other bony or soft tissues, which are classified as pigmented villonodular synovitis (PVNS) when occurring in the jaw or joints. Leukemia, juvenile myelomonocytic: An aggressive pediatric myelodysplastic syndrome/myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Patients have splenomegaly, enlarged lymph nodes, rashes, and hemorrhages. Metachondromatosis: A skeletal disorder with radiologic features of both multiple exostoses and Ollier disease, characterized by the presence of exostoses, commonly of the bones of the hands and feet, and enchondromas of the metaphyses of long bones and iliac crest.",,Cytoplasm Nucleus,10655584|14739280|18559669|18829466|19275884|26742426|28074573|32184441,1280823|7681589|8216283,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
PTPRQ,ENSG00000139304,Unsafe,RNA,False,True,2.6,6.9,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 3.1 nTPM; continuous selectivity;reproductive not higher; heart muscle: 1.1 nTPM; continuous selectivity; kidney: 6.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 2.2 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 2.8 nTPM; continuous selectivity;reproductive not higher; urinary bladder: 3.9 nTPM; continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,kidney: 6.9 nTPM (limit 2); lung: 2.2 nTPM (limit 2); kidney: 6.9 nTPM (baseline 2); lung: 2.2 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 3/50 (6.0%); Bladder Urothelial Carcinoma (TCGA): 8/169 (4.7%); Lung Squamous Cell Carcinoma (validation): 2/68 (2.9%),breast cancer: 9/12 (75.0%); melanoma: 7/10 (70.0%),31,20,,,,,,,,,,False,No exact Ensembl mapping to a reviewed UniProt entry,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
PTRH1,ENSG00000187024,Unsafe,Protein,False,True,16.9,26.0,74,54,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 16.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 24.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 19.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 16.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 4.1 nTPM; positive ihc;absolute ceiling; cerebellum: 4.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 18.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 10 nTPM; absolute ceiling;continuous selectivity; colon: 11.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 4.1 nTPM; positive ihc;absolute ceiling; esophagus: 10.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 17.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 16.4 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 15.6 nTPM; absolute ceiling;continuous selectivity; kidney: 26 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 17.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 12.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 3.2 nTPM; positive ihc; midbrain: 16.7 nTPM; absolute ceiling;continuous selectivity; pancreas: 20.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 7.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 17.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 2.2 nTPM; positive ihc; retina: 2.7 nTPM; absolute ceiling; salivary gland: 11.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 19.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 24 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 7.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 3.4 nTPM; positive ihc;absolute ceiling; spinal cord: 10.1 nTPM; absolute ceiling;continuous selectivity; spleen: 12.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 14.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; thyroid gland: 19.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 12.5 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 16.1 nTPM (limit 10); adrenal gland: 24.7 nTPM (limit 2); amygdala: 19.7 nTPM (limit 2); basal ganglia: 16.9 nTPM (limit 2); bone marrow: 4.1 nTPM (limit 2); cerebellum: 4.6 nTPM (limit 2); cerebral cortex: 18.7 nTPM (limit 2); choroid plexus: 10 nTPM (limit 2); colon: 11.7 nTPM (limit 6); duodenum: 4.1 nTPM (limit 2); esophagus: 10.1 nTPM (limit 6); heart muscle: 17.7 nTPM (limit 2); hippocampal formation: 16.4 nTPM (limit 2); hypothalamus: 15.6 nTPM (limit 2); kidney: 26 nTPM (limit 2); liver: 17.6 nTPM (limit 2); lung: 12.3 nTPM (limit 2); midbrain: 16.7 nTPM (limit 2); pancreas: 20.3 nTPM (limit 2); parathyroid gland: 7.3 nTPM (limit 6); pituitary gland: 17.3 nTPM (limit 2); retina: 2.7 nTPM (limit 2); salivary gland: 11.2 nTPM (limit 6); skeletal muscle: 19.2 nTPM (limit 2); skin: 24 nTPM (limit 10); small intestine: 7.4 nTPM (limit 2); smooth muscle: 3.4 nTPM (limit 2); spinal cord: 10.1 nTPM (limit 2); spleen: 12.3 nTPM (limit 10); stomach: 14.1 nTPM (limit 6); thyroid gland: 19.5 nTPM (limit 10); urinary bladder: 12.5 nTPM (limit 6); adipose tissue: 16.1 nTPM (baseline 10); adrenal gland: 24.7 nTPM (baseline 2); amygdala: 19.7 nTPM (baseline 2); basal ganglia: 16.9 nTPM (baseline 2); bone marrow: 4.1 nTPM (baseline 2); cerebellum: 4.6 nTPM (baseline 2); cerebral cortex: 18.7 nTPM (baseline 2); choroid plexus: 10 nTPM (baseline 2); colon: 11.7 nTPM (baseline 6); duodenum: 4.1 nTPM (baseline 2); esophagus: 10.1 nTPM (baseline 6); heart muscle: 17.7 nTPM (baseline 2); hippocampal formation: 16.4 nTPM (baseline 2); hypothalamus: 15.6 nTPM (baseline 2); kidney: 26 nTPM (baseline 2); liver: 17.6 nTPM (baseline 2); lung: 12.3 nTPM (baseline 2); midbrain: 16.7 nTPM (baseline 2); pancreas: 20.3 nTPM (baseline 2); parathyroid gland: 7.3 nTPM (baseline 6); pituitary gland: 17.3 nTPM (baseline 2); retina: 2.7 nTPM (baseline 2); salivary gland: 11.2 nTPM (baseline 6); skeletal muscle: 19.2 nTPM (baseline 2); skin: 24 nTPM (baseline 10); small intestine: 7.4 nTPM (baseline 2); smooth muscle: 3.4 nTPM (baseline 2); spinal cord: 10.1 nTPM (baseline 2); spleen: 12.3 nTPM (baseline 10); stomach: 14.1 nTPM (baseline 6); thyroid gland: 19.5 nTPM (baseline 10); urinary bladder: 12.5 nTPM (baseline 6),adipose tissue / adipocytes: Low (Uncertain); adrenal gland / glandular cells: High (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / neuronal cells: Low (Uncertain); cerebellum / cells in granular layer: Low (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / endothelial cells: Low (Uncertain); colon / glandular cells: Medium (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Low (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / neuronal cells: Low (Uncertain); kidney / cells in tubules: High (Uncertain); liver / cholangiocytes: Medium (Uncertain); liver / hepatocytes: Low (Uncertain); lung / macrophages: Low (Uncertain); lymph node / non-germinal center cells: Medium (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Low (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); parathyroid gland / glandular cells: High (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: Low (Uncertain); skin 2 / epidermal cells: Low (Uncertain); small intestine / glandular cells: Medium (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); spleen / cells in red pulp: Low (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: High (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Head and Neck Squamous Cell Carcinoma (TCGA): 492/492 (100.0%); Prostate Adenocarcinoma (TCGA): 480/480 (100.0%); Ovary Serous Cystadenocarcinoma (TCGA): 349/349 (100.0%),colorectal cancer: 10/12 (83.3%); prostate cancer: 5/10 (50.0%),31,20,Q86Y79,https://www.uniprot.org/uniprotkb/Q86Y79/entry,"Peptidyl-tRNA hydrolase that cleaves nascent chains-tRNAs that are not stably fixed in the P-site of 60S ribosome-nascent chain complexes (PubMed:30244831). Acts downstream of the ribosome-associated quality control (RQC) pathway to release non-ubiquitinated nascent chains from 60S and 80S ribosome-nascent chain complexes (PubMed:30244831). Does not act on ubiquitinated nascent chains, which are cleaved by ANKZF1 for degradation (PubMed:30244831)",,,,,30244831,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
PTTG1,ENSG00000164611,Unsafe,Protein,False,True,170.3,170.3,106,38,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,Trial registration,positive normal IHC; positive ihc outside permitted; amygdala: 4.4 nTPM; absolute ceiling; basal ganglia: 7.5 nTPM; absolute ceiling; bone marrow: 157.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 10.3 nTPM; absolute ceiling; colon: 32.7 nTPM; positive ihc;absolute ceiling; duodenum: 23.9 nTPM; positive ihc;absolute ceiling; esophagus: 58 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 10.9 nTPM; absolute ceiling; hypothalamus: 6.5 nTPM; absolute ceiling; liver: 5.1 nTPM; positive ihc;absolute ceiling; lymph node: 79.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 3.2 nTPM; absolute ceiling; pancreas: 1.5 nTPM; positive ihc; pituitary gland: 4.2 nTPM; absolute ceiling; rectum: 42.6 nTPM; positive ihc;absolute ceiling; retina: 2.3 nTPM; absolute ceiling; skin: 35 nTPM; positive ihc;absolute ceiling; small intestine: 23.4 nTPM; positive ihc;absolute ceiling; smooth muscle: 18.5 nTPM; absolute ceiling; spinal cord: 2.3 nTPM; absolute ceiling; spleen: 18.2 nTPM; positive ihc;absolute ceiling; thymus: 123.6 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 76.9 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 4.4 nTPM (limit 2); basal ganglia: 7.5 nTPM (limit 2); bone marrow: 157.9 nTPM (limit 2); choroid plexus: 10.3 nTPM (limit 2); colon: 32.7 nTPM (limit 6); duodenum: 23.9 nTPM (limit 2); esophagus: 58 nTPM (limit 6); hippocampal formation: 10.9 nTPM (limit 2); hypothalamus: 6.5 nTPM (limit 2); liver: 5.1 nTPM (limit 2); lymph node: 79.5 nTPM (limit 6); midbrain: 3.2 nTPM (limit 2); pituitary gland: 4.2 nTPM (limit 2); rectum: 42.6 nTPM (limit 6); retina: 2.3 nTPM (limit 2); skin: 35 nTPM (limit 10); small intestine: 23.4 nTPM (limit 2); smooth muscle: 18.5 nTPM (limit 12); spinal cord: 2.3 nTPM (limit 2); spleen: 18.2 nTPM (limit 10); thymus: 123.6 nTPM (limit 10); thyroid gland: 76.9 nTPM (limit 60),bone marrow / hematopoietic cells: Medium (Enhanced); bronchus / respiratory epithelial cells: Medium (Enhanced); colon / glandular cells: Low (Enhanced); duodenum / glandular cells: Low (Enhanced); esophagus / squamous epithelial cells: Medium (Enhanced); liver / hepatocytes: Low (Enhanced); lymph node / germinal center cells: High (Enhanced); lymph node / non-germinal center cells: Low (Enhanced); nasopharynx / respiratory epithelial cells: Medium (Enhanced); oral mucosa / squamous epithelial cells: Medium (Enhanced); pancreas / exocrine glandular cells: Low (Enhanced); rectum / glandular cells: Low (Enhanced); skin 1 / cells in basal layer: Medium (Enhanced); skin 1 / cells in spinous layer: Medium (Enhanced); skin 2 / cells in basal layer: Medium (Enhanced); skin 2 / cells in spinous layer: Medium (Enhanced); small intestine / glandular cells: Low (Enhanced); spleen / cells in red pulp: Low (Enhanced); spleen / cells in white pulp: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 58/91 values ≥5 TPM, max 9.1704; DICE M2 (unstimulated): 23/90 values ≥5 TPM, max 8.50632; DICE NK (unstimulated): 85/90 values ≥5 TPM, max 27.0519; DICE TREG_MEM (unstimulated): 89/89 values ≥5 TPM, max 67.9289; DICE CD4_NAIVE (unstimulated): 64/88 values ≥5 TPM, max 10.5279; DICE CD4_STIM (activated): 25/88 values ≥5 TPM, max 7.65895; DICE TREG_NAIVE (unstimulated): 89/89 values ≥5 TPM, max 23.7395; DICE TFH (unstimulated): 89/89 values ≥5 TPM, max 22.215; DICE TH1 (unstimulated): 81/81 values ≥5 TPM, max 43.4471; DICE THSTAR (unstimulated): 87/88 values ≥5 TPM, max 15.679; DICE TH17 (unstimulated): 89/89 values ≥5 TPM, max 26.0296; DICE TH2 (unstimulated): 89/89 values ≥5 TPM, max 30.9878; DICE CD8_NAIVE (unstimulated): 32/89 values ≥5 TPM, max 11.527; DICE CD8_STIM (activated): 15/88 values ≥5 TPM, max 8.01933; hpa_immune_cell basophil: 9.7 nTPM; hpa_immune_cell eosinophil: 10.4 nTPM; hpa_immune_cell gdT-cell: 25.6 nTPM; hpa_immune_cell intermediate monocyte: 8.7 nTPM; hpa_immune_cell MAIT T-cell: 9.6 nTPM; hpa_immune_cell memory B-cell: 31 nTPM; hpa_immune_cell memory CD4 T-cell: 52.5 nTPM; hpa_immune_cell memory CD8 T-cell: 60.6 nTPM; hpa_immune_cell myeloid DC: 24 nTPM; hpa_immune_cell naive B-cell: 23.7 nTPM; hpa_immune_cell naive CD4 T-cell: 12.7 nTPM; hpa_immune_cell naive CD8 T-cell: 31.5 nTPM; hpa_immune_cell NK-cell: 14.6 nTPM; hpa_immune_cell non-classical monocyte: 5.9 nTPM; hpa_immune_cell plasmacytoid DC: 22.7 nTPM; hpa_immune_cell T-reg: 218.7 nTPM; hpa_immune_cell total PBMC: 19.8 nTPM; hpa_immune_monaco basophil: 10.2 TPM; hpa_immune_monaco Central memory CD8 T-cell: 12.7 TPM; hpa_immune_monaco Effector memory CD8 T-cell: 18.7 TPM; hpa_immune_monaco Exhausted memory B-cell: 9.1 TPM; hpa_immune_monaco Memory CD4 T-cell TFH: 11.5 TPM; hpa_immune_monaco Memory CD4 T-cell Th1: 16.8 TPM; hpa_immune_monaco Memory CD4 T-cell Th1/Th17: 9.2 TPM; hpa_immune_monaco Memory CD4 T-cell Th17: 9.5 TPM; hpa_immune_monaco Memory CD4 T-cell Th2: 9.3 TPM; hpa_immune_monaco myeloid DC: 5.1 TPM; hpa_immune_monaco Non-Vd2 gdTCR: 12 TPM; hpa_immune_monaco Plasmablast: 12.1 TPM; hpa_immune_monaco plasmacytoid DC: 5 TPM; hpa_immune_monaco Progenitor cell: 6.1 TPM; hpa_immune_monaco T-reg: 18.2 TPM; hpa_immune_monaco Terminal effector memory CD4 T-cell: 7.8 TPM; hpa_immune_monaco Terminal effector memory CD8 T-cell: 15.3 TPM; hpa_immune_monaco total PBMC: 9.7 TPM",True,True,True,"limbal neural crest progenitors: max 1.26971 mean CP10K, 4 supported sample groups",True,False,,False,True,True,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,True,238.1854,608.3,"dice_th1: blood/TH1, max 43.4471 TPM, 1 observations >30; dice_th2: blood/TH2, max 30.9878 TPM, 1 observations >30; dice_treg_mem: blood/TREG_MEM, max 67.9289 TPM, 89 observations >30; hpa_immune_cell: blood/T-reg, max 218.7 nTPM, 1 observations >30; hpa_immune_cell: blood/memory B-cell, max 31 nTPM, 1 observations >30; hpa_immune_cell: blood/memory CD4 T-cell, max 52.5 nTPM, 1 observations >30; hpa_immune_cell: blood/memory CD8 T-cell, max 60.6 nTPM, 1 observations >30; hpa_immune_cell: blood/naive CD8 T-cell, max 31.5 nTPM, 1 observations >30; hpa_immune_cell_samples: blood/T-reg, max 238.185 TPM, 6 observations >30; hpa_immune_cell_samples: blood/gdT-cell, max 45.9887 TPM, 2 observations >30; hpa_immune_cell_samples: blood/memory B-cell, max 39.5298 TPM, 1 observations >30; hpa_immune_cell_samples: blood/memory CD4 T-cell, max 69.9384 TPM, 6 observations >30; hpa_immune_cell_samples: blood/memory CD8 T-cell, max 84.2743 TPM, 5 observations >30; hpa_immune_cell_samples: blood/naive CD8 T-cell, max 67.0384 TPM, 2 observations >30; hpa_immune_cell_samples: blood/T-reg, max 286.983 nTPM, 6 observations >30; hpa_immune_cell_samples: blood/gdT-cell, max 43.3486 nTPM, 2 observations >30; hpa_immune_cell_samples: blood/memory B-cell, max 52.2278 nTPM, 3 observations >30; hpa_immune_cell_samples: blood/memory CD4 T-cell, max 72.1362 nTPM, 6 observations >30; hpa_immune_cell_samples: blood/memory CD8 T-cell, max 90.1774 nTPM, 5 observations >30; hpa_immune_cell_samples: blood/myeloid DC, max 30.6794 nTPM, 1 observations >30; hpa_immune_cell_samples: blood/naive B-cell, max 55.9379 nTPM, 1 observations >30; hpa_immune_cell_samples: blood/naive CD8 T-cell, max 63.0299 nTPM, 2 observations >30; hpa_immune_cell_samples: blood/total PBMC, max 34.0061 nTPM, 1 observations >30; hpa_immune_schmiedel: blood/Memory T-reg, max 47 TPM, 1 observations >30; hpa_rna_consensus: bone marrow/, max 157.9 nTPM, 1 observations >30; hpa_rna_consensus: colon/, max 32.7 nTPM, 1 observations >30; hpa_rna_consensus: esophagus/, max 58 nTPM, 1 observations >30; hpa_rna_consensus: lymph node/, max 79.5 nTPM, 1 observations >30; hpa_rna_consensus: rectum/, max 42.6 nTPM, 1 observations >30; hpa_rna_consensus: skin/, max 35 nTPM, 1 observations >30; hpa_rna_consensus: thymus/, max 123.6 nTPM, 1 observations >30; hpa_rna_consensus: thyroid gland/, max 76.9 nTPM, 1 observations >30; hpa_single_cell: /Basal keratinocytes, max 214.4 nTPM, 1 observations >30; hpa_single_cell: /Basal respiratory cells, max 154.9 nTPM, 1 observations >30; hpa_single_cell: /Basal squamous epithelial cells, max 198.3 nTPM, 1 observations >30; hpa_single_cell: /Erythroid cells, max 368.1 nTPM, 1 observations >30; hpa_single_cell: /Gastric mucus-secreting cells, max 31.8 nTPM, 1 observations >30; hpa_single_cell: /Ionocytes, max 53.4 nTPM, 1 observations >30; hpa_single_cell: /Langerhans cells, max 447.2 nTPM, 1 observations >30; hpa_single_cell: /Macrophages, max 33.6 nTPM, 1 observations >30; hpa_single_cell: /Pancreatic endocrine cells, max 59.4 nTPM, 1 observations >30; hpa_single_cell: /Plasma cells, max 116.1 nTPM, 1 observations >30; hpa_single_cell: /Schwann cells, max 47 nTPM, 1 observations >30; hpa_single_cell: /Serous glandular cells, max 35.1 nTPM, 1 observations >30; hpa_single_cell: /Squamous epithelial cells, max 206 nTPM, 1 observations >30; hpa_single_cell: /Suprabasal keratinocytes, max 123.1 nTPM, 1 observations >30; hpa_single_cell: /T-cells, max 67.7 nTPM, 1 observations >30; hpa_single_cell: /Undifferentiated cells, max 136.4 nTPM, 1 observations >30; hpa_single_cell: /dendritic cells, max 52.5 nTPM, 1 observations >30; hpa_single_cell: /granulocytes, max 32.6 nTPM, 1 observations >30; hpa_single_cell_tissue: adipose tissue/dendritic cells, max 94.1 nTPM, 1 observations >30; hpa_single_cell_tissue: adipose tissue/macrophages, max 178 nTPM, 2 observations >30; hpa_single_cell_tissue: adipose tissue/nk-cells, max 55.4 nTPM, 2 observations >30; hpa_single_cell_tissue: adipose tissue/schwann cells, max 109.3 nTPM, 1 observations >30; hpa_single_cell_tissue: adipose tissue/t-cells, max 248.7 nTPM, 7 observations >30; hpa_single_cell_tissue: bone marrow/b-cells, max 46.1 nTPM, 1 observations >30; hpa_single_cell_tissue: bone marrow/erythroid cells, max 128 nTPM, 1 observations >30; hpa_single_cell_tissue: bone marrow/plasma cells, max 123.8 nTPM, 1 observations >30; hpa_single_cell_tissue: bone marrow/t-cells, max 73.2 nTPM, 3 observations >30; hpa_single_cell_tissue: breast/macrophages, max 76.5 nTPM, 3 observations >30; hpa_single_cell_tissue: breast/t-cells, max 141.1 nTPM, 4 observations >30; hpa_single_cell_tissue: bronchus/basal respiratory cells, max 234.5 nTPM, 5 observations >30; hpa_single_cell_tissue: bronchus/ciliated cells, max 45.9 nTPM, 2 observations >30; hpa_single_cell_tissue: bronchus/club cells, max 83.7 nTPM, 3 observations >30; hpa_single_cell_tissue: bronchus/ionocytes, max 53.4 nTPM, 1 observations >30; hpa_single_cell_tissue: bronchus/smooth muscle cells, max 40.5 nTPM, 1 observations >30; hpa_single_cell_tissue: colon/distal enterocytes, max 166.5 nTPM, 1 observations >30; hpa_single_cell_tissue: colon/enteroendocrine cells, max 30.5 nTPM, 1 observations >30; hpa_single_cell_tissue: colon/intestinal goblet cells, max 44.8 nTPM, 1 observations >30; hpa_single_cell_tissue: colon/t-cells, max 114.1 nTPM, 1 observations >30; hpa_single_cell_tissue: colon/undifferentiated cells, max 246 nTPM, 3 observations >30; hpa_single_cell_tissue: endometrium/macrophages, max 51.7 nTPM, 1 observations >30; hpa_single_cell_tissue: endometrium/t-cells, max 48.4 nTPM, 1 observations >30; hpa_single_cell_tissue: esophagus/basal squamous epithelial cells, max 198.3 nTPM, 1 observations >30; hpa_single_cell_tissue: esophagus/macrophages, max 79.6 nTPM, 1 observations >30; hpa_single_cell_tissue: esophagus/squamous epithelial cells, max 381 nTPM, 3 observations >30; hpa_single_cell_tissue: esophagus/t-cells, max 189.8 nTPM, 1 observations >30; hpa_single_cell_tissue: fallopian tube/granulocytes, max 32.5 nTPM, 1 observations >30; hpa_single_cell_tissue: fallopian tube/t-cells, max 82.8 nTPM, 3 observations >30; hpa_single_cell_tissue: kidney/t-cells, max 55.9 nTPM, 1 observations >30; hpa_single_cell_tissue: liver/erythroid cells, max 608.3 nTPM, 1 observations >30; hpa_single_cell_tissue: liver/kupffer cells, max 37.4 nTPM, 1 observations >30; hpa_single_cell_tissue: liver/plasma cells, max 284.9 nTPM, 1 observations >30; hpa_single_cell_tissue: liver/t-cells, max 110.2 nTPM, 3 observations >30; hpa_single_cell_tissue: lung/alveolar cells type 2, max 56.1 nTPM, 2 observations >30; hpa_single_cell_tissue: lung/macrophages, max 158.1 nTPM, 1 observations >30; hpa_single_cell_tissue: lung/t-cells, max 40.7 nTPM, 2 observations >30; hpa_single_cell_tissue: lymph node/t-cells, max 72.8 nTPM, 2 observations >30; hpa_single_cell_tissue: ovary/mixed immune cells, max 39.6 nTPM, 1 observations >30; hpa_single_cell_tissue: pancreas/ductal cells, max 34.2 nTPM, 1 observations >30; hpa_single_cell_tissue: pancreas/fibroblasts, max 149.7 nTPM, 1 observations >30; hpa_single_cell_tissue: pancreas/macrophages, max 78.1 nTPM, 1 observations >30; hpa_single_cell_tissue: pancreas/mixed immune cells, max 39.7 nTPM, 1 observations >30; hpa_single_cell_tissue: pancreas/pancreatic endocrine cells, max 59.4 nTPM, 1 observations >30; hpa_single_cell_tissue: pbmc/t-cells, max 44.7 nTPM, 1 observations >30; hpa_single_cell_tissue: placenta/mixed immune cells, max 555.8 nTPM, 1 observations >30; hpa_single_cell_tissue: placenta/t-cells, max 73.5 nTPM, 1 observations >30; hpa_single_cell_tissue: prostate/t-cells, max 51.5 nTPM, 1 observations >30; hpa_single_cell_tissue: rectum/mixed immune cells, max 450.9 nTPM, 1 observations >30; hpa_single_cell_tissue: rectum/undifferentiated cells, max 214.3 nTPM, 1 observations >30; hpa_single_cell_tissue: skeletal muscle/macrophages, max 30.7 nTPM, 1 observations >30; hpa_single_cell_tissue: skeletal muscle/mixed cell types, max 50 nTPM, 1 observations >30; hpa_single_cell_tissue: skeletal muscle/t-cells, max 33.3 nTPM, 1 observations >30; hpa_single_cell_tissue: skin/b-cells, max 199.9 nTPM, 1 observations >30; hpa_single_cell_tissue: skin/basal keratinocytes, max 227.7 nTPM, 1 observations >30; hpa_single_cell_tissue: skin/endothelial cells, max 36 nTPM, 2 observations >30; hpa_single_cell_tissue: skin/fibroblasts, max 54.3 nTPM, 2 observations >30; hpa_single_cell_tissue: skin/granulocytes, max 53 nTPM, 1 observations >30; hpa_single_cell_tissue: skin/langerhans cells, max 543.2 nTPM, 2 observations >30; hpa_single_cell_tissue: skin/macrophages, max 64.6 nTPM, 1 observations >30; hpa_single_cell_tissue: skin/smooth muscle cells, max 69.3 nTPM, 1 observations >30; hpa_single_cell_tissue: skin/suprabasal keratinocytes, max 163.6 nTPM, 1 observations >30; hpa_single_cell_tissue: skin/t-cells, max 236.6 nTPM, 1 observations >30; hpa_single_cell_tissue: small intestine/intestinal goblet cells, max 152 nTPM, 1 observations >30; hpa_single_cell_tissue: small intestine/undifferentiated cells, max 141.6 nTPM, 2 observations >30; hpa_single_cell_tissue: spleen/b-cells, max 102.1 nTPM, 1 observations >30; hpa_single_cell_tissue: spleen/plasma cells, max 260.8 nTPM, 1 observations >30; hpa_single_cell_tissue: spleen/t-cells, max 92.1 nTPM, 3 observations >30; hpa_single_cell_tissue: stomach/gastric mucus-secreting cells, max 31.8 nTPM, 1 observations >30; hpa_single_cell_tissue: stomach/t-cells, max 53.2 nTPM, 4 observations >30; hpa_single_cell_tissue: testis/macrophages, max 31 nTPM, 1 observations >30; hpa_single_cell_tissue: thymus/plasma cells, max 201.8 nTPM, 3 observations >30; hpa_single_cell_tissue: thymus/t-cells, max 90.2 nTPM, 1 observations >30; hpa_single_cell_tissue: tongue/basal keratinocytes, max 527.7 nTPM, 10 observations >30; hpa_single_cell_tissue: tongue/endothelial cells, max 252.1 nTPM, 1 observations >30; hpa_single_cell_tissue: tongue/granulocytes, max 48.5 nTPM, 1 observations >30; hpa_single_cell_tissue: tongue/macrophages, max 66.9 nTPM, 1 observations >30; hpa_single_cell_tissue: tongue/serous glandular cells, max 66.3 nTPM, 1 observations >30; hpa_single_cell_tissue: tongue/suprabasal keratinocytes, max 288.7 nTPM, 3 observations >30; hpa_single_cell_tissue: tongue/t-cells, max 90.6 nTPM, 2 observations >30; hpa_single_cell_tissue: vascular/fibroblasts, max 70 nTPM, 2 observations >30",Unsafe,oncoref.target-sets.2026-10-23.2,238.2 TPM; blood/T-reg; hpa_immune_cell_samples; vital,608.3 nTPM; liver/erythroid cells; hpa_single_cell_tissue; vital,Thyroid Carcinoma (TCGA): 495/495 (100.0%); Head and Neck Squamous Cell Carcinoma (TCGA): 492/492 (100.0%); Lung Squamous Cell Carcinoma (TCGA): 489/489 (100.0%),endometrial cancer: 7/12 (58.3%); liver cancer: 6/11 (54.5%),31,20,O95997,https://www.uniprot.org/uniprotkb/O95997/entry,"Regulatory protein, which plays a central role in chromosome stability, in the p53/TP53 pathway, and DNA repair. Probably acts by blocking the action of key proteins. During the mitosis, it blocks Separase/ESPL1 function, preventing the proteolysis of the cohesin complex and the subsequent segregation of the chromosomes. At the onset of anaphase, it is ubiquitinated, conducting to its destruction and to the liberation of ESPL1. Its function is however not limited to a blocking activity, since it is required to activate ESPL1. Negatively regulates the transcriptional activity and related apoptosis activity of TP53. The negative regulation of TP53 may explain the strong transforming capability of the protein when it is overexpressed. May also play a role in DNA repair via its interaction with Ku, possibly by connecting DNA damage-response pathways with sister chromatid separation","Expressed at low level in most tissues, except in adult testis, where it is highly expressed. Overexpressed in many patients suffering from pituitary adenomas, primary epithelial neoplasias, and esophageal cancer",,,Cytoplasm Nucleus,10411507|11238996|11371342|12355087,9811450,False,Reviewed UniProt annotation; not a new primary-paper review,Trial registration only,https://clinicaltrials.gov/study/NCT02224599,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
PURG,ENSG00000172733,Unsafe,Protein,False,True,2.5,11.5,102,19,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; amygdala: 4.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 6.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 11.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 5.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 1.3 nTPM; continuous selectivity; colon: 0.3 nTPM; positive ihc; hippocampal formation: 4.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 4.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 0.4 nTPM; positive ihc; lung: 0.2 nTPM; positive ihc; midbrain: 3.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 2.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; retina: 4.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 0.1 nTPM; positive ihc; skin: 0 nTPM; positive ihc; spinal cord: 3.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 4.8 nTPM (limit 2); basal ganglia: 6.4 nTPM (limit 2); cerebellum: 11.5 nTPM (limit 2); cerebral cortex: 5.5 nTPM (limit 2); hippocampal formation: 4.8 nTPM (limit 2); hypothalamus: 4.8 nTPM (limit 2); midbrain: 3.8 nTPM (limit 2); pituitary gland: 2.9 nTPM (limit 2); retina: 4.2 nTPM (limit 2); spinal cord: 3.7 nTPM (limit 2),caudate / glial cells: Low (Enhanced); caudate / neuronal cells: Medium (Enhanced); cerebellum / molecular layer cells - nucleus: Low (Enhanced); cerebral cortex / glial cells: Low (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); colon / peripheral nerve/ganglion: Low (Enhanced); hippocampus / glial cells: Low (Enhanced); hippocampus / neuronal cells: Medium (Enhanced); kidney / cells in tubules: Low (Enhanced); lung / alveolar cells: Low (Enhanced); lung / macrophages: Low (Enhanced); skeletal muscle / myocytes: Low (Enhanced); skin 2 / epidermal cells: Low (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Glioblastoma Multiforme (TCGA): 65/141 (46.1%); Kidney Chromophobe (TCGA): 8/64 (12.5%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q9UJV8,https://www.uniprot.org/uniprotkb/Q9UJV8/entry,,Isoform 1 is expressed in testis and glioblastoma. Isoform 2 is expressed in fetal lung,,,Nucleus,,12034829,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
QRICH2,ENSG00000129646,Unsafe,RNA,False,True,17.7,17.7,86,3,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,amygdala: 2.2 nTPM; absolute ceiling; basal ganglia: 3.2 nTPM; absolute ceiling; hippocampal formation: 2.5 nTPM; absolute ceiling; hypothalamus: 3.1 nTPM; absolute ceiling; midbrain: 2.3 nTPM; absolute ceiling; retina: 2.6 nTPM; absolute ceiling; spinal cord: 2.4 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 2.2 nTPM (limit 2); basal ganglia: 3.2 nTPM (limit 2); hippocampal formation: 2.5 nTPM (limit 2); hypothalamus: 3.1 nTPM (limit 2); midbrain: 2.3 nTPM (limit 2); retina: 2.6 nTPM (limit 2); spinal cord: 2.4 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 38/50 (76.0%); Glioblastoma Multiforme (validation): 41/58 (70.7%); Testicular Germ Cell Tumor (TCGA): 50/133 (37.6%),breast cancer: 0/10 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q9H0J4,https://www.uniprot.org/uniprotkb/Q9H0J4/entry,Has an essential role in the formation of sperm flagella and flagellar structure maintainance. It acts as a suppressor of ubiquitination and degradation of proteins involved in flagellar development and motility,Expressed in the sperm,Spermatogenic failure 35: An autosomal recessive infertility disorder caused by spermatogenesis defects that result in multiple abnormalities of sperm flagellum and severely impaired spermatozoa motility.,,"Nucleus membrane Nucleus Cytoplasm Cell projection, cilium, flagellum",30683861,30683861,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
R3HCC1L,ENSG00000166024,Unsafe,Protein,False,True,30.3,30.3,86,63,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 8.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 6.4 nTPM; absolute ceiling; basal ganglia: 7 nTPM; absolute ceiling; bone marrow: 17.2 nTPM; absolute ceiling;continuous selectivity; cerebellum: 9.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 6 nTPM; positive ihc;absolute ceiling; choroid plexus: 8.8 nTPM; absolute ceiling;continuous selectivity; colon: 11.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 6.2 nTPM; positive ihc;absolute ceiling; esophagus: 12.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 8 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 6.8 nTPM; absolute ceiling; hypothalamus: 6.3 nTPM; absolute ceiling; kidney: 11.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 13.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 10.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 11.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 7.3 nTPM; absolute ceiling; pancreas: 10.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 10.2 nTPM; positive ihc;absolute ceiling; pituitary gland: 8.4 nTPM; absolute ceiling;continuous selectivity; rectum: 9.8 nTPM; positive ihc;absolute ceiling; retina: 9.7 nTPM; absolute ceiling;continuous selectivity; salivary gland: 11.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 9.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 14.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 12 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 6.3 nTPM; positive ihc;absolute ceiling; spinal cord: 9 nTPM; absolute ceiling;continuous selectivity; spleen: 14.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 9.2 nTPM; positive ihc;absolute ceiling; thymus: 13.3 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 9.8 nTPM; positive ihc; tongue: 7.7 nTPM; absolute ceiling; urinary bladder: 12 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 8.3 nTPM (limit 2); amygdala: 6.4 nTPM (limit 2); basal ganglia: 7 nTPM (limit 2); bone marrow: 17.2 nTPM (limit 12); cerebellum: 9.4 nTPM (limit 2); cerebral cortex: 6 nTPM (limit 2); choroid plexus: 8.8 nTPM (limit 2); colon: 11.7 nTPM (limit 6); duodenum: 6.2 nTPM (limit 2); esophagus: 12.7 nTPM (limit 6); heart muscle: 8 nTPM (limit 2); hippocampal formation: 6.8 nTPM (limit 2); hypothalamus: 6.3 nTPM (limit 2); kidney: 11.4 nTPM (limit 2); liver: 13.2 nTPM (limit 2); lung: 10.6 nTPM (limit 2); lymph node: 11.9 nTPM (limit 6); midbrain: 7.3 nTPM (limit 2); pancreas: 10.7 nTPM (limit 2); parathyroid gland: 10.2 nTPM (limit 6); pituitary gland: 8.4 nTPM (limit 2); rectum: 9.8 nTPM (limit 6); retina: 9.7 nTPM (limit 2); salivary gland: 11.5 nTPM (limit 6); skeletal muscle: 9.5 nTPM (limit 2); skin: 14.6 nTPM (limit 10); small intestine: 12 nTPM (limit 2); smooth muscle: 6.3 nTPM (limit 2); spinal cord: 9 nTPM (limit 2); spleen: 14.9 nTPM (limit 10); stomach: 9.2 nTPM (limit 6); thymus: 13.3 nTPM (limit 10); tongue: 7.7 nTPM (limit 6); urinary bladder: 12 nTPM (limit 6),adrenal gland / glandular cells: Low (Enhanced); bronchus / respiratory epithelial cells: Medium (Enhanced); caudate / glial cells: Medium (Enhanced); caudate / neuronal cells: Medium (Enhanced); cerebellum / cells in granular layer: Low (Enhanced); cerebellum / cells in molecular layer: Low (Enhanced); cerebellum / Purkinje cells: Medium (Enhanced); cerebral cortex / glial cells: Medium (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); colon / endothelial cells: Low (Enhanced); colon / glandular cells: Medium (Enhanced); colon / peripheral nerve/ganglion: Low (Enhanced); duodenum / glandular cells: Medium (Enhanced); esophagus / squamous epithelial cells: Medium (Enhanced); heart muscle / cardiomyocytes: Low (Enhanced); hippocampus / glial cells: Low (Enhanced); hippocampus / neuronal cells: Low (Enhanced); kidney / cells in glomeruli: Low (Enhanced); kidney / cells in tubules: Low (Enhanced); liver / cholangiocytes: Low (Enhanced); liver / hepatocytes: Low (Enhanced); lung / macrophages: Medium (Enhanced); lymph node / germinal center cells: Low (Enhanced); lymph node / non-germinal center cells: Low (Enhanced); nasopharynx / respiratory epithelial cells: Medium (Enhanced); oral mucosa / squamous epithelial cells: Medium (Enhanced); pancreas / exocrine glandular cells: Medium (Enhanced); pancreas / pancreatic endocrine cells: Low (Enhanced); parathyroid gland / glandular cells: Medium (Enhanced); rectum / glandular cells: Medium (Enhanced); salivary gland / glandular cells: Low (Enhanced); skeletal muscle / myocytes: Medium (Enhanced); skin 1 / fibroblasts: Low (Enhanced); skin 1 / keratinocytes: Medium (Enhanced); skin 1 / Langerhans: Medium (Enhanced); skin 2 / epidermal cells: Medium (Enhanced); small intestine / glandular cells: Medium (Enhanced); smooth muscle / smooth muscle cells: Medium (Enhanced); spleen / cells in white pulp: Low (Enhanced); stomach 1 / glandular cells: Medium (Enhanced); stomach 2 / glandular cells: Medium (Enhanced); thyroid gland / glandular cells: Low (Enhanced); urinary bladder / urothelial cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Adenocarcinoma (validation): 105/105 (100.0%); Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%),melanoma: 12/12 (100.0%); colorectal cancer: 11/11 (100.0%),29,20,Q7Z5L2,https://www.uniprot.org/uniprotkb/Q7Z5L2/entry,,Expressed in placenta,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
R3HDML,ENSG00000101074,Unsafe,Protein,False,True,0.4,2.3,112,9,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; colon: 0.7 nTPM; positive ihc;continuous selectivity;reproductive not higher; duodenum: 2.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 0.3 nTPM; continuous selectivity; kidney: 0.2 nTPM; positive ihc; small intestine: 2.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; stomach: 0.4 nTPM; continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",duodenum: 2.1 nTPM (limit 2); small intestine: 2.3 nTPM (limit 2),colon / goblet cells: Low (Enhanced); duodenum / goblet cells: Low (Enhanced); kidney / collecting ducts: Medium (Enhanced); kidney / distal tubules: Medium (Enhanced); small intestine / goblet cells: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 197/207 (95.2%); Colon Adenocarcinoma (validation): 315/486 (64.8%); Rectum Adenocarcinoma (TCGA): 55/88 (62.5%),breast cancer: 0/12 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q9H3Y0,https://www.uniprot.org/uniprotkb/Q9H3Y0/entry,Putative serine protease inhibitor,,,"Despite its name, it does not contain a R3H domain",Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
RAB11B,ENSG00000185236,Unsafe,RNA,False,True,110.1,203.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 98.8 nTPM; absolute ceiling;continuous selectivity; adrenal gland: 93.7 nTPM; absolute ceiling;continuous selectivity; amygdala: 123.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 137.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 67.7 nTPM; absolute ceiling;continuous selectivity; cerebellum: 138.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 138.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 64.4 nTPM; absolute ceiling;continuous selectivity; colon: 95.8 nTPM; absolute ceiling;continuous selectivity; duodenum: 74.3 nTPM; absolute ceiling;continuous selectivity; esophagus: 92.5 nTPM; absolute ceiling;continuous selectivity; heart muscle: 162.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 131.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 122.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 125.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; liver: 130.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 95.2 nTPM; absolute ceiling;continuous selectivity; lymph node: 57.3 nTPM; absolute ceiling;continuous selectivity; midbrain: 144.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 126 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 47.2 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 112.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 22.6 nTPM; absolute ceiling; retina: 37 nTPM; absolute ceiling;continuous selectivity; salivary gland: 101.2 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 115.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 98.6 nTPM; absolute ceiling;continuous selectivity; small intestine: 94.5 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 26.8 nTPM; absolute ceiling; spinal cord: 163.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 115.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; stomach: 114.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thymus: 42.9 nTPM; absolute ceiling; thyroid gland: 203.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; tongue: 35.4 nTPM; absolute ceiling; urinary bladder: 96.2 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adipose tissue: 98.8 nTPM (limit 10); adrenal gland: 93.7 nTPM (limit 2); amygdala: 123.8 nTPM (limit 2); basal ganglia: 137.8 nTPM (limit 2); bone marrow: 67.7 nTPM (limit 2); cerebellum: 138.7 nTPM (limit 2); cerebral cortex: 138.7 nTPM (limit 2); choroid plexus: 64.4 nTPM (limit 2); colon: 95.8 nTPM (limit 6); duodenum: 74.3 nTPM (limit 2); esophagus: 92.5 nTPM (limit 6); heart muscle: 162.6 nTPM (limit 2); hippocampal formation: 131.5 nTPM (limit 2); hypothalamus: 122.7 nTPM (limit 2); kidney: 125.7 nTPM (limit 2); liver: 130.6 nTPM (limit 2); lung: 95.2 nTPM (limit 2); lymph node: 57.3 nTPM (limit 6); midbrain: 144.1 nTPM (limit 2); pancreas: 126 nTPM (limit 2); parathyroid gland: 47.2 nTPM (limit 6); pituitary gland: 112.7 nTPM (limit 2); rectum: 22.6 nTPM (limit 6); retina: 37 nTPM (limit 2); salivary gland: 101.2 nTPM (limit 6); skeletal muscle: 115.4 nTPM (limit 2); skin: 98.6 nTPM (limit 10); small intestine: 94.5 nTPM (limit 2); smooth muscle: 26.8 nTPM (limit 2); spinal cord: 163.8 nTPM (limit 2); spleen: 115.8 nTPM (limit 10); stomach: 114.6 nTPM (limit 6); thymus: 42.9 nTPM (limit 10); thyroid gland: 203.6 nTPM (limit 10); tongue: 35.4 nTPM (limit 6); urinary bladder: 96.2 nTPM (limit 6); adipose tissue: 98.8 nTPM (baseline 10); adrenal gland: 93.7 nTPM (baseline 2); amygdala: 123.8 nTPM (baseline 2); basal ganglia: 137.8 nTPM (baseline 2); bone marrow: 67.7 nTPM (baseline 2); cerebellum: 138.7 nTPM (baseline 2); cerebral cortex: 138.7 nTPM (baseline 2); choroid plexus: 64.4 nTPM (baseline 2); colon: 95.8 nTPM (baseline 6); duodenum: 74.3 nTPM (baseline 2); esophagus: 92.5 nTPM (baseline 6); heart muscle: 162.6 nTPM (baseline 2); hippocampal formation: 131.5 nTPM (baseline 2); hypothalamus: 122.7 nTPM (baseline 2); kidney: 125.7 nTPM (baseline 2); liver: 130.6 nTPM (baseline 2); lung: 95.2 nTPM (baseline 2); lymph node: 57.3 nTPM (baseline 6); midbrain: 144.1 nTPM (baseline 2); pancreas: 126 nTPM (baseline 2); parathyroid gland: 47.2 nTPM (baseline 6); pituitary gland: 112.7 nTPM (baseline 2); rectum: 22.6 nTPM (baseline 6); retina: 37 nTPM (baseline 2); salivary gland: 101.2 nTPM (baseline 6); skeletal muscle: 115.4 nTPM (baseline 2); skin: 98.6 nTPM (baseline 10); small intestine: 94.5 nTPM (baseline 2); smooth muscle: 26.8 nTPM (baseline 2); spinal cord: 163.8 nTPM (baseline 2); spleen: 115.8 nTPM (baseline 10); stomach: 114.6 nTPM (baseline 6); thymus: 42.9 nTPM (baseline 10); thyroid gland: 203.6 nTPM (baseline 10); tongue: 35.4 nTPM (baseline 6); urinary bladder: 96.2 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Kidney Renal Clear Cell Carcinoma (TCGA): 521/521 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q15907,https://www.uniprot.org/uniprotkb/Q15907/entry,"The small GTPases Rab are key regulators of intracellular membrane trafficking, from the formation of transport vesicles to their fusion with membranes. Rabs cycle between an inactive GDP-bound form and an active GTP-bound form that is able to recruit to membranes different set of downstream effectors directly responsible for vesicle formation, movement, tethering and fusion (PubMed:14627637, PubMed:19029296, PubMed:19244346, PubMed:20717956, PubMed:21248079, PubMed:22129970, PubMed:26032412). RAB11B plays a role in endocytic recycling, regulating apical recycling of several transmembrane proteins including cystic fibrosis transmembrane conductance regulator/CFTR, epithelial sodium channel/ENaC, potassium voltage-gated channel, and voltage-dependent L-type calcium channel. May also regulate constitutive and regulated secretion, like insulin granule exocytosis. Required for melanosome transport and release from melanocytes. Also regulates V-ATPase intracellular transport in response to extracellular acidosis (PubMed:14627637, PubMed:19029296, PubMed:19244346, PubMed:20717956, PubMed:21248079, PubMed:22129970). Promotes Rabin8/RAB3IP preciliary vesicular trafficking to mother centriole by forming a ciliary targeting complex containing Rab11, ASAP1, Rabin8/RAB3IP, RAB11FIP3 and ARF4, thereby regulating ciliogenesis initiation (PubMed:25673879). On the contrary, upon LPAR1 receptor signaling pathway activation, interaction with phosphorylated WDR44 prevents Rab11-RAB3IP-RAB11FIP3 complex formation and cilia growth (PubMed:31204173). Also interacts with RABL3 to promote ciliary vesicle formation (PubMed:36052645)",,"Neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter: An autosomal dominant neurodevelopmental disorder apparent in infancy and characterized by severe intellectual disability with absent speech, epilepsy, and hypotonia. Additionally, visual problems, musculoskeletal abnormalities, and microcephaly can be present. Brain imaging shows decreased cortical white matter, often with decreased cerebellar white matter, thin corpus callosum, and thin brainstem.",,"Recycling endosome membrane Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane Cytoplasmic vesicle, phagosome membrane Cytoplasmic vesicle",14627637|19029296|19244346|20717956|21248079|22129970|25673879|26032412|31204173|36052645,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
RAB27B,ENSG00000041353,Unsafe,Protein,False,True,19.8,43.0,77,35,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 2.5 nTPM; positive ihc;absolute ceiling; amygdala: 3.7 nTPM; absolute ceiling; bone marrow: 1 nTPM; positive ihc; cerebellum: 0.1 nTPM; positive ihc; cerebral cortex: 14.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 4.7 nTPM; positive ihc; duodenum: 4.9 nTPM; positive ihc;absolute ceiling; esophagus: 13.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 2.7 nTPM; absolute ceiling; hypothalamus: 4.2 nTPM; absolute ceiling; kidney: 0.3 nTPM; positive ihc; liver: 1.2 nTPM; positive ihc; lung: 6.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 0.5 nTPM; positive ihc; midbrain: 2.1 nTPM; absolute ceiling; pancreas: 3.9 nTPM; positive ihc;absolute ceiling; parathyroid gland: 2.2 nTPM; positive ihc; rectum: 5.1 nTPM; positive ihc; salivary gland: 13.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 15.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 4.7 nTPM; positive ihc;absolute ceiling; smooth muscle: 0.9 nTPM; positive ihc; spleen: 1.6 nTPM; positive ihc; stomach: 43 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 6 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 2.5 nTPM (limit 2); amygdala: 3.7 nTPM (limit 2); cerebral cortex: 14.6 nTPM (limit 2); duodenum: 4.9 nTPM (limit 2); esophagus: 13.5 nTPM (limit 6); hippocampal formation: 2.7 nTPM (limit 2); hypothalamus: 4.2 nTPM (limit 2); lung: 6.9 nTPM (limit 2); midbrain: 2.1 nTPM (limit 2); pancreas: 3.9 nTPM (limit 2); salivary gland: 13.6 nTPM (limit 6); skin: 15.2 nTPM (limit 10); small intestine: 4.7 nTPM (limit 2); stomach: 43 nTPM (limit 6),adrenal gland / glandular cells: Medium (Enhanced); bone marrow / hematopoietic cells: Medium (Enhanced); cerebellum / Purkinje cells: Low (Enhanced); cerebral cortex / neuropil: Low (Enhanced); colon / glandular cells: High (Enhanced); duodenum / glandular cells: High (Enhanced); esophagus / squamous epithelial cells: Low (Enhanced); kidney / cells in tubules: High (Enhanced); liver / hepatocytes: Low (Enhanced); lung / macrophages: Low (Enhanced); lymph node / non-germinal center cells: Medium (Enhanced); pancreas / exocrine glandular cells: Medium (Enhanced); parathyroid gland / glandular cells: Low (Enhanced); rectum / glandular cells: Low (Enhanced); salivary gland / glandular cells: Medium (Enhanced); skin 1 / keratinocytes: Low (Enhanced); skin 2 / epidermal cells: Low (Enhanced); small intestine / glandular cells: High (Enhanced); smooth muscle / smooth muscle cells: Medium (Enhanced); spleen / cells in red pulp: Medium (Enhanced); stomach 1 / glandular cells: Medium (Enhanced); stomach 2 / glandular cells: High (Enhanced); urinary bladder / urothelial cells: High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 76/80 (95.0%); Prostate Adenocarcinoma (TCGA): 453/480 (94.4%); Breast Invasive Carcinoma (validation): 47/50 (94.0%),prostate cancer: 12/12 (100.0%); breast cancer: 10/12 (83.3%),31,20,O00194,https://www.uniprot.org/uniprotkb/O00194/entry,"The small GTPases Rab are key regulators of intracellular membrane trafficking, from the formation of transport vesicles to their fusion with membranes. Rabs cycle between an inactive GDP-bound form and an active GTP-bound form that is able to recruit to membranes different sets of downstream effectors directly responsible for vesicle formation, movement, tethering and fusion (PubMed:21775604, PubMed:30771381). RAB27B regulates homeostasis of late endocytic pathway, including endosomal positioning, maturation and secretion (PubMed:30771381). Plays a role in NTRK2/TRKB axonal anterograde transport by facilitating the association of NTRK2/TRKB with KLC1 (PubMed:21775604). May be involved in targeting uroplakins to urothelial apical membranes (By similarity)",Expressed primarily in testis,,,Membrane Late endosome,21775604|30771381,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
RAB41,ENSG00000147127,Unsafe,RNA,False,True,3.9,56.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 1.3 nTPM; continuous selectivity; basal ganglia: 1.6 nTPM; continuous selectivity; cerebral cortex: 1.4 nTPM; continuous selectivity; hypothalamus: 1.2 nTPM; continuous selectivity; midbrain: 1.5 nTPM; continuous selectivity; retina: 56 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 1.1 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 56 nTPM (limit 2); retina: 56 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 53/141 (37.6%); Kidney Renal Papillary Cell Carcinoma (TCGA): 10/282 (3.5%); Testicular Germ Cell Tumor (TCGA): 3/133 (2.3%),pancreatic cancer: 12/12 (100.0%); prostate cancer: 11/11 (100.0%),31,20,Q5JT25,https://www.uniprot.org/uniprotkb/Q5JT25/entry,"The small GTPases Rab are key regulators of intracellular membrane trafficking, from the formation of transport vesicles to their fusion with membranes. Rabs cycle between an inactive GDP-bound form and an active GTP-bound form that is able to recruit to membranes different sets of downstream effectors directly responsible for vesicle formation, movement, tethering and fusion (PubMed:23936529). RAB41 is required for normal Golgi ribbon organization and ER-to-Golgi trafficking (PubMed:23936529)","Widely expressed in brain, testis, lung, heart, ovary, colon, kidney, uterus and spleen but not in liver",,,Cytoplasm,23936529,15018353,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
RABGEF1,ENSG00000154710,Unsafe,RNA,False,True,24.6,76.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 15.7 nTPM; absolute ceiling;continuous selectivity; adrenal gland: 13.8 nTPM; absolute ceiling;continuous selectivity; amygdala: 5.4 nTPM; absolute ceiling; basal ganglia: 6.3 nTPM; absolute ceiling;continuous selectivity; bone marrow: 76 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 13 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 12.5 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 13.5 nTPM; absolute ceiling;continuous selectivity; colon: 10.5 nTPM; absolute ceiling;continuous selectivity; duodenum: 7.8 nTPM; absolute ceiling;continuous selectivity; esophagus: 19.2 nTPM; absolute ceiling;continuous selectivity; heart muscle: 9.6 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 5.9 nTPM; absolute ceiling; hypothalamus: 7.8 nTPM; absolute ceiling;continuous selectivity; kidney: 11.2 nTPM; absolute ceiling;continuous selectivity; liver: 14.6 nTPM; absolute ceiling;continuous selectivity; lung: 10.3 nTPM; absolute ceiling;continuous selectivity; lymph node: 11.4 nTPM; absolute ceiling;continuous selectivity; midbrain: 4.9 nTPM; absolute ceiling; pancreas: 9.4 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 14.4 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 4.3 nTPM; absolute ceiling; rectum: 11.6 nTPM; absolute ceiling;continuous selectivity; retina: 48.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 8.5 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 12.8 nTPM; absolute ceiling;continuous selectivity; skin: 23.3 nTPM; absolute ceiling;continuous selectivity; small intestine: 9 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 12 nTPM; absolute ceiling;continuous selectivity; spinal cord: 4.8 nTPM; absolute ceiling; stomach: 10.3 nTPM; absolute ceiling;continuous selectivity; thymus: 13 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 15.6 nTPM; absolute ceiling;continuous selectivity; tongue: 12.9 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 18.5 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adipose tissue: 15.7 nTPM (limit 10); adrenal gland: 13.8 nTPM (limit 2); amygdala: 5.4 nTPM (limit 2); basal ganglia: 6.3 nTPM (limit 2); bone marrow: 76 nTPM (limit 2); cerebellum: 13 nTPM (limit 2); cerebral cortex: 12.5 nTPM (limit 2); choroid plexus: 13.5 nTPM (limit 2); colon: 10.5 nTPM (limit 6); duodenum: 7.8 nTPM (limit 2); esophagus: 19.2 nTPM (limit 6); heart muscle: 9.6 nTPM (limit 2); hippocampal formation: 5.9 nTPM (limit 2); hypothalamus: 7.8 nTPM (limit 2); kidney: 11.2 nTPM (limit 2); liver: 14.6 nTPM (limit 2); lung: 10.3 nTPM (limit 2); lymph node: 11.4 nTPM (limit 6); midbrain: 4.9 nTPM (limit 2); pancreas: 9.4 nTPM (limit 2); parathyroid gland: 14.4 nTPM (limit 6); pituitary gland: 4.3 nTPM (limit 2); rectum: 11.6 nTPM (limit 6); retina: 48.5 nTPM (limit 2); salivary gland: 8.5 nTPM (limit 6); skeletal muscle: 12.8 nTPM (limit 2); skin: 23.3 nTPM (limit 10); small intestine: 9 nTPM (limit 2); smooth muscle: 12 nTPM (limit 2); spinal cord: 4.8 nTPM (limit 2); stomach: 10.3 nTPM (limit 6); thymus: 13 nTPM (limit 10); thyroid gland: 15.6 nTPM (limit 10); tongue: 12.9 nTPM (limit 6); urinary bladder: 18.5 nTPM (limit 6); adipose tissue: 15.7 nTPM (baseline 10); adrenal gland: 13.8 nTPM (baseline 2); amygdala: 5.4 nTPM (baseline 2); basal ganglia: 6.3 nTPM (baseline 2); bone marrow: 76 nTPM (baseline 2); cerebellum: 13 nTPM (baseline 2); cerebral cortex: 12.5 nTPM (baseline 2); choroid plexus: 13.5 nTPM (baseline 2); colon: 10.5 nTPM (baseline 6); duodenum: 7.8 nTPM (baseline 2); esophagus: 19.2 nTPM (baseline 6); heart muscle: 9.6 nTPM (baseline 2); hippocampal formation: 5.9 nTPM (baseline 2); hypothalamus: 7.8 nTPM (baseline 2); kidney: 11.2 nTPM (baseline 2); liver: 14.6 nTPM (baseline 2); lung: 10.3 nTPM (baseline 2); lymph node: 11.4 nTPM (baseline 6); midbrain: 4.9 nTPM (baseline 2); pancreas: 9.4 nTPM (baseline 2); parathyroid gland: 14.4 nTPM (baseline 6); pituitary gland: 4.3 nTPM (baseline 2); rectum: 11.6 nTPM (baseline 6); retina: 48.5 nTPM (baseline 2); salivary gland: 8.5 nTPM (baseline 6); skeletal muscle: 12.8 nTPM (baseline 2); skin: 23.3 nTPM (baseline 10); small intestine: 9 nTPM (baseline 2); smooth muscle: 12 nTPM (baseline 2); spinal cord: 4.8 nTPM (baseline 2); stomach: 10.3 nTPM (baseline 6); thymus: 13 nTPM (baseline 10); thyroid gland: 15.6 nTPM (baseline 10); tongue: 12.9 nTPM (baseline 6); urinary bladder: 18.5 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (TCGA): 141/141 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9UJ41,https://www.uniprot.org/uniprotkb/Q9UJ41/entry,"Acts as a guanine-nucleotide releasing factor (GEF) for RAB5A by promoting the conversion of inactive RAB-GDP to the active form RAB-GTP (PubMed:15339665, PubMed:9323142). Forms a complex with RABEP1 that acts as Rab4/Rab5 effector regulating endosome fusion. Involved in endocytic membrane fusion and membrane trafficking of recycling endosomes (PubMed:11452015, PubMed:9323142). Also functions as a ubiquitin ligase (By similarity)",,,,Cytoplasm Early endosome Recycling endosome,11452015|15339665|9323142,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
RABL3,ENSG00000144840,Unsafe,Protein,False,True,8.5,15.6,77,54,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 10.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; adrenal gland: 15.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 9.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 10.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 5.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 8.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 9.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 5 nTPM; absolute ceiling;continuous selectivity; colon: 7.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 5.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 7.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 7 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 8.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 9.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 9.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 9.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 5.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 5.8 nTPM; continuous selectivity; midbrain: 12 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 6.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 11.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 6.1 nTPM; absolute ceiling;continuous selectivity; rectum: 8.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 5.6 nTPM; absolute ceiling;continuous selectivity; salivary gland: 6.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 13.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 6.1 nTPM; positive ihc;continuous selectivity; small intestine: 5.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 6 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 13.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 5.4 nTPM; continuous selectivity; stomach: 6.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 6.2 nTPM; continuous selectivity; thyroid gland: 11.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; tongue: 11.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 7.1 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 10.4 nTPM (limit 10); adrenal gland: 15.6 nTPM (limit 2); amygdala: 9.5 nTPM (limit 2); basal ganglia: 10.7 nTPM (limit 2); bone marrow: 5.3 nTPM (limit 2); cerebellum: 8.7 nTPM (limit 2); cerebral cortex: 9.8 nTPM (limit 2); choroid plexus: 5 nTPM (limit 2); colon: 7.9 nTPM (limit 6); duodenum: 5.3 nTPM (limit 2); esophagus: 7.7 nTPM (limit 6); heart muscle: 7 nTPM (limit 2); hippocampal formation: 8.6 nTPM (limit 2); hypothalamus: 9.8 nTPM (limit 2); kidney: 9.5 nTPM (limit 2); liver: 9.4 nTPM (limit 2); lung: 5.4 nTPM (limit 2); midbrain: 12 nTPM (limit 2); pancreas: 6.2 nTPM (limit 2); parathyroid gland: 11.4 nTPM (limit 6); pituitary gland: 6.1 nTPM (limit 2); rectum: 8.3 nTPM (limit 6); retina: 5.6 nTPM (limit 2); salivary gland: 6.7 nTPM (limit 6); skeletal muscle: 13.3 nTPM (limit 2); small intestine: 5.8 nTPM (limit 2); smooth muscle: 6 nTPM (limit 2); spinal cord: 13.9 nTPM (limit 2); stomach: 6.9 nTPM (limit 6); thyroid gland: 11.9 nTPM (limit 10); tongue: 11.4 nTPM (limit 6); urinary bladder: 7.1 nTPM (limit 6); adipose tissue: 10.4 nTPM (baseline 10); adrenal gland: 15.6 nTPM (baseline 2); amygdala: 9.5 nTPM (baseline 2); basal ganglia: 10.7 nTPM (baseline 2); bone marrow: 5.3 nTPM (baseline 2); cerebellum: 8.7 nTPM (baseline 2); cerebral cortex: 9.8 nTPM (baseline 2); choroid plexus: 5 nTPM (baseline 2); colon: 7.9 nTPM (baseline 6); duodenum: 5.3 nTPM (baseline 2); esophagus: 7.7 nTPM (baseline 6); heart muscle: 7 nTPM (baseline 2); hippocampal formation: 8.6 nTPM (baseline 2); hypothalamus: 9.8 nTPM (baseline 2); kidney: 9.5 nTPM (baseline 2); liver: 9.4 nTPM (baseline 2); lung: 5.4 nTPM (baseline 2); midbrain: 12 nTPM (baseline 2); pancreas: 6.2 nTPM (baseline 2); parathyroid gland: 11.4 nTPM (baseline 6); pituitary gland: 6.1 nTPM (baseline 2); rectum: 8.3 nTPM (baseline 6); retina: 5.6 nTPM (baseline 2); salivary gland: 6.7 nTPM (baseline 6); skeletal muscle: 13.3 nTPM (baseline 2); small intestine: 5.8 nTPM (baseline 2); smooth muscle: 6 nTPM (baseline 2); spinal cord: 13.9 nTPM (baseline 2); stomach: 6.9 nTPM (baseline 6); thyroid gland: 11.9 nTPM (baseline 10); tongue: 11.4 nTPM (baseline 6); urinary bladder: 7.1 nTPM (baseline 6),adipose tissue / adipocytes: Low (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / glial cells: Low (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: Low (Uncertain); cerebellum / cells in molecular layer: Medium (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); colon / glandular cells: Medium (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in glomeruli: Low (Uncertain); kidney / cells in tubules: High (Uncertain); liver / hepatocytes: Low (Uncertain); lung / macrophages: Medium (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Low (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Low (Uncertain); skeletal muscle / myocytes: Medium (Uncertain); skin 1 / fibroblasts: Low (Uncertain); skin 1 / keratinocytes: High (Uncertain); skin 1 / Langerhans: High (Uncertain); skin 2 / epidermal cells: High (Uncertain); small intestine / glandular cells: High (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); stomach 1 / glandular cells: Low (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Low (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 80/80 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Lung Adenocarcinoma (validation): 102/105 (97.1%),colorectal cancer: 6/12 (50.0%); lung cancer: 6/12 (50.0%),31,20,Q5HYI8,https://www.uniprot.org/uniprotkb/Q5HYI8/entry,"Small GTPase required for KRAS signaling regulation and modulation of cell proliferation (PubMed:31406347). Regulator of KRAS prenylation, and probably prenylation of other small GTPases (PubMed:31406347). Required for lymphocyte development and function (By similarity). Not required for myeloid cell development (By similarity). Interacts with Rab11 to promote ciliary vesicle formation at the mother centriole, thereby regulating early ciliogenesis. The GTP-binding capacity of RABL3 is essential for ciliogenesis (PubMed:36052645)",,"Pancreatic cancer 5: A malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue.",,"Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Golgi apparatus",31406347|36052645,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
RAD51,ENSG00000051180,Unsafe,Protein,False,True,23.5,23.5,111,52,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 0.5 nTPM; positive ihc; bone marrow: 10.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 8 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 3.2 nTPM; positive ihc;absolute ceiling; esophagus: 4 nTPM; positive ihc; kidney: 0.5 nTPM; positive ihc; lung: 1.1 nTPM; positive ihc; lymph node: 10.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 0.5 nTPM; positive ihc; rectum: 8.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; salivary gland: 1 nTPM; positive ihc; skin: 3 nTPM; positive ihc; small intestine: 4 nTPM; positive ihc;absolute ceiling; stomach: 1.8 nTPM; positive ihc; thymus: 15.2 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 1.7 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 10.3 nTPM (limit 2); colon: 8 nTPM (limit 6); duodenum: 3.2 nTPM (limit 2); lymph node: 10.7 nTPM (limit 6); rectum: 8.8 nTPM (limit 6); small intestine: 4 nTPM (limit 2); thymus: 15.2 nTPM (limit 10),adrenal gland / glandular cells: Low (Enhanced); bone marrow / hematopoietic cells: Low (Enhanced); bronchus / respiratory epithelial cells: Low (Enhanced); caudate / neuronal cells: Low (Enhanced); colon / glandular cells: Low (Enhanced); duodenum / glandular cells: Low (Enhanced); esophagus / squamous epithelial cells: Low (Enhanced); kidney / cells in tubules: Low (Enhanced); lung / macrophages: Low (Enhanced); lymph node / germinal center cells: Low (Enhanced); lymph node / non-germinal center cells: Low (Enhanced); nasopharynx / respiratory epithelial cells: Low (Enhanced); oral mucosa / squamous epithelial cells: Low (Enhanced); parathyroid gland / glandular cells: Low (Enhanced); rectum / glandular cells: Low (Enhanced); salivary gland / glandular cells: Low (Enhanced); skin 1 / cells in basal layer: Medium (Enhanced); skin 1 / cells in spinous layer: Medium (Enhanced); skin 1 / langerhans cells: Medium (Enhanced); skin 2 / cells in basal layer: Medium (Enhanced); skin 2 / cells in spinous layer: Medium (Enhanced); skin 2 / langerhans cells: Medium (Enhanced); skin 2 / sebaceous glands: Low (Enhanced); small intestine / glandular cells: Low (Enhanced); stomach 1 / glandular cells: Low (Enhanced); stomach 2 / glandular cells: Low (Enhanced); thymus / cortical cells: High (Enhanced); thymus / medullary cells: Medium (Enhanced); urinary bladder / urothelial cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 273/283 (96.5%); Colon Adenocarcinoma (TCGA): 245/254 (96.5%); Testicular Germ Cell Tumor (TCGA): 128/133 (96.2%),testis cancer: 11/11 (100.0%); skin cancer: 7/9 (77.8%),31,20,Q06609,https://www.uniprot.org/uniprotkb/Q06609/entry,"Homologous DNA recombinase that catalyzes strand exchange, a key step in DNA repair through homologous recombination (HR) (PubMed:12205100, PubMed:12442171, PubMed:15937124, PubMed:17515904, PubMed:17515903, PubMed:18417535, PubMed:19303847, PubMed:20231364, PubMed:20348101, PubMed:22325354, PubMed:23509288, PubMed:23754376, PubMed:24141787, PubMed:26681308, PubMed:27941124, PubMed:28575658, PubMed:32640219, PubMed:37499663, PubMed:38509361, PubMed:7988572). Binds to single-stranded DNA (ssDNA) in an ATP-dependent manner to form nucleoprotein filaments which are essential for the homology search and strand exchange (PubMed:12205100, PubMed:15937124, PubMed:17515904, PubMed:17515903, PubMed:18417535, PubMed:19303847, PubMed:15226506, PubMed:20231364, PubMed:20348101, PubMed:23509288, PubMed:23754376, PubMed:26681308, PubMed:28575658, PubMed:37499663, PubMed:39636933, PubMed:41166468, PubMed:38509361, PubMed:7988572). Catalyzes the recognition of homology and strand exchange between homologous DNA partners to form a joint molecule between a processed DNA break and the repair template (PubMed:12205100, PubMed:18417535, PubMed:19303847, PubMed:20231364, PubMed:20348101, PubMed:23509288, PubMed:23754376, PubMed:26681308, PubMed:28575658, PubMed:38459011). RAD51 targeting to ssDNA promotes removal of replication protein-A (RPA) from ssDNA and stabilization of RAD51-ssDNA filaments by blocking ATP hydrolysis (PubMed:20729859). Nucleosomal DNA is peeled from the histone surface by the RAD51 filament (PubMed:38509361). Recruited to resolve stalled replication forks during replication stress (PubMed:27797818, PubMed:31844045). Also required for homologous recombination during meiosis by acting as an non-catalytic accessory factor for DMC1 recombinase, enabling proper chromosome pairing and crossing over (By similarity). Plays a role in regulating mitochondrial DNA copy number under conditions of oxidative stress in the presence of RAD51C and XRCC3 (PubMed:20413593). Also involved in interstrand cross-link repair (PubMed:26253028)","Highly expressed in testis and thymus, followed by small intestine, placenta, colon, pancreas and ovary (PubMed:18417535). Weakly expressed in breast (PubMed:18417535)","Breast cancer: A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case. Mirror movements 2: A disorder characterized by contralateral involuntary movements that mirror voluntary ones. While mirror movements are occasionally found in young children, persistence beyond the age of 10 is abnormal. Mirror movements occur more commonly in the upper extremities. Fanconi anemia, complementation group R: A disorder affecting all bone marrow elements and resulting in anemia, leukopenia and thrombopenia. It is associated with cardiac, renal and limb malformations, dermal pigmentary changes, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage) and defective DNA repair.",,"Chromosome Nucleus Cytoplasm Cytoplasm, perinuclear region Mitochondrion matrix Cytoplasm, cytoskeleton, microtubule organizing center, centrosome",12205100|12442171|15226506|15937124|17515903|17515904|18417535|19303847|20231364|20348101|20413593|20729859|22325354|23509288|23754376|24141787|26253028|26681308|27797818|27941124|28575658|31844045|32640219|37499663|38459011|38509361|39636933|41166468|7988572,18417535,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
RAD51AP1,ENSG00000111247,Unsafe,RNA,False,True,6.1,16.7,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 16.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 5 nTPM; continuous selectivity; duodenum: 5 nTPM; absolute ceiling;continuous selectivity; esophagus: 3.1 nTPM; continuous selectivity; liver: 1.8 nTPM; continuous selectivity; lymph node: 8.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 6.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 3.1 nTPM; continuous selectivity; small intestine: 4.7 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 1.8 nTPM; continuous selectivity; spleen: 3.3 nTPM; continuous selectivity; stomach: 2.6 nTPM; continuous selectivity; thymus: 14 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 16.7 nTPM (limit 2); duodenum: 5 nTPM (limit 2); lymph node: 8.7 nTPM (limit 6); rectum: 6.3 nTPM (limit 6); small intestine: 4.7 nTPM (limit 2); thymus: 14 nTPM (limit 10); bone marrow: 16.7 nTPM (baseline 2); duodenum: 5 nTPM (baseline 2); lymph node: 8.7 nTPM (baseline 6); rectum: 6.3 nTPM (baseline 6); small intestine: 4.7 nTPM (baseline 2); thymus: 14 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Lung Squamous Cell Carcinoma (validation): 67/68 (98.5%); Colon Adenocarcinoma (TCGA): 236/254 (92.9%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q96B01,https://www.uniprot.org/uniprotkb/Q96B01/entry,"Structure-specific DNA-binding protein involved in DNA repair by promoting RAD51-mediated homologous recombination (PubMed:17996710, PubMed:17996711, PubMed:20871616, PubMed:25288561, PubMed:26323318). Acts by stimulating D-Loop formation by RAD51: specifically enhances joint molecule formation through its structure-specific DNA interaction and its interaction with RAD51 (PubMed:17996710, PubMed:17996711). Binds single-stranded DNA (ssDNA), double-stranded DNA (dsDNA) and secondary DNA structures, such as D-loop structures: has a strong preference for branched-DNA structures that are obligatory intermediates during joint molecule formation (PubMed:17996710, PubMed:17996711, PubMed:22375013, PubMed:9396801). Cooperates with WDR48/UAF1 to stimulate RAD51-mediated homologous recombination: both WDR48/UAF1 and RAD51AP1 have coordinated role in DNA-binding during homologous recombination and DNA repair (PubMed:27239033, PubMed:27463890, PubMed:32350107). WDR48/UAF1 and RAD51AP1 also have a coordinated role in DNA-binding to promote USP1-mediated deubiquitination of FANCD2 (PubMed:31253762). Also involved in meiosis by promoting DMC1-mediated homologous meiotic recombination (PubMed:21307306). Key mediator of alternative lengthening of telomeres (ALT) pathway, a homology-directed repair mechanism of telomere elongation that controls proliferation in aggressive cancers, by stimulating homologous recombination (PubMed:31400850). May also bind RNA; additional evidence is however required to confirm RNA-binding in vivo (PubMed:9396801)","Highly expressed in testis and thymus (PubMed:9396801). Lower levels in colon and small intestine (PubMed:9396801). Little or no expression in spleen, prostate, ovary and peripheral blood leukocytes (PubMed:9396801)",,,"Chromosome Nucleus Chromosome, telomere",17996710|17996711|20871616|21307306|22375013|25288561|26323318|27239033|27463890|31253762|31400850|32350107|9396801,9396801,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
RAD51B,ENSG00000182185,Unsafe,Protein,False,True,8.7,12.7,83,77,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 3 nTPM; positive ihc; adrenal gland: 2.2 nTPM; positive ihc;absolute ceiling; bone marrow: 7.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 2.1 nTPM; positive ihc;absolute ceiling; choroid plexus: 2.8 nTPM; absolute ceiling;continuous selectivity; colon: 2.9 nTPM; positive ihc; duodenum: 1.1 nTPM; positive ihc; esophagus: 3.6 nTPM; positive ihc;continuous selectivity; heart muscle: 1.6 nTPM; positive ihc; kidney: 2.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 2.1 nTPM; positive ihc;absolute ceiling; lung: 2.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 4.7 nTPM; positive ihc;continuous selectivity; midbrain: 2.2 nTPM; absolute ceiling; pancreas: 2.1 nTPM; positive ihc;absolute ceiling; parathyroid gland: 4.7 nTPM; positive ihc;continuous selectivity; rectum: 2.5 nTPM; positive ihc; retina: 2.9 nTPM; absolute ceiling;continuous selectivity; salivary gland: 12.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 1.2 nTPM; positive ihc; skin: 4 nTPM; positive ihc;continuous selectivity; small intestine: 2.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 4.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 3.4 nTPM; absolute ceiling;continuous selectivity; spleen: 2.6 nTPM; positive ihc; stomach: 2.5 nTPM; positive ihc; thymus: 5.8 nTPM; continuous selectivity; thyroid gland: 2.4 nTPM; positive ihc; urinary bladder: 3.5 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 2.2 nTPM (limit 2); bone marrow: 7.3 nTPM (limit 2); cerebral cortex: 2.1 nTPM (limit 2); choroid plexus: 2.8 nTPM (limit 2); kidney: 2.6 nTPM (limit 2); liver: 2.1 nTPM (limit 2); lung: 2.6 nTPM (limit 2); midbrain: 2.2 nTPM (limit 2); pancreas: 2.1 nTPM (limit 2); retina: 2.9 nTPM (limit 2); salivary gland: 12.7 nTPM (limit 6); small intestine: 2.4 nTPM (limit 2); smooth muscle: 4.2 nTPM (limit 2); spinal cord: 3.4 nTPM (limit 2),adipose tissue / adipocytes: Medium (Enhanced); adrenal gland / glandular cells: High (Enhanced); bone marrow / hematopoietic cells: High (Enhanced); bronchus / respiratory epithelial cells: High (Enhanced); caudate / glial cells: Medium (Enhanced); caudate / neuronal cells: High (Enhanced); cerebral cortex / endothelial cells: Medium (Enhanced); cerebral cortex / glial cells: Medium (Enhanced); cerebral cortex / neuronal cells: High (Enhanced); colon / endothelial cells: High (Enhanced); colon / glandular cells: High (Enhanced); colon / peripheral nerve/ganglion: High (Enhanced); duodenum / glandular cells: High (Enhanced); esophagus / squamous epithelial cells: High (Enhanced); heart muscle / cardiomyocytes: Medium (Enhanced); hippocampus / glial cells: High (Enhanced); hippocampus / neuronal cells: High (Enhanced); kidney / cells in glomeruli: High (Enhanced); kidney / cells in tubules: High (Enhanced); liver / cholangiocytes: High (Enhanced); liver / hepatocytes: Medium (Enhanced); lung / alveolar cells type I: High (Enhanced); lung / alveolar cells type II: High (Enhanced); lymph node / germinal center cells: High (Enhanced); lymph node / non-germinal center cells: High (Enhanced); nasopharynx / respiratory epithelial cells: High (Enhanced); oral mucosa / squamous epithelial cells: High (Enhanced); pancreas / exocrine glandular cells: High (Enhanced); pancreas / pancreatic endocrine cells: High (Enhanced); parathyroid gland / glandular cells: High (Enhanced); rectum / glandular cells: High (Enhanced); salivary gland / glandular cells: High (Enhanced); skeletal muscle / myocytes: High (Enhanced); skin 1 / fibroblasts: High (Enhanced); skin 1 / keratinocytes: Medium (Enhanced); skin 1 / Langerhans: Medium (Enhanced); skin 2 / epidermal cells: High (Enhanced); small intestine / glandular cells: High (Enhanced); smooth muscle / smooth muscle cells: High (Enhanced); spleen / cells in red pulp: High (Enhanced); spleen / cells in white pulp: High (Enhanced); stomach 1 / glandular cells: High (Enhanced); stomach 2 / glandular cells: High (Enhanced); thyroid gland / glandular cells: High (Enhanced); urinary bladder / urothelial cells: High (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 55/58 (94.8%); Pancreatic Adenocarcinoma (validation): 75/80 (93.8%); Rectum Adenocarcinoma (validation): 187/207 (90.3%),breast cancer: 12/12 (100.0%); colorectal cancer: 12/12 (100.0%),30,20,O15315,https://www.uniprot.org/uniprotkb/O15315/entry,"Involved in the homologous recombination repair (HRR) pathway of double-stranded DNA breaks arising during DNA replication or induced by DNA-damaging agents. May promote the assembly of presynaptic RAD51 nucleoprotein filaments. Binds single-stranded DNA and double-stranded DNA and has DNA-dependent ATPase activity. Part of the RAD51 paralog protein complex BCDX2 which acts in the BRCA1-BRCA2-dependent HR pathway. Upon DNA damage, BCDX2 acts downstream of BRCA2 recruitment and upstream of RAD51 recruitment. BCDX2 binds predominantly to the intersection of the four duplex arms of the Holliday junction and to junction of replication forks. The BCDX2 complex was originally reported to bind single-stranded DNA, single-stranded gaps in duplex DNA and specifically to nicks in duplex DNA. The BCDX2 subcomplex RAD51B:RAD51C exhibits single-stranded DNA-dependent ATPase activity suggesting an involvement in early stages of the HR pathway",Expressed in a wide range of tissues,,,Nucleus,11751635|11751636|11842113|12441335|23108668|23149936,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
RAD54B,ENSG00000197275,Unsafe,Protein,False,True,4.9,6.8,77,56,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0.6 nTPM; positive ihc; bone marrow: 2 nTPM; positive ihc;continuous selectivity; cerebellum: 0.6 nTPM; positive ihc; cerebral cortex: 0.6 nTPM; positive ihc; choroid plexus: 2.4 nTPM; absolute ceiling;continuous selectivity; colon: 1.5 nTPM; positive ihc; duodenum: 1.4 nTPM; positive ihc;continuous selectivity; esophagus: 1.3 nTPM; positive ihc; kidney: 0.8 nTPM; positive ihc; liver: 1.4 nTPM; positive ihc;continuous selectivity; lung: 0.7 nTPM; positive ihc; lymph node: 2.7 nTPM; positive ihc;continuous selectivity; pancreas: 0.8 nTPM; positive ihc; parathyroid gland: 0.6 nTPM; positive ihc; rectum: 2 nTPM; positive ihc;continuous selectivity; retina: 6.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 0.8 nTPM; positive ihc; skin: 1.8 nTPM; positive ihc; small intestine: 1.2 nTPM; positive ihc; spleen: 0.9 nTPM; positive ihc; stomach: 1.5 nTPM; positive ihc; thymus: 4.1 nTPM; continuous selectivity; thyroid gland: 1.1 nTPM; positive ihc; urinary bladder: 1.1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 2.4 nTPM (limit 2); retina: 6.8 nTPM (limit 2),adipose tissue / adipocytes: Low (Enhanced); bone marrow / hematopoietic cells: Low (Enhanced); bronchus / respiratory epithelial cells: Medium (Enhanced); caudate / neuronal cells: Low (Enhanced); cerebellum / Purkinje cells: Low (Enhanced); cerebral cortex / endothelial cells: Low (Enhanced); cerebral cortex / glial cells: Low (Enhanced); cerebral cortex / neuronal cells: Low (Enhanced); colon / endothelial cells: Low (Enhanced); colon / glandular cells: Medium (Enhanced); duodenum / glandular cells: Medium (Enhanced); esophagus / squamous epithelial cells: Medium (Enhanced); hippocampus / neuronal cells: Low (Enhanced); kidney / cells in tubules: Medium (Enhanced); liver / cholangiocytes: Low (Enhanced); lung / macrophages: Low (Enhanced); lymph node / germinal center cells: Medium (Enhanced); lymph node / non-germinal center cells: Low (Enhanced); nasopharynx / respiratory epithelial cells: Medium (Enhanced); pancreas / exocrine glandular cells: Medium (Enhanced); parathyroid gland / glandular cells: High (Enhanced); rectum / glandular cells: Medium (Enhanced); salivary gland / glandular cells: Low (Enhanced); skin 1 / keratinocytes: Low (Enhanced); skin 1 / Langerhans: Low (Enhanced); skin 2 / epidermal cells: Low (Enhanced); small intestine / glandular cells: Medium (Enhanced); spleen / cells in white pulp: Medium (Enhanced); stomach 1 / glandular cells: Medium (Enhanced); stomach 2 / glandular cells: Medium (Enhanced); thyroid gland / glandular cells: Low (Enhanced); urinary bladder / urothelial cells: Medium (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 44/50 (88.0%); Colon Adenocarcinoma (validation): 375/486 (77.2%),urothelial cancer: 6/12 (50.0%); lymphoma: 4/12 (33.3%),31,20,Q9Y620,https://www.uniprot.org/uniprotkb/Q9Y620/entry,"Multifunctional ATPase that could play with RAD54, a redundant role in homologous recombination (HR), a major pathway for repairing DNA double-strand breaks (DSBs), single-stranded DNA (ssDNA) gaps, and stalled or collapsed replication forks (PubMed:11884632, PubMed:16428451). Could act as a molecular motor during the homology search and guide RAD51 ssDNA along a donor dsDNA thereby changing the homology search from the diffusion-based mechanism to a motor-guided mechanism (PubMed:11782437, PubMed:11884632, PubMed:16428451). Once DNA strand exchange occured, could dissociate RAD51 from nucleoprotein filaments formed on dsDNA (By similarity). May also function as a molecular adapter, promoting MDM2-MDM4 heterodimerization to facilitate the ubiquitin-dependent degradation of p53, thereby modulating the cellular decision between cell cycle arrest and progression in response to DNA damage (PubMed:25384516)","Abundantly expressed in testis and spleen. Relatively low levels observed in thymus, prostate, ovary and colon",,,"Nucleus, nucleoplasm",11782437|11884632|16428451|25384516,10362364,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
RAD54L,ENSG00000085999,Unsafe,Protein,False,True,15.2,15.2,85,74,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0.5 nTPM; positive ihc; adrenal gland: 0.7 nTPM; positive ihc; basal ganglia: 3.7 nTPM; absolute ceiling; bone marrow: 8.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 2.6 nTPM; positive ihc;absolute ceiling; cerebral cortex: 1.9 nTPM; positive ihc; colon: 3.1 nTPM; positive ihc; duodenum: 1.9 nTPM; positive ihc; esophagus: 5.2 nTPM; positive ihc;continuous selectivity; heart muscle: 0.7 nTPM; positive ihc; kidney: 1.4 nTPM; positive ihc; liver: 0.5 nTPM; positive ihc; lung: 1.1 nTPM; positive ihc; lymph node: 5.4 nTPM; positive ihc;continuous selectivity; pancreas: 0.5 nTPM; positive ihc; rectum: 4.5 nTPM; positive ihc; salivary gland: 0.9 nTPM; positive ihc; skeletal muscle: 1.1 nTPM; positive ihc; skin: 2.2 nTPM; positive ihc; small intestine: 2.7 nTPM; positive ihc;absolute ceiling; smooth muscle: 1.7 nTPM; positive ihc; spinal cord: 3.5 nTPM; absolute ceiling; spleen: 2.7 nTPM; positive ihc; stomach: 1.5 nTPM; positive ihc; thymus: 15 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 1.8 nTPM; positive ihc; urinary bladder: 0.8 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",basal ganglia: 3.7 nTPM (limit 2); bone marrow: 8.6 nTPM (limit 2); cerebellum: 2.6 nTPM (limit 2); small intestine: 2.7 nTPM (limit 2); spinal cord: 3.5 nTPM (limit 2); thymus: 15 nTPM (limit 10),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: High (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: High (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Low (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: High (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 466/486 (95.9%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 270/283 (95.4%); Testicular Germ Cell Tumor (TCGA): 124/133 (93.2%),colorectal cancer: 9/11 (81.8%); glioma: 9/11 (81.8%),31,20,Q92698,https://www.uniprot.org/uniprotkb/Q92698/entry,"Multifunctional ATPase that plays a role in homologous recombination (HR) which is a major pathway for repairing DNA double-strand breaks (DSBs), single-stranded DNA (ssDNA) gaps, and stalled or collapsed replication forks (PubMed:11459989, PubMed:12205100, PubMed:24798879, PubMed:27264870, PubMed:32457312, PubMed:9774452). Acts as a molecular motor during the homology search and guides RAD51 ssDNA along a donor dsDNA thereby changing the homology search from the diffusion-based mechanism to a motor-guided mechanism. Also plays an essential role in RAD51-mediated synaptic complex formation which consists of three strands encased in a protein filament formed once homology is recognized. Once DNA strand exchange occured, dissociates RAD51 from nucleoprotein filaments formed on dsDNA (By similarity)",,,,Nucleus,11459989|12205100|24798879|27264870|32457312|9774452,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
RAD9B,ENSG00000151164,Unsafe,Protein,False,True,11.0,11.0,88,3,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; skeletal muscle: 0.8 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,skeletal muscle / myocytes: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 36/50 (72.0%); Glioblastoma Multiforme (validation): 8/58 (13.8%); Uterine Corpus Endometrial Carcinoma (TCGA): 15/176 (8.5%),melanoma: 10/12 (83.3%); breast cancer: 8/12 (66.7%),31,20,Q6WBX8,https://www.uniprot.org/uniprotkb/Q6WBX8/entry,,Expressed in testis and skeletal muscle,,,,,14500360|14611806,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
RAG1,ENSG00000166349,Unsafe,RNA,False,True,0.8,385.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 0.5 nTPM; continuous selectivity; bone marrow: 4.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 0.4 nTPM; continuous selectivity; duodenum: 0.8 nTPM; continuous selectivity;reproductive not higher; heart muscle: 0.4 nTPM; continuous selectivity; kidney: 1.3 nTPM; continuous selectivity;reproductive not higher; liver: 0.7 nTPM; continuous selectivity; lung: 0.6 nTPM; continuous selectivity; parathyroid gland: 0.6 nTPM; continuous selectivity; retina: 0.6 nTPM; continuous selectivity; salivary gland: 0.4 nTPM; continuous selectivity; small intestine: 1 nTPM; continuous selectivity;reproductive not higher; spleen: 2.7 nTPM; continuous selectivity;reproductive not higher; stomach: 0.5 nTPM; continuous selectivity; thymus: 385 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 2.4 nTPM; continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 4.2 nTPM (limit 2); thymus: 385 nTPM (limit 10); bone marrow: 4.2 nTPM (baseline 2); thymus: 385 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Squamous Cell Carcinoma (validation): 5/68 (7.4%); Glioblastoma Multiforme (validation): 3/58 (5.2%); Pancreatic Adenocarcinoma (validation): 2/80 (2.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P15918,https://www.uniprot.org/uniprotkb/P15918/entry,"Catalytic component of the RAG complex, a multiprotein complex that mediates the DNA cleavage phase during V(D)J recombination. V(D)J recombination assembles a diverse repertoire of immunoglobulin and T-cell receptor genes in developing B and T-lymphocytes through rearrangement of different V (variable), in some cases D (diversity), and J (joining) gene segments. In the RAG complex, RAG1 mediates the DNA-binding to the conserved recombination signal sequences (RSS) and catalyzes the DNA cleavage activities by introducing a double-strand break between the RSS and the adjacent coding segment. RAG2 is not a catalytic component but is required for all known catalytic activities. DNA cleavage occurs in 2 steps: a first nick is introduced in the top strand immediately upstream of the heptamer, generating a 3'-hydroxyl group that can attack the phosphodiester bond on the opposite strand in a direct transesterification reaction, thereby creating 4 DNA ends: 2 hairpin coding ends and 2 blunt, 5'-phosphorylated ends. The chromatin structure plays an essential role in the V(D)J recombination reactions and the presence of histone H3 trimethylated at 'Lys-4' (H3K4me3) stimulates both the nicking and haipinning steps. The RAG complex also plays a role in pre-B cell allelic exclusion, a process leading to expression of a single immunoglobulin heavy chain allele to enforce clonality and monospecific recognition by the B-cell antigen receptor (BCR) expressed on individual B-lymphocytes. The introduction of DNA breaks by the RAG complex on one immunoglobulin allele induces ATM-dependent repositioning of the other allele to pericentromeric heterochromatin, preventing accessibility to the RAG complex and recombination of the second allele. In addition to its endonuclease activity, RAG1 also acts as an E3 ubiquitin-protein ligase that mediates monoubiquitination of histone H3. Histone H3 monoubiquitination is required for the joining step of V(D)J recombination. Mediates polyubiquitination of KPNA1 (By similarity)",Maturing lymphoid cells,"Combined cellular and humoral immune defects with granulomas: Immunodeficiency disease with granulomas in the skin, mucous membranes, and internal organs. Other characteristics include hypogammaglobulinemia, a diminished number of T and B-cells, and sparse thymic tissue on ultrasonography. Severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-negative/NK-cell-positive: A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development. Omenn syndrome: Severe immunodeficiency characterized by the presence of activated, anergic, oligoclonal T-cells, hypereosinophilia, and high IgE levels. Alpha/beta T-cell lymphopenia, with gamma/delta T-cell expansion, severe cytomegalovirus infection and autoimmunity: An immunological disorder characterized by oligoclonal expansion of TCR gamma/delta T-cells, TCR alpha/beta T-cell lymphopenia, severe, disseminated cytomegalovirus infection and autoimmune cytopenia.",,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
RAG2,ENSG00000175097,Unsafe,RNA,False,True,1.0,146.4,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 1.4 nTPM; continuous selectivity;reproductive not higher; thymus: 146.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 23 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,thymus: 146.4 nTPM (limit 10); thyroid gland: 23 nTPM (limit 10); thymus: 146.4 nTPM (baseline 10); thyroid gland: 23 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Thyroid Carcinoma (TCGA): 36/495 (7.3%); Pancreatic Adenocarcinoma (validation): 1/80 (1.2%); Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P55895,https://www.uniprot.org/uniprotkb/P55895/entry,"Core component of the RAG complex, a multiprotein complex that mediates the DNA cleavage phase during V(D)J recombination. V(D)J recombination assembles a diverse repertoire of immunoglobulin and T-cell receptor genes in developing B and T-lymphocytes through rearrangement of different V (variable), in some cases D (diversity), and J (joining) gene segments. DNA cleavage by the RAG complex occurs in 2 steps: a first nick is introduced in the top strand immediately upstream of the heptamer, generating a 3'-hydroxyl group that can attack the phosphodiester bond on the opposite strand in a direct transesterification reaction, thereby creating 4 DNA ends: 2 hairpin coding ends and 2 blunt, 5'-phosphorylated ends. The chromatin structure plays an essential role in the V(D)J recombination reactions and the presence of histone H3 trimethylated at 'Lys-4' (H3K4me3) stimulates both the nicking and haipinning steps. The RAG complex also plays a role in pre-B cell allelic exclusion, a process leading to expression of a single immunoglobulin heavy chain allele to enforce clonality and monospecific recognition by the B-cell antigen receptor (BCR) expressed on individual B-lymphocytes. The introduction of DNA breaks by the RAG complex on one immunoglobulin allele induces ATM-dependent repositioning of the other allele to pericentromeric heterochromatin, preventing accessibility to the RAG complex and recombination of the second allele. In the RAG complex, RAG2 is not the catalytic component but is required for all known catalytic activities mediated by RAG1. It probably acts as a sensor of chromatin state that recruits the RAG complex to H3K4me3 (By similarity)",Cells of the B- and T-lymphocyte lineages,"Combined cellular and humoral immune defects with granulomas: Immunodeficiency disease with granulomas in the skin, mucous membranes, and internal organs. Other characteristics include hypogammaglobulinemia, a diminished number of T and B-cells, and sparse thymic tissue on ultrasonography. Severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-negative/NK-cell-positive: A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development. Omenn syndrome: Severe immunodeficiency characterized by the presence of activated, anergic, oligoclonal T-cells, hypereosinophilia, and high IgE levels.",,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
RALGPS2,ENSG00000116191,Unsafe,Protein,False,True,69.6,69.6,98,40,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; basal ganglia: 3.8 nTPM; absolute ceiling; bone marrow: 10.1 nTPM; positive ihc;absolute ceiling; cerebellum: 4 nTPM; positive ihc;absolute ceiling; cerebral cortex: 3.8 nTPM; positive ihc;absolute ceiling; colon: 13.4 nTPM; positive ihc;absolute ceiling; duodenum: 10.7 nTPM; positive ihc;absolute ceiling; esophagus: 17.3 nTPM; positive ihc;absolute ceiling; heart muscle: 4.5 nTPM; positive ihc;absolute ceiling; hippocampal formation: 2.6 nTPM; absolute ceiling; hypothalamus: 2.5 nTPM; absolute ceiling; kidney: 6.2 nTPM; positive ihc;absolute ceiling; liver: 28.8 nTPM; absolute ceiling; lung: 2.7 nTPM; positive ihc;absolute ceiling; lymph node: 45.3 nTPM; absolute ceiling; pituitary gland: 2.8 nTPM; absolute ceiling; rectum: 12 nTPM; positive ihc;absolute ceiling; retina: 52.1 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 1.3 nTPM; positive ihc; skin: 18.7 nTPM; positive ihc;absolute ceiling; small intestine: 15.9 nTPM; positive ihc;absolute ceiling; spleen: 26.5 nTPM; positive ihc;absolute ceiling; thymus: 14.3 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",basal ganglia: 3.8 nTPM (limit 2); bone marrow: 10.1 nTPM (limit 2); cerebellum: 4 nTPM (limit 2); cerebral cortex: 3.8 nTPM (limit 2); colon: 13.4 nTPM (limit 6); duodenum: 10.7 nTPM (limit 2); esophagus: 17.3 nTPM (limit 6); heart muscle: 4.5 nTPM (limit 2); hippocampal formation: 2.6 nTPM (limit 2); hypothalamus: 2.5 nTPM (limit 2); kidney: 6.2 nTPM (limit 2); liver: 28.8 nTPM (limit 12); lung: 2.7 nTPM (limit 2); lymph node: 45.3 nTPM (limit 24); pituitary gland: 2.8 nTPM (limit 2); rectum: 12 nTPM (limit 6); retina: 52.1 nTPM (limit 2); skin: 18.7 nTPM (limit 10); small intestine: 15.9 nTPM (limit 2); spleen: 26.5 nTPM (limit 10); thymus: 14.3 nTPM (limit 10),bone marrow / hematopoietic cells: Low (Enhanced); bronchus / ciliated cells (cell body): Low (Enhanced); cerebellum / cells in molecular layer: Low (Enhanced); cerebellum / Purkinje cells: Low (Enhanced); cerebral cortex / neuronal cells: Low (Enhanced); colon / endothelial cells: Low (Enhanced); colon / glandular cells: Low (Enhanced); duodenum / glandular cells: Low (Enhanced); esophagus / squamous epithelial cells: Low (Enhanced); heart muscle / cardiomyocytes: Low (Enhanced); kidney / cells in glomeruli: Low (Enhanced); kidney / cells in tubules: Low (Enhanced); lung / macrophages: Low (Enhanced); nasopharynx / ciliated cells (cell body): Medium (Enhanced); rectum / glandular cells: Low (Enhanced); skeletal muscle / myocytes: Low (Enhanced); skin 1 / fibroblasts: Low (Enhanced); skin 1 / keratinocytes: Low (Enhanced); skin 1 / Langerhans: Low (Enhanced); skin 2 / epidermal cells: Low (Enhanced); small intestine / glandular cells: Low (Enhanced); spleen / cells in red pulp: Low (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%); Colon Adenocarcinoma (validation): 485/486 (99.8%),melanoma: 3/12 (25.0%); glioma: 1/11 (9.1%),31,20,Q86X27,https://www.uniprot.org/uniprotkb/Q86X27/entry,Guanine nucleotide exchange factor for the small GTPase RALA. May be involved in cytoskeletal organization. May also be involved in the stimulation of transcription in a Ras-independent fashion (By similarity),,,,Cytoplasm Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
RANBP17,ENSG00000204764,Unsafe,High RNA,False,True,1.3,1.3,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 0.7 nTPM; continuous selectivity; lung: 0.7 nTPM; continuous selectivity; pancreas: 1.3 nTPM; continuous selectivity;reproductive not higher; parathyroid gland: 0.8 nTPM; continuous selectivity; retina: 0.8 nTPM; continuous selectivity; salivary gland: 0.8 nTPM; continuous selectivity; thyroid gland: 1 nTPM; continuous selectivity,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,True,"brain/inhibitory neurons cluster c-6: 215.7 nTPM, 11214 reads; reproductive-cell max 160.2; brain/inhibitory neurons cluster c-14: 188.3 nTPM, 7463 reads; reproductive-cell max 160.2; brain/inhibitory neurons cluster c-15: 187.9 nTPM, 5126 reads; reproductive-cell max 160.2; brain/inhibitory neurons cluster c-17: 201.6 nTPM, 6505 reads; reproductive-cell max 160.2; brain/inhibitory neurons cluster c-23: 211.4 nTPM, 4911 reads; reproductive-cell max 160.2; brain/inhibitory neurons cluster c-25: 211.8 nTPM, 3958 reads; reproductive-cell max 160.2; brain/inhibitory neurons cluster c-26: 189 nTPM, 4231 reads; reproductive-cell max 160.2; brain/inhibitory neurons cluster c-28: 179.3 nTPM, 3645 reads; reproductive-cell max 160.2; brain/excitatory neurons cluster c-29: 342.9 nTPM, 8638 reads; reproductive-cell max 160.2; brain/excitatory neurons cluster c-36: 382.9 nTPM, 6543 reads; reproductive-cell max 160.2; brain/inhibitory neurons cluster c-38: 185.5 nTPM, 1929 reads; reproductive-cell max 160.2",True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA029568; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA029568; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA029568; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA029568; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA029568; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA029568; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA029568; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA029568; conflicting or uncurated primary profile; Colon/Endothelial cells: High, HPA029568; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA029568; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA029568; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA029568; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA029568; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA029568; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA029568; conflicting or uncurated primary profile; Kidney/Cells in tubules: High, HPA029568; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA029568; conflicting or uncurated primary profile; Lung/Alveolar cells: High, HPA029568; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA029568; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA029568; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Low, HPA029568; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA029568; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA029568; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA029568; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA029568; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA029568; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA029568; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA029568; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA029568; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: High, HPA029568; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA029568; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA029568; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA029568; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA029568; conflicting or uncurated primary profile; Adipose tissue/Adipocytes: High, HPA029569; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA029569; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA029569; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA029569; conflicting or uncurated primary profile; Caudate/Neuronal cells: Medium, HPA029569; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Low, HPA029569; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Low, HPA029569; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA029569; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA029569; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Medium, HPA029569; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Medium, HPA029569; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA029569; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA029569; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA029569; conflicting or uncurated primary profile; Duodenum/Glandular cells: High, HPA029569; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Medium, HPA029569; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA029569; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Medium, HPA029569; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA029569; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA029569; conflicting or uncurated primary profile; Liver/Hepatocytes: Medium, HPA029569; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA029569; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA029569; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA029569; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA029569; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA029569; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA029569; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA029569; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA029569; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Medium, HPA029569; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA029569; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA029569; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA029569; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA029569; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Medium, HPA029569; conflicting or uncurated primary profile; Skin 1/Langerhans: Medium, HPA029569; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA029569; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA029569; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA029569; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA029569; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA029569; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA029569; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA029569; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,3.98598611453,382.9,"hpa_single_cell: /Excitatory neurons, max 96.9 nTPM, 1 observations >30; hpa_single_cell: /Glandular and luminal cells, max 44.7 nTPM, 1 observations >30; hpa_single_cell: /Inhibitory neurons, max 145.8 nTPM, 1 observations >30; hpa_single_cell: /Oligodendrocyte precursor cells, max 61.3 nTPM, 1 observations >30; hpa_single_cell: /Oligodendrocytes, max 81.1 nTPM, 1 observations >30; hpa_single_cell_tissue: brain/excitatory neurons, max 382.9 nTPM, 26 observations >30; hpa_single_cell_tissue: brain/inhibitory neurons, max 215.7 nTPM, 14 observations >30; hpa_single_cell_tissue: brain/oligodendrocyte precursor cells, max 61.3 nTPM, 1 observations >30; hpa_single_cell_tissue: brain/oligodendrocytes, max 83 nTPM, 2 observations >30; hpa_single_cell_tissue: eye/rod photoreceptor cells, max 30.2 nTPM, 1 observations >30; hpa_single_cell_tissue: lung/alveolar cells type 1, max 42.3 nTPM, 1 observations >30",Neither,oncoref.target-sets.2026-10-23.2,3.986 TPM; blood/NK; dice_nk; vital,382.9 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (validation): 41/50 (82.0%); Pancreatic Adenocarcinoma (validation): 52/80 (65.0%); Glioblastoma Multiforme (validation): 15/58 (25.9%),liver cancer: 8/12 (66.7%); ovarian cancer: 4/11 (36.4%),31,20,Q9H2T7,https://www.uniprot.org/uniprotkb/Q9H2T7/entry,May function as a nuclear transport receptor,"Highly expressed in testis, moderately in pancreas and weakly in other tissues studied",,,"Cytoplasm Nucleus Nucleus, nuclear pore complex",,11071879,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
RAPGEF6,ENSG00000158987,Unsafe,Protein,False,True,11.8,20.6,80,78,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 3.8 nTPM; positive ihc; adrenal gland: 4.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 3.6 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 3.5 nTPM; absolute ceiling;continuous selectivity; bone marrow: 12.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 17.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 6.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 4.8 nTPM; positive ihc;continuous selectivity; duodenum: 3.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 3.9 nTPM; positive ihc; heart muscle: 3 nTPM; positive ihc;absolute ceiling; hippocampal formation: 4.1 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 4.6 nTPM; absolute ceiling;continuous selectivity; kidney: 4 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 6.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 6.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 20.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 4.1 nTPM; absolute ceiling;continuous selectivity; pancreas: 4.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 6.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 2.8 nTPM; absolute ceiling; rectum: 5.4 nTPM; positive ihc;continuous selectivity; retina: 7.9 nTPM; absolute ceiling;continuous selectivity; salivary gland: 3.9 nTPM; positive ihc; skeletal muscle: 3.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 4.5 nTPM; positive ihc; small intestine: 4 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 3.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 5.1 nTPM; absolute ceiling;continuous selectivity; spleen: 8.6 nTPM; positive ihc;continuous selectivity; stomach: 4.6 nTPM; positive ihc;continuous selectivity; thymus: 14.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 4.8 nTPM; positive ihc; urinary bladder: 5.4 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 4.9 nTPM (limit 2); amygdala: 3.6 nTPM (limit 2); basal ganglia: 3.5 nTPM (limit 2); bone marrow: 12.4 nTPM (limit 2); cerebellum: 17.3 nTPM (limit 2); cerebral cortex: 6.2 nTPM (limit 2); duodenum: 3.7 nTPM (limit 2); heart muscle: 3 nTPM (limit 2); hippocampal formation: 4.1 nTPM (limit 2); hypothalamus: 4.6 nTPM (limit 2); kidney: 4 nTPM (limit 2); liver: 6.3 nTPM (limit 2); lung: 6.7 nTPM (limit 2); lymph node: 20.6 nTPM (limit 6); midbrain: 4.1 nTPM (limit 2); pancreas: 4.1 nTPM (limit 2); parathyroid gland: 6.5 nTPM (limit 6); pituitary gland: 2.8 nTPM (limit 2); retina: 7.9 nTPM (limit 2); skeletal muscle: 3.4 nTPM (limit 2); small intestine: 4 nTPM (limit 2); smooth muscle: 3.9 nTPM (limit 2); spinal cord: 5.1 nTPM (limit 2); thymus: 14.6 nTPM (limit 10),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: High (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: High (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Low (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Pancreatic Adenocarcinoma (validation): 80/80 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%),ovarian cancer: 12/12 (100.0%); breast cancer: 11/12 (91.7%),31,20,Q8TEU7,https://www.uniprot.org/uniprotkb/Q8TEU7/entry,"Guanine nucleotide exchange factor (GEF) for Rap1A, Rap2A and M-Ras GTPases. Does not interact with cAMP","Isoform 3 has highest expression levels in the brain, heart, liver, lung and placenta and is barely detectable in skeletal muscle, kidney and pancreas",,,Cytoplasm Cell membrane,11524421|12581858,11524421,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
RBL1,ENSG00000080839,Unsafe,Protein,False,True,3.3,14.3,98,72,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 1.5 nTPM; positive ihc;continuous selectivity; amygdala: 1.1 nTPM; continuous selectivity; basal ganglia: 1.1 nTPM; continuous selectivity; bone marrow: 14.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 2.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 1.4 nTPM; positive ihc;continuous selectivity; colon: 2.7 nTPM; positive ihc;continuous selectivity; duodenum: 2.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 2.8 nTPM; positive ihc;continuous selectivity; heart muscle: 1.7 nTPM; positive ihc;continuous selectivity; hippocampal formation: 1.1 nTPM; continuous selectivity; hypothalamus: 1 nTPM; continuous selectivity; kidney: 1.6 nTPM; positive ihc;continuous selectivity; liver: 1.3 nTPM; positive ihc;continuous selectivity; lung: 2.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 7.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 1.1 nTPM; continuous selectivity; pancreas: 2.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 2.5 nTPM; positive ihc;continuous selectivity; pituitary gland: 1.1 nTPM; continuous selectivity; rectum: 3.4 nTPM; positive ihc;continuous selectivity;reproductive not higher; retina: 3.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 1.4 nTPM; positive ihc;continuous selectivity; skeletal muscle: 6.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 3.1 nTPM; positive ihc;continuous selectivity; small intestine: 2.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 1.5 nTPM; continuous selectivity; spleen: 3.3 nTPM; positive ihc;continuous selectivity;reproductive not higher; stomach: 2.6 nTPM; positive ihc;continuous selectivity; thymus: 8.5 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 2.6 nTPM; positive ihc;continuous selectivity; tongue: 7.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 1.9 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 14.3 nTPM (limit 2); cerebellum: 2.5 nTPM (limit 2); duodenum: 2.3 nTPM (limit 2); lung: 2.1 nTPM (limit 2); lymph node: 7.1 nTPM (limit 6); pancreas: 2.3 nTPM (limit 2); retina: 3.9 nTPM (limit 2); skeletal muscle: 6.7 nTPM (limit 2); small intestine: 2.4 nTPM (limit 2); smooth muscle: 2.7 nTPM (limit 2); tongue: 7.6 nTPM (limit 6),adrenal gland / glandular cells: Medium (Enhanced); bone marrow / hematopoietic cells: Medium (Enhanced); bronchus / basal cells: Medium (Enhanced); bronchus / ciliated cells (cell body): Medium (Enhanced); bronchus / goblet cells: Medium (Enhanced); caudate / neuronal cells: Low (Enhanced); cerebellum / cells in molecular layer: Low (Enhanced); cerebellum / Purkinje cells: Low (Enhanced); cerebral cortex / neuronal cells: Low (Enhanced); colon / glandular cells: Medium (Enhanced); colon / peripheral nerve/ganglion: Medium (Enhanced); duodenum / glandular cells: Medium (Enhanced); esophagus / squamous epithelial cells: Medium (Enhanced); heart muscle / cardiomyocytes: Low (Enhanced); hippocampus / glial cells: Low (Enhanced); kidney / bowman's capsule: Low (Enhanced); kidney / cells in glomeruli: Medium (Enhanced); kidney / distal tubules: Low (Enhanced); kidney / proximal tubules (cell body): Medium (Enhanced); liver / cholangiocytes: Low (Enhanced); liver / hepatocytes: Low (Enhanced); lung / alveolar cells type I: Low (Enhanced); lung / alveolar cells type II: Low (Enhanced); lung / macrophages: Medium (Enhanced); lymph node / germinal center cells: Low (Enhanced); lymph node / non-germinal center cells: Medium (Enhanced); oral mucosa / squamous epithelial cells: Medium (Enhanced); pancreas / exocrine glandular cells: Low (Enhanced); pancreas / pancreatic endocrine cells: Low (Enhanced); parathyroid gland / glandular cells: Low (Enhanced); rectum / glandular cells: Medium (Enhanced); salivary gland / glandular cells: Medium (Enhanced); skeletal muscle / myocytes: Medium (Enhanced); skin 1 / keratinocytes: Medium (Enhanced); skin 1 / Langerhans: Medium (Enhanced); skin 2 / epidermal cells: Medium (Enhanced); small intestine / glandular cells: Medium (Enhanced); smooth muscle / smooth muscle cells: Low (Enhanced); spleen / cells in red pulp: Low (Enhanced); spleen / cells in white pulp: Low (Enhanced); stomach 1 / glandular cells: Low (Enhanced); stomach 2 / glandular cells: Medium (Enhanced); thyroid gland / glandular cells: Medium (Enhanced); urinary bladder / urothelial cells: Medium (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Rectum Adenocarcinoma (validation): 206/207 (99.5%),melanoma: 12/12 (100.0%); urothelial cancer: 12/12 (100.0%),31,20,P28749,https://www.uniprot.org/uniprotkb/P28749/entry,"Key regulator of entry into cell division (PubMed:17671431). Directly involved in heterochromatin formation by maintaining overall chromatin structure and, in particular, that of constitutive heterochromatin by stabilizing histone methylation (By similarity). Recruits and targets histone methyltransferases KMT5B and KMT5C, leading to epigenetic transcriptional repression (By similarity). Controls histone H4 'Lys-20' trimethylation (By similarity). Probably acts as a transcription repressor by recruiting chromatin-modifying enzymes to promoters (By similarity). Potent inhibitor of E2F-mediated trans-activation (PubMed:8319904). May act as a tumor suppressor (PubMed:8319904)",,,,Nucleus,17671431|8319904,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
RBM12B,ENSG00000183808,Unsafe,Protein,False,True,7.7,10.2,79,37,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 3.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; basal ganglia: 2.2 nTPM; absolute ceiling;continuous selectivity; bone marrow: 3.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 4 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 3.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 3.6 nTPM; positive ihc;continuous selectivity; duodenum: 4.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 3.2 nTPM; positive ihc;continuous selectivity; heart muscle: 4.2 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 2.1 nTPM; absolute ceiling;continuous selectivity; kidney: 4 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 2.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 3.6 nTPM; absolute ceiling;continuous selectivity; lymph node: 7.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 3.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 4.5 nTPM; positive ihc;continuous selectivity; pituitary gland: 3.6 nTPM; absolute ceiling;continuous selectivity; rectum: 4 nTPM; positive ihc;continuous selectivity; retina: 10.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 4.5 nTPM; positive ihc;continuous selectivity; skeletal muscle: 3.8 nTPM; absolute ceiling;continuous selectivity; skin: 4.1 nTPM; positive ihc;continuous selectivity; small intestine: 4.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 3.5 nTPM; absolute ceiling;continuous selectivity; spinal cord: 2.4 nTPM; absolute ceiling;continuous selectivity; spleen: 6.5 nTPM; continuous selectivity; stomach: 4.7 nTPM; positive ihc;continuous selectivity; thymus: 7.1 nTPM; continuous selectivity; thyroid gland: 6.5 nTPM; positive ihc;continuous selectivity; tongue: 2.7 nTPM; continuous selectivity; urinary bladder: 3.8 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 3.6 nTPM (limit 2); basal ganglia: 2.2 nTPM (limit 2); bone marrow: 3.2 nTPM (limit 2); cerebellum: 4 nTPM (limit 2); cerebral cortex: 3.9 nTPM (limit 2); duodenum: 4.3 nTPM (limit 2); heart muscle: 4.2 nTPM (limit 2); hippocampal formation: 2.1 nTPM (limit 2); kidney: 4 nTPM (limit 2); liver: 2.8 nTPM (limit 2); lung: 3.6 nTPM (limit 2); lymph node: 7.9 nTPM (limit 6); pancreas: 3.4 nTPM (limit 2); pituitary gland: 3.6 nTPM (limit 2); retina: 10.2 nTPM (limit 2); skeletal muscle: 3.8 nTPM (limit 2); small intestine: 4.2 nTPM (limit 2); smooth muscle: 3.5 nTPM (limit 2); spinal cord: 2.4 nTPM (limit 2); adrenal gland: 3.6 nTPM (baseline 2); basal ganglia: 2.2 nTPM (baseline 2); bone marrow: 3.2 nTPM (baseline 2); cerebellum: 4 nTPM (baseline 2); cerebral cortex: 3.9 nTPM (baseline 2); duodenum: 4.3 nTPM (baseline 2); heart muscle: 4.2 nTPM (baseline 2); hippocampal formation: 2.1 nTPM (baseline 2); kidney: 4 nTPM (baseline 2); liver: 2.8 nTPM (baseline 2); lung: 3.6 nTPM (baseline 2); lymph node: 7.9 nTPM (baseline 6); pancreas: 3.4 nTPM (baseline 2); pituitary gland: 3.6 nTPM (baseline 2); retina: 10.2 nTPM (baseline 2); skeletal muscle: 3.8 nTPM (baseline 2); small intestine: 4.2 nTPM (baseline 2); smooth muscle: 3.5 nTPM (baseline 2); spinal cord: 2.4 nTPM (baseline 2),adrenal gland / glandular cells: Low (Uncertain); bone marrow / hematopoietic cells: Low (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in molecular layer: Low (Uncertain); cerebellum / Purkinje cells: Low (Uncertain); cerebral cortex / neuronal cells: Low (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / glandular cells: Medium (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in tubules: Low (Uncertain); liver / hepatocytes: Medium (Uncertain); nasopharynx / respiratory epithelial cells: Low (Uncertain); oral mucosa / squamous epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); parathyroid gland / glandular cells: Low (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Low (Uncertain); skin 2 / epidermal cells: Low (Uncertain); small intestine / glandular cells: Medium (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Low (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%),colorectal cancer: 8/12 (66.7%); liver cancer: 7/12 (58.3%),31,20,Q8IXT5,https://www.uniprot.org/uniprotkb/Q8IXT5/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
RBM14,ENSG00000239306,Unsafe,Protein,False,True,43.7,49.1,90,79,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 26 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 31 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 23.4 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 26.7 nTPM; absolute ceiling;continuous selectivity; bone marrow: 32.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 47.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 28.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 28.6 nTPM; absolute ceiling;continuous selectivity; colon: 28.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 15.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 33 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 32.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 23.9 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 23.6 nTPM; absolute ceiling;continuous selectivity; kidney: 49.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 39.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 26.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 27.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 22.2 nTPM; absolute ceiling;continuous selectivity; pancreas: 33.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 16.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 33.6 nTPM; absolute ceiling;continuous selectivity; rectum: 17.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 34.7 nTPM; absolute ceiling;continuous selectivity; salivary gland: 24.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 28.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 27.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 28.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 15.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 21.1 nTPM; absolute ceiling;continuous selectivity; spleen: 39.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 29.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 25 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 27.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 11.1 nTPM; absolute ceiling; urinary bladder: 29.4 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 26 nTPM (limit 10); adrenal gland: 31 nTPM (limit 2); amygdala: 23.4 nTPM (limit 2); basal ganglia: 26.7 nTPM (limit 2); bone marrow: 32.3 nTPM (limit 2); cerebellum: 47.7 nTPM (limit 2); cerebral cortex: 28.5 nTPM (limit 2); choroid plexus: 28.6 nTPM (limit 2); colon: 28.4 nTPM (limit 6); duodenum: 15.2 nTPM (limit 2); esophagus: 33 nTPM (limit 6); heart muscle: 32.2 nTPM (limit 2); hippocampal formation: 23.9 nTPM (limit 2); hypothalamus: 23.6 nTPM (limit 2); kidney: 49.1 nTPM (limit 2); liver: 39.5 nTPM (limit 2); lung: 26.4 nTPM (limit 2); lymph node: 27.6 nTPM (limit 6); midbrain: 22.2 nTPM (limit 2); pancreas: 33.1 nTPM (limit 2); parathyroid gland: 16.9 nTPM (limit 6); pituitary gland: 33.6 nTPM (limit 2); rectum: 17.6 nTPM (limit 6); retina: 34.7 nTPM (limit 2); salivary gland: 24.5 nTPM (limit 6); skeletal muscle: 28.6 nTPM (limit 2); skin: 27.5 nTPM (limit 10); small intestine: 28.3 nTPM (limit 2); smooth muscle: 15.1 nTPM (limit 2); spinal cord: 21.1 nTPM (limit 2); spleen: 39.4 nTPM (limit 10); stomach: 29.2 nTPM (limit 6); thymus: 25 nTPM (limit 10); thyroid gland: 27.6 nTPM (limit 10); tongue: 11.1 nTPM (limit 6); urinary bladder: 29.4 nTPM (limit 6),adipose tissue / adipocytes: Medium (Supported); adrenal gland / glandular cells: High (Supported); bone marrow / hematopoietic cells: High (Supported); bronchus / respiratory epithelial cells: High (Supported); caudate / glial cells: High (Supported); caudate / neuronal cells: Medium (Supported); cerebellum / cells in granular layer: High (Supported); cerebellum / cells in molecular layer: High (Supported); cerebellum / Purkinje cells: High (Supported); cerebral cortex / endothelial cells: Medium (Supported); cerebral cortex / glial cells: High (Supported); cerebral cortex / neuronal cells: High (Supported); colon / endothelial cells: High (Supported); colon / glandular cells: High (Supported); colon / peripheral nerve/ganglion: Medium (Supported); duodenum / glandular cells: High (Supported); esophagus / squamous epithelial cells: High (Supported); heart muscle / cardiomyocytes: High (Supported); hippocampus / glial cells: Medium (Supported); hippocampus / neuronal cells: Medium (Supported); kidney / bowman's capsule: Low (Supported); kidney / cells in glomeruli: Low (Supported); kidney / collecting ducts: Low (Supported); kidney / distal tubules: Medium (Supported); liver / cholangiocytes: Low (Supported); lung / alveolar cells type I: High (Supported); lung / alveolar cells type II: High (Supported); lung / endothelial cells: High (Supported); lung / macrophages: Low (Supported); lymph node / germinal center cells: High (Supported); lymph node / non-germinal center cells: High (Supported); nasopharynx / respiratory epithelial cells: High (Supported); oral mucosa / squamous epithelial cells: Medium (Supported); pancreas / exocrine glandular cells: High (Supported); pancreas / pancreatic endocrine cells: Medium (Supported); parathyroid gland / glandular cells: Low (Supported); rectum / glandular cells: High (Supported); salivary gland / glandular cells: High (Supported); skeletal muscle / myocytes: High (Supported); skin 1 / fibroblasts: Medium (Supported); skin 1 / keratinocytes: Medium (Supported); skin 1 / Langerhans: Medium (Supported); skin 2 / epidermal cells: High (Supported); small intestine / glandular cells: High (Supported); smooth muscle / smooth muscle cells: Medium (Supported); spleen / cells in red pulp: Low (Supported); spleen / cells in white pulp: Medium (Supported); stomach 1 / glandular cells: Medium (Supported); stomach 2 / glandular cells: High (Supported); thyroid gland / glandular cells: High (Supported); urinary bladder / urothelial cells: High (Supported),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%); Thyroid Carcinoma (TCGA): 495/495 (100.0%),breast cancer: 12/12 (100.0%); cervical cancer: 12/12 (100.0%),31,20,Q96PK6,https://www.uniprot.org/uniprotkb/Q96PK6/entry,"Isoform 1 may function as a nuclear receptor coactivator, enhancing transcription through other coactivators such as NCOA6 and CITED1. Isoform 2, functions as a transcriptional repressor, modulating transcriptional activities of coactivators including isoform 1, NCOA6 and CITED1 (PubMed:11443112). Regulates centriole biogenesis by suppressing the formation of aberrant centriolar protein complexes in the cytoplasm and thus preserving mitotic spindle integrity. Prevents the formation of the STIL-CPAP complex (which can induce the formation of aberrant centriolar protein complexes) by interfering with the interaction of STIL with CPAP (PubMed:25385835). Plays a role in the regulation of DNA virus-mediated innate immune response by assembling into the HDP-RNP complex, a complex that serves as a platform for IRF3 phosphorylation and subsequent innate immune response activation through the cGAS-STING pathway (PubMed:28712728). Also involved in the regulation of pre-mRNA alternative splicing (PubMed:37548402)","Expressed in all tissues tested, including brain, heart, skeletal muscle, colon, thymus, spleen, kidney, liver, small intestine, placenta, lung and peripheral blood lymphocytes",,,"Nucleus Nucleus, nucleolus Cytoplasm",11443112|25385835|28712728|37548402,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
RBM34,ENSG00000188739,Unsafe,Protein,False,True,20.7,35.0,74,72,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 11.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 9.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 11.9 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 10.6 nTPM; absolute ceiling;continuous selectivity; bone marrow: 35 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 7.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 12.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 14.8 nTPM; absolute ceiling;continuous selectivity; colon: 12.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 17.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 13.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 15 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 11 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 11.6 nTPM; absolute ceiling;continuous selectivity; kidney: 16.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 14.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 11.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 22.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 12.9 nTPM; absolute ceiling;continuous selectivity; pancreas: 12.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 9 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 8.5 nTPM; absolute ceiling;continuous selectivity; rectum: 13.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 6.1 nTPM; absolute ceiling;continuous selectivity; salivary gland: 19.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 19 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 17.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 15.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 11.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 14.3 nTPM; absolute ceiling;continuous selectivity; spleen: 12.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 13.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 15.9 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 15.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 11.4 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 15.1 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 11.8 nTPM (limit 10); adrenal gland: 9.9 nTPM (limit 2); amygdala: 11.9 nTPM (limit 2); basal ganglia: 10.6 nTPM (limit 2); bone marrow: 35 nTPM (limit 2); cerebellum: 7.3 nTPM (limit 2); cerebral cortex: 12.1 nTPM (limit 2); choroid plexus: 14.8 nTPM (limit 2); colon: 12.1 nTPM (limit 6); duodenum: 17.4 nTPM (limit 2); esophagus: 13.4 nTPM (limit 6); heart muscle: 15 nTPM (limit 2); hippocampal formation: 11 nTPM (limit 2); hypothalamus: 11.6 nTPM (limit 2); kidney: 16.5 nTPM (limit 2); liver: 14.4 nTPM (limit 2); lung: 11.5 nTPM (limit 2); lymph node: 22.6 nTPM (limit 6); midbrain: 12.9 nTPM (limit 2); pancreas: 12.7 nTPM (limit 2); parathyroid gland: 9 nTPM (limit 6); pituitary gland: 8.5 nTPM (limit 2); rectum: 13.6 nTPM (limit 6); retina: 6.1 nTPM (limit 2); salivary gland: 19.4 nTPM (limit 6); skeletal muscle: 19 nTPM (limit 2); skin: 17.8 nTPM (limit 10); small intestine: 15.4 nTPM (limit 2); smooth muscle: 11.2 nTPM (limit 2); spinal cord: 14.3 nTPM (limit 2); spleen: 12.4 nTPM (limit 10); stomach: 13.9 nTPM (limit 6); thymus: 15.9 nTPM (limit 10); thyroid gland: 15.2 nTPM (limit 10); tongue: 11.4 nTPM (limit 6); urinary bladder: 15.1 nTPM (limit 6),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: High (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / glial cells: Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: High (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: High (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: High (Approved); heart muscle / cardiomyocytes: High (Approved); hippocampus / glial cells: Medium (Approved); hippocampus / neuronal cells: High (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: Medium (Approved); liver / hepatocytes: High (Approved); lung / alveolar cells: High (Approved); lung / macrophages: High (Approved); lymph node / germinal center cells: High (Approved); lymph node / non-germinal center cells: High (Approved); nasopharynx / respiratory epithelial cells: High (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: High (Approved); parathyroid gland / glandular cells: High (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: High (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: High (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: High (Approved); spleen / cells in white pulp: High (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: High (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%); Head and Neck Squamous Cell Carcinoma (TCGA): 492/492 (100.0%),cervical cancer: 12/12 (100.0%); colorectal cancer: 12/12 (100.0%),31,20,P42696,https://www.uniprot.org/uniprotkb/P42696/entry,,,,,"Nucleus, nucleolus",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | Jamin2021_CT,GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
RBM4,ENSG00000173933,Unsafe,Protein,False,True,100.3,129.5,80,76,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 79.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 108 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 60 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 60.8 nTPM; absolute ceiling;continuous selectivity; bone marrow: 129.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 110.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 59.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 72.4 nTPM; absolute ceiling;continuous selectivity; colon: 92.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 65.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 97.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 73.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 57.9 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 61.8 nTPM; absolute ceiling;continuous selectivity; kidney: 116.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 80.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 75 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 95.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 56 nTPM; absolute ceiling;continuous selectivity; pancreas: 112.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 74.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 83.8 nTPM; absolute ceiling;continuous selectivity; rectum: 60.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 71.7 nTPM; absolute ceiling;continuous selectivity; salivary gland: 86.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 93.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 78.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 81.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 66.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 56 nTPM; absolute ceiling;continuous selectivity; spleen: 102.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; stomach: 95.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 106.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 83.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 69.5 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 81.5 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 79.9 nTPM (limit 10); adrenal gland: 108 nTPM (limit 2); amygdala: 60 nTPM (limit 2); basal ganglia: 60.8 nTPM (limit 2); bone marrow: 129.5 nTPM (limit 2); cerebellum: 110.1 nTPM (limit 2); cerebral cortex: 59.5 nTPM (limit 2); choroid plexus: 72.4 nTPM (limit 2); colon: 92.9 nTPM (limit 6); duodenum: 65.7 nTPM (limit 2); esophagus: 97.5 nTPM (limit 6); heart muscle: 73.2 nTPM (limit 2); hippocampal formation: 57.9 nTPM (limit 2); hypothalamus: 61.8 nTPM (limit 2); kidney: 116.3 nTPM (limit 2); liver: 80.3 nTPM (limit 2); lung: 75 nTPM (limit 2); lymph node: 95.2 nTPM (limit 6); midbrain: 56 nTPM (limit 2); pancreas: 112.2 nTPM (limit 2); parathyroid gland: 74.6 nTPM (limit 6); pituitary gland: 83.8 nTPM (limit 2); rectum: 60.5 nTPM (limit 6); retina: 71.7 nTPM (limit 2); salivary gland: 86.5 nTPM (limit 6); skeletal muscle: 93.2 nTPM (limit 2); skin: 78.4 nTPM (limit 10); small intestine: 81.3 nTPM (limit 2); smooth muscle: 66.3 nTPM (limit 2); spinal cord: 56 nTPM (limit 2); spleen: 102.3 nTPM (limit 10); stomach: 95.5 nTPM (limit 6); thymus: 106.8 nTPM (limit 10); thyroid gland: 83.1 nTPM (limit 10); tongue: 69.5 nTPM (limit 6); urinary bladder: 81.5 nTPM (limit 6),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: High (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: High (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Kidney Renal Clear Cell Carcinoma (TCGA): 521/521 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%),colorectal cancer: 11/11 (100.0%); endometrial cancer: 10/10 (100.0%),31,20,Q9BWF3,https://www.uniprot.org/uniprotkb/Q9BWF3/entry,"RNA-binding factor involved in multiple aspects of cellular processes like alternative splicing of pre-mRNA and translation regulation. Modulates alternative 5'-splice site and exon selection. Acts as a muscle cell differentiation-promoting factor. Activates exon skipping of the PTB pre-mRNA during muscle cell differentiation. Antagonizes the activity of the splicing factor PTBP1 to modulate muscle cell-specific exon selection of alpha tropomyosin. Binds to intronic pyrimidine-rich sequence of the TPM1 and MAPT pre-mRNAs. Required for the translational activation of PER1 mRNA in response to circadian clock. Binds directly to the 3'-UTR of the PER1 mRNA. Exerts a suppressive activity on Cap-dependent translation via binding to CU-rich responsive elements within the 3'UTR of mRNAs, a process increased under stress conditions or during myocytes differentiation. Recruits EIF4A1 to stimulate IRES-dependent translation initiation in respons to cellular stress. Associates to internal ribosome entry segment (IRES) in target mRNA species under stress conditions. Plays a role for miRNA-guided RNA cleavage and translation suppression by promoting association of AGO2-containing miRNPs with their cognate target mRNAs. Associates with miRNAs during muscle cell differentiation. Binds preferentially to 5'-CGCGCG[GCA]-3' motif in vitro","Expressed in the cerebellum. Expressed in neurons and glial cells, including layers II neurons in the frontal cortex and CA1 pyramidal neurons in the hippocampus. Expressed in heart, liver, pancreas, skeletal muscle, placenta, primary fibroblasts and peripheral blood monocytes (at protein level). Ubiquitously expressed. Highly expressed in heart, placenta and skeletal muscle. Weakly expressed in pancreas, kidney, liver, lung and brain",,,"Nucleus Nucleus, nucleolus Nucleus speckle Cytoplasm Cytoplasmic granule",12628928|16260624|16777844|16934801|17284590|17932509|19801630|21343338|21518792|37548402,12628928|16260624|16777844|18708123,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
RBM48,ENSG00000127993,Unsafe,Protein,False,True,9.4,14.1,79,68,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 8 nTPM; continuous selectivity; adrenal gland: 8.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 9.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 11.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 13.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 14 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 13 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 4.5 nTPM; absolute ceiling;continuous selectivity; colon: 7.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 5.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 7.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 9.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 12.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 11.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 7.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 8.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 6.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 8.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 12.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 8.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 4.5 nTPM; positive ihc;continuous selectivity; pituitary gland: 7.3 nTPM; absolute ceiling;continuous selectivity; rectum: 4.5 nTPM; positive ihc;continuous selectivity; retina: 6.3 nTPM; absolute ceiling;continuous selectivity; salivary gland: 8.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 13 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 7.8 nTPM; positive ihc;continuous selectivity; small intestine: 8.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 3.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 14.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 11.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; stomach: 7.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 6.4 nTPM; continuous selectivity; thyroid gland: 8.1 nTPM; positive ihc;continuous selectivity; tongue: 6.7 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 7.1 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 8.3 nTPM (limit 2); amygdala: 9.8 nTPM (limit 2); basal ganglia: 11.9 nTPM (limit 2); bone marrow: 13.8 nTPM (limit 2); cerebellum: 14 nTPM (limit 2); cerebral cortex: 13 nTPM (limit 2); choroid plexus: 4.5 nTPM (limit 2); colon: 7.8 nTPM (limit 6); duodenum: 5.2 nTPM (limit 2); esophagus: 7.4 nTPM (limit 6); heart muscle: 9.7 nTPM (limit 2); hippocampal formation: 12.4 nTPM (limit 2); hypothalamus: 11.1 nTPM (limit 2); kidney: 7.2 nTPM (limit 2); liver: 8.8 nTPM (limit 2); lung: 6.2 nTPM (limit 2); lymph node: 8.2 nTPM (limit 6); midbrain: 12.5 nTPM (limit 2); pancreas: 8.2 nTPM (limit 2); pituitary gland: 7.3 nTPM (limit 2); retina: 6.3 nTPM (limit 2); salivary gland: 8.1 nTPM (limit 6); skeletal muscle: 13 nTPM (limit 2); small intestine: 8.7 nTPM (limit 2); smooth muscle: 3.5 nTPM (limit 2); spinal cord: 14.1 nTPM (limit 2); spleen: 11.1 nTPM (limit 10); stomach: 7.7 nTPM (limit 6); tongue: 6.7 nTPM (limit 6); urinary bladder: 7.1 nTPM (limit 6); adrenal gland: 8.3 nTPM (baseline 2); amygdala: 9.8 nTPM (baseline 2); basal ganglia: 11.9 nTPM (baseline 2); bone marrow: 13.8 nTPM (baseline 2); cerebellum: 14 nTPM (baseline 2); cerebral cortex: 13 nTPM (baseline 2); choroid plexus: 4.5 nTPM (baseline 2); colon: 7.8 nTPM (baseline 6); duodenum: 5.2 nTPM (baseline 2); esophagus: 7.4 nTPM (baseline 6); heart muscle: 9.7 nTPM (baseline 2); hippocampal formation: 12.4 nTPM (baseline 2); hypothalamus: 11.1 nTPM (baseline 2); kidney: 7.2 nTPM (baseline 2); liver: 8.8 nTPM (baseline 2); lung: 6.2 nTPM (baseline 2); lymph node: 8.2 nTPM (baseline 6); midbrain: 12.5 nTPM (baseline 2); pancreas: 8.2 nTPM (baseline 2); pituitary gland: 7.3 nTPM (baseline 2); retina: 6.3 nTPM (baseline 2); salivary gland: 8.1 nTPM (baseline 6); skeletal muscle: 13 nTPM (baseline 2); small intestine: 8.7 nTPM (baseline 2); smooth muscle: 3.5 nTPM (baseline 2); spinal cord: 14.1 nTPM (baseline 2); spleen: 11.1 nTPM (baseline 10); stomach: 7.7 nTPM (baseline 6); tongue: 6.7 nTPM (baseline 6); urinary bladder: 7.1 nTPM (baseline 6),adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Low (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / glial cells: Low (Uncertain); caudate / neuronal cells: Low (Uncertain); cerebellum / cells in granular layer: Medium (Uncertain); cerebellum / cells in molecular layer: Low (Uncertain); cerebellum / Purkinje cells: High (Uncertain); cerebral cortex / neuronal cells: High (Uncertain); cerebral cortex / neuropil: High (Uncertain); colon / endothelial cells: Low (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: Low (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Low (Uncertain); heart muscle / cardiomyocytes: Low (Uncertain); hippocampus / glial cells: Low (Uncertain); hippocampus / neuronal cells: Low (Uncertain); kidney / cells in glomeruli: Medium (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / cholangiocytes: Medium (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / alveolar cells: Medium (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / germinal center cells: Medium (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); nasopharynx / respiratory epithelial cells: Low (Uncertain); oral mucosa / squamous epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: Medium (Uncertain); skin 1 / fibroblasts: Medium (Uncertain); skin 1 / keratinocytes: Low (Uncertain); skin 1 / Langerhans: Medium (Uncertain); skin 2 / epidermal cells: Low (Uncertain); small intestine / glandular cells: Low (Uncertain); smooth muscle / smooth muscle cells: Low (Uncertain); spleen / cells in red pulp: Low (Uncertain); stomach 1 / glandular cells: Low (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Low (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Pancreatic Adenocarcinoma (validation): 80/80 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%),lymphoma: 7/12 (58.3%); liver cancer: 4/12 (33.3%),29,20,Q5RL73,https://www.uniprot.org/uniprotkb/Q5RL73/entry,"As a component of the minor spliceosome, involved in the splicing of U12-type introns in pre-mRNAs",,,,,33509932,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
RBM7,ENSG00000076053,Unsafe,Protein,False,True,15.9,39.2,101,80,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 17.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; adrenal gland: 8.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 4.9 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 5.7 nTPM; absolute ceiling;continuous selectivity; bone marrow: 39.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 5.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 4.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 5.3 nTPM; absolute ceiling;continuous selectivity; colon: 12.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 6 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 13 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 9.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 4.9 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 4.5 nTPM; absolute ceiling;continuous selectivity; kidney: 12.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 17.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 13.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 6.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 5.1 nTPM; absolute ceiling;continuous selectivity; pancreas: 9.7 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 9.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 7 nTPM; absolute ceiling;continuous selectivity; rectum: 10.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 6.6 nTPM; absolute ceiling;continuous selectivity; salivary gland: 12.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 11.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 10.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 11 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 10.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 6.2 nTPM; absolute ceiling;continuous selectivity; spleen: 9.8 nTPM; positive ihc;continuous selectivity; stomach: 11.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 14.8 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 10.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 13.9 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 12.2 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 17.9 nTPM (limit 10); adrenal gland: 8.8 nTPM (limit 2); amygdala: 4.9 nTPM (limit 2); basal ganglia: 5.7 nTPM (limit 2); bone marrow: 39.2 nTPM (limit 2); cerebellum: 5.4 nTPM (limit 2); cerebral cortex: 4.2 nTPM (limit 2); choroid plexus: 5.3 nTPM (limit 2); colon: 12.7 nTPM (limit 6); duodenum: 6 nTPM (limit 2); esophagus: 13 nTPM (limit 6); heart muscle: 9.6 nTPM (limit 2); hippocampal formation: 4.9 nTPM (limit 2); hypothalamus: 4.5 nTPM (limit 2); kidney: 12.3 nTPM (limit 2); liver: 17.4 nTPM (limit 2); lung: 13.3 nTPM (limit 2); lymph node: 6.6 nTPM (limit 6); midbrain: 5.1 nTPM (limit 2); pancreas: 9.7 nTPM (limit 6); parathyroid gland: 9.2 nTPM (limit 6); pituitary gland: 7 nTPM (limit 2); rectum: 10.8 nTPM (limit 6); retina: 6.6 nTPM (limit 2); salivary gland: 12.3 nTPM (limit 6); skeletal muscle: 11.7 nTPM (limit 2); skin: 10.5 nTPM (limit 10); small intestine: 11 nTPM (limit 2); smooth muscle: 10.5 nTPM (limit 2); spinal cord: 6.2 nTPM (limit 2); stomach: 11.8 nTPM (limit 6); thymus: 14.8 nTPM (limit 10); thyroid gland: 10.1 nTPM (limit 10); tongue: 13.9 nTPM (limit 6); urinary bladder: 12.2 nTPM (limit 6),adipose tissue / adipocytes: Medium (Supported); adrenal gland / glandular cells: Medium (Supported); bone marrow / hematopoietic cells: High (Supported); bronchus / basal cells: Low (Supported); bronchus / ciliated cells (cell body): Medium (Supported); bronchus / goblet cells: Medium (Supported); caudate / glial cells: Low (Supported); cerebellum / cells in granular layer: Medium (Supported); cerebellum / cells in molecular layer: Medium (Supported); cerebellum / Purkinje cells: Medium (Supported); cerebral cortex / endothelial cells: Low (Supported); cerebral cortex / neuronal cells: Medium (Supported); cerebral cortex / neuropil: Low (Supported); colon / endothelial cells: Low (Supported); colon / glandular cells: High (Supported); colon / peripheral nerve/ganglion: Low (Supported); duodenum / glandular cells: High (Supported); esophagus / squamous epithelial cells: High (Supported); heart muscle / cardiomyocytes: Low (Supported); hippocampus / glial cells: Low (Supported); hippocampus / neuronal cells: Low (Supported); kidney / cells in glomeruli: Low (Supported); kidney / cells in tubules: Medium (Supported); liver / hepatocytes: Low (Supported); lung / alveolar cells: Medium (Supported); lymph node / germinal center cells: Low (Supported); lymph node / non-germinal center cells: Low (Supported); nasopharynx / basal cells: Low (Supported); nasopharynx / ciliated cells (cell body): Medium (Supported); nasopharynx / goblet cells: Medium (Supported); oral mucosa / squamous epithelial cells: Medium (Supported); parathyroid gland / glandular cells: Medium (Supported); rectum / glandular cells: High (Supported); salivary gland / glandular cells: Medium (Supported); skeletal muscle / myocytes: Medium (Supported); skin 1 / fibroblasts: Low (Supported); skin 1 / keratinocytes: Medium (Supported); skin 1 / Langerhans: Medium (Supported); skin 2 / epidermal cells: Medium (Supported); small intestine / glandular cells: Medium (Supported); smooth muscle / smooth muscle cells: Low (Supported); spleen / cells in red pulp: Medium (Supported); stomach 1 / glandular cells: Medium (Supported); stomach 2 / glandular cells: Medium (Supported); thyroid gland / glandular cells: High (Supported); urinary bladder / urothelial cells: Low (Supported),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%),ovarian cancer: 8/12 (66.7%); stomach cancer: 8/12 (66.7%),31,20,Q9Y580,https://www.uniprot.org/uniprotkb/Q9Y580/entry,"RNA-binding subunit of the trimeric nuclear exosome targeting (NEXT) complex, a complex that functions as an RNA exosome cofactor that directs a subset of non-coding short-lived RNAs for exosomal degradation (PubMed:25189701, PubMed:25525152, PubMed:25578728, PubMed:25852104, PubMed:27871484). NEXT is involved in surveillance and turnover of aberrant transcripts and non-coding RNAs (PubMed:25189701, PubMed:25852104, PubMed:27871484). Binds preferentially polyuridine sequences and associates with newly synthesized RNAs, including pre-mRNAs and short-lived exosome substrates such as promoter upstream transcripts (PROMPTs), enhancer RNAs (eRNAs), and 3'-extended products from small nuclear RNAs (snRNAs) (PubMed:25189701, PubMed:25525152, PubMed:25578728, PubMed:25852104). Participates in several biological processes including DNA damage response (DDR) and stress response (PubMed:25525152, PubMed:30824372). During stress response, activation of the p38MAPK-MK2 pathway decreases RBM7-RNA-binding and subsequently the RNA exosome degradation activities, thereby modulating the turnover of non-coding transcriptome (PubMed:25525152). Participates in DNA damage response (DDR), through its interaction with MEPCE and LARP7, the core subunits of 7SK snRNP complex, that release the positive transcription elongation factor b (P-TEFb) complex from the 7SK snRNP. In turn, activation of P-TEFb complex induces the transcription of P-TEFb-dependent DDR genes to promote cell viability (PubMed:30824372)",Ubiquitous,,,"Nucleus, nucleoplasm Nucleus",25189701|25525152|25578728|25852104|27871484|30824372,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
RBPJL,ENSG00000124232,Unsafe,Protein,False,True,0.2,944.9,82,1,Positive somewhere,True,True,False,False,Excluded,Normal,False,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 0.2 nTPM; continuous selectivity;reproductive not higher; pancreas: 944.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; stomach: 3.5 nTPM; continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",pancreas: 944.9 nTPM (limit 2); pancreas: 944.9 nTPM (baseline 2),pancreas / pancreatic endocrine cells: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (TCGA): 38/176 (21.6%); Pancreatic Adenocarcinoma (validation): 3/80 (3.8%); Ovary Serous Cystadenocarcinoma (TCGA): 3/349 (0.9%),breast cancer: 0/12 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q9UBG7,https://www.uniprot.org/uniprotkb/Q9UBG7/entry,"Putative transcription factor, which cooperates with EBNA2 to activate transcription",,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
RDH10,ENSG00000121039,Unsafe,RNA,False,True,35.0,83.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 41.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; adrenal gland: 6 nTPM; absolute ceiling; amygdala: 5.4 nTPM; absolute ceiling; basal ganglia: 5.3 nTPM; absolute ceiling; bone marrow: 3.2 nTPM; absolute ceiling; cerebral cortex: 6.8 nTPM; absolute ceiling; choroid plexus: 15.5 nTPM; absolute ceiling;continuous selectivity; colon: 16 nTPM; absolute ceiling;continuous selectivity; duodenum: 31.5 nTPM; absolute ceiling;continuous selectivity; esophagus: 19.2 nTPM; absolute ceiling;continuous selectivity; heart muscle: 11.2 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 3.6 nTPM; absolute ceiling; hypothalamus: 4.3 nTPM; absolute ceiling; kidney: 42.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; liver: 39.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 13.2 nTPM; absolute ceiling;continuous selectivity; lymph node: 10.7 nTPM; absolute ceiling; midbrain: 3.8 nTPM; absolute ceiling; pancreas: 33.4 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 8.1 nTPM; absolute ceiling; pituitary gland: 26 nTPM; absolute ceiling;continuous selectivity; rectum: 14.7 nTPM; absolute ceiling;continuous selectivity; retina: 83.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 38.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 6.7 nTPM; absolute ceiling; small intestine: 29.8 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 14.3 nTPM; absolute ceiling;continuous selectivity; spinal cord: 4.7 nTPM; absolute ceiling; stomach: 24 nTPM; absolute ceiling;continuous selectivity; tongue: 7.9 nTPM; absolute ceiling; urinary bladder: 66.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,adipose tissue: 41.8 nTPM (limit 10); adrenal gland: 6 nTPM (limit 2); amygdala: 5.4 nTPM (limit 2); basal ganglia: 5.3 nTPM (limit 2); bone marrow: 3.2 nTPM (limit 2); cerebral cortex: 6.8 nTPM (limit 2); choroid plexus: 15.5 nTPM (limit 2); colon: 16 nTPM (limit 6); duodenum: 31.5 nTPM (limit 2); esophagus: 19.2 nTPM (limit 6); heart muscle: 11.2 nTPM (limit 2); hippocampal formation: 3.6 nTPM (limit 2); hypothalamus: 4.3 nTPM (limit 2); kidney: 42.1 nTPM (limit 2); liver: 39.7 nTPM (limit 2); lung: 13.2 nTPM (limit 2); lymph node: 10.7 nTPM (limit 6); midbrain: 3.8 nTPM (limit 2); pancreas: 33.4 nTPM (limit 2); parathyroid gland: 8.1 nTPM (limit 6); pituitary gland: 26 nTPM (limit 2); rectum: 14.7 nTPM (limit 6); retina: 83.6 nTPM (limit 2); salivary gland: 38.1 nTPM (limit 6); skeletal muscle: 6.7 nTPM (limit 2); small intestine: 29.8 nTPM (limit 2); smooth muscle: 14.3 nTPM (limit 2); spinal cord: 4.7 nTPM (limit 2); stomach: 24 nTPM (limit 6); tongue: 7.9 nTPM (limit 6); urinary bladder: 66.6 nTPM (limit 6); adipose tissue: 41.8 nTPM (baseline 10); adrenal gland: 6 nTPM (baseline 2); amygdala: 5.4 nTPM (baseline 2); basal ganglia: 5.3 nTPM (baseline 2); bone marrow: 3.2 nTPM (baseline 2); cerebral cortex: 6.8 nTPM (baseline 2); choroid plexus: 15.5 nTPM (baseline 2); colon: 16 nTPM (baseline 6); duodenum: 31.5 nTPM (baseline 2); esophagus: 19.2 nTPM (baseline 6); heart muscle: 11.2 nTPM (baseline 2); hippocampal formation: 3.6 nTPM (baseline 2); hypothalamus: 4.3 nTPM (baseline 2); kidney: 42.1 nTPM (baseline 2); liver: 39.7 nTPM (baseline 2); lung: 13.2 nTPM (baseline 2); lymph node: 10.7 nTPM (baseline 6); midbrain: 3.8 nTPM (baseline 2); pancreas: 33.4 nTPM (baseline 2); parathyroid gland: 8.1 nTPM (baseline 6); pituitary gland: 26 nTPM (baseline 2); rectum: 14.7 nTPM (baseline 6); retina: 83.6 nTPM (baseline 2); salivary gland: 38.1 nTPM (baseline 6); skeletal muscle: 6.7 nTPM (baseline 2); small intestine: 29.8 nTPM (baseline 2); smooth muscle: 14.3 nTPM (baseline 2); spinal cord: 4.7 nTPM (baseline 2); stomach: 24 nTPM (baseline 6); tongue: 7.9 nTPM (baseline 6); urinary bladder: 66.6 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (TCGA): 254/254 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8IZV5,https://www.uniprot.org/uniprotkb/Q8IZV5/entry,"Retinol dehydrogenase with a clear preference for NADP. Converts all-trans-retinol to all-trans-retinal. Has no detectable activity towards 11-cis-retinol, 9-cis-retinol and 13-cis-retinol","Detected in retina, kidney, liver, small intestine, placenta, lung, heart and skeletal muscle",,,Microsome membrane Endoplasmic reticulum membrane,12407145,12407145|14596915,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
REC114,ENSG00000183324,Unsafe,RNA,False,True,38.1,38.1,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,heart muscle: 4.5 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,heart muscle: 4.5 nTPM (limit 2); heart muscle: 4.5 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 14/133 (10.5%); Pancreatic Adenocarcinoma (validation): 1/80 (1.2%); Liver Hepatocellular Carcinoma (TCGA): 2/362 (0.6%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q7Z4M0,https://www.uniprot.org/uniprotkb/Q7Z4M0/entry,"Required for DNA double-strand breaks (DSBs) formation in unsynapsed regions during meiotic recombination (PubMed:38148155). Activates DSBs formation in unsynapsed regions, an essential step to ensure completion of synapsis (By similarity). Required for both spermatogenesis and oogenesis (PubMed:31704776, PubMed:38148155)",,"Oocyte/zygote/embryo maturation arrest 10: An autosomal recessive infertility disorder due to abnormal fertilization of mature oocytes, with development of multiple pronuclei or absent pronucleus, and early embryonic arrest.",,Chromosome,31704776|38148155,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
REM2,ENSG00000139890,Unsafe,RNA,False,True,4.7,9.7,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,basal ganglia: 7.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 9.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 2.9 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 1.5 nTPM; continuous selectivity; choroid plexus: 1.3 nTPM; continuous selectivity; hippocampal formation: 1.4 nTPM; continuous selectivity; hypothalamus: 1.8 nTPM; continuous selectivity; kidney: 1.6 nTPM; continuous selectivity; lung: 2.2 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 5.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 2 nTPM; continuous selectivity; spleen: 5.7 nTPM; continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,basal ganglia: 7.5 nTPM (limit 2); bone marrow: 9.7 nTPM (limit 2); cerebellum: 2.9 nTPM (limit 2); lung: 2.2 nTPM (limit 2); pituitary gland: 5.6 nTPM (limit 2); basal ganglia: 7.5 nTPM (baseline 2); bone marrow: 9.7 nTPM (baseline 2); cerebellum: 2.9 nTPM (baseline 2); lung: 2.2 nTPM (baseline 2); pituitary gland: 5.6 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 39/50 (78.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 29/176 (16.5%); Breast Invasive Carcinoma (TCGA): 51/1022 (5.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8IYK8,https://www.uniprot.org/uniprotkb/Q8IYK8/entry,Binds GTP saturably and exhibits a low intrinsic rate of GTP hydrolysis,,,,Cell membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
REXO5,ENSG00000005189,Unsafe,Protein,False,True,333.9,333.9,85,14,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 11.4 nTPM; absolute ceiling; colon: 2 nTPM; positive ihc; kidney: 1.1 nTPM; positive ihc; parathyroid gland: 38.6 nTPM; absolute ceiling; rectum: 2.9 nTPM; positive ihc; retina: 4.1 nTPM; absolute ceiling; stomach: 4.8 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 11.4 nTPM (limit 4); parathyroid gland: 38.6 nTPM (limit 8); retina: 4.1 nTPM (limit 2),colon / glandular cells: Low (Approved); kidney / cells in tubules: Low (Approved); rectum / glandular cells: Low (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 52/58 (89.7%); Prostate Adenocarcinoma (TCGA): 361/480 (75.2%); Colon Adenocarcinoma (validation): 230/486 (47.3%),liver cancer: 6/12 (50.0%); pancreatic cancer: 2/11 (18.2%),29,20,Q96IC2,https://www.uniprot.org/uniprotkb/Q96IC2/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
RFESD,ENSG00000175449,Unsafe,Protein,False,True,11.9,17.6,79,66,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 2.2 nTPM; positive ihc;absolute ceiling; basal ganglia: 2.6 nTPM; absolute ceiling; bone marrow: 17.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 2.8 nTPM; positive ihc;absolute ceiling; cerebral cortex: 1.6 nTPM; positive ihc; choroid plexus: 2.1 nTPM; absolute ceiling; colon: 1.8 nTPM; positive ihc; duodenum: 0.6 nTPM; positive ihc; esophagus: 1.7 nTPM; positive ihc; heart muscle: 3.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; kidney: 2.4 nTPM; positive ihc;absolute ceiling; liver: 2.2 nTPM; positive ihc;absolute ceiling; lung: 1.4 nTPM; positive ihc; lymph node: 1.8 nTPM; positive ihc; midbrain: 2.2 nTPM; absolute ceiling; pancreas: 3.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 2.4 nTPM; positive ihc; pituitary gland: 2.7 nTPM; absolute ceiling; rectum: 1 nTPM; positive ihc; retina: 2.3 nTPM; absolute ceiling; salivary gland: 2.9 nTPM; positive ihc; skeletal muscle: 4.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 4.7 nTPM; positive ihc; small intestine: 1.1 nTPM; positive ihc; smooth muscle: 0.5 nTPM; positive ihc; spinal cord: 2.5 nTPM; absolute ceiling; spleen: 2.3 nTPM; positive ihc; stomach: 2.4 nTPM; positive ihc; thyroid gland: 1.8 nTPM; positive ihc; urinary bladder: 2.2 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 2.2 nTPM (limit 2); basal ganglia: 2.6 nTPM (limit 2); bone marrow: 17.6 nTPM (limit 2); cerebellum: 2.8 nTPM (limit 2); choroid plexus: 2.1 nTPM (limit 2); heart muscle: 3.4 nTPM (limit 2); kidney: 2.4 nTPM (limit 2); liver: 2.2 nTPM (limit 2); midbrain: 2.2 nTPM (limit 2); pancreas: 3.5 nTPM (limit 2); pituitary gland: 2.7 nTPM (limit 2); retina: 2.3 nTPM (limit 2); skeletal muscle: 4.6 nTPM (limit 2); spinal cord: 2.5 nTPM (limit 2); adrenal gland: 2.2 nTPM (baseline 2); basal ganglia: 2.6 nTPM (baseline 2); bone marrow: 17.6 nTPM (baseline 2); cerebellum: 2.8 nTPM (baseline 2); choroid plexus: 2.1 nTPM (baseline 2); heart muscle: 3.4 nTPM (baseline 2); kidney: 2.4 nTPM (baseline 2); liver: 2.2 nTPM (baseline 2); midbrain: 2.2 nTPM (baseline 2); pancreas: 3.5 nTPM (baseline 2); pituitary gland: 2.7 nTPM (baseline 2); retina: 2.3 nTPM (baseline 2); skeletal muscle: 4.6 nTPM (baseline 2); spinal cord: 2.5 nTPM (baseline 2),adrenal gland / glandular cells: High (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / glial cells: Low (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: Medium (Uncertain); cerebellum / cells in molecular layer: Medium (Uncertain); cerebellum / Purkinje cells: High (Uncertain); cerebral cortex / endothelial cells: Medium (Uncertain); cerebral cortex / glial cells: Low (Uncertain); cerebral cortex / neuronal cells: High (Uncertain); cerebral cortex / neuropil: Medium (Uncertain); colon / endothelial cells: Medium (Uncertain); colon / glandular cells: High (Uncertain); colon / peripheral nerve/ganglion: Medium (Uncertain); duodenum / glandular cells: High (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: High (Uncertain); hippocampus / glial cells: Low (Uncertain); hippocampus / neuronal cells: High (Uncertain); kidney / cells in glomeruli: Low (Uncertain); kidney / cells in tubules: High (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / alveolar cells: Low (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / germinal center cells: Medium (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: High (Uncertain); pancreas / pancreatic endocrine cells: Low (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: High (Uncertain); salivary gland / glandular cells: Low (Uncertain); skeletal muscle / myocytes: High (Uncertain); skin 1 / fibroblasts: Low (Uncertain); skin 1 / keratinocytes: Low (Uncertain); skin 1 / Langerhans: Medium (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: High (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); spleen / cells in white pulp: Medium (Uncertain); stomach 1 / glandular cells: High (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Low (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 29/50 (58.0%); Testicular Germ Cell Tumor (TCGA): 56/133 (42.1%); Glioblastoma Multiforme (TCGA): 51/141 (36.2%),prostate cancer: 11/11 (100.0%); colorectal cancer: 11/12 (91.7%),31,20,Q8TAC1,https://www.uniprot.org/uniprotkb/Q8TAC1/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
RFX6,ENSG00000185002,Unsafe,Protein,False,True,0.9,6.3,79,6,Positive somewhere,True,True,False,False,Excluded,Normal,False,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 4.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 0.5 nTPM; positive ihc;continuous selectivity; duodenum: 2.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 2.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; rectum: 1.2 nTPM; positive ihc;continuous selectivity;reproductive not higher; small intestine: 1.2 nTPM; positive ihc;continuous selectivity;reproductive not higher; stomach: 6.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 4.4 nTPM (limit 4); pancreas: 2.2 nTPM (limit 2); stomach: 6.3 nTPM (limit 6); adrenal gland: 4.4 nTPM (baseline 2); duodenum: 2.2 nTPM (baseline 2); pancreas: 2.2 nTPM (baseline 2); stomach: 6.3 nTPM (baseline 6),colon / glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: High (Approved); rectum / glandular cells: Medium (Approved); small intestine / glandular cells: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (TCGA): 17/176 (9.7%); Breast Invasive Carcinoma (validation): 4/50 (8.0%); Prostate Adenocarcinoma (TCGA): 13/480 (2.7%),endometrial cancer: 1/12 (8.3%); liver cancer: 1/12 (8.3%),31,20,Q8HWS3,https://www.uniprot.org/uniprotkb/Q8HWS3/entry,"Transcription factor required to direct islet cell differentiation during endocrine pancreas development. Specifically required for the differentiation of 4 of the 5 islet cell types and for the production of insulin (PubMed:20148032, PubMed:25497100). Not required for pancreatic PP (polypeptide-producing) cells differentiation. Acts downstream of NEUROG3 and regulates the transcription factors involved in beta-cell maturation and function, thereby restricting the expression of the beta-cell differentiation and specification genes, and thus the beta-cell fate choice. Activates transcription by forming a heterodimer with RFX3 and binding to the X-box in the promoter of target genes (PubMed:20148032). Involved in glucose-stimulated insulin secretion by promoting insulin and L-type calcium channel gene transcription (PubMed:25497100)","Expressed in pancreas (PubMed:25497100). Expressed in pancreatic beta-cells (insulin-positive cells) and alpha-cells (glucagon-positive cells) (at protein level). Specifically expressed in pancreas, small intestine and colon (PubMed:20148032). Expressed in endocrine cells in the islets (PubMed:25497100)","Mitchell-Riley syndrome: A disorder characterized by neonatal diabetes, hypoplastic or annular pancreas, duodenal and jejunal atresia, and absent gallbladder. There is no dysmorphic features.",,Nucleus,20148032|25497100,20148032|25497100,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
RFX7,ENSG00000181827,Unsafe,Protein,False,True,7.0,11.2,122,67,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 4.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 1.9 nTPM; continuous selectivity; basal ganglia: 2.1 nTPM; absolute ceiling;continuous selectivity; bone marrow: 6.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 5.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 4.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 2.5 nTPM; positive ihc;continuous selectivity; duodenum: 4.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 3.5 nTPM; positive ihc;continuous selectivity; heart muscle: 2.7 nTPM; continuous selectivity; hippocampal formation: 1.9 nTPM; continuous selectivity; hypothalamus: 2.1 nTPM; absolute ceiling;continuous selectivity; kidney: 2.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 2.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 3.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 5.5 nTPM; positive ihc;continuous selectivity; midbrain: 1.9 nTPM; continuous selectivity; pancreas: 2.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 3.9 nTPM; positive ihc;continuous selectivity; pituitary gland: 2.6 nTPM; absolute ceiling;continuous selectivity; rectum: 3.1 nTPM; positive ihc;continuous selectivity; retina: 8.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 3 nTPM; positive ihc;continuous selectivity; skeletal muscle: 6.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 6.3 nTPM; positive ihc;continuous selectivity; small intestine: 3.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 3.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 2.1 nTPM; absolute ceiling;continuous selectivity; spleen: 4.4 nTPM; positive ihc;continuous selectivity; stomach: 3 nTPM; positive ihc;continuous selectivity; thymus: 11.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 2.9 nTPM; positive ihc; tongue: 5.6 nTPM; continuous selectivity; urinary bladder: 3.4 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 4.4 nTPM (limit 2); basal ganglia: 2.1 nTPM (limit 2); bone marrow: 6.3 nTPM (limit 2); cerebellum: 5.5 nTPM (limit 2); cerebral cortex: 4.3 nTPM (limit 2); duodenum: 4.4 nTPM (limit 2); hypothalamus: 2.1 nTPM (limit 2); kidney: 2.2 nTPM (limit 2); liver: 2.6 nTPM (limit 2); lung: 3.1 nTPM (limit 2); pancreas: 2.6 nTPM (limit 2); pituitary gland: 2.6 nTPM (limit 2); retina: 8.8 nTPM (limit 2); skeletal muscle: 6.9 nTPM (limit 2); small intestine: 3.4 nTPM (limit 2); smooth muscle: 3.5 nTPM (limit 2); spinal cord: 2.1 nTPM (limit 2); thymus: 11.2 nTPM (limit 10),adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: High (Approved); bronchus / basal cells: Medium (Approved); bronchus / ciliated cells (cell body): Low (Approved); bronchus / goblet cells: Medium (Approved); caudate / glial cells: High (Approved); cerebellum / granular cells - nucleus: High (Approved); cerebellum / molecular layer cells - nucleus: High (Approved); cerebellum / white matter cells - nucleus: High (Approved); cerebral cortex / glial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Low (Approved); hippocampus / glial cells: Medium (Approved); kidney / collecting ducts: Medium (Approved); kidney / distal tubules: Medium (Approved); kidney / proximal tubules (cell body): Medium (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells type I: High (Approved); lung / alveolar cells type II: Medium (Approved); lung / endothelial cells: Low (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / basal cells: High (Approved); nasopharynx / ciliated cells (cell body): High (Approved); nasopharynx / goblet cells: High (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: High (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: High (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / keratinocytes: Low (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Low (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: High (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 485/486 (99.8%),skin cancer: 3/12 (25.0%); liver cancer: 2/12 (16.7%),31,20,Q2KHR2,https://www.uniprot.org/uniprotkb/Q2KHR2/entry,"Transcription factor (PubMed:29967452). Acts as a transcriptional activator by binding to promoter regions of target genes, such as PDCD4, PIK3IP1, MXD4, PNRC1, and RFX5 (PubMed:29967452, PubMed:34197623). Plays a role in natural killer (NK) cell maintenance and immunity (PubMed:29967452). May play a role in the process of ciliogenesis in the neural tube and neural tube closure (By similarity)","Widely expressed in many different tissue types including thymus and placenta, with high expression in brain (PubMed:18673564). Expressed in both inhibitory and excitatory neurons in cortex (PubMed:33658631)","Intellectual developmental disorder, autosomal dominant 71, with behavioral abnormalities: An autosomal dominant neurodevelopmental disorder characterized by global developmental delay, hypotonia, speech delay, and impaired intellectual development. Most patients manifest neurobehavioral features including autism spectrum disorder and attention-deficit/hyperactivity disorder. Other frequent features include hypersensitivity to sensory stimuli and sleep problems.",,Nucleus,29967452|34197623,18673564|33658631,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
RFX8,ENSG00000196460,Unsafe,RNA,False,True,1.1,3.7,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 0.6 nTPM; continuous selectivity; bone marrow: 3.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thymus: 0.7 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 3.7 nTPM (limit 2); bone marrow: 3.7 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 24/50 (48.0%); Glioblastoma Multiforme (validation): 4/58 (6.9%); Pancreatic Adenocarcinoma (validation): 5/80 (6.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q6ZV50,https://www.uniprot.org/uniprotkb/Q6ZV50/entry,May be a transcription factor,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
RFXAP,ENSG00000133111,Unsafe,RNA,False,True,6.6,8.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 4.2 nTPM; continuous selectivity; adrenal gland: 3.3 nTPM; absolute ceiling;continuous selectivity; amygdala: 4.2 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 4.1 nTPM; absolute ceiling;continuous selectivity; bone marrow: 5.9 nTPM; absolute ceiling;continuous selectivity; cerebellum: 7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 6.5 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 1.9 nTPM; continuous selectivity; colon: 4.9 nTPM; continuous selectivity; duodenum: 3 nTPM; absolute ceiling;continuous selectivity; esophagus: 2.9 nTPM; continuous selectivity; heart muscle: 3.3 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 4.1 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 4 nTPM; absolute ceiling;continuous selectivity; kidney: 3.2 nTPM; absolute ceiling;continuous selectivity; liver: 2.5 nTPM; absolute ceiling;continuous selectivity; lung: 4.1 nTPM; absolute ceiling;continuous selectivity; lymph node: 6.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 4.1 nTPM; absolute ceiling;continuous selectivity; pancreas: 4.5 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 6 nTPM; continuous selectivity; pituitary gland: 4.5 nTPM; absolute ceiling;continuous selectivity; rectum: 4 nTPM; continuous selectivity; retina: 5.3 nTPM; absolute ceiling;continuous selectivity; salivary gland: 4.7 nTPM; continuous selectivity; skeletal muscle: 4.1 nTPM; absolute ceiling;continuous selectivity; skin: 3.4 nTPM; continuous selectivity; small intestine: 4.3 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 5.5 nTPM; absolute ceiling;continuous selectivity; spinal cord: 4.9 nTPM; absolute ceiling;continuous selectivity; spleen: 4.9 nTPM; continuous selectivity; stomach: 4.1 nTPM; continuous selectivity; thymus: 8 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 5.7 nTPM; continuous selectivity; tongue: 2.9 nTPM; continuous selectivity; urinary bladder: 3.9 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 3.3 nTPM (limit 2); amygdala: 4.2 nTPM (limit 2); basal ganglia: 4.1 nTPM (limit 2); bone marrow: 5.9 nTPM (limit 2); cerebellum: 7 nTPM (limit 2); cerebral cortex: 6.5 nTPM (limit 2); duodenum: 3 nTPM (limit 2); heart muscle: 3.3 nTPM (limit 2); hippocampal formation: 4.1 nTPM (limit 2); hypothalamus: 4 nTPM (limit 2); kidney: 3.2 nTPM (limit 2); liver: 2.5 nTPM (limit 2); lung: 4.1 nTPM (limit 2); lymph node: 6.6 nTPM (limit 6); midbrain: 4.1 nTPM (limit 2); pancreas: 4.5 nTPM (limit 2); pituitary gland: 4.5 nTPM (limit 2); retina: 5.3 nTPM (limit 2); skeletal muscle: 4.1 nTPM (limit 2); small intestine: 4.3 nTPM (limit 2); smooth muscle: 5.5 nTPM (limit 2); spinal cord: 4.9 nTPM (limit 2); adrenal gland: 3.3 nTPM (baseline 2); amygdala: 4.2 nTPM (baseline 2); basal ganglia: 4.1 nTPM (baseline 2); bone marrow: 5.9 nTPM (baseline 2); cerebellum: 7 nTPM (baseline 2); cerebral cortex: 6.5 nTPM (baseline 2); duodenum: 3 nTPM (baseline 2); heart muscle: 3.3 nTPM (baseline 2); hippocampal formation: 4.1 nTPM (baseline 2); hypothalamus: 4 nTPM (baseline 2); kidney: 3.2 nTPM (baseline 2); liver: 2.5 nTPM (baseline 2); lung: 4.1 nTPM (baseline 2); lymph node: 6.6 nTPM (baseline 6); midbrain: 4.1 nTPM (baseline 2); pancreas: 4.5 nTPM (baseline 2); pituitary gland: 4.5 nTPM (baseline 2); retina: 5.3 nTPM (baseline 2); skeletal muscle: 4.1 nTPM (baseline 2); small intestine: 4.3 nTPM (baseline 2); smooth muscle: 5.5 nTPM (baseline 2); spinal cord: 4.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Breast Invasive Carcinoma (validation): 44/50 (88.0%); Glioblastoma Multiforme (TCGA): 114/141 (80.9%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O00287,https://www.uniprot.org/uniprotkb/O00287/entry,Part of the RFX complex that binds to the X-box of MHC II promoters,Ubiquitous,"MHC class II deficiency 4: An autosomal recessive disorder characterized by immunodeficiency, failure to thrive, and recurrent bacterial, viral, fungal and parasitic infections from birth, usually affecting the respiratory and gastrointestinal tract. Patients may die in infancy or early childhood.",,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
RGR,ENSG00000148604,Unsafe,RNA,False,True,0.8,134.8,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,amygdala: 5.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 6.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 0.4 nTPM; continuous selectivity; cerebral cortex: 10.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 33.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 0.5 nTPM; continuous selectivity; hippocampal formation: 1.8 nTPM; continuous selectivity;reproductive not higher; hypothalamus: 2.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 3.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 0.4 nTPM; continuous selectivity; retina: 134.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 5.4 nTPM (limit 2); basal ganglia: 6.6 nTPM (limit 2); cerebral cortex: 10.4 nTPM (limit 2); choroid plexus: 33.4 nTPM (limit 2); hypothalamus: 2.1 nTPM (limit 2); midbrain: 3.2 nTPM (limit 2); retina: 134.8 nTPM (limit 2); amygdala: 5.4 nTPM (baseline 2); basal ganglia: 6.6 nTPM (baseline 2); cerebral cortex: 10.4 nTPM (baseline 2); choroid plexus: 33.4 nTPM (baseline 2); hypothalamus: 2.1 nTPM (baseline 2); midbrain: 3.2 nTPM (baseline 2); retina: 134.8 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 22/141 (15.6%); Glioblastoma Multiforme (validation): 8/58 (13.8%); Uterine Corpus Endometrial Carcinoma (TCGA): 6/176 (3.4%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P47804,https://www.uniprot.org/uniprotkb/P47804/entry,"Non-visual opsin that functions as a light-dependent facilitator of retinoid isomerization and trafficking in retinal pigment epithelium (RPE) and Mueller glia (PubMed:18474598). Participates in a photic visual cycle by complementing the classical enzymatic RPE65/RDH pathway for chromophore regeneration (By similarity). Binds all-trans-retinal via a conserved Schiff-base lysine and, upon illumination, promotes photoisomerization of all-trans-retinal to 11-cis-retinal required for regeneration of visual pigments (By similarity). Also mediates light-dependent mobilization of stored all-trans-retinyl esters from lipid droplets to endoplasmic reticulum membranes, facilitating their processing into 11-cis-retinoids (PubMed:18474598). May also modulate isomerohydrolase activity independent of light (By similarity). Although RGR is structurally a GPCR-family opsin, there is no consistent evidence that RGR activates G proteins or initiates a canonical second-messenger signaling cascade (Probable)",Preferentially expressed at high levels in the retinal pigment epithelium (RPE) and Mueller cells of the neural retina,"Retinitis pigmentosa 44: A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.",,Membrane,18474598,7947717,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
RGS22,ENSG00000132554,Unsafe,RNA,False,True,59.6,59.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,choroid plexus: 6.4 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 6.4 nTPM (limit 2); choroid plexus: 6.4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 39/58 (67.2%); Breast Invasive Carcinoma (validation): 23/50 (46.0%); Breast Invasive Carcinoma (TCGA): 124/1022 (12.1%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NE09,https://www.uniprot.org/uniprotkb/Q8NE09/entry,Inhibits signal transduction by increasing the GTPase activity of G protein alpha subunits thereby driving them into their inactive GDP-bound form,Testis-specific. Expressed in Leydig cells and spermatogenic cells from the spermatogonia to spermatid stages (at protein level),,,Cytoplasm Nucleus,,18703424,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
RGS7,ENSG00000182901,Unsafe,Protein,False,True,3.9,43.6,95,9,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 5.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 17.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 37.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 42.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 43.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 22.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 15.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 9.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 2.8 nTPM; absolute ceiling;continuous selectivity; retina: 4.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 5.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 17.8 nTPM (limit 2); basal ganglia: 37.2 nTPM (limit 2); cerebellum: 42.3 nTPM (limit 2); cerebral cortex: 43.6 nTPM (limit 2); hippocampal formation: 22.5 nTPM (limit 2); hypothalamus: 15.9 nTPM (limit 2); midbrain: 9.3 nTPM (limit 2); pituitary gland: 2.8 nTPM (limit 2); retina: 4.1 nTPM (limit 2); spinal cord: 5.3 nTPM (limit 2); adrenal gland: 5.1 nTPM (baseline 2); amygdala: 17.8 nTPM (baseline 2); basal ganglia: 37.2 nTPM (baseline 2); cerebellum: 42.3 nTPM (baseline 2); cerebral cortex: 43.6 nTPM (baseline 2); hippocampal formation: 22.5 nTPM (baseline 2); hypothalamus: 15.9 nTPM (baseline 2); midbrain: 9.3 nTPM (baseline 2); pituitary gland: 2.8 nTPM (baseline 2); retina: 4.1 nTPM (baseline 2); spinal cord: 5.3 nTPM (baseline 2),caudate / neuronal cells: Medium (Enhanced); cerebellum / GLUC cells - cytoplasm/membrane: High (Enhanced); cerebellum / molecular layer - neuropil: Medium (Enhanced); cerebellum / molecular layer cells - cytoplasm/membrane: Medium (Enhanced); cerebellum / Purkinje cells - cytoplasm/membrane: Low (Enhanced); cerebellum / synaptic glomeruli - core: Medium (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); cerebral cortex / neuropil: Medium (Enhanced); hippocampus / neuronal cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 37/58 (63.8%); Glioblastoma Multiforme (TCGA): 29/141 (20.6%); Pancreatic Adenocarcinoma (validation): 9/80 (11.2%),breast cancer: 0/11 (0.0%); cervical cancer: 0/11 (0.0%),31,20,P49802,https://www.uniprot.org/uniprotkb/P49802/entry,"GTPase activator component of the RGS7-GNB5 complex that regulates G protein-coupled receptor signaling cascades (PubMed:10521509, PubMed:10862767, PubMed:31189666). The RGS7-GNB5 complex acts as an inhibitor signal transduction by promoting the GTPase activity of G protein alpha subunits, such as GNAO1, thereby driving them into their inactive GDP-bound form (PubMed:10521509, PubMed:10862767). May play a role in synaptic vesicle exocytosis (Probable) (PubMed:12659861). Glycine-dependent regulation of the RGS7-GNB5 complex by GPR158 affects mood and cognition via its ability to regulate neuronal excitability in L2/L3 pyramidal neurons of the prefrontal cortex (By similarity). Modulates the activity of potassium channels that are activated by GNAO1 in response to muscarinic acetylcholine receptor M2/CHRM2 signaling (PubMed:15897264)",,,,"Cytoplasm, cytosol Cytoplasm Cell membrane Membrane",10521509|10862767|12659861|15897264|31189666,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
RGS8,ENSG00000135824,Unsafe,Protein,False,True,2.8,29.5,100,5,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 3.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 26.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 9.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 3.3 nTPM; continuous selectivity;reproductive not higher; choroid plexus: 0.9 nTPM; continuous selectivity; hippocampal formation: 2.3 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 6.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 8.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 1.4 nTPM; continuous selectivity; retina: 29.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 4.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 6.4 nTPM; continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 3.4 nTPM (limit 2); basal ganglia: 26.5 nTPM (limit 2); cerebellum: 9.3 nTPM (limit 2); hippocampal formation: 2.3 nTPM (limit 2); hypothalamus: 6.1 nTPM (limit 2); midbrain: 8.1 nTPM (limit 2); retina: 29.5 nTPM (limit 2); spinal cord: 4.1 nTPM (limit 2),caudate / neuronal cells: High (Enhanced); cerebellum / Purkinje cells - cytoplasm/membrane: High (Enhanced); cerebellum / Purkinje cells - dendrites: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 29/58 (50.0%); Testicular Germ Cell Tumor (TCGA): 17/133 (12.8%); Thyroid Carcinoma (TCGA): 37/495 (7.5%),breast cancer: 0/11 (0.0%); cervical cancer: 0/11 (0.0%),31,20,P57771,https://www.uniprot.org/uniprotkb/P57771/entry,"Regulates G protein-coupled receptor signaling cascades, including signaling via muscarinic acetylcholine receptor CHRM2 and dopamine receptor DRD2 (By similarity). Inhibits signal transduction by increasing the GTPase activity of G protein alpha subunits, thereby driving them into their inactive GDP-bound form (PubMed:18434541). Modulates the activity of potassium channels that are activated in response to DRD2 and CHRM2 signaling (By similarity)",,,,"Cell membrane Membrane Perikaryon Cell projection, dendrite Nucleus",18434541,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
RHOXF1,ENSG00000101883,Unsafe,RNA,False,True,14.6,14.6,87,2,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,cerebellum: 12.6 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 3.8 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 3.7 nTPM; absolute ceiling; retina: 2.5 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebellum: 12.6 nTPM (limit 4); choroid plexus: 3.8 nTPM (limit 2); hypothalamus: 3.7 nTPM (limit 2); retina: 2.5 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 16/133 (12.0%); Breast Invasive Carcinoma (validation): 5/50 (10.0%); Ovary Serous Cystadenocarcinoma (TCGA): 16/349 (4.6%),testis cancer: 1/11 (9.1%); breast cancer: 0/12 (0.0%),31,20,Q8NHV9,https://www.uniprot.org/uniprotkb/Q8NHV9/entry,Transcription factor maybe involved in reproductive processes. Modulates expression of target genes encoding proteins involved in processes relevant to spermatogenesis,"Ovary, testis and epididymis. Also detected in the prostate and the mammary gland. Expressed in many tumor cell lines derived from acute lymphocytic leukemia, prostate, endometrial adenocarcinoma, melanoma, bladder carcinoma, colon carcinoma, erythroleukemia and breast carcinoma. Not expressed in placenta. In testis, mainly expressed in germ cells, but also detected in somatic cells such as Sertoli cells, Leydig cells and peritubular cells (PubMed:28171660)",,,Nucleus,28171660,12490318|28171660,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
RIBC1,ENSG00000158423,Unsafe,RNA,False,True,38.2,38.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 3.8 nTPM; absolute ceiling; amygdala: 2.5 nTPM; absolute ceiling; basal ganglia: 3.8 nTPM; absolute ceiling; choroid plexus: 27.4 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 3.2 nTPM; absolute ceiling; hypothalamus: 4 nTPM; absolute ceiling; kidney: 3.1 nTPM; absolute ceiling; lung: 3.2 nTPM; absolute ceiling; midbrain: 2.4 nTPM; absolute ceiling; pituitary gland: 6.4 nTPM; absolute ceiling; retina: 11 nTPM; absolute ceiling;continuous selectivity; spinal cord: 2.1 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 3.8 nTPM (limit 2); amygdala: 2.5 nTPM (limit 2); basal ganglia: 3.8 nTPM (limit 2); choroid plexus: 27.4 nTPM (limit 2); hippocampal formation: 3.2 nTPM (limit 2); hypothalamus: 4 nTPM (limit 2); kidney: 3.1 nTPM (limit 2); lung: 3.2 nTPM (limit 2); midbrain: 2.4 nTPM (limit 2); pituitary gland: 6.4 nTPM (limit 2); retina: 11 nTPM (limit 2); spinal cord: 2.1 nTPM (limit 2); adrenal gland: 3.8 nTPM (baseline 2); amygdala: 2.5 nTPM (baseline 2); basal ganglia: 3.8 nTPM (baseline 2); choroid plexus: 27.4 nTPM (baseline 2); hippocampal formation: 3.2 nTPM (baseline 2); hypothalamus: 4 nTPM (baseline 2); kidney: 3.1 nTPM (baseline 2); lung: 3.2 nTPM (baseline 2); midbrain: 2.4 nTPM (baseline 2); pituitary gland: 6.4 nTPM (baseline 2); retina: 11 nTPM (baseline 2); spinal cord: 2.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 49/50 (98.0%); Kidney Renal Papillary Cell Carcinoma (TCGA): 162/282 (57.4%); Uterine Corpus Endometrial Carcinoma (TCGA): 81/176 (46.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8N443,https://www.uniprot.org/uniprotkb/Q8N443/entry,,,,,"Cytoplasm, cytoskeleton, flagellum axoneme",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
RIBC2,ENSG00000128408,Unsafe,Protein,False,True,29.8,29.8,86,7,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; cerebral cortex: 0.2 nTPM; positive ihc; choroid plexus: 13 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 13 nTPM (limit 2),bronchus / ciliated cells (tip of cilia): High (Approved); caudate / neuronal cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); hippocampus / neuronal cells: Medium (Approved); nasopharynx / ciliated cells (tip of cilia): High (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 41/50 (82.0%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 187/283 (66.1%); Uterine Corpus Endometrial Carcinoma (TCGA): 50/176 (28.4%),breast cancer: 4/12 (33.3%); endometrial cancer: 2/11 (18.2%),31,20,Q9H4K1,https://www.uniprot.org/uniprotkb/Q9H4K1/entry,"Microtubule inner protein (MIP) part of the dynein-decorated doublet microtubules (DMTs) in cilia axoneme, which is required for motile cilia beating",Expressed in airway epithelial cells,,,"Cytoplasm, cytoskeleton, cilium axoneme Cytoplasm, cytoskeleton, flagellum axoneme",36191189,36191189,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Jamin2021_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
RIC1,ENSG00000107036,Unsafe,Protein,False,True,13.8,17.0,96,62,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 11.4 nTPM; continuous selectivity; adrenal gland: 7 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 3 nTPM; absolute ceiling; basal ganglia: 3.7 nTPM; absolute ceiling;continuous selectivity; bone marrow: 13.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 6.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 5.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 3.6 nTPM; absolute ceiling;continuous selectivity; colon: 8.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 9.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 11 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 6.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 3.3 nTPM; absolute ceiling; hypothalamus: 2.8 nTPM; absolute ceiling; kidney: 7.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 9.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 9.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 16.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 3.1 nTPM; absolute ceiling; pancreas: 10.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 8.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 4.7 nTPM; absolute ceiling;continuous selectivity; rectum: 9.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 7.2 nTPM; absolute ceiling;continuous selectivity; salivary gland: 11 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 17 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 13.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 9.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 12.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 4.1 nTPM; absolute ceiling;continuous selectivity; spleen: 11.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 7.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 14.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 10.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 15.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 10.6 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 7 nTPM (limit 2); amygdala: 3 nTPM (limit 2); basal ganglia: 3.7 nTPM (limit 2); bone marrow: 13.1 nTPM (limit 2); cerebellum: 6.7 nTPM (limit 2); cerebral cortex: 5.3 nTPM (limit 2); choroid plexus: 3.6 nTPM (limit 2); colon: 8.1 nTPM (limit 6); duodenum: 9.7 nTPM (limit 2); esophagus: 11 nTPM (limit 6); heart muscle: 6.7 nTPM (limit 2); hippocampal formation: 3.3 nTPM (limit 2); hypothalamus: 2.8 nTPM (limit 2); kidney: 7.2 nTPM (limit 2); liver: 9.6 nTPM (limit 2); lung: 9.8 nTPM (limit 2); lymph node: 16.9 nTPM (limit 6); midbrain: 3.1 nTPM (limit 2); pancreas: 10.2 nTPM (limit 2); parathyroid gland: 8.6 nTPM (limit 6); pituitary gland: 4.7 nTPM (limit 2); rectum: 9.1 nTPM (limit 6); retina: 7.2 nTPM (limit 2); salivary gland: 11 nTPM (limit 6); skeletal muscle: 17 nTPM (limit 2); skin: 13.1 nTPM (limit 10); small intestine: 9.1 nTPM (limit 2); smooth muscle: 12.8 nTPM (limit 2); spinal cord: 4.1 nTPM (limit 2); spleen: 11.5 nTPM (limit 10); stomach: 7.7 nTPM (limit 6); thymus: 14.4 nTPM (limit 10); thyroid gland: 10.9 nTPM (limit 10); tongue: 15.1 nTPM (limit 6); urinary bladder: 10.6 nTPM (limit 6),adrenal gland / glandular cells: Medium (Supported); bone marrow / hematopoietic cells: Medium (Supported); bronchus / respiratory epithelial cells: Medium (Supported); caudate / glial cells: Low (Supported); cerebellum / synaptic glomeruli - core: Medium (Supported); cerebellum / white matter cells - cytoplasm/membrane: Medium (Supported); cerebral cortex / endothelial cells: Medium (Supported); cerebral cortex / neuropil: Low (Supported); colon / glandular cells: High (Supported); colon / peripheral nerve/ganglion: Low (Supported); duodenum / glandular cells: High (Supported); esophagus / squamous epithelial cells: High (Supported); heart muscle / cardiomyocytes: Low (Supported); kidney / cells in glomeruli: Medium (Supported); kidney / cells in tubules: High (Supported); liver / hepatocytes: Medium (Supported); lung / alveolar cells type II: Medium (Supported); lung / macrophages: Medium (Supported); lymph node / germinal center cells: Medium (Supported); lymph node / non-germinal center cells: Medium (Supported); nasopharynx / respiratory epithelial cells: Medium (Supported); oral mucosa / squamous epithelial cells: Medium (Supported); pancreas / exocrine glandular cells: High (Supported); pancreas / pancreatic endocrine cells: Low (Supported); parathyroid gland / glandular cells: Medium (Supported); rectum / glandular cells: High (Supported); salivary gland / glandular cells: High (Supported); skeletal muscle / myocytes: High (Supported); skin 1 / keratinocytes: High (Supported); skin 1 / Langerhans: Medium (Supported); skin 2 / epidermal cells: High (Supported); small intestine / glandular cells: High (Supported); smooth muscle / smooth muscle cells: Medium (Supported); spleen / cells in red pulp: High (Supported); spleen / cells in white pulp: High (Supported); stomach 1 / glandular cells: High (Supported); stomach 2 / glandular cells: High (Supported); thyroid gland / glandular cells: High (Supported); urinary bladder / urothelial cells: High (Supported),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%); Pancreatic Adenocarcinoma (validation): 80/80 (100.0%),prostate cancer: 12/12 (100.0%); colorectal cancer: 11/11 (100.0%),29,20,Q4ADV7,https://www.uniprot.org/uniprotkb/Q4ADV7/entry,"The RIC1-RGP1 complex acts as a guanine nucleotide exchange factor (GEF), which activates RAB6A by exchanging bound GDP for free GTP, and may thereby be required for efficient fusion of endosome-derived vesicles with the Golgi compartment (PubMed:23091056). The RIC1-RGP1 complex participates in the recycling of mannose-6-phosphate receptors (PubMed:23091056). Required for phosphorylation and localization of GJA1 (PubMed:16112082). Is a regulator of procollagen transport and secretion, and is required for correct cartilage morphogenesis and development of the craniofacial skeleton (PubMed:31932796)",Present in kidney and various cell lines (at protein level). Widely expressed at low level,"CATIFA syndrome: An autosomal recessive disorder characterized by global developmental delay, intellectual disability, and behavioral abnormalities with mild to severe attention deficit-hyperactivity disorder. Motor, speech and cognitive deficits range from mild to severe. Patients show craniofacial dysmorphism including elongated face, short, broad upturned nose with anteverted nares and long philtrum. Additional clinical features are cleft lip/palate, tooth abnormalities, and visual impairment due to cataract, strabismus and poor visual tracking.",,"Cytoplasm, cytosol Membrane",16112082|23091056|31932796,10718198|16112082,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
RIIAD1,ENSG00000178796,Unsafe,Protein,False,True,24.1,33.8,116,15,Positive somewhere,True,True,False,True,Excluded,Normal,False,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 5.4 nTPM; absolute ceiling; basal ganglia: 10 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 4.1 nTPM; absolute ceiling; colon: 1 nTPM; positive ihc; duodenum: 0 nTPM; positive ihc; hippocampal formation: 6.2 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 7.3 nTPM; absolute ceiling;continuous selectivity; midbrain: 3.3 nTPM; absolute ceiling; pituitary gland: 33.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 0.3 nTPM; positive ihc; retina: 4.7 nTPM; absolute ceiling; small intestine: 0.3 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 5.4 nTPM (limit 2); basal ganglia: 10 nTPM (limit 2); choroid plexus: 4.1 nTPM (limit 2); hippocampal formation: 6.2 nTPM (limit 2); hypothalamus: 7.3 nTPM (limit 2); midbrain: 3.3 nTPM (limit 2); pituitary gland: 33.8 nTPM (limit 2); retina: 4.7 nTPM (limit 2),bronchus / ciliated cells (cilia axoneme): High (Enhanced); bronchus / ciliated cells (ciliary rootlets): Medium (Enhanced); bronchus / ciliated cells (tip of cilia): High (Enhanced); colon / goblet cells: Low (Enhanced); duodenum / enterocytes - Microvilli: Medium (Enhanced); nasopharynx / ciliated cells (cilia axoneme): Medium (Enhanced); nasopharynx / ciliated cells (tip of cilia): Medium (Enhanced); rectum / enterocytes - Microvilli: Medium (Enhanced); small intestine / endocrine cells: Medium (Enhanced); small intestine / enterocytes: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 19/176 (10.8%); Rectum Adenocarcinoma (TCGA): 7/88 (8.0%); Pancreatic Adenocarcinoma (TCGA): 11/176 (6.2%),breast cancer: 2/11 (18.2%); liver cancer: 1/9 (11.1%),30,20,A6NNX1,https://www.uniprot.org/uniprotkb/A6NNX1/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
RIMS1,ENSG00000079841,Unsafe,Protein,False,True,4.0,63.6,81,6,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; amygdala: 22.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 63.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 25.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 2 nTPM; continuous selectivity; hippocampal formation: 18.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 6.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 4.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 1.5 nTPM; continuous selectivity; pituitary gland: 2.3 nTPM; absolute ceiling;continuous selectivity; retina: 7.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 2.8 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 22.1 nTPM (limit 2); basal ganglia: 8 nTPM (limit 2); cerebellum: 63.6 nTPM (limit 12); cerebral cortex: 25.3 nTPM (limit 2); hippocampal formation: 18.9 nTPM (limit 2); hypothalamus: 6.8 nTPM (limit 2); midbrain: 4.6 nTPM (limit 2); pituitary gland: 2.3 nTPM (limit 2); retina: 7.1 nTPM (limit 2); spinal cord: 2.8 nTPM (limit 2); amygdala: 22.1 nTPM (baseline 2); basal ganglia: 8 nTPM (baseline 2); cerebellum: 63.6 nTPM (baseline 2); cerebral cortex: 25.3 nTPM (baseline 2); hippocampal formation: 18.9 nTPM (baseline 2); hypothalamus: 6.8 nTPM (baseline 2); midbrain: 4.6 nTPM (baseline 2); pituitary gland: 2.3 nTPM (baseline 2); retina: 7.1 nTPM (baseline 2); spinal cord: 2.8 nTPM (baseline 2),caudate / glial cells: High (Enhanced); cerebral cortex / glial cells: Medium (Enhanced); cerebral cortex / neuronal cells: High (Enhanced); cerebral cortex / neuropil: High (Enhanced); hippocampus / glial cells: Low (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 38/58 (65.5%); Breast Invasive Carcinoma (validation): 10/50 (20.0%); Kidney Chromophobe (TCGA): 9/64 (14.1%),colorectal cancer: 2/12 (16.7%); stomach cancer: 2/12 (16.7%),31,20,Q86UR5,https://www.uniprot.org/uniprotkb/Q86UR5/entry,Rab effector involved in exocytosis (By similarity). May act as scaffold protein that regulates neurotransmitter release at the active zone. Essential for maintaining normal probability of neurotransmitter release and for regulating release during short-term synaptic plasticity (By similarity). Plays a role in dendrite formation by melanocytes (PubMed:23999003),Expressed in melanocytes (PubMed:23999003). Detected in brain and retina (PubMed:23999003),,,Cell membrane Synapse Presynaptic cell membrane,23999003,23999003,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
RNASE8,ENSG00000173431,Unsafe,RNA,False,True,0.0,53.2,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,insufficient positive reproductive evidence; reproductive expression not demonstrated; incomplete tissue evidence,Measured normal RNA exceeds its applicable category/IHC ceiling,salivary gland: 53.2 nTPM (limit 6); salivary gland: 53.2 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 1/80 (1.2%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8TDE3,https://www.uniprot.org/uniprotkb/Q8TDE3/entry,Has a low ribonuclease activity,Expressed prominently in the placenta and is not detected in any other tissues examined,,,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
RNF103-CHMP3,ENSG00000249884,Unsafe,RNA,False,True,1.2,4.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,existing nomination or manual review; nomination unresolved; amygdala: 0.9 nTPM; continuous selectivity; basal ganglia: 1.3 nTPM; continuous selectivity;reproductive not higher; bone marrow: 4.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 0.5 nTPM; continuous selectivity; cerebral cortex: 2.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 0.6 nTPM; continuous selectivity; esophagus: 0.7 nTPM; continuous selectivity; heart muscle: 4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 0.8 nTPM; continuous selectivity; hypothalamus: 0.7 nTPM; continuous selectivity; midbrain: 0.5 nTPM; continuous selectivity; retina: 0.4 nTPM; continuous selectivity; skeletal muscle: 2.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; stomach: 0.9 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 4.1 nTPM (limit 2); cerebral cortex: 2.4 nTPM (limit 2); heart muscle: 4 nTPM (limit 2); skeletal muscle: 2.1 nTPM (limit 2); bone marrow: 4.1 nTPM (baseline 2); cerebral cortex: 2.4 nTPM (baseline 2); heart muscle: 4 nTPM (baseline 2); skeletal muscle: 2.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 100/486 (20.6%); Rectum Adenocarcinoma (validation): 37/207 (17.9%); Kidney Chromophobe (TCGA): 3/64 (4.7%),breast cancer: 12/12 (100.0%); cervical cancer: 12/12 (100.0%),29,20,Q9Y3E7,https://www.uniprot.org/uniprotkb/Q9Y3E7/entry,"Probable core component of the endosomal sorting required for transport complex III (ESCRT-III) which is involved in multivesicular bodies (MVBs) formation and sorting of endosomal cargo proteins into MVBs. MVBs contain intraluminal vesicles (ILVs) that are generated by invagination and scission from the limiting membrane of the endosome and mostly are delivered to lysosomes enabling degradation of membrane proteins, such as stimulated growth factor receptors, lysosomal enzymes and lipids. The MVB pathway appears to require the sequential function of ESCRT-O, -I,-II and -III complexes. ESCRT-III proteins mostly dissociate from the invaginating membrane before the ILV is released. The ESCRT machinery also functions in topologically equivalent membrane fission events, such as the terminal stages of cytokinesis and the budding of enveloped viruses (HIV-1 and other lentiviruses). ESCRT-III proteins are believed to mediate the necessary vesicle extrusion and/or membrane fission activities, possibly in conjunction with the AAA ATPase VPS4. Selectively binds to phosphatidylinositol 3,5-bisphosphate PtdIns(3,5)P2 and PtdIns(3,4)P2 in preference to other phosphoinositides tested. Involved in late stages of cytokinesis. Plays a role in endosomal sorting/trafficking of EGF receptor. Isoform 2 prevents stress-mediated cell death and accumulation of reactive oxygen species when expressed in yeast cells","Widely expressed. Expressed in heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas",,,"Cytoplasm, cytosol Membrane Endosome Late endosome membrane",14505570|15707591|16740483|17331679|18076377,15632132,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
RNF138,ENSG00000134758,Unsafe,RNA,False,True,116.0,116.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 13.2 nTPM; absolute ceiling; adrenal gland: 7.1 nTPM; absolute ceiling; amygdala: 6.9 nTPM; absolute ceiling; basal ganglia: 6.2 nTPM; absolute ceiling; bone marrow: 94.8 nTPM; absolute ceiling;continuous selectivity; cerebellum: 8.4 nTPM; absolute ceiling; cerebral cortex: 9.8 nTPM; absolute ceiling; choroid plexus: 4.2 nTPM; absolute ceiling; colon: 22.7 nTPM; absolute ceiling; duodenum: 16.2 nTPM; absolute ceiling; esophagus: 14.4 nTPM; absolute ceiling; heart muscle: 5.7 nTPM; absolute ceiling; hippocampal formation: 7.3 nTPM; absolute ceiling; hypothalamus: 7 nTPM; absolute ceiling; kidney: 9.3 nTPM; absolute ceiling; liver: 21 nTPM; absolute ceiling; lung: 12.9 nTPM; absolute ceiling; lymph node: 23.6 nTPM; absolute ceiling; midbrain: 7.7 nTPM; absolute ceiling; pancreas: 15.8 nTPM; absolute ceiling; parathyroid gland: 10.8 nTPM; absolute ceiling; pituitary gland: 7.3 nTPM; absolute ceiling; rectum: 19.6 nTPM; absolute ceiling; retina: 8.7 nTPM; absolute ceiling; salivary gland: 9.6 nTPM; absolute ceiling; skeletal muscle: 6.7 nTPM; absolute ceiling; small intestine: 16.8 nTPM; absolute ceiling; smooth muscle: 11.3 nTPM; absolute ceiling; spinal cord: 10.5 nTPM; absolute ceiling; spleen: 21 nTPM; absolute ceiling; stomach: 13.8 nTPM; absolute ceiling; thymus: 28.1 nTPM; absolute ceiling; thyroid gland: 11.5 nTPM; absolute ceiling; tongue: 6.6 nTPM; absolute ceiling; urinary bladder: 12.8 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adipose tissue: 13.2 nTPM (limit 10); adrenal gland: 7.1 nTPM (limit 2); amygdala: 6.9 nTPM (limit 2); basal ganglia: 6.2 nTPM (limit 2); bone marrow: 94.8 nTPM (limit 2); cerebellum: 8.4 nTPM (limit 2); cerebral cortex: 9.8 nTPM (limit 2); choroid plexus: 4.2 nTPM (limit 2); colon: 22.7 nTPM (limit 6); duodenum: 16.2 nTPM (limit 2); esophagus: 14.4 nTPM (limit 6); heart muscle: 5.7 nTPM (limit 2); hippocampal formation: 7.3 nTPM (limit 2); hypothalamus: 7 nTPM (limit 2); kidney: 9.3 nTPM (limit 2); liver: 21 nTPM (limit 2); lung: 12.9 nTPM (limit 2); lymph node: 23.6 nTPM (limit 6); midbrain: 7.7 nTPM (limit 2); pancreas: 15.8 nTPM (limit 2); parathyroid gland: 10.8 nTPM (limit 6); pituitary gland: 7.3 nTPM (limit 2); rectum: 19.6 nTPM (limit 6); retina: 8.7 nTPM (limit 2); salivary gland: 9.6 nTPM (limit 6); skeletal muscle: 6.7 nTPM (limit 2); small intestine: 16.8 nTPM (limit 2); smooth muscle: 11.3 nTPM (limit 2); spinal cord: 10.5 nTPM (limit 2); spleen: 21 nTPM (limit 10); stomach: 13.8 nTPM (limit 6); thymus: 28.1 nTPM (limit 10); thyroid gland: 11.5 nTPM (limit 10); tongue: 6.6 nTPM (limit 6); urinary bladder: 12.8 nTPM (limit 6); adipose tissue: 13.2 nTPM (baseline 10); adrenal gland: 7.1 nTPM (baseline 2); amygdala: 6.9 nTPM (baseline 2); basal ganglia: 6.2 nTPM (baseline 2); bone marrow: 94.8 nTPM (baseline 2); cerebellum: 8.4 nTPM (baseline 2); cerebral cortex: 9.8 nTPM (baseline 2); choroid plexus: 4.2 nTPM (baseline 2); colon: 22.7 nTPM (baseline 6); duodenum: 16.2 nTPM (baseline 2); esophagus: 14.4 nTPM (baseline 6); heart muscle: 5.7 nTPM (baseline 2); hippocampal formation: 7.3 nTPM (baseline 2); hypothalamus: 7 nTPM (baseline 2); kidney: 9.3 nTPM (baseline 2); liver: 21 nTPM (baseline 2); lung: 12.9 nTPM (baseline 2); lymph node: 23.6 nTPM (baseline 6); midbrain: 7.7 nTPM (baseline 2); pancreas: 15.8 nTPM (baseline 2); parathyroid gland: 10.8 nTPM (baseline 6); pituitary gland: 7.3 nTPM (baseline 2); rectum: 19.6 nTPM (baseline 6); retina: 8.7 nTPM (baseline 2); salivary gland: 9.6 nTPM (baseline 6); skeletal muscle: 6.7 nTPM (baseline 2); small intestine: 16.8 nTPM (baseline 2); smooth muscle: 11.3 nTPM (baseline 2); spinal cord: 10.5 nTPM (baseline 2); spleen: 21 nTPM (baseline 10); stomach: 13.8 nTPM (baseline 6); thymus: 28.1 nTPM (baseline 10); thyroid gland: 11.5 nTPM (baseline 10); tongue: 6.6 nTPM (baseline 6); urinary bladder: 12.8 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (TCGA): 141/141 (100.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8WVD3,https://www.uniprot.org/uniprotkb/Q8WVD3/entry,"E3 ubiquitin-protein ligase involved in DNA damage response by promoting DNA resection and homologous recombination (PubMed:26502055, PubMed:26502057). Recruited to sites of double-strand breaks following DNA damage and specifically promotes double-strand break repair via homologous recombination (PubMed:26502055, PubMed:26502057). Two different, non-exclusive, mechanisms have been proposed. According to a report, regulates the choice of double-strand break repair by favoring homologous recombination over non-homologous end joining (NHEJ): acts by mediating ubiquitination of XRCC5/Ku80, leading to remove the Ku complex from DNA breaks, thereby promoting homologous recombination (PubMed:26502055). According to another report, cooperates with UBE2Ds E2 ubiquitin ligases (UBE2D1, UBE2D2, UBE2D3 or UBE2D4) to promote homologous recombination by mediating ubiquitination of RBBP8/CtIP (PubMed:26502057). Together with NLK, involved in the ubiquitination and degradation of TCF/LEF (PubMed:16714285). Also exhibits auto-ubiquitination activity in combination with UBE2K (PubMed:16714285). May act as a negative regulator in the Wnt/beta-catenin-mediated signaling pathway (PubMed:16714285)",,,,Chromosome,16714285|26502055|26502057,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
RNF157,ENSG00000141576,Unsafe,RNA,False,True,30.5,75.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 13.1 nTPM; absolute ceiling; adrenal gland: 3.2 nTPM; absolute ceiling; amygdala: 46.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 41.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 2.1 nTPM; absolute ceiling; cerebellum: 23.8 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 75 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 9.8 nTPM; absolute ceiling;continuous selectivity; colon: 9.5 nTPM; absolute ceiling; duodenum: 9.3 nTPM; absolute ceiling;continuous selectivity; heart muscle: 6.2 nTPM; absolute ceiling; hippocampal formation: 60.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 34.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 5.6 nTPM; absolute ceiling; liver: 2.4 nTPM; absolute ceiling; midbrain: 40.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 3.3 nTPM; absolute ceiling; parathyroid gland: 14.1 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 6.1 nTPM; absolute ceiling; rectum: 6.7 nTPM; absolute ceiling; retina: 57.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 71.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 10.1 nTPM; absolute ceiling;continuous selectivity; spinal cord: 26.9 nTPM; absolute ceiling;continuous selectivity; tongue: 42 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,adipose tissue: 13.1 nTPM (limit 10); adrenal gland: 3.2 nTPM (limit 2); amygdala: 46.2 nTPM (limit 2); basal ganglia: 41.9 nTPM (limit 2); bone marrow: 2.1 nTPM (limit 2); cerebellum: 23.8 nTPM (limit 2); cerebral cortex: 75 nTPM (limit 2); choroid plexus: 9.8 nTPM (limit 2); colon: 9.5 nTPM (limit 6); duodenum: 9.3 nTPM (limit 2); heart muscle: 6.2 nTPM (limit 2); hippocampal formation: 60.3 nTPM (limit 2); hypothalamus: 34.1 nTPM (limit 2); kidney: 5.6 nTPM (limit 2); liver: 2.4 nTPM (limit 2); midbrain: 40.9 nTPM (limit 2); pancreas: 3.3 nTPM (limit 2); parathyroid gland: 14.1 nTPM (limit 6); pituitary gland: 6.1 nTPM (limit 2); rectum: 6.7 nTPM (limit 6); retina: 57.2 nTPM (limit 2); skeletal muscle: 71.2 nTPM (limit 2); small intestine: 10.1 nTPM (limit 2); spinal cord: 26.9 nTPM (limit 2); tongue: 42 nTPM (limit 6); adipose tissue: 13.1 nTPM (baseline 10); adrenal gland: 3.2 nTPM (baseline 2); amygdala: 46.2 nTPM (baseline 2); basal ganglia: 41.9 nTPM (baseline 2); bone marrow: 2.1 nTPM (baseline 2); cerebellum: 23.8 nTPM (baseline 2); cerebral cortex: 75 nTPM (baseline 2); choroid plexus: 9.8 nTPM (baseline 2); colon: 9.5 nTPM (baseline 6); duodenum: 9.3 nTPM (baseline 2); heart muscle: 6.2 nTPM (baseline 2); hippocampal formation: 60.3 nTPM (baseline 2); hypothalamus: 34.1 nTPM (baseline 2); kidney: 5.6 nTPM (baseline 2); liver: 2.4 nTPM (baseline 2); midbrain: 40.9 nTPM (baseline 2); pancreas: 3.3 nTPM (baseline 2); parathyroid gland: 14.1 nTPM (baseline 6); pituitary gland: 6.1 nTPM (baseline 2); rectum: 6.7 nTPM (baseline 6); retina: 57.2 nTPM (baseline 2); skeletal muscle: 71.2 nTPM (baseline 2); small intestine: 10.1 nTPM (baseline 2); spinal cord: 26.9 nTPM (baseline 2); tongue: 42 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Glioblastoma Multiforme (TCGA): 137/141 (97.2%); Colon Adenocarcinoma (validation): 429/486 (88.3%),prostate cancer: 12/12 (100.0%); breast cancer: 11/11 (100.0%),31,20,Q96PX1,https://www.uniprot.org/uniprotkb/Q96PX1/entry,E3 ubiquitin ligase that ubiquitinates APBB1 for its degradation by the proteasome and thus prevents apoptosis and promotes survival of neurons (PubMed:25342469). Has a dual role in neurons as it is also required for dendrite growth and maintenance for which its ligase activity is not critical (PubMed:25342469). May act as a scaffold molecule to regulate this process (PubMed:25342469). Acts as a downstream effector of the interconnected PI3K and MAPK signaling pathways and thus participates in the regulation of the cell cycle (PubMed:28655764),,,,Cytoplasm,25342469|28655764,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
RNF169,ENSG00000166439,Unsafe,RNA,False,True,7.4,14.3,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 4 nTPM; continuous selectivity; adrenal gland: 2.8 nTPM; absolute ceiling;continuous selectivity; bone marrow: 14.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 2.6 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 3.7 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 3.7 nTPM; absolute ceiling;continuous selectivity; colon: 4.2 nTPM; continuous selectivity; duodenum: 3.9 nTPM; absolute ceiling;continuous selectivity; esophagus: 9.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 3.1 nTPM; absolute ceiling;continuous selectivity; kidney: 4.5 nTPM; absolute ceiling;continuous selectivity; liver: 4.9 nTPM; absolute ceiling;continuous selectivity; lung: 5.7 nTPM; absolute ceiling;continuous selectivity; lymph node: 6.2 nTPM; absolute ceiling;continuous selectivity; pancreas: 4.3 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 5.4 nTPM; continuous selectivity; pituitary gland: 2 nTPM; continuous selectivity; rectum: 5.1 nTPM; continuous selectivity; retina: 5.9 nTPM; absolute ceiling;continuous selectivity; salivary gland: 4.4 nTPM; continuous selectivity; skeletal muscle: 6.5 nTPM; absolute ceiling;continuous selectivity; skin: 5.4 nTPM; continuous selectivity; small intestine: 4.3 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 7.3 nTPM; absolute ceiling;continuous selectivity; spinal cord: 2.1 nTPM; absolute ceiling;continuous selectivity; spleen: 7.2 nTPM; continuous selectivity; stomach: 4.5 nTPM; continuous selectivity; thymus: 7.5 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 5.7 nTPM; continuous selectivity; tongue: 5.6 nTPM; continuous selectivity; urinary bladder: 5 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 2.8 nTPM (limit 2); bone marrow: 14.3 nTPM (limit 2); cerebellum: 2.6 nTPM (limit 2); cerebral cortex: 3.7 nTPM (limit 2); choroid plexus: 3.7 nTPM (limit 2); duodenum: 3.9 nTPM (limit 2); esophagus: 9.8 nTPM (limit 6); heart muscle: 3.1 nTPM (limit 2); kidney: 4.5 nTPM (limit 2); liver: 4.9 nTPM (limit 2); lung: 5.7 nTPM (limit 2); lymph node: 6.2 nTPM (limit 6); pancreas: 4.3 nTPM (limit 2); retina: 5.9 nTPM (limit 2); skeletal muscle: 6.5 nTPM (limit 2); small intestine: 4.3 nTPM (limit 2); smooth muscle: 7.3 nTPM (limit 2); spinal cord: 2.1 nTPM (limit 2); adrenal gland: 2.8 nTPM (baseline 2); bone marrow: 14.3 nTPM (baseline 2); cerebellum: 2.6 nTPM (baseline 2); cerebral cortex: 3.7 nTPM (baseline 2); choroid plexus: 3.7 nTPM (baseline 2); duodenum: 3.9 nTPM (baseline 2); esophagus: 9.8 nTPM (baseline 6); heart muscle: 3.1 nTPM (baseline 2); kidney: 4.5 nTPM (baseline 2); liver: 4.9 nTPM (baseline 2); lung: 5.7 nTPM (baseline 2); lymph node: 6.2 nTPM (baseline 6); pancreas: 4.3 nTPM (baseline 2); retina: 5.9 nTPM (baseline 2); skeletal muscle: 6.5 nTPM (baseline 2); small intestine: 4.3 nTPM (baseline 2); smooth muscle: 7.3 nTPM (baseline 2); spinal cord: 2.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Pancreatic Adenocarcinoma (validation): 80/80 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%),urothelial cancer: 1/10 (10.0%); breast cancer: 1/11 (9.1%),31,20,Q8NCN4,https://www.uniprot.org/uniprotkb/Q8NCN4/entry,"Probable E3 ubiquitin-protein ligase that acts as a regulator of double-strand breaks (DSBs) repair following DNA damage. Functions in a non-canonical fashion to harness RNF168-mediated protein recruitment to DSB-containing chromatin, thereby contributing to regulation of DSB repair pathway utilization (PubMed:22492721, PubMed:30773093). Once recruited to DSB repair sites by recognizing and binding ubiquitin catalyzed by RNF168, competes with TP53BP1 and BRCA1 for association with RNF168-modified chromatin, thereby favouring homologous recombination repair (HRR) and single-strand annealing (SSA) instead of non-homologous end joining (NHEJ) mediated by TP53BP1 (PubMed:30104380, PubMed:30773093). E3 ubiquitin-protein ligase activity is not required for regulation of DSBs repair",,,,"Chromosome Nucleus, nucleoplasm",22492721|22733822|22742833|30104380|30773093,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
RNF17,ENSG00000132972,Unsafe,Protein,False,True,23.6,23.6,87,68,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0 nTPM; positive ihc; adrenal gland: 0.3 nTPM; positive ihc; bone marrow: 0 nTPM; positive ihc; cerebellum: 0.1 nTPM; positive ihc; cerebral cortex: 0 nTPM; positive ihc; colon: 0 nTPM; positive ihc; duodenum: 0 nTPM; positive ihc; esophagus: 0 nTPM; positive ihc; kidney: 0.1 nTPM; positive ihc; lung: 0 nTPM; positive ihc; lymph node: 0 nTPM; positive ihc; pancreas: 0 nTPM; positive ihc; parathyroid gland: 0 nTPM; positive ihc; rectum: 0 nTPM; positive ihc; salivary gland: 0 nTPM; positive ihc; skeletal muscle: 0 nTPM; positive ihc; skin: 0 nTPM; positive ihc; small intestine: 0 nTPM; positive ihc; spleen: 0 nTPM; positive ihc; stomach: 0.1 nTPM; positive ihc; thyroid gland: 0 nTPM; positive ihc; urinary bladder: 0 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); hippocampus / glial cells: Low (Approved); kidney / cells in tubules: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); spleen / cells in red pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 69/133 (51.9%); Liver Hepatocellular Carcinoma (validation): 7/231 (3.0%); Breast Invasive Carcinoma (validation): 1/50 (2.0%),breast cancer: 11/12 (91.7%); testis cancer: 11/12 (91.7%),31,20,Q9BXT8,https://www.uniprot.org/uniprotkb/Q9BXT8/entry,"Seems to be involved in regulation of transcriptional activity of MYC. In vitro, inhibits DNA-binding activity of Mad-MAX heterodimers. Can recruit Mad transcriptional repressors (MXD1, MXD3, MXD4 and MXI1) to the cytoplasm. May be involved in spermiogenesis (By similarity)",Testis specific,,,Cytoplasm Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Loriot2025_S1 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
RNF183,ENSG00000165188,Unsafe,RNA,False,True,15.8,15.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,kidney: 11.2 nTPM; absolute ceiling;continuous selectivity; salivary gland: 6.6 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,kidney: 11.2 nTPM (limit 2); salivary gland: 6.6 nTPM (limit 6); kidney: 11.2 nTPM (baseline 2); salivary gland: 6.6 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 121/176 (68.8%); Kidney Renal Clear Cell Carcinoma (validation): 52/100 (52.0%); Breast Invasive Carcinoma (validation): 26/50 (52.0%),breast cancer: 0/12 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q96D59,https://www.uniprot.org/uniprotkb/Q96D59/entry,Acts as an E3 ubiquitin ligase catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins (PubMed:29507230). Triggers apoptosis in response to prolonged ER stress by mediating the polyubiquitination and subsequent proteasomal degradation of BCL2L1 (PubMed:29507230). May collaborate with FATE1 to restrain BIK protein levels thus regulating apoptotic signaling (PubMed:26567849). Mediates the ubiquitination and subsequent lysosomal degradation of ATP1B1 (By similarity),Kidney and testis,,,"Endoplasmic reticulum membrane Endoplasmic reticulum Golgi apparatus, cis-Golgi network membrane Lysosome membrane",26567849|29507230,29300766,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
RNF212B,ENSG00000215277,Unsafe,RNA,False,True,5.2,25.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,kidney: 25 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,kidney: 25 nTPM (limit 2); kidney: 25 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Chromophobe (TCGA): 5/64 (7.8%); Kidney Renal Papillary Cell Carcinoma (TCGA): 7/282 (2.5%); Testicular Germ Cell Tumor (TCGA): 3/133 (2.3%),pancreatic cancer: 1/10 (10.0%); cervical cancer: 1/11 (9.1%),29,20,A8MTL3,https://www.uniprot.org/uniprotkb/A8MTL3/entry,"Ubiquitin E3 ligase that acts as a crucial factor for crossing-over (CO) formation during meiosis. Essential for normal prophase I progression and for ensuring appropriate CO designation in meiosis. Recruits key components of the cross-over machinery either directly ou indirectly, leading to the activation of the MutL-gamma complex. The function of RNF212B in CO designation is dependent on its catalytic activity",,,,Chromosome,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | Chang2019_TGCT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
RNF32,ENSG00000105982,Unsafe,RNA,False,True,59.0,59.0,107,2,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,amygdala: 2.5 nTPM; absolute ceiling; basal ganglia: 2.5 nTPM; absolute ceiling; hippocampal formation: 2.3 nTPM; absolute ceiling; hypothalamus: 2.3 nTPM; absolute ceiling; midbrain: 2.2 nTPM; absolute ceiling; retina: 2.7 nTPM; absolute ceiling; spinal cord: 3.4 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 2.5 nTPM (limit 2); basal ganglia: 2.5 nTPM (limit 2); hippocampal formation: 2.3 nTPM (limit 2); hypothalamus: 2.3 nTPM (limit 2); midbrain: 2.2 nTPM (limit 2); retina: 2.7 nTPM (limit 2); spinal cord: 3.4 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 38/50 (76.0%); Rectum Adenocarcinoma (validation): 140/207 (67.6%); Colon Adenocarcinoma (validation): 284/486 (58.4%),breast cancer: 0/12 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q9H0A6,https://www.uniprot.org/uniprotkb/Q9H0A6/entry,May play a role in sperm formation,"Highly expressed in testis, less abundant in ovary",,,Cytoplasm,11890671,11890671,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
RNF6,ENSG00000127870,Unsafe,Protein,False,True,32.6,32.6,84,31,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 18.3 nTPM; continuous selectivity; adrenal gland: 16.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 13.6 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 17 nTPM; absolute ceiling;continuous selectivity; bone marrow: 32.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 17.9 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 21.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 10.3 nTPM; absolute ceiling;continuous selectivity; colon: 17.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 17 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 17.9 nTPM; absolute ceiling;continuous selectivity; heart muscle: 13.2 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 13.3 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 11.5 nTPM; absolute ceiling;continuous selectivity; kidney: 17.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 16.1 nTPM; absolute ceiling;continuous selectivity; lung: 15.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 21.9 nTPM; absolute ceiling;continuous selectivity; midbrain: 10.3 nTPM; absolute ceiling;continuous selectivity; pancreas: 13.7 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 21.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 10.5 nTPM; absolute ceiling;continuous selectivity; rectum: 17.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 25.8 nTPM; absolute ceiling;continuous selectivity; salivary gland: 13.1 nTPM; absolute ceiling; skeletal muscle: 20.4 nTPM; absolute ceiling;continuous selectivity; skin: 16.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 18.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 15.1 nTPM; absolute ceiling;continuous selectivity; spinal cord: 8.9 nTPM; absolute ceiling;continuous selectivity; spleen: 19.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 16.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 24.6 nTPM; absolute ceiling;continuous selectivity; tongue: 14.7 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 17.7 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 16.8 nTPM (limit 2); amygdala: 13.6 nTPM (limit 2); basal ganglia: 17 nTPM (limit 2); bone marrow: 32.1 nTPM (limit 2); cerebellum: 17.9 nTPM (limit 4); cerebral cortex: 21.5 nTPM (limit 2); choroid plexus: 10.3 nTPM (limit 2); colon: 17.8 nTPM (limit 6); duodenum: 17 nTPM (limit 2); esophagus: 17.9 nTPM (limit 8); heart muscle: 13.2 nTPM (limit 4); hippocampal formation: 13.3 nTPM (limit 2); hypothalamus: 11.5 nTPM (limit 2); kidney: 17.6 nTPM (limit 2); liver: 16.1 nTPM (limit 4); lung: 15.7 nTPM (limit 2); lymph node: 21.9 nTPM (limit 8); midbrain: 10.3 nTPM (limit 2); pancreas: 13.7 nTPM (limit 4); parathyroid gland: 21.6 nTPM (limit 6); pituitary gland: 10.5 nTPM (limit 2); rectum: 17.9 nTPM (limit 6); retina: 25.8 nTPM (limit 2); salivary gland: 13.1 nTPM (limit 8); skeletal muscle: 20.4 nTPM (limit 4); skin: 16.9 nTPM (limit 10); small intestine: 18.3 nTPM (limit 2); smooth muscle: 15.1 nTPM (limit 4); spinal cord: 8.9 nTPM (limit 2); spleen: 19.2 nTPM (limit 10); stomach: 16.7 nTPM (limit 6); thymus: 24.6 nTPM (limit 10); tongue: 14.7 nTPM (limit 6); urinary bladder: 17.7 nTPM (limit 6),adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: High (Approved); bronchus / respiratory epithelial cells: Medium (Approved); cerebral cortex / neuropil: High (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Medium (Approved); skin 1 / keratinocytes: Low (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Medium (Approved); spleen / cells in red pulp: Low (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Low (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Stomach Adenocarcinoma (TCGA): 346/346 (100.0%); Colon Adenocarcinoma (TCGA): 254/254 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%),skin cancer: 12/12 (100.0%); melanoma: 11/11 (100.0%),31,20,Q9Y252,https://www.uniprot.org/uniprotkb/Q9Y252/entry,"E3 ubiquitin-protein ligase mediating 'Lys-48'-linked polyubiquitination of LIMK1 and its subsequent targeting to the proteasome for degradation (By similarity). Negatively regulates axonal outgrowth through regulation of the LIMK1 turnover (By similarity). Mediates 'Lys-6' and 'Lys-27'-linked polyubiquitination of AR/androgen receptor thereby modulating its transcriptional activity (PubMed:19345326). May also bind DNA and function as a transcriptional regulator (By similarity). Mediates polyubiquitination of QKI in macrophages, leading to its degradation (By similarity)","Weakly expressed in peripheral blood, spleen, prostate, testis and ovary (PubMed:19345326). According to a report, it is preferentially expressed in testis and ovary and hardly detected in other tissues (PubMed:18368307)",Esophageal cancer: A malignancy of the esophagus. The most common types are esophageal squamous cell carcinoma and adenocarcinoma. Cancer of the esophagus remains a devastating disease because it is usually not detected until it has progressed to an advanced incurable stage.,,"Nucleus Cytoplasm Cell projection, axon Nucleus, PML body",19345326,18368307|19345326,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
RNFT2,ENSG00000135119,Unsafe,Protein,False,True,3.6,10.9,80,16,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 1 nTPM; positive ihc;continuous selectivity; amygdala: 6.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 9.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 10.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 4.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 7.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 8.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 1 nTPM; positive ihc; midbrain: 6.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; retina: 4.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 4.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 0.5 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 6.5 nTPM (limit 2); basal ganglia: 8 nTPM (limit 2); cerebellum: 9.5 nTPM (limit 2); cerebral cortex: 10.9 nTPM (limit 2); choroid plexus: 4.9 nTPM (limit 2); hippocampal formation: 7.8 nTPM (limit 2); hypothalamus: 8.5 nTPM (limit 2); midbrain: 6.7 nTPM (limit 2); pituitary gland: 5 nTPM (limit 2); retina: 4.8 nTPM (limit 2); spinal cord: 4.9 nTPM (limit 2),adrenal gland / glandular cells: Low (Enhanced); caudate / neuronal cells: Medium (Enhanced); cerebellum / Purkinje cells: Medium (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); hippocampus / neuronal cells: Medium (Enhanced); lymph node / non-germinal center cells: Low (Enhanced); thyroid gland / glandular cells: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Colon Adenocarcinoma (validation): 341/486 (70.2%); Breast Invasive Carcinoma (validation): 33/50 (66.0%),pancreatic cancer: 1/8 (12.5%); breast cancer: 0/9 (0.0%),31,20,Q96EX2,https://www.uniprot.org/uniprotkb/Q96EX2/entry,"E3 ubiquitin-protein ligase that negatively regulates IL3-dependent cellular responses through IL3RA ubiquitination and degradation by the proteasome, having an anti-inflammatory effect",,,,Membrane,31990690,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
ROPN1,ENSG00000065371,Unsafe,High RNA,False,True,154.4,154.4,85,2,Positive somewhere,False,False,False,True,Retained,Reproductive,False,,Not assessed,,Antigen family named in a trial,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,CTA,Pass,oncoref.target-sets.2026-10-23.1,False,False,,CTA → Unsafe,True,True,True,0.594864119713,32.9,"hpa_single_cell_tissue: salivary gland/serous glandular cells, max 32.9 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,0.5949 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,32.9 nTPM; salivary gland/serous glandular cells; hpa_single_cell_tissue; protected,Skin Cuteneous Melanoma (TCGA): 81/99 (81.8%); Breast Invasive Carcinoma (validation): 15/50 (30.0%); Breast Invasive Carcinoma (TCGA): 160/1022 (15.7%),colorectal cancer: 2/11 (18.2%); liver cancer: 1/9 (11.1%),31,20,Q9HAT0,https://www.uniprot.org/uniprotkb/Q9HAT0/entry,"Important for male fertility. With ROPN1L, involved in fibrous sheath integrity and sperm motility, plays a role in PKA-dependent signaling processes required for spermatozoa capacitation",Testis specific in adult. Overexpressed in hematologic tumor cells,,,"Cell projection, cilium, flagellum",,17551920,False,Reviewed UniProt annotation; not a new primary-paper review,Clinical family label; locus unresolved,https://clinicaltrials.gov/study/NCT02224599,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | Jamin2021_CT | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,Is the salivary serous-cell RNA above 30 nTPM a genuine local signal?,Review the underlying cluster and gene-specific reads with reliable local protein evidence before reconsideration.,The value is close to the hard ceiling; a general rule is applied rather than a benchmark exception.,All audited maxima are within 10% above 30; other gates still require review,,,,
ROPN1B,ENSG00000114547,Unsafe,RNA,False,True,208.3,208.3,85,2,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,Antigen family named in a trial,basal ganglia: 2.9 nTPM; absolute ceiling; pituitary gland: 2.9 nTPM; absolute ceiling; salivary gland: 14.1 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,basal ganglia: 2.9 nTPM (limit 2); pituitary gland: 2.9 nTPM (limit 2); salivary gland: 14.1 nTPM (limit 12),,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,True,"melanocytes: max 1.33175 mean CP10K, 2 supported sample groups",True,False,,False,True,True,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,True,1.62370439916,36.8,"hpa_single_cell_tissue: heart muscle/cardiomyocytes, max 36.8 nTPM, 2 observations >30; hpa_single_cell_tissue: salivary gland/serous glandular cells, max 31.6 nTPM, 1 observations >30",Unsafe,oncoref.target-sets.2026-10-23.2,1.624 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,36.8 nTPM; heart muscle/cardiomyocytes; hpa_single_cell_tissue; vital,Skin Cuteneous Melanoma (TCGA): 95/99 (96.0%); Breast Invasive Carcinoma (validation): 19/50 (38.0%); Breast Invasive Carcinoma (TCGA): 181/1022 (17.7%),colorectal cancer: 2/11 (18.2%); liver cancer: 1/9 (11.1%),31,20,Q9BZX4,https://www.uniprot.org/uniprotkb/Q9BZX4/entry,"Important for male fertility. With ROPN1L, involved in fibrous sheath integrity and sperm motility, plays a role in PKA-dependent signaling processes required for spermatozoa capacitation",,,,"Cell projection, cilium, flagellum",,,False,Reviewed UniProt annotation; not a new primary-paper review,Clinical family label; locus unresolved,https://clinicaltrials.gov/study/NCT02224599,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | Jamin2021_CT | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
ROPN1L,ENSG00000145491,Unsafe,Protein,False,True,314.0,314.0,109,14,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; amygdala: 3.4 nTPM; absolute ceiling; basal ganglia: 4 nTPM; absolute ceiling; choroid plexus: 11 nTPM; absolute ceiling; hippocampal formation: 5.7 nTPM; absolute ceiling; hypothalamus: 4.6 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 3.4 nTPM (limit 2); basal ganglia: 4 nTPM (limit 2); choroid plexus: 11 nTPM (limit 2); hippocampal formation: 5.7 nTPM (limit 2); hypothalamus: 4.6 nTPM (limit 2),bronchus / ciliated cells (cell body): Low (Enhanced); bronchus / ciliated cells (cilia axoneme): High (Enhanced); bronchus / ciliated cells (tip of cilia): High (Enhanced); nasopharynx / ciliated cells (tip of cilia): Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 22/50 (44.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 45/176 (25.6%); Ovary Serous Cystadenocarcinoma (TCGA): 73/349 (20.9%),ovarian cancer: 1/12 (8.3%); breast cancer: 0/11 (0.0%),31,20,Q96C74,https://www.uniprot.org/uniprotkb/Q96C74/entry,"Functions as part of axonemal radial spoke complexes that play an important part in the motility of sperm and cilia. Important for male fertility. With ROPN1, involved in fibrous sheath integrity and sperm motility, plays a role in PKA-dependent signaling processes required for spermatozoa capacitation",,,,"Cell projection, cilium, flagellum Cell projection, cilium",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Jamin2021_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
RPA4,ENSG00000204086,Unsafe,Protein,False,True,1.6,1.6,85,80,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0.4 nTPM; positive ihc; adrenal gland: 0.1 nTPM; positive ihc; bone marrow: 0.2 nTPM; positive ihc; cerebellum: 0 nTPM; positive ihc; cerebral cortex: 0 nTPM; positive ihc; colon: 0.1 nTPM; positive ihc; duodenum: 0.1 nTPM; positive ihc; esophagus: 0.1 nTPM; positive ihc; heart muscle: 0.3 nTPM; positive ihc; kidney: 0.1 nTPM; positive ihc; liver: 0.4 nTPM; positive ihc; lung: 0.3 nTPM; positive ihc; lymph node: 0 nTPM; positive ihc; pancreas: 0.1 nTPM; positive ihc; parathyroid gland: 0 nTPM; positive ihc; rectum: 0.1 nTPM; positive ihc; salivary gland: 0.1 nTPM; positive ihc; skeletal muscle: 0.2 nTPM; positive ihc; skin: 0.1 nTPM; positive ihc; small intestine: 0.1 nTPM; positive ihc; smooth muscle: 0 nTPM; positive ihc; spleen: 0.1 nTPM; positive ihc; stomach: 0.1 nTPM; positive ihc; thyroid gland: 0.1 nTPM; positive ihc; urinary bladder: 0.2 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: High (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: High (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: High (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Low (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: High (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 4/58 (6.9%); Pancreatic Adenocarcinoma (validation): 3/80 (3.8%); Testicular Germ Cell Tumor (TCGA): 3/133 (2.3%),colorectal cancer: 12/12 (100.0%); lung cancer: 12/12 (100.0%),31,20,Q13156,https://www.uniprot.org/uniprotkb/Q13156/entry,"As part of the alternative replication protein A complex, aRPA, binds single-stranded DNA and probably plays a role in DNA repair. Compared to the RPA2-containing, canonical RPA complex, may not support chromosomal DNA replication and cell cycle progression through S-phase. The aRPA may not promote efficient priming by DNA polymerase alpha but could support DNA polymerase delta synthesis in the presence of PCNA and replication factor C (RFC), the dual incision/excision reaction of nucleotide excision repair and RAD51-dependent strand exchange",Preferentially expressed in placental and colon mucosa. Widely expressed at intermediate or lower levels,,,Nucleus,19116208|19942684|19996105|20545304,19996105,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
RPAP3,ENSG00000005175,Unsafe,Protein,False,True,16.9,28.9,84,83,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 9.6 nTPM; positive ihc;continuous selectivity; adrenal gland: 10.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 6.5 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 6.6 nTPM; absolute ceiling;continuous selectivity; bone marrow: 12.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 8.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 12.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 8.7 nTPM; absolute ceiling;continuous selectivity; colon: 12.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 13.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 13.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 15.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 6.2 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 8.5 nTPM; absolute ceiling;continuous selectivity; kidney: 12.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 15 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 9.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 28.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 6.6 nTPM; absolute ceiling;continuous selectivity; pancreas: 8.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 16.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 8 nTPM; absolute ceiling;continuous selectivity; rectum: 12.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 10.8 nTPM; absolute ceiling;continuous selectivity; salivary gland: 9.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 22 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 10.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 12.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 14.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 7.7 nTPM; absolute ceiling;continuous selectivity; spleen: 16.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; stomach: 10.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 22.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 13.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 22.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 16.3 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 10.3 nTPM (limit 2); amygdala: 6.5 nTPM (limit 2); basal ganglia: 6.6 nTPM (limit 2); bone marrow: 12.6 nTPM (limit 2); cerebellum: 8.9 nTPM (limit 2); cerebral cortex: 12.2 nTPM (limit 2); choroid plexus: 8.7 nTPM (limit 2); colon: 12.1 nTPM (limit 6); duodenum: 13.4 nTPM (limit 2); esophagus: 13.1 nTPM (limit 6); heart muscle: 15.6 nTPM (limit 2); hippocampal formation: 6.2 nTPM (limit 2); hypothalamus: 8.5 nTPM (limit 2); kidney: 12.5 nTPM (limit 2); liver: 15 nTPM (limit 2); lung: 9.9 nTPM (limit 2); lymph node: 28.9 nTPM (limit 6); midbrain: 6.6 nTPM (limit 2); pancreas: 8.3 nTPM (limit 2); parathyroid gland: 16.7 nTPM (limit 6); pituitary gland: 8 nTPM (limit 2); rectum: 12.4 nTPM (limit 6); retina: 10.8 nTPM (limit 2); salivary gland: 9.5 nTPM (limit 6); skeletal muscle: 22 nTPM (limit 2); skin: 10.9 nTPM (limit 10); small intestine: 12.3 nTPM (limit 2); smooth muscle: 14.8 nTPM (limit 2); spinal cord: 7.7 nTPM (limit 2); spleen: 16.9 nTPM (limit 10); stomach: 10.8 nTPM (limit 6); thymus: 22.9 nTPM (limit 10); thyroid gland: 13.4 nTPM (limit 10); tongue: 22.7 nTPM (limit 6); urinary bladder: 16.3 nTPM (limit 6),adipose tissue / adipocytes: High (Enhanced); adrenal gland / glandular cells: Medium (Enhanced); bone marrow / hematopoietic cells: Medium (Enhanced); bronchus / respiratory epithelial cells: High (Enhanced); caudate / glial cells: Low (Enhanced); caudate / neuronal cells: Medium (Enhanced); cerebellum / cells in granular layer: Medium (Enhanced); cerebellum / cells in molecular layer: Medium (Enhanced); cerebellum / Purkinje cells: Medium (Enhanced); cerebral cortex / endothelial cells: Medium (Enhanced); cerebral cortex / glial cells: Low (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); cerebral cortex / neuropil: Low (Enhanced); colon / endothelial cells: High (Enhanced); colon / glandular cells: High (Enhanced); colon / peripheral nerve/ganglion: High (Enhanced); duodenum / glandular cells: High (Enhanced); esophagus / squamous epithelial cells: High (Enhanced); heart muscle / cardiomyocytes: Medium (Enhanced); hippocampus / glial cells: Medium (Enhanced); hippocampus / neuronal cells: Medium (Enhanced); kidney / cells in glomeruli: High (Enhanced); kidney / cells in tubules: Medium (Enhanced); liver / cholangiocytes: Low (Enhanced); liver / hepatocytes: Medium (Enhanced); lung / alveolar cells: Medium (Enhanced); lung / macrophages: Medium (Enhanced); lymph node / germinal center cells: Medium (Enhanced); lymph node / non-germinal center cells: High (Enhanced); nasopharynx / respiratory epithelial cells: High (Enhanced); oral mucosa / squamous epithelial cells: Medium (Enhanced); pancreas / exocrine glandular cells: Medium (Enhanced); pancreas / pancreatic endocrine cells: Medium (Enhanced); parathyroid gland / glandular cells: Medium (Enhanced); rectum / glandular cells: High (Enhanced); salivary gland / glandular cells: Medium (Enhanced); skeletal muscle / myocytes: Medium (Enhanced); skin 1 / fibroblasts: Medium (Enhanced); skin 1 / keratinocytes: Medium (Enhanced); skin 1 / Langerhans: Medium (Enhanced); skin 2 / epidermal cells: High (Enhanced); small intestine / glandular cells: High (Enhanced); smooth muscle / smooth muscle cells: Medium (Enhanced); spleen / cells in red pulp: Low (Enhanced); spleen / cells in white pulp: Medium (Enhanced); stomach 1 / glandular cells: High (Enhanced); stomach 2 / glandular cells: High (Enhanced); thyroid gland / glandular cells: Medium (Enhanced); urinary bladder / urothelial cells: Medium (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Colon Adenocarcinoma (TCGA): 254/254 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%),lymphoma: 12/12 (100.0%); melanoma: 12/12 (100.0%),31,20,Q9H6T3,https://www.uniprot.org/uniprotkb/Q9H6T3/entry,"Forms an interface between the RNA polymerase II enzyme and chaperone/scaffolding protein, suggesting that it is required to connect RNA polymerase II to regulators of protein complex formation",,,,,17643375,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
RPGR,ENSG00000156313,Unsafe,Protein,False,True,16.2,32.0,96,66,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 18.6 nTPM; continuous selectivity;reproductive not higher; adrenal gland: 5.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 7.3 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 10.1 nTPM; absolute ceiling;continuous selectivity; bone marrow: 12.1 nTPM; absolute ceiling;continuous selectivity; cerebellum: 8.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 7.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 15.4 nTPM; absolute ceiling;continuous selectivity; colon: 8.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 2.9 nTPM; positive ihc;absolute ceiling; esophagus: 5.3 nTPM; positive ihc; heart muscle: 9.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 9.1 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 11.7 nTPM; absolute ceiling;continuous selectivity; kidney: 6 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 3.6 nTPM; positive ihc;absolute ceiling; lung: 14.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 3.6 nTPM; positive ihc; midbrain: 9.7 nTPM; absolute ceiling;continuous selectivity; pancreas: 7.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 2.5 nTPM; positive ihc; pituitary gland: 32 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 3.5 nTPM; positive ihc; retina: 11.8 nTPM; absolute ceiling;continuous selectivity; salivary gland: 5.1 nTPM; positive ihc; skeletal muscle: 11.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 5.8 nTPM; positive ihc; small intestine: 9.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 4.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 10.9 nTPM; absolute ceiling;continuous selectivity; stomach: 6.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; thyroid gland: 9.4 nTPM; positive ihc;continuous selectivity; urinary bladder: 8.4 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 5.6 nTPM (limit 2); amygdala: 7.3 nTPM (limit 2); basal ganglia: 10.1 nTPM (limit 2); bone marrow: 12.1 nTPM (limit 4); cerebellum: 8.6 nTPM (limit 2); cerebral cortex: 7.4 nTPM (limit 2); choroid plexus: 15.4 nTPM (limit 2); colon: 8.8 nTPM (limit 6); duodenum: 2.9 nTPM (limit 2); heart muscle: 9.5 nTPM (limit 2); hippocampal formation: 9.1 nTPM (limit 2); hypothalamus: 11.7 nTPM (limit 2); kidney: 6 nTPM (limit 2); liver: 3.6 nTPM (limit 2); lung: 14.4 nTPM (limit 2); midbrain: 9.7 nTPM (limit 2); pancreas: 7.2 nTPM (limit 2); pituitary gland: 32 nTPM (limit 2); retina: 11.8 nTPM (limit 2); skeletal muscle: 11.6 nTPM (limit 2); small intestine: 9.1 nTPM (limit 2); smooth muscle: 4.3 nTPM (limit 2); spinal cord: 10.9 nTPM (limit 2); stomach: 6.6 nTPM (limit 6); urinary bladder: 8.4 nTPM (limit 6),adrenal gland / glandular cells: High (Approved); bronchus / ciliated cells (cell body): High (Approved); bronchus / ciliated cells (cilia axoneme): Medium (Approved); bronchus / ciliated cells (ciliary rootlets): High (Approved); bronchus / ciliated cells (tip of cilia): Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: High (Approved); liver / hepatocytes: High (Approved); lung / macrophages: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); retina / ganglion cells : High (Approved); retina / inner nuclear layer: Medium (Approved); retina / limiting membrane: Medium (Approved); retina / nerve fiber layer: High (Approved); retina / outer plexiform layer: High (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 48/50 (96.0%); Pancreatic Adenocarcinoma (validation): 71/80 (88.8%),liver cancer: 11/11 (100.0%); skin cancer: 11/11 (100.0%),31,20,Q92834,https://www.uniprot.org/uniprotkb/Q92834/entry,Acts as a guanine-nucleotide releasing factor (GEF) for RAB8A and RAB37 by promoting the conversion of inactive RAB-GDP to the active form RAB-GTP (PubMed:20631154). GEF activity towards RAB8A may facilitate ciliary trafficking by modulating ciliary intracellular localization of RAB8A (PubMed:20631154). GEF activity towards RAB37 maintains autophagic homeostasis and retinal function (By similarity). Involved in photoreceptor integrity (By similarity). May control cilia formation by regulating actin stress filaments and cell contractility. May be involved in microtubule organization and regulation of transport in primary cilia (PubMed:21933838). May play a critical role in spermatogenesis and in intraflagellar transport processes (By similarity),"Heart, brain, placenta, lung, liver, muscle, kidney, retina, pancreas and fetal retinal pigment epithelium. Isoform 3 is found only in the retina. Colocalizes with RPGRIP1 in the outer segment of rod photoreceptors and cone outer segments","Retinitis pigmentosa 3: An X-linked retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. In RP3, affected males have a severe phenotype, and carrier females show a wide spectrum of clinical features ranging from completely asymptomatic to severe retinitis pigmentosa. Heterozygous women can manifest a form of choroidoretinal degeneration which is distinguished from other types by the absence of visual defects in the presence of a brilliant, scintillating, golden-hued, patchy appearance most striking around the macula, called a tapetal-like retinal reflex. Retinitis pigmentosa, X-linked, and sinorespiratory infections with or without deafness: A disease characterized by the association of retinitis pigmentosa with recurrent upper and lower airway infections. Some patients also develop progressive hearing loss. Cone-rod dystrophy, X-linked 1: An inherited retinal dystrophy characterized by retinal pigment deposits visible on fundus examination, predominantly in the macular region, and initial loss of cone photoreceptors followed by rod degeneration. This leads to decreased visual acuity and sensitivity in the central visual field, followed by loss of peripheral vision. Severe loss of vision occurs earlier than in retinitis pigmentosa. In cone-rod dystrophy X-linked type 1 the degree of rod-photoreceptor involvement can be variable, with degeneration increasing as the disease progresses. Affected individuals (essentially all of whom are males) present with decreased visual acuity, myopia, photophobia, abnormal color vision, full peripheral visual fields, decreased photopic electroretinographic responses, and granularity of the macular retinal pigment epithelium. Although penetrance appears to be nearly 100%, there is variable expressivity with respect to age at onset and severity of symptoms. Macular degeneration, atrophic, X-linked: An ocular disorder characterized by macular atrophy causing progressive loss of visual acuity with minimal peripheral visual impairment. Some patients manifest extensive macular degeneration plus peripheral loss of retinal pigment epithelium and choriocapillaries. Full-field electroretinograms (ERGs) show normal cone and rod responses in some affected males despite advanced macular degeneration.",,"Cytoplasm, cytoskeleton, flagellum axoneme Golgi apparatus Cell projection, cilium Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Cytoplasm, cytoskeleton, cilium basal body Cytoplasm, cytoskeleton, cilium axoneme",20631154|21933838,12140192,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
RPGRIP1,ENSG00000092200,Unsafe,Protein,False,True,57.6,179.2,95,2,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; retina: 179.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",retina: 179.2 nTPM (limit 2),retina / photoreceptor cells: High (Supported),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 26/133 (19.5%); Breast Invasive Carcinoma (validation): 8/50 (16.0%); Lung Adenocarcinoma (validation): 2/105 (1.9%),melanoma: 1/12 (8.3%); breast cancer: 0/9 (0.0%),31,20,Q96KN7,https://www.uniprot.org/uniprotkb/Q96KN7/entry,May function as scaffolding protein. Required for normal location of RPGR at the connecting cilium of photoreceptor cells. Required for normal disk morphogenesis and disk organization in the outer segment of photoreceptor cells and for survival of photoreceptor cells,"Strong expression in retina, with weaker expression in testis. Expressed in other neurons such as amacrine cells. Colocalizes with RGPR in the outer segment of rod photoreceptors and cone outer segments","Leber congenital amaurosis 6: A severe dystrophy of the retina, typically becoming evident in the first years of life. Visual function is usually poor and often accompanied by nystagmus, sluggish or near-absent pupillary responses, photophobia, high hyperopia and keratoconus. Cone-rod dystrophy 13: An inherited retinal dystrophy characterized by retinal pigment deposits visible on fundus examination, predominantly in the macular region, and initial loss of cone photoreceptors followed by rod degeneration. This leads to decreased visual acuity and sensitivity in the central visual field, followed by loss of peripheral vision. Severe loss of vision occurs earlier than in retinitis pigmentosa, due to cone photoreceptors degenerating at a higher rate than rod photoreceptors.",,"Cell projection, cilium",10958648,10958647|10958648|12140192,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
RPL10L,ENSG00000165496,Unsafe,High RNA,False,True,89.4,89.4,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adipose tissue/Adipocytes: Medium, HPA011311; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: High, HPA011311; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: High, HPA011311; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA011311; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA011311; conflicting or uncurated primary profile; Caudate/Neuronal cells: High, HPA011311; conflicting or uncurated primary profile; Cerebellum/Cells in molecular layer: Medium, HPA011311; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: High, HPA011311; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA011311; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Medium, HPA011311; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: High, HPA011311; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA011311; conflicting or uncurated primary profile; Colon/Endocrine cells: High, HPA011311; conflicting or uncurated primary profile; Colon/Endothelial cells: High, HPA011311; conflicting or uncurated primary profile; Colon/Enterocytes: High, HPA011311; conflicting or uncurated primary profile; Colon/Fibroblasts: High, HPA011311; conflicting or uncurated primary profile; Colon/Goblet cells: High, HPA011311; conflicting or uncurated primary profile; Colon/Mucosal lymphoid cells: High, HPA011311; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: High, HPA011311; conflicting or uncurated primary profile; Duodenum/Endocrine cells: High, HPA011311; conflicting or uncurated primary profile; Duodenum/Enterocytes: High, HPA011311; conflicting or uncurated primary profile; Duodenum/Glands of Brunner: High, HPA011311; conflicting or uncurated primary profile; Duodenum/Goblet cells: High, HPA011311; conflicting or uncurated primary profile; Duodenum/Paneth cells: High, HPA011311; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: High, HPA011311; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA011311; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: High, HPA011311; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA011311; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA011311; conflicting or uncurated primary profile; Liver/Cholangiocytes: High, HPA011311; conflicting or uncurated primary profile; Liver/Hepatocytes: High, HPA011311; conflicting or uncurated primary profile; Lung/Alveolar cells: Low, HPA011311; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA011311; conflicting or uncurated primary profile; Lymph node/Germinal center cells: High, HPA011311; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA011311; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: High, HPA011311; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: High, HPA011311; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: High, HPA011311; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA011311; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: High, HPA011311; conflicting or uncurated primary profile; Rectum/Endocrine cells: High, HPA011311; conflicting or uncurated primary profile; Rectum/Endothelial cells: Medium, HPA011311; conflicting or uncurated primary profile; Rectum/Enterocytes: High, HPA011311; conflicting or uncurated primary profile; Rectum/Goblet cells: High, HPA011311; conflicting or uncurated primary profile; Rectum/Mucosal lymphoid cells: High, HPA011311; conflicting or uncurated primary profile; Salivary gland/Glandular cells: High, HPA011311; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA011311; conflicting or uncurated primary profile; Skin 1/Cells in basal layer: Medium, HPA011311; conflicting or uncurated primary profile; Skin 1/Cells in granular layer: Medium, HPA011311; conflicting or uncurated primary profile; Skin 1/Cells in spinous layer: Medium, HPA011311; conflicting or uncurated primary profile; Skin 1/Endothelial cells: Medium, HPA011311; conflicting or uncurated primary profile; Skin 1/Fibrohistiocytic cells: Medium, HPA011311; conflicting or uncurated primary profile; Skin 1/Langerhans cells: Medium, HPA011311; conflicting or uncurated primary profile; Skin 1/Lymphocytes: Low, HPA011311; conflicting or uncurated primary profile; Skin 1/Sebaceous glands: Medium, HPA011311; conflicting or uncurated primary profile; Skin 2/Arrector pili muscle cells: Low, HPA011311; conflicting or uncurated primary profile; Skin 2/Cells in basal layer: High, HPA011311; conflicting or uncurated primary profile; Skin 2/Cells in granular layer: High, HPA011311; conflicting or uncurated primary profile; Skin 2/Cells in spinous layer: High, HPA011311; conflicting or uncurated primary profile; Skin 2/Endothelial cells: Medium, HPA011311; conflicting or uncurated primary profile; Skin 2/Fibrohistiocytic cells: High, HPA011311; conflicting or uncurated primary profile; Skin 2/Langerhans cells: High, HPA011311; conflicting or uncurated primary profile; Skin 2/Lymphocytes: Low, HPA011311; conflicting or uncurated primary profile; Small intestine/Endocrine cells: High, HPA011311; conflicting or uncurated primary profile; Small intestine/Enterocytes: High, HPA011311; conflicting or uncurated primary profile; Small intestine/Goblet cells: Medium, HPA011311; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Low, HPA011311; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Low, HPA011311; conflicting or uncurated primary profile; Spleen/Cells in white pulp: High, HPA011311; conflicting or uncurated primary profile; Stomach 1/Glandular cells: High, HPA011311; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA011311; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: High, HPA011311; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: High, HPA011311; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,1.85669909115,41.3,"hpa_single_cell_tissue: bronchus/smooth muscle cells, max 41.3 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,1.857 TPM; blood/M2; dice_m2; vital,41.3 nTPM; bronchus/smooth muscle cells; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 75/133 (56.4%); Liver Hepatocellular Carcinoma (validation): 13/231 (5.6%); Liver Hepatocellular Carcinoma (TCGA): 12/362 (3.3%),breast cancer: 12/12 (100.0%); cervical cancer: 12/12 (100.0%),31,20,Q96L21,https://www.uniprot.org/uniprotkb/Q96L21/entry,"Testis-specific component of the ribosome, which is required for the transition from prophase to metaphase in male meiosis I (By similarity). Compensates for the inactivated X-linked RPL10 paralog during spermatogenesis (PubMed:12490704). The ribosome is a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell (PubMed:23636399, PubMed:25901680, PubMed:32669547). The male germ cell-specific ribosome displays a ribosomal polypeptide exit tunnel of distinct size and charge states compared with the classical ribosome (By similarity). It is responsible for regulating the biosynthesis and folding of a subset of male germ-cell-specific proteins that are essential for the formation of sperm (By similarity)","Almost testis-specific (PubMed:12490704, PubMed:19333399, PubMed:28502657). Also expressed in pre- and postmenopausal ovary (PubMed:19333399)",Spermatogenic failure 63: An autosomal recessive male infertility disorder characterized by severe oligozoospermia and reduced progressive sperm motility.,,Cytoplasm,12490704|23636399|25901680|32669547,12490704|19333399|28502657,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
RPL39L,ENSG00000163923,Unsafe,Protein,False,True,204.7,204.7,84,16,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 11.7 nTPM; absolute ceiling; basal ganglia: 11.2 nTPM; absolute ceiling; bone marrow: 19.1 nTPM; absolute ceiling; cerebral cortex: 10.7 nTPM; absolute ceiling; choroid plexus: 6.6 nTPM; absolute ceiling; colon: 12.1 nTPM; positive ihc;absolute ceiling; duodenum: 3.3 nTPM; positive ihc;absolute ceiling; esophagus: 8.7 nTPM; absolute ceiling; heart muscle: 11.2 nTPM; positive ihc;absolute ceiling; hippocampal formation: 9.6 nTPM; absolute ceiling; hypothalamus: 9.5 nTPM; absolute ceiling; kidney: 6.7 nTPM; positive ihc;absolute ceiling; liver: 4.4 nTPM; positive ihc;absolute ceiling; lung: 5.3 nTPM; absolute ceiling; lymph node: 12.9 nTPM; absolute ceiling; midbrain: 9.2 nTPM; absolute ceiling; pancreas: 19.8 nTPM; absolute ceiling; pituitary gland: 4.6 nTPM; absolute ceiling; rectum: 4.5 nTPM; positive ihc; retina: 7.3 nTPM; absolute ceiling; salivary gland: 8.1 nTPM; positive ihc;absolute ceiling; skeletal muscle: 2.1 nTPM; positive ihc;absolute ceiling; small intestine: 6 nTPM; positive ihc;absolute ceiling; smooth muscle: 7.9 nTPM; absolute ceiling; spinal cord: 8.9 nTPM; absolute ceiling; thymus: 16.1 nTPM; absolute ceiling; urinary bladder: 8.2 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 11.7 nTPM (limit 2); basal ganglia: 11.2 nTPM (limit 2); bone marrow: 19.1 nTPM (limit 4); cerebral cortex: 10.7 nTPM (limit 4); choroid plexus: 6.6 nTPM (limit 2); colon: 12.1 nTPM (limit 6); duodenum: 3.3 nTPM (limit 2); esophagus: 8.7 nTPM (limit 8); heart muscle: 11.2 nTPM (limit 2); hippocampal formation: 9.6 nTPM (limit 2); hypothalamus: 9.5 nTPM (limit 2); kidney: 6.7 nTPM (limit 2); liver: 4.4 nTPM (limit 2); lung: 5.3 nTPM (limit 4); lymph node: 12.9 nTPM (limit 8); midbrain: 9.2 nTPM (limit 2); pancreas: 19.8 nTPM (limit 4); pituitary gland: 4.6 nTPM (limit 2); retina: 7.3 nTPM (limit 2); salivary gland: 8.1 nTPM (limit 6); skeletal muscle: 2.1 nTPM (limit 2); small intestine: 6 nTPM (limit 2); smooth muscle: 7.9 nTPM (limit 4); spinal cord: 8.9 nTPM (limit 2); thymus: 16.1 nTPM (limit 10); urinary bladder: 8.2 nTPM (limit 8),colon / glandular cells: Low (Approved); duodenum / glandular cells: Low (Approved); heart muscle / cardiomyocytes: Low (Approved); kidney / cells in tubules: Low (Approved); liver / hepatocytes: Low (Approved); rectum / glandular cells: Low (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Low (Approved); small intestine / glandular cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 133/133 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%); Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%),liver cancer: 3/12 (25.0%); breast cancer: 1/12 (8.3%),31,20,Q96EH5,https://www.uniprot.org/uniprotkb/Q96EH5/entry,"Male germ cell-specific component of the ribosome, which is required for the formation of sperm and male fertility. Replaces the RPL39 paralog in the ribosome of male germ cells. The ribosome is a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell. The male germ cell-specific ribosome displays a ribosomal polypeptide exit tunnel of distinct size and charge states compared with the classical ribosome. It is responsible for regulating the biosynthesis and folding of a subset of male germ-cell-specific proteins that are essential for the formation of sperm",Testis specific,,,Cytoplasm,,12490704,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
RPP14,ENSG00000163684,Unsafe,RNA,False,True,5.3,39.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 5 nTPM; continuous selectivity; adrenal gland: 5.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 4 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 5 nTPM; absolute ceiling;continuous selectivity; bone marrow: 4.7 nTPM; absolute ceiling;continuous selectivity; cerebellum: 6.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 5.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 3.5 nTPM; absolute ceiling;continuous selectivity; colon: 6.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 6.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 5.7 nTPM; continuous selectivity;reproductive not higher; heart muscle: 10.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 3.9 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 4.1 nTPM; absolute ceiling;continuous selectivity; kidney: 8.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; liver: 11.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 3.9 nTPM; absolute ceiling;continuous selectivity; lymph node: 3.9 nTPM; continuous selectivity; midbrain: 3.6 nTPM; absolute ceiling;continuous selectivity; pancreas: 5.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 7.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 5.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 6.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; retina: 4.9 nTPM; absolute ceiling;continuous selectivity; salivary gland: 4.8 nTPM; continuous selectivity; skeletal muscle: 39.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 5.1 nTPM; continuous selectivity; small intestine: 6.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 6.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 3.3 nTPM; absolute ceiling;continuous selectivity; spleen: 5.6 nTPM; continuous selectivity;reproductive not higher; stomach: 5.2 nTPM; continuous selectivity; thymus: 6.3 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 5.3 nTPM; continuous selectivity;reproductive not higher; tongue: 37.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 5 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 5.5 nTPM (limit 2); amygdala: 4 nTPM (limit 2); basal ganglia: 5 nTPM (limit 2); bone marrow: 4.7 nTPM (limit 2); cerebellum: 6.4 nTPM (limit 2); cerebral cortex: 5.3 nTPM (limit 2); choroid plexus: 3.5 nTPM (limit 2); colon: 6.6 nTPM (limit 6); duodenum: 6.6 nTPM (limit 2); heart muscle: 10.5 nTPM (limit 2); hippocampal formation: 3.9 nTPM (limit 2); hypothalamus: 4.1 nTPM (limit 2); kidney: 8.7 nTPM (limit 2); liver: 11.2 nTPM (limit 2); lung: 3.9 nTPM (limit 2); midbrain: 3.6 nTPM (limit 2); pancreas: 5.9 nTPM (limit 2); parathyroid gland: 7.4 nTPM (limit 6); pituitary gland: 5.7 nTPM (limit 2); rectum: 6.2 nTPM (limit 6); retina: 4.9 nTPM (limit 2); skeletal muscle: 39.2 nTPM (limit 2); small intestine: 6.7 nTPM (limit 2); smooth muscle: 6.9 nTPM (limit 2); spinal cord: 3.3 nTPM (limit 2); tongue: 37.5 nTPM (limit 6); adrenal gland: 5.5 nTPM (baseline 2); amygdala: 4 nTPM (baseline 2); basal ganglia: 5 nTPM (baseline 2); bone marrow: 4.7 nTPM (baseline 2); cerebellum: 6.4 nTPM (baseline 2); cerebral cortex: 5.3 nTPM (baseline 2); choroid plexus: 3.5 nTPM (baseline 2); colon: 6.6 nTPM (baseline 6); duodenum: 6.6 nTPM (baseline 2); heart muscle: 10.5 nTPM (baseline 2); hippocampal formation: 3.9 nTPM (baseline 2); hypothalamus: 4.1 nTPM (baseline 2); kidney: 8.7 nTPM (baseline 2); liver: 11.2 nTPM (baseline 2); lung: 3.9 nTPM (baseline 2); midbrain: 3.6 nTPM (baseline 2); pancreas: 5.9 nTPM (baseline 2); parathyroid gland: 7.4 nTPM (baseline 6); pituitary gland: 5.7 nTPM (baseline 2); rectum: 6.2 nTPM (baseline 6); retina: 4.9 nTPM (baseline 2); skeletal muscle: 39.2 nTPM (baseline 2); small intestine: 6.7 nTPM (baseline 2); smooth muscle: 6.9 nTPM (baseline 2); spinal cord: 3.3 nTPM (baseline 2); tongue: 37.5 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Liver Hepatocellular Carcinoma (validation): 228/231 (98.7%); Colon Adenocarcinoma (validation): 478/486 (98.4%),colorectal cancer: 11/11 (100.0%); liver cancer: 9/11 (81.8%),31,20,O95059,https://www.uniprot.org/uniprotkb/O95059/entry,"Component of ribonuclease P, a ribonucleoprotein complex that generates mature tRNA molecules by cleaving their 5'-ends",,,,"Nucleus, nucleolus",10024167|30454648,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
RPP38,ENSG00000152464,Unsafe,Protein,False,True,46.7,46.7,84,38,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 12.5 nTPM; absolute ceiling; amygdala: 9.3 nTPM; absolute ceiling; basal ganglia: 11 nTPM; absolute ceiling; bone marrow: 12.3 nTPM; absolute ceiling; cerebellum: 21.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 10.1 nTPM; positive ihc;absolute ceiling; choroid plexus: 17 nTPM; absolute ceiling;continuous selectivity; colon: 15.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 15.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 15.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 12.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 9.8 nTPM; absolute ceiling; hypothalamus: 10.2 nTPM; absolute ceiling; kidney: 16.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 18.9 nTPM; absolute ceiling;continuous selectivity; lung: 13.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 19.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 10.1 nTPM; absolute ceiling; pancreas: 14.8 nTPM; absolute ceiling; parathyroid gland: 13.8 nTPM; absolute ceiling; pituitary gland: 13.1 nTPM; absolute ceiling;continuous selectivity; rectum: 16.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 13 nTPM; absolute ceiling;continuous selectivity; salivary gland: 14 nTPM; positive ihc;absolute ceiling; skeletal muscle: 18.3 nTPM; absolute ceiling;continuous selectivity; skin: 16.7 nTPM; positive ihc;absolute ceiling; small intestine: 16.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 12 nTPM; absolute ceiling; spinal cord: 10.1 nTPM; absolute ceiling; stomach: 15 nTPM; positive ihc;absolute ceiling; thymus: 15.3 nTPM; absolute ceiling; tongue: 14.3 nTPM; absolute ceiling; urinary bladder: 17 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 12.5 nTPM (limit 4); amygdala: 9.3 nTPM (limit 2); basal ganglia: 11 nTPM (limit 2); bone marrow: 12.3 nTPM (limit 4); cerebellum: 21.5 nTPM (limit 2); cerebral cortex: 10.1 nTPM (limit 2); choroid plexus: 17 nTPM (limit 2); colon: 15.8 nTPM (limit 6); duodenum: 15.4 nTPM (limit 2); esophagus: 15.8 nTPM (limit 6); heart muscle: 12.6 nTPM (limit 2); hippocampal formation: 9.8 nTPM (limit 2); hypothalamus: 10.2 nTPM (limit 2); kidney: 16.7 nTPM (limit 2); liver: 18.9 nTPM (limit 4); lung: 13.3 nTPM (limit 2); lymph node: 19.6 nTPM (limit 6); midbrain: 10.1 nTPM (limit 2); pancreas: 14.8 nTPM (limit 4); parathyroid gland: 13.8 nTPM (limit 8); pituitary gland: 13.1 nTPM (limit 2); rectum: 16.1 nTPM (limit 6); retina: 13 nTPM (limit 2); salivary gland: 14 nTPM (limit 6); skeletal muscle: 18.3 nTPM (limit 4); skin: 16.7 nTPM (limit 10); small intestine: 16.1 nTPM (limit 2); smooth muscle: 12 nTPM (limit 4); spinal cord: 10.1 nTPM (limit 2); stomach: 15 nTPM (limit 6); thymus: 15.3 nTPM (limit 10); tongue: 14.3 nTPM (limit 6); urinary bladder: 17 nTPM (limit 6),bronchus / respiratory epithelial cells: Medium (Approved); caudate / neuronal cells: Low (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); colon / glandular cells: Low (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skin 1 / keratinocytes: Low (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%); Head and Neck Squamous Cell Carcinoma (TCGA): 492/492 (100.0%),stomach cancer: 9/12 (75.0%); lung cancer: 8/12 (66.7%),31,20,P78345,https://www.uniprot.org/uniprotkb/P78345/entry,"Component of ribonuclease P, a ribonucleoprotein complex that generates mature tRNA molecules by cleaving their 5'-ends (PubMed:10444065, PubMed:30454648, PubMed:9037013, PubMed:9630247). Also a component of the MRP ribonuclease complex, which cleaves pre-rRNA sequences (PubMed:28115465)",,,,"Nucleus, nucleolus",10444065|28115465|30454648|9037013|9630247,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
RPRD1A,ENSG00000141425,Unsafe,Protein,False,True,112.4,112.4,107,97,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 22.5 nTPM; positive ihc;absolute ceiling; adrenal gland: 33.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 43.8 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 35.8 nTPM; absolute ceiling;continuous selectivity; bone marrow: 11.2 nTPM; positive ihc;absolute ceiling; cerebellum: 39.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 46 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 19.4 nTPM; absolute ceiling; colon: 28.6 nTPM; positive ihc;absolute ceiling; duodenum: 18.5 nTPM; positive ihc;absolute ceiling; esophagus: 22.8 nTPM; positive ihc;absolute ceiling; heart muscle: 28.1 nTPM; positive ihc;absolute ceiling; hippocampal formation: 41.9 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 39.6 nTPM; absolute ceiling;continuous selectivity; kidney: 25.8 nTPM; positive ihc;absolute ceiling; liver: 21.1 nTPM; positive ihc;absolute ceiling; lung: 18.7 nTPM; positive ihc;absolute ceiling; lymph node: 19 nTPM; positive ihc;absolute ceiling; midbrain: 39.5 nTPM; absolute ceiling;continuous selectivity; pancreas: 22.7 nTPM; positive ihc;absolute ceiling; parathyroid gland: 25.2 nTPM; positive ihc;absolute ceiling; pituitary gland: 27.1 nTPM; absolute ceiling; rectum: 19.9 nTPM; positive ihc;absolute ceiling; retina: 40.2 nTPM; absolute ceiling;continuous selectivity; salivary gland: 27.4 nTPM; positive ihc;absolute ceiling; skeletal muscle: 52.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 20.2 nTPM; positive ihc;absolute ceiling; small intestine: 18.4 nTPM; positive ihc;absolute ceiling; smooth muscle: 20.6 nTPM; positive ihc;absolute ceiling; spinal cord: 42.7 nTPM; absolute ceiling;continuous selectivity; spleen: 21.7 nTPM; positive ihc;absolute ceiling; stomach: 20.7 nTPM; positive ihc;absolute ceiling; thymus: 19.4 nTPM; absolute ceiling; thyroid gland: 31.1 nTPM; positive ihc;absolute ceiling; tongue: 44.7 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 26.7 nTPM; positive ihc;absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 22.5 nTPM (limit 10); adrenal gland: 33.7 nTPM (limit 2); amygdala: 43.8 nTPM (limit 2); basal ganglia: 35.8 nTPM (limit 2); bone marrow: 11.2 nTPM (limit 2); cerebellum: 39.9 nTPM (limit 2); cerebral cortex: 46 nTPM (limit 2); choroid plexus: 19.4 nTPM (limit 2); colon: 28.6 nTPM (limit 6); duodenum: 18.5 nTPM (limit 2); esophagus: 22.8 nTPM (limit 6); heart muscle: 28.1 nTPM (limit 2); hippocampal formation: 41.9 nTPM (limit 2); hypothalamus: 39.6 nTPM (limit 2); kidney: 25.8 nTPM (limit 2); liver: 21.1 nTPM (limit 2); lung: 18.7 nTPM (limit 2); lymph node: 19 nTPM (limit 6); midbrain: 39.5 nTPM (limit 2); pancreas: 22.7 nTPM (limit 2); parathyroid gland: 25.2 nTPM (limit 6); pituitary gland: 27.1 nTPM (limit 2); rectum: 19.9 nTPM (limit 6); retina: 40.2 nTPM (limit 2); salivary gland: 27.4 nTPM (limit 6); skeletal muscle: 52.8 nTPM (limit 2); skin: 20.2 nTPM (limit 10); small intestine: 18.4 nTPM (limit 2); smooth muscle: 20.6 nTPM (limit 2); spinal cord: 42.7 nTPM (limit 2); spleen: 21.7 nTPM (limit 10); stomach: 20.7 nTPM (limit 6); thymus: 19.4 nTPM (limit 10); thyroid gland: 31.1 nTPM (limit 10); tongue: 44.7 nTPM (limit 6); urinary bladder: 26.7 nTPM (limit 6),adipose tissue / adipocytes: Medium (Supported); adrenal gland / glandular cells: High (Supported); bone marrow / hematopoietic cells: Low (Supported); bronchus / respiratory epithelial cells: High (Supported); caudate / glial cells: Medium (Supported); caudate / neuronal cells: High (Supported); cerebellum / cells in granular layer: Medium (Supported); cerebellum / cells in molecular layer: High (Supported); cerebellum / Purkinje cells: High (Supported); cerebral cortex / glial cells: High (Supported); cerebral cortex / neuronal cells: High (Supported); cerebral cortex / neuropil: Medium (Supported); colon / endocrine cells: High (Supported); colon / endothelial cells: Low (Supported); colon / enterocytes: High (Supported); colon / fibroblasts: Medium (Supported); colon / goblet cells: High (Supported); colon / mucosal lymphoid cells: Medium (Supported); colon / peripheral nerve/ganglion: High (Supported); duodenum / endocrine cells: High (Supported); duodenum / enterocytes: High (Supported); duodenum / glands of Brunner: High (Supported); duodenum / goblet cells: High (Supported); duodenum / paneth cells: High (Supported); esophagus / squamous epithelial cells: High (Supported); heart muscle / cardiomyocytes: Medium (Supported); hippocampus / glial cells: Medium (Supported); hippocampus / neuronal cells: High (Supported); kidney / cells in glomeruli: High (Supported); kidney / cells in tubules: High (Supported); liver / cholangiocytes: Low (Supported); liver / hepatocytes: Low (Supported); lung / alveolar cells type I: High (Supported); lung / macrophages: Low (Supported); lymph node / germinal center cells: Medium (Supported); lymph node / non-germinal center cells: Medium (Supported); oral mucosa / squamous epithelial cells: High (Supported); pancreas / exocrine glandular cells: High (Supported); pancreas / pancreatic endocrine cells: High (Supported); parathyroid gland / glandular cells: Medium (Supported); rectum / endocrine cells: High (Supported); rectum / enterocytes: High (Supported); rectum / goblet cells: High (Supported); rectum / mucosal lymphoid cells: Medium (Supported); salivary gland / glandular cells: High (Supported); skeletal muscle / myocytes: High (Supported); skin 1 / fibroblasts: Medium (Supported); skin 1 / keratinocytes: High (Supported); skin 1 / Langerhans: Medium (Supported); skin 2 / epidermal cells: High (Supported); small intestine / endocrine cells: High (Supported); small intestine / enterocytes: High (Supported); small intestine / goblet cells: High (Supported); small intestine / paneth cells: High (Supported); smooth muscle / smooth muscle cells: Medium (Supported); spleen / cells in red pulp: Low (Supported); spleen / cells in white pulp: Low (Supported); stomach 1 / glandular cells: High (Supported); stomach 2 / glandular cells: High (Supported); thyroid gland / glandular cells: High (Supported); urinary bladder / urothelial cells: High (Supported),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Adenocarcinoma (TCGA): 497/497 (100.0%); Lung Squamous Cell Carcinoma (TCGA): 489/489 (100.0%); Prostate Adenocarcinoma (TCGA): 480/480 (100.0%),colorectal cancer: 11/11 (100.0%); cervical cancer: 11/12 (91.7%),31,20,Q96P16,https://www.uniprot.org/uniprotkb/Q96P16/entry,"Interacts with phosphorylated C-terminal heptapeptide repeat domain (CTD) of the largest RNA polymerase II subunit POLR2A, and participates in dephosphorylation of the CTD by RPAP2. May act as a negative regulator of cyclin-D1 (CCND1) and cyclin-E (CCNE1) in the cell cycle",,,,Nucleus,22231121|24399136|24997600,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
RSPH10B,ENSG00000155026,Unsafe,Protein,False,True,19.2,19.2,91,7,Positive somewhere,True,True,False,True,Excluded,Normal,False,,Not assessed,,,positive ihc outside permitted; choroid plexus: 4.2 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 4.2 nTPM (limit 2),bronchus / ciliated cells (cilia axoneme): High (Supported); bronchus / ciliated cells (tip of cilia): High (Supported),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 100/176 (56.8%); Prostate Adenocarcinoma (TCGA): 115/480 (24.0%); Testicular Germ Cell Tumor (TCGA): 31/133 (23.3%),liver cancer: 2/11 (18.2%); breast cancer: 1/12 (8.3%),30,20,B2RC85 | P0C881,https://www.uniprot.org/uniprotkb/B2RC85/entry | https://www.uniprot.org/uniprotkb/P0C881/entry,May function as part of the axonemal radial spoke complex 3 (RS3). Radial spoke complexes are important for ciliary motility,,,,"Cytoplasm, cytoskeleton, cilium axoneme Cell projection, cilium Cell projection, cilium, flagellum",,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
RSPH10B2,ENSG00000169402,Unsafe,Protein,False,True,18.9,18.9,91,7,Positive somewhere,True,True,False,True,Excluded,Normal,False,,Not assessed,,,positive ihc outside permitted; choroid plexus: 3.6 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 3.6 nTPM (limit 2),bronchus / ciliated cells (cilia axoneme): High (Supported); bronchus / ciliated cells (tip of cilia): High (Supported),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 12/133 (9.0%); Pancreatic Adenocarcinoma (validation): 6/80 (7.5%); Glioblastoma Multiforme (validation): 1/58 (1.7%),liver cancer: 2/11 (18.2%); breast cancer: 1/12 (8.3%),31,20,B2RC85,https://www.uniprot.org/uniprotkb/B2RC85/entry,May function as part of the axonemal radial spoke complex 3 (RS3). Radial spoke complexes are important for ciliary motility,,,,"Cytoplasm, cytoskeleton, cilium axoneme Cell projection, cilium Cell projection, cilium, flagellum",,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Jamin2021_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
RTEL1,ENSG00000258366,Unsafe,RNA,False,True,9.6,14.5,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 4.7 nTPM; continuous selectivity; adrenal gland: 6.8 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 3.1 nTPM; absolute ceiling;continuous selectivity; bone marrow: 5.2 nTPM; absolute ceiling;continuous selectivity; cerebellum: 14.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 5.9 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 2.4 nTPM; absolute ceiling; colon: 8.3 nTPM; absolute ceiling;continuous selectivity; duodenum: 3.2 nTPM; absolute ceiling;continuous selectivity; esophagus: 4.5 nTPM; continuous selectivity; heart muscle: 3.8 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 2.3 nTPM; absolute ceiling; hypothalamus: 3.2 nTPM; absolute ceiling;continuous selectivity; kidney: 4 nTPM; absolute ceiling;continuous selectivity; liver: 4.7 nTPM; absolute ceiling;continuous selectivity; lung: 5.8 nTPM; absolute ceiling;continuous selectivity; pancreas: 6 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 11.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 5.6 nTPM; continuous selectivity; skeletal muscle: 4.5 nTPM; absolute ceiling;continuous selectivity; skin: 4.4 nTPM; continuous selectivity; small intestine: 5.7 nTPM; absolute ceiling;continuous selectivity; spleen: 5.9 nTPM; continuous selectivity; stomach: 6.4 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 7.6 nTPM; continuous selectivity; urinary bladder: 6.3 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 6.8 nTPM (limit 2); basal ganglia: 3.1 nTPM (limit 2); bone marrow: 5.2 nTPM (limit 2); cerebellum: 14.5 nTPM (limit 2); cerebral cortex: 5.9 nTPM (limit 2); choroid plexus: 2.4 nTPM (limit 2); colon: 8.3 nTPM (limit 6); duodenum: 3.2 nTPM (limit 2); heart muscle: 3.8 nTPM (limit 2); hippocampal formation: 2.3 nTPM (limit 2); hypothalamus: 3.2 nTPM (limit 2); kidney: 4 nTPM (limit 2); liver: 4.7 nTPM (limit 2); lung: 5.8 nTPM (limit 2); pancreas: 6 nTPM (limit 2); pituitary gland: 11.9 nTPM (limit 2); skeletal muscle: 4.5 nTPM (limit 2); small intestine: 5.7 nTPM (limit 2); stomach: 6.4 nTPM (limit 6); urinary bladder: 6.3 nTPM (limit 6); adrenal gland: 6.8 nTPM (baseline 2); basal ganglia: 3.1 nTPM (baseline 2); bone marrow: 5.2 nTPM (baseline 2); cerebellum: 14.5 nTPM (baseline 2); cerebral cortex: 5.9 nTPM (baseline 2); choroid plexus: 2.4 nTPM (baseline 2); colon: 8.3 nTPM (baseline 6); duodenum: 3.2 nTPM (baseline 2); heart muscle: 3.8 nTPM (baseline 2); hippocampal formation: 2.3 nTPM (baseline 2); hypothalamus: 3.2 nTPM (baseline 2); kidney: 4 nTPM (baseline 2); liver: 4.7 nTPM (baseline 2); lung: 5.8 nTPM (baseline 2); pancreas: 6 nTPM (baseline 2); pituitary gland: 11.9 nTPM (baseline 2); skeletal muscle: 4.5 nTPM (baseline 2); small intestine: 5.7 nTPM (baseline 2); stomach: 6.4 nTPM (baseline 6); urinary bladder: 6.3 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Colon Adenocarcinoma (validation): 485/486 (99.8%); Breast Invasive Carcinoma (validation): 47/50 (94.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9NZ71,https://www.uniprot.org/uniprotkb/Q9NZ71/entry,"A probable ATP-dependent DNA helicase implicated in telomere-length regulation, DNA repair and the maintenance of genomic stability. Acts as an anti-recombinase to counteract toxic recombination and limit crossover during meiosis. Regulates meiotic recombination and crossover homeostasis by physically dissociating strand invasion events and thereby promotes noncrossover repair by meiotic synthesis dependent strand annealing (SDSA) as well as disassembly of D loop recombination intermediates. Also disassembles T loops and prevents telomere fragility by counteracting telomeric G4-DNA structures, which together ensure the dynamics and stability of the telomere",,"Dyskeratosis congenita, autosomal recessive, 5: A form of dyskeratosis congenita, a rare multisystem disorder caused by defective telomere maintenance. It is characterized by progressive bone marrow failure, and the clinical triad of reticulated skin hyperpigmentation, nail dystrophy, and mucosal leukoplakia. Common but variable features include premature graying, aplastic anemia, low platelets, osteoporosis, pulmonary fibrosis, and liver fibrosis among others. Early mortality is often associated with bone marrow failure, infections, fatal pulmonary complications, or malignancy. DKCB5 is characterized by onset of bone marrow failure and immunodeficiency in early childhood. Most patients also have growth and developmental delay and cerebellar hypoplasia, consistent with a clinical diagnosis of Hoyeraal-Hreidarsson syndrome. Dyskeratosis congenita, autosomal dominant, 4: A rare multisystem disorder caused by defective telomere maintenance. It is characterized by progressive bone marrow failure, and the clinical triad of reticulated skin hyperpigmentation, nail dystrophy, and mucosal leukoplakia. Common but variable features include premature graying, aplastic anemia, low platelets, osteoporosis, pulmonary fibrosis, and liver fibrosis among others. Early mortality is often associated with bone marrow failure, infections, fatal pulmonary complications, or malignancy. Pulmonary fibrosis, and/or bone marrow failure syndrome, telomere-related, 3: An autosomal dominant disease associated with shortened telomeres. Pulmonary fibrosis is the most common manifestation. Other manifestations include aplastic anemia due to bone marrow failure, hepatic fibrosis, and increased cancer risk, particularly myelodysplastic syndrome and acute myeloid leukemia. Phenotype, age at onset, and severity are determined by telomere length.",,Nucleus,18957201|23453664|24009516,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
S100A7A,ENSG00000184330,Unsafe,Protein,False,True,2.6,5.7,78,9,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; esophagus: 5.5 nTPM; positive ihc;continuous selectivity;reproductive not higher; skin: 1.6 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",,esophagus / squamous epithelial cells: Medium (Supported); oral mucosa / squamous epithelial cells: Low (Supported); skin 1 / keratinocytes: High (Supported); skin 1 / Langerhans: Low (Supported); skin 2 / epidermal cells: High (Supported),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Head and Neck Squamous Cell Carcinoma (TCGA): 292/492 (59.3%); Skin Cuteneous Melanoma (TCGA): 32/99 (32.3%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 75/283 (26.5%),skin cancer: 5/10 (50.0%); cervical cancer: 5/12 (41.7%),31,20,Q86SG5,https://www.uniprot.org/uniprotkb/Q86SG5/entry,May be involved in epidermal differentiation and inflammation and might therefore be important for the pathogenesis of psoriasis and other diseases,Overexpressed in psoriasis,,,Cytoplasm,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
SAC3D1,ENSG00000168061,Unsafe,Protein,False,True,13.1,13.1,73,68,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 3.7 nTPM; positive ihc; adrenal gland: 3.3 nTPM; positive ihc;absolute ceiling; amygdala: 2.4 nTPM; absolute ceiling; basal ganglia: 2.7 nTPM; absolute ceiling; bone marrow: 4 nTPM; absolute ceiling;continuous selectivity; cerebellum: 4.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 2.6 nTPM; positive ihc;absolute ceiling; choroid plexus: 6.8 nTPM; absolute ceiling;continuous selectivity; colon: 3.5 nTPM; positive ihc; duodenum: 3.1 nTPM; positive ihc;absolute ceiling; esophagus: 3.5 nTPM; positive ihc; heart muscle: 2.5 nTPM; positive ihc;absolute ceiling; hippocampal formation: 2.5 nTPM; absolute ceiling; hypothalamus: 2.3 nTPM; absolute ceiling; kidney: 2 nTPM; positive ihc; liver: 3.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 2 nTPM; positive ihc; midbrain: 2.3 nTPM; absolute ceiling; pancreas: 2.7 nTPM; positive ihc;absolute ceiling; parathyroid gland: 1.2 nTPM; positive ihc; pituitary gland: 2.7 nTPM; absolute ceiling; rectum: 1.2 nTPM; positive ihc; salivary gland: 2.6 nTPM; positive ihc; skeletal muscle: 8.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 3.6 nTPM; positive ihc; small intestine: 2.5 nTPM; positive ihc;absolute ceiling; smooth muscle: 1.9 nTPM; positive ihc; spinal cord: 2.4 nTPM; absolute ceiling; spleen: 3 nTPM; positive ihc; stomach: 2.8 nTPM; positive ihc; thymus: 6.9 nTPM; continuous selectivity; thyroid gland: 1.3 nTPM; positive ihc; urinary bladder: 2.5 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 3.3 nTPM (limit 2); amygdala: 2.4 nTPM (limit 2); basal ganglia: 2.7 nTPM (limit 2); bone marrow: 4 nTPM (limit 2); cerebellum: 4.7 nTPM (limit 2); cerebral cortex: 2.6 nTPM (limit 2); choroid plexus: 6.8 nTPM (limit 2); duodenum: 3.1 nTPM (limit 2); heart muscle: 2.5 nTPM (limit 2); hippocampal formation: 2.5 nTPM (limit 2); hypothalamus: 2.3 nTPM (limit 2); liver: 3.6 nTPM (limit 2); midbrain: 2.3 nTPM (limit 2); pancreas: 2.7 nTPM (limit 2); pituitary gland: 2.7 nTPM (limit 2); skeletal muscle: 8.9 nTPM (limit 2); small intestine: 2.5 nTPM (limit 2); spinal cord: 2.4 nTPM (limit 2); adrenal gland: 3.3 nTPM (baseline 2); amygdala: 2.4 nTPM (baseline 2); basal ganglia: 2.7 nTPM (baseline 2); bone marrow: 4 nTPM (baseline 2); cerebellum: 4.7 nTPM (baseline 2); cerebral cortex: 2.6 nTPM (baseline 2); choroid plexus: 6.8 nTPM (baseline 2); duodenum: 3.1 nTPM (baseline 2); heart muscle: 2.5 nTPM (baseline 2); hippocampal formation: 2.5 nTPM (baseline 2); hypothalamus: 2.3 nTPM (baseline 2); liver: 3.6 nTPM (baseline 2); midbrain: 2.3 nTPM (baseline 2); pancreas: 2.7 nTPM (baseline 2); pituitary gland: 2.7 nTPM (baseline 2); skeletal muscle: 8.9 nTPM (baseline 2); small intestine: 2.5 nTPM (baseline 2); spinal cord: 2.4 nTPM (baseline 2),adipose tissue / adipocytes: Medium (Uncertain); adrenal gland / glandular cells: Medium (Uncertain); bronchus / respiratory epithelial cells: High (Uncertain); caudate / glial cells: Low (Uncertain); caudate / neuronal cells: Low (Uncertain); cerebellum / cells in granular layer: Low (Uncertain); cerebellum / Purkinje cells: High (Uncertain); cerebral cortex / endothelial cells: Low (Uncertain); cerebral cortex / glial cells: Medium (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: Medium (Uncertain); colon / endothelial cells: High (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: High (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Low (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / glial cells: Low (Uncertain); kidney / cells in glomeruli: Low (Uncertain); kidney / cells in tubules: High (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / alveolar cells: Low (Uncertain); lung / macrophages: Medium (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); parathyroid gland / glandular cells: High (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: Medium (Uncertain); skin 1 / fibroblasts: Medium (Uncertain); skin 1 / keratinocytes: High (Uncertain); skin 1 / Langerhans: Medium (Uncertain); skin 2 / epidermal cells: Low (Uncertain); small intestine / glandular cells: Medium (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); spleen / cells in red pulp: Low (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Ovary Serous Cystadenocarcinoma (TCGA): 348/349 (99.7%); Glioblastoma Multiforme (TCGA): 140/141 (99.3%); Ovary Serous Cystadenocarcinoma (validation): 79/81 (97.5%),melanoma: 10/11 (90.9%); ovarian cancer: 10/11 (90.9%),31,20,,,,,,,,,,False,No exact Ensembl mapping to a reviewed UniProt entry,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
SAG,ENSG00000130561,Unsafe,Protein,False,True,3.0,1421.5,83,1,Positive somewhere,True,True,False,False,Excluded,Normal,False,,Not assessed,,,positive ihc outside permitted; basal ganglia: 3.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; retina: 1421.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",basal ganglia: 3.7 nTPM (limit 2); retina: 1421.5 nTPM (limit 2); basal ganglia: 3.7 nTPM (baseline 2); retina: 1421.5 nTPM (baseline 2),retina / photoreceptor cells: High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 6/80 (7.5%); Breast Invasive Carcinoma (validation): 1/50 (2.0%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),skin cancer: 1/11 (9.1%); breast cancer: 0/12 (0.0%),31,20,P10523,https://www.uniprot.org/uniprotkb/P10523/entry,"Involved in the regulation of phototransduction, playing a key role in signal termination after rhodopsin (RHO) has been activated by light in rod photoreceptors. Binds to photoactivated and phosphorylated RHO, preventing its interaction with transducin (GNAT1) and terminating transducin-mediated opsin signaling (By similarity). May play a role in preventing light-dependent degeneration of retinal photoreceptor cells (PubMed:9565049)","Detected in retina, in the proximal portion of the outer segment of rod photoreceptor cells (at protein level)","Night blindness, congenital stationary, Oguchi type 1: A non-progressive retinal disorder characterized by impaired night vision, often associated with nystagmus and myopia. Congenital stationary night blindness Oguchi type is an autosomal recessive form associated with fundus discoloration and abnormally slow dark adaptation. Retinitis pigmentosa 47: A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. Retinitis pigmentosa 96: An autosomal dominant form of retinitis pigmentosa, a retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field.",,"Photoreceptor inner segment Cell projection, cilium, photoreceptor outer segment Membrane",9565049,3720866,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
SAMD15,ENSG00000100583,Unsafe,Protein,False,True,15.6,15.6,81,81,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0.5 nTPM; positive ihc; adrenal gland: 0.7 nTPM; positive ihc; bone marrow: 0.7 nTPM; positive ihc; cerebellum: 0.2 nTPM; positive ihc; cerebral cortex: 1.6 nTPM; positive ihc; choroid plexus: 3 nTPM; absolute ceiling; colon: 0.2 nTPM; positive ihc; duodenum: 0.3 nTPM; positive ihc; esophagus: 0.2 nTPM; positive ihc; heart muscle: 0.1 nTPM; positive ihc; kidney: 1.8 nTPM; positive ihc; liver: 0.1 nTPM; positive ihc; lung: 0.7 nTPM; positive ihc; lymph node: 1.4 nTPM; positive ihc; pancreas: 1.9 nTPM; positive ihc; parathyroid gland: 2.3 nTPM; positive ihc; pituitary gland: 2.4 nTPM; absolute ceiling; rectum: 0.3 nTPM; positive ihc; retina: 14.5 nTPM; absolute ceiling;continuous selectivity; salivary gland: 0.3 nTPM; positive ihc; skeletal muscle: 0.2 nTPM; positive ihc; skin: 0.5 nTPM; positive ihc; small intestine: 0.2 nTPM; positive ihc; smooth muscle: 0.3 nTPM; positive ihc; spleen: 0.2 nTPM; positive ihc; stomach: 0.4 nTPM; positive ihc; thyroid gland: 3.6 nTPM; positive ihc; urinary bladder: 0.8 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 3 nTPM (limit 2); pituitary gland: 2.4 nTPM (limit 2); retina: 14.5 nTPM (limit 2),adipose tissue / adipocytes: Medium (Enhanced); adrenal gland / glandular cells: Medium (Enhanced); bone marrow / hematopoietic cells: High (Enhanced); bronchus / respiratory epithelial cells: High (Enhanced); caudate / glial cells: High (Enhanced); caudate / neuronal cells: Medium (Enhanced); cerebellum / cells in granular layer: Medium (Enhanced); cerebellum / cells in molecular layer: High (Enhanced); cerebellum / Purkinje cells: High (Enhanced); cerebral cortex / endothelial cells: Medium (Enhanced); cerebral cortex / glial cells: High (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); cerebral cortex / neuropil: Medium (Enhanced); colon / endothelial cells: High (Enhanced); colon / glandular cells: Medium (Enhanced); colon / peripheral nerve/ganglion: Medium (Enhanced); duodenum / glandular cells: Medium (Enhanced); esophagus / squamous epithelial cells: Medium (Enhanced); heart muscle / cardiomyocytes: Medium (Enhanced); hippocampus / glial cells: High (Enhanced); hippocampus / neuronal cells: Medium (Enhanced); kidney / cells in glomeruli: Medium (Enhanced); kidney / cells in tubules: Medium (Enhanced); liver / cholangiocytes: Medium (Enhanced); liver / hepatocytes: Low (Enhanced); lung / alveolar cells: Medium (Enhanced); lung / macrophages: Medium (Enhanced); lymph node / germinal center cells: Medium (Enhanced); lymph node / non-germinal center cells: Medium (Enhanced); nasopharynx / respiratory epithelial cells: High (Enhanced); oral mucosa / squamous epithelial cells: Medium (Enhanced); pancreas / exocrine glandular cells: Medium (Enhanced); pancreas / pancreatic endocrine cells: Low (Enhanced); parathyroid gland / glandular cells: Medium (Enhanced); rectum / glandular cells: Medium (Enhanced); salivary gland / glandular cells: Medium (Enhanced); skeletal muscle / myocytes: Medium (Enhanced); skin 1 / fibroblasts: High (Enhanced); skin 1 / keratinocytes: High (Enhanced); skin 1 / Langerhans: High (Enhanced); skin 2 / epidermal cells: Medium (Enhanced); small intestine / glandular cells: Medium (Enhanced); smooth muscle / smooth muscle cells: Medium (Enhanced); spleen / cells in red pulp: Medium (Enhanced); spleen / cells in white pulp: Low (Enhanced); stomach 1 / glandular cells: Medium (Enhanced); stomach 2 / glandular cells: Medium (Enhanced); thyroid gland / glandular cells: High (Enhanced); urinary bladder / urothelial cells: Medium (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 53/58 (91.4%); Uterine Corpus Endometrial Carcinoma (TCGA): 45/176 (25.6%); Breast Invasive Carcinoma (TCGA): 170/1022 (16.6%),cervical cancer: 12/12 (100.0%); colorectal cancer: 12/12 (100.0%),30,20,Q9P1V8,https://www.uniprot.org/uniprotkb/Q9P1V8/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
SAMD3,ENSG00000164483,Unsafe,RNA,False,True,4.2,10.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 2.2 nTPM; absolute ceiling;continuous selectivity; bone marrow: 4.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 1.4 nTPM; continuous selectivity; hippocampal formation: 2.4 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 1.6 nTPM; continuous selectivity; liver: 1.7 nTPM; continuous selectivity; lung: 3.2 nTPM; absolute ceiling;continuous selectivity; lymph node: 10.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 4.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 2.2 nTPM; continuous selectivity; retina: 1.3 nTPM; continuous selectivity; small intestine: 1.4 nTPM; continuous selectivity; smooth muscle: 1.7 nTPM; continuous selectivity; spleen: 9 nTPM; continuous selectivity;reproductive not higher; stomach: 1.6 nTPM; continuous selectivity; thymus: 6.1 nTPM; continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 2.2 nTPM (limit 2); bone marrow: 4.2 nTPM (limit 2); hippocampal formation: 2.4 nTPM (limit 2); lung: 3.2 nTPM (limit 2); lymph node: 10.1 nTPM (limit 6); pituitary gland: 4.7 nTPM (limit 2); adrenal gland: 2.2 nTPM (baseline 2); bone marrow: 4.2 nTPM (baseline 2); hippocampal formation: 2.4 nTPM (baseline 2); lung: 3.2 nTPM (baseline 2); lymph node: 10.1 nTPM (baseline 6); pituitary gland: 4.7 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 33/50 (66.0%); Kidney Renal Clear Cell Carcinoma (validation): 29/100 (29.0%); Lung Adenocarcinoma (validation): 19/105 (18.1%),urothelial cancer: 9/12 (75.0%); liver cancer: 8/11 (72.7%),31,20,Q8N6K7,https://www.uniprot.org/uniprotkb/Q8N6K7/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
SAMD7,ENSG00000187033,Unsafe,RNA,False,True,0.1,130.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,lymph node: 0.2 nTPM; continuous selectivity;reproductive not higher; retina: 130 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 130 nTPM (limit 2); retina: 130 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 2/176 (1.1%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Ovary Serous Cystadenocarcinoma (TCGA): 1/349 (0.3%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q7Z3H4,https://www.uniprot.org/uniprotkb/Q7Z3H4/entry,"Component of a Polycomb group (PcG) multiprotein PRC1-like complex, essential for establishing rod photoreceptor cell identity and function by silencing nonrod gene expression in developing rod photoreceptor cells. Via its association with the PRC1-like complex, promotes epigenetic repressive marks H3K27me3 and H2AK119ub marks in nonrod genes, silencing their transcription. Represses Crx-controlled photoreceptor-specific gene expression",Expressed in the retina (at protein level) (PubMed:26887858). Expressed in the retinal inner and outer nuclear layers (PubMed:38272031),"Macular dystrophy with or without cone dysfunction: A form of macular dystrophy, a retinal disease in which various forms of deposits, pigmentary changes, and atrophic lesions are observed in the macula lutea. MDCD is a progressive, autosomal recessive form characterized by reduced visual acuity and macular atrophy involving the fovea. Some patients also exhibit mild generalized cone dysfunction.",,Nucleus Cytoplasm,,26887858|38272031,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
SARS2,ENSG00000104835,Unsafe,Protein,False,True,11.9,18.2,85,64,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 7.1 nTPM; continuous selectivity; adrenal gland: 16.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 7.8 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 8.4 nTPM; absolute ceiling;continuous selectivity; bone marrow: 9.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 10.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 12.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 7.7 nTPM; absolute ceiling;continuous selectivity; colon: 9.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 9 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 13.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 12 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 8.3 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 8.4 nTPM; absolute ceiling;continuous selectivity; kidney: 14.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 18.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 6.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 9.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 7.2 nTPM; absolute ceiling;continuous selectivity; pancreas: 15.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 7.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 11.6 nTPM; absolute ceiling;continuous selectivity; rectum: 5.1 nTPM; positive ihc;continuous selectivity; retina: 2.2 nTPM; absolute ceiling; salivary gland: 11 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 15.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 12 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 9.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 5 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 7.3 nTPM; absolute ceiling;continuous selectivity; spleen: 11.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 11.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 7.3 nTPM; continuous selectivity; thyroid gland: 13.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; tongue: 11.1 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 9.1 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 16.8 nTPM (limit 2); amygdala: 7.8 nTPM (limit 2); basal ganglia: 8.4 nTPM (limit 2); bone marrow: 9.2 nTPM (limit 2); cerebellum: 10.9 nTPM (limit 2); cerebral cortex: 12.7 nTPM (limit 2); choroid plexus: 7.7 nTPM (limit 2); colon: 9.8 nTPM (limit 6); duodenum: 9 nTPM (limit 2); esophagus: 13.9 nTPM (limit 6); heart muscle: 12 nTPM (limit 2); hippocampal formation: 8.3 nTPM (limit 2); hypothalamus: 8.4 nTPM (limit 2); kidney: 14.2 nTPM (limit 2); liver: 18.2 nTPM (limit 2); lung: 6.4 nTPM (limit 2); lymph node: 9.6 nTPM (limit 6); midbrain: 7.2 nTPM (limit 2); pancreas: 15.5 nTPM (limit 2); parathyroid gland: 7.5 nTPM (limit 6); pituitary gland: 11.6 nTPM (limit 2); retina: 2.2 nTPM (limit 2); salivary gland: 11 nTPM (limit 6); skeletal muscle: 15.9 nTPM (limit 2); skin: 12 nTPM (limit 10); small intestine: 9.9 nTPM (limit 2); smooth muscle: 5 nTPM (limit 2); spinal cord: 7.3 nTPM (limit 2); spleen: 11.7 nTPM (limit 10); stomach: 11.6 nTPM (limit 6); thyroid gland: 13.9 nTPM (limit 10); tongue: 11.1 nTPM (limit 6); urinary bladder: 9.1 nTPM (limit 6),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Low (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / macrophages: Low (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (TCGA): 254/254 (100.0%); Breast Invasive Carcinoma (validation): 50/50 (100.0%); Lung Squamous Cell Carcinoma (TCGA): 486/489 (99.4%),colorectal cancer: 11/11 (100.0%); ovarian cancer: 11/12 (91.7%),31,20,Q9NP81,https://www.uniprot.org/uniprotkb/Q9NP81/entry,"Catalyzes the attachment of serine to tRNA(Ser). Is also probably able to aminoacylate tRNA(Sec) with serine, to form the misacylated tRNA L-seryl-tRNA(Sec), which will be further converted into selenocysteinyl-tRNA(Sec)",,"Hyperuricemia, pulmonary hypertension, renal failure, and alkalosis syndrome: A multisystem disorder characterized by onset in infancy of progressive renal failure leading to electrolyte imbalances, metabolic alkalosis, pulmonary hypertension, hypotonia, and delayed development. Affected individuals are born prematurely.",,Mitochondrion matrix,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
SASS6,ENSG00000156876,Unsafe,Protein,False,True,6.5,6.5,77,43,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 1.3 nTPM; positive ihc; bone marrow: 5.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 3 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 1.1 nTPM; positive ihc; colon: 2.1 nTPM; positive ihc; duodenum: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 2 nTPM; positive ihc; kidney: 1 nTPM; positive ihc; liver: 1.4 nTPM; positive ihc; lymph node: 4.1 nTPM; continuous selectivity; pancreas: 1.3 nTPM; positive ihc; parathyroid gland: 3.8 nTPM; continuous selectivity; rectum: 2.9 nTPM; positive ihc;continuous selectivity; retina: 5.5 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 1.3 nTPM; positive ihc; skin: 2.1 nTPM; positive ihc; small intestine: 2.2 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 1.7 nTPM; positive ihc; spinal cord: 1.9 nTPM; continuous selectivity; stomach: 2 nTPM; positive ihc; thymus: 4.2 nTPM; continuous selectivity; thyroid gland: 1.5 nTPM; positive ihc; urinary bladder: 1.4 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 5.9 nTPM (limit 2); cerebellum: 3 nTPM (limit 2); duodenum: 2.7 nTPM (limit 2); retina: 5.5 nTPM (limit 2); small intestine: 2.2 nTPM (limit 2); bone marrow: 5.9 nTPM (baseline 2); cerebellum: 3 nTPM (baseline 2); duodenum: 2.7 nTPM (baseline 2); retina: 5.5 nTPM (baseline 2); small intestine: 2.2 nTPM (baseline 2),adipose tissue / adipocytes: Medium (Uncertain); bone marrow / hematopoietic cells: Low (Uncertain); caudate / glial cells: Medium (Uncertain); cerebral cortex / endothelial cells: Medium (Uncertain); cerebral cortex / glial cells: Medium (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / endothelial cells: Medium (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: Low (Uncertain); duodenum / glandular cells: Low (Uncertain); esophagus / squamous epithelial cells: Low (Uncertain); hippocampus / glial cells: Low (Uncertain); kidney / cells in glomeruli: Medium (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / hepatocytes: Medium (Uncertain); nasopharynx / respiratory epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); rectum / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: Medium (Uncertain); skin 1 / fibroblasts: Medium (Uncertain); skin 2 / epidermal cells: Low (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Low (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Low (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 47/50 (94.0%); Colon Adenocarcinoma (validation): 343/486 (70.6%),lung cancer: 5/11 (45.5%); liver cancer: 5/12 (41.7%),31,20,Q6UVJ0,https://www.uniprot.org/uniprotkb/Q6UVJ0/entry,"Central scaffolding component of the centrioles ensuring their 9-fold symmetry (By similarity). Required for centrosome biogenesis and duplication: required both for mother-centriole-dependent centriole duplication and deuterosome-dependent centriole amplification in multiciliated cells (PubMed:15665853, PubMed:16244668, PubMed:17681131). Not required for centriole formation in embryonic stem cells but necessary to maintain centriole architecture (By similarity). Required for the recruitment of STIL to the procentriole and for STIL-mediated centriole amplification (PubMed:22020124). Overexpression results in excess foci-bearing centriolar markers (PubMed:15665853)",,"Microcephaly 14, primary, autosomal recessive: A form of microcephaly, a disease defined as a head circumference more than 3 standard deviations below the age, sex and ethnically matched mean. Brain weight is markedly reduced and the cerebral cortex is disproportionately small.",,"Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriole",15665853|16244668|17681131|22020124,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
SAXO1,ENSG00000155875,Unsafe,Protein,False,True,37.4,37.4,86,5,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted,"Positive IHC in a Vital, Protected or Manageable compartment",,bronchus / respiratory epithelial cells: Low (Enhanced); nasopharynx / respiratory epithelial cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Breast Invasive Carcinoma (TCGA): 0/1022 (0.0%),breast cancer: 0/11 (0.0%); cervical cancer: 0/11 (0.0%),29,20,Q8IYX7,https://www.uniprot.org/uniprotkb/Q8IYX7/entry,May play a role in the regulation of cilium length. Stabilizes microtubules at low temperature,"Widely expressed, with highest levels in testis. Expressed in mature spermatozoa (at protein level)",,,"Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriole Cytoplasm, cytoskeleton, cilium basal body Cytoplasm, cytoskeleton, cilium axoneme Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Cytoplasm, cytoskeleton, flagellum axoneme",25673876,25673876,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
SAXO4,ENSG00000162148,Unsafe,Protein,False,True,91.2,91.2,120,16,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 10.9 nTPM; absolute ceiling; basal ganglia: 16.9 nTPM; absolute ceiling; choroid plexus: 52 nTPM; absolute ceiling;continuous selectivity; colon: 6.2 nTPM; positive ihc;absolute ceiling; duodenum: 3.6 nTPM; positive ihc;absolute ceiling; hippocampal formation: 14.3 nTPM; absolute ceiling; hypothalamus: 14.1 nTPM; absolute ceiling; midbrain: 5.6 nTPM; absolute ceiling; pituitary gland: 13.6 nTPM; absolute ceiling; retina: 2.5 nTPM; absolute ceiling; small intestine: 4.8 nTPM; absolute ceiling; spinal cord: 5.2 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 10.9 nTPM (limit 2); basal ganglia: 16.9 nTPM (limit 2); choroid plexus: 52 nTPM (limit 2); colon: 6.2 nTPM (limit 6); duodenum: 3.6 nTPM (limit 2); hippocampal formation: 14.3 nTPM (limit 2); hypothalamus: 14.1 nTPM (limit 2); midbrain: 5.6 nTPM (limit 2); pituitary gland: 13.6 nTPM (limit 2); retina: 2.5 nTPM (limit 2); small intestine: 4.8 nTPM (limit 2); spinal cord: 5.2 nTPM (limit 2),bronchus / ciliated cells (cilia axoneme): High (Enhanced); bronchus / ciliated cells (tip of cilia): High (Enhanced); colon / enterocytes - Microvilli: Medium (Enhanced); colon / mucosal lymphoid cells: Low (Enhanced); duodenum / enterocytes - Microvilli: Low (Enhanced); nasopharynx / ciliated cells (cilia axoneme): Medium (Enhanced); nasopharynx / ciliated cells (tip of cilia): Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 107/141 (75.9%); Rectum Adenocarcinoma (validation): 130/207 (62.8%); Colon Adenocarcinoma (validation): 249/486 (51.2%),renal cancer: 1/12 (8.3%); breast cancer: 0/11 (0.0%),29,20,Q7Z5V6,https://www.uniprot.org/uniprotkb/Q7Z5V6/entry,,,,,"Cell projection, cilium Cytoplasm Cytoplasm, cytoskeleton, flagellum axoneme",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
SCAI,ENSG00000173611,Unsafe,Protein,False,True,2.2,10.9,76,72,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 1.7 nTPM; positive ihc;continuous selectivity; adrenal gland: 2.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 2.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 3.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 2.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 3.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 6.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 2.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 1.8 nTPM; positive ihc;continuous selectivity; duodenum: 1.1 nTPM; positive ihc;continuous selectivity; esophagus: 1.3 nTPM; positive ihc;continuous selectivity; heart muscle: 1.3 nTPM; positive ihc;continuous selectivity; hippocampal formation: 2.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 2.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 1.4 nTPM; positive ihc;continuous selectivity; liver: 1.4 nTPM; positive ihc;continuous selectivity; lung: 3.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 2.8 nTPM; positive ihc;continuous selectivity;reproductive not higher; midbrain: 1.4 nTPM; continuous selectivity; pancreas: 1.7 nTPM; positive ihc;continuous selectivity; parathyroid gland: 1.5 nTPM; positive ihc;continuous selectivity; pituitary gland: 1.6 nTPM; continuous selectivity; rectum: 1.7 nTPM; positive ihc;continuous selectivity; retina: 7.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 1.3 nTPM; positive ihc;continuous selectivity; skeletal muscle: 1.6 nTPM; positive ihc;continuous selectivity; skin: 2.3 nTPM; positive ihc;continuous selectivity;reproductive not higher; small intestine: 1.5 nTPM; positive ihc;continuous selectivity; smooth muscle: 1.3 nTPM; positive ihc;continuous selectivity; spinal cord: 1.3 nTPM; continuous selectivity; spleen: 1.9 nTPM; positive ihc;continuous selectivity; stomach: 1.5 nTPM; positive ihc;continuous selectivity; thymus: 10.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 1.8 nTPM; positive ihc;continuous selectivity; tongue: 0.9 nTPM; continuous selectivity; urinary bladder: 1.5 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 2.5 nTPM (limit 2); amygdala: 2.3 nTPM (limit 2); basal ganglia: 3.4 nTPM (limit 2); bone marrow: 2.8 nTPM (limit 2); cerebellum: 3.1 nTPM (limit 2); cerebral cortex: 6.9 nTPM (limit 2); choroid plexus: 2.2 nTPM (limit 2); hippocampal formation: 2.3 nTPM (limit 2); hypothalamus: 2.6 nTPM (limit 2); lung: 3.1 nTPM (limit 2); retina: 7.2 nTPM (limit 2); thymus: 10.9 nTPM (limit 10),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: High (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Low (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: Low (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Low (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Breast Invasive Carcinoma (validation): 43/50 (86.0%); Colon Adenocarcinoma (validation): 364/486 (74.9%),colorectal cancer: 11/11 (100.0%); prostate cancer: 10/11 (90.9%),31,20,Q8N9R8,https://www.uniprot.org/uniprotkb/Q8N9R8/entry,Tumor suppressor which functions to suppress MRTFA-induced SRF transcriptional activity. May function in the RHOA-DIAPH1 signal transduction pathway and regulate cell migration through transcriptional regulation of ITGB1,,,,Membrane Nucleus Cytoplasm,19350017,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
SCML2,ENSG00000102098,Unsafe,Protein,False,True,11.2,11.2,99,19,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 6.2 nTPM; continuous selectivity; colon: 1.8 nTPM; positive ihc; esophagus: 1 nTPM; positive ihc; kidney: 0.7 nTPM; positive ihc; lung: 0.5 nTPM; positive ihc; rectum: 1.2 nTPM; positive ihc; retina: 3.4 nTPM; absolute ceiling;continuous selectivity; salivary gland: 8.5 nTPM; continuous selectivity; small intestine: 0.9 nTPM; positive ihc; thyroid gland: 2.3 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",retina: 3.4 nTPM (limit 2),bronchus / ciliated cells (cell body): Low (Enhanced); colon / glandular cells: Medium (Enhanced); esophagus / squamous epithelial cells: Medium (Enhanced); kidney / cells in tubules: Low (Enhanced); lung / alveolar cells: Low (Enhanced); oral mucosa / squamous epithelial cells: Medium (Enhanced); rectum / glandular cells: Medium (Enhanced); small intestine / glandular cells: Low (Enhanced); thyroid gland / glandular cells: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 45/58 (77.6%); Testicular Germ Cell Tumor (TCGA): 83/133 (62.4%); Breast Invasive Carcinoma (validation): 23/50 (46.0%),testis cancer: 1/11 (9.1%); colorectal cancer: 1/12 (8.3%),31,20,Q9UQR0,https://www.uniprot.org/uniprotkb/Q9UQR0/entry,"Putative Polycomb group (PcG) protein. PcG proteins act by forming multiprotein complexes, which are required to maintain the transcriptionally repressive state of homeotic genes throughout development (By similarity)","Highly expressed in placenta, thymus and testis. Detected at lower levels in brain, liver, skeletal muscle, pancreas and ovary",,,Nucleus,,10331946,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
SDE2,ENSG00000143751,Unsafe,Protein,False,True,11.4,32.4,81,81,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 16.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; adrenal gland: 8.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 5.5 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 4.9 nTPM; absolute ceiling;continuous selectivity; bone marrow: 32.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 4.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 6.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 3.8 nTPM; absolute ceiling;continuous selectivity; colon: 8 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 8.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 9.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 7.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 5.5 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 5.6 nTPM; absolute ceiling;continuous selectivity; kidney: 8.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 14.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 8.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 12.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 5.7 nTPM; absolute ceiling;continuous selectivity; pancreas: 9.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 10.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 4.2 nTPM; absolute ceiling;continuous selectivity; rectum: 8.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 4.9 nTPM; absolute ceiling;continuous selectivity; salivary gland: 6.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 12.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 10.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 8.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 9.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 7 nTPM; absolute ceiling;continuous selectivity; spleen: 10.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 7.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 22.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 12.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; tongue: 9.3 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 11.2 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 16.9 nTPM (limit 10); adrenal gland: 8.3 nTPM (limit 2); amygdala: 5.5 nTPM (limit 2); basal ganglia: 4.9 nTPM (limit 2); bone marrow: 32.4 nTPM (limit 2); cerebellum: 4.2 nTPM (limit 2); cerebral cortex: 6.9 nTPM (limit 2); choroid plexus: 3.8 nTPM (limit 2); colon: 8 nTPM (limit 6); duodenum: 8.7 nTPM (limit 2); esophagus: 9.3 nTPM (limit 6); heart muscle: 7.4 nTPM (limit 2); hippocampal formation: 5.5 nTPM (limit 2); hypothalamus: 5.6 nTPM (limit 2); kidney: 8.9 nTPM (limit 2); liver: 14.1 nTPM (limit 2); lung: 8.9 nTPM (limit 2); lymph node: 12.1 nTPM (limit 6); midbrain: 5.7 nTPM (limit 2); pancreas: 9.3 nTPM (limit 2); parathyroid gland: 10.8 nTPM (limit 6); pituitary gland: 4.2 nTPM (limit 2); rectum: 8.8 nTPM (limit 6); retina: 4.9 nTPM (limit 2); salivary gland: 6.5 nTPM (limit 6); skeletal muscle: 12.3 nTPM (limit 2); skin: 10.4 nTPM (limit 10); small intestine: 8.7 nTPM (limit 2); smooth muscle: 9.4 nTPM (limit 2); spinal cord: 7 nTPM (limit 2); spleen: 10.1 nTPM (limit 10); stomach: 7.5 nTPM (limit 6); thymus: 22.2 nTPM (limit 10); thyroid gland: 12.1 nTPM (limit 10); tongue: 9.3 nTPM (limit 6); urinary bladder: 11.2 nTPM (limit 6),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: Low (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Medium (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Low (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: High (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Low (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: High (Approved); pancreas / exocrine glandular cells: Low (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: High (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%); Pancreatic Adenocarcinoma (validation): 80/80 (100.0%),pancreatic cancer: 8/11 (72.7%); breast cancer: 8/12 (66.7%),29,20,Q6IQ49,https://www.uniprot.org/uniprotkb/Q6IQ49/entry,"Inhibits translesion DNA synthesis by preventing monoubiquitination of PCNA, this is necessary to counteract damage due to ultraviolet light-induced replication stress (PubMed:27906959). SDE2 is cleaved following PCNA binding, and its complete degradation is necessary to allow S-phase progression following DNA damage (PubMed:27906959) Plays a role in pre-mRNA splicing by facilitating excision of relatively short introns featuring weak 3'-splice sites (ss) and high GC content (PubMed:34365507). May recruit CACTIN to the spliceosome (By similarity) Plays a role in ribosome biogenesis by enabling SNORD3- and SNORD118-dependent cleavage of the 47S rRNA precursor (PubMed:34365507). Binds ncRNA (non-coding RNA) including the snoRNAs SNORD3 and SNORD118 (PubMed:34365507)","Ubiquitously expressed; enriched in brain, lung and liver",,,Nucleus Cytoplasm,27906959|34365507,34365507,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
SDHAF2,ENSG00000167985,Unsafe,Protein,False,True,34.0,45.3,85,77,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 26.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 35.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 23.3 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 25.9 nTPM; absolute ceiling;continuous selectivity; bone marrow: 45.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 16 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 24.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 37.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 26.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 24 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 28 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 39.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 20.1 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 29.1 nTPM; absolute ceiling;continuous selectivity; kidney: 35.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 45.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 23 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 38.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 25.2 nTPM; absolute ceiling;continuous selectivity; pancreas: 23.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 31.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 39.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 28.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 22.7 nTPM; absolute ceiling;continuous selectivity; salivary gland: 25.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 37.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 25.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 26.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 25.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 21.1 nTPM; absolute ceiling;continuous selectivity; spleen: 33.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 26.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 37 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 27.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 43.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 31.6 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 26.6 nTPM (limit 10); adrenal gland: 35.9 nTPM (limit 2); amygdala: 23.3 nTPM (limit 2); basal ganglia: 25.9 nTPM (limit 2); bone marrow: 45.1 nTPM (limit 2); cerebellum: 16 nTPM (limit 2); cerebral cortex: 24.4 nTPM (limit 2); choroid plexus: 37.4 nTPM (limit 2); colon: 26.3 nTPM (limit 6); duodenum: 24 nTPM (limit 2); esophagus: 28 nTPM (limit 6); heart muscle: 39.1 nTPM (limit 2); hippocampal formation: 20.1 nTPM (limit 2); hypothalamus: 29.1 nTPM (limit 2); kidney: 35.5 nTPM (limit 2); liver: 45.3 nTPM (limit 2); lung: 23 nTPM (limit 2); lymph node: 38.9 nTPM (limit 6); midbrain: 25.2 nTPM (limit 2); pancreas: 23.2 nTPM (limit 2); parathyroid gland: 31.8 nTPM (limit 6); pituitary gland: 39.9 nTPM (limit 2); rectum: 28.2 nTPM (limit 6); retina: 22.7 nTPM (limit 2); salivary gland: 25.5 nTPM (limit 6); skeletal muscle: 37.6 nTPM (limit 2); skin: 25.5 nTPM (limit 10); small intestine: 26.3 nTPM (limit 2); smooth muscle: 25.9 nTPM (limit 2); spinal cord: 21.1 nTPM (limit 2); spleen: 33.9 nTPM (limit 10); stomach: 26.8 nTPM (limit 6); thymus: 37 nTPM (limit 10); thyroid gland: 27.8 nTPM (limit 10); tongue: 43.1 nTPM (limit 6); urinary bladder: 31.6 nTPM (limit 6),adipose tissue / adipocytes: Medium (Supported); adrenal gland / glandular cells: High (Supported); bone marrow / hematopoietic cells: High (Supported); bronchus / respiratory epithelial cells: High (Supported); caudate / glial cells: Low (Supported); caudate / neuronal cells: High (Supported); cerebellum / cells in granular layer: Medium (Supported); cerebellum / cells in molecular layer: Medium (Supported); cerebellum / Purkinje cells: Medium (Supported); cerebral cortex / endothelial cells: Medium (Supported); cerebral cortex / glial cells: Medium (Supported); cerebral cortex / neuronal cells: Medium (Supported); cerebral cortex / neuropil: Medium (Supported); colon / endothelial cells: Medium (Supported); colon / glandular cells: High (Supported); duodenum / glandular cells: High (Supported); esophagus / squamous epithelial cells: Medium (Supported); heart muscle / cardiomyocytes: Medium (Supported); hippocampus / glial cells: Medium (Supported); hippocampus / neuronal cells: Medium (Supported); kidney / cells in glomeruli: Medium (Supported); kidney / cells in tubules: Medium (Supported); liver / cholangiocytes: Medium (Supported); liver / hepatocytes: Medium (Supported); lung / alveolar cells: Low (Supported); lung / macrophages: Medium (Supported); lymph node / germinal center cells: Low (Supported); lymph node / non-germinal center cells: Low (Supported); nasopharynx / respiratory epithelial cells: High (Supported); oral mucosa / squamous epithelial cells: Medium (Supported); pancreas / exocrine glandular cells: Medium (Supported); pancreas / pancreatic endocrine cells: High (Supported); parathyroid gland / glandular cells: High (Supported); rectum / glandular cells: High (Supported); salivary gland / glandular cells: High (Supported); skeletal muscle / myocytes: Medium (Supported); skin 1 / fibroblasts: High (Supported); skin 1 / keratinocytes: Medium (Supported); skin 1 / Langerhans: Low (Supported); skin 2 / epidermal cells: Medium (Supported); small intestine / glandular cells: High (Supported); smooth muscle / smooth muscle cells: Medium (Supported); spleen / cells in red pulp: High (Supported); spleen / cells in white pulp: High (Supported); stomach 1 / glandular cells: Medium (Supported); stomach 2 / glandular cells: High (Supported); thyroid gland / glandular cells: Medium (Supported); urinary bladder / urothelial cells: High (Supported),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Kidney Renal Clear Cell Carcinoma (TCGA): 521/521 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%),breast cancer: 12/12 (100.0%); cervical cancer: 12/12 (100.0%),31,20,Q9NX18,https://www.uniprot.org/uniprotkb/Q9NX18/entry,"Plays an essential role in the assembly of succinate dehydrogenase (SDH), an enzyme complex (also referred to as respiratory complex II) that is a component of both the tricarboxylic acid (TCA) cycle and the mitochondrial electron transport chain, and which couples the oxidation of succinate to fumarate with the reduction of ubiquinone (coenzyme Q) to ubiquinol. Required for flavinylation (covalent attachment of FAD) of the flavoprotein subunit SDHA of the SDH catalytic dimer",,"Pheochromocytoma/paraganglioma syndrome 2: A form of pheochromocytoma/paraganglioma syndrome, a tumor predisposition syndrome characterized by the development of neuroendocrine tumors, usually in adulthood. Pheochromocytomas are catecholamine-producing tumors that arise from chromaffin cells in the adrenal medulla. Paragangliomas develop from sympathetic paraganglia in the thorax, abdomen, and pelvis, as well as from parasympathetic paraganglia in the head and neck. PPGL2 inheritance is autosomal dominant.",,Mitochondrion matrix,19628817|32887801,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
SDK2,ENSG00000069188,Unsafe,RNA,False,True,9.4,9.4,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,spinal cord: 2.2 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,spinal cord: 2.2 nTPM (limit 2); spinal cord: 2.2 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 20/50 (40.0%); Lung Squamous Cell Carcinoma (TCGA): 171/489 (35.0%); Head and Neck Squamous Cell Carcinoma (TCGA): 167/492 (33.9%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q58EX2,https://www.uniprot.org/uniprotkb/Q58EX2/entry,Adhesion molecule that promotes lamina-specific synaptic connections in the retina and is specifically required for the formation of neuronal circuits that detect motion. Acts by promoting formation of synapses between two specific retinal cell types: the retinal ganglion cells W3B-RGCs and the excitatory amacrine cells VG3-ACs. Formation of synapses between these two cells plays a key role in detection of motion. Promotes synaptic connectivity via homophilic interactions,,,,Cell membrane Synapse,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,Failed bulk numeric comparisons are within 20% of their cutoffs; not an automatic rescue,,,,
SEC16B,ENSG00000120341,Unsafe,Protein,False,True,4.2,40.0,103,9,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 4.3 nTPM; continuous selectivity;reproductive not higher; adrenal gland: 2.6 nTPM; continuous selectivity; bone marrow: 0.3 nTPM; positive ihc; choroid plexus: 1.2 nTPM; continuous selectivity; colon: 4 nTPM; continuous selectivity; duodenum: 28.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 2.8 nTPM; continuous selectivity; kidney: 3.8 nTPM; continuous selectivity; liver: 40 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 2.6 nTPM; continuous selectivity; pancreas: 10 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 1.4 nTPM; continuous selectivity; rectum: 4.3 nTPM; continuous selectivity;reproductive not higher; retina: 6.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 3.5 nTPM; continuous selectivity; skeletal muscle: 9.1 nTPM; continuous selectivity;reproductive not higher; small intestine: 28.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 3 nTPM; continuous selectivity; spleen: 6.1 nTPM; continuous selectivity;reproductive not higher; stomach: 9 nTPM; continuous selectivity;reproductive not higher; tongue: 3.2 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",duodenum: 28.6 nTPM (limit 2); liver: 40 nTPM (limit 12); pancreas: 10 nTPM (limit 2); retina: 6.5 nTPM (limit 2); small intestine: 28.4 nTPM (limit 2),bone marrow / hematopoietic cells: Low (Enhanced); duodenum / endocrine cells: Medium (Enhanced); duodenum / enterocytes: Medium (Enhanced); pancreas / exocrine glandular cells: Low (Enhanced); small intestine / endocrine cells: Medium (Enhanced); small intestine / enterocytes: Medium (Enhanced); small intestine / enterocytes - Gradient: Ascending (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (validation): 228/231 (98.7%); Kidney Renal Clear Cell Carcinoma (validation): 93/100 (93.0%); Rectum Adenocarcinoma (validation): 189/207 (91.3%),breast cancer: 0/9 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q96JE7,https://www.uniprot.org/uniprotkb/Q96JE7/entry,"Plays a role in the organization of the endoplasmic reticulum exit sites (ERES), also known as transitional endoplasmic reticulum (tER). Required for secretory cargo traffic from the endoplasmic reticulum to the Golgi apparatus (PubMed:17192411, PubMed:21768384, PubMed:22355596). Involved in peroxisome biogenesis. Regulates the transport of peroxisomal biogenesis factors PEX3 and PEX16 from the ER to peroxisomes (PubMed:21768384)",Ubiquitous,,,Endoplasmic reticulum membrane Golgi apparatus membrane,17192411|21768384|22355596,12244571|17192411,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
SENP5,ENSG00000119231,Unsafe,RNA,False,True,20.2,20.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 6.8 nTPM; absolute ceiling;continuous selectivity; amygdala: 9.7 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 9.3 nTPM; absolute ceiling;continuous selectivity; bone marrow: 15.6 nTPM; absolute ceiling;continuous selectivity; cerebellum: 15.5 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 11.5 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 6.7 nTPM; absolute ceiling;continuous selectivity; colon: 9.9 nTPM; absolute ceiling;continuous selectivity; duodenum: 5.7 nTPM; absolute ceiling;continuous selectivity; esophagus: 8.2 nTPM; absolute ceiling;continuous selectivity; heart muscle: 9 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 10.8 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 12.1 nTPM; absolute ceiling;continuous selectivity; kidney: 7.6 nTPM; absolute ceiling;continuous selectivity; liver: 9.8 nTPM; absolute ceiling;continuous selectivity; lung: 9.6 nTPM; absolute ceiling;continuous selectivity; lymph node: 8.8 nTPM; absolute ceiling;continuous selectivity; midbrain: 10.7 nTPM; absolute ceiling;continuous selectivity; pancreas: 7.8 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 8.5 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 10 nTPM; absolute ceiling;continuous selectivity; rectum: 6.7 nTPM; absolute ceiling; retina: 16.9 nTPM; absolute ceiling;continuous selectivity; salivary gland: 7.5 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 11.4 nTPM; absolute ceiling;continuous selectivity; skin: 9.1 nTPM; continuous selectivity; small intestine: 8.1 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 7.6 nTPM; absolute ceiling;continuous selectivity; spinal cord: 10.6 nTPM; absolute ceiling;continuous selectivity; spleen: 10.2 nTPM; absolute ceiling;continuous selectivity; stomach: 8 nTPM; absolute ceiling;continuous selectivity; thymus: 10.3 nTPM; absolute ceiling;continuous selectivity; tongue: 11.7 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 8.7 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 6.8 nTPM (limit 2); amygdala: 9.7 nTPM (limit 2); basal ganglia: 9.3 nTPM (limit 2); bone marrow: 15.6 nTPM (limit 2); cerebellum: 15.5 nTPM (limit 2); cerebral cortex: 11.5 nTPM (limit 2); choroid plexus: 6.7 nTPM (limit 2); colon: 9.9 nTPM (limit 6); duodenum: 5.7 nTPM (limit 2); esophagus: 8.2 nTPM (limit 6); heart muscle: 9 nTPM (limit 2); hippocampal formation: 10.8 nTPM (limit 2); hypothalamus: 12.1 nTPM (limit 2); kidney: 7.6 nTPM (limit 2); liver: 9.8 nTPM (limit 2); lung: 9.6 nTPM (limit 2); lymph node: 8.8 nTPM (limit 6); midbrain: 10.7 nTPM (limit 2); pancreas: 7.8 nTPM (limit 2); parathyroid gland: 8.5 nTPM (limit 6); pituitary gland: 10 nTPM (limit 2); rectum: 6.7 nTPM (limit 6); retina: 16.9 nTPM (limit 2); salivary gland: 7.5 nTPM (limit 6); skeletal muscle: 11.4 nTPM (limit 2); small intestine: 8.1 nTPM (limit 2); smooth muscle: 7.6 nTPM (limit 2); spinal cord: 10.6 nTPM (limit 2); spleen: 10.2 nTPM (limit 10); stomach: 8 nTPM (limit 6); thymus: 10.3 nTPM (limit 10); tongue: 11.7 nTPM (limit 6); urinary bladder: 8.7 nTPM (limit 6); adrenal gland: 6.8 nTPM (baseline 2); amygdala: 9.7 nTPM (baseline 2); basal ganglia: 9.3 nTPM (baseline 2); bone marrow: 15.6 nTPM (baseline 2); cerebellum: 15.5 nTPM (baseline 2); cerebral cortex: 11.5 nTPM (baseline 2); choroid plexus: 6.7 nTPM (baseline 2); colon: 9.9 nTPM (baseline 6); duodenum: 5.7 nTPM (baseline 2); esophagus: 8.2 nTPM (baseline 6); heart muscle: 9 nTPM (baseline 2); hippocampal formation: 10.8 nTPM (baseline 2); hypothalamus: 12.1 nTPM (baseline 2); kidney: 7.6 nTPM (baseline 2); liver: 9.8 nTPM (baseline 2); lung: 9.6 nTPM (baseline 2); lymph node: 8.8 nTPM (baseline 6); midbrain: 10.7 nTPM (baseline 2); pancreas: 7.8 nTPM (baseline 2); parathyroid gland: 8.5 nTPM (baseline 6); pituitary gland: 10 nTPM (baseline 2); rectum: 6.7 nTPM (baseline 6); retina: 16.9 nTPM (baseline 2); salivary gland: 7.5 nTPM (baseline 6); skeletal muscle: 11.4 nTPM (baseline 2); small intestine: 8.1 nTPM (baseline 2); smooth muscle: 7.6 nTPM (baseline 2); spinal cord: 10.6 nTPM (baseline 2); spleen: 10.2 nTPM (baseline 10); stomach: 8 nTPM (baseline 6); thymus: 10.3 nTPM (baseline 10); tongue: 11.7 nTPM (baseline 6); urinary bladder: 8.7 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Pancreatic Adenocarcinoma (validation): 80/80 (100.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q96HI0,https://www.uniprot.org/uniprotkb/Q96HI0/entry,Protease that catalyzes two essential functions in the SUMO pathway: processing of full-length SUMO3 to its mature form and deconjugation of SUMO2 and SUMO3 from targeted proteins. Has weak proteolytic activity against full-length SUMO1 or SUMO1 conjugates. Required for cell division,,,,"Nucleus, nucleolus",16608850|16738315,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
SENP8,ENSG00000166192,Unsafe,Protein,False,True,15.2,15.2,87,75,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 1 nTPM; positive ihc; adrenal gland: 1.7 nTPM; positive ihc; basal ganglia: 2.1 nTPM; absolute ceiling; bone marrow: 2.8 nTPM; positive ihc;absolute ceiling; cerebellum: 1.5 nTPM; positive ihc; cerebral cortex: 2.8 nTPM; positive ihc;absolute ceiling; colon: 1.9 nTPM; positive ihc; duodenum: 1.7 nTPM; positive ihc; esophagus: 2.2 nTPM; positive ihc; heart muscle: 3.8 nTPM; positive ihc;absolute ceiling; hypothalamus: 2.3 nTPM; absolute ceiling; kidney: 4.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 2.4 nTPM; positive ihc;absolute ceiling; lung: 1.4 nTPM; positive ihc; lymph node: 1.5 nTPM; positive ihc; midbrain: 2.2 nTPM; absolute ceiling; pancreas: 1.5 nTPM; positive ihc; parathyroid gland: 2.3 nTPM; positive ihc; pituitary gland: 2.1 nTPM; absolute ceiling; rectum: 1.9 nTPM; positive ihc; retina: 4.5 nTPM; absolute ceiling;continuous selectivity; salivary gland: 1.6 nTPM; positive ihc; skeletal muscle: 6.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 1.5 nTPM; positive ihc; small intestine: 1.4 nTPM; positive ihc; smooth muscle: 1.5 nTPM; positive ihc; spleen: 1.4 nTPM; positive ihc; stomach: 2 nTPM; positive ihc; thyroid gland: 4.9 nTPM; positive ihc; tongue: 5.5 nTPM; continuous selectivity; urinary bladder: 1.6 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",basal ganglia: 2.1 nTPM (limit 2); bone marrow: 2.8 nTPM (limit 2); cerebral cortex: 2.8 nTPM (limit 2); heart muscle: 3.8 nTPM (limit 2); hypothalamus: 2.3 nTPM (limit 2); kidney: 4.3 nTPM (limit 2); liver: 2.4 nTPM (limit 2); midbrain: 2.2 nTPM (limit 2); pituitary gland: 2.1 nTPM (limit 2); retina: 4.5 nTPM (limit 2); skeletal muscle: 6.1 nTPM (limit 2),adipose tissue / adipocytes: High (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: High (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: High (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: High (Approved); liver / hepatocytes: High (Approved); lung / macrophages: Low (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: High (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Low (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: High (Approved); skeletal muscle / myocytes: High (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: Low (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: High (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 459/486 (94.4%); Breast Invasive Carcinoma (validation): 45/50 (90.0%),ovarian cancer: 12/12 (100.0%); breast cancer: 11/11 (100.0%),31,20,Q96LD8,https://www.uniprot.org/uniprotkb/Q96LD8/entry,Protease that catalyzes two essential functions in the NEDD8 pathway: processing of full-length NEDD8 to its mature form and deconjugation of NEDD8 from targeted proteins such as cullins or p53,"Broadly expressed, with highest levels in kidney and pancreas",,,,12730221|12759362|12759363|15242646|15775960,12730221,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
SEPSECS,ENSG00000109618,Unsafe,RNA,False,True,4.7,25.3,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 4.5 nTPM; continuous selectivity; adrenal gland: 3.4 nTPM; absolute ceiling;continuous selectivity; amygdala: 2.2 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 2.1 nTPM; absolute ceiling;continuous selectivity; cerebellum: 3.4 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 1.7 nTPM; continuous selectivity; choroid plexus: 1.5 nTPM; continuous selectivity; colon: 5.1 nTPM; continuous selectivity;reproductive not higher; duodenum: 4.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 3.1 nTPM; continuous selectivity; heart muscle: 2.7 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 2.5 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 2.2 nTPM; absolute ceiling;continuous selectivity; kidney: 7.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; liver: 25.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 3.8 nTPM; absolute ceiling;continuous selectivity; lymph node: 2 nTPM; continuous selectivity; midbrain: 2.8 nTPM; absolute ceiling;continuous selectivity; pancreas: 7.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 3.2 nTPM; continuous selectivity; pituitary gland: 3 nTPM; absolute ceiling;continuous selectivity; rectum: 2.7 nTPM; continuous selectivity; retina: 1.5 nTPM; continuous selectivity; salivary gland: 3.7 nTPM; continuous selectivity; skeletal muscle: 3.3 nTPM; absolute ceiling;continuous selectivity; skin: 5 nTPM; continuous selectivity;reproductive not higher; small intestine: 7.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 1.3 nTPM; continuous selectivity; spinal cord: 4 nTPM; absolute ceiling;continuous selectivity; spleen: 5.5 nTPM; continuous selectivity;reproductive not higher; stomach: 4.9 nTPM; continuous selectivity;reproductive not higher; thymus: 5 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 4.7 nTPM; continuous selectivity;reproductive not higher; tongue: 2.5 nTPM; continuous selectivity; urinary bladder: 3.7 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 3.4 nTPM (limit 2); amygdala: 2.2 nTPM (limit 2); basal ganglia: 2.1 nTPM (limit 2); cerebellum: 3.4 nTPM (limit 2); duodenum: 4.7 nTPM (limit 2); heart muscle: 2.7 nTPM (limit 2); hippocampal formation: 2.5 nTPM (limit 2); hypothalamus: 2.2 nTPM (limit 2); kidney: 7.9 nTPM (limit 2); liver: 25.3 nTPM (limit 2); lung: 3.8 nTPM (limit 2); midbrain: 2.8 nTPM (limit 2); pancreas: 7.2 nTPM (limit 2); pituitary gland: 3 nTPM (limit 2); skeletal muscle: 3.3 nTPM (limit 2); small intestine: 7.4 nTPM (limit 2); spinal cord: 4 nTPM (limit 2); adrenal gland: 3.4 nTPM (baseline 2); amygdala: 2.2 nTPM (baseline 2); basal ganglia: 2.1 nTPM (baseline 2); cerebellum: 3.4 nTPM (baseline 2); duodenum: 4.7 nTPM (baseline 2); heart muscle: 2.7 nTPM (baseline 2); hippocampal formation: 2.5 nTPM (baseline 2); hypothalamus: 2.2 nTPM (baseline 2); kidney: 7.9 nTPM (baseline 2); liver: 25.3 nTPM (baseline 2); lung: 3.8 nTPM (baseline 2); midbrain: 2.8 nTPM (baseline 2); pancreas: 7.2 nTPM (baseline 2); pituitary gland: 3 nTPM (baseline 2); skeletal muscle: 3.3 nTPM (baseline 2); small intestine: 7.4 nTPM (baseline 2); spinal cord: 4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 49/50 (98.0%); Pancreatic Adenocarcinoma (validation): 77/80 (96.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9HD40,https://www.uniprot.org/uniprotkb/Q9HD40/entry,Converts O-phosphoseryl-tRNA(Sec) to selenocysteinyl-tRNA(Sec) required for selenoprotein biosynthesis,"Primarily expressed in liver, pancreas, kidney and lung. Overexpressed in PHA-stimulated T-cells","Pontocerebellar hypoplasia 2D: A disorder characterized by postnatal onset of progressive atrophy of the cerebrum and cerebellum, microcephaly, profound intellectual disability, spasticity, and variable seizures.",,Cytoplasm,17142313,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
SEPTIN12,ENSG00000140623,Unsafe,RNA,False,True,96.1,96.1,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,cerebellum: 3.1 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebellum: 3.1 nTPM (limit 2); cerebellum: 3.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 4/133 (3.0%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Kidney Renal Papillary Cell Carcinoma (TCGA): 1/282 (0.4%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q8IYM1,https://www.uniprot.org/uniprotkb/Q8IYM1/entry,"Filament-forming cytoskeletal GTPase (By similarity). Involved in the morphogenesis of sperm heads and the elongation of sperm tails probably implicating the association with alpha- and beta-tubulins (PubMed:24213608). Facilitates the formation of Septin filament structures with SEPTIN7, SEPTIN6, SEPTIN2 and SEPTIN4 at the sperm annulus (PubMed:25588830, PubMed:28346465). Correct formation of the annulus is required for development of normal structural morphology and motility of the sperm during steps 13 to 16 of spermiogenesis (PubMed:25588830). Essential component of the LMNB1/SUN5/SEPT12 bridge that connects the sperm proximal centriole to the implantation fossa, the bridge functions to prevent detachment of the proximal centriole from the posterior nucleus during steps 13 to 16 of spermiogenesis (PubMed:38870534). Required for PLCZ1 localization at the sperm acrosome during spermiogenesis (By similarity). May also play a role in the initiation of calcium oscillations in embryos (By similarity)",Widely expressed. Expressed in lymph node,"Spermatogenic failure 10: An infertility disorder caused by spermatogenesis defects. It results in decreased sperm motility, concentration, and multiple sperm structural defects. The most prominent feature is a defective sperm annulus, a ring structure that demarcates the midpiece and the principal piece of the sperm tail.",,"Cytoplasm Cytoplasm, cytoskeleton Cytoplasm, cytoskeleton, spindle Nucleus Cell projection, cilium, flagellum Cytoplasmic vesicle, secretory vesicle, acrosome",24213608|25588830|28346465|38870534,15915442|17967425,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
SERINC4,ENSG00000184716,Unsafe,RNA,False,True,1.2,14.9,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,choroid plexus: 3.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; retina: 14.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 3.5 nTPM (limit 2); retina: 14.9 nTPM (limit 2); choroid plexus: 3.5 nTPM (baseline 2); retina: 14.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (validation): 116/231 (50.2%); Breast Invasive Carcinoma (validation): 20/50 (40.0%); Prostate Adenocarcinoma (TCGA): 44/480 (9.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,A6NH21,https://www.uniprot.org/uniprotkb/A6NH21/entry,"Incorporates a polar amino acid serine into membranes and facilitates the synthesis of two serine-derived lipids, phosphatidylserine and sphingolipids",,,,Membrane,16120614,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
SESN3,ENSG00000149212,Unsafe,RNA,False,True,56.1,56.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 16.9 nTPM; absolute ceiling;continuous selectivity; amygdala: 18.2 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 30.7 nTPM; absolute ceiling;continuous selectivity; bone marrow: 17.7 nTPM; absolute ceiling;continuous selectivity; cerebellum: 7.1 nTPM; absolute ceiling; cerebral cortex: 20 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 9.6 nTPM; absolute ceiling; duodenum: 6.3 nTPM; absolute ceiling; esophagus: 8.6 nTPM; absolute ceiling; heart muscle: 5.2 nTPM; absolute ceiling; hippocampal formation: 11.9 nTPM; absolute ceiling; hypothalamus: 13.5 nTPM; absolute ceiling; kidney: 10.1 nTPM; absolute ceiling; liver: 7.3 nTPM; absolute ceiling; lung: 8.8 nTPM; absolute ceiling; lymph node: 23.8 nTPM; absolute ceiling;continuous selectivity; midbrain: 14.2 nTPM; absolute ceiling;continuous selectivity; pancreas: 3 nTPM; absolute ceiling; parathyroid gland: 25 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 10.9 nTPM; absolute ceiling; rectum: 6.3 nTPM; absolute ceiling; retina: 22.7 nTPM; absolute ceiling;continuous selectivity; salivary gland: 9.6 nTPM; absolute ceiling; skeletal muscle: 5.1 nTPM; absolute ceiling; skin: 10.4 nTPM; absolute ceiling; small intestine: 12.1 nTPM; absolute ceiling; smooth muscle: 8.9 nTPM; absolute ceiling; spinal cord: 12.2 nTPM; absolute ceiling; spleen: 16.8 nTPM; absolute ceiling; thymus: 21.2 nTPM; absolute ceiling; thyroid gland: 21.1 nTPM; absolute ceiling; tongue: 12.7 nTPM; absolute ceiling; urinary bladder: 10.8 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 16.9 nTPM (limit 2); amygdala: 18.2 nTPM (limit 2); basal ganglia: 30.7 nTPM (limit 2); bone marrow: 17.7 nTPM (limit 2); cerebellum: 7.1 nTPM (limit 2); cerebral cortex: 20 nTPM (limit 2); choroid plexus: 9.6 nTPM (limit 2); duodenum: 6.3 nTPM (limit 2); esophagus: 8.6 nTPM (limit 6); heart muscle: 5.2 nTPM (limit 2); hippocampal formation: 11.9 nTPM (limit 2); hypothalamus: 13.5 nTPM (limit 2); kidney: 10.1 nTPM (limit 2); liver: 7.3 nTPM (limit 2); lung: 8.8 nTPM (limit 2); lymph node: 23.8 nTPM (limit 6); midbrain: 14.2 nTPM (limit 2); pancreas: 3 nTPM (limit 2); parathyroid gland: 25 nTPM (limit 6); pituitary gland: 10.9 nTPM (limit 2); rectum: 6.3 nTPM (limit 6); retina: 22.7 nTPM (limit 2); salivary gland: 9.6 nTPM (limit 6); skeletal muscle: 5.1 nTPM (limit 2); skin: 10.4 nTPM (limit 10); small intestine: 12.1 nTPM (limit 2); smooth muscle: 8.9 nTPM (limit 2); spinal cord: 12.2 nTPM (limit 2); spleen: 16.8 nTPM (limit 10); thymus: 21.2 nTPM (limit 10); thyroid gland: 21.1 nTPM (limit 10); tongue: 12.7 nTPM (limit 6); urinary bladder: 10.8 nTPM (limit 6); adrenal gland: 16.9 nTPM (baseline 2); amygdala: 18.2 nTPM (baseline 2); basal ganglia: 30.7 nTPM (baseline 2); bone marrow: 17.7 nTPM (baseline 2); cerebellum: 7.1 nTPM (baseline 2); cerebral cortex: 20 nTPM (baseline 2); choroid plexus: 9.6 nTPM (baseline 2); duodenum: 6.3 nTPM (baseline 2); esophagus: 8.6 nTPM (baseline 6); heart muscle: 5.2 nTPM (baseline 2); hippocampal formation: 11.9 nTPM (baseline 2); hypothalamus: 13.5 nTPM (baseline 2); kidney: 10.1 nTPM (baseline 2); liver: 7.3 nTPM (baseline 2); lung: 8.8 nTPM (baseline 2); lymph node: 23.8 nTPM (baseline 6); midbrain: 14.2 nTPM (baseline 2); pancreas: 3 nTPM (baseline 2); parathyroid gland: 25 nTPM (baseline 6); pituitary gland: 10.9 nTPM (baseline 2); rectum: 6.3 nTPM (baseline 6); retina: 22.7 nTPM (baseline 2); salivary gland: 9.6 nTPM (baseline 6); skeletal muscle: 5.1 nTPM (baseline 2); skin: 10.4 nTPM (baseline 10); small intestine: 12.1 nTPM (baseline 2); smooth muscle: 8.9 nTPM (baseline 2); spinal cord: 12.2 nTPM (baseline 2); spleen: 16.8 nTPM (baseline 10); thymus: 21.2 nTPM (baseline 10); thyroid gland: 21.1 nTPM (baseline 10); tongue: 12.7 nTPM (baseline 6); urinary bladder: 10.8 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Glioblastoma Multiforme (TCGA): 140/141 (99.3%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P58005,https://www.uniprot.org/uniprotkb/P58005/entry,May function as an intracellular leucine sensor that negatively regulates the TORC1 signaling pathway (PubMed:25263562). May also regulate the insulin-receptor signaling pathway through activation of TORC2 (By similarity). This metabolic regulator may also play a role in protection against oxidative and genotoxic stresses (By similarity). May prevent the accumulation of reactive oxygen species (ROS) through the alkylhydroperoxide reductase activity born by the N-terminal domain of the protein (By similarity),Widely expressed,,,Cytoplasm,25263562,12607115,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
SFR1,ENSG00000156384,Unsafe,RNA,False,True,17.8,17.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 4.3 nTPM; absolute ceiling; amygdala: 5 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 5.2 nTPM; absolute ceiling;continuous selectivity; bone marrow: 9.8 nTPM; absolute ceiling;continuous selectivity; cerebellum: 3.4 nTPM; absolute ceiling; cerebral cortex: 6.6 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 7.8 nTPM; absolute ceiling;continuous selectivity; duodenum: 4.5 nTPM; absolute ceiling; heart muscle: 7.3 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 5.7 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 4.5 nTPM; absolute ceiling; kidney: 4.7 nTPM; absolute ceiling;continuous selectivity; liver: 3 nTPM; absolute ceiling; lung: 6.1 nTPM; absolute ceiling;continuous selectivity; lymph node: 8.8 nTPM; absolute ceiling;continuous selectivity; midbrain: 6.7 nTPM; absolute ceiling;continuous selectivity; pancreas: 5.7 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 2.8 nTPM; absolute ceiling; rectum: 6.2 nTPM; absolute ceiling;continuous selectivity; retina: 4.2 nTPM; absolute ceiling; skeletal muscle: 4 nTPM; absolute ceiling; small intestine: 5.9 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 5.4 nTPM; absolute ceiling;continuous selectivity; spinal cord: 10.2 nTPM; absolute ceiling;continuous selectivity; thymus: 11.3 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 4.3 nTPM (limit 2); amygdala: 5 nTPM (limit 2); basal ganglia: 5.2 nTPM (limit 2); bone marrow: 9.8 nTPM (limit 2); cerebellum: 3.4 nTPM (limit 2); cerebral cortex: 6.6 nTPM (limit 2); choroid plexus: 7.8 nTPM (limit 2); duodenum: 4.5 nTPM (limit 2); heart muscle: 7.3 nTPM (limit 2); hippocampal formation: 5.7 nTPM (limit 2); hypothalamus: 4.5 nTPM (limit 2); kidney: 4.7 nTPM (limit 2); liver: 3 nTPM (limit 2); lung: 6.1 nTPM (limit 2); lymph node: 8.8 nTPM (limit 6); midbrain: 6.7 nTPM (limit 2); pancreas: 5.7 nTPM (limit 2); pituitary gland: 2.8 nTPM (limit 2); rectum: 6.2 nTPM (limit 6); retina: 4.2 nTPM (limit 2); skeletal muscle: 4 nTPM (limit 2); small intestine: 5.9 nTPM (limit 2); smooth muscle: 5.4 nTPM (limit 2); spinal cord: 10.2 nTPM (limit 2); thymus: 11.3 nTPM (limit 10); adrenal gland: 4.3 nTPM (baseline 2); amygdala: 5 nTPM (baseline 2); basal ganglia: 5.2 nTPM (baseline 2); bone marrow: 9.8 nTPM (baseline 2); cerebellum: 3.4 nTPM (baseline 2); cerebral cortex: 6.6 nTPM (baseline 2); choroid plexus: 7.8 nTPM (baseline 2); duodenum: 4.5 nTPM (baseline 2); heart muscle: 7.3 nTPM (baseline 2); hippocampal formation: 5.7 nTPM (baseline 2); hypothalamus: 4.5 nTPM (baseline 2); kidney: 4.7 nTPM (baseline 2); liver: 3 nTPM (baseline 2); lung: 6.1 nTPM (baseline 2); lymph node: 8.8 nTPM (baseline 6); midbrain: 6.7 nTPM (baseline 2); pancreas: 5.7 nTPM (baseline 2); pituitary gland: 2.8 nTPM (baseline 2); rectum: 6.2 nTPM (baseline 6); retina: 4.2 nTPM (baseline 2); skeletal muscle: 4 nTPM (baseline 2); small intestine: 5.9 nTPM (baseline 2); smooth muscle: 5.4 nTPM (baseline 2); spinal cord: 10.2 nTPM (baseline 2); thymus: 11.3 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Adenocarcinoma (validation): 105/105 (100.0%); Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%),melanoma: 4/11 (36.4%); liver cancer: 2/11 (18.2%),29,20,Q86XK3,https://www.uniprot.org/uniprotkb/Q86XK3/entry,"Component of the SWI5-SFR1 complex, a complex required for double-strand break repair via homologous recombination (PubMed:21252223). Acts as a transcriptional modulator for ESR1 (PubMed:23874500)",Widely expressed,,,Nucleus,21252223|23874500,21252223,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
SGMS2,ENSG00000164023,Unsafe,Protein,False,True,12.2,38.2,121,100,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 8.2 nTPM; positive ihc;continuous selectivity; adrenal gland: 2.9 nTPM; positive ihc;absolute ceiling; bone marrow: 4.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 0.8 nTPM; positive ihc; cerebral cortex: 3.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 15.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 11.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 18.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 15.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 8.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; kidney: 13.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 19.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 26.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 1.1 nTPM; positive ihc; pancreas: 11.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 3.5 nTPM; positive ihc; pituitary gland: 4.5 nTPM; absolute ceiling;continuous selectivity; rectum: 10.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; salivary gland: 9 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 2.4 nTPM; positive ihc;absolute ceiling; skin: 3.5 nTPM; positive ihc; small intestine: 15.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 27.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 3.3 nTPM; absolute ceiling;continuous selectivity; spleen: 1 nTPM; positive ihc; stomach: 13.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 17.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 13.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 2.9 nTPM (limit 2); bone marrow: 4.5 nTPM (limit 2); cerebral cortex: 3.2 nTPM (limit 2); choroid plexus: 15.6 nTPM (limit 2); colon: 11.9 nTPM (limit 6); duodenum: 18.9 nTPM (limit 2); esophagus: 15.8 nTPM (limit 12); heart muscle: 8.8 nTPM (limit 2); kidney: 13.9 nTPM (limit 2); liver: 19.6 nTPM (limit 2); lung: 26.6 nTPM (limit 2); pancreas: 11.3 nTPM (limit 2); pituitary gland: 4.5 nTPM (limit 2); rectum: 10.2 nTPM (limit 6); salivary gland: 9 nTPM (limit 6); skeletal muscle: 2.4 nTPM (limit 2); small intestine: 15.6 nTPM (limit 2); smooth muscle: 27.7 nTPM (limit 2); spinal cord: 3.3 nTPM (limit 2); stomach: 13.4 nTPM (limit 6); thyroid gland: 17.5 nTPM (limit 10); urinary bladder: 13.4 nTPM (limit 6),adipose tissue / adipocytes: Low (Supported); adrenal gland / glandular cells: High (Supported); bone marrow / hematopoietic cells: Medium (Supported); bronchus / basal cells: Medium (Supported); bronchus / ciliated cells (cell body): High (Supported); bronchus / ciliated cells (cilia axoneme): Low (Supported); bronchus / ciliated cells (tip of cilia): Medium (Supported); caudate / neuronal cells: Medium (Supported); cerebellum / cells in granular layer: High (Supported); cerebellum / cells in molecular layer: Medium (Supported); cerebellum / Purkinje cells: High (Supported); cerebral cortex / endothelial cells: Medium (Supported); cerebral cortex / glial cells: Low (Supported); cerebral cortex / neuronal cells: Medium (Supported); cerebral cortex / neuropil: High (Supported); colon / endocrine cells: Medium (Supported); colon / endothelial cells: Medium (Supported); colon / enterocytes: High (Supported); colon / enterocytes - Microvilli: Medium (Supported); colon / fibroblasts: Medium (Supported); colon / goblet cells: Medium (Supported); colon / mucosal lymphoid cells: Medium (Supported); colon / peripheral nerve/ganglion: Medium (Supported); duodenum / endocrine cells: Medium (Supported); duodenum / enterocytes: High (Supported); duodenum / enterocytes - Microvilli: High (Supported); duodenum / goblet cells: Medium (Supported); heart muscle / cardiomyocytes: Medium (Supported); hippocampus / glial cells: Low (Supported); hippocampus / neuronal cells: Medium (Supported); kidney / cells in glomeruli: Medium (Supported); kidney / cells in tubules: High (Supported); liver / cholangiocytes: Low (Supported); liver / hepatocytes: Medium (Supported); lung / alveolar cells type I: Medium (Supported); lung / endothelial cells: High (Supported); lymph node / germinal center cells: Medium (Supported); lymph node / non-germinal center cells: Low (Supported); nasopharynx / basal cells: Medium (Supported); nasopharynx / ciliated cells (cell body): Medium (Supported); nasopharynx / ciliated cells (cilia axoneme): Low (Supported); nasopharynx / ciliated cells (ciliary rootlets): High (Supported); nasopharynx / ciliated cells (tip of cilia): Medium (Supported); pancreas / exocrine glandular cells: Medium (Supported); pancreas / pancreatic endocrine cells: Medium (Supported); parathyroid gland / glandular cells: High (Supported); rectum / endocrine cells: High (Supported); rectum / endothelial cells: High (Supported); rectum / enterocytes: High (Supported); rectum / enterocytes - Microvilli: High (Supported); rectum / fibroblasts: Medium (Supported); rectum / goblet cells: High (Supported); rectum / peripheral nerve/ganglion: High (Supported); salivary gland / glandular cells: Medium (Supported); skeletal muscle / myocytes: Low (Supported); skin 2 / epidermal cells: Medium (Supported); small intestine / endocrine cells: High (Supported); small intestine / enterocytes: High (Supported); small intestine / enterocytes - Microvilli: Medium (Supported); small intestine / goblet cells: High (Supported); small intestine / paneth cells: High (Supported); smooth muscle / smooth muscle cells: Low (Supported); spleen / cells in red pulp: Medium (Supported); stomach 1 / glandular cells: Medium (Supported); stomach 2 / glandular cells: Medium (Supported); thyroid gland / glandular cells: Medium (Supported); urinary bladder / urothelial cells: Medium (Supported),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%); Colon Adenocarcinoma (validation): 485/486 (99.8%),colorectal cancer: 11/11 (100.0%); stomach cancer: 11/11 (100.0%),31,20,Q8NHU3,https://www.uniprot.org/uniprotkb/Q8NHU3/entry,"Sphingomyelin synthase that primarily contributes to sphingomyelin synthesis and homeostasis at the plasma membrane. Catalyzes the reversible transfer of phosphocholine moiety in sphingomyelin biosynthesis: in the forward reaction transfers phosphocholine head group of phosphatidylcholine (PC) on to ceramide (CER) to form ceramide phosphocholine (sphingomyelin, SM) and diacylglycerol (DAG) as by-product, and in the reverse reaction transfers phosphocholine from SM to DAG to form PC and CER (PubMed:14685263, PubMed:17449912, PubMed:17982138, PubMed:18370930, PubMed:38388831). The direction of the reaction appears to depend on the levels of CER and DAG in the plasma membrane (PubMed:14685263, PubMed:17449912, PubMed:17982138, PubMed:18370930). Does not use free phosphorylcholine or CDP-choline as donors (PubMed:14685263). Can also transfer phosphoethanolamine head group of phosphatidylethanolamine (PE) on to ceramide (CER) to form ceramide phosphoethanolamine (CPE) (PubMed:19454763). Regulates receptor-mediated signal transduction via mitogenic DAG and proapoptotic CER, as well as via SM, a structural component of membrane rafts that serve as platforms for signal transduction and protein sorting (PubMed:17449912, PubMed:17982138). To a lesser extent, plays a role in secretory transport via regulation of DAG pool at the Golgi apparatus and its downstream effects on PRKD1 (PubMed:18370930, PubMed:21980337). Required for normal bone matrix mineralization (PubMed:30779713)","Brain, heart, kidney, liver, muscle and stomach. Also expressed in a number of cell lines such as carcinoma HeLa cells, hepatoma Hep-G2 cells, and colon carcinoma Caco-2 cells","Calvarial doughnut lesions with bone fragility: A rare autosomal dominant bone disease characterized by low bone density, distinctive X-ray translucencies of the skull, multiple fractures, elevated serum alkaline phosphatase, and dental caries. Patients present with childhood onset of primary osteoporosis and typical sclerotic doughnut-shaped lesions in the cranial bones. Calvarial doughnut lesions with bone fragility and spondylometaphyseal dysplasia: A severe form of calvarial doughnut lesions with bone fragility, a rare autosomal dominant disease characterized by low bone density, distinctive X-ray translucencies of the skull, multiple fractures, elevated serum alkaline phosphatase, and dental caries. CDLSMD patients show neonatal onset of fractures, severe short stature, marked cranial sclerosis, and spondylometaphyseal dysplasia.",,Cell membrane Golgi apparatus membrane,14685263|17449912|17982138|18370930|19454763|21980337|30779713|38388831,14685263,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
SGO1,ENSG00000129810,Unsafe,Protein,False,True,6.5,12.6,109,29,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 8.6 nTPM; continuous selectivity;reproductive not higher; colon: 2 nTPM; positive ihc; duodenum: 2.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 1.9 nTPM; positive ihc; lymph node: 6.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; rectum: 2.7 nTPM; positive ihc;continuous selectivity; skin: 1.1 nTPM; positive ihc; small intestine: 2.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; spleen: 1.3 nTPM; positive ihc; stomach: 1.4 nTPM; positive ihc; thymus: 12.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 0.9 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",duodenum: 2.2 nTPM (limit 2); lymph node: 6.1 nTPM (limit 6); small intestine: 2.4 nTPM (limit 2); thymus: 12.6 nTPM (limit 10),colon / enterocytes: Medium (Enhanced); colon / goblet cells: Medium (Enhanced); duodenum / enterocytes: Medium (Enhanced); duodenum / goblet cells: Medium (Enhanced); esophagus / squamous epithelial cells: Low (Enhanced); lymph node / non-germinal center cells: Low (Enhanced); oral mucosa / squamous epithelial cells: Low (Enhanced); rectum / enterocytes: Medium (Enhanced); rectum / goblet cells: Medium (Enhanced); skin 1 / keratinocytes: Medium (Enhanced); skin 2 / epidermal cells: Medium (Enhanced); small intestine / enterocytes: Medium (Enhanced); small intestine / goblet cells: Medium (Enhanced); spleen / cells in white pulp: Low (Enhanced); stomach 2 / glandular cells: Low (Enhanced); urinary bladder / urothelial cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 476/486 (97.9%); Rectum Adenocarcinoma (validation): 196/207 (94.7%); Testicular Germ Cell Tumor (TCGA): 109/133 (82.0%),melanoma: 5/10 (50.0%); cervical cancer: 5/12 (41.7%),29,20,Q5FBB7,https://www.uniprot.org/uniprotkb/Q5FBB7/entry,"Plays a central role in chromosome cohesion during mitosis by preventing premature dissociation of cohesin complex from centromeres after prophase, when most of cohesin complex dissociates from chromosomes arms. May act by preventing phosphorylation of the STAG2 subunit of cohesin complex at the centromere, ensuring cohesin persistence at centromere until cohesin cleavage by ESPL1/separase at anaphase. Essential for proper chromosome segregation during mitosis and this function requires interaction with PPP2R1A. Its phosphorylated form is necessary for chromosome congression and for the proper attachment of spindle microtubule to the kinetochore. Necessary for kinetochore localization of PLK1 and CENPF. May play a role in the tension sensing mechanism of the spindle-assembly checkpoint by regulating PLK1 kinetochore affinity. Isoform 3 plays a role in maintaining centriole cohesion involved in controlling spindle pole integrity. Involved in centromeric enrichment of AUKRB in prometaphase","Widely expressed. Highly expressed in testis. Expressed in lung, small intestine, breast, liver and placenta. Strongly overexpressed in 90% of breast cancers tested","Chronic atrial and intestinal dysrhythmia: A disease characterized by dysregulation of the cardiac sinus node resulting in sick sinus syndrome, in association with chronic intestinal pseudo-obstruction, a disorder of gastrointestinal motility in which intestinal obstruction occurs in the absence of a mechanical obstacle.",,"Nucleus Chromosome, centromere Chromosome, centromere, kinetochore Cytoplasm, cytoskeleton, spindle pole Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Nucleus speckle",15604152|15723797|15737064|16580887|17617734|17621308|18331714|20739936,12747765,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
SGO2,ENSG00000163535,Unsafe,Protein,False,True,31.6,31.6,124,21,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; colon: 3 nTPM; positive ihc; duodenum: 2.4 nTPM; positive ihc;absolute ceiling; esophagus: 2.3 nTPM; positive ihc; lymph node: 7.8 nTPM; positive ihc;absolute ceiling; rectum: 3.1 nTPM; positive ihc; skin: 2.2 nTPM; positive ihc; small intestine: 2.5 nTPM; positive ihc;absolute ceiling; stomach: 1.7 nTPM; positive ihc; thymus: 14.5 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",duodenum: 2.4 nTPM (limit 2); lymph node: 7.8 nTPM (limit 6); small intestine: 2.5 nTPM (limit 2); thymus: 14.5 nTPM (limit 10),bronchus / basal cells: Low (Enhanced); colon / enterocytes: Low (Enhanced); colon / goblet cells: Low (Enhanced); duodenum / endocrine cells: Medium (Enhanced); duodenum / goblet cells: Low (Enhanced); esophagus / squamous epithelial cells: Low (Enhanced); lymph node / non-germinal center cells: Low (Enhanced); nasopharynx / basal cells: Low (Enhanced); oral mucosa / squamous epithelial cells: Low (Enhanced); rectum / enterocytes: Medium (Enhanced); skin 1 / keratinocytes: Low (Enhanced); small intestine / enterocytes: Low (Enhanced); stomach 2 / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 460/486 (94.7%); Rectum Adenocarcinoma (validation): 183/207 (88.4%),cervical cancer: 2/12 (16.7%); colorectal cancer: 1/11 (9.1%),29,20,Q562F6,https://www.uniprot.org/uniprotkb/Q562F6/entry,"Cooperates with PPP2CA to protect centromeric cohesin from separase-mediated cleavage in oocytes specifically during meiosis I. Has a crucial role in protecting REC8 at centromeres from cleavage by separase. During meiosis, protects centromeric cohesion complexes until metaphase II/anaphase II transition, preventing premature release of meiosis-specific REC8 cohesin complexes from anaphase I centromeres. Is thus essential for an accurate gametogenesis. May act by targeting PPP2CA to centromeres, thus leading to cohesin dephosphorylation (By similarity). Essential for recruiting KIF2C to the inner centromere and for correcting defective kinetochore attachments. Involved in centromeric enrichment of AUKRB in prometaphase",,,,"Nucleus Chromosome, centromere Chromosome, centromere, kinetochore",16541025|17485487|20739936,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
SH2D7,ENSG00000183476,Unsafe,Protein,False,True,3.0,3.0,110,11,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; colon: 1.7 nTPM; positive ihc;continuous selectivity; duodenum: 2.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; rectum: 0.2 nTPM; positive ihc; small intestine: 1.8 nTPM; positive ihc;continuous selectivity; stomach: 0.2 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",duodenum: 2.3 nTPM (limit 2),colon / endocrine cells: High (Enhanced); duodenum / endocrine cells: High (Enhanced); duodenum / enterocytes - Microvilli: Low (Enhanced); rectum / endocrine cells: High (Enhanced); small intestine / endocrine cells: High (Enhanced); small intestine / enterocytes - Microvilli: Low (Enhanced); stomach 1 / glandular cells: Low (Enhanced); stomach 2 / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 18/176 (10.2%); Pancreatic Adenocarcinoma (validation): 4/80 (5.0%); Pancreatic Adenocarcinoma (TCGA): 3/176 (1.7%),pancreatic cancer: 7/11 (63.6%); skin cancer: 2/12 (16.7%),31,20,A6NKC9,https://www.uniprot.org/uniprotkb/A6NKC9/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
SHC4,ENSG00000185634,Unsafe,RNA,False,True,10.2,15.4,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 8.5 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 10.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 7.5 nTPM; absolute ceiling;continuous selectivity; heart muscle: 3.2 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 10.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 6.1 nTPM; absolute ceiling;continuous selectivity; midbrain: 12.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 15.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 8.5 nTPM (limit 2); basal ganglia: 10.2 nTPM (limit 2); cerebral cortex: 7.5 nTPM (limit 2); heart muscle: 3.2 nTPM (limit 2); hippocampal formation: 10.8 nTPM (limit 2); hypothalamus: 6.1 nTPM (limit 2); midbrain: 12.5 nTPM (limit 2); spinal cord: 15.4 nTPM (limit 2); amygdala: 8.5 nTPM (baseline 2); basal ganglia: 10.2 nTPM (baseline 2); cerebral cortex: 7.5 nTPM (baseline 2); heart muscle: 3.2 nTPM (baseline 2); hippocampal formation: 10.8 nTPM (baseline 2); hypothalamus: 6.1 nTPM (baseline 2); midbrain: 12.5 nTPM (baseline 2); spinal cord: 15.4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Skin Cuteneous Melanoma (TCGA): 72/99 (72.7%); Glioblastoma Multiforme (TCGA): 76/141 (53.9%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q6S5L8,https://www.uniprot.org/uniprotkb/Q6S5L8/entry,Activates both Ras-dependent and Ras-independent migratory pathways in melanomas. Contributes to the early phases of agrin-induced tyrosine phosphorylation of CHRNB1,"Only expressed in melanomas. Weakly expressed in normal melanocytes and benign nevi. Highly expressed at the transition from radial growth phase to vertical growth phase and metastatic melanomas, when tumor cells acquire migratory competence and invasive potential",,,Postsynaptic cell membrane,17409413,17409413,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
SHCBP1L,ENSG00000157060,Unsafe,Protein,False,True,111.3,111.3,91,5,Positive somewhere,True,False,False,True,Excluded,Normal,False,,Not assessed,,,positive normal IHC; positive ihc outside permitted; kidney: 0 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,kidney / distal tubules: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 2/133 (1.5%); Pancreatic Adenocarcinoma (validation): 1/80 (1.2%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 3/283 (1.1%),breast cancer: 0/11 (0.0%); cervical cancer: 0/9 (0.0%),30,20,Q9BZQ2,https://www.uniprot.org/uniprotkb/Q9BZQ2/entry,"Testis-specific spindle-associated factor that plays a role in spermatogenesis. In association with HSPA2, participates in the maintenance of spindle integrity during meiosis in male germ cells","Expressed in spermatocytes and elongating spermatids inside the seminiferous tubules (at protein level) (PubMed:24557841). Testis-specific (PubMed:11318611, PubMed:24557841)",,,"Cytoplasm, cytoskeleton, spindle",,11318611|24557841,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Carter2023_CT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
SHOC1,ENSG00000165181,Unsafe,RNA,False,True,21.3,21.3,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 3.7 nTPM; absolute ceiling; kidney: 2.2 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 3.7 nTPM (limit 2); kidney: 2.2 nTPM (limit 2); adrenal gland: 3.7 nTPM (baseline 2); kidney: 2.2 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Chromophobe (TCGA): 34/64 (53.1%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 20/283 (7.1%); Lung Adenocarcinoma (validation): 5/105 (4.8%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q5VXU9,https://www.uniprot.org/uniprotkb/Q5VXU9/entry,"ATPase required during meiosis for the formation of crossover recombination intermediates (By similarity). Binds DNA: preferentially binds to single-stranded DNA and DNA branched structures (PubMed:29742103). Does not show nuclease activity in vitro, but shows ATPase activity, which is stimulated by the presence of single-stranded DNA (PubMed:29742103). Plays a key role in homologous recombination and crossing-over in meiotic prophase I in male and female germ cells (By similarity). Required for proper synaptonemal complex assembly and homologous chromosome pairing (By similarity). Requiref for recruitment TEX11 and MSH4 to recombination intermediates (By similarity)",,Spermatogenic failure 75: An autosomal recessive disorder characterized by male infertility due to non-obstructive azoospermia resulting from maturation arrest at the spermatocyte stage.,"Although related to the XPF family, the nuclease active site is not conserved",Chromosome,29742103,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
SI,ENSG00000090402,Unsafe,Protein,False,True,1.6,530.0,106,3,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; colon: 17 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 530 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; rectum: 30 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 435.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 0.8 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",colon: 17 nTPM (limit 6); duodenum: 530 nTPM (limit 2); rectum: 30 nTPM (limit 6); small intestine: 435.9 nTPM (limit 2); colon: 17 nTPM (baseline 6); duodenum: 530 nTPM (baseline 2); rectum: 30 nTPM (baseline 6); small intestine: 435.9 nTPM (baseline 2),duodenum / enterocytes - Microvilli: High (Enhanced); small intestine / enterocytes - Microvilli: High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 123/207 (59.4%); Colon Adenocarcinoma (validation): 284/486 (58.4%); Stomach Adenocarcinoma (TCGA): 96/346 (27.7%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),31,20,P14410,https://www.uniprot.org/uniprotkb/P14410/entry,"Bifunctional enzyme with both sucrase and isomaltase activities involved in breakdown of dietary starch oligosaccharides in small intestine. The isomaltase domain hydrolazes alpha-1,6-glycosidic linkages in isomaltose. The sucrase domain cleaves the alpha-1,2-glycosidic linkages in sucrose to form glucose and fructose, and contributes to the cleavage of the alpha-1,4-glycosidic linkage in maltose to form two glucose monosaccharides",Expressed in the poorly differentiated crypt cells of the small intestine as well as in the mature villous cells. Expressed at very low levels in the colon,"Congenital sucrase-isomaltase deficiency: Autosomal recessive intestinal disorder that is clinically characterized by fermentative diarrhea, abdominal pain, and cramps upon ingestion of sugar. The symptoms are the consequence of absent or drastically reduced enzymatic activities of sucrase and isomaltase. The prevalence of CSID is 0.02 % in individuals of European descent and appears to be much higher in Greenland, Alaskan, and Canadian native people. CSID arises due to post-translational perturbations in the intracellular transport, polarized sorting, aberrant processing, and defective function of SI.",,Apical cell membrane,20356844|28522605,1677636,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
SIAH1,ENSG00000196470,Unsafe,Protein,False,True,48.4,48.4,91,78,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 22.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 13.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 13.1 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 12.4 nTPM; absolute ceiling;continuous selectivity; bone marrow: 27.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 14.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 15.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 9.5 nTPM; absolute ceiling; colon: 15.5 nTPM; positive ihc;absolute ceiling; duodenum: 15.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 13.6 nTPM; positive ihc;absolute ceiling; heart muscle: 14.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 14.1 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 13.3 nTPM; absolute ceiling;continuous selectivity; kidney: 14.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 22 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 17.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 13.6 nTPM; positive ihc;absolute ceiling; midbrain: 13.2 nTPM; absolute ceiling;continuous selectivity; pancreas: 13.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 14.1 nTPM; positive ihc;absolute ceiling; pituitary gland: 10.1 nTPM; absolute ceiling; rectum: 14.1 nTPM; positive ihc;absolute ceiling; retina: 18.5 nTPM; absolute ceiling;continuous selectivity; salivary gland: 15.6 nTPM; positive ihc;absolute ceiling; skeletal muscle: 20.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 21.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 15.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 14 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 14.6 nTPM; absolute ceiling;continuous selectivity; spleen: 13.1 nTPM; positive ihc;absolute ceiling; stomach: 15.3 nTPM; positive ihc;absolute ceiling; thymus: 13.7 nTPM; absolute ceiling; thyroid gland: 17 nTPM; positive ihc;absolute ceiling; tongue: 16.6 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 13.7 nTPM; positive ihc;absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 22.5 nTPM (limit 10); adrenal gland: 13.7 nTPM (limit 2); amygdala: 13.1 nTPM (limit 2); basal ganglia: 12.4 nTPM (limit 2); bone marrow: 27.8 nTPM (limit 2); cerebellum: 14.3 nTPM (limit 2); cerebral cortex: 15.3 nTPM (limit 2); choroid plexus: 9.5 nTPM (limit 2); colon: 15.5 nTPM (limit 6); duodenum: 15.5 nTPM (limit 2); esophagus: 13.6 nTPM (limit 6); heart muscle: 14.4 nTPM (limit 2); hippocampal formation: 14.1 nTPM (limit 2); hypothalamus: 13.3 nTPM (limit 2); kidney: 14.1 nTPM (limit 2); liver: 22 nTPM (limit 2); lung: 17.1 nTPM (limit 2); lymph node: 13.6 nTPM (limit 6); midbrain: 13.2 nTPM (limit 2); pancreas: 13.7 nTPM (limit 2); parathyroid gland: 14.1 nTPM (limit 6); pituitary gland: 10.1 nTPM (limit 2); rectum: 14.1 nTPM (limit 6); retina: 18.5 nTPM (limit 2); salivary gland: 15.6 nTPM (limit 6); skeletal muscle: 20.8 nTPM (limit 2); skin: 21.6 nTPM (limit 10); small intestine: 15.8 nTPM (limit 2); smooth muscle: 14 nTPM (limit 2); spinal cord: 14.6 nTPM (limit 2); spleen: 13.1 nTPM (limit 10); stomach: 15.3 nTPM (limit 6); thymus: 13.7 nTPM (limit 10); thyroid gland: 17 nTPM (limit 10); tongue: 16.6 nTPM (limit 6); urinary bladder: 13.7 nTPM (limit 6),adipose tissue / adipocytes: Medium (Enhanced); adrenal gland / glandular cells: Medium (Enhanced); bone marrow / hematopoietic cells: Medium (Enhanced); bronchus / respiratory epithelial cells: Medium (Enhanced); caudate / glial cells: High (Enhanced); caudate / neuronal cells: Low (Enhanced); cerebellum / cells in granular layer: Low (Enhanced); cerebellum / cells in molecular layer: High (Enhanced); cerebellum / Purkinje cells: Low (Enhanced); cerebral cortex / endothelial cells: Medium (Enhanced); cerebral cortex / glial cells: High (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); cerebral cortex / neuropil: Low (Enhanced); colon / endothelial cells: Medium (Enhanced); colon / glandular cells: Medium (Enhanced); colon / peripheral nerve/ganglion: Medium (Enhanced); duodenum / glandular cells: Medium (Enhanced); esophagus / squamous epithelial cells: Medium (Enhanced); heart muscle / cardiomyocytes: Medium (Enhanced); hippocampus / glial cells: High (Enhanced); hippocampus / neuronal cells: Low (Enhanced); kidney / collecting ducts: Low (Enhanced); kidney / distal tubules: Low (Enhanced); kidney / proximal tubules (cell body): Medium (Enhanced); liver / hepatocytes: Medium (Enhanced); lung / alveolar cells type I: High (Enhanced); lung / alveolar cells type II: Low (Enhanced); lung / macrophages: Low (Enhanced); lymph node / non-germinal center cells: Low (Enhanced); nasopharynx / respiratory epithelial cells: Medium (Enhanced); oral mucosa / squamous epithelial cells: Medium (Enhanced); pancreas / exocrine glandular cells: Medium (Enhanced); pancreas / pancreatic endocrine cells: Low (Enhanced); parathyroid gland / glandular cells: High (Enhanced); rectum / glandular cells: Medium (Enhanced); salivary gland / glandular cells: Medium (Enhanced); skeletal muscle / myocytes: Low (Enhanced); skin 1 / fibroblasts: Medium (Enhanced); skin 1 / keratinocytes: Low (Enhanced); skin 1 / Langerhans: Low (Enhanced); skin 2 / epidermal cells: Medium (Enhanced); small intestine / glandular cells: Medium (Enhanced); smooth muscle / smooth muscle cells: Medium (Enhanced); spleen / cells in red pulp: Medium (Enhanced); spleen / cells in white pulp: Medium (Enhanced); stomach 1 / glandular cells: Medium (Enhanced); stomach 2 / glandular cells: Medium (Enhanced); thyroid gland / glandular cells: High (Enhanced); urinary bladder / urothelial cells: Medium (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Adenocarcinoma (TCGA): 497/497 (100.0%); Stomach Adenocarcinoma (TCGA): 346/346 (100.0%); Colon Adenocarcinoma (TCGA): 254/254 (100.0%),colorectal cancer: 12/12 (100.0%); ovarian cancer: 12/12 (100.0%),31,20,Q8IUQ4,https://www.uniprot.org/uniprotkb/Q8IUQ4/entry,"E3 ubiquitin-protein ligase that mediates ubiquitination and subsequent proteasomal degradation of target proteins (PubMed:14506261, PubMed:14645235, PubMed:14654780, PubMed:15064394, PubMed:16085652, PubMed:19224863, PubMed:20508617, PubMed:22483617, PubMed:28546513, PubMed:32430360, PubMed:33591310, PubMed:9334332, PubMed:9858595, PubMed:41062835). E3 ubiquitin ligases accept ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates (PubMed:14506261, PubMed:14645235, PubMed:14654780, PubMed:15064394, PubMed:16085652, PubMed:19224863, PubMed:20508617, PubMed:22483617, PubMed:9334332, PubMed:9858595). Mediates E3 ubiquitin ligase activity either through direct binding to substrates or by functioning as the essential RING domain subunit of larger E3 complexes (PubMed:14506261, PubMed:14645235, PubMed:14654780, PubMed:15064394, PubMed:16085652, PubMed:19224863, PubMed:20508617, PubMed:22483617, PubMed:9334332, PubMed:9858595). Triggers the ubiquitin-mediated degradation of many substrates, including proteins involved in transcription regulation (ELL2, MYB, POU2AF1, PML and RBBP8), in transcriptional restart after DNA damage (AFF1), a cell surface receptor (DCC), the cell-surface receptor-type tyrosine kinase FLT3, the cytoplasmic signal transduction molecules (KLF10/TIEG1 and NUMB), an antiapoptotic protein (BAG1), a microtubule motor protein (KIF22), a protein involved in synaptic vesicle function in neurons (SYP), a structural protein (CTNNB1) and SNCAIP (PubMed:10747903, PubMed:11146551, PubMed:11389839, PubMed:11389840, PubMed:11483517, PubMed:11483518, PubMed:11752454, PubMed:12072443, PubMed:41062835). Confers constitutive instability to HIPK2 through proteasomal degradation (PubMed:18536714, PubMed:33591310). It is thereby involved in many cellular processes such as apoptosis, tumor suppression, cell cycle, axon guidance, transcription regulation, spermatogenesis and TNF signaling (PubMed:14506261, PubMed:14645235, PubMed:14654780, PubMed:15064394, PubMed:16085652, PubMed:19224863, PubMed:20508617, PubMed:22483617, PubMed:9334332, PubMed:9858595). Has some overlapping function with SIAH2 (PubMed:14506261, PubMed:14645235, PubMed:14654780, PubMed:15064394, PubMed:16085652, PubMed:19224863, PubMed:20508617, PubMed:22483617, PubMed:9334332, PubMed:9858595). Induces apoptosis in cooperation with PEG3 (By similarity). Upon nitric oxid (NO) generation that follows apoptotic stimulation, interacts with S-nitrosylated GAPDH, mediating the translocation of GAPDH to the nucleus (By similarity). GAPDH acts as a stabilizer of SIAH1, facilitating the degradation of nuclear proteins (By similarity). Mediates ubiquitination and degradation of EGLN2 and EGLN3 in response to the unfolded protein response (UPR), leading to their degradation and subsequent stabilization of ATF4 (By similarity). Also part of the Wnt signaling pathway in which it mediates the Wnt-induced ubiquitin-mediated proteasomal degradation of AXIN1 (PubMed:28546513, PubMed:32430360)",Widely expressed at a low level. Down-regulated in advanced hepatocellular carcinomas,"Buratti-Harel syndrome: An autosomal dominant neurodevelopmental disorder characterized by hypotonia apparent in early infancy, global developmental delay, delayed walking, language and speech delay, impaired intellectual development, and dysmorphic facial features.",,Cytoplasm Nucleus,10747903|11146551|11389839|11389840|11483517|11483518|11752454|12072443|14506261|14645235|14654780|15064394|16085652|18536714|19224863|20508617|22483617|28546513|32430360|41062835|9334332|9858595,12557228|9403064,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
SIGLEC6,ENSG00000105492,Unsafe,Protein,False,True,103.1,103.1,101,3,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; colon: 2.2 nTPM; positive ihc; duodenum: 2.2 nTPM; absolute ceiling; small intestine: 3.2 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",duodenum: 2.2 nTPM (limit 2); small intestine: 3.2 nTPM (limit 2),colon / mucosal lymphoid cells: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Thyroid Carcinoma (TCGA): 117/495 (23.6%); Breast Invasive Carcinoma (validation): 8/50 (16.0%); Bladder Urothelial Carcinoma (TCGA): 17/169 (10.1%),breast cancer: 1/12 (8.3%); cervical cancer: 0/10 (0.0%),31,20,O43699,https://www.uniprot.org/uniprotkb/O43699/entry,"Putative adhesion molecule that mediates sialic-acid dependent binding to cells. Binds to alpha-2,6-linked sialic acid. The sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface","Expressed at high levels in placenta (cyto- and syncytiotrophoblastic cells) and at lower levels in spleen, peripheral blood leukocytes (predominantly B-cells) and small intestine",,,Cell membrane Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Gong2021_reproductive_PC,No tumor-antigen validation in this source | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
SIM1,ENSG00000112246,Unsafe,RNA,False,True,2.8,9.5,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,adipose tissue: 1.6 nTPM; continuous selectivity; hypothalamus: 0.8 nTPM; continuous selectivity; kidney: 9.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 1.8 nTPM; continuous selectivity; skeletal muscle: 3.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,kidney: 9.5 nTPM (limit 2); skeletal muscle: 3.4 nTPM (limit 2); kidney: 9.5 nTPM (baseline 2); skeletal muscle: 3.4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Chromophobe (TCGA): 43/64 (67.2%); Kidney Renal Papillary Cell Carcinoma (TCGA): 64/282 (22.7%); Kidney Renal Clear Cell Carcinoma (validation): 10/100 (10.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P81133,https://www.uniprot.org/uniprotkb/P81133/entry,Transcriptional factor that may have pleiotropic effects during embryogenesis and in the adult,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
SIRPD,ENSG00000125900,Unsafe,Protein,False,True,56.2,56.2,86,6,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; kidney: 0.1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,kidney / cells in tubules: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 5/133 (3.8%); Kidney Chromophobe (TCGA): 1/64 (1.6%); Kidney Renal Clear Cell Carcinoma (validation): 1/100 (1.0%),breast cancer: 0/12 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q9H106,https://www.uniprot.org/uniprotkb/Q9H106/entry,,,,,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
SIX6,ENSG00000184302,Unsafe,Protein,False,True,0.1,27.7,91,3,Positive somewhere,True,True,False,False,Excluded,Normal,False,,Not assessed,,,positive ihc outside permitted; hypothalamus: 3.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 27.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; retina: 6.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 0.2 nTPM; continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",hypothalamus: 3.1 nTPM (limit 2); pituitary gland: 27.7 nTPM (limit 2); retina: 6.4 nTPM (limit 2); hypothalamus: 3.1 nTPM (baseline 2); pituitary gland: 27.7 nTPM (baseline 2); retina: 6.4 nTPM (baseline 2),pituitary gland / cells in anterior : Medium (Approved); retina / inner nuclear layer: Medium (Approved); retina / photoreceptor cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Chromophobe (TCGA): 7/64 (10.9%); Glioblastoma Multiforme (validation): 5/58 (8.6%); Glioblastoma Multiforme (TCGA): 11/141 (7.8%),ovarian cancer: 1/12 (8.3%); breast cancer: 0/11 (0.0%),31,20,O95475,https://www.uniprot.org/uniprotkb/O95475/entry,May be involved in eye development,Expressed in the developing and adult retina. Also expressed in the hypothalamic and the pituitary regions,"Optic disk anomalies with retinal and/or macular dystrophy: An ocular disorder characterized by optic nerve dysplasia, optic disk anomalies, chorioretinal dystrophy and macular atrophy. Some patients have microphthalmia.",,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | daSilva2017_tumor_proteomics,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
SKA1,ENSG00000154839,Unsafe,Protein,False,True,4.1,11.8,77,70,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0.4 nTPM; positive ihc; adrenal gland: 0.5 nTPM; positive ihc; bone marrow: 11.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 0.7 nTPM; positive ihc; cerebral cortex: 0.3 nTPM; positive ihc; colon: 1.6 nTPM; positive ihc;continuous selectivity; duodenum: 1.7 nTPM; positive ihc;continuous selectivity; esophagus: 2.5 nTPM; positive ihc;continuous selectivity; heart muscle: 0.2 nTPM; positive ihc; kidney: 0.1 nTPM; positive ihc; liver: 0.3 nTPM; positive ihc; lung: 0.3 nTPM; positive ihc; lymph node: 4.7 nTPM; positive ihc;continuous selectivity;reproductive not higher; pancreas: 0.4 nTPM; positive ihc; parathyroid gland: 0.1 nTPM; positive ihc; rectum: 2 nTPM; positive ihc;continuous selectivity; salivary gland: 0.3 nTPM; positive ihc; skeletal muscle: 0.5 nTPM; positive ihc; skin: 1.5 nTPM; positive ihc; small intestine: 1.3 nTPM; positive ihc;continuous selectivity; smooth muscle: 1.1 nTPM; positive ihc; stomach: 0.8 nTPM; positive ihc; thymus: 3.5 nTPM; continuous selectivity; thyroid gland: 0.3 nTPM; positive ihc; urinary bladder: 0.5 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 11.8 nTPM (limit 2),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Low (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: High (Approved); liver / hepatocytes: High (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: High (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: High (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: High (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 123/133 (92.5%); Colon Adenocarcinoma (validation): 449/486 (92.4%); Glioblastoma Multiforme (validation): 53/58 (91.4%),breast cancer: 12/12 (100.0%); melanoma: 11/12 (91.7%),31,20,Q96BD8,https://www.uniprot.org/uniprotkb/Q96BD8/entry,"Component of the SKA complex, a microtubule plus end-binding complex of the outer kinetochore that stabilizes spindle microtubule-kinetochore attachments, promotes alignment of chromosomes at the mitotic spindle equator (chromosome congression) and assists suppression of the spindle assembly checkpoint (PubMed:17093495, PubMed:19289083, PubMed:22371557, PubMed:22483620, PubMed:23085020, PubMed:26981768, PubMed:27697923, PubMed:29487209, PubMed:31804178). Kinetochores, consisting of a centromere-associated inner segment and a microtubule-contacting outer segment, play a crucial role in chromosome segregation by mediating the physical connection between centromeric DNA and spindle microtubules (PubMed:19289083, PubMed:22483620, PubMed:23085020, PubMed:28479321, PubMed:29487209). The outer kinetochore is made up of the ten-subunit KMN network complex, comprising the MIS12, NDC80 and KNL1 complexes, and auxiliary microtubule-associated components such as the SKA complex; together they connect the outer kinetochore with the inner kinetochore, bind microtubules, and mediate interactions with mitotic checkpoint proteins that delay anaphase until chromosomes are bioriented on the spindle (PubMed:17093495, PubMed:19289083, PubMed:23085020, PubMed:28479321, PubMed:29487209). The SKA complex is loaded onto bioriented kinetochores and it facilitates chromosome congression by stabilizing microtubules together with MAPRE1, and end-on attachment of the NDC80 complex to depolymerizing spindle microtubules, thereby assisting the poleward-moving kinetochore in withstanding microtubule pulling forces (PubMed:19289083, PubMed:22371557, PubMed:22454517, PubMed:23085020, PubMed:24413531, PubMed:27697923, PubMed:28479321, PubMed:28495837, PubMed:29487209). The complex associates with dynamic microtubule plus-ends and can track both depolymerizing and elongating microtubules (PubMed:23085020, PubMed:29153323). The complex recruits protein phosphatase 1 (PP1) to the kinetochore in prometaphase and metaphase, to oppose spindle assembly checkpoint signaling and promote the onset of anaphase (PubMed:26981768). In the complex, it mediates interactions with microtubules (PubMed:19289083, PubMed:22483620, PubMed:23085020, PubMed:24413531, PubMed:27667719, PubMed:29153323, PubMed:36592928). It also stimulates AURKB/Aurora B catalytic activity (PubMed:27697923). During meiosis the SKA complex stabilizes the meiotic spindle and is required for its migration to the cortex (By similarity)",,,,"Cytoplasm, cytoskeleton, spindle Chromosome, centromere, kinetochore Cytoplasm, cytoskeleton, microtubule organizing center, centrosome",17093495|19289083|22371557|22454517|22483620|23085020|24413531|26981768|27667719|27697923|28479321|28495837|29153323|29487209|31804178|36592928,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
SKA3,ENSG00000165480,Unsafe,RNA,False,True,6.1,11.8,85,4,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,bone marrow: 4.7 nTPM; absolute ceiling;continuous selectivity; lymph node: 4.2 nTPM; continuous selectivity; rectum: 2.9 nTPM; continuous selectivity; thymus: 11.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 4.7 nTPM (limit 4); thymus: 11.8 nTPM (limit 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Colon Adenocarcinoma (validation): 459/486 (94.4%); Rectum Adenocarcinoma (validation): 190/207 (91.8%),testis cancer: 2/12 (16.7%); endometrial cancer: 1/12 (8.3%),31,20,Q8IX90,https://www.uniprot.org/uniprotkb/Q8IX90/entry,"Component of the SKA1 complex, a microtubule-binding subcomplex of the outer kinetochore that is essential for proper chromosome segregation (PubMed:19289083, PubMed:19360002, PubMed:23085020). The SKA1 complex is a direct component of the kinetochore-microtubule interface and directly associates with microtubules as oligomeric assemblies (PubMed:19289083, PubMed:19360002). The complex facilitates the processive movement of microspheres along a microtubule in a depolymerization-coupled manner (PubMed:19289083). In the complex, it mediates the microtubule-stimulated oligomerization (PubMed:19289083). Affinity for microtubules is synergistically enhanced in the presence of the ndc-80 complex and may allow the ndc-80 complex to track depolymerizing microtubules (PubMed:23085020)",,,,"Cytoplasm, cytoskeleton, spindle Chromosome, centromere, kinetochore",19289083|19360002|23085020,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | daSilva2017_tumor_proteomics,GC RNA nomination across cancer types; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
SKIL,ENSG00000136603,Unsafe,Protein,False,True,13.5,23.0,79,53,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 11.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 11.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 4.8 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 5.2 nTPM; absolute ceiling;continuous selectivity; bone marrow: 23 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 11.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 3.8 nTPM; absolute ceiling;continuous selectivity; colon: 10.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 13.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 8.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 11.6 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 5.2 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 5.3 nTPM; absolute ceiling;continuous selectivity; kidney: 9.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 15.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 15.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 13.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 5.5 nTPM; absolute ceiling;continuous selectivity; pancreas: 9.3 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 5.5 nTPM; positive ihc;continuous selectivity; pituitary gland: 10.7 nTPM; absolute ceiling;continuous selectivity; rectum: 9.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 9.3 nTPM; absolute ceiling;continuous selectivity; salivary gland: 7.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 10.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 5.7 nTPM; positive ihc; small intestine: 13.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 10.1 nTPM; absolute ceiling;continuous selectivity; spinal cord: 6.3 nTPM; absolute ceiling;continuous selectivity; spleen: 7 nTPM; continuous selectivity; stomach: 15.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; thymus: 9 nTPM; continuous selectivity; thyroid gland: 11 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 20.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 14.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 11.5 nTPM (limit 10); adrenal gland: 11.7 nTPM (limit 2); amygdala: 4.8 nTPM (limit 2); basal ganglia: 5.2 nTPM (limit 2); bone marrow: 23 nTPM (limit 2); cerebral cortex: 11.6 nTPM (limit 2); choroid plexus: 3.8 nTPM (limit 2); colon: 10.1 nTPM (limit 6); duodenum: 13.4 nTPM (limit 2); esophagus: 8.9 nTPM (limit 6); heart muscle: 11.6 nTPM (limit 2); hippocampal formation: 5.2 nTPM (limit 2); hypothalamus: 5.3 nTPM (limit 2); kidney: 9.9 nTPM (limit 2); liver: 15.1 nTPM (limit 2); lung: 15.6 nTPM (limit 2); lymph node: 13.5 nTPM (limit 6); midbrain: 5.5 nTPM (limit 2); pancreas: 9.3 nTPM (limit 2); pituitary gland: 10.7 nTPM (limit 2); rectum: 9.4 nTPM (limit 6); retina: 9.3 nTPM (limit 2); salivary gland: 7.2 nTPM (limit 6); skeletal muscle: 10.7 nTPM (limit 2); small intestine: 13.8 nTPM (limit 2); smooth muscle: 10.1 nTPM (limit 2); spinal cord: 6.3 nTPM (limit 2); stomach: 15.5 nTPM (limit 6); thyroid gland: 11 nTPM (limit 10); tongue: 20.6 nTPM (limit 6); urinary bladder: 14.1 nTPM (limit 6); adipose tissue: 11.5 nTPM (baseline 10); adrenal gland: 11.7 nTPM (baseline 2); amygdala: 4.8 nTPM (baseline 2); basal ganglia: 5.2 nTPM (baseline 2); bone marrow: 23 nTPM (baseline 2); cerebral cortex: 11.6 nTPM (baseline 2); choroid plexus: 3.8 nTPM (baseline 2); colon: 10.1 nTPM (baseline 6); duodenum: 13.4 nTPM (baseline 2); esophagus: 8.9 nTPM (baseline 6); heart muscle: 11.6 nTPM (baseline 2); hippocampal formation: 5.2 nTPM (baseline 2); hypothalamus: 5.3 nTPM (baseline 2); kidney: 9.9 nTPM (baseline 2); liver: 15.1 nTPM (baseline 2); lung: 15.6 nTPM (baseline 2); lymph node: 13.5 nTPM (baseline 6); midbrain: 5.5 nTPM (baseline 2); pancreas: 9.3 nTPM (baseline 2); pituitary gland: 10.7 nTPM (baseline 2); rectum: 9.4 nTPM (baseline 6); retina: 9.3 nTPM (baseline 2); salivary gland: 7.2 nTPM (baseline 6); skeletal muscle: 10.7 nTPM (baseline 2); small intestine: 13.8 nTPM (baseline 2); smooth muscle: 10.1 nTPM (baseline 2); spinal cord: 6.3 nTPM (baseline 2); stomach: 15.5 nTPM (baseline 6); thyroid gland: 11 nTPM (baseline 10); tongue: 20.6 nTPM (baseline 6); urinary bladder: 14.1 nTPM (baseline 6),adipose tissue / adipocytes: Low (Uncertain); adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: High (Uncertain); caudate / neuronal cells: Low (Uncertain); cerebral cortex / endothelial cells: Low (Uncertain); cerebral cortex / neuronal cells: Low (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / endothelial cells: Low (Uncertain); colon / glandular cells: High (Uncertain); colon / peripheral nerve/ganglion: Low (Uncertain); duodenum / glandular cells: High (Uncertain); esophagus / squamous epithelial cells: High (Uncertain); kidney / cells in tubules: High (Uncertain); liver / cholangiocytes: High (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / alveolar cells: Medium (Uncertain); nasopharynx / respiratory epithelial cells: High (Uncertain); oral mucosa / squamous epithelial cells: High (Uncertain); parathyroid gland / glandular cells: High (Uncertain); rectum / glandular cells: High (Uncertain); salivary gland / glandular cells: High (Uncertain); skeletal muscle / myocytes: Low (Uncertain); skin 1 / keratinocytes: High (Uncertain); skin 1 / Langerhans: Low (Uncertain); skin 2 / epidermal cells: High (Uncertain); small intestine / glandular cells: High (Uncertain); stomach 1 / glandular cells: High (Uncertain); stomach 2 / glandular cells: High (Uncertain); thyroid gland / glandular cells: Low (Uncertain); urinary bladder / urothelial cells: High (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%),breast cancer: 12/12 (100.0%); skin cancer: 12/12 (100.0%),31,20,P12757,https://www.uniprot.org/uniprotkb/P12757/entry,May have regulatory role in cell division or differentiation in response to extracellular signals,"Isoform SNON and isoform SNOA are widely expressed. Highest expression is found in skeletal muscle, followed by placenta and lung. Lowest expression in heart, brain and pancreas. Isoform SNOI expression is restricted to skeletal muscle",,,,,8233802,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
SLAIN2,ENSG00000109171,Unsafe,Protein,False,True,40.0,94.8,87,20,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 24.2 nTPM; absolute ceiling;continuous selectivity; adrenal gland: 12.5 nTPM; absolute ceiling; amygdala: 5.8 nTPM; absolute ceiling; basal ganglia: 5.8 nTPM; absolute ceiling; bone marrow: 16 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 6.2 nTPM; absolute ceiling; cerebral cortex: 6.1 nTPM; absolute ceiling; choroid plexus: 11.3 nTPM; absolute ceiling;continuous selectivity; colon: 26.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 13.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 37.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 39.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 5.4 nTPM; absolute ceiling; hypothalamus: 5.4 nTPM; absolute ceiling; kidney: 18.5 nTPM; absolute ceiling;continuous selectivity; liver: 26.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 20.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 16.6 nTPM; absolute ceiling; midbrain: 6.1 nTPM; absolute ceiling; pancreas: 14.6 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 29.6 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 7.6 nTPM; absolute ceiling; rectum: 24 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 15.9 nTPM; absolute ceiling;continuous selectivity; salivary gland: 19.4 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 69.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 31.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 16.9 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 34.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 5.4 nTPM; absolute ceiling; stomach: 18.1 nTPM; absolute ceiling;continuous selectivity; thymus: 24 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 20.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 94.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 25.5 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 24.2 nTPM (limit 20); adrenal gland: 12.5 nTPM (limit 4); amygdala: 5.8 nTPM (limit 2); basal ganglia: 5.8 nTPM (limit 2); bone marrow: 16 nTPM (limit 2); cerebellum: 6.2 nTPM (limit 4); cerebral cortex: 6.1 nTPM (limit 4); choroid plexus: 11.3 nTPM (limit 2); colon: 26.4 nTPM (limit 6); duodenum: 13.1 nTPM (limit 2); esophagus: 37.9 nTPM (limit 6); heart muscle: 39.2 nTPM (limit 2); hippocampal formation: 5.4 nTPM (limit 2); hypothalamus: 5.4 nTPM (limit 2); kidney: 18.5 nTPM (limit 4); liver: 26.1 nTPM (limit 2); lung: 20.8 nTPM (limit 2); lymph node: 16.6 nTPM (limit 8); midbrain: 6.1 nTPM (limit 2); pancreas: 14.6 nTPM (limit 4); parathyroid gland: 29.6 nTPM (limit 8); pituitary gland: 7.6 nTPM (limit 2); rectum: 24 nTPM (limit 6); retina: 15.9 nTPM (limit 2); salivary gland: 19.4 nTPM (limit 8); skeletal muscle: 69.6 nTPM (limit 2); skin: 31.7 nTPM (limit 10); small intestine: 16.9 nTPM (limit 4); smooth muscle: 34.2 nTPM (limit 2); spinal cord: 5.4 nTPM (limit 2); stomach: 18.1 nTPM (limit 8); thymus: 24 nTPM (limit 10); thyroid gland: 20.4 nTPM (limit 10); tongue: 94.8 nTPM (limit 6); urinary bladder: 25.5 nTPM (limit 6),bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Low (Approved); colon / glandular cells: Low (Approved); duodenum / glandular cells: Low (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); liver / hepatocytes: Low (Approved); lung / macrophages: Low (Approved); oral mucosa / squamous epithelial cells: Low (Approved); rectum / glandular cells: Low (Approved); skeletal muscle / myocytes: High (Approved); skin 2 / epidermal cells: Medium (Approved); smooth muscle / smooth muscle cells: High (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Squamous Cell Carcinoma (TCGA): 489/489 (100.0%); Colon Adenocarcinoma (validation): 486/486 (100.0%); Stomach Adenocarcinoma (TCGA): 346/346 (100.0%),cervical cancer: 3/11 (27.3%); liver cancer: 1/10 (10.0%),31,20,Q9P270,https://www.uniprot.org/uniprotkb/Q9P270/entry,Binds to the plus end of microtubules and regulates microtubule dynamics and microtubule organization. Promotes cytoplasmic microtubule nucleation and elongation. Required for normal structure of the microtubule cytoskeleton during interphase,"Widely expressed with highest levels in adult liver, testis and ovary, and lowest levels in adult pancreas and spleen and in fetal brain",,,"Cytoplasm, cytoskeleton",21646404,10819331,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
SLC10A7,ENSG00000120519,Unsafe,RNA,False,True,11.9,11.9,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 5.3 nTPM; continuous selectivity; adrenal gland: 4.4 nTPM; absolute ceiling;continuous selectivity; bone marrow: 5.9 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 2.5 nTPM; absolute ceiling; colon: 6.7 nTPM; absolute ceiling;continuous selectivity; duodenum: 4.5 nTPM; absolute ceiling;continuous selectivity; esophagus: 5.6 nTPM; continuous selectivity; heart muscle: 2.8 nTPM; absolute ceiling; kidney: 3.6 nTPM; absolute ceiling;continuous selectivity; liver: 7 nTPM; absolute ceiling;continuous selectivity; lung: 5.7 nTPM; absolute ceiling;continuous selectivity; lymph node: 5.4 nTPM; continuous selectivity; midbrain: 2.3 nTPM; absolute ceiling; pancreas: 6.3 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 3.5 nTPM; absolute ceiling;continuous selectivity; rectum: 8.9 nTPM; absolute ceiling;continuous selectivity; retina: 3.8 nTPM; absolute ceiling;continuous selectivity; salivary gland: 6.6 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 2.2 nTPM; absolute ceiling; small intestine: 5.3 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 5.6 nTPM; absolute ceiling;continuous selectivity; spinal cord: 2.8 nTPM; absolute ceiling; stomach: 9.6 nTPM; absolute ceiling;continuous selectivity; thymus: 6.3 nTPM; continuous selectivity; thyroid gland: 6.7 nTPM; continuous selectivity; urinary bladder: 4.5 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 4.4 nTPM (limit 2); bone marrow: 5.9 nTPM (limit 2); cerebral cortex: 2.5 nTPM (limit 2); colon: 6.7 nTPM (limit 6); duodenum: 4.5 nTPM (limit 2); heart muscle: 2.8 nTPM (limit 2); kidney: 3.6 nTPM (limit 2); liver: 7 nTPM (limit 2); lung: 5.7 nTPM (limit 2); midbrain: 2.3 nTPM (limit 2); pancreas: 6.3 nTPM (limit 2); pituitary gland: 3.5 nTPM (limit 2); rectum: 8.9 nTPM (limit 6); retina: 3.8 nTPM (limit 2); salivary gland: 6.6 nTPM (limit 6); skeletal muscle: 2.2 nTPM (limit 2); small intestine: 5.3 nTPM (limit 2); smooth muscle: 5.6 nTPM (limit 2); spinal cord: 2.8 nTPM (limit 2); stomach: 9.6 nTPM (limit 6); adrenal gland: 4.4 nTPM (baseline 2); bone marrow: 5.9 nTPM (baseline 2); cerebral cortex: 2.5 nTPM (baseline 2); colon: 6.7 nTPM (baseline 6); duodenum: 4.5 nTPM (baseline 2); heart muscle: 2.8 nTPM (baseline 2); kidney: 3.6 nTPM (baseline 2); liver: 7 nTPM (baseline 2); lung: 5.7 nTPM (baseline 2); midbrain: 2.3 nTPM (baseline 2); pancreas: 6.3 nTPM (baseline 2); pituitary gland: 3.5 nTPM (baseline 2); rectum: 8.9 nTPM (baseline 6); retina: 3.8 nTPM (baseline 2); salivary gland: 6.6 nTPM (baseline 6); skeletal muscle: 2.2 nTPM (baseline 2); small intestine: 5.3 nTPM (baseline 2); smooth muscle: 5.6 nTPM (baseline 2); spinal cord: 2.8 nTPM (baseline 2); stomach: 9.6 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 485/486 (99.8%),liver cancer: 9/12 (75.0%); pancreatic cancer: 4/10 (40.0%),31,20,Q0GE19,https://www.uniprot.org/uniprotkb/Q0GE19/entry,"Involved in teeth and skeletal development. Has an essential role in the biosynthesis and trafficking of glycosaminoglycans and glycoproteins, to produce a proper functioning extracellular matrix. Required for extracellular matrix mineralization (PubMed:29878199, PubMed:30082715). Also involved in the regulation of cellular calcium homeostasis (PubMed:30082715, PubMed:31191616). Does not show transport activity towards bile acids or steroid sulfates (including taurocholate, cholate, chenodeoxycholate, estrone-3-sulfate, dehydroepiandrosterone sulfate (DHEAS) and pregnenolone sulfate)","Widely expressed (PubMed:15932064, PubMed:17628207). Expressed at high levels in liver and at lower levels in prostate, placenta, kidney, heart, lung, thymus and spleen (PubMed:15932064, PubMed:17628207). Strongly expressed in testis and also detected in brain, ovary, colon and small intestine (PubMed:17628207). Weakly expressed in testis and not detected in brain, ovary, colon or small intestine (PubMed:15932064). Isoform 1: Expressed in liver, testis and placenta (PubMed:17628207). Isoform 4: Expressed in liver, testis and placenta (PubMed:17628207)","Short stature, amelogenesis imperfecta, and skeletal dysplasia with scoliosis: An autosomal recessive disorder characterized by disproportionate short stature, defective tooth enamel formation, and skeletal dysplasia with severe scoliosis in some patients. Variable features include facial dysmorphism, hearing impairment, and mildly impaired intellectual development.",,Cell membrane Endoplasmic reticulum membrane Golgi apparatus membrane,17628207|29878199|30082715|31191616,15932064|17628207,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
SLC12A6,ENSG00000140199,Unsafe,Protein,False,True,25.1,30.1,79,43,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 3.9 nTPM; positive ihc;absolute ceiling; amygdala: 6 nTPM; absolute ceiling; basal ganglia: 6.9 nTPM; absolute ceiling;continuous selectivity; bone marrow: 26.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 7.7 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 8.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 2.3 nTPM; absolute ceiling; colon: 5.3 nTPM; positive ihc; duodenum: 7.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 18.3 nTPM; absolute ceiling;continuous selectivity; heart muscle: 7.1 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 6.5 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 6.5 nTPM; absolute ceiling;continuous selectivity; kidney: 15.3 nTPM; absolute ceiling;continuous selectivity; liver: 3.8 nTPM; absolute ceiling; lung: 8.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 9.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 7 nTPM; absolute ceiling;continuous selectivity; pancreas: 3.4 nTPM; positive ihc;absolute ceiling; pituitary gland: 5.5 nTPM; absolute ceiling; rectum: 5.9 nTPM; positive ihc; retina: 30.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 6.2 nTPM; positive ihc;absolute ceiling; skeletal muscle: 10.2 nTPM; absolute ceiling;continuous selectivity; small intestine: 8.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 4.7 nTPM; absolute ceiling; spinal cord: 8.5 nTPM; absolute ceiling;continuous selectivity; spleen: 12.5 nTPM; absolute ceiling;continuous selectivity; stomach: 6.5 nTPM; positive ihc;absolute ceiling; thymus: 15.1 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 8.7 nTPM; positive ihc; tongue: 10.5 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 8 nTPM; positive ihc;absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 3.9 nTPM (limit 2); amygdala: 6 nTPM (limit 2); basal ganglia: 6.9 nTPM (limit 2); bone marrow: 26.5 nTPM (limit 2); cerebellum: 7.7 nTPM (limit 2); cerebral cortex: 8.1 nTPM (limit 2); choroid plexus: 2.3 nTPM (limit 2); duodenum: 7.1 nTPM (limit 2); esophagus: 18.3 nTPM (limit 6); heart muscle: 7.1 nTPM (limit 2); hippocampal formation: 6.5 nTPM (limit 2); hypothalamus: 6.5 nTPM (limit 2); kidney: 15.3 nTPM (limit 2); liver: 3.8 nTPM (limit 2); lung: 8.8 nTPM (limit 2); lymph node: 9.8 nTPM (limit 6); midbrain: 7 nTPM (limit 2); pancreas: 3.4 nTPM (limit 2); pituitary gland: 5.5 nTPM (limit 2); retina: 30.1 nTPM (limit 2); salivary gland: 6.2 nTPM (limit 6); skeletal muscle: 10.2 nTPM (limit 2); small intestine: 8.8 nTPM (limit 2); smooth muscle: 4.7 nTPM (limit 2); spinal cord: 8.5 nTPM (limit 2); spleen: 12.5 nTPM (limit 10); stomach: 6.5 nTPM (limit 6); thymus: 15.1 nTPM (limit 10); tongue: 10.5 nTPM (limit 6); urinary bladder: 8 nTPM (limit 6); adrenal gland: 3.9 nTPM (baseline 2); amygdala: 6 nTPM (baseline 2); basal ganglia: 6.9 nTPM (baseline 2); bone marrow: 26.5 nTPM (baseline 2); cerebellum: 7.7 nTPM (baseline 2); cerebral cortex: 8.1 nTPM (baseline 2); choroid plexus: 2.3 nTPM (baseline 2); duodenum: 7.1 nTPM (baseline 2); esophagus: 18.3 nTPM (baseline 6); heart muscle: 7.1 nTPM (baseline 2); hippocampal formation: 6.5 nTPM (baseline 2); hypothalamus: 6.5 nTPM (baseline 2); kidney: 15.3 nTPM (baseline 2); liver: 3.8 nTPM (baseline 2); lung: 8.8 nTPM (baseline 2); lymph node: 9.8 nTPM (baseline 6); midbrain: 7 nTPM (baseline 2); pancreas: 3.4 nTPM (baseline 2); pituitary gland: 5.5 nTPM (baseline 2); retina: 30.1 nTPM (baseline 2); salivary gland: 6.2 nTPM (baseline 6); skeletal muscle: 10.2 nTPM (baseline 2); small intestine: 8.8 nTPM (baseline 2); smooth muscle: 4.7 nTPM (baseline 2); spinal cord: 8.5 nTPM (baseline 2); spleen: 12.5 nTPM (baseline 10); stomach: 6.5 nTPM (baseline 6); thymus: 15.1 nTPM (baseline 10); tongue: 10.5 nTPM (baseline 6); urinary bladder: 8 nTPM (baseline 6),adrenal gland / glandular cells: High (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / neuronal cells: Low (Uncertain); cerebral cortex / glial cells: Low (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: Low (Uncertain); duodenum / glandular cells: Medium (Uncertain); lung / macrophages: Low (Uncertain); lymph node / germinal center cells: Low (Uncertain); lymph node / non-germinal center cells: Medium (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: High (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Medium (Uncertain); small intestine / glandular cells: Low (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 485/486 (99.8%),prostate cancer: 12/12 (100.0%); testis cancer: 8/11 (72.7%),31,20,Q9UHW9,https://www.uniprot.org/uniprotkb/Q9UHW9/entry,"Mediates electroneutral potassium-chloride cotransport when activated by cell swelling (PubMed:10600773, PubMed:11551954, PubMed:16048901, PubMed:18566107, PubMed:19665974, PubMed:21628467, PubMed:27485015). May contribute to cell volume homeostasis in single cells (PubMed:16048901, PubMed:27485015) Mediates electroneutral potassium-chloride cotransport when activated by cell swelling (PubMed:16048901, PubMed:33199848, PubMed:34031912). May contribute to cell volume homeostasis in single cells (Probable) Mediates electroneutral potassium-chloride cotransport when activated by cell swelling (PubMed:16048901). May contribute to cell volume homeostasis in single cells (Probable)","Expressed in brain (at protein level) (PubMed:21628467). Highly expressed in heart, brain and kidney. Detected at lower levels in skeletal muscle, placenta, lung and pancreas (PubMed:10600773). Detected in umbilical vein endothelial cells (PubMed:16048901) More abundant in kidney Testis specific","Agenesis of the corpus callosum, with peripheral neuropathy: A disease that is characterized by severe progressive sensorimotor neuropathy, intellectual disability, dysmorphic features and complete or partial agenesis of the corpus callosum. Charcot-Marie-Tooth disease, axonal, type 2II: A dominant axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy.",,Cell membrane Basolateral cell membrane,10600773|11551954|16048901|18566107|19665974|21628467|27485015|33199848|34031912,10600773|16048901|21628467,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
SLC16A7,ENSG00000118596,Unsafe,Protein,False,True,3.9,33.2,80,35,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 19.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; adrenal gland: 6.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 4.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 2.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 1.1 nTPM; continuous selectivity; colon: 2 nTPM; positive ihc;continuous selectivity; duodenum: 1.5 nTPM; positive ihc;continuous selectivity; esophagus: 6.2 nTPM; continuous selectivity;reproductive not higher; heart muscle: 33.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 11.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 3.8 nTPM; continuous selectivity; lung: 4.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 4.8 nTPM; continuous selectivity;reproductive not higher; pancreas: 9.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 1 nTPM; positive ihc; pituitary gland: 1.4 nTPM; continuous selectivity; rectum: 2.4 nTPM; positive ihc;continuous selectivity; retina: 1.7 nTPM; continuous selectivity; salivary gland: 2.7 nTPM; positive ihc;continuous selectivity; skeletal muscle: 1.8 nTPM; positive ihc;continuous selectivity; skin: 7.6 nTPM; continuous selectivity;reproductive not higher; small intestine: 2.4 nTPM; continuous selectivity; smooth muscle: 3.4 nTPM; continuous selectivity; spinal cord: 1.6 nTPM; continuous selectivity; spleen: 6.1 nTPM; continuous selectivity;reproductive not higher; stomach: 9.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; thymus: 4.4 nTPM; continuous selectivity;reproductive not higher; tongue: 3.4 nTPM; continuous selectivity; urinary bladder: 3.8 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 19.3 nTPM (limit 10); adrenal gland: 6.6 nTPM (limit 2); bone marrow: 4.6 nTPM (limit 2); cerebellum: 2.4 nTPM (limit 2); cerebral cortex: 2.7 nTPM (limit 2); heart muscle: 33.2 nTPM (limit 4); kidney: 11.2 nTPM (limit 2); lung: 4.3 nTPM (limit 2); pancreas: 9.4 nTPM (limit 2); stomach: 9.7 nTPM (limit 6),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Low (Approved); duodenum / glandular cells: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Low (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Low (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Low (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Low (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Chromophobe (TCGA): 62/64 (96.9%); Pancreatic Adenocarcinoma (validation): 74/80 (92.5%); Glioblastoma Multiforme (validation): 46/58 (79.3%),breast cancer: 4/10 (40.0%); colorectal cancer: 4/10 (40.0%),31,20,O60669,https://www.uniprot.org/uniprotkb/O60669/entry,"Proton-coupled monocarboxylate symporter. Catalyzes the rapid transport across the plasma membrane of monocarboxylates such as L-lactate, pyruvate and ketone bodies, acetoacetate, beta-hydroxybutyrate and acetate (PubMed:32415067, PubMed:9786900). Dimerization is functionally required and both subunits work cooperatively in transporting substrate (PubMed:32415067)","Detected in heart and in blood lymphocytes and monocytes (at protein level) (PubMed:15505343). High expression in testis, moderate to low in spleen, heart, kidney, pancreas, skeletal muscle, brain and leukocyte (PubMed:9786900). Restricted expression in normal tissues, but widely expressed in cancer cells",,,Cell membrane Basolateral cell membrane Cytoplasm,32415067|9786900,15505343|9786900,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
SLC1A6,ENSG00000105143,Unsafe,Protein,False,True,27.2,117.1,118,22,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 7.7 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 21.8 nTPM; absolute ceiling;continuous selectivity; cerebellum: 117.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 11.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 0.2 nTPM; positive ihc; hippocampal formation: 12 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 10.1 nTPM; absolute ceiling;continuous selectivity; lung: 0.2 nTPM; positive ihc; midbrain: 3.2 nTPM; absolute ceiling; retina: 2.2 nTPM; absolute ceiling; skeletal muscle: 0.3 nTPM; positive ihc; skin: 8.3 nTPM; positive ihc; spinal cord: 3.3 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 7.7 nTPM (limit 2); basal ganglia: 21.8 nTPM (limit 2); cerebellum: 117.1 nTPM (limit 2); cerebral cortex: 11.5 nTPM (limit 2); hippocampal formation: 12 nTPM (limit 2); hypothalamus: 10.1 nTPM (limit 2); midbrain: 3.2 nTPM (limit 2); retina: 2.2 nTPM (limit 2); spinal cord: 3.3 nTPM (limit 2),caudate / neuronal cells: Medium (Enhanced); cerebellum / Purkinje cells - cytoplasm/membrane: Medium (Enhanced); cerebellum / Purkinje cells - dendrites: High (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); colon / peripheral nerve/ganglion: Low (Enhanced); lung / macrophages: Low (Enhanced); skeletal muscle / myocytes: Low (Enhanced); skin 1 / endothelial cells: High (Enhanced); skin 1 / fibrohistiocytic cells: High (Enhanced); skin 2 / cells in basal layer: Low (Enhanced); skin 2 / cells in spinous layer: Low (Enhanced); skin 2 / endothelial cells: Medium (Enhanced); skin 2 / fibrohistiocytic cells: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Bladder Urothelial Carcinoma (TCGA): 69/169 (40.8%); Lung Squamous Cell Carcinoma (TCGA): 96/489 (19.6%); Lung Squamous Cell Carcinoma (validation): 12/68 (17.6%),ovarian cancer: 6/12 (50.0%); urothelial cancer: 3/12 (25.0%),31,20,P48664,https://www.uniprot.org/uniprotkb/P48664/entry,"Sodium-dependent, high-affinity amino acid transporter that mediates the uptake of L-glutamate and also L-aspartate and D-aspartate (PubMed:26690923, PubMed:7791878). Functions as a symporter that transports one amino acid molecule together with two or three Na(+) ions and one proton, in parallel with the counter-transport of one K(+) ion. Mediates Cl(-) flux that is not coupled to amino acid transport; this avoids the accumulation of negative charges due to aspartate and Na(+) symport (PubMed:7791878). Plays a redundant role in the rapid removal of released glutamate from the synaptic cleft, which is essential for terminating the postsynaptic action of glutamate (Probable)","Brain, mainly in the cerebellum (PubMed:7791878). Expressed densely and selectively in cell bodies of Purkinje cells",,,Cell membrane,26690923|7791878,7791878,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Jamin2021_CT | Jamin2021_core | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
SLC22A16,ENSG00000004809,Unsafe,Protein,False,True,20.8,20.8,81,44,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 0 nTPM; positive ihc; bone marrow: 20.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 0 nTPM; positive ihc; cerebral cortex: 0 nTPM; positive ihc; colon: 0 nTPM; positive ihc; duodenum: 0 nTPM; positive ihc; esophagus: 0 nTPM; positive ihc; heart muscle: 0 nTPM; positive ihc; kidney: 0 nTPM; positive ihc; liver: 0.1 nTPM; positive ihc; lung: 0.3 nTPM; positive ihc; lymph node: 0 nTPM; positive ihc; pancreas: 0 nTPM; positive ihc; parathyroid gland: 3.7 nTPM; positive ihc; rectum: 0 nTPM; positive ihc; salivary gland: 0.1 nTPM; positive ihc; skeletal muscle: 0 nTPM; positive ihc; skin: 0.1 nTPM; positive ihc; small intestine: 0 nTPM; positive ihc; spleen: 0.5 nTPM; positive ihc; stomach: 0 nTPM; positive ihc; thyroid gland: 0 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 20.2 nTPM (limit 2); bone marrow: 20.2 nTPM (baseline 2),adrenal gland / glandular cells: Low (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Low (Uncertain); caudate / neuronal cells: Low (Uncertain); cerebellum / cells in granular layer: Medium (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / neuronal cells: Low (Uncertain); colon / glandular cells: Medium (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Low (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / cholangiocytes: Low (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / macrophages: Low (Uncertain); lymph node / non-germinal center cells: Medium (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Low (Uncertain); skeletal muscle / myocytes: Low (Uncertain); skin 2 / epidermal cells: Low (Uncertain); small intestine / glandular cells: Medium (Uncertain); spleen / cells in red pulp: Low (Uncertain); spleen / cells in white pulp: Low (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Low (Uncertain); thyroid gland / glandular cells: Low (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 29/176 (16.5%); Ovary Serous Cystadenocarcinoma (TCGA): 8/349 (2.3%); Breast Invasive Carcinoma (validation): 1/50 (2.0%),stomach cancer: 6/9 (66.7%); endometrial cancer: 6/11 (54.5%),31,20,Q86VW1,https://www.uniprot.org/uniprotkb/Q86VW1/entry,"Facilitative organic cation transporter that mediates the transport of carnitine as well as the polyamine spermidine (PubMed:12089149, PubMed:20037140). Mediates the partially Na(+)-dependent bidirectional transport of carnitine (PubMed:12089149). May mediate L-carnitine secretion from testis epididymal epithelium into the lumen which is involved in the maturation of spermatozoa (PubMed:12089149)","Expressed in testis and epididymis (at protein level) (PubMed:12089149, PubMed:12384147, PubMed:15963465). Expressed in endometrium (at protein level); highly expressed during the normal secretory phase, but expression is significantly reduced in the proliferative phase (PubMed:17197897). Expressed at lower levels in adult tissues including bone marrow (at protein level) (PubMed:12372408, PubMed:12384147, PubMed:15963465). Expressed in hematopoietic cells, including CD34(+) leukocytes (PubMed:12384147). Expressed in fetal liver (at protein level), brain, lung, kidney, heart, skeletal muscle, spleen and thymus (PubMed:12372408, PubMed:12384147, PubMed:15963465). Expressed in leukemia cells (PubMed:12384147). Abundantly expressed in ovarian cancer clear-cell adenocarcinoma (PubMed:17581421)",,,Cell membrane,12089149|20037140,12089149|12372408|12384147|15963465|17197897|17581421,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
SLC24A4,ENSG00000140090,Unsafe,RNA,False,True,1.0,44.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 2.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 3.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 3.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 0.5 nTPM; continuous selectivity; cerebral cortex: 4.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 44.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 1.8 nTPM; continuous selectivity;reproductive not higher; hypothalamus: 2.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 0.7 nTPM; continuous selectivity; lymph node: 1.1 nTPM; continuous selectivity;reproductive not higher; midbrain: 5.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 1.3 nTPM; continuous selectivity;reproductive not higher; retina: 12 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 0.8 nTPM; continuous selectivity; smooth muscle: 0.4 nTPM; continuous selectivity; spinal cord: 2.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 2.6 nTPM; continuous selectivity;reproductive not higher; tongue: 1 nTPM; continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 2.9 nTPM (limit 2); basal ganglia: 3.9 nTPM (limit 2); bone marrow: 3.5 nTPM (limit 2); cerebral cortex: 4.7 nTPM (limit 2); choroid plexus: 44.8 nTPM (limit 2); hypothalamus: 2.1 nTPM (limit 2); midbrain: 5.1 nTPM (limit 2); retina: 12 nTPM (limit 2); spinal cord: 2.3 nTPM (limit 2); amygdala: 2.9 nTPM (baseline 2); basal ganglia: 3.9 nTPM (baseline 2); bone marrow: 3.5 nTPM (baseline 2); cerebral cortex: 4.7 nTPM (baseline 2); choroid plexus: 44.8 nTPM (baseline 2); hypothalamus: 2.1 nTPM (baseline 2); midbrain: 5.1 nTPM (baseline 2); retina: 12 nTPM (baseline 2); spinal cord: 2.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 16/58 (27.6%); Skin Cuteneous Melanoma (TCGA): 10/99 (10.1%); Glioblastoma Multiforme (TCGA): 6/141 (4.3%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NFF2,https://www.uniprot.org/uniprotkb/Q8NFF2/entry,"Calcium, potassium:sodium antiporter that transports 1 Ca(2+) and 1 K(+) in exchange for 4 Na(+) (PubMed:12379639, PubMed:26631410). Controls the rapid response termination and proper regulation of adaptation in olfactory sensory neurons (OSNs) which subsequently influences how odor information is encoded and perceived (By similarity). May play a role in calcium transport during amelogenesis (PubMed:23375655, PubMed:24621671)","Expressed abundantly in all regions of the brain, aorta, lung and thymus (PubMed:12379639). Expressed at lower levels in the stomach and intestine (PubMed:12379639)","Amelogenesis imperfecta, hypomaturation type, 2A5: A defect of enamel formation. The disorder involves both primary and secondary dentitions. The teeth have a shiny agar jelly appearance and the enamel is softer than normal. Brown pigment is present in middle layers of enamel.",It is uncertain whether Met-1 or Met-18 is the initiator,Cell membrane Cytoplasm,12379639|23375655|24621671|26631410,12379639,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
SLC25A31,ENSG00000151475,Unsafe,Protein,False,True,45.9,45.9,81,17,Positive somewhere,True,False,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; colon: 0 nTPM; positive ihc; duodenum: 0 nTPM; positive ihc; heart muscle: 0 nTPM; positive ihc; kidney: 0 nTPM; positive ihc; pancreas: 0 nTPM; positive ihc; parathyroid gland: 0 nTPM; positive ihc; rectum: 0 nTPM; positive ihc; salivary gland: 0 nTPM; positive ihc; skin: 0 nTPM; positive ihc; small intestine: 0 nTPM; positive ihc; stomach: 0 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,bronchus / respiratory epithelial cells: Low (Uncertain); colon / glandular cells: Low (Uncertain); duodenum / glandular cells: Medium (Uncertain); heart muscle / cardiomyocytes: Low (Uncertain); kidney / cells in tubules: Medium (Uncertain); nasopharynx / respiratory epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Low (Uncertain); parathyroid gland / glandular cells: Low (Uncertain); rectum / glandular cells: Low (Uncertain); salivary gland / glandular cells: Low (Uncertain); skin 1 / keratinocytes: Low (Uncertain); skin 2 / epidermal cells: Low (Uncertain); small intestine / glandular cells: Medium (Uncertain); stomach 1 / glandular cells: Low (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 5/133 (3.8%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),glioma: 2/12 (16.7%); melanoma: 1/10 (10.0%),31,20,Q9H0C2,https://www.uniprot.org/uniprotkb/Q9H0C2/entry,"ADP:ATP antiporter that mediates import of ADP into the mitochondrial matrix for ATP synthesis, and export of ATP out to fuel the cell (By similarity) (PubMed:15670820). Cycles between the cytoplasmic-open state (c-state) and the matrix-open state (m-state): operates by the alternating access mechanism with a single substrate-binding site intermittently exposed to either the cytosolic (c-state) or matrix (m-state) side of the inner mitochondrial membrane (By similarity). Specifically required during spermatogenesis, probably to mediate ADP:ATP exchange in spermatocytes (PubMed:17137571). Large ATP supplies from mitochondria may be critical for normal progression of spermatogenesis during early stages of meiotic prophase I, including DNA double-strand break repair and chromosomal synapsis (By similarity). In addition to its ADP:ATP antiporter activity, also involved in mitochondrial uncoupling and mitochondrial permeability transition pore (mPTP) activity (By similarity). Plays a role in mitochondrial uncoupling by acting as a proton transporter: proton transport uncouples the proton flows via the electron transport chain and ATP synthase to reduce the efficiency of ATP production and cause mitochondrial thermogenesis (By similarity). Proton transporter activity is inhibited by ADP:ATP antiporter activity, suggesting that SLC25A31/ANT4 acts as a master regulator of mitochondrial energy output by maintaining a delicate balance between ATP production (ADP:ATP antiporter activity) and thermogenesis (proton transporter activity) (By similarity). Proton transporter activity requires free fatty acids as cofactor, but does not transport it (By similarity). Among nucleotides, may also exchange ADP for dATP and dADP (PubMed:15670820). Also plays a key role in mPTP opening, a non-specific pore that enables free passage of the mitochondrial membranes to solutes of up to 1.5 kDa, and which contributes to cell death (By similarity). It is however unclear if SLC25A31/ANT4 constitutes a pore-forming component of mPTP or regulates it (By similarity)","Expressed in brain, liver, sperm and testis (PubMed:15670820, PubMed:17137571). In testis, expressed at higher level in spermatocytes, while it is expressed at lower level in spermatogonial cells (PubMed:17681941). Expressed in erythrocytes (at protein level) (PubMed:27641616)",,,"Mitochondrion inner membrane Membrane Cell projection, cilium, flagellum membrane",15670820|17137571,15670820|17137571|17681941|27641616,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
SLC27A6,ENSG00000113396,Unsafe,Protein,False,True,20.6,23.6,87,31,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 23.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 0.1 nTPM; positive ihc; cerebral cortex: 1 nTPM; positive ihc; esophagus: 4.1 nTPM; positive ihc; heart muscle: 22.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 2.5 nTPM; absolute ceiling; parathyroid gland: 0 nTPM; positive ihc; pituitary gland: 5.9 nTPM; absolute ceiling;continuous selectivity; retina: 7.2 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 0.4 nTPM; positive ihc; smooth muscle: 0.8 nTPM; positive ihc; spinal cord: 5.4 nTPM; absolute ceiling;continuous selectivity; thymus: 9.4 nTPM; continuous selectivity; thyroid gland: 1.7 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 23.6 nTPM (limit 2); heart muscle: 22.7 nTPM (limit 2); hypothalamus: 2.5 nTPM (limit 2); pituitary gland: 5.9 nTPM (limit 2); retina: 7.2 nTPM (limit 2); spinal cord: 5.4 nTPM (limit 2),adrenal gland / glandular cells: High (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); cerebral cortex / neuropil: Low (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: High (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Low (Approved); parathyroid gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Medium (Approved); smooth muscle / smooth muscle cells: Low (Approved); thyroid gland / glandular cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Thyroid Carcinoma (TCGA): 355/495 (71.7%); Breast Invasive Carcinoma (validation): 25/50 (50.0%); Ovary Serous Cystadenocarcinoma (validation): 26/81 (32.1%),liver cancer: 3/11 (27.3%); glioma: 2/12 (16.7%),31,20,Q9Y2P4,https://www.uniprot.org/uniprotkb/Q9Y2P4/entry,Mediates the import of long-chain fatty acids (LCFA) into the cell by facilitating their transport at the plasma membrane (PubMed:12556534). Also functions as an acyl-CoA ligase catalyzing the ATP-dependent formation of fatty acyl-CoA using LCFA and very-long-chain fatty acids (VLCFA) as substrates (By similarity). Plays a pivotal role in regulating available LCFA substrates from exogenous sources in tissues undergoing high levels of beta-oxidation such as the heart (PubMed:12556534),"Strongly expressed in heart and localizes to cardiac myocytes (PubMed:12556534). Expressed at moderate levels in placenta, testis, and adrenal glands. Expressed at very low levels in kidney, bladder and uterus",,,"Cell membrane, sarcolemma Cell membrane",12556534,12556534,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
SLC2A14,ENSG00000173262,Unsafe,Protein,False,True,79.4,79.4,78,6,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 5.5 nTPM; absolute ceiling; bone marrow: 6.2 nTPM; positive ihc;absolute ceiling; pancreas: 6.4 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 5.5 nTPM (limit 2); bone marrow: 6.2 nTPM (limit 2); pancreas: 6.4 nTPM (limit 6),bone marrow / hematopoietic cells: Low (Supported),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 108/133 (81.2%); Liver Hepatocellular Carcinoma (TCGA): 49/362 (13.5%); Kidney Renal Clear Cell Carcinoma (TCGA): 54/521 (10.4%),testis cancer: 6/12 (50.0%); ovarian cancer: 2/12 (16.7%),31,20,Q8TDB8,https://www.uniprot.org/uniprotkb/Q8TDB8/entry,Hexose transporter that can mediate the transport of glucose and dehydroascorbate across the cell membrane,"Mainly expressed in testis (PubMed:12504846, PubMed:27460888). Also expressed in small intestine, liver and kidney (PubMed:27460888)",,,Cell membrane,28971850,12504846|27460888,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | Loriot2025_S2 | Gong2021_reproductive_PC,GC RNA nomination across cancer types; no antigen validation asserted | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
SLC30A3,ENSG00000115194,Unsafe,Protein,False,True,66.8,66.8,88,6,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 15.9 nTPM; absolute ceiling; cerebral cortex: 28.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 11.5 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 15.9 nTPM (limit 2); cerebral cortex: 28.8 nTPM (limit 2); hippocampal formation: 11.5 nTPM (limit 2),cerebral cortex / neuronal cells: Low (Enhanced); cerebral cortex / neuropil: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Thyroid Carcinoma (TCGA): 82/495 (16.6%); Testicular Germ Cell Tumor (TCGA): 12/133 (9.0%); Liver Hepatocellular Carcinoma (validation): 19/231 (8.2%),breast cancer: 0/11 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q99726,https://www.uniprot.org/uniprotkb/Q99726/entry,Probable proton-coupled zinc ion antiporter mediating the import of zinc from cytoplasm into synaptic vesicles and participating to cellular zinc ion homeostasis in the brain,,,,"Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane Synapse, synaptosome Late endosome membrane Lysosome membrane",17349999|19521526|26647834,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
SLC35A1,ENSG00000164414,Unsafe,RNA,False,True,35.5,46.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 15.8 nTPM; absolute ceiling;continuous selectivity; adrenal gland: 23.2 nTPM; absolute ceiling;continuous selectivity; amygdala: 17.4 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 18.9 nTPM; absolute ceiling;continuous selectivity; bone marrow: 11.1 nTPM; absolute ceiling;continuous selectivity; cerebellum: 30.8 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 21.4 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 34.8 nTPM; absolute ceiling;continuous selectivity; colon: 38.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 18.2 nTPM; absolute ceiling;continuous selectivity; esophagus: 13.5 nTPM; absolute ceiling;continuous selectivity; heart muscle: 15.5 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 20 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 18.1 nTPM; absolute ceiling;continuous selectivity; kidney: 20.4 nTPM; absolute ceiling;continuous selectivity; liver: 31.8 nTPM; absolute ceiling;continuous selectivity; lung: 36.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 17.5 nTPM; absolute ceiling;continuous selectivity; midbrain: 14.6 nTPM; absolute ceiling;continuous selectivity; pancreas: 15.3 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 22.9 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 18.4 nTPM; absolute ceiling;continuous selectivity; rectum: 46.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; retina: 14 nTPM; absolute ceiling;continuous selectivity; salivary gland: 30.7 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 13.3 nTPM; absolute ceiling;continuous selectivity; skin: 24.2 nTPM; absolute ceiling;continuous selectivity; small intestine: 20.9 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 21.3 nTPM; absolute ceiling;continuous selectivity; spinal cord: 15.4 nTPM; absolute ceiling;continuous selectivity; spleen: 18.5 nTPM; absolute ceiling;continuous selectivity; stomach: 28.5 nTPM; absolute ceiling;continuous selectivity; thymus: 15.8 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 16.4 nTPM; absolute ceiling;continuous selectivity; tongue: 15 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 20.8 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adipose tissue: 15.8 nTPM (limit 10); adrenal gland: 23.2 nTPM (limit 2); amygdala: 17.4 nTPM (limit 2); basal ganglia: 18.9 nTPM (limit 2); bone marrow: 11.1 nTPM (limit 2); cerebellum: 30.8 nTPM (limit 2); cerebral cortex: 21.4 nTPM (limit 2); choroid plexus: 34.8 nTPM (limit 2); colon: 38.3 nTPM (limit 6); duodenum: 18.2 nTPM (limit 2); esophagus: 13.5 nTPM (limit 6); heart muscle: 15.5 nTPM (limit 2); hippocampal formation: 20 nTPM (limit 2); hypothalamus: 18.1 nTPM (limit 2); kidney: 20.4 nTPM (limit 2); liver: 31.8 nTPM (limit 2); lung: 36.4 nTPM (limit 2); lymph node: 17.5 nTPM (limit 6); midbrain: 14.6 nTPM (limit 2); pancreas: 15.3 nTPM (limit 2); parathyroid gland: 22.9 nTPM (limit 6); pituitary gland: 18.4 nTPM (limit 2); rectum: 46.1 nTPM (limit 6); retina: 14 nTPM (limit 2); salivary gland: 30.7 nTPM (limit 6); skeletal muscle: 13.3 nTPM (limit 2); skin: 24.2 nTPM (limit 10); small intestine: 20.9 nTPM (limit 2); smooth muscle: 21.3 nTPM (limit 2); spinal cord: 15.4 nTPM (limit 2); spleen: 18.5 nTPM (limit 10); stomach: 28.5 nTPM (limit 6); thymus: 15.8 nTPM (limit 10); thyroid gland: 16.4 nTPM (limit 10); tongue: 15 nTPM (limit 6); urinary bladder: 20.8 nTPM (limit 6); adipose tissue: 15.8 nTPM (baseline 10); adrenal gland: 23.2 nTPM (baseline 2); amygdala: 17.4 nTPM (baseline 2); basal ganglia: 18.9 nTPM (baseline 2); bone marrow: 11.1 nTPM (baseline 2); cerebellum: 30.8 nTPM (baseline 2); cerebral cortex: 21.4 nTPM (baseline 2); choroid plexus: 34.8 nTPM (baseline 2); colon: 38.3 nTPM (baseline 6); duodenum: 18.2 nTPM (baseline 2); esophagus: 13.5 nTPM (baseline 6); heart muscle: 15.5 nTPM (baseline 2); hippocampal formation: 20 nTPM (baseline 2); hypothalamus: 18.1 nTPM (baseline 2); kidney: 20.4 nTPM (baseline 2); liver: 31.8 nTPM (baseline 2); lung: 36.4 nTPM (baseline 2); lymph node: 17.5 nTPM (baseline 6); midbrain: 14.6 nTPM (baseline 2); pancreas: 15.3 nTPM (baseline 2); parathyroid gland: 22.9 nTPM (baseline 6); pituitary gland: 18.4 nTPM (baseline 2); rectum: 46.1 nTPM (baseline 6); retina: 14 nTPM (baseline 2); salivary gland: 30.7 nTPM (baseline 6); skeletal muscle: 13.3 nTPM (baseline 2); skin: 24.2 nTPM (baseline 10); small intestine: 20.9 nTPM (baseline 2); smooth muscle: 21.3 nTPM (baseline 2); spinal cord: 15.4 nTPM (baseline 2); spleen: 18.5 nTPM (baseline 10); stomach: 28.5 nTPM (baseline 6); thymus: 15.8 nTPM (baseline 10); thyroid gland: 16.4 nTPM (baseline 10); tongue: 15 nTPM (baseline 6); urinary bladder: 20.8 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Prostate Adenocarcinoma (TCGA): 480/480 (100.0%); Stomach Adenocarcinoma (TCGA): 346/346 (100.0%); Colon Adenocarcinoma (TCGA): 254/254 (100.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P78382,https://www.uniprot.org/uniprotkb/P78382/entry,"Transports CMP-sialic acid from the cytosol into the Golgi apparatus, functioning as an antiporter that exchanges CMP-sialic acid for CMP (PubMed:12682060, PubMed:15576474, PubMed:23873973). Binds both CMP-sialic acid and free CMP, but has higher affinity for free CMP (By similarity). Also able to exchange CMP-sialic acid for AMP and UMP (PubMed:12682060). Also mediates the transport of CDP-ribitol (By similarity)",,"Congenital disorder of glycosylation 2F: CDGs are a family of severe inherited diseases caused by a defect in protein N-glycosylation. They are characterized by under-glycosylated serum proteins. These multisystem disorders present with a wide variety of clinical features, such as disorders of the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.",,Golgi apparatus membrane Golgi apparatus,12682060|15576474|23873973,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
SLC38A9,ENSG00000177058,Unsafe,Protein,False,True,55.8,55.8,74,16,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 4.7 nTPM; positive ihc;absolute ceiling; amygdala: 3.3 nTPM; absolute ceiling; basal ganglia: 3.7 nTPM; absolute ceiling; bone marrow: 7 nTPM; absolute ceiling; cerebellum: 4.8 nTPM; absolute ceiling; cerebral cortex: 4.8 nTPM; absolute ceiling; choroid plexus: 2.9 nTPM; absolute ceiling; colon: 9.1 nTPM; positive ihc;absolute ceiling; duodenum: 7.8 nTPM; positive ihc;absolute ceiling; esophagus: 8.1 nTPM; positive ihc;absolute ceiling; heart muscle: 3.7 nTPM; absolute ceiling; hippocampal formation: 3.8 nTPM; absolute ceiling; hypothalamus: 3.9 nTPM; absolute ceiling; kidney: 7.1 nTPM; absolute ceiling; liver: 16.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 7.7 nTPM; absolute ceiling; lymph node: 10.9 nTPM; absolute ceiling; midbrain: 3.6 nTPM; absolute ceiling; pancreas: 11.8 nTPM; positive ihc;absolute ceiling; parathyroid gland: 10.3 nTPM; absolute ceiling; pituitary gland: 3.2 nTPM; absolute ceiling; rectum: 9.4 nTPM; positive ihc;absolute ceiling; retina: 9.6 nTPM; absolute ceiling; salivary gland: 6.2 nTPM; absolute ceiling; skeletal muscle: 4.2 nTPM; absolute ceiling; skin: 7.4 nTPM; positive ihc; small intestine: 6.4 nTPM; positive ihc;absolute ceiling; smooth muscle: 8.2 nTPM; absolute ceiling; spinal cord: 4 nTPM; absolute ceiling; stomach: 7.9 nTPM; absolute ceiling; urinary bladder: 8.1 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 4.7 nTPM (limit 2); amygdala: 3.3 nTPM (limit 2); basal ganglia: 3.7 nTPM (limit 2); bone marrow: 7 nTPM (limit 2); cerebellum: 4.8 nTPM (limit 2); cerebral cortex: 4.8 nTPM (limit 2); choroid plexus: 2.9 nTPM (limit 2); colon: 9.1 nTPM (limit 6); duodenum: 7.8 nTPM (limit 2); esophagus: 8.1 nTPM (limit 6); heart muscle: 3.7 nTPM (limit 2); hippocampal formation: 3.8 nTPM (limit 2); hypothalamus: 3.9 nTPM (limit 2); kidney: 7.1 nTPM (limit 2); liver: 16.1 nTPM (limit 2); lung: 7.7 nTPM (limit 2); lymph node: 10.9 nTPM (limit 6); midbrain: 3.6 nTPM (limit 2); pancreas: 11.8 nTPM (limit 2); parathyroid gland: 10.3 nTPM (limit 6); pituitary gland: 3.2 nTPM (limit 2); rectum: 9.4 nTPM (limit 6); retina: 9.6 nTPM (limit 2); salivary gland: 6.2 nTPM (limit 6); skeletal muscle: 4.2 nTPM (limit 2); small intestine: 6.4 nTPM (limit 2); smooth muscle: 8.2 nTPM (limit 2); spinal cord: 4 nTPM (limit 2); stomach: 7.9 nTPM (limit 6); urinary bladder: 8.1 nTPM (limit 6); adrenal gland: 4.7 nTPM (baseline 2); amygdala: 3.3 nTPM (baseline 2); basal ganglia: 3.7 nTPM (baseline 2); bone marrow: 7 nTPM (baseline 2); cerebellum: 4.8 nTPM (baseline 2); cerebral cortex: 4.8 nTPM (baseline 2); choroid plexus: 2.9 nTPM (baseline 2); colon: 9.1 nTPM (baseline 6); duodenum: 7.8 nTPM (baseline 2); esophagus: 8.1 nTPM (baseline 6); heart muscle: 3.7 nTPM (baseline 2); hippocampal formation: 3.8 nTPM (baseline 2); hypothalamus: 3.9 nTPM (baseline 2); kidney: 7.1 nTPM (baseline 2); liver: 16.1 nTPM (baseline 2); lung: 7.7 nTPM (baseline 2); lymph node: 10.9 nTPM (baseline 6); midbrain: 3.6 nTPM (baseline 2); pancreas: 11.8 nTPM (baseline 2); parathyroid gland: 10.3 nTPM (baseline 6); pituitary gland: 3.2 nTPM (baseline 2); rectum: 9.4 nTPM (baseline 6); retina: 9.6 nTPM (baseline 2); salivary gland: 6.2 nTPM (baseline 6); skeletal muscle: 4.2 nTPM (baseline 2); small intestine: 6.4 nTPM (baseline 2); smooth muscle: 8.2 nTPM (baseline 2); spinal cord: 4 nTPM (baseline 2); stomach: 7.9 nTPM (baseline 6); urinary bladder: 8.1 nTPM (baseline 6),adrenal gland / glandular cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / neuronal cells: Low (Uncertain); colon / glandular cells: Low (Uncertain); duodenum / glandular cells: High (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); liver / hepatocytes: High (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Low (Uncertain); rectum / glandular cells: Low (Uncertain); skin 2 / epidermal cells: Low (Uncertain); small intestine / glandular cells: High (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%); Pancreatic Adenocarcinoma (validation): 80/80 (100.0%),liver cancer: 8/12 (66.7%); stomach cancer: 5/12 (41.7%),31,20,Q8NBW4,https://www.uniprot.org/uniprotkb/Q8NBW4/entry,"Lysosomal amino acid transporter involved in the activation of mTORC1 in response to amino acid levels (PubMed:25561175, PubMed:25567906, PubMed:29053970). Probably acts as an amino acid sensor of the Rag GTPases and Ragulator complexes, 2 complexes involved in amino acid sensing and activation of mTORC1, a signaling complex promoting cell growth in response to growth factors, energy levels, and amino acids (PubMed:25567906, PubMed:29053970). Following activation by amino acids, the Ragulator and Rag GTPases function as a scaffold recruiting mTORC1 to lysosomes where it is in turn activated (PubMed:25561175, PubMed:25567906). SLC38A9 mediates transport of amino acids with low capacity and specificity with a slight preference for polar amino acids (PubMed:25561175, PubMed:25567906). Acts as an arginine sensor (PubMed:25567906, PubMed:29053970, PubMed:31295473). Following activation by arginine binding, mediates transport of L-glutamine, leucine and tyrosine with high efficiency, and is required for the efficient utilization of these amino acids after lysosomal protein degradation (PubMed:29053970, PubMed:31295473). However, the transport mechanism is not well defined and the role of sodium is not clear (PubMed:25561175, PubMed:31295473). Can disassemble the lysosomal folliculin complex (LFC), and thereby triggers GAP activity of FLCN:FNIP2 toward RRAGC (PubMed:32868926). Acts as an cholesterol sensor that conveys increases in lysosomal cholesterol, leading to lysosomal recruitment and activation of mTORC1 via the Rag GTPases (PubMed:28336668). Guanine exchange factor (GEF) that, upon arginine binding, stimulates GDP release from RRAGA and therefore activates the Rag GTPase heterodimer and the mTORC1 pathway in response to nutrient sufficiency (PubMed:30181260)",,,,Lysosome membrane Late endosome membrane,25561175|25567906|28336668|29053970|30181260|31295473|32868926,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bradley2020_CPA | Bruggeman2018_GC,Expression-nominated CPA; not newly validated by this study | GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
SLC44A5,ENSG00000137968,Unsafe,RNA,False,True,5.4,10.4,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 2 nTPM; continuous selectivity; cerebral cortex: 3.2 nTPM; absolute ceiling;continuous selectivity; colon: 2 nTPM; continuous selectivity; esophagus: 6.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 2.4 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 2.3 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 2.4 nTPM; absolute ceiling;continuous selectivity; kidney: 1.9 nTPM; continuous selectivity; midbrain: 1.9 nTPM; continuous selectivity; pancreas: 1.7 nTPM; continuous selectivity; parathyroid gland: 3.6 nTPM; continuous selectivity; pituitary gland: 3.1 nTPM; absolute ceiling;continuous selectivity; rectum: 2.7 nTPM; continuous selectivity; retina: 2.4 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 1.5 nTPM; continuous selectivity; skin: 10.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thymus: 2.5 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebral cortex: 3.2 nTPM (limit 2); esophagus: 6.4 nTPM (limit 6); heart muscle: 2.4 nTPM (limit 2); hippocampal formation: 2.3 nTPM (limit 2); hypothalamus: 2.4 nTPM (limit 2); pituitary gland: 3.1 nTPM (limit 2); retina: 2.4 nTPM (limit 2); skin: 10.4 nTPM (limit 10); cerebral cortex: 3.2 nTPM (baseline 2); esophagus: 6.4 nTPM (baseline 6); heart muscle: 2.4 nTPM (baseline 2); hippocampal formation: 2.3 nTPM (baseline 2); hypothalamus: 2.4 nTPM (baseline 2); pituitary gland: 3.1 nTPM (baseline 2); retina: 2.4 nTPM (baseline 2); skin: 10.4 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 41/58 (70.7%); Lung Squamous Cell Carcinoma (validation): 45/68 (66.2%); Lung Adenocarcinoma (validation): 62/105 (59.0%),urothelial cancer: 3/10 (30.0%); lung cancer: 2/11 (18.2%),31,20,Q8NCS7,https://www.uniprot.org/uniprotkb/Q8NCS7/entry,Choline/H+ antiporter,,,,Cell membrane,23651124|40972734,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
SLC4A5,ENSG00000188687,Unsafe,Protein,False,True,15.4,42.7,79,32,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; cerebellum: 3.3 nTPM; positive ihc;absolute ceiling; choroid plexus: 42.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 1.1 nTPM; positive ihc; duodenum: 0.7 nTPM; positive ihc; esophagus: 0.9 nTPM; positive ihc; kidney: 0.9 nTPM; positive ihc; lung: 2.5 nTPM; absolute ceiling; pancreas: 1.5 nTPM; positive ihc; parathyroid gland: 11.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 2.3 nTPM; absolute ceiling; rectum: 0.7 nTPM; positive ihc; retina: 40.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 1.6 nTPM; positive ihc; small intestine: 1 nTPM; positive ihc; stomach: 0.9 nTPM; positive ihc; thyroid gland: 25.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",cerebellum: 3.3 nTPM (limit 2); choroid plexus: 42.7 nTPM (limit 2); lung: 2.5 nTPM (limit 2); parathyroid gland: 11.8 nTPM (limit 6); pituitary gland: 2.3 nTPM (limit 2); retina: 40.6 nTPM (limit 2); thyroid gland: 25.9 nTPM (limit 10); cerebellum: 3.3 nTPM (baseline 2); choroid plexus: 42.7 nTPM (baseline 2); lung: 2.5 nTPM (baseline 2); parathyroid gland: 11.8 nTPM (baseline 6); pituitary gland: 2.3 nTPM (baseline 2); retina: 40.6 nTPM (baseline 2); thyroid gland: 25.9 nTPM (baseline 10),bronchus / respiratory epithelial cells: Low (Uncertain); cerebellum / Purkinje cells: Low (Uncertain); colon / glandular cells: Medium (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Low (Uncertain); kidney / cells in tubules: Medium (Uncertain); nasopharynx / respiratory epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Low (Uncertain); pancreas / pancreatic endocrine cells: Low (Uncertain); parathyroid gland / glandular cells: Low (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Low (Uncertain); small intestine / glandular cells: Medium (Uncertain); stomach 1 / glandular cells: Low (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 47/50 (94.0%); Thyroid Carcinoma (TCGA): 444/495 (89.7%); Kidney Chromophobe (TCGA): 46/64 (71.9%),breast cancer: 9/11 (81.8%); prostate cancer: 9/12 (75.0%),31,20,Q9BY07,https://www.uniprot.org/uniprotkb/Q9BY07/entry,"Mediates sodium- and bicarbonate-dependent electrogenic sodium bicarbonate cotransport, with a Na(+):HCO3(-) stoichiometry varying from 1:2 to 1:3","Highest expression observed in liver, spleen and testis; moderate expression in the choroid plexus, hippocampus, cerebrum and cerebellum of brain, and in kidney cortex and kidney medulla. Also observed in heart, pancreas, muscle, lung, placenta, stomach and small intestine. Weakest expression seen in peripheral blood lymphocytes, colon, duodenum, jejunum, ileum and skeletal muscle Expressed in the brain, heart, kidney, testis, pancreas, muscle and peripheral blood leukocytes",,,Apical cell membrane Basolateral cell membrane,26447209,10978526|11087115|11788353|17715183|26447209,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
SLC52A3,ENSG00000101276,Unsafe,Protein,False,True,39.3,39.3,87,39,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; amygdala: 4.5 nTPM; absolute ceiling; basal ganglia: 5.4 nTPM; absolute ceiling; cerebellum: 2.2 nTPM; positive ihc;absolute ceiling; cerebral cortex: 4.9 nTPM; positive ihc;absolute ceiling; colon: 11.1 nTPM; absolute ceiling; duodenum: 13.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 5 nTPM; positive ihc; heart muscle: 5.9 nTPM; absolute ceiling; hippocampal formation: 5.2 nTPM; absolute ceiling; hypothalamus: 5 nTPM; absolute ceiling; kidney: 10.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 6.4 nTPM; absolute ceiling; rectum: 6.9 nTPM; positive ihc;absolute ceiling; salivary gland: 5.9 nTPM; positive ihc; small intestine: 18.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 5.4 nTPM; absolute ceiling; stomach: 5.4 nTPM; positive ihc; thyroid gland: 0.6 nTPM; positive ihc; urinary bladder: 4.7 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 4.5 nTPM (limit 2); basal ganglia: 5.4 nTPM (limit 2); cerebellum: 2.2 nTPM (limit 2); cerebral cortex: 4.9 nTPM (limit 2); colon: 11.1 nTPM (limit 8); duodenum: 13.9 nTPM (limit 2); heart muscle: 5.9 nTPM (limit 4); hippocampal formation: 5.2 nTPM (limit 2); hypothalamus: 5 nTPM (limit 2); kidney: 10.2 nTPM (limit 2); midbrain: 6.4 nTPM (limit 2); rectum: 6.9 nTPM (limit 6); small intestine: 18.6 nTPM (limit 2); spinal cord: 5.4 nTPM (limit 2),caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Low (Approved); kidney / cells in tubules: Medium (Approved); oral mucosa / squamous epithelial cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); small intestine / glandular cells: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Colon Adenocarcinoma (validation): 485/486 (99.8%); Rectum Adenocarcinoma (TCGA): 86/88 (97.7%),colorectal cancer: 8/12 (66.7%); melanoma: 5/11 (45.5%),29,20,Q9NQ40,https://www.uniprot.org/uniprotkb/Q9NQ40/entry,"Plasma membrane transporter mediating the uptake by cells of the water soluble vitamin B2/riboflavin that plays a key role in biochemical oxidation-reduction reactions of the carbohydrate, lipid, and amino acid metabolism (PubMed:20463145, PubMed:22273710, PubMed:24264046, PubMed:27702554). Humans are unable to synthesize vitamin B2/riboflavin and must obtain it via intestinal absorption (PubMed:20463145)",Predominantly expressed in testis. Highly expressed in small intestine and prostate,"Brown-Vialetto-Van Laere syndrome 1: A rare neurologic disorder characterized by sensorineural hearing loss and a variety of cranial nerve palsies, which develop over a relatively short period of time in a previously healthy individual. Sensorineural hearing loss may precede the neurological signs. The course is invariably progressive, but the rate of decline is variable within and between families. With disease evolution, long tract signs, lower motor neuron signs, cerebellar ataxia and lower cranial nerve (III-VI) palsies develop, giving rise to a complex picture resembling amyotrophic lateral sclerosis. Diaphragmatic weakness and respiratory compromise are some of the most distressing features, leading to recurrent chest infections and respiratory failure, which are often the cause of patients' demise. Fazio-Londe disease: A rare neurological disease characterized by progressive weakness of the muscles innervated by cranial nerves of the lower brain stem. It may present in childhood with severe neurological deterioration with hypotonia, respiratory insufficiency leading to premature death, or later in life with bulbar weakness which progresses to involve motor neurons throughout the neuroaxis. Clinical manifestations include dysarthria, dysphagia, facial weakness, tongue weakness, and fasciculations of the tongue and facial muscles.",It is uncertain whether Met-1 or Met-5 is the initiator,Apical cell membrane Cell membrane Nucleus membrane Cytoplasm,20463145|22273710|24264046|27702554,20463145,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
SLC6A16,ENSG00000063127,Unsafe,RNA,False,True,91.4,91.4,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 3.8 nTPM; absolute ceiling; choroid plexus: 15.5 nTPM; absolute ceiling; heart muscle: 2.4 nTPM; absolute ceiling; kidney: 8.3 nTPM; absolute ceiling; liver: 9.7 nTPM; absolute ceiling; lung: 4.8 nTPM; absolute ceiling; lymph node: 6.7 nTPM; absolute ceiling; pancreas: 6.7 nTPM; absolute ceiling; retina: 4.8 nTPM; absolute ceiling; small intestine: 3.6 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 3.8 nTPM (limit 2); choroid plexus: 15.5 nTPM (limit 2); heart muscle: 2.4 nTPM (limit 2); kidney: 8.3 nTPM (limit 2); liver: 9.7 nTPM (limit 2); lung: 4.8 nTPM (limit 2); lymph node: 6.7 nTPM (limit 6); pancreas: 6.7 nTPM (limit 2); retina: 4.8 nTPM (limit 2); small intestine: 3.6 nTPM (limit 2); bone marrow: 3.8 nTPM (baseline 2); choroid plexus: 15.5 nTPM (baseline 2); heart muscle: 2.4 nTPM (baseline 2); kidney: 8.3 nTPM (baseline 2); liver: 9.7 nTPM (baseline 2); lung: 4.8 nTPM (baseline 2); lymph node: 6.7 nTPM (baseline 6); pancreas: 6.7 nTPM (baseline 2); retina: 4.8 nTPM (baseline 2); small intestine: 3.6 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Chromophobe (TCGA): 22/64 (34.4%); Kidney Renal Papillary Cell Carcinoma (TCGA): 92/282 (32.6%); Liver Hepatocellular Carcinoma (validation): 71/231 (30.7%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9GZN6,https://www.uniprot.org/uniprotkb/Q9GZN6/entry,,"Highly expressed in peripheral tissues, particularly in testis, pancreas, and prostate",,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
SLC6A2,ENSG00000103546,Unsafe,Protein,False,True,6.6,10.1,110,12,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 10.1 nTPM; continuous selectivity;reproductive not higher; cerebellum: 0 nTPM; positive ihc; cerebral cortex: 0 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,cerebellum / processes in granular layer: High (Enhanced); cerebellum / processes in molecular layer: High (Enhanced); cerebellum / processes in white matter: High (Enhanced); cerebral cortex / neuronal projections: High (Enhanced); cerebral cortex / neuropil: Medium (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Chromophobe (TCGA): 19/64 (29.7%); Head and Neck Squamous Cell Carcinoma (TCGA): 130/492 (26.4%); Bladder Urothelial Carcinoma (TCGA): 28/169 (16.6%),colorectal cancer: 3/10 (30.0%); breast cancer: 1/11 (9.1%),31,20,P23975,https://www.uniprot.org/uniprotkb/P23975/entry,"Mediates sodium- and chloride-dependent transport of norepinephrine (also known as noradrenaline), the primary signaling neurotransmitter in the autonomic sympathetic nervous system (PubMed:2008212, PubMed:8125921, PubMed:38750358). Is responsible for norepinephrine re-uptake and clearance from the synaptic cleft, thus playing a crucial role in norepinephrine inactivation and homeostasis (By similarity). Can also mediate sodium- and chloride-dependent transport of dopamine (PubMed:11093780, PubMed:8125921, PubMed:39395208, PubMed:39048818)",,"Orthostatic intolerance: An autosomal dominant disorder characterized by lightheadedness, palpitations, fatigue, blurred vision and tachycardia following postural change from a supine to an upright position, in the absence of hypotension. A syncope with transient cognitive impairment and dyspnea may also occur. Plasma norepinephrine concentration is abnormally high.",,"Cell membrane Cell projection, axon Synapse, synaptosome",11093780|2008212|38750358|39048818|8125921,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT | Gong2021_reproductive_PC,No tumor-antigen validation in this source | Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
SLC9B1,ENSG00000164037,Unsafe,High RNA,False,True,39.2,39.2,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE CD4_NAIVE (unstimulated): 5/88 values ≥5 TPM, max 5.89642; DICE TREG_NAIVE (unstimulated): 4/89 values ≥5 TPM, max 5.39882; hpa_immune_monaco naive CD4 T-cell: 5.1 TPM; hpa_immune_monaco naive CD8 T-cell: 5.5 TPM; hpa_immune_monaco Progenitor cell: 5.1 TPM",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,5.896422966599999,38.8,"hpa_single_cell: /Oligodendrocytes, max 37.7 nTPM, 1 observations >30; hpa_single_cell_tissue: brain/oligodendrocytes, max 38.8 nTPM, 2 observations >30",CTA,oncoref.target-sets.2026-10-23.2,5.896 TPM; blood/CD4_NAIVE; dice_cd4_naive; vital,38.8 nTPM; brain/oligodendrocytes; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 25/58 (43.1%); Kidney Chromophobe (TCGA): 2/64 (3.1%); Skin Cuteneous Melanoma (TCGA): 3/99 (3.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q4ZJI4,https://www.uniprot.org/uniprotkb/Q4ZJI4/entry,Sperm-specific Na(+)/H(+) exchanger involved in intracellular pH regulation of spermatozoa. Involved in sperm motility and fertility,Expressed only in the testis,,,"Cell projection, cilium, flagellum membrane",,16850186,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
SLC9C1,ENSG00000172139,Unsafe,High RNA,False,True,7.8,7.8,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,CTA,Pass,oncoref.target-sets.2026-10-23.1,False,False,,CTA → Unsafe,True,True,True,3.702850828919999,31.6,"hpa_single_cell_tissue: heart muscle/endothelial cells, max 31.6 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,3.703 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,31.6 nTPM; heart muscle/endothelial cells; hpa_single_cell_tissue; vital,Pancreatic Adenocarcinoma (validation): 1/80 (1.2%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 1/283 (0.4%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q4G0N8,https://www.uniprot.org/uniprotkb/Q4G0N8/entry,"Sperm-specific solute carrier involved in intracellular pH regulation of spermatozoa. Required for sperm motility and fertility. Involved in sperm cell hyperactivation, a step needed for sperm motility which is essential late in the preparation of sperm for fertilization. Required for the expression and bicarbonate regulation of the soluble adenylyl cyclase (ADCY10)",Sperm,,"The transport mechanisms that drive proton efflux in sperm appear to be species-specific. While sea urchin SLC9C1 ortholog functions as a voltage-gated and cAMP-sensitive sodium:proton exchanger that dominantly regulates proton efflux in sperm, no such transporter activity is observed for human SLC9C1. Consistently, functionally conserved residues in the transport, voltage sensor and cyclic nucleotide-binding domains present in sea urchin SLC9C1 are missing in mammalian SLC9C1, suggesting alternative transport mechanisms between species. The transport activity of SLC9C1 remains to be elucidated","Cell projection, cilium, flagellum membrane",,37669933,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,All audited maxima are within 10% above 30; other gates still require review,,,,
SLC9C2,ENSG00000162753,Unsafe,Protein,False,True,5.8,5.8,94,5,Positive somewhere,True,False,False,True,Excluded,Normal,False,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 0 nTPM; positive ihc; parathyroid gland: 0 nTPM; positive ihc; smooth muscle: 0 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,adrenal gland / glandular cells: Low (Enhanced); parathyroid gland / glandular cells: Low (Enhanced); smooth muscle / smooth muscle cells: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 10/58 (17.2%); Ovary Serous Cystadenocarcinoma (validation): 5/81 (6.2%); Pancreatic Adenocarcinoma (validation): 2/80 (2.5%),melanoma: 1/10 (10.0%); breast cancer: 1/11 (9.1%),29,20,Q5TAH2,https://www.uniprot.org/uniprotkb/Q5TAH2/entry,Involved in pH regulation,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
SLCO4C1,ENSG00000173930,Unsafe,RNA,False,True,3.5,40.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 8.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 2.1 nTPM; absolute ceiling;continuous selectivity; kidney: 40.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; liver: 7.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 7.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 1.9 nTPM; continuous selectivity; small intestine: 1.5 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 8.5 nTPM (limit 2); duodenum: 2.1 nTPM (limit 2); kidney: 40.1 nTPM (limit 2); liver: 7.3 nTPM (limit 2); lung: 7.6 nTPM (limit 2); bone marrow: 8.5 nTPM (baseline 2); duodenum: 2.1 nTPM (baseline 2); kidney: 40.1 nTPM (baseline 2); liver: 7.3 nTPM (baseline 2); lung: 7.6 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Renal Clear Cell Carcinoma (validation): 95/100 (95.0%); Kidney Renal Papillary Cell Carcinoma (TCGA): 258/282 (91.5%); Kidney Renal Clear Cell Carcinoma (TCGA): 457/521 (87.7%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q6ZQN7,https://www.uniprot.org/uniprotkb/Q6ZQN7/entry,"Mediates the transport of organic anions such as steroids (estrone 3-sulfate, chenodeoxycholate, glycocholate) and thyroid hormones (3,3',5-triiodo-L-thyronine (T3), L-thyroxine (T4)), in the kidney (PubMed:14993604, PubMed:19129463, PubMed:20610891). Capable of transporting cAMP and pharmacological substances such as digoxin, ouabain and methotrexate (PubMed:14993604). Transport is independent of sodium, chloride ion, and ATP (PubMed:14993604). Transport activity is stimulated by an acidic extracellular environment due to increased substrate affinity to the transporter (PubMed:19129463). The driving force for this transport activity is currently not known (By similarity). The role of hydrogencarbonate (HCO3(-), bicarbonate) as the probable counteranion that exchanges for organic anions is still not well defined (PubMed:19129463). Functions as an uptake transporter at the apical membrane, suggesting a role in renal reabsorption (By similarity). Involved in the renal secretion of the uremic toxin ADMA (N(omega),N(omega)-dimethyl-L-arginine or asymmetrical dimethylarginine), which is associated to cardiovascular events and mortality, and the structurally related amino acids L-arginine and L-homoarginine (a cardioprotective biomarker) (PubMed:30865704). Can act bidirectionally, suggesting a dual protective role of this transport protein; exporting L-homoarginine after being synthesized in proximal tubule cells, and mediating uptake of ADMA from the blood into proximal tubule cells where it is degraded by the enzyme dimethylarginine dimethylaminohydrolase 1 (DDAH1) (PubMed:30865704, PubMed:32642843). May be involved in sperm maturation by enabling directed movement of organic anions and compounds within or between cells (By similarity). This ion-transporting process is important to maintain the strict epididymal homeostasis necessary for sperm maturation (By similarity). May have a role in secretory functions since seminal vesicle epithelial cells are assumed to secrete proteins involved in decapacitation by modifying surface proteins to facilitate the acquisition of the ability to fertilize the egg (By similarity)",Predominantly expressed in kidney but also weakly expressed in both fetal liver and kidney,,,Basolateral cell membrane,14993604|19129463|20610891|30865704|32642843,14993604,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
SLIT1,ENSG00000187122,Unsafe,RNA,False,True,1.7,33.9,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 18.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 23 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 1 nTPM; continuous selectivity; cerebral cortex: 33.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 20 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 14.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 5.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 13.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; retina: 0.7 nTPM; continuous selectivity; spinal cord: 2 nTPM; continuous selectivity;reproductive not higher; thymus: 2.3 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 2.4 nTPM; continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 18.9 nTPM (limit 2); basal ganglia: 23 nTPM (limit 2); cerebral cortex: 33.9 nTPM (limit 2); hippocampal formation: 20 nTPM (limit 2); hypothalamus: 14.3 nTPM (limit 2); midbrain: 5.5 nTPM (limit 2); pituitary gland: 13.1 nTPM (limit 2); amygdala: 18.9 nTPM (baseline 2); basal ganglia: 23 nTPM (baseline 2); cerebral cortex: 33.9 nTPM (baseline 2); hippocampal formation: 20 nTPM (baseline 2); hypothalamus: 14.3 nTPM (baseline 2); midbrain: 5.5 nTPM (baseline 2); pituitary gland: 13.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 106/141 (75.2%); Thyroid Carcinoma (TCGA): 262/495 (52.9%); Prostate Adenocarcinoma (TCGA): 103/480 (21.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O75093,https://www.uniprot.org/uniprotkb/O75093/entry,"Thought to act as molecular guidance cue in cellular migration, and function appears to be mediated by interaction with roundabout homolog receptors. During neural development involved in axonal navigation at the ventral midline of the neural tube and projection of axons to different regions (By similarity). SLIT1 and SLIT2 together seem to be essential for midline guidance in the forebrain by acting as repulsive signal preventing inappropriate midline crossing by axons projecting from the olfactory bulb","Predominantly expressed in adult forebrain. Expressed in fetal brain, lung and kidney",,,Secreted,,9813312,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
SLX4IP,ENSG00000149346,Unsafe,Protein,False,True,4.6,5.2,80,67,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 1.9 nTPM; positive ihc;continuous selectivity; amygdala: 1.9 nTPM; continuous selectivity; basal ganglia: 2.7 nTPM; absolute ceiling;continuous selectivity; bone marrow: 1.7 nTPM; positive ihc;continuous selectivity; cerebellum: 1.6 nTPM; positive ihc;continuous selectivity; cerebral cortex: 1.9 nTPM; positive ihc;continuous selectivity; choroid plexus: 1.4 nTPM; continuous selectivity; colon: 2 nTPM; positive ihc;continuous selectivity; duodenum: 1.8 nTPM; positive ihc;continuous selectivity; esophagus: 2.6 nTPM; positive ihc;continuous selectivity; heart muscle: 1.3 nTPM; positive ihc;continuous selectivity; hippocampal formation: 2 nTPM; continuous selectivity; hypothalamus: 2.5 nTPM; absolute ceiling;continuous selectivity; kidney: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 3.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 1.4 nTPM; positive ihc;continuous selectivity; lymph node: 2.1 nTPM; positive ihc;continuous selectivity; midbrain: 2.2 nTPM; absolute ceiling;continuous selectivity; pancreas: 2.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 3.2 nTPM; positive ihc;continuous selectivity; pituitary gland: 4.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 2.2 nTPM; positive ihc;continuous selectivity; retina: 5.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 1.8 nTPM; positive ihc;continuous selectivity; skeletal muscle: 4 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 3.6 nTPM; positive ihc;continuous selectivity; small intestine: 2 nTPM; positive ihc;continuous selectivity; smooth muscle: 1 nTPM; positive ihc; spinal cord: 2.6 nTPM; absolute ceiling;continuous selectivity; stomach: 2.2 nTPM; positive ihc;continuous selectivity; thymus: 2.5 nTPM; continuous selectivity; thyroid gland: 2.6 nTPM; positive ihc;continuous selectivity; urinary bladder: 1.6 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",basal ganglia: 2.7 nTPM (limit 2); hypothalamus: 2.5 nTPM (limit 2); kidney: 2.7 nTPM (limit 2); liver: 3.1 nTPM (limit 2); midbrain: 2.2 nTPM (limit 2); pancreas: 2.8 nTPM (limit 2); pituitary gland: 4.6 nTPM (limit 2); retina: 5.2 nTPM (limit 2); skeletal muscle: 4 nTPM (limit 2); spinal cord: 2.6 nTPM (limit 2),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: High (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: High (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: High (Approved); colon / peripheral nerve/ganglion: High (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: High (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: High (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: High (Approved); oral mucosa / squamous epithelial cells: High (Approved); pancreas / exocrine glandular cells: High (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 472/486 (97.1%); Rectum Adenocarcinoma (validation): 199/207 (96.1%),colorectal cancer: 11/11 (100.0%); liver cancer: 11/11 (100.0%),29,20,Q5VYV7,https://www.uniprot.org/uniprotkb/Q5VYV7/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
SMCP,ENSG00000163206,Unsafe,High RNA,False,True,727.3,727.3,86,3,Positive somewhere,False,False,False,True,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,CTA,Pass,oncoref.target-sets.2026-10-23.1,False,False,,CTA → Unsafe,True,True,True,0.0,45.3,"hpa_single_cell_tissue: testis/macrophages, max 45.3 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,0 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,45.3 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 6/133 (4.5%); Head and Neck Squamous Cell Carcinoma (TCGA): 17/492 (3.5%); Glioblastoma Multiforme (validation): 2/58 (3.4%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),31,20,P49901,https://www.uniprot.org/uniprotkb/P49901/entry,Involved in sperm motility. Its absence is associated with genetic background dependent male infertility. Infertility may be due to reduced sperm motility in the female reproductive tract and inability to penetrate the oocyte zona pellucida (By similarity),Testis. Is selectively expressed in the spermatids of seminiferous tubules,,Was originally thought to be a selenoprotein and was known as sperm mitochondrial capsule selenoprotein,Cytoplasm Mitochondrion membrane,,8833144,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
SMIM36,ENSG00000261873,Unsafe,RNA,False,True,2.7,10.5,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,existing nomination or manual review; nomination unresolved; retina: 10.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 10.5 nTPM (limit 2); retina: 10.5 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 4/176 (2.3%); Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 2/283 (0.7%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,A0A1B0GVT2,https://www.uniprot.org/uniprotkb/A0A1B0GVT2/entry,,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
SMKR1,ENSG00000240204,Unsafe,RNA,False,True,120.1,120.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 5 nTPM; absolute ceiling; basal ganglia: 10 nTPM; absolute ceiling; cerebral cortex: 6.6 nTPM; absolute ceiling; hippocampal formation: 4.9 nTPM; absolute ceiling; hypothalamus: 4.7 nTPM; absolute ceiling; midbrain: 2.2 nTPM; absolute ceiling; pancreas: 2.2 nTPM; absolute ceiling; parathyroid gland: 6.2 nTPM; absolute ceiling; pituitary gland: 5.9 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 5 nTPM (limit 2); basal ganglia: 10 nTPM (limit 2); cerebral cortex: 6.6 nTPM (limit 2); hippocampal formation: 4.9 nTPM (limit 2); hypothalamus: 4.7 nTPM (limit 2); midbrain: 2.2 nTPM (limit 2); pancreas: 2.2 nTPM (limit 2); parathyroid gland: 6.2 nTPM (limit 6); pituitary gland: 5.9 nTPM (limit 2); amygdala: 5 nTPM (baseline 2); basal ganglia: 10 nTPM (baseline 2); cerebral cortex: 6.6 nTPM (baseline 2); hippocampal formation: 4.9 nTPM (baseline 2); hypothalamus: 4.7 nTPM (baseline 2); midbrain: 2.2 nTPM (baseline 2); pancreas: 2.2 nTPM (baseline 2); parathyroid gland: 6.2 nTPM (baseline 6); pituitary gland: 5.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Ovary Serous Cystadenocarcinoma (validation): 57/81 (70.4%); Ovary Serous Cystadenocarcinoma (TCGA): 234/349 (67.0%); Glioblastoma Multiforme (validation): 37/58 (63.8%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,H3BMG3,https://www.uniprot.org/uniprotkb/H3BMG3/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Chang2019_TGCT | Gong2021_reproductive_PC,Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
SNAP91,ENSG00000065609,Unsafe,Protein,False,True,11.8,110.6,99,16,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 7.6 nTPM; continuous selectivity; amygdala: 40.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 30.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 110.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 89.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 10 nTPM; absolute ceiling;continuous selectivity; colon: 1.2 nTPM; positive ihc; hippocampal formation: 43.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 46.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 29.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 25.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; retina: 89 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 18.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 40.7 nTPM (limit 2); basal ganglia: 30.1 nTPM (limit 2); cerebellum: 110.6 nTPM (limit 2); cerebral cortex: 89.2 nTPM (limit 2); choroid plexus: 10 nTPM (limit 2); hippocampal formation: 43.5 nTPM (limit 2); hypothalamus: 46.3 nTPM (limit 2); midbrain: 29.8 nTPM (limit 2); pituitary gland: 25.1 nTPM (limit 2); retina: 89 nTPM (limit 2); spinal cord: 18.5 nTPM (limit 2),caudate / glial cells: Low (Enhanced); caudate / neuronal cells: Medium (Enhanced); cerebellum / granular cells - cytoplasm/membrane: Medium (Enhanced); cerebellum / molecular layer - neuropil: High (Enhanced); cerebellum / processes in granular layer: High (Enhanced); cerebellum / Purkinje cells - cytoplasm/membrane: Low (Enhanced); cerebellum / synaptic glomeruli - core: High (Enhanced); cerebral cortex / glial cells: Low (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); cerebral cortex / neuropil: High (Enhanced); colon / peripheral nerve/ganglion: High (Enhanced); hippocampus / glial cells: Low (Enhanced); hippocampus / neuronal cells: High (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 35/58 (60.3%); Glioblastoma Multiforme (TCGA): 63/141 (44.7%); Prostate Adenocarcinoma (TCGA): 193/480 (40.2%),renal cancer: 4/11 (36.4%); glioma: 2/9 (22.2%),31,20,O60641,https://www.uniprot.org/uniprotkb/O60641/entry,"Adaptins are components of the adapter complexes which link clathrin to receptors in coated vesicles. Clathrin-associated protein complexes are believed to interact with the cytoplasmic tails of membrane proteins, leading to their selection and concentration. Binding of AP180 to clathrin triskelia induces their assembly into 60-70 nm coats (By similarity)",,,,"Cell membrane Membrane, coated pit",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
SNAPC3,ENSG00000164975,Unsafe,RNA,False,True,7.9,11.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 4.6 nTPM; continuous selectivity; adrenal gland: 7.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 6.3 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 6 nTPM; absolute ceiling;continuous selectivity; cerebellum: 10.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 6.8 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 6.1 nTPM; absolute ceiling;continuous selectivity; colon: 5.6 nTPM; continuous selectivity; duodenum: 3.9 nTPM; absolute ceiling;continuous selectivity; esophagus: 6.9 nTPM; absolute ceiling;continuous selectivity; heart muscle: 11.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 6.6 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 5.6 nTPM; absolute ceiling;continuous selectivity; kidney: 4.5 nTPM; absolute ceiling;continuous selectivity; liver: 3.7 nTPM; absolute ceiling;continuous selectivity; lung: 4.2 nTPM; absolute ceiling;continuous selectivity; lymph node: 3.2 nTPM; continuous selectivity; midbrain: 6 nTPM; absolute ceiling;continuous selectivity; pancreas: 5.1 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 6.3 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 5 nTPM; absolute ceiling;continuous selectivity; rectum: 4.2 nTPM; continuous selectivity; retina: 6.1 nTPM; absolute ceiling;continuous selectivity; salivary gland: 4.4 nTPM; continuous selectivity; skeletal muscle: 9.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 3.9 nTPM; continuous selectivity; small intestine: 4.7 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 6.2 nTPM; absolute ceiling;continuous selectivity; spinal cord: 6.1 nTPM; absolute ceiling;continuous selectivity; spleen: 4 nTPM; continuous selectivity; stomach: 4.6 nTPM; continuous selectivity; thymus: 4 nTPM; continuous selectivity; thyroid gland: 4.3 nTPM; continuous selectivity; tongue: 11.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 4.9 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 7.9 nTPM (limit 2); amygdala: 6.3 nTPM (limit 2); basal ganglia: 6 nTPM (limit 2); cerebellum: 10.2 nTPM (limit 2); cerebral cortex: 6.8 nTPM (limit 2); choroid plexus: 6.1 nTPM (limit 2); duodenum: 3.9 nTPM (limit 2); esophagus: 6.9 nTPM (limit 6); heart muscle: 11.6 nTPM (limit 2); hippocampal formation: 6.6 nTPM (limit 2); hypothalamus: 5.6 nTPM (limit 2); kidney: 4.5 nTPM (limit 2); liver: 3.7 nTPM (limit 2); lung: 4.2 nTPM (limit 2); midbrain: 6 nTPM (limit 2); pancreas: 5.1 nTPM (limit 2); parathyroid gland: 6.3 nTPM (limit 6); pituitary gland: 5 nTPM (limit 2); retina: 6.1 nTPM (limit 2); skeletal muscle: 9.3 nTPM (limit 2); small intestine: 4.7 nTPM (limit 2); smooth muscle: 6.2 nTPM (limit 2); spinal cord: 6.1 nTPM (limit 2); tongue: 11.4 nTPM (limit 6); adrenal gland: 7.9 nTPM (baseline 2); amygdala: 6.3 nTPM (baseline 2); basal ganglia: 6 nTPM (baseline 2); cerebellum: 10.2 nTPM (baseline 2); cerebral cortex: 6.8 nTPM (baseline 2); choroid plexus: 6.1 nTPM (baseline 2); duodenum: 3.9 nTPM (baseline 2); esophagus: 6.9 nTPM (baseline 6); heart muscle: 11.6 nTPM (baseline 2); hippocampal formation: 6.6 nTPM (baseline 2); hypothalamus: 5.6 nTPM (baseline 2); kidney: 4.5 nTPM (baseline 2); liver: 3.7 nTPM (baseline 2); lung: 4.2 nTPM (baseline 2); midbrain: 6 nTPM (baseline 2); pancreas: 5.1 nTPM (baseline 2); parathyroid gland: 6.3 nTPM (baseline 6); pituitary gland: 5 nTPM (baseline 2); retina: 6.1 nTPM (baseline 2); skeletal muscle: 9.3 nTPM (baseline 2); small intestine: 4.7 nTPM (baseline 2); smooth muscle: 6.2 nTPM (baseline 2); spinal cord: 6.1 nTPM (baseline 2); tongue: 11.4 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 80/80 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 50/50 (100.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q92966,https://www.uniprot.org/uniprotkb/Q92966/entry,"Part of the SNAPc complex required for the transcription of both RNA polymerase II and III small-nuclear RNA genes. Binds to the proximal sequence element (PSE), a non-TATA-box basal promoter element common to these 2 types of genes. Recruits TBP and BRF2 to the U6 snRNA TATA box",,,,Nucleus,12621023,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
SNAPC5,ENSG00000174446,Unsafe,Protein,False,True,40.1,58.0,80,64,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 21.6 nTPM; absolute ceiling;continuous selectivity; adrenal gland: 25.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 45.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 44.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 14.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 43.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 47.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 43.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 31.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 15.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 15.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 41 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 32.7 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 40.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 32 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 34 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 18.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 23.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 34.5 nTPM; absolute ceiling;continuous selectivity; pancreas: 21.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 31.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 26.6 nTPM; absolute ceiling;continuous selectivity; rectum: 18.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 27.6 nTPM; absolute ceiling;continuous selectivity; salivary gland: 17.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 58 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 14.7 nTPM; positive ihc;absolute ceiling; small intestine: 19.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 19.5 nTPM; absolute ceiling;continuous selectivity; spinal cord: 25.3 nTPM; absolute ceiling;continuous selectivity; spleen: 22.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 22.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 20.7 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 26.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 26.6 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 26.5 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 21.6 nTPM (limit 10); adrenal gland: 25.2 nTPM (limit 2); amygdala: 45.6 nTPM (limit 2); basal ganglia: 44.2 nTPM (limit 2); bone marrow: 14.7 nTPM (limit 2); cerebellum: 43.1 nTPM (limit 2); cerebral cortex: 47.2 nTPM (limit 2); choroid plexus: 43.9 nTPM (limit 2); colon: 31.7 nTPM (limit 6); duodenum: 15.2 nTPM (limit 2); esophagus: 15.3 nTPM (limit 6); heart muscle: 41 nTPM (limit 2); hippocampal formation: 32.7 nTPM (limit 2); hypothalamus: 40.4 nTPM (limit 2); kidney: 32 nTPM (limit 2); liver: 34 nTPM (limit 2); lung: 18.8 nTPM (limit 2); lymph node: 23.1 nTPM (limit 6); midbrain: 34.5 nTPM (limit 2); pancreas: 21.7 nTPM (limit 2); parathyroid gland: 31.8 nTPM (limit 6); pituitary gland: 26.6 nTPM (limit 2); rectum: 18.1 nTPM (limit 6); retina: 27.6 nTPM (limit 2); salivary gland: 17.9 nTPM (limit 6); skeletal muscle: 58 nTPM (limit 2); skin: 14.7 nTPM (limit 10); small intestine: 19.2 nTPM (limit 2); smooth muscle: 19.5 nTPM (limit 2); spinal cord: 25.3 nTPM (limit 2); spleen: 22.2 nTPM (limit 10); stomach: 22.5 nTPM (limit 6); thymus: 20.7 nTPM (limit 10); thyroid gland: 26.1 nTPM (limit 10); tongue: 26.6 nTPM (limit 6); urinary bladder: 26.5 nTPM (limit 6); adipose tissue: 21.6 nTPM (baseline 10); adrenal gland: 25.2 nTPM (baseline 2); amygdala: 45.6 nTPM (baseline 2); basal ganglia: 44.2 nTPM (baseline 2); bone marrow: 14.7 nTPM (baseline 2); cerebellum: 43.1 nTPM (baseline 2); cerebral cortex: 47.2 nTPM (baseline 2); choroid plexus: 43.9 nTPM (baseline 2); colon: 31.7 nTPM (baseline 6); duodenum: 15.2 nTPM (baseline 2); esophagus: 15.3 nTPM (baseline 6); heart muscle: 41 nTPM (baseline 2); hippocampal formation: 32.7 nTPM (baseline 2); hypothalamus: 40.4 nTPM (baseline 2); kidney: 32 nTPM (baseline 2); liver: 34 nTPM (baseline 2); lung: 18.8 nTPM (baseline 2); lymph node: 23.1 nTPM (baseline 6); midbrain: 34.5 nTPM (baseline 2); pancreas: 21.7 nTPM (baseline 2); parathyroid gland: 31.8 nTPM (baseline 6); pituitary gland: 26.6 nTPM (baseline 2); rectum: 18.1 nTPM (baseline 6); retina: 27.6 nTPM (baseline 2); salivary gland: 17.9 nTPM (baseline 6); skeletal muscle: 58 nTPM (baseline 2); skin: 14.7 nTPM (baseline 10); small intestine: 19.2 nTPM (baseline 2); smooth muscle: 19.5 nTPM (baseline 2); spinal cord: 25.3 nTPM (baseline 2); spleen: 22.2 nTPM (baseline 10); stomach: 22.5 nTPM (baseline 6); thymus: 20.7 nTPM (baseline 10); thyroid gland: 26.1 nTPM (baseline 10); tongue: 26.6 nTPM (baseline 6); urinary bladder: 26.5 nTPM (baseline 6),adrenal gland / glandular cells: Low (Uncertain); bone marrow / hematopoietic cells: Low (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: Medium (Uncertain); cerebellum / cells in molecular layer: Medium (Uncertain); cerebellum / Purkinje cells: Low (Uncertain); cerebral cortex / glial cells: Low (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: Medium (Uncertain); colon / endothelial cells: Low (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: Medium (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / alveolar cells: Low (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / germinal center cells: Low (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: Low (Uncertain); skin 1 / fibroblasts: Low (Uncertain); skin 1 / keratinocytes: Low (Uncertain); skin 1 / Langerhans: Low (Uncertain); skin 2 / epidermal cells: Low (Uncertain); small intestine / glandular cells: Medium (Uncertain); spleen / cells in white pulp: Low (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Kidney Renal Clear Cell Carcinoma (TCGA): 521/521 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%),prostate cancer: 9/10 (90.0%); melanoma: 9/12 (75.0%),31,20,O75971,https://www.uniprot.org/uniprotkb/O75971/entry,"Part of the SNAPc complex required for the transcription of both RNA polymerase II and III small-nuclear RNA genes. Binds to the proximal sequence element (PSE), a non-TATA-box basal promoter element common to these 2 types of genes. Recruits TBP and BRF2 to the U6 snRNA TATA box",,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
SNN,ENSG00000184602,Unsafe,Protein,False,True,23.5,168.2,87,72,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 55.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; adrenal gland: 28.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 113.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 168.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 24.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 90.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 136.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 14.6 nTPM; absolute ceiling;continuous selectivity; colon: 16.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 8.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 18.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 27.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 111.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 53.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 14 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 9 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 20.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 30.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 108.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 8.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 9.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 15 nTPM; absolute ceiling;continuous selectivity; rectum: 5.6 nTPM; positive ihc; retina: 39.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 17.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 110.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 14.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 14 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 10.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 52 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 33.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; stomach: 13.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 27.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 16.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 35.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 17.8 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 55.4 nTPM (limit 10); adrenal gland: 28.6 nTPM (limit 2); amygdala: 113.5 nTPM (limit 2); basal ganglia: 168.2 nTPM (limit 2); bone marrow: 24.2 nTPM (limit 2); cerebellum: 90.9 nTPM (limit 2); cerebral cortex: 136.5 nTPM (limit 2); choroid plexus: 14.6 nTPM (limit 2); colon: 16.3 nTPM (limit 6); duodenum: 8.8 nTPM (limit 2); esophagus: 18.5 nTPM (limit 6); heart muscle: 27.5 nTPM (limit 2); hippocampal formation: 111.5 nTPM (limit 2); hypothalamus: 53.8 nTPM (limit 2); kidney: 14 nTPM (limit 2); liver: 9 nTPM (limit 2); lung: 20.9 nTPM (limit 2); lymph node: 30.1 nTPM (limit 6); midbrain: 108.7 nTPM (limit 2); pancreas: 8.4 nTPM (limit 2); parathyroid gland: 9.6 nTPM (limit 6); pituitary gland: 15 nTPM (limit 2); retina: 39.3 nTPM (limit 2); salivary gland: 17.8 nTPM (limit 6); skeletal muscle: 110.8 nTPM (limit 2); skin: 14.4 nTPM (limit 10); small intestine: 14 nTPM (limit 2); smooth muscle: 10.2 nTPM (limit 2); spinal cord: 52 nTPM (limit 2); spleen: 33.7 nTPM (limit 10); stomach: 13.6 nTPM (limit 6); thymus: 27.8 nTPM (limit 10); thyroid gland: 16.7 nTPM (limit 10); tongue: 35.5 nTPM (limit 6); urinary bladder: 17.8 nTPM (limit 6),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: High (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: High (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: High (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: High (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Low (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: High (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 141/141 (100.0%); Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%); Kidney Chromophobe (TCGA): 64/64 (100.0%),testis cancer: 12/12 (100.0%); melanoma: 10/10 (100.0%),31,20,O75324,https://www.uniprot.org/uniprotkb/O75324/entry,Plays a role in the toxic effects of organotins (PubMed:15269288). Plays a role in endosomal maturation (PubMed:27015288),,,,Mitochondrion outer membrane,15269288|27015288,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
SNX16,ENSG00000104497,Unsafe,Protein,False,True,14.3,16.2,100,85,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 9.6 nTPM; positive ihc;continuous selectivity; adrenal gland: 5 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 3.8 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 3.5 nTPM; absolute ceiling; bone marrow: 10.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 4.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 5 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 6 nTPM; positive ihc;continuous selectivity; duodenum: 6.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 16.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 7.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 4.2 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 5.7 nTPM; absolute ceiling;continuous selectivity; kidney: 6.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 5.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 6.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 4.9 nTPM; positive ihc;continuous selectivity; midbrain: 6.4 nTPM; absolute ceiling;continuous selectivity; pancreas: 3 nTPM; positive ihc;absolute ceiling; parathyroid gland: 8.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 3.6 nTPM; absolute ceiling; rectum: 6.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 4.7 nTPM; absolute ceiling;continuous selectivity; salivary gland: 5.5 nTPM; positive ihc;continuous selectivity; skeletal muscle: 4.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 10.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 5.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 11.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 6.5 nTPM; absolute ceiling;continuous selectivity; spleen: 11.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 8.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 9.2 nTPM; continuous selectivity; thyroid gland: 8.4 nTPM; positive ihc;continuous selectivity; tongue: 8.9 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 6.8 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 5 nTPM (limit 2); amygdala: 3.8 nTPM (limit 2); basal ganglia: 3.5 nTPM (limit 2); bone marrow: 10.4 nTPM (limit 2); cerebellum: 4.1 nTPM (limit 2); cerebral cortex: 5 nTPM (limit 2); duodenum: 6.2 nTPM (limit 2); esophagus: 16.2 nTPM (limit 6); heart muscle: 7.8 nTPM (limit 2); hippocampal formation: 4.2 nTPM (limit 2); hypothalamus: 5.7 nTPM (limit 2); kidney: 6.4 nTPM (limit 2); liver: 5.3 nTPM (limit 2); lung: 6.5 nTPM (limit 2); midbrain: 6.4 nTPM (limit 2); pancreas: 3 nTPM (limit 2); parathyroid gland: 8.6 nTPM (limit 6); pituitary gland: 3.6 nTPM (limit 2); rectum: 6.3 nTPM (limit 6); retina: 4.7 nTPM (limit 2); skeletal muscle: 4.4 nTPM (limit 2); skin: 10.9 nTPM (limit 10); small intestine: 5.5 nTPM (limit 2); smooth muscle: 11.4 nTPM (limit 2); spinal cord: 6.5 nTPM (limit 2); spleen: 11.7 nTPM (limit 10); stomach: 8.7 nTPM (limit 6); tongue: 8.9 nTPM (limit 6); urinary bladder: 6.8 nTPM (limit 6),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / ciliated cells (cell body): Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Low (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Medium (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / ciliated cells (cell body): Low (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Lung Adenocarcinoma (validation): 103/105 (98.1%),liver cancer: 9/12 (75.0%); cervical cancer: 7/12 (58.3%),31,20,P57768,https://www.uniprot.org/uniprotkb/P57768/entry,May be involved in several stages of intracellular trafficking. Plays a role in protein transport from early to late endosomes. Plays a role in protein transport to the lysosome. Promotes degradation of EGFR after EGF signaling. Plays a role in intracellular transport of vesicular stomatitis virus nucleocapsids from the endosome to the cytoplasm,"Detected in placenta, lung, liver,heart and pancreas",,,Early endosome membrane Late endosome membrane Cytoplasm Lysosome,12813048|15951806,12813048,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
SNX19,ENSG00000120451,Unsafe,Protein,False,True,20.7,24.4,74,31,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 15.4 nTPM; absolute ceiling;continuous selectivity; adrenal gland: 17.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 17.1 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 18.8 nTPM; absolute ceiling;continuous selectivity; bone marrow: 8.6 nTPM; absolute ceiling;continuous selectivity; cerebellum: 13.5 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 16 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 9.8 nTPM; absolute ceiling;continuous selectivity; colon: 21.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 11.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 14.3 nTPM; absolute ceiling;continuous selectivity; heart muscle: 19.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 17.3 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 16.9 nTPM; absolute ceiling;continuous selectivity; kidney: 16.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 18.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 14.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 10.7 nTPM; absolute ceiling;continuous selectivity; midbrain: 20.2 nTPM; absolute ceiling;continuous selectivity; pancreas: 18.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 15.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 16.7 nTPM; absolute ceiling;continuous selectivity; rectum: 13.6 nTPM; absolute ceiling;continuous selectivity; retina: 15 nTPM; absolute ceiling;continuous selectivity; salivary gland: 18.9 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 23 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 12.5 nTPM; absolute ceiling;continuous selectivity; small intestine: 15 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 18.8 nTPM; absolute ceiling;continuous selectivity; spinal cord: 24.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 14.9 nTPM; absolute ceiling;continuous selectivity; stomach: 18.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 10.8 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 20.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; tongue: 12.7 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 18.5 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 15.4 nTPM (limit 10); adrenal gland: 17.9 nTPM (limit 2); amygdala: 17.1 nTPM (limit 2); basal ganglia: 18.8 nTPM (limit 2); bone marrow: 8.6 nTPM (limit 2); cerebellum: 13.5 nTPM (limit 2); cerebral cortex: 16 nTPM (limit 2); choroid plexus: 9.8 nTPM (limit 2); colon: 21.5 nTPM (limit 6); duodenum: 11.4 nTPM (limit 2); esophagus: 14.3 nTPM (limit 6); heart muscle: 19.5 nTPM (limit 2); hippocampal formation: 17.3 nTPM (limit 2); hypothalamus: 16.9 nTPM (limit 2); kidney: 16.1 nTPM (limit 2); liver: 18.8 nTPM (limit 2); lung: 14.2 nTPM (limit 2); lymph node: 10.7 nTPM (limit 6); midbrain: 20.2 nTPM (limit 2); pancreas: 18.9 nTPM (limit 2); parathyroid gland: 15.5 nTPM (limit 6); pituitary gland: 16.7 nTPM (limit 2); rectum: 13.6 nTPM (limit 6); retina: 15 nTPM (limit 2); salivary gland: 18.9 nTPM (limit 6); skeletal muscle: 23 nTPM (limit 2); skin: 12.5 nTPM (limit 10); small intestine: 15 nTPM (limit 2); smooth muscle: 18.8 nTPM (limit 2); spinal cord: 24.4 nTPM (limit 2); spleen: 14.9 nTPM (limit 10); stomach: 18.4 nTPM (limit 6); thymus: 10.8 nTPM (limit 10); thyroid gland: 20.9 nTPM (limit 10); tongue: 12.7 nTPM (limit 6); urinary bladder: 18.5 nTPM (limit 6); adipose tissue: 15.4 nTPM (baseline 10); adrenal gland: 17.9 nTPM (baseline 2); amygdala: 17.1 nTPM (baseline 2); basal ganglia: 18.8 nTPM (baseline 2); bone marrow: 8.6 nTPM (baseline 2); cerebellum: 13.5 nTPM (baseline 2); cerebral cortex: 16 nTPM (baseline 2); choroid plexus: 9.8 nTPM (baseline 2); colon: 21.5 nTPM (baseline 6); duodenum: 11.4 nTPM (baseline 2); esophagus: 14.3 nTPM (baseline 6); heart muscle: 19.5 nTPM (baseline 2); hippocampal formation: 17.3 nTPM (baseline 2); hypothalamus: 16.9 nTPM (baseline 2); kidney: 16.1 nTPM (baseline 2); liver: 18.8 nTPM (baseline 2); lung: 14.2 nTPM (baseline 2); lymph node: 10.7 nTPM (baseline 6); midbrain: 20.2 nTPM (baseline 2); pancreas: 18.9 nTPM (baseline 2); parathyroid gland: 15.5 nTPM (baseline 6); pituitary gland: 16.7 nTPM (baseline 2); rectum: 13.6 nTPM (baseline 6); retina: 15 nTPM (baseline 2); salivary gland: 18.9 nTPM (baseline 6); skeletal muscle: 23 nTPM (baseline 2); skin: 12.5 nTPM (baseline 10); small intestine: 15 nTPM (baseline 2); smooth muscle: 18.8 nTPM (baseline 2); spinal cord: 24.4 nTPM (baseline 2); spleen: 14.9 nTPM (baseline 10); stomach: 18.4 nTPM (baseline 6); thymus: 10.8 nTPM (baseline 10); thyroid gland: 20.9 nTPM (baseline 10); tongue: 12.7 nTPM (baseline 6); urinary bladder: 18.5 nTPM (baseline 6),adrenal gland / glandular cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Low (Uncertain); cerebral cortex / glial cells: Medium (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / peripheral nerve/ganglion: Low (Uncertain); duodenum / glandular cells: Medium (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / glial cells: Medium (Uncertain); hippocampus / neuronal cells: Low (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / macrophages: Low (Uncertain); pancreas / exocrine glandular cells: Low (Uncertain); pancreas / pancreatic endocrine cells: Low (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: Low (Uncertain); small intestine / glandular cells: Medium (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Low (Uncertain); urinary bladder / urothelial cells: Low (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%),endometrial cancer: 9/12 (75.0%); colorectal cancer: 6/11 (54.5%),31,20,Q92543,https://www.uniprot.org/uniprotkb/Q92543/entry,Plays a role in intracellular vesicle trafficking and exocytosis (PubMed:24843546). May play a role in maintaining insulin-containing dense core vesicles in pancreatic beta-cells and in preventing their degradation. May play a role in insulin secretion (PubMed:24843546). Interacts with membranes containing phosphatidylinositol 3-phosphate (PtdIns(3P)) (By similarity),,,,Early endosome membrane Cytoplasmic vesicle membrane,24843546,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
SOHLH1,ENSG00000165643,Unsafe,RNA,False,True,16.4,41.6,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,amygdala: 8.5 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 5 nTPM; absolute ceiling;continuous selectivity; cerebellum: 3.6 nTPM; absolute ceiling; cerebral cortex: 41.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 18.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 2.8 nTPM; absolute ceiling; midbrain: 2.7 nTPM; absolute ceiling; pituitary gland: 3.1 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 8.5 nTPM (limit 2); basal ganglia: 5 nTPM (limit 2); cerebellum: 3.6 nTPM (limit 2); cerebral cortex: 41.6 nTPM (limit 2); hippocampal formation: 18.8 nTPM (limit 2); hypothalamus: 2.8 nTPM (limit 2); midbrain: 2.7 nTPM (limit 2); pituitary gland: 3.1 nTPM (limit 2); amygdala: 8.5 nTPM (baseline 2); basal ganglia: 5 nTPM (baseline 2); cerebellum: 3.6 nTPM (baseline 2); cerebral cortex: 41.6 nTPM (baseline 2); hippocampal formation: 18.8 nTPM (baseline 2); hypothalamus: 2.8 nTPM (baseline 2); midbrain: 2.7 nTPM (baseline 2); pituitary gland: 3.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Squamous Cell Carcinoma (TCGA): 145/489 (29.7%); Head and Neck Squamous Cell Carcinoma (TCGA): 60/492 (12.2%); Lung Squamous Cell Carcinoma (validation): 8/68 (11.8%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q5JUK2,https://www.uniprot.org/uniprotkb/Q5JUK2/entry,"Transcription regulator of both male and female germline differentiation. Suppresses genes involved in spermatogonial stem cells maintenance, and induces genes important for spermatogonial differentiation. Coordinates oocyte differentiation without affecting meiosis I (By similarity)",,"Spermatogenic failure 32: An autosomal dominant infertility disorder caused by spermatogenesis defects that result in non-obstructive azoospermia. Ovarian dysgenesis 5: A disorder characterized by lack of spontaneous pubertal development, primary amenorrhea, uterine hypoplasia, and hypergonadotropic hypogonadism as a result of streak gonads. ODG5 is an autosomal recessive condition.",,Cytoplasm Nucleus,20506135,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
SOS2,ENSG00000100485,Unsafe,Protein,False,True,27.0,61.3,74,63,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 22.9 nTPM; absolute ceiling;continuous selectivity; adrenal gland: 14.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 14.4 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 14.7 nTPM; absolute ceiling;continuous selectivity; bone marrow: 39 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 8.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 13.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 5.9 nTPM; absolute ceiling; colon: 16.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 20.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 15.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 20.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 15.2 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 11.7 nTPM; absolute ceiling;continuous selectivity; kidney: 23.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 12.7 nTPM; absolute ceiling;continuous selectivity; lung: 15.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 14 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 16.7 nTPM; absolute ceiling;continuous selectivity; pancreas: 15.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 37.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 8.9 nTPM; absolute ceiling;continuous selectivity; rectum: 16.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 13.3 nTPM; absolute ceiling;continuous selectivity; salivary gland: 14.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 55.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 17.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 23.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 17.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 20.9 nTPM; absolute ceiling;continuous selectivity; spleen: 17.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 13.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 15.9 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 24.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 61.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 14.2 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 22.9 nTPM (limit 20); adrenal gland: 14.4 nTPM (limit 2); amygdala: 14.4 nTPM (limit 2); basal ganglia: 14.7 nTPM (limit 2); bone marrow: 39 nTPM (limit 2); cerebellum: 8.6 nTPM (limit 2); cerebral cortex: 13.6 nTPM (limit 2); choroid plexus: 5.9 nTPM (limit 2); colon: 16.8 nTPM (limit 6); duodenum: 20.8 nTPM (limit 2); esophagus: 15.8 nTPM (limit 6); heart muscle: 20.7 nTPM (limit 2); hippocampal formation: 15.2 nTPM (limit 2); hypothalamus: 11.7 nTPM (limit 2); kidney: 23.6 nTPM (limit 2); liver: 12.7 nTPM (limit 4); lung: 15.2 nTPM (limit 2); lymph node: 14 nTPM (limit 6); midbrain: 16.7 nTPM (limit 2); pancreas: 15.3 nTPM (limit 2); parathyroid gland: 37.9 nTPM (limit 6); pituitary gland: 8.9 nTPM (limit 2); rectum: 16.7 nTPM (limit 6); retina: 13.3 nTPM (limit 2); salivary gland: 14.1 nTPM (limit 6); skeletal muscle: 55.4 nTPM (limit 2); skin: 17.1 nTPM (limit 10); small intestine: 23.7 nTPM (limit 2); smooth muscle: 17.3 nTPM (limit 2); spinal cord: 20.9 nTPM (limit 2); spleen: 17.3 nTPM (limit 10); stomach: 13.3 nTPM (limit 6); thymus: 15.9 nTPM (limit 10); thyroid gland: 24.4 nTPM (limit 10); tongue: 61.3 nTPM (limit 6); urinary bladder: 14.2 nTPM (limit 6),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: High (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: High (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Medium (Approved); hippocampus / neuronal cells: High (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Medium (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: High (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: High (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: High (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: Low (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%); Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%),colorectal cancer: 12/12 (100.0%); melanoma: 12/12 (100.0%),31,20,Q07890,https://www.uniprot.org/uniprotkb/Q07890/entry,"Acts as guanine nucleotide exchange factor (GEF) for RAS proteins. Catalyzes the GDP-to-GTP exchange, resulting in an increase of the active GTP-bound form of HRAS (PubMed:20639119). Acts as a key modulator of PI3K-AKT signaling",,"Noonan syndrome 9: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells.",,,20639119,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
SOX1,ENSG00000182968,Unsafe,RNA,False,True,0.8,5.4,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,amygdala: 4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 3.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 1.8 nTPM; continuous selectivity;reproductive not higher; cerebral cortex: 3.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 2.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 5.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 2 nTPM; continuous selectivity;reproductive not higher; spinal cord: 0.6 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 4 nTPM (limit 2); basal ganglia: 3.9 nTPM (limit 2); cerebral cortex: 3.4 nTPM (limit 2); hippocampal formation: 2.4 nTPM (limit 2); hypothalamus: 5.4 nTPM (limit 2); amygdala: 4 nTPM (baseline 2); basal ganglia: 3.9 nTPM (baseline 2); cerebral cortex: 3.4 nTPM (baseline 2); hippocampal formation: 2.4 nTPM (baseline 2); hypothalamus: 5.4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 18/58 (31.0%); Glioblastoma Multiforme (TCGA): 23/141 (16.3%); Rectum Adenocarcinoma (TCGA): 9/88 (10.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O00570,https://www.uniprot.org/uniprotkb/O00570/entry,Transcriptional activator. May function as a switch in neuronal development. Keeps neural cells undifferentiated by counteracting the activity of proneural proteins and suppresses neuronal differentiation (By similarity),Mainly expressed in the developing central nervous system,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
SOX3,ENSG00000134595,Unsafe,RNA,False,True,8.9,8.9,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,hypothalamus: 3.1 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,hypothalamus: 3.1 nTPM (limit 2); hypothalamus: 3.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 30/141 (21.3%); Glioblastoma Multiforme (validation): 10/58 (17.2%); Breast Invasive Carcinoma (validation): 5/50 (10.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P41225,https://www.uniprot.org/uniprotkb/P41225/entry,Transcription factor required during the formation of the hypothalamo-pituitary axis. May function as a switch in neuronal development. Keeps neural cells undifferentiated by counteracting the activity of proneural proteins and suppresses neuronal differentiation. Required also within the pharyngeal epithelia for craniofacial morphogenesis. Controls a genetic switch in male development. Is necessary for initiating male sex determination by directing the development of supporting cell precursors (pre-Sertoli cells) as Sertoli rather than granulosa cells (By similarity),,"Panhypopituitarism X-linked: Affected individuals have absent infundibulum, anterior pituitary hypoplasia, and ectopic posterior pituitary. Intellectual developmental disorder, X-linked, with isolated growth hormone deficiency: A disorder characterized by the association of variable degrees of intellectual disability with panhypopituitarism, variable combinations of hypothyroidism, delayed pubertal development, and short stature due to growth hormone deficiency. 46,XX sex reversal 3: A condition in which male gonads develop in a genetic female (female to male sex reversal). Hypoparathyroidism, X-linked: An X-linked form of true hypoparathyroidism characterized by neonatal or infantile onset and absence of parathyroid glands. Clinical features are hypocalcemia, hyperphosphatemia, seizures, tetany and cramps.",Was originally termed SOX-9,Nucleus,21183788,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
SOX6,ENSG00000110693,Unsafe,Protein,False,True,13.9,26.5,122,44,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 1.7 nTPM; positive ihc; amygdala: 3.5 nTPM; absolute ceiling; basal ganglia: 3.2 nTPM; absolute ceiling; bone marrow: 26.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 0.7 nTPM; positive ihc; cerebral cortex: 6.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 1.2 nTPM; positive ihc; duodenum: 6.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 2.6 nTPM; absolute ceiling; hypothalamus: 2.5 nTPM; absolute ceiling; kidney: 10.6 nTPM; continuous selectivity; liver: 4.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 0.8 nTPM; positive ihc; lymph node: 0.1 nTPM; positive ihc; midbrain: 2.9 nTPM; absolute ceiling; pancreas: 6.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 2.8 nTPM; absolute ceiling; rectum: 1.2 nTPM; positive ihc; retina: 3 nTPM; absolute ceiling; skeletal muscle: 9 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 5.5 nTPM; positive ihc; small intestine: 10.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 1 nTPM; positive ihc; tongue: 5.7 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 3.5 nTPM (limit 2); basal ganglia: 3.2 nTPM (limit 2); bone marrow: 26.5 nTPM (limit 2); cerebral cortex: 6.1 nTPM (limit 2); duodenum: 6.2 nTPM (limit 2); hippocampal formation: 2.6 nTPM (limit 2); hypothalamus: 2.5 nTPM (limit 2); liver: 4.6 nTPM (limit 2); midbrain: 2.9 nTPM (limit 2); pancreas: 6.6 nTPM (limit 2); pituitary gland: 2.8 nTPM (limit 2); retina: 3 nTPM (limit 2); skeletal muscle: 9 nTPM (limit 2); small intestine: 10.7 nTPM (limit 2),adipose tissue / adipocytes: Medium (Enhanced); bone marrow / hematopoietic cells: Medium (Enhanced); caudate / glial cells: Low (Enhanced); caudate / neuronal cells: Low (Enhanced); cerebellum / cells in granular layer: Low (Enhanced); cerebellum / cells in molecular layer: Low (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); cerebral cortex / neuropil: Medium (Enhanced); colon / mucosal lymphoid cells: Medium (Enhanced); duodenum / endocrine cells: Low (Enhanced); hippocampus / glial cells: Low (Enhanced); hippocampus / neuronal cells: Low (Enhanced); liver / cholangiocytes: Low (Enhanced); lung / macrophages: Low (Enhanced); lymph node / germinal center cells: Medium (Enhanced); lymph node / non-germinal center cells: Low (Enhanced); nasopharynx / respiratory epithelial cells: Low (Enhanced); pancreas / exocrine glandular cells: Low (Enhanced); rectum / endocrine cells: Low (Enhanced); rectum / endothelial cells: Low (Enhanced); rectum / fibroblasts: Low (Enhanced); rectum / mucosal lymphoid cells: Low (Enhanced); skeletal muscle / myocytes: Low (Enhanced); skin 1 / cells in basal layer: Low (Enhanced); skin 1 / fibrohistiocytic cells: Low (Enhanced); skin 2 / cells in basal layer: Low (Enhanced); skin 2 / fibrohistiocytic cells: Low (Enhanced); small intestine / endocrine cells: Low (Enhanced); small intestine / paneth cells: Low (Enhanced); stomach 1 / glandular cells: Low (Enhanced); stomach 2 / glandular cells: Low (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Kidney Renal Clear Cell Carcinoma (validation): 64/100 (64.0%); Kidney Renal Papillary Cell Carcinoma (TCGA): 179/282 (63.5%),glioma: 7/11 (63.6%); melanoma: 3/12 (25.0%),31,20,P35712,https://www.uniprot.org/uniprotkb/P35712/entry,"Transcription factor that plays a key role in several developmental processes, including neurogenesis, chondrocytes differentiation and cartilage formation (Probable). Specifically binds the 5'-AACAAT-3' DNA motif present in enhancers and super-enhancers and promotes expression of genes important for chondrogenesis. Required for overt chondrogenesis when condensed prechondrocytes differentiate into early stage chondrocytes: SOX5 and SOX6 cooperatively bind with SOX9 on active enhancers and super-enhancers associated with cartilage-specific genes, and thereby potentiate SOX9's ability to transactivate. Not involved in precartilaginous condensation, the first step in chondrogenesis, during which skeletal progenitors differentiate into prechondrocytes. Together with SOX5, required to form and maintain a pool of highly proliferating chondroblasts between epiphyses and metaphyses, to form columnar chondroblasts, delay chondrocyte prehypertrophy but promote hypertrophy, and to delay terminal differentiation of chondrocytes on contact with ossification fronts. Binds to the proximal promoter region of the myelin protein MPZ gene, and is thereby involved in the differentiation of oligodendroglia in the developing spinal tube. Binds to the gene promoter of MBP and acts as a transcriptional repressor (By similarity)","Expressed in a wide variety of tissues, most abundantly in skeletal musclen","Tolchin-Le Caignec syndrome: An autosomal dominant disorder characterized by mildly to moderately impaired intellectual development and behavioral problems, such as autism, attention deficit and hyperactivity disorder, and aggressive episodes. Highly variable, additional features include osteochondroma, craniosynostosis, dysmorphic facies, arachnodactyly, and large head circumference.",,Nucleus Cytoplasm,32442410,11255018,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
SPA17,ENSG00000064199,Unsafe,Protein,False,True,224.8,224.8,100,19,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,Trial registration,positive normal IHC; positive ihc outside permitted; amygdala: 12 nTPM; absolute ceiling; basal ganglia: 13.4 nTPM; absolute ceiling; choroid plexus: 15.2 nTPM; absolute ceiling; hippocampal formation: 12.6 nTPM; absolute ceiling; hypothalamus: 16.1 nTPM; absolute ceiling; kidney: 11.3 nTPM; positive ihc;absolute ceiling; midbrain: 9.4 nTPM; absolute ceiling; pituitary gland: 13.1 nTPM; absolute ceiling; spinal cord: 5.7 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 12 nTPM (limit 2); basal ganglia: 13.4 nTPM (limit 2); choroid plexus: 15.2 nTPM (limit 2); hippocampal formation: 12.6 nTPM (limit 2); hypothalamus: 16.1 nTPM (limit 2); kidney: 11.3 nTPM (limit 2); midbrain: 9.4 nTPM (limit 2); pituitary gland: 13.1 nTPM (limit 2); spinal cord: 5.7 nTPM (limit 2),bronchus / ciliated cells (cell body): Low (Enhanced); bronchus / ciliated cells (cilia axoneme): High (Enhanced); bronchus / ciliated cells (tip of cilia): High (Enhanced); kidney / cells in glomeruli: High (Enhanced); kidney / proximal tubules (microvilli): High (Enhanced); nasopharynx / ciliated cells (cell body): Low (Enhanced); nasopharynx / ciliated cells (cilia axoneme): High (Enhanced); nasopharynx / ciliated cells (ciliary rootlets): Medium (Enhanced); nasopharynx / ciliated cells (tip of cilia): High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,True,2.32703328988,345.8,"hpa_single_cell: /Ciliated cells, max 295.2 nTPM, 1 observations >30; hpa_single_cell: /Ionocytes, max 69.2 nTPM, 1 observations >30; hpa_single_cell: /Proximal tubular cells, max 44 nTPM, 1 observations >30; hpa_single_cell_tissue: bronchus/basal respiratory cells, max 30.9 nTPM, 1 observations >30; hpa_single_cell_tissue: bronchus/ciliated cells, max 275.8 nTPM, 3 observations >30; hpa_single_cell_tissue: bronchus/club cells, max 88.6 nTPM, 4 observations >30; hpa_single_cell_tissue: bronchus/ionocytes, max 69.2 nTPM, 1 observations >30; hpa_single_cell_tissue: bronchus/smooth muscle cells, max 70 nTPM, 1 observations >30; hpa_single_cell_tissue: fallopian tube/neutrophils, max 39.8 nTPM, 1 observations >30; hpa_single_cell_tissue: fallopian tube/t-cells, max 49.1 nTPM, 1 observations >30; hpa_single_cell_tissue: kidney/proximal tubular cells, max 61 nTPM, 6 observations >30; hpa_single_cell_tissue: lung/ciliated cells, max 345.8 nTPM, 1 observations >30; hpa_single_cell_tissue: pancreas/ductal cells, max 30.9 nTPM, 1 observations >30",Unsafe,oncoref.target-sets.2026-10-23.2,2.327 TPM; blood/M2; dice_m2; vital,345.8 nTPM; lung/ciliated cells; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (validation): 50/50 (100.0%); Pancreatic Adenocarcinoma (validation): 75/80 (93.8%); Glioblastoma Multiforme (validation): 53/58 (91.4%),breast cancer: 0/10 (0.0%); cervical cancer: 0/9 (0.0%),31,20,Q15506,https://www.uniprot.org/uniprotkb/Q15506/entry,Sperm surface zona pellucida binding protein. Helps to bind spermatozoa to the zona pellucida with high affinity. Might function in binding zona pellucida and carbohydrates (By similarity),Testis and sperm specific,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,Trial registration only,https://clinicaltrials.gov/study/NCT02224599,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
SPACA3,ENSG00000141316,Unsafe,RNA,False,True,121.8,121.8,81,2,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,pancreas: 20.3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,pancreas: 20.3 nTPM (limit 12),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (TCGA): 13/88 (14.8%); Colon Adenocarcinoma (TCGA): 17/254 (6.7%); Skin Cuteneous Melanoma (TCGA): 5/99 (5.1%),breast cancer: 0/12 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q8IXA5,https://www.uniprot.org/uniprotkb/Q8IXA5/entry,"Sperm surface membrane protein that may be involved in sperm-egg plasma membrane adhesion and fusion during fertilization. It could be a potential receptor for the egg oligosaccharide residue N-acetylglucosamine, which is present in the extracellular matrix over the egg plasma membrane. The processed form has no detectable bacteriolytic activity in vitro","The processed form is expressed in sperm (at protein level). Expressed in testis, epididymis and placenta",,"Although it belongs to the glycosyl hydrolase 22 family, Thr-122 and Asn-139 are present instead of the conserved Glu and Asp which are active site residues. It is therefore expected that this protein lacks hydrolase activity","Cytoplasmic vesicle, secretory vesicle, acrosome membrane Secreted",12606493,12606493|16014814,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
SPACA9,ENSG00000165698,Unsafe,Protein,False,True,127.6,127.6,99,9,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; amygdala: 14.6 nTPM; absolute ceiling; basal ganglia: 17.7 nTPM; absolute ceiling; cerebral cortex: 14.9 nTPM; absolute ceiling; choroid plexus: 18.9 nTPM; absolute ceiling; hippocampal formation: 14.3 nTPM; absolute ceiling; hypothalamus: 18.4 nTPM; absolute ceiling; midbrain: 15.9 nTPM; absolute ceiling; pituitary gland: 11.2 nTPM; absolute ceiling; retina: 7.9 nTPM; absolute ceiling; spinal cord: 16.8 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 14.6 nTPM (limit 2); basal ganglia: 17.7 nTPM (limit 2); cerebral cortex: 14.9 nTPM (limit 12); choroid plexus: 18.9 nTPM (limit 2); hippocampal formation: 14.3 nTPM (limit 2); hypothalamus: 18.4 nTPM (limit 2); midbrain: 15.9 nTPM (limit 2); pituitary gland: 11.2 nTPM (limit 2); retina: 7.9 nTPM (limit 2); spinal cord: 16.8 nTPM (limit 2),bronchus / ciliated cells (ciliary rootlets): Medium (Enhanced); bronchus / ciliated cells (tip of cilia): High (Enhanced); nasopharynx / ciliated cells (ciliary rootlets): High (Enhanced); nasopharynx / ciliated cells (tip of cilia): High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 139/141 (98.6%); Glioblastoma Multiforme (validation): 57/58 (98.3%); Thyroid Carcinoma (TCGA): 485/495 (98.0%),breast cancer: 0/12 (0.0%); cervical cancer: 0/11 (0.0%),29,20,Q96E40,https://www.uniprot.org/uniprotkb/Q96E40/entry,Microtubule inner protein (MIP) part of the dynein-decorated doublet microtubules (DMTs) of multiciliated respiratory cells and the distal singlet microtubules of monoflagellated spermatozoa (PubMed:36191189). Forms an extensive interaction network cross-linking the lumen of axonemal doublet microtubules (By similarity),,,,"Cytoplasm Cytoplasmic vesicle, secretory vesicle, acrosome Cytoplasm, cytoskeleton, cilium basal body Cytoplasm, cytoskeleton, flagellum axoneme Cytoplasm, cytoskeleton, cilium axoneme Nucleus",36191189,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
SPACDR,ENSG00000185955,Unsafe,RNA,False,True,66.5,66.5,86,2,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,amygdala: 7.3 nTPM; absolute ceiling; basal ganglia: 7.6 nTPM; absolute ceiling; hippocampal formation: 8.1 nTPM; absolute ceiling; hypothalamus: 6.8 nTPM; absolute ceiling; midbrain: 9.1 nTPM; absolute ceiling; pituitary gland: 2.8 nTPM; absolute ceiling; spinal cord: 8.8 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 7.3 nTPM (limit 2); basal ganglia: 7.6 nTPM (limit 2); hippocampal formation: 8.1 nTPM (limit 2); hypothalamus: 6.8 nTPM (limit 2); midbrain: 9.1 nTPM (limit 2); pituitary gland: 2.8 nTPM (limit 2); spinal cord: 8.8 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 126/141 (89.4%); Glioblastoma Multiforme (validation): 20/58 (34.5%); Uterine Corpus Endometrial Carcinoma (TCGA): 11/176 (6.2%),breast cancer: 0/10 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q8IZ16,https://www.uniprot.org/uniprotkb/Q8IZ16/entry,May play a role in acrosome formation and nucleus shaping during spermiogenesis,Expressed in sperm (at protein level),,,"Cytoplasmic vesicle, secretory vesicle, acrosome",31985809,23634713,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
SPAG1,ENSG00000104450,Unsafe,Protein,False,True,18.9,18.9,100,15,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 2.5 nTPM; absolute ceiling; basal ganglia: 3.7 nTPM; absolute ceiling; bone marrow: 10 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 10.6 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 3.1 nTPM; absolute ceiling; hypothalamus: 4.1 nTPM; absolute ceiling; midbrain: 2.8 nTPM; absolute ceiling; pituitary gland: 5.5 nTPM; absolute ceiling;continuous selectivity; rectum: 17.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 0.4 nTPM; positive ihc; small intestine: 2.6 nTPM; positive ihc;absolute ceiling; smooth muscle: 1.8 nTPM; positive ihc; spinal cord: 2.4 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 2.5 nTPM (limit 2); basal ganglia: 3.7 nTPM (limit 2); bone marrow: 10 nTPM (limit 2); choroid plexus: 10.6 nTPM (limit 2); hippocampal formation: 3.1 nTPM (limit 2); hypothalamus: 4.1 nTPM (limit 2); midbrain: 2.8 nTPM (limit 2); pituitary gland: 5.5 nTPM (limit 2); rectum: 17.7 nTPM (limit 6); small intestine: 2.6 nTPM (limit 2); spinal cord: 2.4 nTPM (limit 2),bone marrow / hematopoietic cells: Medium (Enhanced); bronchus / ciliated cells (cell body): Medium (Enhanced); bronchus / ciliated cells (ciliary rootlets): Medium (Enhanced); nasopharynx / ciliated cells (cell body): Medium (Enhanced); rectum / glandular cells: Low (Enhanced); skeletal muscle / myocytes: Low (Enhanced); small intestine / glandular cells: Low (Enhanced); smooth muscle / smooth muscle cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 205/207 (99.0%); Glioblastoma Multiforme (validation): 57/58 (98.3%); Breast Invasive Carcinoma (validation): 49/50 (98.0%),glioma: 1/11 (9.1%); cervical cancer: 1/12 (8.3%),31,20,Q07617,https://www.uniprot.org/uniprotkb/Q07617/entry,May play a role in the cytoplasmic assembly of the ciliary dynein arms (By similarity). May play a role in fertilization. Binds GTP and has GTPase activity,"Present in most tissues, including lung, with the strongest expression in brain, colon, kidney, and testis. In sperm and testis, detected in particular in pachytene primary spermatocytes. Up-regulated in pancreatic tumor tissues and not in normal pancreatic tissue","Ciliary dyskinesia, primary, 28: A disorder characterized by abnormalities of motile cilia. Respiratory infections leading to chronic inflammation and bronchiectasis are recurrent, due to defects in the respiratory cilia. Patients may exhibit randomization of left-right body asymmetry and situs inversus, due to dysfunction of monocilia at the embryonic node. Primary ciliary dyskinesia associated with situs inversus is referred to as Kartagener syndrome.",,Cytoplasm Dynein axonemal particle,11517287|1299558,11517287|1299558|16983343|24055112,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
SPAG6,ENSG00000077327,Unsafe,Protein,False,True,93.5,96.8,98,15,Positive somewhere,True,True,False,True,Excluded,Normal,False,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 4.7 nTPM; absolute ceiling; basal ganglia: 7.9 nTPM; absolute ceiling; choroid plexus: 96.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 8.1 nTPM; absolute ceiling; hypothalamus: 9.8 nTPM; absolute ceiling; lung: 6.8 nTPM; positive ihc;absolute ceiling; pituitary gland: 14.2 nTPM; absolute ceiling; retina: 5.6 nTPM; absolute ceiling; spinal cord: 2.4 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 4.7 nTPM (limit 2); basal ganglia: 7.9 nTPM (limit 2); choroid plexus: 96.8 nTPM (limit 2); hippocampal formation: 8.1 nTPM (limit 2); hypothalamus: 9.8 nTPM (limit 2); lung: 6.8 nTPM (limit 2); pituitary gland: 14.2 nTPM (limit 2); retina: 5.6 nTPM (limit 2); spinal cord: 2.4 nTPM (limit 2),bronchus / ciliated cells (cilia axoneme): High (Enhanced); bronchus / ciliated cells (tip of cilia): High (Enhanced); caudate / glial cells: High (Enhanced); lung / macrophages: Medium (Enhanced); nasopharynx / ciliated cells (cell body): Medium (Enhanced); nasopharynx / ciliated cells (cilia axoneme): High (Enhanced); nasopharynx / ciliated cells (tip of cilia): High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Renal Papillary Cell Carcinoma (TCGA): 100/282 (35.5%); Breast Invasive Carcinoma (validation): 12/50 (24.0%); Lung Adenocarcinoma (validation): 24/105 (22.9%),breast cancer: 0/12 (0.0%); cervical cancer: 0/11 (0.0%),31,20,O75602,https://www.uniprot.org/uniprotkb/O75602/entry,Important for structural integrity of the central apparatus in the sperm tail and for flagellar motility,Highly expressed in testis,,,"Cytoplasm, cytoskeleton Cell projection, cilium, flagellum Cytoplasm, cytoskeleton, cilium axoneme",10493827,10493827,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Jamin2021_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
SPAG9,ENSG00000008294,Unsafe,Protein,False,True,49.5,66.3,88,41,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,Institutional treatment report,positive normal IHC; positive ihc outside permitted; adrenal gland: 22 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 40.4 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 33.4 nTPM; absolute ceiling;continuous selectivity; bone marrow: 26.6 nTPM; absolute ceiling; cerebellum: 23.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 60 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 19.5 nTPM; absolute ceiling;continuous selectivity; colon: 22.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 20 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 28.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 21.7 nTPM; absolute ceiling; hippocampal formation: 40 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 30.7 nTPM; absolute ceiling;continuous selectivity; kidney: 31.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 32 nTPM; absolute ceiling;continuous selectivity; lung: 29 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 47 nTPM; absolute ceiling;continuous selectivity; pancreas: 29.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 26.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 11.3 nTPM; absolute ceiling; rectum: 19.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 35.7 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 46 nTPM; absolute ceiling;continuous selectivity; skin: 18.9 nTPM; positive ihc;absolute ceiling; small intestine: 20.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 26.2 nTPM; absolute ceiling; spinal cord: 66.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; stomach: 15 nTPM; positive ihc;absolute ceiling; thymus: 18.8 nTPM; absolute ceiling; thyroid gland: 39 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 39.2 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 28.6 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 22 nTPM (limit 2); amygdala: 40.4 nTPM (limit 2); basal ganglia: 33.4 nTPM (limit 2); bone marrow: 26.6 nTPM (limit 12); cerebellum: 23.8 nTPM (limit 2); cerebral cortex: 60 nTPM (limit 2); choroid plexus: 19.5 nTPM (limit 2); colon: 22.3 nTPM (limit 6); duodenum: 20 nTPM (limit 2); esophagus: 28.2 nTPM (limit 6); heart muscle: 21.7 nTPM (limit 12); hippocampal formation: 40 nTPM (limit 2); hypothalamus: 30.7 nTPM (limit 2); kidney: 31.9 nTPM (limit 2); liver: 32 nTPM (limit 12); lung: 29 nTPM (limit 2); midbrain: 47 nTPM (limit 2); pancreas: 29.7 nTPM (limit 2); parathyroid gland: 26.5 nTPM (limit 6); pituitary gland: 11.3 nTPM (limit 2); rectum: 19.1 nTPM (limit 6); retina: 35.7 nTPM (limit 2); skeletal muscle: 46 nTPM (limit 12); skin: 18.9 nTPM (limit 10); small intestine: 20.4 nTPM (limit 2); smooth muscle: 26.2 nTPM (limit 12); spinal cord: 66.3 nTPM (limit 2); stomach: 15 nTPM (limit 6); thymus: 18.8 nTPM (limit 10); thyroid gland: 39 nTPM (limit 10); tongue: 39.2 nTPM (limit 6); urinary bladder: 28.6 nTPM (limit 6),adrenal gland / glandular cells: Low (Enhanced); bronchus / respiratory epithelial cells: Medium (Enhanced); caudate / glial cells: Low (Enhanced); caudate / neuronal cells: Low (Enhanced); cerebellum / cells in granular layer: Medium (Enhanced); cerebral cortex / glial cells: Low (Enhanced); cerebral cortex / neuronal cells: High (Enhanced); colon / endothelial cells: Low (Enhanced); colon / glandular cells: Medium (Enhanced); duodenum / glandular cells: Medium (Enhanced); esophagus / squamous epithelial cells: Medium (Enhanced); hippocampus / glial cells: Medium (Enhanced); hippocampus / neuronal cells: Medium (Enhanced); kidney / cells in tubules: Medium (Enhanced); lung / alveolar cells type II: Low (Enhanced); oral mucosa / squamous epithelial cells: Medium (Enhanced); pancreas / exocrine glandular cells: High (Enhanced); parathyroid gland / glandular cells: Low (Enhanced); rectum / glandular cells: Medium (Enhanced); skin 2 / epidermal cells: Low (Enhanced); small intestine / glandular cells: Medium (Enhanced); stomach 1 / glandular cells: Medium (Enhanced); stomach 2 / glandular cells: High (Enhanced); thyroid gland / glandular cells: High (Enhanced); urinary bladder / urothelial cells: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 91/91 values ≥5 TPM, max 50.3613; DICE MONOCYTES (unstimulated): 91/91 values ≥5 TPM, max 49.3261; DICE M2 (unstimulated): 90/90 values ≥5 TPM, max 50.363; DICE NK (unstimulated): 90/90 values ≥5 TPM, max 58.2204; DICE TREG_MEM (unstimulated): 89/89 values ≥5 TPM, max 47.7951; DICE CD4_NAIVE (unstimulated): 88/88 values ≥5 TPM, max 39.5418; DICE CD4_STIM (activated): 88/88 values ≥5 TPM, max 207.455; DICE TREG_NAIVE (unstimulated): 89/89 values ≥5 TPM, max 45.5037; DICE TFH (unstimulated): 89/89 values ≥5 TPM, max 39.6414; DICE TH1 (unstimulated): 81/81 values ≥5 TPM, max 49.9095; DICE THSTAR (unstimulated): 88/88 values ≥5 TPM, max 57.0098; DICE TH17 (unstimulated): 89/89 values ≥5 TPM, max 49.0383; DICE TH2 (unstimulated): 89/89 values ≥5 TPM, max 52.1686; DICE CD8_NAIVE (unstimulated): 89/89 values ≥5 TPM, max 34.7723; DICE CD8_STIM (activated): 88/88 values ≥5 TPM, max 133.878; hpa_immune_cell basophil: 9.2 nTPM; hpa_immune_cell neutrophil: 12.3 nTPM; hpa_immune_monaco basophil: 11.2 TPM; hpa_immune_monaco Central memory CD8 T-cell: 6.1 TPM; hpa_immune_monaco classical monocyte: 9.8 TPM; hpa_immune_monaco Effector memory CD8 T-cell: 6.7 TPM; hpa_immune_monaco intermediate monocyte: 6.8 TPM; hpa_immune_monaco MAIT T-cell: 7.3 TPM; hpa_immune_monaco Memory CD4 T-cell TFH: 6.1 TPM; hpa_immune_monaco Memory CD4 T-cell Th1: 8.3 TPM; hpa_immune_monaco Memory CD4 T-cell Th1/Th17: 6.7 TPM; hpa_immune_monaco Memory CD4 T-cell Th17: 8.1 TPM; hpa_immune_monaco Memory CD4 T-cell Th2: 5.9 TPM; hpa_immune_monaco myeloid DC: 11.2 TPM; hpa_immune_monaco naive B-cell: 5.7 TPM; hpa_immune_monaco neutrophil: 30.8 TPM; hpa_immune_monaco NK-cell: 6.9 TPM; hpa_immune_monaco non-classical monocyte: 5.1 TPM; hpa_immune_monaco Non-Vd2 gdTCR: 6.7 TPM; hpa_immune_monaco plasmacytoid DC: 7.4 TPM; hpa_immune_monaco Progenitor cell: 10.9 TPM; hpa_immune_monaco Switched memory B-cell: 5.1 TPM; hpa_immune_monaco T-reg: 5.9 TPM; hpa_immune_monaco Terminal effector memory CD4 T-cell: 9.6 TPM; hpa_immune_monaco Terminal effector memory CD8 T-cell: 7.6 TPM; hpa_immune_monaco total PBMC: 6.1 TPM; hpa_immune_monaco Vd2 gdTCR: 5.2 TPM",True,True,True,"blood vessels: max 1.83643 mean CP10K, 4 supported sample groups; conjunctival basal epithelium: max 2.59539 mean CP10K, 4 supported sample groups; conjunctival superficial epithelium: max 2.24438 mean CP10K, 3 supported sample groups; corneal stroma keratocytes: max 1.92771 mean CP10K, 2 supported sample groups; corneal stromal stem cells: max 1.63805 mean CP10K, 3 supported sample groups; corneal superficial epithelium: max 1.91558 mean CP10K, 4 supported sample groups; corneal suprabasal epithelial cells: max 1.20866 mean CP10K, 3 supported sample groups; immune cells 1: max 3.78776 mean CP10K, 4 supported sample groups; limbal fibroblasts: max 1.49365 mean CP10K, 3 supported sample groups; limbal neural crest progenitors: max 2.01803 mean CP10K, 2 supported sample groups; limbal progenitor cells: max 2.16387 mean CP10K, 4 supported sample groups; limbal superficial epithelium: max 1.91349 mean CP10K, 3 supported sample groups; limbal suprabasal epithelial cells: max 1.90428 mean CP10K, 3 supported sample groups; lymphatic vessels: max 1.69754 mean CP10K, 2 supported sample groups; melanocytes: max 1.65728 mean CP10K, 2 supported sample groups",True,False,,False,True,True,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,True,207.45515592,480.1,"dice_b_cell_naive: blood/B_CELL_NAIVE, max 50.3613 TPM, 71 observations >30; dice_cd4_naive: blood/CD4_NAIVE, max 39.5418 TPM, 66 observations >30; dice_cd4_stim: blood/CD4_STIM, max 207.455 TPM, 88 observations >30; dice_cd8_naive: blood/CD8_NAIVE, max 34.7723 TPM, 9 observations >30; dice_cd8_stim: blood/CD8_STIM, max 133.878 TPM, 88 observations >30; dice_m2: blood/M2, max 50.363 TPM, 73 observations >30; dice_monocytes: blood/MONOCYTES, max 49.3261 TPM, 89 observations >30; dice_nk: blood/NK, max 58.2204 TPM, 85 observations >30; dice_tfh: blood/TFH, max 39.6414 TPM, 39 observations >30; dice_th1: blood/TH1, max 49.9095 TPM, 72 observations >30; dice_th17: blood/TH17, max 49.0383 TPM, 83 observations >30; dice_th2: blood/TH2, max 52.1686 TPM, 89 observations >30; dice_thstar: blood/THSTAR, max 57.0098 TPM, 88 observations >30; dice_treg_mem: blood/TREG_MEM, max 47.7951 TPM, 75 observations >30; dice_treg_naive: blood/TREG_NAIVE, max 45.5037 TPM, 70 observations >30; hpa_immune_cell_samples: blood/basophil, max 32.2247 nTPM, 1 observations >30; hpa_immune_monaco: blood/neutrophil, max 30.8 TPM, 1 observations >30; hpa_immune_schmiedel: blood/Memory CD4 T-cell Th1, max 34.7 TPM, 1 observations >30; hpa_immune_schmiedel: blood/Memory CD4 T-cell Th1/Th17, max 42.3 TPM, 1 observations >30; hpa_immune_schmiedel: blood/Memory CD4 T-cell Th17, max 36.4 TPM, 1 observations >30; hpa_immune_schmiedel: blood/Memory CD4 T-cell Th2, max 39.8 TPM, 1 observations >30; hpa_immune_schmiedel: blood/Memory T-reg, max 34.3 TPM, 1 observations >30; hpa_immune_schmiedel: blood/NK-cell, max 38 TPM, 1 observations >30; hpa_immune_schmiedel: blood/Naive CD4 T-cell activated, max 150.6 TPM, 1 observations >30; hpa_immune_schmiedel: blood/Naive CD8 T-cell activated, max 99.7 TPM, 1 observations >30; hpa_immune_schmiedel: blood/Naive T-reg, max 33.3 TPM, 1 observations >30; hpa_immune_schmiedel: blood/classical monocyte, max 37.8 TPM, 1 observations >30; hpa_immune_schmiedel: blood/naive B-cell, max 33.3 TPM, 1 observations >30; hpa_immune_schmiedel: blood/naive CD4 T-cell, max 32.3 TPM, 1 observations >30; hpa_immune_schmiedel: blood/non-classical monocyte, max 35.3 TPM, 1 observations >30; hpa_rna_consensus: adipose tissue/, max 31.2 nTPM, 1 observations >30; hpa_rna_consensus: amygdala/, max 40.4 nTPM, 1 observations >30; hpa_rna_consensus: basal ganglia/, max 33.4 nTPM, 1 observations >30; hpa_rna_consensus: cerebral cortex/, max 60 nTPM, 1 observations >30; hpa_rna_consensus: hippocampal formation/, max 40 nTPM, 1 observations >30; hpa_rna_consensus: hypothalamus/, max 30.7 nTPM, 1 observations >30; hpa_rna_consensus: kidney/, max 31.9 nTPM, 1 observations >30; hpa_rna_consensus: liver/, max 32 nTPM, 1 observations >30; hpa_rna_consensus: midbrain/, max 47 nTPM, 1 observations >30; hpa_rna_consensus: retina/, max 35.7 nTPM, 1 observations >30; hpa_rna_consensus: skeletal muscle/, max 46 nTPM, 1 observations >30; hpa_rna_consensus: spinal cord/, max 66.3 nTPM, 1 observations >30; hpa_rna_consensus: thyroid gland/, max 39 nTPM, 1 observations >30; hpa_rna_consensus: tongue/, max 39.2 nTPM, 1 observations >30; hpa_single_cell: /Adipocytes, max 160.2 nTPM, 1 observations >30; hpa_single_cell: /Alveolar cells type 1, max 127.4 nTPM, 1 observations >30; hpa_single_cell: /Alveolar cells type 2, max 147.4 nTPM, 1 observations >30; hpa_single_cell: /Astrocytes, max 180.5 nTPM, 1 observations >30; hpa_single_cell: /B-cells, max 54.1 nTPM, 1 observations >30; hpa_single_cell: /Basal keratinocytes, max 147.8 nTPM, 1 observations >30; hpa_single_cell: /Basal respiratory cells, max 36.7 nTPM, 1 observations >30; hpa_single_cell: /Basal squamous epithelial cells, max 103.7 nTPM, 1 observations >30; hpa_single_cell: /Bipolar cells, max 89.9 nTPM, 1 observations >30; hpa_single_cell: /Cardiomyocytes, max 71.5 nTPM, 1 observations >30; hpa_single_cell: /Cholangiocytes, max 40.1 nTPM, 1 observations >30; hpa_single_cell: /Ciliated cells, max 74 nTPM, 1 observations >30; hpa_single_cell: /Club cells, max 44.9 nTPM, 1 observations >30; hpa_single_cell: /Cone photoreceptor cells, max 98.6 nTPM, 1 observations >30; hpa_single_cell: /Distal enterocytes, max 157.5 nTPM, 1 observations >30; hpa_single_cell: /Ductal cells, max 56 nTPM, 1 observations >30; hpa_single_cell: /Endothelial cells, max 113.7 nTPM, 1 observations >30; hpa_single_cell: /Enteroendocrine cells, max 51.8 nTPM, 1 observations >30; hpa_single_cell: /Excitatory neurons, max 106.5 nTPM, 1 observations >30; hpa_single_cell: /Exocrine glandular cells, max 66.5 nTPM, 1 observations >30; hpa_single_cell: /Fibroblasts, max 93.1 nTPM, 1 observations >30; hpa_single_cell: /Gastric mucus-secreting cells, max 79 nTPM, 1 observations >30; hpa_single_cell: /Glandular and luminal cells, max 294.6 nTPM, 1 observations >30; hpa_single_cell: /Hepatocytes, max 45.1 nTPM, 1 observations >30; hpa_single_cell: /Horizontal cells, max 78.7 nTPM, 1 observations >30; hpa_single_cell: /Inhibitory neurons, max 125 nTPM, 1 observations >30; hpa_single_cell: /Intestinal goblet cells, max 42.5 nTPM, 1 observations >30; hpa_single_cell: /Ionocytes, max 37.9 nTPM, 1 observations >30; hpa_single_cell: /Kupffer cells, max 41.3 nTPM, 1 observations >30; hpa_single_cell: /Langerhans cells, max 260.9 nTPM, 1 observations >30; hpa_single_cell: /Lymphatic endothelial cells, max 136.1 nTPM, 1 observations >30; hpa_single_cell: /Macrophages, max 145.6 nTPM, 1 observations >30; hpa_single_cell: /Mesothelial cells, max 59 nTPM, 1 observations >30; hpa_single_cell: /Microglial cells, max 100.2 nTPM, 1 observations >30; hpa_single_cell: /Mucus glandular cells, max 129 nTPM, 1 observations >30; hpa_single_cell: /Muller glia cells, max 37.8 nTPM, 1 observations >30; hpa_single_cell: /NK-cells, max 63.7 nTPM, 1 observations >30; hpa_single_cell: /Oligodendrocyte precursor cells, max 180.6 nTPM, 1 observations >30; hpa_single_cell: /Oligodendrocytes, max 283.6 nTPM, 1 observations >30; hpa_single_cell: /Pancreatic endocrine cells, max 40.8 nTPM, 1 observations >30; hpa_single_cell: /Paneth cells, max 79.6 nTPM, 1 observations >30; hpa_single_cell: /Plasma cells, max 46.8 nTPM, 1 observations >30; hpa_single_cell: /Proximal enterocytes, max 65.2 nTPM, 1 observations >30; hpa_single_cell: /Proximal tubular cells, max 87.1 nTPM, 1 observations >30; hpa_single_cell: /Rod photoreceptor cells, max 89 nTPM, 1 observations >30; hpa_single_cell: /Salivary duct cells, max 130 nTPM, 1 observations >30; hpa_single_cell: /Schwann cells, max 148.8 nTPM, 1 observations >30; hpa_single_cell: /Secretory cells, max 54.8 nTPM, 1 observations >30; hpa_single_cell: /Serous glandular cells, max 72.1 nTPM, 1 observations >30; hpa_single_cell: /Skeletal myocytes, max 114.2 nTPM, 1 observations >30; hpa_single_cell: /Smooth muscle cells, max 86.2 nTPM, 1 observations >30; hpa_single_cell: /Squamous epithelial cells, max 84.5 nTPM, 1 observations >30; hpa_single_cell: /Suprabasal keratinocytes, max 150.7 nTPM, 1 observations >30; hpa_single_cell: /T-cells, max 61.5 nTPM, 1 observations >30; hpa_single_cell: /dendritic cells, max 82 nTPM, 1 observations >30; hpa_single_cell: /granulocytes, max 83.6 nTPM, 1 observations >30; hpa_single_cell: /monocytes, max 152 nTPM, 1 observations >30; hpa_single_cell_tissue: adipose tissue/adipocytes, max 219.9 nTPM, 1 observations >30; hpa_single_cell_tissue: adipose tissue/b-cells, max 146.1 nTPM, 1 observations >30; hpa_single_cell_tissue: adipose tissue/dendritic cells, max 138.7 nTPM, 1 observations >30; hpa_single_cell_tissue: adipose tissue/fibroblasts, max 159.4 nTPM, 4 observations >30; hpa_single_cell_tissue: adipose tissue/macrophages, max 480.1 nTPM, 3 observations >30; hpa_single_cell_tissue: adipose tissue/monocytes, max 152 nTPM, 1 observations >30; hpa_single_cell_tissue: adipose tissue/nk-cells, max 133.2 nTPM, 2 observations >30; hpa_single_cell_tissue: adipose tissue/schwann cells, max 239.3 nTPM, 1 observations >30; hpa_single_cell_tissue: adipose tissue/smooth muscle cells, max 134.1 nTPM, 1 observations >30; hpa_single_cell_tissue: adipose tissue/t-cells, max 196.9 nTPM, 7 observations >30; hpa_single_cell_tissue: bone marrow/b-cells, max 46.1 nTPM, 1 observations >30; hpa_single_cell_tissue: bone marrow/macrophages, max 39.5 nTPM, 1 observations >30; hpa_single_cell_tissue: bone marrow/t-cells, max 32 nTPM, 2 observations >30; hpa_single_cell_tissue: brain/astrocytes, max 180.5 nTPM, 1 observations >30; hpa_single_cell_tissue: brain/excitatory neurons, max 120.7 nTPM, 26 observations >30; hpa_single_cell_tissue: brain/inhibitory neurons, max 146.9 nTPM, 14 observations >30; hpa_single_cell_tissue: brain/microglial cells, max 100.2 nTPM, 1 observations >30; hpa_single_cell_tissue: brain/oligodendrocyte precursor cells, max 180.6 nTPM, 1 observations >30; hpa_single_cell_tissue: brain/oligodendrocytes, max 287.1 nTPM, 2 observations >30; hpa_single_cell_tissue: breast/macrophages, max 165.7 nTPM, 3 observations >30; hpa_single_cell_tissue: breast/t-cells, max 77.9 nTPM, 4 observations >30; hpa_single_cell_tissue: bronchus/basal respiratory cells, max 47.3 nTPM, 4 observations >30; hpa_single_cell_tissue: bronchus/ciliated cells, max 43.5 nTPM, 3 observations >30; hpa_single_cell_tissue: bronchus/club cells, max 55.9 nTPM, 4 observations >30; hpa_single_cell_tissue: bronchus/ionocytes, max 37.9 nTPM, 1 observations >30; hpa_single_cell_tissue: bronchus/smooth muscle cells, max 34.6 nTPM, 1 observations >30; hpa_single_cell_tissue: colon/distal enterocytes, max 352.9 nTPM, 3 observations >30; hpa_single_cell_tissue: colon/enteroendocrine cells, max 79 nTPM, 1 observations >30; hpa_single_cell_tissue: colon/intestinal goblet cells, max 66.9 nTPM, 1 observations >30; hpa_single_cell_tissue: colon/paneth cells, max 173.7 nTPM, 1 observations >30; hpa_single_cell_tissue: colon/t-cells, max 64.3 nTPM, 1 observations >30; hpa_single_cell_tissue: colon/undifferentiated cells, max 180.4 nTPM, 3 observations >30; hpa_single_cell_tissue: endometrium/macrophages, max 207.2 nTPM, 1 observations >30; hpa_single_cell_tissue: endometrium/t-cells, max 124.6 nTPM, 1 observations >30; hpa_single_cell_tissue: esophagus/b-cells, max 35.4 nTPM, 1 observations >30; hpa_single_cell_tissue: esophagus/basal squamous epithelial cells, max 103.7 nTPM, 1 observations >30; hpa_single_cell_tissue: esophagus/endothelial cells, max 130 nTPM, 1 observations >30; hpa_single_cell_tissue: esophagus/fibroblasts, max 82 nTPM, 3 observations >30; hpa_single_cell_tissue: esophagus/macrophages, max 111.7 nTPM, 1 observations >30; hpa_single_cell_tissue: esophagus/schwann cells, max 71.9 nTPM, 1 observations >30; hpa_single_cell_tissue: esophagus/smooth muscle cells, max 69.7 nTPM, 1 observations >30; hpa_single_cell_tissue: esophagus/squamous epithelial cells, max 92.5 nTPM, 3 observations >30; hpa_single_cell_tissue: esophagus/t-cells, max 63.3 nTPM, 1 observations >30; hpa_single_cell_tissue: eye/bipolar cells, max 92.6 nTPM, 3 observations >30; hpa_single_cell_tissue: eye/cone photoreceptor cells, max 98.6 nTPM, 1 observations >30; hpa_single_cell_tissue: eye/horizontal cells, max 78.7 nTPM, 1 observations >30; hpa_single_cell_tissue: eye/muller glia cells, max 83.1 nTPM, 2 observations >30; hpa_single_cell_tissue: eye/rod photoreceptor cells, max 95.7 nTPM, 3 observations >30; hpa_single_cell_tissue: fallopian tube/granulocytes, max 96.3 nTPM, 1 observations >30; hpa_single_cell_tissue: fallopian tube/macrophages, max 331.8 nTPM, 2 observations >30; hpa_single_cell_tissue: fallopian tube/neutrophils, max 315.8 nTPM, 1 observations >30; hpa_single_cell_tissue: fallopian tube/plasma cells, max 97.1 nTPM, 1 observations >30; hpa_single_cell_tissue: fallopian tube/t-cells, max 86.5 nTPM, 4 observations >30; hpa_single_cell_tissue: heart muscle/cardiomyocytes, max 92.8 nTPM, 5 observations >30; hpa_single_cell_tissue: heart muscle/endothelial cells, max 112.9 nTPM, 2 observations >30; hpa_single_cell_tissue: heart muscle/fibroblasts, max 68.8 nTPM, 1 observations >30; hpa_single_cell_tissue: heart muscle/smooth muscle cells, max 85.2 nTPM, 1 observations >30; hpa_single_cell_tissue: kidney/macrophages, max 34.5 nTPM, 1 observations >30; hpa_single_cell_tissue: kidney/proximal tubular cells, max 117.4 nTPM, 8 observations >30; hpa_single_cell_tissue: liver/b-cells, max 38.6 nTPM, 1 observations >30; hpa_single_cell_tissue: liver/cholangiocytes, max 40.1 nTPM, 1 observations >30; hpa_single_cell_tissue: liver/endothelial cells, max 50.4 nTPM, 1 observations >30; hpa_single_cell_tissue: liver/fibroblasts, max 73.5 nTPM, 1 observations >30; hpa_single_cell_tissue: liver/hepatocytes, max 54.1 nTPM, 5 observations >30; hpa_single_cell_tissue: liver/kupffer cells, max 48.7 nTPM, 4 observations >30; hpa_single_cell_tissue: liver/smooth muscle cells, max 67.5 nTPM, 1 observations >30; hpa_single_cell_tissue: lung/alveolar cells type 1, max 139.8 nTPM, 2 observations >30; hpa_single_cell_tissue: lung/alveolar cells type 2, max 154.8 nTPM, 4 observations >30; hpa_single_cell_tissue: lung/b-cells, max 38.9 nTPM, 1 observations >30; hpa_single_cell_tissue: lung/ciliated cells, max 73.8 nTPM, 2 observations >30; hpa_single_cell_tissue: lung/club cells, max 42.2 nTPM, 1 observations >30; hpa_single_cell_tissue: lung/endothelial cells, max 165 nTPM, 5 observations >30; hpa_single_cell_tissue: lung/fibroblasts, max 75.6 nTPM, 1 observations >30; hpa_single_cell_tissue: lung/granulocytes, max 47.9 nTPM, 1 observations >30; hpa_single_cell_tissue: lung/macrophages, max 130.8 nTPM, 7 observations >30; hpa_single_cell_tissue: lung/smooth muscle cells, max 50.6 nTPM, 1 observations >30; hpa_single_cell_tissue: lung/t-cells, max 52.6 nTPM, 2 observations >30; hpa_single_cell_tissue: lymph node/b-cells, max 53.8 nTPM, 3 observations >30; hpa_single_cell_tissue: lymph node/mixed cell types, max 63.5 nTPM, 1 observations >30; hpa_single_cell_tissue: lymph node/t-cells, max 42.4 nTPM, 3 observations >30; hpa_single_cell_tissue: ovary/mixed immune cells, max 84.4 nTPM, 1 observations >30; hpa_single_cell_tissue: pancreas/ductal cells, max 64.8 nTPM, 5 observations >30; hpa_single_cell_tissue: pancreas/endothelial cells, max 77.6 nTPM, 1 observations >30; hpa_single_cell_tissue: pancreas/exocrine glandular cells, max 90.9 nTPM, 5 observations >30; hpa_single_cell_tissue: pancreas/fibroblasts, max 38 nTPM, 1 observations >30; hpa_single_cell_tissue: pancreas/macrophages, max 53.4 nTPM, 1 observations >30; hpa_single_cell_tissue: pancreas/mixed cell types, max 100.1 nTPM, 3 observations >30; hpa_single_cell_tissue: pancreas/mixed immune cells, max 50.2 nTPM, 1 observations >30; hpa_single_cell_tissue: pancreas/pancreatic endocrine cells, max 40.8 nTPM, 1 observations >30; hpa_single_cell_tissue: pbmc/b-cells, max 30.8 nTPM, 1 observations >30; hpa_single_cell_tissue: pbmc/macrophages, max 47.8 nTPM, 1 observations >30; hpa_single_cell_tissue: pbmc/monocytes, max 36 nTPM, 1 observations >30; hpa_single_cell_tissue: pbmc/t-cells, max 54.4 nTPM, 3 observations >30; hpa_single_cell_tissue: placenta/mixed immune cells, max 37.2 nTPM, 1 observations >30; hpa_single_cell_tissue: prostate/macrophages, max 83.6 nTPM, 1 observations >30; hpa_single_cell_tissue: prostate/t-cells, max 60.9 nTPM, 2 observations >30; hpa_single_cell_tissue: rectum/distal enterocytes, max 36.9 nTPM, 1 observations >30; hpa_single_cell_tissue: rectum/enteroendocrine cells, max 35.2 nTPM, 1 observations >30; hpa_single_cell_tissue: salivary gland/b-cells, max 62.8 nTPM, 2 observations >30; hpa_single_cell_tissue: salivary gland/endothelial cells, max 162.1 nTPM, 1 observations >30; hpa_single_cell_tissue: salivary gland/fibroblasts, max 129.3 nTPM, 3 observations >30; hpa_single_cell_tissue: salivary gland/macrophages, max 139.5 nTPM, 2 observations >30; hpa_single_cell_tissue: salivary gland/mixed immune cells, max 60.5 nTPM, 1 observations >30; hpa_single_cell_tissue: salivary gland/mucus glandular cells, max 130.7 nTPM, 2 observations >30; hpa_single_cell_tissue: salivary gland/plasma cells, max 88.6 nTPM, 1 observations >30; hpa_single_cell_tissue: salivary gland/salivary duct cells, max 130 nTPM, 1 observations >30; hpa_single_cell_tissue: salivary gland/serous glandular cells, max 162.1 nTPM, 7 observations >30; hpa_single_cell_tissue: salivary gland/smooth muscle cells, max 133.5 nTPM, 2 observations >30; hpa_single_cell_tissue: salivary gland/t-cells, max 67.5 nTPM, 2 observations >30; hpa_single_cell_tissue: skeletal muscle/endothelial cells, max 197.7 nTPM, 3 observations >30; hpa_single_cell_tissue: skeletal muscle/fibroblasts, max 160.8 nTPM, 9 observations >30; hpa_single_cell_tissue: skeletal muscle/macrophages, max 291.3 nTPM, 2 observations >30; hpa_single_cell_tissue: skeletal muscle/mixed cell types, max 119.2 nTPM, 2 observations >30; hpa_single_cell_tissue: skeletal muscle/skeletal myocytes, max 114.2 nTPM, 1 observations >30; hpa_single_cell_tissue: skeletal muscle/smooth muscle cells, max 118.8 nTPM, 2 observations >30; hpa_single_cell_tissue: skeletal muscle/t-cells, max 83.9 nTPM, 1 observations >30; hpa_single_cell_tissue: skin/b-cells, max 159.2 nTPM, 1 observations >30; hpa_single_cell_tissue: skin/basal keratinocytes, max 173.6 nTPM, 1 observations >30; hpa_single_cell_tissue: skin/endothelial cells, max 237.7 nTPM, 3 observations >30; hpa_single_cell_tissue: skin/fibroblasts, max 206.8 nTPM, 4 observations >30; hpa_single_cell_tissue: skin/granulocytes, max 48.2 nTPM, 1 observations >30; hpa_single_cell_tissue: skin/langerhans cells, max 304.6 nTPM, 2 observations >30; hpa_single_cell_tissue: skin/macrophages, max 219.5 nTPM, 1 observations >30; hpa_single_cell_tissue: skin/smooth muscle cells, max 97.8 nTPM, 3 observations >30; hpa_single_cell_tissue: skin/suprabasal keratinocytes, max 171.3 nTPM, 1 observations >30; hpa_single_cell_tissue: skin/t-cells, max 64.5 nTPM, 1 observations >30; hpa_single_cell_tissue: small intestine/enteroendocrine cells, max 41.2 nTPM, 1 observations >30; hpa_single_cell_tissue: small intestine/intestinal goblet cells, max 42.4 nTPM, 1 observations >30; hpa_single_cell_tissue: small intestine/paneth cells, max 38 nTPM, 1 observations >30; hpa_single_cell_tissue: small intestine/proximal enterocytes, max 72.4 nTPM, 5 observations >30; hpa_single_cell_tissue: small intestine/undifferentiated cells, max 31.9 nTPM, 1 observations >30; hpa_single_cell_tissue: spleen/b-cells, max 44.5 nTPM, 1 observations >30; hpa_single_cell_tissue: spleen/macrophages, max 82.2 nTPM, 1 observations >30; hpa_single_cell_tissue: spleen/plasma cells, max 34.9 nTPM, 1 observations >30; hpa_single_cell_tissue: spleen/t-cells, max 49.1 nTPM, 5 observations >30; hpa_single_cell_tissue: stomach/b-cells, max 36.3 nTPM, 1 observations >30; hpa_single_cell_tissue: stomach/fibroblasts, max 70.6 nTPM, 1 observations >30; hpa_single_cell_tissue: stomach/gastric mucus-secreting cells, max 79 nTPM, 1 observations >30; hpa_single_cell_tissue: stomach/macrophages, max 131.2 nTPM, 1 observations >30; hpa_single_cell_tissue: stomach/plasma cells, max 35.6 nTPM, 1 observations >30; hpa_single_cell_tissue: stomach/t-cells, max 45.1 nTPM, 4 observations >30; hpa_single_cell_tissue: testis/macrophages, max 49.6 nTPM, 1 observations >30; hpa_single_cell_tissue: thymus/b-cells, max 49.2 nTPM, 2 observations >30; hpa_single_cell_tissue: thymus/endothelial cells, max 146.8 nTPM, 3 observations >30; hpa_single_cell_tissue: thymus/fibroblasts, max 113.5 nTPM, 3 observations >30; hpa_single_cell_tissue: thymus/macrophages, max 97 nTPM, 1 observations >30; hpa_single_cell_tissue: thymus/mesothelial cells, max 59 nTPM, 1 observations >30; hpa_single_cell_tissue: thymus/plasma cells, max 47.1 nTPM, 3 observations >30; hpa_single_cell_tissue: thymus/smooth muscle cells, max 109.6 nTPM, 3 observations >30; hpa_single_cell_tissue: thymus/t-cells, max 50.3 nTPM, 4 observations >30; hpa_single_cell_tissue: tongue/basal keratinocytes, max 246.5 nTPM, 10 observations >30; hpa_single_cell_tissue: tongue/endothelial cells, max 140.9 nTPM, 2 observations >30; hpa_single_cell_tissue: tongue/granulocytes, max 106.7 nTPM, 1 observations >30; hpa_single_cell_tissue: tongue/macrophages, max 237 nTPM, 1 observations >30; hpa_single_cell_tissue: tongue/serous glandular cells, max 88.4 nTPM, 1 observations >30; hpa_single_cell_tissue: tongue/smooth muscle cells, max 115.3 nTPM, 1 observations >30; hpa_single_cell_tissue: tongue/suprabasal keratinocytes, max 142.7 nTPM, 3 observations >30; hpa_single_cell_tissue: tongue/t-cells, max 98.5 nTPM, 2 observations >30; hpa_single_cell_tissue: vascular/endothelial cells, max 156.7 nTPM, 4 observations >30; hpa_single_cell_tissue: vascular/fibroblasts, max 162.8 nTPM, 6 observations >30; hpa_single_cell_tissue: vascular/macrophages, max 142.9 nTPM, 2 observations >30; hpa_single_cell_tissue: vascular/schwann cells, max 135.3 nTPM, 1 observations >30; hpa_single_cell_tissue: vascular/smooth muscle cells, max 150.1 nTPM, 6 observations >30; hpa_single_cell_tissue: vascular/t-cells, max 66.7 nTPM, 1 observations >30",Unsafe,oncoref.target-sets.2026-10-23.2,207.5 TPM; blood/CD4_STIM; dice_cd4_stim; vital,480.1 nTPM; adipose tissue/macrophages; hpa_single_cell_tissue; vital,Colon Adenocarcinoma (validation): 486/486 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (TCGA): 141/141 (100.0%),testis cancer: 11/11 (100.0%); colorectal cancer: 10/12 (83.3%),31,20,O60271,https://www.uniprot.org/uniprotkb/O60271/entry,The JNK-interacting protein (JIP) group of scaffold proteins selectively mediates JNK signaling by aggregating specific components of the MAPK cascade to form a functional JNK signaling module (PubMed:14743216). Regulates lysosomal positioning by acting as an adapter protein which links PIP4P1-positive lysosomes to the dynein-dynactin complex (PubMed:29146937). Assists PIKFYVE selective functionality in microtubule-based endosome-to-TGN trafficking (By similarity),"Expressed only in testis on the round spermatids of stage I, II and II. Absent in spermatogonia and spermatocyte Expressed in testis and in acute myeloid leukemia (AML) patients Expressed in testis",,,"Cytoplasm Cytoplasm, perinuclear region Lysosome membrane Cytoplasmic vesicle, secretory vesicle, acrosome",14743216|29146937,14662895|16112646|9480848,False,Reviewed UniProt annotation; not a new primary-paper review,Institutional clinical report,https://cancerinstitutewia.in/wp-content/uploads/2024/08/Annual-Report-2022-2023-Final-Draft-for-Print-proofread_organized-for-website.pdf,"Ovarian-cancer expression and patient antibody responses establish interest, not reproductive exclusivity. Current normal RNA and protein counterevidence supports exclusion.",https://pubmed.ncbi.nlm.nih.gov/17332284/,Tumor expression and immunity,Garg2007_SPAG9,Ovarian-cancer RNA/protein expression and patient antibody responses; no HLA presentation or T-cell validation claimed,,,,,,,,
SPAST,ENSG00000021574,Unsafe,Protein,False,True,9.8,13.7,77,73,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 5.7 nTPM; positive ihc;continuous selectivity; adrenal gland: 5.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 7.9 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 7.1 nTPM; absolute ceiling;continuous selectivity; bone marrow: 10.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 7.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 13 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; colon: 6.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 7.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 6.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 3.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 8.8 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 8.1 nTPM; absolute ceiling;continuous selectivity; kidney: 5.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 9.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 6.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 9.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 9.3 nTPM; absolute ceiling;continuous selectivity; pancreas: 5.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 6 nTPM; positive ihc;continuous selectivity; pituitary gland: 4.2 nTPM; absolute ceiling;continuous selectivity; rectum: 7.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 7.1 nTPM; absolute ceiling;continuous selectivity; salivary gland: 4.2 nTPM; positive ihc;continuous selectivity; skeletal muscle: 7.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 7.2 nTPM; positive ihc;continuous selectivity; small intestine: 7.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 7.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 12.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 6.9 nTPM; positive ihc;continuous selectivity; stomach: 6.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 13.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 8.5 nTPM; positive ihc;continuous selectivity; tongue: 9.6 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 7.2 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 5.8 nTPM (limit 2); amygdala: 7.9 nTPM (limit 2); basal ganglia: 7.1 nTPM (limit 2); bone marrow: 10.1 nTPM (limit 2); cerebellum: 7.9 nTPM (limit 2); cerebral cortex: 13 nTPM (limit 2); colon: 6.9 nTPM (limit 6); duodenum: 7.3 nTPM (limit 2); esophagus: 6.9 nTPM (limit 6); heart muscle: 3.9 nTPM (limit 2); hippocampal formation: 8.8 nTPM (limit 2); hypothalamus: 8.1 nTPM (limit 2); kidney: 5.7 nTPM (limit 2); liver: 9.3 nTPM (limit 2); lung: 6.1 nTPM (limit 2); lymph node: 9.7 nTPM (limit 6); midbrain: 9.3 nTPM (limit 2); pancreas: 5.3 nTPM (limit 2); pituitary gland: 4.2 nTPM (limit 2); rectum: 7.3 nTPM (limit 6); retina: 7.1 nTPM (limit 2); skeletal muscle: 7.6 nTPM (limit 2); small intestine: 7.9 nTPM (limit 2); smooth muscle: 7.1 nTPM (limit 2); spinal cord: 12.6 nTPM (limit 2); stomach: 6.3 nTPM (limit 6); thymus: 13.7 nTPM (limit 10); tongue: 9.6 nTPM (limit 6); urinary bladder: 7.2 nTPM (limit 6),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / endothelial cells: High (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: High (Approved); colon / glandular cells: High (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: High (Approved); hippocampus / glial cells: Low (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: High (Approved); lymph node / non-germinal center cells: High (Approved); nasopharynx / respiratory epithelial cells: High (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: High (Approved); skin 1 / fibroblasts: Low (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: High (Approved); spleen / cells in white pulp: High (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%); Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%),colorectal cancer: 12/12 (100.0%); stomach cancer: 11/11 (100.0%),31,20,Q9UBP0,https://www.uniprot.org/uniprotkb/Q9UBP0/entry,"ATP-dependent microtubule severing protein that specifically recognizes and cuts microtubules that are polyglutamylated (PubMed:11809724, PubMed:15716377, PubMed:16219033, PubMed:17389232, PubMed:20530212, PubMed:22637577, PubMed:26875866). Preferentially recognizes and acts on microtubules decorated with short polyglutamate tails: severing activity increases as the number of glutamates per tubulin rises from one to eight, but decreases beyond this glutamylation threshold (PubMed:26875866). Severing activity is not dependent on tubulin acetylation or detyrosination (PubMed:26875866). Microtubule severing promotes reorganization of cellular microtubule arrays and the release of microtubules from the centrosome following nucleation. It is critical for the biogenesis and maintenance of complex microtubule arrays in axons, spindles and cilia. SPAST is involved in abscission step of cytokinesis and nuclear envelope reassembly during anaphase in cooperation with the ESCRT-III complex (PubMed:19000169, PubMed:21310966, PubMed:26040712). Recruited at the midbody, probably by IST1, and participates in membrane fission during abscission together with the ESCRT-III complex (PubMed:21310966). Recruited to the nuclear membrane by IST1 and mediates microtubule severing, promoting nuclear envelope sealing and mitotic spindle disassembly during late anaphase (PubMed:26040712). Required for membrane traffic from the endoplasmic reticulum (ER) to the Golgi and endosome recycling (PubMed:23897888). Recruited by IST1 to endosomes and regulates early endosomal tubulation and recycling by mediating microtubule severing (PubMed:23897888). Probably plays a role in axon growth and the formation of axonal branches (PubMed:15716377) Involved in lipid metabolism by regulating the size and distribution of lipid droplets","Expressed in brain, heart, kidney, liver, lung, pancreas, placenta and skeletal muscle. The short isoforms may predominate in brain and spinal cord","Spastic paraplegia 4, autosomal dominant: A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body.",,"Membrane Endoplasmic reticulum Midbody Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Cytoplasm, cytoskeleton Cytoplasm, perinuclear region Nucleus Cytoplasm, cytoskeleton, spindle Cytoplasm Cell projection, axon Endoplasmic reticulum membrane Nucleus membrane Lipid droplet Endosome",11809724|15716377|16219033|17389232|19000169|20530212|21310966|22637577|23897888|25875445|26040712|26875866,10610178,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
SPATA17,ENSG00000162814,Unsafe,Protein,False,True,9.9,9.9,99,12,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; choroid plexus: 2.7 nTPM; absolute ceiling;continuous selectivity; kidney: 0.7 nTPM; positive ihc; parathyroid gland: 2.5 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 2.7 nTPM (limit 2),bronchus / ciliated cells (cilia axoneme): Medium (Enhanced); bronchus / ciliated cells (tip of cilia): Medium (Enhanced); kidney / cells in tubules: Low (Enhanced); nasopharynx / ciliated cells (cilia axoneme): Medium (Enhanced); nasopharynx / ciliated cells (tip of cilia): Low (Enhanced); parathyroid gland / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 43/50 (86.0%); Glioblastoma Multiforme (validation): 22/58 (37.9%); Ovary Serous Cystadenocarcinoma (validation): 20/81 (24.7%),breast cancer: 0/10 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q96L03,https://www.uniprot.org/uniprotkb/Q96L03/entry,,,,,Cytoplasm,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Jamin2021_CT | Chang2019_TGCT | Loriot2025_S2,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct,,,,,,,,
SPATA22,ENSG00000141255,Unsafe,High RNA,False,True,223.4,223.4,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,CTA,Pass,oncoref.target-sets.2026-10-23.1,False,False,,CTA → Unsafe,True,True,True,3.4957,47.2,"hpa_single_cell: /Oligodendrocytes, max 42.6 nTPM, 1 observations >30; hpa_single_cell_tissue: brain/excitatory neurons, max 32.7 nTPM, 1 observations >30; hpa_single_cell_tissue: brain/oligodendrocytes, max 47.2 nTPM, 2 observations >30",CTA,oncoref.target-sets.2026-10-23.2,3.496 TPM; blood/naive CD8 T-cell; hpa_immune_cell_samples; vital,47.2 nTPM; brain/oligodendrocytes; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 87/133 (65.4%); Glioblastoma Multiforme (validation): 3/58 (5.2%); Bladder Urothelial Carcinoma (TCGA): 5/169 (3.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NHS9,https://www.uniprot.org/uniprotkb/Q8NHS9/entry,Meiosis-specific protein required for homologous recombination in meiosis I,Highly expressed in adult testis,"Spermatogenic failure 96: An autosomal recessive, male infertility disorder characterized by non-obstructive azoospermia due to spermatogenesis arrest at the zygotene stage. Premature ovarian failure 25: A form of premature ovarian failure, an ovarian disorder defined as the cessation of ovarian function under the age of 40 years. It is characterized by oligomenorrhea or amenorrhea, in the presence of elevated levels of serum gonadotropins and low estradiol. POF25 inheritance is autosomal recessive.",,Chromosome Nucleus,,15713825,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
SPATA24,ENSG00000170469,Unsafe,RNA,False,True,142.9,142.9,85,1,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,amygdala: 6.1 nTPM; absolute ceiling; basal ganglia: 5.5 nTPM; absolute ceiling; choroid plexus: 9.7 nTPM; absolute ceiling; heart muscle: 19.9 nTPM; absolute ceiling; hippocampal formation: 5.3 nTPM; absolute ceiling; hypothalamus: 6.1 nTPM; absolute ceiling; kidney: 14.4 nTPM; absolute ceiling; midbrain: 5.9 nTPM; absolute ceiling; pituitary gland: 12.3 nTPM; absolute ceiling; retina: 6.3 nTPM; absolute ceiling; skeletal muscle: 22.2 nTPM; absolute ceiling; spinal cord: 4.2 nTPM; absolute ceiling; tongue: 18.4 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 6.1 nTPM (limit 2); basal ganglia: 5.5 nTPM (limit 2); choroid plexus: 9.7 nTPM (limit 2); heart muscle: 19.9 nTPM (limit 12); hippocampal formation: 5.3 nTPM (limit 2); hypothalamus: 6.1 nTPM (limit 2); kidney: 14.4 nTPM (limit 12); midbrain: 5.9 nTPM (limit 2); pituitary gland: 12.3 nTPM (limit 2); retina: 6.3 nTPM (limit 2); skeletal muscle: 22.2 nTPM (limit 12); spinal cord: 4.2 nTPM (limit 2); tongue: 18.4 nTPM (limit 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Prostate Adenocarcinoma (TCGA): 453/480 (94.4%); Rectum Adenocarcinoma (validation): 194/207 (93.7%),breast cancer: 0/12 (0.0%); cervical cancer: 0/9 (0.0%),31,20,Q86W54,https://www.uniprot.org/uniprotkb/Q86W54/entry,Binds DNA with high affinity but does not bind to TATA boxes. Synergises with GMNN and TBP in activation of TATA box-containing promoters and with GMNN and TBPL1 in activation of the NF1 TATA-less promoter. May play a role in cytoplasm movement and removal during spermiogenesis (By similarity),,,,"Cytoplasm Nucleus, nucleolus Nucleus, nucleoplasm",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
SPATA31G1,ENSG00000174038,Unsafe,RNA,False,True,34.8,34.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 2.6 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 2.6 nTPM (limit 2); bone marrow: 2.6 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 152/207 (73.4%); Colon Adenocarcinoma (validation): 313/486 (64.4%); Bladder Urothelial Carcinoma (TCGA): 14/169 (8.3%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q5VYM1,https://www.uniprot.org/uniprotkb/Q5VYM1/entry,Dispensable for normal development and fertility,,,It is uncertain whether Met-1 or Met-15 is the initiator,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
SPATA33,ENSG00000167523,Unsafe,Protein,False,True,110.8,110.8,127,28,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 7.9 nTPM; absolute ceiling; basal ganglia: 7.2 nTPM; absolute ceiling; choroid plexus: 13.3 nTPM; absolute ceiling; colon: 5 nTPM; positive ihc; duodenum: 4.8 nTPM; positive ihc;absolute ceiling; hippocampal formation: 8.3 nTPM; absolute ceiling; hypothalamus: 9.3 nTPM; absolute ceiling; kidney: 11.5 nTPM; positive ihc;absolute ceiling; midbrain: 5.7 nTPM; absolute ceiling; pituitary gland: 9.5 nTPM; absolute ceiling; rectum: 2.8 nTPM; positive ihc; retina: 6.5 nTPM; absolute ceiling; small intestine: 8.9 nTPM; positive ihc;absolute ceiling; spinal cord: 5.1 nTPM; absolute ceiling; stomach: 4.9 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 7.9 nTPM (limit 2); basal ganglia: 7.2 nTPM (limit 2); choroid plexus: 13.3 nTPM (limit 2); duodenum: 4.8 nTPM (limit 2); hippocampal formation: 8.3 nTPM (limit 2); hypothalamus: 9.3 nTPM (limit 2); kidney: 11.5 nTPM (limit 2); midbrain: 5.7 nTPM (limit 2); pituitary gland: 9.5 nTPM (limit 2); retina: 6.5 nTPM (limit 2); small intestine: 8.9 nTPM (limit 2); spinal cord: 5.1 nTPM (limit 2),bronchus / ciliated cells (cell body): Medium (Enhanced); bronchus / ciliated cells (cilia axoneme): High (Enhanced); bronchus / ciliated cells (ciliary rootlets): Low (Enhanced); bronchus / ciliated cells (tip of cilia): High (Enhanced); colon / enterocytes: Low (Enhanced); duodenum / paneth cells: Medium (Enhanced); kidney / distal tubules: Medium (Enhanced); kidney / proximal tubules (cell body): Low (Enhanced); nasopharynx / ciliated cells (cell body): Medium (Enhanced); nasopharynx / ciliated cells (cilia axoneme): Low (Enhanced); nasopharynx / ciliated cells (ciliary rootlets): Low (Enhanced); nasopharynx / ciliated cells (tip of cilia): Medium (Enhanced); rectum / enterocytes: Low (Enhanced); small intestine / paneth cells: Medium (Enhanced); stomach 1 / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 202/207 (97.6%); Colon Adenocarcinoma (validation): 463/486 (95.3%); Glioblastoma Multiforme (TCGA): 125/141 (88.7%),breast cancer: 0/9 (0.0%); cervical cancer: 0/12 (0.0%),29,20,Q96N06,https://www.uniprot.org/uniprotkb/Q96N06/entry,"Plays an important role in sperm motility and male fertility (By similarity). Required for sperm midpiece flexibility and for the localization of sperm calcineurin to the mitochondria (By similarity). Promotes mitophagy as well as acts as an autophagy mediator in male germline cells (By similarity). Links damaged mitochondria to autophagosomes via its binding to the outer mitochondrial membrane protein VDAC2, as well as to key autophagy machinery component ATG16L1 (By similarity)",,,,"Cytoplasm, cytosol Nucleus Cytoplasm Mitochondrion",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Jamin2021_CT | Chang2019_TGCT | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
SPATA4,ENSG00000150628,Unsafe,RNA,False,True,135.4,135.4,85,2,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,retina: 2.2 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 2.2 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 11/50 (22.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 10/176 (5.7%); Glioblastoma Multiforme (TCGA): 3/141 (2.1%),breast cancer: 0/11 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q8NEY3,https://www.uniprot.org/uniprotkb/Q8NEY3/entry,May play a role in apoptosis regulation,"Highly expressed in testis, the expression is observed precisely in seminiferous tubules",,,Nucleus,26424010,15158438,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,Failed bulk numeric comparisons are within 20% of their cutoffs; not an automatic rescue,,,,
SPATA45,ENSG00000185523,Unsafe,RNA,False,True,11.5,11.5,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,pancreas: 2.9 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,pancreas: 2.9 nTPM (limit 2); pancreas: 2.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 6/58 (10.3%); Kidney Chromophobe (TCGA): 1/64 (1.6%); Testicular Germ Cell Tumor (TCGA): 2/133 (1.5%),renal cancer: 11/12 (91.7%); urothelial cancer: 8/10 (80.0%),29,20,Q537H7,https://www.uniprot.org/uniprotkb/Q537H7/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
SPATA46,ENSG00000171722,Unsafe,RNA,False,True,30.1,30.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 3.1 nTPM; absolute ceiling; retina: 2.3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 3.1 nTPM (limit 2); retina: 2.3 nTPM (limit 2); adrenal gland: 3.1 nTPM (baseline 2); retina: 2.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 1/80 (1.2%); Breast Invasive Carcinoma (TCGA): 12/1022 (1.2%); Lung Adenocarcinoma (validation): 1/105 (1.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q5T0L3,https://www.uniprot.org/uniprotkb/Q5T0L3/entry,Plays a role in spermiogenesis and fertilization,Testis-specific (PubMed:27488028),,,Nucleus membrane,,27488028,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
SPATA6,ENSG00000132122,Unsafe,RNA,False,True,48.6,48.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 7.8 nTPM; absolute ceiling; amygdala: 5.4 nTPM; absolute ceiling; basal ganglia: 5.1 nTPM; absolute ceiling; cerebral cortex: 3.8 nTPM; absolute ceiling; choroid plexus: 6.1 nTPM; absolute ceiling; duodenum: 2.6 nTPM; absolute ceiling; heart muscle: 4.2 nTPM; absolute ceiling; hippocampal formation: 5.7 nTPM; absolute ceiling; hypothalamus: 5.1 nTPM; absolute ceiling; kidney: 5.8 nTPM; absolute ceiling; lung: 5.7 nTPM; absolute ceiling; midbrain: 6.8 nTPM; absolute ceiling; pancreas: 4.5 nTPM; absolute ceiling; parathyroid gland: 10.3 nTPM; absolute ceiling; pituitary gland: 8.3 nTPM; absolute ceiling; retina: 12.8 nTPM; absolute ceiling;continuous selectivity; salivary gland: 6.1 nTPM; absolute ceiling; small intestine: 3.2 nTPM; absolute ceiling; smooth muscle: 4.3 nTPM; absolute ceiling; spinal cord: 6.5 nTPM; absolute ceiling; stomach: 6.5 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 7.8 nTPM (limit 2); amygdala: 5.4 nTPM (limit 2); basal ganglia: 5.1 nTPM (limit 2); cerebral cortex: 3.8 nTPM (limit 2); choroid plexus: 6.1 nTPM (limit 2); duodenum: 2.6 nTPM (limit 2); heart muscle: 4.2 nTPM (limit 2); hippocampal formation: 5.7 nTPM (limit 2); hypothalamus: 5.1 nTPM (limit 2); kidney: 5.8 nTPM (limit 2); lung: 5.7 nTPM (limit 2); midbrain: 6.8 nTPM (limit 2); pancreas: 4.5 nTPM (limit 2); parathyroid gland: 10.3 nTPM (limit 6); pituitary gland: 8.3 nTPM (limit 2); retina: 12.8 nTPM (limit 2); salivary gland: 6.1 nTPM (limit 6); small intestine: 3.2 nTPM (limit 2); smooth muscle: 4.3 nTPM (limit 2); spinal cord: 6.5 nTPM (limit 2); stomach: 6.5 nTPM (limit 6); adrenal gland: 7.8 nTPM (baseline 2); amygdala: 5.4 nTPM (baseline 2); basal ganglia: 5.1 nTPM (baseline 2); cerebral cortex: 3.8 nTPM (baseline 2); choroid plexus: 6.1 nTPM (baseline 2); duodenum: 2.6 nTPM (baseline 2); heart muscle: 4.2 nTPM (baseline 2); hippocampal formation: 5.7 nTPM (baseline 2); hypothalamus: 5.1 nTPM (baseline 2); kidney: 5.8 nTPM (baseline 2); lung: 5.7 nTPM (baseline 2); midbrain: 6.8 nTPM (baseline 2); pancreas: 4.5 nTPM (baseline 2); parathyroid gland: 10.3 nTPM (baseline 6); pituitary gland: 8.3 nTPM (baseline 2); retina: 12.8 nTPM (baseline 2); salivary gland: 6.1 nTPM (baseline 6); small intestine: 3.2 nTPM (baseline 2); smooth muscle: 4.3 nTPM (baseline 2); spinal cord: 6.5 nTPM (baseline 2); stomach: 6.5 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Glioblastoma Multiforme (TCGA): 135/141 (95.7%); Pancreatic Adenocarcinoma (validation): 72/80 (90.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9NWH7,https://www.uniprot.org/uniprotkb/Q9NWH7/entry,Required for formation of the sperm connecting piece during spermiogenesis. Sperm connecting piece is essential for linking the developing flagellum to the head during late spermiogenesis. May be involved in myosin-based microfilament transport through interaction with myosin subunits,,,,"Secreted Cell projection, cilium, flagellum",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
SPATA9,ENSG00000145757,Unsafe,Protein,False,True,26.0,26.0,83,24,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; cerebellum: 0.1 nTPM; positive ihc; cerebral cortex: 0.2 nTPM; positive ihc; colon: 0 nTPM; positive ihc; duodenum: 0 nTPM; positive ihc; heart muscle: 0 nTPM; positive ihc; pancreas: 0.3 nTPM; positive ihc; rectum: 0.1 nTPM; positive ihc; salivary gland: 0.2 nTPM; positive ihc; small intestine: 0.1 nTPM; positive ihc; stomach: 0 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,caudate / glial cells: Low (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Low (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuropil: Low (Approved); colon / glandular cells: Low (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: Low (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / glial cells: Low (Approved); pancreas / exocrine glandular cells: Low (Approved); rectum / glandular cells: Low (Approved); salivary gland / glandular cells: Low (Approved); small intestine / glandular cells: Low (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 3/50 (6.0%); Glioblastoma Multiforme (validation): 2/58 (3.4%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),glioma: 11/11 (100.0%); colorectal cancer: 5/12 (41.7%),31,20,Q9BWV2,https://www.uniprot.org/uniprotkb/Q9BWV2/entry,May play a role in testicular development/spermatogenesis and may be an important factor in male infertility,"Highly expressed in testes and pancreas. Low levels found in the heart, lungs, and brain. Very low expression detected in the placenta. No expression seen in skeletal muscle, liver, kidney, thymus, small intestine, colons, spleen, leukocytes, prostate gland, and ovary. In the adult testes, expression was about 6.44-fold higher than in the embryo testes. No expression in testes of patients with Sertoli-cell-only syndrome. In patients with arrest at spermatogonium and primary spermatocyte stages, no expression was detected. In patients with arrest at the spermatid stage, expression level was weak or absent. Variable expression was seen in patients with spermatogenic arrest",,,Membrane,12493713,12493713,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
SPATC1,ENSG00000186583,Unsafe,RNA,False,True,36.5,36.5,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 8.4 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 8.4 nTPM (limit 2); bone marrow: 8.4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 2/176 (1.1%); Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Kidney Renal Papillary Cell Carcinoma (TCGA): 2/282 (0.7%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q76KD6,https://www.uniprot.org/uniprotkb/Q76KD6/entry,,Detected only in testis,,,"Cytoplasm Cytoplasm, cytoskeleton, microtubule organizing center, centrosome",,20542897,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
SPC25,ENSG00000152253,Unsafe,Protein,False,True,3.3,8.4,86,32,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 1.1 nTPM; continuous selectivity; bone marrow: 3.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; colon: 2 nTPM; positive ihc;continuous selectivity; duodenum: 3.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 4.3 nTPM; positive ihc;continuous selectivity;reproductive not higher; kidney: 1.1 nTPM; positive ihc;continuous selectivity; lymph node: 3.9 nTPM; positive ihc;continuous selectivity;reproductive not higher; rectum: 1.5 nTPM; positive ihc;continuous selectivity; retina: 1.6 nTPM; continuous selectivity; skin: 1 nTPM; positive ihc; small intestine: 2 nTPM; positive ihc;continuous selectivity; spleen: 2.1 nTPM; positive ihc;continuous selectivity; stomach: 1.6 nTPM; positive ihc;continuous selectivity; thymus: 8.4 nTPM; continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 3.9 nTPM (limit 2); duodenum: 3.2 nTPM (limit 2),bone marrow / hematopoietic cells: Low (Enhanced); colon / glandular cells: Medium (Enhanced); duodenum / glandular cells: Low (Enhanced); esophagus / squamous epithelial cells: Low (Enhanced); kidney / cells in tubules: Low (Enhanced); lymph node / germinal center cells: High (Enhanced); lymph node / non-germinal center cells: Low (Enhanced); nasopharynx / respiratory epithelial cells: Low (Enhanced); oral mucosa / squamous epithelial cells: Medium (Enhanced); rectum / glandular cells: Low (Enhanced); skin 1 / keratinocytes: Low (Enhanced); skin 2 / epidermal cells: Low (Enhanced); small intestine / glandular cells: Low (Enhanced); spleen / cells in red pulp: Low (Enhanced); spleen / cells in white pulp: Low (Enhanced); stomach 1 / glandular cells: Medium (Enhanced); stomach 2 / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 79/80 (98.8%); Glioblastoma Multiforme (validation): 55/58 (94.8%); Breast Invasive Carcinoma (validation): 46/50 (92.0%),cervical cancer: 8/12 (66.7%); testis cancer: 8/12 (66.7%),31,20,Q9HBM1,https://www.uniprot.org/uniprotkb/Q9HBM1/entry,"Acts as a component of the essential kinetochore-associated NDC80 complex, which is required for chromosome segregation and spindle checkpoint activity (PubMed:14699129, PubMed:14738735). Required for kinetochore integrity and the organization of stable microtubule binding sites in the outer plate of the kinetochore (PubMed:14699129, PubMed:14738735). The NDC80 complex synergistically enhances the affinity of the SKA1 complex for microtubules and may allow the NDC80 complex to track depolymerizing microtubules (PubMed:23085020)",,,,"Nucleus Chromosome, centromere, kinetochore",14699129|14738735|23085020,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
SPDYA,ENSG00000163806,Unsafe,High RNA,False,True,32.0,32.0,87,7,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 15/91 values ≥5 TPM, max 8.19565; DICE MONOCYTES (unstimulated): 81/91 values ≥5 TPM, max 16.8787; DICE M2 (unstimulated): 42/90 values ≥5 TPM, max 8.75327; DICE NK (unstimulated): 5/90 values ≥5 TPM, max 8.22398; DICE TREG_MEM (unstimulated): 23/89 values ≥5 TPM, max 8.64042; DICE CD4_NAIVE (unstimulated): 23/88 values ≥5 TPM, max 11.4939; DICE TREG_NAIVE (unstimulated): 14/89 values ≥5 TPM, max 10.2865; DICE TFH (unstimulated): 47/89 values ≥5 TPM, max 11.9082; DICE TH1 (unstimulated): 51/81 values ≥5 TPM, max 10.6871; DICE THSTAR (unstimulated): 72/88 values ≥5 TPM, max 12.1999; DICE TH17 (unstimulated): 30/89 values ≥5 TPM, max 8.76089; DICE TH2 (unstimulated): 61/89 values ≥5 TPM, max 12.4041; DICE CD8_NAIVE (unstimulated): 5/89 values ≥5 TPM, max 6.31122",True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,16.8787174046,37.0,"hpa_single_cell_tissue: skeletal muscle/macrophages, max 37 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,16.88 TPM; blood/MONOCYTES; dice_monocytes; vital,37 nTPM; skeletal muscle/macrophages; hpa_single_cell_tissue; vital,Prostate Adenocarcinoma (TCGA): 407/480 (84.8%); Uterine Corpus Endometrial Carcinoma (TCGA): 119/176 (67.6%); Liver Hepatocellular Carcinoma (validation): 143/231 (61.9%),colorectal cancer: 1/10 (10.0%); skin cancer: 1/10 (10.0%),31,20,Q5MJ70,https://www.uniprot.org/uniprotkb/Q5MJ70/entry,"Regulates the G1/S phase transition of the cell cycle by binding and activating CDK1 and CDK2 (PubMed:12972555). Contributes to CDK2 activation without promoting CDK2 phosphorylation, by inducing a conformation change of the CDK2 T-loop that obstructs the substrate-binding cleft prior to kinase activation (PubMed:28666995). Mediates cell survival during the DNA damage process through activation of CDK2 (PubMed:12839962)","Highly expressed in testis. Expressed at a low level in wide range of tissues including bone marrow, brain, heart, kidney, colon, liver, placenta, spleen, skeletal muscle, salivary gland, thyroid gland, thymus, trachea and uterus. Expressed at a slightly higher level in adrenal gland, cerebellum, small intestine, lung, prostate and trachea. Expression is cell cycle-dependent, being restricted to cells in G1/S phase",,,Nucleus,11980914|12839962|12972555|28666995,11980914|15611625,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
SPDYE17,ENSG00000186645,Unsafe,Protein,False,True,0.5,0.5,85,5,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,"existing nomination or manual review; incomplete routine rna; nomination unresolved; positive normal IHC; positive ihc outside permitted; incomplete routine rna; missing normal RNA: amygdala, basal ganglia, cerebellum, hippocampal formation, hypothalamus, midbrain, pituitary gland, spinal cord; kidney: 0 nTPM; positive ihc; skin: 0.5 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 0 nTPM; positive ihc","Positive IHC in a Vital, Protected or Manageable compartment",,kidney / cells in tubules: Low (Supported); thyroid gland / glandular cells: Low (Supported),incomplete_routine_rna,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 122/207 (58.9%); Colon Adenocarcinoma (validation): 231/486 (47.5%); Pancreatic Adenocarcinoma (validation): 1/80 (1.2%),breast cancer: 0/10 (0.0%); cervical cancer: 0/11 (0.0%),29,20,A0A494C191 | P0DTA3 | P0DUD1 | P0DUD2 | P0DUX0,https://www.uniprot.org/uniprotkb/A0A494C191/entry | https://www.uniprot.org/uniprotkb/P0DTA3/entry | https://www.uniprot.org/uniprotkb/P0DUD1/entry | https://www.uniprot.org/uniprotkb/P0DUD2/entry | https://www.uniprot.org/uniprotkb/P0DUX0/entry,Acts as a modulator of the nicotinic acetylcholine receptor alpha-7 (CHRNA7) activity,,,,,27789755,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
SPECC1,ENSG00000128487,Unsafe,Protein,False,True,22.2,36.2,99,75,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 12.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 9.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 21.3 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 20.1 nTPM; absolute ceiling;continuous selectivity; bone marrow: 22.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 10.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 22 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 36.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 14.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 9.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 8.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 25.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 17.8 nTPM; absolute ceiling;continuous selectivity; kidney: 4.6 nTPM; positive ihc;absolute ceiling; lung: 5.6 nTPM; positive ihc;absolute ceiling; lymph node: 5.1 nTPM; positive ihc; midbrain: 27.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 4.6 nTPM; positive ihc;absolute ceiling; parathyroid gland: 2.9 nTPM; positive ihc; pituitary gland: 6.2 nTPM; absolute ceiling;continuous selectivity; rectum: 9.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 5.7 nTPM; absolute ceiling;continuous selectivity; salivary gland: 6 nTPM; positive ihc; skeletal muscle: 4.8 nTPM; positive ihc;absolute ceiling; skin: 3.5 nTPM; positive ihc; small intestine: 10.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 9 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 35.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 13 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 10 nTPM; positive ihc;absolute ceiling;continuous selectivity; thyroid gland: 5 nTPM; positive ihc; urinary bladder: 4.4 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 12.1 nTPM (limit 10); adrenal gland: 9.3 nTPM (limit 2); amygdala: 21.3 nTPM (limit 2); basal ganglia: 20.1 nTPM (limit 2); bone marrow: 22.9 nTPM (limit 2); cerebellum: 10.8 nTPM (limit 2); cerebral cortex: 22 nTPM (limit 2); choroid plexus: 36.2 nTPM (limit 2); colon: 14.5 nTPM (limit 6); duodenum: 9.5 nTPM (limit 2); esophagus: 8.9 nTPM (limit 6); hippocampal formation: 25.7 nTPM (limit 2); hypothalamus: 17.8 nTPM (limit 2); kidney: 4.6 nTPM (limit 2); lung: 5.6 nTPM (limit 2); midbrain: 27.3 nTPM (limit 2); pancreas: 4.6 nTPM (limit 2); pituitary gland: 6.2 nTPM (limit 2); rectum: 9.4 nTPM (limit 6); retina: 5.7 nTPM (limit 2); skeletal muscle: 4.8 nTPM (limit 2); small intestine: 10.1 nTPM (limit 2); smooth muscle: 9 nTPM (limit 2); spinal cord: 35.5 nTPM (limit 2); spleen: 13 nTPM (limit 10); stomach: 10 nTPM (limit 6),adipose tissue / adipocytes: Medium (Enhanced); adrenal gland / glandular cells: Medium (Enhanced); bone marrow / hematopoietic cells: Medium (Enhanced); bronchus / ciliated cells (cell body): High (Enhanced); bronchus / ciliated cells (cilia axoneme): Medium (Enhanced); bronchus / ciliated cells (ciliary rootlets): Medium (Enhanced); bronchus / ciliated cells (tip of cilia): Medium (Enhanced); caudate / neuronal cells: Medium (Enhanced); cerebellum / cells in granular layer: Medium (Enhanced); cerebellum / cells in molecular layer: Low (Enhanced); cerebral cortex / glial cells: Low (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); cerebral cortex / neuropil: Medium (Enhanced); colon / endothelial cells: Medium (Enhanced); colon / glandular cells: Medium (Enhanced); colon / peripheral nerve/ganglion: Low (Enhanced); duodenum / glandular cells: Medium (Enhanced); esophagus / squamous epithelial cells: Low (Enhanced); hippocampus / glial cells: Low (Enhanced); hippocampus / neuronal cells: Medium (Enhanced); kidney / cells in glomeruli: Medium (Enhanced); kidney / cells in tubules: Medium (Enhanced); lung / alveolar cells: Medium (Enhanced); lung / macrophages: Medium (Enhanced); lymph node / germinal center cells: Medium (Enhanced); lymph node / non-germinal center cells: Medium (Enhanced); nasopharynx / ciliated cells (cell body): Medium (Enhanced); nasopharynx / ciliated cells (ciliary rootlets): Medium (Enhanced); nasopharynx / ciliated cells (tip of cilia): Medium (Enhanced); oral mucosa / squamous epithelial cells: Low (Enhanced); pancreas / exocrine glandular cells: Medium (Enhanced); pancreas / pancreatic endocrine cells: Low (Enhanced); parathyroid gland / glandular cells: Medium (Enhanced); rectum / glandular cells: High (Enhanced); salivary gland / glandular cells: Medium (Enhanced); skeletal muscle / myocytes: Low (Enhanced); skin 1 / fibroblasts: Medium (Enhanced); skin 1 / keratinocytes: Low (Enhanced); skin 2 / epidermal cells: Medium (Enhanced); small intestine / glandular cells: Medium (Enhanced); smooth muscle / smooth muscle cells: Medium (Enhanced); spleen / cells in red pulp: Medium (Enhanced); stomach 1 / glandular cells: High (Enhanced); stomach 2 / glandular cells: High (Enhanced); thyroid gland / glandular cells: Low (Enhanced); urinary bladder / urothelial cells: Medium (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Pancreatic Adenocarcinoma (validation): 80/80 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%),glioma: 11/12 (91.7%); stomach cancer: 11/12 (91.7%),30,20,Q5M775,https://www.uniprot.org/uniprotkb/Q5M775/entry,,Highly expressed in testis. Barely detectable in other tissues. Also highly expressed in some cancer cell lines,,,Nucleus Membrane,,15602574,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
SPEF2,ENSG00000152582,Unsafe,Protein,False,True,15.3,18.5,93,6,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; amygdala: 2.5 nTPM; absolute ceiling; basal ganglia: 5.1 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 18.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 2.7 nTPM; absolute ceiling; hypothalamus: 4.1 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 6.3 nTPM; absolute ceiling;continuous selectivity; retina: 9.9 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 2.5 nTPM (limit 2); basal ganglia: 5.1 nTPM (limit 2); choroid plexus: 18.5 nTPM (limit 2); hippocampal formation: 2.7 nTPM (limit 2); hypothalamus: 4.1 nTPM (limit 2); pituitary gland: 6.3 nTPM (limit 2); retina: 9.9 nTPM (limit 2),bronchus / ciliated cells (cilia axoneme): High (Enhanced); bronchus / ciliated cells (tip of cilia): High (Enhanced); nasopharynx / ciliated cells (cilia axoneme): High (Enhanced); nasopharynx / ciliated cells (tip of cilia): High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 48/50 (96.0%); Kidney Renal Clear Cell Carcinoma (validation): 74/100 (74.0%); Ovary Serous Cystadenocarcinoma (validation): 41/81 (50.6%),breast cancer: 0/11 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q9C093,https://www.uniprot.org/uniprotkb/Q9C093/entry,"Required for correct axoneme development in spermatozoa. Important for normal development of the manchette and sperm head morphology. Essential for male fertility. Plays a role in localization of the intraflagellar transport protein IFT20 to the manchette, suggesting function as an adapter for dynein-mediated protein transport during spermatogenesis (PubMed:31048344, PubMed:31151990, PubMed:31278745). Plays a role in bone growth where it seems to be required for normal osteoblast differentiation (By similarity). Required for normal beat frequency of tracheal epithelial cilia and oviduct cilia (By similarity)",,"Spermatogenic failure 43: An autosomal recessive infertility disorder characterized by asthenospermia due to multiple morphologic abnormalities of sperm flagella, including short, absent, coiled, and bent flagella.",,"Cell projection, cilium, flagellum Cytoplasm, cytoskeleton, flagellum basal body Cytoplasm Cytoplasm, cytoskeleton Golgi apparatus Cytoplasm, cytoskeleton, cilium axoneme",31048344|31151990|31278745,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
SPINK2,ENSG00000128040,Unsafe,RNA,False,True,5123.9,5123.9,87,6,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,bone marrow: 13.1 nTPM; absolute ceiling; choroid plexus: 9.3 nTPM; absolute ceiling; pituitary gland: 4 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 13.1 nTPM (limit 12); choroid plexus: 9.3 nTPM (limit 2); pituitary gland: 4 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 55/133 (41.4%); Thyroid Carcinoma (TCGA): 166/495 (33.5%); Breast Invasive Carcinoma (validation): 8/50 (16.0%),breast cancer: 0/12 (0.0%); cervical cancer: 0/11 (0.0%),31,20,P20155,https://www.uniprot.org/uniprotkb/P20155/entry,"As a strong inhibitor of acrosin, it is required for normal spermiogenesis. It probably hinders premature activation of proacrosin and other proteases, thus preventing the cascade of events leading to spermiogenesis defects (PubMed:28554943). May be involved in the regulation of serine protease-dependent germ cell apoptosis (By similarity). It also inhibits trypsin",Expressed in epididymis (at protein level),"Spermatogenic failure 29: An autosomal recessive infertility disorder caused by spermatogenesis defects that result in non-obstructive azoospermia or oligozoospermia. When produced, spermatozoa are immotile and have abnormal morphology, primarily defects of the acrosome and head-neck junction.",,"Secreted Cytoplasmic vesicle, secretory vesicle, acrosome",19422058|28554943,20736409,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
SPINT3,ENSG00000101446,Unsafe,Protein,False,True,10.3,10.3,95,5,Positive somewhere,True,False,False,True,Excluded,Normal,False,,Not assessed,,,existing nomination or manual review; nomination unresolved; positive normal IHC; positive ihc outside permitted; skin: 1.2 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,skin 1 / fibrohistiocytic cells: Medium (Enhanced); skin 1 / lymphocytes: High (Enhanced); skin 2 / fibrohistiocytic cells: Low (Enhanced); skin 2 / lymphocytes: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Bladder Urothelial Carcinoma (TCGA): 3/169 (1.8%); Kidney Renal Papillary Cell Carcinoma (TCGA): 2/282 (0.7%); Liver Hepatocellular Carcinoma (TCGA): 2/362 (0.6%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),31,20,P49223,https://www.uniprot.org/uniprotkb/P49223/entry,,,,,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
SPINT4,ENSG00000149651,Unsafe,Protein,False,True,272.1,272.1,79,7,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,existing nomination or manual review; nomination unresolved; positive normal IHC; positive ihc outside permitted; adrenal gland: 0 nTPM; positive ihc; salivary gland: 0 nTPM; positive ihc; small intestine: 0 nTPM; positive ihc; spleen: 0 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,adrenal gland / glandular cells: Low (Enhanced); salivary gland / glandular cells: Low (Enhanced); small intestine / glandular cells: Low (Enhanced); spleen / cells in red pulp: Low (Enhanced); spleen / cells in white pulp: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 6/207 (2.9%); Colon Adenocarcinoma (validation): 5/486 (1.0%); Colon Adenocarcinoma (TCGA): 2/254 (0.8%),liver cancer: 3/9 (33.3%); melanoma: 2/11 (18.2%),31,20,Q6UDR6,https://www.uniprot.org/uniprotkb/Q6UDR6/entry,,,,,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
SPMIP4,ENSG00000153790,Unsafe,RNA,False,True,63.6,63.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 7.6 nTPM; absolute ceiling; basal ganglia: 2.5 nTPM; absolute ceiling; cerebellum: 3.8 nTPM; absolute ceiling; colon: 6.6 nTPM; absolute ceiling; duodenum: 4.3 nTPM; absolute ceiling; heart muscle: 2.1 nTPM; absolute ceiling; kidney: 2.7 nTPM; absolute ceiling; lung: 2.5 nTPM; absolute ceiling; pituitary gland: 2.1 nTPM; absolute ceiling; retina: 2.6 nTPM; absolute ceiling; small intestine: 3.7 nTPM; absolute ceiling; smooth muscle: 2.9 nTPM; absolute ceiling; spinal cord: 2.9 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 7.6 nTPM (limit 2); basal ganglia: 2.5 nTPM (limit 2); cerebellum: 3.8 nTPM (limit 2); colon: 6.6 nTPM (limit 6); duodenum: 4.3 nTPM (limit 2); heart muscle: 2.1 nTPM (limit 2); kidney: 2.7 nTPM (limit 2); lung: 2.5 nTPM (limit 2); pituitary gland: 2.1 nTPM (limit 2); retina: 2.6 nTPM (limit 2); small intestine: 3.7 nTPM (limit 2); smooth muscle: 2.9 nTPM (limit 2); spinal cord: 2.9 nTPM (limit 2); adrenal gland: 7.6 nTPM (baseline 2); basal ganglia: 2.5 nTPM (baseline 2); cerebellum: 3.8 nTPM (baseline 2); colon: 6.6 nTPM (baseline 6); duodenum: 4.3 nTPM (baseline 2); heart muscle: 2.1 nTPM (baseline 2); kidney: 2.7 nTPM (baseline 2); lung: 2.5 nTPM (baseline 2); pituitary gland: 2.1 nTPM (baseline 2); retina: 2.6 nTPM (baseline 2); small intestine: 3.7 nTPM (baseline 2); smooth muscle: 2.9 nTPM (baseline 2); spinal cord: 2.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 87/133 (65.4%); Rectum Adenocarcinoma (validation): 129/207 (62.3%); Breast Invasive Carcinoma (validation): 31/50 (62.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8N865,https://www.uniprot.org/uniprotkb/Q8N865/entry,Microtubule inner protein (MIP) part of the dynein-decorated doublet microtubules (DMTs) in flagellum axoneme. May serve to reinforce and thus stabilize the microtubule structure in the sperm flagella,Predominantly expressed in the testes,,,"Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Cytoplasm, cytoskeleton, flagellum axoneme",,32588039,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
SPMIP5,ENSG00000165863,Unsafe,High RNA,False,True,82.2,82.2,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,hpa_immune_cell basophil: 10.2 nTPM; hpa_immune_monaco basophil: 30.8 TPM,True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,30.8,29.3301,"hpa_immune_monaco: blood/basophil, max 30.8 TPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,30.8 TPM; blood/basophil; hpa_immune_monaco; vital,29.33 nTPM; blood/basophil; hpa_immune_cell_samples; vital,Breast Invasive Carcinoma (validation): 32/50 (64.0%); Breast Invasive Carcinoma (TCGA): 146/1022 (14.3%); Uterine Corpus Endometrial Carcinoma (TCGA): 19/176 (10.8%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8WW14,https://www.uniprot.org/uniprotkb/Q8WW14/entry,Microtubule inner protein (MIP) part of the dynein-decorated doublet microtubules (DMTs) in flagellum axoneme. May serve to reinforce and thus stabilize the microtubule structure in the sperm flagella,Expressed in testis (at protein level). Strongly expressed in peritubular cells and Leydig cells and weakly expressed in the cytoplasm of spermatocytes,,,"Cytoplasm, cytoskeleton, flagellum axoneme Cytoplasm Nucleus",,25609838,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Jamin2021_CT | Jamin2021_core | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,All audited maxima are within 10% above 30; other gates still require review,,,,
SPRED1,ENSG00000166068,Unsafe,Protein,False,True,13.5,30.2,79,54,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 12.2 nTPM; continuous selectivity; adrenal gland: 7.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 14.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 16.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 0.7 nTPM; positive ihc; cerebellum: 5.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 20 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 2.6 nTPM; absolute ceiling; colon: 11 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 8 nTPM; absolute ceiling;continuous selectivity; esophagus: 5.9 nTPM; positive ihc;continuous selectivity; heart muscle: 7.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 12.9 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 9.8 nTPM; absolute ceiling;continuous selectivity; kidney: 8.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 5.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 16.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 7 nTPM; continuous selectivity; midbrain: 11.4 nTPM; absolute ceiling;continuous selectivity; pancreas: 4.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 6.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 3.9 nTPM; absolute ceiling;continuous selectivity; rectum: 10.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 7.2 nTPM; absolute ceiling;continuous selectivity; salivary gland: 5.4 nTPM; positive ihc;continuous selectivity; skeletal muscle: 2.6 nTPM; positive ihc;absolute ceiling; skin: 6 nTPM; positive ihc;continuous selectivity; small intestine: 8.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 9.2 nTPM; absolute ceiling;continuous selectivity; spinal cord: 11.6 nTPM; absolute ceiling;continuous selectivity; spleen: 8.8 nTPM; continuous selectivity; stomach: 10 nTPM; positive ihc;absolute ceiling;continuous selectivity; thyroid gland: 30.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; tongue: 7.7 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 12.7 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 7.9 nTPM (limit 2); amygdala: 14.4 nTPM (limit 2); basal ganglia: 16.5 nTPM (limit 2); cerebellum: 5.5 nTPM (limit 2); cerebral cortex: 20 nTPM (limit 2); choroid plexus: 2.6 nTPM (limit 2); colon: 11 nTPM (limit 6); duodenum: 8 nTPM (limit 4); heart muscle: 7.1 nTPM (limit 2); hippocampal formation: 12.9 nTPM (limit 2); hypothalamus: 9.8 nTPM (limit 2); kidney: 8.8 nTPM (limit 2); liver: 5.4 nTPM (limit 2); lung: 16.9 nTPM (limit 2); midbrain: 11.4 nTPM (limit 2); pancreas: 4.4 nTPM (limit 2); parathyroid gland: 6.6 nTPM (limit 6); pituitary gland: 3.9 nTPM (limit 2); rectum: 10.6 nTPM (limit 6); retina: 7.2 nTPM (limit 2); skeletal muscle: 2.6 nTPM (limit 2); small intestine: 8.1 nTPM (limit 2); smooth muscle: 9.2 nTPM (limit 4); spinal cord: 11.6 nTPM (limit 2); stomach: 10 nTPM (limit 6); thyroid gland: 30.2 nTPM (limit 10); tongue: 7.7 nTPM (limit 6); urinary bladder: 12.7 nTPM (limit 6),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Low (Approved); cerebral cortex / neuropil: Medium (Approved); colon / glandular cells: Low (Approved); colon / peripheral nerve/ganglion: Low (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in tubules: Low (Approved); liver / hepatocytes: Medium (Approved); lung / macrophages: Low (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Low (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (TCGA): 141/141 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%),liver cancer: 6/12 (50.0%); glioma: 4/11 (36.4%),31,20,Q7Z699,https://www.uniprot.org/uniprotkb/Q7Z699/entry,"Tyrosine kinase substrate that inhibits growth-factor-mediated activation of MAP kinase (By similarity). Negatively regulates hematopoiesis of bone marrow (By similarity). Inhibits fibroblast growth factor (FGF)-induced retinal lens fiber differentiation, probably by inhibiting FGF-mediated phosphorylation of ERK1/2 (By similarity). Attenuates actin stress fiber formation via inhibition of TESK1-mediated phosphorylation of cofilin (PubMed:18216281). Inhibits TGFB-induced epithelial-to-mesenchymal transition in lens epithelial cells (By similarity)",Weakly expressed in embryonic cell line HEK293,"Legius syndrome: An autosomal dominant syndrome characterized mainly by cafe-au-lait macules without neurofibromas or other tumor manifestations of neurofibromatosis type 1, axillary freckling, and macrocephaly. Additional clinical manifestations include Noonan-like facial dysmorphism, lipomas, learning disabilities, and features of attention deficit-hyperactivity disorder.",,"Cell membrane Membrane, caveola Nucleus",18216281,15580519,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
SPRN,ENSG00000203772,Unsafe,RNA,False,True,3.6,25.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 9.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 8.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 16.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 25.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 2.3 nTPM; continuous selectivity; esophagus: 2.8 nTPM; continuous selectivity; heart muscle: 1.7 nTPM; continuous selectivity; hippocampal formation: 13.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 6.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 5.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; liver: 17.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 1.6 nTPM; continuous selectivity; midbrain: 4.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 2.9 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 2.1 nTPM; continuous selectivity; skeletal muscle: 1.9 nTPM; continuous selectivity; skin: 1.8 nTPM; continuous selectivity; small intestine: 3.2 nTPM; absolute ceiling;continuous selectivity; spinal cord: 3.3 nTPM; absolute ceiling;continuous selectivity; spleen: 4.6 nTPM; continuous selectivity;reproductive not higher; stomach: 3.5 nTPM; continuous selectivity; thyroid gland: 3.4 nTPM; continuous selectivity; urinary bladder: 1.6 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 4 nTPM (limit 2); amygdala: 9.4 nTPM (limit 2); basal ganglia: 8.7 nTPM (limit 2); cerebellum: 16.7 nTPM (limit 2); cerebral cortex: 25.1 nTPM (limit 2); hippocampal formation: 13.3 nTPM (limit 2); hypothalamus: 6.5 nTPM (limit 2); kidney: 5.3 nTPM (limit 2); liver: 17.3 nTPM (limit 2); midbrain: 4.3 nTPM (limit 2); pancreas: 2.9 nTPM (limit 2); pituitary gland: 5 nTPM (limit 2); small intestine: 3.2 nTPM (limit 2); spinal cord: 3.3 nTPM (limit 2); adrenal gland: 4 nTPM (baseline 2); amygdala: 9.4 nTPM (baseline 2); basal ganglia: 8.7 nTPM (baseline 2); cerebellum: 16.7 nTPM (baseline 2); cerebral cortex: 25.1 nTPM (baseline 2); hippocampal formation: 13.3 nTPM (baseline 2); hypothalamus: 6.5 nTPM (baseline 2); kidney: 5.3 nTPM (baseline 2); liver: 17.3 nTPM (baseline 2); midbrain: 4.3 nTPM (baseline 2); pancreas: 2.9 nTPM (baseline 2); pituitary gland: 5 nTPM (baseline 2); small intestine: 3.2 nTPM (baseline 2); spinal cord: 3.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 42/50 (84.0%); Liver Hepatocellular Carcinoma (validation): 105/231 (45.5%); Uterine Corpus Endometrial Carcinoma (TCGA): 65/176 (36.9%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q5BIV9,https://www.uniprot.org/uniprotkb/Q5BIV9/entry,Prion-like protein that has PrP(C)-like neuroprotective activity. May act as a modulator for the biological actions of normal and abnormal PrP (By similarity),"Mainly expressed in brain. In brain, it is expressed in hippocampus",,,Cell membrane,,14527721,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
SPRR4,ENSG00000184148,Unsafe,Protein,False,True,7.2,140.9,97,8,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; esophagus: 1.1 nTPM; positive ihc; skin: 140.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",skin: 140.9 nTPM (limit 10),esophagus / squamous epithelial cells: Low (Enhanced); oral mucosa / squamous epithelial cells: Low (Enhanced); skin 1 / cells in granular layer: Medium (Enhanced); skin 2 / cells in granular layer: Medium (Enhanced); skin 2 / cells in spinous layer: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Head and Neck Squamous Cell Carcinoma (TCGA): 263/492 (53.5%); Skin Cuteneous Melanoma (TCGA): 19/99 (19.2%); Lung Squamous Cell Carcinoma (TCGA): 70/489 (14.3%),skin cancer: 6/10 (60.0%); cervical cancer: 5/12 (41.7%),31,20,Q96PI1,https://www.uniprot.org/uniprotkb/Q96PI1/entry,Cross-linked envelope protein of keratinocytes. Involved in UV-induced cornification,,,,"Cytoplasm Cytoplasm, cell cortex",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
SPRTN,ENSG00000010072,Unsafe,Protein,False,True,14.1,14.1,81,23,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 3.5 nTPM; positive ihc;absolute ceiling; amygdala: 2.5 nTPM; absolute ceiling; basal ganglia: 2.5 nTPM; absolute ceiling; bone marrow: 11.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 2.1 nTPM; positive ihc;absolute ceiling; cerebral cortex: 4.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 2.1 nTPM; absolute ceiling; colon: 3.6 nTPM; positive ihc; duodenum: 3.9 nTPM; absolute ceiling;continuous selectivity; esophagus: 5.5 nTPM; continuous selectivity; heart muscle: 4.3 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 2.8 nTPM; absolute ceiling; hypothalamus: 2.7 nTPM; absolute ceiling; kidney: 4.4 nTPM; absolute ceiling;continuous selectivity; liver: 5 nTPM; absolute ceiling;continuous selectivity; lung: 3.6 nTPM; absolute ceiling; lymph node: 6.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 2.9 nTPM; absolute ceiling; pancreas: 2.6 nTPM; absolute ceiling; pituitary gland: 2.7 nTPM; absolute ceiling; retina: 4.7 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 8.2 nTPM; absolute ceiling;continuous selectivity; skin: 5.7 nTPM; positive ihc; small intestine: 3.5 nTPM; absolute ceiling; smooth muscle: 4.7 nTPM; absolute ceiling;continuous selectivity; spinal cord: 4 nTPM; absolute ceiling;continuous selectivity; thymus: 7 nTPM; continuous selectivity; thyroid gland: 4.9 nTPM; positive ihc; tongue: 5.1 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 3.5 nTPM (limit 2); amygdala: 2.5 nTPM (limit 2); basal ganglia: 2.5 nTPM (limit 2); bone marrow: 11.7 nTPM (limit 2); cerebellum: 2.1 nTPM (limit 2); cerebral cortex: 4.4 nTPM (limit 2); choroid plexus: 2.1 nTPM (limit 2); duodenum: 3.9 nTPM (limit 2); heart muscle: 4.3 nTPM (limit 2); hippocampal formation: 2.8 nTPM (limit 2); hypothalamus: 2.7 nTPM (limit 2); kidney: 4.4 nTPM (limit 2); liver: 5 nTPM (limit 2); lung: 3.6 nTPM (limit 2); lymph node: 6.2 nTPM (limit 6); midbrain: 2.9 nTPM (limit 2); pancreas: 2.6 nTPM (limit 2); pituitary gland: 2.7 nTPM (limit 2); retina: 4.7 nTPM (limit 2); skeletal muscle: 8.2 nTPM (limit 2); small intestine: 3.5 nTPM (limit 2); smooth muscle: 4.7 nTPM (limit 2); spinal cord: 4 nTPM (limit 2); adrenal gland: 3.5 nTPM (baseline 2); amygdala: 2.5 nTPM (baseline 2); basal ganglia: 2.5 nTPM (baseline 2); bone marrow: 11.7 nTPM (baseline 2); cerebellum: 2.1 nTPM (baseline 2); cerebral cortex: 4.4 nTPM (baseline 2); choroid plexus: 2.1 nTPM (baseline 2); duodenum: 3.9 nTPM (baseline 2); heart muscle: 4.3 nTPM (baseline 2); hippocampal formation: 2.8 nTPM (baseline 2); hypothalamus: 2.7 nTPM (baseline 2); kidney: 4.4 nTPM (baseline 2); liver: 5 nTPM (baseline 2); lung: 3.6 nTPM (baseline 2); lymph node: 6.2 nTPM (baseline 6); midbrain: 2.9 nTPM (baseline 2); pancreas: 2.6 nTPM (baseline 2); pituitary gland: 2.7 nTPM (baseline 2); retina: 4.7 nTPM (baseline 2); skeletal muscle: 8.2 nTPM (baseline 2); small intestine: 3.5 nTPM (baseline 2); smooth muscle: 4.7 nTPM (baseline 2); spinal cord: 4 nTPM (baseline 2),adrenal gland / glandular cells: Low (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); caudate / glial cells: Low (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in molecular layer: Medium (Uncertain); cerebellum / Purkinje cells: High (Uncertain); cerebral cortex / endothelial cells: Low (Uncertain); cerebral cortex / glial cells: Low (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / endothelial cells: Low (Uncertain); colon / peripheral nerve/ganglion: Low (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); lymph node / non-germinal center cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Low (Uncertain); skin 1 / keratinocytes: Medium (Uncertain); skin 1 / Langerhans: Low (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); thyroid gland / glandular cells: Low (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 80/80 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Rectum Adenocarcinoma (validation): 204/207 (98.6%),melanoma: 1/11 (9.1%); cervical cancer: 1/12 (8.3%),29,20,Q9H040,https://www.uniprot.org/uniprotkb/Q9H040/entry,"DNA-dependent metalloendopeptidase that mediates the proteolytic cleavage of covalent DNA-protein cross-links (DPCs) during DNA synthesis and mitosis, thereby playing a key role in maintaining genomic integrity (PubMed:27852435, PubMed:27871365, PubMed:27871366, PubMed:30893605, PubMed:32649882, PubMed:36608669, PubMed:41610251). DPCs are highly toxic DNA lesions that interfere with essential chromatin transactions, such as replication and transcription, and which are induced by reactive agents, such as UV light or formaldehyde (PubMed:27852435, PubMed:27871365, PubMed:27871366, PubMed:32649882, PubMed:36608669, PubMed:41610251). Associates with the DNA replication machinery and specifically removes DPCs during DNA synthesis (PubMed:27852435, PubMed:27871365, PubMed:27871366, PubMed:32649882). Catalyzes proteolytic cleavage of the HMCES DNA-protein cross-link following unfolding by the BRIP1/FANCJ helicase (PubMed:36608669). Acts as a pleiotropic protease for DNA-binding proteins cross-linked with DNA, such as TOP1, TOP2A, histones H3 and H4 (PubMed:27871366). Mediates degradation of DPCs that are not ubiquitinated, while it is not able to degrade ubiquitinated DPCs (By similarity). SPRTN activation requires polymerase collision with DPCs followed by helicase bypass of DPCs (By similarity). Involved in recruitment of VCP/p97 to sites of DNA damage (PubMed:22902628, PubMed:23042605, PubMed:23042607, PubMed:32152270). Also acts as an activator of CHEK1 during normal DNA replication by mediating proteolytic cleavage of CHEK1, thereby promoting CHEK1 removal from chromatin and subsequent activation (PubMed:31316063). Does not activate CHEK1 in response to DNA damage (PubMed:31316063). May also act as a 'reader' of ubiquitinated PCNA: recruited to sites of UV damage and interacts with ubiquitinated PCNA and RAD18, the E3 ubiquitin ligase that monoubiquitinates PCNA (PubMed:22681887, PubMed:22894931, PubMed:22902628, PubMed:22987070). Facilitates chromatin association of RAD18 and is required for efficient PCNA monoubiquitination, promoting a feed-forward loop to enhance PCNA ubiquitination and translesion DNA synthesis (PubMed:22681887)",,"Ruijs-Aalfs progeroid syndrome: An autosomal recessive syndrome characterized by genomic instability, progeroid features, and susceptibility toward early onset hepatocellular carcinoma.",,Nucleus Chromosome,22681887|22894931|22902628|22987070|23042605|23042607|27852435|27871365|27871366|30893605|31316063|32152270|32649882|36608669|41610251,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
SPTA1,ENSG00000163554,Unsafe,Protein,False,True,1.6,74.7,81,2,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 74.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; spleen: 1.1 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 74.7 nTPM (limit 2); bone marrow: 74.7 nTPM (baseline 2),bone marrow / hematopoietic cells: High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Squamous Cell Carcinoma (validation): 1/68 (1.5%); Liver Hepatocellular Carcinoma (validation): 3/231 (1.3%); Liver Hepatocellular Carcinoma (TCGA): 3/362 (0.8%),testis cancer: 9/12 (75.0%); renal cancer: 7/12 (58.3%),31,20,P02549,https://www.uniprot.org/uniprotkb/P02549/entry,Spectrin is the major constituent of the cytoskeletal network underlying the erythrocyte plasma membrane. It associates with band 4.1 and actin to form the cytoskeletal superstructure of the erythrocyte plasma membrane,,"Elliptocytosis 2: A Rhesus-unlinked form of hereditary elliptocytosis, a genetically heterogeneous, autosomal dominant hematologic disorder. It is characterized by variable hemolytic anemia and elliptical or oval red cell shape. Hereditary pyropoikilocytosis: Autosomal recessive hematologic disorder characterized by hemolytic anemia, microspherocytosis, poikilocytosis, and an unusual thermal sensitivity of red cells. Spherocytosis 3: Spherocytosis is a hematologic disorder leading to chronic hemolytic anemia and characterized by numerous abnormally shaped erythrocytes which are generally spheroidal. SPH3 is characterized by severe hemolytic anemia. Inheritance is autosomal recessive.",,"Cytoplasm, cytoskeleton Cytoplasm, cell cortex",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
SRSF12,ENSG00000154548,Unsafe,RNA,False,True,11.1,11.1,84,3,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,amygdala: 3.7 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 3.3 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 4.2 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 3 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 3.9 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 2.5 nTPM; absolute ceiling; retina: 2.3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 3.7 nTPM (limit 2); basal ganglia: 3.3 nTPM (limit 2); cerebral cortex: 4.2 nTPM (limit 4); hippocampal formation: 3 nTPM (limit 2); hypothalamus: 3.9 nTPM (limit 2); pituitary gland: 2.5 nTPM (limit 2); retina: 2.3 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 56/58 (96.6%); Testicular Germ Cell Tumor (TCGA): 39/133 (29.3%); Glioblastoma Multiforme (TCGA): 39/141 (27.7%),colorectal cancer: 2/11 (18.2%); cervical cancer: 1/8 (12.5%),30,20,Q8WXF0,https://www.uniprot.org/uniprotkb/Q8WXF0/entry,Splicing factor that seems to antagonize SR proteins in pre-mRNA splicing regulation,Expressed in testis,,,Nucleus,11684676,11684676,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
SSX2IP,ENSG00000117155,Unsafe,Protein,False,True,102.6,115.1,102,85,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 3 nTPM; positive ihc;absolute ceiling; amygdala: 8.2 nTPM; absolute ceiling; basal ganglia: 14.6 nTPM; absolute ceiling; bone marrow: 14.7 nTPM; positive ihc;absolute ceiling; cerebellum: 20.4 nTPM; positive ihc;absolute ceiling; cerebral cortex: 27.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 6.6 nTPM; absolute ceiling; colon: 7.9 nTPM; positive ihc;absolute ceiling; duodenum: 42 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 6.2 nTPM; positive ihc;absolute ceiling; heart muscle: 9.1 nTPM; positive ihc;absolute ceiling; hippocampal formation: 10.4 nTPM; absolute ceiling; hypothalamus: 5.4 nTPM; absolute ceiling; kidney: 15.9 nTPM; positive ihc;absolute ceiling; liver: 14.1 nTPM; positive ihc;absolute ceiling; lung: 3.7 nTPM; positive ihc;absolute ceiling; lymph node: 6.2 nTPM; positive ihc;absolute ceiling; midbrain: 3.3 nTPM; absolute ceiling; pancreas: 6.9 nTPM; positive ihc;absolute ceiling; parathyroid gland: 8.9 nTPM; positive ihc;absolute ceiling; pituitary gland: 9.3 nTPM; absolute ceiling; rectum: 7.6 nTPM; positive ihc;absolute ceiling; retina: 115.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 6.7 nTPM; positive ihc;absolute ceiling; skin: 6.3 nTPM; positive ihc; small intestine: 26.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 10.3 nTPM; positive ihc;absolute ceiling; spinal cord: 3.3 nTPM; absolute ceiling; spleen: 5.2 nTPM; positive ihc; stomach: 6.9 nTPM; positive ihc;absolute ceiling; thymus: 11.7 nTPM; absolute ceiling; thyroid gland: 8 nTPM; positive ihc; urinary bladder: 5.5 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 3 nTPM (limit 2); amygdala: 8.2 nTPM (limit 2); basal ganglia: 14.6 nTPM (limit 2); bone marrow: 14.7 nTPM (limit 2); cerebellum: 20.4 nTPM (limit 2); cerebral cortex: 27.1 nTPM (limit 2); choroid plexus: 6.6 nTPM (limit 2); colon: 7.9 nTPM (limit 6); duodenum: 42 nTPM (limit 2); esophagus: 6.2 nTPM (limit 6); heart muscle: 9.1 nTPM (limit 2); hippocampal formation: 10.4 nTPM (limit 2); hypothalamus: 5.4 nTPM (limit 2); kidney: 15.9 nTPM (limit 2); liver: 14.1 nTPM (limit 2); lung: 3.7 nTPM (limit 2); lymph node: 6.2 nTPM (limit 6); midbrain: 3.3 nTPM (limit 2); pancreas: 6.9 nTPM (limit 2); parathyroid gland: 8.9 nTPM (limit 6); pituitary gland: 9.3 nTPM (limit 2); rectum: 7.6 nTPM (limit 6); retina: 115.1 nTPM (limit 2); salivary gland: 6.7 nTPM (limit 6); small intestine: 26.1 nTPM (limit 2); smooth muscle: 10.3 nTPM (limit 2); spinal cord: 3.3 nTPM (limit 2); stomach: 6.9 nTPM (limit 6); thymus: 11.7 nTPM (limit 10),adrenal gland / glandular cells: Medium (Supported); bone marrow / hematopoietic cells: High (Supported); bronchus / respiratory epithelial cells: High (Supported); caudate / glial cells: Medium (Supported); caudate / neuronal cells: High (Supported); cerebellum / Purkinje cells: Low (Supported); cerebral cortex / glial cells: High (Supported); cerebral cortex / neuronal cells: High (Supported); cerebral cortex / neuropil: Low (Supported); colon / glandular cells: High (Supported); colon / peripheral nerve/ganglion: High (Supported); duodenum / glandular cells: High (Supported); esophagus / squamous epithelial cells: Low (Supported); heart muscle / cardiomyocytes: Low (Supported); hippocampus / glial cells: High (Supported); hippocampus / neuronal cells: High (Supported); kidney / cells in glomeruli: High (Supported); kidney / cells in tubules: High (Supported); liver / cholangiocytes: Medium (Supported); liver / hepatocytes: Low (Supported); lung / alveolar cells type I: Medium (Supported); lung / endothelial cells: Low (Supported); lung / macrophages: Medium (Supported); lymph node / non-germinal center cells: High (Supported); nasopharynx / respiratory epithelial cells: Medium (Supported); oral mucosa / squamous epithelial cells: Medium (Supported); pancreas / exocrine glandular cells: High (Supported); pancreas / pancreatic endocrine cells: High (Supported); parathyroid gland / glandular cells: High (Supported); rectum / glandular cells: High (Supported); salivary gland / glandular cells: High (Supported); skin 1 / arrector pili muscle cells: Low (Supported); skin 1 / cells in basal layer: Low (Supported); skin 1 / cells in granular layer: Low (Supported); skin 1 / cells in spinous layer: Low (Supported); skin 1 / endothelial cells: Low (Supported); skin 1 / fibrohistiocytic cells: Medium (Supported); skin 1 / langerhans cells: Low (Supported); skin 1 / lymphocytes: Medium (Supported); skin 2 / cells in basal layer: Medium (Supported); skin 2 / cells in granular layer: Low (Supported); skin 2 / cells in spinous layer: Low (Supported); skin 2 / endothelial cells: Medium (Supported); skin 2 / fibrohistiocytic cells: Medium (Supported); skin 2 / langerhans cells: Low (Supported); skin 2 / lymphocytes: Medium (Supported); small intestine / glandular cells: High (Supported); smooth muscle / smooth muscle cells: Medium (Supported); spleen / cells in red pulp: Medium (Supported); spleen / cells in white pulp: Medium (Supported); stomach 1 / glandular cells: High (Supported); stomach 2 / glandular cells: High (Supported); thyroid gland / glandular cells: High (Supported); urinary bladder / urothelial cells: Medium (Supported),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 484/486 (99.6%),colorectal cancer: 11/11 (100.0%); endometrial cancer: 11/11 (100.0%),31,20,Q9Y2D8,https://www.uniprot.org/uniprotkb/Q9Y2D8/entry,"Belongs to an adhesion system, which plays a role in the organization of homotypic, interneuronal and heterotypic cell-cell adherens junctions (AJs). May connect the nectin-afadin and E-cadherin-catenin system through alpha-actinin and may be involved in organization of the actin cytoskeleton at AJs through afadin and alpha-actinin (By similarity). Involved in cell movement: localizes at the leading edge of moving cells in response to PDGF and is required for the formation of the leading edge and the promotion of cell movement, possibly via activation of Rac signaling (By similarity). Acts as a centrosome maturation factor, probably by maintaining the integrity of the pericentriolar material and proper microtubule nucleation at mitotic spindle poles. The function seems to implicate at least in part WRAP73; the SSX2IP:WRAP73 complex is proposed to act as regulator of spindle anchoring at the mitotic centrosome (PubMed:23816619, PubMed:26545777). Involved in ciliogenesis (PubMed:24356449). It is required for targeted recruitment of the BBSome, CEP290, RAB8, and SSTR3 to the cilia (PubMed:24356449)","Widely expressed, with the highest expression in brain, intermediate expression in kidney, testis, spinal cord, liver, heart, lung, skeletal muscle, ovary, fetal liver and fetal brain, and little to no expression in pancreas and spleen. All specific brain regions showed intermediate to high expression, with highest expression in amygdala. Also expressed in fetal tissues, mainly in liver and brain",,,"Cell junction, adherens junction Nucleus Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriolar satellite Cytoplasm, cytoskeleton, cilium basal body",23816619|24356449|26545777,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Jamin2021_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
STAG3,ENSG00000066923,Unsafe,Protein,False,True,51.7,51.7,84,6,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; heart muscle: 0.9 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,heart muscle / cardiomyocytes: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 26/50 (52.0%); Ovary Serous Cystadenocarcinoma (validation): 29/81 (35.8%); Liver Hepatocellular Carcinoma (validation): 63/231 (27.3%),breast cancer: 0/10 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q9UJ98,https://www.uniprot.org/uniprotkb/Q9UJ98/entry,"Meiosis specific component of cohesin complex. The cohesin complex is required for the cohesion of sister chromatids after DNA replication. The cohesin complex apparently forms a large proteinaceous ring within which sister chromatids can be trapped. At anaphase, the complex is cleaved and dissociates from chromatin, allowing sister chromatids to segregate. The meiosis-specific cohesin complex probably replaces mitosis specific cohesin complex when it dissociates from chromatin during prophase I",Testis specific,"Premature ovarian failure 8: An ovarian disorder defined as the cessation of ovarian function under the age of 40 years. It is characterized by oligomenorrhea or amenorrhea, in the presence of elevated levels of serum gonadotropins and low estradiol. Spermatogenic failure 61: An autosomal recessive male infertility disorder characterized by non-obstructive azoospermia, due to complete meiotic arrest at the primary spermatocyte stage.",,"Nucleus Chromosome Chromosome, centromere",31682730,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
STAP1,ENSG00000035720,Unsafe,Protein,False,True,2.7,49.5,104,32,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 5.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; colon: 2.3 nTPM; positive ihc;continuous selectivity; duodenum: 1.7 nTPM; positive ihc;continuous selectivity; kidney: 8.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 39.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; rectum: 2.2 nTPM; positive ihc;continuous selectivity; small intestine: 7.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; spleen: 15.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; stomach: 2.2 nTPM; continuous selectivity; thymus: 6.3 nTPM; continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 5.8 nTPM (limit 2); kidney: 8.9 nTPM (limit 2); lymph node: 39.8 nTPM (limit 6); small intestine: 7.9 nTPM (limit 2); spleen: 15.7 nTPM (limit 10),bone marrow / hematopoietic cells: Low (Enhanced); colon / endocrine cells: Low (Enhanced); colon / enterocytes: Low (Enhanced); colon / goblet cells: Low (Enhanced); colon / mucosal lymphoid cells: High (Enhanced); duodenum / endocrine cells: Medium (Enhanced); duodenum / enterocytes: Medium (Enhanced); duodenum / enterocytes - Microvilli: Medium (Enhanced); duodenum / glands of Brunner: Medium (Enhanced); duodenum / goblet cells: Medium (Enhanced); duodenum / paneth cells: Medium (Enhanced); kidney / collecting ducts: High (Enhanced); kidney / distal tubules: Medium (Enhanced); kidney / proximal tubules (cell body): High (Enhanced); lymph node / germinal center cells: High (Enhanced); lymph node / non-germinal center cells: Medium (Enhanced); rectum / enterocytes: Medium (Enhanced); rectum / goblet cells: Medium (Enhanced); rectum / mucosal lymphoid cells: High (Enhanced); small intestine / endocrine cells: Medium (Enhanced); small intestine / enterocytes: Medium (Enhanced); small intestine / enterocytes - Microvilli: Medium (Enhanced); small intestine / goblet cells: Medium (Enhanced); small intestine / paneth cells: Low (Enhanced); spleen / cells in red pulp: Low (Enhanced); spleen / cells in white pulp: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Chromophobe (TCGA): 58/64 (90.6%); Breast Invasive Carcinoma (validation): 24/50 (48.0%); Lung Adenocarcinoma (validation): 13/105 (12.4%),lymphoma: 6/11 (54.5%); prostate cancer: 2/10 (20.0%),31,20,Q9ULZ2,https://www.uniprot.org/uniprotkb/Q9ULZ2/entry,"In BCR signaling, appears to function as a docking protein acting downstream of TEC and participates in a positive feedback loop by increasing the activity of TEC",,,,Nucleus Cytoplasm Mitochondrion,10518561,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
STEAP1B,ENSG00000105889,Unsafe,RNA,False,True,2.2,5.5,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 1.5 nTPM; continuous selectivity; basal ganglia: 2.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 1.8 nTPM; continuous selectivity; choroid plexus: 5.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 2.1 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 1.2 nTPM; continuous selectivity; lymph node: 1.6 nTPM; continuous selectivity; midbrain: 2.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 1.2 nTPM; continuous selectivity; spinal cord: 3.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 1.8 nTPM; continuous selectivity; thymus: 1.1 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,basal ganglia: 2.3 nTPM (limit 2); choroid plexus: 5.5 nTPM (limit 2); hippocampal formation: 2.1 nTPM (limit 2); midbrain: 2.5 nTPM (limit 2); spinal cord: 3.1 nTPM (limit 2); basal ganglia: 2.3 nTPM (baseline 2); choroid plexus: 5.5 nTPM (baseline 2); hippocampal formation: 2.1 nTPM (baseline 2); midbrain: 2.5 nTPM (baseline 2); spinal cord: 3.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Skin Cuteneous Melanoma (TCGA): 66/99 (66.7%); Lung Squamous Cell Carcinoma (validation): 28/68 (41.2%); Head and Neck Squamous Cell Carcinoma (TCGA): 202/492 (41.1%),No exact-ID IHC coverage in the HPA cancer snapshot,30,0,Q6NZ63,https://www.uniprot.org/uniprotkb/Q6NZ63/entry,,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
STIL,ENSG00000123473,Unsafe,RNA,False,True,5.7,8.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 8.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 3.6 nTPM; continuous selectivity; duodenum: 2.6 nTPM; absolute ceiling;continuous selectivity; esophagus: 2.4 nTPM; continuous selectivity; lymph node: 4.3 nTPM; continuous selectivity; rectum: 5.3 nTPM; continuous selectivity; skin: 2.8 nTPM; continuous selectivity; small intestine: 2.3 nTPM; absolute ceiling;continuous selectivity; thymus: 8.6 nTPM; continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 8.8 nTPM (limit 2); duodenum: 2.6 nTPM (limit 2); small intestine: 2.3 nTPM (limit 2); bone marrow: 8.8 nTPM (baseline 2); duodenum: 2.6 nTPM (baseline 2); small intestine: 2.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Rectum Adenocarcinoma (validation): 204/207 (98.6%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q15468,https://www.uniprot.org/uniprotkb/Q15468/entry,"Immediate-early gene. Plays an important role in embryonic development as well as in cellular growth and proliferation; its long-term silencing affects cell survival and cell cycle distribution as well as decreases CDK1 activity correlated with reduced phosphorylation of CDK1. Plays a role as a positive regulator of the sonic hedgehog pathway, acting downstream of PTCH1 (PubMed:16024801, PubMed:9372240). Plays an important role in the regulation of centriole duplication. Required for the onset of procentriole formation and proper mitotic progression. During procentriole formation, is essential for the correct loading of SASS6 and CPAP to the base of the procentriole to initiate procentriole assembly (PubMed:22020124). In complex with STIL acts as a modulator of PLK4-driven cytoskeletal rearrangements and directional cell motility (PubMed:29712910, PubMed:32107292)",Expressed in all hematopoietic tissues and cell lines. Highly expressed in a variety of tumors characterized by increased mitotic activity with highest expression in lung cancer,"Microcephaly 7, primary, autosomal recessive: A disease defined as a head circumference more than 3 standard deviations below the age-related mean. Brain weight is markedly reduced and the cerebral cortex is disproportionately small. Despite this marked reduction in size, the gyral pattern is relatively well preserved, with no major abnormality in cortical architecture. Affected individuals have mild to severe intellectual disability. Primary microcephaly is further defined by the absence of other syndromic features or significant neurological deficits due to degenerative brain disorder.",,"Cytoplasm, cytosol Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriole Cytoplasm, cell cortex",16024801|22020124|29712910|32107292|9372240,15107824|1922059,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
STK31,ENSG00000196335,Unsafe,Protein,False,True,62.2,62.2,84,8,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; stomach: 0.4 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,stomach 1 / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 39/133 (29.3%); Pancreatic Adenocarcinoma (validation): 21/80 (26.2%); Lung Adenocarcinoma (validation): 24/105 (22.9%),breast cancer: 0/10 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q9BXU1,https://www.uniprot.org/uniprotkb/Q9BXU1/entry,,Testis specific,,Ser-854 is present instead of the conserved Asp which is expected to be an active site residue,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | Jamin2021_CT | Jamin2021_core | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination; inclusion depends on TGCT under this study's thresholds | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
STPG3,ENSG00000197768,Unsafe,RNA,False,True,41.3,41.3,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,duodenum: 3.8 nTPM; absolute ceiling; small intestine: 2.8 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,duodenum: 3.8 nTPM (limit 2); small intestine: 2.8 nTPM (limit 2); duodenum: 3.8 nTPM (baseline 2); small intestine: 2.8 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Renal Clear Cell Carcinoma (validation): 14/100 (14.0%); Kidney Renal Clear Cell Carcinoma (TCGA): 16/521 (3.1%); Rectum Adenocarcinoma (validation): 4/207 (1.9%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q8N7X2,https://www.uniprot.org/uniprotkb/Q8N7X2/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
STT3B,ENSG00000163527,Unsafe,Protein,False,True,92.2,92.2,85,68,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 41.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 58.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 19.5 nTPM; absolute ceiling; basal ganglia: 20.3 nTPM; absolute ceiling; bone marrow: 62.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 18.6 nTPM; positive ihc;absolute ceiling; cerebral cortex: 26.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 22.1 nTPM; absolute ceiling; colon: 57.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 46.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 43.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 47.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 18.9 nTPM; absolute ceiling; hypothalamus: 19.1 nTPM; absolute ceiling; kidney: 47.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 72.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 47.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 58.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 20.4 nTPM; absolute ceiling; pancreas: 44.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 74.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 24.2 nTPM; absolute ceiling;continuous selectivity; rectum: 59.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 37.4 nTPM; absolute ceiling;continuous selectivity; salivary gland: 48.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 59.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 43.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 47.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 55.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 25.6 nTPM; absolute ceiling;continuous selectivity; spleen: 43.1 nTPM; absolute ceiling; stomach: 53.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 69.9 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 78.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 55.6 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 54.6 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 41.3 nTPM (limit 10); adrenal gland: 58.1 nTPM (limit 2); amygdala: 19.5 nTPM (limit 2); basal ganglia: 20.3 nTPM (limit 2); bone marrow: 62.9 nTPM (limit 2); cerebellum: 18.6 nTPM (limit 2); cerebral cortex: 26.8 nTPM (limit 2); choroid plexus: 22.1 nTPM (limit 2); colon: 57.7 nTPM (limit 6); duodenum: 46.6 nTPM (limit 2); esophagus: 43.3 nTPM (limit 6); heart muscle: 47.7 nTPM (limit 2); hippocampal formation: 18.9 nTPM (limit 2); hypothalamus: 19.1 nTPM (limit 2); kidney: 47.9 nTPM (limit 2); liver: 72.6 nTPM (limit 2); lung: 47.7 nTPM (limit 2); lymph node: 58.5 nTPM (limit 6); midbrain: 20.4 nTPM (limit 2); pancreas: 44.4 nTPM (limit 2); parathyroid gland: 74.1 nTPM (limit 6); pituitary gland: 24.2 nTPM (limit 2); rectum: 59.5 nTPM (limit 6); retina: 37.4 nTPM (limit 2); salivary gland: 48.5 nTPM (limit 6); skeletal muscle: 59.9 nTPM (limit 2); skin: 43.6 nTPM (limit 10); small intestine: 47.8 nTPM (limit 2); smooth muscle: 55.6 nTPM (limit 2); spinal cord: 25.6 nTPM (limit 2); spleen: 43.1 nTPM (limit 20); stomach: 53.7 nTPM (limit 6); thymus: 69.9 nTPM (limit 10); thyroid gland: 78.4 nTPM (limit 10); tongue: 55.6 nTPM (limit 6); urinary bladder: 54.6 nTPM (limit 6),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: High (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Low (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Kidney Renal Clear Cell Carcinoma (TCGA): 521/521 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%),pancreatic cancer: 9/11 (81.8%); stomach cancer: 8/10 (80.0%),31,20,Q8TCJ2,https://www.uniprot.org/uniprotkb/Q8TCJ2/entry,"Catalytic subunit of the oligosaccharyl transferase (OST) complex that catalyzes the initial transfer of a defined glycan (Glc(3)Man(9)GlcNAc(2) in eukaryotes) from the lipid carrier dolichol-pyrophosphate to an asparagine residue within an Asn-X-Ser/Thr consensus motif in nascent polypeptide chains, the first step in protein N-glycosylation (PubMed:19167329, PubMed:31296534, PubMed:31831667, PubMed:39509507). N-glycosylation occurs cotranslationally and the complex associates with the Sec61 complex at the channel-forming translocon complex that mediates protein translocation across the endoplasmic reticulum (ER) (PubMed:19167329, PubMed:31296534, PubMed:31831667, PubMed:39509507). All subunits are required for a maximal enzyme activity. This subunit contains the active site and the acceptor peptide and donor lipid-linked oligosaccharide (LLO) binding pockets (PubMed:19167329, PubMed:31296534, PubMed:31831667, PubMed:39509507). STT3B is present in a small subset of OST complexes (OST-B) and mediates both cotranslational and post-translational N-glycosylation of target proteins: STT3B-containing complexes are required for efficient post-translational glycosylation and while they are less competent than STT3A-containing complexes for cotranslational glycosylation, they have the ability to mediate glycosylation of some nascent sites that are not accessible for STT3A (PubMed:19167329, PubMed:22607976, PubMed:31296534, PubMed:39509507). STT3B-containing complexes also act post-translationally and mediate modification of skipped glycosylation sites in unfolded proteins (PubMed:19167329, PubMed:22607976, PubMed:39509507). Plays a role in ER-associated degradation (ERAD) pathway that mediates ubiquitin-dependent degradation of misfolded endoplasmic reticulum proteins by mediating N-glycosylation of unfolded proteins, which are then recognized by the ERAD pathway and targeted for degradation (PubMed:19167329, PubMed:22607976). Mediates glycosylation of the disease variant AMYL-TTR 'Asp-38' of TTR at 'Asn-118', leading to its degradation (PubMed:19167329, PubMed:22607976)","Expressed in heart, brain, placenta, lung, liver, muscle, kidney and pancreas. Expressed in skin fibroblasts (at protein level)","Congenital disorder of glycosylation 1X: A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.",,Endoplasmic reticulum Endoplasmic reticulum membrane,19167329|22607976|31296534|31831667|39509507,12887896,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
STXBP4,ENSG00000166263,Unsafe,Protein,False,True,3.4,5.8,80,80,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 1.4 nTPM; positive ihc; adrenal gland: 1.9 nTPM; positive ihc;continuous selectivity; bone marrow: 1.4 nTPM; positive ihc;continuous selectivity; cerebellum: 0.6 nTPM; positive ihc; cerebral cortex: 1.2 nTPM; positive ihc;continuous selectivity; choroid plexus: 2.2 nTPM; absolute ceiling;continuous selectivity; colon: 1.6 nTPM; positive ihc;continuous selectivity; duodenum: 2.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 1.8 nTPM; positive ihc;continuous selectivity; heart muscle: 1.7 nTPM; positive ihc;continuous selectivity; kidney: 4.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 0.9 nTPM; positive ihc; lung: 2.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 1.2 nTPM; positive ihc; pancreas: 1.5 nTPM; positive ihc;continuous selectivity; parathyroid gland: 5.8 nTPM; positive ihc;continuous selectivity;reproductive not higher; pituitary gland: 1.9 nTPM; continuous selectivity; rectum: 1.6 nTPM; positive ihc;continuous selectivity; retina: 4.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 1.4 nTPM; positive ihc;continuous selectivity; skeletal muscle: 1.1 nTPM; positive ihc;continuous selectivity; skin: 1 nTPM; positive ihc; small intestine: 1.3 nTPM; positive ihc;continuous selectivity; smooth muscle: 2.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; spleen: 1 nTPM; positive ihc; stomach: 1.5 nTPM; positive ihc;continuous selectivity; thymus: 1.8 nTPM; continuous selectivity; thyroid gland: 3 nTPM; positive ihc;continuous selectivity; urinary bladder: 1.8 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 2.2 nTPM (limit 2); duodenum: 2.5 nTPM (limit 2); kidney: 4.2 nTPM (limit 2); lung: 2.1 nTPM (limit 2); retina: 4.4 nTPM (limit 2); smooth muscle: 2.6 nTPM (limit 2),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: High (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / glial cells: Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: High (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Medium (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: High (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: High (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: High (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: High (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 424/486 (87.2%); Pancreatic Adenocarcinoma (validation): 68/80 (85.0%),colorectal cancer: 12/12 (100.0%); melanoma: 12/12 (100.0%),31,20,Q6ZWJ1,https://www.uniprot.org/uniprotkb/Q6ZWJ1/entry,"Plays a role in the translocation of transport vesicles from the cytoplasm to the plasma membrane. Inhibits the translocation of SLC2A4 from intracellular vesicles to the plasma membrane by STX4A binding and preventing the interaction between STX4A and VAMP2. Stimulation with insulin disrupts the interaction with STX4A, leading to increased levels of SLC2A4 at the plasma membrane. May also play a role in the regulation of insulin release by pancreatic beta cells after stimulation by glucose (By similarity)",,,,Cytoplasm,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
STXBP5,ENSG00000164506,Unsafe,Protein,False,True,8.7,36.8,101,57,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 7.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 3.1 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 3.1 nTPM; absolute ceiling;continuous selectivity; bone marrow: 4.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 9.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 9.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; colon: 6.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 3.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 8.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 3.6 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 4.2 nTPM; absolute ceiling;continuous selectivity; kidney: 1.7 nTPM; positive ihc; liver: 1.6 nTPM; positive ihc; lung: 3.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 3 nTPM; absolute ceiling;continuous selectivity; pancreas: 8.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 36.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 6.5 nTPM; absolute ceiling;continuous selectivity; rectum: 5 nTPM; positive ihc;continuous selectivity; retina: 5.1 nTPM; absolute ceiling;continuous selectivity; salivary gland: 4.8 nTPM; positive ihc;continuous selectivity; skeletal muscle: 7.1 nTPM; continuous selectivity; skin: 9.6 nTPM; positive ihc;continuous selectivity;reproductive not higher; small intestine: 7.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 2.8 nTPM; absolute ceiling;continuous selectivity; stomach: 3.4 nTPM; positive ihc;continuous selectivity; thyroid gland: 3.8 nTPM; positive ihc; tongue: 4 nTPM; continuous selectivity; urinary bladder: 4.2 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 7.1 nTPM (limit 2); amygdala: 3.1 nTPM (limit 2); basal ganglia: 3.1 nTPM (limit 2); bone marrow: 4.4 nTPM (limit 2); cerebellum: 9.1 nTPM (limit 2); cerebral cortex: 9.6 nTPM (limit 2); colon: 6.5 nTPM (limit 6); duodenum: 3.7 nTPM (limit 2); esophagus: 8.5 nTPM (limit 6); hippocampal formation: 3.6 nTPM (limit 2); hypothalamus: 4.2 nTPM (limit 2); lung: 3.5 nTPM (limit 2); midbrain: 3 nTPM (limit 2); pancreas: 8.5 nTPM (limit 2); parathyroid gland: 36.8 nTPM (limit 6); pituitary gland: 6.5 nTPM (limit 2); retina: 5.1 nTPM (limit 2); small intestine: 7.7 nTPM (limit 2); spinal cord: 2.8 nTPM (limit 2),adrenal gland / glandular cells: Medium (Enhanced); bone marrow / hematopoietic cells: Medium (Enhanced); bronchus / ciliated cells (cell body): Medium (Enhanced); bronchus / ciliated cells (ciliary rootlets): Medium (Enhanced); bronchus / ciliated cells (tip of cilia): High (Enhanced); caudate / neuronal cells: Medium (Enhanced); cerebellum / cells in granular layer: Low (Enhanced); cerebellum / cells in molecular layer: Low (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); cerebral cortex / neuropil: Medium (Enhanced); colon / glandular cells: Medium (Enhanced); colon / peripheral nerve/ganglion: Low (Enhanced); duodenum / glandular cells: Medium (Enhanced); esophagus / squamous epithelial cells: Low (Enhanced); hippocampus / neuronal cells: Medium (Enhanced); kidney / collecting ducts: Low (Enhanced); kidney / proximal tubules (cell body): Medium (Enhanced); liver / hepatocytes: Low (Enhanced); lung / alveolar cells type I: Low (Enhanced); lung / alveolar cells type II: Low (Enhanced); nasopharynx / ciliated cells (cell body): Low (Enhanced); nasopharynx / ciliated cells (ciliary rootlets): Low (Enhanced); oral mucosa / squamous epithelial cells: Low (Enhanced); pancreas / exocrine glandular cells: Low (Enhanced); pancreas / pancreatic endocrine cells: Medium (Enhanced); parathyroid gland / glandular cells: High (Enhanced); rectum / glandular cells: Medium (Enhanced); salivary gland / glandular cells: Medium (Enhanced); skin 1 / keratinocytes: Low (Enhanced); skin 2 / epidermal cells: Medium (Enhanced); small intestine / glandular cells: Medium (Enhanced); stomach 1 / glandular cells: Medium (Enhanced); stomach 2 / glandular cells: Medium (Enhanced); thyroid gland / glandular cells: Low (Enhanced); urinary bladder / urothelial cells: Low (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 485/486 (99.8%),pancreatic cancer: 4/12 (33.3%); ovarian cancer: 3/10 (30.0%),31,20,Q5T5C0,https://www.uniprot.org/uniprotkb/Q5T5C0/entry,Plays a regulatory role in calcium-dependent exocytosis and neurotransmitter release. Inhibits membrane fusion between transport vesicles and the plasma membrane. May modulate the assembly of trans-SNARE complexes between transport vesicles and the plasma membrane. Inhibits translocation of GLUT4 from intracellular vesicles to the plasma membrane. Competes with STXBP1 for STX1 binding (By similarity),,,,"Cytoplasm Cell membrane Cytoplasmic vesicle membrane Cytoplasmic vesicle, secretory vesicle, synaptic vesicle Synapse",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
SUN3,ENSG00000164744,Unsafe,Protein,False,True,40.4,40.4,85,5,Positive somewhere,True,False,False,True,Excluded,Normal,False,,Not assessed,,,positive normal IHC; positive ihc outside permitted; kidney: 0 nTPM; positive ihc; skin: 0 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,bronchus / respiratory epithelial cells: Low (Enhanced); kidney / cells in tubules: Low (Enhanced); skin 1 / keratinocytes: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 10/133 (7.5%); Uterine Corpus Endometrial Carcinoma (TCGA): 8/176 (4.5%); Kidney Chromophobe (TCGA): 2/64 (3.1%),breast cancer: 0/9 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q8TAQ9,https://www.uniprot.org/uniprotkb/Q8TAQ9/entry,"As a probable component of the LINC (LInker of Nucleoskeleton and Cytoskeleton) complex, involved in the connection between the nuclear lamina and the cytoskeleton. The nucleocytoplasmic interactions established by the LINC complex play an important role in the transmission of mechanical forces across the nuclear envelope and in nuclear movement and positioning. May be involved in nuclear remodeling during sperm head formation in spermatogenesis. A probable SUN3:SYNE1 LINC complex may tether spermatid nuclei to posterior cytoskeletal structures such as the manchette",,,,Membrane Nucleus envelope Nucleus inner membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Carter2023_CT | Loriot2025_S1 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
SUV39H2,ENSG00000152455,Unsafe,RNA,False,True,38.1,38.1,88,4,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,retina: 3.3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 3.3 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 471/486 (96.9%); Rectum Adenocarcinoma (validation): 200/207 (96.6%),breast cancer: 2/9 (22.2%); stomach cancer: 1/11 (9.1%),31,20,Q9H5I1,https://www.uniprot.org/uniprotkb/Q9H5I1/entry,"Histone methyltransferase that specifically mediates trimethylation of 'Lys-9' of histone H3 (H3K9me3) using monomethylated H3 'Lys-9' (H3K9me1) as substrate (PubMed:10949293). H3 'Lys-9' trimethylation represents a specific tag for epigenetic transcriptional repression by recruiting HP1 (CBX1, CBX3 and/or CBX5) proteins to methylated histones (PubMed:10949293). Mainly functions in heterochromatin regions, thereby playing a central role in the establishment of constitutive heterochromatin at pericentric and telomere regions (PubMed:10949293). H3 'Lys-9' trimethylation is also required to direct DNA methylation at pericentric repeats (PubMed:10949293, PubMed:41094145). SUV39H2 is targeted to histone H3 via its interaction with RB1 and is involved in many processes, such as cell cycle regulation, transcriptional repression and regulation of telomere length (PubMed:14765126). May participate in regulation of higher-order chromatin organization during spermatogenesis (By similarity). Recruited by the large PER complex to the E-box elements of the circadian target genes such as PER2 itself or PER1, contributes to the conversion of local chromatin to a heterochromatin-like repressive state through H3 'Lys-9' trimethylation (By similarity)",,,,"Nucleus Chromosome Chromosome, centromere",10949293|14765126|41094145,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
SVOPL,ENSG00000157703,Unsafe,RNA,False,True,1.8,8.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 2 nTPM; continuous selectivity;reproductive not higher; choroid plexus: 8.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 0.8 nTPM; continuous selectivity; kidney: 2.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 4 nTPM; continuous selectivity;reproductive not higher; pituitary gland: 0.9 nTPM; continuous selectivity; retina: 3.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 3.9 nTPM; continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 8.8 nTPM (limit 2); kidney: 2.7 nTPM (limit 2); retina: 3.1 nTPM (limit 2); choroid plexus: 8.8 nTPM (baseline 2); kidney: 2.7 nTPM (baseline 2); retina: 3.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Chromophobe (TCGA): 43/64 (67.2%); Ovary Serous Cystadenocarcinoma (validation): 28/81 (34.6%); Ovary Serous Cystadenocarcinoma (TCGA): 78/349 (22.3%),glioma: 11/12 (91.7%); liver cancer: 11/12 (91.7%),31,20,Q8N434,https://www.uniprot.org/uniprotkb/Q8N434/entry,,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
SYCE1,ENSG00000171772,Unsafe,RNA,False,True,68.9,68.9,88,2,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,amygdala: 9.8 nTPM; absolute ceiling; basal ganglia: 11.2 nTPM; absolute ceiling; cerebellum: 17.5 nTPM; absolute ceiling; cerebral cortex: 16.3 nTPM; absolute ceiling; hippocampal formation: 8.9 nTPM; absolute ceiling; hypothalamus: 7.3 nTPM; absolute ceiling; midbrain: 3 nTPM; absolute ceiling; retina: 2.2 nTPM; absolute ceiling; spinal cord: 4 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 9.8 nTPM (limit 2); basal ganglia: 11.2 nTPM (limit 2); cerebellum: 17.5 nTPM (limit 12); cerebral cortex: 16.3 nTPM (limit 12); hippocampal formation: 8.9 nTPM (limit 2); hypothalamus: 7.3 nTPM (limit 2); midbrain: 3 nTPM (limit 2); retina: 2.2 nTPM (limit 2); spinal cord: 4 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 53/133 (39.8%); Liver Hepatocellular Carcinoma (TCGA): 45/362 (12.4%); Prostate Adenocarcinoma (TCGA): 59/480 (12.3%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q8N0S2,https://www.uniprot.org/uniprotkb/Q8N0S2/entry,"Major component of the transverse central element of synaptonemal complexes (SCS), formed between homologous chromosomes during meiotic prophase. Requires SYCP1 in order to be incorporated into the central element. May have a role in the synaptonemal complex assembly, stabilization and recombination",,"Premature ovarian failure 12: An ovarian disorder defined as the cessation of ovarian function under the age of 40 years. It is characterized by oligomenorrhea or amenorrhea, in the presence of elevated levels of serum gonadotropins and low estradiol. Spermatogenic failure, 15: An infertility disorder caused by spermatogenesis defects and characterized by non-obstructive azoospermia due to complete meiotic maturation arrest. SPGF15 inheritance is autosomal recessive.",,Nucleus Chromosome,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
SYCE1L,ENSG00000205078,Unsafe,RNA,False,True,22.8,22.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 2.7 nTPM; absolute ceiling; cerebellum: 2.4 nTPM; absolute ceiling; hippocampal formation: 2.5 nTPM; absolute ceiling; hypothalamus: 3.1 nTPM; absolute ceiling; kidney: 3.1 nTPM; absolute ceiling; pituitary gland: 2.1 nTPM; absolute ceiling; retina: 2.7 nTPM; absolute ceiling; small intestine: 2.1 nTPM; absolute ceiling; spinal cord: 2.2 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 2.7 nTPM (limit 2); cerebellum: 2.4 nTPM (limit 2); hippocampal formation: 2.5 nTPM (limit 2); hypothalamus: 3.1 nTPM (limit 2); kidney: 3.1 nTPM (limit 2); pituitary gland: 2.1 nTPM (limit 2); retina: 2.7 nTPM (limit 2); small intestine: 2.1 nTPM (limit 2); spinal cord: 2.2 nTPM (limit 2); amygdala: 2.7 nTPM (baseline 2); cerebellum: 2.4 nTPM (baseline 2); hippocampal formation: 2.5 nTPM (baseline 2); hypothalamus: 3.1 nTPM (baseline 2); kidney: 3.1 nTPM (baseline 2); pituitary gland: 2.1 nTPM (baseline 2); retina: 2.7 nTPM (baseline 2); small intestine: 2.1 nTPM (baseline 2); spinal cord: 2.2 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 46/50 (92.0%); Kidney Renal Papillary Cell Carcinoma (TCGA): 188/282 (66.7%); Prostate Adenocarcinoma (TCGA): 289/480 (60.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,A8MT33,https://www.uniprot.org/uniprotkb/A8MT33/entry,May be involved in meiosis,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
SYCE3,ENSG00000217442,Unsafe,RNA,False,True,138.1,138.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 2.2 nTPM; absolute ceiling; basal ganglia: 2.4 nTPM; absolute ceiling; kidney: 2.7 nTPM; absolute ceiling; midbrain: 2.5 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 2.2 nTPM (limit 2); basal ganglia: 2.4 nTPM (limit 2); kidney: 2.7 nTPM (limit 2); midbrain: 2.5 nTPM (limit 2); amygdala: 2.2 nTPM (baseline 2); basal ganglia: 2.4 nTPM (baseline 2); kidney: 2.7 nTPM (baseline 2); midbrain: 2.5 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Renal Papillary Cell Carcinoma (TCGA): 104/282 (36.9%); Breast Invasive Carcinoma (TCGA): 292/1022 (28.6%); Thyroid Carcinoma (TCGA): 137/495 (27.7%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,A1L190,https://www.uniprot.org/uniprotkb/A1L190/entry,"Major component of the transverse central element of synaptonemal complexes (SCS), formed between homologous chromosomes during meiotic prophase (PubMed:36635604). Required for the assembly of the central element of the synaptonemal complex during meiosis, via remodeling of SYCP1 lattice structures and promoting recruitment of SYCE2-TEX12 and SYCE1-SIX60S1 complexes (PubMed:36635604). Required for chromosome loading of the central element-specific SCS proteins, and for initiating synapsis between homologous chromosomes (By similarity). Chromosome loading appears to require SYCP1 (By similarity). Required for fertility and normal testis development (By similarity)",,,,Nucleus Chromosome,36635604,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
SYCN,ENSG00000179751,Unsafe,Protein,False,True,27.4,27446.4,76,1,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; duodenum: 3.8 nTPM; absolute ceiling; heart muscle: 4.3 nTPM; absolute ceiling; liver: 2.9 nTPM; absolute ceiling; pancreas: 27446.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",pancreas: 27446.4 nTPM (limit 2); duodenum: 3.8 nTPM (baseline 2); heart muscle: 4.3 nTPM (baseline 2); liver: 2.9 nTPM (baseline 2); pancreas: 27446.4 nTPM (baseline 2),pancreas / exocrine glandular cells: High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (TCGA): 89/176 (50.6%); Pancreatic Adenocarcinoma (validation): 11/80 (13.8%); Testicular Germ Cell Tumor (TCGA): 6/133 (4.5%),breast cancer: 0/12 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q0VAF6,https://www.uniprot.org/uniprotkb/Q0VAF6/entry,Functions in exocytosis in pancreatic acinar cells regulating the fusion of zymogen granules with each other. May have a pore-forming activity on membranes and regulate exocytosis in other exocrine tissues (By similarity),,,,Zymogen granule membrane Zymogen granule lumen,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
SYCP2,ENSG00000196074,Unsafe,RNA,False,True,41.8,41.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,basal ganglia: 2.2 nTPM; absolute ceiling; bone marrow: 2.3 nTPM; absolute ceiling; cerebellum: 2.7 nTPM; absolute ceiling; cerebral cortex: 2.8 nTPM; absolute ceiling; heart muscle: 2.4 nTPM; absolute ceiling; kidney: 4.2 nTPM; absolute ceiling; lung: 2.1 nTPM; absolute ceiling; pancreas: 6.4 nTPM; absolute ceiling; small intestine: 2.3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,basal ganglia: 2.2 nTPM (limit 2); bone marrow: 2.3 nTPM (limit 2); cerebellum: 2.7 nTPM (limit 2); cerebral cortex: 2.8 nTPM (limit 2); heart muscle: 2.4 nTPM (limit 2); kidney: 4.2 nTPM (limit 2); lung: 2.1 nTPM (limit 2); pancreas: 6.4 nTPM (limit 2); small intestine: 2.3 nTPM (limit 2); basal ganglia: 2.2 nTPM (baseline 2); bone marrow: 2.3 nTPM (baseline 2); cerebellum: 2.7 nTPM (baseline 2); cerebral cortex: 2.8 nTPM (baseline 2); heart muscle: 2.4 nTPM (baseline 2); kidney: 4.2 nTPM (baseline 2); lung: 2.1 nTPM (baseline 2); pancreas: 6.4 nTPM (baseline 2); small intestine: 2.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 46/50 (92.0%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 231/283 (81.6%); Breast Invasive Carcinoma (TCGA): 809/1022 (79.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9BX26,https://www.uniprot.org/uniprotkb/Q9BX26/entry,"Major component of the axial/lateral elements of synaptonemal complexes (SCS) during meiotic prophase. Plays a role in the assembly of synaptonemal complexes. Required for normal meiotic chromosome synapsis during oocyte and spermatocyte development and for normal male and female fertility. Required for insertion of SYCP3 into synaptonemal complexes. May be involved in the organization of chromatin by temporarily binding to DNA scaffold attachment regions. Requires SYCP3, but not SYCP1, in order to be incorporated into the axial/lateral elements",,"Spermatogenic failure 1: An infertility disorder characterized by azoospermia due to spermatogenic arrest during meiosis. Meiotic arrest is characterized by germ cells that enter meiosis and undergo the first chromosomal reduction from 4n to 2n, but that are then unable to proceed further. This results in tubules containing spermatocytes as the latest developmental stage of germ cells. Meiotically arrested spermatocytes accumulate in the tubules and degenerate. Both autosomal recessive and autosomal dominant inheritance have been reported.",,Nucleus Chromosome,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Jamin2021_CT | Jamin2021_core | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
SYCP2L,ENSG00000153157,Unsafe,RNA,False,True,3.1,66.4,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,cerebellum: 1.2 nTPM; continuous selectivity; heart muscle: 1.2 nTPM; continuous selectivity; kidney: 1.1 nTPM; continuous selectivity; lung: 1.7 nTPM; continuous selectivity; pancreas: 1.6 nTPM; continuous selectivity; parathyroid gland: 66.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,parathyroid gland: 66.4 nTPM (limit 6); parathyroid gland: 66.4 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 10/58 (17.2%); Testicular Germ Cell Tumor (TCGA): 19/133 (14.3%); Breast Invasive Carcinoma (validation): 7/50 (14.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q5T4T6,https://www.uniprot.org/uniprotkb/Q5T4T6/entry,Oocyte-specific protein that localizes to centromeres at the dictyate stage and regulates the survival of primordial oocytes,"Expressed in the ovary (at protein level) (PubMed:17374641). In the ovaries, expressed in oocytes, including germinal vesicle oocytes, metaphase I and metaphase II oocytes (PubMed:32303603). Also expressed in testis (PubMed:32303603)","Premature ovarian failure 24: A form of premature ovarian failure, an ovarian disorder defined as the cessation of ovarian function under the age of 40 years. It is characterized by oligomenorrhea or amenorrhea, in the presence of elevated levels of serum gonadotropins and low estradiol. POF24 inheritance is autosomal recessive.",,"Nucleus Chromosome, centromere",,17374641|32303603,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination; inclusion depends on TGCT under this study's thresholds,,,,,,,,
SYN3,ENSG00000185666,Unsafe,Protein,False,True,3.7,5.1,80,6,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 2 nTPM; continuous selectivity; basal ganglia: 2.1 nTPM; absolute ceiling;continuous selectivity; bone marrow: 2.2 nTPM; absolute ceiling;continuous selectivity; cerebellum: 1.3 nTPM; positive ihc;continuous selectivity; cerebral cortex: 5.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 1.8 nTPM; continuous selectivity; hypothalamus: 1.9 nTPM; continuous selectivity; midbrain: 1.2 nTPM; continuous selectivity; pituitary gland: 1.6 nTPM; continuous selectivity; retina: 3.5 nTPM; absolute ceiling;continuous selectivity; spinal cord: 1.4 nTPM; continuous selectivity; thyroid gland: 0.6 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",basal ganglia: 2.1 nTPM (limit 2); bone marrow: 2.2 nTPM (limit 2); cerebral cortex: 5.1 nTPM (limit 2); retina: 3.5 nTPM (limit 2); basal ganglia: 2.1 nTPM (baseline 2); bone marrow: 2.2 nTPM (baseline 2); cerebral cortex: 5.1 nTPM (baseline 2); retina: 3.5 nTPM (baseline 2),caudate / neuronal cells: Low (Uncertain); cerebellum / cells in granular layer: Low (Uncertain); cerebellum / Purkinje cells: Low (Uncertain); cerebral cortex / neuropil: Medium (Uncertain); thyroid gland / glandular cells: Low (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 190/207 (91.8%); Colon Adenocarcinoma (validation): 427/486 (87.9%); Testicular Germ Cell Tumor (TCGA): 89/133 (66.9%),endometrial cancer: 4/11 (36.4%); lung cancer: 4/12 (33.3%),31,20,O14994,https://www.uniprot.org/uniprotkb/O14994/entry,May be involved in the regulation of neurotransmitter release and synaptogenesis,Neuron specific. Detected predominantly in brain,,,"Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
SYNGR4,ENSG00000105467,Unsafe,Protein,False,True,52.9,52.9,84,8,Positive somewhere,True,False,False,True,Excluded,Normal,False,,Not assessed,,,positive normal IHC; positive ihc outside permitted; colon: 0.2 nTPM; positive ihc; duodenum: 0 nTPM; positive ihc; liver: 0.1 nTPM; positive ihc; rectum: 0.2 nTPM; positive ihc; small intestine: 0.1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,colon / glandular cells: Low (Enhanced); duodenum / glandular cells: Low (Enhanced); liver / hepatocytes: Low (Enhanced); rectum / glandular cells: Low (Enhanced); small intestine / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (TCGA): 26/176 (14.8%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 15/283 (5.3%); Lung Adenocarcinoma (TCGA): 23/497 (4.6%),breast cancer: 0/10 (0.0%); cervical cancer: 0/12 (0.0%),31,20,O95473,https://www.uniprot.org/uniprotkb/O95473/entry,,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
SYNJ1,ENSG00000159082,Unsafe,Protein,False,True,9.9,46.9,103,58,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 6.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 18.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 23.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 23.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 28.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 41.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 9.1 nTPM; absolute ceiling;continuous selectivity; colon: 5.5 nTPM; positive ihc;continuous selectivity; duodenum: 3.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 6.2 nTPM; continuous selectivity; hippocampal formation: 25.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 25.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 7.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 5.5 nTPM; continuous selectivity; lung: 7.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 6.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 21.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 4.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 8.1 nTPM; continuous selectivity; pituitary gland: 13.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 5.3 nTPM; positive ihc;continuous selectivity; retina: 46.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 7.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 6.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 4.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 11.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 7.7 nTPM; positive ihc;continuous selectivity; stomach: 4.8 nTPM; positive ihc;continuous selectivity; thymus: 6.9 nTPM; continuous selectivity; thyroid gland: 7.1 nTPM; positive ihc;continuous selectivity; tongue: 6.2 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 5.4 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 6.6 nTPM (limit 2); amygdala: 18.6 nTPM (limit 2); basal ganglia: 23.6 nTPM (limit 2); bone marrow: 23.5 nTPM (limit 2); cerebellum: 28.4 nTPM (limit 2); cerebral cortex: 41.2 nTPM (limit 2); choroid plexus: 9.1 nTPM (limit 2); duodenum: 3.8 nTPM (limit 2); hippocampal formation: 25.2 nTPM (limit 2); hypothalamus: 25.7 nTPM (limit 2); kidney: 7.1 nTPM (limit 2); lung: 7.8 nTPM (limit 2); lymph node: 6.1 nTPM (limit 6); midbrain: 21.6 nTPM (limit 2); pancreas: 4.7 nTPM (limit 2); pituitary gland: 13.4 nTPM (limit 2); retina: 46.9 nTPM (limit 2); skeletal muscle: 7.4 nTPM (limit 2); small intestine: 6.1 nTPM (limit 2); smooth muscle: 4.8 nTPM (limit 2); spinal cord: 11.1 nTPM (limit 2); tongue: 6.2 nTPM (limit 6),adrenal gland / glandular cells: Low (Enhanced); bone marrow / hematopoietic cells: Medium (Enhanced); bronchus / respiratory epithelial cells: Medium (Enhanced); caudate / glial cells: Low (Enhanced); caudate / neuronal cells: Low (Enhanced); cerebellum / GLUC cells - cytoplasm/membrane: High (Enhanced); cerebellum / granular cells - cytoplasm/membrane: Medium (Enhanced); cerebellum / molecular layer cells - cytoplasm/membrane: High (Enhanced); cerebellum / processes in granular layer: Medium (Enhanced); cerebellum / processes in molecular layer: High (Enhanced); cerebellum / processes in white matter: Medium (Enhanced); cerebellum / Purkinje cells - cytoplasm/membrane: Medium (Enhanced); cerebellum / synaptic glomeruli - capsule: Medium (Enhanced); cerebellum / synaptic glomeruli - core: High (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); cerebral cortex / neuropil: High (Enhanced); colon / endothelial cells: Low (Enhanced); colon / glandular cells: Low (Enhanced); colon / peripheral nerve/ganglion: Medium (Enhanced); duodenum / glandular cells: Medium (Enhanced); hippocampus / neuronal cells: Low (Enhanced); kidney / cells in tubules: Low (Enhanced); lung / alveolar cells type II: Low (Enhanced); lung / macrophages: Medium (Enhanced); lymph node / non-germinal center cells: Low (Enhanced); nasopharynx / respiratory epithelial cells: Medium (Enhanced); pancreas / exocrine glandular cells: Low (Enhanced); pancreas / pancreatic endocrine cells: Medium (Enhanced); rectum / glandular cells: Medium (Enhanced); skeletal muscle / myocytes: Low (Enhanced); small intestine / glandular cells: Medium (Enhanced); smooth muscle / smooth muscle cells: Low (Enhanced); spleen / cells in red pulp: Low (Enhanced); spleen / cells in white pulp: Low (Enhanced); stomach 1 / glandular cells: Low (Enhanced); stomach 2 / glandular cells: Medium (Enhanced); thyroid gland / glandular cells: Medium (Enhanced); urinary bladder / urothelial cells: Medium (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Rectum Adenocarcinoma (validation): 205/207 (99.0%); Colon Adenocarcinoma (validation): 476/486 (97.9%),liver cancer: 3/11 (27.3%); glioma: 2/12 (16.7%),31,20,O43426,https://www.uniprot.org/uniprotkb/O43426/entry,"Phosphatase that hydrolyzes phosphate groups from the inositol ring of phosphoinositides and inositol phosphates, in a domain-specific manner (PubMed:10224048, PubMed:18093523, PubMed:23804563, PubMed:27435091, PubMed:33349335, PubMed:40969890). The 5-PPase domain catalyzes removal of the 5-phosphate from substrates such as phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2), phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P3), inositol-1,4,5-trisphosphate (Ins(1,4,5)P3) and inositol-1,3,4,5-tetrakisphosphate (Ins(1,3,4,5)P4) (PubMed:18093523, PubMed:23804563, PubMed:27435091, PubMed:33349335, PubMed:40969890). The SAC domain hydrolyzes phosphates at the 3- and 4-positions of the inositol ring, targeting phosphatidylinositol-3-phosphate (PI(3)P), phosphatidylinositol-4-phosphate (PI(4)P), and phosphatidylinositol-3,5-bisphosphate (PI(3,5)P2) (PubMed:10224048, PubMed:18093523, PubMed:23804563, PubMed:27435091). Plays a role in the phosphatidylinositol metabolic process during an unconventional endocytic mechanism, the ultrafast endocytosis where it participates in the rapide neck formation of the newly generated synaptic vesicle through its phosphoinositide 5-phosphatase activity (By similarity). Also, participates in the clathrin uncoating of synaptc vesicle formed via budding from synaptic endosomes after ultrafast endocytosis through combined activity of its phosphatase domains (By similarity). Additionally, regulates actin filament rearrangement by hydrolyzing PIP2 bound to actin regulatory proteins (By similarity)",,"Parkinson disease 20, early-onset: An early-onset form of Parkinson disease, a complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. PARK20 is characterized by young adult-onset of parkinsonism. Additional features may include seizures, cognitive decline, abnormal eye movements, and dystonia. Developmental and epileptic encephalopathy 53: A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE53 inheritance is autosomal recessive.",,"Cytoplasm, perinuclear region Presynapse Membrane",10224048|18093523|23804563|27435091|33349335|40969890,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
SYT10,ENSG00000110975,Unsafe,High RNA,False,True,2.1,2.1,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,kidney: 0.8 nTPM; continuous selectivity,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,True,"vascular/schwann cells cluster c-18: 106 nTPM, 203 reads; reproductive-cell max 91.6",True,False,,True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,0.121275377014,106.0,"hpa_single_cell: /Schwann cells, max 35.3 nTPM, 1 observations >30; hpa_single_cell_tissue: brain/excitatory neurons, max 46.4 nTPM, 1 observations >30; hpa_single_cell_tissue: brain/inhibitory neurons, max 61.8 nTPM, 3 observations >30; hpa_single_cell_tissue: vascular/schwann cells, max 106 nTPM, 1 observations >30",Neither,oncoref.target-sets.2026-10-23.2,0.1213 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,106 nTPM; vascular/schwann cells; hpa_single_cell_tissue; vital,Kidney Chromophobe (TCGA): 15/64 (23.4%); Breast Invasive Carcinoma (validation): 3/50 (6.0%); Kidney Renal Papillary Cell Carcinoma (TCGA): 11/282 (3.9%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q6XYQ8,https://www.uniprot.org/uniprotkb/Q6XYQ8/entry,Ca(2+) sensor specifically required for the Ca(2+)-dependent exocytosis of secretory vesicles containing IGF1 in neurons of the olfactory bulb. Exocytosis of IGF1 is required for sensory perception of smell. Not involved in Ca(2+)-dependent synaptic vesicle exocytosis (By similarity). Acts through Ca(2+) and phospholipid binding to the C2 domain: Ca(2+) induces binding of the C2-domains to phospholipid membranes and to assembled SNARE-complexes; both actions contribute to triggering exocytosis (By similarity),"Expressed only in pancreas, lung and kidney",,,"Cytoplasmic vesicle, secretory vesicle membrane",,14756426,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
SYT14,ENSG00000143469,Unsafe,RNA,False,True,3.2,6.0,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,adrenal gland: 1.3 nTPM; continuous selectivity; cerebral cortex: 1.9 nTPM; continuous selectivity; retina: 3.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 6 nTPM; continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 3.8 nTPM (limit 2); retina: 3.8 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 45/58 (77.6%); Skin Cuteneous Melanoma (TCGA): 3/99 (3.0%); Lung Squamous Cell Carcinoma (validation): 2/68 (2.9%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NB59,https://www.uniprot.org/uniprotkb/Q8NB59/entry,May be involved in the trafficking and exocytosis of secretory vesicles in non-neuronal tissues. Is Ca(2+)-independent,Highly expressed in fetal and adult brain tissue,"Spinocerebellar ataxia, autosomal recessive, 11: A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCAR11 is associated with psychomotor retardation.",,Membrane,,21835308,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
TACC3,ENSG00000013810,Unsafe,Protein,False,True,49.1,55.5,102,34,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 55.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 2.2 nTPM; positive ihc;absolute ceiling; choroid plexus: 4 nTPM; absolute ceiling; colon: 9.6 nTPM; positive ihc;absolute ceiling; duodenum: 5.9 nTPM; positive ihc;absolute ceiling; esophagus: 14.4 nTPM; positive ihc;absolute ceiling; kidney: 2.6 nTPM; positive ihc;absolute ceiling; lymph node: 39 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 2.5 nTPM; absolute ceiling; rectum: 10.1 nTPM; positive ihc;absolute ceiling; salivary gland: 3.6 nTPM; positive ihc; skeletal muscle: 1.6 nTPM; positive ihc; skin: 5.4 nTPM; positive ihc; small intestine: 12.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; spleen: 21.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 5 nTPM; positive ihc; thymus: 50.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 55.5 nTPM (limit 2); cerebral cortex: 2.2 nTPM (limit 2); choroid plexus: 4 nTPM (limit 2); colon: 9.6 nTPM (limit 6); duodenum: 5.9 nTPM (limit 2); esophagus: 14.4 nTPM (limit 6); kidney: 2.6 nTPM (limit 2); lymph node: 39 nTPM (limit 6); pituitary gland: 2.5 nTPM (limit 2); rectum: 10.1 nTPM (limit 6); small intestine: 12.5 nTPM (limit 2); spleen: 21.5 nTPM (limit 10); thymus: 50.2 nTPM (limit 10),bone marrow / hematopoietic cells: Low (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); colon / glandular cells: Medium (Enhanced); duodenum / glandular cells: Medium (Enhanced); esophagus / squamous epithelial cells: Low (Enhanced); kidney / distal tubules: Medium (Enhanced); kidney / proximal tubules (cell body): Low (Enhanced); lymph node / germinal center cells: High (Enhanced); lymph node / non-germinal center cells: Medium (Enhanced); oral mucosa / squamous epithelial cells: Medium (Enhanced); rectum / glandular cells: Medium (Enhanced); salivary gland / glandular cells: Low (Enhanced); skeletal muscle / myocytes: Low (Enhanced); skin 1 / cells in basal layer: Medium (Enhanced); skin 1 / cells in spinous layer: Medium (Enhanced); skin 2 / cells in basal layer: Medium (Enhanced); skin 2 / cells in spinous layer: Medium (Enhanced); skin 2 / extracellular matrix: Low (Enhanced); small intestine / glandular cells: Medium (Enhanced); spleen / cells in red pulp: Medium (Enhanced); spleen / cells in white pulp: High (Enhanced); stomach 2 / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (TCGA): 254/254 (100.0%); Testicular Germ Cell Tumor (TCGA): 133/133 (100.0%); Rectum Adenocarcinoma (TCGA): 88/88 (100.0%),colorectal cancer: 12/12 (100.0%); cervical cancer: 11/12 (91.7%),31,20,Q9Y6A5,https://www.uniprot.org/uniprotkb/Q9Y6A5/entry,"Plays a role in the microtubule-dependent coupling of the nucleus and the centrosome. Involved in the processes that regulate centrosome-mediated interkinetic nuclear migration (INM) of neural progenitors (By similarity). Acts as a component of the TACC3/ch-TOG/clathrin complex proposed to contribute to stabilization of kinetochore fibers of the mitotic spindle by acting as inter-microtubule bridge. The TACC3/ch-TOG/clathrin complex is required for the maintenance of kinetochore fiber tension (PubMed:21297582, PubMed:23532825). May be involved in the control of cell growth and differentiation. May contribute to cancer (PubMed:14767476)",,,,"Cytoplasm Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Cytoplasm, cytoskeleton, spindle Cytoplasm, cytoskeleton, spindle pole",14767476|21297582|23532825,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
TADA2A,ENSG00000276234,Unsafe,RNA,False,True,9.8,10.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 3.4 nTPM; absolute ceiling;continuous selectivity; amygdala: 5.8 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 6.2 nTPM; absolute ceiling;continuous selectivity; bone marrow: 2.5 nTPM; absolute ceiling; cerebellum: 10.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 7.6 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 2.5 nTPM; absolute ceiling; colon: 4.8 nTPM; continuous selectivity; esophagus: 3.7 nTPM; continuous selectivity; heart muscle: 4.1 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 5.5 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 6.2 nTPM; absolute ceiling;continuous selectivity; kidney: 3.8 nTPM; absolute ceiling;continuous selectivity; liver: 4.6 nTPM; absolute ceiling;continuous selectivity; lung: 3.2 nTPM; absolute ceiling;continuous selectivity; midbrain: 6.2 nTPM; absolute ceiling;continuous selectivity; pancreas: 4.8 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 4.5 nTPM; absolute ceiling;continuous selectivity; retina: 4.8 nTPM; absolute ceiling;continuous selectivity; salivary gland: 3.8 nTPM; continuous selectivity; skeletal muscle: 6 nTPM; absolute ceiling;continuous selectivity; skin: 4.6 nTPM; continuous selectivity; small intestine: 5.2 nTPM; absolute ceiling;continuous selectivity; spinal cord: 6.1 nTPM; absolute ceiling;continuous selectivity; spleen: 5.3 nTPM; continuous selectivity; stomach: 4.1 nTPM; continuous selectivity; thyroid gland: 5.3 nTPM; continuous selectivity; urinary bladder: 4.8 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 3.4 nTPM (limit 2); amygdala: 5.8 nTPM (limit 2); basal ganglia: 6.2 nTPM (limit 2); bone marrow: 2.5 nTPM (limit 2); cerebellum: 10.2 nTPM (limit 2); cerebral cortex: 7.6 nTPM (limit 2); choroid plexus: 2.5 nTPM (limit 2); heart muscle: 4.1 nTPM (limit 2); hippocampal formation: 5.5 nTPM (limit 2); hypothalamus: 6.2 nTPM (limit 2); kidney: 3.8 nTPM (limit 2); liver: 4.6 nTPM (limit 2); lung: 3.2 nTPM (limit 2); midbrain: 6.2 nTPM (limit 2); pancreas: 4.8 nTPM (limit 2); pituitary gland: 4.5 nTPM (limit 2); retina: 4.8 nTPM (limit 2); skeletal muscle: 6 nTPM (limit 2); small intestine: 5.2 nTPM (limit 2); spinal cord: 6.1 nTPM (limit 2); adrenal gland: 3.4 nTPM (baseline 2); amygdala: 5.8 nTPM (baseline 2); basal ganglia: 6.2 nTPM (baseline 2); bone marrow: 2.5 nTPM (baseline 2); cerebellum: 10.2 nTPM (baseline 2); cerebral cortex: 7.6 nTPM (baseline 2); choroid plexus: 2.5 nTPM (baseline 2); heart muscle: 4.1 nTPM (baseline 2); hippocampal formation: 5.5 nTPM (baseline 2); hypothalamus: 6.2 nTPM (baseline 2); kidney: 3.8 nTPM (baseline 2); liver: 4.6 nTPM (baseline 2); lung: 3.2 nTPM (baseline 2); midbrain: 6.2 nTPM (baseline 2); pancreas: 4.8 nTPM (baseline 2); pituitary gland: 4.5 nTPM (baseline 2); retina: 4.8 nTPM (baseline 2); skeletal muscle: 6 nTPM (baseline 2); small intestine: 5.2 nTPM (baseline 2); spinal cord: 6.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 45/50 (90.0%); Rectum Adenocarcinoma (validation): 182/207 (87.9%); Colon Adenocarcinoma (validation): 404/486 (83.1%),No exact-ID IHC coverage in the HPA cancer snapshot,28,0,,,,,,,,,,False,No exact Ensembl mapping to a reviewed UniProt entry,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
TAF1A,ENSG00000143498,Unsafe,Protein,False,True,6.1,6.3,82,70,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 3.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; basal ganglia: 1.7 nTPM; continuous selectivity; bone marrow: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 1.8 nTPM; positive ihc;continuous selectivity; cerebral cortex: 3 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 2 nTPM; positive ihc; duodenum: 2.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 2.5 nTPM; positive ihc;continuous selectivity; heart muscle: 1.8 nTPM; positive ihc;continuous selectivity; hypothalamus: 2.1 nTPM; absolute ceiling;continuous selectivity; kidney: 2 nTPM; positive ihc;continuous selectivity; liver: 1.8 nTPM; positive ihc;continuous selectivity; lung: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 6.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 1.7 nTPM; continuous selectivity; pancreas: 1.9 nTPM; positive ihc;continuous selectivity; parathyroid gland: 1.8 nTPM; positive ihc; pituitary gland: 2.4 nTPM; absolute ceiling;continuous selectivity; rectum: 2.5 nTPM; positive ihc;continuous selectivity; retina: 3.9 nTPM; absolute ceiling;continuous selectivity; salivary gland: 1.9 nTPM; positive ihc; skeletal muscle: 1.2 nTPM; positive ihc; skin: 2 nTPM; positive ihc; small intestine: 2.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 2.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 2 nTPM; continuous selectivity; spleen: 4.3 nTPM; positive ihc;continuous selectivity; stomach: 3.3 nTPM; positive ihc;continuous selectivity; thymus: 4.3 nTPM; continuous selectivity; thyroid gland: 4.9 nTPM; positive ihc;continuous selectivity; urinary bladder: 5.1 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 3.3 nTPM (limit 2); bone marrow: 2.7 nTPM (limit 2); cerebral cortex: 3 nTPM (limit 2); duodenum: 2.4 nTPM (limit 2); hypothalamus: 2.1 nTPM (limit 2); lung: 2.7 nTPM (limit 2); lymph node: 6.3 nTPM (limit 6); pituitary gland: 2.4 nTPM (limit 2); retina: 3.9 nTPM (limit 2); small intestine: 2.3 nTPM (limit 2); smooth muscle: 2.4 nTPM (limit 2),adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: High (Approved); cerebral cortex / neuropil: Low (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Low (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: High (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: High (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 50/50 (100.0%); Pancreatic Adenocarcinoma (validation): 79/80 (98.8%),testis cancer: 10/10 (100.0%); colorectal cancer: 10/11 (90.9%),31,20,Q15573,https://www.uniprot.org/uniprotkb/Q15573/entry,"Component of the transcription factor SL1/TIF-IB complex, which is involved in the assembly of the PIC (pre-initiation complex) during RNA polymerase I-dependent transcription. The rate of PIC formation probably is primarily dependent on the rate of association of SL1/TIF-IB with the rDNA promoter. SL1/TIF-IB is involved in stabilization of nucleolar transcription factor 1/UBTF on rDNA. Formation of SL1/TIF-IB excludes the association of TBP with TFIID subunits",,,,"Nucleus, nucleolus",11250903|11283244|15970593|7801123,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
TAF4B,ENSG00000141384,Unsafe,Protein,False,True,4.5,4.5,81,45,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 2 nTPM; positive ihc;continuous selectivity; bone marrow: 2.8 nTPM; absolute ceiling;continuous selectivity; cerebellum: 0.7 nTPM; positive ihc; cerebral cortex: 1.1 nTPM; positive ihc; colon: 1.6 nTPM; positive ihc; duodenum: 0.4 nTPM; positive ihc; esophagus: 1 nTPM; positive ihc; heart muscle: 0.3 nTPM; positive ihc; kidney: 1.5 nTPM; positive ihc;continuous selectivity; liver: 0.1 nTPM; positive ihc; lung: 0.9 nTPM; positive ihc; lymph node: 3 nTPM; positive ihc;continuous selectivity; pancreas: 1.1 nTPM; positive ihc; parathyroid gland: 0.6 nTPM; positive ihc; rectum: 1.3 nTPM; positive ihc; salivary gland: 1.1 nTPM; positive ihc; skeletal muscle: 1.3 nTPM; positive ihc;continuous selectivity; small intestine: 0.8 nTPM; positive ihc; smooth muscle: 1.1 nTPM; positive ihc; spleen: 2.4 nTPM; continuous selectivity; stomach: 1.8 nTPM; positive ihc;continuous selectivity; thyroid gland: 1.7 nTPM; positive ihc; urinary bladder: 1.5 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 2.8 nTPM (limit 2); bone marrow: 2.8 nTPM (baseline 2),adrenal gland / glandular cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Low (Uncertain); caudate / glial cells: Low (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: Low (Uncertain); cerebellum / cells in molecular layer: Low (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / endothelial cells: Low (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: Medium (Uncertain); colon / endothelial cells: Low (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: Low (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Low (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / alveolar cells: Low (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Low (Uncertain); pancreas / pancreatic endocrine cells: Low (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: Low (Uncertain); small intestine / glandular cells: Medium (Uncertain); smooth muscle / smooth muscle cells: Low (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Low (Uncertain); urinary bladder / urothelial cells: Low (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 53/58 (91.4%); Breast Invasive Carcinoma (validation): 42/50 (84.0%); Colon Adenocarcinoma (validation): 296/486 (60.9%),colorectal cancer: 6/12 (50.0%); ovarian cancer: 3/12 (25.0%),31,20,Q92750,https://www.uniprot.org/uniprotkb/Q92750/entry,"Cell type-specific subunit of the general transcription factor TFIID that may function as a gene-selective coactivator in certain cells. TFIID is a multimeric protein complex that plays a central role in mediating promoter responses to various activators and repressors. TAF4B is a transcriptional coactivator of the p65/RELA NF-kappa-B subunit. Involved in the activation of a subset of antiapoptotic genes including TNFAIP3. May be involved in regulating folliculogenesis. Through interaction with OCBA/POU2AF1, acts as a coactivator of B-cell-specific transcription. Plays a role in spermiogenesis and oogenesis",Preferentially expressed in ovarian granulosa cells (at protein level). Highly expressed in B-cells,"Spermatogenic failure 13: A disorder resulting in the absence (azoospermia) or reduction (oligozoospermia) of sperm in the semen, leading to male infertility.",,Nucleus Cytoplasm,10828057|10849440|16088961|24431330,16088961|8858156,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
TAF7L,ENSG00000102387,Unsafe,RNA,False,True,30.7,30.7,83,1,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,choroid plexus: 3.9 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 3.9 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 79/283 (27.9%); Kidney Chromophobe (TCGA): 6/64 (9.4%); Skin Cuteneous Melanoma (TCGA): 7/99 (7.1%),melanoma: 8/11 (72.7%); colorectal cancer: 7/11 (63.6%),31,20,Q5H9L4,https://www.uniprot.org/uniprotkb/Q5H9L4/entry,"Probably functions as a spermatogenesis-specific component of the DNA-binding general transcription factor complex TFIID, a multimeric protein complex that plays a central role in mediating promoter responses to various activators and repressors. May play a role in spermatogenesis (By similarity)",Testis-specific,,,Nucleus Cytoplasm,,11279525,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TAFA3,ENSG00000184599,Unsafe,Protein,False,True,7.8,44.5,88,3,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 13.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 3.7 nTPM; continuous selectivity; midbrain: 2.7 nTPM; absolute ceiling;continuous selectivity; retina: 44.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 13.2 nTPM (limit 2); midbrain: 2.7 nTPM (limit 2); retina: 44.5 nTPM (limit 2),adrenal gland / glandular cells: High (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Skin Cuteneous Melanoma (TCGA): 15/99 (15.2%); Glioblastoma Multiforme (TCGA): 17/141 (12.1%); Glioblastoma Multiforme (validation): 6/58 (10.3%),melanoma: 5/9 (55.6%); renal cancer: 4/12 (33.3%),29,20,Q7Z5A8,https://www.uniprot.org/uniprotkb/Q7Z5A8/entry,Plays a role in the regulation of microglia polarization,Brain-specific,,,Secreted,,15028294|25595455,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
TATDN2,ENSG00000157014,Unsafe,Protein,False,True,23.9,34.0,79,74,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 15 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 15.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 21.4 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 20.1 nTPM; absolute ceiling;continuous selectivity; bone marrow: 34 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 18 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 23 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 10.5 nTPM; absolute ceiling;continuous selectivity; colon: 15 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 12.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 19.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 15.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 19.9 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 14.8 nTPM; absolute ceiling;continuous selectivity; kidney: 17.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 13.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 16.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 21.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 14.5 nTPM; absolute ceiling;continuous selectivity; pancreas: 19.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 17.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 17.3 nTPM; absolute ceiling;continuous selectivity; rectum: 14.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 8.7 nTPM; absolute ceiling;continuous selectivity; salivary gland: 17.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 14.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 20 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 18.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 13 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 14.6 nTPM; absolute ceiling;continuous selectivity; spleen: 23.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 16.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 31.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 20.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 10.4 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 16 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 15 nTPM (limit 10); adrenal gland: 15.3 nTPM (limit 2); amygdala: 21.4 nTPM (limit 2); basal ganglia: 20.1 nTPM (limit 2); bone marrow: 34 nTPM (limit 2); cerebellum: 18 nTPM (limit 2); cerebral cortex: 23 nTPM (limit 2); choroid plexus: 10.5 nTPM (limit 2); colon: 15 nTPM (limit 6); duodenum: 12.3 nTPM (limit 2); esophagus: 19.4 nTPM (limit 6); heart muscle: 15.7 nTPM (limit 2); hippocampal formation: 19.9 nTPM (limit 2); hypothalamus: 14.8 nTPM (limit 2); kidney: 17.3 nTPM (limit 2); liver: 13.7 nTPM (limit 2); lung: 16.8 nTPM (limit 2); lymph node: 21.1 nTPM (limit 6); midbrain: 14.5 nTPM (limit 2); pancreas: 19.3 nTPM (limit 2); parathyroid gland: 17.3 nTPM (limit 6); pituitary gland: 17.3 nTPM (limit 2); rectum: 14.2 nTPM (limit 6); retina: 8.7 nTPM (limit 2); salivary gland: 17.2 nTPM (limit 6); skeletal muscle: 14.4 nTPM (limit 2); skin: 20 nTPM (limit 10); small intestine: 18.3 nTPM (limit 2); smooth muscle: 13 nTPM (limit 2); spinal cord: 14.6 nTPM (limit 2); spleen: 23.3 nTPM (limit 10); stomach: 16.2 nTPM (limit 6); thymus: 31.7 nTPM (limit 10); thyroid gland: 20.2 nTPM (limit 10); tongue: 10.4 nTPM (limit 6); urinary bladder: 16 nTPM (limit 6),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: High (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: High (Approved); colon / peripheral nerve/ganglion: High (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: High (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Medium (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: High (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: High (Approved); lung / macrophages: Low (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: High (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: High (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: High (Approved); skeletal muscle / myocytes: High (Approved); skin 1 / fibroblasts: High (Approved); skin 1 / keratinocytes: High (Approved); skin 1 / Langerhans: High (Approved); skin 2 / epidermal cells: High (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Low (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: High (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Prostate Adenocarcinoma (TCGA): 480/480 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%),ovarian cancer: 11/11 (100.0%); cervical cancer: 10/11 (90.9%),31,20,Q93075,https://www.uniprot.org/uniprotkb/Q93075/entry,"Mg(2+)-dependent 3'RNA exonuclease and endonuclease that resolves R-loops via specific degradation of R-loop RNA structure (PubMed:37953292). Shows no activity against D-loop and minimal activity against the RNA strand of an RNA-DNA hybrid duplex oligomer. Has no 3' or 5' exonuclease activity, no uracil glycosylase activity, and no 5' flap endonuclease activity on DNA substrates (PubMed:37953292). May have a role in maintaining genomic stability through its role in R-loop resolution (PubMed:37953292)",,,,Nucleus,37953292,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
TBATA,ENSG00000166220,Unsafe,RNA,False,True,20.3,125.3,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,thymus: 125.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,thymus: 125.3 nTPM (limit 10); thymus: 125.3 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Chromophobe (TCGA): 10/64 (15.6%); Ovary Serous Cystadenocarcinoma (validation): 1/81 (1.2%); Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q96M53,https://www.uniprot.org/uniprotkb/Q96M53/entry,May play a role in spermatid differentiation. Modulates thymic stromal cell proliferation and thymus function,,,,"Cytoplasm, cytosol",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TBC1D26,ENSG00000214946,Unsafe,RNA,False,True,15.4,15.4,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,basal ganglia: 4.2 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,basal ganglia: 4.2 nTPM (limit 2); hippocampal formation: 3 nTPM (limit 2); basal ganglia: 4.2 nTPM (baseline 2); hippocampal formation: 3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Lung Squamous Cell Carcinoma (TCGA): 1/489 (0.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q86UD7,https://www.uniprot.org/uniprotkb/Q86UD7/entry,May act as a GTPase-activating protein for Rab family protein(s),,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
TBC1D3D,ENSG00000274419,Unsafe,Protein,False,True,7.1,7.1,86,6,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,existing nomination or manual review; nomination unresolved; positive normal IHC; positive ihc outside permitted; adrenal gland: 3.1 nTPM; continuous selectivity; basal ganglia: 2.5 nTPM; absolute ceiling;continuous selectivity; cerebellum: 7 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 2.5 nTPM; continuous selectivity; choroid plexus: 6.8 nTPM; absolute ceiling;continuous selectivity; esophagus: 4 nTPM; continuous selectivity; hypothalamus: 2.1 nTPM; absolute ceiling;continuous selectivity; liver: 3.3 nTPM; continuous selectivity; pancreas: 2.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 3.1 nTPM; absolute ceiling;continuous selectivity; retina: 2.2 nTPM; absolute ceiling;continuous selectivity; small intestine: 4.1 nTPM; absolute ceiling;continuous selectivity; spleen: 4.1 nTPM; continuous selectivity; urinary bladder: 3.4 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",basal ganglia: 2.5 nTPM (limit 2); cerebellum: 7 nTPM (limit 4); choroid plexus: 6.8 nTPM (limit 2); hypothalamus: 2.1 nTPM (limit 2); pancreas: 2.6 nTPM (limit 2); pituitary gland: 3.1 nTPM (limit 2); retina: 2.2 nTPM (limit 2); small intestine: 4.1 nTPM (limit 4),pancreas / exocrine glandular cells: Low (Approved); urinary bladder / urothelial cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 26/176 (14.8%); Kidney Renal Papillary Cell Carcinoma (TCGA): 38/282 (13.5%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 30/283 (10.6%),breast cancer: 0/11 (0.0%); cervical cancer: 0/11 (0.0%),26,20,A0A087WVF3,https://www.uniprot.org/uniprotkb/A0A087WVF3/entry,Acts as a GTPase activating protein for RAB5. Does not act on RAB4 or RAB11 (By similarity),"Expressed in pancreas, thymus and testis",,,Cell membrane,,16863688,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
TBC1D3G,ENSG00000260287,Unsafe,Protein,False,True,25.4,25.4,86,4,Positive somewhere,True,True,False,True,Excluded,Normal,False,,Not assessed,,,existing nomination or manual review; nomination unresolved; positive normal IHC; positive ihc outside permitted; kidney: 2.7 nTPM; positive ihc;absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",kidney: 2.7 nTPM (limit 2),kidney / cells in tubules: Low (Supported),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 17/50 (34.0%); Bladder Urothelial Carcinoma (TCGA): 2/169 (1.2%); Glioblastoma Multiforme (TCGA): 1/141 (0.7%),breast cancer: 0/11 (0.0%); cervical cancer: 0/11 (0.0%),28,20,Q6DHY5,https://www.uniprot.org/uniprotkb/Q6DHY5/entry,Acts as a GTPase activating protein for RAB5. Does not act on RAB4 or RAB11 (By similarity),,,,Cell membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
TBC1D7,ENSG00000145979,Unsafe,Protein,False,True,19.4,30.5,79,16,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 11.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 13 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 12.1 nTPM; absolute ceiling;continuous selectivity; bone marrow: 26.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 10.7 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 18.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 9.3 nTPM; absolute ceiling;continuous selectivity; colon: 14.7 nTPM; absolute ceiling;continuous selectivity; duodenum: 14.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 16.7 nTPM; absolute ceiling;continuous selectivity; heart muscle: 30.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 13.6 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 12.7 nTPM; absolute ceiling;continuous selectivity; kidney: 20.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 17.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 10.6 nTPM; absolute ceiling;continuous selectivity; lymph node: 13.6 nTPM; absolute ceiling;continuous selectivity; midbrain: 12.2 nTPM; absolute ceiling;continuous selectivity; pancreas: 9.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 12 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 10.4 nTPM; absolute ceiling;continuous selectivity; rectum: 15.9 nTPM; absolute ceiling;continuous selectivity; retina: 11.1 nTPM; absolute ceiling;continuous selectivity; salivary gland: 11.8 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 15.7 nTPM; absolute ceiling;continuous selectivity; skin: 13.3 nTPM; continuous selectivity; small intestine: 10.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 9.7 nTPM; absolute ceiling;continuous selectivity; spinal cord: 12.9 nTPM; absolute ceiling;continuous selectivity; spleen: 12 nTPM; continuous selectivity; stomach: 9.5 nTPM; absolute ceiling;continuous selectivity; thymus: 16.4 nTPM; absolute ceiling;continuous selectivity; tongue: 13.9 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 9.6 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 11.6 nTPM (limit 2); amygdala: 13 nTPM (limit 2); basal ganglia: 12.1 nTPM (limit 2); bone marrow: 26.1 nTPM (limit 4); cerebellum: 10.7 nTPM (limit 4); cerebral cortex: 18.5 nTPM (limit 2); choroid plexus: 9.3 nTPM (limit 2); colon: 14.7 nTPM (limit 8); duodenum: 14.1 nTPM (limit 2); esophagus: 16.7 nTPM (limit 8); heart muscle: 30.5 nTPM (limit 4); hippocampal formation: 13.6 nTPM (limit 2); hypothalamus: 12.7 nTPM (limit 2); kidney: 20.5 nTPM (limit 2); liver: 17.1 nTPM (limit 2); lung: 10.6 nTPM (limit 4); lymph node: 13.6 nTPM (limit 8); midbrain: 12.2 nTPM (limit 2); pancreas: 9.9 nTPM (limit 2); parathyroid gland: 12 nTPM (limit 6); pituitary gland: 10.4 nTPM (limit 2); rectum: 15.9 nTPM (limit 8); retina: 11.1 nTPM (limit 2); salivary gland: 11.8 nTPM (limit 8); skeletal muscle: 15.7 nTPM (limit 4); small intestine: 10.5 nTPM (limit 2); smooth muscle: 9.7 nTPM (limit 4); spinal cord: 12.9 nTPM (limit 2); stomach: 9.5 nTPM (limit 8); thymus: 16.4 nTPM (limit 10); tongue: 13.9 nTPM (limit 6); urinary bladder: 9.6 nTPM (limit 8),adrenal gland / glandular cells: Medium (Approved); caudate / glial cells: Low (Approved); cerebral cortex / glial cells: Medium (Approved); duodenum / glandular cells: Low (Approved); hippocampus / glial cells: Low (Approved); kidney / cells in tubules: High (Approved); liver / hepatocytes: High (Approved); pancreas / exocrine glandular cells: Low (Approved); parathyroid gland / glandular cells: Low (Approved); small intestine / glandular cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%); Head and Neck Squamous Cell Carcinoma (TCGA): 492/492 (100.0%),prostate cancer: 6/12 (50.0%); liver cancer: 5/11 (45.5%),31,20,Q9P0N9,https://www.uniprot.org/uniprotkb/Q9P0N9/entry,"Non-catalytic component of the TSC-TBC complex, a multiprotein complex that acts as a negative regulator of the canonical mTORC1 complex, an evolutionarily conserved central nutrient sensor that stimulates anabolic reactions and macromolecule biosynthesis to promote cellular biomass generation and growth (PubMed:22795129, PubMed:24529379). The TSC-TBC complex acts as a GTPase-activating protein (GAP) for the small GTPase RHEB, a direct activator of the protein kinase activity of mTORC1 (PubMed:22795129, PubMed:24529379). In absence of nutrients, the TSC-TBC complex inhibits mTORC1, thereby preventing phosphorylation of ribosomal protein S6 kinase (RPS6KB1 and RPS6KB2) and EIF4EBP1 (4E-BP1) by the mTORC1 signaling (PubMed:22795129). The TSC-TBC complex is inactivated in response to nutrients, relieving inhibition of mTORC1 (PubMed:24529379)","Highly expressed in heart, and slightly in kidney, liver and placenta","Macrocephaly/megalencephaly syndrome, autosomal recessive: An autosomal recessive disorder characterized by abnormal enlargement of the cerebral hemispheres, intellectual disability, large head, optic atrophy and underdeveloped skeletal musculature. Head enlargement may be evident at birth or the head may become abnormally large in the early years of life. Additional clinical features include behavioral abnormalities, psychosis, learning difficulties, prognathism, myopia and astigmatism.","Was initially identified as a negative regulator of the TSC-TBC complex (PubMed:17658474). However, it was later shown that TBC1D7 is part of the TSC-TBC complex and participates in GTPase-activating protein activity, leading to inhibition of the TOR signaling cascade (PubMed:22795129). The differences between 2 reports might be explained by experimental conditions in the initial report, in which they overexpressed the TBC1D7 subunit, possibly leading to disrupt the stoichiometric complex and its downstream functions","Lysosome membrane Cytoplasmic vesicle Cytoplasm, cytosol",22795129|24529379,17658474,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
TBCE,ENSG00000284770,Unsafe,Protein,False,True,3.1,8.4,82,54,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,"incomplete routine rna; positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; incomplete routine rna; unresolved positive anatomy; missing normal RNA: amygdala, basal ganglia, cerebellum, hippocampal formation, hypothalamus, midbrain, pituitary gland, spinal cord; adipose tissue: 2.8 nTPM; positive ihc;continuous selectivity; adrenal gland: 4.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 2.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 1.8 nTPM; positive ihc;continuous selectivity; choroid plexus: 2.2 nTPM; absolute ceiling;continuous selectivity; colon: 3.8 nTPM; positive ihc;continuous selectivity;reproductive not higher; duodenum: 2.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 3.4 nTPM; positive ihc;continuous selectivity;reproductive not higher; heart muscle: 4.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; kidney: 3.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 5.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 1.9 nTPM; continuous selectivity; lymph node: 2.1 nTPM; continuous selectivity; pancreas: 1.8 nTPM; positive ihc;continuous selectivity; parathyroid gland: 2.9 nTPM; continuous selectivity; rectum: 3.1 nTPM; positive ihc;continuous selectivity;reproductive not higher; retina: 4.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 3.4 nTPM; positive ihc;continuous selectivity;reproductive not higher; skeletal muscle: 8.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 2.1 nTPM; positive ihc;continuous selectivity; small intestine: 1.3 nTPM; positive ihc;continuous selectivity; smooth muscle: 1.9 nTPM; continuous selectivity; spleen: 2 nTPM; positive ihc;continuous selectivity; stomach: 3.7 nTPM; positive ihc;continuous selectivity;reproductive not higher; thymus: 2 nTPM; continuous selectivity; thyroid gland: 6.6 nTPM; positive ihc;continuous selectivity;reproductive not higher; tongue: 1.5 nTPM; continuous selectivity; urinary bladder: 2.5 nTPM; positive ihc;continuous selectivity","Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 4.2 nTPM (limit 2); bone marrow: 2.2 nTPM (limit 2); choroid plexus: 2.2 nTPM (limit 2); duodenum: 2.6 nTPM (limit 2); heart muscle: 4.9 nTPM (limit 2); kidney: 3.5 nTPM (limit 2); liver: 5.4 nTPM (limit 2); retina: 4.4 nTPM (limit 2); skeletal muscle: 8.4 nTPM (limit 2),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: Low (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Low (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / neuropil: Low (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Low (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Medium (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Low (Approved); pancreas / pancreatic endocrine cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / fibroblasts: Low (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Medium (Approved); spleen / cells in red pulp: High (Approved); spleen / cells in white pulp: High (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Low (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Low (Approved),incomplete_routine_rna;unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Adenocarcinoma (validation): 95/105 (90.5%); Lung Squamous Cell Carcinoma (validation): 60/68 (88.2%); Breast Invasive Carcinoma (TCGA): 792/1022 (77.5%),colorectal cancer: 10/12 (83.3%); liver cancer: 7/12 (58.3%),26,20,Q15813,https://www.uniprot.org/uniprotkb/Q15813/entry,"Tubulin-folding protein; involved in the second step of the tubulin folding pathway and in the regulation of tubulin heterodimer dissociation. Required for correct organization of microtubule cytoskeleton and mitotic splindle, and maintenance of the neuronal microtubule network",,"Hypoparathyroidism-retardation-dysmorphism syndrome: An autosomal recessive multisystem disorder characterized by hypoparathyroidism, intrauterine and postnatal growth retardation, psychomotor retardation, epilepsy, microcephaly, and facial dysmorphism. Kenny-Caffey syndrome 1: An autosomal recessive form of Kenny-Caffey syndrome, a disorder characterized by impaired skeletal development with small and dense bones, short stature, and primary hypoparathyroidism with hypocalcemia. Clinical features include cortical thickening and medullary stenosis of the tubular bones, delayed closure of fontanels, defective dentition, small eyes with hypermetropia, and frontal bossing with a triangular face. Encephalopathy, progressive, with amyotrophy and optic atrophy: An autosomal recessive, progressive, neurodegenerative encephalopathy with onset in infancy. Affected individuals manifest delayed psychomotor development, severe hypotonia, motor regression, spinal muscular atrophy, distal amyotrophy and weakness of all limbs, and intellectual disability of variable severity. Additional features include optic atrophy, thin corpus callosum, and cerebellar atrophy.",,"Cytoplasm Cytoplasm, cytoskeleton",11847227|27666369,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
TBCEL,ENSG00000154114,Unsafe,Protein,False,True,12.7,14.9,93,68,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 7.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 4.4 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 4.9 nTPM; absolute ceiling;continuous selectivity; bone marrow: 5.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 4.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 6.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 14.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 7 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 4.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 5.5 nTPM; positive ihc;continuous selectivity; heart muscle: 9.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 5 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 4.7 nTPM; absolute ceiling;continuous selectivity; kidney: 7.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 14.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 9.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 7 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 5 nTPM; absolute ceiling;continuous selectivity; pancreas: 5.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 14.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 7.5 nTPM; absolute ceiling;continuous selectivity; rectum: 5.5 nTPM; positive ihc;continuous selectivity; retina: 8 nTPM; absolute ceiling;continuous selectivity; salivary gland: 6.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 5.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 4.7 nTPM; positive ihc; small intestine: 5.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 8.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 6.1 nTPM; absolute ceiling;continuous selectivity; spleen: 7.7 nTPM; positive ihc;continuous selectivity; stomach: 5.7 nTPM; positive ihc;continuous selectivity; thymus: 6.9 nTPM; continuous selectivity; thyroid gland: 9.7 nTPM; positive ihc;continuous selectivity; tongue: 7.4 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 5.9 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 7.3 nTPM (limit 2); amygdala: 4.4 nTPM (limit 2); basal ganglia: 4.9 nTPM (limit 2); bone marrow: 5.5 nTPM (limit 2); cerebellum: 4.7 nTPM (limit 2); cerebral cortex: 6.5 nTPM (limit 2); choroid plexus: 14.4 nTPM (limit 2); colon: 7 nTPM (limit 6); duodenum: 4.8 nTPM (limit 2); heart muscle: 9.2 nTPM (limit 2); hippocampal formation: 5 nTPM (limit 2); hypothalamus: 4.7 nTPM (limit 2); kidney: 7.6 nTPM (limit 2); liver: 14.1 nTPM (limit 4); lung: 9.1 nTPM (limit 2); lymph node: 7 nTPM (limit 6); midbrain: 5 nTPM (limit 2); pancreas: 5.9 nTPM (limit 2); parathyroid gland: 14.9 nTPM (limit 6); pituitary gland: 7.5 nTPM (limit 2); retina: 8 nTPM (limit 2); salivary gland: 6.7 nTPM (limit 6); skeletal muscle: 5.7 nTPM (limit 2); small intestine: 5.5 nTPM (limit 2); smooth muscle: 8.9 nTPM (limit 2); spinal cord: 6.1 nTPM (limit 2); tongue: 7.4 nTPM (limit 6),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / ciliated cells (cell body): Low (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: High (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: High (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: High (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Medium (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / ciliated cells (cell body): Medium (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: High (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in red pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Lung Adenocarcinoma (validation): 103/105 (98.1%); Lung Squamous Cell Carcinoma (validation): 65/68 (95.6%),breast cancer: 12/12 (100.0%); ovarian cancer: 11/11 (100.0%),31,20,Q5QJ74,https://www.uniprot.org/uniprotkb/Q5QJ74/entry,Acts as a regulator of tubulin stability,"Abundantly expressed in testis, but is also present in several tissues at a much lower level",,,"Cytoplasm, cytoskeleton",15728251,15728251,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
TBL2,ENSG00000106638,Unsafe,RNA,False,True,18.8,18.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 7.5 nTPM; absolute ceiling;continuous selectivity; heart muscle: 3.2 nTPM; absolute ceiling; kidney: 3.7 nTPM; absolute ceiling; liver: 4.5 nTPM; absolute ceiling; lung: 4 nTPM; absolute ceiling; pancreas: 15.5 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 2.9 nTPM; absolute ceiling; small intestine: 3.9 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 7.5 nTPM (limit 2); heart muscle: 3.2 nTPM (limit 2); kidney: 3.7 nTPM (limit 2); liver: 4.5 nTPM (limit 2); lung: 4 nTPM (limit 2); pancreas: 15.5 nTPM (limit 2); pituitary gland: 2.9 nTPM (limit 2); small intestine: 3.9 nTPM (limit 2); adrenal gland: 7.5 nTPM (baseline 2); heart muscle: 3.2 nTPM (baseline 2); kidney: 3.7 nTPM (baseline 2); liver: 4.5 nTPM (baseline 2); lung: 4 nTPM (baseline 2); pancreas: 15.5 nTPM (baseline 2); pituitary gland: 2.9 nTPM (baseline 2); small intestine: 3.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (validation): 231/231 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Ovary Serous Cystadenocarcinoma (validation): 81/81 (100.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9Y4P3,https://www.uniprot.org/uniprotkb/Q9Y4P3/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
TCEAL1,ENSG00000172465,Unsafe,Protein,False,True,169.3,169.3,91,55,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 33.8 nTPM; absolute ceiling; adrenal gland: 53 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 42.3 nTPM; absolute ceiling; basal ganglia: 37.7 nTPM; absolute ceiling; bone marrow: 9.8 nTPM; positive ihc;absolute ceiling; cerebellum: 56.2 nTPM; absolute ceiling; cerebral cortex: 55.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 32.5 nTPM; absolute ceiling; colon: 59 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 14.7 nTPM; positive ihc;absolute ceiling; esophagus: 36.6 nTPM; positive ihc;absolute ceiling; heart muscle: 31.1 nTPM; absolute ceiling; hippocampal formation: 43.2 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 53.3 nTPM; absolute ceiling;continuous selectivity; kidney: 24.4 nTPM; positive ihc;absolute ceiling; liver: 18.5 nTPM; absolute ceiling; lung: 29.6 nTPM; positive ihc;absolute ceiling; lymph node: 13.7 nTPM; positive ihc;absolute ceiling; midbrain: 31.4 nTPM; absolute ceiling; pancreas: 19.7 nTPM; absolute ceiling; parathyroid gland: 30.8 nTPM; absolute ceiling; pituitary gland: 33 nTPM; absolute ceiling; rectum: 16.2 nTPM; positive ihc;absolute ceiling; retina: 14.3 nTPM; absolute ceiling; salivary gland: 15.6 nTPM; positive ihc;absolute ceiling; skeletal muscle: 53.2 nTPM; absolute ceiling; skin: 16.8 nTPM; positive ihc;absolute ceiling; small intestine: 28.3 nTPM; positive ihc;absolute ceiling; smooth muscle: 91.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 28.1 nTPM; absolute ceiling; spleen: 25.6 nTPM; absolute ceiling; stomach: 39 nTPM; absolute ceiling; thymus: 11.9 nTPM; absolute ceiling; thyroid gland: 31 nTPM; positive ihc;absolute ceiling; tongue: 32.3 nTPM; absolute ceiling; urinary bladder: 94.7 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 33.8 nTPM (limit 20); adrenal gland: 53 nTPM (limit 2); amygdala: 42.3 nTPM (limit 2); basal ganglia: 37.7 nTPM (limit 2); bone marrow: 9.8 nTPM (limit 2); cerebellum: 56.2 nTPM (limit 4); cerebral cortex: 55.1 nTPM (limit 2); choroid plexus: 32.5 nTPM (limit 2); colon: 59 nTPM (limit 6); duodenum: 14.7 nTPM (limit 2); esophagus: 36.6 nTPM (limit 6); heart muscle: 31.1 nTPM (limit 4); hippocampal formation: 43.2 nTPM (limit 2); hypothalamus: 53.3 nTPM (limit 2); kidney: 24.4 nTPM (limit 2); liver: 18.5 nTPM (limit 4); lung: 29.6 nTPM (limit 2); lymph node: 13.7 nTPM (limit 6); midbrain: 31.4 nTPM (limit 2); pancreas: 19.7 nTPM (limit 4); parathyroid gland: 30.8 nTPM (limit 8); pituitary gland: 33 nTPM (limit 2); rectum: 16.2 nTPM (limit 6); retina: 14.3 nTPM (limit 2); salivary gland: 15.6 nTPM (limit 6); skeletal muscle: 53.2 nTPM (limit 4); skin: 16.8 nTPM (limit 10); small intestine: 28.3 nTPM (limit 2); smooth muscle: 91.4 nTPM (limit 2); spinal cord: 28.1 nTPM (limit 2); spleen: 25.6 nTPM (limit 20); stomach: 39 nTPM (limit 8); thymus: 11.9 nTPM (limit 10); thyroid gland: 31 nTPM (limit 10); tongue: 32.3 nTPM (limit 6); urinary bladder: 94.7 nTPM (limit 6),adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / basal cells: High (Approved); bronchus / ciliated cells (cell body): High (Approved); bronchus / goblet cells: High (Approved); caudate / neuronal cells: Low (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: High (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Low (Approved); lung / macrophages: Low (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / basal cells: Medium (Approved); nasopharynx / ciliated cells (cell body): High (Approved); nasopharynx / goblet cells: High (Approved); oral mucosa / squamous epithelial cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Low (Approved); smooth muscle / smooth muscle cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Prostate Adenocarcinoma (TCGA): 480/480 (100.0%); Colon Adenocarcinoma (TCGA): 254/254 (100.0%); Glioblastoma Multiforme (TCGA): 141/141 (100.0%),cervical cancer: 10/11 (90.9%); melanoma: 10/11 (90.9%),31,20,Q15170,https://www.uniprot.org/uniprotkb/Q15170/entry,"May be involved in transcriptional regulation. Modulates various viral and cellular promoters in a promoter context-dependent manner. For example, transcription from the FOS promoter is increased, while Rous sarcoma virus (RSV) long terminal repeat (LTR) promoter activity is repressed. Does not bind DNA directly","Expressed in all tissues examined. Highly expressed in heart, ovary, prostate and skeletal muscle. Moderately expressed in brain, placenta, testis and small intestine. Weakly expressed in lung, liver and spleen. Expressed in several cancer cell lines","Hijazi-Reis syndrome: A neurodevelopmental disorder characterized by hypotonia, abnormal gait, developmental delay, intellectual disability especially affecting expressive language, and autistic behavior. Additional features include facial dysmorphism,ocular anomalies, and gastrointestinal issues. Rare patients have seizures. Disease severity is variable. Males tend to be more severely affected than females.",,Nucleus,,10051408,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
TCL1B,ENSG00000213231,Unsafe,High RNA,False,True,2.5,2.5,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 1.1 nTPM; continuous selectivity; lymph node: 2.1 nTPM; continuous selectivity,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 37/91 values ≥5 TPM, max 11.8843; hpa_immune_cell naive B-cell: 11.8 nTPM; hpa_immune_cell plasmacytoid DC: 6.2 nTPM; hpa_immune_monaco naive B-cell: 26.9 TPM; hpa_immune_monaco plasmacytoid DC: 6.5 TPM",True,True,False,,True,True,"Adipose tissue/Adipocytes: Low, HPA053163; conflicting or uncurated primary profile; Adrenal gland/Glandular cells: Medium, HPA053163; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Medium, HPA053163; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA053163; conflicting or uncurated primary profile; Caudate/Glial cells: Low, HPA053163; conflicting or uncurated primary profile; Caudate/Neuronal cells: Low, HPA053163; conflicting or uncurated primary profile; Cerebellum/Cells in granular layer: Low, HPA053163; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Low, HPA053163; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA053163; conflicting or uncurated primary profile; Cerebral cortex/Neuronal cells: Low, HPA053163; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA053163; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA053163; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA053163; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA053163; conflicting or uncurated primary profile; Duodenum/Glandular cells: Low, HPA053163; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA053163; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Medium, HPA053163; conflicting or uncurated primary profile; Hippocampus/Neuronal cells: Low, HPA053163; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA053163; conflicting or uncurated primary profile; Kidney/Cells in tubules: Medium, HPA053163; conflicting or uncurated primary profile; Liver/Hepatocytes: Low, HPA053163; conflicting or uncurated primary profile; Lung/Alveolar cells: Medium, HPA053163; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA053163; conflicting or uncurated primary profile; Lymph node/Germinal center cells: Low, HPA053163; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA053163; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA053163; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA053163; conflicting or uncurated primary profile; Parathyroid gland/Glandular cells: Low, HPA053163; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA053163; conflicting or uncurated primary profile; Salivary gland/Glandular cells: Medium, HPA053163; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA053163; conflicting or uncurated primary profile; Skin 1/Fibroblasts: Medium, HPA053163; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA053163; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA053163; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA053163; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA053163; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA053163; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA053163; conflicting or uncurated primary profile; Stomach 2/Glandular cells: High, HPA053163; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Medium, HPA053163; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA053163; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,34.4592,44.6861,"hpa_immune_cell_samples: blood/naive B-cell, max 34.4592 TPM, 1 observations >30; hpa_immune_cell_samples: blood/naive B-cell, max 44.6861 nTPM, 1 observations >30",Neither,oncoref.target-sets.2026-10-23.2,34.46 TPM; blood/naive B-cell; hpa_immune_cell_samples; vital,44.69 nTPM; blood/naive B-cell; hpa_immune_cell_samples; vital,Testicular Germ Cell Tumor (TCGA): 100/133 (75.2%); Breast Invasive Carcinoma (validation): 4/50 (8.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 9/176 (5.1%),prostate cancer: 6/11 (54.5%); glioma: 5/10 (50.0%),31,20,O95988,https://www.uniprot.org/uniprotkb/O95988/entry,Enhances the phosphorylation and activation of AKT1 and AKT2,Expressed in a variety of tissues including placenta and testis,,,,10983986,10077617|10344735,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
TCP10L,ENSG00000242220,Unsafe,Protein,False,True,198.0,198.0,86,5,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 2.4 nTPM; absolute ceiling; basal ganglia: 2.7 nTPM; absolute ceiling; hippocampal formation: 2.4 nTPM; absolute ceiling; hypothalamus: 2.5 nTPM; absolute ceiling; liver: 18.4 nTPM; positive ihc;absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 2.4 nTPM (limit 2); basal ganglia: 2.7 nTPM (limit 2); hippocampal formation: 2.4 nTPM (limit 2); hypothalamus: 2.5 nTPM (limit 2); liver: 18.4 nTPM (limit 2),liver / hepatocytes: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (TCGA): 154/362 (42.5%); Glioblastoma Multiforme (validation): 19/58 (32.8%); Liver Hepatocellular Carcinoma (validation): 39/231 (16.9%),liver cancer: 4/12 (33.3%); testis cancer: 1/9 (11.1%),31,20,Q8TDR4,https://www.uniprot.org/uniprotkb/Q8TDR4/entry,May be involved in transcriptional regulation. Has in vitro transcription inhibition activity. Acts as a tumor suppressor in hepatocellular carcinoma (HCC) cells,Expressed in liver and testis. Expressed in the seminiferous tubules (at protein level),,,Nucleus,14586771|24565846,14586771|15910542,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TCP11L1,ENSG00000176148,Unsafe,Protein,False,True,6.8,12.2,70,66,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 6.1 nTPM; positive ihc;continuous selectivity; adrenal gland: 4.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 4.8 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 3.8 nTPM; absolute ceiling;continuous selectivity; bone marrow: 7.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 5.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 12.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 3.7 nTPM; absolute ceiling;continuous selectivity; colon: 6.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 5.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 4.7 nTPM; continuous selectivity; heart muscle: 4.5 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 5.3 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 5.5 nTPM; absolute ceiling;continuous selectivity; kidney: 5.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 3.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 4.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 4.8 nTPM; positive ihc;continuous selectivity; midbrain: 6.3 nTPM; absolute ceiling;continuous selectivity; pancreas: 5.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 3.9 nTPM; positive ihc;continuous selectivity; pituitary gland: 4.9 nTPM; absolute ceiling;continuous selectivity; rectum: 7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; retina: 5.8 nTPM; absolute ceiling;continuous selectivity; salivary gland: 4.8 nTPM; positive ihc;continuous selectivity; skeletal muscle: 2.9 nTPM; continuous selectivity; skin: 5.2 nTPM; positive ihc;continuous selectivity; small intestine: 8.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 8.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 6.5 nTPM; absolute ceiling;continuous selectivity; spleen: 5.2 nTPM; positive ihc;continuous selectivity; stomach: 4.1 nTPM; positive ihc;continuous selectivity; thymus: 7.4 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 3.1 nTPM; positive ihc;continuous selectivity; tongue: 3.9 nTPM; continuous selectivity; urinary bladder: 5.6 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 4.9 nTPM (limit 2); amygdala: 4.8 nTPM (limit 2); basal ganglia: 3.8 nTPM (limit 2); bone marrow: 7.3 nTPM (limit 2); cerebellum: 5.3 nTPM (limit 2); cerebral cortex: 12.2 nTPM (limit 2); choroid plexus: 3.7 nTPM (limit 2); colon: 6.7 nTPM (limit 6); duodenum: 5.9 nTPM (limit 2); heart muscle: 4.5 nTPM (limit 4); hippocampal formation: 5.3 nTPM (limit 2); hypothalamus: 5.5 nTPM (limit 2); kidney: 5.7 nTPM (limit 2); liver: 3.9 nTPM (limit 2); lung: 4.5 nTPM (limit 2); midbrain: 6.3 nTPM (limit 2); pancreas: 5.5 nTPM (limit 2); pituitary gland: 4.9 nTPM (limit 2); rectum: 7 nTPM (limit 6); retina: 5.8 nTPM (limit 2); small intestine: 8.6 nTPM (limit 2); smooth muscle: 8.4 nTPM (limit 2); spinal cord: 6.5 nTPM (limit 2),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / glial cells: Low (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / endothelial cells: High (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: High (Approved); colon / glandular cells: High (Approved); colon / peripheral nerve/ganglion: High (Approved); duodenum / glandular cells: High (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: High (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: High (Approved); lung / alveolar cells: High (Approved); lung / macrophages: High (Approved); lymph node / germinal center cells: High (Approved); lymph node / non-germinal center cells: High (Approved); oral mucosa / squamous epithelial cells: High (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: High (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: High (Approved); skin 1 / Langerhans: High (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: High (Approved); spleen / cells in white pulp: High (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: High (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 483/486 (99.4%),cervical cancer: 12/12 (100.0%); colorectal cancer: 12/12 (100.0%),31,20,Q9NUJ3,https://www.uniprot.org/uniprotkb/Q9NUJ3/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
TCTE1,ENSG00000146221,Unsafe,RNA,False,True,29.2,29.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 3.1 nTPM; absolute ceiling; basal ganglia: 2.6 nTPM; absolute ceiling; cerebellum: 7.6 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 2.7 nTPM; absolute ceiling; hippocampal formation: 4.3 nTPM; absolute ceiling; hypothalamus: 2.8 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 3.1 nTPM (limit 2); basal ganglia: 2.6 nTPM (limit 2); cerebellum: 7.6 nTPM (limit 2); cerebral cortex: 2.7 nTPM (limit 2); hippocampal formation: 4.3 nTPM (limit 2); hypothalamus: 2.8 nTPM (limit 2); amygdala: 3.1 nTPM (baseline 2); basal ganglia: 2.6 nTPM (baseline 2); cerebellum: 7.6 nTPM (baseline 2); cerebral cortex: 2.7 nTPM (baseline 2); hippocampal formation: 4.3 nTPM (baseline 2); hypothalamus: 2.8 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 26/176 (14.8%); Testicular Germ Cell Tumor (TCGA): 6/133 (4.5%); Lung Adenocarcinoma (TCGA): 11/497 (2.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q5JU00,https://www.uniprot.org/uniprotkb/Q5JU00/entry,Component of the nexin-dynein regulatory complex (N-DRC) a key regulator of ciliary/flagellar motility which maintains the alignment and integrity of the distal axoneme and regulates microtubule sliding in motile axonemes. May play a role in the assembly of N-DRC. May be required for sperm motility,,,,"Cell projection, cilium, flagellum Cytoplasm, cytoskeleton, flagellum axoneme",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
TDRD10,ENSG00000163239,Unsafe,RNA,False,True,54.1,54.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 10.7 nTPM; absolute ceiling; adrenal gland: 4.3 nTPM; absolute ceiling; heart muscle: 7.4 nTPM; absolute ceiling; kidney: 3.4 nTPM; absolute ceiling; liver: 4.4 nTPM; absolute ceiling; lung: 7.8 nTPM; absolute ceiling; pituitary gland: 2.5 nTPM; absolute ceiling; small intestine: 3.4 nTPM; absolute ceiling; thyroid gland: 10.7 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adipose tissue: 10.7 nTPM (limit 10); adrenal gland: 4.3 nTPM (limit 2); heart muscle: 7.4 nTPM (limit 2); kidney: 3.4 nTPM (limit 2); liver: 4.4 nTPM (limit 2); lung: 7.8 nTPM (limit 2); pituitary gland: 2.5 nTPM (limit 2); small intestine: 3.4 nTPM (limit 2); thyroid gland: 10.7 nTPM (limit 10); adipose tissue: 10.7 nTPM (baseline 10); adrenal gland: 4.3 nTPM (baseline 2); heart muscle: 7.4 nTPM (baseline 2); kidney: 3.4 nTPM (baseline 2); liver: 4.4 nTPM (baseline 2); lung: 7.8 nTPM (baseline 2); pituitary gland: 2.5 nTPM (baseline 2); small intestine: 3.4 nTPM (baseline 2); thyroid gland: 10.7 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 55/133 (41.4%); Liver Hepatocellular Carcinoma (validation): 82/231 (35.5%); Breast Invasive Carcinoma (validation): 17/50 (34.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q5VZ19,https://www.uniprot.org/uniprotkb/Q5VZ19/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
TDRD5,ENSG00000162782,Unsafe,Protein,False,True,21.2,21.2,89,6,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; basal ganglia: 2.3 nTPM; absolute ceiling; kidney: 1.8 nTPM; positive ihc; pituitary gland: 2.2 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",basal ganglia: 2.3 nTPM (limit 2); pituitary gland: 2.2 nTPM (limit 2),kidney / collecting ducts: Medium (Enhanced); kidney / distal tubules: Medium (Enhanced); kidney / proximal tubules (cell body): Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 45/50 (90.0%); Breast Invasive Carcinoma (TCGA): 487/1022 (47.7%); Lung Squamous Cell Carcinoma (TCGA): 128/489 (26.2%),liver cancer: 2/9 (22.2%); breast cancer: 0/9 (0.0%),31,20,Q8NAT2,https://www.uniprot.org/uniprotkb/Q8NAT2/entry,"Required during spermiogenesis to participate in the repression transposable elements and prevent their mobilization, which is essential for the germline integrity. Probably acts via the piRNA metabolic process, which mediates the repression of transposable elements during meiosis by forming complexes composed of piRNAs and Piwi proteins and govern the methylation and subsequent repression of transposons. Required for chromatoid body (CB) assembly (By similarity)",,,,Cytoplasm,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
TDRD6,ENSG00000180113,Unsafe,RNA,False,True,29.5,29.5,86,1,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,choroid plexus: 3 nTPM; absolute ceiling; pituitary gland: 2.9 nTPM; absolute ceiling; retina: 8.6 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 3 nTPM (limit 2); pituitary gland: 2.9 nTPM (limit 2); retina: 8.6 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Prostate Adenocarcinoma (TCGA): 254/480 (52.9%); Lung Adenocarcinoma (validation): 23/105 (21.9%); Lung Squamous Cell Carcinoma (validation): 10/68 (14.7%),breast cancer: 2/12 (16.7%); liver cancer: 1/10 (10.0%),31,20,O60522,https://www.uniprot.org/uniprotkb/O60522/entry,"Tudor domain-containing protein involved in germ cell development, more specifically the formation of chromatoid body (during spermiogenesis), Balbiani body (during oogenesis), germ plasm (upon fertilization), and for proper miRNA expression and spliceosome maturation (By similarity). Essential for RNA-dependent helicase UPF1 localization to chromatoid body, for UPF1-UPF2 and UPF1-DDX4 interactions which are required for mRNA degradation, using the extended 3' UTR-triggered nonsense-mediated mRNA decay (NMD) pathway. Involved in spliceosome maturation and mRNA splicing in prophase I spermatocytes through interaction with arginine N-methyltransferase PRMT5 and symmetrically arginine dimethylated SNRPB (small nuclear ribonucleoprotein-associated protein) (By similarity)",,,,Cytoplasm,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Jamin2021_CT | Jamin2021_core | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
TDRKH,ENSG00000182134,Unsafe,Protein,False,True,21.5,29.1,84,59,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 2.4 nTPM; positive ihc; adrenal gland: 3 nTPM; positive ihc;absolute ceiling; amygdala: 5.8 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 5.5 nTPM; absolute ceiling;continuous selectivity; bone marrow: 1.4 nTPM; positive ihc; cerebellum: 13.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 7.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 2.8 nTPM; absolute ceiling; colon: 3.1 nTPM; positive ihc; duodenum: 2.2 nTPM; positive ihc;absolute ceiling; heart muscle: 3.4 nTPM; positive ihc;absolute ceiling; hippocampal formation: 5.9 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 7.2 nTPM; absolute ceiling;continuous selectivity; kidney: 3.9 nTPM; positive ihc;absolute ceiling; liver: 3.5 nTPM; positive ihc;absolute ceiling; lung: 4.2 nTPM; positive ihc;absolute ceiling; lymph node: 5.8 nTPM; positive ihc; midbrain: 6.6 nTPM; absolute ceiling;continuous selectivity; pancreas: 2.9 nTPM; positive ihc;absolute ceiling; parathyroid gland: 29.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 4.5 nTPM; absolute ceiling; rectum: 3.9 nTPM; positive ihc; retina: 9.3 nTPM; absolute ceiling;continuous selectivity; salivary gland: 6.8 nTPM; positive ihc;absolute ceiling; skeletal muscle: 4.1 nTPM; positive ihc;absolute ceiling; skin: 2.2 nTPM; positive ihc; small intestine: 2.1 nTPM; positive ihc;absolute ceiling; smooth muscle: 2.7 nTPM; positive ihc;absolute ceiling; spinal cord: 6.6 nTPM; absolute ceiling;continuous selectivity; spleen: 6.1 nTPM; positive ihc; stomach: 2.8 nTPM; positive ihc; thymus: 9.8 nTPM; continuous selectivity; thyroid gland: 7.1 nTPM; positive ihc; urinary bladder: 2.5 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 3 nTPM (limit 2); amygdala: 5.8 nTPM (limit 2); basal ganglia: 5.5 nTPM (limit 2); cerebellum: 13.1 nTPM (limit 2); cerebral cortex: 7.5 nTPM (limit 2); choroid plexus: 2.8 nTPM (limit 2); duodenum: 2.2 nTPM (limit 2); heart muscle: 3.4 nTPM (limit 2); hippocampal formation: 5.9 nTPM (limit 2); hypothalamus: 7.2 nTPM (limit 2); kidney: 3.9 nTPM (limit 2); liver: 3.5 nTPM (limit 2); lung: 4.2 nTPM (limit 2); midbrain: 6.6 nTPM (limit 2); pancreas: 2.9 nTPM (limit 2); parathyroid gland: 29.1 nTPM (limit 6); pituitary gland: 4.5 nTPM (limit 2); retina: 9.3 nTPM (limit 2); salivary gland: 6.8 nTPM (limit 6); skeletal muscle: 4.1 nTPM (limit 2); small intestine: 2.1 nTPM (limit 2); smooth muscle: 2.7 nTPM (limit 2); spinal cord: 6.6 nTPM (limit 2),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: Medium (Approved); heart muscle / cardiomyocytes: Low (Approved); kidney / cells in tubules: Low (Approved); liver / cholangiocytes: Medium (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: High (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / keratinocytes: Low (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in red pulp: Medium (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Low (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Adenocarcinoma (validation): 105/105 (100.0%); Glioblastoma Multiforme (validation): 57/58 (98.3%); Breast Invasive Carcinoma (validation): 48/50 (96.0%),renal cancer: 10/12 (83.3%); ovarian cancer: 8/12 (66.7%),31,20,Q9Y2W6,https://www.uniprot.org/uniprotkb/Q9Y2W6/entry,"Participates in the primary piRNA biogenesis pathway and is required during spermatogenesis to repress transposable elements and prevent their mobilization, which is essential for the germline integrity. The piRNA metabolic process mediates the repression of transposable elements during meiosis by forming complexes composed of piRNAs and Piwi proteins and govern the methylation and subsequent repression of transposons. Required for the final steps of primary piRNA biogenesis by participating in the processing of 31-37 nt intermediates into mature piRNAs. May act in pi-bodies and piP-bodies by transferring piRNA precursors or intermediates to or between these granules",,,,Cytoplasm Mitochondrion,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
TECTA,ENSG00000109927,Unsafe,Protein,False,True,0.8,1.7,84,20,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 0.3 nTPM; positive ihc; adrenal gland: 0.5 nTPM; continuous selectivity; amygdala: 0.6 nTPM; continuous selectivity; basal ganglia: 1.5 nTPM; continuous selectivity;reproductive not higher; cerebellum: 1.4 nTPM; continuous selectivity;reproductive not higher; cerebral cortex: 1.7 nTPM; continuous selectivity;reproductive not higher; choroid plexus: 1.3 nTPM; continuous selectivity;reproductive not higher; colon: 0.5 nTPM; positive ihc;continuous selectivity; duodenum: 0.1 nTPM; positive ihc; esophagus: 0.1 nTPM; positive ihc; heart muscle: 1.1 nTPM; positive ihc;continuous selectivity;reproductive not higher; hippocampal formation: 0.8 nTPM; continuous selectivity;reproductive not higher; hypothalamus: 1.2 nTPM; continuous selectivity;reproductive not higher; kidney: 0.5 nTPM; positive ihc;continuous selectivity; liver: 0.4 nTPM; continuous selectivity; lung: 0.4 nTPM; positive ihc;continuous selectivity; midbrain: 0.7 nTPM; continuous selectivity; parathyroid gland: 0.8 nTPM; continuous selectivity;reproductive not higher; pituitary gland: 1.3 nTPM; continuous selectivity;reproductive not higher; retina: 1.1 nTPM; continuous selectivity;reproductive not higher; skeletal muscle: 0.7 nTPM; continuous selectivity; skin: 0.1 nTPM; positive ihc; spinal cord: 0.6 nTPM; continuous selectivity; thyroid gland: 0.7 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",,adipose tissue / adipocytes: Low (Approved); bronchus / respiratory epithelial cells: Low (Approved); colon / endothelial cells: Low (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: Low (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Low (Approved); kidney / cells in glomeruli: Low (Approved); lung / macrophages: Low (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); oral mucosa / squamous epithelial cells: Low (Approved); skin 1 / fibroblasts: Low (Approved); skin 2 / epidermal cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 14/58 (24.1%); Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Glioblastoma Multiforme (TCGA): 1/141 (0.7%),testis cancer: 2/11 (18.2%); cervical cancer: 2/12 (16.7%),31,20,O75443,https://www.uniprot.org/uniprotkb/O75443/entry,"One of the major non-collagenous components of the tectorial membrane (By similarity). The tectorial membrane is an extracellular matrix of the inner ear that covers the neuroepithelium of the cochlea and contacts the stereocilia bundles of specialized sensory hair cells. Sound induces movement of these hair cells relative to the tectorial membrane, deflects the stereocilia and leads to fluctuations in hair-cell membrane potential, transducing sound into electrical signals",,"Deafness, autosomal dominant, 12: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. Deafness, autosomal recessive, 21: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information.",,"Cell membrane Secreted, extracellular space, extracellular matrix",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
TEDC2,ENSG00000162062,Unsafe,Protein,False,True,4.8,4.8,78,12,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; basal ganglia: 1.6 nTPM; continuous selectivity; bone marrow: 4 nTPM; continuous selectivity; cerebral cortex: 2 nTPM; continuous selectivity; duodenum: 1.5 nTPM; positive ihc;continuous selectivity; esophagus: 2.2 nTPM; continuous selectivity; kidney: 0.6 nTPM; positive ihc; lung: 0.4 nTPM; positive ihc; lymph node: 2.1 nTPM; continuous selectivity; rectum: 0.7 nTPM; positive ihc; skeletal muscle: 0.3 nTPM; positive ihc; spleen: 1.2 nTPM; positive ihc; thyroid gland: 0.3 nTPM; positive ihc; urinary bladder: 0.4 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,duodenum / glandular cells: Low (Approved); hippocampus / glial cells: Low (Approved); kidney / cells in tubules: Low (Approved); lung / macrophages: Low (Approved); rectum / glandular cells: Low (Approved); skeletal muscle / myocytes: Low (Approved); spleen / cells in red pulp: Low (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 258/283 (91.2%); Testicular Germ Cell Tumor (TCGA): 114/133 (85.7%); Skin Cuteneous Melanoma (TCGA): 76/99 (76.8%),lung cancer: 4/12 (33.3%); skin cancer: 2/12 (16.7%),29,20,Q7L2K0,https://www.uniprot.org/uniprotkb/Q7L2K0/entry,Acts as a positive regulator of ciliary hedgehog signaling. Required for centriole stability,,,,"Cell projection, cilium Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriole",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
TEKT3,ENSG00000125409,Unsafe,Protein,False,True,30.2,30.2,99,7,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; lung: 0.8 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,bronchus / ciliated cells (cilia axoneme): Medium (Enhanced); bronchus / ciliated cells (tip of cilia): Medium (Enhanced); lung / macrophages: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 6/50 (12.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 11/176 (6.2%); Testicular Germ Cell Tumor (TCGA): 7/133 (5.3%),renal cancer: 3/12 (25.0%); colorectal cancer: 2/12 (16.7%),31,20,Q9BXF9,https://www.uniprot.org/uniprotkb/Q9BXF9/entry,Microtubule inner protein (MIP) part of the dynein-decorated doublet microtubules (DMTs) in cilia and flagellar axoneme (PubMed:36191189). Forms filamentous polymers in the walls of ciliary and flagellar microtubules (By similarity). Required for normal sperm mobility (By similarity),Expressed in spermatozoa (PubMed:36708031). Expressed in airway epithelial cells (PubMed:36191189),Spermatogenic failure 81: A male infertility disorder due to oligoasthenoteratozoospermia and characterized by reduced progressive sperm motility. Patient spermatozoa exhibit acrosomal hypoplasia and detachment of the acrosome from the sperm head.,,"Cytoplasm, cytoskeleton, cilium axoneme Cytoplasm, cytoskeleton, flagellum axoneme Cytoplasmic vesicle, secretory vesicle, acrosome outer membrane",36191189,36191189|36708031,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
TEKT4,ENSG00000163060,Unsafe,Protein,False,True,13.1,13.1,90,7,Positive somewhere,True,False,False,True,Excluded,Normal,False,,Not assessed,,,positive ihc outside permitted,"Positive IHC in a Vital, Protected or Manageable compartment",,bronchus / ciliated cells (cilia axoneme): High (Enhanced); bronchus / ciliated cells (tip of cilia): High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 8/50 (16.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 27/176 (15.3%); Ovary Serous Cystadenocarcinoma (TCGA): 16/349 (4.6%),endometrial cancer: 5/11 (45.5%); urothelial cancer: 5/11 (45.5%),31,20,Q8WW24,https://www.uniprot.org/uniprotkb/Q8WW24/entry,Microtubule inner protein (MIP) part of the dynein-decorated doublet microtubules (DMTs) in cilia and flagellar axoneme (PubMed:36191189). Forms filamentous polymers in the walls of ciliary and flagellar microtubules (By similarity). Contributes to normal sperm motility (By similarity),Strongly expressed in spermatozoa. Also detected at low levels in pancreas. Expressed in airway epithelial cells (PubMed:36191189),,,"Cytoplasm, cytoskeleton, cilium axoneme Cytoplasm, cytoskeleton, flagellum axoneme",36191189,17244819|36191189,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
TEKTL1,ENSG00000160994,Unsafe,Protein,False,True,15.0,15.0,87,27,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 0 nTPM; positive ihc; colon: 0 nTPM; positive ihc; duodenum: 0 nTPM; positive ihc; esophagus: 0 nTPM; positive ihc; kidney: 0 nTPM; positive ihc; rectum: 0 nTPM; positive ihc; skin: 0 nTPM; positive ihc; small intestine: 0 nTPM; positive ihc; stomach: 0 nTPM; positive ihc; urinary bladder: 0 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Medium (Approved); colon / glandular cells: Low (Approved); duodenum / glandular cells: Low (Approved); esophagus / squamous epithelial cells: Medium (Approved); kidney / cells in tubules: Low (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); rectum / glandular cells: Low (Approved); skin 1 / fibroblasts: Low (Approved); skin 1 / keratinocytes: Medium (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Low (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Low (Approved); urinary bladder / urothelial cells: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Ovary Serous Cystadenocarcinoma (TCGA): 1/349 (0.3%),testis cancer: 3/11 (27.3%); lymphoma: 1/11 (9.1%),31,20,Q8IYK2,https://www.uniprot.org/uniprotkb/Q8IYK2/entry,"Microtubule inner protein (MIP) part of the dynein-decorated doublet microtubules (DMTs) in sperm flagellar axoneme, which is required for motile flagellum beating (By similarity). Forms an extensive interaction network cross-linking the lumen of axonemal doublet microtubules (By similarity)",,,,"Cytoplasm, cytoskeleton, flagellum axoneme",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TESMIN,ENSG00000132749,Unsafe,RNA,False,True,51.0,51.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 7.4 nTPM; absolute ceiling; kidney: 3 nTPM; absolute ceiling; pituitary gland: 2.3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 7.4 nTPM (limit 2); kidney: 3 nTPM (limit 2); pituitary gland: 2.3 nTPM (limit 2); bone marrow: 7.4 nTPM (baseline 2); kidney: 3 nTPM (baseline 2); pituitary gland: 2.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Ovary Serous Cystadenocarcinoma (validation): 73/81 (90.1%); Breast Invasive Carcinoma (TCGA): 880/1022 (86.1%); Kidney Chromophobe (TCGA): 48/64 (75.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q9Y4I5,https://www.uniprot.org/uniprotkb/Q9Y4I5/entry,Essential for normal spermatogenesis and male fertility (By similarity). Required for the completion of meiosis in male germ cells (By similarity),Expressed specifically in testis,,,Cytoplasm Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
TET1,ENSG00000138336,Unsafe,High RNA,False,True,1.2,1.9,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,cerebellum: 0.6 nTPM; continuous selectivity; cerebral cortex: 0.7 nTPM; continuous selectivity; parathyroid gland: 0.7 nTPM; continuous selectivity; retina: 1.5 nTPM; continuous selectivity;reproductive not higher; salivary gland: 1 nTPM; continuous selectivity; skeletal muscle: 0.8 nTPM; continuous selectivity; smooth muscle: 0.5 nTPM; continuous selectivity; spinal cord: 0.5 nTPM; continuous selectivity; thymus: 1.9 nTPM; continuous selectivity;reproductive not higher,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE NK (unstimulated): 13/90 values ≥5 TPM, max 7.02848; DICE TREG_MEM (unstimulated): 25/89 values ≥5 TPM, max 7.04491; DICE CD4_NAIVE (unstimulated): 38/88 values ≥5 TPM, max 7.88225; DICE TREG_NAIVE (unstimulated): 12/89 values ≥5 TPM, max 5.77317; DICE THSTAR (unstimulated): 5/88 values ≥5 TPM, max 6.97564; DICE TH17 (unstimulated): 6/89 values ≥5 TPM, max 7.24877; DICE TH2 (unstimulated): 3/89 values ≥5 TPM, max 5.90338; DICE CD8_NAIVE (unstimulated): 52/89 values ≥5 TPM, max 8.08815; hpa_immune_monaco Progenitor cell: 5.2 TPM",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,8.08815271771,51.7,"hpa_single_cell: /Astrocytes, max 51.7 nTPM, 1 observations >30; hpa_single_cell: /Oligodendrocyte precursor cells, max 42 nTPM, 1 observations >30; hpa_single_cell: /Oligodendrocytes, max 42.2 nTPM, 1 observations >30; hpa_single_cell_tissue: brain/astrocytes, max 51.7 nTPM, 1 observations >30; hpa_single_cell_tissue: brain/oligodendrocyte precursor cells, max 42 nTPM, 1 observations >30; hpa_single_cell_tissue: brain/oligodendrocytes, max 42.7 nTPM, 2 observations >30; hpa_single_cell_tissue: salivary gland/fibroblasts, max 32.2 nTPM, 1 observations >30; hpa_single_cell_tissue: salivary gland/mucus glandular cells, max 32.6 nTPM, 1 observations >30; hpa_single_cell_tissue: salivary gland/plasma cells, max 47 nTPM, 1 observations >30; hpa_single_cell_tissue: salivary gland/serous glandular cells, max 41.9 nTPM, 1 observations >30; hpa_single_cell_tissue: skeletal muscle/fibroblasts, max 37.8 nTPM, 3 observations >30; hpa_single_cell_tissue: skeletal muscle/mixed cell types, max 36.7 nTPM, 1 observations >30; hpa_single_cell_tissue: vascular/schwann cells, max 47 nTPM, 1 observations >30",Neither,oncoref.target-sets.2026-10-23.2,8.088 TPM; blood/CD8_NAIVE; dice_cd8_naive; vital,51.7 nTPM; unsited/Astrocytes; hpa_single_cell; unresolved,Glioblastoma Multiforme (validation): 58/58 (100.0%); Testicular Germ Cell Tumor (TCGA): 108/133 (81.2%); Breast Invasive Carcinoma (validation): 7/50 (14.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NFU7,https://www.uniprot.org/uniprotkb/Q8NFU7/entry,"Dioxygenase that plays a key role in active DNA demethylation, by catalyzing the sequential oxidation of the modified genomic base 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) (PubMed:19372391, PubMed:21496894, PubMed:21778364, PubMed:35798741). In addition to its role in DNA demethylation, plays a more general role in chromatin regulation by recruiting histone modifying protein complexes to alter histone marks and chromatin accessibility, leading to both activation and repression of gene expression (PubMed:33833093). Plays therefore a role in many biological processes, including stem cell maintenance, T- and B-cell development, inflammation regulation, genomic imprinting, neural activity or DNA repair (PubMed:31278917). Involved in the balance between pluripotency and lineage commitment of cells and plays a role in embryonic stem cells maintenance and inner cell mass cell specification. Together with QSER1, plays an essential role in the protection and maintenance of transcriptional and developmental programs to inhibit the binding of DNMT3A/3B and therefore de novo methylation (PubMed:33833093). May play a role in pancreatic beta-cell specification during development. In this context, may function as an upstream epigenetic regulator of PAX4 presumably through direct recruitment by FOXA2 to a PAX4 enhancer to preserve its unmethylated status, thereby potentiating PAX4 expression to adopt beta-cell fate during endocrine lineage commitment (PubMed:35798741). Under DNA hypomethylation conditions, such as in female meiotic germ cells, may induce epigenetic reprogramming of pericentromeric heterochromatin (PCH), the constitutive heterochromatin of pericentromeric regions. PCH forms chromocenters in the interphase nucleus and chromocenters cluster at the prophase of meiosis. In this context, may also be essential for chromocenter clustering in a catalytic activity-independent manner, possibly through the recruitment polycomb repressive complex 1 (PRC1) to the chromocenters (By similarity). During embryonic development, may be required for normal meiotic progression in oocytes and meiotic gene activation (By similarity). Binds preferentially to DNA containing cytidine-phosphate-guanosine (CpG) dinucleotides over CpH (H=A, T, and C), hemimethylated-CpG and hemimethylated-hydroxymethyl-CpG (PubMed:29276034) Dioxygenase that plays a key role in active DNA demethylation (PubMed:28531272). Binds to promoters, particularly to those with high CG content (By similarity). In hippocampal neurons, isoform 1 regulates the expression of a unique subset of genes compared to isoform 2, although some overlap exists between both isoforms, hence differentially regulates excitatory synaptic transmission (By similarity). In hippocampal neuron cell cultures, isoform 1 controls both miniature excitatory postsynaptic current amplitude and frequency (By similarity). Isoform 1 may regulate genes involved in hippocampal-dependent memory, leading to positive regulation of memory, contrary to isoform 2 that may decrease memory (By similarity) Dioxygenase that plays a key role in active DNA demethylation (PubMed:28531272). As isoform 1, binds to promoters, particularly to those with high CG content, however displays reduced global chromatin affinity compared with isoform 1, leading to decreased global DNA demethylation compared with isoform 1 (By similarity). Contrary to isoform 1, isoform 2 localizes during S phase to sites of ongoing DNA replication in heterochromatin, causing a significant de novo 5hmC formation, globally, and more so in heterochromatin, including LINE 1 interspersed DNA repeats leading to their activation (By similarity). In hippocampal neurons, isoform 2 regulates the expression of a unique subset of genes compared to isoform 1, although some overlap between both isoforms, hence differentially regulates excitatory synaptic transmission (By similarity). In hippocampal neuron cell cultures, isoform 2 controls miniature excitatory postsynaptic current frequency, but not amplitude (By similarity). Isoform 2 may regulate genes involved in hippocampal-dependent memory, leading to negative regulation of memory, contrary to isoform 1 that may improve memory (By similarity). In immature and partially differentiated gonadotrope cells, directly represses luteinizing hormone gene LHB expression and does not catalyze 5hmC at the gene promoter (By similarity)","Expressed in fetal heart, lung and brain, and in adult skeletal muscle, thymus and ovary. Not detected in adult heart, lung or brain. Up-regulated in glioblastoma cells (at protein level) (PubMed:25284789) Expressed in embryonic stem cells (at protein level)",,"Subsequent steps in cytosine demethylation are subject to discussion. According to a first model cytosine demethylation occurs through deamination of 5hmC into 5-hydroxymethyluracil (5hmU) and subsequent replacement by unmethylated cytosine by the base excision repair system (PubMed:21496894). According to another model, cytosine demethylation is rather mediated via conversion of 5hmC into 5fC and 5caC, followed by excision by TDG and replacement by unmethylated cytosine",Nucleus Chromosome,12124344|19372391|19372393|21496894|21778364|25284789|28531272|29276034|31278917|33833093|35798741,12124344|12646957|25284789|28531272,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
TEX101,ENSG00000131126,Unsafe,High RNA,False,True,114.4,114.4,81,3,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,hpa_immune_cell basophil: 55.7 nTPM; hpa_immune_monaco basophil: 74.9 TPM,True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,74.9,119.7224,"hpa_immune_cell: blood/basophil, max 55.7 nTPM, 1 observations >30; hpa_immune_cell_samples: blood/basophil, max 66.4757 TPM, 2 observations >30; hpa_immune_cell_samples: blood/basophil, max 119.722 nTPM, 2 observations >30; hpa_immune_monaco: blood/basophil, max 74.9 TPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,74.9 TPM; blood/basophil; hpa_immune_monaco; vital,119.7 nTPM; blood/basophil; hpa_immune_cell_samples; vital,Lung Squamous Cell Carcinoma (TCGA): 17/489 (3.5%); Ovary Serous Cystadenocarcinoma (TCGA): 12/349 (3.4%); Stomach Adenocarcinoma (TCGA): 11/346 (3.2%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q9BY14,https://www.uniprot.org/uniprotkb/Q9BY14/entry,Plays a role in fertilization by controlling binding of sperm to zona pellucida and migration of spermatozoa into the oviduct (By similarity). May play a role in signal transduction and promote protein tyrosine phosphorylation (By similarity),Detected in testis and spermatogonia. Not detected in spermatocytes. Detected in blood leukocytes,,,"Cell membrane Membrane raft Cytoplasmic vesicle, secretory vesicle, acrosome Secreted Cytoplasmic vesicle",,16516155,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,What explains high basophil RNA in HPA and Monaco?,Resolve basophil RNA identity and local protein evidence before reconsideration.,TPM and nTPM are separate measurements; DICE has no basophil population.,,,,,
TEX11,ENSG00000120498,Unsafe,RNA,False,True,11.3,57.0,88,3,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,choroid plexus: 13.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 57 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 13.6 nTPM (limit 2); pancreas: 57 nTPM (limit 4),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Renal Clear Cell Carcinoma (validation): 49/100 (49.0%); Kidney Renal Clear Cell Carcinoma (TCGA): 171/521 (32.8%); Testicular Germ Cell Tumor (TCGA): 22/133 (16.5%),endometrial cancer: 2/11 (18.2%); melanoma: 2/11 (18.2%),31,20,Q8IYF3,https://www.uniprot.org/uniprotkb/Q8IYF3/entry,Regulator of crossing-over during meiosis. Involved in initiation and/or maintenance of chromosome synapsis and formation of crossovers,Testis-specific. Not expressed in adult ovaries,"Spermatogenic failure, X-linked, 2: An infertility disorder caused by spermatogenesis defects. It is characterized by mixed testicular atrophy and azoospermia with meiotic arrest.",,Chromosome,,18369460,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
TEX12,ENSG00000150783,Unsafe,RNA,False,True,20.1,20.1,87,3,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,retina: 8.4 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 8.4 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 4/133 (3.0%); Bladder Urothelial Carcinoma (TCGA): 2/169 (1.2%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 3/283 (1.1%),endometrial cancer: 1/12 (8.3%); breast cancer: 0/11 (0.0%),31,20,Q9BXU0,https://www.uniprot.org/uniprotkb/Q9BXU0/entry,"Component of the transverse central element of synaptonemal complexes (SCS), formed between homologous chromosomes during meiotic prophase (By similarity). Requires SYCP1 in order to be incorporated into the central element (By similarity)",Testis specific,,,Chromosome,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
TEX26,ENSG00000175664,Unsafe,RNA,False,True,20.9,20.9,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,choroid plexus: 11.6 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 3.4 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 11.6 nTPM (limit 2); hypothalamus: 3.4 nTPM (limit 2); choroid plexus: 11.6 nTPM (baseline 2); hypothalamus: 3.4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 32/58 (55.2%); Glioblastoma Multiforme (TCGA): 37/141 (26.2%); Uterine Corpus Endometrial Carcinoma (TCGA): 5/176 (2.8%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q8N6G2,https://www.uniprot.org/uniprotkb/Q8N6G2/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
TEX29,ENSG00000153495,Unsafe,RNA,False,True,50.4,50.4,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 5.9 nTPM; absolute ceiling; basal ganglia: 3.8 nTPM; absolute ceiling; cerebral cortex: 12 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 5.9 nTPM (limit 2); basal ganglia: 3.8 nTPM (limit 2); cerebral cortex: 12 nTPM (limit 2); amygdala: 5.9 nTPM (baseline 2); basal ganglia: 3.8 nTPM (baseline 2); cerebral cortex: 12 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 11/58 (19.0%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 12/283 (4.2%); Bladder Urothelial Carcinoma (TCGA): 5/169 (3.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q8N6K0,https://www.uniprot.org/uniprotkb/Q8N6K0/entry,,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
TEX30,ENSG00000151287,Unsafe,Protein,False,True,119.2,119.2,101,9,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 8 nTPM; absolute ceiling; basal ganglia: 5.8 nTPM; absolute ceiling; bone marrow: 14.2 nTPM; absolute ceiling; choroid plexus: 6.5 nTPM; absolute ceiling; hippocampal formation: 6.5 nTPM; absolute ceiling; hypothalamus: 9.5 nTPM; absolute ceiling; kidney: 18.5 nTPM; absolute ceiling; liver: 38.8 nTPM; absolute ceiling; lymph node: 11.6 nTPM; absolute ceiling; midbrain: 7.8 nTPM; absolute ceiling; pituitary gland: 7 nTPM; absolute ceiling; retina: 7.3 nTPM; absolute ceiling; skin: 7.3 nTPM; positive ihc; spinal cord: 7.8 nTPM; absolute ceiling; thymus: 15.7 nTPM; absolute ceiling; tongue: 9 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 8 nTPM (limit 2); basal ganglia: 5.8 nTPM (limit 2); bone marrow: 14.2 nTPM (limit 12); choroid plexus: 6.5 nTPM (limit 2); hippocampal formation: 6.5 nTPM (limit 2); hypothalamus: 9.5 nTPM (limit 2); kidney: 18.5 nTPM (limit 12); liver: 38.8 nTPM (limit 12); lymph node: 11.6 nTPM (limit 6); midbrain: 7.8 nTPM (limit 2); pituitary gland: 7 nTPM (limit 2); retina: 7.3 nTPM (limit 2); spinal cord: 7.8 nTPM (limit 2); thymus: 15.7 nTPM (limit 10); tongue: 9 nTPM (limit 6),skin 1 / cells in corneal layer: High (Enhanced); skin 2 / cells in corneal layer: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 141/141 (100.0%); Kidney Renal Clear Cell Carcinoma (validation): 100/100 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%),testis cancer: 1/11 (9.1%); liver cancer: 1/12 (8.3%),29,20,Q5JUR7,https://www.uniprot.org/uniprotkb/Q5JUR7/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
TEX54,ENSG00000283268,Unsafe,High RNA,False,True,74.7,74.7,0,0,Missing,False,False,False,False,Excluded,Reproductive,True,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE TH1 (unstimulated): 3/81 values ≥5 TPM, max 7.72444; DICE TH2 (unstimulated): 5/89 values ≥5 TPM, max 6.88325; DICE CD8_NAIVE (unstimulated): 3/89 values ≥5 TPM, max 10.3275; hpa_immune_cell basophil: 23.5 nTPM; hpa_immune_cell classical monocyte: 8.4 nTPM; hpa_immune_cell eosinophil: 19.2 nTPM; hpa_immune_cell intermediate monocyte: 5.8 nTPM; hpa_immune_cell MAIT T-cell: 7.9 nTPM; hpa_immune_cell memory B-cell: 6.1 nTPM; hpa_immune_cell naive B-cell: 6.3 nTPM; hpa_immune_cell naive CD4 T-cell: 8.3 nTPM; hpa_immune_cell naive CD8 T-cell: 6.1 nTPM; hpa_immune_cell neutrophil: 139.5 nTPM; hpa_immune_cell plasmacytoid DC: 7.1 nTPM; hpa_immune_monaco neutrophil: 8.8 TPM",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,127.807,179.5312,"hpa_immune_cell: blood/neutrophil, max 139.5 nTPM, 1 observations >30; hpa_immune_cell_samples: blood/basophil, max 30.0817 TPM, 2 observations >30; hpa_immune_cell_samples: blood/neutrophil, max 127.807 TPM, 6 observations >30; hpa_immune_cell_samples: blood/basophil, max 54.1033 nTPM, 2 observations >30; hpa_immune_cell_samples: blood/eosinophil, max 34.9372 nTPM, 1 observations >30; hpa_immune_cell_samples: blood/neutrophil, max 179.531 nTPM, 6 observations >30",Neither,oncoref.target-sets.2026-10-23.2,127.8 TPM; blood/neutrophil; hpa_immune_cell_samples; vital,179.5 nTPM; blood/neutrophil; hpa_immune_cell_samples; vital,Testicular Germ Cell Tumor (TCGA): 2/133 (1.5%); Prostate Adenocarcinoma (TCGA): 7/480 (1.5%); Kidney Renal Papillary Cell Carcinoma (TCGA): 3/282 (1.1%),No exact-ID IHC coverage in the HPA cancer snapshot,26,0,A0A1B0GVG6,https://www.uniprot.org/uniprotkb/A0A1B0GVG6/entry,,Expressed in Testis,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TEX55,ENSG00000163424,Unsafe,Protein,False,True,52.2,52.2,86,7,Positive somewhere,True,False,False,True,Excluded,Normal,False,,Not assessed,,,positive ihc outside permitted,"Positive IHC in a Vital, Protected or Manageable compartment",,bronchus / respiratory epithelial cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 2/133 (1.5%); Pancreatic Adenocarcinoma (validation): 1/80 (1.2%); Uterine Corpus Endometrial Carcinoma (TCGA): 2/176 (1.1%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),29,20,Q96M34,https://www.uniprot.org/uniprotkb/Q96M34/entry,,Testis-specific,,,"Nucleus Cell projection, cilium, flagellum",,19821082,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TEX9,ENSG00000151575,Unsafe,RNA,False,True,11.6,11.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 3.1 nTPM; absolute ceiling;continuous selectivity; amygdala: 2.8 nTPM; absolute ceiling; basal ganglia: 3.7 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 6.8 nTPM; absolute ceiling;continuous selectivity; duodenum: 5.4 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 3.5 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 4.7 nTPM; absolute ceiling;continuous selectivity; kidney: 6.3 nTPM; absolute ceiling;continuous selectivity; lung: 2.2 nTPM; absolute ceiling; midbrain: 2.7 nTPM; absolute ceiling; pancreas: 2.9 nTPM; absolute ceiling; parathyroid gland: 6.6 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 9 nTPM; absolute ceiling;continuous selectivity; retina: 5.7 nTPM; absolute ceiling;continuous selectivity; salivary gland: 7 nTPM; absolute ceiling;continuous selectivity; small intestine: 3.8 nTPM; absolute ceiling;continuous selectivity; spinal cord: 2.9 nTPM; absolute ceiling; stomach: 5.5 nTPM; continuous selectivity; thyroid gland: 7.8 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 3.1 nTPM (limit 2); amygdala: 2.8 nTPM (limit 2); basal ganglia: 3.7 nTPM (limit 2); choroid plexus: 6.8 nTPM (limit 2); duodenum: 5.4 nTPM (limit 2); hippocampal formation: 3.5 nTPM (limit 2); hypothalamus: 4.7 nTPM (limit 2); kidney: 6.3 nTPM (limit 2); lung: 2.2 nTPM (limit 2); midbrain: 2.7 nTPM (limit 2); pancreas: 2.9 nTPM (limit 2); parathyroid gland: 6.6 nTPM (limit 6); pituitary gland: 9 nTPM (limit 2); retina: 5.7 nTPM (limit 2); salivary gland: 7 nTPM (limit 6); small intestine: 3.8 nTPM (limit 2); spinal cord: 2.9 nTPM (limit 2); adrenal gland: 3.1 nTPM (baseline 2); amygdala: 2.8 nTPM (baseline 2); basal ganglia: 3.7 nTPM (baseline 2); choroid plexus: 6.8 nTPM (baseline 2); duodenum: 5.4 nTPM (baseline 2); hippocampal formation: 3.5 nTPM (baseline 2); hypothalamus: 4.7 nTPM (baseline 2); kidney: 6.3 nTPM (baseline 2); lung: 2.2 nTPM (baseline 2); midbrain: 2.7 nTPM (baseline 2); pancreas: 2.9 nTPM (baseline 2); parathyroid gland: 6.6 nTPM (baseline 6); pituitary gland: 9 nTPM (baseline 2); retina: 5.7 nTPM (baseline 2); salivary gland: 7 nTPM (baseline 6); small intestine: 3.8 nTPM (baseline 2); spinal cord: 2.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 485/486 (99.8%); Rectum Adenocarcinoma (validation): 206/207 (99.5%); Kidney Renal Clear Cell Carcinoma (validation): 96/100 (96.0%),cervical cancer: 12/12 (100.0%); endometrial cancer: 12/12 (100.0%),31,20,Q8N6V9,https://www.uniprot.org/uniprotkb/Q8N6V9/entry,,,,,"Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriolar satellite",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
TFPI2,ENSG00000105825,Unsafe,RNA,False,True,925.7,925.7,89,6,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,adrenal gland: 27.4 nTPM; absolute ceiling; hypothalamus: 4.3 nTPM; absolute ceiling; kidney: 19.8 nTPM; absolute ceiling; liver: 20.6 nTPM; absolute ceiling; pancreas: 74.1 nTPM; absolute ceiling; pituitary gland: 9.4 nTPM; absolute ceiling; retina: 50.1 nTPM; absolute ceiling; urinary bladder: 25.6 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 27.4 nTPM (limit 12); hypothalamus: 4.3 nTPM (limit 2); kidney: 19.8 nTPM (limit 12); liver: 20.6 nTPM (limit 12); pancreas: 74.1 nTPM (limit 12); pituitary gland: 9.4 nTPM (limit 2); retina: 50.1 nTPM (limit 2); urinary bladder: 25.6 nTPM (limit 24),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Renal Papillary Cell Carcinoma (TCGA): 263/282 (93.3%); Kidney Renal Clear Cell Carcinoma (TCGA): 446/521 (85.6%); Uterine Corpus Endometrial Carcinoma (TCGA): 144/176 (81.8%),endometrial cancer: 2/10 (20.0%); lung cancer: 2/12 (16.7%),31,20,P48307,https://www.uniprot.org/uniprotkb/P48307/entry,"May play a role in the regulation of plasmin-mediated matrix remodeling. Inhibits trypsin, plasmin, factor VIIa/tissue factor and weakly factor Xa. Has no effect on thrombin","Umbilical vein endothelial cells, liver, placenta, heart, pancreas, and maternal serum at advanced pregnancy",,,Secreted,7872799,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Gong2021_reproductive_PC,No tumor-antigen validation in this source | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
THADA,ENSG00000115970,Unsafe,Protein,False,True,12.6,16.9,81,41,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 10.7 nTPM; absolute ceiling;continuous selectivity; adrenal gland: 9 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 4.5 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 5.7 nTPM; absolute ceiling;continuous selectivity; bone marrow: 8.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 4.2 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 4.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 16.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 8.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 4 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 9.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 8.7 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 4.9 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 5 nTPM; absolute ceiling;continuous selectivity; kidney: 9.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 16.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 9.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 14 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 5.2 nTPM; absolute ceiling;continuous selectivity; pancreas: 11.2 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 12 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 10.8 nTPM; absolute ceiling;continuous selectivity; rectum: 5.9 nTPM; positive ihc;continuous selectivity; retina: 8.1 nTPM; absolute ceiling;continuous selectivity; salivary gland: 9.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 9.7 nTPM; absolute ceiling;continuous selectivity; skin: 13.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 9.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 7 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 5.3 nTPM; absolute ceiling;continuous selectivity; spleen: 11.4 nTPM; absolute ceiling;continuous selectivity; stomach: 8.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 9.9 nTPM; continuous selectivity; thyroid gland: 13.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; tongue: 5.9 nTPM; continuous selectivity; urinary bladder: 10.2 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 10.7 nTPM (limit 10); adrenal gland: 9 nTPM (limit 2); amygdala: 4.5 nTPM (limit 2); basal ganglia: 5.7 nTPM (limit 2); bone marrow: 8.7 nTPM (limit 2); cerebellum: 4.2 nTPM (limit 2); cerebral cortex: 4.3 nTPM (limit 2); choroid plexus: 16.3 nTPM (limit 2); colon: 8.8 nTPM (limit 6); duodenum: 4 nTPM (limit 2); esophagus: 9.6 nTPM (limit 6); heart muscle: 8.7 nTPM (limit 2); hippocampal formation: 4.9 nTPM (limit 2); hypothalamus: 5 nTPM (limit 2); kidney: 9.3 nTPM (limit 2); liver: 16.9 nTPM (limit 2); lung: 9.5 nTPM (limit 2); lymph node: 14 nTPM (limit 6); midbrain: 5.2 nTPM (limit 2); pancreas: 11.2 nTPM (limit 2); parathyroid gland: 12 nTPM (limit 6); pituitary gland: 10.8 nTPM (limit 2); retina: 8.1 nTPM (limit 2); salivary gland: 9.9 nTPM (limit 6); skeletal muscle: 9.7 nTPM (limit 2); skin: 13.4 nTPM (limit 10); small intestine: 9.2 nTPM (limit 2); smooth muscle: 7 nTPM (limit 2); spinal cord: 5.3 nTPM (limit 2); spleen: 11.4 nTPM (limit 10); stomach: 8.8 nTPM (limit 6); thyroid gland: 13.1 nTPM (limit 10); urinary bladder: 10.2 nTPM (limit 6); adipose tissue: 10.7 nTPM (baseline 10); adrenal gland: 9 nTPM (baseline 2); amygdala: 4.5 nTPM (baseline 2); basal ganglia: 5.7 nTPM (baseline 2); bone marrow: 8.7 nTPM (baseline 2); cerebellum: 4.2 nTPM (baseline 2); cerebral cortex: 4.3 nTPM (baseline 2); choroid plexus: 16.3 nTPM (baseline 2); colon: 8.8 nTPM (baseline 6); duodenum: 4 nTPM (baseline 2); esophagus: 9.6 nTPM (baseline 6); heart muscle: 8.7 nTPM (baseline 2); hippocampal formation: 4.9 nTPM (baseline 2); hypothalamus: 5 nTPM (baseline 2); kidney: 9.3 nTPM (baseline 2); liver: 16.9 nTPM (baseline 2); lung: 9.5 nTPM (baseline 2); lymph node: 14 nTPM (baseline 6); midbrain: 5.2 nTPM (baseline 2); pancreas: 11.2 nTPM (baseline 2); parathyroid gland: 12 nTPM (baseline 6); pituitary gland: 10.8 nTPM (baseline 2); retina: 8.1 nTPM (baseline 2); salivary gland: 9.9 nTPM (baseline 6); skeletal muscle: 9.7 nTPM (baseline 2); skin: 13.4 nTPM (baseline 10); small intestine: 9.2 nTPM (baseline 2); smooth muscle: 7 nTPM (baseline 2); spinal cord: 5.3 nTPM (baseline 2); spleen: 11.4 nTPM (baseline 10); stomach: 8.8 nTPM (baseline 6); thyroid gland: 13.1 nTPM (baseline 10); urinary bladder: 10.2 nTPM (baseline 6),adrenal gland / glandular cells: Low (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Low (Uncertain); caudate / neuronal cells: Low (Uncertain); cerebral cortex / neuronal cells: Low (Uncertain); cerebral cortex / neuropil: Medium (Uncertain); colon / endothelial cells: Low (Uncertain); colon / glandular cells: Medium (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); kidney / cells in tubules: Low (Uncertain); liver / hepatocytes: Low (Uncertain); lung / macrophages: Low (Uncertain); lymph node / non-germinal center cells: Medium (Uncertain); nasopharynx / respiratory epithelial cells: Low (Uncertain); oral mucosa / squamous epithelial cells: Low (Uncertain); rectum / glandular cells: Low (Uncertain); salivary gland / glandular cells: Low (Uncertain); skin 1 / fibroblasts: Low (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: Medium (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); stomach 1 / glandular cells: Low (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Prostate Adenocarcinoma (TCGA): 480/480 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (TCGA): 141/141 (100.0%),liver cancer: 3/12 (25.0%); skin cancer: 3/12 (25.0%),31,20,Q6YHU6,https://www.uniprot.org/uniprotkb/Q6YHU6/entry,"Together with methyltransferase FTSJ1, methylates the 2'-O-ribose of nucleotides at position 32 of the anticodon loop of substrate tRNAs","Expressed in pancreas, adrenal medulla, thyroid, adrenal cortex, testis, thymus, small intestine and stomach",,,,25404562,12955091,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
THAP2,ENSG00000173451,Unsafe,Protein,False,True,17.6,27.2,100,60,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 15.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 25.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 4.2 nTPM; absolute ceiling; basal ganglia: 4.1 nTPM; absolute ceiling; bone marrow: 14.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 6.4 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 4.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 3.2 nTPM; absolute ceiling; colon: 4 nTPM; positive ihc; duodenum: 5.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 6.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 5 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 4.1 nTPM; absolute ceiling; hypothalamus: 4.9 nTPM; absolute ceiling;continuous selectivity; kidney: 5.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 4.3 nTPM; positive ihc;absolute ceiling; lung: 4.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 7.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 4.4 nTPM; absolute ceiling; pancreas: 3.7 nTPM; positive ihc;absolute ceiling; parathyroid gland: 3.3 nTPM; positive ihc; pituitary gland: 10.8 nTPM; absolute ceiling;continuous selectivity; rectum: 5.5 nTPM; positive ihc; retina: 10.9 nTPM; absolute ceiling;continuous selectivity; salivary gland: 4.6 nTPM; positive ihc; skeletal muscle: 4.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 5.5 nTPM; positive ihc; small intestine: 4.1 nTPM; positive ihc;absolute ceiling; smooth muscle: 4.3 nTPM; absolute ceiling; spinal cord: 5.6 nTPM; absolute ceiling;continuous selectivity; stomach: 6.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; thyroid gland: 4.4 nTPM; positive ihc; urinary bladder: 27.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 15.5 nTPM (limit 10); adrenal gland: 25.2 nTPM (limit 2); amygdala: 4.2 nTPM (limit 2); basal ganglia: 4.1 nTPM (limit 2); bone marrow: 14.6 nTPM (limit 2); cerebellum: 6.4 nTPM (limit 4); cerebral cortex: 4.9 nTPM (limit 2); choroid plexus: 3.2 nTPM (limit 2); duodenum: 5.5 nTPM (limit 2); esophagus: 6.4 nTPM (limit 6); heart muscle: 5 nTPM (limit 2); hippocampal formation: 4.1 nTPM (limit 2); hypothalamus: 4.9 nTPM (limit 2); kidney: 5.4 nTPM (limit 2); liver: 4.3 nTPM (limit 2); lung: 4.6 nTPM (limit 2); lymph node: 7.7 nTPM (limit 6); midbrain: 4.4 nTPM (limit 2); pancreas: 3.7 nTPM (limit 2); pituitary gland: 10.8 nTPM (limit 2); retina: 10.9 nTPM (limit 2); skeletal muscle: 4.8 nTPM (limit 2); small intestine: 4.1 nTPM (limit 2); smooth muscle: 4.3 nTPM (limit 4); spinal cord: 5.6 nTPM (limit 2); stomach: 6.2 nTPM (limit 6); urinary bladder: 27.2 nTPM (limit 8),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / basal cells: High (Approved); bronchus / ciliated cells (cell body): High (Approved); bronchus / goblet cells: High (Approved); caudate / neuronal cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Low (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / basal cells: High (Approved); nasopharynx / ciliated cells (cell body): High (Approved); nasopharynx / goblet cells: High (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Low (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Lung Squamous Cell Carcinoma (validation): 66/68 (97.1%); Lung Adenocarcinoma (validation): 99/105 (94.3%),prostate cancer: 10/11 (90.9%); breast cancer: 7/12 (58.3%),31,20,Q9H0W7,https://www.uniprot.org/uniprotkb/Q9H0W7/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
THAP6,ENSG00000174796,Unsafe,RNA,False,True,23.1,23.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 11.1 nTPM; absolute ceiling;continuous selectivity; amygdala: 5.8 nTPM; absolute ceiling; basal ganglia: 6 nTPM; absolute ceiling;continuous selectivity; bone marrow: 12.4 nTPM; absolute ceiling;continuous selectivity; cerebellum: 11.4 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 12.4 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 6.5 nTPM; absolute ceiling;continuous selectivity; colon: 9.6 nTPM; absolute ceiling;continuous selectivity; duodenum: 12.1 nTPM; absolute ceiling;continuous selectivity; esophagus: 9.4 nTPM; absolute ceiling;continuous selectivity; heart muscle: 14 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 6.1 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 6.1 nTPM; absolute ceiling;continuous selectivity; kidney: 9.6 nTPM; absolute ceiling;continuous selectivity; liver: 12.1 nTPM; absolute ceiling;continuous selectivity; lung: 9.1 nTPM; absolute ceiling;continuous selectivity; lymph node: 15.4 nTPM; absolute ceiling;continuous selectivity; midbrain: 6.8 nTPM; absolute ceiling;continuous selectivity; pancreas: 8.3 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 11.9 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 9.2 nTPM; absolute ceiling;continuous selectivity; rectum: 11.4 nTPM; absolute ceiling;continuous selectivity; retina: 21 nTPM; absolute ceiling;continuous selectivity; salivary gland: 13 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 15 nTPM; absolute ceiling;continuous selectivity; skin: 16.2 nTPM; absolute ceiling;continuous selectivity; small intestine: 12.7 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 10.3 nTPM; absolute ceiling;continuous selectivity; spinal cord: 9.1 nTPM; absolute ceiling;continuous selectivity; spleen: 12.3 nTPM; absolute ceiling;continuous selectivity; stomach: 10.6 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 15 nTPM; absolute ceiling;continuous selectivity; tongue: 13 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 8.9 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 11.1 nTPM (limit 2); amygdala: 5.8 nTPM (limit 2); basal ganglia: 6 nTPM (limit 2); bone marrow: 12.4 nTPM (limit 2); cerebellum: 11.4 nTPM (limit 2); cerebral cortex: 12.4 nTPM (limit 2); choroid plexus: 6.5 nTPM (limit 2); colon: 9.6 nTPM (limit 6); duodenum: 12.1 nTPM (limit 2); esophagus: 9.4 nTPM (limit 6); heart muscle: 14 nTPM (limit 2); hippocampal formation: 6.1 nTPM (limit 2); hypothalamus: 6.1 nTPM (limit 2); kidney: 9.6 nTPM (limit 2); liver: 12.1 nTPM (limit 2); lung: 9.1 nTPM (limit 2); lymph node: 15.4 nTPM (limit 6); midbrain: 6.8 nTPM (limit 2); pancreas: 8.3 nTPM (limit 2); parathyroid gland: 11.9 nTPM (limit 6); pituitary gland: 9.2 nTPM (limit 2); rectum: 11.4 nTPM (limit 6); retina: 21 nTPM (limit 2); salivary gland: 13 nTPM (limit 6); skeletal muscle: 15 nTPM (limit 2); skin: 16.2 nTPM (limit 10); small intestine: 12.7 nTPM (limit 2); smooth muscle: 10.3 nTPM (limit 2); spinal cord: 9.1 nTPM (limit 2); spleen: 12.3 nTPM (limit 10); stomach: 10.6 nTPM (limit 6); thyroid gland: 15 nTPM (limit 10); tongue: 13 nTPM (limit 6); urinary bladder: 8.9 nTPM (limit 6); adrenal gland: 11.1 nTPM (baseline 2); amygdala: 5.8 nTPM (baseline 2); basal ganglia: 6 nTPM (baseline 2); bone marrow: 12.4 nTPM (baseline 2); cerebellum: 11.4 nTPM (baseline 2); cerebral cortex: 12.4 nTPM (baseline 2); choroid plexus: 6.5 nTPM (baseline 2); colon: 9.6 nTPM (baseline 6); duodenum: 12.1 nTPM (baseline 2); esophagus: 9.4 nTPM (baseline 6); heart muscle: 14 nTPM (baseline 2); hippocampal formation: 6.1 nTPM (baseline 2); hypothalamus: 6.1 nTPM (baseline 2); kidney: 9.6 nTPM (baseline 2); liver: 12.1 nTPM (baseline 2); lung: 9.1 nTPM (baseline 2); lymph node: 15.4 nTPM (baseline 6); midbrain: 6.8 nTPM (baseline 2); pancreas: 8.3 nTPM (baseline 2); parathyroid gland: 11.9 nTPM (baseline 6); pituitary gland: 9.2 nTPM (baseline 2); rectum: 11.4 nTPM (baseline 6); retina: 21 nTPM (baseline 2); salivary gland: 13 nTPM (baseline 6); skeletal muscle: 15 nTPM (baseline 2); skin: 16.2 nTPM (baseline 10); small intestine: 12.7 nTPM (baseline 2); smooth muscle: 10.3 nTPM (baseline 2); spinal cord: 9.1 nTPM (baseline 2); spleen: 12.3 nTPM (baseline 10); stomach: 10.6 nTPM (baseline 6); thyroid gland: 15 nTPM (baseline 10); tongue: 13 nTPM (baseline 6); urinary bladder: 8.9 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%),liver cancer: 6/11 (54.5%); pancreatic cancer: 2/11 (18.2%),31,20,Q8TBB0,https://www.uniprot.org/uniprotkb/Q8TBB0/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
THAP9,ENSG00000168152,Unsafe,Protein,False,True,6.5,6.6,80,80,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 1.3 nTPM; positive ihc; adrenal gland: 1.5 nTPM; positive ihc; amygdala: 2.2 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 2.2 nTPM; absolute ceiling;continuous selectivity; bone marrow: 2 nTPM; positive ihc;continuous selectivity; cerebellum: 1.8 nTPM; positive ihc;continuous selectivity; cerebral cortex: 2 nTPM; positive ihc;continuous selectivity; colon: 1.5 nTPM; positive ihc; duodenum: 1.4 nTPM; positive ihc; esophagus: 1.2 nTPM; positive ihc; heart muscle: 2.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 2.6 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 2 nTPM; continuous selectivity; kidney: 2.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 3.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 1.6 nTPM; positive ihc; lymph node: 1.7 nTPM; positive ihc; midbrain: 2.8 nTPM; absolute ceiling;continuous selectivity; pancreas: 2.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 3.1 nTPM; positive ihc;continuous selectivity; pituitary gland: 2.6 nTPM; absolute ceiling;continuous selectivity; rectum: 1.6 nTPM; positive ihc; retina: 4.2 nTPM; absolute ceiling;continuous selectivity; salivary gland: 2 nTPM; positive ihc; skeletal muscle: 5 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 1.7 nTPM; positive ihc; small intestine: 1.4 nTPM; positive ihc; smooth muscle: 1.4 nTPM; positive ihc; spinal cord: 3.5 nTPM; absolute ceiling;continuous selectivity; spleen: 1.4 nTPM; positive ihc; stomach: 1.4 nTPM; positive ihc; thyroid gland: 4 nTPM; positive ihc;continuous selectivity; tongue: 6.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 1.5 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 2.2 nTPM (limit 2); basal ganglia: 2.2 nTPM (limit 2); heart muscle: 2.6 nTPM (limit 2); hippocampal formation: 2.6 nTPM (limit 2); kidney: 2.9 nTPM (limit 2); liver: 3.1 nTPM (limit 2); midbrain: 2.8 nTPM (limit 2); pancreas: 2.4 nTPM (limit 2); pituitary gland: 2.6 nTPM (limit 2); retina: 4.2 nTPM (limit 2); skeletal muscle: 5 nTPM (limit 2); spinal cord: 3.5 nTPM (limit 2); tongue: 6.6 nTPM (limit 6); amygdala: 2.2 nTPM (baseline 2); basal ganglia: 2.2 nTPM (baseline 2); heart muscle: 2.6 nTPM (baseline 2); hippocampal formation: 2.6 nTPM (baseline 2); kidney: 2.9 nTPM (baseline 2); liver: 3.1 nTPM (baseline 2); midbrain: 2.8 nTPM (baseline 2); pancreas: 2.4 nTPM (baseline 2); pituitary gland: 2.6 nTPM (baseline 2); retina: 4.2 nTPM (baseline 2); skeletal muscle: 5 nTPM (baseline 2); spinal cord: 3.5 nTPM (baseline 2); tongue: 6.6 nTPM (baseline 6),adipose tissue / adipocytes: Low (Uncertain); adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: High (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / glial cells: Low (Uncertain); caudate / neuronal cells: Low (Uncertain); cerebellum / cells in granular layer: Medium (Uncertain); cerebellum / cells in molecular layer: Low (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / endothelial cells: Medium (Uncertain); cerebral cortex / glial cells: Medium (Uncertain); cerebral cortex / neuronal cells: Low (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / endothelial cells: Medium (Uncertain); colon / glandular cells: High (Uncertain); colon / peripheral nerve/ganglion: Medium (Uncertain); duodenum / glandular cells: High (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: High (Uncertain); hippocampus / glial cells: Low (Uncertain); hippocampus / neuronal cells: Low (Uncertain); kidney / cells in glomeruli: High (Uncertain); kidney / cells in tubules: High (Uncertain); liver / cholangiocytes: Low (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / alveolar cells: Low (Uncertain); lung / macrophages: Low (Uncertain); lymph node / germinal center cells: Medium (Uncertain); lymph node / non-germinal center cells: Medium (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: High (Uncertain); pancreas / exocrine glandular cells: High (Uncertain); pancreas / pancreatic endocrine cells: Low (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: High (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: High (Uncertain); skin 1 / fibroblasts: Low (Uncertain); skin 1 / keratinocytes: Low (Uncertain); skin 1 / Langerhans: Low (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: High (Uncertain); smooth muscle / smooth muscle cells: High (Uncertain); spleen / cells in red pulp: Medium (Uncertain); spleen / cells in white pulp: Low (Uncertain); stomach 1 / glandular cells: High (Uncertain); stomach 2 / glandular cells: High (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 46/50 (92.0%); Pancreatic Adenocarcinoma (validation): 27/80 (33.8%),breast cancer: 12/12 (100.0%); colorectal cancer: 12/12 (100.0%),31,20,Q9H5L6,https://www.uniprot.org/uniprotkb/Q9H5L6/entry,Active transposase that specifically recognizes the bipartite 5'-TXXGGGX(A/T)-3' consensus motif and mediates transposition,,,,,20010837|23349291,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
TICRR,ENSG00000140534,Unsafe,RNA,False,True,1.4,4.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 3.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 0.8 nTPM; continuous selectivity; duodenum: 1 nTPM; continuous selectivity; esophagus: 4.1 nTPM; continuous selectivity;reproductive not higher; lymph node: 1.4 nTPM; continuous selectivity;reproductive not higher; rectum: 1.1 nTPM; continuous selectivity; small intestine: 0.9 nTPM; continuous selectivity; thymus: 4 nTPM; continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 3.4 nTPM (limit 2); bone marrow: 3.4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 417/486 (85.8%); Rectum Adenocarcinoma (validation): 166/207 (80.2%); Testicular Germ Cell Tumor (TCGA): 92/133 (69.2%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q7Z2Z1,https://www.uniprot.org/uniprotkb/Q7Z2Z1/entry,Regulator of DNA replication and S/M and G2/M checkpoints. Regulates the triggering of DNA replication initiation via its interaction with TOPBP1 by participating in CDK2-mediated loading of CDC45L onto replication origins. Required for the transition from pre-replication complex (pre-RC) to pre-initiation complex (pre-IC). Required to prevent mitotic entry after treatment with ionizing radiation,,,,Nucleus,20116089,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
TIGD7,ENSG00000140993,Unsafe,Protein,False,True,9.8,9.8,78,54,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 3.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 4.6 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 4.6 nTPM; absolute ceiling;continuous selectivity; bone marrow: 0.8 nTPM; positive ihc; cerebellum: 6.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 4.8 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 9.5 nTPM; absolute ceiling;continuous selectivity; colon: 4.8 nTPM; positive ihc;continuous selectivity; duodenum: 1.9 nTPM; positive ihc; esophagus: 2.2 nTPM; positive ihc; heart muscle: 5.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 4.6 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 5.2 nTPM; absolute ceiling;continuous selectivity; kidney: 5.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 2.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 4 nTPM; positive ihc;continuous selectivity; midbrain: 4.5 nTPM; absolute ceiling;continuous selectivity; pancreas: 3.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 6.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 7.9 nTPM; absolute ceiling;continuous selectivity; rectum: 1.8 nTPM; positive ihc; retina: 8 nTPM; absolute ceiling;continuous selectivity; salivary gland: 2.6 nTPM; positive ihc; skeletal muscle: 4 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 2.5 nTPM; positive ihc; small intestine: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 3.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 4.6 nTPM; absolute ceiling;continuous selectivity; spleen: 4.7 nTPM; continuous selectivity; stomach: 2.6 nTPM; positive ihc; thyroid gland: 7 nTPM; positive ihc;continuous selectivity; tongue: 5 nTPM; continuous selectivity; urinary bladder: 3.9 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 3.6 nTPM (limit 2); amygdala: 4.6 nTPM (limit 2); basal ganglia: 4.6 nTPM (limit 2); cerebellum: 6.4 nTPM (limit 2); cerebral cortex: 4.8 nTPM (limit 2); choroid plexus: 9.5 nTPM (limit 2); heart muscle: 5.2 nTPM (limit 2); hippocampal formation: 4.6 nTPM (limit 2); hypothalamus: 5.2 nTPM (limit 2); kidney: 5.8 nTPM (limit 2); liver: 3 nTPM (limit 2); lung: 2.9 nTPM (limit 2); midbrain: 4.5 nTPM (limit 2); pancreas: 3.1 nTPM (limit 2); parathyroid gland: 6.3 nTPM (limit 6); pituitary gland: 7.9 nTPM (limit 2); retina: 8 nTPM (limit 2); skeletal muscle: 4 nTPM (limit 2); small intestine: 2.7 nTPM (limit 2); smooth muscle: 3.3 nTPM (limit 2); spinal cord: 4.6 nTPM (limit 2); adrenal gland: 3.6 nTPM (baseline 2); amygdala: 4.6 nTPM (baseline 2); basal ganglia: 4.6 nTPM (baseline 2); cerebellum: 6.4 nTPM (baseline 2); cerebral cortex: 4.8 nTPM (baseline 2); choroid plexus: 9.5 nTPM (baseline 2); heart muscle: 5.2 nTPM (baseline 2); hippocampal formation: 4.6 nTPM (baseline 2); hypothalamus: 5.2 nTPM (baseline 2); kidney: 5.8 nTPM (baseline 2); liver: 3 nTPM (baseline 2); lung: 2.9 nTPM (baseline 2); midbrain: 4.5 nTPM (baseline 2); pancreas: 3.1 nTPM (baseline 2); parathyroid gland: 6.3 nTPM (baseline 6); pituitary gland: 7.9 nTPM (baseline 2); retina: 8 nTPM (baseline 2); skeletal muscle: 4 nTPM (baseline 2); small intestine: 2.7 nTPM (baseline 2); smooth muscle: 3.3 nTPM (baseline 2); spinal cord: 4.6 nTPM (baseline 2),adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: Low (Uncertain); colon / endothelial cells: Low (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: Low (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: Low (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / hepatocytes: Low (Uncertain); lung / alveolar cells: Low (Uncertain); lung / macrophages: Low (Uncertain); lymph node / non-germinal center cells: Medium (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Low (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: Low (Uncertain); skin 1 / fibroblasts: Low (Uncertain); skin 1 / keratinocytes: Low (Uncertain); small intestine / glandular cells: Medium (Uncertain); smooth muscle / smooth muscle cells: Low (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 48/50 (96.0%); Prostate Adenocarcinoma (TCGA): 404/480 (84.2%),colorectal cancer: 11/12 (91.7%); cervical cancer: 10/11 (90.9%),31,20,Q6NT04,https://www.uniprot.org/uniprotkb/Q6NT04/entry,,Expressed in all tissues tested. Higher expression in testis and ovary,,,Nucleus,,15487591,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | Jamin2021_CT,GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
TIMD4,ENSG00000145850,Unsafe,Protein,False,True,140.0,140.0,84,12,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 15.8 nTPM; positive ihc;absolute ceiling; liver: 15.8 nTPM; absolute ceiling; lymph node: 53.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; spleen: 7.8 nTPM; positive ihc; thymus: 21.8 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 15.8 nTPM (limit 2); liver: 15.8 nTPM (limit 4); lymph node: 53.9 nTPM (limit 6); thymus: 21.8 nTPM (limit 10),bone marrow / hematopoietic cells: Medium (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); spleen / cells in red pulp: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Chromophobe (TCGA): 58/64 (90.6%); Kidney Renal Clear Cell Carcinoma (validation): 79/100 (79.0%); Kidney Renal Papillary Cell Carcinoma (TCGA): 184/282 (65.2%),breast cancer: 4/12 (33.3%); prostate cancer: 4/12 (33.3%),31,20,Q96H15,https://www.uniprot.org/uniprotkb/Q96H15/entry,"Phosphatidylserine receptor that plays different role in immune response including phagocytosis of apoptotic cells and T-cell regulation (PubMed:18082433, PubMed:32640697). Involved in efferocytosis, the process by which apoptotic cells are removed by phagocytic cells by promoting the engulfment of apoptotic cells or exogenous particles (PubMed:18082433, PubMed:32703939, PubMed:34067457). Mechanistically, acts by securing apoptotic cells to phagocytes through direct binding to phosphatidylserine present on apoptotic cells, while other engulfment receptors such as MERTK efficiently recognize apoptotic cells and mediate their ingestion (PubMed:32640697). Controls T-cell activation in a bimodal fashion, decreasing the activation of naive T-cells by inducing cell cycle arrest, while increasing proliferation of activated T-cells by activating AKT1 and ERK1/2 phosphorylations and subsequent signaling pathways (By similarity). Also promotes autophagy process by suppressing NLRP3 inflammasome activity via activation of LKB1/PRKAA1 pathway in a phosphatidylserine-dependent mechanism (By similarity) (Microbial infection) Plays a positive role in exosome-mediated trafficking of HIV-1 virus and its entry into immune cells",Expressed by macrophages and dendritic cells,,,"Cell membrane Secreted, extracellular exosome",18082433|28740388|32640697|32703939|34067457,18082433,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
TIPIN,ENSG00000075131,Unsafe,Protein,False,True,19.9,19.9,91,27,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 3.9 nTPM; absolute ceiling; basal ganglia: 3.8 nTPM; absolute ceiling; bone marrow: 12.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 3.8 nTPM; absolute ceiling; colon: 4.6 nTPM; positive ihc; duodenum: 2.7 nTPM; positive ihc;absolute ceiling; esophagus: 4.8 nTPM; positive ihc; hippocampal formation: 3.6 nTPM; absolute ceiling; hypothalamus: 4.1 nTPM; absolute ceiling; lymph node: 9.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 3.9 nTPM; absolute ceiling; pituitary gland: 3.1 nTPM; absolute ceiling; rectum: 5.1 nTPM; positive ihc; retina: 7.8 nTPM; absolute ceiling;continuous selectivity; skin: 3.8 nTPM; positive ihc; small intestine: 2.9 nTPM; positive ihc;absolute ceiling; spinal cord: 4 nTPM; absolute ceiling; spleen: 3.6 nTPM; positive ihc; stomach: 3.7 nTPM; positive ihc; urinary bladder: 3.4 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 3.9 nTPM (limit 2); basal ganglia: 3.8 nTPM (limit 2); bone marrow: 12.5 nTPM (limit 2); choroid plexus: 3.8 nTPM (limit 2); duodenum: 2.7 nTPM (limit 2); hippocampal formation: 3.6 nTPM (limit 2); hypothalamus: 4.1 nTPM (limit 2); lymph node: 9.2 nTPM (limit 6); midbrain: 3.9 nTPM (limit 2); pituitary gland: 3.1 nTPM (limit 2); retina: 7.8 nTPM (limit 2); small intestine: 2.9 nTPM (limit 2); spinal cord: 4 nTPM (limit 2),bone marrow / hematopoietic cells: Low (Enhanced); colon / glandular cells: Medium (Enhanced); duodenum / glandular cells: Low (Enhanced); esophagus / squamous epithelial cells: Low (Enhanced); lymph node / germinal center cells: Medium (Enhanced); oral mucosa / squamous epithelial cells: Medium (Enhanced); rectum / glandular cells: Medium (Enhanced); skin 1 / keratinocytes: Medium (Enhanced); skin 2 / epidermal cells: Low (Enhanced); small intestine / glandular cells: Low (Enhanced); spleen / cells in white pulp: Low (Enhanced); stomach 1 / glandular cells: Low (Enhanced); stomach 2 / glandular cells: Low (Enhanced); urinary bladder / urothelial cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Glioblastoma Multiforme (TCGA): 139/141 (98.6%),cervical cancer: 10/12 (83.3%); testis cancer: 9/11 (81.8%),31,20,Q9BVW5,https://www.uniprot.org/uniprotkb/Q9BVW5/entry,"Plays an important role in the control of DNA replication and the maintenance of replication fork stability (PubMed:17102137, PubMed:23359676, PubMed:35585232). Important for cell survival after DNA damage or replication stress (PubMed:17116885). May be specifically required for the ATR-CHEK1 pathway in the replication checkpoint induced by hydroxyurea or ultraviolet light (PubMed:17296725). Forms a complex with TIMELESS and this complex regulates DNA replication processes under both normal and stress conditions, stabilizes replication forks and influences both CHEK1 phosphorylation and the intra-S phase checkpoint in response to genotoxic stress (PubMed:17102137, PubMed:17116885, PubMed:17296725, PubMed:23359676, PubMed:35585232)",,,,Cytoplasm Nucleus,17102137|17116885|17296725|23359676|35585232,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | Jamin2021_CT,GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
TIRAP,ENSG00000150455,Unsafe,RNA,False,True,6.5,8.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 4.4 nTPM; continuous selectivity; adrenal gland: 4.3 nTPM; absolute ceiling;continuous selectivity; amygdala: 1.9 nTPM; continuous selectivity; basal ganglia: 2 nTPM; continuous selectivity; bone marrow: 1.9 nTPM; continuous selectivity; cerebellum: 2.6 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 2.8 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 3.7 nTPM; absolute ceiling;continuous selectivity; colon: 5.5 nTPM; continuous selectivity; duodenum: 7.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 4.8 nTPM; continuous selectivity; heart muscle: 6.2 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 2.4 nTPM; absolute ceiling;continuous selectivity; kidney: 4 nTPM; absolute ceiling;continuous selectivity; liver: 6.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 3.8 nTPM; absolute ceiling;continuous selectivity; lymph node: 3.8 nTPM; continuous selectivity; midbrain: 2.4 nTPM; absolute ceiling;continuous selectivity; pancreas: 6.1 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 6.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 3.5 nTPM; absolute ceiling;continuous selectivity; rectum: 5.5 nTPM; continuous selectivity; retina: 3 nTPM; absolute ceiling;continuous selectivity; salivary gland: 8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 4.7 nTPM; absolute ceiling;continuous selectivity; skin: 4 nTPM; continuous selectivity; small intestine: 7.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 4.7 nTPM; absolute ceiling;continuous selectivity; spleen: 4.6 nTPM; continuous selectivity; stomach: 3.8 nTPM; continuous selectivity; thymus: 3.1 nTPM; continuous selectivity; thyroid gland: 5.1 nTPM; continuous selectivity; tongue: 4.9 nTPM; continuous selectivity; urinary bladder: 4.4 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 4.3 nTPM (limit 2); cerebellum: 2.6 nTPM (limit 2); cerebral cortex: 2.8 nTPM (limit 2); choroid plexus: 3.7 nTPM (limit 2); duodenum: 7.7 nTPM (limit 2); heart muscle: 6.2 nTPM (limit 2); hypothalamus: 2.4 nTPM (limit 2); kidney: 4 nTPM (limit 2); liver: 6.6 nTPM (limit 2); lung: 3.8 nTPM (limit 2); midbrain: 2.4 nTPM (limit 2); pancreas: 6.1 nTPM (limit 2); parathyroid gland: 6.6 nTPM (limit 6); pituitary gland: 3.5 nTPM (limit 2); retina: 3 nTPM (limit 2); salivary gland: 8 nTPM (limit 6); skeletal muscle: 4.7 nTPM (limit 2); small intestine: 7.9 nTPM (limit 2); smooth muscle: 4.7 nTPM (limit 2); adrenal gland: 4.3 nTPM (baseline 2); cerebellum: 2.6 nTPM (baseline 2); cerebral cortex: 2.8 nTPM (baseline 2); choroid plexus: 3.7 nTPM (baseline 2); duodenum: 7.7 nTPM (baseline 2); heart muscle: 6.2 nTPM (baseline 2); hypothalamus: 2.4 nTPM (baseline 2); kidney: 4 nTPM (baseline 2); liver: 6.6 nTPM (baseline 2); lung: 3.8 nTPM (baseline 2); midbrain: 2.4 nTPM (baseline 2); pancreas: 6.1 nTPM (baseline 2); parathyroid gland: 6.6 nTPM (baseline 6); pituitary gland: 3.5 nTPM (baseline 2); retina: 3 nTPM (baseline 2); salivary gland: 8 nTPM (baseline 6); skeletal muscle: 4.7 nTPM (baseline 2); small intestine: 7.9 nTPM (baseline 2); smooth muscle: 4.7 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 484/486 (99.6%); Rectum Adenocarcinoma (validation): 206/207 (99.5%); Glioblastoma Multiforme (validation): 57/58 (98.3%),colorectal cancer: 4/10 (40.0%); renal cancer: 2/11 (18.2%),31,20,P58753,https://www.uniprot.org/uniprotkb/P58753/entry,"Adapter involved in TLR2, TLR4 and RAGE signaling pathways in the innate immune response. Acts via IRAK2 and TRAF-6, leading to the activation of NF-kappa-B, MAPK1, MAPK3 and JNK, and resulting in cytokine secretion and the inflammatory response. Positively regulates the production of TNF (TNF) and interleukin-6 (IL6)","Highly expressed in liver, kidney, spleen, skeletal muscle and heart. Also detected in peripheral blood leukocytes, lung, placenta, small intestine, thymus, colon and brain",,,Cytoplasm Cell membrane Membrane,18292575|19509286|21829704,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
TKTL1,ENSG00000007350,Unsafe,RNA,False,True,123.4,123.4,85,5,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,retina: 2.1 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 2.1 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 53/133 (39.8%); Glioblastoma Multiforme (validation): 12/58 (20.7%); Ovary Serous Cystadenocarcinoma (TCGA): 72/349 (20.6%),lung cancer: 2/12 (16.7%); breast cancer: 0/11 (0.0%),31,20,P51854,https://www.uniprot.org/uniprotkb/P51854/entry,"Catalyzes the transfer of a two-carbon ketol group from a ketose donor to an aldose acceptor, via a covalent intermediate with the cofactor thiamine pyrophosphate (By similarity). Thus, catalyzes the reversible transfer of a two-carbon ketol group from sedoheptulose-7-phosphate to glyceraldehyde-3-phosphate, producing xylulose-5-phosphate and ribose-5-phosphate (By similarity). The phosphate group of the substrate plays a role in stabilizing the substrate-thiamine intermediate while preventing the formation of the reactive enamine intermediate (By similarity). Can also use fructose-6-phosphate as a ketose donor (By similarity) During fetal neocortex development, may be essential to maintain the full number of basal radial glia (bRG). bRG are neural progenitor cells that undergo asymmetric divisions, generating a bRG (self-renewal) and a neuron, in contrast to basal intermediate progenitors (bIPs), which typically divide once to give rise to 2 neurons. bRG generate more cortical neurons over time than bIPs",Widely expressed (PubMed:8838793). Expressed in endothelial cells and in peripheral neurons (at protein level) (PubMed:15991799) Not expressed in fetal neocortex Expressed in fetal neocortex,,,Cytoplasm,36074851,15991799|36074851|8838793,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | Jamin2021_CT | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination; inclusion depends on TGCT under this study's thresholds | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,Failed bulk numeric comparisons are within 20% of their cutoffs; not an automatic rescue,,,,
TLCD3B,ENSG00000149926,Unsafe,RNA,False,True,101.9,101.9,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 24.5 nTPM; absolute ceiling; basal ganglia: 21.8 nTPM; absolute ceiling; cerebellum: 85.2 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 42 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 30.7 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 18.5 nTPM; absolute ceiling; midbrain: 15.8 nTPM; absolute ceiling; pituitary gland: 20.9 nTPM; absolute ceiling; retina: 65.8 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 11.1 nTPM; absolute ceiling; spinal cord: 9.8 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 24.5 nTPM (limit 2); basal ganglia: 21.8 nTPM (limit 2); cerebellum: 85.2 nTPM (limit 2); cerebral cortex: 42 nTPM (limit 2); hippocampal formation: 30.7 nTPM (limit 2); hypothalamus: 18.5 nTPM (limit 2); midbrain: 15.8 nTPM (limit 2); pituitary gland: 20.9 nTPM (limit 2); retina: 65.8 nTPM (limit 2); skeletal muscle: 11.1 nTPM (limit 2); spinal cord: 9.8 nTPM (limit 2); amygdala: 24.5 nTPM (baseline 2); basal ganglia: 21.8 nTPM (baseline 2); cerebellum: 85.2 nTPM (baseline 2); cerebral cortex: 42 nTPM (baseline 2); hippocampal formation: 30.7 nTPM (baseline 2); hypothalamus: 18.5 nTPM (baseline 2); midbrain: 15.8 nTPM (baseline 2); pituitary gland: 20.9 nTPM (baseline 2); retina: 65.8 nTPM (baseline 2); skeletal muscle: 11.1 nTPM (baseline 2); spinal cord: 9.8 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 101/141 (71.6%); Breast Invasive Carcinoma (TCGA): 117/1022 (11.4%); Testicular Germ Cell Tumor (TCGA): 15/133 (11.3%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q71RH2,https://www.uniprot.org/uniprotkb/Q71RH2/entry,Involved in ceramide synthesis,Expressed in testis (PubMed:33077892). Expressed in the retina with higher expression levels in the macular than in the peripheral region (PubMed:33077892),"Cone-rod dystrophy 22: An autosomal recessive form of cone-rod dystrophy, an inherited retinal dystrophy characterized by retinal pigment deposits visible on fundus examination, predominantly in the macular region, and initial loss of cone photoreceptors followed by rod degeneration. This leads to decreased visual acuity and sensitivity in the central visual field, followed by loss of peripheral vision. Severe loss of vision occurs earlier than in retinitis pigmentosa, due to cone photoreceptors degenerating at a higher rate than rod photoreceptors.",,Golgi apparatus membrane Endoplasmic reticulum membrane,,33077892,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
TLE4,ENSG00000106829,Unsafe,RNA,False,True,98.1,98.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 15.1 nTPM; absolute ceiling; amygdala: 11 nTPM; absolute ceiling; basal ganglia: 26.3 nTPM; absolute ceiling;continuous selectivity; bone marrow: 68.1 nTPM; absolute ceiling;continuous selectivity; cerebellum: 22.6 nTPM; absolute ceiling; cerebral cortex: 15.8 nTPM; absolute ceiling; choroid plexus: 21.3 nTPM; absolute ceiling; colon: 9.6 nTPM; absolute ceiling; duodenum: 7 nTPM; absolute ceiling; esophagus: 15.4 nTPM; absolute ceiling; heart muscle: 7.1 nTPM; absolute ceiling; hippocampal formation: 15.7 nTPM; absolute ceiling; hypothalamus: 13.1 nTPM; absolute ceiling; kidney: 6.4 nTPM; absolute ceiling; liver: 5.6 nTPM; absolute ceiling; lung: 12.1 nTPM; absolute ceiling; lymph node: 15.4 nTPM; absolute ceiling; midbrain: 15.2 nTPM; absolute ceiling; pancreas: 6.1 nTPM; absolute ceiling; parathyroid gland: 10.2 nTPM; absolute ceiling; pituitary gland: 23.5 nTPM; absolute ceiling; rectum: 10.1 nTPM; absolute ceiling; retina: 24.3 nTPM; absolute ceiling; salivary gland: 9.7 nTPM; absolute ceiling; skeletal muscle: 22.3 nTPM; absolute ceiling; skin: 19.4 nTPM; absolute ceiling; small intestine: 11 nTPM; absolute ceiling; smooth muscle: 13.8 nTPM; absolute ceiling; spinal cord: 30 nTPM; absolute ceiling;continuous selectivity; spleen: 18 nTPM; absolute ceiling; stomach: 13 nTPM; absolute ceiling; thymus: 26.7 nTPM; absolute ceiling; tongue: 10.5 nTPM; absolute ceiling; urinary bladder: 17.6 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 15.1 nTPM (limit 2); amygdala: 11 nTPM (limit 2); basal ganglia: 26.3 nTPM (limit 2); bone marrow: 68.1 nTPM (limit 2); cerebellum: 22.6 nTPM (limit 2); cerebral cortex: 15.8 nTPM (limit 2); choroid plexus: 21.3 nTPM (limit 2); colon: 9.6 nTPM (limit 6); duodenum: 7 nTPM (limit 2); esophagus: 15.4 nTPM (limit 6); heart muscle: 7.1 nTPM (limit 2); hippocampal formation: 15.7 nTPM (limit 2); hypothalamus: 13.1 nTPM (limit 2); kidney: 6.4 nTPM (limit 2); liver: 5.6 nTPM (limit 2); lung: 12.1 nTPM (limit 2); lymph node: 15.4 nTPM (limit 6); midbrain: 15.2 nTPM (limit 2); pancreas: 6.1 nTPM (limit 2); parathyroid gland: 10.2 nTPM (limit 6); pituitary gland: 23.5 nTPM (limit 2); rectum: 10.1 nTPM (limit 6); retina: 24.3 nTPM (limit 2); salivary gland: 9.7 nTPM (limit 6); skeletal muscle: 22.3 nTPM (limit 2); skin: 19.4 nTPM (limit 10); small intestine: 11 nTPM (limit 2); smooth muscle: 13.8 nTPM (limit 2); spinal cord: 30 nTPM (limit 2); spleen: 18 nTPM (limit 10); stomach: 13 nTPM (limit 6); thymus: 26.7 nTPM (limit 10); tongue: 10.5 nTPM (limit 6); urinary bladder: 17.6 nTPM (limit 6); adrenal gland: 15.1 nTPM (baseline 2); amygdala: 11 nTPM (baseline 2); basal ganglia: 26.3 nTPM (baseline 2); bone marrow: 68.1 nTPM (baseline 2); cerebellum: 22.6 nTPM (baseline 2); cerebral cortex: 15.8 nTPM (baseline 2); choroid plexus: 21.3 nTPM (baseline 2); colon: 9.6 nTPM (baseline 6); duodenum: 7 nTPM (baseline 2); esophagus: 15.4 nTPM (baseline 6); heart muscle: 7.1 nTPM (baseline 2); hippocampal formation: 15.7 nTPM (baseline 2); hypothalamus: 13.1 nTPM (baseline 2); kidney: 6.4 nTPM (baseline 2); liver: 5.6 nTPM (baseline 2); lung: 12.1 nTPM (baseline 2); lymph node: 15.4 nTPM (baseline 6); midbrain: 15.2 nTPM (baseline 2); pancreas: 6.1 nTPM (baseline 2); parathyroid gland: 10.2 nTPM (baseline 6); pituitary gland: 23.5 nTPM (baseline 2); rectum: 10.1 nTPM (baseline 6); retina: 24.3 nTPM (baseline 2); salivary gland: 9.7 nTPM (baseline 6); skeletal muscle: 22.3 nTPM (baseline 2); skin: 19.4 nTPM (baseline 10); small intestine: 11 nTPM (baseline 2); smooth muscle: 13.8 nTPM (baseline 2); spinal cord: 30 nTPM (baseline 2); spleen: 18 nTPM (baseline 10); stomach: 13 nTPM (baseline 6); thymus: 26.7 nTPM (baseline 10); tongue: 10.5 nTPM (baseline 6); urinary bladder: 17.6 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 205/207 (99.0%); Glioblastoma Multiforme (validation): 57/58 (98.3%); Colon Adenocarcinoma (validation): 474/486 (97.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q04727,https://www.uniprot.org/uniprotkb/Q04727/entry,"Transcriptional corepressor that binds to a number of transcription factors. Inhibits the transcriptional activation mediated by PAX5, and by CTNNB1 and TCF family members in Wnt signaling. The effects of full-length TLE family members may be modulated by association with dominant-negative AES. Essential for the transcriptional repressor activity of SIX3 during retina and lens development and for SIX3 transcriptional auto-repression (By similarity). Involved in transcriptional repression of GNRHR and enhances MSX1-mediated transcriptional repression of CGA/alpha-GSU (By similarity)","In all tissues examined, mostly in brain, and muscle",,It is uncertain whether Met-1 or Met-8 is the initiator,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
TLK1,ENSG00000198586,Unsafe,Protein,False,True,17.1,17.5,79,79,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 7.4 nTPM; positive ihc; adrenal gland: 9.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 10.6 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 10.1 nTPM; absolute ceiling;continuous selectivity; bone marrow: 10.9 nTPM; absolute ceiling;continuous selectivity; cerebellum: 6.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 13 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 7.9 nTPM; absolute ceiling;continuous selectivity; colon: 12.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 9.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 9 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 6.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 10.3 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 9.5 nTPM; absolute ceiling;continuous selectivity; kidney: 12.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 14.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 8.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 14.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 10.7 nTPM; absolute ceiling;continuous selectivity; pancreas: 10.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 17.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 6 nTPM; absolute ceiling;continuous selectivity; rectum: 11.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 15.3 nTPM; absolute ceiling;continuous selectivity; salivary gland: 8.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 15.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 8.3 nTPM; positive ihc;continuous selectivity; small intestine: 11.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 11.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 9.9 nTPM; absolute ceiling;continuous selectivity; spleen: 12.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 13.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 13.4 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 17.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 11.3 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 9.9 nTPM (limit 2); amygdala: 10.6 nTPM (limit 2); basal ganglia: 10.1 nTPM (limit 2); bone marrow: 10.9 nTPM (limit 2); cerebellum: 6.1 nTPM (limit 2); cerebral cortex: 13 nTPM (limit 2); choroid plexus: 7.9 nTPM (limit 2); colon: 12.6 nTPM (limit 6); duodenum: 9.2 nTPM (limit 2); esophagus: 9 nTPM (limit 6); heart muscle: 6.7 nTPM (limit 2); hippocampal formation: 10.3 nTPM (limit 2); hypothalamus: 9.5 nTPM (limit 2); kidney: 12.5 nTPM (limit 2); liver: 14.3 nTPM (limit 2); lung: 8.1 nTPM (limit 2); lymph node: 14.7 nTPM (limit 6); midbrain: 10.7 nTPM (limit 2); pancreas: 10.1 nTPM (limit 2); parathyroid gland: 17.5 nTPM (limit 6); pituitary gland: 6 nTPM (limit 2); rectum: 11.9 nTPM (limit 6); retina: 15.3 nTPM (limit 2); salivary gland: 8.9 nTPM (limit 6); skeletal muscle: 15.7 nTPM (limit 2); small intestine: 11.4 nTPM (limit 2); smooth muscle: 11.3 nTPM (limit 2); spinal cord: 9.9 nTPM (limit 2); spleen: 12.8 nTPM (limit 10); stomach: 13.1 nTPM (limit 6); thymus: 13.4 nTPM (limit 10); thyroid gland: 17.1 nTPM (limit 10); urinary bladder: 11.3 nTPM (limit 6),adipose tissue / adipocytes: High (Approved); adrenal gland / glandular cells: High (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / glial cells: High (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: High (Approved); cerebellum / cells in molecular layer: High (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / endothelial cells: High (Approved); cerebral cortex / glial cells: High (Approved); cerebral cortex / neuronal cells: High (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: High (Approved); colon / glandular cells: High (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: High (Approved); heart muscle / cardiomyocytes: High (Approved); hippocampus / glial cells: High (Approved); hippocampus / neuronal cells: High (Approved); kidney / cells in glomeruli: High (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: Medium (Approved); liver / hepatocytes: High (Approved); lung / alveolar cells type I: High (Approved); lung / alveolar cells type II: High (Approved); lung / endothelial cells: Medium (Approved); lung / macrophages: High (Approved); lymph node / germinal center cells: High (Approved); lymph node / non-germinal center cells: High (Approved); nasopharynx / respiratory epithelial cells: High (Approved); oral mucosa / squamous epithelial cells: High (Approved); pancreas / exocrine glandular cells: High (Approved); pancreas / pancreatic endocrine cells: High (Approved); parathyroid gland / glandular cells: High (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: High (Approved); skeletal muscle / myocytes: High (Approved); skin 1 / fibroblasts: High (Approved); skin 1 / keratinocytes: High (Approved); skin 1 / Langerhans: High (Approved); skin 2 / epidermal cells: High (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: High (Approved); spleen / cells in red pulp: High (Approved); spleen / cells in white pulp: High (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: High (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%),breast cancer: 12/12 (100.0%); cervical cancer: 12/12 (100.0%),31,20,Q9UKI8,https://www.uniprot.org/uniprotkb/Q9UKI8/entry,"Rapidly and transiently inhibited by phosphorylation following the generation of DNA double-stranded breaks during S-phase. This is cell cycle checkpoint and ATM-pathway dependent and appears to regulate processes involved in chromatin assembly. Isoform 3 phosphorylates and enhances the stability of the t-SNARE SNAP23, augmenting its assembly with syntaxin. Isoform 3 protects the cells from the ionizing radiation by facilitating the repair of DSBs. In vitro, phosphorylates histone H3 at 'Ser-10'","Widely expressed. Present in fetal placenta, liver, kidney and pancreas but not heart or skeletal muscle. Also found in adult cell lines. Isoform 3 is ubiquitously expressed in all tissues examined",,,Nucleus,10523312|10588641|11314006|11470414|12660173|9427565,10588641|9427565,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
TMED7,ENSG00000134970,Unsafe,Protein,False,True,68.5,77.9,99,85,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 33.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 39.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 19.9 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 21 nTPM; absolute ceiling;continuous selectivity; bone marrow: 31.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 10.9 nTPM; positive ihc;absolute ceiling; cerebral cortex: 31.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 11.7 nTPM; absolute ceiling; colon: 40.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 35.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 31.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 42 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 22 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 20.8 nTPM; absolute ceiling;continuous selectivity; kidney: 52.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 77.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 29.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 22.9 nTPM; positive ihc;absolute ceiling; midbrain: 22.4 nTPM; absolute ceiling;continuous selectivity; pancreas: 34.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 51.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 27.2 nTPM; absolute ceiling;continuous selectivity; rectum: 40.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 18.6 nTPM; absolute ceiling;continuous selectivity; salivary gland: 42.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 21.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 18.4 nTPM; positive ihc;absolute ceiling; small intestine: 37.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 43.4 nTPM; absolute ceiling;continuous selectivity; spinal cord: 34.7 nTPM; absolute ceiling;continuous selectivity; spleen: 25.3 nTPM; positive ihc;absolute ceiling; stomach: 40.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 19 nTPM; absolute ceiling; thyroid gland: 77.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; tongue: 23.8 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 36.3 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 33.8 nTPM (limit 10); adrenal gland: 39.9 nTPM (limit 2); amygdala: 19.9 nTPM (limit 2); basal ganglia: 21 nTPM (limit 2); bone marrow: 31.4 nTPM (limit 2); cerebellum: 10.9 nTPM (limit 2); cerebral cortex: 31.6 nTPM (limit 2); choroid plexus: 11.7 nTPM (limit 2); colon: 40.7 nTPM (limit 6); duodenum: 35.9 nTPM (limit 2); esophagus: 31.4 nTPM (limit 6); heart muscle: 42 nTPM (limit 2); hippocampal formation: 22 nTPM (limit 2); hypothalamus: 20.8 nTPM (limit 2); kidney: 52.3 nTPM (limit 2); liver: 77.9 nTPM (limit 2); lung: 29.6 nTPM (limit 2); lymph node: 22.9 nTPM (limit 6); midbrain: 22.4 nTPM (limit 2); pancreas: 34.2 nTPM (limit 2); parathyroid gland: 51.8 nTPM (limit 6); pituitary gland: 27.2 nTPM (limit 2); rectum: 40.9 nTPM (limit 6); retina: 18.6 nTPM (limit 2); salivary gland: 42.2 nTPM (limit 6); skeletal muscle: 21.2 nTPM (limit 2); skin: 18.4 nTPM (limit 10); small intestine: 37.3 nTPM (limit 2); smooth muscle: 43.4 nTPM (limit 6); spinal cord: 34.7 nTPM (limit 2); spleen: 25.3 nTPM (limit 10); stomach: 40.4 nTPM (limit 6); thymus: 19 nTPM (limit 10); thyroid gland: 77.4 nTPM (limit 10); tongue: 23.8 nTPM (limit 6); urinary bladder: 36.3 nTPM (limit 6),adipose tissue / adipocytes: Low (Supported); adrenal gland / glandular cells: Low (Supported); bone marrow / hematopoietic cells: Low (Supported); bronchus / respiratory epithelial cells: Medium (Supported); caudate / glial cells: Medium (Supported); caudate / neuronal cells: Medium (Supported); cerebellum / cells in granular layer: Low (Supported); cerebellum / cells in molecular layer: Medium (Supported); cerebellum / Purkinje cells: Medium (Supported); cerebral cortex / endothelial cells: Low (Supported); cerebral cortex / glial cells: Medium (Supported); cerebral cortex / neuronal cells: Medium (Supported); cerebral cortex / neuropil: Low (Supported); colon / endothelial cells: Low (Supported); colon / glandular cells: Medium (Supported); colon / peripheral nerve/ganglion: Medium (Supported); duodenum / glandular cells: Medium (Supported); esophagus / squamous epithelial cells: Low (Supported); heart muscle / cardiomyocytes: Low (Supported); hippocampus / glial cells: Medium (Supported); hippocampus / neuronal cells: Medium (Supported); kidney / cells in glomeruli: Low (Supported); kidney / cells in tubules: Low (Supported); liver / cholangiocytes: Low (Supported); liver / hepatocytes: Medium (Supported); lung / alveolar cells: Low (Supported); lung / macrophages: Medium (Supported); lymph node / germinal center cells: Low (Supported); lymph node / non-germinal center cells: Low (Supported); nasopharynx / respiratory epithelial cells: Medium (Supported); oral mucosa / squamous epithelial cells: Low (Supported); pancreas / exocrine glandular cells: High (Supported); pancreas / pancreatic endocrine cells: Medium (Supported); parathyroid gland / glandular cells: Low (Supported); rectum / glandular cells: Medium (Supported); salivary gland / glandular cells: Low (Supported); skeletal muscle / myocytes: Low (Supported); skin 1 / cells in basal layer: Low (Supported); skin 1 / cells in granular layer: Low (Supported); skin 1 / cells in spinous layer: Low (Supported); skin 1 / endothelial cells: Low (Supported); skin 1 / fibrohistiocytic cells: Medium (Supported); skin 1 / langerhans cells: Low (Supported); skin 1 / lymphocytes: Medium (Supported); skin 1 / vascular mural cells: Low (Supported); skin 2 / cells in basal layer: Low (Supported); skin 2 / endothelial cells: Medium (Supported); skin 2 / fibrohistiocytic cells: Medium (Supported); skin 2 / lymphocytes: Medium (Supported); small intestine / glandular cells: Medium (Supported); spleen / cells in red pulp: Low (Supported); spleen / cells in white pulp: Low (Supported); stomach 1 / glandular cells: Medium (Supported); stomach 2 / glandular cells: Medium (Supported); thyroid gland / glandular cells: Low (Supported); urinary bladder / urothelial cells: Medium (Supported),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Adenocarcinoma (TCGA): 497/497 (100.0%); Thyroid Carcinoma (TCGA): 495/495 (100.0%); Lung Squamous Cell Carcinoma (TCGA): 489/489 (100.0%),endometrial cancer: 10/11 (90.9%); liver cancer: 9/12 (75.0%),31,20,Q9Y3B3,https://www.uniprot.org/uniprotkb/Q9Y3B3/entry,"Potential role in vesicular protein trafficking, mainly in the early secretory pathway. Appears to play a role in the biosynthesis of secreted cargo including processing and post-translational modifications",,,,"Endoplasmic reticulum membrane Golgi apparatus, cis-Golgi network membrane Endoplasmic reticulum-Golgi intermediate compartment membrane Cytoplasmic vesicle, COPI-coated vesicle membrane Cytoplasmic vesicle, COPII-coated vesicle membrane",,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
TMEM140,ENSG00000146859,Unsafe,RNA,False,True,27.4,84.5,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 34.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; adrenal gland: 18.6 nTPM; absolute ceiling;continuous selectivity; amygdala: 6.4 nTPM; absolute ceiling; basal ganglia: 8.9 nTPM; absolute ceiling;continuous selectivity; bone marrow: 10.8 nTPM; absolute ceiling;continuous selectivity; cerebellum: 2.6 nTPM; absolute ceiling; cerebral cortex: 8 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 5.5 nTPM; absolute ceiling; colon: 16.6 nTPM; absolute ceiling;continuous selectivity; duodenum: 17.3 nTPM; absolute ceiling;continuous selectivity; esophagus: 8.9 nTPM; absolute ceiling; heart muscle: 29.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 9.3 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 7.1 nTPM; absolute ceiling;continuous selectivity; kidney: 26.4 nTPM; absolute ceiling;continuous selectivity; liver: 52 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 29.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 19.7 nTPM; absolute ceiling;continuous selectivity; midbrain: 13.5 nTPM; absolute ceiling;continuous selectivity; pancreas: 14.4 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 5.1 nTPM; absolute ceiling; rectum: 8.1 nTPM; absolute ceiling; retina: 2.9 nTPM; absolute ceiling; salivary gland: 17 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 84.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 16.7 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 10.1 nTPM; absolute ceiling;continuous selectivity; spinal cord: 23.7 nTPM; absolute ceiling;continuous selectivity; spleen: 27.1 nTPM; absolute ceiling;continuous selectivity; stomach: 12.2 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 10.6 nTPM; absolute ceiling; tongue: 20.1 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 16 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adipose tissue: 34.5 nTPM (limit 10); adrenal gland: 18.6 nTPM (limit 2); amygdala: 6.4 nTPM (limit 2); basal ganglia: 8.9 nTPM (limit 2); bone marrow: 10.8 nTPM (limit 2); cerebellum: 2.6 nTPM (limit 2); cerebral cortex: 8 nTPM (limit 2); choroid plexus: 5.5 nTPM (limit 2); colon: 16.6 nTPM (limit 6); duodenum: 17.3 nTPM (limit 2); esophagus: 8.9 nTPM (limit 6); heart muscle: 29.7 nTPM (limit 2); hippocampal formation: 9.3 nTPM (limit 2); hypothalamus: 7.1 nTPM (limit 2); kidney: 26.4 nTPM (limit 2); liver: 52 nTPM (limit 2); lung: 29.8 nTPM (limit 2); lymph node: 19.7 nTPM (limit 6); midbrain: 13.5 nTPM (limit 2); pancreas: 14.4 nTPM (limit 2); pituitary gland: 5.1 nTPM (limit 2); rectum: 8.1 nTPM (limit 6); retina: 2.9 nTPM (limit 2); salivary gland: 17 nTPM (limit 6); skeletal muscle: 84.5 nTPM (limit 2); small intestine: 16.7 nTPM (limit 2); smooth muscle: 10.1 nTPM (limit 2); spinal cord: 23.7 nTPM (limit 2); spleen: 27.1 nTPM (limit 10); stomach: 12.2 nTPM (limit 6); thyroid gland: 10.6 nTPM (limit 10); tongue: 20.1 nTPM (limit 6); urinary bladder: 16 nTPM (limit 6); adipose tissue: 34.5 nTPM (baseline 10); adrenal gland: 18.6 nTPM (baseline 2); amygdala: 6.4 nTPM (baseline 2); basal ganglia: 8.9 nTPM (baseline 2); bone marrow: 10.8 nTPM (baseline 2); cerebellum: 2.6 nTPM (baseline 2); cerebral cortex: 8 nTPM (baseline 2); choroid plexus: 5.5 nTPM (baseline 2); colon: 16.6 nTPM (baseline 6); duodenum: 17.3 nTPM (baseline 2); esophagus: 8.9 nTPM (baseline 6); heart muscle: 29.7 nTPM (baseline 2); hippocampal formation: 9.3 nTPM (baseline 2); hypothalamus: 7.1 nTPM (baseline 2); kidney: 26.4 nTPM (baseline 2); liver: 52 nTPM (baseline 2); lung: 29.8 nTPM (baseline 2); lymph node: 19.7 nTPM (baseline 6); midbrain: 13.5 nTPM (baseline 2); pancreas: 14.4 nTPM (baseline 2); pituitary gland: 5.1 nTPM (baseline 2); rectum: 8.1 nTPM (baseline 6); retina: 2.9 nTPM (baseline 2); salivary gland: 17 nTPM (baseline 6); skeletal muscle: 84.5 nTPM (baseline 2); small intestine: 16.7 nTPM (baseline 2); smooth muscle: 10.1 nTPM (baseline 2); spinal cord: 23.7 nTPM (baseline 2); spleen: 27.1 nTPM (baseline 10); stomach: 12.2 nTPM (baseline 6); thyroid gland: 10.6 nTPM (baseline 10); tongue: 20.1 nTPM (baseline 6); urinary bladder: 16 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Renal Clear Cell Carcinoma (TCGA): 521/521 (100.0%); Liver Hepatocellular Carcinoma (TCGA): 362/362 (100.0%); Liver Hepatocellular Carcinoma (validation): 231/231 (100.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9NV12,https://www.uniprot.org/uniprotkb/Q9NV12/entry,,Expression significantly higher in gliomas than in normal brain tissues,,,Membrane,,26198430,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
TMEM217,ENSG00000172738,Unsafe,RNA,False,True,8.7,8.7,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 2.9 nTPM; absolute ceiling;continuous selectivity; bone marrow: 2.7 nTPM; absolute ceiling;continuous selectivity; pancreas: 2.6 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 2.9 nTPM (limit 2); bone marrow: 2.7 nTPM (limit 2); pancreas: 2.6 nTPM (limit 2); adrenal gland: 2.9 nTPM (baseline 2); bone marrow: 2.7 nTPM (baseline 2); pancreas: 2.6 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 8/50 (16.0%); Glioblastoma Multiforme (validation): 7/58 (12.1%); Thyroid Carcinoma (TCGA): 46/495 (9.3%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8N7C4,https://www.uniprot.org/uniprotkb/Q8N7C4/entry,"Transmembrane protein essential for sperm motility and male fertility. Forms a complex with SLC9C1 in the flagellum, which regulates sperm motility by maintaining the stability of soluble adenylyl cyclase, which produces cAMP to power flagellar movement",,,,"Cell projection, cilium, flagellum membrane",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | Jamin2021_CT | Jamin2021_core | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
TMEM225B,ENSG00000244219,Unsafe,RNA,False,True,133.2,133.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,existing nomination or manual review; nomination unresolved; amygdala: 2.8 nTPM; absolute ceiling; basal ganglia: 2.5 nTPM; absolute ceiling; cerebral cortex: 2.3 nTPM; absolute ceiling; hippocampal formation: 2.6 nTPM; absolute ceiling; hypothalamus: 2.7 nTPM; absolute ceiling; kidney: 3.4 nTPM; absolute ceiling; midbrain: 2.9 nTPM; absolute ceiling; pituitary gland: 2.8 nTPM; absolute ceiling; spinal cord: 2.3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 2.8 nTPM (limit 2); basal ganglia: 2.5 nTPM (limit 2); cerebral cortex: 2.3 nTPM (limit 2); hippocampal formation: 2.6 nTPM (limit 2); hypothalamus: 2.7 nTPM (limit 2); kidney: 3.4 nTPM (limit 2); midbrain: 2.9 nTPM (limit 2); pituitary gland: 2.8 nTPM (limit 2); spinal cord: 2.3 nTPM (limit 2); amygdala: 2.8 nTPM (baseline 2); basal ganglia: 2.5 nTPM (baseline 2); cerebral cortex: 2.3 nTPM (baseline 2); hippocampal formation: 2.6 nTPM (baseline 2); hypothalamus: 2.7 nTPM (baseline 2); kidney: 3.4 nTPM (baseline 2); midbrain: 2.9 nTPM (baseline 2); pituitary gland: 2.8 nTPM (baseline 2); spinal cord: 2.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Chromophobe (TCGA): 32/64 (50.0%); Thyroid Carcinoma (TCGA): 187/495 (37.8%); Glioblastoma Multiforme (validation): 18/58 (31.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,P0DP42,https://www.uniprot.org/uniprotkb/P0DP42/entry,,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
TMEM232,ENSG00000186952,Unsafe,RNA,False,True,16.4,16.4,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,choroid plexus: 3.3 nTPM; absolute ceiling; kidney: 3.5 nTPM; absolute ceiling; retina: 3.5 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 3.3 nTPM (limit 2); kidney: 3.5 nTPM (limit 2); retina: 3.5 nTPM (limit 2); choroid plexus: 3.3 nTPM (baseline 2); kidney: 3.5 nTPM (baseline 2); retina: 3.5 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 27/58 (46.6%); Breast Invasive Carcinoma (validation): 17/50 (34.0%); Pancreatic Adenocarcinoma (validation): 9/80 (11.2%),breast cancer: 11/11 (100.0%); colorectal cancer: 11/12 (91.7%),31,20,C9JQI7,https://www.uniprot.org/uniprotkb/C9JQI7/entry,Plays a critical role for male fertility and sperm motility by regulating sperm cytoplasm removal and maintaining axoneme integrity,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
TMEM241,ENSG00000134490,Unsafe,RNA,False,True,2.2,2.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 2 nTPM; continuous selectivity; basal ganglia: 1 nTPM; continuous selectivity; bone marrow: 1.1 nTPM; continuous selectivity; cerebral cortex: 2.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 1.6 nTPM; continuous selectivity; duodenum: 1.5 nTPM; continuous selectivity; esophagus: 1.6 nTPM; continuous selectivity; heart muscle: 1.5 nTPM; continuous selectivity; hypothalamus: 0.7 nTPM; continuous selectivity; kidney: 1 nTPM; continuous selectivity; liver: 1.6 nTPM; continuous selectivity; lung: 1.4 nTPM; continuous selectivity; lymph node: 1.4 nTPM; continuous selectivity; pancreas: 1.2 nTPM; continuous selectivity; parathyroid gland: 2.3 nTPM; continuous selectivity;reproductive not higher; pituitary gland: 1 nTPM; continuous selectivity; rectum: 2.2 nTPM; continuous selectivity;reproductive not higher; salivary gland: 1.1 nTPM; continuous selectivity; skeletal muscle: 1 nTPM; continuous selectivity; small intestine: 1.1 nTPM; continuous selectivity; smooth muscle: 2.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 1.4 nTPM; continuous selectivity; stomach: 1.4 nTPM; continuous selectivity; thyroid gland: 2.1 nTPM; continuous selectivity; urinary bladder: 1.5 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebral cortex: 2.6 nTPM (limit 2); smooth muscle: 2.8 nTPM (limit 2); cerebral cortex: 2.6 nTPM (baseline 2); smooth muscle: 2.8 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 56/58 (96.6%); Pancreatic Adenocarcinoma (validation): 70/80 (87.5%); Lung Adenocarcinoma (validation): 27/105 (25.7%),liver cancer: 2/11 (18.2%); breast cancer: 1/11 (9.1%),29,20,Q24JQ0,https://www.uniprot.org/uniprotkb/Q24JQ0/entry,"Golgi-localized UDP-N-acetylglucosamine (UDP-GlcNAc) transporter that transports UDP-N-acetylglucosamine into Golgi lumen. Contributes to lysosomal targeting of NPC2, a key protein required for lysosomal cholesterol exiting, and that utilizes the mannose-6-phosphate (M6P) modification pathway for its lysosomal targeting",,,,"Golgi apparatus, cis-Golgi network membrane",37890669,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
TMEM31,ENSG00000179363,Unsafe,RNA,False,True,107.0,107.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,hypothalamus: 2.2 nTPM; absolute ceiling; spinal cord: 2.2 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,hypothalamus: 2.2 nTPM (limit 2); spinal cord: 2.2 nTPM (limit 2); hypothalamus: 2.2 nTPM (baseline 2); spinal cord: 2.2 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 25/133 (18.8%); Uterine Corpus Endometrial Carcinoma (TCGA): 6/176 (3.4%); Kidney Chromophobe (TCGA): 2/64 (3.1%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q5JXX7,https://www.uniprot.org/uniprotkb/Q5JXX7/entry,,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Jamin2021_CT | Jamin2021_core | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,Failed bulk numeric comparisons are within 20% of their cutoffs; not an automatic rescue,,,,
TMEM95,ENSG00000182896,Unsafe,High RNA,False,True,10.8,10.8,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,False,True,CTA,Pass,oncoref.target-sets.2026-10-23.1,False,False,,CTA → Unsafe,True,True,True,0.7017018794230001,35.9,"hpa_single_cell_tissue: esophagus/schwann cells, max 35.9 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,0.7017 TPM; blood/CD8_STIM; dice_cd8_stim; vital,35.9 nTPM; esophagus/schwann cells; hpa_single_cell_tissue; protected,Rectum Adenocarcinoma (validation): 1/207 (0.5%); Kidney Renal Papillary Cell Carcinoma (TCGA): 1/282 (0.4%); Bladder Urothelial Carcinoma (TCGA): 0/169 (0.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q3KNT9,https://www.uniprot.org/uniprotkb/Q3KNT9/entry,Sperm protein required for fusion of sperm with the egg membrane during fertilization,Spermatozoa (at protein level),,,"Cytoplasmic vesicle, secretory vesicle, acrosome membrane",36161911,36161911,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TMPPE,ENSG00000188167,Unsafe,Protein,False,True,1.2,5.4,79,71,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0.6 nTPM; positive ihc; adrenal gland: 0.5 nTPM; positive ihc;continuous selectivity; bone marrow: 5.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 0.3 nTPM; positive ihc; cerebral cortex: 1 nTPM; positive ihc;continuous selectivity; choroid plexus: 0.5 nTPM; continuous selectivity; colon: 0.9 nTPM; positive ihc;continuous selectivity; duodenum: 1.2 nTPM; positive ihc;continuous selectivity;reproductive not higher; esophagus: 0.6 nTPM; positive ihc;continuous selectivity; heart muscle: 0.4 nTPM; positive ihc;continuous selectivity; kidney: 0.9 nTPM; positive ihc;continuous selectivity; liver: 0.5 nTPM; positive ihc;continuous selectivity; lung: 1 nTPM; positive ihc;continuous selectivity; lymph node: 1.1 nTPM; positive ihc;continuous selectivity; pancreas: 0.6 nTPM; positive ihc;continuous selectivity; parathyroid gland: 1.8 nTPM; positive ihc;continuous selectivity;reproductive not higher; rectum: 1.2 nTPM; positive ihc;continuous selectivity;reproductive not higher; retina: 2.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 0.7 nTPM; positive ihc;continuous selectivity; skeletal muscle: 0.2 nTPM; positive ihc; skin: 1.1 nTPM; positive ihc;continuous selectivity; small intestine: 1.1 nTPM; positive ihc;continuous selectivity; smooth muscle: 0.8 nTPM; continuous selectivity; spleen: 1.5 nTPM; positive ihc;continuous selectivity;reproductive not higher; stomach: 1.3 nTPM; positive ihc;continuous selectivity;reproductive not higher; thyroid gland: 1 nTPM; positive ihc;continuous selectivity; urinary bladder: 0.7 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 5.4 nTPM (limit 2); retina: 2.7 nTPM (limit 2),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: High (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: High (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: High (Approved); cerebral cortex / neuropil: Medium (Approved); colon / glandular cells: High (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: High (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: High (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Low (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: High (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 485/486 (99.8%); Rectum Adenocarcinoma (validation): 206/207 (99.5%),breast cancer: 12/12 (100.0%); endometrial cancer: 12/12 (100.0%),31,20,Q6ZT21,https://www.uniprot.org/uniprotkb/Q6ZT21/entry,,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
TMPRSS11F,ENSG00000198092,Unsafe,RNA,False,True,4.7,14.7,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,esophagus: 14.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 9 nTPM; continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,esophagus: 14.7 nTPM (limit 6); esophagus: 14.7 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Head and Neck Squamous Cell Carcinoma (TCGA): 93/492 (18.9%); Lung Squamous Cell Carcinoma (validation): 12/68 (17.6%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 38/283 (13.4%),prostate cancer: 11/12 (91.7%); breast cancer: 9/12 (75.0%),31,20,Q6ZWK6,https://www.uniprot.org/uniprotkb/Q6ZWK6/entry,Probable serine protease,,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
TMPRSS9,ENSG00000178297,Unsafe,RNA,False,True,3.6,4.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,liver: 4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 2.3 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,liver: 4 nTPM (limit 2); liver: 4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (validation): 39/231 (16.9%); Liver Hepatocellular Carcinoma (TCGA): 36/362 (9.9%); Skin Cuteneous Melanoma (TCGA): 8/99 (8.1%),melanoma: 10/12 (83.3%); endometrial cancer: 2/11 (18.2%),31,20,Q7Z410,https://www.uniprot.org/uniprotkb/Q7Z410/entry,"Serase-1 and serase-2 are serine proteases that hydrolyze the peptides N-t-Boc-Gln-Ala-Arg-AMC and N-t-Boc-Gln-Gly-Arg-AMC. In contrast, N-t-Boc-Ala-Phe-Lys-AMC and N-t-Boc-Ala-Pro-Ala-AMC are not significantly hydrolyzed","Expressed in fetal human tissues, such as kidney, liver, lung and brain, and in a variety of tumor cell lines. Weakly expressed in adult tissues including skeletal muscle, liver, placenta and heart",,,Cell membrane,,12886014,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
TNFSF11,ENSG00000120659,Unsafe,Protein,False,True,2.7,12.0,81,6,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 0.2 nTPM; positive ihc; liver: 4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 12 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; rectum: 1.7 nTPM; continuous selectivity; small intestine: 1.6 nTPM; continuous selectivity; spleen: 0.4 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",lymph node: 12 nTPM (limit 6); liver: 4 nTPM (baseline 2); lymph node: 12 nTPM (baseline 6),bone marrow / hematopoietic cells: Medium (Enhanced); lymph node / germinal center cells: Medium (Enhanced); lymph node / non-germinal center cells: Medium (Enhanced); spleen / cells in red pulp: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 45/80 (56.2%); Rectum Adenocarcinoma (validation): 110/207 (53.1%); Colon Adenocarcinoma (validation): 206/486 (42.4%),skin cancer: 1/10 (10.0%); endometrial cancer: 1/12 (8.3%),31,20,O14788,https://www.uniprot.org/uniprotkb/O14788/entry,"Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy (PubMed:22664871). Induces osteoclastogenesis by activating multiple signaling pathways in osteoclast precursor cells, chief among which is induction of long lasting oscillations in the intracellular concentration of Ca (2+) resulting in the activation of NFATC1, which translocates to the nucleus and induces osteoclast-specific gene transcription to allow differentiation of osteoclasts. During osteoclast differentiation, in a TMEM64 and ATP2A2-dependent manner induces activation of CREB1 and mitochondrial ROS generation necessary for proper osteoclast generation (By similarity)","Highest in the peripheral lymph nodes, weak in spleen, peripheral blood Leukocytes, bone marrow, heart, placenta, skeletal muscle, stomach and thyroid","Osteopetrosis, autosomal recessive 2: A rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. Osteopetrosis occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. Recessive osteopetrosis commonly manifests in early infancy with macrocephaly, feeding difficulties, evolving blindness and deafness, bone marrow failure, severe anemia, and hepatosplenomegaly. Deafness and blindness are generally thought to represent effects of pressure on nerves. OPTB2 is characterized by paucity of osteoclasts, suggesting a molecular defect in osteoclast development.",,Cell membrane Cytoplasm Secreted,22664871,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
TNFSF4,ENSG00000117586,Unsafe,Protein,False,True,3.8,3.8,93,62,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 1.9 nTPM; positive ihc;continuous selectivity; bone marrow: 0.5 nTPM; positive ihc; cerebellum: 1.9 nTPM; positive ihc;continuous selectivity; cerebral cortex: 0.9 nTPM; positive ihc; colon: 1 nTPM; positive ihc; duodenum: 0.3 nTPM; positive ihc; esophagus: 0.6 nTPM; positive ihc; heart muscle: 1 nTPM; positive ihc; kidney: 0.8 nTPM; positive ihc; liver: 0.9 nTPM; positive ihc; lung: 1.2 nTPM; positive ihc;continuous selectivity; lymph node: 2.2 nTPM; positive ihc;continuous selectivity; pancreas: 1.1 nTPM; positive ihc;continuous selectivity; pituitary gland: 1.5 nTPM; continuous selectivity; rectum: 1.2 nTPM; positive ihc; retina: 1.3 nTPM; continuous selectivity; salivary gland: 0.4 nTPM; positive ihc; skeletal muscle: 0.2 nTPM; positive ihc; skin: 0.3 nTPM; positive ihc; small intestine: 0.8 nTPM; positive ihc; smooth muscle: 0.8 nTPM; positive ihc; stomach: 0.7 nTPM; positive ihc; thymus: 3.6 nTPM; continuous selectivity; thyroid gland: 0.4 nTPM; positive ihc; urinary bladder: 1.4 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",,adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / ciliated cells (cell body): Medium (Approved); bronchus / ciliated cells (ciliary rootlets): Medium (Approved); bronchus / ciliated cells (tip of cilia): Medium (Approved); caudate / glial cells: Medium (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: High (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: High (Approved); heart muscle / cardiomyocytes: High (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Low (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / ciliated cells (cell body): Medium (Approved); nasopharynx / goblet cells: Medium (Approved); oral mucosa / squamous epithelial cells: High (Approved); pancreas / exocrine glandular cells: Low (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: High (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 2 / epidermal cells: High (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: High (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 37/50 (74.0%); Glioblastoma Multiforme (validation): 33/58 (56.9%); Pancreatic Adenocarcinoma (validation): 44/80 (55.0%),prostate cancer: 8/11 (72.7%); liver cancer: 7/12 (58.3%),31,20,P23510,https://www.uniprot.org/uniprotkb/P23510/entry,Cytokine that binds to TNFRSF4. Co-stimulates T-cell proliferation and cytokine production,,"Systemic lupus erythematosus: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.",,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
TNP1,ENSG00000118245,Unsafe,High RNA,False,True,5787.7,5787.7,84,2,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,CTA,Pass,oncoref.target-sets.2026-10-23.1,False,False,,CTA → Unsafe,True,True,True,1.8023859866900005,250.5,"hpa_single_cell_tissue: testis/macrophages, max 250.5 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,1.802 TPM; blood/CD8_STIM; dice_cd8_stim; vital,250.5 nTPM; testis/macrophages; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 12/133 (9.0%); Liver Hepatocellular Carcinoma (validation): 4/231 (1.7%); Lung Adenocarcinoma (validation): 1/105 (1.0%),breast cancer: 0/12 (0.0%); cervical cancer: 0/10 (0.0%),31,20,P09430,https://www.uniprot.org/uniprotkb/P09430/entry,"Plays a key role in the replacement of histones to protamine in the elongating spermatids of mammals. In condensing spermatids, loaded onto the nucleosomes, where it promotes the recruitment and processing of protamines, which are responsible for histone eviction",Expressed by spermatids (at protein level),,,Nucleus Chromosome,,9809674,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TOMM20L,ENSG00000196860,Unsafe,Protein,False,True,10.6,10.6,83,3,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; duodenum: 0 nTPM; positive ihc; small intestine: 0.3 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,duodenum / glandular cells: Low (Enhanced); small intestine / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Chromophobe (TCGA): 2/64 (3.1%); Kidney Renal Papillary Cell Carcinoma (TCGA): 4/282 (1.4%); Pancreatic Adenocarcinoma (validation): 1/80 (1.2%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q6UXN7,https://www.uniprot.org/uniprotkb/Q6UXN7/entry,,,,,Mitochondrion outer membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
TOP2A,ENSG00000131747,Unsafe,Protein,False,True,63.8,124.5,108,47,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 2.5 nTPM; positive ihc;absolute ceiling; bone marrow: 41.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 17.2 nTPM; positive ihc;absolute ceiling; duodenum: 17.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 28.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 3.9 nTPM; positive ihc;absolute ceiling; lymph node: 39.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 0.3 nTPM; positive ihc; rectum: 19.1 nTPM; positive ihc;absolute ceiling; skin: 14.9 nTPM; positive ihc;absolute ceiling; small intestine: 16.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; spleen: 9.6 nTPM; positive ihc; stomach: 8.6 nTPM; positive ihc;absolute ceiling; thymus: 124.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 5.8 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 2.5 nTPM (limit 2); bone marrow: 41.5 nTPM (limit 2); colon: 17.2 nTPM (limit 6); duodenum: 17.6 nTPM (limit 2); esophagus: 28.2 nTPM (limit 6); lung: 3.9 nTPM (limit 2); lymph node: 39.4 nTPM (limit 6); rectum: 19.1 nTPM (limit 6); skin: 14.9 nTPM (limit 10); small intestine: 16.5 nTPM (limit 2); stomach: 8.6 nTPM (limit 6); thymus: 124.5 nTPM (limit 10),adrenal gland / glandular cells: Low (Enhanced); bone marrow / hematopoietic cells: High (Enhanced); bronchus / respiratory epithelial cells: Low (Enhanced); colon / glandular cells: Medium (Enhanced); duodenum / glandular cells: Medium (Enhanced); esophagus / squamous epithelial cells: Medium (Enhanced); lung / alveolar cells: Low (Enhanced); lymph node / germinal center cells: High (Enhanced); lymph node / non-germinal center cells: Medium (Enhanced); nasopharynx / respiratory epithelial cells: Low (Enhanced); oral mucosa / squamous epithelial cells: Medium (Enhanced); parathyroid gland / glandular cells: Low (Enhanced); rectum / glandular cells: Medium (Enhanced); skin 1 / cells in basal layer: Medium (Enhanced); skin 2 / cells in basal layer: High (Enhanced); skin 2 / cells in spinous layer: Medium (Enhanced); skin 2 / fibrohistiocytic cells: Medium (Enhanced); small intestine / glandular cells: Medium (Enhanced); spleen / cells in red pulp: Medium (Enhanced); spleen / cells in white pulp: Medium (Enhanced); stomach 1 / glandular cells: Medium (Enhanced); stomach 2 / glandular cells: Medium (Enhanced); urinary bladder / urothelial cells: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 283/283 (100.0%); Colon Adenocarcinoma (TCGA): 254/254 (100.0%),colorectal cancer: 12/12 (100.0%); lymphoma: 12/12 (100.0%),31,20,P11388,https://www.uniprot.org/uniprotkb/P11388/entry,"Key decatenating enzyme that alters DNA topology by binding to two double-stranded DNA molecules, generating a double-stranded break in one of the strands, passing the intact strand through the broken strand, and religating the broken strand (PubMed:17567603, PubMed:18790802, PubMed:22013166, PubMed:22323612, PubMed:27754753). May play a role in regulating the period length of BMAL1 transcriptional oscillation (By similarity)","Expressed in the tonsil, spleen, lymph node, thymus, skin, pancreas, testis, colon, kidney, liver, brain and lung (PubMed:9155056). Also found in high-grade lymphomas, squamous cell lung tumors and seminomas (PubMed:9155056)",,,"Cytoplasm Nucleus, nucleoplasm Nucleus Nucleus, nucleolus",17567603|18790802|22013166|22323612|27754753,9155056,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
TPK1,ENSG00000196511,Unsafe,Protein,False,True,5.0,13.6,85,68,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 4.1 nTPM; positive ihc;continuous selectivity; adrenal gland: 3.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 2.2 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 2 nTPM; continuous selectivity; bone marrow: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 1.7 nTPM; positive ihc;continuous selectivity; cerebral cortex: 3.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 4.7 nTPM; absolute ceiling;continuous selectivity; colon: 6.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 13.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 1.8 nTPM; positive ihc;continuous selectivity; heart muscle: 3.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 2 nTPM; continuous selectivity; hypothalamus: 2.7 nTPM; absolute ceiling;continuous selectivity; kidney: 3.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 4.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 4.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 5.6 nTPM; positive ihc;continuous selectivity;reproductive not higher; midbrain: 2.2 nTPM; absolute ceiling;continuous selectivity; pancreas: 1.9 nTPM; positive ihc;continuous selectivity; parathyroid gland: 1.7 nTPM; positive ihc; pituitary gland: 1.4 nTPM; continuous selectivity; rectum: 5.8 nTPM; positive ihc;continuous selectivity;reproductive not higher; retina: 2.2 nTPM; absolute ceiling;continuous selectivity; salivary gland: 3.5 nTPM; positive ihc;continuous selectivity; skeletal muscle: 1.6 nTPM; positive ihc;continuous selectivity; skin: 1.3 nTPM; positive ihc; small intestine: 7.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 3.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 2.4 nTPM; absolute ceiling;continuous selectivity; spleen: 7.7 nTPM; positive ihc;continuous selectivity;reproductive not higher; stomach: 2.1 nTPM; positive ihc;continuous selectivity; thymus: 2.7 nTPM; continuous selectivity; thyroid gland: 3 nTPM; positive ihc;continuous selectivity; tongue: 2.8 nTPM; continuous selectivity; urinary bladder: 3.9 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 3.3 nTPM (limit 2); amygdala: 2.2 nTPM (limit 2); bone marrow: 2.7 nTPM (limit 2); cerebral cortex: 3.3 nTPM (limit 2); choroid plexus: 4.7 nTPM (limit 2); colon: 6.1 nTPM (limit 6); duodenum: 13.6 nTPM (limit 2); heart muscle: 3.1 nTPM (limit 2); hypothalamus: 2.7 nTPM (limit 2); kidney: 3.8 nTPM (limit 2); liver: 4.2 nTPM (limit 2); lung: 4.9 nTPM (limit 2); midbrain: 2.2 nTPM (limit 2); retina: 2.2 nTPM (limit 2); small intestine: 7.2 nTPM (limit 2); smooth muscle: 3.4 nTPM (limit 2); spinal cord: 2.4 nTPM (limit 2),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: High (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / macrophages: Low (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: High (Approved); skin 1 / fibroblasts: Low (Approved); skin 1 / keratinocytes: Low (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in red pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Renal Clear Cell Carcinoma (validation): 93/100 (93.0%); Kidney Renal Papillary Cell Carcinoma (TCGA): 255/282 (90.4%); Breast Invasive Carcinoma (validation): 45/50 (90.0%),prostate cancer: 11/11 (100.0%); breast cancer: 10/11 (90.9%),31,20,Q9H3S4,https://www.uniprot.org/uniprotkb/Q9H3S4/entry,"Catalyzes the phosphorylation of thiamine to thiamine pyrophosphate (TPP) utilizing UTP and therefore links the biosynthesis of TPP to pyrimidines metabolism (PubMed:38547260). By producing thiamine pyrophosphate, a cofactor of the mitochondrial pyruvate dehydrogenase indirectly regulates pyruvate oxidation and lipogenesis (PubMed:38547260). Although it can also catalyze thiamine phosphorylation using ATP and CTP in vitro, it does so with significantly lower efficiency and without physiological relevance evidence (PubMed:11342111, PubMed:38547260)","Detected in heart, kidney, testis, small intestine and peripheral blood leukocytes, and at very low levels in a variety of tissues","Thiamine metabolism dysfunction syndrome 5, episodic encephalopathy type: An autosomal recessive metabolic disorder due to an inborn error of thiamine metabolism. The phenotype is highly variable, but in general, affected individuals have onset in early childhood of acute encephalopathic episodes associated with increased serum and CSF lactate. These episodes result in progressive neurologic dysfunction manifest as gait disturbances, ataxia, dystonia, and spasticity, which in some cases may result in loss of ability to walk. Cognitive function is usually preserved, although mildly delayed development has been reported. These episodes are usually associated with infection and metabolic decompensation. Some patients may have recovery of some neurologic deficits.",,,11342111|38547260,11342111|11342117,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
TPPP2,ENSG00000179636,Unsafe,Protein,False,True,247.7,247.7,85,6,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; liver: 12.8 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",liver: 12.8 nTPM (limit 12),bronchus / respiratory epithelial cells: Medium (Enhanced); nasopharynx / respiratory epithelial cells: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (validation): 26/231 (11.3%); Liver Hepatocellular Carcinoma (TCGA): 19/362 (5.2%); Kidney Chromophobe (TCGA): 2/64 (3.1%),breast cancer: 0/12 (0.0%); cervical cancer: 0/9 (0.0%),31,20,P59282,https://www.uniprot.org/uniprotkb/P59282/entry,"Probable regulator of microtubule dynamics required for sperm motility (Probable). In contrast to other members of the family, has no microtubule bundling activity (PubMed:17105200)",Expressed in spermatids (PubMed:23436708). Detected in liver cancer (at protein level) (PubMed:23436708),,,"Cytoplasm, cytosol Cell projection, cilium, flagellum",17105200|30680919,23436708,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TPX2,ENSG00000088325,Unsafe,Protein,False,True,29.8,68.5,81,54,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 1.4 nTPM; positive ihc; bone marrow: 47.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 1.1 nTPM; positive ihc; cerebral cortex: 1.8 nTPM; positive ihc; colon: 11.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 9.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 12.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; kidney: 0.7 nTPM; positive ihc; liver: 4.1 nTPM; positive ihc;absolute ceiling; lung: 1.9 nTPM; positive ihc; lymph node: 25.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; pancreas: 0.4 nTPM; positive ihc; parathyroid gland: 0.4 nTPM; positive ihc; rectum: 13.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 1.3 nTPM; positive ihc; skin: 9.6 nTPM; positive ihc; small intestine: 9.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 6.5 nTPM; positive ihc;absolute ceiling; stomach: 6 nTPM; positive ihc; thymus: 68.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 0.9 nTPM; positive ihc; urinary bladder: 3.3 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 47.4 nTPM (limit 2); colon: 11.3 nTPM (limit 6); duodenum: 9.2 nTPM (limit 2); esophagus: 12.8 nTPM (limit 6); liver: 4.1 nTPM (limit 2); lymph node: 25.9 nTPM (limit 6); rectum: 13.8 nTPM (limit 6); small intestine: 9.1 nTPM (limit 2); smooth muscle: 6.5 nTPM (limit 2); thymus: 68.5 nTPM (limit 10),adrenal gland / glandular cells: High (Enhanced); bone marrow / hematopoietic cells: High (Enhanced); bronchus / respiratory epithelial cells: Medium (Enhanced); caudate / glial cells: Low (Enhanced); caudate / neuronal cells: Medium (Enhanced); cerebellum / cells in molecular layer: Low (Enhanced); cerebellum / Purkinje cells: Medium (Enhanced); cerebral cortex / glial cells: Low (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); colon / glandular cells: Medium (Enhanced); duodenum / glandular cells: Medium (Enhanced); esophagus / squamous epithelial cells: Medium (Enhanced); hippocampus / glial cells: Low (Enhanced); hippocampus / neuronal cells: Medium (Enhanced); kidney / cells in tubules: Low (Enhanced); liver / cholangiocytes: Low (Enhanced); liver / hepatocytes: Low (Enhanced); lung / alveolar cells: Low (Enhanced); lung / macrophages: Medium (Enhanced); lymph node / germinal center cells: Low (Enhanced); nasopharynx / respiratory epithelial cells: Medium (Enhanced); oral mucosa / squamous epithelial cells: Medium (Enhanced); pancreas / pancreatic endocrine cells: Medium (Enhanced); parathyroid gland / glandular cells: Medium (Enhanced); rectum / glandular cells: Medium (Enhanced); skeletal muscle / myocytes: Low (Enhanced); skin 1 / keratinocytes: Medium (Enhanced); skin 2 / epidermal cells: Medium (Enhanced); small intestine / glandular cells: Low (Enhanced); smooth muscle / smooth muscle cells: Low (Enhanced); stomach 1 / glandular cells: High (Enhanced); stomach 2 / glandular cells: High (Enhanced); thyroid gland / glandular cells: Medium (Enhanced); urinary bladder / urothelial cells: Medium (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 283/283 (100.0%); Colon Adenocarcinoma (TCGA): 254/254 (100.0%),breast cancer: 11/11 (100.0%); cervical cancer: 11/11 (100.0%),31,20,Q9ULW0,https://www.uniprot.org/uniprotkb/Q9ULW0/entry,"Spindle assembly factor required for normal assembly of mitotic spindles. Required for normal assembly of microtubules during apoptosis. Required for chromatin and/or kinetochore dependent microtubule nucleation. Mediates AURKA localization to spindle microtubules (PubMed:18663142, PubMed:19208764, PubMed:37728657). Activates AURKA by promoting its autophosphorylation at 'Thr-288' and protects this residue against dephosphorylation (PubMed:18663142, PubMed:19208764). TPX2 is inactivated upon binding to importin-alpha (PubMed:26165940). At the onset of mitosis, GOLGA2 interacts with importin-alpha, liberating TPX2 from importin-alpha, allowing TPX2 to activate AURKA kinase and stimulate local microtubule nucleation (PubMed:26165940)",Expressed in lung carcinoma cell lines but not in normal lung tissues,,,"Nucleus Cytoplasm, cytoskeleton, spindle Cytoplasm, cytoskeleton, spindle pole",18663142|19208764|26165940,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
TRAPPC5,ENSG00000181029,Unsafe,Protein,False,True,176.4,176.4,80,43,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 57.1 nTPM; absolute ceiling; adrenal gland: 84.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 99.2 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 101.8 nTPM; absolute ceiling;continuous selectivity; bone marrow: 62.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 60.6 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 97 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 88 nTPM; absolute ceiling;continuous selectivity; colon: 51.4 nTPM; positive ihc;absolute ceiling; duodenum: 26.7 nTPM; positive ihc;absolute ceiling; esophagus: 83.2 nTPM; absolute ceiling;continuous selectivity; heart muscle: 101.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 97 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 85.2 nTPM; absolute ceiling;continuous selectivity; kidney: 73.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 97.2 nTPM; absolute ceiling;continuous selectivity; lung: 34.8 nTPM; positive ihc;absolute ceiling; lymph node: 22.8 nTPM; positive ihc;absolute ceiling; midbrain: 81 nTPM; absolute ceiling;continuous selectivity; pancreas: 65.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 19.1 nTPM; positive ihc;absolute ceiling; pituitary gland: 56.8 nTPM; absolute ceiling;continuous selectivity; rectum: 8.1 nTPM; positive ihc;absolute ceiling; retina: 8.7 nTPM; absolute ceiling; salivary gland: 62.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 108.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 87.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 47.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 11.2 nTPM; absolute ceiling; spinal cord: 63.7 nTPM; absolute ceiling;continuous selectivity; spleen: 59.1 nTPM; positive ihc;absolute ceiling; stomach: 55.9 nTPM; positive ihc;absolute ceiling; thymus: 16.3 nTPM; absolute ceiling; thyroid gland: 54.3 nTPM; positive ihc;absolute ceiling; tongue: 26.1 nTPM; absolute ceiling; urinary bladder: 53.7 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 57.1 nTPM (limit 10); adrenal gland: 84.1 nTPM (limit 2); amygdala: 99.2 nTPM (limit 2); basal ganglia: 101.8 nTPM (limit 2); bone marrow: 62.3 nTPM (limit 2); cerebellum: 60.6 nTPM (limit 2); cerebral cortex: 97 nTPM (limit 2); choroid plexus: 88 nTPM (limit 2); colon: 51.4 nTPM (limit 6); duodenum: 26.7 nTPM (limit 2); esophagus: 83.2 nTPM (limit 6); heart muscle: 101.8 nTPM (limit 2); hippocampal formation: 97 nTPM (limit 2); hypothalamus: 85.2 nTPM (limit 2); kidney: 73.6 nTPM (limit 2); liver: 97.2 nTPM (limit 2); lung: 34.8 nTPM (limit 2); lymph node: 22.8 nTPM (limit 6); midbrain: 81 nTPM (limit 2); pancreas: 65.2 nTPM (limit 2); parathyroid gland: 19.1 nTPM (limit 6); pituitary gland: 56.8 nTPM (limit 2); rectum: 8.1 nTPM (limit 6); retina: 8.7 nTPM (limit 2); salivary gland: 62.9 nTPM (limit 6); skeletal muscle: 108.4 nTPM (limit 2); skin: 87.8 nTPM (limit 10); small intestine: 47.2 nTPM (limit 2); smooth muscle: 11.2 nTPM (limit 2); spinal cord: 63.7 nTPM (limit 2); spleen: 59.1 nTPM (limit 10); stomach: 55.9 nTPM (limit 6); thymus: 16.3 nTPM (limit 10); thyroid gland: 54.3 nTPM (limit 10); tongue: 26.1 nTPM (limit 6); urinary bladder: 53.7 nTPM (limit 6); adipose tissue: 57.1 nTPM (baseline 10); adrenal gland: 84.1 nTPM (baseline 2); amygdala: 99.2 nTPM (baseline 2); basal ganglia: 101.8 nTPM (baseline 2); bone marrow: 62.3 nTPM (baseline 2); cerebellum: 60.6 nTPM (baseline 2); cerebral cortex: 97 nTPM (baseline 2); choroid plexus: 88 nTPM (baseline 2); colon: 51.4 nTPM (baseline 6); duodenum: 26.7 nTPM (baseline 2); esophagus: 83.2 nTPM (baseline 6); heart muscle: 101.8 nTPM (baseline 2); hippocampal formation: 97 nTPM (baseline 2); hypothalamus: 85.2 nTPM (baseline 2); kidney: 73.6 nTPM (baseline 2); liver: 97.2 nTPM (baseline 2); lung: 34.8 nTPM (baseline 2); lymph node: 22.8 nTPM (baseline 6); midbrain: 81 nTPM (baseline 2); pancreas: 65.2 nTPM (baseline 2); parathyroid gland: 19.1 nTPM (baseline 6); pituitary gland: 56.8 nTPM (baseline 2); rectum: 8.1 nTPM (baseline 6); retina: 8.7 nTPM (baseline 2); salivary gland: 62.9 nTPM (baseline 6); skeletal muscle: 108.4 nTPM (baseline 2); skin: 87.8 nTPM (baseline 10); small intestine: 47.2 nTPM (baseline 2); smooth muscle: 11.2 nTPM (baseline 2); spinal cord: 63.7 nTPM (baseline 2); spleen: 59.1 nTPM (baseline 10); stomach: 55.9 nTPM (baseline 6); thymus: 16.3 nTPM (baseline 10); thyroid gland: 54.3 nTPM (baseline 10); tongue: 26.1 nTPM (baseline 6); urinary bladder: 53.7 nTPM (baseline 6),adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Low (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); colon / glandular cells: Low (Uncertain); duodenum / glandular cells: Medium (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / neuronal cells: Low (Uncertain); kidney / cells in tubules: Low (Uncertain); lung / alveolar cells: Low (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / germinal center cells: Low (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); nasopharynx / respiratory epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); parathyroid gland / glandular cells: Low (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: Medium (Uncertain); skin 2 / epidermal cells: Low (Uncertain); small intestine / glandular cells: Medium (Uncertain); spleen / cells in red pulp: Low (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%); Thyroid Carcinoma (TCGA): 495/495 (100.0%),colorectal cancer: 10/11 (90.9%); endometrial cancer: 10/12 (83.3%),31,20,Q8IUR0,https://www.uniprot.org/uniprotkb/Q8IUR0/entry,May play a role in vesicular transport from endoplasmic reticulum to Golgi,,,,"Golgi apparatus, cis-Golgi network Endoplasmic reticulum",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
TRAPPC9,ENSG00000167632,Unsafe,RNA,False,True,11.8,32.4,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 8.3 nTPM; continuous selectivity; adrenal gland: 13 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 11.5 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 13.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 11 nTPM; absolute ceiling;continuous selectivity; cerebellum: 15.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 18.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 12.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 10.8 nTPM; absolute ceiling;continuous selectivity; duodenum: 7.8 nTPM; absolute ceiling;continuous selectivity; esophagus: 12 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 14.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 11.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 11.6 nTPM; absolute ceiling;continuous selectivity; kidney: 13.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; liver: 11.3 nTPM; absolute ceiling;continuous selectivity; lung: 9.2 nTPM; absolute ceiling;continuous selectivity; lymph node: 7.8 nTPM; absolute ceiling;continuous selectivity; midbrain: 13 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 11.5 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 26.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 20.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 5.8 nTPM; continuous selectivity; retina: 13.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 11.3 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 32.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 11 nTPM; absolute ceiling;continuous selectivity; small intestine: 10.5 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 6.9 nTPM; absolute ceiling;continuous selectivity; spinal cord: 13.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 11 nTPM; absolute ceiling;continuous selectivity; stomach: 12.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thymus: 11 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 12.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; tongue: 17 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 10.8 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 13 nTPM (limit 2); amygdala: 11.5 nTPM (limit 2); basal ganglia: 13.6 nTPM (limit 2); bone marrow: 11 nTPM (limit 2); cerebellum: 15.8 nTPM (limit 2); cerebral cortex: 18.7 nTPM (limit 2); choroid plexus: 12.1 nTPM (limit 2); colon: 10.8 nTPM (limit 6); duodenum: 7.8 nTPM (limit 2); esophagus: 12 nTPM (limit 6); heart muscle: 14.6 nTPM (limit 2); hippocampal formation: 11.8 nTPM (limit 2); hypothalamus: 11.6 nTPM (limit 2); kidney: 13.4 nTPM (limit 2); liver: 11.3 nTPM (limit 2); lung: 9.2 nTPM (limit 2); lymph node: 7.8 nTPM (limit 6); midbrain: 13 nTPM (limit 2); pancreas: 11.5 nTPM (limit 2); parathyroid gland: 26.5 nTPM (limit 6); pituitary gland: 20.2 nTPM (limit 2); retina: 13.8 nTPM (limit 2); salivary gland: 11.3 nTPM (limit 6); skeletal muscle: 32.4 nTPM (limit 2); skin: 11 nTPM (limit 10); small intestine: 10.5 nTPM (limit 2); smooth muscle: 6.9 nTPM (limit 2); spinal cord: 13.6 nTPM (limit 2); spleen: 11 nTPM (limit 10); stomach: 12.1 nTPM (limit 6); thymus: 11 nTPM (limit 10); thyroid gland: 12.5 nTPM (limit 10); tongue: 17 nTPM (limit 6); urinary bladder: 10.8 nTPM (limit 6); adrenal gland: 13 nTPM (baseline 2); amygdala: 11.5 nTPM (baseline 2); basal ganglia: 13.6 nTPM (baseline 2); bone marrow: 11 nTPM (baseline 2); cerebellum: 15.8 nTPM (baseline 2); cerebral cortex: 18.7 nTPM (baseline 2); choroid plexus: 12.1 nTPM (baseline 2); colon: 10.8 nTPM (baseline 6); duodenum: 7.8 nTPM (baseline 2); esophagus: 12 nTPM (baseline 6); heart muscle: 14.6 nTPM (baseline 2); hippocampal formation: 11.8 nTPM (baseline 2); hypothalamus: 11.6 nTPM (baseline 2); kidney: 13.4 nTPM (baseline 2); liver: 11.3 nTPM (baseline 2); lung: 9.2 nTPM (baseline 2); lymph node: 7.8 nTPM (baseline 6); midbrain: 13 nTPM (baseline 2); pancreas: 11.5 nTPM (baseline 2); parathyroid gland: 26.5 nTPM (baseline 6); pituitary gland: 20.2 nTPM (baseline 2); retina: 13.8 nTPM (baseline 2); salivary gland: 11.3 nTPM (baseline 6); skeletal muscle: 32.4 nTPM (baseline 2); skin: 11 nTPM (baseline 10); small intestine: 10.5 nTPM (baseline 2); smooth muscle: 6.9 nTPM (baseline 2); spinal cord: 13.6 nTPM (baseline 2); spleen: 11 nTPM (baseline 10); stomach: 12.1 nTPM (baseline 6); thymus: 11 nTPM (baseline 10); thyroid gland: 12.5 nTPM (baseline 10); tongue: 17 nTPM (baseline 6); urinary bladder: 10.8 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Prostate Adenocarcinoma (TCGA): 480/480 (100.0%); Colon Adenocarcinoma (TCGA): 254/254 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q96Q05,https://www.uniprot.org/uniprotkb/Q96Q05/entry,Functions as an activator of NF-kappa-B through increased phosphorylation of the IKK complex. May function in neuronal cells differentiation. May play a role in vesicular transport from endoplasmic reticulum to Golgi,"Expressed at high levels in muscle and kidney and to a lower extent in brain, heart and placenta","Intellectual developmental disorder, autosomal recessive 13: A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. Brain magnetic resonance imaging of MRT13 patients indicates the presence of mild cerebral white matter hypoplasia. Microcephaly is present in some but not all affected individuals.",,"Golgi apparatus, cis-Golgi network Endoplasmic reticulum Cytoplasm",15951441,15951441,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
TRDMT1,ENSG00000107614,Unsafe,Protein,False,True,4.5,5.6,80,73,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 1.4 nTPM; positive ihc;continuous selectivity; bone marrow: 1.4 nTPM; positive ihc;continuous selectivity; cerebellum: 1.4 nTPM; positive ihc;continuous selectivity; cerebral cortex: 0.9 nTPM; positive ihc; choroid plexus: 1.3 nTPM; continuous selectivity; colon: 1.1 nTPM; positive ihc; duodenum: 0.8 nTPM; positive ihc; esophagus: 1.1 nTPM; positive ihc; heart muscle: 1.3 nTPM; positive ihc;continuous selectivity; kidney: 2 nTPM; positive ihc;continuous selectivity; liver: 0.7 nTPM; positive ihc; lung: 1.4 nTPM; positive ihc;continuous selectivity; lymph node: 2.1 nTPM; positive ihc;continuous selectivity; pancreas: 1.4 nTPM; positive ihc;continuous selectivity; parathyroid gland: 2.5 nTPM; positive ihc;continuous selectivity; pituitary gland: 1.3 nTPM; continuous selectivity; rectum: 0.9 nTPM; positive ihc; retina: 5.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 1.4 nTPM; positive ihc; skeletal muscle: 1.2 nTPM; positive ihc; skin: 1.5 nTPM; positive ihc; small intestine: 1.3 nTPM; positive ihc;continuous selectivity; smooth muscle: 1.1 nTPM; positive ihc; spinal cord: 1.3 nTPM; continuous selectivity; spleen: 1.3 nTPM; positive ihc; stomach: 1.5 nTPM; positive ihc; thymus: 3.2 nTPM; continuous selectivity; thyroid gland: 3.6 nTPM; positive ihc;continuous selectivity; urinary bladder: 1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",retina: 5.6 nTPM (limit 2),adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: High (Approved); colon / peripheral nerve/ganglion: High (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: High (Approved); heart muscle / cardiomyocytes: High (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: High (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: High (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: High (Approved); oral mucosa / squamous epithelial cells: High (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: High (Approved); skeletal muscle / myocytes: High (Approved); skin 1 / fibroblasts: High (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: High (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: High (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: High (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 54/58 (93.1%); Breast Invasive Carcinoma (validation): 43/50 (86.0%); Colon Adenocarcinoma (validation): 277/486 (57.0%),colorectal cancer: 12/12 (100.0%); endometrial cancer: 12/12 (100.0%),31,20,O14717,https://www.uniprot.org/uniprotkb/O14717/entry,Specifically methylates cytosine 38 in the anticodon loop of tRNA(Asp) (PubMed:16424344). Has higher activity on tRNA(Asp) modified with queuosine at position 34 (PubMed:30093495),"Ubiquitous. Higher expression in testis, ovary and thymus and at much lower levels in spleen, prostate, colon, small intestine, and peripheral blood leukocytes",,,Cytoplasm,16424344|30093495,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
TRIM16,ENSG00000221926,Unsafe,Protein,False,True,68.1,141.8,78,18,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 17.7 nTPM; absolute ceiling; adrenal gland: 31.6 nTPM; absolute ceiling;continuous selectivity; amygdala: 7.8 nTPM; absolute ceiling; basal ganglia: 9.2 nTPM; absolute ceiling; bone marrow: 17.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 5.1 nTPM; absolute ceiling; cerebral cortex: 7.9 nTPM; absolute ceiling; choroid plexus: 7.1 nTPM; absolute ceiling; colon: 13.6 nTPM; absolute ceiling; duodenum: 22.5 nTPM; absolute ceiling;continuous selectivity; esophagus: 141.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 22.3 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 7.3 nTPM; absolute ceiling; hypothalamus: 10.8 nTPM; absolute ceiling; kidney: 8.3 nTPM; positive ihc;absolute ceiling; liver: 5.8 nTPM; absolute ceiling; lung: 14.1 nTPM; absolute ceiling; lymph node: 9.8 nTPM; absolute ceiling; midbrain: 12.2 nTPM; absolute ceiling; pancreas: 5.9 nTPM; absolute ceiling; parathyroid gland: 3.8 nTPM; positive ihc; pituitary gland: 4.3 nTPM; absolute ceiling; rectum: 11.5 nTPM; absolute ceiling; retina: 4.5 nTPM; absolute ceiling; salivary gland: 36.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 35.5 nTPM; absolute ceiling;continuous selectivity; skin: 43.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 12.4 nTPM; absolute ceiling; smooth muscle: 9.6 nTPM; absolute ceiling; spinal cord: 14.8 nTPM; absolute ceiling; stomach: 32 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 10.1 nTPM; absolute ceiling; thyroid gland: 18.2 nTPM; positive ihc;absolute ceiling; tongue: 30.1 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 34.8 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 17.7 nTPM (limit 10); adrenal gland: 31.6 nTPM (limit 2); amygdala: 7.8 nTPM (limit 2); basal ganglia: 9.2 nTPM (limit 2); bone marrow: 17.8 nTPM (limit 2); cerebellum: 5.1 nTPM (limit 2); cerebral cortex: 7.9 nTPM (limit 2); choroid plexus: 7.1 nTPM (limit 2); colon: 13.6 nTPM (limit 6); duodenum: 22.5 nTPM (limit 2); esophagus: 141.8 nTPM (limit 6); heart muscle: 22.3 nTPM (limit 2); hippocampal formation: 7.3 nTPM (limit 2); hypothalamus: 10.8 nTPM (limit 2); kidney: 8.3 nTPM (limit 2); liver: 5.8 nTPM (limit 2); lung: 14.1 nTPM (limit 2); lymph node: 9.8 nTPM (limit 6); midbrain: 12.2 nTPM (limit 2); pancreas: 5.9 nTPM (limit 2); pituitary gland: 4.3 nTPM (limit 2); rectum: 11.5 nTPM (limit 6); retina: 4.5 nTPM (limit 2); salivary gland: 36.9 nTPM (limit 6); skeletal muscle: 35.5 nTPM (limit 2); skin: 43.5 nTPM (limit 10); small intestine: 12.4 nTPM (limit 2); smooth muscle: 9.6 nTPM (limit 2); spinal cord: 14.8 nTPM (limit 2); stomach: 32 nTPM (limit 6); thymus: 10.1 nTPM (limit 10); thyroid gland: 18.2 nTPM (limit 10); tongue: 30.1 nTPM (limit 6); urinary bladder: 34.8 nTPM (limit 6); adipose tissue: 17.7 nTPM (baseline 10); adrenal gland: 31.6 nTPM (baseline 2); amygdala: 7.8 nTPM (baseline 2); basal ganglia: 9.2 nTPM (baseline 2); bone marrow: 17.8 nTPM (baseline 2); cerebellum: 5.1 nTPM (baseline 2); cerebral cortex: 7.9 nTPM (baseline 2); choroid plexus: 7.1 nTPM (baseline 2); colon: 13.6 nTPM (baseline 6); duodenum: 22.5 nTPM (baseline 2); esophagus: 141.8 nTPM (baseline 6); heart muscle: 22.3 nTPM (baseline 2); hippocampal formation: 7.3 nTPM (baseline 2); hypothalamus: 10.8 nTPM (baseline 2); kidney: 8.3 nTPM (baseline 2); liver: 5.8 nTPM (baseline 2); lung: 14.1 nTPM (baseline 2); lymph node: 9.8 nTPM (baseline 6); midbrain: 12.2 nTPM (baseline 2); pancreas: 5.9 nTPM (baseline 2); pituitary gland: 4.3 nTPM (baseline 2); rectum: 11.5 nTPM (baseline 6); retina: 4.5 nTPM (baseline 2); salivary gland: 36.9 nTPM (baseline 6); skeletal muscle: 35.5 nTPM (baseline 2); skin: 43.5 nTPM (baseline 10); small intestine: 12.4 nTPM (baseline 2); smooth muscle: 9.6 nTPM (baseline 2); spinal cord: 14.8 nTPM (baseline 2); stomach: 32 nTPM (baseline 6); thymus: 10.1 nTPM (baseline 10); thyroid gland: 18.2 nTPM (baseline 10); tongue: 30.1 nTPM (baseline 6); urinary bladder: 34.8 nTPM (baseline 6),bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Low (Uncertain); esophagus / squamous epithelial cells: High (Uncertain); kidney / cells in tubules: Medium (Uncertain); oral mucosa / squamous epithelial cells: Low (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Low (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); stomach 2 / glandular cells: Low (Uncertain); thyroid gland / glandular cells: Low (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (TCGA): 141/141 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%),cervical cancer: 12/12 (100.0%); colorectal cancer: 12/12 (100.0%),31,20,O95361,https://www.uniprot.org/uniprotkb/O95361/entry,"E3 ubiquitin-protein ligase that plays an essential role in the organization of autophagic response and ubiquitination upon lysosomal and phagosomal damages (PubMed:22629402, PubMed:27693506). Plays a role in the stress-induced biogenesis and degradation of protein aggresomes by regulating the p62-KEAP1-NRF2 signaling and particularly by modulating the ubiquitination levels and thus stability of NRF2 (PubMed:30143514). Acts as a scaffold protein and facilitates autophagic degradation of protein aggregates by interacting with p62/SQSTM, ATG16L1 and LC3B/MAP1LC3B. In turn, protects the cell against oxidative stress-induced cell death as a consequence of endomembrane damage","Highest levels found in testis, ovary, small intestine, colon, placenta, heart, skeletal muscle and mammary gland. More highly expressed in the fetus than in the corresponding adult tissues. Expressed in basal keratinocytes",,,Cytoplasm,22629402|27693506|30143514,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
TRIM17,ENSG00000162931,Unsafe,Protein,False,True,40.8,46.1,83,56,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 1.2 nTPM; positive ihc; amygdala: 4.9 nTPM; absolute ceiling; basal ganglia: 21.9 nTPM; absolute ceiling;continuous selectivity; cerebellum: 46.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 15.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 0.6 nTPM; positive ihc; duodenum: 0.2 nTPM; positive ihc; esophagus: 1.9 nTPM; positive ihc; heart muscle: 1.7 nTPM; positive ihc; hippocampal formation: 8.3 nTPM; absolute ceiling; hypothalamus: 5.7 nTPM; absolute ceiling; kidney: 2.9 nTPM; positive ihc;absolute ceiling; lung: 1.4 nTPM; positive ihc; lymph node: 0.6 nTPM; positive ihc; pancreas: 0.6 nTPM; positive ihc; pituitary gland: 2.1 nTPM; absolute ceiling; rectum: 0 nTPM; positive ihc; salivary gland: 4.5 nTPM; positive ihc; skeletal muscle: 0.1 nTPM; positive ihc; skin: 2.1 nTPM; positive ihc; small intestine: 1 nTPM; positive ihc; stomach: 0.9 nTPM; positive ihc; thyroid gland: 3.1 nTPM; positive ihc; urinary bladder: 1.6 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 4.9 nTPM (limit 2); basal ganglia: 21.9 nTPM (limit 2); cerebellum: 46.1 nTPM (limit 2); cerebral cortex: 15.1 nTPM (limit 2); hippocampal formation: 8.3 nTPM (limit 2); hypothalamus: 5.7 nTPM (limit 2); kidney: 2.9 nTPM (limit 2); pituitary gland: 2.1 nTPM (limit 2),adrenal gland / glandular cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / neuronal cells: Low (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Low (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Medium (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Low (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Ovary Serous Cystadenocarcinoma (validation): 51/81 (63.0%); Breast Invasive Carcinoma (validation): 27/50 (54.0%); Ovary Serous Cystadenocarcinoma (TCGA): 145/349 (41.5%),prostate cancer: 9/9 (100.0%); breast cancer: 10/11 (90.9%),31,20,Q9Y577,https://www.uniprot.org/uniprotkb/Q9Y577/entry,"E3 ubiquitin ligase that plays important roles in the regulation of neuronal apoptosis, selective autophagy or cell proliferation (PubMed:19358823, PubMed:22023800, PubMed:27562068). Stimulates the degradation of kinetochore ZW10 interacting protein ZWINT in a proteasome-dependent manner, leading to negative regulation of cell proliferation (PubMed:22023800). Inhibits autophagic degradation of diverse known targets while contributing to autophagy of midbodies. Autophagy-inhibitory activity involves MCL1, which TRIM17 assembles into complexes with the key autophagy regulator BECN1 (PubMed:27562068). Controls neuronal apoptosis by mediating ubiquitination and degradation of MCL1 to initiate neuronal death. In addition, regulates NFAT transcription factors NFATC3 and NFATC4 activities by preventing their nuclear localization, thus inhibiting their transcriptional activities. Decreases TRIM41-mediated degradation of ZSCAN2 thereby stimulating alpha-synuclein/SNCA transcription in neuronal cells (By similarity). Prevents the E3 ubiquitin-ligase activity of TRIM28 and its interaction with anti-apoptotic BCL2A1, blocking TRIM28 from ubiquitinating BCL2A1 (PubMed:19358823)",Almost exclusively in the testis,,,Cytoplasm Lysosome,19358823|22023800|27562068,19358823,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
TRIM36,ENSG00000152503,Unsafe,RNA,False,True,169.2,169.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 10.9 nTPM; absolute ceiling; basal ganglia: 4.7 nTPM; absolute ceiling; cerebral cortex: 15.8 nTPM; absolute ceiling; choroid plexus: 14.4 nTPM; absolute ceiling; colon: 7.2 nTPM; absolute ceiling; duodenum: 13.7 nTPM; absolute ceiling; hippocampal formation: 13 nTPM; absolute ceiling; hypothalamus: 13.1 nTPM; absolute ceiling; midbrain: 12.2 nTPM; absolute ceiling; pituitary gland: 13 nTPM; absolute ceiling; rectum: 7.3 nTPM; absolute ceiling; retina: 42.9 nTPM; absolute ceiling;continuous selectivity; small intestine: 13.4 nTPM; absolute ceiling; spinal cord: 16.8 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 10.9 nTPM (limit 2); basal ganglia: 4.7 nTPM (limit 2); cerebral cortex: 15.8 nTPM (limit 2); choroid plexus: 14.4 nTPM (limit 2); colon: 7.2 nTPM (limit 6); duodenum: 13.7 nTPM (limit 2); hippocampal formation: 13 nTPM (limit 2); hypothalamus: 13.1 nTPM (limit 2); midbrain: 12.2 nTPM (limit 2); pituitary gland: 13 nTPM (limit 2); rectum: 7.3 nTPM (limit 6); retina: 42.9 nTPM (limit 2); small intestine: 13.4 nTPM (limit 2); spinal cord: 16.8 nTPM (limit 2); amygdala: 10.9 nTPM (baseline 2); basal ganglia: 4.7 nTPM (baseline 2); cerebral cortex: 15.8 nTPM (baseline 2); choroid plexus: 14.4 nTPM (baseline 2); colon: 7.2 nTPM (baseline 6); duodenum: 13.7 nTPM (baseline 2); hippocampal formation: 13 nTPM (baseline 2); hypothalamus: 13.1 nTPM (baseline 2); midbrain: 12.2 nTPM (baseline 2); pituitary gland: 13 nTPM (baseline 2); rectum: 7.3 nTPM (baseline 6); retina: 42.9 nTPM (baseline 2); small intestine: 13.4 nTPM (baseline 2); spinal cord: 16.8 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Prostate Adenocarcinoma (TCGA): 476/480 (99.2%); Glioblastoma Multiforme (validation): 57/58 (98.3%); Glioblastoma Multiforme (TCGA): 118/141 (83.7%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9NQ86,https://www.uniprot.org/uniprotkb/Q9NQ86/entry,"E3 ubiquitin-protein ligase which mediates ubiquitination and subsequent proteasomal degradation of target proteins including CTNNB1, FOXA2 and AKT1 (PubMed:35768649, PubMed:37875418, PubMed:41323265). Involved in chromosome segregation and cell cycle regulation (PubMed:28087737). May play a role in the acrosome reaction and fertilization. Inhibits lung fibroblast proliferation, migration, and differentiation. Mechanistically, mediates 'Lys-48'-linked polyubiquitination of phospho-AKT1, leading to its proteasomal degradation and consequent inhibition of AKT signaling (PubMed:41323265). Promotes apoptosis via inhibition of the Wnt/beta-catenin signaling pathway (PubMed:35768649). Regulates ferroptosis by ubiquitinating and degrading FOXA2 (PubMed:37875418)","Highly expressed in testis, prostate and brain (PubMed:15145053). Weakly expressed in kidney, lung and heart (PubMed:15145053). Expressed in fetal tissues (PubMed:28087737)","Anencephaly 1: An extreme form of neural tube defect resulting in the absence of brain tissues, and death in utero or perinatally. Infants are born with intact spinal cords, cerebellums, and brainstems, but lack formation of neural structures above this level. The skull is only partially formed. ANPH1 inheritance is autosomal recessive.",,"Cytoplasm Cytoplasmic vesicle, secretory vesicle, acrosome Cytoplasm, cytoskeleton",28087737|35768649|37875418|41323265,15145053|28087737,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
TRIM40,ENSG00000204614,Unsafe,RNA,False,True,1.4,2.9,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,colon: 2 nTPM; continuous selectivity;reproductive not higher; liver: 1.5 nTPM; continuous selectivity;reproductive not higher; small intestine: 2.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,small intestine: 2.9 nTPM (limit 2); small intestine: 2.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (validation): 6/231 (2.6%); Colon Adenocarcinoma (validation): 6/486 (1.2%); Rectum Adenocarcinoma (validation): 2/207 (1.0%),testis cancer: 9/12 (75.0%); prostate cancer: 8/12 (66.7%),31,20,Q6P9F5,https://www.uniprot.org/uniprotkb/Q6P9F5/entry,"E3 ubiquitin-protein ligase that plays a role in the limitation of the innate immune response (PubMed:21474709, PubMed:29117565). Mediates inhibition of the RLR signaling pathway by ubiquitinating RIGI and IFIH1 receptors, leading to their proteasomal degradation (PubMed:21474709). Also promotes the neddylation of IKBKG/NEMO, stabilizing NFKBIA, and thereby inhibiting of NF-kappa-B nuclear translocation and activation (PubMed:21474709)",Highly expressed in normal gastrointestinal epithelia but that is down-regulated in gastrointestinal carcinomas and chronic inflammatory lesions of the gastrointestinal tract,,,,21474709|29117565,21474709,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Gong2021_reproductive_PC,No tumor-antigen validation in this source | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TRIM49D2,ENSG00000233802,Unsafe,High RNA,False,True,0.1,0.1,0,0,Missing,False,False,False,False,Excluded,Reproductive,False,,Not assessed,,,existing nomination or manual review; nomination unresolved,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,hpa_immune_cell basophil: 32 nTPM; hpa_immune_monaco basophil: 381 TPM,True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,381.0,57.7047,"hpa_immune_cell: blood/basophil, max 32 nTPM, 1 observations >30; hpa_immune_cell_samples: blood/basophil, max 53.8603 TPM, 2 observations >30; hpa_immune_cell_samples: blood/basophil, max 57.7047 nTPM, 2 observations >30; hpa_immune_monaco: blood/basophil, max 381 TPM, 1 observations >30",Neither,oncoref.target-sets.2026-10-23.2,381 TPM; blood/basophil; hpa_immune_monaco; vital,57.7 nTPM; blood/basophil; hpa_immune_cell_samples; vital,Prostate Adenocarcinoma (TCGA): 9/480 (1.9%); Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Ovary Serous Cystadenocarcinoma (TCGA): 1/349 (0.3%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,C9J1S8,https://www.uniprot.org/uniprotkb/C9J1S8/entry,,,,The two loci are in opposite orientation,,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required,,,,,,,,
TRIM59,ENSG00000213186,Unsafe,RNA,False,True,8.4,17.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 5 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 6.4 nTPM; absolute ceiling;continuous selectivity; bone marrow: 17 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 10.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 2.7 nTPM; absolute ceiling;continuous selectivity; esophagus: 4.7 nTPM; continuous selectivity; hippocampal formation: 8.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 4.2 nTPM; absolute ceiling;continuous selectivity; lymph node: 11.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 5.3 nTPM; continuous selectivity; small intestine: 2.8 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 2.7 nTPM; absolute ceiling;continuous selectivity; spinal cord: 10 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 5 nTPM; continuous selectivity; thymus: 13.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 3 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 5 nTPM (limit 2); basal ganglia: 6.4 nTPM (limit 2); bone marrow: 17 nTPM (limit 2); cerebral cortex: 10.4 nTPM (limit 2); duodenum: 2.7 nTPM (limit 2); hippocampal formation: 8.8 nTPM (limit 2); hypothalamus: 4.2 nTPM (limit 2); lymph node: 11.8 nTPM (limit 6); midbrain: 9 nTPM (limit 2); small intestine: 2.8 nTPM (limit 2); smooth muscle: 2.7 nTPM (limit 2); spinal cord: 10 nTPM (limit 2); thymus: 13.3 nTPM (limit 10); amygdala: 5 nTPM (baseline 2); basal ganglia: 6.4 nTPM (baseline 2); bone marrow: 17 nTPM (baseline 2); cerebral cortex: 10.4 nTPM (baseline 2); duodenum: 2.7 nTPM (baseline 2); hippocampal formation: 8.8 nTPM (baseline 2); hypothalamus: 4.2 nTPM (baseline 2); lymph node: 11.8 nTPM (baseline 6); midbrain: 9 nTPM (baseline 2); small intestine: 2.8 nTPM (baseline 2); smooth muscle: 2.7 nTPM (baseline 2); spinal cord: 10 nTPM (baseline 2); thymus: 13.3 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%); Colon Adenocarcinoma (validation): 485/486 (99.8%); Rectum Adenocarcinoma (validation): 206/207 (99.5%),prostate cancer: 12/12 (100.0%); urothelial cancer: 9/11 (81.8%),31,20,Q8IWR1,https://www.uniprot.org/uniprotkb/Q8IWR1/entry,"E3 ubiquitin ligase involved in different processes such as development and immune response (PubMed:22588174, PubMed:30231667). Serves as a negative regulator for innate immune signaling pathways by suppressing RLR-induced activation of IRF3/7 and NF-kappa-B via interaction with adapter ECSIT (PubMed:22588174). Regulates autophagy through modulating both the transcription and the ubiquitination of BECN1 (PubMed:30231667). On the one hand, regulates the transcription of BECN1 through negatively modulating the NF-kappa-B pathway. On the other hand, regulates TRAF6-mediated 'Lys-63'-linked ubiquitination of BECN1, thus affecting the formation of the BECN1-PIK3C3 complex. In addition, mediates 'Lys-48'-linked ubiquitination of TRAF6 and thereby promotes TRAF6 proteasomal degradation (PubMed:30231667). Also acts as a critical regulator for early embryo development from blastocyst stage to gastrula through modulating F-actin assembly and WASH1 'Lys-63'-linked ubiquitination (By similarity)",,,,Endoplasmic reticulum membrane,22588174|30231667,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
TRIP13,ENSG00000071539,Unsafe,High RNA,False,True,29.0,29.0,108,6,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE CD4_STIM (activated): 8/88 values ≥5 TPM, max 7.21408; DICE CD8_STIM (activated): 41/88 values ≥5 TPM, max 8.63936; hpa_immune_monaco Plasmablast: 7.4 TPM",True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,8.63935625216,88.8,"hpa_single_cell: /Ciliated cells, max 46.8 nTPM, 1 observations >30; hpa_single_cell_tissue: adipose tissue/t-cells, max 33.6 nTPM, 1 observations >30; hpa_single_cell_tissue: bone marrow/plasma cells, max 37.8 nTPM, 1 observations >30; hpa_single_cell_tissue: bronchus/ciliated cells, max 51.6 nTPM, 1 observations >30; hpa_single_cell_tissue: liver/erythroid cells, max 35 nTPM, 1 observations >30; hpa_single_cell_tissue: lung/ciliated cells, max 88.8 nTPM, 1 observations >30; hpa_single_cell_tissue: pancreas/fibroblasts, max 30.1 nTPM, 1 observations >30; hpa_single_cell_tissue: placenta/mixed immune cells, max 60.2 nTPM, 1 observations >30; hpa_single_cell_tissue: spleen/plasma cells, max 45.7 nTPM, 1 observations >30; hpa_single_cell_tissue: thymus/plasma cells, max 48.4 nTPM, 2 observations >30",CTA,oncoref.target-sets.2026-10-23.2,8.639 TPM; blood/CD8_STIM; dice_cd8_stim; vital,88.8 nTPM; lung/ciliated cells; hpa_single_cell_tissue; vital,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Colon Adenocarcinoma (validation): 482/486 (99.2%); Lung Squamous Cell Carcinoma (validation): 67/68 (98.5%),prostate cancer: 2/12 (16.7%); breast cancer: 1/12 (8.3%),31,20,Q15645,https://www.uniprot.org/uniprotkb/Q15645/entry,"Plays a key role in chromosome recombination and chromosome structure development during meiosis. Required at early steps in meiotic recombination that leads to non-crossovers pathways. Also needed for efficient completion of homologous synapsis by influencing crossover distribution along the chromosomes affecting both crossovers and non-crossovers pathways. Also required for development of higher-order chromosome structures and is needed for synaptonemal-complex formation. In males, required for efficient synapsis of the sex chromosomes and for sex body formation. Promotes early steps of the DNA double-strand breaks (DSBs) repair process upstream of the assembly of RAD51 complexes. Required for depletion of HORMAD1 and HORMAD2 from synapsed chromosomes (By similarity). Plays a role in mitotic spindle assembly checkpoint (SAC) activation (PubMed:28553959)",,"Mosaic variegated aneuploidy syndrome 3: A form of mosaic variegated aneuploidy syndrome, a severe disorder characterized by mosaic aneuploidies, predominantly trisomies and monosomies, involving multiple different chromosomes and tissues. Affected individuals typically present with severe intrauterine growth retardation and microcephaly. Eye anomalies, mild dysmorphism, variable developmental delay, and a broad spectrum of additional congenital abnormalities and medical conditions may also occur. The risk of malignancy is high, with rhabdomyosarcoma, Wilms tumor and leukemia reported in several cases. MVA3 inheritance is autosomal recessive. Oocyte/zygote/embryo maturation arrest 9: An autosomal recessive infertility disorder due to oocyte meiotic arrest at metaphase I. Abnormal zygotic cleavage has been observed in some patients.",,,28553959,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,Does its broader normal-cell expression permit a reproductive-restricted classification?,Resolve the documented non-permitted cell expression before any reproductive-restricted designation.,Tumor relevance and reproductive enrichment do not establish normal-cell restriction.,,,,,
TRIQK,ENSG00000205133,Unsafe,RNA,False,True,18.9,30.4,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 12.3 nTPM; absolute ceiling;continuous selectivity; adrenal gland: 21.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 12.3 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 14.8 nTPM; absolute ceiling;continuous selectivity; bone marrow: 14.3 nTPM; absolute ceiling;continuous selectivity; cerebellum: 15.7 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 17.6 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 8.1 nTPM; absolute ceiling;continuous selectivity; colon: 20 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 12 nTPM; absolute ceiling;continuous selectivity; esophagus: 9.5 nTPM; absolute ceiling;continuous selectivity; heart muscle: 19.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 11.7 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 11.6 nTPM; absolute ceiling;continuous selectivity; kidney: 18.7 nTPM; absolute ceiling;continuous selectivity; liver: 30.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 16.5 nTPM; absolute ceiling;continuous selectivity; midbrain: 11.4 nTPM; absolute ceiling;continuous selectivity; pancreas: 17.4 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 19.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 10.4 nTPM; absolute ceiling;continuous selectivity; rectum: 20.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; retina: 12 nTPM; absolute ceiling;continuous selectivity; salivary gland: 10.8 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 2.3 nTPM; absolute ceiling; small intestine: 11.8 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 11 nTPM; absolute ceiling;continuous selectivity; spinal cord: 15.6 nTPM; absolute ceiling;continuous selectivity; spleen: 12.8 nTPM; absolute ceiling;continuous selectivity; stomach: 17 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 22.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 14.9 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adipose tissue: 12.3 nTPM (limit 10); adrenal gland: 21.2 nTPM (limit 2); amygdala: 12.3 nTPM (limit 2); basal ganglia: 14.8 nTPM (limit 2); bone marrow: 14.3 nTPM (limit 2); cerebellum: 15.7 nTPM (limit 2); cerebral cortex: 17.6 nTPM (limit 2); choroid plexus: 8.1 nTPM (limit 2); colon: 20 nTPM (limit 6); duodenum: 12 nTPM (limit 2); esophagus: 9.5 nTPM (limit 6); heart muscle: 19.4 nTPM (limit 2); hippocampal formation: 11.7 nTPM (limit 2); hypothalamus: 11.6 nTPM (limit 2); kidney: 18.7 nTPM (limit 2); liver: 30.4 nTPM (limit 2); lung: 16.5 nTPM (limit 2); midbrain: 11.4 nTPM (limit 2); pancreas: 17.4 nTPM (limit 2); parathyroid gland: 19.9 nTPM (limit 6); pituitary gland: 10.4 nTPM (limit 2); rectum: 20.3 nTPM (limit 6); retina: 12 nTPM (limit 2); salivary gland: 10.8 nTPM (limit 6); skeletal muscle: 2.3 nTPM (limit 2); small intestine: 11.8 nTPM (limit 2); smooth muscle: 11 nTPM (limit 2); spinal cord: 15.6 nTPM (limit 2); spleen: 12.8 nTPM (limit 10); stomach: 17 nTPM (limit 6); thyroid gland: 22.7 nTPM (limit 10); urinary bladder: 14.9 nTPM (limit 6); adipose tissue: 12.3 nTPM (baseline 10); adrenal gland: 21.2 nTPM (baseline 2); amygdala: 12.3 nTPM (baseline 2); basal ganglia: 14.8 nTPM (baseline 2); bone marrow: 14.3 nTPM (baseline 2); cerebellum: 15.7 nTPM (baseline 2); cerebral cortex: 17.6 nTPM (baseline 2); choroid plexus: 8.1 nTPM (baseline 2); colon: 20 nTPM (baseline 6); duodenum: 12 nTPM (baseline 2); esophagus: 9.5 nTPM (baseline 6); heart muscle: 19.4 nTPM (baseline 2); hippocampal formation: 11.7 nTPM (baseline 2); hypothalamus: 11.6 nTPM (baseline 2); kidney: 18.7 nTPM (baseline 2); liver: 30.4 nTPM (baseline 2); lung: 16.5 nTPM (baseline 2); midbrain: 11.4 nTPM (baseline 2); pancreas: 17.4 nTPM (baseline 2); parathyroid gland: 19.9 nTPM (baseline 6); pituitary gland: 10.4 nTPM (baseline 2); rectum: 20.3 nTPM (baseline 6); retina: 12 nTPM (baseline 2); salivary gland: 10.8 nTPM (baseline 6); skeletal muscle: 2.3 nTPM (baseline 2); small intestine: 11.8 nTPM (baseline 2); smooth muscle: 11 nTPM (baseline 2); spinal cord: 15.6 nTPM (baseline 2); spleen: 12.8 nTPM (baseline 10); stomach: 17 nTPM (baseline 6); thyroid gland: 22.7 nTPM (baseline 10); urinary bladder: 14.9 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%); Kidney Renal Clear Cell Carcinoma (validation): 100/100 (100.0%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q629K1,https://www.uniprot.org/uniprotkb/Q629K1/entry,May play a role in cell growth and maintenance of cell morphology,,,,Endoplasmic reticulum membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
TRMT10A,ENSG00000145331,Unsafe,RNA,False,True,9.6,9.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 3.6 nTPM; absolute ceiling;continuous selectivity; amygdala: 2.2 nTPM; absolute ceiling; basal ganglia: 2.6 nTPM; absolute ceiling;continuous selectivity; bone marrow: 2.2 nTPM; absolute ceiling; cerebral cortex: 3.1 nTPM; absolute ceiling;continuous selectivity; colon: 3.5 nTPM; continuous selectivity; duodenum: 4.2 nTPM; absolute ceiling;continuous selectivity; esophagus: 3.5 nTPM; continuous selectivity; heart muscle: 2.2 nTPM; absolute ceiling; hippocampal formation: 2.3 nTPM; absolute ceiling; hypothalamus: 2.3 nTPM; absolute ceiling; kidney: 4.8 nTPM; absolute ceiling;continuous selectivity; liver: 9.5 nTPM; absolute ceiling;continuous selectivity; lung: 2.4 nTPM; absolute ceiling; lymph node: 4.3 nTPM; continuous selectivity; midbrain: 2.8 nTPM; absolute ceiling;continuous selectivity; pancreas: 5.7 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 3.6 nTPM; continuous selectivity; pituitary gland: 2.3 nTPM; absolute ceiling; rectum: 3.5 nTPM; continuous selectivity; retina: 2.7 nTPM; absolute ceiling;continuous selectivity; salivary gland: 3.8 nTPM; continuous selectivity; skeletal muscle: 3.8 nTPM; absolute ceiling;continuous selectivity; small intestine: 4.4 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 2.6 nTPM; absolute ceiling;continuous selectivity; spinal cord: 3.8 nTPM; absolute ceiling;continuous selectivity; stomach: 4.3 nTPM; continuous selectivity; thyroid gland: 5.9 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 3.6 nTPM (limit 2); amygdala: 2.2 nTPM (limit 2); basal ganglia: 2.6 nTPM (limit 2); bone marrow: 2.2 nTPM (limit 2); cerebral cortex: 3.1 nTPM (limit 2); duodenum: 4.2 nTPM (limit 2); heart muscle: 2.2 nTPM (limit 2); hippocampal formation: 2.3 nTPM (limit 2); hypothalamus: 2.3 nTPM (limit 2); kidney: 4.8 nTPM (limit 2); liver: 9.5 nTPM (limit 2); lung: 2.4 nTPM (limit 2); midbrain: 2.8 nTPM (limit 2); pancreas: 5.7 nTPM (limit 2); pituitary gland: 2.3 nTPM (limit 2); retina: 2.7 nTPM (limit 2); skeletal muscle: 3.8 nTPM (limit 2); small intestine: 4.4 nTPM (limit 2); smooth muscle: 2.6 nTPM (limit 2); spinal cord: 3.8 nTPM (limit 2); adrenal gland: 3.6 nTPM (baseline 2); amygdala: 2.2 nTPM (baseline 2); basal ganglia: 2.6 nTPM (baseline 2); bone marrow: 2.2 nTPM (baseline 2); cerebral cortex: 3.1 nTPM (baseline 2); duodenum: 4.2 nTPM (baseline 2); heart muscle: 2.2 nTPM (baseline 2); hippocampal formation: 2.3 nTPM (baseline 2); hypothalamus: 2.3 nTPM (baseline 2); kidney: 4.8 nTPM (baseline 2); liver: 9.5 nTPM (baseline 2); lung: 2.4 nTPM (baseline 2); midbrain: 2.8 nTPM (baseline 2); pancreas: 5.7 nTPM (baseline 2); pituitary gland: 2.3 nTPM (baseline 2); retina: 2.7 nTPM (baseline 2); skeletal muscle: 3.8 nTPM (baseline 2); small intestine: 4.4 nTPM (baseline 2); smooth muscle: 2.6 nTPM (baseline 2); spinal cord: 3.8 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Lung Adenocarcinoma (validation): 75/105 (71.4%); Pancreatic Adenocarcinoma (validation): 49/80 (61.3%),pancreatic cancer: 5/11 (45.5%); colorectal cancer: 5/12 (41.7%),29,20,Q8TBZ6,https://www.uniprot.org/uniprotkb/Q8TBZ6/entry,"S-adenosyl-L-methionine-dependent guanine N(1)-methyltransferase that catalyzes the formation of N(1)-methylguanine at position 9 (m1G9) in tRNAs (PubMed:23042678, PubMed:25053765). Probably not able to catalyze formation of N(1)-methyladenine at position 9 (m1A9) in tRNAs (PubMed:23042678)","Expressed in embryonic and fetal brain. It is expressed throughout the dorsal telencephalon at 8 and 11 weeks of gestation, with highest expression in ventricular zone and marginal zone. Detected in cerebellar cortex and nuclei, but not in dorsal telencephalon, at later stages","Microcephaly, short stature, and impaired glucose metabolism 1: An autosomal recessive disease characterized by microcephaly, intellectual disability, short stature, and disturbed glucose metabolism. Additional clinical features include delayed puberty, hypoglycemia-related seizures, hyperinsulinemic hypoglycemia, and early-onset diabetes.",,"Nucleus Nucleus, nucleolus",23042678|25053765,24204302,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
TROAP,ENSG00000135451,Unsafe,Protein,False,True,28.3,50.5,77,60,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 1.4 nTPM; positive ihc; bone marrow: 50.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 0.1 nTPM; positive ihc; cerebral cortex: 0.3 nTPM; positive ihc; colon: 6.5 nTPM; positive ihc;absolute ceiling; duodenum: 8.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 13.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 0.7 nTPM; positive ihc; kidney: 0.9 nTPM; positive ihc; lung: 2.3 nTPM; positive ihc;absolute ceiling; lymph node: 11 nTPM; positive ihc;absolute ceiling;continuous selectivity; pancreas: 0.8 nTPM; positive ihc; rectum: 8.9 nTPM; positive ihc;absolute ceiling; salivary gland: 2.4 nTPM; positive ihc; skeletal muscle: 0.3 nTPM; positive ihc; skin: 7.5 nTPM; positive ihc; small intestine: 7.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 2.7 nTPM; absolute ceiling; spleen: 6.9 nTPM; positive ihc; stomach: 5.2 nTPM; positive ihc; thymus: 35.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 0.8 nTPM; positive ihc; urinary bladder: 1.8 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 50.5 nTPM (limit 2); colon: 6.5 nTPM (limit 6); duodenum: 8.7 nTPM (limit 2); esophagus: 13.2 nTPM (limit 6); lung: 2.3 nTPM (limit 2); lymph node: 11 nTPM (limit 6); rectum: 8.9 nTPM (limit 6); small intestine: 7.3 nTPM (limit 2); smooth muscle: 2.7 nTPM (limit 2); thymus: 35.9 nTPM (limit 10); bone marrow: 50.5 nTPM (baseline 2); colon: 6.5 nTPM (baseline 6); duodenum: 8.7 nTPM (baseline 2); esophagus: 13.2 nTPM (baseline 6); lung: 2.3 nTPM (baseline 2); lymph node: 11 nTPM (baseline 6); rectum: 8.9 nTPM (baseline 6); small intestine: 7.3 nTPM (baseline 2); smooth muscle: 2.7 nTPM (baseline 2); thymus: 35.9 nTPM (baseline 10),adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / neuronal cells: Low (Uncertain); cerebellum / cells in granular layer: Medium (Uncertain); cerebellum / cells in molecular layer: Medium (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / endothelial cells: Low (Uncertain); cerebral cortex / glial cells: Low (Uncertain); cerebral cortex / neuronal cells: Low (Uncertain); colon / endothelial cells: Low (Uncertain); colon / glandular cells: Medium (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Low (Uncertain); heart muscle / cardiomyocytes: Low (Uncertain); hippocampus / neuronal cells: Low (Uncertain); kidney / cells in glomeruli: Low (Uncertain); kidney / cells in tubules: Medium (Uncertain); lung / alveolar cells: Low (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Low (Uncertain); pancreas / pancreatic endocrine cells: Low (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Low (Uncertain); skeletal muscle / myocytes: Low (Uncertain); skin 1 / fibroblasts: Low (Uncertain); skin 1 / keratinocytes: Low (Uncertain); skin 1 / Langerhans: Medium (Uncertain); skin 2 / epidermal cells: Low (Uncertain); small intestine / glandular cells: Medium (Uncertain); spleen / cells in red pulp: Medium (Uncertain); stomach 1 / glandular cells: Low (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 283/283 (100.0%); Testicular Germ Cell Tumor (TCGA): 133/133 (100.0%); Rectum Adenocarcinoma (TCGA): 88/88 (100.0%),ovarian cancer: 9/12 (75.0%); urothelial cancer: 6/11 (54.5%),31,20,Q12815,https://www.uniprot.org/uniprotkb/Q12815/entry,Could be involved with bystin and trophinin in a cell adhesion molecule complex that mediates an initial attachment of the blastocyst to uterine epithelial cells at the time of the embryo implantation,Strong expression at implantation sites. Was exclusively localized to the apical side of the syncytiotrophoblast. Also found in macrophages,,,Cytoplasm,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
TRPM1,ENSG00000134160,Unsafe,Protein,False,True,2.1,17.0,87,2,Positive somewhere,True,True,False,False,Excluded,Normal,False,,Not assessed,,,positive ihc outside permitted; midbrain: 0.7 nTPM; continuous selectivity; retina: 17 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 4.7 nTPM; continuous selectivity;reproductive not higher; spinal cord: 0.8 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",retina: 17 nTPM (limit 2); retina: 17 nTPM (baseline 2),retina / inner nuclear layer: Medium (Enhanced); retina / outer plexiform layer: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Skin Cuteneous Melanoma (TCGA): 78/99 (78.8%); Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),breast cancer: 0/12 (0.0%); cervical cancer: 0/10 (0.0%),31,20,Q7Z4N2,https://www.uniprot.org/uniprotkb/Q7Z4N2/entry,"Constitutively open nonselective divalent cation-conducting channels which mediate the influx of Ca(2+), Mg(2+), Mn(2+), Ba(2+), and Ni(2+) into the cytoplasm, leading to membrane depolarization (PubMed:11535825, PubMed:19436059, PubMed:21278253). Impermeable to zinc ions (PubMed:21278253). In addition, forms heteromultimeric ion channels with TRPM3 which are permeable for calcium and zinc ions (PubMed:21278253). Plays an essential role for the depolarizing photoresponse of retinal ON bipolar cells (PubMed:19878917, PubMed:19896109). In the dark, tonic release of glutamate activates the G protein-coupled receptor for glutamate, GRM6, its activation induces the release of G(o) protein and the beta-gamma G protein dimer. Both subunits can interact and inactivate the TRPM1 channel. A light onset, induces decrease in glutamate release and deactivation of GRM6 leading to channel opening and membrane depolarization (By similarity). May play a role in metastasis suppression (PubMed:9537257)","Expressed in the retina where it localizes to the outer plexiform layer. Specifically, it is expressed in retinal bipolar cells (BPCs) of the ON subtype (PubMed:30027108). Highly expressed in benign melanocytic nevi and diffusely expressed in various in situ melanomas, but not detected in melanoma metastases. Also expressed in melanocytes and pigmented metastatic melanoma cell lines. In melanocytes expression appears to be regulated at the level of transcription and mRNA processing","Night blindness, congenital stationary, 1C: A non-progressive retinal disorder characterized by impaired night vision, often associated with nystagmus and myopia.",,"Cell membrane Endoplasmic reticulum membrane Cell projection, axon",11535825|19436059|19878917|19896109|21278253|9537257,11112417|19896109|30027108|9537257,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | Jamin2021_CT,GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
TRPM3,ENSG00000083067,Unsafe,Protein,False,True,4.9,676.9,81,5,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 5.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 3.7 nTPM; absolute ceiling;continuous selectivity; cerebellum: 13 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 3.7 nTPM; continuous selectivity; choroid plexus: 676.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 3.9 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 5.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 15 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 2.8 nTPM; absolute ceiling;continuous selectivity; retina: 18.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 3.1 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 5.1 nTPM (limit 2); basal ganglia: 3.7 nTPM (limit 2); cerebellum: 13 nTPM (limit 12); choroid plexus: 676.9 nTPM (limit 2); hippocampal formation: 3.9 nTPM (limit 2); hypothalamus: 5.2 nTPM (limit 2); kidney: 15 nTPM (limit 2); midbrain: 8 nTPM (limit 2); pituitary gland: 2.8 nTPM (limit 2); retina: 18.8 nTPM (limit 2); spinal cord: 3.1 nTPM (limit 2),kidney / proximal tubules (cell body): High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 28/58 (48.3%); Kidney Renal Clear Cell Carcinoma (validation): 39/100 (39.0%); Kidney Renal Papillary Cell Carcinoma (TCGA): 65/282 (23.0%),liver cancer: 1/10 (10.0%); prostate cancer: 1/12 (8.3%),31,20,Q9HCF6,https://www.uniprot.org/uniprotkb/Q9HCF6/entry,"Constitutively active, non-selective divalent cation-conducting channel that is permeable to Ca(2+), Mn(2+), and Mg(2+), with a high permeability for Ca(2+). However, can be enhanced by increasing temperature and by ligands, including the endogenous neurosteroid pregnenolone sulfate and sphingosine-1 and suppressed by intracellular Mg(2+) (PubMed:12672799, PubMed:12672827, PubMed:32343227). Implicated in a variety of cellular processes, including insulin/peptide secretion, vascular constriction and dilation, noxious heat sensing, inflammatory and spontaneous pain sensitivity. In neurons of the dorsal root ganglia, functions as thermosensitive channel for the detection of noxious heat and spontaneous pain. Suggested to function as an ionotropic steroid receptor in beta-cell, indeed pregnenolone sulfate leads to Ca(2+) influx and enhanced insulin secretion. Mediates Zn(2+) uptake into the lumen of pancreatic beta cell secretory granules, thereby regulating insulin secretion (By similarity). Forms heteromultimeric ion channels with TRPM1 which are permeable for Ca(2+) and Zn(2+) ions (PubMed:21278253). Exists as multiple splice variants which differ significantly in their biophysical properties (By similarity)","Expressed primarily in the kidney and, at lower levels, in brain, testis, ovary, pancreas and spinal cord. Expression in the brain and kidney was determined at protein level. In the kidney, expressed predominantly in the collecting tubular epithelium in the medulla, medullary rays, and periglomerular regions; in the brain, highest levels are found in the cerebellum, choroid plexus, the locus coeruleus, the posterior thalamus and the substantia nigra. Down-regulated in renal tumors compared to normal kidney. Expressed in the lens (PubMed:25090642)","Neurodevelopmental disorder with hypotonia, dysmorphic facies, and skeletal anomalies, with or without seizures: An autosomal dominant disorder characterized by global developmental delay, moderate to severely impaired intellectual development, poor or absent speech, congenital hypotonia, dysmorphic facial features, exotropia, and musculoskeletal issues such as hip dysplasia, hip dislocation and scoliosis. About half of patients develop various types of seizures. Cataract 50 with or without glaucoma: A form of cataract, an opacification of the crystalline lens of the eye that frequently results in visual impairment or blindness. Opacities vary in morphology, are often confined to a portion of the lens, and may be static or progressive. In general, the more posteriorly located and dense an opacity, the greater the impact on visual function. CTRCT50 is an autosomal dominant form characterized by early onset. Affected individuals may also exhibit high-tension glaucoma and variable anterior segment defects.",,Cell membrane,12672799|12672827|21278253|32343227,12672799|12672827|25090642,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
TRPV1,ENSG00000196689,Unsafe,RNA,False,True,9.9,24.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 5.7 nTPM; continuous selectivity; adrenal gland: 4.8 nTPM; absolute ceiling;continuous selectivity; amygdala: 6.2 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 6.2 nTPM; absolute ceiling;continuous selectivity; cerebellum: 13 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 6.4 nTPM; absolute ceiling;continuous selectivity; colon: 5.5 nTPM; continuous selectivity; duodenum: 7.1 nTPM; absolute ceiling;continuous selectivity; heart muscle: 7.3 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 6.9 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 6.1 nTPM; absolute ceiling;continuous selectivity; kidney: 7.9 nTPM; absolute ceiling;continuous selectivity; liver: 24 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 3.1 nTPM; absolute ceiling;continuous selectivity; midbrain: 6.9 nTPM; absolute ceiling;continuous selectivity; pancreas: 7.6 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 5.7 nTPM; absolute ceiling;continuous selectivity; retina: 12.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 4.2 nTPM; continuous selectivity; skeletal muscle: 6.3 nTPM; absolute ceiling;continuous selectivity; skin: 5.3 nTPM; continuous selectivity; small intestine: 8.4 nTPM; absolute ceiling;continuous selectivity; spinal cord: 6.7 nTPM; absolute ceiling;continuous selectivity; stomach: 5.7 nTPM; continuous selectivity; thyroid gland: 4.5 nTPM; continuous selectivity; urinary bladder: 4.8 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 4.8 nTPM (limit 2); amygdala: 6.2 nTPM (limit 2); basal ganglia: 6.2 nTPM (limit 2); cerebellum: 13 nTPM (limit 2); cerebral cortex: 6.4 nTPM (limit 2); duodenum: 7.1 nTPM (limit 2); heart muscle: 7.3 nTPM (limit 2); hippocampal formation: 6.9 nTPM (limit 2); hypothalamus: 6.1 nTPM (limit 2); kidney: 7.9 nTPM (limit 2); liver: 24 nTPM (limit 2); lung: 3.1 nTPM (limit 2); midbrain: 6.9 nTPM (limit 2); pancreas: 7.6 nTPM (limit 2); pituitary gland: 5.7 nTPM (limit 2); retina: 12.5 nTPM (limit 2); skeletal muscle: 6.3 nTPM (limit 2); small intestine: 8.4 nTPM (limit 2); spinal cord: 6.7 nTPM (limit 2); adrenal gland: 4.8 nTPM (baseline 2); amygdala: 6.2 nTPM (baseline 2); basal ganglia: 6.2 nTPM (baseline 2); cerebellum: 13 nTPM (baseline 2); cerebral cortex: 6.4 nTPM (baseline 2); duodenum: 7.1 nTPM (baseline 2); heart muscle: 7.3 nTPM (baseline 2); hippocampal formation: 6.9 nTPM (baseline 2); hypothalamus: 6.1 nTPM (baseline 2); kidney: 7.9 nTPM (baseline 2); liver: 24 nTPM (baseline 2); lung: 3.1 nTPM (baseline 2); midbrain: 6.9 nTPM (baseline 2); pancreas: 7.6 nTPM (baseline 2); pituitary gland: 5.7 nTPM (baseline 2); retina: 12.5 nTPM (baseline 2); skeletal muscle: 6.3 nTPM (baseline 2); small intestine: 8.4 nTPM (baseline 2); spinal cord: 6.7 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 43/50 (86.0%); Liver Hepatocellular Carcinoma (validation): 195/231 (84.4%); Testicular Germ Cell Tumor (TCGA): 92/133 (69.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NER1,https://www.uniprot.org/uniprotkb/Q8NER1/entry,"Non-selective calcium permeant cation channel involved in detection of noxious chemical and thermal stimuli (PubMed:11050376, PubMed:11243859, PubMed:11226139, PubMed:12077606). Seems to mediate proton influx and may be involved in intracellular acidosis in nociceptive neurons. Involved in mediation of inflammatory pain and hyperalgesia. Sensitized by a phosphatidylinositol second messenger system activated by receptor tyrosine kinases, which involves PKC isozymes and PCL. Activated by vanilloids, like capsaicin, and temperatures higher than 42 degrees Celsius (PubMed:37117175). Upon activation, exhibits a time- and Ca(2+)-dependent outward rectification, followed by a long-lasting refractory state. Mild extracellular acidic pH (6.5) potentiates channel activation by noxious heat and vanilloids, whereas acidic conditions (pH <6) directly activate the channel. Can be activated by endogenous compounds, including 12-hydroperoxytetraenoic acid and bradykinin. Acts as ionotropic endocannabinoid receptor with central neuromodulatory effects. Triggers a form of long-term depression (TRPV1-LTD) mediated by the endocannabinoid anandamine in the hippocampus and nucleus accumbens by affecting AMPA receptors endocytosis","Widely expressed at low levels. Expression is elevated in dorsal root ganglia. In skin, expressed in cutaneous sensory nerve fibers, mast cells, epidermal keratinocytes, dermal blood vessels, the inner root sheet and the infundibulum of hair follicles, differentiated sebocytes, sweat gland ducts, and the secretory portion of eccrine sweat glands (at protein level)",,,"Postsynaptic cell membrane Cell projection, dendritic spine membrane Cell membrane",11050376|11226139|11243859|12077606|37117175,11050376|11243859|14987252,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
TSACC,ENSG00000163467,Unsafe,RNA,False,True,899.2,899.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,retina: 2.2 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 2.2 nTPM (limit 2); retina: 2.2 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 87/133 (65.4%); Rectum Adenocarcinoma (validation): 91/207 (44.0%); Colon Adenocarcinoma (validation): 181/486 (37.2%),No exact-ID IHC coverage in the HPA cancer snapshot,29,0,Q96A04,https://www.uniprot.org/uniprotkb/Q96A04/entry,Co-chaperone that facilitates HSP-mediated activation of TSSK6,Expressed in testis but is absent from mature sperm,,,,20829357,20829357,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,Failed bulk numeric comparisons are within 20% of their cutoffs; not an automatic rescue,,,,
TSGA10,ENSG00000135951,Unsafe,RNA,False,True,50.1,50.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,choroid plexus: 3.1 nTPM; absolute ceiling; kidney: 3 nTPM; absolute ceiling; pituitary gland: 2.4 nTPM; absolute ceiling; retina: 2.5 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 3.1 nTPM (limit 2); kidney: 3 nTPM (limit 2); pituitary gland: 2.4 nTPM (limit 2); retina: 2.5 nTPM (limit 2); choroid plexus: 3.1 nTPM (baseline 2); kidney: 3 nTPM (baseline 2); pituitary gland: 2.4 nTPM (baseline 2); retina: 2.5 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 44/50 (88.0%); Glioblastoma Multiforme (validation): 39/58 (67.2%); Pancreatic Adenocarcinoma (validation): 52/80 (65.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9BZW7,https://www.uniprot.org/uniprotkb/Q9BZW7/entry,"Plays a role in spermatogenesis (PubMed:28905369). When overexpressed, prevents nuclear localization of HIF1A (By similarity)","Expressed in the testis, in spermatozoa (at protein level) (PubMed:11179690, PubMed:28905369). Expressed in actively dividing fetal tissues, including sternum, intestine, limb, kidney and stomach (PubMed:14585816)",Spermatogenic failure 26: An autosomal recessive infertility disorder caused by spermatogenesis defects that result in acephalic spermatozoa.,,"Cytoplasm Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriole",28905369,11179690|14585816|28905369,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
TSPAN16,ENSG00000130167,Unsafe,Protein,False,True,130.9,130.9,84,7,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 0 nTPM; positive ihc; kidney: 0 nTPM; positive ihc; stomach: 0 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,adrenal gland / glandular cells: Low (Enhanced); kidney / cells in tubules: Medium (Enhanced); stomach 1 / glandular cells: Low (Enhanced); stomach 2 / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 3/133 (2.3%); Glioblastoma Multiforme (validation): 1/58 (1.7%); Uterine Corpus Endometrial Carcinoma (TCGA): 2/176 (1.1%),breast cancer: 0/10 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q9UKR8,https://www.uniprot.org/uniprotkb/Q9UKR8/entry,,Broadly expressed in most human tissues and cell lines including neural and bone marrow derived tissues,,,Membrane,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TSPY9,ENSG00000238074,Unsafe,Protein,False,True,14.5,14.5,86,5,Positive somewhere,True,False,False,True,Excluded,Normal,False,,Not assessed,,,"incomplete routine rna; positive normal IHC; positive ihc outside permitted; incomplete routine rna; missing normal RNA: amygdala, basal ganglia, cerebellum, hippocampal formation, hypothalamus, midbrain, pituitary gland, spinal cord; adrenal gland: 0 nTPM; positive ihc; stomach: 0.2 nTPM; positive ihc","Positive IHC in a Vital, Protected or Manageable compartment",,adrenal gland / glandular cells: Low (Supported); stomach 1 / glandular cells: Low (Supported); stomach 2 / glandular cells: Low (Supported),incomplete_routine_rna,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 33/133 (24.8%); Lung Squamous Cell Carcinoma (validation): 3/68 (4.4%); Lung Squamous Cell Carcinoma (TCGA): 20/489 (4.1%),testis cancer: 3/12 (25.0%); breast cancer: 0/10 (0.0%),29,20,A0A494C1R9,https://www.uniprot.org/uniprotkb/A0A494C1R9/entry,May be involved in sperm differentiation and proliferation,,,,Cytoplasm Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Loriot2025_S1,Cancer-germline RNA nomination; strict and preferential classes remain distinct,,,,,,,,
TSSK3,ENSG00000162526,Unsafe,RNA,False,True,33.1,33.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 2.6 nTPM; absolute ceiling; bone marrow: 12.5 nTPM; absolute ceiling;continuous selectivity; cerebellum: 5.4 nTPM; absolute ceiling; duodenum: 3.3 nTPM; absolute ceiling; liver: 2.6 nTPM; absolute ceiling; lung: 2.6 nTPM; absolute ceiling; pancreas: 2.1 nTPM; absolute ceiling; retina: 4.2 nTPM; absolute ceiling; skeletal muscle: 2.9 nTPM; absolute ceiling; small intestine: 3.9 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 2.6 nTPM (limit 2); bone marrow: 12.5 nTPM (limit 2); cerebellum: 5.4 nTPM (limit 2); duodenum: 3.3 nTPM (limit 2); liver: 2.6 nTPM (limit 2); lung: 2.6 nTPM (limit 2); pancreas: 2.1 nTPM (limit 2); retina: 4.2 nTPM (limit 2); skeletal muscle: 2.9 nTPM (limit 2); small intestine: 3.9 nTPM (limit 2); adrenal gland: 2.6 nTPM (baseline 2); bone marrow: 12.5 nTPM (baseline 2); cerebellum: 5.4 nTPM (baseline 2); duodenum: 3.3 nTPM (baseline 2); liver: 2.6 nTPM (baseline 2); lung: 2.6 nTPM (baseline 2); pancreas: 2.1 nTPM (baseline 2); retina: 4.2 nTPM (baseline 2); skeletal muscle: 2.9 nTPM (baseline 2); small intestine: 3.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 42/50 (84.0%); Liver Hepatocellular Carcinoma (validation): 146/231 (63.2%); Rectum Adenocarcinoma (validation): 50/207 (24.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q96PN8,https://www.uniprot.org/uniprotkb/Q96PN8/entry,Serine/threonine protein kinase required for spermatid development and male fertility,,,,"Cell projection, cilium, flagellum",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
TTC16,ENSG00000167094,Unsafe,High RNA,False,True,15.5,15.5,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE NK (unstimulated): 90/90 values ≥5 TPM, max 69.4791; DICE TREG_MEM (unstimulated): 20/89 values ≥5 TPM, max 8.98567; DICE CD4_NAIVE (unstimulated): 57/88 values ≥5 TPM, max 20.2273; DICE TREG_NAIVE (unstimulated): 21/89 values ≥5 TPM, max 16.0743; DICE TFH (unstimulated): 57/89 values ≥5 TPM, max 14.7838; DICE TH1 (unstimulated): 79/81 values ≥5 TPM, max 82.5633; DICE THSTAR (unstimulated): 76/88 values ≥5 TPM, max 25.7786; DICE TH17 (unstimulated): 62/89 values ≥5 TPM, max 17.2192; DICE TH2 (unstimulated): 65/89 values ≥5 TPM, max 20.8248; DICE CD8_NAIVE (unstimulated): 89/89 values ≥5 TPM, max 51.7021; hpa_immune_monaco Non-Vd2 gdTCR: 5.9 TPM; hpa_immune_monaco Terminal effector memory CD4 T-cell: 7.8 TPM; hpa_immune_monaco Terminal effector memory CD8 T-cell: 9 TPM",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,82.5633018045,65.6,"dice_cd8_naive: blood/CD8_NAIVE, max 51.7021 TPM, 12 observations >30; dice_nk: blood/NK, max 69.4791 TPM, 30 observations >30; dice_th1: blood/TH1, max 82.5633 TPM, 6 observations >30; hpa_single_cell_tissue: bronchus/ciliated cells, max 41.4 nTPM, 1 observations >30; hpa_single_cell_tissue: liver/t-cells, max 30.2 nTPM, 1 observations >30; hpa_single_cell_tissue: lung/ciliated cells, max 38.1 nTPM, 1 observations >30; hpa_single_cell_tissue: lung/t-cells, max 39.9 nTPM, 1 observations >30; hpa_single_cell_tissue: pbmc/t-cells, max 65.6 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,82.56 TPM; blood/TH1; dice_th1; vital,65.6 nTPM; pbmc/t-cells; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (validation): 8/50 (16.0%); Lung Adenocarcinoma (TCGA): 6/497 (1.2%); Uterine Corpus Endometrial Carcinoma (TCGA): 2/176 (1.1%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NEE8,https://www.uniprot.org/uniprotkb/Q8NEE8/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Loriot2025_S2,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct,,,,,,,,
TTC21A,ENSG00000168026,Unsafe,High RNA,False,True,44.7,44.7,85,3,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 91/91 values ≥5 TPM, max 58.204; DICE MONOCYTES (unstimulated): 90/91 values ≥5 TPM, max 16.2539; DICE M2 (unstimulated): 22/90 values ≥5 TPM, max 8.77092; DICE TREG_MEM (unstimulated): 30/89 values ≥5 TPM, max 9.76946; DICE CD4_NAIVE (unstimulated): 5/88 values ≥5 TPM, max 6.39486; DICE TFH (unstimulated): 25/89 values ≥5 TPM, max 9.75833; DICE TH1 (unstimulated): 38/81 values ≥5 TPM, max 10.8951; DICE THSTAR (unstimulated): 13/88 values ≥5 TPM, max 9.00558; DICE TH17 (unstimulated): 70/89 values ≥5 TPM, max 11.4083; DICE TH2 (unstimulated): 73/89 values ≥5 TPM, max 11.1228; DICE CD8_NAIVE (unstimulated): 3/89 values ≥5 TPM, max 6.60182; hpa_immune_monaco Exhausted memory B-cell: 5.4 TPM; hpa_immune_monaco naive B-cell: 8.5 TPM; hpa_immune_monaco Non-switched memory B-cell: 11.2 TPM; hpa_immune_monaco Switched memory B-cell: 6.3 TPM",True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,58.2039688085,107.0,"dice_b_cell_naive: blood/B_CELL_NAIVE, max 58.204 TPM, 87 observations >30; hpa_immune_schmiedel: blood/naive B-cell, max 41.1 TPM, 1 observations >30; hpa_single_cell: /Ciliated cells, max 53 nTPM, 1 observations >30; hpa_single_cell_tissue: bronchus/ciliated cells, max 107 nTPM, 3 observations >30; hpa_single_cell_tissue: lung/ciliated cells, max 78.2 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,58.2 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,107 nTPM; bronchus/ciliated cells; hpa_single_cell_tissue; vital,Breast Invasive Carcinoma (validation): 47/50 (94.0%); Glioblastoma Multiforme (validation): 33/58 (56.9%); Pancreatic Adenocarcinoma (validation): 20/80 (25.0%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q8NDW8,https://www.uniprot.org/uniprotkb/Q8NDW8/entry,Intraflagellar transport (IFT)-associated protein required for spermatogenesis (PubMed:30929735). Required for sperm flagellar formation and intraflagellar transport (PubMed:30929735),Strongly expressed in testis,"Spermatogenic failure 37: An autosomal recessive infertility disorder characterized by asthenoteratozoospermia. Spermatozoa exhibit multiple morphologic abnormalities, primarily consisting of short or absent flagella, and neck defects at the head-tail junction.",,,30929735,12543795,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
TTC29,ENSG00000137473,Unsafe,Protein,False,True,69.8,69.8,81,18,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; choroid plexus: 5.9 nTPM; absolute ceiling; duodenum: 0 nTPM; positive ihc; heart muscle: 0 nTPM; positive ihc; kidney: 0.2 nTPM; positive ihc; rectum: 0 nTPM; positive ihc; small intestine: 0 nTPM; positive ihc; stomach: 0 nTPM; positive ihc; thyroid gland: 0.1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 5.9 nTPM (limit 2); choroid plexus: 5.9 nTPM (baseline 2),bronchus / respiratory epithelial cells: Low (Uncertain); duodenum / glandular cells: Low (Uncertain); heart muscle / cardiomyocytes: Low (Uncertain); kidney / cells in tubules: Medium (Uncertain); nasopharynx / respiratory epithelial cells: Low (Uncertain); rectum / glandular cells: Low (Uncertain); small intestine / glandular cells: Low (Uncertain); stomach 2 / glandular cells: Low (Uncertain); thyroid gland / glandular cells: Low (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 17/176 (9.7%); Breast Invasive Carcinoma (validation): 4/50 (8.0%); Glioblastoma Multiforme (validation): 4/58 (6.9%),stomach cancer: 1/12 (8.3%); breast cancer: 0/10 (0.0%),31,20,Q8NA56,https://www.uniprot.org/uniprotkb/Q8NA56/entry,Axonemal protein which is implicated in axonemal and/or peri-axonemal structure assembly and regulates flagellum assembly and beating and therefore sperm motility,Expressed in spermatozoa (at protein level),"Spermatogenic failure 42: An autosomal recessive infertility disorder characterized by almost immotile spermatozoa due to multiple morphologic abnormalities of the flagella, including short, absent, coiled, and bent flagella. Some spermatozoa also show abnormalities of the head, acrosome, midpiece, or endpiece.",,"Cytoplasm, cytoskeleton, flagellum axoneme",31735292|31735294,31735292|31735294,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TTK,ENSG00000112742,Unsafe,Protein,False,True,33.3,45.4,87,60,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,Trial registration,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; bone marrow: 25 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 0.4 nTPM; positive ihc; colon: 4.7 nTPM; positive ihc; duodenum: 3.9 nTPM; positive ihc;absolute ceiling; esophagus: 4.6 nTPM; positive ihc; kidney: 0.2 nTPM; positive ihc; lung: 0.8 nTPM; positive ihc; lymph node: 7.9 nTPM; positive ihc;absolute ceiling; pancreas: 0.2 nTPM; positive ihc; parathyroid gland: 0.3 nTPM; positive ihc; rectum: 5.7 nTPM; positive ihc; salivary gland: 0.7 nTPM; positive ihc; skeletal muscle: 0 nTPM; positive ihc; skin: 3.6 nTPM; positive ihc; small intestine: 4 nTPM; positive ihc;absolute ceiling; spleen: 1.3 nTPM; positive ihc; stomach: 3.2 nTPM; positive ihc; thymus: 45.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 0.4 nTPM; positive ihc; urinary bladder: 1.2 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 25 nTPM (limit 2); duodenum: 3.9 nTPM (limit 2); lymph node: 7.9 nTPM (limit 6); small intestine: 4 nTPM (limit 2); thymus: 45.4 nTPM (limit 10),bone marrow / hematopoietic cells: Medium (Enhanced); bronchus / respiratory epithelial cells: Low (Enhanced); caudate / neuronal cells: Low (Enhanced); cerebral cortex / glial cells: Low (Enhanced); cerebral cortex / neuronal cells: Low (Enhanced); cerebral cortex / neuropil: Low (Enhanced); colon / endothelial cells: Low (Enhanced); colon / glandular cells: Medium (Enhanced); colon / peripheral nerve/ganglion: Low (Enhanced); duodenum / glandular cells: Medium (Enhanced); esophagus / squamous epithelial cells: Medium (Enhanced); hippocampus / glial cells: Low (Enhanced); hippocampus / neuronal cells: Low (Enhanced); kidney / cells in tubules: Medium (Enhanced); lung / alveolar cells: Low (Enhanced); lung / macrophages: Low (Enhanced); lymph node / germinal center cells: High (Enhanced); lymph node / non-germinal center cells: Medium (Enhanced); oral mucosa / squamous epithelial cells: Medium (Enhanced); pancreas / exocrine glandular cells: Medium (Enhanced); parathyroid gland / glandular cells: Low (Enhanced); rectum / glandular cells: High (Enhanced); salivary gland / glandular cells: Low (Enhanced); skeletal muscle / myocytes: Low (Enhanced); skin 1 / fibroblasts: Low (Enhanced); skin 1 / keratinocytes: Medium (Enhanced); skin 2 / epidermal cells: Medium (Enhanced); small intestine / glandular cells: Medium (Enhanced); spleen / cells in white pulp: Low (Enhanced); stomach 1 / glandular cells: Medium (Enhanced); stomach 2 / glandular cells: Medium (Enhanced); thyroid gland / glandular cells: Low (Enhanced); urinary bladder / urothelial cells: Medium (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,True,True,True,4.673725313359999,62.3,"hpa_rna_consensus: thymus/, max 45.4 nTPM, 1 observations >30; hpa_single_cell_tissue: adipose tissue/t-cells, max 45.4 nTPM, 1 observations >30; hpa_single_cell_tissue: liver/erythroid cells, max 35 nTPM, 1 observations >30; hpa_single_cell_tissue: placenta/mixed immune cells, max 33.1 nTPM, 1 observations >30; hpa_single_cell_tissue: tongue/basal keratinocytes, max 62.3 nTPM, 1 observations >30",Unsafe,oncoref.target-sets.2026-10-23.2,4.674 TPM; blood/TREG_MEM; dice_treg_mem; vital,62.3 nTPM; tongue/basal keratinocytes; hpa_single_cell_tissue; protected,Colon Adenocarcinoma (validation): 483/486 (99.4%); Lung Squamous Cell Carcinoma (validation): 67/68 (98.5%); Rectum Adenocarcinoma (validation): 201/207 (97.1%),testis cancer: 11/11 (100.0%); skin cancer: 11/12 (91.7%),31,20,P33981,https://www.uniprot.org/uniprotkb/P33981/entry,"Involved in mitotic spindle assembly checkpoint signaling, a process that delays anaphase until chromosomes are bioriented on the spindle, and in the repair of incorrect mitotic kinetochore-spindle microtubule attachments (PubMed:18243099, PubMed:28441529, PubMed:29162720). Phosphorylates MAD1L1 to promote the mitotic spindle assembly checkpoint (PubMed:18243099, PubMed:29162720). Phosphorylates CDCA8/Borealin leading to enhanced AURKB activity at the kinetochore (PubMed:18243099). Phosphorylates SKA3 at 'Ser-34' leading to dissociation of the SKA complex from microtubules and destabilization of microtubule-kinetochore attachments (PubMed:28441529). Phosphorylates KNL1, KNTC1 and autophosphorylates (PubMed:28441529). Phosphorylates MCRS1 which enhances recruitment of KIF2A to the minus end of spindle microtubules and promotes chromosome alignment (PubMed:30785839)",Present in rapidly proliferating cell lines,,,,18243099|28441529|29162720|30785839,,False,Reviewed UniProt annotation; not a new primary-paper review,Trial registration only,https://clinicaltrials.gov/study/NCT00669292,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
TTLL10,ENSG00000162571,Unsafe,RNA,False,True,40.8,40.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,choroid plexus: 2.9 nTPM; absolute ceiling; lung: 2.7 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 2.9 nTPM (limit 2); lung: 2.7 nTPM (limit 2); choroid plexus: 2.9 nTPM (baseline 2); lung: 2.7 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Uterine Corpus Endometrial Carcinoma (TCGA): 24/176 (13.6%); Pancreatic Adenocarcinoma (validation): 7/80 (8.8%); Ovary Serous Cystadenocarcinoma (TCGA): 19/349 (5.4%),breast cancer: 12/12 (100.0%); colorectal cancer: 11/12 (91.7%),31,20,Q6ZVT0,https://www.uniprot.org/uniprotkb/Q6ZVT0/entry,Inactive polyglycylase,,,Two inactivating mutations in human TTLL10 (Ser-448 and Lys-467) are proposed to explain the lack of polyglycylation,,19524510,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TTLL11,ENSG00000175764,Unsafe,Protein,False,True,11.8,26.5,86,52,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 5.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 8.7 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 8.3 nTPM; absolute ceiling;continuous selectivity; bone marrow: 1.5 nTPM; positive ihc; cerebellum: 6.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 10.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 5 nTPM; absolute ceiling;continuous selectivity; colon: 9.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 2.5 nTPM; positive ihc;absolute ceiling; esophagus: 6.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 5 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 11.2 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 7 nTPM; absolute ceiling;continuous selectivity; kidney: 2.9 nTPM; positive ihc;absolute ceiling; liver: 5.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 13.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 5 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 2.9 nTPM; absolute ceiling; rectum: 4 nTPM; positive ihc; retina: 6.6 nTPM; absolute ceiling;continuous selectivity; salivary gland: 4.8 nTPM; positive ihc;continuous selectivity; skeletal muscle: 26.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 4.5 nTPM; positive ihc; small intestine: 3.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 9.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 21.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 3.5 nTPM; positive ihc; stomach: 4.1 nTPM; positive ihc;continuous selectivity; thyroid gland: 3.4 nTPM; positive ihc; tongue: 8.5 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 5.5 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 5.3 nTPM (limit 2); amygdala: 8.7 nTPM (limit 2); basal ganglia: 8.3 nTPM (limit 2); cerebellum: 6.1 nTPM (limit 2); cerebral cortex: 10.6 nTPM (limit 2); choroid plexus: 5 nTPM (limit 2); colon: 9.9 nTPM (limit 6); duodenum: 2.5 nTPM (limit 2); esophagus: 6.9 nTPM (limit 6); heart muscle: 5 nTPM (limit 2); hippocampal formation: 11.2 nTPM (limit 2); hypothalamus: 7 nTPM (limit 2); kidney: 2.9 nTPM (limit 2); liver: 5.2 nTPM (limit 2); midbrain: 13.1 nTPM (limit 2); pancreas: 5 nTPM (limit 2); pituitary gland: 2.9 nTPM (limit 2); retina: 6.6 nTPM (limit 2); skeletal muscle: 26.5 nTPM (limit 2); small intestine: 3.1 nTPM (limit 2); smooth muscle: 9.4 nTPM (limit 2); spinal cord: 21.8 nTPM (limit 2); tongue: 8.5 nTPM (limit 6),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Low (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Low (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Low (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Low (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in red pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 42/50 (84.0%); Rectum Adenocarcinoma (validation): 162/207 (78.3%),renal cancer: 9/12 (75.0%); pancreatic cancer: 8/11 (72.7%),31,20,Q8NHH1,https://www.uniprot.org/uniprotkb/Q8NHH1/entry,"Polyglutamylase which modifies tubulin, generating polyglutamate side chains of variable lengths on the gamma-carboxyl group of specific glutamate residues within the C-terminal tail of tubulin. Preferentially mediates ATP-dependent polyglutamate long side-chain elongation over the initiation step of the polyglutamylation reaction. Preferentially modifies the alpha-tubulin tail over a beta-tail (By similarity). Required for CCSAP localization to both spindle and cilia microtubules (PubMed:22493317). Promotes tubulin polyglutamylation which stimulates spastin/SPAST-mediated microtubule severing, thereby regulating microtubule functions (By similarity)",,,,"Cytoplasm, cytoskeleton, cilium basal body Cytoplasm, cytoskeleton",22493317,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
TTLL6,ENSG00000170703,Unsafe,Protein,False,True,18.3,18.3,119,6,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive ihc outside permitted; choroid plexus: 4.7 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 4.7 nTPM (limit 2),bronchus / ciliated cells (ciliary rootlets): High (Enhanced); bronchus / ciliated cells (tip of cilia): Low (Enhanced); nasopharynx / ciliated cells (ciliary rootlets): High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Renal Clear Cell Carcinoma (validation): 17/100 (17.0%); Kidney Renal Papillary Cell Carcinoma (TCGA): 33/282 (11.7%); Glioblastoma Multiforme (validation): 5/58 (8.6%),melanoma: 1/12 (8.3%); breast cancer: 0/12 (0.0%),31,20,Q8N841,https://www.uniprot.org/uniprotkb/Q8N841/entry,"Polyglutamylase which modifies both tubulin and non-tubulin proteins, generating alpha-linked polyglutamate side chains on the gamma-carboxyl group of specific glutamate residues of target proteins. Preferentially mediates ATP-dependent long polyglutamate chain elongation over the initiation step of the polyglutamylation reaction. Preferentially modifies the alpha-tubulin tail over a beta-tail. Promotes tubulin polyglutamylation which stimulates spastin/SPAST-mediated microtubule severing, thereby regulating microtubule functions. Mediates microtubule polyglutamylation in primary cilia axoneme, which is important for ciliary structural formation and motility. Mediates microtubule polyglutamylation in motile cilia, necessary for the regulation of ciliary coordinated beating. Polyglutamylates non-tubulin protein nucleotidyltransferase CGAS, leading to CGAS DNA-binding inhibition, thereby preventing antiviral defense response",,,,"Cytoplasm Cytoplasm, cytoskeleton Cytoplasm, cytoskeleton, cilium axoneme Cytoplasm, cytoskeleton, cilium basal body",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
TTLL9,ENSG00000131044,Unsafe,RNA,False,True,6.0,15.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 1.8 nTPM; continuous selectivity; basal ganglia: 2.7 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 15 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 2.5 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 2.6 nTPM; absolute ceiling;continuous selectivity; midbrain: 1.9 nTPM; continuous selectivity; spinal cord: 2.3 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,basal ganglia: 2.7 nTPM (limit 2); choroid plexus: 15 nTPM (limit 2); hippocampal formation: 2.5 nTPM (limit 2); hypothalamus: 2.6 nTPM (limit 2); spinal cord: 2.3 nTPM (limit 2); basal ganglia: 2.7 nTPM (baseline 2); choroid plexus: 15 nTPM (baseline 2); hippocampal formation: 2.5 nTPM (baseline 2); hypothalamus: 2.6 nTPM (baseline 2); spinal cord: 2.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 50/58 (86.2%); Breast Invasive Carcinoma (validation): 21/50 (42.0%); Ovary Serous Cystadenocarcinoma (validation): 9/81 (11.1%),skin cancer: 7/11 (63.6%); testis cancer: 7/12 (58.3%),31,20,Q3SXZ7,https://www.uniprot.org/uniprotkb/Q3SXZ7/entry,"Probable tubulin polyglutamylase that generates side chains of glutamate on the gamma-carboxyl group of specific glutamate residues within the C-terminal tail of target proteins. Similar to TTLL1, may acquire enzymatic activity only in complex with other proteins as it is most likely lacking domains important for autonomous activity. Mediates tubulin polyglutamylation which induces establishment of microtubule heterogeneity in sperm flagella, thereby playing a role in normal motile flagella axoneme structure and sperm flagella beating pattern",,,,"Cytoplasm, cytoskeleton, cilium basal body Cytoplasm, cytoskeleton Cytoplasm, cytoskeleton, flagellum axoneme",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
TUBA3D,ENSG00000075886,Unsafe,RNA,False,True,214.1,214.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,family exclusion; family exclusion; heart muscle: 83.4 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,heart muscle: 83.4 nTPM (limit 2); heart muscle: 83.4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 34/50 (68.0%); Prostate Adenocarcinoma (TCGA): 212/480 (44.2%); Testicular Germ Cell Tumor (TCGA): 56/133 (42.1%),testis cancer: 7/11 (63.6%); glioma: 5/11 (45.5%),31,20,P0DPH7 | P0DPH8,https://www.uniprot.org/uniprotkb/P0DPH7/entry | https://www.uniprot.org/uniprotkb/P0DPH8/entry,"Tubulin is the major constituent of microtubules, a cylinder consisting of laterally associated linear protofilaments composed of alpha- and beta-tubulin heterodimers. Microtubules grow by the addition of GTP-tubulin dimers to the microtubule end, where a stabilizing cap forms. Below the cap, tubulin dimers are in GDP-bound state, owing to GTPase activity of alpha-tubulin","Expressed in testis | Expressed in the cornea, sclera, and peripheral blood (PubMed:29051577)","Keratoconus 9: An autosomal dominant form of keratoconus, a common degenerative corneal disease characterized by progressive, non-inflammatory thinning of the corneal stroma, corneal ectasia, and cone-shaped corneal protrusion that results in reduced vision.",,"Cytoplasm, cytoskeleton",,29051577,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TUBA3E,ENSG00000152086,Unsafe,RNA,False,True,170.4,170.4,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,family exclusion; family exclusion; heart muscle: 51.5 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,heart muscle: 51.5 nTPM (limit 2); heart muscle: 51.5 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 18/50 (36.0%); Testicular Germ Cell Tumor (TCGA): 21/133 (15.8%); Uterine Corpus Endometrial Carcinoma (TCGA): 17/176 (9.7%),testis cancer: 7/11 (63.6%); glioma: 5/11 (45.5%),31,20,Q6PEY2,https://www.uniprot.org/uniprotkb/Q6PEY2/entry,"Tubulin is the major constituent of microtubules, a cylinder consisting of laterally associated linear protofilaments composed of alpha- and beta-tubulin heterodimers. Microtubules grow by the addition of GTP-tubulin dimers to the microtubule end, where a stabilizing cap forms. Below the cap, tubulin dimers are in GDP-bound state, owing to GTPase activity of alpha-tubulin",,,,"Cytoplasm, cytoskeleton",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Loriot2025_S2 | Gong2021_reproductive_PC | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
TUBB8B,ENSG00000173213,Unsafe,Protein,False,True,1.5,1.5,86,68,Positive somewhere,True,False,False,False,Excluded,Normal,True,,Not assessed,,,"incomplete routine rna; positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; incomplete routine rna; unresolved positive anatomy; missing normal RNA: amygdala, basal ganglia, cerebellum, hippocampal formation, hypothalamus, midbrain, pituitary gland, spinal cord; adipose tissue: 0 nTPM; positive ihc; adrenal gland: 0 nTPM; positive ihc; bone marrow: 0 nTPM; positive ihc; cerebral cortex: 0 nTPM; positive ihc; colon: 0 nTPM; positive ihc; duodenum: 0 nTPM; positive ihc; esophagus: 0 nTPM; positive ihc; kidney: 0 nTPM; positive ihc; liver: 0 nTPM; positive ihc; lung: 0 nTPM; positive ihc; lymph node: 0 nTPM; positive ihc; pancreas: 0 nTPM; positive ihc; rectum: 0 nTPM; positive ihc; salivary gland: 0 nTPM; positive ihc; skin: 0 nTPM; positive ihc; small intestine: 0 nTPM; positive ihc; spleen: 0 nTPM; positive ihc; stomach: 0 nTPM; positive ihc; thyroid gland: 0 nTPM; positive ihc; urinary bladder: 0 nTPM; positive ihc","Positive IHC in a Vital, Protected or Manageable compartment",,adipose tissue / adipocytes: Low (Uncertain); adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: High (Uncertain); caudate / glial cells: Low (Uncertain); caudate / neuronal cells: Low (Uncertain); cerebral cortex / glial cells: Low (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: Medium (Uncertain); colon / endothelial cells: Medium (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: Medium (Uncertain); duodenum / glandular cells: Low (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in glomeruli: Low (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / cholangiocytes: Low (Uncertain); lung / alveolar cells: Low (Uncertain); lung / macrophages: Low (Uncertain); lymph node / germinal center cells: High (Uncertain); lymph node / non-germinal center cells: Medium (Uncertain); nasopharynx / respiratory epithelial cells: High (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skin 1 / fibroblasts: Medium (Uncertain); skin 1 / keratinocytes: Low (Uncertain); skin 1 / Langerhans: Low (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: Medium (Uncertain); spleen / cells in white pulp: Medium (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),incomplete_routine_rna;unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 48/133 (36.1%); Uterine Corpus Endometrial Carcinoma (TCGA): 10/176 (5.7%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 9/283 (3.2%),glioma: 2/9 (22.2%); pancreatic cancer: 1/10 (10.0%),29,20,A6NNZ2,https://www.uniprot.org/uniprotkb/A6NNZ2/entry,"Tubulin is the major constituent of microtubules, a cylinder consisting of laterally associated linear protofilaments composed of alpha- and beta-tubulin heterodimers. Microtubules grow by the addition of GTP-tubulin dimers to the microtubule end, where a stabilizing cap forms. Below the cap, tubulin dimers are in GDP-bound state, owing to GTPase activity of alpha-tubulin",,,,"Cytoplasm, cytoskeleton",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Chang2019_TGCT | Loriot2025_S2,Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct,,,,,,,,
TUBGCP3,ENSG00000126216,Unsafe,Protein,False,True,16.3,30.9,76,65,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 12.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 9.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 7.4 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 7.8 nTPM; absolute ceiling;continuous selectivity; bone marrow: 30.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 11.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 9.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 4.6 nTPM; absolute ceiling;continuous selectivity; colon: 10.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 8.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 10.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 9.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 7.7 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 7.6 nTPM; absolute ceiling;continuous selectivity; kidney: 8.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 14.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 10.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 14.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 7.9 nTPM; absolute ceiling;continuous selectivity; pancreas: 10.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 8.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 7.6 nTPM; absolute ceiling;continuous selectivity; rectum: 9.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 11.3 nTPM; absolute ceiling;continuous selectivity; salivary gland: 10 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 11.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 13.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 10.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 12.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 9.8 nTPM; absolute ceiling;continuous selectivity; spleen: 14.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 9.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 18.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 10.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 8.6 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 10.6 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 12.4 nTPM (limit 10); adrenal gland: 9.6 nTPM (limit 2); amygdala: 7.4 nTPM (limit 2); basal ganglia: 7.8 nTPM (limit 2); bone marrow: 30.9 nTPM (limit 2); cerebellum: 11.8 nTPM (limit 2); cerebral cortex: 9.5 nTPM (limit 2); choroid plexus: 4.6 nTPM (limit 2); colon: 10.3 nTPM (limit 6); duodenum: 8.5 nTPM (limit 2); esophagus: 10.4 nTPM (limit 6); heart muscle: 9.1 nTPM (limit 2); hippocampal formation: 7.7 nTPM (limit 2); hypothalamus: 7.6 nTPM (limit 2); kidney: 8.4 nTPM (limit 2); liver: 14.3 nTPM (limit 2); lung: 10.3 nTPM (limit 2); lymph node: 14.5 nTPM (limit 6); midbrain: 7.9 nTPM (limit 2); pancreas: 10.1 nTPM (limit 2); parathyroid gland: 8.5 nTPM (limit 6); pituitary gland: 7.6 nTPM (limit 2); rectum: 9.7 nTPM (limit 6); retina: 11.3 nTPM (limit 2); salivary gland: 10 nTPM (limit 6); skeletal muscle: 11.6 nTPM (limit 2); skin: 13.7 nTPM (limit 10); small intestine: 10.9 nTPM (limit 2); smooth muscle: 12.1 nTPM (limit 2); spinal cord: 9.8 nTPM (limit 2); spleen: 14.5 nTPM (limit 10); stomach: 9.3 nTPM (limit 6); thymus: 18.5 nTPM (limit 10); thyroid gland: 10.3 nTPM (limit 10); tongue: 8.6 nTPM (limit 6); urinary bladder: 10.6 nTPM (limit 6),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: High (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / glial cells: Low (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: High (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: High (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Low (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: Medium (Approved); liver / hepatocytes: High (Approved); lung / alveolar cells: Low (Approved); lymph node / germinal center cells: High (Approved); lymph node / non-germinal center cells: High (Approved); nasopharynx / respiratory epithelial cells: High (Approved); oral mucosa / squamous epithelial cells: High (Approved); pancreas / exocrine glandular cells: High (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: High (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: High (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: High (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: High (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%); Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%),colorectal cancer: 12/12 (100.0%); ovarian cancer: 12/12 (100.0%),31,20,Q96CW5,https://www.uniprot.org/uniprotkb/Q96CW5/entry,"Component of the gamma-tubulin ring complex (gTuRC) which mediates microtubule nucleation (PubMed:38305685, PubMed:38609661, PubMed:39321809, PubMed:9566967). The gTuRC regulates the minus-end nucleation of alpha-beta tubulin heterodimers that grow into microtubule protafilaments, a critical step in centrosome duplication and spindle formation (PubMed:38305685, PubMed:38609661, PubMed:39321809)",Ubiquitously expressed,,,"Cytoplasm, cytoskeleton, microtubule organizing center, centrosome",38305685|38609661|39321809|9566967,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
TULP2,ENSG00000104804,Unsafe,High RNA,False,True,30.4,30.4,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE MONOCYTES (unstimulated): 79/91 values ≥5 TPM, max 34.0291; DICE TREG_MEM (unstimulated): 22/89 values ≥5 TPM, max 19.3528; DICE CD4_NAIVE (unstimulated): 3/88 values ≥5 TPM, max 9.00054; DICE TH1 (unstimulated): 20/81 values ≥5 TPM, max 43.486; DICE THSTAR (unstimulated): 25/88 values ≥5 TPM, max 41.355; DICE TH17 (unstimulated): 17/89 values ≥5 TPM, max 34.8607; DICE TH2 (unstimulated): 27/89 values ≥5 TPM, max 27.656; DICE CD8_NAIVE (unstimulated): 3/89 values ≥5 TPM, max 11.4493",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,43.4859627103,12.0,"dice_monocytes: blood/MONOCYTES, max 34.0291 TPM, 2 observations >30; dice_th1: blood/TH1, max 43.486 TPM, 1 observations >30; dice_th17: blood/TH17, max 34.8607 TPM, 1 observations >30; dice_thstar: blood/THSTAR, max 41.355 TPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,43.49 TPM; blood/TH1; dice_th1; vital,12 nTPM; esophagus/schwann cells; hpa_single_cell_tissue; protected,Testicular Germ Cell Tumor (TCGA): 28/133 (21.1%); Rectum Adenocarcinoma (validation): 24/207 (11.6%); Colon Adenocarcinoma (validation): 16/486 (3.3%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O00295,https://www.uniprot.org/uniprotkb/O00295/entry,,Strongly expressed in testis. Also expressed in retina. Expressed in cancer cell lines,,,Cytoplasm Secreted,,15905330|9096357,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
TVP23C,ENSG00000175106,Unsafe,Protein,False,True,8.5,10.7,79,37,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 3.7 nTPM; positive ihc; adrenal gland: 6.4 nTPM; absolute ceiling;continuous selectivity; amygdala: 3.1 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 2.9 nTPM; absolute ceiling;continuous selectivity; bone marrow: 10.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 3.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 2.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 6.6 nTPM; absolute ceiling;continuous selectivity; colon: 3.2 nTPM; positive ihc;continuous selectivity; duodenum: 2.1 nTPM; positive ihc;absolute ceiling; esophagus: 5.7 nTPM; positive ihc;continuous selectivity; heart muscle: 3.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 3.6 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 3.7 nTPM; absolute ceiling;continuous selectivity; kidney: 6.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 3.8 nTPM; absolute ceiling;continuous selectivity; lung: 4.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 2.7 nTPM; positive ihc; midbrain: 3.8 nTPM; absolute ceiling;continuous selectivity; pancreas: 5 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 3.6 nTPM; continuous selectivity; pituitary gland: 9.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 2 nTPM; positive ihc; retina: 4 nTPM; absolute ceiling;continuous selectivity; salivary gland: 5.8 nTPM; positive ihc;continuous selectivity; skeletal muscle: 2.9 nTPM; absolute ceiling;continuous selectivity; skin: 4.3 nTPM; continuous selectivity; small intestine: 3.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 2.1 nTPM; positive ihc;absolute ceiling; spinal cord: 4.9 nTPM; absolute ceiling;continuous selectivity; spleen: 4.6 nTPM; continuous selectivity; stomach: 3.7 nTPM; positive ihc;continuous selectivity; thyroid gland: 6.6 nTPM; positive ihc;continuous selectivity; urinary bladder: 3.8 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 6.4 nTPM (limit 2); amygdala: 3.1 nTPM (limit 2); basal ganglia: 2.9 nTPM (limit 2); bone marrow: 10.7 nTPM (limit 2); cerebellum: 3.9 nTPM (limit 2); cerebral cortex: 2.3 nTPM (limit 2); choroid plexus: 6.6 nTPM (limit 2); duodenum: 2.1 nTPM (limit 2); heart muscle: 3.9 nTPM (limit 2); hippocampal formation: 3.6 nTPM (limit 2); hypothalamus: 3.7 nTPM (limit 2); kidney: 6.2 nTPM (limit 2); liver: 3.8 nTPM (limit 2); lung: 4.4 nTPM (limit 2); midbrain: 3.8 nTPM (limit 2); pancreas: 5 nTPM (limit 2); pituitary gland: 9.8 nTPM (limit 2); retina: 4 nTPM (limit 2); skeletal muscle: 2.9 nTPM (limit 2); small intestine: 3.7 nTPM (limit 2); smooth muscle: 2.1 nTPM (limit 2); spinal cord: 4.9 nTPM (limit 2); adrenal gland: 6.4 nTPM (baseline 2); amygdala: 3.1 nTPM (baseline 2); basal ganglia: 2.9 nTPM (baseline 2); bone marrow: 10.7 nTPM (baseline 2); cerebellum: 3.9 nTPM (baseline 2); cerebral cortex: 2.3 nTPM (baseline 2); choroid plexus: 6.6 nTPM (baseline 2); duodenum: 2.1 nTPM (baseline 2); heart muscle: 3.9 nTPM (baseline 2); hippocampal formation: 3.6 nTPM (baseline 2); hypothalamus: 3.7 nTPM (baseline 2); kidney: 6.2 nTPM (baseline 2); liver: 3.8 nTPM (baseline 2); lung: 4.4 nTPM (baseline 2); midbrain: 3.8 nTPM (baseline 2); pancreas: 5 nTPM (baseline 2); pituitary gland: 9.8 nTPM (baseline 2); retina: 4 nTPM (baseline 2); skeletal muscle: 2.9 nTPM (baseline 2); small intestine: 3.7 nTPM (baseline 2); smooth muscle: 2.1 nTPM (baseline 2); spinal cord: 4.9 nTPM (baseline 2),adipose tissue / adipocytes: Medium (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Low (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / endothelial cells: High (Uncertain); colon / endothelial cells: High (Uncertain); colon / glandular cells: Medium (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Low (Uncertain); heart muscle / cardiomyocytes: Low (Uncertain); kidney / cells in glomeruli: Low (Uncertain); kidney / cells in tubules: Low (Uncertain); lung / alveolar cells: Medium (Uncertain); lymph node / germinal center cells: Low (Uncertain); nasopharynx / respiratory epithelial cells: Low (Uncertain); oral mucosa / squamous epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Medium (Uncertain); small intestine / glandular cells: Low (Uncertain); smooth muscle / smooth muscle cells: High (Uncertain); stomach 1 / glandular cells: Low (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Low (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 69/80 (86.2%); Colon Adenocarcinoma (validation): 345/486 (71.0%); Rectum Adenocarcinoma (validation): 145/207 (70.0%),prostate cancer: 10/11 (90.9%); melanoma: 3/8 (37.5%),29,20,Q96ET8,https://www.uniprot.org/uniprotkb/Q96ET8/entry,,,,,Membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
TXNDC2,ENSG00000168454,Unsafe,Protein,False,True,99.4,99.4,86,21,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; colon: 0.1 nTPM; positive ihc; duodenum: 0 nTPM; positive ihc; kidney: 0 nTPM; positive ihc; lung: 0.1 nTPM; positive ihc; parathyroid gland: 0 nTPM; positive ihc; rectum: 0 nTPM; positive ihc; skin: 0 nTPM; positive ihc; small intestine: 0 nTPM; positive ihc; stomach: 0 nTPM; positive ihc; thyroid gland: 0 nTPM; positive ihc; urinary bladder: 0 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,bronchus / respiratory epithelial cells: Low (Enhanced); colon / glandular cells: Low (Enhanced); duodenum / glandular cells: Low (Enhanced); kidney / cells in tubules: Low (Enhanced); lung / macrophages: Low (Enhanced); parathyroid gland / glandular cells: Low (Enhanced); rectum / glandular cells: Low (Enhanced); skin 1 / keratinocytes: Low (Enhanced); small intestine / glandular cells: Low (Enhanced); stomach 1 / glandular cells: Low (Enhanced); thyroid gland / glandular cells: Low (Enhanced); urinary bladder / urothelial cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 2/133 (1.5%); Lung Squamous Cell Carcinoma (validation): 1/68 (1.5%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),liver cancer: 1/12 (8.3%); breast cancer: 0/12 (0.0%),31,20,Q86VQ3,https://www.uniprot.org/uniprotkb/Q86VQ3/entry,Probably plays a regulatory role in sperm development. May participate in regulation of fibrous sheath (FS) assembly by supporting the formation of disulfide bonds during sperm tail morphogenesis. May also be required to rectify incorrect disulfide pairing and generate suitable pairs between the FS constituents. Can reduce disulfide bonds in vitro in the presence of NADP and thioredoxin reductase,"Testis-specific. Only expressed during spermiogenesis, prominently in round and elongating spermatids",,,Cytoplasm,,11399755,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
UBE2S,ENSG00000108106,Unsafe,Protein,False,True,153.9,153.9,81,8,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 17 nTPM; absolute ceiling; amygdala: 36.5 nTPM; absolute ceiling; basal ganglia: 30.6 nTPM; absolute ceiling; bone marrow: 114.3 nTPM; absolute ceiling;continuous selectivity; cerebellum: 25.9 nTPM; absolute ceiling; cerebral cortex: 36.4 nTPM; absolute ceiling; choroid plexus: 19.4 nTPM; absolute ceiling; colon: 17.9 nTPM; positive ihc;absolute ceiling; duodenum: 11 nTPM; absolute ceiling; esophagus: 36 nTPM; absolute ceiling; heart muscle: 24 nTPM; absolute ceiling; hippocampal formation: 36.8 nTPM; absolute ceiling; hypothalamus: 36.1 nTPM; absolute ceiling; kidney: 12.7 nTPM; absolute ceiling; liver: 11.2 nTPM; absolute ceiling; lung: 15.7 nTPM; absolute ceiling; lymph node: 34.8 nTPM; positive ihc;absolute ceiling; midbrain: 27.2 nTPM; absolute ceiling; pancreas: 7.5 nTPM; absolute ceiling; pituitary gland: 28.1 nTPM; absolute ceiling; rectum: 9 nTPM; absolute ceiling; retina: 9.1 nTPM; absolute ceiling; salivary gland: 11.7 nTPM; absolute ceiling; skeletal muscle: 14.9 nTPM; absolute ceiling; small intestine: 15.7 nTPM; absolute ceiling; smooth muscle: 14.5 nTPM; absolute ceiling; spinal cord: 34.4 nTPM; absolute ceiling; spleen: 25.1 nTPM; absolute ceiling; stomach: 17.1 nTPM; absolute ceiling; thymus: 46.5 nTPM; absolute ceiling; urinary bladder: 15.7 nTPM; positive ihc;absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 17 nTPM (limit 4); amygdala: 36.5 nTPM (limit 2); basal ganglia: 30.6 nTPM (limit 2); bone marrow: 114.3 nTPM (limit 4); cerebellum: 25.9 nTPM (limit 4); cerebral cortex: 36.4 nTPM (limit 4); choroid plexus: 19.4 nTPM (limit 2); colon: 17.9 nTPM (limit 6); duodenum: 11 nTPM (limit 4); esophagus: 36 nTPM (limit 8); heart muscle: 24 nTPM (limit 4); hippocampal formation: 36.8 nTPM (limit 2); hypothalamus: 36.1 nTPM (limit 2); kidney: 12.7 nTPM (limit 4); liver: 11.2 nTPM (limit 4); lung: 15.7 nTPM (limit 4); lymph node: 34.8 nTPM (limit 6); midbrain: 27.2 nTPM (limit 2); pancreas: 7.5 nTPM (limit 4); pituitary gland: 28.1 nTPM (limit 2); rectum: 9 nTPM (limit 8); retina: 9.1 nTPM (limit 2); salivary gland: 11.7 nTPM (limit 8); skeletal muscle: 14.9 nTPM (limit 4); small intestine: 15.7 nTPM (limit 4); smooth muscle: 14.5 nTPM (limit 4); spinal cord: 34.4 nTPM (limit 2); spleen: 25.1 nTPM (limit 20); stomach: 17.1 nTPM (limit 8); thymus: 46.5 nTPM (limit 10); urinary bladder: 15.7 nTPM (limit 6),colon / endothelial cells: Low (Approved); lymph node / germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); urinary bladder / urothelial cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Head and Neck Squamous Cell Carcinoma (TCGA): 492/492 (100.0%); Lung Squamous Cell Carcinoma (TCGA): 489/489 (100.0%),melanoma: 3/12 (25.0%); breast cancer: 1/12 (8.3%),31,20,Q16763,https://www.uniprot.org/uniprotkb/Q16763/entry,"Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins (PubMed:19820702, PubMed:19822757, PubMed:22496338, PubMed:27259151). Catalyzes 'Lys-11'-linked polyubiquitination. Acts as an essential factor of the anaphase promoting complex/cyclosome (APC/C), a cell cycle-regulated ubiquitin ligase that controls progression through mitosis (PubMed:19820702, PubMed:19822757, PubMed:27259151, PubMed:27910872). Acts by specifically elongating 'Lys-11'-linked polyubiquitin chains initiated by the E2 enzyme UBE2C/UBCH10 on APC/C substrates, enhancing the degradation of APC/C substrates by the proteasome and promoting mitotic exit (PubMed:19820702, PubMed:19822757, PubMed:27259151). Also acts by elongating ubiquitin chains initiated by the E2 enzyme UBE2D1/UBCH5 in vitro; it is however unclear whether UBE2D1/UBCH5 acts as an E2 enzyme for the APC/C in vivo. Also involved in ubiquitination and subsequent degradation of VHL, resulting in an accumulation of HIF1A (PubMed:16819549). In vitro able to promote polyubiquitination using all 7 ubiquitin Lys residues, except 'Lys-48'-linked polyubiquitination (PubMed:20061386, PubMed:20622874)",,,,,16819549|19820702|19822757|20061386|20622874|22496338|27259151|27910872,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
UBE2V1,ENSG00000244687,Unsafe,RNA,False,True,64.1,86.7,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 59.1 nTPM; absolute ceiling;continuous selectivity; adrenal gland: 54.4 nTPM; absolute ceiling;continuous selectivity; amygdala: 61.1 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 53.6 nTPM; absolute ceiling;continuous selectivity; bone marrow: 50.6 nTPM; absolute ceiling;continuous selectivity; cerebellum: 53.1 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 78.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 77 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 67.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 56.8 nTPM; absolute ceiling;continuous selectivity; esophagus: 69.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 60.1 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 51 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 55.3 nTPM; absolute ceiling;continuous selectivity; kidney: 55.8 nTPM; absolute ceiling;continuous selectivity; liver: 75.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 56.6 nTPM; absolute ceiling;continuous selectivity; lymph node: 66.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 50.3 nTPM; absolute ceiling;continuous selectivity; pancreas: 62.7 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 59.1 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 33.4 nTPM; absolute ceiling;continuous selectivity; rectum: 59.3 nTPM; absolute ceiling;continuous selectivity; retina: 45.7 nTPM; absolute ceiling;continuous selectivity; salivary gland: 54 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 84.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 61.9 nTPM; absolute ceiling;continuous selectivity; small intestine: 50.4 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 70.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 35.9 nTPM; absolute ceiling;continuous selectivity; spleen: 50.5 nTPM; absolute ceiling;continuous selectivity; stomach: 54.3 nTPM; absolute ceiling;continuous selectivity; thymus: 59.2 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 48.4 nTPM; absolute ceiling;continuous selectivity; tongue: 68.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 65.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,adipose tissue: 59.1 nTPM (limit 10); adrenal gland: 54.4 nTPM (limit 2); amygdala: 61.1 nTPM (limit 2); basal ganglia: 53.6 nTPM (limit 2); bone marrow: 50.6 nTPM (limit 2); cerebellum: 53.1 nTPM (limit 2); cerebral cortex: 78.3 nTPM (limit 2); choroid plexus: 77 nTPM (limit 2); colon: 67.1 nTPM (limit 6); duodenum: 56.8 nTPM (limit 2); esophagus: 69.2 nTPM (limit 6); heart muscle: 60.1 nTPM (limit 2); hippocampal formation: 51 nTPM (limit 2); hypothalamus: 55.3 nTPM (limit 2); kidney: 55.8 nTPM (limit 2); liver: 75.8 nTPM (limit 2); lung: 56.6 nTPM (limit 2); lymph node: 66.8 nTPM (limit 6); midbrain: 50.3 nTPM (limit 2); pancreas: 62.7 nTPM (limit 2); parathyroid gland: 59.1 nTPM (limit 6); pituitary gland: 33.4 nTPM (limit 2); rectum: 59.3 nTPM (limit 6); retina: 45.7 nTPM (limit 2); salivary gland: 54 nTPM (limit 6); skeletal muscle: 84.8 nTPM (limit 2); skin: 61.9 nTPM (limit 10); small intestine: 50.4 nTPM (limit 2); smooth muscle: 70.8 nTPM (limit 2); spinal cord: 35.9 nTPM (limit 2); spleen: 50.5 nTPM (limit 10); stomach: 54.3 nTPM (limit 6); thymus: 59.2 nTPM (limit 10); thyroid gland: 48.4 nTPM (limit 10); tongue: 68.2 nTPM (limit 6); urinary bladder: 65.3 nTPM (limit 6); adipose tissue: 59.1 nTPM (baseline 10); adrenal gland: 54.4 nTPM (baseline 2); amygdala: 61.1 nTPM (baseline 2); basal ganglia: 53.6 nTPM (baseline 2); bone marrow: 50.6 nTPM (baseline 2); cerebellum: 53.1 nTPM (baseline 2); cerebral cortex: 78.3 nTPM (baseline 2); choroid plexus: 77 nTPM (baseline 2); colon: 67.1 nTPM (baseline 6); duodenum: 56.8 nTPM (baseline 2); esophagus: 69.2 nTPM (baseline 6); heart muscle: 60.1 nTPM (baseline 2); hippocampal formation: 51 nTPM (baseline 2); hypothalamus: 55.3 nTPM (baseline 2); kidney: 55.8 nTPM (baseline 2); liver: 75.8 nTPM (baseline 2); lung: 56.6 nTPM (baseline 2); lymph node: 66.8 nTPM (baseline 6); midbrain: 50.3 nTPM (baseline 2); pancreas: 62.7 nTPM (baseline 2); parathyroid gland: 59.1 nTPM (baseline 6); pituitary gland: 33.4 nTPM (baseline 2); rectum: 59.3 nTPM (baseline 6); retina: 45.7 nTPM (baseline 2); salivary gland: 54 nTPM (baseline 6); skeletal muscle: 84.8 nTPM (baseline 2); skin: 61.9 nTPM (baseline 10); small intestine: 50.4 nTPM (baseline 2); smooth muscle: 70.8 nTPM (baseline 2); spinal cord: 35.9 nTPM (baseline 2); spleen: 50.5 nTPM (baseline 10); stomach: 54.3 nTPM (baseline 6); thymus: 59.2 nTPM (baseline 10); thyroid gland: 48.4 nTPM (baseline 10); tongue: 68.2 nTPM (baseline 6); urinary bladder: 65.3 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Kidney Renal Clear Cell Carcinoma (TCGA): 521/521 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q13404,https://www.uniprot.org/uniprotkb/Q13404/entry,"Has no ubiquitin ligase activity on its own. The UBE2V1-UBE2N heterodimer catalyzes the synthesis of non-canonical poly-ubiquitin chains that are linked through Lys-63. This type of poly-ubiquitination activates IKK and does not seem to involve protein degradation by the proteasome. Plays a role in the activation of NF-kappa-B mediated by IL1B, TNF, TRAF6 and TRAF2. Mediates transcriptional activation of target genes. Plays a role in the control of progress through the cell cycle and differentiation. Plays a role in the error-free DNA repair pathway and contributes to the survival of cells after DNA damage. Promotes TRIM5 capsid-specific restriction activity and the UBE2V1-UBE2N heterodimer acts in concert with TRIM5 to generate 'Lys-63'-linked polyubiquitin chains which activate the MAP3K7/TAK1 complex which in turn results in the induction and expression of NF-kappa-B and MAPK-responsive inflammatory genes. Together with RNF135 and UBE2N, catalyzes the viral RNA-dependent 'Lys-63'-linked polyubiquitination of RIGI to activate the downstream signaling pathway that leads to interferon beta production (PubMed:31006531). UBE2V1-UBE2N together with TRAF3IP2 E3 ubiquitin ligase mediate 'Lys-63'-linked polyubiquitination of TRAF6, a component of IL17A-mediated signaling pathway","Highly expressed in thyroid, pancreas, spinal cord, lymph node, trachea, adrenal gland, bone marrow and pancreas. Detected at low levels in heart, breast, placenta, brain, liver, kidney, stomach and lung",,,Nucleus,11057907|19825828|20061386|21512573|31006531|9305758|9418904|9580084|9705497,9418904|9705497,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
UBE3C,ENSG00000009335,Unsafe,Protein,False,True,25.5,63.3,91,66,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 24.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 16.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 10.5 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 13 nTPM; absolute ceiling;continuous selectivity; bone marrow: 16 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 19.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 16.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 13.3 nTPM; absolute ceiling;continuous selectivity; colon: 21.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 19.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 27.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 27.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 10.9 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 10.3 nTPM; absolute ceiling;continuous selectivity; kidney: 19.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 22.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 18.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 20.5 nTPM; absolute ceiling;continuous selectivity; midbrain: 10.9 nTPM; absolute ceiling;continuous selectivity; pancreas: 21.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 35 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 10.8 nTPM; absolute ceiling;continuous selectivity; rectum: 22.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 19.6 nTPM; absolute ceiling;continuous selectivity; salivary gland: 22.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 63.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 20.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 20.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 28.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 12.7 nTPM; absolute ceiling;continuous selectivity; spleen: 17.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 20.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 18.1 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 16.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 56.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 27.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 24.8 nTPM (limit 10); adrenal gland: 16.8 nTPM (limit 2); amygdala: 10.5 nTPM (limit 2); basal ganglia: 13 nTPM (limit 2); bone marrow: 16 nTPM (limit 2); cerebellum: 19.2 nTPM (limit 2); cerebral cortex: 16.3 nTPM (limit 2); choroid plexus: 13.3 nTPM (limit 2); colon: 21.6 nTPM (limit 6); duodenum: 19.4 nTPM (limit 2); esophagus: 27.3 nTPM (limit 6); heart muscle: 27.5 nTPM (limit 2); hippocampal formation: 10.9 nTPM (limit 2); hypothalamus: 10.3 nTPM (limit 2); kidney: 19.6 nTPM (limit 2); liver: 22.3 nTPM (limit 2); lung: 18.4 nTPM (limit 2); lymph node: 20.5 nTPM (limit 8); midbrain: 10.9 nTPM (limit 2); pancreas: 21.7 nTPM (limit 2); parathyroid gland: 35 nTPM (limit 6); pituitary gland: 10.8 nTPM (limit 2); rectum: 22.5 nTPM (limit 6); retina: 19.6 nTPM (limit 2); salivary gland: 22.1 nTPM (limit 6); skeletal muscle: 63.3 nTPM (limit 2); skin: 20.2 nTPM (limit 10); small intestine: 20.3 nTPM (limit 2); smooth muscle: 28.1 nTPM (limit 4); spinal cord: 12.7 nTPM (limit 2); spleen: 17.5 nTPM (limit 10); stomach: 20.4 nTPM (limit 6); thymus: 18.1 nTPM (limit 10); thyroid gland: 16.8 nTPM (limit 10); tongue: 56.3 nTPM (limit 6); urinary bladder: 27.1 nTPM (limit 6),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / basal cells: High (Approved); bronchus / ciliated cells (cell body): Medium (Approved); bronchus / ciliated cells (ciliary rootlets): High (Approved); caudate / glial cells: Low (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); cerebral cortex / neuropil: Medium (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: High (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Medium (Approved); nasopharynx / basal cells: Medium (Approved); nasopharynx / ciliated cells (cell body): Medium (Approved); nasopharynx / ciliated cells (ciliary rootlets): High (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: High (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Low (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Medium (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Low (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Stomach Adenocarcinoma (TCGA): 346/346 (100.0%); Colon Adenocarcinoma (TCGA): 254/254 (100.0%),liver cancer: 12/12 (100.0%); stomach cancer: 10/10 (100.0%),31,20,Q15386,https://www.uniprot.org/uniprotkb/Q15386/entry,"E3 ubiquitin-protein ligase that specifically catalyzes 'Lys-29'- and 'Lys-48'-linked polyubiquitin chains (PubMed:11278995, PubMed:12692129, PubMed:16341092, PubMed:16601690, PubMed:24158444, PubMed:24811749, PubMed:25752573, PubMed:25752577, PubMed:32039437, PubMed:33637724, PubMed:34239127). Accepts ubiquitin from the E2 ubiquitin-conjugating enzyme UBE2D1 in the form of a thioester and then directly transfers the ubiquitin to targeted substrates (PubMed:32039437, PubMed:9575161). Associates with the proteasome and promotes elongation of ubiquitin chains on substrates bound to the 26S proteasome (PubMed:24158444, PubMed:28396413, PubMed:31375563). Also catalyzes 'Lys-29'- and 'Lys-48'-linked ubiquitination of 26S proteasome subunit ADRM1/RPN13 in response to proteotoxic stress, impairing the ability of the proteasome to bind and degrade ubiquitin-conjugated proteins (PubMed:24811749, PubMed:31375563). Acts as a negative regulator of autophagy by mediating 'Lys-29'- and 'Lys-48'-linked ubiquitination of PIK3C3/VPS34, promoting its degradation (PubMed:33637724). Can assemble unanchored poly-ubiquitin chains in either 'Lys-29'- or 'Lys-48'-linked polyubiquitin chains; with some preference for 'Lys-48' linkages (PubMed:11278995, PubMed:16601690, PubMed:25752577). Acts as a negative regulator of type I interferon by mediating 'Lys-48'-linked ubiquitination of IRF3 and IRF7, leading to their degradation by the proteasome (PubMed:21167755). Catalyzes ubiquitination and degradation of CAND2 (PubMed:12692129)",Highly expressed in skeletal muscle. Detected at much lower levels in kidney and pancreas,"Neurodevelopmental disorder with absent speech and movement and behavioral abnormalities: An autosomal recessive disorder characterized by global developmental delay apparent in infancy, severely impaired intellectual development, absent speech, and aggressive behavior.",,,11278995|12692129|16341092|16601690|21167755|24158444|24811749|25752573|25752577|28396413|31375563|32039437|33637724|34239127|9575161,11278995|12692129|9575161,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
UBE3D,ENSG00000118420,Unsafe,Protein,False,True,4.8,4.8,77,59,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 2.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 1.8 nTPM; continuous selectivity; basal ganglia: 2.6 nTPM; absolute ceiling;continuous selectivity; bone marrow: 0.8 nTPM; positive ihc; cerebellum: 2.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 2.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 1.6 nTPM; positive ihc; duodenum: 2.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 1.7 nTPM; positive ihc; heart muscle: 1.4 nTPM; positive ihc;continuous selectivity; hippocampal formation: 1.7 nTPM; continuous selectivity; hypothalamus: 2.7 nTPM; absolute ceiling;continuous selectivity; kidney: 2.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 1.2 nTPM; positive ihc; lung: 1.1 nTPM; positive ihc; lymph node: 1.6 nTPM; positive ihc; midbrain: 2.1 nTPM; absolute ceiling;continuous selectivity; pancreas: 2.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 1.9 nTPM; positive ihc;continuous selectivity; pituitary gland: 2.3 nTPM; absolute ceiling;continuous selectivity; rectum: 1.6 nTPM; positive ihc; retina: 3.3 nTPM; absolute ceiling;continuous selectivity; salivary gland: 1.8 nTPM; positive ihc;continuous selectivity; skeletal muscle: 2.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 1.3 nTPM; positive ihc; small intestine: 1.4 nTPM; positive ihc;continuous selectivity; smooth muscle: 1.5 nTPM; positive ihc;continuous selectivity; spinal cord: 1.8 nTPM; continuous selectivity; spleen: 1.6 nTPM; positive ihc; stomach: 1.7 nTPM; positive ihc; thyroid gland: 2.6 nTPM; positive ihc;continuous selectivity; tongue: 2.4 nTPM; continuous selectivity; urinary bladder: 2 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 2.3 nTPM (limit 2); basal ganglia: 2.6 nTPM (limit 2); cerebellum: 2.3 nTPM (limit 2); cerebral cortex: 2.8 nTPM (limit 2); duodenum: 2.1 nTPM (limit 2); hypothalamus: 2.7 nTPM (limit 2); kidney: 2.1 nTPM (limit 2); midbrain: 2.1 nTPM (limit 2); pancreas: 2.2 nTPM (limit 2); pituitary gland: 2.3 nTPM (limit 2); retina: 3.3 nTPM (limit 2); skeletal muscle: 2.6 nTPM (limit 2),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: High (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: Low (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: High (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Low (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: High (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: High (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Low (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 51/58 (87.9%); Pancreatic Adenocarcinoma (validation): 28/80 (35.0%); Rectum Adenocarcinoma (TCGA): 30/88 (34.1%),liver cancer: 5/12 (41.7%); ovarian cancer: 3/12 (25.0%),29,20,Q7Z6J8,https://www.uniprot.org/uniprotkb/Q7Z6J8/entry,"E3 ubiquitin-protein ligase which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and transfers it to substrates, generally promoting their degradation by the proteasome (PubMed:15749827). Independently of its E3 ubiquitin-protein ligase activity, acts as an inhibitor of CPSF3 endonuclease activity by blocking CPSF3 active site (PubMed:39032490)",,,,Cytoplasm,15749827|39032490,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
UBL4B,ENSG00000186150,Unsafe,RNA,False,True,102.0,102.0,86,2,Positive somewhere,False,True,False,True,Excluded,Normal,False,,Not assessed,,,choroid plexus: 3.2 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 3.2 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 1/58 (1.7%); Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%); Glioblastoma Multiforme (TCGA): 1/141 (0.7%),lung cancer: 3/12 (25.0%); melanoma: 3/12 (25.0%),31,20,Q8N7F7,https://www.uniprot.org/uniprotkb/Q8N7F7/entry,,,,,Cytoplasm,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
UBXN10,ENSG00000162543,Unsafe,Protein,False,True,48.1,48.1,79,66,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0.6 nTPM; positive ihc; adrenal gland: 1.3 nTPM; positive ihc; basal ganglia: 2.4 nTPM; absolute ceiling; bone marrow: 2 nTPM; positive ihc; cerebellum: 1.1 nTPM; positive ihc; cerebral cortex: 3 nTPM; positive ihc;absolute ceiling; choroid plexus: 23.1 nTPM; absolute ceiling;continuous selectivity; colon: 9.3 nTPM; positive ihc;absolute ceiling; duodenum: 0.8 nTPM; positive ihc; esophagus: 3.9 nTPM; positive ihc; heart muscle: 3.4 nTPM; positive ihc;absolute ceiling; hippocampal formation: 2.1 nTPM; absolute ceiling; hypothalamus: 2.8 nTPM; absolute ceiling; kidney: 2 nTPM; positive ihc; liver: 5.7 nTPM; positive ihc;absolute ceiling; lung: 5.1 nTPM; positive ihc;absolute ceiling; midbrain: 2.2 nTPM; absolute ceiling; pancreas: 1.5 nTPM; positive ihc; parathyroid gland: 4.7 nTPM; positive ihc; pituitary gland: 2.9 nTPM; absolute ceiling; rectum: 4.6 nTPM; positive ihc; retina: 2.1 nTPM; absolute ceiling; salivary gland: 0.9 nTPM; positive ihc; skin: 0.5 nTPM; positive ihc; small intestine: 1.9 nTPM; positive ihc; smooth muscle: 3.2 nTPM; positive ihc;absolute ceiling; stomach: 2.2 nTPM; positive ihc; thyroid gland: 5.3 nTPM; positive ihc; urinary bladder: 2.5 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",basal ganglia: 2.4 nTPM (limit 2); cerebral cortex: 3 nTPM (limit 2); choroid plexus: 23.1 nTPM (limit 2); colon: 9.3 nTPM (limit 6); heart muscle: 3.4 nTPM (limit 2); hippocampal formation: 2.1 nTPM (limit 2); hypothalamus: 2.8 nTPM (limit 2); liver: 5.7 nTPM (limit 2); lung: 5.1 nTPM (limit 2); midbrain: 2.2 nTPM (limit 2); pituitary gland: 2.9 nTPM (limit 2); retina: 2.1 nTPM (limit 2); smooth muscle: 3.2 nTPM (limit 2); basal ganglia: 2.4 nTPM (baseline 2); cerebral cortex: 3 nTPM (baseline 2); choroid plexus: 23.1 nTPM (baseline 2); colon: 9.3 nTPM (baseline 6); heart muscle: 3.4 nTPM (baseline 2); hippocampal formation: 2.1 nTPM (baseline 2); hypothalamus: 2.8 nTPM (baseline 2); liver: 5.7 nTPM (baseline 2); lung: 5.1 nTPM (baseline 2); midbrain: 2.2 nTPM (baseline 2); pituitary gland: 2.9 nTPM (baseline 2); retina: 2.1 nTPM (baseline 2); smooth muscle: 3.2 nTPM (baseline 2),adipose tissue / adipocytes: Medium (Uncertain); adrenal gland / glandular cells: High (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: High (Uncertain); caudate / glial cells: Low (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: Medium (Uncertain); cerebellum / cells in molecular layer: Low (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / glial cells: Low (Uncertain); cerebral cortex / neuronal cells: High (Uncertain); colon / endothelial cells: Low (Uncertain); colon / glandular cells: Medium (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / glial cells: Low (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in glomeruli: Low (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / cholangiocytes: Low (Uncertain); liver / hepatocytes: Low (Uncertain); lung / alveolar cells: Low (Uncertain); lung / macrophages: Medium (Uncertain); nasopharynx / respiratory epithelial cells: High (Uncertain); oral mucosa / squamous epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skin 1 / keratinocytes: Medium (Uncertain); skin 1 / Langerhans: Low (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: Medium (Uncertain); smooth muscle / smooth muscle cells: Low (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 50/50 (100.0%); Thyroid Carcinoma (TCGA): 344/495 (69.5%); Colon Adenocarcinoma (validation): 309/486 (63.6%),colorectal cancer: 12/12 (100.0%); melanoma: 10/11 (90.9%),31,20,Q96LJ8,https://www.uniprot.org/uniprotkb/Q96LJ8/entry,VCP/p97-binding protein required for ciliogenesis (PubMed:26389662). Acts as a tethering factor that facilitates recruitment of VCP/p97 to the intraflagellar transport complex B (IFT-B) in cilia (PubMed:26389662). UBX domain-containing proteins act as tethering factors for VCP/p97 and may specify substrate specificity of VCP/p97 (PubMed:26389662),,,,"Cell projection, cilium",26389662,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
UCN2,ENSG00000145040,Unsafe,RNA,False,True,4.3,12.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,esophagus: 3.3 nTPM; continuous selectivity; kidney: 1.4 nTPM; continuous selectivity; salivary gland: 1.6 nTPM; continuous selectivity; skin: 12.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,skin: 12.8 nTPM (limit 10); skin: 12.8 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Skin Cuteneous Melanoma (TCGA): 58/99 (58.6%); Head and Neck Squamous Cell Carcinoma (TCGA): 236/492 (48.0%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 109/283 (38.5%),breast cancer: 0/10 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q96RP3,https://www.uniprot.org/uniprotkb/Q96RP3/entry,"Hormone that plays a central role in whole body adaptation to stress (PubMed:11329063). Released by the hypothalamus primarily in response to physical or psychological stress and acts by binding to CRH receptor CRHR2 (PubMed:20966082). UCN2-dependent signaling regulates cardiovascular function, promotes skeletal muscle hypertrophy and manage energy balance and acts as an anorexigenic agent (By similarity). In contrast to CRH and UCN, does not activate the hypothalamus-pituitary-adrenal axis to promote corticotropin hormone (ACTH) production (PubMed:11329063)",,,,Secreted,11329063|20966082,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
UGGT2,ENSG00000102595,Unsafe,RNA,False,True,15.6,15.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 11.4 nTPM; absolute ceiling;continuous selectivity; adrenal gland: 6.7 nTPM; absolute ceiling;continuous selectivity; amygdala: 4.3 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 3.7 nTPM; absolute ceiling; bone marrow: 3.7 nTPM; absolute ceiling; cerebral cortex: 5.3 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 6.9 nTPM; absolute ceiling;continuous selectivity; colon: 6.6 nTPM; absolute ceiling;continuous selectivity; duodenum: 5.2 nTPM; absolute ceiling;continuous selectivity; heart muscle: 8.4 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 5.4 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 5.5 nTPM; absolute ceiling;continuous selectivity; kidney: 7.3 nTPM; absolute ceiling;continuous selectivity; liver: 8.1 nTPM; absolute ceiling;continuous selectivity; lung: 6.4 nTPM; absolute ceiling;continuous selectivity; midbrain: 4.6 nTPM; absolute ceiling;continuous selectivity; pancreas: 10.3 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 7.4 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 8.5 nTPM; absolute ceiling;continuous selectivity; rectum: 6 nTPM; continuous selectivity; retina: 7.4 nTPM; absolute ceiling;continuous selectivity; salivary gland: 7.8 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 3.9 nTPM; absolute ceiling; small intestine: 4.5 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 9.6 nTPM; absolute ceiling;continuous selectivity; spinal cord: 5.7 nTPM; absolute ceiling;continuous selectivity; stomach: 7.7 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 11.1 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 8 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adipose tissue: 11.4 nTPM (limit 10); adrenal gland: 6.7 nTPM (limit 2); amygdala: 4.3 nTPM (limit 2); basal ganglia: 3.7 nTPM (limit 2); bone marrow: 3.7 nTPM (limit 2); cerebral cortex: 5.3 nTPM (limit 2); choroid plexus: 6.9 nTPM (limit 2); colon: 6.6 nTPM (limit 6); duodenum: 5.2 nTPM (limit 2); heart muscle: 8.4 nTPM (limit 2); hippocampal formation: 5.4 nTPM (limit 2); hypothalamus: 5.5 nTPM (limit 2); kidney: 7.3 nTPM (limit 2); liver: 8.1 nTPM (limit 2); lung: 6.4 nTPM (limit 2); midbrain: 4.6 nTPM (limit 2); pancreas: 10.3 nTPM (limit 2); parathyroid gland: 7.4 nTPM (limit 6); pituitary gland: 8.5 nTPM (limit 2); retina: 7.4 nTPM (limit 2); salivary gland: 7.8 nTPM (limit 6); skeletal muscle: 3.9 nTPM (limit 2); small intestine: 4.5 nTPM (limit 2); smooth muscle: 9.6 nTPM (limit 2); spinal cord: 5.7 nTPM (limit 2); stomach: 7.7 nTPM (limit 6); thyroid gland: 11.1 nTPM (limit 10); urinary bladder: 8 nTPM (limit 6); adipose tissue: 11.4 nTPM (baseline 10); adrenal gland: 6.7 nTPM (baseline 2); amygdala: 4.3 nTPM (baseline 2); basal ganglia: 3.7 nTPM (baseline 2); bone marrow: 3.7 nTPM (baseline 2); cerebral cortex: 5.3 nTPM (baseline 2); choroid plexus: 6.9 nTPM (baseline 2); colon: 6.6 nTPM (baseline 6); duodenum: 5.2 nTPM (baseline 2); heart muscle: 8.4 nTPM (baseline 2); hippocampal formation: 5.4 nTPM (baseline 2); hypothalamus: 5.5 nTPM (baseline 2); kidney: 7.3 nTPM (baseline 2); liver: 8.1 nTPM (baseline 2); lung: 6.4 nTPM (baseline 2); midbrain: 4.6 nTPM (baseline 2); pancreas: 10.3 nTPM (baseline 2); parathyroid gland: 7.4 nTPM (baseline 6); pituitary gland: 8.5 nTPM (baseline 2); retina: 7.4 nTPM (baseline 2); salivary gland: 7.8 nTPM (baseline 6); skeletal muscle: 3.9 nTPM (baseline 2); small intestine: 4.5 nTPM (baseline 2); smooth muscle: 9.6 nTPM (baseline 2); spinal cord: 5.7 nTPM (baseline 2); stomach: 7.7 nTPM (baseline 6); thyroid gland: 11.1 nTPM (baseline 10); urinary bladder: 8 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%),endometrial cancer: 9/11 (81.8%); cervical cancer: 7/12 (58.3%),31,20,Q9NYU1,https://www.uniprot.org/uniprotkb/Q9NYU1/entry,"Recognizes glycoproteins with minor folding defects. Reglucosylates single N-glycans near the misfolded part of the protein, thus providing quality control for protein folding in the endoplasmic reticulum. Reglucosylated proteins are recognized by calreticulin for recycling to the endoplasmic reticulum and refolding or degradation","Higher levels in kidney, pancreas, heart, and skeletal muscle",,Has no enzymatic activity towards unfolded RNase B or thyroglobulin,Endoplasmic reticulum lumen Endoplasmic reticulum-Golgi intermediate compartment,24415556,10694380,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
ULBP3,ENSG00000131019,Unsafe,Protein,False,True,6.1,6.3,86,21,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 0.7 nTPM; positive ihc; esophagus: 1.5 nTPM; positive ihc; lymph node: 0.5 nTPM; positive ihc; rectum: 0.7 nTPM; positive ihc; skeletal muscle: 6.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 1 nTPM; positive ihc; spleen: 0.6 nTPM; positive ihc; stomach: 1.8 nTPM; positive ihc; thyroid gland: 4.8 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",skeletal muscle: 6.3 nTPM (limit 4),bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Low (Approved); caudate / neuronal cells: Low (Approved); esophagus / squamous epithelial cells: Low (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); rectum / glandular cells: Low (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: Low (Approved); spleen / cells in white pulp: Low (Approved); stomach 2 / glandular cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Thyroid Carcinoma (TCGA): 378/495 (76.4%); Colon Adenocarcinoma (validation): 368/486 (75.7%); Glioblastoma Multiforme (validation): 40/58 (69.0%),breast cancer: 1/11 (9.1%); cervical cancer: 0/12 (0.0%),31,20,Q9BZM4,https://www.uniprot.org/uniprotkb/Q9BZM4/entry,"Binds and activates the KLRK1/NKG2D receptor, mediating natural killer cell cytotoxicity",,,,Cell membrane,11491531|11754823|11777960,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
ULK2,ENSG00000083290,Unsafe,Protein,False,True,32.8,35.9,87,86,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 10.2 nTPM; positive ihc;absolute ceiling; adrenal gland: 6.7 nTPM; positive ihc;absolute ceiling; amygdala: 18.2 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 15.9 nTPM; absolute ceiling;continuous selectivity; bone marrow: 3 nTPM; positive ihc;absolute ceiling; cerebellum: 18.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 17.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 11.8 nTPM; absolute ceiling;continuous selectivity; colon: 10.5 nTPM; positive ihc;absolute ceiling; duodenum: 2.9 nTPM; positive ihc;absolute ceiling; esophagus: 6.1 nTPM; positive ihc;absolute ceiling; heart muscle: 8 nTPM; positive ihc;absolute ceiling; hippocampal formation: 17.8 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 13.4 nTPM; absolute ceiling;continuous selectivity; kidney: 6.4 nTPM; positive ihc;absolute ceiling; liver: 3.3 nTPM; positive ihc;absolute ceiling; lung: 8.2 nTPM; positive ihc;absolute ceiling; lymph node: 4.7 nTPM; positive ihc; midbrain: 20.1 nTPM; absolute ceiling;continuous selectivity; pancreas: 7.3 nTPM; positive ihc;absolute ceiling; parathyroid gland: 12.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 5.2 nTPM; absolute ceiling; rectum: 4.1 nTPM; positive ihc; retina: 9.2 nTPM; absolute ceiling;continuous selectivity; salivary gland: 5.7 nTPM; positive ihc; skeletal muscle: 14.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 7.3 nTPM; positive ihc; small intestine: 4.5 nTPM; positive ihc;absolute ceiling; smooth muscle: 9.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 35.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 7 nTPM; positive ihc; stomach: 7.2 nTPM; positive ihc;absolute ceiling; thyroid gland: 6.2 nTPM; positive ihc; tongue: 14.1 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 8.7 nTPM; positive ihc;absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 10.2 nTPM (limit 10); adrenal gland: 6.7 nTPM (limit 2); amygdala: 18.2 nTPM (limit 2); basal ganglia: 15.9 nTPM (limit 2); bone marrow: 3 nTPM (limit 2); cerebellum: 18.1 nTPM (limit 2); cerebral cortex: 17.7 nTPM (limit 2); choroid plexus: 11.8 nTPM (limit 2); colon: 10.5 nTPM (limit 6); duodenum: 2.9 nTPM (limit 2); esophagus: 6.1 nTPM (limit 6); heart muscle: 8 nTPM (limit 2); hippocampal formation: 17.8 nTPM (limit 2); hypothalamus: 13.4 nTPM (limit 2); kidney: 6.4 nTPM (limit 2); liver: 3.3 nTPM (limit 2); lung: 8.2 nTPM (limit 2); midbrain: 20.1 nTPM (limit 2); pancreas: 7.3 nTPM (limit 2); parathyroid gland: 12.8 nTPM (limit 6); pituitary gland: 5.2 nTPM (limit 2); retina: 9.2 nTPM (limit 2); skeletal muscle: 14.7 nTPM (limit 2); small intestine: 4.5 nTPM (limit 2); smooth muscle: 9.2 nTPM (limit 2); spinal cord: 35.9 nTPM (limit 2); stomach: 7.2 nTPM (limit 6); tongue: 14.1 nTPM (limit 6); urinary bladder: 8.7 nTPM (limit 6),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Low (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Low (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Low (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Low (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Breast Invasive Carcinoma (validation): 48/50 (96.0%); Kidney Renal Clear Cell Carcinoma (validation): 87/100 (87.0%),liver cancer: 12/12 (100.0%); ovarian cancer: 12/12 (100.0%),31,20,Q8IYT8,https://www.uniprot.org/uniprotkb/Q8IYT8/entry,"Serine/threonine-protein kinase involved in autophagy in response to starvation. Acts upstream of phosphatidylinositol 3-kinase PIK3C3 to regulate the formation of autophagophores, the precursors of autophagosomes. Part of regulatory feedback loops in autophagy: acts both as a downstream effector and a negative regulator of mammalian target of rapamycin complex 1 (mTORC1) via interaction with RPTOR. Activated via phosphorylation by AMPK, also acts as a negative regulator of AMPK through phosphorylation of the AMPK subunits PRKAA1, PRKAB2 and PRKAG1. May phosphorylate ATG13/KIAA0652, FRS2, FRS3 and RPTOR; however such data need additional evidence. Not involved in ammonia-induced autophagy or in autophagic response of cerebellar granule neurons (CGN) to low potassium concentration. Plays a role early in neuronal differentiation and is required for granule cell axon formation: may govern axon formation via Ras-like GTPase signaling and through regulation of the Rab5-mediated endocytic pathways within developing axons",,,,Cytoplasmic vesicle membrane,18936157|21460634|21460635|21690395|21795849,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
ULK4,ENSG00000168038,Unsafe,Protein,False,True,22.7,22.7,80,52,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 2.6 nTPM; positive ihc; adrenal gland: 3 nTPM; positive ihc;absolute ceiling; bone marrow: 8.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 0.6 nTPM; positive ihc; cerebral cortex: 1 nTPM; positive ihc; choroid plexus: 7 nTPM; absolute ceiling;continuous selectivity; colon: 1.6 nTPM; positive ihc; duodenum: 1.1 nTPM; positive ihc; esophagus: 1.5 nTPM; positive ihc; heart muscle: 8.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; kidney: 3.7 nTPM; positive ihc;absolute ceiling; liver: 2 nTPM; positive ihc; lung: 3.4 nTPM; positive ihc;absolute ceiling; lymph node: 3 nTPM; positive ihc; parathyroid gland: 7.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 2.8 nTPM; absolute ceiling; rectum: 1.6 nTPM; positive ihc; retina: 5.8 nTPM; absolute ceiling;continuous selectivity; salivary gland: 1.6 nTPM; positive ihc; skeletal muscle: 0.4 nTPM; positive ihc; skin: 2.1 nTPM; positive ihc; small intestine: 1.9 nTPM; positive ihc; smooth muscle: 3.4 nTPM; positive ihc;absolute ceiling; spleen: 2 nTPM; positive ihc; stomach: 2.3 nTPM; positive ihc; thyroid gland: 4.7 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 3 nTPM (limit 2); bone marrow: 8.4 nTPM (limit 2); choroid plexus: 7 nTPM (limit 2); heart muscle: 8.3 nTPM (limit 2); kidney: 3.7 nTPM (limit 2); lung: 3.4 nTPM (limit 2); parathyroid gland: 7.7 nTPM (limit 6); pituitary gland: 2.8 nTPM (limit 2); retina: 5.8 nTPM (limit 2); smooth muscle: 3.4 nTPM (limit 2); adrenal gland: 3 nTPM (baseline 2); bone marrow: 8.4 nTPM (baseline 2); choroid plexus: 7 nTPM (baseline 2); heart muscle: 8.3 nTPM (baseline 2); kidney: 3.7 nTPM (baseline 2); lung: 3.4 nTPM (baseline 2); parathyroid gland: 7.7 nTPM (baseline 6); pituitary gland: 2.8 nTPM (baseline 2); retina: 5.8 nTPM (baseline 2); smooth muscle: 3.4 nTPM (baseline 2),adipose tissue / adipocytes: Low (Uncertain); adrenal gland / glandular cells: Low (Uncertain); bone marrow / hematopoietic cells: Low (Uncertain); bronchus / respiratory epithelial cells: Low (Uncertain); caudate / glial cells: Low (Uncertain); caudate / neuronal cells: Low (Uncertain); cerebellum / cells in granular layer: Low (Uncertain); cerebellum / Purkinje cells: Low (Uncertain); cerebral cortex / endothelial cells: Low (Uncertain); colon / endothelial cells: Low (Uncertain); colon / glandular cells: Low (Uncertain); colon / peripheral nerve/ganglion: Low (Uncertain); duodenum / glandular cells: Low (Uncertain); esophagus / squamous epithelial cells: Low (Uncertain); heart muscle / cardiomyocytes: Low (Uncertain); hippocampus / neuronal cells: Low (Uncertain); kidney / cells in tubules: Low (Uncertain); liver / hepatocytes: Low (Uncertain); lung / macrophages: Low (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); nasopharynx / respiratory epithelial cells: Low (Uncertain); parathyroid gland / glandular cells: Low (Uncertain); rectum / glandular cells: Low (Uncertain); salivary gland / glandular cells: Low (Uncertain); skeletal muscle / myocytes: Low (Uncertain); skin 1 / fibroblasts: Low (Uncertain); skin 2 / epidermal cells: Low (Uncertain); small intestine / glandular cells: Low (Uncertain); smooth muscle / smooth muscle cells: Low (Uncertain); spleen / cells in red pulp: Low (Uncertain); stomach 1 / glandular cells: Low (Uncertain); stomach 2 / glandular cells: Low (Uncertain); thyroid gland / glandular cells: Low (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 42/50 (84.0%); Colon Adenocarcinoma (validation): 379/486 (78.0%),melanoma: 9/10 (90.0%); colorectal cancer: 9/12 (75.0%),31,20,Q96C45,https://www.uniprot.org/uniprotkb/Q96C45/entry,"Pseudokinase that acts as a molecular adapter in the smoothened signaling pathway (PubMed:38096226). Required to relieve inhibition of the GLI2 transcription factor in the presence of hedgehog (DHH, IHH or SHH) ligand: acts by mediating the association between STK36 and its ligand GLI2 in ciliary tip, promoting GLI2 phosphorylation and dissociation from SUFU inhibitor, followed by GLI2 translocation to the nucleus (PubMed:38096226)","Expressed in the brain, mainly in postmitotic neurons, including GABAergic neurons, but not in astrocytes (at protein level)",,,"Cell projection, cilium",38096226,24284070,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
UQCR11,ENSG00000127540,Unsafe,RNA,False,True,60.1,301.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 68.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; adrenal gland: 77.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 139.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 112.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 39 nTPM; absolute ceiling;continuous selectivity; cerebellum: 47.2 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 106.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 95.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 88.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 57.9 nTPM; absolute ceiling;continuous selectivity; esophagus: 69.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 288.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 105.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 83.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 100.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; liver: 133 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 47.2 nTPM; absolute ceiling;continuous selectivity; lymph node: 26.8 nTPM; absolute ceiling;continuous selectivity; midbrain: 128.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 47.9 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 45.1 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 61 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 22 nTPM; absolute ceiling;continuous selectivity; retina: 13.3 nTPM; absolute ceiling; salivary gland: 52.3 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 301.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 48.9 nTPM; absolute ceiling;continuous selectivity; small intestine: 60.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 21.6 nTPM; absolute ceiling;continuous selectivity; spinal cord: 88.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 59.5 nTPM; absolute ceiling;continuous selectivity; stomach: 74.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thymus: 23.4 nTPM; absolute ceiling; thyroid gland: 51 nTPM; absolute ceiling;continuous selectivity; tongue: 105.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 58.9 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adipose tissue: 68.8 nTPM (limit 10); adrenal gland: 77.7 nTPM (limit 2); amygdala: 139.8 nTPM (limit 2); basal ganglia: 112.7 nTPM (limit 2); bone marrow: 39 nTPM (limit 2); cerebellum: 47.2 nTPM (limit 2); cerebral cortex: 106.3 nTPM (limit 2); choroid plexus: 95.4 nTPM (limit 2); colon: 88.6 nTPM (limit 6); duodenum: 57.9 nTPM (limit 2); esophagus: 69.6 nTPM (limit 6); heart muscle: 288.2 nTPM (limit 2); hippocampal formation: 105.5 nTPM (limit 2); hypothalamus: 83.5 nTPM (limit 2); kidney: 100.6 nTPM (limit 2); liver: 133 nTPM (limit 2); lung: 47.2 nTPM (limit 2); lymph node: 26.8 nTPM (limit 6); midbrain: 128.8 nTPM (limit 2); pancreas: 47.9 nTPM (limit 2); parathyroid gland: 45.1 nTPM (limit 6); pituitary gland: 61 nTPM (limit 2); rectum: 22 nTPM (limit 6); retina: 13.3 nTPM (limit 2); salivary gland: 52.3 nTPM (limit 6); skeletal muscle: 301.2 nTPM (limit 2); skin: 48.9 nTPM (limit 10); small intestine: 60.8 nTPM (limit 2); smooth muscle: 21.6 nTPM (limit 2); spinal cord: 88.7 nTPM (limit 2); spleen: 59.5 nTPM (limit 10); stomach: 74.9 nTPM (limit 6); thymus: 23.4 nTPM (limit 10); thyroid gland: 51 nTPM (limit 10); tongue: 105.5 nTPM (limit 6); urinary bladder: 58.9 nTPM (limit 6); adipose tissue: 68.8 nTPM (baseline 10); adrenal gland: 77.7 nTPM (baseline 2); amygdala: 139.8 nTPM (baseline 2); basal ganglia: 112.7 nTPM (baseline 2); bone marrow: 39 nTPM (baseline 2); cerebellum: 47.2 nTPM (baseline 2); cerebral cortex: 106.3 nTPM (baseline 2); choroid plexus: 95.4 nTPM (baseline 2); colon: 88.6 nTPM (baseline 6); duodenum: 57.9 nTPM (baseline 2); esophagus: 69.6 nTPM (baseline 6); heart muscle: 288.2 nTPM (baseline 2); hippocampal formation: 105.5 nTPM (baseline 2); hypothalamus: 83.5 nTPM (baseline 2); kidney: 100.6 nTPM (baseline 2); liver: 133 nTPM (baseline 2); lung: 47.2 nTPM (baseline 2); lymph node: 26.8 nTPM (baseline 6); midbrain: 128.8 nTPM (baseline 2); pancreas: 47.9 nTPM (baseline 2); parathyroid gland: 45.1 nTPM (baseline 6); pituitary gland: 61 nTPM (baseline 2); rectum: 22 nTPM (baseline 6); retina: 13.3 nTPM (baseline 2); salivary gland: 52.3 nTPM (baseline 6); skeletal muscle: 301.2 nTPM (baseline 2); skin: 48.9 nTPM (baseline 10); small intestine: 60.8 nTPM (baseline 2); smooth muscle: 21.6 nTPM (baseline 2); spinal cord: 88.7 nTPM (baseline 2); spleen: 59.5 nTPM (baseline 10); stomach: 74.9 nTPM (baseline 6); thymus: 23.4 nTPM (baseline 10); thyroid gland: 51 nTPM (baseline 10); tongue: 105.5 nTPM (baseline 6); urinary bladder: 58.9 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Kidney Renal Clear Cell Carcinoma (TCGA): 521/521 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O14957,https://www.uniprot.org/uniprotkb/O14957/entry,"Component of the ubiquinol-cytochrome c oxidoreductase, a multisubunit transmembrane complex that is part of the mitochondrial electron transport chain which drives oxidative phosphorylation. The respiratory chain contains 3 multisubunit complexes succinate dehydrogenase (complex II, CII), ubiquinol-cytochrome c oxidoreductase (cytochrome b-c1 complex, complex III, CIII) and cytochrome c oxidase (complex IV, CIV), that cooperate to transfer electrons derived from NADH and succinate to molecular oxygen, creating an electrochemical gradient over the inner membrane that drives transmembrane transport and the ATP synthase. The cytochrome b-c1 complex catalyzes electron transfer from ubiquinol to cytochrome c, linking this redox reaction to translocation of protons across the mitochondrial inner membrane, with protons being carried across the membrane as hydrogens on the quinol. In the process called Q cycle, 2 protons are consumed from the matrix, 4 protons are released into the intermembrane space and 2 electrons are passed to cytochrome c. QCR10 has a role in CIII assembly and RIP1 stability",,,,Mitochondrion inner membrane,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
USH2A,ENSG00000042781,Unsafe,RNA,False,True,0.5,18.6,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,liver: 6.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; retina: 18.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,liver: 6.7 nTPM (limit 2); retina: 18.6 nTPM (limit 2); liver: 6.7 nTPM (baseline 2); retina: 18.6 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Liver Hepatocellular Carcinoma (validation): 14/231 (6.1%); Liver Hepatocellular Carcinoma (TCGA): 5/362 (1.4%); Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O75445,https://www.uniprot.org/uniprotkb/O75445/entry,"Involved in hearing and vision as member of the USH2 complex. In the inner ear, required for the maintenance of the hair bundle ankle formation, which connects growing stereocilia in developing cochlear hair cells. In retina photoreceptors, the USH2 complex is required for the maintenance of periciliary membrane complex that seems to play a role in regulating intracellular protein transport","Present in the basement membrane of many, but not all tissues. Expressed in retina, cochlea, small and large intestine, pancreas, bladder, prostate, esophagus, trachea, thymus, salivary glands, placenta, ovary, fallopian tube, uterus and testis. Absent in many other tissues such as heart, lung, liver, kidney and brain. In the retina, it is present in the basement membranes in the Bruch's layer choroid capillary basement membranes, where it localizes just beneath the retinal pigment epithelial cells (at protein level). Weakly expressed. Isoform 2 is expressed in fetal eye, cochlea and heart, and at very low level in brain, CNS, intestine, skeleton, tongue, kidney and lung. Isoform 2 is not expressed in stomach and liver. In adult tissues, isoform 2 is expressed in neural retina and testis, and at low level in brain, heart, kidney and liver. Isoform 1 displays a similar pattern of expression but is expressed at very low level in fetal cochlea","Usher syndrome 2A: USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH2 is characterized by congenital mild hearing impairment with normal vestibular responses. Retinitis pigmentosa 39: A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.",,"Cell projection, stereocilium membrane Secreted",,11788194|12433396|15015129|9624053,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
USP25,ENSG00000155313,Unsafe,Protein,False,True,52.5,116.3,80,77,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 24.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 12.5 nTPM; positive ihc;absolute ceiling; amygdala: 12.8 nTPM; absolute ceiling; basal ganglia: 15.3 nTPM; absolute ceiling;continuous selectivity; bone marrow: 26.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 7 nTPM; positive ihc;absolute ceiling; cerebral cortex: 14.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 9.2 nTPM; absolute ceiling; colon: 14.8 nTPM; positive ihc;absolute ceiling; duodenum: 12.3 nTPM; positive ihc;absolute ceiling; esophagus: 21 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 27.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 13 nTPM; absolute ceiling; hypothalamus: 7.5 nTPM; absolute ceiling; kidney: 20.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 19.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 23 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 19.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 8.6 nTPM; absolute ceiling; pancreas: 15.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 13.7 nTPM; positive ihc;absolute ceiling; pituitary gland: 7.4 nTPM; absolute ceiling; rectum: 15.6 nTPM; positive ihc;absolute ceiling; retina: 9.3 nTPM; absolute ceiling; salivary gland: 16.8 nTPM; positive ihc;absolute ceiling; skeletal muscle: 116.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 12.6 nTPM; positive ihc;absolute ceiling; small intestine: 13 nTPM; positive ihc;absolute ceiling; smooth muscle: 35.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 9.5 nTPM; absolute ceiling; spleen: 18.6 nTPM; positive ihc;absolute ceiling; stomach: 12.7 nTPM; positive ihc;absolute ceiling; thymus: 24.9 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 15 nTPM; positive ihc;absolute ceiling; tongue: 72.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 14.9 nTPM; positive ihc;absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 24.6 nTPM (limit 10); adrenal gland: 12.5 nTPM (limit 2); amygdala: 12.8 nTPM (limit 2); basal ganglia: 15.3 nTPM (limit 2); bone marrow: 26.8 nTPM (limit 2); cerebellum: 7 nTPM (limit 2); cerebral cortex: 14.5 nTPM (limit 2); choroid plexus: 9.2 nTPM (limit 2); colon: 14.8 nTPM (limit 6); duodenum: 12.3 nTPM (limit 2); esophagus: 21 nTPM (limit 6); heart muscle: 27.2 nTPM (limit 2); hippocampal formation: 13 nTPM (limit 2); hypothalamus: 7.5 nTPM (limit 2); kidney: 20.5 nTPM (limit 2); liver: 19.4 nTPM (limit 2); lung: 23 nTPM (limit 2); lymph node: 19.6 nTPM (limit 6); midbrain: 8.6 nTPM (limit 2); pancreas: 15.4 nTPM (limit 2); parathyroid gland: 13.7 nTPM (limit 6); pituitary gland: 7.4 nTPM (limit 2); rectum: 15.6 nTPM (limit 6); retina: 9.3 nTPM (limit 2); salivary gland: 16.8 nTPM (limit 6); skeletal muscle: 116.3 nTPM (limit 2); skin: 12.6 nTPM (limit 10); small intestine: 13 nTPM (limit 2); smooth muscle: 35.2 nTPM (limit 2); spinal cord: 9.5 nTPM (limit 2); spleen: 18.6 nTPM (limit 10); stomach: 12.7 nTPM (limit 6); thymus: 24.9 nTPM (limit 10); thyroid gland: 15 nTPM (limit 10); tongue: 72.7 nTPM (limit 6); urinary bladder: 14.9 nTPM (limit 6),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: High (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: High (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: High (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: High (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: High (Approved); skin 1 / fibroblasts: Low (Approved); skin 1 / keratinocytes: Low (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in red pulp: High (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%),endometrial cancer: 11/11 (100.0%); lymphoma: 11/11 (100.0%),31,20,Q9UHP3,https://www.uniprot.org/uniprotkb/Q9UHP3/entry,"Deubiquitinating enzyme that hydrolyzes ubiquitin moieties conjugated to substrates and thus, functions in various biological processes including inflammation and immune response (PubMed:29518389, PubMed:37683630). Modulates the Wnt/beta-catenin pathway by deubiquitinating and stabilizing tankyrases TNKS1 and TNKS2 (PubMed:28619731, PubMed:30926243, PubMed:38875478). Regulates KEAP1-NRF2 axis in the defense against oxidative assaults by deubiquitinating KEAP1 and protecting it from degradation leading to degradation of the NRF2 transcription factor that is responsible for mounting an anti-oxidation gene expression program (PubMed:37339955). Positively regulates RNA virus-induced innate signaling by interacting with and deubiquitinating ERLIN1 and ERLIN2 (PubMed:37683630). In turn, restricts virus production by regulating cholesterol biosynthetic flux (PubMed:37683630). Acts as a negative regulator of interleukin-17-mediated signaling and inflammation through the removal of 'Lys-63'-linked ubiquitination of TRAF5 and TRAF6 (PubMed:23042150). Prevents the ubiquitination and degradation of TRAF3 to reduce the phosphorylation levels of JNK and P38, the secretion of IL-1B and to induce endotoxin tolerance (PubMed:30579117) The muscle-specific isoform (USP25m) may have a role in the regulation of muscular differentiation and function","Isoform USP25a is found in most adult and fetal tissues; expression is moderately high in testis, pancreas, kidney, skeletal muscle, liver, lung, placenta, heart, but very low in peripheral blood, colon, small intestine, ovary, prostate, thymus and spleen. Expressed in the brain, with high levels in the cerebral cortex (PubMed:38875478). Isoform USP25b is found in all tissues except heart and skeletal muscle. Isoform USP25m is heart and skeletal muscle specific","Epilepsy, idiopathic generalized 19: An autosomal dominant form of idiopathic generalized epilepsy, a disorder characterized by recurring generalized seizures in the absence of detectable brain lesions and/or metabolic abnormalities. Generalized seizures arise diffusely and simultaneously from both hemispheres of the brain. Seizure types include juvenile myoclonic seizures, absence seizures, and generalized tonic-clonic seizures. EIG19 is characterized by onset of variable types of seizures in the first two decades of life.",,Cytoplasm Nucleus,23042150|28619731|29518389|30579117|30926243|37339955|37683630|38875478,10644437|11597335|38875478,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
USP37,ENSG00000135913,Unsafe,Protein,False,True,12.3,12.3,81,58,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 2.6 nTPM; positive ihc; adrenal gland: 4 nTPM; positive ihc;absolute ceiling;continuous selectivity; bone marrow: 11.5 nTPM; absolute ceiling;continuous selectivity; cerebellum: 2.7 nTPM; positive ihc;absolute ceiling; cerebral cortex: 3.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 2.9 nTPM; positive ihc; duodenum: 2.9 nTPM; positive ihc;absolute ceiling; esophagus: 3.8 nTPM; positive ihc; heart muscle: 2.2 nTPM; positive ihc;absolute ceiling; kidney: 2.8 nTPM; positive ihc;absolute ceiling; liver: 3.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 2.9 nTPM; positive ihc;absolute ceiling; lymph node: 5.8 nTPM; positive ihc;continuous selectivity; pancreas: 2.9 nTPM; positive ihc;absolute ceiling; parathyroid gland: 3.8 nTPM; positive ihc; rectum: 3.4 nTPM; positive ihc; retina: 8.6 nTPM; absolute ceiling;continuous selectivity; salivary gland: 3.7 nTPM; positive ihc; skin: 3.7 nTPM; positive ihc; small intestine: 3.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 3.1 nTPM; positive ihc;absolute ceiling; stomach: 3.3 nTPM; positive ihc; thymus: 6.1 nTPM; continuous selectivity; thyroid gland: 4.8 nTPM; positive ihc; urinary bladder: 3.5 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 4 nTPM (limit 2); bone marrow: 11.5 nTPM (limit 4); cerebellum: 2.7 nTPM (limit 2); cerebral cortex: 3.7 nTPM (limit 2); duodenum: 2.9 nTPM (limit 2); heart muscle: 2.2 nTPM (limit 2); kidney: 2.8 nTPM (limit 2); liver: 3.7 nTPM (limit 2); lung: 2.9 nTPM (limit 2); pancreas: 2.9 nTPM (limit 2); retina: 8.6 nTPM (limit 2); small intestine: 3.3 nTPM (limit 2); smooth muscle: 3.1 nTPM (limit 2),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Low (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Low (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 485/486 (99.8%),colorectal cancer: 4/11 (36.4%); ovarian cancer: 3/11 (27.3%),31,20,Q86T82,https://www.uniprot.org/uniprotkb/Q86T82/entry,"Deubiquitinase that plays a role in different processes including cell cycle regulation, DNA replication or DNA damage response (PubMed:26299517, PubMed:27296872, PubMed:31911859, PubMed:34509474). Antagonizes the anaphase-promoting complex (APC/C) during G1/S transition by mediating deubiquitination of cyclin-A (CCNA1 and CCNA2), thereby promoting S phase entry. Specifically mediates deubiquitination of 'Lys-11'-linked polyubiquitin chains, a specific ubiquitin-linkage type mediated by the APC/C complex. Phosphorylation at Ser-628 during G1/S phase maximizes the deubiquitinase activity, leading to prevent degradation of cyclin-A (CCNA1 and CCNA2) (PubMed:21596315). Plays an important role in the regulation of DNA replication by stabilizing the licensing factor CDT1 (PubMed:27296872). Also plays an essential role beyond S-phase entry to promote the efficiency and fidelity of replication by deubiquitinating checkpoint kinase 1/CHK1, promoting its stability (PubMed:34509474). Sustains the DNA damage response (DDR) by deubiquitinating and stabilizing the ATP-dependent DNA helicase BLM (PubMed:34606619). Mechanistically, DNA double-strand breaks (DSB) promotes ATM-mediated phosphorylation of USP37 and enhances the binding between USP37 and BLM (PubMed:34606619). Promotes cell migration by deubiquitinating and stabilizing the epithelial-mesenchymal transition (EMT)-inducing transcription factor SNAI (PubMed:31911859). Plays a role in the regulation of mitotic spindle assembly and mitotic progression by associating with chromatin-associated WAPL and stabilizing it through deubiquitination (PubMed:26299517)",Expressed in brain and prostate,,,Nucleus Chromosome,21596315|26299517|27296872|31911859|34509474|34606619,14715245,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
USP44,ENSG00000136014,Unsafe,RNA,False,True,23.5,23.5,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,cerebellum: 3.9 nTPM; absolute ceiling; lung: 3.7 nTPM; absolute ceiling; pancreas: 2.3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebellum: 3.9 nTPM (limit 2); lung: 3.7 nTPM (limit 2); pancreas: 2.3 nTPM (limit 2); cerebellum: 3.9 nTPM (baseline 2); lung: 3.7 nTPM (baseline 2); pancreas: 2.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Adenocarcinoma (validation): 32/105 (30.5%); Testicular Germ Cell Tumor (TCGA): 39/133 (29.3%); Lung Adenocarcinoma (TCGA): 51/497 (10.3%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9H0E7,https://www.uniprot.org/uniprotkb/Q9H0E7/entry,"Deubiquitinase that plays a key regulatory role in the spindle assembly checkpoint or mitotic checkpoint by preventing premature anaphase onset. Acts by specifically mediating deubiquitination of CDC20, a negative regulator of the anaphase promoting complex/cyclosome (APC/C) (PubMed:17443180). Deubiquitination of CDC20 leads to stabilize the MAD2L1-CDC20-APC/C ternary complex (also named mitotic checkpoint complex), thereby preventing premature activation of the APC/C (PubMed:17443180). Promotes association of MAD2L1 with CDC20 and reinforces the spindle assembly checkpoint (PubMed:17443180). Also promotes the deubiquitination of histone H2A and H2B (PubMed:23615962, PubMed:27880911). Recruited to RNF8/RNF168-ubiquitinated chromatin surrounding double stranded breaks (DSBs), promotes hydrolysis of such ubiquitin conjugates, thus negatively regulating protein recruitment to damaged chromatin (PubMed:23615962). Participates in nucleotide excision repair (NER) pathway by deubiquitinating DDB2 to prevent its premature degradation so it can remain on damaged chromatin (By similarity). Promotes FOXP3 stabilization through 'Lys-48'-linked deubiquitination leading to increased stability and increased regulatory T-cell lineage stability (PubMed:32644293). Also plays a positive role in innate immune response to DNA viruses by deubiquitinating STING1, selectively removing its 'Lys-48'-linked polyubiquitin chains and stabilizing it (PubMed:31968013)",Expressed in testis. Expressed at high levels in T-cell acute lymphoblastic leukemia,,,Nucleus Cytoplasm,17443180|22681888|23615962|27880911|31968013|32644293,14715245|21853124,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
USP49,ENSG00000164663,Unsafe,Protein,False,True,4.7,8.7,77,67,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 2.8 nTPM; continuous selectivity; adrenal gland: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 3.2 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 3 nTPM; absolute ceiling;continuous selectivity; bone marrow: 4.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 6.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 3.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 2.5 nTPM; positive ihc;continuous selectivity; duodenum: 1.6 nTPM; positive ihc;continuous selectivity; esophagus: 1.8 nTPM; positive ihc;continuous selectivity; heart muscle: 2 nTPM; positive ihc;continuous selectivity; hippocampal formation: 3.3 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 3.5 nTPM; absolute ceiling;continuous selectivity; kidney: 1.9 nTPM; positive ihc;continuous selectivity; liver: 1.6 nTPM; positive ihc;continuous selectivity; lung: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 2.4 nTPM; positive ihc;continuous selectivity; midbrain: 2.5 nTPM; absolute ceiling;continuous selectivity; pancreas: 1.9 nTPM; positive ihc;continuous selectivity; parathyroid gland: 1.4 nTPM; positive ihc; pituitary gland: 2.7 nTPM; absolute ceiling;continuous selectivity; rectum: 1.4 nTPM; positive ihc; retina: 8.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 2 nTPM; positive ihc;continuous selectivity; skeletal muscle: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 2.9 nTPM; positive ihc;continuous selectivity; small intestine: 1.7 nTPM; positive ihc;continuous selectivity; smooth muscle: 1.4 nTPM; continuous selectivity; spinal cord: 2.5 nTPM; absolute ceiling;continuous selectivity; spleen: 2.4 nTPM; positive ihc;continuous selectivity; stomach: 1.8 nTPM; positive ihc;continuous selectivity; thymus: 6.3 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 6.8 nTPM; positive ihc;continuous selectivity;reproductive not higher; urinary bladder: 2.4 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 2.7 nTPM (limit 2); amygdala: 3.2 nTPM (limit 2); basal ganglia: 3 nTPM (limit 2); bone marrow: 4.9 nTPM (limit 2); cerebellum: 6.2 nTPM (limit 2); cerebral cortex: 3.9 nTPM (limit 2); hippocampal formation: 3.3 nTPM (limit 2); hypothalamus: 3.5 nTPM (limit 2); lung: 2.7 nTPM (limit 2); midbrain: 2.5 nTPM (limit 2); pituitary gland: 2.7 nTPM (limit 2); retina: 8.7 nTPM (limit 2); skeletal muscle: 2.7 nTPM (limit 2); spinal cord: 2.5 nTPM (limit 2); adrenal gland: 2.7 nTPM (baseline 2); amygdala: 3.2 nTPM (baseline 2); basal ganglia: 3 nTPM (baseline 2); bone marrow: 4.9 nTPM (baseline 2); cerebellum: 6.2 nTPM (baseline 2); cerebral cortex: 3.9 nTPM (baseline 2); hippocampal formation: 3.3 nTPM (baseline 2); hypothalamus: 3.5 nTPM (baseline 2); lung: 2.7 nTPM (baseline 2); midbrain: 2.5 nTPM (baseline 2); pituitary gland: 2.7 nTPM (baseline 2); retina: 8.7 nTPM (baseline 2); skeletal muscle: 2.7 nTPM (baseline 2); spinal cord: 2.5 nTPM (baseline 2),adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Low (Uncertain); bronchus / respiratory epithelial cells: High (Uncertain); caudate / glial cells: Low (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: High (Uncertain); cerebellum / cells in molecular layer: Medium (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / endothelial cells: Medium (Uncertain); cerebral cortex / glial cells: Medium (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: High (Uncertain); colon / endothelial cells: Medium (Uncertain); colon / glandular cells: Medium (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: Low (Uncertain); hippocampus / glial cells: Low (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in glomeruli: Medium (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / alveolar cells: Medium (Uncertain); lung / macrophages: Low (Uncertain); lymph node / germinal center cells: Low (Uncertain); lymph node / non-germinal center cells: High (Uncertain); nasopharynx / respiratory epithelial cells: High (Uncertain); oral mucosa / squamous epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Low (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: Medium (Uncertain); skin 1 / keratinocytes: Medium (Uncertain); skin 1 / Langerhans: Medium (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: Medium (Uncertain); spleen / cells in red pulp: Low (Uncertain); spleen / cells in white pulp: Medium (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 51/58 (87.9%); Rectum Adenocarcinoma (validation): 129/207 (62.3%); Colon Adenocarcinoma (validation): 267/486 (54.9%),colorectal cancer: 11/11 (100.0%); breast cancer: 11/12 (91.7%),31,20,Q70CQ1,https://www.uniprot.org/uniprotkb/Q70CQ1/entry,"Deubiquitinase that plays a role in several cellular processes including transcriptional regulation, cell cycle progression or innate immunity. Specifically deubiquitinates histone H2B at 'Lys-120' (H2BK120Ub), a specific tag for epigenetic transcriptional activation and acts as a regulator of mRNA splicing (PubMed:23824326). Antagonizes DNA double-strand break-induced ubiquitination of H2AX thereby participating in the maintenance of genome integrity (PubMed:35598681). Plays a role in the negative regulation of cell proliferation through the AKT pathway by deubiquitinating FKBP51, leading to enhanced AKT1 dephosphorylation by PHLPP1 (PubMed:28363942). Also regulates the mitotic spindle checkpoint and prevents aneuploidy (PubMed:36702832). Negatively regulates cellular antiviral responses via deconjugating 'Lys-63'-linked ubiquitination of STING1 (PubMed:30943264). Significantly enhances the anti-HIV-1 activity of APOBEC3G. Mechanistically, stabilizes APOBEC3G by counteracting HIV-1 Vif-mediated APOBEC3G ubiquitination (PubMed:31397674)",,,,Nucleus Cytoplasm,23824326|28363942|30943264|31397674|35598681|36702832,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
USP51,ENSG00000247746,Unsafe,Protein,False,True,48.3,48.3,74,67,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 1.4 nTPM; positive ihc; adrenal gland: 3 nTPM; positive ihc;absolute ceiling; bone marrow: 0.5 nTPM; positive ihc; cerebellum: 1.6 nTPM; positive ihc; cerebral cortex: 2.6 nTPM; positive ihc;absolute ceiling; choroid plexus: 2.1 nTPM; absolute ceiling; colon: 0.8 nTPM; positive ihc; duodenum: 0.4 nTPM; positive ihc; esophagus: 0.7 nTPM; positive ihc; heart muscle: 2 nTPM; positive ihc; hypothalamus: 2.4 nTPM; absolute ceiling; kidney: 3.5 nTPM; positive ihc;absolute ceiling; lung: 1.5 nTPM; positive ihc; lymph node: 1.1 nTPM; positive ihc; pancreas: 1.1 nTPM; positive ihc; parathyroid gland: 5.4 nTPM; positive ihc; rectum: 0.7 nTPM; positive ihc; retina: 3 nTPM; absolute ceiling; salivary gland: 0.8 nTPM; positive ihc; skin: 1 nTPM; positive ihc; small intestine: 0.7 nTPM; positive ihc; spleen: 1.8 nTPM; positive ihc; stomach: 0.8 nTPM; positive ihc; thyroid gland: 5.1 nTPM; positive ihc; urinary bladder: 0.9 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 3 nTPM (limit 2); cerebral cortex: 2.6 nTPM (limit 2); choroid plexus: 2.1 nTPM (limit 2); hypothalamus: 2.4 nTPM (limit 2); kidney: 3.5 nTPM (limit 2); retina: 3 nTPM (limit 2); adrenal gland: 3 nTPM (baseline 2); cerebral cortex: 2.6 nTPM (baseline 2); choroid plexus: 2.1 nTPM (baseline 2); hypothalamus: 2.4 nTPM (baseline 2); kidney: 3.5 nTPM (baseline 2); retina: 3 nTPM (baseline 2),adipose tissue / adipocytes: Medium (Uncertain); adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: High (Uncertain); caudate / glial cells: Low (Uncertain); caudate / neuronal cells: Low (Uncertain); cerebellum / cells in granular layer: Medium (Uncertain); cerebellum / cells in molecular layer: High (Uncertain); cerebellum / Purkinje cells: High (Uncertain); cerebral cortex / endothelial cells: Medium (Uncertain); cerebral cortex / neuronal cells: High (Uncertain); colon / endothelial cells: High (Uncertain); colon / glandular cells: High (Uncertain); duodenum / glandular cells: High (Uncertain); esophagus / squamous epithelial cells: High (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / neuronal cells: High (Uncertain); kidney / cells in glomeruli: Low (Uncertain); kidney / cells in tubules: Medium (Uncertain); lung / alveolar cells: High (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / germinal center cells: High (Uncertain); lymph node / non-germinal center cells: Medium (Uncertain); nasopharynx / respiratory epithelial cells: High (Uncertain); oral mucosa / squamous epithelial cells: High (Uncertain); pancreas / exocrine glandular cells: High (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); parathyroid gland / glandular cells: High (Uncertain); rectum / glandular cells: High (Uncertain); salivary gland / glandular cells: High (Uncertain); skin 1 / fibroblasts: Medium (Uncertain); skin 1 / keratinocytes: High (Uncertain); skin 1 / Langerhans: Medium (Uncertain); skin 2 / epidermal cells: High (Uncertain); small intestine / glandular cells: High (Uncertain); spleen / cells in red pulp: Medium (Uncertain); spleen / cells in white pulp: High (Uncertain); stomach 1 / glandular cells: High (Uncertain); stomach 2 / glandular cells: High (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: High (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 45/58 (77.6%); Breast Invasive Carcinoma (validation): 34/50 (68.0%); Kidney Chromophobe (TCGA): 30/64 (46.9%),breast cancer: 12/12 (100.0%); colorectal cancer: 12/12 (100.0%),31,20,Q70EK9,https://www.uniprot.org/uniprotkb/Q70EK9/entry,"Specifically deubiquitinates 'Lys-14' (H2AK13Ub) and 'Lys-16'(H2AK15Ub) of histone H2A regulating the DNA damage response at double-strand breaks (DSBs) (PubMed:27083998, PubMed:33022275). USP51 is recruited to chromatin after DNA damage and regulates the dynamic assembly/disassembly of TP53BP1 and BRCA1. Functions in DNA double-strand break repair also by mediating the deubiquitination and subsequent stabilization of DGCR8, leading to the recruitment of DGCR8 binding partners to double strand breaks such as RNF168 or MDC1 (PubMed:34188037). In addition, promotes the deubiquitination and stabilization of the transcriptional repressor ZEB1 (PubMed:29119051)","Expressed in prostate, brain, lung, aorta and kidney",,,Chromosome,27083998|29119051|33022275|34188037,14715245,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
UTF1,ENSG00000171794,Unsafe,High RNA,False,True,5.8,5.8,81,1,Positive somewhere,False,False,False,True,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,CTA,Pass,oncoref.target-sets.2026-10-23.1,False,False,,CTA → Unsafe,True,True,True,1.70322800553,66.6,"hpa_single_cell: /Langerhans cells, max 50.9 nTPM, 1 observations >30; hpa_single_cell_tissue: adipose tissue/macrophages, max 66.6 nTPM, 1 observations >30; hpa_single_cell_tissue: adipose tissue/schwann cells, max 35.5 nTPM, 1 observations >30; hpa_single_cell_tissue: skin/langerhans cells, max 58 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,1.703 TPM; blood/MONOCYTES; dice_monocytes; vital,66.6 nTPM; adipose tissue/macrophages; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 117/133 (88.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 2/176 (1.1%); Rectum Adenocarcinoma (validation): 1/207 (0.5%),testis cancer: 8/11 (72.7%); breast cancer: 0/11 (0.0%),31,20,Q5T230,https://www.uniprot.org/uniprotkb/Q5T230/entry,Acts as a transcriptional coactivator of ATF2,,,,Nucleus,9748258,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Carter2023_CT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Final CT-expression set without detectable thymic expression; functional vaccination evidence is not assigned to every gene | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
VAMP2,ENSG00000220205,Unsafe,RNA,False,True,165.5,470.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 85.7 nTPM; absolute ceiling;continuous selectivity; adrenal gland: 122.7 nTPM; absolute ceiling;continuous selectivity; amygdala: 326.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 296.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 170.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 377.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 470.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 75 nTPM; absolute ceiling;continuous selectivity; colon: 92.3 nTPM; absolute ceiling;continuous selectivity; duodenum: 41.9 nTPM; absolute ceiling;continuous selectivity; esophagus: 59.1 nTPM; absolute ceiling;continuous selectivity; heart muscle: 96.8 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 325.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 286 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 127 nTPM; absolute ceiling;continuous selectivity; liver: 58.3 nTPM; absolute ceiling;continuous selectivity; lung: 82.7 nTPM; absolute ceiling;continuous selectivity; lymph node: 68.6 nTPM; absolute ceiling;continuous selectivity; midbrain: 256.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 78.2 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 175.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 221.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 49.7 nTPM; absolute ceiling; retina: 437.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 70 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 95.2 nTPM; absolute ceiling;continuous selectivity; skin: 115.1 nTPM; absolute ceiling;continuous selectivity; small intestine: 89 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 65.1 nTPM; absolute ceiling;continuous selectivity; spinal cord: 170.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 112.7 nTPM; absolute ceiling;continuous selectivity; stomach: 85.6 nTPM; absolute ceiling;continuous selectivity; thymus: 69.6 nTPM; absolute ceiling; thyroid gland: 99 nTPM; absolute ceiling;continuous selectivity; tongue: 61.1 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 76.4 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adipose tissue: 85.7 nTPM (limit 10); adrenal gland: 122.7 nTPM (limit 2); amygdala: 326.1 nTPM (limit 2); basal ganglia: 296.4 nTPM (limit 2); bone marrow: 170.1 nTPM (limit 2); cerebellum: 377.7 nTPM (limit 2); cerebral cortex: 470.8 nTPM (limit 2); choroid plexus: 75 nTPM (limit 2); colon: 92.3 nTPM (limit 6); duodenum: 41.9 nTPM (limit 2); esophagus: 59.1 nTPM (limit 6); heart muscle: 96.8 nTPM (limit 2); hippocampal formation: 325.8 nTPM (limit 2); hypothalamus: 286 nTPM (limit 2); kidney: 127 nTPM (limit 2); liver: 58.3 nTPM (limit 2); lung: 82.7 nTPM (limit 2); lymph node: 68.6 nTPM (limit 6); midbrain: 256.6 nTPM (limit 2); pancreas: 78.2 nTPM (limit 2); parathyroid gland: 175.2 nTPM (limit 6); pituitary gland: 221.4 nTPM (limit 2); rectum: 49.7 nTPM (limit 6); retina: 437.2 nTPM (limit 2); salivary gland: 70 nTPM (limit 6); skeletal muscle: 95.2 nTPM (limit 2); skin: 115.1 nTPM (limit 10); small intestine: 89 nTPM (limit 2); smooth muscle: 65.1 nTPM (limit 2); spinal cord: 170.6 nTPM (limit 2); spleen: 112.7 nTPM (limit 10); stomach: 85.6 nTPM (limit 6); thymus: 69.6 nTPM (limit 10); thyroid gland: 99 nTPM (limit 10); tongue: 61.1 nTPM (limit 6); urinary bladder: 76.4 nTPM (limit 6); adipose tissue: 85.7 nTPM (baseline 10); adrenal gland: 122.7 nTPM (baseline 2); amygdala: 326.1 nTPM (baseline 2); basal ganglia: 296.4 nTPM (baseline 2); bone marrow: 170.1 nTPM (baseline 2); cerebellum: 377.7 nTPM (baseline 2); cerebral cortex: 470.8 nTPM (baseline 2); choroid plexus: 75 nTPM (baseline 2); colon: 92.3 nTPM (baseline 6); duodenum: 41.9 nTPM (baseline 2); esophagus: 59.1 nTPM (baseline 6); heart muscle: 96.8 nTPM (baseline 2); hippocampal formation: 325.8 nTPM (baseline 2); hypothalamus: 286 nTPM (baseline 2); kidney: 127 nTPM (baseline 2); liver: 58.3 nTPM (baseline 2); lung: 82.7 nTPM (baseline 2); lymph node: 68.6 nTPM (baseline 6); midbrain: 256.6 nTPM (baseline 2); pancreas: 78.2 nTPM (baseline 2); parathyroid gland: 175.2 nTPM (baseline 6); pituitary gland: 221.4 nTPM (baseline 2); rectum: 49.7 nTPM (baseline 6); retina: 437.2 nTPM (baseline 2); salivary gland: 70 nTPM (baseline 6); skeletal muscle: 95.2 nTPM (baseline 2); skin: 115.1 nTPM (baseline 10); small intestine: 89 nTPM (baseline 2); smooth muscle: 65.1 nTPM (baseline 2); spinal cord: 170.6 nTPM (baseline 2); spleen: 112.7 nTPM (baseline 10); stomach: 85.6 nTPM (baseline 6); thymus: 69.6 nTPM (baseline 10); thyroid gland: 99 nTPM (baseline 10); tongue: 61.1 nTPM (baseline 6); urinary bladder: 76.4 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%); Thyroid Carcinoma (TCGA): 495/495 (100.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P63027,https://www.uniprot.org/uniprotkb/P63027/entry,"SNAREs (soluble N-ethylmaleimide-sensitive factor-attachment protein receptors) are essential proteins for intracellular membrane fusion. SNAREs localized on opposing membranes assemble to form a trans-SNARE complex, an extended, parallel four-helix bundle whose assembly releases energy that drives membrane fusion. The core SNARE complex typically consists of four alpha-helical domains, three from target membrane SNAREs (t-SNAREs) and one from a vesicle SNARE (v-SNARE) (PubMed:10036234, PubMed:30929742). VAMP2 is a v-SNARE assembling into a SNARE complex with the t-SNAREs SNAP25 and STX1A to mediate the fusion of synaptic vesicles with the presynaptic plasma membrane in neurotransmitter release (PubMed:30929742). Also functions in compensatory endocytosis for synaptic vesicle recycling (By similarity). In adipocytes, it is involved in the insulin-dependent exocytosis of GLUT4 storage vesicles (By similarity). Independently of its SNARE activity, it could modulate the gating characteristics of the delayed rectifier voltage-dependent potassium channel KCNB1 (By similarity)",Nervous system and skeletal muscle,"Neurodevelopmental disorder with hypotonia and autistic features with or without hyperkinetic movements: An autosomal dominant disorder characterized by axial hypotonia apparent at birth, global developmental delay, intellectual disability, seizures, and autistic features. Involuntary hyperkinetic movements are present in some patients.","A structure of a fragment of this protein in complex with the catalytic domain of C.botulinum neurotoxin type B (BoNT/B, botB) was reported; because of the lack of clear and continuous electron density for the VAMP2 peptide in the complex structure, the paper was retracted (PubMed:10932255, PubMed:19578378). However this protein is a substrate for BoNT/B (PubMed:22289120, PubMed:7803399)","Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane Cell membrane",10036234|30929742,8760387,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
VASH2,ENSG00000143494,Unsafe,RNA,False,True,7.7,7.7,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,esophagus: 3.9 nTPM; continuous selectivity; pituitary gland: 2.5 nTPM; absolute ceiling;continuous selectivity; thymus: 4.1 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,pituitary gland: 2.5 nTPM (limit 2); pituitary gland: 2.5 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 38/50 (76.0%); Testicular Germ Cell Tumor (TCGA): 86/133 (64.7%); Glioblastoma Multiforme (validation): 17/58 (29.3%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q86V25,https://www.uniprot.org/uniprotkb/Q86V25/entry,"Tyrosine carboxypeptidase that removes the C-terminal tyrosine residue of alpha-tubulin, thereby regulating microtubule dynamics and function (PubMed:29146869). Critical for spindle function and accurate chromosome segregation during mitosis since microtubule detyrosination regulates mitotic spindle length and postioning (PubMed:31171830). Acts as an activator of angiogenesis: expressed in infiltrating mononuclear cells in the sprouting front to promote angiogenesis (PubMed:19204325). Plays a role in axon formation (PubMed:31235911)",,,,"Cytoplasm Secreted Cytoplasm, cytoskeleton",19204325|29146869|31235911,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
VAV3,ENSG00000134215,Unsafe,Protein,False,True,33.2,81.0,74,58,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 3 nTPM; positive ihc; adrenal gland: 1.7 nTPM; positive ihc; basal ganglia: 2.1 nTPM; absolute ceiling; bone marrow: 19.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 2.7 nTPM; positive ihc;absolute ceiling; cerebral cortex: 2.2 nTPM; positive ihc;absolute ceiling; choroid plexus: 6.7 nTPM; absolute ceiling; colon: 39.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 9 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 33.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 81 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 2.3 nTPM; positive ihc;absolute ceiling; lung: 3.9 nTPM; positive ihc;absolute ceiling; lymph node: 10.1 nTPM; positive ihc;absolute ceiling; midbrain: 3.7 nTPM; absolute ceiling; pancreas: 16.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 1.5 nTPM; positive ihc; rectum: 49.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; retina: 7.1 nTPM; absolute ceiling; salivary gland: 7.1 nTPM; positive ihc;absolute ceiling; skin: 47.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 14.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 3.5 nTPM; absolute ceiling; spleen: 10.9 nTPM; positive ihc;absolute ceiling; stomach: 7.1 nTPM; positive ihc;absolute ceiling; thyroid gland: 9.6 nTPM; positive ihc; urinary bladder: 12.3 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",basal ganglia: 2.1 nTPM (limit 2); bone marrow: 19.1 nTPM (limit 2); cerebellum: 2.7 nTPM (limit 2); cerebral cortex: 2.2 nTPM (limit 2); choroid plexus: 6.7 nTPM (limit 2); colon: 39.9 nTPM (limit 6); duodenum: 9 nTPM (limit 2); esophagus: 33.8 nTPM (limit 6); kidney: 81 nTPM (limit 2); liver: 2.3 nTPM (limit 2); lung: 3.9 nTPM (limit 2); lymph node: 10.1 nTPM (limit 6); midbrain: 3.7 nTPM (limit 2); pancreas: 16.8 nTPM (limit 2); rectum: 49.2 nTPM (limit 6); retina: 7.1 nTPM (limit 2); salivary gland: 7.1 nTPM (limit 6); skin: 47.7 nTPM (limit 10); small intestine: 14.8 nTPM (limit 2); smooth muscle: 3.5 nTPM (limit 2); spleen: 10.9 nTPM (limit 10); stomach: 7.1 nTPM (limit 6); urinary bladder: 12.3 nTPM (limit 6); basal ganglia: 2.1 nTPM (baseline 2); bone marrow: 19.1 nTPM (baseline 2); cerebellum: 2.7 nTPM (baseline 2); cerebral cortex: 2.2 nTPM (baseline 2); choroid plexus: 6.7 nTPM (baseline 2); colon: 39.9 nTPM (baseline 6); duodenum: 9 nTPM (baseline 2); esophagus: 33.8 nTPM (baseline 6); kidney: 81 nTPM (baseline 2); liver: 2.3 nTPM (baseline 2); lung: 3.9 nTPM (baseline 2); lymph node: 10.1 nTPM (baseline 6); midbrain: 3.7 nTPM (baseline 2); pancreas: 16.8 nTPM (baseline 2); rectum: 49.2 nTPM (baseline 6); retina: 7.1 nTPM (baseline 2); salivary gland: 7.1 nTPM (baseline 6); skin: 47.7 nTPM (baseline 10); small intestine: 14.8 nTPM (baseline 2); smooth muscle: 3.5 nTPM (baseline 2); spleen: 10.9 nTPM (baseline 10); stomach: 7.1 nTPM (baseline 6); urinary bladder: 12.3 nTPM (baseline 6),adipose tissue / adipocytes: Medium (Uncertain); adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Low (Uncertain); caudate / glial cells: Medium (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in molecular layer: Low (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / glial cells: Low (Uncertain); cerebral cortex / neuronal cells: Low (Uncertain); colon / endothelial cells: Low (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: Low (Uncertain); duodenum / glandular cells: Medium (Uncertain); hippocampus / glial cells: Medium (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in glomeruli: Medium (Uncertain); kidney / cells in tubules: Low (Uncertain); liver / cholangiocytes: Low (Uncertain); liver / hepatocytes: Low (Uncertain); lung / alveolar cells: Low (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); nasopharynx / respiratory epithelial cells: Low (Uncertain); oral mucosa / squamous epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Low (Uncertain); parathyroid gland / glandular cells: Low (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Low (Uncertain); skin 1 / fibroblasts: Medium (Uncertain); skin 1 / keratinocytes: Medium (Uncertain); skin 1 / Langerhans: Medium (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: Medium (Uncertain); spleen / cells in red pulp: Low (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Low (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 50/50 (100.0%); Rectum Adenocarcinoma (validation): 203/207 (98.1%); Kidney Renal Papillary Cell Carcinoma (TCGA): 276/282 (97.9%),colorectal cancer: 7/12 (58.3%); pancreatic cancer: 6/12 (50.0%),31,20,Q9UKW4,https://www.uniprot.org/uniprotkb/Q9UKW4/entry,"Exchange factor for GTP-binding proteins RhoA, RhoG and, to a lesser extent, Rac1. Binds physically to the nucleotide-free states of those GTPases. Plays an important role in angiogenesis. Its recruitment by phosphorylated EPHA2 is critical for EFNA1-induced RAC1 GTPase activation and vascular endothelial cell migration and assembly (By similarity). May be important for integrin-mediated signaling, at least in some cell types. In osteoclasts, along with SYK tyrosine kinase, required for signaling through integrin alpha-v/beta-1 (ITAGV-ITGB1), a crucial event for osteoclast proper cytoskeleton organization and function. This signaling pathway involves RAC1, but not RHO, activation. Necessary for proper wound healing. In the course of wound healing, required for the phagocytotic cup formation preceding macrophage phagocytosis of apoptotic neutrophils. Responsible for integrin beta-2 (ITGB2)-mediated macrophage adhesion and, to a lesser extent, contributes to beta-3 (ITGB3)-mediated adhesion. Does not affect integrin beta-1 (ITGB1)-mediated adhesion (By similarity)","Isoform 1 and isoform 3 are widely expressed; both are expressed at very low levels in skeletal muscle. In keratinocytes, isoform 1 is less abundant than isoform 3. Isoform 3 is detected at very low levels, if any, in adrenal gland, bone marrow, spleen, fetal brain and spinal cord; in these tissues, isoform 1 is readily detectable",,,,,11094073|9705494,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
VCPIP1,ENSG00000175073,Unsafe,RNA,False,True,5.5,20.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 4.4 nTPM; continuous selectivity; adrenal gland: 3.5 nTPM; absolute ceiling;continuous selectivity; amygdala: 2.8 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 2.9 nTPM; absolute ceiling;continuous selectivity; bone marrow: 20 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 2.9 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 5.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 1.6 nTPM; continuous selectivity; colon: 4.3 nTPM; continuous selectivity; duodenum: 3.7 nTPM; absolute ceiling;continuous selectivity; esophagus: 3.3 nTPM; continuous selectivity; heart muscle: 2.8 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 3 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 2.8 nTPM; absolute ceiling;continuous selectivity; kidney: 4.2 nTPM; absolute ceiling;continuous selectivity; liver: 6.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 4 nTPM; absolute ceiling;continuous selectivity; lymph node: 8.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 2.8 nTPM; absolute ceiling;continuous selectivity; pancreas: 3.9 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 5.4 nTPM; continuous selectivity; pituitary gland: 1.5 nTPM; continuous selectivity; rectum: 3.9 nTPM; continuous selectivity; retina: 4.4 nTPM; absolute ceiling;continuous selectivity; salivary gland: 4.1 nTPM; continuous selectivity; skeletal muscle: 5.1 nTPM; absolute ceiling;continuous selectivity; skin: 3.2 nTPM; continuous selectivity; small intestine: 3.5 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 3.2 nTPM; absolute ceiling;continuous selectivity; spinal cord: 2.6 nTPM; absolute ceiling;continuous selectivity; spleen: 8.6 nTPM; continuous selectivity;reproductive not higher; stomach: 4.4 nTPM; continuous selectivity; thymus: 5.2 nTPM; continuous selectivity; thyroid gland: 4.1 nTPM; continuous selectivity; tongue: 5.1 nTPM; continuous selectivity; urinary bladder: 4 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 3.5 nTPM (limit 2); amygdala: 2.8 nTPM (limit 2); basal ganglia: 2.9 nTPM (limit 2); bone marrow: 20 nTPM (limit 2); cerebellum: 2.9 nTPM (limit 2); cerebral cortex: 5.7 nTPM (limit 2); duodenum: 3.7 nTPM (limit 2); heart muscle: 2.8 nTPM (limit 2); hippocampal formation: 3 nTPM (limit 2); hypothalamus: 2.8 nTPM (limit 2); kidney: 4.2 nTPM (limit 2); liver: 6.8 nTPM (limit 2); lung: 4 nTPM (limit 2); lymph node: 8.3 nTPM (limit 6); midbrain: 2.8 nTPM (limit 2); pancreas: 3.9 nTPM (limit 2); retina: 4.4 nTPM (limit 2); skeletal muscle: 5.1 nTPM (limit 2); small intestine: 3.5 nTPM (limit 2); smooth muscle: 3.2 nTPM (limit 2); spinal cord: 2.6 nTPM (limit 2); adrenal gland: 3.5 nTPM (baseline 2); amygdala: 2.8 nTPM (baseline 2); basal ganglia: 2.9 nTPM (baseline 2); bone marrow: 20 nTPM (baseline 2); cerebellum: 2.9 nTPM (baseline 2); cerebral cortex: 5.7 nTPM (baseline 2); duodenum: 3.7 nTPM (baseline 2); heart muscle: 2.8 nTPM (baseline 2); hippocampal formation: 3 nTPM (baseline 2); hypothalamus: 2.8 nTPM (baseline 2); kidney: 4.2 nTPM (baseline 2); liver: 6.8 nTPM (baseline 2); lung: 4 nTPM (baseline 2); lymph node: 8.3 nTPM (baseline 6); midbrain: 2.8 nTPM (baseline 2); pancreas: 3.9 nTPM (baseline 2); retina: 4.4 nTPM (baseline 2); skeletal muscle: 5.1 nTPM (baseline 2); small intestine: 3.5 nTPM (baseline 2); smooth muscle: 3.2 nTPM (baseline 2); spinal cord: 2.6 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 485/486 (99.8%),endometrial cancer: 2/12 (16.7%); ovarian cancer: 2/12 (16.7%),31,20,Q96JH7,https://www.uniprot.org/uniprotkb/Q96JH7/entry,"Deubiquitinating enzyme involved in DNA repair and reassembly of the Golgi apparatus and the endoplasmic reticulum following mitosis (PubMed:32649882). Necessary for VCP-mediated reassembly of Golgi stacks after mitosis (By similarity). Plays a role in VCP-mediated formation of transitional endoplasmic reticulum (tER) (By similarity). Mediates dissociation of the ternary complex containing STX5A, NSFL1C and VCP (By similarity). Also involved in DNA repair following phosphorylation by ATM or ATR: acts by catalyzing deubiquitination of SPRTN, thereby promoting SPRTN recruitment to chromatin and subsequent proteolytic cleavage of covalent DNA-protein cross-links (DPCs) (PubMed:32649882). Hydrolyzes 'Lys-11'- and 'Lys-48'-linked polyubiquitin chains (PubMed:23827681) (Microbial infection) Regulates the duration of C.botulinum neurotoxin type A (BoNT/A) intoxication by catalyzing deubiquitination of Botulinum neurotoxin A light chain (LC), thereby preventing LC degradation by the proteasome, and accelerating botulinum neurotoxin intoxication in patients",,,,"Nucleus Cytoplasm Endoplasmic reticulum Golgi apparatus, Golgi stack",23827681|28584101|32649882,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
VCX2,ENSG00000177504,Unsafe,Protein,False,True,27.2,27.2,87,5,Positive somewhere,True,False,False,True,Excluded,Normal,False,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 0 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,adrenal gland / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 7/133 (5.3%); Skin Cuteneous Melanoma (TCGA): 2/99 (2.0%); Stomach Adenocarcinoma (TCGA): 5/346 (1.4%),melanoma: 1/11 (9.1%); breast cancer: 0/10 (0.0%),31,20,Q9H322,https://www.uniprot.org/uniprotkb/Q9H322/entry,May mediate a process in spermatogenesis or may play a role in sex ratio distortion,Expressed exclusively in testis,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | Chang2019_TGCT | Loriot2025_S1 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
VGLL1,ENSG00000102243,Unsafe,RNA,False,True,196.9,196.9,84,1,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,kidney: 6.4 nTPM; absolute ceiling; urinary bladder: 21.9 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,kidney: 6.4 nTPM (limit 6); urinary bladder: 21.9 nTPM (limit 12),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Bladder Urothelial Carcinoma (TCGA): 139/169 (82.2%); Ovary Serous Cystadenocarcinoma (TCGA): 275/349 (78.8%); Ovary Serous Cystadenocarcinoma (validation): 55/81 (67.9%),glioma: 1/12 (8.3%); urothelial cancer: 1/12 (8.3%),31,20,Q99990,https://www.uniprot.org/uniprotkb/Q99990/entry,May act as a specific coactivator for the mammalian TEFs,,,,Nucleus,10518497,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Bradley2020_CPA | Gong2021_reproductive_PC,No tumor-antigen validation in this source | HLA peptide and antigen-specific T-cell validation | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
VIRMA,ENSG00000164944,Unsafe,Protein,False,True,17.0,27.0,93,72,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 12.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 7.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 5.5 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 5.5 nTPM; absolute ceiling;continuous selectivity; bone marrow: 27 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 8.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 7.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 5.1 nTPM; absolute ceiling;continuous selectivity; colon: 9.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 7.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 9.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 9.6 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 5.3 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 4.7 nTPM; absolute ceiling;continuous selectivity; kidney: 10.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 12.1 nTPM; absolute ceiling;continuous selectivity; lung: 10.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 14.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 5.3 nTPM; absolute ceiling;continuous selectivity; pancreas: 10 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 14.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 6.1 nTPM; absolute ceiling;continuous selectivity; rectum: 11.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 12 nTPM; absolute ceiling;continuous selectivity; salivary gland: 9.3 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 8.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 9.4 nTPM; positive ihc;continuous selectivity; small intestine: 8.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 13.4 nTPM; absolute ceiling;continuous selectivity; spinal cord: 6.1 nTPM; absolute ceiling;continuous selectivity; spleen: 11.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 11.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 19.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 12.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 8.9 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 10.1 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 12.1 nTPM (limit 10); adrenal gland: 7.6 nTPM (limit 2); amygdala: 5.5 nTPM (limit 2); basal ganglia: 5.5 nTPM (limit 2); bone marrow: 27 nTPM (limit 2); cerebellum: 8.5 nTPM (limit 2); cerebral cortex: 7.6 nTPM (limit 2); choroid plexus: 5.1 nTPM (limit 2); colon: 9.6 nTPM (limit 6); duodenum: 7.9 nTPM (limit 2); esophagus: 9.4 nTPM (limit 6); heart muscle: 9.6 nTPM (limit 4); hippocampal formation: 5.3 nTPM (limit 2); hypothalamus: 4.7 nTPM (limit 2); kidney: 10.5 nTPM (limit 2); liver: 12.1 nTPM (limit 4); lung: 10.4 nTPM (limit 2); lymph node: 14.1 nTPM (limit 6); midbrain: 5.3 nTPM (limit 2); pancreas: 10 nTPM (limit 2); parathyroid gland: 14.3 nTPM (limit 6); pituitary gland: 6.1 nTPM (limit 2); rectum: 11.3 nTPM (limit 6); retina: 12 nTPM (limit 2); salivary gland: 9.3 nTPM (limit 8); skeletal muscle: 8.4 nTPM (limit 2); small intestine: 8.8 nTPM (limit 2); smooth muscle: 13.4 nTPM (limit 4); spinal cord: 6.1 nTPM (limit 2); spleen: 11.1 nTPM (limit 10); stomach: 11.3 nTPM (limit 6); thymus: 19.5 nTPM (limit 10); thyroid gland: 12.9 nTPM (limit 10); tongue: 8.9 nTPM (limit 6); urinary bladder: 10.1 nTPM (limit 6),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / basal cells: Medium (Approved); bronchus / ciliated cells (cell body): Medium (Approved); bronchus / ciliated cells (tip of cilia): Medium (Approved); bronchus / goblet cells: Medium (Approved); caudate / glial cells: Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Low (Approved); colon / peripheral nerve/ganglion: High (Approved); duodenum / glandular cells: Low (Approved); esophagus / squamous epithelial cells: Medium (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Low (Approved); nasopharynx / basal cells: Medium (Approved); nasopharynx / ciliated cells (cell body): Medium (Approved); nasopharynx / goblet cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Low (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Medium (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Low (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%),testis cancer: 11/12 (91.7%); urothelial cancer: 8/11 (72.7%),29,20,Q69YN4,https://www.uniprot.org/uniprotkb/Q69YN4/entry,"Associated component of the WMM complex, a complex that mediates N6-methyladenosine (m6A) methylation of RNAs, a modification that plays a role in the efficiency of mRNA splicing and RNA processing (PubMed:24981863, PubMed:29507755). Acts as a key regulator of m6A methylation by promoting m6A methylation of mRNAs in the 3'-UTR near the stop codon: recruits the catalytic core components METTL3 and METTL14, thereby guiding m6A methylation at specific sites (PubMed:29507755). Required for mRNA polyadenylation via its role in selective m6A methylation: m6A methylation of mRNAs in the 3'-UTR near the stop codon correlating with alternative polyadenylation (APA) (PubMed:29507755)",,,,"Nucleus speckle Nucleus, nucleoplasm Cytoplasm",24981863|29507755,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
VKORC1,ENSG00000167397,Unsafe,Protein,False,True,111.4,443.7,83,51,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 96.2 nTPM; absolute ceiling;continuous selectivity; adrenal gland: 104.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 43.2 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 51.2 nTPM; absolute ceiling;continuous selectivity; bone marrow: 54.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 41.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 40.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 151.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 93.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 42.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 50.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 95.8 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 46.9 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 47.5 nTPM; absolute ceiling;continuous selectivity; kidney: 119.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 443.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 75 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 35 nTPM; positive ihc;absolute ceiling; midbrain: 53.1 nTPM; absolute ceiling;continuous selectivity; pancreas: 162.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 49.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 112.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 39.7 nTPM; absolute ceiling; retina: 22.2 nTPM; absolute ceiling; salivary gland: 89.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 33.2 nTPM; absolute ceiling; skin: 78.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 79.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 81.6 nTPM; absolute ceiling;continuous selectivity; spinal cord: 58.5 nTPM; absolute ceiling;continuous selectivity; spleen: 60.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 85.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 34 nTPM; absolute ceiling; thyroid gland: 74 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 31.1 nTPM; absolute ceiling; urinary bladder: 97.3 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 96.2 nTPM (limit 20); adrenal gland: 104.2 nTPM (limit 2); amygdala: 43.2 nTPM (limit 2); basal ganglia: 51.2 nTPM (limit 2); bone marrow: 54.4 nTPM (limit 2); cerebellum: 41.6 nTPM (limit 2); cerebral cortex: 40.3 nTPM (limit 2); choroid plexus: 151.6 nTPM (limit 2); colon: 93.8 nTPM (limit 6); duodenum: 42.9 nTPM (limit 2); esophagus: 50.4 nTPM (limit 6); heart muscle: 95.8 nTPM (limit 4); hippocampal formation: 46.9 nTPM (limit 2); hypothalamus: 47.5 nTPM (limit 2); kidney: 119.3 nTPM (limit 2); liver: 443.7 nTPM (limit 2); lung: 75 nTPM (limit 2); lymph node: 35 nTPM (limit 6); midbrain: 53.1 nTPM (limit 2); pancreas: 162.7 nTPM (limit 2); parathyroid gland: 49.5 nTPM (limit 6); pituitary gland: 112.6 nTPM (limit 2); rectum: 39.7 nTPM (limit 8); retina: 22.2 nTPM (limit 2); salivary gland: 89.7 nTPM (limit 6); skeletal muscle: 33.2 nTPM (limit 4); skin: 78.6 nTPM (limit 10); small intestine: 79.9 nTPM (limit 2); smooth muscle: 81.6 nTPM (limit 4); spinal cord: 58.5 nTPM (limit 2); spleen: 60.7 nTPM (limit 10); stomach: 85.4 nTPM (limit 6); thymus: 34 nTPM (limit 10); thyroid gland: 74 nTPM (limit 10); tongue: 31.1 nTPM (limit 6); urinary bladder: 97.3 nTPM (limit 6),adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: High (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Low (Approved); esophagus / squamous epithelial cells: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: High (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: High (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Low (Approved); spleen / cells in red pulp: Low (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Kidney Renal Clear Cell Carcinoma (TCGA): 521/521 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%),renal cancer: 11/12 (91.7%); liver cancer: 7/12 (58.3%),31,20,Q9BQB6,https://www.uniprot.org/uniprotkb/Q9BQB6/entry,"Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development","Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas","Combined deficiency of vitamin K-dependent clotting factors 2: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. Coumarin resistance: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti-coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement.",,Endoplasmic reticulum membrane,14765194|14765195|15879509|16270630|20978134|22923610|33154105,14765194,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
VPREB1,ENSG00000169575,Unsafe,Protein,False,True,0.1,29.4,80,4,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 29.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 0.5 nTPM; continuous selectivity;reproductive not higher; small intestine: 0.1 nTPM; reproductive not higher; thymus: 1.1 nTPM; continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 29.4 nTPM (limit 2); bone marrow: 29.4 nTPM (baseline 2),bone marrow / hematopoietic cells: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 1/283 (0.4%),testis cancer: 3/10 (30.0%); skin cancer: 1/10 (10.0%),31,20,P12018,https://www.uniprot.org/uniprotkb/P12018/entry,Associates with the Ig-mu chain to form a molecular complex that is expressed on the surface of pre-B-cells. This complex presumably regulates Ig gene rearrangements in the early steps of B-cell differentiation,Only expressed by pre-B-cells,,,Endoplasmic reticulum,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,daSilva2017_testis_biased | daSilva2017_CT,At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination,,,,,,,,
VPS33A,ENSG00000139719,Unsafe,RNA,False,True,8.2,10.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 4.7 nTPM; continuous selectivity; adrenal gland: 6.6 nTPM; absolute ceiling;continuous selectivity; amygdala: 5.6 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 6.4 nTPM; absolute ceiling;continuous selectivity; bone marrow: 6.3 nTPM; absolute ceiling;continuous selectivity; cerebellum: 7.5 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 7.8 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 5.7 nTPM; absolute ceiling;continuous selectivity; colon: 6.6 nTPM; absolute ceiling;continuous selectivity; duodenum: 5 nTPM; absolute ceiling;continuous selectivity; esophagus: 4.9 nTPM; continuous selectivity; heart muscle: 4.6 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 6.1 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 6.4 nTPM; absolute ceiling;continuous selectivity; kidney: 4.3 nTPM; absolute ceiling;continuous selectivity; liver: 5.7 nTPM; absolute ceiling;continuous selectivity; lung: 5.1 nTPM; absolute ceiling;continuous selectivity; lymph node: 7.8 nTPM; absolute ceiling;continuous selectivity; midbrain: 6 nTPM; absolute ceiling;continuous selectivity; pancreas: 5.3 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 5.9 nTPM; continuous selectivity; pituitary gland: 9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 5.3 nTPM; continuous selectivity; retina: 10.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 4.4 nTPM; continuous selectivity; skeletal muscle: 8.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 6.7 nTPM; continuous selectivity; small intestine: 5.8 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 6.2 nTPM; absolute ceiling;continuous selectivity; spinal cord: 6.2 nTPM; absolute ceiling;continuous selectivity; spleen: 6.8 nTPM; continuous selectivity; stomach: 5.4 nTPM; continuous selectivity; thymus: 9.3 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 4.2 nTPM; continuous selectivity; tongue: 5.8 nTPM; continuous selectivity; urinary bladder: 5.1 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 6.6 nTPM (limit 2); amygdala: 5.6 nTPM (limit 2); basal ganglia: 6.4 nTPM (limit 2); bone marrow: 6.3 nTPM (limit 2); cerebellum: 7.5 nTPM (limit 2); cerebral cortex: 7.8 nTPM (limit 2); choroid plexus: 5.7 nTPM (limit 2); colon: 6.6 nTPM (limit 6); duodenum: 5 nTPM (limit 2); heart muscle: 4.6 nTPM (limit 2); hippocampal formation: 6.1 nTPM (limit 2); hypothalamus: 6.4 nTPM (limit 2); kidney: 4.3 nTPM (limit 2); liver: 5.7 nTPM (limit 2); lung: 5.1 nTPM (limit 2); lymph node: 7.8 nTPM (limit 6); midbrain: 6 nTPM (limit 2); pancreas: 5.3 nTPM (limit 2); pituitary gland: 9 nTPM (limit 2); retina: 10.1 nTPM (limit 2); skeletal muscle: 8.6 nTPM (limit 2); small intestine: 5.8 nTPM (limit 2); smooth muscle: 6.2 nTPM (limit 2); spinal cord: 6.2 nTPM (limit 2); adrenal gland: 6.6 nTPM (baseline 2); amygdala: 5.6 nTPM (baseline 2); basal ganglia: 6.4 nTPM (baseline 2); bone marrow: 6.3 nTPM (baseline 2); cerebellum: 7.5 nTPM (baseline 2); cerebral cortex: 7.8 nTPM (baseline 2); choroid plexus: 5.7 nTPM (baseline 2); colon: 6.6 nTPM (baseline 6); duodenum: 5 nTPM (baseline 2); heart muscle: 4.6 nTPM (baseline 2); hippocampal formation: 6.1 nTPM (baseline 2); hypothalamus: 6.4 nTPM (baseline 2); kidney: 4.3 nTPM (baseline 2); liver: 5.7 nTPM (baseline 2); lung: 5.1 nTPM (baseline 2); lymph node: 7.8 nTPM (baseline 6); midbrain: 6 nTPM (baseline 2); pancreas: 5.3 nTPM (baseline 2); pituitary gland: 9 nTPM (baseline 2); retina: 10.1 nTPM (baseline 2); skeletal muscle: 8.6 nTPM (baseline 2); small intestine: 5.8 nTPM (baseline 2); smooth muscle: 6.2 nTPM (baseline 2); spinal cord: 6.2 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 141/141 (100.0%); Pancreatic Adenocarcinoma (validation): 80/80 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q96AX1,https://www.uniprot.org/uniprotkb/Q96AX1/entry,"Plays a role in vesicle-mediated protein trafficking to lysosomal compartments including the endocytic membrane transport and autophagic pathways. Believed to act as a core component of the putative HOPS and CORVET endosomal tethering complexes which are proposed to be involved in the Rab5-to-Rab7 endosome conversion probably implicating MON1A/B, and via binding SNAREs and SNARE complexes to mediate tethering and docking events during SNARE-mediated membrane fusion. The HOPS complex is proposed to be recruited to Rab7 on the late endosomal membrane and to regulate late endocytic, phagocytic and autophagic traffic towards lysosomes. The CORVET complex is proposed to function as a Rab5 effector to mediate early endosome fusion probably in specific endosome subpopulations (PubMed:23351085, PubMed:24554770, PubMed:25266290, PubMed:25783203). Required for fusion of endosomes and autophagosomes with lysosomes; the function is dependent on its association with VPS16 but not VIPAS39 (PubMed:25783203). The function in autophagosome-lysosome fusion implicates STX17 but not UVRAG (PubMed:24554770)",,"Mucopolysaccharidosis-plus syndrome: A form of mucopolysaccharidosis, a group of lysosomal storage diseases characterized by defective degradation of glycosaminoglycans, resulting in their excessive accumulation and secretion. The diseases are progressive and often display a wide spectrum of clinical severity. MPSPS is an autosomal recessive form characterized by coarse facial features, dysostosis multiplex, hepatosplenomegaly, respiratory difficulties, intellectual disability, developmental delay, pyramidal signs, severe chronic anemia, renal involvement and cardiac defects. Laboratory analyses show proteinuria with glomerular foamy cells, excess secretion of urinary glycosaminoglycans, and extremely high levels of plasma heparan sulphate. Disease onset is in infancy. Most patients die in the first years of life due to cardiorespiratory failure.",,"Cytoplasmic vesicle Late endosome membrane Lysosome membrane Early endosome Cytoplasmic vesicle, autophagosome Cytoplasmic vesicle, clathrin-coated vesicle",23351085|24554770|25266290|25783203,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
VSIG1,ENSG00000101842,Unsafe,Protein,False,True,46.2,188.6,83,11,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; duodenum: 1.2 nTPM; positive ihc; pituitary gland: 2.5 nTPM; absolute ceiling; stomach: 188.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 8.6 nTPM; positive ihc;absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",pituitary gland: 2.5 nTPM (limit 2); stomach: 188.6 nTPM (limit 6); urinary bladder: 8.6 nTPM (limit 6),duodenum / glandular cells: Medium (Enhanced); stomach 1 / glandular cells: High (Enhanced); stomach 2 / glandular cells: High (Enhanced); urinary bladder / urothelial cells: High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 59/80 (73.8%); Pancreatic Adenocarcinoma (TCGA): 110/176 (62.5%); Stomach Adenocarcinoma (TCGA): 193/346 (55.8%),stomach cancer: 6/12 (50.0%); pancreatic cancer: 3/10 (30.0%),31,20,Q86XK7,https://www.uniprot.org/uniprotkb/Q86XK7/entry,,"Detected only in stomach mucosa and testis, and to a much lesser level in pancreas (at protein level). Detected in gastric cancers (31%), esophageal carcinomas (50%) and ovarian cancers (23%)",,,Membrane,,16405301,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
VWA3B,ENSG00000168658,Unsafe,Protein,False,True,29.2,29.2,99,7,Positive somewhere,True,True,False,True,Excluded,Normal,False,,Not assessed,,,existing nomination or manual review; nomination unresolved; positive ihc outside permitted; choroid plexus: 9.1 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",choroid plexus: 9.1 nTPM (limit 2),bronchus / ciliated cells (cell body): Low (Approved); bronchus / ciliated cells (ciliary rootlets): Medium (Approved); nasopharynx / ciliated cells (cell body): Low (Approved); nasopharynx / ciliated cells (ciliary rootlets): Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 6/58 (10.3%); Lung Adenocarcinoma (TCGA): 26/497 (5.2%); Uterine Corpus Endometrial Carcinoma (TCGA): 8/176 (4.5%),breast cancer: 4/12 (33.3%); skin cancer: 2/11 (18.2%),31,20,Q502W6,https://www.uniprot.org/uniprotkb/Q502W6/entry,,,"Spinocerebellar ataxia, autosomal recessive, 22: A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCAR22 patients manifest variable severity of intellectual disability associated with adult-onset cerebellar ataxia.",,Cytoplasm,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
WBP2NL,ENSG00000183066,Unsafe,High RNA,False,True,17.3,17.3,84,1,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 4/91 values ≥5 TPM, max 5.45927",True,True,False,,True,False,,False,True,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,5.45926562399,48.0,"hpa_single_cell: /Astrocytes, max 48 nTPM, 1 observations >30; hpa_single_cell_tissue: brain/astrocytes, max 48 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,5.459 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,48 nTPM; unsited/Astrocytes; hpa_single_cell; unresolved,Pancreatic Adenocarcinoma (validation): 8/80 (10.0%); Breast Invasive Carcinoma (validation): 3/50 (6.0%); Glioblastoma Multiforme (validation): 3/58 (5.2%),breast cancer: 0/10 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q6ICG8,https://www.uniprot.org/uniprotkb/Q6ICG8/entry,"May play a role in meiotic resumption and pronuclear formation, mediated by a WW domain-signaling pathway during fertilization",Expressed in testis,,,,,17289678,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
WDHD1,ENSG00000198554,Unsafe,Protein,False,True,5.1,7.8,97,46,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 7.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 2.7 nTPM; positive ihc;continuous selectivity; duodenum: 1.8 nTPM; positive ihc;continuous selectivity; esophagus: 2.4 nTPM; positive ihc;continuous selectivity; kidney: 1 nTPM; positive ihc; lung: 1.3 nTPM; positive ihc; lymph node: 5.4 nTPM; positive ihc;continuous selectivity;reproductive not higher; pancreas: 0.9 nTPM; positive ihc; parathyroid gland: 1.4 nTPM; positive ihc; rectum: 3.9 nTPM; positive ihc;continuous selectivity; retina: 1.7 nTPM; continuous selectivity; salivary gland: 0.7 nTPM; positive ihc; skin: 2 nTPM; positive ihc; small intestine: 1.6 nTPM; positive ihc;continuous selectivity; spleen: 1.7 nTPM; positive ihc; stomach: 1.5 nTPM; positive ihc; thymus: 7.8 nTPM; continuous selectivity;reproductive not higher; urinary bladder: 1.6 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 7.1 nTPM (limit 2),bronchus / basal cells: Low (Enhanced); colon / glandular cells: Medium (Enhanced); duodenum / glandular cells: High (Enhanced); esophagus / squamous epithelial cells: Medium (Enhanced); kidney / cells in glomeruli: Low (Enhanced); lung / alveolar cells: Low (Enhanced); lymph node / germinal center cells: High (Enhanced); lymph node / non-germinal center cells: Medium (Enhanced); nasopharynx / basal cells: High (Enhanced); nasopharynx / ciliated cells (cell body): High (Enhanced); oral mucosa / squamous epithelial cells: Medium (Enhanced); pancreas / pancreatic endocrine cells: Low (Enhanced); parathyroid gland / glandular cells: Low (Enhanced); rectum / glandular cells: High (Enhanced); salivary gland / glandular cells: Low (Enhanced); skin 1 / keratinocytes: Medium (Enhanced); skin 2 / epidermal cells: High (Enhanced); small intestine / glandular cells: Low (Enhanced); spleen / cells in red pulp: Low (Enhanced); spleen / cells in white pulp: High (Enhanced); stomach 1 / glandular cells: High (Enhanced); stomach 2 / glandular cells: Medium (Enhanced); urinary bladder / urothelial cells: High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 472/486 (97.1%); Lung Squamous Cell Carcinoma (validation): 65/68 (95.6%),lymphoma: 12/12 (100.0%); testis cancer: 12/12 (100.0%),31,20,O75717,https://www.uniprot.org/uniprotkb/O75717/entry,Core replisome component that acts as a replication initiation factor. Binds directly to the CMG complex and functions as a hub to recruit additional proteins to the replication fork,,,,"Nucleus, nucleoplasm",19805216|34694004|35585232,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
WDPCP,ENSG00000143951,Unsafe,Protein,False,True,4.6,11.5,77,51,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 4.4 nTPM; positive ihc;continuous selectivity; adrenal gland: 3.3 nTPM; absolute ceiling;continuous selectivity; amygdala: 1.4 nTPM; continuous selectivity; basal ganglia: 2 nTPM; continuous selectivity; bone marrow: 7.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 1.3 nTPM; positive ihc;continuous selectivity; cerebral cortex: 4 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 4.3 nTPM; absolute ceiling;continuous selectivity; colon: 1.4 nTPM; positive ihc; duodenum: 1.6 nTPM; positive ihc;continuous selectivity; esophagus: 1.8 nTPM; positive ihc;continuous selectivity; heart muscle: 4.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 1.7 nTPM; continuous selectivity; hypothalamus: 1.6 nTPM; continuous selectivity; kidney: 3.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 2.2 nTPM; absolute ceiling;continuous selectivity; lung: 2.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 3.1 nTPM; positive ihc;continuous selectivity; midbrain: 1.4 nTPM; continuous selectivity; pancreas: 1.4 nTPM; positive ihc;continuous selectivity; parathyroid gland: 2.8 nTPM; positive ihc;continuous selectivity; pituitary gland: 1.9 nTPM; continuous selectivity; rectum: 1.6 nTPM; positive ihc; retina: 11.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 2 nTPM; positive ihc;continuous selectivity; skeletal muscle: 4.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 3.1 nTPM; positive ihc;continuous selectivity; small intestine: 1.5 nTPM; positive ihc;continuous selectivity; smooth muscle: 2.8 nTPM; absolute ceiling;continuous selectivity; spinal cord: 2.1 nTPM; absolute ceiling;continuous selectivity; spleen: 3.1 nTPM; continuous selectivity; stomach: 3.2 nTPM; positive ihc;continuous selectivity; thymus: 3.4 nTPM; continuous selectivity; thyroid gland: 3.2 nTPM; positive ihc;continuous selectivity; tongue: 2.8 nTPM; continuous selectivity; urinary bladder: 1.7 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 3.3 nTPM (limit 2); bone marrow: 7.3 nTPM (limit 2); cerebral cortex: 4 nTPM (limit 2); choroid plexus: 4.3 nTPM (limit 2); heart muscle: 4.6 nTPM (limit 2); kidney: 3.3 nTPM (limit 2); liver: 2.2 nTPM (limit 2); lung: 2.4 nTPM (limit 2); retina: 11.5 nTPM (limit 2); skeletal muscle: 4.8 nTPM (limit 2); smooth muscle: 2.8 nTPM (limit 2); spinal cord: 2.1 nTPM (limit 2); adrenal gland: 3.3 nTPM (baseline 2); bone marrow: 7.3 nTPM (baseline 2); cerebral cortex: 4 nTPM (baseline 2); choroid plexus: 4.3 nTPM (baseline 2); heart muscle: 4.6 nTPM (baseline 2); kidney: 3.3 nTPM (baseline 2); liver: 2.2 nTPM (baseline 2); lung: 2.4 nTPM (baseline 2); retina: 11.5 nTPM (baseline 2); skeletal muscle: 4.8 nTPM (baseline 2); smooth muscle: 2.8 nTPM (baseline 2); spinal cord: 2.1 nTPM (baseline 2),adipose tissue / adipocytes: Low (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / glial cells: Medium (Uncertain); caudate / neuronal cells: High (Uncertain); cerebellum / cells in granular layer: Low (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / glial cells: Medium (Uncertain); cerebral cortex / neuronal cells: High (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: Low (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / glial cells: Low (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in tubules: Low (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Low (Uncertain); parathyroid gland / glandular cells: Low (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: Medium (Uncertain); skin 1 / fibroblasts: Low (Uncertain); skin 1 / keratinocytes: Low (Uncertain); skin 2 / epidermal cells: Low (Uncertain); small intestine / glandular cells: Medium (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Low (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Pancreatic Adenocarcinoma (validation): 80/80 (100.0%),breast cancer: 6/10 (60.0%); pancreatic cancer: 5/12 (41.7%),30,20,O95876,https://www.uniprot.org/uniprotkb/O95876/entry,"Probable effector of the planar cell polarity signaling pathway which regulates the septin cytoskeleton in both ciliogenesis and collective cell movements. Together with FUZ and WDPCP proposed to function as core component of the CPLANE (ciliogenesis and planar polarity effectors) complex involved in the recruitment of peripheral IFT-A proteins to basal bodies (By similarity). Binds phosphatidylinositol 3-phosphate with highest affinity, followed by phosphatidylinositol 4-phosphate and phosphatidylinositol 5-phosphate (PubMed:35427153)",,"Bardet-Biedl syndrome 15: A syndrome characterized by usually severe pigmentary retinopathy, early-onset obesity, polydactyly, hypogenitalism, renal malformation and intellectual disability. Secondary features include diabetes mellitus, hypertension and congenital heart disease. Bardet-Biedl syndrome inheritance is autosomal recessive, but three mutated alleles (two at one locus, and a third at a second locus) may be required for clinical manifestation of some forms of the disease. Congenital heart defects, hamartomas of tongue, and polysyndactyly: A disease characterized by a constellation of anomalies including tongue hamartomas, polysyndactyly, and congenital heart defects such as atrioventricular canal and coarctation of the aorta.",It is uncertain whether Met-1 or Met-34 is the initiator,"Cell membrane Cytoplasm, cytoskeleton, cilium axoneme Cytoplasm, cytoskeleton, cilium basal body",35427153,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
WDR35,ENSG00000118965,Unsafe,Protein,False,True,11.0,13.9,81,51,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 4.9 nTPM; absolute ceiling;continuous selectivity; amygdala: 3.5 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 4.5 nTPM; absolute ceiling;continuous selectivity; bone marrow: 2 nTPM; positive ihc; cerebellum: 2.4 nTPM; absolute ceiling; cerebral cortex: 5 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 13.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 4.7 nTPM; positive ihc;continuous selectivity; duodenum: 1.7 nTPM; positive ihc; esophagus: 2.8 nTPM; positive ihc; heart muscle: 3.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 3.6 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 4.6 nTPM; absolute ceiling;continuous selectivity; kidney: 7.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 1.9 nTPM; positive ihc; lung: 4.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 2.6 nTPM; positive ihc; midbrain: 3.7 nTPM; absolute ceiling;continuous selectivity; pancreas: 3.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 13.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 8.8 nTPM; absolute ceiling;continuous selectivity; rectum: 2.9 nTPM; positive ihc; retina: 12.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 2.9 nTPM; positive ihc; skin: 3.3 nTPM; positive ihc; small intestine: 2.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 6 nTPM; absolute ceiling;continuous selectivity; spinal cord: 3.6 nTPM; absolute ceiling;continuous selectivity; spleen: 2 nTPM; positive ihc; stomach: 3.5 nTPM; positive ihc; thyroid gland: 8.5 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 4.9 nTPM (limit 4); amygdala: 3.5 nTPM (limit 2); basal ganglia: 4.5 nTPM (limit 2); cerebellum: 2.4 nTPM (limit 2); cerebral cortex: 5 nTPM (limit 2); choroid plexus: 13.1 nTPM (limit 2); heart muscle: 3.2 nTPM (limit 2); hippocampal formation: 3.6 nTPM (limit 2); hypothalamus: 4.6 nTPM (limit 2); kidney: 7.6 nTPM (limit 2); lung: 4.3 nTPM (limit 2); midbrain: 3.7 nTPM (limit 2); pancreas: 3.7 nTPM (limit 2); parathyroid gland: 13.9 nTPM (limit 6); pituitary gland: 8.8 nTPM (limit 2); retina: 12.2 nTPM (limit 2); small intestine: 2.9 nTPM (limit 2); smooth muscle: 6 nTPM (limit 4); spinal cord: 3.6 nTPM (limit 2),bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / neuronal cells: High (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: High (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Medium (Approved); spleen / cells in red pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: High (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Kidney Renal Clear Cell Carcinoma (validation): 95/100 (95.0%); Pancreatic Adenocarcinoma (validation): 75/80 (93.8%),pancreatic cancer: 6/11 (54.5%); liver cancer: 4/11 (36.4%),31,20,Q9P2L0,https://www.uniprot.org/uniprotkb/Q9P2L0/entry,"As a component of the IFT complex A (IFT-A), a complex required for retrograde ciliary transport and entry into cilia of G protein-coupled receptors (GPCRs), it is involved in ciliogenesis and ciliary protein trafficking (PubMed:21473986, PubMed:28400947, PubMed:29220510, PubMed:36775821). May promote CASP3 activation and TNF-stimulated apoptosis",,"Cranioectodermal dysplasia 2: A disorder characterized by craniofacial, skeletal and ectodermal abnormalities. Clinical features include short stature, dolichocephaly, craniosynostosis, narrow thorax with pectus excavatum, short limbs, brachydactyly, joint laxity, narrow palpebral fissures, telecanthus with hypertelorism, low-set simple ears, everted lower lip, and short neck. Teeth abnormalities include widely spaced, hypoplastic and fused teeth. Short-rib thoracic dysplasia 7 with or without polydactyly: A form of short-rib thoracic dysplasia, a group of autosomal recessive ciliopathies that are characterized by a constricted thoracic cage, short ribs, shortened tubular bones, and a 'trident' appearance of the acetabular roof. Polydactyly is variably present. Non-skeletal involvement can include cleft lip/palate as well as anomalies of major organs such as the brain, eye, heart, kidneys, liver, pancreas, intestines, and genitalia. Some forms of the disease are lethal in the neonatal period due to respiratory insufficiency secondary to a severely restricted thoracic cage, whereas others are compatible with life. Disease spectrum encompasses Ellis-van Creveld syndrome, asphyxiating thoracic dystrophy (Jeune syndrome), Mainzer-Saldino syndrome, and short rib-polydactyly syndrome. SRTD7 hallmarks are acromesomelic hypomineralization, campomelia, polysyndactyly, laterality defects, and cystic kidneys. Short-rib thoracic dysplasia 7/20 with polydactyly, digenic: A digenic form of short-rib thoracic dysplasia caused by double heterozygosity for a mutation in the WDR35 gene and a mutation in the INTU gene. Short-rib thoracic dysplasia is part of a group of ciliopathies that are characterized by a constricted thoracic cage, short ribs, shortened tubular bones, and a 'trident' appearance of the acetabular roof. Polydactyly is variably present. Non-skeletal involvement can include cleft lip/palate as well as anomalies of major organs such as the brain, eye, heart, kidneys, liver, pancreas, intestines, and genitalia. Some forms of the disease are lethal in the neonatal period due to respiratory insufficiency secondary to a severely restricted thoracic cage, whereas others are compatible with life. Disease spectrum encompasses Ellis-van Creveld syndrome, asphyxiating thoracic dystrophy (Jeune syndrome), Mainzer-Saldino syndrome, and short rib-polydactyly syndrome.",,"Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Cytoplasm, cytoskeleton, cilium axoneme Cytoplasm, cytoskeleton, cilium basal body",20193664|21473986|28400947|29220510|36775821,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
WDR49,ENSG00000174776,Unsafe,RNA,False,True,8.8,9.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,choroid plexus: 9.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 2.3 nTPM; absolute ceiling; midbrain: 2.2 nTPM; absolute ceiling; small intestine: 4.3 nTPM; absolute ceiling;continuous selectivity; spinal cord: 2.3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 9.1 nTPM (limit 2); hypothalamus: 2.3 nTPM (limit 2); midbrain: 2.2 nTPM (limit 2); small intestine: 4.3 nTPM (limit 2); spinal cord: 2.3 nTPM (limit 2); choroid plexus: 9.1 nTPM (baseline 2); hypothalamus: 2.3 nTPM (baseline 2); midbrain: 2.2 nTPM (baseline 2); small intestine: 4.3 nTPM (baseline 2); spinal cord: 2.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Lung Squamous Cell Carcinoma (validation): 10/68 (14.7%); Glioblastoma Multiforme (TCGA): 19/141 (13.5%),liver cancer: 6/12 (50.0%); melanoma: 2/11 (18.2%),31,20,Q8IV35,https://www.uniprot.org/uniprotkb/Q8IV35/entry,"Associates with components of the nexin-dynein regulatory complex (N-DRC), a key regulator of ciliary/flagellar motility, and might act as an inner dynein arm (IDA) hub or linkage",,,,"Cell projection, cilium",,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
WDR53,ENSG00000185798,Unsafe,Protein,False,True,72.1,72.1,93,34,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 7.1 nTPM; positive ihc;absolute ceiling; amygdala: 6 nTPM; absolute ceiling; basal ganglia: 6.8 nTPM; absolute ceiling; bone marrow: 14.5 nTPM; absolute ceiling; cerebellum: 7 nTPM; absolute ceiling; cerebral cortex: 5.9 nTPM; positive ihc;absolute ceiling; choroid plexus: 11.5 nTPM; absolute ceiling; colon: 7.8 nTPM; positive ihc;absolute ceiling; duodenum: 4.2 nTPM; positive ihc;absolute ceiling; esophagus: 8.7 nTPM; absolute ceiling; heart muscle: 7.8 nTPM; absolute ceiling; hippocampal formation: 6.4 nTPM; absolute ceiling; hypothalamus: 6.3 nTPM; absolute ceiling; kidney: 8.6 nTPM; positive ihc;absolute ceiling; liver: 9.7 nTPM; absolute ceiling; lung: 6.7 nTPM; absolute ceiling; lymph node: 10.3 nTPM; absolute ceiling; midbrain: 6.4 nTPM; absolute ceiling; pancreas: 5.7 nTPM; positive ihc;absolute ceiling; parathyroid gland: 9.6 nTPM; positive ihc;absolute ceiling; pituitary gland: 6.5 nTPM; absolute ceiling; rectum: 6.9 nTPM; positive ihc;absolute ceiling; retina: 8.6 nTPM; absolute ceiling; salivary gland: 6.8 nTPM; positive ihc;absolute ceiling; skeletal muscle: 12.6 nTPM; absolute ceiling; small intestine: 7.7 nTPM; positive ihc;absolute ceiling; smooth muscle: 7.1 nTPM; absolute ceiling; spinal cord: 6.7 nTPM; absolute ceiling; stomach: 7 nTPM; positive ihc;absolute ceiling; thymus: 11.8 nTPM; absolute ceiling; thyroid gland: 6.9 nTPM; positive ihc; tongue: 12.1 nTPM; absolute ceiling; urinary bladder: 7 nTPM; positive ihc;absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 7.1 nTPM (limit 2); amygdala: 6 nTPM (limit 2); basal ganglia: 6.8 nTPM (limit 2); bone marrow: 14.5 nTPM (limit 4); cerebellum: 7 nTPM (limit 4); cerebral cortex: 5.9 nTPM (limit 2); choroid plexus: 11.5 nTPM (limit 2); colon: 7.8 nTPM (limit 6); duodenum: 4.2 nTPM (limit 2); esophagus: 8.7 nTPM (limit 8); heart muscle: 7.8 nTPM (limit 4); hippocampal formation: 6.4 nTPM (limit 2); hypothalamus: 6.3 nTPM (limit 2); kidney: 8.6 nTPM (limit 2); liver: 9.7 nTPM (limit 4); lung: 6.7 nTPM (limit 4); lymph node: 10.3 nTPM (limit 8); midbrain: 6.4 nTPM (limit 2); pancreas: 5.7 nTPM (limit 2); parathyroid gland: 9.6 nTPM (limit 6); pituitary gland: 6.5 nTPM (limit 2); rectum: 6.9 nTPM (limit 6); retina: 8.6 nTPM (limit 2); salivary gland: 6.8 nTPM (limit 6); skeletal muscle: 12.6 nTPM (limit 4); small intestine: 7.7 nTPM (limit 2); smooth muscle: 7.1 nTPM (limit 4); spinal cord: 6.7 nTPM (limit 2); stomach: 7 nTPM (limit 6); thymus: 11.8 nTPM (limit 10); tongue: 12.1 nTPM (limit 6); urinary bladder: 7 nTPM (limit 6),adrenal gland / glandular cells: Low (Approved); bronchus / ciliated cells (ciliary rootlets): Medium (Approved); bronchus / ciliated cells (tip of cilia): Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); colon / glandular cells: Low (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in tubules: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Low (Approved); salivary gland / glandular cells: Low (Approved); small intestine / glandular cells: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Head and Neck Squamous Cell Carcinoma (TCGA): 492/492 (100.0%); Lung Squamous Cell Carcinoma (TCGA): 489/489 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%),renal cancer: 11/12 (91.7%); testis cancer: 7/11 (63.6%),31,20,Q7Z5U6,https://www.uniprot.org/uniprotkb/Q7Z5U6/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
WDR62,ENSG00000075702,Unsafe,RNA,False,True,61.9,106.5,82,3,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,bone marrow: 5.3 nTPM; absolute ceiling; heart muscle: 21.4 nTPM; absolute ceiling; retina: 6.5 nTPM; absolute ceiling; skeletal muscle: 106.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; tongue: 60.6 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 5.3 nTPM (limit 2); heart muscle: 21.4 nTPM (limit 12); retina: 6.5 nTPM (limit 2); skeletal muscle: 106.5 nTPM (limit 12); tongue: 60.6 nTPM (limit 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 115/133 (86.5%); Breast Invasive Carcinoma (validation): 41/50 (82.0%); Colon Adenocarcinoma (validation): 376/486 (77.4%),breast cancer: 0/12 (0.0%); cervical cancer: 0/11 (0.0%),31,20,O43379,https://www.uniprot.org/uniprotkb/O43379/entry,"Required for cerebral cortical development. Plays a role in neuronal proliferation and migration (PubMed:20729831, PubMed:20890278). Plays a role in mother-centriole-dependent centriole duplication; the function also seems to involve CEP152, CDK5RAP2 and CEP63 through a stepwise assembled complex at the centrosome that recruits CDK2 required for centriole duplication (PubMed:26297806)","Present in fetal brain, enriched within the ventricular and subventricular zone (at protein level). In the embryonic brain it is expressed in mitotic neural precursor cells","Microcephaly 2, primary, autosomal recessive, with or without cortical malformations: A disease characterized by microcephaly, moderate to severe intellectual disability, and various type of cortical malformations in most patients. Microcephaly is defined as a head circumference more than 3 standard deviations below the age-related mean. Cortical malformations include pachygyria with cortical thickening, microgyria, lissencephaly, hypoplasia of the corpus callosum, schizencephaly. All affected individuals have delayed psychomotor development. Some patients have seizures.",,"Nucleus Cytoplasm, cytoskeleton, spindle pole Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriole",20729831|20890278|26297806,20890279,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
WDR64,ENSG00000162843,Unsafe,High RNA,False,True,2.3,2.3,0,0,Missing,False,False,False,False,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,True,"Adrenal gland/Glandular cells: Low, HPA046186; conflicting or uncurated primary profile; Bone marrow/Hematopoietic cells: Low, HPA046186; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Low, HPA046186; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA046186; conflicting or uncurated primary profile; Colon/Glandular cells: Medium, HPA046186; conflicting or uncurated primary profile; Colon/Peripheral nerve/ganglion: Medium, HPA046186; conflicting or uncurated primary profile; Duodenum/Glandular cells: Low, HPA046186; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA046186; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA046186; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Low, HPA046186; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA046186; conflicting or uncurated primary profile; Lung/Macrophages: Medium, HPA046186; conflicting or uncurated primary profile; Lymph node/Non-germinal center cells: Low, HPA046186; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA046186; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA046186; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA046186; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA046186; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Low, HPA046186; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA046186; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Low, HPA046186; conflicting or uncurated primary profile; Small intestine/Glandular cells: Medium, HPA046186; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: Medium, HPA046186; conflicting or uncurated primary profile; Spleen/Cells in red pulp: Medium, HPA046186; conflicting or uncurated primary profile; Spleen/Cells in white pulp: Low, HPA046186; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA046186; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA046186; conflicting or uncurated primary profile; Thyroid gland/Glandular cells: Low, HPA046186; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Low, HPA046186; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,2.1275141045900003,30.5,"hpa_single_cell_tissue: brain/excitatory neurons, max 30.5 nTPM, 1 observations >30",Neither,oncoref.target-sets.2026-10-23.2,2.128 TPM; blood/THSTAR; dice_thstar; vital,30.5 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Bladder Urothelial Carcinoma (TCGA): 1/169 (0.6%); Rectum Adenocarcinoma (validation): 1/207 (0.5%); Breast Invasive Carcinoma (TCGA): 1/1022 (0.1%),ovarian cancer: 5/12 (41.7%); breast cancer: 4/12 (33.3%),31,20,B1ANS9,https://www.uniprot.org/uniprotkb/B1ANS9/entry,,Expressed in testis,,,"Cytoplasm Cell projection, cilium, flagellum",,30315278,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Loriot2025_S1 | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Cancer-germline RNA nomination; strict and preferential classes remain distinct | Normal reproductive-tissue enrichment; no tumor validation,,,,All audited maxima are within 10% above 30; other gates still require review,,,,
WDR89,ENSG00000140006,Unsafe,Protein,False,True,7.9,11.0,76,40,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 4.8 nTPM; continuous selectivity; adrenal gland: 5.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 4.2 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 4.3 nTPM; absolute ceiling;continuous selectivity; bone marrow: 3 nTPM; absolute ceiling;continuous selectivity; cerebellum: 5.7 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 5.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 2.7 nTPM; absolute ceiling;continuous selectivity; colon: 5.9 nTPM; positive ihc;continuous selectivity; duodenum: 4.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 5.1 nTPM; continuous selectivity; heart muscle: 4.2 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 4.1 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 4.1 nTPM; absolute ceiling;continuous selectivity; kidney: 8.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 8.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 5.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 11 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 3.6 nTPM; absolute ceiling;continuous selectivity; pancreas: 5.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 7.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 3 nTPM; absolute ceiling;continuous selectivity; rectum: 6.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 11 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 3.9 nTPM; positive ihc;continuous selectivity; skeletal muscle: 5.6 nTPM; absolute ceiling;continuous selectivity; skin: 6 nTPM; continuous selectivity; small intestine: 3.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 5.1 nTPM; absolute ceiling;continuous selectivity; spinal cord: 4.4 nTPM; absolute ceiling;continuous selectivity; spleen: 8.4 nTPM; continuous selectivity;reproductive not higher; stomach: 5.3 nTPM; positive ihc;continuous selectivity; thymus: 9.8 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 8.9 nTPM; positive ihc;continuous selectivity;reproductive not higher; tongue: 7 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 6.4 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 5.7 nTPM (limit 2); amygdala: 4.2 nTPM (limit 2); basal ganglia: 4.3 nTPM (limit 2); bone marrow: 3 nTPM (limit 2); cerebellum: 5.7 nTPM (limit 2); cerebral cortex: 5.1 nTPM (limit 2); choroid plexus: 2.7 nTPM (limit 2); duodenum: 4.9 nTPM (limit 2); heart muscle: 4.2 nTPM (limit 2); hippocampal formation: 4.1 nTPM (limit 2); hypothalamus: 4.1 nTPM (limit 2); kidney: 8.5 nTPM (limit 2); liver: 8.5 nTPM (limit 2); lung: 5.3 nTPM (limit 2); lymph node: 11 nTPM (limit 6); midbrain: 3.6 nTPM (limit 2); pancreas: 5.7 nTPM (limit 2); parathyroid gland: 7.2 nTPM (limit 6); pituitary gland: 3 nTPM (limit 2); rectum: 6.5 nTPM (limit 6); retina: 11 nTPM (limit 2); skeletal muscle: 5.6 nTPM (limit 2); small intestine: 3.9 nTPM (limit 2); smooth muscle: 5.1 nTPM (limit 2); spinal cord: 4.4 nTPM (limit 2); tongue: 7 nTPM (limit 6); urinary bladder: 6.4 nTPM (limit 6); adrenal gland: 5.7 nTPM (baseline 2); amygdala: 4.2 nTPM (baseline 2); basal ganglia: 4.3 nTPM (baseline 2); bone marrow: 3 nTPM (baseline 2); cerebellum: 5.7 nTPM (baseline 2); cerebral cortex: 5.1 nTPM (baseline 2); choroid plexus: 2.7 nTPM (baseline 2); duodenum: 4.9 nTPM (baseline 2); heart muscle: 4.2 nTPM (baseline 2); hippocampal formation: 4.1 nTPM (baseline 2); hypothalamus: 4.1 nTPM (baseline 2); kidney: 8.5 nTPM (baseline 2); liver: 8.5 nTPM (baseline 2); lung: 5.3 nTPM (baseline 2); lymph node: 11 nTPM (baseline 6); midbrain: 3.6 nTPM (baseline 2); pancreas: 5.7 nTPM (baseline 2); parathyroid gland: 7.2 nTPM (baseline 6); pituitary gland: 3 nTPM (baseline 2); rectum: 6.5 nTPM (baseline 6); retina: 11 nTPM (baseline 2); skeletal muscle: 5.6 nTPM (baseline 2); small intestine: 3.9 nTPM (baseline 2); smooth muscle: 5.1 nTPM (baseline 2); spinal cord: 4.4 nTPM (baseline 2); tongue: 7 nTPM (baseline 6); urinary bladder: 6.4 nTPM (baseline 6),adrenal gland / glandular cells: Low (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); cerebral cortex / neuronal cells: Low (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: Low (Uncertain); duodenum / glandular cells: Medium (Uncertain); hippocampus / neuronal cells: Low (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / cholangiocytes: Medium (Uncertain); liver / hepatocytes: Low (Uncertain); lung / alveolar cells: Medium (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Low (Uncertain); parathyroid gland / glandular cells: Low (Uncertain); rectum / glandular cells: Low (Uncertain); salivary gland / glandular cells: Medium (Uncertain); small intestine / glandular cells: Medium (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Low (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 484/486 (99.6%),colorectal cancer: 11/12 (91.7%); pancreatic cancer: 10/12 (83.3%),31,20,Q96FK6,https://www.uniprot.org/uniprotkb/Q96FK6/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
WDR93,ENSG00000140527,Unsafe,RNA,False,True,11.2,11.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,choroid plexus: 6.8 nTPM; absolute ceiling;continuous selectivity; retina: 2.7 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 6.8 nTPM (limit 2); retina: 2.7 nTPM (limit 2); choroid plexus: 6.8 nTPM (baseline 2); retina: 2.7 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 26/50 (52.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 20/176 (11.4%); Glioblastoma Multiforme (validation): 4/58 (6.9%),liver cancer: 4/11 (36.4%); colorectal cancer: 3/12 (25.0%),31,20,Q6P2C0,https://www.uniprot.org/uniprotkb/Q6P2C0/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
WFDC11,ENSG00000180083,Unsafe,RNA,False,True,91.7,91.7,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 2.9 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 2.9 nTPM (limit 2); bone marrow: 2.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 89/207 (43.0%); Colon Adenocarcinoma (validation): 181/486 (37.2%); Stomach Adenocarcinoma (TCGA): 13/346 (3.8%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8NEX6,https://www.uniprot.org/uniprotkb/Q8NEX6/entry,,,,,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Gong2021_reproductive_PC | daSilva2017_tumor_proteomics,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Normal reproductive-tissue enrichment; no tumor validation | Gene-labelled tumor proteomics; unique-locus peptide assignment is not established,,,,,,,,
WFDC3,ENSG00000124116,Unsafe,RNA,False,True,19.4,19.4,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,skin: 16.2 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,skin: 16.2 nTPM (limit 10); skin: 16.2 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 21/50 (42.0%); Pancreatic Adenocarcinoma (validation): 30/80 (37.5%); Ovary Serous Cystadenocarcinoma (validation): 14/81 (17.3%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8IUB2,https://www.uniprot.org/uniprotkb/Q8IUB2/entry,,Ubiquitously expressed,,,Secreted,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
WFIKKN2,ENSG00000173714,Unsafe,RNA,False,True,141.6,1135.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,existing nomination or manual review; nomination unresolved; choroid plexus: 1135.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 2.2 nTPM; absolute ceiling; skeletal muscle: 2.1 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 1135.6 nTPM (limit 2); pituitary gland: 2.2 nTPM (limit 2); skeletal muscle: 2.1 nTPM (limit 2); choroid plexus: 1135.6 nTPM (baseline 2); pituitary gland: 2.2 nTPM (baseline 2); skeletal muscle: 2.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 11/133 (8.3%); Glioblastoma Multiforme (validation): 4/58 (6.9%); Glioblastoma Multiforme (TCGA): 6/141 (4.3%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8TEU8,https://www.uniprot.org/uniprotkb/Q8TEU8/entry,"Protease-inhibitor that contains multiple distinct protease inhibitor domains. Probably has serine protease- and metalloprotease-inhibitor activity. Inhibits the biological activity of mature myostatin, but not activin (By similarity)","Primarily expressed in ovary, testis and brain, but not in liver. In fetal tissues, it is primarily expressed in brain, skeletal muscle, thymus and kidney",,,Secreted,,11928817,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_reproductive_PC,Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
WNK3,ENSG00000196632,Unsafe,RNA,False,True,11.5,11.5,81,2,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,pituitary gland: 2.4 nTPM; absolute ceiling; retina: 3.2 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,pituitary gland: 2.4 nTPM (limit 2); retina: 3.2 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Testicular Germ Cell Tumor (TCGA): 24/133 (18.0%); Liver Hepatocellular Carcinoma (validation): 41/231 (17.7%),cervical cancer: 1/11 (9.1%); ovarian cancer: 1/12 (8.3%),31,20,Q9BYP7,https://www.uniprot.org/uniprotkb/Q9BYP7/entry,"Serine/threonine-protein kinase component of the WNK3-SPAK/OSR1 kinase cascade, which plays an important role in the regulation of electrolyte homeostasis and regulatory volume increase in response to hyperosmotic stress (PubMed:16275911, PubMed:16275913, PubMed:16501604, PubMed:22989884, PubMed:36318922). WNK3 mediates regulatory volume increase in response to hyperosmotic stress by acting as a molecular crowding sensor, which senses cell shrinkage and mediates formation of a membraneless compartment by undergoing liquid-liquid phase separation (PubMed:36318922). The membraneless compartment concentrates WNK3 with its substrates, OXSR1/OSR1 and STK39/SPAK, promoting WNK3-dependent phosphorylation and activation of downstream kinases OXSR1/OSR1 and STK39/SPAK (PubMed:22989884). Following activation, OXSR1/OSR1 and STK39/SPAK catalyze phosphorylation of ion cotransporters SLC12A1/NKCC2, SLC12A2/NKCC1, SLC12A3/NCC, SLC12A4/KCC1, SLC12A5/KCC2 or SLC12A6/KCC3, regulating their activity (PubMed:16275911, PubMed:16275913). Phosphorylation of Na-K-Cl cotransporters SLC12A2/NKCC1 and SLC12A2/NKCC1 promote their activation and ion influx; simultaneously, phosphorylation of K-Cl cotransporters SLC12A4/KCC1, SLC12A5/KCC2 and SLC12A6/KCC3 inhibits its activity, blocking ion efflux (PubMed:16275911, PubMed:16275913, PubMed:16357011, PubMed:19470686, PubMed:21613606). Phosphorylates WNK4, possibly regulating the activity of SLC12A3/NCC (PubMed:17975670). May also phosphorylate NEDD4L (PubMed:20525693). Also acts as a scaffold protein independently of its protein kinase activity: negatively regulates cell membrane localization of various transporters and channels, such as KCNJ1 and SLC26A9 (PubMed:16357011, PubMed:17673510). Increases Ca(2+) influx mediated by TRPV5 and TRPV6 by enhancing their membrane expression level via a kinase-dependent pathway (PubMed:18768590)","Expressed in brain, lung, kidney, liver and pancreas, and in fetal tissues including placenta, fetal brain, lung and kidney. Very low levels of expression were also detected in fetal heart, thymus, liver and spleen. Isoform 1 is brain-specific. Isoform 3 is kidney-specific","Prieto syndrome: An X-linked recessive disorder characterized by impaired intellectual development, developmental delay, autism spectrum disorder, variable epilepsy, craniofacial dysmorphism, and structural brain abnormalities including polymicrogyria and cerebral atrophy.","According to a report, isoform 1 inhibits the activity of SLC12A3/NCC (PubMed:19470686). According to another publication, it stimulates the activity of SLC12A3/NCC (PubMed:21613606) Was named WNK/'with no lysine(K)' because key residues for catalysis, including the lysine involved in ATP binding, are either not conserved or differ compared to the residues described in other kinase family proteins",Cytoplasm,16275911|16275913|16357011|16501604|17673510|17975670|18768590|19470686|20525693|21613606|22989884|36318922,11571656|15194194|16275913,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
WNT7A,ENSG00000154764,Unsafe,RNA,False,True,2.6,4.0,80,0,Negative where measured,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 3.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 3.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 1.6 nTPM; continuous selectivity; hypothalamus: 1.3 nTPM; continuous selectivity; lung: 2 nTPM; continuous selectivity; midbrain: 1.5 nTPM; continuous selectivity; spinal cord: 0.9 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 3.7 nTPM (limit 2); basal ganglia: 3.2 nTPM (limit 2); amygdala: 3.7 nTPM (baseline 2); basal ganglia: 3.2 nTPM (baseline 2); cerebral cortex: 4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Ovary Serous Cystadenocarcinoma (TCGA): 229/349 (65.6%); Ovary Serous Cystadenocarcinoma (validation): 51/81 (63.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 92/176 (52.3%),prostate cancer: 4/12 (33.3%); glioma: 2/12 (16.7%),31,20,O00755,https://www.uniprot.org/uniprotkb/O00755/entry,"Ligand for members of the frizzled family of seven transmembrane receptors that functions in the canonical Wnt/beta-catenin signaling pathway (By similarity). Plays an important role in embryonic development, including dorsal versus ventral patterning during limb development, skeleton development and urogenital tract development (PubMed:16826533). Required for central nervous system (CNS) angiogenesis and blood-brain barrier regulation (PubMed:30026314). Required for normal, sexually dimorphic development of the Mullerian ducts, and for normal fertility in both sexes (By similarity). Required for normal neural stem cell proliferation in the hippocampus dentate gyrus (By similarity). Required for normal progress through the cell cycle in neural progenitor cells, for self-renewal of neural stem cells, and for normal neuronal differentiation and maturation (By similarity). Promotes formation of synapses via its interaction with FZD5 (By similarity)","Expression is restricted to placenta, kidney, testis, uterus, fetal lung, and fetal and adult brain","Limb pelvis hypoplasia aplasia syndrome: A syndrome of severe deficiency of the extremities due to hypo- or aplasia of one or more long bones of one or more limbs. Pelvic manifestations include hip dislocation, hypoplastic iliac bone and aplastic pubic bones. Thoracic deformity, unusual facies and genitourinary anomalies can be present. Fuhrmann syndrome: An autosomal recessive disorder characterized by severe bowing of femora, aplasia or hypoplasia of fibulae, hypoplasia of the pelvis, and congenital dislocation of the hip. Patients exhibit absence or coalescence of tarsal bones, absence of various metatarsals, hypoplasia and aplasia of toes, clinodactyly, hypoplasia of fingers and fingernails, and postaxial polydactyly. Santos syndrome: An autosomal recessive syndrome characterized by short stature due to mesomelic shortening of the lower limbs with fibular agenesis or hypoplasia, clubfeet with severe oligodactyly, upper limbs with acromial dimples and variable motion limitation of the forearms and/or hands, and severe nail hypoplasia or anonychia that is associated with brachydactyly in some cases. Pre-axial polydactyly may also be present.",,"Secreted, extracellular space, extracellular matrix Secreted",16826533|30026314,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
XAGE2,ENSG00000155622,Unsafe,RNA,False,True,192.5,192.5,77,8,Positive somewhere,False,True,False,False,Excluded,Normal,False,,Not assessed,,,reviewed unreliable ihc; reviewed unreliable ihc; lung: 5.5 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,lung: 5.5 nTPM (limit 2); lung: 5.5 nTPM (baseline 2),small intestine / glandular cells: Low (Supported); stomach 1 / glandular cells: Low (Supported); thyroid gland / glandular cells: Low (Supported),reviewed_unreliable_ihc,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Ovary Serous Cystadenocarcinoma (TCGA): 93/349 (26.6%); Lung Adenocarcinoma (validation): 23/105 (21.9%); Lung Adenocarcinoma (TCGA): 80/497 (16.1%),urothelial cancer: 2/12 (16.7%); prostate cancer: 1/10 (10.0%),31,20,Q96GT9,https://www.uniprot.org/uniprotkb/Q96GT9/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Gong2021_reproductive_PC,No tumor-antigen validation in this source | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
XAGE3,ENSG00000171402,Unsafe,High RNA,False,True,368.3,368.3,81,1,Positive somewhere,False,False,False,True,Retained,Reproductive,False,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,CTA,Pass,oncoref.target-sets.2026-10-23.1,False,False,,CTA → Unsafe,True,True,True,0.8567,68.6,"hpa_single_cell_tissue: placenta/mixed immune cells, max 50.9 nTPM, 1 observations >30; hpa_single_cell_tissue: placenta/t-cells, max 68.6 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,0.8567 TPM; blood/memory B-cell; hpa_immune_cell_samples; vital,68.6 nTPM; placenta/t-cells; hpa_single_cell_tissue; vital,Skin Cuteneous Melanoma (TCGA): 6/99 (6.1%); Ovary Serous Cystadenocarcinoma (TCGA): 14/349 (4.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 5/176 (2.8%),urothelial cancer: 2/12 (16.7%); prostate cancer: 1/10 (10.0%),31,20,Q8WTP9,https://www.uniprot.org/uniprotkb/Q8WTP9/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Wang2016_CT | Gong2021_reproductive_PC,No tumor-antigen validation in this source | Cancer-associated RNA nomination; no antigen validation asserted | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
XKR9,ENSG00000221947,Unsafe,Protein,False,True,7.1,7.1,78,30,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 1.1 nTPM; positive ihc; bone marrow: 0.2 nTPM; positive ihc; cerebellum: 0 nTPM; positive ihc; cerebral cortex: 0.4 nTPM; positive ihc; colon: 0.8 nTPM; positive ihc; duodenum: 2.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 0.5 nTPM; positive ihc; heart muscle: 0.2 nTPM; positive ihc; kidney: 0.4 nTPM; positive ihc; lung: 0.6 nTPM; positive ihc; pancreas: 0.3 nTPM; positive ihc; retina: 2 nTPM; continuous selectivity; salivary gland: 0.5 nTPM; positive ihc; skeletal muscle: 0.1 nTPM; positive ihc; skin: 0.9 nTPM; positive ihc; small intestine: 5.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 1.6 nTPM; positive ihc; thyroid gland: 0.4 nTPM; positive ihc; urinary bladder: 0.9 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",duodenum: 2.6 nTPM (limit 2); small intestine: 5.2 nTPM (limit 2),adrenal gland / glandular cells: Medium (Enhanced); bone marrow / hematopoietic cells: Low (Enhanced); caudate / neuronal cells: Medium (Enhanced); cerebellum / cells in molecular layer: Low (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); colon / glandular cells: Low (Enhanced); duodenum / glandular cells: Medium (Enhanced); esophagus / squamous epithelial cells: Low (Enhanced); heart muscle / cardiomyocytes: Low (Enhanced); hippocampus / neuronal cells: Medium (Enhanced); kidney / cells in tubules: Medium (Enhanced); lung / macrophages: Low (Enhanced); oral mucosa / squamous epithelial cells: Low (Enhanced); pancreas / pancreatic endocrine cells: Medium (Enhanced); salivary gland / glandular cells: Low (Enhanced); skeletal muscle / myocytes: Low (Enhanced); skin 2 / epidermal cells: Medium (Enhanced); small intestine / glandular cells: Low (Enhanced); stomach 2 / glandular cells: Medium (Enhanced); thyroid gland / glandular cells: Low (Enhanced); urinary bladder / urothelial cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 72/80 (90.0%); Lung Adenocarcinoma (validation): 30/105 (28.6%); Colon Adenocarcinoma (validation): 131/486 (27.0%),prostate cancer: 4/10 (40.0%); endometrial cancer: 3/10 (30.0%),31,20,Q5GH70,https://www.uniprot.org/uniprotkb/Q5GH70/entry,Phospholipid scramblase that promotes phosphatidylserine exposure on apoptotic cell surface (PubMed:25231987). Phosphatidylserine is a specific marker only present at the surface of apoptotic cells and acts as a specific signal for engulfment (PubMed:25231987),,,,Cell membrane,25231987,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
XPO4,ENSG00000132953,Unsafe,RNA,False,True,6.0,42.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 4.2 nTPM; continuous selectivity; adrenal gland: 3.5 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 1.7 nTPM; continuous selectivity; bone marrow: 10.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 4.7 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 4 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 2.8 nTPM; absolute ceiling;continuous selectivity; colon: 4.5 nTPM; continuous selectivity; duodenum: 3.6 nTPM; absolute ceiling;continuous selectivity; esophagus: 4.7 nTPM; continuous selectivity; heart muscle: 10.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 4.9 nTPM; absolute ceiling;continuous selectivity; liver: 4 nTPM; absolute ceiling;continuous selectivity; lung: 5.9 nTPM; absolute ceiling;continuous selectivity; lymph node: 7.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 1.8 nTPM; continuous selectivity; pancreas: 4.1 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 6.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 2.9 nTPM; absolute ceiling;continuous selectivity; rectum: 5.5 nTPM; continuous selectivity; retina: 13.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 3.6 nTPM; continuous selectivity; skeletal muscle: 42.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 5.5 nTPM; continuous selectivity; small intestine: 3.7 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 5.4 nTPM; absolute ceiling;continuous selectivity; spinal cord: 2.7 nTPM; absolute ceiling;continuous selectivity; spleen: 5.7 nTPM; continuous selectivity; stomach: 4.6 nTPM; continuous selectivity; thymus: 6.9 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 6.3 nTPM; continuous selectivity;reproductive not higher; tongue: 16.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 4.5 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 3.5 nTPM (limit 2); bone marrow: 10.1 nTPM (limit 2); cerebellum: 4.7 nTPM (limit 2); cerebral cortex: 4 nTPM (limit 2); choroid plexus: 2.8 nTPM (limit 2); duodenum: 3.6 nTPM (limit 2); heart muscle: 10.4 nTPM (limit 2); kidney: 4.9 nTPM (limit 2); liver: 4 nTPM (limit 2); lung: 5.9 nTPM (limit 2); lymph node: 7.2 nTPM (limit 6); pancreas: 4.1 nTPM (limit 2); parathyroid gland: 6.3 nTPM (limit 6); pituitary gland: 2.9 nTPM (limit 2); retina: 13.2 nTPM (limit 2); skeletal muscle: 42.8 nTPM (limit 2); small intestine: 3.7 nTPM (limit 2); smooth muscle: 5.4 nTPM (limit 2); spinal cord: 2.7 nTPM (limit 2); tongue: 16.2 nTPM (limit 6); adrenal gland: 3.5 nTPM (baseline 2); bone marrow: 10.1 nTPM (baseline 2); cerebellum: 4.7 nTPM (baseline 2); cerebral cortex: 4 nTPM (baseline 2); choroid plexus: 2.8 nTPM (baseline 2); duodenum: 3.6 nTPM (baseline 2); heart muscle: 10.4 nTPM (baseline 2); kidney: 4.9 nTPM (baseline 2); liver: 4 nTPM (baseline 2); lung: 5.9 nTPM (baseline 2); lymph node: 7.2 nTPM (baseline 6); pancreas: 4.1 nTPM (baseline 2); parathyroid gland: 6.3 nTPM (baseline 6); pituitary gland: 2.9 nTPM (baseline 2); retina: 13.2 nTPM (baseline 2); skeletal muscle: 42.8 nTPM (baseline 2); small intestine: 3.7 nTPM (baseline 2); smooth muscle: 5.4 nTPM (baseline 2); spinal cord: 2.7 nTPM (baseline 2); tongue: 16.2 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 484/486 (99.6%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9C0E2,https://www.uniprot.org/uniprotkb/Q9C0E2/entry,"Mediates the nuclear export of proteins (cargos), such as EIF5A, SMAD3 and isoform M2 of PKM (PKM2) (PubMed:10944119, PubMed:16449645, PubMed:26787900). In the nucleus binds cooperatively to its cargo and to the GTPase Ran in its active GTP-bound form. Docking of this trimeric complex to the nuclear pore complex (NPC) is mediated through binding to nucleoporins (PubMed:10944119, PubMed:16449645). Upon transit of a nuclear export complex into the cytoplasm, disassembling of the complex and hydrolysis of Ran-GTP to Ran-GDP (induced by RANBP1 and RANGAP1, respectively) cause release of the cargo from the export receptor (PubMed:10944119, PubMed:16449645). XPO4 then return to the nuclear compartment and mediate another round of transport (PubMed:10944119, PubMed:16449645). The directionality of nuclear export is thought to be conferred by an asymmetric distribution of the GTP- and GDP-bound forms of Ran between the cytoplasm and nucleus (PubMed:10944119, PubMed:16449645). Catalyzes the nuclear export of hypusinated EIF5A; a small cytoplasmic protein that enters nucleus and accumulates within nucleolus if not exported back by XPO4 (PubMed:10944119). Specifically mediates nuclear export of isoform M2 of PKM (PKM2) following PKM2 deacetylation by SIRT6 (PubMed:26787900). Also mediates the nuclear import of SOX transcription factors SRY and SOX2 (By similarity)",,,,Cytoplasm Nucleus,10944119|16449645|26787900,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
XRCC2,ENSG00000196584,Unsafe,RNA,False,True,3.3,5.7,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 5.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 1.8 nTPM; continuous selectivity; heart muscle: 1.3 nTPM; continuous selectivity; lymph node: 3.1 nTPM; continuous selectivity; rectum: 1.9 nTPM; continuous selectivity; retina: 2 nTPM; continuous selectivity; skin: 2.1 nTPM; continuous selectivity; small intestine: 1.6 nTPM; continuous selectivity; thymus: 3.8 nTPM; continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 5.7 nTPM (limit 2); bone marrow: 5.7 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 55/58 (94.8%); Colon Adenocarcinoma (validation): 460/486 (94.7%); Rectum Adenocarcinoma (validation): 192/207 (92.8%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O43543,https://www.uniprot.org/uniprotkb/O43543/entry,"Involved in the homologous recombination repair (HRR) pathway of double-stranded DNA, thought to repair chromosomal fragmentation, translocations and deletions. Part of the RAD51 paralog protein complex BCDX2 which acts in the BRCA1-BRCA2-dependent HR pathway. Upon DNA damage, BCDX2 acts downstream of BRCA2 recruitment and upstream of RAD51 recruitment. BCDX2 binds predominantly to the intersection of the four duplex arms of the Holliday junction and to junction of replication forks. The BCDX2 complex was originally reported to bind single-stranded DNA, single-stranded gaps in duplex DNA and specifically to nicks in duplex DNA",,"Fanconi anemia, complementation group U: A disorder affecting all bone marrow elements and resulting in anemia, leukopenia and thrombopenia. It is associated with cardiac, renal and limb malformations, dermal pigmentary changes, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage) and defective DNA repair. Spermatogenic failure 50: An autosomal recessive infertility disorder characterized by azoospermia due to meiotic arrest at the zygotene stage of prophase I. Premature ovarian failure 17: A form of premature ovarian failure, an ovarian disorder defined as the cessation of ovarian function under the age of 40 years. It is characterized by oligomenorrhea or amenorrhea, in the presence of elevated levels of serum gonadotropins and low estradiol. POF17 transmission pattern is consistent with autosomal recessive inheritance.",,"Nucleus Cytoplasm, cytoskeleton, microtubule organizing center, centrosome",11751635|11834724|21276791|23149936|27233470,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
XRCC4,ENSG00000152422,Unsafe,Protein,False,True,8.5,10.0,84,76,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 4.3 nTPM; positive ihc;continuous selectivity; adrenal gland: 4.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 3.6 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 4.2 nTPM; absolute ceiling;continuous selectivity; bone marrow: 4.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 1.6 nTPM; positive ihc; cerebral cortex: 3.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 5.7 nTPM; positive ihc;continuous selectivity; duodenum: 7.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 3.7 nTPM; positive ihc;continuous selectivity; heart muscle: 7.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 3.9 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 3.1 nTPM; absolute ceiling;continuous selectivity; kidney: 7 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 5.3 nTPM; continuous selectivity; lung: 4.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 8.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 4 nTPM; absolute ceiling;continuous selectivity; pancreas: 2.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 2.1 nTPM; absolute ceiling; rectum: 5.5 nTPM; positive ihc;continuous selectivity; retina: 2.3 nTPM; absolute ceiling;continuous selectivity; salivary gland: 3.3 nTPM; positive ihc;continuous selectivity; skeletal muscle: 2.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 3.2 nTPM; positive ihc; small intestine: 5 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 4 nTPM; absolute ceiling;continuous selectivity; spleen: 4.7 nTPM; positive ihc;continuous selectivity; stomach: 4.2 nTPM; positive ihc;continuous selectivity; thymus: 10 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 4.2 nTPM; positive ihc;continuous selectivity; urinary bladder: 5.3 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 4.1 nTPM (limit 2); amygdala: 3.6 nTPM (limit 2); basal ganglia: 4.2 nTPM (limit 2); bone marrow: 4.4 nTPM (limit 2); cerebral cortex: 3.3 nTPM (limit 2); duodenum: 7.3 nTPM (limit 2); heart muscle: 7.7 nTPM (limit 2); hippocampal formation: 3.9 nTPM (limit 2); hypothalamus: 3.1 nTPM (limit 2); kidney: 7 nTPM (limit 2); lung: 4.5 nTPM (limit 2); lymph node: 8.3 nTPM (limit 6); midbrain: 4 nTPM (limit 2); pancreas: 2.4 nTPM (limit 2); pituitary gland: 2.1 nTPM (limit 2); retina: 2.3 nTPM (limit 2); skeletal muscle: 2.5 nTPM (limit 2); small intestine: 5 nTPM (limit 2); spinal cord: 4 nTPM (limit 2),adipose tissue / adipocytes: High (Supported); adrenal gland / glandular cells: High (Supported); bone marrow / hematopoietic cells: High (Supported); bronchus / respiratory epithelial cells: High (Supported); caudate / glial cells: High (Supported); caudate / neuronal cells: Medium (Supported); cerebellum / cells in granular layer: High (Supported); cerebellum / cells in molecular layer: High (Supported); cerebellum / Purkinje cells: High (Supported); cerebral cortex / endothelial cells: Medium (Supported); cerebral cortex / glial cells: High (Supported); cerebral cortex / neuronal cells: High (Supported); colon / endothelial cells: High (Supported); colon / glandular cells: High (Supported); duodenum / glandular cells: High (Supported); esophagus / squamous epithelial cells: High (Supported); heart muscle / cardiomyocytes: High (Supported); hippocampus / glial cells: High (Supported); hippocampus / neuronal cells: High (Supported); kidney / cells in glomeruli: High (Supported); kidney / cells in tubules: High (Supported); lung / alveolar cells type I: Medium (Supported); lung / alveolar cells type II: High (Supported); lung / endothelial cells: Low (Supported); lung / macrophages: High (Supported); lymph node / germinal center cells: High (Supported); lymph node / non-germinal center cells: High (Supported); nasopharynx / respiratory epithelial cells: High (Supported); oral mucosa / squamous epithelial cells: High (Supported); pancreas / exocrine glandular cells: High (Supported); pancreas / pancreatic endocrine cells: High (Supported); rectum / glandular cells: High (Supported); salivary gland / glandular cells: High (Supported); skeletal muscle / myocytes: High (Supported); skin 1 / fibroblasts: Medium (Supported); skin 1 / keratinocytes: High (Supported); skin 1 / Langerhans: Medium (Supported); skin 2 / epidermal cells: High (Supported); small intestine / glandular cells: High (Supported); spleen / cells in red pulp: High (Supported); spleen / cells in white pulp: High (Supported); stomach 1 / glandular cells: High (Supported); stomach 2 / glandular cells: High (Supported); thyroid gland / glandular cells: High (Supported); urinary bladder / urothelial cells: High (Supported),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Adenocarcinoma (validation): 105/105 (100.0%); Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%),lymphoma: 12/12 (100.0%); breast cancer: 11/11 (100.0%),31,20,Q13426,https://www.uniprot.org/uniprotkb/Q13426/entry,"DNA non-homologous end joining (NHEJ) core factor, required for double-strand break repair and V(D)J recombination (PubMed:10757784, PubMed:10854421, PubMed:12517771, PubMed:16412978, PubMed:17124166, PubMed:17290226, PubMed:22228831, PubMed:25597996, PubMed:25742519, PubMed:25934149, PubMed:26100018, PubMed:26774286, PubMed:8548796). Acts as a scaffold protein that regulates recruitment of other proteins to DNA double-strand breaks (DSBs) (PubMed:15385968, PubMed:20852255, PubMed:26774286, PubMed:27437582). Associates with NHEJ1/XLF to form alternating helical filaments that bridge DNA and act like a bandage, holding together the broken DNA until it is repaired (PubMed:21768349, PubMed:21775435, PubMed:22287571, PubMed:26100018, PubMed:27437582, PubMed:28500754). The XRCC4-NHEJ1/XLF subcomplex binds to the DNA fragments of a DSB in a highly diffusive manner and robustly bridges two independent DNA molecules, holding the broken DNA fragments in close proximity to one other (PubMed:27437582). The mobility of the bridges ensures that the ends remain accessible for further processing by other repair factors (PubMed:27437582). Plays a key role in the NHEJ ligation step of the broken DNA during DSB repair via direct interaction with DNA ligase IV (LIG4): the LIG4-XRCC4 subcomplex reseals the DNA breaks after the gap filling is completed (PubMed:10757784, PubMed:10854421, PubMed:12517771, PubMed:17290226, PubMed:19837014, PubMed:9242410). XRCC4 stabilizes LIG4, regulates its subcellular localization and enhances LIG4's joining activity (PubMed:10757784, PubMed:10854421, PubMed:12517771, PubMed:17290226, PubMed:21982441, PubMed:22228831, PubMed:9242410). Binding of the LIG4-XRCC4 subcomplex to DNA ends is dependent on the assembly of the DNA-dependent protein kinase complex DNA-PK to these DNA ends (PubMed:10757784, PubMed:10854421). Promotes displacement of PNKP from processed strand break termini (PubMed:20852255, PubMed:28453785) Acts as an activator of the phospholipid scramblase activity of XKR4 (PubMed:33725486). This form, which is generated upon caspase-3 (CASP3) cleavage, translocates into the cytoplasm and interacts with XKR4, thereby promoting phosphatidylserine scramblase activity of XKR4 and leading to phosphatidylserine exposure on apoptotic cell surface (PubMed:33725486)",Widely expressed,"Short stature, microcephaly, and endocrine dysfunction: A disease characterized by short stature and microcephaly apparent at birth, progressive postnatal growth failure, and endocrine dysfunction. In affected adults endocrine features include hypergonadotropic hypogonadism, multinodular goiter, and diabetes mellitus. Variable features observed in some patients are progressive ataxia, and lymphopenia or borderline leukopenia.",Sumoylation at Lys-210 was initially reported to regulate nuclear localization and recombination efficiency of XRCC4 (PubMed:16478998). This result is however not confirmed by another study (PubMed:25934149),Nucleus Chromosome Cytoplasm,10757784|10854421|12517771|15385968|16412978|17124166|17290226|19837014|20852255|21768349|21775435|21982441|22228831|22287571|25597996|25742519|25934149|26100018|26774286|27437582|28453785|28500754|33725486|8548796|9242410,8548796,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
YEATS4,ENSG00000127337,Unsafe,RNA,False,True,36.0,45.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 11.5 nTPM; absolute ceiling;continuous selectivity; amygdala: 8.7 nTPM; absolute ceiling; basal ganglia: 8.8 nTPM; absolute ceiling; bone marrow: 45.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 16.6 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 10.6 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 14.9 nTPM; absolute ceiling;continuous selectivity; colon: 11.9 nTPM; absolute ceiling; duodenum: 13.1 nTPM; absolute ceiling;continuous selectivity; esophagus: 11.3 nTPM; absolute ceiling; heart muscle: 10.7 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 8 nTPM; absolute ceiling; hypothalamus: 9.7 nTPM; absolute ceiling;continuous selectivity; kidney: 14.8 nTPM; absolute ceiling;continuous selectivity; liver: 14.4 nTPM; absolute ceiling;continuous selectivity; lung: 8.6 nTPM; absolute ceiling; lymph node: 22 nTPM; absolute ceiling;continuous selectivity; midbrain: 8.9 nTPM; absolute ceiling; pancreas: 16.8 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 10.8 nTPM; absolute ceiling; pituitary gland: 9.9 nTPM; absolute ceiling;continuous selectivity; rectum: 13.3 nTPM; absolute ceiling;continuous selectivity; retina: 19.4 nTPM; absolute ceiling;continuous selectivity; salivary gland: 11.7 nTPM; absolute ceiling; skeletal muscle: 13.8 nTPM; absolute ceiling;continuous selectivity; skin: 11 nTPM; absolute ceiling; small intestine: 13.1 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 8.1 nTPM; absolute ceiling; spinal cord: 10 nTPM; absolute ceiling;continuous selectivity; spleen: 10.7 nTPM; absolute ceiling; stomach: 10.7 nTPM; absolute ceiling; thymus: 25.2 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 13.4 nTPM; absolute ceiling; tongue: 18.7 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 10.9 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 11.5 nTPM (limit 2); amygdala: 8.7 nTPM (limit 2); basal ganglia: 8.8 nTPM (limit 2); bone marrow: 45.2 nTPM (limit 2); cerebellum: 16.6 nTPM (limit 2); cerebral cortex: 10.6 nTPM (limit 2); choroid plexus: 14.9 nTPM (limit 2); colon: 11.9 nTPM (limit 6); duodenum: 13.1 nTPM (limit 2); esophagus: 11.3 nTPM (limit 6); heart muscle: 10.7 nTPM (limit 2); hippocampal formation: 8 nTPM (limit 2); hypothalamus: 9.7 nTPM (limit 2); kidney: 14.8 nTPM (limit 2); liver: 14.4 nTPM (limit 2); lung: 8.6 nTPM (limit 2); lymph node: 22 nTPM (limit 6); midbrain: 8.9 nTPM (limit 2); pancreas: 16.8 nTPM (limit 2); parathyroid gland: 10.8 nTPM (limit 6); pituitary gland: 9.9 nTPM (limit 2); rectum: 13.3 nTPM (limit 6); retina: 19.4 nTPM (limit 2); salivary gland: 11.7 nTPM (limit 6); skeletal muscle: 13.8 nTPM (limit 2); skin: 11 nTPM (limit 10); small intestine: 13.1 nTPM (limit 2); smooth muscle: 8.1 nTPM (limit 2); spinal cord: 10 nTPM (limit 2); spleen: 10.7 nTPM (limit 10); stomach: 10.7 nTPM (limit 6); thymus: 25.2 nTPM (limit 10); thyroid gland: 13.4 nTPM (limit 10); tongue: 18.7 nTPM (limit 6); urinary bladder: 10.9 nTPM (limit 6); adrenal gland: 11.5 nTPM (baseline 2); amygdala: 8.7 nTPM (baseline 2); basal ganglia: 8.8 nTPM (baseline 2); bone marrow: 45.2 nTPM (baseline 2); cerebellum: 16.6 nTPM (baseline 2); cerebral cortex: 10.6 nTPM (baseline 2); choroid plexus: 14.9 nTPM (baseline 2); colon: 11.9 nTPM (baseline 6); duodenum: 13.1 nTPM (baseline 2); esophagus: 11.3 nTPM (baseline 6); heart muscle: 10.7 nTPM (baseline 2); hippocampal formation: 8 nTPM (baseline 2); hypothalamus: 9.7 nTPM (baseline 2); kidney: 14.8 nTPM (baseline 2); liver: 14.4 nTPM (baseline 2); lung: 8.6 nTPM (baseline 2); lymph node: 22 nTPM (baseline 6); midbrain: 8.9 nTPM (baseline 2); pancreas: 16.8 nTPM (baseline 2); parathyroid gland: 10.8 nTPM (baseline 6); pituitary gland: 9.9 nTPM (baseline 2); rectum: 13.3 nTPM (baseline 6); retina: 19.4 nTPM (baseline 2); salivary gland: 11.7 nTPM (baseline 6); skeletal muscle: 13.8 nTPM (baseline 2); skin: 11 nTPM (baseline 10); small intestine: 13.1 nTPM (baseline 2); smooth muscle: 8.1 nTPM (baseline 2); spinal cord: 10 nTPM (baseline 2); spleen: 10.7 nTPM (baseline 10); stomach: 10.7 nTPM (baseline 6); thymus: 25.2 nTPM (baseline 10); thyroid gland: 13.4 nTPM (baseline 10); tongue: 18.7 nTPM (baseline 6); urinary bladder: 10.9 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Ovary Serous Cystadenocarcinoma (TCGA): 349/349 (100.0%); Colon Adenocarcinoma (TCGA): 254/254 (100.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O95619,https://www.uniprot.org/uniprotkb/O95619/entry,"Chromatin reader component of the NuA4 histone acetyltransferase (HAT) complex, a complex involved in transcriptional activation of select genes principally by acetylation of nucleosomal histones H4 and H2A (PubMed:12963728, PubMed:14966270). Specifically recognizes and binds acylated histone H3, with a preference for histone H3 diacetylated at 'Lys-18' and 'Lys-27' (H3K18ac and H3K27ac) or histone H3 diacetylated at 'Lys-14' and 'Lys-27' (H3K14ac and H3K27ac) (PubMed:29437725, PubMed:29900004, PubMed:30071723). Also able to recognize and bind crotonylated histone H3 (PubMed:30071723). May also recognize and bind histone H3 succinylated at 'Lys-122' (H3K122succ); additional evidence is however required to confirm this result in vivo (PubMed:29463709). Plays a key role in histone variant H2AZ1/H2A.Z deposition into specific chromatin regions: recognizes and binds H3K14ac and H3K27ac on the promoters of actively transcribed genes and recruits NuA4-related complex to deposit H2AZ1/H2A.Z (PubMed:29437725). H2AZ1/H2A.Z deposition is required for maintenance of embryonic stem cell (By similarity)","Expressed in brain, heart, kidney, liver, lung, pancreas, placenta and skeletal muscle",,"According to a report, recognizes and binds histone H3 succinylated at 'Lys-122' (H3K122succ) (PubMed:29463709). However, another report only observed poor binding with succinylated histone H3 (PubMed:30071723)",Nucleus,12963728|14966270|29437725|29463709|29900004|30071723,10913114,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
YPEL1,ENSG00000100027,Unsafe,Protein,False,True,75.4,75.4,79,77,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 3.2 nTPM; positive ihc; adrenal gland: 2.2 nTPM; positive ihc;absolute ceiling; amygdala: 9.6 nTPM; absolute ceiling; basal ganglia: 25.3 nTPM; absolute ceiling;continuous selectivity; bone marrow: 6.3 nTPM; positive ihc;absolute ceiling; cerebellum: 7.4 nTPM; positive ihc;absolute ceiling; cerebral cortex: 12.1 nTPM; positive ihc;absolute ceiling; choroid plexus: 11.6 nTPM; absolute ceiling; colon: 3.2 nTPM; positive ihc; duodenum: 2.3 nTPM; positive ihc;absolute ceiling; esophagus: 1.9 nTPM; positive ihc; heart muscle: 7 nTPM; positive ihc;absolute ceiling; hippocampal formation: 7.8 nTPM; absolute ceiling; hypothalamus: 6.2 nTPM; absolute ceiling; kidney: 2.3 nTPM; positive ihc;absolute ceiling; liver: 2.4 nTPM; positive ihc;absolute ceiling; lung: 5.4 nTPM; positive ihc;absolute ceiling; lymph node: 5.7 nTPM; positive ihc; midbrain: 3 nTPM; absolute ceiling; pancreas: 3.8 nTPM; positive ihc;absolute ceiling; parathyroid gland: 3.2 nTPM; positive ihc; pituitary gland: 2.5 nTPM; absolute ceiling; rectum: 1.7 nTPM; positive ihc; retina: 3.6 nTPM; absolute ceiling; salivary gland: 2.6 nTPM; positive ihc; skeletal muscle: 15.2 nTPM; positive ihc;absolute ceiling; skin: 1.6 nTPM; positive ihc; small intestine: 2.4 nTPM; positive ihc;absolute ceiling; smooth muscle: 2.4 nTPM; positive ihc;absolute ceiling; spinal cord: 4 nTPM; absolute ceiling; spleen: 8.2 nTPM; positive ihc; stomach: 3.3 nTPM; positive ihc; thymus: 14.2 nTPM; absolute ceiling; thyroid gland: 2.6 nTPM; positive ihc; tongue: 6.2 nTPM; absolute ceiling; urinary bladder: 2 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 2.2 nTPM (limit 2); amygdala: 9.6 nTPM (limit 2); basal ganglia: 25.3 nTPM (limit 2); bone marrow: 6.3 nTPM (limit 2); cerebellum: 7.4 nTPM (limit 2); cerebral cortex: 12.1 nTPM (limit 2); choroid plexus: 11.6 nTPM (limit 2); duodenum: 2.3 nTPM (limit 2); heart muscle: 7 nTPM (limit 2); hippocampal formation: 7.8 nTPM (limit 2); hypothalamus: 6.2 nTPM (limit 2); kidney: 2.3 nTPM (limit 2); liver: 2.4 nTPM (limit 2); lung: 5.4 nTPM (limit 2); midbrain: 3 nTPM (limit 2); pancreas: 3.8 nTPM (limit 2); pituitary gland: 2.5 nTPM (limit 2); retina: 3.6 nTPM (limit 2); skeletal muscle: 15.2 nTPM (limit 2); small intestine: 2.4 nTPM (limit 2); smooth muscle: 2.4 nTPM (limit 2); spinal cord: 4 nTPM (limit 2); thymus: 14.2 nTPM (limit 10); tongue: 6.2 nTPM (limit 6); adrenal gland: 2.2 nTPM (baseline 2); amygdala: 9.6 nTPM (baseline 2); basal ganglia: 25.3 nTPM (baseline 2); bone marrow: 6.3 nTPM (baseline 2); cerebellum: 7.4 nTPM (baseline 2); cerebral cortex: 12.1 nTPM (baseline 2); choroid plexus: 11.6 nTPM (baseline 2); duodenum: 2.3 nTPM (baseline 2); heart muscle: 7 nTPM (baseline 2); hippocampal formation: 7.8 nTPM (baseline 2); hypothalamus: 6.2 nTPM (baseline 2); kidney: 2.3 nTPM (baseline 2); liver: 2.4 nTPM (baseline 2); lung: 5.4 nTPM (baseline 2); midbrain: 3 nTPM (baseline 2); pancreas: 3.8 nTPM (baseline 2); pituitary gland: 2.5 nTPM (baseline 2); retina: 3.6 nTPM (baseline 2); skeletal muscle: 15.2 nTPM (baseline 2); small intestine: 2.4 nTPM (baseline 2); smooth muscle: 2.4 nTPM (baseline 2); spinal cord: 4 nTPM (baseline 2); thymus: 14.2 nTPM (baseline 10); tongue: 6.2 nTPM (baseline 6),adipose tissue / adipocytes: Low (Uncertain); adrenal gland / glandular cells: High (Uncertain); bone marrow / hematopoietic cells: Low (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / glial cells: Low (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: High (Uncertain); cerebellum / cells in molecular layer: Medium (Uncertain); cerebellum / Purkinje cells: High (Uncertain); cerebral cortex / endothelial cells: Low (Uncertain); cerebral cortex / glial cells: Low (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: Medium (Uncertain); colon / endothelial cells: Medium (Uncertain); colon / glandular cells: High (Uncertain); colon / peripheral nerve/ganglion: Medium (Uncertain); duodenum / glandular cells: High (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: High (Uncertain); hippocampus / glial cells: Low (Uncertain); hippocampus / neuronal cells: High (Uncertain); kidney / cells in glomeruli: Low (Uncertain); kidney / cells in tubules: High (Uncertain); liver / cholangiocytes: Low (Uncertain); liver / hepatocytes: High (Uncertain); lung / alveolar cells: Low (Uncertain); lung / macrophages: Low (Uncertain); lymph node / germinal center cells: Low (Uncertain); lymph node / non-germinal center cells: Medium (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: High (Uncertain); pancreas / pancreatic endocrine cells: High (Uncertain); parathyroid gland / glandular cells: High (Uncertain); rectum / glandular cells: High (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: Medium (Uncertain); skin 1 / fibroblasts: Medium (Uncertain); skin 1 / keratinocytes: Medium (Uncertain); skin 1 / Langerhans: Medium (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: High (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); spleen / cells in red pulp: Low (Uncertain); spleen / cells in white pulp: Medium (Uncertain); stomach 1 / glandular cells: High (Uncertain); stomach 2 / glandular cells: High (Uncertain); thyroid gland / glandular cells: High (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 56/58 (96.6%); Prostate Adenocarcinoma (TCGA): 457/480 (95.2%); Breast Invasive Carcinoma (validation): 45/50 (90.0%),liver cancer: 12/12 (100.0%); colorectal cancer: 11/12 (91.7%),31,20,O60688,https://www.uniprot.org/uniprotkb/O60688/entry,May play a role in epithelioid conversion of fibroblasts,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
ZBBX,ENSG00000169064,Unsafe,Protein,False,True,34.9,34.9,101,10,Positive somewhere,True,True,False,True,Excluded,Normal,False,,Not assessed,,,positive ihc outside permitted; basal ganglia: 2.4 nTPM; absolute ceiling; choroid plexus: 13.3 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 2.3 nTPM; absolute ceiling; hypothalamus: 2.8 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",basal ganglia: 2.4 nTPM (limit 2); choroid plexus: 13.3 nTPM (limit 2); hippocampal formation: 2.3 nTPM (limit 2); hypothalamus: 2.8 nTPM (limit 2),bronchus / ciliated cells (ciliary rootlets): Low (Enhanced); bronchus / ciliated cells (tip of cilia): High (Enhanced); nasopharynx / ciliated cells (cilia axoneme): Medium (Enhanced); nasopharynx / ciliated cells (tip of cilia): High (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 21/58 (36.2%); Ovary Serous Cystadenocarcinoma (validation): 14/81 (17.3%); Breast Invasive Carcinoma (validation): 5/50 (10.0%),breast cancer: 0/9 (0.0%); cervical cancer: 0/12 (0.0%),31,20,A8MT70,https://www.uniprot.org/uniprotkb/A8MT70/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
ZBTB20,ENSG00000181722,Unsafe,Protein,False,True,15.3,15.3,84,57,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 4.1 nTPM; positive ihc; adrenal gland: 3.9 nTPM; positive ihc;absolute ceiling; cerebellum: 1.6 nTPM; positive ihc; cerebral cortex: 4.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 1.7 nTPM; positive ihc; heart muscle: 3.6 nTPM; positive ihc;absolute ceiling; kidney: 5.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 5.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 1.9 nTPM; positive ihc; lymph node: 1.9 nTPM; positive ihc; pancreas: 3.4 nTPM; positive ihc;absolute ceiling; parathyroid gland: 2.3 nTPM; positive ihc; retina: 8.6 nTPM; absolute ceiling;continuous selectivity; salivary gland: 3 nTPM; positive ihc; skeletal muscle: 8 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 2.5 nTPM; positive ihc; smooth muscle: 2.8 nTPM; positive ihc;absolute ceiling; spleen: 2.6 nTPM; positive ihc; thyroid gland: 4.9 nTPM; positive ihc; tongue: 8.6 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 1.6 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 3.9 nTPM (limit 2); cerebral cortex: 4.7 nTPM (limit 2); heart muscle: 3.6 nTPM (limit 2); kidney: 5.1 nTPM (limit 2); liver: 5.4 nTPM (limit 2); pancreas: 3.4 nTPM (limit 2); retina: 8.6 nTPM (limit 2); skeletal muscle: 8 nTPM (limit 2); smooth muscle: 2.8 nTPM (limit 2); tongue: 8.6 nTPM (limit 6),adipose tissue / adipocytes: High (Approved); adrenal gland / glandular cells: High (Approved); bronchus / respiratory epithelial cells: Low (Approved); caudate / glial cells: High (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: High (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: High (Approved); colon / endothelial cells: High (Approved); colon / peripheral nerve/ganglion: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: High (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: High (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: High (Approved); lung / macrophages: Low (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: High (Approved); pancreas / pancreatic endocrine cells: High (Approved); parathyroid gland / glandular cells: High (Approved); salivary gland / glandular cells: High (Approved); skeletal muscle / myocytes: High (Approved); skin 1 / fibroblasts: High (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: Medium (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: Low (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Pancreatic Adenocarcinoma (validation): 80/80 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%),glioma: 11/12 (91.7%); renal cancer: 8/12 (66.7%),31,20,Q9HC78,https://www.uniprot.org/uniprotkb/Q9HC78/entry,"May be a transcription factor that may be involved in hematopoiesis, oncogenesis, and immune responses (PubMed:11352661). Plays a role in postnatal myogenesis, may be involved in the regulation of satellite cells self-renewal (By similarity)","Expressed in spleen, lymph node, thymus, peripheral blood leukocytes, and fetal liver","Primrose syndrome: A disease characterized by macrocephaly, intellectual disability, disturbed behavior, dysmorphic facial features, ectopic calcifications, large calcified ear auricles, and progressive muscle wasting.",,Nucleus,11352661,11352661,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZBTB3,ENSG00000185670,Unsafe,Protein,False,True,4.2,5.6,80,66,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 1.3 nTPM; positive ihc; adrenal gland: 1.3 nTPM; positive ihc;continuous selectivity; amygdala: 1.3 nTPM; continuous selectivity; basal ganglia: 1.5 nTPM; continuous selectivity; bone marrow: 2.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 1.5 nTPM; positive ihc;continuous selectivity; cerebral cortex: 2.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 2.3 nTPM; positive ihc;continuous selectivity; duodenum: 2.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 1.8 nTPM; positive ihc;continuous selectivity; heart muscle: 2.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 1.4 nTPM; continuous selectivity; kidney: 1.7 nTPM; positive ihc;continuous selectivity; liver: 1.7 nTPM; continuous selectivity; lung: 2.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 2.3 nTPM; positive ihc;continuous selectivity; midbrain: 1.4 nTPM; continuous selectivity; pancreas: 2.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 2.1 nTPM; positive ihc;continuous selectivity; rectum: 2 nTPM; positive ihc;continuous selectivity; retina: 3 nTPM; absolute ceiling;continuous selectivity; salivary gland: 3.3 nTPM; positive ihc;continuous selectivity; skeletal muscle: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 5.6 nTPM; positive ihc;continuous selectivity;reproductive not higher; small intestine: 2.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 1.7 nTPM; positive ihc;continuous selectivity; spinal cord: 1.6 nTPM; continuous selectivity; stomach: 4.8 nTPM; positive ihc;continuous selectivity;reproductive not higher; thymus: 2.7 nTPM; continuous selectivity; thyroid gland: 2.6 nTPM; positive ihc;continuous selectivity; tongue: 3.1 nTPM; continuous selectivity; urinary bladder: 1.4 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 2.3 nTPM (limit 2); cerebral cortex: 2.4 nTPM (limit 2); duodenum: 2.2 nTPM (limit 2); heart muscle: 2.9 nTPM (limit 2); lung: 2.8 nTPM (limit 2); pancreas: 2.4 nTPM (limit 2); retina: 3 nTPM (limit 2); skeletal muscle: 2.7 nTPM (limit 2); small intestine: 2.2 nTPM (limit 2),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in tubules: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: High (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / keratinocytes: Low (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Rectum Adenocarcinoma (validation): 196/207 (94.7%); Colon Adenocarcinoma (validation): 455/486 (93.6%),liver cancer: 11/11 (100.0%); ovarian cancer: 11/11 (100.0%),31,20,Q9H5J0,https://www.uniprot.org/uniprotkb/Q9H5J0/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZBTB32,ENSG00000011590,Unsafe,Protein,False,True,47.7,47.7,81,12,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 0.6 nTPM; positive ihc; cerebral cortex: 0 nTPM; positive ihc; lung: 0.3 nTPM; positive ihc; lymph node: 3.3 nTPM; positive ihc; skin: 0.1 nTPM; positive ihc; spleen: 2.6 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,bone marrow / hematopoietic cells: Medium (Enhanced); cerebral cortex / neuronal cells: Low (Enhanced); lung / macrophages: Medium (Enhanced); lymph node / non-germinal center cells: Low (Enhanced); skin 1 / Langerhans: Medium (Enhanced); spleen / cells in red pulp: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 8/50 (16.0%); Pancreatic Adenocarcinoma (validation): 2/80 (2.5%); Testicular Germ Cell Tumor (TCGA): 3/133 (2.3%),lymphoma: 3/11 (27.3%); breast cancer: 0/11 (0.0%),31,20,Q9Y2Y4,https://www.uniprot.org/uniprotkb/Q9Y2Y4/entry,DNA-binding protein that binds to the to a 5'-TGTACAGTGT-3' core sequence. May function as a transcriptional transactivator and transcriptional repressor. Probably exerts its repressor effect by preventing GATA3 from binding to DNA. May play a role in regulating the differentiation and activation of helper T-cells (By similarity),Predominantly expressed in testis. Some isoforms are ubiquitously expressed,,,Nucleus,10572087,10544010,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
ZBTB37,ENSG00000185278,Unsafe,Protein,False,True,8.3,10.2,79,78,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 2.8 nTPM; positive ihc; adrenal gland: 1.6 nTPM; positive ihc; bone marrow: 5.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 1.7 nTPM; positive ihc; cerebral cortex: 2 nTPM; positive ihc; colon: 1.8 nTPM; positive ihc; duodenum: 1.4 nTPM; positive ihc; esophagus: 1.3 nTPM; positive ihc; heart muscle: 2 nTPM; positive ihc; kidney: 1.9 nTPM; positive ihc; liver: 1.8 nTPM; positive ihc; lung: 2.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 3.4 nTPM; positive ihc;continuous selectivity; midbrain: 2.1 nTPM; absolute ceiling; pancreas: 1.7 nTPM; positive ihc; parathyroid gland: 1.7 nTPM; positive ihc; pituitary gland: 2.5 nTPM; absolute ceiling;continuous selectivity; rectum: 1.5 nTPM; positive ihc; retina: 10.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 1.9 nTPM; positive ihc; skeletal muscle: 1.7 nTPM; positive ihc; skin: 3 nTPM; positive ihc; small intestine: 2.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 1.6 nTPM; positive ihc; spinal cord: 2.7 nTPM; absolute ceiling;continuous selectivity; spleen: 3.5 nTPM; positive ihc; stomach: 1.8 nTPM; positive ihc; thyroid gland: 2.5 nTPM; positive ihc; urinary bladder: 1.9 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 5.2 nTPM (limit 2); lung: 2.6 nTPM (limit 2); midbrain: 2.1 nTPM (limit 2); pituitary gland: 2.5 nTPM (limit 2); retina: 10.2 nTPM (limit 2); small intestine: 2.2 nTPM (limit 2); spinal cord: 2.7 nTPM (limit 2),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: High (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: High (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: High (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: High (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: High (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: High (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: High (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 447/486 (92.0%); Rectum Adenocarcinoma (validation): 185/207 (89.4%),colorectal cancer: 12/12 (100.0%); prostate cancer: 11/11 (100.0%),31,20,Q5TC79,https://www.uniprot.org/uniprotkb/Q5TC79/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZBTB8A,ENSG00000160062,Unsafe,Protein,False,True,6.0,6.0,79,77,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 3.7 nTPM; positive ihc;continuous selectivity; adrenal gland: 2.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; bone marrow: 1.1 nTPM; positive ihc; cerebellum: 3.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 2.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 2.8 nTPM; positive ihc;continuous selectivity; duodenum: 1.8 nTPM; positive ihc;continuous selectivity; esophagus: 3.3 nTPM; positive ihc;continuous selectivity; heart muscle: 2.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; kidney: 2.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 2 nTPM; positive ihc;continuous selectivity; lung: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 0.8 nTPM; positive ihc; pancreas: 2.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 3.5 nTPM; positive ihc;continuous selectivity; pituitary gland: 1.8 nTPM; continuous selectivity; rectum: 2.9 nTPM; positive ihc;continuous selectivity; salivary gland: 2.4 nTPM; positive ihc;continuous selectivity; skeletal muscle: 2.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 1.7 nTPM; positive ihc; small intestine: 2 nTPM; positive ihc;continuous selectivity; smooth muscle: 4.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 1.6 nTPM; continuous selectivity; spleen: 1.2 nTPM; positive ihc; stomach: 3.1 nTPM; positive ihc;continuous selectivity; thyroid gland: 5.3 nTPM; positive ihc;continuous selectivity; tongue: 5.9 nTPM; continuous selectivity; urinary bladder: 3.6 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 2.2 nTPM (limit 2); cerebellum: 3.1 nTPM (limit 2); cerebral cortex: 2.2 nTPM (limit 2); heart muscle: 2.3 nTPM (limit 2); kidney: 2.3 nTPM (limit 2); lung: 2.7 nTPM (limit 2); pancreas: 2.6 nTPM (limit 2); skeletal muscle: 2.6 nTPM (limit 2); smooth muscle: 4.9 nTPM (limit 2),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Low (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: High (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 45/50 (90.0%); Pancreatic Adenocarcinoma (validation): 71/80 (88.8%); Glioblastoma Multiforme (validation): 45/58 (77.6%),pancreatic cancer: 9/10 (90.0%); stomach cancer: 7/8 (87.5%),31,20,Q96BR9,https://www.uniprot.org/uniprotkb/Q96BR9/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZBTB9,ENSG00000213588,Unsafe,RNA,False,True,7.2,9.7,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 3.8 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 2.4 nTPM; absolute ceiling;continuous selectivity; cerebellum: 2.7 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 2.7 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 2.6 nTPM; absolute ceiling;continuous selectivity; duodenum: 2.3 nTPM; absolute ceiling;continuous selectivity; esophagus: 3.7 nTPM; continuous selectivity; heart muscle: 2.9 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 2 nTPM; continuous selectivity; hypothalamus: 2.6 nTPM; absolute ceiling;continuous selectivity; kidney: 4.3 nTPM; absolute ceiling;continuous selectivity; liver: 3.1 nTPM; absolute ceiling;continuous selectivity; lung: 2.3 nTPM; absolute ceiling;continuous selectivity; midbrain: 2.2 nTPM; absolute ceiling;continuous selectivity; pancreas: 2.9 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 9.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 2.8 nTPM; continuous selectivity; skin: 3.7 nTPM; continuous selectivity; small intestine: 2.7 nTPM; absolute ceiling;continuous selectivity; spinal cord: 2.1 nTPM; absolute ceiling;continuous selectivity; spleen: 3.4 nTPM; continuous selectivity; stomach: 2.6 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 3.8 nTPM (limit 2); basal ganglia: 2.4 nTPM (limit 2); cerebellum: 2.7 nTPM (limit 2); cerebral cortex: 2.7 nTPM (limit 2); choroid plexus: 2.6 nTPM (limit 2); duodenum: 2.3 nTPM (limit 2); heart muscle: 2.9 nTPM (limit 2); hypothalamus: 2.6 nTPM (limit 2); kidney: 4.3 nTPM (limit 2); liver: 3.1 nTPM (limit 2); lung: 2.3 nTPM (limit 2); midbrain: 2.2 nTPM (limit 2); pancreas: 2.9 nTPM (limit 2); pituitary gland: 9.7 nTPM (limit 2); small intestine: 2.7 nTPM (limit 2); spinal cord: 2.1 nTPM (limit 2); adrenal gland: 3.8 nTPM (baseline 2); basal ganglia: 2.4 nTPM (baseline 2); cerebellum: 2.7 nTPM (baseline 2); cerebral cortex: 2.7 nTPM (baseline 2); choroid plexus: 2.6 nTPM (baseline 2); duodenum: 2.3 nTPM (baseline 2); heart muscle: 2.9 nTPM (baseline 2); hypothalamus: 2.6 nTPM (baseline 2); kidney: 4.3 nTPM (baseline 2); liver: 3.1 nTPM (baseline 2); lung: 2.3 nTPM (baseline 2); midbrain: 2.2 nTPM (baseline 2); pancreas: 2.9 nTPM (baseline 2); pituitary gland: 9.7 nTPM (baseline 2); small intestine: 2.7 nTPM (baseline 2); spinal cord: 2.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 48/50 (96.0%); Ovary Serous Cystadenocarcinoma (validation): 61/81 (75.3%),liver cancer: 10/12 (83.3%); prostate cancer: 10/12 (83.3%),31,20,Q96C00,https://www.uniprot.org/uniprotkb/Q96C00/entry,May be involved in transcriptional regulation,,,,Nucleus,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Gong2021_reproductive_PC,No tumor-antigen validation in this source | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
ZC2HC1C,ENSG00000119703,Unsafe,Protein,False,True,53.7,53.7,83,10,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 2.8 nTPM; absolute ceiling; basal ganglia: 4.3 nTPM; absolute ceiling; cerebellum: 1.4 nTPM; positive ihc; cerebral cortex: 3.1 nTPM; positive ihc;absolute ceiling; choroid plexus: 8.5 nTPM; absolute ceiling; hippocampal formation: 2.9 nTPM; absolute ceiling; hypothalamus: 3.8 nTPM; absolute ceiling; midbrain: 3.3 nTPM; absolute ceiling; pituitary gland: 6 nTPM; absolute ceiling; retina: 2.5 nTPM; absolute ceiling; smooth muscle: 0.9 nTPM; positive ihc; spinal cord: 2.4 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 2.8 nTPM (limit 2); basal ganglia: 4.3 nTPM (limit 2); cerebral cortex: 3.1 nTPM (limit 2); choroid plexus: 8.5 nTPM (limit 2); hippocampal formation: 2.9 nTPM (limit 2); hypothalamus: 3.8 nTPM (limit 2); midbrain: 3.3 nTPM (limit 2); pituitary gland: 6 nTPM (limit 2); retina: 2.5 nTPM (limit 2); spinal cord: 2.4 nTPM (limit 2),caudate / neuronal cells: Low (Enhanced); cerebellum / cells in molecular layer: Low (Enhanced); cerebral cortex / neuronal cells: Low (Enhanced); cerebral cortex / neuropil: Medium (Enhanced); hippocampus / neuronal cells: Low (Enhanced); smooth muscle / smooth muscle cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Kidney Chromophobe (TCGA): 49/64 (76.6%); Thyroid Carcinoma (TCGA): 372/495 (75.2%); Kidney Renal Papillary Cell Carcinoma (TCGA): 162/282 (57.4%),breast cancer: 0/10 (0.0%); cervical cancer: 0/11 (0.0%),29,20,Q53FD0,https://www.uniprot.org/uniprotkb/Q53FD0/entry,,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
ZCWPW1,ENSG00000078487,Unsafe,RNA,False,True,41.3,41.3,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 2.5 nTPM; absolute ceiling; amygdala: 3.5 nTPM; absolute ceiling; basal ganglia: 3.1 nTPM; absolute ceiling; bone marrow: 2.8 nTPM; absolute ceiling; cerebral cortex: 3.2 nTPM; absolute ceiling; choroid plexus: 4 nTPM; absolute ceiling; heart muscle: 3.7 nTPM; absolute ceiling; hippocampal formation: 3.6 nTPM; absolute ceiling; hypothalamus: 3 nTPM; absolute ceiling; kidney: 3.3 nTPM; absolute ceiling; liver: 5.7 nTPM; absolute ceiling; lung: 2.3 nTPM; absolute ceiling; midbrain: 4.6 nTPM; absolute ceiling; pancreas: 2.2 nTPM; absolute ceiling; retina: 3.1 nTPM; absolute ceiling; skeletal muscle: 3.7 nTPM; absolute ceiling; small intestine: 2.5 nTPM; absolute ceiling; smooth muscle: 2.6 nTPM; absolute ceiling; spinal cord: 5.5 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 2.5 nTPM (limit 2); amygdala: 3.5 nTPM (limit 2); basal ganglia: 3.1 nTPM (limit 2); bone marrow: 2.8 nTPM (limit 2); cerebral cortex: 3.2 nTPM (limit 2); choroid plexus: 4 nTPM (limit 2); heart muscle: 3.7 nTPM (limit 2); hippocampal formation: 3.6 nTPM (limit 2); hypothalamus: 3 nTPM (limit 2); kidney: 3.3 nTPM (limit 2); liver: 5.7 nTPM (limit 2); lung: 2.3 nTPM (limit 2); midbrain: 4.6 nTPM (limit 2); pancreas: 2.2 nTPM (limit 2); retina: 3.1 nTPM (limit 2); skeletal muscle: 3.7 nTPM (limit 2); small intestine: 2.5 nTPM (limit 2); smooth muscle: 2.6 nTPM (limit 2); spinal cord: 5.5 nTPM (limit 2); adrenal gland: 2.5 nTPM (baseline 2); amygdala: 3.5 nTPM (baseline 2); basal ganglia: 3.1 nTPM (baseline 2); bone marrow: 2.8 nTPM (baseline 2); cerebral cortex: 3.2 nTPM (baseline 2); choroid plexus: 4 nTPM (baseline 2); heart muscle: 3.7 nTPM (baseline 2); hippocampal formation: 3.6 nTPM (baseline 2); hypothalamus: 3 nTPM (baseline 2); kidney: 3.3 nTPM (baseline 2); liver: 5.7 nTPM (baseline 2); lung: 2.3 nTPM (baseline 2); midbrain: 4.6 nTPM (baseline 2); pancreas: 2.2 nTPM (baseline 2); retina: 3.1 nTPM (baseline 2); skeletal muscle: 3.7 nTPM (baseline 2); small intestine: 2.5 nTPM (baseline 2); smooth muscle: 2.6 nTPM (baseline 2); spinal cord: 5.5 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Breast Invasive Carcinoma (validation): 46/50 (92.0%); Ovary Serous Cystadenocarcinoma (validation): 38/81 (46.9%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9H0M4,https://www.uniprot.org/uniprotkb/Q9H0M4/entry,"Dual histone methylation reader specific for PRDM9-catalyzed histone marks (H3K4me3 and H3K36me3) (PubMed:20826339, PubMed:32744506). Facilitates the repair of PRDM9-induced meiotic double-strand breaks (DSBs) (By similarity). Essential for male fertility and spermatogenesis (By similarity). Required for meiosis prophase I progression in male but not in female germ cells (By similarity)",Testis,,,Nucleus Chromosome,20826339|32744506,32352380|32744506,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
ZDHHC15,ENSG00000102383,Unsafe,Protein,False,True,2.2,4.3,76,46,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 1.5 nTPM; positive ihc;continuous selectivity; amygdala: 1 nTPM; continuous selectivity; basal ganglia: 1.1 nTPM; continuous selectivity; bone marrow: 0.1 nTPM; positive ihc; cerebellum: 1.4 nTPM; positive ihc;continuous selectivity; cerebral cortex: 2.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 1.1 nTPM; continuous selectivity; colon: 0.9 nTPM; positive ihc;continuous selectivity; duodenum: 0.2 nTPM; positive ihc; esophagus: 0.8 nTPM; positive ihc; heart muscle: 1.6 nTPM; positive ihc;continuous selectivity; hippocampal formation: 1 nTPM; continuous selectivity; hypothalamus: 1.9 nTPM; continuous selectivity; kidney: 1.5 nTPM; positive ihc;continuous selectivity; liver: 0.1 nTPM; positive ihc; lung: 1.1 nTPM; positive ihc;continuous selectivity; midbrain: 1.1 nTPM; continuous selectivity; pancreas: 1 nTPM; positive ihc;continuous selectivity; parathyroid gland: 1.1 nTPM; continuous selectivity; pituitary gland: 1 nTPM; continuous selectivity; rectum: 0.5 nTPM; positive ihc; retina: 1.9 nTPM; continuous selectivity; salivary gland: 4.3 nTPM; positive ihc;continuous selectivity;reproductive not higher; skeletal muscle: 0.3 nTPM; positive ihc; skin: 0.7 nTPM; positive ihc; small intestine: 0.3 nTPM; positive ihc; smooth muscle: 1.4 nTPM; continuous selectivity; spinal cord: 1.3 nTPM; continuous selectivity; stomach: 0.4 nTPM; positive ihc; thyroid gland: 1.9 nTPM; positive ihc;continuous selectivity; urinary bladder: 0.6 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",cerebral cortex: 2.8 nTPM (limit 2),adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / macrophages: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: High (Approved); pancreas / exocrine glandular cells: Low (Approved); pancreas / pancreatic endocrine cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: High (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: High (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Glioblastoma Multiforme (TCGA): 75/141 (53.2%); Breast Invasive Carcinoma (validation): 22/50 (44.0%),liver cancer: 8/11 (72.7%); urothelial cancer: 8/12 (66.7%),31,20,Q96MV8,https://www.uniprot.org/uniprotkb/Q96MV8/entry,"Palmitoyltransferase that catalyzes the addition of palmitate onto various protein substrates (PubMed:18817523, PubMed:23034182). Has no stringent fatty acid selectivity and in addition to palmitate can also transfer onto target proteins myristate from tetradecanoyl-CoA and stearate from octadecanoyl-CoA (By similarity). Palmitoylates IGF2R and SORT1, promoting their partitioning to an endosomal membrane subdomain where they can interact with the retromer cargo-selective complex (PubMed:18817523). Thereby, regulates retrograde transport from endosomes to the Golgi apparatus of these lysosomal sorting receptors and plays a role in trafficking of lysosomal proteins (PubMed:18817523). In the nervous system, catalyzes the palmitoylation of DLG4/PSD95 and regulates its synaptic clustering and function in synaptogenesis (By similarity). Could be involved in the differentiation of dopaminergic neurons and the development of the diencephalon (By similarity). Could also catalyze the palmitoylation of GAP43 (By similarity). Could also palmitoylate DNAJC5 and regulate its localization to the Golgi membrane (By similarity). Could also palmitoylate FYN as shown in vitro (PubMed:19956733). May palmitoylate CALHM3 subunit of gustatory voltage-gated ion channels and modulate channel gating and kinetics","Expressed in placenta, liver, lung, kidney, heart and brain","Intellectual developmental disorder, X-linked 91: A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period.",,Golgi apparatus membrane Postsynaptic density,18817523|19956733|23034182,15915161,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZDHHC19,ENSG00000163958,Unsafe,High RNA,False,True,48.7,48.7,0,0,Missing,False,False,False,False,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,True,"DICE B_CELL_NAIVE (unstimulated): 65/91 values ≥5 TPM, max 22.3646",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,22.3646050552,170.0,"hpa_single_cell_tissue: fallopian tube/neutrophils, max 74 nTPM, 1 observations >30; hpa_single_cell_tissue: pbmc/b-cells, max 30.8 nTPM, 1 observations >30; hpa_single_cell_tissue: salivary gland/serous glandular cells, max 170 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,22.36 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,170 nTPM; salivary gland/serous glandular cells; hpa_single_cell_tissue; protected,Liver Hepatocellular Carcinoma (validation): 24/231 (10.4%); Ovary Serous Cystadenocarcinoma (validation): 1/81 (1.2%); Testicular Germ Cell Tumor (TCGA): 1/133 (0.8%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8WVZ1,https://www.uniprot.org/uniprotkb/Q8WVZ1/entry,"Palmitoyltransferase that mediates palmitoylation oproteins, such as RRAS and SQSTM1 (PubMed:20074548, PubMed:37802024). Catalyzes palmitoylation of RRAS, leading to increased cell viability (PubMed:20074548). Acts as a positive regulator of autophagy by mediating palmitoylation of SQSTM1, promoting affinity between SQSTM1 and ATG8 proteins and recruitment of ubiquitinated cargo proteins to autophagosomes (PubMed:37802024). Palmitoyltransferase activity may be crucial for spermatogenesis (By similarity) (Microbial infection) Promotes Chikungunya virus (CHIKV) replication by mediating viral nsp1 palmitoylation",,,"Was shown to mediate palmitoylation of STAT3, leading to homodimerization and transcriptional activation of STAT3. However, this study was later retracted","Golgi apparatus membrane Cytoplasm, perinuclear region Cell membrane",20074548|30404808|37802024,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
ZDHHC20,ENSG00000180776,Unsafe,Protein,False,True,28.0,38.0,77,66,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 10.4 nTPM; positive ihc;absolute ceiling; adrenal gland: 8.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 5.3 nTPM; absolute ceiling; basal ganglia: 4.8 nTPM; absolute ceiling; bone marrow: 28.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 5.3 nTPM; positive ihc;absolute ceiling; cerebral cortex: 14.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 16.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 18.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 28.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 7.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 9.2 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 8.7 nTPM; absolute ceiling;continuous selectivity; kidney: 6.4 nTPM; positive ihc;absolute ceiling; liver: 9.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 16.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 17.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 14.6 nTPM; absolute ceiling;continuous selectivity; pancreas: 8.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 8.5 nTPM; positive ihc;absolute ceiling; pituitary gland: 4.3 nTPM; absolute ceiling; rectum: 15.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 5.2 nTPM; absolute ceiling; salivary gland: 8.2 nTPM; positive ihc;absolute ceiling; skeletal muscle: 3.8 nTPM; positive ihc;absolute ceiling; skin: 21.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 18.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 14.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 32.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 15.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 38 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; thymus: 21.5 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 15.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 9 nTPM; absolute ceiling; urinary bladder: 21.8 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 10.4 nTPM (limit 10); adrenal gland: 8.8 nTPM (limit 2); amygdala: 5.3 nTPM (limit 2); basal ganglia: 4.8 nTPM (limit 2); bone marrow: 28.8 nTPM (limit 2); cerebellum: 5.3 nTPM (limit 2); cerebral cortex: 14.4 nTPM (limit 2); colon: 16.2 nTPM (limit 6); duodenum: 18.3 nTPM (limit 2); esophagus: 28.9 nTPM (limit 6); heart muscle: 7.4 nTPM (limit 2); hippocampal formation: 9.2 nTPM (limit 2); hypothalamus: 8.7 nTPM (limit 2); kidney: 6.4 nTPM (limit 2); liver: 9.3 nTPM (limit 2); lung: 16.1 nTPM (limit 2); lymph node: 17.3 nTPM (limit 6); midbrain: 14.6 nTPM (limit 2); pancreas: 8.7 nTPM (limit 2); parathyroid gland: 8.5 nTPM (limit 6); pituitary gland: 4.3 nTPM (limit 2); rectum: 15.2 nTPM (limit 6); retina: 5.2 nTPM (limit 2); salivary gland: 8.2 nTPM (limit 6); skeletal muscle: 3.8 nTPM (limit 2); skin: 21.2 nTPM (limit 10); small intestine: 18.2 nTPM (limit 2); smooth muscle: 14.3 nTPM (limit 2); spinal cord: 32.6 nTPM (limit 2); spleen: 15.3 nTPM (limit 10); stomach: 38 nTPM (limit 6); thymus: 21.5 nTPM (limit 10); thyroid gland: 15.7 nTPM (limit 10); tongue: 9 nTPM (limit 6); urinary bladder: 21.8 nTPM (limit 6),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Low (Approved); caudate / glial cells: Medium (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Medium (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Low (Approved); skin 1 / keratinocytes: Low (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Low (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%),colorectal cancer: 11/11 (100.0%); endometrial cancer: 11/11 (100.0%),31,20,Q5W0Z9,https://www.uniprot.org/uniprotkb/Q5W0Z9/entry,"Palmitoyltransferase that could catalyze the addition of palmitate onto various protein substrates (PubMed:27153536, PubMed:29326245, PubMed:33219126). Catalyzes palmitoylation of Cys residues in the cytoplasmic C-terminus of EGFR, and modulates the duration of EGFR signaling by modulating palmitoylation-dependent EGFR internalization and degradation (PubMed:27153536). Has a preference for acyl-CoA with C16 fatty acid chains (PubMed:29326245). Can also utilize acyl-CoA with C14 and C18 fatty acid chains (PubMed:29326245). May palmitoylate CALHM1 subunit of gustatory voltage-gated ion channels and modulate channel gating and kinetics. Palmitoylates TRIM28 and thereby plays an important role in the DNA damage repair response (PubMed:41109928) (Microbial infection) Dominant palmitoyltransferase responsible for lipidation of SARS coronavirus-2/SARS-CoV-2 spike protein. Through a sequential action with ZDHHC9, rapidly and efficiently palmitoylates spike protein following its synthesis in the endoplasmic reticulum (ER). In the infected cell, promotes spike biogenesis by protecting it from premature ER degradation, increases half-life and controls the lipid organization of its immediate membrane environment. Once the virus has formed, spike palmitoylation controls fusion with the target cell",,,,"Golgi apparatus membrane Cell membrane Cytoplasm, perinuclear region Endoplasmic reticulum membrane Endoplasmic reticulum-Golgi intermediate compartment membrane",27153536|29326245|33219126|34599882|41109928,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
ZFAND4,ENSG00000172671,Unsafe,Protein,False,True,36.3,36.3,83,6,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; amygdala: 2.2 nTPM; absolute ceiling; duodenum: 2 nTPM; positive ihc; hippocampal formation: 2.3 nTPM; absolute ceiling; hypothalamus: 3.4 nTPM; absolute ceiling; kidney: 2 nTPM; positive ihc; midbrain: 2.9 nTPM; absolute ceiling; pituitary gland: 2.9 nTPM; absolute ceiling; retina: 2.1 nTPM; absolute ceiling; small intestine: 2 nTPM; positive ihc; spinal cord: 4.1 nTPM; absolute ceiling; stomach: 1.8 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 2.2 nTPM (limit 2); hippocampal formation: 2.3 nTPM (limit 2); hypothalamus: 3.4 nTPM (limit 2); midbrain: 2.9 nTPM (limit 2); pituitary gland: 2.9 nTPM (limit 2); retina: 2.1 nTPM (limit 2); spinal cord: 4.1 nTPM (limit 2),duodenum / glandular cells: Low (Enhanced); kidney / cells in tubules: Low (Enhanced); small intestine / glandular cells: Low (Enhanced); stomach 1 / glandular cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 75/80 (93.8%); Glioblastoma Multiforme (validation): 52/58 (89.7%); Ovary Serous Cystadenocarcinoma (validation): 29/81 (35.8%),breast cancer: 0/11 (0.0%); cervical cancer: 0/12 (0.0%),29,20,Q86XD8,https://www.uniprot.org/uniprotkb/Q86XD8/entry,,,,"A report observed N-glycosylation at Asn-235 (PubMed:19139490). However, as the protein is not predicted to localize in an extracellular compartment of the cell, additional evidence is required to confirm this result",,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Jamin2021_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
ZFP37,ENSG00000136866,Unsafe,RNA,False,True,6.5,6.5,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 1.8 nTPM; continuous selectivity; basal ganglia: 2.1 nTPM; absolute ceiling;continuous selectivity; cerebellum: 4.2 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 3.5 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 1.8 nTPM; continuous selectivity; hypothalamus: 2.1 nTPM; absolute ceiling;continuous selectivity; kidney: 2.2 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 2.8 nTPM; continuous selectivity; pituitary gland: 3.7 nTPM; absolute ceiling;continuous selectivity; retina: 6.1 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 2.4 nTPM; absolute ceiling;continuous selectivity; spinal cord: 2.4 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,basal ganglia: 2.1 nTPM (limit 2); cerebellum: 4.2 nTPM (limit 2); cerebral cortex: 3.5 nTPM (limit 2); hypothalamus: 2.1 nTPM (limit 2); kidney: 2.2 nTPM (limit 2); pituitary gland: 3.7 nTPM (limit 2); retina: 6.1 nTPM (limit 2); smooth muscle: 2.4 nTPM (limit 2); spinal cord: 2.4 nTPM (limit 2); basal ganglia: 2.1 nTPM (baseline 2); cerebellum: 4.2 nTPM (baseline 2); cerebral cortex: 3.5 nTPM (baseline 2); hypothalamus: 2.1 nTPM (baseline 2); kidney: 2.2 nTPM (baseline 2); pituitary gland: 3.7 nTPM (baseline 2); retina: 6.1 nTPM (baseline 2); smooth muscle: 2.4 nTPM (baseline 2); spinal cord: 2.4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 37/50 (74.0%); Glioblastoma Multiforme (TCGA): 72/141 (51.1%),breast cancer: 0/11 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q9Y6Q3,https://www.uniprot.org/uniprotkb/Q9Y6Q3/entry,May be involved in transcriptional regulation,Expressed at low level in several tissues including fetal cartilage,,It is uncertain whether Met-1 or Met-34 is the initiator. Orthologous sequences start at a downstream Met,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZFP64,ENSG00000020256,Unsafe,RNA,False,True,7.2,10.7,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 4.1 nTPM; continuous selectivity; adrenal gland: 4.7 nTPM; absolute ceiling;continuous selectivity; amygdala: 3.9 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 4.3 nTPM; absolute ceiling;continuous selectivity; bone marrow: 5 nTPM; absolute ceiling;continuous selectivity; cerebellum: 4.6 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 6 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 3.4 nTPM; absolute ceiling;continuous selectivity; colon: 6 nTPM; continuous selectivity; duodenum: 6.3 nTPM; absolute ceiling;continuous selectivity; esophagus: 6.8 nTPM; absolute ceiling;continuous selectivity; heart muscle: 4.6 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 3.9 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 3.9 nTPM; absolute ceiling;continuous selectivity; kidney: 4.6 nTPM; absolute ceiling;continuous selectivity; liver: 5.1 nTPM; absolute ceiling;continuous selectivity; lung: 4.3 nTPM; absolute ceiling;continuous selectivity; lymph node: 6.4 nTPM; absolute ceiling;continuous selectivity; midbrain: 3.8 nTPM; absolute ceiling;continuous selectivity; pancreas: 5.5 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 6.9 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 4.5 nTPM; absolute ceiling;continuous selectivity; rectum: 5.4 nTPM; continuous selectivity; retina: 4.7 nTPM; absolute ceiling;continuous selectivity; salivary gland: 5.6 nTPM; continuous selectivity; skeletal muscle: 5 nTPM; absolute ceiling;continuous selectivity; skin: 10.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 5.6 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 5.3 nTPM; absolute ceiling;continuous selectivity; spinal cord: 3.7 nTPM; absolute ceiling;continuous selectivity; spleen: 5.4 nTPM; continuous selectivity; stomach: 5.7 nTPM; continuous selectivity; thymus: 7.1 nTPM; continuous selectivity; thyroid gland: 6.6 nTPM; continuous selectivity; tongue: 4.3 nTPM; continuous selectivity; urinary bladder: 5.4 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 4.7 nTPM (limit 2); amygdala: 3.9 nTPM (limit 2); basal ganglia: 4.3 nTPM (limit 2); bone marrow: 5 nTPM (limit 2); cerebellum: 4.6 nTPM (limit 2); cerebral cortex: 6 nTPM (limit 2); choroid plexus: 3.4 nTPM (limit 2); duodenum: 6.3 nTPM (limit 2); esophagus: 6.8 nTPM (limit 6); heart muscle: 4.6 nTPM (limit 2); hippocampal formation: 3.9 nTPM (limit 2); hypothalamus: 3.9 nTPM (limit 2); kidney: 4.6 nTPM (limit 2); liver: 5.1 nTPM (limit 2); lung: 4.3 nTPM (limit 2); lymph node: 6.4 nTPM (limit 6); midbrain: 3.8 nTPM (limit 2); pancreas: 5.5 nTPM (limit 2); parathyroid gland: 6.9 nTPM (limit 6); pituitary gland: 4.5 nTPM (limit 2); retina: 4.7 nTPM (limit 2); skeletal muscle: 5 nTPM (limit 2); skin: 10.7 nTPM (limit 10); small intestine: 5.6 nTPM (limit 2); smooth muscle: 5.3 nTPM (limit 2); spinal cord: 3.7 nTPM (limit 2); adrenal gland: 4.7 nTPM (baseline 2); amygdala: 3.9 nTPM (baseline 2); basal ganglia: 4.3 nTPM (baseline 2); bone marrow: 5 nTPM (baseline 2); cerebellum: 4.6 nTPM (baseline 2); cerebral cortex: 6 nTPM (baseline 2); choroid plexus: 3.4 nTPM (baseline 2); duodenum: 6.3 nTPM (baseline 2); esophagus: 6.8 nTPM (baseline 6); heart muscle: 4.6 nTPM (baseline 2); hippocampal formation: 3.9 nTPM (baseline 2); hypothalamus: 3.9 nTPM (baseline 2); kidney: 4.6 nTPM (baseline 2); liver: 5.1 nTPM (baseline 2); lung: 4.3 nTPM (baseline 2); lymph node: 6.4 nTPM (baseline 6); midbrain: 3.8 nTPM (baseline 2); pancreas: 5.5 nTPM (baseline 2); parathyroid gland: 6.9 nTPM (baseline 6); pituitary gland: 4.5 nTPM (baseline 2); retina: 4.7 nTPM (baseline 2); skeletal muscle: 5 nTPM (baseline 2); skin: 10.7 nTPM (baseline 10); small intestine: 5.6 nTPM (baseline 2); smooth muscle: 5.3 nTPM (baseline 2); spinal cord: 3.7 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (TCGA): 254/254 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Rectum Adenocarcinoma (TCGA): 88/88 (100.0%),urothelial cancer: 1/11 (9.1%); ovarian cancer: 1/12 (8.3%),31,20,Q9NTW7,https://www.uniprot.org/uniprotkb/Q9NTW7/entry,May be involved in the regulation of mesenchymal cell differentiation through transactivation of NOTCH1 target genes,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
ZFP69,ENSG00000187815,Unsafe,RNA,False,True,3.5,3.9,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 1.9 nTPM; continuous selectivity; adrenal gland: 1.3 nTPM; continuous selectivity; amygdala: 3.1 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 3.2 nTPM; absolute ceiling;continuous selectivity; bone marrow: 1.9 nTPM; continuous selectivity; cerebellum: 2.3 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 2.3 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 1.9 nTPM; continuous selectivity; colon: 2.6 nTPM; continuous selectivity; duodenum: 1.8 nTPM; continuous selectivity; esophagus: 1.9 nTPM; continuous selectivity; heart muscle: 1.7 nTPM; continuous selectivity; hippocampal formation: 2.9 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 2.5 nTPM; absolute ceiling;continuous selectivity; kidney: 2.1 nTPM; absolute ceiling;continuous selectivity; liver: 1.9 nTPM; continuous selectivity; lung: 2.3 nTPM; absolute ceiling;continuous selectivity; lymph node: 2.8 nTPM; continuous selectivity; midbrain: 3 nTPM; absolute ceiling;continuous selectivity; pancreas: 2.4 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 2.4 nTPM; continuous selectivity; pituitary gland: 1.3 nTPM; continuous selectivity; rectum: 1.9 nTPM; continuous selectivity; retina: 2 nTPM; continuous selectivity; salivary gland: 1.7 nTPM; continuous selectivity; skin: 2.7 nTPM; continuous selectivity; small intestine: 2.3 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 2.5 nTPM; absolute ceiling;continuous selectivity; spinal cord: 3.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 3.1 nTPM; continuous selectivity; stomach: 2 nTPM; continuous selectivity; thymus: 2.9 nTPM; continuous selectivity; thyroid gland: 2 nTPM; continuous selectivity; urinary bladder: 2.6 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 3.1 nTPM (limit 2); basal ganglia: 3.2 nTPM (limit 2); cerebellum: 2.3 nTPM (limit 2); cerebral cortex: 2.3 nTPM (limit 2); hippocampal formation: 2.9 nTPM (limit 2); hypothalamus: 2.5 nTPM (limit 2); kidney: 2.1 nTPM (limit 2); lung: 2.3 nTPM (limit 2); midbrain: 3 nTPM (limit 2); pancreas: 2.4 nTPM (limit 2); small intestine: 2.3 nTPM (limit 2); smooth muscle: 2.5 nTPM (limit 2); spinal cord: 3.9 nTPM (limit 2); amygdala: 3.1 nTPM (baseline 2); basal ganglia: 3.2 nTPM (baseline 2); cerebellum: 2.3 nTPM (baseline 2); cerebral cortex: 2.3 nTPM (baseline 2); hippocampal formation: 2.9 nTPM (baseline 2); hypothalamus: 2.5 nTPM (baseline 2); kidney: 2.1 nTPM (baseline 2); lung: 2.3 nTPM (baseline 2); midbrain: 3 nTPM (baseline 2); pancreas: 2.4 nTPM (baseline 2); small intestine: 2.3 nTPM (baseline 2); smooth muscle: 2.5 nTPM (baseline 2); spinal cord: 3.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 49/58 (84.5%); Testicular Germ Cell Tumor (TCGA): 67/133 (50.4%); Glioblastoma Multiforme (TCGA): 49/141 (34.8%),liver cancer: 4/12 (33.3%); stomach cancer: 3/11 (27.3%),29,20,Q49AA0,https://www.uniprot.org/uniprotkb/Q49AA0/entry,Putative transcription factor that appears to regulate lipid metabolism,Expressed in visceral and subcutaneous adipose tissue,,,Nucleus,,19578398,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZFPL1,ENSG00000162300,Unsafe,Protein,False,True,30.6,39.5,83,68,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 29.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 31.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 28.1 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 30.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; bone marrow: 28.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 22.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 28 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 33 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 29.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 17.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 29.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 29.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 29 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 25 nTPM; absolute ceiling;continuous selectivity; kidney: 27.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 31.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 20.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 11.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 30.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 31.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 15.1 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 39.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 8.8 nTPM; positive ihc;absolute ceiling; retina: 7.3 nTPM; absolute ceiling; salivary gland: 29.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 36.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 34.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 27.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 12.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 30.1 nTPM; absolute ceiling;continuous selectivity; spleen: 24.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 29.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 10.7 nTPM; absolute ceiling; thyroid gland: 26.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 19.6 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 30.1 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 29.8 nTPM (limit 10); adrenal gland: 31.5 nTPM (limit 2); amygdala: 28.1 nTPM (limit 2); basal ganglia: 30.7 nTPM (limit 2); bone marrow: 28.9 nTPM (limit 2); cerebellum: 22.9 nTPM (limit 2); cerebral cortex: 28 nTPM (limit 2); choroid plexus: 33 nTPM (limit 2); colon: 29.5 nTPM (limit 6); duodenum: 17.4 nTPM (limit 2); esophagus: 29.1 nTPM (limit 6); heart muscle: 29.7 nTPM (limit 2); hippocampal formation: 29 nTPM (limit 2); hypothalamus: 25 nTPM (limit 2); kidney: 27.2 nTPM (limit 2); liver: 31.8 nTPM (limit 2); lung: 20.7 nTPM (limit 2); lymph node: 11.6 nTPM (limit 6); midbrain: 30.9 nTPM (limit 2); pancreas: 31.1 nTPM (limit 2); parathyroid gland: 15.1 nTPM (limit 6); pituitary gland: 39.5 nTPM (limit 2); rectum: 8.8 nTPM (limit 6); retina: 7.3 nTPM (limit 2); salivary gland: 29.9 nTPM (limit 6); skeletal muscle: 36.5 nTPM (limit 2); skin: 34.1 nTPM (limit 10); small intestine: 27.3 nTPM (limit 2); smooth muscle: 12.2 nTPM (limit 2); spinal cord: 30.1 nTPM (limit 2); spleen: 24.8 nTPM (limit 10); stomach: 29.5 nTPM (limit 6); thymus: 10.7 nTPM (limit 10); thyroid gland: 26.3 nTPM (limit 10); tongue: 19.6 nTPM (limit 6); urinary bladder: 30.1 nTPM (limit 6),adipose tissue / adipocytes: Low (Enhanced); adrenal gland / glandular cells: Medium (Enhanced); bone marrow / hematopoietic cells: Medium (Enhanced); bronchus / respiratory epithelial cells: Medium (Enhanced); caudate / glial cells: Medium (Enhanced); caudate / neuronal cells: Medium (Enhanced); cerebellum / cells in granular layer: Low (Enhanced); cerebellum / cells in molecular layer: Medium (Enhanced); cerebellum / Purkinje cells: Medium (Enhanced); cerebral cortex / endothelial cells: Medium (Enhanced); cerebral cortex / glial cells: Medium (Enhanced); cerebral cortex / neuronal cells: Medium (Enhanced); colon / endothelial cells: Medium (Enhanced); colon / glandular cells: High (Enhanced); colon / peripheral nerve/ganglion: Medium (Enhanced); duodenum / glandular cells: High (Enhanced); esophagus / squamous epithelial cells: Medium (Enhanced); heart muscle / cardiomyocytes: Low (Enhanced); hippocampus / glial cells: Low (Enhanced); hippocampus / neuronal cells: Medium (Enhanced); kidney / cells in glomeruli: Medium (Enhanced); kidney / cells in tubules: Medium (Enhanced); liver / hepatocytes: Medium (Enhanced); lung / alveolar cells type II: Low (Enhanced); lung / macrophages: High (Enhanced); lymph node / germinal center cells: Medium (Enhanced); lymph node / non-germinal center cells: Medium (Enhanced); nasopharynx / respiratory epithelial cells: Medium (Enhanced); oral mucosa / squamous epithelial cells: Medium (Enhanced); pancreas / exocrine glandular cells: Medium (Enhanced); pancreas / pancreatic endocrine cells: Medium (Enhanced); rectum / glandular cells: High (Enhanced); salivary gland / glandular cells: Medium (Enhanced); skeletal muscle / myocytes: Low (Enhanced); skin 1 / keratinocytes: Medium (Enhanced); skin 1 / Langerhans: Medium (Enhanced); skin 2 / epidermal cells: Medium (Enhanced); small intestine / glandular cells: High (Enhanced); smooth muscle / smooth muscle cells: Low (Enhanced); spleen / cells in red pulp: Low (Enhanced); stomach 1 / glandular cells: Medium (Enhanced); stomach 2 / glandular cells: High (Enhanced); thyroid gland / glandular cells: Medium (Enhanced); urinary bladder / urothelial cells: Medium (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%); Thyroid Carcinoma (TCGA): 495/495 (100.0%),endometrial cancer: 11/12 (91.7%); glioma: 11/12 (91.7%),31,20,O95159,https://www.uniprot.org/uniprotkb/O95159/entry,"Required for cis-Golgi integrity and efficient ER to Golgi transport. Involved in the maintenance of the integrity of the cis-Golgi, possibly via its interaction with GOLGA2/GM130",Expressed strongly in the exocrine pancreas,,,"Golgi apparatus, cis-Golgi network membrane",18323775,9653652,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
ZFX,ENSG00000005889,Unsafe,Protein,False,True,15.1,29.2,84,72,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 12.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 6.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 4.8 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 4.7 nTPM; absolute ceiling;continuous selectivity; bone marrow: 29.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 6.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 6.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 3.6 nTPM; absolute ceiling; colon: 9.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 6.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 6.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 8.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 4.7 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 4.2 nTPM; absolute ceiling;continuous selectivity; kidney: 7.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 9.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 8.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 11.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 4.8 nTPM; absolute ceiling;continuous selectivity; pancreas: 9.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 14.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 5.9 nTPM; absolute ceiling;continuous selectivity; rectum: 5.9 nTPM; positive ihc;continuous selectivity; retina: 9.9 nTPM; absolute ceiling;continuous selectivity; salivary gland: 7.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 14.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 7.8 nTPM; positive ihc;continuous selectivity; small intestine: 7.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 14 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 5.4 nTPM; absolute ceiling;continuous selectivity; spleen: 12 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 7.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 16.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 10.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 12 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 8.8 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 12.7 nTPM (limit 10); adrenal gland: 6.6 nTPM (limit 2); amygdala: 4.8 nTPM (limit 2); basal ganglia: 4.7 nTPM (limit 2); bone marrow: 29.2 nTPM (limit 2); cerebellum: 6.9 nTPM (limit 2); cerebral cortex: 6.7 nTPM (limit 2); choroid plexus: 3.6 nTPM (limit 2); colon: 9.5 nTPM (limit 6); duodenum: 6.6 nTPM (limit 2); esophagus: 6.9 nTPM (limit 6); heart muscle: 8.5 nTPM (limit 2); hippocampal formation: 4.7 nTPM (limit 2); hypothalamus: 4.2 nTPM (limit 2); kidney: 7.7 nTPM (limit 2); liver: 9.8 nTPM (limit 2); lung: 8.3 nTPM (limit 2); lymph node: 11.3 nTPM (limit 6); midbrain: 4.8 nTPM (limit 2); pancreas: 9.6 nTPM (limit 2); parathyroid gland: 14.9 nTPM (limit 6); pituitary gland: 5.9 nTPM (limit 2); retina: 9.9 nTPM (limit 2); salivary gland: 7.2 nTPM (limit 6); skeletal muscle: 14.6 nTPM (limit 2); small intestine: 7.9 nTPM (limit 2); smooth muscle: 14 nTPM (limit 2); spinal cord: 5.4 nTPM (limit 2); spleen: 12 nTPM (limit 10); stomach: 7.7 nTPM (limit 6); thymus: 16.8 nTPM (limit 10); thyroid gland: 10.4 nTPM (limit 10); tongue: 12 nTPM (limit 6); urinary bladder: 8.8 nTPM (limit 6),adipose tissue / adipocytes: Low (Supported); adrenal gland / glandular cells: Low (Supported); bone marrow / hematopoietic cells: Medium (Supported); bronchus / respiratory epithelial cells: Low (Supported); caudate / glial cells: Low (Supported); caudate / neuronal cells: Low (Supported); cerebellum / cells in granular layer: Medium (Supported); cerebellum / cells in molecular layer: Medium (Supported); cerebellum / Purkinje cells: Medium (Supported); cerebral cortex / endothelial cells: Low (Supported); cerebral cortex / glial cells: Low (Supported); cerebral cortex / neuronal cells: Medium (Supported); colon / endothelial cells: Medium (Supported); colon / glandular cells: Medium (Supported); colon / peripheral nerve/ganglion: Medium (Supported); duodenum / glandular cells: Medium (Supported); esophagus / squamous epithelial cells: Low (Supported); heart muscle / cardiomyocytes: Low (Supported); hippocampus / neuronal cells: Low (Supported); kidney / cells in glomeruli: Medium (Supported); kidney / cells in tubules: Medium (Supported); liver / hepatocytes: Low (Supported); lung / alveolar cells: Low (Supported); lung / macrophages: Low (Supported); lymph node / germinal center cells: Medium (Supported); lymph node / non-germinal center cells: Medium (Supported); nasopharynx / respiratory epithelial cells: Medium (Supported); oral mucosa / squamous epithelial cells: Medium (Supported); pancreas / exocrine glandular cells: Low (Supported); pancreas / pancreatic endocrine cells: Medium (Supported); parathyroid gland / glandular cells: Low (Supported); rectum / glandular cells: Low (Supported); salivary gland / glandular cells: Low (Supported); skeletal muscle / myocytes: Low (Supported); skin 1 / fibroblasts: Medium (Supported); skin 1 / keratinocytes: Medium (Supported); skin 1 / Langerhans: Medium (Supported); skin 2 / epidermal cells: Medium (Supported); small intestine / glandular cells: Low (Supported); smooth muscle / smooth muscle cells: Low (Supported); spleen / cells in red pulp: Low (Supported); spleen / cells in white pulp: Low (Supported); stomach 1 / glandular cells: Medium (Supported); stomach 2 / glandular cells: Medium (Supported); thyroid gland / glandular cells: Medium (Supported); urinary bladder / urothelial cells: Low (Supported),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%),breast cancer: 9/12 (75.0%); prostate cancer: 6/12 (50.0%),31,20,P17010,https://www.uniprot.org/uniprotkb/P17010/entry,Probable transcriptional activator,,"Intellectual developmental disorder, X-linked, syndromic 37: A syndromic neurodevelopmental disorder characterized by developmental delay, intellectual disability, behavioral abnormalities, hypotonia, congenital anomalies, and facial dysmorphism.",,Nucleus,2512506|38325380,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
ZFY,ENSG00000067646,Unsafe,Protein,False,True,7.0,7.9,84,67,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 7.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 2.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 1.9 nTPM; positive ihc;continuous selectivity; colon: 2.2 nTPM; positive ihc; duodenum: 2.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 4.4 nTPM; continuous selectivity; kidney: 1.7 nTPM; positive ihc; liver: 4.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 1.7 nTPM; positive ihc; lymph node: 1.2 nTPM; positive ihc; pancreas: 2.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 1.9 nTPM; positive ihc; rectum: 4.9 nTPM; positive ihc;continuous selectivity; retina: 2.2 nTPM; absolute ceiling;continuous selectivity; salivary gland: 2.6 nTPM; positive ihc;continuous selectivity; skeletal muscle: 3.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 1.7 nTPM; positive ihc; small intestine: 4.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 0 nTPM; positive ihc; spleen: 2.1 nTPM; positive ihc; stomach: 2.4 nTPM; positive ihc; thyroid gland: 2.7 nTPM; positive ihc; tongue: 7.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 3.1 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 7.9 nTPM (limit 2); cerebellum: 2.9 nTPM (limit 2); duodenum: 2.6 nTPM (limit 2); liver: 4.3 nTPM (limit 2); pancreas: 2.5 nTPM (limit 2); retina: 2.2 nTPM (limit 2); skeletal muscle: 3.3 nTPM (limit 2); small intestine: 4.1 nTPM (limit 2); tongue: 7.1 nTPM (limit 6); bone marrow: 7.9 nTPM (baseline 2); cerebellum: 2.9 nTPM (baseline 2); duodenum: 2.6 nTPM (baseline 2); liver: 4.3 nTPM (baseline 2); pancreas: 2.5 nTPM (baseline 2); retina: 2.2 nTPM (baseline 2); skeletal muscle: 3.3 nTPM (baseline 2); small intestine: 4.1 nTPM (baseline 2); tongue: 7.1 nTPM (baseline 6),bone marrow / hematopoietic cells: Medium (Uncertain); caudate / glial cells: Low (Uncertain); caudate / neuronal cells: Low (Uncertain); cerebellum / cells in granular layer: Medium (Uncertain); cerebellum / cells in molecular layer: Medium (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / endothelial cells: Low (Uncertain); cerebral cortex / glial cells: Low (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); colon / endothelial cells: Medium (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: Medium (Uncertain); duodenum / glandular cells: Medium (Uncertain); hippocampus / neuronal cells: Low (Uncertain); kidney / cells in glomeruli: Medium (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / hepatocytes: Low (Uncertain); lung / alveolar cells: Low (Uncertain); lung / macrophages: Low (Uncertain); lymph node / germinal center cells: Medium (Uncertain); lymph node / non-germinal center cells: Medium (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Low (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); parathyroid gland / glandular cells: Low (Uncertain); rectum / glandular cells: Low (Uncertain); salivary gland / glandular cells: Low (Uncertain); skeletal muscle / myocytes: Low (Uncertain); skin 1 / fibroblasts: Medium (Uncertain); skin 1 / keratinocytes: Medium (Uncertain); skin 1 / Langerhans: Medium (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: Low (Uncertain); smooth muscle / smooth muscle cells: Low (Uncertain); spleen / cells in red pulp: Low (Uncertain); spleen / cells in white pulp: Low (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Low (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 33/58 (56.9%); Rectum Adenocarcinoma (validation): 108/207 (52.2%); Colon Adenocarcinoma (validation): 221/486 (45.5%),breast cancer: 9/12 (75.0%); prostate cancer: 6/12 (50.0%),31,20,P08048,https://www.uniprot.org/uniprotkb/P08048/entry,Probable transcriptional activator. Binds to the consensus sequence 5'-AGGCCY-3',,,Was originally thought to be the testis determining factor (TDF),Nucleus,20028140,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
ZIC2,ENSG00000043355,Unsafe,RNA,False,True,1.2,155.1,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,amygdala: 5.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 155.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 9.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 19.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 7.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 5.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 3.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 1.1 nTPM; continuous selectivity; retina: 2.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 5.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 5.9 nTPM (limit 2); basal ganglia: 4 nTPM (limit 2); cerebellum: 155.1 nTPM (limit 2); cerebral cortex: 9.9 nTPM (limit 2); choroid plexus: 19.5 nTPM (limit 2); hippocampal formation: 7.9 nTPM (limit 2); hypothalamus: 5.6 nTPM (limit 2); midbrain: 3.7 nTPM (limit 2); retina: 2.4 nTPM (limit 2); spinal cord: 5.7 nTPM (limit 2); amygdala: 5.9 nTPM (baseline 2); basal ganglia: 4 nTPM (baseline 2); cerebellum: 155.1 nTPM (baseline 2); cerebral cortex: 9.9 nTPM (baseline 2); choroid plexus: 19.5 nTPM (baseline 2); hippocampal formation: 7.9 nTPM (baseline 2); hypothalamus: 5.6 nTPM (baseline 2); midbrain: 3.7 nTPM (baseline 2); retina: 2.4 nTPM (baseline 2); spinal cord: 5.7 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 32/58 (55.2%); Glioblastoma Multiforme (TCGA): 70/141 (49.6%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 139/283 (49.1%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O95409,https://www.uniprot.org/uniprotkb/O95409/entry,Acts as a transcriptional activator or repressor. Plays important roles in the early stage of organogenesis of the CNS. Activates the transcription of the serotonin transporter SERT in uncrossed ipsilateral retinal ganglion cells (iRGCs) to refine eye-specific projections in primary visual targets. Its transcriptional activity is repressed by MDFIC. Involved in the formation of the ipsilateral retinal projection at the optic chiasm midline. Drives the expression of EPHB1 on ipsilaterally projecting growth cones. Binds to the minimal GLI-consensus sequence 5'-TGGGTGGTC-3'. Associates to the basal SERT promoter region from ventrotemporal retinal segments of retinal embryos,,"Holoprosencephaly 5: A form of holoprosencephaly, a structural anomaly of the brain in which the developing forebrain fails to correctly separate into right and left hemispheres. It is a genetically and clinically heterogeneous disorder with a wide spectrum of severity, ranging from alobar holoprosencephaly with severe facial abnormalities, such as cyclopia and proboscis, to mild forms that include lobar or microform holoprosencephaly, without cerebral malformations and with mild craniofacial defects. HPE5 inheritance is autosomal dominant.",,Nucleus Cytoplasm,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
ZIC5,ENSG00000139800,Unsafe,RNA,False,True,3.6,27.0,0,0,Missing,False,True,False,False,Excluded,Normal,False,,Not assessed,,,amygdala: 1.6 nTPM; continuous selectivity; cerebellum: 27 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 2.3 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 5.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 1.7 nTPM; continuous selectivity; retina: 3.3 nTPM; absolute ceiling;continuous selectivity; spinal cord: 1.1 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebellum: 27 nTPM (limit 2); cerebral cortex: 2.3 nTPM (limit 2); choroid plexus: 5.3 nTPM (limit 2); retina: 3.3 nTPM (limit 2); cerebellum: 27 nTPM (baseline 2); cerebral cortex: 2.3 nTPM (baseline 2); choroid plexus: 5.3 nTPM (baseline 2); retina: 3.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 32/58 (55.2%); Colon Adenocarcinoma (validation): 119/486 (24.5%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 43/283 (15.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q96T25,https://www.uniprot.org/uniprotkb/Q96T25/entry,"Essential for neural crest development, converting cells from an epidermal fate to a neural crest cell fate. Binds to DNA (By similarity)",,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
ZKSCAN2,ENSG00000155592,Unsafe,RNA,False,True,4.0,4.4,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 1.3 nTPM; continuous selectivity; amygdala: 1.6 nTPM; continuous selectivity; basal ganglia: 1.5 nTPM; continuous selectivity; bone marrow: 1.8 nTPM; continuous selectivity; cerebellum: 1.8 nTPM; continuous selectivity; cerebral cortex: 2.2 nTPM; absolute ceiling;continuous selectivity; heart muscle: 1.8 nTPM; continuous selectivity; hippocampal formation: 1.6 nTPM; continuous selectivity; hypothalamus: 1.9 nTPM; continuous selectivity; kidney: 1.5 nTPM; continuous selectivity; liver: 1.6 nTPM; continuous selectivity; midbrain: 1.5 nTPM; continuous selectivity; parathyroid gland: 2.8 nTPM; continuous selectivity; pituitary gland: 1.6 nTPM; continuous selectivity; retina: 4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 3.1 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 1.8 nTPM; continuous selectivity; spinal cord: 1.6 nTPM; continuous selectivity; thymus: 2.3 nTPM; continuous selectivity; thyroid gland: 2 nTPM; continuous selectivity; tongue: 4.4 nTPM; continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebral cortex: 2.2 nTPM (limit 2); retina: 4 nTPM (limit 2); skeletal muscle: 3.1 nTPM (limit 2); cerebral cortex: 2.2 nTPM (baseline 2); retina: 4 nTPM (baseline 2); skeletal muscle: 3.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 49/50 (98.0%); Testicular Germ Cell Tumor (TCGA): 38/133 (28.6%),cervical cancer: 4/11 (36.4%); colorectal cancer: 4/12 (33.3%),31,20,Q63HK3,https://www.uniprot.org/uniprotkb/Q63HK3/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZKSCAN3,ENSG00000189298,Unsafe,Protein,False,True,5.1,5.1,84,64,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 2.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; bone marrow: 1.1 nTPM; positive ihc; cerebellum: 1.5 nTPM; positive ihc;continuous selectivity; cerebral cortex: 2.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 2.4 nTPM; absolute ceiling;continuous selectivity; colon: 3.3 nTPM; positive ihc;continuous selectivity; duodenum: 2.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 2.3 nTPM; positive ihc;continuous selectivity; heart muscle: 2.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; kidney: 3.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 2.9 nTPM; positive ihc;continuous selectivity; midbrain: 1.4 nTPM; continuous selectivity; pancreas: 2.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 4.6 nTPM; positive ihc;continuous selectivity; pituitary gland: 2.6 nTPM; absolute ceiling;continuous selectivity; rectum: 3.7 nTPM; positive ihc;continuous selectivity; retina: 3.7 nTPM; absolute ceiling;continuous selectivity; salivary gland: 2.3 nTPM; continuous selectivity; skeletal muscle: 2.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 3.7 nTPM; positive ihc;continuous selectivity; small intestine: 2.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 4.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 1.6 nTPM; continuous selectivity; spleen: 3.3 nTPM; positive ihc;continuous selectivity; stomach: 4 nTPM; positive ihc;continuous selectivity; thymus: 4.2 nTPM; continuous selectivity; thyroid gland: 4.2 nTPM; positive ihc;continuous selectivity; tongue: 2.4 nTPM; continuous selectivity; urinary bladder: 2.7 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 2.5 nTPM (limit 2); cerebral cortex: 2.2 nTPM (limit 2); choroid plexus: 2.4 nTPM (limit 2); duodenum: 2.1 nTPM (limit 2); heart muscle: 2.3 nTPM (limit 2); kidney: 3.2 nTPM (limit 2); liver: 2.7 nTPM (limit 2); lung: 3 nTPM (limit 2); pancreas: 2.2 nTPM (limit 2); pituitary gland: 2.6 nTPM (limit 2); retina: 3.7 nTPM (limit 2); skeletal muscle: 2.4 nTPM (limit 2); small intestine: 2.3 nTPM (limit 2); smooth muscle: 4.5 nTPM (limit 2),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: High (Approved); bronchus / respiratory epithelial cells: Low (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Low (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: High (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Medium (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Low (Approved); lung / macrophages: High (Approved); lymph node / germinal center cells: High (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Low (Approved); skin 1 / keratinocytes: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: High (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 45/50 (90.0%); Rectum Adenocarcinoma (validation): 153/207 (73.9%),cervical cancer: 11/12 (91.7%); lymphoma: 11/12 (91.7%),31,20,Q9BRR0,https://www.uniprot.org/uniprotkb/Q9BRR0/entry,"Transcriptional factor that binds to the consensus sequence 5'-[GT][AG][AGT]GGGG-3' and acts as a repressor of autophagy. Specifically represses expression of genes involved in autophagy and lysosome biogenesis/function such as MAP1LC3B, ULK1 or WIPI2. Associates with chromatin at the ITGB4 and VEGF promoters. Also acts as a transcription activator and promotes cancer cell progression and/or migration in various tumors and myelomas",,,,Nucleus Cytoplasm,18940803|21057542|22531714|23434374,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZMYM5,ENSG00000132950,Unsafe,Protein,False,True,22.7,22.7,79,71,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 7.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 2.7 nTPM; absolute ceiling; basal ganglia: 2.9 nTPM; absolute ceiling; bone marrow: 12.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 2.9 nTPM; positive ihc;absolute ceiling; cerebral cortex: 5.1 nTPM; positive ihc;absolute ceiling; choroid plexus: 3.3 nTPM; absolute ceiling; colon: 5.7 nTPM; positive ihc; duodenum: 6 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 7.4 nTPM; positive ihc;absolute ceiling; heart muscle: 5.2 nTPM; positive ihc;absolute ceiling; hippocampal formation: 3 nTPM; absolute ceiling; hypothalamus: 2.9 nTPM; absolute ceiling; kidney: 6.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 6.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 6.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 10 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 3.5 nTPM; absolute ceiling; pancreas: 5.3 nTPM; positive ihc;absolute ceiling; parathyroid gland: 5.3 nTPM; positive ihc; pituitary gland: 4.7 nTPM; absolute ceiling; rectum: 6 nTPM; positive ihc; retina: 8.8 nTPM; absolute ceiling;continuous selectivity; salivary gland: 5.6 nTPM; positive ihc; skeletal muscle: 6 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 7.6 nTPM; positive ihc; small intestine: 6.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 6.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 4.6 nTPM; absolute ceiling; spleen: 7.3 nTPM; positive ihc; stomach: 7.1 nTPM; positive ihc;absolute ceiling; thyroid gland: 8.3 nTPM; positive ihc; tongue: 7.4 nTPM; absolute ceiling; urinary bladder: 6.9 nTPM; positive ihc;absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 7.6 nTPM (limit 2); amygdala: 2.7 nTPM (limit 2); basal ganglia: 2.9 nTPM (limit 2); bone marrow: 12.1 nTPM (limit 2); cerebellum: 2.9 nTPM (limit 2); cerebral cortex: 5.1 nTPM (limit 2); choroid plexus: 3.3 nTPM (limit 2); duodenum: 6 nTPM (limit 2); esophagus: 7.4 nTPM (limit 6); heart muscle: 5.2 nTPM (limit 2); hippocampal formation: 3 nTPM (limit 2); hypothalamus: 2.9 nTPM (limit 2); kidney: 6.3 nTPM (limit 2); liver: 6.7 nTPM (limit 2); lung: 6.5 nTPM (limit 2); lymph node: 10 nTPM (limit 6); midbrain: 3.5 nTPM (limit 2); pancreas: 5.3 nTPM (limit 2); pituitary gland: 4.7 nTPM (limit 2); retina: 8.8 nTPM (limit 2); skeletal muscle: 6 nTPM (limit 2); small intestine: 6.4 nTPM (limit 2); smooth muscle: 6.6 nTPM (limit 2); spinal cord: 4.6 nTPM (limit 2); stomach: 7.1 nTPM (limit 6); tongue: 7.4 nTPM (limit 6); urinary bladder: 6.9 nTPM (limit 6); adrenal gland: 7.6 nTPM (baseline 2); amygdala: 2.7 nTPM (baseline 2); basal ganglia: 2.9 nTPM (baseline 2); bone marrow: 12.1 nTPM (baseline 2); cerebellum: 2.9 nTPM (baseline 2); cerebral cortex: 5.1 nTPM (baseline 2); choroid plexus: 3.3 nTPM (baseline 2); duodenum: 6 nTPM (baseline 2); esophagus: 7.4 nTPM (baseline 6); heart muscle: 5.2 nTPM (baseline 2); hippocampal formation: 3 nTPM (baseline 2); hypothalamus: 2.9 nTPM (baseline 2); kidney: 6.3 nTPM (baseline 2); liver: 6.7 nTPM (baseline 2); lung: 6.5 nTPM (baseline 2); lymph node: 10 nTPM (baseline 6); midbrain: 3.5 nTPM (baseline 2); pancreas: 5.3 nTPM (baseline 2); pituitary gland: 4.7 nTPM (baseline 2); retina: 8.8 nTPM (baseline 2); skeletal muscle: 6 nTPM (baseline 2); small intestine: 6.4 nTPM (baseline 2); smooth muscle: 6.6 nTPM (baseline 2); spinal cord: 4.6 nTPM (baseline 2); stomach: 7.1 nTPM (baseline 6); tongue: 7.4 nTPM (baseline 6); urinary bladder: 6.9 nTPM (baseline 6),adrenal gland / glandular cells: High (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: High (Uncertain); caudate / glial cells: Low (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / endothelial cells: Medium (Uncertain); cerebral cortex / glial cells: Low (Uncertain); cerebral cortex / neuronal cells: Low (Uncertain); cerebral cortex / neuropil: Medium (Uncertain); colon / endothelial cells: Medium (Uncertain); colon / glandular cells: High (Uncertain); colon / peripheral nerve/ganglion: Medium (Uncertain); duodenum / glandular cells: High (Uncertain); esophagus / squamous epithelial cells: High (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / glial cells: Low (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in tubules: High (Uncertain); liver / cholangiocytes: Low (Uncertain); liver / hepatocytes: High (Uncertain); lung / macrophages: High (Uncertain); lymph node / germinal center cells: High (Uncertain); lymph node / non-germinal center cells: High (Uncertain); oral mucosa / squamous epithelial cells: High (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: High (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: High (Uncertain); skin 1 / fibroblasts: High (Uncertain); skin 1 / keratinocytes: Medium (Uncertain); skin 1 / Langerhans: Medium (Uncertain); skin 2 / epidermal cells: High (Uncertain); small intestine / glandular cells: High (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); spleen / cells in red pulp: Medium (Uncertain); spleen / cells in white pulp: Medium (Uncertain); stomach 1 / glandular cells: High (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: High (Uncertain); urinary bladder / urothelial cells: High (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 80/80 (100.0%); Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%),renal cancer: 12/12 (100.0%); pancreatic cancer: 11/11 (100.0%),31,20,Q9UJ78,https://www.uniprot.org/uniprotkb/Q9UJ78/entry,Functions as a transcriptional regulator,,,,Nucleus,17126306,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
ZMYM6,ENSG00000163867,Unsafe,Protein,False,True,9.2,15.3,78,75,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 5.5 nTPM; positive ihc;continuous selectivity; adrenal gland: 7.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 2.4 nTPM; absolute ceiling; basal ganglia: 3 nTPM; absolute ceiling;continuous selectivity; bone marrow: 15.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 5.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 5.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 2.2 nTPM; absolute ceiling; colon: 6 nTPM; positive ihc;continuous selectivity; duodenum: 6.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 6.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 6.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 2.4 nTPM; absolute ceiling; hypothalamus: 2.8 nTPM; absolute ceiling;continuous selectivity; kidney: 6.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 4.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 6.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 9.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 2.4 nTPM; absolute ceiling; pancreas: 4.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 7.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 6.7 nTPM; absolute ceiling;continuous selectivity; rectum: 7.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 9 nTPM; absolute ceiling;continuous selectivity; salivary gland: 5 nTPM; positive ihc;continuous selectivity; skeletal muscle: 3.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 8 nTPM; positive ihc;continuous selectivity; small intestine: 6.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 6.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 3.2 nTPM; absolute ceiling;continuous selectivity; spleen: 10.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; stomach: 7 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 7.9 nTPM; continuous selectivity; thyroid gland: 9.2 nTPM; positive ihc;continuous selectivity;reproductive not higher; tongue: 4.5 nTPM; continuous selectivity; urinary bladder: 5.3 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 7.3 nTPM (limit 2); amygdala: 2.4 nTPM (limit 2); basal ganglia: 3 nTPM (limit 2); bone marrow: 15.3 nTPM (limit 2); cerebellum: 5.6 nTPM (limit 2); cerebral cortex: 5.1 nTPM (limit 2); choroid plexus: 2.2 nTPM (limit 2); duodenum: 6.2 nTPM (limit 2); esophagus: 6.7 nTPM (limit 6); heart muscle: 6.5 nTPM (limit 2); hippocampal formation: 2.4 nTPM (limit 2); hypothalamus: 2.8 nTPM (limit 2); kidney: 6.5 nTPM (limit 2); liver: 4.5 nTPM (limit 2); lung: 6.2 nTPM (limit 2); lymph node: 9.3 nTPM (limit 6); midbrain: 2.4 nTPM (limit 2); pancreas: 4.8 nTPM (limit 2); parathyroid gland: 7.3 nTPM (limit 6); pituitary gland: 6.7 nTPM (limit 2); rectum: 7.2 nTPM (limit 6); retina: 9 nTPM (limit 2); skeletal muscle: 3.4 nTPM (limit 2); small intestine: 6.9 nTPM (limit 2); smooth muscle: 6.3 nTPM (limit 2); spinal cord: 3.2 nTPM (limit 2); spleen: 10.3 nTPM (limit 10); stomach: 7 nTPM (limit 6),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: High (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Medium (Approved); caudate / neuronal cells: High (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: High (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: High (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Medium (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Low (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: High (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Low (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: High (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: High (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Low (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Low (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Low (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 80/80 (100.0%); Rectum Adenocarcinoma (validation): 206/207 (99.5%); Colon Adenocarcinoma (validation): 482/486 (99.2%),glioma: 12/12 (100.0%); lymphoma: 11/12 (91.7%),31,20,O95789,https://www.uniprot.org/uniprotkb/O95789/entry,Required for regulation of cell morphology and cytoskeletal organization,"Expressed at high levels in heart, skeletal muscle, kidney and liver",,,Nucleus,21834987,10486218,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
ZMYND10,ENSG00000004838,Unsafe,RNA,False,True,251.3,251.3,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 5.8 nTPM; absolute ceiling; basal ganglia: 12.3 nTPM; absolute ceiling; choroid plexus: 82.5 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 8.2 nTPM; absolute ceiling; hypothalamus: 10.8 nTPM; absolute ceiling; kidney: 2.1 nTPM; absolute ceiling; lung: 10.8 nTPM; absolute ceiling; pituitary gland: 5.8 nTPM; absolute ceiling; retina: 3.1 nTPM; absolute ceiling; spinal cord: 2.4 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 5.8 nTPM (limit 2); basal ganglia: 12.3 nTPM (limit 2); choroid plexus: 82.5 nTPM (limit 2); hippocampal formation: 8.2 nTPM (limit 2); hypothalamus: 10.8 nTPM (limit 2); kidney: 2.1 nTPM (limit 2); lung: 10.8 nTPM (limit 2); pituitary gland: 5.8 nTPM (limit 2); retina: 3.1 nTPM (limit 2); spinal cord: 2.4 nTPM (limit 2); amygdala: 5.8 nTPM (baseline 2); basal ganglia: 12.3 nTPM (baseline 2); choroid plexus: 82.5 nTPM (baseline 2); hippocampal formation: 8.2 nTPM (baseline 2); hypothalamus: 10.8 nTPM (baseline 2); kidney: 2.1 nTPM (baseline 2); lung: 10.8 nTPM (baseline 2); pituitary gland: 5.8 nTPM (baseline 2); retina: 3.1 nTPM (baseline 2); spinal cord: 2.4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 48/50 (96.0%); Kidney Renal Papillary Cell Carcinoma (TCGA): 198/282 (70.2%); Breast Invasive Carcinoma (TCGA): 636/1022 (62.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O75800,https://www.uniprot.org/uniprotkb/O75800/entry,"Plays a role in axonemal structure organization and motility (PubMed:23891469, PubMed:23891471). Involved in axonemal pre-assembly of inner and outer dynein arms (IDA and ODA, respectively) for proper axoneme building for cilia motility (By similarity). May act by indirectly regulating transcription of dynein proteins (By similarity)",,"Ciliary dyskinesia, primary, 22: A disorder characterized by abnormalities of motile cilia. Respiratory infections leading to chronic inflammation and bronchiectasis are recurrent, due to defects in the respiratory cilia. Patients may exhibit randomization of left-right body asymmetry and situs inversus, due to dysfunction of monocilia at the embryonic node. Primary ciliary dyskinesia associated with situs inversus is referred to as Kartagener syndrome.",,"Cytoplasm Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriolar satellite Apical cell membrane Dynein axonemal particle",23891469|23891471,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
ZMYND12,ENSG00000066185,Unsafe,RNA,False,True,27.9,27.9,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 2.2 nTPM; absolute ceiling; amygdala: 3 nTPM; absolute ceiling; basal ganglia: 4 nTPM; absolute ceiling; cerebral cortex: 2.5 nTPM; absolute ceiling; choroid plexus: 9.9 nTPM; absolute ceiling;continuous selectivity; heart muscle: 2.2 nTPM; absolute ceiling; hippocampal formation: 2.8 nTPM; absolute ceiling; hypothalamus: 4.3 nTPM; absolute ceiling; kidney: 9 nTPM; absolute ceiling;continuous selectivity; liver: 6.7 nTPM; absolute ceiling; midbrain: 3.4 nTPM; absolute ceiling; pancreas: 3.2 nTPM; absolute ceiling; pituitary gland: 3.3 nTPM; absolute ceiling; retina: 3.9 nTPM; absolute ceiling; spinal cord: 2.9 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 2.2 nTPM (limit 2); amygdala: 3 nTPM (limit 2); basal ganglia: 4 nTPM (limit 2); cerebral cortex: 2.5 nTPM (limit 2); choroid plexus: 9.9 nTPM (limit 2); heart muscle: 2.2 nTPM (limit 2); hippocampal formation: 2.8 nTPM (limit 2); hypothalamus: 4.3 nTPM (limit 2); kidney: 9 nTPM (limit 2); liver: 6.7 nTPM (limit 2); midbrain: 3.4 nTPM (limit 2); pancreas: 3.2 nTPM (limit 2); pituitary gland: 3.3 nTPM (limit 2); retina: 3.9 nTPM (limit 2); spinal cord: 2.9 nTPM (limit 2); adrenal gland: 2.2 nTPM (baseline 2); amygdala: 3 nTPM (baseline 2); basal ganglia: 4 nTPM (baseline 2); cerebral cortex: 2.5 nTPM (baseline 2); choroid plexus: 9.9 nTPM (baseline 2); heart muscle: 2.2 nTPM (baseline 2); hippocampal formation: 2.8 nTPM (baseline 2); hypothalamus: 4.3 nTPM (baseline 2); kidney: 9 nTPM (baseline 2); liver: 6.7 nTPM (baseline 2); midbrain: 3.4 nTPM (baseline 2); pancreas: 3.2 nTPM (baseline 2); pituitary gland: 3.3 nTPM (baseline 2); retina: 3.9 nTPM (baseline 2); spinal cord: 2.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 36/50 (72.0%); Glioblastoma Multiforme (validation): 24/58 (41.4%); Ovary Serous Cystadenocarcinoma (TCGA): 143/349 (41.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9H0C1,https://www.uniprot.org/uniprotkb/Q9H0C1/entry,Required for sperm flagellum function and male fertility,Expressed predominantly in the testis,,,"Cell projection, cilium, flagellum",37934199,37934199,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
ZMYND15,ENSG00000141497,Unsafe,RNA,False,True,27.5,27.5,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,choroid plexus: 2.3 nTPM; absolute ceiling; duodenum: 3.9 nTPM; absolute ceiling; liver: 3 nTPM; absolute ceiling; lung: 4.5 nTPM; absolute ceiling; small intestine: 2.9 nTPM; absolute ceiling; spinal cord: 3.2 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 2.3 nTPM (limit 2); duodenum: 3.9 nTPM (limit 2); liver: 3 nTPM (limit 2); lung: 4.5 nTPM (limit 2); small intestine: 2.9 nTPM (limit 2); spinal cord: 3.2 nTPM (limit 2); choroid plexus: 2.3 nTPM (baseline 2); duodenum: 3.9 nTPM (baseline 2); liver: 3 nTPM (baseline 2); lung: 4.5 nTPM (baseline 2); small intestine: 2.9 nTPM (baseline 2); spinal cord: 3.2 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 40/50 (80.0%); Kidney Renal Papillary Cell Carcinoma (TCGA): 102/282 (36.2%); Liver Hepatocellular Carcinoma (validation): 83/231 (35.9%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9H091,https://www.uniprot.org/uniprotkb/Q9H091/entry,Acts as a transcriptional repressor through interaction with histone deacetylases (HDACs). May be important for spermiogenesis,,"Spermatogenic failure 14: A disorder resulting in the absence (azoospermia) or reduction (oligozoospermia) of sperm in the semen, leading to male infertility.",,Nucleus Cytoplasm,24431330,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
ZNF10,ENSG00000256223,Unsafe,RNA,False,True,22.9,44.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 13.8 nTPM; absolute ceiling;continuous selectivity; amygdala: 4.5 nTPM; absolute ceiling; basal ganglia: 4.9 nTPM; absolute ceiling; bone marrow: 8.5 nTPM; absolute ceiling;continuous selectivity; cerebellum: 6.7 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 5.6 nTPM; absolute ceiling; choroid plexus: 11.7 nTPM; absolute ceiling;continuous selectivity; colon: 10.6 nTPM; absolute ceiling;continuous selectivity; duodenum: 3.6 nTPM; absolute ceiling; heart muscle: 8 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 4.4 nTPM; absolute ceiling; hypothalamus: 6.1 nTPM; absolute ceiling;continuous selectivity; kidney: 10.6 nTPM; absolute ceiling;continuous selectivity; liver: 10.4 nTPM; absolute ceiling;continuous selectivity; lung: 7.4 nTPM; absolute ceiling;continuous selectivity; midbrain: 4.2 nTPM; absolute ceiling; pancreas: 12.8 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 16.8 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 44.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; retina: 12.7 nTPM; absolute ceiling;continuous selectivity; salivary gland: 7.7 nTPM; absolute ceiling; skeletal muscle: 4.7 nTPM; absolute ceiling; small intestine: 6.9 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 8.3 nTPM; absolute ceiling;continuous selectivity; spinal cord: 4.8 nTPM; absolute ceiling; stomach: 10.2 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 20.5 nTPM; absolute ceiling;continuous selectivity; tongue: 6.1 nTPM; absolute ceiling; urinary bladder: 10.4 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 13.8 nTPM (limit 2); amygdala: 4.5 nTPM (limit 2); basal ganglia: 4.9 nTPM (limit 2); bone marrow: 8.5 nTPM (limit 2); cerebellum: 6.7 nTPM (limit 2); cerebral cortex: 5.6 nTPM (limit 2); choroid plexus: 11.7 nTPM (limit 2); colon: 10.6 nTPM (limit 6); duodenum: 3.6 nTPM (limit 2); heart muscle: 8 nTPM (limit 2); hippocampal formation: 4.4 nTPM (limit 2); hypothalamus: 6.1 nTPM (limit 2); kidney: 10.6 nTPM (limit 2); liver: 10.4 nTPM (limit 2); lung: 7.4 nTPM (limit 2); midbrain: 4.2 nTPM (limit 2); pancreas: 12.8 nTPM (limit 2); parathyroid gland: 16.8 nTPM (limit 6); pituitary gland: 44.1 nTPM (limit 2); retina: 12.7 nTPM (limit 2); salivary gland: 7.7 nTPM (limit 6); skeletal muscle: 4.7 nTPM (limit 2); small intestine: 6.9 nTPM (limit 2); smooth muscle: 8.3 nTPM (limit 2); spinal cord: 4.8 nTPM (limit 2); stomach: 10.2 nTPM (limit 6); thyroid gland: 20.5 nTPM (limit 10); tongue: 6.1 nTPM (limit 6); urinary bladder: 10.4 nTPM (limit 6); adrenal gland: 13.8 nTPM (baseline 2); amygdala: 4.5 nTPM (baseline 2); basal ganglia: 4.9 nTPM (baseline 2); bone marrow: 8.5 nTPM (baseline 2); cerebellum: 6.7 nTPM (baseline 2); cerebral cortex: 5.6 nTPM (baseline 2); choroid plexus: 11.7 nTPM (baseline 2); colon: 10.6 nTPM (baseline 6); duodenum: 3.6 nTPM (baseline 2); heart muscle: 8 nTPM (baseline 2); hippocampal formation: 4.4 nTPM (baseline 2); hypothalamus: 6.1 nTPM (baseline 2); kidney: 10.6 nTPM (baseline 2); liver: 10.4 nTPM (baseline 2); lung: 7.4 nTPM (baseline 2); midbrain: 4.2 nTPM (baseline 2); pancreas: 12.8 nTPM (baseline 2); parathyroid gland: 16.8 nTPM (baseline 6); pituitary gland: 44.1 nTPM (baseline 2); retina: 12.7 nTPM (baseline 2); salivary gland: 7.7 nTPM (baseline 6); skeletal muscle: 4.7 nTPM (baseline 2); small intestine: 6.9 nTPM (baseline 2); smooth muscle: 8.3 nTPM (baseline 2); spinal cord: 4.8 nTPM (baseline 2); stomach: 10.2 nTPM (baseline 6); thyroid gland: 20.5 nTPM (baseline 10); tongue: 6.1 nTPM (baseline 6); urinary bladder: 10.4 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Thyroid Carcinoma (TCGA): 446/495 (90.1%); Breast Invasive Carcinoma (validation): 45/50 (90.0%),prostate cancer: 9/10 (90.0%); colorectal cancer: 6/10 (60.0%),31,20,P21506,https://www.uniprot.org/uniprotkb/P21506/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
ZNF101,ENSG00000181896,Unsafe,RNA,False,True,10.3,26.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 2.5 nTPM; absolute ceiling; basal ganglia: 2.4 nTPM; absolute ceiling; bone marrow: 13.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 2.3 nTPM; absolute ceiling; cerebral cortex: 2.6 nTPM; absolute ceiling; choroid plexus: 3 nTPM; absolute ceiling;continuous selectivity; colon: 4.6 nTPM; continuous selectivity; duodenum: 3.1 nTPM; absolute ceiling;continuous selectivity; esophagus: 6.7 nTPM; absolute ceiling;continuous selectivity; heart muscle: 2.1 nTPM; absolute ceiling; hippocampal formation: 3 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 2.4 nTPM; absolute ceiling; kidney: 4 nTPM; absolute ceiling;continuous selectivity; liver: 3 nTPM; absolute ceiling;continuous selectivity; lung: 3.3 nTPM; absolute ceiling;continuous selectivity; lymph node: 26.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 2.6 nTPM; absolute ceiling; pancreas: 2.3 nTPM; absolute ceiling; rectum: 4.4 nTPM; continuous selectivity; retina: 4.1 nTPM; absolute ceiling;continuous selectivity; small intestine: 7.9 nTPM; absolute ceiling;continuous selectivity; spinal cord: 2.7 nTPM; absolute ceiling;continuous selectivity; spleen: 10.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; stomach: 4.4 nTPM; continuous selectivity; thymus: 24.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 5.4 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 2.5 nTPM (limit 2); basal ganglia: 2.4 nTPM (limit 2); bone marrow: 13.4 nTPM (limit 2); cerebellum: 2.3 nTPM (limit 2); cerebral cortex: 2.6 nTPM (limit 2); choroid plexus: 3 nTPM (limit 2); duodenum: 3.1 nTPM (limit 2); esophagus: 6.7 nTPM (limit 6); heart muscle: 2.1 nTPM (limit 2); hippocampal formation: 3 nTPM (limit 2); hypothalamus: 2.4 nTPM (limit 2); kidney: 4 nTPM (limit 2); liver: 3 nTPM (limit 2); lung: 3.3 nTPM (limit 2); lymph node: 26.8 nTPM (limit 6); midbrain: 2.6 nTPM (limit 2); pancreas: 2.3 nTPM (limit 2); retina: 4.1 nTPM (limit 2); small intestine: 7.9 nTPM (limit 2); spinal cord: 2.7 nTPM (limit 2); spleen: 10.7 nTPM (limit 10); thymus: 24.6 nTPM (limit 10); amygdala: 2.5 nTPM (baseline 2); basal ganglia: 2.4 nTPM (baseline 2); bone marrow: 13.4 nTPM (baseline 2); cerebellum: 2.3 nTPM (baseline 2); cerebral cortex: 2.6 nTPM (baseline 2); choroid plexus: 3 nTPM (baseline 2); duodenum: 3.1 nTPM (baseline 2); esophagus: 6.7 nTPM (baseline 6); heart muscle: 2.1 nTPM (baseline 2); hippocampal formation: 3 nTPM (baseline 2); hypothalamus: 2.4 nTPM (baseline 2); kidney: 4 nTPM (baseline 2); liver: 3 nTPM (baseline 2); lung: 3.3 nTPM (baseline 2); lymph node: 26.8 nTPM (baseline 6); midbrain: 2.6 nTPM (baseline 2); pancreas: 2.3 nTPM (baseline 2); retina: 4.1 nTPM (baseline 2); small intestine: 7.9 nTPM (baseline 2); spinal cord: 2.7 nTPM (baseline 2); spleen: 10.7 nTPM (baseline 10); thymus: 24.6 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Rectum Adenocarcinoma (validation): 203/207 (98.1%); Colon Adenocarcinoma (validation): 476/486 (97.9%),melanoma: 1/11 (9.1%); breast cancer: 1/12 (8.3%),31,20,Q8IZC7,https://www.uniprot.org/uniprotkb/Q8IZC7/entry,May be involved in transcriptional regulation,Expressed in a variety of adult and fetal tissues,,,Nucleus,,14727140,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
ZNF112,ENSG00000062370,Unsafe,Protein,False,True,7.3,7.3,81,24,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 2.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 2.2 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 2.2 nTPM; absolute ceiling;continuous selectivity; cerebellum: 5.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 2.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 2.9 nTPM; positive ihc;continuous selectivity; duodenum: 2.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 3.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 2.4 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 2.4 nTPM; absolute ceiling;continuous selectivity; kidney: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 2.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 2.5 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 4.3 nTPM; positive ihc;continuous selectivity; pituitary gland: 3.3 nTPM; absolute ceiling;continuous selectivity; retina: 5 nTPM; absolute ceiling;continuous selectivity; salivary gland: 2.9 nTPM; positive ihc;continuous selectivity; skeletal muscle: 1.8 nTPM; positive ihc; small intestine: 2.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 2.8 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 2.9 nTPM (limit 2); amygdala: 2.2 nTPM (limit 2); basal ganglia: 2.2 nTPM (limit 2); cerebellum: 5.7 nTPM (limit 2); cerebral cortex: 2.8 nTPM (limit 2); duodenum: 2.5 nTPM (limit 2); heart muscle: 3.3 nTPM (limit 2); hippocampal formation: 2.4 nTPM (limit 2); hypothalamus: 2.4 nTPM (limit 2); kidney: 2.7 nTPM (limit 2); lung: 2.4 nTPM (limit 2); midbrain: 2.5 nTPM (limit 2); pituitary gland: 3.3 nTPM (limit 2); retina: 5 nTPM (limit 2); small intestine: 2.6 nTPM (limit 2); smooth muscle: 2.7 nTPM (limit 2); spinal cord: 2.8 nTPM (limit 2),adrenal gland / glandular cells: Medium (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Low (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); kidney / cells in tubules: Low (Approved); lung / macrophages: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Medium (Approved); small intestine / glandular cells: Low (Approved); smooth muscle / smooth muscle cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Pancreatic Adenocarcinoma (validation): 47/80 (58.8%); Glioblastoma Multiforme (TCGA): 66/141 (46.8%),melanoma: 4/12 (33.3%); liver cancer: 2/12 (16.7%),29,20,Q9UJU3,https://www.uniprot.org/uniprotkb/Q9UJU3/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF124,ENSG00000196418,Unsafe,RNA,False,True,3.7,6.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 2.2 nTPM; continuous selectivity; adrenal gland: 1.9 nTPM; continuous selectivity; amygdala: 1.2 nTPM; continuous selectivity; basal ganglia: 1.1 nTPM; continuous selectivity; bone marrow: 4.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 1.7 nTPM; continuous selectivity; cerebral cortex: 1.6 nTPM; continuous selectivity; colon: 6 nTPM; continuous selectivity;reproductive not higher; duodenum: 5.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 1.7 nTPM; continuous selectivity; heart muscle: 1.7 nTPM; continuous selectivity; hippocampal formation: 1.4 nTPM; continuous selectivity; hypothalamus: 1.6 nTPM; continuous selectivity; kidney: 3.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; liver: 2.7 nTPM; absolute ceiling;continuous selectivity; lung: 3.4 nTPM; absolute ceiling;continuous selectivity; lymph node: 5.1 nTPM; continuous selectivity;reproductive not higher; midbrain: 1.6 nTPM; continuous selectivity; pancreas: 3.3 nTPM; absolute ceiling;continuous selectivity; rectum: 5.5 nTPM; continuous selectivity;reproductive not higher; retina: 3.1 nTPM; absolute ceiling;continuous selectivity; salivary gland: 2.1 nTPM; continuous selectivity; skeletal muscle: 1.5 nTPM; continuous selectivity; skin: 3 nTPM; continuous selectivity; small intestine: 5.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 2.9 nTPM; absolute ceiling;continuous selectivity; spinal cord: 1.9 nTPM; continuous selectivity; spleen: 4.7 nTPM; continuous selectivity;reproductive not higher; stomach: 3.7 nTPM; continuous selectivity;reproductive not higher; thymus: 5.9 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 2.9 nTPM; continuous selectivity; urinary bladder: 2.7 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 4.5 nTPM (limit 2); duodenum: 5.3 nTPM (limit 2); kidney: 3.9 nTPM (limit 2); liver: 2.7 nTPM (limit 2); lung: 3.4 nTPM (limit 2); pancreas: 3.3 nTPM (limit 2); retina: 3.1 nTPM (limit 2); small intestine: 5.2 nTPM (limit 2); smooth muscle: 2.9 nTPM (limit 2); bone marrow: 4.5 nTPM (baseline 2); duodenum: 5.3 nTPM (baseline 2); kidney: 3.9 nTPM (baseline 2); liver: 2.7 nTPM (baseline 2); lung: 3.4 nTPM (baseline 2); pancreas: 3.3 nTPM (baseline 2); retina: 3.1 nTPM (baseline 2); small intestine: 5.2 nTPM (baseline 2); smooth muscle: 2.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Pancreatic Adenocarcinoma (validation): 80/80 (100.0%),colorectal cancer: 12/12 (100.0%); endometrial cancer: 9/11 (81.8%),31,20,Q15973,https://www.uniprot.org/uniprotkb/Q15973/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF165,ENSG00000197279,Unsafe,RNA,False,True,19.2,19.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,choroid plexus: 4.9 nTPM; absolute ceiling;continuous selectivity; duodenum: 2.9 nTPM; absolute ceiling; kidney: 4.4 nTPM; absolute ceiling; liver: 2.4 nTPM; absolute ceiling; lung: 2.5 nTPM; absolute ceiling; pancreas: 4.6 nTPM; absolute ceiling; parathyroid gland: 6.2 nTPM; absolute ceiling; pituitary gland: 3.7 nTPM; absolute ceiling; retina: 2.2 nTPM; absolute ceiling; small intestine: 2.3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,choroid plexus: 4.9 nTPM (limit 2); duodenum: 2.9 nTPM (limit 2); kidney: 4.4 nTPM (limit 2); liver: 2.4 nTPM (limit 2); lung: 2.5 nTPM (limit 2); pancreas: 4.6 nTPM (limit 2); parathyroid gland: 6.2 nTPM (limit 6); pituitary gland: 3.7 nTPM (limit 2); retina: 2.2 nTPM (limit 2); small intestine: 2.3 nTPM (limit 2); choroid plexus: 4.9 nTPM (baseline 2); duodenum: 2.9 nTPM (baseline 2); kidney: 4.4 nTPM (baseline 2); liver: 2.4 nTPM (baseline 2); lung: 2.5 nTPM (baseline 2); pancreas: 4.6 nTPM (baseline 2); parathyroid gland: 6.2 nTPM (baseline 6); pituitary gland: 3.7 nTPM (baseline 2); retina: 2.2 nTPM (baseline 2); small intestine: 2.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 47/50 (94.0%); Colon Adenocarcinoma (validation): 410/486 (84.4%); Rectum Adenocarcinoma (validation): 147/207 (71.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P49910,https://www.uniprot.org/uniprotkb/P49910/entry,May be involved in transcriptional regulation,Expressed specifically in testis,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Jamin2021_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
ZNF169,ENSG00000175787,Unsafe,Protein,False,True,5.2,5.9,78,77,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 2.9 nTPM; positive ihc;continuous selectivity; adrenal gland: 2.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 3.5 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 4 nTPM; absolute ceiling;continuous selectivity; bone marrow: 3 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 5.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 5.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 1.9 nTPM; continuous selectivity; colon: 4.2 nTPM; positive ihc;continuous selectivity; duodenum: 2.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 2.5 nTPM; positive ihc;continuous selectivity; heart muscle: 2.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 4.7 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 3.1 nTPM; absolute ceiling;continuous selectivity; kidney: 3.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 2.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 3.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 5.8 nTPM; positive ihc;continuous selectivity;reproductive not higher; midbrain: 3.1 nTPM; absolute ceiling;continuous selectivity; pancreas: 3.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 2.2 nTPM; positive ihc;continuous selectivity; pituitary gland: 2.6 nTPM; absolute ceiling;continuous selectivity; rectum: 5.2 nTPM; positive ihc;continuous selectivity;reproductive not higher; retina: 3.9 nTPM; absolute ceiling;continuous selectivity; salivary gland: 3.8 nTPM; positive ihc;continuous selectivity; skeletal muscle: 4 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 4.9 nTPM; positive ihc;continuous selectivity; small intestine: 5.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 3.5 nTPM; absolute ceiling;continuous selectivity; spleen: 5.9 nTPM; positive ihc;continuous selectivity;reproductive not higher; stomach: 3.9 nTPM; positive ihc;continuous selectivity; thymus: 3.6 nTPM; continuous selectivity; thyroid gland: 4.7 nTPM; positive ihc;continuous selectivity; urinary bladder: 3.9 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 2.6 nTPM (limit 2); amygdala: 3.5 nTPM (limit 2); basal ganglia: 4 nTPM (limit 2); bone marrow: 3 nTPM (limit 2); cerebellum: 5.9 nTPM (limit 2); cerebral cortex: 5.4 nTPM (limit 2); duodenum: 2.8 nTPM (limit 2); heart muscle: 2.5 nTPM (limit 2); hippocampal formation: 4.7 nTPM (limit 2); hypothalamus: 3.1 nTPM (limit 2); kidney: 3.6 nTPM (limit 2); liver: 2.1 nTPM (limit 2); lung: 3.1 nTPM (limit 2); midbrain: 3.1 nTPM (limit 2); pancreas: 3.2 nTPM (limit 2); pituitary gland: 2.6 nTPM (limit 2); retina: 3.9 nTPM (limit 2); skeletal muscle: 4 nTPM (limit 2); small intestine: 5.5 nTPM (limit 2); smooth muscle: 2.7 nTPM (limit 2); spinal cord: 3.5 nTPM (limit 2); adrenal gland: 2.6 nTPM (baseline 2); amygdala: 3.5 nTPM (baseline 2); basal ganglia: 4 nTPM (baseline 2); bone marrow: 3 nTPM (baseline 2); cerebellum: 5.9 nTPM (baseline 2); cerebral cortex: 5.4 nTPM (baseline 2); duodenum: 2.8 nTPM (baseline 2); heart muscle: 2.5 nTPM (baseline 2); hippocampal formation: 4.7 nTPM (baseline 2); hypothalamus: 3.1 nTPM (baseline 2); kidney: 3.6 nTPM (baseline 2); liver: 2.1 nTPM (baseline 2); lung: 3.1 nTPM (baseline 2); midbrain: 3.1 nTPM (baseline 2); pancreas: 3.2 nTPM (baseline 2); pituitary gland: 2.6 nTPM (baseline 2); retina: 3.9 nTPM (baseline 2); skeletal muscle: 4 nTPM (baseline 2); small intestine: 5.5 nTPM (baseline 2); smooth muscle: 2.7 nTPM (baseline 2); spinal cord: 3.5 nTPM (baseline 2),adipose tissue / adipocytes: High (Uncertain); adrenal gland / glandular cells: High (Uncertain); bone marrow / hematopoietic cells: High (Uncertain); bronchus / respiratory epithelial cells: High (Uncertain); caudate / glial cells: High (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: Medium (Uncertain); cerebellum / cells in molecular layer: Medium (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / endothelial cells: Medium (Uncertain); cerebral cortex / glial cells: Medium (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); colon / endothelial cells: High (Uncertain); colon / glandular cells: High (Uncertain); colon / peripheral nerve/ganglion: High (Uncertain); duodenum / glandular cells: High (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / glial cells: High (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in glomeruli: High (Uncertain); kidney / cells in tubules: High (Uncertain); liver / cholangiocytes: Low (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / alveolar cells: Medium (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / germinal center cells: High (Uncertain); lymph node / non-germinal center cells: High (Uncertain); nasopharynx / respiratory epithelial cells: High (Uncertain); oral mucosa / squamous epithelial cells: High (Uncertain); pancreas / exocrine glandular cells: High (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: High (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: Medium (Uncertain); skin 1 / fibroblasts: Medium (Uncertain); skin 1 / keratinocytes: High (Uncertain); skin 1 / Langerhans: High (Uncertain); skin 2 / epidermal cells: High (Uncertain); small intestine / glandular cells: High (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); spleen / cells in red pulp: High (Uncertain); spleen / cells in white pulp: High (Uncertain); stomach 1 / glandular cells: High (Uncertain); stomach 2 / glandular cells: High (Uncertain); thyroid gland / glandular cells: High (Uncertain); urinary bladder / urothelial cells: High (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 200/207 (96.6%); Colon Adenocarcinoma (validation): 469/486 (96.5%); Breast Invasive Carcinoma (validation): 47/50 (94.0%),lymphoma: 12/12 (100.0%); breast cancer: 11/11 (100.0%),31,20,Q14929,https://www.uniprot.org/uniprotkb/Q14929/entry,May be involved in transcriptional regulation,"Highly expressed in kidney, weakly expressed in heart, liver, spleen, and small intestine. Not expressed in adult brain or spinal cord",,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF174,ENSG00000103343,Unsafe,Protein,False,True,11.4,13.6,79,59,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 6.5 nTPM; positive ihc;continuous selectivity; adrenal gland: 6.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 6.1 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 6.6 nTPM; absolute ceiling;continuous selectivity; bone marrow: 4 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 8.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 7.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 6 nTPM; absolute ceiling;continuous selectivity; colon: 10.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 6 nTPM; absolute ceiling;continuous selectivity; esophagus: 5.9 nTPM; positive ihc;continuous selectivity; heart muscle: 9.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 6.6 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 6.8 nTPM; absolute ceiling;continuous selectivity; kidney: 6.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 6.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 5.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 8 nTPM; continuous selectivity; midbrain: 6.6 nTPM; absolute ceiling;continuous selectivity; pancreas: 5.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 13.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 9 nTPM; absolute ceiling;continuous selectivity; rectum: 6.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 9.6 nTPM; absolute ceiling;continuous selectivity; salivary gland: 7.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 9.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 7.2 nTPM; positive ihc;continuous selectivity; small intestine: 6.3 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 10 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 8.1 nTPM; absolute ceiling;continuous selectivity; spleen: 7.1 nTPM; continuous selectivity; stomach: 6.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 9.3 nTPM; continuous selectivity; thyroid gland: 7.3 nTPM; positive ihc;continuous selectivity; tongue: 10.2 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 8.7 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 6.8 nTPM (limit 2); amygdala: 6.1 nTPM (limit 2); basal ganglia: 6.6 nTPM (limit 2); bone marrow: 4 nTPM (limit 2); cerebellum: 8.8 nTPM (limit 2); cerebral cortex: 7.3 nTPM (limit 2); choroid plexus: 6 nTPM (limit 2); colon: 10.1 nTPM (limit 6); duodenum: 6 nTPM (limit 4); heart muscle: 9.7 nTPM (limit 2); hippocampal formation: 6.6 nTPM (limit 2); hypothalamus: 6.8 nTPM (limit 2); kidney: 6.4 nTPM (limit 2); liver: 6.5 nTPM (limit 2); lung: 5.2 nTPM (limit 2); midbrain: 6.6 nTPM (limit 2); pancreas: 5.7 nTPM (limit 2); parathyroid gland: 13.6 nTPM (limit 6); pituitary gland: 9 nTPM (limit 2); rectum: 6.9 nTPM (limit 6); retina: 9.6 nTPM (limit 2); salivary gland: 7.7 nTPM (limit 6); skeletal muscle: 9.5 nTPM (limit 2); small intestine: 6.3 nTPM (limit 4); smooth muscle: 10 nTPM (limit 2); spinal cord: 8.1 nTPM (limit 2); stomach: 6.6 nTPM (limit 6); tongue: 10.2 nTPM (limit 6); urinary bladder: 8.7 nTPM (limit 6),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: High (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: High (Approved); cerebellum / cells in molecular layer: High (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / glial cells: High (Approved); cerebral cortex / neuronal cells: High (Approved); colon / peripheral nerve/ganglion: Low (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: High (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Low (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); nasopharynx / respiratory epithelial cells: High (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Low (Approved); skin 1 / keratinocytes: Low (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: Low (Approved); smooth muscle / smooth muscle cells: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: High (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (TCGA): 141/141 (100.0%); Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%),glioma: 10/12 (83.3%); melanoma: 9/12 (75.0%),31,20,Q15697,https://www.uniprot.org/uniprotkb/Q15697/entry,Transcriptional repressor,"Expressed in a variety of organs, but most strongly in adult testis and ovary followed by small intestine, colon, prostate, thymus, spleen, pancreas, skeletal muscle, heart, brain and kidney. Also expressed in umbilical vein endothelial cells, foreskin fibroblast and Hep-G2 cells",,,Nucleus,7673192,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
ZNF19,ENSG00000157429,Unsafe,Protein,False,True,15.5,15.5,100,53,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 2.7 nTPM; positive ihc;absolute ceiling; cerebellum: 0.9 nTPM; positive ihc; cerebral cortex: 4.6 nTPM; absolute ceiling; choroid plexus: 9 nTPM; absolute ceiling;continuous selectivity; colon: 2.3 nTPM; positive ihc; duodenum: 3.6 nTPM; positive ihc;absolute ceiling; esophagus: 4.2 nTPM; positive ihc; heart muscle: 4.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; kidney: 3.4 nTPM; positive ihc;absolute ceiling; liver: 2.1 nTPM; positive ihc;absolute ceiling; lung: 4.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 2.9 nTPM; positive ihc; pancreas: 6 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 4.2 nTPM; positive ihc; pituitary gland: 5.2 nTPM; absolute ceiling;continuous selectivity; rectum: 2 nTPM; positive ihc; retina: 10.6 nTPM; absolute ceiling;continuous selectivity; salivary gland: 3.3 nTPM; positive ihc; skeletal muscle: 9.3 nTPM; absolute ceiling;continuous selectivity; skin: 6.2 nTPM; positive ihc; small intestine: 2.9 nTPM; positive ihc;absolute ceiling; spleen: 2.7 nTPM; positive ihc; stomach: 2.7 nTPM; positive ihc; thyroid gland: 7.8 nTPM; positive ihc;continuous selectivity; urinary bladder: 1.6 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 2.7 nTPM (limit 2); cerebral cortex: 4.6 nTPM (limit 4); choroid plexus: 9 nTPM (limit 2); duodenum: 3.6 nTPM (limit 2); heart muscle: 4.1 nTPM (limit 2); kidney: 3.4 nTPM (limit 2); liver: 2.1 nTPM (limit 2); lung: 4.2 nTPM (limit 2); pancreas: 6 nTPM (limit 2); pituitary gland: 5.2 nTPM (limit 2); retina: 10.6 nTPM (limit 2); skeletal muscle: 9.3 nTPM (limit 4); small intestine: 2.9 nTPM (limit 2),adrenal gland / glandular cells: Low (Approved); caudate / glial cells: Low (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Low (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Low (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Low (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / basal cells: High (Approved); nasopharynx / ciliated cells (cell body): Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skin 1 / Langerhans: Medium (Approved); small intestine / glandular cells: Medium (Approved); spleen / cells in red pulp: Medium (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Low (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 203/207 (98.1%); Colon Adenocarcinoma (validation): 469/486 (96.5%); Breast Invasive Carcinoma (validation): 46/50 (92.0%),liver cancer: 6/10 (60.0%); prostate cancer: 7/12 (58.3%),31,20,P17023,https://www.uniprot.org/uniprotkb/P17023/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF2,ENSG00000275111,Unsafe,RNA,False,True,4.2,4.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 2.5 nTPM; absolute ceiling;continuous selectivity; amygdala: 1.6 nTPM; continuous selectivity; basal ganglia: 1.8 nTPM; continuous selectivity; cerebellum: 2.2 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 2.4 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 1.4 nTPM; continuous selectivity; colon: 2.3 nTPM; continuous selectivity; duodenum: 2 nTPM; continuous selectivity; esophagus: 2.2 nTPM; continuous selectivity; heart muscle: 2.9 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 1.7 nTPM; continuous selectivity; hypothalamus: 1.6 nTPM; continuous selectivity; kidney: 2.5 nTPM; absolute ceiling;continuous selectivity; liver: 1.8 nTPM; continuous selectivity; lung: 2.3 nTPM; absolute ceiling;continuous selectivity; lymph node: 2.9 nTPM; continuous selectivity; midbrain: 1.6 nTPM; continuous selectivity; pancreas: 2.1 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 3.7 nTPM; continuous selectivity; pituitary gland: 1.8 nTPM; continuous selectivity; rectum: 1.7 nTPM; continuous selectivity; retina: 2.7 nTPM; absolute ceiling;continuous selectivity; salivary gland: 2.1 nTPM; continuous selectivity; skeletal muscle: 2.9 nTPM; absolute ceiling;continuous selectivity; skin: 2.8 nTPM; continuous selectivity; small intestine: 1.7 nTPM; continuous selectivity; smooth muscle: 2.5 nTPM; absolute ceiling;continuous selectivity; spinal cord: 1.8 nTPM; continuous selectivity; spleen: 2.7 nTPM; continuous selectivity; stomach: 2.3 nTPM; continuous selectivity; thymus: 3.1 nTPM; continuous selectivity; thyroid gland: 3 nTPM; continuous selectivity; tongue: 3.5 nTPM; continuous selectivity; urinary bladder: 2.2 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 2.5 nTPM (limit 2); cerebellum: 2.2 nTPM (limit 2); cerebral cortex: 2.4 nTPM (limit 2); heart muscle: 2.9 nTPM (limit 2); kidney: 2.5 nTPM (limit 2); lung: 2.3 nTPM (limit 2); pancreas: 2.1 nTPM (limit 2); retina: 2.7 nTPM (limit 2); skeletal muscle: 2.9 nTPM (limit 2); smooth muscle: 2.5 nTPM (limit 2); adrenal gland: 2.5 nTPM (baseline 2); cerebellum: 2.2 nTPM (baseline 2); cerebral cortex: 2.4 nTPM (baseline 2); heart muscle: 2.9 nTPM (baseline 2); kidney: 2.5 nTPM (baseline 2); lung: 2.3 nTPM (baseline 2); pancreas: 2.1 nTPM (baseline 2); retina: 2.7 nTPM (baseline 2); skeletal muscle: 2.9 nTPM (baseline 2); smooth muscle: 2.5 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 43/50 (86.0%); Testicular Germ Cell Tumor (TCGA): 57/133 (42.9%); Rectum Adenocarcinoma (validation): 80/207 (38.6%),ovarian cancer: 9/12 (75.0%); pancreatic cancer: 7/10 (70.0%),28,20,Q9BSG1,https://www.uniprot.org/uniprotkb/Q9BSG1/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF208,ENSG00000160321,Unsafe,RNA,False,True,8.2,12.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 4 nTPM; continuous selectivity; amygdala: 2.2 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 2.4 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 2.8 nTPM; absolute ceiling;continuous selectivity; colon: 4.7 nTPM; continuous selectivity; heart muscle: 10.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 4 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 8.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 4.4 nTPM; absolute ceiling;continuous selectivity; midbrain: 8 nTPM; absolute ceiling;continuous selectivity; pancreas: 2.1 nTPM; absolute ceiling; parathyroid gland: 12.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 6.9 nTPM; absolute ceiling;continuous selectivity; retina: 2.3 nTPM; absolute ceiling;continuous selectivity; skin: 3.8 nTPM; continuous selectivity; small intestine: 2.1 nTPM; absolute ceiling; smooth muscle: 5.8 nTPM; absolute ceiling;continuous selectivity; spinal cord: 4.4 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 7.5 nTPM; continuous selectivity; urinary bladder: 3.1 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 2.2 nTPM (limit 2); basal ganglia: 2.4 nTPM (limit 2); cerebral cortex: 2.8 nTPM (limit 2); heart muscle: 10.9 nTPM (limit 2); hippocampal formation: 4 nTPM (limit 2); hypothalamus: 8.7 nTPM (limit 2); kidney: 4.4 nTPM (limit 2); midbrain: 8 nTPM (limit 2); pancreas: 2.1 nTPM (limit 2); parathyroid gland: 12.8 nTPM (limit 6); pituitary gland: 6.9 nTPM (limit 2); retina: 2.3 nTPM (limit 2); small intestine: 2.1 nTPM (limit 2); smooth muscle: 5.8 nTPM (limit 2); spinal cord: 4.4 nTPM (limit 2); amygdala: 2.2 nTPM (baseline 2); basal ganglia: 2.4 nTPM (baseline 2); cerebral cortex: 2.8 nTPM (baseline 2); heart muscle: 10.9 nTPM (baseline 2); hippocampal formation: 4 nTPM (baseline 2); hypothalamus: 8.7 nTPM (baseline 2); kidney: 4.4 nTPM (baseline 2); midbrain: 8 nTPM (baseline 2); pancreas: 2.1 nTPM (baseline 2); parathyroid gland: 12.8 nTPM (baseline 6); pituitary gland: 6.9 nTPM (baseline 2); retina: 2.3 nTPM (baseline 2); small intestine: 2.1 nTPM (baseline 2); smooth muscle: 5.8 nTPM (baseline 2); spinal cord: 4.4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 123/133 (92.5%); Thyroid Carcinoma (TCGA): 429/495 (86.7%); Rectum Adenocarcinoma (validation): 117/207 (56.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O43345,https://www.uniprot.org/uniprotkb/O43345/entry,May be involved in transcriptional regulation,Ubiquitous,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF214,ENSG00000149050,Unsafe,RNA,False,True,3.7,5.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,basal ganglia: 1.3 nTPM; continuous selectivity; cerebellum: 1.1 nTPM; continuous selectivity; cerebral cortex: 1.4 nTPM; continuous selectivity; choroid plexus: 1.6 nTPM; continuous selectivity; hypothalamus: 1.1 nTPM; continuous selectivity; kidney: 2.3 nTPM; absolute ceiling;continuous selectivity; liver: 1.2 nTPM; continuous selectivity; lung: 1.2 nTPM; continuous selectivity; parathyroid gland: 2.4 nTPM; continuous selectivity; pituitary gland: 1.3 nTPM; continuous selectivity; retina: 5.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 1.7 nTPM; continuous selectivity; thyroid gland: 3.3 nTPM; continuous selectivity; urinary bladder: 1.4 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,kidney: 2.3 nTPM (limit 2); retina: 5.2 nTPM (limit 2); kidney: 2.3 nTPM (baseline 2); retina: 5.2 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 46/58 (79.3%); Breast Invasive Carcinoma (validation): 34/50 (68.0%); Pancreatic Adenocarcinoma (validation): 12/80 (15.0%),colorectal cancer: 4/11 (36.4%); breast cancer: 1/11 (9.1%),31,20,Q9UL59,https://www.uniprot.org/uniprotkb/Q9UL59/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF215,ENSG00000149054,Unsafe,Protein,False,True,1.5,4.1,86,17,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; bone marrow: 0.7 nTPM; positive ihc;continuous selectivity; colon: 2 nTPM; continuous selectivity;reproductive not higher; duodenum: 2.1 nTPM; continuous selectivity;reproductive not higher; heart muscle: 0.4 nTPM; positive ihc; hypothalamus: 0.6 nTPM; continuous selectivity; kidney: 1 nTPM; continuous selectivity; lung: 0.5 nTPM; positive ihc;continuous selectivity; lymph node: 3.3 nTPM; positive ihc;continuous selectivity;reproductive not higher; pancreas: 2.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; rectum: 2.5 nTPM; continuous selectivity;reproductive not higher; salivary gland: 1.3 nTPM; continuous selectivity; skin: 0.5 nTPM; positive ihc; small intestine: 1.9 nTPM; continuous selectivity;reproductive not higher; smooth muscle: 0.5 nTPM; positive ihc;continuous selectivity; spleen: 1.6 nTPM; positive ihc;continuous selectivity;reproductive not higher; thymus: 1.1 nTPM; continuous selectivity; thyroid gland: 0.8 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",pancreas: 2.2 nTPM (limit 2),bone marrow / hematopoietic cells: Medium (Enhanced); heart muscle / cardiomyocytes: Low (Enhanced); lung / alveolar cells: Low (Enhanced); lymph node / non-germinal center cells: Low (Enhanced); pancreas / exocrine glandular cells: Low (Enhanced); skin 2 / epidermal cells: Low (Enhanced); smooth muscle / smooth muscle cells: Low (Enhanced); spleen / cells in red pulp: Medium (Enhanced); thyroid gland / glandular cells: Medium (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 139/207 (67.1%); Colon Adenocarcinoma (validation): 313/486 (64.4%); Pancreatic Adenocarcinoma (validation): 20/80 (25.0%),liver cancer: 1/9 (11.1%); breast cancer: 0/12 (0.0%),31,20,Q9UL58,https://www.uniprot.org/uniprotkb/Q9UL58/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF221,ENSG00000159905,Unsafe,RNA,False,True,1.5,2.9,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 0.8 nTPM; continuous selectivity; adrenal gland: 1.1 nTPM; continuous selectivity; amygdala: 0.5 nTPM; continuous selectivity; basal ganglia: 0.5 nTPM; continuous selectivity; bone marrow: 0.5 nTPM; continuous selectivity; cerebellum: 2.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 1.5 nTPM; continuous selectivity;reproductive not higher; choroid plexus: 0.7 nTPM; continuous selectivity; colon: 0.7 nTPM; continuous selectivity; duodenum: 0.5 nTPM; continuous selectivity; esophagus: 0.8 nTPM; continuous selectivity; heart muscle: 1.2 nTPM; continuous selectivity; hippocampal formation: 0.5 nTPM; continuous selectivity; hypothalamus: 0.7 nTPM; continuous selectivity; kidney: 1 nTPM; continuous selectivity; liver: 1.1 nTPM; continuous selectivity; lung: 0.9 nTPM; continuous selectivity; midbrain: 0.5 nTPM; continuous selectivity; pancreas: 0.7 nTPM; continuous selectivity; parathyroid gland: 2.2 nTPM; continuous selectivity;reproductive not higher; pituitary gland: 0.9 nTPM; continuous selectivity; rectum: 0.8 nTPM; continuous selectivity; retina: 2.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 0.7 nTPM; continuous selectivity; skin: 1.1 nTPM; continuous selectivity; small intestine: 0.7 nTPM; continuous selectivity; smooth muscle: 1.3 nTPM; continuous selectivity; spinal cord: 0.8 nTPM; continuous selectivity; spleen: 1 nTPM; continuous selectivity; stomach: 0.8 nTPM; continuous selectivity; thymus: 1.1 nTPM; continuous selectivity; thyroid gland: 1.7 nTPM; continuous selectivity;reproductive not higher; tongue: 0.7 nTPM; continuous selectivity; urinary bladder: 1 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebellum: 2.5 nTPM (limit 2); retina: 2.9 nTPM (limit 2); cerebellum: 2.5 nTPM (baseline 2); retina: 2.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Pancreatic Adenocarcinoma (validation): 34/80 (42.5%); Breast Invasive Carcinoma (validation): 13/50 (26.0%),breast cancer: 4/12 (33.3%); ovarian cancer: 2/11 (18.2%),31,20,Q9UK13,https://www.uniprot.org/uniprotkb/Q9UK13/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF223,ENSG00000178386,Unsafe,Protein,False,True,6.3,6.3,73,30,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 3.1 nTPM; continuous selectivity; adrenal gland: 3.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 2.7 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 3.6 nTPM; absolute ceiling;continuous selectivity; bone marrow: 2 nTPM; positive ihc;continuous selectivity; cerebellum: 5.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 4.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 2.2 nTPM; absolute ceiling;continuous selectivity; colon: 4.3 nTPM; positive ihc;continuous selectivity; duodenum: 3.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 2.9 nTPM; positive ihc;continuous selectivity; heart muscle: 4.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 3.1 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 3.6 nTPM; absolute ceiling;continuous selectivity; kidney: 3.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 2.5 nTPM; continuous selectivity; lung: 3.8 nTPM; continuous selectivity; lymph node: 3.5 nTPM; continuous selectivity; midbrain: 2.7 nTPM; absolute ceiling;continuous selectivity; pancreas: 2.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 4.7 nTPM; positive ihc;continuous selectivity; pituitary gland: 4 nTPM; absolute ceiling;continuous selectivity; rectum: 5.5 nTPM; positive ihc;continuous selectivity; retina: 4.3 nTPM; absolute ceiling;continuous selectivity; salivary gland: 3.5 nTPM; positive ihc;continuous selectivity; skin: 4.8 nTPM; continuous selectivity; small intestine: 4.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 3.7 nTPM; continuous selectivity; spinal cord: 2.5 nTPM; absolute ceiling;continuous selectivity; spleen: 4.8 nTPM; continuous selectivity; stomach: 4.7 nTPM; positive ihc;continuous selectivity; thyroid gland: 6.2 nTPM; positive ihc;continuous selectivity; urinary bladder: 3.8 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 3.6 nTPM (limit 2); amygdala: 2.7 nTPM (limit 2); basal ganglia: 3.6 nTPM (limit 2); cerebellum: 5.1 nTPM (limit 2); cerebral cortex: 4.2 nTPM (limit 2); choroid plexus: 2.2 nTPM (limit 2); duodenum: 3.9 nTPM (limit 2); heart muscle: 4.7 nTPM (limit 2); hippocampal formation: 3.1 nTPM (limit 2); hypothalamus: 3.6 nTPM (limit 2); kidney: 3.8 nTPM (limit 2); midbrain: 2.7 nTPM (limit 2); pancreas: 2.8 nTPM (limit 2); pituitary gland: 4 nTPM (limit 2); retina: 4.3 nTPM (limit 2); small intestine: 4.2 nTPM (limit 2); spinal cord: 2.5 nTPM (limit 2),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: High (Approved); heart muscle / cardiomyocytes: High (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in tubules: Low (Approved); pancreas / exocrine glandular cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 43/50 (86.0%); Glioblastoma Multiforme (validation): 47/58 (81.0%); Rectum Adenocarcinoma (validation): 167/207 (80.7%),stomach cancer: 8/11 (72.7%); urothelial cancer: 6/12 (50.0%),31,20,Q9UK11,https://www.uniprot.org/uniprotkb/Q9UK11/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF225,ENSG00000256294,Unsafe,RNA,False,True,12.4,12.4,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 3.1 nTPM; absolute ceiling; bone marrow: 2.3 nTPM; absolute ceiling; cerebellum: 3.2 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 3.3 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 3.8 nTPM; absolute ceiling;continuous selectivity; duodenum: 2.4 nTPM; absolute ceiling; heart muscle: 3.1 nTPM; absolute ceiling; kidney: 2.9 nTPM; absolute ceiling; liver: 2.7 nTPM; absolute ceiling; lung: 2.7 nTPM; absolute ceiling; parathyroid gland: 4.3 nTPM; continuous selectivity; pituitary gland: 2.4 nTPM; absolute ceiling; retina: 6.7 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 2.5 nTPM; absolute ceiling; small intestine: 2.1 nTPM; absolute ceiling; smooth muscle: 2.4 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 3.1 nTPM (limit 2); bone marrow: 2.3 nTPM (limit 2); cerebellum: 3.2 nTPM (limit 2); cerebral cortex: 3.3 nTPM (limit 2); choroid plexus: 3.8 nTPM (limit 2); duodenum: 2.4 nTPM (limit 2); heart muscle: 3.1 nTPM (limit 2); kidney: 2.9 nTPM (limit 2); liver: 2.7 nTPM (limit 2); lung: 2.7 nTPM (limit 2); pituitary gland: 2.4 nTPM (limit 2); retina: 6.7 nTPM (limit 2); skeletal muscle: 2.5 nTPM (limit 2); small intestine: 2.1 nTPM (limit 2); smooth muscle: 2.4 nTPM (limit 2); adrenal gland: 3.1 nTPM (baseline 2); bone marrow: 2.3 nTPM (baseline 2); cerebellum: 3.2 nTPM (baseline 2); cerebral cortex: 3.3 nTPM (baseline 2); choroid plexus: 3.8 nTPM (baseline 2); duodenum: 2.4 nTPM (baseline 2); heart muscle: 3.1 nTPM (baseline 2); kidney: 2.9 nTPM (baseline 2); liver: 2.7 nTPM (baseline 2); lung: 2.7 nTPM (baseline 2); pituitary gland: 2.4 nTPM (baseline 2); retina: 6.7 nTPM (baseline 2); skeletal muscle: 2.5 nTPM (baseline 2); small intestine: 2.1 nTPM (baseline 2); smooth muscle: 2.4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 48/50 (96.0%); Lung Adenocarcinoma (validation): 59/105 (56.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9UK10,https://www.uniprot.org/uniprotkb/Q9UK10/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF227,ENSG00000131115,Unsafe,Protein,False,True,10.5,16.7,80,47,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 6.1 nTPM; continuous selectivity; adrenal gland: 6.7 nTPM; absolute ceiling;continuous selectivity; amygdala: 6.9 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 6.5 nTPM; absolute ceiling;continuous selectivity; bone marrow: 4.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 9.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 6.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 5.3 nTPM; absolute ceiling;continuous selectivity; colon: 6.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 5.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 6.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 5.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 6.8 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 6.7 nTPM; absolute ceiling;continuous selectivity; kidney: 6.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 7.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 5.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 10.1 nTPM; absolute ceiling;continuous selectivity; midbrain: 7.7 nTPM; absolute ceiling;continuous selectivity; pancreas: 6.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 10 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 7.8 nTPM; absolute ceiling;continuous selectivity; rectum: 5.6 nTPM; positive ihc;continuous selectivity; retina: 8.5 nTPM; absolute ceiling;continuous selectivity; salivary gland: 5.4 nTPM; positive ihc;continuous selectivity; skeletal muscle: 6.2 nTPM; absolute ceiling;continuous selectivity; skin: 6.3 nTPM; positive ihc;continuous selectivity; small intestine: 5.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 6.5 nTPM; absolute ceiling;continuous selectivity; spinal cord: 8.2 nTPM; absolute ceiling;continuous selectivity; spleen: 9.2 nTPM; positive ihc;continuous selectivity; stomach: 8.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 16.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 8 nTPM; positive ihc;continuous selectivity; tongue: 6.2 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 6.9 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 6.7 nTPM (limit 2); amygdala: 6.9 nTPM (limit 2); basal ganglia: 6.5 nTPM (limit 2); bone marrow: 4.9 nTPM (limit 2); cerebellum: 9.8 nTPM (limit 2); cerebral cortex: 6.6 nTPM (limit 2); choroid plexus: 5.3 nTPM (limit 2); colon: 6.7 nTPM (limit 6); duodenum: 5.3 nTPM (limit 2); esophagus: 6.4 nTPM (limit 6); heart muscle: 5.5 nTPM (limit 2); hippocampal formation: 6.8 nTPM (limit 2); hypothalamus: 6.7 nTPM (limit 2); kidney: 6.7 nTPM (limit 2); liver: 7.2 nTPM (limit 2); lung: 5.9 nTPM (limit 2); lymph node: 10.1 nTPM (limit 6); midbrain: 7.7 nTPM (limit 2); pancreas: 6.4 nTPM (limit 2); parathyroid gland: 10 nTPM (limit 6); pituitary gland: 7.8 nTPM (limit 2); retina: 8.5 nTPM (limit 2); skeletal muscle: 6.2 nTPM (limit 2); small intestine: 5.6 nTPM (limit 2); smooth muscle: 6.5 nTPM (limit 2); spinal cord: 8.2 nTPM (limit 2); stomach: 8.4 nTPM (limit 6); thymus: 16.7 nTPM (limit 10); tongue: 6.2 nTPM (limit 6); urinary bladder: 6.9 nTPM (limit 6); adrenal gland: 6.7 nTPM (baseline 2); amygdala: 6.9 nTPM (baseline 2); basal ganglia: 6.5 nTPM (baseline 2); bone marrow: 4.9 nTPM (baseline 2); cerebellum: 9.8 nTPM (baseline 2); cerebral cortex: 6.6 nTPM (baseline 2); choroid plexus: 5.3 nTPM (baseline 2); colon: 6.7 nTPM (baseline 6); duodenum: 5.3 nTPM (baseline 2); esophagus: 6.4 nTPM (baseline 6); heart muscle: 5.5 nTPM (baseline 2); hippocampal formation: 6.8 nTPM (baseline 2); hypothalamus: 6.7 nTPM (baseline 2); kidney: 6.7 nTPM (baseline 2); liver: 7.2 nTPM (baseline 2); lung: 5.9 nTPM (baseline 2); lymph node: 10.1 nTPM (baseline 6); midbrain: 7.7 nTPM (baseline 2); pancreas: 6.4 nTPM (baseline 2); parathyroid gland: 10 nTPM (baseline 6); pituitary gland: 7.8 nTPM (baseline 2); retina: 8.5 nTPM (baseline 2); skeletal muscle: 6.2 nTPM (baseline 2); small intestine: 5.6 nTPM (baseline 2); smooth muscle: 6.5 nTPM (baseline 2); spinal cord: 8.2 nTPM (baseline 2); stomach: 8.4 nTPM (baseline 6); thymus: 16.7 nTPM (baseline 10); tongue: 6.2 nTPM (baseline 6); urinary bladder: 6.9 nTPM (baseline 6),bone marrow / hematopoietic cells: Medium (Uncertain); caudate / neuronal cells: Low (Uncertain); cerebellum / cells in molecular layer: Medium (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / glial cells: Low (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / endothelial cells: Medium (Uncertain); colon / glandular cells: Medium (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: Low (Uncertain); hippocampus / neuronal cells: Low (Uncertain); kidney / cells in tubules: Low (Uncertain); liver / hepatocytes: Low (Uncertain); lung / alveolar cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Low (Uncertain); pancreas / pancreatic endocrine cells: Low (Uncertain); parathyroid gland / glandular cells: Low (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Low (Uncertain); skin 1 / keratinocytes: Medium (Uncertain); skin 1 / Langerhans: Medium (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: Medium (Uncertain); spleen / cells in red pulp: High (Uncertain); stomach 1 / glandular cells: Low (Uncertain); stomach 2 / glandular cells: Low (Uncertain); thyroid gland / glandular cells: Low (Uncertain); urinary bladder / urothelial cells: Low (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 80/80 (100.0%); Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%),colorectal cancer: 4/12 (33.3%); liver cancer: 2/11 (18.2%),31,20,Q86WZ6,https://www.uniprot.org/uniprotkb/Q86WZ6/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF229,ENSG00000278318,Unsafe,RNA,False,True,2.1,4.3,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 1.6 nTPM; continuous selectivity; amygdala: 1.1 nTPM; continuous selectivity; basal ganglia: 1.4 nTPM; continuous selectivity; cerebellum: 0.9 nTPM; continuous selectivity; cerebral cortex: 1.3 nTPM; continuous selectivity; choroid plexus: 1.4 nTPM; continuous selectivity; colon: 0.9 nTPM; continuous selectivity; duodenum: 0.7 nTPM; continuous selectivity; heart muscle: 1.4 nTPM; continuous selectivity; hippocampal formation: 0.9 nTPM; continuous selectivity; hypothalamus: 1.1 nTPM; continuous selectivity; kidney: 0.8 nTPM; continuous selectivity; midbrain: 1.1 nTPM; continuous selectivity; pancreas: 0.7 nTPM; continuous selectivity; parathyroid gland: 2.6 nTPM; continuous selectivity;reproductive not higher; pituitary gland: 1.2 nTPM; continuous selectivity; retina: 4.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 0.7 nTPM; continuous selectivity; smooth muscle: 0.8 nTPM; continuous selectivity; spinal cord: 0.9 nTPM; continuous selectivity; thymus: 1.1 nTPM; continuous selectivity; thyroid gland: 1.9 nTPM; continuous selectivity; tongue: 1.1 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 4.3 nTPM (limit 2); retina: 4.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 32/50 (64.0%); Testicular Germ Cell Tumor (TCGA): 46/133 (34.6%); Kidney Chromophobe (TCGA): 7/64 (10.9%),glioma: 7/11 (63.6%); melanoma: 5/8 (62.5%),28,20,Q9UJW7,https://www.uniprot.org/uniprotkb/Q9UJW7/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF23,ENSG00000167377,Unsafe,RNA,False,True,7.7,15.4,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 5.3 nTPM; continuous selectivity; adrenal gland: 4.1 nTPM; absolute ceiling;continuous selectivity; amygdala: 5.5 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 5.6 nTPM; absolute ceiling;continuous selectivity; bone marrow: 4.3 nTPM; absolute ceiling;continuous selectivity; cerebellum: 10.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 6.4 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 15.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 5.4 nTPM; continuous selectivity; duodenum: 2.9 nTPM; absolute ceiling;continuous selectivity; esophagus: 4 nTPM; continuous selectivity; heart muscle: 5 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 6.2 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 6 nTPM; absolute ceiling;continuous selectivity; kidney: 5.5 nTPM; absolute ceiling;continuous selectivity; liver: 5.2 nTPM; absolute ceiling;continuous selectivity; lung: 5.2 nTPM; absolute ceiling;continuous selectivity; lymph node: 6 nTPM; continuous selectivity; midbrain: 4.9 nTPM; absolute ceiling;continuous selectivity; pancreas: 4.4 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 5 nTPM; continuous selectivity; pituitary gland: 13.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 5.4 nTPM; continuous selectivity; retina: 15.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 4.2 nTPM; continuous selectivity; skeletal muscle: 6.6 nTPM; absolute ceiling;continuous selectivity; skin: 5.5 nTPM; continuous selectivity; small intestine: 4.9 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 6.6 nTPM; absolute ceiling;continuous selectivity; spinal cord: 5.8 nTPM; absolute ceiling;continuous selectivity; spleen: 5.6 nTPM; continuous selectivity; stomach: 4 nTPM; continuous selectivity; thymus: 4.6 nTPM; continuous selectivity; thyroid gland: 7.2 nTPM; continuous selectivity; tongue: 6.9 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 4.1 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 4.1 nTPM (limit 2); amygdala: 5.5 nTPM (limit 2); basal ganglia: 5.6 nTPM (limit 2); bone marrow: 4.3 nTPM (limit 2); cerebellum: 10.5 nTPM (limit 2); cerebral cortex: 6.4 nTPM (limit 2); choroid plexus: 15.4 nTPM (limit 2); duodenum: 2.9 nTPM (limit 2); heart muscle: 5 nTPM (limit 2); hippocampal formation: 6.2 nTPM (limit 2); hypothalamus: 6 nTPM (limit 2); kidney: 5.5 nTPM (limit 2); liver: 5.2 nTPM (limit 2); lung: 5.2 nTPM (limit 2); midbrain: 4.9 nTPM (limit 2); pancreas: 4.4 nTPM (limit 2); pituitary gland: 13.9 nTPM (limit 2); retina: 15.3 nTPM (limit 2); skeletal muscle: 6.6 nTPM (limit 2); small intestine: 4.9 nTPM (limit 2); smooth muscle: 6.6 nTPM (limit 2); spinal cord: 5.8 nTPM (limit 2); tongue: 6.9 nTPM (limit 6); adrenal gland: 4.1 nTPM (baseline 2); amygdala: 5.5 nTPM (baseline 2); basal ganglia: 5.6 nTPM (baseline 2); bone marrow: 4.3 nTPM (baseline 2); cerebellum: 10.5 nTPM (baseline 2); cerebral cortex: 6.4 nTPM (baseline 2); choroid plexus: 15.4 nTPM (baseline 2); duodenum: 2.9 nTPM (baseline 2); heart muscle: 5 nTPM (baseline 2); hippocampal formation: 6.2 nTPM (baseline 2); hypothalamus: 6 nTPM (baseline 2); kidney: 5.5 nTPM (baseline 2); liver: 5.2 nTPM (baseline 2); lung: 5.2 nTPM (baseline 2); midbrain: 4.9 nTPM (baseline 2); pancreas: 4.4 nTPM (baseline 2); pituitary gland: 13.9 nTPM (baseline 2); retina: 15.3 nTPM (baseline 2); skeletal muscle: 6.6 nTPM (baseline 2); small intestine: 4.9 nTPM (baseline 2); smooth muscle: 6.6 nTPM (baseline 2); spinal cord: 5.8 nTPM (baseline 2); tongue: 6.9 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 47/50 (94.0%); Lung Adenocarcinoma (validation): 96/105 (91.4%); Lung Squamous Cell Carcinoma (validation): 59/68 (86.8%),skin cancer: 10/11 (90.9%); lymphoma: 9/11 (81.8%),31,20,P17027,https://www.uniprot.org/uniprotkb/P17027/entry,May be involved in transcriptional regulation. May have a role in embryonic development,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF230,ENSG00000159882,Unsafe,RNA,False,True,3.4,4.5,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 1.9 nTPM; continuous selectivity; adrenal gland: 2.1 nTPM; absolute ceiling;continuous selectivity; amygdala: 1.2 nTPM; continuous selectivity; basal ganglia: 1.4 nTPM; continuous selectivity; bone marrow: 3.2 nTPM; absolute ceiling;continuous selectivity; cerebellum: 3.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 1.4 nTPM; continuous selectivity; choroid plexus: 2.1 nTPM; absolute ceiling;continuous selectivity; colon: 1.9 nTPM; continuous selectivity; duodenum: 1.2 nTPM; continuous selectivity; esophagus: 1.4 nTPM; continuous selectivity; heart muscle: 1.8 nTPM; continuous selectivity; hippocampal formation: 1.2 nTPM; continuous selectivity; hypothalamus: 1.3 nTPM; continuous selectivity; kidney: 1.7 nTPM; continuous selectivity; liver: 2 nTPM; continuous selectivity; lung: 2.3 nTPM; absolute ceiling;continuous selectivity; lymph node: 3.3 nTPM; continuous selectivity; midbrain: 1.2 nTPM; continuous selectivity; pancreas: 1.4 nTPM; continuous selectivity; parathyroid gland: 2.6 nTPM; continuous selectivity; pituitary gland: 2.6 nTPM; absolute ceiling;continuous selectivity; rectum: 1.9 nTPM; continuous selectivity; retina: 4.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 1.8 nTPM; continuous selectivity; skin: 2.8 nTPM; continuous selectivity; small intestine: 2.3 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 1.8 nTPM; continuous selectivity; spinal cord: 1.4 nTPM; continuous selectivity; spleen: 3.8 nTPM; continuous selectivity;reproductive not higher; stomach: 1.8 nTPM; continuous selectivity; thymus: 3.9 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 2.9 nTPM; continuous selectivity; tongue: 1.8 nTPM; continuous selectivity; urinary bladder: 2 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 2.1 nTPM (limit 2); bone marrow: 3.2 nTPM (limit 2); cerebellum: 3.6 nTPM (limit 2); choroid plexus: 2.1 nTPM (limit 2); lung: 2.3 nTPM (limit 2); pituitary gland: 2.6 nTPM (limit 2); retina: 4.5 nTPM (limit 2); small intestine: 2.3 nTPM (limit 2); adrenal gland: 2.1 nTPM (baseline 2); bone marrow: 3.2 nTPM (baseline 2); cerebellum: 3.6 nTPM (baseline 2); choroid plexus: 2.1 nTPM (baseline 2); lung: 2.3 nTPM (baseline 2); pituitary gland: 2.6 nTPM (baseline 2); retina: 4.5 nTPM (baseline 2); small intestine: 2.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 44/50 (88.0%); Pancreatic Adenocarcinoma (validation): 24/80 (30.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9UIE0,https://www.uniprot.org/uniprotkb/Q9UIE0/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF233,ENSG00000159915,Unsafe,RNA,False,True,14.2,14.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,basal ganglia: 2.3 nTPM; absolute ceiling; cerebellum: 4.2 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 3.1 nTPM; absolute ceiling; heart muscle: 3 nTPM; absolute ceiling; hippocampal formation: 2.3 nTPM; absolute ceiling; hypothalamus: 2.7 nTPM; absolute ceiling; pituitary gland: 3 nTPM; absolute ceiling; retina: 4.7 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,basal ganglia: 2.3 nTPM (limit 2); cerebellum: 4.2 nTPM (limit 2); cerebral cortex: 3.1 nTPM (limit 2); heart muscle: 3 nTPM (limit 2); hippocampal formation: 2.3 nTPM (limit 2); hypothalamus: 2.7 nTPM (limit 2); pituitary gland: 3 nTPM (limit 2); retina: 4.7 nTPM (limit 2); basal ganglia: 2.3 nTPM (baseline 2); cerebellum: 4.2 nTPM (baseline 2); cerebral cortex: 3.1 nTPM (baseline 2); heart muscle: 3 nTPM (baseline 2); hippocampal formation: 2.3 nTPM (baseline 2); hypothalamus: 2.7 nTPM (baseline 2); pituitary gland: 3 nTPM (baseline 2); retina: 4.7 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 175/207 (84.5%); Colon Adenocarcinoma (validation): 390/486 (80.2%); Breast Invasive Carcinoma (validation): 38/50 (76.0%),testis cancer: 10/10 (100.0%); lymphoma: 11/12 (91.7%),31,20,A6NK53,https://www.uniprot.org/uniprotkb/A6NK53/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF257,ENSG00000197134,Unsafe,RNA,False,True,2.6,4.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 4.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 0.8 nTPM; continuous selectivity; lung: 0.8 nTPM; continuous selectivity; lymph node: 2.5 nTPM; continuous selectivity; pancreas: 2.1 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 1 nTPM; continuous selectivity; smooth muscle: 0.8 nTPM; continuous selectivity; spleen: 1.6 nTPM; continuous selectivity; stomach: 1.4 nTPM; continuous selectivity; thymus: 1.6 nTPM; continuous selectivity; thyroid gland: 2.2 nTPM; continuous selectivity; urinary bladder: 1 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 4.1 nTPM (limit 2); pancreas: 2.1 nTPM (limit 2); bone marrow: 4.1 nTPM (baseline 2); pancreas: 2.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 32/50 (64.0%); Glioblastoma Multiforme (validation): 20/58 (34.5%); Testicular Germ Cell Tumor (TCGA): 39/133 (29.3%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9Y2Q1,https://www.uniprot.org/uniprotkb/Q9Y2Q1/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | Jamin2021_CT | Jamin2021_core,GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
ZNF264,ENSG00000083844,Unsafe,RNA,False,True,9.6,9.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 5.9 nTPM; continuous selectivity; adrenal gland: 4.2 nTPM; absolute ceiling;continuous selectivity; amygdala: 2.2 nTPM; absolute ceiling; basal ganglia: 2.6 nTPM; absolute ceiling;continuous selectivity; bone marrow: 8 nTPM; absolute ceiling;continuous selectivity; cerebellum: 3.8 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 3 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 3.1 nTPM; absolute ceiling;continuous selectivity; colon: 3.8 nTPM; continuous selectivity; duodenum: 4.6 nTPM; absolute ceiling;continuous selectivity; esophagus: 4.7 nTPM; continuous selectivity; heart muscle: 3.2 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 2.6 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 2.5 nTPM; absolute ceiling; kidney: 4.8 nTPM; absolute ceiling;continuous selectivity; liver: 5.1 nTPM; absolute ceiling;continuous selectivity; lung: 5.1 nTPM; absolute ceiling;continuous selectivity; lymph node: 6.9 nTPM; absolute ceiling;continuous selectivity; midbrain: 2.4 nTPM; absolute ceiling; pancreas: 7.8 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 6.2 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 4.8 nTPM; absolute ceiling;continuous selectivity; rectum: 4.3 nTPM; continuous selectivity; retina: 8.5 nTPM; absolute ceiling;continuous selectivity; salivary gland: 5 nTPM; continuous selectivity; skeletal muscle: 3.7 nTPM; absolute ceiling;continuous selectivity; skin: 6.6 nTPM; continuous selectivity; small intestine: 5.2 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 5 nTPM; absolute ceiling;continuous selectivity; spinal cord: 2.9 nTPM; absolute ceiling;continuous selectivity; spleen: 8 nTPM; continuous selectivity; stomach: 7.1 nTPM; absolute ceiling;continuous selectivity; thymus: 7.7 nTPM; continuous selectivity; thyroid gland: 7.1 nTPM; continuous selectivity; tongue: 3.8 nTPM; continuous selectivity; urinary bladder: 4.3 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 4.2 nTPM (limit 2); amygdala: 2.2 nTPM (limit 2); basal ganglia: 2.6 nTPM (limit 2); bone marrow: 8 nTPM (limit 2); cerebellum: 3.8 nTPM (limit 2); cerebral cortex: 3 nTPM (limit 2); choroid plexus: 3.1 nTPM (limit 2); duodenum: 4.6 nTPM (limit 2); heart muscle: 3.2 nTPM (limit 2); hippocampal formation: 2.6 nTPM (limit 2); hypothalamus: 2.5 nTPM (limit 2); kidney: 4.8 nTPM (limit 2); liver: 5.1 nTPM (limit 2); lung: 5.1 nTPM (limit 2); lymph node: 6.9 nTPM (limit 6); midbrain: 2.4 nTPM (limit 2); pancreas: 7.8 nTPM (limit 2); parathyroid gland: 6.2 nTPM (limit 6); pituitary gland: 4.8 nTPM (limit 2); retina: 8.5 nTPM (limit 2); skeletal muscle: 3.7 nTPM (limit 2); small intestine: 5.2 nTPM (limit 2); smooth muscle: 5 nTPM (limit 2); spinal cord: 2.9 nTPM (limit 2); stomach: 7.1 nTPM (limit 6); adrenal gland: 4.2 nTPM (baseline 2); amygdala: 2.2 nTPM (baseline 2); basal ganglia: 2.6 nTPM (baseline 2); bone marrow: 8 nTPM (baseline 2); cerebellum: 3.8 nTPM (baseline 2); cerebral cortex: 3 nTPM (baseline 2); choroid plexus: 3.1 nTPM (baseline 2); duodenum: 4.6 nTPM (baseline 2); heart muscle: 3.2 nTPM (baseline 2); hippocampal formation: 2.6 nTPM (baseline 2); hypothalamus: 2.5 nTPM (baseline 2); kidney: 4.8 nTPM (baseline 2); liver: 5.1 nTPM (baseline 2); lung: 5.1 nTPM (baseline 2); lymph node: 6.9 nTPM (baseline 6); midbrain: 2.4 nTPM (baseline 2); pancreas: 7.8 nTPM (baseline 2); parathyroid gland: 6.2 nTPM (baseline 6); pituitary gland: 4.8 nTPM (baseline 2); retina: 8.5 nTPM (baseline 2); skeletal muscle: 3.7 nTPM (baseline 2); small intestine: 5.2 nTPM (baseline 2); smooth muscle: 5 nTPM (baseline 2); spinal cord: 2.9 nTPM (baseline 2); stomach: 7.1 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Pancreatic Adenocarcinoma (validation): 79/80 (98.8%); Rectum Adenocarcinoma (validation): 198/207 (95.7%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,O43296,https://www.uniprot.org/uniprotkb/O43296/entry,May be involved in transcriptional regulation,"Relatively highly expressed in kidney, thymus, testis, ovary, brain, lung, placenta, and prostate, and relatively low expression in heart, liver, skeletal muscle, pancreas, spleen, and small intestine",,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF268,ENSG00000090612,Unsafe,Protein,False,True,9.2,12.6,85,69,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 5.5 nTPM; positive ihc;continuous selectivity; adrenal gland: 6.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 2.9 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 3.1 nTPM; absolute ceiling;continuous selectivity; bone marrow: 3.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 3.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 6.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 4.9 nTPM; absolute ceiling;continuous selectivity; colon: 5.4 nTPM; positive ihc;continuous selectivity; duodenum: 4.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 6.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 4.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 2.5 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 2.8 nTPM; absolute ceiling;continuous selectivity; kidney: 9 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 12.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 5.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 6 nTPM; continuous selectivity; midbrain: 2.4 nTPM; absolute ceiling; pancreas: 5.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 12.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 3.8 nTPM; absolute ceiling;continuous selectivity; rectum: 5.2 nTPM; positive ihc;continuous selectivity; retina: 11.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 5.4 nTPM; positive ihc;continuous selectivity; skeletal muscle: 2.3 nTPM; positive ihc;absolute ceiling; skin: 5 nTPM; positive ihc;continuous selectivity; small intestine: 5 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 5.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 2.5 nTPM; absolute ceiling;continuous selectivity; spleen: 5.8 nTPM; positive ihc;continuous selectivity; stomach: 7 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 7.1 nTPM; continuous selectivity; thyroid gland: 10.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; tongue: 4.7 nTPM; continuous selectivity; urinary bladder: 6.1 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 6.3 nTPM (limit 2); amygdala: 2.9 nTPM (limit 2); basal ganglia: 3.1 nTPM (limit 2); bone marrow: 3.5 nTPM (limit 2); cerebellum: 3.5 nTPM (limit 2); cerebral cortex: 6.6 nTPM (limit 2); choroid plexus: 4.9 nTPM (limit 2); duodenum: 4.3 nTPM (limit 2); esophagus: 6.2 nTPM (limit 6); heart muscle: 4.2 nTPM (limit 2); hippocampal formation: 2.5 nTPM (limit 2); hypothalamus: 2.8 nTPM (limit 2); kidney: 9 nTPM (limit 2); liver: 12.4 nTPM (limit 2); lung: 5.4 nTPM (limit 2); midbrain: 2.4 nTPM (limit 2); pancreas: 5.1 nTPM (limit 2); parathyroid gland: 12.6 nTPM (limit 6); pituitary gland: 3.8 nTPM (limit 2); retina: 11.6 nTPM (limit 2); skeletal muscle: 2.3 nTPM (limit 2); small intestine: 5 nTPM (limit 2); smooth muscle: 5.6 nTPM (limit 2); spinal cord: 2.5 nTPM (limit 2); stomach: 7 nTPM (limit 6); thyroid gland: 10.4 nTPM (limit 10); urinary bladder: 6.1 nTPM (limit 6),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: High (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: High (Approved); lung / macrophages: High (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Low (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: High (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / fibroblasts: High (Approved); skin 1 / keratinocytes: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: High (Approved); spleen / cells in red pulp: Medium (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Pancreatic Adenocarcinoma (validation): 78/80 (97.5%); Lung Adenocarcinoma (validation): 102/105 (97.1%),ovarian cancer: 12/12 (100.0%); breast cancer: 11/11 (100.0%),31,20,Q14587,https://www.uniprot.org/uniprotkb/Q14587/entry,"Acts as a transcriptional repressor. Inhibits erythroid differentiation and tumor cell proliferation. Plays a role during ovarian cancer development and progression Contributes to cervical carcinogenesis in part through the TNF-induced NF-kappa-B signaling pathway by interacting with the I-kappa-B-kinase (IKK) core complex Involved in the regulation of antiviral interferon signaling. During viral infection, recruits SETD4 to TBK1, leading to TBK1 monomethylation, which is critical for the assembly of TBK1 complex and IRF3 signaling","Overexpressed in ovarian cancer tissues compared to normal ovarian tissues. Isoform 1 and isoform 2 are expressed in squamous epithelium tissues. Isoform 2 is overexpressed in squamous cervical cancer (at protein level). Expressed in blood cells. Isoform 1 is expressed in pancreas, lung, skeletal muscle, heart, placenta, liver, kidney and brain. Isoform 2 expressed in chronic lymphocytic leukemia (CLL) and several tumor cell lines. Isoform 3 is expressed in several tumor cells. Isoform 5 is expressed in fetal liver and several tumor cells. Isoform 6 is weakly expressed in brain, lung amd small intestin and in several tumor cells. Isoform 7 is expressed in fetal liver and several tumor cells",,,Nucleus Cytoplasm,37926288,12200376|16735226|16865230|18949428|23091055|23946776,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF280B,ENSG00000275004,Unsafe,RNA,False,True,13.0,13.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,cerebellum: 2.4 nTPM; absolute ceiling; cerebral cortex: 2.6 nTPM; absolute ceiling; hypothalamus: 3 nTPM; absolute ceiling; retina: 3.2 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebellum: 2.4 nTPM (limit 2); cerebral cortex: 2.6 nTPM (limit 2); hypothalamus: 3 nTPM (limit 2); retina: 3.2 nTPM (limit 2); cerebellum: 2.4 nTPM (baseline 2); cerebral cortex: 2.6 nTPM (baseline 2); hypothalamus: 3 nTPM (baseline 2); retina: 3.2 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 41/133 (30.8%); Skin Cuteneous Melanoma (TCGA): 17/99 (17.2%); Rectum Adenocarcinoma (validation): 14/207 (6.8%),liver cancer: 2/12 (16.7%); stomach cancer: 1/11 (9.1%),28,20,Q86YH2,https://www.uniprot.org/uniprotkb/Q86YH2/entry,May function as a transcription factor,,,,Nucleus,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | Jamin2021_CT,GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
ZNF280C,ENSG00000056277,Unsafe,Protein,False,True,9.1,9.1,86,63,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 1.4 nTPM; positive ihc; bone marrow: 2.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 1.5 nTPM; positive ihc; cerebral cortex: 1.5 nTPM; positive ihc; colon: 1.4 nTPM; positive ihc; duodenum: 1.3 nTPM; positive ihc; esophagus: 1.3 nTPM; positive ihc; heart muscle: 0.9 nTPM; positive ihc; kidney: 1.1 nTPM; positive ihc; liver: 1.2 nTPM; positive ihc; lung: 1.4 nTPM; positive ihc; lymph node: 2.2 nTPM; positive ihc; pancreas: 1.2 nTPM; positive ihc; parathyroid gland: 1.6 nTPM; positive ihc; rectum: 1.3 nTPM; positive ihc; salivary gland: 1.1 nTPM; positive ihc; skeletal muscle: 1.3 nTPM; positive ihc; skin: 1.6 nTPM; positive ihc; small intestine: 1.3 nTPM; positive ihc; smooth muscle: 1.7 nTPM; positive ihc; spleen: 1.6 nTPM; positive ihc; stomach: 1.1 nTPM; positive ihc; thyroid gland: 1.5 nTPM; positive ihc; urinary bladder: 1.5 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 2.6 nTPM (limit 2),adrenal gland / glandular cells: Low (Enhanced); bone marrow / hematopoietic cells: Medium (Enhanced); bronchus / respiratory epithelial cells: Medium (Enhanced); caudate / glial cells: High (Enhanced); cerebellum / cells in granular layer: Medium (Enhanced); cerebellum / cells in molecular layer: Medium (Enhanced); cerebellum / Purkinje cells: Low (Enhanced); cerebral cortex / glial cells: Medium (Enhanced); cerebral cortex / neuronal cells: Low (Enhanced); colon / glandular cells: Medium (Enhanced); duodenum / glandular cells: Low (Enhanced); esophagus / squamous epithelial cells: Medium (Enhanced); heart muscle / cardiomyocytes: Medium (Enhanced); hippocampus / glial cells: High (Enhanced); kidney / cells in glomeruli: Medium (Enhanced); kidney / cells in tubules: Medium (Enhanced); liver / cholangiocytes: Low (Enhanced); liver / hepatocytes: Medium (Enhanced); lung / alveolar cells: Medium (Enhanced); lung / macrophages: Medium (Enhanced); lymph node / non-germinal center cells: Medium (Enhanced); nasopharynx / respiratory epithelial cells: Medium (Enhanced); oral mucosa / squamous epithelial cells: Medium (Enhanced); pancreas / exocrine glandular cells: Medium (Enhanced); pancreas / pancreatic endocrine cells: Low (Enhanced); parathyroid gland / glandular cells: Medium (Enhanced); rectum / glandular cells: Medium (Enhanced); salivary gland / glandular cells: Low (Enhanced); skeletal muscle / myocytes: Medium (Enhanced); skin 1 / keratinocytes: Low (Enhanced); skin 2 / epidermal cells: Medium (Enhanced); small intestine / glandular cells: Medium (Enhanced); smooth muscle / smooth muscle cells: Low (Enhanced); spleen / cells in red pulp: Low (Enhanced); spleen / cells in white pulp: Low (Enhanced); stomach 1 / glandular cells: Medium (Enhanced); stomach 2 / glandular cells: Low (Enhanced); thyroid gland / glandular cells: Low (Enhanced); urinary bladder / urothelial cells: Medium (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Rectum Adenocarcinoma (validation): 206/207 (99.5%); Colon Adenocarcinoma (validation): 480/486 (98.8%),renal cancer: 8/11 (72.7%); liver cancer: 6/11 (54.5%),31,20,Q8ND82,https://www.uniprot.org/uniprotkb/Q8ND82/entry,May function as a transcription factor,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF284,ENSG00000186026,Unsafe,RNA,False,True,1.4,2.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 1.2 nTPM; continuous selectivity; adrenal gland: 1.6 nTPM; continuous selectivity;reproductive not higher; amygdala: 0.8 nTPM; continuous selectivity; basal ganglia: 1 nTPM; continuous selectivity; bone marrow: 0.7 nTPM; continuous selectivity; cerebellum: 2 nTPM; continuous selectivity;reproductive not higher; cerebral cortex: 1 nTPM; continuous selectivity; choroid plexus: 1.1 nTPM; continuous selectivity; colon: 1.2 nTPM; continuous selectivity; duodenum: 1.2 nTPM; continuous selectivity; esophagus: 0.9 nTPM; continuous selectivity; heart muscle: 1.3 nTPM; continuous selectivity; hippocampal formation: 1 nTPM; continuous selectivity; hypothalamus: 1 nTPM; continuous selectivity; kidney: 1.2 nTPM; continuous selectivity; liver: 1 nTPM; continuous selectivity; lung: 1.1 nTPM; continuous selectivity; lymph node: 1.6 nTPM; continuous selectivity;reproductive not higher; midbrain: 1 nTPM; continuous selectivity; pancreas: 1.1 nTPM; continuous selectivity; parathyroid gland: 1 nTPM; continuous selectivity; pituitary gland: 1.5 nTPM; continuous selectivity;reproductive not higher; rectum: 0.7 nTPM; continuous selectivity; retina: 2.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 1.3 nTPM; continuous selectivity; skeletal muscle: 1.6 nTPM; continuous selectivity;reproductive not higher; skin: 2.8 nTPM; continuous selectivity;reproductive not higher; small intestine: 1.4 nTPM; continuous selectivity;reproductive not higher; smooth muscle: 0.7 nTPM; continuous selectivity; spinal cord: 1 nTPM; continuous selectivity; spleen: 2.1 nTPM; continuous selectivity;reproductive not higher; stomach: 1.1 nTPM; continuous selectivity; thymus: 1.6 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 1.5 nTPM; continuous selectivity;reproductive not higher; urinary bladder: 1.1 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 2.2 nTPM (limit 2); retina: 2.2 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 53/58 (91.4%); Breast Invasive Carcinoma (validation): 41/50 (82.0%); Colon Adenocarcinoma (validation): 62/486 (12.8%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q2VY69,https://www.uniprot.org/uniprotkb/Q2VY69/entry,May be involved in transcriptional regulation,"Expressed in lung, liver, pancreas and thymus. Lower expression in heart, placenta, spleen, prostate, ovary, small intestine and colon. No expression seen in brain, skeletal muscle, kidney, testis and peripheral blood leukocyte",,,Nucleus,,12743021|16817023,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF286A,ENSG00000187607,Unsafe,RNA,False,True,15.4,15.4,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 7.6 nTPM; absolute ceiling;continuous selectivity; amygdala: 5.7 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 5.5 nTPM; absolute ceiling;continuous selectivity; bone marrow: 3.9 nTPM; absolute ceiling; cerebellum: 6.7 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 8.1 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 7.4 nTPM; absolute ceiling;continuous selectivity; colon: 5.6 nTPM; continuous selectivity; duodenum: 3.7 nTPM; absolute ceiling; esophagus: 9.7 nTPM; absolute ceiling;continuous selectivity; heart muscle: 15 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 6.4 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 5.6 nTPM; absolute ceiling;continuous selectivity; kidney: 7.5 nTPM; absolute ceiling;continuous selectivity; liver: 4 nTPM; absolute ceiling;continuous selectivity; lung: 4.9 nTPM; absolute ceiling;continuous selectivity; lymph node: 8.6 nTPM; absolute ceiling;continuous selectivity; midbrain: 7.4 nTPM; absolute ceiling;continuous selectivity; pancreas: 3.9 nTPM; absolute ceiling; parathyroid gland: 13.9 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 5.5 nTPM; absolute ceiling;continuous selectivity; retina: 11.4 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 4 nTPM; absolute ceiling;continuous selectivity; small intestine: 3.7 nTPM; absolute ceiling; smooth muscle: 10.6 nTPM; absolute ceiling;continuous selectivity; spinal cord: 9.6 nTPM; absolute ceiling;continuous selectivity; thymus: 12.6 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 10.1 nTPM; absolute ceiling;continuous selectivity; tongue: 9.4 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 8.6 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 7.6 nTPM (limit 2); amygdala: 5.7 nTPM (limit 2); basal ganglia: 5.5 nTPM (limit 2); bone marrow: 3.9 nTPM (limit 2); cerebellum: 6.7 nTPM (limit 2); cerebral cortex: 8.1 nTPM (limit 2); choroid plexus: 7.4 nTPM (limit 2); duodenum: 3.7 nTPM (limit 2); esophagus: 9.7 nTPM (limit 6); heart muscle: 15 nTPM (limit 2); hippocampal formation: 6.4 nTPM (limit 2); hypothalamus: 5.6 nTPM (limit 2); kidney: 7.5 nTPM (limit 2); liver: 4 nTPM (limit 2); lung: 4.9 nTPM (limit 2); lymph node: 8.6 nTPM (limit 6); midbrain: 7.4 nTPM (limit 2); pancreas: 3.9 nTPM (limit 2); parathyroid gland: 13.9 nTPM (limit 6); pituitary gland: 5.5 nTPM (limit 2); retina: 11.4 nTPM (limit 2); skeletal muscle: 4 nTPM (limit 2); small intestine: 3.7 nTPM (limit 2); smooth muscle: 10.6 nTPM (limit 2); spinal cord: 9.6 nTPM (limit 2); thymus: 12.6 nTPM (limit 10); thyroid gland: 10.1 nTPM (limit 10); tongue: 9.4 nTPM (limit 6); urinary bladder: 8.6 nTPM (limit 6); adrenal gland: 7.6 nTPM (baseline 2); amygdala: 5.7 nTPM (baseline 2); basal ganglia: 5.5 nTPM (baseline 2); bone marrow: 3.9 nTPM (baseline 2); cerebellum: 6.7 nTPM (baseline 2); cerebral cortex: 8.1 nTPM (baseline 2); choroid plexus: 7.4 nTPM (baseline 2); duodenum: 3.7 nTPM (baseline 2); esophagus: 9.7 nTPM (baseline 6); heart muscle: 15 nTPM (baseline 2); hippocampal formation: 6.4 nTPM (baseline 2); hypothalamus: 5.6 nTPM (baseline 2); kidney: 7.5 nTPM (baseline 2); liver: 4 nTPM (baseline 2); lung: 4.9 nTPM (baseline 2); lymph node: 8.6 nTPM (baseline 6); midbrain: 7.4 nTPM (baseline 2); pancreas: 3.9 nTPM (baseline 2); parathyroid gland: 13.9 nTPM (baseline 6); pituitary gland: 5.5 nTPM (baseline 2); retina: 11.4 nTPM (baseline 2); skeletal muscle: 4 nTPM (baseline 2); small intestine: 3.7 nTPM (baseline 2); smooth muscle: 10.6 nTPM (baseline 2); spinal cord: 9.6 nTPM (baseline 2); thymus: 12.6 nTPM (baseline 10); thyroid gland: 10.1 nTPM (baseline 10); tongue: 9.4 nTPM (baseline 6); urinary bladder: 8.6 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Lung Adenocarcinoma (validation): 104/105 (99.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9HBT8,https://www.uniprot.org/uniprotkb/Q9HBT8/entry,May be involved in transcriptional regulation,,,,Nucleus,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF311,ENSG00000197935,Unsafe,Protein,False,True,2.4,2.4,87,9,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; cerebellum: 0.2 nTPM; positive ihc; cerebral cortex: 0.2 nTPM; positive ihc; kidney: 1 nTPM; continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",,bronchus / respiratory epithelial cells: Low (Approved); caudate / glial cells: Medium (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuropil: Medium (Approved); hippocampus / glial cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 50/58 (86.2%); Breast Invasive Carcinoma (validation): 38/50 (76.0%); Ovary Serous Cystadenocarcinoma (validation): 3/81 (3.7%),glioma: 5/10 (50.0%); breast cancer: 0/10 (0.0%),31,20,Q5JNZ3,https://www.uniprot.org/uniprotkb/Q5JNZ3/entry,May be involved in transcriptional regulation,,,,Nucleus,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF324B,ENSG00000249471,Unsafe,RNA,False,True,3.3,3.7,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 2.3 nTPM; continuous selectivity; adrenal gland: 2.1 nTPM; absolute ceiling;continuous selectivity; amygdala: 1.7 nTPM; continuous selectivity; basal ganglia: 2 nTPM; continuous selectivity; bone marrow: 1.7 nTPM; continuous selectivity; cerebellum: 2.7 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 3 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 1.5 nTPM; continuous selectivity; colon: 2.2 nTPM; continuous selectivity; duodenum: 1.8 nTPM; continuous selectivity; esophagus: 2.9 nTPM; continuous selectivity; heart muscle: 1.7 nTPM; continuous selectivity; hippocampal formation: 1.8 nTPM; continuous selectivity; hypothalamus: 1.7 nTPM; continuous selectivity; kidney: 2.2 nTPM; absolute ceiling;continuous selectivity; liver: 2.4 nTPM; absolute ceiling;continuous selectivity; lung: 2.2 nTPM; absolute ceiling;continuous selectivity; lymph node: 2.2 nTPM; continuous selectivity; midbrain: 1.3 nTPM; continuous selectivity; pancreas: 3.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 2.5 nTPM; continuous selectivity; pituitary gland: 3 nTPM; absolute ceiling;continuous selectivity; rectum: 1.7 nTPM; continuous selectivity; retina: 1.8 nTPM; continuous selectivity; salivary gland: 2.6 nTPM; continuous selectivity; skeletal muscle: 3 nTPM; absolute ceiling;continuous selectivity; skin: 3.7 nTPM; continuous selectivity;reproductive not higher; small intestine: 2.2 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 2.1 nTPM; absolute ceiling;continuous selectivity; spinal cord: 1.2 nTPM; continuous selectivity; spleen: 3.3 nTPM; continuous selectivity;reproductive not higher; stomach: 2.6 nTPM; continuous selectivity; thymus: 2.5 nTPM; continuous selectivity; thyroid gland: 2.7 nTPM; continuous selectivity; tongue: 1.6 nTPM; continuous selectivity; urinary bladder: 2.9 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 2.1 nTPM (limit 2); cerebellum: 2.7 nTPM (limit 2); cerebral cortex: 3 nTPM (limit 2); kidney: 2.2 nTPM (limit 2); liver: 2.4 nTPM (limit 2); lung: 2.2 nTPM (limit 2); pancreas: 3.5 nTPM (limit 2); pituitary gland: 3 nTPM (limit 2); skeletal muscle: 3 nTPM (limit 2); small intestine: 2.2 nTPM (limit 2); smooth muscle: 2.1 nTPM (limit 2); adrenal gland: 2.1 nTPM (baseline 2); cerebellum: 2.7 nTPM (baseline 2); cerebral cortex: 3 nTPM (baseline 2); kidney: 2.2 nTPM (baseline 2); liver: 2.4 nTPM (baseline 2); lung: 2.2 nTPM (baseline 2); pancreas: 3.5 nTPM (baseline 2); pituitary gland: 3 nTPM (baseline 2); skeletal muscle: 3 nTPM (baseline 2); small intestine: 2.2 nTPM (baseline 2); smooth muscle: 2.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 48/50 (96.0%); Rectum Adenocarcinoma (validation): 198/207 (95.7%); Colon Adenocarcinoma (validation): 459/486 (94.4%),testis cancer: 5/9 (55.6%); liver cancer: 2/12 (16.7%),31,20,Q6AW86,https://www.uniprot.org/uniprotkb/Q6AW86/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF358,ENSG00000198816,Unsafe,Protein,False,True,85.8,169.4,85,53,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 68.4 nTPM; absolute ceiling;continuous selectivity; adrenal gland: 55.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 115.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; basal ganglia: 84.4 nTPM; absolute ceiling;continuous selectivity; bone marrow: 2.2 nTPM; positive ihc;absolute ceiling; cerebellum: 77.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 145.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 37.4 nTPM; absolute ceiling;continuous selectivity; colon: 104.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 28.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 31 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 105.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 109.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 80.7 nTPM; absolute ceiling;continuous selectivity; kidney: 51.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 65.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 49.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 10.3 nTPM; positive ihc;absolute ceiling; midbrain: 86.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pancreas: 49.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 47.9 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 59.3 nTPM; absolute ceiling;continuous selectivity; rectum: 17.7 nTPM; positive ihc;absolute ceiling; retina: 11.4 nTPM; absolute ceiling; salivary gland: 49.7 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 169.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 37.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 46.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 36 nTPM; absolute ceiling;continuous selectivity; spinal cord: 64.9 nTPM; absolute ceiling;continuous selectivity; spleen: 38.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 65.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 13.7 nTPM; absolute ceiling; thyroid gland: 58.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 141.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 85.5 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 68.4 nTPM (limit 20); adrenal gland: 55.6 nTPM (limit 2); amygdala: 115.3 nTPM (limit 2); basal ganglia: 84.4 nTPM (limit 2); bone marrow: 2.2 nTPM (limit 2); cerebellum: 77.8 nTPM (limit 2); cerebral cortex: 145.6 nTPM (limit 2); choroid plexus: 37.4 nTPM (limit 2); colon: 104.3 nTPM (limit 6); duodenum: 28.6 nTPM (limit 2); esophagus: 31 nTPM (limit 6); heart muscle: 105.9 nTPM (limit 2); hippocampal formation: 109.8 nTPM (limit 2); hypothalamus: 80.7 nTPM (limit 2); kidney: 51.4 nTPM (limit 2); liver: 65.4 nTPM (limit 2); lung: 49.1 nTPM (limit 2); lymph node: 10.3 nTPM (limit 6); midbrain: 86.6 nTPM (limit 2); pancreas: 49.1 nTPM (limit 2); parathyroid gland: 47.9 nTPM (limit 8); pituitary gland: 59.3 nTPM (limit 2); rectum: 17.7 nTPM (limit 6); retina: 11.4 nTPM (limit 2); salivary gland: 49.7 nTPM (limit 8); skeletal muscle: 169.4 nTPM (limit 4); skin: 37.5 nTPM (limit 10); small intestine: 46.5 nTPM (limit 2); smooth muscle: 36 nTPM (limit 4); spinal cord: 64.9 nTPM (limit 2); spleen: 38.6 nTPM (limit 10); stomach: 65.9 nTPM (limit 6); thymus: 13.7 nTPM (limit 10); thyroid gland: 58.1 nTPM (limit 10); tongue: 141.1 nTPM (limit 6); urinary bladder: 85.5 nTPM (limit 6),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Low (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: High (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Medium (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Low (Approved); lung / macrophages: Low (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: High (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Low (Approved); pancreas / pancreatic endocrine cells: Low (Approved); rectum / glandular cells: High (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Low (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: High (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Low (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Thyroid Carcinoma (TCGA): 495/495 (100.0%); Prostate Adenocarcinoma (TCGA): 480/480 (100.0%),ovarian cancer: 8/11 (72.7%); breast cancer: 8/12 (66.7%),31,20,Q9NW07,https://www.uniprot.org/uniprotkb/Q9NW07/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF367,ENSG00000165244,Unsafe,Protein,False,True,5.9,25.8,77,41,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 0.6 nTPM; positive ihc; basal ganglia: 1.6 nTPM; continuous selectivity; bone marrow: 25.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 1.2 nTPM; positive ihc; cerebral cortex: 1.2 nTPM; positive ihc; colon: 2.9 nTPM; continuous selectivity; duodenum: 2.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 2.3 nTPM; positive ihc;continuous selectivity; heart muscle: 2 nTPM; positive ihc;continuous selectivity; kidney: 2.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 10.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 4.4 nTPM; continuous selectivity; parathyroid gland: 1.5 nTPM; positive ihc; rectum: 3.2 nTPM; continuous selectivity; skeletal muscle: 1.4 nTPM; positive ihc; skin: 3.4 nTPM; positive ihc;continuous selectivity; small intestine: 2.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 2.3 nTPM; absolute ceiling;continuous selectivity; spinal cord: 1.9 nTPM; continuous selectivity; spleen: 1.3 nTPM; positive ihc; stomach: 2.1 nTPM; positive ihc;continuous selectivity; thymus: 8.4 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 1.1 nTPM; positive ihc; tongue: 2.6 nTPM; continuous selectivity; urinary bladder: 1.4 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 25.8 nTPM (limit 2); duodenum: 2.8 nTPM (limit 2); kidney: 2.9 nTPM (limit 2); liver: 10.5 nTPM (limit 2); small intestine: 2.9 nTPM (limit 2); smooth muscle: 2.3 nTPM (limit 2); bone marrow: 25.8 nTPM (baseline 2); duodenum: 2.8 nTPM (baseline 2); kidney: 2.9 nTPM (baseline 2); liver: 10.5 nTPM (baseline 2); small intestine: 2.9 nTPM (baseline 2); smooth muscle: 2.3 nTPM (baseline 2),adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Low (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / neuronal cells: Low (Uncertain); cerebellum / cells in molecular layer: Medium (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / endothelial cells: Low (Uncertain); cerebral cortex / glial cells: Low (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: Medium (Uncertain); duodenum / glandular cells: Low (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / neuronal cells: Low (Uncertain); kidney / cells in glomeruli: Medium (Uncertain); kidney / cells in tubules: High (Uncertain); liver / hepatocytes: Medium (Uncertain); nasopharynx / respiratory epithelial cells: Low (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: Medium (Uncertain); skin 1 / fibroblasts: Low (Uncertain); skin 1 / keratinocytes: Low (Uncertain); skin 2 / epidermal cells: High (Uncertain); small intestine / glandular cells: Low (Uncertain); spleen / cells in red pulp: Low (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: High (Uncertain); urinary bladder / urothelial cells: High (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 445/486 (91.6%); Breast Invasive Carcinoma (validation): 45/50 (90.0%),glioma: 7/11 (63.6%); urothelial cancer: 5/11 (45.5%),31,20,Q7RTV3,https://www.uniprot.org/uniprotkb/Q7RTV3/entry,Transcriptional activator. Isoform 1 may be involved in transcriptional activation of erythroid genes,,,,Nucleus,15344908,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF385D,ENSG00000151789,Unsafe,RNA,False,True,6.2,7.9,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 3.4 nTPM; continuous selectivity; basal ganglia: 1.9 nTPM; continuous selectivity; cerebellum: 7.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 3.8 nTPM; absolute ceiling;continuous selectivity; heart muscle: 1.7 nTPM; continuous selectivity; kidney: 1.7 nTPM; continuous selectivity; midbrain: 2.4 nTPM; absolute ceiling;continuous selectivity; retina: 7.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; tongue: 3.5 nTPM; continuous selectivity; urinary bladder: 2.8 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebellum: 7.2 nTPM (limit 2); cerebral cortex: 3.8 nTPM (limit 2); midbrain: 2.4 nTPM (limit 2); retina: 7.9 nTPM (limit 2); cerebellum: 7.2 nTPM (baseline 2); cerebral cortex: 3.8 nTPM (baseline 2); midbrain: 2.4 nTPM (baseline 2); retina: 7.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 30/50 (60.0%); Glioblastoma Multiforme (validation): 31/58 (53.4%); Glioblastoma Multiforme (TCGA): 23/141 (16.3%),ovarian cancer: 2/11 (18.2%); cervical cancer: 1/11 (9.1%),31,20,Q9H6B1,https://www.uniprot.org/uniprotkb/Q9H6B1/entry,,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
ZNF391,ENSG00000124613,Unsafe,RNA,False,True,5.2,5.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 2 nTPM; continuous selectivity; amygdala: 2 nTPM; continuous selectivity; basal ganglia: 3 nTPM; absolute ceiling;continuous selectivity; cerebellum: 2.7 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 3.1 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 2.2 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 2 nTPM; continuous selectivity; kidney: 2.7 nTPM; absolute ceiling;continuous selectivity; lung: 1.8 nTPM; continuous selectivity; pancreas: 2.1 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 3.6 nTPM; continuous selectivity; pituitary gland: 1.7 nTPM; continuous selectivity; retina: 2 nTPM; continuous selectivity; salivary gland: 2.1 nTPM; continuous selectivity; smooth muscle: 2.3 nTPM; absolute ceiling;continuous selectivity; spinal cord: 1.5 nTPM; continuous selectivity; thyroid gland: 3.9 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,basal ganglia: 3 nTPM (limit 2); cerebellum: 2.7 nTPM (limit 2); cerebral cortex: 3.1 nTPM (limit 2); hippocampal formation: 2.2 nTPM (limit 2); kidney: 2.7 nTPM (limit 2); pancreas: 2.1 nTPM (limit 2); smooth muscle: 2.3 nTPM (limit 2); basal ganglia: 3 nTPM (baseline 2); cerebellum: 2.7 nTPM (baseline 2); cerebral cortex: 3.1 nTPM (baseline 2); hippocampal formation: 2.2 nTPM (baseline 2); kidney: 2.7 nTPM (baseline 2); pancreas: 2.1 nTPM (baseline 2); smooth muscle: 2.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 55/58 (94.8%); Testicular Germ Cell Tumor (TCGA): 90/133 (67.7%); Breast Invasive Carcinoma (validation): 30/50 (60.0%),breast cancer: 12/12 (100.0%); prostate cancer: 12/12 (100.0%),31,20,Q9UJN7,https://www.uniprot.org/uniprotkb/Q9UJN7/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination; inclusion depends on TGCT under this study's thresholds,,,,,,,,
ZNF395,ENSG00000186918,Unsafe,Protein,False,True,51.3,51.3,77,48,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 31.9 nTPM; absolute ceiling;continuous selectivity; adrenal gland: 17.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 13.9 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 15.7 nTPM; absolute ceiling;continuous selectivity; bone marrow: 36.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 12.3 nTPM; absolute ceiling; cerebral cortex: 12.9 nTPM; positive ihc;absolute ceiling; choroid plexus: 22.3 nTPM; absolute ceiling;continuous selectivity; colon: 24.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 20.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 46.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 26.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 11.4 nTPM; absolute ceiling; hypothalamus: 9.3 nTPM; absolute ceiling; kidney: 22.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 36.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 19.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 20.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 11.2 nTPM; absolute ceiling; pancreas: 46 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 17.1 nTPM; positive ihc;absolute ceiling; pituitary gland: 16 nTPM; absolute ceiling;continuous selectivity; rectum: 13.5 nTPM; positive ihc;absolute ceiling; retina: 26.3 nTPM; absolute ceiling;continuous selectivity; salivary gland: 37.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 15.7 nTPM; absolute ceiling;continuous selectivity; skin: 41.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 24 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 9.2 nTPM; absolute ceiling; spinal cord: 9.2 nTPM; absolute ceiling; spleen: 21.3 nTPM; absolute ceiling; stomach: 25.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 18.4 nTPM; absolute ceiling; thyroid gland: 18 nTPM; positive ihc;absolute ceiling; tongue: 13.4 nTPM; absolute ceiling; urinary bladder: 25.4 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 31.9 nTPM (limit 10); adrenal gland: 17.9 nTPM (limit 2); amygdala: 13.9 nTPM (limit 2); basal ganglia: 15.7 nTPM (limit 2); bone marrow: 36.6 nTPM (limit 2); cerebellum: 12.3 nTPM (limit 2); cerebral cortex: 12.9 nTPM (limit 2); choroid plexus: 22.3 nTPM (limit 2); colon: 24.8 nTPM (limit 6); duodenum: 20.3 nTPM (limit 2); esophagus: 46.3 nTPM (limit 6); heart muscle: 26.3 nTPM (limit 2); hippocampal formation: 11.4 nTPM (limit 2); hypothalamus: 9.3 nTPM (limit 2); kidney: 22.7 nTPM (limit 2); liver: 36.1 nTPM (limit 2); lung: 19.1 nTPM (limit 2); lymph node: 20.8 nTPM (limit 6); midbrain: 11.2 nTPM (limit 2); pancreas: 46 nTPM (limit 2); parathyroid gland: 17.1 nTPM (limit 6); pituitary gland: 16 nTPM (limit 2); rectum: 13.5 nTPM (limit 6); retina: 26.3 nTPM (limit 2); salivary gland: 37.7 nTPM (limit 6); skeletal muscle: 15.7 nTPM (limit 2); skin: 41.5 nTPM (limit 10); small intestine: 24 nTPM (limit 2); smooth muscle: 9.2 nTPM (limit 2); spinal cord: 9.2 nTPM (limit 2); spleen: 21.3 nTPM (limit 10); stomach: 25.4 nTPM (limit 6); thymus: 18.4 nTPM (limit 10); thyroid gland: 18 nTPM (limit 10); tongue: 13.4 nTPM (limit 6); urinary bladder: 25.4 nTPM (limit 6); adipose tissue: 31.9 nTPM (baseline 10); adrenal gland: 17.9 nTPM (baseline 2); amygdala: 13.9 nTPM (baseline 2); basal ganglia: 15.7 nTPM (baseline 2); bone marrow: 36.6 nTPM (baseline 2); cerebellum: 12.3 nTPM (baseline 2); cerebral cortex: 12.9 nTPM (baseline 2); choroid plexus: 22.3 nTPM (baseline 2); colon: 24.8 nTPM (baseline 6); duodenum: 20.3 nTPM (baseline 2); esophagus: 46.3 nTPM (baseline 6); heart muscle: 26.3 nTPM (baseline 2); hippocampal formation: 11.4 nTPM (baseline 2); hypothalamus: 9.3 nTPM (baseline 2); kidney: 22.7 nTPM (baseline 2); liver: 36.1 nTPM (baseline 2); lung: 19.1 nTPM (baseline 2); lymph node: 20.8 nTPM (baseline 6); midbrain: 11.2 nTPM (baseline 2); pancreas: 46 nTPM (baseline 2); parathyroid gland: 17.1 nTPM (baseline 6); pituitary gland: 16 nTPM (baseline 2); rectum: 13.5 nTPM (baseline 6); retina: 26.3 nTPM (baseline 2); salivary gland: 37.7 nTPM (baseline 6); skeletal muscle: 15.7 nTPM (baseline 2); skin: 41.5 nTPM (baseline 10); small intestine: 24 nTPM (baseline 2); smooth muscle: 9.2 nTPM (baseline 2); spinal cord: 9.2 nTPM (baseline 2); spleen: 21.3 nTPM (baseline 10); stomach: 25.4 nTPM (baseline 6); thymus: 18.4 nTPM (baseline 10); thyroid gland: 18 nTPM (baseline 10); tongue: 13.4 nTPM (baseline 6); urinary bladder: 25.4 nTPM (baseline 6),adrenal gland / glandular cells: High (Uncertain); bone marrow / hematopoietic cells: Low (Uncertain); bronchus / respiratory epithelial cells: High (Uncertain); caudate / glial cells: High (Uncertain); cerebral cortex / glial cells: Medium (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / glandular cells: High (Uncertain); duodenum / glandular cells: High (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / glial cells: Medium (Uncertain); kidney / cells in tubules: High (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / germinal center cells: Low (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); nasopharynx / respiratory epithelial cells: High (Uncertain); oral mucosa / squamous epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: High (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skin 1 / keratinocytes: Low (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: High (Uncertain); stomach 1 / glandular cells: High (Uncertain); stomach 2 / glandular cells: High (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: High (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (TCGA): 254/254 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Lung Adenocarcinoma (validation): 105/105 (100.0%),liver cancer: 9/12 (75.0%); breast cancer: 8/12 (66.7%),31,20,Q9H8N7,https://www.uniprot.org/uniprotkb/Q9H8N7/entry,Plays a role in papillomavirus genes transcription,Widely expressed,,,Cytoplasm Nucleus,,11853404|14625278,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF397,ENSG00000186812,Unsafe,Protein,False,True,15.6,24.1,78,75,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 12.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 13 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 10.7 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 11.3 nTPM; absolute ceiling;continuous selectivity; bone marrow: 4.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 11.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 14.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 10.9 nTPM; absolute ceiling;continuous selectivity; colon: 12.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 10.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 9.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 10.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 12.9 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 10 nTPM; absolute ceiling;continuous selectivity; kidney: 10.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 10.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 10.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 15.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 13.1 nTPM; absolute ceiling;continuous selectivity; pancreas: 12 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 14.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 11.7 nTPM; absolute ceiling;continuous selectivity; rectum: 13.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 24.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 12 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 11.2 nTPM; absolute ceiling;continuous selectivity; skin: 13.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 12.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 11 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 15 nTPM; absolute ceiling;continuous selectivity; spleen: 15.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; stomach: 12.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 12.7 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 15.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 10.6 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 11.5 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 12.4 nTPM (limit 10); adrenal gland: 13 nTPM (limit 2); amygdala: 10.7 nTPM (limit 2); basal ganglia: 11.3 nTPM (limit 2); bone marrow: 4.9 nTPM (limit 2); cerebellum: 11.2 nTPM (limit 2); cerebral cortex: 14.5 nTPM (limit 2); choroid plexus: 10.9 nTPM (limit 2); colon: 12.4 nTPM (limit 6); duodenum: 10.3 nTPM (limit 2); esophagus: 9.5 nTPM (limit 6); heart muscle: 10.1 nTPM (limit 2); hippocampal formation: 12.9 nTPM (limit 2); hypothalamus: 10 nTPM (limit 2); kidney: 10.9 nTPM (limit 2); liver: 10.4 nTPM (limit 2); lung: 10.1 nTPM (limit 2); lymph node: 15.7 nTPM (limit 6); midbrain: 13.1 nTPM (limit 2); pancreas: 12 nTPM (limit 2); parathyroid gland: 14.3 nTPM (limit 6); pituitary gland: 11.7 nTPM (limit 2); rectum: 13.4 nTPM (limit 6); retina: 24.1 nTPM (limit 2); salivary gland: 12 nTPM (limit 6); skeletal muscle: 11.2 nTPM (limit 2); skin: 13.2 nTPM (limit 10); small intestine: 12.2 nTPM (limit 2); smooth muscle: 11 nTPM (limit 2); spinal cord: 15 nTPM (limit 2); spleen: 15.6 nTPM (limit 10); stomach: 12.9 nTPM (limit 6); thymus: 12.7 nTPM (limit 10); thyroid gland: 15.3 nTPM (limit 10); tongue: 10.6 nTPM (limit 6); urinary bladder: 11.5 nTPM (limit 6); adipose tissue: 12.4 nTPM (baseline 10); adrenal gland: 13 nTPM (baseline 2); amygdala: 10.7 nTPM (baseline 2); basal ganglia: 11.3 nTPM (baseline 2); bone marrow: 4.9 nTPM (baseline 2); cerebellum: 11.2 nTPM (baseline 2); cerebral cortex: 14.5 nTPM (baseline 2); choroid plexus: 10.9 nTPM (baseline 2); colon: 12.4 nTPM (baseline 6); duodenum: 10.3 nTPM (baseline 2); esophagus: 9.5 nTPM (baseline 6); heart muscle: 10.1 nTPM (baseline 2); hippocampal formation: 12.9 nTPM (baseline 2); hypothalamus: 10 nTPM (baseline 2); kidney: 10.9 nTPM (baseline 2); liver: 10.4 nTPM (baseline 2); lung: 10.1 nTPM (baseline 2); lymph node: 15.7 nTPM (baseline 6); midbrain: 13.1 nTPM (baseline 2); pancreas: 12 nTPM (baseline 2); parathyroid gland: 14.3 nTPM (baseline 6); pituitary gland: 11.7 nTPM (baseline 2); rectum: 13.4 nTPM (baseline 6); retina: 24.1 nTPM (baseline 2); salivary gland: 12 nTPM (baseline 6); skeletal muscle: 11.2 nTPM (baseline 2); skin: 13.2 nTPM (baseline 10); small intestine: 12.2 nTPM (baseline 2); smooth muscle: 11 nTPM (baseline 2); spinal cord: 15 nTPM (baseline 2); spleen: 15.6 nTPM (baseline 10); stomach: 12.9 nTPM (baseline 6); thymus: 12.7 nTPM (baseline 10); thyroid gland: 15.3 nTPM (baseline 10); tongue: 10.6 nTPM (baseline 6); urinary bladder: 11.5 nTPM (baseline 6),adipose tissue / adipocytes: Medium (Uncertain); adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: High (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / glial cells: Medium (Uncertain); caudate / neuronal cells: Low (Uncertain); cerebellum / cells in granular layer: Medium (Uncertain); cerebellum / cells in molecular layer: Low (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / glial cells: Medium (Uncertain); cerebral cortex / neuronal cells: Low (Uncertain); cerebral cortex / neuropil: High (Uncertain); colon / endothelial cells: High (Uncertain); colon / glandular cells: Medium (Uncertain); duodenum / glandular cells: High (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / glial cells: Medium (Uncertain); hippocampus / neuronal cells: Low (Uncertain); kidney / cells in glomeruli: Medium (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / cholangiocytes: High (Uncertain); liver / hepatocytes: Low (Uncertain); lung / alveolar cells: Medium (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / germinal center cells: High (Uncertain); lymph node / non-germinal center cells: High (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Low (Uncertain); skin 1 / fibroblasts: High (Uncertain); skin 1 / keratinocytes: Low (Uncertain); skin 1 / Langerhans: High (Uncertain); skin 2 / epidermal cells: Low (Uncertain); small intestine / glandular cells: Medium (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); spleen / cells in red pulp: Low (Uncertain); spleen / cells in white pulp: Medium (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Low (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Pancreatic Adenocarcinoma (validation): 80/80 (100.0%); Lung Squamous Cell Carcinoma (validation): 68/68 (100.0%),endometrial cancer: 12/12 (100.0%); lung cancer: 12/12 (100.0%),31,20,Q8NF99,https://www.uniprot.org/uniprotkb/Q8NF99/entry,Isoform 3 acts as a DNA-dependent transcriptional repressor,"Expressed strongly in testis, moderately in skeletal muscle, pancreas and prostate, and weakly in heart, placenta, liver, kidney, spleen, thymus and small intestine",,,Nucleus Cytoplasm,12801647,12801647,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
ZNF407,ENSG00000215421,Unsafe,Protein,False,True,3.8,5.1,75,72,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 2.1 nTPM; continuous selectivity; adrenal gland: 1.8 nTPM; positive ihc;continuous selectivity; amygdala: 1.1 nTPM; continuous selectivity; basal ganglia: 1.3 nTPM; continuous selectivity; bone marrow: 5.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 2.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 2.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 1.2 nTPM; continuous selectivity; colon: 2.7 nTPM; positive ihc;continuous selectivity; duodenum: 2 nTPM; positive ihc;continuous selectivity; esophagus: 2.3 nTPM; positive ihc;continuous selectivity; heart muscle: 3 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 1.1 nTPM; continuous selectivity; kidney: 2.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 2.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 2.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 3.1 nTPM; positive ihc;continuous selectivity; pancreas: 2 nTPM; positive ihc;continuous selectivity; parathyroid gland: 3.6 nTPM; positive ihc;continuous selectivity; pituitary gland: 1.5 nTPM; continuous selectivity; rectum: 2.1 nTPM; positive ihc;continuous selectivity; retina: 2.7 nTPM; absolute ceiling;continuous selectivity; salivary gland: 2.2 nTPM; positive ihc;continuous selectivity; skeletal muscle: 3.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 2.2 nTPM; positive ihc;continuous selectivity; small intestine: 2.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 2.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 1.3 nTPM; continuous selectivity; spleen: 3.2 nTPM; positive ihc;continuous selectivity; stomach: 2.1 nTPM; positive ihc;continuous selectivity; thymus: 5 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 3.4 nTPM; positive ihc;continuous selectivity; tongue: 3.2 nTPM; continuous selectivity; urinary bladder: 2.3 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 5.1 nTPM (limit 2); cerebellum: 2.1 nTPM (limit 2); cerebral cortex: 2.2 nTPM (limit 2); heart muscle: 3 nTPM (limit 2); kidney: 2.2 nTPM (limit 2); liver: 2.1 nTPM (limit 2); lung: 2.2 nTPM (limit 2); retina: 2.7 nTPM (limit 2); skeletal muscle: 3.8 nTPM (limit 2); small intestine: 2.2 nTPM (limit 2); smooth muscle: 2.9 nTPM (limit 2); bone marrow: 5.1 nTPM (baseline 2); cerebellum: 2.1 nTPM (baseline 2); cerebral cortex: 2.2 nTPM (baseline 2); heart muscle: 3 nTPM (baseline 2); kidney: 2.2 nTPM (baseline 2); liver: 2.1 nTPM (baseline 2); lung: 2.2 nTPM (baseline 2); retina: 2.7 nTPM (baseline 2); skeletal muscle: 3.8 nTPM (baseline 2); small intestine: 2.2 nTPM (baseline 2); smooth muscle: 2.9 nTPM (baseline 2),adrenal gland / glandular cells: High (Uncertain); bone marrow / hematopoietic cells: High (Uncertain); bronchus / respiratory epithelial cells: High (Uncertain); caudate / glial cells: Medium (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: Low (Uncertain); cerebellum / cells in molecular layer: Medium (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / endothelial cells: Medium (Uncertain); cerebral cortex / glial cells: Medium (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / endothelial cells: Low (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: Medium (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: High (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / glial cells: Medium (Uncertain); hippocampus / neuronal cells: Low (Uncertain); kidney / cells in glomeruli: Medium (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / cholangiocytes: Low (Uncertain); liver / hepatocytes: Low (Uncertain); lung / alveolar cells: Medium (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / germinal center cells: Low (Uncertain); lymph node / non-germinal center cells: Medium (Uncertain); nasopharynx / respiratory epithelial cells: High (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: Medium (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: Low (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); spleen / cells in red pulp: Low (Uncertain); spleen / cells in white pulp: Low (Uncertain); stomach 1 / glandular cells: High (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: High (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 483/486 (99.4%); Rectum Adenocarcinoma (validation): 203/207 (98.1%),skin cancer: 11/12 (91.7%); colorectal cancer: 9/11 (81.8%),31,20,Q9C0G0,https://www.uniprot.org/uniprotkb/Q9C0G0/entry,May be involved in transcriptional regulation,,"Short stature, impaired intellectual development, microcephaly, hypotonia, and ocular anomalies: An autosomal recessive syndrome characterized by short stature, impaired intellectual development, microcephaly, hypotonia, and ocular anomalies.",,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF410,ENSG00000119725,Unsafe,RNA,False,True,43.7,57.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 28 nTPM; absolute ceiling;continuous selectivity; adrenal gland: 32 nTPM; absolute ceiling;continuous selectivity; amygdala: 17 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 17.1 nTPM; absolute ceiling;continuous selectivity; bone marrow: 57 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 16.9 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 17 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 30.7 nTPM; absolute ceiling;continuous selectivity; colon: 29.5 nTPM; absolute ceiling;continuous selectivity; duodenum: 18.5 nTPM; absolute ceiling;continuous selectivity; esophagus: 32.4 nTPM; absolute ceiling;continuous selectivity; heart muscle: 20.2 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 15.9 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 15.8 nTPM; absolute ceiling;continuous selectivity; kidney: 32 nTPM; absolute ceiling;continuous selectivity; liver: 28 nTPM; absolute ceiling;continuous selectivity; lung: 26.7 nTPM; absolute ceiling;continuous selectivity; lymph node: 25.1 nTPM; absolute ceiling;continuous selectivity; midbrain: 17.7 nTPM; absolute ceiling;continuous selectivity; pancreas: 20 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 26 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 26.2 nTPM; absolute ceiling;continuous selectivity; rectum: 23.4 nTPM; absolute ceiling;continuous selectivity; retina: 22 nTPM; absolute ceiling;continuous selectivity; salivary gland: 23.7 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 20.3 nTPM; absolute ceiling;continuous selectivity; skin: 36.4 nTPM; absolute ceiling;continuous selectivity; small intestine: 24.5 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 26.7 nTPM; absolute ceiling;continuous selectivity; spinal cord: 18.3 nTPM; absolute ceiling;continuous selectivity; spleen: 25.5 nTPM; absolute ceiling;continuous selectivity; stomach: 24.9 nTPM; absolute ceiling;continuous selectivity; thymus: 28.9 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 23.8 nTPM; absolute ceiling;continuous selectivity; tongue: 17.7 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 28.1 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adipose tissue: 28 nTPM (limit 10); adrenal gland: 32 nTPM (limit 2); amygdala: 17 nTPM (limit 2); basal ganglia: 17.1 nTPM (limit 2); bone marrow: 57 nTPM (limit 2); cerebellum: 16.9 nTPM (limit 2); cerebral cortex: 17 nTPM (limit 2); choroid plexus: 30.7 nTPM (limit 2); colon: 29.5 nTPM (limit 6); duodenum: 18.5 nTPM (limit 2); esophagus: 32.4 nTPM (limit 6); heart muscle: 20.2 nTPM (limit 2); hippocampal formation: 15.9 nTPM (limit 2); hypothalamus: 15.8 nTPM (limit 2); kidney: 32 nTPM (limit 2); liver: 28 nTPM (limit 2); lung: 26.7 nTPM (limit 2); lymph node: 25.1 nTPM (limit 6); midbrain: 17.7 nTPM (limit 2); pancreas: 20 nTPM (limit 2); parathyroid gland: 26 nTPM (limit 6); pituitary gland: 26.2 nTPM (limit 2); rectum: 23.4 nTPM (limit 6); retina: 22 nTPM (limit 2); salivary gland: 23.7 nTPM (limit 6); skeletal muscle: 20.3 nTPM (limit 2); skin: 36.4 nTPM (limit 10); small intestine: 24.5 nTPM (limit 2); smooth muscle: 26.7 nTPM (limit 2); spinal cord: 18.3 nTPM (limit 2); spleen: 25.5 nTPM (limit 10); stomach: 24.9 nTPM (limit 6); thymus: 28.9 nTPM (limit 10); thyroid gland: 23.8 nTPM (limit 10); tongue: 17.7 nTPM (limit 6); urinary bladder: 28.1 nTPM (limit 6); adipose tissue: 28 nTPM (baseline 10); adrenal gland: 32 nTPM (baseline 2); amygdala: 17 nTPM (baseline 2); basal ganglia: 17.1 nTPM (baseline 2); bone marrow: 57 nTPM (baseline 2); cerebellum: 16.9 nTPM (baseline 2); cerebral cortex: 17 nTPM (baseline 2); choroid plexus: 30.7 nTPM (baseline 2); colon: 29.5 nTPM (baseline 6); duodenum: 18.5 nTPM (baseline 2); esophagus: 32.4 nTPM (baseline 6); heart muscle: 20.2 nTPM (baseline 2); hippocampal formation: 15.9 nTPM (baseline 2); hypothalamus: 15.8 nTPM (baseline 2); kidney: 32 nTPM (baseline 2); liver: 28 nTPM (baseline 2); lung: 26.7 nTPM (baseline 2); lymph node: 25.1 nTPM (baseline 6); midbrain: 17.7 nTPM (baseline 2); pancreas: 20 nTPM (baseline 2); parathyroid gland: 26 nTPM (baseline 6); pituitary gland: 26.2 nTPM (baseline 2); rectum: 23.4 nTPM (baseline 6); retina: 22 nTPM (baseline 2); salivary gland: 23.7 nTPM (baseline 6); skeletal muscle: 20.3 nTPM (baseline 2); skin: 36.4 nTPM (baseline 10); small intestine: 24.5 nTPM (baseline 2); smooth muscle: 26.7 nTPM (baseline 2); spinal cord: 18.3 nTPM (baseline 2); spleen: 25.5 nTPM (baseline 10); stomach: 24.9 nTPM (baseline 6); thymus: 28.9 nTPM (baseline 10); thyroid gland: 23.8 nTPM (baseline 10); tongue: 17.7 nTPM (baseline 6); urinary bladder: 28.1 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%); Lung Squamous Cell Carcinoma (TCGA): 489/489 (100.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q86VK4,https://www.uniprot.org/uniprotkb/Q86VK4/entry,"Transcription factor that binds to the sequence motif 5'-CATCCCATAATA-3', and is specifically required to silence expression of fetal hemoglobin in adult erythroid cells (PubMed:33301730, PubMed:33859416). Prevents expression of fetal hemoglobin genes HBG1 and HBG2 through CHD4: acts as a direct transcriptional activator of CHD4, a central component of the NuRD complex that represses transcription of fetal hemoglobin genes HBG1 and HBG2 in erythroid cells (PubMed:33301730, PubMed:33859416). May also activate transcription of matrix-remodeling genes such as MMP1 during fibroblast senescence (PubMed:12370286). May activate transcription of the gap junction gene GJC1, perhaps in response to increasing glucose (PubMed:30078215). However, recent studies suggest that ZNF410 is dedicated to regulate expression of a single gene: CHD4 (PubMed:33301730, PubMed:33859416)",Widely expressed,,,Nucleus Chromosome,12370286|30078215|33301730|33859416,12370286,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF416,ENSG00000083817,Unsafe,RNA,False,True,4.5,4.9,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 2.1 nTPM; continuous selectivity; adrenal gland: 2.2 nTPM; absolute ceiling;continuous selectivity; amygdala: 1.5 nTPM; continuous selectivity; basal ganglia: 2.3 nTPM; absolute ceiling;continuous selectivity; bone marrow: 2.6 nTPM; absolute ceiling;continuous selectivity; cerebellum: 3.3 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 2.1 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 2.5 nTPM; absolute ceiling;continuous selectivity; colon: 2.2 nTPM; continuous selectivity; duodenum: 1.3 nTPM; continuous selectivity; esophagus: 3.1 nTPM; continuous selectivity; heart muscle: 2.6 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 1.5 nTPM; continuous selectivity; hypothalamus: 1.6 nTPM; continuous selectivity; kidney: 2.5 nTPM; absolute ceiling;continuous selectivity; liver: 2 nTPM; continuous selectivity; lung: 2.4 nTPM; absolute ceiling;continuous selectivity; lymph node: 2.7 nTPM; continuous selectivity; pancreas: 1.3 nTPM; continuous selectivity; parathyroid gland: 4.3 nTPM; continuous selectivity; pituitary gland: 2 nTPM; continuous selectivity; rectum: 2 nTPM; continuous selectivity; retina: 3.6 nTPM; absolute ceiling;continuous selectivity; salivary gland: 2.1 nTPM; continuous selectivity; skeletal muscle: 2.5 nTPM; absolute ceiling;continuous selectivity; skin: 4.9 nTPM; continuous selectivity;reproductive not higher; small intestine: 1.6 nTPM; continuous selectivity; smooth muscle: 2.7 nTPM; absolute ceiling;continuous selectivity; spleen: 2.7 nTPM; continuous selectivity; stomach: 2.1 nTPM; continuous selectivity; thymus: 3.9 nTPM; continuous selectivity; thyroid gland: 3.5 nTPM; continuous selectivity; tongue: 2.9 nTPM; continuous selectivity; urinary bladder: 2.3 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 2.2 nTPM (limit 2); basal ganglia: 2.3 nTPM (limit 2); bone marrow: 2.6 nTPM (limit 2); cerebellum: 3.3 nTPM (limit 2); cerebral cortex: 2.1 nTPM (limit 2); choroid plexus: 2.5 nTPM (limit 2); heart muscle: 2.6 nTPM (limit 2); kidney: 2.5 nTPM (limit 2); lung: 2.4 nTPM (limit 2); retina: 3.6 nTPM (limit 2); skeletal muscle: 2.5 nTPM (limit 2); smooth muscle: 2.7 nTPM (limit 2); adrenal gland: 2.2 nTPM (baseline 2); basal ganglia: 2.3 nTPM (baseline 2); bone marrow: 2.6 nTPM (baseline 2); cerebellum: 3.3 nTPM (baseline 2); cerebral cortex: 2.1 nTPM (baseline 2); choroid plexus: 2.5 nTPM (baseline 2); heart muscle: 2.6 nTPM (baseline 2); kidney: 2.5 nTPM (baseline 2); lung: 2.4 nTPM (baseline 2); retina: 3.6 nTPM (baseline 2); skeletal muscle: 2.5 nTPM (baseline 2); smooth muscle: 2.7 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 41/50 (82.0%); Testicular Germ Cell Tumor (TCGA): 98/133 (73.7%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9BWM5,https://www.uniprot.org/uniprotkb/Q9BWM5/entry,"Acts as a mechanosensitive transcriptional activator in fibroblasts, regulating the expression of genes involved in proliferation, extracellular matrix synthesis, and contractility in response to increased matrix stiffness",,,,Nucleus,33625469,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
ZNF425,ENSG00000204947,Unsafe,RNA,False,True,3.2,3.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 1.2 nTPM; continuous selectivity; amygdala: 2.5 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 2.7 nTPM; absolute ceiling;continuous selectivity; cerebellum: 3.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 3.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 1.5 nTPM; continuous selectivity; colon: 2 nTPM; continuous selectivity; duodenum: 0.9 nTPM; continuous selectivity; esophagus: 2.1 nTPM; continuous selectivity; hippocampal formation: 2.3 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 2.3 nTPM; absolute ceiling;continuous selectivity; kidney: 2.2 nTPM; absolute ceiling;continuous selectivity; liver: 1 nTPM; continuous selectivity; lung: 1 nTPM; continuous selectivity; midbrain: 2 nTPM; continuous selectivity; pancreas: 1.4 nTPM; continuous selectivity; parathyroid gland: 2.3 nTPM; continuous selectivity; pituitary gland: 1.4 nTPM; continuous selectivity; retina: 1.3 nTPM; continuous selectivity; salivary gland: 1.7 nTPM; continuous selectivity; skeletal muscle: 3.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 2.4 nTPM; continuous selectivity; small intestine: 0.9 nTPM; continuous selectivity; smooth muscle: 1.7 nTPM; continuous selectivity; spinal cord: 1.9 nTPM; continuous selectivity; stomach: 1.5 nTPM; continuous selectivity; thymus: 1.5 nTPM; continuous selectivity; thyroid gland: 1.9 nTPM; continuous selectivity; tongue: 1.8 nTPM; continuous selectivity; urinary bladder: 1.8 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 2.5 nTPM (limit 2); basal ganglia: 2.7 nTPM (limit 2); cerebellum: 3.4 nTPM (limit 2); cerebral cortex: 3.4 nTPM (limit 2); hippocampal formation: 2.3 nTPM (limit 2); hypothalamus: 2.3 nTPM (limit 2); kidney: 2.2 nTPM (limit 2); skeletal muscle: 3.6 nTPM (limit 2); amygdala: 2.5 nTPM (baseline 2); basal ganglia: 2.7 nTPM (baseline 2); cerebellum: 3.4 nTPM (baseline 2); cerebral cortex: 3.4 nTPM (baseline 2); hippocampal formation: 2.3 nTPM (baseline 2); hypothalamus: 2.3 nTPM (baseline 2); kidney: 2.2 nTPM (baseline 2); skeletal muscle: 3.6 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 53/58 (91.4%); Breast Invasive Carcinoma (validation): 42/50 (84.0%); Glioblastoma Multiforme (TCGA): 68/141 (48.2%),ovarian cancer: 2/11 (18.2%); stomach cancer: 1/10 (10.0%),31,20,Q6IV72,https://www.uniprot.org/uniprotkb/Q6IV72/entry,Acts as a transcriptional repressor,,,,Nucleus Cytoplasm,21266108,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF43,ENSG00000198521,Unsafe,RNA,False,True,9.8,10.7,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 3.9 nTPM; absolute ceiling;continuous selectivity; amygdala: 2.7 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 2.4 nTPM; absolute ceiling; bone marrow: 10.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 3.7 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 5.8 nTPM; absolute ceiling;continuous selectivity; colon: 4.3 nTPM; continuous selectivity; duodenum: 3.9 nTPM; absolute ceiling;continuous selectivity; esophagus: 3.5 nTPM; continuous selectivity; heart muscle: 4.8 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 2.7 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 2.9 nTPM; absolute ceiling;continuous selectivity; kidney: 4.9 nTPM; absolute ceiling;continuous selectivity; lung: 4.1 nTPM; absolute ceiling;continuous selectivity; lymph node: 8.1 nTPM; absolute ceiling;continuous selectivity; midbrain: 2.8 nTPM; absolute ceiling;continuous selectivity; pancreas: 2.9 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 6.4 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 2.5 nTPM; absolute ceiling; rectum: 5.1 nTPM; continuous selectivity; retina: 6.7 nTPM; absolute ceiling;continuous selectivity; salivary gland: 3.5 nTPM; continuous selectivity; skeletal muscle: 4.1 nTPM; absolute ceiling;continuous selectivity; skin: 7.2 nTPM; continuous selectivity; small intestine: 4.2 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 4.3 nTPM; absolute ceiling;continuous selectivity; spinal cord: 3.3 nTPM; absolute ceiling;continuous selectivity; spleen: 6.5 nTPM; continuous selectivity; stomach: 4.8 nTPM; continuous selectivity; thymus: 9.8 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 8.5 nTPM; continuous selectivity; tongue: 4.7 nTPM; continuous selectivity; urinary bladder: 3.5 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 3.9 nTPM (limit 2); amygdala: 2.7 nTPM (limit 2); basal ganglia: 2.4 nTPM (limit 2); bone marrow: 10.7 nTPM (limit 2); cerebellum: 3.7 nTPM (limit 2); cerebral cortex: 5.8 nTPM (limit 2); duodenum: 3.9 nTPM (limit 2); heart muscle: 4.8 nTPM (limit 2); hippocampal formation: 2.7 nTPM (limit 2); hypothalamus: 2.9 nTPM (limit 2); kidney: 4.9 nTPM (limit 2); lung: 4.1 nTPM (limit 2); lymph node: 8.1 nTPM (limit 6); midbrain: 2.8 nTPM (limit 2); pancreas: 2.9 nTPM (limit 2); parathyroid gland: 6.4 nTPM (limit 6); pituitary gland: 2.5 nTPM (limit 2); retina: 6.7 nTPM (limit 2); skeletal muscle: 4.1 nTPM (limit 2); small intestine: 4.2 nTPM (limit 2); smooth muscle: 4.3 nTPM (limit 2); spinal cord: 3.3 nTPM (limit 2); adrenal gland: 3.9 nTPM (baseline 2); amygdala: 2.7 nTPM (baseline 2); basal ganglia: 2.4 nTPM (baseline 2); bone marrow: 10.7 nTPM (baseline 2); cerebellum: 3.7 nTPM (baseline 2); cerebral cortex: 5.8 nTPM (baseline 2); duodenum: 3.9 nTPM (baseline 2); heart muscle: 4.8 nTPM (baseline 2); hippocampal formation: 2.7 nTPM (baseline 2); hypothalamus: 2.9 nTPM (baseline 2); kidney: 4.9 nTPM (baseline 2); lung: 4.1 nTPM (baseline 2); lymph node: 8.1 nTPM (baseline 6); midbrain: 2.8 nTPM (baseline 2); pancreas: 2.9 nTPM (baseline 2); parathyroid gland: 6.4 nTPM (baseline 6); pituitary gland: 2.5 nTPM (baseline 2); retina: 6.7 nTPM (baseline 2); skeletal muscle: 4.1 nTPM (baseline 2); small intestine: 4.2 nTPM (baseline 2); smooth muscle: 4.3 nTPM (baseline 2); spinal cord: 3.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Rectum Adenocarcinoma (validation): 203/207 (98.1%); Colon Adenocarcinoma (validation): 474/486 (97.5%),breast cancer: 0/12 (0.0%); cervical cancer: 0/11 (0.0%),31,20,P17038,https://www.uniprot.org/uniprotkb/P17038/entry,May be involved in transcriptional regulation,T- and B-cell lines,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF430,ENSG00000118620,Unsafe,RNA,False,True,10.8,11.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 2.9 nTPM; absolute ceiling;continuous selectivity; amygdala: 2.1 nTPM; absolute ceiling; basal ganglia: 3.4 nTPM; absolute ceiling;continuous selectivity; bone marrow: 11.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 4.1 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 3.7 nTPM; absolute ceiling;continuous selectivity; duodenum: 3.4 nTPM; absolute ceiling;continuous selectivity; esophagus: 6.6 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 2.2 nTPM; absolute ceiling; kidney: 2.6 nTPM; absolute ceiling; lung: 3.6 nTPM; absolute ceiling;continuous selectivity; lymph node: 10.1 nTPM; absolute ceiling;continuous selectivity; midbrain: 2.3 nTPM; absolute ceiling; pancreas: 4 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 7.5 nTPM; absolute ceiling;continuous selectivity; rectum: 4.1 nTPM; continuous selectivity; retina: 2.7 nTPM; absolute ceiling; skin: 7.2 nTPM; continuous selectivity; small intestine: 3.4 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 3.3 nTPM; absolute ceiling;continuous selectivity; spinal cord: 3.2 nTPM; absolute ceiling;continuous selectivity; spleen: 6.4 nTPM; continuous selectivity; stomach: 4.8 nTPM; continuous selectivity; thymus: 9.5 nTPM; continuous selectivity; thyroid gland: 8.2 nTPM; continuous selectivity; urinary bladder: 4.4 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 2.9 nTPM (limit 2); amygdala: 2.1 nTPM (limit 2); basal ganglia: 3.4 nTPM (limit 2); bone marrow: 11.6 nTPM (limit 2); cerebellum: 4.1 nTPM (limit 2); cerebral cortex: 3.7 nTPM (limit 2); duodenum: 3.4 nTPM (limit 2); esophagus: 6.6 nTPM (limit 6); hippocampal formation: 2.2 nTPM (limit 2); kidney: 2.6 nTPM (limit 2); lung: 3.6 nTPM (limit 2); lymph node: 10.1 nTPM (limit 6); midbrain: 2.3 nTPM (limit 2); pancreas: 4 nTPM (limit 2); parathyroid gland: 7.5 nTPM (limit 6); retina: 2.7 nTPM (limit 2); small intestine: 3.4 nTPM (limit 2); smooth muscle: 3.3 nTPM (limit 2); spinal cord: 3.2 nTPM (limit 2); adrenal gland: 2.9 nTPM (baseline 2); amygdala: 2.1 nTPM (baseline 2); basal ganglia: 3.4 nTPM (baseline 2); bone marrow: 11.6 nTPM (baseline 2); cerebellum: 4.1 nTPM (baseline 2); cerebral cortex: 3.7 nTPM (baseline 2); duodenum: 3.4 nTPM (baseline 2); esophagus: 6.6 nTPM (baseline 6); hippocampal formation: 2.2 nTPM (baseline 2); kidney: 2.6 nTPM (baseline 2); lung: 3.6 nTPM (baseline 2); lymph node: 10.1 nTPM (baseline 6); midbrain: 2.3 nTPM (baseline 2); pancreas: 4 nTPM (baseline 2); parathyroid gland: 7.5 nTPM (baseline 6); retina: 2.7 nTPM (baseline 2); small intestine: 3.4 nTPM (baseline 2); smooth muscle: 3.3 nTPM (baseline 2); spinal cord: 3.2 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Rectum Adenocarcinoma (validation): 205/207 (99.0%); Colon Adenocarcinoma (validation): 480/486 (98.8%),liver cancer: 6/12 (50.0%); colorectal cancer: 3/12 (25.0%),31,20,Q9H8G1,https://www.uniprot.org/uniprotkb/Q9H8G1/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF460,ENSG00000197714,Unsafe,RNA,False,True,2.2,5.9,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 1.8 nTPM; continuous selectivity; adrenal gland: 4.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 0.7 nTPM; continuous selectivity; basal ganglia: 0.8 nTPM; continuous selectivity; bone marrow: 5.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 1.2 nTPM; continuous selectivity; cerebral cortex: 1 nTPM; continuous selectivity; choroid plexus: 1.1 nTPM; continuous selectivity; colon: 0.9 nTPM; continuous selectivity; esophagus: 1.2 nTPM; continuous selectivity; heart muscle: 1.4 nTPM; continuous selectivity; hippocampal formation: 0.7 nTPM; continuous selectivity; kidney: 1.1 nTPM; continuous selectivity; liver: 1.4 nTPM; continuous selectivity; lung: 1.3 nTPM; continuous selectivity; pancreas: 1 nTPM; continuous selectivity; parathyroid gland: 1.3 nTPM; continuous selectivity; pituitary gland: 1.6 nTPM; continuous selectivity; retina: 2.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 1.3 nTPM; continuous selectivity; skeletal muscle: 1.5 nTPM; continuous selectivity; skin: 1.8 nTPM; continuous selectivity; small intestine: 0.7 nTPM; continuous selectivity; smooth muscle: 1.1 nTPM; continuous selectivity; spinal cord: 0.9 nTPM; continuous selectivity; spleen: 1.4 nTPM; continuous selectivity; stomach: 0.9 nTPM; continuous selectivity; thyroid gland: 1.4 nTPM; continuous selectivity; tongue: 1.2 nTPM; continuous selectivity; urinary bladder: 1.1 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 4.8 nTPM (limit 2); bone marrow: 5.9 nTPM (limit 2); retina: 2.5 nTPM (limit 2); adrenal gland: 4.8 nTPM (baseline 2); bone marrow: 5.9 nTPM (baseline 2); retina: 2.5 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 485/486 (99.8%),prostate cancer: 9/11 (81.8%); melanoma: 8/10 (80.0%),31,20,Q14592,https://www.uniprot.org/uniprotkb/Q14592/entry,May be involved in transcriptional regulation,Ubiquitously expressed at low levels. Highest levels are found in pancreas and liver,,,Nucleus,,15004467,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF483,ENSG00000173258,Unsafe,RNA,False,True,8.1,11.3,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 5.8 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 2.1 nTPM; absolute ceiling; bone marrow: 3.4 nTPM; absolute ceiling;continuous selectivity; cerebellum: 4.2 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 10.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 7.6 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 2.4 nTPM; absolute ceiling;continuous selectivity; kidney: 2.1 nTPM; absolute ceiling; midbrain: 2.4 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 3.8 nTPM; continuous selectivity; pituitary gland: 5.8 nTPM; absolute ceiling;continuous selectivity; retina: 11.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 2.2 nTPM; absolute ceiling;continuous selectivity; spinal cord: 2.8 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 5.8 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 5.8 nTPM (limit 2); basal ganglia: 2.1 nTPM (limit 2); bone marrow: 3.4 nTPM (limit 2); cerebellum: 4.2 nTPM (limit 2); cerebral cortex: 10.6 nTPM (limit 2); choroid plexus: 7.6 nTPM (limit 2); hypothalamus: 2.4 nTPM (limit 2); kidney: 2.1 nTPM (limit 2); midbrain: 2.4 nTPM (limit 2); pituitary gland: 5.8 nTPM (limit 2); retina: 11.3 nTPM (limit 2); smooth muscle: 2.2 nTPM (limit 2); spinal cord: 2.8 nTPM (limit 2); adrenal gland: 5.8 nTPM (baseline 2); basal ganglia: 2.1 nTPM (baseline 2); bone marrow: 3.4 nTPM (baseline 2); cerebellum: 4.2 nTPM (baseline 2); cerebral cortex: 10.6 nTPM (baseline 2); choroid plexus: 7.6 nTPM (baseline 2); hypothalamus: 2.4 nTPM (baseline 2); kidney: 2.1 nTPM (baseline 2); midbrain: 2.4 nTPM (baseline 2); pituitary gland: 5.8 nTPM (baseline 2); retina: 11.3 nTPM (baseline 2); smooth muscle: 2.2 nTPM (baseline 2); spinal cord: 2.8 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Pancreatic Adenocarcinoma (validation): 61/80 (76.2%); Testicular Germ Cell Tumor (TCGA): 83/133 (62.4%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8TF39,https://www.uniprot.org/uniprotkb/Q8TF39/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF485,ENSG00000198298,Unsafe,RNA,False,True,3.8,4.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 1.6 nTPM; continuous selectivity; amygdala: 1.2 nTPM; continuous selectivity; basal ganglia: 1.3 nTPM; continuous selectivity; cerebellum: 1.5 nTPM; continuous selectivity; cerebral cortex: 1.3 nTPM; continuous selectivity; colon: 1.9 nTPM; continuous selectivity; duodenum: 1.6 nTPM; continuous selectivity; esophagus: 1.8 nTPM; continuous selectivity; heart muscle: 1.3 nTPM; continuous selectivity; hippocampal formation: 1.3 nTPM; continuous selectivity; hypothalamus: 1.2 nTPM; continuous selectivity; kidney: 2 nTPM; continuous selectivity; liver: 1.7 nTPM; continuous selectivity; lung: 1.2 nTPM; continuous selectivity; lymph node: 3.1 nTPM; continuous selectivity; midbrain: 1.4 nTPM; continuous selectivity; pancreas: 4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 1.4 nTPM; continuous selectivity; rectum: 1.8 nTPM; continuous selectivity; retina: 1.1 nTPM; continuous selectivity; salivary gland: 1.7 nTPM; continuous selectivity; skeletal muscle: 3 nTPM; absolute ceiling;continuous selectivity; skin: 3.2 nTPM; continuous selectivity; small intestine: 1.5 nTPM; continuous selectivity; smooth muscle: 1.4 nTPM; continuous selectivity; spinal cord: 1.4 nTPM; continuous selectivity; spleen: 2.1 nTPM; continuous selectivity; stomach: 2.2 nTPM; continuous selectivity; thymus: 1.9 nTPM; continuous selectivity; tongue: 2.4 nTPM; continuous selectivity; urinary bladder: 1.6 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,pancreas: 4 nTPM (limit 2); skeletal muscle: 3 nTPM (limit 2); pancreas: 4 nTPM (baseline 2); skeletal muscle: 3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 46/50 (92.0%); Rectum Adenocarcinoma (validation): 160/207 (77.3%),breast cancer: 1/11 (9.1%); lung cancer: 1/12 (8.3%),31,20,Q8NCK3,https://www.uniprot.org/uniprotkb/Q8NCK3/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF490,ENSG00000188033,Unsafe,High RNA,False,True,2.0,2.4,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 0.9 nTPM; continuous selectivity; bone marrow: 1.6 nTPM; continuous selectivity; cerebellum: 0.7 nTPM; continuous selectivity; cerebral cortex: 1.9 nTPM; continuous selectivity; choroid plexus: 1.4 nTPM; continuous selectivity; colon: 1.1 nTPM; continuous selectivity; duodenum: 1.1 nTPM; continuous selectivity; esophagus: 0.8 nTPM; continuous selectivity; heart muscle: 0.8 nTPM; continuous selectivity; kidney: 1.2 nTPM; continuous selectivity; liver: 1.7 nTPM; continuous selectivity; lung: 1.3 nTPM; continuous selectivity; lymph node: 2 nTPM; continuous selectivity;reproductive not higher; pancreas: 1.4 nTPM; continuous selectivity; parathyroid gland: 1.8 nTPM; continuous selectivity; rectum: 1.2 nTPM; continuous selectivity; retina: 2 nTPM; continuous selectivity;reproductive not higher; salivary gland: 1.1 nTPM; continuous selectivity; skeletal muscle: 0.9 nTPM; continuous selectivity; skin: 1.7 nTPM; continuous selectivity; small intestine: 0.8 nTPM; continuous selectivity; smooth muscle: 0.9 nTPM; continuous selectivity; spleen: 2.3 nTPM; continuous selectivity;reproductive not higher; stomach: 1.1 nTPM; continuous selectivity; thymus: 2.1 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 2.2 nTPM; continuous selectivity;reproductive not higher; tongue: 1 nTPM; continuous selectivity; urinary bladder: 0.9 nTPM; continuous selectivity,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,True,"brain/excitatory neurons cluster c-0: 11 nTPM, 1655 reads; reproductive-cell max 11; brain/excitatory neurons cluster c-22: 11.3 nTPM, 489 reads; reproductive-cell max 11; brain/excitatory neurons cluster c-33: 12.4 nTPM, 307 reads; reproductive-cell max 11; brain/excitatory neurons cluster c-34: 13.4 nTPM, 334 reads; reproductive-cell max 11; brain/excitatory neurons cluster c-39: 11.1 nTPM, 125 reads; reproductive-cell max 11; esophagus/fibroblasts cluster c-0: 13.3 nTPM, 50 reads; reproductive-cell max 11; esophagus/fibroblasts cluster c-4: 11 nTPM, 26 reads; reproductive-cell max 11; lymph node/b-cells cluster c-0: 19.3 nTPM, 92 reads; reproductive-cell max 11; lymph node/b-cells cluster c-1: 21.3 nTPM, 66 reads; reproductive-cell max 11; lymph node/t-cells cluster c-2: 15.2 nTPM, 56 reads; reproductive-cell max 11; lymph node/t-cells cluster c-3: 13.1 nTPM, 34 reads; reproductive-cell max 11; lymph node/b-cells cluster c-4: 30.7 nTPM, 41 reads; reproductive-cell max 11; bone marrow/t-cells cluster c-0: 12.7 nTPM, 39 reads; reproductive-cell max 11; spleen/b-cells cluster c-0: 11.1 nTPM, 31 reads; reproductive-cell max 11; spleen/t-cells cluster c-1: 15.1 nTPM, 30 reads; reproductive-cell max 11; spleen/t-cells cluster c-2: 13.7 nTPM, 25 reads; reproductive-cell max 11; spleen/plasma cells cluster c-4: 13.2 nTPM, 55 reads; reproductive-cell max 11; stomach/b-cells cluster c-0: 12.2 nTPM, 29 reads; reproductive-cell max 11; stomach/t-cells cluster c-1: 17.4 nTPM, 45 reads; reproductive-cell max 11; stomach/t-cells cluster c-2: 14.5 nTPM, 39 reads; reproductive-cell max 11; stomach/t-cells cluster c-3: 13.9 nTPM, 22 reads; reproductive-cell max 11; stomach/t-cells cluster c-4: 12.4 nTPM, 21 reads; reproductive-cell max 11; stomach/plasma cells cluster c-5: 25.5 nTPM, 61 reads; reproductive-cell max 11; prostate/macrophages cluster c-6: 12.1 nTPM, 71 reads; reproductive-cell max 11; thymus/t-cells cluster c-0: 11.4 nTPM, 270 reads; reproductive-cell max 11; thymus/b-cells cluster c-2: 11.6 nTPM, 129 reads; reproductive-cell max 11; thymus/t-cells cluster c-18: 16.7 nTPM, 28 reads; reproductive-cell max 11; thymus/plasma cells cluster c-19: 11.6 nTPM, 21 reads; reproductive-cell max 11; breast/macrophages cluster c-3: 16.4 nTPM, 154 reads; reproductive-cell max 11; breast/macrophages cluster c-18: 13.2 nTPM, 112 reads; reproductive-cell max 11",True,True,"DICE NK (unstimulated): 29/90 values ≥5 TPM, max 7.49745; hpa_immune_monaco basophil: 15.7 TPM; hpa_immune_monaco Central memory CD8 T-cell: 9.3 TPM; hpa_immune_monaco Effector memory CD8 T-cell: 10.1 TPM; hpa_immune_monaco Exhausted memory B-cell: 5.2 TPM; hpa_immune_monaco intermediate monocyte: 6.5 TPM; hpa_immune_monaco MAIT T-cell: 8.3 TPM; hpa_immune_monaco Memory CD4 T-cell TFH: 6.1 TPM; hpa_immune_monaco Memory CD4 T-cell Th1: 5.8 TPM; hpa_immune_monaco Memory CD4 T-cell Th1/Th17: 7.7 TPM; hpa_immune_monaco Memory CD4 T-cell Th17: 5 TPM; hpa_immune_monaco Memory CD4 T-cell Th2: 7.1 TPM; hpa_immune_monaco naive B-cell: 9.9 TPM; hpa_immune_monaco naive CD4 T-cell: 5.3 TPM; hpa_immune_monaco naive CD8 T-cell: 7.7 TPM; hpa_immune_monaco NK-cell: 11.2 TPM; hpa_immune_monaco non-classical monocyte: 8.3 TPM; hpa_immune_monaco Non-switched memory B-cell: 9.1 TPM; hpa_immune_monaco Non-Vd2 gdTCR: 9.7 TPM; hpa_immune_monaco plasmacytoid DC: 11.2 TPM; hpa_immune_monaco Progenitor cell: 15.8 TPM; hpa_immune_monaco Switched memory B-cell: 6.2 TPM; hpa_immune_monaco T-reg: 5.6 TPM; hpa_immune_monaco Terminal effector memory CD4 T-cell: 10.9 TPM; hpa_immune_monaco Terminal effector memory CD8 T-cell: 8.5 TPM; hpa_immune_monaco Vd2 gdTCR: 8.9 TPM",True,True,False,,True,True,"Adrenal gland/Glandular cells: Low, HPA005576; conflicting or uncurated primary profile; Bronchus/Respiratory epithelial cells: Medium, HPA005576; conflicting or uncurated primary profile; Cerebellum/Purkinje cells: Low, HPA005576; conflicting or uncurated primary profile; Cerebral cortex/Endothelial cells: Medium, HPA005576; conflicting or uncurated primary profile; Cerebral cortex/Glial cells: Low, HPA005576; conflicting or uncurated primary profile; Cerebral cortex/Neuropil: Low, HPA005576; conflicting or uncurated primary profile; Colon/Endothelial cells: Medium, HPA005576; conflicting or uncurated primary profile; Colon/Glandular cells: High, HPA005576; conflicting or uncurated primary profile; Duodenum/Glandular cells: Medium, HPA005576; conflicting or uncurated primary profile; Esophagus/Squamous epithelial cells: Low, HPA005576; conflicting or uncurated primary profile; Heart muscle/Cardiomyocytes: Low, HPA005576; conflicting or uncurated primary profile; Hippocampus/Glial cells: Low, HPA005576; conflicting or uncurated primary profile; Kidney/Cells in glomeruli: Medium, HPA005576; conflicting or uncurated primary profile; Kidney/Cells in tubules: Low, HPA005576; conflicting or uncurated primary profile; Lung/Macrophages: Low, HPA005576; conflicting or uncurated primary profile; Nasopharynx/Respiratory epithelial cells: Medium, HPA005576; conflicting or uncurated primary profile; Oral mucosa/Squamous epithelial cells: Medium, HPA005576; conflicting or uncurated primary profile; Pancreas/Exocrine glandular cells: Medium, HPA005576; conflicting or uncurated primary profile; Pancreas/Pancreatic endocrine cells: Low, HPA005576; conflicting or uncurated primary profile; Rectum/Glandular cells: Medium, HPA005576; conflicting or uncurated primary profile; Skeletal muscle/Myocytes: Medium, HPA005576; conflicting or uncurated primary profile; Skin 1/Keratinocytes: Low, HPA005576; conflicting or uncurated primary profile; Skin 1/Langerhans: Low, HPA005576; conflicting or uncurated primary profile; Skin 2/Epidermal cells: Medium, HPA005576; conflicting or uncurated primary profile; Small intestine/Glandular cells: High, HPA005576; conflicting or uncurated primary profile; Smooth muscle/Smooth muscle cells: High, HPA005576; conflicting or uncurated primary profile; Stomach 1/Glandular cells: Medium, HPA005576; conflicting or uncurated primary profile; Stomach 2/Glandular cells: Medium, HPA005576; conflicting or uncurated primary profile; Urinary bladder/Urothelial cells: Medium, HPA005576; conflicting or uncurated primary profile",False,True,True,Neither,Antibody,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,15.8,41.6,"hpa_single_cell_tissue: esophagus/plasma cells, max 41.6 nTPM, 1 observations >30; hpa_single_cell_tissue: lymph node/b-cells, max 30.7 nTPM, 1 observations >30",Neither,oncoref.target-sets.2026-10-23.2,15.8 TPM; blood/Progenitor cell; hpa_immune_monaco; vital,41.6 nTPM; esophagus/plasma cells; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 58/58 (100.0%); Rectum Adenocarcinoma (validation): 192/207 (92.8%); Colon Adenocarcinoma (validation): 433/486 (89.1%),colorectal cancer: 9/11 (81.8%); pancreatic cancer: 8/11 (72.7%),31,20,Q9ULM2,https://www.uniprot.org/uniprotkb/Q9ULM2/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF492,ENSG00000229676,Unsafe,RNA,False,True,1.9,2.5,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 2.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 2.5 nTPM (limit 2); bone marrow: 2.5 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 88/133 (66.2%); Glioblastoma Multiforme (validation): 11/58 (19.0%); Uterine Corpus Endometrial Carcinoma (TCGA): 13/176 (7.4%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q9P255,https://www.uniprot.org/uniprotkb/Q9P255/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination; inclusion depends on TGCT under this study's thresholds,,,,,,,,
ZNF525,ENSG00000203326,Unsafe,RNA,False,True,10.5,13.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 4.5 nTPM; absolute ceiling;continuous selectivity; amygdala: 2.1 nTPM; absolute ceiling; basal ganglia: 2.4 nTPM; absolute ceiling; bone marrow: 4.8 nTPM; absolute ceiling;continuous selectivity; cerebellum: 5.7 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 2.8 nTPM; absolute ceiling;continuous selectivity; colon: 3.8 nTPM; continuous selectivity; duodenum: 3.8 nTPM; absolute ceiling;continuous selectivity; esophagus: 4.1 nTPM; continuous selectivity; heart muscle: 2.3 nTPM; absolute ceiling; hippocampal formation: 2.3 nTPM; absolute ceiling; hypothalamus: 2.2 nTPM; absolute ceiling; kidney: 6 nTPM; absolute ceiling;continuous selectivity; liver: 2.3 nTPM; absolute ceiling; lung: 3.3 nTPM; absolute ceiling;continuous selectivity; lymph node: 7.7 nTPM; absolute ceiling;continuous selectivity; pancreas: 5.9 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 13.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 5.4 nTPM; absolute ceiling;continuous selectivity; rectum: 5 nTPM; continuous selectivity; retina: 4.8 nTPM; absolute ceiling;continuous selectivity; salivary gland: 4.4 nTPM; continuous selectivity; skin: 8.2 nTPM; continuous selectivity; small intestine: 5.2 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 2.5 nTPM; absolute ceiling; spinal cord: 2.2 nTPM; absolute ceiling; spleen: 6.2 nTPM; continuous selectivity; stomach: 5.4 nTPM; continuous selectivity; thymus: 6.3 nTPM; continuous selectivity; thyroid gland: 5.1 nTPM; continuous selectivity; urinary bladder: 4.7 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 4.5 nTPM (limit 2); amygdala: 2.1 nTPM (limit 2); basal ganglia: 2.4 nTPM (limit 2); bone marrow: 4.8 nTPM (limit 2); cerebellum: 5.7 nTPM (limit 2); choroid plexus: 2.8 nTPM (limit 2); duodenum: 3.8 nTPM (limit 2); heart muscle: 2.3 nTPM (limit 2); hippocampal formation: 2.3 nTPM (limit 2); hypothalamus: 2.2 nTPM (limit 2); kidney: 6 nTPM (limit 2); liver: 2.3 nTPM (limit 2); lung: 3.3 nTPM (limit 2); lymph node: 7.7 nTPM (limit 6); pancreas: 5.9 nTPM (limit 2); parathyroid gland: 13.6 nTPM (limit 6); pituitary gland: 5.4 nTPM (limit 2); retina: 4.8 nTPM (limit 2); small intestine: 5.2 nTPM (limit 2); smooth muscle: 2.5 nTPM (limit 2); spinal cord: 2.2 nTPM (limit 2); adrenal gland: 4.5 nTPM (baseline 2); amygdala: 2.1 nTPM (baseline 2); basal ganglia: 2.4 nTPM (baseline 2); bone marrow: 4.8 nTPM (baseline 2); cerebellum: 5.7 nTPM (baseline 2); choroid plexus: 2.8 nTPM (baseline 2); duodenum: 3.8 nTPM (baseline 2); heart muscle: 2.3 nTPM (baseline 2); hippocampal formation: 2.3 nTPM (baseline 2); hypothalamus: 2.2 nTPM (baseline 2); kidney: 6 nTPM (baseline 2); liver: 2.3 nTPM (baseline 2); lung: 3.3 nTPM (baseline 2); lymph node: 7.7 nTPM (baseline 6); pancreas: 5.9 nTPM (baseline 2); parathyroid gland: 13.6 nTPM (baseline 6); pituitary gland: 5.4 nTPM (baseline 2); retina: 4.8 nTPM (baseline 2); small intestine: 5.2 nTPM (baseline 2); smooth muscle: 2.5 nTPM (baseline 2); spinal cord: 2.2 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Rectum Adenocarcinoma (validation): 198/207 (95.7%); Testicular Germ Cell Tumor (TCGA): 127/133 (95.5%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8N782,https://www.uniprot.org/uniprotkb/Q8N782/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF527,ENSG00000189164,Unsafe,RNA,False,True,3.2,3.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 2 nTPM; continuous selectivity; adrenal gland: 2 nTPM; continuous selectivity; amygdala: 1.4 nTPM; continuous selectivity; basal ganglia: 1.6 nTPM; continuous selectivity; bone marrow: 2.3 nTPM; absolute ceiling;continuous selectivity; cerebellum: 2 nTPM; continuous selectivity; cerebral cortex: 1.7 nTPM; continuous selectivity; choroid plexus: 1 nTPM; continuous selectivity; colon: 2.5 nTPM; continuous selectivity; esophagus: 1.4 nTPM; continuous selectivity; heart muscle: 2.2 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 1.5 nTPM; continuous selectivity; hypothalamus: 1.7 nTPM; continuous selectivity; kidney: 2.1 nTPM; absolute ceiling;continuous selectivity; liver: 1.7 nTPM; continuous selectivity; lung: 1.4 nTPM; continuous selectivity; lymph node: 2 nTPM; continuous selectivity; midbrain: 1.5 nTPM; continuous selectivity; pancreas: 1.6 nTPM; continuous selectivity; parathyroid gland: 2.6 nTPM; continuous selectivity; pituitary gland: 2.2 nTPM; absolute ceiling;continuous selectivity; rectum: 1.4 nTPM; continuous selectivity; retina: 3.1 nTPM; absolute ceiling;continuous selectivity; salivary gland: 1.8 nTPM; continuous selectivity; skeletal muscle: 2.2 nTPM; absolute ceiling;continuous selectivity; skin: 1.7 nTPM; continuous selectivity; small intestine: 1.7 nTPM; continuous selectivity; smooth muscle: 1.8 nTPM; continuous selectivity; spinal cord: 1.5 nTPM; continuous selectivity; spleen: 1.9 nTPM; continuous selectivity; stomach: 1.7 nTPM; continuous selectivity; thymus: 2.4 nTPM; continuous selectivity; thyroid gland: 2.4 nTPM; continuous selectivity; tongue: 2.9 nTPM; continuous selectivity; urinary bladder: 2.3 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 2.3 nTPM (limit 2); heart muscle: 2.2 nTPM (limit 2); kidney: 2.1 nTPM (limit 2); pituitary gland: 2.2 nTPM (limit 2); retina: 3.1 nTPM (limit 2); skeletal muscle: 2.2 nTPM (limit 2); bone marrow: 2.3 nTPM (baseline 2); heart muscle: 2.2 nTPM (baseline 2); kidney: 2.1 nTPM (baseline 2); pituitary gland: 2.2 nTPM (baseline 2); retina: 3.1 nTPM (baseline 2); skeletal muscle: 2.2 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 43/50 (86.0%); Pancreatic Adenocarcinoma (validation): 57/80 (71.2%),ovarian cancer: 12/12 (100.0%); colorectal cancer: 11/12 (91.7%),31,20,Q8NB42,https://www.uniprot.org/uniprotkb/Q8NB42/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF541,ENSG00000118156,Unsafe,High RNA,False,True,20.8,20.8,86,3,Positive somewhere,False,False,False,True,Retained,Reproductive,True,,Not assessed,,,All available point-screen rules pass,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,False,,True,False,,True,True,False,,True,False,,False,True,True,CTA,Pass,oncoref.target-sets.2026-10-23.1,False,False,,CTA → Unsafe,True,True,True,4.6100323866,34.7,"hpa_single_cell_tissue: kidney/proximal tubular cells, max 34.7 nTPM, 1 observations >30",CTA,oncoref.target-sets.2026-10-23.2,4.61 TPM; blood/TREG_NAIVE; dice_treg_naive; vital,34.7 nTPM; kidney/proximal tubular cells; hpa_single_cell_tissue; vital,Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 108/283 (38.2%); Kidney Renal Papillary Cell Carcinoma (TCGA): 64/282 (22.7%); Breast Invasive Carcinoma (validation): 9/50 (18.0%),breast cancer: 0/12 (0.0%); cervical cancer: 0/12 (0.0%),31,20,Q9H0D2,https://www.uniprot.org/uniprotkb/Q9H0D2/entry,"Transcription regulator which is essential for male fertility and for the completion of meiotic prophase in spermatocytes. Regulates progression of the pachytene stage of meiotic prophase by activating the expression of genes involved in meiosis during spermatogenesis. Maintains the repression of pre-pachytene transcriptional programs, including meiotic double-strand breaks (DSB) formation genes in pachytene spermatocytes and suppresses aberrant DSB formation after mid-pachytene, thus ensuring meiosis progression",,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
ZNF543,ENSG00000178229,Unsafe,RNA,False,True,3.8,3.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 1.4 nTPM; continuous selectivity; basal ganglia: 1.1 nTPM; continuous selectivity; bone marrow: 1.8 nTPM; continuous selectivity; cerebellum: 1.6 nTPM; continuous selectivity; cerebral cortex: 1.5 nTPM; continuous selectivity; esophagus: 1.9 nTPM; continuous selectivity; heart muscle: 1.4 nTPM; continuous selectivity; kidney: 1.5 nTPM; continuous selectivity; liver: 1.1 nTPM; continuous selectivity; lung: 1.6 nTPM; continuous selectivity; lymph node: 2.3 nTPM; continuous selectivity; pancreas: 1.8 nTPM; continuous selectivity; parathyroid gland: 2.9 nTPM; continuous selectivity; pituitary gland: 1.7 nTPM; continuous selectivity; retina: 2.6 nTPM; absolute ceiling;continuous selectivity; salivary gland: 1.6 nTPM; continuous selectivity; skeletal muscle: 1.7 nTPM; continuous selectivity; skin: 2.3 nTPM; continuous selectivity; small intestine: 1.1 nTPM; continuous selectivity; smooth muscle: 1.9 nTPM; continuous selectivity; spleen: 2.5 nTPM; continuous selectivity; stomach: 1.6 nTPM; continuous selectivity; thymus: 3.1 nTPM; continuous selectivity; thyroid gland: 2.5 nTPM; continuous selectivity; tongue: 1.8 nTPM; continuous selectivity; urinary bladder: 1.5 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 2.6 nTPM (limit 2); retina: 2.6 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Pancreatic Adenocarcinoma (validation): 74/80 (92.5%); Breast Invasive Carcinoma (validation): 44/50 (88.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q08ER8,https://www.uniprot.org/uniprotkb/Q08ER8/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF546,ENSG00000187187,Unsafe,RNA,False,True,13.2,13.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 2.7 nTPM; absolute ceiling; basal ganglia: 2.6 nTPM; absolute ceiling; cerebellum: 2.9 nTPM; absolute ceiling; heart muscle: 2.4 nTPM; absolute ceiling; kidney: 2.2 nTPM; absolute ceiling; liver: 3.6 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 2.7 nTPM; absolute ceiling; retina: 2.3 nTPM; absolute ceiling; skeletal muscle: 2.4 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 2.7 nTPM (limit 2); basal ganglia: 2.6 nTPM (limit 2); cerebellum: 2.9 nTPM (limit 2); heart muscle: 2.4 nTPM (limit 2); kidney: 2.2 nTPM (limit 2); liver: 3.6 nTPM (limit 2); pituitary gland: 2.7 nTPM (limit 2); retina: 2.3 nTPM (limit 2); skeletal muscle: 2.4 nTPM (limit 2); adrenal gland: 2.7 nTPM (baseline 2); basal ganglia: 2.6 nTPM (baseline 2); cerebellum: 2.9 nTPM (baseline 2); heart muscle: 2.4 nTPM (baseline 2); kidney: 2.2 nTPM (baseline 2); liver: 3.6 nTPM (baseline 2); pituitary gland: 2.7 nTPM (baseline 2); retina: 2.3 nTPM (baseline 2); skeletal muscle: 2.4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 40/50 (80.0%); Pancreatic Adenocarcinoma (validation): 32/80 (40.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q86UE3,https://www.uniprot.org/uniprotkb/Q86UE3/entry,May be involved in transcriptional regulation,,,,Nucleus,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF548,ENSG00000188785,Unsafe,Protein,False,True,11.9,25.9,78,63,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 13.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; adrenal gland: 6.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 3.9 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 4.3 nTPM; absolute ceiling;continuous selectivity; bone marrow: 25.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 10.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 5.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 8.4 nTPM; absolute ceiling;continuous selectivity; colon: 9.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 6.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 7.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 10.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 4.3 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 4.1 nTPM; absolute ceiling;continuous selectivity; kidney: 6.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 6.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 11.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 23.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 3.7 nTPM; absolute ceiling;continuous selectivity; pancreas: 6.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 8.3 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 6.9 nTPM; absolute ceiling;continuous selectivity; rectum: 7.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 12.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 6.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 7.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 10 nTPM; positive ihc;continuous selectivity; small intestine: 14.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; smooth muscle: 11.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 4.6 nTPM; absolute ceiling;continuous selectivity; spleen: 18.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; stomach: 7 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 13 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 11.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 5.3 nTPM; continuous selectivity; urinary bladder: 8.1 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 13.4 nTPM (limit 10); adrenal gland: 6.6 nTPM (limit 2); amygdala: 3.9 nTPM (limit 2); basal ganglia: 4.3 nTPM (limit 2); bone marrow: 25.9 nTPM (limit 2); cerebellum: 10.5 nTPM (limit 2); cerebral cortex: 5.5 nTPM (limit 2); choroid plexus: 8.4 nTPM (limit 2); colon: 9.6 nTPM (limit 6); duodenum: 6.6 nTPM (limit 2); esophagus: 7.8 nTPM (limit 6); heart muscle: 10.7 nTPM (limit 2); hippocampal formation: 4.3 nTPM (limit 2); hypothalamus: 4.1 nTPM (limit 2); kidney: 6.3 nTPM (limit 2); liver: 6.6 nTPM (limit 2); lung: 11.6 nTPM (limit 2); lymph node: 23.2 nTPM (limit 6); midbrain: 3.7 nTPM (limit 2); pancreas: 6.6 nTPM (limit 2); parathyroid gland: 8.3 nTPM (limit 6); pituitary gland: 6.9 nTPM (limit 2); rectum: 7.9 nTPM (limit 6); retina: 12.2 nTPM (limit 2); salivary gland: 6.9 nTPM (limit 6); skeletal muscle: 7.3 nTPM (limit 2); small intestine: 14.2 nTPM (limit 2); smooth muscle: 11.2 nTPM (limit 2); spinal cord: 4.6 nTPM (limit 2); spleen: 18.4 nTPM (limit 10); stomach: 7 nTPM (limit 6); thymus: 13 nTPM (limit 10); thyroid gland: 11.4 nTPM (limit 10); urinary bladder: 8.1 nTPM (limit 6); adipose tissue: 13.4 nTPM (baseline 10); adrenal gland: 6.6 nTPM (baseline 2); amygdala: 3.9 nTPM (baseline 2); basal ganglia: 4.3 nTPM (baseline 2); bone marrow: 25.9 nTPM (baseline 2); cerebellum: 10.5 nTPM (baseline 2); cerebral cortex: 5.5 nTPM (baseline 2); choroid plexus: 8.4 nTPM (baseline 2); colon: 9.6 nTPM (baseline 6); duodenum: 6.6 nTPM (baseline 2); esophagus: 7.8 nTPM (baseline 6); heart muscle: 10.7 nTPM (baseline 2); hippocampal formation: 4.3 nTPM (baseline 2); hypothalamus: 4.1 nTPM (baseline 2); kidney: 6.3 nTPM (baseline 2); liver: 6.6 nTPM (baseline 2); lung: 11.6 nTPM (baseline 2); lymph node: 23.2 nTPM (baseline 6); midbrain: 3.7 nTPM (baseline 2); pancreas: 6.6 nTPM (baseline 2); parathyroid gland: 8.3 nTPM (baseline 6); pituitary gland: 6.9 nTPM (baseline 2); rectum: 7.9 nTPM (baseline 6); retina: 12.2 nTPM (baseline 2); salivary gland: 6.9 nTPM (baseline 6); skeletal muscle: 7.3 nTPM (baseline 2); small intestine: 14.2 nTPM (baseline 2); smooth muscle: 11.2 nTPM (baseline 2); spinal cord: 4.6 nTPM (baseline 2); spleen: 18.4 nTPM (baseline 10); stomach: 7 nTPM (baseline 6); thymus: 13 nTPM (baseline 10); thyroid gland: 11.4 nTPM (baseline 10); urinary bladder: 8.1 nTPM (baseline 6),adrenal gland / glandular cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / neuronal cells: Low (Uncertain); cerebellum / cells in granular layer: Medium (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / neuronal cells: Low (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / endothelial cells: Medium (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: Medium (Uncertain); duodenum / glandular cells: High (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / neuronal cells: Low (Uncertain); kidney / cells in glomeruli: Low (Uncertain); kidney / cells in tubules: High (Uncertain); liver / cholangiocytes: Low (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / alveolar cells: Low (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Low (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: Low (Uncertain); skin 1 / keratinocytes: Low (Uncertain); skin 1 / Langerhans: Low (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: High (Uncertain); smooth muscle / smooth muscle cells: Low (Uncertain); spleen / cells in white pulp: Medium (Uncertain); stomach 1 / glandular cells: High (Uncertain); stomach 2 / glandular cells: High (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 80/80 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Lung Squamous Cell Carcinoma (validation): 67/68 (98.5%),breast cancer: 7/11 (63.6%); pancreatic cancer: 7/11 (63.6%),31,20,Q8NEK5,https://www.uniprot.org/uniprotkb/Q8NEK5/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF555,ENSG00000186300,Unsafe,RNA,False,True,5.6,5.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 1.8 nTPM; continuous selectivity; bone marrow: 2.7 nTPM; absolute ceiling;continuous selectivity; cerebellum: 2.4 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 2 nTPM; continuous selectivity; colon: 2.4 nTPM; continuous selectivity; esophagus: 3.2 nTPM; continuous selectivity; heart muscle: 2.9 nTPM; absolute ceiling;continuous selectivity; kidney: 2.9 nTPM; absolute ceiling;continuous selectivity; liver: 2.2 nTPM; absolute ceiling;continuous selectivity; lung: 2.1 nTPM; absolute ceiling;continuous selectivity; lymph node: 2.3 nTPM; continuous selectivity; pancreas: 2.6 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 3.2 nTPM; continuous selectivity; pituitary gland: 1.8 nTPM; continuous selectivity; retina: 5.4 nTPM; absolute ceiling;continuous selectivity; salivary gland: 2.2 nTPM; continuous selectivity; skeletal muscle: 2.6 nTPM; absolute ceiling;continuous selectivity; small intestine: 1.6 nTPM; continuous selectivity; smooth muscle: 2.1 nTPM; absolute ceiling;continuous selectivity; spleen: 2.7 nTPM; continuous selectivity; stomach: 2.1 nTPM; continuous selectivity; thyroid gland: 3.9 nTPM; continuous selectivity; tongue: 4.5 nTPM; continuous selectivity; urinary bladder: 2.6 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 2.7 nTPM (limit 2); cerebellum: 2.4 nTPM (limit 2); heart muscle: 2.9 nTPM (limit 2); kidney: 2.9 nTPM (limit 2); liver: 2.2 nTPM (limit 2); lung: 2.1 nTPM (limit 2); pancreas: 2.6 nTPM (limit 2); retina: 5.4 nTPM (limit 2); skeletal muscle: 2.6 nTPM (limit 2); smooth muscle: 2.1 nTPM (limit 2); bone marrow: 2.7 nTPM (baseline 2); cerebellum: 2.4 nTPM (baseline 2); heart muscle: 2.9 nTPM (baseline 2); kidney: 2.9 nTPM (baseline 2); liver: 2.2 nTPM (baseline 2); lung: 2.1 nTPM (baseline 2); pancreas: 2.6 nTPM (baseline 2); retina: 5.4 nTPM (baseline 2); skeletal muscle: 2.6 nTPM (baseline 2); smooth muscle: 2.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 47/50 (94.0%); Pancreatic Adenocarcinoma (validation): 37/80 (46.2%),skin cancer: 6/12 (50.0%); prostate cancer: 4/8 (50.0%),31,20,Q8NEP9,https://www.uniprot.org/uniprotkb/Q8NEP9/entry,Transcriptional regulator that positively regulates SLC25A4 expression,Expressed in myoblasts (at protein level),,,Nucleus,26184877,26184877,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF557,ENSG00000130544,Unsafe,RNA,False,True,2.1,3.7,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 1.5 nTPM; continuous selectivity; adrenal gland: 1.9 nTPM; continuous selectivity; amygdala: 1 nTPM; continuous selectivity; basal ganglia: 1.1 nTPM; continuous selectivity; bone marrow: 3.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 2 nTPM; continuous selectivity; cerebral cortex: 1.8 nTPM; continuous selectivity; choroid plexus: 0.8 nTPM; continuous selectivity; colon: 1.5 nTPM; continuous selectivity; duodenum: 1.1 nTPM; continuous selectivity; esophagus: 1.7 nTPM; continuous selectivity; heart muscle: 1.2 nTPM; continuous selectivity; hippocampal formation: 1.2 nTPM; continuous selectivity; hypothalamus: 1.1 nTPM; continuous selectivity; kidney: 1.7 nTPM; continuous selectivity; liver: 2.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 1.3 nTPM; continuous selectivity; lymph node: 2.5 nTPM; continuous selectivity;reproductive not higher; midbrain: 1 nTPM; continuous selectivity; pancreas: 1.7 nTPM; continuous selectivity; parathyroid gland: 1.7 nTPM; continuous selectivity; pituitary gland: 1.5 nTPM; continuous selectivity; rectum: 1.3 nTPM; continuous selectivity; retina: 1.7 nTPM; continuous selectivity; salivary gland: 1.4 nTPM; continuous selectivity; skeletal muscle: 1.3 nTPM; continuous selectivity; skin: 1.9 nTPM; continuous selectivity; small intestine: 1.6 nTPM; continuous selectivity; smooth muscle: 1.5 nTPM; continuous selectivity; spinal cord: 1.2 nTPM; continuous selectivity; spleen: 2.3 nTPM; continuous selectivity;reproductive not higher; stomach: 1.7 nTPM; continuous selectivity; thymus: 2.3 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 2.1 nTPM; continuous selectivity;reproductive not higher; tongue: 1 nTPM; continuous selectivity; urinary bladder: 1.5 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 3.7 nTPM (limit 2); liver: 2.1 nTPM (limit 2); bone marrow: 3.7 nTPM (baseline 2); liver: 2.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Rectum Adenocarcinoma (validation): 205/207 (99.0%); Colon Adenocarcinoma (validation): 479/486 (98.6%),melanoma: 8/12 (66.7%); endometrial cancer: 3/11 (27.3%),31,20,Q8N988,https://www.uniprot.org/uniprotkb/Q8N988/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF559,ENSG00000188321,Unsafe,Protein,False,True,31.7,31.7,89,80,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 13.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 9.6 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 10.8 nTPM; absolute ceiling;continuous selectivity; bone marrow: 3.9 nTPM; positive ihc;absolute ceiling; cerebellum: 13.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 8.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 20.6 nTPM; absolute ceiling;continuous selectivity; colon: 16.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 6.2 nTPM; positive ihc;absolute ceiling; esophagus: 7.2 nTPM; positive ihc;absolute ceiling; heart muscle: 19.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 11 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 11 nTPM; absolute ceiling;continuous selectivity; kidney: 18.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 10.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 12.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 15.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 10.1 nTPM; absolute ceiling;continuous selectivity; pancreas: 10.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 21.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 25.2 nTPM; absolute ceiling;continuous selectivity; rectum: 10.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 19.8 nTPM; absolute ceiling;continuous selectivity; salivary gland: 12 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 4.6 nTPM; positive ihc;absolute ceiling; skin: 10.4 nTPM; positive ihc;absolute ceiling; small intestine: 14.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 18.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 10.2 nTPM; absolute ceiling;continuous selectivity; spleen: 21.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 12.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 21.9 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 19.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 10.2 nTPM; absolute ceiling; urinary bladder: 16.4 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 13.7 nTPM (limit 2); amygdala: 9.6 nTPM (limit 2); basal ganglia: 10.8 nTPM (limit 2); bone marrow: 3.9 nTPM (limit 2); cerebellum: 13.1 nTPM (limit 2); cerebral cortex: 8.3 nTPM (limit 2); choroid plexus: 20.6 nTPM (limit 2); colon: 16.1 nTPM (limit 6); duodenum: 6.2 nTPM (limit 2); esophagus: 7.2 nTPM (limit 6); heart muscle: 19.1 nTPM (limit 2); hippocampal formation: 11 nTPM (limit 2); hypothalamus: 11 nTPM (limit 2); kidney: 18.6 nTPM (limit 2); liver: 10.8 nTPM (limit 2); lung: 12.1 nTPM (limit 2); lymph node: 15.6 nTPM (limit 6); midbrain: 10.1 nTPM (limit 2); pancreas: 10.3 nTPM (limit 2); parathyroid gland: 21.5 nTPM (limit 6); pituitary gland: 25.2 nTPM (limit 2); rectum: 10.7 nTPM (limit 6); retina: 19.8 nTPM (limit 2); salivary gland: 12 nTPM (limit 6); skeletal muscle: 4.6 nTPM (limit 2); skin: 10.4 nTPM (limit 10); small intestine: 14.4 nTPM (limit 2); smooth muscle: 18.5 nTPM (limit 2); spinal cord: 10.2 nTPM (limit 2); spleen: 21.5 nTPM (limit 10); stomach: 12.6 nTPM (limit 6); thymus: 21.9 nTPM (limit 10); thyroid gland: 19.1 nTPM (limit 10); tongue: 10.2 nTPM (limit 6); urinary bladder: 16.4 nTPM (limit 6),adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: High (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / glial cells: Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: High (Approved); colon / peripheral nerve/ganglion: High (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: High (Approved); heart muscle / cardiomyocytes: High (Approved); hippocampus / glial cells: High (Approved); kidney / cells in glomeruli: High (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: Medium (Approved); liver / hepatocytes: High (Approved); lung / alveolar cells type I: High (Approved); lung / alveolar cells type II: High (Approved); lung / endothelial cells: High (Approved); lung / macrophages: High (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: High (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: High (Approved); pancreas / exocrine glandular cells: High (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: High (Approved); skeletal muscle / myocytes: High (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: High (Approved); small intestine / glandular cells: High (Approved); smooth muscle / smooth muscle cells: High (Approved); spleen / cells in red pulp: High (Approved); spleen / cells in white pulp: High (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: High (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Prostate Adenocarcinoma (TCGA): 480/480 (100.0%); Glioblastoma Multiforme (TCGA): 141/141 (100.0%); Testicular Germ Cell Tumor (TCGA): 133/133 (100.0%),cervical cancer: 12/12 (100.0%); melanoma: 12/12 (100.0%),31,20,Q9BR84,https://www.uniprot.org/uniprotkb/Q9BR84/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF564,ENSG00000249709,Unsafe,RNA,False,True,7.2,7.7,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 4.5 nTPM; continuous selectivity; adrenal gland: 3.4 nTPM; absolute ceiling;continuous selectivity; amygdala: 2.3 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 2.8 nTPM; absolute ceiling;continuous selectivity; bone marrow: 4.3 nTPM; absolute ceiling;continuous selectivity; cerebellum: 2.4 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 2.8 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 4 nTPM; absolute ceiling;continuous selectivity; colon: 7.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 6.1 nTPM; absolute ceiling;continuous selectivity; esophagus: 2.9 nTPM; continuous selectivity; heart muscle: 4.9 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 2.3 nTPM; absolute ceiling;continuous selectivity; kidney: 7.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; liver: 5.5 nTPM; absolute ceiling;continuous selectivity; lung: 4.1 nTPM; absolute ceiling;continuous selectivity; lymph node: 6.7 nTPM; absolute ceiling;continuous selectivity; midbrain: 2 nTPM; continuous selectivity; pancreas: 3.6 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 7.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 3.1 nTPM; absolute ceiling;continuous selectivity; rectum: 7 nTPM; absolute ceiling;continuous selectivity; retina: 6.9 nTPM; absolute ceiling;continuous selectivity; salivary gland: 4.7 nTPM; continuous selectivity; skeletal muscle: 6 nTPM; absolute ceiling;continuous selectivity; skin: 5.2 nTPM; continuous selectivity; small intestine: 6.9 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 4.2 nTPM; absolute ceiling;continuous selectivity; spleen: 6.7 nTPM; continuous selectivity; stomach: 6.6 nTPM; absolute ceiling;continuous selectivity; thymus: 7.3 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 7.7 nTPM; continuous selectivity;reproductive not higher; tongue: 7.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 5.1 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 3.4 nTPM (limit 2); amygdala: 2.3 nTPM (limit 2); basal ganglia: 2.8 nTPM (limit 2); bone marrow: 4.3 nTPM (limit 2); cerebellum: 2.4 nTPM (limit 2); cerebral cortex: 2.8 nTPM (limit 2); choroid plexus: 4 nTPM (limit 2); colon: 7.2 nTPM (limit 6); duodenum: 6.1 nTPM (limit 2); heart muscle: 4.9 nTPM (limit 2); hippocampal formation: 2.3 nTPM (limit 2); kidney: 7.4 nTPM (limit 2); liver: 5.5 nTPM (limit 2); lung: 4.1 nTPM (limit 2); lymph node: 6.7 nTPM (limit 6); pancreas: 3.6 nTPM (limit 2); parathyroid gland: 7.3 nTPM (limit 6); pituitary gland: 3.1 nTPM (limit 2); rectum: 7 nTPM (limit 6); retina: 6.9 nTPM (limit 2); skeletal muscle: 6 nTPM (limit 2); small intestine: 6.9 nTPM (limit 2); smooth muscle: 4.2 nTPM (limit 2); stomach: 6.6 nTPM (limit 6); tongue: 7.7 nTPM (limit 6); adrenal gland: 3.4 nTPM (baseline 2); amygdala: 2.3 nTPM (baseline 2); basal ganglia: 2.8 nTPM (baseline 2); bone marrow: 4.3 nTPM (baseline 2); cerebellum: 2.4 nTPM (baseline 2); cerebral cortex: 2.8 nTPM (baseline 2); choroid plexus: 4 nTPM (baseline 2); colon: 7.2 nTPM (baseline 6); duodenum: 6.1 nTPM (baseline 2); heart muscle: 4.9 nTPM (baseline 2); hippocampal formation: 2.3 nTPM (baseline 2); kidney: 7.4 nTPM (baseline 2); liver: 5.5 nTPM (baseline 2); lung: 4.1 nTPM (baseline 2); lymph node: 6.7 nTPM (baseline 6); pancreas: 3.6 nTPM (baseline 2); parathyroid gland: 7.3 nTPM (baseline 6); pituitary gland: 3.1 nTPM (baseline 2); rectum: 7 nTPM (baseline 6); retina: 6.9 nTPM (baseline 2); skeletal muscle: 6 nTPM (baseline 2); small intestine: 6.9 nTPM (baseline 2); smooth muscle: 4.2 nTPM (baseline 2); stomach: 6.6 nTPM (baseline 6); tongue: 7.7 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Colon Adenocarcinoma (validation): 485/486 (99.8%); Breast Invasive Carcinoma (validation): 49/50 (98.0%),cervical cancer: 2/12 (16.7%); endometrial cancer: 2/12 (16.7%),31,20,Q8TBZ8,https://www.uniprot.org/uniprotkb/Q8TBZ8/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF565,ENSG00000196357,Unsafe,RNA,False,True,6.6,6.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 2.5 nTPM; absolute ceiling;continuous selectivity; amygdala: 3.1 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 3.2 nTPM; absolute ceiling;continuous selectivity; bone marrow: 3.6 nTPM; absolute ceiling;continuous selectivity; cerebellum: 2.7 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 3.5 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 3.7 nTPM; absolute ceiling;continuous selectivity; colon: 2.4 nTPM; continuous selectivity; duodenum: 2 nTPM; continuous selectivity; heart muscle: 2.3 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 3.2 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 3.1 nTPM; absolute ceiling;continuous selectivity; kidney: 2.4 nTPM; absolute ceiling;continuous selectivity; liver: 2.9 nTPM; absolute ceiling;continuous selectivity; lung: 2.1 nTPM; absolute ceiling;continuous selectivity; midbrain: 3.4 nTPM; absolute ceiling;continuous selectivity; pancreas: 2.4 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 2.8 nTPM; continuous selectivity; pituitary gland: 2.6 nTPM; absolute ceiling;continuous selectivity; rectum: 2.6 nTPM; continuous selectivity; retina: 3.4 nTPM; absolute ceiling;continuous selectivity; salivary gland: 3.6 nTPM; continuous selectivity; skeletal muscle: 4 nTPM; absolute ceiling;continuous selectivity; skin: 3 nTPM; continuous selectivity; small intestine: 1.9 nTPM; continuous selectivity; smooth muscle: 2.8 nTPM; absolute ceiling;continuous selectivity; spinal cord: 4.2 nTPM; absolute ceiling;continuous selectivity; stomach: 2.9 nTPM; continuous selectivity; thyroid gland: 3 nTPM; continuous selectivity; tongue: 4.4 nTPM; continuous selectivity; urinary bladder: 2.6 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 2.5 nTPM (limit 2); amygdala: 3.1 nTPM (limit 2); basal ganglia: 3.2 nTPM (limit 2); bone marrow: 3.6 nTPM (limit 2); cerebellum: 2.7 nTPM (limit 2); cerebral cortex: 3.5 nTPM (limit 2); choroid plexus: 3.7 nTPM (limit 2); heart muscle: 2.3 nTPM (limit 2); hippocampal formation: 3.2 nTPM (limit 2); hypothalamus: 3.1 nTPM (limit 2); kidney: 2.4 nTPM (limit 2); liver: 2.9 nTPM (limit 2); lung: 2.1 nTPM (limit 2); midbrain: 3.4 nTPM (limit 2); pancreas: 2.4 nTPM (limit 2); pituitary gland: 2.6 nTPM (limit 2); retina: 3.4 nTPM (limit 2); skeletal muscle: 4 nTPM (limit 2); smooth muscle: 2.8 nTPM (limit 2); spinal cord: 4.2 nTPM (limit 2); adrenal gland: 2.5 nTPM (baseline 2); amygdala: 3.1 nTPM (baseline 2); basal ganglia: 3.2 nTPM (baseline 2); bone marrow: 3.6 nTPM (baseline 2); cerebellum: 2.7 nTPM (baseline 2); cerebral cortex: 3.5 nTPM (baseline 2); choroid plexus: 3.7 nTPM (baseline 2); heart muscle: 2.3 nTPM (baseline 2); hippocampal formation: 3.2 nTPM (baseline 2); hypothalamus: 3.1 nTPM (baseline 2); kidney: 2.4 nTPM (baseline 2); liver: 2.9 nTPM (baseline 2); lung: 2.1 nTPM (baseline 2); midbrain: 3.4 nTPM (baseline 2); pancreas: 2.4 nTPM (baseline 2); pituitary gland: 2.6 nTPM (baseline 2); retina: 3.4 nTPM (baseline 2); skeletal muscle: 4 nTPM (baseline 2); smooth muscle: 2.8 nTPM (baseline 2); spinal cord: 4.2 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 48/50 (96.0%); Pancreatic Adenocarcinoma (validation): 48/80 (60.0%),melanoma: 11/11 (100.0%); prostate cancer: 9/12 (75.0%),31,20,Q8N9K5,https://www.uniprot.org/uniprotkb/Q8N9K5/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF568,ENSG00000198453,Unsafe,RNA,False,True,5.8,8.4,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 3.3 nTPM; continuous selectivity; adrenal gland: 4.4 nTPM; absolute ceiling;continuous selectivity; amygdala: 4.9 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 4.2 nTPM; absolute ceiling;continuous selectivity; bone marrow: 1.9 nTPM; continuous selectivity; cerebellum: 5.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 4.3 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 3.3 nTPM; absolute ceiling;continuous selectivity; colon: 3.5 nTPM; continuous selectivity; esophagus: 2.5 nTPM; continuous selectivity; heart muscle: 3 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 4.6 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 5.4 nTPM; absolute ceiling;continuous selectivity; kidney: 3.1 nTPM; absolute ceiling;continuous selectivity; liver: 2.1 nTPM; absolute ceiling;continuous selectivity; lung: 2.6 nTPM; absolute ceiling;continuous selectivity; lymph node: 2.9 nTPM; continuous selectivity; midbrain: 5.2 nTPM; absolute ceiling;continuous selectivity; pancreas: 3 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 5.9 nTPM; continuous selectivity;reproductive not higher; pituitary gland: 4.2 nTPM; absolute ceiling;continuous selectivity; retina: 8.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 3.5 nTPM; continuous selectivity; skeletal muscle: 8.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 3.4 nTPM; continuous selectivity; small intestine: 2.3 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 4.3 nTPM; absolute ceiling;continuous selectivity; spinal cord: 5.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spleen: 4.1 nTPM; continuous selectivity; stomach: 2.8 nTPM; continuous selectivity; thymus: 3.2 nTPM; continuous selectivity; thyroid gland: 5.3 nTPM; continuous selectivity; tongue: 4.3 nTPM; continuous selectivity; urinary bladder: 3.6 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 4.4 nTPM (limit 2); amygdala: 4.9 nTPM (limit 2); basal ganglia: 4.2 nTPM (limit 2); cerebellum: 5.9 nTPM (limit 2); cerebral cortex: 4.3 nTPM (limit 2); choroid plexus: 3.3 nTPM (limit 2); heart muscle: 3 nTPM (limit 2); hippocampal formation: 4.6 nTPM (limit 2); hypothalamus: 5.4 nTPM (limit 2); kidney: 3.1 nTPM (limit 2); liver: 2.1 nTPM (limit 2); lung: 2.6 nTPM (limit 2); midbrain: 5.2 nTPM (limit 2); pancreas: 3 nTPM (limit 2); pituitary gland: 4.2 nTPM (limit 2); retina: 8.4 nTPM (limit 2); skeletal muscle: 8.1 nTPM (limit 2); small intestine: 2.3 nTPM (limit 2); smooth muscle: 4.3 nTPM (limit 2); spinal cord: 5.8 nTPM (limit 2); adrenal gland: 4.4 nTPM (baseline 2); amygdala: 4.9 nTPM (baseline 2); basal ganglia: 4.2 nTPM (baseline 2); cerebellum: 5.9 nTPM (baseline 2); cerebral cortex: 4.3 nTPM (baseline 2); choroid plexus: 3.3 nTPM (baseline 2); heart muscle: 3 nTPM (baseline 2); hippocampal formation: 4.6 nTPM (baseline 2); hypothalamus: 5.4 nTPM (baseline 2); kidney: 3.1 nTPM (baseline 2); liver: 2.1 nTPM (baseline 2); lung: 2.6 nTPM (baseline 2); midbrain: 5.2 nTPM (baseline 2); pancreas: 3 nTPM (baseline 2); pituitary gland: 4.2 nTPM (baseline 2); retina: 8.4 nTPM (baseline 2); skeletal muscle: 8.1 nTPM (baseline 2); small intestine: 2.3 nTPM (baseline 2); smooth muscle: 4.3 nTPM (baseline 2); spinal cord: 5.8 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Glioblastoma Multiforme (TCGA): 131/141 (92.9%); Breast Invasive Carcinoma (validation): 43/50 (86.0%),renal cancer: 1/11 (9.1%); breast cancer: 0/12 (0.0%),31,20,Q3ZCX4,https://www.uniprot.org/uniprotkb/Q3ZCX4/entry,"Has transcriptional repression activity, partially through the recruitment of the corepressor TRIM28 but also has repression activity independently of this interaction. Essential during embryonic development, where it acts as a direct repressor of a placental-specific transcript of IGF2 in early development and regulates convergent extension movements required for axis elongation and tissue morphogenesis in all germ layers. Also important for normal morphogenesis of extraembryonic tissues including the yolk sac, extraembryonic mesoderm and placenta. May enhance proliferation or maintenance of neural stem cells",,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF569,ENSG00000196437,Unsafe,RNA,False,True,10.6,13.3,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 4 nTPM; absolute ceiling;continuous selectivity; amygdala: 3.5 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 3.7 nTPM; absolute ceiling;continuous selectivity; bone marrow: 4.5 nTPM; absolute ceiling;continuous selectivity; cerebellum: 5.5 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 4.7 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 2.6 nTPM; absolute ceiling; heart muscle: 4.1 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 3.1 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 4.4 nTPM; absolute ceiling;continuous selectivity; kidney: 3.4 nTPM; absolute ceiling;continuous selectivity; liver: 3.2 nTPM; absolute ceiling;continuous selectivity; lung: 2.4 nTPM; absolute ceiling; lymph node: 3.9 nTPM; continuous selectivity; midbrain: 3.5 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 4.3 nTPM; continuous selectivity; pituitary gland: 3.2 nTPM; absolute ceiling;continuous selectivity; retina: 13.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 4.2 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 3.3 nTPM; absolute ceiling;continuous selectivity; spinal cord: 3.6 nTPM; absolute ceiling;continuous selectivity; thymus: 5 nTPM; continuous selectivity; thyroid gland: 5.4 nTPM; continuous selectivity; tongue: 4.5 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 4 nTPM (limit 2); amygdala: 3.5 nTPM (limit 2); basal ganglia: 3.7 nTPM (limit 2); bone marrow: 4.5 nTPM (limit 2); cerebellum: 5.5 nTPM (limit 2); cerebral cortex: 4.7 nTPM (limit 2); choroid plexus: 2.6 nTPM (limit 2); heart muscle: 4.1 nTPM (limit 2); hippocampal formation: 3.1 nTPM (limit 2); hypothalamus: 4.4 nTPM (limit 2); kidney: 3.4 nTPM (limit 2); liver: 3.2 nTPM (limit 2); lung: 2.4 nTPM (limit 2); midbrain: 3.5 nTPM (limit 2); pituitary gland: 3.2 nTPM (limit 2); retina: 13.3 nTPM (limit 2); skeletal muscle: 4.2 nTPM (limit 2); smooth muscle: 3.3 nTPM (limit 2); spinal cord: 3.6 nTPM (limit 2); adrenal gland: 4 nTPM (baseline 2); amygdala: 3.5 nTPM (baseline 2); basal ganglia: 3.7 nTPM (baseline 2); bone marrow: 4.5 nTPM (baseline 2); cerebellum: 5.5 nTPM (baseline 2); cerebral cortex: 4.7 nTPM (baseline 2); choroid plexus: 2.6 nTPM (baseline 2); heart muscle: 4.1 nTPM (baseline 2); hippocampal formation: 3.1 nTPM (baseline 2); hypothalamus: 4.4 nTPM (baseline 2); kidney: 3.4 nTPM (baseline 2); liver: 3.2 nTPM (baseline 2); lung: 2.4 nTPM (baseline 2); midbrain: 3.5 nTPM (baseline 2); pituitary gland: 3.2 nTPM (baseline 2); retina: 13.3 nTPM (baseline 2); skeletal muscle: 4.2 nTPM (baseline 2); smooth muscle: 3.3 nTPM (baseline 2); spinal cord: 3.6 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 43/50 (86.0%); Rectum Adenocarcinoma (validation): 147/207 (71.0%),cervical cancer: 12/12 (100.0%); colorectal cancer: 12/12 (100.0%),31,20,Q5MCW4,https://www.uniprot.org/uniprotkb/Q5MCW4/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
ZNF570,ENSG00000171827,Unsafe,Protein,False,True,5.8,5.8,80,72,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 2 nTPM; positive ihc; adrenal gland: 2.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 2.2 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 2.3 nTPM; absolute ceiling;continuous selectivity; bone marrow: 2.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 1.7 nTPM; continuous selectivity; colon: 1.6 nTPM; positive ihc; duodenum: 1.8 nTPM; positive ihc;continuous selectivity; esophagus: 2.2 nTPM; positive ihc;continuous selectivity; heart muscle: 2.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 2.3 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 2.3 nTPM; absolute ceiling;continuous selectivity; kidney: 2.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 1.7 nTPM; positive ihc;continuous selectivity; lung: 2 nTPM; positive ihc;continuous selectivity; lymph node: 2.6 nTPM; positive ihc;continuous selectivity; midbrain: 2.7 nTPM; absolute ceiling;continuous selectivity; pancreas: 1.5 nTPM; positive ihc; parathyroid gland: 3.9 nTPM; positive ihc;continuous selectivity; pituitary gland: 1.7 nTPM; continuous selectivity; rectum: 1.1 nTPM; positive ihc; retina: 3 nTPM; absolute ceiling;continuous selectivity; salivary gland: 2.3 nTPM; positive ihc;continuous selectivity; skeletal muscle: 1.9 nTPM; positive ihc;continuous selectivity; skin: 1.7 nTPM; positive ihc; small intestine: 1.4 nTPM; positive ihc; smooth muscle: 2.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 3.4 nTPM; absolute ceiling;continuous selectivity; stomach: 2 nTPM; positive ihc; thyroid gland: 3.1 nTPM; positive ihc;continuous selectivity; tongue: 2.7 nTPM; continuous selectivity; urinary bladder: 1.9 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 2.4 nTPM (limit 2); amygdala: 2.2 nTPM (limit 2); basal ganglia: 2.3 nTPM (limit 2); bone marrow: 2.2 nTPM (limit 2); cerebellum: 2.7 nTPM (limit 2); cerebral cortex: 2.7 nTPM (limit 2); heart muscle: 2.4 nTPM (limit 2); hippocampal formation: 2.3 nTPM (limit 2); hypothalamus: 2.3 nTPM (limit 2); kidney: 2.7 nTPM (limit 2); midbrain: 2.7 nTPM (limit 2); retina: 3 nTPM (limit 2); smooth muscle: 2.2 nTPM (limit 2); spinal cord: 3.4 nTPM (limit 2); adrenal gland: 2.4 nTPM (baseline 2); amygdala: 2.2 nTPM (baseline 2); basal ganglia: 2.3 nTPM (baseline 2); bone marrow: 2.2 nTPM (baseline 2); cerebellum: 2.7 nTPM (baseline 2); cerebral cortex: 2.7 nTPM (baseline 2); heart muscle: 2.4 nTPM (baseline 2); hippocampal formation: 2.3 nTPM (baseline 2); hypothalamus: 2.3 nTPM (baseline 2); kidney: 2.7 nTPM (baseline 2); midbrain: 2.7 nTPM (baseline 2); retina: 3 nTPM (baseline 2); smooth muscle: 2.2 nTPM (baseline 2); spinal cord: 3.4 nTPM (baseline 2),adipose tissue / adipocytes: Medium (Uncertain); adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: High (Uncertain); caudate / glial cells: Low (Uncertain); cerebellum / cells in granular layer: Low (Uncertain); cerebellum / cells in molecular layer: Low (Uncertain); cerebellum / Purkinje cells: High (Uncertain); cerebral cortex / endothelial cells: Medium (Uncertain); cerebral cortex / glial cells: Low (Uncertain); cerebral cortex / neuronal cells: Low (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / endothelial cells: Medium (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: Medium (Uncertain); duodenum / glandular cells: High (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); kidney / cells in glomeruli: High (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / cholangiocytes: Low (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / alveolar cells: Medium (Uncertain); lung / macrophages: Low (Uncertain); lymph node / germinal center cells: Medium (Uncertain); lymph node / non-germinal center cells: Medium (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: High (Uncertain); pancreas / exocrine glandular cells: High (Uncertain); pancreas / pancreatic endocrine cells: Low (Uncertain); parathyroid gland / glandular cells: High (Uncertain); rectum / glandular cells: High (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: High (Uncertain); skin 1 / keratinocytes: Low (Uncertain); skin 1 / Langerhans: Low (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: High (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); stomach 1 / glandular cells: High (Uncertain); stomach 2 / glandular cells: High (Uncertain); thyroid gland / glandular cells: High (Uncertain); urinary bladder / urothelial cells: High (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 43/50 (86.0%); Pancreatic Adenocarcinoma (validation): 39/80 (48.8%),breast cancer: 11/11 (100.0%); colorectal cancer: 11/11 (100.0%),31,20,Q96NI8,https://www.uniprot.org/uniprotkb/Q96NI8/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF571,ENSG00000180479,Unsafe,RNA,False,True,14.1,75.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 7.3 nTPM; absolute ceiling;continuous selectivity; amygdala: 4.4 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 3.8 nTPM; absolute ceiling;continuous selectivity; bone marrow: 8.4 nTPM; absolute ceiling;continuous selectivity; cerebellum: 5.2 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 5.5 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 5.7 nTPM; absolute ceiling;continuous selectivity; duodenum: 2.1 nTPM; absolute ceiling; heart muscle: 4 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 4.9 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 4.8 nTPM; absolute ceiling;continuous selectivity; kidney: 7.1 nTPM; absolute ceiling;continuous selectivity; liver: 3.5 nTPM; absolute ceiling; lung: 3.8 nTPM; absolute ceiling;continuous selectivity; lymph node: 5.4 nTPM; continuous selectivity; midbrain: 4.4 nTPM; absolute ceiling;continuous selectivity; pancreas: 3.1 nTPM; absolute ceiling; parathyroid gland: 11.6 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 8.6 nTPM; absolute ceiling;continuous selectivity; retina: 28 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 4 nTPM; absolute ceiling;continuous selectivity; skin: 8.3 nTPM; continuous selectivity; small intestine: 2.8 nTPM; absolute ceiling; smooth muscle: 4.6 nTPM; absolute ceiling;continuous selectivity; spinal cord: 5.4 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 75.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 7.3 nTPM (limit 2); amygdala: 4.4 nTPM (limit 2); basal ganglia: 3.8 nTPM (limit 2); bone marrow: 8.4 nTPM (limit 2); cerebellum: 5.2 nTPM (limit 2); cerebral cortex: 5.5 nTPM (limit 2); choroid plexus: 5.7 nTPM (limit 2); duodenum: 2.1 nTPM (limit 2); heart muscle: 4 nTPM (limit 2); hippocampal formation: 4.9 nTPM (limit 2); hypothalamus: 4.8 nTPM (limit 2); kidney: 7.1 nTPM (limit 2); liver: 3.5 nTPM (limit 2); lung: 3.8 nTPM (limit 2); midbrain: 4.4 nTPM (limit 2); pancreas: 3.1 nTPM (limit 2); parathyroid gland: 11.6 nTPM (limit 6); pituitary gland: 8.6 nTPM (limit 2); retina: 28 nTPM (limit 2); skeletal muscle: 4 nTPM (limit 2); small intestine: 2.8 nTPM (limit 2); smooth muscle: 4.6 nTPM (limit 2); spinal cord: 5.4 nTPM (limit 2); thyroid gland: 75.2 nTPM (limit 10); adrenal gland: 7.3 nTPM (baseline 2); amygdala: 4.4 nTPM (baseline 2); basal ganglia: 3.8 nTPM (baseline 2); bone marrow: 8.4 nTPM (baseline 2); cerebellum: 5.2 nTPM (baseline 2); cerebral cortex: 5.5 nTPM (baseline 2); choroid plexus: 5.7 nTPM (baseline 2); duodenum: 2.1 nTPM (baseline 2); heart muscle: 4 nTPM (baseline 2); hippocampal formation: 4.9 nTPM (baseline 2); hypothalamus: 4.8 nTPM (baseline 2); kidney: 7.1 nTPM (baseline 2); liver: 3.5 nTPM (baseline 2); lung: 3.8 nTPM (baseline 2); midbrain: 4.4 nTPM (baseline 2); pancreas: 3.1 nTPM (baseline 2); parathyroid gland: 11.6 nTPM (baseline 6); pituitary gland: 8.6 nTPM (baseline 2); retina: 28 nTPM (baseline 2); skeletal muscle: 4 nTPM (baseline 2); small intestine: 2.8 nTPM (baseline 2); smooth muscle: 4.6 nTPM (baseline 2); spinal cord: 5.4 nTPM (baseline 2); thyroid gland: 75.2 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Testicular Germ Cell Tumor (TCGA): 133/133 (100.0%); Colon Adenocarcinoma (validation): 485/486 (99.8%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q7Z3V5,https://www.uniprot.org/uniprotkb/Q7Z3V5/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF572,ENSG00000180938,Unsafe,Protein,False,True,3.5,3.5,80,48,Positive somewhere,True,False,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 0.3 nTPM; positive ihc; cerebellum: 0.4 nTPM; positive ihc; cerebral cortex: 1 nTPM; positive ihc;continuous selectivity; colon: 1 nTPM; positive ihc; duodenum: 0.9 nTPM; positive ihc; esophagus: 0.5 nTPM; positive ihc; heart muscle: 0.9 nTPM; positive ihc; kidney: 1.6 nTPM; positive ihc;continuous selectivity; liver: 0.9 nTPM; positive ihc; lung: 0.7 nTPM; positive ihc; lymph node: 1.8 nTPM; continuous selectivity; pancreas: 1 nTPM; positive ihc;continuous selectivity; parathyroid gland: 0.5 nTPM; positive ihc; rectum: 1.3 nTPM; positive ihc;continuous selectivity; retina: 1.8 nTPM; continuous selectivity; salivary gland: 1.3 nTPM; positive ihc;continuous selectivity; skin: 0.8 nTPM; positive ihc; small intestine: 0.9 nTPM; positive ihc; smooth muscle: 0.8 nTPM; positive ihc; spinal cord: 1 nTPM; continuous selectivity; stomach: 1.4 nTPM; positive ihc;continuous selectivity; thymus: 1.8 nTPM; continuous selectivity; thyroid gland: 1.7 nTPM; positive ihc;continuous selectivity; urinary bladder: 1.1 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,adrenal gland / glandular cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); colon / glandular cells: Low (Approved); duodenum / glandular cells: Low (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Low (Approved); kidney / cells in tubules: Medium (Approved); liver / hepatocytes: Low (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Low (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Low (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Low (Approved); salivary gland / glandular cells: Medium (Approved); skin 1 / keratinocytes: Low (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Low (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Low (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 37/50 (74.0%); Testicular Germ Cell Tumor (TCGA): 41/133 (30.8%),testis cancer: 8/10 (80.0%); urothelial cancer: 9/12 (75.0%),31,20,Q7Z3I7,https://www.uniprot.org/uniprotkb/Q7Z3I7/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF573,ENSG00000189144,Unsafe,Protein,False,True,2.8,2.8,78,74,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 1.5 nTPM; positive ihc;continuous selectivity; adrenal gland: 1.1 nTPM; positive ihc;continuous selectivity; bone marrow: 1.9 nTPM; positive ihc;continuous selectivity; cerebellum: 0.5 nTPM; positive ihc; cerebral cortex: 1.3 nTPM; positive ihc;continuous selectivity; colon: 0.9 nTPM; positive ihc; duodenum: 1.3 nTPM; positive ihc;continuous selectivity; esophagus: 0.7 nTPM; positive ihc; heart muscle: 0.9 nTPM; positive ihc;continuous selectivity; kidney: 1.2 nTPM; positive ihc;continuous selectivity; liver: 0.6 nTPM; positive ihc; lung: 1.3 nTPM; positive ihc;continuous selectivity; lymph node: 1.1 nTPM; positive ihc;continuous selectivity; pancreas: 1.2 nTPM; positive ihc;continuous selectivity; parathyroid gland: 1.4 nTPM; positive ihc;continuous selectivity; pituitary gland: 0.8 nTPM; continuous selectivity; rectum: 1.1 nTPM; positive ihc;continuous selectivity; retina: 2.5 nTPM; absolute ceiling;continuous selectivity; salivary gland: 0.8 nTPM; positive ihc; skeletal muscle: 0.9 nTPM; positive ihc;continuous selectivity; skin: 2.1 nTPM; positive ihc;continuous selectivity; small intestine: 1 nTPM; positive ihc;continuous selectivity; smooth muscle: 0.8 nTPM; positive ihc;continuous selectivity; spleen: 1.6 nTPM; positive ihc;continuous selectivity; stomach: 1.9 nTPM; positive ihc;continuous selectivity; thyroid gland: 2.4 nTPM; positive ihc;continuous selectivity; urinary bladder: 0.7 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",retina: 2.5 nTPM (limit 2); retina: 2.5 nTPM (baseline 2),adipose tissue / adipocytes: Medium (Uncertain); adrenal gland / glandular cells: High (Uncertain); bone marrow / hematopoietic cells: Low (Uncertain); bronchus / respiratory epithelial cells: High (Uncertain); caudate / glial cells: Low (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: High (Uncertain); cerebellum / cells in molecular layer: Medium (Uncertain); cerebellum / Purkinje cells: High (Uncertain); cerebral cortex / endothelial cells: Medium (Uncertain); cerebral cortex / glial cells: Medium (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: Medium (Uncertain); colon / endothelial cells: Low (Uncertain); colon / glandular cells: High (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: High (Uncertain); heart muscle / cardiomyocytes: High (Uncertain); hippocampus / glial cells: Medium (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in glomeruli: Low (Uncertain); kidney / cells in tubules: High (Uncertain); liver / cholangiocytes: Low (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / alveolar cells: Low (Uncertain); lymph node / germinal center cells: Medium (Uncertain); lymph node / non-germinal center cells: Medium (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Low (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: High (Uncertain); skeletal muscle / myocytes: Medium (Uncertain); skin 1 / fibroblasts: Medium (Uncertain); skin 1 / keratinocytes: Medium (Uncertain); skin 1 / Langerhans: Medium (Uncertain); skin 2 / epidermal cells: High (Uncertain); small intestine / glandular cells: Medium (Uncertain); smooth muscle / smooth muscle cells: Low (Uncertain); spleen / cells in red pulp: Medium (Uncertain); spleen / cells in white pulp: Medium (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Pancreatic Adenocarcinoma (validation): 53/80 (66.2%); Breast Invasive Carcinoma (validation): 26/50 (52.0%),cervical cancer: 12/12 (100.0%); prostate cancer: 12/12 (100.0%),31,20,Q86YE8,https://www.uniprot.org/uniprotkb/Q86YE8/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF578,ENSG00000258405,Unsafe,RNA,False,True,6.2,6.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,retina: 2.9 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 2.9 nTPM (limit 2); retina: 2.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 102/133 (76.7%); Glioblastoma Multiforme (validation): 34/58 (58.6%); Colon Adenocarcinoma (validation): 220/486 (45.3%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q96N58,https://www.uniprot.org/uniprotkb/Q96N58/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF583,ENSG00000198440,Unsafe,RNA,False,True,7.1,7.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 2.3 nTPM; absolute ceiling;continuous selectivity; amygdala: 3.1 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 3 nTPM; absolute ceiling;continuous selectivity; cerebellum: 4 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 3.7 nTPM; absolute ceiling;continuous selectivity; heart muscle: 2 nTPM; continuous selectivity; hippocampal formation: 3.2 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 3 nTPM; absolute ceiling;continuous selectivity; kidney: 2.7 nTPM; absolute ceiling;continuous selectivity; liver: 2.5 nTPM; absolute ceiling;continuous selectivity; lung: 2.7 nTPM; absolute ceiling;continuous selectivity; midbrain: 3.2 nTPM; absolute ceiling;continuous selectivity; pancreas: 2.5 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 3.9 nTPM; continuous selectivity; pituitary gland: 2.6 nTPM; absolute ceiling;continuous selectivity; retina: 3.9 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 2.1 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 2.5 nTPM; absolute ceiling;continuous selectivity; spinal cord: 3.4 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 3.3 nTPM; continuous selectivity; tongue: 3.1 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 2.3 nTPM (limit 2); amygdala: 3.1 nTPM (limit 2); basal ganglia: 3 nTPM (limit 2); cerebellum: 4 nTPM (limit 2); cerebral cortex: 3.7 nTPM (limit 2); hippocampal formation: 3.2 nTPM (limit 2); hypothalamus: 3 nTPM (limit 2); kidney: 2.7 nTPM (limit 2); liver: 2.5 nTPM (limit 2); lung: 2.7 nTPM (limit 2); midbrain: 3.2 nTPM (limit 2); pancreas: 2.5 nTPM (limit 2); pituitary gland: 2.6 nTPM (limit 2); retina: 3.9 nTPM (limit 2); skeletal muscle: 2.1 nTPM (limit 2); smooth muscle: 2.5 nTPM (limit 2); spinal cord: 3.4 nTPM (limit 2); adrenal gland: 2.3 nTPM (baseline 2); amygdala: 3.1 nTPM (baseline 2); basal ganglia: 3 nTPM (baseline 2); cerebellum: 4 nTPM (baseline 2); cerebral cortex: 3.7 nTPM (baseline 2); hippocampal formation: 3.2 nTPM (baseline 2); hypothalamus: 3 nTPM (baseline 2); kidney: 2.7 nTPM (baseline 2); liver: 2.5 nTPM (baseline 2); lung: 2.7 nTPM (baseline 2); midbrain: 3.2 nTPM (baseline 2); pancreas: 2.5 nTPM (baseline 2); pituitary gland: 2.6 nTPM (baseline 2); retina: 3.9 nTPM (baseline 2); skeletal muscle: 2.1 nTPM (baseline 2); smooth muscle: 2.5 nTPM (baseline 2); spinal cord: 3.4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Breast Invasive Carcinoma (validation): 45/50 (90.0%); Glioblastoma Multiforme (TCGA): 75/141 (53.2%),liver cancer: 5/12 (41.7%); urothelial cancer: 1/10 (10.0%),31,20,Q96ND8,https://www.uniprot.org/uniprotkb/Q96ND8/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF587,ENSG00000198466,Unsafe,Protein,False,True,9.7,12.7,77,62,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 4.8 nTPM; positive ihc;continuous selectivity; adrenal gland: 5 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 3.6 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 5.1 nTPM; absolute ceiling;continuous selectivity; bone marrow: 6.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 6.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 4.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 4 nTPM; absolute ceiling;continuous selectivity; colon: 8.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 8 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 6 nTPM; positive ihc;continuous selectivity; heart muscle: 5.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 4.2 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 4.5 nTPM; absolute ceiling;continuous selectivity; kidney: 6.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 6.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 6 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 5.3 nTPM; continuous selectivity; midbrain: 3.2 nTPM; absolute ceiling;continuous selectivity; pancreas: 8.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 4.8 nTPM; positive ihc;continuous selectivity; pituitary gland: 11.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 12.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; retina: 11.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 11.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 4.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 5.8 nTPM; positive ihc;continuous selectivity; small intestine: 7.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 5.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 4.3 nTPM; absolute ceiling;continuous selectivity; spleen: 6 nTPM; continuous selectivity; stomach: 8.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 5.3 nTPM; continuous selectivity; thyroid gland: 7.5 nTPM; positive ihc;continuous selectivity; tongue: 4 nTPM; continuous selectivity; urinary bladder: 6 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 5 nTPM (limit 2); amygdala: 3.6 nTPM (limit 2); basal ganglia: 5.1 nTPM (limit 2); bone marrow: 6.7 nTPM (limit 2); cerebellum: 6.8 nTPM (limit 2); cerebral cortex: 4.3 nTPM (limit 2); choroid plexus: 4 nTPM (limit 2); colon: 8.3 nTPM (limit 6); duodenum: 8 nTPM (limit 2); heart muscle: 5.8 nTPM (limit 2); hippocampal formation: 4.2 nTPM (limit 2); hypothalamus: 4.5 nTPM (limit 2); kidney: 6.3 nTPM (limit 2); liver: 6.1 nTPM (limit 2); lung: 6 nTPM (limit 2); midbrain: 3.2 nTPM (limit 2); pancreas: 8.8 nTPM (limit 2); pituitary gland: 11.2 nTPM (limit 2); rectum: 12.7 nTPM (limit 6); retina: 11.2 nTPM (limit 2); salivary gland: 11.7 nTPM (limit 6); skeletal muscle: 4.3 nTPM (limit 2); small intestine: 7.7 nTPM (limit 2); smooth muscle: 5.3 nTPM (limit 2); spinal cord: 4.3 nTPM (limit 2); stomach: 8.7 nTPM (limit 6); adrenal gland: 5 nTPM (baseline 2); amygdala: 3.6 nTPM (baseline 2); basal ganglia: 5.1 nTPM (baseline 2); bone marrow: 6.7 nTPM (baseline 2); cerebellum: 6.8 nTPM (baseline 2); cerebral cortex: 4.3 nTPM (baseline 2); choroid plexus: 4 nTPM (baseline 2); colon: 8.3 nTPM (baseline 6); duodenum: 8 nTPM (baseline 2); heart muscle: 5.8 nTPM (baseline 2); hippocampal formation: 4.2 nTPM (baseline 2); hypothalamus: 4.5 nTPM (baseline 2); kidney: 6.3 nTPM (baseline 2); liver: 6.1 nTPM (baseline 2); lung: 6 nTPM (baseline 2); midbrain: 3.2 nTPM (baseline 2); pancreas: 8.8 nTPM (baseline 2); pituitary gland: 11.2 nTPM (baseline 2); rectum: 12.7 nTPM (baseline 6); retina: 11.2 nTPM (baseline 2); salivary gland: 11.7 nTPM (baseline 6); skeletal muscle: 4.3 nTPM (baseline 2); small intestine: 7.7 nTPM (baseline 2); smooth muscle: 5.3 nTPM (baseline 2); spinal cord: 4.3 nTPM (baseline 2); stomach: 8.7 nTPM (baseline 6),adipose tissue / adipocytes: Low (Uncertain); adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Low (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: Medium (Uncertain); cerebellum / Purkinje cells: Low (Uncertain); cerebral cortex / endothelial cells: Medium (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / endothelial cells: Medium (Uncertain); colon / glandular cells: High (Uncertain); colon / peripheral nerve/ganglion: Low (Uncertain); duodenum / glandular cells: High (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: High (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in glomeruli: Low (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / cholangiocytes: Medium (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / alveolar cells: Low (Uncertain); lung / macrophages: Low (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Low (Uncertain); parathyroid gland / glandular cells: High (Uncertain); rectum / glandular cells: High (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: High (Uncertain); skin 1 / fibroblasts: Medium (Uncertain); skin 1 / keratinocytes: Medium (Uncertain); skin 1 / Langerhans: Low (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: High (Uncertain); smooth muscle / smooth muscle cells: High (Uncertain); stomach 1 / glandular cells: High (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Rectum Adenocarcinoma (validation): 207/207 (100.0%); Pancreatic Adenocarcinoma (validation): 80/80 (100.0%),liver cancer: 10/11 (90.9%); testis cancer: 9/12 (75.0%),31,20,Q96SQ5,https://www.uniprot.org/uniprotkb/Q96SQ5/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF593,ENSG00000142684,Unsafe,Protein,False,True,31.1,97.7,91,89,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 34.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; adrenal gland: 30.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 26.7 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 25.4 nTPM; absolute ceiling;continuous selectivity; bone marrow: 20.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 14.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 25.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 41 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 22.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 12.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 31.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 36.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 24.6 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 28.2 nTPM; absolute ceiling;continuous selectivity; kidney: 39.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 62.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 21.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 9.8 nTPM; positive ihc;absolute ceiling; midbrain: 28.6 nTPM; absolute ceiling;continuous selectivity; pancreas: 59.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 15.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; pituitary gland: 25 nTPM; absolute ceiling;continuous selectivity; rectum: 6 nTPM; positive ihc; retina: 2.4 nTPM; absolute ceiling; salivary gland: 23.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 97.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skin: 31.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 20.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 6.7 nTPM; positive ihc;absolute ceiling; spinal cord: 19.9 nTPM; absolute ceiling;continuous selectivity; spleen: 27.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 37.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 27.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 21 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 24.7 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 34.7 nTPM (limit 10); adrenal gland: 30.8 nTPM (limit 2); amygdala: 26.7 nTPM (limit 2); basal ganglia: 25.4 nTPM (limit 2); bone marrow: 20.1 nTPM (limit 2); cerebellum: 14.1 nTPM (limit 2); cerebral cortex: 25.8 nTPM (limit 2); choroid plexus: 41 nTPM (limit 2); colon: 22.9 nTPM (limit 6); duodenum: 12.6 nTPM (limit 2); esophagus: 31.6 nTPM (limit 6); heart muscle: 36.7 nTPM (limit 2); hippocampal formation: 24.6 nTPM (limit 2); hypothalamus: 28.2 nTPM (limit 2); kidney: 39.1 nTPM (limit 2); liver: 62.3 nTPM (limit 2); lung: 21.1 nTPM (limit 2); lymph node: 9.8 nTPM (limit 6); midbrain: 28.6 nTPM (limit 2); pancreas: 59.7 nTPM (limit 2); parathyroid gland: 15.8 nTPM (limit 6); pituitary gland: 25 nTPM (limit 2); retina: 2.4 nTPM (limit 2); salivary gland: 23.5 nTPM (limit 6); skeletal muscle: 97.7 nTPM (limit 2); skin: 31.4 nTPM (limit 10); small intestine: 20.5 nTPM (limit 2); smooth muscle: 6.7 nTPM (limit 2); spinal cord: 19.9 nTPM (limit 2); spleen: 27.5 nTPM (limit 10); stomach: 37.9 nTPM (limit 6); thyroid gland: 27.2 nTPM (limit 10); tongue: 21 nTPM (limit 6); urinary bladder: 24.7 nTPM (limit 6),adipose tissue / adipocytes: High (Supported); adrenal gland / glandular cells: Medium (Supported); bone marrow / hematopoietic cells: High (Supported); bronchus / respiratory epithelial cells: High (Supported); caudate / glial cells: High (Supported); caudate / neuronal cells: Medium (Supported); cerebellum / cells in granular layer: High (Supported); cerebellum / cells in molecular layer: High (Supported); cerebellum / Purkinje cells: Medium (Supported); cerebral cortex / endothelial cells: High (Supported); cerebral cortex / glial cells: High (Supported); cerebral cortex / neuronal cells: Medium (Supported); cerebral cortex / neuropil: Low (Supported); colon / endothelial cells: High (Supported); colon / glandular cells: High (Supported); colon / peripheral nerve/ganglion: High (Supported); duodenum / glandular cells: High (Supported); esophagus / squamous epithelial cells: High (Supported); heart muscle / cardiomyocytes: High (Supported); hippocampus / glial cells: High (Supported); hippocampus / neuronal cells: Medium (Supported); kidney / bowman's capsule: High (Supported); kidney / cells in glomeruli: High (Supported); kidney / collecting ducts: High (Supported); kidney / distal tubules: High (Supported); kidney / proximal tubules (cell body): High (Supported); liver / cholangiocytes: Medium (Supported); liver / hepatocytes: High (Supported); lung / alveolar cells type I: High (Supported); lung / alveolar cells type II: High (Supported); lung / endothelial cells: High (Supported); lung / macrophages: High (Supported); lymph node / germinal center cells: High (Supported); lymph node / non-germinal center cells: Medium (Supported); nasopharynx / respiratory epithelial cells: High (Supported); oral mucosa / squamous epithelial cells: High (Supported); pancreas / exocrine glandular cells: High (Supported); pancreas / pancreatic endocrine cells: High (Supported); parathyroid gland / glandular cells: High (Supported); rectum / glandular cells: High (Supported); salivary gland / glandular cells: Medium (Supported); skeletal muscle / myocytes: Medium (Supported); skin 1 / fibroblasts: High (Supported); skin 1 / keratinocytes: High (Supported); skin 1 / Langerhans: High (Supported); skin 2 / epidermal cells: High (Supported); small intestine / glandular cells: High (Supported); smooth muscle / smooth muscle cells: High (Supported); spleen / cells in red pulp: High (Supported); spleen / cells in white pulp: High (Supported); stomach 1 / glandular cells: High (Supported); stomach 2 / glandular cells: High (Supported); thyroid gland / glandular cells: High (Supported); urinary bladder / urothelial cells: Medium (Supported),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (TCGA): 1022/1022 (100.0%); Lung Adenocarcinoma (TCGA): 497/497 (100.0%); Thyroid Carcinoma (TCGA): 495/495 (100.0%),breast cancer: 12/12 (100.0%); endometrial cancer: 12/12 (100.0%),31,20,O00488,https://www.uniprot.org/uniprotkb/O00488/entry,Involved in pre-60S ribosomal particles maturation by promoting the nuclear export of the 60S ribosome (PubMed:32669547). Negatively modulates the DNA binding activity of Oct-2 and therefore its transcriptional regulatory activity (PubMed:9115366),"Ubiquitous. Detected in spleen, prostate, testis, small intestine, colon and to a minor level in thymus and peripheral blood leukocytes",,,"Nucleus, nucleolus Cytoplasm",32669547|9115366,9115366,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Gong2021_placenta_PC | Gong2021_reproductive_PC,No tumor-antigen validation in this source | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
ZNF597,ENSG00000167981,Unsafe,Protein,False,True,3.8,3.8,83,8,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 1.8 nTPM; continuous selectivity; basal ganglia: 1.2 nTPM; continuous selectivity; bone marrow: 1.8 nTPM; continuous selectivity; cerebral cortex: 2.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; hypothalamus: 1.1 nTPM; continuous selectivity; kidney: 1.3 nTPM; positive ihc;continuous selectivity; liver: 1.7 nTPM; continuous selectivity; lung: 2.3 nTPM; continuous selectivity; lymph node: 2.1 nTPM; continuous selectivity; pancreas: 1.5 nTPM; continuous selectivity; pituitary gland: 1.3 nTPM; continuous selectivity; retina: 2.3 nTPM; absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",cerebral cortex: 2.1 nTPM (limit 2); retina: 2.3 nTPM (limit 2),caudate / neuronal cells: Low (Approved); cerebral cortex / neuropil: Low (Approved); kidney / cells in tubules: Low (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Breast Invasive Carcinoma (validation): 45/50 (90.0%); Pancreatic Adenocarcinoma (validation): 33/80 (41.2%),breast cancer: 0/12 (0.0%); cervical cancer: 0/11 (0.0%),31,20,Q96LX8,https://www.uniprot.org/uniprotkb/Q96LX8/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination; inclusion depends on TGCT under this study's thresholds,,,,,,,,
ZNF607,ENSG00000198182,Unsafe,RNA,False,True,8.8,8.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 2.8 nTPM; absolute ceiling;continuous selectivity; amygdala: 2.9 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 3.3 nTPM; absolute ceiling;continuous selectivity; cerebellum: 5.7 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 3.7 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 3.4 nTPM; absolute ceiling;continuous selectivity; heart muscle: 2.8 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 3.2 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 3.3 nTPM; absolute ceiling;continuous selectivity; kidney: 3.2 nTPM; absolute ceiling;continuous selectivity; midbrain: 3.2 nTPM; absolute ceiling;continuous selectivity; pancreas: 2.7 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 5 nTPM; continuous selectivity; pituitary gland: 5.3 nTPM; absolute ceiling;continuous selectivity; retina: 4.6 nTPM; absolute ceiling;continuous selectivity; small intestine: 2.6 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 2.2 nTPM; absolute ceiling; spinal cord: 3.6 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 2.8 nTPM (limit 2); amygdala: 2.9 nTPM (limit 2); basal ganglia: 3.3 nTPM (limit 2); cerebellum: 5.7 nTPM (limit 2); cerebral cortex: 3.7 nTPM (limit 2); choroid plexus: 3.4 nTPM (limit 2); heart muscle: 2.8 nTPM (limit 2); hippocampal formation: 3.2 nTPM (limit 2); hypothalamus: 3.3 nTPM (limit 2); kidney: 3.2 nTPM (limit 2); midbrain: 3.2 nTPM (limit 2); pancreas: 2.7 nTPM (limit 2); pituitary gland: 5.3 nTPM (limit 2); retina: 4.6 nTPM (limit 2); small intestine: 2.6 nTPM (limit 2); smooth muscle: 2.2 nTPM (limit 2); spinal cord: 3.6 nTPM (limit 2); adrenal gland: 2.8 nTPM (baseline 2); amygdala: 2.9 nTPM (baseline 2); basal ganglia: 3.3 nTPM (baseline 2); cerebellum: 5.7 nTPM (baseline 2); cerebral cortex: 3.7 nTPM (baseline 2); choroid plexus: 3.4 nTPM (baseline 2); heart muscle: 2.8 nTPM (baseline 2); hippocampal formation: 3.2 nTPM (baseline 2); hypothalamus: 3.3 nTPM (baseline 2); kidney: 3.2 nTPM (baseline 2); midbrain: 3.2 nTPM (baseline 2); pancreas: 2.7 nTPM (baseline 2); pituitary gland: 5.3 nTPM (baseline 2); retina: 4.6 nTPM (baseline 2); small intestine: 2.6 nTPM (baseline 2); smooth muscle: 2.2 nTPM (baseline 2); spinal cord: 3.6 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 47/50 (94.0%); Testicular Germ Cell Tumor (TCGA): 109/133 (82.0%),lung cancer: 12/12 (100.0%); ovarian cancer: 12/12 (100.0%),31,20,Q96SK3,https://www.uniprot.org/uniprotkb/Q96SK3/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF610,ENSG00000167554,Unsafe,Protein,False,True,11.7,11.7,86,61,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; amygdala: 3.9 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 4.7 nTPM; absolute ceiling;continuous selectivity; bone marrow: 0.3 nTPM; positive ihc; cerebellum: 2.8 nTPM; positive ihc;absolute ceiling; cerebral cortex: 3.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 3.6 nTPM; absolute ceiling;continuous selectivity; colon: 1.6 nTPM; positive ihc; duodenum: 0.7 nTPM; positive ihc; esophagus: 1.1 nTPM; positive ihc; heart muscle: 2.5 nTPM; positive ihc;absolute ceiling; hippocampal formation: 4.1 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 4.3 nTPM; absolute ceiling;continuous selectivity; kidney: 3.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 1.8 nTPM; positive ihc; lymph node: 1.5 nTPM; positive ihc; midbrain: 4.3 nTPM; absolute ceiling;continuous selectivity; pancreas: 1.4 nTPM; positive ihc; pituitary gland: 2.4 nTPM; absolute ceiling; rectum: 1.4 nTPM; positive ihc; retina: 6 nTPM; absolute ceiling;continuous selectivity; salivary gland: 1.1 nTPM; positive ihc; skeletal muscle: 1.1 nTPM; positive ihc; skin: 0.7 nTPM; positive ihc; small intestine: 0.9 nTPM; positive ihc; smooth muscle: 2.4 nTPM; positive ihc;absolute ceiling; spinal cord: 4.9 nTPM; absolute ceiling;continuous selectivity; stomach: 1.5 nTPM; positive ihc; thyroid gland: 4.5 nTPM; positive ihc; urinary bladder: 1.7 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",amygdala: 3.9 nTPM (limit 2); basal ganglia: 4.7 nTPM (limit 2); cerebellum: 2.8 nTPM (limit 2); cerebral cortex: 3.7 nTPM (limit 2); choroid plexus: 3.6 nTPM (limit 2); heart muscle: 2.5 nTPM (limit 2); hippocampal formation: 4.1 nTPM (limit 2); hypothalamus: 4.3 nTPM (limit 2); kidney: 3.4 nTPM (limit 2); midbrain: 4.3 nTPM (limit 2); pituitary gland: 2.4 nTPM (limit 2); retina: 6 nTPM (limit 2); smooth muscle: 2.4 nTPM (limit 2); spinal cord: 4.9 nTPM (limit 2),bone marrow / hematopoietic cells: Low (Enhanced); bronchus / respiratory epithelial cells: Medium (Enhanced); caudate / glial cells: Medium (Enhanced); caudate / neuronal cells: Medium (Enhanced); cerebellum / cells in granular layer: Low (Enhanced); cerebellum / cells in molecular layer: Medium (Enhanced); cerebellum / Purkinje cells: High (Enhanced); cerebral cortex / glial cells: Low (Enhanced); cerebral cortex / neuronal cells: High (Enhanced); colon / endothelial cells: Low (Enhanced); colon / glandular cells: Medium (Enhanced); colon / peripheral nerve/ganglion: Medium (Enhanced); duodenum / glandular cells: Medium (Enhanced); esophagus / squamous epithelial cells: Medium (Enhanced); heart muscle / cardiomyocytes: Medium (Enhanced); hippocampus / neuronal cells: Medium (Enhanced); kidney / cells in tubules: Medium (Enhanced); lung / alveolar cells: Low (Enhanced); lung / macrophages: Medium (Enhanced); lymph node / germinal center cells: Low (Enhanced); nasopharynx / respiratory epithelial cells: Medium (Enhanced); oral mucosa / squamous epithelial cells: Medium (Enhanced); pancreas / exocrine glandular cells: Low (Enhanced); rectum / glandular cells: Medium (Enhanced); salivary gland / glandular cells: Low (Enhanced); skeletal muscle / myocytes: Low (Enhanced); skin 1 / keratinocytes: Low (Enhanced); skin 1 / Langerhans: Low (Enhanced); skin 2 / epidermal cells: Low (Enhanced); small intestine / glandular cells: Medium (Enhanced); smooth muscle / smooth muscle cells: Medium (Enhanced); stomach 1 / glandular cells: Medium (Enhanced); stomach 2 / glandular cells: Medium (Enhanced); thyroid gland / glandular cells: Low (Enhanced); urinary bladder / urothelial cells: Medium (Enhanced),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Breast Invasive Carcinoma (validation): 43/50 (86.0%); Testicular Germ Cell Tumor (TCGA): 104/133 (78.2%),urothelial cancer: 12/12 (100.0%); pancreatic cancer: 10/11 (90.9%),31,20,Q8N9Z0,https://www.uniprot.org/uniprotkb/Q8N9Z0/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC | Jamin2021_CT | Jamin2021_core,GC RNA nomination across cancer types; no antigen validation asserted | CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
ZNF611,ENSG00000213020,Unsafe,RNA,False,True,6.7,6.7,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,basal ganglia: 2.6 nTPM; absolute ceiling;continuous selectivity; bone marrow: 3.4 nTPM; absolute ceiling;continuous selectivity; cerebellum: 2.6 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 2.8 nTPM; absolute ceiling;continuous selectivity; colon: 2.6 nTPM; continuous selectivity; duodenum: 2.3 nTPM; absolute ceiling;continuous selectivity; heart muscle: 2.8 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 1.8 nTPM; continuous selectivity; hypothalamus: 1.9 nTPM; continuous selectivity; kidney: 3.8 nTPM; absolute ceiling;continuous selectivity; lung: 2.9 nTPM; absolute ceiling;continuous selectivity; lymph node: 3.4 nTPM; continuous selectivity; pancreas: 4.1 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 2.8 nTPM; continuous selectivity; pituitary gland: 2.2 nTPM; absolute ceiling;continuous selectivity; rectum: 3 nTPM; continuous selectivity; retina: 4.1 nTPM; absolute ceiling;continuous selectivity; small intestine: 1.9 nTPM; continuous selectivity; smooth muscle: 3.1 nTPM; absolute ceiling;continuous selectivity; spinal cord: 1.9 nTPM; continuous selectivity; spleen: 3.5 nTPM; continuous selectivity; stomach: 2.6 nTPM; continuous selectivity; thymus: 4.2 nTPM; continuous selectivity; thyroid gland: 3.8 nTPM; continuous selectivity; urinary bladder: 2.4 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,basal ganglia: 2.6 nTPM (limit 2); bone marrow: 3.4 nTPM (limit 2); cerebellum: 2.6 nTPM (limit 2); cerebral cortex: 2.8 nTPM (limit 2); duodenum: 2.3 nTPM (limit 2); heart muscle: 2.8 nTPM (limit 2); kidney: 3.8 nTPM (limit 2); lung: 2.9 nTPM (limit 2); pancreas: 4.1 nTPM (limit 2); pituitary gland: 2.2 nTPM (limit 2); retina: 4.1 nTPM (limit 2); smooth muscle: 3.1 nTPM (limit 2); basal ganglia: 2.6 nTPM (baseline 2); bone marrow: 3.4 nTPM (baseline 2); cerebellum: 2.6 nTPM (baseline 2); cerebral cortex: 2.8 nTPM (baseline 2); duodenum: 2.3 nTPM (baseline 2); heart muscle: 2.8 nTPM (baseline 2); kidney: 3.8 nTPM (baseline 2); lung: 2.9 nTPM (baseline 2); pancreas: 4.1 nTPM (baseline 2); pituitary gland: 2.2 nTPM (baseline 2); retina: 4.1 nTPM (baseline 2); smooth muscle: 3.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 80/80 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 461/486 (94.9%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8N823,https://www.uniprot.org/uniprotkb/Q8N823/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF619,ENSG00000177873,Unsafe,Protein,False,True,2.8,4.0,78,76,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 1.6 nTPM; positive ihc;continuous selectivity; adrenal gland: 1.6 nTPM; positive ihc;continuous selectivity; amygdala: 1.2 nTPM; continuous selectivity; basal ganglia: 1.3 nTPM; continuous selectivity; bone marrow: 3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 1.5 nTPM; positive ihc;continuous selectivity; cerebral cortex: 1.8 nTPM; positive ihc;continuous selectivity; choroid plexus: 1.1 nTPM; continuous selectivity; colon: 2 nTPM; positive ihc;continuous selectivity; duodenum: 2.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 1.4 nTPM; positive ihc;continuous selectivity; heart muscle: 1.7 nTPM; positive ihc;continuous selectivity; hippocampal formation: 1.2 nTPM; continuous selectivity; hypothalamus: 1.1 nTPM; continuous selectivity; kidney: 2.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 2.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 1.9 nTPM; positive ihc;continuous selectivity; lymph node: 2.3 nTPM; positive ihc;continuous selectivity; midbrain: 1.3 nTPM; continuous selectivity; pancreas: 2.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 3 nTPM; positive ihc;continuous selectivity;reproductive not higher; pituitary gland: 1.1 nTPM; continuous selectivity; rectum: 2.5 nTPM; positive ihc;continuous selectivity; retina: 4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 2.6 nTPM; positive ihc;continuous selectivity; skeletal muscle: 2.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 2.3 nTPM; positive ihc;continuous selectivity; small intestine: 1.9 nTPM; positive ihc;continuous selectivity; smooth muscle: 2.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 1.6 nTPM; continuous selectivity; spleen: 2.9 nTPM; positive ihc;continuous selectivity;reproductive not higher; stomach: 2.3 nTPM; positive ihc;continuous selectivity; thymus: 1.5 nTPM; continuous selectivity; thyroid gland: 2.9 nTPM; positive ihc;continuous selectivity;reproductive not higher; tongue: 2.1 nTPM; continuous selectivity; urinary bladder: 1.6 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 3 nTPM (limit 2); duodenum: 2.3 nTPM (limit 2); kidney: 2.1 nTPM (limit 2); liver: 2.3 nTPM (limit 2); pancreas: 2.4 nTPM (limit 2); retina: 4 nTPM (limit 2); skeletal muscle: 2.5 nTPM (limit 2); smooth muscle: 2.2 nTPM (limit 2); bone marrow: 3 nTPM (baseline 2); duodenum: 2.3 nTPM (baseline 2); kidney: 2.1 nTPM (baseline 2); liver: 2.3 nTPM (baseline 2); pancreas: 2.4 nTPM (baseline 2); retina: 4 nTPM (baseline 2); skeletal muscle: 2.5 nTPM (baseline 2); smooth muscle: 2.2 nTPM (baseline 2),adipose tissue / adipocytes: Low (Uncertain); adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: High (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / glial cells: Low (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: Medium (Uncertain); cerebellum / cells in molecular layer: Medium (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / endothelial cells: Low (Uncertain); cerebral cortex / glial cells: Low (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / endothelial cells: Medium (Uncertain); colon / glandular cells: High (Uncertain); colon / peripheral nerve/ganglion: Medium (Uncertain); duodenum / glandular cells: High (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / glial cells: Low (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in glomeruli: Medium (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / alveolar cells: Medium (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / non-germinal center cells: Medium (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: High (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); parathyroid gland / glandular cells: Low (Uncertain); rectum / glandular cells: High (Uncertain); salivary gland / glandular cells: High (Uncertain); skeletal muscle / myocytes: Low (Uncertain); skin 1 / fibroblasts: Medium (Uncertain); skin 1 / keratinocytes: Medium (Uncertain); skin 1 / Langerhans: Medium (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: High (Uncertain); smooth muscle / smooth muscle cells: Low (Uncertain); spleen / cells in red pulp: High (Uncertain); spleen / cells in white pulp: Low (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: High (Uncertain); thyroid gland / glandular cells: High (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 477/486 (98.1%); Rectum Adenocarcinoma (validation): 198/207 (95.7%),colorectal cancer: 12/12 (100.0%); melanoma: 12/12 (100.0%),31,20,Q8N2I2,https://www.uniprot.org/uniprotkb/Q8N2I2/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF620,ENSG00000177842,Unsafe,RNA,False,True,2.2,4.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 1.3 nTPM; continuous selectivity; adrenal gland: 1.8 nTPM; continuous selectivity; amygdala: 1.4 nTPM; continuous selectivity; basal ganglia: 1.6 nTPM; continuous selectivity; bone marrow: 3.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 3.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 2.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 1.4 nTPM; continuous selectivity; colon: 1.8 nTPM; continuous selectivity; duodenum: 1.6 nTPM; continuous selectivity; esophagus: 1 nTPM; continuous selectivity; heart muscle: 1.6 nTPM; continuous selectivity; hippocampal formation: 1.4 nTPM; continuous selectivity; hypothalamus: 1.5 nTPM; continuous selectivity; kidney: 2.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; liver: 1.4 nTPM; continuous selectivity; lung: 2.1 nTPM; absolute ceiling;continuous selectivity; lymph node: 1.2 nTPM; continuous selectivity; midbrain: 1.6 nTPM; continuous selectivity; pancreas: 2.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 2.6 nTPM; continuous selectivity;reproductive not higher; pituitary gland: 2.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 2.1 nTPM; continuous selectivity; retina: 4.1 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 1 nTPM; continuous selectivity; skeletal muscle: 2.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 1.5 nTPM; continuous selectivity; smooth muscle: 1.5 nTPM; continuous selectivity; spinal cord: 1.5 nTPM; continuous selectivity; spleen: 1.7 nTPM; continuous selectivity; stomach: 2.6 nTPM; continuous selectivity;reproductive not higher; thymus: 1.5 nTPM; continuous selectivity; thyroid gland: 3.3 nTPM; continuous selectivity;reproductive not higher; tongue: 2.2 nTPM; continuous selectivity;reproductive not higher; urinary bladder: 1.3 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 3.1 nTPM (limit 2); cerebellum: 3.2 nTPM (limit 2); cerebral cortex: 2.3 nTPM (limit 2); kidney: 2.3 nTPM (limit 2); lung: 2.1 nTPM (limit 2); pancreas: 2.4 nTPM (limit 2); pituitary gland: 2.4 nTPM (limit 2); retina: 4.1 nTPM (limit 2); skeletal muscle: 2.5 nTPM (limit 2); bone marrow: 3.1 nTPM (baseline 2); cerebellum: 3.2 nTPM (baseline 2); cerebral cortex: 2.3 nTPM (baseline 2); kidney: 2.3 nTPM (baseline 2); lung: 2.1 nTPM (baseline 2); pancreas: 2.4 nTPM (baseline 2); pituitary gland: 2.4 nTPM (baseline 2); retina: 4.1 nTPM (baseline 2); skeletal muscle: 2.5 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Breast Invasive Carcinoma (validation): 42/50 (84.0%); Colon Adenocarcinoma (validation): 301/486 (61.9%),colorectal cancer: 12/12 (100.0%); liver cancer: 12/12 (100.0%),31,20,Q6ZNG0,https://www.uniprot.org/uniprotkb/Q6ZNG0/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF624,ENSG00000197566,Unsafe,Protein,False,True,4.7,4.7,81,76,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 1.6 nTPM; positive ihc; adrenal gland: 0.7 nTPM; positive ihc; bone marrow: 1.1 nTPM; positive ihc; cerebellum: 0.8 nTPM; positive ihc; cerebral cortex: 1.8 nTPM; positive ihc;continuous selectivity; colon: 1.7 nTPM; positive ihc;continuous selectivity; duodenum: 1.3 nTPM; positive ihc;continuous selectivity; esophagus: 1.2 nTPM; positive ihc; heart muscle: 1.4 nTPM; positive ihc;continuous selectivity; kidney: 1.8 nTPM; positive ihc;continuous selectivity; liver: 0.8 nTPM; positive ihc; lung: 1.9 nTPM; positive ihc;continuous selectivity; lymph node: 2.4 nTPM; positive ihc;continuous selectivity; pancreas: 0.8 nTPM; positive ihc; parathyroid gland: 2.4 nTPM; positive ihc;continuous selectivity; rectum: 1.7 nTPM; positive ihc;continuous selectivity; retina: 2.6 nTPM; absolute ceiling;continuous selectivity; salivary gland: 0.8 nTPM; positive ihc; skeletal muscle: 0.4 nTPM; positive ihc; skin: 1.5 nTPM; positive ihc; small intestine: 1.3 nTPM; positive ihc;continuous selectivity; smooth muscle: 1.9 nTPM; positive ihc;continuous selectivity; spinal cord: 1.7 nTPM; continuous selectivity; spleen: 3.4 nTPM; positive ihc;continuous selectivity; stomach: 1.8 nTPM; positive ihc;continuous selectivity; thymus: 3 nTPM; continuous selectivity; thyroid gland: 2.3 nTPM; positive ihc;continuous selectivity; urinary bladder: 1.3 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",retina: 2.6 nTPM (limit 2); retina: 2.6 nTPM (baseline 2),adipose tissue / adipocytes: Low (Uncertain); adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Low (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / glial cells: Low (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: Medium (Uncertain); cerebellum / cells in molecular layer: Medium (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / endothelial cells: Medium (Uncertain); cerebral cortex / glial cells: Low (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / endothelial cells: Medium (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: Medium (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / glial cells: Low (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in glomeruli: Medium (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / hepatocytes: Low (Uncertain); lung / alveolar cells: Medium (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / germinal center cells: Medium (Uncertain); lymph node / non-germinal center cells: Medium (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); parathyroid gland / glandular cells: Low (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: Low (Uncertain); skin 1 / fibroblasts: Low (Uncertain); skin 1 / keratinocytes: Low (Uncertain); skin 1 / Langerhans: Low (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: Medium (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); spleen / cells in red pulp: Medium (Uncertain); spleen / cells in white pulp: Medium (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Low (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 46/50 (92.0%); Pancreatic Adenocarcinoma (validation): 22/80 (27.5%),colorectal cancer: 9/12 (75.0%); cervical cancer: 8/11 (72.7%),31,20,Q9P2J8,https://www.uniprot.org/uniprotkb/Q9P2J8/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF626,ENSG00000188171,Unsafe,Protein,False,True,20.9,21.7,78,50,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 8.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 3.6 nTPM; absolute ceiling; basal ganglia: 3.6 nTPM; absolute ceiling; bone marrow: 3.7 nTPM; positive ihc;absolute ceiling; cerebellum: 2.5 nTPM; positive ihc;absolute ceiling; cerebral cortex: 7.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 4.1 nTPM; absolute ceiling; colon: 3.4 nTPM; positive ihc; duodenum: 1.5 nTPM; positive ihc; esophagus: 6 nTPM; positive ihc; heart muscle: 9.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 3.5 nTPM; absolute ceiling; hypothalamus: 3.7 nTPM; absolute ceiling; kidney: 10.4 nTPM; absolute ceiling;continuous selectivity; liver: 5.3 nTPM; absolute ceiling; lung: 4.9 nTPM; positive ihc;absolute ceiling; lymph node: 11.8 nTPM; absolute ceiling;continuous selectivity; midbrain: 3.7 nTPM; absolute ceiling; pancreas: 6.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 19.3 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 3.4 nTPM; absolute ceiling; rectum: 3 nTPM; positive ihc; retina: 7.1 nTPM; absolute ceiling;continuous selectivity; salivary gland: 6.7 nTPM; positive ihc;absolute ceiling; skeletal muscle: 4.3 nTPM; positive ihc;absolute ceiling; skin: 9 nTPM; positive ihc; small intestine: 2.3 nTPM; positive ihc;absolute ceiling; smooth muscle: 8.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 3.6 nTPM; absolute ceiling; spleen: 6.7 nTPM; positive ihc; stomach: 7.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; thyroid gland: 21.7 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; urinary bladder: 13.8 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 8.5 nTPM (limit 2); amygdala: 3.6 nTPM (limit 2); basal ganglia: 3.6 nTPM (limit 2); bone marrow: 3.7 nTPM (limit 2); cerebellum: 2.5 nTPM (limit 2); cerebral cortex: 7.5 nTPM (limit 2); choroid plexus: 4.1 nTPM (limit 2); heart muscle: 9.5 nTPM (limit 2); hippocampal formation: 3.5 nTPM (limit 2); hypothalamus: 3.7 nTPM (limit 2); kidney: 10.4 nTPM (limit 2); liver: 5.3 nTPM (limit 2); lung: 4.9 nTPM (limit 2); lymph node: 11.8 nTPM (limit 6); midbrain: 3.7 nTPM (limit 2); pancreas: 6.8 nTPM (limit 2); parathyroid gland: 19.3 nTPM (limit 6); pituitary gland: 3.4 nTPM (limit 2); retina: 7.1 nTPM (limit 2); salivary gland: 6.7 nTPM (limit 6); skeletal muscle: 4.3 nTPM (limit 2); small intestine: 2.3 nTPM (limit 2); smooth muscle: 8.8 nTPM (limit 2); spinal cord: 3.6 nTPM (limit 2); stomach: 7.8 nTPM (limit 6); thyroid gland: 21.7 nTPM (limit 10); urinary bladder: 13.8 nTPM (limit 6); adrenal gland: 8.5 nTPM (baseline 2); amygdala: 3.6 nTPM (baseline 2); basal ganglia: 3.6 nTPM (baseline 2); bone marrow: 3.7 nTPM (baseline 2); cerebellum: 2.5 nTPM (baseline 2); cerebral cortex: 7.5 nTPM (baseline 2); choroid plexus: 4.1 nTPM (baseline 2); heart muscle: 9.5 nTPM (baseline 2); hippocampal formation: 3.5 nTPM (baseline 2); hypothalamus: 3.7 nTPM (baseline 2); kidney: 10.4 nTPM (baseline 2); liver: 5.3 nTPM (baseline 2); lung: 4.9 nTPM (baseline 2); lymph node: 11.8 nTPM (baseline 6); midbrain: 3.7 nTPM (baseline 2); pancreas: 6.8 nTPM (baseline 2); parathyroid gland: 19.3 nTPM (baseline 6); pituitary gland: 3.4 nTPM (baseline 2); retina: 7.1 nTPM (baseline 2); salivary gland: 6.7 nTPM (baseline 6); skeletal muscle: 4.3 nTPM (baseline 2); small intestine: 2.3 nTPM (baseline 2); smooth muscle: 8.8 nTPM (baseline 2); spinal cord: 3.6 nTPM (baseline 2); stomach: 7.8 nTPM (baseline 6); thyroid gland: 21.7 nTPM (baseline 10); urinary bladder: 13.8 nTPM (baseline 6),adrenal gland / glandular cells: Low (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); cerebellum / cells in granular layer: Medium (Uncertain); cerebral cortex / endothelial cells: Low (Uncertain); cerebral cortex / glial cells: Low (Uncertain); cerebral cortex / neuronal cells: Low (Uncertain); cerebral cortex / neuropil: Medium (Uncertain); colon / endothelial cells: Medium (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: Low (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Low (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); lung / alveolar cells: Low (Uncertain); lung / macrophages: Low (Uncertain); nasopharynx / respiratory epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Low (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: Medium (Uncertain); skin 1 / fibroblasts: Low (Uncertain); skin 1 / keratinocytes: Low (Uncertain); skin 1 / Langerhans: Low (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: Medium (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); spleen / cells in red pulp: Low (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Kidney Renal Clear Cell Carcinoma (validation): 96/100 (96.0%); Glioblastoma Multiforme (TCGA): 133/141 (94.3%),prostate cancer: 8/9 (88.9%); breast cancer: 9/11 (81.8%),31,20,Q68DY1,https://www.uniprot.org/uniprotkb/Q68DY1/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF646,ENSG00000167395,Unsafe,Protein,False,True,25.0,25.0,78,12,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 4 nTPM; positive ihc;absolute ceiling; amygdala: 3.6 nTPM; absolute ceiling; basal ganglia: 3.8 nTPM; absolute ceiling; bone marrow: 9.1 nTPM; absolute ceiling;continuous selectivity; cerebellum: 6.5 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 4.5 nTPM; positive ihc;absolute ceiling; colon: 4.9 nTPM; positive ihc; duodenum: 6.2 nTPM; absolute ceiling; heart muscle: 4.6 nTPM; absolute ceiling; hippocampal formation: 4 nTPM; absolute ceiling; hypothalamus: 3.3 nTPM; absolute ceiling; kidney: 4.7 nTPM; positive ihc;absolute ceiling; liver: 4.2 nTPM; positive ihc;absolute ceiling; lung: 4.5 nTPM; absolute ceiling; lymph node: 7 nTPM; absolute ceiling; midbrain: 3.4 nTPM; absolute ceiling; pancreas: 5.4 nTPM; absolute ceiling; pituitary gland: 4.9 nTPM; absolute ceiling; skeletal muscle: 7.6 nTPM; absolute ceiling;continuous selectivity; small intestine: 6.3 nTPM; absolute ceiling; smooth muscle: 3.1 nTPM; absolute ceiling; spinal cord: 3.9 nTPM; absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 4 nTPM (limit 2); amygdala: 3.6 nTPM (limit 2); basal ganglia: 3.8 nTPM (limit 2); bone marrow: 9.1 nTPM (limit 2); cerebellum: 6.5 nTPM (limit 2); cerebral cortex: 4.5 nTPM (limit 2); duodenum: 6.2 nTPM (limit 2); heart muscle: 4.6 nTPM (limit 2); hippocampal formation: 4 nTPM (limit 2); hypothalamus: 3.3 nTPM (limit 2); kidney: 4.7 nTPM (limit 2); liver: 4.2 nTPM (limit 2); lung: 4.5 nTPM (limit 2); lymph node: 7 nTPM (limit 6); midbrain: 3.4 nTPM (limit 2); pancreas: 5.4 nTPM (limit 2); pituitary gland: 4.9 nTPM (limit 2); skeletal muscle: 7.6 nTPM (limit 2); small intestine: 6.3 nTPM (limit 2); smooth muscle: 3.1 nTPM (limit 2); spinal cord: 3.9 nTPM (limit 2); adrenal gland: 4 nTPM (baseline 2); amygdala: 3.6 nTPM (baseline 2); basal ganglia: 3.8 nTPM (baseline 2); bone marrow: 9.1 nTPM (baseline 2); cerebellum: 6.5 nTPM (baseline 2); cerebral cortex: 4.5 nTPM (baseline 2); duodenum: 6.2 nTPM (baseline 2); heart muscle: 4.6 nTPM (baseline 2); hippocampal formation: 4 nTPM (baseline 2); hypothalamus: 3.3 nTPM (baseline 2); kidney: 4.7 nTPM (baseline 2); liver: 4.2 nTPM (baseline 2); lung: 4.5 nTPM (baseline 2); lymph node: 7 nTPM (baseline 6); midbrain: 3.4 nTPM (baseline 2); pancreas: 5.4 nTPM (baseline 2); pituitary gland: 4.9 nTPM (baseline 2); skeletal muscle: 7.6 nTPM (baseline 2); small intestine: 6.3 nTPM (baseline 2); smooth muscle: 3.1 nTPM (baseline 2); spinal cord: 3.9 nTPM (baseline 2),adrenal gland / glandular cells: Low (Uncertain); caudate / neuronal cells: Low (Uncertain); cerebral cortex / neuronal cells: Low (Uncertain); colon / peripheral nerve/ganglion: Low (Uncertain); hippocampus / neuronal cells: Low (Uncertain); kidney / cells in glomeruli: Low (Uncertain); liver / hepatocytes: Low (Uncertain); nasopharynx / respiratory epithelial cells: Low (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 485/486 (99.8%),testis cancer: 1/11 (9.1%); breast cancer: 0/11 (0.0%),31,20,O15015,https://www.uniprot.org/uniprotkb/O15015/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF655,ENSG00000197343,Unsafe,Protein,False,True,14.4,26.2,79,68,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 11.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; adrenal gland: 11.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 8.2 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 7.6 nTPM; absolute ceiling;continuous selectivity; bone marrow: 8.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 8.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 11.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 10.2 nTPM; absolute ceiling;continuous selectivity; colon: 15 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; duodenum: 15.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 26.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 8.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 8.2 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 8.4 nTPM; absolute ceiling;continuous selectivity; kidney: 13.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 14.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 14.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lymph node: 19.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; midbrain: 10.6 nTPM; absolute ceiling;continuous selectivity; pancreas: 20.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 13.9 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 8 nTPM; absolute ceiling;continuous selectivity; rectum: 11.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 8.2 nTPM; absolute ceiling;continuous selectivity; salivary gland: 16.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 12.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 17.9 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; small intestine: 13.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 11.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 13.5 nTPM; absolute ceiling;continuous selectivity; spleen: 13.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 17.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; thymus: 22 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; thyroid gland: 11.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; tongue: 13 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 18.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",adipose tissue: 11.2 nTPM (limit 10); adrenal gland: 11.5 nTPM (limit 2); amygdala: 8.2 nTPM (limit 2); basal ganglia: 7.6 nTPM (limit 2); bone marrow: 8.8 nTPM (limit 2); cerebellum: 8.3 nTPM (limit 2); cerebral cortex: 11.7 nTPM (limit 2); choroid plexus: 10.2 nTPM (limit 2); colon: 15 nTPM (limit 6); duodenum: 15.3 nTPM (limit 2); esophagus: 26.2 nTPM (limit 6); heart muscle: 8.1 nTPM (limit 2); hippocampal formation: 8.2 nTPM (limit 2); hypothalamus: 8.4 nTPM (limit 2); kidney: 13.3 nTPM (limit 2); liver: 14.4 nTPM (limit 2); lung: 14.8 nTPM (limit 2); lymph node: 19.2 nTPM (limit 6); midbrain: 10.6 nTPM (limit 2); pancreas: 20.5 nTPM (limit 2); parathyroid gland: 13.9 nTPM (limit 6); pituitary gland: 8 nTPM (limit 2); rectum: 11.4 nTPM (limit 6); retina: 8.2 nTPM (limit 2); salivary gland: 16.2 nTPM (limit 6); skeletal muscle: 12.2 nTPM (limit 2); skin: 17.9 nTPM (limit 10); small intestine: 13.5 nTPM (limit 2); smooth muscle: 11.3 nTPM (limit 2); spinal cord: 13.5 nTPM (limit 2); spleen: 13.8 nTPM (limit 10); stomach: 17.5 nTPM (limit 6); thymus: 22 nTPM (limit 10); thyroid gland: 11.5 nTPM (limit 10); tongue: 13 nTPM (limit 6); urinary bladder: 18.1 nTPM (limit 6); adipose tissue: 11.2 nTPM (baseline 10); adrenal gland: 11.5 nTPM (baseline 2); amygdala: 8.2 nTPM (baseline 2); basal ganglia: 7.6 nTPM (baseline 2); bone marrow: 8.8 nTPM (baseline 2); cerebellum: 8.3 nTPM (baseline 2); cerebral cortex: 11.7 nTPM (baseline 2); choroid plexus: 10.2 nTPM (baseline 2); colon: 15 nTPM (baseline 6); duodenum: 15.3 nTPM (baseline 2); esophagus: 26.2 nTPM (baseline 6); heart muscle: 8.1 nTPM (baseline 2); hippocampal formation: 8.2 nTPM (baseline 2); hypothalamus: 8.4 nTPM (baseline 2); kidney: 13.3 nTPM (baseline 2); liver: 14.4 nTPM (baseline 2); lung: 14.8 nTPM (baseline 2); lymph node: 19.2 nTPM (baseline 6); midbrain: 10.6 nTPM (baseline 2); pancreas: 20.5 nTPM (baseline 2); parathyroid gland: 13.9 nTPM (baseline 6); pituitary gland: 8 nTPM (baseline 2); rectum: 11.4 nTPM (baseline 6); retina: 8.2 nTPM (baseline 2); salivary gland: 16.2 nTPM (baseline 6); skeletal muscle: 12.2 nTPM (baseline 2); skin: 17.9 nTPM (baseline 10); small intestine: 13.5 nTPM (baseline 2); smooth muscle: 11.3 nTPM (baseline 2); spinal cord: 13.5 nTPM (baseline 2); spleen: 13.8 nTPM (baseline 10); stomach: 17.5 nTPM (baseline 6); thymus: 22 nTPM (baseline 10); thyroid gland: 11.5 nTPM (baseline 10); tongue: 13 nTPM (baseline 6); urinary bladder: 18.1 nTPM (baseline 6),adipose tissue / adipocytes: Medium (Uncertain); adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / glial cells: Low (Uncertain); caudate / neuronal cells: Low (Uncertain); cerebellum / cells in molecular layer: Medium (Uncertain); cerebellum / Purkinje cells: Low (Uncertain); cerebral cortex / endothelial cells: Medium (Uncertain); cerebral cortex / glial cells: Medium (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); colon / endothelial cells: High (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: Medium (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / glial cells: Low (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in glomeruli: Medium (Uncertain); kidney / cells in tubules: Low (Uncertain); lung / alveolar cells: Medium (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / germinal center cells: Low (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: Medium (Uncertain); skin 1 / fibroblasts: Medium (Uncertain); skin 1 / keratinocytes: Medium (Uncertain); skin 1 / Langerhans: Low (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: Medium (Uncertain); smooth muscle / smooth muscle cells: Low (Uncertain); spleen / cells in red pulp: Medium (Uncertain); spleen / cells in white pulp: Low (Uncertain); stomach 1 / glandular cells: Low (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (TCGA): 141/141 (100.0%); Pancreatic Adenocarcinoma (validation): 80/80 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%),testis cancer: 5/11 (45.5%); pancreatic cancer: 4/10 (40.0%),31,20,Q8N720,https://www.uniprot.org/uniprotkb/Q8N720/entry,Probable transcription factor,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection,,,,,,,,
ZNF660,ENSG00000144792,Unsafe,RNA,False,True,3.3,4.4,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 1 nTPM; continuous selectivity; basal ganglia: 1 nTPM; continuous selectivity; cerebellum: 2.3 nTPM; absolute ceiling;continuous selectivity; colon: 1.4 nTPM; continuous selectivity; heart muscle: 1 nTPM; continuous selectivity; hippocampal formation: 1 nTPM; continuous selectivity; hypothalamus: 1.2 nTPM; continuous selectivity; kidney: 1 nTPM; continuous selectivity; midbrain: 1 nTPM; continuous selectivity; pituitary gland: 2.4 nTPM; absolute ceiling;continuous selectivity; retina: 4.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; spinal cord: 1.1 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebellum: 2.3 nTPM (limit 2); pituitary gland: 2.4 nTPM (limit 2); retina: 4.4 nTPM (limit 2); cerebellum: 2.3 nTPM (baseline 2); pituitary gland: 2.4 nTPM (baseline 2); retina: 4.4 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Pancreatic Adenocarcinoma (validation): 7/80 (8.8%); Breast Invasive Carcinoma (validation): 3/50 (6.0%),colorectal cancer: 12/12 (100.0%); liver cancer: 12/12 (100.0%),31,20,Q6AZW8,https://www.uniprot.org/uniprotkb/Q6AZW8/entry,May be involved in transcriptional regulation,,,,Nucleus,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF668,ENSG00000167394,Unsafe,Protein,False,True,7.3,7.8,79,70,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 5.4 nTPM; positive ihc;continuous selectivity; adrenal gland: 6.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 5.8 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 6.1 nTPM; absolute ceiling;continuous selectivity; bone marrow: 7.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 7.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 7.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 2.1 nTPM; absolute ceiling;continuous selectivity; colon: 5.4 nTPM; positive ihc;continuous selectivity; duodenum: 4.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 6.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 5.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 6.4 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 5.4 nTPM; absolute ceiling;continuous selectivity; kidney: 4.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 4.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 4.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 2.6 nTPM; positive ihc;continuous selectivity; midbrain: 4.9 nTPM; absolute ceiling;continuous selectivity; pancreas: 3.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 2.2 nTPM; positive ihc; pituitary gland: 4.8 nTPM; absolute ceiling;continuous selectivity; rectum: 1.3 nTPM; positive ihc; salivary gland: 4.5 nTPM; positive ihc;continuous selectivity; skeletal muscle: 5.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 7.1 nTPM; positive ihc;continuous selectivity; small intestine: 4.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 3.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 5 nTPM; absolute ceiling;continuous selectivity; spleen: 5.8 nTPM; positive ihc;continuous selectivity; stomach: 4.6 nTPM; positive ihc;continuous selectivity; thyroid gland: 4 nTPM; positive ihc;continuous selectivity; urinary bladder: 6 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 6.4 nTPM (limit 2); amygdala: 5.8 nTPM (limit 2); basal ganglia: 6.1 nTPM (limit 2); bone marrow: 7.8 nTPM (limit 2); cerebellum: 7.2 nTPM (limit 2); cerebral cortex: 7.2 nTPM (limit 2); choroid plexus: 2.1 nTPM (limit 2); duodenum: 4.3 nTPM (limit 2); esophagus: 6.2 nTPM (limit 6); heart muscle: 5.5 nTPM (limit 2); hippocampal formation: 6.4 nTPM (limit 2); hypothalamus: 5.4 nTPM (limit 2); kidney: 4.3 nTPM (limit 2); liver: 4.7 nTPM (limit 2); lung: 4.3 nTPM (limit 2); midbrain: 4.9 nTPM (limit 2); pancreas: 3.8 nTPM (limit 2); pituitary gland: 4.8 nTPM (limit 2); skeletal muscle: 5.9 nTPM (limit 2); small intestine: 4.7 nTPM (limit 2); smooth muscle: 3.3 nTPM (limit 2); spinal cord: 5 nTPM (limit 2); adrenal gland: 6.4 nTPM (baseline 2); amygdala: 5.8 nTPM (baseline 2); basal ganglia: 6.1 nTPM (baseline 2); bone marrow: 7.8 nTPM (baseline 2); cerebellum: 7.2 nTPM (baseline 2); cerebral cortex: 7.2 nTPM (baseline 2); choroid plexus: 2.1 nTPM (baseline 2); duodenum: 4.3 nTPM (baseline 2); esophagus: 6.2 nTPM (baseline 6); heart muscle: 5.5 nTPM (baseline 2); hippocampal formation: 6.4 nTPM (baseline 2); hypothalamus: 5.4 nTPM (baseline 2); kidney: 4.3 nTPM (baseline 2); liver: 4.7 nTPM (baseline 2); lung: 4.3 nTPM (baseline 2); midbrain: 4.9 nTPM (baseline 2); pancreas: 3.8 nTPM (baseline 2); pituitary gland: 4.8 nTPM (baseline 2); skeletal muscle: 5.9 nTPM (baseline 2); small intestine: 4.7 nTPM (baseline 2); smooth muscle: 3.3 nTPM (baseline 2); spinal cord: 5 nTPM (baseline 2),adipose tissue / adipocytes: Low (Uncertain); adrenal gland / glandular cells: High (Uncertain); bone marrow / hematopoietic cells: High (Uncertain); bronchus / respiratory epithelial cells: High (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: Low (Uncertain); cerebellum / Purkinje cells: Low (Uncertain); cerebral cortex / endothelial cells: Medium (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / endothelial cells: Medium (Uncertain); colon / glandular cells: High (Uncertain); colon / peripheral nerve/ganglion: Medium (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: High (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in glomeruli: High (Uncertain); kidney / cells in tubules: High (Uncertain); liver / hepatocytes: Low (Uncertain); lung / alveolar cells: Medium (Uncertain); lung / macrophages: Low (Uncertain); lymph node / germinal center cells: Medium (Uncertain); lymph node / non-germinal center cells: High (Uncertain); nasopharynx / respiratory epithelial cells: High (Uncertain); oral mucosa / squamous epithelial cells: High (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: High (Uncertain); salivary gland / glandular cells: High (Uncertain); skeletal muscle / myocytes: High (Uncertain); skin 1 / fibroblasts: Medium (Uncertain); skin 1 / keratinocytes: Medium (Uncertain); skin 1 / Langerhans: Medium (Uncertain); small intestine / glandular cells: Medium (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); spleen / cells in red pulp: Medium (Uncertain); spleen / cells in white pulp: Low (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: High (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 50/50 (100.0%); Testicular Germ Cell Tumor (TCGA): 132/133 (99.2%); Rectum Adenocarcinoma (validation): 203/207 (98.1%),pancreatic cancer: 8/8 (100.0%); prostate cancer: 11/12 (91.7%),31,20,Q96K58,https://www.uniprot.org/uniprotkb/Q96K58/entry,May be involved in transcriptional regulation. May play a role in DNA repair process,,"Neurodevelopmental disorder with poor growth, large ears, and dysmorphic facies: An autosomal recessive neurodevelopmental disorder characterized by severe global developmental delay, brain malformation, microcephaly, growth deficiency, and distinct facial dysmorphism. Disease severity is variable and death in infancy may occur.",,Nucleus,34313816,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF669,ENSG00000188295,Unsafe,RNA,False,True,5.3,11.5,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 3.3 nTPM; continuous selectivity; adrenal gland: 1.8 nTPM; continuous selectivity; bone marrow: 11.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 2.9 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 3.2 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 1.8 nTPM; continuous selectivity; colon: 3.6 nTPM; continuous selectivity; duodenum: 2.8 nTPM; absolute ceiling;continuous selectivity; esophagus: 2.4 nTPM; continuous selectivity; heart muscle: 2.4 nTPM; absolute ceiling;continuous selectivity; kidney: 3.6 nTPM; absolute ceiling;continuous selectivity; liver: 2.1 nTPM; absolute ceiling;continuous selectivity; lung: 3.2 nTPM; absolute ceiling;continuous selectivity; lymph node: 5.3 nTPM; continuous selectivity;reproductive not higher; pancreas: 4.1 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 4.1 nTPM; continuous selectivity; pituitary gland: 1.5 nTPM; continuous selectivity; rectum: 3.4 nTPM; continuous selectivity; retina: 4.9 nTPM; absolute ceiling;continuous selectivity; salivary gland: 2.8 nTPM; continuous selectivity; skeletal muscle: 1.9 nTPM; continuous selectivity; skin: 2.7 nTPM; continuous selectivity; small intestine: 2.3 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 3.5 nTPM; absolute ceiling;continuous selectivity; spleen: 3.9 nTPM; continuous selectivity; stomach: 3.2 nTPM; continuous selectivity; thymus: 8.6 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 4.8 nTPM; continuous selectivity; tongue: 3.5 nTPM; continuous selectivity; urinary bladder: 2.6 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 11.5 nTPM (limit 2); cerebellum: 2.9 nTPM (limit 2); cerebral cortex: 3.2 nTPM (limit 2); duodenum: 2.8 nTPM (limit 2); heart muscle: 2.4 nTPM (limit 2); kidney: 3.6 nTPM (limit 2); liver: 2.1 nTPM (limit 2); lung: 3.2 nTPM (limit 2); pancreas: 4.1 nTPM (limit 2); retina: 4.9 nTPM (limit 2); small intestine: 2.3 nTPM (limit 2); smooth muscle: 3.5 nTPM (limit 2); bone marrow: 11.5 nTPM (baseline 2); cerebellum: 2.9 nTPM (baseline 2); cerebral cortex: 3.2 nTPM (baseline 2); duodenum: 2.8 nTPM (baseline 2); heart muscle: 2.4 nTPM (baseline 2); kidney: 3.6 nTPM (baseline 2); liver: 2.1 nTPM (baseline 2); lung: 3.2 nTPM (baseline 2); pancreas: 4.1 nTPM (baseline 2); retina: 4.9 nTPM (baseline 2); small intestine: 2.3 nTPM (baseline 2); smooth muscle: 3.5 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Rectum Adenocarcinoma (validation): 205/207 (99.0%); Colon Adenocarcinoma (validation): 477/486 (98.1%),colorectal cancer: 9/11 (81.8%); liver cancer: 7/12 (58.3%),31,20,Q96BR6,https://www.uniprot.org/uniprotkb/Q96BR6/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF670,ENSG00000277462,Unsafe,Protein,False,True,2.3,2.3,81,70,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 2.2 nTPM; positive ihc;continuous selectivity; adrenal gland: 1.4 nTPM; positive ihc;continuous selectivity; amygdala: 1 nTPM; continuous selectivity; basal ganglia: 0.9 nTPM; continuous selectivity; cerebellum: 2.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 1.6 nTPM; positive ihc;continuous selectivity; colon: 1.5 nTPM; positive ihc;continuous selectivity; duodenum: 1 nTPM; positive ihc;continuous selectivity; esophagus: 1.2 nTPM; positive ihc;continuous selectivity; heart muscle: 1 nTPM; positive ihc;continuous selectivity; hippocampal formation: 0.9 nTPM; continuous selectivity; hypothalamus: 1.1 nTPM; continuous selectivity; kidney: 1.7 nTPM; positive ihc;continuous selectivity; liver: 1.6 nTPM; continuous selectivity; lung: 1.5 nTPM; positive ihc;continuous selectivity; lymph node: 1.4 nTPM; positive ihc;continuous selectivity; midbrain: 0.9 nTPM; continuous selectivity; pancreas: 1.8 nTPM; positive ihc;continuous selectivity; parathyroid gland: 1.5 nTPM; positive ihc;continuous selectivity; pituitary gland: 1 nTPM; continuous selectivity; rectum: 1.3 nTPM; positive ihc;continuous selectivity; retina: 2.1 nTPM; absolute ceiling;continuous selectivity; salivary gland: 1.5 nTPM; positive ihc;continuous selectivity; skeletal muscle: 0.9 nTPM; positive ihc;continuous selectivity; skin: 1.4 nTPM; positive ihc;continuous selectivity; small intestine: 1.5 nTPM; positive ihc;continuous selectivity; smooth muscle: 1.6 nTPM; positive ihc;continuous selectivity; spinal cord: 1 nTPM; continuous selectivity; spleen: 1.4 nTPM; positive ihc;continuous selectivity; stomach: 2 nTPM; positive ihc;continuous selectivity; thymus: 1.8 nTPM; continuous selectivity; thyroid gland: 1.4 nTPM; positive ihc;continuous selectivity; tongue: 1.4 nTPM; continuous selectivity; urinary bladder: 1.6 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",cerebellum: 2.2 nTPM (limit 2); retina: 2.1 nTPM (limit 2); cerebellum: 2.2 nTPM (baseline 2); retina: 2.1 nTPM (baseline 2),adipose tissue / adipocytes: Medium (Uncertain); adrenal gland / glandular cells: Low (Uncertain); bronchus / respiratory epithelial cells: Low (Uncertain); caudate / glial cells: Low (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: Low (Uncertain); cerebellum / cells in molecular layer: Medium (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / glial cells: Low (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / glandular cells: Low (Uncertain); colon / peripheral nerve/ganglion: Low (Uncertain); duodenum / glandular cells: Low (Uncertain); esophagus / squamous epithelial cells: Low (Uncertain); heart muscle / cardiomyocytes: Low (Uncertain); hippocampus / glial cells: Medium (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in tubules: Low (Uncertain); lung / alveolar cells: Medium (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / germinal center cells: Low (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); nasopharynx / respiratory epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Low (Uncertain); pancreas / pancreatic endocrine cells: Low (Uncertain); parathyroid gland / glandular cells: Low (Uncertain); rectum / glandular cells: Low (Uncertain); salivary gland / glandular cells: Low (Uncertain); skeletal muscle / myocytes: Low (Uncertain); skin 1 / fibroblasts: Medium (Uncertain); skin 1 / keratinocytes: Low (Uncertain); skin 1 / Langerhans: Low (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: Low (Uncertain); smooth muscle / smooth muscle cells: Low (Uncertain); spleen / cells in red pulp: Low (Uncertain); spleen / cells in white pulp: Low (Uncertain); stomach 1 / glandular cells: Low (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Low (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 42/50 (84.0%); Testicular Germ Cell Tumor (TCGA): 37/133 (27.8%); Lung Squamous Cell Carcinoma (validation): 9/68 (13.2%),testis cancer: 10/12 (83.3%); urothelial cancer: 6/12 (50.0%),28,20,Q9BS34,https://www.uniprot.org/uniprotkb/Q9BS34/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF675,ENSG00000197372,Unsafe,RNA,False,True,13.0,13.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 7.2 nTPM; continuous selectivity; adrenal gland: 5.3 nTPM; absolute ceiling;continuous selectivity; amygdala: 4.8 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 4.3 nTPM; absolute ceiling;continuous selectivity; bone marrow: 11.2 nTPM; absolute ceiling;continuous selectivity; cerebellum: 5 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 10.7 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 3.8 nTPM; absolute ceiling;continuous selectivity; colon: 8 nTPM; absolute ceiling;continuous selectivity; duodenum: 6.5 nTPM; absolute ceiling;continuous selectivity; esophagus: 5.8 nTPM; continuous selectivity; heart muscle: 3.2 nTPM; absolute ceiling; hippocampal formation: 5.2 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 4.6 nTPM; absolute ceiling;continuous selectivity; kidney: 5 nTPM; absolute ceiling;continuous selectivity; liver: 6.3 nTPM; absolute ceiling;continuous selectivity; lung: 6.6 nTPM; absolute ceiling;continuous selectivity; lymph node: 12.6 nTPM; absolute ceiling;continuous selectivity; midbrain: 3.7 nTPM; absolute ceiling;continuous selectivity; pancreas: 7.4 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 7.2 nTPM; absolute ceiling;continuous selectivity; rectum: 11.8 nTPM; absolute ceiling;continuous selectivity; retina: 10.3 nTPM; absolute ceiling;continuous selectivity; salivary gland: 6.6 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 3.3 nTPM; absolute ceiling; skin: 9.5 nTPM; continuous selectivity; small intestine: 5.8 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 4 nTPM; absolute ceiling;continuous selectivity; spinal cord: 4.3 nTPM; absolute ceiling;continuous selectivity; spleen: 9.2 nTPM; continuous selectivity; stomach: 8.8 nTPM; absolute ceiling;continuous selectivity; thymus: 10.2 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 8.3 nTPM; continuous selectivity; urinary bladder: 5.3 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 5.3 nTPM (limit 2); amygdala: 4.8 nTPM (limit 2); basal ganglia: 4.3 nTPM (limit 2); bone marrow: 11.2 nTPM (limit 2); cerebellum: 5 nTPM (limit 2); cerebral cortex: 10.7 nTPM (limit 2); choroid plexus: 3.8 nTPM (limit 2); colon: 8 nTPM (limit 6); duodenum: 6.5 nTPM (limit 2); heart muscle: 3.2 nTPM (limit 2); hippocampal formation: 5.2 nTPM (limit 2); hypothalamus: 4.6 nTPM (limit 2); kidney: 5 nTPM (limit 2); liver: 6.3 nTPM (limit 2); lung: 6.6 nTPM (limit 2); lymph node: 12.6 nTPM (limit 6); midbrain: 3.7 nTPM (limit 2); pancreas: 7.4 nTPM (limit 2); parathyroid gland: 7.2 nTPM (limit 6); rectum: 11.8 nTPM (limit 6); retina: 10.3 nTPM (limit 2); salivary gland: 6.6 nTPM (limit 6); skeletal muscle: 3.3 nTPM (limit 2); small intestine: 5.8 nTPM (limit 2); smooth muscle: 4 nTPM (limit 2); spinal cord: 4.3 nTPM (limit 2); stomach: 8.8 nTPM (limit 6); thymus: 10.2 nTPM (limit 10); adrenal gland: 5.3 nTPM (baseline 2); amygdala: 4.8 nTPM (baseline 2); basal ganglia: 4.3 nTPM (baseline 2); bone marrow: 11.2 nTPM (baseline 2); cerebellum: 5 nTPM (baseline 2); cerebral cortex: 10.7 nTPM (baseline 2); choroid plexus: 3.8 nTPM (baseline 2); colon: 8 nTPM (baseline 6); duodenum: 6.5 nTPM (baseline 2); heart muscle: 3.2 nTPM (baseline 2); hippocampal formation: 5.2 nTPM (baseline 2); hypothalamus: 4.6 nTPM (baseline 2); kidney: 5 nTPM (baseline 2); liver: 6.3 nTPM (baseline 2); lung: 6.6 nTPM (baseline 2); lymph node: 12.6 nTPM (baseline 6); midbrain: 3.7 nTPM (baseline 2); pancreas: 7.4 nTPM (baseline 2); parathyroid gland: 7.2 nTPM (baseline 6); rectum: 11.8 nTPM (baseline 6); retina: 10.3 nTPM (baseline 2); salivary gland: 6.6 nTPM (baseline 6); skeletal muscle: 3.3 nTPM (baseline 2); small intestine: 5.8 nTPM (baseline 2); smooth muscle: 4 nTPM (baseline 2); spinal cord: 4.3 nTPM (baseline 2); stomach: 8.8 nTPM (baseline 6); thymus: 10.2 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 484/486 (99.6%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8TD23,https://www.uniprot.org/uniprotkb/Q8TD23/entry,May be involved in transcriptional regulation. May play a role during osteoclast differentiation by modulating TRAF6 signaling activity,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF676,ENSG00000196109,Unsafe,High RNA,False,True,3.7,3.7,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,cerebral cortex: 1.1 nTPM; continuous selectivity; heart muscle: 1.3 nTPM; continuous selectivity; kidney: 1.5 nTPM; continuous selectivity; parathyroid gland: 3.6 nTPM; continuous selectivity; pituitary gland: 1.1 nTPM; continuous selectivity; thyroid gland: 3.2 nTPM; continuous selectivity,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,True,"brain/oligodendrocytes cluster c-12: 35.6 nTPM, 432 reads; reproductive-cell max 33.5",True,False,,True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,3.62893313182,35.6,"hpa_single_cell: /Distal tubular cells, max 30.7 nTPM, 1 observations >30; hpa_single_cell: /Oligodendrocytes, max 34.6 nTPM, 1 observations >30; hpa_single_cell_tissue: brain/oligodendrocytes, max 35.6 nTPM, 2 observations >30; hpa_single_cell_tissue: kidney/distal tubular cells, max 30.7 nTPM, 1 observations >30",Neither,oncoref.target-sets.2026-10-23.2,3.629 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,35.6 nTPM; brain/oligodendrocytes; hpa_single_cell_tissue; vital,Testicular Germ Cell Tumor (TCGA): 84/133 (63.2%); Glioblastoma Multiforme (validation): 14/58 (24.1%); Breast Invasive Carcinoma (validation): 9/50 (18.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q8N7Q3,https://www.uniprot.org/uniprotkb/Q8N7Q3/entry,May be involved in transcriptional regulation,,,,Nucleus,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination; inclusion depends on TGCT under this study's thresholds,,,,,,,,
ZNF677,ENSG00000197928,Unsafe,Protein,False,True,43.5,43.5,81,53,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 6.1 nTPM; positive ihc;absolute ceiling; amygdala: 3.9 nTPM; absolute ceiling; basal ganglia: 4 nTPM; absolute ceiling; bone marrow: 5.4 nTPM; positive ihc;absolute ceiling; cerebellum: 4.4 nTPM; positive ihc;absolute ceiling; cerebral cortex: 7.7 nTPM; positive ihc;absolute ceiling; choroid plexus: 3.7 nTPM; absolute ceiling; colon: 6.6 nTPM; positive ihc;absolute ceiling; duodenum: 3.4 nTPM; positive ihc;absolute ceiling; esophagus: 5.3 nTPM; positive ihc; heart muscle: 11 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 3.8 nTPM; absolute ceiling; hypothalamus: 3.1 nTPM; absolute ceiling; kidney: 6.2 nTPM; positive ihc;absolute ceiling; liver: 2.7 nTPM; positive ihc;absolute ceiling; lung: 6.1 nTPM; positive ihc;absolute ceiling; midbrain: 3.1 nTPM; absolute ceiling; pancreas: 5.2 nTPM; positive ihc;absolute ceiling; parathyroid gland: 9.3 nTPM; positive ihc;absolute ceiling; pituitary gland: 4.7 nTPM; absolute ceiling; rectum: 3.9 nTPM; positive ihc; retina: 11.3 nTPM; absolute ceiling;continuous selectivity; salivary gland: 7.6 nTPM; positive ihc;absolute ceiling; skeletal muscle: 5.1 nTPM; positive ihc;absolute ceiling; skin: 8.7 nTPM; positive ihc; small intestine: 3.3 nTPM; positive ihc;absolute ceiling; smooth muscle: 9 nTPM; positive ihc;absolute ceiling; spinal cord: 4.6 nTPM; absolute ceiling; stomach: 5.2 nTPM; positive ihc; thyroid gland: 11.5 nTPM; positive ihc;absolute ceiling; tongue: 6.9 nTPM; absolute ceiling; urinary bladder: 7.5 nTPM; positive ihc;absolute ceiling,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 6.1 nTPM (limit 2); amygdala: 3.9 nTPM (limit 2); basal ganglia: 4 nTPM (limit 2); bone marrow: 5.4 nTPM (limit 2); cerebellum: 4.4 nTPM (limit 2); cerebral cortex: 7.7 nTPM (limit 2); choroid plexus: 3.7 nTPM (limit 2); colon: 6.6 nTPM (limit 6); duodenum: 3.4 nTPM (limit 2); heart muscle: 11 nTPM (limit 2); hippocampal formation: 3.8 nTPM (limit 2); hypothalamus: 3.1 nTPM (limit 2); kidney: 6.2 nTPM (limit 2); liver: 2.7 nTPM (limit 2); lung: 6.1 nTPM (limit 2); midbrain: 3.1 nTPM (limit 2); pancreas: 5.2 nTPM (limit 2); parathyroid gland: 9.3 nTPM (limit 6); pituitary gland: 4.7 nTPM (limit 2); retina: 11.3 nTPM (limit 2); salivary gland: 7.6 nTPM (limit 6); skeletal muscle: 5.1 nTPM (limit 2); small intestine: 3.3 nTPM (limit 2); smooth muscle: 9 nTPM (limit 2); spinal cord: 4.6 nTPM (limit 2); thyroid gland: 11.5 nTPM (limit 10); tongue: 6.9 nTPM (limit 6); urinary bladder: 7.5 nTPM (limit 6),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / neuronal cells: Low (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: Low (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in tubules: Low (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Medium (Approved); lung / macrophages: Low (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Low (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Low (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Low (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Prostate Adenocarcinoma (TCGA): 479/480 (99.8%); Glioblastoma Multiforme (validation): 57/58 (98.3%); Glioblastoma Multiforme (TCGA): 136/141 (96.5%),liver cancer: 3/12 (25.0%); melanoma: 1/9 (11.1%),31,20,Q86XU0,https://www.uniprot.org/uniprotkb/Q86XU0/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF678,ENSG00000181450,Unsafe,RNA,False,True,4.1,5.7,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 2.5 nTPM; continuous selectivity; adrenal gland: 3 nTPM; absolute ceiling;continuous selectivity; amygdala: 1.5 nTPM; continuous selectivity; basal ganglia: 1.4 nTPM; continuous selectivity; bone marrow: 3.5 nTPM; absolute ceiling;continuous selectivity; cerebellum: 1.8 nTPM; continuous selectivity; cerebral cortex: 3.8 nTPM; absolute ceiling;continuous selectivity; colon: 2.8 nTPM; continuous selectivity; duodenum: 2.2 nTPM; absolute ceiling;continuous selectivity; esophagus: 2 nTPM; continuous selectivity; heart muscle: 1.8 nTPM; continuous selectivity; hippocampal formation: 1.4 nTPM; continuous selectivity; hypothalamus: 1.3 nTPM; continuous selectivity; kidney: 2.5 nTPM; absolute ceiling;continuous selectivity; liver: 2.1 nTPM; absolute ceiling;continuous selectivity; lung: 3.1 nTPM; absolute ceiling;continuous selectivity; lymph node: 4.4 nTPM; continuous selectivity;reproductive not higher; midbrain: 1.5 nTPM; continuous selectivity; pancreas: 3.2 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 2.3 nTPM; continuous selectivity; pituitary gland: 1.5 nTPM; continuous selectivity; rectum: 3.9 nTPM; continuous selectivity; retina: 5.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 2.7 nTPM; continuous selectivity; skeletal muscle: 1.4 nTPM; continuous selectivity; small intestine: 2.2 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 2.3 nTPM; absolute ceiling;continuous selectivity; spinal cord: 1.8 nTPM; continuous selectivity; spleen: 3.6 nTPM; continuous selectivity; stomach: 3.2 nTPM; continuous selectivity; thymus: 4.3 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 5.3 nTPM; continuous selectivity;reproductive not higher; tongue: 2.6 nTPM; continuous selectivity; urinary bladder: 2.1 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 3 nTPM (limit 2); bone marrow: 3.5 nTPM (limit 2); cerebral cortex: 3.8 nTPM (limit 2); duodenum: 2.2 nTPM (limit 2); kidney: 2.5 nTPM (limit 2); liver: 2.1 nTPM (limit 2); lung: 3.1 nTPM (limit 2); pancreas: 3.2 nTPM (limit 2); retina: 5.7 nTPM (limit 2); small intestine: 2.2 nTPM (limit 2); smooth muscle: 2.3 nTPM (limit 2); adrenal gland: 3 nTPM (baseline 2); bone marrow: 3.5 nTPM (baseline 2); cerebral cortex: 3.8 nTPM (baseline 2); duodenum: 2.2 nTPM (baseline 2); kidney: 2.5 nTPM (baseline 2); liver: 2.1 nTPM (baseline 2); lung: 3.1 nTPM (baseline 2); pancreas: 3.2 nTPM (baseline 2); retina: 5.7 nTPM (baseline 2); small intestine: 2.2 nTPM (baseline 2); smooth muscle: 2.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Rectum Adenocarcinoma (validation): 205/207 (99.0%); Colon Adenocarcinoma (validation): 480/486 (98.8%),colorectal cancer: 3/11 (27.3%); pancreatic cancer: 3/12 (25.0%),31,20,Q5SXM1,https://www.uniprot.org/uniprotkb/Q5SXM1/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF681,ENSG00000196172,Unsafe,RNA,False,True,2.4,3.8,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 1.2 nTPM; continuous selectivity; amygdala: 0.8 nTPM; continuous selectivity; cerebellum: 2 nTPM; continuous selectivity; cerebral cortex: 2.3 nTPM; absolute ceiling;continuous selectivity; colon: 1.5 nTPM; continuous selectivity; duodenum: 0.9 nTPM; continuous selectivity; esophagus: 1.9 nTPM; continuous selectivity; hypothalamus: 1 nTPM; continuous selectivity; lung: 0.9 nTPM; continuous selectivity; lymph node: 2.7 nTPM; continuous selectivity;reproductive not higher; pancreas: 1.8 nTPM; continuous selectivity; rectum: 1.8 nTPM; continuous selectivity; retina: 0.9 nTPM; continuous selectivity; skin: 2.1 nTPM; continuous selectivity; smooth muscle: 0.8 nTPM; continuous selectivity; spinal cord: 0.8 nTPM; continuous selectivity; spleen: 1.8 nTPM; continuous selectivity; stomach: 1 nTPM; continuous selectivity; thymus: 3.8 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 1.8 nTPM; continuous selectivity; urinary bladder: 1.5 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebral cortex: 2.3 nTPM (limit 2); cerebral cortex: 2.3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 46/50 (92.0%); Glioblastoma Multiforme (validation): 48/58 (82.8%); Testicular Germ Cell Tumor (TCGA): 69/133 (51.9%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q96N22,https://www.uniprot.org/uniprotkb/Q96N22/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF683,ENSG00000176083,Unsafe,Protein,False,True,79.6,79.6,79,70,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0.2 nTPM; positive ihc; adrenal gland: 0.4 nTPM; positive ihc; cerebellum: 0 nTPM; positive ihc; cerebral cortex: 0.6 nTPM; positive ihc; colon: 0.2 nTPM; positive ihc; duodenum: 0.3 nTPM; positive ihc; esophagus: 0.7 nTPM; positive ihc; heart muscle: 0.7 nTPM; positive ihc; kidney: 0.3 nTPM; positive ihc; lung: 4.6 nTPM; positive ihc;absolute ceiling; lymph node: 1.8 nTPM; positive ihc; pancreas: 0.3 nTPM; positive ihc; parathyroid gland: 0.1 nTPM; positive ihc; rectum: 0.5 nTPM; positive ihc; salivary gland: 9.8 nTPM; positive ihc;absolute ceiling; skeletal muscle: 0.1 nTPM; positive ihc; skin: 0.4 nTPM; positive ihc; small intestine: 0.6 nTPM; positive ihc; smooth muscle: 0.3 nTPM; positive ihc; spleen: 2.1 nTPM; positive ihc; stomach: 3.3 nTPM; positive ihc; thyroid gland: 1 nTPM; positive ihc; urinary bladder: 0.9 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",lung: 4.6 nTPM (limit 2); salivary gland: 9.8 nTPM (limit 6); lung: 4.6 nTPM (baseline 2); salivary gland: 9.8 nTPM (baseline 6),adipose tissue / adipocytes: Medium (Uncertain); adrenal gland / glandular cells: High (Uncertain); bronchus / respiratory epithelial cells: High (Uncertain); caudate / glial cells: Low (Uncertain); caudate / neuronal cells: High (Uncertain); cerebellum / cells in granular layer: Medium (Uncertain); cerebellum / cells in molecular layer: High (Uncertain); cerebellum / Purkinje cells: High (Uncertain); cerebral cortex / glial cells: Medium (Uncertain); cerebral cortex / neuronal cells: High (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / endothelial cells: Medium (Uncertain); colon / glandular cells: Medium (Uncertain); colon / peripheral nerve/ganglion: High (Uncertain); duodenum / glandular cells: Low (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / neuronal cells: High (Uncertain); kidney / cells in glomeruli: High (Uncertain); kidney / cells in tubules: High (Uncertain); lung / alveolar cells: Low (Uncertain); lung / macrophages: Low (Uncertain); lymph node / germinal center cells: Low (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); nasopharynx / respiratory epithelial cells: High (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); parathyroid gland / glandular cells: High (Uncertain); rectum / glandular cells: High (Uncertain); salivary gland / glandular cells: Low (Uncertain); skeletal muscle / myocytes: Low (Uncertain); skin 1 / fibroblasts: Medium (Uncertain); skin 1 / keratinocytes: Medium (Uncertain); skin 1 / Langerhans: Medium (Uncertain); skin 2 / epidermal cells: Low (Uncertain); small intestine / glandular cells: Medium (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); spleen / cells in red pulp: Low (Uncertain); stomach 1 / glandular cells: High (Uncertain); stomach 2 / glandular cells: High (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: High (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 34/50 (68.0%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 141/283 (49.8%); Lung Adenocarcinoma (TCGA): 119/497 (23.9%),glioma: 12/12 (100.0%); urothelial cancer: 10/12 (83.3%),31,20,Q8IZ20,https://www.uniprot.org/uniprotkb/Q8IZ20/entry,"Transcription factor that mediates a transcriptional program in various innate and adaptive immune tissue-resident lymphocyte T-cell types such as tissue-resident memory T (Trm), natural killer (trNK) and natural killer T (NKT) cells and negatively regulates gene expression of proteins that promote the egress of tissue-resident T-cell populations from non-lymphoid organs. Plays a role in the development, retention and long-term establishment of adaptive and innate tissue-resident lymphocyte T cell types in non-lymphoid organs, such as the skin and gut, but also in other nonbarrier tissues like liver and kidney, and therefore may provide immediate immunological protection against reactivating infections or viral reinfection. Also plays a role in the differentiation of both thymic and peripheral NKT cells. Negatively regulates the accumulation of interferon-gamma (IFN-gamma) in NKT cells at steady state or after antigenic stimulation. Positively regulates granzyme B production in NKT cells after innate stimulation. Associates with the transcriptional repressor PRDM1/BLIMP1 to chromatin at gene promoter regions Lacks transcriptional repressor activity. Binds to DNA within promoter regions of the transcriptional repressor PRDM1/BLIMP1 target sites. Unable to regulate interferon-gamma (IFN-gamma) production in cytomegalovirus (CMV)-infected effector CD8(+) T-cells Transcriptional repressor that binds to DNA within promoter regions of the transcriptional repressor PRDM1/BLIMP1 target sites. Regulates interferon-gamma (IFN-gamma) production in cytomegalovirus (CMV)-infected effector CD8(+) T cells","Expressed in terminally differentiated effector CD8(+) T-cells, but not in naive and central memory cells (PubMed:26179882). Expressed in terminally differentiated natural killer (NK) cells and natural killer (NKT) T-cells (at protein level) (PubMed:26179882). Expressed strongly in effector-type CD8(+) T-cells and weakly in naive and memory CD8(+) T-cells (PubMed:26179882). Expressed in terminally differentiated natural killer (NK) cells (PubMed:26179882). Isoform 2 is strongly expressed in effector CD8(+) T and natural killer (NK) cells (PubMed:26179882). Isoform 1 is expressed in effector CD8(+) T and natural killer (NK) cells (PubMed:26179882) (Microbial infection) Expressed in cytomegalovirus (CMV)-infected effector CD8(+) T-cells (at protein level) (PubMed:20921622)",,,Nucleus,26179882,20921622|26179882,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | Bruggeman2018_GC | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | GC RNA nomination across cancer types; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
ZNF696,ENSG00000185730,Unsafe,RNA,False,True,4.3,6.3,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 3.8 nTPM; continuous selectivity; adrenal gland: 3.2 nTPM; absolute ceiling;continuous selectivity; amygdala: 4 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 4 nTPM; absolute ceiling;continuous selectivity; bone marrow: 3.5 nTPM; absolute ceiling;continuous selectivity; cerebellum: 5.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 5.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; choroid plexus: 1.6 nTPM; continuous selectivity; colon: 3.2 nTPM; continuous selectivity; duodenum: 5.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 2.5 nTPM; continuous selectivity; heart muscle: 2.8 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 4.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; hypothalamus: 5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; kidney: 3.2 nTPM; absolute ceiling;continuous selectivity; liver: 4.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; lung: 2.7 nTPM; absolute ceiling;continuous selectivity; lymph node: 3.7 nTPM; continuous selectivity; midbrain: 3.8 nTPM; absolute ceiling;continuous selectivity; pancreas: 4.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 4.2 nTPM; continuous selectivity; pituitary gland: 3.1 nTPM; absolute ceiling;continuous selectivity; rectum: 1.9 nTPM; continuous selectivity; retina: 3.5 nTPM; absolute ceiling;continuous selectivity; salivary gland: 5.5 nTPM; continuous selectivity;reproductive not higher; skeletal muscle: 3.7 nTPM; absolute ceiling;continuous selectivity; skin: 6.3 nTPM; continuous selectivity;reproductive not higher; small intestine: 3.6 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 2.2 nTPM; absolute ceiling;continuous selectivity; spinal cord: 3.6 nTPM; absolute ceiling;continuous selectivity; spleen: 3.9 nTPM; continuous selectivity; stomach: 3.2 nTPM; continuous selectivity; thymus: 2.1 nTPM; continuous selectivity; thyroid gland: 3.6 nTPM; continuous selectivity; tongue: 2.3 nTPM; continuous selectivity; urinary bladder: 3.6 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 3.2 nTPM (limit 2); amygdala: 4 nTPM (limit 2); basal ganglia: 4 nTPM (limit 2); bone marrow: 3.5 nTPM (limit 2); cerebellum: 5.4 nTPM (limit 2); cerebral cortex: 5.8 nTPM (limit 2); duodenum: 5.9 nTPM (limit 2); heart muscle: 2.8 nTPM (limit 2); hippocampal formation: 4.3 nTPM (limit 2); hypothalamus: 5 nTPM (limit 2); kidney: 3.2 nTPM (limit 2); liver: 4.5 nTPM (limit 2); lung: 2.7 nTPM (limit 2); midbrain: 3.8 nTPM (limit 2); pancreas: 4.9 nTPM (limit 2); pituitary gland: 3.1 nTPM (limit 2); retina: 3.5 nTPM (limit 2); skeletal muscle: 3.7 nTPM (limit 2); small intestine: 3.6 nTPM (limit 2); smooth muscle: 2.2 nTPM (limit 2); spinal cord: 3.6 nTPM (limit 2); adrenal gland: 3.2 nTPM (baseline 2); amygdala: 4 nTPM (baseline 2); basal ganglia: 4 nTPM (baseline 2); bone marrow: 3.5 nTPM (baseline 2); cerebellum: 5.4 nTPM (baseline 2); cerebral cortex: 5.8 nTPM (baseline 2); duodenum: 5.9 nTPM (baseline 2); heart muscle: 2.8 nTPM (baseline 2); hippocampal formation: 4.3 nTPM (baseline 2); hypothalamus: 5 nTPM (baseline 2); kidney: 3.2 nTPM (baseline 2); liver: 4.5 nTPM (baseline 2); lung: 2.7 nTPM (baseline 2); midbrain: 3.8 nTPM (baseline 2); pancreas: 4.9 nTPM (baseline 2); pituitary gland: 3.1 nTPM (baseline 2); retina: 3.5 nTPM (baseline 2); skeletal muscle: 3.7 nTPM (baseline 2); small intestine: 3.6 nTPM (baseline 2); smooth muscle: 2.2 nTPM (baseline 2); spinal cord: 3.6 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 206/207 (99.5%); Colon Adenocarcinoma (validation): 469/486 (96.5%); Breast Invasive Carcinoma (validation): 48/50 (96.0%),colorectal cancer: 9/12 (75.0%); skin cancer: 9/12 (75.0%),31,20,Q9H7X3,https://www.uniprot.org/uniprotkb/Q9H7X3/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF70,ENSG00000187792,Unsafe,RNA,False,True,3.1,3.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 1.2 nTPM; continuous selectivity; basal ganglia: 0.9 nTPM; continuous selectivity; bone marrow: 1.6 nTPM; continuous selectivity; cerebellum: 1.4 nTPM; continuous selectivity; cerebral cortex: 1.2 nTPM; continuous selectivity; colon: 1.4 nTPM; continuous selectivity; heart muscle: 1.5 nTPM; continuous selectivity; hippocampal formation: 1 nTPM; continuous selectivity; hypothalamus: 0.9 nTPM; continuous selectivity; kidney: 1 nTPM; continuous selectivity; lung: 1.2 nTPM; continuous selectivity; lymph node: 1.4 nTPM; continuous selectivity; midbrain: 0.9 nTPM; continuous selectivity; pancreas: 1.7 nTPM; continuous selectivity; parathyroid gland: 2.1 nTPM; continuous selectivity; pituitary gland: 1.6 nTPM; continuous selectivity; rectum: 1.2 nTPM; continuous selectivity; retina: 2.9 nTPM; absolute ceiling;continuous selectivity; salivary gland: 2 nTPM; continuous selectivity; skeletal muscle: 2.5 nTPM; absolute ceiling;continuous selectivity; small intestine: 1.2 nTPM; continuous selectivity; smooth muscle: 1.6 nTPM; continuous selectivity; spinal cord: 1.1 nTPM; continuous selectivity; stomach: 1.3 nTPM; continuous selectivity; thyroid gland: 1.8 nTPM; continuous selectivity; tongue: 2.1 nTPM; continuous selectivity; urinary bladder: 1.3 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 2.9 nTPM (limit 2); skeletal muscle: 2.5 nTPM (limit 2); retina: 2.9 nTPM (baseline 2); skeletal muscle: 2.5 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 45/50 (90.0%); Rectum Adenocarcinoma (validation): 162/207 (78.3%),breast cancer: 12/12 (100.0%); prostate cancer: 11/11 (100.0%),31,20,Q9UC06,https://www.uniprot.org/uniprotkb/Q9UC06/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF701,ENSG00000167562,Unsafe,RNA,False,True,5.9,7.2,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 2.9 nTPM; continuous selectivity; adrenal gland: 2.5 nTPM; absolute ceiling;continuous selectivity; bone marrow: 5.3 nTPM; absolute ceiling;continuous selectivity; cerebellum: 1.9 nTPM; continuous selectivity; choroid plexus: 1.8 nTPM; continuous selectivity; colon: 3.8 nTPM; continuous selectivity; duodenum: 3.2 nTPM; absolute ceiling;continuous selectivity; esophagus: 2.7 nTPM; continuous selectivity; heart muscle: 2.7 nTPM; absolute ceiling;continuous selectivity; kidney: 3.5 nTPM; absolute ceiling;continuous selectivity; lung: 3.7 nTPM; absolute ceiling;continuous selectivity; lymph node: 5.6 nTPM; continuous selectivity; pancreas: 2.8 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 3.7 nTPM; continuous selectivity; pituitary gland: 2.2 nTPM; absolute ceiling;continuous selectivity; rectum: 4.7 nTPM; continuous selectivity; retina: 3.3 nTPM; absolute ceiling;continuous selectivity; salivary gland: 3.1 nTPM; continuous selectivity; skeletal muscle: 2.1 nTPM; absolute ceiling;continuous selectivity; skin: 4.1 nTPM; continuous selectivity; small intestine: 4.4 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 3.2 nTPM; absolute ceiling;continuous selectivity; spinal cord: 1.7 nTPM; continuous selectivity; spleen: 4.7 nTPM; continuous selectivity; stomach: 4.4 nTPM; continuous selectivity; thymus: 7.2 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 5.7 nTPM; continuous selectivity; tongue: 2.9 nTPM; continuous selectivity; urinary bladder: 3.1 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 2.5 nTPM (limit 2); bone marrow: 5.3 nTPM (limit 2); duodenum: 3.2 nTPM (limit 2); heart muscle: 2.7 nTPM (limit 2); kidney: 3.5 nTPM (limit 2); lung: 3.7 nTPM (limit 2); pancreas: 2.8 nTPM (limit 2); pituitary gland: 2.2 nTPM (limit 2); retina: 3.3 nTPM (limit 2); skeletal muscle: 2.1 nTPM (limit 2); small intestine: 4.4 nTPM (limit 2); smooth muscle: 3.2 nTPM (limit 2); adrenal gland: 2.5 nTPM (baseline 2); bone marrow: 5.3 nTPM (baseline 2); duodenum: 3.2 nTPM (baseline 2); heart muscle: 2.7 nTPM (baseline 2); kidney: 3.5 nTPM (baseline 2); lung: 3.7 nTPM (baseline 2); pancreas: 2.8 nTPM (baseline 2); pituitary gland: 2.2 nTPM (baseline 2); retina: 3.3 nTPM (baseline 2); skeletal muscle: 2.1 nTPM (baseline 2); small intestine: 4.4 nTPM (baseline 2); smooth muscle: 3.2 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Rectum Adenocarcinoma (validation): 206/207 (99.5%); Colon Adenocarcinoma (validation): 476/486 (97.9%),prostate cancer: 11/12 (91.7%); urothelial cancer: 11/12 (91.7%),31,20,Q9NV72,https://www.uniprot.org/uniprotkb/Q9NV72/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF709,ENSG00000242852,Unsafe,RNA,False,True,14.9,14.9,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,basal ganglia: 2.3 nTPM; absolute ceiling; cerebellum: 2.8 nTPM; absolute ceiling; retina: 3 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,basal ganglia: 2.3 nTPM (limit 2); cerebellum: 2.8 nTPM (limit 2); retina: 3 nTPM (limit 2); basal ganglia: 2.3 nTPM (baseline 2); cerebellum: 2.8 nTPM (baseline 2); retina: 3 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 39/50 (78.0%); Testicular Germ Cell Tumor (TCGA): 24/133 (18.0%); Ovary Serous Cystadenocarcinoma (TCGA): 49/349 (14.0%),colorectal cancer: 11/11 (100.0%); skin cancer: 11/11 (100.0%),31,20,Q8N972,https://www.uniprot.org/uniprotkb/Q8N972/entry,May be involved in transcriptional regulation,,,,Nucleus,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF711,ENSG00000147180,Unsafe,Protein,False,True,36.2,36.2,82,22,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 14.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 9 nTPM; absolute ceiling; basal ganglia: 8 nTPM; absolute ceiling; cerebellum: 11.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 18.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 3.5 nTPM; positive ihc; duodenum: 3 nTPM; positive ihc;absolute ceiling; heart muscle: 3.6 nTPM; positive ihc;absolute ceiling; hippocampal formation: 8.2 nTPM; absolute ceiling; hypothalamus: 9 nTPM; absolute ceiling; kidney: 5 nTPM; positive ihc;absolute ceiling; lung: 1.7 nTPM; positive ihc; midbrain: 7 nTPM; absolute ceiling; pituitary gland: 10.6 nTPM; absolute ceiling;continuous selectivity; rectum: 1.7 nTPM; positive ihc; retina: 5.5 nTPM; absolute ceiling; small intestine: 4.5 nTPM; positive ihc;absolute ceiling; spinal cord: 7 nTPM; absolute ceiling; thymus: 15.9 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 2.9 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 14.7 nTPM (limit 2); amygdala: 9 nTPM (limit 2); basal ganglia: 8 nTPM (limit 2); cerebellum: 11.2 nTPM (limit 2); cerebral cortex: 18.3 nTPM (limit 2); duodenum: 3 nTPM (limit 2); heart muscle: 3.6 nTPM (limit 2); hippocampal formation: 8.2 nTPM (limit 2); hypothalamus: 9 nTPM (limit 2); kidney: 5 nTPM (limit 2); midbrain: 7 nTPM (limit 2); pituitary gland: 10.6 nTPM (limit 2); retina: 5.5 nTPM (limit 2); small intestine: 4.5 nTPM (limit 2); spinal cord: 7 nTPM (limit 2); thymus: 15.9 nTPM (limit 10),adrenal gland / glandular cells: High (Enhanced); caudate / glial cells: Low (Enhanced); caudate / neuronal cells: Medium (Enhanced); cerebellum / cells in molecular layer: Low (Enhanced); cerebellum / Purkinje cells: Low (Enhanced); cerebral cortex / glial cells: High (Enhanced); cerebral cortex / neuronal cells: High (Enhanced); colon / peripheral nerve/ganglion: Low (Enhanced); duodenum / glandular cells: Low (Enhanced); heart muscle / cardiomyocytes: Medium (Enhanced); hippocampus / glial cells: Medium (Enhanced); hippocampus / neuronal cells: Medium (Enhanced); kidney / cells in tubules: Low (Enhanced); lung / macrophages: Medium (Enhanced); rectum / glandular cells: Low (Enhanced); small intestine / glandular cells: Low (Enhanced); urinary bladder / urothelial cells: Low (Enhanced),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Glioblastoma Multiforme (TCGA): 120/141 (85.1%); Breast Invasive Carcinoma (validation): 40/50 (80.0%),glioma: 7/10 (70.0%); skin cancer: 2/9 (22.2%),31,20,Q9Y462,https://www.uniprot.org/uniprotkb/Q9Y462/entry,"Transcription regulator required for brain development (PubMed:20346720). Probably acts as a transcription factor that binds to the promoter of target genes and recruits PHF8 histone demethylase, leading to activated expression of genes involved in neuron development, such as KDM5C (PubMed:20346720, PubMed:31691806). May compete with transcription factor ARX for activation of expression of KDM5C (PubMed:31691806)",Expressed in neural tissues,"Intellectual developmental disorder, X-linked 97: A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period.",,Nucleus,20346720|31691806,20346720,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
ZNF713,ENSG00000178665,Unsafe,RNA,False,True,3.6,3.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,amygdala: 1.6 nTPM; continuous selectivity; basal ganglia: 1.5 nTPM; continuous selectivity; bone marrow: 1.6 nTPM; continuous selectivity; cerebral cortex: 2.3 nTPM; absolute ceiling;continuous selectivity; duodenum: 1 nTPM; continuous selectivity; hippocampal formation: 1.6 nTPM; continuous selectivity; hypothalamus: 1.5 nTPM; continuous selectivity; kidney: 1 nTPM; continuous selectivity; midbrain: 1.6 nTPM; continuous selectivity; pancreas: 1.2 nTPM; continuous selectivity; pituitary gland: 1.7 nTPM; continuous selectivity; retina: 2.3 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 1.7 nTPM; continuous selectivity; smooth muscle: 1 nTPM; continuous selectivity; spinal cord: 2.7 nTPM; absolute ceiling;continuous selectivity; stomach: 1.4 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebral cortex: 2.3 nTPM (limit 2); retina: 2.3 nTPM (limit 2); spinal cord: 2.7 nTPM (limit 2); cerebral cortex: 2.3 nTPM (baseline 2); retina: 2.3 nTPM (baseline 2); spinal cord: 2.7 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 48/50 (96.0%); Pancreatic Adenocarcinoma (validation): 29/80 (36.2%),melanoma: 2/11 (18.2%); testis cancer: 1/10 (10.0%),31,20,Q8N859,https://www.uniprot.org/uniprotkb/Q8N859/entry,May be involved in transcriptional regulation,Expressed in fetal and adult brain,,,Nucleus,,25196122,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF714,ENSG00000160352,Unsafe,RNA,False,True,14.3,14.3,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 4.3 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 3.1 nTPM; absolute ceiling; bone marrow: 6.8 nTPM; absolute ceiling;continuous selectivity; cerebellum: 6.3 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 3.9 nTPM; absolute ceiling;continuous selectivity; duodenum: 2.4 nTPM; absolute ceiling; esophagus: 5.1 nTPM; continuous selectivity; pancreas: 3.7 nTPM; absolute ceiling;continuous selectivity; retina: 3.1 nTPM; absolute ceiling; skeletal muscle: 2.7 nTPM; absolute ceiling; skin: 6.4 nTPM; continuous selectivity; small intestine: 3.2 nTPM; absolute ceiling; thyroid gland: 13.9 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 4.3 nTPM (limit 2); basal ganglia: 3.1 nTPM (limit 2); bone marrow: 6.8 nTPM (limit 2); cerebellum: 6.3 nTPM (limit 2); cerebral cortex: 3.9 nTPM (limit 2); duodenum: 2.4 nTPM (limit 2); pancreas: 3.7 nTPM (limit 2); retina: 3.1 nTPM (limit 2); skeletal muscle: 2.7 nTPM (limit 2); small intestine: 3.2 nTPM (limit 2); thyroid gland: 13.9 nTPM (limit 10); adrenal gland: 4.3 nTPM (baseline 2); basal ganglia: 3.1 nTPM (baseline 2); bone marrow: 6.8 nTPM (baseline 2); cerebellum: 6.3 nTPM (baseline 2); cerebral cortex: 3.9 nTPM (baseline 2); duodenum: 2.4 nTPM (baseline 2); pancreas: 3.7 nTPM (baseline 2); retina: 3.1 nTPM (baseline 2); skeletal muscle: 2.7 nTPM (baseline 2); small intestine: 3.2 nTPM (baseline 2); thyroid gland: 13.9 nTPM (baseline 10),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 409/486 (84.2%); Rectum Adenocarcinoma (validation): 166/207 (80.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,,,,,,,,,,False,No exact Ensembl mapping to a reviewed UniProt entry,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF717,ENSG00000227124,Unsafe,RNA,False,True,15.0,15.0,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 5.6 nTPM; absolute ceiling;continuous selectivity; amygdala: 4.4 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 5.1 nTPM; absolute ceiling;continuous selectivity; bone marrow: 2.7 nTPM; absolute ceiling; cerebellum: 4.1 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 4.3 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 4 nTPM; absolute ceiling;continuous selectivity; duodenum: 5.5 nTPM; absolute ceiling;continuous selectivity; esophagus: 5.2 nTPM; continuous selectivity; heart muscle: 5.7 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 4.8 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 5.2 nTPM; absolute ceiling;continuous selectivity; kidney: 9.6 nTPM; absolute ceiling;continuous selectivity; liver: 7.7 nTPM; absolute ceiling;continuous selectivity; lung: 4.5 nTPM; absolute ceiling;continuous selectivity; midbrain: 5.3 nTPM; absolute ceiling;continuous selectivity; pancreas: 8.7 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 8.1 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 9 nTPM; absolute ceiling;continuous selectivity; rectum: 6.5 nTPM; absolute ceiling;continuous selectivity; retina: 7.5 nTPM; absolute ceiling;continuous selectivity; salivary gland: 7 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 4.1 nTPM; absolute ceiling;continuous selectivity; skin: 9.7 nTPM; continuous selectivity; small intestine: 5 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 4.1 nTPM; absolute ceiling;continuous selectivity; spinal cord: 6.2 nTPM; absolute ceiling;continuous selectivity; spleen: 6.9 nTPM; continuous selectivity; stomach: 7.2 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 9.2 nTPM; continuous selectivity; urinary bladder: 5.6 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 5.6 nTPM (limit 2); amygdala: 4.4 nTPM (limit 2); basal ganglia: 5.1 nTPM (limit 2); bone marrow: 2.7 nTPM (limit 2); cerebellum: 4.1 nTPM (limit 2); cerebral cortex: 4.3 nTPM (limit 2); choroid plexus: 4 nTPM (limit 2); duodenum: 5.5 nTPM (limit 2); heart muscle: 5.7 nTPM (limit 2); hippocampal formation: 4.8 nTPM (limit 2); hypothalamus: 5.2 nTPM (limit 2); kidney: 9.6 nTPM (limit 2); liver: 7.7 nTPM (limit 2); lung: 4.5 nTPM (limit 2); midbrain: 5.3 nTPM (limit 2); pancreas: 8.7 nTPM (limit 2); parathyroid gland: 8.1 nTPM (limit 6); pituitary gland: 9 nTPM (limit 2); rectum: 6.5 nTPM (limit 6); retina: 7.5 nTPM (limit 2); salivary gland: 7 nTPM (limit 6); skeletal muscle: 4.1 nTPM (limit 2); small intestine: 5 nTPM (limit 2); smooth muscle: 4.1 nTPM (limit 2); spinal cord: 6.2 nTPM (limit 2); stomach: 7.2 nTPM (limit 6); adrenal gland: 5.6 nTPM (baseline 2); amygdala: 4.4 nTPM (baseline 2); basal ganglia: 5.1 nTPM (baseline 2); bone marrow: 2.7 nTPM (baseline 2); cerebellum: 4.1 nTPM (baseline 2); cerebral cortex: 4.3 nTPM (baseline 2); choroid plexus: 4 nTPM (baseline 2); duodenum: 5.5 nTPM (baseline 2); heart muscle: 5.7 nTPM (baseline 2); hippocampal formation: 4.8 nTPM (baseline 2); hypothalamus: 5.2 nTPM (baseline 2); kidney: 9.6 nTPM (baseline 2); liver: 7.7 nTPM (baseline 2); lung: 4.5 nTPM (baseline 2); midbrain: 5.3 nTPM (baseline 2); pancreas: 8.7 nTPM (baseline 2); parathyroid gland: 8.1 nTPM (baseline 6); pituitary gland: 9 nTPM (baseline 2); rectum: 6.5 nTPM (baseline 6); retina: 7.5 nTPM (baseline 2); salivary gland: 7 nTPM (baseline 6); skeletal muscle: 4.1 nTPM (baseline 2); small intestine: 5 nTPM (baseline 2); smooth muscle: 4.1 nTPM (baseline 2); spinal cord: 6.2 nTPM (baseline 2); stomach: 7.2 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 205/207 (99.0%); Glioblastoma Multiforme (validation): 56/58 (96.6%); Colon Adenocarcinoma (validation): 463/486 (95.3%),colorectal cancer: 6/12 (50.0%); ovarian cancer: 5/12 (41.7%),31,20,Q9BY31,https://www.uniprot.org/uniprotkb/Q9BY31/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF718,ENSG00000250312,Unsafe,RNA,False,True,3.2,4.6,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 1.8 nTPM; continuous selectivity; adrenal gland: 2.9 nTPM; absolute ceiling;continuous selectivity; amygdala: 1.3 nTPM; continuous selectivity; basal ganglia: 1.4 nTPM; continuous selectivity; bone marrow: 2.9 nTPM; absolute ceiling;continuous selectivity; cerebellum: 2.1 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 2.8 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 1.2 nTPM; continuous selectivity; colon: 2.4 nTPM; continuous selectivity; duodenum: 1.6 nTPM; continuous selectivity; esophagus: 1.7 nTPM; continuous selectivity; heart muscle: 1.9 nTPM; continuous selectivity; hippocampal formation: 1.3 nTPM; continuous selectivity; hypothalamus: 1.5 nTPM; continuous selectivity; kidney: 2.4 nTPM; absolute ceiling;continuous selectivity; liver: 1.4 nTPM; continuous selectivity; lung: 1.9 nTPM; continuous selectivity; lymph node: 3.7 nTPM; continuous selectivity;reproductive not higher; midbrain: 1.5 nTPM; continuous selectivity; pancreas: 2.5 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 2.6 nTPM; continuous selectivity; pituitary gland: 1.9 nTPM; continuous selectivity; rectum: 2.1 nTPM; continuous selectivity; retina: 2.6 nTPM; absolute ceiling;continuous selectivity; salivary gland: 2.1 nTPM; continuous selectivity; skeletal muscle: 0.9 nTPM; continuous selectivity; skin: 2.9 nTPM; continuous selectivity; small intestine: 1.8 nTPM; continuous selectivity; smooth muscle: 1.8 nTPM; continuous selectivity; spinal cord: 1.8 nTPM; continuous selectivity; spleen: 2.8 nTPM; continuous selectivity; stomach: 1.8 nTPM; continuous selectivity; thymus: 4.5 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 4.6 nTPM; continuous selectivity;reproductive not higher; tongue: 1.7 nTPM; continuous selectivity; urinary bladder: 1.9 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 2.9 nTPM (limit 2); bone marrow: 2.9 nTPM (limit 2); cerebellum: 2.1 nTPM (limit 2); cerebral cortex: 2.8 nTPM (limit 2); kidney: 2.4 nTPM (limit 2); pancreas: 2.5 nTPM (limit 2); retina: 2.6 nTPM (limit 2); adrenal gland: 2.9 nTPM (baseline 2); bone marrow: 2.9 nTPM (baseline 2); cerebellum: 2.1 nTPM (baseline 2); cerebral cortex: 2.8 nTPM (baseline 2); kidney: 2.4 nTPM (baseline 2); pancreas: 2.5 nTPM (baseline 2); retina: 2.6 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 56/58 (96.6%); Breast Invasive Carcinoma (validation): 47/50 (94.0%); Pancreatic Adenocarcinoma (validation): 59/80 (73.8%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q3SXZ3,https://www.uniprot.org/uniprotkb/Q3SXZ3/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF749,ENSG00000186230,Unsafe,RNA,False,True,1.6,3.9,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 1.3 nTPM; continuous selectivity; adrenal gland: 1.2 nTPM; continuous selectivity; amygdala: 0.8 nTPM; continuous selectivity; basal ganglia: 1 nTPM; continuous selectivity; bone marrow: 1.4 nTPM; continuous selectivity; cerebellum: 2.3 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebral cortex: 1.6 nTPM; continuous selectivity;reproductive not higher; choroid plexus: 0.5 nTPM; continuous selectivity; colon: 0.9 nTPM; continuous selectivity; duodenum: 1.4 nTPM; continuous selectivity; esophagus: 1.4 nTPM; continuous selectivity; heart muscle: 1 nTPM; continuous selectivity; hippocampal formation: 0.8 nTPM; continuous selectivity; hypothalamus: 1 nTPM; continuous selectivity; kidney: 1 nTPM; continuous selectivity; liver: 1.5 nTPM; continuous selectivity; lung: 1 nTPM; continuous selectivity; lymph node: 1.7 nTPM; continuous selectivity;reproductive not higher; midbrain: 0.7 nTPM; continuous selectivity; pancreas: 1.1 nTPM; continuous selectivity; parathyroid gland: 1.4 nTPM; continuous selectivity; pituitary gland: 1 nTPM; continuous selectivity; rectum: 0.9 nTPM; continuous selectivity; retina: 3.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 1.5 nTPM; continuous selectivity; skeletal muscle: 1.3 nTPM; continuous selectivity; skin: 2.1 nTPM; continuous selectivity;reproductive not higher; small intestine: 1.2 nTPM; continuous selectivity; smooth muscle: 1.1 nTPM; continuous selectivity; spinal cord: 0.8 nTPM; continuous selectivity; spleen: 1.6 nTPM; continuous selectivity;reproductive not higher; stomach: 1.2 nTPM; continuous selectivity; thymus: 1.8 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 1.2 nTPM; continuous selectivity; urinary bladder: 1.2 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,cerebellum: 2.3 nTPM (limit 2); retina: 3.9 nTPM (limit 2); cerebellum: 2.3 nTPM (baseline 2); retina: 3.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 414/486 (85.2%); Breast Invasive Carcinoma (validation): 41/50 (82.0%),liver cancer: 5/12 (41.7%); colorectal cancer: 3/11 (27.3%),31,20,O43361,https://www.uniprot.org/uniprotkb/O43361/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF763,ENSG00000197054,Unsafe,Protein,False,True,5.8,6.7,83,60,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 3.7 nTPM; positive ihc;continuous selectivity; adrenal gland: 3 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 1.9 nTPM; continuous selectivity; basal ganglia: 2 nTPM; continuous selectivity; cerebellum: 2.7 nTPM; continuous selectivity; cerebral cortex: 1.9 nTPM; positive ihc;continuous selectivity; choroid plexus: 3.1 nTPM; absolute ceiling;continuous selectivity; colon: 3.3 nTPM; positive ihc;continuous selectivity; duodenum: 2.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 1.9 nTPM; positive ihc; heart muscle: 3.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 2.1 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 1.7 nTPM; continuous selectivity; kidney: 5.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 2.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 2.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 3.5 nTPM; positive ihc;continuous selectivity; midbrain: 2.3 nTPM; absolute ceiling;continuous selectivity; pancreas: 4.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 4.6 nTPM; positive ihc;continuous selectivity; pituitary gland: 2.8 nTPM; absolute ceiling;continuous selectivity; rectum: 2.9 nTPM; positive ihc;continuous selectivity; retina: 6.7 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 3.2 nTPM; positive ihc;continuous selectivity; skin: 2.7 nTPM; positive ihc;continuous selectivity; small intestine: 4.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 2.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 2 nTPM; continuous selectivity; spleen: 5.2 nTPM; positive ihc;continuous selectivity; stomach: 3.4 nTPM; positive ihc;continuous selectivity; thymus: 4.2 nTPM; continuous selectivity; thyroid gland: 4.7 nTPM; positive ihc;continuous selectivity; urinary bladder: 3.4 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 3 nTPM (limit 2); choroid plexus: 3.1 nTPM (limit 2); duodenum: 2.2 nTPM (limit 2); heart muscle: 3.8 nTPM (limit 2); hippocampal formation: 2.1 nTPM (limit 2); kidney: 5.7 nTPM (limit 2); liver: 2.4 nTPM (limit 2); lung: 2.8 nTPM (limit 2); midbrain: 2.3 nTPM (limit 2); pancreas: 4.4 nTPM (limit 2); pituitary gland: 2.8 nTPM (limit 2); retina: 6.7 nTPM (limit 2); small intestine: 4.2 nTPM (limit 2); smooth muscle: 2.1 nTPM (limit 2),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: Medium (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / glial cells: Medium (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Low (Approved); skin 2 / epidermal cells: Low (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 45/50 (90.0%); Glioblastoma Multiforme (validation): 28/58 (48.3%); Kidney Chromophobe (TCGA): 28/64 (43.8%),colorectal cancer: 4/11 (36.4%); liver cancer: 3/11 (27.3%),31,20,Q0D2J5,https://www.uniprot.org/uniprotkb/Q0D2J5/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF765,ENSG00000196417,Unsafe,RNA,False,True,7.9,8.5,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 3.7 nTPM; absolute ceiling;continuous selectivity; bone marrow: 4.1 nTPM; absolute ceiling;continuous selectivity; colon: 3.3 nTPM; continuous selectivity; duodenum: 3 nTPM; absolute ceiling;continuous selectivity; kidney: 2.7 nTPM; absolute ceiling;continuous selectivity; lung: 3 nTPM; absolute ceiling;continuous selectivity; lymph node: 3.8 nTPM; continuous selectivity; pancreas: 4.4 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 8.5 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 3.6 nTPM; continuous selectivity; skin: 4 nTPM; continuous selectivity; small intestine: 2.7 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 2.1 nTPM; absolute ceiling;continuous selectivity; stomach: 2.8 nTPM; continuous selectivity; thymus: 4.2 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 3.7 nTPM (limit 2); bone marrow: 4.1 nTPM (limit 2); duodenum: 3 nTPM (limit 2); kidney: 2.7 nTPM (limit 2); lung: 3 nTPM (limit 2); pancreas: 4.4 nTPM (limit 2); parathyroid gland: 8.5 nTPM (limit 6); small intestine: 2.7 nTPM (limit 2); smooth muscle: 2.1 nTPM (limit 2); adrenal gland: 3.7 nTPM (baseline 2); bone marrow: 4.1 nTPM (baseline 2); duodenum: 3 nTPM (baseline 2); kidney: 2.7 nTPM (baseline 2); lung: 3 nTPM (baseline 2); pancreas: 4.4 nTPM (baseline 2); parathyroid gland: 8.5 nTPM (baseline 6); small intestine: 2.7 nTPM (baseline 2); smooth muscle: 2.1 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Pancreatic Adenocarcinoma (validation): 80/80 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 482/486 (99.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q7L2R6,https://www.uniprot.org/uniprotkb/Q7L2R6/entry,May be involved in transcriptional regulation,,,,Nucleus,,,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF774,ENSG00000196391,Unsafe,RNA,False,True,5.5,6.9,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 2.6 nTPM; absolute ceiling;continuous selectivity; amygdala: 2.2 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 3.5 nTPM; absolute ceiling;continuous selectivity; cerebellum: 5.1 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 4.6 nTPM; absolute ceiling;continuous selectivity; colon: 4.4 nTPM; continuous selectivity; duodenum: 2.3 nTPM; absolute ceiling;continuous selectivity; heart muscle: 2.7 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 2 nTPM; continuous selectivity; hypothalamus: 3 nTPM; absolute ceiling;continuous selectivity; midbrain: 2.2 nTPM; absolute ceiling;continuous selectivity; pancreas: 3.8 nTPM; absolute ceiling;continuous selectivity; parathyroid gland: 3 nTPM; continuous selectivity; pituitary gland: 2.9 nTPM; absolute ceiling;continuous selectivity; rectum: 6.8 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; retina: 4.1 nTPM; absolute ceiling;continuous selectivity; salivary gland: 3.8 nTPM; continuous selectivity; skeletal muscle: 5.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; skin: 3 nTPM; continuous selectivity; small intestine: 2 nTPM; continuous selectivity; smooth muscle: 1.7 nTPM; continuous selectivity; spinal cord: 1.7 nTPM; continuous selectivity; stomach: 2.6 nTPM; continuous selectivity; thyroid gland: 2.7 nTPM; continuous selectivity; tongue: 6.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 2.6 nTPM (limit 2); amygdala: 2.2 nTPM (limit 2); basal ganglia: 3.5 nTPM (limit 2); cerebellum: 5.1 nTPM (limit 2); cerebral cortex: 4.6 nTPM (limit 2); duodenum: 2.3 nTPM (limit 2); heart muscle: 2.7 nTPM (limit 2); hypothalamus: 3 nTPM (limit 2); midbrain: 2.2 nTPM (limit 2); pancreas: 3.8 nTPM (limit 2); pituitary gland: 2.9 nTPM (limit 2); rectum: 6.8 nTPM (limit 6); retina: 4.1 nTPM (limit 2); skeletal muscle: 5.9 nTPM (limit 2); tongue: 6.9 nTPM (limit 6); adrenal gland: 2.6 nTPM (baseline 2); amygdala: 2.2 nTPM (baseline 2); basal ganglia: 3.5 nTPM (baseline 2); cerebellum: 5.1 nTPM (baseline 2); cerebral cortex: 4.6 nTPM (baseline 2); duodenum: 2.3 nTPM (baseline 2); heart muscle: 2.7 nTPM (baseline 2); hypothalamus: 3 nTPM (baseline 2); midbrain: 2.2 nTPM (baseline 2); pancreas: 3.8 nTPM (baseline 2); pituitary gland: 2.9 nTPM (baseline 2); rectum: 6.8 nTPM (baseline 6); retina: 4.1 nTPM (baseline 2); skeletal muscle: 5.9 nTPM (baseline 2); tongue: 6.9 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 203/207 (98.1%); Colon Adenocarcinoma (validation): 468/486 (96.3%); Breast Invasive Carcinoma (validation): 34/50 (68.0%),glioma: 10/11 (90.9%); renal cancer: 2/11 (18.2%),31,20,Q6NX45,https://www.uniprot.org/uniprotkb/Q6NX45/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF776,ENSG00000152443,Unsafe,RNA,False,True,21.1,21.1,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 6.3 nTPM; absolute ceiling;continuous selectivity; amygdala: 5.5 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 5.9 nTPM; absolute ceiling;continuous selectivity; bone marrow: 16.9 nTPM; absolute ceiling;continuous selectivity; cerebellum: 14.2 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 6.3 nTPM; absolute ceiling;continuous selectivity; choroid plexus: 6 nTPM; absolute ceiling;continuous selectivity; colon: 6.2 nTPM; absolute ceiling; duodenum: 6.2 nTPM; absolute ceiling;continuous selectivity; heart muscle: 6.9 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 5.7 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 5.8 nTPM; absolute ceiling;continuous selectivity; kidney: 7.4 nTPM; absolute ceiling;continuous selectivity; liver: 6.6 nTPM; absolute ceiling;continuous selectivity; lung: 6.1 nTPM; absolute ceiling;continuous selectivity; lymph node: 8.1 nTPM; absolute ceiling;continuous selectivity; midbrain: 5.1 nTPM; absolute ceiling; pancreas: 4.5 nTPM; absolute ceiling; parathyroid gland: 10.5 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 8 nTPM; absolute ceiling;continuous selectivity; rectum: 6.5 nTPM; absolute ceiling; retina: 20 nTPM; absolute ceiling;continuous selectivity; salivary gland: 7.6 nTPM; absolute ceiling;continuous selectivity; skeletal muscle: 8.8 nTPM; absolute ceiling;continuous selectivity; small intestine: 5.8 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 4 nTPM; absolute ceiling; spinal cord: 5.8 nTPM; absolute ceiling;continuous selectivity; stomach: 7.4 nTPM; absolute ceiling;continuous selectivity; thymus: 12.3 nTPM; absolute ceiling;continuous selectivity; tongue: 9.9 nTPM; absolute ceiling;continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,adrenal gland: 6.3 nTPM (limit 2); amygdala: 5.5 nTPM (limit 2); basal ganglia: 5.9 nTPM (limit 2); bone marrow: 16.9 nTPM (limit 2); cerebellum: 14.2 nTPM (limit 2); cerebral cortex: 6.3 nTPM (limit 2); choroid plexus: 6 nTPM (limit 2); colon: 6.2 nTPM (limit 6); duodenum: 6.2 nTPM (limit 2); heart muscle: 6.9 nTPM (limit 2); hippocampal formation: 5.7 nTPM (limit 2); hypothalamus: 5.8 nTPM (limit 2); kidney: 7.4 nTPM (limit 2); liver: 6.6 nTPM (limit 2); lung: 6.1 nTPM (limit 2); lymph node: 8.1 nTPM (limit 6); midbrain: 5.1 nTPM (limit 2); pancreas: 4.5 nTPM (limit 2); parathyroid gland: 10.5 nTPM (limit 6); pituitary gland: 8 nTPM (limit 2); rectum: 6.5 nTPM (limit 6); retina: 20 nTPM (limit 2); salivary gland: 7.6 nTPM (limit 6); skeletal muscle: 8.8 nTPM (limit 2); small intestine: 5.8 nTPM (limit 2); smooth muscle: 4 nTPM (limit 2); spinal cord: 5.8 nTPM (limit 2); stomach: 7.4 nTPM (limit 6); thymus: 12.3 nTPM (limit 10); tongue: 9.9 nTPM (limit 6); adrenal gland: 6.3 nTPM (baseline 2); amygdala: 5.5 nTPM (baseline 2); basal ganglia: 5.9 nTPM (baseline 2); bone marrow: 16.9 nTPM (baseline 2); cerebellum: 14.2 nTPM (baseline 2); cerebral cortex: 6.3 nTPM (baseline 2); choroid plexus: 6 nTPM (baseline 2); colon: 6.2 nTPM (baseline 6); duodenum: 6.2 nTPM (baseline 2); heart muscle: 6.9 nTPM (baseline 2); hippocampal formation: 5.7 nTPM (baseline 2); hypothalamus: 5.8 nTPM (baseline 2); kidney: 7.4 nTPM (baseline 2); liver: 6.6 nTPM (baseline 2); lung: 6.1 nTPM (baseline 2); lymph node: 8.1 nTPM (baseline 6); midbrain: 5.1 nTPM (baseline 2); pancreas: 4.5 nTPM (baseline 2); parathyroid gland: 10.5 nTPM (baseline 6); pituitary gland: 8 nTPM (baseline 2); rectum: 6.5 nTPM (baseline 6); retina: 20 nTPM (baseline 2); salivary gland: 7.6 nTPM (baseline 6); skeletal muscle: 8.8 nTPM (baseline 2); small intestine: 5.8 nTPM (baseline 2); smooth muscle: 4 nTPM (baseline 2); spinal cord: 5.8 nTPM (baseline 2); stomach: 7.4 nTPM (baseline 6); thymus: 12.3 nTPM (baseline 10); tongue: 9.9 nTPM (baseline 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Rectum Adenocarcinoma (validation): 207/207 (100.0%); Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 483/486 (99.4%),colorectal cancer: 12/12 (100.0%); liver cancer: 12/12 (100.0%),31,20,Q68DI1,https://www.uniprot.org/uniprotkb/Q68DI1/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF778,ENSG00000170100,Unsafe,Protein,False,True,5.0,7.8,82,73,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 2.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 1.8 nTPM; continuous selectivity; basal ganglia: 1.9 nTPM; continuous selectivity; bone marrow: 1.5 nTPM; positive ihc;continuous selectivity; cerebellum: 3.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 2.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 1.4 nTPM; continuous selectivity; colon: 2.2 nTPM; positive ihc;continuous selectivity; duodenum: 1.1 nTPM; positive ihc; esophagus: 1.9 nTPM; positive ihc;continuous selectivity; heart muscle: 2.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 1.8 nTPM; continuous selectivity; hypothalamus: 1.8 nTPM; continuous selectivity; kidney: 3.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 2 nTPM; positive ihc;continuous selectivity; lung: 2.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 1.8 nTPM; positive ihc;continuous selectivity; midbrain: 1.8 nTPM; continuous selectivity; pancreas: 4.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 7.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 2.5 nTPM; absolute ceiling;continuous selectivity; rectum: 1.8 nTPM; positive ihc;continuous selectivity; retina: 3.8 nTPM; absolute ceiling;continuous selectivity; salivary gland: 2.4 nTPM; positive ihc;continuous selectivity; skeletal muscle: 3.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 3.1 nTPM; positive ihc;continuous selectivity; small intestine: 1.7 nTPM; positive ihc;continuous selectivity; smooth muscle: 2.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 2.2 nTPM; absolute ceiling;continuous selectivity; spleen: 2.2 nTPM; positive ihc; stomach: 2.3 nTPM; positive ihc;continuous selectivity; thyroid gland: 3 nTPM; positive ihc;continuous selectivity; tongue: 4.1 nTPM; continuous selectivity; urinary bladder: 2 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 2.2 nTPM (limit 2); cerebellum: 3.4 nTPM (limit 2); cerebral cortex: 2.9 nTPM (limit 2); heart muscle: 2.2 nTPM (limit 2); kidney: 3.1 nTPM (limit 2); lung: 2.1 nTPM (limit 2); pancreas: 4.9 nTPM (limit 2); parathyroid gland: 7.8 nTPM (limit 6); pituitary gland: 2.5 nTPM (limit 2); retina: 3.8 nTPM (limit 2); skeletal muscle: 3.7 nTPM (limit 2); smooth muscle: 2.5 nTPM (limit 2); spinal cord: 2.2 nTPM (limit 2); adrenal gland: 2.2 nTPM (baseline 2); cerebellum: 3.4 nTPM (baseline 2); cerebral cortex: 2.9 nTPM (baseline 2); heart muscle: 2.2 nTPM (baseline 2); kidney: 3.1 nTPM (baseline 2); lung: 2.1 nTPM (baseline 2); pancreas: 4.9 nTPM (baseline 2); parathyroid gland: 7.8 nTPM (baseline 6); pituitary gland: 2.5 nTPM (baseline 2); retina: 3.8 nTPM (baseline 2); skeletal muscle: 3.7 nTPM (baseline 2); smooth muscle: 2.5 nTPM (baseline 2); spinal cord: 2.2 nTPM (baseline 2),adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / glial cells: Medium (Uncertain); caudate / neuronal cells: Low (Uncertain); cerebellum / cells in molecular layer: Low (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / endothelial cells: Medium (Uncertain); cerebral cortex / glial cells: Medium (Uncertain); cerebral cortex / neuronal cells: High (Uncertain); colon / endothelial cells: Medium (Uncertain); colon / glandular cells: High (Uncertain); colon / peripheral nerve/ganglion: Medium (Uncertain); duodenum / glandular cells: High (Uncertain); esophagus / squamous epithelial cells: High (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); hippocampus / glial cells: Low (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in glomeruli: Medium (Uncertain); kidney / cells in tubules: High (Uncertain); liver / cholangiocytes: Medium (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / germinal center cells: Low (Uncertain); lymph node / non-germinal center cells: Medium (Uncertain); nasopharynx / respiratory epithelial cells: High (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: High (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: High (Uncertain); salivary gland / glandular cells: Low (Uncertain); skeletal muscle / myocytes: Low (Uncertain); skin 1 / fibroblasts: Low (Uncertain); skin 1 / keratinocytes: Medium (Uncertain); skin 1 / Langerhans: Low (Uncertain); skin 2 / epidermal cells: High (Uncertain); small intestine / glandular cells: High (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); spleen / cells in red pulp: Medium (Uncertain); spleen / cells in white pulp: Low (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: High (Uncertain); urinary bladder / urothelial cells: High (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 44/50 (88.0%); Testicular Germ Cell Tumor (TCGA): 52/133 (39.1%),glioma: 12/12 (100.0%); lung cancer: 12/12 (100.0%),31,20,Q96MU6,https://www.uniprot.org/uniprotkb/Q96MU6/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF782,ENSG00000196597,Unsafe,Protein,False,True,6.0,9.0,78,78,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 1.5 nTPM; positive ihc; adrenal gland: 1.6 nTPM; positive ihc;continuous selectivity; bone marrow: 1.5 nTPM; positive ihc; cerebellum: 2.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 2.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 1.8 nTPM; continuous selectivity; colon: 2 nTPM; positive ihc; duodenum: 2.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 1.6 nTPM; positive ihc; heart muscle: 1 nTPM; positive ihc; kidney: 2.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 1.7 nTPM; positive ihc;continuous selectivity; lung: 1.5 nTPM; positive ihc; lymph node: 2.7 nTPM; positive ihc;continuous selectivity; pancreas: 4.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 3.1 nTPM; positive ihc;continuous selectivity; pituitary gland: 1.8 nTPM; continuous selectivity; rectum: 2.8 nTPM; positive ihc;continuous selectivity; retina: 9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 2.2 nTPM; positive ihc;continuous selectivity; skeletal muscle: 2.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 3.9 nTPM; positive ihc;continuous selectivity; small intestine: 2.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 2.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; spleen: 2.2 nTPM; positive ihc; stomach: 2.7 nTPM; positive ihc;continuous selectivity; thymus: 3.3 nTPM; continuous selectivity; thyroid gland: 3.3 nTPM; positive ihc;continuous selectivity; urinary bladder: 1.5 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",cerebellum: 2.9 nTPM (limit 2); cerebral cortex: 2.8 nTPM (limit 2); duodenum: 2.2 nTPM (limit 2); kidney: 2.6 nTPM (limit 2); pancreas: 4.6 nTPM (limit 2); retina: 9 nTPM (limit 2); skeletal muscle: 2.2 nTPM (limit 2); small intestine: 2.9 nTPM (limit 2); smooth muscle: 2.2 nTPM (limit 2),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / glial cells: Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: High (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: Low (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: High (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Medium (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: High (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Colon Adenocarcinoma (validation): 470/486 (96.7%); Rectum Adenocarcinoma (validation): 198/207 (95.7%),prostate cancer: 12/12 (100.0%); stomach cancer: 11/12 (91.7%),31,20,Q6ZMW2,https://www.uniprot.org/uniprotkb/Q6ZMW2/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF790,ENSG00000197863,Unsafe,Protein,False,True,10.7,10.7,79,61,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 3.4 nTPM; positive ihc; adrenal gland: 4.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 3.7 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 3.6 nTPM; absolute ceiling;continuous selectivity; bone marrow: 2.1 nTPM; positive ihc;absolute ceiling; cerebellum: 3.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 4.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 5 nTPM; absolute ceiling;continuous selectivity; colon: 3 nTPM; positive ihc; duodenum: 3.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 4.2 nTPM; continuous selectivity; heart muscle: 5.3 nTPM; absolute ceiling;continuous selectivity; hippocampal formation: 3.3 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 3.2 nTPM; absolute ceiling;continuous selectivity; kidney: 5.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 8.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 3.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 5.3 nTPM; positive ihc;continuous selectivity; midbrain: 3.5 nTPM; absolute ceiling;continuous selectivity; pancreas: 4.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 5.6 nTPM; continuous selectivity; pituitary gland: 2.9 nTPM; absolute ceiling;continuous selectivity; rectum: 2.5 nTPM; positive ihc; retina: 7.8 nTPM; absolute ceiling;continuous selectivity; salivary gland: 2.9 nTPM; positive ihc; skeletal muscle: 4.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 9.2 nTPM; positive ihc;continuous selectivity; small intestine: 3.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 3.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 3 nTPM; absolute ceiling;continuous selectivity; stomach: 4.7 nTPM; positive ihc;continuous selectivity; thyroid gland: 7.8 nTPM; positive ihc;continuous selectivity; tongue: 4.8 nTPM; continuous selectivity; urinary bladder: 3.5 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 4.7 nTPM (limit 2); amygdala: 3.7 nTPM (limit 2); basal ganglia: 3.6 nTPM (limit 2); bone marrow: 2.1 nTPM (limit 2); cerebellum: 3.2 nTPM (limit 2); cerebral cortex: 4.5 nTPM (limit 2); choroid plexus: 5 nTPM (limit 2); duodenum: 3.8 nTPM (limit 2); heart muscle: 5.3 nTPM (limit 2); hippocampal formation: 3.3 nTPM (limit 2); hypothalamus: 3.2 nTPM (limit 2); kidney: 5.7 nTPM (limit 2); liver: 8.5 nTPM (limit 2); lung: 3.6 nTPM (limit 2); midbrain: 3.5 nTPM (limit 2); pancreas: 4.3 nTPM (limit 2); pituitary gland: 2.9 nTPM (limit 2); retina: 7.8 nTPM (limit 2); skeletal muscle: 4.8 nTPM (limit 2); small intestine: 3.6 nTPM (limit 2); smooth muscle: 3.2 nTPM (limit 2); spinal cord: 3 nTPM (limit 2); adrenal gland: 4.7 nTPM (baseline 2); amygdala: 3.7 nTPM (baseline 2); basal ganglia: 3.6 nTPM (baseline 2); bone marrow: 2.1 nTPM (baseline 2); cerebellum: 3.2 nTPM (baseline 2); cerebral cortex: 4.5 nTPM (baseline 2); choroid plexus: 5 nTPM (baseline 2); duodenum: 3.8 nTPM (baseline 2); heart muscle: 5.3 nTPM (baseline 2); hippocampal formation: 3.3 nTPM (baseline 2); hypothalamus: 3.2 nTPM (baseline 2); kidney: 5.7 nTPM (baseline 2); liver: 8.5 nTPM (baseline 2); lung: 3.6 nTPM (baseline 2); midbrain: 3.5 nTPM (baseline 2); pancreas: 4.3 nTPM (baseline 2); pituitary gland: 2.9 nTPM (baseline 2); retina: 7.8 nTPM (baseline 2); skeletal muscle: 4.8 nTPM (baseline 2); small intestine: 3.6 nTPM (baseline 2); smooth muscle: 3.2 nTPM (baseline 2); spinal cord: 3 nTPM (baseline 2),adipose tissue / adipocytes: Medium (Uncertain); adrenal gland / glandular cells: High (Uncertain); bone marrow / hematopoietic cells: Low (Uncertain); bronchus / respiratory epithelial cells: High (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / Purkinje cells: High (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: High (Uncertain); colon / endothelial cells: High (Uncertain); colon / glandular cells: High (Uncertain); colon / peripheral nerve/ganglion: High (Uncertain); duodenum / glandular cells: High (Uncertain); hippocampus / neuronal cells: High (Uncertain); kidney / cells in glomeruli: Medium (Uncertain); kidney / cells in tubules: High (Uncertain); liver / cholangiocytes: High (Uncertain); liver / hepatocytes: High (Uncertain); lung / alveolar cells: Medium (Uncertain); lung / macrophages: High (Uncertain); lymph node / non-germinal center cells: Low (Uncertain); nasopharynx / respiratory epithelial cells: High (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Low (Uncertain); rectum / glandular cells: High (Uncertain); salivary gland / glandular cells: High (Uncertain); skeletal muscle / myocytes: Low (Uncertain); skin 1 / fibroblasts: High (Uncertain); small intestine / glandular cells: High (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); stomach 1 / glandular cells: High (Uncertain); stomach 2 / glandular cells: High (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Medium (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Glioblastoma Multiforme (TCGA): 123/141 (87.2%); Kidney Renal Clear Cell Carcinoma (validation): 83/100 (83.0%),breast cancer: 11/11 (100.0%); prostate cancer: 10/10 (100.0%),31,20,Q6PG37,https://www.uniprot.org/uniprotkb/Q6PG37/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF799,ENSG00000196466,Unsafe,Protein,False,True,4.6,4.6,78,75,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 2.8 nTPM; positive ihc;continuous selectivity; adrenal gland: 2.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; amygdala: 1.7 nTPM; continuous selectivity; basal ganglia: 1.8 nTPM; continuous selectivity; bone marrow: 1.5 nTPM; positive ihc;continuous selectivity; cerebellum: 1.9 nTPM; positive ihc;continuous selectivity; cerebral cortex: 1.4 nTPM; positive ihc;continuous selectivity; colon: 2.5 nTPM; positive ihc;continuous selectivity; duodenum: 2.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 1.8 nTPM; positive ihc;continuous selectivity; heart muscle: 2 nTPM; positive ihc;continuous selectivity; hippocampal formation: 1.9 nTPM; continuous selectivity; hypothalamus: 1.7 nTPM; continuous selectivity; kidney: 3.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 3.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; lung: 2.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 2.5 nTPM; positive ihc;continuous selectivity; midbrain: 1.9 nTPM; continuous selectivity; pancreas: 2.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 2.3 nTPM; positive ihc;continuous selectivity; rectum: 2.5 nTPM; positive ihc;continuous selectivity; retina: 1.5 nTPM; continuous selectivity; salivary gland: 2.1 nTPM; positive ihc;continuous selectivity; skeletal muscle: 1.8 nTPM; positive ihc;continuous selectivity; skin: 2.3 nTPM; positive ihc;continuous selectivity; small intestine: 2.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 2.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 1.9 nTPM; continuous selectivity; spleen: 2.9 nTPM; positive ihc;continuous selectivity; stomach: 1.9 nTPM; positive ihc;continuous selectivity; thymus: 3.1 nTPM; continuous selectivity; thyroid gland: 1.9 nTPM; positive ihc; tongue: 2.2 nTPM; continuous selectivity; urinary bladder: 2.6 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 2.8 nTPM (limit 2); duodenum: 2.1 nTPM (limit 2); kidney: 3.3 nTPM (limit 2); liver: 3.7 nTPM (limit 2); lung: 2.8 nTPM (limit 2); pancreas: 2.1 nTPM (limit 2); small intestine: 2.4 nTPM (limit 2); smooth muscle: 2.3 nTPM (limit 2),adipose tissue / adipocytes: Low (Approved); adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: High (Approved); liver / cholangiocytes: Medium (Approved); liver / hepatocytes: High (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Low (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Low (Approved); skin 1 / keratinocytes: Low (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 56/58 (96.6%); Breast Invasive Carcinoma (validation): 47/50 (94.0%); Pancreatic Adenocarcinoma (validation): 57/80 (71.2%),breast cancer: 12/12 (100.0%); pancreatic cancer: 11/11 (100.0%),31,20,Q96GE5,https://www.uniprot.org/uniprotkb/Q96GE5/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF805,ENSG00000204524,Unsafe,Protein,False,True,2.1,6.6,74,62,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 1.5 nTPM; continuous selectivity; adrenal gland: 1.9 nTPM; positive ihc;continuous selectivity; bone marrow: 6.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 0.6 nTPM; positive ihc; cerebral cortex: 1.1 nTPM; positive ihc;continuous selectivity; choroid plexus: 1.4 nTPM; continuous selectivity; colon: 1.2 nTPM; positive ihc;continuous selectivity; duodenum: 1 nTPM; positive ihc;continuous selectivity; esophagus: 1.1 nTPM; positive ihc;continuous selectivity; heart muscle: 1.5 nTPM; positive ihc;continuous selectivity; kidney: 1.3 nTPM; positive ihc;continuous selectivity; liver: 1.9 nTPM; positive ihc;continuous selectivity; lung: 1.5 nTPM; positive ihc;continuous selectivity; lymph node: 1.5 nTPM; continuous selectivity; pancreas: 1.3 nTPM; positive ihc;continuous selectivity; parathyroid gland: 2.1 nTPM; positive ihc;continuous selectivity;reproductive not higher; pituitary gland: 1.3 nTPM; continuous selectivity; rectum: 1.5 nTPM; positive ihc;continuous selectivity; retina: 2.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 1.4 nTPM; positive ihc;continuous selectivity; skeletal muscle: 1.7 nTPM; positive ihc;continuous selectivity; skin: 1.9 nTPM; positive ihc;continuous selectivity; small intestine: 1.1 nTPM; positive ihc;continuous selectivity; smooth muscle: 1.7 nTPM; positive ihc;continuous selectivity; spleen: 2.1 nTPM; positive ihc;continuous selectivity;reproductive not higher; stomach: 1.5 nTPM; positive ihc;continuous selectivity; thymus: 1.6 nTPM; continuous selectivity; thyroid gland: 1.6 nTPM; positive ihc;continuous selectivity; tongue: 2 nTPM; continuous selectivity; urinary bladder: 1.3 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",bone marrow: 6.6 nTPM (limit 2); retina: 2.6 nTPM (limit 2); bone marrow: 6.6 nTPM (baseline 2); retina: 2.6 nTPM (baseline 2),adrenal gland / glandular cells: High (Uncertain); bone marrow / hematopoietic cells: Low (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / glial cells: Medium (Uncertain); caudate / neuronal cells: Medium (Uncertain); cerebellum / cells in granular layer: Low (Uncertain); cerebellum / cells in molecular layer: Low (Uncertain); cerebellum / Purkinje cells: Medium (Uncertain); cerebral cortex / endothelial cells: Medium (Uncertain); cerebral cortex / glial cells: Low (Uncertain); cerebral cortex / neuronal cells: Medium (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / endothelial cells: Medium (Uncertain); colon / glandular cells: Medium (Uncertain); duodenum / glandular cells: Medium (Uncertain); esophagus / squamous epithelial cells: Medium (Uncertain); heart muscle / cardiomyocytes: High (Uncertain); hippocampus / glial cells: Low (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in glomeruli: Low (Uncertain); kidney / cells in tubules: High (Uncertain); liver / cholangiocytes: Low (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / alveolar cells: Low (Uncertain); lung / macrophages: Medium (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); parathyroid gland / glandular cells: Low (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Low (Uncertain); skeletal muscle / myocytes: Medium (Uncertain); skin 1 / fibroblasts: Low (Uncertain); skin 1 / keratinocytes: Low (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: Medium (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); spleen / cells in red pulp: Low (Uncertain); spleen / cells in white pulp: Medium (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Low (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Low (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Pancreatic Adenocarcinoma (validation): 79/80 (98.8%); Colon Adenocarcinoma (validation): 479/486 (98.6%),prostate cancer: 10/11 (90.9%); breast cancer: 6/11 (54.5%),31,20,Q5CZA5,https://www.uniprot.org/uniprotkb/Q5CZA5/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF81,ENSG00000197779,Unsafe,Protein,False,True,2.5,4.2,78,64,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 1.7 nTPM; continuous selectivity; adrenal gland: 1.8 nTPM; positive ihc;continuous selectivity; amygdala: 1.3 nTPM; continuous selectivity; basal ganglia: 1.3 nTPM; continuous selectivity; bone marrow: 3.2 nTPM; continuous selectivity;reproductive not higher; cerebellum: 1.9 nTPM; positive ihc;continuous selectivity; cerebral cortex: 2.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 1.7 nTPM; continuous selectivity; colon: 2.3 nTPM; positive ihc;continuous selectivity; duodenum: 1.5 nTPM; positive ihc;continuous selectivity; esophagus: 2.1 nTPM; positive ihc;continuous selectivity; heart muscle: 3.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 1.2 nTPM; continuous selectivity; hypothalamus: 1.1 nTPM; continuous selectivity; kidney: 2.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 1.5 nTPM; positive ihc;continuous selectivity; lung: 1.9 nTPM; positive ihc;continuous selectivity; lymph node: 2.2 nTPM; positive ihc;continuous selectivity; midbrain: 1.6 nTPM; continuous selectivity; pancreas: 1.7 nTPM; positive ihc;continuous selectivity; parathyroid gland: 3.4 nTPM; positive ihc;continuous selectivity;reproductive not higher; pituitary gland: 2.2 nTPM; absolute ceiling;continuous selectivity; rectum: 2.8 nTPM; positive ihc;continuous selectivity;reproductive not higher; retina: 4.2 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 1.5 nTPM; positive ihc;continuous selectivity; skeletal muscle: 1.8 nTPM; positive ihc;continuous selectivity; skin: 3.5 nTPM; positive ihc;continuous selectivity;reproductive not higher; small intestine: 1.6 nTPM; positive ihc;continuous selectivity; smooth muscle: 2.2 nTPM; continuous selectivity; spinal cord: 1.6 nTPM; continuous selectivity; spleen: 2.7 nTPM; positive ihc;continuous selectivity;reproductive not higher; stomach: 1.7 nTPM; positive ihc;continuous selectivity; thymus: 2.9 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 2.8 nTPM; positive ihc;continuous selectivity;reproductive not higher; urinary bladder: 2 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",cerebral cortex: 2.1 nTPM (limit 2); heart muscle: 3.4 nTPM (limit 2); kidney: 2.5 nTPM (limit 2); pituitary gland: 2.2 nTPM (limit 2); retina: 4.2 nTPM (limit 2),adrenal gland / glandular cells: High (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: High (Approved); cerebellum / cells in molecular layer: Low (Approved); cerebellum / Purkinje cells: Medium (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Low (Approved); cerebral cortex / neuropil: Medium (Approved); colon / endothelial cells: Low (Approved); colon / glandular cells: High (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: High (Approved); esophagus / squamous epithelial cells: High (Approved); heart muscle / cardiomyocytes: High (Approved); hippocampus / neuronal cells: High (Approved); kidney / cells in tubules: High (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Low (Approved); lung / macrophages: Low (Approved); lymph node / germinal center cells: High (Approved); lymph node / non-germinal center cells: High (Approved); nasopharynx / respiratory epithelial cells: High (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: High (Approved); pancreas / pancreatic endocrine cells: Medium (Approved); parathyroid gland / glandular cells: High (Approved); rectum / glandular cells: High (Approved); salivary gland / glandular cells: High (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / fibroblasts: Medium (Approved); skin 1 / keratinocytes: High (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: High (Approved); small intestine / glandular cells: High (Approved); spleen / cells in red pulp: Low (Approved); spleen / cells in white pulp: High (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: High (Approved); urinary bladder / urothelial cells: High (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Rectum Adenocarcinoma (validation): 196/207 (94.7%); Colon Adenocarcinoma (validation): 451/486 (92.8%),colorectal cancer: 12/12 (100.0%); ovarian cancer: 12/12 (100.0%),31,20,P51508,https://www.uniprot.org/uniprotkb/P51508/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF845,ENSG00000213799,Unsafe,RNA,False,True,3.9,4.9,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,adipose tissue: 2.5 nTPM; continuous selectivity; adrenal gland: 1.7 nTPM; continuous selectivity; bone marrow: 4.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; cerebellum: 1.6 nTPM; continuous selectivity; cerebral cortex: 1.3 nTPM; continuous selectivity; choroid plexus: 1.2 nTPM; continuous selectivity; colon: 2.8 nTPM; continuous selectivity; duodenum: 2.4 nTPM; absolute ceiling;continuous selectivity; esophagus: 2.4 nTPM; continuous selectivity; heart muscle: 2 nTPM; continuous selectivity; kidney: 2.4 nTPM; absolute ceiling;continuous selectivity; liver: 1.5 nTPM; continuous selectivity; lung: 2.8 nTPM; absolute ceiling;continuous selectivity; lymph node: 4.2 nTPM; continuous selectivity;reproductive not higher; pancreas: 2 nTPM; continuous selectivity; parathyroid gland: 3.5 nTPM; continuous selectivity; rectum: 3 nTPM; continuous selectivity; retina: 1.3 nTPM; continuous selectivity; salivary gland: 2 nTPM; continuous selectivity; skin: 3 nTPM; continuous selectivity; small intestine: 2.5 nTPM; absolute ceiling;continuous selectivity; smooth muscle: 1.9 nTPM; continuous selectivity; spinal cord: 1.1 nTPM; continuous selectivity; spleen: 3.5 nTPM; continuous selectivity; stomach: 3.5 nTPM; continuous selectivity; thymus: 4.1 nTPM; continuous selectivity;reproductive not higher; thyroid gland: 3.6 nTPM; continuous selectivity; tongue: 1.9 nTPM; continuous selectivity; urinary bladder: 2.6 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 4.9 nTPM (limit 2); duodenum: 2.4 nTPM (limit 2); kidney: 2.4 nTPM (limit 2); lung: 2.8 nTPM (limit 2); small intestine: 2.5 nTPM (limit 2); bone marrow: 4.9 nTPM (baseline 2); duodenum: 2.4 nTPM (baseline 2); kidney: 2.4 nTPM (baseline 2); lung: 2.8 nTPM (baseline 2); small intestine: 2.5 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Pancreatic Adenocarcinoma (validation): 79/80 (98.8%); Breast Invasive Carcinoma (validation): 47/50 (94.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q96IR2,https://www.uniprot.org/uniprotkb/Q96IR2/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF846,ENSG00000196605,Unsafe,Protein,False,True,18.0,18.0,80,35,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adrenal gland: 6.1 nTPM; absolute ceiling; amygdala: 6.6 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 5.5 nTPM; absolute ceiling;continuous selectivity; bone marrow: 4.4 nTPM; positive ihc;absolute ceiling; cerebral cortex: 5.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 6.9 nTPM; absolute ceiling;continuous selectivity; colon: 7.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 4.1 nTPM; absolute ceiling; esophagus: 9 nTPM; positive ihc;absolute ceiling;continuous selectivity; heart muscle: 7.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 6.6 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 5.9 nTPM; absolute ceiling;continuous selectivity; kidney: 4.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 4.5 nTPM; absolute ceiling; lung: 6.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 7.8 nTPM; absolute ceiling;continuous selectivity; pituitary gland: 5.4 nTPM; absolute ceiling;continuous selectivity; retina: 6.7 nTPM; absolute ceiling;continuous selectivity; salivary gland: 6.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; skeletal muscle: 5 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 7.3 nTPM; positive ihc; small intestine: 5.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 10.1 nTPM; absolute ceiling;continuous selectivity; spinal cord: 9.4 nTPM; absolute ceiling;continuous selectivity; stomach: 6.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; urinary bladder: 12.7 nTPM; positive ihc;absolute ceiling;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 6.1 nTPM (limit 4); amygdala: 6.6 nTPM (limit 2); basal ganglia: 5.5 nTPM (limit 2); bone marrow: 4.4 nTPM (limit 2); cerebral cortex: 5.2 nTPM (limit 2); choroid plexus: 6.9 nTPM (limit 2); colon: 7.9 nTPM (limit 6); duodenum: 4.1 nTPM (limit 4); esophagus: 9 nTPM (limit 6); heart muscle: 7.9 nTPM (limit 2); hippocampal formation: 6.6 nTPM (limit 2); hypothalamus: 5.9 nTPM (limit 2); kidney: 4.9 nTPM (limit 2); liver: 4.5 nTPM (limit 4); lung: 6.6 nTPM (limit 2); midbrain: 7.8 nTPM (limit 2); pituitary gland: 5.4 nTPM (limit 2); retina: 6.7 nTPM (limit 2); salivary gland: 6.9 nTPM (limit 6); skeletal muscle: 5 nTPM (limit 2); small intestine: 5.1 nTPM (limit 2); smooth muscle: 10.1 nTPM (limit 4); spinal cord: 9.4 nTPM (limit 2); stomach: 6.3 nTPM (limit 6); urinary bladder: 12.7 nTPM (limit 6),bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Low (Approved); cerebral cortex / endothelial cells: Medium (Approved); colon / endothelial cells: Medium (Approved); colon / peripheral nerve/ganglion: Low (Approved); esophagus / squamous epithelial cells: Low (Approved); heart muscle / cardiomyocytes: Medium (Approved); kidney / cells in tubules: Low (Approved); lung / macrophages: Medium (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); oral mucosa / squamous epithelial cells: Low (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / keratinocytes: Low (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Low (Approved); stomach 1 / glandular cells: Low (Approved); stomach 2 / glandular cells: Low (Approved); urinary bladder / urothelial cells: Low (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Rectum Adenocarcinoma (validation): 204/207 (98.6%); Colon Adenocarcinoma (validation): 455/486 (93.6%),liver cancer: 1/11 (9.1%); breast cancer: 0/11 (0.0%),31,20,Q147U1,https://www.uniprot.org/uniprotkb/Q147U1/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Jamin2021_CT | Jamin2021_core,CT-pattern microarray nomination; tumor upregulation with no corresponding normal-tissue detection | Core CT annotation; underlying microarray probes may recognize several loci,,,,,,,,
ZNF85,ENSG00000105750,Unsafe,Protein,False,True,11.2,11.2,75,73,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 2.6 nTPM; positive ihc; adrenal gland: 4.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; bone marrow: 4.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 2.9 nTPM; positive ihc;absolute ceiling; cerebral cortex: 2.4 nTPM; positive ihc;absolute ceiling; colon: 1.9 nTPM; positive ihc; duodenum: 0.4 nTPM; positive ihc; esophagus: 2.8 nTPM; positive ihc; heart muscle: 1.7 nTPM; positive ihc; kidney: 2.4 nTPM; positive ihc;absolute ceiling; liver: 0.8 nTPM; positive ihc; lung: 1.7 nTPM; positive ihc; lymph node: 5.6 nTPM; positive ihc;continuous selectivity; pancreas: 7.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 2 nTPM; positive ihc; rectum: 2.4 nTPM; positive ihc; salivary gland: 2.8 nTPM; positive ihc; skeletal muscle: 0.7 nTPM; positive ihc; skin: 2.7 nTPM; positive ihc; small intestine: 2.2 nTPM; positive ihc;absolute ceiling; smooth muscle: 2.3 nTPM; positive ihc;absolute ceiling; spinal cord: 2.4 nTPM; absolute ceiling; spleen: 3.5 nTPM; positive ihc; stomach: 5.4 nTPM; positive ihc;continuous selectivity; thymus: 5.2 nTPM; continuous selectivity; thyroid gland: 7.5 nTPM; positive ihc;continuous selectivity; urinary bladder: 2.2 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 4.8 nTPM (limit 2); bone marrow: 4.8 nTPM (limit 2); cerebellum: 2.9 nTPM (limit 2); cerebral cortex: 2.4 nTPM (limit 2); kidney: 2.4 nTPM (limit 2); pancreas: 7.9 nTPM (limit 2); small intestine: 2.2 nTPM (limit 2); smooth muscle: 2.3 nTPM (limit 2); spinal cord: 2.4 nTPM (limit 2),adipose tissue / adipocytes: Medium (Approved); adrenal gland / glandular cells: High (Approved); bone marrow / hematopoietic cells: Medium (Approved); bronchus / respiratory epithelial cells: High (Approved); caudate / glial cells: Low (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / cells in molecular layer: Medium (Approved); cerebellum / Purkinje cells: High (Approved); cerebral cortex / endothelial cells: Low (Approved); cerebral cortex / glial cells: Low (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Low (Approved); colon / endothelial cells: Medium (Approved); colon / glandular cells: Medium (Approved); colon / peripheral nerve/ganglion: Medium (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / glial cells: Low (Approved); hippocampus / neuronal cells: Medium (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: Low (Approved); liver / cholangiocytes: Medium (Approved); liver / hepatocytes: Medium (Approved); lung / alveolar cells: Medium (Approved); lung / macrophages: Low (Approved); lymph node / germinal center cells: Low (Approved); lymph node / non-germinal center cells: Low (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); oral mucosa / squamous epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); parathyroid gland / glandular cells: Low (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Medium (Approved); skin 1 / fibroblasts: Low (Approved); skin 1 / keratinocytes: Medium (Approved); skin 1 / Langerhans: Low (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Medium (Approved); spleen / cells in red pulp: Medium (Approved); stomach 1 / glandular cells: High (Approved); stomach 2 / glandular cells: High (Approved); thyroid gland / glandular cells: Medium (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 44/50 (88.0%); Testicular Germ Cell Tumor (TCGA): 96/133 (72.2%),testis cancer: 11/12 (91.7%); pancreatic cancer: 10/11 (90.9%),31,20,Q03923,https://www.uniprot.org/uniprotkb/Q03923/entry,May be a transcriptional repressor,"Widely expressed, including in testis",,,Nucleus,9839802,2023909|9839802,True,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF879,ENSG00000234284,Unsafe,Protein,False,True,6.0,6.9,75,55,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 2.2 nTPM; positive ihc; adrenal gland: 1.5 nTPM; positive ihc; amygdala: 1.6 nTPM; continuous selectivity; basal ganglia: 1.7 nTPM; continuous selectivity; bone marrow: 0.8 nTPM; positive ihc; cerebellum: 4.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 2 nTPM; positive ihc;continuous selectivity; colon: 2.1 nTPM; positive ihc; duodenum: 1.1 nTPM; positive ihc; esophagus: 1.9 nTPM; positive ihc; heart muscle: 2.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 1.6 nTPM; continuous selectivity; kidney: 2.2 nTPM; positive ihc;absolute ceiling;continuous selectivity; liver: 1.4 nTPM; positive ihc; lung: 1.9 nTPM; positive ihc;continuous selectivity; lymph node: 3 nTPM; positive ihc;continuous selectivity; midbrain: 1.7 nTPM; continuous selectivity; pancreas: 1.6 nTPM; positive ihc;continuous selectivity; parathyroid gland: 2.4 nTPM; positive ihc;continuous selectivity; pituitary gland: 2.5 nTPM; absolute ceiling;continuous selectivity; rectum: 1.1 nTPM; positive ihc; retina: 6.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 2.1 nTPM; positive ihc; skeletal muscle: 2.1 nTPM; absolute ceiling;continuous selectivity; skin: 3.4 nTPM; positive ihc;continuous selectivity; small intestine: 1.8 nTPM; positive ihc;continuous selectivity; smooth muscle: 2.2 nTPM; absolute ceiling;continuous selectivity; spinal cord: 1.8 nTPM; continuous selectivity; spleen: 3.1 nTPM; continuous selectivity; stomach: 1.7 nTPM; positive ihc; thymus: 3.3 nTPM; continuous selectivity; thyroid gland: 3.6 nTPM; positive ihc;continuous selectivity; tongue: 3 nTPM; continuous selectivity; urinary bladder: 1.8 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",cerebellum: 4.5 nTPM (limit 2); heart muscle: 2.6 nTPM (limit 2); kidney: 2.2 nTPM (limit 2); pituitary gland: 2.5 nTPM (limit 2); retina: 6.9 nTPM (limit 2); skeletal muscle: 2.1 nTPM (limit 2); smooth muscle: 2.2 nTPM (limit 2); cerebellum: 4.5 nTPM (baseline 2); heart muscle: 2.6 nTPM (baseline 2); kidney: 2.2 nTPM (baseline 2); pituitary gland: 2.5 nTPM (baseline 2); retina: 6.9 nTPM (baseline 2); skeletal muscle: 2.1 nTPM (baseline 2); smooth muscle: 2.2 nTPM (baseline 2),adipose tissue / adipocytes: Medium (Uncertain); adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Low (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); caudate / neuronal cells: Low (Uncertain); cerebellum / cells in granular layer: Medium (Uncertain); cerebellum / Purkinje cells: Low (Uncertain); cerebral cortex / neuropil: Medium (Uncertain); colon / endothelial cells: Medium (Uncertain); colon / glandular cells: Medium (Uncertain); duodenum / glandular cells: High (Uncertain); esophagus / squamous epithelial cells: Low (Uncertain); heart muscle / cardiomyocytes: Low (Uncertain); hippocampus / neuronal cells: Medium (Uncertain); kidney / cells in glomeruli: Low (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / hepatocytes: Medium (Uncertain); lung / alveolar cells: High (Uncertain); lymph node / germinal center cells: Medium (Uncertain); lymph node / non-germinal center cells: Medium (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Medium (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); parathyroid gland / glandular cells: Medium (Uncertain); rectum / glandular cells: High (Uncertain); salivary gland / glandular cells: Low (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); small intestine / glandular cells: High (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: High (Uncertain); urinary bladder / urothelial cells: High (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 40/50 (80.0%); Testicular Germ Cell Tumor (TCGA): 49/133 (36.8%),colorectal cancer: 10/10 (100.0%); lung cancer: 11/12 (91.7%),31,20,B4DU55,https://www.uniprot.org/uniprotkb/B4DU55/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF93,ENSG00000184635,Unsafe,RNA,False,True,6.4,6.7,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,bone marrow: 3 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 2.1 nTPM; absolute ceiling;continuous selectivity; kidney: 2 nTPM; continuous selectivity; lymph node: 4.9 nTPM; continuous selectivity; pancreas: 3 nTPM; absolute ceiling;continuous selectivity; rectum: 2.6 nTPM; continuous selectivity; retina: 3.2 nTPM; absolute ceiling;continuous selectivity; skin: 3.6 nTPM; continuous selectivity; smooth muscle: 3.8 nTPM; absolute ceiling;continuous selectivity; spleen: 3 nTPM; continuous selectivity; stomach: 2.3 nTPM; continuous selectivity; thymus: 5.9 nTPM; continuous selectivity; thyroid gland: 6.7 nTPM; continuous selectivity;reproductive not higher; urinary bladder: 3.1 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,bone marrow: 3 nTPM (limit 2); cerebral cortex: 2.1 nTPM (limit 2); pancreas: 3 nTPM (limit 2); retina: 3.2 nTPM (limit 2); smooth muscle: 3.8 nTPM (limit 2); bone marrow: 3 nTPM (baseline 2); cerebral cortex: 2.1 nTPM (baseline 2); pancreas: 3 nTPM (baseline 2); retina: 3.2 nTPM (baseline 2); smooth muscle: 3.8 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Testicular Germ Cell Tumor (TCGA): 128/133 (96.2%); Rectum Adenocarcinoma (validation): 185/207 (89.4%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,P35789,https://www.uniprot.org/uniprotkb/P35789/entry,"Transcription factor specifically required to repress long interspersed nuclear element 1 (L1) retrotransposons: recognizes and binds L1 sequences and repress their expression by recruiting a repressive complex containing TRIM28/KAP1 (PubMed:25274305). Not able to repress expression of all subtypes of L1 elements. Binds to the 5' end of L1PA4, L1PA5 and L1PA6 subtypes, and some L1PA3 subtypes. Does not bind to L1PA7 or older subtypes nor at the most recently evolved L1PA2 and L1Hs. 50% of L1PA3 elements have lost the ZNF93-binding site, explaining why ZNF93 is not able to repress their expression (PubMed:25274305)",,,,Nucleus,25274305,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNF98,ENSG00000197360,Unsafe,RNA,False,True,9.1,35.9,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,basal ganglia: 5 nTPM; absolute ceiling;continuous selectivity; cerebral cortex: 3.2 nTPM; absolute ceiling;continuous selectivity; pancreas: 35.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 3.7 nTPM; continuous selectivity; thyroid gland: 4.5 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,basal ganglia: 5 nTPM (limit 2); cerebral cortex: 3.2 nTPM (limit 2); pancreas: 35.9 nTPM (limit 2); basal ganglia: 5 nTPM (baseline 2); cerebral cortex: 3.2 nTPM (baseline 2); pancreas: 35.9 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 79/133 (59.4%); Breast Invasive Carcinoma (validation): 14/50 (28.0%); Kidney Chromophobe (TCGA): 16/64 (25.0%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,A6NK75,https://www.uniprot.org/uniprotkb/A6NK75/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination; inclusion depends on TGCT under this study's thresholds,,,,,,,,
ZNG1A,ENSG00000172785,Unsafe,Protein,False,True,22.0,39.0,84,61,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 18.4 nTPM; continuous selectivity; adrenal gland: 34.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 12.9 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 15.4 nTPM; absolute ceiling;continuous selectivity; bone marrow: 12.9 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebellum: 14.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; cerebral cortex: 13.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; choroid plexus: 31.4 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; colon: 16.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; duodenum: 13 nTPM; positive ihc;absolute ceiling;continuous selectivity; esophagus: 26.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; heart muscle: 20 nTPM; positive ihc;absolute ceiling;continuous selectivity; hippocampal formation: 11.2 nTPM; absolute ceiling;continuous selectivity; hypothalamus: 15.6 nTPM; absolute ceiling;continuous selectivity; kidney: 39 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 26.8 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 16 nTPM; positive ihc;absolute ceiling;continuous selectivity; lymph node: 13.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; midbrain: 13.4 nTPM; absolute ceiling;continuous selectivity; pancreas: 29.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 37.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; pituitary gland: 18.9 nTPM; absolute ceiling;continuous selectivity; rectum: 15.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; retina: 26.9 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; salivary gland: 23.4 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; skeletal muscle: 21.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; skin: 21.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 13.7 nTPM; positive ihc;absolute ceiling;continuous selectivity; smooth muscle: 11.8 nTPM; positive ihc;absolute ceiling;continuous selectivity; spinal cord: 11 nTPM; absolute ceiling;continuous selectivity; spleen: 16.5 nTPM; positive ihc;absolute ceiling;continuous selectivity; stomach: 18.6 nTPM; positive ihc;absolute ceiling;continuous selectivity; thymus: 13.3 nTPM; absolute ceiling;continuous selectivity; thyroid gland: 25.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; tongue: 17.6 nTPM; absolute ceiling;continuous selectivity; urinary bladder: 23.6 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 34.2 nTPM (limit 2); amygdala: 12.9 nTPM (limit 2); basal ganglia: 15.4 nTPM (limit 2); bone marrow: 12.9 nTPM (limit 2); cerebellum: 14.4 nTPM (limit 2); cerebral cortex: 13.1 nTPM (limit 2); choroid plexus: 31.4 nTPM (limit 2); colon: 16.4 nTPM (limit 6); duodenum: 13 nTPM (limit 2); esophagus: 26.1 nTPM (limit 6); heart muscle: 20 nTPM (limit 2); hippocampal formation: 11.2 nTPM (limit 2); hypothalamus: 15.6 nTPM (limit 2); kidney: 39 nTPM (limit 2); liver: 26.8 nTPM (limit 2); lung: 16 nTPM (limit 2); lymph node: 13.4 nTPM (limit 6); midbrain: 13.4 nTPM (limit 2); pancreas: 29.2 nTPM (limit 2); parathyroid gland: 37.5 nTPM (limit 6); pituitary gland: 18.9 nTPM (limit 2); rectum: 15.3 nTPM (limit 6); retina: 26.9 nTPM (limit 2); salivary gland: 23.4 nTPM (limit 6); skeletal muscle: 21.1 nTPM (limit 2); skin: 21.6 nTPM (limit 10); small intestine: 13.7 nTPM (limit 2); smooth muscle: 11.8 nTPM (limit 2); spinal cord: 11 nTPM (limit 2); spleen: 16.5 nTPM (limit 10); stomach: 18.6 nTPM (limit 6); thymus: 13.3 nTPM (limit 10); thyroid gland: 25.1 nTPM (limit 10); tongue: 17.6 nTPM (limit 6); urinary bladder: 23.6 nTPM (limit 6),adrenal gland / glandular cells: Medium (Approved); bone marrow / hematopoietic cells: Low (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Medium (Approved); caudate / neuronal cells: Medium (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: Medium (Approved); cerebral cortex / neuropil: Medium (Approved); colon / glandular cells: Low (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in glomeruli: Medium (Approved); kidney / cells in tubules: High (Approved); liver / hepatocytes: Medium (Approved); lung / macrophages: Medium (Approved); lymph node / germinal center cells: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Medium (Approved); pancreas / pancreatic endocrine cells: Low (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Low (Approved); salivary gland / glandular cells: Low (Approved); skeletal muscle / myocytes: Low (Approved); skin 1 / keratinocytes: Low (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); smooth muscle / smooth muscle cells: Low (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Medium (Approved),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Colon Adenocarcinoma (validation): 486/486 (100.0%); Prostate Adenocarcinoma (TCGA): 480/480 (100.0%); Colon Adenocarcinoma (TCGA): 254/254 (100.0%),prostate cancer: 12/12 (100.0%); pancreatic cancer: 11/11 (100.0%),31,20,Q9BRT8,https://www.uniprot.org/uniprotkb/Q9BRT8/entry,"Zinc chaperone that directly transfers zinc cofactor to target metalloproteins, thereby activating them. Catalyzes zinc insertion into the active site of methionine aminopeptidase METAP1, which function to cleave the initiator methionine from polypeptides during or after protein translation. Mechanistically, the N-terminal psi-PxLVp motif binds to the C6H2-type zinc finger of inactive form of METAP1. After formation of the docked complex, zinc is transferred from the CXCC motif in the GTPase domain of ZNG1A to the zinc binding site in the peptidase domain of METAP1 in a process requiring GTP hydrolysis. GTP/GDP exchange is required for release of active METAP1",Ubiquitously expressed. Up-regulated in cultured astrocytes treated with dopamine,,,Nucleus,,15233989,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZNG1F,ENSG00000215126,Unsafe,Protein,False,True,2.4,7.1,80,51,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 1.9 nTPM; continuous selectivity; adrenal gland: 5.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; amygdala: 2.1 nTPM; absolute ceiling;continuous selectivity; basal ganglia: 1.5 nTPM; continuous selectivity; bone marrow: 2.2 nTPM; continuous selectivity; cerebellum: 1.1 nTPM; positive ihc;continuous selectivity; cerebral cortex: 1.7 nTPM; positive ihc;continuous selectivity; colon: 1.8 nTPM; positive ihc;continuous selectivity; duodenum: 1.2 nTPM; positive ihc;continuous selectivity; esophagus: 2.8 nTPM; positive ihc;continuous selectivity;reproductive not higher; heart muscle: 3.2 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; hippocampal formation: 1.2 nTPM; continuous selectivity; hypothalamus: 1.9 nTPM; continuous selectivity; kidney: 3.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; liver: 7.1 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; lung: 1.9 nTPM; positive ihc;continuous selectivity; lymph node: 0.3 nTPM; positive ihc; midbrain: 2 nTPM; continuous selectivity; pancreas: 3.3 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; parathyroid gland: 0.2 nTPM; positive ihc; pituitary gland: 2.6 nTPM; absolute ceiling;continuous selectivity;reproductive not higher; rectum: 0.3 nTPM; positive ihc; retina: 1.7 nTPM; continuous selectivity; salivary gland: 2.4 nTPM; positive ihc;continuous selectivity;reproductive not higher; skeletal muscle: 3.5 nTPM; continuous selectivity;reproductive not higher; skin: 1.4 nTPM; positive ihc;continuous selectivity; small intestine: 1.8 nTPM; positive ihc;continuous selectivity; spinal cord: 2.1 nTPM; absolute ceiling;continuous selectivity; spleen: 2 nTPM; positive ihc;continuous selectivity; stomach: 2.2 nTPM; positive ihc;continuous selectivity; thyroid gland: 2.1 nTPM; positive ihc;continuous selectivity; urinary bladder: 1.1 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 5.1 nTPM (limit 2); amygdala: 2.1 nTPM (limit 2); heart muscle: 3.2 nTPM (limit 2); kidney: 3.3 nTPM (limit 2); liver: 7.1 nTPM (limit 2); pancreas: 3.3 nTPM (limit 2); pituitary gland: 2.6 nTPM (limit 2); spinal cord: 2.1 nTPM (limit 2),adrenal gland / glandular cells: Medium (Approved); bronchus / respiratory epithelial cells: Medium (Approved); caudate / glial cells: Medium (Approved); caudate / neuronal cells: High (Approved); cerebellum / cells in granular layer: Low (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / endothelial cells: Medium (Approved); cerebral cortex / glial cells: Medium (Approved); cerebral cortex / neuronal cells: High (Approved); cerebral cortex / neuropil: Medium (Approved); colon / glandular cells: Low (Approved); colon / peripheral nerve/ganglion: Low (Approved); duodenum / glandular cells: Medium (Approved); esophagus / squamous epithelial cells: Medium (Approved); heart muscle / cardiomyocytes: Low (Approved); hippocampus / neuronal cells: Low (Approved); kidney / cells in tubules: High (Approved); liver / hepatocytes: High (Approved); lung / macrophages: Medium (Approved); lymph node / non-germinal center cells: Medium (Approved); nasopharynx / respiratory epithelial cells: Low (Approved); oral mucosa / squamous epithelial cells: Low (Approved); pancreas / exocrine glandular cells: Medium (Approved); parathyroid gland / glandular cells: Medium (Approved); rectum / glandular cells: Low (Approved); salivary gland / glandular cells: Low (Approved); skin 1 / keratinocytes: Low (Approved); skin 2 / epidermal cells: Medium (Approved); small intestine / glandular cells: Medium (Approved); spleen / cells in red pulp: Medium (Approved); spleen / cells in white pulp: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 43/50 (86.0%); Pancreatic Adenocarcinoma (validation): 46/80 (57.5%); Lung Squamous Cell Carcinoma (validation): 11/68 (16.2%),colorectal cancer: 12/12 (100.0%); breast cancer: 11/11 (100.0%),31,20,Q4V339,https://www.uniprot.org/uniprotkb/Q4V339/entry,"Zinc chaperone that directly transfers zinc cofactor to target metalloproteins, thereby activating them (By similarity). Catalyzes zinc insertion into the active site of methionine aminopeptidase METAP1, which function to cleave the initiator methionine from polypeptides during or after protein translation (PubMed:35584702). Mechanistically, the N-terminal psi-PxLVp motif binds to the C6H2-type zinc finger of inactive form of METAP1 (By similarity). After formation of the docked complex, zinc is transferred from the CXCC motif in the GTPase domain of ZNG1F to the zinc binding site in the peptidase domain of METAP1 in a process requiring GTP hydrolysis (By similarity). GTP/GDP exchange is required for release of active METAP1 (By similarity)",,,,Nucleus,35584702,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZPBP,ENSG00000042813,Unsafe,RNA,False,True,138.9,138.9,88,2,Positive somewhere,False,True,False,True,Excluded,Normal,False,,Not assessed,,,retina: 4.5 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,retina: 4.5 nTPM (limit 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 2/133 (1.5%); Kidney Renal Papillary Cell Carcinoma (TCGA): 2/282 (0.7%); Uterine Corpus Endometrial Carcinoma (TCGA): 1/176 (0.6%),glioma: 2/10 (20.0%); breast cancer: 0/12 (0.0%),31,20,Q9BS86,https://www.uniprot.org/uniprotkb/Q9BS86/entry,Plays a role in acrosome compaction and sperm morphogenesis (PubMed:21911476). Is implicated in sperm-oocyte interaction during fertilization (By similarity),Expressed specifically in testis,"Spermatogenic failure 66: An autosomal recessive male infertility disorder characterized by globozoospermia. Affected individuals have a normal sperm count, but spermatozoa are round-headed and lack the acrosome. In addition to pure globozoospermia, some patients have a mixture of acrosomeless spermatozoa and spermatozoa with small or detached acrosomes, which is defined as acrosomal hypoplasia.",,"Cytoplasmic vesicle, secretory vesicle, acrosome Cytoplasmic vesicle, secretory vesicle, acrosome membrane Secreted",21911476,17664285,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT | Gong2021_reproductive_PC,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim | Normal reproductive-tissue enrichment; no tumor validation,,,,,,,,
ZRANB3,ENSG00000121988,Unsafe,High RNA,False,True,3.1,3.1,0,0,Missing,False,False,False,False,Excluded,Normal,True,,Not assessed,,,adrenal gland: 1.3 nTPM; continuous selectivity; amygdala: 0.9 nTPM; continuous selectivity; basal ganglia: 1.1 nTPM; continuous selectivity; bone marrow: 1 nTPM; continuous selectivity; cerebral cortex: 1.2 nTPM; continuous selectivity; heart muscle: 0.9 nTPM; continuous selectivity; hippocampal formation: 0.9 nTPM; continuous selectivity; hypothalamus: 1 nTPM; continuous selectivity; liver: 1 nTPM; continuous selectivity; pancreas: 1.2 nTPM; continuous selectivity; pituitary gland: 1.3 nTPM; continuous selectivity; retina: 1.3 nTPM; continuous selectivity; skeletal muscle: 1.9 nTPM; continuous selectivity; spinal cord: 1 nTPM; continuous selectivity,"Observed RNA above 30 TPM or nTPM outside explicitly permitted reproductive/disposable contexts; research exclusion, not proven clinical toxicity",,,,oncoref.target-sets.2026-10-24.1,True,"brain/excitatory neurons cluster c-0: 63.4 nTPM, 9537 reads; reproductive-cell max 27.1; brain/excitatory neurons cluster c-1: 82.7 nTPM, 10377 reads; reproductive-cell max 27.1; brain/excitatory neurons cluster c-2: 54.3 nTPM, 6185 reads; reproductive-cell max 27.1; brain/excitatory neurons cluster c-3: 71 nTPM, 8166 reads; reproductive-cell max 27.1; brain/excitatory neurons cluster c-4: 56.3 nTPM, 7720 reads; reproductive-cell max 27.1; brain/inhibitory neurons cluster c-5: 55.6 nTPM, 4945 reads; reproductive-cell max 27.1; brain/inhibitory neurons cluster c-6: 31.3 nTPM, 1626 reads; reproductive-cell max 27.1; brain/excitatory neurons cluster c-7: 89.5 nTPM, 8366 reads; reproductive-cell max 27.1; brain/inhibitory neurons cluster c-8: 44.2 nTPM, 3677 reads; reproductive-cell max 27.1; brain/excitatory neurons cluster c-9: 74.1 nTPM, 5160 reads; reproductive-cell max 27.1; brain/excitatory neurons cluster c-10: 64.4 nTPM, 3401 reads; reproductive-cell max 27.1; brain/excitatory neurons cluster c-11: 57.3 nTPM, 4194 reads; reproductive-cell max 27.1; brain/oligodendrocytes cluster c-12: 63.8 nTPM, 774 reads; reproductive-cell max 27.1; brain/excitatory neurons cluster c-13: 61.2 nTPM, 2878 reads; reproductive-cell max 27.1; brain/inhibitory neurons cluster c-14: 34.1 nTPM, 1351 reads; reproductive-cell max 27.1; brain/inhibitory neurons cluster c-15: 30.2 nTPM, 825 reads; reproductive-cell max 27.1; brain/excitatory neurons cluster c-16: 63.6 nTPM, 5025 reads; reproductive-cell max 27.1; brain/inhibitory neurons cluster c-17: 46.9 nTPM, 1513 reads; reproductive-cell max 27.1; brain/excitatory neurons cluster c-18: 66.5 nTPM, 3294 reads; reproductive-cell max 27.1; brain/excitatory neurons cluster c-19: 59.9 nTPM, 2676 reads; reproductive-cell max 27.1; brain/excitatory neurons cluster c-20: 66.5 nTPM, 3247 reads; reproductive-cell max 27.1; brain/inhibitory neurons cluster c-21: 54.2 nTPM, 1648 reads; reproductive-cell max 27.1; brain/excitatory neurons cluster c-22: 52.8 nTPM, 2285 reads; reproductive-cell max 27.1; brain/inhibitory neurons cluster c-23: 40.5 nTPM, 940 reads; reproductive-cell max 27.1; brain/excitatory neurons cluster c-24: 75.9 nTPM, 1767 reads; reproductive-cell max 27.1; brain/inhibitory neurons cluster c-25: 42.8 nTPM, 799 reads; reproductive-cell max 27.1; brain/inhibitory neurons cluster c-26: 63.6 nTPM, 1425 reads; reproductive-cell max 27.1; brain/excitatory neurons cluster c-27: 81.5 nTPM, 2899 reads; reproductive-cell max 27.1; brain/inhibitory neurons cluster c-28: 59.7 nTPM, 1214 reads; reproductive-cell max 27.1; brain/excitatory neurons cluster c-29: 48 nTPM, 1210 reads; reproductive-cell max 27.1; brain/inhibitory neurons cluster c-30: 51.7 nTPM, 1240 reads; reproductive-cell max 27.1; brain/excitatory neurons cluster c-31: 78.5 nTPM, 3120 reads; reproductive-cell max 27.1; brain/excitatory neurons cluster c-32: 70 nTPM, 2029 reads; reproductive-cell max 27.1; brain/excitatory neurons cluster c-33: 75.4 nTPM, 1871 reads; reproductive-cell max 27.1; brain/excitatory neurons cluster c-34: 66.4 nTPM, 1661 reads; reproductive-cell max 27.1; brain/astrocytes cluster c-35: 33.1 nTPM, 107 reads; reproductive-cell max 27.1; brain/excitatory neurons cluster c-36: 41.7 nTPM, 712 reads; reproductive-cell max 27.1; brain/oligodendrocytes cluster c-37: 56.3 nTPM, 198 reads; reproductive-cell max 27.1; brain/inhibitory neurons cluster c-38: 39.2 nTPM, 408 reads; reproductive-cell max 27.1; brain/excitatory neurons cluster c-39: 75.2 nTPM, 843 reads; reproductive-cell max 27.1; brain/excitatory neurons cluster c-40: 54.9 nTPM, 554 reads; reproductive-cell max 27.1; brain/inhibitory neurons cluster c-41: 47.1 nTPM, 248 reads; reproductive-cell max 27.1; brain/excitatory neurons cluster c-44: 55.5 nTPM, 158 reads; reproductive-cell max 27.1",True,True,"DICE B_CELL_NAIVE (unstimulated): 67/91 values ≥5 TPM, max 8.11492; DICE CD4_NAIVE (unstimulated): 39/88 values ≥5 TPM, max 7.64493; DICE TREG_NAIVE (unstimulated): 18/89 values ≥5 TPM, max 6.00218; DICE TH2 (unstimulated): 3/89 values ≥5 TPM, max 5.54747; DICE CD8_NAIVE (unstimulated): 41/89 values ≥5 TPM, max 6.89752",True,True,False,,True,False,,False,False,True,Neither,Cellular,oncoref.target-sets.2026-10-23.1,False,False,,Neither → Unsafe,True,True,True,8.114923978410001,89.5,"hpa_single_cell: /Astrocytes, max 33.1 nTPM, 1 observations >30; hpa_single_cell: /Excitatory neurons, max 67 nTPM, 1 observations >30; hpa_single_cell: /Inhibitory neurons, max 44.2 nTPM, 1 observations >30; hpa_single_cell: /Oligodendrocytes, max 62.4 nTPM, 1 observations >30; hpa_single_cell_tissue: brain/astrocytes, max 33.1 nTPM, 1 observations >30; hpa_single_cell_tissue: brain/excitatory neurons, max 89.5 nTPM, 26 observations >30; hpa_single_cell_tissue: brain/inhibitory neurons, max 63.6 nTPM, 14 observations >30; hpa_single_cell_tissue: brain/oligodendrocytes, max 63.8 nTPM, 2 observations >30",Neither,oncoref.target-sets.2026-10-23.2,8.115 TPM; blood/B_CELL_NAIVE; dice_b_cell_naive; vital,89.5 nTPM; brain/excitatory neurons; hpa_single_cell_tissue; vital,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 41/50 (82.0%); Pancreatic Adenocarcinoma (validation): 29/80 (36.2%),No exact-ID IHC coverage in the HPA cancer snapshot,31,0,Q5FWF4,https://www.uniprot.org/uniprotkb/Q5FWF4/entry,"DNA annealing helicase and endonuclease required to maintain genome stability at stalled or collapsed replication forks by facilitating fork restart and limiting inappropriate recombination that could occur during template switching events (PubMed:21078962, PubMed:22704558, PubMed:22705370, PubMed:22759634, PubMed:26884333). Recruited to the sites of stalled DNA replication by polyubiquitinated PCNA and acts as a structure-specific endonuclease that cleaves the replication fork D-loop intermediate, generating an accessible 3'-OH group in the template of the leading strand, which is amenable to extension by DNA polymerase (PubMed:22759634, PubMed:28621305). In addition to endonuclease activity, also catalyzes the fork regression via annealing helicase activity in order to prevent disintegration of the replication fork and the formation of double-strand breaks (PubMed:22704558, PubMed:22705370)",,,,Nucleus Chromosome,21078962|22704558|22705370|22759634|26884333|28621305,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZSCAN20,ENSG00000121903,Unsafe,Protein,False,True,1.9,2.5,79,77,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0.8 nTPM; positive ihc; adrenal gland: 0.8 nTPM; positive ihc;continuous selectivity; basal ganglia: 0.6 nTPM; continuous selectivity; bone marrow: 0.2 nTPM; positive ihc; cerebellum: 0.9 nTPM; positive ihc;continuous selectivity; cerebral cortex: 0.9 nTPM; positive ihc;continuous selectivity; choroid plexus: 1 nTPM; continuous selectivity; colon: 1 nTPM; positive ihc;continuous selectivity; duodenum: 2.5 nTPM; positive ihc;absolute ceiling;continuous selectivity;reproductive not higher; esophagus: 0.8 nTPM; positive ihc;continuous selectivity; heart muscle: 1.8 nTPM; continuous selectivity; kidney: 1 nTPM; positive ihc;continuous selectivity; liver: 0.5 nTPM; positive ihc; lung: 0.9 nTPM; positive ihc;continuous selectivity; lymph node: 0.6 nTPM; positive ihc; midbrain: 0.6 nTPM; continuous selectivity; pancreas: 0.8 nTPM; positive ihc;continuous selectivity; parathyroid gland: 2.5 nTPM; positive ihc;continuous selectivity;reproductive not higher; pituitary gland: 0.9 nTPM; continuous selectivity; rectum: 1.2 nTPM; positive ihc;continuous selectivity; retina: 1.6 nTPM; continuous selectivity; salivary gland: 0.9 nTPM; positive ihc;continuous selectivity; skeletal muscle: 1.1 nTPM; positive ihc;continuous selectivity; skin: 0.8 nTPM; positive ihc; small intestine: 1.2 nTPM; positive ihc;continuous selectivity; smooth muscle: 1.4 nTPM; positive ihc;continuous selectivity; spinal cord: 0.6 nTPM; continuous selectivity; spleen: 0.9 nTPM; positive ihc; stomach: 1.2 nTPM; positive ihc;continuous selectivity; thymus: 1.2 nTPM; continuous selectivity; thyroid gland: 1.2 nTPM; positive ihc;continuous selectivity; tongue: 1.9 nTPM; continuous selectivity;reproductive not higher; urinary bladder: 0.9 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",duodenum: 2.5 nTPM (limit 2); duodenum: 2.5 nTPM (baseline 2),adipose tissue / adipocytes: High (Uncertain); adrenal gland / glandular cells: High (Uncertain); bone marrow / hematopoietic cells: High (Uncertain); bronchus / respiratory epithelial cells: High (Uncertain); caudate / glial cells: Medium (Uncertain); caudate / neuronal cells: High (Uncertain); cerebellum / cells in granular layer: High (Uncertain); cerebellum / cells in molecular layer: High (Uncertain); cerebellum / Purkinje cells: Low (Uncertain); cerebral cortex / endothelial cells: Medium (Uncertain); cerebral cortex / glial cells: High (Uncertain); cerebral cortex / neuronal cells: High (Uncertain); cerebral cortex / neuropil: Low (Uncertain); colon / endothelial cells: High (Uncertain); colon / glandular cells: High (Uncertain); colon / peripheral nerve/ganglion: High (Uncertain); duodenum / glandular cells: High (Uncertain); esophagus / squamous epithelial cells: High (Uncertain); hippocampus / glial cells: Medium (Uncertain); hippocampus / neuronal cells: High (Uncertain); kidney / cells in glomeruli: High (Uncertain); kidney / cells in tubules: High (Uncertain); liver / cholangiocytes: Medium (Uncertain); liver / hepatocytes: Low (Uncertain); lung / alveolar cells: Medium (Uncertain); lung / macrophages: Medium (Uncertain); lymph node / germinal center cells: High (Uncertain); lymph node / non-germinal center cells: High (Uncertain); nasopharynx / respiratory epithelial cells: High (Uncertain); oral mucosa / squamous epithelial cells: High (Uncertain); pancreas / exocrine glandular cells: High (Uncertain); parathyroid gland / glandular cells: High (Uncertain); rectum / glandular cells: High (Uncertain); salivary gland / glandular cells: High (Uncertain); skeletal muscle / myocytes: Medium (Uncertain); skin 1 / fibroblasts: High (Uncertain); skin 1 / keratinocytes: High (Uncertain); skin 1 / Langerhans: High (Uncertain); skin 2 / epidermal cells: High (Uncertain); small intestine / glandular cells: High (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); spleen / cells in red pulp: High (Uncertain); spleen / cells in white pulp: High (Uncertain); stomach 1 / glandular cells: High (Uncertain); stomach 2 / glandular cells: High (Uncertain); thyroid gland / glandular cells: High (Uncertain); urinary bladder / urothelial cells: High (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 57/58 (98.3%); Breast Invasive Carcinoma (validation): 40/50 (80.0%); Rectum Adenocarcinoma (validation): 70/207 (33.8%),breast cancer: 12/12 (100.0%); cervical cancer: 12/12 (100.0%),31,20,P17040,https://www.uniprot.org/uniprotkb/P17040/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZSCAN23,ENSG00000187987,Unsafe,Protein,False,True,1.1,1.2,80,51,Positive somewhere,True,False,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; unresolved positive anatomy; unresolved positive anatomy; adipose tissue: 0.1 nTPM; positive ihc; adrenal gland: 0.3 nTPM; positive ihc; bone marrow: 0 nTPM; positive ihc; cerebellum: 0.3 nTPM; positive ihc; cerebral cortex: 0.2 nTPM; positive ihc; colon: 0.2 nTPM; positive ihc; esophagus: 0.1 nTPM; positive ihc; heart muscle: 0.2 nTPM; positive ihc; kidney: 0.2 nTPM; positive ihc; liver: 0 nTPM; positive ihc; lung: 0.2 nTPM; positive ihc; pancreas: 0.3 nTPM; positive ihc; parathyroid gland: 0.7 nTPM; continuous selectivity; rectum: 0.3 nTPM; positive ihc; retina: 1.2 nTPM; continuous selectivity;reproductive not higher; salivary gland: 0.5 nTPM; positive ihc;continuous selectivity; skeletal muscle: 0 nTPM; positive ihc; skin: 0.1 nTPM; positive ihc; smooth muscle: 0.3 nTPM; positive ihc; stomach: 0.1 nTPM; positive ihc; thyroid gland: 0.8 nTPM; positive ihc;continuous selectivity; urinary bladder: 0.2 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,adipose tissue / adipocytes: Low (Uncertain); adrenal gland / glandular cells: Medium (Uncertain); bone marrow / hematopoietic cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); cerebellum / cells in granular layer: Medium (Uncertain); cerebral cortex / glial cells: Low (Uncertain); cerebral cortex / neuropil: Medium (Uncertain); colon / endothelial cells: Low (Uncertain); colon / glandular cells: Low (Uncertain); esophagus / squamous epithelial cells: Low (Uncertain); heart muscle / cardiomyocytes: Medium (Uncertain); kidney / cells in tubules: Medium (Uncertain); liver / cholangiocytes: Medium (Uncertain); lung / macrophages: Low (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); oral mucosa / squamous epithelial cells: Low (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); pancreas / pancreatic endocrine cells: Medium (Uncertain); rectum / glandular cells: Medium (Uncertain); salivary gland / glandular cells: Medium (Uncertain); skeletal muscle / myocytes: High (Uncertain); skin 1 / fibroblasts: Low (Uncertain); skin 1 / keratinocytes: Low (Uncertain); skin 2 / epidermal cells: Medium (Uncertain); smooth muscle / smooth muscle cells: High (Uncertain); stomach 1 / glandular cells: Medium (Uncertain); stomach 2 / glandular cells: Medium (Uncertain); thyroid gland / glandular cells: Medium (Uncertain); urinary bladder / urothelial cells: Low (Uncertain),unresolved_positive_anatomy,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 56/58 (96.6%); Breast Invasive Carcinoma (validation): 24/50 (48.0%); Ovary Serous Cystadenocarcinoma (validation): 1/81 (1.2%),ovarian cancer: 6/11 (54.5%); breast cancer: 6/12 (50.0%),31,20,Q3MJ62,https://www.uniprot.org/uniprotkb/Q3MJ62/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZSCAN5A,ENSG00000131848,Unsafe,Protein,False,True,24.4,24.4,80,15,Positive somewhere,True,True,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adrenal gland: 3.1 nTPM; positive ihc;absolute ceiling; amygdala: 3.1 nTPM; absolute ceiling; basal ganglia: 4.7 nTPM; absolute ceiling; bone marrow: 2.2 nTPM; absolute ceiling; cerebral cortex: 3.2 nTPM; absolute ceiling; choroid plexus: 5.6 nTPM; absolute ceiling; colon: 2.9 nTPM; positive ihc; duodenum: 3.6 nTPM; positive ihc;absolute ceiling; heart muscle: 4 nTPM; absolute ceiling; hippocampal formation: 3.2 nTPM; absolute ceiling; hypothalamus: 2.8 nTPM; absolute ceiling; kidney: 3.5 nTPM; positive ihc;absolute ceiling; liver: 2.5 nTPM; absolute ceiling; lung: 2.7 nTPM; absolute ceiling; midbrain: 2.9 nTPM; absolute ceiling; pancreas: 2.5 nTPM; absolute ceiling; parathyroid gland: 3.2 nTPM; positive ihc; pituitary gland: 3.2 nTPM; absolute ceiling; retina: 2.2 nTPM; absolute ceiling; salivary gland: 3.1 nTPM; positive ihc; skeletal muscle: 3.8 nTPM; absolute ceiling; small intestine: 2.9 nTPM; positive ihc;absolute ceiling; smooth muscle: 3.1 nTPM; positive ihc;absolute ceiling; stomach: 2.3 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",adrenal gland: 3.1 nTPM (limit 2); amygdala: 3.1 nTPM (limit 2); basal ganglia: 4.7 nTPM (limit 2); bone marrow: 2.2 nTPM (limit 2); cerebral cortex: 3.2 nTPM (limit 2); choroid plexus: 5.6 nTPM (limit 2); duodenum: 3.6 nTPM (limit 2); heart muscle: 4 nTPM (limit 2); hippocampal formation: 3.2 nTPM (limit 2); hypothalamus: 2.8 nTPM (limit 2); kidney: 3.5 nTPM (limit 2); liver: 2.5 nTPM (limit 2); lung: 2.7 nTPM (limit 2); midbrain: 2.9 nTPM (limit 2); pancreas: 2.5 nTPM (limit 2); pituitary gland: 3.2 nTPM (limit 2); retina: 2.2 nTPM (limit 2); skeletal muscle: 3.8 nTPM (limit 2); small intestine: 2.9 nTPM (limit 2); smooth muscle: 3.1 nTPM (limit 2); adrenal gland: 3.1 nTPM (baseline 2); amygdala: 3.1 nTPM (baseline 2); basal ganglia: 4.7 nTPM (baseline 2); bone marrow: 2.2 nTPM (baseline 2); cerebral cortex: 3.2 nTPM (baseline 2); choroid plexus: 5.6 nTPM (baseline 2); duodenum: 3.6 nTPM (baseline 2); heart muscle: 4 nTPM (baseline 2); hippocampal formation: 3.2 nTPM (baseline 2); hypothalamus: 2.8 nTPM (baseline 2); kidney: 3.5 nTPM (baseline 2); liver: 2.5 nTPM (baseline 2); lung: 2.7 nTPM (baseline 2); midbrain: 2.9 nTPM (baseline 2); pancreas: 2.5 nTPM (baseline 2); pituitary gland: 3.2 nTPM (baseline 2); retina: 2.2 nTPM (baseline 2); skeletal muscle: 3.8 nTPM (baseline 2); small intestine: 2.9 nTPM (baseline 2); smooth muscle: 3.1 nTPM (baseline 2),adrenal gland / glandular cells: Medium (Uncertain); bronchus / respiratory epithelial cells: Medium (Uncertain); colon / glandular cells: Medium (Uncertain); duodenum / glandular cells: Medium (Uncertain); kidney / cells in tubules: Medium (Uncertain); nasopharynx / respiratory epithelial cells: Medium (Uncertain); parathyroid gland / glandular cells: Low (Uncertain); salivary gland / glandular cells: Low (Uncertain); small intestine / glandular cells: Medium (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain); stomach 1 / glandular cells: Medium (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Breast Invasive Carcinoma (validation): 43/50 (86.0%); Glioblastoma Multiforme (TCGA): 103/141 (73.0%); Glioblastoma Multiforme (validation): 40/58 (69.0%),stomach cancer: 1/9 (11.1%); testis cancer: 1/10 (10.0%),31,20,Q9BUG6,https://www.uniprot.org/uniprotkb/Q9BUG6/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZSCAN5B,ENSG00000197213,Unsafe,Protein,False,True,1.7,1.7,80,18,Positive somewhere,True,False,False,False,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; cerebral cortex: 0.1 nTPM; positive ihc; colon: 0 nTPM; positive ihc; duodenum: 0 nTPM; positive ihc; kidney: 0 nTPM; positive ihc; liver: 0 nTPM; positive ihc; pancreas: 0 nTPM; positive ihc; rectum: 0 nTPM; positive ihc; salivary gland: 0 nTPM; positive ihc; skin: 0.1 nTPM; positive ihc; small intestine: 0 nTPM; positive ihc; smooth muscle: 0 nTPM; positive ihc,"Positive IHC in a Vital, Protected or Manageable compartment",,cerebral cortex / neuronal cells: Low (Uncertain); colon / glandular cells: High (Uncertain); duodenum / glandular cells: Medium (Uncertain); kidney / cells in tubules: High (Uncertain); liver / cholangiocytes: Low (Uncertain); pancreas / exocrine glandular cells: Medium (Uncertain); rectum / glandular cells: High (Uncertain); salivary gland / glandular cells: Low (Uncertain); skin 1 / keratinocytes: Low (Uncertain); skin 2 / epidermal cells: Low (Uncertain); small intestine / glandular cells: Medium (Uncertain); smooth muscle / smooth muscle cells: Medium (Uncertain),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Bladder Urothelial Carcinoma (TCGA): 3/169 (1.8%); Liver Hepatocellular Carcinoma (validation): 4/231 (1.7%); Testicular Germ Cell Tumor (TCGA): 2/133 (1.5%),colorectal cancer: 9/12 (75.0%); stomach cancer: 6/12 (50.0%),31,20,A6NJL1,https://www.uniprot.org/uniprotkb/A6NJL1/entry,May be involved in transcriptional regulation,,,,Nucleus,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Wang2016_CT | daSilva2017_testis_biased | daSilva2017_CT | Chang2019_TGCT,Cancer-associated RNA nomination; no antigen validation asserted | At least 90% normal-tissue RNA attributable to testis; tumor positivity not required | RSEM >1 in at least 10% of samples in a tumor type; RNA nomination | Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,
ZXDA,ENSG00000198205,Unsafe,Protein,False,True,3.5,3.5,75,35,Positive somewhere,True,True,False,True,Excluded,Normal,True,,Not assessed,,,positive normal IHC; positive ihc outside permitted; adipose tissue: 2.1 nTPM; continuous selectivity; adrenal gland: 1.9 nTPM; continuous selectivity; bone marrow: 2.8 nTPM; continuous selectivity; cerebellum: 1.3 nTPM; positive ihc;continuous selectivity; cerebral cortex: 2.4 nTPM; positive ihc;absolute ceiling;continuous selectivity; colon: 1.7 nTPM; positive ihc;continuous selectivity; duodenum: 1.3 nTPM; positive ihc;continuous selectivity; heart muscle: 2.1 nTPM; positive ihc;absolute ceiling;continuous selectivity; kidney: 2 nTPM; positive ihc;continuous selectivity; liver: 1.7 nTPM; positive ihc;continuous selectivity; lung: 1.8 nTPM; continuous selectivity; lymph node: 2.9 nTPM; continuous selectivity; pancreas: 2.3 nTPM; positive ihc;absolute ceiling;continuous selectivity; parathyroid gland: 2.6 nTPM; continuous selectivity; pituitary gland: 1.1 nTPM; continuous selectivity; rectum: 1.5 nTPM; positive ihc;continuous selectivity; retina: 1.7 nTPM; continuous selectivity; salivary gland: 1.6 nTPM; positive ihc;continuous selectivity; skeletal muscle: 3 nTPM; positive ihc;absolute ceiling;continuous selectivity; small intestine: 1.3 nTPM; positive ihc;continuous selectivity; smooth muscle: 2.1 nTPM; continuous selectivity; spleen: 3.1 nTPM; continuous selectivity; stomach: 2.4 nTPM; positive ihc;continuous selectivity; thymus: 2.2 nTPM; continuous selectivity; thyroid gland: 2.9 nTPM; positive ihc;continuous selectivity; tongue: 2.9 nTPM; continuous selectivity; urinary bladder: 1.7 nTPM; positive ihc;continuous selectivity,"Positive IHC in a Vital, Protected or Manageable compartment",cerebral cortex: 2.4 nTPM (limit 2); heart muscle: 2.1 nTPM (limit 2); pancreas: 2.3 nTPM (limit 2); skeletal muscle: 3 nTPM (limit 2),bronchus / respiratory epithelial cells: Medium (Approved); caudate / neuronal cells: Low (Approved); cerebellum / cells in granular layer: Medium (Approved); cerebellum / Purkinje cells: Low (Approved); cerebral cortex / neuronal cells: Low (Approved); colon / glandular cells: Medium (Approved); duodenum / glandular cells: Medium (Approved); heart muscle / cardiomyocytes: Medium (Approved); kidney / cells in tubules: Medium (Approved); liver / cholangiocytes: Medium (Approved); liver / hepatocytes: Medium (Approved); nasopharynx / respiratory epithelial cells: Medium (Approved); pancreas / exocrine glandular cells: Medium (Approved); rectum / glandular cells: Medium (Approved); salivary gland / glandular cells: Medium (Approved); skeletal muscle / myocytes: Low (Approved); small intestine / glandular cells: Medium (Approved); stomach 1 / glandular cells: Medium (Approved); stomach 2 / glandular cells: Medium (Approved); thyroid gland / glandular cells: Low (Approved); urinary bladder / urothelial cells: Medium (Approved),,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,Protein,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Glioblastoma Multiforme (validation): 58/58 (100.0%); Breast Invasive Carcinoma (validation): 42/50 (84.0%); Rectum Adenocarcinoma (validation): 121/207 (58.5%),prostate cancer: 12/12 (100.0%); stomach cancer: 12/12 (100.0%),31,20,P98168,https://www.uniprot.org/uniprotkb/P98168/entry,Cooperates with CIITA to promote transcription of MHC class I and MHC class II genes,"May be expressed in brain, heart, kidney, liver, lung, muscle and placenta",,,Nucleus,17493635,8268913,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
ZYG11A,ENSG00000203995,Unsafe,RNA,False,True,3.7,3.7,0,0,Missing,False,True,False,False,Excluded,Normal,True,,Not assessed,,,kidney: 2.8 nTPM; absolute ceiling;continuous selectivity; liver: 1.2 nTPM; continuous selectivity; thyroid gland: 2.2 nTPM; continuous selectivity,Measured normal RNA exceeds its applicable category/IHC ceiling,kidney: 2.8 nTPM (limit 2); kidney: 2.8 nTPM (baseline 2),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Testicular Germ Cell Tumor (TCGA): 107/133 (80.5%); Breast Invasive Carcinoma (validation): 36/50 (72.0%); Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA): 46/283 (16.3%),stomach cancer: 9/10 (90.0%); colorectal cancer: 7/12 (58.3%),31,20,Q6WRX3,https://www.uniprot.org/uniprotkb/Q6WRX3/entry,Probably acts as a target recruitment subunit in an E3 ubiquitin ligase complex ZYGA-CUL2-elongin BC,,,,,,,False,Reviewed UniProt annotation; not a new primary-paper review,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Bruggeman2018_GC,GC RNA nomination across cancer types; no antigen validation asserted,,,,,,,,
,ENSG00000187186,Unsafe,RNA,False,True,284.3,284.3,85,4,Positive somewhere,False,True,False,True,Excluded,Normal,True,,Not assessed,,,amygdala: 57.3 nTPM; absolute ceiling; basal ganglia: 95.6 nTPM; absolute ceiling;continuous selectivity; cerebellum: 33 nTPM; absolute ceiling; cerebral cortex: 75.4 nTPM; absolute ceiling; choroid plexus: 28.6 nTPM; absolute ceiling; heart muscle: 27 nTPM; absolute ceiling; hippocampal formation: 56.4 nTPM; absolute ceiling; hypothalamus: 47.3 nTPM; absolute ceiling; kidney: 14.2 nTPM; absolute ceiling; midbrain: 46.6 nTPM; absolute ceiling; pituitary gland: 59 nTPM; absolute ceiling; retina: 6.3 nTPM; absolute ceiling; skeletal muscle: 35.4 nTPM; absolute ceiling; spinal cord: 26.7 nTPM; absolute ceiling; tongue: 21.6 nTPM; absolute ceiling,Measured normal RNA exceeds its applicable category/IHC ceiling,amygdala: 57.3 nTPM (limit 2); basal ganglia: 95.6 nTPM (limit 2); cerebellum: 33 nTPM (limit 12); cerebral cortex: 75.4 nTPM (limit 12); choroid plexus: 28.6 nTPM (limit 2); heart muscle: 27 nTPM (limit 12); hippocampal formation: 56.4 nTPM (limit 2); hypothalamus: 47.3 nTPM (limit 2); kidney: 14.2 nTPM (limit 12); midbrain: 46.6 nTPM (limit 2); pituitary gland: 59 nTPM (limit 2); retina: 6.3 nTPM (limit 2); skeletal muscle: 35.4 nTPM (limit 12); spinal cord: 26.7 nTPM (limit 2); tongue: 21.6 nTPM (limit 6),,,oncoref.target-sets.2026-10-24.1,False,,,False,,,,False,,,False,,False,,False,Unsafe,RNA,oncoref.target-sets.2026-10-23.1,False,False,,Unchanged,False,,False,,,,Unsafe,oncoref.target-sets.2026-10-23.2,,,Thyroid Carcinoma (TCGA): 495/495 (100.0%); Pancreatic Adenocarcinoma (TCGA): 166/176 (94.3%); Prostate Adenocarcinoma (TCGA): 449/480 (93.5%),stomach cancer: 2/11 (18.2%); urothelial cancer: 2/11 (18.2%),29,20,,,,,,,,,,False,No exact Ensembl mapping to a reviewed UniProt entry,No trial link in the curated intake; not an exhaustive negative search,,No individual clinical-outcome review in this report; no inference of safety or ineffectiveness,,,Chang2019_TGCT,Testis-specific coding gene expressed in at least 1% of TGCT; no broad somatic-cancer claim,,,,,,,,